A	O
subunit	O
of	O
the	O
oligosaccharyltransferase	B-GP
complex	O
is	O
required	O
for	O
interspecific	O
gametophyte	O
recognition	O
in	O
Arabidopsis	B-OG

Present	O
address	O
:	O
Boyce	O
-	O
Thompson	O
Institute	O
for	O
Plant	B-OG
Research	O
,	O
533	O
Tower	O
Road	O
,	O
Ithaca	O
,	O
New	O
York	O
14853	O
,	O
USA	O

Present	O
address	O
:	O
Carnegie	O
Institution	O
for	O
Science	O
,	O
Department	O
of	O
Plant	O
Biology	O
,	O
260	O
Panama	O
Street	O
,	O
Stanford	O
,	O
California	O
94305	O
,	O
USA	O

Species	O
-	O
specific	O
gamete	O
recognition	O
is	O
a	O
key	O
premise	O
to	O
ensure	O
reproductive	O
success	O
and	O
the	O
maintenance	O
of	O
species	O
boundaries	O
.	O

During	O
plant	B-OG
pollen	O
tube	O
(	O
PT	O
)	O
reception	O
,	O
gametophyte	O
interactions	O
likely	O
allow	O
the	O
species	O
-	O
specific	O
recognition	O
of	O
signals	O
from	O
the	O
PT	O
(	O
male	O
gametophyte	O
)	O
by	O
the	O
embryo	O
sac	O
(	O
female	O
gametophyte	O
),	O
resulting	O
in	O
PT	O
rupture	O
,	O
sperm	O
release	O
,	O
and	O
double	O
fertilization	O
.	O

This	O
process	O
is	O
impaired	O
in	O
interspecific	O
crosses	O
between	O
Arabidopsis	B-OG
thaliana	I-OG
and	O
related	O
species	O
,	O
leading	O
to	O
PT	O
overgrowth	O
and	O
a	O
failure	O
to	O
deliver	O
the	O
sperm	O
cells	O
.	O

Here	O
we	O
show	O
that	O
ARTUMES	B-GP
(	O
ARU	B-GP
)	O
specifically	O
regulates	O
the	O
recognition	O
of	O
interspecific	O
PTs	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
.	O
ARU	B-GP
,	O
identified	O
in	O
a	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
),	O
exclusively	O
influences	O
interspecific	O
—	O
but	O
not	O
intraspecific	O
—	O
gametophyte	O
interactions	O
.	O
ARU	B-GP
encodes	O
the	O
OST3	B-GP
/	O
6	O
subunit	O
of	O
the	O
oligosaccharyltransferase	B-GP
complex	O
conferring	O
protein	O
N	O
-	O
glycosylation	O
.	O

Our	O
results	O
suggest	O
that	O
glycosylation	O
patterns	O
of	O
cell	B-GP
surface	I-GP
proteins	I-GP
may	O
represent	O
an	O
important	O
mechanism	O
of	O
gametophyte	O
recognition	O
and	O
thus	O
speciation	O
.	O

Species	O
-	O
specific	O
gamete	O
recognition	O
is	O
needed	O
to	O
maintain	O
species	O
boundaries	O
.	O

Here	O
,	O
Müller	O
et	O
al	O
.	O
show	O
that	O
ARTUMES	B-GP
regulates	O
pollen	O
tube	O
recognition	O
between	O
different	O
Arabidopsis	B-OG
species	O
,	O
representing	O
the	O
first	O
gene	O
known	O
to	O
exclusively	O
influence	O
inter	O
-	O
but	O
not	O
intraspecific	O
gamete	O
interaction	O
in	O
plants	B-OG
.	O

Species	O
evolve	O
and	O
are	O
maintained	O
by	O
a	O
variety	O
of	O
hybridization	O
barriers	O
that	O
prevent	O
interspecific	O
gene	O
flow	O
and	O
thus	O
the	O
formation	O
of	O
potentially	O
unviable	O
or	O
sterile	O
hybrids1	O
.	O

To	O
date	O
,	O
the	O
molecular	O
basis	O
of	O
hybridization	O
barriers	O
is	O
still	O
poorly	O
understood	O
.	O

In	O
plants	B-OG
,	O
such	O
barriers	O
can	O
either	O
act	O
before	O
(	O
pre	O
-	O
pollination	O
barriers	O
)	O
or	O
after	O
pollination	O
(	O
post	O
-	O
pollination	O
barriers	O
).	O

Pre	O
-	O
pollination	O
barriers	O
can	O
be	O
spatial	O
or	O
temporal	O
patterns	O
preventing	O
plants	B-OG
from	O
being	O
pollinated	O
by	O
pollen	O
from	O
a	O
different	O
species	O
,	O
whereas	O
post	O
-	O
pollination	O
barriers	O
come	O
into	O
play	O
only	O
after	O
an	O
interspecific	O
pollination	O
event	O
occurs	O
and	O
can	O
be	O
further	O
divided	O
into	O
pre	O
-	O
and	O
post	O
-	O
zygotic	O
barriers2	O
.	O

The	O
latter	O
usually	O
act	O
at	O
the	O
genomic	O
level	O
(	O
for	O
example	O
,	O
incompatibilities	O
leading	O
to	O
hybrid	O
lethality	O
or	O
sterility	O
),	O
while	O
pre	O
-	O
zygotic	O
barriers	O
prevent	O
the	O
formation	O
of	O
a	O
zygote	O
and	O
usually	O
rely	O
on	O
direct	O
cell	O
–	O
cell	O
communication	O
between	O
the	O
male	O
and	O
female	O
tissues	O
.	O

Most	O
species	O
pairs	O
are	O
isolated	O
by	O
a	O
complex	O
interplay	O
of	O
different	O
types	O
of	O
isolation	O
barriers	O
.	O

Whereas	O
barriers	O
that	O
prevent	O
fertilization	O
(	O
both	O
pre	O
-	O
pollination	O
and	O
pre	O
-	O
zygotic	O
barriers	O
)	O
often	O
represent	O
the	O
most	O
important	O
means	O
to	O
reduce	O
interspecific	O
gene	O
flow	O
,	O
post	O
-	O
zygotic	O
hybridization	O
barriers	O
appear	O
to	O
contribute	O
less	O
to	O
reproductive	O
isolation	O
in	O
many	O
species	O
pairs3	O
.	O

In	O
plants	B-OG
,	O
successful	O
fertilization	O
starts	O
with	O
the	O
deposition	O
of	O
intraspecific	O
(	O
same	O
-	O
species	O
)	O
pollen	O
(	O
male	O
gametophyte	O
)	O
onto	O
the	O
stigma	O
of	O
a	O
gynoecium	O
.	O

The	O
subsequent	O
steps	O
involve	O
extensive	O
communication	O
between	O
the	O
male	O
and	O
female	O
tissues	O
,	O
leading	O
to	O
pollen	O
adherence	O
,	O
hydration	O
,	O
and	O
the	O
germination	O
of	O
a	O
pollen	O
tube	O
(	O
PT	O
).	O

Within	O
its	O
cytoplasm	O
,	O
the	O
tip	O
-	O
growing	O
PT	O
transports	O
the	O
two	O
sperm	O
cells	O
through	O
the	O
transmitting	O
tract	O
of	O
the	O
pistil	O
to	O
the	O
embryo	O
sac	O
(	O
female	O
gametophyte	O
),	O
which	O
is	O
deeply	O
embedded	O
in	O
the	O
ovule	O
,	O
the	O
precursor	O
of	O
seed	O
.	O

During	O
its	O
journey	O
,	O
the	O
PT	O
is	O
guided	O
towards	O
the	O
embryo	O
sacs	O
by	O
attractants	O
secreted	O
by	O
female	O
tissues4	O
.	O

On	O
arrival	O
at	O
the	O
embryo	O
sac	O
,	O
communication	O
between	O
the	O
PT	O
and	O
the	O
synergid	O
cells	O
of	O
the	O
female	O
gametophyte	O
is	O
initiated	O
(	O
Fig	O
.	O
1a	O
).	O

The	O
two	O
synergid	O
cells	O
are	O
located	O
at	O
the	O
micropylar	O
end	O
of	O
the	O
embryo	O
sac	O
and	O
possess	O
a	O
secretory	O
region	O
characterized	O
by	O
membrane	O
invaginations	O
and	O
thickened	O
cell	O
wall	O
structures5	O
.	O

This	O
so	O
-	O
called	O
filiform	O
apparatus	O
is	O
the	O
first	O
point	O
of	O
contact	O
between	O
the	O
male	O
and	O
female	O
gametophytes	O
,	O
which	O
communicate	O
in	O
preparation	O
for	O
penetration	O
of	O
the	O
receptive	O
synergid	O
cell	O
by	O
the	O
PT	O
,	O
PT	O
rupture	O
,	O
sperm	O
release	O
,	O
and	O
double	O
fertilization6	O
.	O

While	O
one	O
sperm	O
fuses	O
with	O
the	O
egg	O
cell	O
to	O
form	O
the	O
diploid	O
zygote	O
,	O
the	O
other	O
fertilizes	O
the	O
homo	O
-	O
diploid	O
central	O
cell	O
to	O
produce	O
the	O
triploid	O
endosperm	O
,	O
an	O
embryo	O
-	O
nourishing	O
tissue	O
.	O

The	O
communication	O
process	O
between	O
the	O
male	O
and	O
female	O
gametophytes	O
leading	O
to	O
PT	O
rupture	O
and	O
sperm	O
cell	O
discharge	O
is	O
known	O
as	O
PT	O
reception	O
,	O
and	O
its	O
success	O
or	O
failure	O
is	O
under	O
female	O
gametophytic	O
control6	O
.	O

However	O
,	O
if	O
a	O
pollen	O
grain	O
originating	O
from	O
a	O
different	O
species	O
(	O
interspecific	O
pollination	O
)	O
is	O
placed	O
on	O
a	O
plant	B-OG
'	O
s	O
stigma	O
,	O
all	O
the	O
communication	O
processes	O
described	O
above	O
have	O
the	O
potential	O
to	O
act	O
as	O
pre	O
-	O
zygotic	O
post	O
-	O
pollination	O
barriers	O
.	O

Several	O
studies	O
describe	O
a	O
species	O
-	O
preferential	O
behaviour	O
of	O
molecular	O
factors	O
involved	O
in	O
pollen	O
adherence	O
to	O
the	O
stigma	O
,	O
PT	O
growth	O
,	O
and	O
PT	O
guidance	O
towards	O
the	O
ovules47891011	O
.	O

In	O
interspecific	O
crosses	O
between	O
closely	O
related	O
Ericaceae	B-OG
or	O
Brassicaceae	B-OG
,	O
respectively	O
,	O
hybridization	O
barriers	O
act	O
at	O
the	O
stage	O
of	O
PT	O
reception1213	O
.	O

In	O
such	O
crosses	O
,	O
PTs	O
are	O
properly	O
targeted	O
to	O
the	O
female	O
gametophyte	O
but	O
,	O
upon	O
arrival	O
at	O
the	O
embryo	O
sacs	O
,	O
interspecific	O
PTs	O
are	O
not	O
recognized	O
and	O
fail	O
to	O
arrest	O
growth	O
and	O
discharge	O
their	O
sperm	O
.	O

Instead	O
,	O
they	O
continue	O
growing	O
inside	O
the	O
embryo	O
sacs	O
(	O
referred	O
to	O
as	O
PT	O
overgrowth	O
)	O
and	O
cannot	O
effect	O
double	O
fertilization	O
.	O

Therefore	O
,	O
we	O
consider	O
PT	O
reception	O
to	O
be	O
an	O
integral	O
part	O
of	O
the	O
hybridization	O
barrier	O
in	O
these	O
species	O
.	O

Interspecific	O
PT	O
overgrowth	O
phenocopies	O
the	O
female	O
gametophytic	O
mutants	O
feronia	O
/	O
sirène	O
(	O
fer	O
/	O
srn	O
),	O
lorelei	B-GP
(	O
lre	O
),	O
nortia	O
(	O
nta	O
),	O
turan	O
(	O
tun	O
),	O
evan	O
(	O
evn	O
),	O
and	O
Zea	B-OG
mays	I-OG
embryo	B-GP
sac	I-GP
4	I-GP
(	O
ZmES4	B-GP
)	O
RNAi	O
-	O
lines1314151617181920	O
,	O
which	O
are	O
defective	O
in	O
the	O
reception	O
of	O
intraspecific	O
PTs	O
.	O

In	O
addition	O
,	O
FER	B-GP
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
interspecific	O
PT	O
recognition13	O
,	O
and	O
there	O
is	O
evidence	O
that	O
ZmES4	B-GP
is	O
sufficient	O
to	O
trigger	O
PT	O
growth	O
arrest	O
and	O
rupture	O
in	O
a	O
species	O
-	O
preferential	O
manner20	O
.	O

Despite	O
the	O
rapid	O
advance	O
in	O
our	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
intraspecific	O
PT	O
reception21	O
,	O
the	O
genetic	O
basis	O
of	O
post	O
-	O
pollination	O
hybridization	O
barriers	O
remains	O
largely	O
unknown	O
.	O

All	O
molecular	O
factors	O
that	O
have	O
so	O
far	O
been	O
described	O
to	O
be	O
involved	O
in	O
pre	O
-	O
zygotic	O
species	O
-	O
discrimination	O
,	O
including	O
species	O
-	O
preferential	O
pollen	O
adherence	O
,	O
PT	O
guidance	O
,	O
growth	O
,	O
and	O
reception	O
,	O
act	O
primarily	O
during	O
intraspecific	O
pollination	O
and	O
have	O
additional	O
species	O
-	O
preferential	O
effects47891011	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
first	O
gene	O
required	O
exclusively	O
for	O
inter	O
-	O
but	O
not	O
for	O
intraspecific	O
pollination	O
,	O
thus	O
likely	O
representing	O
a	O
specific	O
component	O
for	O
the	O
establishment	O
of	O
a	O
hybridization	O
barrier	O
.	O

By	O
making	O
use	O
of	O
the	O
striking	O
natural	O
variation	O
of	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
in	O
interspecific	O
PT	O
reception	O
,	O
we	O
identified	O
ARTUMES	B-GP
(	O
ARU	B-GP
)	O
as	O
an	O
indispensable	O
factor	O
for	O
the	O
recognition	O
of	O
interspecific	O
A	B-OG
.	I-OG
lyrata	I-OG
PTs	O
by	O
A	B-OG
.	I-OG
thaliana	I-OG
embryo	O
sacs	O
.	O

In	O
contrast	O
,	O
aru	B-GP
mutants	O
do	O
not	O
affect	O
gametophytic	O
communication	O
in	O
intraspecific	O
A	B-OG
.	I-OG
thaliana	I-OG
crosses	O
.	O
ARU	B-GP
encodes	O
the	O
OST3	B-GP
/	O
6	O
subunit	O
of	O
the	O
oligosaccharyltransferase	B-GP
complex	O
,	O
which	O
is	O
known	O
to	O
regulate	O
site	O
-	O
and	O
substrate	O
-	O
specific	O
N	O
-	O
glycosylation	O
of	O
proteins	O
in	O
yeast2223	B-OG
and	O
a	O
similar	O
substrate	O
specificity	O
has	O
been	O
reported	O
for	O
A	B-OG
.	I-OG
thaliana	I-OG
OST3	B-GP
/	O
6	O
(	O
ref	O
.	O
24	O
).	O

Thus	O
,	O
a	O
possible	O
mechanism	O
for	O
the	O
discrimination	O
of	O
inter	O
-	O
and	O
intraspecific	O
PTs	O
may	O
depend	O
on	O
the	O
species	O
-	O
specific	O
glycosylation	O
of	O
proteins	O
on	O
the	O
surface	O
of	O
the	O
synergid	O
cells	O
of	O
the	O
female	O
gametophyte	O
.	O

Results	O

PT	O
overgrowth	O
restricts	O
gene	O
flow	O
between	O
Arabidopsis	B-OG
species	O

Self	O
-	O
fertilizing	O
A	B-OG
.	I-OG
thaliana	I-OG
and	O
its	O
outcrossing	O
relative	O
A	B-OG
.	I-OG
lyrata	I-OG
are	O
separated	O
by	O
strong	O
pre	O
-	O
pollination	O
barriers	O
due	O
to	O
their	O
different	O
mating	O
systems1	O
.	O

In	O
addition	O
,	O
they	O
are	O
isolated	O
by	O
post	O
-	O
pollination	O
barriers	O
based	O
on	O
direct	O
male	O
–	O
female	O
interactions	O
.	O

Although	O
A	B-OG
.	I-OG
thaliana	I-OG
(	O
Col	O
-	O
0	O
)	O
pollen	O
germination	O
is	O
inhibited	O
at	O
the	O
A	B-OG
.	I-OG
lyrata	I-OG
stigma	O
,	O
A	B-OG
.	I-OG
lyrata	I-OG
PTs	O
are	O
guided	O
towards	O
A	B-OG
.	I-OG
thaliana	I-OG
embryo	O
sacs	O
,	O
but	O
PT	O
reception	O
fails	O
(	O
Fig	O
.	O
1c	O
,	O
as	O
opposed	O
to	O
Fig	O
.	O
1b	O
showing	O
successful	O
PT	O
reception	O
,	O
Supplementary	O
Fig	O
.	O
1	O
).	O

Such	O
unilateral	O
incompatibility	O
is	O
similar	O
to	O
that	O
observed	O
in	O
other	O
crosses	O
between	O
self	O
-	O
compatible	O
and	O
self	O
-	O
incompatible	O
species25	O
.	O

We	O
also	O
observed	O
PT	O
overgrowth	O
in	O
interspecific	O
crosses	O
between	O
A	B-OG
.	I-OG
arenosa	I-OG
and	O
A	B-OG
.	I-OG
lyrata	I-OG
(	O
Supplementary	O
Fig	O
.	O
2	O
),	O
between	O
which	O
natural	O
gene	O
flow	O
occurs26	O
.	O

This	O
finding	O
indicates	O
that	O
A	B-OG
.	I-OG
lyrata	I-OG
PT	O
overgrowth	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
ovules	O
does	O
not	O
only	O
occur	O
between	O
species	O
that	O
do	O
not	O
interbreed	O
in	O
nature	O
(	O
A	B-OG
.	I-OG
thaliana	I-OG
×	O
A	B-OG
.	I-OG
lyrata	I-OG
)	O
but	O
also	O
between	O
species	O
that	O
are	O
only	O
partially	O
reproductively	O
isolated	O
and	O
do	O
interbreed	O
(	O
A	B-OG
.	I-OG
arenosa	I-OG
×	O
A	B-OG
.	I-OG
lyrata	I-OG
).	O

Natural	O
variation	O
in	O
interspecific	O
PT	O
reception	O

To	O
analyse	O
interspecific	O
hybridization	O
barriers	O
within	O
the	O
genus	O
Arabidopsis	B-OG
,	O
we	O
assessed	O
PT	O
overgrowth	O
in	O
86	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
that	O
were	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
(	O
Supplementary	O
Table	O
1	O
).	O

PTs	O
were	O
visualized	O
by	O
staining	O
callose	B-CD
in	O
PT	O
cell	O
walls	O
with	O
aniline	B-CD
blue	I-CD
.	O

We	O
scored	O
the	O
proportion	O
of	O
ovules	O
that	O
failed	O
to	O
recognize	O
interspecific	O
PTs	O
—	O
leading	O
to	O
PT	O
overgrowth	O
—	O
in	O
relation	O
to	O
the	O
total	O
number	O
of	O
ovules	O
that	O
attracted	O
a	O
PT	O
in	O
a	O
silique	O
(	O
overgrowth	O
per	O
silique	O
,	O
OG	O
/	O
S	O
).	O

We	O
found	O
a	O
striking	O
variation	O
in	O
the	O
ability	O
to	O
recognize	O
interspecific	O
PTs	O
between	O
different	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
,	O
with	O
OG	O
/	O
S	O
ranging	O
from	O
about	O
10	O
to	O
90	O
%	O
(	O
Fig	O
.	O
1d	O
,	O
broad	O
-	O
sense	O
heritability	O
H2	O
=	O
0	O
.	O
7	O
).	O

Examples	O
of	O
accessions	O
with	O
extreme	O
phenotypes	O
are	O
Lz	O
-	O
0	O
(	O
10	O
%	O
OG	O
/	O
S	O
,	O
n	O
=	O
12	O
siliques	O
)	O
and	O
Kz	O
-	O
9	O
(	O
87	O
.	O
3	O
%	O
OG	O
/	O
S	O
,	O
n	O
=	O
10	O
;	O
Fig	O
.	O
1e	O
,	O
f	O
).	O

There	O
is	O
no	O
obvious	O
correlation	O
between	O
the	O
geographical	O
origin	O
of	O
the	O
accessions	O
and	O
their	O
phenotype	O
(	O
Supplementary	O
Fig	O
.	O
3	O
).	O

To	O
analyse	O
whether	O
the	O
variation	O
in	O
the	O
ability	O
to	O
recognize	O
interspecific	O
PTs	O
is	O
species	O
-	O
dependent	O
,	O
we	O
pollinated	O
a	O
subset	O
of	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
with	O
low	O
or	O
high	O
OG	O
/	O
S	O
in	O
crosses	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
(	O
Lz	B-GP
-	I-GP
0	I-GP
,	O
Kas	B-GP
-	I-GP
1	I-GP
,	O
Ga	B-GP
-	I-GP
0	I-GP
,	O
Lp2	B-GP
-	I-GP
6	I-GP
and	O
Col	B-GP
-	I-GP
0	I-GP
,	O
Kz	B-GP
-	I-GP
1	I-GP
,	O
Nd	B-GP
-	I-GP
1	I-GP
,	O
respectively	O
)	O
also	O
with	O
pollen	O
of	O
A	B-OG
.	I-OG
halleri	I-OG
and	O
A	B-OG
.	I-OG
arenosa	I-OG
.	O

Although	O
OG	O
/	O
S	O
in	O
the	O
accessions	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
or	O
A	B-OG
.	I-OG
halleri	I-OG
pollen	O
was	O
highly	O
comparable	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
),	O
the	O
values	O
were	O
slightly	O
lower	O
for	O
all	O
accessions	O
when	O
pollinated	O
by	O
A	B-OG
.	I-OG
arenosa	I-OG
(	O
Fig	O
.	O
2c	O
),	O
indicating	O
that	O
A	B-OG
.	I-OG
thaliana	I-OG
recognizes	O
A	B-OG
.	I-OG
arenosa	I-OG
PTs	O
better	O
than	O
those	O
of	O
A	B-OG
.	I-OG
lyrata	I-OG
or	O
A	B-OG
.	I-OG
halleri	I-OG
.	O

However	O
,	O
accessions	O
showing	O
very	O
low	O
or	O
high	O
OG	O
/	O
S	O
in	O
crosses	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
,	O
respectively	O
,	O
displayed	O
a	O
similar	O
phenotype	O
with	O
A	B-OG
.	I-OG
halleri	I-OG
and	O
A	B-OG
.	I-OG
arenosa	I-OG
as	O
pollen	O
donors	O
,	O
suggesting	O
a	O
common	O
molecular	O
PT	O
reception	O
mechanism	O
for	O
all	O
three	O
species	O
.	O

Thus	O
,	O
PT	O
overgrowth	O
is	O
a	O
hallmark	O
of	O
interspecific	O
crosses	O
with	O
close	O
Brassicaceae	B-OG
relatives	O
and	O
not	O
a	O
species	O
-	O
specific	O
feature	O
of	O
A	B-OG
.	I-OG
thaliana	I-OG
and	O
A	B-OG
.	I-OG
lyrata	I-OG
.	O

To	O
investigate	O
whether	O
intraspecific	O
PT	O
reception	O
was	O
affected	O
in	O
accessions	O
with	O
high	O
OG	O
/	O
S	O
(	O
Col	O
-	O
0	O
,	O
Kz	O
-	O
1	O
,	O
Kz	O
-	O
9	O
,	O
Nd	B-GP
-	I-GP
1	I-GP
,	O
Fei	O
-	O
0	O
,	O
and	O
Sq	O
-	O
8	O
),	O
we	O
crossed	O
them	O
with	O
A	B-OG
.	I-OG
thaliana	I-OG
pollen	O
(	O
from	O
both	O
low	O
and	O
high	O
OG	O
/	O
S	O
accessions	O
).	O

Intraspecific	O
PT	O
reception	O
was	O
normal	O
in	O
all	O
the	O
tested	O
accessions	O
(	O
Supplementary	O
Fig	O
.	O
3	O
),	O
indicating	O
that	O
high	O
OG	O
/	O
S	O
frequencies	O
result	O
from	O
a	O
failure	O
in	O
the	O
recognition	O
of	O
interspecific	O
PTs	O
only	O
,	O
and	O
are	O
not	O
due	O
to	O
a	O
general	O
defect	O
in	O
PT	O
reception	O
.	O

ARTUMES	B-GP
regulates	O
inter	O
-	O
but	O
not	O
intraspecific	O
PT	B-GP
reception	O

To	O
identify	O
loci	O
causing	O
the	O
variation	O
in	O
interspecific	O
PT	O
reception	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
,	O
we	O
used	O
publicly	O
available	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
data	O
from	O
the	O
86	O
accessions	O
to	O
perform	O
a	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
27	O
.	O

To	O
date	O
,	O
most	O
GWAS	O
in	O
Arabidopsis	B-OG
have	O
identified	O
previously	O
known	O
candidate	O
genes	O
,	O
with	O
only	O
a	O
few	O
studies	O
identifying	O
novel	O
regulatory	O
genes	O
in	O
the	O
respective	O
pathways2829	O
.	O

Applying	O
the	O
GLM	O
function	O
implemented	O
in	O
TASSEL30	O
,	O
we	O
identified	O
a	O
region	O
on	O
chromosome	O
1	O
containing	O
8	O
of	O
the	O
top	O
20	O
SNPs	O
with	O
the	O
highest	O
correlation	O
to	O
the	O
OG	O
/	O
S	O
trait	O
(	O
Fig	O
.	O
3a	O
and	O
Supplementary	O
Table	O
2	O
).	O

This	O
28	O
-	O
kb	O
region	O
(	O
positions	O
22	O
,	O
814	O
,	O
316	O
to	O
22	O
,	O
842	O
,	O
689	O
)	O
contains	O
six	O
genes	O
and	O
one	O
pseudogene	O
(	O
Fig	O
.	O
3b	O
).	O

Interestingly	O
,	O
calculation	O
with	O
mixed	O
linear	O
models	O
that	O
simultaneously	O
correct	O
for	O
population	O
structure	O
and	O
unequal	O
genetic	O
relatedness	O
between	O
individuals	O
masked	O
the	O
peak	O
,	O
whereas	O
it	O
could	O
be	O
detected	O
—	O
although	O
below	O
the	O
significance	O
threshold	O
—	O
using	O
a	O
step	O
-	O
wise	O
multi	O
-	O
locus	O
mixed	O
model	O
(	O
MLMM	O
)	O
specifically	O
designed	O
for	O
mapping	O
complex	O
traits31	O
(	O
Supplementary	O
Fig	O
.	O
4	O
).	O

With	O
each	O
step	O
of	O
MLMM	O
,	O
new	O
peaks	O
appear	O
,	O
consistent	O
with	O
a	O
multigenic	O
basis	O
for	O
interspecific	O
PT	O
reception	O
.	O

To	O
narrow	O
down	O
the	O
28	O
-	O
kb	O
candidate	O
region	O
to	O
a	O
single	O
gene	O
,	O
we	O
analysed	O
OG	O
/	O
S	O
in	O
T	O
-	O
DNA	O
insertion	O
lines	O
of	O
three	O
synergid	O
-	O
expressed	O
genes32	O
in	O
this	O
region	O
because	O
the	O
synergids	O
control	O
PT	O
reception	O
(	O
At1g61780	O
,	O
At1g61790	B-GP
and	O
At1g61810	B-GP
;	O
as	O
well	O
as	O
At1g61795	B-GP
,	O
for	O
which	O
no	O
expression	O
data	O
was	O
available	O
;	O
Supplementary	O
Fig	O
.	O
5	O
).	O

In	O
a	O
homozygous	O
T	O
-	O
DNA	O
insertion	O
allele	O
disrupting	O
the	O
coding	O
sequence	O
of	O
At1g61790	O
(	O
Fig	O
.	O
4a	O
),	O
an	O
average	O
of	O
84	O
.	O
3	O
%	O
(	O
n	O
=	O
18	O
siliques	O
)	O
of	O
ovules	O
display	O
A	B-OG
.	I-OG
lyrata	I-OG
PT	O
overgrowth	O
,	O
significantly	O
more	O
than	O
in	O
the	O
Col	B-GP
-	I-GP
0	I-GP
wild	O
-	O
type	O
control	O
(	O
58	O
.	O
7	O
%	O
OG	O
/	O
S	O
,	O
n	O
=	O
28	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
P	O
<	O
0	O
.	O
001	O
,	O
Fig	O
.	O
4b	O
,	O
d	O
,	O
e	O
).	O

We	O
named	O
the	O
At1g61790	B-GP
gene	O
,	O
which	O
has	O
previously	O
been	O
described	O
as	O
OST3	B-GP
/	O
6	O
based	O
on	O
homology24	O
,	O
ARTUMES	O
(	O
ARU	O
)	O
after	O
the	O
Etruscan	O
goddess	O
of	O
night	O
,	O
nature	O
,	O
and	O
fertility33	O
.	O

The	O
T	O
-	O
DNA	O
allele	O
was	O
denoted	O
aru	O
-	O
1	O
.	O
A	O
second	O
mutant	O
allele	O
,	O
aru	O
-	O
2	O
,	O
carrying	O
an	O
EMS	O
-	O
induced	O
premature	O
stop	O
-	O
codon	O
after	O
aa	O
residue	O
129	O
(	O
ref	O
.	O
34	O
),	O
also	O
showed	O
an	O
increase	O
in	O
interspecific	O
OG	O
/	O
S	O
(	O
96	O
.	O
1	O
%,	O
n	O
=	O
20	O
,	O
Fig	O
.	O
4a	O
,	O
b	O
,	O
f	O
).	O

Likewise	O
,	O
aru	B-GP
-	I-GP
1	I-GP
mutants	O
pollinated	O
with	O
A	B-OG
.	I-OG
arenosa	I-OG
pollen	O
showed	O
significantly	O
more	O
ovules	O
with	O
PT	O
overgrowth	O
(	O
67	O
.	O
6	O
%	O
OG	O
/	O
S	O
,	O
n	O
=	O
8	O
)	O
than	O
the	O
wild	O
type	O
(	O
34	O
.	O
9	O
%	O
OG	O
/	O
S	O
,	O
n	O
=	O
12	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
P	O
<	O
0	O
.	O
001	O
,	O
Supplementary	O
Fig	O
.	O
6	O
),	O
suggesting	O
a	O
common	O
basis	O
for	O
interspecific	O
PT	O
recognition	O
.	O

In	O
contrast	O
,	O
aru	B-GP
mutant	O
ovules	B-OG
have	O
no	O
problem	O
recognizing	O
and	O
receiving	O
intraspecific	O
PTs	O
from	O
A	B-OG
.	I-OG
thaliana	I-OG
(	O
Fig	O
.	O
4c	O
,	O
g	O
),	O
indicating	O
that	O
the	O
PT	O
reception	O
pathway	O
is	O
fully	O
functional	O
within	O
the	O
species	O
.	O

To	O
confirm	O
that	O
ARU	B-GP
function	O
is	O
required	O
for	O
interspecific	O
PT	O
recognition	O
in	O
the	O
synergids	O
,	O
we	O
expressed	O
an	O
ARU	B-GP
-	O
GFP	B-GP
translational	O
fusion	O
protein	O
under	O
the	O
control	O
of	O
the	O
MYB98	B-GP
and	O
FERONIA	B-GP
promoters	O
(	O
pMYB98	O
::	O
ARU	B-GP
-	O
GFP	B-GP
and	O
pFER	O
::	O
ARU	B-GP
-	O
GFP	B-GP
)	O
in	O
aru	B-GP
-	I-GP
1	I-GP
mutants	O
.	O

These	O
promoters	O
are	O
highly	O
active	O
in	O
synergids1335	O
,	O
and	O
in	O
ovules	O
the	O
strongest	O
ARU	O
-	O
GFP	B-GP
signal	O
was	O
detected	O
in	O
these	O
cells	O
(	O
Fig	O
.	O
5a	O
and	O
Supplementary	O
Fig	O
.	O
7	O
).	O

ARU	B-GP
-	O
GFP	B-GP
localized	O
to	O
perinuclear	O
structures	O
resembling	O
the	O
ER	O
in	O
synergids	O
(	O
Fig	O
.	O
5a	O
,	O
inset	O
),	O
and	O
co	O
-	O
localized	O
with	O
an	O
ER	O
-	O
marker	O
in	O
transiently	O
transformed	O
onion	O
epidermal	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
7	O
).	O

These	O
results	O
are	O
consistent	O
with	O
the	O
previously	O
reported	O
ER	O
-	O
localization	O
of	O
ARU	B-GP
-	O
GFP	B-GP
in	O
infiltrated	O
tobacco	B-OG
leaves24	O
.	O

Mutant	O
aru	B-GP
-	I-GP
1	I-GP
plants	B-OG
expressing	O
a	O
functional	O
copy	O
of	O
ARU	B-GP
-	O
GFP	B-GP
in	O
their	O
synergids	O
displayed	O
wild	O
-	O
type	O
-	O
like	O
PT	O
reception	O
in	O
interspecific	O
crosses	O
(	O
Fig	O
.	O
5b	O
and	O
Supplementary	O
Fig	O
.	O
7	O
),	O
indicating	O
that	O
ARU	B-GP
expression	O
in	O
synergid	O
cells	O
is	O
sufficient	O
to	O
complement	O
the	O
aru	B-GP
mutant	O
phenotype	O
.	O

Consistent	O
with	O
this	O
,	O
the	O
ARU	B-GP
-	O
GFP	B-GP
translational	O
fusion	O
protein	O
driven	O
by	O
the	O
endogenous	O
promoter	O
(	O
pARU	O
::	O
ARU	B-GP
-	O
GFP	B-GP
)	O
is	O
highly	O
expressed	O
in	O
wild	O
-	O
type	O
synergids	O
(	O
Supplementary	O
Fig	O
.	O
7	O
),	O
suggesting	O
an	O
important	O
role	O
for	O
ARU	B-GP
in	O
these	O
cells	O
.	O

Functional	O
complementation	O
of	O
the	O
aru	B-GP
-	I-GP
1	I-GP
mutant	O
was	O
also	O
observed	O
when	O
ARU	O
was	O
driven	O
by	O
the	O
endogenous	O
promoter	O
in	O
a	O
construct	O
also	O
containing	O
865	O
bp	O
downstream	O
sequence	O
(	O
pARU	O
::	O
ARU	O
),	O
although	O
there	O
was	O
more	O
line	O
-	O
to	O
-	O
line	O
variability	O
than	O
when	O
the	O
pMYB98	O
promoter	O
was	O
used	O
(	O
Supplementary	O
Fig	O
.	O
7	O
).	O

Since	O
ARU	O
is	O
not	O
fused	O
to	O
a	O
fluorescent	O
tag	O
here	O
,	O
technical	O
difficulties	O
in	O
measuring	O
synergid	O
specific	O
expression	O
of	O
the	O
transgene	O
make	O
it	O
hard	O
to	O
explore	O
this	O
difference	O
experimentally	O
.	O

However	O
,	O
it	O
is	O
conceivable	O
that	O
additional	O
regulatory	O
sequences	O
,	O
up	O
-	O
or	O
downstream	O
of	O
the	O
ARU	O
coding	O
sequence	O
that	O
are	O
present	O
in	O
the	O
pARU	O
::	O
ARU	O
construct	O
but	O
not	O
in	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
or	O
pFER	O
::	O
ARU	O
-	O
GFP	B-GP
,	O
contributed	O
to	O
the	O
observed	O
phenotypic	O
variability	O
.	O

SNPs	O
around	O
ARTUMES	O
correlate	O
with	O
phenotypic	O
variation	O

We	O
assessed	O
the	O
correlation	O
of	O
amino	B-CD
acid	I-CD
differences	O
in	O
the	O
ARU	O
coding	O
sequence	O
in	O
all	O
accessions	O
to	O
determine	O
whether	O
differences	O
in	O
the	O
protein	O
sequence	O
could	O
explain	O
the	O
phenotypic	O
variation	O
.	O

Within	O
this	O
population	O
,	O
we	O
detected	O
a	O
total	O
of	O
10	O
amino	B-CD
acid	I-CD
differences	O
,	O
four	O
of	O
which	O
are	O
significantly	O
correlated	O
to	O
variation	O
in	O
OG	O
/	O
S	O
(	O
Pearson	O
'	O
s	O
correlation	O
coefficient	O
R	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
Supplementary	O
Data	O
1	O
).	O

However	O
,	O
differing	O
residues	O
had	O
similar	O
chemical	O
properties	O
,	O
implying	O
small	O
,	O
if	O
any	O
,	O
differences	O
in	O
protein	O
function	O
.	O

Alternatively	O
,	O
differential	O
expression	O
levels	O
could	O
cause	O
the	O
observed	O
phenotypic	O
variation	O
.	O

Therefore	O
,	O
we	O
examined	O
alignments	O
of	O
1	O
,	O
000	O
bp	O
up	O
-	O
and	O
downstream	O
sequence	O
of	O
ARU	O
.	O

We	O
found	O
9	O
of	O
49	O
and	O
39	O
of	O
79	O
upstream	O
and	O
downstream	O
SNPs	O
,	O
respectively	O
,	O
to	O
be	O
correlated	O
with	O
phenotypic	O
variation	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Supplementary	O
Data	O
1	O
),	O
suggesting	O
that	O
phenotypic	O
variation	O
could	O
be	O
due	O
to	O
differences	O
in	O
gene	O
expression	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
used	O
RNA	O
extracts	O
from	O
pistils	O
and	O
ovules	O
collected	O
2	O
days	O
after	O
emasculation	O
from	O
selected	O
accessions	O
(	O
Lz	O
-	O
0	O
,	O
Kas	B-GP
-	O
1	O
,	O
Ga	B-GP
-	O
0	O
and	O
Col	B-GP
-	I-GP
0	I-GP
,	O
Nd	B-GP
-	I-GP
1	I-GP
,	O
Fei	O
-	O
0	O
,	O
Kz	O
-	O
1	O
,	O
Kz	O
-	O
9	O
)	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
digital	O
droplet	O
PCR	O
,	O
respectively36	O
.	O

We	O
found	O
ARU	B-GP
mRNA	O
levels	O
differed	O
between	O
accessions	O
(	O
Supplementary	O
Fig	O
.	O
8	O
),	O
but	O
they	O
did	O
not	O
correlate	O
with	O
the	O
OG	O
/	O
S	O
phenotype	O
among	O
the	O
selected	O
set	O
of	O
accessions	O
.	O

Because	O
we	O
used	O
RNA	O
from	O
whole	O
pistils	O
and	O
ovules	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
ARU	O
is	O
differentially	O
expressed	O
in	O
synergids	O
only	O
,	O
where	O
it	O
is	O
required	O
and	O
sufficient	O
for	O
interspecific	O
PT	O
reception	O
.	O

In	O
addition	O
,	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
could	O
play	O
a	O
role	O
in	O
mediating	O
ARU	B-GP
protein	O
levels	O
.	O
ARU	B-GP
has	O
a	O
410	O
bp	O
long	O
3	O
′-	O
UTR	O
(	O
3	O
′-	O
untranslated	O
region	O
)	O
37	O
containing	O
17	O
SNPs	O
that	O
are	O
correlated	O
with	O
the	O
OG	O
/	O
S	O
phenotype	O
and	O
might	O
contribute	O
to	O
accession	O
-	O
specific	O
differences	O
in	O
ARU	B-GP
protein	O
levels	O
.	O

To	O
further	O
investigate	O
the	O
role	O
of	O
ARU	O
in	O
different	O
accessions	O
,	O
we	O
transformed	O
high	O
OG	O
/	O
S	O
accessions	O
(	O
Fei	O
-	O
0	O
,	O
Kz	O
-	O
1	O
,	O
Kz	O
-	O
9	O
)	O
with	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
to	O
ensure	O
strong	O
expression	O
in	O
synergid	O
cells	O
and	O
assessed	O
interspecific	O
PT	O
reception	O
in	O
these	O
lines	O
.	O

Of	O
several	O
independent	O
transformants	O
of	O
all	O
accessions	O
,	O
none	O
showed	O
a	O
significant	O
reduction	O
of	O
OG	O
/	O
S	O
(	O
Supplementary	O
Fig	O
.	O
8	O
),	O
which	O
would	O
be	O
expected	O
if	O
low	O
expression	O
of	O
ARU	O
alone	O
would	O
be	O
the	O
cause	O
of	O
impaired	O
interspecific	O
PT	O
reception	O
in	O
these	O
accessions	O
.	O

Similarly	O
,	O
the	O
ARU	O
allele	O
(	O
including	O
1	O
,	O
492	O
bp	O
up	O
-	O
and	O
865	O
bp	O
downstream	O
sequence	O
)	O
from	O
Ga	O
-	O
0	O
could	O
not	O
better	O
complement	O
the	O
aru	B-GP
mutant	O
—	O
which	O
is	O
in	O
the	O
Col	O
-	O
0	O
background	O
—	O
than	O
the	O
Col	O
-	O
0	O
allele	O
,	O
as	O
it	O
would	O
be	O
expected	O
if	O
differences	O
in	O
ARU	O
alone	O
caused	O
the	O
phenotypic	O
difference	O
between	O
Ga	O
-	O
0	O
and	O
Col	O
-	O
0	O
(	O
Supplementary	O
Fig	O
.	O
7	O
).	O

Although	O
these	O
experiments	O
could	O
not	O
establish	O
a	O
mechanistic	O
link	O
between	O
variation	O
in	O
ARU	O
and	O
variation	O
in	O
OG	O
/	O
S	O
,	O
they	O
are	O
not	O
inconsistent	O
with	O
the	O
hypothesis	O
that	O
ARU	O
is	O
differentially	O
regulated	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
.	O

Because	O
ARU	O
is	O
likely	O
only	O
one	O
of	O
several	O
factors	O
involved	O
in	O
interspecific	O
PT	O
reception	O
,	O
we	O
cannot	O
rule	O
out	O
that	O
crucial	O
epistatic	O
interactions	O
with	O
other	O
factors	O
were	O
missing	O
in	O
the	O
particular	O
accessions	O
we	O
tested	O
.	O

At	O
present	O
,	O
it	O
is	O
conceivable	O
that	O
population	O
structure	O
or	O
co	O
-	O
segregating	O
SNPs	O
,	O
which	O
do	O
not	O
directly	O
influence	O
ARU	O
expression	O
or	O
protein	O
function	O
,	O
caused	O
the	O
GWAS	O
peak	O
on	O
chromosome	O
1	O
and	O
that	O
ARU	O
itself	O
—	O
although	O
undoubtedly	O
involved	O
in	O
interspecific	O
PT	O
reception	O
—	O
is	O
not	O
responsible	O
for	O
the	O
observed	O
natural	O
variation	O
among	O
the	O
86	O
accessions	O
tested	O
.	O

We	O
consider	O
co	O
-	O
segregating	O
SNPs	O
a	O
highly	O
unlikely	O
explanation	O
,	O
however	O
,	O
because	O
mutations	O
disrupting	O
other	O
genes	O
in	O
the	O
region	O
identified	O
by	O
GWAS	O
did	O
not	O
show	O
a	O
phenotype	O
in	O
interspecific	O
crosses	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Signatures	O
of	O
selection	O
at	O
the	O
ARTUMES	O
locus	O

Genes	O
involved	O
in	O
reproductive	O
isolation	O
and	O
speciation	O
are	O
often	O
subject	O
to	O
selective	O
pressures	O
driving	O
rapid	O
divergence38	O
.	O

We	O
tested	O
ARU	O
plus	O
1	O
,	O
000	O
bp	O
up	O
-	O
and	O
downstream	O
sequence	O
for	O
signatures	O
of	O
positive	O
selection	O
by	O
estimating	O
Tajima	O
'	O
s	O
D39	O
for	O
a	O
set	O
of	O
96	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions40	O
,	O
including	O
all	O
accessions	O
used	O
in	O
this	O
study	O
.	O

A	O
negative	O
D	O
is	O
due	O
to	O
an	O
excess	O
of	O
low	O
frequency	O
polymorphisms	O
that	O
can	O
be	O
caused	O
by	O
positive	O
selection	O
on	O
the	O
locus	O
or	O
by	O
population	O
expansion	O
.	O

Tajima	O
'	O
s	O
D	O
was	O
−	O
2	O
.	O
07	O
for	O
the	O
1	O
,	O
000	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
,	O
−	O
1	O
.	O
57	O
for	O
the	O
coding	O
sequence	O
and	O
−	O
1	O
.	O
58	O
for	O
the	O
1	O
,	O
000	O
bp	O
downstream	O
of	O
the	O
ARU	O
stop	O
-	O
codon	O
.	O

All	O
values	O
significantly	O
deviate	O
from	O
the	O
neutral	O
model	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
but	O
do	O
not	O
fall	O
into	O
the	O
5	O
%	O
tail	O
of	O
the	O
estimated	O
genomic	O
distribution	O
of	O
D	O
in	O
A	B-OG
.	I-OG
thaliana40	I-OG
(	O
cut	O
-	O
off	O
value	O
:	O
−	O
2	O
.	O
08	O
).	O

Thus	O
,	O
although	O
the	O
1	O
,	O
000	O
bp	O
upstream	O
region	O
was	O
very	O
close	O
to	O
this	O
cut	O
-	O
off	O
,	O
the	O
observed	O
negative	O
values	O
might	O
be	O
influenced	O
by	O
demographic	O
factors	O
that	O
shaped	O
the	O
entire	O
genome	O
rather	O
than	O
selective	O
pressure	O
acting	O
on	O
the	O
ARU	O
locus	O
.	O

In	O
addition	O
,	O
we	O
estimated	O
Fay	O
and	O
Wu	O
'	O
s	O
H	O
,	O
another	O
test	O
statistic	O
to	O
detect	O
positive	O
selection41	O
,	O
which	O
is	O
not	O
as	O
sensitive	O
to	O
demographic	O
factors	O
as	O
Tajima	O
'	O
s	O
D42	O
.	O

All	O
values	O
for	O
H	O
were	O
strongly	O
negative	O
(	O
upstream	O
region	O
:	O
−	O
20	O
.	O
20	O
,	O
coding	O
sequence	O
:	O
−	O
21	O
.	O
79	O
,	O
downstream	O
region	O
:	O
−	O
20	O
.	O
73	O
,	O
P	O
<	O
0	O
.	O
02	O
),	O
and	O
fall	O
into	O
the	O
very	O
extreme	O
tails	O
of	O
both	O
an	O
empirical	O
and	O
a	O
simulated	O
distribution	O
of	O
H	O
calculated	O
with	O
12	O
accessions	O
,	O
which	O
represent	O
a	O
world	O
-	O
wide	O
distribution	O
and	O
are	O
a	O
subset	O
of	O
the	O
accessions	O
used	O
in	O
this	O
study42	O
.	O

Such	O
strongly	O
negative	O
values	O
for	O
H	O
indicate	O
that	O
positive	O
selection	O
may	O
indeed	O
have	O
acted	O
on	O
each	O
of	O
the	O
regions	O
of	O
the	O
ARU	O
locus	O
.	O

The	O
fact	O
that	O
D	O
for	O
the	O
upstream	O
region	O
was	O
very	O
close	O
to	O
the	O
5	O
%	O
tail	O
and	O
the	O
strongly	O
negative	O
values	O
for	O
H	O
provide	O
evidence	O
for	O
possible	O
positive	O
selection	O
and	O
indicate	O
that	O
ARU	O
may	O
have	O
undergone	O
a	O
recent	O
selective	O
sweep	O
.	O

This	O
is	O
consistent	O
with	O
the	O
lack	O
of	O
variation	O
in	O
ARU	O
amino	B-CD
acid	I-CD
sequence	O
and	O
expression	O
level	O
but	O
is	O
difficult	O
,	O
although	O
not	O
impossible	O
,	O
to	O
reconcile	O
with	O
the	O
fact	O
that	O
we	O
identified	O
ARU	O
in	O
a	O
GWAS	O
for	O
variation	O
in	O
the	O
OG	O
/	O
S	O
phenotype	O
.	O

As	O
pointed	O
out	O
above	O
,	O
this	O
may	O
be	O
due	O
to	O
epistatic	O
interactions	O
with	O
additional	O
factors	O
involved	O
in	O
this	O
complex	O
process	O
.	O

Nevertheless	O
,	O
as	O
in	O
animal	B-OG
speciation	O
genes	O
,	O
selective	O
pressures	O
appear	O
to	O
have	O
contributed	O
to	O
shaping	O
the	O
genetic	O
basis	O
that	O
underlies	O
interspecific	O
PT	O
reception	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
.	O

Interspecific	O
PT	O
reception	O
depends	O
on	O
protein	O
N	O
-	O
glycosylation	O

ARU	B-GP
encodes	O
the	O
OST3	B-GP
/	O
6	O
subunit	O
of	O
the	O
hetero	O
-	O
oligomeric	O
plant	B-OG
oligosaccharyltransferase	B-GP
complex	O
(	O
OST	B-GP
),	O
which	O
catalyses	O
the	O
co	O
-	O
or	O
posttranslational	O
transfer	O
of	O
pre	O
-	O
assembled	O
carbohydrate	B-CD
oligomers	O
(	O
Glc3Man9GlcNAc2	O
)	O
to	O
asparagine	B-CD
(	O
N	O
)	O
residues	O
of	O
polypeptides43	O
.	O
N	O
-	O
glycosylation	O
affects	O
the	O
substrate	O
protein	O
'	O
s	O
folding	O
,	O
targeting	O
,	O
and	O
/	O
or	O
processing	O
through	O
the	O
ER	O
.	O

Subsequently	O
,	O
the	O
N	O
-	O
linked	O
glycan	O
can	O
be	O
modified	O
in	O
the	O
Golgi	O
apparatus	O
in	O
a	O
cell	O
-	O
type	O
and	O
species	O
-	O
specific	O
manner	O
,	O
accounting	O
for	O
the	O
functionality	O
and	O
binding	O
specificity	O
of	O
the	O
glycoprotein43	B-GP
.	O

The	O
yeast	B-OG
OST	B-GP
consists	O
of	O
eight	O
subunits	O
and	O
the	O
homologues	O
of	O
OST3	B-GP
/	O
6	O
,	O
Ost3p	B-GP
and	O
Ost6p	B-GP
,	O
differ	O
in	O
their	O
protein	O
substrate	O
and	O
site	O
-	O
specific	O
glycosylation	O
efficiency2223	O
.	O

In	O
plants	B-OG
,	O
OST3	B-GP
/	O
6	O
confers	O
similar	O
substrate	O
specificity	O
since	O
in	O
the	O
A	B-OG
.	I-OG
thaliana	I-OG
ost3	B-GP
/	O
6	O
(	O
aru	O
)	O
mutant	O
only	O
a	O
subset	O
of	O
glycoproteins	O
is	O
misglycosylated	O
and	O
therefore	O
non	O
-	O
functional24	O
.	O

Among	O
these	O
are	O
the	O
pathogen	O
-	O
associated	O
molecular	O
pattern	O
(	O
PAMP	O
)	O
receptor	B-GP
kinase	B-GP
EF	B-GP
-	I-GP
TU	I-GP
RECEPTOR	I-GP
(	O
EFR	B-GP
),	O
and	O
KORRIGAN1	B-GP
,	O
an	O
endo	B-GP
-	I-GP
β	I-GP
-	I-GP
1	I-GP
,	I-GP
4	I-GP
-	I-GP
glucanase	I-GP
involved	O
in	O
cellulose	O
biosynthesis	O
.	O

In	O
line	O
with	O
this	O
,	O
aru	B-GP
has	O
previously	O
been	O
identified	O
in	O
an	O
EMS	O
-	O
screen	O
for	O
cell	O
wall	O
mutants34	O
.	O

Some	O
of	O
the	O
known	O
members	O
in	O
the	O
PT	O
reception	O
pathway	O
,	O
FER	O
and	O
NTA	O
,	O
have	O
been	O
implicated	O
in	O
the	O
perception	O
of	O
cell	O
wall	O
perturbations	O
,	O
pathogen	O
resistance	O
,	O
and	O
innate	O
immunity174445	O
.	O

After	O
pollination	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
,	O
fer	O
heterozygous	O
mutants	O
show	O
higher	O
OG	O
/	O
S	O
(	O
74	O
.	O
9	O
%)	O
than	O
wild	O
-	O
type	O
segregants	O
(	O
61	O
.	O
2	O
%,	O
P	O
<	O
0	O
.	O
01	O
,	O
Supplementary	O
Fig	O
.	O
9	O
),	O
suggesting	O
that	O
inter	O
-	O
and	O
intraspecific	O
PT	O
reception	O
both	O
involve	O
the	O
FER	O
pathway	O
.	O

Moreover	O
,	O
FER	B-GP
(	O
a	O
receptor	B-GP
-	I-GP
like	I-GP
kinase	I-GP
with	O
an	O
extracellular	O
malectin	B-GP
-	O
binding	O
domain	O
)	O
and	O
LRE	B-GP
(	O
a	O
glycosylphosphatidylinositol	B-GP
-	I-GP
anchored	I-GP
protein	I-GP
)	O
are	O
likely	O
to	O
be	O
glycosylated131646	O
and	O
could	O
be	O
substrates	O
of	O
ARU	B-GP
.	O

To	O
test	O
this	O
,	O
we	O
analysed	O
the	O
expression	O
and	O
localization	O
of	O
fluorescent	O
FER	O
and	O
LRE	O
fusion	O
proteins	O
in	O
aru	B-OG
ovules	O
.	O

We	O
included	O
NTA	B-GP
,	O
which	O
itself	O
does	O
not	O
contain	O
any	O
putative	O
glycosylation	O
sites	O
but	O
whose	O
subcellular	O
localization	O
depends	O
on	O
FER	B-GP
signalling17	O
.	O

All	O
fusion	O
proteins	O
displayed	O
a	O
wild	O
-	O
type	O
-	O
like	O
subcellular	O
localization	O
in	O
the	O
synergids	O
of	O
aru	O
embryo	O
sacs	O
:	O
FER	O
-	O
GFP	B-GP
and	O
LRE	O
-	O
Citrine	B-CD
were	O
observed	O
at	O
the	O
micropylar	O
end	O
of	O
the	O
synergids	O
,	O
and	O
NTA	O
-	O
GFP	B-GP
was	O
re	O
-	O
localized	O
there	O
upon	O
PT	O
arrival	O
(	O
Supplementary	O
Fig	O
.	O
10	O
).	O

These	O
results	O
indicate	O
that	O
,	O
in	O
the	O
absence	O
of	O
functional	O
ARU	B-GP
,	O
these	O
proteins	O
are	O
properly	O
targeted	O
to	O
their	O
subcellular	O
compartment	O
.	O

However	O
,	O
we	O
cannot	O
rule	O
out	O
that	O
the	O
extracellular	O
domain	O
of	O
FER	B-GP
is	O
un	O
-	O
or	O
misglycosylated	O
at	O
specific	O
glycosylation	O
sites	O
in	O
aru	O
,	O
which	O
may	O
allow	O
the	O
protein	O
to	O
recognize	O
intra	O
-	O
but	O
not	O
interspecific	O
PTs	O
.	O

The	O
synergid	O
has	O
a	O
specialized	O
secretory	O
region	O
at	O
its	O
micropylar	O
end	O
,	O
the	O
filiform	O
apparatus	O
,	O
which	O
contains	O
a	O
large	O
amount	O
of	O
secreted	O
material	O
and	O
is	O
believed	O
to	O
be	O
the	O
site	O
of	O
PT	O
recognition6	O
.	O

It	O
is	O
possible	O
that	O
even	O
subtle	O
differences	O
in	O
ARU	B-GP
protein	O
levels	O
could	O
lead	O
to	O
the	O
misglycosylation	O
of	O
target	O
proteins	O
,	O
including	O
FER	B-GP
,	O
such	O
that	O
a	O
few	O
specific	O
glycosylation	O
sites	O
remain	O
unglycosylated	O
.	O

Given	O
the	O
high	O
secretory	O
activity	O
of	O
the	O
filiform	O
apparatus	O
,	O
such	O
small	O
changes	O
could	O
have	O
a	O
large	O
effect	O
on	O
PT	O
reception	O
.	O

Further	O
work	O
will	O
be	O
necessary	O
to	O
shed	O
more	O
light	O
on	O
the	O
target	O
proteins	O
of	O
ARU	O
and	O
to	O
elucidate	O
the	O
role	O
of	O
specific	O
glycosylated	O
surface	B-GP
proteins	I-GP
in	O
PT	O
reception	O
.	O

Discussion	O

A	O
possible	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
FER	B-GP
,	O
and	O
/	O
or	B-GP
yet	B-GP
unknown	O
synergid	B-GP
(	I-GP
co	I-GP
-)	I-GP
receptors	I-GP
,	O
bind	O
putative	O
ligands	O
from	O
intraspecific	O
PTs	O
both	O
via	O
specific	O
interactions	O
with	O
carbohydrates	B-CD
on	O
the	O
receptor	O
protein	O
and	O
via	O
direct	O
protein	O
–	O
protein	O
interactions	O
,	O
a	O
mechanism	O
similar	O
to	O
the	O
proposed	O
‘	O
domain	O
-	O
specific	O
model	O
'	O
in	O
mammalian	O
sperm	O
-	O
egg	O
binding47	O
(	O
Fig	O
.	O
6a	O
).	O

Ligands	O
from	O
interspecific	O
PTs	O
might	O
not	O
be	O
able	O
to	O
sufficiently	O
interact	O
via	O
protein	O
–	O
protein	O
contacts	O
alone	O
but	O
could	O
still	O
be	O
recognized	O
to	O
some	O
extent	O
via	O
the	O
carbohydrate	B-CD
moieties	O
,	O
explaining	O
the	O
partial	O
A	B-OG
.	I-OG
lyrata	I-OG
PT	O
reception	O
success	O
in	O
Col	O
-	O
0	O
ovules	O
(	O
Fig	O
.	O
6b	O
).	O

It	O
is	O
conceivable	O
that	O
in	O
aru	O
,	O
and	O
potentially	O
also	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
with	O
a	O
similar	O
phenotype	O
,	O
changes	O
in	O
the	O
glycosylation	O
status	O
of	O
the	O
receptor	O
could	O
completely	O
abolish	O
the	O
ability	O
to	O
recognize	O
and	O
receive	O
interspecific	O
PTs	O
(	O
Fig	O
.	O
6d	O
),	O
while	O
ligands	O
from	O
A	B-OG
.	I-OG
thaliana	I-OG
PTs	O
are	O
still	O
efficiently	O
recognized	O
via	O
protein	O
–	O
protein	O
interactions	O
,	O
leading	O
to	O
normal	O
PT	O
reception	O
(	O
Fig	O
.	O
6c	O
).	O

The	O
crosstalk	O
between	O
gametophytes	O
constitutes	O
a	O
specific	O
form	O
of	O
cell	O
–	O
cell	O
communication	O
.	O

Cellular	O
interactions	O
are	O
often	O
mediated	O
by	O
specific	O
binding	O
of	O
an	O
extracellular	O
ligand	O
to	O
a	O
receptor	O
,	O
triggering	O
downstream	O
signalling	O
cascades	O
in	O
the	O
recipient	O
cell	O
.	O

Most	O
extracellular	O
ligands	O
and	O
receptors	O
are	O
heavily	O
glycosylated48	O
,	O
which	O
influences	O
their	O
binding	O
specificities	O
and	O
conformation	O
,	O
such	O
that	O
already	O
the	O
absence	O
of	O
a	O
single	O
glycosylation	O
motif	O
can	O
reduce	O
or	O
abolish	O
a	O
receptor	O
'	O
s	O
function	O
and	O
ligand	O
-	O
binding	O
affinity4950	O
.	O

Our	O
results	O
suggest	O
that	O
both	O
protein	O
–	O
protein	O
interactions	O
and	O
recognition	O
mediated	O
by	O
carbohydrates	B-CD
may	O
be	O
crucial	O
factors	O
to	O
ensure	O
species	O
-	O
specific	O
PT	O
reception	O
.	O

Thus	O
,	O
divergent	O
evolution	O
of	O
receptor	O
–	O
ligand	O
pairs	O
,	O
as	O
well	O
as	O
of	O
the	O
factors	O
controlling	O
their	O
glycosylation	O
status	O
,	O
could	O
establish	O
new	O
species	O
barriers	O
.	O

Deciphering	O
the	O
molecular	O
basis	O
of	O
speciation	O
in	O
plants	B-OG
might	O
enable	O
us	O
to	O
overcome	O
existing	O
hybridization	O
barriers	O
,	O
which	O
could	O
eventually	O
be	O
of	O
great	O
agronomic	O
importance	O
.	O

Methods	O

Plant	B-OG
material	O
and	O
growth	O
conditions	O

The	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
were	O
part	O
of	O
the	O
Nordborg	O
collection	O
for	O
GWAS2740	O
.	O

Amplified	O
seed	O
stocks	O
were	O
kindly	O
donated	O
by	O
Ortrun	O
Mittelsten	O
Scheid	O
(	O
Gregor	O
Mendel	O
Institute	O
,	O
Vienna	O
).	O

After	O
stratification	O
(	O
2	O
days	O
at	O
4	O
°	O
C	O
),	O
the	O
seeds	O
were	O
allowed	O
to	O
germinate	O
for	O
6	O
days	O
on	O
MS	O
plates	O
(	O
22	O
°	O
C	O
,	O
16	O
h	O
light	O
,	O
MS	O
from	O
Carolina	O
Biological	O
Supply	O
).	O

Because	O
some	O
accessions	O
require	O
vernalization	O
,	O
all	O
the	O
seedlings	O
were	O
kept	O
in	O
a	O
vernalization	O
chamber	O
for	O
5	O
weeks	O
(	O
4	O
°	O
C	O
,	O
16	O
h	O
light	O
)	O
on	O
MS	O
plates	O
before	O
they	O
were	O
transferred	O
to	O
the	O
soil	O
(	O
ED73	O
,	O
Universalerde	O
).	O

The	O
accessions	O
were	O
grouped	O
into	O
early	O
-	O
(	O
four	O
incomplete	O
blocks	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
),	O
mid	O
-,	O
and	O
late	O
flowering	O
plants	B-OG
(	O
three	O
complete	O
blocks	O
A	O
,	O
B	O
,	O
C	O
each	O
)	O
according	O
to	O
the	O
flowering	O
time27	O
,	O
and	O
were	O
grown	O
in	O
a	O
greenhouse	O
chamber	O
(	O
22	O
°	O
C	O
,	O
16	O
h	O
light	O
)	O
in	O
an	O
incomplete	O
randomized	O
block	O
design	O
.	O

See	O
Supplementary	O
Table	O
1	O
for	O
the	O
assignment	O
of	O
accessions	O
to	O
the	O
blocks	O
.	O

A	O
.	O
lyrata13	O
,	O
A	B-OG
.	I-OG
halleri	I-OG
(	O
a	O
gift	O
from	O
Marcus	O
Koch	O
,	O
University	O
of	O
Heidelberg	O
),	O
and	O
A	B-OG
.	I-OG
arenosa	I-OG
(	O
donated	O
by	O
Matthias	O
Helling	O
,	O
University	O
of	O
Zurich	O
)	O
plants	B-OG
were	O
stratified	O
for	O
10	O
days	O
and	O
grown	O
in	O
the	O
same	O
greenhouse	O
chamber	O
.	O

Plants	B-OG
were	O
vernalized	O
to	O
induce	O
flowering	O
(	O
see	O
above	O
).	O

SALK	B-GP
-	O
lines	O
were	O
obtained	O
from	O
NASC	O
:	O
SALK_067271	O
(	O
At1g61790	O
,	O
aru	B-GP
-	I-GP
1	I-GP
),	O
SALK_137883C	O
(	O
At1g61780	O
),	O
SALK_052207C	O
and	O
SALK_026074C	O
(	O
At1g61795	O
),	O
SALK_104077	O
(	O
At1g61810	O
).	O

The	O
EMS	O
allele	O
aru	O
-	O
2	O
(	O
ref	O
.	O
34	O
)	O
was	O
a	O
gift	O
from	O
Peter	O
McCourt	O
(	O
University	O
of	O
Toronto	O
).	O

The	O
plants	B-OG
were	O
grown	O
as	O
described	O
before17	O
.	O

Crosses	O
and	O
aniline	B-CD
blue	I-CD
staining	O

Flowers	O
were	O
emasculated	O
and	O
the	O
pistils	O
were	O
pollinated	O
2	O
days	O
after	O
emasculation	O
(	O
dae	O
).	O

Siliques	O
were	O
collected	O
two	O
days	O
after	O
pollination	O
and	O
fixed	O
for	O
aniline	B-CD
blue	I-CD
staining	O
in	O
9	O
:	O
1	O
ethanol	O
:	O
acidic	O
acid	O
.	O

Aniline	B-CD
blue	I-CD
staining	O
was	O
performed	O
as	O
described	O
previously17	O
,	O
and	O
the	O
samples	O
were	O
analysed	O
with	O
a	O
Leica	O
DM6000B	O
microscope	O
(	O
Leica	O
Microsystems	O
).	O

For	O
GWAS	O
phenotyping	O
,	O
9	O
–	O
20	O
siliques	O
of	O
a	O
minimum	O
of	O
three	O
individuals	O
were	O
analysed	O
for	O
each	O
accession	O
(	O
Exceptions	O
:	O
Zdr	O
-	O
1	O
:	O
seven	O
siliques	O
,	O
Got	O
-	O
7	O
:	O
four	O
siliques	O
from	O
two	O
individuals	O
).	O

GWAS	O
analyses	O

Association	O
mapping	O
was	O
conducted	O
using	O
the	O
mean	O
values	O
of	O
the	O
proportions	O
of	O
ovules	O
with	O
PT	O
overgrowth	O
per	O
silique	O
(	O
OG	O
/	O
S	O
)	O
as	O
phenotypes	O
.	O

An	O
A	B-OG
.	I-OG
thaliana	I-OG
250	O
K	O
Affymetrix	O
SNP	O
genotyping	O
data	O
set27	O
was	O
downloaded	O
from	O
https	O
://	O
cynin	O
.	O
gmi	O
.	O
oeaw	O
.	O
ac	O
.	O
at	O
/	O
home	O
/	O
resources	O
/	O
atpolydb	O
.	O

GWAS	O
analyses	O
were	O
performed	O
using	O
a	O
compressed	O
mixed	O
linear	O
model	O
,	O
using	O
population	O
parameters	O
previously	O
determined5152	O
,	O
and	O
a	O
kinship	O
matrix	O
to	O
account	O
for	O
family	O
relatedness	O
,	O
in	O
the	O
R	O
package	O
GAPIT53	O
.	O

The	O
mixed	O
linear	O
models	O
were	O
run	O
with	O
and	O
without	O
principal	O
components	O
as	O
fixed	O
effects	O
to	O
correct	O
for	O
population	O
structure	O
.	O

Multiple	O
testing	O
was	O
controlled	O
using	O
the	O
Bonferroni	O
correction	O
and	O
false	O
-	O
discovery	O
rate54	O
.	O

GWAS	O
analyses	O
were	O
also	O
run	O
using	O
a	O
general	O
linear	O
model	O
in	O
the	O
web	O
-	O
based	O
interface	O
TASSEL3	O
.	O
0	O
(	O
ref	O
.	O
30	O
)	O
and	O
an	O
accelerated	O
mixed	O
model	O
with	O
Box	O
-	O
Cox	O
transformed	O
phenotypes	O
in	O
GWAPP55	O
.	O

MLMM	O
analysis	O
was	O
conducted	O
as	O
previously	O
described31	O
.	O

Constructs	O
for	O
stable	O
plant	B-OG
transformation	O

For	O
pMYB98	O
/	O
pFER	O
::	O
ARU	O
-	O
GFP	B-GP
the	O
complete	O
coding	O
sequence	O
of	O
ARU	O
without	O
the	O
stop	O
-	O
codon	O
was	O
amplified	O
using	O
gene	O
-	O
specific	O
primers	O
with	O
attB	B-GP
-	O
sites	O
for	O
Gateway	O
cloning	O
:	O
5	O
′-	O
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCGCTCAAATCAAAACTCGTC	O
-	O
3	O
′	O
and	O
5	O
′-	O
GGGGACCACTTTGTACAAGAAAGCTGGGTCACGCCAACTCGATGGCCAATACGGA	O
-	O
3	O
′.	O

We	O
introduced	O
the	O
PCR	O
-	O
fragment	O
into	O
pDONR207	O
,	O
and	O
subsequently	O
into	O
the	O
destination	O
vector	O
(	O
using	O
the	O
E	B-OG
.	I-OG
coli	I-OG
strain	I-OG
DH5	I-OG
-	I-OG
alpha	I-OG
F	O
'	O
Iq	O
from	O
New	O
England	O
Biolabs	O
).	O

The	O
destination	O
vector	O
was	O
a	O
modification	O
of	O
the	O
plant	B-OG
Gateway	O
vector	O
pMDC83	O
,	O
which	O
contains	O
the	O
2x35S	O
-	O
promotor	O
before	O
and	O
GFP	B-GP
after	O
the	O
Gateway	O
cassette56	O
.	O

For	O
our	O
purpose	O
,	O
we	O
exchanged	O
the	O
original	O
2x35S	O
-	O
promoter	O
with	O
the	O
promoters	O
of	O
FER13	B-GP
and	O
MYB98	B-GP
(	O
ref	O
.	O
35	O
)	O
to	O
express	O
ARU	O
specifically	O
in	O
synergid	O
cells	O
.	O

The	O
MYB98	B-GP
promoter	O
was	O
amplified	O
from	O
Col	O
-	O
0	O
with	O
primers	O
5	O
′-	O
TTTAAGCTTATACACTCATTGTCCTTCG	O
-	O
3	O
′	O
and	O
5	O
′-	O
CCCTCTAGATGTTTTGGAAAGGAGAAAAAA	O
-	O
3	O
′,	O
introducing	O
a	O
HindIII	B-GP
and	O
XbaI	B-GP
restriction	O
site	O
,	O
respectively	O
.	O

The	O
FER	B-GP
promoter	O
was	O
amplified	O
from	O
the	O
pFER	O
::	O
FER	O
-	O
GFP	B-GP
construct13	O
using	O
specific	O
primers	O
5	O
′-	O
TTTGGTAAGCTTCGATTTAAGCGAG	O
-	O
3	O
′	O
and	O
5	O
′-	O
TTTTCTAGACGATCAAGAGCACTTCTCCGGG	O
-	O
3	O
′,	O
which	O
introduce	O
HindIII	B-GP
and	O
XbaI	B-GP
restriction	O
sites	O
as	O
well	O
.	O

The	O
2x35S	O
-	O
promoter	O
was	O
cut	O
out	O
of	O
pMDC83	O
(	O
ref	O
.	O
56	O
)	O
with	O
HindIII	B-GP
/	O
XbaI	B-GP
(	O
New	O
England	O
Biolabs	O
),	O
and	O
the	O
PCR	O
fragments	O
were	O
introduced	O
into	O
the	O
dephosphorylated	O
vector	O
backbone	O
by	O
ligation	O
.	O

pDONR207	O
carrying	O
the	O
ARU	O
coding	O
sequence	O
and	O
the	O
modified	O
destination	O
vector	O
were	O
combined	O
in	O
an	O
LR	O
reaction	O
.	O

The	O
resulting	O
vectors	O
,	O
pFER	O
::	O
ARU	O
-	O
GFP	B-GP
and	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
were	O
transformed	O
into	O
Agrobacterium	B-OG
tumefaciens	I-OG
strain	I-OG
CV1310	I-OG
,	O
and	O
homozygous	O
aru	B-OG
-	I-OG
1	I-OG
plants	B-OG
were	O
transformed	O
by	O
the	O
floral	O
dip	O
method57	O
.	O

The	O
complementation	O
assays	O
were	O
conducted	O
in	O
the	O
T2	O
and	O
T3	O
generations	O
with	O
plants	B-OG
homozygous	O
for	O
the	O
complementation	O
construct	O
and	O
the	O
aru	B-GP
-	I-GP
1	I-GP
mutation	O
.	O

For	O
experiments	O
with	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
in	O
accessions	O
with	O
high	O
OG	O
/	O
S	O
,	O
the	O
construct	O
was	O
transformed	O
into	O
Fei	O
-	O
0	O
,	O
Kz	O
-	O
1	O
,	O
and	O
Kz	O
-	O
9	O
,	O
and	O
OG	O
/	O
S	O
was	O
assessed	O
in	O
heterozygous	O
plants	B-OG
(	O
T1	O
generation	O
).	O

For	O
the	O
constructs	O
with	O
ARU	O
under	O
the	O
control	O
of	O
its	O
endogenous	O
promoter	O
,	O
the	O
ARU	O
fragment	O
(	O
including	O
1	O
,	O
492	O
bp	O
of	O
upstream	O
,	O
ARU	O
CDS	O
,	O
and	O
865	O
bp	O
of	O
downstream	O
sequence	O
)	O
was	O
amplified	O
from	O
Col	O
-	O
0	O
and	O
Ga	B-GP
-	O
0	O
genomic	O
DNA	O
using	O
primers	O
5	O
′-	O
TTTTACTAGTAGGCAATTCCATCAGTTGTT	O
-	O
3	O
′	O
and	O
5	O
′-	O
TTTTGGTACCGTTACTTCACTTTCTCGAGT	O
-	O
3	O
′,	O
introducing	O
a	O
SpeI	B-GP
and	O
a	O
KpnI	B-GP
restriction	O
site	O
,	O
respectively	O
.	O

The	O
fragments	O
were	O
cloned	O
into	O
pMDC99	O
(	O
ref	O
.	O
56	O
)	O
using	O
restriction	O
-	O
ligation	O
and	O
transformed	O
into	O
aru	B-GP
mutants	O
(	O
Col	O
-	O
0	O
background	O
).	O

pARU	O
::	O
ARU	O
-	O
GFP	B-GP
was	O
cloned	O
by	O
amplification	O
of	O
a	O
part	O
of	O
ARU	O
coupled	O
to	O
GFP	B-GP
-	O
tNOS	B-GP
from	O
pFER	O
::	O
ARU	O
-	O
GFP	B-GP
with	O
primers	O
5	O
′-	O
GCGTTAACGCTTTACCTCA	O
-	O
3	O
′	O
(	O
including	O
the	O
natural	O
HpaI	B-GP
site	O
in	O
ARU	O
)	O
and	O
5	O
′-	O
TTTGGATCCAGTAACATAGATGACACCGCG	O
-	O
3	O
′	O
(	O
introducing	O
a	O
BamHI	B-GP
site	O
after	O
tNOS	B-GP
).	O

This	O
fragment	O
was	O
introduced	O
by	O
ligation	O
into	O
the	O
pMDC99	O
vector	O
carrying	O
the	O
genomic	O
fragment	O
of	O
ARU	O
(	O
Col	O
-	O
0	O
).	O

By	O
cutting	O
this	O
vector	O
with	O
HpaI	B-GP
and	O
BamHI	B-GP
,	O
part	O
of	O
the	O
ARU	O
coding	O
sequence	O
and	O
the	O
downstream	O
sequence	O
were	O
removed	O
and	O
replaced	O
with	O
the	O
respective	O
fragment	O
of	O
ARU	O
coupled	O
to	O
GFP	B-GP
-	O
tNOS	B-GP
,	O
resulting	O
in	O
pARU	O
(	O
1	O
,	O
492	O
bp	O
)::	O
ARU	O
-	O
GFP	B-GP
,	O
which	O
was	O
transformed	O
into	O
Col	O
-	O
0	O
.	O

pLRE	O
::	O
LRE	O
-	O
Citrine	B-CD
was	O
cloned	O
with	O
overlapping	O
PCR	O
fragments	O
that	O
were	O
assembled	O
using	O
the	O
Gibson	O
cloning	O
Master	O
Mix	O
from	O
New	O
England	O
Biolabs	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

The	O
779	O
-	O
bp	O
long	O
promoter	O
sequence	O
with	O
the	O
predicted	O
signal	O
peptide	O
from	O
LRE16	B-GP
was	O
amplified	O
with	O
primers	O
5	O
′-	O
GTGCTGCAAGGCGATTAAGTCCGTGTGCTCTGTCTGCATT	O
-	O
3	O
′	O
and	O
5	O
′-	O
CACAGCTCCACCTCCACCTCCAGGCCGGCCTATGGAACTTGAAGAGGAGAGAGA	O
-	O
3	O
′,	O
introducing	O
an	O
overhang	O
complementary	O
to	O
the	O
vector	O
pMDC99	O
(	O
ref	O
.	O
56	O
).	O
Citrine	B-CD
was	O
amplified	O
from	O
the	O
transgenic	O
line	O
CS36962	O
(	O
ordered	O
from	O
Arabidopsis	B-OG
Biological	O
Resource	O
Center	O
,	O
ABRC	O
),	O
using	O
gene	O
-	O
specific	O
primers	O
with	O
overhang	O
primers	O
for	O
the	O
signal	O
peptide	O
of	O
LRE	O
and	O
overhang	O
primers	O
for	O
the	O
GPI	O
-	O
anchor	O
of	O
LRE	O
:	O
5	O
′-	O
GGCCGGCCTGGAGGTGGAGGTGGAGCTGTGAGCAAGGGCGAGGAGCT	O
-	O
3	O
′	O
and	O
5	O
′-	O
GGCCCCAGCGGCCGCAGCAGCACCAGCAGGATCCTTGTACAGCTCGTCCA	O
-	O
3	O
′.	O

The	O
GPI	O
-	O
anchor	O
of	O
LRE	O
was	O
amplified	O
with	O
overhang	O
primers	O
for	O
pMDC99	O
:	O
5	O
′-	O
TGCTGGTGCTGCTGCGGCCGCTGGGGCCTCGGGTATGTCTTTTTGTTGTC	O
-	O
3	O
′	O
and	O
5	O
′-	O
AGCTCCACCGCGGTGGCGGCCGCTCTAGAAGTCTCGCTTCTTCTTTTGT	O
-	O
3	O
′.	O

pMDC99	O
was	O
amplified	O
with	O
overhang	O
primers	O
for	O
the	O
LRE	O
promoter	O
and	O
the	O
GPI	O
-	O
anchor	O
using	O
primers	O
:	O
5	O
′-	O
ACTTAATCGCCTTGCAGCAC	O
-	O
3	O
′	O
and	O
5	O
′-	O
TCTAGAGCGGCCGCCACCGCGG	O
-	O
3	O
′.	O

All	O
the	O
constructs	O
were	O
verified	O
by	O
sequencing	O
.	O
pFER	O
::	O
FER	O
-	O
GFP	B-GP
and	O
pNTA	O
::	O
NTA	O
-	O
GFP	B-GP
were	O
described	O
previously1317	O
.	O

ARU	B-GP
-	O
GFP	B-GP
subcellular	O
localization	O

We	O
used	O
the	O
pFER	O
::	O
ARU	O
-	O
GFP	B-GP
construct	O
for	O
microprojectile	O
bombardment	O
of	O
onion	O
epidermal	O
cells	O
and	O
co	O
-	O
localized	O
it	O
with	O
the	O
ER	O
-	O
marker	O
pER	O
-	O
rk	B-GP
(	O
mCherry	B-GP
)	O
obtained	O
from	O
ABRC58	O
.	O

Biolistic	O
bombardment	O
of	O
onion	O
epidermis	O
was	O
performed	O
as	O
described17	O
.	O

For	O
visualizing	O
GFP	B-GP
expression	O
in	O
the	O
synergids	O
,	O
flowers	O
were	O
emasculated	O
and	O
pistils	O
were	O
dissected	O
2	O
dae	O
to	O
ensure	O
the	O
development	O
of	O
mature	O
,	O
unfertilized	O
embryo	O
sacs	O
.	O

The	O
tissue	O
was	O
mounted	O
on	O
slides	O
in	O
1	O
M	O
glycine	B-CD
,	O
pH	O
9	O
.	O
6	O
.	O

Images	O
were	O
captured	O
on	O
Leica	O
Confocal	O
Microscopes	O
SP2	O
and	O
SP5	O
(	O
Leica	O
Microsystems	O
).	O

RNA	O
extraction	O
and	O
reverse	B-GP
transcriptase	I-GP
PCR	O

RNA	O
from	O
pistils	O
(	O
25	O
pistils	O
,	O
2	O
dae	O
),	O
inflorescences	O
,	O
and	O
ovules	O
(	O
extracted	O
from	O
30	O
pistils	O
,	O
2	O
dae	O
)	O
was	O
extracted	O
using	O
the	O
Trizol	O
reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

Pistil	O
and	O
inflorescence	O
cDNA	O
was	O
reverse	O
transcribed	O
using	O
Oligo	O
-	O
dT	O
primers	O
and	O
Superscript	O
II	O
reverse	B-GP
transcriptase	I-GP
from	O
Invitrogen	O
.	O

Ovule	O
cDNA	O
was	O
amplified	O
using	O
the	O
Ovation	O
Pico	O
SL	O
WTA	O
system	O
V2	O
from	O
Nugen	O
.	O

Reverse	B-GP
transcriptase	O
PCR	O
(	O
RT	O
–	O
PCR	O
)	O
of	O
ARU	O
was	O
done	O
using	O
primers	O
5	O
′-	O
CAATGTGCTTGTTCGAGTG	O
-	O
3	O
′	O
and	O
5	O
′-	O
ATCCAGTCTTCCAGTTATCCA	O
-	O
3	O
′.	O

For	O
quantitative	O
RT	O
and	O
digital	O
droplet	O
PCR	O
of	O
ARU	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
,	O
the	O
primers	O
5	O
′-	O
GTTTGTTACCAATGTGCTTGTTCG	O
-	O
3	O
′	O
and	O
5	O
′-	O
TCCATATCCAGTCTTCCAGTTATCC	O
-	O
3	O
′	O
were	O
used	O
and	O
expression	O
levels	O
were	O
normalized	O
against	O
UBIQUITIN	B-GP
C	I-GP
(	O
UBC9	B-GP
,	O
primers	O
:	O
5	O
′-	O
ATGCTTGGAGTCCTGCTTGG	O
-	O
3	O
′	O
and	O
5	O
′-	O
TGCCATTGAATTGAACCCTCTC	O
-	O
3	O
′).	O

For	O
digital	O
droplet	O
PCR	O
on	O
ovule	O
cDNA	O
,	O
the	O
UBC9	B-GP
assay	O
was	O
performed	O
as	O
an	O
EvaGreen	O
assay	O
,	O
whereas	O
ARU	B-GP
transcripts	O
were	O
detected	O
using	O
a	O
gene	O
-	O
specific	O
probe	O
(	O
5	O
′-	O
FAM	O
-	O
TACTGCACAAAGGTTG	O
-	O
MGB	O
-	O
3	O
′).	O

The	O
samples	O
were	O
analysed	O
with	O
the	O
QX200	O
system	O
from	O
Bio	O
-	O
Rad	O
.	O

Population	O
genetic	O
analyses	O
and	O
statistical	O
tests	O

Determination	O
of	O
ARU	O
gene	O
structure	O
and	O
UTRs	O
is	O
based	O
on	O
annotations	O
in	O
the	O
ARAMEMNON	O
database37	O
.	O

Sequences	O
of	O
ARU	O
and	O
1	O
,	O
000	O
bp	O
up	O
-	O
and	O
downstream	O
flanking	O
regions	O
were	O
downloaded	O
from	O
http	O
://	O
signal	O
.	O
salk	O
.	O
edu	O
/	O
atg1001	O
/	O
3	O
.	O
0	O
/	O
gebrowser	O
.	O
php	O
.	O

For	O
accessions	O
for	O
which	O
no	O
sequences	O
or	O
only	O
sequences	O
with	O
missing	O
data	O
were	O
available	O
,	O
we	O
amplified	O
the	O
whole	O
region	O
from	O
genomic	O
DNA	O
using	O
primers	O
5	O
′-	O
TTTGCTATAGGCACATGTGT	O
-	O
3	O
′	O
and	O
5	O
′-	O
GACCCGAAATTGTCAAATGA	O
-	O
3	O
′,	O
and	O
sequenced	O
the	O
resulting	O
PCR	O
products	O
of	O
Bay	O
-	O
0	O
,	O
Fab	O
-	O
2	O
,	O
Fab	O
-	O
4	O
,	O
Omo	O
-	O
2	O
-	O
3	O
,	O
Knox	O
-	O
10	O
,	O
Kz	O
-	O
1	O
,	O
LL	O
-	O
0	O
,	O
Lz	O
-	O
0	O
,	O
Mr	O
-	O
0	O
,	O
Mrk	O
-	O
0	O
,	O
Zdr	O
-	O
6	O
.	O

The	O
upstream	O
region	O
was	O
sequenced	O
additionally	O
from	O
Got	B-GP
-	O
7	O
,	O
Pu2	B-GP
-	O
23	O
,	O
and	O
Spr1	B-GP
-	O
6	O
(	O
primer	O
5	O
′-	O
TTTGCTATAGGCACATGTGT	O
-	O
3	O
′	O
and	O
5	O
′-	O
CGGAGGTTAGGAATTTTGAGA	O
-	O
3	O
′),	O
and	O
the	O
downstream	O
region	O
from	O
Got	B-GP
-	I-GP
7	I-GP
,	O
Pu2	B-GP
-	I-GP
23	I-GP
,	O
Kz	O
-	O
9	O
,	O
Mz	O
-	O
0	O
,	O
Pro	O
-	O
0	O
,	O
Van	O
-	O
0	O
,	O
and	O
Var2	O
-	O
1	O
(	O
primer	O
5	O
′-	O
CAATGTGCTTGTTCGAGTG	O
-	O
3	O
′	O
and	O
5	O
′-	O
GACCCGAAATTGTCAAATGA	O
-	O
3	O
′).	O

Tajima	O
'	O
s	O
D	O
and	O
Fay	O
and	O
Wu	O
'	O
s	O
H	O
were	O
calculated	O
separately	O
for	O
the	O
1	O
,	O
000	O
bp	O
up	O
-	O
and	O
downstream	O
as	O
well	O
as	O
the	O
coding	O
sequence	O
with	O
the	O
set	O
of	O
96	O
accessions40	O
using	O
DnaSP	O
5	O
.	O
10	O
(	O
ref	O
.	O
59	O
).	O

Several	O
accessions	O
that	O
had	O
big	O
indels	O
in	O
the	O
up	O
-	O
and	O
downstream	O
regions	O
were	O
left	O
out	O
from	O
the	O
analysis	O
(	O
Mr	O
-	O
0	O
,	O
Got	O
-	O
7	O
,	O
Pu2	O
-	O
23	O
,	O
and	O
Spr1	O
-	O
6	O
for	O
the	O
upstream	O
,	O
Var2	O
-	O
1	O
,	O
Nok	O
-	O
3	O
,	O
and	O
Got	O
-	O
7	O
for	O
the	O
downstream	O
region	O
).	O
A	B-OG
.	I-OG
lyrata	I-OG
was	O
used	O
as	O
outgroup	O
.	O
P	O
values	O
against	O
the	O
null	O
model	O
were	O
obtained	O
by	O
running	O
10	O
,	O
000	O
coalescent	O
simulations	O
and	O
for	O
Tajima	O
'	O
s	O
D	O
,	O
the	O
5	O
%	O
quantile	O
was	O
calculated	O
using	O
previously	O
published	O
estimates	O
for	O
D40	O
.	O

Additional	O
information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Müller	O
,	O
L	O
.	O

M	O
.	O
et	O
al	O
.	O

A	O
subunit	O
of	O
the	O
oligosaccharyltransferase	B-GP
complex	O
is	O
required	O
for	O
interspecific	O
gametophyte	O
recognition	O
in	O
Arabidopsis	B-OG
.	O
Nat	O
.	O

Commun	O
.	O
7	O
:	O
10826	O
doi	O
:	O
10	O
.	O
1038	O
/	O
ncomms10826	O
(	O
2016	O
).	O

Supplementary	O
Material	O

Supplementary	O
Information	O

Supplementary	O
Figures	O
1	O
-	O
10	O
,	O
Supplementary	O
Tables	O
1	O
-	O
2	O
and	O
Supplementary	O
References	O

Supplementary	O
Data	O
1	O

Correlation	O
of	O
SNPs	O
(	O
1000	O
bp	O
downstream	O
region	O
)	O
with	O
OG	O
/	O
S	O
phenotype	O
of	O
accessions	O

Author	O
contributions	O
U	O
.	O
G	O
.	O
initiated	O
and	O
supervised	O
the	O
project	O
.	O

L	O
.	O
M	O
.	O
M	O
.	O
and	O
U	O
.	O
G	O
.	O
conceived	O
the	O
experiments	O
and	O
wrote	O
the	O
manuscript	O
;	O
H	O
.	O
L	O
.	O
and	O
N	O
.	O
D	O
.	O
P	O
.	O
critically	O
read	O
and	O
commented	O
on	O
the	O
manuscript	O
;	O
L	O
.	O
M	O
.	O
M	O
.,	O
H	O
.	O
L	O
.,	O
N	O
.	O
D	O
.	O
P	O
.,	O
and	O
V	O
.	O
G	O
.	O
performed	O
the	O
experiments	O
.	O

All	O
the	O
authors	O
were	O
involved	O
in	O
data	O
analysis	O
and	O
interpretation	O
.	O

(	O
a	O
)	O
Diagram	O
of	O
the	O
female	O
gametophyte	O
with	O
its	O
cell	O
types	O
.	O

The	O
synergids	O
with	O
their	O
membrane	O
-	O
rich	O
filiform	O
apparatus	O
are	O
crucial	O
for	O
communication	O
with	O
the	O
arriving	O
PT	O
.	O

(	O
b	O
)	O
Ovule	O
with	O
normal	O
PT	O
reception	O
,	O
visualized	O
by	O
callose	O
staining	O
of	O
the	O
PT	O
cell	O
walls	O
with	O
Aniline	B-CD
Blue	I-CD
.	O

The	O
PT	O
stopped	O
its	O
growth	O
and	O
ruptured	O
.	O

Dashed	O
line	O
indicates	O
outline	O
of	O
the	O
ovule	O
.	O

(	O
c	O
)	O
Ovule	O
with	O
PT	O
overgrowth	O
.	O

The	O
PT	O
continues	O
growing	O
inside	O
the	O
female	O
gametophyte	O
.	O

Dashed	O
line	O
indicates	O
outline	O
of	O
the	O
ovule	O
.	O

(	O
d	O
)	O
Natural	O
variation	O
in	O
the	O
proportion	O
of	O
ovules	O
with	O
PT	O
overgrowth	O
per	O
silique	O
(	O
OG	O
/	O
S	O
)	O
in	O
86	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
that	O
were	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

OG	O
/	O
S	O
varies	O
between	O
10	O
%	O
and	O
more	O
than	O
90	O
%,	O
depending	O
on	O
the	O
genotype	O
of	O
the	O
mother	O
.	O

(	O
e	O
)	O
A	O
silique	O
of	O
Lz	O
-	O
0	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Most	O
of	O
the	O
ovules	O
show	O
normal	O
PT	O
reception	O
.	O

Ovules	O
with	O
PT	O
overgrowth	O
are	O
marked	O
with	O
an	O
arrowhead	O
.	O

(	O
f	O
)	O
A	O
silique	O
of	O
Kz	O
-	O
9	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Most	O
of	O
the	O
ovules	O
display	O
PT	O
overgrowth	O
.	O

Asterisks	O
mark	O
ovules	O
with	O
normal	O
PT	O
reception	O
.	O

Per	O
accession	O
and	O
per	O
pollen	O
donor	O
,	O
5	O
–	O
10	O
siliques	O
were	O
analysed	O
.	O

Scale	O
bars	O
,	O
50	O
μm	O
(	O
b	O
and	O
c	O
),	O
250	O
μm	O
(	O
e	O
and	O
f	O
).	O

(	O
a	O
)	O
A	O
subset	O
of	O
A	B-OG
.	I-OG
thaliana	I-OG
accessions	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Per	O
accession	O
,	O
four	O
to	O
eight	O
siliques	O
were	O
analysed	O
.	O

Box	O
plots	O
are	O
ordered	O
by	O
the	O
mean	O
OG	O
/	O
S	O
value	O
and	O
colour	O
-	O
coded	O
to	O
facilitate	O
comparison	O
with	O
b	O
and	O
c	O
.	O

(	O
b	O
,	O
c	O
)	O
The	O
same	O
subset	O
pollinated	O
with	O
pollen	O
from	O
A	B-OG
.	I-OG
halleri	I-OG
(	O
b	O
)	O
and	O
A	B-OG
.	I-OG
arenosa	I-OG
(	O
c	O
).	O

The	O
accessions	O
show	O
comparable	O
OG	O
/	O
S	O
with	O
all	O
three	O
interspecific	O
pollen	O
donors	O
.	O

(	O
a	O
)	O
Manhattan	O
plot	O
showing	O
a	O
peak	O
on	O
chromosome	O
1	O
(	O
grey	O
box	O
)	O
with	O
its	O
highest	O
correlated	O
SNP	O
showing	O
significance	O
at	O
P	O
<	O
0	O
.	O
1	O
(	O
after	O
Bonferroni	O
correction	O
;	O
dotted	O
line	O
).	O

The	O
peak	O
corresponds	O
to	O
a	O
28	O
kb	O
region	O
spanning	O
position	O
22	O
,	O
842	O
,	O
689	O
–	O
22	O
,	O
814	O
,	O
316	O
(	O
magnified	O
in	O
the	O
second	O
panel	O
).	O

The	O
eight	O
SNPs	O
that	O
were	O
identified	O
to	O
be	O
among	O
the	O
20	O
most	O
highly	O
correlated	O
ones	O
in	O
the	O
GWAS	O
are	O
annotated	O
with	O
their	O
PERL	O
identifiers	O
.	O

(	O
b	O
)	O
Genes	O
and	O
pseudogenes	O
(	O
grey	O
)	O
in	O
the	O
28	O
kb	O
region	O
.	O

Genes	O
expressed	O
in	O
synergids	O
are	O
marked	O
in	O
red	O
,	O
genes	O
without	O
available	O
expression	O
data	O
are	O
in	O
orange32	O
.	O

(	O
a	O
)	O
Genomic	O
region	O
of	O
ARTUMES	O
(	O
At1g61790	O
)	O
with	O
the	O
two	O
mutant	O
alleles	O
aru	O
-	O
1	O
and	O
aru	O
-	O
2	O
,	O
and	O
the	O
surrounding	O
polymorphisms	O
identified	O
by	O
GWAS	O
.	O

(	O
b	O
)	O
PT	O
overgrowth	O
of	O
Col	O
-	O
0	O
wild	O
-	O
type	O
(	O
n	O
=	O
28	O
siliques	O
)	O
and	O
aru	B-GP
mutant	O
plants	B-OG
in	O
interspecific	O
crosses	O
.	O

Both	O
aru	B-GP
mutant	O
alleles	O
show	O
significantly	O
higher	O
proportions	O
of	O
ovules	O
with	O
PT	O
overgrowth	O
per	O
silique	O
(	O
OG	O
/	O
S	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
***	O
P	O
<	O
0	O
.	O
001	O
;	O
n	O
=	O
18	O
and	O
20	O
siliques	O
,	O
respectively	O
).	O

(	O
c	O
)	O
PT	O
overgrowth	O
of	O
aru	B-GP
-	I-GP
1	I-GP
in	O
inter	O
-	O
and	O
intraspecific	O
crosses	O
.	O

The	O
mutant	O
is	O
impaired	O
in	O
interspecific	O
crosses	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
(	O
n	O
=	O
9	O
siliques	O
),	O
but	O
not	O
in	O
intraspecific	O
crosses	O
with	O
Col	O
-	O
0	O
(	O
n	O
=	O
6	O
)	O
or	O
self	O
pollen	O
(	O
n	O
=	O
9	O
).	O

(	O
d	O
)	O
A	O
silique	O
of	O
Col	O
-	O
0	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Ovules	O
with	O
normal	O
PT	O
reception	O
(	O
marked	O
with	O
asterisks	O
)	O
and	O
with	O
PT	O
overgrowth	O
are	O
visible	O
.	O

(	O
e	O
,	O
f	O
)	O
aru	O
-	O
1	O
and	O
aru	O
-	O
2	O
siliques	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
.	O

Both	O
mutant	O
alleles	O
show	O
high	O
proportions	O
of	O
ovules	O
with	O
PT	O
overgrowth	O
in	O
interspecific	O
crosses	O
.	O

Ovules	O
with	O
normal	O
PT	O
reception	O
are	O
marked	O
with	O
asterisks	O
.	O

(	O
g	O
)	O
A	O
silique	O
of	O
aru	O
-	O
1	O
pollinated	O
with	O
intraspecific	O
Col	O
-	O
0	O
pollen	O
.	O

All	O
ovules	O
display	O
normal	O
PT	O
reception	O
.	O

Scale	O
bars	O
,	O
250	O
μm	O
.	O

(	O
a	O
)	O
An	O
ovule	O
expressing	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
in	O
the	O
synergids	O
.	O

Inset	O
:	O
ARU	B-GP
-	O
GFP	B-GP
localizes	O
to	O
perinuclear	O
structures	O
resembling	O
the	O
ER	O
.	O

(	O
b	O
)	O
PT	O
overgrowth	O
in	O
interspecific	O
crosses	O
using	O
aru	B-GP
-	O
1	O
(	O
n	O
=	O
22	O
siliques	O
),	O
Col	O
-	O
0	O
(	O
n	O
=	O
28	O
),	O
and	O
three	O
independent	O
transformant	O
lines	O
of	O
pMYB98	O
::	O
ARU	O
-	O
GFP	B-GP
in	O
the	O
aru	B-GP
-	I-GP
1	I-GP
background	O
as	O
mother	O
plants	B-OG
and	O
A	B-OG
.	I-OG
lyrata	I-OG
as	O
pollen	O
donor	O
.	O

All	O
the	O
three	O
transformant	O
lines	O
complement	O
the	O
mutant	O
phenotype	O
(	O
n	O
=	O
16	O
,	O
22	O
,	O
and	O
27	O
siliques	O
,	O
respectively	O
);	O
line	O
2	O
shows	O
even	O
lower	O
OG	O
/	O
S	O
than	O
the	O
wild	O
type	O
.	O

Significance	O
levels	O
in	O
comparison	O
with	O
Col	O
-	O
0	O
(	O
Student	O
'	O
s	O
t	O
-	O
test	O
***	O
P	O
<	O
0	O
.	O
001	O
).	O

Scale	O
bar	O
,	O
50	O
μm	O
.	O

(	O
a	O
)	O
In	O
wild	O
-	O
type	O
Col	O
-	O
0	O
synergid	O
cells	O
,	O
a	O
receptor	O
is	O
glycosylated	O
by	O
ARU	O
and	O
can	O
bind	O
putative	O
signals	O
from	O
the	O
A	B-OG
.	I-OG
thaliana	I-OG
PT	O
with	O
its	O
carbohydrate	B-CD
moieties	O
and	O
via	O
protein	O
–	O
protein	O
interactions	O
.	O

(	O
b	O
)	O
A	B-OG
.	I-OG
lyrata	I-OG
PT	O
signals	O
might	O
not	O
be	O
properly	O
recognized	O
by	O
protein	O
–	O
protein	O
contacts	O
but	O
partially	O
by	O
carbohydrate	B-CD
interactions	O
,	O
thus	O
leading	O
to	O
PT	O
overgrowth	O
in	O
some	O
ovules	O
and	O
normal	O
PT	O
reception	O
in	O
others	O
.	O

(	O
c	O
)	O
In	O
aru	B-GP
mutants	O
,	O
the	O
synergid	O
receptor	O
is	O
un	O
-	O
or	O
misglycosylated	O
;	O
nevertheless	O
,	O
A	B-OG
.	I-OG
thaliana	I-OG
PTs	O
can	O
be	O
efficiently	O
received	O
through	O
protein	O
–	O
protein	O
interactions	O
of	O
the	O
receptor	O
with	O
the	O
PT	O
signals	O
.	O

(	O
d	O
)	O
In	O
aru	B-GP
mutants	O
pollinated	O
with	O
A	B-OG
.	I-OG
lyrata	I-OG
pollen	O
,	O
PT	O
reception	O
is	O
neither	O
possible	O
by	O
carbohydrate	B-CD
,	O
nor	O
by	O
protein	O
–	O
protein	O
interactions	O
.	O

Therefore	O
,	O
almost	O
all	O
ovules	O
show	O
PT	O
overgrowth	O
.	O

The	O
CULTEX	O
RFS	O
:	O
A	O
Comprehensive	O
Technical	O
Approach	O
for	O
the	O
In	O
Vitro	O
Exposure	O
of	O
Airway	O
Epithelial	O
Cells	O
to	O
the	O
Particulate	O
Matter	O
at	O
the	O
Air	O
-	O
Liquid	O
Interface	O

Academic	O
Editor	O
:	O
Abderrahim	O
Nemmar	O

The	O
EU	O
Regulation	O
on	O
Registration	O
,	O
Evaluation	O
,	O
Authorization	O
and	O
Restriction	O
of	O
Chemicals	O
(	O
REACH	O
)	O
demands	O
the	O
implementation	O
of	O
alternative	O
methods	O
for	O
analyzing	O
the	O
hazardous	O
effects	O
of	O
chemicals	O
including	O
particulate	O
formulations	O
.	O

In	O
the	O
field	O
of	O
inhalation	O
toxicology	O
,	O
a	O
variety	O
of	O
in	O
vitro	O
models	O
have	O
been	O
developed	O
for	O
such	O
studies	O
.	O

To	O
simulate	O
the	O
in	O
vivo	O
situation	O
,	O
an	O
adequate	O
exposure	O
device	O
is	O
necessary	O
for	O
the	O
direct	O
exposure	O
of	O
cultivated	O
lung	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
(	O
ALI	O
).	O

The	O
CULTEX	O
RFS	O
fulfills	O
these	O
requirements	O
and	O
has	O
been	O
optimized	O
for	O
the	O
exposure	O
of	O
cells	O
to	O
atomized	O
suspensions	O
,	O
gases	O
,	O
and	O
volatile	O
compounds	O
as	O
well	O
as	O
micro	O
-	O
and	O
nanosized	O
particles	O
.	O

This	O
study	O
provides	O
information	O
on	O
the	O
construction	O
and	O
functional	O
aspects	O
of	O
the	O
exposure	O
device	O
.	O

By	O
using	O
the	O
Computational	O
Fluid	O
Dynamics	O
(	O
CFD	O
)	O
analysis	O
,	O
the	O
technical	O
design	O
was	O
optimized	O
to	O
realize	O
a	O
stable	O
,	O
reproducible	O
,	O
and	O
homogeneous	O
deposition	O
of	O
particles	O
.	O

The	O
efficiency	O
of	O
the	O
exposure	O
procedure	O
is	O
demonstrated	O
by	O
exposing	O
A549	O
cells	O
dose	O
dependently	O
to	O
lactose	O
monohydrate	O
,	O
copper	O
(	O
II	O
)	O
sulfate	O
,	O
copper	O
(	O
II	O
)	O
oxide	O
,	O
and	O
micro	O
-	O
and	O
nanoparticles	O
.	O

All	O
copper	O
compounds	O
induced	O
cytotoxic	O
effects	O
,	O
most	O
pronounced	O
for	O
soluble	O
copper	O
(	O
II	O
)	O
sulfate	O
.	O

Micro	O
-	O
and	O
nanosized	O
copper	O
(	O
II	O
)	O
oxide	O
also	O
showed	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
the	O
cell	O
viability	O
,	O
whereby	O
the	O
nanosized	O
particles	O
decreased	O
the	O
metabolic	O
activity	O
of	O
the	O
cells	O
more	O
severely	O
.	O

1	O
.	O

Introduction	O

Provoked	O
by	O
public	O
pressure	O
and	O
triggered	O
by	O
an	O
increasing	O
number	O
of	O
lethal	O
lung	B-DS
diseases	I-DS
over	O
the	O
last	O
few	O
decades	O
[	O
1	O
,	O
2	O
],	O
more	O
and	O
more	O
studies	O
in	O
the	O
field	O
of	O
inhalation	O
toxicology	O
now	O
concentrate	O
on	O
the	O
understanding	O
of	O
particle	O
-	O
lung	O
interactions	O
.	O

Investigations	O
of	O
the	O
toxicological	O
effects	O
of	O
inhalable	O
substances	O
on	O
the	O
respiratory	O
tract	O
mainly	O
focus	O
on	O
results	O
from	O
animal	B-OG
experiments	O
based	O
on	O
the	O
OECD	O
guideline	O
403	O
on	O
acute	O
inhalation	O
toxicology	O
.	O

So	O
far	O
,	O
only	O
a	O
few	O
in	O
vitro	O
alternatives	O
to	O
animal	B-OG
inhalation	O
tests	O
for	O
toxicology	O
have	O
been	O
described	O
[	O
3	O
,	O
4	O
].	O

However	O
,	O
none	O
of	O
them	O
is	O
validated	O
or	O
officially	O
accepted	O
by	O
the	O
authorities	O
.	O

Recent	O
changes	O
in	O
the	O
EU	O
chemical	O
policy	O
,	O
namely	O
,	O
the	O
new	O
Registration	O
,	O
Evaluation	O
,	O
Authorization	O
and	O
Restriction	O
of	O
Chemicals	O
directive	O
(	O
REACH	O
;	O
EC	O
no	O
.	O
1907	O
/	O
2006	O
),	O
and	O
complaints	O
about	O
the	O
immense	O
number	O
of	O
animals	B-OG
needed	O
to	O
fulfill	O
the	O
requirements	O
of	O
REACH	O
[	O
6	O
]	O
demand	O
the	O
development	O
and	O
implementation	O
of	O
novel	O
in	O
vitro	O
technologies	O
—	O
also	O
in	O
the	O
field	O
of	O
inhalation	O
toxicology	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
effects	O
of	O
relevant	O
particulate	O
substances	O
,	O
only	O
classic	O
methodological	O
approaches	O
are	O
available	O
using	O
either	O
suspended	O
or	O
dissolved	O
particles	O
under	O
submerged	O
conditions	O
in	O
cell	O
culture	O
experiments	O
[	O
4	O
,	O
7	O
].	O

The	O
main	O
concerns	O
about	O
these	O
test	O
methods	O
are	O
(	O
1	O
)	O
the	O
unrealistic	O
behavior	O
of	O
suspended	O
particles	O
and	O
(	O
2	O
)	O
culture	O
and	O
exposure	O
conditions	O
which	O
do	O
not	O
reflect	O
the	O
situation	O
in	O
the	O
lung	O
.	O

The	O
fact	O
of	O
losing	O
nanosized	O
particles	O
by	O
agglomeration	O
or	O
the	O
uncontrollable	O
behavior	O
of	O
nanosized	O
particles	O
in	O
suspensions	O
may	O
lead	O
to	O
uncertainties	O
in	O
the	O
results	O
[	O
8	O
].	O

Another	O
major	O
point	O
of	O
the	O
discussion	O
is	O
the	O
transferability	O
of	O
data	O
from	O
animal	B-OG
experiments	O
to	O
the	O
human	B-OG
organism	O
due	O
to	O
species	O
-	O
specific	O
reactions	O
and	O
the	O
generation	O
of	O
false	O
positive	O
or	O
negative	O
results	O
[	O
9	O
].	O

One	O
of	O
the	O
“	O
first	O
”	O
approaches	O
for	O
direct	O
cell	O
exposure	O
came	O
from	O
Tarkington	O
et	O
al	O
.	O
[	O
10	O
]	O
who	O
conducted	O
the	O
atmosphere	O
via	O
a	O
vertical	O
stream	O
directly	O
over	O
the	O
cultivated	O
test	O
organisms	O
.	O

The	O
system	O
is	O
also	O
based	O
on	O
a	O
biphasic	O
cell	O
culture	O
exposed	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
[	O
11	O
].	O

The	O
basic	O
idea	O
is	O
to	O
mimic	O
the	O
inhalation	O
cycle	O
in	O
vitro	O
by	O
taking	O
into	O
consideration	O
the	O
most	O
important	O
biological	O
and	O
technical	O
aspects	O
.	O

The	O
selection	O
of	O
an	O
appropriate	O
cell	O
model	O
and	O
its	O
cultivation	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
are	O
the	O
basic	O
prerequisites	O
for	O
such	O
a	O
system	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
technical	O
implementation	O
should	O
guarantee	O
the	O
direct	O
contact	O
of	O
the	O
test	O
substances	O
with	O
the	O
cells	O
,	O
as	O
well	O
as	O
the	O
homogeneous	O
exposure	O
of	O
the	O
entire	O
cell	O
layer	O
without	O
interfering	O
with	O
the	O
cell	O
viability	O
.	O

These	O
theoretical	O
concepts	O
led	O
to	O
the	O
development	O
of	O
the	O
CULTEX	O
exposure	O
module	O
in	O
1999	O
by	O
Aufderheide	O
and	O
Mohr	O
[	O
12	O
]	O
for	O
the	O
exposure	O
of	O
cultivated	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
.	O

The	O
test	O
aerosol	O
is	O
conducted	O
directly	O
over	O
the	O
cells	O
through	O
specially	O
designed	O
inlet	O
nozzles	O
.	O

This	O
setup	O
guarantees	O
a	O
close	O
contact	O
between	O
the	O
test	O
aerosol	O
and	O
the	O
cells	O
without	O
any	O
interference	O
of	O
the	O
cell	O
culture	O
media	O
.	O

The	O
first	O
CULTEX	O
exposure	O
devices	O
were	O
used	O
for	O
the	O
exposure	O
to	O
complex	O
mixtures	O
like	O
cigarette	O
smoke	O
and	O
gases	O
,	O
or	O
in	O
a	O
modified	O
version	O
to	O
analyze	O
the	O
mutagenic	O
potency	O
of	O
airborne	O
materials	O
in	O
the	O
AMES	O
assay	O
[	O
13	O
].	O

Nowadays	O
,	O
a	O
large	O
number	O
of	O
other	O
air	O
-	O
liquid	O
interface	O
exposure	O
systems	O
are	O
available	O
,	O
ranging	O
from	O
the	O
exposure	O
of	O
two	O
-	O
cell	O
culture	O
plates	O
(	O
6	O
-	O
well	O
),	O
like	O
the	O
ALICE	O
exposure	O
device	O
[	O
14	O
]	O
or	O
a	O
flow	O
-	O
through	O
system	O
[	O
15	O
]	O
to	O
a	O
radial	O
multiwell	O
module	O
[	O
16	O
].	O

All	O
of	O
these	O
modules	O
have	O
certain	O
advantages	O
and	O
disadvantages	O
and	O
may	O
therefore	O
only	O
be	O
used	O
for	O
a	O
limited	O
test	O
assembly	O
.	O

The	O
results	O
obtained	O
from	O
exposure	O
studies	O
with	O
the	O
CULTEX	O
RFS	O
module	O
have	O
shown	O
that	O
the	O
interactions	O
between	O
cells	O
and	O
particles	O
are	O
closely	O
linked	O
to	O
the	O
physical	O
and	O
chemical	O
properties	O
of	O
these	O
compounds	O
and	O
have	O
advanced	O
the	O
redesign	O
of	O
the	O
handmade	O
CULTEX	O
glass	O
modules	O
.	O

The	O
CULTEX	O
Radial	O
Flow	O
System	O
(	O
RFS	O
)	O
presented	O
here	O
overcomes	O
the	O
limitations	O
of	O
its	O
predecessor	O
model	O
and	O
includes	O
all	O
features	O
that	O
are	O
required	O
to	O
realize	O
the	O
exposure	O
of	O
cultivated	O
cells	O
to	O
airborne	O
particles	O
under	O
realistic	O
conditions	O
.	O

2	O
.	O

Material	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Technical	O
Description	O

The	O
CULTEX	O
RFS	O
module	O
was	O
designed	O
for	O
exposing	O
adherent	O
growing	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
and	O
is	O
a	O
precision	O
instrument	O
,	O
characterized	O
by	O
a	O
modular	O
construction	O
(	O
Figure	O
1	O
).	O

The	O
basic	O
CULTEX	O
RFS	O
consists	O
of	O
the	O
following	O
parts	O
:	O
(	O
1	O
)	O
the	O
inlet	O
adapter	O
which	O
connects	O
the	O
aerosol	O
generation	O
and	O
aerosol	O
guiding	O
module	O
(	O
Figure	O
1	O
),	O
(	O
2	O
)	O
the	O
aerosol	O
guiding	O
module	O
to	O
conduct	O
and	O
distribute	O
the	O
particles	O
to	O
be	O
deposited	O
on	O
the	O
cell	O
culture	O
inserts	O
in	O
the	O
sampling	O
module	O
(	O
Figures	O
2	O
(	O
a	O
)	O
and	O
2	O
(	O
b	O
)),	O
and	O
(	O
3	O
)	O
the	O
sampling	O
and	O
socket	O
module	O
with	O
three	O
exposure	O
chambers	O
where	O
the	O
cell	O
culture	O
inserts	O
or	O
Petri	O
dishes	O
are	O
located	O
(	O
Figures	O
1	O
and	O
2	O
(	O
c	O
)).	O

The	O
aerosol	O
guiding	O
module	O
as	O
well	O
as	O
the	O
sampling	O
module	O
can	O
be	O
heated	O
to	O
the	O
appropriate	O
temperature	O
(	O
e	O
.	O
g	O
.,	O
37	O
°	O
C	O
)	O
by	O
the	O
connection	O
to	O
an	O
external	O
water	O
bath	O
.	O

The	O
socket	O
module	O
(	O
4	O
)	O
guides	O
the	O
sampling	O
module	O
on	O
the	O
slide	O
rails	O
of	O
the	O
locking	O
device	O
(	O
5	O
)	O
and	O
serves	O
as	O
a	O
spacer	O
for	O
integrating	O
additional	O
functions	O
,	O
like	O
a	O
control	O
unit	O
for	O
electrostatic	O
precipitation	O
.	O

In	O
addition	O
to	O
the	O
above	O
-	O
mentioned	O
modular	O
components	O
,	O
the	O
system	O
can	O
also	O
be	O
equipped	O
with	O
special	O
adapters	O
to	O
enable	O
the	O
use	O
of	O
commercial	O
inserts	O
from	O
different	O
suppliers	O
and	O
of	O
different	O
sizes	O
or	O
for	O
Petri	O
dishes	O
.	O

The	O
aerosol	O
emission	O
ducts	O
are	O
adapted	O
correspondingly	O
.	O

To	O
increase	O
the	O
particle	O
deposition	O
efficiency	O
,	O
notably	O
for	O
nanosized	O
particles	O
,	O
the	O
electrical	O
deposition	O
device	O
(	O
Cultex	O
EDD	O
)	O
can	O
further	O
be	O
integrated	O
into	O
the	O
technical	O
setup	O
(	O
Figure	O
3	O
).	O

2	O
.	O
2	O
.	O

Test	O
Materials	O

Dry	O
powder	O
atmospheres	O
were	O
prepared	O
from	O
the	O
substances	O
listed	O
in	O
Tables	O
1	O
and	O
2	O
and	O
used	O
for	O
the	O
exposure	O
studies	O
.	O

The	O
substances	O
were	O
pressed	O
into	O
powder	O
cakes	O
by	O
the	O
CULTEX	O
HyP	O
-	O
Hydraulic	O
Press	O
(	O
Cultex	O
Laboratories	O
GmbH	O
,	O
Germany	O
),	O
which	O
allows	O
electronically	O
controlled	O
compression	O
of	O
a	O
high	O
variety	O
of	O
powders	O
by	O
a	O
pneumo	O
-	O
hydraulic	O
cylinder	O
.	O

2	O
.	O
3	O
.	O

Aerosol	O
Generation	O

The	O
aerosol	O
was	O
generated	O
from	O
the	O
prepared	O
powder	O
cakes	O
with	O
the	O
CULTEX	O
DG	O
(	O
Dust	O
Generator	O
)	O
(	O
Cultex	O
Laboratories	O
GmbH	O
)	O
according	O
to	O
Wright	O
[	O
5	O
]	O
(	O
Figure	O
4	O
).	O

The	O
fully	O
computerized	O
generator	O
is	O
able	O
to	O
provide	O
uniform	O
airborne	O
concentrations	O
of	O
dust	O
over	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
highly	O
compressed	O
substances	O
are	O
scraped	O
off	O
by	O
a	O
rotating	O
scraper	O
under	O
standardized	O
controlled	O
conditions	O
(	O
feed	O
rate	O
0	O
.	O
24	O
to	O
20	O
mm	O
/	O
h	O
,	O
rotation	O
1	O
to	O
800	O
revs	O
/	O
h	O
).	O

The	O
total	O
exposure	O
time	O
is	O
varied	O
from	O
15	O
,	O
30	O
,	O
to	O
60	O
minutes	O
to	O
generate	O
different	O
particle	O
concentrations	O
on	O
the	O
cell	O
culture	O
membranes	O
without	O
changing	O
the	O
aerosol	O
generation	O
or	O
any	O
other	O
physical	O
or	O
chemical	O
parameter	O
.	O

The	O
generated	O
particles	O
were	O
transported	O
to	O
the	O
integrated	O
elutriator	O
by	O
a	O
constant	O
air	O
stream	O
(	O
8	O
L	O
/	O
min	O
).	O

The	O
elutriator	O
retains	O
undesired	O
large	O
particles	O
(>	O
approx	O
.	O

8	O
μm	O
)	O
and	O
serves	O
as	O
a	O
reservoir	O
for	O
a	O
uniform	O
aerosol	O
which	O
is	O
finally	O
drawn	O
through	O
the	O
CULTEX	O
RFS	O
.	O

The	O
complete	O
experimental	O
setup	O
is	O
shown	O
in	O
Figure	O
5	O
consisting	O
of	O
the	O
particle	O
generation	O
unit	O
,	O
two	O
CULTEX	O
RFS	O
devices	O
,	O
and	O
two	O
pumps	O
for	O
the	O
medium	O
supply	O
.	O

The	O
cells	O
are	O
exposed	O
to	O
the	O
test	O
aerosol	O
and	O
clean	O
air	O
(	O
process	O
control	O
)	O
in	O
parallel	O
,	O
in	O
order	O
to	O
preclude	O
process	O
-	O
related	O
reactions	O
which	O
might	O
interfere	O
with	O
the	O
substance	O
-	O
specific	O
effects	O
.	O

2	O
.	O
4	O
.	O

CFD	O
Analysis	O

The	O
aerosol	O
flow	O
within	O
the	O
experimental	O
setup	O
was	O
simulated	O
and	O
optimized	O
by	O
means	O
of	O
Computational	O
Fluid	O
Dynamics	O
(	O
CFD	O
)	O
software	O
(	O
ANSYS	O
CFX	O
,	O
ANSYS	O
Incorporated	O
).	O

2	O
.	O
5	O
.	O

Particle	O
Number	O
and	O
Mass	O
Distribution	O

The	O
determination	O
of	O
the	O
particle	O
number	O
and	O
mass	O
distribution	O
was	O
conducted	O
with	O
an	O
Aerodynamic	O
Particle	O
Sizer	O
APS	O
(	O
3321	O
/	O
TSI	O
Incorporated	O
)	O
in	O
the	O
size	O
range	O
of	O
0	O
.	O
5	O
to	O
20	O
μm	O
.	O

By	O
accelerating	O
particles	O
through	O
a	O
nozzle	O
and	O
optical	O
time	O
-	O
of	O
-	O
flight	O
measurement	O
of	O
the	O
particles	O
,	O
they	O
are	O
classified	O
into	O
51	O
logarithmic	O
size	O
ranges	O
between	O
0	O
.	O
523	O
and	O
20	O
μm	O
.	O

2	O
.	O
6	O
.	O

Particle	O
Deposition	O

The	O
deposition	O
of	O
the	O
particles	O
was	O
analyzed	O
by	O
gravimetric	O
methods	O
,	O
using	O
the	O
precision	O
balance	O
(	O
SE2	O
-	O
F	O
filter	O
ultra	O
-	O
microbalance	O
,	O
Sartorius	O
).	O

In	O
preliminary	O
tests	O
,	O
the	O
particle	O
mass	O
concentration	O
within	O
the	O
exposure	O
system	O
was	O
analyzed	O
at	O
three	O
sampling	O
points	O
(	O
sampling	O
point	O
1	O
:	O
200	O
seconds	O
,	O
sampling	O
point	O
2	O
+	O
3	O
:	O
60	O
minutes	O
)	O
to	O
determine	O
appropriate	O
exposure	O
times	O
for	O
the	O
corresponding	O
test	O
particles	O
(	O
Figure	O
6	O
)	O
and	O
to	O
check	O
for	O
uniform	O
particle	O
distribution	O
.	O

The	O
first	O
sampling	O
point	O
was	O
located	O
directly	O
after	O
the	O
elutriator	O
,	O
the	O
second	O
at	O
the	O
outlet	O
port	O
of	O
the	O
aerosol	O
emission	O
duct	O
to	O
estimate	O
the	O
particle	O
mass	O
entering	O
the	O
exposure	O
chamber	O
,	O
and	O
the	O
third	O
at	O
the	O
insert	O
membrane	O
surface	O
to	O
measure	O
the	O
particle	O
mass	O
deposited	O
on	O
the	O
cultivated	O
cells	O
.	O

The	O
particle	O
mass	O
was	O
determined	O
by	O
collecting	O
the	O
particles	O
on	O
filter	O
pads	O
(	O
glass	O
fiber	O
filter	O
/	O
GF	O
-	O
A	O
/	O
Macherey	O
-	O
Nagel	O
),	O
which	O
were	O
weighed	O
before	O
and	O
after	O
the	O
exposure	O
over	O
a	O
constant	O
period	O
(	O
15	O
minutes	O
).	O

This	O
approach	O
allows	O
the	O
analysis	O
of	O
the	O
deposition	O
efficiency	O
of	O
each	O
test	O
atmosphere	O
within	O
the	O
exposure	O
module	O
.	O

Under	O
these	O
experimental	O
conditions	O
,	O
the	O
deposited	O
particle	O
numbers	O
on	O
the	O
cell	O
cultures	O
can	O
only	O
be	O
calculated	O
by	O
taking	O
into	O
consideration	O
the	O
measurements	O
of	O
the	O
Aerodynamic	O
Particle	O
Sizer	O
APS	O
(	O
3321	O
/	O
TSI	O
Incorporated	O
)	O
and	O
the	O
system	O
-	O
specific	O
deposition	O
capacities	O
(	O
Aufderheide	O
et	O
al	O
.	O
[	O
17	O
],	O
Supplementary	O
Material	O
).	O

2	O
.	O
7	O
.	O

Cell	O
Cultivation	O
and	O
Exposure	O

For	O
particle	O
exposure	O
experiments	O
,	O
the	O
human	B-OG
lung	B-DS
adenocarcinoma	I-DS
epithelial	O
cell	O
line	O
A549	O
(	O
ATCC	O
number	O
:	O
CCL	O
-	O
185	O
)	O
was	O
used	O
[	O
18	O
,	O
19	O
].	O

The	O
cells	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
MEM	O
(	O
Biochrom	O
FG	O
0145	O
,	O
Germany	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
gentamicin	B-CD
(	O
5	O
μg	O
/	O
mL	O
).	O

A549	O
cells	O
were	O
seeded	O
onto	O
microporous	O
membranes	O
(	O
growth	O
area	O
:	O
4	O
.	O
2	O
cm²	O
)	O
of	O
cell	O
culture	O
inserts	O
(	O
0	O
.	O
4	O
μm	O
pore	O
size	O
,	O
BD	O
Biosciences	O
)	O
with	O
a	O
density	O
of	O
1	O
∗	O
105	O
cells	O
/	O
cm2	O
and	O
cultivated	O
submerged	O
in	O
a	O
cell	O
culture	O
medium	O
.	O

After	O
24	O
hours	O
,	O
the	O
apical	O
medium	O
was	O
removed	O
from	O
the	O
confluent	O
cell	O
layers	O
and	O
the	O
direct	O
exposure	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
with	O
the	O
CULTEX	O
RFS	O
was	O
started	O
.	O

The	O
cells	O
were	O
exposed	O
either	O
to	O
the	O
test	O
substances	O
(	O
deposition	O
rate	O
:	O
25	O
μg	O
/	O
cm²	O
/	O
15	O
min	O
)	O
or	O
clean	O
air	O
(	O
process	O
control	O
)	O
for	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
.	O

The	O
incubator	O
control	O
cultures	O
were	O
cultivated	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
in	O
the	O
incubator	O
during	O
the	O
exposure	O
period	O
.	O

2	O
.	O
8	O
.	O

WST	O
Assay	O

The	O
aim	O
of	O
our	O
study	O
was	O
the	O
characterization	O
of	O
the	O
exposure	O
device	O
,	O
limited	O
to	O
the	O
functional	O
description	O
of	O
the	O
system	O
.	O

Accordingly	O
,	O
we	O
used	O
only	O
one	O
biological	O
endpoint	O
,	O
the	O
metabolic	O
activity	O
of	O
the	O
cells	O
,	O
to	O
demonstrate	O
dose	O
-	O
dependent	O
cytotoxic	O
reactions	O
,	O
not	O
investigating	O
further	O
into	O
the	O
mechanisms	O
behind	O
these	O
effects	O
.	O

After	O
a	O
postincubation	O
time	O
of	O
24	O
hours	O
(	O
air	O
-	O
liquid	O
interface	O
;	O
37	O
°	O
C	O
/	O
5	O
%	O
CO2	O
),	O
the	O
particle	O
-	O
exposed	O
cells	O
and	O
the	O
control	O
cultures	O
(	O
incubator	O
control	O
:	O
unexposed	O
cells	O
,	O
process	O
control	O
:	O
clean	O
air	O
-	O
exposed	O
cells	O
)	O
were	O
analyzed	O
for	O
cell	O
viability	O
by	O
using	O
the	O
WST	O
-	O
1	O
assay	O
for	O
the	O
mitochondrial	O
activity	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Roche	O
Diagnostics	O
,	O
Germany	O
).	O

The	O
data	O
of	O
the	O
exposed	O
cells	O
were	O
normalized	O
to	O
the	O
values	O
of	O
the	O
clean	O
air	O
control	O
.	O

The	O
incubator	O
controls	O
were	O
not	O
considered	O
,	O
because	O
they	O
did	O
not	O
show	O
significant	O
differences	O
to	O
the	O
clean	O
air	O
controls	O
.	O

2	O
.	O
9	O
.	O

Statistical	O
Analysis	O

The	O
results	O
of	O
three	O
independent	O
tests	O
with	O
three	O
samples	O
each	O
is	O
expressed	O
as	O
mean	O
±	O
SD	O
.	O

A	O
Student	O
'	O
s	O
t	O
-	O
test	O
was	O
performed	O
to	O
analyze	O
whether	O
the	O
differences	O
between	O
the	O
mean	O
values	O
of	O
the	O
three	O
exposure	O
times	O
are	O
significant	O
[	O
20	O
].	O

3	O
.	O

Results	O

3	O
.	O
1	O
.	O

Deposition	O
Efficiency	O

The	O
CULTEX	O
RFS	O
was	O
designed	O
for	O
exposing	O
adherent	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
to	O
airborne	O
materials	O
like	O
gases	O
,	O
complex	O
mixtures	O
,	O
and	O
particles	O
.	O

When	O
dealing	O
with	O
particulate	O
matter	O
especially	O
,	O
questions	O
arise	O
concerning	O
the	O
deposition	O
efficiency	O
of	O
such	O
an	O
exposure	O
device	O
.	O

The	O
basic	O
and	O
theoretical	O
considerations	O
forming	O
the	O
basis	O
of	O
the	O
efficiency	O
of	O
the	O
system	O
are	O
already	O
described	O
by	O
Aufderheide	O
et	O
al	O
.	O
([	O
17	O
],	O
Electronic	O
Supplementary	O
Material	O
).	O

3	O
.	O
2	O
.	O

CFD	O
Analysis	O
—	O
Flow	O
Conditions	O
within	O
the	O
System	O

When	O
developing	O
the	O
CULTEX	O
RFS	O
and	O
its	O
peripheral	O
devices	O
,	O
a	O
key	O
to	O
achieve	O
uniform	O
particle	O
deposition	O
on	O
the	O
cell	O
cultures	O
was	O
the	O
simulation	O
and	O
optimization	O
of	O
the	O
particle	O
flow	O
within	O
the	O
system	O
by	O
means	O
of	O
CFD	O
analysis	O
(	O
Figures	O
7	O
to	O
9	O
).	O

Figure	O
7	O
shows	O
a	O
cross	O
-	O
section	O
through	O
the	O
elutriator	O
(	O
a	O
)	O
and	O
a	O
streamline	O
velocity	O
plot	O
(	O
b	O
)	O
of	O
the	O
CFD	O
analysis	O
.	O

The	O
basic	O
principle	O
of	O
an	O
elutriator	O
consists	O
of	O
separating	O
small	O
(	O
light	O
)	O
from	O
large	O
(	O
heavy	O
)	O
particles	O
in	O
a	O
vertically	O
upward	O
directed	O
stream	O
.	O

The	O
elutriator	O
features	O
an	O
additional	O
outlet	O
at	O
the	O
bottom	O
for	O
discharging	O
excess	O
aerosol	O
,	O
as	O
aerosol	O
generation	O
may	O
require	O
higher	O
flow	O
rates	O
(	O
e	O
.	O
g	O
.,	O
8	O
L	O
/	O
min	O
)	O
than	O
those	O
for	O
the	O
CULTEX	O
RFS	O
exposure	O
module	O
(	O
e	O
.	O
g	O
.,	O
1	O
.	O
6	O
L	O
/	O
min	O
).	O

The	O
streamline	O
plot	O
shows	O
a	O
curl	O
in	O
the	O
lower	O
zone	O
of	O
the	O
device	O
but	O
a	O
uniform	O
upstream	O
above	O
,	O
which	O
is	O
essential	O
for	O
a	O
reliable	O
particle	O
separation	O
.	O

The	O
results	O
are	O
based	O
on	O
flow	O
rates	O
of	O
8	O
.	O
0	O
L	O
/	O
min	O
at	O
the	O
inlet	O
,	O
1	O
.	O
09	O
L	O
/	O
min	O
at	O
the	O
outlet	O
,	O
and	O
6	O
.	O
91	O
L	O
/	O
min	O
at	O
the	O
aerosol	O
excess	O
outlet	O
.	O

Further	O
calculations	O
with	O
the	O
same	O
flow	O
rate	O
at	O
the	O
inlet	O
but	O
1	O
.	O
59	O
L	O
/	O
min	O
at	O
the	O
aerosol	O
outlet	O
showed	O
no	O
substantial	O
differences	O
.	O

Figure	O
8	O
shows	O
particle	O
trajectory	O
simulations	O
with	O
particle	O
sizes	O
of	O
2	O
μm	O
(	O
a	O
)	O
and	O
10	O
μm	O
(	O
b	O
).	O

While	O
small	O
particles	O
are	O
transported	O
upwards	O
to	O
the	O
aerosol	O
outlet	O
and	O
the	O
Cultex	O
RFS	O
module	O
,	O
large	O
particles	O
remain	O
in	O
the	O
elutriator	O
.	O

The	O
major	O
portion	O
of	O
the	O
particles	O
is	O
carried	O
to	O
the	O
excess	O
outlet	O
,	O
as	O
a	O
flow	O
rate	O
of	O
only	O
1	O
.	O
09	O
L	O
/	O
min	O
from	O
totally	O
8	O
L	O
/	O
min	O
was	O
conducted	O
to	O
the	O
module	O
in	O
this	O
simulation	O
.	O

When	O
testing	O
prototypes	O
of	O
the	O
Cultex	O
RFS	O
module	O
,	O
the	O
distribution	O
patterns	O
between	O
the	O
three	O
deposition	O
chambers	O
and	O
within	O
the	O
individual	O
chambers	O
showed	O
considerable	O
differences	O
.	O

CFD	O
calculations	O
of	O
the	O
gas	O
flow	O
lines	O
and	O
particle	O
trajectories	O
resulted	O
in	O
the	O
following	O
essential	O
findings	O
.	O

Figure	O
9	O
(	O
a	O
)	O
shows	O
the	O
aerosol	O
flow	O
channels	O
within	O
the	O
Cultex	O
RFS	O
module	O
including	O
a	O
curved	O
aerosol	O
feeding	O
tube	O
with	O
6	O
mm	O
diameter	O
and	O
200	O
mm	O
length	O
.	O

The	O
flow	O
lines	O
represent	O
an	O
aerosol	O
flow	O
of	O
1590	O
mL	O
/	O
min	O
in	O
the	O
feeding	O
tube	O
,	O
which	O
is	O
divided	O
into	O
three	O
minor	O
flows	O
of	O
30	O
mL	O
/	O
min	O
leading	O
to	O
the	O
deposition	O
chambers	O
and	O
an	O
excess	O
flow	O
of	O
1500	O
mL	O
/	O
min	O
.	O

Backtracking	O
a	O
defined	O
number	O
of	O
particles	O
from	O
the	O
deposition	O
chamber	O
to	O
the	O
beginning	O
of	O
the	O
curved	O
aerosol	O
feeding	O
tube	O
(	O
which	O
is	O
equal	O
to	O
the	O
elutriator	O
outlet	O
)	O
showed	O
that	O
these	O
particles	O
originate	O
from	O
specific	O
locations	O
in	O
the	O
tube	O
profile	O
(	O
Figure	O
9	O
(	O
b	O
)).	O

Further	O
calculations	O
showed	O
that	O
the	O
specific	O
locations	O
are	O
sensitive	O
to	O
changes	O
in	O
tube	O
bending	O
radius	O
,	O
tube	O
length	O
,	O
or	O
flow	O
rate	O
.	O

As	O
the	O
particle	O
concentration	O
and	O
particle	O
size	O
distribution	O
at	O
the	O
beginning	O
of	O
the	O
feeding	O
tube	O
is	O
usually	O
nonuniform	O
across	O
the	O
tube	O
profile	O
,	O
the	O
distribution	O
pattern	O
in	O
the	O
deposition	O
chambers	O
are	O
consequently	O
also	O
nonuniform	O
.	O

An	O
optimal	O
solution	O
to	O
completely	O
avoid	O
these	O
undesired	O
effects	O
was	O
the	O
integration	O
of	O
a	O
jet	O
nozzle	O
into	O
the	O
inlet	O
adapter	O
of	O
the	O
Cultex	O
RFS	O
module	O
.	O
Figure	O
10	O
(	O
a	O
)	O
shows	O
the	O
deposition	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
on	O
insert	O
membranes	O
without	O
using	O
a	O
jet	O
nozzle	O
.	O

The	O
integration	O
of	O
a	O
jet	O
nozzle	O
into	O
the	O
inlet	O
adapter	O
(	O
Figure	O
10	O
(	O
b	O
))	O
resulted	O
in	O
a	O
homogenous	O
distribution	O
of	O
the	O
particles	O
on	O
the	O
insert	O
membranes	O
(	O
Figure	O
10	O
(	O
c	O
),	O
Table	O
3	O
).	O

3	O
.	O
3	O
.	O

Dose	O
-	O
Response	O
Relationship	O

After	O
optimizing	O
the	O
deposition	O
characteristics	O
within	O
the	O
CULTEX	O
RFS	O
module	O
,	O
A549	O
cells	O
were	O
exposed	O
to	O
lactose	B-CD
monohydrate	O
(	O
process	O
control	O
),	O
copper	O
(	O
II	O
)	O
sulfate	O
(	O
soluble	O
substance	O
),	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
as	O
well	O
as	O
copper	O
(	O
II	O
)	O
oxide	O
nanoparticles	O
(	O
insoluble	O
)	O
for	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
.	O

The	O
particle	O
generation	O
was	O
adjusted	O
for	O
each	O
substance	O
to	O
result	O
in	O
a	O
particle	O
deposition	O
of	O
25	O
μg	O
/	O
cm²	O
(	O
low	O
dose	O
)	O
during	O
an	O
exposure	O
time	O
of	O
15	O
minutes	O
.	O

The	O
concentration	O
(	O
low	O
effect	O
level	O
,	O
LOEL	O
)	O
is	O
based	O
on	O
an	O
interdisciplinary	O
European	O
project	O
in	O
which	O
the	O
cytotoxic	O
potency	O
of	O
a	O
variety	O
of	O
particles	O
was	O
analyzed	O
with	O
different	O
cell	O
types	O
under	O
submersed	O
culture	O
conditions	O
[	O
21	O
].	O

The	O
conditions	O
for	O
the	O
particle	O
generation	O
had	O
to	O
be	O
adjusted	O
in	O
preliminary	O
experiments	O
due	O
to	O
substance	O
-	O
specific	O
variations	O
.	O

24	O
hours	O
after	O
exposure	O
,	O
the	O
cell	O
viability	O
was	O
measured	O
.	O

The	O
values	O
obtained	O
for	O
the	O
particle	O
-	O
exposed	O
cultures	O
were	O
normalized	O
to	O
the	O
clean	O
air	O
-	O
exposed	O
cells	O
.	O

The	O
results	O
are	O
shown	O
in	O
Figures	O
11	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
and	O
18	O
.	O

Generally	O
the	O
clean	O
air	O
-	O
exposed	O
cells	O
(	O
process	O
control	O
)	O
showed	O
no	O
significant	O
reduction	O
in	O
the	O
cell	O
viability	O
in	O
comparison	O
with	O
the	O
incubator	O
control	O
.	O

Accordingly	O
,	O
the	O
exposure	O
process	O
itself	O
had	O
no	O
influence	O
on	O
the	O
metabolic	O
activity	O
of	O
the	O
cells	O
.	O

The	O
exposure	O
of	O
the	O
cell	O
cultures	O
to	O
the	O
test	O
compounds	O
showed	O
,	O
dependent	O
on	O
the	O
chemical	O
and	O
physical	O
properties	O
of	O
the	O
particulate	O
atmosphere	O
,	O
considerable	O
differences	O
in	O
the	O
cytotoxic	O
response	O
among	O
the	O
three	O
exposure	O
times	O
.	O

The	O
comparison	O
of	O
the	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
exposures	O
in	O
a	O
Student	O
'	O
s	O
t	O
-	O
test	O
demonstrates	O
significant	O
differences	O
with	O
a	O
5	O
%	O
error	O
probability	O
.	O

No	O
significant	O
differences	O
could	O
be	O
obtained	O
for	O
lactose	B-CD
monohydrate	O
(	O
30	O
minutes	O
compared	O
to	O
15	O
minutes	O
)	O
and	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
-	O
sized	O
(	O
60	O
minutes	O
compared	O
to	O
30	O
minutes	O
)	O
due	O
to	O
the	O
low	O
number	O
of	O
tests	O
.	O

The	O
exposure	O
of	O
A549	O
cells	O
to	O
lactose	B-CD
monohydrate	O
(	O
negative	O
substance	O
)	O
led	O
to	O
a	O
slight	O
decrease	O
in	O
the	O
cell	O
viability	O
of	O
the	O
cells	O
after	O
15	O
minutes	O
(	O
94	O
%	O
of	O
the	O
clean	O
air	O
control	O
).	O

By	O
increasing	O
the	O
exposure	O
time	O
to	O
60	O
minutes	O
,	O
the	O
metabolic	O
activity	O
of	O
the	O
cells	O
was	O
reduced	O
by	O
30	O
%	O
in	O
comparison	O
to	O
the	O
clean	O
air	O
control	O
.	O

At	O
that	O
point	O
,	O
the	O
cultures	O
were	O
covered	O
by	O
a	O
dense	O
layer	O
of	O
the	O
particulate	O
matter	O
thus	O
pointing	O
to	O
an	O
overload	O
effect	O
.	O

The	O
particle	O
number	O
(	O
black	O
line	O
)	O
and	O
mass	O
distribution	O
(	O
red	O
line	O
)	O
of	O
the	O
lactose	B-CD
monohydrate	O
aerosol	O
dependent	O
on	O
particle	O
size	O
are	O
shown	O
in	O
Figure	O
12	O
.	O

The	O
units	O
number	O
,	O
respectively	O
,	O
mass	O
per	O
μm	O
∗	O
cm3	O
may	O
be	O
unfamiliar	O
at	O
first	O
glance	O
.	O

As	O
the	O
curves	O
are	O
based	O
on	O
particle	O
counts	O
,	O
classified	O
to	O
51	O
particle	O
size	O
intervals	O
,	O
the	O
counts	O
have	O
to	O
be	O
divided	O
not	O
only	O
through	O
the	O
volume	O
but	O
also	O
through	O
the	O
interval	O
width	O
to	O
get	O
the	O
required	O
values	O
for	O
particle	O
distribution	O
curves	O
.	O

The	O
particle	O
number	O
distribution	O
curve	O
exhibits	O
its	O
peak	O
value	O
at	O
a	O
particle	O
size	O
of	O
0	O
.	O
7	O
μm	O
while	O
the	O
particle	O
mass	O
distribution	O
curve	O
shows	O
its	O
peak	O
value	O
at	O
a	O
particle	O
size	O
of	O
4	O
.	O
2	O
μm	O
due	O
to	O
the	O
greater	O
mass	O
of	O
larger	O
particles	O
.	O

The	O
exposure	O
of	O
the	O
cell	O
populations	O
to	O
copper	O
(	O
II	O
)	O
sulfate	O
led	O
to	O
a	O
pronounced	O
decrease	O
in	O
the	O
cell	O
viability	O
after	O
15	O
minutes	O
19	O
%	O
of	O
the	O
clean	O
air	O
control	O
.	O

By	O
increasing	O
the	O
time	O
to	O
60	O
minutes	O
,	O
the	O
metabolic	O
activity	O
was	O
reduced	O
by	O
more	O
than	O
91	O
%	O
compared	O
to	O
the	O
clean	O
air	O
control	O
.	O

The	O
peak	O
for	O
the	O
particle	O
number	O
distribution	O
was	O
at	O
0	O
.	O
9	O
μm	O
and	O
the	O
peak	O
for	O
the	O
particle	O
mass	O
distribution	O
was	O
at	O
3	O
.	O
8	O
μm	O
(	O
Figure	O
14	O
).	O

Both	O
particle	O
number	O
and	O
particle	O
mass	O
were	O
about	O
five	O
times	O
higher	O
than	O
for	O
lactose	B-CD
monohydrate	O
.	O

The	O
results	O
after	O
the	O
exposure	O
of	O
A549	O
cells	O
to	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
also	O
indicated	O
a	O
dose	O
-	O
dependent	O
decrease	O
of	O
the	O
metabolic	O
activity	O
over	O
the	O
exposure	O
time	O
(	O
Figure	O
15	O
).	O

The	O
decrease	O
of	O
cell	O
viability	O
after	O
60	O
minutes	O
exposure	O
(	O
61	O
%	O
reduction	O
in	O
comparison	O
to	O
the	O
synthetic	O
air	O
control	O
)	O
is	O
significantly	O
higher	O
than	O
for	O
lactose	B-CD
monohydrate	I-CD
but	O
not	O
as	O
clear	O
as	O
for	O
copper	O
(	O
II	O
)	O
sulfate	O
.	O

In	O
comparison	O
with	O
copper	O
(	O
II	O
)	O
sulfate	O
,	O
the	O
particle	O
number	O
distribution	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
also	O
showed	O
a	O
peak	O
at	O
0	O
.	O
9	O
μm	O
,	O
but	O
with	O
a	O
more	O
than	O
four	O
times	O
lower	O
number	O
of	O
particles	O
(	O
Figure	O
16	O
).	O

The	O
values	O
for	O
the	O
particle	O
mass	O
distribution	O
were	O
about	O
25	O
%	O
lower	O
compared	O
to	O
copper	O
(	O
II	O
)	O
sulfate	O
,	O
indicating	O
that	O
the	O
substances	O
mostly	O
differ	O
in	O
their	O
content	O
of	O
small	O
particles	O
.	O

The	O
cell	O
viability	O
of	O
the	O
A549	O
cells	O
was	O
significantly	O
reduced	O
after	O
the	O
exposure	O
to	O
copper	O
(	O
II	O
)	O
oxide	O
nanoparticles	O
.	O

After	O
15	O
minutes	O
,	O
the	O
metabolic	O
activity	O
was	O
reduced	O
to	O
less	O
than	O
50	O
%	O
compared	O
to	O
the	O
clean	O
air	O
and	O
incubator	O
control	O
.	O

A	O
particle	O
mass	O
of	O
100	O
μg	O
/	O
cm2	O
(	O
60	O
minutes	O
)	O
led	O
to	O
a	O
reduction	O
in	O
the	O
metabolic	O
activity	O
of	O
85	O
%,	O
indicating	O
a	O
higher	O
cytotoxic	O
effect	O
by	O
the	O
nanopowder	O
compared	O
to	O
the	O
micro	O
.	O

Copper	O
(	O
II	O
)	O
oxide	O
nano	O
does	O
not	O
differ	O
strongly	O
from	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
in	O
numbers	O
of	O
sub	O
-	O
μm	O
particles	O
.	O

The	O
nanopowder	O
exhibits	O
much	O
lower	O
mass	O
distribution	O
values	O
,	O
however	O
,	O
due	O
to	O
few	O
particles	O
in	O
the	O
size	O
range	O
over	O
1	O
μm	O
.	O

4	O
.	O

Discussion	O

Due	O
to	O
changes	O
in	O
the	O
EU	O
regulations	O
concerning	O
the	O
approval	O
of	O
chemical	O
substances	O
(	O
Regulation	O
(	O
EU	O
)	O
no	O
.	O
1907	O
/	O
2006	O
)	O
and	O
the	O
ongoing	O
demand	O
for	O
alternative	O
methods	O
,	O
new	O
cell	O
systems	O
and	O
exposure	O
techniques	O
were	O
developed	O
and	O
characterized	O
,	O
also	O
in	O
the	O
field	O
of	O
inhalation	O
toxicology	O
.	O

The	O
latter	O
should	O
meet	O
special	O
requirements	O
with	O
regard	O
to	O
the	O
cell	O
type	O
and	O
the	O
type	O
of	O
exposure	O
.	O

The	O
biological	O
test	O
systems	O
include	O
bronchial	O
(	O
Calu	O
-	O
3	O
,	O
16HBE14o	O
-,	O
BEAS	O
-	O
2B	O
)	O
and	O
alveolar	O
epithelial	O
(	O
A549	O
)	O
cell	O
lines	O
,	O
mostly	O
from	O
tumors	B-DS
as	O
well	O
as	O
human	B-OG
primary	O
cells	O
isolated	O
from	O
different	O
regions	O
of	O
the	O
respiratory	O
tract	O
[	O
22	O
–	O
25	O
].	O

At	O
the	O
moment	O
primary	O
cell	O
cultures	O
are	O
mostly	O
studied	O
under	O
mechanistic	O
aspects	O
(	O
differentiation	O
,	O
cellular	O
interactions	O
)	O
[	O
26	O
]	O
and	O
are	O
not	O
used	O
routinely	O
for	O
screening	O
methods	O
to	O
address	O
acute	O
toxicity	O
.	O

Therefore	O
,	O
the	O
studies	O
are	O
mostly	O
performed	O
with	O
cell	O
lines	O
like	O
the	O
alveolar	O
epithelial	O
cell	O
line	O
A549	O
,	O
which	O
allows	O
the	O
generation	O
of	O
stable	O
cultures	O
(	O
undifferentiated	O
).	O

The	O
advantage	O
of	O
these	O
cultures	O
is	O
the	O
delivery	O
of	O
stable	O
,	O
reproducible	O
,	O
and	O
significant	O
data	O
for	O
the	O
calculation	O
of	O
dose	O
-	O
response	O
curves	O
as	O
well	O
as	O
the	O
definition	O
of	O
key	O
values	O
(	O
effective	O
dose	O
:	O
EC50	O
).	O

The	O
exposure	O
of	O
cultivated	O
cells	O
from	O
the	O
respiratory	O
tract	O
for	O
studying	O
the	O
effects	O
of	O
airborne	O
substances	O
represents	O
a	O
challenge	O
with	O
regard	O
to	O
the	O
experimental	O
design	O
.	O

The	O
exposure	O
of	O
cells	O
under	O
conventional	O
submerged	O
conditions	O
,	O
mostly	O
with	O
soluble	O
test	O
substances	O
,	O
shows	O
a	O
variety	O
of	O
shortcomings	O
like	O
the	O
interference	O
of	O
the	O
test	O
atmosphere	O
with	O
medium	O
components	O
,	O
unrealistic	O
exposure	O
conditions	O
including	O
uncertain	O
effective	O
doses	O
for	O
gases	O
and	O
particles	O
.	O

Therefore	O
,	O
several	O
approaches	O
have	O
been	O
made	O
for	O
the	O
development	O
of	O
exposure	O
systems	O
(	O
Table	O
4	O
)	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
[	O
3	O
,	O
12	O
,	O
14	O
,	O
17	O
,	O
27	O
–	O
35	O
].	O

Under	O
such	O
conditions	O
,	O
the	O
cells	O
are	O
in	O
direct	O
contact	O
with	O
the	O
test	O
aerosol	O
,	O
which	O
is	O
conducted	O
through	O
the	O
exposure	O
device	O
to	O
the	O
cells	O
.	O

The	O
exposure	O
systems	O
have	O
to	O
fulfill	O
cell	O
-	O
specific	O
requirements	O
,	O
meaning	O
the	O
maintenance	O
of	O
the	O
cell	O
cultures	O
during	O
the	O
exposure	O
process	O
by	O
medium	O
supply	O
and	O
the	O
establishment	O
of	O
a	O
cell	O
-	O
specific	O
environment	O
(	O
pH	O
value	O
,	O
37	O
°	O
C	O
).	O

All	O
described	O
systems	O
have	O
taken	O
into	O
consideration	O
those	O
basic	O
requirements	O
.	O

The	O
inserts	O
are	O
located	O
in	O
medium	O
-	O
containing	O
chambers	O
,	O
connected	O
with	O
a	O
medium	O
supply	O
for	O
intermittent	O
or	O
continuous	O
medium	O
exchange	O
.	O

In	O
the	O
system	O
described	O
by	O
Adamson	O
et	O
al	O
.	O
[	O
36	O
],	O
4	O
culture	O
vessels	O
are	O
placed	O
together	O
in	O
a	O
chamber	O
filled	O
up	O
with	O
medium	O
to	O
the	O
bottom	O
of	O
the	O
cell	O
culture	O
inserts	O
.	O

In	O
the	O
CULTEX	O
RFS	O
,	O
and	O
also	O
the	O
CULTEX	O
glass	O
modules	O
[	O
27	O
,	O
28	O
],	O
the	O
inserts	O
are	O
housed	O
separately	O
and	O
are	O
supplied	O
individually	O
with	O
nutrients	O
,	O
as	O
independent	O
exposure	O
chambers	O
within	O
one	O
module	O
.	O

The	O
medium	O
level	O
is	O
adjusted	O
via	O
an	O
overflow	O
tube	O
to	O
establish	O
comparable	O
conditions	O
in	O
all	O
three	O
chambers	O
.	O

The	O
basic	O
principle	O
of	O
cellular	O
exposure	O
to	O
airborne	O
materials	O
is	O
based	O
on	O
the	O
treatment	O
of	O
the	O
cultivated	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
(	O
ALI	O
).	O

The	O
experimental	O
setup	O
to	O
realize	O
a	O
direct	O
contact	O
between	O
the	O
cells	O
and	O
the	O
test	O
atmosphere	O
differs	O
considerably	O
in	O
the	O
different	O
systems	O
,	O
which	O
are	O
listed	O
in	O
Table	O
4	O
.	O

A	O
limited	O
number	O
of	O
devices	O
favor	O
the	O
exposure	O
of	O
the	O
cultures	O
to	O
an	O
aerosol	O
passing	O
through	O
a	O
box	O
or	O
exposure	O
chamber	O
[	O
35	O
,	O
36	O
],	O
but	O
most	O
of	O
the	O
exposure	O
systems	O
prefer	O
a	O
stream	O
directed	O
towards	O
the	O
cell	O
culture	O
to	O
realize	O
a	O
close	O
contact	O
between	O
the	O
test	O
atmosphere	O
and	O
the	O
cell	O
surface	O
for	O
depositing	O
particles	O
.	O

Gaseous	O
compounds	O
can	O
be	O
studied	O
in	O
all	O
systems	O
due	O
to	O
the	O
homogeneous	O
distribution	O
of	O
their	O
test	O
atmosphere	O
,	O
whereas	O
the	O
exposure	O
of	O
particulate	O
materials	O
is	O
based	O
mostly	O
on	O
a	O
directed	O
aerosol	O
flow	O
.	O

A	O
comparative	O
study	O
of	O
the	O
different	O
test	O
systems	O
is	O
limited	O
due	O
to	O
the	O
limited	O
availability	O
of	O
the	O
modules	O
and	O
the	O
absence	O
of	O
information	O
.	O

The	O
CULTEX	O
glass	O
modules	O
as	O
well	O
as	O
the	O
RFS	O
are	O
designed	O
to	O
establish	O
an	O
incoming	O
flow	O
which	O
is	O
directed	O
immediately	O
via	O
emission	O
ducts	O
to	O
the	O
surface	O
of	O
the	O
cells	O
to	O
guarantee	O
a	O
close	O
contact	O
with	O
the	O
test	O
atmosphere	O
,	O
both	O
qualitatively	O
and	O
quantitatively	O
.	O

In	O
comparison	O
with	O
the	O
glass	O
modules	O
,	O
the	O
aerosol	O
guiding	O
module	O
of	O
the	O
RFS	O
has	O
been	O
optimized	O
concerning	O
the	O
uniform	O
distribution	O
of	O
the	O
incoming	O
test	O
atmosphere	O
to	O
the	O
three	O
exposure	O
chambers	O
,	O
thus	O
stabilizing	O
the	O
whole	O
exposure	O
process	O
.	O

In	O
the	O
glass	O
modules	O
,	O
the	O
aerosol	O
is	O
guided	O
linearly	O
above	O
the	O
module	O
and	O
the	O
sampling	O
points	O
for	O
the	O
test	O
atmosphere	O
are	O
arranged	O
in	O
succession	O
.	O

In	O
the	O
case	O
of	O
gaseous	O
compounds	O
,	O
the	O
homogeneous	O
distribution	O
of	O
the	O
atmosphere	O
is	O
not	O
limited	O
,	O
but	O
airborne	O
particles	O
belong	O
to	O
another	O
category	O
,	O
especially	O
with	O
regard	O
to	O
their	O
aerosol	O
physical	O
properties	O
.	O

A	O
linear	O
flow	O
path	O
above	O
the	O
glass	O
module	O
leads	O
to	O
a	O
concentration	O
gradient	O
,	O
which	O
may	O
result	O
,	O
due	O
to	O
the	O
sequentially	O
arranged	O
sampling	O
points	O
,	O
at	O
different	O
exposure	O
levels	O
.	O

In	O
contrast	O
,	O
the	O
CULTEX	O
RFS	O
module	O
is	O
characterized	O
by	O
a	O
central	O
inlet	O
for	O
the	O
test	O
atmosphere	O
into	O
the	O
exposure	O
device	O
,	O
wherefrom	O
the	O
aerosol	O
is	O
distributed	O
into	O
the	O
chambers	O
and	O
the	O
particles	O
deposited	O
on	O
the	O
cell	O
cultures	O
.	O

The	O
resulting	O
data	O
are	O
characterized	O
by	O
a	O
small	O
standard	O
deviation	O
within	O
a	O
test	O
or	O
for	O
multiple	O
experiments	O
.	O

Another	O
relevant	O
advantage	O
of	O
the	O
new	O
system	O
is	O
the	O
adjustment	O
of	O
the	O
medium	O
level	O
,	O
which	O
ensures	O
a	O
comparable	O
microenvironment	O
for	O
all	O
cultures	O
.	O

The	O
level	O
in	O
the	O
Cultex	O
RFS	O
is	O
controlled	O
by	O
special	O
overflow	O
tubes	O
to	O
stabilize	O
the	O
sensitive	O
microclimate	O
around	O
the	O
cells	O
.	O

An	O
autonomous	O
medium	O
supply	O
for	O
each	O
cell	O
culture	O
insert	O
offers	O
the	O
opportunity	O
to	O
test	O
different	O
medium	O
additives	O
without	O
interaction	O
between	O
the	O
three	O
test	O
chambers	O
.	O

The	O
new	O
modular	O
design	O
of	O
the	O
Cultex	O
RFS	O
guarantees	O
a	O
high	O
flexibility	O
in	O
working	O
with	O
different	O
types	O
of	O
cell	O
culture	O
inserts	O
or	O
even	O
Petri	O
dishes	O
(	O
for	O
the	O
AMES	O
assay	O
)	O
by	O
using	O
special	O
adapters	O
.	O

The	O
efficiency	O
of	O
the	O
exposure	O
process	O
depends	O
on	O
the	O
deposition	O
efficiency	O
and	O
represents	O
,	O
especially	O
in	O
the	O
case	O
of	O
fine	O
and	O
ultrafine	O
particles	O
(	O
nano	O
particles	O
),	O
one	O
of	O
the	O
main	O
challenges	O
[	O
17	O
].	O

The	O
deposition	O
efficiency	O
of	O
the	O
particles	O
in	O
most	O
air	O
-	O
liquid	O
interface	O
systems	O
is	O
based	O
on	O
sedimentation	O
and	O
diffusion	O
.	O

Accordingly	O
,	O
a	O
characterization	O
of	O
the	O
test	O
aerosol	O
with	O
regard	O
to	O
the	O
particle	O
number	O
and	O
particle	O
mass	O
dependent	O
on	O
the	O
particle	O
size	O
is	O
one	O
of	O
the	O
main	O
requirements	O
to	O
judge	O
the	O
biological	O
activity	O
of	O
the	O
airborne	O
material	O
.	O

Due	O
to	O
changes	O
within	O
the	O
aerosol	O
during	O
the	O
generation	O
process	O
and	O
due	O
to	O
particle	O
-	O
particle	O
interactions	O
,	O
the	O
primary	O
particle	O
size	O
should	O
only	O
be	O
used	O
as	O
a	O
basic	O
indication	O
.	O

In	O
this	O
context	O
,	O
particle	O
loss	O
within	O
the	O
system	O
and	O
agglomeration	O
of	O
the	O
particles	O
has	O
to	O
be	O
taken	O
into	O
account	O
.	O

In	O
the	O
literature	O
,	O
the	O
deposition	O
efficiency	O
rate	O
of	O
in	O
vitro	O
exposure	O
devices	O
is	O
described	O
inconsistently	O
.	O

Theoretical	O
considerations	O
and	O
experimental	O
exposure	O
data	O
with	O
ultrafine	O
carbonaceous	O
model	O
particles	O
with	O
a	O
CMD	O
of	O
95	O
nm	O
resulted	O
in	O
an	O
efficiency	O
of	O
2	O
%	O
[	O
37	O
].	O

The	O
combination	O
of	O
such	O
air	O
-	O
liquid	O
interface	O
exposure	O
systems	O
with	O
an	O
electrical	O
charger	O
and	O
precipitator	O
could	O
improve	O
particle	O
deposition	O
.	O

Experimental	O
data	O
from	O
Savi	O
et	O
al	O
.	O
[	O
16	O
]	O
showed	O
that	O
the	O
deposition	O
efficiency	O
can	O
be	O
increased	O
to	O
30	O
%	O
with	O
this	O
type	O
of	O
setup	O
without	O
causing	O
a	O
cytotoxic	O
effect	O
on	O
the	O
exposed	O
cells	O
.	O

First	O
results	O
obtained	O
with	O
the	O
Cultex	O
RFS	O
in	O
combination	O
with	O
an	O
electrical	O
deposition	O
device	O
(	O
Cultex	O
EDD	O
)	O
indicated	O
that	O
the	O
efficiency	O
for	O
particles	O
which	O
are	O
not	O
deposited	O
by	O
sedimentation	O
or	O
diffusion	O
can	O
be	O
increased	O
up	O
to	O
95	O
%	O
(	O
data	O
not	O
shown	O
).	O

The	O
outstanding	O
importance	O
of	O
particle	O
size	O
and	O
mass	O
for	O
the	O
deposition	O
efficiency	O
highlights	O
the	O
importance	O
of	O
a	O
controlled	O
and	O
stable	O
generation	O
of	O
particulate	O
atmospheres	O
as	O
well	O
as	O
the	O
behavior	O
of	O
such	O
particles	O
in	O
an	O
exposure	O
device	O
.	O

To	O
obtain	O
more	O
insights	O
into	O
the	O
flow	O
conditions	O
within	O
our	O
Cultex	O
RFS	O
module	O
,	O
CFD	O
analysis	O
was	O
conducted	O
by	O
taking	O
into	O
consideration	O
all	O
components	O
of	O
the	O
experimental	O
setup	O
.	O

CFD	O
simulations	O
included	O
the	O
particle	O
distribution	O
in	O
the	O
tubing	O
system	O
(	O
connection	O
between	O
the	O
elutriator	O
and	O
the	O
exposure	O
module	O
)	O
and	O
the	O
exposure	O
module	O
itself	O
.	O

Here	O
,	O
we	O
found	O
that	O
inhomogeneous	O
particle	O
distributions	O
propagate	O
over	O
long	O
distances	O
due	O
to	O
laminar	O
flow	O
conditions	O
.	O

The	O
integration	O
of	O
a	O
jet	O
nozzle	O
into	O
the	O
inlet	O
adapter	O
enabled	O
a	O
homogeneous	O
particle	O
distribution	O
and	O
deposition	O
on	O
the	O
insert	O
membranes	O
as	O
shown	O
in	O
Figure	O
10	O
at	O
the	O
example	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
.	O

The	O
CFD	O
analysis	O
provides	O
a	O
good	O
method	O
to	O
simulate	O
the	O
trajectories	O
of	O
the	O
particles	O
from	O
generation	O
to	O
deposition	O
.	O

The	O
consideration	O
of	O
different	O
experimental	O
conditions	O
like	O
the	O
air	O
flow	O
rate	O
or	O
dimensions	O
of	O
the	O
connecting	O
tubes	O
allows	O
the	O
selection	O
of	O
the	O
appropriate	O
experimental	O
design	O
to	O
enhance	O
the	O
efficiency	O
of	O
the	O
exposure	O
system	O
.	O

Besides	O
the	O
experimental	O
setup	O
,	O
the	O
chemical	O
and	O
physical	O
properties	O
of	O
the	O
particles	O
highly	O
influence	O
their	O
deposition	O
efficiency	O
.	O

To	O
compare	O
the	O
biological	O
activity	O
of	O
the	O
different	O
copper	O
compounds	O
,	O
the	O
particle	O
mass	O
concentration	O
per	O
area	O
was	O
adjusted	O
for	O
each	O
substance	O
to	O
establish	O
a	O
comparable	O
particle	O
mass	O
deposition	O
(	O
deposition	O
rate	O
:	O
25	O
μg	O
/	O
cm²	O
/	O
15	O
min	O
).	O

A549	O
cells	O
were	O
exposed	O
for	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
to	O
the	O
different	O
test	O
atmospheres	O
and	O
the	O
metabolic	O
activity	O
of	O
the	O
cells	O
was	O
analyzed	O
as	O
an	O
estimate	O
for	O
cytotoxicity	O
.	O

In	O
comparison	O
to	O
the	O
incubator	O
control	O
,	O
the	O
cells	O
that	O
were	O
exposed	O
to	O
clean	O
air	O
showed	O
no	O
reduction	O
in	O
the	O
cell	O
viability	O
,	O
indicating	O
that	O
the	O
exposure	O
procedure	O
itself	O
had	O
no	O
effect	O
on	O
this	O
analyzed	O
endpoint	O
.	O

As	O
a	O
negative	O
substance	O
control	O
we	O
used	O
lactose	B-CD
,	O
which	O
induced	O
no	O
considerable	O
cell	O
damage	O
(	O
13	O
%	O
after	O
an	O
exposure	O
time	O
of	O
30	O
minutes	O
).	O

At	O
the	O
end	O
of	O
the	O
exposure	O
period	O
,	O
the	O
cultures	O
were	O
covered	O
by	O
a	O
dense	O
particle	O
layer	O
and	O
a	O
further	O
reduction	O
in	O
cell	O
viability	O
(	O
37	O
%	O
of	O
the	O
clean	O
air	O
control	O
)	O
was	O
measured	O
probably	O
due	O
to	O
an	O
overload	O
effect	O
.	O

In	O
comparison	O
with	O
lactose	B-CD
monohydrate	O
,	O
all	O
copper	O
compounds	O
induced	O
significant	O
dose	O
-	O
related	O
effects	O
.	O

The	O
cytotoxic	O
signal	O
correlated	O
strongly	O
with	O
the	O
chemical	O
and	O
physical	O
properties	O
of	O
the	O
test	O
compound	O
.	O

Copper	O
(	O
II	O
)	O
sulfate	O
,	O
as	O
soluble	O
compound	O
,	O
induced	O
a	O
pronounced	O
cytotoxic	O
effect	O
already	O
after	O
an	O
exposure	O
time	O
of	O
15	O
minutes	O
(	O
reduction	O
of	O
cell	O
viability	O
of	O
80	O
%).	O

Comparable	O
effects	O
could	O
also	O
be	O
observed	O
for	O
the	O
insoluble	O
copper	O
(	O
II	O
)	O
oxide	O
compounds	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

As	O
described	O
by	O
Karlsson	O
and	O
coworkers	O
[	O
38	O
],	O
the	O
exposure	O
of	O
the	O
cells	O
to	O
both	O
substances	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
the	O
cell	O
viability	O
by	O
increasing	O
the	O
particle	O
concentration	O
,	O
whereby	O
the	O
copper	O
(	O
II	O
)	O
oxide	O
nanomaterial	O
appeared	O
to	O
be	O
more	O
harmful	O
to	O
the	O
cells	O
than	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
,	O
based	O
on	O
the	O
exposed	O
particle	O
mass	O
.	O

In	O
the	O
literature	O
,	O
nanoparticles	O
are	O
repeatedly	O
described	O
to	O
be	O
more	O
potent	O
in	O
causing	O
a	O
cellular	O
damage	O
than	O
microparticles	O
[	O
38	O
–	O
40	O
],	O
but	O
there	O
is	O
also	O
evidence	O
that	O
there	O
is	O
no	O
difference	O
in	O
their	O
biological	O
activity	O
[	O
41	O
–	O
43	O
].	O

In	O
agreement	O
with	O
the	O
above	O
-	O
mentioned	O
studies	O
,	O
our	O
direct	O
exposure	O
studies	O
with	O
nanosized	O
copper	O
(	O
II	O
)	O
oxide	O
exhibited	O
a	O
stronger	O
cytotoxicity	O
than	O
the	O
micro	O
-	O
sized	O
particles	O
.	O

Most	O
of	O
the	O
studies	O
on	O
micro	O
-	O
or	O
nanosized	O
particles	O
have	O
been	O
conducted	O
under	O
submersed	O
conditions	O
.	O

Ahamed	O
and	O
coworkers	O
also	O
used	O
A549	O
cells	O
,	O
which	O
were	O
treated	O
with	O
CuO	O
nanoparticles	O
(	O
NP	O
)	O
suspended	O
in	O
medium	O
(	O
0	O
,	O
10	O
,	O
25	O
,	O
and	O
50	O
μg	O
/	O
mL	O
for	O
24	O
hours	O
)	O
[	O
44	O
].	O

CuO	O
NPs	O
significantly	O
decreased	O
cell	O
viability	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
highest	O
concentration	O
(	O
50	O
μg	O
/	O
mL	O
)	O
induced	O
a	O
reduction	O
in	O
viability	O
of	O
52	O
%,	O
whereas	O
the	O
directly	O
exposed	O
A549	O
cells	O
showed	O
a	O
decrease	O
of	O
more	O
than	O
75	O
%,	O
pointing	O
to	O
a	O
more	O
efficient	O
contact	O
and	O
interaction	O
between	O
deposited	O
particles	O
and	O
the	O
lung	O
cells	O
.	O

Investigations	O
of	O
Karlsson	O
et	O
al	O
.	O
support	O
this	O
assessment	O
[	O
38	O
,	O
45	O
].	O

Concerning	O
the	O
number	O
of	O
particles	O
per	O
cm2	O
for	O
each	O
substance	O
,	O
A549	O
cells	O
were	O
exposed	O
in	O
the	O
case	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
nano	O
to	O
more	O
particles	O
in	O
comparison	O
to	O
copper	O
(	O
II	O
)	O
oxide	O
micro	O
.	O

Accordingly	O
,	O
the	O
higher	O
cytotoxicity	O
may	O
also	O
be	O
a	O
result	O
of	O
the	O
higher	O
number	O
of	O
smaller	O
particles	O
coming	O
into	O
contact	O
with	O
the	O
surface	O
of	O
the	O
cells	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
that	O
an	O
efficient	O
and	O
stable	O
cell	O
exposure	O
system	O
like	O
the	O
Cultex	O
RFS	O
module	O
allows	O
a	O
reproducible	O
analysis	O
of	O
dose	O
-	O
dependent	O
reactions	O
to	O
airborne	O
materials	O
.	O

The	O
cell	O
cultures	O
can	O
be	O
exposed	O
to	O
the	O
generated	O
particulate	O
atmospheres	O
,	O
characterized	O
with	O
regard	O
to	O
particle	O
size	O
and	O
mass	O
distribution	O
,	O
under	O
controlled	O
conditions	O
thus	O
favoring	O
the	O
generation	O
of	O
valid	O
data	O
for	O
the	O
calculation	O
of	O
key	O
values	O
(	O
effective	O
dose	O
).	O

These	O
data	O
can	O
be	O
compared	O
with	O
animal	B-OG
or	O
clinical	O
data	O
and	O
offer	O
the	O
possibility	O
to	O
verify	O
the	O
relevance	O
and	O
meaningfulness	O
of	O
these	O
in	O
vitro	O
studies	O
.	O

Overview	O
image	O
of	O
the	O
modular	O
CULTEX	O
RFS	O
exposure	O
system	O
.	O

The	O
device	O
is	O
composed	O
of	O
the	O
following	O
components	O
:	O
(	O
1	O
)	O
inlet	O
adapter	O
,	O
(	O
2	O
)	O
aerosol	O
guiding	O
module	O
,	O
(	O
3	O
)	O
sampling	O
module	O
and	O
socket	O
module	O
,	O
and	O
(	O
4	O
)	O
locking	O
module	O
with	O
a	O
hand	O
wheel	O
.	O

Aerosol	O
guiding	O
module	O
of	O
the	O
CULTEX	O
RFS	O
:	O
(	O
a	O
)	O
top	O
view	O
,	O
(	O
b	O
)	O
bottom	O
view	O
,	O
and	O
(	O
c	O
)	O
sampling	O
module	O
.	O

The	O
CULTEX	O
RFS	O
exposure	O
device	O
extended	O
with	O
an	O
electrical	O
deposition	O
device	O
(	O
Cultex	O
EDD	O
)	O
for	O
the	O
increased	O
particle	O
deposition	O
efficiency	O
.	O

The	O
CULTEX	O
DG	O
(	O
Dust	O
Generator	O
)	O
(	O
Cultex	O
Laboratories	O
GmbH	O
,	O
Germany	O
)	O
enables	O
the	O
generation	O
of	O
aerosols	O
from	O
a	O
powder	O
cake	O
according	O
to	O
Wright	O
[	O
5	O
].	O

Experimental	O
setup	O
for	O
exposing	O
cultivated	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
to	O
particles	O
.	O

The	O
components	O
of	O
the	O
exposure	O
station	O
are	O
the	O
particle	O
generator	O
according	O
to	O
Wright	O
,	O
the	O
elutriator	O
,	O
two	O
CULTEX	O
RFS	O
devices	O
for	O
exposure	O
to	O
particles	O
and	O
clean	O
air	O
and	O
medium	O
pumps	O
for	O
the	O
automatic	O
nutrient	O
supply	O
.	O

Schematic	O
overview	O
of	O
the	O
CULTEX	O
system	O
for	O
exposing	O
cultivated	O
cells	O
to	O
particles	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
.	O

Components	O
of	O
the	O
exposure	O
station	O
:	O
(	O
a	O
)	O
particle	O
generator	O
according	O
to	O
Wright	O
(	O
CULTEX	O
Dust	O
Generator	O
);	O
(	O
b	O
)	O
elutriator	O
:	O
glass	O
tube	O
with	O
vertical	O
upward	O
flow	O
,	O
where	O
large	O
particles	O
are	O
removed	O
from	O
the	O
aerosol	O
due	O
to	O
sedimentation	O
;	O
(	O
c	O
)	O
CULTEX	O
RFS	O
modules	O
for	O
exposure	O
to	O
particles	O
and	O
synthetic	O
air	O
.	O

The	O
sampling	O
points	O
(	O
1	O
–	O
3	O
)	O
for	O
the	O
test	O
aerosols	O
in	O
the	O
overall	O
stream	O
are	O
marked	O
.	O

Sectional	O
view	O
of	O
the	O
elutriator	O
(	O
a	O
)	O
and	O
streamline	O
plot	O
calculated	O
by	O
CFD	O
Analysis	O
(	O
b	O
).	O

Particle	O
track	O
simulation	O
for	O
2	O
μm	O
(	O
a	O
)	O
and	O
10	O
μm	O
(	O
b	O
)	O
particles	O
.	O

8	O
L	O
/	O
min	O
inlet	O
flow	O
rate	O
(	O
1	O
)	O
and	O
1	O
.	O
09	O
L	O
/	O
min	O
outlet	O
low	O
rate	O
(	O
2	O
).	O

(	O
a	O
)	O
Backtracking	O
of	O
flow	O
lines	O
from	O
deposition	O
chambers	O
and	O
excess	O
outlet	O
to	O
the	O
beginning	O
of	O
the	O
aerosol	O
feeding	O
tube	O
.	O

(	O
b	O
)	O
Flow	O
lines	O
running	O
to	O
the	O
deposition	O
chambers	O
start	O
at	O
specific	O
locations	O
at	O
the	O
beginning	O
of	O
the	O
feeding	O
tube	O
.	O

(	O
a	O
)	O
Unequal	O
deposition	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
microparticles	O
on	O
filter	O
membranes	O
after	O
a	O
60	O
min	O
exposure	O
.	O

(	O
b	O
)	O
Inlet	O
-	O
adapter	O
with	O
an	O
integrated	O
jet	O
nozzle	O
to	O
avoid	O
unequal	O
particle	O
deposition	O
within	O
the	O
CULTEX	O
RFS	O
module	O
.	O

(	O
c	O
)	O
Uniform	O
deposition	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
on	O
filter	O
membranes	O
after	O
a	O
60	O
min	O
exposure	O
with	O
a	O
jet	O
nozzle	O
.	O

Relative	O
cell	O
viability	O
of	O
A549	O
cells	O
after	O
exposure	O
to	O
lactose	B-CD
monohydrate	O
particles	O
normalized	O
to	O
the	O
clean	O
air	O
control	O
dependent	O
on	O
time	O
(	O
15	O
,	O
30	O
,	O
and	O
60	O
min	O
).	O

Particle	O
number	O
(	O
black	O
line	O
)	O
and	O
particle	O
mass	O
distribution	O
(	O
red	O
line	O
)	O
of	O
the	O
generated	O
lactose	B-CD
monohydrate	I-CD
aerosol	O
entering	O
the	O
exposure	O
module	O
.	O

The	O
analysis	O
was	O
performed	O
with	O
an	O
Aerodynamic	O
Particle	O
Sizer	O
(	O
TSI	O
Inc	O
.).	O

Relative	O
cell	O
viability	O
of	O
A549	O
cells	O
after	O
exposure	O
to	O
copper	O
(	O
II	O
)	O
sulfate	O
particles	O
normalized	O
to	O
the	O
clean	O
air	O
control	O
dependent	O
on	O
time	O
(	O
15	O
,	O
30	O
,	O
and	O
60	O
min	O
).	O

Particle	O
number	O
(	O
black	O
line	O
)	O
and	O
particle	O
mass	O
distribution	O
(	O
red	O
line	O
)	O
of	O
the	O
generated	O
copper	O
(	O
II	O
)	O
sulfate	O
aerosol	O
entering	O
the	O
exposure	O
module	O
.	O

The	O
analysis	O
was	O
performed	O
with	O
an	O
Aerodynamic	O
Particle	O
Sizer	O
(	O
TSI	O
Inc	O
.).	O

Relative	O
cell	O
viability	O
of	O
A549	O
cells	O
after	O
exposure	O
to	O
copper	O
(	O
II	O
)	O
oxide	O
microparticles	O
normalized	O
to	O
the	O
clean	O
air	O
control	O
dependent	O
on	O
time	O
(	O
15	O
,	O
30	O
,	O
and	O
60	O
min	O
).	O

Particle	O
number	O
(	O
black	O
line	O
)	O
and	O
particle	O
mass	O
distribution	O
(	O
red	O
line	O
)	O
of	O
the	O
generated	O
copper	O
(	O
II	O
)	O
oxide	O
microaerosol	O
entering	O
the	O
exposure	O
module	O
.	O

The	O
analysis	O
was	O
performed	O
with	O
an	O
Aerodynamic	O
Particle	O
Sizer	O
(	O
TSI	O
Inc	O
.).	O

Relative	O
cell	O
viability	O
of	O
A549	O
cells	O
after	O
exposure	O
to	O
copper	O
(	O
II	O
)	O
oxide	O
nanoparticles	O
normalized	O
to	O
the	O
clean	O
air	O
control	O
dependent	O
on	O
time	O
(	O
15	O
,	O
30	O
,	O
and	O
60	O
min	O
).	O

Particle	O
number	O
(	O
black	O
line	O
)	O
and	O
particle	O
mass	O
distribution	O
(	O
red	O
line	O
)	O
of	O
the	O
generated	O
copper	O
(	O
II	O
)	O
oxide	O
nano	O
aerosol	O
entering	O
the	O
exposure	O
module	O
.	O

The	O
analysis	O
was	O
performed	O
with	O
an	O
Aerodynamic	O
Particle	O
Sizer	O
(	O
TSI	O
Inc	O
.).	O

Substances	O
used	O
for	O
the	O
generation	O
of	O
dry	O
powder	O
atmospheres	O
.	O

Substance	O

Producer	O
/	O
catalogue	O
number	O

Primary	O
particle	O
size	O

Lactose	B-CD
monohydrat	I-CD

Fluka	O
/	O
61341	O

Not	O
available	O


Copper	O
(	O
II	O
)	O
oxide	O
nano	O

Ionic	O
Liquids	O
Technologies	O
GmbH	O
/	O
NO	O
-	O
0031	O
-	O
HP	O

40	O
–	O
80	O
nm	O


Copper	O
(	O
II	O
)	O
oxide	O
mikro	O

Sigma	O
Aldrich	O
/	O
20844	O
-	O
1	O

5	O
μm	O


Copper	O
(	O
II	O
)	O
sulfat	O

Sigma	O
Aldrich	O
/	O
12852	O

Not	O
available	O

Conditions	O
for	O
the	O
generation	O
of	O
powder	O
cakes	O
and	O
particulate	O
atmospheres	O
.	O

Substance	O

Powder	O
cake	O
generation	O

Particle	O
generation	O

Pressure	O
(	O
bar	O
)	O

Scraper	O
(	O
rev	O
/	O
h	O
)	O

Feed	O
rate	O
(	O
mm	O
/	O
h	O
)	O

Lactose	B-CD
monohydrat	I-CD

110	O

800	O

10	O
.	O
0	O

Copper	O
(	O
II	O
)	O
oxide	O
nano	O

82	O

800	O

2	O
.	O
5	O

Copper	O
(	O
II	O
)	O
oxide	O
micro	O

82	O

800	O

2	O
.	O
0	O

Copper	O
(	O
II	O
)	O
sulfate	O

82	O

800	O

4	O
.	O
5	O

Deposition	O
of	O
copper	O
(	O
II	O
)	O
oxide	O
microparticles	O
on	O
filter	O
membranes	O
after	O
an	O
exposure	O
time	O
of	O
60	O
minutes	O
with	O
a	O
jet	O
nozzle	O
in	O
the	O
inlet	O
adapter	O
.	O

60	O
minutes	O
exposure	O
of	O
copper	O
(	O
II	O
)	O
oxide	O

Chamber	O
1	O

Chamber	O
2	O

Chamber	O
3	O

Weight	O
gain	O
of	O
filter	O
paper	O
(	O
μg	O
)	O

530	O

529	O

549	O

Weight	O
gain	O
of	O
filter	O
paper	O
(	O
μg	O
)	O

529	O

537	O

521	O

Weight	O
gain	O
of	O
filter	O
paper	O
(	O
μg	O
)	O

548	O

553	O

548	O

Exposure	O
systems	O
for	O
exposing	O
cultivated	O
cells	O
at	O
the	O
air	O
-	O
liquid	O
interface	O
.	O

Exposure	O
system	O

Electrostatic	O
precipitation	O

Cell	O
type	O

Test	O
atmosphere	O

Literature	O

Cultex	O
CG	O

No	O

LK004HFBE	O
-	O
21CHO	O
-	O
K1A549BEAS	O
-	O
2B	O

Cigarette	O
smokeDiesel	O
exhaust	O
Ozone	O
and	O
nitrogene	O
dioxidePhosgeneVolatile	O
organic	O
compoundsPharmaceuticalsTrichloramineFly	O
ashParticles	O

Aufderheide	O
and	O
Mohr	O
1999	O
[	O
12	O
]	O
Ritter	O
et	O
al	O
.	O

2001	O
[	O
46	O
]	O
Knebel	O
et	O
al	O
.	O

2002	O
[	O
47	O
]	O
Diabaté	O
et	O
al	O
.	O

2008	O
[	O
48	O
]	O
Pariselli	O
et	O
al	O
.	O

2009	O
[	O
49	O
]	O
Deschl	O
et	O
al	O
.	O

2011	O
[	O
50	O
]	O
Schmalz	O
et	O
al	O
.	O

2011	O
[	O
51	O
]	O
Wijte	O
et	O
al	O
.	O

2011	O
[	O
52	O
]	O
Nara	O
et	O
al	O
.	O
[	O
53	O
]	O
Elihn	O
et	O
al	O
.	O

2012	O
[	O
54	O
]	O


Cultex	O
RFS	O

Yes	O

A54916HBE14o	O
-	O

Cigarette	O
smoke	O

Aufderheide	O
et	O
al	O
.	O

2011	O
[	O
17	O
]	O


ALICE	O

No	O

A549	O

Carbon	O
black	O
nanoparticlesZinc	O
oxide	O
nanoparticlesGold	O
nanoparticles	O

Lenz	O
et	O
al	O
.	O

2009	O
[	O
14	O
]	O


NACIVT	O

Yes	O

BEAS	O
-	O
2BPorcine	O
lung	O
macrophages	O

Secondary	O
organic	O
aerosolsPolystyrene	O
particles	O

Gaschen	O
et	O
al	O
.	O

2010	O
[	O
55	O
]	O
Savi	O
et	O
al	O
.	O

2008	O
[	O
16	O
]	O


Vitrocell	O

No	O

A549	O

Laser	O
printer	O
emissionsVolatile	O
organic	O
compoundsCarbon	O
nanotubes	O

Tang	O
et	O
al	O
.	O

2012	O
[	O
56	O
]	O
Frohlich	O
et	O
al	O
.	O

2012	O
[	O
57	O
]	O
Anderson	O
et	O
al	O
.	O

2010	O
[	O
58	O
]	O
Gminski	O
et	O
al	O
.	O

2011	O
[	O
59	O
]	O


BAT	O

No	O

NCI	O
-	O
H292	O

Cigarette	O
smoke	O

Phillips	O
et	O
al	O
.	O

2005	O
[	O
35	O
]	O


EAVES	O

Yes	O

A549	O

Polystyrene	O
particlesDiesel	O
exhaustCoarse	O
ambient	O
particles	O

de	O
Bruijne	O
et	O
al	O
.	O

2009	O
[	O
15	O
]	O
Volckens	O
et	O
al	O
.	O

2009	O
[	O
60	O
]	O

Constitutive	O
Neutrophil	O
Apoptosis	O
:	O
Regulation	O
by	O
Cell	O
Concentration	O
via	O
S100	B-GP
A8	I-GP
/	O
9	O
and	O
the	O
MEK	B-GP
–	O
ERK	B-GP
Pathway	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MA	O
DM	O
.	O

Performed	O
the	O
experiments	O
:	O
MA	O
AK	O
UT	O
SB	O
AG	O
IV	O
DM	O
.	O

Analyzed	O
the	O
data	O
:	O
MA	O
AK	O
UT	O
SB	O
AG	O
IV	O
DM	O
.	O

Wrote	O
the	O
paper	O
:	O
MA	O
DM	O
.	O

Programmed	O
cell	O
death	O
(	O
PCD	O
)	O
is	O
a	O
fundamental	O
mechanism	O
in	O
tissue	O
and	O
cell	O
homeostasis	O
.	O

It	O
was	O
long	O
suggested	O
that	O
apoptosis	O
regulates	O
the	O
cell	O
number	O
in	O
diverse	O
cell	O
populations	O
;	O
however	O
no	O
clear	O
mechanism	O
was	O
shown	O
.	O

Neutrophils	O
are	O
the	O
short	O
-	O
lived	O
,	O
first	O
-	O
line	O
defense	O
of	O
innate	O
immunity	O
,	O
with	O
an	O
estimated	O
t	O
=	O
1	O
/	O
2	O
of	O
8	O
hours	O
and	O
a	O
high	O
turnover	O
rate	O
.	O

Here	O
we	O
first	O
show	O
that	O
spontaneous	O
neutrophil	O
constitutive	O
PCD	O
is	O
regulated	O
by	O
cell	O
concentrations	O
.	O

Using	O
a	O
proteomic	O
approach	O
,	O
we	O
identified	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
,	O
which	O
constitutes	O
roughly	O
40	O
%	O
of	O
cytosolic	O
protein	O
in	O
neutrophils	O
,	O
as	O
mediating	O
this	O
effect	O
.	O

We	O
further	O
demonstrate	O
that	O
it	O
regulates	O
cell	O
survival	O
via	O
a	O
signaling	O
mechanism	O
involving	O
MEK	B-GP
-	O
ERK	B-GP
via	O
TLR4	B-GP
and	O
CD11B	B-GP
/	O
CD18	B-GP
.	O

This	O
mechanism	O
is	O
suggested	O
to	O
have	O
a	O
fine	O
-	O
tuning	O
role	O
in	O
regulating	O
the	O
neutrophil	O
number	O
in	O
bone	O
marrow	O
,	O
peripheral	O
blood	O
,	O
and	O
inflammatory	O
sites	O
.	O

Introduction	O

Programmed	O
cell	O
death	O
(	O
PCD	O
)	O
is	O
a	O
fundamental	O
mechanism	O
in	O
tissue	O
and	O
cell	O
homeostasis	O
,	O
long	O
thought	O
to	O
regulate	O
cell	O
number	O
in	O
diverse	O
populations	O
.	O

In	O
developmental	O
biology	O
,	O
PCD	O
provides	O
an	O
efficient	O
mechanism	O
for	O
eliminating	O
unwanted	O
cells	O
,	O
as	O
shown	O
in	O
studies	O
with	O
the	O
nematode	B-OG
Caenorhabditis	B-OG
elegans	I-OG
[	O
1	O
].	O

Of	O
the	O
1090	O
somatic	O
cells	O
formed	O
during	O
the	O
development	O
of	O
an	O
adult	O
hermaphrodite	O
,	O
exactly	O
131	O
die	O
,	O
demonstrating	O
the	O
morphological	O
features	O
of	O
apoptosis	O
.	O

In	O
the	O
mammalian	O
immune	O
system	O
,	O
clonal	O
triggering	O
results	O
in	O
lymphocyte	O
proliferation	O
followed	O
by	O
activation	O
-	O
induced	O
cell	O
death	O
that	O
ensures	O
T	O
cells	O
will	O
return	O
to	O
their	O
original	O
concentration	O
,	O
adding	O
only	O
a	O
negligible	O
number	O
of	O
memory	O
cells	O
[	O
2	O
].	O

Few	O
studies	O
in	O
the	O
human	B-OG
immune	O
system	O
have	O
questioned	O
the	O
mechanism	O
of	O
constitutive	O
leukocyte	O
blood	O
concentration	O
regulation	O
via	O
PCD	O
.	O

In	O
humans	B-OG
,	O
neutrophils	O
are	O
the	O
short	O
-	O
lived	O
,	O
first	O
-	O
line	O
defense	O
of	O
innate	O
immunity	O
,	O
with	O
estimated	O
t	O
=	O
1	O
/	O
2	O
of	O
8	O
hours	O
and	O
a	O
high	O
turnover	O
rate	O
[	O
3	O
].	O

These	O
cells	O
,	O
which	O
represent	O
50	O
–	O
60	O
%	O
of	O
the	O
circulating	O
leukocytes	O
in	O
normal	O
conditions	O
,	O
are	O
considered	O
terminally	O
differentiated	O
cells	O
.	O

They	O
are	O
rapidly	O
recruited	O
and	O
accumulate	O
in	O
the	O
early	O
phase	O
of	O
inflammation	O
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
absent	O
triggers	O
initiating	O
neutrophil	O
exit	O
from	O
the	O
blood	O
pool	O
into	O
tissues	O
,	O
human	B-OG
blood	O
neutrophil	O
counts	O
are	O
determined	O
by	O
the	O
balance	O
between	O
neutrophil	O
hematopoiesis	O
,	O
neutrophil	O
mobilization	O
from	O
the	O
bone	O
marrow	O
,	O
the	O
marginal	O
pool	O
,	O
spontaneous	O
constitutive	O
PCD	O
,	O
and	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
.	O

Human	B-OG
neutrophils	O
are	O
generated	O
in	O
bone	O
marrow	O
,	O
mainly	O
under	O
the	O
control	O
of	O
G	B-GP
-	I-GP
CSF	I-GP
and	O
additional	O
cytokines	B-GP
and	O
growth	O
factors	O
,	O
including	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
3	I-GP
(	O
reviewed	O
by	O
Metcalf	O
[	O
4	O
]),	O
and	O
possibly	O
IL	B-GP
-	I-GP
17	I-GP
and	O
IL	B-GP
-	I-GP
23	I-GP
[	O
5	O
],	O
as	O
well	O
as	O
IL	B-GP
-	I-GP
22	I-GP
.	O

Martin	O
et	O
al	O
.,	O
and	O
others	O
,	O
suggested	O
that	O
neutrophils	O
are	O
retained	O
in	O
the	O
bone	O
marrow	O
through	O
interaction	O
of	O
CXCL12	B-GP
(	O
stromal	B-GP
derived	I-GP
factor	I-GP
1	I-GP
,	O
or	O
SDF	B-GP
-	I-GP
1	I-GP
)	O
with	O
its	O
receptor	O
CXCR4	B-GP
[	O
6	O
]–[	O
7	O
].	O

In	O
the	O
blood	O
pool	O
,	O
neutrophils	O
circulate	O
until	O
they	O
are	O
marginated	O
or	O
develop	O
morphological	O
changes	O
due	O
to	O
PCD	O
,	O
and	O
are	O
cleared	O
by	O
Kupfer	O
cells	O
in	O
the	O
liver	O
[	O
8	O
]	O
or	O
by	O
bone	O
marrow	O
macrophages	O
[	O
9	O
].	O

Various	O
cytokines	B-GP
regulate	O
blood	O
neutrophil	O
counts	O
.	O

Catecholamines	B-CD
mobilize	O
the	O
marginal	O
pool	O
[	O
10	O
],	O
while	O
G	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
17	I-GP
,	O
and	O
IL	B-GP
-	I-GP
23	I-GP
[	O
5	O
]	O
may	O
modify	O
counts	O
via	O
bone	O
marrow	O
.	O

Yet	O
,	O
the	O
major	O
regulator	O
of	O
blood	O
neutrophil	O
counts	O
and	O
neutrophils	O
at	O
inflammatory	O
sites	O
is	O
PCD	B-GP
,	O
which	O
allows	O
only	O
a	O
short	O
neutrophil	O
life	O
span	O
,	O
modulated	O
according	O
to	O
specific	O
needs	O
,	O
such	O
as	O
inflammation	O
.	O

Molecular	O
events	O
leading	O
to	O
this	O
short	O
neutrophil	O
lifespan	O
are	O
better	O
understood	O
now	O
.	O

An	O
important	O
regulator	O
of	O
neutrophil	O
apoptosis	O
seems	O
to	O
be	O
the	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
family	O
,	O
and	O
a	O
major	O
event	O
in	O
spontaneous	O
neutrophil	O
PCD	O
appears	O
related	O
to	O
loss	O
of	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

Bcl	B-GP
-	I-GP
2	I-GP
is	O
lost	O
during	O
neutrophil	O
differentiation	O
,	O
and	O
not	O
expressed	O
by	O
peripheral	O
blood	O
neutrophils	O
[	O
11	O
]–[	O
14	O
].	O

Bcl	B-GP
-	I-GP
xl	I-GP
is	O
also	O
expressed	O
by	O
neutrophils	O
,	O
and	O
expression	O
decreases	O
upon	O
TNFα	B-GP
-	O
mediated	O
apoptosis	O
[	O
14	O
].	O

Mcl1	B-GP
declines	O
as	O
neutrophils	O
undergo	O
spontaneous	O
apoptosis	O
,	O
and	O
is	O
upregulated	O
when	O
cells	O
are	O
exposed	O
to	O
survival	O
factors	O
such	O
as	O
GMCSF	O
,	O
butyrate	O
,	O
ILβ	B-GP
,	O
and	O
LPS	O
[	O
12	O
].	O

A1	O
,	O
expressed	O
in	O
neutrophils	O
at	O
the	O
mRNA	O
level	O
[	O
13	O
],	O
[	O
15	O
],	O
is	O
also	O
upregulated	O
by	O
survival	O
factors	O
GCSF	B-GP
and	O
LPS	O
[	O
15	O
].	O

Furthermore	O
,	O
neutrophils	O
do	O
not	O
express	O
survivin	B-GP
,	O
an	O
inhibitor	B-GP
-	I-GP
of	I-GP
-	I-GP
apoptosis	I-GP
protein	I-GP
(	O
IAP	B-GP
),	O
unless	O
expression	O
is	O
induced	O
by	O
GCSF	B-GP
and	O
GMCSF	B-GP
or	O
in	O
inflammatory	O
conditions	O
[	O
16	O
].	O

In	O
contrast	O
,	O
pro	O
-	O
apoptotic	O
proteins	O
Bax	B-GP
,	O
Bak	B-GP
,	O
and	O
Bad	B-GP
are	O
constitutively	O
expressed	O
[	O
13	O
],	O
[	O
14	O
],	O
[	O
17	O
].	O

The	O
extrinsic	O
pathway	O
may	O
also	O
be	O
involved	O
.	O

Neutrophils	O
constitutively	O
express	O
Fas	B-GP
and	O
Fas	B-GP
ligand	O
,	O
although	O
the	O
importance	O
of	O
Fas	B-GP
-	O
induced	O
death	O
remains	O
controversial	O
[	O
11	O
],	O
[	O
18	O
]–[	O
20	O
].	O

In	O
addition	O
,	O
neutrophil	O
life	O
expectancy	O
can	O
be	O
modulated	O
by	O
various	O
mediators	O
(	O
G	B-GP
-	I-GP
CSF	I-GP
,	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
IL1β	B-GP
,	O
IFN	B-GP
-	I-GP
gamma	I-GP
,	O
and	O
LPS	O
[	O
21	O
]–[	O
25	O
])	O
or	O
functional	O
events	O
such	O
as	O
transmigration	O
across	O
the	O
endothelium	O
[	O
26	O
].	O

Despite	O
our	O
growing	O
understanding	O
of	O
molecular	O
control	O
of	O
neutrophil	O
PCD	O
,	O
it	O
remains	O
unclear	O
how	O
specific	O
neutrophil	O
blood	O
concentration	O
is	O
maintained	O
.	O

We	O
hypothesized	O
that	O
cell	O
concentration	O
might	O
serve	O
as	O
a	O
neutrophil	O
count	O
regulator	O
via	O
a	O
feedback	O
mechanism	O
affecting	O
PCD	O
.	O

We	O
examined	O
the	O
in	O
vitro	O
effect	O
of	O
cell	O
number	O
on	O
spontaneous	O
neutrophil	O
PCD	O
,	O
and	O
demonstrated	O
that	O
neutrophil	O
PCD	O
is	O
strongly	O
influenced	O
by	O
cell	O
concentration	O
.	O

We	O
hypothesized	O
that	O
secreted	O
molecules	O
mediate	O
this	O
effect	O
,	O
and	O
used	O
a	O
proteomic	O
approach	O
,	O
which	O
showed	O
that	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
is	O
regulated	O
by	O
cell	O
concentration	O
through	O
molecules	O
released	O
during	O
neutrophil	O
PCD	O
.	O

We	O
further	O
show	O
that	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
is	O
a	O
primary	O
regulatory	O
molecule	O
regulating	O
cell	O
survival	O
via	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
,	O
and	O
through	O
a	O
signaling	O
mechanism	O
involving	O
MEK	B-GP
-	O
ERK	B-GP
.	O

Materials	O
and	O
Methods	O

Materials	O

Cell	O
culture	O
medium	O
consisted	O
of	O
RPMI	O
1640	O
(	O
Invitrogen	O
-	O
Gibco	O
,	O
NY	O
)	O
supplemented	O
with	O
1	O
%	O
L	B-CD
-	I-CD
glutamine	I-CD
and	O
1	O
%	O
penicillin	B-CD
/	O
streptomycin	B-CD
(	O
Biological	O
Industries	O
,	O
Kibbutz	O
Beit	O
-	O
Haemek	O
,	O
Israel	O
).	O

The	O
APOPTEST	O
-	O
FITC	O
Kit	O
containing	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
was	O
obtained	O
from	O
Nexins	O
Research	O
B	O
.	O
V	O
.	O

(	O
Hoeven	O
,	O
The	O
Netherlands	O
)	O
or	O
from	O
MBL	O
International	O
(	O
Cambridge	O
,	O
MA	O
).	O

Propidium	B-CD
iodide	I-CD
(	O
PI	O
)	O
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
).	O

Recombinant	O
proteins	O
S100A8	B-GP
and	O
S100A9	B-GP
,	O
and	O
blocking	O
antibodies	B-GP
were	O
generously	O
supplied	O
by	O
Dr	O
.	O
Philippe	O
A	O
.	O

Tessier	O
.	O
(	O
Laval	O
University	O
,	O
Quebec	O
,	O
Canada	O
).	O

The	O
pan	O
-	O
caspase	B-GP
inhibitor	O
zVAD	O
-	O
fmk	O
was	O
purchased	O
from	O
R	O
&	O
D	O
systems	O
(	O
Minneapolis	O
,	O
MN	O
).	O

Mouse	B-OG
anti	O
-	O
human	B-OG
CD36	B-GP
-	O
PE	O
,	O
mouse	B-OG
anti	O
-	O
human	B-OG
CD11b	B-GP
-	O
PE	O
,	O
and	O
isotype	O
control	O
IgG1	B-GP
-	O
PE	B-GP
were	O
obtained	O
from	O
Serotec	O
(	O
Oxford	O
,	O
UK	O
),	O
and	O
isotype	O
control	O
mouse	B-OG
IgM	B-GP
-	O
PE	B-GP
from	O
Dako	O
(	O
Glostrup	O
,	O
Denmark	O
).	O

DiOC6	O
(	O
3	O
)	O
(	O
3	O
,	O
3	O
-	O
dihexyloxacarbocyanine	O
iodide	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
).	O

MEK	B-GP
inhibitor	O
PD98059	B-CD
was	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Danvers	O
,	O
MA	O
).	O

Antibody	B-GP
against	O
the	O
complex	O
S100A8	B-GP
/	O
9	O
for	O
flow	O
cytometry	O
analysis	O
was	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
).	O

For	O
blocking	O
assays	O
,	O
rabbit	B-OG
polyclonal	O
anti	O
-	O
S100A9	B-GP
and	O
anti	O
-	O
S100A8	B-GP
were	O
generously	O
supplied	O
by	O
Dr	O
Philippe	O
A	O
.	O

Tessier	O
,	O
and	O
blocking	O
antibody	B-GP
against	O
CD11b	B-GP
(	O
BioLegend	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
used	O
at	O
different	O
dilutions	O
as	O
indicated	O
.	O

Rabbit	B-OG
serum	O
was	O
obtained	O
from	O
Jackson	O
Laboratories	O
(	O
Jackson	O
ImmunoResearch	O
,	O
West	O
Grove	O
,	O
PA	O
).	O

Cell	O
isolation	O
and	O
culturing	O

Blood	O
neutrophils	O
were	O
isolated	O
from	O
fresh	O
buffy	O
coats	O
obtained	O
from	O
healthy	O
donors	O
.	O

RBCs	O
were	O
sedimented	O
by	O
adding	O
6	O
%	O
hetastarch	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
Vancouver	O
,	O
Canada	O
)	O
and	O
kept	O
at	O
25	O
°	O
C	O
for	O
up	O
to	O
45	O
min	O
.	O

The	O
leukocyte	O
-	O
rich	O
upper	O
layer	O
of	O
the	O
suspension	O
was	O
then	O
collected	O
and	O
centrifuged	O
on	O
a	O
density	O
gradient	O
with	O
Ficoll	O
-	O
Paque	O
(	O
Amersham	O
Biosciences	O
,	O
Uppsala	O
,	O
Sweden	O
).	O

Residual	O
erythrocytes	O
were	O
removed	O
by	O
hypotonic	O
lysis	O
.	O

Neutrophils	O
were	O
maintained	O
in	O
suspension	O
,	O
at	O
different	O
concentrations	O
as	O
indicated	O
,	O
in	O
RPMI	O
1640	O
medium	O
,	O
1	O
%	O
L	B-CD
-	I-CD
glutamine	I-CD
,	O
and	O
1	O
%	O
penicillin	B-CD
/	O
streptomycin	B-CD
,	O
in	O
24	O
-	O
well	O
plates	O
at	O
37	O
°	O
C	O
,	O
in	O
a	O
humidified	O
incubator	O
containing	O
5	O
%	O
CO2	O
.	O

Cells	O
were	O
>	O
95	O
%	O
neutrophils	O
as	O
determined	O
by	O
morphological	O
analysis	O
and	O
>	O
99	O
%	O
viable	O
as	O
determined	O
by	O
Trypan	B-CD
blue	I-CD
dye	O
exclusion	O

Apoptosis	O
assessment	O

Apoptosis	O
assessment	O
was	O
performed	O
as	O
previously	O
described	O
[	O
27	O
]	O
(	O
For	O
detailed	O
method	O
see	O
–	O
Methods	O
S1	O
).	O

Supernatant	O
transfer	O

Neutrophils	O
were	O
suspended	O
at	O
concentrations	O
of	O
either	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
or	O
16	O
×	O
106	O
/	O
ml	O
,	O
for	O
different	O
times	O
as	O
indicated	O
,	O
at	O
37	O
°	O
C	O
/	O
5	O
%	O
CO2	O
.	O

After	O
culturing	O
,	O
the	O
supernatants	O
of	O
the	O
high	O
concentration	O
were	O
collected	O
and	O
added	O
to	O
fresh	O
neutrophils	O
from	O
the	O
same	O
donor	O
at	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
and	O
vice	O
versa	O
.	O

The	O
neutrophils	O
were	O
then	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
and	O
apoptosis	O
was	O
detected	O
as	O
described	O
.	O

Transmission	O
electron	O
microscopy	O

Cells	O
were	O
fixed	O
in	O
2	O
%	O
glutaraldedyde	O
in	O
cacodylate	O
buffer	O
(	O
0	O
.	O
1M	O
,	O
PH	O
7	O
.	O
2	O
–	O
7	O
.	O
4	O
)	O
and	O
washed	O
three	O
times	O
in	O
the	O
same	O
buffer	O
.	O

Cells	O
were	O
then	O
postfixed	O
in	O
1	O
%	O
OSO4	O
for	O
1	O
h	O
at	O
room	O
temperature	O
,	O
washed	O
in	O
cacodylate	O
buffer	O
,	O
dedydrated	O
in	O
gradient	O
series	O
of	O
ethanol	O
(	O
25	O
%,	O
50	O
%,	O
75	O
%,	O
95	O
%,	O
100	O
%×	O
2	O
),	O
treated	O
with	O
propylene	O
-	O
oxide	O
for	O
20	O
min	O
(	O
2	O
changes	O
),	O
and	O
embedded	O
in	O
Araldite	O
Resin	O
.	O

Thin	O
sections	O
were	O
prepared	O
with	O
an	O
ultramicrotom	O
and	O
examined	O
at	O
an	O
accelerated	O
voltage	O
of	O
100KW	O
by	O
transmission	O
electron	O
microscope	O
(	O
CM12	O
,	O
Philips	O
,	O
Eindhoeven	O
,	O
The	O
Netherlands	O
).	O

Proteomic	O
(	O
SDS	O
-	O
PAGE	O
and	O
MS	O
)	O
and	O
Western	O
blotting	O

Proteomic	O
(	O
SDS	O
-	O
PAGE	O
and	O
MS	O
)	O
and	O
Western	O
blotting	O
were	O
performed	O
as	O
previously	O
described	O
[	O
28	O
]	O
(	O
For	O
detailed	O
method	O
see	O
–	O
Methods	O
S1	O
).	O

Transfection	O

The	O
two	O
cell	O
lines	O
,	O
Chinese	B-OG
hamster	I-OG
ovary	I-OG
(	O
CHO	O
),	O
and	O
CHO	O
stably	O
transfected	O
with	O
complement	B-GP
receptor	I-GP
CR3	I-GP
,	O
were	O
kindly	O
provided	O
by	O
Drs	O
.	O

R	O
.	O
R	O
.	O

Ingalls	O
and	O
D	O
.	O
T	O
.	O

Golenbock	O
,	O
Boston	O
Medical	O
Center	O
,	O
Boston	O
,	O
MA	O
.	O

Leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
patients	O
and	O
controls	O

LAD	O
patients	O
signed	O
an	O
informed	O
consent	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Hadassah	O
-	O
Hebrew	O
University	O
Medical	O
Center	O
.	O

Controls	O
consisted	O
of	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
donors	O
,	O
who	O
signed	O
an	O
informed	O
consent	O
.	O

Blood	O
(	O
10	O
ml	O
)	O
from	O
healthy	O
donors	O
and	O
heparinized	O
blood	O
(	O
10	O
ml	O
)	O
from	O
patients	O
was	O
drawn	O
and	O
evaluated	O
on	O
the	O
same	O
day	O
.	O

Detection	O
of	O
intracellular	O
phosphorylated	O
ERK	B-GP
by	O
flow	O
cytometry	O

For	O
the	O
assessment	O
of	O
phosphorylation	O
of	O
the	O
ERK	B-GP
,	O
freshly	O
isolated	O
neutrophils	O
were	O
treated	O
as	O
indicated	O
and	O
prepared	O
for	O
intracellular	O
staining	O
.	O

Cells	O
were	O
washed	O
with	O
PBS	O
,	O
fixed	O
with	O
2	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
,	O
and	O
permeabilized	O
with	O
90	O
%	O
methanol	O
for	O
30	O
min	O
on	O
ice	O
.	O

Cells	O
then	O
were	O
rinsed	O
and	O
incubated	O
for	O
10	O
min	O
at	O
RT	O
in	O
PBS	O
containing	O
0	O
.	O
5	O
%	O
BSA	B-GP
(	O
for	O
blocking	O
),	O
and	O
stained	O
with	O
either	O
mouse	B-OG
anti	O
-	O
human	B-OG
phospho	O
-	O
p44	B-GP
/	O
42	O
MAPK	B-GP
alexa	O
fluor	O
488	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
or	O
isotype	O
control	O
mouse	B-OG
IgG1	B-GP
alexa	O
fluor	O
488	O
(	O
BioLegend	O
).	O

Statistical	O
analysis	O

The	O
Student	O
'	O
s	O
t	O
test	O
and	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
to	O
compare	O
mean	O
data	O
.	O

The	O
Kolmogorov	O
-	O
Smirnov	O
test	O
was	O
used	O
to	O
analyze	O
flow	O
cytometry	O
results	O
.	O

Differences	O
were	O
considered	O
statistically	O
significant	O
for	O
p	O
<	O
0	O
.	O
05	O
.	O

Results	O

The	O
effect	O
of	O
cell	O
concentration	O
on	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O

We	O
assumed	O
constitutive	O
spontaneous	O
PCD	O
requires	O
one	O
or	O
more	O
autoregulatory	O
negative	O
feedback	O
mechanisms	O
exerted	O
by	O
dying	O
neutrophils	O
that	O
affect	O
survival	O
rates	O
of	O
the	O
remaining	O
cells	O
(	O
Fig	O
.	O
1	O
).	O

Without	O
this	O
effect	O
,	O
one	O
might	O
assume	O
that	O
PCD	O
increases	O
at	O
higher	O
concentrations	O
due	O
to	O
competition	O
for	O
nutrition	O
and	O
other	O
ingredients	O
.	O

We	O
designed	O
an	O
experiment	O
to	O
examine	O
the	O
effect	O
of	O
various	O
cell	O
concentrations	O
in	O
the	O
physiological	O
range	O
(	O
peripheral	O
blood	O
neutrophil	O
concentration	O
∼	O
2	O
−	O
6	O
×	O
106	O
/	O
ml	O
)	O
on	O
the	O
constitutive	O
spontaneous	O
PCD	O
rate	O
.	O

A	O
higher	O
apoptotic	O
cell	O
concentration	O
had	O
a	O
protective	O
anti	O
-	O
apoptotic	O
effect	O
,	O
and	O
the	O
rate	O
of	O
neutrophil	O
PCD	O
was	O
inversely	O
proportional	O
to	O
cell	O
concentration	O
,	O
indicating	O
an	O
anti	O
-	O
apoptotic	O
effect	O
(	O
Fig	O
.	O
2A	O
).	O

Whereas	O
following	O
12h	O
of	O
spontaneous	O
constitutive	O
PCD	O
only	O
5	O
%	O
of	O
cells	O
were	O
still	O
alive	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
neutrophils	O
/	O
ml	O
,	O
in	O
conditions	O
of	O
32	O
fold	O
concentration	O
,	O
at	O
16	O
×	O
106	O
neutrophils	O
/	O
ml	O
,	O
more	O
than	O
40	O
%	O
of	O
the	O
cells	O
were	O
still	O
alive	O
,	O
as	O
shown	O
by	O
Annexin	B-GP
V	I-GP
and	O
PI	B-GP
negative	O
staining	O
(	O
Fig	O
.	O
2B	O
)	O
and	O
verified	O
by	O
mitochondrial	O
potential	O
loss	O
studies	O
(	O
not	O
shown	O
),	O
both	O
methods	O
of	O
apoptosis	O
detection	O
indicated	O
early	O
apoptosis	O
state	O
.	O

This	O
phenomenon	O
was	O
further	O
emphasized	O
using	O
cell	O
count	O
.	O

There	O
was	O
loss	O
of	O
over	O
50	O
%	O
of	O
cells	O
through	O
constitutive	O
spontaneous	O
PCD	O
at	O
concentrations	O
of	O
­­­­	O
0	O
.	O
5x106	O
/	O
ml	O
for	O
12h	O
(	O
Fig	O
.	O
2C	O
),	O
and	O
this	O
loss	O
decreased	O
in	O
proportion	O
to	O
increasing	O
cell	O
concentrations	O
up	O
to	O
16x106	O
/	O
ml	O
.	O

At	O
concentrations	O
above	O
16x106	O
/	O
ml	O
,	O
there	O
was	O
a	O
decline	O
in	O
cell	O
number	O
and	O
a	O
prodeath	O
effect	O
,	O
probably	O
as	O
a	O
result	O
of	O
competition	O
for	O
nutrition	O
and	O
other	O
ingredients	O
.	O

Constitutive	O
spontaneous	O
neutrophil	O
PCD	O
.	O

A	O
.	O
Kinetics	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
.	O

Neutrophils	O
were	O
isolated	O
and	O
allowed	O
to	O
undergo	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
.	O

Samples	O
were	O
obtained	O
at	O
the	O
indicated	O
intervals	O
,	O
and	O
the	O
apoptosis	O
rate	O
was	O
measured	O
using	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O
B	O
.	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
.	O

Morphology	O
of	O
viable	O
or	O
early	O
apoptotic	O
(	O
white	O
arrow	O
)	O
and	O
apoptotic	O
(	O
black	O
arrows	O
)	O
neutrophils	O
is	O
shown	O
.	O

Apoptotic	O
cells	O
show	O
the	O
typical	O
morphology	O
of	O
condensed	O
cytoplasm	O
and	O
chromatin	O
.	O

Cells	O
were	O
prepared	O
for	O
TEM	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O
C	O
.	O
Inhibition	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
by	O
pan	O
-	O
caspase	B-GP
inhibitor	O
zVAD	O
-	O
fmk	O
.	O

Sample	O
dot	O
plots	O
of	O
AnnexinV	B-GP
-	O
PI	O
staining	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
for	O
14	O
h	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
µM	O
Zvad	B-GP
-	O
fmk	O
.	O

Pan	O
-	O
caspase	B-GP
inhibition	O
rescued	O
cells	O
from	O
apoptotic	O
death	O
and	O
viable	O
cells	O
are	O
increased	O
from	O
19	O
to	O
49	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Data	O
are	O
representative	O
of	O
3	O
or	O
more	O
experiments	O
.	O

Spontaneous	O
constitutive	O
neutrophil	O
PCD	O
is	O
cell	O
concentration	O
-	O
dependent	O
.	O

A	O
.	O
Neutrophils	O
underwent	O
spontaneous	O
constitutive	O
PCD	O
for	O
12	O
h	O
at	O
cell	O
concentrations	O
ranging	O
from	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
up	O
to	O
50	O
×	O
106	O
/	O
ml	O
.	O

(	O
The	O
physiological	O
blood	O
concentration	O
is	O
2	O
−	O
6	O
×	O
106	O
/	O
ml	O
.)	O
Apoptosis	O
was	O
assessed	O
by	O
AnnexinV	B-GP
-	O
FITC	O
and	O
PI	O
staining	O
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Data	O
represents	O
the	O
mean	O
±	O
SD	O
of	O
3	O
experiments	O
.	O
B	O
.	O
Sample	O
dot	O
plots	O
of	O
AnnexinV	B-GP
-	O
PI	O
staining	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
for	O
12	O
h	O
in	O
(	O
a	O
)	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
,	O
and	O
(	O
b	O
)	O
16	O
×	O
106	O
/	O
ml	O
.	O

The	O
percentage	O
of	O
viable	O
,	O
early	O
(	O
AnnexinV	B-GP
+/	O
PI	O
−)	O
and	O
late	O
(	O
AnnexinV	B-GP
+/	O
PI	O
+)	O
apoptotic	O
cells	O
is	O
indicated	O
within	O
the	O
respective	O
quadrants	O
.	O
C	O
.	O
Survival	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
,	O
based	O
on	O
cell	O
counts	O
.	O

Data	O
presented	O
is	O
the	O
mean	O
±	O
SD	O
of	O
3	O
experiments	O
.	O

Thus	O
,	O
at	O
physiological	O
concentrations	O
of	O
neutrophils	O
,	O
there	O
was	O
an	O
anti	O
-	O
apoptotic	O
effect	O
at	O
higher	O
neutrophil	O
concentrations	O
.	O

We	O
termed	O
this	O
a	O
“	O
community	O
effect	O
”	O
―	O
neutrophils	O
are	O
encouraged	O
to	O
live	O
longer	O
as	O
their	O
community	O
is	O
enlarged	O
.	O

Factors	O
mediating	O
the	O
community	O
effect	O
are	O
present	O
in	O
the	O
supernatant	O

In	O
order	O
to	O
determine	O
whether	O
the	O
factor	O
(	O
s	O
)	O
responsible	O
for	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
are	O
found	O
in	O
the	O
supernatant	O
,	O
we	O
exchanged	O
media	O
obtained	O
from	O
low	O
-	O
and	O
high	O
concentrations	O
of	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
.	O

The	O
supernatants	O
from	O
high	O
concentrations	O
were	O
collected	O
and	O
used	O
as	O
media	O
for	O
low	O
-	O
concentration	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
of	O
the	O
same	O
donor	O
,	O
and	O
the	O
supernatants	O
of	O
low	O
concentrations	O
were	O
used	O
as	O
media	O
for	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
high	O
cell	O
concentration	O
.	O

Media	O
based	O
on	O
high	O
-	O
concentration	O
PCD	O
donors	O
(	O
16	O
×	O
106	O
cells	O
/	O
ml	O
)	O
rescued	O
cells	O
undergoing	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
low	O
concentration	O
(	O
0	O
.	O
5	O
×	O
106	O
cells	O
/	O
ml	O
)	O
from	O
apoptosis	O
,	O
as	O
compared	O
with	O
normal	O
medium	O
(	O
Fig	O
.	O
3A	O
).	O

High	O
-	O
concentration	O
medium	O
increased	O
the	O
rate	O
of	O
viable	O
cells	O
from	O
9	O
%	O
(	O
upper	O
left	O
panel	O
,	O
Fig	O
.	O
3B	O
)	O
to	O
31	O
%	O
(	O
upper	O
right	O
panel	O
,	O
Fig	O
.	O
3B	O
).	O

In	O
the	O
opposite	O
experiment	O
,	O
low	O
-	O
concentration	O
media	O
had	O
no	O
effect	O
on	O
survival	O
in	O
high	O
cell	O
concentration	O
samples	O
(	O
left	O
and	O
right	O
lower	O
panels	O
,	O
Fig	O
.	O
3B	O
).	O

All	O
these	O
experiments	O
were	O
based	O
on	O
at	O
least	O
three	O
experiments	O
each	O
and	O
results	O
with	O
Annexin	B-GP
V	I-GP
were	O
verified	O
using	O
mitochondrial	O
potential	O
loss	O
studies	O
.	O

Identification	O
of	O
candidate	O
molecules	O
that	O
induce	O
the	O
community	O
effect	O
.	O

A	O
.	O
Supernatant	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
concentrations	O
has	O
rescued	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
from	O
apoptosis	O
at	O
low	O
concentrations	O
,	O
and	O
improved	O
their	O
survival	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Data	O
is	O
representative	O
of	O
3	O
experiments	O
.	O
B	O
.	O
Representative	O
dot	O
plot	O
of	O
supernatant	O
transfer	O
assay	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
AnnexinV	B-GP
and	O
PI	O
staining	O
of	O
neutrophils	O
after	O
12	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
.	O

The	O
transfer	O
assay	O
was	O
performed	O
as	O
follows	O
:	O
neutrophils	O
underwent	O
spontaneous	O
constitutive	O
PCD	O
at	O
low	O
(	O
a	O
,	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
)	O
or	O
high	O
(	O
c	O
,	O
16	O
×	O
106	O
/	O
ml	O
)	O
concentration	O
for	O
12	O
h	O
.	O

The	O
supernatant	O
of	O
the	O
cells	O
incubated	O
at	O
high	O
concentrations	O
was	O
collected	O
and	O
used	O
as	O
media	O
for	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
PCD	O
at	O
low	O
concentrations	O
(	O
b	O
),	O
and	O
the	O
supernatant	O
of	O
the	O
cells	O
incubated	O
at	O
low	O
concentrations	O
was	O
collected	O
and	O
used	O
for	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
PCD	O
at	O
high	O
concentrations	O
(	O
d	O
).	O
C	O
.	O
SDS	O
-	O
PAGE	O
of	O
differentially	O
displayed	O
proteins	O
from	O
high	O
-	O
and	O
low	O
-	O
concentration	O
spontaneous	O
constitutive	O
PCD	O
.	O

The	O
supernatants	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
-	O
and	O
low	O
concentrations	O
were	O
collected	O
,	O
and	O
the	O
proteins	O
were	O
purified	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Protein	O
samples	O
were	O
electrophorized	O
and	O
stained	O
with	O
Coomassie	B-CD
,	O
as	O
shown	O
.	O

Two	O
proteins	O
,	O
∼	O
14	O
KD	O
and	O
∼	O
10	O
KD	O
,	O
were	O
identified	O
in	O
the	O
supernatant	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
concentrations	O
(	O
16	O
×	O
106	O
/	O
ml	O
).	O

These	O
results	O
suggest	O
that	O
in	O
the	O
presence	O
of	O
high	O
neutrophil	O
concentrations	O
,	O
anti	O
-	O
apoptotic	O
factor	O
(	O
s	O
)	O
are	O
secreted	O
and	O
provide	O
a	O
survival	O
signal	O
to	O
the	O
viable	O
neutrophil	O
community	O
.	O

Proteomic	O
analysis	O
of	O
the	O
supernatants	O
and	O
identification	O
of	O
S100A8	B-GP
and	O
S100A9	B-GP
as	O
candidate	O
molecules	O
for	O
mediation	O
of	O
the	O
community	O
anti	O
-	O
apoptotic	O
signal	O

We	O
used	O
a	O
differentially	O
displayed	O
proteomic	O
approach	O
,	O
as	O
we	O
have	O
previously	O
described	O
[	O
28	O
],	O
to	O
search	O
for	O
secreted	O
factor	O
(	O
s	O
)	O
in	O
the	O
supernatant	O
that	O
may	O
be	O
responsible	O
for	O
the	O
“	O
community	O
effect	O
”	O
on	O
neutrophil	O
survival	O
.	O

The	O
secreted	O
proteomes	O
of	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
high	O
concentrations	O
(	O
16	O
×	O
106	O
/	O
ml	O
)	O
and	O
low	O
concentrations	O
(	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
)	O
were	O
collected	O
and	O
compared	O
by	O
SDS	O
-	O
PAGE	O
and	O
Coomassie	O
staining	O
.	O

Differentially	O
expressed	O
proteins	O
were	O
further	O
analyzed	O
by	O
mass	O
spectrometry	O
(	O
MS	O
).	O

Expression	O
of	O
two	O
proteins	O
,	O
∼	O
10	O
KD	O
and	O
∼	O
14KD	O
,	O
represented	O
the	O
primary	O
difference	O
between	O
the	O
supernatants	O
(	O
Fig	O
.	O
3C	O
).	O

Both	O
were	O
expressed	O
at	O
significantly	O
greater	O
levels	O
in	O
supernatant	O
of	O
cells	O
cultured	O
at	O
high	O
neutrophil	O
concentrations	O
,	O
versus	O
supernatant	O
of	O
cells	O
cultured	O
at	O
low	O
concentrations	O
,	O
despite	O
protein	O
normalization	O
according	O
to	O
cell	O
number	O
and	O
equal	O
protein	O
loading	O
in	O
the	O
gel	O
.	O

Proteins	O
were	O
further	O
identified	O
by	O
MS	O
as	O
S100A8	B-GP
and	O
S100A9	B-GP
,	O
as	O
the	O
best	O
candidates	O
for	O
the	O
community	O
effect	O
(	O
Table	O
1	O
).	O

The	O
experimental	O
approach	O
was	O
designed	O
to	O
use	O
2D	O
gel	O
;	O
however	O
,	O
1D	O
gel	O
identified	O
with	O
high	O
certainty	O
two	O
candidate	O
proteins	O
that	O
were	O
chosen	O
for	O
further	O
functional	O
studies	O
.	O

Table	O
1	O
.	O
Proteins	O
identified	O
by	O
mass	O
spectrometry	O
.	O

Peptide	O
sequence	O

Protein	O
score	O
(	O
Mowse	O
)	O

Identified	O
protein	O

Remarks	O

MTCKMSQLER	O
NIETIINTFH	O
QYSVKLGHPD	O
TLNQGEFKEL	O
VRKDLQNFLK	O
KENKNEKVIE	O
HIMEDLDTNA	O
DKQLSFEEFI	O
MLMARLTWAS	O
HEKMHEGDEG	O
PGHHHKPGLG	O
EGTP	O

330	O

S100A9	B-GP

Reported	O
role	O
in	O
inflammation	O

MLTELEKALN	O
SIIDVYHKYS	O
LIKGNFHAVY	O
RDDLKKLLET	O
ECPQYIRKKG	O
ADVWFKELDI	O
NTDGAVNFQE	O
FLILVIKMAW	O
QPTKKAMKKA	O
TKSS	O

458	O

S100A8	B-GP

Reported	O
role	O
in	O
inflammation	O

MVHLTPEEKS	O
AVTALWGKVN	O
VDEVGGEALG	O
RLLVVYPWTQ	O
RFFESFGDLS	O
TPDAVMGNPK	O
VKAHGKKVLG	O
AFSDGLAHLD	O
NLKGTFATLS	O
ELHCDKLHVD	O
PENFRLLGNV	O
LVCVLAHHFG	O
KKFTPPVQAA	O
YQKVVAGVAN	O
ALAHKYH	O

207	O

beta	O
globin	O
chain	O
variant	O

Beta	O
globin	O
chain	O

VLSPADKTNV	O
KAAWGKVGAH	O
AGEYGAEALE	O
RMFLSFPTTK	O
TYFPHFDLSH	O
GSAQVKGHGK	O
KVADALTNAV	O
AHVDDMPNAL	O
SALSDLHAHK	O
LRVDPWNFKL	O
LSHCLLVTLA	O
AHLPAEFTPA	O
VHASLDKFLA	O
SVSTVLTSKY	O
R	O

94	O

Chain	O
C	O
,	O
T	O
State	O
Human	B-OG
Hemoglobin	B-GP
[	O
alpha	O
V96w	O
]	O

Hemoglobin	B-GP
chain	O

RRPDFCLEPP	O
YTGPCKARII	O
RYFYNAKAGL	O
CQTFVYGGCR	O
AKRNNFKSAE	O
DCMRTCGGA	O

113	O

Aprotinin	O

Protease	B-GP
inhibitor	O
(	O
synthetic	O
)	O

Analysis	O
of	O
proteins	O
identified	O
by	O
mass	O
spectrometry	O
.	O

Sequences	O
corresponding	O
to	O
the	O
identified	O
peptides	O
are	O
bolded	O
.	O

Score	O
was	O
based	O
on	O
molecular	O
weight	O
search	O
(	O
MOWSE	O
)	O
peptide	O
-	O
mass	O
database	O
.	O

The	O
results	O
identified	O
S100A8	B-GP
and	O
S100A9	B-GP
as	O
candidate	O
proteins	O
.	O

Functional	O
studies	O
suggest	O
that	O
S100A8	B-GP
-	I-GP
9	I-GP
mediates	O
the	O
community	O
effect	O

We	O
sought	O
to	O
verify	O
S100A8	B-GP
and	O
A9	B-GP
mediation	O
of	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
using	O
recombinant	O
human	B-OG
S100A8	B-GP
and	O
A9	O
(	O
kindly	O
provided	O
by	O
Philippe	O
A	O
.	O

Tessier	O
,	O
Laval	O
University	O
,	O
Quebec	O
,	O
Canada	O
)	O
added	O
to	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
.	O

Increased	O
S100A9	B-GP
and	O
S100A8	B-GP
/	O
9	O
levels	O
had	O
a	O
dramatic	O
rescue	O
effect	O
on	O
the	O
number	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
low	O
cell	O
concentrations	O
(*	O
p	O
<	O
0	O
.	O
05	O
),	O
paralleling	O
the	O
rescue	O
effect	O
of	O
the	O
high	O
cell	O
concentration	O
supernatant	O
(	O
Fig	O
.	O
4A	O
).	O

Survival	O
increased	O
by	O
more	O
than	O
150	O
%±	O
35	O
%	O
in	O
the	O
presence	O
of	O
5	O
µg	O
/	O
ml	O
of	O
S100A8	B-GP
/	O
9	O
,	O
as	O
measured	O
by	O
Annexin	B-GP
V	I-GP
and	O
PI	O
(**	O
p	O
<	O
0	O
.	O
02	O
).	O

The	O
survival	O
effect	O
of	O
S100A9	B-GP
and	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
was	O
more	O
prominent	O
compared	O
to	O
S100A9	B-GP
alone	O
.	O

Only	O
S100A9	B-GP
had	O
an	O
effect	O
already	O
at	O
a	O
concentration	O
of	O
1	O
µg	O
/	O
ml	O
.	O

Nonetheless	O
,	O
S100A8	B-GP
in	O
higher	O
concentrations	O
of	O
2	O
and	O
5	O
µg	O
/	O
ml	O
also	O
had	O
a	O
significant	O
rescue	O
effect	O
(	O
Fig	O
.	O
4A	O
).	O

To	O
further	O
verify	O
the	O
anti	O
-	O
apoptotic	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
,	O
we	O
measured	O
mitochondrial	O
transmemebrane	O
potential	O
as	O
an	O
additional	O
early	O
PCD	O
evaluation	O
,	O
demonstrating	O
a	O
perfect	O
correlation	O
to	O
the	O
Annexin	B-GP
V	I-GP
-	O
PI	O
measurements	O
(	O
Fig	O
.	O
4B	O
).	O

Effect	O
of	O
S100A9	B-GP
and	O
S100A8	B-GP
on	O
neutrophil	O
apoptosis	O
.	O

A	O
.	O
S100A9	B-GP
and	O
S100A8	B-GP
add	O
-	O
in	O
experiments	O
.	O

Varying	O
concentrations	O
of	O
S100A9	B-GP
,	O
S100A8	B-GP
,	O
and	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
were	O
added	O
to	O
supernatants	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
.	O

After	O
10	O
hours	O
apoptosis	O
was	O
evaluated	O
using	O
Annexin	B-GP
V	I-GP
-	O
PI	O
and	O
mitochondrial	O
staining	O
.	O

Data	O
is	O
presented	O
as	O
mean	O
±	O
SD	O
of	O
Annexin	B-GP
V	I-GP
-	O
PI	O
staining	O
(*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
02	O
).	O
B	O
.	O
S100A9	B-GP
and	O
S100A8	B-GP
add	O
-	O
in	O
experiments	O
.	O

A	O
representative	O
sample	O
of	O
Annexin	B-GP
V	I-GP
-	O
PI	O
and	O
mitochondrial	O
staining	O
.	O

Neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
without	O
(	O
a	O
and	O
c	O
)	O
or	O
with	O
(	O
b	O
and	O
d	O
)	O
the	O
addition	O
of	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Cells	O
were	O
stained	O
either	O
with	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
(	O
a	O
and	O
b	O
)	O
or	O
with	O
DiOC6	O
(	O
c	O
and	O
d	O
),	O
as	O
well	O
as	O
PI	O
(	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
)	O
and	O
assessed	O
by	O
flow	O
cytometry	O
.	O

Dot	O
plots	O
are	O
representative	O
of	O
6	O
experiments	O
.	O
C	O
.	O
The	O
effect	O
of	O
anti	O
-	O
S100A8	B-GP
and	O
A9	B-GP
on	O
add	O
-	O
in	O
experiments	O
.	O

Neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
for	O
12h	O
,	O
with	O
rabbit	B-OG
polyclonal	O
antibody	B-GP
dilutions	O
of	O
1	O
∶	O
100	O
,	O
1	O
∶	O
1000	O
,	O
and	O
1	O
∶	O
10	O
,	O
000	O
against	O
S100A9	B-GP
and	O
S100A8	B-GP
,	O
were	O
then	O
treated	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
complex	O
.	O

Rabbit	B-OG
serum	O
at	O
the	O
same	O
dilutions	O
of	O
1	O
∶	O
100	O
,	O
1	O
∶	O
1000	O
,	O
and	O
1	O
∶	O
10	O
,	O
000	O
was	O
used	O
as	O
a	O
control	O
.	O

Apoptosis	O
was	O
assessed	O
using	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O

Percentages	O
of	O
viable	O
,	O
early	O
-,	O
and	O
late	O
apoptotic	O
cells	O
are	O
indicated	O
within	O
the	O
respective	O
quadrants	O
.	O

Dot	O
plots	O
are	O
representative	O
of	O
6	O
experiments	O
.	O

We	O
sought	O
to	O
verify	O
whether	O
S100A9	B-GP
and	O
S100A8	B-GP
/	O
9	O
effects	O
are	O
blocked	O
with	O
specific	O
antibodies	O
,	O
using	O
rabbit	B-OG
polyclonal	O
antibodies	O
raised	O
against	O
human	B-OG
S100A8	B-GP
or	O
S100A9	B-GP
.	O

Antisera	O
were	O
used	O
at	O
a	O
range	O
of	O
dilutions	O
between	O
1	O
/	O
10	O
and	O
1	O
/	O
10	O
,	O
000	O
,	O
as	O
indicated	O
.	O

Adding	O
the	O
antibodies	O
reduced	O
neutrophil	O
survival	O
by	O
30	O
−	O
40	O
%	O
in	O
various	O
dilutions	O
(	O
Fig	O
.	O
4C	O
),	O
compared	O
to	O
control	O
antibodies	O
,	O
and	O
induced	O
accelerated	O
PCD	O
similar	O
to	O
that	O
seen	O
in	O
spontaneous	O
constitutive	O
PCD	O
in	O
low	O
cell	O
concentration	O
supernatants	O
.	O

Mitochondrial	O
transmemebrane	O
potential	O
as	O
an	O
additional	O
early	O
PCD	B-DS
evaluation	O
,	O
demonstrated	O
a	O
perfect	O
correlation	O
to	O
the	O
Annexin	B-GP
V	I-GP
-	O
PI	O
measurements	O
.	O

This	O
further	O
supports	O
a	O
role	O
for	O
S100A8	B-GP
/	O
9	O
as	O
the	O
main	O
factor	O
triggering	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
.	O

S100A8	B-GP
/	O
9	O
does	O
not	O
mediate	O
the	O
community	O
effect	O
via	O
McL1	B-GP
,	O
A1	O
,	O
the	O
bcl	B-GP
-	I-GP
2	I-GP
protein	O
family	O
,	O
or	O
survivin	B-GP

We	O
examined	O
the	O
expression	O
of	O
different	O
members	O
of	O
the	O
PCD	O
intrinsic	O
pathway	O
,	O
focusing	O
on	O
those	O
known	O
to	O
be	O
important	O
in	O
neutrophil	O
PCD	O
.	O

McL1	B-GP
,	O
an	O
anti	O
-	O
apoptotic	O
member	O
,	O
was	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
(	O
see	O
Figure	O
S3	O
),	O
and	O
expression	O
was	O
still	O
detected	O
during	O
spontaneous	O
constitutive	O
apoptosis	O
.	O

Adding	O
S100A8	B-GP
/	O
9	O
did	O
not	O
change	O
McL1	B-GP
expression	O
.	O

A1	O
protein	O
has	O
also	O
been	O
found	O
to	O
be	O
expressed	O
in	O
neutrophils	O
[	O
13	O
],	O
[	O
15	O
].	O

We	O
found	O
that	O
A1	O
was	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
,	O
with	O
expression	O
dramatically	O
decreased	O
during	O
constitutive	O
spontaneous	O
PCD	O
(	O
see	O
Figure	O
S3	O
).	O

Adding	O
S100A8	B-GP
/	O
9	O
did	O
not	O
prevent	O
decreased	O
A1	O
expression	O
.	O

Bclxl	B-GP
was	O
found	O
to	O
be	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
.	O

Expression	O
was	O
neither	O
decreased	O
by	O
constitutive	O
spontaneous	O
PCD	O
,	O
nor	O
increased	O
by	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

We	O
also	O
examined	O
the	O
expression	O
of	O
Bcl2	B-GP
and	O
survivin	B-GP
proteins	O
.	O

These	O
two	O
proteins	O
were	O
not	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
or	O
during	O
induction	O
of	O
constitutive	O
spontaneous	O
PCD	O
,	O
which	O
is	O
consistent	O
with	O
observations	O
that	O
peripheral	O
blood	O
neutrophils	O
don	O
'	O
t	O
express	O
these	O
two	O
proteins	O
[	O
11	O
−	O
14	O
],	O
.	O

In	O
conclusion	O
,	O
we	O
could	O
not	O
identify	O
an	O
anti	O
-	O
apoptotic	O
mechanism	O
in	O
the	O
main	O
intrinsic	O
pathway	O
players	O
of	O
neutrophil	O
PCD	O
.	O

The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
involves	O
the	O
MEK	B-GP
-	O
ERK	B-GP
signaling	O
pathway	O
,	O
and	O
is	O
partially	O
mediated	O
through	O
TLR4	B-GP
and	O
the	O
integrin	B-GP
CD11b	B-GP
/	O
CD18	B-GP

S100A8	B-GP
and	O
A9	B-GP
specific	O
receptors	O
have	O
not	O
yet	O
been	O
identified	O
.	O

However	O
,	O
Vogl	O
et	O
al	O
demonstrated	O
that	O
S100A8	B-GP
specifically	O
interacts	O
with	O
the	O
TLR4	B-GP
-	O
MD2	B-GP
complex	O
[	O
29	O
],	O
and	O
Newton	O
RA	O
et	O
al	O
suggested	O
that	O
a	O
pertusis	O
toxin	O
-	O
sensitive	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
could	O
be	O
the	O
S100A9	B-GP
receptor	I-GP
[	O
30	O
].	O

S100A8	B-GP
and	O
A9	B-GP
have	O
been	O
shown	O
to	O
exert	O
their	O
effects	O
via	O
CD36	B-GP
and	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
Mac	B-GP
-	I-GP
1	I-GP
)	O
[	O
30	O
−	O
32	O
].	O
CD11b	B-GP
/	O
CD18	B-GP
is	O
well	O
expressed	O
in	O
freshly	O
isolated	O
neutrophils	O
,	O
but	O
CD36	B-GP
is	O
not	O
(	O
Fig	O
.	O
5A	O
,	O
upper	O
panel	O
).	O

Furthermore	O
,	O
CD11b	B-GP
/	O
CD18	B-GP
was	O
suggested	O
as	O
a	O
pro	O
-	O
apoptotic	O
integrin	B-GP
[	O
33	O
],	O
[	O
34	O
].	O

The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
is	O
mediated	O
through	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
.	O

A	O
.	O
Expression	O
of	O
CD11b	B-GP
on	O
neutrophils	O
.	O

Upper	O
panel	O
.	O

Freshly	O
isolated	O
neutrophils	O
express	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
and	O
anti	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
PE	O
in	O
dotted	O
line	O
,	O
middle	O
)	O
but	O
not	O
CD36	B-GP
(	O
left	O
).	O

Following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
middle	O
)	O
there	O
was	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
CD11b	B-GP
/	O
CD18	B-GP
in	O
comparison	O
to	O
freshly	O
isolated	O
neutrophils	O
.	O

Addition	O
of	O
S100A8	B-GP
/	O
9	O
resulted	O
in	O
two	O
different	O
cell	O
populations	O
:	O
high	O
and	O
low	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
black	O
line	O
,	O
right	O
).	O

Lower	O
panel	O
.	O

Left	O
.	O

Correlation	O
between	O
CD11b	B-GP
and	O
phosphatidylserine	B-CD
expression	O
demonstrates	O
that	O
when	O
neutrophils	O
become	O
apoptotic	O
they	O
downregulate	O
CD11b	B-GP
expression	O
.	O

Right	O
.	O

S100A8	B-GP
/	O
9	O
upregulates	O
CD11b	B-GP
expression	O
.	O
B	O
.	O
S100A8	B-GP
/	O
9	O
dramatically	O
increases	O
CD11b	B-GP
on	O
viable	O
cells	O
.	O

Viable	O
cells	O
(	O
R1	O
,	O
black	O
line	O
)	O
increase	O
CD11b	B-GP
expression	O
from	O
a	O
mean	O
fluorescence	O
of	O
552	O
to	O
1094	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Apoptotic	O
cells	O
(	O
R2	O
,	O
gray	O
line	O
)	O
still	O
maintain	O
some	O
of	O
this	O
effect	O
and	O
show	O
a	O
mean	O
fluorescence	O
of	O
473	O
,	O
compared	O
to	O
362	O
in	O
the	O
absence	O
of	O
S100A8	B-GP
/	O
9	O
.	O

Filled	O
histograms	O
represent	O
isotype	O
control	O
.	O

Neutrophils	O
were	O
harvested	O
after	O
12	O
h	O
spontaneous	O
constitutive	O
PCD	O
,	O
with	O
or	O
without	O
treatment	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Histograms	O
are	O
representative	O
of	O
at	O
least	O
3	O
different	O
experiments	O
.	O
C	O
.	O
The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
anti	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Upper	O
panel	O
.	O

Right	O
.	O

Neutrophils	O
were	O
incubated	O
for	O
12	O
h	O
and	O
treated	O
with	O
either	O
anti	O
-	O
CD11b	B-GP
or	O
the	O
isotype	O
control	O
IgG1	B-GP
before	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
complex	O
.	O

Integrin	B-GP
inhibition	O
reduced	O
the	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
40	O
−	O
100	O
%	O
in	O
comparison	O
with	O
the	O
isotype	O
control	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
average	O
of	O
6	O
experiments	O
is	O
presented	O
.	O

Lower	O
panel	O
.	O

A	O
representative	O
dot	O
plot	O
is	O
shown	O
.	O

Upper	O
panel	O
.	O

Left	O
.	O

S100A8	B-GP
/	O
9	O
binds	O
to	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

CHO	O
cells	O
transfected	O
with	O
CR3	B-GP
(	O
black	O
)	O
or	O
vector	O
(	O
gray	O
)	O
were	O
evaluated	O
for	O
S100A8	B-GP
/	O
9	O
binding	O
.	O

CR3	O
-	O
ransfected	O
cells	O
bound	O
at	O
rates	O
almost	O
twofold	O
higher	O
than	O
CHO	O
control	O
cells	O
(	O
median	O
fluorescence	O
13	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
filled	O
curve	O
represents	O
isotype	O
control	O
;	O
the	O
histogram	O
is	O
representative	O
of	O
3	O
experiments	O
.	O
D	O
.	O
S100A8	B-GP
/	O
9	O
effect	O
on	O
neutrophils	O
from	O
a	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
deficient	O
patient	O
.	O

Neutrophil	O
expression	O
of	O
CD11b	B-GP
from	O
a	O
healthy	O
control	O
and	O
a	O
patient	O
with	O
leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
is	O
shown	O
in	O
the	O
upper	O
panel	O
.	O

Spontaneous	O
constitutive	O
apoptosis	O
is	O
shown	O
in	O
the	O
lower	O
panel	O
,	O
together	O
with	O
the	O
S100A8	B-GP
/	O
9	O
effect	O
.	O

Neutrophils	O
were	O
isolated	O
from	O
a	O
CD11b	B-GP
-	O
deficient	O
patient	O
and	O
a	O
healthy	O
control	O
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
,	O
incubated	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
and	O
allowed	O
to	O
undergo	O
spontaneous	O
constitutive	O
PCD	O
for	O
10	O
h	O
,	O
with	O
or	O
without	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
Annexin	B-GP
V	I-GP
-	O
PI	O
staining	O
.	O
E	O
.	O
The	O
survival	O
effect	O
induced	O
by	O
the	O
complex	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
pertussis	B-GP
toxin	I-GP
.	O
Bordetella	B-GP
pertussis	I-GP
toxin	I-GP
at	O
100	O
and	O
500	O
ng	O
/	O
ml	O
were	O
added	O
to	O
neutrophils	O
45	O
min	O
before	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

Neutrophils	O
then	O
were	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
that	O
was	O
assessed	O
using	O
AnnexinV	B-GP
-	O
FITC	O
and	O
PI	O
staining	O
after	O
12	O
h	O
.	O

The	O
dot	O
plots	O
are	O
representative	O
of	O
3	O
experiments	O
.	O
F	O
.	O
The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
anti	O
-	O
TLR4	B-GP
.	O

Neutrophils	O
were	O
incubated	O
for	O
10	O
h	O
and	O
treated	O
with	O
either	O
anti	O
-	O
TLR4	B-GP
or	O
the	O
isotype	O
control	O
IgG2a	B-GP
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Inhibition	O
of	O
TLR4	B-GP
abrogated	O
the	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
30	O
−	O
60	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
comparison	O
with	O
the	O
isotype	O
control	O
,	O
as	O
seen	O
in	O
upper	O
panel	O
.	O

The	O
upper	O
panel	O
is	O
presented	O
as	O
percentage	O
of	O
control	O
.	O

The	O
experiment	O
is	O
a	O
summary	O
of	O
four	O
experiments	O
(	O
upper	O
panel	O
)	O
with	O
representative	O
Plots	O
in	O
the	O
lower	O
panel	O
.	O

Following	O
spontaneous	O
constitutive	O
PCD	O
,	O
we	O
detected	O
a	O
homogeneous	O
decrease	O
in	O
neutrophil	O
expression	O
of	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Gating	O
apoptotic	O
(	O
Annexin	B-GP
V	I-GP
-	O
positive	O
)	O
versus	O
nonapoptotic	O
(	O
Annexin	B-GP
V	I-GP
-	O
negative	O
)	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
revealed	O
higher	O
CD11b	B-GP
/	O
CD18	B-GP
expression	O
on	O
viable	O
-	O
versus	O
apoptotic	O
neutrophils	O
(	O
Fig	O
.	O
5A	O
−	O
B	O
).	O

Furthermore	O
,	O
adding	O
S100A8	B-GP
/	O
9	O
dramatically	O
upregulated	O
CD11b	B-GP
/	O
CD18	B-GP
,	O
establishing	O
a	O
new	O
subpopulation	O
with	O
very	O
high	O
expression	O
on	O
viable	O
cells	O
(	O
Fig	O
.	O
5A	O
−	O
B	O
).	O

We	O
then	O
blocked	O
CD11b	B-GP
/	O
CD18	B-GP
prior	O
to	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

CD11b	B-GP
inhibition	O
during	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
decreased	O
cell	O
survival	O
by	O
20	O
%,	O
and	O
in	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
,	O
CD11b	B-GP
inhibition	O
cut	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
50	O
−	O
75	O
%	O
(	O
Fig	O
.	O
5C	O
),	O
suggesting	O
that	O
S100A8	B-GP
/	O
9	O
may	O
exert	O
its	O
survival	O
effect	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
either	O
binding	O
or	O
expressing	O
CD11b	B-GP
,	O
a	O
known	O
receptor	O
involved	O
in	O
neutrophil	O
apoptosis	O
.	O

For	O
further	O
assessments	O
,	O
we	O
used	O
a	O
CHO	O
cell	O
line	O
transfected	O
with	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Transfected	O
CHO	O
cells	O
increased	O
binding	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
by	O
almost	O
twofold	O
in	O
comparison	O
with	O
control	O
CHO	O
cells	O
(	O
Fig	O
.	O
5C	O
,	O
upper	O
right	O
).	O

However	O
,	O
when	O
we	O
examined	O
the	O
effect	O
of	O
recombinant	O
S100A8	B-GP
/	O
9	O
on	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
deficient	O
neutrophils	O
from	O
a	O
leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
(	O
LAD	O
)	O
patient	O
,	O
results	O
were	O
less	O
clear	O
.	O

As	O
expected	O
,	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
showed	O
delayed	O
PCD	O
in	O
comparison	O
with	O
neutrophils	O
from	O
healthy	O
donors	O
(	O
Fig	O
.	O
5D	O
),	O
however	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
kept	O
its	O
protective	O
anti	O
-	O
apoptotic	O
effect	O
on	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
,	O
and	O
survival	O
was	O
increased	O
by	O
50	O
−	O
90	O
%.	O

This	O
supports	O
the	O
hypothesis	O
that	O
these	O
proteins	O
exert	O
their	O
survival	O
effect	O
only	O
partially	O
by	O
CD11b	B-GP
/	O
CD18	B-GP
,	O
and	O
other	O
receptors	O
are	O
involved	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
one	O
alternative	O
candidate	O
,	O
we	O
examined	O
a	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
.	O

Pertusis	B-GP
toxin	I-GP
,	O
which	O
abrogates	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
function	O
,	O
did	O
not	O
influence	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
(	O
Fig	O
.	O
5E	O
).	O

An	O
additional	O
possible	O
receptor	O
is	O
Toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
4	I-GP
[	O
29	O
].	O

Inhibiting	O
TLR4	B-GP
abrogated	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
25	O
−	O
60	O
%	O
(	O
Fig	O
.	O
5F	O
),	O
suggesting	O
that	O
both	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
may	O
be	O
involved	O
in	O
the	O
pathway	O
enabling	O
these	O
proteins	O
to	O
affect	O
neutrophil	O
PCD	O
.	O

Extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
(	O
ERK	B-GP
),	O
one	O
of	O
the	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinases	I-GP
(	O
MAPK	B-GP
),	O
is	O
involved	O
in	O
integrin	B-GP
signaling	O
and	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
in	O
general	O
.	O

It	O
appears	O
to	O
mediate	O
signals	O
promoting	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
,	O
as	O
reviewed	O
by	O
Roux	O
,	O
et	O
al	O
[	O
35	O
].	O

We	O
assessed	O
the	O
role	O
of	O
ERK	B-GP
in	O
the	O
neutrophil	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
using	O
intracellular	O
staining	O
of	O
phosphorylated	O
ERK	B-GP
.	O

Neutrophils	O
exposed	O
to	O
S100A8	B-GP
/	O
9	O
for	O
10	O
min	O
showed	O
more	O
than	O
a	O
threefold	O
increase	O
in	O
phosphorylation	O
of	O
the	O
ERK	B-GP
kinase	I-GP
(	O
Fig	O
.	O
6A	O
).	O

This	O
activation	O
continues	O
to	O
a	O
lesser	O
extent	O
following	O
30	O
and	O
60	O
min	O
exposure	O
.	O

Furthermore	O
,	O
the	O
inhibitor	O
PD98059	B-CD
(	O
MEK	B-GP
inhibitor	O
)	O
reduced	O
ERK	B-GP
phosphorylation	O
by	O
more	O
than	O
50	O
%	O
(	O
Fig	O
.	O
6B	O
)	O
and	O
abolished	O
the	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
by	O
50	O
−	O
100	O
%	O
at	O
various	O
concentrations	O
(	O
Fig	O
.	O
6C	O
),	O
suggesting	O
that	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
survival	O
effect	O
involves	O
the	O
MEK	B-GP
-	O
ERK	B-GP
signaling	O
pathway	O
.	O

Effects	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
are	O
mediated	O
through	O
the	O
MAPK	B-GP
-	O
ERK	B-GP
pathway	O
.	O

A	O
.	O
Phosphorylation	O
of	O
MAPK	B-GP
following	O
exposure	O
to	O
S100A8	B-GP
/	O
9	O
.	O

Freshly	O
isolated	O
neutrophils	O
with	O
or	O
without	O
treatment	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
for	O
various	O
times	O
as	O
indicated	O
,	O
and	O
then	O
prepared	O
for	O
intracellular	O
staining	O
with	O
mouse	B-OG
anti	O
-	O
human	B-OG
phospho	O
-	O
p44	O
/	O
42	O
MAPK	O
alexa	O
fluor	O
488	O
(	O
gray	O
)	O
or	O
isotype	O
control	O
(	O
black	O
),	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

In	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
,	O
phosphorylation	O
was	O
increased	O
by	O
3	O
.	O
22	O
-	O
fold	O
after	O
10	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
1	O
.	O
5	O
-	O
fold	O
after	O
30	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
decayed	O
at	O
60	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Histograms	O
are	O
representative	O
of	O
3	O
independent	O
experiments	O
.	O
B	O
.	O
Reduced	O
phosphorylation	O
of	O
MAPK	B-GP
following	O
exposure	O
to	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
PD98059	B-CD
,	O
a	O
MAPK	B-GP
phosphorylation	O
inhibitor	O
.	O

Freshly	O
isolated	O
neutrophils	O
were	O
treated	O
with	O
the	O
inhibitor	O
PD98059	B-CD
or	O
with	O
DMSO	O
as	O
a	O
control	O
for	O
30	O
min	O
,	O
and	O
then	O
treated	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Cells	O
were	O
then	O
harvested	O
and	O
prepared	O
for	O
intracellular	O
staining	O
of	O
phospho	O
-	O
p44	B-GP
/	O
42	O
MAPK	B-GP
(	O
gray	O
)	O
or	O
isotype	O
control	O
(	O
black	O
),	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Treatment	O
with	O
PD98059	B-CD
inhibitor	O
reduced	O
phosphorylation	O
caused	O
by	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Histograms	O
are	O
representative	O
of	O
3	O
experiments	O
.	O
C	O
.	O
Effect	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
in	O
the	O
presence	O
of	O
MAPK	B-GP
-	O
ERK	B-GP
inhibitor	O
.	O

The	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
was	O
assessed	O
in	O
the	O
presence	O
of	O
PD98059	B-CD
.	O

Freshly	O
isolated	O
neutrophils	O
were	O
treated	O
with	O
varying	O
combinations	O
and	O
concentrations	O
of	O
DMSO	O
(	O
white	O
bars	O
),	O
S100A8	B-GP
/	O
9	O
complex	O
(	O
gray	O
bars	O
),	O
or	O
S100A8	B-GP
/	O
9	O
complex	O
with	O
PD98059	B-CD
(	O
black	O
bars	O
),	O
as	O
indicated	O
,	O
for	O
30	O
min	O
before	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

Neutrophils	O
were	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
.	O

Results	O
represent	O
the	O
percentage	O
of	O
viable	O
cells	O
according	O
to	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O

Data	O
is	O
representative	O
of	O
3	O
experiments	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Apoptotic	O
neutrophils	O
are	O
not	O
activated	O
neutrophils	O

As	O
S100A8	B-GP
/	O
9	O
was	O
mainly	O
reported	O
thus	O
far	O
to	O
be	O
released	O
during	O
inflammation	O
(	O
see	O
discussion	O
),	O
it	O
may	O
be	O
attributed	O
to	O
release	O
due	O
to	O
neutrophil	O
activation	O
.	O

We	O
wanted	O
to	O
further	O
verify	O
that	O
apoptotic	O
neutrophils	O
are	O
not	O
activated	O
due	O
to	O
extraction	O
method	O
or	O
in	O
vitro	O
effect	O
.	O

Therefore	O
we	O
analyzed	O
three	O
surface	O
molecules	O
that	O
are	O
upregulated	O
upon	O
neutrophil	O
activation	O
and	O
downregulated	O
upon	O
neutrophil	O
PCD	O
.	O

In	O
figures	O
S1	O
and	O
S2	O
,	O
CD16	B-GP
and	O
CD62L	B-GP
,	O
both	O
markers	O
of	O
neutrophil	O
activation	O
showed	O
clear	O
down	O
regulation	O
in	O
the	O
examined	O
neutrophils	O
,	O
in	O
correlation	O
to	O
apoptotic	O
state	O
[	O
36	O
].	O

In	O
addition	O
CD11b	B-GP
,	O
is	O
a	O
third	O
molecule	O
,	O
that	O
is	O
upregulated	O
upon	O
activation	O
was	O
downregulated	O
in	O
apoptotic	O
neutrophils	O
releasing	O
S100A8	B-GP
and	O
S100A9	B-GP
(	O
see	O
Figure	O
5	O
).	O

Taken	O
together	O
,	O
S100	B-GP
A8	I-GP
and	O
S100A9	B-GP
were	O
released	O
in	O
the	O
context	O
of	O
apoptotic	O
neutrophil	O
death	O
in	O
non	O
activated	O
neutrophils	O
.	O

Discussion	O

Neutrophils	O
are	O
responsible	O
for	O
the	O
body	O
'	O
s	O
rapid	O
and	O
effective	O
response	O
to	O
infection	B-DS
or	O
injury	O
[	O
37	O
].	O

Efficient	O
function	O
necessitates	O
an	O
optimal	O
balance	O
between	O
a	O
sufficient	O
number	O
of	O
blood	O
neutrophils	O
,	O
response	O
to	O
stimuli	O
,	O
and	O
transmigration	O
properties	O
,	O
on	O
one	O
hand	O
,	O
against	O
regulation	O
of	O
the	O
termination	O
of	O
a	O
neutrophil	O
-	O
mediated	O
inflammatory	O
response	O
on	O
the	O
other	O
.	O

Thus	O
,	O
control	O
of	O
neutrophil	O
turnover	O
in	O
the	O
bone	O
marrow	O
and	O
circulation	O
,	O
and	O
at	O
inflammatory	O
sites	O
,	O
is	O
key	O
to	O
both	O
homeostasis	O
and	O
inflammation	O
.	O

PCD	O
plays	O
a	O
critical	O
role	O
in	O
neutrophil	O
homeostasis	O
for	O
an	O
optimal	O
functioning	O
in	O
the	O
human	B-OG
body	O
.	O

Polymorphonuclears	O
comprise	O
approximately	O
75	O
%	O
of	O
all	O
nucleated	O
cells	O
in	O
the	O
hematopoietic	O
compartment	O
of	O
the	O
newborn	O
marrow	O
,	O
with	O
the	O
majority	O
being	O
neutrophils	O
.	O

Already	O
in	O
the	O
bone	O
marrow	O
,	O
large	O
-	O
scale	O
neutrophil	O
death	O
and	O
removal	O
of	O
neutrophils	O
by	O
phagocytes	O
are	O
seen	O
[	O
38	O
].	O
Yet	O
,	O
the	O
major	O
regulator	O
of	O
blood	O
neutrophil	O
counts	O
,	O
as	O
well	O
as	O
neutrophil	O
counts	O
at	O
inflammatory	O
sites	O
,	O
is	O
PCD	O
,	O
which	O
allows	O
only	O
a	O
short	O
life	O
span	O
,	O
with	O
modulation	O
according	O
to	O
needs	O
such	O
as	O
inflammation	O
.	O

Here	O
we	O
show	O
that	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
regulates	O
neutrophil	O
number	O
and	O
PCD	O
in	O
response	O
to	O
neutrophil	O
concentration	O
,	O
by	O
an	O
anti	O
-	O
apoptotic	O
effect	O
.	O

S100A9	B-GP
(	O
MRP14	B-GP
)	O
and	O
S100A8	B-GP
(	O
MRP8	B-GP
)	O
constitute	O
roughly	O
40	O
%	O
of	O
the	O
cytosolic	O
protein	O
in	O
neutrophils	O
;	O
their	O
pure	O
abundance	O
implies	O
an	O
important	O
role	O
in	O
neutrophil	O
functions	O
.	O

However	O
,	O
our	O
understanding	O
of	O
the	O
mechanisms	O
implicating	O
both	O
molecules	O
in	O
neutrophil	O
/	O
monocyte	O
physiology	O
remains	O
incomplete	O
,	O
as	O
reviewed	O
by	O
Nacken	O
,	O
et	O
al	O
[	O
39	O
].	O

S100A9	B-GP
and	O
S100A8	B-GP
readily	O
form	O
hetero	O
-	O
and	O
homodimeric	O
,	O
trimeric	O
,	O
and	O
tetrameric	O
complexes	O
,	O
but	O
apparently	O
also	O
exert	O
specific	O
functions	O
as	O
monomers	O
.	O

It	O
has	O
been	O
suggested	O
that	O
S100A9	B-GP
plays	O
a	O
prominent	O
role	O
in	O
leukocyte	O
trafficking	O
and	O
arachidonic	B-CD
acid	I-CD
metabolism	O
,	O
and	O
elevated	O
S100A9	B-GP
and	O
S100A8	B-GP
levels	O
are	O
found	O
in	O
body	O
fluids	O
of	O
inflamed	O
tissues	O
.	O

When	O
neutrophils	O
undergo	O
PCD	O
,	O
they	O
release	O
S100A8	B-GP
/	O
9	O
,	O
which	O
partially	O
protects	O
surrounding	O
neutrophils	O
from	O
PCD	O
,	O
a	O
mechanism	O
that	O
may	O
be	O
of	O
crucial	O
importance	O
in	O
fine	O
-	O
tuning	O
neutrophil	O
concentrations	O
in	O
the	O
bone	O
marrow	O
and	O
blood	O
,	O
and	O
in	O
inflammatory	O
sites	O
.	O

This	O
finding	O
is	O
supported	O
by	O
the	O
decrease	O
in	O
bone	O
marrow	O
neutrophils	O
in	O
S100A9	B-GP
-	O
deficient	O
mice	B-OG
[	O
40	O
],	O
and	O
the	O
accumulation	O
of	O
S100A8	B-GP
/	O
9	O
at	O
inflammatory	O
sites	O
,	O
where	O
prolonged	O
survival	O
of	O
neutrophils	O
is	O
usually	O
needed	O
for	O
chemotaxis	O
and	O
neutrophil	O
adhesion	O
[	O
32	O
].	O

As	O
shown	O
in	O
figure	O
5A	O
and	O
supplemental	O
figures	O
1	O
and	O
2	O
,	O
apoptotic	O
neutrophils	O
were	O
not	O
activated	O
and	O
their	O
S100	B-GP
A8	I-GP
and	O
S100	B-GP
A9	I-GP
release	O
was	O
associated	O
with	O
PCD	O
and	O
not	O
inflammation	O
or	O
activation	O
.	O

S100A8	B-GP
deficiency	O
is	O
lethal	O
[	O
41	O
],	O
thus	O
further	O
research	O
to	O
gain	O
understanding	O
of	O
the	O
role	O
of	O
S100A8	B-GP
/	O
9	O
is	O
partially	O
limited	O
to	O
animal	B-OG
models	O
.	O

By	O
prolonging	O
neutrophil	O
life	O
,	O
S100A8	B-GP
/	O
9	O
accumulation	O
could	O
be	O
also	O
a	O
contributing	O
mechanism	O
to	O
autoimmune	O
conditions	O
and	O
the	O
development	O
of	O
chronic	O
inflammation	O
or	O
acute	O
sterile	O
danger	O
-	O
related	O
inflammation	O
.	O

In	O
conditions	O
such	O
as	O
gout	B-DS
,	O
monosodium	O
urate	O
monohydrate	O
crystals	O
induce	O
the	O
release	O
of	O
S100A8	B-GP
/	O
A9	O
from	O
neutrophils	O
[	O
42	O
]	O
and	O
allow	O
inflammatory	O
attack	O
by	O
prolonging	O
neutrophil	O
life	O
.	O

High	O
S100A8	B-GP
/	O
9	O
levels	O
were	O
found	O
in	O
chronically	O
inflamed	O
joints	O
of	O
patients	O
with	O
rheumatoid	B-DS
arthritis	I-DS
[	O
43	O
].	O

Our	O
study	O
also	O
proposes	O
an	O
additional	O
possible	O
mechanism	O
for	O
neutropenia	B-DS
following	O
chemotherapy	O
,	O
suggesting	O
that	O
low	O
neutrophil	O
concentration	O
may	O
be	O
further	O
aggravated	O
due	O
to	O
accelerated	O
PCD	O
,	O
induced	O
at	O
low	O
neutrophil	O
concentrations	O
.	O

This	O
hypothesis	O
needs	O
further	O
investigation	O
.	O

We	O
were	O
also	O
able	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
enabling	O
S100A8	B-GP
/	O
9	O
function	O
.	O

S100A8	B-GP
/	O
9	O
clearly	O
upregulates	O
and	O
binds	O
to	O
CD11b	B-GP
,	O
previously	O
shown	O
to	O
be	O
a	O
major	O
regulator	O
of	O
neutrophil	O
PCD	O
[	O
44	O
],	O
with	O
possible	O
anti	O
-	O
or	O
pro	O
-	O
apoptotic	O
effect	O
.	O

However	O
,	O
as	O
shown	O
here	O
,	O
this	O
effect	O
was	O
retained	O
in	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
,	O
indicating	O
additional	O
mechanisms	O
such	O
as	O
TLR4	B-GP
.	O

Indeed	O
,	O
blocking	O
TLR4	B-GP
partially	O
abrogated	O
the	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
,	O
suggesting	O
that	O
S100A8	B-GP
/	O
9	O
is	O
an	O
endogenous	O
TLR4	B-GP
ligand	O
mediating	O
survival	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
TLR4	B-GP
agonist	O
LPS	O
and	O
others	O
inhibit	O
neutrophil	O
apoptosis	O
[	O
12	O
],	O
[	O
45	O
].	O

Here	O
we	O
show	O
for	O
the	O
first	O
time	O
an	O
endogenous	O
ligand	O
that	O
inhibits	O
neutrophil	O
apoptosis	O
.	O

Our	O
results	O
also	O
show	O
a	O
role	O
for	O
the	O
MEK	B-GP
/	O
ERK	B-GP
pathway	O
following	O
activation	O
by	O
S100A8	B-GP
/	O
9	O
.	O

This	O
pathway	O
has	O
been	O
well	O
documented	O
to	O
mediate	O
signaling	O
of	O
both	O
integrins	B-GP
and	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
,	O
supporting	O
a	O
role	O
for	O
CD11b	B-GP
,	O
TLR4	B-GP
,	O
and	O
possibly	O
additional	O
receptors	O
.	O

This	O
mechanism	O
has	O
been	O
shown	O
in	O
the	O
past	O
to	O
be	O
anti	O
-	O
apoptotic	O
in	O
neutrophils	O
via	O
both	O
intrinsic	O
[	O
46	O
]	O
and	O
extrinsic	O
[	O
47	O
]	O
PCD	O
pathways	O
.	O

The	O
correlation	O
between	O
beta2	B-GP
-	I-GP
integrin	I-GP
and	O
TLR4	B-GP
has	O
been	O
suggested	O
.	O

These	O
two	O
receptors	O
may	O
cooperate	O
to	O
produce	O
signals	O
that	O
are	O
transmitted	O
into	O
the	O
cell	O
.	O

Also	O
,	O
TLR4	B-GP
has	O
been	O
suggested	O
to	O
be	O
an	O
“	O
inside	O
-	O
out	O
”	O
regulator	O
of	O
the	O
beta2	B-GP
-	I-GP
integrins	I-GP
[	O
48	O
],	O
and	O
even	O
a	O
direct	O
TLR4	B-GP
-	O
beta2	B-GP
integrin	I-GP
interaction	O
has	O
been	O
suggested	O
[	O
49	O
].	O

Other	O
possible	O
functional	O
proteins	O
that	O
could	O
have	O
a	O
“	O
community	O
effect	O
”	O
may	O
be	O
found	O
in	O
the	O
secreted	O
proteome	O
of	O
apoptotic	O
cells	O
.	O

An	O
experimental	O
approach	O
using	O
2D	O
gel	O
may	O
discover	O
additional	O
candidate	O
proteins	O
and	O
functional	O
studies	O
may	O
establish	O
their	O
potential	O
role	O
in	O
PCD	O
.	O

In	O
summary	O
,	O
the	O
physiological	O
role	O
of	O
S100A8	B-GP
/	O
9	O
,	O
the	O
most	O
abundant	O
cytosol	O
protein	O
in	O
neutrophils	O
,	O
was	O
not	O
previously	O
understood	O
.	O

We	O
propose	O
that	O
at	O
physiological	O
protein	O
[	O
50	O
]	O
and	O
cell	O
concentrations	O
,	O
its	O
main	O
function	O
is	O
in	O
modulating	O
neutrophil	O
PCD	O
,	O
and	O
that	O
cell	O
concentration	O
is	O
regulated	O
by	O
an	O
autocrine	O
and	O
paracrine	O
mechanism	O
via	O
S100A8	B-GP
/	O
9	O
.	O

Finally	O
,	O
a	O
biological	O
“	O
proof	O
”	O
is	O
presented	O
here	O
,	O
suggesting	O
that	O
nature	O
encourages	O
“	O
community	O
life	O
”	O
at	O
the	O
level	O
of	O
neutrophil	O
survival	O
,	O
which	O
could	O
be	O
seen	O
as	O
a	O
cellular	O
illustration	O
for	O
human	B-OG
life	O
.	O

Supporting	O
Information	O

Apoptotic	O
neutrophils	O
downregulate	O
CD16	B-GP
.	O
The	O
expression	O
of	O
CD16	B-GP
(	O
Fc	B-GP
gamma	I-GP
RIII	I-GP
)	O
on	O
neutrophils	O
.	O

Freshly	O
isolated	O
neutrophils	O
CD16	B-GP
expession	O
at	O
time	O
0	O
(	O
black	O
line	O
,	O
median	O
fluorescence	O
of	O
382	O
)	O
and	O
following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
median	O
fluorescence	O
of	O
35	O
).	O

Isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Apoptotic	O
neutrophils	O
downregulate	O
CD62L	B-GP
.	O
The	O
expression	O
of	O
CD62L	B-GP
(	O
L	B-GP
-	I-GP
selectin	I-GP
)	O
on	O
neutrophils	O
.	O

Freshly	O
isolated	O
neutrophils	O
CD62L	B-GP
expession	O
at	O
time	O
0	O
(	O
black	O
line	O
,	O
median	O
fluorescence	O
of	O
791	O
)	O
and	O
following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
median	O
fluorescence	O
of	O
27	O
).	O

Isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Apoptosis	B-GP
-	I-GP
related	I-GP
proteins	I-GP
during	O
spontaneous	O
constitutive	O
PCD	O
in	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
.	O
SDS	O
-	O
PAGE	O
of	O
McL1	B-GP
,	O
Bcl	B-GP
-	I-GP
xl	I-GP
,	O
A1	O
,	O
Bcl2	B-GP
,	O
and	O
survivin	B-GP
in	O
spontaneous	O
constitutive	O
apoptosis	O
,	O
with	O
and	O
without	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

McL1	B-GP
(	O
39	O
KD	O
)	O
and	O
Bcl	B-GP
-	I-GP
xl	I-GP
(	O
26	O
KD	O
)	O
were	O
detected	O
in	O
all	O
conditions	O
.	O

A1	O
(	O
20KD	O
)	O
was	O
detected	O
from	O
freshly	O
isolated	O
neutrophils	O
but	O
expression	O
was	O
downregulated	O
significantly	O
by	O
spontaneous	O
constitutive	O
apoptosis	O
.	O

Addition	O
of	O
S100A8	B-GP
/	O
9	O
did	O
not	O
rescue	O
protein	O
expression	O
.	O

Bcl2	B-GP
(	O
25KD	O
)	O
and	O
survivin	B-GP
(	O
19KD	O
)	O
were	O
not	O
detected	O
under	O
any	O
experimental	O
conditions	O
.	O

The	O
lysates	O
of	O
40	O
×	O
106	O
neutrophils	O
under	O
different	O
conditions	O
,	O
including	O
freshly	O
isolated	O
,	O
after	O
8	O
–	O
10	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
,	O
or	O
after	O
8	O
–	O
10	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
with	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
,	O
were	O
loaded	O
and	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
as	O
described	O
in	O
Experimental	O
Procedures	O
.	O

Proteins	O
were	O
transferred	O
to	O
the	O
PVDF	O
membrane	O
and	O
exposed	O
to	O
the	O
appropriate	O
primary	O
antibody	B-GP
according	O
to	O
manufacturers	O
'	O
instructions	O
,	O
and	O
then	O
to	O
secondary	O
antibody	B-GP
conjugated	O
with	O
HRP	B-GP
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Additional	O
details	O
of	O
methods	O
used	O
in	O
proteomics	O
and	O
programmed	O
cell	O
death	O
evaluation	O
.	O

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Deletion	O
of	O
JMJD2B	B-GP
in	O
neurons	O
leads	O
to	O
defective	O
spine	O
maturation	O
,	O
hyperactive	O
behavior	O
and	O
memory	O
deficits	O
in	O
mouse	B-OG

JMJD2B	B-GP
is	O
a	O
histone	B-GP
demethylase	I-GP
enzyme	O
that	O
regulates	O
gene	O
expression	O
through	O
demethylation	O
of	O
H3K9me3	O
.	O

Although	O
mutations	O
of	O
JMJD2B	B-GP
have	O
been	O
suggested	O
to	O
be	O
responsible	O
for	O
neurodevelopmental	B-DS
disorders	I-DS
,	O
the	O
function	O
of	O
JMJD2B	B-GP
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
remains	O
to	O
be	O
elucidated	O
.	O

Here	O
we	O
show	O
that	O
JMJD2B	B-GP
has	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
the	O
CNS	O
.	O

We	O
observed	O
JMJD2B	B-GP
expression	O
,	O
which	O
was	O
especially	O
strong	O
in	O
the	O
hippocampus	O
,	O
throughout	O
the	O
CNS	O
from	O
embryonic	O
periods	O
through	O
adulthood	O
.	O

We	O
generated	O
neuron	O
-	O
specific	O
JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
using	O
the	O
cre	O
-	O
loxP	O
system	O
.	O

We	O
found	O
an	O
increase	O
in	O
total	O
spine	O
number	O
,	O
but	O
a	O
decrease	O
in	O
mature	O
spines	O
,	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
exhibited	O
hyperactive	O
behavior	O
,	O
sustained	O
hyperactivity	O
in	O
a	O
novel	O
environment	O
,	O
deficits	O
in	O
working	O
memory	O
and	O
spontaneous	O
epileptic	O
-	O
like	O
seizures	O
.	O

Together	O
these	O
observations	O
indicate	O
that	O
JMJD2B	B-GP
mutant	O
mice	B-OG
display	O
symptoms	O
reminiscent	O
of	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Our	O
findings	O
provide	O
evidence	O
for	O
the	O
involvement	O
of	O
histone	B-GP
demethylation	O
in	O
the	O
formation	O
of	O
functional	O
neural	O
networks	O
during	O
development	O
.	O

Introduction	O

Neurodevelopmental	B-DS
disorders	I-DS
are	O
an	O
essential	O
and	O
poorly	O
understood	O
clinical	O
challenge	O
.	O

The	O
complications	O
they	O
cause	O
such	O
as	O
learning	B-DS
disorders	I-DS
,	O
memory	O
-	O
formation	O
deficits	O
and	O
epilepsy	B-DS
,	O
have	O
profound	O
effects	O
on	O
patients	O
'	O
daily	O
life	O
.	O
1	O
,	O
2	O
Numerous	O
gene	O
mutations	O
are	O
involved	O
in	O
these	O
pathologies	O
,	O
including	O
genes	O
associated	O
with	O
postsynaptic	O
components	O
.	O
3	O
,	O
4	O
Moreover	O
,	O
recent	O
studies	O
provide	O
increasing	O
evidence	O
of	O
the	O
importance	O
of	O
epigenetic	O
mechanisms	O
in	O
the	O
underlying	O
pathobiology	O
,	O
5	O
and	O
mutations	O
of	O
genes	O
involved	O
in	O
epigenetic	O
regulation	O
are	O
found	O
in	O
patients	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
.	O
6	O
,	O
7	O
In	O
addition	O
,	O
recent	O
report	O
suggests	O
that	O
several	O
histone	B-GP
-	O
modification	O
genes	O
,	O
including	O
both	O
histone	B-GP
methyltransferases	I-GP
and	O
demethylases	B-GP
,	O
are	O
causative	O
risk	O
genes	O
for	O
such	O
disorders	O
.	O
8	O
Nevertheless	O
,	O
our	O
knowledge	O
of	O
the	O
involvement	O
of	O
histone	B-GP
modifications	O
in	O
neurodevelopmental	B-DS
disorders	I-DS
is	O
limited	O
.	O

Histone	O
modification	O
is	O
an	O
epigenetic	O
process	O
that	O
regulates	O
gene	O
expression	O
through	O
the	O
modulation	O
of	O
chromatin	O
structure	O
.	O

An	O
important	O
histone	B-GP
-	O
modification	O
process	O
is	O
histone	B-GP
methylation	O
and	O
demethylation	O
.	O

Among	O
the	O
best	O
understood	O
and	O
most	O
essential	O
classes	O
of	O
histone	B-GP
demethylases	I-GP
is	O
the	O
Jumonji	B-GP
family	O
,	O
first	O
cloned	O
by	O
Takeuchi	O
et	O
al	O
.	O
9	O
in	O
1995	O
,	O
which	O
was	O
followed	O
by	O
the	O
identification	O
of	O
the	O
Jmjd2	B-GP
family	O
,	O
a	O
Jumonji	O
family	O
subgroup	O
.	O

The	O
JMJD2	B-GP
family	O
consists	O
of	O
6	O
subtypes	O
(	O
JMJD2A	B-GP
-	O
JMJD2F	B-GP
);	O
JMJD2B	B-GP
acts	O
as	O
a	O
transcriptional	B-GP
activator	O
of	O
targeted	O
genes	O
through	O
demethylation	O
of	O
specific	O
lysine	B-CD
residues	O
on	O
H3K9me3	O
.	O
10	O
,	O
11	O
JMJD2B	B-GP
is	O
located	O
in	O
the	O
nucleus	O
in	O
dividing	O
cells	O
and	O
has	O
demethylase	B-GP
activity	O
to	O
H3K9me3	O
.	O
12	O
Previous	O
research	O
has	O
mainly	O
focused	O
on	O
the	O
oncogenic	O
potential	O
of	O
JMJD2B	B-GP
.	O

In	O
particular	O
,	O
overexpression	O
of	O
JMJD2B	B-GP
exhibits	O
oncogenic	O
activity	O
in	O
various	O
human	B-OG
cancers	B-DS
,	O
including	O
prostate	O
,	O
breast	O
,	O
colon	O
and	O
gastric	B-DS
cancers	I-DS
.	O
13	O
,	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
In	O
addition	O
,	O
JMJD2B	B-GP
was	O
found	O
to	O
be	O
necessary	O
for	O
self	O
-	O
renewal	O
of	O
embryonic	O
stem	O
cells	O
and	O
induced	O
pluripotent	O
stem	O
cell	O
generation	O
.	O
18	O

The	O
Jumonji	O
family	O
appears	O
to	O
also	O
play	O
important	O
roles	O
in	O
the	O
brain	O
.	O

Two	O
mutations	O
of	O
JMJD2B	B-GP
have	O
been	O
found	O
in	O
individuals	O
with	O
autism	B-DS
spectrum	I-DS
disorder	I-DS
(	O
ASD	B-DS
)	O
along	O
with	O
other	O
histone	B-GP
demethylase	I-GP
enzymes	O
,	O
including	O
JMJD1A	B-GP
and	O
,	O
JARID1B	B-GP
.	O
8	O
In	O
addition	O
to	O
these	O
enzymes	O
,	O
mutations	O
of	O
other	O
histone	B-GP
demethylase	I-GP
genes	O
including	O
KDM6A	B-GP
,	O
which	O
is	O
implicated	O
in	O
Kabuki	B-DS
syndrome	I-DS
,	O
19	O
and	O
JARID1C	B-GP
,	O
which	O
is	O
implicated	O
in	O
X	B-DS
-	I-DS
linked	I-DS
mental	I-DS
retardation	I-DS
syndrome	I-DS
,	O
20	O
are	O
found	O
in	O
individuals	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Therefore	O
,	O
histone	B-GP
demethylation	O
appears	O
to	O
be	O
critically	O
associated	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
;	O
however	O
,	O
the	O
function	O
of	O
the	O
Jumonji	B-GP
family	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
remains	O
largely	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
function	O
of	O
JMJD2B	B-GP
in	O
the	O
CNS	O
by	O
generating	O
neuron	O
-	O
specific	O
,	O
JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
.	O

These	O
mice	B-OG
exhibited	O
various	O
symptoms	O
reminiscent	O
of	O
neurodevelopmental	B-DS
disorders	I-DS
,	O
and	O
impaired	O
synaptic	O
maturation	O
in	O
the	O
hippocampus	O
.	O

These	O
observations	O
indicate	O
that	O
JMJD2B	B-GP
is	O
required	O
for	O
neuronal	O
circuit	O
formation	O
,	O
and	O
its	O
deficiency	O
leads	O
to	O
behavioral	O
and	O
physiologic	O
abnormalities	O
observed	O
in	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Materials	O
and	O
methods	O

Mice	B-OG

For	O
all	O
experiments	O
,	O
the	O
mice	B-OG
were	O
of	O
the	O
C57B6	O
/	O
J	O
strain	O
.	O
Jmjd2b	O
floxed	O
mice	B-OG
,	O
in	O
which	O
exon	O
5	O
of	O
the	O
Jmjd2b	O
allele	O
was	O
flanked	O
by	O
loxP	O
sequences	O
bilaterally	O
,	O
13	O
were	O
crossed	O
with	O
mice	B-OG
expressing	O
Cre	B-GP
recombinase	I-GP
under	O
the	O
control	O
of	O
the	O
Tau	B-GP
promoter	O
,	O
21	O
resulting	O
in	O
the	O
specific	O
deletion	O
of	O
JMJD2B	B-GP
in	O
neurons	O
.	O

Both	O
genders	O
were	O
used	O
in	O
all	O
experiments	O
except	O
for	O
behavioral	O
analysis	O
(	O
male	O
mice	B-OG
).	O

In	O
all	O
cases	O
,	O
pups	O
were	O
weaned	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
28	O
,	O
and	O
housed	O
in	O
sex	O
-	O
matched	O
groups	O
in	O
standard	O
mouse	B-OG
cages	O
under	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
according	O
to	O
the	O
protocols	O
approved	O
by	O
Institutional	O
animal	B-OG
care	O
and	O
Use	O
Committee	O
of	O
Osaka	O
University	O
.	O

In	O
situ	O
hybridization	O

Mice	B-OG
were	O
harvested	O
for	O
in	O
situ	O
hybridization	O
analysis	O
at	O
embryonic	O
days	O
(	O
E	O
)	O
13	O
,	O
15	O
and	O
17	O
,	O
and	O
P1	O
,	O
3	O
,	O
5	O
,	O
7	O
,	O
14	O
and	O
56	O
(	O
8	O
weeks	O
;	O
n	O
=	O
1	O
per	O
age	O
).	O

All	O
mice	B-OG
were	O
decapitated	O
under	O
deep	O
anesthesia	O
and	O
brains	O
were	O
quickly	O
put	O
into	O
dry	O
ice	O
powder	O
as	O
fresh	O
frozen	O
samples	O
.	O

P0	O
mice	B-OG
were	O
used	O
for	O
expression	O
analysis	O
and	O
the	O
whole	O
body	O
was	O
quickly	O
put	O
into	O
dry	O
ice	O
powder	O
as	O
fresh	O
frozen	O
samples	O
.	O

The	O
whole	O
brain	O
and	O
whole	O
body	O
were	O
cut	O
into	O
14	O
-	O
μm	O
-	O
thick	O
sagittal	O
sections	O
using	O
a	O
cryostat	O
and	O
mounted	O
on	O
APS	O
-	O
coated	O
glass	O
slides	O
(	O
Matsunami	O
,	O
Osaka	O
,	O
Japan	O
).	O

Probes	O
for	O
JMJD2B	B-GP
were	O
generated	O
from	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
fragments	O
of	O
mouse	B-OG
DNA	O
by	O
reverse	O
transcription	O
–	O
PCR	O
.	O

We	O
prepared	O
two	O
probes	O
to	O
confirm	O
the	O
specificity	O
.	O

The	O
primer	O
sequences	O
for	O
each	O
probe	O
were	O
as	O
follows	O
:	O
Probe1	O
—	O
forward	O
,	O
5	O
′-	O
ACGGCAGACGTATGATGACA	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
AAGGGGATGCCGTACTTCTT	O
-	O
3	O
′:	O
Probe2	O
—	O
forward	O
,	O
5	O
′-	O
TGGTGACTCACAGGGAACAA	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
AACATGTCCAGCCCTCTTTG	O
-	O
3	O
′.	O

Using	O
these	O
primers	O
,	O
we	O
amplified	O
the	O
target	O
probe	O
sequences	O
by	O
PCR	O
and	O
subsequently	O
integrated	O
the	O
PCR	O
products	O
into	O
the	O
pGEM	O
-	O
T	O
easy	O
vector	O
(	O
Promega	O
,	O
Tokyo	O
,	O
Japan	O
).	O

DNA	O
templates	O
were	O
linearized	O
by	O
restriction	B-GP
enzymes	I-GP
(	O
NdeI	B-GP
and	O
NcoI	B-GP
)	O
by	O
incubation	O
at	O
37	O
°	O
C	O
for	O
16	O
h	O
.	O

Complete	O
digestion	O
of	O
the	O
vector	O
was	O
confirmed	O
by	O
agarose	O
electrophoresis	O
.	O

Then	O
,	O
we	O
prepared	O
solution	O
containing	O
1	O
μg	O
template	O
DNA	O
,	O
1	O
×	O
concentration	O
DIG	O
RNA	O
labeling	O
mix	O
2	O
μl	O
,	O
5	O
×	O
transcription	O
buffer	O
,	O
100	O
mm	O
DTT	O
and	O
the	O
appropriate	O
RNA	B-GP
polymerase	I-GP
(	O
T7	B-OG
or	O
SP6	B-GP
).	O

RNA	O
was	O
synthesized	O
by	O
incubation	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
.	O

Then	O
,	O
DNase	B-GP
was	O
added	O
and	O
samples	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
followed	O
by	O
RNA	O
probe	O
extraction	O
by	O
ethanol	O
precipitation	O
.	O

Before	O
beginning	O
hybridization	O
,	O
the	O
sections	O
were	O
air	O
-	O
dried	O
for	O
1	O
h	O
and	O
immediately	O
put	O
into	O
4	O
%	O
paraformaldehyde	O
for	O
30	O
min	O
,	O
followed	O
by	O
washing	O
in	O
0	O
.	O
1	O
%	O
activated	O
DEPC	O
water	O
(	O
not	O
autoclaved	O
)	O
twice	O
for	O
15	O
min	O
.	O

Then	O
samples	O
were	O
equilibrated	O
in	O
5	O
×	O
SCC	O
for	O
15	O
min	O
.	O

Next	O
,	O
the	O
sections	O
were	O
pre	O
-	O
hybridized	O
at	O
58	O
°	O
C	O
for	O
1	O
h	O
in	O
hybridization	O
buffer	O
(	O
5	O
×	O
SCC	O
400	O
μg	O
ml	O
−	O
1	O
,	O
heat	O
-	O
denatured	O
salmon	B-OG
sperm	O
DNA	O
and	O
50	O
%	O
formamide	O
)	O
and	O
subsequently	O
hybridized	O
at	O
58	O
°	O
C	O
for	O
another	O
40	O
h	O
in	O
the	O
same	O
solution	O
,	O
but	O
with	O
400	O
ng	O
ml	O
−	O
1	O
RNA	O
probe	O
added	O
.	O

Then	O
,	O
sections	O
were	O
rinsed	O
in	O
2	O
×	O
SSC	O
at	O
room	O
temperature	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
wash	O
in	O
2	O
×	O
SSC	O
for	O
1	O
h	O
at	O
65	O
°	O
C	O
,	O
and	O
then	O
in	O
0	O
.	O
1	O
×	O
SSC	O
at	O
65	O
°	O
C	O
for	O
another	O
hour	O
.	O

Next	O
,	O
sections	O
were	O
washed	O
in	O
buffer	O
A	O
(	O
100	O
mm	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
5	O
,	O
150	O
mm	O
NaCl	O
)	O
at	O
room	O
temperature	O
for	O
5	O
min	O
.	O

Sections	O
were	O
reacted	O
with	O
AP	O
-	O
conjugated	O
anti	O
-	O
Dig	O
Fab	O
antibody	B-GP
(	O
Roche	O
,	O
Mannheim	O
,	O
Germany	O
;	O
dilution	O
1	O
:	O
5000	O
in	O
wash	O
buffer	O
A	O
)	O
at	O
room	O
temperature	O
for	O
2	O
h	O
.	O

After	O
washing	O
the	O
sections	O
with	O
buffer	O
A	O
twice	O
for	O
15	O
min	O
each	O
,	O
the	O
sections	O
were	O
washed	O
with	O
buffer	O
B	O
(	O
100	O
mm	O
Tris	O
-	O
HCl	O
pH	O
9	O
.	O
5	O
,	O
150	O
mm	O
NaCl	O
,	O
100	O
mm	O
MgCl2	O
)	O
for	O
5	O
min	O
.	O

Next	O
,	O
these	O
sections	O
were	O
incubated	O
with	O
color	O
reagent	O
(	O
NBT	O
45	O
μl	O
,	O
BCIP	O
35	O
μl	O
,	O
each	O
in	O
10	O
ml	O
buffer	O
B	O
)	O
at	O
room	O
temperature	O
for	O
48	O
h	O
.	O

After	O
that	O
,	O
sections	O
were	O
washed	O
with	O
buffer	O
B	O
and	O
the	O
reactions	O
were	O
stopped	O
by	O
applying	O
TE	O
buffer	O
(	O
10	O
mm	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
1	O
mm	O
EDTA	O
).	O

Finally	O
,	O
sections	O
were	O
dehydrated	O
in	O
an	O
ethanol	O
gradient	O
(	O
70	O
,	O
80	O
,	O
95	O
and	O
100	O
%)	O
and	O
mounted	O
with	O
EUKITT	O
(	O
O	O
.	O

Kindler	O
,	O
Freiburg	O
,	O
Germany	O
).	O

Immunohistochemistry	O
followed	O
by	O
in	O
situ	O
hybridization	O

Immunostaining	O
with	O
DAB	O
as	O
the	O
substrate	O
for	O
horseradish	B-OG
peroxidase	B-GP
followed	O
by	O
in	O
situ	O
hybridization	O
was	O
performed	O
according	O
to	O
a	O
previously	O
described	O
method	O
(	O
n	O
=	O
1	O
).	O
22	O
After	O
in	O
situ	O
hybridization	O
by	O
using	O
fresh	O
frozen	O
sections	O
was	O
complete	O
,	O
sections	O
were	O
washed	O
with	O
buffer	O
B	O
as	O
described	O
above	O
.	O

Then	O
,	O
sections	O
were	O
washed	O
with	O
PBS	O
three	O
times	O
for	O
5	O
min	O
each	O
.	O

Next	O
,	O
sections	O
were	O
incubated	O
with	O
NeuN	B-GP
(	O
anti	O
-	O
mouse	B-OG
NeuN	B-GP
1	O
:	O
100	O
MAB377	O
,	O
Millipore	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
or	O
GFAP	B-GP
(	O
anti	O
-	O
mouse	B-OG
GFAP	B-GP
1	O
:	O
500	O
,	O
sc58766	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
antibodies	B-GP
diluted	O
in	O
PBS	O
overnight	O
at	O
4	O
°	O
C	O
followed	O
by	O
washing	O
with	O
PBS	O
three	O
times	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
sections	O
were	O
incubated	O
with	O
biotin	B-CD
-	O
conjugated	O
anti	O
-	O
mouse	B-OG
-	O
IgG	B-GP
antibody	B-GP
for	O
30	O
min	O
in	O
a	O
moisture	O
chamber	O
followed	O
by	O
washing	O
with	O
PBS	O
twice	O
at	O
room	O
temperature	O
.	O

Next	O
,	O
sections	O
were	O
reacted	O
to	O
Avidin	B-GP
–	O
biotin	B-CD
complex	O
using	O
an	O
ABC	O
kit	O
(	O
Vector	O
Laboratories	O
,	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
in	O
a	O
moist	O
box	O
followed	O
by	O
washing	O
with	O
PBS	O
twice	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
sections	O
were	O
transferred	O
to	O
50	O
mm	O
TBS	O
(	O
pH	O
7	O
.	O
4	O
)	O
for	O
5	O
min	O
and	O
reacted	O
in	O
50	O
mm	O
Tris	O
buffer	O
(	O
pH	O
7	O
.	O
6	O
)	O
containing	O
0	O
.	O
02	O
%	O
diaminobenzidine	O
tetrahydrochloride	O
(	O
Sigma	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
0	O
.	O
01	O
%	O
hydrogen	O
peroxide	O
for	O
several	O
minutes	O
until	O
the	O
signal	O
was	O
detected	O
.	O

Reactions	O
were	O
stopped	O
by	O
transferring	O
the	O
sections	O
to	O
50	O
mm	O
TBS	O
at	O
room	O
temperature	O
for	O
5	O
min	O
.	O

Finally	O
sections	O
were	O
dehydrated	O
in	O
an	O
ethanol	O
gradient	O
as	O
described	O
for	O
the	O
in	O
situ	O
hybridization	O
method	O
(	O
70	O
,	O
85	O
,	O
95	O
and	O
100	O
%)	O
and	O
mounted	O
with	O
EUKITT	O
.	O

Genotyping	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
a	O
tail	O
biopsy	O
of	O
each	O
mouse	B-OG
.	O

Tail	O
biopsies	O
were	O
incubated	O
at	O
55	O
°	O
C	O
for	O
several	O
hours	O
with	O
500	O
μl	O
genotyping	O
lysis	O
buffer	O
containing	O
0	O
.	O
01	O
m	O
Tris	O
-	O
HCl	O
(	O
pH	O
8	O
.	O
0	O
),	O
0	O
.	O
05	O
m	O
EDTA	O
(	O
pH	O
8	O
.	O
0	O
),	O
0	O
.	O
1	O
m	O
NaCl	O
,	O
0	O
.	O
5	O
%	O
SDS	O
and	O
0	O
.	O
1	O
mg	O
ml	O
−	O
1	O
proteinase	B-GP
K	I-GP
(	O
Roche	O
,	O
Tokyo	O
,	O
Japan	O
)	O
for	O
several	O
hours	O
and	O
crushed	O
by	O
vortex	O
with	O
410	O
μl	O
of	O
3	O
.	O
75	O
m	O
NaCl	O
.	O

Then	O
samples	O
were	O
put	O
into	O
box	O
with	O
crushed	O
ice	O
for	O
10	O
minutes	O
followed	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
15	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O

Then	O
,	O
500	O
μl	O
of	O
supernatant	O
were	O
collected	O
and	O
mixed	O
with	O
1000	O
μl	O
of	O
99	O
.	O
5	O
%	O
ethanol	O
(	O
Wako	O
,	O
Osaka	O
,	O
Japan	O
)	O
followed	O
by	O
centrifugation	O
at	O
15	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
15	O
min	O
.	O

The	O
supernatant	O
was	O
discarded	O
,	O
70	O
%	O
ethanol	O
was	O
added	O
to	O
the	O
DNA	O
pellet	O
,	O
and	O
samples	O
were	O
centrifuged	O
for	O
5	O
min	O
at	O
15	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O

This	O
supernatant	O
was	O
discarded	O
and	O
the	O
pellet	O
was	O
dehydrated	O
by	O
evaporation	O
at	O
room	O
temperature	O
.	O

Finally	O
,	O
the	O
dry	O
pellet	O
was	O
dissolved	O
in	O
RNase	B-GP
free	O
water	O
(	O
Ambion	O
,	O
Foster	O
,	O
CA	O
,	O
USA	O
).	O

PCR	O
was	O
performed	O
using	O
KOD	O
FX	O
Neo	O
(	O
TOYOBO	O
,	O
Osaka	O
,	O
Japan	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

PCR	O
protocol	O
was	O
as	O
follows	O
;	O
jmjd2b	O
;	O
98	O
°	O
C	O
2	O
min	O
:	O
1	O
cycle	O
;	O
98	O
°	O
C	O
,	O
10	O
s	O
,	O
57	O
°	O
C	O
,	O
15	O
s	O
,	O
68	O
°	O
C	O
,	O
1	O
min	O
:	O
repeat	O
for	O
30	O
cycles	O
;	O
72	O
°	O
C	O
10	O
min	O
:	O
1	O
cycle	O
.	O
Tau	O
-	O
cre	O
;	O
96	O
°	O
C	O
,	O
5	O
min	O
:	O
1	O
cycle	O
;	O
96	O
°	O
C	O
,	O
45	O
s	O
,	O
60	O
°	O
C	O
,	O
30	O
s	O
,	O
72	O
°	O
C	O
30	O
s	O
:	O
repeat	O
for	O
30	O
cycles	O
;	O
72	O
°	O
C	O
,	O
30	O
s	O
:	O
1	O
cycle	O
.	O

The	O
primer	O
sequences	O
were	O
as	O
follows	O
:	O
jmjd2b	B-GP
forward	O
:	O
5	O
′-	O
AAGAAGGGTGGGGTGGCGAA	O
-	O
3	O
′;	O
jmjd2b	O
reverse	O
:	O
5	O
′-	O
CGCCACGTCCTATGGACAATG	O
-	O
3	O
′;	O
Cre	B-GP
forward	O
:	O
5	O
′-	O
AGGTTCGTTCTCTCATGGA	O
-	O
3	O
′;	O
Cre	B-GP
reverse	O
:	O
5	O
′-	O
TCGACCAGTTTAGTTACCC	O
-	O
3	O
′;	O
mTau	B-GP
forward	O
:	O
5	O
′-	O
TATGGCTGACCCTCGCCAGGAGTTT	O
-	O
3	O
′;	O
mTau	B-GP
reverse	O
:	O
5	O
′-	O
GTCCACCCCACTGACCTTTTAAGCC	O
-	O
3	O
′.	O

Real	O
-	O
time	O
PCR	O

The	O
hippocampi	O
of	O
P0	O
mice	B-OG
and	O
adult	O
mice	B-OG
(	O
12	O
weeks	O
)	O
from	O
each	O
genotype	O
(	O
wild	O
type	O
(	O
WT	O
):	O
n	O
=	O
3	O
knock	O
out	O
(	O
KO	O
):	O
n	O
=	O
3	O
)	O
were	O
dissected	O
and	O
crushed	O
with	O
an	O
electric	O
mixer	O
in	O
1	O
ml	O
TRIZOL	O
reagent	O
(	O
Ambion	O
)	O
followed	O
by	O
centrifugation	O
at	O
15	O
000	O
r	O
.	O
p	O
.	O
m	O
.	O
for	O
10	O
min	O
.	O

Then	O
,	O
100	O
μl	O
of	O
chloroform	B-CD
were	O
added	O
to	O
the	O
500	O
μl	O
of	O
supernatant	O
.	O

The	O
mixture	O
was	O
vortexed	O
for	O
15	O
s	O
and	O
left	O
at	O
room	O
temperature	O
for	O
15	O
min	O
.	O

Samples	O
were	O
centrifuged	O
at	O
4	O
°	O
C	O
for	O
15	O
min	O
and	O
subsequently	O
100	O
μl	O
of	O
upper	O
water	O
phase	O
were	O
extracted	O
and	O
mixed	O
with	O
80	O
μl	O
isopropanol	O
.	O

Samples	O
were	O
left	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
centrifuged	O
at	O
4	O
°	O
C	O
for	O
10	O
min	O
.	O

Supernatant	O
was	O
removed	O
and	O
70	O
%	O
ethanol	O
was	O
added	O
,	O
followed	O
by	O
centrifugation	O
at	O
4	O
°	O
C	O
for	O
3	O
min	O
.	O

Finally	O
,	O
the	O
supernatant	O
was	O
removed	O
and	O
the	O
RNA	O
pellet	O
was	O
dried	O
by	O
evaporation	O
and	O
dissolved	O
in	O
50	O
μl	O
of	O
RNase	B-GP
free	O
water	O
.	O

We	O
then	O
performed	O
reverse	O
transcription	O
(	O
High	O
Capacity	O
cDNA	O
Reverse	O
Transcription	O
Kit	O
;	O
Applied	O
Biosystems	O
,	O
Foster	O
,	O
CA	O
,	O
USA	O
)	O
on	O
the	O
RNA	O
samples	O
to	O
obtain	O
cDNA	O
fragments	O
.	O

Gene	O
expression	O
levels	O
were	O
measured	O
by	O
real	O
-	O
time	O
PCR	O
(	O
Quant	O
Studio	O
7Flex	O
,	O
Applied	O
Biosystems	O
)	O
using	O
Taqman	O
probes	O
.	O

Golgi	O
staining	O

Eight	O
-	O
week	O
-	O
old	O
mice	B-OG
of	O
both	O
genotypes	O
were	O
used	O
for	O
Golgi	O
analysis	O
.	O

All	O
mice	B-OG
were	O
decapitated	O
under	O
deep	O
anesthesia	O
and	O
brains	O
were	O
quickly	O
put	O
into	O
dry	O
ice	O
powder	O
as	O
fresh	O
frozen	O
samples	O
.	O

Tissue	O
was	O
stained	O
with	O
the	O
FD	O
Rapid	O
Golgistain	O
Kit	O
(	O
Cat	O
#:	O
PK401	O
,	O
FD	O
Neurotechnologies	O
,	O
Colombia	O
,	O
MD	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Briefly	O
,	O
tissues	O
were	O
immersed	O
in	O
impregnant	O
solution	O
(	O
solution	O
A	O
+	O
solution	O
B	O
)	O
for	O
14	O
days	O
in	O
dark	O
box	O
at	O
room	O
temperature	O
with	O
solution	O
exchange	O
after	O
1	O
h	O
and	O
24	O
h	O
,	O
respectively	O
.	O

Then	O
tissues	O
were	O
transferred	O
to	O
solution	O
C	O
for	O
5	O
days	O
with	O
solution	O
exchange	O
after	O
the	O
first	O
24	O
h	O
.	O

Tissues	O
were	O
immediately	O
moved	O
into	O
dry	O
ice	O
powder	O
and	O
cut	O
into	O
200	O
-	O
μm	O
-	O
thick	O
coronal	O
sections	O
using	O
a	O
cryostat	O
.	O

The	O
cut	O
sections	O
were	O
floated	O
in	O
PBS	O
and	O
placed	O
on	O
double	O
gelatin	O
-	O
coated	O
glass	O
slides	O
.	O

Sections	O
were	O
allowed	O
to	O
dry	O
by	O
evaporation	O
at	O
room	O
temperature	O
for	O
24	O
h	O
and	O
then	O
moved	O
into	O
a	O
mixture	O
solution	O
containing	O
one	O
part	O
solution	O
D	O
,	O
one	O
part	O
solution	O
E	O
and	O
two	O
parts	O
of	O
MilliQ	O
-	O
water	O
for	O
7	O
–	O
10	O
min	O
.	O

Then	O
sections	O
were	O
washed	O
in	O
MilliQ	O
-	O
water	O
(	O
Millipore	O
)	O
(	O
four	O
washes	O
of	O
5	O
min	O
each	O
),	O
dehydrated	O
by	O
immersing	O
the	O
section	O
in	O
Histoclear	O
(	O
National	O
Diagnostics	O
,	O
Atlanta	O
,	O
GA	O
,	O
USA	O
)	O
three	O
times	O
(	O
10	O
min	O
each	O
time	O
)	O
and	O
coverslipped	O
.	O

Analysis	O
was	O
performed	O
using	O
a	O
Neurolucida	O
system	O
(	O
MBF	O
Bioscience	O
,	O
Chiba	O
,	O
Japan	O
).	O

Dendrites	O
of	O
pyramidal	O
neurons	O
located	O
120	O
–	O
300	O
μm	O
from	O
the	O
soma	O
were	O
selected	O
.	O

We	O
counted	O
spine	O
numbers	O
and	O
classified	O
spine	O
class	O
along	O
the	O
first	O
20	O
μm	O
of	O
each	O
dendrite	O
.	O

We	O
defined	O
mature	O
spines	O
as	O
mushroom	O
-	O
like	O
spines	O
in	O
which	O
the	O
head	O
diameter	O
was	O
wider	O
than	O
the	O
neck	O
diameter	O
.	O

We	O
used	O
five	O
mutant	O
mice	B-OG
and	O
six	O
WT	O
littermates	O
and	O
analyzed	O
four	O
to	O
seven	O
dendrites	O
per	O
animal	B-OG
,	O
mainly	O
in	O
the	O
dorsal	O
CA1	O
region	O
.	O

We	O
selected	O
secondary	O
dendrites	O
located	O
120	O
–	O
300	O
μm	O
from	O
the	O
somas	O
of	O
the	O
pyramidal	O
neurons	O
in	O
CA1	O
,	O
which	O
corresponds	O
to	O
the	O
area	O
of	O
CA1	O
that	O
receives	O
inputs	O
from	O
Schaffer	O
collaterals	O
from	O
CA3	O
.	O
23	O
We	O
used	O
3	O
mutant	O
mice	B-OG
and	O
3	O
WT	O
littermates	O
and	O
analyzed	O
6	O
–	O
10	O
apical	O
dendrites	O
of	O
pyramidal	O
neurons	O
per	O
animal	O
in	O
layer	O
2	O
/	O
3	O
of	O
somatosensory	O
cortex	O
.	O

Hippocampal	O
neuron	O
culture	O
and	O
analysis	O
of	O
neuron	O
morphology	O

The	O
hippocampus	O
was	O
isolated	O
from	O
P1	O
mice	B-OG
(	O
n	O
=	O
4	O
:	O
each	O
genotype	O
).	O

Neurons	O
were	O
cultured	O
in	O
DMEM	O
/	O
F12	O
medium	O
supplemented	O
with	O
10	O
%	O
FBS	O
for	O
1day	O
,	O
and	O
subsequently	O
DMEM	O
/	O
F12	O
supplemented	O
with	O
B27	B-GP
(	O
Invitrogen	O
,	O
Foster	O
,	O
CA	O
,	O
USA	O
)	O
for	O
another	O
6	O
days	O
in	O
a	O
37	O
°	O
C	O
incubator	O
containing	O
5	O
.	O
0	O
%	O
CO2	O
.	O

The	O
neuron	O
density	O
was	O
4	O
.	O
0	O
×	O
10	O
cells	O
per	O
3	O
.	O
5	O
-	O
cm	O
dish	O
.	O

After	O
7	O
days	O
of	O
incubation	O
,	O
samples	O
were	O
fixed	O
by	O
4	O
%	O
paraformaldehyde	O
for	O
30	O
min	O
followed	O
by	O
incubation	O
in	O
5	O
%	O
BSA	B-GP
containing	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Samples	O
were	O
stained	O
with	O
anti	O
MAP2	B-GP
antibody	B-GP
(	O
anti	O
-	O
rabbit	B-OG
MAP2	B-GP
1	O
:	O
1000	O
,	O
45425	O
,	O
Cell	O
Signaling	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
for	O
16	O
h	O
at	O
4	O
°	O
C	O
.	O

And	O
then	O
samples	O
were	O
washed	O
in	O
PBS	O
with	O
Tween	B-CD
20	O
three	O
times	O
followed	O
by	O
incubation	O
with	O
a	O
fluorescence	O
-	O
conjugated	O
secondary	O
antibody	B-GP
(	O
anti	O
-	O
rabbit	B-OG
IgG	B-GP
,	O
1	O
:	O
1000	O
,	O
Alexa	O
,	O
Invitrogen	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
in	O
a	O
dark	O
box	O
.	O

Neuron	O
morphology	O
was	O
traced	O
by	O
Neurolucida	O
.	O

We	O
selected	O
labeled	O
neurons	O
with	O
little	O
or	O
no	O
adjacent	O
stained	O
glia	O
for	O
analysis	O
.	O

Timm	O
staining	O

Mice	B-OG
(	O
3	O
–	O
5	O
months	O
old	O
)	O
of	O
both	O
genotypes	O
were	O
deeply	O
anesthetized	O
and	O
transcardially	O
perfused	O
with	O
PBS	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
(	O
WT	O
:	O
n	O
=	O
3	O
KO	O
:	O
n	O
=	O
3	O
).	O

Following	O
perfusion	O
,	O
fixed	O
samples	O
were	O
post	O
-	O
fixed	O
in	O
the	O
same	O
fixative	O
solution	O
at	O
4	O
°	O
C	O
for	O
16	O
h	O
and	O
immersed	O
in	O
30	O
%	O
sucrose	B-CD
in	O
PBS	O
at	O
4	O
°	O
C	O
until	O
the	O
tissue	O
sank	O
.	O

Tissues	O
were	O
cut	O
into	O
40	O
-	O
μm	O
-	O
thick	O
coronal	O
sections	O
using	O
a	O
cryostat	O
and	O
placed	O
on	O
MAS	O
-	O
coated	O
glass	O
slides	O
.	O

Cut	O
sections	O
were	O
dried	O
by	O
evaporation	O
and	O
immersed	O
in	O
1	O
%	O
sodium	O
sulfide	O
solution	O
(	O
Wako	O
)	O
for	O
10	O
min	O
.	O

Then	O
,	O
the	O
sections	O
were	O
fixed	O
again	O
in	O
4	O
%	O
paraformaldehyde	O
followed	O
by	O
washing	O
in	O
PBS	O
twice	O
.	O

The	O
sections	O
were	O
dried	O
by	O
evaporation	O
and	O
reacted	O
with	O
Timm	O
staining	O
solution	O
containing	O
30	O
%	O
gum	O
Arabic	O
solution	O
(	O
Wako	O
),	O
1	O
.	O
7	O
%	O
hydroquinone	O
solution	O
(	O
Wako	O
),	O
0	O
.	O
08	O
%	O
caustic	O
silver	O
solution	O
(	O
Wako	O
)	O
and	O
0	O
.	O
2	O
m	O
citrate	B-CD
buffer	O
solution	O
(	O
pH	O
4	O
.	O
2	O
;	O
Wako	O
)	O
at	O
room	O
temperature	O
for	O
2	O
h	O
in	O
a	O
dark	O
box	O
.	O

The	O
reaction	O
was	O
terminated	O
by	O
immersion	O
in	O
tap	O
water	O
for	O
5	O
min	O
.	O

The	O
sections	O
were	O
counterstained	O
with	O
cresyl	B-CD
violet	I-CD
solution	O
for	O
7	O
min	O
at	O
room	O
temperature	O
.	O

Finally	O
,	O
sections	O
were	O
dehydrated	O
by	O
ethanol	O
(	O
70	O
,	O
80	O
,	O
95	O
,	O
and	O
100	O
%)	O
and	O
mounted	O
with	O
EUKITT	O
.	O

Nissl	O
staining	O

P0	O
mouse	B-OG
brains	O
of	O
both	O
genotypes	O
(	O
WT	O
:	O
n	O
=	O
3	O
;	O
KO	O
:	O
n	O
=	O
3	O
)	O
were	O
fixed	O
in	O
paraformaldehyde	O
at	O
4	O
°	O
C	O
for	O
16	O
h	O
and	O
impregnated	O
with	O
30	O
%	O
sucrose	B-CD
until	O
the	O
tissue	O
sank	O
.	O

Then	O
,	O
fixed	O
samples	O
were	O
immediately	O
moved	O
into	O
dry	O
ice	O
powder	O
and	O
cut	O
into	O
30	O
-	O
μm	O
-	O
thick	O
saggital	O
sections	O
using	O
a	O
cryostat	O
and	O
placed	O
on	O
MAS	O
-	O
coated	O
glass	O
slides	O
.	O

Cut	O
sections	O
were	O
impregnated	O
with	O
Cresyl	B-CD
violet	I-CD
acetate	O
(	O
C5042	O
-	O
10G	O
,	O
Sigma	O
)	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
dehydrated	O
in	O
100	O
%	O
ethanol	O
for	O
5	O
min	O
.	O

Western	O
blotting	O

Hippocampal	O
brain	O
lysates	O
of	O
both	O
genotypes	O
of	O
3	O
or	O
4	O
-	O
month	O
-	O
old	O
mice	B-OG
(	O
WT	O
:	O
n	O
=	O
3	O
KO	O
:	O
n	O
=	O
3	O
)	O
were	O
boiled	O
in	O
sample	O
buffer	O
for	O
5	O
min	O
.	O

The	O
proteins	O
were	O
separated	O
by	O
SDS	O
–	O
PAGE	O
and	O
transferred	O
onto	O
polyvinylidene	O
difluoride	O
membranes	O
(	O
Millipore	O
).	O

The	O
membrane	O
was	O
blocked	O
with	O
5	O
%	O
not	O
-	O
fat	O
dry	O
milk	O
in	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
tween	B-CD
-	I-CD
20	I-CD
(	O
PBS	O
-	O
T	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
or	O
overnight	O
at	O
4	O
°	O
C	O
,	O
with	O
PSD95	B-GP
antibody	B-GP
(	O
anti	O
-	O
mouse	B-OG
PSD95	B-GP
1	O
:	O
500	O
,	O
MA1	O
-	O
046	O
,	O
Thermo	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
or	O
GAPDH	B-GP
antibody	B-GP
(	O
anti	O
-	O
rabbit	B-OG
GAPDH	B-GP
1	O
:	O
1000	O
,	O
sc	O
-	O
25778	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
diluted	O
in	O
PBS	O
-	O
T	O
containing	O
1	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
.	O

After	O
washing	O
in	O
PBS	O
-	O
T	O
,	O
the	O
membrane	O
was	O
incubated	O
with	O
a	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
anti	O
-	O
mouse	B-OG
IgG	B-GP
or	O
anti	O
-	O
rabbit	B-OG
IgG	B-GP
antibody	B-GP
(	O
1	O
:	O
5000	O
,	O
Cell	O
Signaling	O
Technology	O
).	O

For	O
detection	O
,	O
an	O
ECL	O
chemiluminescence	O
system	O
(	O
GE	O
Healthcare	O
)	O
was	O
used	O
.	O

Signals	O
were	O
detected	O
and	O
quantified	O
using	O
the	O
LAS	O
-	O
3000	O
Amersham	O
Imager	O
600	O
(	O
GE	O
Healthcare	O
).	O

Behavioral	O
analysis	O

Adult	O
(	O
8	O
weeks	O
)	O
WT	O
and	O
JMJD2B	B-GP
mutant	O
male	O
mice	B-OG
were	O
subjected	O
to	O
a	O
battery	O
of	O
behavioral	O
tests	O
.	O

For	O
each	O
test	O
,	O
n	O
=	O
8	O
–	O
13	O
mice	B-OG
per	O
genotype	O
were	O
tested	O
.	O

In	O
each	O
behavior	O
test	O
,	O
we	O
analyzed	O
the	O
mice	B-OG
that	O
were	O
able	O
to	O
complete	O
each	O
behavioral	O
task	O
.	O

SHIRPA	O
1st	O
screening	O

Initial	O
behavioral	O
and	O
physical	O
screening	O
was	O
performed	O
using	O
SHIRPA	O
(	O
SmithKline	O
Beecham	O
,	O
Harwell	O
,	O
Imperial	O
College	O
Royal	O
London	O
Hospital	O
,	O
Phenotype	O
Assessment	O
),	O
as	O
previously	O
described	O
.	O
24	O

Locomotor	O
activity	O

Locomotor	O
activity	O
in	O
an	O
open	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
previously	O
reported	O
method	O
.	O
25	O
Briefly	O
,	O
each	O
mouse	B-OG
was	O
placed	O
in	O
the	O
center	O
of	O
an	O
open	O
,	O
transparent	O
,	O
acrylic	O
cubic	O
box	O
with	O
a	O
black	O
,	O
plexiglass	O
floor	O
(	O
45	O
×	O
45	O
×	O
30	O
cm	O
),	O
and	O
allowed	O
to	O
freely	O
explore	O
the	O
environment	O
for	O
60	O
min	O
under	O
dim	O
light	O
(	O
3	O
lux	O
).	O

The	O
distance	O
moved	O
in	O
the	O
first	O
10	O
min	O
was	O
defined	O
as	O
100	O
%	O
in	O
each	O
genotype	O
,	O
and	O
the	O
ratio	O
of	O
the	O
distance	O
moved	O
(%)	O
was	O
assessed	O
.	O

The	O
ambulation	O
of	O
mice	B-OG
was	O
monitored	O
using	O
the	O
Panlab	O
Infrared	O
Actimeter	O
System	O
(	O
LE8815	O
)	O
with	O
acquisition	O
software	O
Acti	O
-	O
Track	O
2	O
.	O
65	O
for	O
Windows	O
(	O
Panlab	O
,	O
Barcelona	O
,	O
Spain	O
).	O

Locomotion	O
in	O
the	O
home	O
cage	O
was	O
monitored	O
for	O
5	O
days	O
,	O
using	O
a	O
digital	O
counter	O
system	O
with	O
an	O
infrared	O
sensor	O
(	O
Supermex	O
;	O
Muromachi	O
Kikai	O
,	O
Kyoto	O
,	O
Japan	O
)	O
as	O
described	O
previously	O
.	O
25	O

Y	O
-	O
maze	O
test	O

The	O
Y	O
-	O
maze	O
test	O
with	O
spontaneous	O
alternation	O
performance	O
was	O
performed	O
as	O
described	O
previously	O
.	O
26	O
Each	O
arm	O
(	O
33	O
×	O
13	O
×	O
30	O
cm	O
)	O
converged	O
in	O
an	O
equilateral	O
triangular	O
central	O
area	O
.	O

Each	O
mouse	B-OG
,	O
naive	O
to	O
the	O
maze	O
,	O
was	O
placed	O
at	O
the	O
end	O
of	O
one	O
arm	O
and	O
allowed	O
to	O
move	O
freely	O
through	O
the	O
maze	O
during	O
an	O
8	O
-	O
min	O
session	O
.	O

The	O
series	O
of	O
arm	O
entries	O
was	O
recorded	O
.	O

Events	O
were	O
counted	O
as	O
entry	O
when	O
the	O
hind	O
paws	O
of	O
the	O
mouse	B-OG
had	O
completely	O
entered	O
the	O
arm	O
.	O

Alternation	O
was	O
defined	O
as	O
successive	O
entries	O
into	O
the	O
three	O
different	O
arms	O
on	O
overlapping	O
triplet	O
sets	O
.	O

The	O
percentage	O
of	O
spontaneous	O
alternations	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
actual	O
to	O
possible	O
alternations	O
(	O
defined	O
as	O
the	O
total	O
number	O
of	O
arm	O
entries	O
−	O
2	O
)	O
multiplied	O
by	O
100	O
,	O
as	O
shown	O
in	O
the	O
following	O
equation	O
:	O
alternation	O
(%)=	O
number	O
of	O
alternations	O
/(	O
total	O
arm	O
entries	O
−	O
2	O
)	O
×	O
100	O
.	O

Elevated	O
plus	O
-	O
maze	O
test	O

The	O
elevated	O
plus	O
-	O
maze	O
test	O
was	O
carried	O
out	O
according	O
to	O
a	O
previously	O
reported	O
method	O
.	O
27	O
The	O
apparatus	O
consisted	O
of	O
four	O
arms	O
(	O
30	O
×	O
5	O
cm	O
each	O
)	O
extending	O
from	O
a	O
central	O
platform	O
(	O
5	O
×	O
5	O
cm	O
).	O

Each	O
set	O
of	O
arms	O
opposed	O
one	O
another	O
and	O
were	O
enclosed	O
by	O
a	O
20	O
-	O
cm	O
-	O
high	O
wall	O
.	O

The	O
maze	O
was	O
elevated	O
40	O
cm	O
above	O
the	O
ground	O
.	O

Each	O
mouse	B-OG
was	O
placed	O
on	O
the	O
central	O
platform	O
with	O
its	O
head	O
facing	O
an	O
open	O
arm	O
and	O
was	O
allowed	O
to	O
move	O
freely	O
for	O
5	O
min	O
under	O
dim	O
light	O
conditions	O
(	O
15	O
lux	O
).	O

The	O
performance	O
of	O
the	O
mouse	B-OG
for	O
5	O
min	O
was	O
videotaped	O
using	O
a	O
digital	O
camera	O
,	O
and	O
then	O
the	O
following	O
parameters	O
were	O
recorded	O
and	O
calculated	O
:	O
(	O
i	O
)	O
time	O
spent	O
in	O
various	O
sections	O
of	O
the	O
maze	O
(	O
open	O
and	O
closed	O
arms	O
,	O
central	O
platform	O
);	O
(	O
ii	O
)	O
number	O
of	O
open	O
and	O
closed	O
arm	O
entries	O
(	O
arm	O
entry	O
defined	O
as	O
all	O
four	O
paws	O
into	O
an	O
arm	O
);	O
(	O
iii	O
)	O
ratio	O
of	O
open	O
arm	O
entries	O
(	O
open	O
arm	O
entries	O
/	O
total	O
entries	O
).	O

Novel	O
object	O
recognition	O
test	O

The	O
object	O
recognition	O
test	O
was	O
performed	O
according	O
to	O
a	O
previous	O
study	O
.	O
28	O
The	O
task	O
consisted	O
of	O
three	O
sessions	O
:	O
habituation	O
,	O
training	O
and	O
retention	O
.	O

Each	O
mouse	B-OG
was	O
individually	O
habituated	O
to	O
the	O
cage	O
(	O
30	O
×	O
30	O
×	O
30	O
cm	O
)	O
with	O
10	O
min	O
of	O
exploration	O
in	O
the	O
absence	O
of	O
objects	O
for	O
3	O
days	O
.	O

Two	O
wooden	O
block	O
objects	O
were	O
placed	O
in	O
the	O
middle	O
of	O
the	O
cage	O
during	O
each	O
training	O
session	O
,	O
and	O
the	O
mouse	B-OG
was	O
allowed	O
to	O
explore	O
the	O
cage	O
for	O
10	O
min	O
.	O

In	O
the	O
retention	O
session	O
,	O
the	O
mouse	B-OG
was	O
placed	O
back	O
into	O
the	O
same	O
cage	O
with	O
a	O
novel	O
wooden	O
ball	O
object	O
together	O
with	O
a	O
familiar	O
wooden	O
block	O
object	O
6	O
h	O
after	O
the	O
training	O
session	O
.	O

The	O
animal	B-OG
was	O
then	O
allowed	O
to	O
explore	O
freely	O
for	O
10	O
min	O
and	O
the	O
time	O
spent	O
exploring	O
each	O
object	O
was	O
recorded	O
.	O

Exploratory	O
behavior	O
was	O
defined	O
as	O
directing	O
the	O
nose	O
to	O
the	O
object	O
at	O
a	O
distance	O
of	O
<	O
2	O
cm	O
and	O
/	O
or	O
touching	O
it	O
with	O
the	O
nose	O
.	O

Preference	O
index	O
,	O
a	O
ratio	O
of	O
the	O
amount	O
of	O
time	O
spent	O
exploring	O
a	O
novel	O
object	O
over	O
the	O
total	O
time	O
spent	O
exploring	O
both	O
objects	O
in	O
the	O
retention	O
session	O
,	O
was	O
used	O
to	O
measure	O
cognitive	O
function	O
.	O

Social	O
interaction	O
test	O

The	O
social	O
interaction	O
test	O
was	O
performed	O
as	O
previously	O
described	O
.	O
29	O
Each	O
mouse	B-OG
was	O
placed	O
in	O
the	O
observation	O
cage	O
and	O
allowed	O
15	O
min	O
of	O
habituation	O
under	O
dim	O
light	O
(	O
15	O
lux	O
).	O

After	O
habituation	O
,	O
a	O
juvenile	O
(	O
3	O
or	O
4	O
-	O
week	O
-	O
old	O
)	O
male	O
C57BL	B-OG
/	I-OG
6	I-OG
mouse	I-OG
(	O
Shimizu	O
Laboratory	O
Supplies	O
,	O
Kyoto	O
,	O
Japan	O
)	O
was	O
placed	O
in	O
the	O
center	O
of	O
the	O
cage	O
,	O
and	O
the	O
behavior	O
of	O
the	O
mouse	B-OG
was	O
recorded	O
for	O
5	O
min	O
.	O

Total	O
duration	O
of	O
social	O
interactions	O
(	O
for	O
example	O
,	O
sniffing	O
,	O
licking	O
)	O
was	O
measured	O
from	O
recordings	O
by	O
a	O
trained	O
and	O
blinded	O
observer	O
.	O

Forced	O
swim	O
test	O

The	O
forced	O
swim	O
test	O
was	O
performed	O
as	O
previously	O
described	O
.	O
25	O
The	O
mice	B-OG
were	O
immersed	O
in	O
a	O
glass	O
cylinder	O
containing	O
25	O
°	O
C	O
water	O
for	O
6	O
min	O
.	O

Immobility	O
was	O
defined	O
as	O
no	O
additional	O
movements	O
by	O
the	O
mouse	B-OG
beyond	O
those	O
that	O
were	O
required	O
to	O
keep	O
the	O
head	O
above	O
the	O
water	O
.	O

The	O
duration	O
of	O
immobility	O
was	O
measured	O
from	O
video	O
recordings	O
.	O

After	O
the	O
test	O
,	O
the	O
mice	B-OG
were	O
dried	O
thoroughly	O
with	O
a	O
towel	O
and	O
returned	O
to	O
their	O
home	O
cage	O
.	O

PPI	O
test	O

Acoustic	O
startle	O
responses	O
in	O
the	O
pre	O
-	O
pulse	O
inhibition	O
(	O
PPI	O
)	O
experiments	O
were	O
measured	O
in	O
a	O
startle	O
chamber	O
(	O
SR	O
-	O
LAB	O
;	O
San	O
Diego	O
Instruments	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
using	O
standard	O
methods	O
described	O
previously	O
.	O
30	O
The	O
testing	O
session	O
started	O
with	O
5	O
min	O
of	O
habituation	O
to	O
the	O
startle	O
chamber	O
in	O
the	O
presence	O
of	O
65	O
dB	O
background	O
white	O
noise	O
.	O

Testing	O
was	O
composed	O
of	O
a	O
single	O
pulse	O
of	O
120	O
dB	O
preceded	O
five	O
prepulses	O
(	O
40	O
ms	O
)	O
of	O
69	O
,	O
73	O
,	O
77	O
or	O
85	O
dB	O
.	O

Pulses	O
were	O
randomly	O
presented	O
with	O
an	O
average	O
of	O
16	O
s	O
between	O
pulses	O
.	O

Ten	O
no	O
-	O
stimulus	O
trials	O
were	O
included	O
to	O
assess	O
spontaneous	O
activity	O
during	O
testing	O
.	O

PPI	O
was	O
calculated	O
as	O
a	O
percentage	O
score	O
:	O
PPI	O
(%)=(	O
1	O
−[(	O
startle	O
response	O
for	O
pulse	O
with	O
pre	O
-	O
pulse	O
)/(	O
startle	O
response	O
for	O
pulse	O
alone	O
)])	O
×	O
100	O
.	O

Statistical	O
analysis	O

Adequate	O
sample	O
size	O
was	O
determined	O
according	O
to	O
the	O
previous	O
studies	O
that	O
performed	O
analogous	O
experiments	O
.	O

The	O
variances	O
between	O
the	O
groups	O
that	O
are	O
being	O
statistically	O
compared	O
were	O
similar	O
.	O

For	O
animal	B-OG
studies	O
,	O
no	O
randomization	O
and	O
blinding	O
were	O
used	O
.	O

Data	O
are	O
expressed	O
throughout	O
the	O
manuscript	O
as	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
Statcel3	O
(	O
OMS	O
,	O
Saitama	O
,	O
Japan	O
)	O
and	O
JMP	O
10	O
pro	O
(	O
SAS	O
Institute	O
of	O
Japan	O
,	O
Tokyo	O
,	O
Japan	O
).	O

Unpaired	O
t	O
-	O
tests	O
were	O
applied	O
to	O
compare	O
:	O
expression	O
levels	O
of	O
JMJD2B	B-GP
,	O
JMJD2C	B-GP
,	O
PSD95	B-GP
(	O
Supplementary	O
Figure	O
3	O
),	O
Homer2	B-GP
,	O
Rhob	B-GP
and	O
Rhog	B-GP
(	O
Supplementary	O
Figure	O
6	O
)	O
in	O
the	O
hippocampus	O
;	O
spine	O
number	O
(	O
Supplementary	O
Figure	O
4b	O
),	O
structure	O
(	O
Supplementary	O
Figure	O
4a	O
),	O
dendrite	O
number	O
and	O
length	O
in	O
the	O
hippocampus	O
and	O
somatosensory	O
cortex	O
.	O

A	O
two	O
-	O
sided	O
test	O
was	O
applied	O
,	O
except	O
for	O
the	O
analysis	O
of	O
spine	O
number	O
(	O
one	O
-	O
sided	O
test	O
).	O

The	O
raw	O
data	O
applying	O
t	O
-	O
test	O
was	O
normally	O
distributed	O
.	O

The	O
variance	O
was	O
similar	O
between	O
the	O
groups	O
that	O
are	O
being	O
statistically	O
compared	O
.	O

Two	O
-	O
way	O
analysis	O
of	O
variance	O
analysis	O
and	O
post	O
hoc	O
tests	O
were	O
applied	O
to	O
compare	O
:	O
Sholl	O
analysis	O
of	O
dendrites	O
of	O
cultured	O
hippocampal	O
neuron	O
total	O
distance	O
moved	O
activity	O
and	O
rearing	O
number	O
.	O

Mann	O
–	O
Whitney	O
tests	O
were	O
applied	O
to	O
compare	O
:	O
decrease	O
ratio	O
of	O
moved	O
distance	O
between	O
the	O
first	O
10	O
min	O
and	O
last	O
10	O
min	O
of	O
the	O
open	O
-	O
field	O
test	O
,	O
social	O
interaction	O
test	O
,	O
novel	O
object	O
cognition	O
test	O
,	O
Y	O
-	O
maze	O
test	O
,	O
elevated	O
-	O
plus	O
-	O
maze	O
test	O
(	O
Supplementary	O
Figure	O
5a	O
),	O
PPI	O
(	O
Supplementary	O
Figure	O
5b	O
),	O
forced	O
swim	O
test	O
(	O
Supplementary	O
Figure	O
5c	O
),	O
rhythm	O
test	O
(	O
Supplementary	O
Figure	O
5d	O
)	O
and	O
SHIRPA	O
test	O
(	O
Supplementary	O
Table	O
2	O
).	O

Results	O

JMJD2B	B-GP
expression	O
in	O
the	O
central	O
nervous	O
system	O

We	O
first	O
carried	O
out	O
in	O
situ	O
hybridization	O
to	O
characterize	O
the	O
expression	O
of	O
Jmjd2b	B-GP
mRNA	O
in	O
P0	O
WT	O
mouse	B-OG
brain	O
.	O

Strong	O
expression	O
was	O
observed	O
in	O
the	O
brain	O
and	O
retina	O
along	O
with	O
weaker	O
expression	O
in	O
other	O
organs	O
(	O
Figure	O
1a	O
).	O

We	O
then	O
analyzed	O
expression	O
of	O
Jmjd2b	B-GP
mRNA	O
in	O
the	O
brain	O
at	O
a	O
series	O
of	O
developmental	O
stages	O
.	O

From	O
E15	O
to	O
P14	O
,	O
Jmjd2b	B-GP
was	O
rather	O
diffusely	O
expressed	O
throughout	O
the	O
brain	O
.	O

Expression	O
was	O
especially	O
strong	O
in	O
the	O
cerebral	O
cortex	O
,	O
hippocampus	O
,	O
basal	O
ganglia	O
,	O
olfactory	O
bulb	O
and	O
cerebellum	O
.	O

In	O
8	O
-	O
week	O
-	O
old	O
mice	B-OG
,	O
the	O
expression	O
level	O
declined	O
,	O
but	O
prominent	O
signal	O
could	O
be	O
observed	O
in	O
hippocampus	O
and	O
cerebellum	O
.	O

The	O
time	O
course	O
of	O
the	O
expression	O
of	O
Jmjd2b	B-GP
mRNA	O
throughout	O
the	O
brain	O
is	O
detailed	O
in	O
Figure	O
1b	O
.	O

In	O
the	O
adult	O
hippocampus	O
,	O
JMJD2B	B-GP
mRNA	O
was	O
expressed	O
in	O
the	O
CA1	O
,	O
CA3	O
and	O
dentate	O
gyrus	O
.	O

To	O
assess	O
the	O
cell	O
types	O
expressing	O
JMJD2B	B-GP
in	O
the	O
hippocampus	O
,	O
we	O
performed	O
immunostaining	O
with	O
DAB	O
as	O
the	O
substrate	O
for	O
horseradish	B-OG
peroxidase	B-GP
using	O
NeuN	B-GP
,	O
GFAP	B-GP
and	O
GAD67	B-GP
primary	O
antibody	B-GP
followed	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
signal	O
for	O
JMJD2B	B-GP
mRNA	O
was	O
observed	O
exclusively	O
in	O
NeuN	B-GP
-	O
positive	O
cells	O
,	O
but	O
not	O
in	O
NeuN	B-GP
-	O
negative	O
cells	O
(	O
Figure	O
1c	O
,	O
left	O
),	O
and	O
could	O
not	O
be	O
detected	O
in	O
GFAP	B-GP
-	O
positive	O
astrocytes	O
.	O

These	O
results	O
demonstrate	O
that	O
Jmjd2b	B-GP
mRNA	O
is	O
predominantly	O
expressed	O
in	O
neurons	O
in	O
the	O
adult	O
mouse	B-OG
hippocampus	O
.	O

Moreover	O
the	O
signal	O
for	O
JMJD2B	B-GP
mRNA	O
was	O
observed	O
also	O
in	O
GAD67	B-GP
-	O
positive	O
cells	O
(	O
Supplementary	O
Figure	O
1a	O
).	O

The	O
signal	O
for	O
JMJD2B	B-GP
mRNA	O
was	O
observed	O
in	O
ganglionic	O
eminence	O
,	O
where	O
the	O
interneurons	O
are	O
originated	O
,	O
in	O
the	O
brain	O
on	O
E13	O
(	O
Supplementary	O
Figure	O
1b	O
).	O

These	O
results	O
suggest	O
that	O
Jmjd2b	B-GP
mRNA	O
is	O
also	O
expressed	O
in	O
GABAergic	O
neuron	O
.	O

Generation	O
of	O
mice	B-OG
lacking	O
JMJD2B	B-GP
in	O
neurons	O

We	O
next	O
explored	O
the	O
function	O
of	O
JMJD2B	B-GP
in	O
neurons	O
in	O
vivo	O
by	O
generating	O
mice	B-OG
lacking	O
JMJD2B	B-GP
specifically	O
in	O
neurons	O
.	O

We	O
crossed	O
mice	B-OG
in	O
which	O
exon	O
5	O
of	O
Jmjd2b	B-GP
was	O
flanked	O
by	O
LoxP	B-GP
sequences	O
biallelically	O
(	O
Jmj2b	B-GP
flox	O
/	O
flox	O
)	O
13	O
with	O
mice	B-OG
expressing	O
Cre	B-GP
recombinase	I-GP
under	O
the	O
tau	B-GP
promoter	O
(	O
tau	B-GP
-	O
Cre	B-GP
mice	B-OG
),	O
21	O
resulting	O
in	O
the	O
deletion	O
of	O
coding	O
regions	O
necessary	O
for	O
demethylase	B-GP
activity	O
of	O
Jmjd2b	B-GP
specifically	O
in	O
the	O
neurons	O
of	O
these	O
compound	O
mutant	O
mice	B-OG
(	O
tau	B-GP
-	O
Cre	B-GP
;	O
Jmj2b	B-GP
flox	O
/	O
flox	O
).	O

JMJD2B	B-GP
gene	O
expression	O
was	O
barely	O
detectable	O
in	O
the	O
brains	O
of	O
tau	B-GP
-	O
Cre	B-GP
;	O
Jmj2b	B-GP
flox	O
/	O
flox	O
mice	B-OG
as	O
determined	O
by	O
reverse	O
transcription	O
–	O
PCR	O
(	O
P	O
=	O
0	O
.	O
009	O
;	O
Figure	O
2a	O
,	O
left	O
).	O

However	O
,	O
the	O
expression	O
level	O
of	O
Jmjd2c	B-GP
,	O
a	O
histone	B-GP
demethylase	I-GP
enzyme	O
closely	O
related	O
to	O
JMJD2B	B-GP
,	O
was	O
not	O
changed	O
in	O
these	O
mice	B-OG
(	O
Figure	O
2a	O
right	O
).	O
In	O
situ	O
hybridization	O
for	O
Jmjd2b	B-GP
confirmed	O
deletion	O
of	O
this	O
gene	O
in	O
these	O
mice	B-OG
(	O
Figure	O
2b	O
).	O

No	O
obvious	O
morphological	O
differences	O
were	O
observed	O
between	O
the	O
two	O
genotypes	O
including	O
in	O
the	O
hippocampus	O
(	O
Figure	O
2c	O
).	O

For	O
the	O
remainder	O
of	O
the	O
paper	O
,	O
we	O
refer	O
to	O
mice	B-OG
lacking	O
JMJD2B	B-GP
in	O
neurons	O
as	O
JMJD2B	B-GP
mutant	O
mice	B-OG
and	O
exon	O
5	O
-	O
biallelic	O
flanked	O
mice	B-OG
as	O
WT	O
mice	B-OG
.	O

JMJD2B	B-GP
regulates	O
spine	O
maturation	O
in	O
the	O
hippocampus	O

Next	O
,	O
we	O
investigated	O
structures	O
of	O
the	O
hippocampus	O
in	O
which	O
JMJD2B	B-GP
was	O
strongly	O
expressed	O
from	O
embryonic	O
stages	O
through	O
adulthood	O
in	O
detail	O
.	O

A	O
previous	O
report	O
revealed	O
that	O
HDAC2	B-GP
,	O
a	O
histone	B-GP
modifier	O
gene	O
,	O
affected	O
spine	O
number	O
in	O
hippocampus	O
and	O
regulated	O
the	O
formation	O
of	O
neural	O
circuits	O
.	O
31	O
These	O
findings	O
prompted	O
us	O
to	O
hypothesize	O
that	O
JMJD2B	B-GP
was	O
associated	O
with	O
synaptic	O
development	O
.	O

To	O
assess	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
spine	O
structure	O
of	O
hippocampal	O
CA1	O
pyramidal	O
neurons	O
using	O
the	O
Golgi	O
staining	O
method	O
.	O

Dendritic	O
spines	O
of	O
pyramidal	O
neurons	O
in	O
the	O
CA1	O
region	O
receive	O
direct	O
and	O
indirect	O
excitatory	O
inputs	O
from	O
various	O
anatomical	O
regions	O
.	O

Schaffer	O
collaterals	O
from	O
CA3	O
are	O
one	O
of	O
the	O
major	O
inputs	O
to	O
CA1	O
and	O
they	O
terminate	O
in	O
the	O
distal	O
two	O
-	O
thirds	O
of	O
the	O
stratum	O
radiatum	O
of	O
the	O
CA1	O
region	O
.	O
32	O
Therefore	O
,	O
we	O
analyzed	O
the	O
spine	O
morphology	O
and	O
density	O
on	O
secondary	O
dendrites	O
of	O
the	O
pyramidal	O
neurons	O
in	O
this	O
area	O
.	O

We	O
first	O
counted	O
the	O
total	O
number	O
of	O
spines	O
per	O
20	O
μm	O
dendrite	O
and	O
found	O
a	O
significant	O
increase	O
in	O
the	O
spine	O
numbers	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
(	O
P	O
=	O
0	O
.	O
041	O
;	O
Figures	O
3a	O
–	O
d	O
).	O

We	O
then	O
performed	O
structural	O
analysis	O
of	O
spines	O
,	O
classifying	O
them	O
into	O
mature	O
spines	O
(	O
mushroom	O
type	O
)	O
and	O
immature	O
spines	O
(	O
thin	O
type	O
,	O
filopodia	O
type	O
and	O
stubby	O
type	O
).	O

We	O
found	O
that	O
the	O
number	O
of	O
mature	O
mushroom	O
type	O
spines	O
was	O
significantly	O
reduced	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
(	O
P	O
=	O
0	O
.	O
006	O
),	O
and	O
that	O
the	O
number	O
of	O
immature	O
filopodia	O
type	O
was	O
increased	O
(	O
filopodia	O
type	O
;	O
P	O
=	O
0	O
.	O
08	O
;	O
Figures	O
3a	O
–	O
c	O
and	O
e	O
).	O

However	O
the	O
expression	O
level	O
of	O
PSD95	B-GP
in	O
hippocampus	O
was	O
not	O
significantly	O
different	O
between	O
the	O
genotypes	O
(	O
Supplementary	O
Figure	O
2	O
).	O

As	O
JMJD2B	B-GP
is	O
expressed	O
also	O
in	O
somatosensory	O
cortex	O
from	O
late	O
prenatal	O
to	O
early	O
postnatal	O
mouse	B-OG
,	O
we	O
analyzed	O
the	O
number	O
and	O
structure	O
of	O
spines	O
in	O
apical	O
dendrite	O
of	O
layer	O
2	O
/	O
3	O
pyramidal	O
neuron	O
in	O
somatosensory	O
cortex	O
.	O

Notably	O
,	O
MeCP2	B-GP
mutant	O
mice	B-OG
,	O
which	O
display	O
neurodevelopmental	O
delay	O
and	O
spontaneous	O
epileptiform	O
activity	O
,	O
reveal	O
increased	O
number	O
of	O
spines	O
in	O
somatosensory	O
cortex	O
.	O
33	O
However	O
,	O
we	O
found	O
no	O
difference	O
between	O
the	O
genotypes	O
in	O
either	O
spine	O
number	O
or	O
structure	O
in	O
somatosensory	O
cortex	O
(	O
Supplementary	O
Figure	O
3	O
).	O

We	O
next	O
attempted	O
to	O
investigate	O
the	O
formation	O
of	O
dendrites	O
in	O
vivo	O
.	O

However	O
,	O
it	O
was	O
difficult	O
to	O
assess	O
the	O
length	O
and	O
elaboration	O
of	O
specific	O
neurons	O
,	O
as	O
the	O
dendrites	O
of	O
Golgi	O
-	O
stained	O
neurons	O
overlapped	O
with	O
each	O
other	O
in	O
the	O
CA1	O
region	O
.	O

Therefore	O
,	O
we	O
cultured	O
hippocampal	O
neurons	O
derived	O
from	O
P1	O
JMJD2B	B-GP
mutant	O
mice	B-OG
and	O
WT	O
mice	B-OG
for	O
7	O
days	O
,	O
and	O
assessed	O
the	O
formation	O
of	O
dendrites	O
in	O
vitro	O
.	O

We	O
found	O
no	O
significant	O
differences	O
in	O
dendrite	O
number	O
,	O
length	O
or	O
elaboration	O
between	O
the	O
two	O
genotypes	O
(	O
Figures	O
3f	O
and	O
i	O
).	O

We	O
further	O
examined	O
whether	O
abnormal	O
mossy	O
fiber	O
sprouting	O
was	O
present	O
in	O
mutant	O
mice	B-OG
using	O
Timm	B-GP
staining	O
and	O
found	O
no	O
differences	O
between	O
genotypes	O
(	O
Supplementary	O
Figure	O
4	O
).	O

Our	O
findings	O
therefore	O
indicate	O
that	O
JMJD2B	B-GP
is	O
required	O
for	O
normal	O
spine	O
formation	O
in	O
the	O
hippocampal	O
CA1	O
region	O
,	O
and	O
disruption	O
of	O
JMJD2B	B-GP
gene	O
leads	O
to	O
impaired	O
dendritic	O
spine	O
maturation	O
.	O

JMJD2B	B-GP
mutant	O
mice	B-OG
show	O
hyperactive	O
behavior	O

Defective	O
histone	B-GP
demethylase	I-GP
function	O
is	O
associated	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

As	O
our	O
observations	O
of	O
impaired	O
dendritic	O
spine	O
formation	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
suggested	O
that	O
JMJD2B	B-GP
has	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
neural	O
networks	O
in	O
the	O
CNS	O
,	O
we	O
hypothesized	O
that	O
JMJD2B	B-GP
mutant	O
mice	B-OG
might	O
display	O
abnormal	O
behavior	O
reminiscent	O
of	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

We	O
therefore	O
subjected	O
JMJD2B	B-GP
mutant	O
mice	B-OG
and	O
their	O
WT	O
littermates	O
to	O
a	O
comprehensive	O
battery	O
of	O
behavioral	O
tests	O
(	O
Supplementary	O
Table	O
1	O
).	O

Mutant	O
mice	B-OG
showed	O
no	O
obvious	O
differences	O
in	O
their	O
physical	O
characteristics	O
.	O

On	O
the	O
other	O
hand	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
displayed	O
significantly	O
increased	O
vocalization	O
,	O
which	O
was	O
the	O
index	O
of	O
the	O
excitability	O
of	O
mice34	B-OG
(	O
SHIRPA	O
test	O
;	O
Supplementary	O
Table	O
2	O
).	O

Spontaneous	O
locomotor	O
activity	O
was	O
assessed	O
by	O
the	O
open	O
-	O
field	O
test	O
.	O

There	O
were	O
significant	O
differences	O
between	O
genotypes	O
in	O
the	O
total	O
distance	O
traveled	O
(	O
between	O
genotypes	O
;	O
P	O
<	O
0	O
.	O
0001	O
,	O
30	O
–	O
40	O
min	O
;	O
P	O
=	O
0	O
.	O
0045	O
,	O
40	O
–	O
50	O
min	O
;	O
P	O
=	O
0	O
.	O
0015	O
;	O
Figure	O
4a	O
),	O
rearing	O
number	O
(	O
between	O
genotypes	O
;	O
P	O
=	O
0	O
.	O
0027	O
;	O
Figure	O
4b	O
)	O
and	O
activity	O
(	O
between	O
genotypes	O
;	O
P	O
<	O
0	O
.	O
0001	O
,	O
30	O
–	O
40	O
min	O
;	O
P	O
=	O
0	O
.	O
0048	O
,	O
40	O
–	O
50	O
min	O
;	O
P	O
=	O
0	O
.	O
0012	O
;	O
Figure	O
4d	O
).	O

We	O
then	O
tested	O
their	O
response	O
to	O
a	O
novel	O
environment	O
,	O
a	O
test	O
of	O
anxiety	B-DS
and	O
exploratory	O
behavior	O
.	O

When	O
WT	O
mice	B-OG
were	O
placed	O
in	O
a	O
novel	O
environment	O
,	O
they	O
initially	O
became	O
hyperactive	O
in	O
response	O
to	O
the	O
unfamiliar	O
surroundings	O
.	O

They	O
then	O
became	O
accustomed	O
to	O
the	O
new	O
environment	O
and	O
their	O
enhanced	O
activity	O
gradually	O
declined	O
.	O

However	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
remained	O
hyperactive	O
even	O
during	O
the	O
last	O
10	O
min	O
of	O
the	O
test	O
.	O
Figure	O
4c	O
shows	O
the	O
ratio	O
of	O
the	O
distance	O
moved	O
in	O
the	O
last	O
10	O
min	O
to	O
the	O
distance	O
moved	O
in	O
the	O
first	O
10	O
min	O
(	O
P	O
=	O
0	O
.	O
024	O
).	O

Mice	B-OG
were	O
also	O
subjected	O
to	O
the	O
elevated	O
-	O
plus	O
-	O
maze	O
test	O
,	O
PPI	O
test	O
,	O
forced	O
swim	O
test	O
and	O
sleep	O
–	O
wake	O
rhythm	O
test	O
(	O
Supplementary	O
Figures	O
5a	O
–	O
d	O
).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
genotypes	O
except	O
for	O
a	O
decrease	O
of	O
immobile	O
time	O
in	O
mutant	O
mice	B-OG
in	O
the	O
forced	O
swim	O
test	O
(	O
P	O
=	O
0	O
.	O
026	O
).	O

Although	O
the	O
forced	O
swim	O
test	O
is	O
used	O
as	O
an	O
index	O
of	O
depressive	O
-	O
like	O
behavior	O
in	O
mice	B-OG
,	O
this	O
result	O
does	O
not	O
necessarily	O
mean	O
that	O
the	O
mutant	O
mice	B-OG
show	O
an	O
anti	O
-	O
depressive	O
tendency	O
,	O
as	O
these	O
mice	B-OG
show	O
hyperactivity	O
at	O
baseline	O
.	O

JMJD2B	B-GP
mutant	O
mice	B-OG
show	O
deficits	O
in	O
working	O
memory	O

As	O
two	O
mutations	O
of	O
JMJD2B	B-GP
are	O
found	O
in	O
individuals	O
of	O
ASD	B-DS
,	O
we	O
performed	O
a	O
series	O
of	O
experiments	O
to	O
assess	O
autistic	O
-	O
like	O
traits	O
in	O
these	O
mice	B-OG
.	O

First	O
,	O
an	O
interest	O
in	O
novelties	O
was	O
tested	O
in	O
the	O
novel	O
object	O
recognition	O
test	O
using	O
a	O
novel	O
wooden	O
ball	O
object	O
.	O

There	O
were	O
no	O
differences	O
between	O
genotypes	O
in	O
the	O
exploration	O
rate	O
to	O
a	O
novel	O
object	O
(	O
Figure	O
5a	O
).	O

Next	O
,	O
sociability	O
was	O
tested	O
in	O
social	O
interaction	O
test	O
with	O
a	O
juvenile	O
WT	O
male	O
mouse	B-OG
as	O
a	O
social	O
partner	O
.	O

There	O
were	O
no	O
differences	O
between	O
genotypes	O
in	O
the	O
interaction	O
time	O
spent	O
with	O
a	O
social	O
partner	O
(	O
Figure	O
5b	O
).	O

Previous	O
reports	O
have	O
revealed	O
that	O
neurodevelopmental	B-DS
disorders	I-DS
are	O
sometimes	O
correlated	O
with	O
intellectual	B-DS
disability	I-DS
.	O
2	O
Therefore	O
,	O
we	O
examined	O
whether	O
working	O
memory	O
was	O
impaired	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
as	O
assessed	O
by	O
spontaneous	O
alteration	O
behavior	O
in	O
the	O
Y	O
-	O
maze	O
task	O
.	O

Mice	B-OG
of	O
each	O
genotype	O
were	O
put	O
into	O
the	O
box	O
with	O
a	O
Y	O
shape	O
and	O
the	O
percentage	O
of	O
correct	O
entry	O
numbers	O
per	O
total	O
entry	O
numbers	O
(	O
alteration	O
rates	O
)	O
was	O
evaluated	O
.	O

WT	O
mice	B-OG
exhibited	O
alteration	O
rates	O
of	O
approximately	O
60	O
%.	O

In	O
contrast	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
showed	O
significantly	O
reduced	O
alteration	O
rates	O
compared	O
with	O
WT	O
littermates	O
(	O
P	O
=	O
0	O
.	O
0074	O
;	O
Figure	O
5c	O
).	O

The	O
total	O
number	O
of	O
entries	O
differed	O
between	O
genotypes	O
,	O
reflecting	O
the	O
hyperactivity	O
of	O
the	O
mutant	O
mice	B-OG
observed	O
at	O
baseline	O
(	O
P	O
=	O
0	O
.	O
0015	O
;	O
Figure	O
5d	O
).	O

These	O
results	O
suggest	O
that	O
working	O
memory	O
is	O
impaired	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

These	O
results	O
are	O
in	O
keeping	O
with	O
the	O
aberrant	O
neuronal	O
morphology	O
observed	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
,	O
as	O
accumulating	O
evidences	O
indicate	O
an	O
association	O
of	O
memory	O
function	O
with	O
alterations	O
in	O
dendritic	O
spine	O
morphology	O
.	O
35	O
Therefore	O
,	O
impaired	O
hippocampal	O
spine	O
maturation	O
may	O
cause	O
working	O
memory	O
deficits	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

Moreover	O
,	O
some	O
JMJD2B	B-GP
mutant	O
mice	B-OG
showed	O
spontaneous	O
epileptiform	O
-	O
like	O
activity	O
(	O
data	O
not	O
shown	O
),	O
which	O
is	O
another	O
important	O
symptom	O
of	O
neurodevelopmental	B-DS
disorders	I-DS
.	O
1	O
It	O
occurred	O
following	O
stressful	O
events	O
such	O
as	O
cage	O
opening	O
,	O
handling	O
or	O
placement	O
in	O
a	O
novel	O
environment	O
.	O

Seizures	O
generally	O
began	O
at	O
about	O
5	O
s	O
after	O
these	O
events	O
beginning	O
with	O
behavioral	O
arrest	O
and	O
rigid	O
motionless	O
posture	O
,	O
followed	O
by	O
head	O
and	O
neck	O
jerks	O
,	O
and	O
clonus	O
of	O
forelimb	O
and	O
hindlimb	O
.	O

We	O
observed	O
such	O
epileptiform	O
-	O
like	O
activity	O
in	O
3	O
mice	B-OG
out	O
of	O
153	O
mutant	O
mice	B-OG
in	O
our	O
experiment	O
(~	O
2	O
%),	O
though	O
WT	O
mice	B-OG
never	O
displayed	O
such	O
activity	O
.	O

These	O
mice	B-OG
that	O
suffered	O
from	O
such	O
epileptiform	O
-	O
like	O
activity	O
were	O
all	O
older	O
than	O
8	O
weeks	O
.	O

In	O
summary	O
,	O
the	O
JMJD2B	B-GP
mutant	O
mice	B-OG
characterized	O
in	O
this	O
study	O
display	O
several	O
symptoms	O
reminiscent	O
of	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
phenotype	O
of	O
JMJD2B	B-GP
mutant	O
mice	B-OG
in	O
brain	O
development	O
.	O

We	O
found	O
a	O
decreased	O
number	O
of	O
mature	O
spines	O
and	O
increased	O
number	O
of	O
immature	O
spines	O
,	O
resulting	O
in	O
increased	O
total	O
number	O
of	O
spines	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

Pyramidal	O
neurons	O
in	O
the	O
CA3	O
region	O
partly	O
transmit	O
electrical	O
signals	O
to	O
distal	O
radial	O
stratum	O
of	O
CA1	O
region	O
through	O
Schaffer	O
collaterals	O
.	O

Therefore	O
,	O
it	O
is	O
intriguing	O
to	O
hypothesize	O
that	O
the	O
abnormalities	O
in	O
spine	O
number	O
and	O
structure	O
in	O
the	O
CA1	O
region	O
induce	O
defective	O
signal	O
transmission	O
from	O
CA3	O
to	O
CA1	O
.	O

The	O
expression	O
level	O
of	O
PSD95	B-GP
in	O
hippocampus	O
was	O
not	O
changed	O
.	O

This	O
is	O
presumably	O
because	O
the	O
change	O
in	O
the	O
PSD95	B-GP
expression	O
in	O
the	O
hippocampal	O
spines	O
was	O
region	O
-	O
specific	O
or	O
the	O
minute	O
change	O
could	O
not	O
be	O
detected	O
by	O
using	O
the	O
western	O
blot	O
test	O
.	O

JMJD2B	B-GP
mutant	O
mice	B-OG
displayed	O
spontaneous	O
epileptiform	O
-	O
like	O
activity	O
.	O

Although	O
it	O
is	O
possible	O
that	O
seizure	O
recurrence	O
can	O
alter	O
synapse	O
connectivity	O
leading	O
to	O
change	O
in	O
spine	O
number	O
and	O
structure	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
,	O
this	O
would	O
not	O
be	O
the	O
case	O
considering	O
the	O
rare	O
incidence	O
rate	O
and	O
age	O
of	O
onset	O
of	O
seizures	O
(	O
we	O
used	O
8	O
-	O
week	O
-	O
old	O
mice	B-OG
for	O
analysis	O
).	O

A	O
previous	O
report	O
suggests	O
that	O
JMJD2B	B-GP
is	O
a	O
causative	O
risk	O
gene	O
for	O
neurodevelopmental	B-DS
disorders	I-DS
,	O
8	O
while	O
accumulating	O
evidence	O
indicates	O
that	O
hippocampal	O
spines	O
in	O
various	O
mouse	B-OG
models	O
of	O
neurodevelopmental	B-DS
disorder	I-DS
are	O
structurally	O
and	O
functionally	O
abnormal	O
.	O
36	O
,	O
37	O
,	O
38	O
,	O
39	O
For	O
example	O
,	O
mice	B-OG
with	O
a	O
mutation	O
in	O
SHANK2	B-GP
,	O
a	O
risk	O
gene	O
for	O
ASD	B-DS
,	O
display	O
an	O
increased	O
number	O
of	O
hippocampal	O
spines	O
and	O
abnormal	O
synaptic	O
transmission	O
in	O
the	O
hippocampus	O
.	O
37	O
Furthermore	O
,	O
high	O
-	O
density	O
and	O
spindle	O
-	O
shaped	O
dendritic	O
spines	O
are	O
also	O
observed	O
in	O
the	O
brains	O
of	O
individuals	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
.	O
40	O

We	O
also	O
observed	O
behavioral	O
alterations	O
in	O
JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
.	O

Recently	O
,	O
mutations	O
of	O
a	O
number	O
of	O
genes	O
involved	O
in	O
epigenetic	O
modification	O
,	O
including	O
DNA	O
methylation	O
,	O
histone	B-GP
acetylation	O
or	O
deacetylation	O
,	O
and	O
histone	B-GP
methylation	O
and	O
demethylation	O
,	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Indeed	O
,	O
two	O
mutations	O
of	O
JMJD2B	B-GP
were	O
identified	O
in	O
ASD	B-DS
patients	O
.	O

The	O
results	O
of	O
open	O
-	O
field	O
test	O
suggest	O
that	O
JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
are	O
hyperactive	O
at	O
baseline	O
and	O
have	O
trouble	O
in	O
becoming	O
accustomed	O
to	O
a	O
novel	O
environment	O
.	O

Neurodevelopmental	B-DS
disorders	I-DS
sometimes	O
correlate	O
with	O
intellectual	B-DS
disability	I-DS
.	O
2	O
JMJD2B	B-GP
-	O
deficient	O
mice	B-OG
did	O
in	O
fact	O
display	O
working	O
memory	O
deficits	O
as	O
determined	O
by	O
assessment	O
of	O
correct	O
entry	O
number	O
in	O
the	O
Y	O
-	O
maze	O
test	O
(	O
Figure	O
5c	O
).	O

Moreover	O
,	O
these	O
mice	B-OG
sometimes	O
displayed	O
epileptiform	O
-	O
like	O
seizures	O
,	O
which	O
are	O
frequently	O
observed	O
in	O
neurodevelopmental	B-DS
disorders	I-DS
.	O
3	O
These	O
mice	B-OG
also	O
displayed	O
anti	O
-	O
depressive	O
-	O
like	O
behavior	O
in	O
the	O
forced	O
swim	O
test	O
.	O

However	O
,	O
we	O
should	O
be	O
careful	O
in	O
the	O
interpretation	O
of	O
this	O
data	O
,	O
as	O
this	O
tendency	O
may	O
just	O
reflect	O
the	O
heightened	O
baseline	O
hyperactivity	O
of	O
these	O
mice	B-OG
.	O

On	O
the	O
other	O
hand	O
,	O
these	O
mice	B-OG
did	O
not	O
display	O
excessive	O
anxiety	B-DS
-	O
like	O
or	O
ASD	B-DS
-	O
like	O
behaviors	O
,	O
such	O
as	O
social	O
interaction	O
deficits	O
or	O
indifference	O
to	O
novel	O
objects	O
,	O
or	O
other	O
abnormalities	O
(	O
PPI	O
and	O
rhythm	O
tests	O
).	O

Taken	O
together	O
these	O
behavioral	O
data	O
indicate	O
that	O
JMJD2B	B-GP
mutant	O
mice	B-OG
display	O
attention	B-DS
deficit	I-DS
hyperactivity	I-DS
disorder	I-DS
-	O
like	O
behavior	O
with	O
memory	O
deficits	O
and	O
epilepsy	B-DS
.	O

However	O
,	O
JMJD2B	B-GP
is	O
suspected	O
to	O
be	O
a	O
risk	O
gene	O
for	O
ASD	B-DS
.	O

One	O
possible	O
reason	O
for	O
this	O
discrepancy	O
is	O
that	O
our	O
behavioral	O
tests	O
may	O
not	O
be	O
appropriate	O
for	O
the	O
detection	O
of	O
ASD	B-DS
-	O
like	O
symptoms	O
in	O
this	O
mouse	B-OG
.	O

For	O
example	O
,	O
several	O
mouse	B-OG
models	O
with	O
mutated	O
risk	O
genes	O
for	O
ASD	B-DS
display	O
abnormalities	O
in	O
ultrasonic	O
vocalization	O
,	O
and	O
this	O
important	O
behavioral	O
characteristic	O
in	O
ASD	B-DS
-	O
model	O
mice	B-OG
was	O
not	O
tested	O
in	O
our	O
study	O
.	O
41	O
,	O
42	O
Although	O
rearing	O
behavior	O
in	O
mice	B-OG
is	O
generally	O
described	O
as	O
an	O
index	O
of	O
exploratory	O
behavior	O
,	O
increases	O
in	O
the	O
frequency	O
of	O
rearing	O
number	O
observed	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
may	O
replicate	O
repetitive	O
behavior	O
in	O
ASD	B-DS
.	O

In	O
fact	O
,	O
recent	O
reports	O
have	O
revealed	O
that	O
Shank3	B-GP
mutant	O
mice	B-OG
,	O
a	O
model	O
of	O
ASD	B-DS
,	O
display	O
enhanced	O
rearing	O
.	O
43	O

JMJD2B	B-GP
is	O
a	O
histone	B-GP
lysine	I-GP
demethylase	I-GP
that	O
acts	O
as	O
a	O
transcriptional	O
activator	O
through	O
demethylation	O
of	O
H3K9me3	O
.	O

Therefore	O
,	O
the	O
transcription	O
of	O
target	O
genes	O
is	O
suppressed	O
when	O
JMJD2B	B-GP
is	O
depleted	O
.	O

Hippocampal	O
spine	O
formation	O
,	O
elimination	O
and	O
maturation	O
are	O
dynamic	O
processes	O
that	O
maintain	O
the	O
synaptic	O
network	O
of	O
the	O
brain	O
.	O

Actin	B-GP
-	I-GP
binding	I-GP
proteins	I-GP
,	O
postsynaptic	B-GP
scaffolding	I-GP
proteins	I-GP
and	O
low	B-GP
-	I-GP
molecular	I-GP
-	I-GP
GTP	I-GP
-	I-GP
binding	I-GP
proteins	I-GP
have	O
been	O
reported	O
to	O
be	O
important	O
factors	O
involved	O
in	O
these	O
processes	O
.	O
44	O
Transcriptional	O
silencing	O
of	O
such	O
factors	O
by	O
JMJD2B	B-GP
depletion	O
may	O
alter	O
their	O
expression	O
level	O
,	O
which	O
may	O
in	O
turn	O
underlie	O
the	O
increase	O
in	O
total	O
spine	O
number	O
with	O
a	O
decrease	O
in	O
mature	O
spines	O
that	O
we	O
observed	O
in	O
the	O
hippocampal	O
CA1	O
region	O
of	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

A	O
previous	O
report	O
demonstrated	O
that	O
G9a	B-GP
histone	B-GP
methyltransferase	I-GP
elevates	O
the	O
density	O
of	O
dendritic	O
spines	O
in	O
nucleus	O
accumbens	O
neurons	O
by	O
reducing	O
H3K9me2	O
levels	O
on	O
exposure	O
to	O
cocaine	B-CD
.	O
45	O
In	O
addition	O
,	O
mutation	O
of	O
MeCP2	B-GP
,	O
the	O
causative	O
gene	O
of	O
Rett	B-DS
syndrome	I-DS
and	O
an	O
epigenetic	O
regulator	O
that	O
acts	O
by	O
binding	O
to	O
methylated	O
DNA	O
,	O
also	O
causes	O
a	O
decrease	O
in	O
the	O
number	O
of	O
dendritic	O
spines	O
.	O
46	O
Thus	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
epigenetic	O
mechanisms	O
affect	O
the	O
development	O
and	O
plasticity	O
of	O
dendritic	O
spines	O
.	O

A	O
differential	O
genome	O
-	O
wide	O
expression	O
study	O
for	O
JMJD2B	B-GP
-	O
deficient	O
ES	O
cells	O
reported	O
that	O
gene	O
expression	O
of	O
several	O
genes	O
involved	O
in	O
synaptic	O
function	O
such	O
as	O
Homer2	B-GP
,	O
Rhob	B-GP
and	O
Rhog	B-GP
was	O
changed	O
.	O
47	O
,	O
48	O
,	O
49	O
However	O
,	O
the	O
expression	O
level	O
of	O
these	O
genes	O
was	O
not	O
changed	O
in	O
hippocampus	O
of	O
JMJD2B	B-GP
mutant	O
mice	B-OG
in	O
our	O
experimental	O
paradigm	O
(	O
Supplementary	O
Figure	O
6	O
).	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
target	O
genes	O
of	O
JMJD2B	B-GP
.	O

However	O
,	O
it	O
should	O
be	O
noted	O
that	O
the	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
spine	O
structure	O
might	O
not	O
be	O
direct	O
targets	O
of	O
JMJD2B	B-GP
.	O

It	O
has	O
been	O
shown	O
that	O
various	O
regions	O
in	O
the	O
brain	O
are	O
affected	O
in	O
the	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

For	O
example	O
,	O
pathological	O
findings	O
are	O
observed	O
in	O
cerebral	O
cortex	O
,	O
amygdala	O
,	O
basal	O
ganglia	O
,	O
and	O
cerebellum	O
and	O
hippocampus	O
in	O
neurodevelopmental	B-DS
disorders	I-DS
.	O
50	O
,	O
51	O
Most	O
notably	O
,	O
abnormal	O
neurogenesis	O
in	O
the	O
cerebral	O
cortex	O
is	O
associated	O
with	O
ASD	B-DS
-	O
like	O
behavior	O
.	O
52	O
Indeed	O
,	O
disorganization	O
of	O
the	O
cerebral	O
cortex	O
is	O
observed	O
in	O
children	O
with	O
ASD	B-DS
.	O
53	O
JMJD2B	B-GP
,	O
which	O
is	O
strongly	O
expressed	O
in	O
the	O
cerebral	O
cortex	O
at	O
perinatal	O
stages	O
,	O
might	O
also	O
play	O
a	O
role	O
in	O
cortical	O
neurogenesis	O
.	O

It	O
is	O
possible	O
that	O
the	O
deficiency	O
of	O
JMJD2B	B-GP
causes	O
abnormal	O
cerebral	O
neurogenesis	O
resulting	O
in	O
abnormal	O
behavior	O
.	O

Further	O
research	O
is	O
needed	O
to	O
examine	O
whether	O
the	O
hippocampus	O
is	O
the	O
region	O
responsible	O
for	O
abnormal	O
behavior	O
in	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

In	O
conclusion	O
,	O
our	O
study	O
elucidates	O
the	O
function	O
of	O
JMJD2B	B-GP
in	O
the	O
dendritic	O
spine	O
regulation	O
and	O
behavior	O
,	O
and	O
provides	O
a	O
new	O
mouse	B-OG
model	O
for	O
neurodevelopmental	B-DS
disorders	I-DS
.	O

Supplementary	O
Information	O
accompanies	O
the	O
paper	O
on	O
the	O
Translational	O
Psychiatry	O
website	O
(	O
http	O
://	O
www	O
.	O
nature	O
.	O
com	O
/	O
tp	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Expression	O
of	O
Jmjd2b	B-GP
in	O
mouse	B-OG
.	O

(	O
a	O
)	O
In	O
situ	O
hybridization	O
revealing	O
expression	O
of	O
Jmjd2b	B-GP
mRNA	O
in	O
E17	O
mouse	B-OG
(	O
left	O
:	O
antisense	O
,	O
right	O
:	O
sense	O
;	O
n	O
=	O
1	O
).	O

(	O
b	O
)	O
In	O
situ	O
hybridization	O
for	O
the	O
detection	O
of	O
Jmjd2b	B-GP
mRNA	O
in	O
the	O
brain	O
at	O
the	O
indicated	O
stages	O
(	O
n	O
=	O
1	O
per	O
age	O
).	O

(	O
c	O
)	O
In	O
situ	O
hybridization	O
for	O
Jmjd2b	B-GP
mRNA	O
,	O
followed	O
by	O
immunostaining	O
with	O
NeuN	B-GP
(	O
left	O
)	O
and	O
GFAP	B-GP
(	O
right	O
;	O
n	O
=	O
1	O
).	O

Scale	O
bars	O
:	O
(	O
a	O
)	O
2	O
mm	O
,	O
(	O
b	O
)	O
1	O
mm	O
,	O
(	O
c	O
)	O
200	O
μm	O
.	O

Generation	O
of	O
neuron	O
-	O
specific	O
Jmjd2b	B-GP
mutant	O
mice	B-OG
.	O

(	O
a	O
)	O
Relative	O
expression	O
level	O
of	O
Jmjd2b	B-GP
and	O
Jmjd2c	B-GP
.	O

The	O
expression	O
level	O
was	O
normalized	O
to	O
Gapdh	B-GP
.	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
NS	O
,	O
not	O
significant	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
3	O
)	O
Error	O
bars	O
represent	O
s	O
.	O
e	O
.	O
m	O
.	O

(	O
b	O
)	O
Expression	O
of	O
Jmjd2b	B-GP
mRNA	O
in	O
WT	O
and	O
KO	O
mice	B-OG
.	O

P0	O
mice	B-OG
were	O
used	O
for	O
in	O
situ	O
hybridization	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
1	O
).	O

(	O
c	O
)	O
Nissl	O
staining	O
showing	O
the	O
gross	O
morphology	O
of	O
the	O
brain	O
in	O
the	O
two	O
genotypes	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
3	O
).	O

KO	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
;	O
WT	O
,	O
wild	O
-	O
type	O
mice	B-OG
.	O

Scale	O
bars	O
:	O
(	O
b	O
)	O
1	O
mm	O
,	O
(	O
c	O
)	O
50	O
μm	O
.	O

Structural	O
analysis	O
of	O
dendrites	O
and	O
spines	O
of	O
hippocampal	O
CA1	O
of	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.(	O
a	O
)	O
Representative	O
Golgi	O
staining	O
image	O
in	O
the	O
hippocampal	O
CA1	O
region	O
.	O

(	O
b	O
and	O
c	O
)	O
Representative	O
Golgi	O
staining	O
images	O
of	O
dendritic	O
spines	O
in	O
the	O
hippocampal	O
CA1	O
region	O
in	O
each	O
genotype	O
.	O

(	O
b	O
′	O
and	O
c	O
′)	O
Magnified	O
images	O
of	O
b	O
and	O
c	O
.	O
(	O
d	O
)	O
The	O
total	O
spine	O
numbers	O
in	O
the	O
CA1	O
region	O
of	O
the	O
two	O
genotypes	O
.	O

(	O
e	O
)	O
The	O
percentage	O
of	O
mature	O
mushroom	O
,	O
filopodia	O
,	O
thin	O
and	O
stubby	O
-	O
type	O
spines	O
of	O
CA1	O
pyramidal	O
neurons	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

WT	O
:	O
n	O
=	O
6	O
,	O
KO	O
:	O
n	O
=	O
5	O
(	O
a	O
–	O
e	O
).	O

Error	O
bars	O
represent	O
s	O
.	O
e	O
.	O
m	O
.	O

(	O
f	O
;	O
left	O
)	O
Representative	O
images	O
of	O
hippocampal	O
neurons	O
cultured	O
for	O
7	O
days	O
,	O
and	O
stained	O
with	O
MAP2	B-GP
.	O

(	O
g	O
)	O
Sholl	O
analysis	O
of	O
hippocampal	O
neurons	O
of	O
each	O
genotype	O
.	O

A	O
concentric	O
circle	O
was	O
drawn	O
every	O
10	O
μm	O
from	O
a	O
central	O
focus	O
on	O
the	O
neuronal	O
soma	O
and	O
the	O
number	O
of	O
intersections	O
were	O
counted	O
.	O

NS	O
,	O
not	O
significant	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
4	O
).	O

(	O
h	O
)	O
The	O
number	O
of	O
dendrites	O
extending	O
from	O
the	O
soma	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
3	O
).	O

(	O
i	O
)	O
Total	O
dendritic	O
length	O
measured	O
from	O
the	O
soma	O
of	O
cultured	O
hippocampal	O
neurons	O
.	O

Total	O
dendritic	O
length	O
measured	O
from	O
the	O
soma	O
of	O
cultured	O
hippocampal	O
neurons	O
.	O

(	O
WT	O
,	O
KO	O
:	O
n	O
=	O
4	O
).	O

WT	O
,	O
wild	O
-	O
type	O
mice	B-OG
;	O
KO	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O

Scale	O
bars	O
:	O
(	O
a	O
)	O
10	O
μm	O
,	O
(	O
b	O
and	O
c	O
)	O
10	O
μm	O
,	O
(	O
b	O
'	O
and	O
c	O
')	O
1	O
μm	O
,	O
(	O
f	O
)	O
20	O
μm	O
.	O

Error	O
bars	O
represent	O
s	O
.	O
e	O
.	O
m	O
.	O

(	O
d	O
,	O
e	O
,	O
h	O
,	O
i	O
).	O

JMJD2B	B-GP
mutant	O
mice	B-OG
reveal	O
hyperactivity	O
in	O
the	O
open	O
-	O
field	O
test	O
.(	O
a	O
)	O
The	O
graph	O
shows	O
the	O
distance	O
moved	O
during	O
the	O
indicated	O
time	O
period	O
.	O

(	O
b	O
)	O
The	O
graph	O
shows	O
the	O
temporal	O
change	O
in	O
the	O
rate	O
of	O
activity	O
(	O
speed	O
).	O

(	O
c	O
)	O
The	O
graph	O
shows	O
the	O
distance	O
moved	O
in	O
the	O
first	O
10	O
min	O
versus	O
the	O
last	O
10	O
min	O
(	O
50	O
to	O
60	O
min	O
)	O
of	O
assessment	O
.	O

(	O
d	O
)	O
The	O
graph	O
shows	O
temporal	O
changes	O
in	O
rearing	O
number	O
.	O

(	O
WT	O
:	O
n	O
=	O
12	O
,	O
KO	O
:	O
n	O
=	O
10	O
).	O

WT	O
,	O
wild	O
-	O
type	O
mice	B-OG
;	O
KO	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

Error	O
bars	O
represent	O
s	O
.	O
e	O
.	O
m	O
.	O

JMJD2B	B-GP
mutant	O
mice	B-OG
show	O
deficits	O
in	O
short	O
-	O
term	O
memory	O
.	O

(	O
a	O
)	O
The	O
result	O
of	O
the	O
social	O
interaction	O
test	O
examining	O
the	O
social	O
affinity	O
to	O
another	O
mouse	B-OG
.	O

The	O
graph	O
shows	O
the	O
relative	O
time	O
of	O
exploration	O
of	O
the	O
novel	O
object	O
.	O

(	O
WT	O
:	O
n	O
=	O
13	O
KO	O
:	O
n	O
=	O
11	O
).	O

(	O
b	O
)	O
Novel	O
object	O
recognition	O
test	O
to	O
examine	O
the	O
interest	O
in	O
unknown	O
object	O
.	O

(	O
WT	O
:	O
n	O
=	O
13	O
KO	O
:	O
n	O
=	O
11	O
).	O

(	O
c	O
and	O
d	O
)	O
Y	O
-	O
maze	O
test	O
results	O
examining	O
short	O
-	O
term	O
memory	O
in	O
the	O
two	O
genotypes	O
.	O

(	O
WT	O
:	O
n	O
=	O
10	O
;	O
KO	O
:	O
n	O
=	O
11	O
).	O

(	O
c	O
)	O
The	O
graph	O
shows	O
the	O
percentage	O
of	O
correct	O
entries	O
.	O

(	O
d	O
)	O
The	O
graph	O
shows	O
the	O
number	O
of	O
total	O
entries	O
.	O

KO	O
,	O
JMJD2B	B-GP
mutant	O
mice	B-OG
;	O
NS	O
,	O
not	O
significant	O
;	O
WT	O
,	O
wild	O
-	O
type	O
mice	B-OG
.	O

Error	O
bars	O
represent	O
s	O
.	O
e	O
.	O
m	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

Implementation	O
of	O
Cognitive	O
Therapy	O
for	O
PTSD	B-DS
in	O
routine	O
clinical	O
care	O
:	O
Effectiveness	O
and	O
moderators	O
of	O
outcome	O
in	O
a	O
consecutive	O
sample	O
☆	O

Objective	O

Trauma	O
-	O
focused	O
psychological	O
treatments	O
are	O
recommended	O
as	O
first	O
-	O
line	O
treatments	O
for	O
Posttraumatic	B-DS
Stress	I-DS
Disorder	I-DS
(	O
PTSD	B-DS
),	O
but	O
clinicians	O
may	O
be	O
concerned	O
that	O
the	O
good	O
outcomes	O
observed	O
in	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
may	O
not	O
generalize	O
to	O
the	O
wide	O
range	O
of	O
traumas	O
and	O
presentations	O
seen	O
in	O
clinical	O
practice	O
.	O

This	O
study	O
investigated	O
whether	O
Cognitive	O
Therapy	O
for	O
PTSD	B-DS
(	O
CT	O
-	O
PTSD	B-DS
)	O
can	O
be	O
effectively	O
implemented	O
into	O
a	O
UK	O
National	O
Health	O
Service	O
Outpatient	O
Clinic	O
serving	O
a	O
defined	O
ethnically	O
mixed	O
urban	O
catchment	O
area	O
.	O

Method	O

A	O
consecutive	O
sample	O
of	O
330	O
patients	O
with	O
PTSD	B-DS
(	O
age	O
17	O
–	O
83	O
)	O
following	O
a	O
wide	O
range	O
of	O
traumas	O
were	O
treated	O
by	O
34	O
therapists	O
,	O
who	O
received	O
training	O
and	O
supervision	O
in	O
CT	O
-	O
PTSD	B-DS
.	O

Pre	O
and	O
post	O
treatment	O
data	O
(	O
PTSD	B-DS
symptoms	O
,	O
anxiety	B-DS
,	O
depression	B-DS
)	O
were	O
collected	O
for	O
all	O
patients	O
,	O
including	O
dropouts	O
.	O

Hierarchical	O
linear	O
modeling	O
investigated	O
candidate	O
moderators	O
of	O
outcome	O
and	O
therapist	O
effects	O
.	O

Results	O

CT	O
-	O
PTSD	B-DS
was	O
well	O
tolerated	O
and	O
led	O
to	O
very	O
large	O
improvement	O
in	O
PTSD	B-DS
symptoms	O
,	O
depression	B-DS
and	O
anxiety	B-DS
.	O

The	O
majority	O
of	O
patients	O
showed	O
reliable	O
improvement	O
/	O
clinically	O
significant	O
change	O
:	O
intent	O
-	O
to	O
-	O
treat	O
:	O
78	O
.	O
8	O
%/	O
57	O
.	O
3	O
%;	O
completer	O
:	O
84	O
.	O
5	O
%/	O
65	O
.	O
1	O
%.	O

Dropouts	O
and	O
unreliable	O
attenders	O
had	O
worse	O
outcome	O
.	O

Statistically	O
reliable	O
symptom	O
exacerbation	O
with	O
treatment	O
was	O
observed	O
in	O
only	O
1	O
.	O
2	O
%	O
of	O
patients	O
.	O

Treatment	O
gains	O
were	O
maintained	O
during	O
follow	O
-	O
up	O
(	O
M	O
=	O
280	O
days	O
,	O
n	O
=	O
220	O
).	O

Few	O
of	O
the	O
selection	O
criteria	O
used	O
in	O
some	O
RCTs	O
,	O
demographic	O
,	O
diagnostic	O
and	O
trauma	O
characteristics	O
moderated	O
treatment	O
outcome	O
,	O
and	O
only	O
social	O
problems	O
and	O
needing	O
treatment	O
for	O
multiple	O
traumas	O
showed	O
unique	O
moderation	O
effects	O
.	O

There	O
were	O
no	O
random	O
effects	O
of	O
therapist	O
on	O
symptom	O
improvement	O
,	O
but	O
therapists	O
who	O
were	O
inexperienced	O
in	O
CT	O
-	O
PTSD	B-DS
had	O
more	O
dropouts	O
than	O
those	O
with	O
greater	O
experience	O
.	O

Conclusions	O

The	O
results	O
support	O
the	O
effectiveness	O
of	O
CT	O
-	O
PTSD	B-DS
and	O
suggest	O
that	O
trauma	O
-	O
focused	O
cognitive	O
behavior	O
therapy	O
can	O
be	O
successfully	O
implemented	O
in	O
routine	O
clinical	O
services	O
treating	O
patients	O
with	O
a	O
wide	O
range	O
of	O
traumas	O
.	O

Highlights	O

•	O
Cognitive	O
Therapy	O
for	O
PTSD	B-DS
can	O
be	O
effectively	O
implemented	O
in	O
routine	O
clinical	O
care	O
.•	O
The	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
showed	O
very	O
large	O
treatment	O
effects	O
.•	O
Patients	O
found	O
the	O
treatment	O
acceptable	O
,	O
and	O
the	O
majority	O
showed	O
clinically	O
significant	O
change	O
.•	O
Few	O
patient	O
characteristics	O
moderated	O
treatment	O
outcome	O
.•	O
Inexperienced	O
therapists	O
had	O
more	O
dropouts	O
.	O

A	O
substantial	O
number	O
of	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
have	O
established	O
the	O
efficacy	O
of	O
trauma	O
-	O
focused	O
cognitive	O
behavioral	O
treatments	O
(	O
TF	O
-	O
CBT	O
)	O
in	O
posttraumatic	B-DS
stress	I-DS
disorder	I-DS
(	O
PTSD	B-DS
)	O
(	O
for	O
reviews	O
see	O
Australian	O
Centre	O
for	O
Posttraumatic	O
Mental	O
Health	O
,	O
2007	O
;	O
Bisson	O
et	O
al	O
.,	O
2007	O
;	O
Bradley	O
,	O
Greene	O
,	O
Russ	O
,	O
Dutra	O
,	O
&	O
Westen	O
,	O
2005	O
;	O
Kitchner	O
,	O
Roberts	O
,	O
Wilcox	O
,	O
&	O
Bisson	O
,	O
2012	O
;	O
Powers	O
,	O
Halpern	O
,	O
Ferenschak	O
,	O
Gillihan	O
,	O
&	O
Foa	O
,	O
2010	O
;	O
Stein	O
et	O
al	O
.,	O
2009	O
).	O

These	O
RCTs	O
have	O
shown	O
very	O
large	O
effect	O
sizes	O
in	O
treating	O
PTSD	B-DS
symptoms	O
and	O
associated	O
symptoms	O
of	O
depression	B-DS
and	O
anxiety	B-DS
for	O
a	O
range	O
of	O
TF	O
-	O
CBT	O
programs	O
.	O

There	O
is	O
as	O
yet	O
less	O
evidence	O
on	O
how	O
effective	O
such	O
treatment	O
programs	O
are	O
when	O
applied	O
in	O
routine	O
clinical	O
settings	O
.	O

Clinicians	O
are	O
often	O
concerned	O
that	O
that	O
the	O
good	O
outcomes	O
observed	O
in	O
RCTs	O
may	O
not	O
generalize	O
to	O
the	O
wide	O
range	O
of	O
traumas	O
and	O
presentations	O
seen	O
in	O
clinical	O
practice	O
.	O

Do	O
the	O
effects	O
of	O
TF	O
-	O
CBT	O
programs	O
generalize	O
to	O
routine	O
clinical	O
care	O
?	O

Several	O
factors	O
are	O
conceivable	O
that	O
could	O
potentially	O
limit	O
the	O
extent	O
to	O
which	O
the	O
treatment	O
effects	O
observed	O
in	O
RCTs	O
generalize	O
to	O
patients	O
seen	O
in	O
routine	O
clinical	O
practice	O
.	O

Although	O
most	O
RCTs	O
studied	O
clinically	O
pertinent	O
samples	O
with	O
moderate	O
to	O
severe	O
PTSD	B-DS
and	O
associated	O
comorbid	O
conditions	O
,	O
they	O
applied	O
certain	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

The	O
selection	O
may	O
influence	O
outcome	O
,	O
for	O
example	O
,	O
by	O
increasing	O
the	O
average	O
size	O
of	O
improvement	O
by	O
requiring	O
a	O
minimum	O
severity	O
or	O
by	O
excluding	O
difficult	O
-	O
to	O
-	O
treat	O
patients	O
.	O

One	O
of	O
these	O
potential	O
factors	O
is	O
that	O
many	O
RCTs	O
selected	O
patients	O
who	O
suffered	O
from	O
discrete	O
traumas	O
such	O
as	O
physical	O
or	O
sexual	B-DS
assault	I-DS
or	O
traffic	O
accidents	O
(	O
but	O
may	O
have	O
also	O
experienced	O
additional	O
other	O
traumas	O
,	O
e	O
.	O
g	O
.,	O
Bryant	O
,	O
Moulds	O
,	O
Guthrie	O
,	O
Dang	O
,	O
&	O
Nixon	O
,	O
2003	O
;	O
Ehlers	O
et	O
al	O
.,	O
2003	O
;	O
Foa	O
et	O
al	O
.,	O
2005	O
;	O
Resick	O
,	O
Nishith	O
,	O
Weaver	O
,	O
Astin	O
,	O
&	O
Feuer	O
,	O
2002	O
;	O
Schnurr	O
et	O
al	O
,	O
2007	O
),	O
whereas	O
in	O
clinical	O
practice	O
patients	O
may	O
require	O
treatment	O
for	O
wider	O
range	O
of	O
traumas	O
including	O
prolonged	O
and	O
multiple	O
traumatic	O
events	O
.	O

It	O
remains	O
unclear	O
whether	O
the	O
exclusion	O
of	O
certain	O
demographic	O
groups	O
such	O
as	O
men	O
,	O
people	O
older	O
than	O
65	O
years	O
of	O
age	O
,	O
or	O
comorbid	O
conditions	O
such	O
as	O
borderline	B-DS
personality	I-DS
disorder	I-DS
influences	O
the	O
overall	O
treatment	O
effects	O
.	O

Second	O
,	O
there	O
have	O
been	O
concerns	O
about	O
a	O
possible	O
risk	O
of	O
symptom	O
exacerbation	O
with	O
exposure	O
to	O
trauma	O
memories	O
(	O
e	O
.	O
g	O
.,	O
Tarrier	O
et	O
al	O
.,	O
1999	O
).	O

Although	O
initial	O
reports	O
have	O
found	O
symptom	O
exacerbation	O
to	O
be	O
uncommon	O
in	O
RCT	O
samples	O
(	O
e	O
.	O
g	O
.,	O
Foa	O
,	O
Zoellner	O
,	O
Feeny	O
,	O
Hembree	O
,	O
&	O
Alvarez	O
-	O
Conrad	O
,	O
2002	O
;	O
Hackmann	O
,	O
Ehlers	O
,	O
Speckens	O
,	O
&	O
Clark	O
,	O
2004	O
),	O
clinicians	O
may	O
be	O
concerned	O
that	O
this	O
problem	O
may	O
be	O
more	O
common	O
in	O
patients	O
seen	O
in	O
routine	O
clinical	O
care	O
.	O

A	O
third	O
concern	O
relates	O
to	O
treatment	O
dropouts	O
.	O

Many	O
of	O
the	O
earlier	O
RCTs	O
reported	O
completer	O
-	O
only	O
analyses	O
.	O

If	O
dropout	O
rates	O
are	O
substantial	O
,	O
completer	O
analyses	O
may	O
overestimate	O
the	O
efficacy	O
of	O
treatments	O
.	O

Some	O
RCTs	O
have	O
observed	O
high	O
dropout	O
rates	O
of	O
between	O
25	O
and	O
43	O
%	O
with	O
trauma	O
-	O
focused	O
PTSD	B-DS
treatments	O
in	O
RCTs	O
(	O
e	O
.	O
g	O
.,	O
Foa	O
et	O
al	O
.,	O
2005	O
;	O
Power	O
et	O
al	O
.,	O
2002	O
;	O
Resick	O
et	O
al	O
.,	O
2002	O
;	O
Schnurr	O
et	O
al	O
,	O
2007	O
),	O
although	O
the	O
average	O
dropout	O
rate	O
may	O
not	O
be	O
higher	O
than	O
for	O
other	O
PTSD	B-DS
treatments	O
(	O
Hembree	O
et	O
al	O
.,	O
2003	O
).	O

Fourth	O
,	O
in	O
RCTs	O
treatment	O
is	O
usually	O
delivered	O
by	O
therapists	O
who	O
receive	O
specialized	O
training	O
and	O
supervision	O
in	O
TF	O
-	O
CBT	O
,	O
and	O
clinicians	O
with	O
less	O
training	O
and	O
supervision	O
may	O
find	O
it	O
difficult	O
to	O
replicate	O
their	O
results	O
.	O

Thus	O
,	O
there	O
is	O
a	O
need	O
to	O
empirically	O
investigate	O
how	O
well	O
the	O
excellent	O
outcomes	O
of	O
TF	O
-	O
CBT	O
observed	O
in	O
RCTs	O
can	O
be	O
replicated	O
in	O
routine	O
clinical	O
settings	O
where	O
patients	O
are	O
not	O
selected	O
for	O
RCT	O
suitability	O
and	O
treatment	O
is	O
delivered	O
by	O
therapists	O
with	O
a	O
range	O
of	O
prior	O
experience	O
with	O
TF	O
-	O
CBT	O
.	O

Preliminary	O
evidence	O
suggests	O
that	O
TF	O
-	O
CBT	O
programs	O
can	O
be	O
successfully	O
implemented	O
in	O
routine	O
clinical	O
services	O
(	O
for	O
reviews	O
see	O
Cohen	O
&	O
Mannarino	O
,	O
2008	O
;	O
Stewart	O
&	O
Chambless	O
,	O
2009	O
).	O
Foa	O
et	O
al	O
.'	O
s	O
(	O
2005	O
)	O
RCT	O
of	O
Prolonged	O
Exposure	O
for	O
sexual	B-DS
assault	I-DS
survivors	O
found	O
equivalent	O
outcomes	O
for	O
expert	O
therapists	O
and	O
newly	O
trained	O
therapists	O
working	O
in	O
a	O
community	O
center	O
.	O
Karlin	O
et	O
al	O
.	O

(	O
2010	O
)	O
reported	O
that	O
veterans	O
treated	O
with	O
Prolonged	O
Exposure	O
or	O
Cognitive	O
Processing	O
Therapy	O
following	O
an	O
extensive	O
therapist	O
training	O
program	O
implemented	O
in	O
the	O
Veteran	O
Health	O
Administration	O
showed	O
a	O
30	O
%	O
decrease	O
in	O
PTSD	B-DS
symptoms	O
in	O
completer	O
analyses	O
(	O
see	O
also	O
Monson	O
et	O
al	O
.,	O
2006	O
;	O
Tuerk	O
et	O
al	O
.,	O
2011	O
).	O
Levitt	O
,	O
Malta	O
,	O
Martin	O
,	O
Davis	O
,	O
and	O
Cloitre	O
(	O
2007	O
)	O
and	O
Brewin	O
et	O
al	O
.	O

(	O
2010	O
)	O
reported	O
large	O
improvements	O
in	O
outreach	O
programs	O
for	O
survivors	O
of	O
9	O
/	O
11	O
and	O
the	O
London	O
bombings	O
who	O
suffered	O
from	O
PTSD	B-DS
.	O

Gillespie	O
,	O
Duffy	O
,	O
Hackmann	O
,	O
and	O
Clark	O
(	O
2002	O
)	O
trained	O
therapists	O
from	O
a	O
range	O
of	O
professional	O
backgrounds	O
in	O
Cognitive	O
Therapy	O
for	O
PTSD	B-DS
,	O
a	O
version	O
of	O
TF	O
-	O
CBT	O
that	O
builds	O
on	O
Ehlers	O
and	O
Clark	O
'	O
s	O
(	O
2000	O
)	O
model	O
of	O
PTSD	B-DS
.	O

The	O
therapists	O
treated	O
an	O
unselected	O
group	O
of	O
patients	O
seeking	O
treatment	O
for	O
PTSD	B-DS
after	O
the	O
Omagh	O
bombing	O
in	O
Northern	O
Ireland	O
and	O
achieved	O
similarly	O
good	O
outcomes	O
as	O
those	O
observed	O
in	O
RCTs	O
.	O
Duffy	O
,	O
Gillespie	O
,	O
and	O
Clark	O
(	O
2007	O
)	O
further	O
successfully	O
disseminated	O
this	O
treatment	O
to	O
an	O
unselected	O
group	O
of	O
patients	O
who	O
had	O
experienced	O
traumas	O
in	O
connection	O
with	O
the	O
civil	O
conflict	O
in	O
Northern	O
Ireland	O
,	O
the	O
majority	O
of	O
whom	O
had	O
experienced	O
multiple	O
traumatic	O
events	O
.	O

Whilst	O
these	O
initial	O
studies	O
evaluating	O
the	O
effectiveness	O
of	O
TF	O
-	O
CBT	O
for	O
PTSD	B-DS
are	O
promising	O
,	O
they	O
are	O
limited	O
in	O
number	O
,	O
and	O
further	O
studies	O
of	O
larger	O
samples	O
of	O
unselected	O
patients	O
with	O
PTSD	B-DS
following	O
the	O
wide	O
range	O
of	O
traumatic	O
events	O
seen	O
in	O
clinical	O
settings	O
are	O
needed	O
to	O
determine	O
the	O
effectiveness	O
of	O
TF	O
-	O
CBT	O
programs	O
.	O

The	O
present	O
study	O
describes	O
treatment	O
outcomes	O
of	O
consecutive	O
referrals	O
to	O
a	O
National	O
Health	O
Service	O
outpatient	O
clinic	O
treated	O
with	O
CT	O
-	O
PTSD	B-DS
.	O

The	O
clinic	O
was	O
newly	O
opened	O
in	O
April	O
2001	O
and	O
thus	O
provided	O
an	O
opportunity	O
to	O
train	O
new	O
therapists	O
in	O
delivering	O
this	O
treatment	O
,	O
and	O
to	O
study	O
treatment	O
effectiveness	O
,	O
moderators	O
of	O
treatment	O
outcome	O
and	O
possible	O
therapist	O
effects	O
in	O
a	O
consecutive	O
patient	O
sample	O
from	O
a	O
defined	O
catchment	O
area	O
.	O

Moderators	O
of	O
treatment	O
effectiveness	O

The	O
study	O
investigated	O
candidate	O
moderators	O
of	O
the	O
effectiveness	O
of	O
TF	O
-	O
CBT	O
in	O
routine	O
clinical	O
settings	O
.	O

We	O
were	O
interested	O
in	O
whether	O
selection	O
criteria	O
for	O
randomized	O
controlled	O
trials	O
actually	O
predict	O
treatment	O
response	O
,	O
and	O
whether	O
other	O
aspects	O
of	O
clinical	O
history	O
,	O
comorbidity	O
or	O
trauma	O
history	O
moderate	O
treatment	O
outcome	O
.	O
Kraemer	O
,	O
Wilson	O
,	O
Fairburn	O
,	O
and	O
Agras	O
(	O
2002	O
)	O
distinguish	O
two	O
types	O
of	O
predictors	O
of	O
outcome	O
.	O
Nonspecific	O
predictors	O
of	O
outcome	O
influence	O
the	O
overall	O
severity	O
of	O
symptoms	O
,	O
but	O
do	O
not	O
influence	O
the	O
slope	O
of	O
treatment	O
-	O
induced	O
improvement	O
.	O

Some	O
TF	O
-	O
CBT	O
studies	O
have	O
correlated	O
candidate	O
predictors	O
with	O
symptom	O
severity	O
at	O
the	O
end	O
of	O
therapy	O
and	O
have	O
generally	O
found	O
that	O
patients	O
with	O
more	O
severe	O
symptoms	O
of	O
PTSD	B-DS
and	O
depression	B-DS
at	O
the	O
beginning	O
of	O
treatment	O
have	O
more	O
remaining	O
symptoms	O
at	O
the	O
end	O
of	O
treatment	O
(	O
e	O
.	O
g	O
.,	O
Blanchard	O
et	O
al	O
.,	O
2003	O
;	O
van	O
Emmerik	O
,	O
Kamphuis	O
,	O
Noordhof	O
,	O
&	O
Emmelkamp	O
,	O
2011	O
;	O
van	O
Minnen	O
,	O
Arntz	O
,	O
&	O
Keijsers	O
,	O
2002	O
;	O
Schulz	O
,	O
Resick	O
,	O
Huber	O
,	O
&	O
Griffin	O
,	O
2006	O
).	O

A	O
moderator	O
of	O
treatment	O
effectiveness	O
is	O
a	O
variable	O
that	O
influences	O
the	O
slope	O
of	O
improvement	O
(	O
Kraemer	O
et	O
al	O
.,	O
2002	O
).	O

Several	O
studies	O
of	O
TF	O
-	O
CBT	O
attempted	O
to	O
identify	O
moderators	O
of	O
treatment	O
response	O
in	O
RCTs	O
(	O
e	O
.	O
g	O
.,	O
Ehlers	O
,	O
Clark	O
,	O
Hackmann	O
,	O
McManus	O
,	O
&	O
Fennell	O
,	O
2005	O
;	O
Feeny	O
,	O
Zoellner	O
,	O
&	O
Foa	O
,	O
2002	O
;	O
Kubany	O
et	O
al	O
.,	O
2004	O
;	O
Rizvi	O
,	O
Vogt	O
,	O
&	O
Resick	O
,	O
2009	O
;	O
Tarrier	O
,	O
Sommerfield	O
,	O
Pilgrim	O
,	O
&	O
Faragher	O
,	O
2000	O
;	O
van	O
Emmerik	O
et	O
al	O
.,	O
2011	O
)	O
and	O
routine	O
clinic	O
samples	O
(	O
e	O
.	O
g	O
.,	O
Gillespie	O
et	O
al	O
.,	O
2002	O
;	O
Richardson	O
,	O
Elhai	O
,	O
&	O
Sareen	O
,	O
2011	O
;	O
Rosenkranz	O
&	O
Muller	O
,	O
2011	O
;	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
).	O

The	O
results	O
were	O
often	O
inconsistent	O
and	O
few	O
moderators	O
have	O
been	O
identified	O
.	O

Variables	O
that	O
were	O
shown	O
in	O
some	O
studies	O
to	O
be	O
associated	O
with	O
less	O
favorable	O
treatment	O
response	O
included	O
•	O
demographic	O
variables	O
such	O
as	O
male	O
sex	O
(	O
Blain	O
,	O
Galovski	O
,	O
&	O
Robinson	O
,	O
2010	O
),	O
younger	O
age	O
(	O
Rizvi	O
et	O
al	O
.,	O
2009	O
;	O
Taylor	O
,	O
Fedoroff	O
,	O
&	O
Koch	O
,	O
1999	O
),	O
higher	O
level	O
of	O
education	O
(	O
Ehlers	O
et	O
al	O
.,	O
2005	O
)	O
or	O
ethnic	O
minority	O
(	O
Walling	O
,	O
Suvak	O
,	O
Howard	O
,	O
Taft	O
,	O
&	O
Murphy	O
,	O
2012	O
);•	O
comorbidity	O
with	O
other	O
anxiety	B-DS
disorders	I-DS
or	O
high	O
symptoms	O
of	O
anxiety	B-DS
and	O
arousal	O
(	O
Rosenkranz	O
&	O
Muller	O
,	O
2011	O
;	O
Tarrier	O
et	O
al	O
.,	O
2000	O
;	O
but	O
see	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
;	O
Richardson	O
et	O
al	O
.,	O
2011	O
;	O
for	O
negative	O
findings	O
);	O
with	O
depression	B-DS
or	O
suicidal	O
ideation	O
(	O
Duffy	O
et	O
al	O
.,	O
2007	O
;	O
Tarrier	O
et	O
al	O
.,	O
2000	O
;	O
but	O
see	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
;	O
Richardson	O
et	O
al	O
.,	O
2011	O
;	O
for	O
negative	O
findings	O
);	O
substance	B-DS
abuse	I-DS
(	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
;	O
but	O
see	O
Richardson	O
et	O
al	O
.,	O
2011	O
;	O
for	O
negative	O
findings	O
);	O
personality	B-DS
disorders	I-DS
(	O
Clarke	O
,	O
Rizvi	O
,	O
&	O
Resick	O
,	O
2008	O
;	O
Feeny	O
et	O
al	O
.,	O
2002	O
);	O
use	O
of	O
psychotropic	O
medication	O
(	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
),	O
and	O
permanent	O
physical	O
disability	O
resulting	O
from	O
the	O
trauma	O
(	O
Gillespie	O
et	O
al	O
.,	O
2002	O
;	O
but	O
see	O
Duffy	O
et	O
al	O
.,	O
2007	O
;	O
for	O
negative	O
findings	O
);•	O
trauma	O
characteristics	O
such	O
as	O
multiple	O
trauma	O
(	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
),	O
childhood	O
trauma	O
(	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
;	O
but	O
also	O
see	O
Jaycox	O
,	O
Foa	O
,	O
&	O
Morral	O
,	O
1998	O
;	O
for	O
negative	O
findings	O
),	O
interpersonal	O
trauma	O
committed	O
by	O
a	O
perpetrator	O
(	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
),	O
longer	O
time	O
since	O
the	O
trauma	O
(	O
Duffy	O
et	O
al	O
.,	O
2007	O
;	O
but	O
see	O
Ehlers	O
et	O
al	O
.,	O
2005	O
;	O
Rizvi	O
et	O
al	O
.,	O
2009	O
;	O
for	O
negative	O
findings	O
).	O

Therapist	O
effects	O

In	O
a	O
meta	O
-	O
analysis	O
of	O
psychotherapy	O
outcome	O
studies	O
,	O
Crits	O
-	O
Christoph	O
et	O
al	O
.	O

(	O
1991	O
)	O
found	O
that	O
on	O
average	O
8	O
.	O
6	O
%	O
of	O
the	O
variance	O
in	O
outcome	O
were	O
due	O
to	O
random	O
therapist	O
effects	O
.	O

Greater	O
therapist	O
effects	O
were	O
found	O
when	O
no	O
treatment	O
manual	O
was	O
used	O
and	O
therapists	O
were	O
inexperienced	O
.	O

More	O
recent	O
studies	O
are	O
consistent	O
with	O
this	O
pattern	O
of	O
results	O
.	O
Wampold	O
and	O
Brown	O
(	O
2005	O
)	O
estimated	O
that	O
about	O
5	O
%	O
of	O
the	O
variation	O
in	O
outcome	O
of	O
6146	O
patients	O
with	O
different	O
diagnoses	O
treated	O
in	O
managed	O
care	O
was	O
due	O
to	O
therapists	O
.	O

Similarly	O
,	O
Lutz	O
,	O
Leon	O
,	O
Martinovich	O
,	O
Lyons	O
,	O
and	O
Stiles	O
(	O
2007	O
)	O
investigated	O
outcomes	O
of	O
patients	O
in	O
managed	O
care	O
treated	O
by	O
therapists	O
of	O
different	O
professional	O
backgrounds	O
and	O
orientations	O
and	O
estimated	O
that	O
8	O
%	O
of	O
the	O
variance	O
in	O
outcome	O
could	O
be	O
attributed	O
to	O
therapists	O
.	O

Other	O
recent	O
studies	O
investigated	O
more	O
homogeneous	O
samples	O
of	O
clients	O
with	O
a	O
particular	O
disorder	O
who	O
were	O
treated	O
according	O
to	O
a	O
particular	O
protocol	O
and	O
found	O
no	O
significant	O
effects	O
of	O
therapist	O
on	O
outcome	O
(	O
e	O
.	O
g	O
.,	O
Cella	O
,	O
Stahl	O
,	O
Reme	O
,	O
&	O
Chalder	O
,	O
2011	O
;	O
Wilson	O
,	O
Wilfley	O
,	O
Agras	O
,	O
&	O
Bryson	O
,	O
2011	O
).	O

In	O
PTSD	B-DS
,	O
there	O
is	O
as	O
yet	O
little	O
data	O
on	O
therapist	O
effects	O
.	O

In	O
RCTs	O
,	O
Ehlers	O
et	O
al	O
.	O

(	O
2003	O
,	O
2005	O
,	O
see	O
Baldwin	O
et	O
al	O
.,	O
2011	O
)	O
and	O
Kubany	O
et	O
al	O
.	O

(	O
2004	O
)	O
found	O
no	O
therapist	O
effects	O
,	O
while	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
reported	O
significantly	O
worse	O
outcome	O
for	O
one	O
therapist	O
who	O
was	O
inexperienced	O
in	O
delivering	O
the	O
treatment	O
protocol	O
.	O

Aims	O
of	O
the	O
study	O

This	O
study	O
had	O
the	O
following	O
aims	O
:(	O
1	O
)	O
to	O
assess	O
the	O
effectiveness	O
of	O
CT	O
-	O
PTSD	B-DS
in	O
unselected	O
patients	O
referred	O
to	O
a	O
National	O
Health	O
Service	O
outpatient	O
clinic	O
,(	O
2	O
)	O
to	O
assess	O
treatment	O
response	O
of	O
patients	O
who	O
do	O
not	O
complete	O
treatment	O
,(	O
3	O
)	O
to	O
investigate	O
whether	O
candidate	O
diagnostic	O
variables	O
,	O
demographic	O
variables	O
and	O
aspects	O
of	O
trauma	O
history	O
moderate	O
treatment	O
response	O
,	O
and	O
(	O
4	O
)	O
to	O
explore	O
therapist	O
effects	O
on	O
treatment	O
outcome	O
.	O

Method	O

Clinical	O
setting	O
and	O
patients	O

The	O
Centre	O
for	O
Anxiety	B-DS
Disorders	I-DS
and	O
Trauma	O
,	O
Maudsley	O
Hospital	O
,	O
UK	O
,	O
is	O
an	O
outpatient	O
clinic	O
specializing	O
in	O
the	O
treatment	O
of	O
anxiety	B-DS
disorders	I-DS
in	O
adults	O
.	O

It	O
was	O
opened	O
in	O
April	O
2001	O
and	O
is	O
part	O
of	O
the	O
British	O
National	O
Health	O
Service	O
,	O
receiving	O
referrals	O
from	O
General	O
Practitioners	O
and	O
Community	O
Mental	O
Health	O
Teams	O
.	O

The	O
clinic	O
offers	O
assessment	O
and	O
treatment	O
for	O
survivors	O
of	O
trauma	O
in	O
adulthood	O
who	O
suffer	O
from	O
PTSD	B-DS
.	O

It	O
serves	O
a	O
population	O
of	O
about	O
867	O
,	O
000	O
people	O
living	O
in	O
the	O
South	O
London	O
Boroughs	O
of	O
Southwark	O
,	O
Lewisham	O
and	O
Lambeth	O
.	O

These	O
areas	O
have	O
substantially	O
higher	O
rates	O
of	O
social	O
deprivation	O
,	O
crime	O
,	O
and	O
a	O
greater	O
proportion	O
of	O
ethnic	O
minorities	O
than	O
the	O
UK	O
average	O
.	O

The	O
present	O
study	O
included	O
all	O
consecutive	O
patients	O
who	O
were	O
referred	O
for	O
assessment	O
for	O
possible	O
PTSD	B-DS
between	O
April	O
2001	O
and	O
August	O
2008	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
research	O
ethics	O
committee	O
.	O
Fig	O
.	O
1	O
shows	O
that	O
577	O
patients	O
completed	O
the	O
assessment	O
,	O
and	O
408	O
were	O
suitable	O
for	O
trauma	O
-	O
focused	O
treatment	O
.	O

The	O
main	O
reasons	O
for	O
not	O
being	O
suitable	O
at	O
the	O
time	O
of	O
assessment	O
were	O
that	O
the	O
patient	O
did	O
not	O
have	O
PTSD	B-DS
(	O
n	O
=	O
42	O
),	O
or	O
first	O
needed	O
treatment	O
for	O
another	O
primary	O
problem	O
such	O
as	O
alcohol	B-DS
dependence	I-DS
or	O
immediate	O
suicide	O
risk	O
(	O
n	O
=	O
73	O
).	O

The	O
main	O
reasons	O
for	O
not	O
being	O
offered	O
CT	O
-	O
PTSD	B-DS
despite	O
suitability	O
for	O
treatment	O
(	O
n	O
=	O
78	O
)	O
were	O
that	O
the	O
patient	O
did	O
not	O
want	O
treatment	O
(	O
n	O
=	O
27	O
)	O
or	O
participated	O
in	O
a	O
trial	O
where	O
they	O
received	O
another	O
psychological	O
treatment	O
(	O
n	O
=	O
21	O
).	O

A	O
total	O
of	O
330	O
patients	O
were	O
offered	O
a	O
course	O
of	O
CT	O
-	O
PTSD	B-DS
.	O

Data	O
for	O
initial	O
assessment	O
and	O
the	O
last	O
treatment	O
session	O
were	O
available	O
for	O
all	O
patients	O
,	O
including	O
dropouts	O
.	O

Two	O
thirds	O
(	O
n	O
=	O
220	O
)	O
of	O
the	O
patients	O
provided	O
follow	O
-	O
up	O
data	O
.	O

Fifty	O
-	O
six	O
percent	O
(	O
n	O
=	O
185	O
)	O
of	O
the	O
330	O
patients	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
sample	O
were	O
female	O
.	O

Their	O
ages	O
ranged	O
from	O
18	O
to	O
83	O
years	O
,	O
M	O
=	O
38	O
.	O
8	O
,	O
SD	O
=	O
11	O
.	O
5	O
.	O

A	O
large	O
proportion	O
(	O
43	O
.	O
7	O
%)	O
of	O
the	O
patients	O
were	O
from	O
ethnic	O
minorities	O
,	O
and	O
either	O
unemployed	O
(	O
33	O
.	O
7	O
%),	O
or	O
on	O
disability	O
/	O
retired	O
(	O
8	O
.	O
7	O
%)	O
or	O
sick	O
leave	O
(	O
16	O
.	O
0	O
%)	O
because	O
of	O
their	O
symptoms	O
.	O

The	O
majority	O
(	O
42	O
.	O
8	O
%)	O
was	O
single	O
,	O
37	O
.	O
7	O
%	O
were	O
married	O
/	O
cohabitating	O
with	O
a	O
partner	O
,	O
and	O
19	O
.	O
5	O
%	O
were	O
divorced	O
/	O
widowed	O
.	O

The	O
majority	O
(	O
43	O
.	O
8	O
%)	O
had	O
completed	O
mandatory	O
school	O
education	O
up	O
to	O
age	O
16	O
(	O
GCSE	O
or	O
equivalent	O
),	O
18	O
%	O
had	O
not	O
completed	O
school	O
exams	O
,	O
15	O
%	O
had	O
taken	O
higher	O
school	O
exams	O
at	O
age	O
18	O
(	O
A	O
level	O
),	O
and	O
23	O
.	O
2	O
%	O
had	O
attended	O
university	O
.	O

The	O
most	O
common	O
type	O
of	O
trauma	O
addressed	O
in	O
treatment	O
was	O
interpersonal	B-DS
violence	I-DS
(	O
including	O
physical	O
assault	B-DS
,	O
sexual	B-DS
assault	I-DS
,	O
terrorist	O
attack	O
and	O
torture	O
,	O
56	O
.	O
7	O
%);	O
followed	O
by	O
accidents	O
or	O
disaster	O
(	O
22	O
.	O
4	O
%),	O
traumatic	O
death	O
/	O
harm	O
to	O
others	O
(	O
9	O
.	O
5	O
%),	O
and	O
other	O
traumas	O
(	O
11	O
.	O
2	O
%).	O

In	O
22	O
.	O
5	O
%	O
of	O
patients	O
,	O
the	O
trauma	O
had	O
involved	O
the	O
death	O
of	O
another	O
person	O
.	O

The	O
main	O
traumas	O
that	O
were	O
addressed	O
in	O
treatment	O
had	O
happened	O
between	O
3	O
and	O
360	O
months	O
ago	O
,	O
M	O
=	O
36	O
.	O
5	O
,	O
SD	O
=	O
56	O
.	O
9	O
.	O

Most	O
patients	O
(	O
82	O
.	O
0	O
%)	O
had	O
been	O
injured	O
during	O
their	O
traumas	O
,	O
and	O
21	O
.	O
5	O
%	O
had	O
suffered	O
permanent	O
physical	O
disabilities	O
or	O
loss	O
of	O
function	O
due	O
to	O
the	O
trauma	O
.	O

A	O
third	O
of	O
the	O
patients	O
(	O
33	O
.	O
7	O
%)	O
had	O
received	O
previous	O
treatment	O
for	O
their	O
PTSD	B-DS
,	O
and	O
9	O
.	O
1	O
%	O
had	O
had	O
a	O
previous	O
course	O
of	O
trauma	O
-	O
focused	O
CBT	O
.	O

The	O
majority	O
(	O
63	O
.	O
0	O
%)	O
reported	O
a	O
history	O
of	O
further	O
traumas	O
,	O
and	O
17	O
.	O
8	O
%	O
reported	O
a	O
history	O
of	O
childhood	O
abuse	O
.	O

Comorbidity	O
with	O
other	O
disorders	O
was	O
common	O
;	O
75	O
.	O
8	O
%	O
met	O
diagnostic	O
criteria	O
for	O
at	O
least	O
one	O
current	O
comorbid	O
Axis	O
1	O
disorders	O
,	O
and	O
29	O
.	O
1	O
%	O
met	O
criteria	O
for	O
Axis	O
II	O
disorders	O
.	O

The	O
most	O
common	O
comorbid	O
Axis	O
1	O
conditions	O
were	O
mood	B-DS
disorders	I-DS
(	O
50	O
.	O
9	O
%),	O
other	O
anxiety	B-DS
disorders	I-DS
(	O
42	O
.	O
7	O
%)	O
and	O
substance	B-DS
abuse	I-DS
(	O
22	O
.	O
1	O
%).	O

Nearly	O
half	O
(	O
48	O
.	O
5	O
%)	O
reported	O
current	O
suicidal	O
ideation	O
,	O
and	O
14	O
.	O
2	O
%	O
reported	O
past	O
suicide	O
attempts	O
.	O

A	O
history	O
of	O
major	B-DS
depression	I-DS
was	O
common	O
(	O
69	O
.	O
7	O
%),	O
and	O
a	O
significant	O
minority	O
(	O
18	O
.	O
8	O
%)	O
reported	O
a	O
history	O
of	O
substance	B-DS
dependence	I-DS
.	O

The	O
mean	O
number	O
of	O
comorbid	O
disorders	O
was	O
2	O
.	O
2	O
,	O
SD	O
=	O
2	O
.	O
1	O
.	O

Patients	O
taking	O
psychotropic	O
medication	O
(	O
n	O
=	O
132	O
,	O
40	O
.	O
0	O
%)	O
were	O
asked	O
to	O
remain	O
on	O
a	O
stable	O
dose	O
for	O
two	O
months	O
before	O
treatment	O
started	O
and	O
to	O
stay	O
on	O
the	O
same	O
dose	O
for	O
the	O
duration	O
of	O
treatment	O
,	O
and	O
the	O
majority	O
of	O
patients	O
reported	O
that	O
they	O
followed	O
this	O
advice	O
.	O

The	O
majority	O
(	O
54	O
.	O
5	O
%)	O
of	O
these	O
patients	O
were	O
taking	O
SSRIs	O
,	O
16	O
.	O
3	O
%	O
tricyclic	O
antidepressants	O
,	O
4	O
.	O
9	O
%	O
benzodiazepines	B-CD
,	O
6	O
.	O
5	O
%	O
hypnotics	O
.	O
and	O
17	O
.	O
9	O
%	O
other	O
medication	O
.	O

Patients	O
who	O
provided	O
follow	O
-	O
up	O
data	O
(	O
n	O
=	O
220	O
)	O
were	O
comparable	O
to	O
those	O
who	O
did	O
not	O
(	O
n	O
=	O
110	O
)	O
on	O
most	O
demographic	O
,	O
diagnostic	O
and	O
trauma	O
history	O
characteristics	O
,	O
but	O
had	O
higher	O
education	O
levels	O
,	O
χ2	O
(	O
3	O
,	O
n	O
=	O
306	O
)	O
=	O
11	O
.	O
91	O
,	O
p	O
=	O
.	O
008	O
;	O
were	O
more	O
likely	O
to	O
be	O
employed	O
,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
312	O
)	O
=	O
4	O
.	O
91	O
,	O
p	O
=	O
.	O
027	O
,	O
and	O
less	O
likely	O
to	O
have	O
comorbid	O
mood	B-DS
disorders	I-DS
,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
14	O
.	O
77	O
,	O
p	O
<	O
.	O
001	O
,	O
current	O
substance	B-DS
abuse	I-DS
,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
5	O
.	O
62	O
,	O
p	O
<	O
.	O
018	O
,	O
or	O
personality	B-DS
disorders	I-DS
,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
4	O
.	O
99	O
,	O
p	O
=	O
.	O
025	O
.	O

Therapists	O

Therapists	O
included	O
both	O
qualified	O
clinicians	O
and	O
therapists	O
in	O
training	O
.	O

A	O
total	O
of	O
34	O
different	O
therapists	O
with	O
a	O
wide	O
range	O
of	O
prior	O
experience	O
in	O
CBT	O
treated	O
patients	O
during	O
the	O
study	O
period	O
.	O

This	O
included	O
clinical	O
psychologists	O
(	O
qualified	O
n	O
=	O
15	O
,	O
44	O
.	O
1	O
%;	O
trainees	O
=	O
11	O
,	O
32	O
.	O
3	O
%),	O
nurse	O
therapists	O
(	O
n	O
=	O
3	O
,	O
8	O
.	O
8	O
%)	O
and	O
psychiatrists	O
(	O
trainees	O
,	O
n	O
=	O
5	O
,	O
14	O
.	O
7	O
%).	O

Each	O
therapist	O
participated	O
in	O
a	O
two	O
-	O
day	O
workshop	O
in	O
CT	O
-	O
PTSD	B-DS
.	O

They	O
then	O
received	O
close	O
individual	O
supervision	O
in	O
treating	O
their	O
first	O
few	O
cases	O
and	O
had	O
the	O
opportunity	O
to	O
act	O
as	O
co	O
-	O
therapists	O
with	O
a	O
trained	O
therapist	O
for	O
at	O
least	O
one	O
case	O
.	O

Thereafter	O
,	O
cases	O
were	O
discussed	O
in	O
weekly	O
CT	O
-	O
PTSD	B-DS
focused	O
group	O
supervision	O
.	O

Data	O
for	O
all	O
patients	O
including	O
training	O
cases	O
were	O
included	O
in	O
the	O
data	O
analysis	O
.	O

Two	O
aspects	O
of	O
therapist	O
experience	O
were	O
coded	O
:	O
first	O
,	O
whether	O
the	O
therapist	O
was	O
a	O
trainee	O
or	O
a	O
staff	O
therapist	O
,	O
and	O
second	O
,	O
the	O
therapists	O
'	O
experience	O
with	O
CT	O
-	O
PTSD	B-DS
(	O
experienced	O
was	O
defined	O
as	O
having	O
treated	O
more	O
than	O
12	O
patients	O
with	O
CT	O
-	O
PTSD	B-DS
).	O

Treatment	O

CT	O
-	O
PTSD	B-DS
is	O
based	O
on	O
Ehlers	O
and	O
Clark	O
'	O
s	O
(	O
2000	O
)	O
model	O
of	O
PTSD	B-DS
and	O
targets	O
three	O
factors	O
specified	O
in	O
this	O
model	O
.	O

It	O
is	O
suggested	O
that	O
people	O
with	O
PTSD	B-DS
perceive	O
a	O
serious	O
current	O
threat	O
which	O
has	O
two	O
sources	O
,	O
excessively	O
negative	O
appraisals	O
of	O
the	O
trauma	O
and	O
/	O
or	O
its	O
sequelae	O
and	O
characteristics	O
of	O
trauma	O
memories	O
that	O
lead	O
to	O
reexperiencing	O
symptoms	O
.	O

The	O
problem	O
is	O
maintained	O
by	O
cognitive	O
strategies	O
and	O
behaviors	O
(	O
such	O
as	O
thought	O
suppression	O
,	O
rumination	O
,	O
and	O
safety	O
-	O
seeking	O
behaviors	O
)	O
that	O
are	O
intended	O
to	O
reduce	O
the	O
sense	O
of	O
current	O
threat	O
,	O
but	O
maintain	O
the	O
problem	O
by	O
preventing	O
change	O
in	O
the	O
appraisals	O
or	O
trauma	O
memory	O
,	O
and	O
/	O
or	O
by	O
increasing	O
symptoms	O
.	O

Details	O
of	O
the	O
treatment	O
procedures	O
are	O
found	O
in	O
Clark	O
and	O
Ehlers	O
(	O
2004	O
),	O
Ehlers	O
et	O
al	O
.	O

(	O
2005	O
)	O
and	O
Ehlers	O
et	O
al	O
.	O

(	O
2010	O
,	O
http	O
://	O
oxcadat	O
.	O
psy	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/	O
downloads	O
/	O
CT	O
-	O
PTSD	B-DS
%	O
20Treatment	O
%	O
20Procedures	O
.	O
pdf	O
/	O
view	O
).	O

Treatment	O
was	O
conducted	O
in	O
English	O
in	O
individual	O
treatment	O
sessions	O
.	O

Patients	O
received	O
a	O
mean	O
of	O
M	O
=	O
10	O
.	O
6	O
weekly	O
treatment	O
sessions	O
,	O
SD	O
=	O
5	O
.	O
0	O
,	O
and	O
M	O
=	O
2	O
.	O
0	O
monthly	O
booster	O
sessions	O
,	O
SD	O
=	O
3	O
.	O
0	O
,	O
similar	O
to	O
previous	O
trials	O
(	O
Ehlers	O
et	O
al	O
.,	O
2003	O
,	O
2005	O
).	O

Therapists	O
kept	O
detailed	O
notes	O
about	O
each	O
treatment	O
session	O
,	O
and	O
an	O
independent	O
rater	O
rated	O
the	O
extent	O
to	O
which	O
the	O
session	O
focused	O
on	O
the	O
PTSD	B-DS
treatment	O
model	O
,	O
on	O
a	O
scale	O
from	O
1	O
to	O
3	O
(	O
1	O
=	O
mainly	O
followed	O
trauma	O
-	O
focused	O
protocol	O
,	O
2	O
=	O
equal	O
focus	O
on	O
trauma	O
-	O
focused	O
protocol	O
and	O
other	O
problems	O
,	O
3	O
=	O
main	O
focus	O
on	O
other	O
problems	O
).	O

The	O
mean	O
rating	O
for	O
all	O
sessions	O
was	O
M	O
=	O
1	O
.	O
35	O
,	O
SD	O
=	O
0	O
.	O
39	O
,	O
and	O
for	O
90	O
.	O
1	O
%	O
of	O
the	O
patients	O
treatment	O
mainly	O
focused	O
on	O
the	O
PTSD	B-DS
treatment	O
protocol	O
(	O
mean	O
rating	O
of	O
below	O
2	O
).	O

The	O
most	O
common	O
other	O
problems	O
addressed	O
in	O
the	O
sessions	O
were	O
comorbid	O
disorders	O
,	O
and	O
other	O
stressors	O
such	O
as	O
social	O
problems	O
(	O
e	O
.	O
g	O
.,	O
financial	O
,	O
housing	O
,	O
legal	O
issues	O
)	O
or	O
physical	O
health	O
problems	O
.	O

Measures	O

Self	O
-	O
reports	O
of	O
symptom	O
severity	O
were	O
taken	O
at	O
initial	O
assessment	O
,	O
at	O
the	O
first	O
and	O
last	O
treatment	O
session	O
,	O
and	O
at	O
follow	O
-	O
up	O
(	O
mean	O
280	O
days	O
).	O

Severity	O
of	O
PTSD	B-DS
symptoms	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	O
in	O
PTSD	B-DS
symptoms	O
.	O

Patients	O
completed	O
the	O
Posttraumatic	O
Diagnostic	O
Scale	O
(	O
PDS	O
,	O
Foa	O
,	O
Cashman	O
,	O
Jaycox	O
,	O
&	O
Perry	O
,	O
1997	O
).	O

The	O
PDS	O
asks	O
patients	O
to	O
rate	O
how	O
often	O
they	O
were	O
bothered	O
by	O
each	O
of	O
the	O
PTSD	B-DS
symptoms	O
specified	O
in	O
DSM	O
-	O
IV	O
ranging	O
from	O
0	O
=	O
never	O
to	O
3	O
=	O
5	O
times	O
per	O
week	O
or	O
more	O
/	O
almost	O
always	O
.	O

The	O
PDS	O
yields	O
a	O
sum	O
score	O
measuring	O
the	O
overall	O
severity	O
of	O
PTSD	B-DS
symptoms	O
.	O
Foa	O
et	O
al	O
.	O

(	O
1997	O
)	O
showed	O
that	O
the	O
self	O
-	O
report	O
questionnaire	O
has	O
good	O
reliability	O
and	O
concurrent	O
validity	O
with	O
other	O
PTSD	B-DS
measures	O
.	O

Internal	O
consistency	O
in	O
this	O
sample	O
was	O
α	O
=	O
.	O
85	O
.	O

Depression	B-DS
and	O
anxiety	B-DS

Symptoms	O
of	O
anxiety	B-DS
and	O
depression	B-DS
were	O
secondary	O
outcome	O
measures	O
.	O

Patients	O
completed	O
the	O
Beck	O
Anxiety	B-DS
Inventory	O
(	O
BAI	O
,	O
Beck	O
&	O
Steer	O
,	O
1993a	O
)	O
and	O
the	O
Beck	O
Depression	B-DS
Inventory	O
(	O
BDI	O
,	O
Beck	O
&	O
Steer	O
,	O
1993b	O
),	O
standard	O
21	O
-	O
item	O
self	O
-	O
report	O
measures	O
with	O
high	O
reliability	O
and	O
validity	O
.	O

Internal	O
consistencies	O
in	O
this	O
sample	O
were	O
α	O
=	O
.	O
92	O
and	O
α	O
=	O
.	O
90	O
,	O
respectively	O
.	O

Candidate	O
moderators	O

At	O
initial	O
assessments	O
,	O
clinicians	O
conducted	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	O
-	O
IV	O
(	O
SCID	O
)	O
to	O
assess	O
Axis	O
I	O
(	O
First	O
,	O
Spitzer	O
,	O
Gibbon	O
,	O
&	O
Williams	O
,	O
1996	O
)	O
and	O
II	O
diagnoses	O
(	O
First	O
,	O
Gibbon	O
,	O
Spitzer	O
,	O
&	O
Williams	O
,	O
1995	O
).	O

Interrater	O
-	O
reliability	O
for	O
PTSD	B-DS
(	O
determined	O
from	O
a	O
random	O
selection	O
of	O
37	O
audiotapes	O
of	O
the	O
interviews	O
)	O
was	O
κ	O
=	O
0	O
.	O
95	O
.	O

Clinicians	O
also	O
determined	O
in	O
the	O
interview	O
what	O
the	O
patient	O
'	O
s	O
main	O
problem	O
was	O
and	O
assessed	O
physical	O
consequences	O
of	O
the	O
trauma	O
(	O
disability	O
,	O
chronic	O
pain	O
)	O
and	O
the	O
patients	O
'	O
treatment	O
and	O
trauma	O
history	O
(	O
adapted	O
from	O
the	O
Clinician	O
Administered	O
PTSD	B-DS
Scale	O
,	O
Blake	O
et	O
al	O
.,	O
1995	O
).	O

Patients	O
provided	O
demographic	O
information	O
.	O

Four	O
groups	O
of	O
potential	O
moderators	O
were	O
extracted	O
on	O
the	O
basis	O
of	O
the	O
literature	O
reviewed	O
above	O
.	O
1	O
.	O
Selection	O
criteria	O
used	O
in	O
some	O
previous	O
RCTs	O
:	O
male	O
sex	O
;	O
age	O
;	O
patient	O
does	O
not	O
meet	O
full	O
DSM	O
-	O
IV	O
criteria	O
(	O
American	O
Psychiatric	O
Association	O
,	O
1994	O
)	O
and	O
only	O
meets	O
ICD	O
-	O
10	O
(	O
World	O
Health	O
Organization	O
,	O
2010	O
)	O
PTSD	B-DS
criteria	O
;	O
PTSD	B-DS
is	O
not	O
the	O
main	O
problem	O
(	O
i	O
.	O
e	O
.,	O
another	O
disorder	O
is	O
so	O
severe	O
that	O
it	O
needs	O
principal	O
concurrent	O
treatment	O
in	O
its	O
own	O
right	O
,	O
e	O
.	O
g	O
.,	O
very	O
severe	O
depression	B-DS
or	O
agoraphobia	B-DS
);	O
borderline	B-DS
personality	I-DS
disorder	I-DS
;	O
current	O
substance	B-DS
abuse	I-DS
;	O
current	O
PTSD	B-DS
is	O
linked	O
to	O
multiple	O
traumas	O
;	O
history	O
of	O
childhood	B-DS
abuse	I-DS
;	O
no	O
memory	O
for	O
the	O
trauma	O
;	O
patient	O
had	O
a	O
previous	O
course	O
of	O
trauma	O
-	O
focused	O
CBT	O
for	O
PTSD	B-DS
.	O
2	O
.	O
Demographic	O
variables	O
:	O
ethnic	O
group	O
;	O
education	O
;	O
social	O
problems	O
(	O
defined	O
as	O
one	O
or	O
more	O
of	O
unemployment	O
,	O
financial	O
hardship	O
,	O
housing	O
problems	O
);	O
relationship	O
status	O
(	O
never	O
married	O
/	O
lived	O
with	O
partner	O
vs	O
.	O
married	O
,	O
cohabiting	O
,	O
widowed	O
or	O
divorced	O
);	O
ongoing	O
legal	O
proceedings	O
,	O
any	O
previous	O
treatment	O
for	O
PTSD	B-DS
.	O
3	O
.	O
Comorbidity	O
:	O
current	O
comorbid	O
anxiety	B-DS
disorder	I-DS
,	O
mood	B-DS
disorders	I-DS
,	O
other	O
axis	B-DS
1	I-DS
disorders	I-DS
,	O
personality	B-DS
disorder	I-DS
,	O
suicidal	O
ideation	O
,	O
taking	O
psychotropic	O
medication	O
;	O
physical	O
disability	O
resulting	O
from	O
trauma	O
,	O
chronic	O
pain	O
;	O
history	O
of	O
major	B-DS
depression	I-DS
,	O
substance	B-DS
dependence	I-DS
,	O
or	O
suicide	O
attempts	O
.	O
4	O
.	O
Aspects	O
of	O
trauma	O
history	O
:	O
Trauma	O
type	O
(	O
interpersonal	O
trauma	O
vs	O
other	O
);	O
trauma	O
involved	O
death	O
of	O
other	O
person	O
;	O
injured	O
in	O
trauma	O
;	O
months	O
since	O
main	O
trauma	O
;	O
history	O
of	O
other	O
traumas	O
;	O
total	O
number	O
of	O
traumas	O
experienced	O
.	O

Treatment	O
variables	O

Three	O
aspects	O
of	O
the	O
course	O
of	O
treatment	O
were	O
coded	O
from	O
the	O
session	O
notes	O
to	O
test	O
possible	O
effects	O
of	O
the	O
moderators	O
on	O
treatment	O
delivery	O
.	O
1	O
.	O
Dropout	O
:	O
This	O
was	O
defined	O
as	O
attending	O
less	O
than	O
8	O
sessions	O
,	O
unless	O
the	O
earlier	O
termination	O
was	O
determined	O
in	O
agreement	O
with	O
the	O
therapist	O
.	O

This	O
criterion	O
was	O
chosen	O
because	O
UK	O
treatment	O
guidelines	O
(	O
National	O
Institute	O
for	O
Health	O
and	O
Clinical	O
Excellence	O
,	O
2005	O
)	O
recommend	O
8	O
sessions	O
as	O
an	O
adequate	O
trial	O
of	O
trauma	O
-	O
focused	O
treatments	O
for	O
PTSD	B-DS
on	O
the	O
basis	O
of	O
prior	O
research	O
.	O
2	O
.	O
Attendance	O
:	O
Therapists	O
indicated	O
in	O
the	O
session	O
notes	O
whether	O
or	O
not	O
the	O
patient	O
was	O
often	O
late	O
or	O
missed	O
appointments	O
without	O
notifying	O
the	O
therapist	O
.	O
3	O
.	O
Trauma	O
focus	O
:	O
the	O
degree	O
to	O
which	O
treatment	O
followed	O
the	O
trauma	O
-	O
focused	O
PTSD	B-DS
treatment	O
protocol	O
,	O
as	O
above	O
.	O

Data	O
analysis	O

Measures	O
of	O
treatment	O
response	O

The	O
main	O
outcome	O
variable	O
was	O
the	O
change	O
in	O
PDS	O
scores	O
with	O
treatment	O
.	O

Several	O
further	O
measures	O
of	O
treatment	O
response	O
were	O
calculated	O
for	O
comparability	O
with	O
previous	O
studies	O
.	O

Reliable	O
improvement	O
and	O
exacerbation	O

Reliable	O
change	O
thresholds	O
for	O
the	O
PDS	O
were	O
calculated	O
by	O
Foa	O
et	O
al	O
.	O

(	O
2002	O
)	O
on	O
the	O
basis	O
of	O
the	O
retest	O
reliability	O
and	O
standard	O
deviation	O
of	O
the	O
scale	O
.	O

Reliable	O
improvement	O
and	O
exacerbation	O
are	O
decreases	O
/	O
increases	O
in	O
PDS	O
scores	O
of	O
greater	O
than	O
6	O
.	O
15	O
,	O
respectively	O
.	O

Clinically	O
significant	O
treatment	O
response	O

Clinical	O
significant	O
response	O
was	O
defined	O
as	O
in	O
Jacobson	O
and	O
Truax	O
(	O
1991	O
).	O

Patients	O
had	O
to	O
show	O
a	O
reliable	O
improvement	O
and	O
their	O
score	O
at	O
the	O
end	O
of	O
treatment	O
had	O
to	O
be	O
lower	O
than	O
the	O
halfway	O
point	O
between	O
2	O
SD	O
below	O
the	O
patients	O
'	O
scores	O
at	O
the	O
beginning	O
of	O
treatment	O
,	O
and	O
2	O
SD	O
above	O
the	O
mean	O
of	O
a	O
sample	O
of	O
466	O
traumatized	O
people	O
without	O
PTSD	B-DS
from	O
the	O
same	O
catchment	O
area	O
(	O
M	O
=	O
7	O
.	O
22	O
,	O
SD	O
=	O
7	O
.	O
75	O
),	O
i	O
.	O
e	O
.,	O
lower	O
than	O
19	O
.	O
775	O
.	O

This	O
criterion	O
is	O
similar	O
to	O
the	O
PDS	O
cut	O
-	O
offs	O
between	O
clinical	O
and	O
nonclinical	O
presentations	O
established	O
by	O
Ehring	O
,	O
Kleim	O
,	O
Clark	O
,	O
Foa	O
,	O
and	O
Ehlers	O
(	O
2007	O
)	O
on	O
the	O
basis	O
of	O
agreement	O
with	O
structured	O
diagnostic	O
interviews	O
.	O

Effect	O
size	O

Treatment	O
effect	O
sizes	O
for	O
changes	O
in	O
symptom	O
scores	O
between	O
the	O
pre	O
treatment	O
assessment	O
and	O
final	O
treatment	O
session	O
were	O
calculated	O
using	O
Cohen	O
'	O
s	O
d	O
statistic	O
(	O
Cohen	O
,	O
1988	O
).	O

As	O
other	O
studies	O
vary	O
in	O
whether	O
effect	O
sizes	O
are	O
reported	O
in	O
relation	O
to	O
pooled	O
pre	O
-	O
post	O
standard	O
deviations	O
,	O
or	O
pre	O
-	O
treatment	O
standard	O
deviations	O
,	O
we	O
report	O
both	O
for	O
comparison	O
.	O

Statistical	O
analysis	O

The	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
,	O
version	O
20	O
,	O
was	O
used	O
for	O
data	O
analysis	O
.	O

Hierarchical	O
linear	O
modeling	O
investigated	O
the	O
effect	O
of	O
candidate	O
moderators	O
and	O
therapist	O
effects	O
on	O
the	O
degree	O
of	O
improvement	O
in	O
the	O
PDS	O
with	O
treatment	O
,	O
following	O
guidelines	O
by	O
Heck	O
,	O
Thomas	O
,	O
and	O
Tabata	O
(	O
2010	O
).	O

This	O
analysis	O
uses	O
data	O
from	O
all	O
patients	O
.	O

All	O
variables	O
were	O
centered	O
for	O
this	O
analysis	O
(	O
Kraemer	O
et	O
al	O
.,	O
2002	O
).	O

At	O
Level	O
1	O
,	O
the	O
effects	O
of	O
repeated	O
observations	O
nested	O
within	O
patients	O
were	O
considered	O
.	O

Model	O
1	O
modeled	O
the	O
slope	O
of	O
improvement	O
in	O
PDS	O
scores	O
from	O
pre	O
treatment	O
to	O
post	O
treatment	O
to	O
follow	O
-	O
up	O
and	O
tested	O
random	O
slopes	O
and	O
intercepts	O
for	O
patients	O
.	O

Linear	O
and	O
quadratic	O
changes	O
in	O
PDS	O
scores	O
with	O
time	O
were	O
fitted	O
,	O
using	O
an	O
autoregressive	O
covariance	O
structure	O
at	O
Level	O
1	O
.	O

At	O
Level	O
2	O
,	O
patient	O
characteristics	O
that	O
may	O
influence	O
outcome	O
were	O
first	O
added	O
individually	O
(	O
because	O
of	O
some	O
missing	O
data	O
on	O
some	O
of	O
the	O
variables	O
)	O
to	O
the	O
model	O
to	O
test	O
for	O
main	O
effects	O
on	O
PDS	O
scores	O
(	O
indicating	O
nonspecific	O
prediction	O
of	O
symptom	O
severity	O
,	O
Kraemer	O
et	O
al	O
.,	O
2002	O
)	O
and	O
interactions	O
with	O
the	O
slope	O
of	O
improvement	O
(	O
moderator	O
effects	O
,	O
Kraemer	O
et	O
al	O
.,	O
2002	O
).	O

Next	O
,	O
variables	O
that	O
showed	O
significant	O
interactions	O
were	O
combined	O
into	O
an	O
overall	O
Model	O
2	O
to	O
determine	O
unique	O
moderators	O
of	O
slope	O
of	O
improvement	O
.	O

At	O
Level	O
3	O
(	O
therapist	O
effects	O
),	O
random	O
slopes	O
and	O
intercepts	O
for	O
therapists	O
were	O
included	O
in	O
Model	O
3	O
.	O

In	O
Model	O
4	O
,	O
the	O
two	O
measures	O
of	O
therapist	O
experience	O
were	O
added	O
,	O
trainee	O
versus	O
staff	O
therapist	O
and	O
experienced	O
versus	O
inexperienced	O
in	O
delivering	O
CT	O
-	O
PTSD	B-DS
.	O

Results	O

Overall	O
effectiveness	O
of	O
treatment	O

There	O
was	O
no	O
significant	O
change	O
in	O
PTSD	B-DS
symptoms	O
during	O
the	O
wait	O
period	O
between	O
assessment	O
and	O
treatment	O
,	O
M	O
=	O
97	O
.	O
1	O
days	O
,	O
SD	O
=	O
77	O
.	O
0	O
,	O
PDS	O
scores	O
M	O
=	O
33	O
.	O
88	O
,	O
SD	O
=	O
8	O
.	O
67	O
to	O
M	O
=	O
33	O
.	O
15	O
,	O
SD	O
=	O
9	O
.	O
25	O
,	O
F	O
(	O
1	O
,	O
275	O
)	O
=	O
2	O
.	O
71	O
,	O
p	O
=	O
.	O
101	O
,	O
d	O
=	O
0	O
.	O
08	O
.	O

Table	O
2	O
shows	O
the	O
PTSD	B-DS
symptom	O
scores	O
(	O
PDS	O
)	O
at	O
initial	O
assessment	O
and	O
the	O
last	O
treatment	O
session	O
for	O
the	O
intent	O
-	O
to	O
-	O
treat	O
sample	O
of	O
330	O
patients	O
(	O
see	O
also	O
Fig	O
.	O
2	O
).	O

Patients	O
received	O
a	O
mean	O
of	O
12	O
.	O
57	O
sessions	O
(	O
SD	O
=	O
6	O
.	O
51	O
).	O

Patients	O
showed	O
very	O
large	O
improvement	O
in	O
PTSD	B-DS
symptom	O
severity	O
with	O
treatment	O
.	O

Two	O
hundred	O
sixty	O
patients	O
(	O
78	O
.	O
8	O
%)	O
showed	O
a	O
reliable	O
improvement	O
(	O
Foa	O
et	O
al	O
.,	O
2002	O
).	O

The	O
mean	O
percent	O
change	O
in	O
PTSD	B-DS
symptoms	O
was	O
50	O
.	O
4	O
%,	O
SD	O
=	O
40	O
.	O
38	O
.	O

The	O
majority	O
of	O
patients	O
(	O
n	O
=	O
189	O
,	O
57	O
.	O
3	O
%)	O
showed	O
a	O
clinically	O
significant	O
change	O
.	O

Clinically	O
significant	O
change	O
was	O
associated	O
with	O
greater	O
trauma	O
focus	O
of	O
the	O
sessions	O
,	O
M	O
=	O
1	O
.	O
31	O
,	O
SD	O
=	O
0	O
.	O
37	O
versus	O
M	O
=	O
1	O
.	O
41	O
,	O
SD	O
=	O
0	O
.	O
42	O
,	O
F	O
(	O
1	O
,	O
322	O
)	O
=	O
5	O
.	O
51	O
,	O
p	O
=	O
.	O
020	O
,	O
d	O
=	O
0	O
.	O
17	O
.	O

In	O
treatment	O
completers	O
,	O
PDS	O
scores	O
decreased	O
from	O
M	O
=	O
33	O
.	O
83	O
,	O
SD	O
=	O
8	O
.	O
67	O
to	O
M	O
=	O
15	O
.	O
18	O
,	O
SD	O
=	O
13	O
.	O
65	O
,	O
d	O
=	O
1	O
.	O
63	O
for	O
pooled	O
SD	O
and	O
d	O
=	O
2	O
.	O
15	O
for	O
pre	O
-	O
treatment	O
SD	O
,	O
and	O
the	O
mean	O
change	O
in	O
PDS	O
scores	O
was	O
57	O
.	O
95	O
%,	O
SD	O
=	O
34	O
.	O
95	O
.	O

A	O
reliable	O
change	O
in	O
PDS	O
scores	O
was	O
observed	O
in	O
240	O
(	O
84	O
.	O
5	O
%)	O
of	O
the	O
completers	O
,	O
and	O
a	O
clinically	O
significant	O
change	O
in	O
185	O
(	O
65	O
.	O
1	O
%).	O

Analysis	O
of	O
dropouts	O
and	O
attendance	O

The	O
overall	O
dropout	O
rate	O
was	O
13	O
.	O
9	O
%,	O
46	O
of	O
330	O
patients	O
.	O

Of	O
these	O
,	O
6	O
patients	O
(	O
13	O
%)	O
dropped	O
out	O
after	O
1	O
session	O
,	O
11	O
(	O
23	O
.	O
9	O
%)	O
after	O
2	O
sessions	O
,	O
8	O
(	O
17	O
.	O
4	O
%)	O
after	O
3	O
sessions	O
,	O
4	O
(	O
8	O
.	O
7	O
%)	O
after	O
4	O
sessions	O
,	O
7	O
(	O
15	O
.	O
2	O
%)	O
after	O
5	O
sessions	O
,	O
4	O
(	O
8	O
.	O
7	O
%)	O
after	O
6	O
sessions	O
,	O
and	O
6	O
(	O
13	O
.	O
0	O
%)	O
after	O
7	O
sessions	O
.	O

Patients	O
who	O
dropped	O
out	O
had	O
waited	O
longer	O
for	O
treatment	O
t	O
(	O
327	O
)	O
=	O
4	O
.	O
89	O
,	O
p	O
=	O
.	O
005	O
.	O

Among	O
dropouts	O
,	O
only	O
8	O
.	O
7	O
%	O
(	O
4	O
/	O
46	O
)	O
showed	O
a	O
clinically	O
significant	O
treatment	O
response	O
,	O
compared	O
to	O
66	O
.	O
9	O
%	O
(	O
190	O
/	O
94	O
)	O
of	O
treatment	O
completers	O
,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
55	O
.	O
36	O
,	O
p	O
<	O
.	O
001	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
the	O
patients	O
(	O
n	O
=	O
71	O
)	O
were	O
classified	O
as	O
unreliable	O
attenders	O
.	O

This	O
variable	O
was	O
independent	O
of	O
dropout	O
status	O
,	O
C	O
=	O
0	O
.	O
049	O
.	O

Unreliable	O
attenders	O
were	O
less	O
likely	O
to	O
show	O
clinically	O
significant	O
change	O
than	O
patients	O
who	O
attended	O
regularly	O
,	O
42	O
.	O
3	O
%	O
versus	O
63	O
.	O
3	O
%,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
10	O
.	O
21	O
,	O
p	O
=	O
.	O
001	O
.	O

Symptom	O
exacerbation	O

Fourteen	O
patients	O
(	O
4	O
.	O
3	O
%)	O
had	O
reliable	O
increases	O
on	O
the	O
PDS	O
between	O
initial	O
assessment	O
and	O
the	O
end	O
of	O
treatment	O
.	O

For	O
10	O
of	O
the	O
14	O
patients	O
(	O
71	O
.	O
4	O
%),	O
the	O
reliable	O
increase	O
had	O
already	O
occurred	O
during	O
the	O
wait	O
period	O
between	O
the	O
initial	O
assessment	O
and	O
the	O
first	O
session	O
.	O

Thus	O
,	O
only	O
4	O
(	O
1	O
.	O
2	O
%)	O
patients	O
showed	O
reliable	O
exacerbation	O
in	O
symptom	O
severity	O
during	O
treatment	O
.	O

Improvement	O
in	O
other	O
symptoms	O

Table	O
1	O
shows	O
the	O
changes	O
in	O
depressive	O
(	O
BDI	O
)	O
and	O
anxiety	B-DS
(	O
BAI	O
)	O
symptoms	O
with	O
treatment	O
.	O

Patients	O
showed	O
large	O
improvement	O
in	O
these	O
secondary	O
outcomes	O
.	O

Stability	O
of	O
treatment	O
effects	O

Two	O
thirds	O
of	O
the	O
patients	O
(	O
n	O
=	O
220	O
)	O
provided	O
follow	O
-	O
up	O
data	O
.	O

The	O
mean	O
duration	O
of	O
the	O
follow	O
-	O
up	O
was	O
280	O
.	O
1	O
days	O
,	O
SD	O
=	O
177	O
.	O
7	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
symptom	O
scores	O
between	O
the	O
end	O
of	O
treatment	O
and	O
follow	O
-	O
up	O
,	O
PDS	O
:	O
F	O
(	O
1	O
,	O
217	O
)	O
=	O
1	O
.	O
01	O
,	O
p	O
=	O
.	O
317	O
,	O
η2	O
=	O
0	O
.	O
005	O
;	O
BDI	O
:	O
F	O
(	O
1	O
,	O
211	O
)	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
.	O
425	O
,	O
η2	O
=	O
0	O
.	O
003	O
;	O
BAI	O
,	O
time	O
effect	O
F	O
(	O
1	O
,	O
212	O
)	O
=	O
0	O
.	O
28	O
,	O
p	O
=	O
.	O
595	O
,	O
η2	O
=	O
0	O
.	O
001	O
.	O

Moderators	O
of	O
treatment	O
response	O

To	O
reduce	O
the	O
number	O
of	O
potential	O
predictors	O
,	O
candidate	O
moderators	O
were	O
first	O
considered	O
individually	O
(	O
see	O
Table	O
2	O
).	O

Few	O
of	O
the	O
RCT	O
selection	O
criteria	O
,	O
comorbidity	O
,	O
trauma	O
and	O
demographic	O
characteristics	O
selected	O
from	O
the	O
literature	O
predicted	O
outcome	O
.	O

Significant	O
univariate	O
moderation	O
effects	O
were	O
found	O
for	O
8	O
predictors	O
:	O
PTSD	B-DS
is	O
not	O
the	O
main	O
problem	O
,	O
patient	O
needs	O
treatment	O
for	O
multiple	O
traumas	O
,	O
social	O
problems	O
,	O
relationship	O
status	O
,	O
comorbid	O
mood	B-DS
disorder	I-DS
,	O
history	O
of	O
suicide	O
attempts	O
,	O
history	O
of	O
substance	B-DS
dependence	I-DS
,	O
longer	O
time	O
since	O
the	O
main	O
trauma	O
were	O
associated	O
with	O
somewhat	O
less	O
improvement	O
.	O

Several	O
other	O
variables	O
predicted	O
a	O
greater	O
overall	O
severity	O
of	O
PTSD	B-DS
symptoms	O
,	O
but	O
not	O
the	O
slope	O
of	O
improvement	O
(	O
non	O
-	O
specific	O
predictors	O
).	O

These	O
included	O
meeting	O
DSM	O
-	O
IV	O
criteria	O
for	O
PTSD	B-DS
,	O
aspects	O
of	O
comorbidity	O
(	O
current	O
substance	B-DS
abuse	I-DS
,	O
suicidal	O
ideation	O
,	O
axis	B-DS
1	I-DS
disorder	I-DS
other	O
than	O
anxiety	B-DS
or	O
mood	B-DS
disorder	I-DS
,	O
comorbid	O
personality	B-DS
disorder	I-DS
,	O
chronic	O
pain	O
,	O
physical	O
disability	O
due	O
to	O
the	O
trauma	O
,	O
history	O
of	O
major	B-DS
depression	I-DS
),	O
taking	O
psychotropic	O
medication	O
,	O
and	O
a	O
higher	O
level	O
of	O
education	O
.	O

Table	O
3	O
shows	O
the	O
results	O
of	O
the	O
hierarchical	O
modeling	O
analyses	O
for	O
four	O
models	O
of	O
increasing	O
complexity	O
,	O
which	O
are	O
shown	O
in	O
separate	O
columns	O
.	O

Overall	O
model	O
fits	O
and	O
random	O
effects	O
for	O
patients	O
and	O
therapists	O
are	O
shown	O
at	O
the	O
top	O
of	O
the	O
table	O
,	O
and	O
fixed	O
effects	O
for	O
candidate	O
moderators	O
and	O
therapist	O
variables	O
at	O
the	O
bottom	O
.	O

Model	O
1	O
(	O
Level	O
1	O
,	O
random	O
slopes	O
and	O
intercepts	O
for	O
patients	O
and	O
improvement	O
in	O
PDS	O
scores	O
from	O
pre	O
treatment	O
to	O
post	O
treatment	O
to	O
follow	O
-	O
up	O
and	O
)	O
showed	O
highly	O
significant	O
linear	O
and	O
quadratic	O
changes	O
in	O
PDS	O
scores	O
across	O
assessment	O
points	O
,	O
indicating	O
a	O
steep	O
decrease	O
in	O
PTSD	B-DS
symptoms	O
with	O
treatment	O
,	O
which	O
flattened	O
out	O
during	O
follow	O
-	O
up	O
.	O

Random	O
slopes	O
and	O
intercepts	O
for	O
patients	O
were	O
also	O
highly	O
significant	O
.	O

Model	O
2	O
added	O
patient	O
characteristics	O
at	O
Level	O
2	O
;	O
analysis	O
was	O
restricted	O
to	O
the	O
8	O
candidate	O
moderators	O
that	O
showed	O
univariate	O
moderation	O
effects	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
unique	O
moderation	O
effects	O
were	O
found	O
for	O
needing	O
treatment	O
for	O
multiple	O
traumas	O
and	O
social	O
problems	O
.	O

There	O
was	O
a	O
trend	O
for	O
relationship	O
status	O
.	O

Comorbid	O
mood	B-DS
disorders	I-DS
and	O
social	O
problems	O
were	O
nonspecific	O
predictors	O
,	O
i	O
.	O
e	O
.,	O
were	O
associated	O
with	O
higher	O
scores	O
both	O
at	O
the	O
beginning	O
and	O
end	O
of	O
treatment	O
.	O

All	O
other	O
effects	O
were	O
nonsignificant	O
.	O

Therapist	O
effects	O

In	O
Model	O
3	O
(	O
Table	O
3	O
)	O
random	O
intercepts	O
and	O
slopes	O
were	O
added	O
for	O
therapists	O
.	O

There	O
were	O
no	O
significant	O
random	O
therapist	O
effects	O
,	O
and	O
the	O
results	O
for	O
patient	O
characteristics	O
were	O
identical	O
to	O
Model	O
2	O
.	O

Model	O
4	O
added	O
two	O
aspects	O
of	O
therapist	O
experience	O
(	O
staff	O
therapist	O
,	O
experience	O
with	O
CT	O
-	O
PTSD	B-DS
)	O
to	O
the	O
prediction	O
.	O

There	O
was	O
a	O
trend	O
for	O
inexperienced	O
therapists	O
to	O
achieve	O
somewhat	O
less	O
good	O
outcome	O
.	O

Association	O
of	O
moderators	O
with	O
treatment	O
variables	O

Patients	O
who	O
needed	O
treatment	O
for	O
multiple	O
trauma	O
were	O
more	O
likely	O
to	O
attend	O
irregularly	O
than	O
those	O
who	O
were	O
treated	O
for	O
one	O
or	O
two	O
traumas	O
,	O
33	O
.	O
3	O
%	O
versus	O
19	O
.	O
6	O
%,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
4	O
.	O
31	O
,	O
p	O
=	O
.	O
038	O
,	O
but	O
did	O
not	O
differ	O
in	O
dropout	O
rates	O
or	O
number	O
of	O
treatment	O
sessions	O
.	O

Their	O
treatment	O
was	O
less	O
trauma	O
-	O
focused	O
than	O
treatment	O
of	O
other	O
patients	O
,	O
M	O
=	O
1	O
.	O
46	O
(	O
SD	O
=	O
0	O
.	O
37	O
)	O
versus	O
M	O
=	O
1	O
.	O
33	O
(	O
SD	O
=	O
0	O
.	O
40	O
),	O
F	O
(	O
1	O
,	O
322	O
)	O
=	O
4	O
.	O
28	O
,	O
p	O
=	O
.	O
039	O
,	O
η2	O
=	O
0	O
.	O
013	O
.	O

Patients	O
who	O
had	O
social	O
problems	O
were	O
more	O
likely	O
to	O
drop	O
out	O
of	O
treatment	O
,	O
18	O
.	O
5	O
%	O
versus	O
7	O
.	O
2	O
%,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
327	O
)	O
=	O
8	O
.	O
54	O
,	O
p	O
=	O
.	O
003	O
.	O

Their	O
treatment	O
tended	O
to	O
be	O
less	O
trauma	O
-	O
focused	O
than	O
treatment	O
of	O
other	O
patients	O
,	O
M	O
=	O
1	O
.	O
39	O
(	O
SD	O
=	O
0	O
.	O
42	O
)	O
versus	O
M	O
=	O
1	O
.	O
30	O
(	O
SD	O
=	O
0	O
.	O
36	O
),	O
F	O
(	O
1	O
,	O
319	O
)	O
=	O
3	O
.	O
432	O
,	O
p	O
=	O
.	O
065	O
,	O
η2	O
=	O
0	O
.	O
011	O
.	O

Associations	O
with	O
unreliable	O
attendance	O
(	O
p	O
.	O
=	O
0	O
.	O
105	O
)	O
and	O
lower	O
number	O
of	O
sessions	O
(	O
p	O
=	O
.	O
094	O
)	O
failed	O
to	O
reach	O
significance	O
.	O

Patients	O
were	O
more	O
likely	O
to	O
drop	O
out	O
if	O
the	O
therapist	O
was	O
inexperienced	O
in	O
delivering	O
CT	O
-	O
PTSD	B-DS
,	O
18	O
.	O
1	O
%	O
versus	O
10	O
.	O
3	O
%,	O
χ2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
4	O
.	O
15	O
,	O
p	O
=	O
.	O
042	O
.	O

Discussion	O

The	O
study	O
supports	O
the	O
effectiveness	O
of	O
CT	O
for	O
PTSD	B-DS
in	O
routine	O
clinical	O
practice	O
.	O

It	O
shows	O
that	O
this	O
treatment	O
can	O
be	O
successfully	O
implemented	O
in	O
a	O
National	O
Health	O
Service	O
clinic	O
serving	O
an	O
ethnically	O
mixed	O
urban	O
catchment	O
area	O
,	O
with	O
therapists	O
who	O
ranged	O
in	O
previous	O
experience	O
in	O
CBT	O
and	O
in	O
treating	O
PTSD	B-DS
.	O

The	O
clinic	O
'	O
s	O
catchment	O
area	O
was	O
clearly	O
defined	O
,	O
referral	O
was	O
by	O
local	O
family	O
doctors	O
and	O
community	O
mental	O
health	O
teams	O
,	O
and	O
a	O
consecutive	O
sample	O
was	O
assessed	O
,	O
supporting	O
the	O
representativeness	O
of	O
the	O
results	O
.	O

The	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
showed	O
very	O
large	O
effect	O
sizes	O
for	O
improvement	O
in	O
PTSD	B-DS
symptoms	O
with	O
treatment	O
.	O

The	O
effect	O
size	O
estimates	O
are	O
conservative	O
as	O
training	O
cases	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
mean	O
improvement	O
in	O
PTSD	B-DS
symptoms	O
was	O
large	O
,	O
50	O
.	O
3	O
%	O
for	O
the	O
intent	O
-	O
to	O
-	O
treat	O
sample	O
,	O
and	O
57	O
.	O
8	O
%	O
for	O
completers	O
,	O
and	O
the	O
majority	O
of	O
patients	O
showed	O
clinically	O
significant	O
change	O
,	O
57	O
.	O
3	O
%	O
and	O
65	O
.	O
1	O
%	O
respectively	O
.	O

Depression	B-DS
and	O
general	O
anxiety	B-DS
symptoms	O
also	O
showed	O
substantial	O
improvement	O
with	O
treatment	O
.	O

Treatment	O
was	O
well	O
tolerated	O
.	O

The	O
overall	O
dropout	O
rate	O
of	O
13	O
.	O
9	O
%	O
was	O
low	O
,	O
despite	O
the	O
fact	O
that	O
the	O
clinic	O
served	O
a	O
catchment	O
area	O
characterized	O
by	O
high	O
social	O
deprivation	O
and	O
high	O
mobility	O
and	O
that	O
some	O
of	O
the	O
therapists	O
were	O
inexperienced	O
in	O
delivering	O
the	O
treatment	O
.	O

It	O
is	O
below	O
that	O
observed	O
in	O
many	O
RCTs	O
(	O
e	O
.	O
g	O
.,	O
34	O
%	O
Resick	O
et	O
al	O
.,	O
2002	O
;	O
43	O
%	O
Power	O
et	O
al	O
.,	O
2002	O
;	O
34	O
%	O
Foa	O
et	O
al	O
.,	O
2005	O
;	O
38	O
%	O
Schnurr	O
et	O
al	O
,	O
2007	O
;	O
26	O
%	O
Galovski	O
,	O
Blain	O
,	O
Mott	O
,	O
Elwood	O
,	O
&	O
Houle	O
,	O
2012	O
)	O
and	O
effectiveness	O
studies	O
of	O
trauma	O
-	O
focused	O
PTSD	B-DS
treatments	O
(	O
e	O
.	O
g	O
.,	O
36	O
%	O
Levitt	O
et	O
al	O
.,	O
2007	O
;	O
24	O
%	O
and	O
32	O
%;	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
).	O

Although	O
limited	O
conclusions	O
can	O
be	O
drawn	O
from	O
comparing	O
dropout	O
rates	O
in	O
different	O
samples	O
across	O
countries	O
with	O
different	O
health	O
systems	O
,	O
it	O
appears	O
safe	O
to	O
conclude	O
that	O
the	O
low	O
dropout	O
rates	O
support	O
the	O
acceptability	O
of	O
CT	O
-	O
PTSD	B-DS
to	O
patients	O
.	O

This	O
study	O
further	O
found	O
that	O
patients	O
who	O
dropped	O
out	O
and	O
those	O
who	O
attended	O
irregularly	O
had	O
poorer	O
outcomes	O
,	O
so	O
that	O
limiting	O
dropout	O
rates	O
is	O
likely	O
to	O
improve	O
the	O
overall	O
effectiveness	O
of	O
interventions	O
.	O

Consistent	O
with	O
previous	O
studies	O
(	O
Foa	O
et	O
al	O
.,	O
2002	O
;	O
Hackmann	O
et	O
al	O
.,	O
2004	O
),	O
symptom	O
exacerbations	O
were	O
only	O
found	O
in	O
a	O
small	O
minority	O
of	O
patients	O
.	O

Interestingly	O
,	O
the	O
results	O
indicated	O
that	O
the	O
exacerbation	O
mainly	O
occurred	O
between	O
assessment	O
and	O
the	O
start	O
of	O
treatment	O
.	O

This	O
result	O
is	O
similar	O
to	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
who	O
found	O
that	O
deterioration	O
was	O
more	O
common	O
in	O
the	O
wait	O
period	O
than	O
during	O
therapy	O
.	O

For	O
the	O
majority	O
of	O
patients	O
,	O
such	O
symptom	O
exacerbations	O
may	O
thus	O
reflect	O
the	O
influence	O
of	O
other	O
factors	O
such	O
as	O
new	O
trauma	O
or	O
additional	O
stressors	O
rather	O
than	O
negative	O
effects	O
of	O
treatment	O
per	O
se	O
.	O

This	O
raises	O
the	O
question	O
of	O
what	O
effect	O
waiting	O
for	O
treatment	O
may	O
have	O
on	O
the	O
probability	O
of	O
engagement	O
with	O
treatment	O
.	O

The	O
average	O
waiting	O
time	O
of	O
about	O
3	O
months	O
was	O
relatively	O
short	O
for	O
psychological	O
services	O
in	O
the	O
UK	O
National	O
Health	O
Service	O
at	O
the	O
time	O
of	O
the	O
study	O
.	O

Overall	O
,	O
symptom	O
scores	O
were	O
stable	O
over	O
the	O
waiting	O
period	O
.	O

Some	O
patients	O
waited	O
longer	O
,	O
partly	O
due	O
to	O
the	O
availability	O
of	O
therapists	O
and	O
partly	O
due	O
to	O
patient	O
-	O
determined	O
factors	O
such	O
as	O
scheduled	O
surgery	O
/	O
physical	O
rehabilitation	O
,	O
work	O
schedules	O
,	O
travel	O
or	O
childbirth	O
.	O

It	O
is	O
unlikely	O
that	O
the	O
wait	O
for	O
treatment	O
contributed	O
to	O
the	O
relatively	O
low	O
dropout	O
rates	O
observed	O
in	O
this	O
study	O
as	O
patients	O
who	O
dropped	O
out	O
had	O
waited	O
longer	O
than	O
completers	O
.	O

This	O
suggests	O
that	O
it	O
is	O
desirable	O
to	O
reduce	O
waiting	O
times	O
to	O
help	O
reduce	O
the	O
risk	O
of	O
symptom	O
deterioration	O
and	O
dropouts	O
.	O

Effect	O
sizes	O
in	O
the	O
present	O
study	O
were	O
comparable	O
to	O
those	O
obtained	O
by	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
with	O
the	O
same	O
treatment	O
in	O
an	O
unselected	O
sample	O
of	O
patients	O
with	O
very	O
chronic	O
PTSD	B-DS
.	O

The	O
intent	O
-	O
to	O
-	O
treat	O
effect	O
sizes	O
were	O
somewhat	O
smaller	O
than	O
those	O
observed	O
in	O
some	O
previous	O
RCTs	O
of	O
CT	O
-	O
PTSD	B-DS
(	O
Ehlers	O
et	O
al	O
.,	O
2003	O
,	O
2005	O
),	O
but	O
similar	O
to	O
or	O
larger	O
than	O
those	O
observed	O
in	O
intent	O
-	O
to	O
-	O
treat	O
analyses	O
in	O
other	O
RCTs	O
of	O
trauma	O
-	O
focused	O
cognitive	O
behavior	O
therapy	O
(	O
Bryant	O
et	O
al	O
.,	O
2003	O
;	O
Resick	O
et	O
al	O
.,	O
2002	O
;	O
Schnurr	O
et	O
al	O
,	O
2007	O
).	O

Given	O
that	O
the	O
study	O
reports	O
on	O
a	O
consecutive	O
intent	O
-	O
to	O
-	O
treat	O
sample	O
with	O
a	O
wide	O
range	O
of	O
traumas	O
from	O
an	O
ethnically	O
diverse	O
and	O
socially	O
deprived	O
catchment	O
area	O
,	O
and	O
patients	O
were	O
treated	O
by	O
both	O
trainees	O
and	O
experienced	O
clinicians	O
,	O
the	O
outcomes	O
can	O
be	O
considered	O
as	O
encouraging	O
.	O

The	O
moderator	O
analysis	O
showed	O
that	O
many	O
of	O
the	O
criteria	O
that	O
have	O
sometimes	O
been	O
used	O
to	O
exclude	O
patients	O
from	O
RCTs	O
were	O
not	O
related	O
to	O
poorer	O
outcome	O
.	O

The	O
only	O
exceptions	O
were	O
that	O
patients	O
who	O
needed	O
treatment	O
for	O
multiple	O
traumas	O
and	O
those	O
for	O
whom	O
PTSD	B-DS
was	O
not	O
the	O
main	O
clinical	O
problem	O
showed	O
somewhat	O
less	O
improvement	O
.	O

Overall	O
the	O
results	O
suggest	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
patients	O
who	O
do	O
not	O
meet	O
all	O
inclusion	O
criteria	O
for	O
RCTs	O
and	O
should	O
not	O
be	O
withheld	O
from	O
these	O
patients	O
(	O
see	O
also	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
).	O

Like	O
other	O
studies	O
of	O
TF	O
-	O
CBT	O
programs	O
(	O
e	O
.	O
g	O
.,	O
Richardson	O
et	O
al	O
.,	O
2011	O
;	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
),	O
this	O
study	O
found	O
few	O
other	O
moderators	O
of	O
treatment	O
response	O
,	O
further	O
indicating	O
that	O
CT	O
-	O
PTSD	B-DS
is	O
effective	O
in	O
a	O
wide	O
range	O
of	O
patients	O
.	O

Most	O
demographic	O
variables	O
such	O
as	O
sex	O
,	O
age	O
,	O
ethnic	O
group	O
or	O
education	O
level	O
were	O
unrelated	O
to	O
treatment	O
response	O
.	O

This	O
is	O
consistent	O
with	O
the	O
results	O
of	O
several	O
other	O
studies	O
(	O
e	O
.	O
g	O
.,	O
Richardson	O
et	O
al	O
..,	O
2011	O
;	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
),	O
although	O
some	O
studies	O
reported	O
poorer	O
outcome	O
or	O
larger	O
drop	O
-	O
out	O
rates	O
for	O
men	B-OG
(	O
Blain	O
et	O
al	O
.,	O
2010	O
).	O

It	O
remains	O
to	O
be	O
tested	O
whether	O
the	O
differences	O
in	O
results	O
are	O
due	O
to	O
sample	O
differences	O
or	O
differences	O
in	O
procedures	O
.	O

With	O
the	O
exception	O
of	O
mood	B-DS
disorders	I-DS
,	O
current	O
comorbidity	O
did	O
not	O
moderate	O
outcome	O
,	O
but	O
acted	O
as	O
a	O
nonspecific	O
predictor	O
of	O
outcome	O
only	O
.	O

High	O
levels	O
of	O
depression	B-DS
were	O
also	O
associated	O
with	O
less	O
favorable	O
outcome	O
in	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
and	O
Tarrier	O
et	O
al	O
.	O

(	O
2000	O
),	O
but	O
not	O
in	O
other	O
studies	O
of	O
TF	O
-	O
CBT	O
(	O
Ehlers	O
et	O
al	O
.,	O
2005	O
;	O
Richardson	O
et	O
al	O
.,	O
2011	O
;	O
van	O
Minnen	O
et	O
al	O
.,	O
2002	O
).	O

One	O
possible	O
explanation	O
for	O
the	O
discrepant	O
results	O
may	O
be	O
the	O
range	O
of	O
depression	B-DS
severity	O
included	O
in	O
the	O
studies	O
.	O

The	O
studies	O
that	O
reported	O
negative	O
findings	O
had	O
lower	O
mean	O
depression	B-DS
scores	O
than	O
those	O
finding	O
an	O
effect	O
of	O
depression	B-DS
.	O

Comorbid	O
depression	B-DS
may	O
only	O
hamper	O
progress	O
in	O
therapy	O
if	O
it	O
is	O
so	O
severe	O
that	O
it	O
affects	O
daily	O
activity	O
levels	O
and	O
motivation	O
to	O
engage	O
in	O
the	O
therapy	O
assignments	O
.	O

The	O
lack	O
of	O
a	O
moderating	O
effect	O
of	O
comorbid	O
personality	B-DS
disorders	I-DS
including	O
borderline	B-DS
personality	I-DS
disorder	I-DS
is	O
noteworthy	O
and	O
consistent	O
with	O
other	O
studies	O
(	O
Clarke	O
et	O
al	O
.,	O
2008	O
;	O
Feeny	O
et	O
al	O
.,	O
2002	O
).	O

Longer	O
time	O
since	O
the	O
trauma	O
,	O
a	O
history	O
of	O
suicide	O
attempts	O
or	O
substance	B-DS
dependence	I-DS
,	O
social	O
problems	O
,	O
and	O
relationship	O
status	O
(	O
never	O
having	O
been	O
married	O
or	O
lived	O
with	O
a	O
partner	O
)	O
were	O
associated	O
with	O
a	O
somewhat	O
less	O
favorable	O
treatment	O
response	O
.	O

The	O
effect	O
of	O
past	O
suicide	O
attempts	O
replicates	O
Tarrier	O
et	O
al	O
.'	O
s	O
(	O
2000	O
)	O
findings	O
.	O

These	O
characteristics	O
,	O
and	O
possibly	O
very	O
high	O
levels	O
of	O
depression	B-DS
,	O
may	O
characterize	O
a	O
group	O
of	O
patients	O
with	O
high	O
levels	O
of	O
demoralization	O
and	O
hopelessness	O
,	O
who	O
may	O
not	O
have	O
been	O
fully	O
engaged	O
in	O
treatment	O
by	O
their	O
therapists	O
.	O

Time	O
since	O
the	O
trauma	O
has	O
shown	O
an	O
inconsistent	O
pattern	O
of	O
associations	O
with	O
outcome	O
.	O

RCTs	O
have	O
generally	O
not	O
found	O
an	O
effect	O
(	O
e	O
.	O
g	O
.,	O
Ehlers	O
et	O
al	O
.,	O
2005	O
;	O
Resick	O
et	O
al	O
.,	O
2002	O
),	O
although	O
Schnurr	O
et	O
al	O
(	O
2007	O
)	O
concluded	O
that	O
the	O
modest	O
treatment	O
gains	O
observed	O
in	O
their	O
study	O
may	O
be	O
related	O
to	O
the	O
extreme	O
chronicity	O
of	O
their	O
sample	O
(	O
M	O
=	O
23	O
years	O
).	O

Like	O
the	O
current	O
study	O
,	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
also	O
found	O
that	O
longer	O
duration	O
since	O
the	O
trauma	O
was	O
associated	O
with	O
less	O
favorable	O
outcome	O
.	O

The	O
differences	O
in	O
results	O
may	O
also	O
be	O
linked	O
to	O
the	O
wide	O
range	O
of	O
traumas	O
included	O
in	O
the	O
latter	O
samples	O
(	O
for	O
example	O
,	O
the	O
inclusion	O
of	O
traumatic	O
death	O
of	O
significant	O
others	O
),	O
or	O
the	O
long	O
-	O
term	O
effects	O
of	O
the	O
trauma	O
and	O
/	O
or	O
PTSD	B-DS
symptoms	O
on	O
important	O
life	O
areas	O
such	O
as	O
employment	O
,	O
significant	O
relationships	O
or	O
other	O
resources	O
(	O
Hobfoll	O
,	O
2002	O
).	O

The	O
present	O
sample	O
,	O
like	O
Duffy	O
et	O
al	O
.'	O
s	O
(	O
2007	O
)	O
included	O
a	O
high	O
percentage	O
of	O
patients	O
with	O
long	O
-	O
term	O
loss	O
of	O
resources	O
and	O
significant	O
relationships	O
.	O

Social	O
problems	O
and	O
social	O
isolation	O
may	O
make	O
it	O
harder	O
to	O
overcome	O
PTSD	B-DS
and	O
may	O
also	O
create	O
additional	O
ongoing	O
stress	O
(	O
see	O
also	O
Galovski	O
et	O
al	O
.,	O
2012	O
).	O

The	O
result	O
that	O
patients	O
who	O
had	O
never	O
lived	O
with	O
a	O
partner	O
had	O
somewhat	O
worse	O
outcome	O
may	O
also	O
point	O
to	O
a	O
role	O
of	O
poor	O
social	O
support	O
and	O
interpersonal	O
skills	O
in	O
the	O
recovery	O
from	O
PTSD	B-DS
(	O
see	O
also	O
Cloitre	O
,	O
Koenen	O
,	O
Cohen	O
,	O
&	O
Han	O
,	O
2002	O
).	O

When	O
the	O
significant	O
moderators	O
were	O
considered	O
together	O
in	O
a	O
multivariate	O
analysis	O
,	O
only	O
social	O
problems	O
and	O
needing	O
treatment	O
for	O
multiple	O
traumas	O
emerged	O
as	O
unique	O
moderators	O
of	O
outcome	O
.	O

The	O
associations	O
of	O
these	O
moderators	O
with	O
treatment	O
characteristics	O
suggest	O
a	O
dose	O
–	O
response	O
effect	O
.	O

Treatment	O
was	O
less	O
trauma	O
-	O
focused	O
for	O
these	O
patients	O
and	O
significant	O
time	O
in	O
the	O
sessions	O
was	O
used	O
to	O
address	O
other	O
important	O
problems	O
such	O
as	O
comorbid	O
disorders	O
or	O
social	O
problems	O
such	O
as	O
problems	O
with	O
state	O
benefits	O
or	O
social	O
housing	O
,	O
with	O
a	O
similar	O
overall	O
treatment	O
duration	O
of	O
between	O
12	O
and	O
13	O
sessions	O
.	O

Patients	O
with	O
multiple	O
trauma	O
were	O
less	O
reliable	O
in	O
attending	O
sessions	O
than	O
other	O
patients	O
,	O
and	O
those	O
with	O
social	O
problems	O
were	O
more	O
likely	O
to	O
drop	O
out	O
.	O

This	O
may	O
have	O
led	O
to	O
a	O
less	O
than	O
optimal	O
dose	O
of	O
treatment	O
for	O
each	O
of	O
the	O
patients	O
'	O
traumas	O
,	O
and	O
more	O
treatment	O
sessions	O
may	O
be	O
necessary	O
to	O
further	O
improve	O
outcome	O
(	O
see	O
also	O
National	O
Institute	O
for	O
Health	O
and	O
Clinical	O
Excellence	O
,	O
2005	O
).	O

For	O
example	O
,	O
Galovski	O
et	O
al	O
.	O

(	O
2012	O
)	O
found	O
significant	O
further	O
treatment	O
gains	O
with	O
cognitive	O
processing	O
therapy	O
for	O
patients	O
who	O
had	O
not	O
fully	O
responded	O
by	O
session	O
12	O
.	O

Therapists	O
may	O
need	O
to	O
pay	O
special	O
attention	O
to	O
engaging	O
these	O
patients	O
in	O
treatment	O
.	O

These	O
patients	O
may	O
also	O
benefit	O
from	O
ancillary	O
case	O
management	O
services	O
.	O

When	O
therapists	O
were	O
included	O
as	O
a	O
random	O
factor	O
in	O
the	O
hierarchical	O
linear	O
model	O
,	O
no	O
significant	O
effects	O
on	O
treatment	O
outcome	O
were	O
observed	O
.	O

This	O
result	O
is	O
consistent	O
with	O
those	O
of	O
other	O
studies	O
of	O
patients	O
with	O
a	O
particular	O
disorder	O
who	O
were	O
treated	O
with	O
a	O
defined	O
treatment	O
protocol	O
(	O
Baldwin	O
et	O
al	O
.,	O
2011	O
;	O
Cella	O
et	O
al	O
.,	O
2011	O
;	O
Kubany	O
et	O
al	O
.,	O
2004	O
;	O
Wilson	O
et	O
al	O
.,	O
2011	O
),	O
and	O
with	O
Crits	O
-	O
Christoph	O
et	O
al	O
.'	O
s	O
(	O
1991	O
)	O
conclusion	O
that	O
the	O
use	O
of	O
a	O
treatment	O
manual	O
reduces	O
therapist	O
effects	O
.	O

Studies	O
of	O
mixed	O
patient	O
samples	O
treated	O
by	O
therapists	O
of	O
different	O
theoretical	O
orientation	O
have	O
tended	O
to	O
show	O
larger	O
random	O
effects	O
of	O
therapists	O
,	O
in	O
the	O
range	O
of	O
5	O
–	O
8	O
%	O
of	O
the	O
variance	O
in	O
outcome	O
(	O
Lutz	O
et	O
al	O
.,	O
2007	O
;	O
Wampold	O
&	O
Brown	O
,	O
2005	O
).	O

These	O
results	O
do	O
not	O
necessarily	O
contradict	O
each	O
other	O
as	O
smaller	O
variation	O
in	O
treatment	O
procedures	O
may	O
restrict	O
the	O
variance	O
due	O
to	O
individual	O
therapists	O
.	O

In	O
this	O
study	O
,	O
therapist	O
experience	O
with	O
the	O
specific	O
treatment	O
protocol	O
showed	O
a	O
trend	O
for	O
an	O
association	O
with	O
somewhat	O
better	O
outcome	O
,	O
and	O
inexperienced	O
therapists	O
had	O
more	O
dropouts	O
.	O

This	O
result	O
is	O
similar	O
to	O
Duffy	O
et	O
al	O
.	O

(	O
2007	O
)	O
who	O
found	O
that	O
one	O
reason	O
for	O
dropouts	O
was	O
that	O
some	O
inexperienced	O
therapists	O
pushed	O
patients	O
into	O
reliving	O
their	O
trauma	O
without	O
adequately	O
addressing	O
their	O
concerns	O
first	O
.	O

Training	O
programs	O
and	O
supervision	O
for	O
novice	O
therapists	O
need	O
attention	O
on	O
how	O
to	O
effectively	O
engage	O
patients	O
with	O
trauma	O
memory	O
work	O
.	O

The	O
study	O
had	O
several	O
limitations	O
.	O

First	O
,	O
the	O
study	O
did	O
not	O
have	O
an	O
untreated	O
control	O
group	O
and	O
the	O
results	O
therefore	O
cannot	O
be	O
unambiguously	O
interpreted	O
as	O
therapy	O
effects	O
.	O

However	O
,	O
several	O
factors	O
suggest	O
that	O
it	O
is	O
unlikely	O
that	O
the	O
symptom	O
changes	O
represented	O
natural	O
recovery	O
.	O

Patients	O
were	O
referred	O
to	O
the	O
clinic	O
as	O
they	O
were	O
judged	O
by	O
health	O
professionals	O
to	O
need	O
professional	O
help	O
,	O
they	O
had	O
chronic	O
,	O
moderate	O
to	O
severe	O
PTSD	B-DS
with	O
a	O
mean	O
duration	O
of	O
3	O
years	O
,	O
high	O
comorbidity	O
,	O
and	O
did	O
not	O
improve	O
during	O
the	O
wait	O
period	O
before	O
treatment	O
started	O
.	O

Second	O
,	O
the	O
clinic	O
focuses	O
on	O
PTSD	B-DS
following	O
trauma	O
in	O
adulthood	O
and	O
it	O
remains	O
unclear	O
whether	O
the	O
results	O
generalize	O
to	O
patients	O
whose	O
main	O
traumas	O
were	O
in	O
childhood	O
.	O

However	O
,	O
a	O
history	O
of	O
childhood	O
abuse	B-DS
was	O
not	O
predictive	O
of	O
poor	O
outcome	O
in	O
this	O
sample	O
(	O
see	O
also	O
Ford	O
&	O
Kidd	O
,	O
1998	O
).	O

Third	O
,	O
although	O
data	O
for	O
the	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
of	O
treatment	O
effects	O
were	O
complete	O
,	O
the	O
sample	O
size	O
was	O
reduced	O
at	O
follow	O
-	O
up	O
and	O
it	O
remains	O
unclear	O
whether	O
loss	O
to	O
follow	O
-	O
up	O
was	O
random	O
.	O

Fourth	O
,	O
we	O
did	O
not	O
have	O
the	O
resources	O
to	O
obtain	O
fidelity	O
or	O
therapist	O
competency	O
ratings	O
from	O
recordings	O
of	O
the	O
therapy	O
sessions	O
.	O

This	O
may	O
have	O
introduced	O
error	O
variance	O
.	O

However	O
,	O
the	O
close	O
supervision	O
of	O
all	O
cases	O
ensured	O
that	O
therapists	O
followed	O
the	O
protocol	O
.	O

The	O
analysis	O
of	O
session	O
notes	O
confirmed	O
that	O
treatment	O
sessions	O
mainly	O
focused	O
on	O
the	O
PTSD	B-DS
treatment	O
protocol	O
.	O

Fifth	O
,	O
some	O
of	O
the	O
577	O
patients	O
who	O
were	O
referred	O
to	O
the	O
clinic	O
for	O
an	O
assessment	O
were	O
not	O
suitable	O
for	O
PTSD	B-DS
treatment	O
at	O
the	O
time	O
and	O
were	O
treated	O
elsewhere	O
.	O

The	O
most	O
common	O
reasons	O
were	O
not	O
having	O
PTSD	B-DS
(	O
n	O
=	O
42	O
)	O
and	O
needing	O
treatment	O
for	O
another	O
problem	O
such	O
as	O
substance	B-DS
dependence	I-DS
or	O
immediate	O
suicide	O
risk	O
first	O
(	O
n	O
=	O
73	O
).	O

This	O
pattern	O
is	O
to	O
be	O
expected	O
as	O
General	O
Practitioners	O
in	O
the	O
UK	O
National	O
Health	O
Service	O
have	O
very	O
limited	O
time	O
for	O
each	O
consultation	O
and	O
may	O
ask	O
for	O
specialist	O
assessment	O
to	O
determine	O
the	O
best	O
care	O
pathway	O
for	O
their	O
patients	O
.	O

Nevertheless	O
,	O
this	O
pattern	O
highlights	O
the	O
fact	O
that	O
not	O
only	O
RCTs	O
,	O
but	O
also	O
routine	O
clinical	O
services	O
have	O
intake	O
criteria	O
and	O
need	O
to	O
exclude	O
some	O
patients	O
,	O
and	O
that	O
some	O
of	O
the	O
reasons	O
for	O
why	O
a	O
trauma	O
-	O
focused	O
treatment	O
is	O
not	O
offered	O
may	O
overlap	O
.	O

Sixth	O
,	O
the	O
sample	O
size	O
was	O
modest	O
for	O
the	O
investigation	O
of	O
therapist	O
effects	O
and	O
larger	O
samples	O
may	O
be	O
more	O
sensitive	O
in	O
detecting	O
therapist	O
variables	O
that	O
are	O
associated	O
with	O
good	O
outcome	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
support	O
the	O
effectiveness	O
of	O
CT	O
-	O
PTSD	B-DS
in	O
a	O
wide	O
range	O
of	O
traumas	O
and	O
suggest	O
that	O
CT	O
-	O
PTSD	B-DS
can	O
be	O
successfully	O
implemented	O
in	O
the	O
routine	O
care	O
of	O
patients	O
with	O
PTSD	B-DS
.	O

Patients	O
who	O
need	O
treatment	O
for	O
multiple	O
traumas	O
,	O
severe	O
comorbid	O
disorders	O
or	O
social	O
problems	O
may	O
benefit	O
from	O
extending	O
the	O
duration	O
of	O
treatment	O
.	O

Training	O
new	O
therapists	O
in	O
CT	O
-	O
PTSD	B-DS
or	O
other	O
TF	O
-	O
CBT	O
protocols	O
may	O
benefit	O
from	O
special	O
attention	O
to	O
engaging	O
patients	O
with	O
treatment	O
to	O
avoid	O
dropouts	O
.	O

This	O
is	O
an	O
open	O
-	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
author	O
and	O
source	O
are	O
credited	O
.	O

Patient	O
flow	O
.	O

Intent	O
-	O
to	O
-	O
treat	O
outcome	O
for	O
patients	O
who	O
were	O
offered	O
treatment	O
(	O
n	O
=	O
330	O
).	O

PDS	O
=	O
Posttraumatic	O
Diagnostic	O
Scale	O
(	O
n	O
=	O
330	O
);	O
BDI	O
=	O
Beck	O
Depression	B-DS
Inventory	O
(	O
n	O
=	O
320	O
);	O
BAI	O
=	O
Beck	O
Anxiety	B-DS
Inventory	O
(	O
n	O
=	O
321	O
).	O

Intent	O
-	O
to	O
-	O
treat	O
treatment	O
outcome	O
for	O
all	O
consecutive	O
patients	O
who	O
were	O
offered	O
treatment	O
including	O
drop	O
-	O
outs	O
.	O

Outcome	O
measure	O
and	O
assessment	O
point	O

All	O
patients	O
(	O
N	O
=	O
330	O
)	O

M	O

SD	O

PDS	O
pre	O
treatment	O

33	O
.	O
98	O

8	O
.	O
77	O

End	O
of	O
treatment	O

17	O
.	O
46	O

14	O
.	O
37	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pooled	O
SD	O
)	O

d	O
=	O
1	O
.	O
39	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pre	O
SD	O
)	O

d	O
=	O
1	O
.	O
88	O


BDI	O
pre	O
treatment	O

27	O
.	O
33	O

11	O
.	O
75	O

End	O
of	O
treatment	O

15	O
.	O
87	O

13	O
.	O
42	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pooled	O
SD	O
)	O

d	O
=	O
0	O
.	O
91	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pre	O
SD	O
)	O

d	O
=	O
0	O
.	O
98	O


BAI	O
pre	O
treatment	O

28	O
.	O
39	O

13	O
.	O
62	O

End	O
of	O
treatment	O

14	O
.	O
52	O

14	O
.	O
92	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pooled	O
SD	O
)	O

d	O
=	O
0	O
.	O
97	O

ES	O
(	O
pre	O
–	O
end	O
,	O
pre	O
SD	O
)	O

d	O
=	O
1	O
.	O
02	O

Overview	O
of	O
individual	O
candidate	O
predictors	O
of	O
outcome	O
and	O
fixed	O
effects	O
estimates	O
from	O
hierarchical	O
linear	O
modeling	O
(	O
in	O
points	O
on	O
centered	O
PDS	O
scale	O
).	O

Predictor	O

Type	O
of	O
effect	O

Size	O
of	O
effect	O
(	O
fixed	O
effect	O
estimate	O
and	O
standard	O
error	O
)	O

Exclusion	O
criteria	O
used	O
in	O
some	O
RCTs	O

Male	O
sex	O

Not	O
a	O
predictor	O

Age	O

Not	O
a	O
predictor	O

Does	O
not	O
meet	O
full	O
DSM	O
-	O
IV	O
criteria	O

Nonspecific	O
predictor	O

−	O
10	O
.	O
35	O
(	O
1	O
.	O
68	O
)***	O

PTSD	B-DS
not	O
main	O
problem	O

Moderator	O

3	O
.	O
31	O
(	O
1	O
.	O
21	O
)**	O

Current	O
substance	B-DS
abuse	I-DS

Nonspecific	O
predictor	O

2	O
.	O
50	O
(	O
1	O
.	O
26	O
)*	O

Borderline	O
personality	B-DS
disorder	I-DS

Not	O
a	O
predictor	O

Needs	O
treatment	O
for	O
multiple	O
traumas	O

Moderator	O

4	O
.	O
01	O
(	O
1	O
.	O
30	O
)**	O

History	O
of	O
childhood	O
abuse	O

Not	O
a	O
predictor	O

No	O
memory	O
of	O
trauma	O

Not	O
a	O
predictor	O

Previous	O
CBT	O
for	O
PTSD	B-DS

Not	O
a	O
predictor	O


Demographics	O

Ethnic	O
minority	O

Not	O
a	O
predictor	O

Lower	O
level	O
of	O
education	O

Nonspecific	O
predictor	O

−	O
2	O
.	O
78	O
(	O
1	O
.	O
03	O
)	O

Social	O
problems	O

Moderator	O
andNonspecific	O
predictor	O

5	O
.	O
23	O
(	O
1	O
.	O
02	O
)***	O
3	O
.	O
76	O
(	O
0	O
.	O
89	O
)***	O

No	O
relationship	O
(	O
never	O
married	O
or	O
living	O
with	O
partner	O
)	O

Moderator	O

2	O
.	O
46	O
(	O
0	O
.	O
93	O
)**	O

Ongoing	O
legal	O
proceedings	O

Not	O
a	O
predictor	O

Any	O
previous	O
treatment	O
for	O
PTSD	B-DS

Not	O
a	O
predictor	O


Comorbidity	O

Current	O
comorbid	O
anxiety	B-DS
disorder	I-DS

Not	O
a	O
predictor	O

Current	O
mood	B-DS
disorder	I-DS

Moderator	O
andNonspecific	O
predictor	O

1	O
.	O
95	O
(	O
0	O
.	O
92	O
)*	O
7	O
.	O
00	O
(	O
0	O
.	O
97	O
)***	O

Current	O
other	O
axis	O
1	O
disorder	O

Nonspecific	O
predictor	O

4	O
.	O
73	O
(	O
1	O
.	O
78	O
)**	O

Any	O
personality	B-DS
disorder	I-DS

Nonspecific	O
predictor	O

2	O
.	O
57	O
(	O
1	O
.	O
15	O
)*	O

Current	O
suicidal	O
ideation	O

Nonspecific	O
predictor	O

5	O
.	O
92	O
(	O
0	O
.	O
99	O
)***	O

Taking	O
psychotropic	O
medication	O

Nonspecific	O
predictor	O

5	O
.	O
87	O
(	O
1	O
.	O
08	O
)***	O

Chronic	O
pain	O

Nonspecific	O
predictor	O

3	O
.	O
08	O
(	O
1	O
.	O
14	O
)**	O

Physical	O
disability	O
due	O
to	O
trauma	O

Nonspecific	O
predictor	O

2	O
.	O
54	O
(	O
1	O
.	O
27	O
)*	O

History	O
of	O
major	B-DS
depression	I-DS

Nonspecific	O
predictor	O

5	O
.	O
39	O
(	O
1	O
.	O
10	O
)***	O

History	O
of	O
substance	B-DS
dependence	I-DS

Moderator	O
andNonspecific	O
predictor	O

3	O
.	O
34	O
(	O
1	O
.	O
19	O
)**	O
3	O
.	O
48	O
(	O
1	O
.	O
33	O
)**	O

Past	O
suicide	O
attempts	O

Moderator	O
andNonspecific	O
predictor	O

2	O
.	O
96	O
(	O
1	O
.	O
30	O
)*	O
3	O
.	O
34	O
(	O
1	O
.	O
50	O
)*	O

Trauma	O
History	O

Main	O
trauma	O
interpersonal	O

Not	O
a	O
predictor	O

Someone	O
died	O
in	O
main	O
trauma	O

Not	O
a	O
predictor	O

Injured	O
in	O
trauma	O

Not	O
a	O
predictor	O

Months	O
since	O
main	O
trauma	O

Moderator	O

1	O
.	O
06	O
(	O
0	O
.	O
46	O
)*	O

History	O
of	O
other	O
traumas	O

Not	O
a	O
predictor	O

Number	O
of	O
traumas	O

Not	O
a	O
predictor	O

History	O
of	O
child	O
abuse	B-DS

Not	O
a	O
predictor	O

Injured	O
in	O
trauma	O

Not	O
a	O
predictor	O

Hierarchical	O
linear	O
modeling	O
:	O
Estimates	O
of	O
random	O
effects	O
(	O
patient	O
,	O
therapist	O
)	O
and	O
fixed	O
effects	O
(	O
time	O
,	O
patient	O
characteristics	O
,	O
therapist	O
experience	O
)	O
on	O
improvement	O
in	O
PTSD	B-DS
symptoms	O
with	O
therapy	O
.	O

Model	O
1	O
slope	O
of	O
improvement	O
and	O
random	O
patient	O
effects	O

Model	O
2	O
including	O
patient	O
characteristics	O

Model	O
3	O
including	O
random	O
therapist	O
effects	O

Model	O
4	O
including	O
therapist	O
experience	O

Overall	O
fit	O
:	O
AIC	O

6608	O
.	O
21	O

5967	O
.	O
25	O

5967	O
.	O
19	O

5951	O
.	O
56	O


Variance	O
-	O
covariance	O
estimates	O
for	O
random	O
parameters	O

Level	O
1	O
:	O
patient	O

Patient	O
random	O
intercept	O

66	O
.	O
46	O
(	O
12	O
.	O
16	O
)***	O

41	O
.	O
09	O
(	O
10	O
.	O
44	O
)***	O

37	O
.	O
41	O
(	O
11	O
.	O
22	O
)***	O

35	O
.	O
39	O
(	O
11	O
.	O
85	O
)**	O

Patient	O
random	O
slope	O

40	O
.	O
71	O
(	O
6	O
.	O
87	O
)***	O

29	O
.	O
66	O
(	O
5	O
.	O
49	O
)***	O

28	O
.	O
11	O
(	O
5	O
.	O
49	O
)***	O

27	O
.	O
11	O
(	O
5	O
.	O
46	O
)***	O


Level	O
2	O
:	O
therapist	O

Therapist	O
random	O
intercept	O

1	O
.	O
88	O
(	O
1	O
.	O
84	O
)	O

1	O
.	O
69	O
(	O
1	O
.	O
78	O
)	O

Therapist	O
random	O
slope	O

0	O
.	O
79	O
(	O
1	O
.	O
29	O
)	O

1	O
.	O
02	O
(	O
1	O
.	O
35	O
)	O


Fixed	O
effect	O
estimates	O

Level	O
1	O
:	O
time	O
effects	O

Intercept	O

11	O
.	O
00	O
(	O
0	O
.	O
55	O
)***	O

18	O
.	O
90	O
(	O
2	O
.	O
23	O
)***	O

18	O
.	O
89	O
(	O
2	O
.	O
26	O
)***	O

18	O
.	O
50	O
(	O
2	O
.	O
30	O
)***	O

Linear	O
time	O
effect	O

−	O
24	O
.	O
88	O
(	O
1	O
.	O
01	O
)***	O

−	O
18	O
.	O
33	O
(	O
2	O
.	O
29	O
)***	O

−	O
18	O
.	O
63	O
(	O
2	O
.	O
30	O
)***	O

−	O
19	O
.	O
23	O
(	O
2	O
.	O
34	O
)***	O

Quadratic	O
time	O
effect	O

8	O
.	O
42	O
(	O
0	O
.	O
50	O
)***	O

8	O
.	O
38	O
(	O
0	O
.	O
52	O
)***	O

8	O
.	O
35	O
(	O
0	O
.	O
52	O
)***	O

8	O
.	O
36	O
(	O
0	O
.	O
52	O
)***	O


Level	O
2	O
:	O
patient	O
characteristics	O

PTSD	B-DS
not	O
main	O
problem	O

-	O
Nonspecific	O
predictor	O

2	O
.	O
43	O
(	O
1	O
.	O
37	O
)(*)	O

2	O
.	O
28	O
(	O
1	O
.	O
38	O
)	O

2	O
.	O
11	O
(	O
1	O
.	O
40	O
)	O

-	O
Moderator	O
effect	O

0	O
.	O
71	O
(	O
1	O
.	O
33	O
)	O

0	O
.	O
79	O
(	O
1	O
.	O
33	O
)	O

0	O
.	O
44	O
(	O
1	O
.	O
35	O
)	O

Multiple	O
traumas	O
need	O
treatment	O

-	O
Nonspecific	O
predictor	O

1	O
.	O
99	O
(	O
1	O
.	O
50	O
)	O

1	O
.	O
79	O
(	O
1	O
.	O
49	O
)	O

1	O
.	O
69	O
(	O
1	O
.	O
51	O
)	O

-	O
Moderator	O
effect	O

3	O
.	O
81	O
(	O
1	O
.	O
38	O
)**	O

3	O
.	O
66	O
(	O
1	O
.	O
39	O
)**	O

3	O
.	O
25	O
(	O
1	O
.	O
40	O
)*	O

Social	O
problems	O

-	O
Nonspecific	O
predictor	O

3	O
.	O
26	O
(	O
1	O
.	O
04	O
)**	O

3	O
.	O
05	O
(	O
1	O
.	O
04	O
)**	O

3	O
.	O
17	O
(	O
1	O
.	O
05	O
)**	O

-	O
Moderator	O
effect	O

2	O
.	O
89	O
(	O
0	O
.	O
94	O
)**	O

2	O
.	O
79	O
(	O
0	O
.	O
94	O
)**	O

2	O
.	O
99	O
(	O
0	O
.	O
96	O
)**	O

No	O
relationship	O

-	O
Nonspecific	O
predictor	O

0	O
.	O
14	O
(	O
1	O
.	O
00	O
)	O

0	O
.	O
08	O
(	O
1	O
.	O
00	O
)	O

0	O
.	O
02	O
(	O
1	O
.	O
00	O
)	O

-	O
Moderator	O
effect	O

1	O
.	O
68	O
(	O
0	O
.	O
92	O
)(*)	O

1	O
.	O
70	O
(	O
0	O
.	O
92	O
)(*)	O

1	O
.	O
55	O
(	O
0	O
.	O
93	O
)(*)	O

Comorbid	O
mood	B-DS
disorder	I-DS

-	O
Nonspecific	O
predictor	O

5	O
.	O
85	O
(	O
1	O
.	O
02	O
)***	O

5	O
.	O
79	O
(	O
1	O
.	O
01	O
)***	O

5	O
.	O
79	O
(	O
1	O
.	O
02	O
)***	O

-	O
Moderator	O
effect	O

0	O
.	O
22	O
(	O
0	O
.	O
94	O
)	O

0	O
.	O
17	O
(	O
0	O
.	O
94	O
)	O

0	O
.	O
22	O
(	O
0	O
.	O
94	O
)	O

Suicide	O
attempts	O

-	O
Nonspecific	O
predictor	O

0	O
.	O
87	O
(	O
1	O
.	O
46	O
)	O

0	O
.	O
95	O
(	O
1	O
.	O
47	O
)	O

0	O
.	O
95	O
(	O
1	O
.	O
48	O
)	O

-	O
Moderator	O
effect	O

1	O
.	O
31	O
(	O
1	O
.	O
35	O
)	O

1	O
.	O
33	O
(	O
1	O
.	O
36	O
)	O

1	O
.	O
37	O
(	O
1	O
.	O
36	O
)	O

History	O
of	O
substance	B-DS
dependence	I-DS

-	O
Nonspecific	O
predictor	O

2	O
.	O
26	O
(	O
1	O
.	O
32	O
)(*)	O

2	O
.	O
39	O
(	O
1	O
.	O
32	O
)(*)	O

2	O
.	O
37	O
(	O
1	O
.	O
32	O
)	O
(*)	O

-	O
Moderator	O
effect	O

1	O
.	O
76	O
(	O
1	O
.	O
24	O
)	O

1	O
.	O
77	O
(	O
1	O
.	O
24	O
)	O

1	O
.	O
84	O
(	O
1	O
.	O
24	O
)	O

Months	O
since	O
trauma	O

-	O
Nonspecific	O
predictor	O

−	O
0	O
.	O
59	O
(	O
0	O
.	O
50	O
)	O

−	O
0	O
.	O
64	O
(	O
0	O
.	O
50	O
)	O

−	O
0	O
.	O
60	O
(	O
0	O
.	O
50	O
)	O

-	O
Moderator	O
effect	O

0	O
.	O
59	O
(	O
0	O
.	O
46	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
46	O
)	O

0	O
.	O
66	O
(	O
0	O
.	O
47	O
)	O


Level	O
3	O
:	O
therapist	O
effects	O

Staff	O
therapist	O

-	O
Nonspecific	O
predictor	O

0	O
.	O
69	O
(	O
1	O
.	O
49	O
)	O

-	O
Moderator	O
effect	O

2	O
.	O
05	O
(	O
1	O
.	O
37	O
)	O

Experienced	O
in	O
CT	O
-	O
PTSD	B-DS

-	O
Nonspecific	O
predictor	O

−	O
1	O
.	O
19	O
(	O
1	O
.	O
24	O
)	O

-	O
Moderator	O
effect	O

−	O
2	O
.	O
23	O
(	O
1	O
.	O
15	O
)	O
(*)	O

Identification	O
of	O
gene	O
expression	O
patterns	O
crucially	O
involved	O
in	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
and	O
multiple	B-DS
sclerosis	I-DS

ABSTRACT	O

After	O
encounter	O
with	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)-	O
derived	O
autoantigen	O
,	O
lymphocytes	O
leave	O
the	O
lymph	O
nodes	O
and	O
enter	O
the	O
CNS	O
.	O

This	O
event	O
leads	O
only	O
rarely	O
to	O
subsequent	O
tissue	O
damage	O
.	O

Genes	O
relevant	O
to	O
CNS	O
pathology	O
after	O
cell	O
infiltration	O
are	O
largely	O
undefined	O
.	O

Myelin	B-GP
-	I-GP
oligodendrocyte	I-GP
-	I-GP
glycoprotein	I-GP
(	O
MOG	B-GP
)-	O
induced	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
is	O
an	O
animal	B-OG
model	O
of	O
multiple	B-DS
sclerosis	I-DS
(	O
MS	B-DS
),	O
a	O
chronic	B-DS
autoimmune	I-DS
disease	I-DS
of	I-DS
the	I-DS
CNS	O
that	O
results	O
in	O
disability	O
.	O

To	O
assess	O
genes	O
that	O
are	O
involved	O
in	O
encephalitogenicity	O
and	O
subsequent	O
tissue	O
damage	O
mediated	O
by	O
CNS	O
-	O
infiltrating	O
cells	O
,	O
we	O
performed	O
a	O
DNA	O
microarray	O
analysis	O
from	O
cells	O
derived	O
from	O
lymph	O
nodes	O
and	O
eluted	O
from	O
CNS	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
91	O
-	O
108	O
.	O

The	O
data	O
was	O
compared	O
to	O
immunizations	O
with	O
adjuvant	O
alone	O
or	O
naive	O
rats	B-OG
and	O
to	O
immunizations	O
with	O
the	O
immunogenic	O
but	O
not	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
peptide	O
.	O

Here	O
,	O
we	O
show	O
involvement	O
of	O
Cd38	B-GP
,	O
Cxcr4	B-GP
and	O
Akt	B-GP
and	O
confirm	O
these	O
findings	O
by	O
the	O
use	O
of	O
Cd38	B-GP
-	O
knockout	O
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
mice	B-OG
,	O
S1P	B-GP
-	I-GP
receptor	I-GP
modulation	O
during	O
EAE	B-DS
and	O
quantitative	O
expression	O
analysis	O
in	O
individuals	O
with	O
MS	B-DS
.	O

The	O
hereby	O
-	O
defined	O
underlying	O
pathways	O
indicate	O
cellular	O
activation	O
and	O
migration	O
pathways	O
mediated	O
by	O
G	B-GP
-	I-GP
protein	I-GP
-	I-GP
coupled	I-GP
receptors	I-GP
as	O
crucial	O
events	O
in	O
CNS	O
tissue	O
damage	O
.	O

These	O
pathways	O
can	O
be	O
further	O
explored	O
for	O
novel	O
therapeutic	O
interventions	O
.	O

Summary	O
:	O
To	O
define	O
disease	O
-	O
inducing	O
immune	O
responses	O
,	O
unbiased	O
gene	O
expression	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
autoantigen	O
-	O
derived	O
encephalitogenic	O
and	O
non	O
-	O
encephalitogenic	O
peptides	O
was	O
investigated	O
in	O
MOG	B-GP
-	O
EAE	B-DS
.	O

CXCR4	B-GP
,	O
CXCL12	B-GP
,	O
AKT	B-GP
and	O
CD38	B-GP
control	O
CNS	O
inflammation	O
.	O

INTRODUCTION	O

Multiple	B-DS
sclerosis	I-DS
(	O
MS	B-DS
)	O
is	O
a	O
disease	O
of	B-DS
the	I-DS
central	I-DS
nervous	I-DS
system	I-DS
(	O
CNS	O
)	O
that	O
leads	O
to	O
chronic	O
inflammation	O
,	O
demyelination	O
,	O
and	O
axonal	O
and	O
neuronal	O
loss	O
,	O
resulting	O
in	O
disability	O
(	O
Noseworthy	O
et	O
al	O
.,	O
2000	O
;	O
Weissert	O
,	O
2013	O
).	O

Myelin	B-GP
-	I-GP
oligodendrocyte	I-GP
-	I-GP
glycoprotein	I-GP
(	O
MOG	B-GP
)-	O
induced	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
in	O
rats	B-OG
reproduces	O
major	O
aspects	O
of	O
the	O
human	B-OG
pathology	O
(	O
Weissert	O
et	O
al	O
.,	O
1998b	O
;	O
Storch	O
et	O
al	O
.,	O
1998	O
;	O
Kornek	O
et	O
al	O
.,	O
2000	O
;	O
Weissert	O
,	O
2016	O
).	O

MOG	B-GP
is	O
expressed	O
on	O
the	O
outer	O
surface	O
of	O
the	O
myelin	O
sheath	O
.	O

In	O
contrast	O
to	O
merely	O
T	O
-	O
cell	O
-	O
mediated	O
animal	B-OG
models	O
,	O
the	O
pathogenesis	O
of	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
in	O
the	O
rat	B-OG
involves	O
the	O
combined	O
action	O
of	O
T	O
and	O
B	O
cells	O
,	O
antibodies	B-GP
and	O
macrophages	O
,	O
mimicking	O
type	O
II	O
lesions	O
in	O
MS	B-DS
(	O
Genain	O
et	O
al	O
.,	O
1995	O
;	O
Mathey	O
et	O
al	O
.,	O
2004	O
;	O
Lucchinetti	O
et	O
al	O
.,	O
2000	O
).	O

Encephalitogenic	O
peptides	O
presented	O
on	O
MHC	B-GP
class	O
II	O
molecules	O
to	O
T	O
cells	O
lead	O
to	O
a	O
program	O
that	O
forces	O
lymphocytes	O
to	O
be	O
activated	O
and	O
migrate	O
towards	O
the	O
CNS	O
(	O
Riedhammer	O
and	O
Weissert	O
,	O
2015	O
).	O

Adjuvant	O
contributes	O
by	O
affecting	O
multiple	O
signaling	O
pathways	O
in	O
lymphocytes	O
as	O
well	O
as	O
in	O
organ	O
-	O
resident	O
cells	O
like	O
in	O
the	O
CNS	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
MOG	B-GP
91	O
-	O
108	O
is	O
the	O
major	O
determinant	O
to	O
trigger	O
disease	O
in	O
rats	B-OG
expressing	O
RT1av1	B-GP
or	O
RT1n	B-GP
haplotypes	O
(	O
Weissert	O
et	O
al	O
.,	O
2001	O
).	O

Interestingly	O
,	O
the	O
capacity	O
of	O
MOG	B-GP
91	O
-	O
108	O
to	O
induce	O
EAE	B-DS
was	O
dissociated	O
in	O
regard	O
to	O
Th1	O
or	O
Th2	B-GP
cytokine	B-GP
expression	O
in	O
lymphoid	O
tissue	O
compared	O
to	O
the	O
CNS	O
.	O

Moreover	O
,	O
different	O
MOG	B-GP
1	O
-	O
125	O
-	O
derived	O
peptides	O
,	O
such	O
as	O
MOG	B-GP
73	O
-	O
90	O
,	O
were	O
immunogenic	O
,	O
showing	O
strong	O
Th1	O
responses	O
,	O
but	O
were	O
not	O
encephalitogenic	O
.	O

The	O
induction	O
of	O
active	O
EAE	B-DS
in	O
LEW	O
MHC	O
congenic	O
rat	B-OG
strains	O
and	O
Dark	B-OG
Agouti	I-OG
(	O
DA	O
)	O
(	O
RT1av1	O
)	O
rats	B-OG
does	O
not	O
require	O
the	O
application	O
of	O
pertussis	B-GP
toxin	I-GP
like	O
in	O
mice	B-OG
.	O

This	O
is	O
an	O
advantage	O
because	O
the	O
exact	O
role	O
of	O
pertussis	B-GP
toxin	I-GP
in	O
EAE	B-DS
induction	O
is	O
not	O
clear	O
so	O
far	O
.	O

Pertussis	B-GP
toxin	I-GP
inhibits	O
Gi	B-GP
proteins	O
and	O
thereby	O
influences	O
multiple	O
cellular	O
processes	O
and	O
pathways	O
(	O
Dumas	O
et	O
al	O
.,	O
2014	O
).	O

Active	O
EAE	B-DS
in	O
susceptible	O
rat	B-OG
strains	O
is	O
induced	O
by	O
immunization	O
with	O
an	O
encephalitogenic	O
peptide	O
mixed	O
with	O
mineral	O
oil	O
[	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
IFA	O
)]	O
with	O
the	O
addition	O
of	O
heat	O
-	O
inactivated	O
mycobacterium	B-OG
tuberculosis	I-OG
(	O
MT	B-OG
)	O
as	O
adjuvant	O
[	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)].	O

MT	O
leads	O
by	O
binding	O
and	O
signaling	O
through	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
)	O
to	O
an	O
activation	O
program	O
in	O
a	O
number	O
of	O
cell	O
types	O
and	O
is	O
also	O
a	O
systemic	O
‘	O
danger	O
signal	O
’	O
(	O
Mills	O
,	O
2011	O
).	O

In	O
regard	O
to	O
susceptibility	O
to	O
EAE	B-DS
and	O
MS	B-DS
,	O
gene	O
expression	O
profiling	O
studies	O
have	O
been	O
performed	O
to	O
elucidate	O
genes	O
that	O
are	O
involved	O
in	O
disease	O
pathogenesis	O
.	O

A	O
number	O
of	O
interesting	O
genes	O
were	O
described	O
,	O
such	O
as	O
osteopontin	B-GP
(	O
Hur	O
et	O
al	O
.,	O
2007	O
).	O

In	O
no	O
study	O
was	O
a	O
systematic	O
comparison	O
of	O
gene	O
expression	O
profiles	O
performed	O
in	O
EAE	B-DS
in	O
which	O
the	O
influence	O
of	O
adjuvant	O
and	O
antigen	O
was	O
systematically	O
compared	O
on	O
the	O
expression	O
profile	O
of	O
lymph	O
node	O
(	O
LN	O
)-	O
derived	O
cells	O
or	O
cells	O
eluted	O
from	O
CNS	O
of	O
diseased	O
animals	B-OG
.	O

In	O
the	O
present	O
study	O
,	O
we	O
systematically	O
compared	O
the	O
gene	O
expression	O
profiles	O
of	O
cells	O
from	O
draining	O
LNs	O
and	O
CNS	O
-	O
infiltrating	O
cells	O
that	O
were	O
eluted	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
,	O
CFA	O
alone	O
and	O
in	O
naive	O
rats	B-OG
.	O

Moreover	O
,	O
we	O
compared	O
the	O
gene	O
expression	O
profile	O
of	O
rats	B-OG
immunized	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
peptide	O
91	O
-	O
108	O
with	O
rats	B-OG
immunized	O
with	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
peptide	O
73	O
-	O
90	O
.	O

We	O
found	O
differentially	O
expressed	O
genes	O
that	O
are	O
of	O
major	O
importance	O
for	O
encephalitogenicity	O
.	O

The	O
influence	O
of	O
these	O
genes	O
was	O
subsequently	O
verified	O
by	O
different	O
means	O
.	O

RESULTS	O

Gene	O
expression	O
after	O
immunization	O
with	O
encephalitogenic	O
and	O
non	O
-	O
encephalitogenic	O
peptides	O

One	O
of	O
the	O
important	O
issues	O
in	O
MS	B-DS
and	O
other	O
inflammatory	B-DS
diseases	I-DS
of	I-DS
the	I-DS
CNS	I-DS
is	O
understanding	O
the	O
requisites	O
of	O
autoantigenic	O
peptides	O
to	O
induce	O
CNS	O
inflammation	O
(	O
Riedhammer	O
and	O
Weissert	O
,	O
2015	O
).	O

Beside	O
presentation	O
of	O
autoantigen	O
-	O
derived	O
peptides	O
on	O
MHC	B-GP
molecules	O
and	O
the	O
availability	O
of	O
reactive	O
T	O
-	O
cell	O
and	O
B	O
-	O
cell	O
repertoires	O
as	O
well	O
as	O
the	O
presence	O
of	O
the	O
target	O
antigen	O
in	O
the	O
CNS	O
,	O
pathways	O
of	O
cellular	O
activation	O
exist	O
that	O
allow	O
disease	O
development	O
.	O

These	O
pathways	O
are	O
presently	O
only	O
partly	O
elucidated	O
.	O

We	O
used	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
as	O
a	O
model	O
system	O
for	O
CNS	O
inflammation	O
.	O

In	O
this	O
EAE	B-DS
model	O
,	O
the	O
determinant	O
MOG	B-GP
91	O
-	O
108	O
is	O
immunogenic	O
and	O
encephalitogenic	O
.	O

In	O
contrast	O
,	O
the	O
determinant	O
MOG	B-GP
73	O
-	O
90	O
is	O
immunogenic	O
but	O
not	O
encephalitogenic	O
.	O

We	O
assessed	O
the	O
gene	O
expression	O
profiles	O
by	O
gene	O
arrays	O
of	O
lymphocytes	O
from	O
draining	O
LNs	O
and	O
from	O
lymphocytes	O
eluted	O
from	O
the	O
CNS	O
.	O

To	O
focus	O
on	O
genes	O
that	O
are	O
truly	O
relevant	O
to	O
encephalitogenicity	O
and	O
not	O
simply	O
involved	O
in	O
general	O
inflammatory	O
responses	O
,	O
we	O
compared	O
gene	O
arrays	O
of	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
stretch	O
MOG	B-GP
91	O
-	O
108	O
to	O
naive	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
and	O
rats	B-OG
immunized	O
with	O
the	O
adjuvant	O
CFA	O
alone	O
as	O
well	O
as	O
rats	B-OG
immunized	O
with	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
determinant	O
.	O

We	O
analyzed	O
ten	O
comparisons	O
for	O
each	O
of	O
the	O
naive	O
and	O
CFA	O
groups	O
versus	O
MOG	B-GP
91	O
-	O
108	O
and	O
five	O
comparisons	O
for	O
MOG	B-GP
73	O
-	O
90	O
versus	O
MOG	B-GP
91	O
-	O
108	O
.	O

The	O
number	O
of	O
comparisons	O
in	O
which	O
a	O
given	O
gene	O
had	O
a	O
signal	O
log	O
ratio	O
(	O
SLR	O
)	O
of	O
above	O
1	O
was	O
counted	O
.	O

In	O
Table	O
1	O
,	O
we	O
show	O
genes	O
that	O
are	O
upregulated	O
in	O
at	O
least	O
half	O
of	O
the	O
comparisons	O
(=	O
50	O
%).	O

Besides	O
Cxcr4	B-GP
and	O
Cd38	B-GP
,	O
which	O
were	O
subsequently	O
analyzed	O
in	O
greater	O
detail	O
,	O
many	O
genes	O
with	O
a	O
known	O
function	O
in	O
EAE	B-DS
and	O
MS	B-DS
pathology	O
were	O
found	O
to	O
have	O
an	O
increased	O
expression	O
in	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
as	O
compared	O
to	O
controls	O
.	O

This	O
validates	O
our	O
gene	O
list	O
and	O
supports	O
the	O
relevance	O
of	O
the	O
genes	O
not	O
previously	O
described	O
in	O
EAE	B-DS
.	O

In	O
Table	O
S1	O
,	O
genes	O
with	O
decreased	O
expression	O
in	O
EAE	B-DS
are	O
listed	O
.	O

In	O
this	O
analysis	O
,	O
the	O
variability	O
between	O
gene	O
arrays	O
was	O
much	O
higher	O
and	O
fewer	O
genes	O
were	O
found	O
to	O
be	O
regulated	O
with	O
a	O
clear	O
pattern	O
according	O
to	O
our	O
criteria	O
.	O
Table	O
1	O
.	O
Genes	O
with	O
increased	O
expression	O
in	O
lymph	O
-	O
node	O
cells	O
of	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	B-GP
)	O
rats	B-OG

Comparisons	O
of	O
microarrays	O
of	O
CNS	O
-	O
infiltrating	O
lymphocytes	O
derived	O
from	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
after	O
immunization	O
with	O
MOG	B-GP
91	O
-	O
108	O
,	O
MOG	B-GP
73	O
-	O
90	O
and	O
CFA	O
alone	O
resulted	O
in	O
many	O
more	O
genes	O
being	O
differentially	O
expressed	O
as	O
compared	O
to	O
the	O
analysis	O
of	O
LN	O
cells	O
(	O
Tables	O
S2	O
and	O
S3	O
).	O

This	O
could	O
mirror	O
the	O
influx	O
of	O
different	O
cell	O
populations	O
into	O
the	O
CNS	O
during	O
an	O
inflammatory	O
attack	O
.	O

Similar	O
to	O
the	O
analysis	O
of	O
LN	O
cells	O
,	O
we	O
found	O
that	O
Cd38	B-GP
and	O
Cxcr4	B-GP
mRNA	O
was	O
strongly	O
increased	O
in	O
CNS	O
-	O
infiltrating	O
cells	O
.	O

Subsequently	O
,	O
we	O
analyzed	O
purified	O
CD4	B-GP
+	O
cells	O
from	O
LNs	O
and	O
CNS	O
of	O
MOG	B-GP
91	O
-	O
108	O
-	O
and	O
MOG	B-GP
73	O
-	O
90	O
-	O
immunized	O
rats	B-OG
.	O

To	O
some	O
extent	O
,	O
similar	O
gene	O
expression	O
profiles	O
were	O
found	O
in	O
the	O
purified	O
CD4	B-GP
+	O
cell	O
population	O
compared	O
to	O
non	O
-	O
separated	O
LN	O
cells	O
(	O
Table	O
1	O
,	O
Tables	O
S4	O
and	O
S5	O
).	O

Owing	O
to	O
their	O
strong	O
expression	O
in	O
MOG	O
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
naive	O
,	O
CFA	O
-	O
immunized	O
and	O
MOG	B-GP
73	O
-	O
90	O
-	O
immunized	O
rats	B-OG
,	O
we	O
chose	O
Cxcr4	B-GP
and	O
Cd38	B-GP
for	O
further	O
analysis	O
.	O

Cxcr4	B-GP
and	O
Cd38	B-GP
in	O
EAE	B-DS
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG

Confirming	O
our	O
microarray	O
results	O
by	O
quantitative	O
PCR	O
,	O
we	O
found	O
a	O
significant	O
upregulation	O
of	O
Cxcr4	B-GP
expression	O
in	O
LN	O
cells	O
of	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
(	O
n	O
=	O
8	O
)	O
as	O
compared	O
to	O
CFA	O
-	O
immunized	O
(	O
n	O
=	O
8	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
naive	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
Fig	O
.	O
1A	O
).	O

Also	O
,	O
an	O
increased	O
expression	O
of	O
Cd38	B-GP
was	O
measured	O
[	O
MOG	O
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
(	O
n	O
=	O
8	O
)	O
as	O
compared	O
to	O
CFA	O
-	O
immunized	O
(	O
n	O
=	O
8	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
naive	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
].	O
Fig	O
.	O
1	O
.	O
Cxcr4	B-GP
and	O
Cd38	B-GP
expression	O
in	O
lymph	O
node	O
cells	O
and	O
CNS	O
.	O
(	O
A	O
)	O
Quantitative	O
SYBR	O
green	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
Cxcr4	B-GP
and	O
Cd38	B-GP
in	O
lymph	O
node	O
(	O
LN	O
)	O
cells	O
from	O
naive	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
black	O
bars	O
,	O
n	O
=	O
6	O
),	O
or	O
those	O
immunized	O
with	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
8	O
)	O
or	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
8	O
),	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Increased	O
Cxcr4	B-GP
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
Cd38	B-GP
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
expression	O
was	O
found	O
in	O
MOG	O
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
naive	O
and	O
CFA	O
-	O
alone	O
-	O
immunized	O
rats	B-OG
.	O

(	O
B	O
)	O
Quantitative	O
expression	O
of	O
Cxcr4	B-GP
in	O
cells	O
eluted	O
from	O
the	O
CNS	O
of	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
6	O
)-,	O
MOG	B-GP
73	O
-	O
90	O
in	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
6	O
)-	O
and	O
MOG	O
91	O
-	O
108	O
in	O
CFA	O
(	O
n	O
=	O
6	O
)-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O
Cxcr4	B-GP
was	O
upregulated	O
in	O
MOG	O
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
the	O
other	O
groups	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

(	O
C	O
)	O
Quantitative	O
expression	O
of	O
Cd38	B-GP
of	O
lymphocytes	O
eluted	O
from	O
the	O
CNS	O
of	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
6	O
)-,	O
MOG	B-GP
73	O
-	O
90	O
in	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
6	O
)-	O
and	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
(	O
n	O
=	O
6	O
)-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
on	O
day	O
12	O
p	O
.	O
i	O
.	O
Cd38	B-GP
was	O
upregulated	O
in	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
the	O
other	O
groups	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
).	O

Results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔ	O
CT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

In	O
cells	O
eluted	O
from	O
the	O
CNS	O
,	O
we	O
found	O
upregulation	O
of	O
Cxcr4	B-GP
(	O
Fig	O
.	O
1B	O
)	O
and	O
Cd38	B-GP
(	O
Fig	O
.	O
1C	O
)	O
in	O
MOG	O
91	O
-	O
108	O
-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
6	O
)	O
compared	O
to	O
rats	B-OG
immunized	O
with	O
MOG	O
73	O
-	O
90	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
each	O
P	O
<	O
0	O
.	O
001	O
)	O
or	O
CFA	O
alone	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
each	O
P	O
<	O
0	O
.	O
001	O
).	O

Cxcr4	B-GP
and	O
Cxcl12	B-GP
expression	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG

Next	O
,	O
we	O
assessed	O
the	O
mRNA	O
expression	O
of	O
Cxcr4	B-GP
(	O
Fig	O
.	O
2A	O
)	O
and	O
its	O
ligand	O
Cxcl12	B-GP
(	O
Fig	O
.	O
2B	O
)	O
in	O
spinal	O
cord	O
of	O
either	O
naive	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
or	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
IFA	O
or	O
CFA	O
alone	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
each	O
n	O
=	O
4	O
).	O

Upregulation	O
of	O
both	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
mRNA	O
expression	O
was	O
observed	O
in	O
CFA	O
-	O
and	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
in	O
spinal	O
cord	O
compared	O
to	O
naive	O
rats	B-OG
,	O
IFA	O
-	O
injected	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Increased	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
mRNA	O
expression	O
was	O
observed	O
in	O
MOG	O
1	O
-	O
125	O
in	O
CFA	O
-	O
compared	O
to	O
CFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O
Fig	O
.	O
2	O
.	O
Cxr4	B-GP
and	O
Cxcl12	B-GP
expression	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O
Quantitative	O
SYBR	O
green	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
Cxcr4	B-GP
(	O
A	O
)	O
and	O
Cxcl12	B-GP
(	O
B	O
)	O
from	O
PBS	O
-	O
perfused	O
spinal	O
cord	O
tissue	O
of	O
naive	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
4	O
),	O
rats	B-OG
immunized	O
with	O
IFA	O
(	O
n	O
=	O
4	O
)	O
or	O
CFA	O
alone	O
(	O
n	O
=	O
4	O
)	O
and	O
DA	O
rats	B-OG
immunized	O
with	O
MOG	O
1	O
-	O
125	O
in	O
IFA	O
(	O
n	O
=	O
4	O
)	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
n	O
=	O
4	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Increased	O
Cxcr4	B-GP
and	O
Cxcl12	B-GP
expression	O
was	O
observed	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
CFA	O
and	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
).	O

There	O
was	O
an	O
upregulation	O
of	O
Cxcr4	B-GP
and	O
Cxcl12	B-GP
mRNA	O
in	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
compared	O
to	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
CFA	O
alone	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
01	O
).	O

Quantitative	O
PCR	O
results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Cxcr4	B-GP
and	O
CXCL12	B-GP
in	O
individuals	O
with	O
MS	B-DS

Upregulation	O
of	O
CXCR4	B-GP
mRNA	O
was	O
also	O
observed	O
in	O
white	O
blood	O
cells	O
of	O
individuals	O
with	O
MS	B-DS
with	O
a	O
relapsing	B-DS
-	I-DS
remitting	I-DS
disease	I-DS
course	O
(	O
RRMS	O
;	O
n	O
=	O
32	O
)	O
and	O
a	O
secondary	O
chronic	B-DS
progressive	I-DS
disease	I-DS
course	O
(	O
SPMS	B-DS
;	O
n	O
=	O
22	O
),	O
and	O
compared	O
to	O
controls	O
(	O
n	O
=	O
25	O
,	O
ANOVA	O
,	O
RRMS	O
and	O
SPMS	O
each	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3A	O
,	O
Tables	O
S6	O
and	O
S7	O
).	O

Also	O
,	O
we	O
detected	O
increased	O
protein	O
CXCL12	B-GP
serum	O
levels	O
in	O
both	O
individuals	O
with	O
RRMS	O
(	O
n	O
=	O
24	O
)	O
and	O
SPMS	O
(	O
n	O
=	O
28	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
21	O
,	O
ANOVA	O
,	O
RRMS	O
and	O
SPMS	O
each	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3B	O
,	O
Tables	O
S6	O
and	O
S7	O
).	O
Fig	O
.	O
3	O
.	O
Cxcr4	B-GP
expression	O
in	O
white	O
blood	O
cells	O
and	O
CXCL12	B-GP
protein	O
in	O
serum	O
of	O
individuals	O
with	O
MS	B-DS
.	O
(	O
A	O
)	O
Cxcr4	B-GP
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
from	O
white	O
blood	O
cells	O
of	O
individuals	O
with	O
relapsing	B-DS
-	I-DS
remitting	I-DS
MS	I-DS
(	O
RR	O
-	O
MS	B-DS
;	O
gray	O
bars	O
,	O
n	O
=	O
32	O
),	O
secondary	O
chronic	B-DS
-	I-DS
progressive	I-DS
MS	I-DS
(	O
SP	O
-	O
MS	B-DS
;	O
black	O
bars	O
,	O
n	O
=	O
22	O
)	O
and	O
controls	O
(	O
white	O
bars	O
,	O
n	O
=	O
25	O
).	O

Upregulation	O
of	O
Cxcr4	B-GP
in	O
both	O
patient	O
groups	O
compared	O
to	O
controls	O
was	O
observed	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
B	O
)	O
CXCL12	B-GP
serum	O
levels	O
were	O
assessed	O
by	O
ELISA	O
in	O
individuals	O
with	O
RR	O
-	O
MS	O
(	O
gray	O
bars	O
,	O
n	O
=	O
24	O
),	O
SP	O
-	O
MS	O
(	O
black	O
bars	O
,	O
n	O
=	O
28	O
)	O
and	O
controls	O
(	O
white	O
bars	O
,	O
n	O
=	O
21	O
).	O

Increased	O
serum	O
levels	O
of	O
CXCL12	B-GP
were	O
measured	O
in	O
both	O
MS	B-DS
groups	O
compared	O
to	O
controls	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

Quantitative	O
PCR	O
results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

EAE	B-DS
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	B-OG
J	I-OG
mice	B-OG

Cd38	B-GP
was	O
strongly	O
upregulated	O
in	O
encephalitogenic	O
LN	O
cells	O
.	O

To	O
functionally	O
validate	O
our	O
data	O
and	O
to	O
elucidate	O
the	O
role	O
of	O
CD38	B-GP
in	O
EAE	B-DS
,	O
we	O
induced	O
disease	O
with	O
the	O
extracellular	O
domain	O
of	O
MOG	B-GP
(	O
MOG	B-GP
1	O
-	O
125	O
)	O
in	O
Cd38	B-GP
-	O
knockout	O
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
mice	B-OG
and	O
appropriate	O
controls	O
.	O

We	O
found	O
reduced	O
disease	O
severity	O
in	O
MOG	B-GP
1	O
-	O
125	O
-	O
immunized	O
B6	B-OG
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
22	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	B-OG
(	O
n	O
=	O
21	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
4A	O
).	O

Next	O
,	O
we	O
determined	O
the	O
height	O
of	O
the	O
antibody	B-GP
response	O
to	O
MOG	B-GP
1	O
-	O
125	O
.	O

Reduced	O
anti	O
-	O
MOG	B-GP
IgG	B-GP
autoantibody	B-GP
responses	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
4	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	B-OG
(	O
n	O
=	O
4	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
immunization	O
with	O
MOG	B-GP
1	O
-	O
125	O
were	O
seen	O
(	O
Fig	O
.	O
4B	O
)	O
on	O
day	O
12	O
post	O
-	O
immunization	O
(	O
p	O
.	O
i	O
.).	O

Furthermore	O
,	O
also	O
T	O
-	O
cell	O
responses	O
upon	O
restimulation	O
with	O
MOG	B-GP
1	O
-	O
125	O
were	O
reduced	O
in	O
the	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	B-OG
J	I-OG
mice	I-OG
(	O
n	O
=	O
4	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O
compared	O
to	O
control	O
mice	B-OG
(	O
n	O
=	O
4	O
,	O
t	O
-	O
test	O
for	O
stimulation	O
with	O
50	O
µg	O
/	O
ml	O
MOG	B-GP
1	O
-	O
125	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
as	O
measured	O
in	O
a	O
proliferation	O
assay	O
,	O
indicating	O
in	O
addition	O
a	O
T	O
-	O
cell	O
priming	O
or	O
expansion	O
defect	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
Fig	O
.	O
4C	O
).	O
Fig	O
.	O
4	O
.	O
EAE	B-DS
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	B-OG
mice	I-OG
.	O
(	O
A	O
)	O
EAE	B-DS
was	O
induced	O
in	O
female	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	B-OG
mice	I-OG
(	O
white	O
triangles	O
)	O
and	O
C57BL	O
/	O
6J	O
000664	O
controls	O
(	O
black	O
triangles	O
)	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

On	O
days	O
0	O
and	O
2	O
p	O
.	O
i	O
.,	O
mice	B-OG
received	O
an	O
intravenous	O
injection	O
of	O
150	O
ng	O
pertussis	B-GP
toxin	I-GP
.	O

EAE	B-DS
was	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
disease	O
;	O
1	O
,	O
tail	O
paralysis	O
;	O
2	O
,	O
paraparesis	O
;	O
3	O
,	O
paraplegia	O
;	O
4	O
,	O
tetraparalysis	O
;	O
5	O
,	O
moribund	O
or	O
dead	O
.	O

Immunization	O
with	O
the	O
extracellular	O
domain	O
of	O
MOG	B-GP
1	O
-	O
125	O
resulted	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	B-OG
J	I-OG
mice	B-OG
(	O
n	O
=	O
22	O
)	O
with	O
lower	O
disease	O
severity	O
compared	O
to	O
C57BL	B-OG
/	I-OG
6J	I-OG
000664	I-OG
mice	I-OG
(	O
n	O
=	O
21	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

(	O
B	O
)	O
Antibodies	B-GP
against	O
MOG	B-GP
1	O
-	O
125	O
were	O
measured	O
by	O
ELISA	O
as	O
described	O
(	O
Weissert	O
et	O
al	O
.,	O
2001	O
).	O

B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	B-OG
J	O
mice	B-OG
(	O
white	O
bars	O
,	O
n	O
=	O
4	O
)	O
had	O
reduced	O
IgG	B-GP
and	O
IgG1	B-GP
antibodies	B-GP
compared	O
to	O
C57BL	O
/	B-OG
6J	O
000664	O
mice	B-OG
(	O
black	O
bars	O
,	O
n	O
=	O
4	O
)	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

(	O
C	O
)	O
T	O
-	O
cell	O
responses	O
upon	O
restimulation	O
against	O
MOG	O
1	O
-	O
125	O
from	O
draining	O
lymph	O
nodes	O
(	O
LNs	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O
were	O
reduced	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
(	O
white	O
triangles	O
,	O
n	O
=	O
4	O
)	O
compared	O
to	O
C57BL	O
/	O
6J	O
000664	O
(	O
black	O
triangles	O
,	O
n	O
=	O
4	O
)	O
mice	B-OG
(	O
t	O
-	O
test	O
for	O
stimulation	O
with	O
50	O
µg	O
/	O
ml	O
MOG	O
1	O
-	O
125	O
,	O
*	O
P	O
=	O
0	O
.	O
05	O
).	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Targeting	O
cellular	O
migration	O
by	O
FTY720	B-CD

We	O
found	O
an	O
upregulation	O
of	O
Akt	B-GP
in	O
our	O
differential	O
gene	O
expression	O
studies	O
(	O
Table	O
1	O
).	O

FTY720	B-CD
is	O
an	O
S1P	B-GP
-	I-GP
receptor	I-GP
modulator	O
known	O
to	O
influence	O
T	O
-	O
cell	O
trafficking	O
by	O
an	O
Akt	B-GP
-	O
dependent	O
mechanism	O
,	O
as	O
does	O
CXCR4	B-GP
(	O
Mandala	O
et	O
al	O
.,	O
2002	O
;	O
Cyster	O
,	O
2005	O
;	O
Lee	O
et	O
al	O
.,	O
2001	O
;	O
Brinkmann	O
et	O
al	O
.,	O
2002	O
;	O
Matloubian	O
et	O
al	O
.,	O
2004	O
).	O

We	O
evaluated	O
inhibition	O
of	O
Akt	B-GP
-	O
dependent	O
cell	O
trafficking	O
in	O
MOG	O
91	O
-	O
108	O
-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O

Disease	O
was	O
completely	O
inhibited	O
in	O
rats	B-OG
treated	O
from	O
day	O
0	O
p	O
.	O
i	O
.	O
with	O
FTY720	B-CD
(	O
n	O
=	O
10	O
)	O
as	O
compared	O
to	O
the	O
vehicle	O
-	O
treated	O
controls	O
(	O
n	O
=	O
10	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
5A	O
).	O

Next	O
,	O
we	O
tested	O
the	O
efficacy	O
of	O
FTY720	B-CD
to	O
treat	O
established	O
relapsing	O
-	O
remitting	O
MOG	B-GP
1	O
-	O
125	O
-	O
induced	O
EAE	B-DS
in	O
the	O
DA	O
(	O
RT1av1	O
)	O
rat	B-OG
.	O

FTY720	B-CD
treatment	O
was	O
started	O
on	O
day	O
21	O
p	O
.	O
i	O
.,	O
after	O
the	O
first	O
bout	O
of	O
disease	O
(	O
n	O
=	O
8	O
),	O
and	O
showed	O
a	O
significant	O
effect	O
on	O
the	O
disease	O
course	O
as	O
compared	O
to	O
vehicle	O
treatment	O
(	O
n	O
=	O
8	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
21	O
-	O
44	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
5B	O
).	O

To	O
further	O
examine	O
the	O
beneficial	O
effect	O
of	O
FTY720	B-CD
treatment	O
on	O
EAE	B-DS
,	O
we	O
boosted	O
the	O
rats	B-OG
with	O
MOG	B-GP
1	O
-	O
125	O
on	O
day	O
44	O
after	O
the	O
first	O
immunization	O
.	O

Although	O
a	O
relapse	O
was	O
induced	O
in	O
both	O
groups	O
,	O
the	O
DA	O
rats	B-OG
under	O
FTY720	B-CD
treatment	O
had	O
a	O
better	O
clinical	O
outcome	O
compared	O
to	O
the	O
vehicle	O
-	O
treated	O
animals	B-OG
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
45	O
-	O
56	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
0001	O
).	O

On	O
day	O
14	O
p	O
.	O
i	O
.,	O
FTY720	B-CD
treatment	O
led	O
to	O
an	O
increase	O
of	O
the	O
relative	O
size	O
of	O
the	O
CD4	B-GP
T	O
-	O
cell	O
compartment	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
treated	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
10	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
9	O
)	O
concurrent	O
with	O
a	O
decrease	O
in	O
the	O
CD8	B-GP
T	O
-	O
cell	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
B	O
-	O
cell	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
compartment	O
(	O
Fig	O
.	O
5C	O
;	O
Fig	O
.	O
S1	O
).	O

FTY720	B-CD
treatment	O
(	O
n	O
=	O
9	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
9	O
)	O
led	O
to	O
the	O
downregulation	O
of	O
mRNA	O
expression	O
of	O
its	O
receptor	O
,	O
S1p1	B-GP
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
and	O
of	O
Akt2	B-GP
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
one	O
of	O
the	O
genes	O
involved	O
in	O
the	O
intracellular	O
signaling	O
cascade	O
connected	O
to	O
S1P1	B-GP
and	O
CXCR4	B-GP
,	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O

Treatment	O
also	O
had	O
a	O
negative	O
effect	O
on	O
the	O
expression	O
levels	O
of	O
Cd38	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
).	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
Cxcr4	B-GP
was	O
not	O
altered	O
(	O
ANOVA	O
,	O
not	O
significant	O
)	O
(	O
Fig	O
.	O
5D	O
).	O
Fig	O
.	O
5	O
.	O
Influence	O
of	O
FTY720	B-CD
in	O
EAE	B-DS
.	O
(	O
A	O
)	O
Female	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
immunized	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

EAE	B-DS
was	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
disease	O
;	O
1	O
,	O
tail	O
paralysis	O
;	O
2	O
,	O
paraparesis	O
;	O
3	O
,	O
paraplegia	O
;	O
4	O
,	O
tetraparalysis	O
;	O
5	O
,	O
moribund	O
or	O
dead	O
.	O

FTY720	B-CD
completely	O
inhibited	O
EAE	B-DS
in	O
rats	B-OG
treated	O
orally	O
with	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
from	O
day	O
0	O
p	O
.	O
i	O
.	O
daily	O
(	O
white	O
triangles	O
,	O
n	O
=	O
10	O
)	O
as	O
compared	O
to	O
vehicle	O
(	O
PBS	O
)-	O
treated	O
controls	O
(	O
black	O
triangles	O
,	O
n	O
=	O
10	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
,	O
P	O
<	O
0	O
.	O
0001	O
).	O

(	O
B	O
)	O
Female	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
treated	O
orally	O
with	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
FTY720	B-CD
daily	O
starting	O
on	O
day	O
21	O
p	O
.	O
i	O
.	O
after	O
a	O
first	O
bout	O
of	O
disease	O
(	O
white	O
triangles	O
,	O
n	O
=	O
8	O
)	O
showed	O
a	O
reduced	O
disease	O
course	O
compared	O
to	O
vehicle	O
(	O
PBS	O
)-	O
treated	O
controls	O
(	O
black	O
triangles	O
,	O
n	O
=	O
8	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
21	O
-	O
44	O
p	O
.	O
i	O
.,	O
P	O
=	O
0	O
.	O
01	O
).	O

On	O
day	O
44	O
p	O
.	O
i	O
.,	O
rats	B-OG
were	O
boosted	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

Both	O
groups	O
relapsed	O
but	O
with	O
a	O
better	O
outcome	O
for	O
the	O
FTY720	B-CD
-	O
treated	O
group	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
45	O
-	O
56	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
0001	O
).	O

(	O
C	O
)	O
FACS	O
analysis	O
of	O
cells	O
from	O
draining	O
lymph	O
nodes	O
(	O
LNs	O
)	O
demonstrated	O
an	O
increase	O
in	O
relative	O
size	O
of	O
the	O
CD4	B-GP
T	O
-	O
cell	O
compartment	O
and	O
a	O
decrease	O
in	O
the	O
size	O
of	O
the	O
CD8	B-GP
and	O
B	O
-	O
cell	O
compartment	O
in	O
FTY720	B-CD
-	O
treated	O
(	O
white	O
bars	O
,	O
n	O
=	O
10	O
)	O
rats	B-OG
compared	O
to	O
controls	O
(	O
black	O
bars	O
,	O
n	O
=	O
9	O
)	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
01	O
)	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
Expression	O
of	O
S1p1	B-GP
(	O
Edg1	B-GP
),	O
Akt2	B-GP
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
was	O
assessed	O
in	O
FTY720	B-CD
-	O
treated	O
rats	B-OG
(	O
white	O
bars	O
,	O
n	O
=	O
9	O
)	O
compared	O
to	O
vehicle	O
-	O
treated	O
controls	O
(	O
black	O
bars	O
,	O
n	O
=	O
9	O
)	O
by	O
quantitative	O
PCR	O
.	O

FTY720	B-CD
treatment	O
led	O
to	O
downregulation	O
of	O
S1p1	B-GP
and	O
Akt2	B-GP
as	O
well	O
as	O
Cd38	B-GP
,	O
but	O
not	O
of	O
Cxcr4	B-GP
(	O
ANOVA	O
for	O
all	O
except	O
Cxcr4	B-GP
,	O
*	O
P	O
<	O
0	O
.	O
0001	O
)	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O
from	O
cells	O
derived	O
from	O
LNs	O
.	O

Results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

DISCUSSION	O

In	O
this	O
study	O
we	O
identified	O
gene	O
networks	O
that	O
are	O
crucially	O
involved	O
not	O
only	O
in	O
raising	O
an	O
autoantigen	O
-	O
specific	O
immune	O
response	O
but	O
also	O
in	O
constituting	O
encephalitogenicity	O
.	O

We	O
analyzed	O
the	O
expression	O
and	O
functional	O
relevance	O
of	O
genes	O
and	O
their	O
products	O
expressed	O
on	O
lymphocytes	O
after	O
immunization	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
91	O
-	O
108	O
peptide	O
in	O
adjuvant	O
,	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
peptide	O
in	O
adjuvant	O
,	O
adjuvant	O
alone	O
or	O
naive	O
rats	B-OG
.	O

Most	O
interestingly	O
,	O
in	O
the	O
comparison	O
of	O
MOG	B-GP
91	O
-	O
108	O
in	O
adjuvant	O
to	O
MOG	B-GP
73	O
-	O
90	O
in	O
adjuvant	O
immunized	O
rats	B-OG
,	O
compared	O
to	O
the	O
other	O
analyses	O
,	O
only	O
a	O
small	O
number	O
of	O
genes	O
were	O
differentially	O
expressed	O
.	O

These	O
genes	O
seem	O
to	O
be	O
of	O
major	O
importance	O
because	O
they	O
are	O
genes	O
involved	O
in	O
the	O
encephalitogenic	O
response	O
leading	O
to	O
disease	O
manifestation	O
.	O

From	O
the	O
overall	O
expression	O
data	O
,	O
we	O
selected	O
three	O
genes	O
that	O
were	O
upregulated	O
in	O
many	O
comparisons	O
:	O
Cxcr4	B-GP
,	O
Cd38	B-GP
and	O
Akt	B-GP
.	O

We	O
performed	O
functional	O
studies	O
regarding	O
these	O
genes	O
in	O
EAE	B-DS
and	O
analyzed	O
tissue	O
samples	O
from	O
individuals	O
with	O
MS	B-DS
.	O

CXCR4	B-GP
(	O
CD184	B-GP
)	O
is	O
a	O
seven	B-GP
-	I-GP
transmembrane	I-GP
G	I-GP
-	I-GP
coupled	I-GP
receptor	I-GP
expressed	O
by	O
a	O
number	O
of	O
tissues	O
,	O
including	O
cells	O
of	O
the	O
immune	O
system	O
(	O
Campbell	O
et	O
al	O
.,	O
2003	O
).	O
Cxcr4	B-GP
-	O
knockout	O
mice	B-OG
die	O
in	O
utero	O
or	O
perinatally	O
and	O
do	O
not	O
only	O
have	O
defects	O
in	O
the	O
hematopoietic	O
system	O
(	O
impairment	O
of	O
myeloid	O
and	O
B	O
-	O
cell	O
generation	O
,	O
reduced	O
proliferation	O
of	O
triple	O
-	O
negative	O
and	O
double	O
-	O
positive	O
lymphocytes	O
),	O
but	O
also	O
in	O
the	O
circulatory	O
system	O
and	O
in	O
the	O
CNS	O
(	O
Zou	O
et	O
al	O
.,	O
1998	O
;	O
Tachibana	O
et	O
al	O
.,	O
1998	O
).	O

Overexpression	O
of	O
CXCR4	B-GP
on	O
T	O
cells	O
induces	O
their	O
accumulation	O
in	O
the	O
bone	O
marrow	O
and	O
reduction	O
of	O
these	O
cells	O
in	O
the	O
peripheral	O
blood	O
.	O

CXCR4	B-GP
signaling	O
leads	O
to	O
a	O
prolonged	O
protein	B-GP
kinase	I-GP
B	I-GP
(	O
AKT	B-GP
)	O
and	O
extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
2	I-GP
activation	O
in	O
T	O
cells	O
.	O

AKT	B-GP
activation	O
promotes	O
cell	O
survival	O
and	O
can	O
act	O
as	O
a	O
co	O
-	O
stimulation	O
for	O
T	O
-	O
cell	O
activation	O
(	O
Tilton	O
et	O
al	O
.,	O
2000	O
).	O

CXCR4	B-GP
has	O
only	O
one	O
known	O
cognate	O
ligand	O
,	O
which	O
is	O
CXCL12	B-GP
.	O

CXCL12	B-GP
is	O
constitutively	O
produced	O
by	O
stromal	O
and	O
endothelial	O
cells	O
.	O

CXCL12	B-GP
activates	O
numerous	O
signaling	O
pathways	O
,	O
such	O
as	O
receptor	B-GP
-	I-GP
associated	I-GP
trimeric	I-GP
G	I-GP
proteins	I-GP
,	O
phospholipase	B-GP
Cγ	I-GP
,	O
PI3K	B-GP
and	O
small	B-GP
G	I-GP
proteins	I-GP
(	O
Pawig	O
et	O
al	O
.,	O
2015	O
).	O

Signaling	O
through	O
these	O
receptors	O
leads	O
to	O
an	O
increase	O
in	O
the	O
intracellular	O
calcium	O
concentration	O
,	O
cytoskeleton	O
reorganization	O
and	O
cellular	O
migration	O
.	O

Several	O
modulating	O
factors	O
such	O
as	O
phosphatases	B-GP
,	O
regulator	O
of	O
G	B-GP
-	I-GP
protein	I-GP
signaling	O
,	O
adaptor	B-GP
proteins	I-GP
and	O
ubiquitin	B-GP
may	O
affect	O
signaling	O
and	O
/	O
or	O
chemotactic	O
response	O
of	O
CXCR4	B-GP
to	O
its	O
ligand	O
(	O
CXCL12	B-GP
).	O

An	O
important	O
function	O
of	O
CXCR4	B-GP
/	O
CXCL12	B-GP
is	O
the	O
regulation	O
of	O
bone	O
-	O
marrow	O
homeostasis	O
and	O
lymphocyte	O
trafficking	O
.	O

Chemotaxis	B-GP
and	O
integrin	B-GP
-	O
mediated	O
adhesion	O
are	O
the	O
main	O
cellular	O
responses	O
to	O
CXCL12	B-GP
.	O
Cxcl12	B-GP
-	O
knockout	O
mice	B-OG
display	O
the	O
same	O
phenotype	O
as	O
Cxcr4	B-GP
-	O
knockout	O
mice	B-OG
(	O
Nagasawa	O
et	O
al	O
.,	O
1996	O
).	O

In	O
autoimmunity	B-DS
there	O
are	O
indications	O
that	O
the	O
interaction	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
could	O
be	O
important	O
.	O

CXCL12	B-GP
recruits	O
B	O
cells	O
to	O
inflamed	O
glomeruli	O
,	O
in	O
which	O
these	O
cells	O
can	O
produce	O
autoantibodies	B-GP
(	O
Balabanian	O
et	O
al	O
.,	O
2003	O
).	O

Also	O
,	O
in	O
rheumatoid	B-DS
arthritis	I-DS
,	O
CXCR4	B-GP
and	O
CXCL12	B-GP
have	O
been	O
proposed	O
to	O
be	O
important	O
in	O
the	O
disease	O
precipitation	O
(	O
Zhang	O
et	O
al	O
.,	O
2005	O
).	O

A	O
role	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
in	O
EAE	B-DS
(	O
Meiron	O
et	O
al	O
.,	O
2008	O
;	O
Kohler	O
et	O
al	O
.,	O
2008	O
;	O
McCandless	O
et	O
al	O
.,	O
2006	O
)	O
as	O
well	O
as	O
in	O
MS	B-DS
(	O
Azin	O
et	O
al	O
.,	O
2012	O
;	O
Krumbholz	O
et	O
al	O
.,	O
2006	O
)	O
has	O
been	O
described	O
.	O

Our	O
data	O
indicate	O
that	O
,	O
also	O
in	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
and	O
possibly	O
in	O
MS	B-DS
,	O
the	O
interaction	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
is	O
of	O
paramount	O
importance	O
for	O
disease	O
development	O
.	O

We	O
found	O
specific	O
upregulation	O
of	O
Cxcr4	B-GP
on	O
cells	O
derived	O
from	O
LNs	O
and	O
eluted	O
from	O
the	O
CNS	O
of	O
rats	B-OG
immunized	O
with	O
encephalitogenic	O
MOG	B-GP
91	O
-	O
108	O
peptide	O
in	O
comparison	O
to	O
controls	O
.	O

In	O
addition	O
,	O
we	O
measured	O
upregulation	O
of	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
in	O
spinal	O
cords	O
in	O
EAE	B-DS
rats	B-OG
compared	O
to	O
controls	O
.	O

CXCL12	B-GP
is	O
upregulated	O
in	O
the	O
CNS	O
of	O
individuals	O
with	O
MS	B-DS
(	O
Krumbholz	O
et	O
al	O
.,	O
2006	O
and	O
our	O
own	O
unpublished	O
observations	O
).	O

Together	O
,	O
the	O
presented	O
data	O
would	O
argue	O
for	O
a	O
scenario	O
in	O
which	O
LN	O
-	O
derived	O
cells	O
are	O
,	O
in	O
the	O
context	O
of	O
an	O
encounter	O
with	O
an	O
encephalitogenic	O
antigen	O
,	O
activated	O
and	O
migrate	O
towards	O
CXCL12	B-GP
in	O
the	O
CNS	O
.	O

This	O
is	O
further	O
underscored	O
by	O
the	O
fact	O
that	O
nitric	O
oxide	O
enhances	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
expression	O
of	O
CXCR4	B-GP
and	O
migration	O
towards	O
CXCL12	B-GP
(	O
Giordano	O
et	O
al	O
.,	O
2006	O
).	O

CD38	B-GP
is	O
a	O
membrane	B-GP
-	I-GP
associated	I-GP
type	I-GP
II	I-GP
glycoprotein	I-GP
that	O
acts	O
both	O
as	O
a	O
receptor	O
and	O
enzyme	O
(	O
Cockayne	O
et	O
al	O
.,	O
1998	O
;	O
Kato	O
et	O
al	O
.,	O
1999	O
;	O
Salmi	O
and	O
Jalkanen	O
,	O
2005	O
).	O

As	O
an	O
enzyme	O
it	O
catalyzes	O
NAD	O
+	O
into	O
cyclic	O
ADP	O
-	O
ribose	O
and	O
further	O
into	O
ADP	O
-	O
ribose	O
.	O

It	O
also	O
regulates	O
Ca2	O
+	O
levels	O
from	O
ryanodine	B-GP
receptor	I-GP
stores	O
.	O

CD38	B-GP
is	O
expressed	O
on	O
a	O
variety	O
of	O
myeloid	O
and	O
lymphoid	O
cells	O
.	O

CD38	B-GP
ligation	O
in	O
B	O
cells	O
leads	O
to	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
proteins	O
such	O
as	O
Syk	B-GP
,	O
p85	B-GP
of	O
phophatidylinositol	B-GP
-	I-GP
3	I-GP
kinase	I-GP
and	O
phospholipase	B-GP
C	I-GP
-	I-GP
γ	I-GP
(	O
Silvennoinen	O
et	O
al	O
.,	O
1996	O
).	O

CD38	B-GP
ligation	O
in	O
T	O
cells	O
results	O
in	O
phosphorylation	O
of	O
the	O
Raf	B-GP
-	I-GP
1	I-GP
/	O
MAP	B-GP
kinase	I-GP
and	O
CD3	B-GP
-	I-GP
ζ	I-GP
/	O
ZAP	B-GP
-	I-GP
70	I-GP
signaling	O
pathway	O
(	O
Zubiaur	O
et	O
al	O
.,	O
1997	O
).	O

Furthermore	O
,	O
it	O
is	O
involved	O
in	O
dendritic	O
cell	O
migration	O
and	O
adhesion	O
between	O
lymphocytes	O
and	O
endothelial	O
cells	O
(	O
Partida	O
-	O
Sanchez	O
et	O
al	O
.,	O
2004	O
).	O

B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	B-OG
mice	I-OG
show	O
a	O
slight	O
reduction	O
of	O
antibody	B-GP
titers	O
to	O
T	O
-	O
cell	O
-	O
dependent	O
antigens	O
(	O
Cockayne	O
et	O
al	O
.,	O
1998	O
).	O

Additionally	O
,	O
these	O
mice	B-OG
had	O
increased	O
susceptibility	O
to	O
bacterial	B-DS
infections	I-DS
,	O
which	O
is	O
thought	O
to	O
be	O
caused	O
by	O
a	O
defective	O
chemotactic	O
response	O
of	O
neutrophils	O
towards	O
bacteria	B-OG
,	O
underscoring	O
a	O
role	O
in	O
innate	O
immunity	O
as	O
well	O
(	O
Partida	O
-	O
Sanchez	O
et	O
al	O
.,	O
2001	O
).	O

We	O
induced	O
EAE	B-DS
in	O
Cd38	B-GP
-	O
knockout	O
mice	B-OG
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
and	O
controls	O
.	O
Cd38	B-GP
-	O
knockout	O
mice	B-OG
had	O
a	O
reduced	O
disease	O
severity	O
and	O
lower	O
autoantibody	B-GP
and	O
T	O
-	O
cell	O
responses	O
as	O
compared	O
to	O
the	O
controls	O
.	O

These	O
findings	O
show	O
the	O
importance	O
of	O
CD38	B-GP
in	O
EAE	B-DS
and	O
possibly	O
MS	B-DS
.	O

This	O
work	O
forms	O
the	O
basis	O
for	O
further	O
analysis	O
of	O
the	O
involved	O
cellular	O
compartments	O
and	O
regulation	O
of	O
human	B-OG
disease	O
(	O
Mayo	O
et	O
al	O
.,	O
2008	O
;	O
Lischke	O
et	O
al	O
.,	O
2013	O
).	O

FTY720	B-CD
is	O
a	O
potent	O
drug	O
that	O
affects	O
lymphocyte	O
trafficking	O
and	O
homing	O
.	O

Our	O
studies	O
and	O
studies	O
by	O
others	O
(	O
Brinkmann	O
et	O
al	O
.,	O
2002	O
;	O
Balatoni	O
et	O
al	O
.,	O
2007	O
)	O
showed	O
a	O
strong	O
beneficial	O
effect	O
of	O
FTY720	B-CD
on	O
EAE	B-DS
under	O
various	O
experimental	O
settings	O
.	O

The	O
drug	O
was	O
approved	O
for	O
treatment	O
of	O
MS	B-DS
(	O
Kappos	O
et	O
al	O
.,	O
2010	O
).	O

We	O
demonstrate	O
that	O
treatment	O
of	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
with	O
FTY720	B-CD
impacts	O
the	O
gene	O
expression	O
of	O
the	O
genes	O
that	O
are	O
involved	O
in	O
encephalitogenic	O
immune	O
responses	O
.	O

This	O
further	O
validates	O
our	O
approach	O
.	O

We	O
measured	O
changes	O
in	O
expression	O
of	O
S1P1	B-GP
,	O
Akt2	B-GP
and	O
Cd38	B-GP
.	O

Interestingly	O
,	O
no	O
changes	O
in	O
expression	O
of	O
Cxcr4	B-GP
was	O
observed	O
.	O

The	O
reason	O
for	O
this	O
is	O
not	O
fully	O
understood	O
and	O
deserves	O
further	O
investigations	O
.	O

In	O
conclusion	O
,	O
in	O
this	O
study	O
we	O
have	O
identified	O
genes	O
that	O
are	O
involved	O
not	O
only	O
in	O
raising	O
autoantigen	O
-	O
specific	O
immune	O
responses	O
but	O
which	O
constitute	O
encephalitogenicity	O
.	O

The	O
immunization	O
with	O
encephalitogenic	O
peptides	O
induces	O
a	O
network	O
of	O
genes	O
involved	O
in	O
activation	O
and	O
migration	O
of	O
lymphocytes	O
.	O

Based	O
on	O
this	O
platform	O
,	O
we	O
have	O
established	O
the	O
paramount	O
importance	O
of	O
G	B-GP
-	I-GP
coupled	I-GP
proteins	I-GP
in	O
encephalitogenicity	O
of	O
adaptive	O
immune	O
responses	O
.	O

We	O
speculate	O
that	O
similar	O
involvement	O
might	O
operate	O
also	O
in	O
other	O
autoimmune	B-DS
diseases	I-DS
and	O
possibly	O
in	O
transplant	O
rejection	O
,	O
thereby	O
establishing	O
common	O
mechanisms	O
.	O

These	O
pathways	O
might	O
be	O
valuable	O
targets	O
of	O
therapeutic	O
approaches	O
as	O
we	O
have	O
shown	O
attenuation	O
of	O
EAE	B-DS
after	O
treatment	O
with	O
FTY720	B-CD
or	O
reduced	O
EAE	B-DS
severity	O
in	O
CD38	B-GP
-	O
deficient	O
mice	B-OG
.	O

These	O
findings	O
not	O
only	O
validate	O
our	O
gene	O
expression	O
data	O
,	O
but	O
also	O
underscore	O
the	O
importance	O
of	O
the	O
rat	B-OG
EAE	B-DS
model	O
in	O
translational	O
medicine	O
.	O

MATERIALS	O
AND	O
METHODS	O

Animals	B-OG
and	O
EAE	B-DS
induction	O

Female	O
rats	B-OG
or	O
mice	B-OG
,	O
10	O
-	O
14	O
weeks	O
of	O
age	O
,	O
were	O
used	O
in	O
all	O
experiments	O
.	O

LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
obtained	O
from	O
Hans	O
Hedrich	O
(	O
Central	O
Animal	B-OG
Laboratory	O
,	O
Hannover	O
Medical	O
School	O
,	O
Hannover	O
,	O
Germany	O
)	O
and	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
obtained	O
from	O
Harlan	O
Winkelmann	O
(	O
Borchen	O
,	O
Germany	O
).	O

Female	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	B-OG
J	O
mice	B-OG
and	O
the	O
appropriate	O
controls	O
(	O
C57BL	O
/	O
6J	O
000664	O
)	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
USA	O
).	O

Animals	B-OG
were	O
bred	O
and	O
kept	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

Animals	B-OG
were	O
injected	O
intradermally	O
at	O
the	O
base	O
of	O
the	O
tail	O
(	O
rats	B-OG
)	O
or	O
both	O
flanks	O
(	O
mice	B-OG
)	O
with	O
100	O
µg	O
of	O
MOG	B-GP
91	O
-	O
108	O
(	O
rats	B-OG
)	O
or	O
50	O
µg	O
of	O
rat	B-OG
recombinant	O
MOG	B-GP
1	O
-	O
125	O
(	O
rats	B-OG
)	O
or	O
100	O
µg	O
MOG	B-GP
35	O
-	O
55	O
(	O
mice	B-OG
)	O
or	O
20	O
µg	O
rat	B-OG
recombinant	O
MOG	B-GP
1	I-GP
-	O
125	O
(	O
mice	B-OG
).	O

The	O
antigens	O
in	O
a	O
total	O
volume	O
of	O
100	O
µl	O
were	O
mixed	O
with	O
100	O
µl	O
of	O
CFA	O
(	O
1	O
:	O
1	O
).	O

A	O
total	O
of	O
100	O
µl	O
of	O
CFA	O
consisted	O
of	O
IFA	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
and	O
500	O
µg	O
for	O
rats	B-OG
or	O
400	O
µg	O
for	O
mice	B-OG
of	O
heat	O
-	O
inactivated	O
Mycobacterium	B-OG
tuberculosis	I-OG
(	O
strain	O
H37	O
RA	O
;	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
MI	O
)	O
(	O
Weissert	O
,	O
2016	O
).	O

Mice	B-OG
additionally	O
received	O
100	O
ng	O
of	O
pertussis	B-GP
toxin	I-GP
(	O
Calbiochem	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
on	O
day	O
0	O
and	O
2	O
intravenously	O
.	O

Some	O
groups	O
of	O
rats	B-OG
were	O
also	O
injected	O
with	O
100	O
µl	O
IFA	O
mixed	O
with	O
100	O
µl	O
MOG	B-GP
1	O
-	O
125	O
in	O
PBS	O
(	O
50	O
µg	O
)	O
without	O
the	O
addition	O
of	O
Mycobacterium	B-OG
tuberculosis	I-OG
or	O
with	O
IFA	O
or	O
CFA	O
alone	O
.	O

The	O
clinical	O
scoring	O
was	O
as	O
follows	O
:	O
0	O
=	O
no	O
illness	O
;	O
1	O
=	O
tail	O
weakness	O
or	O
paralysis	O
;	O
2	O
=	O
hind	O
-	O
leg	O
paraparesis	O
or	O
hemiparesis	O
;	O
3	O
=	O
hind	O
-	O
leg	O
paralysis	O
or	O
hemiparalysis	O
;	O
4	O
=	O
tetraparesis	O
or	O
moribund	O
.	O

All	O
experiments	O
were	O
approved	O
by	O
the	O
regional	O
board	O
in	O
Tübingen	O
,	O
Germany	O
.	O

Human	B-OG
samples	O

Blood	O
samples	O
were	O
obtained	O
after	O
consent	O
from	O
individuals	O
with	O
MS	B-DS
and	O
controls	O
.	O

The	O
characteristics	O
of	O
the	O
MS	B-DS
individuals	O
and	O
controls	O
are	O
indicated	O
in	O
Tables	O
S6	O
and	O
S7	O
.	O

The	O
research	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Tübingen	O
in	O
Germany	O
(	O
Permission	O
125	O
/	O
2001	O
).	O

Isolation	O
of	O
CNS	O
-	O
infiltrating	O
cells	O

Infiltrating	O
cells	O
from	O
the	O
CNS	O
were	O
prepared	O
as	O
described	O
before	O
(	O
Weissert	O
et	O
al	O
.,	O
1998a	O
,	O
2001	O
).	O

In	O
brief	O
,	O
rats	B-OG
were	O
perfused	O
with	O
cold	O
PBS	O
,	O
and	O
brains	O
and	O
spinal	O
cords	O
were	O
dissected	O
out	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Subsequently	O
,	O
brains	O
and	O
spinal	O
cords	O
were	O
homogenized	O
in	O
10	O
ml	O
50	O
%	O
Percoll	O
/	O
0	O
.	O
1	O
%	O
BSA	B-GP
/	O
1	O
%	O
glucose	B-CD
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
containing	O
500	O
U	O
DNase	B-GP
type	I-GP
I	I-GP
(	O
Life	O
Technologies	O
).	O

Ten	O
ml	O
of	O
50	O
%	O
Percoll	O
was	O
added	O
to	O
each	O
sample	O
after	O
homogenization	O
.	O

A	O
discontinuous	O
Percoll	O
gradient	O
was	O
obtained	O
by	O
adding	O
7	O
ml	O
of	O
63	O
%	O
Percoll	O
below	O
and	O
20	O
ml	O
of	O
30	O
%	O
Percoll	O
above	O
the	O
sample	O
.	O

Samples	O
were	O
centrifuged	O
for	O
40	O
min	O
at	O
1000	O
g	O
at	O
4	O
°	O
C	O
.	O

Lymphocytes	O
were	O
collected	O
from	O
the	O
63	O
/	O
50	O
%	O
Percoll	O
interface	O
.	O

The	O
cells	O
were	O
subsequently	O
washed	O
twice	O
in	O
15	O
-	O
25	O
ml	O
PBS	O
with	O
centrifugation	O
at	O
600	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

Isolation	O
of	O
mononuclear	O
cells	O
from	O
lymph	O
nodes	O
and	O
spleens	O

Draining	O
inguinal	O
LNs	O
and	O
spleens	O
were	O
dissected	O
out	O
under	O
deep	O
anesthesia	O
.	O

LNs	O
were	O
disrupted	O
and	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
washed	O
twice	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
;	O
Life	O
Technologies	O
,	O
Paisley	O
,	O
UK	O
),	O
resuspended	O
in	O
complete	O
medium	O
(	O
CM	O
)	O
containing	O
DMEM	O
supplemented	O
with	O
5	O
%	O
fetal	O
calf	O
serum	O
(	O
PAA	O
Laboratories	O
Linz	O
,	O
Austria	O
),	O
1	O
%	O
penicillin	B-CD
/	O
streptomycin	B-CD
(	O
Life	O
Technologies	O
),	O
1	O
%	O
glutamine	B-CD
(	O
Life	O
Technologies	O
)	O
and	O
50	O
µM	O
2	O
-	O
mercaptoethanol	O
(	O
Life	O
Technologies	O
),	O
and	O
flushed	O
through	O
a	O
70	O
-	O
µm	O
plastic	O
strainer	O
(	O
Falcon	O
;	O
BD	O
Biosciences	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
).	O

MNCs	O
from	O
spleen	O
were	O
prepared	O
in	O
the	O
same	O
way	O
as	O
from	O
LNs	O
with	O
the	O
difference	O
that	O
red	O
blood	O
cells	O
were	O
lysed	O
with	O
lysis	O
buffer	O
consisting	O
of	O
0	O
.	O
15	O
M	O
NH4Cl	O
,	O
10	O
mM	O
KHCO3	O
and	O
0	O
.	O
1	O
mM	O
Na2	O
EDTA	O
adjusted	O
to	O
pH	O
7	O
.	O
4	O
.	O

CD4	B-GP
+	O
cells	O
were	O
isolated	O
by	O
anti	O
-	O
rat	B-OG
CD4	B-GP
microbeads	O
using	O
MACS	O
technology	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

CD4	B-GP
+	O
cell	O
purification	O

CD4	B-GP
+	O
cells	O
from	O
the	O
LNs	O
were	O
purified	O
by	O
MACS	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
and	O
subsequently	O
analyzed	O
by	O
Affymetrix	O
gene	O
array	O
for	O
differential	O
gene	O
expression	O
.	O

Spinal	O
cord	O
tissue	O

From	O
PBS	O
-	O
perfused	O
naive	O
rats	B-OG
or	O
in	O
DA	O
rats	B-OG
immunized	O
with	O
either	O
IFA	O
,	O
CFA	O
,	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
,	O
spinal	O
cord	O
tissue	O
was	O
dissected	O
and	O
homogenized	O
and	O
subsequently	O
assessed	O
for	O
mRNA	O
expression	O
.	O

RNA	O
preparation	O

Total	O
RNA	O
of	O
brain	O
-	O
infiltrating	O
leukocytes	O
or	O
lymphocytes	O
or	O
spinal	O
cord	O
tissue	O
was	O
isolated	O
by	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
RNA	O
quality	O
was	O
analyzed	O
with	O
a	O
Bioanalyser	O
2100	O
(	O
Agilent	O
,	O
Palo	O
Alto	O
,	O
CA	O
).	O

Microarrays	O

Affymetrix	O
microarrays	O
of	O
the	O
type	O
RG	O
U34	O
A	O
(	O
Affymetrix	O
Inc	O
.,	O
Santa	O
Clara	O
,	O
CA	O
)	O
representing	O
approximately	O
7000	O
full	O
-	O
length	O
genes	O
and	O
1000	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
clusters	O
were	O
used	O
.	O

For	O
the	O
purified	O
CD4	B-GP
+	O
cells	O
,	O
the	O
rat	B-OG
expression	O
set	O
230A	O
(	O
Affymetrix	O
)	O
containing	O
about	O
30	O
,	O
000	O
features	O
was	O
used	O
.	O

For	O
each	O
array	O
,	O
samples	O
from	O
at	O
least	O
three	O
rats	B-OG
were	O
pooled	O
.	O

Biotin	O
-	O
labeled	O
cRNA	O
was	O
prepared	O
and	O
hybridized	O
to	O
the	O
arrays	O
.	O

In	O
brief	O
,	O
double	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
whole	O
RNA	O
using	O
a	O
superscript	O
choice	O
kit	O
(	O
Invitrogen	O
)	O
with	O
a	O
T7	B-OG
-(	O
dT	O
)	O
24	O
primer	O
(	O
Metabion	O
)	O
and	O
in	O
vitro	O
transcribed	O
into	O
biotin	B-CD
-	O
labeled	O
cRNA	O
.	O

After	O
hybridization	O
,	O
gene	O
arrays	O
were	O
washed	O
and	O
stained	O
by	O
a	O
fluidics	O
station	O
(	O
Affymetrix	O
)	O
and	O
scanned	O
by	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
(	O
Agilent	O
).	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
microarray	O
suite	O
software	O
,	O
micro	O
DB	O
,	O
and	O
data	O
-	O
mining	O
tool	O
(	O
Affymetrix	O
).	O

Only	O
genes	O
and	O
ESTs	O
that	O
were	O
‘	O
present	O
’	O
and	O
gave	O
a	O
difference	O
call	O
of	O
either	O
‘	O
increase	O
’	O
or	O
‘	O
decrease	O
’	O
according	O
to	O
the	O
Affymetrix	O
software	O
were	O
included	O
in	O
further	O
analysis	O
.	O

The	O
extent	O
of	O
differential	O
expression	O
is	O
expressed	O
as	O
an	O
SLR	O
.	O

For	O
the	O
tables	O
,	O
the	O
cut	O
-	O
off	O
was	O
set	O
to	O
an	O
SLR	O
of	O
1	O
signifying	O
a	O
twofold	O
change	O
in	O
expression	O
.	O

Doubles	O
,	O
ESTs	O
and	O
sequences	O
not	O
corresponding	O
to	O
a	O
gene	O
were	O
not	O
included	O
in	O
the	O
tables	O
.	O

Real	O
-	O
time	O
PCR	O

To	O
avoid	O
amplification	O
/	O
detection	O
of	O
contaminating	O
genomic	O
DNA	O
,	O
extracted	O
RNA	O
was	O
treated	O
with	O
RNase	B-GP
free	O
DNase	B-GP
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
).	O

Subsequently	O
,	O
cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
with	O
Moloney	B-OG
murine	I-OG
leukemia	I-OG
virus	I-OG
reverse	B-GP
transcriptase	I-GP
and	O
random	O
pdN6	B-GP
primers	O
in	O
the	O
presence	O
of	O
RNase	B-GP
inhibitor	O
(	O
Promega	O
).	O

Amplification	O
was	O
performed	O
on	O
an	O
Applied	O
Biosystems	O
Prism	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
using	O
a	O
SYBR	O
green	O
protocol	O
.	O

Results	O
were	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

The	O
primer	O
sequences	O
5	O
′	O
to	O
3	O
′	O
were	O
as	O
follows	O
:	O

Rat	B-OG
primers	O

forward	O
:	O
GGTTGTCTCCTGTGACTTCAA	O

reverse	O
:	O
CATACCAGGAAATGAGCTTCAC	O

forward	O
:	O
TAGCCGCAGCAAATCAGAC	O

reverse	O
:	O
GCAGCAGTGGAGAAAGAGAGA	O

forward	O
:	O
GATGGTGGTGTTCCAGTTCC	O

reverse	O
:	O
CAGCTTGGAGATGATGATGC	O

forward	O
:	O
CGATTCTTTGAGAGCCATGT	O

reverse	O
:	O
AGGGCACAGTTTGGAGTGTT	O

forward	O
:	O
AGGACACACTGCTGGGCTAT	O

reverse	O
:	O
CAGGGTTGTTGGGACAATTT	O

forward	O
:	O
GAAGACTGAGAGGCCACGAC	O

reverse	O
:	O
GGGAGCCACACTTGTAATCC	O

Human	B-OG
primers	O

forward	O
:	O
CGGCTACCACATCCAAGGAA	O

reverse	O
:	O
GCTGGAATTACCGCGGCT	O

forward	O
:	O
CATCAGTCTGGACCGCTACC	O

reverse	O
:	O
GGATCCAGACGCCAACATAG	O
.	O

FACS	O

FITC	O
-	O
conjugated	O
monoclonal	O
antibody	B-GP
(	O
mAb	O
)	O
against	O
CD45RA	B-GP
(	O
OX	B-GP
-	I-GP
33	I-GP
)	O
and	O
TCRAB	B-GP
(	O
R73	B-GP
)	O
and	O
phycoerythrin	B-CD
(	O
PE	O
)-	O
conjugated	O
mAb	O
against	O
CD4	B-GP
(	O
OX	B-GP
-	I-GP
35	I-GP
)	O
and	O
MHC	B-GP
II	I-GP
(	O
OX	B-GP
-	I-GP
6	I-GP
)	O
and	O
appropriate	O
isotype	O
controls	O
were	O
purchased	O
from	O
Becton	O
Dickinson	O
(	O
Heidelberg	O
,	O
Germany	O
).	O

Flow	O
cytometry	O
was	O
performed	O
on	O
a	O
FACScalibur	O
running	O
with	O
Cellquest	O
software	O
(	O
Becton	O
Dickinson	O
).	O

Cells	O
were	O
gated	O
on	O
the	O
lymphocyte	O
population	O
in	O
the	O
forward	O
scatter	O
(	O
FSC	O
)-	O
side	O
scatter	O
(	O
SSC	O
)	O
dot	O
plot	O
.	O

For	O
data	O
analysis	O
,	O
Flowing	O
Software	O
2	O
.	O
5	O
.	O
1	O
(	O
Turku	O
Center	O
for	O
Biotechnology	O
,	O
Finland	O
)	O
was	O
used	O
.	O

ELISA	O

Serum	O
taken	O
at	O
the	O
time	O
point	O
of	O
euthanasia	O
was	O
subject	O
to	O
an	O
anti	O
-	O
MOG	B-GP
autoantibody	B-GP
ELISA	O
.	O

ELISA	O
plates	O
(	O
96	O
-	O
well	O
;	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
were	O
coated	O
with	O
2	O
.	O
5	O
µg	O
/	O
ml	O
(	O
100	O
µl	O
/	O
well	O
)	O
MOG	B-GP
1	O
-	O
125	O
overnight	O
at	O
4	O
°	O
C	O
.	O

Plates	O
were	O
washed	O
with	O
PBS	O
/	O
0	O
.	O
05	O
%	O
Tween	B-CD
20	I-CD
and	O
blocked	O
with	O
milk	O
powder	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
,	O
diluted	O
serum	O
samples	O
were	O
added	O
and	O
plates	O
were	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
plates	O
were	O
washed	O
and	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
antiserum	O
(	O
IgG	B-GP
,	O
IgG1	B-GP
,	O
IgG2a	B-GP
,	O
IgG2b	B-GP
,	O
IgG3	B-GP
,	O
IgM	B-GP
;	O
Nordic	O
,	O
Tilburg	O
,	O
The	O
Netherlands	O
)	O
was	O
added	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Plates	O
were	O
washed	O
prior	O
to	O
the	O
addition	O
of	O
peroxidase	B-GP
-	O
conjugated	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
antiserum	O
(	O
Nordic	O
)	O
diluted	O
in	O
PBS	O
/	O
0	O
.	O
05	O
%	O
Tween	B-CD
20	I-CD
.	O

After	O
30	O
min	O
incubation	O
,	O
plates	O
were	O
washed	O
and	O
bound	O
antibodies	B-GP
were	O
visualized	O
by	O
addition	O
of	O
2	O
,	O
2	O
′	O
azino	O
-	O
bis	O
(	O
3	O
-	O
ethylbenzothiazoline	O
-	O
6	O
-	O
sulphonic	O
acid	O
)	O
(	O
ABTS	O
)	O
(	O
Roche	O
Diagnostics	O
,	O
Mannheim	O
,	O
Germany	O
).	O

After	O
15	O
min	O
of	O
incubation	O
,	O
optical	O
density	O
was	O
read	O
at	O
405	O
nm	O
.	O

ELISA	O
with	O
human	B-OG
serum	O
was	O
performed	O
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
[	O
Quantikine	O
human	B-OG
SDF1alpha	B-GP
Immunoassay	O
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)].	O

Proliferation	O
assay	O

Cells	O
from	O
draining	O
LNs	O
were	O
prepared	O
as	O
described	O
above	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
rrMOG	B-GP
in	O
96	O
-	O
well	O
plates	O
as	O
described	O
by	O
Weissert	O
et	O
al	O
.	O
(	O
1998b	O
).	O

Cells	O
were	O
cultured	O
for	O
48	O
h	O
and	O
pulsed	O
with	O
1	O
µCi	O
[	O
3H	O
]	O
thymidine	B-CD
for	O
the	O
last	O
18	O
h	O
.	O

The	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	B-CD
was	O
measured	O
using	O
a	O
beta	O
-	O
scintillation	O
counter	O
.	O

FTY720	B-CD
treatment	O

Rats	B-OG
were	O
treated	O
with	O
FTY720	B-CD
(	O
generous	O
gift	O
of	O
Novartis	O
AG	O
,	O
Switzerland	O
)	O
and	O
received	O
a	O
daily	O
dose	O
of	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
sterile	O
water	O
by	O
oral	O
gavage	O
as	O
described	O
(	O
Balatoni	O
et	O
al	O
.,	O
2007	O
).	O

This	O
article	O
is	O
part	O
of	O
a	O
special	O
subject	O
collection	O
‘	O
Spotlight	O
on	O
Rat	B-OG
:	O
Translational	O
Impact	O
’,	O
guest	O
edited	O
by	O
Tim	O
Aitman	O
and	O
Aron	O
Geurts	O
.	O

See	O
related	O
articles	O
in	O
this	O
collection	O
at	O
http	O
://	O
dmm	O
.	O
biologists	O
.	O
org	O
/	O
collection	O
/	O
rat	B-OG
-	O
disease	O
-	O
model	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
no	O
competing	O
or	O
financial	O
interests	O
.	O

Author	O
contributions	O

M	O
.	O
M	O
.	O
H	O
.	O
performed	O
the	O
gene	O
arrays	O
,	O
data	O
analysis	O
,	O
target	O
validation	O
in	O
rats	B-OG
and	O
revised	O
the	O
paper	O
.	O

S	O
.	O
B	O
.	O
performed	O
the	O
gene	O
arrays	O
,	O
data	O
analysis	O
and	O
the	O
target	O
validation	O
.	O

B	O
.	O
G	O
.	O
did	O
the	O
work	O
on	O
CD38	B-GP
in	O
mice	B-OG
.	O

K	O
.	O
M	O
.	O
S	O
.	O
performed	O
target	O
validation	O
studies	O
in	O
rats	B-OG
and	O
analyzed	O
the	O
data	O
.	O

A	O
.	O
B	O
.	O
performed	O
studies	O
in	O
individuals	O
with	O
MS	B-DS
and	O
controls	O
.	O

R	O
.	O
W	O
.	O
designed	O
the	O
study	O
,	O
raised	O
the	O
funding	O
,	O
performed	O
the	O
data	O
analysis	O
,	O
and	O
wrote	O
and	O
revised	O
the	O
paper	O
.	O

Funding	O

This	O
study	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Interdisciplinary	O
Centre	O
for	O
Clinical	O
Research	O
(	O
Bundesministerium	O
für	O
Bildung	O
und	O
Forschung	O
)	O
(	O
Fö	O
.	O

01KS9602	O
),	O
and	O
German	O
Research	O
Foundation	O
(	O
Deutsche	O
Forschungsgemeinschaft	O
)	O
to	O
R	O
.	O
W	O
.	O

(	O
DFG	O
We	O
1947	O
).	O

Supplementary	O
information	O

Supplementary	O
information	O
available	O
online	O
at	O
http	O
://	O
dmm	O
.	O
biologists	O
.	O
org	O
/	O
lookup	O
/	O
doi	O
/	O
10	O
.	O
1242	O
/	O
dmm	O
.	O
025536	O
.	O
supplemental	O

Socioeconomic	O
and	O
Geographic	O
Patterning	O
of	O
Smoking	O
Behaviour	O
in	O
Canada	O
:	O
A	O
Cross	O
-	O
Sectional	O
Multilevel	O
Analysis	O

Competing	O
Interests	O
:	O
All	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
or	O
competing	O
interests	O
.	O

Participated	O
in	O
critical	O
revisions	O
of	O
the	O
manuscript	O
:	O
DJC	O
SL	O
CC	O
SVS	O
MB	O
KT	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
DJC	O
SVS	O
CC	O
SL	O
MB	O
KT	O
.	O

Performed	O
the	O
experiments	O
:	O
DJC	O
.	O

Analyzed	O
the	O
data	O
:	O
DJC	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
DJC	O
SVS	O
CC	O
MB	O
SL	O
KT	O
.	O

Wrote	O
the	O
paper	O
:	O
DJC	O
.	O

Objective	O

To	O
describe	O
the	O
socioeconomic	O
and	O
geographic	O
distribution	O
of	O
smoking	O
behaviour	O
in	O
Canada	O
among	O
19	O
,	O
383	O
individuals	O
(	O
51	O
%	O
women	O
)	O
aged	O
15	O
–	O
85	O
years	O
.	O

Methods	O

Current	O
smoking	O
and	O
quitting	O
were	O
modeled	O
using	O
standard	O
and	O
multilevel	O
logistic	O
regression	O
.	O

Markers	O
of	O
socioeconomic	O
status	O
(	O
SES	O
)	O
were	O
education	O
and	O
occupation	O
.	O

Geography	O
was	O
defined	O
by	O
Canadian	O
Provinces	O
.	O

Results	O

The	O
adjusted	O
prevalence	O
of	O
current	O
smoking	O
was	O
20	O
.	O
2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
18	O
.	O
8	O
–	O
21	O
.	O
7	O
)	O
and	O
63	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
61	O
.	O
1	O
–	O
66	O
.	O
3	O
)	O
of	O
ever	O
smokers	O
had	O
quit	O
.	O

Current	O
smoking	O
decreased	O
and	O
quitting	O
increased	O
with	O
increasing	O
SES	O
.	O

The	O
adjusted	O
prevalence	O
of	O
current	O
smoking	O
was	O
32	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
:	O
28	O
.	O
4	O
–	O
37	O
.	O
5	O
)	O
among	O
the	O
least	O
educated	O
compared	O
to	O
11	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
:	O
8	O
.	O
9	O
–	O
13	O
.	O
4	O
)	O
for	O
the	O
highest	O
educated	O
.	O

Among	O
the	O
least	O
educated	O
,	O
53	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
:	O
46	O
.	O
8	O
–	O
59	O
.	O
2	O
)	O
had	O
quit	O
,	O
rising	O
to	O
68	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
62	O
.	O
7	O
–	O
74	O
.	O
1	O
)	O
for	O
the	O
most	O
educated	O
.	O

There	O
was	O
substantial	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
at	O
the	O
provincial	O
level	O
;	O
current	O
smoking	O
varied	O
from	O
17	O
.	O
9	O
%	O
in	O
British	O
Columbia	O
to	O
26	O
.	O
1	O
%	O
in	O
Nova	O
Scotia	O
,	O
and	O
quitting	O
varied	O
from	O
57	O
.	O
4	O
%	O
in	O
Nova	O
Scotia	O
to	O
67	O
.	O
8	O
%	O
in	O
Prince	O
Edward	O
Island	O
.	O

Nationally	O
,	O
increasing	O
education	O
and	O
occupation	O
level	O
were	O
inversely	O
associated	O
with	O
current	O
smoking	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0	O
.	O
64	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
60	O
–	O
0	O
.	O
68	O
for	O
education	O
;	O
OR	O
0	O
.	O
82	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
77	O
–	O
0	O
.	O
87	O
for	O
occupation	O
)	O
and	O
positively	O
associated	O
with	O
quitting	O
(	O
OR	O
1	O
.	O
27	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
16	O
–	O
1	O
.	O
40	O
for	O
education	O
;	O
OR	O
1	O
.	O
20	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
12	O
–	O
1	O
.	O
27	O
for	O
occupation	O
).	O

These	O
associations	O
were	O
consistent	O
in	O
direction	O
across	O
provinces	O
although	O
with	O
some	O
variability	O
in	O
magnitude	O
.	O

Conclusion	O

Our	O
findings	O
indicate	O
that	O
socioeconomic	O
inequalities	O
in	O
smoking	O
have	O
persisted	O
in	O
Canada	O
;	O
current	O
smoking	O
was	O
less	O
likely	O
and	O
quitting	O
was	O
more	O
likely	O
among	O
the	O
better	O
off	O
groups	O
and	O
in	O
certain	O
provinces	O
.	O

Current	O
prevention	O
and	O
cessation	O
policies	O
have	O
not	O
been	O
successful	O
in	O
improving	O
the	O
situation	O
for	O
all	O
areas	O
and	O
groups	O
.	O

Future	O
efforts	O
to	O
reduce	O
smoking	O
uptake	O
and	O
increase	O
cessation	O
in	O
Canada	O
will	O
need	O
consideration	O
of	O
socioeconomic	O
and	O
geographic	O
factors	O
to	O
be	O
successful	O
.	O

Introduction	O

Smoking	O
is	O
the	O
leading	O
cause	O
of	O
death	O
in	O
high	O
income	O
countries	O
such	O
as	O
Canada	O
[	O
1	O
]	O
and	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiovascular	B-DS
disease	I-DS
and	O
cancer	B-DS
.	O
[	O
2	O
],	O
[	O
3	O
]	O
In	O
Canada	O
,	O
approximately	O
20	O
%	O
of	O
all	O
deaths	O
are	O
attributable	O
smoking	O
according	O
to	O
2005	O
estimates	O
.	O
[	O
4	O
]	O
The	O
majority	O
of	O
these	O
deaths	O
are	O
due	O
to	O
the	O
following	O
causes	O
:	O
lung	B-DS
cancer	I-DS
,	O
chronic	B-DS
obstructive	I-DS
pulmonary	I-DS
disease	I-DS
and	O
ischemic	B-DS
heart	I-DS
disease	I-DS
.	O
[	O
5	O
]	O
About	O
50	O
%	O
of	O
smokers	O
die	O
of	O
smoking	B-DS
-	I-DS
related	I-DS
diseases	I-DS
and	O
smokers	O
who	O
die	O
between	O
the	O
ages	O
of	O
35	O
and	O
69	O
in	O
Canada	O
lose	O
on	O
average	O
more	O
than	O
20	O
years	O
of	O
life	O
.[	O
6	O
]–[	O
8	O
]	O
Importantly	O
,	O
however	O
,	O
smoking	O
cessation	O
can	O
reverse	O
the	O
risk	O
for	O
mortality	O
;	O
quitting	O
by	O
age	O
50	O
can	O
halve	O
the	O
lifetime	O
risk	O
,	O
while	O
quitting	O
by	O
age	O
30	O
can	O
reduce	O
the	O
risk	O
close	O
to	O
that	O
of	O
never	O
smokers	O
.	O
[	O
9	O
],	O
[	O
10	O
].	O

In	O
2010	O
,	O
the	O
Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
(	O
CTUMS	O
)	O
reported	O
an	O
overall	O
smoking	O
prevalence	O
of	O
17	O
%	O
in	O
the	O
Canadian	O
population	O
(	O
aged	O
15	O
years	O
and	O
older	O
),	O
down	O
from	O
25	O
%	O
and	O
the	O
lowest	O
since	O
the	O
surveys	O
began	O
in	O
1999	O
[	O
11	O
];	O
however	O
the	O
rate	O
of	O
decline	O
appears	O
to	O
have	O
slowed	O
in	O
recent	O
years	O
.	O
[	O
12	O
]	O
Although	O
declines	O
in	O
the	O
rates	O
of	O
smoking	O
are	O
good	O
news	O
,	O
the	O
overall	O
trends	O
may	O
hide	O
important	O
socioeconomic	O
and	O
/	O
or	O
geographic	O
variation	O
.	O

Uncovering	O
such	O
variation	O
is	O
key	O
to	O
informing	O
tobacco	O
control	O
policies	O
and	O
identifying	O
areas	O
where	O
more	O
or	O
differing	O
strategies	O
are	O
required	O
to	O
increase	O
smoking	O
cessation	O
and	O
decrease	O
smoking	O
uptake	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
the	O
distribution	O
of	O
smoking	O
is	O
not	O
uniform	O
across	O
the	O
Canadian	O
population	O
.	O

Geographically	O
,	O
rates	O
of	O
smoking	O
vary	O
considerably	O
,	O
with	O
a	O
higher	O
prevalence	O
of	O
current	O
smoking	O
generally	O
found	O
in	O
the	O
Eastern	O
and	O
Atlantic	O
provinces	O
compared	O
to	O
Ontario	O
and	O
British	O
Columbia	O
.	O
[	O
12	O
]	O
In	O
addition	O
,	O
smoking	O
has	O
consistently	O
been	O
found	O
to	O
be	O
concentrated	O
among	O
individuals	O
of	O
lower	O
socioeconomic	O
status	O
(	O
SES	O
)	O
in	O
Canada	O
[	O
13	O
]	O
and	O
other	O
high	O
income	O
countries	O
[	O
14	O
]–[	O
16	O
];	O
while	O
higher	O
SES	O
has	O
been	O
related	O
to	O
increased	O
smoking	O
cessation	O
.[	O
17	O
]–[	O
20	O
]	O
For	O
example	O
,	O
evidence	O
from	O
the	O
National	O
Population	O
Health	O
Survey	O
in	O
Canada	O
indicated	O
that	O
high	O
levels	O
of	O
education	O
and	O
household	O
income	O
were	O
associated	O
with	O
quitting	O
over	O
a	O
two	O
year	O
period	O
in	O
men	B-OG
and	O
women	B-OG
.	O
[	O
21	O
]	O
Despite	O
these	O
important	O
findings	O
,	O
many	O
questions	O
remain	O
including	O
:	O
to	O
what	O
extent	O
are	O
socioeconomic	O
differences	O
a	O
source	O
of	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
across	O
provinces	O
?	O

And	O
is	O
the	O
between	O
-	O
provincial	O
variation	O
consistent	O
for	O
all	O
SES	O
groups	O
?	O

Identifying	O
geographic	O
variation	O
that	O
is	O
independent	O
of	O
individual	O
characteristics	O
and	O
the	O
consistency	O
of	O
this	O
variation	O
across	O
SES	O
groups	O
will	O
be	O
an	O
important	O
step	O
in	O
tailoring	O
future	O
tobacco	O
control	O
priorities	O
and	O
/	O
or	O
priorities	O
for	O
resource	O
allocations	O
to	O
programs	O
aimed	O
at	O
tobacco	O
use	O
prevention	O
and	O
/	O
or	O
cessation	O
.	O

Further	O
,	O
it	O
has	O
not	O
previously	O
been	O
shown	O
whether	O
the	O
SES	O
-	O
smoking	O
and	O
SES	O
-	O
quitting	O
relationships	O
are	O
qualitatively	O
similar	O
in	O
both	O
direction	O
and	O
magnitude	O
across	O
Canadian	O
provinces	O
.	O

Identifying	O
provinces	O
where	O
the	O
gradients	O
are	O
shallower	O
may	O
be	O
indicative	O
of	O
the	O
success	O
of	O
certain	O
programs	O
aimed	O
at	O
tobacco	O
use	O
prevention	O
and	O
/	O
or	O
cessation	O
in	O
reaching	O
all	O
SES	O
groups	O
or	O
suggestive	O
of	O
other	O
social	O
programs	O
which	O
aim	O
to	O
reduce	O
overall	O
inequalities	O
in	O
the	O
provinces	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
socioeconomic	O
and	O
geographic	O
patterning	O
of	O
current	O
smoking	O
and	O
quitting	O
in	O
Canada	O
using	O
the	O
most	O
recent	O
and	O
nationally	O
representative	O
survey	O
on	O
smoking	O
.	O

In	O
addition	O
,	O
we	O
assess	O
the	O
consistency	O
of	O
the	O
SES	O
-	O
smoking	O
and	O
SES	O
-	O
quitting	O
associations	O
across	O
Canadian	O
provinces	O
using	O
education	O
and	O
occupation	O
as	O
markers	O
of	O
SES	O
.	O

Methods	O

Data	O

The	O
data	O
are	O
from	O
the	O
Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
(	O
CTUMS	O
),	O
conducted	O
in	O
two	O
cycles	O
in	O
the	O
ten	O
Canadian	O
provinces	O
from	O
February	O
to	O
June	O
and	O
from	O
July	O
to	O
December	O
2010	O
.	O

CTUMS	O
was	O
conducted	O
by	O
Statistics	O
Canada	O
on	O
behalf	O
of	O
Health	O
Canada	O
to	O
provide	O
nationally	O
representative	O
data	O
on	O
tobacco	O
use	O
and	O
related	O
issues	O
in	O
Canada	O
.	O
[	O
22	O
]	O
CTUMS	O
covered	O
all	O
persons	O
in	O
Canada	O
aged	O
15	O
and	O
older	O
except	O
for	O
residents	O
of	O
the	O
Yukon	O
,	O
Northwest	O
Territories	O
,	O
Nunavut	O
,	O
and	O
those	O
living	O
in	O
long	O
-	O
term	O
care	O
institutions	O
or	O
Canadian	O
Forces	O
bases	O
.	O

The	O
sampling	O
frame	O
only	O
included	O
land	O
line	O
telephone	O
numbers	O
,	O
thus	O
excluding	O
people	O
without	O
telephone	O
land	O
lines	O
(	O
about	O
16	O
%	O
of	O
the	O
target	O
population	O
).	O
[	O
22	O
]	O
The	O
sampling	O
weights	O
provided	O
with	O
CTUMS	O
have	O
been	O
adjusted	O
to	O
account	O
for	O
these	O
individuals	O
.	O

Survey	O
Design	O

A	O
stratified	O
two	O
-	O
stage	O
sampling	O
strategy	O
was	O
used	O
in	O
the	O
CTUMS	O
.	O
[	O
22	O
]	O
In	O
each	O
of	O
the	O
ten	O
provinces	O
,	O
geographic	O
strata	O
were	O
defined	O
according	O
to	O
a	O
census	O
metropolitan	O
area	O
(	O
CMA	O
)	O
stratum	O
and	O
a	O
non	O
-	O
CMA	O
stratum	O
.	O

CMAs	O
are	O
census	O
defined	O
areas	O
corresponding	O
to	O
cities	O
and	O
urban	O
areas	O
with	O
populations	O
of	O
100	O
,	O
000	O
or	O
more	O
.	O

In	O
Prince	O
Edward	O
Island	O
,	O
only	O
1	O
geographic	O
stratum	O
was	O
defined	O
,	O
and	O
in	O
Ontario	O
and	O
Quebec	O
,	O
a	O
third	O
stratum	O
was	O
defined	O
for	O
Toronto	O
and	O
Montreal	O
,	O
respectively	O
.	O

The	O
CTUMS	O
sampling	O
frame	O
was	O
a	O
list	O
of	O
in	O
-	O
service	O
telephone	O
prefixes	O
(	O
3	O
digit	O
area	O
code	O
+	O
next	O
5	O
digits	O
)	O
compiled	O
from	O
telephone	O
company	O
files	O
within	O
each	O
of	O
the	O
province	O
-	O
stratum	O
combinations	O
.	O

In	O
the	O
first	O
stage	O
,	O
telephone	O
prefixes	O
were	O
systematically	O
sampled	O
within	O
each	O
stratum	O
and	O
a	O
random	O
2	O
-	O
digit	O
number	O
was	O
appended	O
to	O
the	O
prefix	O
to	O
form	O
a	O
complete	O
telephone	O
number	O
.	O

Known	O
business	O
and	O
not	O
-	O
in	O
-	O
service	O
telephone	O
numbers	O
were	O
then	O
screened	O
and	O
removed	O
from	O
the	O
sample	O
prior	O
to	O
dialing	O
.	O

In	O
the	O
second	O
stage	O
,	O
and	O
in	O
order	O
to	O
increase	O
the	O
number	O
of	O
respondents	O
in	O
the	O
15	O
to	O
19	O
and	O
20	O
to	O
24	O
age	O
groups	O
,	O
one	O
or	O
two	O
individuals	O
(	O
or	O
none	O
)	O
were	O
selected	O
to	O
participate	O
in	O
the	O
survey	O
based	O
on	O
the	O
age	O
composition	O
of	O
the	O
household	O
.	O

Sampling	O
weights	O
were	O
provided	O
with	O
the	O
CTUMS	O
in	O
order	O
to	O
adjust	O
estimates	O
for	O
non	O
-	O
response	O
,	O
household	O
composition	O
,	O
and	O
an	O
external	O
adjustment	O
to	O
national	O
population	O
estimates	O
from	O
the	O
Canadian	O
census	O
.	O
[	O
22	O
]	O
The	O
household	O
response	O
rate	O
(	O
defined	O
as	O
the	O
proportion	O
of	O
households	O
who	O
were	O
reached	O
and	O
provided	O
ages	O
of	O
all	O
household	O
members	O
)	O
was	O
73	O
.	O
8	O
%	O
for	O
both	O
cycles	O
of	O
the	O
CTUMS	O
from	O
February	O
to	O
December	O
2010	O
,	O
and	O
the	O
individual	O
response	O
rate	O
was	O
84	O
.	O
2	O
%.	O
[	O
23	O
].	O

Interviews	O
for	O
CTUMS	O
were	O
conducted	O
using	O
a	O
computer	O
-	O
assisted	O
telephone	O
interviewing	O
(	O
CATI	O
)	O
application	O
.	O

The	O
CATI	O
application	O
was	O
employed	O
in	O
conjunction	O
with	O
extensive	O
interviewer	O
training	O
in	O
order	O
to	O
minimize	O
data	O
collection	O
errors	O
.	O
[	O
23	O
]	O
In	O
total	O
CTUMS	O
collected	O
information	O
from	O
19	O
,	O
822	O
respondents	O
aged	O
15	O
–	O
85	O
years	O
in	O
ten	O
Canadian	O
provinces	O
.	O

All	O
respondents	O
had	O
complete	O
information	O
on	O
current	O
smoking	O
status	O
,	O
age	O
,	O
gender	O
,	O
and	O
province	O
of	O
residence	O
.	O

Respondents	O
with	O
incomplete	O
information	O
for	O
any	O
of	O
the	O
other	O
independent	O
variables	O
(	O
marital	O
status	O
,	O
occupation	O
,	O
or	O
education	O
)	O
were	O
excluded	O
(	O
n	O
=	O
439	O
,	O
2	O
.	O
2	O
%).	O

An	O
examination	O
of	O
the	O
basic	O
demographic	O
characteristics	O
between	O
complete	O
and	O
partial	O
respondents	O
did	O
not	O
reveal	O
any	O
substantive	O
differences	O
.	O

The	O
final	O
sample	O
for	O
analysis	O
was	O
19	O
,	O
383	O
.	O

Outcome	O

Categories	O
of	O
smoking	O
behaviour	O
at	O
the	O
time	O
of	O
survey	O
were	O
defined	O
as	O
follows	O
:	O
current	O
cigarette	O
smokers	O
were	O
individuals	O
who	O
had	O
smoked	O
100	O
or	O
more	O
cigarettes	O
in	O
their	O
lifetime	O
and	O
reported	O
smoking	O
daily	O
or	O
occasionally	O
during	O
the	O
past	O
30	O
days	O
.	O

Former	O
smokers	O
had	O
smoked	O
100	O
cigarettes	O
in	O
their	O
lifetime	O
and	O
reported	O
having	O
quit	O
and	O
did	O
not	O
smoke	O
any	O
cigarettes	O
in	O
the	O
30	O
days	O
prior	O
to	O
the	O
survey	O
.	O

Never	O
smokers	O
were	O
lifelong	O
never	O
smokers	O
(<	O
100	O
cigarettes	O
smoked	O
in	O
their	O
lifetime	O
).	O

For	O
these	O
analyses	O
,	O
quitting	O
was	O
defined	O
as	O
the	O
proportion	O
of	O
former	O
smokers	O
relative	O
to	O
ever	O
smokers	O
(	O
current	O
and	O
former	O
smokers	O
).	O
[	O
24	O
]	O
Overall	O
in	O
the	O
CTUMS	O
sample	O
,	O
the	O
weighted	O
prevalence	O
of	O
current	O
smoking	O
was	O
16	O
.	O
57	O
%;	O
26	O
.	O
6	O
%	O
were	O
former	O
smokers	O
,	O
and	O
56	O
.	O
8	O
%	O
were	O
never	O
smokers	O
.	O

Descriptive	O
characteristics	O
of	O
the	O
sample	O
population	O
by	O
sex	O
and	O
categories	O
of	O
smoking	O
behaviour	O
have	O
been	O
tabulated	O
in	O
Table	O
1	O
.	O

Sample	O
sizes	O
and	O
weighted	O
estimates	O
(%)	O
of	O
current	O
smoking	O
,	O
former	O
smoking	O
,	O
never	O
smoking	O
,	O
and	O
quitting	O
for	O
men	O
and	O
women	O
across	O
demographic	O
and	O
socioeconomic	O
characteristics	O
and	O
province	O
of	O
residence	O
.	O

Men	O

Women	B-OG

Variables	O

Current	O
smoker	O

Former	O
smoker	O

Never	O
smoker	O

Quit	O

Total	O

Current	O
smoker	O

Former	O
smoker	O

Never	O
smoker	O

Quit	O

Total	O

n	O

%	O

n	O

%	O

n	O

%	O

%	O

n	O

n	O

%	O

n	O

%	O

n	O

%	O

%	O

n	O

Total	O

1762	O

19	O
.	O
7	O

1886	O

29	O
.	O
3	O

5198	O

51	O
.	O
0	O

59	O
.	O
9	O

8846	O

1710	O

13	O
.	O
6	O

1990	O

24	O
.	O
0	O

6837	O

62	O
.	O
5	O

63	O
.	O
9	O

10537	O

Age	O

15	O
–	O
19	O
yrs	O

375	O

13	O
.	O
1	O

51	O

2	O
.	O
0	O

2085	O

84	O
.	O
9	O

13	O
.	O
3	O

2511	O

284	O

10	O
.	O
6	O

39	O

1	O
.	O
4	O

2160	O

88	O
.	O
0	O

11	O
.	O
8	O

2483	O

20	O
–	O
24	O
yrs	O

468	O

23	O
.	O
9	O

140	O

8	O
.	O
8	O

1176	O

67	O
.	O
4	O

26	O
.	O
9	O

1784	O

447	O

20	O
.	O
0	O

164	O

8	O
.	O
2	O

1377	O

71	O
.	O
8	O

29	O
.	O
0	O

1988	O

25	O
–	O
44	O
yrs	O

388	O

24	O
.	O
5	O

275	O

18	O
.	O
2	O

803	O

57	O
.	O
3	O

42	O
.	O
6	O

1466	O

403	O

15	O
.	O
4	O

367	O

19	O
.	O
3	O

1169	O

65	O
.	O
3	O

55	O
.	O
5	O

1939	O

45	O
–	O
64	O
yrs	O

439	O

20	O
.	O
3	O

833	O

38	O
.	O
3	O

833	O

41	O
.	O
4	O

65	O
.	O
4	O

2105	O

459	O

13	O
.	O
7	O

927	O

33	O
.	O
7	O

1280	O

52	O
.	O
6	O

71	O
.	O
1	O

2666	O

65	O
+	O
yrs	O

92	O

7	O
.	O
7	O

587	O

62	O
.	O
5	O

301	O

29	O
.	O
9	O

89	O
.	O
1	O

980	O

117	O

7	O
.	O
8	O

493	O

31	O
.	O
4	O

851	O

60	O
.	O
8	O

80	O
.	O
1	O

1461	O

Marital	O
status	O

Common	O
-	O
law	O
/	O
Married	O

625	O

17	O
.	O
3	O

1282	O

35	O
.	O
8	O

1498	O

46	O
.	O
9	O

67	O
.	O
4	O

3405	O

593	O

11	O
.	O
3	O

1150	O

27	O
.	O
8	O

2287	O

61	O
.	O
0	O

71	O
.	O
2	O

4030	O

Widowed	O
/	O
Divorced	O
/	O
Separated	O

155	O

24	O
.	O
5	O

254	O

39	O
.	O
8	O

202	O

35	O
.	O
6	O

61	O
.	O
9	O

611	O

306	O

15	O
.	O
8	O

512	O

30	O
.	O
1	O

842	O

54	O
.	O
1	O

65	O
.	O
5	O

1660	O

Single	O

982	O

23	O
.	O
8	O

350	O

12	O
.	O
2	O

3498	O

64	O
.	O
0	O

33	O
.	O
8	O

4830	O

811	O

17	O
.	O
8	O

328	O

11	O
.	O
3	O

3708	O

71	O
.	O
0	O

38	O
.	O
8	O

4847	O

Education	O

Completed	O
university	O

173	O

12	O
.	O
7	O

401	O

26	O
.	O
2	O

900	O

61	O
.	O
1	O

67	O
.	O
5	O

1474	O

174	O

7	O
.	O
3	O

426	O

20	O
.	O
2	O

1339	O

72	O
.	O
5	O

73	O
.	O
4	O

1939	O

Completed	O
college	O

358	O

18	O
.	O
1	O

385	O

25	O
.	O
9	O

1158	O

56	O
.	O
0	O

59	O
.	O
0	O

1901	O

447	O

13	O
.	O
5	O

571	O

27	O
.	O
1	O

1779	O

59	O
.	O
4	O

66	O
.	O
8	O

2797	O

Completed	O
secondary	O

700	O

25	O
.	O
5	O

588	O

32	O
.	O
5	O

1445	O

42	O
.	O
0	O

56	O
.	O
0	O

2733	O

615	O

17	O
.	O
4	O

673	O

27	O
.	O
3	O

1831	O

55	O
.	O
3	O

61	O
.	O
1	O

3119	O

Less	O
than	O
secondary	O

531	O

23	O
.	O
1	O

512	O

33	O
.	O
7	O

1695	O

43	O
.	O
3	O

59	O
.	O
4	O

2738	O

474	O

17	O
.	O
0	O

320	O

18	O
.	O
1	O

1888	O

64	O
.	O
9	O

51	O
.	O
6	O

2682	O

Occupation	O

Professional	O
specialty	O

145	O

13	O
.	O
1	O

244	O

23	O
.	O
9	O

815	O

63	O
.	O
1	O

64	O
.	O
6	O

1204	O

236	O

8	O
.	O
4	O

367	O

22	O
.	O
7	O

1315	O

69	O
.	O
0	O

73	O
.	O
0	O

1918	O

Not	O
working	O

298	O

13	O
.	O
8	O

696	O

46	O
.	O
2	O

1151	O

40	O
.	O
0	O

77	O
.	O
0	O

2145	O

512	O

12	O
.	O
2	O

776	O

25	O
.	O
6	O

2054	O

62	O
.	O
3	O

67	O
.	O
8	O

3342	O

Not	O
reported	O

28	O

17	O
.	O
4	O

35	O

33	O
.	O
3	O

91	O

49	O
.	O
3	O

65	O
.	O
7	O

154	O

17	O

9	O
.	O
1	O

23	O

32	O
.	O
2	O

76	O

58	O
.	O
7	O

78	O
.	O
0	O

116	O

Executive	O
,	O
managerial	O

168	O

17	O
.	O
9	O

218	O

28	O
.	O
8	O

565	O

53	O
.	O
3	O

61	O
.	O
7	O

951	O

297	O

15	O
.	O
6	O

409	O

27	O
.	O
5	O

1066	O

57	O
.	O
0	O

63	O
.	O
8	O

1772	O

Sales	O
or	O
Service	O

388	O

20	O
.	O
8	O

214	O

17	O
.	O
1	O

1281	O

62	O
.	O
1	O

45	O
.	O
2	O

1883	O

566	O

19	O
.	O
6	O

352	O

18	O
.	O
2	O

2085	O

62	O
.	O
2	O

48	O
.	O
0	O

3003	O

Manual	O

735	O

30	O
.	O
0	O

479	O

25	O
.	O
5	O

1295	O

44	O
.	O
5	O

45	O
.	O
9	O

2509	O

82	O

18	O
.	O
9	O

63	O

22	O
.	O
1	O

241	O

59	O
.	O
0	O

53	O
.	O
8	O

386	O

Province	O

British	O
Columbia	O

121	O

14	O
.	O
9	O

172	O

27	O
.	O
7	O

523	O

57	O
.	O
4	O

65	O
.	O
0	O

816	O

126	O

14	O
.	O
6	O

175	O

25	O
.	O
8	O

614	O

59	O
.	O
6	O

63	O
.	O
9	O

915	O

Ontario	O

143	O

18	O
.	O
7	O

164	O

29	O
.	O
3	O

553	O

52	O
.	O
1	O

61	O
.	O
1	O

860	O

123	O

11	O
.	O
1	O

157	O

22	O
.	O
2	O

746	O

66	O
.	O
7	O

66	O
.	O
8	O

1026	O

Prince	O
Edward	O
Island	O

153	O

18	O
.	O
8	O

226	O

35	O
.	O
0	O

476	O

46	O
.	O
2	O

65	O
.	O
1	O

855	O

135	O

13	O
.	O
0	O

223	O

27	O
.	O
3	O

685	O

59	O
.	O
7	O

67	O
.	O
8	O

1043	O

Newfoundland	O

160	O

20	O
.	O
8	O

184	O

35	O
.	O
5	O

396	O

43	O
.	O
8	O

63	O
.	O
0	O

740	O

191	O

19	O
.	O
0	O

220	O

28	O
.	O
1	O

609	O

52	O
.	O
9	O

53	O
.	O
5	O

1020	O

Quebec	O

189	O

21	O
.	O
0	O

211	O

32	O
.	O
5	O

499	O

46	O
.	O
5	O

60	O
.	O
7	O

899	O

162	O

13	O
.	O
7	O

203	O

27	O
.	O
4	O

679	O

59	O
.	O
0	O

66	O
.	O
7	O

1044	O

Alberta	O

194	O

21	O
.	O
9	O

181	O

24	O
.	O
9	O

604	O

53	O
.	O
2	O

53	O
.	O
1	O

979	O

182	O

16	O
.	O
3	O

164	O

19	O
.	O
6	O

736	O

64	O
.	O
1	O

54	O
.	O
6	O

1082	O

New	O
Brunswick	O

178	O

22	O
.	O
0	O

180	O

33	O
.	O
3	O

444	O

44	O
.	O
8	O

60	O
.	O
2	O

802	O

170	O

15	O
.	O
6	O

199	O

25	O
.	O
2	O

640	O

59	O
.	O
2	O

61	O
.	O
8	O

1009	O

Nova	O
Scotia	O

193	O

22	O
.	O
7	O

208	O

30	O
.	O
9	O

531	O

46	O
.	O
4	O

57	O
.	O
7	O

932	O

194	O

18	O
.	O
8	O

196	O

22	O
.	O
9	O

673	O

58	O
.	O
3	O

55	O
.	O
0	O

1063	O

Manitoba	O

219	O

24	O
.	O
2	O

171	O

23	O
.	O
8	O

640	O

52	O
.	O
0	O

62	O
.	O
0	O

1030	O

217	O

17	O
.	O
5	O

232	O

23	O
.	O
4	O

758	O

59	O
.	O
1	O

57	O
.	O
2	O

1207	O

Saskatchewan	O

212	O

24	O
.	O
8	O

189	O

26	O
.	O
8	O

532	O

48	O
.	O
4	O

59	O
.	O
8	O

933	O

210	O

17	O
.	O
4	O

221	O

25	O
.	O
2	O

697	O

57	O
.	O
5	O

59	O
.	O
2	O

1128	O

Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
2010	O
.	O

Independent	O
Variables	O

We	O
considered	O
age	O
,	O
sex	O
,	O
and	O
marital	O
status	O
as	O
demographic	O
characteristics	O
.	O

Age	O
was	O
grouped	O
into	O
the	O
following	O
categories	O
:	O
15	O
–	O
19	O
,	O
20	O
–	O
24	O
,	O
25	O
–	O
44	O
,	O
45	O
–	O
64	O
,	O
65	O
+	O
years	O
for	O
descriptive	O
analyses	O
,	O
and	O
centred	O
about	O
its	O
weighted	O
mean	O
(	O
45	O
years	O
)	O
and	O
treated	O
as	O
a	O
continuous	O
measure	O
in	O
regression	O
models	O
.	O

In	O
addition	O
,	O
polynomial	O
terms	O
were	O
included	O
for	O
age	O
to	O
allow	O
for	O
the	O
assessment	O
of	O
non	O
-	O
linearity	O
.	O

Sex	O
was	O
based	O
on	O
self	O
-	O
report	O
.	O

Marital	O
status	O
was	O
categorized	O
as	O
common	O
-	O
law	O
/	O
married	O
,	O
single	O
,	O
or	O
widowed	O
/	O
divorced	O
/	O
separated	O
(	O
reference	O
:	O
married	O
).	O

Socioeconomic	O
status	O
was	O
measured	O
by	O
education	O
and	O
occupation	O
.	O

Education	O
was	O
grouped	O
into	O
four	O
categories	O
based	O
on	O
the	O
highest	O
level	O
completed	O
:	O
less	O
than	O
secondary	O
school	O
,	O
completed	O
secondary	O
,	O
completed	O
post	O
-	O
secondary	O
/	O
college	O
,	O
and	O
completed	O
university	O
(	O
reference	O
:	O
completed	O
university	O
).	O

Occupational	O
categories	O
were	O
adapted	O
from	O
the	O
2006	O
National	O
Occupational	O
Classification	O
for	O
Statistics	O
(	O
NOC	O
-	O
S	O
)	O
[	O
25	O
],	O
and	O
included	O
professional	O
specialties	O
,	O
executive	O
or	O
managerial	O
positions	O
,	O
sales	O
/	O
service	O
positions	O
,	O
and	O
manual	O
occupations	O
(	O
including	O
trades	O
,	O
transport	O
,	O
industry	O
,	O
manufacturing	O
,	O
and	O
utilities	O
).	O

Additional	O
categories	O
were	O
specified	O
for	O
individuals	O
not	O
currently	O
working	O
and	O
for	O
respondents	O
who	O
did	O
not	O
report	O
their	O
occupation	O
and	O
professionals	O
were	O
taken	O
as	O
the	O
reference	O
category	O
.	O

Geographic	O
location	O
was	O
defined	O
as	O
province	O
of	O
residence	O
at	O
the	O
time	O
of	O
survey	O
and	O
verified	O
by	O
telephone	O
company	O
administrative	O
files	O
.	O

Statistical	O
Analysis	O

We	O
used	O
logistic	O
regression	O
to	O
model	O
current	O
smoking	O
(	O
current	O
smokers	O
vs	O
never	O
smokers	O
)	O
and	O
quitting	O
(	O
former	O
smokers	O
vs	O
current	O
smokers	O
)	O
conditional	O
on	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
education	O
,	O
occupation	O
,	O
and	O
province	O
.	O

Province	O
of	O
residence	O
was	O
‘	O
dummy	O
’	O
coded	O
and	O
treated	O
as	O
a	O
fixed	O
classification	O
in	O
these	O
models	O
.	O

To	O
examine	O
potential	O
differences	O
in	O
smoking	O
patterns	O
between	O
men	O
and	O
women	O
,	O
interaction	O
effects	O
were	O
considered	O
between	O
sex	O
and	O
age	O
,	O
sex	O
and	O
education	O
,	O
and	O
sex	O
and	O
occupation	O
.	O

Adjusted	O
prevalence	O
estimates	O
were	O
calculated	O
for	O
each	O
independent	O
variable	O
separately	O
while	O
keeping	O
the	O
remaining	O
independent	O
variables	O
at	O
their	O
mean	O
values	O
and	O
expressed	O
as	O
a	O
percent	O
from	O
0	O
.	O
0	O
to	O
100	O
.	O
0	O
.	O

Next	O
,	O
models	O
were	O
extended	O
by	O
including	O
a	O
random	O
effect	O
for	O
province	O
and	O
specifying	O
two	O
-	O
level	O
multilevel	O
models	O
.	O

The	O
multilevel	O
modeling	O
strategy	O
is	O
described	O
below	O
,	O
using	O
the	O
example	O
of	O
current	O
smoking	O
.	O

Two	O
-	O
level	O
models	O
were	O
specified	O
with	O
a	O
binary	O
response	O
(	O
y	O
,	O
current	O
smoking	O
vs	O
never	O
smoking	O
)	O
for	O
individual	O
i	O
in	O
province	O
j	O
.	O

Current	O
smoking	O
Pr	O
(	O
yij	O
=	O
1	O
),	O
was	O
assumed	O
to	O
be	O
binomially	O
distributed	O
with	O
probability	O
related	O
to	O
the	O
set	O
of	O
independent	O
variables	O
and	O
a	O
random	O
effect	O
for	O
each	O
level	O
by	O
a	O
logit	O
link	O
function	O
:(	O
1	O
)	O

The	O
right	O
hand	O
side	O
of	O
Equation	O
2	O
consists	O
of	O
the	O
fixed	O
part	O
linear	O
predictor	O
()	O
and	O
random	O
intercepts	O
for	O
provinces	O
().	O

The	O
intercept	O
and	O
the	O
-	O
coefficients	O
are	O
interpreted	O
as	O
before	O
in	O
Equation	O
1	O
.	O

The	O
set	O
of	O
independent	O
variables	O
remained	O
consistent	O
between	O
models	O
although	O
the	O
indicator	O
variables	O
for	O
provinces	O
were	O
included	O
in	O
the	O
random	O
part	O
of	O
Equation	O
2	O
().	O

In	O
this	O
model	O
,	O
the	O
random	O
intercepts	O
for	O
provinces	O
were	O
assumed	O
to	O
be	O
independently	O
and	O
identically	O
distributed	O
with	O
variance	O
.	O
[	O
26	O
]	O
The	O
variance	O
parameter	O
quantifies	O
heterogeneity	O
in	O
the	O
log	O
odds	O
of	O
smoking	O
between	O
provinces	O
.	O

We	O
expressed	O
the	O
provincial	O
-	O
level	O
variance	O
as	O
a	O
percentage	O
of	O
the	O
total	O
variance	O
from	O
an	O
initial	O
model	O
without	O
covariates	O
and	O
from	O
a	O
final	O
model	O
accounting	O
for	O
all	O
covariates	O
.	O

In	O
order	O
to	O
examine	O
the	O
consistency	O
of	O
provincial	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
by	O
SES	O
(	O
defined	O
by	O
education	O
and	O
occupation	O
)	O
and	O
to	O
determine	O
whether	O
the	O
SES	O
-	O
smoking	O
and	O
SES	O
-	O
quitting	O
associations	O
varied	O
across	O
provinces	O
in	O
terms	O
of	O
strength	O
or	O
direction	O
,	O
we	O
expanded	O
Equation	O
1	O
to	O
allow	O
the	O
slope	O
for	O
SES	O
to	O
vary	O
across	O
provinces	O
:(	O
2	O
)	O

The	O
key	O
feature	O
of	O
Equation	O
2	O
is	O
that	O
the	O
effect	O
of	O
education	O
on	O
smoking	O
in	O
province	O
j	O
consists	O
of	O
the	O
overall	O
average	O
effect	O
across	O
all	O
provinces	O
(),	O
plus	O
a	O
province	O
-	O
specific	O
()	O
differential	O
in	O
this	O
effect	O
.	O

We	O
summarized	O
this	O
model	O
by	O
presenting	O
the	O
odds	O
ratio	O
for	O
current	O
smoking	O
and	O
quitting	O
overall	O
in	O
Canada	O
and	O
for	O
each	O
province	O
given	O
a	O
1	O
-	O
category	O
increase	O
in	O
education	O
and	O
occupation	O
.	O

The	O
sampling	O
weights	O
provided	O
with	O
the	O
CTUMS	O
were	O
used	O
in	O
all	O
analyses	O
.	O

Logistic	O
regression	O
models	O
were	O
estimated	O
with	O
Stata	O
(	O
version	O
12	O
.	O
1	O
)	O
[	O
27	O
],	O
[	O
28	O
]	O
and	O
multilevel	O
models	O
were	O
estimated	O
with	O
MLwiN	O
(	O
version	O
2	O
.	O
26	O
)	O
using	O
the	O
second	O
order	O
penalized	O
quasi	O
likelihood	O
(	O
PQL	O
)	O
procedure	O
.	O
[	O
29	O
].	O

Results	O

In	O
the	O
2010	O
CTUMS	O
,	O
the	O
prevalence	O
(	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
education	O
,	O
and	O
province	O
)	O
for	O
current	O
smoking	O
among	O
Canadians	O
15	O
years	O
of	O
age	O
and	O
older	O
was	O
20	O
.	O
2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
18	O
.	O
8	O
–	O
21	O
.	O
7	O
)	O
and	O
63	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
61	O
.	O
1	O
–	O
66	O
.	O
3	O
)	O
for	O
quitting	O
.	O

At	O
the	O
provincial	O
level	O
,	O
current	O
smoking	O
varied	O
from	O
17	O
.	O
9	O
%	O
in	O
British	O
Columbia	O
to	O
26	O
.	O
1	O
%	O
in	O
Nova	O
Scotia	O
(	O
Figure	O
1	O
),	O
and	O
quitting	O
varied	O
from	O
57	O
.	O
4	O
%	O
in	O
Nova	O
Scotia	O
to	O
67	O
.	O
8	O
%	O
in	O
Prince	O
Edward	O
Island	O
(	O
Figure	O
2	O
).	O

Odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
current	O
smoking	O
and	O
quitting	O
from	O
the	O
mutually	O
adjusted	O
logistic	O
regression	O
models	O
are	O
presented	O
in	O
Table	O
2	O
.	O

The	O
relationship	O
between	O
current	O
regular	O
smoking	O
and	O
age	O
was	O
strongly	O
non	O
-	O
linear	O
and	O
this	O
was	O
emphasized	O
by	O
the	O
statistical	O
significance	O
of	O
the	O
quadratic	O
and	O
cubic	O
terms	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

This	O
relationship	O
had	O
an	O
inverse	O
-	O
U	O
shape	O
with	O
a	O
peak	O
smoking	O
prevalence	O
found	O
between	O
the	O
ages	O
of	O
35	O
and	O
40	O
years	O
.	O

The	O
prevalence	O
increased	O
rapidly	O
at	O
younger	O
ages	O
;	O
it	O
was	O
8	O
.	O
6	O
%	O
at	O
age	O
15	O
and	O
27	O
.	O
8	O
%	O
at	O
age	O
30	O
,	O
equivalent	O
to	O
a	O
3	O
.	O
3	O
-	O
fold	O
increase	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
0	O
–	O
5	O
.	O
5	O
).	O

Adjusted	O
prevalence	O
of	O
current	O
smoking	O
in	O
Canadian	O
provinces	O
for	O
men	O
(	O
left	O
)	O
and	O
women	O
(	O
right	O
)	O
aged	O
15	O
years	O
and	O
above	O
,	O
Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
2010	O
.	O

Darker	O
colours	O
indicate	O
higher	O
prevalence	O
.	O

Estimates	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
education	O
.	O

Province	O
name	O
abbreviations	O
:	O
Alta	O
.	O

Alberta	O
;	O
B	O
.	O
C	O
.	O

British	O
Columbia	O
;	O
Man	O
.	O

Manitoba	O
;	O
N	O
.	O
B	O
.	O

New	O
Brunswick	O
;	O
N	O
.	O
L	O
.	O

Newfoundland	O
;	O
N	O
.	O
S	O
.	O

Nova	O
Scotia	O
;	O
O	O
.	O
N	O
.	O

Ontario	O
;	O
P	O
.	O
E	O
.	O
I	O
.	O

Prince	O
Edward	O
Island	O
;	O
Que	O
.	O

Quebec	O
;	O
Sask	O
.	O

Saskatchewan	O
;	O
data	O
not	O
available	O
for	O
Yukon	O
Territory	O
(	O
Y	O
.	O
T	O
.),	O
Northwest	O
Territories	O
(	O
N	O
.	O
W	O
.	O
T	O
),	O
or	O
Nunavut	O
(	O
Nvt	O
.).	O

Adjusted	O
prevalence	O
of	O
quitting	O
in	O
Canadian	O
provinces	O
for	O
men	O
(	O
left	O
)	O
and	O
women	O
(	O
right	O
)	O
aged	O
15	O
years	O
and	O
above	O
,	O
Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
2010	O
.	O

Darker	O
colours	O
indicate	O
higher	O
prevalence	O
.	O

Estimates	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
education	O
.	O

Province	O
name	O
abbreviations	O
:	O
Alta	O
.	O

Alberta	O
;	O
B	O
.	O
C	O
.	O

British	O
Columbia	O
;	O
Man	O
.	O

Manitoba	O
;	O
N	O
.	O
B	O
.	O

New	O
Brunswick	O
;	O
N	O
.	O
L	O
.	O

Newfoundland	O
;	O
N	O
.	O
S	O
.	O

Nova	O
Scotia	O
;	O
O	O
.	O
N	O
.	O

Ontario	O
;	O
P	O
.	O
E	O
.	O
I	O
.	O

Prince	O
Edward	O
Island	O
;	O
Que	O
.	O

Quebec	O
;	O
Sask	O
.	O

Saskatchewan	O
;	O
data	O
not	O
available	O
for	O
Yukon	O
Territory	O
(	O
Y	O
.	O
T	O
.),	O
Northwest	O
Territories	O
(	O
N	O
.	O
W	O
.	O
T	O
),	O
or	O
Nunavut	O
(	O
Nvt	O
.).	O

Mutually	O
adjusted	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
from	O
logistic	O
regressions	O
of	O
current	O
smoking	O
and	O
quitting	O
on	O
demographic	O
and	O
socioeconomic	O
characteristics	O
and	O
province	O
of	O
residence	O
.	O

Current	O
smoking	O

Quitting	O

Variable	O

Odds	O
ratio	O

95	O
%	O
CI	O

Odds	O
ratio	O

95	O
%	O
CI	O

Age	O

10	O
year	O
change	O

0	O
.	O
92	O

(	O
0	O
.	O
82	O
–	O
1	O
.	O
04	O
)	O

1	O
.	O
58	O

(	O
1	O
.	O
37	O
–	O
1	O
.	O
82	O
)	O

Squared	O

0	O
.	O
82	O

(	O
0	O
.	O
79	O
–	O
0	O
.	O
85	O
)	O

1	O
.	O
04	O

(	O
1	O
.	O
00	O
–	O
1	O
.	O
10	O
)	O

Sex	O

Female	O

1	O
.	O
00	O

1	O
.	O
19	O

(	O
0	O
.	O
95	O
–	O
1	O
.	O
49	O
)	O

Male	O

1	O
.	O
62	O

(	O
1	O
.	O
35	O
–	O
1	O
.	O
94	O
)	O

1	O
.	O
00	O

Martial	O
status	O

Common	O
-	O
law	O
/	O
Married	O

1	O
.	O
00	O

2	O
.	O
01	O

(	O
1	O
.	O
48	O
–	O
2	O
.	O
74	O
)	O

Widowed	O
/	O
Divorced	O
/	O
Separated	O

1	O
.	O
85	O

(	O
1	O
.	O
42	O
–	O
2	O
.	O
43	O
)	O

0	O
.	O
97	O

(	O
0	O
.	O
67	O
–	O
1	O
.	O
41	O
)	O

Single	O

1	O
.	O
86	O

(	O
1	O
.	O
44	O
–	O
2	O
.	O
41	O
)	O

1	O
.	O
00	O

Education	O

Completed	O
university	O

1	O
.	O
00	O

1	O
.	O
82	O

(	O
1	O
.	O
24	O
–	O
2	O
.	O
68	O
)	O

Completed	O
college	O

1	O
.	O
78	O

(	O
1	O
.	O
34	O
–	O
2	O
.	O
36	O
)	O

1	O
.	O
82	O

(	O
1	O
.	O
28	O
–	O
2	O
.	O
58	O
)	O

Completed	O
secondary	O

2	O
.	O
95	O

(	O
2	O
.	O
23	O
–	O
3	O
.	O
91	O
)	O

1	O
.	O
36	O

(	O
1	O
.	O
00	O
–	O
1	O
.	O
86	O
)	O

Less	O
than	O
secondary	O

3	O
.	O
92	O

(	O
2	O
.	O
78	O
–	O
5	O
.	O
52	O
)	O

1	O
.	O
00	O

Occupation	O

Professional	O
specialty	O

1	O
.	O
00	O

1	O
.	O
93	O

(	O
1	O
.	O
30	O
–	O
2	O
.	O
87	O
)	O

Not	O
reported	O

1	O
.	O
17	O

(	O
0	O
.	O
57	O
–	O
2	O
.	O
42	O
)	O

1	O
.	O
86	O

(	O
0	O
.	O
89	O
–	O
3	O
.	O
90	O
)	O

Not	O
working	O

1	O
.	O
39	O

(	O
1	O
.	O
05	O
–	O
1	O
.	O
85	O
)	O

1	O
.	O
12	O

(	O
0	O
.	O
78	O
–	O
1	O
.	O
61	O
)	O

Executive	O
,	O
managerial	O

1	O
.	O
54	O

(	O
1	O
.	O
14	O
–	O
2	O
.	O
10	O
)	O

1	O
.	O
40	O

(	O
0	O
.	O
94	O
–	O
2	O
.	O
08	O
)	O

Sales	O
or	O
Service	O

1	O
.	O
68	O

(	O
1	O
.	O
25	O
–	O
2	O
.	O
25	O
)	O

0	O
.	O
98	O

(	O
0	O
.	O
67	O
–	O
1	O
.	O
45	O
)	O

Manual	O

2	O
.	O
05	O

(	O
1	O
.	O
49	O
–	O
2	O
.	O
83	O
)	O

1	O
.	O
00	O

Province	O

Ontario	O

1	O
.	O
00	O

1	O
.	O
43	O

(	O
1	O
.	O
05	O
–	O
1	O
.	O
94	O
)	O

British	O
Columbia	O

0	O
.	O
96	O

(	O
0	O
.	O
74	O
–	O
1	O
.	O
26	O
)	O

1	O
.	O
42	O

(	O
1	O
.	O
05	O
–	O
1	O
.	O
92	O
)	O

Prince	O
Edward	O
Island	O

1	O
.	O
12	O

(	O
0	O
.	O
87	O
–	O
1	O
.	O
45	O
)	O

1	O
.	O
58	O

(	O
1	O
.	O
20	O
–	O
2	O
.	O
09	O
)	O

Alberta	O

1	O
.	O
27	O

(	O
0	O
.	O
99	O
–	O
1	O
.	O
62	O
)	O

1	O
.	O
31	O

(	O
1	O
.	O
00	O
–	O
1	O
.	O
71	O
)	O

Quebec	O

1	O
.	O
27	O

(	O
0	O
.	O
99	O
–	O
1	O
.	O
64	O
)	O

1	O
.	O
03	O

(	O
0	O
.	O
78	O
–	O
1	O
.	O
35	O
)	O

Manitoba	O

1	O
.	O
32	O

(	O
1	O
.	O
05	O
–	O
1	O
.	O
67	O
)	O

1	O
.	O
05	O

(	O
0	O
.	O
80	O
–	O
1	O
.	O
38	O
)	O

New	O
Brunswick	O

1	O
.	O
35	O

(	O
1	O
.	O
06	O
–	O
1	O
.	O
72	O
)	O

1	O
.	O
37	O

(	O
1	O
.	O
04	O
–	O
1	O
.	O
80	O
)	O

Newfoundland	O

1	O
.	O
42	O

(	O
1	O
.	O
11	O
–	O
1	O
.	O
81	O
)	O

1	O
.	O
08	O

(	O
0	O
.	O
83	O
–	O
1	O
.	O
41	O
)	O

Saskatchewan	O

1	O
.	O
42	O

(	O
1	O
.	O
12	O
–	O
1	O
.	O
80	O
)	O

1	O
.	O
40	O

(	O
1	O
.	O
07	O
–	O
1	O
.	O
84	O
)	O

Nova	O
Scotia	O

1	O
.	O
58	O

(	O
1	O
.	O
24	O
–	O
2	O
.	O
01	O
)	O

1	O
.	O
00	O

Canadian	O
Tobacco	O
Use	O
Monitoring	O
Survey	O
2010	O
.	O

Men	O
were	O
more	O
likely	O
to	O
smoke	O
than	O
women	O
and	O
had	O
an	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
1	O
.	O
62	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
35	O
–	O
1	O
.	O
94	O
)	O
for	O
current	O
smoking	O
.	O

In	O
addition	O
,	O
those	O
who	O
were	O
widowed	O
,	O
divorced	O
,	O
or	O
separated	O
(	O
OR	O
1	O
.	O
85	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
–	O
2	O
.	O
43	O
)	O
and	O
singles	O
(	O
OR	O
1	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
44	O
–	O
2	O
.	O
41	O
)	O
smoked	O
more	O
than	O
married	O
individuals	O
.	O

Quitters	O
were	O
more	O
likely	O
to	O
be	O
married	O
(	O
OR	O
2	O
.	O
01	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
48	O
–	O
2	O
.	O
74	O
)	O
and	O
women	O
(	O
OR	O
1	O
.	O
18	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
95	O
–	O
1	O
.	O
49	O
),	O
although	O
the	O
OR	O
for	O
sex	O
was	O
not	O
statistically	O
significant	O
at	O
the	O
conventional	O
5	O
%	O
level	O
.	O

Age	O
was	O
strongly	O
associated	O
with	O
quitting	O
;	O
a	O
10	O
year	O
change	O
in	O
age	O
was	O
associated	O
with	O
an	O
increase	O
of	O
1	O
.	O
58	O
in	O
the	O
odds	O
of	O
quitting	O
and	O
the	O
non	O
-	O
linear	O
terms	O
were	O
non	O
-	O
significant	O
indicating	O
that	O
quitting	O
generally	O
increased	O
with	O
age	O
in	O
a	O
linear	O
fashion	O
among	O
surviving	O
ever	O
smokers	O
.	O

Socioeconomic	O
Variation	O
in	O
Current	O
Smoking	O
and	O
Quitting	O

A	O
strong	O
and	O
graded	O
association	O
was	O
observed	O
between	O
education	O
and	O
current	O
smoking	O
,	O
with	O
the	O
odds	O
of	O
smoking	O
being	O
3	O
.	O
92	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
78	O
–	O
5	O
.	O
52	O
)	O
times	O
higher	O
among	O
those	O
who	O
had	O
not	O
completed	O
secondary	O
school	O
compared	O
to	O
those	O
who	O
had	O
completed	O
university	O
(	O
Table	O
2	O
).	O

There	O
was	O
no	O
evidence	O
of	O
an	O
interaction	O
in	O
this	O
association	O
by	O
sex	O
(	O
P	O
=	O
0	O
.	O
24	O
).	O

Current	O
smoking	O
was	O
higher	O
among	O
those	O
working	O
manual	O
occupations	O
(	O
OR	O
2	O
.	O
05	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
49	O
–	O
2	O
.	O
83	O
)	O
and	O
in	O
sales	O
or	O
service	O
occupations	O
(	O
OR	O
1	O
.	O
68	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
25	O
–	O
2	O
.	O
25	O
)	O
compared	O
to	O
those	O
in	O
professional	O
specialties	O
with	O
no	O
indication	O
of	O
interaction	O
by	O
sex	O
(	O
P	O
=	O
0	O
.	O
43	O
).	O

The	O
adjusted	O
prevalence	O
of	O
current	O
smoking	O
across	O
all	O
of	O
the	O
study	O
variables	O
and	O
for	O
men	O
and	O
women	O
is	O
presented	O
in	O
Figure	O
3A	O
.	O

We	O
observed	O
substantial	O
variation	O
in	O
prevalence	O
according	O
to	O
education	O
;	O
overall	O
the	O
prevalence	O
varied	O
from	O
11	O
.	O
0	O
%	O
among	O
individuals	O
who	O
had	O
completed	O
university	O
to	O
32	O
.	O
8	O
%	O
among	O
those	O
with	O
less	O
than	O
high	O
school	O
education	O
,	O
corresponding	O
to	O
a	O
difference	O
of	O
21	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
:	O
16	O
.	O
4	O
–	O
27	O
.	O
3	O
).	O

Large	O
variation	O
in	O
the	O
prevalence	O
of	O
current	O
smoking	O
was	O
also	O
observed	O
by	O
occupation	O
group	O
with	O
a	O
difference	O
of	O
10	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
2	O
–	O
16	O
.	O
3	O
)	O
between	O
those	O
in	O
professional	O
specialties	O
(	O
14	O
.	O
6	O
%)	O
and	O
those	O
in	O
manual	O
occupations	O
(	O
24	O
.	O
7	O
%).	O

Adjusted	O
prevalence	O
of	O
current	O
smoking	O
and	O
quitting	O
in	O
Canada	O
by	O
demographic	O
and	O
socioeconomic	O
characteristics	O
and	O
province	O
.	O

BC	O
British	O
Columbia	O
;	O
PEI	O
Prince	O
Edward	O
Island	O
.	O

Similarly	O
,	O
we	O
observed	O
strong	O
SES	O
-	O
quitting	O
associations	O
for	O
education	O
and	O
occupation	O
,	O
with	O
quitting	O
being	O
more	O
likely	O
among	O
those	O
with	O
university	O
education	O
(	O
OR	O
1	O
.	O
82	O
)	O
and	O
in	O
higher	O
status	O
occupations	O
(	O
OR	O
1	O
.	O
93	O
for	O
professionals	O
),	O
although	O
the	O
overall	O
educational	O
gradient	O
was	O
not	O
as	O
pronounced	O
as	O
compared	O
to	O
current	O
smoking	O
(	O
Table	O
2	O
).	O

In	O
addition	O
,	O
there	O
was	O
indication	O
of	O
an	O
interaction	O
in	O
the	O
education	O
-	O
quitting	O
association	O
by	O
sex	O
,	O
with	O
the	O
gradient	O
being	O
sharper	O
for	O
women	O
compared	O
to	O
men	O
(	O
P	O
=	O
0	O
.	O
02	O
),	O
although	O
there	O
was	O
no	O
indication	O
of	O
an	O
interaction	O
by	O
sex	O
in	O
the	O
occupation	O
-	O
quitting	O
association	O
(	O
P	O
=	O
0	O
.	O
20	O
).	O

Conditional	O
on	O
all	O
covariates	O
,	O
a	O
15	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
6	O
.	O
7	O
–	O
24	O
.	O
3	O
)	O
difference	O
was	O
observed	O
in	O
the	O
rate	O
of	O
quitting	O
between	O
those	O
in	O
highest	O
and	O
lowest	O
educated	O
groups	O
overall	O
,	O
although	O
this	O
difference	O
was	O
27	O
.	O
3	O
%	O
among	O
women	O
compared	O
to	O
6	O
.	O
0	O
%	O
among	O
men	O
(	O
Figure	O
3B	O
).	O

Overal	O
a	O
14	O
.	O
7	O
%	O
difference	O
was	O
observed	O
in	O
the	O
prevalence	O
of	O
quitting	O
between	O
those	O
in	O
professional	O
(	O
72	O
.	O
6	O
%)	O
and	O
manual	O
occupations	O
(	O
57	O
.	O
9	O
%).	O

Geographic	O
Variation	O
in	O
Current	O
Smoking	O
and	O
Quitting	O

A	O
statistically	O
significant	O
difference	O
in	O
current	O
smoking	O
was	O
observed	O
between	O
provinces	O
in	O
the	O
logistic	O
regression	O
model	O
treating	O
provinces	O
as	O
a	O
fixed	O
effect	O
(	O
p	O
=	O
0	O
.	O
0009	O
).	O

In	O
this	O
model	O
,	O
the	O
odds	O
of	O
current	O
smoking	O
were	O
greatest	O
in	O
Nova	O
Scotia	O
(	O
OR	O
1	O
.	O
58	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
24	O
–	O
2	O
.	O
01	O
)	O
and	O
lowest	O
in	O
B	O
.	O
C	O
.	O

(	O
OR	O
0	O
.	O
96	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
74	O
–	O
1	O
.	O
26	O
)	O
compared	O
to	O
Ontario	O
.	O

Based	O
on	O
this	O
model	O
,	O
the	O
adjusted	O
prevalence	O
of	O
current	O
smoking	O
varied	O
from	O
17	O
.	O
9	O
%	O
in	O
British	O
Columbia	O
and	O
Ontario	O
to	O
26	O
.	O
1	O
%	O
in	O
Nova	O
Scotia	O
,	O
equivalent	O
to	O
a	O
difference	O
of	O
8	O
.	O
2	O
%	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
0	O
–	O
12	O
.	O
2	O
).	O

In	O
addition	O
,	O
the	O
prevalence	O
of	O
current	O
smoking	O
was	O
lower	O
in	O
British	O
Columbia	O
and	O
Ontario	O
compared	O
to	O
the	O
national	O
average	O
(	O
Figure	O
3A	O
).	O

The	O
adjusted	O
prevalence	O
of	O
quitting	O
across	O
provinces	O
was	O
also	O
calculated	O
from	O
a	O
logistic	O
regression	O
model	O
treating	O
province	O
as	O
a	O
fixed	O
effect	O
.	O

From	O
this	O
model	O
,	O
a	O
10	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
:	O
3	O
.	O
9	O
–	O
16	O
.	O
8	O
)	O
difference	O
was	O
observed	O
in	O
quit	O
rates	O
between	O
the	O
provinces	O
with	O
the	O
highest	O
rate	O
(	O
Prince	O
Edward	O
Island	O
,	O
67	O
.	O
8	O
%)	O
and	O
lowest	O
rate	O
(	O
Nova	O
Scotia	O
,	O
57	O
.	O
4	O
%).	O

Nova	O
Scotia	O
,	O
along	O
with	O
the	O
western	O
and	O
prairie	O
provinces	O
(	O
Manitoba	O
,	O
Alberta	O
,	O
and	O
Saskatchewan	O
)	O
had	O
quitter	O
percentages	O
lower	O
than	O
the	O
Canadian	O
average	O
of	O
63	O
.	O
7	O
%.	O

We	O
examined	O
geographic	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
between	O
provinces	O
using	O
a	O
multilevel	O
modeling	O
approach	O
.	O

In	O
this	O
approach	O
,	O
provinces	O
were	O
treated	O
as	O
a	O
random	O
sample	O
and	O
between	O
provincial	O
differences	O
in	O
current	O
smoking	O
and	O
quitting	O
were	O
assumed	O
to	O
come	O
from	O
a	O
distribution	O
estimated	O
in	O
the	O
model	O
.	O

Compared	O
to	O
treating	O
provinces	O
as	O
a	O
fixed	O
classification	O
,	O
the	O
multilevel	O
model	O
yielded	O
similar	O
provincial	O
-	O
level	O
estimates	O
although	O
the	O
differences	O
between	O
provinces	O
were	O
found	O
to	O
be	O
2	O
.	O
2	O
%	O
narrower	O
(	O
6	O
.	O
0	O
%	O
vs	O
8	O
.	O
2	O
%)	O
for	O
current	O
smoking	O
and	O
3	O
.	O
2	O
%	O
narrower	O
(	O
7	O
.	O
2	O
%	O
vs	O
10	O
.	O
4	O
%)	O
for	O
quitting	O
.	O

The	O
fixed	O
effects	O
estimates	O
for	O
each	O
province	O
,	O
compared	O
to	O
the	O
multilevel	O
model	O
estimates	O
are	O
shown	O
for	O
current	O
smoking	O
in	O
Figure	O
4A	O
and	O
quitting	O
in	O
Figure	O
4B	O
.	O

The	O
ordering	O
of	O
provinces	O
was	O
generally	O
consistent	O
in	O
the	O
two	O
approaches	O
.	O

For	O
current	O
smoking	O
,	O
the	O
provinces	O
with	O
lower	O
than	O
average	O
rates	O
of	O
smoking	O
(	O
British	O
Columbia	O
,	O
Ontario	O
,	O
and	O
Prince	O
Edward	O
Island	O
)	O
in	O
the	O
fixed	O
effects	O
model	O
also	O
emerged	O
as	O
lower	O
than	O
average	O
in	O
the	O
multilevel	O
model	O
,	O
indicating	O
the	O
reliability	O
of	O
these	O
estimates	O
.	O

The	O
multilevel	O
model	O
tends	O
to	O
‘	O
shrink	O
’	O
less	O
reliable	O
provincial	O
estimates	O
towards	O
the	O
national	O
average	O
;	O
this	O
is	O
apparent	O
in	O
the	O
quit	O
rate	O
model	O
where	O
a	O
smaller	O
range	O
in	O
the	O
multilevel	O
estimates	O
for	O
quitting	O
was	O
observed	O
compared	O
to	O
the	O
fixed	O
effects	O
approach	O
(	O
Figure	O
4B	O
).	O

Comparison	O
of	O
adjusted	O
prevalence	O
estimates	O
for	O
current	O
smoking	O
and	O
quitting	O
for	O
Canadian	O
provinces	O
based	O
on	O
mutually	O
adjusted	O
fixed	O
effects	O
and	O
multilevel	O
logistic	O
regression	O
models	O
.	O

Province	O
name	O
abbreviations	O
:	O
AB	O
Alberta	O
;	O
BC	O
British	O
Columbia	O
;	O
MB	O
Manitoba	O
;	O
NB	O
New	O
Brunswick	O
;	O
NL	O
Newfoundland	O
;	O
NS	O
Nova	O
Scotia	O
;	O
ON	O
Ontario	O
;	O
PE	O
Prince	O
Edward	O
Island	O
;	O
QC	O
Quebec	O
;	O
SK	O
Saskatchewan	O
.	O

In	O
addition	O
to	O
providing	O
estimates	O
of	O
the	O
between	O
provincial	O
differences	O
in	O
current	O
smoking	O
and	O
quitting	O
,	O
the	O
multilevel	O
modeling	O
approach	O
allows	O
for	O
a	O
more	O
detailed	O
examination	O
of	O
several	O
research	O
questions	O
that	O
are	O
of	O
substantive	O
interest	O
.	O

These	O
analyses	O
revealed	O
the	O
amount	O
of	O
between	O
-	O
provincial	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
before	O
and	O
after	O
accounting	O
for	O
individual	O
characteristics	O
(	O
Table	O
3	O
).	O

In	O
an	O
initial	O
random	O
intercepts	O
null	O
model	O
,	O
provinces	O
accounted	O
for	O
0	O
.	O
9	O
%	O
and	O
1	O
.	O
1	O
%	O
of	O
the	O
total	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
,	O
respectively	O
.	O

The	O
addition	O
of	O
demographic	O
and	O
socioeconomic	O
characteristics	O
to	O
the	O
model	O
reduced	O
the	O
variance	O
in	O
current	O
smoking	O
by	O
26	O
.	O
7	O
%	O
and	O
in	O
quitting	O
by	O
25	O
.	O
7	O
%.	O

Variance	O
in	O
current	O
smoking	O
and	O
quitting	O
between	O
provinces	O
in	O
Canada	O
;	O
expressed	O
as	O
percentage	O
of	O
the	O
contribution	O
to	O
the	O
total	O
variance	O
.	O

Null	O
model	O
*	O

Fully	O
adjusted	O
model	O
**	O

Response	O

Variance	O

SE	O

%	O

Variance	O

SE	O

%	O

Current	O
smoking	O

0	O
.	O
030	O

0	O
.	O
014	O

0	O
.	O
9	O

0	O
.	O
022	O

0	O
.	O
010	O

0	O
.	O
7	O

Quitting	O

0	O
.	O
035	O

0	O
.	O
016	O

1	O
.	O
1	O

0	O
.	O
026	O

0	O
.	O
005	O

0	O
.	O
8	O

Notes	O
:	O

Multilevel	O
null	O
model	O
with	O
random	O
intercepts	O
for	O
province	O
adjusted	O
.	O

Multilevel	O
model	O
with	O
random	O
intercepts	O
for	O
province	O
and	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
and	O
education	O
.	O

In	O
order	O
to	O
assess	O
consistency	O
in	O
the	O
SES	O
-	O
current	O
smoking	O
and	O
SES	O
-	O
quitting	O
relationships	O
across	O
provinces	O
,	O
we	O
estimated	O
random	O
-	O
intercept	O
,	O
random	O
slope	O
multilevel	O
models	O
(	O
Equation	O
2	O
).	O

In	O
these	O
models	O
,	O
the	O
SES	O
-	O
current	O
smoking	O
and	O
SES	O
-	O
quitting	O
relationships	O
were	O
allowed	O
to	O
vary	O
across	O
provinces	O
for	O
education	O
and	O
occupation	O
.	O

The	O
overall	O
odds	O
ratio	O
for	O
current	O
smoking	O
in	O
Canada	O
for	O
a	O
one	O
-	O
category	O
increase	O
in	O
education	O
was	O
0	O
.	O
64	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
60	O
–	O
0	O
.	O
68	O
)	O
(	O
Figure	O
5A	O
)	O
and	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
77	O
–	O
0	O
.	O
87	O
)	O
for	O
a	O
one	O
-	O
category	O
increase	O
in	O
occupation	O
(	O
Figure	O
5B	O
).	O

The	O
direction	O
of	O
these	O
relationships	O
were	O
consistent	O
and	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
all	O
provinces	O
for	O
both	O
education	O
and	O
occupation	O
.	O

The	O
magnitude	O
of	O
the	O
association	O
was	O
greater	O
than	O
the	O
national	O
average	O
in	O
the	O
provinces	O
of	O
British	O
Columbia	O
,	O
Alberta	O
,	O
and	O
Saskatchewan	O
for	O
the	O
education	O
relationship	O
and	O
in	O
the	O
provinces	O
of	O
Nova	O
Scotia	O
,	O
British	O
Columbia	O
,	O
Alberta	O
,	O
Newfoundland	O
,	O
and	O
Ontario	O
for	O
the	O
occupation	O
relationship	O
.	O

In	O
general	O
,	O
the	O
magnitude	O
of	O
the	O
SES	O
-	O
current	O
smoking	O
relationship	O
was	O
stronger	O
for	O
education	O
compared	O
to	O
occupation	O
.	O

The	O
associations	O
between	O
education	O
and	O
quitting	O
and	O
occupation	O
and	O
quitting	O
were	O
positive	O
across	O
all	O
provinces	O
,	O
and	O
statistically	O
significant	O
in	O
8	O
/	O
10	O
provinces	O
for	O
education	O
(	O
Figure	O
6A	O
)	O
and	O
9	O
/	O
10	O
provinces	O
for	O
occupation	O
(	O
Figure	O
6B	O
).	O

The	O
overall	O
odds	O
ratio	O
for	O
quitting	O
with	O
each	O
successive	O
increase	O
in	O
the	O
level	O
of	O
education	O
was	O
1	O
.	O
27	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
16	O
–	O
1	O
.	O
40	O
)	O
and	O
1	O
.	O
20	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
12	O
–	O
1	O
.	O
27	O
)	O
for	O
each	O
successive	O
increase	O
in	O
level	O
of	O
occupation	O
.	O

The	O
education	O
-	O
quitting	O
relationship	O
was	O
stronger	O
than	O
the	O
national	O
average	O
in	O
Saskatchewan	O
,	O
Alberta	O
,	O
Newfoundland	O
,	O
and	O
was	O
highest	O
in	O
British	O
Columbia	O
(	O
OR	O
1	O
.	O
56	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
29	O
–	O
1	O
.	O
88	O
).	O

The	O
occupation	O
-	O
quitting	O
relationship	O
was	O
stronger	O
than	O
the	O
national	O
average	O
in	O
Ontario	O
,	O
British	O
Columbia	O
,	O
and	O
Prince	O
Edward	O
Island	O
.	O

Associations	O
were	O
shallower	O
than	O
the	O
national	O
average	O
in	O
Quebec	O
,	O
Nova	O
Scotia	O
,	O
Manitoba	O
,	O
and	O
New	O
Brunswick	O
for	O
both	O
education	O
and	O
occupation	O
;	O
in	O
Ontario	O
and	O
Prince	O
Edward	O
Island	O
for	O
education	O
;	O
and	O
in	O
Alberta	O
for	O
occupation	O
.	O

Odds	O
ratios	O
for	O
current	O
smoking	O
for	O
a	O
one	O
-	O
category	O
increase	O
in	O
the	O
level	O
of	O
education	O
and	O
occupation	O
across	O
Canadian	O
provinces	O
.	O

BC	O
British	O
Columbia	O
;	O
PEI	O
Prince	O
Edward	O
Island	O
.	O

Odds	O
ratios	O
for	O
quitting	O
for	O
a	O
one	O
-	O
category	O
increase	O
in	O
the	O
level	O
of	O
education	O
and	O
occupation	O
across	O
Canadian	O
provinces	O
.	O

BC	O
British	O
Columbia	O
;	O
PEI	O
Prince	O
Edward	O
Island	O
.	O

Discussion	O

This	O
paper	O
has	O
four	O
principal	O
findings	O
.	O

First	O
,	O
current	O
smoking	O
in	O
Canada	O
was	O
strongly	O
influenced	O
by	O
socioeconomic	O
status	O
;	O
people	O
who	O
had	O
not	O
completed	O
secondary	O
level	O
education	O
were	O
more	O
than	O
three	O
times	O
as	O
likely	O
to	O
smoke	O
compared	O
to	O
those	O
who	O
had	O
completed	O
university	O
.	O

Second	O
,	O
geographic	O
analyses	O
revealed	O
that	O
the	O
adjusted	O
prevalence	O
of	O
current	O
smoking	O
was	O
statistically	O
significantly	O
lower	O
than	O
the	O
Canadian	O
average	O
in	O
three	O
provinces	O
:	O
British	O
Columbia	O
,	O
Ontario	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
Prince	O
Edward	O
Island	O
.	O

This	O
finding	O
was	O
consistent	O
when	O
provinces	O
were	O
treated	O
as	O
a	O
fixed	O
classification	O
and	O
as	O
a	O
random	O
classification	O
in	O
a	O
multilevel	O
model	O
.	O

In	O
addition	O
,	O
the	O
relationships	O
between	O
education	O
and	O
current	O
smoking	O
and	O
between	O
occupation	O
and	O
current	O
smoking	O
were	O
consistent	O
,	O
negative	O
,	O
and	O
statistically	O
significant	O
across	O
all	O
provinces	O
in	O
Canada	O
.	O

Third	O
,	O
although	O
roughly	O
six	O
out	O
of	O
ten	O
Canadians	O
who	O
had	O
ever	O
smoked	O
had	O
quit	O
,	O
quitting	O
was	O
more	O
likely	O
to	O
occur	O
among	O
those	O
of	O
higher	O
socioeconomic	O
status	O
.	O

Geographically	O
,	O
large	O
differences	O
in	O
quit	O
rates	O
were	O
found	O
between	O
provinces	O
,	O
although	O
the	O
magnitude	O
of	O
difference	O
was	O
attenuated	O
when	O
province	O
was	O
treated	O
as	O
a	O
random	O
classification	O
using	O
a	O
multilevel	O
model	O
.	O

Forth	O
,	O
although	O
the	O
associations	O
between	O
education	O
and	O
quitting	O
and	O
between	O
occupation	O
and	O
quitting	O
were	O
positive	O
in	O
all	O
provinces	O
,	O
some	O
heterogeneity	O
in	O
the	O
magnitude	O
was	O
found	O
,	O
especially	O
in	O
the	O
education	O
-	O
quitting	O
relationship	O
which	O
was	O
noticeably	O
steeper	O
in	O
British	O
Columbia	O
and	O
shallower	O
in	O
Nova	O
Scotia	O
compared	O
to	O
the	O
national	O
average	O
.	O

There	O
are	O
some	O
limitations	O
in	O
this	O
work	O
.	O

First	O
,	O
the	O
CTUMS	O
data	O
are	O
cross	O
-	O
sectional	O
therefore	O
causal	O
inferences	O
from	O
our	O
findings	O
must	O
be	O
interpreted	O
cautiously	O
.	O

The	O
primary	O
motivation	O
for	O
this	O
study	O
,	O
however	O
,	O
was	O
to	O
investigate	O
variability	O
in	O
smoking	O
behaviour	O
across	O
socioeconomic	O
and	O
geographic	O
dimensions	O
and	O
such	O
a	O
design	O
is	O
appropriate	O
.	O

Second	O
,	O
the	O
data	O
are	O
from	O
a	O
telephone	O
survey	O
,	O
which	O
as	O
a	O
design	O
has	O
several	O
inherent	O
potential	O
sources	O
of	O
bias	O
in	O
terms	O
of	O
population	O
coverage	O
.	O

For	O
example	O
,	O
one	O
limitation	O
of	O
telephone	O
sampling	O
is	O
that	O
some	O
individuals	O
either	O
do	O
not	O
have	O
telephones	O
or	O
have	O
only	O
a	O
mobile	O
phone	O
,	O
which	O
were	O
not	O
part	O
of	O
the	O
random	O
telephone	O
prefix	O
sampling	O
frames	O
in	O
the	O
CTUMS	O
.	O

Estimates	O
from	O
the	O
2010	O
Residential	O
Telephone	O
Service	O
Survey	O
suggest	O
that	O
14	O
–	O
16	O
%	O
of	O
the	O
Canadian	O
population	O
do	O
not	O
have	O
a	O
landline	O
and	O
that	O
these	O
individuals	O
are	O
concentrated	O
among	O
those	O
of	O
18	O
–	O
34	O
years	O
of	O
age	O
and	O
with	O
below	O
-	O
average	O
income	O
.	O
[	O
30	O
]	O
Although	O
efforts	O
were	O
made	O
to	O
weight	O
the	O
CTUMS	O
survey	O
data	O
for	O
individuals	O
without	O
land	O
lines	O
,	O
it	O
is	O
conceivable	O
that	O
some	O
of	O
the	O
prevalence	O
estimates	O
may	O
be	O
biased	O
downwards	O
given	O
that	O
our	O
findings	O
suggest	O
smoking	O
to	O
be	O
higher	O
among	O
these	O
ages	O
and	O
lower	O
SES	O
groups	O
.	O

In	O
addition	O
,	O
telephone	O
surveys	O
can	O
produce	O
a	O
potential	O
reporting	O
bias	O
among	O
younger	O
respondents	O
who	O
may	O
be	O
prone	O
to	O
give	O
socially	O
desirable	O
answers	O
about	O
their	O
smoking	O
habits	O
in	O
the	O
presence	O
of	O
their	O
parents	O
or	O
family	O
.	O

Estimates	O
of	O
youth	O
smoking	O
among	O
15	O
–	O
19	O
year	O
olds	O
in	O
the	O
CTUMS	O
were	O
lower	O
than	O
what	O
has	O
been	O
reported	O
among	O
16	O
–	O
19	O
year	O
olds	O
the	O
UK	O
(	O
12	O
%	O
vs	O
24	O
%)	O
[	O
31	O
],	O
although	O
the	O
CTUMS	O
data	O
for	O
youth	O
smoking	O
have	O
demonstrated	O
good	O
concordance	O
with	O
other	O
prevalence	O
estimates	O
in	O
Canada	O
from	O
general	O
health	O
surveys	O
such	O
as	O
the	O
Canadian	O
Community	O
Heath	O
Survey	O
,	O
which	O
uses	O
a	O
combination	O
of	O
in	O
-	O
person	O
and	O
telephone	O
-	O
based	O
interviews	O
.[	O
32	O
]–[	O
34	O
]	O
Second	O
,	O
we	O
only	O
considered	O
cigarette	O
smoking	O
in	O
the	O
present	O
study	O
.	O

Socioeconomic	O
and	O
geographic	O
differences	O
for	O
the	O
use	O
of	O
cigars	O
,	O
or	O
smokeless	O
(	O
chewing	O
)	O
tobacco	O
were	O
not	O
considered	O
these	O
analyses	O
although	O
these	O
forms	O
of	O
tobacco	O
use	O
may	O
be	O
important	O
to	O
consider	O
among	O
certain	O
population	O
groups	O
in	O
Canada	O
.	O

These	O
forms	O
of	O
tobacco	O
are	O
,	O
however	O
,	O
used	O
less	O
frequently	O
and	O
only	O
in	O
a	O
minority	O
of	O
the	O
Canadian	O
population	O
.	O
[	O
12	O
]	O
Further	O
research	O
on	O
the	O
patterning	O
of	O
occasional	O
smoking	O
in	O
Canada	O
,	O
the	O
use	O
of	O
other	O
forms	O
of	O
tobacco	O
,	O
and	O
potentially	O
related	O
factors	O
such	O
as	O
alcohol	B-CD
use	O
is	O
needed	O
.	O

The	O
overall	O
relationship	O
observed	O
between	O
socioeconomic	O
status	O
markers	O
and	O
smoking	O
in	O
this	O
study	O
was	O
similar	O
to	O
what	O
has	O
been	O
reported	O
previously	O
in	O
Canada	O
.	O
[	O
13	O
],	O
[	O
35	O
],	O
[	O
36	O
]	O
We	O
noted	O
strong	O
gradients	O
in	O
current	O
smoking	O
by	O
level	O
of	O
education	O
and	O
occupation	O
,	O
which	O
were	O
minimally	O
changed	O
after	O
adjustment	O
for	O
potentially	O
confounding	O
variables	O
.	O

Differences	O
remained	O
in	O
rates	O
of	O
current	O
smoking	O
between	O
provinces	O
after	O
accounting	O
for	O
demographic	O
and	O
socioeconomic	O
characteristics	O
in	O
both	O
the	O
fixed	O
and	O
random	O
effects	O
models	O
,	O
although	O
the	O
estimated	O
prevalence	O
for	O
several	O
provinces	O
(	O
for	O
example	O
Nova	O
Scotia	O
and	O
Manitoba	O
)	O
were	O
‘	O
shrunk	O
’	O
towards	O
the	O
national	O
mean	O
in	O
the	O
multilevel	O
model	O
.	O

Due	O
to	O
the	O
treatment	O
of	O
higher	O
level	O
units	O
as	O
part	O
of	O
a	O
distribution	O
,	O
the	O
multilevel	O
approach	O
is	O
typically	O
more	O
conservative	O
in	O
estimating	O
between	O
group	O
-	O
differences	O
.	O
[	O
26	O
]	O
The	O
between	O
provincial	O
differences	O
in	O
quit	O
rates	O
were	O
approximately	O
a	O
third	O
narrower	O
in	O
the	O
multilevel	O
modeling	O
approach	O
,	O
and	O
the	O
most	O
obvious	O
pattern	O
of	O
attenuation	O
compared	O
to	O
the	O
fixed	O
effects	O
model	O
was	O
found	O
for	O
provinces	O
with	O
quit	O
rates	O
lower	O
than	O
the	O
national	O
average	O
.	O

In	O
this	O
way	O
,	O
the	O
random	O
effects	O
approach	O
is	O
favoured	O
because	O
it	O
protects	O
against	O
the	O
over	O
interpretation	O
of	O
extreme	O
group	O
-	O
level	O
differences	O
which	O
are	O
potentially	O
less	O
reliable	O
.	O

Conditional	O
on	O
socioeconomic	O
and	O
demographic	O
characteristics	O
,	O
province	O
of	O
residence	O
was	O
associated	O
with	O
<	O
1	O
%	O
of	O
the	O
total	O
variability	O
in	O
current	O
smoking	O
and	O
quitting	O
in	O
the	O
fully	O
adjusted	O
multilevel	O
models	O
.	O

Although	O
the	O
magnitude	O
of	O
this	O
variability	O
was	O
not	O
large	O
,	O
adjustment	O
for	O
individual	O
characteristics	O
explained	O
about	O
one	O
quarter	O
of	O
the	O
provincial	O
-	O
level	O
variation	O
in	O
current	O
smoking	O
and	O
quitting	O
,	O
indirectly	O
suggesting	O
the	O
potential	O
relevance	O
of	O
geographic	O
context	O
in	O
influencing	O
smoking	O
behaviour	O
in	O
Canada	O
.	O
[	O
37	O
],	O
[	O
38	O
]	O
Province	O
was	O
the	O
only	O
higher	O
-	O
level	O
geographic	O
unit	O
that	O
was	O
available	O
in	O
the	O
CTUMS	O
;	O
thus	O
potentially	O
important	O
geographic	O
variability	O
in	O
smoking	O
behaviour	O
at	O
lower	O
levels	O
of	O
aggregation	O
(	O
for	O
example	O
health	O
regions	O
,	O
or	O
communities	O
)	O
may	O
have	O
been	O
masked	O
in	O
these	O
analyses	O
.	O
[	O
39	O
].	O

Our	O
study	O
documents	O
that	O
current	O
smoking	O
in	O
Canada	O
follows	O
an	O
inverse	O
gradient	O
by	O
SES	O
which	O
was	O
consistent	O
in	O
direction	O
across	O
all	O
provinces	O
.	O

Similarly	O
,	O
a	O
consistent	O
and	O
positive	O
gradient	O
was	O
observed	O
with	O
quitting	O
for	O
increasing	O
SES	O
.	O

Interestingly	O
,	O
there	O
was	O
some	O
variability	O
in	O
the	O
magnitude	O
of	O
these	O
associations	O
,	O
with	O
larger	O
variability	O
observed	O
for	O
quitting	O
.	O

The	O
education	O
and	O
occupation	O
gradients	O
appear	O
to	O
be	O
stronger	O
in	O
British	O
Columbia	O
,	O
a	O
province	O
with	O
the	O
lowest	O
prevalence	O
of	O
current	O
smoking	O
and	O
second	O
highest	O
quit	O
rate	O
.	O

In	O
comparison	O
,	O
the	O
education	O
gradients	O
were	O
considerably	O
shallower	O
in	O
Manitoba	O
,	O
New	O
Brunswick	O
,	O
and	O
Ontario	O
.	O

This	O
may	O
indicate	O
that	O
programs	O
aimed	O
at	O
tobacco	O
use	O
prevention	O
and	O
/	O
or	O
cessation	O
or	O
other	O
social	O
assistance	O
programs	O
have	O
been	O
better	O
able	O
to	O
reach	O
all	O
SES	O
groups	O
in	O
certain	O
provinces	O
compared	O
to	O
others	O
.	O

Further	O
comparative	O
analyses	O
of	O
provincial	O
policies	O
are	O
required	O
to	O
understand	O
why	O
SES	O
gradients	O
vary	O
across	O
provinces	O
.	O

Our	O
findings	O
related	O
to	O
the	O
socioeconomic	O
differentials	O
in	O
quitting	O
are	O
of	O
public	O
health	O
importance	O
.	O

On	O
average	O
,	O
individuals	O
who	O
where	O
married	O
,	O
highly	O
educated	O
,	O
and	O
working	O
in	O
higher	O
status	O
occupations	O
had	O
the	O
highest	O
likelihood	O
of	O
quitting	O
.	O

While	O
a	O
positive	O
SES	O
-	O
quitting	O
relationship	O
has	O
been	O
previously	O
reported	O
[	O
17	O
]–[	O
20	O
],	O
the	O
implications	O
of	O
these	O
findings	O
have	O
been	O
given	O
less	O
attention	O
in	O
recent	O
years	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
suggested	O
that	O
policies	O
aimed	O
at	O
reducing	O
tobacco	O
consumption	O
may	O
be	O
responsible	O
for	O
widening	O
the	O
socioeconomic	O
differentials	O
in	O
smoking	O
,	O
at	O
least	O
in	O
the	O
short	O
-	O
term	O
.	O
[	O
15	O
]	O
Individuals	O
with	O
greater	O
education	O
and	O
/	O
or	O
material	O
resources	O
may	O
be	O
more	O
responsive	O
to	O
accessing	O
health	O
services	O
in	O
general	O
[	O
40	O
]	O
and	O
this	O
may	O
extend	O
to	O
primary	O
care	O
and	O
other	O
sources	O
of	O
cessation	O
support	O
including	O
telephone	O
quitlines	O
[	O
41	O
],	O
medication	O
,	O
nicotine	B-CD
replacement	O
,	O
or	O
counselling	O
.	O

Interventions	O
carried	O
out	O
at	O
a	O
population	O
level	O
including	O
taxation	O
,	O
dissemination	O
of	O
health	O
information	O
and	O
pictorial	O
warnings	O
on	O
tobacco	O
products	O
,	O
restrictions	O
on	O
use	O
,	O
advertisements	O
,	O
and	O
sale	O
of	O
cigarettes	O
have	O
been	O
effective	O
at	O
reducing	O
average	O
consumption	O
[	O
42	O
],	O
[	O
43	O
],	O
although	O
it	O
is	O
less	O
clear	O
whether	O
these	O
interventions	O
are	O
reaching	O
all	O
segments	O
of	O
the	O
population	O
.	O

Indeed	O
,	O
there	O
is	O
evidence	O
that	O
taxation	O
policies	O
are	O
being	O
circumvented	O
among	O
some	O
population	O
groups	O
and	O
in	O
some	O
geographic	O
areas	O
.	O

For	O
example	O
,	O
a	O
quarter	O
of	O
respondents	O
in	O
the	O
Ontario	O
Tobacco	O
Survey	O
reported	O
recent	O
purchasing	O
of	O
contraband	O
cigarettes	O
from	O
First	O
Nations	O
reserves	O
without	O
paying	O
applicable	O
federal	O
or	O
provincial	O
taxes	O
.	O
[	O
44	O
]	O
In	O
addition	O
,	O
the	O
usual	O
purchasing	O
of	O
contraband	O
or	O
low	O
-	O
tax	O
cigarettes	O
was	O
more	O
common	O
among	O
lower	O
educated	O
groups	O
,	O
heavy	O
smokers	O
,	O
and	O
those	O
who	O
do	O
not	O
intend	O
to	O
quit	O
.	O
[	O
44	O
].	O

In	O
Canada	O
,	O
all	O
provinces	O
and	O
territories	O
have	O
legislation	O
restricting	O
smoking	O
in	O
workplaces	O
and	O
public	O
places	O
including	O
restaurants	O
,	O
bars	O
,	O
and	O
public	O
transportation	O
.	O
[	O
45	O
]	O
Although	O
such	O
contextual	O
factors	O
were	O
not	O
explicitly	O
considered	O
in	O
the	O
present	O
study	O
,	O
evidence	O
from	O
New	O
Zealand	O
suggests	O
that	O
such	O
workplace	O
restrictions	O
may	O
have	O
been	O
more	O
effective	O
in	O
reducing	O
rates	O
of	O
smoking	O
and	O
exposure	O
to	O
environmental	O
tobacco	O
smoke	O
among	O
those	O
in	O
professional	O
occupations	O
.	O
[	O
46	O
]	O
In	O
addition	O
,	O
previous	O
research	O
in	O
Canada	O
has	O
revealed	O
the	O
importance	O
of	O
social	O
factors	O
such	O
as	O
family	O
norms	O
discouraging	O
smoking	O
in	O
explaining	O
between	O
-	O
area	O
differences	O
in	O
prevalence	O
.	O
[	O
39	O
]	O
Successful	O
efforts	O
to	O
increase	O
smoking	O
prevention	O
and	O
cessation	O
across	O
the	O
entire	O
Canadian	O
population	O
will	O
therefore	O
need	O
explicit	O
consideration	O
of	O
lower	O
socioeconomic	O
,	O
Aboriginal	O
,	O
other	O
disadvantaged	O
groups	O
along	O
with	O
contextual	O
factors	O
at	O
the	O
local	O
and	O
provincial	O
levels	O
.	O

Policies	O
such	O
as	O
tax	O
increases	O
and	O
smoking	O
restrictions	O
may	O
not	O
be	O
effective	O
in	O
increasing	O
cessation	O
among	O
the	O
poor	O
or	O
less	O
educated	O
without	O
additional	O
support	O
or	O
assistance	O
in	O
reducing	O
tobacco	O
dependence	O
in	O
these	O
groups	O
.	O

In	O
addition	O
,	O
further	O
research	O
is	O
needed	O
to	O
understand	O
the	O
underlying	O
causes	O
of	O
geographic	O
variability	O
in	O
smoking	O
behaviour	O
in	O
Canada	O
.	O

Such	O
variation	O
may	O
be	O
a	O
result	O
of	O
different	O
legislation	O
or	O
taxation	O
but	O
may	O
also	O
be	O
influenced	O
by	O
different	O
social	O
or	O
cultural	O
norms	O
across	O
provinces	O
.	O
[	O
47	O
].	O

The	O
persistence	O
of	O
high	O
rates	O
of	O
current	O
smoking	O
and	O
low	O
quit	O
rates	O
in	O
certain	O
geographical	O
areas	O
and	O
among	O
certain	O
socioeconomic	O
groups	O
in	O
Canada	O
indicates	O
the	O
failure	O
of	O
current	O
smoking	O
cessation	O
policies	O
to	O
be	O
effective	O
in	O
improving	O
the	O
situation	O
for	O
these	O
areas	O
and	O
groups	O
.	O

Identifying	O
these	O
areas	O
and	O
groups	O
is	O
one	O
step	O
to	O
examining	O
the	O
barriers	O
to	O
decreasing	O
smoking	O
in	O
the	O
population	O
;	O
further	O
study	O
is	O
required	O
to	O
identify	O
what	O
barriers	O
exist	O
in	O
these	O
areas	O
and	O
what	O
interventions	O
may	O
improve	O
the	O
situation	O
.	O

The	O
Puf	B-GP
-	I-GP
Family	I-GP
RNA	B-GP
-	I-GP
Binding	I-GP
Protein	I-GP
Puf2	B-GP
Controls	O
Sporozoite	O
Conversion	O
to	O
Liver	O
Stages	O
in	O
the	O
Malaria	B-DS
Parasite	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
K	O
.	O

Müller	O
K	O
.	O

Matuschewski	O
OS	O
.	O

Performed	O
the	O
experiments	O
:	O
K	O
.	O

Müller	O
OS	O
.	O

Analyzed	O
the	O
data	O
:	O
K	O
.	O

Müller	O
K	O
.	O

Matuschewski	O
OS	O
.	O

Wrote	O
the	O
paper	O
:	O
K	O
.	O

Matuschewski	O
OS	O
.	O

Current	O
address	O
:	O
INSERM	O
UMR_S	O
945	O
""""	O
Immunity	O
and	O
infection	B-DS
""","	O
Centre	O
Hospitalier	O
Universitaire	O
Pitié	O
-	O
Salpêtrière	O
,	O
Faculté	O
de	O
Médecine	O
et	O
Université	O
Pierre	O
et	O
Marie	O
Curie	O
,	O
Paris	O
,	O
France	O

Malaria	B-DS
is	O
a	O
vector	B-DS
-	I-DS
borne	I-DS
infectious	I-DS
disease	I-DS
caused	O
by	O
unicellular	O
,	O
obligate	O
intracellular	O
parasites	O
of	O
the	O
genus	O
Plasmodium	B-OG
.	O

During	O
host	O
switch	O
the	O
malaria	B-DS
parasite	O
employs	O
specialized	O
latent	O
stages	O
that	O
colonize	O
the	O
new	O
host	O
environment	O
.	O

Previous	O
work	O
has	O
established	O
that	O
gametocytes	O
,	O
sexually	O
differentiated	O
stages	O
that	O
are	O
taken	O
up	O
by	O
the	O
mosquito	B-OG
vector	O
,	O
control	O
expression	O
of	O
genes	O
required	O
for	O
mosquito	B-OG
colonization	O
by	O
translational	O
repression	O
.	O

Sexual	O
parasite	O
development	O
is	O
controlled	O
by	O
a	O
DEAD	B-GP
-	I-GP
box	I-GP
RNA	I-GP
helicase	I-GP
of	O
the	O
DDX6	B-GP
family	O
,	O
termed	O
DOZI	B-GP
.	O

Latency	O
of	O
sporozoites	O
,	O
the	O
transmission	O
stage	O
injected	O
during	O
an	O
infectious	O
blood	O
meal	O
,	O
is	O
controlled	O
by	O
the	O
eIF2alpha	B-GP
kinase	I-GP
IK2	B-GP
,	O
a	O
general	O
inhibitor	O
of	O
protein	O
synthesis	O
.	O

Whether	O
RNA	B-GP
-	I-GP
binding	I-GP
proteins	I-GP
participate	O
in	O
translational	O
regulation	O
in	O
sporozoites	O
remains	O
to	O
be	O
studied	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
two	O
RNA	B-GP
-	I-GP
binding	I-GP
proteins	I-GP
of	O
the	O
Puf	B-GP
-	O
family	O
,	O
Plasmodium	B-OG
Puf1	B-GP
and	O
Puf2	B-GP
,	O
during	O
sporozoite	O
stage	O
conversion	O
.	O

Our	O
data	O
reveal	O
that	O
,	O
in	O
the	O
rodent	B-OG
malaria	B-DS
parasite	O
P	B-OG
.	I-OG
berghei	I-OG
,	O
Puf2	B-GP
participates	O
in	O
the	O
regulation	O
of	O
IK2	B-GP
and	O
inhibits	O
premature	O
sporozoite	O
transformation	O
.	O

Inside	O
mosquito	B-OG
salivary	O
glands	O
puf2	B-GP
(-)	O
sporozoites	O
transform	O
over	O
time	O
to	O
round	O
forms	O
resembling	O
early	O
intra	O
-	O
hepatic	O
stages	O
.	O

As	O
a	O
result	O
,	O
mutant	O
parasites	O
display	O
strong	O
defects	O
in	O
initiating	O
a	O
malaria	B-DS
infection	I-DS
.	O

In	O
contrast	O
,	O
Puf1	B-GP
is	O
dispensable	O
in	O
vivo	O
throughout	O
the	O
entire	O
Plasmodium	B-OG
life	O
cycle	O
.	O

Our	O
findings	O
support	O
the	O
notion	O
of	O
a	O
central	O
role	O
for	O
Puf2	B-GP
in	O
parasite	O
latency	O
during	O
switch	O
between	O
the	O
insect	B-OG
and	O
mammalian	O
hosts	O
.	O

Introduction	O

Plasmodium	B-OG
parasites	O
,	O
the	O
causative	O
agents	O
of	O
malaria	B-DS
,	O
are	O
transmitted	O
by	O
female	O
Anopheles	B-OG
mosquitoes	I-OG
.	O

During	O
the	O
probing	O
phase	O
prior	O
to	O
the	O
blood	O
meal	O
,	O
sporozoites	B-OG
are	O
injected	O
into	O
the	O
skin	O
of	O
the	O
mammalian	O
host	O
[	O
1	O
].	O

The	O
motile	O
sporozoites	B-OG
actively	O
migrate	O
in	O
the	O
skin	O
,	O
enter	O
the	O
peripheral	O
blood	O
circulation	O
,	O
and	O
then	O
rapidly	O
reach	O
the	O
liver	O
.	O

Sporozoites	B-OG
invade	O
hepatocytes	O
by	O
forming	O
a	O
parasitophorous	O
vacuole	O
(	O
PV	O
)	O
[	O
2	O
],	O
where	O
they	O
transform	O
into	O
replicative	O
exo	O
-	O
erythrocytic	O
forms	O
(	O
EEFs	O
).	O

After	O
intense	O
multiplication	O
during	O
2	O
–	O
6	O
days	O
,	O
depending	O
on	O
the	O
Plasmodium	B-OG
species	O
,	O
mature	O
EEFs	O
release	O
thousands	O
of	O
merozoites	B-OG
,	O
which	O
invade	O
erythrocytes	O
and	O
initiate	O
the	O
pathogenic	O
blood	O
stage	O
cycle	O
[	O
3	O
].	O

Plasmodium	B-OG
sporozoites	O
are	O
formed	O
inside	O
oocysts	O
in	O
the	O
mosquito	B-OG
midgut	O
,	O
but	O
become	O
fully	O
infective	O
only	O
after	O
colonization	O
of	O
the	O
insect	B-OG
salivary	O
glands	O
.	O

This	O
maturation	O
process	O
is	O
associated	O
with	O
the	O
up	O
-	O
regulation	O
of	O
a	O
specific	O
subset	O
of	O
genes	O
,	O
referred	O
to	O
as	O
Up	O
-	O
regulated	O
in	O
Infective	O
Sporozoites	O
(	O
UIS	O
)	O
genes	O
[	O
4	O
].	O

Regulation	O
of	O
gene	O
expression	O
in	O
Plasmodium	B-OG
remains	O
poorly	O
understood	O
.	O

Genome	O
sequencing	O
data	O
initially	O
revealed	O
a	O
paucity	O
of	O
specific	O
transcription	B-GP
factors	I-GP
in	O
Plasmodium	B-OG
[	O
5	O
].	O

Recently	O
however	O
,	O
a	O
family	O
of	O
genes	O
related	O
to	O
the	O
plant	B-OG
Apetala	B-GP
-	I-GP
2	I-GP
(	O
AP2	B-GP
)	I-GP
transcription	B-GP
factors	I-GP
has	O
been	O
identified	O
in	O
Plasmodium	B-OG
and	O
related	O
apicomplexan	B-OG
parasites	O
[	O
6	O
],	O
[	O
7	O
],	O
and	O
proposed	O
to	O
play	O
a	O
central	O
role	O
during	O
life	O
cycle	O
progression	O
.	O

Molecular	O
genetic	O
studies	O
have	O
demonstrated	O
vital	O
roles	O
of	O
two	O
stage	O
-	O
specific	O
AP2	B-GP
factors	O
in	O
Plasmodium	B-OG
berghei	I-OG
,	O
a	O
rodent	B-OG
malaria	B-DS
parasite	O
widely	O
used	O
as	O
a	O
model	O
[	O
8	O
],	O
[	O
9	O
].	O

One	O
of	O
these	O
factors	O
,	O
the	O
AP2	B-GP
-	O
Sp	B-GP
transcription	B-GP
factor	I-GP
,	O
is	O
required	O
during	O
sporozoite	O
differentiation	O
and	O
binds	O
to	O
a	O
specific	O
DNA	O
sequence	O
found	O
in	O
the	O
promoter	O
region	O
of	O
many	O
genes	O
expressed	O
in	O
sporozoites	O
,	O
including	O
,	O
but	O
not	O
restricted	O
to	O
,	O
UIS	B-GP
genes	O
[	O
8	O
].	O

Intriguingly	O
,	O
genes	O
containing	O
AP2	B-GP
-	O
Sp	B-GP
binding	O
sites	O
are	O
associated	O
with	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
,	O
such	O
as	O
sporozoite	O
formation	O
,	O
host	O
cell	O
invasion	O
or	O
liver	O
stage	O
development	O
.	O

This	O
observation	O
strongly	O
suggests	O
that	O
additional	O
mechanisms	O
participate	O
in	O
the	O
fine	O
-	O
tuning	O
of	O
gene	O
expression	O
during	O
sporozoite	O
development	O
and	O
stage	O
conversion	O
.	O

Another	O
factor	O
,	O
called	O
SLARP	B-GP
or	O
SAP1	B-GP
,	O
controls	O
the	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
in	O
sporozoites	O
,	O
and	O
plays	O
a	O
critical	O
role	O
during	O
intrahepatic	O
development	O
of	O
the	O
parasite	O
[	O
10	O
],	O
[	O
11	O
].	O

It	O
is	O
still	O
unclear	O
whether	O
SLARP	B-GP
/	O
SAP1	B-GP
acts	O
on	O
a	O
transcriptional	O
or	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

The	O
cellular	O
localization	O
of	O
SLARP	B-GP
/	O
SAP1	B-GP
remains	O
controversial	O
[	O
10	O
],	O
[	O
11	O
],	O
and	O
the	O
absence	O
of	O
any	O
domain	O
known	O
to	O
bind	O
nucleic	O
acids	O
suggests	O
an	O
indirect	O
role	O
.	O

More	O
recently	O
,	O
Zhang	O
and	O
colleagues	O
reported	O
that	O
the	O
protein	B-GP
kinase	I-GP
IK2	I-GP
,	O
initially	O
termed	O
UIS1	B-GP
[	O
4	O
],	O
controls	O
global	O
gene	O
expression	O
in	O
sporozoites	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
[	O
12	O
].	O

IK2	B-GP
phosphorylates	O
the	O
translation	B-GP
initiation	I-GP
factor	I-GP
eIF2alpha	B-GP
and	O
down	O
-	O
regulates	O
protein	O
synthesis	O
[	O
12	O
],	O
[	O
13	O
].	O
P	B-OG
.	I-OG
berghei	I-OG
lacking	O
UIS1	B-GP
/	O
IK2	B-GP
display	O
a	O
partial	O
loss	O
of	O
infectivity	O
associated	O
with	O
premature	O
transformation	O
of	O
sporozoites	O
in	O
the	O
mosquito	B-OG
salivary	O
glands	O
[	O
12	O
].	O

The	O
contribution	O
of	O
RNA	B-GP
-	I-GP
binding	I-GP
prxoteins	I-GP
in	O
translational	O
regulation	O
has	O
not	O
been	O
studied	O
in	O
sporozoites	O
yet	O
,	O
but	O
has	O
been	O
well	O
characterized	O
in	O
Plasmodium	B-OG
sexual	O
stages	O
.	O

In	O
female	O
gametocytes	O
,	O
many	O
transcripts	O
encoding	O
ookinete	O
proteins	O
are	O
translationally	O
repressed	O
by	O
a	O
DEAD	B-GP
-	I-GP
box	I-GP
RNA	I-GP
helicase	I-GP
called	O
DOZI	B-GP
,	O
which	O
binds	O
to	O
the	O
3	O
′	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
target	O
mRNAs	O
such	O
as	O
P28	O
and	O
blocks	O
their	O
translation	O
until	O
occurrence	O
of	O
gamete	O
fertilization	O
and	O
differentiation	O
into	O
a	O
zygote	O
and	O
ookinete	O
[	O
14	O
],	O
[	O
15	O
].	O

Whether	O
DOZI	B-GP
plays	O
a	O
role	O
in	O
sporozoites	O
is	O
not	O
known	O
,	O
but	O
other	O
RNA	B-GP
-	I-GP
binding	I-GP
proteins	I-GP
may	O
participate	O
in	O
translational	O
regulation	O
in	O
sporozoites	O
,	O
including	O
members	O
of	O
the	O
Puf	B-GP
-	O
family	O
.	O

Puf	B-GP
proteins	O
are	O
evolutionary	O
conserved	O
in	O
eukaryotes	B-OG
and	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
RNA	O
-	O
binding	O
Puf	B-GP
domain	O
,	O
named	O
after	O
the	O
Drosophila	B-OG
melanogaster	I-OG
protein	O
Pumilio	B-GP
and	O
the	O
Caenorhabditis	B-OG
elegans	I-OG
protein	O
fem	B-GP
-	I-GP
3	I-GP
binding	I-GP
factor	I-GP
(	O
FBF	B-GP
),	O
and	O
consisting	O
of	O
eight	O
imperfect	O
repeats	O
of	O
36	O
amino	B-CD
acids	I-CD
(	O
PFAM	B-GP
:	O
PF00806	B-GP
)	O
[	O
16	O
],	O
[	O
17	O
].	O

Puf	B-GP
proteins	O
typically	O
bind	O
to	O
the	O
3	O
′	O
UTR	O
of	O
target	O
mRNAs	O
and	O
repress	O
their	O
translation	O
or	O
induce	O
their	O
degradation	O
(	O
reviewed	O
in	O
[	O
18	O
]	O
and	O
[	O
19	O
]).	O
Plasmodium	B-OG
parasites	O
possess	O
two	O
genes	O
encoding	O
proteins	O
with	O
Puf	B-GP
domains	O
,	O
Puf1	B-GP
and	O
Puf2	B-GP
[	O
20	O
].	O

In	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
both	O
Puf1	B-GP
(	O
PFE0935c	O
)	O
and	O
Puf2	B-GP
(	O
PFD0825c	O
)	O
are	O
differentially	O
expressed	O
in	O
gametocytes	O
[	O
20	O
],	O
[	O
21	O
].	O

Targeted	O
gene	O
disruption	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
recently	O
revealed	O
a	O
role	O
of	O
PfPuf2	B-GP
in	O
repressing	O
gametocytogenesis	O
and	O
male	O
gametocyte	O
differentiation	O
in	O
the	O
human	B-OG
malaria	B-DS
parasite	O
[	O
22	O
].	O

Whether	O
the	O
Puf2	B-GP
protein	O
plays	O
additional	O
,	O
perhaps	O
vital	O
,	O
roles	O
in	O
subsequent	O
life	O
cycle	O
stages	O
remains	O
to	O
be	O
shown	O
.	O

Interestingly	O
,	O
microarray	O
data	O
indicate	O
that	O
Puf2	B-GP
is	O
most	O
highly	O
expressed	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
sporozoites	O
[	O
23	O
],	O
and	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
,	O
expression	O
of	O
both	O
Puf1	B-GP
(	O
PBANKA_123350	O
)	O
and	O
Puf2	B-GP
(	O
PBANKA_071920	O
)	O
has	O
been	O
reported	O
in	O
sporozoites	O
,	O
where	O
Puf1	B-GP
was	O
initially	O
identified	O
as	O
UIS9	B-GP
[	O
4	O
],	O
[	O
24	O
].	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
reverse	O
genetic	O
approach	O
to	O
investigate	O
the	O
roles	O
of	O
Puf1	B-GP
and	O
Puf2	B-GP
in	O
P	B-OG
.	I-OG
berghei	I-OG
,	O
with	O
the	O
aim	O
to	O
identify	O
potential	O
mRNA	O
binding	O
proteins	O
that	O
play	O
critical	O
roles	O
in	O
sporozoite	O
stage	O
conversion	O
.	O

Results	O

Targeted	O
gene	O
deletion	O
of	O
P	B-OG
.	I-OG
berghei	I-OG
Puf1	B-GP
and	O
Puf2	B-GP

We	O
first	O
assessed	O
the	O
expression	O
of	O
Puf1	B-GP
and	O
Puf2	B-GP
during	O
P	B-OG
.	I-OG
berghei	I-OG
development	O
in	O
the	O
insect	B-OG
vector	O
,	O
in	O
comparison	O
to	O
DOZI	O
and	O
UIS1	B-GP
/	O
IK2	B-GP
,	O
using	O
quantitative	O
RT	O
-	O
PCR	O
(	O
Figure	O
1	O
).	O

Similarly	O
to	O
UIS1	B-GP
/	O
IK2	B-GP
[	O
12	O
],	O
we	O
found	O
that	O
Puf1	B-GP
and	O
Puf2	B-GP
are	O
upregulated	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
salivary	O
gland	O
sporozoites	O
(	O
Figure	O
1	O
).	O

This	O
was	O
expected	O
for	O
Puf1	B-GP
,	O
which	O
was	O
initially	O
described	O
as	O
UIS9	B-GP
[	O
4	O
],	O
[	O
24	O
].	O

Furthermore	O
,	O
Puf1	B-GP
was	O
also	O
upregulated	O
in	O
gametocytes	O
and	O
ookinetes	O
,	O
similarly	O
to	O
IK2	B-GP
and	O
DOZI	B-GP
.	O

In	O
good	O
agreement	O
with	O
published	O
microarray	O
data	O
[	O
24	O
],	O
only	O
low	O
levels	O
of	O
DOZI	B-GP
mRNA	O
were	O
detected	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	O
(	O
Figure	O
1	O
).	O

In	O
contrast	O
to	O
Puf1	B-GP
and	O
Puf2	B-GP
,	O
DOZI	B-GP
steady	O
state	O
mRNA	O
levels	O
were	O
down	O
-	O
regulated	O
in	O
infectious	O
salivary	O
gland	O
-	O
associated	O
sporozoites	O
resulting	O
in	O
∼	O
100	O
fold	O
lower	O
levels	O
in	O
the	O
latent	O
transmission	O
stage	O
.	O

Together	O
,	O
the	O
expression	O
profiling	O
indicated	O
that	O
both	O
Puf	B-GP
members	O
could	O
play	O
a	O
role	O
in	O
sporozoite	O
stage	O
conversion	O
,	O
as	O
has	O
been	O
described	O
previously	O
for	O
the	O
eIF2alpha	B-GP
kinase	I-GP
UIS1	B-GP
/	O
IK2	B-GP
[	O
12	O
].	O

Puf1	B-GP
and	O
Puf2	B-GP
are	O
upregulated	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	O
.	O

Shown	O
is	O
an	O
expression	O
profiling	O
of	O
selected	O
transcripts	O
of	O
RNA	B-GP
regulatory	I-GP
proteins	I-GP
,	O
the	O
DDX6	B-GP
-	I-GP
family	I-GP
DEAD	B-GP
-	I-GP
box	I-GP
helicase	I-GP
DOZI	I-GP
[	O
15	O
],	O
the	O
Puf	B-GP
proteins	O
Puf1	B-GP
and	O
Puf2	B-GP
[	O
20	O
],	O
and	O
of	O
the	O
eIF2alpha	B-GP
kinase	I-GP
UIS1	B-GP
/	O
IK2	B-GP
that	O
controls	O
sporozoite	O
latency	O
[	O
12	O
].	O
P	B-OG
.	I-OG
berghei	I-OG
purified	O
gametocytes	O
,	O
ookinetes	O
,	O
oocysts	O
and	O
salivary	O
gland	O
sporozoites	O
were	O
analyzed	O
by	O
RT	O
-	O
qPCR	O
using	O
primers	O
specific	O
for	O
DOZI	B-GP
,	O
UIS1	B-GP
/	O
IK2	O
,	O
Puf1	B-GP
and	O
Puf2	B-GP
.	O

Expression	O
data	O
from	O
two	O
independent	O
experiments	O
are	O
shown	O
and	O
were	O
normalized	O
to	O
the	O
level	O
of	O
GFP	B-GP
transcripts	O
,	O
which	O
are	O
expressed	O
under	O
the	O
control	O
of	O
the	O
EF1alpha	B-GP
promoter	O
[	O
26	O
].	O

In	O
order	O
to	O
investigate	O
the	O
functional	O
importance	O
of	O
Puf1	B-GP
/	O
UIS9	B-GP
and	O
Puf2	B-GP
in	O
P	B-OG
.	I-OG
berghei	I-OG
,	O
we	O
generated	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
(	O
Figure	O
2	O
).	O

We	O
used	O
a	O
replacement	O
strategy	O
to	O
disrupt	O
the	O
endogenous	O
Puf1	B-GP
(	O
Figure	O
2A	O
)	O
or	O
Puf2	B-GP
(	O
Figure	O
2B	O
)	O
gene	O
copy	O
by	O
double	O
crossover	O
homologous	O
recombination	O
[	O
25	O
].	O

Targeting	O
constructs	O
containing	O
5	O
′	O
and	O
3	O
′	O
fragments	O
of	O
either	O
Puf1	B-GP
or	O
Puf2	B-GP
flanking	O
a	O
pyrimethamine	B-CD
-	O
resistance	O
cassette	O
were	O
used	O
to	O
transfect	O
P	B-OG
.	I-OG
berghei	I-OG
parasites	O
that	O
constitutively	O
express	O
GFP	B-GP
(	O
ANKA	O
cl507	O
)	O
[	O
26	O
].	O

Recombinant	O
parasites	O
were	O
selected	O
with	O
pyrimethamine	B-CD
in	O
the	O
mouse	B-OG
drinking	O
water	O
,	O
and	O
cloned	O
by	O
limiting	O
dilutions	O
.	O

For	O
both	O
genes	O
we	O
were	O
successful	O
in	O
generating	O
clonal	O
knockout	O
parasite	O
populations	O
,	O
as	O
demonstrated	O
by	O
PCR	O
and	O
Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
(	O
Figures	O
2C	O
–	O
F	O
).	O

For	O
Puf2	B-GP
we	O
also	O
generated	O
a	O
second	O
independent	O
knockout	O
clone	O
,	O
which	O
was	O
phenotypically	O
identical	O
to	O
the	O
first	O
puf2	B-GP
(-)	O
clonal	O
parasite	O
line	O
(	O
unpublished	O
data	O
).	O

This	O
indicates	O
that	O
Puf1	B-GP
and	O
Puf2	B-GP
do	O
not	O
play	O
any	O
vital	O
role	O
during	O
P	B-OG
.	I-OG
berghei	I-OG
erythrocytic	O
stages	O
,	O
in	O
good	O
agreement	O
with	O
successful	O
generation	O
of	O
Pfpuf2	B-GP
(-)	O
parasites	O
[	O
22	O
].	O

Targeted	O
gene	O
deletion	O
of	O
Puf1	B-GP
/	O
UIS9	B-GP
and	O
Puf2	B-GP
in	O
P	B-OG
.	I-OG
berghei	I-OG
.	O

(	O
A	O
–	O
B	O
)	O
Replacement	O
strategy	O
to	O
generate	O
the	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasites	O
.	O
P	B-OG
.	I-OG
berghei	I-OG
PUF1	B-GP
gene	O
(	O
A	O
)	O
consists	O
of	O
five	O
exons	O
encoding	O
an	O
1183	O
amino	B-CD
-	I-CD
acid	I-CD
protein	O
(	O
PBANKA_123350	O
),	O
whereas	O
PUF2	B-GP
(	O
B	O
)	O
consists	O
of	O
four	O
exons	O
encoding	O
a	O
477	O
amino	B-CD
-	I-CD
acid	I-CD
protein	O
(	O
PBANKA_071920	O
).	O

The	O
PUF	O
domains	O
are	O
shown	O
in	O
blue	O
.	O

For	O
each	O
gene	O
,	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
genomic	O
locus	O
was	O
targeted	O
with	O
a	O
replacement	O
plasmid	O
containing	O
5	O
′	O
and	O
3	O
′	O
regions	O
of	O
PUF1	B-GP
or	O
PUF2	B-GP
and	O
a	O
positive	O
selectable	O
marker	O
,	O
Toxoplasma	B-OG
gondii	I-OG
dhfr	B-GP
/	O
ts	B-GP
or	O
human	B-OG
DHFR	B-GP
,	O
respectively	O
.	O

Upon	O
a	O
double	O
crossover	O
event	O
,	O
the	O
PUF1	B-GP
or	O
PUF2	B-GP
gene	O
is	O
replaced	O
by	O
the	O
selectable	O
marker	O
.	O

Replacement	O
-	O
and	O
wild	O
type	O
-	O
specific	O
test	O
primer	O
combinations	O
and	O
expected	O
PCR	O
fragments	O
(	O
WT	O
,	O
5	O
′	O
integration	O
and	O
3	O
′	O
integration	O
)	O
are	O
indicated	O
by	O
arrows	O
and	O
lines	O
,	O
respectively	O
.	O

Restriction	O
sites	O
,	O
Southern	O
probes	O
and	O
expected	O
restriction	O
fragments	O
are	O
also	O
shown	O
.	O
S	O
,	O
SpeI	B-GP
;	O
X	O
,	O
XhoI	B-GP
;	O
A	O
,	O
AfeI	B-GP
;	O
E	O
,	O
EcoRV	B-GP
.	O

(	O
C	O
)	O
Puf1	B-GP
replacement	O
-	O
specific	O
PCR	O
analysis	O
.	O

Confirmation	O
of	O
the	O
predicted	O
gene	O
targeting	O
is	O
achieved	O
by	O
specific	O
primer	O
combinations	O
(	O
5	O
′	O
and	O
3	O
′	O
integration	O
),	O
which	O
can	O
only	O
amplify	O
a	O
signal	O
from	O
the	O
recombinant	O
locus	O
.	O

A	O
wild	O
type	O
-	O
specific	O
PCR	O
reaction	O
confirms	O
the	O
absence	O
of	O
residual	O
wild	O
-	O
type	O
parasites	O
in	O
the	O
clonal	O
puf1	B-GP
(-)	O
population	O
.	O

(	O
D	O
)	O
Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
isolated	O
from	O
WT	O
,	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasites	O
,	O
using	O
digoxigenin	B-CD
-	O
labelled	O
probes	O
specific	O
for	O
Puf1	B-GP
.	O

After	O
digest	O
with	O
SpeI	B-GP
and	O
XhoI	B-GP
,	O
the	O
Puf1	B-GP
probe	O
hybridizes	O
to	O
a	O
8	O
.	O
3	O
or	O
a	O
6	O
.	O
9	O
kb	O
fragment	O
in	O
WT	O
and	O
puf1	B-GP
(-)	O
parasites	O
,	O
respectively	O
.	O

(	O
E	O
)	O
Puf2	B-GP
replacement	O
-	O
specific	O
PCR	O
analysis	O
.	O

Confirmation	O
of	O
the	O
predicted	O
gene	O
targeting	O
is	O
achieved	O
by	O
specific	O
primer	O
combinations	O
(	O
5	O
′	O
and	O
3	O
′	O
integration	O
),	O
which	O
can	O
only	O
amplify	O
a	O
signal	O
from	O
the	O
recombinant	O
locus	O
.	O

A	O
wild	O
type	O
-	O
specific	O
PCR	O
reaction	O
confirms	O
the	O
absence	O
of	O
residual	O
wild	O
-	O
type	O
parasites	O
in	O
the	O
clonal	O
puf2	B-GP
(-)	O
population	O
.	O

(	O
F	O
)	O
Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
isolated	O
from	O
WT	O
,	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasites	O
,	O
using	O
digoxigenin	B-CD
-	O
labelled	O
probes	O
specific	O
for	O
Puf2	B-GP
.	O

After	O
digest	O
with	O
AfeI	B-GP
and	O
EcoRV	B-GP
,	O
the	O
Puf2	B-GP
probe	O
hybridizes	O
to	O
a	O
8	O
.	O
4	O
kb	O
fragment	O
in	O
WT	O
and	O
a	O
4	O
.	O
0	O
kb	O
fragment	O
in	O
puf2	B-GP
(-)	O
parasites	O
.	O

puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasites	O
produce	O
gametocytes	O
that	O
develop	O
to	O
sporozoites	O
in	O
mosquitoes	B-OG

puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasites	O
were	O
indistinguishable	O
from	O
WT	O
parasites	O
in	O
development	O
and	O
growth	O
of	O
asexual	O
blood	O
stages	O
and	O
produced	O
gametocytes	O
.	O

Because	O
PfPuf2	B-GP
has	O
been	O
shown	O
to	O
control	O
gametocytogenesis	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
[	O
22	O
],	O
we	O
analyzed	O
in	O
more	O
detail	O
the	O
sexual	O
development	O
of	O
P	B-OG
.	I-OG
berghei	I-OG
puf2	B-GP
(-)	O
parasites	O
.	O

After	O
injection	O
of	O
107	O
infected	O
erythrocytes	O
intravenously	O
into	O
groups	O
of	O
five	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
,	O
parasitemia	B-DS
at	O
day	O
4	O
were	O
similar	O
in	O
mice	B-OG
infected	O
with	O
WT	O
or	O
puf2	B-GP
(-)	O
(	O
Figure	O
3A	O
).	O

However	O
,	O
the	O
proportion	O
of	O
gametocytes	O
among	O
all	O
parasite	O
stages	O
was	O
significantly	O
higher	O
in	O
puf2	B-GP
(-)	O
than	O
in	O
WT	O
parasites	O
(	O
Figure	O
3B	O
).	O

We	O
then	O
examined	O
the	O
ability	O
of	O
mature	O
male	O
gametocytes	O
to	O
exflagellate	O
in	O
puf2	B-GP
(-)	O
parasites	O
.	O

The	O
number	O
of	O
exflagellation	O
centers	O
in	O
mouse	B-OG
blood	O
was	O
significantly	O
higher	O
for	O
puf2	B-GP
(-)	O
parasites	O
than	O
for	O
WT	O
parasites	O
(	O
Figure	O
3C	O
),	O
suggesting	O
that	O
male	O
gametocytes	O
contribute	O
to	O
the	O
increased	O
gametocytogenesis	O
in	O
Pbpuf2	B-GP
(-)	O
parasites	O
,	O
in	O
full	O
support	O
of	O
the	O
data	O
reported	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
Puf2	B-GP
-	O
deficient	O
parasites	O
[	O
22	O
].	O

Gametocytogenesis	O
is	O
increased	O
in	O
puf2	B-GP
(-)	O
parasites	O
.	O

Groups	O
of	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
(	O
n	O
=	O
5	O
)	O
were	O
injected	O
intravenously	O
with	O
107	O
WT	O
or	O
puf2	B-GP
(-)	O
infected	O
erythrocytes	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
mice	B-OG
4	O
days	O
later	O
to	O
determine	O
the	O
parasitemia	B-DS
(	O
A	O
),	O
the	O
proportion	O
of	O
gametocytes	O
among	O
parasites	O
(	O
B	O
),	O
and	O
the	O
number	O
of	O
exflagellation	O
centers	O
per	O
µl	O
of	O
blood	O
(	O
C	O
).	O
Results	O
are	O
expressed	O
as	O
mean	O
+/−	O
SEM	O
.	O
**,	O
p	O
<	O
0	O
.	O
01	O
(	O
Mann	O
-	O
Whitney	O
test	O
).	O

After	O
transmission	O
to	O
Anopheles	B-OG
stephensi	I-OG
mosquitoes	B-OG
,	O
both	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
parasite	O
lines	O
produced	O
oocysts	O
and	O
high	O
numbers	O
of	O
sporozoites	O
(	O
Table	O
1	O
).	O

The	O
number	O
of	O
puf2	B-GP
(-)	O
oocysts	O
was	O
significantly	O
higher	O
than	O
for	O
WT	O
,	O
consistent	O
with	O
the	O
higher	O
gametocyte	O
rates	O
.	O

Intriguingly	O
,	O
we	O
found	O
lower	O
numbers	O
of	O
oocysts	O
and	O
salivary	O
gland	O
sporozoites	O
in	O
puf1	B-GP
(-)-	O
infected	O
mosquitoes	B-OG
,	O
as	O
compared	O
to	O
WT	O
parasites	O
(	O
Table	O
1	O
).	O

Although	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
,	O
we	O
cannot	O
exclude	O
an	O
effect	O
of	O
puf1	B-GP
depletion	O
on	O
oocyst	O
development	O
and	O
sporogony	O
.	O

Loss	O
of	O
infectivity	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
in	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
.	O

Parasites	O

Number	O
of	O
oocysts	O
/	O
mosquitoa	B-OG
(	O
mean	O
±	O
SD	O
)	O

Number	O
of	O
salivary	O
gland	O
sporozoites	O
/	O
mosquitoa	B-OG
(	O
mean	O
±	O
SD	O
)	O

Route	O
of	O
injectionb	O

Number	O
of	O
infected	O
/	O
Number	O
of	O
injected	O

Prepatency	O
period	O
(	O
days	O
)	O
c	O

WT	O

182	O
(±	O
164	O
)	O

31	O
,	O
600	O
(±	O
18	O
,	O
600	O
)	O

bites	O
(	O
d	O
21	O
)	O

3	O
/	O
3	O

3	O

i	O
.	O
v	O
.	O

(	O
d	O
18	O
)	O

2	O
/	O
2	O

3	O

i	O
.	O
v	O
.	O

(	O
d	O
21	O
)	O

6	O
/	O
6	O

3	O
.	O
5	O

i	O
.	O
v	O
.	O

(	O
d	O
25	O
)	O

4	O
/	O
4	O

3	O

puf1	B-GP
(-)	O

137	O
(±	O
100	O
)	O

11	O
,	O
400	O
(±	O
4	O
,	O
700	O
)	O

bites	O
(	O
d	O
17	O
)	O

3	O
/	O
3	O

3	O

i	O
.	O
v	O
.	O

(	O
d	O
21	O
)	O

6	O
/	O
6	O

3	O
.	O
5	O

puf2	B-GP
(-)	O

320	O
(±	O
234	O
)	O
d	O

25	O
,	O
000	O
(±	O
18	O
,	O
800	O
)	O

bites	O
(	O
d	O
21	O
)	O

3	O
/	O
4	O

(	O
5	O
)	O

i	O
.	O
v	O
.	O

(	O
d	O
18	O
)	O

2	O
/	O
4	O

(	O
5	O
)	O

i	O
.	O
v	O
.	O

(	O
d	O
25	O
)	O

0	O
/	O
4	O

NA	O

The	O
number	O
of	O
midgut	O
oocysts	O
and	O
salivary	O
gland	O
sporozoites	O
was	O
determined	O
at	O
d10	O
–	O
14	O
and	O
d18	O
–	O
25	O
,	O
respectively	O
,	O
after	O
the	O
infectious	O
blood	O
meal	O
,	O
from	O
at	O
least	O
three	O
independent	O
feeding	O
experiments	O
.	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
exposed	O
to	O
the	O
bites	O
of	O
10	O
infected	O
mosquitoes	B-OG
or	O
injected	O
intravenously	O
(	O
i	O
.	O
v	O
.)	O
with	O
1	O
,	O
000	O
sporozoites	O
,	O
18	O
–	O
25	O
days	O
after	O
mosquito	B-DS
infection	I-DS
.	O

The	O
prepatent	O
period	O
is	O
defined	O
as	O
the	O
number	O
of	O
days	O
after	O
sporozoite	O
inoculation	O
until	O
detection	O
of	O
infected	O
erythrocytes	O
by	O
microscopic	O
blood	O
smear	O
examination	O
.	O

Brackets	O
indicate	O
that	O
not	O
all	O
animals	B-OG
became	O
infected	O
.	O

NA	O
,	O
not	O
applicable	O
.	O

p	O
<	O
0	O
.	O
05	O
in	O
comparison	O
to	O
WT	O
,	O
as	O
determined	O
by	O
Kruskal	O
-	O
Wallis	O
followed	O
by	O
Dunn	O
'	O
s	O
test	O
.	O

Liver	B-DS
infection	I-DS
is	O
impaired	O
in	O
Puf2	B-GP
-	O
deficient	O
parasites	O

We	O
then	O
analysed	O
the	O
infectivity	O
of	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
sporozoites	O
to	O
susceptible	O
mice	B-OG
.	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
injected	O
intravenously	O
with	O
1	O
,	O
000	O
WT	O
,	O
puf1	B-GP
(-)	O
or	O
puf2	B-GP
(-)	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	O
,	O
or	O
exposed	O
to	O
the	O
bites	O
of	O
10	O
infected	O
mosquitoes	B-OG
,	O
the	O
natural	O
transmission	O
route	O
(	O
Table	O
1	O
).	O

Emergence	O
of	O
erythrocytic	O
stages	O
,	O
resulting	O
from	O
complete	O
liver	O
stage	O
development	O
,	O
was	O
monitored	O
by	O
microscopic	O
examination	O
of	O
daily	O
blood	O
smears	O
.	O

With	O
both	O
inoculation	O
routes	O
,	O
all	O
mice	B-OG
injected	O
with	O
puf1	B-GP
(-)	O
sporozoites	O
developed	O
a	O
parasitemia	B-DS
,	O
with	O
no	O
delay	O
as	O
compared	O
to	O
WT	O
parasites	O
(	O
Table	O
1	O
).	O

In	O
contrast	O
,	O
only	O
a	O
fraction	O
of	O
the	O
mice	B-OG
injected	O
with	O
puf2	B-GP
(-)	O
sporozoites	O
developed	O
a	O
parasitemia	B-DS
,	O
with	O
a	O
two	O
-	O
day	O
delay	O
as	O
compared	O
to	O
WT	O
,	O
indicative	O
of	O
at	O
least	O
100	O
-	O
fold	O
reduction	O
of	O
infectivity	O
(	O
Table	O
1	O
).	O

Moreover	O
,	O
puf2	B-GP
(-)	O
sporozoites	O
isolated	O
late	O
after	O
mosquito	B-DS
infection	I-DS
(	O
at	O
day	O
25	O
)	O
were	O
not	O
capable	O
of	O
inducing	O
a	O
blood	O
stage	O
infection	B-DS
in	O
mice	B-OG
.	O

We	O
next	O
injected	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
intravenously	O
with	O
WT	O
,	O
puf1	B-GP
(-)	O
or	O
puf2	B-GP
(-)	O
sporozoites	O
isolated	O
on	O
day	O
18	O
from	O
mosquito	B-OG
salivary	O
glands	O
.	O

Forty	O
-	O
two	O
hours	O
after	O
infection	B-DS
,	O
livers	O
were	O
removed	O
and	O
the	O
parasite	O
loads	O
were	O
quantified	O
by	O
RT	O
-	O
qPCR	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
the	O
puf2	B-GP
(-)	O
liver	O
loads	O
were	O
extremely	O
reduced	O
(∼	O
500	O
fold	O
)	O
as	O
compared	O
to	O
WT	O
,	O
confirming	O
that	O
infectivity	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
to	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
is	O
severely	O
impaired	O
.	O

The	O
reduction	O
of	O
parasite	O
liver	O
loads	O
as	O
measured	O
by	O
RT	O
-	O
qPCR	O
is	O
consistent	O
with	O
the	O
delay	O
or	O
absence	O
of	O
parasitemia	B-DS
in	O
mice	B-OG
injected	O
with	O
puf2	B-GP
(-)	O
sporozoites	O
(	O
Table	O
1	O
),	O
therefore	O
we	O
assume	O
that	O
the	O
absence	O
of	O
Puf2	B-GP
did	O
not	O
interfere	O
with	O
18S	O
rRNA	O
quantification	O
.	O

Interestingly	O
,	O
we	O
also	O
observed	O
a	O
significant	O
,	O
although	O
less	O
pronounced	O
(∼	O
4	O
fold	O
),	O
reduction	O
of	O
puf1	B-GP
(-)	O
parasite	O
liver	O
loads	O
(	O
Figure	O
4	O
).	O

Our	O
findings	O
demonstrate	O
that	O
PbPuf2	B-GP
plays	O
an	O
important	O
in	O
vivo	O
role	O
only	O
in	O
the	O
pre	O
-	O
erythrocytic	O
phase	O
of	O
the	O
Plasmodium	B-OG
life	O
cycle	O
.	O

In	O
contrast	O
,	O
Puf1	B-GP
/	O
UIS9	B-GP
appears	O
to	O
be	O
dispensable	O
for	O
parasite	O
life	O
cycle	O
progression	O
,	O
at	O
least	O
under	O
the	O
conditions	O
tested	O
.	O

Liver	B-DS
infection	I-DS
is	O
severely	O
impaired	O
in	O
puf2	B-GP
(-)	O
parasites	O
.	O

Parasite	O
loads	O
were	O
determined	O
by	O
RT	O
-	O
qPCR	O
analysis	O
of	O
mouse	B-OG
livers	O
(	O
n	O
=	O
4	O
or	O
5	O
per	O
group	O
)	O
harvested	O
42	O
hours	O
after	O
intravenous	O
injection	O
of	O
10	O
,	O
000	O
WT	O
,	O
puf1	B-GP
(-)	O
or	O
puf2	B-GP
(-)	O
sporozoites	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
relative	O
expression	O
of	O
Pb18S	O
normalized	O
to	O
mouse	B-OG
GAPDH	B-GP
.	O

The	O
means	O
+/−	O
SEM	O
are	O
indicated	O
by	O
lines	O
**,	O
p	O
<	O
0	O
.	O
01	O
(	O
Mann	O
-	O
Whitney	O
test	O
).	O

We	O
also	O
determined	O
the	O
In	O
vitro	O
infectivity	O
of	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
sporozoites	O
isolated	O
on	O
day	O
22	O
from	O
mosquito	B-OG
salivary	O
glands	O
,	O
in	O
cultured	O
HepG2	O
hepatoma	B-DS
cells	O
(	O
Figure	O
5	O
).	O

Both	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
sporozoites	O
entered	O
hepatoma	O
cells	O
as	O
efficiently	O
as	O
WT	O
,	O
as	O
evidenced	O
by	O
similar	O
numbers	O
of	O
infected	O
cells	O
at	O
early	O
time	O
points	O
(	O
4	O
–	O
6	O
hours	O
)	O
(	O
Figure	O
5A	O
).	O

While	O
the	O
number	O
of	O
EEFs	O
at	O
later	O
time	O
points	O
(	O
24	O
–	O
48	O
hours	O
)	O
was	O
similar	O
in	O
WT	O
-	O
and	O
puf1	B-GP
(-)-	O
infected	O
cultures	O
(	O
Figure	O
5A	O
),	O
it	O
was	O
reduced	O
in	O
the	O
case	O
of	O
puf2	B-GP
(-)	O
parasites	O
(	O
Figure	O
5B	O
).	O

Whereas	O
early	O
after	O
infection	B-DS
a	O
vast	O
majority	O
(	O
81	O
%	O
±	O
3	O
%;	O
n	O
=	O
122	O
)	O
of	O
intracellular	O
WT	O
sporozoites	O
expressed	O
UIS4	B-GP
,	O
a	O
transmembrane	B-GP
protein	I-GP
that	O
localizes	O
to	O
the	O
membrane	O
of	O
the	O
PV	O
[	O
27	O
],	O
only	O
half	O
of	O
puf2	B-GP
(-)	O
parasites	O
were	O
stained	O
with	O
UIS4	B-GP
antibodies	B-GP
(	O
53	O
%	O
±	O
9	O
%;	O
n	O
=	O
127	O
).	O

This	O
indicates	O
that	O
a	O
substantial	O
fraction	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
failed	O
to	O
form	O
and	O
/	O
or	O
remodel	O
the	O
PV	O
in	O
vitro	O
,	O
which	O
probably	O
explains	O
the	O
reduced	O
EEF	O
numbers	O
quantified	O
at	O
later	O
time	O
points	O
.	O

In	O
addition	O
,	O
we	O
cannot	O
exclude	O
a	O
moderate	O
impairment	O
during	O
liver	O
stage	O
development	O
in	O
puf2	B-GP
(-)	O
parasites	O
,	O
as	O
suggested	O
by	O
the	O
reduction	O
of	O
EEF	O
numbers	O
observed	O
between	O
24	O
and	O
48	O
hours	O
post	O
-	O
infection	B-DS
in	O
vitro	O
.	O

Nevertheless	O
,	O
most	O
puf2	B-GP
(-)	O
sporozoites	O
that	O
formed	O
a	O
PV	O
and	O
expressed	O
UIS4	B-GP
were	O
capable	O
of	O
developing	O
into	O
EEFs	O
like	O
WT	O
and	O
puf1	B-GP
(-)	O
parasites	O
(	O
Figure	O
5C	O
).	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
Puf2	B-GP
plays	O
a	O
critical	O
role	O
during	O
transmission	O
of	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	B-OG
to	O
the	O
mammalian	O
host	O
,	O
but	O
is	O
not	O
required	O
for	O
liver	O
stage	O
development	O
per	O
se	O
.	O

puf2	B-GP
(-)	O
sporozoites	O
are	O
infective	O
in	O
vitro	O
.	O

(	O
A	O
)	O
HepG2	O
cells	O
were	O
infected	O
with	O
WT	O
or	O
puf1	B-GP
(-)	O
sporozoites	O
and	O
the	O
numbers	O
of	O
infected	O
cells	O
were	O
determined	O
at	O
6	O
,	O
24	O
and	O
48	O
h	O
post	O
-	O
infection	B-DS
(	O
p	O
.	O
i	O
.).	O

Results	O
are	O
expressed	O
as	O
the	O
mean	O
number	O
of	O
infected	O
cells	O
in	O
triplicate	O
wells	O
+/−	O
SD	O
.	O

(	O
B	O
)	O
HepG2	O
cells	O
were	O
infected	O
with	O
WT	O
or	O
puf2	B-GP
(-)	O
sporozoites	O
and	O
the	O
numbers	O
of	O
infected	O
cells	O
were	O
determined	O
at	O
4	O
,	O
24	O
and	O
48	O
h	O
post	O
-	O
infection	B-DS
(	O
p	O
.	O
i	O
.).	O

Results	O
are	O
expressed	O
as	O
the	O
mean	O
number	O
of	O
infected	O
cells	O
in	O
triplicate	O
wells	O
+/−	O
SD	O
.	O

(	O
C	O
)	O
Confocal	O
microscopy	O
analysis	O
of	O
HepG2	O
cells	O
cultured	O
for	O
5	O
and	O
24	O
hours	O
post	O
-	O
infection	B-DS
(	O
p	O
.	O
i	O
.)	O
with	O
WT	O
,	O
puf1	B-GP
(-)	O
or	O
puf2	B-GP
(-)	O
sporozoites	O
,	O
using	O
antibodies	O
against	O
UIS4	B-GP
(	O
red	O
),	O
CSP	B-GP
(	O
5	O
h	O
p	O
.	O
i	O
.,	O
green	O
)	O
or	O
HSP70	B-GP
(	O
24	O
h	O
p	O
.	O
i	O
.,	O
green	O
).	O

Nuclei	O
were	O
stained	O
with	O
DRAQ5	O
(	O
blue	O
).	O

Bars	O
,	O
10	O
µm	O
.	O

puf2	B-GP
(-)	O
sporozoites	O
transform	O
prematurely	O
in	O
the	O
mosquito	B-OG

In	O
vivo	O
data	O
suggested	O
that	O
,	O
over	O
time	O
,	O
Puf2	B-GP
-	O
knockout	O
sporozoites	O
rapidly	O
loose	O
infectivity	O
in	O
the	O
mosquito	B-OG
(	O
Table	O
1	O
).	O

To	O
better	O
characterize	O
this	O
phenomenon	O
,	O
we	O
carefully	O
analyzed	O
puf2	B-GP
(-)	O
sporozoite	O
development	O
in	O
the	O
mosquito	B-OG
(	O
Figure	O
6	O
).	O

Strikingly	O
,	O
we	O
observed	O
that	O
a	O
major	O
proportion	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
showed	O
signs	O
of	O
premature	O
transformation	O
,	O
characterized	O
by	O
a	O
bulb	O
-	O
like	O
aspect	O
or	O
even	O
complete	O
rounding	O
-	O
up	O
(	O
Figure	O
6A	O
).	O

In	O
WT	O
parasites	O
,	O
transformation	O
of	O
sporozoites	O
is	O
typically	O
observed	O
at	O
37	O
°	O
C	O
in	O
culture	O
medium	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
host	O
cells	O
[	O
28	O
].	O

In	O
puf2	B-GP
(-)-	O
infected	O
mosquitoes	B-OG
,	O
however	O
,	O
the	O
proportion	O
of	O
transformed	O
sporozoites	O
increased	O
over	O
time	O
during	O
the	O
course	O
of	O
infection	B-DS
in	O
the	O
mosquitoes	B-OG
,	O
which	O
are	O
kept	O
at	O
20	O
°	O
C	O
(	O
Figure	O
6B	O
).	O

Quantification	O
of	O
partial	O
and	O
complete	O
transformation	O
in	O
all	O
three	O
parasite	O
populations	O
revealed	O
that	O
at	O
day	O
29	O
almost	O
all	O
puf2	B-GP
(-)	O
sporozoites	O
had	O
transformed	O
,	O
whereas	O
only	O
a	O
minor	O
fraction	O
of	O
WT	O
and	O
puf1	B-GP
(-)	O
sporozoites	O
exhibited	O
signs	O
of	O
premature	O
transformation	O
(	O
Figure	O
6B	O
).	O

Interestingly	O
,	O
we	O
did	O
not	O
observe	O
expression	O
of	O
the	O
liver	O
stage	O
marker	O
UIS4	B-GP
or	O
nuclear	O
divisions	O
,	O
as	O
seen	O
in	O
EEFs	O
(	O
Figure	O
5C	O
),	O
in	O
the	O
transformed	O
puf2	B-GP
(-)	O
sporozoites	O
(	O
Figure	O
6A	O
).	O

Premature	O
transformation	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
in	O
the	O
mosquito	B-OG
.	O

(	O
A	O
)	O
Fluorescence	O
microscopy	O
of	O
WT	O
and	O
puf2	B-GP
(-)	O
sporozoites	O
isolated	O
from	O
mosquito	O
salivary	O
glands	O
25	O
days	O
after	O
infection	B-DS
,	O
and	O
labelled	O
with	O
anti	O
-	O
UIS4	B-GP
(	O
red	O
)	O
and	O
anti	O
-	O
CSP	B-GP
(	O
green	O
)	O
antibodies	B-GP
.	O

Nuclei	O
were	O
stained	O
with	O
DRAQ5	O
(	O
blue	O
).	O

Bars	O
,	O
10	O
µm	O
.	O

(	O
B	O
)	O
The	O
proportion	O
of	O
non	O
-	O
transformed	O
,	O
partially	O
transformed	O
and	O
fully	O
transformed	O
sporozoites	O
was	O
determined	O
by	O
microscopic	O
examination	O
of	O
sporozoites	O
isolated	O
from	O
mosquito	O
salivary	O
glands	O
18	O
,	O
21	O
,	O
25	O
or	O
29	O
days	O
after	O
infection	B-DS
with	O
WT	O
,	O
puf1	B-GP
(-)	O
or	O
puf2	B-GP
(-)	O
parasites	O
.	O

puf2	B-GP
(-)	O
sporozoites	O
have	O
reduced	O
levels	O
of	O
Puf1	B-GP
and	O
UIS1	B-GP
/	O
IK2	B-GP
mRNA	O

The	O
phenotype	O
of	O
puf2	B-GP
(-)	O
parasites	O
is	O
essentially	O
identical	O
to	O
that	O
of	O
parasites	O
that	O
contain	O
a	O
targeted	O
deletion	O
of	O
the	O
kinase	B-GP
UIS1	B-GP
/	O
IK2	B-GP
[	O
12	O
].	O

Similarly	O
to	O
puf2	B-GP
(-)	O
parasites	O
,	O
ik2	B-GP
(-)	O
sporozoites	O
transform	O
prematurely	O
in	O
the	O
mosquito	B-OG
salivary	O
glands	O
and	O
have	O
a	O
decreased	O
infectivity	O
in	O
vivo	O
but	O
not	O
in	O
vitro	O
[	O
12	O
].	O

Therefore	O
,	O
we	O
sought	O
to	O
test	O
expression	O
of	O
IK2	B-GP
in	O
puf2	B-GP
(-)	O
sporozoites	O
,	O
in	O
comparison	O
to	O
WT	O
and	O
puf1	B-GP
(-)	O
sporozoites	O
,	O
using	O
RT	O
-	O
qPCR	O
.	O

As	O
expected	O
from	O
gene	O
deletion	O
,	O
no	O
Puf1	B-GP
and	O
Puf2	B-GP
mRNA	O
were	O
detected	O
in	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
sporozoites	O
,	O
respectively	O
(	O
Figure	O
7	O
).	O

Whereas	O
expression	O
of	O
UIS1	B-GP
/	O
IK2	B-GP
was	O
not	O
modified	O
in	O
puf1	B-GP
(-)	O
sporozoites	O
,	O
we	O
observed	O
a	O
∼	O
14	O
fold	O
reduction	O
of	O
UIS1	B-GP
/	O
IK2	B-GP
mRNA	O
in	O
Puf2	B-GP
-	O
deficient	O
sporozoites	O
as	O
compared	O
to	O
WT	O
(	O
Figure	O
7	O
).	O

Additionally	O
,	O
we	O
found	O
a	O
∼	O
17	O
fold	O
reduction	O
of	O
Puf1	B-GP
transcript	O
levels	O
in	O
puf2	B-GP
(-)	O
parasites	O
.	O

Conversely	O
,	O
Puf2	B-GP
transcript	O
levels	O
were	O
not	O
affected	O
in	O
the	O
absence	O
of	O
Puf1	B-GP
(	O
Figure	O
7	O
).	O

As	O
controls	O
,	O
UIS4	B-GP
and	O
HSP70	B-GP
mRNA	O
levels	O
were	O
similar	O
in	O
the	O
mutant	O
and	O
WT	O
sporozoites	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
Puf2	B-GP
regulates	O
a	O
subset	O
of	O
genes	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	O
,	O
including	O
Puf1	B-GP
and	O
the	O
kinase	B-GP
UIS1	B-GP
/	O
IK2	B-GP
.	O

The	O
latter	O
probably	O
explains	O
,	O
at	O
least	O
in	O
part	O
,	O
why	O
the	O
phenotype	O
of	O
puf2	B-GP
(-)	O
sporozoites	O
recapitulates	O
that	O
of	O
IK2	B-GP
-	O
knockout	O
parasites	O
.	O

puf2	B-GP
(-)	O
sporozoites	O
have	O
reduced	O
levels	O
of	O
Puf1	B-GP
and	O
UIS1	B-GP
/	O
IK2	B-GP
mRNA	O
.	O

Shown	O
is	O
an	O
expression	O
profiling	O
by	O
RT	O
-	O
qPCR	O
analysis	O
of	O
Puf1	B-GP
,	O
Puf2	B-GP
,	O
UIS1	B-GP
/	O
IK2	B-GP
,	O
UIS4	B-GP
and	O
HSP70	B-GP
mRNA	O
levels	O
in	O
WT	O
,	O
puf1	B-GP
(-)	O
and	O
puf2	B-GP
(-)	O
P	B-OG
.	I-OG
berghei	I-OG
sporozoites	O
.	O

Expression	O
data	O
from	O
three	O
independent	O
experiments	O
are	O
shown	O
and	O
were	O
normalized	O
to	O
the	O
level	O
of	O
GFP	B-GP
transcripts	O
,	O
which	O
are	O
expressed	O
under	O
the	O
control	O
of	O
the	O
EF1alpha	B-GP
promoter	O
[	O
26	O
].	O
no	O
amplif	O
.,	O
no	O
amplification	O
.	O

Discussion	O

Plasmodium	B-OG
sporozoites	B-OG
must	O
persist	O
and	O
remain	O
infectious	O
within	O
the	O
salivary	O
glands	O
of	O
the	O
mosquito	B-OG
for	O
many	O
days	O
until	O
they	O
are	O
eventually	O
transmitted	O
to	O
a	O
mammalian	O
host	O
.	O

Inside	O
the	O
warm	O
-	O
blooded	O
host	O
they	O
need	O
to	O
quickly	O
leave	O
the	O
site	O
of	O
deposition	O
in	O
order	O
to	O
travel	O
to	O
the	O
liver	O
,	O
invade	O
hepatocytes	O
and	O
differentiate	O
into	O
liver	O
stages	O
[	O
29	O
].	O

The	O
transient	O
developmental	O
arrest	O
of	O
sporozoites	B-OG
inside	O
mosquito	B-OG
salivary	O
glands	O
,	O
termed	O
latency	O
[	O
12	O
],	O
implies	O
efficient	O
control	O
mechanisms	O
to	O
prevent	O
premature	O
transformation	O
before	O
transmission	O
and	O
during	O
transmigration	O
before	O
reaching	O
a	O
suitable	O
host	O
cell	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
factor	O
controlling	O
sporozoite	O
latency	O
in	O
P	B-OG
.	I-OG
berghei	I-OG
,	O
the	O
RNA	B-GP
-	I-GP
binding	I-GP
protein	I-GP
Puf2	B-GP
.	O

In	O
the	O
absence	O
of	O
Puf2	B-GP
,	O
sporozoites	O
transform	O
prematurely	O
in	O
the	O
mosquito	B-OG
,	O
resulting	O
in	O
a	O
severe	O
loss	O
of	O
infectivity	O
.	O

Sporozoite	O
conversion	O
into	O
liver	O
stages	O
requires	O
initial	O
remodelling	O
of	O
the	O
parasite	O
pellicle	O
,	O
with	O
disassembly	O
of	O
the	O
inner	O
membrane	O
complex	O
(	O
IMC	O
)	O
and	O
appearance	O
of	O
a	O
bulb	O
that	O
progressively	O
enlarges	O
until	O
the	O
initially	O
elongated	O
sporozoite	O
has	O
transformed	O
into	O
a	O
round	O
form	O
[	O
28	O
],	O
[	O
30	O
].	O

Previous	O
work	O
has	O
shown	O
that	O
transformation	O
of	O
salivary	O
gland	O
sporozoites	O
is	O
induced	O
at	O
37	O
°	O
C	O
in	O
culture	O
medium	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
host	O
cells	O
[	O
28	O
].	O

It	O
should	O
be	O
noted	O
that	O
differentiation	O
into	O
EEFs	O
involves	O
additional	O
events	O
,	O
including	O
expression	O
of	O
liver	O
stage	O
specific	O
proteins	O
,	O
onset	O
of	O
nuclear	O
divisions	O
and	O
parasite	O
growth	O
.	O

None	O
of	O
these	O
events	O
are	O
observed	O
in	O
axenic	O
culture	O
conditions	O
[	O
28	O
],	O
where	O
instead	O
extracellular	O
sporozoites	O
die	O
rapidly	O
after	O
transformation	O
[	O
31	O
].	O

We	O
show	O
that	O
puf2	B-GP
(-)	O
sporozoites	O
transform	O
prematurely	O
in	O
the	O
mosquito	B-OG
salivary	O
glands	O
,	O
as	O
evidenced	O
by	O
the	O
characteristic	O
bulb	O
-	O
like	O
structures	O
and	O
rounding	O
-	O
up	O
of	O
the	O
parasites	O
.	O

Premature	O
transformation	O
probably	O
impairs	O
the	O
sporozoite	O
functions	O
that	O
depend	O
on	O
IMC	O
integrity	O
,	O
such	O
as	O
parasite	O
motility	O
,	O
cell	O
traversal	O
and	O
invasion	O
,	O
thus	O
resulting	O
in	O
a	O
loss	O
of	O
infectivity	O
.	O

In	O
the	O
absence	O
of	O
Puf2	B-GP
,	O
the	O
proportion	O
of	O
transformed	O
salivary	O
gland	O
sporozoites	O
increases	O
over	O
time	O
,	O
which	O
correlates	O
with	O
a	O
progressive	O
loss	O
of	O
infectivity	O
to	O
mice	B-OG
.	O

Interestingly	O
,	O
although	O
most	O
puf2	B-GP
(-)	O
sporozoites	O
eventually	O
transform	O
into	O
completely	O
round	O
forms	O
,	O
these	O
forms	O
do	O
not	O
progress	O
to	O
EEF	O
differentiation	O
,	O
as	O
shown	O
by	O
minimal	O
expression	O
of	O
the	O
liver	O
stage	O
marker	O
UIS4	B-GP
and	O
absence	O
of	O
nuclear	O
division	O
or	O
growth	O
.	O

In	O
contrast	O
,	O
normal	O
differentiation	O
of	O
puf2	B-GP
(-)	O
parasites	O
is	O
observed	O
once	O
sporozoites	O
invade	O
cultured	O
hepatoma	B-DS
cells	O
.	O

Collectively	O
,	O
these	O
data	O
strongly	O
suggest	O
that	O
Puf2	B-GP
plays	O
a	O
major	O
role	O
in	O
preventing	O
premature	O
remodelling	O
of	O
the	O
sporozoites	O
prior	O
to	O
liver	B-DS
infection	I-DS
,	O
but	O
is	O
not	O
required	O
for	O
EEF	O
differentiation	O
.	O

The	O
defects	O
observed	O
in	O
puf2	B-GP
(-)	O
parasites	O
are	O
reminiscent	O
of	O
those	O
described	O
in	O
IK2	B-GP
-	O
knockout	O
parasites	O
[	O
12	O
].	O

Both	O
puf2	B-GP
(-)	O
and	O
ik2	B-GP
(-)	O
sporozoites	O
transform	O
prematurely	O
in	O
the	O
mosquito	B-OG
and	O
display	O
greatly	O
reduced	O
infectivity	O
to	O
mice	B-OG
.	O

However	O
,	O
both	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
are	O
able	O
to	O
invade	O
and	O
differentiate	O
into	O
EEFs	O
in	O
cultured	O
cells	O
in	O
vitro	O
,	O
indicating	O
that	O
they	O
do	O
not	O
play	O
any	O
essential	O
role	O
after	O
host	O
cell	O
infection	B-DS
.	O

These	O
observations	O
,	O
combined	O
with	O
a	O
major	O
down	O
-	O
regulation	O
of	O
IK2	B-GP
expression	O
in	O
puf2	B-GP
(-)	O
sporozoites	O
,	O
suggest	O
that	O
the	O
phenotype	O
of	O
Puf2	B-GP
-	O
deficient	O
parasites	O
can	O
be	O
explained	O
,	O
to	O
a	O
large	O
extent	O
,	O
by	O
IK2	B-GP
depletion	O
.	O

How	O
IK2	B-GP
prevents	O
sporozoite	O
transformation	O
has	O
yet	O
to	O
be	O
determined	O
.	O

Phosphorylation	O
of	O
the	O
alpha	O
subunit	O
of	O
eIF2	B-GP
by	O
distinct	O
kinases	B-GP
,	O
such	O
as	O
Plasmodium	B-OG
IK2	B-GP
,	O
is	O
a	O
central	O
mechanism	O
in	O
stress	O
-	O
induced	O
translational	O
regulation	O
[	O
32	O
],	O
including	O
in	O
protozoans	B-OG
.	O

For	O
example	O
,	O
the	O
eIF2alpha	B-GP
kinase	I-GP
IK1	B-GP
regulates	O
responses	O
to	O
starvation	O
stress	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
blood	O
stages	O
[	O
13	O
],	O
and	O
in	O
Toxoplasma	B-OG
gondii	I-OG
,	O
phosphorylation	O
of	O
eIF2alpha	B-GP
promotes	O
survival	O
of	O
extracellular	O
tachyzoites	B-OG
[	O
33	O
].	O

Our	O
data	O
corroborate	O
the	O
findings	O
of	O
Zhang	O
et	O
al	O
.	O
[	O
12	O
],	O
which	O
together	O
suggest	O
that	O
a	O
similar	O
stress	O
response	O
operates	O
in	O
sporozoites	O
to	O
maintain	O
them	O
in	O
a	O
quiescent	O
stage	O
.	O

The	O
founding	O
member	O
of	O
the	O
Puf	B-GP
family	O
,	O
Drosophila	B-OG
melanogaster	I-OG
Pumilio	B-GP
(	O
DmPUM	B-GP
),	O
regulates	O
,	O
amongst	O
other	O
functions	O
,	O
abdominal	O
development	O
in	O
the	O
fly	B-OG
via	O
translational	O
repression	O
of	O
the	O
maternally	O
inherited	O
hunchback	O
(	O
hb	O
)	O
mRNA	O
[	O
34	O
].	O

The	O
Puf	B-GP
domain	O
of	O
DmPUM	O
binds	O
to	O
a	O
nanos	O
response	O
element	O
(	O
NRE	O
)	O
sequence	O
located	O
in	O
the	O
3	O
′	O
UTR	O
of	O
hb	B-GP
mRNA	O
.	O

Biochemical	O
data	O
,	O
such	O
as	O
in	O
vitro	O
binding	O
assays	O
using	O
recombinant	O
Puf	B-GP
domains	O
expressed	O
in	O
bacteria	B-OG
and	O
heterologous	O
in	O
vivo	O
studies	O
using	O
the	O
yeast	B-OG
three	O
-	O
hybrid	O
system	O
,	O
have	O
demonstrated	O
intrinsic	O
binding	O
activity	O
of	O
the	O
P	B-OG
.	I-OG
falciparum	I-OG
PfPuf1	B-GP
and	O
PfPuf2	B-GP
to	O
the	O
NRE	O
sequence	O
[	O
20	O
],	O
[	O
21	O
].	O

Signature	O
RNA	O
sequences	O
that	O
are	O
recognized	O
by	O
the	O
Puf	B-GP
domain	O
vary	O
between	O
species	O
and	O
members	O
of	O
the	O
Puf	B-GP
family	O
,	O
but	O
typically	O
contain	O
a	O
UGUR	O
motif	O
[	O
35	O
],	O
[	O
36	O
],	O
[	O
37	O
],	O
[	O
38	O
].	O

A	O
large	O
number	O
of	O
Plasmodium	B-OG
genes	O
contain	O
UGUR	O
motifs	O
in	O
their	O
3	O
′	O
UTR	O
,	O
but	O
their	O
functional	O
significance	O
remains	O
uncertain	O
,	O
especially	O
in	O
the	O
context	O
of	O
the	O
exceptional	O
AT	O
-	O
richness	O
of	O
the	O
Plasmodium	B-OG
genome	O
.	O

Therefore	O
,	O
endogenous	O
targets	O
of	O
Plasmodium	B-OG
Puf	B-GP
proteins	O
still	O
remain	O
elusive	O
.	O

The	O
P	B-OG
.	I-OG
falciparum	I-OG
[	O
22	O
]	O
and	O
P	B-OG
.	I-OG
berghei	I-OG
(	O
this	O
study	O
)	O
mutants	O
now	O
constitute	O
potential	O
tools	O
to	O
identify	O
Puf2	B-GP
target	O
genes	O
in	O
Plasmodium	B-OG
.	O

In	O
sporozoites	O
,	O
Puf2	B-GP
regulates	O
at	O
least	O
two	O
other	O
genes	O
in	O
addition	O
to	O
IK2	B-GP
and	O
Puf1	B-GP
.	O

Indeed	O
,	O
using	O
RT	O
-	O
qPCR	O
,	O
we	O
found	O
a	O
4	O
-	O
fold	O
reduction	O
of	O
Spect	B-GP
and	O
Spect2	B-GP
mRNA	O
levels	O
in	O
puf2	B-GP
(-)	O
sporozoites	O
,	O
whereas	O
actin	B-GP
and	O
AMA1	B-GP
were	O
not	O
affected	O
(	O
unpublished	O
data	O
).	O

Reduced	O
expression	O
of	O
Spect	B-GP
and	O
Spect2	B-GP
genes	O
,	O
which	O
are	O
both	O
essential	O
for	O
sporozoite	O
cell	O
traversal	O
and	O
migration	O
to	O
the	O
liver	O
[	O
29	O
],	O
[	O
39	O
],	O
[	O
40	O
],	O
may	O
also	O
contribute	O
to	O
the	O
loss	O
of	O
infectivity	O
of	O
puf2	B-GP
(-)	O
parasites	O
in	O
vivo	O
.	O

Whereas	O
Puf	B-GP
proteins	O
typically	O
modulate	O
target	O
mRNA	O
expression	O
by	O
either	O
promoting	O
mRNA	O
turnover	O
or	O
translational	O
repression	O
,	O
they	O
can	O
also	O
activate	O
gene	O
expression	O
or	O
control	O
mRNA	O
subcellular	O
localization	O
(	O
reviewed	O
in	O
[	O
18	O
]	O
and	O
[	O
19	O
]).	O

Our	O
results	O
are	O
not	O
compatible	O
with	O
a	O
role	O
of	O
Puf2	B-GP
in	O
repressing	O
IK2	B-GP
,	O
because	O
puf2	B-GP
(-)	O
and	O
ik2	B-GP
(-)	O
share	O
a	O
similar	O
phenotype	O
.	O

Puf2	B-GP
may	O
instead	O
participate	O
in	O
stabilization	O
of	O
IK2	B-GP
transcripts	O
.	O

Alternatively	O
,	O
depletion	O
of	O
IK2	B-GP
mRNA	O
in	O
puf2	B-GP
(-)	O
could	O
be	O
an	O
indirect	O
effect	O
due	O
to	O
activation	O
of	O
an	O
upstream	O
factor	O
that	O
regulates	O
IK2	B-GP
.	O

Whereas	O
Drosophila	B-OG
encodes	O
only	O
DmPUM	B-GP
,	O
many	O
organisms	O
,	O
including	O
C	B-OG
.	I-OG
elegans	I-OG
,	O
contain	O
two	O
or	O
more	O
genes	O
encoding	O
Puf	B-GP
proteins	O
,	O
which	O
can	O
fulfil	O
partly	O
redundant	O
functions	O
[	O
41	O
].	O

Therefore	O
,	O
presence	O
of	O
two	O
Puf	B-GP
genes	O
in	O
the	O
Plasmodium	B-OG
genome	O
might	O
be	O
explained	O
by	O
overlapping	O
or	O
distinct	O
roles	O
.	O

However	O
,	O
our	O
molecular	O
genetics	O
data	O
clearly	O
exclude	O
a	O
vital	O
role	O
for	O
Puf1	B-GP
under	O
normal	O
conditions	O
throughout	O
the	O
P	B-OG
.	I-OG
berghei	I-OG
life	O
cycle	O
.	O
Puf1	B-GP
may	O
be	O
critical	O
under	O
specific	O
conditions	O
,	O
similarly	O
to	O
the	O
role	O
of	O
IK1	B-GP
in	O
P	B-OG
.	I-OG
falciparum	I-OG
during	O
starvation	O
-	O
induced	O
stress	O
[	O
13	O
].	O

Puf2	B-GP
might	O
compensate	O
for	O
the	O
absence	O
of	O
Puf1	B-GP
in	O
puf1	B-GP
(-)	O
parasites	O
,	O
but	O
not	O
vice	O
versa	O
.	O

While	O
Puf1	B-GP
in	O
principle	O
might	O
be	O
able	O
to	O
functionally	O
complement	O
for	O
Puf2	B-GP
function	O
,	O
depletion	O
of	O
Puf1	B-GP
at	O
the	O
mRNA	O
level	O
precludes	O
a	O
hypothetical	O
functional	O
overlap	O
in	O
vivo	O
.	O
In	O
this	O
regard	O
,	O
it	O
should	O
be	O
noted	O
that	O
P	B-OG
.	I-OG
berghei	I-OG
Puf1	B-GP
and	O
Puf2	B-GP
proteins	O
are	O
very	O
different	O
in	O
size	O
(	O
1183	O
versus	O
477	O
amino	B-CD
acids	I-CD
,	O
respectively	O
),	O
and	O
share	O
only	O
little	O
homology	O
(∼	O
27	O
%	O
identity	O
)	O
restricted	O
to	O
the	O
Puf	B-GP
domains	O
.	O

P	B-OG
.	I-OG
falciparum	I-OG
parasites	O
that	O
lack	O
Puf2	B-GP
show	O
increased	O
gametocyte	O
rates	O
and	O
a	O
bias	O
towards	O
male	O
gametocytes	O
[	O
22	O
].	O

These	O
observations	O
fit	O
with	O
the	O
proposed	O
unifying	O
,	O
and	O
perhaps	O
ancestral	O
,	O
role	O
of	O
Pufs	B-GP
in	O
promoting	O
cell	O
proliferation	O
and	O
repressing	O
differentiation	O
[	O
18	O
].	O

Our	O
findings	O
that	O
Puf2	B-GP
inhibits	O
sporozoite	O
transformation	O
further	O
support	O
the	O
notion	O
of	O
a	O
central	O
role	O
in	O
suppression	O
of	O
cellular	O
differentiation	O
.	O

Because	O
of	O
the	O
published	O
data	O
from	O
P	B-OG
.	I-OG
falciparum	I-OG
puf2	B-GP
(-)	O
parasites	O
we	O
did	O
not	O
investigate	O
sexual	O
development	O
and	O
differentiation	O
of	O
Pbpuf2	B-GP
(-)	O
parasites	O
in	O
great	O
detail	O
other	O
than	O
to	O
confirm	O
the	O
previous	O
findings	O
,	O
i	O
.	O
e	O
.	O
an	O
increase	O
in	O
gametocytogenesis	O
in	O
puf2	B-GP
(-)	O
parasites	O
,	O
partly	O
due	O
to	O
increased	O
male	O
gametocyte	O
differentiation	O
.	O

In	O
the	O
previous	O
study	O
,	O
life	O
cycle	O
progression	O
of	O
Pfpuf2	B-GP
(-)	O
parasites	O
beyond	O
gametocytogenesis	O
was	O
not	O
analyzed	O
[	O
22	O
].	O

Based	O
on	O
our	O
results	O
in	O
the	O
rodent	B-OG
malaria	B-DS
model	O
system	O
,	O
we	O
predict	O
that	O
P	B-OG
.	I-OG
falciparum	I-OG
sporozoites	O
lacking	O
Puf2	B-GP
will	O
present	O
a	O
similar	O
phenotype	O
,	O
that	O
is	O
premature	O
sporozoite	O
transformation	O
in	O
the	O
mosquito	B-OG
and	O
decreased	O
infectivity	O
.	O

Therefore	O
,	O
our	O
findings	O
might	O
be	O
of	O
considerable	O
interest	O
in	O
the	O
context	O
of	O
development	O
of	O
genetically	O
attenuated	O
parasites	O
for	O
vaccination	O
[	O
42	O
].	O

In	O
conclusion	O
,	O
we	O
show	O
here	O
that	O
Puf2	B-GP
plays	O
a	O
major	O
role	O
in	O
controlling	O
sporozoite	O
latency	O
during	O
host	O
switch	O
,	O
possibly	O
through	O
the	O
regulation	O
of	O
IK2	B-GP
.	O

Our	O
results	O
also	O
highlight	O
the	O
functional	O
importance	O
of	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
during	O
transmission	O
of	O
the	O
malaria	B-DS
parasite	B-OG
between	O
hosts	O
.	O

Materials	O
and	O
Methods	O

Ethics	O
statement	O

All	O
animal	B-OG
work	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
German	O
‘	O
Tierschutzgesetz	O
in	O
der	O
Fassung	O
vom	O
18	O
.	O

Mai	O
2006	O
(	O
BGBl	O
.	O

I	O
S	O
.	O

1207	O
)',	O
which	O
implements	O
the	O
directive	O
86	O
/	O
609	O
/	O
EEC	O
from	O
the	O
European	O
Union	O
and	O
the	O
European	O
Convention	O
for	O
the	O
protection	O
of	O
vertebrate	B-OG
animals	B-OG
used	O
for	O
experimental	O
and	O
other	O
scientific	O
purposes	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
MPI	O
-	O
IB	O
and	O
the	O
Berlin	O
state	O
authorities	O
(	O
LAGeSo	O
Reg	O
#	O
G0469	O
/	O
09	O
).	O

Experimental	O
animals	B-OG
,	O
parasites	O
and	O
cell	O
lines	O

Female	O
NMRI	O
and	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
from	O
Charles	O
River	O
Laboratories	O
.	O

We	O
used	O
P	B-OG
.	I-OG
berghei	I-OG
ANKA	I-OG
clone	O
507	O
parasites	O
,	O
which	O
constitutively	O
express	O
the	O
green	B-GP
fluorescent	I-GP
protein	I-GP
(	O
GFP	B-GP
)	O
[	O
26	O
].	O

HepG2	O
cells	O
(	O
ATCC	O
HB	O
-	O
8065	O
)	O
were	O
cultured	O
as	O
described	O
[	O
43	O
].	O

P	B-OG
.	I-OG
berghei	I-OG
Puf1	B-GP
and	O
Puf2	B-GP
gene	O
deletion	O

A	O
targeting	O
construct	O
for	O
Puf1	B-GP
gene	O
knockout	O
was	O
generated	O
by	O
inserting	O
a	O
503	O
-	O
bp	O
5	O
′	O
fragment	O
and	O
a	O
575	O
-	O
bp	O
3	O
′	O
fragment	O
on	O
either	O
side	O
of	O
a	O
T	B-OG
.	I-OG
gondii	I-OG
DHFR	O
/	O
TS	B-GP
expression	O
cassette	O
.	O

A	O
construct	O
for	O
Puf2	B-GP
gene	O
knockout	O
was	O
generated	O
by	O
inserting	O
a	O
1001	O
-	O
bp	O
5	O
′	O
fragment	O
and	O
a	O
945	O
-	O
bp	O
3	O
′	O
fragment	O
on	O
either	O
side	O
of	O
a	O
human	B-OG
DHFR	B-GP
expression	O
cassette	O
.	O

Oligonucleotide	O
sequences	O
are	O
indicated	O
in	O
Table	O
S1	O
.	O
P	B-OG
.	I-OG
berghei	I-OG
parasites	O
were	O
transfected	O
with	O
linearized	O
plasmids	O
,	O
using	O
the	O
Nucleofector	O
®	O
device	O
(	O
Amaxa	O
GmbH	O
)	O
as	O
described	O
[	O
44	O
],	O
injected	O
intravenously	O
into	O
naïve	O
NMRI	O
mice	B-OG
,	O
and	O
selected	O
by	O
pyrimethamine	B-CD
treatment	O
in	O
the	O
drinking	O
water	O
.	O

Clonal	O
parasite	O
populations	O
were	O
obtained	O
by	O
limiting	O
dilution	O
series	O
and	O
intravenous	O
injection	O
of	O
one	O
parasite	O
in	O
10	O
recipient	O
NMRI	O
mice	B-OG
.	O

One	O
puf1	B-GP
(-)	O
and	O
two	O
puf2	B-GP
(-)	O
clonal	O
parasite	O
lines	O
were	O
established	O
and	O
phenotypically	O
characterized	O
.	O

Genotyping	O
of	O
WT	O
and	O
recombinant	O
parasites	O
was	O
performed	O
by	O
PCR	O
and	O
Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
.	O

Standard	O
Southern	O
blot	O
analysis	O
was	O
performed	O
using	O
the	O
PCR	O
DIG	O
Probe	O
synthesis	O
kit	O
and	O
the	O
DIG	O
Luminescent	O
Detection	O
kit	O
(	O
Roche	O
),	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Real	O
time	O
quantitative	O
RT	O
-	O
PCR	O

Parasite	O
total	O
RNA	O
was	O
extracted	O
with	O
the	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
and	O
reverse	O
transcribed	O
with	O
the	O
RETROScript	O
kit	O
(	O
Ambion	O
).	O

Real	O
time	O
PCR	O
was	O
performed	O
on	O
cDNA	O
preparations	O
as	O
described	O
[	O
11	O
],	O
using	O
the	O
StepOnePlus	O
™	O
Real	O
-	O
Time	O
PCR	O
System	O
and	O
Power	O
SYBR	O
®	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
),	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Expression	O
data	O
were	O
normalized	O
using	O
the	O
constitutively	O
expressed	O
GFP	B-GP
gene	O
.	O

Immunofluorescence	O

Parasites	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
and	O
permeabilized	O
with	O
1	O
%	O
Triton	O
X	O
-	O
100	O
.	O

Immunofluorescence	O
was	O
then	O
carried	O
out	O
using	O
previously	O
described	O
monoclonal	O
antibodies	B-GP
against	O
P	B-OG
.	I-OG
berghei	I-OG
CSP	B-GP
[	O
45	O
]	O
and	O
HSP70	B-GP
[	O
46	O
].	O

Polyclonal	O
anti	O
-	O
UIS4	B-GP
antibodies	B-GP
were	O
raised	O
in	O
rabbits	B-OG
immunized	O
with	O
two	O
synthetic	O
peptides	O
from	O
P	B-OG
.	I-OG
berghei	I-OG
UIS4	B-GP
(	O
CLFTDEHKDEINDNIV	O
and	O
CNNVYNMENKSFGPYI	O
)	O
(	O
Eurogentec	O
).	O

DRAQ5	O
(	O
Biostatus	O
)	O
was	O
used	O
to	O
stain	O
nuclei	O
.	O

Confocal	O
pictures	O
were	O
obtained	O
with	O
a	O
Leica	O
TCS	O
-	O
SP	O
microscope	O
equipped	O
with	O
appropriate	O
filters	O
,	O
and	O
processed	O
with	O
Photoshop	O
software	O
(	O
Adobe	O
Inc	O
.).	O

Parasite	O
growth	O
and	O
sexual	O
development	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
(	O
n	O
=	O
5	O
)	O
were	O
injected	O
intravenously	O
with	O
107	O
infected	O
erythrocytes	O
.	O

Four	O
days	O
later	O
,	O
the	O
parasitemia	B-DS
was	O
determined	O
by	O
microscopic	O
examination	O
of	O
Giemsa	O
-	O
stained	O
blood	O
smears	O
.	O

To	O
analyse	O
exflagellation	O
of	O
male	O
gametocytes	O
,	O
five	O
microliters	O
of	O
tail	O
blood	O
were	O
diluted	O
1	O
∶	O
25	O
in	O
RPMI	O
1640	O
containing	O
10	O
%	O
FCS	O
and	O
50	O
µM	O
xanthurenic	B-CD
acid	I-CD
,	O
and	O
adjusted	O
to	O
pH	O
8	O
.	O
0	O
.	O

After	O
12	O
min	O
incubation	O
at	O
room	O
temperature	O
,	O
exflagellation	O
centers	O
were	O
counted	O
in	O
a	O
Neubauer	O
chamber	O
.	O

Mean	O
parasitemia	B-DS
and	O
gametocyte	O
rates	O
were	O
compared	O
using	O
the	O
Mann	O
-	O
Whitney	O
non	O
-	O
parametric	O
test	O
.	O

After	O
parasite	O
transmission	O
to	O
Anopheles	B-OG
stephensi	I-OG
mosquitoes	B-OG
,	O
the	O
numbers	O
of	O
midgut	O
oocysts	O
and	O
salivary	O
gland	O
sporozoites	O
were	O
determined	O
at	O
day	O
10	O
–	O
14	O
and	O
day	O
18	O
–	O
25	O
,	O
respectively	O
,	O
and	O
compared	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
followed	O
by	O
Dunn	O
'	O
s	O
multiple	O
comparison	O
tests	O
.	O

Analysis	O
of	O
sporozoite	O
in	O
vivo	O
infectivity	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
injected	O
intravenously	O
with	O
1	O
,	O
000	O
WT	O
or	O
mutant	O
sporozoites	O
isolated	O
from	O
the	O
salivary	O
glands	O
of	O
infected	O
mosquitoes	B-OG
,	O
or	O
exposed	O
to	O
10	O
infected	O
mosquito	B-OG
bites	O
,	O
as	O
indicated	O
.	O

Infection	B-DS
was	O
then	O
monitored	O
daily	O
by	O
examination	O
of	O
Giemsa	O
-	O
stained	O
blood	O
smears	O
.	O

The	O
delay	O
of	O
patency	O
was	O
defined	O
as	O
the	O
time	O
before	O
detection	O
of	O
at	O
least	O
one	O
erythrocytic	O
stage	O
in	O
the	O
smears	O
.	O

For	O
quantification	O
of	O
parasite	O
liver	O
loads	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
,	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
infected	O
intravenously	O
with	O
10	O
,	O
000	O
sporozoites	O
.	O

At	O
42	O
hours	O
post	O
-	O
infection	B-DS
,	O
livers	O
were	O
harvested	O
,	O
total	O
RNA	O
was	O
extracted	O
with	O
the	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
and	O
cDNA	O
synthesized	O
with	O
the	O
RETROScript	O
kit	O
(	O
Ambion	O
).	O

Real	O
-	O
time	O
PCR	O
was	O
then	O
performed	O
with	O
the	O
StepOnePlus	O
™	O
Real	O
-	O
Time	O
PCR	O
System	O
and	O
Power	O
SYBR	O
®	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
),	O
using	O
primers	O
specific	O
for	O
P	B-OG
.	I-OG
berghei	I-OG
18S	O
rRNA	O
and	O
mouse	B-OG
GAPDH	B-GP
,	O
as	O
described	O
[	O
47	O
].	O

Liver	O
parasite	O
loads	O
were	O
compared	O
using	O
the	O
Mann	O
-	O
Whitney	O
non	O
-	O
parametric	O
test	O
.	O

Supporting	O
Information	O

List	O
of	O
oligonucleotides	O
used	O
in	O
this	O
study	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

A	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
of	O
a	O
ligand	O
cellular	O
system	O
for	O
key	O
structural	O
modifications	O
around	O
ligand	O
binding	O

Background	O

A	O
tandem	O
technique	O
of	O
hard	O
equipment	O
is	O
often	O
used	O
for	O
the	O
chemical	O
analysis	O
of	O
a	O
single	O
cell	O
to	O
first	O
isolate	O
and	O
then	O
detect	O
the	O
wanted	O
identities	O
.	O

The	O
first	O
part	O
is	O
the	O
separation	O
of	O
wanted	O
chemicals	O
from	O
the	O
bulk	O
of	O
a	O
cell	O
;	O
the	O
second	O
part	O
is	O
the	O
actual	O
detection	O
of	O
the	O
important	O
identities	O
.	O

To	O
identify	O
the	O
key	O
structural	O
modifications	O
around	O
ligand	O
binding	O
,	O
the	O
present	O
study	O
aims	O
to	O
develop	O
a	O
counterpart	O
of	O
tandem	O
technique	O
for	O
cheminformatics	O
.	O

A	O
statistical	O
regression	O
and	O
its	O
outliers	O
act	O
as	O
a	O
computational	O
technique	O
for	O
separation	O
.	O

Results	O

A	O
PPARγ	B-GP
(	O
peroxisome	B-GP
proliferator	I-GP
-	I-GP
activated	I-GP
receptor	I-GP
gamma	I-GP
)	O
agonist	O
cellular	O
system	O
was	O
subjected	O
to	O
such	O
an	O
investigation	O
.	O

Results	O
show	O
that	O
this	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
,	O
or	O
the	O
prioritization	O
of	O
the	O
context	O
equations	O
tagged	O
with	O
features	O
of	O
the	O
outliers	O
,	O
is	O
an	O
effective	O
regression	O
technique	O
of	O
cheminformatics	O
to	O
detect	O
key	O
structural	O
modifications	O
,	O
as	O
well	O
as	O
their	O
tendency	O
of	O
impact	O
to	O
ligand	O
binding	O
.	O

Conclusions	O

The	O
key	O
structural	O
modifications	O
around	O
ligand	O
binding	O
are	O
effectively	O
extracted	O
or	O
characterized	O
out	O
of	O
cellular	O
reactions	O
.	O

This	O
is	O
because	O
molecular	O
binding	O
is	O
the	O
paramount	O
factor	O
in	O
such	O
ligand	O
cellular	O
system	O
and	O
key	O
structural	O
modifications	O
around	O
ligand	O
binding	O
are	O
expected	O
to	O
create	O
outliers	O
.	O

Therefore	O
,	O
such	O
outliers	O
can	O
be	O
captured	O
by	O
this	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
.	O

Background	O

In	O
any	O
chemical	O
analysis	O
of	O
a	O
single	O
cell	O
,	O
the	O
first	O
step	O
is	O
the	O
separation	O
of	O
wanted	O
chemicals	O
from	O
the	O
bulk	O
of	O
a	O
cell	O
.	O

This	O
is	O
due	O
to	O
the	O
fact	O
that	O
a	O
cellular	O
system	O
has	O
a	O
complex	O
,	O
heterogeneous	O
composition	O
.	O

Various	O
methods	O
[	O
1	O
]	O
using	O
hard	O
equipment	O
have	O
been	O
developed	O
for	O
such	O
uses	O
.	O

After	O
a	O
single	O
cell	O
is	O
separated	O
from	O
the	O
other	O
cells	O
,	O
the	O
wanted	O
component	O
can	O
be	O
further	O
isolated	O
and	O
then	O
detected	O
through	O
what	O
is	O
called	O
a	O
tandem	O
technique	O
[	O
1	O
].	O

The	O
first	O
part	O
of	O
a	O
tandem	O
technique	O
,	O
as	O
mentioned	O
above	O
,	O
is	O
the	O
separation	O
of	O
wanted	O
chemicals	O
from	O
the	O
bulk	O
of	O
a	O
cell	O
;	O
the	O
second	O
part	O
is	O
the	O
detection	O
of	O
the	O
components	O
.	O

By	O
mimicking	O
such	O
a	O
tandem	O
technique	O
,	O
a	O
computational	O
counterpart	O
was	O
developed	O
herein	O
;	O
a	O
statistical	O
regression	O
and	O
its	O
outliers	O
(	O
influential	O
observations	O
[	O
2	O
])	O
act	O
as	O
a	O
computational	O
technique	O
for	O
separation	O
,	O
which	O
can	O
cause	O
the	O
important	O
identities	O
(	O
i	O
.	O
e	O
.	O
the	O
factors	O
causing	O
outliers	O
)	O
to	O
be	O
isolated	O
from	O
the	O
bulk	O
of	O
a	O
cellular	O
system	O
.	O

As	O
a	O
pioneer	O
investigation	O
,	O
one	O
molecular	O
descriptor	O
and	O
one	O
class	O
of	O
descriptors	O
will	O
be	O
prepared	O
:	O
the	O
descriptor	O
resembles	O
the	O
filter	O
in	O
the	O
tandem	O
equipment	O
;	O
the	O
class	O
resembles	O
the	O
detector	O
.	O

In	O
a	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
cellular	O
system	O
(	O
or	O
ligand	O
cellular	O
system	O
),	O
key	O
structural	O
modifications	O
surrounding	O
ligand	O
binding	O
are	O
expected	O
to	O
cause	O
outliers	O
.	O

For	O
example	O
,	O
hydrogen	O
bond	O
formation	O
,	O
or	O
deformation	O
,	O
can	O
cause	O
drastic	O
alterations	O
in	O
cellular	O
reaction	O
.	O

These	O
singular	O
situations	O
are	O
,	O
at	O
times	O
,	O
the	O
reasons	O
for	O
statistical	O
breakdown	O
points	O
in	O
many	O
analyses	O
that	O
are	O
otherwise	O
correct	O
(	O
i	O
.	O
e	O
.	O
resulting	O
in	O
the	O
outliers	O
of	O
a	O
statistical	O
regression	O
[	O
3	O
,	O
4	O
]).	O

At	O
the	O
same	O
time	O
,	O
such	O
outliers	O
can	O
have	O
the	O
most	O
prominent	O
and	O
often	O
most	O
informative	O
features	O
of	O
the	O
target	O
-	O
specific	O
activity	O
landscapes	O
[	O
5	O
].	O

Therefore	O
,	O
the	O
concept	O
that	O
after	O
this	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
,	O
the	O
features	O
of	O
these	O
resulting	O
outliers	O
can	O
correspond	O
to	O
important	O
structural	O
modifications	O
around	O
molecular	O
binding	O
in	O
such	O
a	O
ligand	O
cellular	O
system	O
,	O
if	O
correct	O
,	O
would	O
be	O
very	O
useful	O
.	O

For	O
this	O
first	O
tandem	O
part	O
,	O
we	O
sought	O
the	O
most	O
representative	O
descriptor	O
for	O
the	O
bulk	O
system	O
of	O
a	O
cell	O
.	O

We	O
found	O
Jurs_RNCG	O
[	O
6	O
],	O
after	O
observing	O
more	O
than	O
521	O
×	O
17	O
data	O
sets	O
of	O
PPARγ	B-GP
(	O
peroxisome	B-GP
proliferator	I-GP
-	I-GP
activated	I-GP
receptor	I-GP
gamma	I-GP
)	O
agonists	O
[	O
7	O
-	O
21	O
].	O

The	O
methods	O
and	O
results	O
are	O
depicted	O
in	O
the	O
first	O
body	O
of	O
materials	O
,	O
methods	O
,	O
and	O
results	O
.	O

To	O
connect	O
this	O
to	O
the	O
second	O
tandem	O
part	O
,	O
the	O
descriptor	O
that	O
is	O
sought	O
in	O
the	O
first	O
part	O
has	O
functionality	O
,	O
which	O
yields	O
outlier	O
residues	O
for	O
the	O
second	O
part	O
.	O

Acting	O
as	O
an	O
assay	O
for	O
detection	O
in	O
the	O
second	O
tandem	O
part	O
,	O
for	O
which	O
the	O
electrotopological	O
state	O
(	O
ES	O
)	O
class	O
of	O
descriptors	O
[	O
22	O
-	O
26	O
]	O
is	O
used	O
.	O

All	O
possible	O
structural	O
modifications	O
in	O
a	O
given	O
collected	O
analog	O
set	O
are	O
pre	O
-	O
assigned	O
by	O
ES	O
descriptors	O
.	O

The	O
ES	O
descriptors	O
involve	O
atom	O
types	O
in	O
various	O
electro	O
-	O
topological	O
states	O
.	O

For	O
example	O
,	O
in	O
ES	O
terminology	O
,	O
an	O
ES_Count_ssO	O
of	O
a	O
molecular	O
structure	O
is	O
the	O
count	O
of	O
“	O
ssO	O
”	O
linkages	O
,	O
and	O
here	O
the	O
“	O
ssO	O
”	O
represents	O
a	O
bonding	O
oxygen	O
atom	O
(	O
O	O
)	O
linked	O
via	O
two	O
single	O
bonds	O
(	O
ss	O
).	O

A	O
structural	O
modification	O
is	O
considered	O
a	O
fundamental	O
element	O
(	O
an	O
action	O
)	O
for	O
the	O
reaction	O
of	O
such	O
a	O
ligand	O
cellular	O
system	O
.	O

In	O
actuality	O
,	O
any	O
structural	O
modification	O
of	O
such	O
an	O
analog	O
set	O
can	O
be	O
expressed	O
by	O
the	O
change	O
of	O
an	O
associated	O
ES	O
descriptor	O
.	O

The	O
details	O
and	O
results	O
of	O
the	O
second	O
part	O
are	O
also	O
depicted	O
in	O
the	O
second	O
body	O
of	O
materials	O
,	O
methods	O
and	O
results	O
.	O

This	O
tandem	O
regression	O
-	O
outlier	O
technique	O
is	O
,	O
therefore	O
,	O
in	O
mathematical	O
terms	O
,	O
carried	O
out	O
so	O
as	O
to	O
prioritize	O
the	O
context	O
equations	O
tagged	O
with	O
features	O
of	O
these	O
outliers	O
.	O

We	O
want	O
to	O
know	O
if	O
the	O
top	O
-	O
ranked	O
structural	O
modifications	O
correspond	O
to	O
the	O
key	O
interactions	O
around	O
molecular	O
binding	O
as	O
we	O
expected	O
them	O
to	O
.	O

This	O
expectation	O
was	O
based	O
on	O
the	O
fact	O
that	O
:	O
I	O
:	O
this	O
singular	O
situation	O
causes	O
outliers	O
in	O
a	O
regression	O
.	O

II	O
:	O
molecular	O
binding	O
is	O
the	O
paramount	O
factor	O
in	O
such	O
a	O
ligand	O
cellular	O
system	O
,	O
and	O
III	O
,	O
key	O
structural	O
modifications	O
around	O
ligand	O
binding	O
are	O
expected	O
to	O
create	O
singular	O
situations	O
,	O
i	O
.	O
e	O
.	O
cause	O
outliers	O
in	O
a	O
statistical	O
regression	O
.	O

In	O
the	O
end	O
,	O
after	O
this	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
for	O
the	O
PPARγ	B-GP
agonist	O
cellular	O
system	O
,	O
a	O
top	O
ranked	O
ES	O
symbol	O
can	O
faithfully	O
correspond	O
to	O
key	O
interactions	O
around	O
molecular	O
binding	O
with	O
the	O
correct	O
order	O
of	O
potency	O
.	O

The	O
outcome	O
of	O
such	O
an	O
analysis	O
confirmed	O
the	O
two	O
main	O
underlying	O
and	O
mutually	O
-	O
dependent	O
speculations	O
;	O
one	O
being	O
that	O
,	O
in	O
the	O
second	O
tandem	O
part	O
,	O
the	O
top	O
ranked	O
ES	O
symbols	O
reflect	O
the	O
key	O
interactions	O
around	O
ligand	O
binding	O
,	O
and	O
the	O
other	O
that	O
,	O
in	O
the	O
first	O
tandem	O
part	O
,	O
the	O
designation	O
of	O
Jurs_RNCG	O
(	O
relative	O
negative	O
charge	O
)	O
can	O
effectively	O
remove	O
the	O
general	O
effects	O
of	O
such	O
a	O
ligand	O
cellular	O
system	O
.	O

Methods	O

The	O
first	O
tandem	O
filter	O
:	O
in	O
order	O
to	O
seek	O
the	O
most	O
representative	O
descriptor	O
for	O
a	O
ligand	O
cellular	O
system	O

In	O
mathematics	O
,	O
the	O
dependent	O
variable	O
Y	O
is	O
the	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
cellular	O
reaction	O
.	O

The	O
context	O
equation	O
of	O
the	O
descriptor	O
selection	O
is	O
given	O
as	O
follows	O
:	O

(	O
1	O
)	O
Y	O
=	O
β0	O
+	O
βchXch	O

where	O
Y	O
is	O
the	O
dependent	O
variable	O
that	O
stands	O
for	O
the	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
cellular	O
reaction	O
,	O
Xch	O
is	O
the	O
descriptor	O
to	O
be	O
chosen	O
,	O
and	O
β0	O
and	O
βch	O
are	O
the	O
regression	O
coefficients	O
after	O
the	O
least	O
squares	O
fit	O
.	O

Once	O
the	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
cellular	O
data	O
of	O
a	O
given	O
set	O
of	O
analogs	O
are	O
available	O
,	O
the	O
r2	O
correlation	O
fit	O
can	O
be	O
obtained	O
for	O
each	O
descriptor	O
.	O

Here	O
,	O
521	O
descriptors	O
of	O
eminent	O
classes	O
are	O
used	O
.	O

All	O
descriptors	O
in	O
the	O
working	O
equation	O
with	O
correlation	O
fits	O
are	O
prioritized	O
by	O
correlation	O
coefficient	O
.	O

All	O
calculations	O
of	O
descriptors	O
were	O
performed	O
using	O
the	O
Discovery	O
Studio	O
2	O
.	O
1	O
QSAR	O
module	O
[	O
27	O
].	O

The	O
regression	O
fits	O
were	O
conducted	O
for	O
each	O
descriptor	O
in	O
the	O
context	O
equation	O
and	O
Pearson	O
’	O
s	O
coefficients	O
were	O
performed	O
using	O
R	O
2	O
.	O
11	O
.	O
0	O
[	O
28	O
].	O

The	O
second	O
tandem	O
detector	O
:	O
to	O
prioritize	O
the	O
context	O
equations	O
tagged	O
with	O
all	O
possible	O
features	O
of	O
the	O
outliers	O

Following	O
the	O
designation	O
of	O
the	O
Jurs_RNCG	O
descriptor	O
,	O
a	O
three	O
-	O
variable	O
equation	O
is	O
used	O
for	O
the	O
prioritization	O
of	O
all	O
the	O
ES	O
descriptors	O
.	O

The	O
context	O
equation	O
using	O
Jurs_RNCG	O
,	O
tagged	O
with	O
all	O
possible	O
features	O
of	O
the	O
outliers	O
,	O
is	O
given	O
as	O
follows	O
:	O

(	O
2	O
)	O
Y	O
=	O
β0	O
+	O
βJurs_RNCGJurs_RNCG	O
+	O
βESES	O

where	O
Y	O
is	O
the	O
dependent	O
variable	O
standing	O
for	O
the	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
cellular	O
reaction	O
,	O
Jurs_RNCG	O
is	O
the	O
calculated	O
Jurs	O
descriptor	O
,	O
ES	O
are	O
all	O
the	O
possible	O
ES	O
descriptors	O
;	O
and	O
all	O
βs	O
are	O
the	O
estimated	O
regression	O
coefficients	O
after	O
the	O
least	O
squares	O
fit	O
.	O

The	O
context	O
equations	O
tagged	O
with	O
all	O
possible	O
ES	O
descriptors	O
are	O
prioritized	O
by	O
correlation	O
coefficient	O
.	O

12	O
top	O
-	O
ranked	O
ES	O
descriptors	O
monitored	O
in	O
the	O
table	O
indicate	O
12	O
important	O
structural	O
modifications	O
in	O
a	O
given	O
analog	O
set	O
.	O

Materials	O

Three	O
data	O
sets	O
of	O
analogs	O
with	O
two	O
cores	O

To	O
demonstrate	O
the	O
ability	O
of	O
this	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
to	O
remove	O
all	O
interference	O
from	O
any	O
general	O
effects	O
in	O
a	O
ligand	O
cellular	O
system	O
,	O
three	O
data	O
sets	O
of	O
the	O
ligand	O
-	O
dependent	O
receptor	O
-	O
mediated	O
data	O
are	O
used	O
here	O
.	O

The	O
first	O
data	O
set	O
is	O
a	O
collection	O
of	O
46	O
PPARγ	B-GP
agonists	O
with	O
the	O
thiazolidinedione	B-CD
(	O
TZD	O
)	O
core	O
.	O

The	O
second	O
data	O
set	O
is	O
composed	O
of	O
178	O
PPARγ	B-GP
agonists	O
with	O
a	O
carboxylic	O
acid	O
core	O
.	O

The	O
third	O
data	O
set	O
is	O
a	O
merger	O
of	O
the	O
first	O
and	O
second	O
data	O
set	O
(	O
i	O
.	O
e	O
.,	O
224	O
PPARγ	B-GP
agonists	O
mixed	O
with	O
both	O
TZD	O
and	O
carboxylic	O
acid	O
cores	O
).	O

The	O
two	O
main	O
cores	O
of	O
PPARγ	B-GP
agonists	O
and	O
their	O
merger	O
are	O
adopted	O
,	O
so	O
as	O
to	O
observe	O
the	O
variations	O
of	O
top	O
-	O
ranked	O
structural	O
modifications	O
.	O

All	O
EC50	O
(	O
50	O
%	O
efficacy	O
concentration	O
)	O
data	O
were	O
extracted	O
from	O
the	O
literature	O
[	O
7	O
-	O
21	O
].	O

The	O
cellular	O
reaction	O
is	O
the	O
measurement	O
of	O
the	O
activation	O
of	O
PPARγ	B-GP
within	O
the	O
construct	O
of	O
the	O
cellular	O
transactivation	O
assays	O
.	O

Indeterminate	O
and	O
uncertain	O
EC50	O
values	O
were	O
excluded	O
.	O

A	O
negative	O
logarithm	O
of	O
the	O
EC50	O
values	O
of	O
PPARγ	B-GP
agonists	O
was	O
then	O
taken	O
.	O

The	O
original	O
publication	O
of	O
all	O
agonists	O
and	O
the	O
activity	O
quantities	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
:	O
Tables	O
S1	O
and	O
S2	O
.	O

All	O
images	O
of	O
molecular	O
structures	O
were	O
created	O
by	O
using	O
Pybel	O
[	O
29	O
,	O
30	O
].	O

All	O
molecular	O
structures	O
were	O
energetically	O
geometry	O
-	O
optimized	O
using	O
molecular	O
mechanics	O
and	O
MMF97	O
calculations	O
,	O
which	O
were	O
implemented	O
using	O
the	O
ChemBio3D	O
software	O
of	O
the	O
ChemBioOffice	O
package	O
[	O
31	O
].	O

Results	O

Jurs_RNCG	O
as	O
most	O
representative	O
descriptor	O

In	O
the	O
mathematical	O
formulation	O
in	O
the	O
first	O
tandem	O
filter	O
,	O
we	O
used	O
a	O
large	O
number	O
data	O
set	O
,	O
or	O
178	O
collected	O
carboxylic	B-CD
acid	O
PPARγ	B-GP
agonists	O
,	O
as	O
a	O
base	O
to	O
seek	O
the	O
most	O
representative	O
descriptor	O
.	O

More	O
details	O
about	O
PPARγ	B-GP
agonists	O
are	O
available	O
in	O
Material	O
Section	O
.	O

To	O
check	O
the	O
size	O
dependency	O
,	O
for	O
each	O
data	O
size	O
from	O
10	O
to	O
170	O
,	O
a	O
total	O
of	O
521	O
×	O
17	O
data	O
sets	O
were	O
taken	O
for	O
the	O
selection	O
of	O
the	O
descriptor	O
just	O
for	O
the	O
enough	O
randomness	O
.	O

Sample	O
agonists	O
of	O
each	O
size	O
were	O
picked	O
out	O
by	O
prioritizing	O
521	O
molecular	O
properties	O
.	O

The	O
dominant	O
descriptor	O
and	O
the	O
frequency	O
of	O
the	O
Jurs	O
type	O
descriptor	O
for	O
each	O
size	O
,	O
including	O
Jurs_RNCG	O
[	O
6	O
],	O
is	O
listed	O
in	O
Table	O
1	O
.	O

For	O
example	O
,	O
in	O
the	O
data	O
size	O
of	O
170	O
agonists	O
,	O
the	O
dominant	O
descriptors	O
of	O
369	O
data	O
sets	O
among	O
a	O
total	O
of	O
521	O
sets	O
are	O
all	O
Jurs_RNCG	O
.	O

We	O
can	O
clearly	O
see	O
that	O
when	O
the	O
data	O
size	O
increases	O
,	O
the	O
Jurs_RNCG	O
is	O
more	O
frequently	O
dominant	O
or	O
near	O
dominant	O
(	O
rank	O
>	O
4	O
).	O

In	O
Jurs	O
terminology	O
,	O
RNCG	O
means	O
a	O
relative	O
negative	O
charge	O
[	O
6	O
].	O

Dominant	O
descriptors	O
for	O
each	O
data	O
size	O
and	O
the	O
frequency	O
of	O
Jurs_RNCG	O
(	O
Jurs	O
type	O
descriptors	O
)	O
throughout	O
521	O
data	O
sets	O
are	O
summarized	O
here	O

Data	O
size	O

Dominant	O
descriptor	O
(	O
Near	O
dominant	O
)	O

Frequency	O
of	O
Jurs	O
descriptors	O
(	O
Jurs_RNCG	O
/	O
Jurs	O
type	O
/	O
521	O
data	O
sets	O
)	O

10	O

Molecular_PolarSASA	O

4	O
/	O
41	O
/	O
521	O

20	O

Molecular_FractionalPolarSASA	O

5	O
/	O
25	O
/	O
521	O

30	O

ES_Count_dOb	O

4	O
/	O
14	O
/	O
521	O

40	O

Num_RingBonds	O

10	O
/	O
14	O
/	O
521	O

50	O

SC_3_Pa	O

9	O
/	O
16	O
/	O
521	O

60	O

SC_3_Pa	O

9	O
/	O
12	O
/	O
521	O

70	O

ICa	O

18	O
/	O
31	O
/	O
521	O

80	O

ICa	O

18	O
/	O
33	O
/	O
521	O

90	O

Jurs_RNCG	O

21	O
/	O
31	O
/	O
521	O

100	O

ICa	O
(	O
Jurs_RNCG	O
)	O

19	O
/	O
31	O
/	O
521	O

110	O

Jurs_RNCG	O

16	O
/	O
21	O
/	O
521	O

120	O

Num_AtomClasses	O
(	O
Jurs_RNCG	O
)	O

21	O
/	O
23	O
/	O
521	O

130	O

ICa	O
(	O
Jurs_RNCG	O
)	O

28	O
/	O
29	O
/	O
521	O

140	O

ICa	O
(	O
Jurs_RNCG	O
)	O

39	O
/	O
306	O
/	O
521	O

150	O

Jurs_RNCG	O

39	O
/	O
39	O
/	O
521	O

160	O

ICa	O
(	O
Jurs_RNCG	O
)	O

53	O
/	O
53	O
/	O
521	O

170	O

Jurs_RNCG	O

369	O
/	O
369	O
/	O
521	O

a	O
The	O
descriptors	O
SC_3_P	O
and	O
IC	O
are	O
calculated	O
based	O
on	O
graph	O
theory	O
.	O

b	O
The	O
descriptor	O
ES_Count_dO	O
is	O
a	O
fractional	O
descriptor	O
(	O
The	O
definition	O
of	O
a	O
fractional	O
descriptor	O
is	O
in	O
the	O
discussion	O
section	O
).	O

Agonists	O
of	O
each	O
data	O
set	O
are	O
selected	O
out	O
of	O
the	O
178	O
carboxylic	B-CD
acid	O
PPARγ	B-GP
agonists	O
.	O

The	O
top	O
-	O
ranked	O
descriptor	O
of	O
each	O
set	O
was	O
selected	O
from	O
521	O
descriptors	O
of	O
eminent	O
classes	O
.	O

In	O
a	O
realistic	O
physical	O
-	O
chemical	O
representation	O
,	O
one	O
would	O
prefer	O
the	O
Jurs_RNCG	O
to	O
the	O
IC	O
(	O
Information	O
Content	O
)	O
[	O
32	O
]	O
as	O
the	O
most	O
representative	O
descriptor	O
for	O
all	O
general	O
effects	O
.	O

This	O
is	O
because	O
Jurs_RNCG	O
was	O
originally	O
designed	O
based	O
on	O
the	O
charge	O
-	O
related	O
nature	O
.	O

The	O
descriptor	O
IC	O
,	O
as	O
an	O
index	O
of	O
graph	O
theory	O
,	O
deals	O
with	O
the	O
topological	O
aspect	O
in	O
nature	O
.	O

Therefore	O
,	O
the	O
Jurs_RNCG	O
descriptor	O
here	O
is	O
thought	O
to	O
be	O
the	O
most	O
representative	O
single	O
descriptor	O
for	O
all	O
general	O
effects	O
in	O
the	O
PPARγ	B-GP
agonist	O
cellular	O
system	O
.	O

After	O
this	O
designation	O
,	O
to	O
our	O
surprise	O
,	O
the	O
Jurs_RNCG	O
is	O
further	O
shown	O
to	O
be	O
a	O
linear	O
combination	O
of	O
three	O
important	O
descriptors	O
:	O
LogD	O
(	O
partition	O
coefficient	O
),	O
PSA	O
(	O
polar	O
surface	O
area	O
),	O
and	O
shape	O
-	O
like	O
descriptors	O
in	O
a	O
subsequent	O
work	O
[	O
33	O
].	O

These	O
three	O
descriptors	O
happen	O
to	O
be	O
the	O
three	O
most	O
important	O
factors	O
of	O
investigation	O
in	O
medicinal	O
chemistry	O
over	O
the	O
past	O
50	O
years	O
[	O
34	O
].	O

Top	O
-	O
ranked	O
ES	O
descriptors	O
as	O
important	O
structural	O
modifications	O
around	O
ligand	O
binding	O

Table	O
2	O
lists	O
the	O
12	O
top	O
-	O
ranked	O
ES	O
descriptors	O
for	O
the	O
46	O
TZD	O
PPARγ	B-GP
agonists	O
after	O
the	O
conduct	O
of	O
prioritization	O
in	O
the	O
second	O
tandem	O
detector	O
.	O

Table	O
3	O
lists	O
the	O
12	O
top	O
-	O
ranked	O
ES	O
descriptors	O
for	O
the	O
178	O
carboxylic	B-CD
acid	O
PPARγ	B-GP
agonists	O
.	O

Table	O
4	O
,	O
which	O
is	O
the	O
merger	O
of	O
the	O
two	O
former	O
sets	O
,	O
lists	O
the	O
12	O
top	O
-	O
ranked	O
ES	O
descriptors	O
for	O
the	O
224	O
PPARγ	B-GP
agonists	O
.	O

The	O
striking	O
feature	O
in	O
all	O
three	O
tables	O
is	O
that	O
the	O
ES	O
symbol	O
,	O
ssO	O
,	O
ranks	O
in	O
the	O
first	O
position	O
.	O
‘	O
s	O
’	O
indicates	O
a	O
single	O
bond	O
.	O
‘	O
ss	O
’	O
indicates	O
two	O
single	O
bonds	O
linked	O
in	O
structure	O
.	O

This	O
feature	O
reflects	O
a	O
key	O
interaction	O
between	O
potent	O
agonist	O
and	O
PPARγ	B-GP
receptors	I-GP
,	O
which	O
shows	O
concurrence	O
with	O
the	O
inference	O
of	O
the	O
X	O
-	O
ray	O
crystallography	O
depicted	O
in	O
the	O
next	O
section	O
.	O

The	O
top	O
-	O
ranked	O
ES	O
descriptors	O
of	O
46	O
TZD	O
PPARγ	B-GP
agonists	O

ES	O
descriptors	O

Rank	O

Sign	O
of	O
βES	O

Count_ssO	O

1	O

-	O

Sum_ssO	O

2	O

-	O

Sum_sssN	O

3	O

+	O

Count_sssN	O

4	O

+	O

Count_ssCH2	O

5	O

+	O

Sum_aaO	O

6	O

+	O

Count_aaO	O

7	O

+	O

Count_sCH3	O

8	O

-	O

Sum_aaN	O

9	O

+	O

Count_aaN	O

10	O

+	O

Count_dsCH	O

11	O

-	O

Sum_dsCH	O

12	O

-	O

The	O
top	O
-	O
ranked	O
ES	O
descriptors	O
of	O
178	O
carboxylic	O
acid	O
PPARγ	B-GP
agonists	O

ES	O
descriptors	O

Rank	O

Sign	O
of	O
βES	O

Sum_ssO	O

1	O

-	O

Count_ssO	O

2	O

-	O

Sum_aaO	O

3	O

+	O

Count_aaO	O

4	O

+	O

Count_aaaC	O

5	O

+	O

Sum_ssCH2	O

6	O

-	O

Count_aaaC	O

7	O

+	O

Count_ssCH2	O

8	O

-	O

Count_aaNH	O

9	O

+	O

Sum_aaNH	O

10	O

+	O

Count_ssssC	O

11	O

-	O

Sum_sssN	O

12	O

+	O

The	O
top	O
-	O
ranked	O
ES	O
descriptors	O
of	O
224	O
PPARγ	B-GP
agonists	O
with	O
both	O
TZD	O
and	O
carboxylic	B-CD
acid	O
cores	O

ES	O
descriptors	O

Rank	O

Sign	O
of	O
βES	O

Count_ssO	O

1	O

-	O

Sum_ssO	O

2	O

-	O

Sum_aaO	O

3	O

+	O

Count_aaO	O

4	O

+	O

Sum_aaaC	O

5	O

+	O

Count_aaaC	O

6	O

+	O

Count_sssN	O

7	O

+	O

Sum_sssN	O

8	O

+	O

Count_aaNH	O

9	O

+	O

Sum_aaNH	O

10	O

+	O

Sum_aaN	O

11	O

+	O

Count_aaN	O

12	O

+	O

To	O
begin	O
with	O
,	O
in	O
Table	O
2	O
,	O
the	O
ES_Count_ssO	O
and	O
ES_Sum_ssO	O
rank	O
in	O
most	O
top	O
positions	O
with	O
a	O
negative	O
regression	O
coefficient	O
.	O

Basically	O
,	O
this	O
is	O
a	O
negative	O
structural	O
modification	O
with	O
respect	O
to	O
cellular	O
reaction	O
.	O

But	O
care	O
should	O
be	O
taken	O
here	O
:	O
this	O
does	O
not	O
mean	O
that	O
the	O
existence	O
of	O
ssO	O
moiety	O
in	O
the	O
structure	O
is	O
bad	O
.	O

On	O
the	O
contrary	O
,	O
the	O
existence	O
of	O
single	O
ssO	O
moiety	O
is	O
extremely	O
good	O
.	O

(	O
We	O
can	O
read	O
this	O
from	O
the	O
most	O
potent	O
leads	O
which	O
all	O
have	O
tyrosine	B-CD
moiety	O
.)	O
When	O
examining	O
the	O
original	O
data	O
,	O
each	O
collected	O
TZD	O
PPARγ	B-GP
agonist	O
has	O
at	O
least	O
one	O
ssO	O
moiety	O
in	O
the	O
structure	O
,	O
here	O
known	O
as	O
an	O
oxygen	O
atom	O
in	O
tyrosine	B-CD
moiety	O
.	O

The	O
correct	O
interpretation	O
for	O
the	O
sign	O
of	O
such	O
a	O
symbol	O
here	O
therefore	O
is	O
that	O
the	O
introduction	O
of	O
more	O
than	O
one	O
ssO	O
moiety	O
importantly	O
decreases	O
cellular	O
reaction	O
.	O

Rosiglitazone	B-CD
,	O
an	O
established	O
drug	O
that	O
is	O
one	O
of	O
the	O
collected	O
TZD	O
agonists	O
,	O
shows	O
this	O
corresponding	O
feature	O
with	O
the	O
ES	O
symbol	O
,	O
ssO	O
in	O
Figure	O
1	O
(	O
a	O
).	O

Molecular	O
structures	O
of	O
:	O
(	O
a	O
)	O
Rosiglitzaone	B-CD
with	O
tyrosine	B-CD
moiety	O
(	O
ssO	O
),	O
(	O
b	O
)	O
Rosiglitzaone	B-CD
with	O
tertiary	O
alkylamine	O
moiety	O
(	O
sssN	O
),	O
(	O
c	O
)	O
AD	B-CD
-	O
7075	O
and	O
BRL48482	B-CD
with	O
oxazole	B-CD
moiety	O
(	O
aaO	O
),	O
and	O
(	O
d	O
)	O
Two	O
carboxylic	O
acid	O
agonists	O
with	O
Fmoc	O
-	O
like	O
moiety	O
(	O
aaaC	O
).	O
All	O
moiety	O
structures	O
are	O
colored	O
in	O
blue	O
and	O
the	O
atom	O
of	O
the	O
ES	O
symbol	O
is	O
colored	O
in	O
red	O
.	O

Next	O
,	O
the	O
ES	O
symbol	O
sssN	O
,	O
indicates	O
the	O
introduction	O
of	O
a	O
tertiary	O
amine	O
(	O
sssN	O
)	O
moiety	O
,	O
which	O
is	O
a	O
positive	O
structural	O
modification	O
.	O
‘	O
sss	O
’	O
indicates	O
three	O
single	O
bonds	O
linked	O
in	O
structure	O
.	O

Nine	O
agonists	O
have	O
1	O
sssN	O
moiety	O
of	O
the	O
46	O
collected	O
agonists	O
.	O

The	O
corresponding	O
feature	O
of	O
the	O
ES	O
symbol	O
,	O
sssN	O
,	O
in	O
the	O
tertiary	O
amine	O
(	O
sssN	O
)	O
moiety	O
,	O
is	O
shown	O
in	O
Figure	O
1	O
(	O
b	O
).	O

The	O
next	O
ES	O
symbol	O
in	O
Table	O
2	O
is	O
ssCH2	O
.	O

The	O
positive	O
regression	O
coefficient	O
indicates	O
that	O
the	O
elongation	O
of	O
a	O
ligand	O
structure	O
through	O
the	O
addition	O
of	O
carbon	O
moiety	O
(	O
ssCH2	O
)	O
is	O
a	O
positive	O
structural	O
modification	O
.	O

This	O
topological	O
elongation	O
of	O
the	O
agonist	O
makes	O
a	O
large	O
impact	O
to	O
the	O
molecular	O
binding	O
.	O

However	O
,	O
we	O
notice	O
that	O
the	O
ssCH2	O
symbol	O
is	O
negative	O
in	O
Table	O
3	O
.	O

And	O
,	O
when	O
combining	O
two	O
data	O
sets	O
in	O
Table	O
4	O
,	O
the	O
topological	O
structural	O
modification	O
ssCH2	O
falls	O
out	O
of	O
the	O
monitor	O
table	O
.	O

Apparently	O
,	O
the	O
suitable	O
length	O
of	O
the	O
TZD	O
agonist	O
is	O
optimal	O
for	O
cellular	O
binding	O
.	O

The	O
ES	O
symbol	O
following	O
this	O
in	O
Table	O
2	O
is	O
aaO	O
.	O
‘	O
aa	O
’	O
indicates	O
oxygen	O
atom	O
in	O
an	O
aromatic	O
ring	O
.	O

Throughout	O
the	O
whole	O
46	O
TZD	O
agonists	O
there	O
are	O
only	O
two	O
agonists	O
:	O
AD	B-CD
-	I-CD
7075	I-CD
and	O
BRL48482	B-CD
,	O
in	O
Figure	O
1	O
(	O
c	O
),	O
that	O
have	O
the	O
oxazole	B-CD
moiety	O
.	O

We	O
notice	O
that	O
these	O
two	O
agonists	O
serve	O
as	O
very	O
good	O
examples	O
of	O
“	O
analog	O
outliers	O
”,	O
which	O
bear	O
specific	O
feature	O
of	O
outliers	O
The	O
other	O
ES	O
symbols	O
,	O
aaO	O
,	O
aaN	O
and	O
aaCH	O
,	O
also	O
indicate	O
this	O
oxazole	B-CD
moiety	O
.	O

The	O
5	O
-	O
methyl	O
-	O
oxazole	O
of	O
AD	B-CD
-	I-CD
7075	I-CD
has	O
the	O
additional	O
symbols	O
aasC	O
and	O
sCH3	O
whereas	O
the	O
benzo	O
-	O
oxazole	O
of	O
BRL48482	B-CD
has	O
the	O
additional	O
symbol	O
aaaC	O
.	O

Taken	O
together	O
,	O
the	O
significance	O
of	O
oxazole	B-CD
moieties	O
are	O
faithfully	O
pointed	O
out	O
by	O
these	O
symbols	O
.	O

The	O
other	O
monitored	O
symbols	O
,	O
sCH3	O
and	O
dsCH	O
,	O
indicate	O
other	O
,	O
less	O
important	O
,	O
structural	O
modifications	O
.	O

Lastly	O
,	O
in	O
Table	O
3	O
and	O
Table	O
4	O
,	O
we	O
find	O
a	O
similar	O
picture	O
regarding	O
the	O
potency	O
order	O
of	O
structural	O
modifications	O
.	O

The	O
top	O
ES	O
symbol	O
,	O
ssO	O
,	O
represents	O
the	O
most	O
important	O
structural	O
modification	O
,	O
tyrosine	B-CD
moiety	O
,	O
performed	O
on	O
the	O
middle	O
part	O
of	O
PPARγ	B-GP
agonist	O
.	O

The	O
rest	O
of	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
represent	O
important	O
structural	O
modifications	O
done	O
to	O
the	O
tail	O
part	O
.	O

For	O
example	O
,	O
a	O
fmoc	O
-	O
like	O
moiety	O
(	O
fluorenylmethyloxycarbonyl	O
-	O
like	O
),	O
other	O
than	O
oxazole	B-CD
moiety	O
and	O
tertiary	O
amine	O
,	O
is	O
another	O
case	O
which	O
has	O
an	O
ES	O
symbol	O
of	O
significance	O
:	O
aaaC	O
.	O

Again	O
,	O
serving	O
as	O
analog	O
outliers	O
,	O
these	O
two	O
potent	O
agonists	O
[	O
18	O
]	O
are	O
shown	O
in	O
Figure	O
1	O
(	O
d	O
).	O

There	O
is	O
one	O
more	O
observation	O
:	O
we	O
can	O
clearly	O
see	O
that	O
no	O
ES	O
symbol	O
regarding	O
TZD	O
moieties	O
,	O
dssC	O
,	O
dO	O
,	O
sssCH	O
,	O
ssNH	O
,	O
or	O
ssS	O
,	O
appears	O
in	O
Table	O
2	O
;	O
and	O
we	O
can	O
also	O
see	O
that	O
no	O
carboxylic	B-CD
acid	I-CD
symbols	O
,	O
such	O
as	O
dssC	O
,	O
dO	O
,	O
or	O
sOH	O
,	O
appear	O
in	O
Table	O
3	O
.	O
‘	O
d	O
’	O
indicates	O
double	O
bond	O
.	O

When	O
combining	O
the	O
two	O
data	O
sets	O
,	O
no	O
ES	O
symbols	O
regarding	O
TZD	O
or	O
carboxylic	O
acid	O
appear	O
in	O
Table	O
4	O
.	O

There	O
are	O
two	O
simple	O
interpretations	O
of	O
this	O
:	O
1	O
,	O
the	O
lack	O
of	O
modification	O
of	O
the	O
core	O
part	O
of	O
analogs	O
in	O
a	O
given	O
set	O
will	O
naturally	O
lead	O
to	O
no	O
ES	O
symbols	O
monitored	O
in	O
the	O
table	O
,	O
and	O
2	O
,	O
a	O
core	O
shift	O
in	O
the	O
combined	O
set	O
without	O
causing	O
a	O
large	O
difference	O
of	O
reaction	O
will	O
not	O
produce	O
related	O
ES	O
symbols	O
of	O
significance	O
.	O

Thus	O
,	O
in	O
conclusion	O
,	O
the	O
TZD	O
and	O
carboxylic	O
acid	O
are	O
known	O
as	O
the	O
necessary	O
parts	O
of	O
full	O
PPARγ	B-GP
agonists	O
without	O
synthetic	O
modifications	O
.	O

The	O
necessity	O
of	O
two	O
essential	O
cores	O
for	O
full	O
cellular	O
activity	O
can	O
be	O
immediately	O
inferred	O
when	O
comparing	O
the	O
inactive	O
compounds	O
at	O
initial	O
synthesis	O
.	O

The	O
top	O
-	O
ranked	O
ES	O
symbols	O
point	O
out	O
key	O
ligand	O
binding	O
interactions	O

As	O
mentioned	O
in	O
the	O
introduction	O
,	O
we	O
would	O
like	O
to	O
see	O
if	O
the	O
top	O
-	O
ranked	O
ES	O
descriptor	O
finds	O
its	O
corresponding	O
key	O
interactions	O
for	O
molecular	O
binding	O
.	O

In	O
this	O
section	O
we	O
examine	O
real	O
physical	O
pictures	O
.	O

First	O
,	O
in	O
Table	O
2	O
,	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
are	O
ssO	O
and	O
sssN	O
.	O

We	O
can	O
go	O
to	O
the	O
crystallographic	O
image	O
of	O
the	O
rosiglitazone	B-CD
-	O
PPARγ	B-GP
complex	O
(	O
PDB	O
code	O
:	O
2PRG	O
)	O
[	O
35	O
].	O

Figure	O
2	O
shows	O
,	O
around	O
the	O
bound	O
structure	O
of	O
rosiglitazone	B-CD
,	O
that	O
the	O
ES	O
symbol	O
ssO	O
can	O
detect	O
the	O
key	O
interaction	O
between	O
rosiglitazone	B-CD
ether	O
oxygen	O
and	O
two	O
sulfurs	O
of	O
Cys285	O
(	O
3	O
.	O
79	O
Å	O
)	O
and	O
Met364	O
(	O
4	O
.	O
70	O
Å	O
).	O

Another	O
important	O
ES	O
symbol	O
,	O
sssN	O
,	O
detects	O
the	O
key	O
interaction	O
between	O
rosiglitazone	B-CD
tertiary	O
amine	O
nitrogen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
4	O
.	O
44	O
Å	O
),	O
or	O
Leu340	O
backbone	O
oxygen	O
(	O
4	O
.	O
46	O
Å	O
).	O

We	O
noticed	O
that	O
all	O
the	O
measured	O
distances	O
are	O
between	O
relevant	O
heavy	O
atoms	O
because	O
hydrogen	O
is	O
transparent	O
in	O
X	O
-	O
ray	O
crystallography	O
.	O

Illustration	O
of	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
,	O
ssO	O
and	O
sssN	O
.	O
Around	O
the	O
bound	O
structure	O
of	O
rosiglitazone	B-CD
(	O
PDB	O
:	O
2PRG	O
),	O
the	O
ES	O
symbol	O
ssO	O
can	O
detect	O
the	O
key	O
interaction	O
between	O
rosiglitazone	B-CD
ether	O
oxygen	O
and	O
the	O
two	O
sulfurs	O
of	O
Cys285	O
(	O
3	O
.	O
79	O
Å	O
)	O
and	O
Met364	O
(	O
4	O
.	O
70	O
Å	O
).	O

Another	O
important	O
ES	O
symbol	O
,	O
sssN	O
,	O
detects	O
the	O
key	O
interaction	O
between	O
rosiglitazone	B-CD
trialkylamine	B-CD
nitrogen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
4	O
.	O
44	O
Å	O
),	O
or	O
Leu340	O
backbone	O
oxygen	O
(	O
4	O
.	O
46	O
Å	O
).	O

Notice	O
that	O
all	O
the	O
measured	O
distances	O
are	O
between	O
relevant	O
heavy	O
atoms	O
because	O
hydrogen	O
is	O
transparent	O
in	O
the	O
X	O
-	O
ray	O
crystallography	O
.	O

Second	O
,	O
in	O
Table	O
3	O
,	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
are	O
ssO	O
and	O
aaO	O
.	O

We	O
then	O
look	O
at	O
the	O
crystallographic	O
image	O
of	O
the	O
1K74	O
ligand	O
-	O
PPARγ	B-GP
complex	O
(	O
PDB	O
code	O
:	O
1K47	O
)	O
[	O
36	O
].	O

Figure	O
3	O
shows	O
that	O
,	O
around	O
the	O
bound	O
structure	O
of	O
the	O
1K47	O
ligand	O
,	O
a	O
important	O
ES	O
symbol	O
,	O
ssO	O
,	O
can	O
detect	O
the	O
key	O
interaction	O
between	O
1K74	O
ligand	O
ether	O
oxygen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
3	O
.	O
63	O
Å	O
)	O
or	O
Met364	O
sulfur	O
(	O
4	O
.	O
87	O
Å	O
).	O

Another	O
important	O
ES	O
symbol	O
,	O
aaO	O
,	O
detects	O
the	O
key	O
interactions	O
between	O
1K74	O
ligand	O
oxazole	O
oxygen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
3	O
.	O
61	O
Å	O
).	O

Here	O
we	O
also	O
measured	O
the	O
distance	O
(	O
4	O
.	O
95	O
Å	O
)	O
between	O
oxazole	B-CD
nitrogen	O
(	O
aaN	O
)	O
and	O
Leu340	O
backbone	O
oxygen	O
.	O

The	O
symbol	O
,	O
aaN	O
,	O
as	O
a	O
important	O
structural	O
modification	O
of	O
the	O
tail	O
part	O
,	O
is	O
indicated	O
in	O
Tables	O
2	O
and	O
4	O
.	O

More	O
ES	O
symbols	O
regarding	O
the	O
tail	O
part	O
modifications	O
of	O
PPARγ	B-GP
agonists	O
,	O
as	O
mentioned	O
above	O
,	O
can	O
also	O
detect	O
their	O
corresponding	O
key	O
interactions	O
in	O
other	O
crystallographic	O
images	O
of	O
potent	O
PPARγ	B-GP
agonists	O
.	O

Illustration	O
of	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
ssO	O
,	O
aaO	O
,	O
and	O
aaN	O
.	O
Around	O
a	O
bound	O
structure	O
of	O
1K47	O
ligand	O
(	O
PDB	O
:	O
1k47	O
),	O
the	O
important	O
ES	O
symbol	O
ssO	O
can	O
detect	O
the	O
key	O
interaction	O
between	O
1K74	O
ligand	O
ether	O
oxygen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
3	O
.	O
63	O
Å	O
)	O
or	O
Met364	O
sulfur	O
(	O
4	O
.	O
87	O
Å	O
).	O

Another	O
key	O
ES	O
symbol	O
,	O
aaO	O
,	O
detects	O
the	O
key	O
interactions	O
between	O
1K74	O
ligand	O
oxazole	O
oxygen	O
and	O
Cys285	O
side	O
-	O
chain	O
sulfur	O
(	O
3	O
.	O
61	O
Å	O
).	O

Here	O
we	O
also	O
measured	O
the	O
distance	O
(	O
4	O
.	O
95	O
Å	O
)	O
between	O
oxazole	B-CD
nitrogen	O
(	O
aaN	O
)	O
and	O
Leu340	O
backbone	O
oxygen	O
.	O

Taken	O
together	O
,	O
these	O
correspondences	O
clearly	O
point	O
out	O
that	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
are	O
the	O
key	O
structural	O
modifications	O
surrounding	O
molecular	O
binding	O
.	O

Discussion	O

Jurs_RNCG	O
as	O
a	O
filter	O

The	O
descriptor	O
Jurs_RNCG	O
acts	O
as	O
a	O
filter	O
.	O

One	O
might	O
expect	O
to	O
see	O
some	O
outcomes	O
if	O
the	O
single	O
Jurs_RNCG	O
descriptor	O
is	O
not	O
included	O
,	O
i	O
.	O
e	O
.	O
there	O
is	O
no	O
first	O
filter	O
of	O
this	O
tandem	O
technique	O
.	O

Apparently	O
,	O
all	O
general	O
effects	O
will	O
contribute	O
to	O
the	O
top	O
-	O
ranked	O
ES	O
descriptor	O
.	O

In	O
Additional	O
file	O
1	O
:	O
Table	O
S3	O
,	O
for	O
example	O
,	O
the	O
top	O
-	O
ranked	O
ES	O
symbol	O
,	O
ssO	B-GP
,	O
tyrosine	B-CD
moiety	O
,	O
of	O
PPARγ	B-GP
agonists	O
,	O
falls	O
outside	O
the	O
monitor	O
table	O
.	O

In	O
other	O
words	O
,	O
we	O
need	O
a	O
descriptor	O
in	O
the	O
first	O
regression	O
that	O
can	O
effectively	O
remove	O
the	O
general	O
effect	O
of	O
a	O
ligand	O
cellular	O
system	O
.	O

As	O
mentioned	O
above	O
,	O
one	O
purpose	O
for	O
using	O
Jurs_RNCG	O
is	O
to	O
leave	O
outliers	O
for	O
the	O
second	O
part	O
.	O

Moreover	O
,	O
the	O
potency	O
orders	O
and	O
tendencies	O
(	O
signs	O
of	O
regression	O
coefficients	O
)	O
of	O
structural	O
modifications	O
coincide	O
with	O
our	O
knowledge	O
about	O
the	O
structural	O
modifications	O
of	O
PPARγ	B-GP
agonists	O
.	O

So	O
the	O
top	O
-	O
ranked	O
structural	O
modifications	O
can	O
detect	O
their	O
corresponding	O
key	O
interactions	O
surrounding	O
molecular	O
binding	O
,	O
as	O
shown	O
in	O
the	O
X	O
-	O
ray	O
image	O
of	O
a	O
potent	O
agonist	O
-	O
PPARγ	B-GP
complex	O
.	O

The	O
outcomes	O
of	O
such	O
a	O
regression	O
-	O
outlier	O
analysis	O
also	O
tell	O
us	O
that	O
the	O
Jurs_RNCG	O
is	O
truly	O
an	O
adequate	O
filter	O
.	O

In	O
addition	O
,	O
and	O
exceeding	O
our	O
expectations	O
,	O
the	O
Jurs_RNCG	O
can	O
be	O
expressed	O
in	O
a	O
linear	O
combination	O
of	O
partition	O
coefficients	O
,	O
polar	O
surface	O
area	O
,	O
and	O
shape	O
-	O
like	O
descriptors	O
[	O
33	O
],	O
which	O
further	O
reveals	O
three	O
essential	O
factors	O
for	O
drug	O
-	O
cell	O
interfaces	O
in	O
such	O
a	O
ligand	O
cellular	O
system	O
[	O
34	O
].	O

Three	O
types	O
of	O
dependency	O
in	O
the	O
top	O
-	O
ranked	O
ES	O
descriptors	O

For	O
a	O
closer	O
inspection	O
of	O
the	O
top	O
-	O
ranked	O
ES	O
descriptors	O
,	O
the	O
ES	O
symbols	O
from	O
Table	O
2	O
were	O
intentionally	O
combined	O
in	O
a	O
single	O
fitting	O
equation	O
.	O

Three	O
fitting	O
equations	O
are	O
listed	O
in	O
Table	O
5	O
.	O

First	O
,	O
in	O
Equation	O
1	O
of	O
Table	O
5	O
,	O
the	O
ES	O
symbol	O
Sum_ssO	O
,	O
has	O
a	O
positive	O
regression	O
coefficient	O
opposite	O
to	O
the	O
sign	O
presented	O
in	O
Table	O
2	O
.	O

In	O
Equation	O
2	O
,	O
the	O
symbol	O
Count_sssN	O
,	O
has	O
a	O
negative	O
regression	O
coefficient	O
opposite	O
to	O
the	O
sign	O
provided	O
in	O
Table	O
2	O
.	O

At	O
the	O
same	O
time	O
,	O
we	O
noticed	O
that	O
the	O
correlation	O
(	O
r	O
)	O
between	O
Count_ssO	O
and	O
Sum_ssO	O
in	O
this	O
46	O
TZD	O
data	O
set	O
is	O
+	O
0	O
.	O
98	O
and	O
the	O
correlation	O
(	O
r	O
)	O
between	O
Count_sssN	O
and	O
Sum_sssN	O
is	O
+	O
0	O
.	O
99	O
;	O
i	O
.	O
e	O
.,	O
they	O
have	O
extremely	O
significant	O
positive	O
correlations	O
.	O

In	O
the	O
interest	O
of	O
realistic	O
representation	O
,	O
it	O
is	O
impossible	O
that	O
an	O
identical	O
important	O
structural	O
modification	O
be	O
represented	O
by	O
two	O
highly	O
positive	O
-	O
correlated	O
descriptors	O
indicating	O
different	O
tendencies	O
.	O

However	O
,	O
the	O
fitting	O
regression	O
coefficient	O
resulting	O
in	O
the	O
different	O
signs	O
in	O
these	O
2	O
equations	O
is	O
obvious	O
.	O

Therefore	O
,	O
the	O
Count_ssO	O
and	O
Sum_ssO	O
(	O
or	O
,	O
the	O
Count_sssN	O
and	O
Sum_sssN	O
)	O
have	O
a	O
dependency	O
of	O
description	O
on	O
identical	O
structural	O
modification	O
.	O

The	O
ES	O
symbols	O
monitored	O
in	O
the	O
Table2are	O
intentionally	O
combined	O
in	O
a	O
single	O
fitting	O
equation	O

#	O

Equation	O

1	O

Y	O
=	O
4	O
.	O
97	O
−	O
20	O
.	O
8Jurs	O
_	O
RNCG	O
−	O
2	O
.	O
81	O
Count	O
_	O
ssO	O
+	O
0	O
.	O
38	O
Sum	O
_	O
ssO	O
*	O

2	O

Y	O
=	O
3	O
.	O
41	O
−	O
4	O
.	O
50	O
Jurs_RNCG	O
−	O
3	O
.	O
09	O
Count_ssO	O
+	O
0	O
.	O
47	O
Sum_ssO	O
*	O
+	O
0	O
.	O
95	O
Sum_sssN	O
−	O
0	O
.	O
86	O
Count_ssN	O
*	O

3	O

Y	O
=	O
3	O
.	O
34	O
−	O
11	O
.	O
1	O
Jurs_RNCG	O
−	O
0	O
.	O
33	O
Count_ssO	O
+	O
0	O
.	O
31Count_sssN	O
+	O
0	O
.	O
47	O
Count_aaO	O
−	O
0	O
.	O
33	O
Count_sCH3	O
−	O
0	O
.	O
079	O
Count_aaN	O
*	O

*	O
The	O
coefficient	O
signs	O
of	O
these	O
ES	O
symbols	O
labeled	O
with	O
star	O
signs	O
(*)	O
contradict	O
the	O
ones	O
presented	O
in	O
Table	O
2	O
.	O

Three	O
fitting	O
equations	O
with	O
signs	O
of	O
regression	O
coefficients	O
are	O
presented	O
.	O

Second	O
,	O
by	O
removing	O
the	O
modification	O
description	O
dependency	O
,	O
the	O
Count	O
and	O
Sum	O
values	O
of	O
the	O
same	O
ES	O
symbol	O
are	O
not	O
in	O
the	O
same	O
equation	O
.	O

In	O
Equation	O
3	O
of	O
Table	O
5	O
,	O
the	O
symbol	O
Count_aaN	O
has	O
a	O
negative	O
regression	O
coefficient	O
compared	O
to	O
the	O
sign	O
listed	O
in	O
Table	O
2	O
.	O

It	O
therefore	O
contradicts	O
the	O
observation	O
that	O
the	O
captured	O
symbols	O
,	O
aaO	O
,	O
aaaC	O
,	O
sssN	O
,	O
aaNH	O
,	O
and	O
aaN	O
,	O
represent	O
positive	O
structural	O
modifications	O
to	O
the	O
tail	O
part	O
of	O
PPARγ	B-GP
agonists	O
.	O

Obviously	O
,	O
in	O
this	O
equation	O
form	O
3	O
,	O
the	O
symbols	O
aaO	O
and	O
sssN	O
represent	O
the	O
identical	O
key	O
interaction	O
in	O
the	O
tail	O
part	O
of	O
PPARγ	B-GP
agonists	O
,	O
and	O
the	O
simultaneous	O
appearance	O
of	O
them	O
for	O
the	O
same	O
moiety	O
turned	O
the	O
regression	O
coefficient	O
of	O
the	O
additional	O
aaN	O
into	O
the	O
opposite	O
sign	O
.	O

Thus	O
,	O
one	O
can	O
say	O
here	O
that	O
the	O
ES	O
symbols	O
aaN	O
,	O
aaO	O
and	O
sssN	O
have	O
dependency	O
of	O
description	O
on	O
the	O
identical	O
moiety	O
.	O

Third	O
,	O
throughout	O
all	O
of	O
the	O
46	O
TZD	O
PPARγ	B-GP
agonists	O
,	O
when	O
examining	O
the	O
values	O
of	O
the	O
symbol	O
aaO	O
and	O
related	O
structural	O
moieties	O
,	O
we	O
found	O
that	O
no	O
structural	O
moiety	O
contains	O
this	O
aaO	O
feature	O
aside	O
for	O
oxazole	B-CD
.	O

The	O
moiety	O
oxazole	B-CD
exists	O
only	O
in	O
the	O
two	O
potent	O
agonists	O
AD	B-CD
-	I-CD
7057	I-CD
and	O
BRL48482	B-CD
[	O
10	O
].	O

The	O
value	O
of	O
ES_Count_aaO	O
is	O
1	O
for	O
these	O
2	O
agonists	O
whereas	O
the	O
value	O
is	O
0	O
for	O
the	O
rest	O
of	O
collected	O
PPARγ	B-GP
agonists	O
.	O

The	O
ES	O
symbols	O
of	O
oxazole	B-CD
have	O
aaO	O
,	O
aaN	O
,	O
and	O
aaCH	O
.	O

Four	O
agonists	O
have	O
the	O
aaN	O
structural	O
moiety	O
of	O
these	O
46	O
collected	O
agonists	O
and	O
,	O
among	O
those	O
four	O
,	O
two	O
compounds	O
are	O
AD	B-CD
-	I-CD
7057	I-CD
and	O
BRL48482	B-CD
.	O

Moreover	O
,	O
all	O
agonists	O
have	O
the	O
aaCH	B-GP
structural	O
moiety	O
,	O
but	O
the	O
symbol	O
aaCH	B-GP
does	O
not	O
appear	O
in	O
Table	O
2	O
.	O

Clearly	O
,	O
the	O
symbols	O
aaO	O
,	O
aaN	O
and	O
aaCH	O
have	O
unequal	O
dependencies	O
of	O
description	O
in	O
these	O
data	O
samples	O
.	O

Especially	O
,	O
these	O
dependencies	O
of	O
descriptor	O
will	O
actually	O
cause	O
serious	O
consequence	O
to	O
all	O
QSARs	O
of	O
four	O
categories	O
(	O
classical	O
,	O
3	O
-	O
dimensional	O
,	O
decisional	O
and	O
orthogonal	O
)	O
[	O
37	O
-	O
39	O
],	O
their	O
existence	O
would	O
make	O
a	O
model	O
lose	O
its	O
interpretability	O
.	O

Put	O
together	O
,	O
the	O
three	O
types	O
of	O
dependencies	O
in	O
the	O
top	O
-	O
ranked	O
ES	O
symbols	O
actually	O
play	O
a	O
major	O
role	O
in	O
the	O
design	O
of	O
the	O
context	O
equation	O
.	O

That	O
is	O
,	O
two	O
ES	O
symbols	O
don	O
’	O
t	O
appear	O
simultaneously	O
in	O
a	O
context	O
equation	O
.	O

Obviously	O
,	O
if	O
one	O
forces	O
two	O
dependent	O
ES	O
descriptors	O
to	O
be	O
combined	O
in	O
a	O
single	O
equation	O
,	O
the	O
signs	O
in	O
the	O
regression	O
coefficients	O
of	O
key	O
structural	O
modifications	O
may	O
change	O
,	O
and	O
thus	O
fail	O
to	O
point	O
out	O
the	O
real	O
tendency	O
of	O
impact	O
to	O
ligand	O
binding	O
in	O
an	O
analog	O
set	O
.	O

If	O
one	O
mixes	O
two	O
ES	O
descriptors	O
in	O
a	O
single	O
equation	O
acting	O
as	O
a	O
detector	O
,	O
the	O
one	O
in	O
this	O
regression	O
-	O
outlier	O
analysis	O
will	O
lose	O
its	O
ability	O
to	O
correctly	O
detect	O
the	O
real	O
tendencies	O
of	O
key	O
structural	O
modifications	O
in	O
the	O
given	O
analog	O
sets	O
.	O

Conclusions	O

The	O
innovative	O
point	O
of	O
the	O
present	O
study	O
is	O
the	O
fact	O
that	O
we	O
used	O
a	O
statistical	O
regression	O
and	O
its	O
outlier	O
as	O
a	O
computational	O
technique	O
for	O
separation	O
.	O

This	O
technique	O
was	O
used	O
specifically	O
in	O
the	O
ligand	O
cellular	O
system	O
.	O

As	O
a	O
counterpart	O
to	O
the	O
hard	O
equipment	O
in	O
the	O
tandem	O
technique	O
,	O
the	O
prior	O
molecular	O
descriptor	O
resembles	O
a	O
filter	O
that	O
removes	O
the	O
influence	O
from	O
the	O
bulk	O
of	O
a	O
cell	O
and	O
the	O
latter	O
class	O
of	O
descriptors	O
is	O
an	O
array	O
of	O
detectors	O
that	O
can	O
identify	O
any	O
important	O
identities	O
.	O

In	O
the	O
case	O
of	O
the	O
PPARγ	B-GP
agonist	O
cellular	O
system	O
,	O
the	O
key	O
structural	O
modifications	O
surrounding	O
ligand	O
binding	O
were	O
successfully	O
detected	O
and	O
the	O
tendencies	O
of	O
impact	O
were	O
examined	O
.	O

In	O
the	O
end	O
,	O
after	O
the	O
tandem	O
regression	O
-	O
outlier	O
analysis	O
of	O
this	O
ligand	O
cellular	O
system	O
,	O
the	O
results	O
show	O
that	O
this	O
prioritization	O
of	O
the	O
context	O
equations	O
(	O
filter	O
)	O
tagged	O
with	O
features	O
of	O
outliers	O
(	O
detector	O
)	O
is	O
an	O
effective	O
computational	O
tool	O
for	O
cheminformatics	O
to	O
detect	O
possible	O
features	O
of	O
outliers	O
(	O
key	O
structural	O
modifications	O
),	O
as	O
well	O
as	O
their	O
impact	O
tendencies	O
to	O
ligand	O
binding	O
.	O

Competing	O
interests	O

The	O
author	O
declares	O
that	O
he	O
has	O
no	O
competing	O
interests	O
.	O

Supplementary	O
Material	O

Additional	O
file	O
1	O
:	O
Table	O
S1	O

Lists	O
the	O
structures	O
of	O
the	O
TZD	O
PPARγ	B-GP
agonists	O
with	O
their	O
activities	O
.	O

All	O
images	O
of	O
molecular	O
structures	O
were	O
created	O
by	O
using	O
Pybel	O
[	O
29	O
,	O
30	O
].	O
Table	O
S2	O
lists	O
the	O
structures	O
of	O
the	O
Carboxylic	O
(	O
COOH	O
)	O
PPARγ	B-GP
agonists	O
with	O
their	O
activities	O
.	O

All	O
images	O
of	O
molecular	O
structures	O
were	O
created	O
by	O
using	O
Pybel	O
[	O
29	O
,	O
30	O
].	O
Table	O
S3	O
lists	O
the	O
top	O
-	O
ranked	O
ES	O
descriptors	O
of	O
178	O
carboxylic	B-CD
acid	I-CD
PPARγ	B-GP
agonists	O
against	O
cellular	O
reactions	O
,	O
without	O
the	O
inclusion	O
of	O
Jurs_RNCG	O
.	O

Click	O
here	O
for	O
file	O

Tuberculosis	B-DS
treatment	O
outcomes	O
of	O
six	O
and	O
eight	O
month	O
treatment	O
regimens	O
in	O
districts	O
of	O
Southwestern	O
Ethiopia	O
:	O
a	O
comparative	O
cross	O
-	O
sectional	O
study	O

Background	O

A	O
switch	O
of	O
continuation	O
phase	O
tuberculosis	B-DS
(	O
TB	B-DS
)	O
treatment	O
regimen	O
from	O
Ethambutol	B-CD
(	O
E	O
)	O
and	O
Isoniazid	B-CD
(	O
H	O
)	O
combination	O
for	O
6	O
months	O
(	O
6EH	O
)	O
to	O
Rifampicin	B-CD
(	O
R	O
)	O
and	O
Isoniazid	B-CD
(	O
H	O
)	O
combination	O
for	O
4	O
months	O
(	O
4RH	O
)	O
was	O
recommended	O
.	O

However	O
,	O
the	O
effect	O
of	O
the	O
regimen	O
switch	O
in	O
Ethiopian	O
setting	O
is	O
not	O
known	O
.	O

Methods	O

A	O
comparative	O
cross	O
-	O
sectional	O
study	O
among	O
790	O
randomly	O
selected	O
new	O
cases	O
of	O
TB	B-DS
(	O
395	O
each	O
treated	O
with	O
4RH	O
and	O
6EH	O
during	O
the	O
continuation	O
phase	O
)	O
was	O
conducted	O
in	O
nine	O
health	O
centers	O
and	O
one	O
hospital	O
in	O
three	O
zones	O
in	O
southwestern	O
Ethiopia	O
.	O

Data	O
were	O
abstracted	O
from	O
the	O
standard	O
unit	O
TB	B-DS
register	O
composed	O
of	O
standard	O
case	O
and	O
treatment	O
outcome	O
definitions	O
.	O

Data	O
were	O
analyzed	O
using	O
STATA	O
version	O
13	O
where	O
binary	O
logistic	O
regression	O
was	O
fitted	O
to	O
identify	O
independent	O
predictors	O
of	O
unsuccessful	O
treatment	O
outcomes	O
at	O
5	O
%	O
significance	O
level	O
.	O

Results	O

Over	O
all	O
,	O
695	O
(	O
88	O
%)	O
of	O
the	O
patients	O
had	O
a	O
successful	O
treatment	O
outcome	O
with	O
statistically	O
significant	O
difference	O
(	O
85	O
.	O
3	O
%	O
vs	O
90	O
.	O
6	O
%,	O
p	O
=	O
0	O
.	O
02	O
)	O
among	O
the	O
6HE	O
and	O
4RH	O
regimens	O
,	O
respectively	O
.	O

After	O
adjusting	O
for	O
confounders	O
,	O
4RH	O
continuation	O
phase	O
treatment	O
regimen	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
[(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
))	O
0	O
.	O
55	O
(	O
0	O
.	O
34	O
,	O
0	O
.	O
89	O
)],	O
age	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
1	O
.	O
02	O
(	O
1	O
.	O
001	O
,	O
1	O
.	O
022	O
)],	O
rural	O
residence	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
2	O
.	O
1	O
(	O
1	O
.	O
18	O
,	O
3	O
.	O
75	O
)]	O
Human	B-OG
Immunodeficiency	I-OG
virus	I-OG
(	O
HIV	B-OG
)	O
positives	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
2	O
.	O
39	O
(	O
1	O
.	O
12	O
,	O
5	O
.	O
07	O
)]	O
and	O
increased	O
weight	O
at	O
the	O
end	O
of	O
the	O
second	O
month	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
0	O
.	O
28	O
(	O
0	O
.	O
11	O
,	O
0	O
.	O
72	O
)]	O
independently	O
predicted	O
treatment	O
outcome	O
.	O

Conclusion	O

The	O
switch	O
of	O
continuation	O
phase	O
TB	B-DS
treatment	O
regimen	O
from	O
6EH	O
to	O
4RH	O
has	O
brought	O
better	O
treatment	O
outcomes	O
which	O
imply	O
applicability	O
of	O
the	O
recommendation	O
in	O
high	O
prevalent	O
and	O
resource	O
constrained	O
settings	O
.	O

Therefore	O
,	O
it	O
should	O
be	O
maintained	O
and	O
augmented	O
through	O
further	O
studies	O
on	O
its	O
impact	O
among	O
the	O
older	O
,	O
rural	O
residents	O
and	O
HIV	B-OG
positives	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12879	O
-	O
016	O
-	O
1917	O
-	O
0	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

In	O
the	O
history	O
of	O
tuberculosis	B-DS
(	O
TB	B-DS
)	O
control	O
,	O
discovery	O
of	O
chemotherapy	O
[	O
1	O
]	O
brought	O
about	O
dramatic	O
changes	O
in	O
patient	O
survival	O
.	O

Before	O
the	O
advent	O
of	O
chemotherapy	O
,	O
30	O
–	O
40	O
%	O
of	O
TB	B-DS
cases	O
used	O
to	O
die	O
within	O
a	O
year	O
and	O
50	O
–	O
70	O
%	O
within	O
5	O
–	O
7	O
years	O
after	O
the	O
onset	O
of	O
TB	B-DS
illness	O
[	O
2	O
].	O

Introduction	O
of	O
chemotherapy	O
resulted	O
in	O
cure	O
and	O
reduction	O
of	O
mortality	O
for	O
majority	O
of	O
TB	B-DS
cases	O
[	O
1	O
,	O
3	O
].	O

However	O
,	O
shortly	O
after	O
the	O
therapy	O
,	O
resistance	O
to	O
drug	O
and	O
poor	O
adherence	O
by	O
patients	O
were	O
reported	O
[	O
4	O
].	O

Consequently	O
,	O
the	O
first	O
standard	O
combination	O
therapy	O
for	O
12	O
months	O
comprised	O
of	O
Thiacetazone	B-CD
(	O
T	O
),	O
Isoniazid	B-CD
(	O
H	O
)	O
and	O
streptomycin	B-CD
(	O
S	O
)	O
for	O
the	O
first	O
2	O
months	O
(	O
2STH	O
)	O
followed	O
by	O
T	O
and	O
H	O
for	O
10	O
months	O
(	O
10TH	O
)	O
was	O
issued	O
[	O
2	O
].	O

Subsequent	O
to	O
the	O
introduction	O
of	O
rifampicin	B-CD
(	O
R	O
),	O
effective	O
short	O
-	O
course	O
chemotherapy	O
regimens	O
for	O
less	O
than	O
12	O
months	O
became	O
standard	O
therapy	O
[	O
2	O
,	O
5	O
–	O
7	O
].	O

The	O
short	O
-	O
course	O
regimens	O
comprised	O
of	O
an	O
initial	O
,	O
or	O
bactericidal	O
,	O
phase	O
called	O
intensive	O
that	O
aimed	O
to	O
kill	O
bacilli	B-OG
and	O
make	O
patients	O
non	O
infectious	O
and	O
a	O
continuation	O
or	O
sterilizing	O
phase	O
which	O
eliminates	O
persisting	O
mycobacteria	B-OG
to	O
prevent	O
relapse	O
[	O
1	O
,	O
8	O
].	O

Thus	O
evidence	O
based	O
combinations	O
of	O
drugs	O
for	O
different	O
categories	O
of	O
cases	O
have	O
been	O
recommended	O
for	O
the	O
two	O
phases	O
across	O
the	O
different	O
regimens	O
[	O
5	O
–	O
7	O
].	O

Introduction	O
of	O
Rifampicin	B-CD
has	O
shortened	O
TB	B-DS
treatment	O
duration	O
[	O
1	O
,	O
9	O
].	O

In	O
1991	O
,	O
an	O
eight	O
months	O
treatment	O
regimen	O
composed	O
of	O
2	O
months	O
intensive	O
with	O
Isoniazid	B-CD
(	O
H	O
),	O
Rifampicin	B-CD
(	O
R	O
),	O
Pyrazinamide	B-CD
(	O
Z	O
)	O
and	O
Ethambutol	B-CD
(	O
E	O
)	O
(	O
2RHZE	O
/	O
S	O
)	O
and	O
6	O
months	O
continuation	O
(	O
6HE	O
)	O
phases	O
were	O
recommended	O
for	O
all	O
new	O
cases	O
of	O
TB	B-DS
across	O
the	O
world	O
[	O
6	O
].	O

To	O
avoid	O
resistance	O
to	O
the	O
most	O
potent	O
drugs	O
,	O
isoniazid	B-CD
and	O
rifampcin	B-CD
and	O
ensure	O
patient	O
adherence	O
,	O
directly	O
observed	O
treatment	O
short	O
course	O
(	O
DOTS	O
)	O
strategy	O
was	O
launched	O
in	O
1994	O
[	O
10	O
].	O

Later	O
in	O
2003	O
,	O
a	O
directly	O
observed	O
intensive	O
phase	O
treatment	O
followed	O
by	O
two	O
continuation	O
phase	O
regimens	O
,	O
6	O
months	O
of	O
isoniazid	B-CD
plus	O
ethambutol	B-CD
(	O
6HE	O
)	O
or	O
4	O
months	O
of	O
isoniazid	B-CD
plus	O
rifampicin	B-CD
(	O
4HR	O
)	O
were	O
recommended	O
.	O

The	O
4HR	O
continuation	O
phase	O
treatment	O
regimen	O
needed	O
to	O
be	O
observed	O
throughout	O
the	O
treatment	O
period	O
whereas	O
the	O
6EH	O
regimen	O
relied	O
on	O
self	O
administered	O
treatment	O
[	O
5	O
].	O

As	O
a	O
result	O
,	O
regimens	O
without	O
rifampicin	B-CD
had	O
been	O
considered	O
safer	O
in	O
developing	O
countries	O
owing	O
to	O
irregular	O
treatments	O
and	O
high	O
absentee	O
rates	O
[	O
1	O
,	O
5	O
].	O

However	O
,	O
the	O
latest	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
guideline	O
recommends	O
2	O
-	O
month	O
initial	O
phase	O
of	O
(	O
2RHZE	O
)	O
and	O
a	O
4	O
-	O
month	O
continuation	O
phase	O
(	O
4RH	O
)	O
for	O
the	O
treatment	O
of	O
virtually	O
all	O
forms	O
of	O
new	O
TB	B-DS
cases	O
across	O
the	O
globe	O
[	O
7	O
].	O

The	O
government	O
of	O
Ethiopia	O
has	O
adopted	O
the	O
switch	O
of	O
4HR	O
continuation	O
phase	O
TB	B-DS
treatment	O
for	O
all	O
new	O
cases	O
and	O
accommodated	O
in	O
the	O
latest	O
TB	B-DS
treatment	O
guideline	O
[	O
11	O
].	O

Though	O
global	O
strategies	O
are	O
relevant	O
,	O
investigation	O
of	O
the	O
applicability	O
to	O
the	O
local	O
settings	O
is	O
highly	O
required	O
.	O

A	O
continuation	O
phase	O
treatment	O
with	O
4HR	O
regimen	O
elsewhere	O
has	O
demonstrated	O
lower	O
unsuccessful	O
treatment	O
outcomes	O
and	O
costs	O
as	O
compared	O
to	O
6EH	O
continuation	O
phase	O
[	O
12	O
–	O
15	O
].	O

But	O
well	O
designed	O
studies	O
evaluating	O
effects	O
of	O
the	O
introduction	O
of	O
4RH	O
for	O
the	O
continuation	O
phase	O
TB	B-DS
treatment	O
in	O
high	O
TB	B-DS
burden	O
and	O
resource	O
limited	O
settings	O
like	O
Ethiopia	O
are	O
limited	O
.	O

Thus	O
,	O
we	O
compared	O
treatment	O
outcomes	O
of	O
TB	B-DS
cases	O
who	O
received	O
4RH	O
and	O
6EH	O
continuation	O
phase	O
regimens	O
under	O
routine	O
program	O
condition	O
in	O
high	O
burden	O
and	O
resource	O
limited	O
setting	O
.	O

Our	O
objective	O
was	O
to	O
compare	O
baseline	O
patients	O
’	O
bacteriologic	O
,	O
socio	O
-	O
demographics	O
,	O
clinical	O
characteristics	O
and	O
treatment	O
outcomes	O
among	O
those	O
TB	B-DS
patients	O
treated	O
with	O
the	O
4RH	O
and	O
6EH	O
continuation	O
phase	O
treatment	O
regimens	O
.	O

Methods	O

Study	O
setting	O

We	O
conducted	O
this	O
study	O
in	O
ten	O
health	O
facilities	O
(	O
one	O
hospital	O
and	O
nine	O
health	O
centres	O
)	O
in	O
three	O
remote	O
zones	O
of	O
Southern	O
Nation	O
Nationalities	O
and	O
Peoples	O
Region	O
(	O
SNNPR	O
),	O
one	O
of	O
the	O
nine	O
regions	O
in	O
Ethiopia	O
with	O
about	O
18million	O
population	O
[	O
16	O
].	O

Ethiopia	O
is	O
among	O
the	O
22	O
TB	B-DS
High	O
Burden	O
Countries	O
(	O
HBC	O
)	O
where	O
230	O
,	O
000	O
incident	O
cases	O
of	O
which	O
147	O
,	O
592	O
(	O
64	O
%)	O
were	O
notified	O
.	O

In	O
the	O
same	O
year	O
,	O
16100	O
deaths	O
and	O
90	O
%	O
treatment	O
success	O
among	O
the	O
smear	O
positives	O
cases	O
registered	O
in	O
2011	O
were	O
reported	O
[	O
17	O
,	O
18	O
].	O

The	O
country	O
has	O
adopted	O
and	O
implemented	O
the	O
DOTS	O
strategy	O
for	O
the	O
treatment	O
of	O
all	O
forms	O
of	O
TB	B-DS
.	O

Accordingly	O
new	O
cases	O
of	O
TB	B-DS
had	O
been	O
treated	O
with	O
directly	O
observed	O
RHZE	O
combinations	O
for	O
the	O
first	O
2	O
months	O
(	O
2RHZE	O
)	O
followed	O
by	O
self	O
administered	O
EH	O
combinations	O
for	O
six	O
months	O
(	O
6EH	O
)	O
[	O
19	O
].	O

As	O
of	O
the	O
end	O
of	O
2011	O
,	O
the	O
continuation	O
phase	O
treatment	O
was	O
switched	O
from	O
6EH	O
to	O
4RH	O
.	O

Thus	O
the	O
regimen	O
became	O
directly	O
observed	O
2RHZE	O
/	O
4RH	O
combinations	O
for	O
all	O
forms	O
of	O
new	O
TB	B-DS
cases	O
throughout	O
the	O
6	O
months	O
treatment	O
period	O
[	O
11	O
].	O

The	O
three	O
study	O
Zones	O
,	O
Bench	O
Maji	O
,	O
Kaffa	O
and	O
Sheka	O
are	O
located	O
at	O
the	O
southwestern	O
border	O
of	O
the	O
SNNPR	O
where	O
about	O
2	O
,	O
064	O
,	O
102	O
peoples	O
reside	O
[	O
16	O
].	O

The	O
zones	O
(	O
an	O
administrative	O
unit	O
that	O
liaison	O
weredas	O
with	O
the	O
region	O
)	O
are	O
organized	O
in	O
to	O
four	O
town	O
administrations	O
and	O
26	O
weredas	O
(	O
lowest	O
administrative	O
unit	O
closer	O
to	O
the	O
community	O
)	O
those	O
have	O
three	O
hospitals	O
and	O
65	O
health	O
centers	O
those	O
provide	O
TB	O
DOTS	O
services	O
for	O
free	O
.	O

However	O
,	O
the	O
three	O
hospitals	O
and	O
only	O
27	O
health	O
centers	O
were	O
providing	O
TB	B-DS
/	O
Human	B-OG
Immunodeficeincy	I-OG
Virus	I-OG
(	O
HIV	B-OG
)	O
collaborative	O
activities	O
[	O
20	O
].	O

Study	O
design	O
and	O
sampling	O

A	O
comparative	O
cross	O
-	O
sectional	O
study	O
among	O
TB	B-DS
cases	O
treated	O
with	O
2RHZE	O
/	O
6EH	O
and	O
2RHZE	O
/	O
4RH	O
regimens	O
was	O
carried	O
out	O
.	O

New	O
cases	O
registered	O
between	O
2008	O
and	O
2014	O
were	O
eligible	O
of	O
which	O
those	O
aged	O
above	O
15	O
years	O
were	O
studied	O
.	O

Sample	O
size	O
was	O
estimated	O
using	O
the	O
Stat	O
Calc	O
program	O
of	O
Epi	O
Info	O
version	O
7	O
[	O
21	O
]	O
with	O
95	O
%	O
confidence	O
level	O
,	O
80	O
%	O
power	O
and	O
ratio	O
of	O
6EH	O
to	O
4RH	O
(	O
r	O
=	O
1	O
).	O

Accordingly	O
,	O
512	O
cases	O
(	O
256	O
from	O
each	O
group	O
)	O
was	O
required	O
to	O
detect	O
7	O
%	O
difference	O
[	O
12	O
]	O
in	O
the	O
proportion	O
of	O
unsuccessful	O
outcome	O
among	O
the	O
6EH	O
and	O
4RH	O
groups	O
.	O

Finally	O
,	O
considering	O
the	O
design	O
effect	O
of	O
1	O
.	O
5	O
and	O
10	O
%	O
missing	O
records	O
,	O
a	O
total	O
of	O
846	O
cases	O
were	O
required	O
.	O

The	O
samples	O
were	O
selected	O
through	O
proportional	O
allocation	O
to	O
the	O
three	O
zones	O
followed	O
by	O
selection	O
of	O
weredas	O
and	O
health	O
facilities	O
from	O
the	O
zone	O
using	O
probability	O
proportional	O
to	O
size	O
.	O

The	O
allocation	O
and	O
selection	O
was	O
made	O
based	O
on	O
total	O
number	O
of	O
cases	O
reported	O
from	O
the	O
weredas	O
and	O
health	O
facilities	O
during	O
2008	O
through	O
2014	O
.	O

Lastly	O
,	O
cases	O
from	O
the	O
selected	O
health	O
facilities	O
were	O
selected	O
randomly	O
using	O
SPSS	O
statistical	O
software	O
using	O
TB	O
unit	O
number	O
of	O
the	O
cases	O
.	O

Data	O
were	O
extracted	O
from	O
a	O
standard	O
unit	O
TB	O
register	O
recommended	O
by	O
the	O
WHO	O
[	O
11	O
,	O
19	O
,	O
22	O
]	O
using	O
extraction	O
format	O
prepared	O
for	O
the	O
study	O
.	O

Thus	O
patients	O
’	O
baseline	O
attributes	O
(	O
age	O
,	O
gender	O
,	O
residence	O
,	O
sputum	O
smear	O
,	O
type	O
of	O
TB	B-DS
,	O
HIV	B-OG
status	O
)	O
and	O
follow	O
-	O
up	O
measures	O
(	O
sputum	O
smear	O
,	O
weight	O
,	O
drug	O
regimen	O
and	O
treatment	O
outcomes	O
)	O
were	O
extracted	O
.	O

The	O
following	O
standard	O
case	O
and	O
outcome	O
definitions	O
were	O
adopted	O
and	O
used	O
for	O
the	O
study	O
[	O
11	O
,	O
19	O
].	O
New	O
case	O
of	O
TB	B-DS
a	O
patient	O
who	O
never	O
had	O
treatment	O
for	O
TB	B-DS
,	O
or	O
had	O
been	O
on	O
anti	O
-	O
TB	B-DS
treatment	O
for	O
less	O
than	O
four	O
weeks	O
in	O
the	O
past	O
Other	O
cases	O
are	O
those	O
patients	O
who	O
do	O
not	O
fulfill	O
the	O
criteria	O
for	O
new	O
,	O
relapse	O
,	O
and	O
return	O
after	O
default	O
or	O
treatment	O
after	O
failure	O
.	O
Cured	O
:	O
a	O
patient	O
whose	O
sputum	O
smear	O
or	O
culture	O
was	O
positive	O
at	O
the	O
beginning	O
of	O
the	O
treatment	O
but	O
who	O
was	O
smear	O
or	O
culture	O
-	O
negative	O
in	O
the	O
last	O
month	O
of	O
treatment	O
and	O
on	O
at	O
least	O
one	O
previous	O
occasion	O
.	O
Treatment	O
completed	O
:	O
completed	O
treatment	O
but	O
does	O
not	O
have	O
a	O
negative	O
sputum	O
smear	O
or	O
culture	O
result	O
in	O
the	O
last	O
month	O
of	O
treatment	O
and	O
on	O
at	O
least	O
one	O
previous	O
occasion	O
.	O
Treatment	O
failure	O
:	O
a	O
patient	O
whose	O
sputum	O
smear	O
or	O
culture	O
is	O
positive	O
at	O
5	O
months	O
or	O
later	O
during	O
treatment	O
or	O
patients	O
found	O
to	O
harbor	O
Multidrug	O
Resistant	O
(	O
MDR	O
)	O
TB	B-DS
strain	O
at	O
any	O
point	O
of	O
time	O
during	O
the	O
treatment	O
,	O
whether	O
they	O
are	O
smear	O
-	O
negative	O
or	O
-	O
positive	O
.	O
Died	O
:	O
a	O
patient	O
who	O
dies	O
for	O
any	O
reason	O
during	O
the	O
course	O
of	O
TB	B-DS
treatment	O
.	O
Defaulter	O
/	O
loss	O
to	O
follow	O
-	O
up	O
:	O
a	O
patient	O
who	O
has	O
been	O
on	O
treatment	O
for	O
at	O
least	O
4	O
weeks	O
and	O
interrupted	O
treatment	O
for	O
eight	O
or	O
more	O
consecutive	O
weeks	O
.	O
Successful	O
treatment	O
:	O
a	O
treatment	O
that	O
ends	O
up	O
in	O
cure	O
or	O
treatment	O
completion	O
Unsuccessful	O
treatment	O
:	O
a	O
treatment	O
that	O
end	O
up	O
in	O
treatment	O
default	O
or	O
loss	O
to	O
follow	O
up	O
,	O
treatment	O
failure	O
or	O
death	O
.	O

The	O
extracted	O
data	O
were	O
checked	O
for	O
consistency	O
and	O
completeness	O
and	O
entered	O
in	O
to	O
Epinfo	O
version	O
7	O
that	O
later	O
exported	O
to	O
STATA	O
12	O
[	O
23	O
]	O
for	O
analysis	O
.	O

Data	O
were	O
described	O
separately	O
for	O
the	O
two	O
groups	O
(	O
6EH	O
and	O
4RH	O
)	O
using	O
frequencies	O
,	O
mean	O
,	O
standard	O
deviations	O
and	O
tables	O
.	O

Besides	O
,	O
crude	O
comparisons	O
of	O
the	O
baseline	O
and	O
follow	O
up	O
measures	O
among	O
the	O
6EH	O
and	O
4RH	O
groups	O
were	O
made	O
using	O
chi	O
square	O
(	O
x	O
2	O
)	O
or	O
t	O
-	O
tests	O
as	O
appropriate	O
.	O

Subsequently	O
,	O
bivariate	O
and	O
multiple	O
binary	O
logistic	O
regression	O
analysis	O
were	O
made	O
to	O
compute	O
crude	O
and	O
adjusted	O
odds	O
ratios	O
respectively	O
between	O
the	O
explanatory	O
and	O
outcome	O
variables	O
.	O

Multiple	O
logistic	O
regression	O
model	O
was	O
fitted	O
with	O
those	O
variables	O
having	O
p	O
≤	O
0	O
.	O
2	O
on	O
bivariate	O
analysis	O
.	O

Finally	O
,	O
statistical	O
significance	O
was	O
judged	O
at	O
p	O
<	O
0	O
.	O
05	O
and	O
/	O
or	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
of	O
odds	O
ratio	O
(	O
OR	O
)	O
excluding	O
one	O
.	O

Ethical	O
considerations	O

We	O
received	O
ethical	O
approval	O
from	O
the	O
institutional	O
review	O
board	O
of	O
the	O
College	O
of	O
Health	O
Sciences	O
at	O
Addis	O
Ababa	O
University	O
.	O

Accordingly	O
,	O
anonymous	O
patient	O
data	O
were	O
extracted	O
from	O
routine	O
service	O
registry	O
upon	O
permission	O
from	O
the	O
respective	O
institutions	O
.	O

Results	O

Demographic	O
and	O
baseline	O
clinical	O
characteristics	O

We	O
retrieved	O
846	O
patient	O
records	O
of	O
which	O
790	O
(	O
93	O
.	O
4	O
%)	O
with	O
complete	O
outcome	O
records	O
[	O
395	O
each	O
treated	O
with	O
2RHZE	O
/	O
6HE	O
and	O
2RHZE	O
/	O
4RHregimens	O
respectively	O
]	O
were	O
described	O
and	O
analyzed	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
30	O
.	O
8	O
(	O
31	O
.	O
5	O
vs	O
30	O
.	O
9	O
years	O
,	O
p	O
=	O
0	O
.	O

5	O
)	O
respectively	O
,	O
for	O
those	O
treated	O
with	O
6HE	O
and	O
4HR	O
(	O
Table	O
1	O
).	O

More	O
than	O
half	O
,	O
56	O
.	O
6	O
%	O
and	O
55	O
.	O
7	O
%	O
of	O
the	O
patients	O
were	O
male	O
and	O
reside	O
in	O
rural	O
areas	O
,	O
respectively	O
,	O
with	O
no	O
statistically	O
significant	O
difference	O
among	O
the	O
two	O
groups	O
.	O

With	O
regard	O
to	O
the	O
patient	O
profile	O
,	O
86	O
.	O
8	O
%	O
and	O
77	O
%	O
were	O
registered	O
at	O
health	O
center	O
and	O
had	O
pulmonary	B-DS
TB	I-DS
,	O
respectively	O
.	O

Of	O
the	O
patients	O
,	O
765	O
(	O
96	O
.	O
8	O
%)	O
were	O
new	O
cases	O
(	O
378	O
treated	O
with	O
6EH	O
vs387	O
with	O
4RH	O
regimen	O
)	O
and	O
the	O
rest	O
((	O
25	O
(	O
3	O
.	O
2	O
%)	O
(	O
17	O
from	O
6EH	O
vs	O
8	O
from	O
4RH	O
)	O
were	O
transferred	O
in	O
and	O
other	O
cases	O
treated	O
with	O
new	O
case	O
regimen	O
.	O

Human	B-OG
Immunodeficiency	I-OG
virus	I-OG
(	O
HIV	B-OG
)	O
test	O
result	O
was	O
available	O
for	O
612	O
(	O
77	O
.	O
5	O
%)	O
with	O
statistically	O
significant	O
difference	O
among	O
the	O
two	O
groups	O
[	O
283	O
(	O
71	O
.	O
6	O
%)	O
from	O
6EH	O
and	O
329	O
(	O
83	O
.	O
3	O
%)	O
from	O
4RH	O
,	O
p	O
<	O
0	O
.	O
001	O
].	O

Among	O
those	O
tested	O
HIV	B-OG
positives	O
,	O
44	O
(	O
57	O
.	O
1	O
%)	O
received	O
either	O
Cotrimoxazole	B-CD
Prophylactic	O
Therapy	O
(	O
CPT	O
)	O
or	O
Antiretroviral	O
Therapy	O
(	O
ART	O
)	O
with	O
no	O
statistically	O
significant	O
difference	O
among	O
the	O
regimens	O
24	O
(	O
64	O
.	O
9	O
%)	O
from	O
6EH	O
and	O
20	O
(	O
50	O
%),	O
p	O
=	O
0	O
.	O
2	O
.	O
Table	O
1Demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
tuberculosis	B-DS
patients	O
registered	O
between	O
,	O
2008	O
–	O
2014	O
,	O
Southwest	O
EthiopiaVariableContinuation	O
phase	O
treatment	O
regimenTotal	O
P	O
value6EH	O
(	O
n	O
=	O
395	O
)	O
n	O
(%)	O
4RH	O
(	O
n	O
=	O
395	O
)	O
n	O
(%)	O
Age	O
(	O
years	O
)	O
Mean	O
±	O
SDa	O
31	O
.	O
1	O
±	O
12	O
.	O
930	O
.	O
5	O
±	O
11	O
.	O
930	O
.	O
8	O
±	O
12	O
.	O
40	O
.	O
5GenderMale221	O
(	O
55	O
.	O
9	O
)	O
226	O
(	O
57	O
.	O
2	O
)	O
447	O
(	O
56	O
.	O
6	O
)	O
0	O
.	O
7Female174	O
(	O
44	O
.	O
1	O
)	O
169	O
(	O
42	O
.	O
8	O
)	O
343	O
(	O
43	O
.	O
4	O
)	O
ResidenceUrban175	O
(	O
44	O
.	O
3	O
)	O
175	O
(	O
44	O
.	O
3	O
)	O
350	O
(	O
44	O
.	O
3	O
)	O
1Rural220	O
(	O
55	O
.	O
7	O
)	O
220	O
(	O
55	O
.	O
7	O
)	O
440	O
(	O
55	O
.	O
7	O
)	O
ZoneKaffa106	O
(	O
26	O
.	O
8	O
)	O
104	O
(	O
26	O
.	O
3	O
)	O
210	O
(	O
26	O
.	O
6	O
)	O
0	O
.	O
9Bench	O
Maji206	O
(	O
52	O
.	O
2	O
)	O
203	O
(	O
26	O
.	O
3	O
)	O
409	O
(	O
51	O
.	O
8	O
)	O
Sheka83	O
(	O
21	O
.	O
0	O
)	O
88	O
(	O
22	O
.	O
3	O
)	O
171	O
(	O
21	O
.	O
6	O
)	O
Treatment	O
centerHospital55	O
(	O
13	O
.	O
9	O
)	O
49	O
(	O
12	O
.	O
4	O
)	O
104	O
(	O
13	O
.	O
2	O
)	O
0	O
.	O
5Health	O
center340	O
(	O
86	O
.	O
1	O
)	O
346	O
(	O
87	O
.	O
6	O
)	O
686	O
(	O
86	O
.	O
8	O
)	O
Baseline	O
weightMean	O
±	O
SDa	O
47	O
.	O
6	O
±	O
8	O
.	O
648	O
.	O
4	O
±	O
8	O
.	O
548	O
±	O
8	O
.	O
50	O
.	O
2Baseline	O
sputum	O
smearPositive186	O
(	O
47	O
.	O
1	O
)	O
173	O
(	O
43	O
.	O
8	O
)	O
359	O
(	O
45	O
.	O
4	O
)	O
0	O
.	O
6Negative151	O
(	O
38	O
.	O
2	O
)	O
165	O
(	O
41	O
.	O
8	O
)	O
316	O
(	O
40	O
)	O
Unknown58	O
(	O
14	O
.	O
7	O
)	O
57	O
(	O
14	O
.	O
4	O
)	O
115	O
(	O
14	O
.	O
6	O
)	O
Type	O
of	O
TBPulmonary303	O
(	O
76	O
.	O
7305	O
(	O
77	O
.	O
2	O
)	O
608	O
(	O
77	O
.	O
0	O
)	O
0	O
.	O
9Positive186	O
(	O
47	O
.	O
1	O
)	O
173	O
(	O
43	O
.	O
8	O
)	O
359	O
(	O
45	O
.	O
4	O
)	O
Negative117	O
(	O
30	O
.	O
4	O
)	O
132	O
(	O
33	O
.	O
4	O
)	O
252	O
(	O
31	O
.	O
9	O
)	O
Extra	O
pulmonary92	O
(	O
23	O
.	O
3	O
)	O
90	O
(	O
22	O
.	O
8	O
)	O
179	O
(	O
23	O
)	O
HIV	O
statusPositive37	O
(	O
9	O
.	O
4	O
)	O
40	O
(	O
10	O
.	O
1	O
)	O
77	O
(	O
9	O
.	O
7	O
)<	O
0	O
.	O
001Negative246	O
(	O
62	O
.	O
3	O
)	O
289	O
(	O
73	O
.	O
2	O
)	O
535	O
(	O
67	O
.	O
7	O
)	O
Unknown112	O
(	O
28	O
.	O
4	O
)	O
66	O
(	O
16	O
.	O
7	O
)	O
178	O
(	O
22	O
.	O
5	O
)	O
Received	O
CPTb	O
(	O
n	O
=	O
77	O
)	O
Yes18	O
(	O
48	O
.	O
6	O
)	O
17	O
(	O
42	O
.	O
5	O
)	O
35	O
(	O
45	O
.	O
5	O
)	O
0	O
.	O
6Received	O
CPT	O
or	O
ARTc	O
(	O
n	O
=	O
77	O
)	O
Yes6	O
(	O
16	O
.	O
2	O
)	O
6	O
(	O
15	O
.	O
0	O
)	O
12	O
(	O
15	O
.	O
6	O
)	O
0	O
.	O
8Received	O
ART	O
(	O
n	O
=	O
77	O
)	O
Yes12	O
(	O
32	O
.	O
4	O
)	O
9	O
(	O
22	O
.	O
5	O
)	O
21	O
(	O
27	O
.	O
3	O
)	O
0	O
.	O
3Baseline	O
sputum	O
smearPositive186	O
(	O
47	O
.	O
1	O
)	O
173	O
(	O
43	O
.	O
8	O
)	O
359	O
(	O
45	O
.	O
4	O
)	O
0	O
.	O
6Negative151	O
(	O
38	O
.	O
2	O
)	O
165	O
(	O
41	O
.	O
8	O
)	O
316	O
(	O
40	O
)	O
Unknown58	O
(	O
14	O
.	O
7	O
)	O
57	O
(	O
14	O
.	O
4	O
)	O
115	O
(	O
14	O
.	O
6	O
)	O
aStandard	O
deviation	O
,	O
b	O
CPT	O
Cotrimoxazole	O
prophylactic	O
therapy	O
,	O
c	O
ART	O
antiretroviral	O
therapy	O

Patient	O
follow	O
-	O
ups	O
and	O
treatment	O
outcomes	O

A	O
total	O
of	O
695	O
(	O
88	O
%)	O
of	O
the	O
patients	O
had	O
successful	O
treatment	O
outcomes	O
with	O
statistically	O
significant	O
difference	O
(	O
85	O
.	O
3	O
%	O
vs	O
90	O
.	O
6	O
%,	O
p	O
=	O
0	O
.	O
02	O
)	O
among	O
the	O
6HE	O
and	O
4RH	O
groups	O
,	O
respectively	O
(	O
Table	O
2	O
).	O

A	O
total	O
of	O
,	O
324	O
(	O
90	O
.	O
3	O
%),	O
208	O
(	O
85	O
.	O
4	O
%)	O
and	O
163	O
(	O
91	O
.	O
1	O
%)	O
of	O
pulmonary	O
positive	O
,	O
pulmonary	O
negative	O
and	O
extra	O
pulmonary	B-DS
TB	I-DS
cases	O
respectively	O
had	O
successful	O
outcomes	O
with	O
statistically	O
significant	O
difference	O
,	O
P	O
=	O
0	O
.	O
03	O
.	O

Besides	O
,	O
statistically	O
significant	O
differences	O
in	O
successful	O
outcomes	O
,	O
64	O
(	O
83	O
.	O
1	O
%),	O
482	O
(	O
90	O
.	O
1	O
%)	O
and	O
149	O
(	O
83	O
.	O
7	O
%,	O
p	O
=	O
0	O
.	O
005	O
were	O
also	O
found	O
among	O
HIV	B-OG
positive	O
,	O
HIV	B-OG
negatives	O
and	O
unknown	O
HIV	B-OG
status	O
TB	B-DS
cases	O
,	O
respectively	O
.	O
Table	O
2Patient	O
follow	O
-	O
up	O
measures	O
and	O
treatment	O
outcomes	O
of	O
TB	B-DS
patients	O
registered	O
during	O
2008	O
–	O
2014	O
,	O
Southwest	O
EthiopiaVariablesContinuation	O
phase	O
treatment	O
regimen6EH	O
(	O
n	O
=	O
395	O
)	O
n	O
(%)	O
4RH	O
(	O
n	O
=	O
395	O
)	O
n	O
(%)	O
Total	O
N	O
(%)	O
P	O
valueWeight	O
at	O
2nd	O
monthMean	O
±	O
SD49	O
.	O
9	O
±	O
8	O
.	O
950	O
.	O
8	O
±	O
8	O
.	O
250	O
.	O
4	O
±	O
8	O
.	O
60	O
.	O
2Weight	O
at	O
5th	O
monthMean	O
±	O
SD51	O
.	O
4	O
±	O
8	O
.	O
651	O
.	O
3	O
±	O
7	O
.	O
351	O
.	O
3	O
±	O
7	O
.	O
90	O
.	O
9Weight	O
at	O
6	O
/	O
7th	O
monthMean	O
±	O
SD51	O
.	O
1	O
±	O
8	O
.	O
952	O
.	O
5	O
±	O
6	O
.	O
551	O
.	O
7	O
±	O
7	O
.	O
90	O
.	O
3Change	O
in	O
weight	O
at	O
2nd	O
monthNot	O
increased49	O
(	O
12	O
.	O
4	O
)	O
61	O
(	O
15	O
.	O
4	O
)	O
110	O
(	O
13	O
.	O
9	O
)	O
0	O
.	O
4Increased191	O
(	O
48	O
.	O
4	O
)	O
177	O
(	O
44	O
.	O
8	O
)	O
368	O
(	O
46	O
.	O
6	O
)	O
Unknown155	O
(	O
39	O
.	O
2	O
)	O
157	O
(	O
39	O
.	O
7	O
)	O
312	O
(	O
39	O
.	O
5	O
)	O
Sputum	O
smear	O
end	O
of	O
2nd	O
month	O
(	O
n	O
=	O
359	O
)	O
Positive4	O
(	O
2	O
.	O
2	O
)	O
2	O
(	O
1	O
.	O
2	O
)	O
6	O
(	O
1	O
.	O
7	O
)	O
0	O
.	O
09Negative130	O
(	O
69	O
.	O
9	O
)	O
138	O
(	O
79	O
.	O
8	O
)	O
268	O
(	O
74	O
.	O
7	O
)	O
Unknown52	O
(	O
28	O
)	O
33	O
(	O
19	O
.	O
1	O
)	O
85	O
(	O
23	O
.	O
7	O
)	O
Sputum	O
smear	O
end	O
of	O
5th	O
month	O
(	O
n	O
=	O
359	O
)	O
Positive1	O
(	O
0	O
.	O
5	O
)	O
0	O
(	O
0	O
)	O
1	O
(	O
0	O
.	O
3	O
)	O
0	O
.	O
03Negative83	O
(	O
44	O
.	O
6	O
)	O
100	O
(	O
57	O
.	O
8	O
)	O
183	O
(	O
51	O
)	O
Unknown102	O
(	O
54	O
.	O
8	O
)	O
73	O
(	O
42	O
.	O
2	O
)	O
175	O
(	O
48	O
.	O
7	O
)	O
Sputum	O
smear	O
end	O
of	O
6	O
/	O
7th	O
month	O
(	O
n	O
=	O
359	O
)	O
Positive0000	O
.	O
8Negative94	O
(	O
50	O
.	O
5	O
)	O
85	O
(	O
49	O
.	O
1	O
)	O
179	O
(	O
49	O
.	O
9	O
)	O
Unknown92	O
(	O
49	O
.	O
5	O
)	O
88	O
(	O
50	O
.	O
9	O
)	O
180	O
(	O
50	O
.	O
1	O
)	O
Sputum	O
smear	O
done	O
during	O
treatment	O
(	O
n	O
=	O
359	O
)	O
No44	O
(	O
23	O
.	O
7	O
)	O
33	O
(	O
19	O
.	O
1	O
)	O
77	O
(	O
21	O
.	O
4	O
)	O
0	O
.	O
3At	O
least	O
once142	O
(	O
76	O
.	O
3	O
)	O
140	O
(	O
80	O
.	O
9	O
)	O
282	O
(	O
78	O
.	O
6	O
)	O
Continuation	O
phase	O
visitMean	O
±	O
SD5	O
.	O
8	O
±	O
1	O
.	O
15	O
.	O
4	O
±	O
3	O
.	O
10	O
.	O
09Treatment	O
outcomeSuccessful337	O
(	O
85	O
.	O
3	O
)	O
358	O
(	O
90	O
.	O
6	O
)	O
695	O
(	O
88	O
)	O
0	O
.	O
02Cured77	O
(	O
19	O
.	O
5	O
)	O
85	O
(	O
21	O
.	O
5	O
)	O
162	O
(	O
20	O
.	O
5	O
)	O
Completed260	O
(	O
65	O
.	O
8	O
)	O
273	O
(	O
69	O
.	O
1	O
)	O
533	O
(	O
67	O
)	O
Unsuccessful58	O
(	O
14	O
.	O
7	O
)	O
37	O
(	O
9	O
.	O
4	O
)	O
95	O
(	O
12	O
)	O
Died28	O
(	O
7	O
.	O
1	O
)	O
18	O
(	O
4	O
.	O
6	O
)	O
46	O
(	O
5	O
.	O
8	O
)	O
Defaulted29	O
(	O
7	O
.	O
3	O
)	O
19	O
(	O
4	O
.	O
8	O
)	O
48	O
(	O
6	O
.	O
1	O
)	O
Failure1	O
(	O
0	O
.	O
3	O
)	O
01	O
(	O
0	O
.	O
1	O
)	O

Measurements	O
of	O
patient	O
weight	O
at	O
the	O
end	O
of	O
second	O
,	O
fifth	O
and	O
sixth	O
/	O
seventh	O
months	O
of	O
treatment	O
were	O
available	O
for	O
504	O
(	O
63	O
.	O
8	O
%),	O
145	O
(	O
18	O
.	O
4	O
%)	O
and	O
141	O
(	O
17	O
.	O
8	O
%)	O
respectively	O
.	O

Thus	O
,	O
368	O
(	O
46	O
.	O
6	O
%)	O
or	O
(	O
48	O
.	O
4	O
%	O
from	O
6EH	O
and	O
44	O
.	O
8	O
%	O
from	O
4RH	O
,	O
p	O
=	O
0	O
.	O
4	O
)	O
have	O
gained	O
some	O
amount	O
of	O
weight	O
at	O
the	O
end	O
of	O
second	O
month	O
of	O
treatment	O
.	O

On	O
the	O
other	O
hand	O
,	O
of	O
those	O
initially	O
smear	O
positive	O
pulmonary	B-DS
TB	I-DS
cases	O
,	O
78	O
.	O
6	O
%	O
had	O
undergone	O
sputum	O
follow	O
up	O
examination	O
at	O
least	O
once	O
after	O
the	O
diagnosis	O
(	O
76	O
.	O
3	O
%	O
among	O
6HE	O
and	O
80	O
.	O
9	O
%	O
among	O
4HR	O
,	O
p	O
=	O
0	O
.	O
3	O
).	O

Thus	O
sputum	O
smear	O
results	O
at	O
the	O
end	O
of	O
second	O
,	O
fifth	O
and	O
sixth	O
/	O
seventh	O
months	O
of	O
treatment	O
were	O
available	O
for274	O
(	O
76	O
.	O
3	O
%),	O
184	O
(	O
51	O
.	O
3	O
%)	O
and	O
179	O
(	O
49	O
.	O
9	O
%)	O
cases	O
respectively	O
with	O
no	O
statistically	O
significant	O
differences	O
among	O
the	O
6EH	O
and	O
4RH	O
regimens	O
.	O

The	O
majority	O
of	O
the	O
smear	O
positives	O
(	O
69	O
.	O
9	O
%	O
vs	O
79	O
.	O
8	O
%	O
respectively	O
from	O
the	O
6EH	O
and	O
4RH	O
regimens	O
,	O
p	O
=	O
0	O
.	O
4	O
)	O
converted	O
to	O
negative	O
at	O
the	O
end	O
of	O
second	O
month	O
treatment	O
.	O

Factors	O
associated	O
with	O
unsuccessful	O
treatment	O
outcomes	O

In	O
bivariate	O
analysis	O
patient	O
age	O
,	O
residence	O
,	O
zone	O
,	O
weight	O
change	O
at	O
the	O
end	O
of	O
the	O
second	O
month	O
of	O
treatment	O
,	O
sputum	O
smear	O
follow	O
-	O
up	O
and	O
continuation	O
phase	O
regimen	O
are	O
associated	O
with	O
treatment	O
success	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

But	O
,	O
in	O
multivariate	O
analysis	O
4RH	O
continuation	O
phase	O
treatment	O
regimen	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
0	O
.	O
55	O
(	O
0	O
.	O
34	O
,	O
0	O
.	O
89	O
)],	O
patient	O
age	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
1	O
.	O
02	O
(	O
1	O
.	O
001	O
,	O
1	O
.	O
022	O
)],	O
rural	O
residence	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
2	O
.	O
1	O
(	O
1	O
.	O
18	O
,	O
3	O
.	O
75	O
)],	O
treated	O
at	O
health	O
center	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
14	O
,	O
0	O
.	O
97	O
)],	O
HIV	B-OG
positives	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
2	O
.	O
38	O
(	O
1	O
.	O
12	O
,	O
5	O
.	O
07	O
)],	O
gained	O
weight	O
at	O
the	O
end	O
of	O
the	O
second	O
month	O
[	O
AOR	O
(	O
95	O
%	O
CI	O
)	O
0	O
.	O
28	O
(	O
0	O
.	O
11	O
,	O
0	O
.	O
72	O
)]	O
independently	O
predicted	O
unsuccessful	O
treatment	O
outcome	O
(	O
Table	O
3	O
).	O

The	O
odds	O
of	O
unsuccessful	O
outcome	O
was	O
higher	O
among	O
the	O
older	O
,	O
rural	O
residents	O
,	O
HIV	B-OG
positives	O
and	O
unknown	O
weight	O
change	O
at	O
the	O
end	O
of	O
second	O
month	O
treatment	O
.	O

The	O
odds	O
of	O
having	O
unsuccessful	O
outcome	O
increase	O
by	O
2	O
%	O
for	O
every	O
one	O
year	O
increase	O
in	O
age	O
(	O
AOR	O
=	O
1	O
.	O
02	O
).	O
On	O
the	O
other	O
hand	O
,	O
treated	O
with	O
4RH	O
continuation	O
phase	O
regimen	O
,	O
being	O
treated	O
at	O
health	O
center	O
and	O
weight	O
gain	O
at	O
the	O
end	O
of	O
second	O
month	O
have	O
lower	O
likelihood	O
of	O
unsuccessful	O
outcome	O
.	O

Patients	O
put	O
on	O
4RH	O
continuation	O
phase	O
of	O
treatment	O
regimen	O
are	O
45	O
%	O
less	O
likely	O
to	O
have	O
unsuccessful	O
outcome	O
compared	O
to	O
those	O
put	O
on	O
6EH	O
regimen	O
.	O

Patients	O
treated	O
at	O
health	O
center	O
have	O
about	O
63	O
%	O
lower	O
odds	O
of	O
unsuccessful	O
outcome	O
as	O
compared	O
to	O
those	O
treated	O
at	O
hospitals	O
.	O

HIV	B-OG
co	O
infected	O
TB	B-DS
patients	O
have	O
more	O
than	O
two	O
fold	O
higher	O
risk	O
of	O
unsuccessful	O
outcomes	O
compared	O
to	O
HIV	B-OG
negatives	O
(	O
AOR	O
=	O
2	O
.	O
38	O
).	O

Those	O
patients	O
gained	O
weight	O
at	O
the	O
end	O
of	O
the	O
second	O
month	O
of	O
treatment	O
have	O
72	O
%	O
lower	O
odds	O
of	O
unsuccessful	O
outcomes	O
compared	O
to	O
those	O
with	O
reduced	O
or	O
unchanged	O
weight	O
(	O
AOR	O
=	O
0	O
.	O
28	O
).	O

A	O
subgroup	O
analysis	O
among	O
smear	O
positive	O
pulmonary	O
cases	O
showed	O
having	O
a	O
sputum	O
checkup	O
at	O
least	O
once	O
during	O
treatment	O
independently	O
predicted	O
96	O
%	O
lower	O
odds	O
of	O
unsuccessful	O
outcomes	O
compared	O
to	O
those	O
unchecked	O
(	O
AOR	O
0	O
.	O
04	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
01	O
–	O
0	O
.	O
12	O
),	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Additional	O
file	O
1	O
).	O
Table	O
3Factors	O
associated	O
with	O
unsuccessful	O
treatment	O
outcomes	O
among	O
TB	B-DS
patients	O
registered	O
during	O
2008	O
–	O
2014	O
,	O
Southwestern	O
EthiopiaVariablesTreatment	O
outcomesOdds	O
ratio	O
(	O
OR	O
)	O
Unsuccessful	O
n	O
(%)	O
Successful	O
n	O
(%)	O
Crude	O
OR95	O
%	O
CIa	O
Adjusted	O
OR95	O
%	O
CIAge	O
(	O
years	O
)	O
Mean	O
(	O
SD	O
)	O
33	O
.	O
5	O
(	O
14	O
)	O
30	O
.	O
4	O
(	O
12	O
.	O
0	O
)	O
1	O
.	O
02	O
(	O
1	O
.	O
002	O
,	O
1	O
.	O
03	O
)	O
1	O
.	O
02	O
(	O
1	O
.	O
001	O
,	O
1	O
.	O
022	O
)	O
GenderMale60	O
(	O
13	O
.	O
4	O
)	O
387	O
(	O
86	O
.	O
6	O
)	O
11Female35	O
(	O
10	O
.	O
2	O
)	O
308	O
(	O
89	O
.	O
8	O
)	O
0	O
.	O
73	O
(	O
0	O
.	O
47	O
.	O
1	O
.	O
14	O
)	O
0	O
.	O
63	O
(	O
0	O
.	O
38	O
,	O
1	O
.	O
03	O
)	O
ResidenceUrban32	O
(	O
9	O
.	O
1	O
)	O
318	O
(	O
90	O
.	O
9	O
)	O
11Rural63	O
(	O
14	O
.	O
3	O
)	O
377	O
(	O
85	O
.	O
7	O
)	O
1	O
.	O
66	O
(	O
1	O
.	O
06	O
,	O
2	O
.	O
61	O
)	O
2	O
.	O
1	O
(	O
1	O
.	O
18	O
,	O
3	O
.	O
75	O
)	O
ZoneKaffa34	O
(	O
16	O
.	O
2	O
)	O
176	O
(	O
83	O
.	O
8	O
)	O
11Bench	O
Maji50	O
(	O
12	O
.	O
2	O
)	O
359	O
(	O
87	O
.	O
8	O
)	O
0	O
.	O
72	O
(	O
0	O
.	O
45	O
,	O
1	O
.	O
14	O
)	O
1	O
.	O
41	O
(	O
0	O
.	O
73	O
,	O
2	O
.	O
75	O
)	O
Sheka11	O
(	O
6	O
.	O
4	O
)	O
160	O
(	O
93	O
.	O
6	O
)	O
0	O
.	O
36	O
(	O
0	O
.	O
17	O
,	O
0	O
.	O
73	O
)	O
1	O
.	O
2	O
(	O
0	O
.	O
44	O
,	O
3	O
.	O
32	O
)	O
Treatment	O
centerHospital17	O
(	O
16	O
.	O
3	O
)	O
87	O
(	O
83	O
.	O
7	O
)	O
11HC78	O
(	O
11	O
.	O
4	O
)	O
608	O
(	O
88	O
.	O
6	O
)	O
0	O
.	O
66	O
(	O
0	O
.	O
37	O
,	O
1	O
.	O
16	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
14	O
,	O
0	O
.	O
97	O
)	O
Type	O
of	O
TBPulmonary78	O
(	O
12	O
.	O
8	O
)	O
530	O
(	O
87	O
.	O
2	O
)	O
11EPTBb	O
17	O
(	O
9	O
.	O
3	O
)	O
165	O
(	O
90	O
.	O
7	O
)	O
0	O
.	O
70	O
(	O
0	O
.	O
40	O
,	O
1	O
.	O
22	O
)	O
0	O
.	O
57	O
(	O
0	O
.	O
32	O
,	O
1	O
.	O
04	O
)	O
HIV	B-OG
statusNegative53	O
(	O
9	O
.	O
9	O
)	O
482	O
(	O
90	O
.	O
1	O
)	O
11Positive13	O
(	O
16	O
.	O
9	O
)	O
64	O
(	O
83	O
.	O
1	O
)	O
1	O
.	O
85	O
(	O
0	O
.	O
95	O
,	O
3	O
.	O
57	O
)	O
2	O
.	O
39	O
(	O
1	O
.	O
12	O
,	O
5	O
.	O
07	O
)	O
Unknown29	O
(	O
16	O
.	O
3	O
)	O
178	O
(	O
83	O
.	O
7	O
)	O
1	O
.	O
77	O
(	O
1	O
.	O
08	O
,	O
2	O
.	O
88	O
)	O
2	O
.	O
26	O
(	O
1	O
.	O
23	O
,	O
4	O
.	O
11	O
)	O
Weight	O
change	O
end	O
of	O
2nd	O
monthNo	O
increase11	O
(	O
8	O
.	O
2	O
)	O
357	O
(	O
91	O
.	O
8	O
)	O
11Increased9	O
(	O
3	O
)	O
101	O
(	O
97	O
)	O
0	O
.	O
35	O
(	O
0	O
.	O
14	O
,	O
0	O
.	O
86	O
)	O
0	O
.	O
28	O
(	O
0	O
.	O
11	O
,	O
0	O
.	O
72	O
)	O
Unknown75	O
(	O
24	O
)	O
237	O
(	O
76	O
)	O
3	O
.	O
55	O
(	O
1	O
.	O
71	O
,	O
7	O
.	O
37	O
)	O
3	O
.	O
48	O
(	O
1	O
.	O
60	O
,	O
7	O
.	O
54	O
)	O
Continuation	O
phase	O
regimen6EH58	O
(	O
14	O
.	O
7	O
)	O
337	O
(	O
85	O
.	O
3	O
)	O
114RH37	O
(	O
9	O
.	O
4	O
)	O
358	O
(	O
90	O
.	O
6	O
)	O
0	O
.	O
60	O
(	O
0	O
.	O
39	O
,	O
0	O
.	O
93	O
)	O
0	O
.	O
55	O
(	O
0	O
.	O
34	O
,	O
0	O
.	O
89	O
)	O
aConfidence	O
interval	O
,	O
bExtra	O
pulmonary	O
Tuberculosis	O
,	O
bold	O
figures	O
indicate	O
statisticaly	O
significant	O
at	O
p	O
<	O
0	O
.	O
05	O

Discussion	O

Treatment	O
outcomes	O
among	O
TB	B-DS
patients	O
treated	O
with	O
RHZE	O
for	O
the	O
first	O
2	O
months	O
,	O
followed	O
by	O
HE	O
for	O
6	O
months	O
(	O
2RHZE	O
/	O
6EH	O
)	O
and	O
RH	O
for	O
4	O
months	O
(	O
2RHZE	O
/	O
4RH	O
)	O
was	O
compared	O
.	O

Both	O
groups	O
of	O
the	O
cases	O
had	O
no	O
statistically	O
significant	O
difference	O
with	O
respect	O
to	O
socio	O
-	O
demographic	O
,	O
baseline	O
clinical	O
,	O
bacteriologic	O
and	O
follow	O
up	O
measures	O
that	O
depict	O
comparability	O
of	O
the	O
groups	O
.	O

The	O
comparison	O
was	O
made	O
between	O
regimens	O
used	O
during	O
the	O
continuation	O
phase	O
treatment	O
(	O
4RH	O
vs	O
6EH	O
).	O

Thus	O
a	O
lower	O
rate	O
of	O
unsuccessful	O
outcomes	O
was	O
reported	O
among	O
those	O
treated	O
with	O
4RH	O
continuation	O
phase	O
regimen	O
.	O

A	O
statistically	O
significant	O
difference	O
in	O
treatment	O
outcomes	O
where	O
lower	O
unsuccessful	O
treatment	O
outcome	O
(	O
9	O
.	O
4	O
%	O
vs	O
14	O
.	O
7	O
%)	O
was	O
observed	O
among	O
patients	O
treated	O
with	O
4RH	O
and	O
6EH	O
regimen	O
respectively	O
.	O

Similarly	O
,	O
a	O
study	O
conducted	O
in	O
Nigeria	O
[	O
14	O
]	O
reported	O
higher	O
odds	O
of	O
unsuccessful	O
outcome	O
among	O
those	O
treated	O
with	O
6EH	O
.	O

This	O
could	O
be	O
due	O
to	O
the	O
differences	O
in	O
length	O
and	O
type	O
of	O
drugs	O
used	O
during	O
the	O
continuation	O
phase	O
treatment	O
those	O
influence	O
adherence	O
and	O
ultimate	O
outcome	O
.	O

Studies	O
reported	O
that	O
reduced	O
continuation	O
phase	O
(	O
from	O
6EH	O
to	O
4HR	O
)	O
treatment	O
is	O
associated	O
with	O
lower	O
cost	O
and	O
expected	O
mortality	O
[	O
12	O
]	O
that	O
enhance	O
successful	O
treatment	O
outcome	O
.	O

On	O
the	O
other	O
hand	O
,	O
use	O
of	O
rifampcin	B-CD
for	O
longer	O
period	O
of	O
time	O
during	O
the	O
treatment	O
of	O
TB	B-DS
is	O
associated	O
with	O
better	O
outcomes	O
[	O
13	O
]	O
that	O
might	O
be	O
related	O
with	O
efficacy	O
of	O
the	O
drug	O
.	O

The	O
finding	O
implies	O
the	O
adoption	O
[	O
11	O
]	O
of	O
the	O
latest	O
WHO	O
recommendation	O
[	O
7	O
]	O
in	O
high	O
prevalent	O
and	O
resource	O
constrained	O
settings	O
is	O
working	O
well	O
.	O

Apart	O
from	O
the	O
treatment	O
regimens	O
,	O
patient	O
attribute	O
like	O
age	O
and	O
residence	O
independently	O
predicted	O
treatment	O
outcomes	O
.	O

We	O
found	O
that	O
age	O
had	O
an	O
inverse	O
relation	O
with	O
unsuccessful	O
outcome	O
where	O
the	O
odds	O
of	O
unsuccessful	O
outcome	O
increase	O
with	O
age	O
.	O

Several	O
studies	O
also	O
reported	O
that	O
older	O
patients	O
were	O
more	O
likely	O
to	O
have	O
unsuccessful	O
outcomes	O
than	O
younger	O
[	O
24	O
–	O
27	O
].	O

This	O
could	O
be	O
due	O
to	O
higher	O
risk	O
of	O
age	O
related	O
co	O
morbid	O
situations	O
those	O
lead	O
to	O
poor	O
adherence	O
and	O
outcomes	O
[	O
28	O
].	O

Patients	O
residing	O
in	O
rural	O
areas	O
had	O
higher	O
risk	O
of	O
unsuccessful	O
outcomes	O
which	O
could	O
be	O
attributed	O
to	O
the	O
low	O
access	O
to	O
TB	B-DS
care	O
and	O
unfavorable	O
living	O
conditions	O
.	O

The	O
findings	O
imply	O
need	O
for	O
focused	O
intervention	O
targeted	O
to	O
those	O
older	O
age	O
groups	O
and	O
rural	O
dwellers	O
besides	O
the	O
treatment	O
regimen	O
.	O

Monitoring	O
of	O
patient	O
weight	O
and	O
sputum	O
are	O
among	O
the	O
recommended	O
follow	O
-	O
up	O
measures	O
required	O
for	O
TB	B-DS
patients	O
on	O
treatment	O
[	O
7	O
].	O

The	O
results	O
of	O
both	O
weight	O
and	O
sputum	O
monitoring	O
are	O
used	O
to	O
adjust	O
for	O
drug	O
dose	O
and	O
predict	O
outcomes	O
of	O
the	O
treatment	O
.	O

The	O
proportion	O
of	O
smear	O
positive	O
patients	O
converted	O
to	O
negative	O
at	O
the	O
end	O
of	O
the	O
intensive	O
phase	O
has	O
been	O
taken	O
among	O
indicators	O
of	O
TB	B-DS
programme	O
performance	O
[	O
7	O
].	O

However	O
,	O
only	O
small	O
proportion	O
of	O
patients	O
had	O
documented	O
results	O
of	O
the	O
weight	O
and	O
sputum	O
follow	O
-	O
ups	O
particularly	O
at	O
the	O
later	O
periods	O
of	O
treatment	O
.	O

Consistent	O
to	O
findings	O
from	O
African	O
settings	O
[	O
29	O
]	O
majority	O
of	O
those	O
patients	O
undergone	O
sputum	O
checkup	O
during	O
treatment	O
converted	O
to	O
negative	O
.	O

Patients	O
gained	O
some	O
amount	O
of	O
weight	O
at	O
the	O
end	O
of	O
second	O
month	O
treatment	O
had	O
lower	O
risk	O
of	O
unsuccessful	O
outcomes	O
which	O
is	O
consistent	O
with	O
other	O
studies	O
[	O
30	O
,	O
31	O
].	O

This	O
could	O
be	O
explained	O
by	O
the	O
fact	O
that	O
weight	O
gain	O
marks	O
some	O
level	O
of	O
improvement	O
from	O
the	O
TB	B-DS
illness	O
including	O
reduced	O
appetite	O
.	O

In	O
addition	O
,	O
changes	O
in	O
weight	O
while	O
on	O
treatment	O
might	O
be	O
an	O
indication	O
of	O
appropriateness	O
of	O
the	O
drug	O
dose	O
to	O
treat	O
the	O
illness	O
.	O

On	O
the	O
other	O
hand	O
those	O
with	O
unknown	O
weight	O
change	O
at	O
the	O
end	O
of	O
first	O
two	O
months	O
treatment	O
had	O
higher	O
odds	O
of	O
unsuccessful	O
outcomes	O
.	O

This	O
might	O
have	O
occurred	O
due	O
to	O
possible	O
misclassification	O
of	O
cases	O
with	O
reduced	O
or	O
remains	O
unchanged	O
to	O
unknown	O
.	O

The	O
weight	O
change	O
might	O
be	O
unknown	O
due	O
to	O
patients	O
’	O
treatment	O
interruption	O
subsequent	O
to	O
treatment	O
default	O
or	O
death	O
those	O
constitute	O
unsuccessful	O
outcome	O
.	O

So	O
that	O
patient	O
’	O
s	O
status	O
of	O
weight	O
during	O
treatment	O
might	O
be	O
left	O
undetermined	O
.	O

Having	O
sputum	O
checkup	O
at	O
least	O
once	O
during	O
treatment	O
among	O
initially	O
smear	O
positives	O
predicted	O
lower	O
risk	O
of	O
unsuccessful	O
outcome	O
.	O

However	O
,	O
reviews	O
showed	O
low	O
sensitivity	O
and	O
modest	O
specificity	O
of	O
sputum	O
results	O
at	O
the	O
end	O
of	O
intensive	O
phase	O
to	O
predict	O
failure	O
and	O
relapse	O
[	O
32	O
].	O

On	O
the	O
other	O
hand	O
,	O
detection	O
of	O
sputum	O
positive	O
during	O
treatment	O
trigger	O
further	O
patient	O
assessment	O
that	O
influence	O
treatment	O
regimens	O
and	O
ultimate	O
outcome	O
.	O

Hence	O
,	O
the	O
routine	O
sputum	O
monitoring	O
adopted	O
by	O
the	O
country	O
[	O
11	O
]	O
during	O
treatment	O
should	O
be	O
improved	O
as	O
it	O
is	O
an	O
indicator	O
of	O
program	O
performance	O
and	O
trigger	O
for	O
patient	O
assessment	O
.	O

Consistent	O
with	O
other	O
studies	O
[	O
33	O
,	O
34	O
],	O
HIV	B-OG
positive	O
TB	B-DS
patients	O
are	O
more	O
likely	O
to	O
have	O
unsuccessful	O
outcomes	O
compared	O
to	O
those	O
negatives	O
.	O

This	O
could	O
be	O
due	O
to	O
multifaceted	O
influences	O
of	O
HIV	B-OG
on	O
TB	B-DS
diagnosis	O
and	O
response	O
to	O
TB	B-DS
treatment	O
those	O
negatively	O
affect	O
the	O
outcomes	O
of	O
TB	B-DS
treatment	O
[	O
35	O
].	O

Consequently	O
,	O
collaborative	O
services	O
have	O
been	O
recommended	O
in	O
order	O
to	O
curb	O
the	O
influence	O
of	O
HIV	B-OG
on	O
TB	B-DS
and	O
vice	O
versa	O
[	O
36	O
].	O

Evidences	O
from	O
systematic	O
review	O
in	O
African	O
context	O
supported	O
the	O
recommendation	O
and	O
reported	O
better	O
outcomes	O
among	O
concurrently	O
screened	O
and	O
managed	O
TB	B-DS
and	O
HIV	B-OG
infected	O
patients	O
[	O
37	O
].	O

Nonetheless	O
,	O
we	O
found	O
no	O
statistically	O
significant	O
difference	O
in	O
treatment	O
success	O
among	O
those	O
infected	O
TB	B-DS
patients	O
provided	O
with	O
CPT	O
and	O
/	O
or	O
ART	O
.	O

The	O
indifference	O
could	O
be	O
explained	O
by	O
the	O
low	O
uptake	O
of	O
integrated	O
TB	B-DS
/	O
HIV	B-OG
collaborative	O
services	O
among	O
the	O
studied	O
patients	O
.	O

In	O
this	O
study	O
,	O
more	O
than	O
three	O
quarter	O
of	O
the	O
patients	O
were	O
offered	O
HIV	B-OG
test	O
which	O
is	O
little	O
higher	O
than	O
the	O
national	O
average	O
of	O
65	O
%	O
[	O
18	O
]	O
and	O
9	O
.	O
7	O
%	O
TB	B-DS
/	O
HIV	B-OG
co	O
infected	O
patients	O
which	O
is	O
almost	O
similar	O
to	O
the	O
national	O
average	O
of	O
10	O
%.	O

However	O
,	O
only	O
few	O
HIV	B-OG
co	O
infected	O
patients	O
(	O
45	O
%	O
on	O
CPT	O
and	O
27	O
.	O
3	O
%	O
on	O
ART	O
)	O
were	O
found	O
to	O
have	O
documented	O
service	O
provision	O
.	O

[	O
18	O
].	O

The	O
discrepancies	O
could	O
be	O
due	O
to	O
differences	O
in	O
reporting	O
periods	O
where	O
the	O
national	O
average	O
is	O
a	O
single	O
year	O
attainment	O
but	O
that	O
of	O
this	O
study	O
is	O
over	O
a	O
period	O
of	O
six	O
years	O
including	O
the	O
nationally	O
reported	O
year	O
.	O

Over	O
all	O
,	O
the	O
targets	O
set	O
for	O
the	O
TB	B-DS
/	O
HIV	B-OG
service	O
collaboration	O
has	O
not	O
yet	O
met	O
which	O
calls	O
for	O
in	O
depth	O
understanding	O
and	O
focused	O
intervention	O
that	O
suit	O
local	O
settings	O
.	O

On	O
the	O
other	O
hand	O
,	O
unknown	O
HIV	B-OG
status	O
predicted	O
higher	O
odds	O
of	O
unsuccessful	O
outcomes	O
.	O

This	O
could	O
be	O
due	O
to	O
possible	O
misclassification	O
of	O
HIV	B-OG
positive	O
cases	O
those	O
predict	O
worse	O
outcome	O
in	O
to	O
unknown	O
.	O

The	O
study	O
is	O
limited	O
to	O
control	O
for	O
changes	O
in	O
medical	O
resources	O
,	O
polices	O
and	O
quality	O
of	O
care	O
across	O
the	O
study	O
periods	O
.	O

Since	O
only	O
few	O
variables	O
were	O
captured	O
on	O
the	O
register	O
,	O
we	O
could	O
not	O
control	O
for	O
possible	O
confounding	O
effect	O
of	O
socioeconomic	O
,	O
lifestyle	O
and	O
co	O
morbid	O
illness	O
.	O

Furthermore	O
resistance	O
pattern	O
of	O
the	O
treatment	O
regimens	O
could	O
not	O
be	O
evaluated	O
which	O
is	O
recommended	O
for	O
the	O
assessment	O
of	O
impact	O
of	O
treatment	O
regimens	O
.	O

On	O
the	O
other	O
hand	O
the	O
random	O
selection	O
of	O
relatively	O
large	O
sample	O
from	O
both	O
groups	O
minimized	O
risk	O
of	O
selection	O
bias	O
.	O

The	O
groups	O
treated	O
with	O
4RH	O
and	O
6EH	O
had	O
insignificant	O
differences	O
with	O
regard	O
to	O
baseline	O
and	O
follow	O
-	O
up	O
clinical	O
and	O
bacteriologic	O
attributes	O
that	O
enhanced	O
comparability	O
of	O
the	O
groups	O
.	O

Besides	O
,	O
we	O
extracted	O
data	O
from	O
a	O
standardized	O
routine	O
programme	O
register	O
that	O
reflect	O
operational	O
reality	O
.	O

In	O
general	O
,	O
our	O
study	O
is	O
valid	O
and	O
can	O
apply	O
in	O
similar	O
settings	O
given	O
the	O
limitations	O
.	O

Conclusion	O

In	O
conclusion	O
,	O
the	O
switch	O
of	O
continuation	O
phase	O
TB	B-DS
treatment	O
regimen	O
for	O
new	O
cases	O
from	O
6EH	O
to	O
4RH	O
has	O
brought	O
better	O
treatment	O
outcomes	O
.	O

The	O
findings	O
verified	O
the	O
applicability	O
of	O
latest	O
WHO	O
recommendation	O
and	O
national	O
adoption	O
to	O
the	O
high	O
prevalent	O
and	O
resource	O
constrained	O
settings	O
.	O

However	O
,	O
the	O
unsuccessful	O
outcome	O
among	O
the	O
older	O
,	O
rural	O
dwellers	O
and	O
HIV	B-OG
positives	O
is	O
higher	O
independent	O
of	O
the	O
treatment	O
regimen	O
that	O
need	O
further	O
investigation	O
and	O
focused	O
intervention	O
.	O

Therefore	O
,	O
the	O
recommended	O
switch	O
of	O
treatment	O
regimen	O
should	O
be	O
maintained	O
and	O
progressively	O
assessed	O
for	O
outcomes	O
,	O
including	O
drug	O
resistance	O
survey	O
or	O
surveillance	O
.	O

Moreover	O
,	O
further	O
studies	O
should	O
be	O
carried	O
out	O
on	O
the	O
impact	O
of	O
treatment	O
regimens	O
among	O
older	O
,	O
rural	O
residents	O
and	O
HIV	B-OG
positives	O
.	O

Table	O
4	O
:	O
Factors	O
associated	O
with	O
unsuccessful	O
treatment	O
outcome	O
among	O
smear	O
positive	O
pulmonary	B-DS
TB	I-DS
cases	O
registered	O
during	O
2008	O
-	O
2014	O
,	O
southwestern	O
Ethiopia	O
(	O
n	O
=	O
359	O
).	O

Table	O
5	O
:	O
Factors	O
associated	O
with	O
unsuccessful	O
outcome	O
among	O
clinically	O
diagnosed	O
(	O
smear	O
negative	O
10	O
.	O
1186	O
/	O
s12879	O
-	O
016	O
-	O
1917	O
-	O
0	O
pulmonary	O
and	O
extra	O
pulmonary	O
)	O
TB	B-DS
cases	O
registered	O
during	O
2008	O
-	O
2014	O
,	O
Southwestern	O
Ethiopia	O
(	O
n	O
=	O
431	O
).	O

(	O
DOCX	O
17	O
kb	O
)	O

Fructooligosacharides	O
Reduce	O
Pseudomonas	B-OG
aeruginosa	I-OG
PAO1	I-OG
Pathogenicity	O
through	O
Distinct	O
Mechanisms	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MG	O
OMA	O
DA	O
.	O

Performed	O
the	O
experiments	O
:	O
OMA	O
FSM	O
TK	O
DA	O
.	O

Analyzed	O
the	O
data	O
:	O
DA	O
OMA	O
TK	O
FSM	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CM	O
RP	O
DP	O
DA	O
.	O

Wrote	O
the	O
paper	O
:	O
FSM	O
OMA	O
TK	O
DA	O
.	O

Pseudomonas	B-OG
aeruginosa	I-OG
is	O
ubiquitously	O
present	O
in	O
the	O
environment	O
and	O
acts	O
as	O
an	O
opportunistic	O
pathogen	O
on	O
humans	B-OG
,	O
animals	B-OG
and	O
plants	B-OG
.	O

We	O
report	O
here	O
the	O
effects	O
of	O
the	O
prebiotic	O
polysaccharide	O
inulin	B-CD
and	O
its	O
hydrolysed	O
form	O
FOS	O
on	O
this	O
bacterium	B-OG
.	O

FOS	O
was	O
found	O
to	O
inhibit	O
bacterial	O
growth	O
of	O
strain	O
PAO1	O
,	O
while	O
inulin	B-CD
did	O
not	O
affect	O
growth	O
rate	O
or	O
yield	O
in	O
a	O
significant	O
manner	O
.	O

Inulin	B-GP
stimulated	O
biofilm	O
formation	O
,	O
whereas	O
a	O
dramatic	O
reduction	O
of	O
the	O
biofilm	O
formation	O
was	O
observed	O
in	O
the	O
presence	O
of	O
FOS	B-GP
.	O

Similar	O
opposing	O
effects	O
were	O
observed	O
for	O
bacterial	O
motility	O
,	O
where	O
FOS	O
inhibited	O
the	O
swarming	O
and	O
twitching	O
behaviour	O
whereas	O
inulin	B-CD
caused	O
its	O
stimulation	O
.	O

In	O
co	O
-	O
cultures	O
with	O
eukaryotic	O
cells	O
(	O
macrophages	O
)	O
FOS	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
inulin	B-CD
reduced	O
the	O
secretion	O
of	O
the	O
inflammatory	B-GP
cytokines	I-GP
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

Western	O
blot	O
experiments	O
indicated	O
that	O
the	O
effects	O
mediated	O
by	O
FOS	B-GP
in	O
macrophages	O
are	O
associated	O
with	O
a	O
decreased	O
activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
.	O

Since	O
FOS	O
and	O
inulin	B-CD
stimulate	O
pathway	O
activation	O
in	O
the	O
absence	O
of	O
bacteria	B-OG
,	O
the	O
FOS	O
mediated	O
effect	O
is	O
likely	O
to	O
be	O
of	O
indirect	O
nature	O
,	O
such	O
as	O
via	O
a	O
reduction	O
of	O
bacterial	O
virulence	O
.	O

Further	O
,	O
this	O
modulatory	O
effect	O
is	O
observed	O
also	O
with	O
the	O
highly	O
virulent	O
ptxS	B-GP
mutated	O
strain	O
.	O

Co	O
-	O
culture	O
experiments	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
with	O
IEC18	O
eukaryotic	O
cells	O
showed	O
that	O
FOS	B-GP
reduces	O
the	O
concentration	O
of	O
the	O
major	O
virulence	B-GP
factor	I-GP
,	O
exotoxin	B-GP
A	I-GP
,	O
suggesting	O
that	O
this	O
is	O
a	O
possible	O
mechanism	O
for	O
the	O
reduction	O
of	O
pathogenicity	O
.	O

The	O
potential	O
of	O
these	O
compounds	O
as	O
components	O
of	O
antibacterial	O
and	O
anti	O
-	O
inflammatory	O
cocktails	O
is	O
discussed	O
.	O

Introduction	O

Strains	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
are	O
ubiquitously	O
present	O
in	O
the	O
environment	O
[	O
1	O
],	O
which	O
is	O
due	O
to	O
their	O
capacity	O
to	O
colonize	O
different	O
ecological	O
niches	O
[	O
2	O
],	O
[	O
3	O
]	O
and	O
metabolic	O
versatility	O
[	O
4	O
].	O
P	B-OG
.	I-OG
aeruginosa	I-OG
is	O
an	O
opportunistic	O
pathogen	O
able	O
to	O
infect	O
different	O
animals	B-OG
and	O
plants	B-OG
[	O
5	O
],	O
[	O
6	O
],	O
being	O
a	O
frequent	O
cause	O
of	O
hospital	B-DS
-	I-DS
acquired	I-DS
infections	I-DS
including	O
ventilator	B-DS
associated	I-DS
pneumonia	I-DS
[	O
7	O
]	O
and	O
catheter	B-DS
infections	I-DS
in	O
immuno	O
-	O
compromised	O
patients	O
.	O
P	B-OG
.	I-OG
aeruginosa	I-OG
lung	B-DS
infections	I-DS
are	O
the	O
main	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
cystic	B-DS
fibrosis	I-DS
(	O
CF	B-DS
)	O
patients	O
[	O
8	O
].	O

The	O
bacterium	B-OG
is	O
highly	O
resistant	O
to	O
antibiotic	O
treatment	O
and	O
difficult	O
to	O
eradicate	O
once	O
established	O
in	O
the	O
host	O
[	O
9	O
].	O

One	O
of	O
the	O
important	O
antibiotic	O
resistance	O
mechanisms	O
is	O
the	O
formation	O
of	O
biofilms	O
[	O
10	O
],	O
hence	O
a	O
great	O
deal	O
of	O
attention	O
has	O
been	O
given	O
to	O
the	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
its	O
generation	O
,	O
maturation	O
and	O
dispersal	O
[	O
11	O
],	O
[	O
12	O
].	O

It	O
has	O
been	O
shown	O
that	O
flagella	O
and	O
type	B-GP
IV	I-GP
pili	I-GP
-	O
mediated	O
motility	O
are	O
required	O
for	O
efficient	O
biofilm	O
formation	O
[	O
13	O
]–[	O
15	O
].	O

Bacteria	B-OG
use	O
different	O
secretion	O
systems	O
to	O
inject	O
virulence	O
factors	O
into	O
the	O
cytoplasm	O
of	O
eukaryotic	O
cells	O
,	O
leading	O
to	O
bacterial	O
replication	O
within	O
macrophages	O
and	O
,	O
consequently	O
,	O
evasion	O
from	O
the	O
immune	O
system	O
[	O
16	O
].	O

In	O
Gram	B-OG
-	I-OG
negative	I-OG
bacteria	I-OG
several	O
secretion	O
systems	O
have	O
been	O
characterized	O
,	O
referred	O
to	O
as	O
type	O
I	O
to	O
type	O
VI	O
systems	O
[	O
17	O
],	O
[	O
18	O
].	O

The	O
type	O
II	O
(	O
T2SS	O
)	O
and	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
secrete	O
the	O
majority	O
of	O
known	O
toxins	O
[	O
19	O
].	O

They	O
differ	O
in	O
their	O
molecular	O
mechanisms	O
and	O
operate	O
on	O
several	O
substrates	O
.	O

The	O
secretion	O
system	O
type	O
I	O
is	O
an	O
ABC	B-GP
transporter	I-GP
composed	O
of	O
an	O
ABC	B-GP
protein	I-GP
,	O
a	O
membrane	B-GP
fusion	I-GP
protein	I-GP
and	O
an	O
outer	B-GP
membrane	I-GP
protein	I-GP
.	O

This	O
system	O
transports	O
various	O
molecules	O
of	O
diverse	O
nature	O
such	O
as	O
ions	O
,	O
drugs	O
,	O
and	O
proteins	O
[	O
20	O
].	O

Similarly	O
,	O
type	O
II	O
and	O
V	O
secretion	O
systems	O
generally	O
transport	O
proteins	O
to	O
the	O
surface	O
of	O
the	O
host	O
cell	O
and	O
are	O
involved	O
in	O
the	O
extracellular	O
release	O
of	O
various	O
toxins	O
and	O
hydrolytic	O
enzymes	O
such	O
as	O
exotoxin	B-GP
A	I-GP
,	O
Las	B-GP
A	I-GP
,	O
Las	B-GP
B	I-GP
,	O
protease	B-GP
and	O
elastase	B-GP
[	O
21	O
],	O
[	O
22	O
].	O

In	O
contrast	O
,	O
the	O
type	O
III	O
secretion	O
system	O
(	O
T3SS	O
)	O
injects	O
proteins	O
,	O
small	O
molecular	O
weight	O
compounds	O
and	O
hydrolytic	O
enzymes	O
into	O
the	O
cytosol	O
of	O
eukaryotic	O
cells	O
[	O
23	O
],	O
which	O
corresponds	O
to	O
a	O
potent	O
virulence	O
mechanism	O
shared	O
by	O
many	O
pathogenic	O
Gram	B-OG
-	I-OG
negative	I-OG
bacteria	I-OG
.	O

This	O
protein	O
injection	O
in	O
turn	O
triggers	O
a	O
cytoskeletal	O
reorganization	O
of	O
the	O
host	O
cell	O
as	O
shown	O
by	O
the	O
inhibition	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
internalization	O
upon	O
incubation	O
with	O
cytochalasin	B-CD
D	I-CD
[	O
24	O
],	O
which	O
destroys	O
microfilaments	O
,	O
thereby	O
preventing	O
further	O
uptake	O
of	O
bacteria	B-OG
[	O
16	O
],	O
[	O
23	O
],	O
[	O
25	O
].	O

A	O
significant	O
number	O
of	O
natural	O
compounds	O
have	O
been	O
found	O
to	O
inhibit	O
bacterial	O
growth	O
,	O
although	O
their	O
mechanism	O
of	O
action	O
remains	O
unclear	O
in	O
most	O
cases	O
[	O
26	O
],	O
[	O
27	O
].	O

Here	O
we	O
report	O
a	O
study	O
on	O
the	O
activity	O
of	O
the	O
fructo	B-CD
-	O
oligosaccharides	O
(	O
FOS	O
)	O
and	O
inulin	B-CD
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
proliferation	O
.	O

Inulin	B-CD
is	O
a	O
linear	O
polymer	O
formed	O
by	O
20	O
to	O
over	O
60	O
β	O
-	O
2	O
,	O
1	O
-	O
linked	O
fructose	B-CD
monomers	O
with	O
a	O
terminal	O
glucose	B-CD
residue	O
,	O
whereas	O
FOS	B-GP
are	O
short	O
-	O
chain	O
oligosaccharides	O
with	O
the	O
same	O
structure	O
but	O
a	O
maximal	O
chain	O
length	O
of	O
2	O
to	O
20	O
monomeric	O
units	O
which	O
are	O
generated	O
by	O
hydrolysis	O
of	O
inulin	B-CD
[	O
28	O
].	O

Inulin	B-GP
is	O
found	O
in	O
different	O
nutrients	O
such	O
as	O
wheat	B-OG
,	O
onion	B-OG
,	O
garlic	B-OG
and	O
banana	B-OG
[	O
29	O
].	O

Inulin	B-CD
and	O
FOS	O
are	O
considered	O
prebiotics	O
,	O
based	O
on	O
the	O
observation	O
that	O
they	O
promote	O
the	O
growth	O
of	O
certain	O
beneficial	O
gut	B-OG
bacteria	I-OG
such	O
as	O
bifidobacteria	B-OG
[	O
30	O
],	O
[	O
31	O
],	O
but	O
they	O
have	O
been	O
also	O
found	O
to	O
inhibit	O
the	O
growth	O
of	O
pathogenic	O
bacteria	B-OG
such	O
as	O
Salmonella	B-OG
typhimurium	I-OG
[	O
32	O
],	O
S	B-OG
.	I-OG
enteritidis	I-OG
[	O
33	O
]	O
Listeria	B-OG
monocytogenes	I-OG
or	O
the	O
fungus	B-OG
Candida	B-OG
albicans	I-OG
[	O
34	O
].	O

In	O
addition	O
inulin	B-CD
and	O
FOS	O
have	O
been	O
found	O
to	O
have	O
a	O
beneficial	O
impact	O
on	O
human	B-OG
health	O
,	O
including	O
the	O
stimulation	O
of	O
calcium	O
,	O
iron	O
and	O
zinc	O
absorption	O
[	O
35	O
]	O
and	O
the	O
modulation	O
of	O
local	O
and	O
systemic	O
immune	O
responses	O
[	O
36	O
].	O

Here	O
we	O
show	O
that	O
the	O
addition	O
of	O
FOS	B-GP
to	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
cultures	O
decreases	O
growth	O
and	O
biofilm	O
formation	O
.	O

This	O
effect	O
appears	O
to	O
be	O
specific	O
for	O
FOS	B-GP
since	O
it	O
was	O
not	O
observed	O
following	O
inulin	B-CD
treatment	O
.	O

In	O
addition	O
,	O
FOS	B-GP
reduces	O
the	O
cytokine	B-GP
response	O
of	O
rat	B-OG
primary	O
monocytes	O
to	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infection	I-DS
,	O
an	O
effect	O
considered	O
indirect	O
since	O
this	O
oligosaccharide	O
was	O
found	O
to	O
activate	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
.	O

Attenuated	O
responses	O
are	O
observed	O
also	O
with	O
the	O
virulent	O
ptxS	B-GP
mutant	O
strain	O
.	O

Exotoxin	O
A	O
production	O
is	O
lowered	O
by	O
FOS	B-GP
treatment	O
,	O
suggesting	O
that	O
FOS	B-GP
may	O
interfere	O
with	O
exotoxin	O
synthesis	O
and	O
/	O
or	O
secretion	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
FOS	O
may	O
be	O
a	O
useful	O
component	O
of	O
drug	O
cocktails	O
for	O
the	O
treatment	O
of	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infections	I-DS
.	O

Results	O

Differential	O
effect	O
of	O
FOS	B-GP
and	O
inulin	B-CD
on	O
the	O
growth	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG

As	O
stated	O
in	O
the	O
introduction	O
,	O
a	O
number	O
of	O
natural	O
compounds	O
can	O
either	O
promote	O
or	O
slow	O
down	O
the	O
growth	O
of	O
microorganisms	B-OG
.	O

To	O
assess	O
the	O
effect	O
of	O
inulin	B-CD
and	O
FOS	B-GP
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
,	O
growth	O
curves	O
were	O
recorded	O
in	O
minimal	O
medium	O
M9	O
supplemented	O
with	O
citrate	B-CD
.	O

Under	O
these	O
conditions	O
only	O
minor	O
changes	O
in	O
the	O
bacterial	O
growth	O
rate	O
and	O
yield	O
were	O
observed	O
in	O
the	O
presence	O
of	O
5	O
–	O
20	O
mg	O
/	O
ml	O
inulin	B-CD
.	O

Namely	O
,	O
5	O
and	O
15	O
mg	O
/	O
ml	O
of	O
inulin	B-CD
resulted	O
in	O
a	O
slight	O
to	O
moderate	O
stimulation	O
of	O
growth	O
,	O
whereas	O
at	O
the	O
concentration	O
of	O
20	O
mg	O
/	O
ml	O
a	O
slight	O
reduction	O
was	O
noted	O
(	O
Fig	O
.	O
1A	O
).	O

Effect	O
of	O
inulin	B-CD
and	O
FOS	O
on	O
the	O
growth	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
.	O

Growth	O
curves	O
in	O
minimal	O
medium	O
M9	O
supplemented	O
with	O
50	O
(	O
A	O
)	O
and	O
FOS	B-GP
(	O
B	O
)	O
are	O
shown	O
.	O

As	O
a	O
control	O
,	O
growth	O
in	O
the	O
minimal	O
medium	O
M9	O
supplemented	O
with	O
20	O
mg	O
/	O
ml	O
of	O
goat	B-OG
milk	O
oligosaccharides	O
(	O
OS	O
)	O
is	O
shown	O
.	O

Growth	O
curves	O
were	O
recorded	O
at	O
37	O
°	O
C	O
for	O
24	O
hours	O
.	O

Representative	O
data	O
from	O
one	O
of	O
three	O
independent	O
experiments	O
with	O
similar	O
results	O
are	O
shown	O
.	O

Similarly	O
,	O
in	O
the	O
presence	O
of	O
5	O
–	O
15	O
mg	O
/	O
ml	O
of	O
FOS	B-GP
a	O
minor	O
stimulation	O
of	O
bacterial	O
growth	O
was	O
noted	O
(	O
Fig	O
.	O
1B	O
);	O
however	O
,	O
at	O
the	O
concentration	O
of	O
20	O
mg	O
/	O
ml	O
a	O
marked	O
inhibition	O
was	O
observed	O
(	O
Fig	O
.	O
1B	O
).	O

Since	O
inulin	B-CD
and	O
FOS	B-GP
differ	O
only	O
in	O
the	O
carbohydrate	B-CD
chain	O
length	O
,	O
this	O
parameter	O
appears	O
to	O
be	O
central	O
for	O
antibacterial	O
activity	O
.	O

In	O
comparison	O
,	O
a	O
growth	O
curve	O
was	O
recorded	O
in	O
the	O
presence	O
of	O
20	O
mg	O
/	O
ml	O
of	O
control	O
goat	B-OG
milk	O
oligosaccharides	O
(	O
OS	O
),	O
showing	O
promotion	O
of	O
bacterial	O
growth	O
at	O
the	O
same	O
concentration	O
at	O
which	O
FOS	O
inhibits	O
growth	O
.	O

In	O
fact	O
,	O
both	O
FOS	O
and	O
inulin	B-CD
(	O
at	O
15	O
–	O
20	O
mg	O
/	O
ml	O
)	O
are	O
able	O
to	O
support	O
bacterial	O
growth	O
when	O
M9	O
minimal	O
medium	O
is	O
used	O
(	O
data	O
not	O
shown	O
).	O

Reduction	O
of	O
biofilm	O
formation	O
in	O
the	O
presence	O
of	O
FOS	B-GP

To	O
assess	O
the	O
influence	O
of	O
FOS	B-GP
and	O
inulin	B-CD
on	O
biofilm	O
formation	O
,	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
was	O
cultured	O
in	O
24	O
-	O
well	O
plates	O
in	O
the	O
absence	O
or	O
presence	O
of	O
different	O
concentrations	O
of	O
both	O
compounds	O
for	O
6	O
hours	O
(	O
Fig	O
.	O
2A	O
),	O
followed	O
by	O
a	O
quantification	O
of	O
biofilm	O
formation	O
.	O
Fig	O
.	O
2	O
B	O
and	O
Fig	O
.	O

S1	O
show	O
the	O
relative	O
amount	O
of	O
biofilm	O
formation	O
as	O
a	O
function	O
of	O
the	O
inulin	B-CD
/	O
FOS	O
concentration	O
(	O
logarithmic	O
scale	O
).	O

It	O
became	O
apparent	O
that	O
both	O
compounds	O
have	O
opposite	O
effects	O
;	O
whereas	O
inulin	B-CD
stimulated	O
biofilm	O
formation	O
,	O
FOS	O
had	O
a	O
concentration	O
dependent	O
inhibitory	O
effect	O
.	O

Fitting	O
of	O
data	O
(	O
Fig	O
.	O
2B	O
)	O
resulted	O
in	O
an	O
EC50	O
value	O
of	O
2	O
.	O
1	O
mg	O
/	O
ml	O
for	O
FOS	B-GP
(	O
inhibition	O
)	O
and	O
5	O
.	O
8	O
mg	O
/	O
ml	O
for	O
inulin	B-CD
(	O
stimulation	O
).	O

Biofilm	O
formation	O
was	O
almost	O
completely	O
inhibited	O
at	O
a	O
FOS	B-GP
concentration	O
of	O
4	O
–	O
8	O
mg	O
/	O
ml	O
,	O
which	O
is	O
in	O
sharp	O
contrast	O
with	O
inulin	B-CD
that	O
produced	O
a	O
∼	O
10	O
-	O
fold	O
enhancement	O
at	O
concentrations	O
up	O
to	O
approximately	O
10	O
mg	O
/	O
ml	O
.	O

Formation	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
biofilm	O
.	O

A	O
)	O
Biofilm	O
formation	O
in	O
the	O
absence	O
and	O
presence	O
of	O
different	O
concentrations	O
of	O
FOS	O
and	O
inulin	B-CD
in	O
24	O
-	O
well	O
plates	O
.	O

Biofilm	O
formation	O
was	O
monitored	O
in	O
M9	O
minimal	O
medium	O
supplemented	O
with	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	B-CD
and	O
casamino	B-CD
acids	I-CD
and	O
quantified	O
after	O
6	O
h	O
.	O

B	O
)	O
The	O
relative	O
amounts	O
of	O
biofilm	O
formation	O
in	O
the	O
experiments	O
shown	O
in	O
Fig	O
.	O
2A	O
are	O
plotted	O
against	O
the	O
logarithm	O
of	O
inulin	B-CD
/	O
FOS	B-GP
concentration	O
.	O

Data	O
were	O
fitted	O
with	O
the	O
sigmoidal	O
model	O
of	O
the	O
ORIGIN	O
software	O
package	O
to	O
determine	O
EC50	O
values	O
.	O

Data	O
are	O
the	O
average	O
of	O
three	O
independent	O
assays	O
.	O

C	O
)	O
Microscopic	O
inspection	O
of	O
biofilm	O
formation	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
20	O
mg	O
/	O
ml	O
inulin	B-CD
or	O
FOS	B-GP
at	O
2	O
,	O
4	O
and	O
6	O
hours	O
.	O

Subsequently	O
,	O
biofilms	O
formed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
both	O
compounds	O
(	O
at	O
20	O
mg	O
/	O
ml	O
)	O
were	O
observed	O
under	O
the	O
microscope	O
(	O
Fig	O
.	O
2C	O
).	O

To	O
this	O
end	O
bacteria	B-OG
were	O
grown	O
in	O
M9	O
minimal	O
medium	O
supplemented	O
with	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	B-CD
,	O
0	O
.	O
4	O
%	O
(	O
wt	O
/	O
v	O
)	O
casamino	B-CD
acids	I-CD
and	O
with	O
inulin	B-CD
or	O
FOS	O
.	O

In	O
control	O
conditions	O
clear	O
biofilm	O
formation	O
was	O
observed	O
after	O
4	O
and	O
6	O
hours	O
of	O
culture	O
,	O
as	O
expected	O
(	O
Fig	O
.	O
2C	O
).	O

Similar	O
results	O
were	O
obtained	O
with	O
20	O
mg	O
/	O
ml	O
of	O
inulin	B-CD
,	O
but	O
the	O
biofilm	O
was	O
more	O
prominent	O
after	O
6	O
h	O
as	O
compared	O
to	O
the	O
control	O
sample	O
.	O

In	O
contrast	O
,	O
while	O
biofilm	O
formation	O
in	O
the	O
presence	O
of	O
FOS	B-GP
was	O
comparable	O
to	O
that	O
in	O
control	O
conditions	O
after	O
4	O
hours	O
,	O
it	O
was	O
virtually	O
absent	O
at	O
6	O
h	O
(	O
Fig	O
.	O
2C	O
).	O

FOS	O
and	O
inulin	B-CD
have	O
opposite	O
effects	O
on	O
bacterial	O
motility	O

P	B-OG
.	I-OG
aeruginosa	I-OG
has	O
been	O
shown	O
to	O
exhibit	O
three	O
different	O
types	O
of	O
motility	O
,	O
namely	O
swimming	O
,	O
swarming	O
and	O
twitching	O
[	O
37	O
],	O
[	O
38	O
].	O

Twitching	O
motility	O
across	O
solid	O
surfaces	O
[	O
39	O
]	O
has	O
been	O
found	O
to	O
be	O
required	O
for	O
biofilm	O
development	O
[	O
13	O
],	O
[	O
40	O
],	O
as	O
well	O
as	O
for	O
a	O
persistent	O
colonization	O
of	O
lungs	O
,	O
and	O
it	O
is	O
associated	O
with	O
virulence	O
in	O
corneal	B-DS
infection	I-DS
models	O
[	O
39	O
],	O
[	O
41	O
].	O

We	O
have	O
studied	O
the	O
effect	O
of	O
inulin	B-CD
and	O
FOS	O
at	O
5	O
mg	O
/	O
ml	O
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
bacterial	O
motility	O
on	O
agar	O
plates	O
and	O
in	O
bacterial	O
suspension	O
(	O
Fig	O
.	O
3	O
).	O

Neither	O
FOS	B-GP
nor	O
inulin	B-CD
affected	O
swimming	O
behaviour	O
(	O
Fig	O
.	O
3A	O
).	O

Interestingly	O
,	O
FOS	B-GP
inhibited	O
both	O
swarming	O
and	O
twitching	O
motility	O
,	O
whereas	O
inulin	B-CD
treatment	O
resulted	O
in	O
the	O
opposite	O
effect	O
,	O
i	O
.	O
e	O
.	O
stimulation	O
(	O
Fig	O
.	O
3B	O
and	O
C	O
).	O

Effects	O
of	O
FOS	O
and	O
inulin	B-CD
on	O
the	O
motility	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
.	O

Motility	O
assays	O
were	O
carried	O
out	O
as	O
described	O
in	O
materials	O
and	O
methods	O
.	O

Inulin	O
or	O
FOS	B-GP
at	O
5	O
mg	O
/	O
ml	O
was	O
present	O
in	O
the	O
agar	O
plates	O
and	O
in	O
the	O
bacterial	O
suspensions	O
.	O

A	O
)	O
Swimming	O
assays	O
.	O

B	O
)	O
Swarming	O
assays	O
and	O
C	O
)	O
Twitching	O
assays	O
.	O

Average	O
values	O
of	O
the	O
distances	O
of	O
bacterial	O
migration	O
are	O
shown	O
.	O

Data	O
are	O
the	O
average	O
of	O
three	O
independent	O
assays	O
.	O

Values	O
are	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.,	O
n	O
=	O
6	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
without	O
effectors	O
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

Inulin	B-GP
and	O
FOS	B-GP
reduce	O
cytokine	B-GP
secretion	O
in	O
P	B-OG
.	I-OG
aeruginosa	I-OG
infected	O
macrophages	O

Tissue	O
injury	O
or	O
infection	B-DS
results	O
in	O
the	O
recruitment	O
and	O
activation	O
of	O
host	O
immune	O
cells	O
.	O

Macrophages	O
are	O
the	O
first	O
immune	O
cells	O
likely	O
to	O
encounter	O
P	B-OG
.	I-OG
aeruginosa	I-OG
.	O

The	O
activation	O
of	O
macrophages	O
is	O
based	O
largely	O
on	O
the	O
recognition	O
of	O
pathogens	O
by	O
molecular	O
pattern	B-GP
receptors	I-GP
,	O
including	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
),	O
such	O
as	O
TLR4	B-GP
[	O
16	O
],	O
[	O
42	O
].	O

Macrophages	O
can	O
internalize	O
and	O
kill	O
bacterial	O
pathogens	O
;	O
however	O
,	O
during	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infections	I-DS
their	O
role	O
in	O
pathogen	O
sensing	O
is	O
of	O
primary	O
importance	O
[	O
43	O
].	O

This	O
in	O
turn	O
causes	O
significant	O
changes	O
in	O
gene	O
expression	O
and	O
the	O
secretion	O
of	O
proinflammatory	O
cytokines	B-GP
IL	B-GP
-	I-GP
6	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
that	O
recruit	O
inflammatory	O
cells	O
in	O
response	O
to	O
bacterial	O
virulence	O
factors	O
,	O
while	O
IL	B-GP
-	I-GP
10	I-GP
tends	O
to	O
mitigate	O
this	O
response	O
[	O
44	O
]–[	O
47	O
].	O

These	O
are	O
among	O
the	O
main	O
signalling	O
mediators	O
released	O
by	O
monocyte	O
/	O
macrophages	O
.	O

Initial	O
experiments	O
were	O
carried	O
out	O
to	O
establish	O
the	O
experimental	O
conditions	O
for	O
the	O
assessment	O
of	O
the	O
effect	O
of	O
FOS	B-CD
and	O
inulin	B-CD
on	O
cytokine	B-GP
secretion	O
(	O
Fig	O
.	O

S2	O
).	O

Macrophages	O
were	O
incubated	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
and	O
interleukin	B-GP
6	I-GP
secretion	O
was	O
measured	O
at	O
different	O
time	O
intervals	O
(	O
Fig	O
.	O

S2	O
).	O

Maximal	O
secretion	O
was	O
observed	O
after	O
4	O
hours	O
of	O
incubation	O
.	O

Therefore	O
,	O
these	O
experimental	O
conditions	O
were	O
used	O
to	O
quantify	O
the	O
effect	O
of	O
FOS	O
/	O
inulin	B-CD
on	O
the	O
secretion	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

In	O
the	O
absence	O
of	O
bacteria	B-OG
(	O
Fig	O
.	O
4	O
,	O
column	O
–	O
PAO1	O
),	O
inulin	B-CD
and	O
FOS	O
had	O
no	O
significant	O
effect	O
on	O
cytokine	B-GP
secretion	O
,	O
although	O
a	O
slight	O
increase	O
was	O
noted	O
.	O

PAO	B-DS
-	I-DS
1	I-DS
infection	I-DS
caused	O
the	O
expected	O
significant	O
increase	O
in	O
cytokine	B-GP
secretion	O
.	O

This	O
response	O
was	O
markedly	O
attenuated	O
for	O
the	O
three	O
cytokines	B-GP
in	O
the	O
presence	O
of	O
FOS	B-GP
,	O
while	O
inulin	B-CD
caused	O
exclusively	O
a	O
reduction	O
in	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
(	O
Fig	O
.	O
4	O
).	O

These	O
data	O
therefore	O
show	O
that	O
the	O
presence	O
of	O
inulin	B-CD
and	O
particularly	O
FOS	B-GP
reduced	O
the	O
inflammatory	O
response	O
of	O
macrophages	O
to	O
bacterial	B-DS
infection	I-DS
.	O

Since	O
FOS	O
/	O
inulin	B-CD
did	O
not	O
reduce	O
the	O
cytokine	B-GP
release	O
in	O
the	O
absence	O
of	O
bacteria	B-OG
,	O
our	O
results	O
suggest	O
that	O
the	O
inhibitory	O
effect	O
of	O
FOS	O
is	O
probably	O
due	O
to	O
a	O
direct	O
interaction	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
.	O

Effect	O
of	O
inulin	B-CD
and	O
FOS	O
on	O
inflammatory	O
response	O
of	O
macrophages	O
against	O
P	B-OG
.	I-OG
aeruginosa	I-OG
(	O
WT	O
).	O

Macrophages	O
were	O
incubated	O
with	O
WT	O
P	B-OG
.	I-OG
aeruginosa	I-OG
cells	O
(	O
ratio	O
1	O
/	O
5	O
)	O
for	O
4	O
hours	O
in	O
either	O
the	O
absence	O
or	O
the	O
presence	O
of	O
5	O
mg	O
/	O
ml	O
FOS	B-GP
and	O
inulin	B-CD
prior	O
to	O
the	O
determination	O
of	O
IL	B-GP
-	I-GP
6	I-GP
(	O
A	O
),	O
IL	B-GP
-	I-GP
10	I-GP
(	O
B	O
)	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
secretion	O
(	O
C	O
).	O

Values	O
are	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.,	O
n	O
=	O
6	O
–	O
8	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
without	O
bacteria	B-OG
and	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
WT	O
in	O
the	O
absence	O
of	O
inulin	B-CD
or	O
FOS	B-GP
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

Activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
signal	O
transduction	O
pathway	O
is	O
downregulated	O
by	O
FOS	B-GP

The	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	O
MAPK	B-GP
)	O
and	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
signalling	O
pathways	O
are	O
implicated	O
in	O
the	O
production	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
in	O
macrophages	O
[	O
48	O
].	O

In	O
addition	O
,	O
it	O
has	O
been	O
reported	O
that	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infection	I-DS
is	O
associated	O
to	O
stimulation	O
of	O
TLR4	B-GP
receptors	I-GP
,	O
leading	O
to	O
an	O
activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
[	O
49	O
].	O

To	O
assess	O
the	O
impact	O
of	O
inulin	B-CD
and	O
FOS	B-GP
on	O
the	O
inflammatory	O
response	O
,	O
the	O
role	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
signalling	O
pathways	O
in	O
the	O
FOS	B-GP
-	O
mediated	O
modulation	O
of	O
macrophages	O
was	O
assessed	O
.	O

One	O
of	O
the	O
ways	O
to	O
activate	O
NF	B-GP
-	I-GP
κB	I-GP
by	O
extracellular	O
stimuli	O
involves	O
the	O
rapid	O
degradation	O
of	O
IκB	B-GP
-	I-GP
α	I-GP
as	O
a	O
consequence	O
of	O
IκB	B-GP
-	I-GP
α	I-GP
phosphorylation	O
at	O
Ser32	O
by	O
IκB	B-GP
kinase	I-GP
,	O
which	O
corresponds	O
to	O
IKK	B-GP
in	O
the	O
so	O
-	O
called	O
canonical	O
pathway	O
.	O

We	O
studied	O
the	O
effect	O
of	O
inulin	B-CD
and	O
FOS	B-GP
on	O
the	O
activation	O
(	O
phosphorylation	O
)	O
of	O
IκB	B-GP
-	I-GP
α	I-GP
and	O
MAPK	B-GP
,	O
ERK	B-GP
,	O
JNK	B-GP
and	O
p38	B-GP
by	O
Western	O
blot	O
analysis	O
in	O
macrophages	O
infected	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
.	O

As	O
shown	O
in	O
Fig	O
.	O
5A	O
,	O
neither	O
FOS	B-GP
nor	O
inulin	B-CD
affected	O
the	O
phosphospecific	O
signal	O
of	O
the	O
three	O
MAPK	B-GP
,	O
suggesting	O
that	O
they	O
are	O
not	O
involved	O
in	O
the	O
observed	O
changes	O
.	O

In	O
contrast	O
,	O
FOS	B-GP
but	O
not	O
inulin	B-CD
reduced	O
IκB	B-GP
-	I-GP
α	I-GP
phosphorylation	O
,	O
pointing	O
to	O
a	O
modulation	O
of	O
the	O
NFκ	B-GP
-	I-GP
B	I-GP
canonical	O
pathway	O
.	O

FOS	B-GP
but	O
not	O
inulin	B-CD
reduces	O
the	O
amount	O
of	O
phosphorylated	O
IkB	B-GP
-	I-GP
α	I-GP
.	O

A	O
)	O
Macrophages	O
were	O
infected	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
in	O
the	O
absence	O
or	O
presence	O
of	O
either	O
5	O
mg	O
/	O
ml	O
FOS	O
or	O
inulin	B-CD
.	O

After	O
4	O
h	O
growth	O
Western	O
blots	O
were	O
performed	O
using	O
cell	O
extracts	O
and	O
the	O
corresponding	O
antibodies	B-GP
against	O
ERK	B-GP
(	O
Extracellular	B-GP
Regulated	I-GP
Kinase	I-GP
),	O
p	O
-	O
ERK	B-GP
(	O
the	O
phosphorylated	O
form	O
of	O
Extracellular	B-GP
Regulated	I-GP
Kinase	I-GP
),	O
p	O
-	O
P38	B-GP
(	O
activated	O
and	O
phosphorylated	O
form	O
of	O
P38	B-GP
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinases	I-GP
),	O
p	O
-	O
JNK	B-GP
(	O
Jun	B-GP
N	I-GP
-	I-GP
terminal	I-GP
kinases	I-GP
)	O
and	O
after	O
1	O
h	O
for	O
p	O
-	O
IκB	B-GP
-	I-GP
α	I-GP
(	O
activated	O
form	O
in	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
canonical	O
pathway	O
).	O

As	O
control	O
,	O
actin	B-GP
was	O
quantified	O
in	O
all	O
samples	O
using	O
an	O
anti	O
-	O
α	B-GP
-	I-GP
actin	I-GP
antibody	B-GP
.	O

Duplicate	O
samples	O
in	O
the	O
absence	O
of	O
added	O
effectors	O
and	O
triplicate	O
samples	O
in	O
the	O
presence	O
of	O
FOS	B-GP
and	O
inulin	B-CD
are	O
shown	O
.	O

B	O
)	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
was	O
determined	O
by	O
measuring	O
the	O
nuclear	O
translocation	O
of	O
the	O
p65	B-GP
component	O
,	O
expressed	O
as	O
the	O
OD450	O
nm	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
without	O
bacteria	B-OG
and	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
WT	O
in	O
the	O
absence	O
of	O
inulin	B-CD
or	O
FOS	B-GP
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

Moreover	O
,	O
the	O
activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
transcription	I-GP
factor	I-GP
is	O
associated	O
with	O
the	O
nuclear	O
translocation	O
of	O
the	O
p65	B-GP
component	O
of	O
the	O
complex	O
.	O

To	O
confirm	O
the	O
effect	O
of	O
inulin	B-CD
or	O
FOS	B-GP
on	O
nuclear	O
NF	B-GP
-	I-GP
κB	I-GP
/	O
p65	B-GP
translocation	O
,	O
p65	B-GP
was	O
quantified	O
by	O
ELISA	O
in	O
cell	O
nuclei	O
following	O
1	O
h	O
activation	O
.	O

In	O
contrast	O
to	O
inulin	B-CD
,	O
FOS	B-GP
(	O
5	O
mg	O
/	O
ml	O
)	O
effectively	O
reduced	O
NF	B-GP
-	I-GP
κB	I-GP
/	O
p65	B-GP
translocation	O
(	O
Fig	O
.	O
5B	O
).	O

Therefore	O
,	O
the	O
effect	O
of	O
FOS	B-GP
is	O
associated	O
with	O
a	O
minor	O
activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
signalling	O
pathway	O
.	O

The	O
effect	O
of	O
FOS	O
is	O
observed	O
in	O
P	B-OG
.	I-OG
aeruginosa	I-OG
mutant	O
strains	O
with	O
different	O
degrees	O
of	O
virulence	O

Since	O
the	O
FOS	B-GP
-	O
mediated	O
inhibition	O
of	O
bacterial	O
growth	O
and	O
biofilm	O
formation	O
may	O
reduce	O
virulence	O
,	O
we	O
hypothesized	O
that	O
the	O
response	O
of	O
eukaryotic	O
cells	O
to	O
infection	B-DS
may	O
be	O
modulated	O
by	O
the	O
presence	O
of	O
this	O
oligosaccharide	O
.	O

Subsequent	O
experiments	O
were	O
aimed	O
at	O
assessing	O
the	O
effect	O
of	O
FOS	O
and	O
inulin	B-CD
in	O
two	O
strains	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
showing	O
different	O
levels	O
of	O
virulence	O
compared	O
as	O
compared	O
to	O
wild	O
type	O
strain	O
.	O

We	O
used	O
mutants	O
deficient	O
in	O
PtxS	B-GP
and	O
PtxR	B-GP
,	O
two	O
transcriptional	B-GP
regulators	I-GP
that	O
control	O
the	O
expression	O
of	O
the	O
toxA	B-GP
gene	O
,	O
encoding	O
the	O
exotoxin	B-GP
A	I-GP
virulence	B-GP
factor	I-GP
[	O
50	O
].	O

Both	O
,	O
PtxR	B-GP
and	O
PtxS	B-GP
play	O
a	O
role	O
in	O
regulating	O
the	O
activity	O
from	O
the	O
PtoxA	B-GP
promoter	O
[	O
51	O
].	O

Mutation	O
of	O
ptxS	B-GP
increases	O
toxA	B-GP
expression	O
by	O
a	O
factor	O
of	O
∼	O
4	O
,	O
whereas	O
deletion	O
of	O
ptxR	B-GP
causes	O
a	O
∼	O
2	O
-	O
fold	O
reduction	O
[	O
51	O
].	O

The	O
increase	O
in	O
toxicity	O
of	O
the	O
ptxS	B-GP
mutant	O
(	O
Fig	O
.	O
6A	O
)	O
is	O
reflected	O
in	O
the	O
colour	O
of	O
bacterial	O
cultures	O
due	O
to	O
the	O
increased	O
production	O
of	O
the	O
bright	O
blue	O
-	O
green	O
siderophore	O
pyocyanin	B-GP
,	O
an	O
important	O
virulence	O
factor	O
of	O
fluorescent	O
Pseudomonads	B-OG
[	O
52	O
]–[	O
54	O
].	O

In	O
contrast	O
the	O
colour	O
of	O
the	O
ptxR	B-GP
mutant	O
is	O
similar	O
to	O
that	O
of	O
the	O
wild	O
type	O
strain	O
.	O

Further	O
,	O
anti	O
-	O
exotoxin	B-GP
A	I-GP
western	O
blot	O
showed	O
that	O
ptxS	B-GP
mutant	O
produces	O
significantly	O
more	O
exotoxin	B-GP
A	I-GP
than	O
the	O
ptxR	B-GP
mutant	O
(	O
Fig	O
.	O
6B	O
).	O

Subsequently	O
,	O
the	O
cytotoxic	O
activity	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
on	O
macrophages	O
was	O
analysed	O
4	O
hours	O
after	O
infection	B-DS
,	O
using	O
the	O
Cytotox	O
96	O
®	O
non	O
-	O
radioactive	O
cytotoxicity	O
assay	O
kit	O
.	O

As	O
expected	O
,	O
cytotoxicity	O
was	O
highest	O
for	O
the	O
ptxS	B-GP
mutant	O
(	O
Fig	O
.	O
6C	O
)	O
where	O
approximately	O
25	O
%	O
of	O
cells	O
died	O
,	O
followed	O
by	O
the	O
wild	O
type	O
strain	O
(	O
10	O
%	O
of	O
cell	O
death	O
)	O
and	O
the	O
ptxR	B-GP
mutant	O
for	O
which	O
no	O
toxicity	O
was	O
detected	O
(	O
Figure	O
6C	O
).	O

The	O
lactase	B-GP
dehydrogenase	I-GP
(	O
LDH	B-GP
)	O
is	O
a	O
marker	O
for	O
cytotoxicity	O
.	O

We	O
have	O
determined	O
the	O
LDH	B-GP
levels	O
of	O
0	O
.	O
1	O
–	O
0	O
.	O
2	O
mU	O
/	O
µl	O
in	O
the	O
absence	O
of	O
bacteria	B-OG
but	O
in	O
the	O
presence	O
of	O
FOS	O
or	O
inulin	B-CD
(	O
data	O
not	O
shown	O
).	O

Both	O
compounds	O
did	O
not	O
induce	O
any	O
significant	O
changes	O
in	O
the	O
LDH	B-GP
levels	O
,	O
indicating	O
that	O
they	O
are	O
not	O
cytotoxic	O
to	O
macrophages	O
under	O
the	O
conditions	O
used	O
(	O
data	O
not	O
shown	O
).	O

Effect	O
of	O
wild	O
type	O
and	O
mutant	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
on	O
macrophages	O
.	O

A	O
)	O
Cultures	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
and	O
its	O
mutants	O
deficient	O
in	O
ptxS	B-GP
and	O
ptxR	B-GP
were	O
grown	O
in	O
M9	O
Minimum	O
medium	O
supplemented	O
with	O
50	O
mM	O
citrate	O
for	O
24	O
hours	O
.	O

The	O
blue	O
-	O
green	O
colour	O
is	O
indicative	O
of	O
an	O
increased	O
pyocyanin	B-GP
secretion	O
.	O

B	O
)	O
Western	O
blot	O
determination	O
of	O
exotoxin	O
A	O
concentration	O
secreted	O
by	O
P	B-OG
.	I-OG
aeruginosa	I-OG
WT	O
and	O
its	O
isogenic	O
mutants	O
ptxS	B-GP
and	O
ptxR	B-GP
.	O

C	O
)	O
The	O
macrophage	O
mortality	O
induced	O
by	O
WT	O
P	B-OG
.	I-OG
aeruginosa	I-OG
and	O
its	O
ptxS	B-GP
and	O
ptxR	B-GP
mutants	O
was	O
measured	O
by	O
the	O
total	O
release	O
of	O
cytoplasmic	O
lactate	B-GP
dehydrogenase	I-GP
(	O
LDH	B-GP
).	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
without	O
bacteria	B-OG
and	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
with	O
WT	O
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

As	O
expected	O
,	O
the	O
cytokine	B-GP
secretory	O
response	O
followed	O
the	O
same	O
pattern	O
,	O
being	O
higher	O
with	O
the	O
ptxS	O
mutant	O
,	O
followed	O
by	O
the	O
wild	O
type	O
and	O
lower	O
for	O
the	O
ptxR	O
mutant	O
(	O
Fig	O
.	O
7	O
)	O
(	O
Data	O
from	O
Fig	O
.	O
4	O
are	O
included	O
for	O
comparison	O
)	O
[	O
51	O
].	O

For	O
all	O
three	O
bacterial	O
strains	O
analysed	O
,	O
FOS	O
caused	O
a	O
very	O
pronounced	O
reduction	O
(	O
Fig	O
.	O
7	O
),	O
while	O
inulin	B-CD
caused	O
a	O
more	O
moderate	O
reduction	O
.	O

Interestingly	O
,	O
the	O
FOS	O
/	O
inulin	B-CD
mediated	O
reduction	O
was	O
more	O
pronounced	O
in	O
the	O
ptxS	B-GP
mutant	O
than	O
in	O
WT	O
strain	O
,	O
suggesting	O
that	O
virulent	O
strains	O
may	O
be	O
more	O
sensitive	O
to	O
the	O
effect	O
of	O
fructose	B-CD
oligosaccharides	O
.	O

Effect	O
of	O
inulin	B-CD
and	O
FOS	O
on	O
inflammatory	O
response	O
of	O
macrophages	O
against	O
WT	O
P	B-OG
.	I-OG
aeruginosa	I-OG
and	O
its	O
isogenic	O
mutants	O
ptxS	B-GP
and	O
ptxR	B-GP
.	O

Macrophages	O
were	O
incubated	O
with	O
WT	O
and	O
mutant	O
P	B-OG
.	I-OG
aeruginosa	I-OG
cells	O
(	O
ratio	O
1	O
/	O
5	O
)	O
for	O
4	O
hours	O
in	O
either	O
the	O
absence	O
or	O
the	O
presence	O
of	O
5	O
mg	O
/	O
ml	O
FOS	O
and	O
inulin	B-CD
prior	O
to	O
the	O
determination	O
of	O
IL	B-GP
-	I-GP
6	I-GP
(	O
A	O
),	O
IL	B-GP
-	I-GP
10	I-GP
(	O
B	O
)	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
secretion	O
(	O
C	O
).	O

Values	O
are	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.,	O
n	O
=	O
6	O
–	O
8	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
WT	O
in	O
the	O
absence	O
of	O
inulin	B-CD
or	O
FOS	B-GP
;	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
ptxS	O
mutant	O
without	O
effectors	O
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

P	B-OG
.	I-OG
aeruginosa	I-OG
employs	O
a	O
number	O
of	O
systems	O
to	O
secrete	O
proteins	O
which	O
play	O
different	O
roles	O
during	O
infection	B-DS
.	O

To	O
analyse	O
the	O
role	O
of	O
FOS	O
or	O
inulin	B-CD
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
virulence	O
,	O
exotoxin	B-GP
A	I-GP
was	O
quantified	O
in	O
supernatants	O
of	O
bacterial	O
co	O
-	O
cultures	O
with	O
eukaryotic	O
cells	O
as	O
well	O
as	O
within	O
eukaryotic	O
cells	O
.	O

To	O
achieve	O
a	O
good	O
separation	O
of	O
eukaryotic	O
cells	O
from	O
bacteria	B-OG
,	O
we	O
used	O
the	O
rat	B-OG
small	O
intestinal	O
cell	O
line	O
IEC18	O
that	O
grows	O
on	O
surfaces	O
and	O
exhibits	O
inflammatory	O
responses	O
[	O
55	O
],	O
[	O
56	O
].	O

Bacteria	B-OG
are	O
removed	O
by	O
a	O
washing	O
step	O
with	O
fresh	O
PBS	O
solution	O
,	O
leaving	O
an	O
intact	O
IEC18	O
cell	O
monolayer	O
containing	O
infecting	O
Pseudomonas	B-OG
.	O

Anti	O
-	O
exotoxin	B-GP
A	I-GP
western	O
blot	O
analysis	O
showed	O
that	O
the	O
addition	O
of	O
FOS	O
and	O
inulin	B-CD
to	O
eukaryotic	O
cells	O
did	O
not	O
alter	O
exotoxin	B-GP
A	I-GP
levels	O
present	O
in	O
the	O
culture	O
medium	O
(	O
data	O
not	O
shown	O
).	O

In	O
contrast	O
,	O
FOS	B-GP
was	O
found	O
to	O
reduce	O
intracellular	O
exotoxin	B-GP
A	I-GP
levels	O
in	O
IEC18	O
cells	O
co	O
-	O
cultured	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
,	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
in	O
the	O
presence	O
of	O
inulin	B-CD
(	O
Fig	O
.	O
8A	O
and	O
B	O
).	O

These	O
data	O
suggest	O
that	O
the	O
type	O
II	O
-	O
dependent	O
exotoxin	B-GP
A	I-GP
secretion	O
from	O
P	B-OG
.	I-OG
aeruginosa	I-OG
to	O
the	O
cell	O
cytosol	O
is	O
inhibited	O
by	O
FOS	B-GP
,	O
presumably	O
limiting	O
its	O
virulence	O
.	O

Because	O
we	O
cannot	O
rule	O
out	O
the	O
presence	O
of	O
extracellular	O
,	O
cell	O
adherent	O
bacteria	B-OG
in	O
the	O
sample	O
,	O
it	O
may	O
be	O
possible	O
that	O
FOS	B-GP
also	O
downregulates	O
exotoxin	B-GP
A	I-GP
in	O
extracellular	O
Pseudomonas	B-OG
.	O

FOS	B-GP
reduces	O
exotoxin	B-GP
A	I-GP
expression	O
.	O

A	O
)	O
Western	O
blot	O
determination	O
of	O
the	O
cellular	O
concentration	O
of	O
exotoxin	B-GP
A	I-GP
in	O
IEC18	O
cells	O
following	O
co	O
-	O
culture	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
in	O
the	O
presence	O
and	O
absence	O
of	O
FOS	O
and	O
inulin	B-CD
.	O

B	O
)	O
Densitometric	O
analysis	O
of	O
above	O
data	O
.	O

Exotoxin	O
A	O
densities	O
were	O
corrected	O
with	O
those	O
obtained	O
for	O
α	B-GP
-	I-GP
actin	I-GP
.	O

Values	O
are	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.,	O
n	O
=	O
3	O
;	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
/	O
WT	O
without	O
inulin	B-CD
or	O
FOS	B-GP
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

Discussion	O

Prebiotics	O
are	O
defined	O
as	O
compounds	O
that	O
have	O
beneficial	O
effects	O
on	O
humans	B-OG
by	O
altering	O
the	O
intestinal	O
microbiota	B-OG
in	O
a	O
manner	O
that	O
is	O
beneficial	O
to	O
health	O
.	O

The	O
mechanism	O
of	O
their	O
action	O
is	O
not	O
clear	O
,	O
but	O
it	O
is	O
thought	O
to	O
involve	O
preferential	O
utilization	O
of	O
oligosaccharides	O
by	O
host	O
-	O
friendly	O
bacterial	O
species	O
such	O
as	O
bifidobacteria	B-OG
or	O
lactobacilli	B-OG
,	O
indicating	O
that	O
prebiotic	O
substances	O
might	O
have	O
the	O
capacity	O
to	O
protect	O
against	O
infections	B-DS
and	O
reduce	O
the	O
presence	O
of	O
clinically	O
relevant	O
pathogens	O
in	O
the	O
faecal	O
flora	O
[	O
57	O
],	O
[	O
58	O
].	O

Another	O
proposed	O
mechanism	O
involves	O
enhanced	O
bacteriocin	B-GP
secretion	O
by	O
lactobacilli	B-OG
[	O
59	O
],	O
which	O
in	O
turn	O
facilitates	O
the	O
incorporation	O
of	O
bacteria	B-OG
into	O
a	O
niche	O
and	O
inhibits	O
the	O
invasion	O
of	O
competing	O
strains	O
or	O
pathogens	O
,	O
leading	O
ultimately	O
to	O
a	O
modulation	O
of	O
the	O
microbiota	B-OG
and	O
of	O
the	O
host	O
immune	O
system	O
.	O

Therefore	O
,	O
the	O
inhibition	O
of	O
pathogens	O
by	O
prebiotics	O
is	O
thought	O
to	O
be	O
largely	O
due	O
to	O
indirect	O
effects	O
[	O
60	O
].	O

However	O
,	O
antimicrobial	O
properties	O
have	O
been	O
described	O
for	O
a	O
number	O
of	O
oligosaccharides	O
[	O
61	O
].	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
showing	O
that	O
FOS	O
,	O
one	O
of	O
the	O
most	O
studied	O
and	O
used	O
prebiotics	O
,	O
has	O
specific	O
effects	O
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
.	O

We	O
were	O
able	O
to	O
show	O
that	O
FOS	B-GP
(	O
1	O
)	O
inhibits	O
P	B-OG
.	I-OG
aeruginosa	I-OG
growth	O
,	O
biofilm	O
formation	O
and	O
motility	O
;	O
(	O
2	O
)	O
limits	O
the	O
P	B-OG
.	I-OG
aeruginosa	I-OG
evoked	O
NF	B-GP
-	I-GP
κB	I-GP
dependent	O
cytokine	B-GP
secretion	O
in	O
macrophages	O
;	O
and	O
(	O
3	O
)	O
decreases	O
exotoxin	B-GP
A	I-GP
levels	O
in	O
P	B-OG
.	I-OG
aeruginosa	I-OG
infected	O
IEC18	O
cells	O
.	O

These	O
effects	O
have	O
also	O
been	O
observed	O
for	O
inulin	B-CD
,	O
but	O
in	O
general	O
the	O
magnitude	O
of	O
the	O
changes	O
induced	O
by	O
FOS	B-GP
was	O
superior	O
to	O
that	O
of	O
inulin	B-CD
.	O

This	O
indicates	O
that	O
the	O
length	O
of	O
the	O
oligosaccharide	O
chains	O
is	O
an	O
essential	O
determinant	O
for	O
the	O
magnitude	O
of	O
the	O
biological	O
activities	O
observed	O
.	O

This	O
is	O
exemplified	O
by	O
growth	O
inhibition	O
:	O
both	O
FOS	B-GP
and	O
inulin	B-CD
can	O
be	O
used	O
as	O
carbon	O
and	O
energy	O
source	O
by	O
P	B-OG
.	I-OG
aeruginosa	I-OG
and	O
it	O
is	O
therefore	O
not	O
surprising	O
to	O
see	O
a	O
growth	O
stimulation	O
in	O
the	O
presence	O
of	O
up	O
to	O
10	O
mg	O
/	O
ml	O
of	O
both	O
compounds	O
(	O
Fig	O
.	O
1	O
and	O
data	O
not	O
shown	O
).	O

However	O
,	O
at	O
a	O
concentration	O
of	O
20	O
mg	O
/	O
ml	O
inulin	B-CD
had	O
a	O
very	O
modest	O
effect	O
on	O
growth	O
which	O
contrasts	O
with	O
FOS	B-GP
that	O
caused	O
a	O
very	O
significant	O
growth	O
inhibition	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
biphasic	O
response	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
to	O
FOS	B-GP
/	O
inulin	B-CD
:	O
growth	O
is	O
stimulated	O
at	O
low	O
concentrations	O
of	O
inulin	B-CD
and	O
then	O
inhibited	O
to	O
a	O
certain	O
extent	O
;	O
the	O
same	O
response	O
is	O
observed	O
with	O
FOS	B-GP
,	O
but	O
growth	O
inhibition	O
is	O
clearly	O
more	O
pronounced	O
.	O

The	O
control	O
goat	B-OG
milk	O
oligosaccharides	O
did	O
not	O
produce	O
any	O
inhibition	O
at	O
similar	O
concentrations	O
,	O
underlining	O
the	O
specificity	O
of	O
action	O
of	O
FOS	O
.	O

The	O
variety	O
of	O
cellular	O
processes	O
modulated	O
by	O
FOS	B-GP
was	O
a	O
surprising	O
finding	O
and	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
glycoside	B-GP
receptors	I-GP
may	O
be	O
involved	O
in	O
the	O
recognition	O
of	O
FOS	B-GP
and	O
that	O
these	O
receptors	O
signal	O
via	O
different	O
cascades	O
modulating	O
different	O
cellular	O
processes	O
.	O

Such	O
a	O
mechanism	O
would	O
be	O
comparable	O
to	O
that	O
for	O
the	O
sensing	O
of	O
other	O
antimicrobial	O
glycosides	O
[	O
62	O
].	O

Otherwise	O
,	O
biofilm	O
formation	O
is	O
a	O
major	O
mechanism	O
that	O
confers	O
bacterial	O
resistance	O
and	O
biofilm	O
induced	O
antibiotics	O
tolerance	O
is	O
of	O
major	O
clinical	O
importance	O
[	O
63	O
].	O

Currently	O
significant	O
research	O
efforts	O
are	O
being	O
made	O
to	O
identify	O
compounds	O
that	O
interfere	O
with	O
biofilm	O
formation	O
,	O
maturation	O
and	O
dispersion	O
and	O
to	O
explore	O
their	O
effect	O
in	O
infection	B-DS
models	O
[	O
64	O
].	O

Here	O
we	O
show	O
that	O
FOS	B-GP
and	O
inulin	B-CD
have	O
opposite	O
effects	O
on	O
biofilm	O
formation	O
.	O

While	O
inulin	B-CD
caused	O
a	O
stimulation	O
,	O
a	O
dramatic	O
reduction	O
was	O
observed	O
in	O
the	O
presence	O
of	O
FOS	B-GP
(	O
Fig	O
.	O
2	O
and	O
Fig	O
.	O

S1	O
).	O

Interestingly	O
,	O
FOS	B-GP
did	O
not	O
appear	O
to	O
affect	O
the	O
early	O
stages	O
of	O
biofilm	O
formation	O
since	O
no	O
significant	O
changes	O
were	O
observed	O
after	O
4	O
hours	O
growth	O
(	O
Fig	O
.	O
2C	O
).	O

In	O
turn	O
,	O
a	O
dramatic	O
reduction	O
was	O
seen	O
after	O
6	O
hours	O
(	O
Fig	O
.	O
2C	O
),	O
suggesting	O
that	O
FOS	B-GP
interferes	O
with	O
later	O
stages	O
of	O
biofilm	O
formation	O
or	O
triggers	O
its	O
dispersal	O
.	O

Further	O
experiments	O
to	O
elucidate	O
this	O
point	O
are	O
underway	O
.	O

We	O
hypothesized	O
that	O
these	O
effects	O
may	O
alter	O
P	B-OG
.	I-OG
aeruginosa	I-OG
virulence	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
infected	O
rat	B-OG
primary	O
monocyte	O
cultures	O
with	O
PAO1	O
and	O
measured	O
cytokine	B-GP
release	O
in	O
the	O
presence	O
and	O
absence	O
of	O
oligosaccharides	O
.	O

Monocytes	O
display	O
an	O
enhanced	O
release	O
of	O
cytokines	B-GP
in	O
response	O
to	O
infection	B-DS
,	O
which	O
was	O
shown	O
to	O
be	O
chiefly	O
dependent	O
on	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
and	O
p65	B-GP
nuclear	O
translocation	O
.	O

These	O
are	O
early	O
changes	O
associated	O
with	O
modest	O
cytotoxicity	O
due	O
to	O
the	O
short	O
incubation	O
time	O
.	O

Remarkably	O
,	O
treatment	O
with	O
FOS	B-GP
attenuated	O
significantly	O
all	O
the	O
steps	O
of	O
this	O
response	O
,	O
i	O
.	O
e	O
.	O
secretion	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IκB	B-GP
-	I-GP
α	I-GP
phosphorylation	O
and	O
p65	B-GP
nuclear	O
translocation	O
(	O
Figs	O
.	O

4	O
and	O
5	O
).	O

Inulin	O
in	O
contrast	O
had	O
a	O
significantly	O
more	O
moderate	O
effect	O
.	O

In	O
the	O
absence	O
of	O
bacteria	B-OG
neither	O
FOS	O
nor	O
inulin	B-CD
caused	O
an	O
effect	O
on	O
cytokine	B-GP
secretion	O
and	O
their	O
long	O
-	O
term	O
effect	O
on	O
macrophages	O
(	O
and	O
intestinal	O
epithelial	O
cells	O
)	O
is	O
an	O
activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
[	O
65	O
]	O
and	O
thus	O
contrary	O
to	O
the	O
oligosaccharide	O
reduction	O
of	O
pathway	O
activity	O
.	O

Thus	O
it	O
follows	O
that	O
the	O
inhibited	O
NF	B-GP
-	I-GP
κB	I-GP
response	O
in	O
this	O
case	O
is	O
likely	O
to	O
be	O
of	O
indirect	O
nature	O
,	O
i	O
.	O
e	O
.	O
borne	O
out	O
of	O
a	O
reduced	O
stimulation	O
by	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infection	I-DS
,	O
confirming	O
our	O
hypothesis	O
.	O

This	O
may	O
also	O
explain	O
why	O
inulin	B-CD
failed	O
to	O
inhibit	O
IκB	B-GP
-	I-GP
α	I-GP
phosphorylation	O
,	O
since	O
it	O
is	O
also	O
capable	O
of	O
activating	O
this	O
signalling	O
pathway	O
;	O
however	O
,	O
it	O
is	O
unclear	O
why	O
inulin	B-CD
decreases	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
secretion	O
.	O

Our	O
data	O
suggest	O
that	O
MAPK	B-GP
is	O
not	O
involved	O
in	O
this	O
process	O
.	O

We	O
then	O
investigated	O
potential	O
links	O
between	O
FOS	B-GP
and	O
other	O
determinants	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
virulence	O
,	O
such	O
as	O
the	O
PtxS	B-GP
and	O
PtxR	B-GP
regulators	O
that	O
modulate	O
exotoxin	B-GP
A	I-GP
expression	O
(	O
Fig	O
.	O
6B	O
).	O

Mutation	O
of	O
the	O
corresponding	O
genes	O
showed	O
the	O
expected	O
alterations	O
in	O
cytokine	B-GP
release	O
and	O
cytotoxicity	O
in	O
infected	O
monocytes	O
,	O
respectively	O
,	O
confirming	O
previous	O
observations	O
[	O
51	O
].	O

These	O
changes	O
correlated	O
with	O
toxA	B-GP
expression	O
,	O
since	O
the	O
highest	O
cytokine	B-GP
secretion	O
/	O
toxA	B-GP
transcription	O
was	O
observed	O
in	O
the	O
ptxS	B-GP
mutant	O
,	O
followed	O
by	O
the	O
WT	O
strain	O
and	O
the	O
ptxR	B-GP
mutant	O
[	O
51	O
].	O

It	O
is	O
therefore	O
likely	O
that	O
exotoxin	B-GP
A	I-GP
plays	O
a	O
role	O
in	O
stimulating	O
cytokine	B-GP
secretion	O
in	O
the	O
host	O
cell	O
.	O

The	O
main	O
finding	O
of	O
this	O
series	O
of	O
experiments	O
is	O
that	O
FOS	B-GP
exerts	O
its	O
modulatory	O
effects	O
also	O
on	O
the	O
more	O
virulent	O
ptxS	B-GP
mutant	O
.	O

Of	O
note	O
,	O
the	O
effect	O
of	O
inulin	B-CD
was	O
somewhat	O
increased	O
compared	O
to	O
that	O
on	O
the	O
wild	O
type	O
,	O
although	O
always	O
lower	O
than	O
that	O
of	O
FOS	B-GP
.	O

Our	O
results	O
therefore	O
suggest	O
that	O
FOS	O
effectively	O
reduces	O
the	O
virulence	O
of	O
3	O
different	O
strains	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
.	O

Modulation	O
of	O
exotoxin	B-GP
A	I-GP
expression	O
or	O
transport	O
can	O
probably	O
be	O
associated	O
with	O
this	O
effect	O
.	O

P	B-OG
.	I-OG
aeruginosa	I-OG
is	O
an	O
opportunistic	O
pathogen	O
and	O
can	O
infect	O
immunocompromised	O
individuals	O
at	O
different	O
sites	O
such	O
as	O
the	O
respiratory	O
tract	O
,	O
intestine	O
,	O
skin	O
,	O
urinary	O
tract	O
,	O
and	O
wounds	O
.	O

The	O
severity	O
of	O
the	O
opportunistic	B-DS
infection	I-DS
depends	O
to	O
a	O
great	O
extent	O
on	O
the	O
virulence	O
factors	O
expressed	O
by	O
the	O
bacterium	B-OG
,	O
which	O
in	O
turn	O
influence	O
cytotoxicity	O
and	O
antibiotic	O
resistance	O
.	O

As	O
a	O
result	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infections	I-DS
are	O
notoriously	O
difficult	O
to	O
treat	O
.	O

Several	O
classes	O
of	O
antibiotics	O
including	O
cephalosporins	B-CD
,	O
penicillins	B-CD
,	O
carbapenems	B-CD
,	O
quinolones	B-CD
and	O
aminoglycosides	B-CD
are	O
currently	O
been	O
used	O
to	O
combat	O
P	B-OG
.	I-OG
aeruginosa	I-OG
clinically	O
,	O
but	O
specific	O
sensitivity	O
testing	O
is	O
mandatory	O
[	O
66	O
].	O

Our	O
data	O
suggest	O
that	O
FOS	B-GP
may	O
be	O
a	O
useful	O
component	O
of	O
a	O
drug	O
cocktail	O
to	O
combat	O
P	B-DS
.	I-DS
aeruginosa	I-DS
infection	I-DS
.	O

Alternatively	O
,	O
it	O
appears	O
also	O
plausible	O
to	O
use	O
FOS	O
in	O
a	O
prophylactic	O
context	O
to	O
prevent	O
gastrointestinal	B-DS
infections	I-DS
.	O

Oral	O
FOS	O
supplements	O
are	O
currently	O
been	O
used	O
to	O
prevent	O
gastrointestinal	B-DS
infections	I-DS
[	O
67	O
],	O
which	O
implies	O
that	O
the	O
oral	O
route	O
may	O
be	O
also	O
valid	O
to	O
administer	O
FOS	O
to	O
fight	O
Pseudomonas	B-DS
infection	I-DS
.	O

However	O
,	O
any	O
clinical	O
application	O
will	O
require	O
an	O
extensive	O
study	O
of	O
the	O
potential	O
effects	O
of	O
FOS	B-GP
on	O
the	O
human	B-OG
body	O
which	O
are	O
issues	O
that	O
are	O
to	O
be	O
addressed	O
in	O
the	O
future	O
.	O

Materials	O
and	O
Methods	O

Animals	B-OG

Wistar	B-OG
rats	I-OG
(	O
200	O
–	O
250	O
g	O
)	O
obtained	O
from	O
the	O
Animal	B-OG
Service	O
Laboratory	O
of	O
the	O
University	O
of	O
Granada	O
(	O
Spain	O
)	O
were	O
used	O
,	O
housed	O
in	O
macrolon	O
cages	O
,	O
and	O
maintained	O
in	O
air	O
-	O
conditioned	O
animal	B-OG
quarters	O
with	O
a	O
12	O
-	O
h	O
light	O
-	O
dark	O
cycle	O
.	O

Rats	B-OG
were	O
given	O
free	O
access	O
to	O
tap	O
water	O
and	O
food	O
.	O

This	O
study	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
Directive	O
for	O
the	O
Protection	O
of	O
Vertebrate	B-OG
Animals	B-OG
used	O
for	O
Experimental	O
and	O
other	O
Scientific	O
Purposes	O
of	O
the	O
European	O
Union	O
(	O
86	O
/	O
609	O
/	O
EEC	O
)	O
and	O
the	O
animal	B-OG
protocol	O
used	O
has	O
been	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Granada	O
University	O
.	O

Bacterial	O
strains	O
used	O
in	O
this	O
study	O

P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
and	O
its	O
mutants	O
deficient	O
in	O
ptxS	B-GP
and	O
ptxR	B-GP
obtained	O
through	O
insertion	O
of	O
streptomycin	B-CD
and	O
tetracycline	B-CD
cassettes	O
,	O
respectively	O
[	O
51	O
],	O
were	O
grown	O
in	O
LB	O
medium	O
or	O
M9	O
minimal	O
medium	O
(	O
Na2HPO4	O
:	O
6	O
g	O
/	O
l	O
;	O
KH2PO4	O
:	O
3	O
g	O
/	O
l	O
;	O
NaCl	O
:	O
0	O
.	O
5	O
g	O
/	O
l	O
;	O
NH4Cl	O
:	O
1	O
g	O
/	O
l	O
,	O
1	O
mM	O
MgSO4	O
,	O
0	O
.	O
3	O
mM	O
CaCl2	O
and	O
0	O
.	O
2	O
ml	O
/	O
l	O
of	O
1	O
%	O
ferric	O
ammonium	O
citrate	O
)	O
[	O
68	O
].	O

When	O
required	O
,	O
antibiotics	O
were	O
added	O
to	O
the	O
culture	O
medium	O
to	O
reach	O
a	O
final	O
concentration	O
of	O
50	O
µg	O
/	O
ml	O
ampicillin	B-CD
,	O
50	O
µg	O
/	O
ml	O
streptomycin	B-CD
and	O
30	O
µg	O
/	O
ml	O
tetracycline	B-CD
.	O

Chemicals	O

Inulin	O
and	O
FOS	B-GP
were	O
provided	O
by	O
BENEO	O
-	O
Orafti	O
(	O
Tienen	O
,	O
Belgium	O
).	O

FOS	O
and	O
inulin	B-CD
were	O
kindly	O
provided	O
by	O
BENEO	O
Orafti	O
®	O
(	O
Tienen	O
,	O
Belgium	O
).	O

Orafti	O
®	O
GR	O
(	O
inulin	B-CD
)	O
is	O
a	O
food	O
ingredient	O
consisting	O
mainly	O
of	O
chicory	O
root	O
inulin	B-CD
,	O
a	O
mixture	O
of	O
oligo	O
-	O
and	O
polysaccharides	O
which	O
are	O
composed	O
of	O
fructose	B-CD
units	O
linked	O
together	O
by	O
β	O
(	O
2	O
-	O
1	O
)	O
linkages	O
.	O

Almost	O
every	O
molecule	O
is	O
terminated	O
by	O
a	O
glucose	B-CD
unit	O
.	O

The	O
total	O
number	O
of	O
fructose	B-CD
or	O
glucose	B-CD
units	O
(	O
=	O
Degree	O
of	O
Polymerization	O
or	O
DP	O
)	O
of	O
chicory	O
inulin	B-CD
ranges	O
mainly	O
between	O
2	O
and	O
60	O
.	O

Orafti	O
®	O
P95	O
oligofructose	B-CD
(	O
FOS	O
)	O
is	O
produced	O
by	O
the	O
partial	O
enzymatic	O
hydrolysis	O
of	O
chicory	B-OG
-	O
derived	O
inulin	B-CD
,	O
consisting	O
mainly	O
of	O
molecules	O
with	O
DP	O
between	O
2	O
and	O
8	O
.	O

Solutions	O
were	O
made	O
at	O
200	O
g	O
/	O
l	O
in	O
M9	O
minimal	O
medium	O
and	O
,	O
in	O
the	O
case	O
of	O
eukaryotic	O
cell	O
cultures	O
,	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
containing	O
fetal	O
bovine	O
serum	O
(	O
10	O
%),	O
2	O
mM	O
L	B-CD
-	I-CD
glutamine	I-CD
,	O
and	O
2	O
.	O
5	O
mg	O
/	O
mL	O
amphotericin	B-CD
B	I-CD
,	O
all	O
provided	O
by	O
Sigma	O
.	O

Solutions	O
were	O
filtered	O
using	O
0	O
.	O
22	O
µm	O
cut	O
-	O
off	O
filters	O
and	O
aliquots	O
were	O
stored	O
at	O
−	O
20	O
°	O
C	O
.	O

The	O
goat	B-OG
milk	O
oligosaccharides	O
(	O
OS	O
)	O
were	O
obtained	O
according	O
to	O
the	O
method	O
described	O
in	O
[	O
69	O
].	O

A	O
product	O
containing	O
>	O
80	O
%	O
of	O
the	O
original	O
oligosaccharide	O
content	O
,	O
only	O
5	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
lactose	B-CD
and	O
virtually	O
salt	O
free	O
,	O
was	O
obtained	O
and	O
used	O
to	O
carry	O
out	O
all	O
the	O
experiments	O
.	O

Effects	O
of	O
inulin	B-CD
and	O
FOS	O
on	O
P	B-OG
.	I-OG
aeruginosa	I-OG
growth	O

Individual	O
colonies	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
were	O
picked	O
from	O
the	O
surface	O
of	O
freshly	O
grown	O
LB	O
plates	O
and	O
grown	O
overnight	O
in	O
M9	O
minimum	O
medium	O
(	O
supplemented	O
with	O
5	O
mM	O
of	O
citrate	B-CD
)	O
at	O
37	O
°	O
C	O
.	O

The	O
overnight	O
culture	O
was	O
diluted	O
with	O
fresh	O
M9	O
minimum	O
medium	O
to	O
an	O
OD660	O
nm	O
of	O
0	O
.	O
05	O
and	O
96	O
well	O
flat	O
-	O
bottomed	O
polystyrene	O
microtiter	O
plates	O
were	O
filled	O
with	O
180	O
µl	O
of	O
this	O
cellular	O
suspension	O
.	O

Then	O
,	O
20	O
µl	O
of	O
either	O
inulin	B-CD
or	O
FOS	B-GP
were	O
added	O
to	O
reach	O
final	O
concentrations	O
of	O
5	O
,	O
15	O
and	O
20	O
mg	O
/	O
ml	O
.	O

Plates	O
were	O
incubated	O
at	O
37	O
°	O
C	O
under	O
continuous	O
agitation	O
in	O
a	O
Bioscreen	O
C	O
MBR	O
analyser	O
FP	O
-	O
1100	O
-	O
C	O
(	O
OY	O
Growth	O
Curves	O
Ab	O
Ltd	O
.,	O
Raisio	O
,	O
Finland	O
).	O

The	O
turbidity	O
was	O
measured	O
using	O
a	O
wideband	O
filter	O
at	O
420	O
–	O
660	O
nm	O
every	O
60	O
minutes	O
over	O
a	O
24	O
h	O
period	O
.	O

The	O
measurements	O
at	O
580	O
nm	O
were	O
used	O
to	O
generate	O
growth	O
curves	O
.	O

Some	O
cultures	O
were	O
carried	O
out	O
with	O
the	O
same	O
medium	O
without	O
citrate	O
.	O

Semiquantitative	O
determination	O
of	O
biofilm	O
formation	O

Semiquantitative	O
determination	O
of	O
biofilm	O
formation	O
was	O
performed	O
as	O
described	O
[	O
70	O
].	O

Experiments	O
were	O
conducted	O
in	O
24	O
well	O
flat	O
-	O
bottomed	O
polystyrene	O
microtiter	O
plates	O
in	O
M9	O
minimal	O
medium	O
supplemented	O
with	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
glucose	B-CD
and	O
0	O
.	O
4	O
%	O
(	O
w	O
/	O
v	O
)	O
casamino	B-CD
acids	I-CD
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
different	O
concentrations	O
(	O
up	O
to	O
20	O
mg	O
/	O
ml	O
)	O
of	O
inulin	B-CD
or	O
FOS	B-GP
.	O

Biofilm	O
formation	O
was	O
quantified	O
after	O
6	O
h	O
by	O
staining	O
with	O
crystal	O
violet	O
following	O
the	O
method	O
described	O
in	O
[	O
71	O
].	O

The	O
structure	O
of	O
biofilms	O
was	O
observed	O
under	O
contrast	O
-	O
phase	O
microscopy	O
using	O
a	O
Zeiss	O
Axioscope	O
fluorescence	O
microscope	O
coupled	O
to	O
a	O
Nikon	O
DSS	O
-	O
Mc	O
CCD	O
camera	O
and	O
a	O
100	O
-	O
fold	O
magnifier	O
.	O

Data	O
reported	O
are	O
means	O
from	O
two	O
independent	O
experiments	O
each	O
conducted	O
in	O
quadruplet	O
repeats	O
.	O

Motility	O
assays	O

Assays	O
were	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
inulin	B-CD
and	O
FOS	O
(	O
each	O
at	O
a	O
concentration	O
of	O
5	O
mg	O
/	O
ml	O
)	O
on	O
swimming	O
,	O
twitching	O
and	O
swarming	O
.	O

In	O
all	O
assays	O
these	O
compounds	O
were	O
added	O
at	O
identical	O
concentrations	O
to	O
the	O
bacterial	O
suspension	O
in	O
the	O
plates	O
.	O

For	O
swimming	O
assays	O
bacteria	B-OG
were	O
placed	O
with	O
the	O
help	O
of	O
a	O
sterile	O
tooth	O
-	O
pick	O
at	O
the	O
centre	O
of	O
plates	O
containing	O
a	O
5	O
mm	O
layer	O
of	O
LB	O
medium	O
with	O
0	O
.	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
Bacto	O
agar	O
,	O
0	O
.	O
2	O
%	O
casamino	B-CD
acids	I-CD
(	O
w	O
/	O
v	O
)	O
and	O
30	O
mM	O
glucose	B-CD
.	O

Plates	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
24	O
h	O
and	O
the	O
radial	O
diffusion	O
of	O
bacteria	B-OG
,	O
due	O
to	O
swimming	O
,	O
was	O
measured	O
.	O

To	O
monitor	O
twitching	O
motility	O
bacteria	B-OG
were	O
placed	O
with	O
a	O
toothpick	O
into	O
a	O
2	O
mm	O
thick	O
layer	O
containing	O
1	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
Bacto	O
agar	O
,	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
casamino	B-CD
acids	I-CD
and	O
30	O
mM	O
glucose	B-CD
.	O

After	O
incubation	O
for	O
24	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
expansion	O
of	O
bacteria	B-OG
on	O
the	O
plate	O
was	O
observed	O
.	O

For	O
swarming	O
assays	O
5	O
µl	O
of	O
an	O
overnight	O
culture	O
of	O
bacteria	B-OG
were	O
placed	O
into	O
the	O
centre	O
of	O
swarm	O
plates	O
,	O
which	O
are	O
made	O
of	O
0	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
Bacto	O
agar	O
supplement	O
with	O
0	O
.	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
casamino	B-CD
acids	I-CD
and	O
30	O
mM	O
glucose	B-CD
.	O

Plates	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
24	O
h	O
,	O
followed	O
by	O
an	O
inspection	O
of	O
the	O
bacterial	O
surface	O
movement	O
[	O
72	O
].	O

All	O
the	O
motility	O
assays	O
were	O
performed	O
in	O
triplicates	O
.	O

Macrophage	O
cell	O
isolation	O
by	O
magnetic	O
activated	O
cell	O
sorting	O

Female	O
Wistar	B-OG
rats	I-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
and	O
the	O
spleen	O
was	O
extracted	O
aseptically	O
.	O

Cell	O
suspensions	O
were	O
obtained	O
by	O
disrupting	O
the	O
tissues	O
between	O
dissecting	O
forceps	O
in	O
medium	O
.	O

After	O
centrifugation	O
(	O
1500	O
×	O
rpm	O
/	O
5	O
min	O
),	O
cells	O
were	O
cleared	O
of	O
erythrocytes	O
by	O
resuspension	O
in	O
hypotonic	O
lysis	O
buffer	O
(	O
15	O
mM	O
NH4Cl	O
,	O
10	O
mM	O
KHCO3	O
,	O
0	O
.	O
1	O
mM	O
Na2EDTA	O
,	O
pH	O
7	O
.	O
3	O
)	O
for	O
30	O
min	O
on	O
ice	O
.	O

Mononuclear	O
cells	O
were	O
washed	O
and	O
resuspended	O
in	O
MACs	O
buffer	O
(	O
PBS	O
containing	O
0	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
BSA	B-GP
,	O
2	O
mM	O
EDTA	O
,	O
pH	O
7	O
.	O
2	O
).	O

To	O
obtain	O
a	O
monocellular	O
suspension	O
,	O
cells	O
were	O
passed	O
through	O
70	O
µm	O
nylon	O
mesh	O
prior	O
to	O
magnetic	O
labelling	O
and	O
subsequently	O
isolated	O
by	O
negative	O
selection	O
.	O

To	O
remove	O
lymphocytes	O
,	O
CD161	B-GP
.	O
1	O
-	O
biotin	B-CD
(	O
1	O
∶	O
200	O
),	O
CD45RA	B-GP
-	O
PE	B-GP
(	O
1	O
∶	O
200	O
)	O
and	O
CD3	B-GP
(	O
1	O
∶	O
150	O
)	O
(	O
Biosciences	O
),	O
were	O
added	O
and	O
incubated	O
at	O
4	O
°	O
C	O
for	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
and	O
sedimented	O
by	O
centrifugation	O
at	O
1500	O
×	O
rpm	O
for	O
5	O
min	O
.	O

After	O
resuspension	O
in	O
MACs	O
buffer	O
,	O
25	O
µl	O
of	O
each	O
antibiotin	O
Microbeads	O
and	O
anti	O
-	O
PE	B-GP
-	O
microbeads	O
(	O
Miltenyi	O
Biotec	O
),	O
were	O
added	O
and	O
the	O
resulting	O
suspension	O
incubated	O
at	O
4	O
°	O
C	O
during	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
,	O
centrifuged	O
and	O
dissolved	O
in	O
DMEM	O
medium	O
(	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
).	O

CD161	B-GP
.	I-GP
1	I-GP
+,	O
CD45RA	B-GP
+	O
and	O
CD3	B-GP
+	O
cells	O
were	O
discarded	O
using	O
an	O
LD	O
column	O
(	O
Miltenyi	O
Biotec	O
).	O

Macrophages	O
in	O
the	O
flow	O
-	O
through	O
were	O
centrifuged	O
at	O
1500	O
×	O
rpm	O
for	O
5	O
min	O
and	O
resuspended	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
Sigma	O
®)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
sigma	O
),	O
2	O
.	O
5	O
mg	O
/	O
L	O
amphotericin	B-CD
B	I-CD
and	O
2	O
mM	O
L	B-CD
-	I-CD
glutamine	I-CD
.	O

Measurement	O
of	O
inulin	B-CD
-	O
and	O
FOS	B-GP
-	O
induced	O
changes	O
in	O
cytokine	B-GP
secretion	O
from	O
macrophages	O
following	O
infection	B-DS
by	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG

For	O
the	O
determination	O
of	O
cytokine	B-GP
levels	O
the	O
macrophage	O
suspensions	O
(	O
106	O
cells	O
/	O
ml	O
DMEM	O
medium	O
)	O
were	O
co	O
-	O
cultured	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
and	O
incubated	O
with	O
5	O
mg	O
/	O
ml	O
FOS	O
or	O
inulin	B-CD
for	O
4	O
hours	O
.	O

Following	O
centrifugation	O
at	O
4	O
°	O
C	O
and	O
10	O
.	O
000	O
×	O
rpm	O
for	O
5	O
min	O
,	O
the	O
resulting	O
supernatants	O
were	O
frozen	O
at	O
−	O
80	O
°	O
C	O
.	O

Aliquots	O
were	O
thawed	O
and	O
cytokine	B-GP
levels	O
determined	O
using	O
ELISA	O
-	O
based	O
kits	O
(	O
BD	O
Biosciences	O
,	O
Erembodegem	O
,	O
Belgium	O
)	O
following	O
the	O
protocol	O
provided	O
by	O
the	O
manufacturer	O
.	O

In	O
addition	O
,	O
macrophage	O
cells	O
were	O
used	O
for	O
the	O
quantification	O
of	O
phosphorylated	O
IκB	B-GP
-	I-GP
α	I-GP
and	O
MAP	B-GP
kinases	I-GP
by	O
Western	O
blot	O
determination	O
as	O
described	O
below	O
.	O

Western	O
blot	O

For	O
the	O
detection	O
of	O
ERK	B-GP
,	O
p	O
-	O
ERK	B-GP
,	O
p	O
-	O
P38	O
,	O
p	O
-	O
JNK	B-GP
and	O
phosphorylated	O
IκB	B-GP
-	I-GP
P	I-GP
,	O
cells	O
were	O
homogenized	O
in	O
lysis	O
buffer	O
(	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
SDS	O
,	O
0	O
.	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
sodium	O
deoxycholate	O
,	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
Triton	O
X	O
-	O
100	O
)	O
with	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Sigma	O
)	O
1	O
∶	O
100	O
(	O
v	O
/	O
v	O
).	O

Subsequently	O
,	O
homogenates	O
were	O
sonicated	O
and	O
centrifuged	O
7000	O
×	O
g	O
for	O
5	O
min	O
at	O
4	O
°	O
C	O
.	O

Protein	O
concentrations	O
were	O
determined	O
using	O
the	O
Bicinchoninic	B-CD
acid	I-CD
assay	O
[	O
73	O
].	O

Samples	O
were	O
boiled	O
in	O
5	O
×	O
Laemmli	O
buffer	O
(	O
220	O
mM	O
Tris	O
,	O
312	O
µM	O
SDS	O
,	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
glycerol	B-CD
,	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
2	O
-	O
mercaptoethanol	O
,	O
22	O
.	O
5	O
mM	O
EDTA	O
,	O
pH	O
6	O
.	O
8	O
,	O
containing	O
traces	O
of	O
bromphenol	B-CD
blue	I-CD
)	O
for	O
5	O
min	O
,	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
electroblotted	O
to	O
PVDF	O
membranes	O
(	O
Millipore	O
,	O
Madrid	O
,	O
Spain	O
),	O
and	O
exposed	O
to	O
the	O
primary	O
antibodies	B-GP
against	O
ERK	B-GP
,	O
p	O
-	O
ERK	B-GP
(	O
both	O
from	O
Sigma	O
),	O
p	O
-	O
P38	O
,	O
p	O
-	O
JNK	B-GP
and	O
phosphorylated	O
IkB	B-GP
-	I-GP
P	I-GP
,	O
respectively	O
(	O
all	O
three	O
from	O
Cell	O
signalling	O
,	O
Danvers	O
,	O
MA	O
).	O

Prior	O
to	O
exposure	O
to	O
the	O
secondary	O
IgG	B-GP
Peroxidase	B-GP
antibody	B-GP
(	O
anti	O
-	O
mouse	B-OG
IgG	B-GP
for	O
ERK	B-GP
and	O
p	O
-	O
ERK	B-GP
,	O
anti	O
-	O
rabit	B-GP
IgG	B-GP
for	O
p	O
-	O
P38	O
,	O
p	O
-	O
JNK	B-GP
and	O
p	O
-	O
IkB	B-GP
,	O
(	O
Sigma	O
)	O
the	O
bands	O
were	O
visualized	O
by	O
enhanced	O
chemiluminescence	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
and	O
quantified	O
with	O
the	O
NIH	O
software	O
(	O
Scion	O
Image	O
).	O

Determination	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
subunit	O
in	O
macrophages	O
nuclear	O
extracts	O

Macrophages	O
were	O
co	O
-	O
cultured	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
with	O
a	O
1	O
∶	O
5	O
ratio	O
and	O
incubated	O
with	O
FOS	B-GP
(	O
5	O
mg	O
/	O
ml	O
)	O
or	O
inulin	B-CD
(	O
5	O
mg	O
/	O
ml	O
).	O

After	O
1	O
h	O
,	O
nuclear	O
extracts	O
were	O
obtained	O
using	O
a	O
nuclear	O
extract	O
kit	O
(	O
Active	O
Motif	O
,	O
Belgium	O
)	O
and	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
was	O
determined	O
by	O
quantifying	O
the	O
p65	B-GP
component	O
using	O
a	O
TransAM	O
kit	O
following	O
the	O
protocols	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Active	O
Motif	O
,	O
Belgium	O
).	O

Cytotoxicity	O
Assays	O

Measurement	O
of	O
P	B-OG
.	I-OG
aeruginosa	I-OG
induced	O
cytotoxicity	O
in	O
macrophages	O
:	O
Macrophages	O
were	O
incubated	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
with	O
a	O
ratio	O
of	O
1	O
∶	O
5	O
for	O
4	O
hours	O
and	O
the	O
percentage	O
of	O
cytotoxicity	O
was	O
determinate	O
using	O
cytotox	O
96	O
non	O
-	O
radioactive	O
cytotoxicity	O
assay	O
kit	O
following	O
the	O
protocols	O
recommended	O
by	O
the	O
manufacturers	O
(	O
Promega	O
)	O
which	O
evaluates	O
cytotoxicity	O
by	O
assessing	O
the	O
total	O
release	O
of	O
cytoplasmic	O
lactate	B-GP
dehydrogenase	I-GP
(	O
LDH	B-GP
),	O
by	O
the	O
calorimetric	O
detection	O
,	O
into	O
culture	O
medium	O
as	O
a	O
consequence	O
of	O
damaged	O
cell	O
membranes	O
[	O
74	O
].	O

Determination	O
of	O
exotoxin	B-CD
A	I-CD
concentration	O
in	O
rat	B-OG
IEC18	O
cells	O
infected	O
by	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG

IEC18	O
cells	O
were	O
cultured	O
in	O
6	O
well	O
plates	O
.	O

At	O
confluence	O
IEC18	O
cells	O
were	O
infected	O
with	O
P	B-OG
.	I-OG
aeruginosa	I-OG
at	O
a	O
ratio	O
of	O
5	O
bacterial	O
cells	O
per	O
eukaryotic	O
cell	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
5	O
mg	O
/	O
ml	O
FOS	O
or	O
inulin	B-CD
.	O

Plates	O
containing	O
cells	O
were	O
washed	O
3	O
times	O
with	O
PBS	O
and	O
incubated	O
with	O
gentamicin	B-CD
at	O
100	O
µg	O
/	O
ml	O
for	O
1	O
h	O
to	O
eliminate	O
bacteria	B-OG
.	O

Subsequently	O
,	O
plates	O
were	O
washed	O
3	O
times	O
with	O
PBS	O
prior	O
to	O
cell	O
collection	O
using	O
RIPA	O
buffer	O
[	O
25	O
mM	O
Tris	O
–	O
HCl	O
,	O
pH	O
7	O
.	O
2	O
,	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
1	O
%	O
sodium	O
deoxycholate	O
and	O
0	O
.	O
1	O
%	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)]	O
containing	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Sigma	O
).	O

Proteins	O
were	O
extracted	O
for	O
Western	O
blot	O
analysis	O
,	O
as	O
described	O
above	O
.	O

Western	O
blot	O
were	O
carried	O
out	O
as	O
outlined	O
above	O
using	O
the	O
Exotoxin	O
A	O
antibody	O
(	O
Sigma	O
)	O
at	O
a	O
1	O
∶	O
2	O
.	O
000	O
dilution	O
.	O

Following	O
overnight	O
incubation	O
with	O
the	O
primary	O
antibody	B-GP
the	O
membrane	O
was	O
incubated	O
with	O
the	O
secondary	O
IgG	B-GP
Peroxidase	B-GP
anti	O
-	O
rabbit	B-OG
antibody	B-GP
(	O
Sigma	O
)	O
at	O
a	O
1	O
∶	O
3	O
.	O
000	O
dilution	O
for	O
two	O
hours	O
.	O

The	O
bands	O
were	O
detected	O
by	O
enhanced	O
chemiluminescence	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
and	O
quantified	O
with	O
NIH	O
software	O
(	O
Scion	O
Image	O
).	O

Statistical	O
analysis	O

All	O
results	O
are	O
expressed	O
as	O
means	O
with	O
the	O
corresponding	O
standard	O
deviations	O
.	O

Differences	O
among	O
means	O
were	O
analysed	O
for	O
statistical	O
significance	O
by	O
a	O
one	O
-	O
way	O
ANOVA	O
analysis	O
and	O
a	O
posteriori	O
least	O
significance	O
test	O
.	O

All	O
analyses	O
were	O
carried	O
out	O
using	O
the	O
SigmaStat	O
2	O
.	O
03	O
program	O
(	O
Jandel	O
Corporation	O
,	O
San	O
Rafael	O
,	O
CA	O
).	O

Concentration	O
-	O
response	O
curves	O
were	O
fitted	O
to	O
a	O
logarithmic	O
curve	O
when	O
possible	O
with	O
Origin	O
7	O
.	O
0	O
(	O
OriginLab	O
Corporation	O
,	O
Northampton	O
,	O
MA	O
).	O

Differences	O
were	O
considered	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Supporting	O
Information	O

The	O
OD	O
at	O
560	O
nm	O
of	O
crystal	B-CD
violet	O
(	O
CV	O
)	O
stained	O
and	O
resuspended	O
bacteria	B-OG
from	O
biofilm	O
are	O
given	O
.	O
Shown	O
are	O
means	O
and	O
standard	O
deviations	O
with	O
n	O
=	O
3	O
–	O
6	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
WT	O
in	O
the	O
absence	O
of	O
inulin	B-CD
or	O
FOS	B-GP
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

The	O
densitometric	O
analysis	O
of	O
experiments	O
is	O
shown	O
in	O
Fig	O
.	O
2A	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Measurement	O
of	O
interleukin	B-GP
-	I-GP
6	I-GP
secretion	O
of	O
macrophages	O
in	O
the	O
presence	O
of	O
WT	O
P	B-OG
.	I-OG
aeruginosa	I-OG
PAO1	I-OG
and	O
its	O
ptxS	B-GP
and	O
ptxR	B-GP
mutants	O
.	O
The	O
macrophage	O
/	O
bacteria	B-OG
ratio	O
was	O
of	O
1	O
∶	O
5	O
.	O

Experimental	O
conditions	O
involving	O
incubation	O
for	O
4	O
hours	O
were	O
subsequently	O
used	O
to	O
assess	O
the	O
effect	O
of	O
FOS	O
and	O
inulin	B-CD
on	O
interleukin	B-GP
secretion	O
as	O
reported	O
in	O
Fig	O
.	O
4	O
and	O
7	O
.	O

Values	O
are	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.,	O
n	O
=	O
3	O
;	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
without	O
bacteria	B-OG
and	O
&	O
P	O
<	O
0	O
.	O
05	O
vs	O
macrophage	O
with	O
WT	O
(	O
ANOVA	O
followed	O
by	O
least	O
significance	O
tests	O
).	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Phosphoproteomic	O
analysis	O
of	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
downstream	O
signaling	O
pathways	O
identifies	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
as	O
a	O
functional	O
target	O
of	O
activated	O
ALK	B-GP
in	O
neuroblastoma	B-DS
cells	O

Activation	O
of	O
the	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
is	O
a	O
key	O
oncogenic	O
mechanism	O
in	O
a	O
growing	O
number	O
of	O
tumor	B-DS
types	O
.	O

In	O
the	O
majority	O
of	O
cases	O
,	O
ALK	B-GP
is	O
activated	O
by	O
fusion	O
with	O
a	O
dimerizing	O
partner	O
protein	O
as	O
a	O
result	O
of	O
chromosomal	O
translocation	O
events	O
,	O
most	O
studied	O
in	O
the	O
case	O
of	O
the	O
nucleophosmin	B-GP
–	O
ALK	B-GP
and	O
echinoderm	B-GP
microtubule	I-GP
-	I-GP
associated	I-GP
protein	I-GP
-	I-GP
like	I-GP
4	I-GP
–	O
ALK	B-GP
oncoproteins	B-GP
.	O

It	O
is	O
now	O
also	O
appreciated	O
that	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
can	O
be	O
activated	O
by	O
point	O
mutations	O
and	O
by	O
deletions	O
within	O
the	O
extracellular	O
domain	O
,	O
such	O
as	O
those	O
observed	O
in	O
neuroblastoma	B-DS
.	O

Several	O
studies	O
have	O
employed	O
phosphoproteomics	O
approaches	O
to	O
find	O
substrates	O
of	O
ALK	B-GP
fusion	O
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
MS	O
-	O
based	O
phosphotyrosine	B-CD
profiling	O
to	O
characterize	O
phosphotyrosine	B-CD
signaling	O
events	O
associated	O
with	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
.	O

A	O
number	O
of	O
previously	O
identified	O
and	O
novel	O
targets	O
were	O
identified	O
.	O

One	O
of	O
these	O
,	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
(	O
STAT3	B-GP
),	O
has	O
previously	O
been	O
observed	O
to	O
be	O
activated	O
in	O
response	O
to	O
oncogenic	O
ALK	B-GP
signaling	O
,	O
but	O
the	O
significance	O
of	O
this	O
in	O
signaling	O
from	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
has	O
not	O
been	O
explored	O
further	O
.	O

We	O
show	O
here	O
that	O
activated	O
ALK	B-GP
robustly	O
activates	O
STAT3	B-GP
on	O
Tyr705	O
in	O
a	O
number	O
of	O
independent	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

Furthermore	O
,	O
knockdown	O
of	O
STAT3	B-GP
by	O
RNA	O
interference	O
resulted	O
in	O
a	O
reduction	O
in	O
myelocytomatosis	O
neuroblastom	O
(	O
MYCN	B-GP
)	O
protein	O
levels	O
downstream	O
of	O
ALK	B-GP
signaling	O
.	O

These	O
observations	O
,	O
together	O
with	O
a	O
decreased	O
level	O
of	O
MYCN	B-GP
and	O
inhibition	O
of	O
neuroblastoma	B-DS
cell	O
growth	O
in	O
the	O
presence	O
of	O
STAT3	B-GP
inhibitors	O
,	O
suggest	O
that	O
activation	O
of	O
STAT3	B-GP
is	O
important	O
for	O
ALK	B-GP
signaling	O
activity	O
in	O
neuroblastoma	B-DS
.	O

Introduction	O

Many	O
of	O
the	O
tyrosine	B-GP
kinases	I-GP
in	O
the	O
human	B-OG
kinome	O
are	O
implicated	O
in	O
human	B-OG
cancers	B-DS
1	O
,	O
and	O
provide	O
important	O
targets	O
for	O
cancer	B-DS
treatment	O
,	O
as	O
well	O
as	O
biomarkers	O
for	O
patient	O
stratification	O
.	O

Recently	O
,	O
tyrosine	B-GP
kinase	I-GP
inhibitors	O
targeting	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
positive	O
non	B-DS
-	I-DS
small	I-DS
-	I-DS
cell	I-DS
-	I-DS
lung	I-DS
-	I-DS
cancer	I-DS
(	O
NSCLC	B-DS
)	O
2	O
.	O

In	O
NSCLC	B-DS
,	O
ALK	B-GP
activation	O
occurs	O
via	O
chromosomal	O
translocation	O
,	O
leading	O
to	O
activation	O
of	O
the	O
kinase	B-GP
domain	O
.	O

However	O
,	O
ALK	B-GP
is	O
also	O
known	O
to	O
be	O
mutated	O
in	O
the	O
context	O
of	O
the	O
full	O
-	O
length	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
(	O
RTK	B-GP
),	O
this	O
being	O
most	O
clearly	O
understood	O
in	O
neuroblastoma	B-DS
.	O

Neuroblastoma	B-DS
is	O
a	O
childhood	B-DS
cancer	I-DS
that	O
stems	O
from	O
the	O
sympathetic	O
nervous	O
system	O
3	O
,	O
most	O
commonly	O
originating	O
in	O
the	O
adrenal	O
glands	O
,	O
but	O
also	O
developing	O
at	O
additional	O
sites	O
in	O
the	O
neck	O
,	O
chest	O
,	O
and	O
abdomen	O
.	O

It	O
is	O
considered	O
to	O
be	O
a	O
disease	O
of	O
developing	O
tissue	O
,	O
as	O
it	O
originates	O
from	O
precursor	O
cells	O
of	O
neural	O
crest	O
tissue	O
that	O
are	O
active	O
during	O
embryonic	O
development	O
4	O
.	O

ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
mutations	O
have	O
been	O
described	O
in	O
both	O
familial	O
5	O
–	O
6	O
and	O
sporadic	O
6	O
–	O
10	O
neuroblastoma	B-DS
.	O

Although	O
there	O
is	O
currently	O
no	O
clinically	O
approved	O
specific	O
treatment	O
for	O
ALK	B-GP
mutations	O
in	O
neuroblastoma	B-DS
,	O
ongoing	O
clinical	O
trials	O
are	O
being	O
conducted	O
to	O
determine	O
the	O
potential	O
usefulness	O
of	O
ALK	B-GP
-	O
targeted	O
therapies	O
for	O
use	O
in	O
future	O
treatment	O
approaches	O
11	O
.	O

Today	O
,	O
crizotinib	B-CD
(	O
PF	B-CD
-	I-CD
02341066	I-CD
)	O
is	O
in	O
use	O
as	O
a	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drug	O
for	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
positive	O
NSCLC	B-DS
12	O
.	O

Clinical	O
studies	O
today	O
suggest	O
that	O
anti	O
-	O
ALK	B-GP
inhibitor	O
therapy	O
offers	O
promise	O
in	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
mediated	O
tumors	B-DS
2	O
,	O
11	O
.	O

One	O
consistent	O
problem	O
with	O
kinase	B-GP
inhibitors	O
and	O
their	O
use	O
in	O
a	O
more	O
personalized	O
therapy	O
approach	O
is	O
the	O
drug	O
-	O
resistant	O
mutations	O
that	O
arise	O
in	O
response	O
to	O
treatment	O
,	O
most	O
commonly	O
within	O
the	O
ATP	O
-	O
binding	O
site	O
of	O
the	O
kinase	B-GP
in	O
question	O
.	O

Originally	O
described	O
in	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
and	O
breakpoint	O
cluster	O
region	O
–	O
c	B-GP
-	I-GP
abl	I-GP
kinase	I-GP
domains	O
14	O
–	O
18	O
,	O
this	O
has	O
now	O
also	O
been	O
described	O
for	O
echinoderm	B-GP
microtubule	I-GP
-	I-GP
associated	I-GP
protein	I-GP
-	I-GP
like	I-GP
4	I-GP
(	O
EML4	B-GP
)–	O
ALK	B-GP
by	O
Choi	O
et	O
al	O
.,	O
and	O
others	O
who	O
have	O
described	O
the	O
appearance	O
of	O
such	O
mutations	O
in	O
the	O
fusion	O
EML4	B-GP
–	O
ALK	B-GP
protein	O
that	O
confers	O
resistance	O
to	O
crizotinib	B-CD
19	O
–	O
22	O
.	O

Phase	O
I	O
/	O
II	O
studies	O
of	O
crizotinib	B-CD
in	O
children	O
with	O
relapsed	O
/	O
refractory	O
tumors	B-DS
involving	O
ALK	B-GP
,	O
including	O
neuroblastoma	B-DS
patients	O
,	O
have	O
been	O
initiated	O
(	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT01182896	O
)	O
23	O
.	O

Given	O
the	O
increasing	O
clinical	O
importance	O
of	O
ALK	B-GP
activity	O
,	O
we	O
chose	O
to	O
characterize	O
ALK	B-GP
-	O
mediated	O
tyrosine	B-GP
kinase	I-GP
signaling	O
networks	O
by	O
MS	O
-	O
based	O
phosphoproteomics	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
conducted	O
a	O
comprehensive	O
profiling	O
of	O
endogenous	O
proteins	O
that	O
are	O
tyrosine	O
-	O
phosphorylated	O
upon	O
expression	O
and	O
activation	O
of	O
wild	O
-	O
type	O
ALK	B-GP
in	O
PC12	O
cells	O
,	O
a	O
cell	O
line	O
originally	O
from	O
the	O
rat	B-OG
neural	O
crest	O
.	O

This	O
list	O
,	O
which	O
reflects	O
both	O
direct	O
and	O
indirect	O
tyrosine	B-CD
phosphorylation	O
targets	O
as	O
a	O
result	O
of	O
ALK	B-GP
activity	O
within	O
the	O
cell	O
,	O
verifies	O
several	O
recently	O
published	O
results	O
such	O
as	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
substrate	I-GP
2	I-GP
(	O
FRS2	B-GP
)	O
23	O
.	O

One	O
of	O
the	O
proteins	O
that	O
was	O
most	O
significantly	O
tyrosine	O
-	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
in	O
our	O
analysis	O
was	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
(	O
STAT3	B-GP
),	O
which	O
has	O
previously	O
been	O
reported	O
to	O
be	O
phosphorylated	O
by	O
both	O
the	O
full	O
-	O
length	O
ALK	B-GP
and	O
ALK	B-GP
fusion	O
proteins	O
24	O
–	O
27	O
.	O

Here	O
,	O
we	O
investigated	O
this	O
further	O
,	O
and	O
clarified	O
the	O
importance	O
of	O
STAT3	B-GP
as	O
a	O
mediator	O
in	O
the	O
initiation	O
of	O
transcription	O
of	O
MYCN	B-GP
.	O

Results	O

Phosphotyrosine	O
profiling	O
of	O
PC12	O
cells	O
expressing	O
ALK	B-GP

To	O
identify	O
sites	O
with	O
altered	O
phosphorylation	O
associated	O
with	O
ALK	B-GP
RTK	B-GP
activity	O
,	O
we	O
utilized	O
an	O
immunoaffinity	O
-	O
coupled	O
LC	O
-	O
MS	O
/	O
MS	O
approach	O
on	O
PC12	O
Tet	O
-	O
on	O
-	O
inducible	O
cell	O
lines	O
.	O

After	O
induction	O
,	O
ALK	B-GP
was	O
activated	O
by	O
addition	O
of	O
agonist	O
mAbs	O
that	O
have	O
previously	O
been	O
reported	O
to	O
initiate	O
ALK	B-GP
signaling	O
pathways	O
10	O
–	O
28	O
.	O

Comparison	O
with	O
controls	O
expressing	O
unstimulated	O
ALK	B-GP
allowed	O
quantification	O
of	O
336	O
phosphorylation	O
sites	O
(	O
207	O
phosphotyrosine	B-CD
,	O
78	O
phosphoserine	B-CD
,	O
and	O
51	O
phosphothreonine	B-CD
)	O
derived	O
from	O
189	O
different	O
proteins	O
(	O
Table	O
S1	O
).	O

Label	O
-	O
free	O
quantification	O
of	O
ALK	B-GP
-	O
activated	O
versus	O
control	O
cells	O
revealed	O
101	O
phosphorylation	O
sites	O
(	O
73	O
phosphotyrosine	B-CD
,	O
13	O
phosphoserine	B-CD
,	O
and	O
15	O
phosphothreonine	B-CD
)	O
in	O
72	O
proteins	O
,	O
with	O
a	O
more	O
than	O
five	O
-	O
fold	O
increase	O
in	O
corresponding	O
phosphopeptide	O
intensities	O
.	O

In	O
contrast	O
,	O
only	O
19	O
phosphorylation	O
sites	O
in	O
12	O
proteins	O
were	O
found	O
with	O
decreased	O
phosphorylation	O
following	O
ALK	B-GP
induction	O
.	O

Within	O
the	O
list	O
of	O
mapped	O
phosphorylation	O
sites	O
,	O
we	O
identified	O
11	O
phosphotyrosine	B-CD
sites	O
that	O
belong	O
to	O
ALK	B-GP
(	O
Fig	O
.	O
1A	O
).	O

As	O
expected	O
,	O
all	O
of	O
them	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
level	O
of	O
phosphorylation	O
on	O
activation	O
of	O
ALK	B-GP
with	O
mAb	O
as	O
compared	O
with	O
control	O
cells	O
(	O
Table	O
S1	O
).	O

The	O
identified	O
tyrosine	B-CD
phosphorylation	O
sites	O
in	O
full	O
-	O
length	O
ALK	B-GP
overlap	O
with	O
the	O
predicted	O
ones	O
(	O
PhosphoMotif	O
,	O
Human	B-OG
Protein	O
Reference	O
Database	O
,	O
http	O
://	O
www	O
.	O
hprd	O
.	O
org	O
/	O
PhosphoMotif_finder	O
),	O
and	O
cover	O
,	O
with	O
only	O
one	O
exception	O
,	O
the	O
entire	O
set	O
of	O
mapped	O
phosphotyrosine	B-CD
sites	O
from	O
earlier	O
investigations	O
of	O
EML4	B-GP
–	O
ALK	B-GP
and	O
nucleophosmin	B-GP
(	O
NPM	O
)–	O
ALK	B-GP
29	O
,	O
30	O
.	O

(	O
A	O
)	O
Tyrosine	B-CD
residues	O
phosphorylated	O
in	O
the	O
kinase	B-GP
domain	O
of	O
ALK	B-GP
.	O

The	O
intracellular	O
domain	O
of	O
ALK	B-GP
containing	O
the	O
protein	B-GP
kinase	I-GP
domain	O
(	O
PKD	B-GP
)	O
(	O
red	O
)	O
and	O
potential	O
autophosphorylation	O
sites	O
were	O
searched	O
with	O
phosphomotif	O
(	O
http	O
://	O
www	O
.	O
hprd	O
.	O
org	O
/	O
PhosphoMotif_finder	O
)	O
as	O
indicated	O
.	O

Presented	O
and	O
compared	O
side	O
-	O
by	O
-	O
side	O
with	O
our	O
phosphotyrosine	B-CD
mapping	O
of	O
activated	O
full	O
-	O
length	O
ALK	B-GP
are	O
the	O
global	O
surveys	O
of	O
phosphotyrosine	B-CD
peptides	O
identified	O
in	O
EML4	B-GP
–	O
ALK	B-GP
and	O
NPM	B-GP
–	O
ALK	B-GP
29	O
,	O
30	O
.	O

The	O
critical	O
tyrosines	B-CD
in	O
the	O
activation	O
loop	O
of	O
the	O
kinase	B-GP
domain	O
of	O
ALK	B-GP
are	O
boxed	O
45	O
.	O

(	O
B	O
)	O
Protein	O
–	O
protein	O
interactions	O
of	O
human	B-OG
orthologs	O
of	O
the	O
phosphoproteins	O
identified	O
in	O
ALK	B-GP
-	O
expressing	O
PC12	O
cells	O
.	O

In	O
the	O
network	O
,	O
proteins	O
with	O
upregulated	O
phosphorylation	O
sites	O
in	O
activated	O
ALK	B-GP
-	O
expressing	O
PC12	O
cells	O
as	O
compared	O
with	O
control	O
cells	O
are	O
in	O
red	O
,	O
and	O
proteins	O
with	O
downregulated	O
phosphorylation	O
sites	O
are	O
in	O
green	O
.	O

Blue	O
edges	O
indicate	O
protein	O
–	O
protein	O
interactions	O
,	O
and	O
orange	O
edges	O
indicate	O
kinase	B-GP
–	O
substrate	O
relationships	O
.	O

Only	O
the	O
network	O
including	O
ALK	B-GP
is	O
shown	O
.	O

The	O
pale	O
blue	O
balls	O
indicate	O
(	O
human	B-OG
orthologs	O
of	O
)	O
PC12	O
proteins	O
with	O
identified	O
/	O
mapped	O
phosphotyrosines	B-CD
that	O
were	O
not	O
found	O
to	O
be	O
significantly	O
regulated	O
.	O

To	O
highlight	O
potential	O
direct	O
downstream	O
substrates	O
of	O
full	O
-	O
length	O
ALK	B-GP
,	O
a	O
network	O
analysis	O
using	O
known	O
protein	O
–	O
protein	O
interactions	O
and	O
experimentally	O
verified	O
kinase	B-GP
–	O
substrate	O
relationships	O
of	O
the	O
human	B-OG
orthologs	O
of	O
the	O
identified	O
phosphoproteins	B-GP
was	O
performed	O
(	O
Fig	O
.	O
1B	O
).	O

The	O
network	O
model	O
illustrated	O
two	O
of	O
the	O
identified	O
phosphoproteins	B-GP
with	O
increased	O
phosphorylation	O
as	O
potential	O
direct	O
targets	O
of	O
ALK	B-GP
following	O
ALK	B-GP
induction	O
,	O
namely	O
PTPN11	B-GP
(	O
SHP	B-GP
-	I-GP
2	I-GP
)	O
and	O
STAT3	B-GP
.	O

Neither	O
of	O
these	O
has	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
full	O
-	O
length	O
ALK	B-GP
.	O

In	O
agreement	O
with	O
a	O
role	O
for	O
these	O
proteins	O
downstream	O
of	O
ALK	B-GP
,	O
we	O
detected	O
approximately	O
10	O
-	O
fold	O
higher	O
phosphorylation	O
at	O
Tyr546	O
and	O
Tyr584	O
in	O
SHP	B-GP
-	I-GP
2	I-GP
as	O
well	O
as	O
Tyr705	O
in	O
STAT3	B-GP
under	O
ALK	B-GP
-	O
activating	O
conditions	O
in	O
our	O
model	O
.	O

Furthermore	O
,	O
identified	O
downstream	O
targets	O
of	O
ALK	B-GP
detected	O
in	O
this	O
phosphoprofiling	O
,	O
such	O
as	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	B-GP
MAPK	I-GP
)	I-GP
1	I-GP
,	O
MAPK3	B-GP
[	O
extracellular	B-GP
signal	I-GP
-	I-GP
related	I-GP
kinase	I-GP
(	O
ERK	B-GP
)	I-GP
2	I-GP
/	O
1	O
],	O
glycogen	B-GP
synthase	I-GP
kinase	I-GP
-	I-GP
3α	I-GP
,	O
STAT3	B-GP
,	O
FAK	B-GP
,	O
and	O
CRKL	B-GP
(	O
Table	O
S1	O
),	O
showed	O
decreased	O
phosphorylation	O
upon	O
abrogation	O
of	O
ALK	B-GP
activity	O
in	O
several	O
neuroblastoma	B-DS
cell	O
lines	O
(	O
Fig	O
.	O
S1	O
).	O

ALK	B-GP
activates	O
STAT3	B-GP
in	O
PC12	O
cells	O

We	O
subsequently	O
decided	O
to	O
focus	O
in	O
more	O
detail	O
on	O
one	O
of	O
the	O
most	O
prominent	O
hits	O
from	O
the	O
phosphotyrosine	O
proteomics	O
screen	O
,	O
namely	O
STAT3	B-GP
.	O

As	O
observed	O
in	O
the	O
screen	O
,	O
activation	O
of	O
ALK	B-GP
resulted	O
in	O
clear	O
phosphorylation	O
of	O
STAT3	B-GP
at	O
Tyr705	O
.	O

PC12	O
cells	O
expressing	O
either	O
doxycycline	B-CD
-	O
inducible	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
were	O
employed	O
to	O
examine	O
STAT3	B-GP
activation	O
.	O

As	O
ALK	B-GP
is	O
still	O
regarded	O
as	O
an	O
orphan	B-GP
receptor	I-GP
,	O
the	O
ALK	B-GP
receptor	I-GP
was	O
stimulated	O
with	O
an	O
agonist	O
mAb	O
that	O
has	O
been	O
previously	O
reported	O
to	O
bind	O
and	O
activate	O
ALK	B-GP
in	O
a	O
cell	O
culture	O
model	O
28	O
,	O
32	O
.	O

Interestingly	O
,	O
whereas	O
long	O
-	O
term	O
stimulation	O
of	O
the	O
wild	O
-	O
type	O
ALK	B-GP
receptor	I-GP
did	O
lead	O
to	O
visible	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-GP
,	O
this	O
was	O
not	O
prominently	O
observed	O
after	O
30	O
min	O
of	O
stimulation	O
,	O
a	O
time	O
point	O
when	O
ALK	B-GP
and	O
ERK1	B-GP
/	O
2	O
were	O
highly	O
phosphorylated	O
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
).	O

This	O
is	O
in	O
contrast	O
to	O
the	O
robust	O
activation	O
of	O
STAT3	B-GP
observed	O
upon	O
induction	O
of	O
expression	O
of	O
the	O
ALKF1174S	O
mutant	O
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
3	O
and	O
7	O
).	O

In	O
both	O
cases	O
,	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-GP
was	O
abrogated	O
by	O
the	O
addition	O
of	O
the	O
ALK	B-GP
inhibitor	O
crizotinib	B-CD
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
4	O
and	O
7	O
with	O
lanes	O
5	O
and	O
8	O
).	O

STAT3	B-GP
phosphorylation	O
and	O
interaction	O
with	O
ALK	B-GP
on	O
ALK	B-GP
activation	O
.	O

(	O
A	O
)	O
Tet	O
-	O
on	O
-	O
inducible	O
PC12	O
cell	O
clones	O
expressing	O
either	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
receptor	O
were	O
employed	O
.	O

Protein	O
expression	O
was	O
induced	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
doxycycline	B-CD
,	O
and	O
cells	O
were	O
serum	O
-	O
starved	O
for	O
24	O
h	O
prior	O
to	O
stimulation	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
ALK	B-GP
-	O
activating	O
mAb	O
(	O
mAb31	O
)	O
for	O
30	O
min	O
or	O
24	O
h	O
.	O

Whole	O
cell	O
lysates	O
were	O
analyzed	O
by	O
SDS	O
/	O
PAGE	O
,	O
and	O
this	O
was	O
followed	O
by	O
immunoblotting	O
with	O
antibodies	O
against	O
p	O
-	O
ALKY1278	O
,	O
ALK	B-GP
,	O
p	O
-	O
STAT3Y705	O
,	O
and	O
p	O
-	O
ERK	B-GP
.	O

Pan	O
-	O
ERK	B-GP
and	O
pan	O
-	O
STAT3	B-GP
antibodies	B-GP
were	O
employed	O
as	O
loading	O
controls	O
.	O

(	O
B	O
,	O
C	O
)	O
PC12	O
cells	O
were	O
transfected	O
with	O
either	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
together	O
with	O
FLAG	O
-	O
tagged	O
STAT3	B-GP
prior	O
to	O
stimulation	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
ALK	B-GP
-	O
activating	O
mAb	O
(	O
mAb46	O
)	O
for	O
24	O
h	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
250	O
nm	O
crizotinib	B-CD
,	O
as	O
indicated	O
.	O

Lysates	O
were	O
immunoprecipitated	O
(	O
IP	O
)	O
with	O
either	O
antibody	O
against	O
FLAG	O
(	O
M2	O
)	O
(	O
B	O
)	O
or	O
with	O
antibody	O
against	O
ALK	B-GP
(	O
mAb31	O
)	O
(	O
C	O
),	O
and	O
this	O
was	O
followed	O
by	O
immunoblotting	O
for	O
ALK	B-GP
,	O
FLAG	O
,	O
and	O
STAT3	B-GP
,	O
as	O
indicated	O
.	O

WCL	O
,	O
whole	O
cell	O
lysate	O
.	O

To	O
investigate	O
the	O
activation	O
process	O
further	O
,	O
we	O
examined	O
whether	O
an	O
interaction	O
between	O
ALK	B-GP
and	O
STAT3	B-GP
could	O
occur	O
.	O

We	O
were	O
unable	O
to	O
observe	O
an	O
interaction	O
between	O
doxycycline	B-CD
-	O
induced	O
ALK	B-GP
and	O
endogenous	O
STAT3	B-GP
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
).	O

However	O
,	O
an	O
interaction	O
between	O
STAT3	B-GP
and	O
ALK	B-GP
was	O
observed	O
on	O
immmunoprecipitation	O
of	O
tagged	O
STAT3	B-GP
,	O
when	O
wild	O
-	O
type	O
ALK	B-GP
was	O
transiently	O
cotransfected	O
with	O
FLAG	O
-	O
tagged	O
STAT3	B-GP
(	O
Fig	O
.	O
2B	O
).	O

Upon	O
stimulation	O
of	O
ALK	B-GP
,	O
increased	O
interaction	O
between	O
ALK	B-GP
and	O
STAT3	B-GP
was	O
observed	O
(	O
Fig	O
.	O
2B	O
,	O
lane	O
3	O
).	O

This	O
interaction	O
was	O
abrogated	O
by	O
addition	O
of	O
the	O
ALK	B-GP
inhibitor	O
crizotinib	B-CD
(	O
Fig	O
.	O
2B	O
,	O
lane	O
4	O
).	O

Similarly	O
,	O
on	O
cotransfection	O
of	O
activated	O
ALKF1174S	O
with	O
FLAG	O
-	O
tagged	O
STAT3	B-GP
,	O
an	O
interaction	O
was	O
observed	O
that	O
was	O
blocked	O
upon	O
addition	O
of	O
crizotinib	B-CD
prior	O
to	O
immunoprecipitation	O
(	O
Fig	O
.	O
2B	O
,	O
compare	O
lanes	O
5	O
and	O
6	O
).	O

Similarly	O
,	O
we	O
were	O
able	O
to	O
observe	O
STAT3	B-GP
in	O
both	O
wild	O
-	O
type	O
and	O
gain	O
-	O
of	O
-	O
function	O
ALK	B-GP
immunoprecipitates	O
from	O
PC12	O
cells	O
transiently	O
expressing	O
ALK	B-GP
and	O
STAT3	B-GP
(	O
Fig	O
.	O
2C	O
).	O

In	O
agreement	O
with	O
our	O
previous	O
observations	O
,	O
the	O
STAT3	B-GP
–	O
ALK	B-GP
interaction	O
was	O
crizotinib	B-CD
-	O
sensitive	O
(	O
Fig	O
.	O
2C	O
,	O
compare	O
lanes	O
3	O
and	O
5	O
with	O
lanes	O
4	O
and	O
6	O
).	O

Quantification	O
of	O
independent	O
blots	O
showed	O
clear	O
six	O
-	O
fold	O
to	O
10	O
-	O
fold	O
increased	O
binding	O
of	O
STAT3	B-GP
to	O
ALK	B-GP
upon	O
stimulation	O
or	O
when	O
a	O
gain	O
-	O
of	O
-	O
function	O
ALK	B-GP
variant	O
was	O
employed	O
(	O
Fig	O
.	O
S2	O
).	O

These	O
data	O
suggest	O
that	O
,	O
upon	O
activation	O
,	O
STAT3	B-GP
may	O
be	O
recruited	O
to	O
ALK	B-GP
signaling	O
complexes	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
our	O
attempts	O
to	O
verify	O
this	O
interaction	O
at	O
the	O
level	O
of	O
endogenous	O
proteins	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
have	O
not	O
been	O
successful	O
.	O

STAT3	B-GP
is	O
important	O
for	O
MYCN	B-GP
expression	O
in	O
response	O
to	O
ALK	B-GP
activation	O

Given	O
recent	O
observations	O
that	O
ALK	B-GP
regulates	O
MYCN	B-GP
transcription	O
in	O
neuroblastoma	B-DS
cells	O
and	O
collaborates	O
with	O
MYCN	B-GP
in	O
neuroblastoma	B-DS
pathogenesis	O
34	O
–	O
37	O
,	O
we	O
decided	O
to	O
investigate	O
a	O
role	O
for	O
STAT3	B-GP
in	O
this	O
process	O
.	O

Initially	O
,	O
we	O
employed	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
STAT3	B-GP
in	O
a	O
number	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
,	O
including	O
CBL	O
-	O
GE	O
,	O
CBL	O
-	O
BAR	O
,	O
CBL	O
-	O
GA	O
and	O
Kelly	O
cells	O
.	O

These	O
neuroblastoma	B-DS
cell	O
lines	O
are	O
all	O
ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
in	O
nature	O
,	O
containing	O
either	O
an	O
activated	O
ALK	B-GP
mutation	O
(	O
ALKR1275Q	O
,	O
CBL	O
-	O
GA	O
;	O
ALKF1174V	O
,	O
CLB	O
-	O
GE	O
;	O
ALKF1174L	O
,	O
Kelly	O
)	O
or	O
overexpressing	O
an	O
ALK	B-GP
receptor	I-GP
with	O
an	O
extracellular	O
domain	O
deletion	O
(	O
CLB	B-GP
-	O
BARΔexon	O
4	O
–	O
12	O
),	O
and	O
express	O
different	O
levels	O
of	O
MYCN	B-GP
(	O
Fig	O
.	O
S3	O
)	O
38	O
,	O
39	O
.	O

Cell	O
lines	O
were	O
transfected	O
with	O
either	O
scrambled	O
siRNA	O
,	O
two	O
independent	O
siRNAs	O
targeting	O
STAT3	B-GP
,	O
or	O
a	O
mock	O
control	O
.	O

In	O
each	O
cell	O
line	O
tested	O
,	O
the	O
scrambled	O
siRNA	O
transfection	O
did	O
not	O
reduce	O
STAT3	B-GP
levels	O
,	O
which	O
were	O
comparable	O
to	O
those	O
in	O
cells	O
with	O
control	O
transfection	O
without	O
siRNA	O
.	O

However	O
,	O
upon	O
transfection	O
with	O
specific	O
STAT3	B-GP
siRNA	O
,	O
all	O
cell	O
lines	O
tested	O
showed	O
reduced	O
levels	O
of	O
STAT3	B-GP
as	O
compared	O
with	O
the	O
scrambled	O
transfection	O
controls	O
(	O
Fig	O
.	O
3A	O
–	O
D	O
,	O
top	O
panels	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
2	O
).	O

Furthermore	O
,	O
a	O
clear	O
reduction	O
in	O
MYCN	B-GP
levels	O
in	O
CLB	O
-	O
BAR	O
,	O
CLB	O
-	O
GA	O
and	O
Kelly	O
cells	O
was	O
observed	O
upon	O
treatment	O
with	O
siRNA	O
targeting	O
STAT3	B-GP
(	O
Fig	O
.	O
3A	O
–	O
D	O
,	O
middle	O
panels	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
2	O
).	O

Loss	O
of	O
STAT3	B-GP
results	O
in	O
reduced	O
MYCN	B-GP
levels	O
.	O

Two	O
independent	O
STAT3	B-GP
siRNAs	O
(#	O
1	O
or	O
#	O
2	O
)	O
were	O
employed	O
to	O
downregulate	O
STAT3	B-GP
levels	O
in	O
CLB	B-GP
-	O
GE	O
(	O
A	O
),	O
CLB	O
-	O
BAR	O
(	O
B	O
),	O
Kelly	O
(	O
C	O
)	O
and	O
CLB	B-GP
-	O
GA	O
(	O
D	O
)	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

Cells	O
were	O
transfected	O
with	O
either	O
control	O
scrambled	O
siRNA	O
,	O
STAT3	B-GP
siRNA	O
#	O
1	O
or	O
STAT3	B-GP
siRNA	O
#	O
2	O
prior	O
to	O
cell	O
lysis	O
48	O
h	O
post	O
-	O
transfection	O
.	O

Whole	O
cell	O
lysates	O
were	O
subsequently	O
immunoblotted	O
for	O
STAT3	B-GP
,	O
MYCN	B-GP
,	O
and	O
pan	O
-	O
ERK	B-GP
(	O
as	O
loading	O
control	O
),	O
as	O
indicated	O
.	O

Lfm	O
,	O
lipofectamine	O
;	O
scC	O
,	O
scramble	O
control	O
.	O

To	O
further	O
validate	O
these	O
results	O
,	O
we	O
employed	O
a	O
number	O
of	O
STAT3	B-GP
inhibitors	O
,	O
including	O
FLLL32	B-CD
and	O
STATTIC	B-CD
,	O
which	O
have	O
previously	O
been	O
shown	O
to	O
inhibit	O
STAT3	B-GP
activation	O
41	O
,	O
42	O
.	O

We	O
investigated	O
ALK	B-GP
,	O
STAT3	B-GP
and	O
MYCN	B-GP
levels	O
in	O
CLB	O
-	O
GE	O
,	O
CLB	O
-	O
BAR	O
,	O
Kelly	O
and	O
CLB	B-GP
-	O
GA	O
neuroblastoma	B-DS
cell	O
lines	O
upon	O
treatment	O
with	O
STAT3	B-GP
inhibitors	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
).	O

Treatment	O
with	O
either	O
FLLL32	B-CD
or	O
STATTIC	O
efficiently	O
abrogated	O
the	O
phosphorylation	O
of	O
STAT3	B-GP
without	O
affecting	O
general	O
STAT3	B-GP
levels	O
.	O

Importantly	O
,	O
whereas	O
these	O
inhibitors	O
blocked	O
STAT3	B-GP
activity	O
,	O
they	O
did	O
not	O
affect	O
the	O
phosphorylation	O
status	O
of	O
ERK	B-GP
or	O
ALK	B-GP
itself	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
1	O
).	O

In	O
keeping	O
with	O
the	O
results	O
obtained	O
with	O
STAT3	B-GP
siRNA	O
treatment	O
,	O
both	O
inhibitors	O
reduced	O
MYCN	B-GP
levels	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
1	O
),	O
suggesting	O
that	O
STAT3	B-GP
may	O
act	O
between	O
the	O
ALK	B-GP
receptor	I-GP
and	O
expression	O
of	O
MYCN	B-GP
.	O

The	O
ALK	B-GP
inhibitor	O
crizotinib	B-CD
was	O
employed	O
as	O
a	O
control	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
the	O
phosphorylation	O
of	O
STAT3	B-GP
and	O
ALK	B-GP
,	O
expression	O
of	O
MYCN	B-GP
and	O
phosphorylation	O
of	O
ERK	B-GP
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lane	O
2	O
with	O
lanes	O
1	O
,	O
3	O
and	O
4	O
).	O

STAT3	B-GP
activity	O
is	O
required	O
for	O
regulation	O
of	O
MYCN	B-GP
expression	O
by	O
ALK	B-GP
.	O

Neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
(	O
A	O
),	O
CLB	O
-	O
BAR	O
(	O
B	O
),	O
Kelly	O
(	O
C	O
)	O
and	O
CLB	O
-	O
GA	O
(	O
D	O
)	O
were	O
starved	O
and	O
treated	O
with	O
either	O
250	O
nm	O
crizotinib	B-CD
(	O
24	O
h	O
),	O
5	O
μm	O
FLLL32	O
(	O
8	O
h	O
),	O
5	O
μm	O
STATTIC	O
(	O
8	O
h	O
),	O
or	O
control	O
,	O
as	O
indicated	O
.	O

After	O
cell	O
lysis	O
,	O
samples	O
were	O
immunoblotted	O
with	O
antibodies	B-GP
against	O
p	O
-	O
ALKY1278	O
,	O
MYCN	B-GP
,	O
p	O
-	O
STAT3Y705	O
,	O
and	O
p	O
-	O
ERK	B-GP
.	O

Pan	O
-	O
ERK	B-GP
,	O
ALK	B-GP
and	O
STAT3	B-GP
antibodies	B-GP
were	O
employed	O
as	O
loading	O
controls	O
.	O

Three	O
independent	O
experiments	O
with	O
similar	O
results	O
were	O
performed	O
,	O
and	O
representative	O
blots	O
are	O
shown	O
.	O

To	O
investigate	O
further	O
whether	O
STAT3	B-GP
is	O
involved	O
in	O
ALK	B-GP
-	O
activated	O
initiation	O
of	O
MYCN	B-GP
transcription	O
,	O
we	O
employed	O
an	O
MYCNP	B-GP
–	O
luciferase	B-GP
assay	O
in	O
two	O
independent	O
neuroblastoma	B-DS
cell	O
lines	O
36	O
.	O

Cells	O
were	O
transfected	O
with	O
MYCNP	O
–	O
luciferase	B-GP
reporter	O
or	O
control	O
,	O
and	O
treated	O
with	O
either	O
STATTIC	O
or	O
FLLL32	O
.	O

Upon	O
treatment	O
with	O
STAT3	B-GP
inhibitors	O
,	O
both	O
cell	O
lines	O
showed	O
reduced	O
luciferase	B-GP
activity	O
as	O
compared	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
5A	O
).	O

Additionally	O
,	O
we	O
employed	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
to	O
confirm	O
a	O
role	O
for	O
STAT3	B-GP
in	O
ALK	B-GP
regulation	O
of	O
MYCN	B-GP
transcription	O
.	O

As	O
controls	O
,	O
we	O
employed	O
primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
ribosomal	B-GP
protein	I-GP
29	I-GP
(	O
RPL29	B-GP
)	O
or	O
ribosomal	B-GP
protein	I-GP
19	I-GP
(	O
RPL19	B-GP
)	O
(	O
Fig	O
.	O
5B	O
,	O
data	O
not	O
shown	O
).	O

Neuroblastoma	B-DS
cell	O
lines	O
treated	O
with	O
STATTIC	O
or	O
FLLL32	B-CD
for	O
24	O
h	O
showed	O
a	O
significant	O
reduction	O
in	O
MYCN	B-GP
mRNA	O
levels	O
in	O
comparison	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
5B	O
).	O

Thus	O
,	O
pharmacological	O
inhibition	O
of	O
STAT3	B-GP
activity	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
harboring	O
ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
mutations	O
results	O
in	O
reduced	O
transcription	O
of	O
MYCN	B-GP
mRNA	O
.	O

Inhibition	O
of	O
STAT3	B-GP
reduces	O
MYCN	B-GP
transcription	O
.	O

(	O
A	O
)	O
Luciferase	O
assay	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
transfected	O
with	O
MYCNP	O
–	O
luciferase	B-GP
or	O
empty	O
pGL2	O
vector	O
as	O
a	O
control	O
(	O
ctrl	O
).	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
transfected	O
with	O
empty	O
pGL2	O
(	O
ctrl	O
)	O
or	O
MYCNP	O
–	O
luciferase	B-GP
.	O

Cells	O
were	O
then	O
serum	O
-	O
starved	O
,	O
and	O
STAT3	B-GP
was	O
inhibited	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

White	O
bars	O
:	O
untreated	O
neuroblastoma	B-DS
cells	O
.	O

Gray	O
bars	O
:	O
cells	O
treated	O
with	O
FLLL32	B-CD
.	O

Black	O
bars	O
:	O
cells	O
treated	O
with	O
STATTIC	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
luciferase	B-GP
activity	O
,	O
where	O
untreated	O
samples	O
transfected	O
with	O
empty	O
pGL2	O
vector	O
were	O
set	O
to	O
1	O
.	O

(	O
B	O
)	O
qRT	O
-	O
PCR	O
of	O
MYCN	B-GP
mRNA	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
starved	O
and	O
treated	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

Primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
RPL19	B-GP
(	O
B	O
)	O
or	O
RPL29	B-GP
(	O
data	O
not	O
shown	O
)	O
were	O
used	O
to	O
control	O
for	O
differences	O
in	O
cDNA	O
input	O
.	O

Relative	O
expression	O
was	O
calculated	O
according	O
to	O
the	O
ΔΔCt	O
relative	O
quantification	O
method	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
duplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

White	O
bars	O
:	O
untreated	O
cells	O
.	O

Gray	O
bars	O
:	O
cells	O
treated	O
with	O
FLLL32	B-CD
.	O

Black	O
bars	O
:	O
cells	O
treated	O
with	O
STATTIC	O
.	O

STAT3	B-GP
activity	O
is	O
required	O
for	O
growth	O
and	O
viability	O
of	O
neuroblastoma	B-DS
cells	O

We	O
then	O
investigated	O
whether	O
STAT3	B-GP
is	O
not	O
only	O
important	O
for	O
initiation	O
of	O
MYCN	B-GP
transcription	O
but	O
also	O
might	O
influence	O
the	O
proliferation	O
of	O
our	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

In	O
this	O
analysis	O
,	O
we	O
employed	O
CLB	B-GP
-	O
GE	O
,	O
CLB	O
-	O
BAR	O
,	O
Kelly	O
and	O
CLB	O
-	O
GA	O
neuroblastoma	B-DS
cell	O
lines	O
,	O
measuring	O
their	O
growth	O
in	O
response	O
to	O
treatment	O
with	O
the	O
STAT3	B-GP
inhibitor	O
FLLL32	B-CD
or	O
STAT3	B-GP
siRNA	O
.	O

In	O
all	O
cell	O
lines	O
examined	O
,	O
reduction	O
of	O
endogenous	O
STAT3	B-GP
expression	O
levels	O
by	O
siRNA	O
or	O
treatment	O
with	O
the	O
STAT3	B-GP
inhibitor	O
FLLL32	B-CD
resulted	O
in	O
a	O
decrease	O
in	O
cell	O
growth	O
as	O
compared	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
6B	O
,	O
D	O
–	O
G	O
)	O
in	O
a	O
similar	O
manner	O
as	O
crizotinib	B-CD
decreased	O
cell	O
growth	O
(	O
Fig	O
.	O
6A	O
).	O

Furthermore	O
,	O
it	O
was	O
clear	O
that	O
treatment	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
with	O
either	O
FLLL32	B-CD
or	O
crizotinib	B-CD
reduced	O
the	O
phosphorylation	O
status	O
of	O
STAT3	B-GP
to	O
a	O
similar	O
degree	O
,	O
without	O
increasing	O
cleavage	O
of	O
poly	B-GP
(	I-GP
ADP	I-GP
-	I-GP
ribose	I-GP
)	I-GP
polymerase	I-GP
(	O
PARP	B-GP
),	O
which	O
was	O
used	O
as	O
a	O
measure	O
of	O
apoptosis	O
(	O
Fig	O
.	O
6C	O
).	O

Loss	O
of	O
STAT3	B-GP
function	O
decreases	O
neuroblastoma	B-DS
cell	O
proliferation	O
.	O

(	O
A	O
,	O
B	O
)	O
Neuroblastoma	O
cell	O
lines	O
CLB	O
-	O
GE	O
(▪),	O
CLB	O
-	O
BAR	O
(▴),	O
Kelly	O
(‐)	O
and	O
CLB	O
-	O
GA	O
(•)	O
were	O
treated	O
with	O
250	O
nm	O
crizotinib	B-CD
(	O
A	O
)	O
and	O
1	O
.	O
5	O
μm	O
FLLL32	O
(	O
B	O
)	O
for	O
5	O
days	O
.	O

Proliferation	O
was	O
analyzed	O
with	O
the	O
resazurin	B-CD
cell	O
proliferation	O
assay	O
.	O

Values	O
are	O
reported	O
as	O
fold	O
relative	O
fluorescence	O
from	O
FLLL32	O
-	O
treated	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
untreated	O
cells	O
(♦).	O

Results	O
are	O
from	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
performed	O
in	O
triplicate	O
.	O

(	O
C	O
)	O
Neuroblastoma	O
cell	O
lines	O
CLB	O
-	O
BAR	O
,	O
CLB	O
-	O
GE	O
,	O
CLB	O
-	O
GA	O
and	O
Kelly	O
were	O
grown	O
on	O
six	O
-	O
well	O
plates	O
with	O
complete	O
growth	O
medium	O
,	O
starved	O
,	O
and	O
treated	O
with	O
250	O
nm	O
crizotinib	B-CD
and	O
1	O
.	O
5	O
μm	O
FLLL32	O
for	O
6	O
h	O
.	O

Cell	O
lysates	O
were	O
immunoblotted	O
with	O
antibodies	O
against	O
p	O
-	O
STAT3	B-GP
and	O
PARP	B-GP
.	O

Tubulin	B-GP
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
D	O
–	O
G	O
)	O
CLB	O
-	O
BAR	O
(	O
D	O
),	O
CLB	O
-	O
GA	O
(	O
E	O
)	O
CLB	O
-	O
GE	O
(	O
F	O
)	O
and	O
Kelly	O
(	O
G	O
)	O
cell	O
lines	O
were	O
transfected	O
with	O
scrambled	O
siRNA	O
(	O
SiC	O
)	O
(▪),	O
STAT3	B-GP
siRNA	O
#	O
1	O
(	O
Si1	O
)	O
(▴)	O
or	O
STAT3	B-GP
siRNA	O
#	O
2	O
(	O
Si2	O
)	O
(▴)	O
at	O
0	O
and	O
24	O
h	O
.	O

Cell	O
viability	O
was	O
assessed	O
at	O
0	O
,	O
3	O
,	O
4	O
and	O
5	O
days	O
post	O
-	O
transfection	O
,	O
with	O
the	O
resazurin	B-CD
assay	O
.	O

Values	O
are	O
reported	O
as	O
fold	O
relative	O
fluorescence	O
from	O
siRNA	O
-	O
transfected	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
control	O
mock	O
-	O
transfected	O
cells	O
.	O

Results	O
are	O
from	O
one	O
of	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
performed	O
in	O
triplicate	O
.	O

Discussion	O

It	O
is	O
interesting	O
to	O
compare	O
the	O
results	O
of	O
this	O
study	O
with	O
earlier	O
phosphoproteomics	O
analysis	O
on	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
,	O
such	O
as	O
EML4	B-GP
–	O
ALK	B-GP
and	O
NPM	B-GP
–	O
ALK	B-GP
29	O
,	O
30	O
.	O

In	O
terms	O
of	O
phosphorylation	O
of	O
ALK	B-GP
itself	O
,	O
these	O
studies	O
identified	O
overlapping	O
but	O
not	O
identical	O
sites	O
in	O
the	O
ALK	B-GP
intracellular	O
domain	O
.	O

Activation	O
of	O
full	O
-	O
length	O
ALK	B-GP
results	O
in	O
phosphorylation	O
of	O
Tyr1278	O
,	O
Tyr1282	O
,	O
and	O
Tyr1283	O
,	O
which	O
lie	O
in	O
the	O
Y	O
′	O
RAS	B-GP
′	O
YY	O
autophosphorylation	O
motif	O
in	O
the	O
activation	O
loop	O
.	O

Although	O
our	O
data	O
do	O
not	O
allow	O
us	O
to	O
comment	O
on	O
the	O
order	O
of	O
phosphorylation	O
within	O
the	O
Y	O
′	O
RAS	O
′	O
YY	O
motif	O
,	O
they	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
elucidating	O
the	O
mechanism	O
of	O
phosphorylation	O
44	O
,	O
45	O
,	O
and	O
further	O
support	O
the	O
use	O
of	O
antibodies	O
against	O
pTyr1278	O
as	O
an	O
indicator	O
of	O
ALK	B-GP
activation	O
.	O

Another	O
site	O
commonly	O
used	O
to	O
denote	O
activation	O
of	O
the	O
ALK	B-GP
receptor	I-GP
is	O
Tyr1604	O
,	O
which	O
is	O
situated	O
at	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
the	O
receptor	O
,	O
and	O
has	O
been	O
reported	O
to	O
be	O
important	O
for	O
transformation	O
activity	O
and	O
docking	O
of	O
phospholipase	B-GP
Cγ	I-GP
in	O
studies	O
on	O
NPM	O
–	O
ALK	B-GP
47	O
.	O

Although	O
antibodies	O
against	O
pTyr1604	B-GP
are	O
commonly	O
used	O
to	O
assay	O
ALK	B-GP
activity	O
,	O
the	O
importance	O
of	O
Tyr1604	O
in	O
the	O
interaction	O
of	O
phospholipase	B-GP
Cγ	I-GP
with	O
full	O
-	O
length	O
ALK	B-GP
has	O
not	O
been	O
confirmed	O
.	O

The	O
identification	O
in	O
this	O
study	O
reinforces	O
the	O
potential	O
importance	O
of	O
this	O
tyrosine	B-CD
in	O
ALK	B-GP
activation	O
.	O

Of	O
the	O
phosphorylated	O
tyrosines	B-CD
identified	O
outside	O
of	O
the	O
activation	O
loop	O
,	O
Tyr1507	O
of	O
ALK	B-GP
lies	O
within	O
a	O
consensus	O
Shc	O
-	O
binding	O
site	O
(	O
NPTpY	O
),	O
and	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
interaction	O
of	O
full	O
-	O
length	O
ALK	B-GP
with	O
Shc	O
23	O
.	O

These	O
results	O
are	O
consistent	O
with	O
earlier	O
work	O
on	O
NPM	O
–	O
ALK	B-GP
48	O
.	O

The	O
remaining	O
tyrosines	B-CD
that	O
are	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
identified	O
in	O
this	O
study	O
,	O
namely	O
Tyr1078	O
,	O
Tyr1092	O
,	O
Tyr1096	O
,	O
Tyr1131	O
,	O
Tyr1584	O
,	O
and	O
Tyr1586	O
,	O
have	O
been	O
poorly	O
characterized	O
in	O
the	O
context	O
of	O
the	O
full	O
-	O
length	O
ALK	B-GP
RTK	B-GP
,	O
and	O
determination	O
of	O
their	O
significance	O
requires	O
further	O
analysis	O
.	O

However	O
,	O
work	O
on	O
the	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
implicates	O
these	O
residues	O
in	O
binding	O
of	O
IRS	B-GP
-	I-GP
1	I-GP
(	O
Tyr1096	O
)	O
48	O
,	O
and	O
SNT	O
(	O
FRS2	B-GP
)	O
(	O
Tyr1096	O
and	O
Tyr1507	O
)	O
49	O
.	O

As	O
well	O
as	O
identifying	O
tyrosine	B-CD
phosphorylation	O
sites	O
in	O
ALK	B-GP
,	O
we	O
observed	O
phosphorylation	O
of	O
Ser1086	O
,	O
Ser1281	O
and	O
Thr1597	O
on	O
ALK	B-GP
.	O

Although	O
this	O
finding	O
is	O
intriguing	O
,	O
the	O
significance	O
of	O
these	O
phosphorylation	O
events	O
is	O
unclear	O
.	O

Although	O
the	O
phosphorylation	O
of	O
RTKs	B-GP
on	O
serine	B-CD
and	O
threonine	B-CD
is	O
well	O
recognized	O
,	O
its	O
role	O
is	O
much	O
less	O
understood	O
than	O
that	O
of	O
tyrosine	B-CD
phosphorylation	O
.	O

However	O
,	O
serine	B-CD
/	O
threonine	B-CD
phosphorylation	O
is	O
known	O
to	O
have	O
important	O
regulatory	O
functions	O
for	O
,	O
for	O
example	O
,	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
,	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
50	O
–	O
51	O
,	O
and	O
Kit	B-GP
52	I-GP
,	O
to	O
name	O
but	O
a	O
few	O
.	O

Although	O
information	O
on	O
the	O
phosphorylation	O
of	O
ALK	B-GP
itself	O
in	O
response	O
to	O
activation	O
represented	O
an	O
important	O
part	O
of	O
the	O
information	O
obtained	O
with	O
this	O
phosphoproteomics	O
approach	O
,	O
the	O
identification	O
of	O
candidate	O
molecules	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
was	O
the	O
primary	O
aim	O
of	O
this	O
investigation	O
.	O

The	O
list	O
of	O
phosphoproteins	O
contains	O
both	O
known	O
and	O
novel	O
ALK	B-GP
signaling	O
components	O
,	O
some	O
of	O
which	O
have	O
been	O
characterized	O
,	O
but	O
the	O
majority	O
of	O
which	O
remain	O
to	O
be	O
investigated	O
for	O
their	O
relevance	O
in	O
both	O
physiological	O
and	O
pathological	O
ALK	B-GP
signaling	O
.	O

Of	O
those	O
known	O
candidates	O
,	O
several	O
examples	O
can	O
be	O
briefly	O
mentioned	O
.	O

One	O
molecule	O
identified	O
in	O
our	O
screen	O
was	O
FRS2	B-GP
,	O
which	O
was	O
phosphorylated	O
on	O
Tyr349	O
in	O
response	O
to	O
ALK	B-GP
activation	O
.	O

FRS2	B-GP
has	O
previously	O
been	O
reported	O
to	O
bind	O
full	O
-	O
length	O
ALK	B-GP
,	O
although	O
the	O
binding	O
site	O
is	O
unclear	O
23	O
.	O

Similarly	O
,	O
MAPK1	B-GP
–	O
which	O
was	O
phosphorylated	O
on	O
Thr183	O
in	O
this	O
study	O
–	O
has	O
been	O
shown	O
by	O
several	O
groups	O
to	O
be	O
phosphorylated	O
upon	O
stimulation	O
of	O
the	O
ALK	B-GP
receptor	I-GP
53	I-GP
.	O

One	O
of	O
the	O
major	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
identified	O
in	O
this	O
study	O
was	O
STAT3	B-GP
,	O
which	O
was	O
phosphorylated	O
on	O
Tyr705	O
in	O
response	O
to	O
ALK	B-GP
activation	O
.	O

STAT3	B-GP
has	O
been	O
reported	O
to	O
be	O
phosphorylated	O
downstream	O
of	O
several	O
of	O
the	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
25	O
,	O
27	O
.	O

To	O
date	O
,	O
although	O
several	O
articles	O
have	O
reported	O
STAT3	B-GP
phosphorylation	O
downstream	O
of	O
full	O
-	O
length	O
ALK	B-GP
,	O
the	O
significance	O
of	O
this	O
is	O
unclear	O
8	O
–	O
56	O
.	O

One	O
study	O
of	O
NPM	B-GP
–	O
ALK	B-GP
has	O
suggested	O
that	O
oncogenic	O
ALK	B-GP
binds	O
and	O
activates	O
STAT3	B-GP
directly	O
via	O
the	O
first	O
tyrosine	B-CD
(	O
Tyr1278	O
)	O
in	O
the	O
Y	O
′	O
RAS	O
′	O
YY	O
motif	O
of	O
ALK	B-GP
45	O
.	O

The	O
crystal	O
structures	O
of	O
ALK	B-GP
show	O
that	O
unphosphorylated	O
Tyr1278	O
interacts	O
with	O
Cys1097	O
in	O
the	O
N	O
-	O
lobe	O
of	O
the	O
kinase	B-GP
,	O
implying	O
that	O
phosphorylation	O
of	O
Tyr1278	O
should	O
make	O
a	O
binding	O
site	O
for	O
STAT3	B-GP
available	O
,	O
consistent	O
with	O
this	O
hypothesis	O
.	O

In	O
this	O
study	O
,	O
we	O
saw	O
clear	O
phosphorylation	O
of	O
STAT3	B-GP
on	O
Tyr705	O
,	O
which	O
is	O
particularly	O
robust	O
in	O
response	O
to	O
oncogenic	O
forms	O
of	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
,	O
such	O
as	O
ALKF1174S	O
,	O
ALKΔexon	O
2	O
–	O
3	O
,	O
and	O
ALKΔexon	O
4	O
–	O
1239	O
,	O
55	O
.	O

Although	O
it	O
was	O
not	O
investigated	O
in	O
this	O
study	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
examine	O
the	O
importance	O
of	O
STAT3	B-GP
phosphorylation	O
in	O
neuroblastoma	B-DS
cells	O
harboring	O
a	O
wild	O
-	O
type	O
nonactive	O
ALK	B-GP
receptor	I-GP
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
inhibition	O
of	O
the	O
NB1	O
neuroblastoma	B-DS
cells	O
lines	O
with	O
crizotinib	B-CD
,	O
which	O
resulted	O
in	O
a	O
loss	O
of	O
pSTAT3Y705	O
,	O
although	O
the	O
significance	O
of	O
STAT3	B-GP
for	O
cell	O
growth	O
was	O
not	O
discussed	O
54	O
.	O

In	O
light	O
of	O
the	O
activation	O
of	O
STAT3	B-GP
by	O
ALK	B-GP
,	O
we	O
also	O
investigated	O
the	O
interaction	O
of	O
ALK	B-GP
with	O
STAT3	B-GP
.	O

Indeed	O
,	O
we	O
observed	O
an	O
interaction	O
of	O
STAT3	B-GP
with	O
full	O
-	O
length	O
ALK	B-GP
when	O
overexpressed	O
;	O
however	O
,	O
this	O
was	O
not	O
detectable	O
at	O
the	O
level	O
of	O
endogenous	O
proteins	O
,	O
suggesting	O
that	O
care	O
should	O
be	O
taken	O
when	O
interpreting	O
these	O
results	O
.	O

It	O
is	O
unclear	O
whether	O
this	O
is	O
because	O
of	O
limitations	O
of	O
the	O
antibodies	B-GP
employed	O
here	O
,	O
or	O
a	O
masking	O
of	O
the	O
epitope	O
by	O
the	O
interaction	O
,	O
or	O
simply	O
a	O
low	O
level	O
of	O
endogenous	O
interaction	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanisms	O
underlying	O
ALK	B-GP
activation	O
of	O
STAT3	B-GP
are	O
unknown	O
,	O
it	O
is	O
clear	O
from	O
these	O
studies	O
that	O
loss	O
of	O
STAT3	B-GP
activity	O
,	O
either	O
by	O
RNA	O
interference	O
-	O
mediated	O
knockdown	O
of	O
STAT3	B-GP
or	O
by	O
addition	O
of	O
STAT3	B-GP
inhibitors	O
41	O
,	O
42	O
,	O
reduces	O
the	O
growth	O
and	O
viability	O
of	O
four	O
neuroblastoma	B-DS
lines	O
.	O

One	O
key	O
component	O
examined	O
here	O
was	O
the	O
effect	O
of	O
STAT3	B-GP
activity	O
on	O
MYCN	B-GP
levels	O
.	O

Recent	O
work	O
has	O
highlighted	O
the	O
cooperative	O
roles	O
of	O
ALK	B-GP
and	O
MYCN	B-GP
in	O
neuroblastoma	B-DS
,	O
with	O
ALK	B-GP
impacting	O
on	O
both	O
the	O
level	O
of	O
MYCN	B-GP
transcription	O
and	O
the	O
stability	O
of	O
the	O
MYCN	B-GP
protein	O
itself	O
34	O
–	O
37	O
.	O

Given	O
these	O
reports	O
,	O
our	O
finding	O
here	O
that	O
STAT3	B-GP
is	O
important	O
for	O
changes	O
in	O
MYCN	B-GP
levels	O
in	O
response	O
to	O
ALK	B-GP
signaling	O
is	O
significant	O
.	O

Indeed	O
,	O
inhibition	O
of	O
STAT3	B-GP
by	O
addition	O
of	O
inhibitors	O
,	O
or	O
by	O
RNA	O
interference	O
,	O
reduced	O
MYCN	B-GP
levels	O
even	O
in	O
the	O
presence	O
of	O
activated	O
ALK	B-GP
.	O

In	O
conclusion	O
,	O
our	O
phosphoproteomic	O
analysis	O
identifies	O
a	O
number	O
of	O
phosphorylation	O
sites	O
targeted	O
by	O
activation	O
of	O
the	O
ALK	B-GP
RTK	B-GP
.	O

One	O
prominent	O
target	O
identified	O
in	O
this	O
analysis	O
was	O
STAT3	B-GP
,	O
which	O
we	O
show	O
here	O
is	O
important	O
for	O
the	O
regulation	O
of	O
MYCN	B-GP
downstream	O
of	O
activated	O
ALK	B-GP
.	O

From	O
our	O
investigations	O
,	O
it	O
is	O
also	O
clear	O
that	O
there	O
is	O
a	O
difference	O
between	O
the	O
ability	O
of	O
wild	O
-	O
type	O
ALK	B-GP
to	O
activate	O
STAT3	B-GP
and	O
that	O
of	O
oncogenically	O
activated	O
forms	O
of	O
ALK	B-GP
.	O

The	O
molecular	O
mechanisms	O
underlying	O
this	O
difference	O
are	O
not	O
known	O
,	O
and	O
further	O
work	O
is	O
required	O
to	O
understand	O
this	O
.	O

This	O
work	O
suggests	O
that	O
STAT3	B-GP
inhibition	O
may	O
be	O
a	O
viable	O
approach	O
in	O
the	O
regulation	O
of	O
MYCN	B-GP
activity	O
in	O
neuroblastoma	B-DS
cells	O
,	O
and	O
may	O
have	O
potential	O
therapeutic	O
value	O
in	O
the	O
future	O
.	O

Experimental	O
procedures	O

Phosphotyrosine	O
profiling	O

Tyrosine	B-CD
phosphorylation	O
profiling	O
of	O
PC12	O
cells	O
expressing	O
human	B-OG
ALK	B-GP
with	O
and	O
without	O
activation	O
of	O
ALK	B-GP
was	O
undertaken	O
by	O
immunoaffinity	O
purification	O
with	O
P	O
-	O
Tyr	O
-	O
100	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
),	O
followed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O

This	O
was	O
performed	O
as	O
previously	O
described	O
29	O
–	O
57	O
,	O
except	O
that	O
20	O
and	O
0	O
.	O
8	O
pmol	O
of	O
the	O
stable	O
isotope	O
-	O
labeled	O
phosphotyrosine	B-CD
peptides	O
EH	O
[	O
13C3	O
,	O
15N1	O
-	O
A	O
]	O
LLApYTLGVK	O
and	O
HTDDEMTGpYV	O
[	O
13C3	O
,	O
15N1	O
-	O
A	O
]	O
TR	O
,	O
respectively	O
,	O
were	O
spiked	O
into	O
each	O
cell	O
lysate	O
prior	O
to	O
phosphopeptide	O
purification	O
.	O

Mass	O
spectra	O
of	O
two	O
technical	O
replicates	O
were	O
searched	O
against	O
a	O
rat	B-OG
protein	O
database	O
supplemented	O
with	O
the	O
sequence	O
for	O
human	B-OG
ALK	B-GP
(	O
extracted	O
from	O
UniProtKB	O
/	O
TrEMBL	O
ver	O
.	O
2013_01	O
;	O
41	O
749	O
reviewed	O
and	O
unreviewed	O
sequences	O
)	O
with	O
maxquant	O
version	O
1	O
.	O
3	O
.	O
0	O
.	O
5	O
.	O

Standard	O
settings	O
were	O
used	O
in	O
maxquant	O
(	O
false	O
discovery	O
rate	O
of	O
<	O
1	O
%	O
at	O
the	O
protein	O
,	O
peptide	O
and	O
modification	O
site	O
levels	O
),	O
except	O
that	O
the	O
‘	O
match	O
between	O
runs	O
’	O
function	O
was	O
enabled	O
.	O

A	O
list	O
with	O
high	O
-	O
confidence	O
phosphorylation	O
site	O
identifications	O
was	O
generated	O
by	O
filtering	O
the	O
‘	O
Phospho	O
(	O
STY	O
)	O
sites	O
’	O
output	O
table	O
for	O
Localization	O
probability	O
>	O
75	O
%	O
and	O
Score	O
difference	O
>	O
5	O
.	O

Intensity	O
values	O
for	O
phosphorylation	O
sites	O
were	O
normalized	O
between	O
samples	O
by	O
using	O
correction	O
factors	O
based	O
on	O
the	O
intensity	O
values	O
of	O
the	O
phosphotyrosine	B-CD
sites	O
of	O
the	O
heavily	O
labeled	O
peptide	O
standards	O
.	O

Changes	O
in	O
intensity	O
ratios	O
between	O
cells	O
with	O
activated	O
ALK	B-GP
and	O
control	O
cells	O
of	O
≥	O
5	O
were	O
considered	O
to	O
be	O
significantly	O
altered	O
.	O

Network	O
analysis	O

Rat	B-OG
–	O
human	B-OG
orthologs	O
were	O
extracted	O
from	O
ensembl	O
.	O

The	O
protein	O
–	O
protein	O
interactions	O
among	O
proteins	O
of	O
interest	O
were	O
retrieved	O
from	O
the	O
Protein	O
Interaction	O
Network	O
Analysis	O
platform	O
58	O
,	O
and	O
substrate	O
–	O
kinase	B-GP
relationships	O
were	O
downloaded	O
from	O
the	O
PhosphoSitePlus	O
database	O
59	O
.	O
cytoscape	O
60	O
was	O
used	O
for	O
visualization	O
of	O
networks	O
.	O

Cell	O
culture	O

Stable	O
PC12	O
Tet	O
-	O
on	O
clones	O
expressing	O
human	B-OG
pTTP	O
-	O
ALK	B-GP
(	O
wild	O
type	O
)	O
have	O
been	O
described	O
previously	O
33	O
–	O
56	O
.	O

Stable	O
clones	O
were	O
selected	O
in	O
DMEM	O
containing	O
10	O
%	O
horse	B-OG
serum	O
(	O
MP	O
Biomedicals	O
,	O
France	O
),	O
5	O
%	O
tetracycline	B-CD
-	O
screened	O
fetal	O
bovine	O
serum	O
(	O
Thermo	O
Scientific	O
“	O
HyClone	O
”,	O
Belgium	O
),	O
penicillin	B-CD
,	O
streptomycin	B-CD
,	O
l	B-CD
-	I-CD
glutamine	I-CD
,	O
100	O
mg	O
·	O
mL	O
−	O
1	O
G418	B-CD
,	O
and	O
2	O
mg	O
·	O
mL	O
−	O
1	O
puromycin	B-CD
,	O
at	O
37	O
°	O
C	O
and	O
5	O
%	O
CO2	O
.	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GA	O
(	O
1p	O
deletion	O
,	O
11q	O
deletion	O
,	O
17q	O
gain	O
,	O
ALKR1275Q	O
mutation	O
),	O
CLB	O
-	O
GE	O
(	O
MYCN	B-GP
/	O
ALK	B-GP
-	O
amplified	O
,	O
ALKF1174V	O
mutation	O
,	O
1p	O
deletion	O
,	O
17q	O
gain	O
),	O
CLB	O
-	O
BAR	O
(	O
amplified	O
MYCN	B-GP
/	O
ALKΔexon	O
4	O
–	O
12	O
,	O
1p	O
deletion	O
,	O
17q	O
gain	O
)	O
and	O
Kelly	O
(	O
MYCN	B-GP
-	O
amplified	O
,	O
ALKF1174L	O
mutation	O
)	O
were	O
maintained	O
in	O
RPMI	O
-	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
100	O
U	O
·	O
mL	O
−	O
1	O
penicillin	B-CD
,	O
and	O
100	O
μg	O
·	O
mL	O
−	O
1	O
streptomycin	B-CD
,	O
at	O
37	O
°	O
C	O
in	O
humidified	O
air	O
with	O
5	O
%	O
CO2	O
38	O
–	O
40	O
.	O

Cell	O
proliferation	O

CLB	O
-	O
GA	O
(	O
0	O
.	O
035	O
×	O
106	O
per	O
well	O
),	O
CLB	O
-	O
GE	O
(	O
0	O
.	O
025	O
×	O
106	O
per	O
well	O
),	O
CLB	O
-	O
BAR	O
(	O
0	O
.	O
05	O
×	O
106	O
per	O
well	O
)	O
and	O
Kelly	O
(	O
0	O
.	O
035	O
×	O
106	O
per	O
well	O
)	O
cells	O
were	O
seeded	O
in	O
collagen	B-GP
-	O
coated	O
48	O
-	O
well	O
plates	O
overnight	O
,	O
and	O
,	O
starting	O
on	O
the	O
following	O
day	O
,	O
treated	O
with	O
FLLL32	O
(	O
1	O
.	O
5	O
μm	O
)	O
for	O
0	O
–	O
5	O
days	O
.	O

Cell	O
viability	O
was	O
determined	O
at	O
0	O
–	O
5	O
days	O
after	O
drug	O
treatment	O
,	O
with	O
55	O
μm	O
resazurin	B-CD
(	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
61	O
.	O

After	O
2	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
amount	O
of	O
metabolized	O
resazurin	B-CD
was	O
analyzed	O
as	O
relative	O
fluorescence	O
with	O
an	O
Infinit200	O
plate	O
reader	O
(	O
TEKAN	O
,	O
Männedorf	O
,	O
Switzerland	O
).	O

Results	O
are	O
from	O
one	O
of	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
being	O
performed	O
in	O
triplicate	O
.	O

Results	O
are	O
presented	O
as	O
fold	O
relative	O
fluorescence	O
from	O
FLLL32	O
-	O
treated	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
control	O
untreated	O
cells	O
.	O

Cell	O
lysis	O
and	O
immunoblotting	O

Cells	O
were	O
harvested	O
and	O
lysed	O
as	O
described	O
previously	O
33	O
–	O
36	O
.	O

Samples	O
were	O
boiled	O
in	O
SDS	O
/	O
PAGE	O
sample	O
buffer	O
,	O
and	O
analyzed	O
on	O
SDS	O
/	O
PAGE	O
gel	O
.	O

The	O
antibodies	O
used	O
were	O
anti	O
-	O
STAT3	B-GP
(#	O
9132	O
),	O
anti	O
-	O
p	O
-	O
STAT3	B-GP
(	O
Tyr705	O
)	O
(#	O
9145	O
),	O
anti	O
-	O
p	O
-	O
ALK	B-GP
(	O
Tyr1278	O
)	O
(#	O
6941	O
),	O
anti	O
-	O
p	O
-	O
ERK	B-GP
(	O
phospho	O
-	O
p44	O
/	O
42	O
)	O
(#	O
9101	O
),	O
anti	O
-	O
N	O
-	B-GP
MYC	I-GP
(#	O
9405	O
)	O
(	O
all	O
Cell	O
Signaling	O
Technology	O
,	O
MA	O
,	O
USA	O
),	O
anti	O
-	O
FLAG	O
(	O
clone	O
M2	O
,	O
#	O
F3165	O
;	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
anti	O
-	O
ERK	B-GP
(	O
610123	O
;	O
BD	O
Transduction	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
and	O
anti	O
-	O
ALK	B-GP
(	O
mAb135	O
and	O
mAb31	O
)	O
10	O
.	O

STAT3	B-GP
siRNA	O
transfection	O

Cells	O
were	O
transfected	O
with	O
siRNA	O
duplexes	O
STAT3VHS40491	O
(	O
siRNA	O
#	O
1	O
:	O
sense	O
,	O
5	O
′-	O
GCAGUUUCUUCAGAGCAGGUAUCUU	O
-	O
3	O
′;	O
antisense	O
,	O
5	O
′-	O
AAGAUACCUGCUCUGAAGAAACUGC	O
-	O
3	O
′)	O
and	O
STAT3VHS40497	O
(	O
siRNA	O
#	O
2	O
:	O
sense	O
,	O
5	O
′-	O
CCUGCAAGAGUCGAAUGAAUGUUCUCUAU	O
-	O
3	O
′;	O
antisense	O
,	O
5	O
′-	O
AUAGAGAACAUUCGACUCUUGCAGG	O
-	O
3	O
′)	O
with	O
Lipofectamine	O
2000	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

After	O
6	O
h	O
,	O
the	O
medium	O
was	O
changed	O
to	O
complete	O
medium	O
without	O
antibiotic	O
,	O
and	O
allowed	O
to	O
grow	O
for	O
24	O
or	O
48	O
h	O
.	O

Cells	O
were	O
collected	O
and	O
processed	O
for	O
immunoblotting	O
as	O
described	O
above	O
to	O
determine	O
the	O
levels	O
of	O
STAT3	B-GP
,	O
MYCN	B-GP
and	O
pan	O
-	O
ERK	B-GP
for	O
a	O
loading	O
control	O
.	O

Immunoprecipitation	O

PC12	O
cells	O
were	O
transfected	O
with	O
pcDNA3	O
–	O
hALK	B-GP
or	O
pcDNA3	O
–	O
hALKF1174S	O
(	O
0	O
.	O
6	O
μg	O
per	O
2	O
×	O
106	O
cells	O
)	O
together	O
with	O
STAT3	B-GP
–	O
FLAG	O
(	O
0	O
.	O
6	O
μg	O
per	O
2	O
×	O
106	O
cells	O
)	O
or	O
pcDNA3	O
(	O
1	O
.	O
2	O
μg	O
per	O
2	O
×	O
106	O
cells	O
),	O
with	O
the	O
Amaxa	O
Biosystems	O
(	O
Cologne	O
,	O
Germany	O
)	O
electroporation	O
procedure	O
.	O

Cells	O
were	O
harvested	O
,	O
and	O
cell	O
lysates	O
were	O
pretreated	O
with	O
protein	B-GP
G	I-GP
–	O
Sepharose	O
(	O
Sigma	O
),	O
before	O
being	O
incubated	O
with	O
the	O
anti	O
-	O
FLAG	O
M2	O
-	O
coupled	O
protein	B-GP
G	I-GP
–	O
Sepharose	O
beads	O
overnight	O
at	O
4	O
°	O
C	O
,	O
washed	O
five	O
times	O
with	O
NaCl	O
/	O
Tris	O
,	O
boiled	O
in	O
sample	O
loading	O
buffer	O
,	O
run	O
on	O
an	O
SDS	O
/	O
PAGE	O
gel	O
,	O
transferred	O
to	O
poly	O
(	O
vinylidene	O
difluoride	O
)	O
membranes	O
,	O
and	O
probed	O
with	O
antibodies	B-GP
as	O
indicated	O
.	O

Luciferase	B-GP
assay	O

Cells	O
(	O
2	O
×	O
105	O
)	O
of	O
the	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
transfected	O
with	O
empty	O
pGL2	O
(	O
control	O
)	O
or	O
MYCNP	O
–	O
luciferase	B-GP
,	O
by	O
the	O
use	O
of	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Cells	O
were	O
then	O
serum	O
-	O
starved	O
,	O
and	O
STAT3	B-GP
was	O
inhibited	O
by	O
employing	O
2	O
.	O
5	O
μm	O
FLLL32	B-CD
(	O
generated	O
in	O
the	O
laboratory	O
of	O
P	O
.-	O
K	O
.	O

Li	O
)	O
or	O
STATTIC	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
for	O
12	O
h	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
triplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
three	O
times	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
luciferase	B-GP
activity	O
,	O
where	O
untreated	O
samples	O
transfected	O
with	O
empty	O
pGL2	O
vector	O
were	O
set	O
to	O
1	O
.	O

qRT	O
-	O
PCR	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
starved	O
and	O
treated	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

RNA	O
was	O
isolated	O
with	O
the	O
NucleoSpin	O
RNA	O
II	O
Kit	O
(	O
Macherey	O
-	O
Nagel	O
,	O
Duren	O
,	O
Germany	O
).	O

One	O
microgram	O
of	O
total	O
RNA	O
was	O
reverse	O
-	O
transcribed	O
with	O
the	O
iScript	O
cDNA	O
Synthesis	O
Kit	O
(	O
Bio	O
-	O
Rad	O
,	O
Sundbyberg	O
,	O
Sweden	O
).	O

For	O
the	O
PCR	O
amplification	O
in	O
an	O
iCycler	O
iQ5	O
(	O
Bio	O
-	O
Rad	O
),	O
25	O
ng	O
of	O
cDNA	O
was	O
used	O
in	O
a	O
total	O
reaction	O
mixture	O
of	O
20	O
μL	O
containing	O
10	O
μL	O
of	O
Quantimix	O
Easy	O
SYG	O
Kit	O
(	O
Biotools	O
,	O
Madrid	O
,	O
Spain	O
),	O
250	O
nm	O
forward	O
and	O
reverse	O
primers	O
,	O
and	O
0	O
.	O
08	O
μL	O
of	O
fluorescein	B-CD
(	O
USB	O
;	O
Affimetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
).	O

Primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
RPL29	B-GP
were	O
used	O
to	O
control	O
for	O
differences	O
in	O
cDNA	O
input	O
.	O

The	O
following	O
primers	O
were	O
used	O
:	O
human	B-OG
MYCN	B-GP
(	O
forward	O
,	O
5	O
′-	O
ACCACAAGGCCCTCAGTACC	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TCTCCACAGTGACCACGTCGATTT	O
-	O
3	O
′);	O
human	B-OG
RPL19	B-GP
(	O
forward	O
,	O
5	O
′-	O
AACACATCCACAAGCTGAAGGCAG	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TCTTCACGGCGCTTGCGT	O
-	O
3	O
′);	O
and	O
human	B-OG
RPL29	B-GP
(	O
forward	O
,	O
5	O
′-	O
ATGGCCAAGTCCAAGAACCACA	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TTGGCATTGTTGGCCTGCAT	O
-	O
3	O
′).	O

Relative	O
expression	O
was	O
calculated	O
according	O
to	O
the	O
ΔΔCt	O
relative	O
quantification	O
method	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
duplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
MYCN	B-GP
mRNA	O
expression	O
where	O
untreated	O
samples	O
were	O
set	O
to	O
1	O
.	O

Accounting	O
for	O
Genotype	O
-	O
by	O
-	O
Environment	O
Interactions	O
and	O
Residual	O
Genetic	O
Variation	O
in	O
Genomic	O
Selection	O
for	O
Water	O
-	O
Soluble	O
Carbohydrate	B-CD
Concentration	O
in	O
Wheat	B-OG

Present	O
address	O
:	O
The	O
University	O
of	O
Queensland	O
,	O
School	O
of	O
Agriculture	O
and	O
Food	O
Sciences	O
,	O
Brisbane	O
QLD	O
4072	O
,	O
Australia	O

Abiotic	O
stress	O
tolerance	O
traits	O
are	O
often	O
complex	O
and	O
recalcitrant	O
targets	O
for	O
conventional	O
breeding	O
improvement	O
in	O
many	O
crop	O
species	O
.	O

This	O
study	O
evaluated	O
the	O
potential	O
of	O
genomic	O
selection	O
to	O
predict	O
water	O
-	O
soluble	O
carbohydrate	B-CD
concentration	O
(	O
WSCC	O
),	O
an	O
important	O
drought	O
tolerance	O
trait	O
,	O
in	O
wheat	B-OG
under	O
field	O
conditions	O
.	O

A	O
panel	O
of	O
358	O
varieties	O
and	O
breeding	O
lines	O
constrained	O
for	O
maturity	O
was	O
evaluated	O
under	O
rainfed	O
and	O
irrigated	O
treatments	O
across	O
two	O
locations	O
and	O
two	O
years	O
.	O

Whole	O
-	O
genome	O
marker	O
profiles	O
and	O
factor	O
analytic	O
mixed	O
models	O
were	O
used	O
to	O
generate	O
genomic	O
estimated	O
breeding	O
values	O
(	O
GEBVs	O
)	O
for	O
specific	O
environments	O
and	O
environment	O
groups	O
.	O

Additive	O
genetic	O
variance	O
was	O
smaller	O
than	O
residual	O
genetic	O
variance	O
for	O
WSCC	O
,	O
such	O
that	O
genotypic	O
values	O
were	O
dominated	O
by	O
residual	O
genetic	O
effects	O
rather	O
than	O
additive	O
breeding	O
values	O
.	O

As	O
a	O
result	O
,	O
GEBVs	O
were	O
not	O
accurate	O
predictors	O
of	O
genotypic	O
values	O
of	O
the	O
extant	O
lines	O
,	O
but	O
GEBVs	O
should	O
be	O
reliable	O
selection	O
criteria	O
to	O
choose	O
parents	O
for	O
intermating	O
to	O
produce	O
new	O
populations	O
.	O

The	O
accuracy	O
of	O
GEBVs	O
for	O
untested	O
lines	O
was	O
sufficient	O
to	O
increase	O
predicted	O
genetic	O
gain	O
from	O
genomic	O
selection	O
per	O
unit	O
time	O
compared	O
to	O
phenotypic	O
selection	O
if	O
the	O
breeding	O
cycle	O
is	O
reduced	O
by	O
half	O
by	O
the	O
use	O
of	O
GEBVs	O
in	O
off	O
-	O
season	O
generations	O
.	O

Further	O
,	O
genomic	O
prediction	O
accuracy	O
depended	O
on	O
having	O
phenotypic	O
data	O
from	O
environments	O
with	O
strong	O
correlations	O
with	O
target	O
production	O
environments	O
to	O
build	O
prediction	O
models	O
.	O

By	O
combining	O
high	O
-	O
density	O
marker	O
genotypes	O
,	O
stress	O
-	O
managed	O
field	O
evaluations	O
,	O
and	O
mixed	O
models	O
that	O
model	O
simultaneously	O
covariances	O
among	O
genotypes	O
and	O
covariances	O
of	O
complex	O
trait	O
performance	O
between	O
pairs	O
of	O
environments	O
,	O
we	O
were	O
able	O
to	O
train	O
models	O
with	O
good	O
accuracy	O
to	O
facilitate	O
genetic	O
gain	O
from	O
genomic	O
selection	O
.	O

Abiotic	O
stresses	O
such	O
as	O
water	O
deficit	O
during	O
the	O
growing	O
season	O
are	O
a	O
major	O
limitation	O
to	O
crop	O
production	O
worldwide	O
(	O
Fischer	O
et	O
al	O
.	O
2014	O
;	O
Ray	O
et	O
al	O
.	O
2015	O
;	O
Foulkes	O
and	O
Reynolds	O
2015	O
).	O

However	O
,	O
the	O
incidence	O
and	O
severity	O
,	O
as	O
well	O
as	O
the	O
timing	O
of	O
water	O
deficit	O
can	O
differ	O
markedly	O
between	O
sites	O
and	O
years	O
,	O
contributing	O
to	O
the	O
historically	O
low	O
rates	O
of	O
genetic	O
gain	O
for	O
yield	O
in	O
water	O
deficit	O
environments	O
compared	O
to	O
well	O
-	O
watered	O
environments	O
(	O
Richards	O
et	O
al	O
.	O
2010	O
;	O
Araus	O
et	O
al	O
.	O
2002	O
).	O

An	O
alternative	O
to	O
selection	O
for	O
grain	O
yield	O
directly	O
is	O
to	O
identify	O
useful	O
traits	O
that	O
confer	O
physiological	O
adaptation	O
to	O
water	O
deficit	O
conditions	O
(	O
Rebetzke	O
et	O
al	O
.	O
2009	O
;	O
Bernier	O
et	O
al	O
.	O
2008	O
;	O
Reynolds	O
et	O
al	O
.	O
2016	O
;	O
Lopes	O
et	O
al	O
.	O
2011	O
).	O

For	O
example	O
,	O
selection	O
for	O
major	O
genes	O
for	O
reduced	O
height	O
and	O
photoperiod	O
insensitivity	O
has	O
been	O
used	O
to	O
alter	O
plant	B-OG
architecture	O
and	O
provide	O
drought	O
escape	O
potential	O
in	O
wheat	B-OG
(	O
Passioura	O
1996	O
;	O
Bennett	O
et	O
al	O
.	O
2012	O
;	O
Kamran	O
et	O
al	O
.	O
2014	O
).	O

Water	O
soluble	O
carbohydrate	B-CD
(	O
WSC	O
)	O
accumulation	O
and	O
remobilization	O
can	O
contribute	O
to	O
performance	O
under	O
water	O
deficit	O
as	O
a	O
source	O
of	O
assimilate	O
for	O
grain	O
filling	O
in	O
many	O
crop	O
species	O
(	O
Slewinski	O
2012	O
).	O

Carbohydrate	B-CD
accumulation	O
occurs	O
when	O
the	O
crop	O
synthesizes	O
assimilate	O
at	O
a	O
rate	O
greater	O
than	O
needed	O
by	O
the	O
various	O
sinks	O
(	O
for	O
example	O
,	O
developing	O
florets	O
,	O
elongating	O
shoots	O
and	O
roots	O
).	O

For	O
wheat	B-OG
,	O
the	O
excess	O
carbohydrate	B-CD
is	O
stored	O
mainly	O
in	O
the	O
lower	O
parts	O
of	O
stems	O
and	O
culms	O
(	O
Gebbing	O
2003	O
),	O
where	O
the	O
quantity	O
of	O
WSC	O
can	O
reach	O
as	O
much	O
as	O
40	O
%	O
of	O
total	O
stem	O
weight	O
(	O
Schnyder	O
1993	O
).	O

The	O
main	O
sink	O
for	O
remobilization	O
of	O
WSC	O
is	O
the	O
developing	O
grain	O
(	O
Schnyder	O
1993	O
;	O
Takahashi	O
et	O
al	O
.	O
2001	O
;	O
van	O
Herwaarden	O
et	O
al	O
.	O
1998	O
).	O

Remobilized	O
WSC	O
can	O
contribute	O
as	O
much	O
as	O
30	O
–	O
50	O
%	O
of	O
grain	O
yield	O
under	O
terminal	O
drought	O
conditions	O
,	O
and	O
around	O
10	O
–	O
20	O
%	O
under	O
well	O
-	O
watered	O
conditions	O
(	O
Bidinger	O
et	O
al	O
.	O
1977	O
;	O
Schnyder	O
1993	O
;	O
Pheloung	O
and	O
Siddique	O
1991	O
;	O
Gebbing	O
and	O
Schnyder	O
1999	O
).	O

Selection	O
for	O
increased	O
WSC	O
in	O
cereal	O
breeding	O
programs	O
has	O
been	O
advocated	O
for	O
some	O
time	O
(	O
Blum	O
1998	O
),	O
and	O
may	O
be	O
an	O
alternative	O
to	O
direct	O
selection	O
for	O
grain	O
yield	O
under	O
water	O
deficit	O
conditions	O
(	O
Asseng	O
and	O
van	O
Herwaarden	O
2003	O
).	O

Previous	O
studies	O
indicate	O
higher	O
broad	O
-	O
sense	O
heritability	O
for	O
WSC	O
concentration	O
(	O
WSCC	O
)	O
compared	O
to	O
grain	O
yield	O
,	O
and	O
more	O
stable	O
genotype	O
rankings	O
within	O
a	O
target	O
population	O
of	O
environments	O
(	O
Ruuska	O
et	O
al	O
.	O
2006	O
;	O
Dreccer	O
et	O
al	O
.	O
2013	O
;	O
Piaskowski	O
et	O
al	O
.	O
2016	O
).	O

Indirect	O
selection	O
for	O
WSCC	O
by	O
breeders	O
has	O
already	O
occurred	O
in	O
some	O
environments	O
.	O

For	O
example	O
,	O
Rebetzke	O
et	O
al	O
.	O
(	O
2009	O
)	O
reviewed	O
the	O
trend	O
for	O
increasing	O
WSCC	O
with	O
year	O
of	O
variety	O
release	O
observed	O
for	O
Western	O
Australian	O
and	O
the	O
International	O
Maize	O
and	O
Wheat	O
Improvement	O
Center	O
(	O
CIMMYT	O
)	O
wheat	B-OG
breeding	O
programs	O
.	O
Shearman	O
et	O
al	O
.	O
(	O
2005	O
)	O
also	O
reported	O
that	O
UK	O
wheat	B-OG
cultivars	O
showed	O
increased	O
WSCC	O
with	O
progressive	O
year	O
of	O
release	O
.	O

However	O
,	O
WSCC	O
is	O
not	O
predicted	O
to	O
be	O
a	O
useful	O
indirect	O
selection	O
criterion	O
for	O
yield	O
improvement	O
in	O
some	O
cases	O
(	O
Ovenden	O
et	O
al	O
.	O
2017	O
);	O
furthermore	O
,	O
phenotyping	O
for	O
abiotic	O
stress	O
characteristics	O
such	O
as	O
WSCC	O
is	O
resource	O
intensive	O
and	O
phenotypic	O
selection	O
may	O
not	O
always	O
be	O
feasible	O
in	O
a	O
breeding	O
program	O
.	O

The	O
practical	O
utility	O
of	O
WSCC	O
for	O
breeding	O
appears	O
to	O
be	O
context	O
-	O
dependent	O
and	O
requires	O
empirical	O
investigation	O
for	O
specific	O
populations	O
and	O
environments	O
.	O

New	O
genomic	O
approaches	O
may	O
be	O
more	O
efficient	O
to	O
select	O
for	O
abiotic	O
stress	O
traits	O
than	O
conventional	O
phenotypic	O
selection	O
,	O
as	O
genomic	O
selection	O
can	O
leverage	O
the	O
information	O
obtained	O
from	O
difficult	O
and	O
expensive	O
phenotyping	O
(	O
Lin	O
et	O
al	O
.	O
2014	O
;	O
Cooper	O
et	O
al	O
.	O
2014	O
;	O
Leplat	O
et	O
al	O
.	O
2016	O
),	O
to	O
enable	O
more	O
rapid	O
and	O
inexpensive	O
selection	O
for	O
many	O
loci	O
that	O
may	O
be	O
involved	O
in	O
the	O
inheritance	O
of	O
these	O
complex	O
traits	O
(	O
Vivek	O
et	O
al	O
.	O
2016	O
;	O
de	O
los	O
Campos	O
et	O
al	O
.	O
2013	O
).	O

Comprehensive	O
phenotyping	O
is	O
still	O
an	O
important	O
part	O
of	O
the	O
breeding	O
process	O
when	O
genomic	O
selection	O
is	O
applied	O
,	O
as	O
it	O
is	O
essential	O
to	O
build	O
accurate	O
prediction	O
models	O
.	O

However	O
,	O
early	O
generation	O
nursery	O
screens	O
can	O
be	O
replaced	O
with	O
genomic	O
screens	O
(	O
Sallam	O
et	O
al	O
.	O
2015	O
),	O
and	O
expensive	O
field	O
trials	O
can	O
be	O
augmented	O
by	O
genetic	O
material	O
‘	O
enriched	O
’	O
through	O
genomic	O
selection	O
(	O
Heffner	O
et	O
al	O
.	O
2009	O
).	O

Genomic	O
selection	O
methods	O
use	O
marker	O
-	O
based	O
measures	O
of	O
realized	O
relatedness	O
from	O
whole	O
-	O
genome	O
marker	O
profiles	O
to	O
predict	O
genomic	O
estimated	O
breeding	O
values	O
(	O
GEBVs	O
)	O
of	O
progeny	O
(	O
Habier	O
et	O
al	O
.	O
2013	O
;	O
Meuwissen	O
et	O
al	O
.	O
2001	O
;	O
de	O
los	O
Campos	O
et	O
al	O
.	O
2013	O
).	O

For	O
lines	O
that	O
have	O
both	O
genotype	O
and	O
phenotype	O
data	O
,	O
GEBVs	O
can	O
be	O
combined	O
with	O
the	O
residual	O
line	O
effect	O
estimates	O
to	O
produce	O
Genomic	O
Best	O
Linear	O
Unbiased	O
Predictors	O
(	O
G	O
-	O
BLUPs	O
)	O
for	O
the	O
total	O
genotypic	O
value	O
,	O
hereafter	O
referred	O
to	O
as	O
the	O
genotypic	O
value	O
(	O
GV	O
)	O
as	O
described	O
in	O
Oakey	O
et	O
al	O
.	O
(	O
2016	O
).	O

As	O
reviewed	O
by	O
Hill	O
(	O
2012	O
);	O
Nakaya	O
and	O
Isobe	O
(	O
2012	O
)	O
and	O
de	O
los	O
Campos	O
et	O
al	O
.	O
(	O
2013	O
),	O
a	O
key	O
difference	O
between	O
genomic	O
and	O
phenotypic	O
selection	O
is	O
the	O
potential	O
reduction	O
in	O
breeding	O
cycle	O
time	O
.	O

Although	O
genomic	O
predictions	O
of	O
untested	O
individuals	O
are	O
typically	O
less	O
accurate	O
than	O
well	O
-	O
replicated	O
phenotypic	O
evaluations	O
,	O
genomic	O
selection	O
may	O
be	O
more	O
effective	O
over	O
time	O
because	O
of	O
the	O
opportunity	O
to	O
implement	O
selection	O
in	O
additional	O
generations	O
per	O
unit	O
of	O
time	O
.	O

If	O
breeding	O
cycles	O
can	O
be	O
shortened	O
,	O
then	O
relative	O
accuracy	O
can	O
also	O
decrease	O
while	O
still	O
achieving	O
greater	O
genetic	O
gain	O
than	O
phenotypic	O
selection	O
(	O
Desta	O
and	O
Ortiz	O
2014	O
).	O

Developing	O
suitable	O
genomic	O
selection	O
models	O
for	O
abiotic	O
stress	O
tolerance	O
characteristics	O
requires	O
the	O
consideration	O
of	O
complex	O
genotype	O
×	O
environment	O
interactions	O
(	O
hereafter	O
G	O
×	O
E	O
interactions	O
)	O
within	O
and	O
across	O
a	O
target	O
population	O
of	O
environments	O
because	O
expression	O
of	O
these	O
traits	O
is	O
often	O
environmentally	O
-	O
dependent	O
.	O

Complex	O
patterns	O
of	O
G	O
×	O
E	O
interactions	O
can	O
be	O
incorporated	O
into	O
genomic	O
prediction	O
models	O
,	O
and	O
although	O
G	O
×	O
E	O
interactions	O
will	O
necessarily	O
limit	O
gains	O
from	O
selection	O
for	O
wide	O
adaptation	O
,	O
models	O
that	O
incorporate	O
G	O
×	O
E	O
effects	O
can	O
help	O
breeders	O
select	O
sets	O
of	O
lines	O
optimally	O
adapted	O
to	O
different	O
subsets	O
of	O
environments	O
.	O

One	O
such	O
approach	O
is	O
to	O
use	O
parsimonious	O
mixed	O
models	O
,	O
such	O
as	O
factor	O
analytic	O
(	O
FA	O
)	O
models	O
,	O
that	O
attempt	O
to	O
capture	O
most	O
of	O
the	O
G	O
×	O
E	O
signal	O
with	O
a	O
reduced	O
number	O
of	O
parameters	O
compared	O
to	O
a	O
full	O
unstructured	O
covariance	O
model	O
(	O
Guo	O
et	O
al	O
.	O
2013	O
;	O
Burgueño	O
et	O
al	O
.	O
2012	O
;	O
Oakey	O
et	O
al	O
.	O
2016	O
).	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
ability	O
of	O
genomic	O
selection	O
models	O
to	O
predict	O
a	O
complex	O
physiological	O
trait	O
(	O
WSCC	O
)	O
in	O
both	O
untested	O
lines	O
and	O
in	O
new	O
environments	O
using	O
a	O
mixed	O
-	O
model	O
that	O
accounts	O
for	O
variation	O
in	O
the	O
pairwise	O
correlations	O
of	O
performance	O
in	O
different	O
pairs	O
of	O
environments	O
.	O

Materials	O
and	O
Methods	O

Genotypes	O

The	O
set	O
of	O
358	O
lines	O
used	O
in	O
this	O
study	O
was	O
selected	O
from	O
a	O
multi	O
-	O
site	O
,	O
multi	O
-	O
year	O
irrigated	O
winter	O
cereals	O
evaluation	O
trial	O
with	O
a	O
total	O
of	O
1	O
,	O
314	O
genotypes	O
.	O

The	O
genetic	O
entries	O
included	O
both	O
elite	O
breeding	O
lines	O
and	O
contemporary	O
commercial	O
varieties	O
from	O
Australian	O
wheat	B-OG
breeding	O
companies	O
and	O
CIMMYT	O
representing	O
a	O
range	O
of	O
maturity	O
types	O
.	O

As	O
WSC	O
accumulation	O
varies	O
according	O
to	O
development	O
stage	O
(	O
Ehdaie	O
et	O
al	O
.	O
2008	O
),	O
this	O
study	O
aimed	O
to	O
assess	O
genotypes	O
as	O
close	O
as	O
practicable	O
to	O
a	O
common	O
anthesis	O
date	O
.	O

At	O
the	O
Yanco	O
irrigated	O
experiment	O
in	O
2009	O
,	O
a	O
total	O
of	O
358	O
breeding	O
lines	O
and	O
varieties	O
out	O
of	O
the	O
990	O
grown	O
in	O
the	O
experiment	O
were	O
selected	O
based	O
on	O
common	O
Zadoks	O
’	O
development	O
score	O
(	O
Zadoks	O
et	O
al	O
.	O
1974	O
)	O
taken	O
at	O
approximately	O
mid	O
-	O
anthesis	O
.	O

Lines	O
selected	O
were	O
between	O
Z49	O
(	O
early	O
head	O
emergence	O
)	O
and	O
Z56	O
(	O
60	O
%	O
heading	O
)	O
which	O
corresponds	O
to	O
a	O
range	O
of	O
approximately	O
3	O
-	O
5	O
days	O
difference	O
in	O
anthesis	O
date	O
in	O
south	O
-	O
eastern	O
Australia	O
.	O

For	O
the	O
second	O
year	O
of	O
this	O
study	O
in	O
2010	O
,	O
the	O
same	O
breeding	O
lines	O
were	O
selected	O
for	O
WSCC	O
measurement	O
except	O
for	O
11	O
breeding	O
lines	O
that	O
were	O
excluded	O
from	O
the	O
overall	O
experiment	O
in	O
that	O
year	O
.	O

Lines	O
were	O
genotyped	O
using	O
the	O
Illumina	O
9k	O
Infinium	O
iSelect	O
beadchip	O
array	O
(	O
Cavanagh	O
et	O
al	O
.	O
2013	O
)	O
resulting	O
in	O
4	O
,	O
883	O
polymorphic	O
SNPs	O
across	O
the	O
population	O
(	O
File	O
S1	O
).	O

Missing	O
values	O
were	O
imputed	O
using	O
Beagle	O
(	O
Browning	O
and	O
Browning	O
2009	O
)	O
implemented	O
in	O
the	O
R	O
package	O
Synbreed	O
(	O
Wimmer	O
et	O
al	O
.	O
2012	O
).	O

The	O
resulting	O
4	O
,	O
162	O
SNP	O
markers	O
(	O
excluding	O
markers	O
that	O
were	O
duplicated	O
,	O
monomorphic	O
,	O
and	O
those	O
with	O
minor	O
allele	O
frequency	O
of	O
less	O
than	O
5	O
%)	O
were	O
used	O
to	O
compute	O
a	O
scaled	O
identity	O
by	O
descent	O
relationship	O
matrix	O
(	O
K	O
)	O
after	O
Endelman	O
and	O
Jannink	O
(	O
2012	O
)	O
(	O
File	O
S2	O
).	O

There	O
was	O
little	O
evidence	O
of	O
population	O
structure	O
in	O
the	O
set	O
of	O
lines	O
used	O
in	O
this	O
study	O
,	O
with	O
the	O
first	O
two	O
eigenvectors	O
of	O
the	O
K	O
matrix	O
accounting	O
for	O
approximately	O
15	O
%	O
of	O
the	O
observed	O
variation	O
in	O
genomic	O
relationships	O
.	O

A	O
principal	O
components	O
plot	O
of	O
these	O
eigenvectors	O
showed	O
no	O
obvious	O
clustering	O
of	O
lines	O
(	O
File	O
S3	O
).	O

Experimental	O
design	O

Experiments	O
in	O
this	O
study	O
were	O
grown	O
in	O
south	O
-	O
eastern	O
Australia	O
at	O
Coleambally	O
and	O
Yanco	O
in	O
2009	O
and	O
2010	O
.	O

A	O
split	O
-	O
plot	O
design	O
was	O
used	O
,	O
in	O
which	O
the	O
main	O
-	O
plot	O
factor	O
was	O
irrigation	O
treatment	O
(	O
irrigated	O
or	O
rainfed	O
),	O
and	O
the	O
990	O
genotype	O
entries	O
(	O
including	O
the	O
subset	O
of	O
genotypes	O
for	O
WSCC	O
phenotyping	O
)	O
were	O
the	O
sub	O
-	O
plot	O
factor	O
.	O

There	O
were	O
two	O
replicates	O
of	O
each	O
treatment	O
at	O
each	O
site	O
.	O

The	O
placement	O
of	O
genotypes	O
within	O
field	O
experiment	O
layouts	O
was	O
optimized	O
with	O
the	O
spatial	O
design	O
package	O
DiGGer	O
(	O
Coombes	O
2002	O
).	O

For	O
the	O
laboratory	O
phase	O
measuring	O
WSCC	O
using	O
near	O
-	O
infrared	O
spectroscopy	O
(	O
NIRS	O
),	O
an	O
experimental	O
design	O
structured	O
by	O
day	O
of	O
measurement	O
and	O
NIRS	O
instrument	O
carousel	O
and	O
well	O
was	O
implemented	O
to	O
account	O
for	O
laboratory	O
as	O
well	O
as	O
field	O
sources	O
of	O
experimental	O
error	O
.	O

Samples	O
from	O
both	O
field	O
sites	O
were	O
pooled	O
into	O
one	O
experimental	O
design	O
for	O
each	O
year	O
,	O
and	O
the	O
placement	O
of	O
genotypes	O
within	O
the	O
laboratory	O
experimental	O
phase	O
was	O
also	O
optimized	O
with	O
DiGGer	O
(	O
Coombes	O
2002	O
),	O
with	O
partial	O
replication	O
of	O
20	O
%	O
of	O
experiment	O
field	O
plots	O
sampled	O
(	O
i	O
.	O
e	O
.,	O
a	O
replication	O
level	O
of	O
1	O
.	O
20	O
),	O
following	O
the	O
methods	O
in	O
Cullis	O
et	O
al	O
.	O
(	O
2006	O
)	O
and	O
Smith	O
et	O
al	O
.	O
(	O
2006	O
).	O

Experiments	O
were	O
sown	O
on	O
a	O
full	O
profile	O
of	O
moisture	O
,	O
achieved	O
by	O
flood	O
irrigating	O
each	O
site	O
four	O
to	O
six	O
weeks	O
before	O
sowing	O
,	O
so	O
that	O
the	O
focus	O
on	O
water	O
deficit	O
conditions	O
would	O
be	O
in	O
the	O
later	O
stages	O
of	O
crop	O
growth	O
.	O

Sowing	O
dates	O
were	O
targeted	O
for	O
the	O
first	O
two	O
weeks	O
of	O
May	O
.	O

Pre	O
-	O
sowing	O
nitrogen	O
was	O
targeted	O
to	O
be	O
approximately	O
120	O
kg	O
N	O
ha	O
-	O
1	O
.	O

Irrigated	O
experiments	O
were	O
fertilized	O
further	O
to	O
a	O
total	O
of	O
approximately	O
300	O
kg	O
N	O
ha	O
-	O
1	O
,	O
consistent	O
with	O
the	O
estimated	O
nitrogen	O
demand	O
by	O
the	O
crops	O
.	O

Experiments	O
were	O
subject	O
to	O
a	O
strict	O
weed	O
,	O
pest	O
and	O
disease	O
control	O
regime	O
to	O
maximize	O
yield	O
potential	O
.	O

Irrigation	O
scheduling	O
for	O
the	O
irrigated	O
treatments	O
was	O
intended	O
to	O
maintain	O
soil	O
water	O
potentials	O
above	O
-	O
100	O
kPa	O
during	O
the	O
growing	O
season	O
,	O
with	O
irrigations	O
commencing	O
as	O
soil	O
water	O
potential	O
fell	O
below	O
-	O
75	O
kPa	O
.	O

Water	O
-	O
soluble	O
carbohydrate	B-CD
measurement	O

Tissue	O
for	O
WSCC	O
analysis	O
was	O
sampled	O
from	O
a	O
50	O
cm	O
long	O
section	O
of	O
row	O
(	O
0	O
.	O
09	O
m2	O
)	O
in	O
each	O
plot	O
when	O
the	O
irrigated	O
treatments	O
at	O
each	O
site	O
were	O
approximately	O
180	O
°	O
d	O
post	O
-	O
anthesis	O
,	O
following	O
the	O
methods	O
of	O
Rebetzke	O
et	O
al	O
.	O
(	O
2008	O
).	O

Approximately	O
5	O
-	O
10	O
stalks	O
(	O
including	O
leaves	O
,	O
leaf	O
sheaths	O
and	O
heads	O
,	O
but	O
not	O
senesced	O
plant	B-OG
material	O
)	O
from	O
each	O
sample	O
were	O
ground	O
to	O
pass	O
through	O
a	O
2	O
mm	O
sieve	O
.	O

Ground	O
biomass	O
samples	O
were	O
homogenized	O
and	O
subsampled	O
for	O
scanning	O
by	O
NIRS	O
with	O
a	O
Bruker	O
Multi	O
-	O
purpose	O
Analyzer	O
(	O
Bruker	O
Optik	O
GmbH	O
,	O
Ettlingen	O
,	O
Germany	O
)	O
and	O
OPUS	O
software	O
(	O
version	O
5	O
.	O
1	O
),	O
and	O
WSCC	O
for	O
the	O
NIRS	O
calibration	O
samples	O
(	O
10	O
%	O
of	O
the	O
full	O
set	O
)	O
was	O
determined	O
using	O
the	O
alkaline	O
ferricyanide	O
method	O
(	O
Piltz	O
and	O
Law	O
2007	O
).	O

For	O
the	O
2009	O
experiment	O
,	O
the	O
coefficient	O
of	O
determination	O
for	O
the	O
calibration	O
linear	O
model	O
was	O
r2	O
=	O
0	O
.	O
92	O
and	O
the	O
root	O
-	O
mean	O
-	O
square	O
error	O
of	O
cross	O
-	O
validation	O
(	O
RMSECV	O
)	O
was	O
15	O
.	O
4	O
.	O

For	O
the	O
2010	O
experiment	O
,	O
the	O
calibration	O
linear	O
model	O
r2	O
=	O
0	O
.	O
92	O
and	O
the	O
RMSECV	O
=	O
16	O
.	O
0	O
.	O

The	O
WSCC	O
phenotype	O
data	O
are	O
provided	O
in	O
File	O
S4	O
.	O

Statistical	O
methods	O

A	O
single	O
-	O
stage	O
,	O
multiplicative	O
linear	O
mixed	O
model	O
was	O
used	O
to	O
analyze	O
the	O
multi	O
-	O
experiment	O
data	O
with	O
the	O
molecular	O
marker	O
data	O
following	O
the	O
approaches	O
of	O
Beeck	O
et	O
al	O
.	O
(	O
2010	O
)	O
and	O
Oakey	O
et	O
al	O
.	O
(	O
2016	O
).	O

The	O
linear	O
mixed	O
model	O
was	O
:	O
y	O
=	O
Xτ	O
+	O
Zgua	O
+	O
Zgua	O
¯+	O
Zuu	O
+	O
ηwhere	O
y	O
is	O
the	O
n	O
×	O
1	O
data	O
vector	O
of	O
the	O
response	O
variable	O
across	O
p	O
experiments	O
with	O
Nj	O
plots	O
per	O
experiment	O
j	O
.	O

Each	O
combination	O
of	O
year	O
(	O
2009	O
,	O
2010	O
),	O
site	O
(	O
YANA	O
,	O
COLE	O
)	O
and	O
irrigation	O
treatment	O
(	O
IRR	O
,	O
RFD	O
)	O
was	O
treated	O
as	O
a	O
separate	O
experiment	O
so	O
that	O
p	O
=	O
8	O
.	O
τ	O
is	O
a	O
t	O
×	O
1	O
vector	O
of	O
fixed	O
effects	O
for	O
the	O
corresponding	O
n	O
×	O
t	O
design	O
matrix	O
(	O
X	O
),	O
including	O
experiment	O
main	O
and	O
design	O
-	O
based	O
effects	O
.	O

The	O
term	O
u	O
is	O
a	O
random	O
component	O
with	O
associated	O
design	O
matrix	O
Zu	O
and	O
contains	O
experiment	O
-	O
specific	O
terms	O
used	O
to	O
capture	O
extraneous	O
variation	O
(	O
after	O
Gilmour	O
et	O
al	O
.	O
1997	O
),	O
including	O
the	O
blocking	O
structure	O
of	O
the	O
field	O
(	O
row	O
,	O
range	O
,	O
replicate	O
and	O
irrigation	O
bay	O
),	O
and	O
laboratory	O
(	O
day	O
of	O
measurement	O
,	O
instrument	O
carousel	O
and	O
carousel	O
well	O
)	O
phases	O
of	O
the	O
design	O
.	O

The	O
n	O
×	O
1	O
residual	O
vector	O
η	O
was	O
modeled	O
within	O
each	O
year	O
of	O
the	O
laboratory	O
phase	O
design	O
.	O

The	O
m	O
×	O
1	O
vector	O
of	O
genetic	O
line	O
within	O
environment	O
effects	O
g	O
,	O
with	O
corresponding	O
design	O
matrix	O
Zg	O
,	O
is	O
partitioned	O
into	O
a	O
vector	O
of	O
additive	O
line	O
within	O
environment	O
effects	O
ua	O
and	O
residual	O
line	O
within	O
environment	O
effects	O
ua	O
¯	O
such	O
that	O
g	O
=	O
ua	O
+	O
ua	O
¯,	O
following	O
the	O
approach	O
of	O
Oakey	O
et	O
al	O
.	O
(	O
2006	O
).	O

The	O
difference	O
between	O
the	O
‘	O
additive	O
’	O
and	O
‘	O
residual	O
’	O
genetic	O
effects	O
is	O
that	O
the	O
additive	O
effects	O
have	O
a	O
covariance	O
structure	O
proportional	O
to	O
the	O
realized	O
additive	O
genetic	O
relationship	O
matrix	O
,	O
whereas	O
the	O
residual	O
genetic	O
effects	O
are	O
independent	O
among	O
lines	O
.	O

When	O
we	O
arrange	O
the	O
vectors	O
of	O
additive	O
and	O
residual	O
genetic	O
-	O
within	O
-	O
environment	O
effects	O
ordered	O
as	O
m	O
genotypes	O
within	O
each	O
of	O
p	O
environments	O
matrices	O
,	O
their	O
covariance	O
structures	O
are	O
:	O
var	O
(	O
ua	O
)=	O
Gea	O
⊗	O
Kvar	O
(	O
ua	O
¯)=	O
Gea	O
¯	O
⊗	O
Imwhere	O
K	O
is	O
the	O
m	O
×	O
m	O
realized	O
genomic	O
relationship	O
matrix	O
estimated	O
from	O
the	O
marker	O
data	O
described	O
above	O
and	O
Im	O
is	O
an	O
m	O
×	O
m	O
identity	O
matrix	O
.	O

For	O
each	O
variance	O
model	O
above	O
,	O
Gea	O
and	O
Gea	O
¯	O
are	O
the	O
p	O
×	O
p	O
matrices	O
of	O
variances	O
and	O
covariances	O
of	O
additive	O
and	O
residual	O
genetic	O
effects	O
across	O
environments	O
,	O
respectively	O
.	O

Factor	O
analytic	O
models	O
of	O
different	O
orders	O
(	O
different	O
k	O
)	O
can	O
be	O
used	O
to	O
model	O
the	O
two	O
genetic	O
components	O
(	O
Smith	O
et	O
al	O
.	O
2001	O
).	O

For	O
a	O
factor	O
analytic	O
model	O
,	O
these	O
matrices	O
are	O
decomposed	O
asGea	O
=(	O
Λeap	O
×	O
kaΛea	O
’	O
+	O
ψea	O
)	O
Gea	O
¯=(	O
Λea	O
¯	O
p	O
×	O
ka	O
¯	O
Λea	O
¯’	O
+	O
ψea	O
¯).	O
Here	O
,	O
Λ	O
is	O
a	O
p	O
×	O
k	O
matrix	O
of	O
p	O
environment	O
loadings	O
for	O
k	O
factors	O
retained	O
in	O
the	O
factor	O
analytic	O
model	O
,	O
and	O
ψ	O
is	O
a	O
diagonal	O
matrix	O
of	O
the	O
p	O
environment	O
specific	O
variances	O
.	O

A	O
series	O
of	O
mixed	O
models	O
of	O
increasing	O
complexity	O
of	O
the	O
Gea	O
and	O
Gea	O
¯	O
terms	O
were	O
fitted	O
to	O
the	O
data	O
.	O

First	O
,	O
we	O
fitted	O
diagonal	O
covariance	O
structures	O
,	O
in	O
which	O
the	O
genetic	O
variance	O
was	O
allowed	O
to	O
vary	O
among	O
experiments	O
,	O
but	O
genetic	O
effects	O
were	O
uncorrelated	O
between	O
experiments	O
.	O

Then	O
a	O
sequence	O
of	O
factor	O
analytic	O
models	O
in	O
which	O
the	O
covariances	O
of	O
genotype	O
effects	O
were	O
allowed	O
to	O
vary	O
within	O
and	O
among	O
experiments	O
were	O
fitted	O
to	O
the	O
data	O
.	O

Factor	O
analytic	O
models	O
for	O
each	O
combination	O
of	O
k	O
=	O
1	O
or	O
2	O
factors	O
for	O
each	O
of	O
the	O
two	O
genetic	O
effects	O
were	O
used	O
(	O
Table	O
1	O
).	O

Selection	O
of	O
the	O
final	O
model	O
was	O
performed	O
on	O
the	O
basis	O
of	O
Akaike	O
’	O
s	O
Information	O
Criterion	O
(	O
AIC	O
);	O
(	O
Akaike	O
1974	O
),	O
and	O
log	O
likelihood	O
ratio	O
tests	O
comparing	O
the	O
nested	O
FA	O
models	O
(	O
Stram	O
and	O
Lee	O
1994	O
).	O

All	O
data	O
were	O
analyzed	O
using	O
the	O
software	O
package	O
ASReml	O
-	O
R	O
(	O
Butler	O
et	O
al	O
.	O
2009	O
),	O
in	O
the	O
R	O
environment	O
(	O
R	O
Development	O
Core	O
Team	O
2012	O
).	O

Factor	O
analytic	O
models	O
fitted	O
to	O
the	O
dataset	O
for	O
genomic	O
prediction	O
.	O

Increasing	O
order	O
factor	O
models	O
were	O
assessed	O
using	O
AIC	O
and	O
log	O
likelihood	O
ratio	O
tests	O
comparing	O
nested	O
models	O
.	O

The	O
model	O
with	O
additive	O
:	O
FA2	O
and	O
residual	O
genetic	O
:	O
FA2	O
covariance	O
structure	O
shows	O
a	O
significant	O
improvement	O
in	O
fit	O
from	O
both	O
additive	O
:	O
FA1	O
/	O
residual	O
genetic	O
:	O
FA1	O
and	O
additive	O
:	O
FA1	O
/	O
residual	O
genetic	O
:	O
FA2	O
models	O
and	O
is	O
referred	O
to	O
as	O
the	O
final	O
model	O
.	O

Higher	O
order	O
models	O
were	O
not	O
possible	O
to	O
fit	O
with	O
the	O
computing	O
resources	O
available	O

Covariance	O
structure	O
-	O
Additive	O

Covariance	O
structure	O
-	O
Residual	O
genetic	O

REML	O
Log	O
Likelihood	O

AIC	O

Parameters	O

Full	O
/	O
reduced	O
model	O
parameters	O
difference	O

Log	O
likelihood	O
ratio	O
test	O
model	O
comparison	O
:	O

Critical	O
value	O

P	O
value	O

DIAG	O

DIAG	O

4037	O
.	O
480	O

−	O
8042	O
.	O
956	O

16	O

—	O

—	O

—	O

—	O

FA1	O

FA1	O

4405	O
.	O
638	O

−	O
8747	O
.	O
276	O

32	O

16	O

to	O
DIAG	O
/	O
DIAG	O

736	O
.	O
32	O

2	O
.	O
389	O
×	O
10	O
−	O
146	O

FA1	O

FA2	O

4465	O
.	O
921	O

−	O
8853	O
.	O
842	O

39	O

7	O

to	O
FA1	O
/	O
FA1	O

120	O
.	O
57	O

5	O
.	O
840	O
×	O
10	O
−	O
23	O

FA2	O

FA1	O

4453	O
.	O
568	O

−	O
8829	O
.	O
136	O

39	O

7	O

to	O
FA1	O
/	O
FA1	O

95	O
.	O
86	O

7	O
.	O
708	O
×	O
10	O
−	O
18	O

FA2	O

FA2	O

4473	O
.	O
418	O

−	O
8854	O
.	O
836	O

46	O

7	O

to	O
FA1	O
/	O
FA2	O

14	O
.	O
99	O

0	O
.	O
0361	O

Experiment	O
-	O
specific	O
GVs	O
incorporating	O
both	O
additive	O
and	O
residual	O
genetic	O
effects	O
were	O
obtained	O
from	O
the	O
final	O
model	O
for	O
each	O
line	O
following	O
Beeck	O
et	O
al	O
.	O
(	O
2010	O
).	O

The	O
GV	O
for	O
line	O
i	O
at	O
environment	O
j	O
was	O
estimated	O
from	O
the	O
random	O
effect	O
solutions	O
in	O
the	O
final	O
model	O
as	O
:	O
GVij	O
=	O
u	O
^	O
aij	O
+	O
u	O
^	O
a	O
¯	O
ij	O
(	O
1	O
)	O
These	O
GVs	O
were	O
used	O
later	O
in	O
cross	O
-	O
validation	O
analyses	O
as	O
the	O
best	O
estimates	O
of	O
‘	O
true	O
’	O
genotypic	O
values	O
at	O
each	O
experiment	O
.	O

Additive	O
genomic	O
estimated	O
breeding	O
values	O
(	O
GEBVs	O
)	O
were	O
also	O
obtained	O
using	O
the	O
same	O
methods	O
but	O
based	O
only	O
on	O
the	O
additive	O
genetic	O
component	O
of	O
the	O
model	O
.	O

The	O
GEBV	O
for	O
line	O
i	O
at	O
environment	O
j	O
was	O
estimated	O
from	O
the	O
random	O
effect	O
solutions	O
in	O
the	O
final	O
model	O
as	O
:	O
GEBVij	O
=	O
u	O
^	O
aij	O
(	O
2	O
)	O
Experiments	O
were	O
clustered	O
based	O
on	O
the	O
matrix	O
of	O
genetic	O
correlations	O
among	O
experiments	O
,	O
using	O
the	O
agglomerative	O
hierarchical	O
clustering	O
method	O
given	O
in	O
Cullis	O
et	O
al	O
.	O
(	O
2010	O
).	O

Broad	O
and	O
narrow	O
-	O
sense	O
heritability	O
estimates	O
were	O
calculated	O
from	O
the	O
final	O
FA	O
model	O
(	O
Table	O
1	O
).	O

Broad	O
-	O
sense	O
heritability	O
(	O
H	O
)	O
for	O
each	O
trait	O
at	O
each	O
experiment	O
j	O
was	O
calculated	O
following	O
the	O
generalized	O
formula	O
for	O
unbalanced	O
data	O
in	O
Cullis	O
et	O
al	O
.	O
(	O
2006	O
):	O
Hj	O
=	O
1	O
−	O
APPEVGVj2σaj2	O
+	O
2σa	O
¯	O
j2where	O
APPEVGTj	O
is	O
the	O
average	O
pairwise	O
prediction	O
error	O
variance	O
of	O
GVs	O
at	O
experiment	O
j	O
(	O
the	O
variance	O
of	O
pairwise	O
GV	O
differences	O
),	O
and	O
σaj2	O
and	O
σa	O
¯	O
j2	O
are	O
the	O
additive	O
and	O
residual	O
genetic	O
variance	O
components	O
for	O
experiment	O
j	O
,	O
respectively	O
.	O

Narrow	O
-	O
sense	O
heritability	O
was	O
calculated	O
for	O
each	O
trait	O
at	O
each	O
experiment	O
using	O
:	O
hj2	O
=	O
1	O
−	O
APPEVGEBVj2σaj2where	O
APPEVGEBVj	O
is	O
the	O
average	O
variance	O
of	O
comparisons	O
between	O
GEBVs	O
at	O
experiment	O
j	O
,	O
and	O
σaj2	O
is	O
the	O
additive	O
genetic	O
variance	O
component	O
at	O
experiment	O
j	O
.	O

The	O
broad	O
-	O
sense	O
heritabilities	O
for	O
total	O
genotypic	O
values	O
of	O
lines	O
across	O
all	O
experiments	O
and	O
for	O
genotypic	O
values	O
across	O
experiments	O
within	O
each	O
of	O
the	O
water	O
deficit	O
and	O
well	O
-	O
watered	O
environment	O
clusters	O
were	O
also	O
calculated	O
using	O
similar	O
formulae	O
.	O

In	O
these	O
cases	O
,	O
however	O
,	O
we	O
estimated	O
the	O
additive	O
and	O
residual	O
genetic	O
variances	O
across	O
experiments	O
from	O
the	O
average	O
of	O
the	O
additive	O
and	O
residual	O
pairwise	O
covariance	O
estimates	O
respectively	O
between	O
experiments	O
for	O
the	O
experiments	O
within	O
each	O
environment	O
cluster	O
(	O
Zila	O
et	O
al	O
.	O
2013	O
;	O
Isik	O
et	O
al	O
.	O
2017	O
).	O

Cross	O
validation	O
of	O
genomic	O
estimated	O
breeding	O
values	O

Fivefold	O
cross	O
-	O
validation	O
(	O
Ogut	O
et	O
al	O
.	O
2015	O
;	O
Crossa	O
et	O
al	O
.	O
2014	O
;	O
Burgueño	O
et	O
al	O
.	O
2012	O
;	O
Lorenz	O
et	O
al	O
.	O
2011	O
)	O
was	O
used	O
to	O
measure	O
accuracy	O
of	O
breeding	O
value	O
predictions	O
across	O
environments	O
.	O

Lines	O
were	O
randomly	O
assigned	O
to	O
five	O
subsets	O
for	O
a	O
‘	O
fivefold	O
’	O
cross	O
validation	O
scheme	O
across	O
separate	O
experiments	O
in	O
the	O
model	O
.	O

The	O
final	O
FA	O
model	O
(	O
Table	O
1	O
)	O
was	O
fitted	O
to	O
four	O
of	O
the	O
five	O
∼	O
80	O
%	O
subsets	O
(‘	O
training	O
set	O
’)	O
to	O
estimate	O
model	O
parameters	O
and	O
to	O
predict	O
GEBVs	O
for	O
the	O
remaining	O
subset	O
(‘	O
validation	O
set	O
’)	O
(	O
Equation	O
2	O
).	O

This	O
procedure	O
was	O
repeated	O
,	O
holding	O
out	O
a	O
different	O
subset	O
as	O
the	O
validation	O
set	O
each	O
time	O
.	O

The	O
entire	O
process	O
of	O
allocating	O
lines	O
to	O
folds	O
,	O
estimating	O
model	O
parameters	O
,	O
and	O
predicting	O
GEBVs	O
was	O
replicated	O
ten	O
times	O
.	O

The	O
GVs	O
from	O
the	O
full	O
model	O
including	O
all	O
the	O
data	O
(	O
Equation	O
1	O
)	O
were	O
considered	O
the	O
best	O
estimates	O
of	O
the	O
true	O
values	O
of	O
total	O
genotypic	O
value	O
for	O
each	O
line	O
-	O
experiment	O
combination	O
.	O

The	O
correlation	O
between	O
the	O
GVs	O
within	O
an	O
experiment	O
and	O
the	O
GEBVs	O
for	O
each	O
validation	O
set	O
was	O
estimated	O
.	O

We	O
refer	O
to	O
these	O
as	O
within	O
-	O
experiment	O
prediction	O
accuracies	O
.	O

In	O
addition	O
,	O
the	O
ability	O
of	O
experiment	O
-	O
specific	O
GEBVs	O
to	O
predict	O
genotypic	O
values	O
at	O
other	O
experiments	O
was	O
estimated	O
for	O
each	O
validation	O
set	O
as	O
the	O
correlation	O
between	O
the	O
GEBVs	O
for	O
experiment	O
i	O
and	O
the	O
GVs	O
from	O
the	O
full	O
model	O
at	O
experiment	O
j	O
.	O

We	O
refer	O
to	O
these	O
as	O
across	O
-	O
experiment	O
prediction	O
accuracies	O
.	O

Relative	O
accuracy	O
of	O
phenotypic	O
value	O
prediction	O
(	O
RAPV	O
)	O
at	O
experiment	O
j	O
measures	O
the	O
relative	O
accuracy	O
of	O
GEBVs	O
for	O
untested	O
lines	O
compared	O
to	O
the	O
best	O
estimates	O
of	O
their	O
total	O
genetic	O
value	O
within	O
each	O
experiment	O
using	O
both	O
genomic	O
and	O
phenotypic	O
data	O
:	O
RAPVj	O
=	O
corr	O
(	O
GEBVij	O
,	O
GVij	O
)	O
HjIn	O
this	O
case	O
,	O
the	O
correlation	O
value	O
is	O
divided	O
by	O
the	O
square	O
root	O
of	O
the	O
broad	O
-	O
sense	O
heritability	O
estimate	O
to	O
estimate	O
the	O
accuracy	O
of	O
GEBVs	O
relative	O
to	O
total	O
genotypic	O
value	O
estimation	O
with	O
complete	O
phenotypic	O
data	O
(	O
Legarra	O
et	O
al	O
.	O
2008	O
).	O

We	O
also	O
estimated	O
relative	O
accuracy	O
of	O
breeding	O
value	O
prediction	O
at	O
experiment	O
j	O
(	O
RABV	O
):	O
RABVj	O
=	O
corr	O
(	O
GEBVij	O
,	O
GVij	O
)	O
h2The	O
RABV	O
compares	O
the	O
accuracy	O
of	O
GEBVs	O
for	O
untested	O
lines	O
relative	O
to	O
GEBVs	O
based	O
on	O
complete	O
data	O
.	O

The	O
GEBVs	O
are	O
more	O
informative	O
to	O
predict	O
gain	O
from	O
selection	O
after	O
intermating	O
selected	O
lines	O
to	O
generate	O
a	O
new	O
population	O
of	O
breeding	O
lines	O
.	O

Data	O
and	O
reagent	O
availability	O

The	O
supplementary	O
files	O
contain	O
the	O
data	O
used	O
in	O
this	O
study	O
.	O

File	O
S1	O
contains	O
the	O
SNP	O
genotype	O
information	O
,	O
File	O
S2	O
contains	O
the	O
relationship	O
matrix	O
and	O
File	O
S3	O
contains	O
a	O
PCA	O
plot	O
of	O
the	O
first	O
two	O
eigenvectors	O
of	O
the	O
relationship	O
matrix	O
.	O

File	O
S4	O
contains	O
the	O
phenotype	O
dataset	O
for	O
WSCC	O
.	O

File	O
S5	O
is	O
script	O
for	O
the	O
models	O
used	O
for	O
genomic	O
selection	O
and	O
cross	O
-	O
validation	O
and	O
File	O
S6	O
contains	O
the	O
cross	O
-	O
validation	O
sets	O
.	O

Supplemental	O
material	O
available	O
at	O
Figshare	O
:	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
25387	O
/	O
g3	O
.	O
6143243	O
.	O

Results	O

Model	O
selection	O
and	O
genotype	O
×	O
environment	O
interactions	O

The	O
2	O
-	O
factor	O
FA	O
model	O
for	O
both	O
additive	O
and	O
residual	O
variance	O
matrices	O
was	O
selected	O
as	O
the	O
best	O
model	O
using	O
the	O
AIC	O
(	O
Table	O
1	O
)	O
and	O
used	O
for	O
genomic	O
prediction	O
.	O

The	O
proportion	O
of	O
within	O
-	O
experiment	O
total	O
genotypic	O
variance	O
that	O
was	O
due	O
to	O
additive	O
polygenic	O
variance	O
in	O
this	O
model	O
ranged	O
from	O
15	O
to	O
50	O
%	O
across	O
experiments	O
(	O
Table	O
2	O
).	O

In	O
the	O
selected	O
model	O
,	O
environments	O
clustered	O
into	O
two	O
distinct	O
environmental	O
groups	O
based	O
on	O
the	O
correlations	O
between	O
total	O
genetic	O
effects	O
(	O
GV	O
)	O
across	O
experiments	O
(	O
Figure	O
1	O
).	O

The	O
groups	O
consisted	O
of	O
a	O
well	O
-	O
watered	O
environment	O
cluster	O
,	O
including	O
the	O
2009	O
irrigated	O
experiments	O
and	O
all	O
2010	O
experiments	O
,	O
and	O
a	O
water	O
deficit	O
environment	O
represented	O
by	O
the	O
two	O
2009	O
rainfed	O
experiments	O
.	O

This	O
corresponded	O
with	O
environmental	O
conditions	O
encountered	O
in	O
this	O
study	O
.	O

In	O
2009	O
,	O
both	O
sites	O
experienced	O
below	O
average	O
rainfall	O
,	O
and	O
warmer	O
air	O
temperatures	O
,	O
particularly	O
during	O
the	O
later	O
stages	O
of	O
grain	O
-	O
filling	O
.	O

Weather	O
conditions	O
throughout	O
2010	O
were	O
cooler	O
than	O
average	O
,	O
with	O
substantially	O
above	O
average	O
rainfall	O
during	O
late	O
spring	O
(	O
coinciding	O
with	O
the	O
crop	O
grain	O
-	O
filling	O
period	O
).	O

Thus	O
the	O
non	O
-	O
irrigated	O
experiments	O
in	O
2010	O
did	O
not	O
suffer	O
water	O
deficit	O
.	O

Genetic	O
variances	O
,	O
heritability	O
,	O
predictive	O
ability	O
and	O
relative	O
accuracy	O
by	O
experiment	O
and	O
environment	O
cluster	O
,	O
with	O
standard	O
deviations	O
given	O
in	O
parentheses	O
.	O

Experiment	O
codes	O
are	O
given	O
as	O
year	O
-	O
site	O
-	O
irrigation	O
treatment	O
.	O

The	O
experiments	O
09YANA_RFD	O
and	O
09COLE_RFD	O
constitute	O
the	O
water	O
deficit	O
experiment	O
cluster	O
;	O
all	O
other	O
experiments	O
are	O
included	O
in	O
the	O
well	O
-	O
watered	O
experiment	O
cluster	O
.	O

The	O
predictive	O
ability	O
of	O
the	O
GEBVs	O
model	O
at	O
each	O
experiment	O
and	O
environment	O
cluster	O
was	O
divided	O
by	O
the	O
broad	O
-	O
sense	O
heritability	O
to	O
provide	O
measures	O
of	O
accuracy	O
relative	O
to	O
phenotypic	O
selection	O
(	O
RAPV	O
),	O
and	O
by	O
the	O
narrow	O
-	O
sense	O
heritability	O
to	O
provide	O
relative	O
accuracy	O
to	O
total	O
estimated	O
breeding	O
values	O
(	O
RABV	O
)	O

Experiment	O
or	O
experiment	O
cluster	O

Additive	O
genetic	O
variance	O

Residual	O
geneticvariance	O

Proportion	O
of	O
genetic	O
variance	O
that	O
is	O
additive	O

Broad	O
-	O
sense	O
heritability	O
(	O
H	O
)	O

Narrow	O
-	O
sense	O
heritability	O
(	O
h2	O
)	O

Predictive	O
ability	O

Relative	O
accuracy	O
against	O
H	O
(	O
RAPV	O
)	O

Relative	O
accuracy	O
against	O
h2	O
(	O
RABV	O
)	O

All	O
experiments	O

0	O
.	O
00824	O

0	O
.	O
01537	O

34	O
.	O
90	O
%	O

0	O
.	O
778	O

0	O
.	O
363	O

0	O
.	O
480	O
(	O
0	O
.	O
206	O
)	O

0	O
.	O
544	O
(	O
0	O
.	O
234	O
)	O

0	O
.	O
797	O
(	O
0	O
.	O
343	O
)	O

Well	O
-	O
watered	O

0	O
.	O
01297	O

0	O
.	O
02299	O

36	O
.	O
07	O
%	O

0	O
.	O
788	O

0	O
.	O
413	O

0	O
.	O
502	O
(	O
0	O
.	O
192	O
)	O

0	O
.	O
565	O
(	O
0	O
.	O
220	O
)	O

0	O
.	O
781	O
(	O
0	O
.	O
304	O
)	O

Water	O
deficit	O

0	O
.	O
00914	O

0	O
.	O
03028	O

23	O
.	O
19	O
%	O

0	O
.	O
810	O

0	O
.	O
181	O

0	O
.	O
455	O
(	O
0	O
.	O
177	O
)	O

0	O
.	O
506	O
(	O
0	O
.	O
197	O
)	O

1	O
.	O
070	O
(	O
0	O
.	O
417	O
)	O

09COLE_IRR	O

0	O
.	O
012713	O

0	O
.	O
043910	O

22	O
.	O
45	O
%	O

0	O
.	O
853	O

0	O
.	O
345	O

0	O
.	O
503	O
(	O
0	O
.	O
188	O
)	O

0	O
.	O
545	O
(	O
0	O
.	O
203	O
)	O

0	O
.	O
857	O
(	O
0	O
.	O
320	O
)	O

09COLE_RFD	O

0	O
.	O
014623	O

0	O
.	O
031643	O

31	O
.	O
61	O
%	O

0	O
.	O
760	O

0	O
.	O
242	O

0	O
.	O
471	O
(	O
0	O
.	O
169	O
)	O

0	O
.	O
540	O
(	O
0	O
.	O
194	O
)	O

0	O
.	O
958	O
(	O
0	O
.	O
344	O
)	O

09YANA_IRR	O

0	O
.	O
013688	O

0	O
.	O
023822	O

36	O
.	O
49	O
%	O

0	O
.	O
791	O

0	O
.	O
427	O

0	O
.	O
535	O
(	O
0	O
.	O
182	O
)	O

0	O
.	O
602	O
(	O
0	O
.	O
205	O
)	O

0	O
.	O
819	O
(	O
0	O
.	O
279	O
)	O

09YANA_RFD	O

0	O
.	O
006774	O

0	O
.	O
039412	O

14	O
.	O
67	O
%	O

0	O
.	O
891	O

0	O
.	O
260	O

0	O
.	O
445	O
(	O
0	O
.	O
185	O
)	O

0	O
.	O
471	O
(	O
0	O
.	O
196	O
)	O

0	O
.	O
873	O
(	O
0	O
.	O
363	O
)	O

10COLE_IRR	O

0	O
.	O
018323	O

0	O
.	O
021732	O

45	O
.	O
74	O
%	O

0	O
.	O
722	O

0	O
.	O
392	O

0	O
.	O
474	O
(	O
0	O
.	O
192	O
)	O

0	O
.	O
558	O
(	O
0	O
.	O
226	O
)	O

0	O
.	O
757	O
(	O
0	O
.	O
306	O
)	O

10COLE_RFD	O

0	O
.	O
014472	O

0	O
.	O
014562	O

49	O
.	O
84	O
%	O

0	O
.	O
777	O

0	O
.	O
552	O

0	O
.	O
466	O
(	O
0	O
.	O
179	O
)	O

0	O
.	O
529	O
(	O
0	O
.	O
204	O
)	O

0	O
.	O
627	O
(	O
0	O
.	O
241	O
)	O

10YANA_IRR	O

0	O
.	O
012508	O

0	O
.	O
042923	O

22	O
.	O
57	O
%	O

0	O
.	O
862	O

0	O
.	O
388	O

0	O
.	O
520	O
(	O
0	O
.	O
196	O
)	O

0	O
.	O
560	O
(	O
0	O
.	O
211	O
)	O

0	O
.	O
835	O
(	O
0	O
.	O
315	O
)	O

10YANA_RFD	O

0	O
.	O
009967	O

0	O
.	O
020868	O

32	O
.	O
32	O
%	O

0	O
.	O
806	O

0	O
.	O
400	O

0	O
.	O
481	O
(	O
0	O
.	O
196	O
)	O

0	O
.	O
536	O
(	O
0	O
.	O
218	O
)	O

0	O
.	O
760	O
(	O
0	O
.	O
310	O
)	O

Correlations	O
between	O
total	O
additive	O
and	O
residual	O
genetic	O
GV	O
values	O
in	O
different	O
experiments	O
based	O
on	O
the	O
full	O
data	O
set	O
(	O
above	O
the	O
diagonal	O
)	O
and	O
correlations	O
between	O
additive	O
GEBVs	O
in	O
different	O
experiments	O
,	O
based	O
on	O
the	O
full	O
data	O
set	O
(	O
below	O
the	O
diagonal	O
).	O

Experiment	O
codes	O
are	O
given	O
as	O
year	O
-	O
site	O
-	O
irrigation	O
treatment	O
.	O

Averaged	O
across	O
experiments	O
in	O
each	O
environment	O
cluster	O
,	O
the	O
proportion	O
of	O
total	O
genetic	O
variance	O
that	O
was	O
additive	O
was	O
36	O
%	O
for	O
the	O
well	O
-	O
watered	O
environment	O
cluster	O
,	O
and	O
23	O
%	O
for	O
the	O
water	O
deficit	O
environment	O
cluster	O
(	O
Table	O
2	O
).	O

Very	O
similar	O
patterns	O
of	O
relationships	O
and	O
clustering	O
among	O
environments	O
were	O
observed	O
based	O
on	O
the	O
correlations	O
of	O
additive	O
-	O
only	O
genetic	O
effects	O
between	O
environments	O
(	O
Figure	O
1	O
),	O
although	O
the	O
09YANA_RFD	O
experiment	O
was	O
less	O
distinct	O
from	O
the	O
well	O
-	O
watered	O
cluster	O
in	O
this	O
case	O
than	O
when	O
the	O
total	O
genotypic	O
correlations	O
were	O
considered	O
.	O

Correlations	O
between	O
the	O
residual	O
genetic	O
effects	O
of	O
different	O
environments	O
also	O
revealed	O
a	O
similar	O
pattern	O
,	O
but	O
with	O
a	O
slightly	O
weaker	O
correlation	O
between	O
09COLE_IRR	O
and	O
the	O
other	O
well	O
-	O
watered	O
environment	O
experiments	O
(	O
Figure	O
1	O
).	O

The	O
09COLE_IRR	O
experiment	O
was	O
the	O
only	O
experiment	O
to	O
be	O
grown	O
on	O
raised	O
beds	O
with	O
all	O
other	O
irrigated	O
experiments	O
utilizing	O
a	O
flat	O
field	O
layout	O
.	O

Cross	O
-	O
validation	O
of	O
genomic	O
estimated	O
breeding	O
values	O

The	O
predictive	O
ability	O
(	O
Sallam	O
et	O
al	O
.	O
2015	O
)	O
of	O
experiment	O
-	O
specific	O
GEBVs	O
was	O
measured	O
as	O
the	O
average	O
correlation	O
between	O
experiment	O
-	O
specific	O
GEBVs	O
in	O
the	O
test	O
sets	O
and	O
experiment	O
-	O
specific	O
GVs	O
estimated	O
for	O
the	O
same	O
lines	O
when	O
all	O
trait	O
data	O
are	O
used	O
.	O

Within	O
-	O
experiment	O
prediction	O
abilities	O
ranged	O
from	O
r	O
=	O
0	O
.	O
474	O
to	O
0	O
.	O
535	O
for	O
the	O
well	O
-	O
watered	O
experiments	O
and	O
from	O
r	O
=	O
0	O
.	O
445	O
to	O
r	O
=	O
0	O
.	O
481	O
for	O
the	O
water	O
deficit	O
experiments	O
(	O
Table	O
2	O
and	O
diagonal	O
elements	O
in	O
Figure	O
2	O
).	O

The	O
predictive	O
ability	O
across	O
experiments	O
within	O
the	O
well	O
-	O
watered	O
environment	O
cluster	O
averaged	O
r	O
=	O
0	O
.	O
502	O
,	O
and	O
across	O
experiments	O
within	O
the	O
water	O
deficit	O
cluster	O
was	O
r	O
=	O
0	O
.	O
455	O
(	O
Table	O
2	O
and	O
diagonal	O
elements	O
of	O
Figure	O
2	O
).	O

In	O
contrast	O
,	O
GEBVs	O
specific	O
to	O
an	O
experiment	O
within	O
one	O
cluster	O
had	O
much	O
poorer	O
predictive	O
ability	O
of	O
GVs	O
in	O
the	O
other	O
cluster	O
.	O

We	O
also	O
estimated	O
the	O
ability	O
of	O
test	O
set	O
GEBVs	O
specific	O
to	O
one	O
experiment	O
or	O
cluster	O
to	O
predict	O
GVs	O
based	O
on	O
complete	O
phenotype	O
data	O
in	O
a	O
different	O
experiment	O
or	O
cluster	O
(	O
the	O
off	O
-	O
diagonal	O
elements	O
of	O
Figure	O
2	O
).	O

GEBVs	O
for	O
water	O
-	O
deficit	O
experiments	O
had	O
only	O
a	O
weak	O
correlation	O
with	O
the	O
GVs	O
in	O
the	O
well	O
-	O
watered	O
environments	O
(	O
average	O
r	O
=	O
0	O
.	O
196	O
).	O

Similarly	O
,	O
GEBVs	O
for	O
the	O
well	O
-	O
watered	O
environments	O
had	O
an	O
average	O
correlation	O
of	O
r	O
=	O
0	O
.	O
211	O
with	O
GVs	O
in	O
the	O
water	O
deficit	O
environments	O
.	O

Average	O
GEBVs	O
across	O
all	O
experiments	O
also	O
had	O
low	O
correlation	O
with	O
GVs	O
within	O
the	O
water	O
deficit	O
environments	O
(	O
r	O
=	O
0	O
.	O
287	O
).	O

Within	O
each	O
environment	O
cluster	O
,	O
the	O
GEBVs	O
for	O
individual	O
experiments	O
had	O
moderate	O
correlations	O
with	O
GVs	O
at	O
other	O
experiments	O
(	O
r	O
=	O
0	O
.	O
442	O
to	O
r	O
=	O
0	O
.	O
536	O
for	O
the	O
well	O
-	O
watered	O
experiments	O
,	O
and	O
r	O
=	O
0	O
.	O
400	O
to	O
r	O
=	O
0	O
.	O
447	O
for	O
the	O
water	O
deficit	O
experiments	O
).	O

Predictive	O
ability	O
of	O
GEBVs	O
average	O
across	O
all	O
experiments	O
,	O
averaged	O
across	O
experiments	O
within	O
each	O
environment	O
cluster	O
(	O
well	O
-	O
watered	O
or	O
water	O
-	O
deficit	O
),	O
or	O
predicted	O
for	O
each	O
specific	O
experiment	O
.	O

The	O
training	O
set	O
of	O
environments	O
is	O
given	O
by	O
the	O
X	O
axis	O
,	O
and	O
the	O
validation	O
set	O
of	O
environments	O
is	O
given	O
by	O
the	O
Y	O
axis	O
.	O

Experiment	O
codes	O
are	O
given	O
as	O
year	O
-	O
site	O
-	O
irrigation	O
treatment	O
.	O

Diagonal	O
values	O
represent	O
ability	O
of	O
GEBVs	O
within	O
a	O
given	O
environment	O
to	O
predict	O
GVs	O
in	O
the	O
same	O
environment	O
.	O

Off	O
-	O
diagonal	O
values	O
represent	O
the	O
ability	O
of	O
GEBVs	O
in	O
a	O
given	O
environment	O
to	O
predict	O
GVs	O
in	O
a	O
different	O
environment	O
.	O

The	O
relative	O
accuracy	O
statistics	O
were	O
computed	O
with	O
both	O
broad	O
-	O
sense	O
and	O
narrow	O
-	O
sense	O
heritabilities	O
as	O
RAPV	O
and	O
RABV	O
,	O
respectively	O
,	O
so	O
that	O
a	O
measure	O
of	O
accuracy	O
relative	O
to	O
phenotypic	O
selection	O
can	O
be	O
compared	O
to	O
the	O
accuracy	O
relative	O
to	O
breeding	O
value	O
prediction	O
(	O
Table	O
2	O
).	O

As	O
the	O
broad	O
-	O
sense	O
heritability	O
estimates	O
were	O
much	O
higher	O
than	O
narrow	O
-	O
sense	O
,	O
the	O
relative	O
accuracy	O
statistics	O
indicate	O
that	O
the	O
efficiency	O
of	O
genotype	O
value	O
prediction	O
was	O
poor	O
(	O
RAPV	O
ranged	O
from	O
0	O
.	O
471	O
to	O
0	O
.	O
602	O
at	O
individual	O
experiments	O
,	O
with	O
a	O
mean	O
of	O
0	O
.	O
544	O
,	O
Table	O
2	O
),	O
whereas	O
the	O
relative	O
accuracy	O
of	O
breeding	O
value	O
prediction	O
with	O
marker	O
information	O
only	O
compared	O
to	O
complete	O
phenotype	O
data	O
were	O
much	O
higher	O
(	O
RABV	O
ranged	O
from	O
0	O
.	O
627	O
to	O
0	O
.	O
958	O
at	O
individual	O
experiments	O
,	O
with	O
a	O
mean	O
of	O
0	O
.	O
797	O
,	O
Table	O
2	O
).	O

The	O
RABV	O
for	O
the	O
water	O
deficit	O
experiment	O
cluster	O
was	O
1	O
.	O
07	O
,	O
a	O
surprising	O
but	O
valid	O
result	O
analogous	O
to	O
relative	O
efficiency	O
of	O
selection	O
on	O
a	O
correlated	O
trait	O
,	O
which	O
can	O
be	O
>	O
1	O
relative	O
to	O
direct	O
selection	O
.	O

Discussion	O

Integration	O
of	O
genomic	O
selection	O
with	O
genotype	O
×	O
environment	O
effects	O

Our	O
approach	O
in	O
this	O
study	O
combines	O
the	O
concept	O
of	O
a	O
Target	O
Population	O
of	O
Environments	O
(	O
TPE	O
)	O
in	O
regard	O
to	O
selection	O
(	O
Comstock	O
1977	O
;	O
Cooper	O
et	O
al	O
.	O
1997	O
;	O
Basford	O
and	O
Cooper	O
1998	O
)	O
with	O
genomic	O
prediction	O
methods	O
,	O
and	O
extends	O
the	O
work	O
of	O
Oakey	O
et	O
al	O
.	O
(	O
2016	O
)	O
to	O
a	O
large	O
field	O
-	O
based	O
multi	O
-	O
environment	O
trial	O
.	O

The	O
TPE	O
concept	O
applies	O
equally	O
to	O
genomic	O
selection	O
as	O
phenotypic	O
selection	O
in	O
the	O
face	O
of	O
genotype	O
-	O
by	O
-	O
environment	O
interactions	O
.	O

Our	O
results	O
show	O
that	O
predictive	O
ability	O
depends	O
on	O
the	O
extent	O
and	O
nature	O
of	O
the	O
genetic	O
correlation	O
between	O
the	O
training	O
and	O
the	O
validation	O
populations	O
.	O
Heslot	O
et	O
al	O
.	O
(	O
2013	O
)	O
also	O
demonstrated	O
empirically	O
in	O
wheat	B-OG
that	O
G	O
×	O
E	O
patterns	O
impact	O
genomic	O
selection	O
in	O
the	O
same	O
way	O
that	O
they	O
impact	O
phenotypic	O
selection	O
.	O
Heslot	O
et	O
al	O
.	O
(	O
2013	O
)	O
also	O
observed	O
that	O
the	O
main	O
driver	O
of	O
prediction	O
accuracy	O
between	O
environments	O
were	O
G	O
×	O
E	O
effects	O
and	O
that	O
genomic	O
predictions	O
are	O
specific	O
to	O
the	O
TPE	O
they	O
are	O
predicted	O
for	O
–	O
conclusions	O
also	O
supported	O
by	O
Lado	O
et	O
al	O
.	O
(	O
2013	O
)	O
and	O
Oakey	O
et	O
al	O
.	O
(	O
2016	O
),	O
who	O
also	O
showed	O
that	O
multi	O
-	O
year	O
models	O
could	O
give	O
better	O
prediction	O
accuracy	O
when	O
environmental	O
influence	O
is	O
large	O
.	O

Genomic	O
prediction	O
models	O
based	O
on	O
multi	O
-	O
environment	O
trials	O
may	O
involve	O
considerable	O
complexity	O
to	O
allow	O
heterogeneity	O
of	O
genetic	O
correlations	O
and	O
genetic	O
variances	O
among	O
environments	O
,	O
variable	O
sources	O
of	O
extraneous	O
non	O
-	O
genetic	O
variation	O
among	O
environments	O
,	O
in	O
addition	O
to	O
the	O
high	O
dimensionality	O
of	O
marker	O
data	O
.	O

Researchers	O
are	O
faced	O
with	O
making	O
choices	O
about	O
modeling	O
greater	O
complexity	O
in	O
the	O
patterns	O
of	O
genetic	O
correlations	O
among	O
environments	O
vs	O
.	O
greater	O
complexity	O
in	O
the	O
genetic	O
architecture	O
modeled	O
by	O
marker	O
data	O
,	O
based	O
on	O
tradeoffs	O
between	O
capturing	O
more	O
signal	O
vs	O
.	O
overfitting	O
and	O
increasing	O
computational	O
demands	O
as	O
model	O
complexity	O
increases	O
.	O

A	O
variety	O
of	O
modeling	O
approaches	O
have	O
been	O
proposed	O
,	O
reflecting	O
different	O
choices	O
about	O
which	O
aspects	O
of	O
model	O
complexity	O
to	O
emphasize	O
.	O

For	O
example	O
,	O
Sallam	O
et	O
al	O
.	O
(	O
2015	O
)	O
utilized	O
an	O
across	O
-	O
experiments	O
model	O
for	O
TPE	O
identified	O
as	O
having	O
low	O
G	O
×	O
E	O
so	O
the	O
term	O
in	O
the	O
model	O
was	O
minimized	O
,	O
whereas	O
Crossa	O
et	O
al	O
.	O
(	O
2010	O
)	O
modeled	O
genetic	O
effects	O
within	O
each	O
environment	O
separately	O
.	O
Lopez	O
-	O
Cruz	O
et	O
al	O
.	O
(	O
2015	O
)	O
introduced	O
a	O
model	O
with	O
common	O
G	O
×	O
E	O
variance	O
for	O
all	O
sets	O
,	O
but	O
allowed	O
variable	O
marker	O
effects	O
through	O
a	O
Bayesian	O
model	O
.	O
Heslot	O
et	O
al	O
.	O
(	O
2014	O
)	O
and	O
Jarquín	O
et	O
al	O
.	O
(	O
2014	O
)	O
introduced	O
models	O
that	O
accounted	O
for	O
marker	O
interactions	O
with	O
specific	O
climate	O
variables	O
,	O
adding	O
another	O
layer	O
of	O
complexity	O
to	O
the	O
modeling	O
of	O
G	O
×	O
E	O
patterns	O
.	O

Our	O
focus	O
in	O
this	O
study	O
was	O
to	O
emphasize	O
the	O
modeling	O
of	O
complex	O
patterns	O
of	O
heterogeneity	O
in	O
the	O
genetic	O
variation	O
expressed	O
within	O
environments	O
and	O
the	O
pairwise	O
genetic	O
correlations	O
between	O
environments	O
,	O
along	O
with	O
extraneous	O
non	O
-	O
genetic	O
effects	O
.	O

We	O
chose	O
a	O
FA	O
model	O
(	O
Cullis	O
et	O
al	O
.	O
2010	O
;	O
Smith	O
et	O
al	O
.	O
2001	O
)	O
that	O
can	O
capture	O
such	O
heterogeneity	O
more	O
parsimoniously	O
than	O
fully	O
unstructured	O
models	O
.	O

The	O
patterns	O
of	O
genetic	O
correlations	O
between	O
environments	O
observed	O
in	O
training	O
data	O
sets	O
and	O
patterns	O
of	O
the	O
accuracy	O
of	O
GEBVs	O
for	O
one	O
site	O
to	O
predict	O
genetic	O
values	O
at	O
other	O
sites	O
in	O
test	O
sets	O
from	O
the	O
FA	O
model	O
provide	O
a	O
way	O
of	O
characterizing	O
target	O
environments	O
,	O
still	O
following	O
the	O
ideas	O
on	O
exploiting	O
G	O
×	O
E	O
to	O
make	O
genetic	O
gains	O
outlined	O
by	O
Byth	O
(	O
1981	O
).	O

The	O
environment	O
clusters	O
in	O
this	O
study	O
show	O
that	O
year	O
effects	O
are	O
more	O
important	O
than	O
location	O
for	O
WSCC	O
(	O
Figure	O
1	O
),	O
and	O
this	O
observation	O
is	O
borne	O
out	O
by	O
other	O
G	O
×	O
E	O
studies	O
with	O
similar	O
findings	O
,	O
particularly	O
for	O
traits	O
where	O
expression	O
is	O
significantly	O
affected	O
by	O
seasonal	O
conditions	O
(	O
Smith	O
et	O
al	O
.	O
2015	O
;	O
Chenu	O
et	O
al	O
.	O
2011	O
;	O
Milgate	O
et	O
al	O
.	O
2015	O
).	O

Using	O
factor	O
analytic	O
models	O
for	O
genomic	O
predictions	O

Heslot	O
et	O
al	O
.	O
(	O
2014	O
)	O
demonstrate	O
a	O
method	O
to	O
predict	O
genotype	O
performance	O
in	O
untested	O
environments	O
based	O
on	O
climatic	O
variables	O
.	O

In	O
contrast	O
,	O
the	O
FA	O
model	O
approach	O
helps	O
breeders	O
to	O
understand	O
the	O
groupings	O
of	O
environments	O
within	O
the	O
TPE	O
based	O
on	O
their	O
genetic	O
correlations	O
,	O
and	O
breeders	O
can	O
predict	O
average	O
performance	O
in	O
subsets	O
of	O
these	O
environments	O
.	O

Both	O
Burgueño	O
et	O
al	O
.	O
(	O
2012	O
)	O
and	O
Rutkoski	O
et	O
al	O
.	O
(	O
2015	O
)	O
utilized	O
similar	O
FA	O
models	O
for	O
genomic	O
prediction	O
,	O
however	O
this	O
study	O
shows	O
that	O
the	O
power	O
of	O
an	O
FA	O
model	O
lies	O
in	O
the	O
ability	O
to	O
identify	O
environment	O
subsets	O
based	O
on	O
the	O
loadings	O
and	O
predict	O
genotype	O
performance	O
more	O
accurately	O
within	O
those	O
TPE	O
rather	O
than	O
the	O
across	O
-	O
experiments	O
average	O
.	O

Since	O
we	O
predicted	O
values	O
for	O
untested	O
lines	O
within	O
tested	O
environments	O
,	O
our	O
estimated	O
prediction	O
abilities	O
are	O
biased	O
upward	O
compared	O
to	O
prediction	O
of	O
untested	O
lines	O
within	O
untested	O
environments	O
.	O

Our	O
results	O
,	O
which	O
reflect	O
upper	O
bounds	O
on	O
prediction	O
abilities	O
across	O
environments	O
,	O
demonstrate	O
that	O
GEBVs	O
have	O
reasonable	O
accuracy	O
only	O
within	O
a	O
clearly	O
defined	O
cluster	O
of	O
environments	O
,	O
and	O
have	O
substantially	O
worse	O
prediction	O
accuracy	O
of	O
performance	O
in	O
environments	O
outside	O
of	O
the	O
group	O
of	O
related	O
environments	O
for	O
which	O
they	O
were	O
predicted	O
.	O

The	O
FA	O
model	O
permits	O
prediction	O
of	O
genetic	O
values	O
for	O
untested	O
lines	O
within	O
each	O
site	O
based	O
on	O
the	O
genomic	O
relationships	O
between	O
the	O
untested	O
and	O
tested	O
lines	O
and	O
also	O
based	O
on	O
the	O
genetic	O
correlations	O
observed	O
among	O
the	O
tested	O
set	O
of	O
environments	O
.	O

The	O
FA	O
model	O
can	O
improve	O
prediction	O
accuracy	O
within	O
a	O
single	O
site	O
over	O
what	O
is	O
possible	O
from	O
a	O
single	O
-	O
environment	O
analysis	O
by	O
information	O
sharing	O
among	O
environments	O
with	O
high	O
genetic	O
correlations	O
(	O
Guo	O
et	O
al	O
.	O
2013	O
;	O
Cullis	O
et	O
al	O
.	O
2010	O
;	O
Kelly	O
et	O
al	O
.	O
2007	O
).	O

In	O
this	O
study	O
,	O
GEBVs	O
averaged	O
across	O
all	O
environments	O
were	O
less	O
accurate	O
for	O
environment	O
-	O
specific	O
prediction	O
than	O
GEBVs	O
averaged	O
across	O
subsets	O
of	O
sites	O
within	O
the	O
same	O
environmental	O
cluster	O
(	O
Figure	O
2	O
).	O

A	O
drawback	O
to	O
the	O
FA	O
model	O
is	O
that	O
the	O
emphasis	O
on	O
including	O
more	O
complexity	O
in	O
the	O
modeling	O
of	O
extraneous	O
genetic	O
variation	O
and	O
the	O
heterogeneity	O
of	O
genetic	O
covariation	O
among	O
environments	O
may	O
limit	O
the	O
complexity	O
of	O
genetic	O
architecture	O
models	O
that	O
can	O
be	O
tested	O
.	O

The	O
total	O
genotypic	O
value	O
of	O
each	O
line	O
was	O
modeled	O
as	O
the	O
sum	O
of	O
a	O
polygenic	O
additive	O
effect	O
and	O
a	O
residual	O
genetic	O
effect	O
(	O
after	O
Oakey	O
et	O
al	O
.	O
2016	O
).	O

Our	O
results	O
demonstrated	O
that	O
the	O
residual	O
genetic	O
effects	O
were	O
more	O
important	O
than	O
the	O
additive	O
effects	O
in	O
this	O
case	O
,	O
which	O
greatly	O
limits	O
the	O
effectiveness	O
of	O
prediction	O
of	O
untested	O
varieties	O
,	O
as	O
those	O
predictions	O
depend	O
only	O
on	O
the	O
additive	O
effects	O
.	O

The	O
residual	O
genetic	O
effects	O
were	O
modeled	O
as	O
independent	O
among	O
varieties	O
,	O
such	O
that	O
they	O
cannot	O
contribute	O
to	O
prediction	O
of	O
untested	O
varieties	O
.	O

Alternative	O
strategies	O
include	O
explicitly	O
modeling	O
epistatic	O
genomic	O
relationships	O
;	O
we	O
attempted	O
this	O
but	O
could	O
not	O
achieve	O
model	O
convergence	O
.	O
Oakey	O
et	O
al	O
.	O
(	O
2016	O
)	O
discuss	O
the	O
implications	O
of	O
including	O
additional	O
relationship	O
matrices	O
to	O
account	O
for	O
a	O
proportion	O
of	O
non	O
-	O
additive	O
genetic	O
effects	O
,	O
however	O
they	O
also	O
note	O
the	O
difficulty	O
of	O
fitting	O
several	O
relationship	O
matrices	O
to	O
a	O
MET	O
.	O

Bayesian	O
models	O
could	O
be	O
fitted	O
to	O
the	O
genomic	O
relationships	O
,	O
to	O
capture	O
residual	O
genetic	O
relationships	O
and	O
variation	O
among	O
marker	O
effects	O
,	O
but	O
this	O
approach	O
would	O
be	O
even	O
more	O
computationally	O
difficult	O
;	O
future	O
research	O
could	O
focus	O
on	O
integrating	O
heterogeneity	O
of	O
genetic	O
covariances	O
among	O
sites	O
into	O
such	O
models	O
.	O

Practical	O
application	O
of	O
genomic	O
selection	O
for	O
water	O
soluble	O
carbohydrate	B-CD
improvement	O

Breeders	O
focusing	O
on	O
varietal	O
development	O
for	O
target	O
populations	O
of	O
environments	O
that	O
may	O
experience	O
abiotic	O
stresses	O
often	O
seek	O
to	O
incorporate	O
resistance	O
to	O
abiotic	O
stresses	O
,	O
sometimes	O
to	O
contribute	O
to	O
grain	O
yield	O
per	O
se	O
,	O
but	O
also	O
to	O
select	O
for	O
stable	O
grain	O
yield	O
performance	O
in	O
the	O
presence	O
of	O
variable	O
levels	O
of	O
abiotic	O
stress	O
.	O

Thus	O
,	O
abiotic	O
stress	O
resistance	O
traits	O
can	O
be	O
a	O
selection	O
target	O
in	O
their	O
own	O
right	O
,	O
especially	O
in	O
situations	O
where	O
G	O
×	O
E	O
variation	O
is	O
driven	O
by	O
abiotic	O
stresses	O
and	O
resistance	O
to	O
these	O
stresses	O
can	O
ensure	O
grain	O
yield	O
stability	O
across	O
years	O
.	O

Genomic	O
selection	O
may	O
be	O
a	O
good	O
way	O
to	O
select	O
for	O
abiotic	O
stress	O
traits	O
such	O
as	O
WSCC	O
,	O
especially	O
as	O
a	O
substitute	O
for	O
resource	O
-	O
intensive	O
phenotypic	O
selection	O
.	O

Levels	O
of	O
WSCC	O
increase	O
and	O
decrease	O
with	O
crop	O
development	O
and	O
growing	O
conditions	O
,	O
meaning	O
that	O
full	O
expression	O
of	O
the	O
phenotype	O
is	O
not	O
easily	O
captured	O
,	O
and	O
both	O
wet	O
chemistry	O
and	O
NIRS	O
methods	O
for	O
measuring	O
water	O
soluble	O
carbohydrates	B-CD
are	O
time	O
consuming	O
and	O
expensive	O
(	O
Gebbing	O
and	O
Schnyder	O
1999	O
;	O
Ruuska	O
et	O
al	O
.	O
2006	O
).	O

We	O
estimated	O
that	O
most	O
of	O
the	O
genotypic	O
variance	O
for	O
WSCC	O
did	O
not	O
fit	O
a	O
polygenic	O
additive	O
polygenic	O
model	O
,	O
a	O
surprising	O
result	O
considering	O
numerous	O
results	O
showing	O
that	O
wheat	B-OG
grain	O
yield	O
is	O
often	O
adequately	O
described	O
with	O
an	O
additive	O
genetic	O
model	O
(	O
Heslot	O
et	O
al	O
.	O
2012	O
;	O
Pérez	O
-	O
Rodríguez	O
et	O
al	O
.	O
2012	O
;	O
Burgueño	O
et	O
al	O
.	O
2012	O
).	O

However	O
,	O
other	O
studies	O
of	O
wheat	B-OG
yield	O
across	O
diverse	O
environments	O
indicate	O
that	O
residual	O
genetic	O
variation	O
may	O
explain	O
substantial	O
fraction	O
of	O
the	O
total	O
genetic	O
variation	O
(	O
Cuevas	O
et	O
al	O
.	O
2017	O
).	O

Because	O
of	O
the	O
prevalence	O
of	O
residual	O
genetic	O
variance	O
,	O
the	O
GEBVs	O
for	O
WSCC	O
were	O
not	O
very	O
accurate	O
estimates	O
of	O
total	O
genotypic	O
value	O
,	O
regardless	O
of	O
the	O
information	O
used	O
to	O
compute	O
them	O
(	O
markers	O
,	O
phenotype	O
records	O
,	O
or	O
both	O
).	O

In	O
this	O
study	O
,	O
residual	O
genetic	O
effects	O
were	O
modeled	O
by	O
fitting	O
a	O
separate	O
independent	O
random	O
term	O
for	O
residual	O
genetic	O
effects	O
in	O
addition	O
to	O
the	O
additive	O
effects	O
whose	O
covariance	O
is	O
proportional	O
to	O
the	O
additive	O
realized	O
relationship	O
matrix	O
(	O
after	O
Oakey	O
et	O
al	O
.	O
2016	O
).	O

Total	O
genotypic	O
prediction	O
,	O
which	O
includes	O
additive	O
and	O
residual	O
genetic	O
effects	O
,	O
is	O
optimal	O
for	O
identifying	O
the	O
best	O
available	O
lines	O
in	O
a	O
population	O
,	O
but	O
this	O
requires	O
phenotypic	O
records	O
on	O
each	O
line	O
to	O
be	O
predicted	O
.	O

Potentially	O
,	O
predictions	O
can	O
be	O
improved	O
by	O
explicit	O
modeling	O
of	O
non	O
-	O
additive	O
as	O
well	O
as	O
additive	O
genetic	O
relationships	O
,	O
with	O
either	O
parametric	O
models	O
including	O
dominance	O
and	O
epistasis	O
(	O
Muñoz	O
et	O
al	O
.	O
2014	O
;	O
Su	O
et	O
al	O
.	O
2012	O
;	O
Da	O
et	O
al	O
.	O
2014	O
)	O
or	O
non	O
-	O
linear	O
kernel	O
methods	O
(	O
Gianola	O
and	O
van	O
Kaam	O
2008	O
).	O

These	O
models	O
would	O
allow	O
total	O
genotypic	O
values	O
to	O
be	O
predicted	O
on	O
lines	O
in	O
the	O
absence	O
of	O
any	O
phenotypic	O
records	O
.	O

If	O
the	O
total	O
genotypic	O
values	O
are	O
not	O
closely	O
correlated	O
with	O
the	O
true	O
breeding	O
values	O
,	O
they	O
will	O
not	O
be	O
the	O
best	O
predictions	O
to	O
use	O
for	O
parental	O
selection	O
to	O
generate	O
a	O
new	O
population	O
from	O
intermating	O
,	O
as	O
dominance	O
,	O
epistatic	O
,	O
and	O
most	O
other	O
non	O
-	O
additive	O
effects	O
that	O
may	O
contribute	O
to	O
the	O
residual	O
genetic	O
effects	O
do	O
not	O
contribute	O
to	O
long	O
-	O
term	O
genetic	O
gain	O
over	O
meiotic	O
outcrossing	O
generations	O
(	O
Hill	O
et	O
al	O
.	O
2008	O
;	O
Holland	O
2001	O
;	O
Oakey	O
et	O
al	O
.	O
2016	O
;	O
Cockerham	O
1983	O
;	O
Cockerham	O
and	O
Matzinger	O
1985	O
).	O

GEBVs	O
,	O
on	O
the	O
other	O
hand	O
,	O
while	O
they	O
may	O
not	O
be	O
optimal	O
for	O
predicting	O
the	O
best	O
existing	O
lines	O
,	O
should	O
be	O
better	O
estimators	O
of	O
the	O
utility	O
of	O
lines	O
as	O
parents	O
of	O
new	O
breeding	O
populations	O
.	O

To	O
distinguish	O
the	O
different	O
uses	O
of	O
GEBVs	O
in	O
a	O
breeding	O
program	O
,	O
we	O
computed	O
two	O
relative	O
accuracy	O
statistics	O
that	O
refer	O
to	O
the	O
use	O
of	O
GEBVs	O
to	O
identify	O
optimal	O
extant	O
lines	O
or	O
to	O
identify	O
lines	O
with	O
better	O
breeding	O
values	O
for	O
use	O
as	O
parents	O
for	O
intermating	O
to	O
create	O
a	O
new	O
breeding	O
population	O
.	O

Compared	O
to	O
phenotypic	O
selection	O
the	O
RAPV	O
for	O
the	O
well	O
-	O
watered	O
environment	O
cluster	O
was	O
57	O
%,	O
and	O
51	O
%	O
for	O
the	O
water	O
deficit	O
environment	O
cluster	O
,	O
indicating	O
our	O
GEBVs	O
are	O
marginal	O
at	O
predicting	O
phenotypic	O
performance	O
in	O
these	O
environments	O
for	O
new	O
genotypes	O
(	O
Table	O
2	O
),	O
and	O
that	O
genomic	O
selection	O
is	O
unlikely	O
to	O
be	O
a	O
substitute	O
for	O
phenotypic	O
selection	O
of	O
the	O
best	O
performing	O
lines	O
.	O

In	O
contrast	O
,	O
when	O
compared	O
with	O
true	O
breeding	O
values	O
for	O
the	O
purpose	O
of	O
selecting	O
new	O
parents	O
and	O
maximizing	O
genetic	O
gain	O
over	O
time	O
,	O
the	O
relative	O
accuracy	O
(	O
RABV	O
)	O
was	O
higher	O
.	O

The	O
RABV	O
measures	O
can	O
be	O
coupled	O
with	O
the	O
assumptions	O
of	O
Desta	O
and	O
Ortiz	O
(	O
2014	O
);	O
Heffner	O
et	O
al	O
.	O
(	O
2010	O
);	O
and	O
Lorenz	O
et	O
al	O
.	O
(	O
2011	O
)	O
suggesting	O
genomic	O
selection	O
is	O
predicted	O
to	O
facilitate	O
a	O
reduction	O
in	O
the	O
breeding	O
cycle	O
time	O
of	O
the	O
average	O
wheat	B-OG
breeding	O
program	O
of	O
at	O
least	O
half	O
due	O
to	O
the	O
ability	O
to	O
select	O
at	O
earlier	O
generations	O
and	O
also	O
in	O
off	O
-	O
season	O
generations	O
.	O

Therefore	O
,	O
relative	O
to	O
selection	O
using	O
the	O
true	O
breeding	O
values	O
,	O
and	O
making	O
the	O
assumption	O
of	O
a	O
decrease	O
in	O
the	O
breeding	O
cycle	O
time	O
of	O
50	O
%,	O
genetic	O
gain	O
per	O
unit	O
of	O
time	O
from	O
genomic	O
selection	O
in	O
this	O
study	O
is	O
estimated	O
to	O
be	O
2	O
×	O
78	O
%=	O
158	O
%	O
for	O
the	O
well	O
-	O
watered	O
environment	O
cluster	O
and	O
2	O
×	O
107	O
%=	O
214	O
%	O
for	O
the	O
water	O
deficit	O
environment	O
cluster	O
.	O

This	O
indicates	O
that	O
genomic	O
selection	O
methods	O
can	O
increase	O
the	O
rate	O
of	O
genetic	O
gain	O
for	O
WSCC	O
.	O

The	O
challenge	O
in	O
practical	O
terms	O
,	O
as	O
noted	O
by	O
Cooper	O
et	O
al	O
.	O
(	O
2014	O
),	O
may	O
be	O
in	O
implementing	O
the	O
enabling	O
technologies	O
needed	O
to	O
make	O
genomic	O
selection	O
work	O
and	O
readily	O
integrated	O
into	O
a	O
commercial	O
breeding	O
program	O
.	O

Finally	O
,	O
if	O
the	O
ultimate	O
goal	O
of	O
selection	O
is	O
to	O
improve	O
yield	O
performance	O
within	O
or	O
across	O
abiotic	O
stress	O
environments	O
,	O
the	O
genotypic	O
and	O
additive	O
genetic	O
correlations	O
of	O
WSCC	O
with	O
yield	O
and	O
other	O
agronomic	O
traits	O
must	O
be	O
considered	O
.	O
Ovenden	O
et	O
al	O
.	O
(	O
2017	O
)	O
previously	O
demonstrated	O
significant	O
but	O
relatively	O
low	O
genotypic	O
correlations	O
between	O
WSCC	O
and	O
yield	O
in	O
this	O
germplasm	O
sample	O
,	O
suggesting	O
that	O
its	O
utility	O
as	O
an	O
indirect	O
selection	O
criterion	O
needs	O
to	O
be	O
assessed	O
on	O
a	O
case	O
by	O
case	O
basis	O
.	O

Conclusions	O

This	O
study	O
provides	O
empirical	O
evidence	O
that	O
genomic	O
selection	O
methods	O
could	O
improve	O
the	O
rate	O
of	O
genetic	O
gain	O
for	O
carbohydrate	B-CD
accumulation	O
,	O
provided	O
that	O
the	O
TPE	O
are	O
carefully	O
characterized	O
and	O
understood	O
,	O
and	O
predictions	O
are	O
restricted	O
to	O
environment	O
subsets	O
of	O
interest	O
.	O

With	O
additive	O
variance	O
being	O
low	O
in	O
the	O
models	O
under	O
study	O
,	O
the	O
importance	O
of	O
relative	O
accuracy	O
for	O
different	O
genomic	O
selection	O
strategies	O
becomes	O
apparent	O
.	O

Compared	O
to	O
phenotypic	O
selection	O
,	O
the	O
relative	O
accuracy	O
of	O
the	O
GEBVs	O
modeled	O
here	O
is	O
low	O
,	O
however	O
the	O
GEBVs	O
more	O
accurately	O
model	O
the	O
true	O
breeding	O
values	O
.	O

Therefore	O
,	O
genomic	O
selection	O
could	O
well	O
result	O
in	O
higher	O
genetic	O
gain	O
per	O
unit	O
of	O
time	O
through	O
the	O
ability	O
to	O
better	O
select	O
parents	O
for	O
intermating	O
,	O
and	O
genomic	O
selection	O
may	O
be	O
a	O
useful	O
tool	O
for	O
making	O
genetic	O
gains	O
in	O
complex	O
abiotic	O
stress	O
characteristics	O
.	O

Supplemental	O
material	O
available	O
at	O
Figshare	O
:	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
25387	O
/	O
g3	O
.	O
6143243	O
.	O

Communicating	O
editor	O
:	O
E	O
.	O

Akhunov	O

Method	O
for	O
Reading	O
Sensors	O
and	O
Controlling	O
Actuators	O
Using	O
Audio	O
Interfaces	O
of	O
Mobile	O
Devices	O

This	O
article	O
presents	O
a	O
novel	O
closed	O
loop	O
control	O
architecture	O
based	O
on	O
audio	O
channels	O
of	O
several	O
types	O
of	O
computing	O
devices	O
,	O
such	O
as	O
mobile	O
phones	O
and	O
tablet	O
computers	O
,	O
but	O
not	O
restricted	O
to	O
them	O
.	O

The	O
communication	O
is	O
based	O
on	O
an	O
audio	O
interface	O
that	O
relies	O
on	O
the	O
exchange	O
of	O
audio	O
tones	O
,	O
allowing	O
sensors	O
to	O
be	O
read	O
and	O
actuators	O
to	O
be	O
controlled	O
.	O

As	O
an	O
application	O
example	O
,	O
the	O
presented	O
technique	O
is	O
used	O
to	O
build	O
a	O
low	O
cost	O
mobile	O
robot	O
,	O
but	O
the	O
system	O
can	O
also	O
be	O
used	O
in	O
a	O
variety	O
of	O
mechatronics	O
applications	O
and	O
sensor	O
networks	O
,	O
where	O
smartphones	O
are	O
the	O
basic	O
building	O
blocks	O
.	O

Introduction	O
and	O
Motivation	O

Most	O
robots	O
and	O
automation	O
systems	O
rely	O
on	O
processing	O
units	O
to	O
control	O
their	O
behavior	O
.	O

Such	O
processing	O
units	O
can	O
be	O
embedded	O
processors	O
(	O
such	O
as	O
microcontrollers	O
)	O
or	O
general	O
purpose	O
computers	O
(	O
such	O
as	O
PCs	O
)	O
with	O
specialized	O
Input	O
/	O
Output	O
(	O
I	O
/	O
O	O
)	O
accessories	O
.	O

One	O
common	O
practice	O
is	O
the	O
use	O
of	O
USB	O
devices	O
with	O
several	O
I	O
/	O
O	O
options	O
connected	O
to	O
a	O
PC	O
.	O

Another	O
approach	O
consists	O
of	O
using	O
a	O
microcontroller	O
unit	O
that	O
runs	O
a	O
software	O
algorithm	O
to	O
control	O
the	O
system	O
.	O

Frequently	O
this	O
microcontroller	O
is	O
connected	O
to	O
a	O
computer	O
to	O
monitor	O
and	O
set	O
parameters	O
of	O
the	O
running	O
system	O
.	O

Although	O
consolidated	O
,	O
these	O
approaches	O
require	O
specific	O
device	O
drivers	O
on	O
the	O
host	O
computer	O
and	O
special	O
configurations	O
.	O

Moreover	O
,	O
if	O
the	O
control	O
algorithm	O
has	O
to	O
be	O
changed	O
,	O
the	O
user	O
must	O
reprogram	O
the	O
microcontroller	O
,	O
which	O
in	O
some	O
cases	O
requires	O
special	O
hardware	O
tools	O
such	O
as	O
in	O
-	O
circuit	O
programmers	O
and	O
debuggers	O
.	O

Mobile	O
devices	O
such	O
as	O
cell	O
phones	O
,	O
tablets	O
and	O
netbooks	O
are	O
widespread	O
and	O
getting	O
cheaper	O
due	O
to	O
their	O
large	O
production	O
,	O
making	O
them	O
an	O
interesting	O
option	O
to	O
control	O
mechatronics	O
systems	O
.	O

These	O
devices	O
also	O
include	O
several	O
sensors	O
that	O
can	O
be	O
used	O
in	O
a	O
mechatronic	O
system	O
.	O

Examples	O
of	O
sensors	O
available	O
in	O
modern	O
cell	O
phones	O
are	O
the	O
global	O
positioning	O
system	O
receiver	O
(	O
GPS	O
),	O
3	O
-	O
axis	O
accelerometer	O
,	O
compass	O
,	O
liquid	O
crystal	O
display	O
(	O
LCD	O
)	O
with	O
touchscreen	O
,	O
Internet	O
access	O
via	O
WiFi	O
or	O
GPRS	O
/	O
3G	O
services	O
,	O
camera	O
,	O
speakers	O
,	O
microphone	O
,	O
bluetooth	O
module	O
,	O
light	O
sensor	O
and	O
battery	O
(	O
some	O
have	O
even	O
gyroscope	O
,	O
barometer	O
and	O
stereo	O
camera	O
).	O

If	O
all	O
those	O
accessories	O
would	O
be	O
bought	O
separately	O
and	O
installed	O
in	O
a	O
device	O
,	O
the	O
costs	O
would	O
be	O
more	O
expensive	O
than	O
a	O
device	O
with	O
all	O
these	O
features	O
already	O
included	O
.	O

To	O
use	O
a	O
mobile	O
device	O
as	O
a	O
mechatronics	O
system	O
main	O
processing	O
unit	O
,	O
a	O
communication	O
link	O
must	O
established	O
between	O
the	O
control	O
unit	O
and	O
the	O
system	O
under	O
control	O
.	O

Some	O
works	O
[	O
1	O
–	O
3	O
]	O
use	O
the	O
mobile	O
’	O
s	O
device	O
RS	O
-	O
232	O
serial	O
port	O
signals	O
while	O
others	O
use	O
bluetooth	O
[	O
1	O
,	O
4	O
].	O

In	O
all	O
these	O
works	O
,	O
a	O
microcontroller	O
still	O
needs	O
to	O
be	O
used	O
to	O
communicate	O
with	O
the	O
mobile	O
device	O
,	O
to	O
read	O
sensors	O
and	O
to	O
control	O
actuators	O
.	O

The	O
problem	O
is	O
that	O
not	O
all	O
mobile	O
devices	O
have	O
a	O
serial	O
port	O
,	O
or	O
bluetooth	O
communication	O
interface	O
.	O

Analyzing	O
modern	O
mobile	O
devices	O
it	O
is	O
possible	O
to	O
note	O
that	O
most	O
of	O
them	O
have	O
an	O
universal	O
communication	O
interface	O
:	O
audio	O
channels	O
,	O
that	O
usually	O
can	O
be	O
accessed	O
through	O
standard	O
3	O
.	O
5	O
mm	O
P2	O
connectors	O
.	O

If	O
there	O
are	O
no	O
connectors	O
for	O
external	O
audio	O
,	O
this	O
article	O
also	O
offers	O
a	O
solution	O
using	O
suction	O
cups	O
to	O
use	O
the	O
proposed	O
system	O
in	O
mobile	O
devices	O
where	O
the	O
speakers	O
or	O
microphones	O
are	O
built	O
-	O
in	O
.	O

Details	O
of	O
such	O
solution	O
are	O
discussed	O
in	O
Section	O
5	O
.	O
1	O
.	O

In	O
this	O
article	O
,	O
a	O
system	O
that	O
allows	O
closed	O
loop	O
control	O
using	O
any	O
mobile	O
device	O
that	O
can	O
produce	O
and	O
receive	O
sounds	O
was	O
designed	O
and	O
built	O
.	O

In	O
such	O
system	O
,	O
audio	O
tones	O
are	O
used	O
to	O
encode	O
actuators	O
control	O
commands	O
and	O
sensors	O
states	O
.	O

The	O
system	O
cost	O
is	O
low	O
because	O
only	O
a	O
few	O
parts	O
are	O
needed	O
(	O
these	O
parts	O
are	O
widely	O
used	O
in	O
the	O
telephony	O
industry	O
,	O
making	O
them	O
also	O
easy	O
to	O
find	O
on	O
the	O
market	O
).	O

Moreover	O
the	O
system	O
does	O
not	O
need	O
any	O
intermediate	O
processing	O
unit	O
,	O
making	O
it	O
flexible	O
to	O
easily	O
update	O
the	O
running	O
algorithm	O
,	O
avoiding	O
the	O
need	O
of	O
reprogramming	O
microcontrollers	O
.	O

Robots	O
and	O
Smartphones	O

As	O
mentioned	O
,	O
mobile	O
devices	O
have	O
several	O
features	O
that	O
can	O
be	O
used	O
in	O
robotics	O
.	O

Some	O
possibilities	O
of	O
using	O
these	O
features	O
are	O
briefly	O
discussed	O
in	O
the	O
following	O
text	O
.	O

These	O
possibilities	O
are	O
,	O
for	O
sure	O
,	O
non	O
-	O
exhaustive	O
.	O

CPU	O
:	O
Modern	O
smartphones	O
already	O
have	O
processors	O
with	O
clock	O
rates	O
of	O
1	O
GHz	O
or	O
more	O
.	O

Some	O
models	O
also	O
have	O
multi	O
-	O
core	O
processors	O
.	O

These	O
processing	O
units	O
are	O
capable	O
of	O
doing	O
many	O
complex	O
and	O
computationally	O
intensive	O
operations	O
for	O
autonomous	O
robots	O
navigation	O
.	O

Santos	O
et	O
al	O
.	O
[	O
4	O
],	O
for	O
example	O
,	O
showed	O
that	O
it	O
is	O
feasible	O
to	O
execute	O
complex	O
robotics	O
navigation	O
algorithms	O
in	O
processors	O
of	O
older	O
smartphones	O
with	O
300	O
MHz	O
clock	O
speed	O
;	O

Camera	O
:	O
can	O
be	O
used	O
with	O
a	O
variety	O
of	O
algorithms	O
for	O
visual	O
odometry	O
,	O
object	O
recognition	O
,	O
robot	O
attention	O
(	O
the	O
ability	O
to	O
select	O
a	O
topic	O
of	O
interest	O
[	O
5	O
]),	O
obstacle	O
detection	O
and	O
avoidance	O
,	O
object	O
tracking	O
,	O
and	O
others	O
;	O

Compass	O
:	O
can	O
be	O
used	O
to	O
sense	O
the	O
robot	O
’	O
s	O
direction	O
of	O
movement	O
.	O

The	O
system	O
can	O
work	O
with	O
one	O
or	O
two	O
encoders	O
.	O

If	O
only	O
one	O
encoder	O
is	O
used	O
,	O
the	O
compass	O
is	O
used	O
to	O
guarantee	O
that	O
the	O
robot	O
is	O
going	O
in	O
the	O
expected	O
direction	O
and	O
to	O
control	O
the	O
desired	O
curves	O
angles	O
;	O

GPS	O
:	O
can	O
be	O
used	O
to	O
obtain	O
the	O
robot	O
position	O
in	O
outdoor	O
environments	O
,	O
altitude	O
and	O
speed	O
;	O

Accelerometer	O
:	O
can	O
be	O
used	O
to	O
detect	O
speed	O
changes	O
and	O
consequently	O
if	O
the	O
robot	O
has	O
hit	O
an	O
object	O
in	O
any	O
direction	O
(	O
a	O
virtual	O
bumper	O
).	O

It	O
can	O
also	O
detect	O
the	O
robot	O
’	O
s	O
orientation	O
.	O

It	O
is	O
also	O
possible	O
to	O
use	O
Kalman	O
filtering	O
to	O
do	O
sensor	O
fusion	O
of	O
the	O
camera	O
,	O
encoders	O
and	O
accelerometer	O
to	O
get	O
more	O
accurate	O
positioning	O
;	O

Internet	O
:	O
WiFi	O
or	O
other	O
Internet	O
connection	O
can	O
be	O
used	O
to	O
remotely	O
monitor	O
the	O
robot	O
and	O
send	O
commands	O
to	O
it	O
.	O

The	O
robot	O
can	O
also	O
access	O
a	O
cloud	O
system	O
to	O
aid	O
some	O
decision	O
making	O
process	O
and	O
communicate	O
with	O
other	O
robots	O
;	O

Bluetooth	O
:	O
can	O
be	O
used	O
to	O
exchange	O
information	O
with	O
nearby	O
robots	O
and	O
for	O
robot	O
localization	O
;	O

Bluetooth	O
audio	O
:	O
As	O
the	O
standard	O
audio	O
input	O
and	O
output	O
are	O
used	O
for	O
the	O
control	O
system	O
,	O
a	O
bluetooth	O
headset	O
can	O
be	O
paired	O
with	O
the	O
mobile	O
device	O
,	O
allowing	O
the	O
robot	O
to	O
receive	O
voice	O
commands	O
and	O
give	O
synthesized	O
voice	O
feedback	O
to	O
the	O
user	O
.	O

The	O
Android	O
voice	O
recognizer	O
worked	O
well	O
for	O
both	O
English	O
and	O
Portuguese	O
.	O

The	O
user	O
can	O
press	O
a	O
button	O
in	O
the	O
bluetooth	O
headset	O
and	O
say	O
a	O
complex	O
command	O
such	O
as	O
a	O
phrase	O
.	O

The	O
Android	O
system	O
will	O
then	O
return	O
a	O
vector	O
with	O
most	O
probable	O
phrases	O
that	O
the	O
user	O
has	O
said	O
;	O

ROS	O
:	O
The	O
Robot	O
Operating	O
System	O
(	O
ROS	O
)	O
[	O
6	O
]	O
from	O
Willow	O
Garage	O
is	O
already	O
supported	O
in	O
mobile	O
devices	O
running	O
Android	O
using	O
the	O
ros	O
-	O
java	O
branch	O
.	O

Using	O
ROS	O
and	O
the	O
system	O
described	O
in	O
this	O
article	O
,	O
a	O
low	O
cost	O
robot	O
can	O
be	O
built	O
with	O
all	O
the	O
advantages	O
and	O
features	O
of	O
ROS	O
.	O

Contributions	O

The	O
main	O
contributions	O
of	O
this	O
work	O
are	O
:	O
A	O
novel	O
system	O
for	O
controlling	O
actuators	O
using	O
audio	O
channelsA	O
novel	O
system	O
for	O
reading	O
sensors	O
information	O
using	O
audio	O
channelsA	O
closed	O
loop	O
control	O
architecture	O
using	O
the	O
above	O
-	O
mentioned	O
itemsApplication	O
of	O
a	O
camera	O
and	O
laser	O
based	O
distance	O
measurement	O
system	O
for	O
roboticsA	O
low	O
cost	O
mobile	O
robot	O
controlled	O
by	O
smartphones	O
and	O
mobile	O
devices	O
using	O
the	O
techniques	O
introduced	O
in	O
this	O
work	O

Organization	O

This	O
paper	O
is	O
structured	O
as	O
follows	O
:	O
Section	O
2	O
describes	O
previous	O
architectures	O
for	O
mechatronics	O
systems	O
control	O
.	O

Section	O
3	O
introduces	O
the	O
new	O
technique	O
.	O

Section	O
4	O
presents	O
the	O
experimental	O
results	O
of	O
the	O
proposed	O
system	O
.	O

Section	O
5	O
describes	O
a	O
case	O
study	O
with	O
an	O
application	O
of	O
the	O
system	O
to	O
build	O
a	O
low	O
cost	O
mobile	O
robot	O
and	O
in	O
Section	O
6	O
are	O
the	O
final	O
considerations	O
.	O

Related	O
Work	O

This	O
section	O
reviews	O
some	O
of	O
the	O
most	O
relevant	O
related	O
works	O
that	O
uses	O
mobile	O
devices	O
to	O
control	O
robots	O
and	O
their	O
communication	O
interfaces	O
.	O

Digital	O
Data	O
Interfaces	O

Santos	O
et	O
al	O
.	O
[	O
4	O
]	O
analyze	O
the	O
feasibility	O
of	O
using	O
smartphones	O
to	O
execute	O
robot	O
’	O
s	O
autonomous	O
navigation	O
and	O
localization	O
algorithms	O
.	O

In	O
the	O
proposed	O
system	O
,	O
the	O
robot	O
control	O
algorithm	O
is	O
executed	O
in	O
the	O
mobile	O
phone	O
and	O
the	O
motion	O
commands	O
are	O
sent	O
to	O
the	O
robot	O
using	O
bluetooth	O
.	O

Their	O
experiments	O
are	O
made	O
with	O
mobile	O
phones	O
with	O
processor	O
clocks	O
of	O
220	O
MHz	O
and	O
330	O
MHz	O
and	O
they	O
conclude	O
that	O
it	O
is	O
possible	O
and	O
robust	O
to	O
execute	O
complex	O
navigation	O
in	O
these	O
devices	O
even	O
with	O
soft	O
real	O
-	O
time	O
requirements	O
.	O

The	O
tested	O
algorithms	O
are	O
well	O
-	O
known	O
:	O
potential	O
fields	O
,	O
particle	O
filter	O
and	O
extended	O
Kalman	O
filter	O
.	O

Another	O
example	O
of	O
the	O
use	O
of	O
smartphones	O
to	O
control	O
robots	O
is	O
the	O
open	O
source	O
project	O
Cellbots	O
[	O
1	O
]	O
which	O
uses	O
Android	O
based	O
phones	O
to	O
control	O
mobile	O
robots	O
.	O

The	O
project	O
requires	O
a	O
microcontroller	O
that	O
communicates	O
with	O
the	O
phone	O
via	O
bluetooth	O
or	O
serial	O
port	O
and	O
sends	O
the	O
electrical	O
control	O
signals	O
to	O
the	O
motors	O
.	O

The	O
problem	O
is	O
that	O
not	O
all	O
mobile	O
devices	O
have	O
bluetooth	O
or	O
serial	O
ports	O
.	O

Moreover	O
,	O
in	O
some	O
cases	O
the	O
device	O
has	O
the	O
serial	O
port	O
available	O
only	O
internally	O
,	O
requiring	O
disassembly	O
of	O
the	O
device	O
to	O
access	O
the	O
serial	O
port	O
signals	O
.	O

When	O
using	O
bluetooth	O
,	O
the	O
costs	O
are	O
higher	O
because	O
an	O
additional	O
bluetooth	O
module	O
must	O
be	O
installed	O
and	O
connected	O
to	O
the	O
microcontroller	O
.	O

The	O
work	O
of	O
Hess	O
and	O
Rohrig	O
[	O
7	O
]	O
consists	O
of	O
using	O
mobile	O
phones	O
to	O
remotely	O
control	O
a	O
robot	O
.	O

Their	O
system	O
can	O
connect	O
to	O
the	O
robot	O
using	O
TCP	O
/	O
IP	O
interfaces	O
or	O
bluetooth	O
.	O

In	O
the	O
case	O
of	O
the	O
TCP	O
/	O
IP	O
sockets	O
,	O
the	O
connection	O
to	O
the	O
robot	O
is	O
made	O
using	O
an	O
already	O
existing	O
wireless	O
LAN	O
(	O
WiFi	O
)	O
infrastructure	O
.	O

Park	O
et	O
al	O
.	O
[	O
8	O
]	O
describe	O
user	O
interface	O
techniques	O
for	O
using	O
PDAs	O
or	O
smartphones	O
to	O
remotely	O
control	O
robots	O
.	O

Again	O
,	O
the	O
original	O
robot	O
controller	O
is	O
maintained	O
and	O
the	O
mobile	O
device	O
is	O
used	O
simply	O
as	O
a	O
remote	O
control	O
device	O
.	O

Their	O
system	O
commands	O
are	O
exchanged	O
using	O
WiFi	O
wireless	O
networks	O
.	O

Analog	O
Audio	O
Interfaces	O

One	O
interesting	O
alternative	O
is	O
using	O
a	O
dedicated	O
circuit	O
to	O
transform	O
the	O
audio	O
output	O
of	O
the	O
mobile	O
device	O
in	O
a	O
serial	O
port	O
signal	O
[	O
9	O
],	O
but	O
the	O
problem	O
with	O
such	O
approach	O
is	O
that	O
only	O
unidirectional	O
communication	O
is	O
possible	O
,	O
and	O
still	O
,	O
as	O
in	O
the	O
other	O
cases	O
,	O
a	O
microcontroller	O
is	O
needed	O
to	O
decode	O
the	O
serial	O
signal	O
and	O
execute	O
some	O
action	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
telecommunications	O
industry	O
frequently	O
uses	O
the	O
Dial	O
Tone	O
Multi	O
Frequency	O
(	O
DTMF	O
)	O
system	O
to	O
exchange	O
remote	O
control	O
commands	O
between	O
equipments	O
.	O

Section	O
3	O
.	O
1	O
contains	O
a	O
description	O
of	O
the	O
DTMF	O
system	O
.	O

The	O
system	O
is	O
more	O
known	O
in	O
telephony	O
for	O
sending	O
the	O
digits	O
that	O
a	O
caller	O
wants	O
to	O
dial	O
to	O
a	O
switching	O
office	O
.	O

DTMF	O
usage	O
to	O
control	O
robots	O
is	O
not	O
new	O
.	O

There	O
are	O
some	O
recent	O
projects	O
that	O
use	O
DTMF	O
digits	O
exchange	O
to	O
remotely	O
control	O
robots	O
:	O
Patil	O
and	O
Henry	O
[	O
10	O
]	O
used	O
a	O
remote	O
mobile	O
phone	O
to	O
telecommand	O
a	O
robot	O
.	O

DTMF	O
tones	O
are	O
sent	O
from	O
the	O
mobile	O
phone	O
to	O
the	O
remote	O
robot	O
’	O
s	O
phone	O
and	O
decoded	O
by	O
a	O
specific	O
integrated	O
circuit	O
and	O
the	O
binary	O
output	O
is	O
connected	O
to	O
a	O
FPGA	O
that	O
controls	O
the	O
robot	O
.	O

Manikandan	O
et	O
al	O
.	O
[	O
11	O
]	O
proposed	O
and	O
built	O
a	O
robot	O
that	O
uses	O
two	O
cell	O
phones	O
.	O

One	O
phone	O
is	O
placed	O
in	O
the	O
robot	O
and	O
another	O
acts	O
as	O
a	O
remote	O
control	O
.	O

The	O
DTMF	O
audio	O
produced	O
by	O
the	O
keys	O
pressed	O
in	O
the	O
remote	O
control	O
phone	O
is	O
sent	O
to	O
the	O
phone	O
installed	O
in	O
the	O
robot	O
,	O
and	O
the	O
audio	O
output	O
of	O
this	O
phone	O
is	O
connected	O
to	O
a	O
DTMF	O
decoder	O
via	O
the	O
earphone	O
output	O
of	O
the	O
cell	O
phone	O
.	O

The	O
4	O
-	O
bit	O
DTMF	O
output	O
is	O
then	O
connected	O
to	O
a	O
microcontroller	O
that	O
interprets	O
the	O
codes	O
and	O
executes	O
the	O
movements	O
related	O
to	O
the	O
keys	O
pressed	O
in	O
the	O
remote	O
control	O
phone	O
.	O

Sai	O
and	O
Sivaramakrishnan	O
[	O
12	O
]	O
used	O
the	O
same	O
setup	O
,	O
where	O
two	O
mobile	O
phones	O
are	O
used	O
,	O
one	O
located	O
at	O
the	O
robot	O
and	O
another	O
used	O
as	O
a	O
remote	O
control	O
.	O

The	O
difference	O
is	O
that	O
the	O
system	O
is	O
applied	O
to	O
different	O
type	O
of	O
robot	O
(	O
mechanically	O
).	O

Naskar	O
et	O
al	O
.	O
[	O
13	O
]	O
presented	O
a	O
work	O
where	O
a	O
remote	O
DTMF	O
keypad	O
is	O
used	O
to	O
control	O
a	O
military	O
robot	O
.	O

Some	O
DTMF	O
digits	O
are	O
even	O
used	O
to	O
fire	O
real	O
guns	O
.	O

The	O
main	O
difference	O
is	O
that	O
instead	O
of	O
transmitting	O
the	O
DTMF	O
tones	O
using	O
a	O
phone	O
call	O
,	O
the	O
tones	O
are	O
transmitted	O
using	O
a	O
radio	O
frequency	O
link	O
.	O

Still	O
about	O
DTMF	O
based	O
control	O
,	O
Ladwa	O
et	O
al	O
.	O
[	O
14	O
]	O
proposed	O
a	O
system	O
that	O
can	O
remotely	O
control	O
home	O
appliances	O
or	O
robots	O
via	O
DTMF	O
tones	O
over	O
telephone	O
calls	O
.	O

The	O
tones	O
are	O
generated	O
by	O
keys	O
pressed	O
in	O
a	O
remote	O
phone	O
keypad	O
,	O
received	O
by	O
a	O
phone	O
installed	O
in	O
the	O
system	O
under	O
control	O
and	O
decoded	O
by	O
a	O
DTMF	O
decoder	O
circuit	O
.	O

A	O
microcontroller	O
then	O
executes	O
some	O
pre	O
-	O
programmed	O
action	O
.	O

A	O
similar	O
work	O
is	O
presented	O
by	O
Cho	O
and	O
Jeon	O
[	O
15	O
]	O
where	O
key	O
presses	O
in	O
a	O
remote	O
phone	O
are	O
sent	O
through	O
a	O
telephone	O
call	O
to	O
a	O
receiver	O
cell	O
phone	O
modem	O
.	O

Its	O
audio	O
output	O
is	O
connected	O
to	O
a	O
DTMF	O
decoder	O
chip	O
which	O
is	O
then	O
connected	O
to	O
a	O
robot	O
control	O
board	O
.	O

As	O
the	O
user	O
presses	O
keys	O
in	O
the	O
remote	O
phone	O
,	O
the	O
robot	O
goes	O
forward	O
,	O
backwards	O
or	O
do	O
curves	O
according	O
with	O
the	O
pressed	O
key	O
(	O
a	O
numerical	O
digit	O
that	O
is	O
represented	O
by	O
a	O
DTMF	O
code	O
).	O

Recently	O
,	O
a	O
startup	O
company	O
created	O
a	O
mobile	O
robot	O
that	O
can	O
be	O
controlled	O
by	O
audio	O
tones	O
from	O
mobile	O
phones	O
[	O
16	O
].	O

The	O
system	O
is	O
limited	O
to	O
controlling	O
two	O
motors	O
and	O
does	O
not	O
have	O
any	O
feedback	O
or	O
sensor	O
reading	O
capability	O
.	O

The	O
alternative	O
is	O
using	O
camera	O
algorithms	O
such	O
as	O
optical	O
flow	O
to	O
implement	O
visual	O
odometry	O
,	O
but	O
even	O
if	O
so	O
,	O
such	O
limitations	O
make	O
it	O
difficult	O
to	O
build	O
a	O
complete	O
mobile	O
robot	O
because	O
of	O
the	O
lack	O
of	O
important	O
sensory	O
information	O
such	O
as	O
bumpers	O
and	O
distance	O
to	O
objects	O
.	O

Also	O
,	O
the	O
information	O
provided	O
in	O
the	O
company	O
website	O
does	O
not	O
make	O
it	O
clear	O
if	O
the	O
wheel	O
speed	O
can	O
be	O
controlled	O
and	O
which	O
audio	O
frequencies	O
are	O
used	O
.	O

With	O
the	O
exception	O
of	O
the	O
example	O
in	O
the	O
last	O
paragraph	O
,	O
all	O
other	O
mentioned	O
examples	O
and	O
projects	O
use	O
DTMF	O
tones	O
to	O
remotely	O
control	O
a	O
distant	O
robot	O
over	O
radio	O
or	O
telephone	O
lines	O
.	O

This	O
system	O
,	O
in	O
contrast	O
,	O
uses	O
DTMF	O
tones	O
to	O
control	O
actuators	O
and	O
read	O
sensors	O
in	O
a	O
scheme	O
where	O
the	O
control	O
unit	O
is	O
physically	O
attached	O
to	O
the	O
robot	O
,	O
or	O
near	O
the	O
robot	O
(	O
connected	O
by	O
an	O
audio	O
cable	O
).	O

The	O
advantage	O
is	O
that	O
DTMF	O
tones	O
are	O
very	O
robust	O
to	O
interference	O
and	O
widely	O
adopted	O
,	O
making	O
it	O
easy	O
to	O
find	O
electrical	O
components	O
and	O
software	O
support	O
for	O
dealing	O
with	O
such	O
system	O
.	O

System	O
Architecture	O

This	O
section	O
describes	O
the	O
proposed	O
system	O
architecture	O
.	O

Its	O
main	O
advantage	O
is	O
to	O
provide	O
a	O
universal	O
connection	O
system	O
to	O
read	O
sensors	O
and	O
control	O
actuators	O
of	O
mechatronics	O
systems	O
.	O

The	O
data	O
is	O
exchanged	O
using	O
audio	O
tones	O
,	O
allowing	O
the	O
technique	O
to	O
be	O
used	O
with	O
any	O
device	O
that	O
has	O
audio	O
input	O
/	O
output	O
interfaces	O
.	O

Theoretical	O
Background	O

The	O
DTMF	O
system	O
was	O
created	O
in	O
the	O
decade	O
of	O
1950	O
as	O
a	O
faster	O
option	O
to	O
the	O
(	O
now	O
obsolete	O
)	O
pulse	O
dialing	O
system	O
.	O

Its	O
main	O
purpose	O
at	O
that	O
time	O
was	O
to	O
send	O
the	O
digits	O
that	O
a	O
caller	O
wants	O
to	O
dial	O
to	O
the	O
switching	O
system	O
of	O
the	O
telephone	O
company	O
.	O

Although	O
almost	O
60	O
years	O
old	O
,	O
DTMF	O
is	O
still	O
widely	O
used	O
in	O
telecommunication	O
systems	O
and	O
is	O
still	O
used	O
in	O
most	O
new	O
telephone	O
designs	O
[	O
17	O
].	O

DTMF	O
tones	O
can	O
be	O
easily	O
heard	O
by	O
pressing	O
the	O
keys	O
on	O
a	O
phone	O
during	O
a	O
telephone	O
call	O
.	O

The	O
system	O
is	O
composed	O
of	O
16	O
different	O
audio	O
frequencies	O
organized	O
in	O
a	O
4	O
×	O
4	O
matrix	O
.	O
Table	O
1	O
shows	O
these	O
frequencies	O
and	O
the	O
corresponding	O
keys	O
/	O
digits	O
.	O

A	O
valid	O
digit	O
is	O
always	O
composed	O
by	O
a	O
pair	O
of	O
frequencies	O
(	O
one	O
from	O
the	O
table	O
columns	O
and	O
one	O
from	O
the	O
table	O
rows	O
)	O
transmitted	O
simultaneously	O
.	O

For	O
example	O
,	O
to	O
transmit	O
the	O
digit	O
9	O
,	O
an	O
audio	O
signal	O
containing	O
the	O
frequencies	O
852	O
Hz	O
and	O
1	O
,	O
477	O
Hz	O
would	O
have	O
to	O
be	O
generated	O
.	O

As	O
DTMF	O
was	O
designed	O
to	O
exchange	O
data	O
via	O
telephone	O
lines	O
that	O
can	O
be	O
noisy	O
,	O
the	O
use	O
of	O
2	O
frequencies	O
to	O
uniquely	O
identify	O
a	O
digit	O
makes	O
the	O
system	O
efficient	O
and	O
very	O
robust	O
to	O
noise	O
and	O
other	O
sounds	O
that	O
do	O
not	O
characterize	O
a	O
valid	O
DTMF	O
digit	O
.	O

In	O
fact	O
,	O
when	O
the	O
DTMF	O
system	O
was	O
designed	O
,	O
the	O
frequencies	O
were	O
chosen	O
to	O
minimize	O
tone	O
pairs	O
from	O
natural	O
sounds	O
[	O
18	O
].	O

The	O
described	O
robustness	O
of	O
DTMF	O
led	O
its	O
use	O
in	O
a	O
variety	O
of	O
current	O
remote	O
automation	O
systems	O
such	O
as	O
residential	O
alarm	O
monitoring	O
,	O
vehicle	O
tracking	O
systems	O
and	O
interactive	O
voice	O
response	O
systems	O
such	O
as	O
bank	O
’	O
s	O
automatic	O
answering	O
machines	O
menus	O
that	O
allows	O
the	O
user	O
to	O
execute	O
interactive	O
operations	O
like	O
“	O
Press	O
1	O
to	O
check	O
your	O
account	O
balance	O
;	O
Press	O
2	O
to	O
block	O
your	O
credit	O
card	O
”.	O

The	O
wide	O
adoption	O
and	O
reliability	O
of	O
the	O
DTMF	O
system	O
led	O
the	O
semiconductor	O
industry	O
to	O
develop	O
low	O
cost	O
integrated	O
circuits	O
(	O
ICs	O
)	O
that	O
can	O
encode	O
and	O
decode	O
DTMF	O
signals	O
from	O
and	O
to	O
digital	O
binary	O
digits	O
.	O

The	O
system	O
proposed	O
in	O
this	O
article	O
uses	O
such	O
ICs	O
to	O
transmit	O
and	O
receive	O
information	O
.	O

Both	O
actuators	O
control	O
and	O
sensors	O
data	O
are	O
encoded	O
using	O
DTMF	O
tones	O
.	O

The	O
following	O
sections	O
describe	O
the	O
system	O
design	O
.	O

Device	O
Control	O

To	O
control	O
actuators	O
,	O
a	O
mobile	O
device	O
generates	O
a	O
DTMF	O
tone	O
.	O

The	O
tone	O
is	O
decoded	O
by	O
a	O
commercial	O
DTMF	O
decoder	O
chip	O
(	O
such	O
as	O
the	O
MT8870	O
),	O
converting	O
the	O
tone	O
to	O
a	O
4	O
-	O
bit	O
binary	O
word	O
equivalent	O
to	O
the	O
DTMF	O
input	O
.	O

The	O
decoded	O
output	O
remains	O
present	O
while	O
the	O
DTMF	O
tone	O
is	O
present	O
at	O
the	O
input	O
.	O

The	O
resulting	O
bits	O
can	O
feed	O
a	O
power	O
circuit	O
to	O
control	O
up	O
to	O
four	O
independent	O
binary	O
(	O
on	O
/	O
off	O
)	O
devices	O
such	O
as	O
robots	O
brakes	O
,	O
lights	O
or	O
a	O
pneumatic	O
gripper	O
.	O
Figure	O
1	O
shows	O
the	O
basic	O
concept	O
of	O
the	O
system	O
.	O

The	O
audio	O
output	O
from	O
the	O
mobile	O
device	O
can	O
be	O
directly	O
connected	O
to	O
the	O
input	O
of	O
the	O
DTMF	O
decoder	O
,	O
but	O
in	O
some	O
specific	O
cases	O
an	O
audio	O
preamplifier	O
should	O
be	O
used	O
to	O
enhance	O
the	O
audio	O
amplitude	O
.	O

Figure	O
2	O
shows	O
a	O
direct	O
current	O
(	O
DC	O
)	O
motor	O
control	O
application	O
where	O
the	O
4	O
-	O
bit	O
output	O
of	O
the	O
decoder	O
is	O
connected	O
to	O
a	O
motor	O
control	O
circuit	O
(	O
an	O
H	O
-	O
bridge	O
,	O
for	O
example	O
,	O
using	O
the	O
L298	O
commercial	O
dual	O
H	O
-	O
bridge	O
IC	O
).	O

As	O
2	O
bits	O
are	O
required	O
to	O
control	O
each	O
motor	O
,	O
the	O
system	O
can	O
control	O
2	O
DC	O
motors	O
independently	O
.	O
Table	O
2	O
shows	O
the	O
DTMF	O
digits	O
and	O
corresponding	O
motor	O
states	O
.	O

Note	O
that	O
these	O
states	O
can	O
be	O
different	O
according	O
to	O
the	O
pin	O
connections	O
between	O
the	O
DTMF	O
decoder	O
and	O
the	O
H	O
-	O
bridge	O
.	O

In	O
order	O
to	O
control	O
the	O
DC	O
motor	O
’	O
s	O
speed	O
,	O
the	O
mobile	O
device	O
turns	O
the	O
DTMF	O
signals	O
on	O
and	O
off	O
in	O
a	O
fixed	O
frequency	O
,	O
mimicking	O
a	O
pulse	O
width	O
modulation	O
(	O
PWM	O
)	O
signal	O
.	O

To	O
control	O
more	O
devices	O
it	O
is	O
possible	O
to	O
take	O
advantage	O
of	O
the	O
fact	O
that	O
most	O
audio	O
outputs	O
of	O
mobile	O
devices	O
are	O
stereo	O
.	O

Thus	O
,	O
generating	O
different	O
audio	O
tones	O
in	O
the	O
left	O
and	O
right	O
channels	O
doubles	O
the	O
number	O
of	O
controlled	O
devices	O
(	O
8	O
different	O
on	O
/	O
off	O
devices	O
or	O
4	O
DC	O
motors	O
).	O

One	O
interesting	O
option	O
,	O
possible	O
only	O
in	O
devices	O
with	O
USB	O
Host	O
feature	O
,	O
such	O
as	O
netbooks	O
and	O
desktop	O
computers	O
,	O
is	O
to	O
add	O
low	O
cost	O
USB	O
multimedia	O
sound	O
devices	O
,	O
increasing	O
the	O
number	O
of	O
audio	O
ports	O
in	O
the	O
system	O
.	O

Another	O
possibility	O
consists	O
in	O
directly	O
connecting	O
servo	O
-	O
motors	O
(	O
the	O
ones	O
used	O
in	O
model	O
airplanes	O
)	O
control	O
signals	O
to	O
the	O
output	O
of	O
the	O
DTMF	O
decoder	O
.	O

As	O
each	O
servo	O
needs	O
only	O
one	O
PWM	O
input	O
signal	O
,	O
each	O
stereo	O
audio	O
channel	O
can	O
drive	O
up	O
to	O
eight	O
servo	O
-	O
motors	O
.	O

Sensor	O
Reading	O

Most	O
mechatronics	O
systems	O
and	O
sensor	O
networks	O
need	O
sensors	O
to	O
sense	O
the	O
surrounding	O
environment	O
and	O
their	O
own	O
state	O
in	O
order	O
to	O
decide	O
what	O
to	O
do	O
next	O
.	O

To	O
accomplish	O
this	O
task	O
in	O
this	O
system	O
,	O
sensors	O
are	O
connected	O
to	O
the	O
input	O
of	O
a	O
DTMF	O
encoder	O
chip	O
(	O
such	O
as	O
the	O
TCM5087	O
).	O

Each	O
time	O
a	O
sensor	O
state	O
changes	O
,	O
the	O
encoder	O
generates	O
a	O
DTMF	O
tone	O
that	O
is	O
captured	O
and	O
analyzed	O
by	O
the	O
mobile	O
device	O
.	O

According	O
to	O
the	O
digits	O
received	O
it	O
is	O
possible	O
to	O
know	O
which	O
sensor	O
generated	O
the	O
tone	O
.	O

More	O
details	O
on	O
how	O
to	O
identify	O
which	O
sensor	O
and	O
its	O
value	O
are	O
provided	O
in	O
Section	O
5	O
.	O
1	O
.	O

As	O
shown	O
in	O
Figure	O
3	O
,	O
up	O
to	O
four	O
sensors	O
can	O
be	O
connected	O
to	O
a	O
DTMF	O
encoder	O
that	O
generates	O
tones	O
according	O
to	O
the	O
sensors	O
states	O
.	O

The	O
generator	O
’	O
s	O
output	O
itself	O
is	O
connected	O
to	O
the	O
audio	O
input	O
of	O
the	O
mobile	O
device	O
which	O
continuously	O
samples	O
the	O
audio	O
input	O
checking	O
if	O
the	O
frequency	O
pair	O
that	O
characterizes	O
a	O
DTMF	O
digit	O
is	O
present	O
in	O
the	O
signal	O
.	O

To	O
accomplish	O
this	O
task	O
,	O
the	O
discrete	O
Fourier	O
transform	O
(	O
DFT	O
)	O
is	O
used	O
,	O
according	O
to	O
Equation	O
(	O
1	O
).	O
(	O
1	O
)	O
X	O
(	O
m	O
)=∑	O
n	O
=	O
0N	O
−	O
1x	O
(	O
n	O
)	O
e	O
−	O
j2πnm	O
/	O
Nwhere	O
X	O
(	O
m	O
)	O
is	O
the	O
frequency	O
magnitude	O
of	O
the	O
signal	O
under	O
analysis	O
at	O
index	O
m	O
,	O
x	O
(	O
n	O
)	O
is	O
the	O
input	O
sequence	O
in	O
time	O
(	O
representing	O
the	O
signal	O
)	O
with	O
n	O
index	O
and	O
N	O
is	O
the	O
DFT	O
number	O
of	O
points	O
.	O

N	O
determines	O
the	O
resolution	O
of	O
the	O
DFT	O
and	O
the	O
number	O
of	O
samples	O
to	O
be	O
analyzed	O
.	O

For	O
performance	O
reasons	O
,	O
a	O
Fast	O
Fourier	O
Transform	O
(	O
FFT	O
)	O
[	O
19	O
]	O
is	O
used	O
to	O
identify	O
the	O
frequency	O
components	O
of	O
the	O
input	O
signal	O
and	O
consequently	O
detect	O
the	O
DTMF	O
digit	O
generated	O
by	O
the	O
DTMF	O
generator	O
that	O
encodes	O
sensor	O
data	O
.	O

For	O
clear	O
and	O
detailed	O
information	O
about	O
these	O
digital	O
signal	O
processing	O
concepts	O
,	O
please	O
refer	O
to	O
Lyons	O
’	O
book	O
[	O
20	O
]	O
on	O
Digital	O
Signal	O
Processing	O
.	O

To	O
optimize	O
the	O
FFT	O
computation	O
it	O
is	O
necessary	O
to	O
specify	O
adequate	O
values	O
for	O
N	O
and	O
Fs	O
(	O
the	O
sample	O
rate	O
of	O
the	O
input	O
signal	O
).	O

From	O
Table	O
1	O
,	O
the	O
highest	O
frequency	O
present	O
in	O
a	O
DTMF	O
tone	O
is	O
1	O
,	O
633	O
Hz	O
.	O

Applying	O
the	O
fundamental	O
sampling	O
theorem	O
results	O
in	O
Fs	O
=	O
3	O
,	O
266	O
Hz	O
(	O
the	O
theorem	O
states	O
that	O
the	O
sample	O
rate	O
should	O
be	O
at	O
least	O
twice	O
the	O
highest	O
signal	O
to	O
be	O
captured	O
).	O

For	O
implementation	O
convenience	O
and	O
better	O
compatibility	O
,	O
a	O
8	O
KHz	O
sample	O
rate	O
is	O
used	O
,	O
which	O
most	O
mobile	O
devices	O
can	O
perform	O
.	O

The	O
lower	O
the	O
number	O
of	O
points	O
in	O
the	O
FFT	O
,	O
the	O
faster	O
the	O
FFT	O
is	O
computed	O
,	O
and	O
more	O
digits	O
per	O
second	O
can	O
be	O
recognized	O
,	O
leading	O
to	O
a	O
better	O
sensor	O
reading	O
frequency	O
.	O

To	O
compute	O
the	O
smallest	O
adequate	O
number	O
of	O
points	O
for	O
the	O
FFT	O
,	O
Equation	O
(	O
2	O
)	O
is	O
used	O
.	O
(	O
2	O
)	O
f	O
(	O
m	O
)=	O
mFsN	O

In	O
Equation	O
(	O
2	O
),	O
f	O
(	O
m	O
)	O
is	O
each	O
frequency	O
under	O
analysis	O
,	O
Fs	O
is	O
the	O
sampling	O
frequency	O
(	O
8	O
KHz	O
)	O
and	O
N	O
the	O
FFT	O
’	O
s	O
number	O
of	O
points	O
to	O
be	O
minimized	O
.	O

Using	O
N	O
=	O
256	O
,	O
results	O
in	O
an	O
analysis	O
resolution	O
of	O
about	O
30	O
Hz	O
,	O
that	O
is	O
enough	O
to	O
differ	O
from	O
one	O
DTMF	O
frequency	O
component	O
to	O
another	O
.	O

This	O
is	O
consistent	O
with	O
the	O
DFT	O
parameters	O
used	O
by	O
Chitode	O
to	O
detect	O
DTMF	O
digits	O
[	O
21	O
].	O

The	O
work	O
developed	O
by	O
Khan	O
also	O
uses	O
N	O
=	O
256	O
and	O
Fs	O
=	O
8	O
KHz	O
to	O
detect	O
DTMF	O
tones	O
[	O
22	O
].	O

Later	O
in	O
this	O
text	O
,	O
Section	O
5	O
.	O
1	O
and	O
Table	O
3	O
explains	O
the	O
use	O
and	O
application	O
of	O
this	O
technique	O
to	O
read	O
four	O
digital	O
(	O
on	O
/	O
off	O
)	O
sensors	O
simultaneously	O
.	O

One	O
of	O
the	O
limitations	O
of	O
the	O
described	O
method	O
is	O
that	O
it	O
is	O
restricted	O
to	O
binary	O
(	O
on	O
/	O
off	O
)	O
sensors	O
.	O

As	O
it	O
is	O
shown	O
is	O
Section	O
5	O
.	O
1	O
,	O
this	O
is	O
enough	O
for	O
many	O
applications	O
,	O
including	O
measuring	O
angles	O
and	O
speeds	O
using	O
incremental	O
optical	O
encoders	O
.	O

In	O
any	O
case	O
,	O
additional	O
electronics	O
could	O
be	O
used	O
to	O
encode	O
analog	O
signals	O
and	O
transmit	O
these	O
signals	O
using	O
the	O
audio	O
interface	O
.	O

As	O
each	O
DTMF	O
digit	O
encodes	O
4	O
bits	O
,	O
the	O
transmission	O
of	O
an	O
analog	O
value	O
converted	O
with	O
a	O
12	O
-	O
bit	O
analog	O
-	O
digital	O
converter	O
would	O
take	O
3	O
transmission	O
cycles	O
.	O

It	O
would	O
also	O
be	O
possible	O
to	O
use	O
digital	O
signal	O
multiplexing	O
hardware	O
to	O
encode	O
more	O
information	O
in	O
the	O
same	O
system	O
(	O
with	O
worse	O
performance	O
).	O

The	O
demultiplexing	O
would	O
be	O
done	O
in	O
the	O
mobile	O
device	O
by	O
software	O
.	O

Experimental	O
Results	O

In	O
order	O
to	O
evaluate	O
the	O
proposed	O
system	O
,	O
an	O
Android	O
application	O
was	O
developed	O
using	O
the	O
Android	O
development	O
kit	O
,	O
which	O
is	O
available	O
for	O
free	O
.	O

Experiments	O
were	O
executed	O
in	O
several	O
mobile	O
devices	O
and	O
desktop	O
computers	O
.	O

For	O
the	O
actuator	O
control	O
subsystem	O
,	O
experiments	O
showed	O
that	O
generating	O
PWM	O
signals	O
by	O
software	O
is	O
possible	O
,	O
but	O
the	O
resulting	O
signal	O
shows	O
variations	O
(	O
a	O
software	O
generated	O
PWM	O
with	O
1	O
ms	O
ON	O
time	O
and	O
1	O
ms	O
OFF	O
time	O
produces	O
a	O
real	O
signal	O
with	O
50	O
ms	O
ON	O
time	O
and	O
50	O
ms	O
OFF	O
time	O
).	O

A	O
better	O
option	O
is	O
to	O
use	O
pre	O
-	O
recorded	O
PWM	O
DTMF	O
tones	O
resulting	O
in	O
high	O
reliability	O
PWM	O
of	O
DTMF	O
tones	O
with	O
frequencies	O
greater	O
than	O
1	O
KHz	O
.	O

As	O
mobile	O
devices	O
have	O
mature	O
software	O
support	O
for	O
playing	O
pre	O
-	O
recorded	O
audio	O
,	O
the	O
PWM	O
plays	O
smoothly	O
with	O
low	O
processor	O
usage	O
.	O

In	O
these	O
experiments	O
it	O
was	O
also	O
observed	O
that	O
another	O
practical	O
way	O
of	O
doing	O
fine	O
speed	O
adjustments	O
consists	O
in	O
controlling	O
the	O
audio	O
output	O
volume	O
,	O
resulting	O
in	O
proportional	O
speed	O
changes	O
in	O
the	O
motor	O
(	O
s	O
).	O

Experiments	O
of	O
the	O
sensor	O
reading	O
subsystem	O
are	O
based	O
on	O
the	O
FFT	O
.	O

The	O
experiments	O
showed	O
that	O
in	O
the	O
worst	O
case	O
,	O
the	O
FFT	O
computation	O
time	O
is	O
17	O
ms	O
,	O
leading	O
to	O
a	O
theoretical	O
limit	O
of	O
executing	O
up	O
to	O
58	O
.	O
8	O
FFTs	O
per	O
second	O
.	O
Figure	O
4	O
shows	O
experimental	O
results	O
of	O
the	O
system	O
running	O
on	O
3	O
different	O
devices	O
.	O

The	O
tested	O
devices	O
were	O
an	O
early	O
Android	O
based	O
phone	O
,	O
the	O
HTC	O
G1	O
with	O
a	O
528	O
MHz	O
ARM	O
processor	O
,	O
an	O
Android	O
based	O
tablet	O
computer	O
with	O
a	O
dual	O
core	O
1	O
GHz	O
ARM	O
processor	O
and	O
a	O
1	O
GHz	O
PC	O
netbook	O
with	O
an	O
Intel	O
Celeron	O
processor	O
(	O
in	O
this	O
case	O
a	O
version	O
of	O
the	O
Android	O
operating	O
system	O
for	O
the	O
x86	O
architecture	O
was	O
used	O
).	O

The	O
FFT	O
was	O
implemented	O
using	O
Java	O
and	O
executed	O
in	O
the	O
virtual	O
machine	O
(	O
dalvik	O
)	O
of	O
the	O
Android	O
system	O
.	O

Using	O
the	O
native	O
development	O
system	O
for	O
Android	O
,	O
thus	O
bypassing	O
the	O
virtual	O
machine	O
,	O
would	O
enhance	O
these	O
results	O
.	O

Another	O
performance	O
improvement	O
can	O
be	O
reached	O
using	O
the	O
Goertzel	O
algorithm	O
[	O
23	O
,	O
24	O
].	O

From	O
Figure	O
4	O
it	O
is	O
possible	O
to	O
note	O
that	O
even	O
the	O
device	O
with	O
less	O
processing	O
power	O
is	O
able	O
to	O
handle	O
about	O
40	O
DTMF	O
digits	O
per	O
second	O
with	O
zero	O
packet	O
loss	O
.	O

There	O
are	O
several	O
causes	O
for	O
the	O
increasing	O
packet	O
loss	O
that	O
starts	O
at	O
40	O
Hz	O
in	O
the	O
plot	O
.	O

One	O
of	O
the	O
causes	O
are	O
the	O
different	O
audio	O
input	O
timings	O
[	O
25	O
]	O
caused	O
by	O
the	O
different	O
audio	O
hardware	O
of	O
each	O
device	O
.	O

Another	O
cause	O
is	O
related	O
to	O
the	O
task	O
scheduler	O
of	O
the	O
Android	O
operating	O
system	O
(	O
and	O
the	O
underlying	O
Linux	O
kernel	O
)	O
that	O
can	O
be	O
indeterministic	O
when	O
the	O
CPU	O
load	O
is	O
high	O
.	O

As	O
a	O
reference	O
for	O
comparison	O
,	O
some	O
performance	O
tests	O
were	O
made	O
in	O
a	O
Lego	O
Mindstorms	O
(	O
TM	O
)	O
robotics	O
kit	O
that	O
is	O
commonly	O
used	O
in	O
educational	O
robotics	O
and	O
some	O
scientific	O
researches	O
.	O

When	O
connected	O
to	O
a	O
computer	O
or	O
smartphone	O
via	O
a	O
bluetooth	O
wireless	O
link	O
,	O
the	O
maximum	O
sensor	O
reading	O
rate	O
of	O
the	O
Lego	O
-	O
NXT	O
brick	O
is	O
20	O
Hz	O
.	O

If	O
several	O
sensors	O
are	O
used	O
,	O
the	O
bandwidth	O
is	O
divided	O
.	O

For	O
example	O
,	O
using	O
2	O
encoders	O
and	O
2	O
touch	O
sensors	O
reduces	O
the	O
sensor	O
reading	O
rate	O
to	O
5	O
Hz	O
per	O
sensor	O
or	O
less	O
.	O

If	O
the	O
NXT	O
brick	O
is	O
connected	O
to	O
a	O
computer	O
using	O
the	O
USB	O
port	O
,	O
then	O
the	O
maximum	O
sensor	O
reading	O
frequency	O
rises	O
to	O
166	O
Hz	O
.	O

If	O
two	O
encoders	O
and	O
two	O
touch	O
sensors	O
(	O
bumpers	O
)	O
are	O
used	O
,	O
then	O
each	O
sensor	O
will	O
be	O
read	O
at	O
a	O
rate	O
of	O
41	O
.	O
5	O
Hz	O
.	O

The	O
performance	O
of	O
the	O
system	O
proposed	O
in	O
this	O
article	O
is	O
comparable	O
to	O
this	O
commercial	O
product	O
as	O
a	O
40	O
Hz	O
rate	O
can	O
be	O
sustained	O
for	O
each	O
sensor	O
in	O
a	O
system	O
with	O
4	O
sensors	O
.	O

Case	O
Study	O
Application	O

The	O
system	O
described	O
in	O
Section	O
3	O
can	O
be	O
applied	O
to	O
several	O
situations	O
where	O
a	O
computing	O
device	O
needs	O
to	O
control	O
actuators	O
and	O
read	O
sensors	O
,	O
such	O
as	O
laboratory	O
experiments	O
,	O
machine	O
control	O
and	O
robotics	O
.	O

In	O
this	O
section	O
,	O
a	O
mobile	O
robot	O
case	O
study	O
is	O
described	O
.	O

Low	O
Cost	O
Mobile	O
Robot	O

As	O
an	O
application	O
example	O
,	O
the	O
presented	O
technique	O
was	O
used	O
to	O
build	O
a	O
low	O
cost	O
educational	O
mobile	O
robot	O
.	O

For	O
the	O
Robot	O
’	O
s	O
frame	O
,	O
wheels	O
,	O
gears	O
and	O
two	O
motors	O
24	O
US	O
dollars	O
were	O
spent	O
.	O

For	O
electronics	O
parts	O
more	O
6	O
US	O
dollars	O
were	O
spent	O
summing	O
up	O
a	O
total	O
of	O
30	O
US	O
dollars	O
to	O
build	O
the	O
robot	O
.	O

As	O
most	O
people	O
own	O
a	O
mobile	O
phone	O
or	O
a	O
smartphone	O
,	O
there	O
is	O
the	O
assumption	O
that	O
the	O
control	O
device	O
will	O
not	O
have	O
to	O
be	O
bought	O
because	O
a	O
mobile	O
device	O
that	O
the	O
user	O
already	O
has	O
will	O
be	O
used	O
.	O

Even	O
if	O
the	O
control	O
device	O
needed	O
to	O
be	O
purchased	O
,	O
the	O
option	O
of	O
using	O
a	O
smartphone	O
would	O
still	O
be	O
good	O
because	O
single	O
board	O
computers	O
,	O
typically	O
used	O
in	O
robots	O
or	O
other	O
robot	O
computers	O
,	O
are	O
more	O
expensive	O
than	O
smartphones	O
.	O

Furthermore	O
,	O
smartphones	O
include	O
camera	O
,	O
battery	O
,	O
Internet	O
connection	O
and	O
a	O
variety	O
of	O
sensors	O
that	O
would	O
have	O
to	O
be	O
bought	O
separately	O
and	O
connected	O
to	O
the	O
robot	O
’	O
s	O
computer	O
.	O

With	O
multi	O
-	O
core	O
smartphones	O
running	O
with	O
clock	O
speeds	O
faster	O
than	O
1	O
GHz	O
and	O
with	O
512	O
MB	O
or	O
1	O
GB	O
of	O
RAM	O
memory	O
,	O
they	O
are	O
a	O
good	O
alternative	O
to	O
traditional	O
robots	O
computers	O
.	O

Important	O
sensors	O
in	O
such	O
kind	O
of	O
robot	O
are	O
the	O
bumpers	O
to	O
detect	O
collisions	O
and	O
encoders	O
to	O
compute	O
odometry	O
.	O
Figure	O
5	O
shows	O
a	O
block	O
diagram	O
connecting	O
bumpers	O
and	O
2	O
wheel	O
encoders	O
to	O
the	O
DTMF	O
generator	O
.	O
Table	O
3	O
shows	O
a	O
truth	O
table	O
with	O
the	O
possible	O
states	O
of	O
each	O
sensor	O
and	O
the	O
corresponding	O
DTMF	O
digits	O
.	O

Instead	O
of	O
using	O
commercial	O
encoders	O
discs	O
,	O
several	O
encoders	O
were	O
designed	O
and	O
printed	O
with	O
a	O
conventional	O
laser	O
printer	O
.	O

The	O
discs	O
were	O
glued	O
to	O
the	O
robot	O
’	O
s	O
wheels	O
and	O
a	O
standard	O
CNY70	O
light	O
reflection	O
sensor	O
was	O
mounted	O
in	O
front	O
of	O
each	O
disc	O
.	O

As	O
can	O
be	O
seen	O
in	O
Table	O
3	O
,	O
there	O
is	O
a	O
unique	O
DTMF	O
digit	O
that	O
corresponds	O
to	O
each	O
possible	O
sensor	O
state	O
.	O

Using	O
basic	O
binary	O
arithmetic	O
it	O
is	O
possible	O
to	O
obtain	O
the	O
individual	O
state	O
of	O
each	O
sensor	O
.	O

For	O
example	O
,	O
from	O
Table	O
3	O
it	O
is	O
known	O
that	O
the	O
bumpers	O
are	O
the	O
bits	O
0	O
and	O
1	O
.	O

Using	O
a	O
bitwise	O
AND	O
operation	O
with	O
the	O
binary	O
mask	O
0001	O
will	O
filter	O
all	O
other	O
sensor	O
states	O
and	O
the	O
result	O
will	O
be	O
either	O
0	O
or	O
1	O
,	O
indicating	O
the	O
left	O
bumper	O
state	O
.	O

For	O
the	O
right	O
bumper	O
,	O
the	O
same	O
AND	O
operation	O
can	O
be	O
applied	O
with	O
the	O
binary	O
mask	O
0010	O
.	O

Furthermore	O
,	O
using	O
the	O
binary	O
0011	O
mask	O
and	O
the	O
AND	O
operation	O
will	O
only	O
return	O
a	O
value	O
different	O
than	O
zero	O
if	O
both	O
bumpers	O
are	O
activate	O
at	O
the	O
same	O
time	O
.	O

Using	O
these	O
types	O
of	O
comparisons	O
it	O
is	O
then	O
possible	O
to	O
know	O
the	O
state	O
of	O
each	O
sensor	O
.	O

In	O
the	O
case	O
of	O
the	O
optical	O
encoders	O
,	O
the	O
system	O
’	O
s	O
software	O
monitors	O
for	O
state	O
transitions	O
and	O
add	O
a	O
unit	O
for	O
each	O
transition	O
to	O
a	O
counter	O
that	O
keeps	O
how	O
many	O
pulses	O
each	O
encoder	O
generated	O
.	O

As	O
seen	O
in	O
the	O
Figure	O
5	O
,	O
up	O
to	O
four	O
sensors	O
can	O
be	O
connected	O
to	O
each	O
mono	O
audio	O
channel	O
,	O
allowing	O
closed	O
loop	O
control	O
of	O
up	O
to	O
4	O
motors	O
if	O
4	O
encoders	O
are	O
used	O
.	O

Using	O
the	O
number	O
of	O
pulses	O
accounted	O
for	O
each	O
encoder	O
it	O
is	O
possible	O
to	O
compute	O
displacement	O
and	O
speed	O
for	O
each	O
wheel	O
as	O
it	O
is	O
done	O
with	O
other	O
incremental	O
encoders	O
.	O

This	O
information	O
can	O
be	O
used	O
in	O
classical	O
odometry	O
and	O
localization	O
systems	O
to	O
obtain	O
the	O
robot	O
’	O
s	O
position	O
in	O
a	O
Cartesian	O
space	O
[	O
26	O
,	O
27	O
].	O

To	O
properly	O
design	O
a	O
robot	O
with	O
the	O
presented	O
technique	O
,	O
a	O
relation	O
between	O
wheel	O
dimensions	O
and	O
the	O
maximum	O
linear	O
speed	O
that	O
can	O
be	O
measured	O
is	O
introduced	O
here	O
.	O

In	O
Equation	O
(	O
3	O
),	O
VMax	O
is	O
the	O
maximum	O
linear	O
speed	O
of	O
the	O
robot	O
that	O
can	O
be	O
measured	O
,	O
r	O
is	O
radius	O
of	O
the	O
wheel	O
,	O
c	O
is	O
the	O
maximum	O
digits	O
per	O
second	O
detection	O
capacity	O
of	O
the	O
mobile	O
device	O
and	O
s	O
is	O
the	O
encoder	O
disc	O
resolution	O
(	O
number	O
of	O
DTMF	O
digits	O
generated	O
at	O
each	O
complete	O
wheel	O
revolution	O
).	O
(	O
3	O
)	O
VMax	O
=	O
2πrcs	O

Table	O
4	O
shows	O
the	O
distance	O
measurement	O
resolution	O
and	O
maximum	O
speed	O
that	O
can	O
be	O
measured	O
according	O
to	O
the	O
given	O
equation	O
considering	O
several	O
encoder	O
resolutions	O
.	O

Figure	O
6	O
shows	O
odometry	O
experimental	O
results	O
for	O
this	O
low	O
cost	O
robot	O
.	O

The	O
error	O
bars	O
are	O
the	O
standard	O
deviation	O
of	O
the	O
real	O
displacement	O
that	O
occurred	O
.	O

The	O
blue	O
line	O
shows	O
the	O
real	O
traveled	O
distance	O
and	O
the	O
red	O
line	O
shows	O
the	O
distance	O
measured	O
by	O
the	O
mobile	O
phone	O
using	O
the	O
proposed	O
technique	O
.	O

Each	O
point	O
in	O
the	O
graph	O
is	O
the	O
average	O
value	O
of	O
ten	O
samples	O
.	O

According	O
to	O
McComb	O
and	O
Predko	O
,	O
odometry	O
errors	O
are	O
unavoidable	O
due	O
to	O
several	O
factors	O
such	O
as	O
wheels	O
’	O
slip	O
and	O
small	O
measurement	O
errors	O
in	O
the	O
wheel	O
radius	O
that	O
accumulate	O
over	O
time	O
.	O

They	O
say	O
that	O
a	O
displacements	O
of	O
6	O
to	O
9	O
meters	O
leads	O
to	O
15	O
centimeters	O
odometer	O
error	O
[	O
28	O
]	O
or	O
more	O
,	O
which	O
is	O
a	O
percentual	O
error	O
of	O
1	O
.	O
6	O
%–	O
2	O
.	O
5	O
%.	O

The	O
greatest	O
odometry	O
error	O
of	O
the	O
system	O
was	O
3	O
.	O
7	O
%	O
for	O
74	O
cm	O
range	O
.	O

But	O
for	O
130	O
cm	O
displacements	O
the	O
error	O
was	O
1	O
centimeter	O
(	O
0	O
.	O
76	O
%).	O

These	O
values	O
show	O
that	O
the	O
proposed	O
system	O
performance	O
is	O
consistent	O
with	O
classical	O
odometry	O
errors	O
described	O
in	O
the	O
literature	O
.	O

To	O
close	O
the	O
control	O
loop	O
,	O
the	O
computed	O
odometry	O
information	O
is	O
sent	O
to	O
a	O
classical	O
PI	O
(	O
Proportional	O
-	O
Integral	O
)	O
controller	O
that	O
has	O
as	O
set	O
-	O
points	O
(	O
or	O
goals	O
)	O
the	O
desired	O
distance	O
to	O
be	O
displaced	O
by	O
the	O
robot	O
.	O

The	O
encoders	O
are	O
read	O
at	O
a	O
40	O
Hz	O
rate	O
,	O
the	O
position	O
is	O
computed	O
and	O
sent	O
to	O
the	O
controller	O
to	O
decide	O
if	O
the	O
robot	O
has	O
to	O
go	O
faster	O
,	O
stop	O
or	O
walk	O
.	O

If	O
any	O
of	O
the	O
bumpers	O
are	O
activated	O
in	O
the	O
meantime	O
,	O
the	O
control	O
loop	O
is	O
interrupted	O
and	O
the	O
robot	O
immediately	O
stops	O
.	O

Although	O
most	O
mobile	O
devices	O
have	O
the	O
possibility	O
of	O
recording	O
and	O
reproducing	O
sounds	O
,	O
not	O
all	O
of	O
them	O
have	O
physical	O
connectors	O
for	O
both	O
the	O
audio	O
input	O
and	O
output	O
.	O

To	O
solve	O
this	O
problem	O
in	O
one	O
of	O
the	O
tested	O
devices	O
that	O
does	O
not	O
have	O
an	O
audio	O
input	O
connector	O
,	O
an	O
earphone	O
is	O
attached	O
near	O
the	O
built	O
-	O
in	O
microphone	O
of	O
the	O
device	O
using	O
a	O
suction	O
cup	O
.	O

In	O
this	O
particular	O
case	O
,	O
an	O
audio	O
preamplifier	O
must	O
be	O
used	O
to	O
generate	O
tones	O
with	O
sufficient	O
amplitude	O
to	O
be	O
detected	O
.	O

The	O
DTMF	O
tones	O
encoding	O
sensors	O
data	O
is	O
generated	O
,	O
amplified	O
and	O
sent	O
to	O
the	O
earphone	O
fixed	O
very	O
near	O
the	O
built	O
-	O
in	O
microphone	O
of	O
the	O
mobile	O
device	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
this	O
scheme	O
works	O
reliably	O
because	O
DTMF	O
system	O
was	O
designed	O
to	O
avoid	O
interference	O
from	O
natural	O
sounds	O
such	O
as	O
music	O
and	O
people	O
’	O
s	O
voices	O
[	O
18	O
].	O

Human	B-OG
Machine	O
Interface	O

Users	O
can	O
control	O
this	O
robot	O
from	O
the	O
web	O
or	O
using	O
voice	O
commands	O
.	O

Both	O
a	O
web	O
server	O
and	O
a	O
voice	O
recognition	O
system	O
were	O
implemented	O
.	O

The	O
web	O
-	O
server	O
is	O
embedded	O
into	O
the	O
application	O
,	O
therefore	O
no	O
intermediate	O
computers	O
or	O
servers	O
are	O
needed	O
.	O

Any	O
Internet	O
enabled	O
device	O
can	O
access	O
the	O
web	O
-	O
page	O
and	O
issue	O
several	O
commands	O
to	O
move	O
the	O
robot	O
forward	O
,	O
back	O
,	O
or	O
do	O
curves	O
.	O

For	O
debugging	O
purposes	O
the	O
web	O
-	O
server	O
also	O
shows	O
variable	O
values	O
such	O
as	O
distance	O
,	O
encoder	O
pulses	O
and	O
recognized	O
DTMF	O
pulses	O
from	O
sensors	O
.	O

The	O
voice	O
recognizer	O
system	O
is	O
straightforward	O
to	O
implement	O
thanks	O
to	O
the	O
Android	O
API	O
.	O

When	O
the	O
user	O
issues	O
a	O
voice	O
command	O
,	O
the	O
operating	O
systems	O
understands	O
it	O
(	O
in	O
several	O
languages	O
)	O
and	O
passes	O
a	O
vector	O
of	O
strings	O
to	O
the	O
robot	O
’	O
s	O
control	O
application	O
with	O
the	O
most	O
probable	O
phrases	O
said	O
.	O

The	O
application	O
just	O
has	O
to	O
select	O
the	O
one	O
that	O
better	O
fits	O
the	O
expected	O
command	O
.	O

Example	O
voice	O
commands	O
are	O
“	O
Walk	O
30	O
centimeters	O
”	O
or	O
“	O
Forward	O
1	O
meter	O
”.	O

The	O
numbers	O
said	O
by	O
the	O
user	O
are	O
automatically	O
converted	O
to	O
numeric	O
values	O
by	O
the	O
Android	O
API	O
,	O
making	O
it	O
easy	O
to	O
implement	O
softwares	O
that	O
makes	O
the	O
robot	O
move	O
for	O
some	O
distance	O
using	O
closed	O
loop	O
control	O
.	O

Distance	O
Measurement	O

An	O
important	O
sensor	O
to	O
aid	O
the	O
navigation	O
of	O
autonomous	O
mobile	O
robots	O
is	O
the	O
distance	O
measurement	O
from	O
the	O
robot	O
to	O
obstacles	O
in	O
front	O
of	O
it	O
.	O

This	O
task	O
is	O
typically	O
performed	O
by	O
ultrasound	O
or	O
laser	O
sensors	O
.	O

Another	O
approach	O
is	O
based	O
on	O
stereo	O
vision	O
,	O
but	O
the	O
computational	O
costs	O
are	O
high	O
.	O

To	O
support	O
distance	O
measurement	O
in	O
this	O
low	O
cost	O
robot	O
,	O
a	O
laser	O
module	O
(	O
laser	O
pointer	O
)	O
is	O
used	O
to	O
project	O
a	O
brilliant	O
red	O
dot	O
in	O
the	O
object	O
in	O
front	O
of	O
the	O
robot	O
.	O

The	O
camera	O
then	O
captures	O
a	O
frame	O
and	O
uses	O
the	O
projected	O
dot	O
position	O
on	O
its	O
image	O
plane	O
to	O
compute	O
the	O
distance	O
to	O
the	O
obstacle	O
based	O
on	O
simple	O
trigonometry	O
.	O

This	O
method	O
is	O
described	O
by	O
Danko	O
[	O
29	O
]	O
and	O
better	O
explained	O
by	O
Portugal	O
-	O
Zambrano	O
and	O
Mena	O
-	O
Chalco	O
[	O
30	O
].	O

The	O
algorithm	O
assumes	O
that	O
the	O
brightest	O
pixels	O
on	O
the	O
captured	O
image	O
are	O
on	O
the	O
laser	O
projected	O
dot	O
.	O

Figure	O
7	O
depicts	O
how	O
the	O
system	O
works	O
.	O

A	O
laser	O
pointer	O
parallel	O
to	O
the	O
camera	O
emits	O
a	O
focused	O
red	O
dot	O
that	O
is	O
projected	O
in	O
an	O
object	O
at	O
distance	O
D	O
from	O
the	O
robot	O
.	O

This	O
red	O
dot	O
is	O
reflected	O
and	O
projected	O
in	O
the	O
camera	O
’	O
s	O
image	O
plane	O
.	O

The	O
distance	O
pfc	O
(	O
pixels	O
from	O
center	O
)	O
between	O
the	O
center	O
of	O
the	O
image	O
plane	O
(	O
in	O
the	O
optical	O
axis	O
)	O
and	O
the	O
red	O
dot	O
in	O
the	O
image	O
plane	O
is	O
proportional	O
to	O
the	O
distance	O
D	O
.	O

Equation	O
(	O
4	O
)	O
shows	O
how	O
to	O
compute	O
the	O
distance	O
using	O
described	O
system	O
.	O

The	O
distance	O
between	O
the	O
camera	O
and	O
the	O
laser	O
(	O
H	O
)	O
is	O
known	O
previously	O
,	O
the	O
number	O
of	O
pixels	O
from	O
the	O
image	O
center	O
to	O
the	O
red	O
laser	O
dot	O
(	O
pfc	O
)	O
is	O
obtained	O
from	O
the	O
image	O
.	O

The	O
radians	O
per	O
pixels	O
(	O
rpc	O
)	O
and	O
the	O
radian	O
offset	O
(	O
ro	O
)	O
are	O
obtained	O
calibrating	O
the	O
system	O
,	O
which	O
consists	O
of	O
taking	O
several	O
measurements	O
of	O
objects	O
at	O
known	O
distances	O
and	O
their	O
pixels	O
distance	O
from	O
center	O
(	O
pfc	O
).	O

Then	O
a	O
linear	O
regression	O
algorithm	O
finds	O
the	O
best	O
ro	O
and	O
rpc	O
.	O

Details	O
on	O
this	O
calibration	O
can	O
be	O
found	O
on	O
the	O
work	O
of	O
Portugal	O
-	O
Zambrano	O
and	O
Mena	O
-	O
Chalco	O
[	O
30	O
].	O
(	O
4	O
)	O
D	O
=	O
Htan	O
(	O
pfc	O
*	O
rpc	O
+	O
ro	O

As	O
can	O
be	O
seem	O
in	O
Equation	O
(	O
4	O
),	O
the	O
measurement	O
range	O
depends	O
mainly	O
on	O
the	O
baseline	O
H	O
given	O
by	O
the	O
distance	O
between	O
the	O
laser	O
and	O
the	O
camera	O
and	O
the	O
number	O
of	O
pixels	O
from	O
the	O
image	O
center	O
,	O
pfc	O
,	O
that	O
has	O
a	O
limit	O
given	O
by	O
the	O
camera	O
resolution	O
.	O

This	O
equation	O
can	O
be	O
used	O
to	O
determine	O
the	O
measurement	O
range	O
.	O

As	O
the	O
object	O
gets	O
farther	O
away	O
,	O
its	O
pfc	O
tends	O
to	O
zero	O
.	O

Assuming	O
pfc	O
to	O
be	O
zero	O
it	O
is	O
possible	O
to	O
simplify	O
Equation	O
(	O
4	O
)	O
to	O
Equation	O
(	O
5	O
)	O
which	O
gives	O
the	O
maximum	O
distance	O
that	O
can	O
be	O
measured	O
.	O

In	O
the	O
same	O
way	O
,	O
the	O
minimum	O
distance	O
is	O
given	O
by	O
half	O
the	O
camera	O
resolution	O
(	O
because	O
the	O
measurement	O
is	O
made	O
from	O
the	O
point	O
to	O
the	O
center	O
of	O
image	O
).	O
Equation	O
(	O
6	O
)	O
specifies	O
the	O
minimum	O
measurement	O
distance	O
.	O
Table	O
5	O
shows	O
some	O
possible	O
range	O
values	O
computed	O
using	O
these	O
equations	O
.	O
(	O
5	O
)	O
Dmax	O
=	O
Htan	O
(	O
ro	O
)	O
(	O
6	O
)	O
Dmin	O
=	O
Htan	O
(	O
r2	O
*	O
rpc	O
+	O
ro	O
)	O

Block	O
Diagram	O

Figure	O
8	O
shows	O
a	O
block	O
diagram	O
of	O
the	O
system	O
.	O

Each	O
task	O
is	O
executed	O
in	O
a	O
separated	O
thread	O
,	O
thereby	O
reading	O
sensors	O
and	O
controlling	O
motors	O
do	O
not	O
interfere	O
with	O
each	O
other	O
.	O

A	O
task	O
planner	O
module	O
allows	O
the	O
system	O
to	O
integrate	O
the	O
distance	O
measurement	O
,	O
voice	O
commands	O
and	O
web	O
interface	O
.	O

The	O
system	O
running	O
with	O
all	O
these	O
subsystems	O
used	O
between	O
10	O
%	O
and	O
45	O
%	O
of	O
the	O
processor	O
in	O
all	O
devices	O
,	O
leaving	O
room	O
to	O
also	O
execute	O
complex	O
algorithms	O
embedded	O
on	O
the	O
robot	O
.	O

Experimental	O
Results	O

The	O
algorithm	O
implementation	O
is	O
straightforward	O
:	O
the	O
system	O
has	O
to	O
scan	O
a	O
region	O
of	O
the	O
image	O
for	O
a	O
group	O
of	O
pixels	O
with	O
the	O
greatest	O
values	O
(	O
255	O
)	O
in	O
the	O
red	O
channel	O
.	O

The	O
current	O
implementation	O
searches	O
for	O
a	O
pattern	O
of	O
5	O
pixels	O
in	O
a	O
cross	O
shape	O
.	O

The	O
center	O
of	O
this	O
cross	O
is	O
the	O
pfc	O
value	O
.	O
Figure	O
9	O
shows	O
the	O
results	O
for	O
3	O
different	O
distances	O
.	O

The	O
red	O
dot	O
found	O
by	O
the	O
algorithm	O
is	O
shown	O
by	O
a	O
green	O
circle	O
,	O
and	O
the	O
green	O
line	O
shows	O
the	O
distance	O
from	O
the	O
laser	O
dot	O
to	O
the	O
image	O
center	O
.	O

The	O
baseline	O
used	O
is	O
4	O
.	O
5	O
centimeters	O
and	O
after	O
executing	O
a	O
linear	O
regression	O
with	O
a	O
spreadsheet	O
,	O
the	O
calibration	O
values	O
found	O
are	O
ro	O
=	O
0	O
.	O
074	O
and	O
rpc	O
=	O
0	O
.	O
008579	O
.	O

Table	O
6	O
shows	O
experimental	O
results	O
of	O
the	O
system	O
.	O

The	O
average	O
error	O
is	O
2	O
.	O
55	O
%	O
and	O
the	O
maximum	O
observed	O
error	O
is	O
8	O
.	O
5	O
%,	O
which	O
happened	O
at	O
the	O
limit	O
of	O
the	O
measurement	O
range	O
.	O

The	O
range	O
of	O
operation	O
goes	O
from	O
15	O
cm	O
to	O
60	O
cm	O
,	O
but	O
that	O
can	O
be	O
changed	O
modifying	O
the	O
H	O
distance	O
.	O

The	O
advantage	O
of	O
such	O
system	O
is	O
that	O
the	O
processing	O
needed	O
is	O
very	O
low	O
:	O
the	O
system	O
has	O
to	O
find	O
the	O
brightest	O
red	O
dot	O
on	O
a	O
small	O
limited	O
region	O
of	O
interest	O
in	O
the	O
image	O
,	O
and	O
then	O
compute	O
the	O
distance	O
using	O
simple	O
trigonometric	O
relations	O
.	O

The	O
implementation	O
computes	O
distance	O
at	O
a	O
rate	O
of	O
9	O
frames	O
per	O
second	O
in	O
the	O
mobile	O
device	O
while	O
running	O
the	O
FFTs	O
and	O
closed	O
loop	O
control	O
system	O
described	O
.	O

This	O
makes	O
this	O
approach	O
an	O
interesting	O
solution	O
to	O
distance	O
measurement	O
in	O
robotics	O
systems	O
.	O

Figures	O
10	O
,	O
11	O
and	O
12	O
show	O
photos	O
of	O
the	O
robot	O
under	O
the	O
control	O
of	O
different	O
devices	O
.	O

Thanks	O
to	O
the	O
portability	O
of	O
the	O
Android	O
system	O
,	O
the	O
same	O
software	O
can	O
be	O
used	O
in	O
PC	O
computers	O
and	O
mobile	O
devices	O
using	O
ARM	O
processors	O
.	O

Although	O
a	O
proof	O
of	O
concept	O
was	O
developed	O
using	O
the	O
Android	O
operating	O
system	O
,	O
the	O
proposed	O
architecture	O
can	O
be	O
used	O
with	O
any	O
system	O
or	O
programming	O
language	O
that	O
can	O
produce	O
and	O
record	O
sounds	O
.	O

One	O
should	O
note	O
that	O
the	O
main	O
contribution	O
of	O
this	O
work	O
is	O
the	O
communication	O
scheme	O
,	O
so	O
these	O
photos	O
show	O
a	O
provisional	O
robot	O
’	O
s	O
assembly	O
setup	O
used	O
to	O
validate	O
the	O
proposed	O
architecture	O
for	O
robotics	O
.	O

Conclusions	O

This	O
paper	O
introduces	O
a	O
simple	O
but	O
universal	O
control	O
architecture	O
that	O
enables	O
a	O
wide	O
variety	O
of	O
devices	O
to	O
implement	O
control	O
of	O
mechatronics	O
and	O
automation	O
systems	O
.	O

The	O
method	O
can	O
be	O
used	O
to	O
implement	O
closed	O
loop	O
control	O
systems	O
in	O
mechatronics	O
systems	O
using	O
audio	O
channels	O
of	O
computing	O
devices	O
,	O
allowing	O
the	O
processing	O
unit	O
to	O
be	O
easily	O
replaced	O
without	O
the	O
need	O
of	O
pairing	O
or	O
special	O
configurations	O
.	O

Several	O
obsolete	O
and	O
current	O
devices	O
can	O
be	O
used	O
to	O
control	O
robots	O
such	O
as	O
PDAs	O
,	O
phones	O
and	O
computers	O
.	O

Even	O
an	O
MP3	O
player	O
could	O
be	O
used	O
if	O
control	O
without	O
feedback	O
is	O
needed	O
.	O

The	O
sound	O
produced	O
by	O
the	O
player	O
would	O
drive	O
the	O
motors	O
.	O

As	O
an	O
application	O
example	O
,	O
the	O
presented	O
method	O
is	O
used	O
to	O
build	O
a	O
mobile	O
robot	O
with	O
differential	O
drive	O
.	O

The	O
robot	O
’	O
s	O
complete	O
costs	O
,	O
including	O
frame	O
,	O
motors	O
,	O
sensors	O
and	O
electronics	O
is	O
less	O
than	O
30	O
US	O
dollars	O
(	O
in	O
small	O
quantities	O
),	O
and	O
the	O
parts	O
can	O
be	O
easily	O
found	O
in	O
stores	O
or	O
on	O
the	O
Internet	O
.	O

The	O
mentioned	O
price	O
does	O
not	O
include	O
the	O
mobile	O
device	O
.	O

The	O
method	O
can	O
be	O
used	O
for	O
several	O
applications	O
such	O
as	O
educational	O
robotics	O
,	O
low	O
cost	O
robotics	O
research	O
platforms	O
,	O
telepresence	O
robots	O
,	O
autonomous	O
and	O
remotely	O
controlled	O
robots	O
.	O

In	O
engineering	O
courses	O
it	O
is	O
also	O
a	O
motivation	O
for	O
students	O
to	O
learn	O
digital	O
signal	O
processing	O
theory	O
,	O
and	O
all	O
the	O
other	O
multidisciplinary	O
fields	O
involved	O
in	O
robotics	O
.	O

Another	O
interesting	O
application	O
of	O
this	O
system	O
is	O
to	O
build	O
sensor	O
networks	O
composed	O
of	O
smartphones	O
that	O
can	O
gather	O
data	O
from	O
their	O
internal	O
sensors	O
and	O
poll	O
external	O
sensors	O
via	O
audio	O
tones	O
,	O
allowing	O
sensor	O
networks	O
to	O
be	O
easily	O
built	O
and	O
scaled	O
using	O
commercial	O
off	O
-	O
the	O
-	O
shelf	O
mobile	O
devices	O
instead	O
of	O
specific	O
boards	O
and	O
development	O
kits	O
.	O

DTMF	O
decoder	O
with	O
four	O
independent	O
outputs	O
controlled	O
by	O
audio	O
from	O
a	O
mobile	O
device	O
.	O

Dual	O
motor	O
control	O
using	O
one	O
mono	O
audio	O
channel	O
.	O

Sensors	O
input	O
using	O
a	O
DTMF	O
generator	O
.	O

DTMF	O
digit	O
recognition	O
performance	O
in	O
different	O
devices	O
.	O

Sensors	O
connection	O
in	O
a	O
mobile	O
robot	O
with	O
differential	O
drive	O
.	O

Experimental	O
odometry	O
results	O
.	O

X	O
axis	O
is	O
the	O
real	O
traveled	O
distance	O
manually	O
measured	O
with	O
a	O
tape	O
measure	O
.	O

Y	O
axis	O
is	O
the	O
distance	O
computed	O
by	O
the	O
mobile	O
device	O
using	O
the	O
proposed	O
system	O
with	O
data	O
from	O
the	O
encoders	O
.	O

Distance	O
measurement	O
system	O
using	O
a	O
camera	O
and	O
a	O
laser	O
pointer	O
.	O

H	O
is	O
the	O
distance	O
between	O
the	O
camera	O
optical	O
axis	O
and	O
the	O
laser	O
pointer	O
,	O
D	O
the	O
distance	O
between	O
the	O
camera	O
and	O
the	O
object	O
,	O
theta	O
is	O
the	O
angle	O
between	O
the	O
camera	O
’	O
s	O
optical	O
axis	O
and	O
the	O
laser	O
reflected	O
by	O
the	O
object	O
.	O
pfc	O
(	O
pixels	O
from	O
center	O
)	O
is	O
the	O
distance	O
in	O
pixels	O
from	O
the	O
center	O
of	O
the	O
image	O
and	O
the	O
red	O
dot	O
.	O

Figure	O
adapted	O
from	O
Danko	O
and	O
Portugal	O
-	O
Zambrano	O
[	O
29	O
,	O
30	O
].	O

Block	O
diagram	O
of	O
the	O
robot	O
’	O
s	O
software	O
.	O

Image	O
seen	O
by	O
the	O
robot	O
’	O
s	O
camera	O
of	O
the	O
same	O
object	O
at	O
different	O
distances	O
.	O

Note	O
the	O
distance	O
of	O
the	O
laser	O
dot	O
to	O
the	O
image	O
center	O
(	O
shown	O
by	O
the	O
green	O
line	O
)	O
when	O
the	O
object	O
is	O
at	O
different	O
distances	O
.	O

Robot	O
under	O
the	O
control	O
of	O
a	O
mobile	O
phone	O
.	O

The	O
audio	O
input	O
and	O
output	O
channels	O
are	O
connected	O
in	O
a	O
single	O
connector	O
below	O
the	O
phone	O
.	O

Robot	O
under	O
the	O
control	O
of	O
a	O
tablet	O
computer	O
.	O

The	O
audio	O
output	O
is	O
driven	O
from	O
a	O
P2	O
connector	O
attached	O
to	O
the	O
earphone	O
jack	O
and	O
the	O
audio	O
input	O
is	O
captured	O
by	O
the	O
built	O
-	O
in	O
microphone	O
of	O
the	O
device	O
.	O

Note	O
the	O
suction	O
cup	O
holding	O
an	O
earphone	O
near	O
the	O
microphone	O
.	O

Robot	O
under	O
the	O
control	O
of	O
a	O
netbook	O
computer	O
.	O

Audio	O
input	O
and	O
output	O
channels	O
are	O
connected	O
with	O
independent	O
P2	O
connectors	O
.	O

This	O
is	O
the	O
most	O
common	O
case	O
for	O
computers	O
.	O

DTMF	O
frequencies	O
pairs	O
and	O
corresponding	O
digits	O
.	O

Adapted	O
from	O
the	O
Audio	O
Engineer	O
’	O
s	O
Reference	O
Book	O
[	O
17	O
].	O

1	O
,	O
209	O
Hz	O

1	O
,	O
336	O
Hz	O

1	O
,	O
477	O
Hz	O

1	O
,	O
633	O
Hz	O

697	O
Hz	O

1	O

2	O

3	O

A	O

770	O
Hz	O

4	O

5	O

6	O

B	O

852	O
Hz	O

7	O

8	O

9	O

C	O

941	O
Hz	O

*	O

0	O

#	O

D	O

DTMF	O
digits	O
and	O
corresponding	O
motors	O
states	O
.	O

DTMF	O
digit	O

Binary	O
word	O

Motor	O
state	O

Motor	O
A	O

Motor	O
B	O

None	O

00	O
00	O

Stopped	O

Stopped	O

D	O

00	O
00	O

Stopped	O

Stopped	O

1	O

00	O
01	O

Stopped	O

Left	O
spin	O

2	O

00	O
10	O

Stopped	O

Right	O
spin	O

3	O

00	O
11	O

Stopped	O

Invalid	O

4	O

01	O
00	O

Left	O
spin	O

Stopped	O

5	O

01	O
01	O

Left	O
spin	O

Left	O
spin	O

6	O

01	O
10	O

Left	O
spin	O

Right	O
spin	O

7	O

01	O
11	O

Left	O
spin	O

Invalid	O

8	O

10	O
00	O

Right	O
spin	O

Stopped	O

9	O

10	O
01	O

Right	O
spin	O

Left	O
spin	O

0	O

10	O
10	O

Right	O
spin	O

Right	O
spin	O

*	O

10	O
11	O

Right	O
spin	O

Invalid	O

#	O

11	O
00	O

Invalid	O

Stopped	O

A	O

11	O
01	O

Invalid	O

Left	O
spin	O

B	O

11	O
10	O

Invalid	O

Right	O
spin	O

C	O

11	O
11	O

Invalid	O

Invalid	O

Truth	O
table	O
used	O
with	O
4	O
sensors	O
input	O
used	O
in	O
the	O
case	O
study	O
robot	O
.	O

Left	O
Encoder	O
(	O
bit	O
3	O
)	O

Right	O
encoder	O
(	O
bit	O
2	O
)	O

Right	O
bumper	O
(	O
bit	O
1	O
)	O

Left	O
bumper	O
(	O
bit	O
0	O
)	O

DTMF	O
Digit	O

0	O

0	O

0	O

0	O

0	O

0	O

0	O

0	O

1	O

1	O

0	O

0	O

1	O

0	O

2	O

0	O

0	O

1	O

1	O

3	O

0	O

1	O

0	O

0	O

4	O

0	O

1	O

0	O

1	O

5	O

0	O

1	O

1	O

0	O

6	O

0	O

1	O

1	O

1	O

7	O

1	O

0	O

0	O

0	O

8	O

1	O

0	O

0	O

1	O

9	O

1	O

0	O

1	O

0	O

A	O

1	O

0	O

1	O

1	O

B	O

1	O

1	O

0	O

0	O

C	O

1	O

1	O

0	O

1	O

D	O

1	O

1	O

1	O

0	O

*	O

1	O

1	O

1	O

1	O

#	O

Encoder	O
resolution	O
,	O
displacement	O
measurement	O
resolution	O
and	O
maximum	O
speed	O
that	O
can	O
be	O
measured	O
(	O
considering	O
r	O
=	O
25	O
mm	O
and	O
s	O
=	O
40	O
DTMF	O
digits	O
per	O
second	O
).	O

Encoder	O
resolution	O
(	O
digits	O
per	O
revolution	O
)	O

Displacement	O
resolution	O

Maximum	O
speed	O

1	O

157	O
mm	O

6	O
,	O
283	O
mm	O
/	O
s	O

6	O

26	O
mm	O

1	O
,	O
047	O
mm	O
/	O
s	O

12	O

13	O
mm	O

571	O
mm	O
/	O
s	O

24	O

6	O
.	O
5	O
mm	O

261	O
mm	O
/	O
s	O

40	O

3	O
.	O
92	O
mm	O

157	O
mm	O
/	O
s	O

Measurement	O
range	O
for	O
a	O
VGA	O
camera	O
(	O
640	O
×	O
480	O
).	O

All	O
values	O
in	O
centimeters	O
.	O

H	O

Measurement	O
Range	O

Minimum	O

Maximum	O

0	O
.	O
5	O

1	O
.	O
74	O

6	O
.	O
74	O

1	O

3	O
.	O
48	O

13	O
.	O
48	O

4	O
.	O
5	O

15	O
.	O
65	O

60	O
.	O
68	O

10	O

34	O
.	O
79	O

134	O
.	O
86	O

Distance	O
measurement	O
results	O
using	O
a	O
mobile	O
phone	O
camera	O
.	O

Real	O
distance	O
(	O
cm	O
)	O

Measured	O
distance	O
(	O
cm	O
)	O

Error	O
(%)	O

16	O

16	O
.	O
02	O

0	O
.	O
12	O

20	O

20	O
.	O
30	O

1	O
.	O
50	O

25	O

25	O
.	O
29	O

1	O
.	O
16	O

30	O

29	O
.	O
70	O

1	O
.	O
00	O

35	O

35	O
.	O
43	O

1	O
.	O
22	O

40	O

39	O
.	O
79	O

0	O
.	O
50	O

45	O

43	O
.	O
80	O

2	O
.	O
66	O

50	O

47	O
.	O
80	O

4	O
.	O
40	O

55	O

52	O
.	O
57	O

4	O
.	O
41	O

60	O

54	O
.	O
90	O

8	O
.	O
50	O

Human	B-OG
β	B-GP
-	I-GP
Defensin	I-GP
3	I-GP
Reduces	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
Inflammation	O
and	O
Monocyte	O
Adhesion	O
in	O
Human	B-OG
Umbilical	O
Vein	O
Endothelial	O
Cells	O

Academic	O
Editor	O
:	O
Ulrich	O
Eisel	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
(	O
hBD3	B-GP
)	O
in	O
the	O
initiation	O
stage	O
of	O
atherosclerosis	B-DS
with	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
triggered	O
by	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
(	I-GP
TNF	I-GP
-)	I-GP
α	I-GP
.	O

The	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
injury	O
and	O
inflammatory	O
response	O
were	O
evaluated	O
.	O

Our	O
data	O
revealed	O
that	O
first	O
,	O
hBD3	B-GP
reduced	O
the	O
production	O
of	O
interleukin	B-GP
-	I-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
IL	B-GP
-	I-GP
8	I-GP
,	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
-	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
),	O
and	O
macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
in	O
HUVECs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
hBD3	B-GP
significantly	O
prevented	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
by	O
HUVECs	O
.	O

Second	O
,	O
western	O
blot	O
analysis	O
demonstrated	O
that	O
hBD3	B-GP
dose	O
-	O
dependently	O
suppressed	O
the	O
protein	O
levels	O
of	O
intracellular	B-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
ICAM	B-GP
-	I-GP
1	I-GP
)	O
and	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
VCAM	B-GP
-	I-GP
1	I-GP
)	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
HUVECs	O
.	O

As	O
a	O
result	O
,	O
hBD3	B-GP
inhibited	O
monocyte	O
adhesion	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
endothelial	O
cells	O
.	O

Additionally	O
,	O
hBD3	B-GP
suppressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
F	B-GP
-	I-GP
actin	I-GP
reorganization	O
in	O
HUVECs	O
.	O

Third	O
,	O
hBD3	B-GP
markedly	O
inhibited	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
by	O
decreasing	O
the	O
phosphorylation	O
of	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
,	O
IκB	B-GP
,	O
and	O
p65	B-GP
subunit	O
within	O
30	O
min	O
.	O

Moreover	O
,	O
the	O
phosphorylation	O
of	O
p38	B-GP
and	O
c	B-GP
-	I-GP
Jun	I-GP
N	I-GP
-	I-GP
terminal	I-GP
protein	I-GP
kinase	I-GP
(	O
JNK	B-GP
)	O
in	O
the	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	O
MAPK	B-GP
)	O
pathway	O
were	O
also	O
inhibited	O
by	O
hBD3	B-GP
in	O
HUVECs	O
.	O

In	O
conclusion	O
,	O
hBD3	B-GP
exerts	O
anti	O
-	O
inflammatory	O
and	O
antioxidative	O
effects	O
in	O
endothelial	O
cells	O
in	O
response	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
by	O
inhibiting	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
signaling	O
.	O

1	O
.	O

Introduction	O

Atherosclerosis	B-DS
is	O
a	O
vascular	B-DS
inflammatory	I-DS
disease	I-DS
characterized	O
by	O
the	O
accumulation	O
of	O
lipids	O
and	O
immune	O
cells	O
on	O
the	O
inner	O
face	O
of	O
the	O
arterial	O
wall	O
.	O

Inflammatory	O
stimulation	O
,	O
even	O
low	O
level	O
endotoxemia	O
,	O
can	O
aggravate	O
the	O
progression	O
of	O
this	O
disease	O
[	O
1	O
].	O

A	O
monolayer	O
of	O
endothelial	O
cells	O
,	O
which	O
directly	O
contacts	O
the	O
flowing	O
blood	O
,	O
is	O
easily	O
attacked	O
by	O
various	O
stimulating	O
factors	O
.	O

Endothelial	O
cell	O
dysfunction	O
triggered	O
by	O
such	O
stimulations	O
is	O
believed	O
to	O
be	O
the	O
initiation	O
step	O
and	O
key	O
contributor	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
[	O
2	O
].	O

Endothelial	O
cells	O
at	O
sites	O
of	O
inflammation	O
are	O
not	O
only	O
participants	O
but	O
also	O
regulators	O
of	O
inflammation	O
[	O
3	O
,	O
4	O
].	O

During	O
inflammation	O
,	O
a	O
large	O
amount	O
of	O
inflammatory	O
mediators	O
are	O
produced	O
by	O
immune	O
cells	O
,	O
such	O
as	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
are	O
the	O
main	O
targets	O
.	O

Then	O
,	O
the	O
activated	O
endothelial	O
cells	O
secrete	O
a	O
broad	O
spectrum	O
of	O
cytokines	B-GP
and	O
chemokines	B-GP
,	O
recruiting	O
monocytes	O
.	O

Enhanced	O
migration	O
and	O
adhesion	O
of	O
monocytes	O
to	O
the	O
endothelium	O
are	O
suggested	O
to	O
play	O
a	O
crucial	O
role	O
in	O
atherosclerosis	B-DS
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
required	O
for	O
the	O
firm	O
binding	O
of	O
monocytes	O
is	O
also	O
upregulated	O
on	O
endothelial	O
cell	O
surfaces	O
[	O
5	O
].	O

In	O
our	O
previous	O
study	O
,	O
the	O
results	O
demonstrated	O
that	O
chronic	O
exposure	O
to	O
the	O
endotoxin	O
of	O
Porphyromonas	B-OG
gingivalis	I-OG
can	O
aggravate	O
atherosclerotic	O
lesions	O
in	O
ApoE	B-GP
-	O
deficient	O
mice	B-OG
[	O
6	O
].	O

Indeed	O
,	O
compelling	O
evidence	O
has	O
demonstrated	O
the	O
proatherogenic	O
role	O
of	O
inflammatory	B-GP
cytokines	I-GP
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	O
markers	O
in	O
the	O
circulation	O
are	O
risk	O
factors	O
for	O
atherosclerotic	O
events	O
[	O
7	O
].	O

Tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
one	O
of	O
the	O
most	O
potent	O
inflammatory	B-GP
cytokines	I-GP
,	O
is	O
closely	O
associated	O
with	O
atherosclerosis	B-DS
.	O

It	O
is	O
mainly	O
produced	O
by	O
activated	O
macrophages	O
.	O

It	O
is	O
a	O
pleiotropic	O
cytokine	B-GP
mediating	O
inflammation	O
,	O
immunity	O
,	O
and	O
apoptosis	O
.	O

For	O
vascular	O
endothelial	O
cells	O
,	O
exposure	O
to	O
TNF	B-GP
-	I-GP
α	I-GP
triggers	O
several	O
signaling	O
cascades	O
in	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
),	O
especially	O
the	O
nuclear	B-GP
factor	I-GP
κB	I-GP
(	O
NF	B-GP
-	I-GP
κB	I-GP
),	O
c	B-GP
-	I-GP
Jun	I-GP
N	I-GP
-	I-GP
terminal	I-GP
kinase	I-GP
(	O
JNK	B-GP
),	O
and	O
p38	B-GP
mitogen	I-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
pathways	O
,	O
leading	O
to	O
the	O
production	O
of	O
inflammatory	B-GP
cytokines	I-GP
[	O
8	O
].	O

In	O
addition	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
can	O
reorganize	O
the	O
F	B-GP
-	I-GP
actin	I-GP
cytoskeleton	O
of	O
endothelial	O
cells	O
,	O
leading	O
to	O
the	O
formation	O
of	O
stress	O
fibers	O
[	O
9	O
].	O

TNF	B-GP
-	I-GP
α	I-GP
can	O
also	O
modulate	O
EC	O
permeability	O
by	O
enlarging	O
intercellular	O
gaps	O
,	O
promoting	O
vascular	O
leakage	O
at	O
sites	O
of	O
inflammation	O
[	O
10	O
].	O

TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
is	O
also	O
associated	O
with	O
increased	O
intracellular	O
levels	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
formation	O
,	O
enhancing	O
monocyte	O
recruitment	O
and	O
adhesion	O
to	O
the	O
vascular	O
endothelium	O
.	O

This	O
process	O
is	O
mediated	O
mainly	O
by	O
elevated	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
such	O
as	O
intercellular	B-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
ICAM	B-GP
-	I-GP
1	I-GP
),	O
vascular	B-GP
cell	I-GP
adhesion	I-GP
molecule	I-GP
-	I-GP
1	I-GP
(	O
VCAM	B-GP
-	I-GP
1	I-GP
),	O
and	O
endothelial	B-GP
cell	I-GP
selectin	I-GP
(	O
E	B-GP
-	I-GP
selectin	I-GP
).	O

Defensins	B-CD
are	O
naturally	O
occurring	O
peptides	O
with	O
a	O
wide	O
range	O
of	O
antimicrobial	O
,	O
antiviral	O
,	O
and	O
immunomodulatory	O
properties	O
.	O

They	O
are	O
cationic	O
,	O
cysteine	B-CD
-	O
rich	O
,	O
β	O
-	O
sheet	O
,	O
and	O
tridisulfide	O
peptides	O
.	O

In	O
humans	B-OG
,	O
defensins	B-GP
are	O
classified	O
into	O
two	O
categories	O
,	O
α	O
-	O
and	O
β	B-GP
-	I-GP
defensins	I-GP
.	O
β	B-GP
-	I-GP
defensins	I-GP
are	O
mainly	O
produced	O
by	O
the	O
mucosa	O
and	O
epithelial	O
cells	O
.	O

Intraocular	O
tissues	O
and	O
the	O
human	B-OG
endometrium	O
are	O
also	O
reported	O
to	O
express	O
β	B-GP
-	I-GP
defensins	I-GP
[	O
11	O
].	O

Several	O
studies	O
have	O
documented	O
the	O
participation	O
of	O
antimicrobial	B-GP
peptides	I-GP
in	O
endothelial	O
immune	O
defense	O
[	O
12	O
,	O
13	O
].	O

In	O
addition	O
,	O
β	B-GP
-	I-GP
defensins	I-GP
are	O
beneficial	O
for	O
wound	O
healing	O
of	O
endothelial	O
cells	O
[	O
14	O
].	O

Human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
(	O
hBD3	B-GP
)	O
is	O
a	O
member	O
of	O
the	O
β	B-GP
-	I-GP
defensin	I-GP
family	O
.	O

In	O
addition	O
to	O
epithelial	O
cells	O
,	O
hBD3	B-GP
is	O
also	O
expressed	O
in	O
endothelial	O
cells	O
.	O

The	O
gene	O
and	O
protein	O
expression	O
of	O
hBD3	B-GP
are	O
induced	O
in	O
human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
simulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
[	O
15	O
].	O

The	O
upregulation	O
of	O
hBD3	B-GP
by	O
TNF	B-GP
-	I-GP
α	I-GP
in	O
HUVECs	O
illustrates	O
the	O
important	O
role	O
that	O
defensins	B-GP
play	O
in	O
host	O
immune	O
defense	O
against	O
inflammation	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
hBD3	B-GP
strongly	O
inhibited	O
the	O
progression	O
of	O
early	O
-	O
stage	O
atherosclerotic	O
lesions	O
and	O
inflammation	O
levels	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
and	O
human	B-OG
THP	O
-	O
1	O
-	O
derived	O
macrophages	O
[	O
16	O
,	O
17	O
].	O

However	O
,	O
the	O
cell	O
types	O
targeted	O
by	O
hBD3	B-GP
might	O
not	O
be	O
restricted	O
to	O
macrophages	O
.	O

Vascular	O
endothelial	O
cells	O
and	O
monocytes	O
/	O
macrophages	O
are	O
both	O
atherogenic	O
and	O
critical	O
components	O
in	O
the	O
process	O
of	O
atherogenesis	O
[	O
18	O
].	O

The	O
interaction	O
between	O
macrophages	O
and	O
endothelial	O
cells	O
is	O
very	O
crucial	O
in	O
atherosclerosis	B-DS
.	O

In	O
normal	O
conditions	O
,	O
resting	O
endothelial	O
cells	O
form	O
an	O
integrated	O
barrier	O
at	O
the	O
blood	O
-	O
tissue	O
interface	O
.	O

Upon	O
inflammatory	O
stimulation	O
,	O
quiescent	O
endothelial	O
cells	O
may	O
transform	O
into	O
a	O
proatherogenic	O
phenotype	O
,	O
inducing	O
the	O
infiltration	O
of	O
monocytes	O
[	O
19	O
].	O

The	O
recruited	O
monocytes	O
then	O
differentiate	O
into	O
macrophages	O
,	O
contributing	O
to	O
a	O
vicious	O
cycle	O
promoting	O
endothelial	B-DS
dysfunction	I-DS
[	O
20	O
].	O

As	O
the	O
endothelium	O
has	O
already	O
been	O
a	O
therapeutic	O
target	O
,	O
hBD3	B-GP
might	O
also	O
manifest	O
its	O
protective	O
effects	O
by	O
interacting	O
with	O
vessel	O
endothelial	O
cells	O
.	O

The	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
activation	O
remain	O
unknown	O
.	O

Thus	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
focus	O
on	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
endothelial	B-DS
cell	I-DS
dysfunction	I-DS
,	O
including	O
the	O
enhanced	O
production	O
of	O
inflammatory	O
mediators	O
,	O
monocyte	O
adhesion	O
,	O
and	O
the	O
expression	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
,	O
all	O
of	O
which	O
are	O
early	O
events	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
.	O

2	O
.	O

Materials	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Cell	O
Culture	O
and	O
Reagents	O

Human	B-OG
primary	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
(	O
ScienCell	O
Research	O
Laboratories	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
were	O
maintained	O
in	O
endothelial	O
cell	O
medium	O
(	O
ECM	O
)	O
(	O
ScienCell	O
Research	O
Laboratories	O
)	O
supplemented	O
with	O
5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	B-CD
/	O
streptomycin	B-CD
,	O
and	O
1	O
%	O
endothelial	O
cell	O
growth	O
supplement	O
(	O
ECGS	O
).	O

For	O
the	O
present	O
study	O
,	O
cells	O
at	O
passages	O
3	O
–	O
6	O
were	O
seeded	O
and	O
grown	O
until	O
confluence	O
.	O

Recombinant	O
human	B-OG
TNF	B-GP
-	I-GP
α	I-GP
and	O
hBD3	B-GP
were	O
obtained	O
from	O
PeproTech	O
(	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
).	O

Anti	O
-	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
anti	O
-	O
VCAM	B-GP
-	I-GP
1	I-GP
antibodies	B-GP
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
).	O

Antiphosphorylated	O
and	O
total	O
IκBα	B-GP
,	O
p65	B-GP
,	O
p38	B-GP
,	O
ERK	B-GP
,	O
and	O
JNK	B-GP
antibodies	B-GP
were	O
purchased	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Beverly	O
,	O
MA	O
).	O

2	O
.	O
2	O
.	O

Cell	O
Viability	O
Assay	O

The	O
cell	O
viability	O
of	O
HUVECs	O
was	O
determined	O
using	O
a	O
CCK8	O
assay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

HUVECs	O
(	O
5000	O
cells	O
/	O
well	O
)	O
were	O
prepared	O
in	O
96	O
-	O
well	O
plates	O
and	O
incubated	O
overnight	O
before	O
treatment	O
with	O
various	O
concentrations	O
of	O
hBD3	B-GP
(	O
20	O
,	O
10	O
,	O
5	O
,	O
2	O
.	O
5	O
,	O
or	O
1	O
.	O
25	O
μg	O
/	O
mL	O
)	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Subsequently	O
,	O
10	O
μL	O
of	O
CCK8	B-GP
solution	O
(	O
Dojindo	O
Laboratories	O
,	O
Kumamoto	O
,	O
Japan	O
)	O
was	O
added	O
to	O
each	O
well	O
,	O
and	O
the	O
cells	O
were	O
incubated	O
for	O
an	O
additional	O
3	O
h	O
.	O

The	O
optical	O
density	O
of	O
each	O
well	O
was	O
evaluated	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
on	O
a	O
microplate	O
spectrophotometer	O
.	O

2	O
.	O
3	O
.	O

Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O

HUVECs	O
were	O
seeded	O
and	O
cultured	O
in	O
a	O
96	O
-	O
well	O
plate	O
until	O
confluent	O
.	O

The	O
control	O
group	O
was	O
treated	O
with	O
ECM	O
and	O
the	O
other	O
seven	O
groups	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

Then	O
the	O
cell	O
supernatants	O
were	O
collected	O
by	O
centrifugation	O
.	O

The	O
assay	O
was	O
performed	O
with	O
specific	O
ELISA	O
kits	O
(	O
R	O
&	O
D	O
Systems	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

2	O
.	O
4	O
.	O

Monocyte	O
Adhesion	O
Assay	O

Confluent	O
HUVECs	O
were	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
washed	O
with	O
RPMI	O
-	O
1640	O
medium	O
before	O
being	O
cocultured	O
with	O
THP	O
-	O
1	O
cells	O
.	O

THP	O
-	O
1	O
cells	O
were	O
prelabeled	O
with	O
2	O
μM	O
calcein	B-CD
-	I-CD
AM	I-CD
(	O
Dojindo	O
Laboratories	O
)	O
in	O
RPMI	O
-	O
1640	O
medium	O
for	O
20	O
min	O
in	O
the	O
cell	O
incubator	O
before	O
being	O
added	O
to	O
each	O
well	O
of	O
HUVECs	O
and	O
further	O
incubated	O
for	O
30	O
min	O
.	O

After	O
coincubation	O
,	O
each	O
well	O
was	O
washed	O
gently	O
and	O
thoroughly	O
with	O
RPMI	O
-	O
1640	O
medium	O
supplemented	O
with	O
1	O
%	O
FBS	O
to	O
remove	O
the	O
nonadherent	O
THP	O
-	O
1	O
cells	O
.	O

The	O
attached	O
THP	O
-	O
1	O
cells	O
were	O
examined	O
under	O
a	O
microscope	O
(	O
Olympus	O
Corporation	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
fluorescence	O
microplate	O
reader	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
490	O
nm	O
and	O
515	O
nm	O
.	O

2	O
.	O
5	O
.	O

Western	O
Blot	O
Analysis	O

The	O
cells	O
were	O
lysed	O
in	O
RIPA	O
buffer	O
supplemented	O
with	O
protease	B-GP
inhibitors	O
for	O
30	O
min	O
,	O
and	O
the	O
whole	O
cell	O
lysates	O
were	O
separated	O
by	O
electrophoresis	O
in	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gels	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
then	O
transferred	O
to	O
PVDF	O
membranes	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
).	O

The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
BSA	B-GP
at	O
room	O
temperature	O
for	O
2	O
h	O
before	O
incubation	O
overnight	O
with	O
primary	O
antibodies	B-GP
against	O
the	O
target	O
protein	O
.	O

Blots	O
were	O
washed	O
with	O
Tris	O
-	O
buffered	O
saline	O
containing	O
0	O
.	O
1	O
%	O
Tween	B-CD
20	I-CD
three	O
times	O
and	O
then	O
incubated	O
for	O
2	O
h	O
with	O
anti	O
-	O
rabbit	B-OG
secondary	O
antibody	B-GP
at	O
room	O
temperature	O
.	O

The	O
bands	O
were	O
detected	O
using	O
chemiluminescence	O
detection	O
agents	O
.	O

Images	O
were	O
captured	O
with	O
an	O
ImageQuant	O
LAS	O
4000	O
digital	O
imaging	O
system	O
(	O
GE	O
Healthcare	O
,	O
Piscataway	O
,	O
NJ	O
).	O

2	O
.	O
6	O
.	O

Immunofluorescence	O
Analysis	O

HUVECs	O
were	O
seeded	O
onto	O
sterile	O
glass	O
coverslips	O
in	O
a	O
12	O
-	O
well	O
cell	O
culture	O
plate	O
.	O

After	O
incubation	O
overnight	O
,	O
the	O
cells	O
were	O
treated	O
with	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
under	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
for	O
the	O
indicated	O
time	O
.	O

Subsequently	O
,	O
the	O
cells	O
were	O
washed	O
and	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
20	O
min	O
at	O
room	O
temperature	O
and	O
then	O
treated	O
with	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
for	O
15	O
min	O
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
blocked	O
with	O
3	O
%	O
BSA	B-GP
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
cells	O
were	O
further	O
incubated	O
with	O
the	O
indicated	O
rabbit	B-OG
primary	O
antibody	B-GP
at	O
4	O
°	O
C	O
overnight	O
,	O
followed	O
by	O
incubation	O
with	O
a	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
secondary	O
antibody	B-GP
conjugated	O
to	O
Alexa	O
Fluor	O
488	O
(	O
for	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
)	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
)	O
or	O
Alexa	O
Fluor	O
594	O
(	O
for	O
ICAM	B-GP
-	I-GP
1	I-GP
)	O
(	O
1	O
:	O
1000	O
,	O
Abcam	O
)	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

The	O
slides	O
were	O
then	O
mounted	O
with	O
one	O
drop	O
of	O
mounting	O
medium	O
that	O
contained	O
DAPI	O
.	O

NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
and	O
ICAM	B-GP
-	I-GP
1	I-GP
were	O
imaged	O
using	O
a	O
confocal	O
microscope	O
.	O

ICAM	B-GP
-	I-GP
1	I-GP
was	O
visualized	O
as	O
red	O
and	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
was	O
visualized	O
as	O
green	O
,	O
with	O
nuclei	O
as	O
blue	O
.	O

2	O
.	O
7	O
.	O

Measurement	O
of	O
Intracellular	O
Reactive	O
Oxygen	O
Species	O

Intracellular	O
ROS	O
formation	O
was	O
determined	O
with	O
DCFH	O
-	O
DA	O
(	O
KeyGEN	O
,	O
Jiangsu	O
,	O
China	O
).	O

HUVECs	O
were	O
seeded	O
in	O
black	O
96	O
-	O
well	O
plates	O
.	O

Subsequently	O
,	O
the	O
cells	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
with	O
or	O
without	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
2	O
h	O
.	O

The	O
cells	O
were	O
then	O
washed	O
with	O
PBS	O
and	O
incubated	O
with	O
20	O
μM	O
DCFH	O
-	O
DA	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
in	O
the	O
dark	O
.	O

The	O
fluorescence	O
level	O
was	O
determined	O
using	O
a	O
fluorescence	O
microplate	O
reader	O
at	O
an	O
excitation	O
wavelength	O
of	O
485	O
nm	O
and	O
an	O
emission	O
wavelength	O
of	O
530	O
nm	O
.	O

2	O
.	O
8	O
.	O

F	B-GP
-	I-GP
Actin	I-GP
Staining	O

Human	B-OG
umbilical	O
vein	O
endothelial	O
cells	O
were	O
cultured	O
and	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
as	O
indicated	O
.	O

Then	O
,	O
the	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
at	O
room	O
temperature	O
for	O
20	O
min	O
.	O

After	O
that	O
,	O
the	O
actin	B-GP
cytoskeleton	O
was	O
stained	O
with	O
DyLight	O
488	O
-	O
phalloidin	B-CD
,	O
and	O
the	O
nuclei	O
were	O
stained	O
with	O
DAPI	O
.	O

Stained	O
HUVECs	O
were	O
visualized	O
using	O
a	O
confocal	O
microscope	O
(	O
Olympus	O
FV	O
10i	O
).	O

2	O
.	O
9	O
.	O

Statistical	O
Analysis	O

Data	O
are	O
expressed	O
as	O
the	O
means	O
±	O
SD	O
.	O

Comparison	O
between	O
different	O
treatments	O
was	O
performed	O
using	O
GraphPad	O
PRISM	O
software	O
version	O
6	O
.	O
0	O
using	O
one	O
-	O
way	O
ANOVA	O
with	O
Tukey	O
'	O
s	O
post	O
hoc	O
test	O
.	O

Statistical	O
significance	O
was	O
set	O
at	O
p	O
values	O
<	O
0	O
.	O
05	O
.	O

3	O
.	O

Results	O

3	O
.	O
1	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Viability	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
Endothelial	O
Cells	O

Numerous	O
studies	O
have	O
demonstrated	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
can	O
impair	O
endothelial	O
cell	O
viability	O
and	O
induce	O
apoptosis	O
.	O

First	O
,	O
we	O
evaluated	O
the	O
cytotoxic	O
effects	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
on	O
HUVECs	O
using	O
a	O
CCK8	O
assay	O
.	O

All	O
data	O
are	O
expressed	O
as	O
the	O
survival	O
percentage	O
of	O
each	O
group	O
relative	O
to	O
the	O
control	O
group	O
,	O
which	O
is	O
defined	O
as	O
100	O
%.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
at	O
a	O
concentration	O
of	O
40	O
ng	O
/	O
mL	O
could	O
markedly	O
suppress	O
the	O
proliferation	O
of	O
HUVECs	O
by	O
nearly	O
50	O
%.	O

In	O
addition	O
,	O
treatment	O
with	O
hBD3	B-GP
at	O
5	O
μg	O
/	O
mL	O
and	O
10	O
μg	O
/	O
mL	O
markedly	O
recovered	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
impaired	O
cell	O
viability	O
to	O
about	O
79	O
.	O
1	O
%	O
and	O
101	O
.	O
7	O
%,	O
respectively	O
.	O

The	O
results	O
also	O
suggested	O
that	O
hBD3	B-GP
does	O
not	O
influence	O
the	O
viability	O
of	O
HUVECs	O
.	O

3	O
.	O
2	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Production	O
of	O
Proinflammatory	O
Mediators	O
by	O
Endothelial	O
Cells	O
Stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
endothelial	O
cell	O
activation	O
stimulated	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

Endothelial	O
cells	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
produce	O
proinflammatory	O
mediators	O
,	O
including	O
interleukin	B-GP
-	I-GP
(	I-GP
IL	I-GP
-)	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
-	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
),	O
which	O
cause	O
more	O
monocytes	O
to	O
be	O
recruited	O
.	O

These	O
proinflammatory	O
mediators	O
are	O
reported	O
to	O
aggravate	O
endothelial	B-DS
dysfunction	I-DS
.	O

As	O
shown	O
in	O
Figure	O
2	O
(	O
a	O
),	O
when	O
the	O
cells	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
for	O
24	O
h	O
,	O
IL	B-GP
-	I-GP
8	I-GP
production	O
in	O
the	O
supernatant	O
was	O
significantly	O
elevated	O
;	O
however	O
,	O
with	O
hBD3	B-GP
intervention	O
,	O
IL	B-GP
-	I-GP
8	I-GP
level	O
was	O
markedly	O
and	O
dose	O
-	O
dependently	O
inhibited	O
.	O

The	O
same	O
trend	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
MCP	B-GP
-	I-GP
1	I-GP
was	O
also	O
observed	O
in	O
Figures	O
2	O
(	O
b	O
)	O
and	O
2	O
(	O
c	O
).	O

Macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
is	O
a	O
key	O
factor	O
mediating	O
the	O
interactions	O
between	O
macrophages	O
and	O
endothelial	O
cells	O
[	O
21	O
].	O

It	O
is	O
considered	O
to	O
interact	O
with	O
other	O
proinflammatory	O
cytokines	B-GP
during	O
inflammation	O
.	O

There	O
is	O
evidence	O
showing	O
it	O
is	O
a	O
potent	O
activator	O
of	O
macrophages	O
released	O
by	O
activated	O
endothelial	O
cells	O
.	O

The	O
release	O
of	O
MIF	B-GP
by	O
HUVECs	O
was	O
markedly	O
inhibited	O
in	O
response	O
to	O
hBD3	B-GP
treatment	O
(	O
Figure	O
2	O
(	O
d	O
)).	O

3	O
.	O
3	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Expression	O
of	O
Adhesion	B-GP
Molecules	I-GP
by	O
HUVECs	O

Accumulated	O
evidence	O
supports	O
a	O
role	O
for	O
adhesion	B-GP
molecules	I-GP
in	O
the	O
progression	O
of	O
atherosclerosis	B-DS
.	O

ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
are	O
constitutively	O
expressed	O
on	O
the	O
surface	O
of	O
HUVECs	O
,	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
is	O
only	O
expressed	O
on	O
the	O
activated	O
endothelium	O
[	O
22	O
].	O

The	O
interaction	O
of	O
E	B-GP
-	I-GP
selectin	I-GP
and	O
leukocytes	O
mediates	O
the	O
rolling	O
of	O
leukocytes	O
on	O
the	O
activated	O
endothelium	O
,	O
which	O
is	O
the	O
first	O
event	O
in	O
firm	O
adhesion	O
.	O

TNF	B-GP
-	I-GP
α	I-GP
is	O
known	O
to	O
transiently	O
upregulate	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
,	O
such	O
as	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
,	O
in	O
HUVECs	O
[	O
23	O
].	O

We	O
then	O
evaluated	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
induced	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

As	O
demonstrated	O
in	O
Figure	O
3	O
(	O
a	O
),	O
treatment	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
significantly	O
enhanced	O
the	O
expression	O
level	O
of	O
ICAM	B-GP
-	I-GP
1	I-GP
(	O
24	O
h	O
),	O
VCAM	B-GP
-	I-GP
1	I-GP
(	O
24	O
h	O
),	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
(	O
4	O
h	O
).	O

In	O
addition	O
,	O
hBD3	B-GP
treatment	O
dose	O
-	O
dependently	O
prevented	O
the	O
upregulation	O
of	O
ICAM	B-GP
-	I-GP
1	I-GP
,	O
VCAM	B-GP
-	I-GP
1	I-GP
,	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
levels	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

The	O
immunofluorescence	O
staining	O
assay	O
also	O
validated	O
the	O
inhibitory	O
effects	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
on	O
ICAM	B-GP
-	I-GP
1	I-GP
expression	O
levels	O
triggered	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
Figure	O
3	O
(	O
b	O
)).	O

3	O
.	O
4	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
Monocyte	O
Adhesion	O
to	O
Endothelial	O
Cells	O

During	O
the	O
initiation	O
of	O
atherosclerosis	B-DS
,	O
endothelial	O
cells	O
are	O
activated	O
and	O
upregulate	O
adhesion	B-GP
molecules	I-GP
and	O
chemokine	B-GP
and	O
cytokine	B-GP
secretion	O
,	O
which	O
is	O
beneficial	O
for	O
monocyte	O
recruitment	O
.	O

Due	O
to	O
the	O
significant	O
decrease	O
in	O
cell	B-GP
surface	I-GP
adhesion	I-GP
molecules	I-GP
and	O
proinflammatory	O
mediators	O
in	O
hBD3	B-GP
-	O
treated	O
HUVECs	O
,	O
we	O
investigated	O
whether	O
hBD3	B-GP
could	O
affect	O
the	O
attachment	O
of	O
immune	O
cells	O
to	O
endothelial	O
cells	O
.	O

To	O
evaluate	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
THP	O
-	O
1	O
monocyte	O
adhesion	O
to	O
HUVECs	O
in	O
a	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
proinflammatory	O
environment	O
,	O
HUVECs	O
were	O
seeded	O
and	O
cultured	O
to	O
about	O
90	O
%	O
confluence	O
and	O
then	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Subsequently	O
,	O
HUVECs	O
were	O
cocultured	O
with	O
prelabeled	O
THP	O
-	O
1	O
cells	O
for	O
30	O
min	O
.	O

After	O
removal	O
of	O
nonadherent	O
THP	O
-	O
1	O
cells	O
by	O
gentle	O
washing	O
,	O
images	O
were	O
captured	O
under	O
a	O
fluorescence	O
microscope	O
.	O

As	O
shown	O
in	O
Figures	O
4	O
(	O
a	O
)	O
and	O
4	O
(	O
b	O
),	O
we	O
observed	O
that	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
resulted	O
in	O
a	O
4	O
-	O
fold	O
increase	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
THP	O
-	O
1	O
attachment	O
to	O
HUVECs	O
.	O

However	O
,	O
hBD3	B-GP
intervention	O
significantly	O
decreased	O
THP	O
-	O
1	O
adhesion	O
to	O
HUVECs	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
5	O
.	O

hBD3	B-GP
Suppressed	O
Activation	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
Pathways	O
in	O
HUVECs	O

NF	B-GP
-	I-GP
κB	I-GP
is	O
considered	O
as	O
an	O
important	O
regulator	O
of	O
the	O
proinflammatory	O
process	O
and	O
monocyte	O
adhesion	O
.	O

To	O
identify	O
the	O
probable	O
molecular	O
mechanism	O
responsible	O
for	O
hBD3	B-GP
involvement	O
in	O
the	O
modulation	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
HUVECs	O
,	O
we	O
first	O
evaluated	O
the	O
classical	O
NF	B-GP
-	I-GP
κB	I-GP
signaling	O
pathway	O
.	O

Here	O
,	O
we	O
show	O
that	O
hBD3	B-GP
strongly	O
inhibits	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
HUVECs	O
via	O
two	O
distinct	O
signaling	O
pathways	O
,	O
an	O
NF	B-GP
-	I-GP
κB	I-GP
-	O
dependent	O
pathway	O
and	O
the	O
MAPK	B-GP
pathway	O
.	O

We	O
examined	O
key	O
factors	O
in	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
with	O
western	O
blot	O
.	O

Activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
required	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IκB	B-GP
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
a	O
),	O
degradation	O
and	O
phosphorylation	O
of	O
IκB	B-GP
were	O
significantly	O
suppressed	O
by	O
the	O
addition	O
of	O
hBD3	B-GP
.	O

The	O
effective	O
role	O
of	O
hBD3	B-GP
to	O
prevent	O
phosphorylation	O
of	O
p65	B-GP
subunit	O
was	O
also	O
observed	O
.	O

In	O
addition	O
,	O
phosphorylated	O
IKKα	B-GP
,	O
which	O
is	O
the	O
upstream	O
modulator	O
in	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
was	O
also	O
inhibited	O
by	O
hBD3	B-GP
.	O

To	O
validate	O
this	O
result	O
,	O
immunofluorescence	O
staining	O
was	O
used	O
to	O
determine	O
NF	B-GP
-	I-GP
κB	I-GP
nuclear	O
translocation	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
b	O
),	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
was	O
predominantly	O
located	O
within	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
.	O

With	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
,	O
p65	B-GP
translocated	O
to	O
the	O
nucleus	O
within	O
30	O
min	O
.	O

However	O
,	O
treatment	O
with	O
hBD3	B-GP
at	O
15	O
μg	O
/	O
mL	O
led	O
to	O
retention	O
of	O
the	O
p65	B-GP
subunit	O
in	O
the	O
cytoplasm	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
cells	O
.	O

We	O
then	O
investigated	O
the	O
role	O
of	O
the	O
MAPK	B-GP
pathway	O
in	O
this	O
process	O
.	O

The	O
key	O
components	O
of	O
the	O
MAPK	B-GP
pathway	O
,	O
p38	B-GP
,	O
ERK	B-GP
,	O
and	O
JNK	B-GP
were	O
evaluated	O
with	O
a	O
western	O
blot	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
(	O
c	O
),	O
treatment	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
resulted	O
in	O
a	O
significant	O
increase	O
of	O
phosphorylation	O
in	O
the	O
MAPK	B-GP
pathway	O
.	O

The	O
phosphorylation	O
of	O
p38	B-GP
and	O
JNK	B-GP
was	O
significantly	O
and	O
concentration	O
-	O
dependently	O
suppressed	O
by	O
hBD3	B-GP
at	O
30	O
min	O
,	O
while	O
the	O
phosphorylation	O
of	O
ERK	B-GP
was	O
not	O
altered	O
.	O

The	O
cell	O
lysates	O
obtained	O
at	O
45	O
min	O
also	O
validated	O
this	O
result	O
.	O

3	O
.	O
6	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
the	O
Activation	O
of	O
Caspases	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
Expression	O
in	O
HUVECs	O

TNF	B-GP
-	I-GP
α	I-GP
has	O
been	O
reported	O
to	O
stimulate	O
apoptosis	O
in	O
HUVECs	O
.	O

In	O
addition	O
,	O
the	O
cleavage	O
of	O
caspase	B-GP
-	I-GP
3	I-GP
is	O
a	O
key	O
step	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
cell	O
death	O
.	O

Before	O
activation	O
,	O
caspase	B-GP
-	I-GP
3	I-GP
exists	O
as	O
an	O
inactive	O
form	O
.	O

After	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treatment	O
,	O
caspase	B-GP
-	I-GP
3	I-GP
was	O
cleaved	O
to	O
the	O
active	O
form	O
.	O

The	O
activation	O
of	O
caspases	B-GP
is	O
considered	O
one	O
mechanism	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
the	O
activation	O
of	O
caspases	B-GP
.	O

HUVECs	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
for	O
6	O
h	O
.	O

The	O
expression	O
levels	O
of	O
caspase	B-GP
-	I-GP
3	I-GP
were	O
examined	O
with	O
western	O
blot	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
expression	O
levels	O
of	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
significantly	O
increased	O
following	O
TNF	B-GP
-	I-GP
α	I-GP
treatment	O
,	O
while	O
hBD3	B-GP
markedly	O
suppressed	O
this	O
phenomenon	O
.	O

Meanwhile	O
,	O
we	O
examined	O
the	O
expression	O
level	O
of	O
Bcl	B-GP
-	I-GP
2	I-GP
.	O

As	O
shown	O
in	O
Figure	O
6	O
,	O
there	O
was	O
a	O
clear	O
decrease	O
in	O
the	O
expression	O
of	O
Bcl	B-GP
-	I-GP
2	I-GP
after	O
treatment	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

These	O
results	O
suggested	O
that	O
hBD3	B-GP
inhibited	O
the	O
apoptosis	O
of	O
HUVECs	O
stimulated	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

3	O
.	O
7	O
.	O

hBD3	B-GP
Suppressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
ROS	O
Formation	O
in	O
HUVECs	O

It	O
has	O
been	O
suggested	O
that	O
the	O
enhanced	O
production	O
of	O
intracellular	O
ROS	O
can	O
lead	O
to	O
cell	O
apoptosis	O
.	O

To	O
measure	O
the	O
potential	O
modulation	O
of	O
apoptosis	O
and	O
oxidative	O
stress	O
by	O
hBD3	B-GP
,	O
the	O
production	O
of	O
ROS	O
was	O
evaluated	O
for	O
fluorescence	O
intensity	O
in	O
HUVECs	O
.	O

As	O
revealed	O
in	O
Figure	O
7	O
(	O
a	O
),	O
HUVECs	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
produced	O
an	O
intracellular	O
burst	O
of	O
ROS	O
(	O
about	O
3	O
.	O
9	O
-	O
fold	O
change	O
).	O

The	O
intracellular	O
ROS	O
production	O
in	O
HUVECs	O
was	O
significantly	O
suppressed	O
when	O
treated	O
with	O
hBD3	B-GP
.	O

However	O
,	O
the	O
basal	O
level	O
of	O
ROS	O
was	O
not	O
altered	O
by	O
treatment	O
with	O
hBD3	B-GP
alone	O
.	O

3	O
.	O
8	O
.	O

hBD3	B-GP
Repressed	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
Induced	O
F	B-GP
-	I-GP
Actin	I-GP
Reorganization	O
in	O
HUVECs	O

TNF	B-GP
-	I-GP
α	I-GP
is	O
reported	O
to	O
have	O
the	O
ability	O
to	O
alter	O
the	O
permeability	O
and	O
morphology	O
of	O
endothelial	O
cells	O
.	O

To	O
investigate	O
the	O
role	O
of	O
hBD3	B-GP
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
function	O
,	O
HUVECs	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

Then	O
,	O
the	O
cells	O
were	O
fixed	O
and	O
stained	O
with	O
phalloidin	B-CD
.	O

As	O
shown	O
in	O
Figure	O
8	O
,	O
stimulating	O
HUVECs	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
formation	O
of	O
actin	B-GP
stress	O
fibers	O
.	O

In	O
addition	O
,	O
hBD3	B-GP
treatment	O
markedly	O
reduced	O
this	O
alteration	O
in	O
HUVECs	O
.	O

4	O
.	O

Discussion	O

Atherosclerosis	B-DS
is	O
defined	O
as	O
a	O
chronic	O
inflammatory	O
-	O
fibroproliferative	O
response	O
of	O
the	O
vascular	O
wall	O
to	O
various	O
forms	O
of	O
inflammatory	O
stimuli	O
.	O

Disruption	O
of	O
the	O
endothelial	O
cell	O
barrier	O
induced	O
by	O
proinflammatory	O
cytokines	B-GP
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
is	O
the	O
initiating	O
step	O
of	O
this	O
disease	O
.	O

Endothelial	O
cells	O
maintain	O
vascular	O
homeostasis	O
via	O
the	O
secretion	O
of	O
several	O
vasoactive	O
factors	O
,	O
and	O
impairment	O
of	O
barrier	O
integrity	O
leads	O
to	O
the	O
development	O
of	O
vascular	B-DS
inflammatory	I-DS
diseases	I-DS
,	O
such	O
as	O
atherosclerosis	B-DS
.	O

As	O
a	O
monolayer	O
in	O
direct	O
contact	O
with	O
the	O
bloodstream	O
,	O
the	O
vascular	O
endothelium	O
is	O
the	O
principal	O
physiological	O
target	O
of	O
the	O
proinflammatory	O
actions	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
1	I-GP
.	O

Extensive	O
evidence	O
has	O
suggested	O
that	O
the	O
endothelium	O
is	O
not	O
simply	O
the	O
inner	O
cellular	O
lining	O
of	O
blood	O
vessels	O
[	O
24	O
].	O

Beyond	O
being	O
passively	O
targeted	O
,	O
endothelial	O
cells	O
are	O
believed	O
to	O
be	O
profoundly	O
involved	O
in	O
this	O
inflammatory	O
process	O
,	O
especially	O
in	O
the	O
regulation	O
of	O
effector	O
cells	O
,	O
such	O
as	O
monocytes	O
and	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
endothelium	O
may	O
act	O
as	O
a	O
therapeutic	O
target	O
due	O
to	O
its	O
critical	O
role	O
in	O
the	O
inflammatory	O
process	O
[	O
25	O
].	O

Macrophage	B-GP
migration	I-GP
inhibitory	I-GP
factor	I-GP
(	O
MIF	B-GP
)	O
is	O
one	O
of	O
the	O
most	O
important	O
cytokines	B-GP
produced	O
by	O
endothelial	O
cells	O
to	O
control	O
the	O
accumulation	O
of	O
effector	O
cells	O
[	O
26	O
].	O

It	O
is	O
recognized	O
as	O
an	O
effective	O
activator	O
of	O
macrophages	O
,	O
participating	O
in	O
the	O
process	O
of	O
recruitment	O
and	O
the	O
accumulation	O
of	O
macrophages	O
at	O
local	O
inflammatory	O
sites	O
.	O

As	O
monocyte	O
adhesion	O
to	O
the	O
endothelium	O
is	O
a	O
crucial	O
step	O
in	O
the	O
early	O
stages	O
of	O
atherosclerosis	B-DS
,	O
MIF	B-GP
is	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DS
and	O
is	O
closely	O
related	O
to	O
plaque	O
stability	O
[	O
27	O
].	O

Elevated	O
MIF	B-GP
expression	O
was	O
observed	O
in	O
response	O
to	O
some	O
immunostimulants	O
in	O
HUVECs	O
[	O
28	O
].	O

In	O
our	O
experiment	O
,	O
the	O
production	O
of	O
MIF	B-GP
was	O
markedly	O
increased	O
under	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
in	O
HUVECs	O
,	O
while	O
treatment	O
with	O
hBD3	B-GP
dose	O
-	O
dependently	O
reduced	O
MIF	B-GP
expression	O
.	O

This	O
result	O
was	O
also	O
confirmed	O
by	O
the	O
effect	O
of	O
hBD3	B-GP
in	O
inhibiting	O
the	O
adhesion	O
of	O
monocytes	O
to	O
endothelial	O
cells	O
.	O

A	O
prominent	O
feature	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
injury	O
is	O
the	O
excess	O
generation	O
of	O
intracellular	O
ROS	O
.	O

Moderate	O
levels	O
of	O
ROS	O
have	O
been	O
reported	O
to	O
participate	O
in	O
the	O
physiological	O
functions	O
of	O
cells	O
,	O
while	O
the	O
overproduction	O
of	O
intracellular	O
ROS	O
is	O
closely	O
associated	O
with	O
the	O
progression	O
of	O
atherosclerosis	B-DS
[	O
29	O
,	O
30	O
].	O

Oxidative	O
stress	O
activates	O
endothelial	O
cells	O
,	O
causing	O
cell	O
injury	O
,	O
apoptosis	O
,	O
and	O
enhanced	O
monocyte	O
adhesion	O
.	O

In	O
the	O
present	O
study	O
,	O
treatment	O
with	O
hBD3	B-GP
attenuated	O
ROS	O
production	O
in	O
HUVECs	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

The	O
binding	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
to	O
cell	B-GP
surface	I-GP
receptors	I-GP
triggers	O
multiple	O
signaling	O
events	O
,	O
including	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
pathway	O
.	O

NF	B-GP
-	I-GP
κB	I-GP
has	O
been	O
demonstrated	O
to	O
be	O
a	O
key	O
transcription	B-GP
factor	I-GP
in	O
this	O
signaling	O
pathway	O
.	O

Activation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
closely	O
associated	O
with	O
the	O
initiation	O
and	O
progression	O
of	O
atherosclerosis	B-DS
.	O

In	O
resting	O
cells	O
,	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
maintained	O
in	O
an	O
inactive	O
form	O
within	O
the	O
cytoplasm	O
by	O
the	O
inhibitor	B-GP
of	I-GP
κB	I-GP
(	O
IκB	B-GP
)	O
family	O
but	O
enters	O
the	O
nucleus	O
in	O
response	O
to	O
external	O
stimuli	O
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

IκB	B-GP
kinase	I-GP
-	O
(	O
IKK	B-GP
-)	O
dependent	O
phosphorylation	O
and	O
the	O
subsequent	O
ubiquitination	O
and	O
degradation	O
of	O
IκB	B-GP
make	O
NF	B-GP
-	I-GP
κB	I-GP
free	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
induce	O
downstream	O
transcription	O
[	O
31	O
].	O

NF	B-GP
-	I-GP
κB	I-GP
has	O
been	O
identified	O
as	O
an	O
important	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerosis	B-DS
.	O

Our	O
data	O
revealed	O
that	O
hBD3	B-GP
markedly	O
reduced	O
the	O
phosphorylation	O
of	O
IκB	B-GP
.	O

Additionally	O
,	O
the	O
p65	B-GP
subunit	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
constitutively	O
phosphorylated	O
at	O
a	O
low	O
level	O
in	O
unstimulated	O
conditions	O
,	O
and	O
treatment	O
with	O
inflammatory	O
triggers	O
,	O
LPS	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
for	O
example	O
,	O
results	O
in	O
further	O
phosphorylation	O
.	O

The	O
total	O
level	O
of	O
phosphorylation	O
of	O
p65	B-GP
was	O
also	O
suppressed	O
by	O
the	O
addition	O
of	O
hBD3	B-GP
.	O

We	O
also	O
investigated	O
the	O
phosphorylation	O
of	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
,	O
which	O
is	O
an	O
upstream	O
signaling	O
molecule	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
.	O

The	O
results	O
demonstrated	O
that	O
hBD3	B-GP
inhibited	O
IKK	B-GP
-	I-GP
α	I-GP
/	O
β	O
phosphorylation	O
30	O
min	O
after	O
TNF	B-GP
-	I-GP
α	I-GP
stimulation	O
.	O

In	O
addition	O
,	O
the	O
inhibition	O
of	O
ROS	O
generation	O
also	O
contributes	O
to	O
the	O
decrease	O
in	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
,	O
as	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
by	O
ROS	O
through	O
the	O
IKK	B-GP
pathway	O
has	O
been	O
suggested	O
[	O
32	O
].	O

The	O
downregulation	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
in	O
HUVECs	O
by	O
hBD3	B-GP
might	O
be	O
mediated	O
through	O
inhibition	O
of	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
as	O
the	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
mediated	O
increase	O
in	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
expression	O
is	O
mediated	O
through	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
not	O
the	O
MAPK	B-GP
pathway	O
[	O
33	O
].	O

Ample	O
evidence	O
has	O
documented	O
intensive	O
crosstalk	O
between	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
signaling	O
pathways	O
.	O

The	O
MAPK	B-GP
pathway	O
is	O
required	O
for	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
mediated	O
inflammation	O
[	O
34	O
].	O

In	O
addition	O
,	O
the	O
JNK	B-GP
pathway	O
was	O
suggested	O
to	O
promote	O
cell	O
apoptosis	O
[	O
35	O
].	O

hBD3	B-GP
was	O
reported	O
to	O
rapidly	O
enter	O
the	O
cells	O
and	O
impact	O
TLR	B-GP
signaling	O
pathway	O
associated	O
with	O
MyD88	B-GP
and	O
TRIF	B-GP
[	O
36	O
].	O

In	O
this	O
case	O
,	O
there	O
is	O
also	O
possibility	O
that	O
hBD3	B-GP
inhibits	O
TNF	B-GP
signaling	O
via	O
interaction	O
with	O
the	O
upstream	O
molecules	O
in	O
the	O
signaling	O
pathway	O
.	O

Further	O
research	O
needs	O
to	O
be	O
done	O
to	O
elucidate	O
this	O
problem	O
.	O

Human	B-OG
β	B-GP
-	I-GP
defensin	I-GP
3	I-GP
is	O
a	O
multifunctional	O
effector	O
molecule	O
involved	O
in	O
a	O
startling	O
range	O
of	O
cellular	O
processes	O
.	O

First	O
,	O
as	O
an	O
antimicrobial	O
peptide	O
,	O
hBD3	B-GP
exhibits	O
broad	O
antimicrobial	O
activity	O
against	O
Gram	O
-	O
positive	O
and	O
Gram	B-OG
-	I-OG
negative	I-OG
bacteria	I-OG
,	O
fungi	B-OG
,	O
and	O
viruses	B-OG
[	O
37	O
].	O

Second	O
,	O
it	O
was	O
demonstrated	O
to	O
have	O
immunomodulatory	O
effects	O
due	O
to	O
its	O
biphasic	O
effect	O
in	O
the	O
host	O
immune	O
response	O
.	O

It	O
can	O
be	O
either	O
proinflammatory	O
or	O
anti	O
-	O
inflammatory	O
,	O
depending	O
on	O
the	O
circumstances	O
[	O
38	O
,	O
39	O
].	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
hBD3	B-GP
on	O
wound	O
healing	O
were	O
also	O
reported	O
[	O
40	O
].	O

We	O
previously	O
demonstrated	O
that	O
hBD3	B-GP
significantly	O
inhibited	O
the	O
progression	O
of	O
early	O
-	O
stage	O
atherosclerotic	O
lesions	O
,	O
and	O
this	O
effect	O
was	O
correlated	O
with	O
downregulation	O
of	O
macrophage	O
inflammation	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
study	O
focusing	O
on	O
the	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	B-DS
inflammation	I-DS
.	O

In	O
the	O
present	O
study	O
,	O
our	O
data	O
extend	O
the	O
protective	O
effects	O
of	O
hBD3	B-GP
to	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
injury	O
.	O

Owing	O
to	O
their	O
strong	O
antimicrobial	O
activity	O
,	O
low	O
molecular	O
weight	O
,	O
and	O
immunogenicity	O
,	O
several	O
researchers	O
and	O
studies	O
are	O
focusing	O
on	O
the	O
clinical	O
use	O
of	O
antimicrobial	O
peptides	O
as	O
a	O
new	O
class	O
of	O
antibiotics	O
[	O
41	O
],	O
and	O
some	O
of	O
them	O
are	O
already	O
in	O
the	O
clinical	O
development	O
stage	O
[	O
42	O
].	O

However	O
,	O
β	B-GP
-	I-GP
defensins	I-GP
had	O
limited	O
success	O
in	O
clinical	O
application	O
.	O

The	O
reasons	O
include	O
the	O
high	O
synthesis	O
cost	O
and	O
short	O
half	O
-	O
lives	O
in	O
blood	O
.	O

Cationic	O
peptides	O
are	O
not	O
stable	O
in	O
the	O
serum	O
due	O
to	O
high	O
susceptibility	O
to	O
enzymatic	O
degradation	O
.	O

hBD3	B-GP
was	O
observed	O
to	O
be	O
completely	O
digested	O
in	O
contact	O
with	O
simulated	O
gastric	O
fluid	O
[	O
43	O
].	O

One	O
solution	O
to	O
the	O
limitations	O
is	O
gene	O
delivery	O
of	O
hBD3	B-GP
.	O

Another	O
way	O
is	O
to	O
develop	O
a	O
structurally	O
modified	O
peptide	O
of	O
hBD3	B-GP
with	O
certain	O
biological	O
activity	O
.	O

Notable	O
examples	O
include	O
a	O
C	O
-	O
terminus	O
peptide	O
and	O
a	O
linear	O
hBD3	B-GP
peptide	O
with	O
anti	O
-	O
inflammatory	O
and	O
antifungal	O
activities	O
[	O
44	O
–	O
46	O
].	O

This	O
may	O
provide	O
new	O
therapeutic	O
approaches	O
to	O
harness	O
the	O
pharmaceutical	O
potential	O
of	O
hBD3	B-GP
.	O

However	O
,	O
the	O
endothelial	O
cells	O
we	O
used	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
human	B-OG
umbilical	O
vein	O
,	O
not	O
aortas	O
,	O
which	O
are	O
the	O
main	O
location	O
forming	O
atherosclerotic	B-DS
plaques	I-DS
.	O

The	O
difference	O
in	O
physiology	O
and	O
shear	O
stress	O
between	O
veins	O
and	O
arteries	O
might	O
contribute	O
to	O
heterogeneity	O
between	O
ECs	O
in	O
veins	O
and	O
aortas	O
[	O
47	O
–	O
49	O
].	O

In	O
addition	O
,	O
some	O
differences	O
in	O
the	O
immune	O
response	O
to	O
proinflammatory	O
cytokines	B-GP
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
might	O
exist	O
.	O

Further	O
confirmation	O
in	O
animal	B-OG
models	O
should	O
be	O
performed	O
to	O
uncover	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

In	O
addition	O
,	O
cell	O
density	O
was	O
identified	O
to	O
have	O
an	O
impact	O
on	O
the	O
immune	O
response	O
of	O
HUVECs	O
[	O
50	O
].	O

5	O
.	O

Conclusion	O

In	O
summary	O
,	O
the	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
endothelial	O
cell	O
activation	O
can	O
be	O
reversed	O
by	O
treatment	O
with	O
hBD3	B-GP
.	O

Furthermore	O
,	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
hBD3	B-GP
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
treated	O
HUVECs	O
seem	O
to	O
be	O
closely	O
related	O
to	O
downregulation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
and	O
MAPK	B-GP
pathway	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
cell	O
death	O
.	O

HUVECs	O
were	O
treated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
various	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

The	O
cell	O
viability	O
of	O
HUVECs	O
was	O
determined	O
with	O
a	O
CCK8	O
assay	O
according	O
to	O
the	O
instructions	O
of	O
manufacturers	O
.	O

Data	O
are	O
presented	O
as	O
the	O
survival	O
rate	O
compared	O
to	O
the	O
control	O
group	O
,	O
which	O
is	O
defined	O
as	O
100	O
%.	O

Values	O
represent	O
the	O
means	O
±	O
SD	O
(	O
n	O
=	O
6	O
).	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
,	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
group	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
and	O
MIF	B-GP
production	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
stimulated	O
HUVECs	O
.	O

Cells	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
various	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

Then	O
,	O
the	O
culture	O
supernatants	O
were	O
collected	O
by	O
centrifugation	O
and	O
analyzed	O
by	O
ELISA	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
(	O
n	O
=	O
6	O
).	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗	O
p	O
<	O
0	O
.	O
05	O
,	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
,	O
and	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
group	O
.	O

The	O
effects	O
of	O
hBD3	B-GP
on	O
the	O
expression	O
of	O
adhesion	B-GP
molecules	I-GP
in	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
activated	O
HUVECs	O
.	O

(	O
a	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
(	O
ICAM	B-GP
-	I-GP
1	I-GP
and	O
VCAM	B-GP
-	I-GP
1	I-GP
analysis	O
)	O
or	O
4	O
h	O
(	O
E	B-GP
-	I-GP
selectin	I-GP
analysis	O
).	O

Whole	O
cell	O
lysates	O
were	O
extracted	O
and	O
analyzed	O
by	O
western	O
blot	O
using	O
antibodies	O
specific	O
to	O
VCAM	B-GP
-	I-GP
1	I-GP
,	O
ICAM	B-GP
-	I-GP
1	I-GP
,	O
and	O
E	B-GP
-	I-GP
selectin	I-GP
.	O

(	O
b	O
)	O
Immunofluorescence	O
analysis	O
for	O
ICAM	B-GP
-	I-GP
1	I-GP
expression	O
was	O
conducted	O
as	O
mentioned	O
above	O
,	O
and	O
images	O
were	O
obtained	O
using	O
a	O
fluorescence	O
microscope	O
(	O
original	O
magnification	O
:	O
400x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

Effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
adhesion	O
to	O
THP	O
-	O
1	O
cells	O
in	O
HUVECs	O
.	O

HUVECs	O
were	O
stimulated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
24	O
h	O
.	O

After	O
stimulation	O
,	O
HUVECs	O
were	O
cocultured	O
with	O
calcein	B-CD
-	I-CD
AM	I-CD
-	O
labeled	O
THP	O
-	O
1	O
cells	O
for	O
30	O
min	O
.	O

(	O
a	O
)	O
Images	O
were	O
captured	O
using	O
a	O
fluorescence	O
microscope	O
(	O
original	O
magnification	O
:	O
100x	O
).	O

(	O
b	O
)	O
Adherent	O
cells	O
were	O
measured	O
using	O
a	O
microplate	O
reader	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
490	O
nm	O
and	O
515	O
nm	O
,	O
respectively	O
.	O

The	O
results	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
3	O
.	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
.	O
∗∗	O
p	O
<	O
0	O
.	O
01	O
compared	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
group	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
activation	O
in	O
HUVECs	O
.	O

(	O
a	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
30	O
min	O
.	O

Whole	O
cell	O
lysates	O
were	O
centrifuged	O
and	O
analyzed	O
with	O
western	O
blot	O
using	O
specific	O
antibodies	B-GP
.	O

(	O
b	O
)	O
Immunofluorescence	O
analysis	O
for	O
NF	B-GP
-	I-GP
κB	I-GP
p65	B-GP
localization	O
was	O
conducted	O
as	O
mentioned	O
above	O
,	O
and	O
images	O
were	O
captured	O
using	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
system	O
(	O
Nikon	O
A1	O
,	O
Japan	O
)	O
(	O
original	O
magnification	O
:	O
400x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

(	O
c	O
)	O
HUVECs	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
the	O
indicated	O
concentrations	O
of	O
hBD3	B-GP
for	O
30	O
min	O
and	O
45	O
min	O
.	O

Whole	O
cell	O
lysates	O
were	O
centrifuged	O
and	O
analyzed	O
with	O
western	O
blot	O
using	O
specific	O
antibodies	B-GP
.	O

hBD3	B-GP
inhibits	O
HUVEC	O
apoptosis	O
stimulated	O
by	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

After	O
incubation	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
different	O
concentrations	O
of	O
hBD3	B-GP
for	O
6	O
h	O
,	O
the	O
protein	O
levels	O
of	O
cleaved	O
caspase	B-GP
-	I-GP
3	I-GP
and	O
β	B-GP
-	I-GP
actin	I-GP
in	O
HUVECs	O
were	O
detected	O
with	O
an	O
immunoblot	O
assay	O
.	O

Inhibitory	O
effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
ROS	O
formation	O
in	O
HUVECs	O
.	O

HUVECs	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
and	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
2	O
h	O
.	O

Intracellular	O
ROS	O
accumulation	O
was	O
determined	O
by	O
observation	O
under	O
a	O
fluorescence	O
microscope	O
(	O
a	O
)	O
or	O
fluorescence	O
measurement	O
with	O
a	O
microplate	O
reader	O
(	O
b	O
)	O
after	O
incubation	O
with	O
the	O
ROS	O
detector	O
DCFH	O
-	O
DA	O
for	O
30	O
min	O
(	O
original	O
magnification	O
:	O
400x	O
).	O

Values	O
represent	O
the	O
mean	O
±	O
SD	O
.	O
###	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
the	O
control	O
group	O
;	O
∗∗∗	O
p	O
<	O
0	O
.	O
001	O
compared	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
alone	O
.	O

Effects	O
of	O
hBD3	B-GP
on	O
TNF	B-GP
-	I-GP
α	I-GP
-	O
induced	O
F	B-GP
-	I-GP
actin	I-GP
rearrangement	O
.	O

HUVECs	O
were	O
incubated	O
with	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
40	O
ng	O
/	O
mL	O
)	O
with	O
or	O
without	O
hBD3	B-GP
(	O
15	O
μg	O
/	O
mL	O
)	O
for	O
24	O
h	O
.	O

After	O
that	O
,	O
cells	O
were	O
washed	O
with	O
PBS	O
.	O

F	B-GP
-	I-GP
actin	I-GP
was	O
stained	O
with	O
DyLight	O
488	O
-	O
phalloidin	B-CD
for	O
15	O
min	O
in	O
the	O
dark	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Images	O
were	O
obtained	O
using	O
a	O
confocal	O
microscope	O
(	O
Olympus	O
FV10i	O
)	O
(	O
original	O
magnification	O
:	O
600x	O
,	O
scale	O
bar	O
50	O
μm	O
).	O

Protective	O
and	O
therapeutic	O
role	O
of	O
2	O
-	O
carba	O
-	O
cyclic	O
phosphatidic	O
acid	O
in	O
demyelinating	B-DS
disease	I-DS

Background	O

Multiple	B-DS
sclerosis	I-DS
is	O
a	O
neuroinflammatory	O
demyelinating	O
and	O
neurodegenerative	B-DS
disease	I-DS
of	I-DS
the	I-DS
central	O
nervous	O
system	O
characterized	O
by	O
recurrent	O
and	O
progressive	O
demyelination	O
/	O
remyelination	O
cycles	O
,	O
neuroinflammation	O
,	O
oligodendrocyte	O
loss	O
,	O
demyelination	O
,	O
and	O
axonal	O
degeneration	O
.	O

Cyclic	B-CD
phosphatidic	I-CD
acid	I-CD
(	O
cPA	O
)	O
is	O
a	O
natural	O
phospholipid	O
mediator	O
with	O
a	O
unique	O
cyclic	O
phosphate	O
ring	O
structure	O
at	O
the	O
sn	O
-	O
2	O
and	O
sn	O
-	O
3	O
positions	O
of	O
the	O
glycerol	B-CD
backbone	O
.	O

We	O
reported	O
earlier	O
that	O
cPA	O
elicits	O
a	O
neurotrophin	B-GP
-	O
like	O
action	O
and	O
protects	O
hippocampal	O
neurons	O
from	O
ischemia	B-DS
-	O
induced	O
delayed	O
neuronal	O
death	O
.	O

We	O
designed	O
,	O
chemically	O
synthesized	O
,	O
and	O
metabolically	O
stabilized	O
derivatives	O
of	O
cPA	O
:	O
2	O
-	O
carba	O
-	O
cPA	O
(	O
2ccPA	O
),	O
a	O
synthesized	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
molecules	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
2ccPA	O
exerts	O
protective	O
effects	O
in	O
oligodendrocytes	O
and	O
suppresses	O
pathology	O
in	O
the	O
two	O
most	O
common	O
mouse	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Methods	O

To	O
evaluate	O
whether	O
2ccPA	O
has	O
potential	O
beneficial	O
effects	O
on	O
the	O
pathology	O
of	O
multiple	B-DS
sclerosis	I-DS
,	O
we	O
investigated	O
the	O
effects	O
of	O
2ccPA	O
on	O
oligodendrocyte	O
cell	O
death	O
in	O
vitro	O
and	O
administrated	O
2ccPA	O
to	O
mouse	B-OG
models	O
of	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
and	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
.	O

Results	O

We	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
increase	O
in	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
expression	O
ratio	O
and	O
phosphorylation	O
levels	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
protein	O
.	O

2ccPA	O
treatment	O
reduced	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
,	O
microglial	O
activation	O
,	O
NLRP3	B-GP
inflammasome	O
,	O
and	O
motor	O
dysfunction	O
.	O

Furthermore	O
,	O
2ccPA	O
treatment	O
reduced	O
autoreactive	O
T	O
cells	O
and	O
macrophages	O
,	O
spinal	O
cord	O
injury	O
,	O
and	O
pathological	O
scores	O
in	O
EAE	B-DS
,	O
the	O
autoimmune	B-DS
multiple	I-DS
sclerosis	I-DS
mouse	B-OG
model	O
.	O

Conclusions	O

We	O
demonstrated	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
.	O

Also	O
,	O
we	O
found	O
beneficial	O
effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
cuprizone	B-CD
-	O
induced	O
demyelination	B-DS
and	O
the	O
pathology	O
of	O
EAE	B-DS
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
may	O
be	O
a	O
promising	O
compound	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
demyelinating	B-DS
disease	I-DS
and	O
ameliorate	O
the	O
symptoms	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Background	O

Multiple	B-DS
sclerosis	I-DS
is	O
an	O
inflammatory	O
demyelinating	O
and	O
neurodegenerative	B-DS
disease	I-DS
of	O
the	O
CNS	O
characterized	O
by	O
recurrent	O
and	O
progressive	O
demyelination	O
/	O
remyelination	O
cycles	O
,	O
neuroinflammation	O
,	O
oligodendrocyte	O
loss	O
,	O
demyelination	O
,	O
and	O
axonal	O
degeneration	O
[	O
1	O
–	O
3	O
].	O

In	O
multiple	B-DS
sclerosis	I-DS
,	O
oligodendrocytes	O
are	O
the	O
target	O
of	O
inflammatory	O
attacks	O
and	O
their	O
cell	O
death	O
mediated	O
by	O
activated	O
lymphocytes	O
,	O
macrophages	O
,	O
and	O
glial	O
activation	O
results	O
in	O
axonal	O
demyelination	B-DS
.	O

Since	O
myelin	O
-	O
forming	O
oligodendrocytes	O
provide	O
critical	O
support	O
to	O
the	O
neuronal	O
axon	O
,	O
demyelination	O
results	O
in	O
diverse	O
neurological	O
symptoms	O
determined	O
by	O
the	O
functions	O
of	O
affected	O
neurons	O
.	O

Therefore	O
,	O
therapies	O
designed	O
to	O
protect	O
oligodendrocytes	O
and	O
myelin	O
during	O
neuroinflammation	O
are	O
important	O
strategies	O
to	O
halt	O
the	O
progression	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

The	O
most	O
commonly	O
studied	O
animal	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
are	O
the	O
autoimmune	B-DS
experimental	I-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
model	O
[	O
4	O
,	O
5	O
]	O
and	O
the	O
cuprizone	B-CD
(	O
bis	O
-	O
cyclohexanone	O
-	O
oxalyldihydrazone	O
,	O
CPZ	O
)-	O
induced	O
demyelination	B-DS
model	O
[	O
6	O
,	O
7	O
].	O

Extensive	O
research	O
regarding	O
the	O
detailed	O
mechanisms	O
underlying	O
immune	O
-	O
mediated	O
demyelination	O
in	O
multiple	B-DS
sclerosis	I-DS
has	O
been	O
conducted	O
using	O
EAE	B-DS
model	O
mice	B-OG
[	O
4	O
,	O
5	O
].	O

Activated	O
autoreactive	O
T	O
cells	O
proliferate	O
and	O
release	O
cytokines	B-GP
,	O
which	O
disrupt	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
and	O
secrete	O
chemokines	B-GP
that	O
lead	O
to	O
the	O
recruitment	O
of	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
macrophages	O
.	O

Infiltrated	O
immune	O
cells	O
secrete	O
autoantibodies	B-GP
against	O
the	O
myelin	O
sheath	O
,	O
ultimately	O
resulting	O
in	O
myelin	O
degeneration	O
[	O
8	O
].	O

The	O
cuprizone	B-CD
model	O
is	O
characterized	O
by	O
the	O
apoptotic	O
death	O
of	O
mature	O
oligodendrocytes	O
[	O
7	O
]	O
and	O
is	O
accompanied	O
by	O
neuroinflammation	O
and	O
motor	O
dysfunction	O
[	O
9	O
].	O

The	O
model	O
is	O
used	O
to	O
study	O
processes	O
of	O
demyelination	O
and	O
remyelination	O
in	O
the	O
CNS	O
.	O

Primary	O
oligodendrocyte	O
apoptosis	O
in	O
connection	O
with	O
microglial	O
activation	O
are	O
the	O
major	O
histopathological	O
hallmarks	O
of	O
the	O
cuprizone	B-CD
animal	B-OG
model	O
.	O

These	O
pathological	O
features	O
are	O
also	O
characteristics	O
of	O
lesion	O
formation	O
in	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
[	O
10	O
].	O

Mitochondrial	O
dysfunction	O
is	O
also	O
an	O
important	O
component	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
lesions	O
and	O
plays	O
a	O
key	O
role	O
in	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
axons	O
,	O
which	O
can	O
be	O
observed	O
in	O
both	O
the	O
EAE	B-DS
and	O
cuprizone	B-CD
models	O
.	O

Cyclic	B-CD
phosphatidic	I-CD
acid	I-CD
(	O
cPA	O
)	O
is	O
a	O
natural	O
phospholipid	O
mediator	O
with	O
a	O
unique	O
cyclic	O
phosphate	O
ring	O
structure	O
at	O
the	O
sn	O
-	O
2	O
and	O
sn	O
-	O
3	O
positions	O
of	O
the	O
glycerol	B-CD
backbone	O
.	O

cPA	B-GP
elicits	O
a	O
neurotrophin	B-GP
-	O
like	O
action	O
[	O
11	O
]	O
and	O
protects	O
neurons	O
from	O
mitochondrial	O
dysfunction	O
-	O
induced	O
apoptosis	O
[	O
12	O
]	O
and	O
ischemia	B-DS
-	O
induced	O
delayed	O
neuronal	O
death	O
[	O
13	O
].	O

We	O
have	O
also	O
reported	O
previously	O
that	O
cPA	B-GP
suppresses	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
and	O
motor	O
dysfunction	O
[	O
14	O
].	O

We	O
designed	O
,	O
chemically	O
synthesized	O
,	O
and	O
metabolically	O
stabilized	O
derivatives	O
of	O
cPA	O
:	O
2	O
-	O
carba	O
-	O
cPA	O
(	O
2ccPA	O
),	O
a	O
synthesized	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
molecules	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
;	O
this	O
showed	O
much	O
more	O
potent	O
biological	O
activity	O
than	O
natural	O
cPA	B-GP
[	O
15	O
–	O
17	O
].	O

Our	O
preliminary	O
experiments	O
revealed	O
that	O
2ccPA	O
was	O
detected	O
in	O
the	O
mouse	B-OG
brain	O
following	O
intraperitoneal	O
administration	O
.	O

Based	O
on	O
this	O
finding	O
,	O
we	O
speculated	O
that	O
circulated	O
2ccPA	O
may	O
gain	O
access	O
to	O
the	O
brain	O
via	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Currently	O
,	O
we	O
are	O
investigating	O
the	O
pharmacokinetics	O
of	O
2ccPA	O
in	O
a	O
separate	O
study	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
2ccPA	O
exerts	O
protective	O
effects	O
in	O
oligodendrocytes	O
and	O
suppresses	O
pathology	O
in	O
EAE	B-DS
and	O
cuprizone	B-CD
-	O
induced	O
mouse	B-OG
models	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

We	O
demonstrated	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
,	O
suppressed	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
and	O
motor	O
dysfunction	O
,	O
and	O
attenuated	O
the	O
clinical	O
symptoms	O
of	O
EAE	B-DS
.	O

Methods	O

Pharmacologic	O
agents	O

2	O
-	O
Carba	O
-	O
cPA	O
(	O
2ccPA	O
)	O
was	O
chemically	O
synthesized	O
as	O
previously	O
described	O
(	O
Fig	O
.	O
2a	O
)	O
[	O
16	O
,	O
18	O
].	O

For	O
in	O
vivo	O
experiments	O
,	O
2ccPA	O
was	O
dissolved	O
in	O
saline	O
(	O
vehicle	O
).	O

For	O
in	O
vitro	O
experiments	O
,	O
2ccPA	O
was	O
dissolved	O
in	O
phosphatase	B-GP
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
containing	O
0	O
.	O
1	O
%	O
fatty	B-CD
acid	I-CD
-	O
free	O
bovine	O
serum	O
albumin	B-GP
(	O
BSA	B-GP
)	O
(	O
vehicle	O
).	O

Cell	O
culture	O
and	O
treatments	O

The	O
MO3	O
.	O
13	O
cell	O
line	O
(	O
CELLutions	O
Biosystems	O
,	O
Inc	O
.)	O
is	O
an	O
immortalized	O
human	B-OG
-	O
human	B-OG
hybrid	O
line	O
that	O
expresses	O
the	O
phenotypic	O
characteristics	O
of	O
primary	O
oligodendrocyte	O
[	O
19	O
,	O
20	O
].	O

MO3	O
.	O
13	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
’	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
(	O
Nacalai	O
Tesque	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
Gibco	O
),	O
penicillin	B-CD
,	O
and	O
streptomycin	B-CD
(	O
Gibco	O
)	O
in	O
a	O
humidified	O
5	O
%	O
CO2	O
incubator	O
at	O
37	O
°	O
C	O
.	O

MO3	O
.	O
13	O
cells	O
attain	O
a	O
flattened	O
bipolar	O
morphology	O
with	O
elongated	O
processes	O
and	O
can	O
be	O
differentiated	O
into	O
an	O
oligodendrocyte	O
phenotype	O
.	O

To	O
induce	O
differentiation	O
,	O
MO3	O
.	O
13	O
cells	O
were	O
cultured	O
in	O
DMEM	O
without	O
FBS	O
for	O
5	O
days	O
.	O

Serum	O
-	O
starved	O
differentiated	O
MO3	O
.	O
13	O
cells	O
were	O
exposed	O
to	O
CoCl2	O
(	O
500	O
μm	O
)	O
and	O
/	O
or	O
2ccPA	O
(	O
10	O
μm	O
)	O
for	O
2	O
days	O
.	O

MTT	O
(	O
5	O
mg	O
/	O
ml	O
)	O
was	O
added	O
to	O
each	O
well	O
,	O
followed	O
by	O
incubation	O
at	O
37	O
°	O
C	O
for	O
4	O
h	O
in	O
a	O
CO2	O
incubator	O
.	O

The	O
supernatants	O
were	O
carefully	O
removed	O
,	O
and	O
200	O
μl	O
of	O
isopropanol	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
optical	O
density	O
(	O
OD	O
)	O
of	O
the	O
solution	O
was	O
measured	O
at	O
570	O
nm	O
using	O
a	O
microplate	O
reader	O
(	O
BIO	O
-	O
RAD	O
).	O

Western	O
blotting	O
analysis	O

MO3	O
.	O
13	O
cells	O
were	O
harvested	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
homogenized	O
in	O
ice	O
-	O
cold	O
RIPA	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
),	O
1	O
%	O
NP	B-CD
-	I-CD
40	I-CD
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
)	O
containing	O
a	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
Roche	O
)	O
and	O
left	O
at	O
4	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
homogenates	O
were	O
centrifuged	O
at	O
×	O
20	O
,	O
000g	O
at	O
4	O
°	O
C	O
for	O
15	O
min	O
,	O
and	O
the	O
resulting	O
supernatants	O
were	O
collected	O
as	O
whole	O
-	O
cell	O
lysates	O
,	O
from	O
which	O
protein	O
concentrations	O
were	O
determined	O
using	O
a	O
protein	O
assay	O
kit	O
(	O
Thermo	O
Scientific	O
).	O

Proteins	O
were	O
separated	O
on	O
conventional	O
12	O
%	O
acrylamide	B-CD
SDS	O
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

After	O
blocking	O
with	O
5	O
%	O
skim	O
milk	O
(	O
MEGMILK	O
SNOW	O
BRAND	O
Co	O
.	O

Ltd	O
.)	O
in	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	B-CD
20	I-CD
(	O
PBS	O
-	O
T	O
),	O
the	O
membranes	O
were	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibodies	O
(	O
anti	O
-	O
GAPDH	B-GP
(	O
Millipore	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
Bax	B-GP
(	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
Bcl	B-GP
-	I-GP
2	I-GP
(	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
phospho	O
-	O
JNK	B-GP
(	O
p	O
-	O
JNK	B-GP
,	O
Cell	O
Signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
phospho	O
-	O
p38MAPK	B-GP
(	O
p	O
-	O
p38MAPK	B-GP
,	O
cell	O
signaling	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
myelin	B-GP
basic	I-GP
protein	I-GP
(	O
MBP	B-GP
,	O
Santa	O
cruz	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
oligodendrocyte	B-GP
transcription	I-GP
factor	I-GP
1	I-GP
(	O
Olig1	B-GP
,	O
Rockland	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
glial	B-GP
fibrillary	I-GP
acidic	I-GP
protein	I-GP
(	O
GFAP	B-GP
,	O
Epitomics	O
,	O
1	O
:	O
1000	O
),	O
anti	O
-	O
glutamine	B-GP
synthetase	I-GP
(	O
GS	B-GP
,	O
Abcam	O
,	O
1	O
:	O
1000	O
))	O
overnight	O
,	O
followed	O
by	O
incubation	O
with	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
secondary	O
antibodies	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
with	O
PBS	O
-	O
T	O
three	O
times	O
,	O
the	O
membranes	O
were	O
treated	O
with	O
reagent	O
for	O
exposure	O
(	O
Chemi	O
-	O
Lumi	O
One	O
Super	O
,	O
Nacalai	O
Tesque	O
;	O
ImmunoStar	O
LD	O
,	O
Wako	O
).	O

Images	O
of	O
the	O
membranes	O
were	O
captured	O
using	O
a	O
C	O
-	O
DiGit	O
Blot	O
Scanner	O
(	O
LI	O
-	O
COR	O
)	O
and	O
subjected	O
to	O
ImageJ	O
1	O
.	O
46r	O
analysis	O
.	O

Animal	B-OG
procedures	O

Mice	B-OG
were	O
housed	O
in	O
appropriate	O
animal	B-OG
care	O
facilities	O
at	O
Saitama	O
Medical	O
University	O
(	O
Saitama	O
,	O
Japan	O
)	O
and	O
handled	O
in	O
accordance	O
with	O
established	O
international	O
guidelines	O
.	O

Experimental	O
protocols	O
were	O
approved	O
by	O
the	O
Animal	B-OG
Research	O
Committee	O
of	O
Saitama	O
Medical	O
University	O
.	O

C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
(	O
Tokyo	O
Laboratory	O
Animals	B-OG
Science	O
)	O
were	O
received	O
at	O
our	O
facility	O
at	O
10	O
weeks	O
of	O
age	O
.	O

Mice	B-OG
were	O
maintained	O
on	O
a	O
12	O
/	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
.	O

For	O
histology	O
,	O
mice	B-OG
were	O
intracardially	O
perfused	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
in	O
PBS	O
.	O

The	O
brain	O
and	O
lumbar	O
spinal	O
cord	O
tissues	O
were	O
removed	O
and	O
post	O
-	O
fixed	O
overnight	O
in	O
4	O
%	O
PFA	O
in	O
PBS	O
,	O
following	O
which	O
they	O
were	O
cryoprotected	O
in	O
30	O
%	O
sucrose	B-CD
solution	O
in	O
PBS	O
,	O
snap	O
frozen	O
,	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
further	O
use	O
.	O

Coronal	O
brain	O
sections	O
(	O
25	O
μm	O
)	O
were	O
obtained	O
using	O
a	O
cryostat	O
(	O
CM1900	O
,	O
LEICA	O
)	O
and	O
mounted	O
on	O
gelatin	O
-	O
coated	O
glass	O
slides	O
[	O
21	O
].	O

Induction	O
of	O
cuprizone	B-CD
model	O
and	O
2ccPA	O
treatment	O

Male	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
given	O
ad	O
libitum	O
access	O
to	O
a	O
powdered	O
diet	O
(	O
CLEA	O
Japan	O
)	O
containing	O
0	O
.	O
2	O
%	O
bis	O
-	O
cyclohexanone	O
-	O
oxaldihydrazone	O
(	O
cuprizone	B-CD
,	O
Merck	O
KGaA	O
).	O

Mice	B-OG
were	O
fed	O
the	O
cuprizone	B-CD
diet	O
for	O
5	O
weeks	O
(	O
acute	O
peak	O
demyelination	O
),	O
6	O
weeks	O
(	O
spontaneous	O
remyelination	O
),	O
and	O
10	O
weeks	O
(	O
chronic	O
demyelination	O
).	O

In	O
the	O
present	O
study	O
,	O
2ccPA	O
was	O
chemically	O
synthesized	O
as	O
previously	O
described	O
(	O
Fig	O
.	O
2a	O
)	O
[	O
17	O
],	O
dissolved	O
in	O
saline	O
,	O
and	O
administered	O
at	O
a	O
dose	O
of	O
1	O
.	O
6	O
mg	O
/	O
kg	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
during	O
the	O
cuprizone	B-CD
exposure	O
period	O
(	O
0	O
–	O
5	O
,	O
3	O
–	O
5	O
,	O
5	O
–	O
6	O
,	O
or	O
5	O
–	O
10	O
weeks	O
from	O
the	O
onset	O
of	O
exposure	O
).	O

The	O
protocol	O
for	O
2ccPA	O
administration	O
is	O
presented	O
in	O
Fig	O
.	O
1	O
.	O

Control	O
mice	B-OG
were	O
fed	O
a	O
cuprizone	B-CD
-	O
free	O
diet	O
and	O
received	O
an	O
equal	O
dose	O
of	O
saline	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
during	O
each	O
experimental	O
period	O
.	O

Coronal	O
brain	O
sections	O
were	O
stained	O
for	O
myelin	O
using	O
Black	O
-	O
Gold	O
II	O
(	O
Histo	O
-	O
Chem	O
)	O
as	O
previously	O
described	O
[	O
22	O
].	O

Briefly	O
,	O
sections	O
were	O
incubated	O
in	O
a	O
0	O
.	O
3	O
%	O
Black	O
-	O
Gold	O
II	O
solution	O
for	O
12	O
min	O
,	O
rinsed	O
in	O
distilled	O
water	O
,	O
fixed	O
in	O
1	O
%	O
sodium	O
thiosulfate	O
,	O
rinsed	O
in	O
tap	O
water	O
,	O
and	O
air	O
-	O
dried	O
.	O

Sections	O
were	O
coverslipped	O
using	O
Poly	O
-	O
Mount	O
(	O
Polysciences	O
Inc	O
).	O

Black	O
-	O
Gold	O
II	O
(	O
Histo	O
-	O
Chem	O
)	O
stained	O
sections	O
were	O
selected	O
between	O
Bregma	O
−	O
0	O
.	O
22	O
and	O
−	O
0	O
.	O
58	O
mm	O
.	O

Sections	O
were	O
photographed	O
at	O
×	O
10	O
magnification	O
on	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
microscope	O
(	O
Keyence	O
Corporation	O
).	O

Images	O
were	O
captured	O
using	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
BZ	O
-	O
X	O
Analyzer	O
and	O
imported	O
into	O
ImageJ	O
1	O
.	O
46r	O
,	O
which	O
was	O
used	O
to	O
measure	O
the	O
mean	O
OD	O
within	O
the	O
middle	O
of	O
the	O
corpus	O
callosum	O
[	O
21	O
].	O

The	O
OD	O
of	O
the	O
tissue	O
-	O
free	O
area	O
was	O
used	O
as	O
a	O
background	O
,	O
and	O
blank	O
was	O
subtracted	O
from	O
the	O
ODs	O
for	O
tissue	O
.	O

The	O
resulting	O
ODs	O
for	O
myelin	O
in	O
each	O
mouse	B-OG
were	O
normalized	O
against	O
values	O
in	O
unchallenged	O
mice	B-OG
using	O
the	O
following	O
formula	O
:	O
myelin	O
score	O
(%)	O
=	O
(	O
density	O
reading	O
/	O
unchallenged	O
density	O
average	O
)	O
×	O
100	O
.	O
Fig	O
.	O
1Multiperiod	O
of	O
2ccPA	O
administration	O
protocol	O
.	O

For	O
protocol	O
A	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
for	O
the	O
duration	O
of	O
the	O
5	O
-	O
week	O
period	O
of	O
cuprizone	B-CD
exposure	O
(	O
0	O
–	O
5	O
weeks	O
:	O
acute	O
peak	O
demyelination	O
).	O

For	O
protocol	O
B	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
3	O
–	O
5	O
of	O
cuprizone	B-CD
exposure	O
(	O
3	O
–	O
5	O
weeks	O
:	O
after	O
onset	O
of	O
demyelination	O
).	O

For	O
protocol	O
C	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
5	O
–	O
6	O
of	O
cuprizone	B-CD
exposure	O
(	O
5	O
–	O
6	O
weeks	O
:	O
spontaneous	O
remyelination	O
).	O

For	O
protocol	O
D	O
,	O
2ccPA	O
was	O
administered	O
once	O
daily	O
via	O
intraperitoneal	O
injection	O
between	O
weeks	O
5	O
–	O
10	O
of	O
cuprizone	B-CD
exposure	O
(	O
5	O
–	O
10	O
weeks	O
:	O
chronic	O
demyelination	O
)	O

Electron	O
microscopy	O
analysis	O
of	O
myelin	O
sheath	O
thickness	O
and	O
axon	O
diameter	O
in	O
the	O
cuprizone	B-CD
model	O

Mice	B-OG
were	O
anesthetized	O
and	O
perfused	O
with	O
PBS	O
as	O
described	O
in	O
the	O
preceding	O
sections	O
,	O
following	O
which	O
they	O
were	O
fixed	O
using	O
4	O
%	O
PFA	O
and	O
2	O
.	O
5	O
%	O
glutaraldehyde	B-CD
in	O
phosphate	O
buffer	O
and	O
re	O
-	O
fixed	O
overnight	O
at	O
4	O
°	O
C	O
.	O

The	O
fixed	O
brains	O
were	O
sliced	O
into	O
1	O
–	O
2	O
-	O
mm	O
sections	O
.	O

Sections	O
containing	O
the	O
corpus	O
callosum	O
area	O
were	O
divided	O
into	O
segments	O
of	O
2	O
–	O
3	O
mm	O
and	O
washed	O
in	O
0	O
.	O
1	O
M	O
sodium	O
cacodylate	O
buffer	O
.	O

After	O
washing	O
,	O
the	O
tissue	O
was	O
post	O
-	O
fixed	O
with	O
1	O
%	O
osmium	O
tetroxide	O
.	O

Sections	O
were	O
dehydrated	O
in	O
an	O
ascending	O
alcohol	O
series	O
and	O
embedded	O
in	O
epoxy	O
resin	O
.	O

Ultrathin	O
sections	O
of	O
the	O
corpus	O
callosum	O
were	O
prepared	O
using	O
a	O
Reichert	O
-	O
Nissei	O
ULTRACUT	O
-	O
N	O
ultramicrotome	O
(	O
Nissei	O
Sangyo	O
).	O

Ultrathin	O
sections	O
were	O
stained	O
with	O
lead	O
nitrate	O
and	O
3	O
%	O
uranyl	O
acetate	O
in	O
water	O
.	O

Digital	O
images	O
were	O
acquired	O
using	O
a	O
JEM	O
-	O
1400	O
Transmission	O
Electron	O
Microscope	O
(	O
JEOL	O
Ltd	O
.).	O

Ultrathin	O
sections	O
(	O
70	O
nm	O
)	O
were	O
examined	O
with	O
a	O
transmission	O
electron	O
microscope	O
at	O
80	O
kV	O
[	O
23	O
].	O

The	O
number	O
of	O
myelinated	O
fibers	O
present	O
in	O
electron	O
microscope	O
pictures	O
was	O
counted	O
.	O

Using	O
ImageJ	O
1	O
.	O
46r	O
,	O
axonal	O
diameters	O
were	O
calculated	O
from	O
the	O
outer	O
perimeter	O
of	O
the	O
axon	O
divided	O
by	O
the	O
total	O
perimeter	O
of	O
the	O
axon	O
.	O

The	O
g	O
-	O
ratio	O
were	O
calculated	O
the	O
numerical	O
ratio	O
between	O
the	O
diameter	O
of	O
the	O
axon	O
proper	O
and	O
the	O
outer	O
diameter	O
of	O
the	O
myelinated	O
fibers	O
.	O

Pictures	O
were	O
randomly	O
chosen	O
for	O
each	O
mouse	B-OG
and	O
100	O
–	O
200	O
fibers	O
per	O
picture	O
were	O
calculated	O
.	O

The	O
data	O
are	O
shown	O
as	O
percent	O
of	O
myelinated	O
fibers	O
and	O
axonal	O
diameter	O
.	O

RNA	O
extraction	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O

Mice	B-OG
were	O
euthanized	O
,	O
and	O
tissue	O
from	O
the	O
corpus	O
callosum	O
was	O
collected	O
for	O
RNA	O
extraction	O
as	O
previously	O
reported	O
[	O
24	O
].	O

Briefly	O
,	O
gross	O
coronal	O
sections	O
were	O
obtained	O
between	O
approximately	O
Bregma	O
−	O
0	O
.	O
25	O
and	O
−	O
1	O
.	O
25	O
mm	O
.	O

Sagittal	O
cuts	O
were	O
made	O
through	O
the	O
cingulum	O
,	O
medial	O
to	O
each	O
lateral	O
ventricle	O
,	O
followed	O
by	O
cuts	O
above	O
and	O
below	O
the	O
corpus	O
callosum	O
to	O
remove	O
most	O
of	O
the	O
cortex	O
and	O
fornix	O
[	O
24	O
].	O

Corpus	O
callosum	O
tissue	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
required	O
for	O
further	O
processing	O
.	O

Samples	O
of	O
fresh	O
frozen	O
corpus	O
callosum	O
were	O
processed	O
for	O
RNA	O
extraction	O
using	O
ISOGEN	O
(	O
Nippon	O
Gene	O
Co	O
.)	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Extracted	O
RNA	O
was	O
resuspended	O
in	O
RNase	B-GP
-	O
free	O
molecular	O
grade	O
water	O
(	O
Takara	O
Bio	O
Inc	O
.)	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
required	O
for	O
analysis	O
.	O

For	O
qPCR	O
,	O
total	O
RNA	O
(	O
3	O
μg	O
)	O
was	O
reverse	O
transcribed	O
using	O
a	O
PrimeScript	O
RT	O
reagent	O
kit	O
(	O
Takara	O
Bio	O
Inc	O
.).	O

qPCR	O
was	O
performed	O
using	O
the	O
7900	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
),	O
with	O
the	O
following	O
gene	O
-	O
specific	O
primers	O
:	O
phosphoglycerate	B-GP
kinase	I-GP
1	I-GP
(	O
PGK1	B-GP
,	O
forward	O
:	O
5	O
′-	O
ctgctgttccaagcatcaaa	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
gcatcttttcccttcccttc	O
-	O
3	O
′),	O
glial	B-GP
fibrillary	I-GP
acidic	I-GP
protein	I-GP
(	O
GFAP	B-GP
,	O
forward	O
:	O
5	O
′-	O
acgcttctccttgtctcgaa	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
cggcgatagtcgttagcttc	O
-	O
3	O
′),	O
ionized	B-GP
calcium	I-GP
binding	I-GP
adapter	I-GP
molecule	I-GP
1	I-GP
(	O
Iba1	B-GP
,	O
forward	O
:	O
5	O
′-	O
atgagccaaagcagggattt	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
gaccagttggcctcttgtgt	O
-	O
3	O
′),	O
NOD	B-GP
-	I-GP
like	I-GP
receptor	I-GP
family	O
,	O
pyrin	B-GP
domain	I-GP
containing	I-GP
3	I-GP
(	O
NLRP3	B-GP
,	O
forward	O
:	O
5	O
′-	O
ccttggaccaggttcagtgt	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
aggagatgtcgaagcagcat	O
-	O
3	O
′),	O
purinergic	B-GP
receptor	I-GP
P2X	B-GP
ligand	I-GP
-	I-GP
gated	I-GP
ion	I-GP
channel	I-GP
7	I-GP
(	O
P2X7R	B-GP
,	O
forward	O
:	O
5	O
′-	O
tgtgtgcattgacttgctca	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
cttgcagacttttcccaagc	O
-	O
3	O
′)	O
Interleukin	B-GP
-	I-GP
1	I-GP
beta	I-GP
(	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
forward	O
:	O
5	O
′-	O
gaccttccaggatgaggaca	O
-	O
3	O
′	O
reverse	O
:	O
5	O
′-	O
aggccacaggtattttgtcg	O
-	O
3	O
′).	O

Q	O
-	O
PCR	O
conditions	O
were	O
95	O
°	O
C	O
for	O
30	O
s	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
5	O
s	O
at	O
95	O
°	O
C	O
and	O
34	O
s	O
at	O
60	O
°	O
C	O
.	O

The	O
level	O
of	O
target	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
ΔΔCT	O
method	O
[	O
25	O
].	O

Data	O
were	O
analyzed	O
using	O
the	O
relative	O
quantification	O
technique	O
.	O

qPCR	O
results	O
were	O
normalized	O
to	O
the	O
expression	O
levels	O
of	O
PGK1	B-GP
,	O
as	O
previously	O
reported	O
[	O
21	O
].	O

Relative	O
changes	O
in	O
gene	O
expression	O
are	O
reported	O
as	O
a	O
percentage	O
of	O
the	O
level	O
of	O
expression	O
in	O
control	O
mice	B-OG
.	O

Rotarod	O
test	O

We	O
used	O
an	O
accelerating	O
rotarod	O
treadmill	O
for	O
mice	B-OG
(	O
Mouse	B-OG
Rotarod	O
,	O
UgoBasile	O
)	O
to	O
evaluate	O
motor	O
balance	O
and	O
coordination	O
following	O
cuprizone	B-CD
exposure	O
.	O

Mice	B-OG
exposed	O
to	O
cuprizone	B-CD
for	O
5	O
weeks	O
(	O
2ccPA	O
administration	O
protocols	O
A	O
and	O
B	O
)	O
were	O
tested	O
on	O
the	O
rotarod	O
at	O
28	O
rpm	O
,	O
while	O
those	O
exposed	O
to	O
cuprizone	B-CD
for	O
10	O
weeks	O
(	O
2ccPA	O
administration	O
protocol	O
D	O
)	O
were	O
tested	O
at	O
20	O
rpm	O
.	O

The	O
time	O
each	O
mouse	B-OG
stayed	O
on	O
the	O
rod	O
(	O
latency	O
time	O
)	O
was	O
recorded	O
by	O
a	O
trip	O
switch	O
under	O
the	O
floor	O
of	O
each	O
rotating	O
drum	O
,	O
with	O
a	O
maximum	O
recording	O
time	O
of	O
300	O
s	O
.	O

The	O
number	O
of	O
falls	O
(	O
from	O
the	O
cylinder	O
)	O
and	O
flips	O
(	O
when	O
the	O
animal	B-OG
clung	O
to	O
the	O
cylinder	O
)	O
were	O
also	O
counted	O
.	O

Induction	O
of	O
EAE	B-DS
and	O
2ccPA	O
treatment	O

Female	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
immunized	O
with	O
MOG35	O
−	O
55	O
/	O
CFA	O
emulsion	O
pertussis	B-GP
toxin	I-GP
kits	O
(	O
EK	O
-	O
2110	O
,	O
Hooke	O
laboratories	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
[	O
26	O
,	O
27	O
].	O

Briefly	O
,	O
0	O
.	O
1	O
ml	O
MOG35	O
−	O
55	O
/	O
CFA	O
emulsion	O
was	O
injected	O
subcutaneously	O
into	O
both	O
flanks	O
of	O
each	O
mouse	B-OG
(	O
0	O
.	O
2	O
ml	O
/	O
animal	B-OG
,	O
200	O
μg	O
of	O
MOG35	O
−	O
55	O
peptide	O
in	O
each	O
0	O
.	O
2	O
ml	O
dose	O
).	O

Mice	B-OG
then	O
received	O
intraperitoneal	O
injections	O
of	O
pertussis	B-GP
toxin	I-GP
(	O
0	O
.	O
1	O
ml	O
/	O
animal	O
/	O
day	O
,	O
400	O
ng	O
pertussis	B-GP
toxin	I-GP
in	O
each	O
0	O
.	O
1	O
ml	O
dose	O
)	O
on	O
the	O
same	O
day	O
and	O
24	O
h	O
later	O
.	O

The	O
day	O
after	O
the	O
last	O
injection	O
of	O
MOG	B-GP
was	O
considered	O
day	O
1	O
.	O

Clinical	O
signs	O
were	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
clinical	O
sign	O
;	O
0	O
.	O
5	O
,	O
partial	O
tail	O
paralysis	O
;	O
1	O
.	O
0	O
,	O
complete	O
tail	O
paralysis	O
;	O
1	O
.	O
5	O
,	O
complete	O
tail	O
paralysis	O
and	O
discrete	O
hind	O
limb	O
weakness	O
;	O
2	O
.	O
0	O
,	O
complete	O
tail	O
paralysis	O
and	O
strong	O
hind	O
limb	O
weakness	O
;	O
2	O
.	O
5	O
,	O
unilateral	O
hind	O
limb	O
paralysis	O
;	O
3	O
,	O
complete	O
hind	O
limb	O
paralysis	O
;	O
3	O
.	O
5	O
,	O
hind	O
limb	O
paralysis	O
and	O
forelimb	O
weakness	O
;	O
4	O
.	O
0	O
,	O
complete	O
paralysis	O
(	O
tetraplegia	O
),	O
and	O
5	O
.	O
0	O
,	O
moribund	O
or	O
dead	O
[	O
26	O
,	O
27	O
].	O

In	O
each	O
mouse	B-OG
,	O
2ccPA	O
was	O
administered	O
at	O
a	O
dose	O
of	O
16	O
mg	O
/	O
kg	O
via	O
intraperitoneal	O
injection	O
once	O
daily	O
for	O
the	O
duration	O
of	O
the	O
EAE	B-DS
protocol	O
(	O
days	O
0	O
–	O
30	O
or	O
17	O
–	O
30	O
).	O

Sections	O
were	O
stained	O
H	O
&	O
E	O
.	O

Five	O
random	O
sections	O
from	O
each	O
mouse	B-OG
were	O
observed	O
to	O
evaluate	O
the	O
degree	O
of	O
inflammation	O
[	O
28	O
].	O

For	O
evaluation	O
of	O
inflammation	O
,	O
a	O
four	O
-	O
point	O
scale	O
was	O
graded	O
as	O
follows	O
:	O
0	O
,	O
no	O
sign	O
or	O
minimal	O
inflammation	O
;	O
1	O
,	O
inflammatory	O
cell	O
infiltrates	O
in	O
meninges	O
;	O
2	O
,	O
perivascular	O
inflammatory	O
cell	O
infiltrates	O
;	O
and	O
3	O
,	O
marked	O
infiltration	O
of	O
inflammatory	O
cells	O
into	O
the	O
parenchyma	O
.	O

The	O
histological	O
score	O
represented	O
the	O
mean	O
of	O
the	O
scores	O
of	O
all	O
sections	O
examined	O
[	O
28	O
].	O

Immunohistochemistry	O

Brain	O
sections	O
were	O
incubated	O
with	O
rabbit	B-OG
anti	O
-	O
Iba1	B-GP
antibody	B-GP
(	O
Wako	O
,	O
1	O
:	O
250	O
),	O
rabbit	B-OG
anti	O
-	O
CD4	B-GP
antibody	B-GP
(	O
Bioss	O
,	O
1	O
:	O
250	O
),	O
and	O
rat	B-OG
anti	O
-	O
F4	B-GP
/	O
80	O
antibody	B-GP
(	O
Bio	O
-	O
Rad	O
,	O
1	O
:	O
250	O
)	O
at	O
4	O
°	O
C	O
overnight	O
,	O
followed	O
by	O
incubation	O
at	O
room	O
temperature	O
for	O
1	O
h	O
with	O
the	O
secondary	O
antibody	B-GP
(	O
Cy3	O
-	O
conjugated	O
AffiniPure	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
IgG	B-GP
,	O
Jackson	O
ImmunoReseach	O
,	O
1	O
:	O
500	O
).	O

Sections	O
were	O
acquired	O
using	O
a	O
KEYENCE	O
BZ	O
-	O
X700	O
microscope	O
(	O
Keyence	O
Corporation	O
).	O

The	O
images	O
were	O
acquired	O
sequentially	O
using	O
the	O
561	O
nm	O
wavelength	O
of	O
a	O
light	O
-	O
emitting	O
diode	O
(	O
LED	O
)	O
to	O
Cy3	O
.	O

All	O
images	O
were	O
acquired	O
using	O
a	O
UPLSAPO	O
×	O
40	O
numerical	O
aperture	O
0	O
.	O
95	O
dry	O
objective	O
lens	O
(	O
Olympus	O
).	O

The	O
fluorescence	O
intensity	O
was	O
measured	O
by	O
ImageJ	O
1	O
.	O
46r	O
.	O

Statistical	O
analysis	O

The	O
number	O
of	O
falls	O
and	O
flips	O
was	O
analyzed	O
using	O
a	O
nonparametric	O
Kruskal	O
-	O
Wallis	O
test	O
.	O

EAE	B-DS
score	O
was	O
analyzed	O
using	O
a	O
nonparametric	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

The	O
protein	O
levels	O
of	O
oligodendrocyte	O
and	O
astrocyte	O
markers	O
were	O
analyzed	O
using	O
a	O
student	O
’	O
s	O
t	O
test	O
.	O

All	O
other	O
data	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Newman	O
-	O
Keuls	O
post	O
hoc	O
test	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
GraphPad	O
Prism	O
Ver	O
.	O

5	O
.	O
01	O
(	O
Graphpad	O
Software	O
Inc	O
.)	O
and	O
expressed	O
as	O
the	O
mean	O
±	O
SEM	O
.	O
P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O

2ccPA	O
protected	O
oligodendrocyte	O
cells	O
from	O
mitochondrial	O
apoptosis	O

We	O
undertook	O
in	O
vitro	O
investigations	O
using	O
the	O
MO3	O
.	O
13	O
oligodendrocyte	O
cell	O
line	O
,	O
an	O
immortalized	O
human	B-OG
-	O
human	B-OG
hybrid	O
cell	O
line	O
that	O
can	O
undergo	O
differentiation	O
into	O
an	O
oligodendrocyte	O
phenotype	O
.	O

In	O
the	O
present	O
study	O
,	O
undifferentiated	O
MO3	O
.	O
13	O
cells	O
with	O
few	O
processes	O
(	O
Fig	O
.	O
2b	O
)	O
were	O
cultured	O
in	O
DMEM	O
without	O
FBS	O
for	O
5	O
days	O
to	O
induce	O
differentiation	O
.	O

Serum	O
-	O
starved	O
differentiated	O
MO3	O
.	O
13	O
cells	O
exhibited	O
increases	O
in	O
process	O
length	O
(	O
Fig	O
.	O
2c	O
).	O

Differentiated	O
cells	O
exhibited	O
expression	O
of	O
the	O
oligodendrocyte	O
markers	O
MBP	B-GP
and	O
Olig1	B-GP
(	O
Fig	O
.	O
2d	O
–	O
f	O
)	O
and	O
decreased	O
expression	O
of	O
the	O
astrocyte	O
marker	O
GS	O
(	O
Fig	O
.	O
2d	O
,	O
g	O
).	O

No	O
GFAP	B-GP
(	O
another	O
astrocytic	O
marker	O
)	O
expression	O
was	O
detected	O
in	O
either	O
phenotype	O
(	O
Fig	O
.	O
2d	O
).	O

Differentiated	O
MO3	O
.	O
13	O
cells	O
were	O
then	O
used	O
for	O
subsequent	O
experiments	O
.	O

To	O
induce	O
mitochondrial	O
apoptosis	O
in	O
vitro	O
,	O
CoCl2	O
(	O
cobalt	O
chloride	O
),	O
a	O
chemical	O
mitochondrial	O
apoptosis	O
-	O
inducing	O
agent	O
,	O
was	O
added	O
in	O
the	O
presence	O
or	O
absence	O
of	O
2ccPA	O
,	O
and	O
cell	O
viability	O
was	O
evaluated	O
using	O
MTT	O
.	O

Treatment	O
with	O
2ccPA	O
significantly	O
increased	O
cell	O
viability	O
in	O
the	O
presence	O
of	O
CoCl2	O
(	O
Fig	O
.	O
2h	O
).	O

The	O
Bcl	B-GP
-	I-GP
2	I-GP
family	O
is	O
an	O
important	O
regulator	O
of	O
mitochondrial	O
dysfunction	O
,	O
which	O
is	O
induced	O
via	O
apoptosis	O
pathways	O
.	O

Mitochondrial	O
dysfunction	O
induces	O
an	O
increase	O
in	O
the	O
expression	O
of	O
proapoptotic	O
proteins	O
,	O
such	O
as	O
Bax	B-GP
,	O
and	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
antiapoptotic	B-GP
proteins	I-GP
,	O
such	O
as	O
Bcl	B-GP
-	I-GP
2	I-GP
.	O

Bax	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
levels	O
were	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
Fig	O
.	O
2i	O
),	O
and	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
expression	O
ratio	O
was	O
evaluated	O
(	O
Fig	O
.	O
2j	O
).	O

The	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
increased	O
with	O
CoCl2	O
exposure	O
.	O

Treatment	O
with	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
increase	O
in	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
,	O
which	O
suggested	O
that	O
2ccPA	O
protected	O
oligodendrocyte	O
cells	O
from	O
CoCl2	O
-	O
induced	O
mitochondrial	O
apoptosis	O
.	O

In	O
addition	O
,	O
we	O
observed	O
activation	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
during	O
CoCl2	O
-	O
induced	O
apoptosis	O
[	O
29	O
,	O
30	O
].	O

CoCl2	O
increased	O
the	O
phosphorylation	O
levels	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
protein	O
,	O
which	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
2k	O
,	O
l	O
).	O

These	O
data	O
indicate	O
that	O
2ccPA	O
suppressed	O
the	O
CoCl2	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
the	O
phosphorylation	O
of	O
p38MAPK	B-GP
and	O
JNK	B-GP
.	O
Fig	O
.	O
2Structure	O
and	O
effect	O
of	O
2ccPA	O
on	O
CoCl2	O
-	O
induced	O
apoptosis	O
.	O

Structure	O
of	O
2ccPA	O
18	O
:	O
1	O
.	O

2ccPA	O
is	O
the	O
compound	O
in	O
which	O
one	O
of	O
the	O
phosphate	O
oxygen	O
is	O
replaced	O
with	O
a	O
methylene	O
group	O
at	O
the	O
sn	O
-	O
2	O
position	O
(	O
a	O
).	O

Chemically	O
synthesized	O
cPA	O
derivative	O
,	O
2ccPA	O
,	O
used	O
for	O
the	O
present	O
experiments	O
.	O

Light	O
microscopic	O
undifferentiated	O
MO3	O
.	O
13	O
cells	O
(	O
b	O
)	O
and	O
differentiated	O
MO3	O
.	O
13	O
cells	O
(	O
c	O
).	O
Scale	O
bar	O
=	O
100	O
μm	O
.	O

The	O
protein	O
levels	O
of	O
MBP	B-GP
,	O
Olig1	B-GP
,	O
GFAP	B-GP
,	O
GS	B-GP
,	O
and	O
GAPDH	B-GP
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
d	O
).	O

Protein	O
levels	O
of	O
MBP	B-GP
(	O
e	O
),	O
Olig1	B-GP
(	O
f	O
),	O
and	O
GS	B-GP
(	O
g	O
).	O

Data	O
are	O
presented	O
as	O
the	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
.	O

Statistical	O
analysis	O
were	O
performed	O
using	O
a	O
student	O
’	O
s	O
t	O
test	O
.	O

(*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
vs	O
.	O
control	O
).	O

MO3	O
.	O
13	O
cells	O
were	O
incubated	O
with	O
500	O
μm	O
CoCl2	O
in	O
the	O
presence	O
of	O
10	O
μm	O
2ccPA	O
.	O

Cell	O
viability	O
of	O
MO3	O
.	O
13	O
cells	O
were	O
evaluated	O
using	O
MTT	O
assay	O
(	O
h	O
).	O

The	O
protein	O
levels	O
of	O
Bax	B-GP
,	O
Bcl	B-GP
-	I-GP
2	I-GP
,	O
phosphorylated	O
-	O
p38MAPK	B-GP
(	O
p	O
-	O
p38MAPK	B-GP
),	O
phosphorylated	O
-	O
JNK	B-GP
(	O
p	O
-	O
JNK	B-GP
),	O
and	O
GAPDH	B-GP
were	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
i	O
).	O

The	O
expression	O
of	O
Bax	B-GP
and	O
Bcl	B-GP
-	I-GP
2	I-GP
was	O
determined	O
using	O
a	O
densitometer	O
,	O
and	O
the	O
Bax	B-GP
/	O
Bcl	B-GP
-	I-GP
2	I-GP
ratio	O
was	O
calculated	O
(	O
j	O
).	O

Protein	O
levels	O
of	O
p	O
-	O
p38MAPK	B-GP
(	O
k	O
)	O
and	O
p	O
-	O
JNK	B-GP
(	O
l	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CoCl2	O
)	O

2ccPA	O
suppressed	O
the	O
cuprizone	B-CD
-	O
induced	O
acute	O
peak	O
demyelination	O

To	O
investigate	O
the	O
effects	O
of	O
2ccPA	O
on	O
cuprizone	B-CD
-	O
induced	O
acute	O
peak	O
demyelination	O
,	O
we	O
fed	O
mice	B-OG
a	O
cuprizone	B-CD
diet	O
and	O
administrated	O
2ccPA	O
for	O
5	O
weeks	O
(	O
Fig	O
.	O
1	O
,	O
protocol	O
A	O
).	O

Myelin	O
content	O
was	O
quantified	O
using	O
Black	O
-	O
Gold	O
II	O
staining	O
.	O

In	O
control	O
mice	B-OG
,	O
the	O
corpus	O
callosum	O
appeared	O
to	O
retain	O
sufficient	O
myelin	O
content	O
(	O
Fig	O
.	O
3a	O
).	O

Five	O
weeks	O
of	O
cuprizone	B-CD
exposure	O
induced	O
acute	O
peak	O
demyelination	O
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
3b	O
).	O

2ccPA	O
treatment	O
suppressed	O
the	O
acute	O
peak	O
demyelination	O
almost	O
completely	O
(	O
Fig	O
.	O
3c	O
,	O
d	O
).	O

Electron	O
microscopy	O
was	O
then	O
used	O
to	O
obtain	O
data	O
for	O
quantitative	O
analysis	O
of	O
myelinated	O
axons	O
,	O
axonal	O
diameter	O
,	O
and	O
g	O
-	O
ratios	O
.	O

Control	O
mice	B-OG
exhibited	O
full	O
myelination	O
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
3e	O
).	O

In	O
contrast	O
,	O
mice	B-OG
exposed	O
to	O
cuprizone	B-CD
for	O
5	O
weeks	O
exhibited	O
a	O
decrease	O
in	O
the	O
extent	O
of	O
myelination	O
and	O
residual	O
myelin	O
sheaths	O
(	O
Fig	O
.	O
3f	O
),	O
while	O
treatment	O
with	O
2ccPA	O
attenuated	O
this	O
decrease	O
in	O
myelination	O
(	O
Fig	O
.	O
3g	O
).	O

In	O
addition	O
,	O
2ccPA	O
treatment	O
significantly	O
increased	O
the	O
number	O
of	O
myelinated	O
axons	O
(	O
Fig	O
.	O
3h	O
),	O
reduced	O
axonal	O
diameter	O
(	O
Fig	O
.	O
3i	O
),	O
and	O
lowered	O
g	O
-	O
ratios	O
(	O
Fig	O
.	O
3j	O
)	O
in	O
comparison	O
to	O
values	O
obtained	O
for	O
cuprizone	B-CD
-	O
treated	O
mice	B-OG
.	O

These	O
findings	O
indicate	O
that	O
treatment	O
with	O
2ccPA	O
suppresses	O
cuprizone	B-CD
-	O
induced	O
axonal	O
damage	O
and	O
demyelination	O
.	O
Fig	O
.	O
32ccPA	O
suppressed	O
the	O
cuprizone	B-CD
-	O
induced	O
acute	O
peak	O
demyelination	O
.	O

Representative	O
photomicrographs	O
of	O
coronal	O
brain	O
sections	O
at	O
the	O
level	O
of	O
the	O
fimbria	O
demonstrate	O
progressive	O
demyelination	O
of	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
cuprizone	B-CD
(	O
CPZ	O
)	O
exposure	O
.	O

Black	O
-	O
Gold	O
II	O
staining	O
in	O
the	O
control	O
(	O
a	O
),	O
CPZ	O
+	O
Ssaline	O
(	O
b	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
c	O
)	O
groups	O
.	O

Myelin	O
densities	O
in	O
the	O
corpus	O
callosum	O
(	O
d	O
)	O
were	O
compared	O
with	O
those	O
of	O
controls	O
and	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
control	O
value	O
using	O
the	O
ImageJ	O
analysis	O
program	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O
Scale	O
bars	O
=	O
500	O
mm	O
.	O

Electron	O
micrographs	O
demonstrate	O
an	O
acute	O
peak	O
demyelination	O
of	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
CPZ	B-GP
exposure	O
.	O

Electron	O
micrographs	O
of	O
control	O
(	O
e	O
),	O
CPZ	O
+	O
Saline	O
(	O
f	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
g	O
)	O
in	O
the	O
corpus	O
callosum	O
.	O

Myelinated	O
axons	O
(	O
h	O
),	O
axonal	O
diameter	O
(	O
i	O
),	O
and	O
g	O
-	O
ratio	O
(	O
j	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
7	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
Saline	O
).	O
Scale	O
bar	O
=	O
5	O
μm	O

2ccPA	O
suppressed	O
the	O
neuroinflammation	O

We	O
evaluated	O
glial	O
activation	O
and	O
inflammasome	O
formation	O
to	O
investigate	O
the	O
effect	O
of	O
2ccPA	O
on	O
the	O
neuroinflammation	O
associated	O
with	O
demyelination	O
.	O

Levels	O
of	O
gene	O
expression	O
for	O
the	O
microglial	O
marker	O
(	O
Iba1	B-GP
)	O
and	O
astrocytic	O
marker	O
(	O
GFAP	B-GP
)	O
were	O
evaluated	O
after	O
5	O
weeks	O
of	O
cuprizone	B-CD
.	O

Cuprizone	B-CD
exposure	O
increased	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
of	O
Iba1	B-GP
and	O
GFAP	B-GP
.	O

2ccPA	O
treatment	O
suppressed	O
cuprizone	B-CD
-	O
induced	O
increases	O
in	O
Iba1	B-GP
and	O
GFAP	B-GP
mRNA	O
expression	O
(	O
Fig	O
.	O
4a	O
,	O
b	O
).	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
NLRP3	B-GP
inflammasome	O
plays	O
an	O
essential	O
role	O
in	O
neuroinflammatory	B-DS
diseases	I-DS
including	O
multiple	B-DS
sclerosis	I-DS
[	O
9	O
].	O

We	O
analyzed	O
the	O
gene	O
expression	O
levels	O
of	O
NLRP3	B-GP
inflammasome	O
-	O
related	O
genes	O
such	O
as	O
NLRP3	B-GP
,	O
P2X7R	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

NLRP3	B-GP
,	O
P2X7R	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
expression	O
levels	O
were	O
increased	O
by	O
cuprizone	B-CD
exposure	O
and	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4c	O
–	O
e	O
).	O

Iba1	B-GP
-	O
positive	O
microglia	O
were	O
detected	O
by	O
immunofluorescence	O
analysis	O
in	O
the	O
corpus	O
callosum	O
(	O
Fig	O
.	O
4f	O
–	O
k	O
).	O

Microglia	O
were	O
seen	O
only	O
sporadically	O
in	O
the	O
corpus	O
callosum	O
of	O
the	O
control	O
mice	B-OG
(	O
Fig	O
.	O
4f	O
,	O
g	O
).	O

Mice	B-OG
exposed	O
to	O
cuprizone	B-CD
exhibited	O
hypertrophic	O
microglia	O
with	O
enlarged	O
cell	O
bodies	O
(	O
Fig	O
.	O
4h	O
,	O
i	O
),	O
which	O
were	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4j	O
,	O
k	O
).	O

The	O
cuprizone	B-CD
-	O
induced	O
increases	O
in	O
microglia	O
in	O
the	O
corpus	O
callosum	O
were	O
reduced	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
4l	O
).	O

We	O
observed	O
no	O
significant	O
difference	O
in	O
levels	O
of	O
gene	O
expression	O
for	O
the	O
alternative	O
markers	O
of	O
microglial	O
activation	O
Arg1	B-GP
,	O
Fizz1	B-GP
,	O
and	O
Ym1	B-GP
among	O
corpus	O
callosum	O
tissue	O
samples	O
(	O
Control	O
,	O
CPZ	O
+	O
saline	O
,	O
CPZ	O
+	O
2ccPA	O
)	O
(	O
data	O
not	O
shown	O
).	O

These	O
findings	O
indicate	O
that	O
treatment	O
with	O
2ccPA	O
effectively	O
suppressed	O
cuprizone	B-CD
-	O
induced	O
NLRP3	B-GP
inflammasome	O
formation	O
and	O
microglial	O
activation	O
.	O
Fig	O
.	O
42ccPA	O
suppressed	O
the	O
neuroinflammation	O
.	O

The	O
mRNA	O
levels	O
of	O
Iba1	B-GP
(	O
a	O
),	O
GFAP	B-GP
(	O
b	O
),	O
NLRP3	B-GP
(	O
c	O
),	O
P2X7R	B-GP
(	O
d	O
),	O
and	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
e	O
)	O
relative	O
to	O
PGK1	B-GP
,	O
as	O
determined	O
by	O
qPCR	O
in	O
the	O
corpus	O
callosum	O
after	O
5	O
weeks	O
of	O
CPZ	O
exposure	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Immunostaining	O
with	O
anti	O
-	O
Iba1	B-GP
showed	O
microglial	O
activation	O
in	O
the	O
corpus	O
callosum	O
.	O

Control	O
(	O
f	O
,	O
g	O
),	O
CPZ	O
+	O
saline	O
(	O
h	O
,	O
i	O
),	O
and	O
CPZ	O
+	O
2ccPA	O
(	O
j	O
,	O
k	O
).	O

Number	O
of	O
microglia	O
in	O
the	O
corpus	O
callosum	O
(	O
l	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
6	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
01	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O
Scale	O
bar	O
500	O
-	O
μm	O
left	O
images	O
;	O
50	O
-	O
μm	O
right	O
images	O

Beneficial	O
effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
cuprizone	B-CD
-	O
induced	O
demyelination	O

We	O
investigated	O
the	O
therapeutic	O
potential	O
of	O
2ccPA	O
in	O
cuprizone	B-CD
-	O
induced	O
demyelination	B-DS
.	O

In	O
three	O
experimental	O
settings	O
,	O
2ccPA	O
treatment	O
was	O
administrated	O
during	O
at	O
weeks	O
3	O
–	O
5	O
(	O
protocol	O
B	O
:	O
beginning	O
of	O
substantial	O
demyelination	O
and	O
motor	O
dysfunction	O
),	O
weeks	O
5	O
–	O
6	O
(	O
protocol	O
C	O
:	O
spontaneous	O
remyelination	O
),	O
or	O
weeks	O
5	O
–	O
10	O
(	O
protocol	O
D	O
:	O
chronic	O
severe	O
demyelination	O
)	O
of	O
cuprizone	B-CD
exposure	O
.	O

Treatment	O
with	O
2ccPA	O
(	O
protocol	O
B	O
)	O
suppressed	O
acute	O
peak	O
demyelination	O
after	O
the	O
onset	O
of	O
cuprizone	B-CD
-	O
induced	O
neurological	O
symptoms	O
(	O
Fig	O
.	O
5a	O
–	O
d	O
).	O

It	O
is	O
well	O
known	O
that	O
spontaneous	O
remyelination	O
occurs	O
following	O
acute	O
demyelination	O
in	O
the	O
corpus	O
callosum	O
of	O
cuprizone	B-CD
model	O
mice	B-OG
.	O

At	O
6	O
weeks	O
of	O
cuprizone	B-CD
exposure	O
,	O
we	O
observed	O
spontaneous	O
remyelination	O
in	O
cuprizone	B-CD
mice	B-OG
(	O
Fig	O
.	O
5f	O
).	O

Treatment	O
with	O
2ccPA	O
during	O
the	O
final	O
week	O
(	O
protocol	O
C	O
)	O
significantly	O
promoted	O
spontaneous	O
remyelination	O
(	O
Fig	O
.	O
5e	O
–	O
h	O
).	O

Prolonged	O
cuprizone	B-CD
exposure	O
resulted	O
in	O
chronic	O
demyelination	O
.	O

Treatment	O
with	O
2ccPA	O
(	O
5	O
–	O
10	O
weeks	O
)	O
reduced	O
chronic	O
demyelination	O
(	O
Fig	O
.	O
5i	O
–	O
l	O
).	O

These	O
results	O
demonstrate	O
that	O
2ccPA	O
exerts	O
beneficial	O
effects	O
in	O
the	O
multiperiod	O
of	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
.	O
Fig	O
.	O
5Effects	O
of	O
2ccPA	O
in	O
the	O
multiperiod	O
of	O
CPZ	B-GP
-	O
induced	O
demyelination	O
and	O
motor	O
dysfunction	O
.	O

Black	O
-	O
Gold	O
II	O
staining	O
of	O
control	O
(	O
a	O
,	O
e	O
,	O
and	O
i	O
),	O
CPZ	O
+	O
saline	O
(	O
b	O
,	O
f	O
,	O
and	O
j	O
),	O
CPZ	O
+	O
2ccPA	O
(	O
c	O
,	O
g	O
,	O
and	O
k	O
).	O

Myelin	O
densities	O
in	O
the	O
corpus	O
callosum	O
(	O
d	O
,	O
h	O
,	O
and	O
l	O
)	O
were	O
compared	O
with	O
controls	O
and	O
expressed	O
as	O
a	O
percentage	O
of	O
control	O
value	O
using	O
the	O
ImageJ	O
analysis	O
program	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
##	O
p	O
<	O
0	O
.	O
01	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O
Scale	O
bars	O
=	O
500	O
μm	O
.	O

Motor	O
performance	O
on	O
the	O
rotarod	O
.	O

Mice	B-OG
were	O
assessed	O
for	O
locomotion	O
time	O
during	O
a	O
period	O
of	O
300	O
s	O
(	O
m	O
,	O
o	O
,	O
and	O
q	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
12	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
).	O

Number	O
of	O
falls	O
and	O
flips	O
(	O
n	O
,	O
p	O
,	O
and	O
r	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
.,	O
n	O
=	O
12	O
animals	B-OG
(	O
0	O
–	O
5	O
weeks	O
group	O
),	O
n	O
=	O
10	O
animals	B-OG
(	O
3	O
–	O
5	O
weeks	O
group	O
),	O
and	O
n	O
=	O
15	O
animals	B-OG
(	O
5	O
–	O
10	O
weeks	O
group	O
).	O

Statistical	O
analysis	O
was	O
performed	O
using	O
non	O
-	O
parametric	O
Kruskal	O
-	O
Wallis	O
test	O
(*	O
p	O
<	O
0	O
.	O
05	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
05	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
CPZ	O
+	O
saline	O
)	O

2ccPA	O
improved	O
cuprizone	B-CD
-	O
induced	O
motor	O
dysfunction	O

To	O
investigate	O
the	O
effects	O
of	O
2ccPA	O
on	O
motor	O
dysfunction	O
caused	O
by	O
cuprizone	B-CD
-	O
induced	O
demyelination	B-DS
,	O
we	O
assessed	O
the	O
locomotor	O
coordination	O
and	O
balance	O
of	O
mice	B-OG
using	O
a	O
rotarod	O
apparatus	O
.	O

Mice	B-OG
exposed	O
to	O
cuprizone	B-CD
(	O
0	O
–	O
5	O
and	O
5	O
–	O
10	O
weeks	O
)	O
exhibited	O
significant	O
decreases	O
in	O
locomotion	O
time	O
as	O
well	O
as	O
significant	O
increases	O
in	O
the	O
number	O
of	O
falls	O
and	O
flips	O
.	O

Treatment	O
with	O
2ccPA	O
(	O
protocols	O
A	O
,	O
B	O
,	O
and	O
D	O
)	O
significantly	O
restored	O
locomotion	O
time	O
remarkably	O
(	O
Fig	O
.	O
5m	O
,	O
o	O
,	O
and	O
q	O
)	O
and	O
suppressed	O
the	O
number	O
of	O
falls	O
and	O
flips	O
(	O
Fig	O
.	O
5n	O
,	O
p	O
,	O
and	O
r	O
).	O

2ccPA	O
treatment	O
significantly	O
suppressed	O
the	O
cuprizone	B-CD
-	O
induced	O
impairment	O
of	O
motor	O
performance	O
.	O

2ccPA	O
ameliorated	O
EAE	B-DS
pathology	O

We	O
assessed	O
the	O
potential	O
of	O
2ccPA	O
to	O
improve	O
the	O
disease	O
course	O
in	O
the	O
EAE	B-DS
model	O
mice	B-OG
.	O

Mice	B-OG
were	O
monitored	O
daily	O
for	O
clinical	O
symptoms	O
and	O
scored	O
in	O
accordance	O
with	O
established	O
criteria	O
[	O
31	O
].	O

Control	O
mice	B-OG
exhibited	O
no	O
obvious	O
symptoms	O
of	O
EAE	B-DS
disease	O
.	O

In	O
contrast	O
,	O
EAE	B-DS
mice	B-OG
developed	O
severe	O
EAE	B-DS
symptoms	O
,	O
although	O
treatment	O
with	O
2ccPA	O
significantly	O
reduced	O
clinical	O
EAE	B-DS
scores	O
.	O

Indeed	O
,	O
a	O
large	O
difference	O
in	O
disease	O
severity	O
between	O
the	O
control	O
and	O
treatment	O
groups	O
was	O
observed	O
throughout	O
the	O
observation	O
period	O
(	O
Fig	O
.	O
6a	O
).	O

Mean	O
clinical	O
EAE	B-DS
scores	O
were	O
significantly	O
lower	O
for	O
2ccPA	O
-	O
treated	O
mice	B-OG
than	O
EAE	B-DS
mice	B-OG
.	O

Although	O
EAE	B-DS
mice	B-OG
peaked	O
at	O
scores	O
of	O
3	O
–	O
4	O
following	O
immunization	O
,	O
2ccPA	O
-	O
treated	O
mice	B-OG
peaked	O
at	O
scores	O
of	O
1	O
following	O
immunization	O
.	O

We	O
then	O
examined	O
the	O
therapeutic	O
potential	O
of	O
2ccPA	O
in	O
mice	B-OG
already	O
exhibiting	O
EAE	B-DS
symptoms	O
.	O

2ccPA	O
successfully	O
attenuated	O
clinical	O
EAE	B-DS
symptoms	O
even	O
after	O
the	O
peak	O
stages	O
of	O
disease	O
(	O
Fig	O
.	O
6b	O
),	O
suggesting	O
that	O
treatment	O
with	O
2ccPA	O
dramatically	O
suppresses	O
impairments	O
in	O
neurological	O
function	O
.	O

Inflammatory	O
infiltration	O
of	O
immune	O
cells	O
in	O
the	O
spinal	O
cord	O
is	O
a	O
well	O
-	O
documented	O
histological	O
feature	O
of	O
the	O
EAE	B-DS
model	O
.	O

Inflammatory	O
infiltration	O
of	O
immune	O
cells	O
in	O
the	O
spinal	O
cords	O
was	O
a	O
histological	O
feature	O
of	O
the	O
EAE	B-DS
model	O
.	O

The	O
spinal	O
cords	O
were	O
stained	O
with	O
H	O
&	O
E	O
to	O
assess	O
the	O
degree	O
of	O
inflammation	O
.	O

Inflammatory	O
cells	O
penetrated	O
the	O
pia	O
mater	O
and	O
infiltrated	O
the	O
perivascular	O
regions	O
and	O
parenchyma	O
.	O

Control	O
myelin	O
of	O
the	O
white	O
matter	O
was	O
highlighted	O
clearly	O
by	O
H	O
&	O
E	O
staining	O
(	O
Fig	O
.	O
6c	O
).	O

In	O
EAE	B-DS
mice	B-OG
,	O
we	O
found	O
mononuclear	O
infiltration	O
in	O
the	O
leptomeninges	O
and	O
scattered	O
throughout	O
the	O
white	O
matter	O
parenchyma	O
(	O
Fig	O
.	O
6d	O
).	O

We	O
observed	O
severe	O
inflammation	O
with	O
vacuolation	O
in	O
the	O
anterior	O
and	O
lateral	O
funiculi	O
of	O
the	O
spinal	O
cord	O
.	O

Treatment	O
with	O
2ccPA	O
reduced	O
infiltration	O
of	O
mononuclear	O
cells	O
(	O
Fig	O
.	O
6e	O
).	O

Treatment	O
with	O
2ccPA	O
suppressed	O
sustained	O
scores	O
for	O
inflammation	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6f	O
).	O
Fig	O
.	O
62ccPA	O
-	O
ameliorated	O
EAE	B-DS
pathological	O
condition	O
and	O
immunopathology	O
.	O

Mice	B-OG
treated	O
with	O
EAE	B-DS
+	O
saline	O
and	O
EAE	B-DS
+	O
2ccPA	O
were	O
immunized	O
with	O
the	O
MOG35	O
−	O
55	O
peptide	O
and	O
clinical	O
scores	O
were	O
assessed	O
daily	O
for	O
30	O
days	O
(	O
a	O
).	O

Treatment	O
with	O
2ccPA	O
after	O
the	O
peak	O
of	O
EAE	B-DS
symptoms	O
had	O
occurred	O
(	O
b	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
two	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Mann	O
-	O
Whitney	O
U	O
test	O
regarding	O
day	O
0	O
–	O
30	O
(	O
a	O
)	O
or	O
day	O
17	O
–	O
30	O
(	O
b	O
),	O
respectively	O
,	O
(**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
EAE	B-DS
+	O
saline	O
).	O

H	O
&	O
E	O
staining	O
revealed	O
histological	O
features	O
of	O
MOG35	O
−	O
55	O
-	O
induced	O
EAE	B-DS
.	O

Control	O
(	O
c	O
),	O
EAE	B-DS
+	O
saline	O
(	O
d	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
e	O
).	O

The	O
degrees	O
of	O
inflammation	O
(	O
f	O
).	O
Scale	O
bar	O
=	O
50	O
μm	O
.	O

Immunostaining	O
with	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O
.	O

Fluorescence	O
for	O
CD4	B-GP
,	O
DAPI	O
,	O
and	O
marge	O
images	O
.	O

Control	O
(	O
g	O
),	O
EAE	B-DS
+	O
saline	O
(	O
h	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
i	O
).	O

Number	O
of	O
infiltrating	O
T	O
cells	O
in	O
the	O
spinal	O
cord	O
(	O
m	O
).	O

Fluorescence	O
for	O
F4	O
/	O
80	O
,	O
DAPI	O
,	O
and	O
marge	O
images	O
.	O

Control	O
(	O
j	O
),	O
EAE	B-DS
+	O
saline	O
(	O
k	O
),	O
EAE	B-DS
+	O
2ccPA	O
(	O
l	O
).	O

Number	O
of	O
infiltrating	O
macrophages	O
in	O
the	O
spinal	O
cord	O
(	O
n	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
,	O
n	O
=	O
5	O
animals	B-OG
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
hoc	O
Newman	O
-	O
Keuls	O
test	O
(**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
control	O
;	O
#	O
p	O
<	O
0	O
.	O
05	O
;	O
###	O
p	O
<	O
0	O
.	O
001	O
vs	O
.	O
EAE	B-DS
+	O
saline	O
).	O
Scale	O
bar	O
=	O
100	O
μm	O

2ccPA	O
suppressed	O
CD4	B-GP
-	O
or	O
F4	B-GP
/	O
80	O
-	O
positive	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O

Infiltration	O
of	O
immune	O
cells	O
(	O
T	O
cells	O
and	O
macrophages	O
)	O
was	O
observed	O
in	O
mice	B-OG
exposed	O
to	O
EAE	B-DS
,	O
although	O
these	O
increases	O
were	O
suppressed	O
following	O
2ccPA	O
administration	O
.	O

Immunofluorescence	O
in	O
the	O
spinal	O
cord	O
was	O
evaluated	O
using	O
the	O
T	O
cell	O
marker	O
CD4	B-GP
and	O
macrophage	O
marker	O
F4	B-GP
/	O
80	O
.	O

In	O
control	O
mice	B-OG
,	O
CD4	B-GP
-	O
and	O
F4	O
/	O
80	O
-	O
positive	O
cells	O
were	O
sporadically	O
distributed	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6g	O
,	O
j	O
),	O
while	O
an	O
accumulation	O
of	O
infiltrative	O
cells	O
was	O
observed	O
in	O
meningeal	O
area	O
of	O
the	O
spinal	O
cord	O
in	O
mice	B-OG
exposed	O
to	O
EAE	B-DS
(	O
Fig	O
.	O
6h	O
,	O
k	O
).	O

Mice	B-OG
exposed	O
to	O
EAE	B-DS
exhibited	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
,	O
although	O
such	O
infiltration	O
was	O
suppressed	O
by	O
2ccPA	O
treatment	O
(	O
Fig	O
.	O
6i	O
,	O
l	O
).	O

Therefore	O
,	O
treatment	O
with	O
2ccPA	O
effectively	O
suppressed	O
EAE	B-DS
-	O
induced	O
T	O
cell	O
and	O
macrophage	O
infiltration	O
in	O
the	O
spinal	O
cord	O
(	O
Fig	O
.	O
6m	O
,	O
n	O
).	O

Discussion	O

Multiple	B-DS
sclerosis	I-DS
is	O
a	O
heterogeneous	O
disease	O
in	O
clinical	O
presentation	O
,	O
in	O
terms	O
of	O
demyelinating	O
lesions	O
,	O
immunopathological	O
subtypes	O
,	O
response	O
to	O
therapy	O
,	O
and	O
genetic	O
associations	O
[	O
6	O
,	O
32	O
].	O

A	O
detailed	O
immunopathological	O
investigation	O
of	O
demyelinating	O
lesions	O
revealed	O
four	O
distinct	O
immunopathological	O
patterns	O
[	O
6	O
].	O

In	O
patterns	O
I	O
and	O
II	O
,	O
demyelination	O
occurs	O
as	O
a	O
consequence	O
of	O
an	O
autoimmune	O
reaction	O
against	O
myelin	O
,	O
whereas	O
demyelination	O
is	O
independent	O
of	O
immune	O
activation	O
and	O
is	O
caused	O
by	O
oligodendrocyte	O
primary	O
cell	O
loss	O
in	O
patterns	O
III	O
and	O
IV	O
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
administration	O
of	O
EAE	B-DS
and	O
cuprizone	B-CD
reproduces	O
the	O
pathology	O
observed	O
in	O
patterns	O
I	O
/	O
II	O
and	O
patterns	O
III	O
/	O
IV	O
,	O
respectively	O
[	O
33	O
].	O

These	O
animal	B-OG
models	O
accurately	O
represent	O
all	O
aspects	O
of	O
the	O
pathology	O
and	O
clinical	O
features	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
[	O
34	O
].	O

The	O
findings	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
treatment	O
with	O
2ccPA	O
improved	O
cuprizone	B-CD
-	O
induced	O
motor	O
dysfunction	O
and	O
pathological	O
EAE	B-DS
scores	O
,	O
suggesting	O
that	O
2ccPA	O
may	O
exert	O
beneficial	O
effects	O
in	O
all	O
subtypes	O
of	O
human	B-OG
multiple	B-DS
sclerosis	I-DS
.	O

Neuroinflammation	O
(	O
e	O
.	O
g	O
.,	O
lymphocyte	O
/	O
macrophage	O
infiltration	O
,	O
microglial	O
activation	O
,	O
enhanced	O
cytokine	B-GP
/	O
chemokine	B-GP
production	O
,	O
demyelination	O
,	O
and	O
axonal	O
damage	O
[	O
35	O
–	O
37	O
])	O
is	O
a	O
key	O
component	O
of	O
the	O
pathological	O
progression	O
of	O
all	O
subtypes	O
of	O
multiple	B-DS
sclerosis	I-DS
and	O
in	O
both	O
the	O
EAE	B-DS
and	O
cuprizone	B-CD
models	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
neuroinflammation	O
in	O
the	O
EAE	B-DS
and	O
cuprizone	B-CD
models	O
.	O

2ccPA	O
treatment	O
suppressed	O
the	O
infiltration	O
of	O
CD4	B-GP
-	O
positive	O
T	O
cells	O
and	O
F4	O
/	O
80	O
-	O
positive	O
macrophages	O
to	O
the	O
spinal	O
cord	O
in	O
EAE	B-DS
model	O
mice	B-OG
.	O

CD4	B-GP
-	O
positive	O
T	O
cells	O
secrete	O
proinflammatory	O
cytokines	B-GP
,	O
which	O
play	O
important	O
roles	O
in	O
the	O
neuroinflammatory	O
,	O
cascade	O
,	O
and	O
mediate	O
the	O
damage	O
to	O
the	O
myelin	O
sheath	O
,	O
demyelination	O
,	O
and	O
eventually	O
damage	O
to	O
the	O
neuronal	O
axon	O
[	O
38	O
,	O
39	O
].	O

F4	B-GP
/	I-GP
80	O
-	O
positive	O
microglia	O
/	O
macrophages	O
produce	O
and	O
respond	O
to	O
a	O
wide	O
variety	O
of	O
cytokines	B-GP
,	O
impair	O
blood	O
-	O
brain	O
barrier	O
function	O
,	O
act	O
as	O
antigen	O
-	O
presenting	O
cells	O
within	O
the	O
CNS	O
,	O
mediate	O
phagocytic	O
events	O
,	O
and	O
damage	O
oligodendrocytes	O
[	O
40	O
,	O
41	O
].	O

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
inhibition	O
of	O
T	O
cells	O
and	O
macrophage	O
infiltrates	O
into	O
CNS	O
by	O
2ccPA	O
treatment	O
should	O
be	O
associated	O
with	O
suppression	O
of	O
neuroinflammation	O
in	O
EAE	B-DS
.	O

Further	O
,	O
we	O
also	O
demonstrated	O
that	O
2ccPA	O
suppressed	O
cuprizone	B-CD
-	O
induced	O
microglial	O
activation	O
and	O
NLRP3	B-GP
inflammasome	O
formation	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
demyelination	O
occurs	O
in	O
parallel	O
with	O
microglial	O
activation	O
in	O
the	O
cuprizone	B-CD
model	O
[	O
9	O
].	O

Activated	O
microglia	O
contribute	O
to	O
the	O
death	O
of	O
oligodendrocytes	O
by	O
secreting	O
proinflammatory	O
cytokines	B-GP
[	O
42	O
]	O
and	O
to	O
axonal	O
damage	O
[	O
43	O
]	O
by	O
stripping	O
synaptic	O
proteins	O
[	O
44	O
].	O

The	O
NLRP3	B-GP
inflammasome	O
signaling	O
pathway	O
is	O
involved	O
in	O
various	O
neuroinflammatory	B-DS
diseases	I-DS
,	O
including	O
multiple	B-DS
sclerosis	I-DS
and	O
the	O
EAE	B-DS
and	O
cuprizone	B-CD
models	O
.	O

Activation	O
of	O
the	O
P2X7	B-GP
receptor	I-GP
,	O
principally	O
by	O
extracellular	O
ATP	O
,	O
induces	O
NLRP3	B-GP
inflammasome	O
activation	O
and	O
promotes	O
the	O
processing	O
and	O
release	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

IL	B-GP
-	I-GP
1β	I-GP
is	O
a	O
pivotal	O
mediator	O
in	O
the	O
neuroinflammatory	O
response	O
[	O
9	O
]	O
and	O
promotes	O
leukocyte	O
infiltration	O
by	O
inducing	O
the	O
expression	O
of	O
many	O
cytokines	B-GP
,	O
chemokines	B-GP
,	O
and	O
adhesion	B-GP
molecules	I-GP
.	O

A	O
recent	O
study	O
has	O
reported	O
that	O
microglia	O
express	O
the	O
NLRP3	B-GP
inflammasome	O
and	O
release	O
IL	B-GP
-	I-GP
1β	I-GP
[	O
45	O
],	O
suggesting	O
that	O
the	O
microglial	O
NLRP3	B-GP
inflammasome	O
probably	O
promotes	O
CNS	O
inflammation	O
and	O
demyelination	O
.	O

In	O
our	O
study	O
,	O
2ccPA	O
suppressed	O
cuprizone	B-CD
-	O
induced	O
microglial	O
activation	O
and	O
NLRP3	B-GP
inflammasome	O
,	O
suggesting	O
that	O
2ccPA	O
suppressed	O
the	O
neuroinflammation	O
to	O
inhibit	O
the	O
microglial	O
NLRP3	B-GP
inflammasome	O
caused	O
by	O
excessive	O
microglial	O
activation	O
.	O

Microglia	O
are	O
known	O
to	O
develop	O
diverse	O
functional	O
phenotypes	O
of	O
proinflammatory	O
(	O
M1	O
)	O
and	O
alternative	O
(	O
M2	O
)	O
activation	O
[	O
46	O
,	O
47	O
].	O

Previous	O
findings	O
have	O
revealed	O
that	O
NLRP3	B-GP
promotes	O
microglial	O
M1	O
activation	O
and	O
that	O
the	O
NLRP3	B-GP
complex	O
is	O
contained	O
in	O
M1	O
microglia	O
[	O
48	O
].	O

In	O
the	O
present	O
study	O
,	O
2ccPA	O
treatment	O
suppressed	O
markers	O
of	O
the	O
NLRP3	B-GP
inflammasome	O
(	O
NLRP3	B-GP
,	O
P2X7	B-GP
,	O
and	O
IL	B-GP
-	I-GP
1b	I-GP
)	O
but	O
not	O
of	O
M2	O
microglia	O
(	O
Arg1	B-GP
,	O
Fizz1	B-GP
,	O
and	O
Ym1	B-GP
),	O
suggested	O
that	O
2ccPA	O
suppressed	O
the	O
microglial	O
M1	O
proinflammatory	O
activation	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
2ccPA	O
improves	O
the	O
pathological	O
state	O
of	O
EAE	B-DS
and	O
cuprizone	B-CD
model	O
mice	B-OG
by	O
mediating	O
the	O
attenuation	O
of	O
neuroinflammatory	O
conditions	O
(	O
i	O
.	O
e	O
.,	O
infiltration	O
of	O
immune	O
cells	O
and	O
microglial	O
NLRP3	B-GP
inflammasome	O
,	O
respectively	O
).	O

Under	O
neuroinflammatory	O
conditions	O
,	O
mitochondrial	O
apoptotic	O
cell	O
death	O
has	O
been	O
observed	O
following	O
damage	O
to	O
the	O
CNS	O
[	O
49	O
].	O

Mitochondrial	O
dysfunction	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
neuronal	O
axons	O
in	O
multiple	B-DS
sclerosis	I-DS
[	O
50	O
]	O
and	O
in	O
the	O
EAE	B-DS
and	O
cuprizone	B-CD
models	O
.	O

The	O
mitochondria	O
-	O
mediated	O
apoptosis	O
pathway	O
is	O
largely	O
controlled	O
by	O
the	O
master	O
apoptosis	O
inducer	O
Bax	B-GP
and	O
the	O
apoptosis	O
suppressor	O
Bcl	B-GP
-	I-GP
2	I-GP
[	O
51	O
].	O

Phosphorylation	O
and	O
activation	O
of	O
JNK	B-GP
and	O
p38MAPK	B-GP
also	O
promote	O
mitochondrial	O
apoptotic	O
cell	O
death	O
[	O
52	O
,	O
53	O
].	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
2ccPA	O
suppressed	O
CoCl2	O
-	O
induced	O
apoptosis	O
.	O

We	O
reported	O
previously	O
that	O
natural	O
cPA	O
suppressed	O
mitochondrial	O
apoptosis	O
of	O
neuronal	O
cells	O
in	O
vitro	O
and	O
delayed	O
neuronal	O
death	O
in	O
vivo	O
.	O

Therefore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
protective	O
function	O
of	O
2ccPA	O
suppressed	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
in	O
both	O
oligodendrocytes	O
and	O
neurons	O
,	O
which	O
is	O
likely	O
to	O
be	O
associated	O
with	O
protection	O
from	O
the	O
loss	O
of	O
oligodendrocytes	O
and	O
axons	O
in	O
demyelinative	O
conditions	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
2ccPA	O
promotes	O
neurite	O
outgrowth	O
and	O
enhances	O
neuronal	O
survival	O
via	O
a	O
signaling	O
pathway	O
similar	O
to	O
that	O
of	O
NGF	B-GP
[	O
11	O
].	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
2ccPA	O
exerts	O
protective	O
effects	O
against	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
and	O
EAE	B-DS
pathology	O
via	O
NGF	B-GP
-	O
like	O
actions	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
NGF	B-GP
exerts	O
a	O
dramatic	O
effect	O
on	O
neuron	O
and	O
oligodendrocyte	O
survival	O
and	O
stimulates	O
axonal	O
regeneration	O
/	O
remyelination	O
[	O
54	O
,	O
55	O
].	O

These	O
findings	O
are	O
in	O
accordance	O
with	O
the	O
protective	O
effects	O
against	O
CPZ	O
-	O
induced	O
demyelination	O
observed	O
in	O
our	O
study	O
.	O

Additional	O
studies	O
have	O
indicated	O
that	O
NGF	B-GP
may	O
exert	O
protective	O
effects	O
in	O
EAE	B-DS
model	O
mice	B-OG
by	O
switching	O
the	O
immune	O
response	O
to	O
an	O
anti	O
-	O
inflammatory	O
status	O
[	O
56	O
,	O
57	O
].	O

Indeed	O
,	O
our	O
findings	O
indicate	O
that	O
a	O
similar	O
process	O
may	O
underlie	O
the	O
protective	O
effect	O
of	O
2ccPA	O
against	O
EAE	B-DS
.	O

Furthermore	O
,	O
NGF	B-GP
is	O
a	O
potent	O
anti	O
-	O
apoptotic	O
factor	O
that	O
regulates	O
levels	O
of	O
anti	O
-	O
apoptotic	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	I-GP
,	O
a	O
common	O
mechanism	O
by	O
which	O
2ccPA	O
protected	O
oligodendrocytes	O
from	O
CoCl2	O
-	O
induced	O
apoptosis	O
[	O
58	O
].	O

These	O
findings	O
suggest	O
that	O
multiple	O
effects	O
of	O
2ccPA	O
are	O
due	O
to	O
its	O
NGF	B-GP
-	O
like	O
actions	O
.	O

There	O
is	O
a	O
need	O
for	O
therapeutic	O
drug	O
treatment	O
of	O
progressive	B-DS
multiple	I-DS
sclerosis	I-DS
that	O
can	O
arrest	O
the	O
progression	O
of	O
demyelination	O
.	O

Our	O
results	O
may	O
indicate	O
that	O
2ccPA	O
has	O
a	O
beneficial	O
effect	O
on	O
progressive	O
demyelination	O
.	O

Treatment	O
with	O
2ccPA	O
suppressed	O
demyelination	O
and	O
motor	O
dysfunction	O
even	O
after	O
the	O
onset	O
of	O
cuprizone	B-CD
-	O
induced	O
pathology	O
(	O
protocol	O
B	O
and	O
D	O
).	O

Further	O
,	O
2ccPA	O
might	O
have	O
a	O
function	O
to	O
enhance	O
remyelination	O
(	O
protocol	O
C	O
).	O

In	O
summary	O
,	O
we	O
found	O
that	O
the	O
administration	O
of	O
2ccPA	O
reduced	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
,	O
microglial	O
activation	O
,	O
NLRP3	B-GP
inflammasome	O
,	O
and	O
motor	O
dysfunction	O
,	O
and	O
promoted	O
remyelination	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
2ccPA	O
reduced	O
autoreactive	O
T	O
cell	O
and	O
macrophage	O
,	O
spinal	O
cord	O
injury	O
,	O
and	O
clinical	O
behavioral	O
dysfunction	O
in	O
the	O
autoimmune	B-DS
multiple	I-DS
sclerosis	I-DS
model	O
of	O
EAE	B-DS
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
may	O
be	O
a	O
promising	O
seed	O
compound	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
demyelinating	B-DS
disease	I-DS
and	O
ameliorate	O
the	O
symptoms	O
of	O
multiple	B-DS
sclerosis	I-DS
.	O

Conclusions	O

The	O
findings	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
2ccPA	O
protected	O
oligodendrocytes	O
via	O
suppression	O
of	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
.	O

Beneficial	O
effects	O
of	O
2ccPA	O
were	O
observed	O
in	O
the	O
multiperiod	O
of	O
cuprizone	B-CD
-	O
induced	O
demyelination	O
and	O
EAE	B-DS
pathology	O
.	O

These	O
data	O
indicate	O
that	O
2ccPA	O
is	O
a	O
promising	O
candidate	O
for	O
the	O
development	O
of	O
new	O
drugs	O
for	O
the	O
treatment	O
of	O
demyelinating	O
conditions	O
such	O
as	O
multiple	B-DS
sclerosis	I-DS
.	O

The	O
Csr	B-GP
System	O
Regulates	O
Escherichia	B-OG
coli	I-OG
Fitness	O
by	O
Controlling	O
Glycogen	O
Accumulation	O
and	O
Energy	O
Levels	O

B	O
.	O
E	O
.	O
and	O
M	O
.	O
C	O
.-	O
B	O
.	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

ABSTRACT	O

In	O
the	O
bacterium	B-OG
Escherichia	B-OG
coli	I-OG
,	O
the	O
posttranscriptional	O
regulatory	O
system	O
Csr	B-GP
was	O
postulated	O
to	O
influence	O
the	O
transition	O
from	O
glycolysis	O
to	O
gluconeogenesis	O
.	O

Here	O
,	O
we	O
explored	O
the	O
role	O
of	O
the	O
Csr	B-GP
system	O
in	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
as	O
a	O
model	O
of	O
the	O
glycolysis	O
-	O
to	O
-	O
gluconeogenesis	O
switch	O
.	O

Mutations	O
in	O
the	O
Csr	B-GP
system	O
influence	O
the	O
reorganization	O
of	O
gene	O
expression	O
after	O
glucose	B-CD
exhaustion	O
and	O
disturb	O
the	O
timing	O
of	O
acetate	O
reconsumption	O
after	O
glucose	B-CD
exhaustion	O
.	O

Analysis	O
of	O
metabolite	O
concentrations	O
during	O
the	O
transition	O
revealed	O
that	O
the	O
Csr	B-GP
system	O
has	O
a	O
major	O
effect	O
on	O
the	O
energy	O
levels	O
of	O
the	O
cells	O
after	O
glucose	B-CD
exhaustion	O
.	O

This	O
influence	O
was	O
demonstrated	O
to	O
result	O
directly	O
from	O
the	O
effect	O
of	O
the	O
Csr	B-GP
system	O
on	O
glycogen	O
accumulation	O
.	O

Mutation	O
in	O
glycogen	O
metabolism	O
was	O
also	O
demonstrated	O
to	O
hinder	O
metabolic	O
adaptation	O
after	O
glucose	B-CD
exhaustion	O
because	O
of	O
insufficient	O
energy	O
.	O

This	O
work	O
explains	O
how	O
the	O
Csr	B-GP
system	O
influences	O
E	B-OG
.	I-OG
coli	I-OG
fitness	O
during	O
the	O
glycolysis	O
-	O
gluconeogenesis	O
switch	O
and	O
demonstrates	O
the	O
role	O
of	O
glycogen	O
in	O
maintenance	O
of	O
the	O
energy	O
charge	O
during	O
metabolic	O
adaptation	O
.	O

IMPORTANCE	O

Glycogen	O
is	O
a	O
polysaccharide	O
and	O
the	O
main	O
storage	O
form	O
of	O
glucose	B-CD
from	O
bacteria	B-OG
such	O
as	O
Escherichia	B-OG
coli	I-OG
to	O
yeasts	B-OG
and	O
mammals	B-OG
.	O

Although	O
its	O
function	O
as	O
a	O
sugar	B-CD
reserve	O
in	O
mammals	B-OG
is	O
well	O
documented	O
,	O
the	O
role	O
of	O
glycogen	O
in	O
bacteria	B-OG
is	O
not	O
as	O
clear	O
.	O

By	O
studying	O
the	O
role	O
of	O
posttranscriptional	O
regulation	O
during	O
metabolic	O
adaptation	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
demonstrate	O
the	O
role	O
of	O
sugar	B-CD
reserve	O
played	O
by	O
glycogen	O
in	O
E	B-OG
.	I-OG
coli	I-OG
.	O

Indeed	O
,	O
glycogen	O
not	O
only	O
makes	O
it	O
possible	O
to	O
maintain	O
sufficient	O
energy	O
during	O
metabolic	O
transitions	O
but	O
is	O
also	O
the	O
key	O
component	O
in	O
the	O
capacity	O
of	O
cells	O
to	O
resume	O
growth	O
.	O

Since	O
the	O
essential	O
posttranscriptional	O
regulatory	O
system	O
Csr	B-GP
is	O
a	O
major	O
regulator	O
of	O
glycogen	O
accumulation	O
,	O
this	O
work	O
also	O
sheds	O
light	O
on	O
the	O
central	O
role	O
of	O
posttranscriptional	O
regulation	O
in	O
metabolic	O
adaptation	O
.	O

INTRODUCTION	O

Metabolic	O
adaptation	O
describes	O
the	O
capacity	O
to	O
switch	O
from	O
one	O
substrate	O
to	O
another	O
.	O

This	O
mechanism	O
is	O
essential	O
for	O
the	O
fitness	O
and	O
survival	O
of	O
microorganisms	B-OG
(	O
1	O
,	O
2	O
).	O

In	O
the	O
model	O
bacterium	B-OG
Escherichia	B-OG
coli	I-OG
,	O
metabolic	O
adaptation	O
influences	O
the	O
productivity	O
of	O
bioprocesses	O
and	O
also	O
its	O
persistence	O
in	O
the	O
gut	O
,	O
with	O
major	O
consequences	O
for	O
human	B-OG
health	O
.	O

The	O
persistence	O
of	O
commensal	O
E	B-OG
.	I-OG
coli	I-OG
strains	O
has	O
already	O
been	O
shown	O
to	O
provide	O
a	O
barrier	O
to	O
infection	B-DS
in	O
the	O
intestine	O
(	O
3	O
,	O
4	O
).	O
E	B-OG
.	I-OG
coli	I-OG
first	O
consumes	O
sugars	B-CD
and	O
sugar	B-CD
derivatives	O
through	O
glycolytic	O
pathways	O
.	O

In	O
the	O
absence	O
of	O
such	O
substrates	O
,	O
it	O
uses	O
less	O
favorable	O
molecules	O
such	O
as	O
acetate	O
,	O
succinate	O
,	O
or	O
formate	O
by	O
activating	O
the	O
gluconeogenic	O
pathway	O
(	O
1	O
,	O
5	O
).	O

The	O
mechanisms	O
involved	O
in	O
pathogen	O
exclusion	O
in	O
natural	O
ecosystems	O
are	O
complex	O
but	O
notably	O
involve	O
competitive	O
metabolic	O
interactions	O
with	O
available	O
nutriments	O
(	O
4	O
,	O
6	O
,	O
7	O
).	O

Since	O
the	O
availability	O
of	O
carbon	O
substrates	O
in	O
the	O
gut	O
is	O
constantly	O
changing	O
,	O
metabolic	O
adaptation	O
and	O
the	O
capacity	O
to	O
switch	O
from	O
glycolysis	O
to	O
gluconeogenesis	O
are	O
essential	O
for	O
colonization	O
and	O
persistence	O
of	O
E	B-OG
.	I-OG
coli	I-OG
and	O
hence	O
for	O
health	O
(	O
8	O
).	O

Although	O
the	O
metabolic	O
organization	O
of	O
E	B-OG
.	I-OG
coli	I-OG
is	O
well	O
described	O
,	O
metabolic	O
adaptation	O
is	O
still	O
not	O
fully	O
understood	O
(	O
9	O
–	O
11	O
).	O

In	O
central	O
carbon	O
metabolism	O
(	O
CCM	O
),	O
the	O
accumulation	O
of	O
several	O
layers	O
of	O
regulatory	O
mechanisms	O
(	O
transcriptional	O
,	O
posttranscriptional	O
,	O
translational	O
,	O
and	O
posttranslational	O
regulatory	O
mechanisms	O
)	O
results	O
in	O
a	O
complex	O
and	O
entangled	O
control	O
of	O
carbon	O
fluxes	O
.	O

At	O
the	O
posttranscriptional	O
level	O
(	O
i	O
.	O
e	O
.,	O
control	O
of	O
the	O
stability	O
and	O
translation	O
of	O
mRNA	O
),	O
the	O
main	O
controller	O
of	O
CCM	O
reported	O
so	O
far	O
is	O
the	O
carbon	B-GP
storage	O
regulator	B-GP
(	O
Csr	B-GP
)	O
system	O
(	O
12	O
–	O
16	O
).	O

This	O
posttranscriptional	O
controller	O
is	O
highly	O
pleiotropic	O
(	O
17	O
,	O
18	O
)	O
and	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
most	O
adaptive	O
phenomena	O
,	O
including	O
virulence	O
(	O
19	O
),	O
motility	O
(	O
20	O
,	O
21	O
),	O
stringent	O
response	O
(	O
12	O
),	O
and	O
glycogen	O
synthesis	O
(	O
14	O
,	O
22	O
).	O

Its	O
main	O
component	O
is	O
the	O
conditionally	O
essential	O
protein	O
CsrA	B-GP
,	O
which	O
is	O
able	O
to	O
bind	O
to	O
target	O
mRNAs	O
,	O
leading	O
to	O
either	O
their	O
degradation	O
or	O
their	O
stabilization	O
.	O

CsrA	B-GP
activity	O
is	O
controlled	O
through	O
sequestration	O
by	O
CsrB	B-GP
and	O
CsrC	B-GP
,	O
two	O
noncoding	O
RNAs	O
(	O
ncRNAs	O
)	O
(	O
23	O
–	O
25	O
).	O

Both	O
of	O
these	O
ncRNAs	O
are	O
targeted	O
by	O
the	O
protein	O
CsrD	B-GP
,	O
which	O
triggers	O
their	O
RNase	B-GP
E	I-GP
-	O
dependent	O
degradation	O
(	O
26	O
),	O
through	O
a	O
molecular	O
mechanism	O
based	O
on	O
CsrD	B-GP
and	O
CsrA	B-GP
antagonism	O
(	O
27	O
).	O

Transcription	O
of	O
CsrB	B-GP
and	O
CsrC	B-GP
is	O
activated	O
by	O
the	O
BarA	B-GP
/	O
UvrY	B-GP
two	O
-	O
component	O
system	O
(	O
23	O
,	O
25	O
,	O
28	O
)	O
and	O
is	O
repressed	O
by	O
cAMP	O
-	O
CRP	B-GP
(	O
29	O
).	O

The	O
Csr	B-GP
system	O
is	O
said	O
to	O
positively	O
regulate	O
glycolysis	O
while	O
inhibiting	O
gluconeogenesis	O
(	O
14	O
–	O
16	O
,	O
30	O
).	O

It	O
is	O
hypothesized	O
to	O
be	O
involved	O
in	O
the	O
switch	O
between	O
the	O
two	O
metabolisms	O
since	O
the	O
BarA	B-GP
/	O
UvrY	B-GP
two	O
-	O
component	O
system	O
is	O
needed	O
for	O
the	O
efficient	O
transition	O
from	O
glycolytic	O
to	O
gluconeogenic	O
metabolism	O
(	O
2	O
).	O

The	O
recently	O
discovered	O
circuitry	O
linking	O
catabolite	O
repression	O
and	O
Csr	B-GP
regulatory	O
systems	O
(	O
29	O
)	O
also	O
suggests	O
the	O
involvement	O
of	O
CsrA	B-GP
in	O
the	O
transition	O
,	O
since	O
the	O
switch	O
to	O
gluconeogenic	O
substrate	O
consumption	O
requires	O
the	O
alleviation	O
of	O
catabolite	O
repression	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
putative	O
role	O
of	O
the	O
Csr	B-GP
system	O
in	O
the	O
metabolic	O
adaptation	O
from	O
glycolysis	O
to	O
gluconeogenesis	O
.	O

Gene	O
expression	O
and	O
metabolite	O
pool	O
analyses	O
were	O
performed	O
with	O
Csr	B-GP
system	O
mutant	O
strains	O
throughout	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
,	O
which	O
was	O
considered	O
a	O
model	O
of	O
metabolic	O
adaptation	O
(	O
9	O
,	O
10	O
,	O
31	O
).	O

We	O
demonstrate	O
the	O
important	O
role	O
of	O
the	O
Csr	B-GP
system	O
during	O
this	O
metabolic	O
transition	O
through	O
its	O
control	O
of	O
glycogen	O
accumulation	O
and	O
cell	O
energy	O
homeostasis	O
.	O

(	O
Parts	O
of	O
this	O
work	O
were	O
conducted	O
as	O
M	O
.	O
M	O
.’	O
s	O
thesis	O
project	O
.)	O

RESULTS	O

The	O
Csr	B-GP
system	O
influences	O
the	O
dynamics	O
of	O
acetate	O
reconsumption	O
after	O
glucose	B-CD
exhaustion	O
.	O

The	O
glucose	B-CD
-	O
acetate	O
transition	O
is	O
a	O
model	O
of	O
adaptation	O
from	O
glycolytic	O
to	O
gluconeogenic	O
metabolism	O
(	O
9	O
,	O
10	O
,	O
31	O
).	O

Briefly	O
,	O
this	O
transition	O
consists	O
of	O
E	B-OG
.	I-OG
coli	I-OG
cells	O
growing	O
exponentially	O
on	O
a	O
glucose	B-CD
minimal	O
medium	O
and	O
excreting	O
acetate	O
into	O
the	O
medium	O
as	O
a	O
metabolic	O
overflow	O
product	O
.	O

When	O
the	O
cells	O
run	O
out	O
of	O
glucose	B-CD
,	O
the	O
CCM	O
is	O
reorganized	O
,	O
thereby	O
enabling	O
the	O
cell	O
to	O
consume	O
the	O
acetate	O
.	O

The	O
behaviors	O
of	O
three	O
strains	O
with	O
modified	O
CsrA	B-GP
activities	O
(	O
csrA51	O
,	O
ΔcsrBC	O
,	O
and	O
ΔcsrD	O
mutant	O
strains	O
)	O
were	O
investigated	O
.	O

Deletions	O
of	O
CsrB	B-GP
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
CsrC	B-GP
ncRNAs	O
are	O
known	O
to	O
increase	O
CsrA	B-GP
activity	O
by	O
preventing	O
its	O
sequestration	O
(	O
24	O
,	O
25	O
).	O

Deletion	O
of	O
csrD	B-GP
triggers	O
an	O
increase	O
in	O
CsrB	B-GP
and	O
CsrC	B-GP
ncRNA	O
concentrations	O
,	O
which	O
promotes	O
the	O
sequestration	O
of	O
CsrA	B-GP
and	O
reduces	O
its	O
activity	O
(	O
26	O
).	O

In	O
the	O
csrA51	B-GP
mutant	O
strain	O
,	O
the	O
deletion	O
of	O
the	O
last	O
11	O
amino	B-CD
acids	I-CD
of	O
CsrA	B-GP
has	O
been	O
reported	O
to	O
dramatically	O
reduce	O
its	O
activity	O
while	O
maintaining	O
strain	O
viability	O
.	O

This	O
construction	O
has	O
been	O
widely	O
used	O
as	O
the	O
gold	O
standard	O
to	O
explore	O
the	O
function	O
of	O
CsrA	B-GP
(	O
17	O
,	O
32	O
,	O
33	O
).	O

To	O
investigate	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
,	O
the	O
three	O
mutants	O
and	O
their	O
wild	O
-	O
type	O
(	O
WT	O
)	O
isogenic	O
control	O
were	O
grown	O
dynamically	O
in	O
controlled	O
bioreactors	O
in	O
M9	O
minimal	O
medium	O
supplemented	O
with	O
0	O
.	O
27	O
%	O
glucose	B-CD
(	O
9	O
).	O

The	O
biomass	O
and	O
extracellular	O
glucose	B-CD
and	O
acetate	O
concentrations	O
were	O
measured	O
at	O
30	O
-	O
min	O
intervals	O
(	O
Fig	O
.	O
1	O
).	O

The	O
growth	O
of	O
all	O
four	O
strains	O
was	O
exponential	O
during	O
glucose	B-CD
consumption	O
(	O
Fig	O
.	O
1A	O
).	O

As	O
expected	O
from	O
previous	O
work	O
(	O
16	O
),	O
the	O
csrA51	O
mutant	O
’	O
s	O
growth	O
rate	O
on	O
glucose	B-CD
was	O
lower	O
than	O
that	O
of	O
the	O
WT	O
(	O
Fig	O
.	O
1A	O
).	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
WT	O
and	O
the	O
ΔcsrBC	O
and	O
ΔcsrD	O
mutant	O
strains	O
during	O
the	O
growth	O
phase	O
on	O
glucose	B-CD
(	O
Fig	O
.	O
1A	O
).	O

This	O
was	O
corroborated	O
by	O
the	O
similar	O
glucose	B-CD
consumption	O
profiles	O
of	O
the	O
strains	O
(	O
Fig	O
.	O
1B	O
).	O

The	O
csrA51	O
mutant	O
strain	O
produced	O
a	O
very	O
low	O
level	O
of	O
acetate	O
during	O
growth	O
on	O
glucose	B-CD
in	O
comparison	O
with	O
the	O
three	O
other	O
strains	O
,	O
whose	O
production	O
rates	O
and	O
final	O
levels	O
of	O
acetate	O
were	O
similar	O
(	O
Fig	O
.	O
1C	O
).	O

The	O
small	O
amount	O
of	O
acetate	O
in	O
the	O
csrA51	O
mutant	O
strain	O
was	O
completely	O
consumed	O
in	O
the	O
minutes	O
following	O
glucose	B-CD
exhaustion	O
.	O

The	O
other	O
three	O
strains	O
also	O
consumed	O
the	O
acetate	O
produced	O
after	O
glucose	B-CD
exhaustion	O
but	O
with	O
different	O
timings	O
,	O
resulting	O
in	O
the	O
ΔcsrD	O
mutant	O
strain	O
consuming	O
its	O
acetate	O
first	O
,	O
followed	O
by	O
the	O
WT	O
and	O
then	O
the	O
ΔcsrBC	O
mutant	O
strain	O
(	O
Fig	O
.	O
1C	O
).	O

Accordingly	O
,	O
during	O
the	O
acetate	O
consumption	O
phase	O
,	O
higher	O
rates	O
of	O
acetate	O
consumption	O
were	O
observed	O
in	O
the	O
ΔcsrD	O
mutant	O
strain	O
,	O
followed	O
by	O
the	O
WT	O
and	O
then	O
the	O
ΔcsrBC	O
mutant	O
strain	O
(	O
Fig	O
.	O
1D	O
).	O

To	O
illustrate	O
,	O
at	O
1	O
h	O
after	O
glucose	B-CD
exhaustion	O
,	O
these	O
rates	O
were	O
,	O
respectively	O
,	O
−	O
1	O
.	O
50	O
±	O
0	O
.	O
26	O
,	O
−	O
0	O
.	O
82	O
±	O
0	O
.	O
32	O
,	O
and	O
−	O
0	O
.	O
58	O
±	O
0	O
.	O
12	O
mM	O
⋅	O
g	O
of	O
dry	O
weight	O
(	O
gDW	O
)−	O
1	O
⋅	O
h	O
−	O
1	O
in	O
the	O
ΔcsrD	O
mutant	O
,	O
WT	O
,	O
and	O
ΔcsrBC	O
mutant	O
strains	O
.	O

We	O
detected	O
no	O
difference	O
in	O
biomass	O
content	O
that	O
could	O
be	O
related	O
to	O
the	O
differences	O
in	O
the	O
timing	O
of	O
acetate	O
consumption	O
(	O
Fig	O
.	O
1A	O
).	O

Behavior	O
of	O
Csr	B-GP
system	O
mutants	O
during	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
.	O

Cultures	O
were	O
monitored	O
from	O
6	O
h	O
before	O
to	O
4	O
h	O
after	O
glucose	B-CD
exhaustion	O
,	O
which	O
was	O
set	O
as	O
time	O
zero	O
.	O

All	O
data	O
concerning	O
the	O
replicates	O
are	O
displayed	O
as	O
dots	O
,	O
and	O
the	O
fitted	O
average	O
value	O
of	O
each	O
strain	O
is	O
displayed	O
as	O
a	O
line	O
.	O

Shaded	O
areas	O
represent	O
±	O
1	O
standard	O
deviation	O
.	O

WT	O
,	O
black	O
circles	O
;	O
csrBC	B-GP
mutant	O
,	O
green	O
squares	O
;	O
csrD	B-GP
mutant	O
,	O
orange	O
triangles	O
;	O
csrA51	B-GP
mutant	O
,	O
red	O
diamonds	O
.	O

(	O
A	O
)	O
Changes	O
in	O
the	O
biomass	O
concentration	O
(	O
gDW	O
⋅	O
liter	O
−	O
1	O
)	O
and	O
growth	O
rate	O
μ	O
(	O
h	O
−	O
1	O
).	O

(	O
B	O
)	O
Extracellular	O
glucose	B-CD
concentration	O
(	O
mM	O
)	O
and	O
specific	O
glucose	B-CD
production	O
rates	O
(	O
mM	O
⋅	O
h	O
−	O
1	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
).	O

(	O
C	O
)	O
Extracellular	O
acetate	O
concentration	O
(	O
mM	O
)	O
and	O
specific	O
acetate	O
production	O
rates	O
(	O
mM	O
⋅	O
h	O
−	O
1	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
).	O

(	O
D	O
)	O
Glycogen	O
concentration	O
(	O
ggluc	O
⋅	O
gDW	O
−	O
1	O
)	O
and	O
specific	O
glycogen	O
production	O
rates	O
(	O
ggluc	O
⋅	O
h	O
−	O
1	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
).	O

Since	O
the	O
csrA51	O
mutant	O
strain	O
is	O
reported	O
to	O
overaccumulate	O
glycogen	O
(	O
14	O
,	O
16	O
,	O
22	O
),	O
we	O
assessed	O
the	O
concentration	O
of	O
this	O
storage	O
polysaccharide	O
in	O
the	O
cell	O
during	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
(	O
Fig	O
.	O
1D	O
).	O

As	O
expected	O
(	O
22	O
),	O
the	O
csrA51	O
mutant	O
strain	O
accumulated	O
up	O
to	O
0	O
.	O
28	O
g	O
of	O
glucose	B-CD
(	O
ggluc	O
)	O
⋅	O
gDW	O
of	O
glycogen	O
−	O
1	O
,	O
representing	O
about	O
30	O
%	O
of	O
the	O
biomass	O
dry	O
weight	O
.	O

Glycogen	O
also	O
accumulated	O
in	O
the	O
ΔcsrD	O
mutant	O
cells	O
but	O
to	O
a	O
lesser	O
extent	O
(	O
maximum	O
of	O
0	O
.	O
07	O
ggluc	O
⋅	O
gDW	O
−	O
1	O
,	O
representing	O
7	O
%	O
of	O
the	O
cell	O
dry	O
weight	O
)	O
and	O
even	O
less	O
in	O
the	O
WT	O
(	O
4	O
%	O
of	O
the	O
cell	O
dry	O
weight	O
).	O

In	O
contrast	O
,	O
the	O
ΔcsrBC	O
mutant	O
cells	O
stored	O
a	O
very	O
small	O
quantity	O
of	O
glycogen	O
(	O
maximum	O
of	O
0	O
.	O
01	O
ggluc	O
⋅	O
gDW	O
−	O
1	O
,	O
representing	O
about	O
1	O
%	O
of	O
the	O
biomass	O
).	O

The	O
glycogen	O
content	O
in	O
the	O
four	O
strains	O
remained	O
mostly	O
stable	O
during	O
the	O
exponential	O
phase	O
of	O
growth	O
on	O
glucose	B-CD
(	O
concentrations	O
and	O
rates	O
remained	O
constant	O
),	O
and	O
all	O
four	O
strains	O
used	O
glycogen	O
after	O
glucose	B-CD
exhaustion	O
.	O

Overall	O
,	O
glycogen	O
production	O
and	O
consumption	O
rates	O
were	O
high	O
in	O
the	O
csrA51	O
mutant	O
strain	O
(	O
respectively	O
,	O
0	O
.	O
078	O
±	O
0	O
.	O
014	O
and	O
−	O
0	O
.	O
057	O
±	O
0	O
.	O
014	O
gglc	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
1	O
h	O
before	O
and	O
1	O
h	O
after	O
glucose	B-CD
exhaustion	O
),	O
medium	O
in	O
the	O
ΔcsrD	O
mutant	O
(	O
0	O
.	O
035	O
±	O
0	O
.	O
004	O
and	O
−	O
0	O
.	O
018	O
±	O
0	O
.	O
001	O
gglc	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
),	O
and	O
low	O
in	O
the	O
ΔcsrBC	O
mutant	O
(	O
0	O
.	O
003	O
±	O
0	O
.	O
001	O
and	O
−	O
0	O
.	O
002	O
±	O
0	O
.	O
001	O
gglc	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
)	O
compared	O
to	O
those	O
of	O
the	O
WT	O
(	O
0	O
.	O
028	O
±	O
0	O
.	O
001	O
and	O
−	O
0	O
.	O
012	O
±	O
0	O
.	O
007	O
gglc	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
).	O

To	O
conclude	O
,	O
the	O
investigated	O
strains	O
showed	O
a	O
range	O
of	O
phenotypes	O
according	O
to	O
their	O
CsrA	B-GP
activity	O
.	O

The	O
csrA51	O
mutant	O
was	O
the	O
most	O
affected	O
strain	O
,	O
with	O
high	O
glycogen	O
and	O
low	O
acetate	O
contents	O
and	O
a	O
reduced	O
growth	O
rate	O
.	O

The	O
ΔcsrD	O
mutant	O
also	O
had	O
a	O
higher	O
glycogen	O
content	O
than	O
the	O
WT	O
and	O
accelerated	O
acetate	O
consumption	O
.	O

The	O
ΔcsrBC	O
mutant	O
displayed	O
the	O
reverse	O
phenotypes	O
(	O
low	O
to	O
no	O
glycogen	O
content	O
and	O
delayed	O
acetate	O
consumption	O
).	O

In	O
addition	O
to	O
its	O
effect	O
on	O
growth	O
rates	O
and	O
glycogen	O
accumulation	O
,	O
the	O
Csr	B-GP
system	O
is	O
involved	O
in	O
the	O
dynamics	O
of	O
the	O
glycolysis	O
-	O
gluconeogenesis	O
transition	O
,	O
notably	O
through	O
its	O
impact	O
on	O
acetate	O
consumption	O
after	O
glucose	B-CD
exhaustion	O
.	O

CCM	O
gene	O
expression	O
is	O
differently	O
influenced	O
by	O
the	O
Csr	B-GP
system	O
before	O
and	O
after	O
glucose	B-CD
exhaustion	O
.	O

We	O
assumed	O
that	O
the	O
differences	O
in	O
acetate	O
consumption	O
between	O
the	O
strains	O
could	O
result	O
from	O
differential	O
gene	O
expression	O
in	O
the	O
CCM	O
after	O
glucose	B-CD
exhaustion	O
.	O

This	O
was	O
assessed	O
by	O
performing	O
quantitative	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
analysis	O
of	O
14	O
key	O
CCM	B-GP
genes	O
(	O
34	O
)	O
during	O
the	O
metabolic	O
transition	O
from	O
3	O
h	O
preceding	O
to	O
2	O
h	O
after	O
glucose	B-CD
exhaustion	O
(	O
Fig	O
.	O
2	O
).	O

During	O
the	O
glucose	B-CD
consumption	O
phase	O
,	O
massive	O
differences	O
in	O
gene	O
expression	O
were	O
observed	O
between	O
the	O
mutant	O
strains	O
and	O
the	O
WT	O
,	O
especially	O
the	O
csrA51	O
mutant	O
strain	O
(	O
as	O
previously	O
described	O
by	O
Morin	O
et	O
al	O
.	O
[	O
16	O
]).	O

In	O
contrast	O
,	O
the	O
differences	O
between	O
the	O
strains	O
were	O
globally	O
reduced	O
after	O
glucose	B-CD
exhaustion	O
,	O
except	O
for	O
the	O
genes	O
involved	O
in	O
acetate	O
and	O
glycogen	O
metabolism	O
(	O
Fig	O
.	O
2	O
).	O

For	O
acetate	O
metabolism	O
(	O
ACS	B-GP
,	O
ack	B-GP
,	O
and	O
pta	B-GP
),	O
higher	O
expression	O
was	O
noticed	O
in	O
the	O
csrA51	O
and	O
ΔcsrD	O
mutant	O
strains	O
than	O
in	O
the	O
WT	O
,	O
which	O
could	O
be	O
consistent	O
with	O
their	O
improved	O
acetate	O
consumption	O
rates	O
.	O

The	O
expression	O
of	O
glycogen	B-GP
-	I-GP
related	I-GP
genes	I-GP
(	O
pgm	B-GP
and	O
glgC	B-GP
)	O
was	O
increased	O
,	O
but	O
only	O
in	O
the	O
csrA51	O
mutant	O
strain	O
.	O

We	O
thus	O
conclude	O
that	O
the	O
Csr	B-GP
system	O
controls	O
different	O
sets	O
of	O
genes	O
before	O
and	O
after	O
glucose	B-CD
exhaustion	O
,	O
the	O
later	O
set	O
being	O
devoted	O
to	O
the	O
use	O
of	O
the	O
remaining	O
carbon	O
sources	O
(	O
acetate	O
and	O
glycogen	O
).	O

Expression	O
of	O
key	O
metabolic	O
genes	O
during	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
of	O
Csr	B-GP
system	O
mutants	O
.	O

Gene	O
expression	O
(	O
relative	O
to	O
the	O
idnT	B-GP
RNA	O
reference	O
)	O
was	O
investigated	O
from	O
3	O
h	O
before	O
to	O
2	O
h	O
after	O
glucose	B-CD
exhaustion	O
.	O

WT	O
,	O
black	O
circles	O
;	O
csrBC	B-GP
mutant	O
,	O
green	O
squares	O
;	O
csrD	B-GP
mutant	O
,	O
orange	O
triangles	O
;	O
csrA51	B-GP
mutant	O
,	O
red	O
diamonds	O
.	O
ptsG	B-GP
,	O
glucose	B-GP
phosphotransferase	I-GP
system	I-GP
permease	I-GP
PtsG	B-GP
subunit	O
(	O
European	O
Bioinformatics	O
Institute	O
European	O
Nucleotide	O
Archive	O
accession	O
no	O
.	O
EG10787	O
);	O
pgm	B-GP
,	O
phosphoglucomutase	B-GP
(	O
accession	O
no	O
.	O
EG12144	O
);	O
glgC	B-GP
,	O
glucose	B-GP
-	I-GP
1	I-GP
-	I-GP
phosphate	I-GP
adenylyltransferase	I-GP
(	O
accession	O
no	O
.	O
EG10379	O
);	O
zwf	B-GP
,	O
glucose	B-GP
6	I-GP
-	I-GP
phosphate	I-GP
-	I-GP
1	I-GP
-	I-GP
dehydrogenase	I-GP
(	O
accession	O
no	O
.	O
EG11221	O
);	O
pgi	B-GP
,	O
phosphoglucose	B-GP
isomerase	I-GP
(	O
accession	O
no	O
.	O
EG10702	O
);	O
pfkA	B-GP
,	O
phosphofructokinase	B-GP
(	O
accession	O
no	O
.	O
EG10699	O
);	O
eno	B-GP
,	O
enolase	B-GP
(	O
accession	O
no	O
.	O
EG10258	O
);	O
icd	B-GP
,	O
isocitrate	B-GP
dehydrogenase	I-GP
(	O
accession	O
no	O
.	O
EG10489	O
);	O
pck	B-GP
,	O
phosphoenolpyruvate	B-GP
carboxykinase	I-GP
(	O
accession	O
no	O
.	O
EG10688	O
);	O
pta	B-GP
,	O
phosphate	B-GP
acetyltransferase	I-GP
(	O
accession	O
no	O
.	O
EG20173	O
);	O
ack	B-GP
,	O
acetate	B-GP
kinase	I-GP
(	O
accession	O
no	O
.	O
EG10027	O
);	O
ACS	B-GP
,	O
acetyl	B-GP
coenzyme	I-GP
A	I-GP
synthetase	I-GP
(	O
accession	O
no	O
.	O
EG11448	O
);	O
pck	B-GP
,	O
phosphoenolpyruvate	B-GP
carboxykinase	I-GP
(	O
accession	O
no	O
.	O
EG10688	O
);	O
fbp	B-GP
,	O
fructose	B-GP
1	I-GP
,	I-GP
6	I-GP
-	I-GP
bisphosphatase	I-GP
(	O
accession	O
no	O
.	O
EG10283	O
).	O

The	O
values	O
are	O
averages	O
of	O
three	O
replicates	O
with	O
error	O
bars	O
representing	O
standard	O
deviations	O
.	O

PPP	O
,	O
pentose	O
phosphate	O
pathway	O
;	O
TCA	O
,	O
tricarboxylic	O
acid	O
cycle	O
.	O

Analysis	O
of	O
the	O
metabolite	O
pools	O
revealed	O
different	O
energy	O
status	O
in	O
the	O
Csr	B-GP
system	O
mutant	O
strains	O
after	O
glucose	B-CD
exhaustion	O
.	O

We	O
then	O
measured	O
key	O
metabolite	O
pools	O
in	O
the	O
CCM	O
over	O
time	O
in	O
the	O
four	O
strains	O
by	O
using	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
(	O
Fig	O
.	O
3	O
).	O

The	O
profiles	O
of	O
the	O
metabolites	O
assessed	O
over	O
time	O
were	O
mostly	O
similar	O
in	O
the	O
four	O
strains	O
,	O
with	O
a	O
drop	O
in	O
concentrations	O
after	O
glucose	B-CD
exhaustion	O
,	O
except	O
for	O
the	O
alarmone	O
cAMP	O
and	O
for	O
phosphoenolpyruvate	O
,	O
as	O
previously	O
described	O
in	O
the	O
WT	O
strain	O
(	O
9	O
).	O

Before	O
glucose	B-CD
exhaustion	O
,	O
the	O
ΔcsrBC	O
mutant	O
strain	O
had	O
higher	O
concentrations	O
of	O
fructose	O
1	O
,	O
6	O
-	O
bisphosphate	O
(	O
FBP	O
)	O
and	O
malate	B-CD
,	O
whereas	O
the	O
ΔcsrD	O
pools	O
were	O
mostly	O
comparable	O
to	O
those	O
of	O
the	O
WT	O
(	O
Fig	O
.	O
3A	O
).	O

As	O
expected	O
(	O
16	O
),	O
the	O
csrA51	O
mutant	O
strain	O
displayed	O
larger	O
metabolite	O
pools	O
in	O
the	O
upper	O
part	O
of	O
the	O
glycolysis	O
process	O
(	O
glucose	O
-	O
6	O
-	O
phosphate	O
[	O
G6P	O
],	O
fructose	O
-	O
6	O
-	O
phosphate	O
[	O
F6P	O
])	O
than	O
the	O
WT	O
.	O

These	O
pools	O
decreased	O
after	O
glucose	B-CD
exhaustion	O
but	O
,	O
unexpectedly	O
,	O
were	O
maintained	O
in	O
the	O
csrA51	O
mutant	O
strain	O
at	O
levels	O
equivalent	O
to	O
those	O
measured	O
in	O
the	O
WT	O
strain	O
during	O
the	O
glucose	B-CD
consumption	O
phase	O
(	O
Fig	O
.	O
3A	O
).	O

Likewise	O
,	O
the	O
nucleotide	B-CD
triphosphate	O
pools	O
remained	O
high	O
in	O
the	O
csrA51	O
mutant	O
strain	O
even	O
after	O
glucose	B-CD
exhaustion	O
.	O

Concentrations	O
of	O
key	O
central	O
carbon	O
metabolites	O
during	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
of	O
Csr	B-GP
system	O
mutants	O
.	O

(	O
A	O
)	O
Metabolite	O
concentrations	O
were	O
investigated	O
from	O
3	O
h	O
before	O
to	O
2	O
h	O
after	O
glucose	B-CD
exhaustion	O
.	O

WT	O
,	O
black	O
circles	O
;	O
csrBC	B-GP
mutant	O
,	O
green	O
squares	O
;	O
csrD	B-GP
mutant	O
,	O
orange	O
triangles	O
;	O
csrA51	B-GP
mutant	O
,	O
red	O
diamonds	O
.	O

PEP	O
,	O
phosphoenolpyruvate	O
.	O

(	O
B	O
)	O
The	O
AECs	O
of	O
the	O
same	O
four	O
strains	O
during	O
glucose	B-CD
consumption	O
(	O
plain	O
bars	O
)	O
and	O
1	O
.	O
5	O
h	O
after	O
glucose	B-CD
exhaustion	O
(	O
striped	O
bars	O
)	O
are	O
shown	O
.	O

A	O
significant	O
difference	O
between	O
a	O
mutant	O
and	O
the	O
WT	O
is	O
represented	O
by	O
an	O
asterisk	O
(	O
P	O
<	O
0	O
.	O
05	O
[	O
t	O
test	O
]).	O

The	O
values	O
in	O
both	O
panels	O
are	O
averages	O
of	O
three	O
independent	O
biological	O
replicates	O
with	O
error	O
bars	O
representing	O
standard	O
deviations	O
.	O

These	O
results	O
suggested	O
that	O
the	O
energy	O
level	O
after	O
glucose	B-CD
exhaustion	O
differs	O
between	O
strains	O
.	O

We	O
therefore	O
investigated	O
the	O
energy	O
status	O
of	O
the	O
cells	O
by	O
calculating	O
the	O
adenylate	B-CD
energy	O
charge	O
(	O
AEC	O
)	O
as	O
an	O
index	O
of	O
the	O
bacterium	B-OG
metabolic	O
state	O
(	O
35	O
).	O

The	O
AEC	O
on	O
glucose	B-CD
was	O
between	O
0	O
.	O
87	O
and	O
0	O
.	O
91	O
in	O
all	O
of	O
the	O
strains	O
during	O
the	O
glucose	B-CD
consumption	O
phase	O
(	O
Fig	O
.	O
3B	O
).	O

Such	O
values	O
are	O
expected	O
in	O
exponentially	O
growing	O
cells	O
(	O
35	O
).	O

At	O
90	O
min	O
after	O
glucose	B-CD
exhaustion	O
,	O
the	O
AEC	O
had	O
decreased	O
in	O
all	O
of	O
the	O
strains	O
.	O

However	O
,	O
in	O
the	O
csrA51	O
mutant	O
strain	O
,	O
the	O
AEC	O
remained	O
significantly	O
higher	O
than	O
in	O
the	O
WT	O
,	O
and	O
the	O
ΔcsrBC	O
mutant	O
AEC	O
collapsed	O
to	O
0	O
.	O
50	O
,	O
a	O
value	O
previously	O
linked	O
to	O
dying	O
cells	O
(	O
35	O
).	O

In	O
conclusion	O
,	O
the	O
csrA51	O
mutant	O
strain	O
maintained	O
high	O
energy	O
levels	O
after	O
glucose	B-CD
exhaustion	O
,	O
whereas	O
there	O
was	O
a	O
dramatic	O
drop	O
in	O
the	O
energy	O
status	O
of	O
the	O
ΔcsrBC	O
mutant	O
strain	O
.	O

We	O
thus	O
hypothesize	O
that	O
the	O
energy	O
levels	O
in	O
the	O
Csr	B-GP
system	O
mutant	O
strains	O
could	O
be	O
linked	O
to	O
the	O
observed	O
differences	O
in	O
the	O
kinetics	O
of	O
acetate	O
consumption	O
.	O

Both	O
glycogen	O
and	O
acetate	O
influence	O
the	O
energy	O
status	O
after	O
glucose	B-CD
exhaustion	O
.	O

We	O
analyzed	O
the	O
relationship	O
between	O
energy	O
fluxes	O
and	O
acetate	O
consumption	O
rates	O
by	O
investigating	O
the	O
distribution	O
of	O
the	O
energy	O
fluxes	O
after	O
glucose	B-CD
exhaustion	O
in	O
the	O
different	O
strains	O
.	O

During	O
the	O
acetate	O
consumption	O
phase	O
,	O
glycogen	O
is	O
also	O
consumed	O
as	O
an	O
intracellular	O
storage	O
sugar	B-CD
and	O
is	O
thus	O
also	O
likely	O
to	O
be	O
involved	O
in	O
the	O
balance	O
between	O
energy	O
fluxes	O
.	O

To	O
examine	O
the	O
influence	O
of	O
glycogen	O
and	O
acetate	O
flux	O
on	O
the	O
growth	O
rate	O
and	O
ATP	O
flux	O
,	O
we	O
used	O
a	O
previously	O
developed	O
constraint	O
-	O
based	O
model	O
of	O
E	B-OG
.	I-OG
coli	I-OG
(	O
16	O
,	O
36	O
).	O

These	O
parameters	O
were	O
analyzed	O
in	O
the	O
ranges	O
of	O
acetate	O
and	O
glycogen	O
consumption	O
rates	O
we	O
monitored	O
after	O
glucose	B-CD
exhaustion	O
(	O
Fig	O
.	O
1	O
;	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
of	O
the	O
procedure	O
).	O

We	O
compared	O
the	O
ATP	O
fluxes	O
predicted	O
by	O
the	O
model	O
with	O
cell	O
maintenance	O
that	O
we	O
estimated	O
at	O
2	O
.	O
9	O
mmol	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
from	O
experimental	O
data	O
obtained	O
with	O
the	O
WT	O
strain	O
(	O
32	O
)	O
and	O
considered	O
to	O
be	O
the	O
same	O
in	O
all	O
four	O
strains	O
.	O

The	O
results	O
of	O
analysis	O
of	O
the	O
flux	O
balance	O
are	O
shown	O
in	O
Fig	O
.	O
4	O
.	O

Acetate	O
and	O
glycogen	O
uptake	O
rates	O
were	O
insufficient	O
to	O
detect	O
growth	O
(	O
µ	O
<	O
0	O
.	O
05	O
h	O
−	O
1	O
)	O
in	O
any	O
of	O
the	O
four	O
strains	O
(	O
Fig	O
.	O
4A	O
),	O
since	O
ATP	O
production	O
barely	O
covered	O
the	O
maintenance	O
costs	O
(	O
Fig	O
.	O
4B	O
).	O

At	O
2	O
.	O
5	O
h	O
after	O
glucose	B-CD
exhaustion	O
,	O
the	O
WT	O
and	O
ΔcsrBC	O
mutant	O
strains	O
produced	O
ATP	O
from	O
acetate	O
in	O
the	O
absence	O
of	O
glycogen	O
(	O
the	O
ATP	O
fluxes	O
produced	O
ranged	O
between	O
5	O
and	O
12	O
mmol	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
),	O
while	O
in	O
the	O
csrA51	O
mutant	O
strain	O
,	O
ATP	O
was	O
produced	O
from	O
glycogen	O
in	O
the	O
absence	O
of	O
acetate	O
.	O

Although	O
the	O
ΔcsrD	O
mutant	O
strain	O
displayed	O
the	O
greatest	O
ATP	O
flux	O
from	O
a	O
mixture	O
of	O
glycogen	O
and	O
acetate	O
90	O
min	O
after	O
glucose	B-CD
exhaustion	O
(	O
Fig	O
.	O
4A	O
),	O
growth	O
was	O
only	O
barely	O
detectable	O
and	O
stopped	O
1	O
h	O
later	O
when	O
both	O
acetate	O
and	O
glycogen	O
were	O
depleted	O
(	O
Fig	O
.	O
1	O
and	O
4	O
).	O

We	O
thus	O
conclude	O
that	O
both	O
acetate	O
and	O
glycogen	O
can	O
be	O
used	O
to	O
maintain	O
the	O
energy	O
status	O
of	O
the	O
cells	O
after	O
glucose	B-CD
exhaustion	O
but	O
that	O
their	O
consumption	O
rates	O
are	O
too	O
low	O
to	O
ensure	O
observable	O
growth	O
.	O

Even	O
in	O
the	O
csrA51	O
mutant	O
strain	O
,	O
which	O
has	O
the	O
highest	O
energy	O
level	O
AEC	O
and	O
glycogen	O
content	O
(	O
up	O
to	O
30	O
%	O
of	O
the	O
biomass	O
),	O
the	O
ATP	O
produced	O
is	O
only	O
sufficient	O
to	O
ensure	O
maintenance	O
,	O
i	O
.	O
e	O
.,	O
to	O
allow	O
the	O
strain	O
to	O
survive	O
but	O
not	O
to	O
grow	O
efficiently	O
.	O

Metabolic	O
capacities	O
of	O
the	O
WT	O
and	O
Csr	B-GP
system	O
mutant	O
strains	O
during	O
growth	O
on	O
glycogen	O
and	O
acetate	O
.	O

Flux	O
balance	O
analysis	O
of	O
the	O
four	O
strains	O
was	O
performed	O
with	O
glycogen	O
and	O
acetate	O
as	O
carbon	O
sources	O
by	O
using	O
two	O
different	O
objective	O
functions	O
,	O
biomass	O
and	O
ATP	O
production	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
).	O

(	O
A	O
)	O
Maximum	O
predicted	O
growth	O
rates	O
(	O
μ	O
)	O
for	O
various	O
pairs	O
of	O
glycogen	O
and	O
acetate	O
uptake	O
rates	O
(	O
qs	O
).	O

(	O
B	O
)	O
Maximum	O
flux	O
of	O
ATP	O
predicted	O
by	O
the	O
model	O
.	O

Bars	O
to	O
the	O
right	O
of	O
each	O
plot	O
indicate	O
the	O
color	O
code	O
used	O
for	O
the	O
growth	O
rate	O
(	O
A	O
)	O
and	O
ATP	O
flux	O
(	O
B	O
)	O
values	O
.	O

The	O
four	O
strains	O
,	O
the	O
WT	O
(	O
gray	O
circles	O
),	O
the	O
csrBC	O
mutant	O
(	O
green	O
squares	O
),	O
the	O
csrD	B-GP
mutant	O
(	O
orange	O
triangles	O
),	O
and	O
the	O
csrA51	O
mutant	O
(	O
red	O
diamonds	O
),	O
were	O
assessed	O
at	O
two	O
different	O
times	O
90	O
min	O
(*)	O
and	O
150	O
min	O
(**).	O

The	O
values	O
are	O
averages	O
of	O
three	O
replicates	O
with	O
error	O
bars	O
representing	O
standard	O
deviations	O
.	O

Suppression	O
of	O
glycogen	O
synthesis	O
hinders	O
the	O
capacity	O
of	O
the	O
csrA51	O
mutant	O
strain	O
to	O
maintain	O
high	O
energy	O
levels	O
after	O
glucose	B-CD
exhaustion	O
.	O

As	O
shown	O
above	O
,	O
both	O
acetate	O
and	O
glycogen	O
can	O
be	O
used	O
to	O
maintain	O
the	O
energy	O
status	O
after	O
glucose	B-CD
exhaustion	O
but	O
the	O
corresponding	O
ATP	O
fluxes	O
did	O
not	O
enable	O
us	O
to	O
distinguish	O
differences	O
in	O
the	O
energy	O
level	O
AEC	O
and	O
fitness	O
related	O
to	O
acetate	O
consumption	O
in	O
the	O
different	O
strains	O
.	O

Only	O
glycogen	O
levels	O
appeared	O
to	O
accompany	O
the	O
high	O
energy	O
level	O
of	O
the	O
csrA51	O
mutant	O
strain	O
and	O
the	O
low	O
energy	O
level	O
of	O
the	O
ΔcsrBC	O
mutant	O
(	O
Fig	O
.	O
1D	O
and	O
3B	O
).	O

We	O
therefore	O
hypothesized	O
that	O
the	O
impact	O
of	O
Csr	B-GP
on	O
the	O
energy	O
status	O
can	O
only	O
be	O
mediated	O
by	O
the	O
impact	O
of	O
CsrA	B-GP
on	O
glycogen	O
accumulation	O
.	O

To	O
confirm	O
this	O
hypothesis	O
,	O
we	O
prevented	O
glycogen	O
synthesis	O
in	O
the	O
WT	O
and	O
csrA51	O
mutant	O
strains	O
by	O
deleting	O
the	O
glgC	B-GP
gene	O
.	O

The	O
same	O
pools	O
of	O
metabolites	O
as	O
those	O
shown	O
in	O
Fig	O
.	O
3	O
were	O
then	O
assessed	O
during	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
in	O
the	O
WT	O
and	O
ΔglgC	O
,	O
csrA51	O
,	O
and	O
csrA51	B-GP
ΔglgC	O
mutant	O
strains	O
(	O
Fig	O
.	O
5A	O
).	O

Some	O
of	O
the	O
WT	O
and	O
csrA51	O
mutant	O
metabolite	O
pools	O
,	O
e	O
.	O
g	O
.,	O
FBP	B-GP
,	O
differed	O
quantitatively	O
from	O
those	O
shown	O
in	O
Fig	O
.	O
3A	O
,	O
very	O
likely	O
because	O
these	O
cultures	O
were	O
performed	O
in	O
Erlenmeyer	O
flasks	O
instead	O
of	O
in	O
reactors	O
with	O
regulated	O
pH	O
and	O
monitored	O
oxygenation	O
.	O

However	O
,	O
the	O
trends	O
were	O
similar	O
under	O
both	O
conditions	O
.	O

Remarkably	O
,	O
the	O
deletion	O
of	O
glgC	B-GP
prevented	O
the	O
maintenance	O
of	O
elevated	O
G6P	O
,	O
F6P	O
,	O
and	O
nucleotide	B-CD
triphosphate	O
in	O
the	O
csrA51	O
mutant	O
strain	O
.	O

Prevention	O
of	O
glycogen	O
synthesis	O
did	O
not	O
affect	O
the	O
AEC	O
before	O
glucose	B-CD
exhaustion	O
(	O
Fig	O
.	O
5B	O
).	O

After	O
glucose	B-CD
exhaustion	O
,	O
the	O
AEC	O
of	O
the	O
two	O
strains	O
unable	O
to	O
store	O
glycogen	O
dropped	O
drastically	O
in	O
comparison	O
to	O
that	O
of	O
the	O
WT	O
and	O
csrA51	O
mutant	O
strains	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
maintenance	O
of	O
the	O
energy	O
status	O
after	O
glucose	B-CD
exhaustion	O
in	O
the	O
csrA51	O
mutant	O
strain	O
results	O
from	O
its	O
high	O
glycogen	O
content	O
.	O

Concentrations	O
of	O
key	O
central	O
carbon	O
metabolites	O
throughout	O
the	O
glucose	B-CD
-	O
acetate	O
transition	O
of	O
Csr	B-GP
system	O
and	O
/	O
or	O
glycogen	O
-	O
deficient	O
mutants	O
.	O

(	O
A	O
)	O
Metabolite	O
concentrations	O
were	O
investigated	O
from	O
3	O
h	O
before	O
to	O
2	O
h	O
after	O
glucose	B-CD
exhaustion	O
.	O

WT	O
,	O
black	O
circles	O
;	O
ΔglgC	O
mutant	O
,	O
gray	O
squares	O
;	O
csrA51	B-GP
mutant	O
,	O
red	O
diamonds	O
;	O
csrA51	B-GP
ΔglgC	O
mutant	O
,	O
brown	O
triangles	O
.	O

PEP	O
,	O
phosphoenolpyruvate	O
.	O

(	O
B	O
)	O
The	O
AECs	O
of	O
the	O
same	O
four	O
strains	O
during	O
glucose	B-CD
consumption	O
(	O
plain	O
bars	O
)	O
and	O
90	O
min	O
after	O
glucose	B-CD
exhaustion	O
(	O
striped	O
bars	O
)	O
are	O
shown	O
.	O

A	O
significant	O
difference	O
between	O
a	O
mutant	O
and	O
the	O
WT	O
is	O
represented	O
by	O
an	O
asterisk	O
(	O
P	O
<	O
0	O
.	O
05	O
[	O
t	O
test	O
]).	O

The	O
values	O
are	O
averages	O
of	O
three	O
independent	O
biological	O
replicates	O
with	O
error	O
bars	O
representing	O
standard	O
deviations	O
.	O

The	O
Csr	B-GP
system	O
affects	O
cellular	O
fitness	O
through	O
its	O
control	O
of	O
glycogen	O
synthesis	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Csr	B-GP
system	O
influences	O
the	O
energy	O
status	O
through	O
the	O
control	O
of	O
glycogen	O
synthesis	O
.	O

This	O
affects	O
the	O
ability	O
of	O
the	O
strain	O
to	O
switch	O
to	O
acetate	O
metabolism	O
after	O
glucose	B-CD
exhaustion	O
.	O

To	O
demonstrate	O
this	O
scenario	O
,	O
we	O
investigated	O
the	O
dynamics	O
of	O
the	O
metabolic	O
adaptation	O
of	O
the	O
cells	O
when	O
switched	O
to	O
fresh	O
medium	O
containing	O
acetate	O
as	O
the	O
sole	O
carbon	O
source	O
.	O

The	O
capacity	O
of	O
Csr	B-GP
and	O
/	O
or	O
glycogen	O
mutant	O
cells	O
to	O
resume	O
growth	O
on	O
fresh	O
acetate	O
minimum	O
medium	O
was	O
assessed	O
before	O
and	O
after	O
glucose	B-CD
exhaustion	O
.	O

The	O
times	O
required	O
to	O
recover	O
full	O
growth	O
on	O
acetate	O
were	O
determined	O
(	O
Fig	O
.	O
6	O
).	O

As	O
previously	O
demonstrated	O
(	O
31	O
),	O
the	O
WT	O
strain	O
required	O
38	O
min	O
to	O
switch	O
from	O
glucose	B-CD
-	O
to	O
acetate	O
-	O
based	O
growth	O
.	O

This	O
delay	O
was	O
reduced	O
to	O
21	O
min	O
when	O
the	O
cells	O
were	O
sampled	O
1	O
h	O
after	O
glucose	B-CD
exhaustion	O
,	O
likely	O
because	O
of	O
the	O
induced	O
expression	O
of	O
gluconeogenic	O
enzymes	O
.	O

The	O
delays	O
were	O
similar	O
in	O
the	O
ΔcsrD	O
mutant	O
strain	O
.	O

In	O
the	O
csrA51	O
mutant	O
strain	O
,	O
the	O
delays	O
increased	O
by	O
40	O
to	O
50	O
%	O
but	O
the	O
same	O
relative	O
decrease	O
was	O
observed	O
after	O
glucose	B-CD
exhaustion	O
.	O

The	O
long	O
delays	O
in	O
the	O
csrA51	O
mutant	O
strain	O
could	O
be	O
explained	O
by	O
the	O
difficulty	O
in	O
setting	O
up	O
acetate	O
consumption	O
in	O
the	O
presence	O
of	O
highly	O
abundant	O
glycogen	O
,	O
which	O
could	O
be	O
a	O
more	O
favorable	O
substrate	O
.	O

The	O
delay	O
in	O
the	O
ΔcsrBC	O
mutant	O
strain	O
growing	O
on	O
glucose	B-CD
was	O
similar	O
to	O
that	O
in	O
the	O
WT	O
strain	O
.	O

In	O
contrast	O
,	O
the	O
delay	O
in	O
the	O
ΔcsrBC	O
mutant	O
strain	O
was	O
not	O
reduced	O
after	O
glucose	B-CD
exhaustion	O
.	O

This	O
property	O
was	O
also	O
observed	O
in	O
the	O
ΔglgC	O
and	O
csrA51	O
ΔglgC	O
mutant	O
strains	O
.	O

The	O
increase	O
in	O
the	O
delays	O
in	O
the	O
csrA51	O
mutant	O
strain	O
switched	O
to	O
acetate	O
was	O
also	O
suppressed	O
in	O
the	O
csrA51	B-GP
ΔglgC	O
mutant	O
strain	O
.	O

Since	O
the	O
glycogen	O
level	O
in	O
the	O
csrBC	O
mutant	O
strain	O
was	O
zero	O
after	O
glucose	B-CD
exhaustion	O
(	O
Fig	O
.	O
1D	O
),	O
we	O
conclude	O
that	O
glycogen	O
is	O
necessary	O
to	O
start	O
acetate	O
uptake	O
1	O
h	O
after	O
glucose	B-CD
exhaustion	O
.	O

Therefore	O
,	O
the	O
Csr	B-GP
system	O
affects	O
the	O
establishment	O
of	O
metabolic	O
adaptation	O
after	O
glucose	B-CD
exhaustion	O
through	O
its	O
control	O
of	O
glycogen	O
synthesis	O
.	O

Delay	O
before	O
the	O
full	O
growth	O
rate	O
was	O
reached	O
on	O
acetate	O
.	O

For	O
each	O
strain	O
,	O
cells	O
from	O
a	O
mother	O
culture	O
on	O
M9	O
-	O
glucose	O
were	O
transferred	O
to	O
M9	O
-	O
acetate	O
and	O
the	O
time	O
lag	O
until	O
full	O
growth	O
on	O
the	O
new	O
substrate	O
was	O
measured	O
.	O

Cells	O
were	O
sampled	O
either	O
60	O
min	O
before	O
(	O
plain	O
bars	O
)	O
or	O
60	O
min	O
after	O
(	O
striped	O
bars	O
)	O
glucose	B-CD
exhaustion	O
.	O

The	O
data	O
are	O
averages	O
of	O
three	O
or	O
more	O
independent	O
biological	O
replicates	O
with	O
error	O
bars	O
representing	O
standard	O
deviations	O
.	O

A	O
significant	O
difference	O
between	O
a	O
mutant	O
and	O
the	O
WT	O
is	O
represented	O
by	O
an	O
asterisk	O
(	O
P	O
<	O
0	O
.	O
05	O
[	O
t	O
test	O
]).	O

DISCUSSION	O

The	O
Csr	B-GP
system	O
was	O
recently	O
demonstrated	O
to	O
be	O
a	O
major	O
controller	O
of	O
upper	O
glycolysis	O
fluxes	O
(	O
16	O
),	O
but	O
its	O
involvement	O
in	O
metabolic	O
adaptation	O
is	O
less	O
clear	O
in	O
the	O
literature	O
.	O

CsrA	B-GP
is	O
known	O
to	O
positively	O
regulate	O
glycolytic	O
genes	O
and	O
negatively	O
regulate	O
gluconeogenic	O
genes	O
(	O
15	O
,	O
16	O
).	O

A	O
study	O
of	O
the	O
BarA	B-GP
/	O
UvrY	B-GP
two	O
-	O
component	O
system	O
during	O
the	O
metabolic	O
switch	O
suggested	O
that	O
the	O
Csr	B-GP
system	O
is	O
crucial	O
for	O
efficient	O
adaptation	O
between	O
different	O
metabolic	O
pathways	O
(	O
2	O
).	O

Here	O
,	O
we	O
showed	O
that	O
gene	O
expression	O
in	O
the	O
CCM	O
(	O
glycolysis	O
,	O
gluconeogenesis	O
,	O
the	O
pentose	O
phosphate	O
pathway	O
,	O
and	O
the	O
tricarboxylic	O
acid	O
cycle	O
)	O
did	O
not	O
present	O
strong	O
discrepancies	O
between	O
the	O
Csr	B-GP
system	O
mutants	O
during	O
the	O
acetate	O
consumption	O
phase	O
,	O
in	O
deep	O
contrast	O
to	O
the	O
situation	O
during	O
glucose	B-CD
consumption	O
.	O

It	O
will	O
be	O
awkward	O
to	O
totally	O
rule	O
out	O
any	O
control	O
of	O
these	O
genes	O
by	O
CsrA	B-GP
,	O
since	O
regulation	O
could	O
be	O
at	O
the	O
posttranscriptional	O
level	O
.	O

The	O
control	O
by	O
CsrA	B-GP
could	O
also	O
be	O
counterbalanced	O
by	O
its	O
higher	O
sequestration	O
by	O
CsrB	B-GP
,	O
since	O
the	O
latter	O
level	O
has	O
been	O
reported	O
to	O
increase	O
during	O
the	O
transition	O
(	O
23	O
,	O
37	O
).	O

Most	O
importantly	O
,	O
CsrA	B-GP
was	O
demonstrated	O
to	O
control	O
the	O
expression	O
of	O
genes	O
encoding	O
functions	O
in	O
acetate	O
and	O
glycogen	O
metabolism	O
after	O
glucose	B-CD
exhaustion	O
.	O

This	O
gene	O
expression	O
profiling	O
,	O
combined	O
with	O
acetate	O
measurements	O
and	O
switch	O
experiments	O
,	O
demonstrated	O
that	O
CsrA	B-GP
influences	O
the	O
timing	O
of	O
acetate	O
and	O
glycogen	O
utilization	O
after	O
glucose	B-CD
exhaustion	O
.	O

We	O
proved	O
that	O
glycogen	O
allows	O
the	O
maintenance	O
of	O
a	O
minimal	O
cellular	O
energy	O
level	O
after	O
glucose	B-CD
exhaustion	O
.	O

The	O
energy	O
related	O
to	O
glycogen	O
and	O
/	O
or	O
acetate	O
catabolism	O
provided	O
the	O
energy	O
required	O
for	O
maintenance	O
but	O
was	O
not	O
sufficient	O
to	O
sustain	O
growth	O
on	O
glycogen	O
alone	O
.	O

We	O
also	O
showed	O
that	O
glycogen	O
accumulation	O
increased	O
cell	O
fitness	O
by	O
allowing	O
a	O
rapid	O
restart	O
on	O
acetate	O
.	O

In	O
the	O
csrA51	O
mutant	O
strain	O
,	O
the	O
overaccumulation	O
of	O
glycogen	O
was	O
also	O
accompanied	O
by	O
levels	O
of	O
G6P	O
and	O
F6P	O
and	O
energy	O
status	O
after	O
glucose	B-CD
exhaustion	O
matching	O
those	O
of	O
the	O
WT	O
during	O
growth	O
on	O
glucose	B-CD
.	O

Conversely	O
,	O
a	O
ΔcsrBC	O
mutant	O
strain	O
that	O
accumulates	O
a	O
very	O
low	O
level	O
of	O
glycogen	O
presents	O
phenotypes	O
similar	O
to	O
those	O
of	O
a	O
ΔglgC	O
mutant	O
strain	O
after	O
glucose	B-CD
exhaustion	O
,	O
with	O
a	O
low	O
energy	O
status	O
and	O
a	O
weaker	O
adaptive	O
capacity	O
to	O
use	O
acetate	O
.	O

From	O
our	O
work	O
,	O
it	O
is	O
now	O
clear	O
that	O
CsrA	B-GP
regulates	O
the	O
metabolic	O
transition	O
from	O
glycolysis	O
to	O
gluconeogenesis	O
in	O
E	B-OG
.	I-OG
coli	I-OG
.	O

Most	O
of	O
the	O
elements	O
presented	O
here	O
strengthen	O
the	O
hypothesis	O
that	O
the	O
transition	O
control	O
by	O
the	O
Csr	B-GP
system	O
is	O
exerted	O
through	O
the	O
regulation	O
of	O
glycogen	O
synthesis	O
and	O
its	O
utilization	O
.	O

The	O
only	O
clue	O
we	O
observed	O
concerning	O
a	O
glycogen	O
-	O
independent	O
effect	O
of	O
CsrA	B-GP
during	O
the	O
transition	O
is	O
in	O
the	O
production	O
of	O
cAMP	O
,	O
an	O
alarmone	O
that	O
has	O
an	O
important	O
function	O
in	O
the	O
catabolite	O
repression	O
process	O
(	O
38	O
).	O

Indeed	O
,	O
a	O
csrA51	O
mutant	O
strain	O
induced	O
cAMP	O
production	O
after	O
glucose	B-CD
exhaustion	O
,	O
but	O
the	O
levels	O
were	O
about	O
five	O
times	O
lower	O
than	O
in	O
the	O
WT	O
(	O
Fig	O
.	O
5A	O
).	O

This	O
could	O
result	O
from	O
the	O
greater	O
availability	O
of	O
G6P	O
,	O
since	O
this	O
substrate	O
indirectly	O
controls	O
adenylate	B-GP
cyclase	I-GP
activity	O
(	O
39	O
).	O

However	O
,	O
the	O
csrA51	O
ΔglgC	O
mutant	O
strain	O
presents	O
the	O
same	O
phenotype	O
,	O
proving	O
that	O
this	O
lower	O
cAMP	O
level	O
does	O
not	O
result	O
from	O
the	O
greater	O
glycogen	O
content	O
and	O
is	O
therefore	O
directly	O
linked	O
to	O
CsrA	B-GP
activity	O
.	O

CsrA	B-GP
could	O
thus	O
affect	O
important	O
metabolic	O
adaption	O
processes	O
,	O
such	O
as	O
catabolite	O
repression	O
,	O
independently	O
of	O
glycogen	O
content	O
.	O

This	O
reinforces	O
the	O
very	O
recently	O
discovered	O
link	O
between	O
Csr	B-GP
and	O
catabolite	O
repression	O
regulatory	O
systems	O
(	O
29	O
).	O

This	O
new	O
regulation	O
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
control	O
of	O
the	O
expression	O
of	O
the	O
CsrB	B-GP
and	O
CsrC	B-GP
ncRNAs	O
via	O
the	O
main	O
catabolic	O
repression	O
actors	O
EIIAGluc	O
and	O
cAMP	O
-	O
CRP	B-GP
.	O

There	O
could	O
be	O
another	O
clue	O
to	O
glycogen	O
-	O
independent	O
control	O
;	O
i	O
.	O
e	O
.,	O
if	O
glycogen	O
exhaustion	O
hinders	O
metabolic	O
adaptation	O
,	O
glycogen	O
overaccumulation	O
(	O
as	O
in	O
the	O
csrA51	O
mutant	O
strain	O
)	O
should	O
favor	O
it	O
.	O

However	O
,	O
the	O
delay	O
before	O
the	O
beginning	O
of	O
acetate	O
anabolism	O
was	O
longer	O
in	O
the	O
csrA51	O
mutant	O
strain	O
.	O

This	O
phenotype	O
is	O
very	O
likely	O
explained	O
by	O
the	O
fact	O
that	O
glycolysis	O
is	O
still	O
supplied	O
in	O
G6P	O
by	O
glycogen	O
after	O
glucose	B-CD
exhaustion	O
in	O
the	O
csrA51	O
mutant	O
and	O
this	O
could	O
impair	O
/	O
prevent	O
the	O
establishment	O
of	O
gluconeogenic	O
metabolism	O
.	O

Therefore	O
,	O
here	O
again	O
,	O
this	O
phenotype	O
is	O
linked	O
to	O
glycogen	O
accumulation	O
.	O

We	O
consequently	O
conclude	O
that	O
CsrA	B-GP
control	O
of	O
metabolic	O
adaptation	O
is	O
mediated	O
mainly	O
through	O
glycogen	O
accumulation	O
.	O

Given	O
its	O
structural	O
characteristics	O
and	O
its	O
metabolic	O
regulation	O
,	O
glycogen	O
was	O
hypothesized	O
to	O
be	O
a	O
storage	O
compound	O
providing	O
both	O
carbon	O
and	O
energy	O
for	O
microorganisms	B-OG
(	O
40	O
).	O

However	O
,	O
no	O
demonstration	O
of	O
this	O
function	O
was	O
previously	O
reported	O
in	O
the	O
literature	O
(	O
41	O
–	O
43	O
).	O

Here	O
,	O
using	O
a	O
metabolomics	O
approach	O
,	O
we	O
proved	O
for	O
the	O
first	O
time	O
that	O
glycogen	O
is	O
essential	O
to	O
maintain	O
the	O
cell	O
energy	O
level	O
after	O
glucose	B-CD
exhaustion	O
.	O

This	O
is	O
especially	O
important	O
since	O
it	O
was	O
postulated	O
that	O
to	O
classify	O
glycogen	O
as	O
an	O
energy	O
storage	O
compound	O
,	O
its	O
use	O
as	O
a	O
supply	O
for	O
energy	O
maintenance	O
had	O
to	O
be	O
demonstrated	O
(	O
40	O
).	O

With	O
this	O
work	O
,	O
this	O
is	O
now	O
the	O
case	O
.	O

Glycogen	O
metabolism	O
was	O
also	O
linked	O
to	O
environmental	O
survival	O
(	O
43	O
).	O

It	O
was	O
recently	O
hypothesized	O
and	O
backed	O
up	O
by	O
modeling	O
that	O
glycogen	O
is	O
an	O
energy	O
supply	O
for	O
immediate	O
use	O
in	O
the	O
following	O
growth	O
phase	O
of	O
E	B-OG
.	I-OG
coli	I-OG
(	O
42	O
).	O

Here	O
again	O
,	O
we	O
experimentally	O
demonstrated	O
the	O
validity	O
of	O
these	O
in	O
silico	O
-	O
based	O
conclusions	O
by	O
showing	O
that	O
metabolic	O
adaptation	O
of	O
cells	O
depends	O
on	O
glycogen	O
content	O
.	O

Thus	O
,	O
this	O
work	O
also	O
provides	O
significant	O
clues	O
to	O
the	O
function	O
of	O
glycogen	O
in	O
E	B-OG
.	I-OG
coli	I-OG
.	O

To	O
conclude	O
,	O
this	O
work	O
is	O
of	O
particular	O
importance	O
in	O
understanding	O
(	O
i	O
)	O
the	O
function	O
of	O
CsrA	B-GP
-	O
mediated	O
posttranscriptional	O
control	O
,	O
(	O
ii	O
)	O
the	O
role	O
of	O
glycogen	O
in	O
bacteria	B-OG
,	O
and	O
(	O
iii	O
)	O
the	O
mechanisms	O
behind	O
metabolic	O
adaptation	O
and	O
fitness	O
.	O

This	O
knowledge	O
is	O
crucial	O
not	O
only	O
for	O
control	O
of	O
the	O
ability	O
of	O
E	B-OG
.	I-OG
coli	I-OG
to	O
efficiently	O
colonize	O
the	O
gut	O
or	O
other	O
microbial	O
communities	O
and	O
environments	O
but	O
also	O
for	O
the	O
optimization	O
of	O
biotechnological	O
processes	O
in	O
which	O
the	O
metabolic	O
flexibility	O
of	O
E	B-OG
.	I-OG
coli	I-OG
is	O
extensively	O
exploited	O
for	O
the	O
use	O
of	O
a	O
broad	O
range	O
of	O
substrates	O
.	O

MATERIALS	O
AND	O
METHODS	O

Strains	O
.	O

All	O
of	O
the	O
strains	O
used	O
in	O
this	O
study	O
came	O
from	O
E	B-OG
.	I-OG
coli	I-OG
K	I-OG
-	I-OG
12	I-OG
MG1655	I-OG
(	O
WT	O
).	O

The	O
csrA51	O
mutant	O
strain	O
was	O
built	O
by	O
deleting	O
the	O
last	O
11	O
amino	B-CD
acids	I-CD
of	O
the	O
CsrA	B-GP
protein	O
by	O
λ	O
Red	O
system	O
recombination	O
(	O
17	O
,	O
32	O
).	O

The	O
csrD	B-GP
mutant	O
strain	O
was	O
constructed	O
by	O
completely	O
deleting	O
the	O
csrD	B-GP
gene	O
by	O
λ	O
Red	O
system	O
recombination	O
(	O
17	O
).	O

Likewise	O
,	O
the	O
csrBC	B-GP
mutant	O
strain	O
was	O
constructed	O
by	O
completely	O
deleting	O
the	O
CsrB	B-GP
and	O
CsrC	B-GP
ncRNAs	O
by	O
λ	O
Red	O
system	O
recombination	O
.	O

The	O
ΔglgC	O
and	O
csrA51	O
ΔglgC	O
mutants	O
were	O
obtained	O
from	O
the	O
JW3393	O
strain	O
(	O
Keio	O
collection	O
[	O
44	O
])	O
by	O
moving	O
the	O
mutation	O
(	O
ΔglgC	O
::	O
Kan	O
)	O
to	O
the	O
WT	O
or	O
the	O
background	O
of	O
the	O
csrA51	O
mutant	O
strain	O
by	O
bacteriophage	B-OG
P1	I-OG
-	O
mediated	O
transduction	O
.	O

Growth	O
conditions	O
.	O

Bioreactor	O
cultures	O
were	O
performed	O
with	O
a	O
volume	O
of	O
500	O
ml	O
of	O
M9	O
medium	O
complemented	O
with	O
2	O
.	O
7	O
g	O
⋅	O
liter	O
−	O
1	O
glucose	B-CD
with	O
pH	O
and	O
oxygenation	O
controls	O
(	O
16	O
).	O

Three	O
biological	O
replicates	O
were	O
produced	O
per	O
strain	O
(	O
two	O
for	O
the	O
csrA51	O
mutant	O
strain	O
).	O

The	O
optical	O
density	O
at	O
600	O
nm	O
(	O
OD600	O
)	O
of	O
extra	O
-	O
and	O
intracellular	O
samples	O
was	O
measured	O
at	O
30	O
-	O
min	O
intervals	O
throughout	O
the	O
culture	O
period	O
.	O

Flask	O
cultures	O
were	O
performed	O
with	O
200	O
-	O
ml	O
baffled	O
Erlenmeyer	O
flasks	O
with	O
a	O
total	O
volume	O
of	O
50	O
ml	O
of	O
M9	O
medium	O
supplemented	O
with	O
2	O
.	O
7	O
g	O
⋅	O
liter	O
−	O
1	O
glucose	B-CD
.	O

All	O
of	O
the	O
cultures	O
were	O
performed	O
at	O
37	O
°	O
C	O
.	O

Extracellular	O
and	O
intracellular	O
metabolites	O
.	O

The	O
extracellular	O
metabolites	O
were	O
identified	O
and	O
quantified	O
by	O
H	O
+	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
(	O
Agilent	O
Technologies	O
1200	O
Series	O
HPLC	O
and	O
an	O
Aminex	O
HPX	O
-	O
87h	O
column	O
to	O
separate	O
acid	O
and	O
sugar	B-CD
).	O

The	O
analysis	O
was	O
carried	O
out	O
at	O
48	O
°	O
C	O
with	O
5	O
mM	O
H2SO4	O
as	O
the	O
eluent	O
.	O

Intracellular	O
metabolites	O
were	O
sampled	O
at	O
four	O
different	O
times	O
during	O
culture	O
by	O
the	O
differential	O
method	O
(	O
45	O
).	O

The	O
metabolic	O
intracellular	O
content	O
was	O
assessed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
as	O
previously	O
described	O
(	O
16	O
).	O

The	O
AEC	O
was	O
quantified	O
as	O
previously	O
described	O
(	O
35	O
).	O

Specific	O
growth	O
rates	O
and	O
consumption	O
and	O
production	O
rates	O
were	O
determined	O
as	O
previously	O
described	O
(	O
46	O
).	O

RT	O
-	O
PCR	O
analysis	O
.	O

Gene	O
expression	O
levels	O
were	O
analyzed	O
by	O
quantitative	O
PCR	O
(	O
EvaGreen	O
;	O
Biotium	O
,	O
CA	O
)	O
on	O
a	O
Biomark	O
96	O
.	O
96	O
Dynamic	O
Array	O
(	O
Fluidigm	O
,	O
CA	O
)	O
as	O
previously	O
described	O
(	O
16	O
).	O

Briefly	O
,	O
the	O
equivalent	O
of	O
5	O
mg	O
of	O
cell	O
dry	O
weight	O
was	O
harvested	O
and	O
directly	O
flash	O
frozen	O
in	O
liquid	O
nitrogen	O
at	O
the	O
same	O
time	O
as	O
the	O
intracellular	O
metabolites	O
.	O

RNA	O
extraction	O
and	O
RT	O
were	O
performed	O
as	O
previously	O
described	O
(	O
32	O
).	O

The	O
transcripts	O
levels	O
were	O
normalized	O
to	O
the	O
idnT	B-GP
reference	O
gene	O
used	O
as	O
a	O
constitutive	O
reference	O
(	O
47	O
).	O

Quantification	O
of	O
intracellular	O
glycogen	O
.	O

Intracellular	O
glycogen	O
was	O
quantified	O
as	O
previously	O
described	O
(	O
48	O
).	O

Briefly	O
,	O
cells	O
were	O
lysed	O
and	O
glycogen	O
was	O
hydrolyzed	O
into	O
glucose	B-CD
subunits	O
by	O
an	O
amyloglucosidase	B-GP
.	O

The	O
glucose	B-CD
subunits	O
were	O
then	O
quantified	O
with	O
the	O
Glucose	B-CD
(	O
GO	O
)	O
Assay	O
kit	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
France	O
).	O

Flux	O
balance	O
analysis	O
.	O

The	O
genome	O
scale	O
model	O
and	O
constraints	O
used	O
in	O
this	O
study	O
were	O
previously	O
described	O
(	O
16	O
),	O
except	O
for	O
the	O
lower	O
boundary	O
of	O
the	O
non	O
-	O
growth	O
-	O
associated	O
maintenance	O
flux	O
,	O
which	O
was	O
set	O
to	O
2	O
.	O
9	O
mmol	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
.	O

The	O
model	O
is	O
a	O
slightly	O
modified	O
version	O
of	O
the	O
genome	O
scale	O
reconstruction	O
iAF1260	O
-	O
flux2	O
(	O
36	O
).	O

Flux	O
balance	O
analyses	O
were	O
performed	O
with	O
the	O
COBRAv2	O
toolbox	O
with	O
GLPK	O
as	O
the	O
linear	O
programming	O
solver	O
(	O
49	O
).	O

The	O
glucose	B-CD
uptake	O
rate	O
was	O
set	O
to	O
zero	O
,	O
while	O
the	O
oxygen	O
uptake	O
rate	O
was	O
set	O
to	O
a	O
limiting	O
value	O
of	O
−	O
15	O
mmol	O
⋅	O
gDW	O
−	O
1	O
⋅	O
h	O
−	O
1	O
to	O
allow	O
growth	O
on	O
acetate	O
.	O

The	O
acetate	O
and	O
glycogen	O
uptake	O
rates	O
were	O
varied	O
within	O
the	O
range	O
of	O
values	O
monitored	O
after	O
glucose	B-CD
exhaustion	O
(	O
see	O
Fig	O
.	O
1	O
),	O
and	O
for	O
each	O
pair	O
of	O
uptake	O
rates	O
,	O
either	O
the	O
biomass	O
or	O
the	O
ATP	O
flux	O
was	O
optimized	O
(	O
with	O
the	O
lower	O
boundary	O
of	O
the	O
maintenance	O
flux	O
set	O
to	O
zero	O
in	O
the	O
latter	O
case	O
).	O

Switch	O
experiments	O
.	O

To	O
investigate	O
the	O
timing	O
of	O
phenotypic	O
adaptation	O
,	O
cell	O
samples	O
were	O
collected	O
from	O
a	O
“	O
mother	O
”	O
culture	O
60	O
min	O
before	O
and	O
60	O
min	O
after	O
glucose	B-CD
exhaustion	O
as	O
previously	O
described	O
(	O
31	O
).	O

Briefly	O
,	O
cell	O
samples	O
were	O
rapidly	O
filtered	O
,	O
rinsed	O
,	O
and	O
used	O
to	O
inoculate	O
250	O
-	O
ml	O
Erlenmeyer	O
flasks	O
filled	O
with	O
30	O
ml	O
of	O
acetate	O
medium	O
.	O

Growth	O
of	O
the	O
“	O
daughter	O
”	O
cultures	O
was	O
monitored	O
by	O
measuring	O
the	O
OD600	O
by	O
spectrophotometry	O
at	O
0	O
,	O
15	O
,	O
80	O
,	O
and	O
120	O
min	O
after	O
inoculation	O
.	O

We	O
made	O
sure	O
that	O
the	O
cells	O
from	O
the	O
daughter	O
cultures	O
reached	O
the	O
maximal	O
growth	O
rate	O
(	O
μmax	O
)	O
by	O
measuring	O
the	O
growth	O
rate	O
between	O
80	O
and	O
120	O
min	O
.	O

The	O
lag	O
time	O
was	O
calculated	O
as	O
previously	O
described	O
(	O
31	O
).	O

Citation	O
Morin	O
M	O
,	O
Ropers	O
D	O
,	O
Cinquemani	O
E	O
,	O
Portais	O
J	O
,	O
Enjalbert	O
B	O
,	O
Cocaign	O
-	O
Bousquet	O
M	O
.	O

2017	O
.	O

The	O
Csr	B-GP
system	O
regulates	O
Escherichia	B-OG
coli	I-OG
fitness	O
by	O
controlling	O
glycogen	O
accumulation	O
and	O
energy	O
levels	O
.	O

mBio	O
8	O
:	O
e01628	O
-	O
17	O
.	O
https	O
://	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
mBio	O
.	O
01628	O
-	O
17	O
.	O

Antimicrobial	O
activities	O
of	O
a	O
promising	O
glycolipid	O
biosurfactant	O
from	O
a	O
novel	O
marine	O
Staphylococcussaprophyticus	B-OG
SBPS	O
15	O

Biosurfactants	O
have	O
gained	O
a	O
renewed	O
interest	O
in	O
the	O
recent	O
years	O
for	O
their	O
commercial	O
application	O
in	O
diverse	O
research	O
areas	O
.	O

Recent	O
evidences	O
suggest	O
that	O
the	O
antimicrobial	O
activities	O
exhibited	O
by	O
biosurfactants	O
make	O
them	O
promising	O
molecules	O
for	O
the	O
application	O
in	O
the	O
field	O
of	O
therapeutics	O
.	O

Marine	O
microbes	B-OG
are	O
well	O
known	O
for	O
their	O
unique	O
metabolic	O
and	O
functional	O
properties	O
;	O
however	O
,	O
few	O
reports	O
are	O
available	O
till	O
date	O
regarding	O
their	O
biosurfactant	O
production	O
and	O
antimicrobial	O
potential	O
.	O

In	O
an	O
ongoing	O
survey	O
for	O
bioactive	O
microbial	O
metabolites	O
from	O
microbes	B-OG
isolated	O
from	O
diverse	O
ecological	O
niches	O
,	O
a	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	I-OG
15	I-OG
isolated	O
from	O
the	O
petroleum	O
hydrocarbon	O
contaminated	O
coastal	O
site	O
,	O
Puducherry	O
,	O
India	O
,	O
was	O
identified	O
as	O
a	O
promising	O
biosurfactant	O
producer	O
based	O
on	O
multiple	O
screening	O
methods	O
.	O

This	O
bacterium	B-OG
exhibited	O
growth	O
-	O
dependent	O
biosurfactant	O
production	O
and	O
the	O
recorded	O
yield	O
was	O
1	O
.	O
345	O
±	O
0	O
.	O
056	O
g	O
/	O
L	O
(	O
on	O
dry	O
weight	O
basis	O
).	O

The	O
biosurfactant	O
was	O
purified	O
and	O
chemically	O
characterized	O
as	O
a	O
glycolipid	O
with	O
a	O
molecular	O
mass	O
of	O
606	O
.	O
7	O
Da	O
,	O
based	O
on	O
TLC	O
,	O
biochemical	O
estimation	O
methods	O
,	O
FT	O
-	O
IR	O
spectrum	O
and	O
MALDI	O
-	O
TOF	O
–	O
MS	O
analysis	O
.	O

Further	O
,	O
the	O
estimated	O
molecular	O
mass	O
was	O
different	O
from	O
the	O
earlier	O
reports	O
on	O
biosurfactants	O
.	O

This	O
new	O
glycolipid	O
biosurfactant	O
exhibited	O
a	O
board	O
range	O
of	O
pH	O
and	O
temperature	O
stability	O
.	O

Furthermore	O
,	O
it	O
revealed	O
a	O
promising	O
antimicrobial	O
activity	O
against	O
many	O
tested	O
human	B-OG
pathogenic	O
bacterial	O
and	O
fungal	O
clinical	O
isolates	O
.	O

Based	O
on	O
these	O
observations	O
,	O
the	O
isolated	O
biosurfactant	O
from	O
the	O
marine	O
S	B-OG
.	I-OG
saprophyticus	I-OG
revealed	O
board	O
physicochemical	O
stabilities	O
and	O
possess	O
excellent	O
antimicrobial	O
activities	O
which	O
proves	O
its	O
significance	O
for	O
possible	O
use	O
in	O
various	O
therapeutic	O
and	O
biomedical	O
applications	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
biosurfactant	O
from	O
the	O
bacterium	B-OG
,	O
S	B-OG
.	I-OG
saprophyticus	I-OG
.	O

Introduction	O

Biosurfactants	O
possess	O
both	O
hydrophilic	O
and	O
hydrophobic	O
moieties	O
that	O
tend	O
to	O
interact	O
with	O
the	O
phase	O
boundary	O
between	O
two	O
distinct	O
phases	O
in	O
a	O
heterogeneous	O
system	O
to	O
solubilize	O
them	O
(	O
Ron	O
and	O
Rosenberg	O
2002	O
).	O

Biosurfactants	O
has	O
several	O
advantages	O
over	O
their	O
synthetic	O
counterparts	O
such	O
as	O
higher	O
biodegradability	O
;	O
lower	O
toxicity	O
;	O
good	O
biocompatibility	O
;	O
stable	O
at	O
different	O
physico	O
-	O
chemical	O
conditions	O
;	O
synthesis	O
under	O
user	O
-	O
friendly	O
conditions	O
,	O
e	O
.	O
g	O
.,	O
low	O
temperatures	O
and	O
pressures	O
(	O
Zhang	O
et	O
al	O
.	O
2004	O
;	O
Ruggeri	O
et	O
al	O
.	O
2009	O
).	O

They	O
exhibit	O
diverse	O
functional	O
properties	O
such	O
as	O
emulsification	O
,	O
wetting	O
,	O
foaming	O
,	O
cleansing	O
,	O
phase	O
separation	O
,	O
surface	O
activity	O
and	O
reduction	O
in	O
viscosity	O
of	O
crude	O
oil	O
,	O
which	O
makes	O
them	O
amenable	O
for	O
the	O
application	O
in	O
diverse	O
niche	O
areas	O
such	O
as	O
agriculture	O
,	O
pharmaceuticals	O
,	O
cosmetics	O
,	O
food	O
industries	O
,	O
oil	O
recovery	O
and	O
environmental	O
remediation	O
(	O
Mulligan	O
2005	O
;	O
Campos	O
et	O
al	O
.	O
2013	O
;	O
Sachdev	O
and	O
Cameotra	O
2013	O
;	O
Gudina	O
et	O
al	O
.	O
2016	O
).	O

In	O
addition	O
to	O
these	O
,	O
recent	O
studies	O
evidenced	O
that	O
biosurfactants	O
exhibited	O
anti	O
-	O
bacterial	O
,	O
anti	O
-	O
fungal	O
and	O
anti	O
-	O
viral	O
activities	O
which	O
makes	O
them	O
potential	O
sources	O
for	O
biomedical	O
applications	O
(	O
Singh	O
and	O
Cameotra	O
2004	O
).	O

Many	O
of	O
the	O
known	O
biosurfactants	O
having	O
bioactive	O
potential	O
have	O
been	O
reported	O
from	O
terrestrial	O
habitats	O
,	O
the	O
well	O
known	O
biosurfactants	O
are	O
surfactin	B-CD
,	O
fengycin	B-CD
,	O
bacillomycins	B-CD
and	O
iturin	B-CD
produced	O
by	O
Bacillus	B-OG
subtilis	I-OG
(	O
Ahimou	O
et	O
al	O
.	O
2000	O
),	O
sophorolipids	B-CD
(	O
Cavalero	O
and	O
Cooper	O
2003	O
),	O
rhamnolipids	B-CD
from	O
Pseudomonas	B-OG
aeruginosa	I-OG
(	O
Benincasa	O
et	O
al	O
.	O
2004	O
)	O
and	O
mannosylerythritol	B-CD
lipids	O
from	O
Candida	B-OG
antarctica	I-OG
(	O
Arutchelvi	O
et	O
al	O
.	O
2008	O
).	O

Despite	O
the	O
fact	O
that	O
marine	O
environment	O
forms	O
>	O
70	O
%	O
of	O
the	O
Earth	O
’	O
s	O
biosphere	O
comprising	O
of	O
diverse	O
group	O
of	O
microorganisms	B-OG
with	O
unique	O
metabolic	O
,	O
structural	O
and	O
functional	O
properties	O
(	O
Fenical	O
1993	O
;	O
Proksch	O
et	O
al	O
.	O
2003	O
);	O
they	O
were	O
less	O
studied	O
till	O
date	O
.	O

The	O
first	O
antimicrobial	O
marine	O
biosurfactant	O
was	O
reported	O
from	O
Bacillus	B-OG
circulans	I-OG
isolated	O
from	O
the	O
Andaman	O
and	O
Nicobar	O
Islands	O
,	O
India	O
,	O
which	O
exhibited	O
antimicrobial	O
potential	O
against	O
several	O
multidrug	O
resistant	O
human	B-OG
pathogens	O
with	O
non	O
-	O
hemolytic	O
property	O
(	O
Das	O
et	O
al	O
.	O
2008	O
).	O

Thereafter	O
,	O
some	O
researchers	O
explored	O
the	O
antimicrobial	O
activities	O
of	O
biosurfactants	O
from	O
marine	O
microbes	B-OG
(	O
Khopade	O
et	O
al	O
.	O
2012	O
;	O
Dusane	O
et	O
al	O
.	O
2011	O
;	O
Kiran	O
et	O
al	O
.	O
2010	O
).	O

However	O
,	O
when	O
compared	O
to	O
biosurfactants	O
from	O
terrestrial	O
isolates	O
,	O
few	O
marine	O
biosurfactants	O
have	O
been	O
explored	O
for	O
its	O
antimicrobial	O
potential	O
,	O
hence	O
warrants	O
this	O
investigation	O
.	O

Staphylococcus	B-OG
is	O
a	O
well	O
known	O
genus	O
for	O
its	O
human	B-OG
and	O
animal	B-OG
infections	B-DS
,	O
but	O
some	O
species	O
have	O
been	O
recognized	O
as	O
common	O
commensals	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
some	O
secondary	O
metabolites	O
produced	O
by	O
Staphylococcus	B-OG
species	O
isolated	O
from	O
natural	O
environments	O
exhibited	O
biotechnological	O
and	O
biomedical	O
significance	O
(	O
Popowicz	O
et	O
al	O
.	O
2006	O
).	O
Staphylococcus	B-OG
saprophyticus	I-OG
isolated	O
from	O
the	O
seawater	O
in	O
Jiangsu	O
,	O
China	O
showed	O
appreciable	O
production	O
of	O
lipase	B-GP
having	O
excellent	O
organic	O
solvent	O
tolerance	O
(	O
Fang	O
et	O
al	O
.	O
2006	O
).	O

Moreover	O
,	O
previous	O
studies	O
showed	O
the	O
possibilities	O
of	O
biosurfactant	O
production	O
in	O
the	O
genus	O
Staphylococcus	B-OG
species	O
(	O
Eddouaouda	O
et	O
al	O
.	O
2012	O
).	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
studies	O
have	O
been	O
reported	O
on	O
Staphylococcus	B-OG
saprophyticus	I-OG
for	O
biosurfactant	O
production	O
.	O

Hence	O
,	O
the	O
present	O
study	O
was	O
undertaken	O
with	O
regard	O
to	O
the	O
isolation	O
of	O
potential	O
biosurfactant	O
strains	O
using	O
multiple	O
screening	O
methods	O
,	O
followed	O
by	O
the	O
production	O
and	O
purification	O
of	O
the	O
biosurfactant	O
from	O
a	O
promising	O
strain	O
of	O
Staphylococcus	B-OG
saprophyticus	I-OG
,	O
and	O
its	O
biochemical	O
characterization	O
,	O
pH	O
and	O
temperature	O
stability	O
studies	O
and	O
evaluation	O
of	O
the	O
antimicrobial	O
potential	O
of	O
the	O
biosurfactant	O
against	O
different	O
human	B-OG
pathogenic	O
clinical	O
isolates	O
.	O

Materials	O
and	O
methods	O

Sample	O
collection	O

Sediment	O
samples	O
were	O
collected	O
using	O
Petersen	O
grab	O
sampler	O
from	O
four	O
different	O
locations	O
of	O
the	O
petroleum	O
hydrocarbon	O
contaminated	O
coastal	O
sites	O
of	O
Puducherry	O
,	O
India	O
.	O

Possible	O
aseptic	O
techniques	O
were	O
applied	O
while	O
sampling	O
to	O
avoid	O
contamination	O
and	O
the	O
collected	O
samples	O
were	O
transferred	O
to	O
pre	O
-	O
sterilized	O
bottle	O
containers	O
which	O
was	O
kept	O
in	O
an	O
icebox	O
maintained	O
at	O
4	O
°	O
C	O
till	O
further	O
processing	O
.	O

The	O
collected	O
samples	O
after	O
reaching	O
the	O
laboratory	O
were	O
processed	O
immediately	O
.	O

Screening	O
of	O
potential	O
biosurfactant	O
producing	O
bacteria	B-OG

All	O
the	O
collected	O
four	O
samples	O
were	O
processed	O
individually	O
,	O
in	O
which	O
1	O
g	O
of	O
central	O
portions	O
of	O
the	O
samples	O
was	O
serially	O
diluted	O
using	O
sterilized	O
natural	O
seawater	O
(	O
34	O
ppt	O
)	O
and	O
spread	O
plated	O
on	O
Bushnell	O
Haas	O
agar	O
plates	O
prepared	O
in	O
sea	O
water	O
and	O
supplemented	O
with	O
1	O
%	O
crude	O
oil	O
.	O

After	O
5	O
days	O
of	O
incubation	O
at	O
37	O
°	O
C	O
,	O
individual	O
colonies	O
with	O
distinct	O
morphologies	O
were	O
isolated	O
and	O
further	O
sub	O
-	O
cultured	O
on	O
Zobell	O
marine	O
agar	O
plates	O
to	O
obtain	O
pure	O
cultures	O
,	O
which	O
were	O
maintained	O
in	O
lyophilized	O
form	O
for	O
further	O
studies	O
.	O

All	O
the	O
axenic	O
cultures	O
were	O
individually	O
cultured	O
in	O
Zobell	O
marine	O
broth	O
2216	O
for	O
48	O
h	O
and	O
the	O
cell	O
free	O
supernatant	O
was	O
used	O
for	O
screening	O
the	O
most	O
promising	O
biosurfactant	O
producers	O
using	O
multiple	O
screening	O
methods	O
,	O
viz	O
.,	O
surface	O
activity	O
(	O
Tadros	O
2005	O
),	O
emulsification	O
activity	O
(	O
Cooper	O
and	O
Goldenberg	O
1987	O
),	O
lipase	B-GP
activity	O
(	O
Kiran	O
et	O
al	O
.	O
2010	O
)	O
and	O
oil	O
displacement	O
test	O
(	O
Youssef	O
et	O
al	O
.	O
2004	O
).	O

Molecular	O
identification	O

Molecular	O
identification	O
of	O
the	O
most	O
potential	O
strain	O
was	O
performed	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
using	O
the	O
bacterial	O
universal	O
primer	O
set	O
of	O
Eubac	B-OG
27F	O
(	O
5	O
′-	O
AGAG	O
TTTG	O
ATCM	O
TGGC	O
TCAG	O
-	O
3	O
′)	O
and	O
1492R	O
(	O
5	O
′-	O
GGTT	O
ACCT	O
TGTT	O
ACGA	O
CTT	O
-	O
3	O
′).	O

The	O
PCR	O
product	O
was	O
purified	O
using	O
the	O
Qiagen	O
PCR	O
purification	O
kit	O
and	O
then	O
sequenced	O
on	O
an	O
ABI	O
Prism	O
377	O
automatic	O
sequencer	O
(	O
Applied	O
Biosystems	O
,	O
CA	O
,	O
USA	O
).	O

The	O
16S	O
rRNA	O
gene	O
sequence	O
from	O
this	O
promising	O
strain	O
was	O
compared	O
with	O
the	O
available	O
bacterial	O
sequences	O
using	O
NCBI	O
BLAST	O
(	O
http	O
://	O
blast	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
Blast	O
.	O
cgi	O
)	O
for	O
their	O
pair	O
-	O
wise	O
identities	O
.	O

Neighbor	O
-	O
joining	O
phylogenetic	O
tree	O
was	O
plotted	O
using	O
the	O
UPGMA	O
statistical	O
method	O
based	O
on	O
the	O
Maximum	O
-	O
Composite	O
-	O
Likelihood	O
model	O
using	O
MEGA	O
6	O
.	O
0	O
software	O
(	O
www	O
.	O
megasoftware	O
.	O
net	O
).	O

Growth	O
kinetics	O
profile	O
as	O
a	O
function	O
of	O
time	O
on	O
biosurfactant	O
production	O

The	O
identified	O
potential	O
strain	O
was	O
standardized	O
for	O
its	O
peak	O
time	O
of	O
biosurfactant	O
production	O
with	O
reference	O
to	O
its	O
cell	O
growth	O
.	O

The	O
production	O
process	O
was	O
carried	O
out	O
in	O
a	O
3	O
L	O
laboratory	O
fermentor	O
(	O
Scigenics	O
,	O
India	O
)	O
with	O
2	O
.	O
1	O
L	O
working	O
volume	O
using	O
sea	O
water	O
prepared	O
glucose	B-CD
mineral	O
salt	O
medium	O
as	O
the	O
production	O
medium	O
under	O
the	O
culture	O
conditions	O
of	O
pH	O
8	O
.	O
0	O
,	O
temperature	O
of	O
37	O
°	O
C	O
,	O
34	O
ppt	O
salinity	O
,	O
agitation	O
at	O
150	O
rpm	O
and	O
aeration	O
at	O
1	O
.	O
0	O
vvm	O
.	O

The	O
inoculum	O
was	O
prepared	O
using	O
the	O
exponential	O
phase	O
culture	O
of	O
this	O
promising	O
strain	O
in	O
the	O
same	O
production	O
medium	O
,	O
where	O
the	O
optical	O
density	O
(	O
OD	O
620	O
nm	O
)	O
of	O
the	O
inoculum	O
culture	O
was	O
adjusted	O
to	O
0	O
.	O
1	O
based	O
on	O
McFarland	O
turbidity	O
0	O
.	O
5	O
standards	O
which	O
was	O
equivalent	O
to	O
the	O
bacterial	O
concentration	O
of	O
1	O
×	O
108	O
cfu	O
/	O
mL	O
.	O

The	O
biosurfactant	O
production	O
was	O
monitored	O
based	O
on	O
the	O
24	O
h	O
emulsification	O
index	O
(	O
E	O
24	O
)	O
(	O
Cooper	O
and	O
Goldenberg	O
1987	O
)	O
and	O
the	O
bacterial	O
growth	O
was	O
monitored	O
based	O
on	O
the	O
dry	O
weight	O
of	O
cell	O
biomass	O
.	O

The	O
fermentation	O
process	O
was	O
monitored	O
for	O
96	O
h	O
and	O
the	O
samples	O
were	O
withdrawn	O
on	O
periodic	O
intervals	O
of	O
6	O
h	O
starting	O
from	O
the	O
lag	O
phase	O
to	O
stationary	O
phase	O
under	O
batch	O
culture	O
conditions	O
.	O

The	O
values	O
are	O
represented	O
as	O
mean	O
±	O
standard	O
deviation	O
of	O
triplicate	O
experiments	O
.	O

Purification	O
of	O
biosurfactant	O

At	O
the	O
standardized	O
incubation	O
time	O
,	O
the	O
cell	O
free	O
supernatant	O
was	O
subjected	O
to	O
acid	O
precipitation	O
using	O
6	O
N	O
HCl	O
until	O
pH	O
2	O
was	O
attained	O
(	O
Nitschke	O
and	O
Pastore	O
2006	O
).	O

After	O
overnight	O
incubation	O
at	O
4	O
°	O
C	O
,	O
the	O
precipitated	O
crude	O
biosurfactant	O
was	O
collected	O
by	O
centrifugation	O
at	O
5000	O
rpm	O
for	O
15	O
minutes	O
.	O

The	O
obtained	O
crude	O
biosurfactant	O
was	O
neutralized	O
using	O
phosphate	O
buffer	O
(	O
pH	O
7	O
)	O
and	O
the	O
resultant	O
biosurfactant	O
was	O
extracted	O
with	O
an	O
equal	O
volume	O
of	O
chloroform	B-CD
.	O

The	O
organic	O
phase	O
was	O
separated	O
,	O
concentrated	O
and	O
rotary	O
vacuum	O
evaporated	O
(	O
Lablinks	O
PBU	O
-	O
6	O
,	O
India	O
)	O
which	O
was	O
further	O
purified	O
on	O
normal	O
phase	O
silica	O
gel	O
(	O
60	O
–	O
120	O
mesh	O
,	O
HiMedia	O
Laboratories	O
Pvt	O
.	O

Ltd	O
.,	O
Mumbai	O
,	O
India	O
)	O
column	O
chromatography	O
using	O
stepwise	O
elution	O
with	O
methanol	O
and	O
chloroform	B-CD
ranging	O
from	O
1	O
:	O
20	O
to	O
1	O
:	O
1	O
(	O
v	O
/	O
v	O
).	O

Twenty	O
fractions	O
were	O
collected	O
and	O
every	O
fraction	O
was	O
screened	O
for	O
the	O
emulsification	O
index	O
(	O
E	O
24	O
)	O
and	O
the	O
purity	O
of	O
biosurfactant	O
was	O
checked	O
by	O
thin	O
layer	O
chromatography	O
.	O

The	O
fraction	O
(	O
s	O
)	O
showing	O
maximum	O
activity	O
were	O
pooled	O
,	O
rotary	O
evaporated	O
and	O
lyophilized	O
for	O
further	O
studies	O
.	O

Biochemical	O
characterization	O

The	O
purified	O
biosurfactant	O
was	O
analyzed	O
on	O
silica	O
gel	O
60	O
TLC	O
plate	O
(	O
F254	O
,	O
Merck	O
)	O
which	O
was	O
separated	O
using	O
CH3Cl	O
:	O
CH3OH	O
:	O
H2O	O
(	O
65	O
/	O
15	O
/	O
2	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
as	O
developing	O
system	O
.	O

Visualizing	O
reagents	O
used	O
were	O
ninhydrin	B-CD
reagent	O
(	O
0	O
.	O
2	O
g	O
ninhydrin	B-CD
in	O
100	O
mL	O
ethanol	O
)	O
to	O
detect	O
peptides	O
,	O
anthrone	O
reagent	O
(	O
1	O
g	O
anthrone	O
in	O
5	O
mL	O
sulfuric	O
acid	O
mixed	O
with	O
95	O
mL	O
ethanol	O
)	O
to	O
examine	O
sugars	B-CD
and	O
lipid	O
portion	O
was	O
evidenced	O
using	O
rhodamine	B-CD
B	I-CD
reagent	O
(	O
0	O
.	O
25	O
g	O
in	O
100	O
mL	O
ethanol	O
).	O

Following	O
this	O
,	O
the	O
total	O
content	O
of	O
protein	O
,	O
carbohydrate	B-CD
and	O
lipid	O
was	O
estimated	O
using	O
Lowry	O
’	O
s	O
method	O
(	O
Lowry	O
et	O
al	O
.	O
1951	O
),	O
phenol	O
sulphuric	O
acid	O
method	O
(	O
Dubois	O
et	O
al	O
.	O
1956	O
)	O
and	O
total	O
free	O
fatty	B-CD
acids	I-CD
(	O
Folch	O
et	O
al	O
.	O
1957	O
),	O
respectively	O
.	O

Further	O
,	O
the	O
FT	O
-	O
IR	O
spectrum	O
was	O
used	O
to	O
elucidate	O
the	O
functional	O
groups	O
present	O
in	O
the	O
purified	O
unknown	O
biosurfactant	O
.	O

One	O
milligram	O
of	O
freeze	O
-	O
dried	O
biosurfactant	O
was	O
grounded	O
with	O
100	O
mg	O
of	O
KBr	O
.	O

Infrared	O
absorption	O
spectrum	O
were	O
recorded	O
on	O
a	O
Thermo	O
Nicolet	O
,	O
AVATAR	O
330	O
FTIR	O
system	O
with	O
a	O
spectral	O
resolution	O
of	O
cm	O
−	O
1	O
with	O
an	O
average	O
of	O
10	O
scans	O
in	O
the	O
wave	O
number	O
range	O
of	O
400	O
–	O
4000	O
cm	O
−	O
1	O
,	O
and	O
KBr	O
pellet	O
was	O
used	O
as	O
the	O
background	O
reference	O
.	O

Molecular	O
mass	O
determination	O

MALDI	O
-	O
TOF	O
MS	O
was	O
used	O
to	O
examine	O
the	O
molecular	O
mass	O
of	O
the	O
purified	O
biosurfactant	O
.	O

MS	O
was	O
carried	O
out	O
using	O
a	O
Voyager	O
DE	O
-	O
Pro	O
MALDI	O
-	O
TOF	O
spectrometer	O
(	O
Applied	O
Biosystems	O
,	O
Inc	O
,	O
CA	O
,	O
USA	O
)	O
in	O
reflector	O
mode	O
with	O
an	O
accelerating	O
voltage	O
of	O
20	O
kV	O
.	O

Equal	O
volume	O
(	O
2	O
µL	O
)	O
of	O
the	O
purified	O
fraction	O
was	O
mixed	O
with	O
an	O
equal	O
volume	O
of	O
matrix	O
solution	O
,	O
i	O
.	O
e	O
.	O
0	O
.	O
1	O
%	O
α	O
-	O
cyano	O
-	O
4	O
-	O
hydroxycinnamic	O
acid	O
in	O
acetonitrile	O
–	O
water	O
–	O
TFA	O
(	O
50	O
:	O
50	O
:	O
0	O
.	O
01	O
,	O
v	O
/	O
v	O
/	O
v	O
).	O

After	O
mixing	O
,	O
the	O
sample	O
was	O
spotted	O
on	O
the	O
target	O
plate	O
,	O
dried	O
,	O
placed	O
inside	O
the	O
sample	O
cabinet	O
and	O
the	O
molecules	O
were	O
separated	O
based	O
on	O
their	O
molecular	O
weight	O
.	O

Stability	O
studies	O

Stability	O
of	O
the	O
biosurfactant	O
was	O
evaluated	O
using	O
24	O
h	O
emulsification	O
index	O
(	O
E	O
24	O
)	O
(	O
Sheppard	O
and	O
Mulligan	O
1987	O
).	O

The	O
emulsification	O
activity	O
was	O
estimated	O
using	O
crude	O
oil	O
as	O
the	O
solvent	O
and	O
the	O
estimations	O
were	O
carried	O
out	O
after	O
exposure	O
for	O
an	O
hour	O
under	O
the	O
specified	O
test	O
conditions	O
.	O

The	O
purified	O
biosurfactant	O
at	O
4	O
mg	O
/	O
mL	O
concentration	O
in	O
distilled	O
water	O
was	O
tested	O
for	O
the	O
effect	O
of	O
different	O
temperatures	O
ranging	O
between	O
30	O
and	O
120	O
°	O
C	O
(	O
Cooper	O
and	O
Goldenberg	O
1987	O
)	O
and	O
the	O
influence	O
of	O
pH	O
was	O
estimated	O
by	O
adjusting	O
the	O
initial	O
pH	O
of	O
the	O
medium	O
from	O
2	O
to	O
10	O
(	O
Nitschke	O
and	O
Pastore	O
2006	O
).	O

Antimicrobial	O
activity	O

The	O
antimicrobial	O
activity	O
of	O
the	O
purified	O
biosurfactant	O
was	O
studied	O
on	O
Muller	O
-	O
Hinton	O
agar	O
(	O
MHA	O
)	O
plates	O
against	O
a	O
panel	O
of	O
different	O
human	B-OG
pathogens	O
using	O
antimicrobial	O
disk	O
susceptibility	O
tests	O
as	O
per	O
the	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
(	O
2015	O
)	O
recommendations	O
.	O

The	O
human	B-OG
bacterial	O
pathogens	O
used	O
were	O
Escherichia	B-OG
coli	I-OG
,	O
Salmonella	B-OG
typhi	I-OG
,	O
S	B-OG
.	I-OG
paratyphi	I-OG
,	O
Klebsiella	B-OG
pneumoniae	I-OG
,	O
K	B-OG
.	I-OG
oxytoca	I-OG
,	O
Vibrio	B-OG
parahemolyticus	I-OG
,	O
V	B-OG
.	I-OG
cholerae	I-OG
,	O
Proteus	B-OG
mirabilis	I-OG
,	O
Streptococcus	B-OG
pneumoniae	I-OG
,	O
Bacillus	B-OG
subtilis	I-OG
,	O
B	B-OG
.	I-OG
cereus	I-OG
and	O
Staphylococcus	B-OG
aureus	I-OG
and	O
human	B-OG
fungal	O
pathogens	O
used	O
were	O
Aspergillus	B-OG
niger	I-OG
,	O
A	B-OG
.	I-OG
flavus	I-OG
,	O
Candida	B-OG
albicans	I-OG
,	O
Cryptococcus	B-OG
neoformans	I-OG
and	O
C	B-OG
.	I-OG
gattii	I-OG
,	O
which	O
were	O
kindly	O
provided	O
by	O
Rajah	O
Muthiah	O
Medical	O
College	O
Hospital	O
,	O
Annamalai	O
University	O
,	O
Tamilnadu	O
,	O
India	O
.	O

These	O
strains	O
were	O
cultured	O
on	O
nutrient	O
broth	O
at	O
37	O
°	O
C	O
and	O
the	O
OD	O
of	O
these	O
broth	O
cultures	O
were	O
adjusted	O
to	O
0	O
.	O
1	O
equivalent	O
to	O
an	O
inoculum	O
concentration	O
of	O
108	O
cfu	O
mL	O
−	O
1	O
(	O
according	O
to	O
McFarland	O
turbidity	O
standard	O
).	O

MHA	O
plates	O
were	O
swab	O
cultured	O
with	O
100	O
µL	O
of	O
individual	O
pathogenic	O
strains	O
and	O
the	O
wells	O
were	O
impregnated	O
with	O
50	O
µL	O
of	O
purified	O
biosurfactant	O
dissolved	O
in	O
phosphate	O
buffer	O
(	O
pH	O
7	O
)	O
at	O
different	O
concentrations	O
(	O
1	O
–	O
128	O
µg	O
/	O
mL	O
)	O
to	O
obtain	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
whereas	O
phosphate	O
buffer	O
solution	O
was	O
used	O
as	O
control	O
.	O

After	O
incubation	O
for	O
24	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
plates	O
were	O
examined	O
for	O
zone	O
diameter	O
of	O
inhibition	O
using	O
an	O
antibiotic	O
zone	O
scale	O
.	O

Results	O
and	O
discussion	O

Isolation	O
and	O
screening	O
of	O
most	O
promising	O
biosurfactant	O
producing	O
bacterium	B-OG

After	O
the	O
specified	O
incubation	O
period	O
,	O
the	O
Bushnell	O
Haas	O
agar	O
plates	O
were	O
examined	O
for	O
distinct	O
morphological	O
colonies	O
which	O
were	O
isolated	O
and	O
pure	O
cultured	O
on	O
Zobell	O
marine	O
agar	O
plates	O
.	O

A	O
total	O
of	O
51	O
axenic	O
strains	O
were	O
isolated	O
and	O
named	O
as	O
SBPS	O
1	O
–	O
51	O
.	O

These	O
isolates	O
were	O
screened	O
to	O
identify	O
the	O
most	O
promising	O
biosurfactant	O
producer	O
(	O
s	O
)	O
using	O
multiple	O
screening	O
tests	O
.	O

Only	O
11	O
–	O
30	O
%	O
of	O
the	O
isolates	O
showed	O
potent	O
activity	O
with	O
respect	O
to	O
surface	O
tension	O
reduction	O
(	O
13	O
%),	O
emulsification	O
activity	O
(	O
11	O
%),	O
lipase	B-GP
activity	O
(	O
20	O
%)	O
and	O
oil	O
displacement	O
test	O
(	O
30	O
%).	O

Among	O
these	O
isolates	O
,	O
only	O
one	O
strain	O
SBPS	O
15	O
showed	O
promising	O
activity	O
with	O
respect	O
to	O
all	O
the	O
screening	O
tests	O
,	O
viz	O
.,	O
surface	O
tension	O
reduction	O
(	O
32	O
mN	O
/	O
m	O
),	O
emulsification	O
activity	O
(	O
77	O
.	O
5	O
%),	O
lipase	B-GP
activity	O
(	O
66	O
U	O
/	O
mL	O
)	O
and	O
oil	O
displacement	O
(	O
3	O
.	O
3	O
cm	O
),	O
while	O
the	O
rest	O
of	O
the	O
strains	O
showed	O
highly	O
variable	O
results	O
against	O
the	O
different	O
screening	O
methods	O
.	O

In	O
accordance	O
to	O
the	O
present	O
investigation	O
,	O
Bodour	O
and	O
Maier	O
(	O
2000	O
)	O
earlier	O
reported	O
the	O
significance	O
of	O
petroleum	O
contaminated	O
sites	O
as	O
the	O
best	O
sources	O
for	O
the	O
isolation	O
of	O
promising	O
biosurfactant	O
producers	O
.	O

Many	O
researchers	O
have	O
also	O
previously	O
reported	O
the	O
significance	O
of	O
multiple	O
screening	O
tests	O
for	O
isolation	O
of	O
potential	O
biosurfactant	O
producers	O
and	O
some	O
methods	O
were	O
chosen	O
as	O
standard	O
techniques	O
for	O
the	O
effective	O
isolation	O
of	O
biosurfactant	O
producers	O
(	O
Khopade	O
et	O
al	O
.	O
2012	O
;	O
Kiran	O
et	O
al	O
.	O
2010	O
).	O

Based	O
on	O
the	O
multiple	O
screening	O
methods	O
adopted	O
in	O
the	O
present	O
study	O
,	O
strain	O
SBPS	O
15	O
was	O
identified	O
as	O
a	O
promising	O
biosurfactant	O
producer	O
.	O

The	O
cell	O
morphology	O
based	O
on	O
Gram	O
staining	O
and	O
microscopic	O
observation	O
revealed	O
the	O
strain	O
SBPS	O
15	O
to	O
be	O
Gram	B-OG
-	I-OG
positive	I-OG
cocci	I-OG
.	O

The	O
molecular	O
identification	O
was	O
performed	O
by	O
amplifying	O
the	O
16S	O
rRNA	O
region	O
and	O
the	O
sequence	O
homology	O
was	O
examined	O
based	O
on	O
BLASTn	O
analysis	O
.	O

The	O
total	O
length	O
of	O
the	O
amplified	O
sequence	O
was	O
1441	O
bp	O
.	O

The	O
BLASTn	O
homology	O
comparison	O
of	O
the	O
16S	O
rRNA	O
gene	O
sequence	O
of	O
the	O
strain	O
SBPS	O
15	O
against	O
the	O
nucleotide	B-CD
sequence	O
collection	O
of	O
the	O
NCBI	O
GenBank	O
sequence	O
database	O
showed	O
100	O
%	O
sequence	O
similarity	O
with	O
Staphylococcus	B-OG
saprophyticus	I-OG
A6	I-OG
(	O
accession	O
number	O
KX262676	O
.	O
1	O
).	O

Based	O
on	O
these	O
comparisons	O
,	O
the	O
strain	O
SBPS	O
15	B-OG
was	O
identified	O
as	O
Staphylococcus	B-OG
saprophyticus	I-OG
and	O
the	O
16S	O
rRNA	O
sequence	O
was	O
deposited	O
in	O
NCBI	O
GenBank	O
with	O
the	O
accession	O
number	O
KX352162	O
.	O

The	O
genus	O
Staphylococcus	B-OG
belongs	O
to	O
the	O
family	O
Staphylococcaceae	B-OG
and	O
the	O
phylum	O
Firmicutes	B-OG
.	O

The	O
phylogenetic	O
tree	O
of	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	I-OG
15	O
plotted	O
with	O
respect	O
to	O
their	O
homology	O
with	O
NCBI	O
strains	O
is	O
shown	O
in	O
Fig	O
.	O
1	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
Staphylococcus	B-OG
saprophyticus	I-OG
was	O
unexplored	O
for	O
the	O
production	O
and	O
characterization	O
of	O
biosurfactant	O
,	O
hence	O
further	O
studies	O
were	O
undertaken	O
to	O
this	O
regard	O
.	O
Fig	O
.	O
1Phylogenetic	O
tree	O
of	O
the	O
most	O
potential	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	O
15	O
and	O
their	O
homology	O
with	O
NCBI	O
strains	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
.	O

Bootstrap	O
values	O
were	O
calculated	O
from	O
1000	O
resamplings	O
using	O
UPGMA	O
statistical	O
model	O
are	O
shown	O
at	O
the	O
respective	O
nodes	O

Growth	O
kinetics	O
profile	O
of	O
biosurfactant	O
production	O

The	O
kinetic	O
profile	O
of	O
biosurfactant	O
production	O
by	O
strain	O
SBPS	O
15	O
as	O
a	O
function	O
of	O
time	O
evidenced	O
that	O
the	O
biosurfactant	O
secretion	O
was	O
observed	O
from	O
the	O
early	O
logarithmic	O
phase	O
of	O
bacterial	O
growth	O
and	O
the	O
peak	O
emulsification	O
index	O
(	O
E	O
24	O
)	O
was	O
measured	O
during	O
the	O
initiation	O
of	O
the	O
stationary	O
growth	O
phase	O
of	O
the	O
bacterium	B-OG
(	O
66th	O
hour	O
).	O

Further	O
,	O
the	O
maximum	O
emulsification	O
activity	O
(	O
E	O
24	O
)	O
of	O
77	O
.	O
8	O
±	O
2	O
.	O
3	O
%	O
was	O
maintained	O
throughout	O
the	O
stationary	O
phase	O
of	O
the	O
bacterium	B-OG
with	O
cell	O
biomass	O
concentration	O
of	O
8	O
.	O
13	O
±	O
0	O
.	O
35	O
g	O
/	O
L	O
(	O
Fig	O
.	O
2	O
).	O

The	O
results	O
revealed	O
that	O
the	O
biosurfactant	O
production	O
with	O
reference	O
to	O
its	O
biomass	O
concentration	O
indicated	O
that	O
they	O
are	O
predominantly	O
produced	O
during	O
the	O
exponential	O
phase	O
and	O
they	O
function	O
as	O
primary	O
metabolites	O
for	O
the	O
normal	O
growth	O
and	O
nutrient	O
uptake	O
,	O
while	O
in	O
the	O
other	O
case	O
they	O
function	O
as	O
secondary	O
metabolite	O
having	O
an	O
ecological	O
role	O
rather	O
than	O
growth	O
,	O
similar	O
to	O
that	O
of	O
antibiotics	O
and	O
pigments	O
(	O
Mulligan	O
et	O
al	O
.	O
2014	O
).	O

A	O
previous	O
study	O
also	O
reported	O
a	O
similar	O
growth	O
-	O
dependent	O
pattern	O
of	O
biosurfactant	O
production	O
in	O
marine	O
Streptomyces	B-OG
species	I-OG
B3	I-OG
(	O
Khopade	O
et	O
al	O
.	O
2012	O
).	O
Fig	O
.	O
2Growth	O
kinetics	O
profile	O
as	O
a	O
function	O
of	O
time	O
on	O
biosurfactant	O
production	O
from	O
a	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	O
15	B-OG

Purification	O
and	O
characterization	O
of	O
the	O
biosurfactant	O

From	O
the	O
cell	O
free	O
supernatant	O
,	O
the	O
crude	O
biosurfactant	O
was	O
recovered	O
by	O
acid	O
precipitation	O
,	O
extracted	O
and	O
further	O
purified	O
using	O
silica	O
gel	O
column	O
chromatography	O
.	O

The	O
maximum	O
emulsification	O
activity	O
quantified	O
in	O
methanol	O
:	O
chloroform	B-CD
(	O
1	O
:	O
11	O
)	O
eluted	O
fraction	O
was	O
1	O
.	O
345	O
±	O
0	O
.	O
056	O
g	O
/	O
L	O
on	O
dry	O
weight	O
basis	O
.	O

The	O
silica	O
gel	O
TLC	O
plate	O
analysis	O
of	O
the	O
purified	O
biosurfactant	O
revealed	O
the	O
presence	O
of	O
two	O
spots	O
corresponding	O
to	O
lipid	O
and	O
carbohydrate	B-CD
with	O
Rf	O
values	O
of	O
0	O
.	O
73	O
and	O
0	O
.	O
45	O
.	O

The	O
carbohydrate	B-CD
and	O
lipid	O
contents	O
estimated	O
were	O
738	O
mg	O
/	O
g	O
(	O
nearly	O
74	O
%	O
of	O
carbohydrates	B-CD
)	O
and	O
262	O
mg	O
/	O
g	O
(	O
nearly	O
26	O
%	O
of	O
lipid	O
)	O
in	O
the	O
biosurfactant	O
based	O
on	O
biochemical	O
estimation	O
methods	O
and	O
protein	O
was	O
not	O
detected	O
.	O

The	O
purified	O
biosurfactant	O
was	O
further	O
analyzed	O
for	O
its	O
functional	O
groups	O
based	O
on	O
FT	O
-	O
IR	O
spectrum	O
(	O
Fig	O
.	O
3a	O
).	O

The	O
presence	O
of	O
characteristic	O
adsorption	O
bands	O
at	O
864	O
,	O
1386	O
,	O
2862	O
and	O
2926	O
cm	O
−	O
1	O
revealed	O
the	O
presence	O
of	O
aliphatic	O
long	O
fatty	B-CD
acid	I-CD
chain	O
(	O
Guo	O
et	O
al	O
.	O
2009	O
;	O
Rahman	O
et	O
al	O
.	O
2010	O
).	O

The	O
important	O
functional	O
groups	O
,	O
viz	O
.,	O
OH	O
bond	O
(	O
3421	O
cm	O
−	O
1	O
),	O
alkene	B-CD
(	O
C	O
=	O
C	O
)	O
(	O
1643	O
cm	O
−	O
1	O
)	O
and	O
carbonyl	B-CD
group	O
(	O
C	O
–	O
O	O
)	O
(	O
1182	O
cm	O
−	O
1	O
)	O
were	O
the	O
characteristic	O
groups	O
present	O
in	O
the	O
biosurfactants	O
(	O
Pornsunthorntawee	O
et	O
al	O
.	O
2008	O
;	O
Rahman	O
et	O
al	O
.	O
2010	O
).	O

The	O
presence	O
of	O
the	O
more	O
important	O
band	O
at	O
1724	O
cm	O
−	O
1	O
deduced	O
the	O
presence	O
of	O
carboxyl	O
group	O
,	O
which	O
represented	O
the	O
linkage	O
group	O
between	O
the	O
sugar	B-CD
and	O
fatty	B-CD
acid	I-CD
(	O
Rodrigues	O
et	O
al	O
.	O
2006	O
)	O
and	O
vibration	O
at	O
1105	O
cm	O
−	O
1	O
was	O
reported	O
as	O
corresponded	O
to	O
the	O
C	O
–	O
O	O
–	O
C	O
stretching	O
,	O
which	O
predicts	O
the	O
presence	O
of	O
sugar	B-CD
moiety	O
(	O
Pornsunthorntawee	O
et	O
al	O
.	O
2008	O
).	O

These	O
results	O
suggest	O
that	O
the	O
isolated	O
biosurfactant	O
belongs	O
to	O
the	O
family	O
of	O
glycolipids	B-GP
.	O
Fig	O
.	O
3FT	O
-	O
IR	O
spectrum	O
(	O
a	O
)	O
and	O
MALDI	O
-	O
TOF	O
–	O
MS	O
analysis	O
(	O
b	O
)	O
of	O
purified	O
glycolipid	O
biosurfactant	O
from	O
a	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	O
15	O

In	O
support	O
to	O
the	O
current	O
prediction	O
,	O
prior	O
studies	O
have	O
reported	O
that	O
microbial	O
strains	O
from	O
the	O
same	O
species	O
isolated	O
from	O
different	O
ecological	O
niches	O
produce	O
different	O
types	O
of	O
biosurfactant	O
,	O
for	O
example	O
,	O
Serratia	B-OG
marcescens	I-OG
isolated	O
from	O
terrestrial	O
habitats	O
produced	O
Serrawettin	B-CD
,	O
an	O
exolipid	O
biosurfactant	O
(	O
Li	O
et	O
al	O
.	O
2005	O
);	O
however	O
,	O
Dusane	O
et	O
al	O
.	O
(	O
2011	O
)	O
reported	O
a	O
glycolipid	O
biosurfactant	O
produced	O
by	O
S	B-OG
.	I-OG
marcescens	I-OG
isolated	O
from	O
marine	O
habitats	O
.	O

Likewise	O
,	O
Pseudomonas	B-OG
aeruginosa	I-OG
is	O
mostly	O
reported	O
to	O
produce	O
rhamnolipids	B-CD
,	O
a	O
glycolipid	O
biosurfactant	O
(	O
Pornsunthorntawee	O
et	O
al	O
.	O
2008	O
);	O
however	O
,	O
a	O
lipopeptide	O
biosurfactant	O
was	O
produced	O
by	O
P	B-OG
.	I-OG
aeruginosa	I-OG
isolated	O
from	O
sea	O
water	O
of	O
Tuticorin	O
Harbor	O
,	O
India	O
(	O
Thavasi	O
et	O
al	O
.	O
2011	O
).	O

Further	O
,	O
in	O
the	O
present	O
investigation	O
,	O
the	O
isolated	O
biosurfactant	O
from	O
the	O
marine	B-OG
bacterium	I-OG
S	B-OG
.	I-OG
saprophyticus	I-OG
revealed	O
an	O
interesting	O
observation	O
in	O
its	O
biochemical	O
diversity	O
,	O
producing	O
a	O
glycolipid	O
biosurfactant	O
which	O
was	O
unique	O
as	O
compared	O
to	O
an	O
earlier	O
report	O
of	O
Staphylococcus	B-OG
sp	I-OG
.	I-OG
strain	I-OG
1E	I-OG
isolated	O
from	O
terrestrial	O
hydrocarbon	B-CD
contaminated	O
soil	O
of	O
Algeria	O
which	O
produced	O
a	O
lipopeptide	O
biosurfactant	O
(	O
Eddouaouda	O
et	O
al	O
.	O
2012	O
).	O

In	O
addition	O
,	O
many	O
researches	O
have	O
earlier	O
evidenced	O
that	O
marine	O
microbes	B-OG
represent	O
a	O
distinctive	O
group	O
owing	O
to	O
their	O
immense	O
genetic	O
(	O
Sogin	O
et	O
al	O
.	O
2006	O
)	O
and	O
biochemical	O
diversity	O
(	O
Rusch	O
et	O
al	O
.	O
2007	O
),	O
and	O
a	O
rich	O
resource	O
for	O
a	O
wide	O
range	O
of	O
bioactive	O
compounds	O
(	O
Debbab	O
et	O
al	O
.	O
2010	O
).	O

The	O
molecular	O
weight	O
of	O
the	O
purified	O
glycolipid	O
biosurfactant	O
from	O
strain	O
SBPS	O
15	O
was	O
examined	O
using	O
MALDI	O
-	O
TOF	O
–	O
MS	O
analysis	O
.	O

The	O
spectral	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
cluster	O
of	O
three	O
molecules	O
at	O
m	O
/	O
z	O
607	O
.	O
7	O
,	O
629	O
.	O
7	O
and	O
645	O
.	O
7	O
which	O
were	O
attributed	O
to	O
the	O
molecules	O
of	O
protonated	O
ion	O
and	O
to	O
the	O
adducts	O
of	O
sodium	O
and	O
potassium	O
ions	O
(	O
Fig	O
.	O
3b	O
).	O

Based	O
on	O
the	O
above	O
observations	O
,	O
the	O
molecular	O
mass	O
of	O
this	O
glycolipid	O
biosurfactant	O
is	O
606	O
.	O
7	O
Da	O
and	O
its	O
molecular	O
weight	O
was	O
found	O
to	O
be	O
different	O
from	O
the	O
earlier	O
reported	O
glycolipid	O
biosurfactants	O
and	O
a	O
new	O
addition	O
to	O
the	O
existing	O
list	O
of	O
glycolipid	O
biosurfactants	O
.	O

This	O
result	O
showed	O
good	O
arguments	O
with	O
Abdel	O
-	O
Mawgoud	O
et	O
al	O
.	O
(	O
2010	O
)	O
who	O
suggested	O
that	O
the	O
molecular	O
mass	O
of	O
most	O
reported	O
glycolipid	O
biosurfactants	O
are	O
present	O
within	O
the	O
molecular	O
mass	O
range	O
of	O
302	O
–	O
803	O
Da	O
.	O

Stability	O
studies	O

Emulsification	O
index	O
(	O
E	O
24	O
)	O
was	O
used	O
for	O
measuring	O
the	O
biosurfactant	O
stability	O
.	O

The	O
purified	O
glycolipid	O
biosurfactant	O
from	O
strain	O
SBPS	O
15	O
showed	O
increased	O
emulsification	O
(	O
E	O
24	O
of	O
82	O
%)	O
in	O
its	O
pure	O
form	O
as	O
compared	O
to	O
the	O
crude	O
form	O
observed	O
during	O
screening	O
(	O
E	O
24	O
of	O
77	O
.	O
5	O
%).	O

It	O
showed	O
good	O
stability	O
over	O
a	O
wide	O
range	O
of	O
pH	O
3	O
–	O
9	O
with	O
E	O
24	O
of	O
72	O
–	O
80	O
%	O
and	O
significantly	O
reduced	O
its	O
activity	O
beyond	O
pH	O
9	O
and	O
above	O
pH	O
3	O
(	O
Fig	O
.	O
4a	O
).	O

Similar	O
results	O
were	O
observed	O
in	O
case	O
of	O
an	O
emulsifier	O
produced	O
by	O
the	O
yeast	B-OG
Yarrowia	B-OG
lipolytica	I-OG
NCIM	I-OG
3589	I-OG
cultivated	O
in	O
n	O
-	O
hexadecane	O
(	O
Sobrinho	O
et	O
al	O
.	O
2008	O
).	O

In	O
terms	O
of	O
temperature	O
stability	O
,	O
the	O
glycolipid	O
biosurfactant	O
from	O
strain	O
SBPS	O
15	O
showed	O
no	O
considerable	O
loss	O
of	O
activity	O
up	O
to	O
80	O
°	O
C	O
(	O
E	O
24	O
of	O
72	O
–	O
80	O
%);	O
however	O
,	O
beyond	O
this	O
temperature	O
,	O
it	O
started	O
to	O
denature	O
and	O
showed	O
no	O
emulsification	O
activity	O
at	O
100	O
°	O
C	O
(	O
Fig	O
.	O
4b	O
).	O

On	O
the	O
other	O
hand	O
,	O
Makkar	O
and	O
Cameotra	O
(	O
2002	O
)	O
reported	O
that	O
the	O
biosurfactant	O
produced	O
by	O
the	O
bacterial	O
isolates	O
were	O
stable	O
at	O
higher	O
temperature	O
up	O
to	O
120	O
°	O
C	O
.	O

The	O
broad	O
stability	O
range	O
observed	O
for	O
this	O
biosurfactant	O
makes	O
it	O
a	O
suitable	O
candidate	O
for	O
many	O
desired	O
applications	O
which	O
mandates	O
a	O
stable	O
emulsion	O
at	O
different	O
physico	O
-	O
chemical	O
conditions	O
.	O
Fig	O
.	O
4Effect	O
of	O
different	O
pH	O
(	O
a	O
)	O
and	O
temperature	O
(	O
b	O
)	O
on	O
stability	O
of	O
biosurfactant	O
produced	O
by	O
a	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	O
15	O

Antimicrobial	O
activity	O

Among	O
the	O
twelve	O
tested	O
bacterial	O
human	B-OG
pathogens	O
,	O
the	O
purified	O
biosurfactant	O
from	O
strain	O
SBPS	O
15	O
showed	O
antimicrobial	O
activity	O
against	O
seven	O
strains	O
.	O

The	O
maximum	O
zone	O
of	O
inhibition	O
and	O
the	O
respective	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
values	O
recorded	O
were	O
Klebsiella	B-OG
pneumoniae	I-OG
(	O
23	O
mm	O
,	O
4	O
µg	O
/	O
mL	O
)	O
followed	O
by	O
Escherichia	B-OG
coli	I-OG
(	O
20	O
mm	O
,	O
12	O
µg	O
/	O
mL	O
),	O
Pseudomonas	B-OG
aeruginosa	I-OG
(	O
20	O
mm	O
,	O
32	O
µg	O
/	O
mL	O
),	O
Vibrio	B-OG
cholerae	I-OG
(	O
18	O
mm	O
,	O
64	O
µg	O
/	O
mL	O
),	O
Bacillus	B-OG
subtilis	I-OG
(	O
15	O
mm	O
,	O
48	O
µg	O
/	O
mL	O
),	O
Salmonella	B-OG
paratyphi	I-OG
(	O
13	O
mm	O
,	O
32	O
µg	O
/	O
mL	O
)	O
and	O
Staphylococcus	B-OG
aureus	I-OG
(	O
11	O
mm	O
,	O
12	O
µg	O
/	O
mL	O
)	O
(	O
Table	O
1	O
).	O

Among	O
the	O
tested	O
pathogens	O
,	O
the	O
inhibitory	O
activity	O
was	O
observed	O
in	O
case	O
of	O
both	O
Gram	O
-	O
positive	O
as	O
well	O
as	O
Gram	O
-	O
negative	O
strains	O
with	O
minimal	O
MIC	O
values	O
which	O
show	O
its	O
promising	O
and	O
diverse	O
antimicrobial	O
potential	O
.	O
Table	O
1Antimicrobial	O
activity	O
of	O
a	O
purified	O
glycolipid	O
biosurfactant	O
from	O
a	O
marine	O
Staphylococcus	B-OG
saprophyticus	I-OG
SBPS	O
15	O
against	O
different	O
human	B-OG
pathogenic	O
clinical	O
isolatesS	O
.	O

No	O
.	O
Bacterial	O
pathogensZone	O
of	O
inhibition	O
(	O
mm	O
)	O
Minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
,	O
µg	O
/	O
mL	O
)	O
1	O
Escherichia	B-OG
coli	I-OG
20122	O
Salmonella	B-OG
typhi	I-OG
–	O
a	O
–	O
3	O
Salmonella	B-OG
paratyphi	I-OG
13324	O
Klebsiella	B-OG
pneumoniae	I-OG
2345	O
Klebsiella	B-OG
oxytoca	I-OG
––	O
6	O
Vibrio	B-OG
cholerae	I-OG
18647	I-OG
Vibrio	B-OG
parahemolyticus	I-OG
––	O
8	O
Proteus	B-OG
mirabilis	I-OG
––	O
9	O
Pseudomonas	B-OG
aeruginosa	I-OG
203210	I-OG
Bacillus	B-OG
subtilis	I-OG
154811	I-OG
Bacillus	B-OG
cereus	I-OG
––	O
12	O
Staphylococcus	B-OG
aureus	I-OG
1112Fungal	O
pathogens13	O
Aspergillus	B-OG
niger	I-OG
151614	O
Aspergillus	B-OG
flavus	I-OG
––	O
15	O
Candida	B-OG
albicans	I-OG
213216	O
Cryptococcus	B-OG
neoformans	I-OG
223217	O
Cryptococcus	B-OG
gattii	I-OG
–––	O
a	O
No	O
activity	O

Regarding	O
the	O
antifungal	O
activity	O
against	O
the	O
tested	O
five	O
different	O
fungal	O
human	B-OG
pathogens	O
,	O
the	O
biosurfactant	O
from	O
strain	O
SBPS	O
15	O
showed	O
activity	O
against	O
three	O
strains	O
with	O
maximum	O
zone	O
of	O
inhibition	O
and	O
the	O
respective	O
MIC	O
values	O
recorded	O
were	O
Cryptococcus	B-OG
neoformans	I-OG
(	O
22	O
mm	O
,	O
32	O
µg	O
/	O
mL	O
)	O
followed	O
by	O
Candida	B-OG
albicans	I-OG
(	O
21	O
mm	O
,	O
32	O
µg	O
/	O
mL	O
)	O
and	O
Aspergillus	B-OG
niger	I-OG
(	O
15	O
mm	O
,	O
16	O
µg	O
/	O
mL	O
)	O
(	O
Table	O
1	O
).	O

Based	O
on	O
these	O
studies	O
,	O
it	O
was	O
observed	O
that	O
the	O
isolated	O
biosurfactant	O
showed	O
a	O
board	O
range	O
of	O
potential	O
antimicrobial	O
activity	O
against	O
both	O
the	O
bacterial	O
and	O
fungal	O
pathogenic	O
strains	O
.	O

According	O
to	O
Das	O
et	O
al	O
.	O
(	O
2008	O
),	O
lipopeptide	O
surfactants	O
are	O
largely	O
reported	O
for	O
wide	O
antimicrobial	O
activities	O
and	O
relatively	O
less	O
number	O
of	O
reports	O
exists	O
on	O
glycolipid	O
biosurfactants	O
exhibiting	O
effective	O
antimicrobial	O
activity	O
.	O

Similar	O
to	O
the	O
present	O
investigation	O
,	O
the	O
glycolipid	O
biosurfactant	O
produced	O
from	O
marine	O
Streptomyces	B-OG
species	I-OG
B3	I-OG
isolated	O
from	O
west	O
coastal	O
sediment	O
of	O
India	O
showed	O
antimicrobial	O
activities	O
towards	O
different	O
human	B-OG
pathogens	O
(	O
Khopade	O
et	O
al	O
.	O
2012	O
).	O

Conclusions	O

In	O
the	O
present	O
study	O
,	O
the	O
isolated	O
biosurfactant	O
from	O
the	O
marine	O
S	B-OG
.	I-OG
saprophyticus	I-OG
SBPS	O
15	O
showed	O
significant	O
surface	O
active	O
properties	O
such	O
as	O
surface	O
tension	O
reduction	O
,	O
emulsification	O
,	O
lipase	B-GP
and	O
oil	O
displacement	O
activities	O
.	O

The	O
purified	O
biosurfactant	O
showed	O
a	O
different	O
molecular	O
mass	O
as	O
compared	O
to	O
the	O
earlier	O
reports	O
which	O
can	O
be	O
designated	O
as	O
a	O
new	O
glycolipid	O
biosurfactant	O
.	O

Further	O
,	O
the	O
purified	O
glycolipid	O
biosurfactant	O
revealed	O
a	O
board	O
range	O
of	O
pH	O
and	O
temperature	O
stability	O
which	O
suggests	O
its	O
significance	O
for	O
possible	O
application	O
in	O
diverse	O
niche	O
areas	O
.	O

Moreover	O
,	O
the	O
excellent	O
antibacterial	O
and	O
antifungal	O
activities	O
of	O
this	O
biosurfactant	O
against	O
a	O
board	O
spectrum	O
of	O
clinical	O
human	B-OG
pathogens	O
evidenced	O
its	O
importance	O
in	O
the	O
field	O
of	O
therapeutics	O
.	O

Taking	O
all	O
together	O
,	O
the	O
isolated	O
new	O
glycolipid	O
biosurfactant	O
from	O
this	O
marine	O
strain	O
exhibited	O
dual	O
functions	O
as	O
a	O
surface	O
-	O
active	O
and	O
antimicrobial	O
agent	O
which	O
qualifies	O
it	O
as	O
a	O
promising	O
candidate	O
for	O
possible	O
use	O
in	O
biomedical	O
applications	O
.	O

Histone	O
hypo	O
-	O
acetylation	O
of	O
Sox9	B-GP
mediates	O
nicotine	B-CD
-	O
induced	O
weak	O
cartilage	O
repair	O
by	O
suppressing	O
BMSC	O
chondrogenic	O
differentiation	O

Background	O

Nicotine	B-CD
has	O
negative	O
effects	O
on	O
tissue	O
repair	O
,	O
little	O
research	O
concerns	O
its	O
effect	O
on	O
the	O
cartilage	O
repair	O
of	O
tissue	O
engineering	O
stem	O
cells	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
nicotine	B-CD
on	O
the	O
bone	O
marrow	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
’	O
(	O
BMSCs	O
)	O
chondrogenic	O
repair	O
function	O
of	O
cartilage	O
defects	O
and	O
explored	O
the	O
molecular	O
mechanism	O
.	O

Methods	O

A	O
cartilage	O
defect	O
model	O
of	O
rat	B-OG
was	O
repaired	O
by	O
BMSC	O
transplantation	O
,	O
and	O
treated	O
with	O
nicotine	B-CD
or	O
saline	O
at	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
in	O
12	O
weeks	O
.	O

Nicotine	B-CD
’	O
s	O
effect	O
on	O
chondrogenic	O
differentiation	O
was	O
studied	O
by	O
exposing	O
BMSCs	O
to	O
nicotine	B-CD
at	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100	O
μM	O
,	O
and	O
methyllycaconitine	B-CD
(	O
MLA	O
),	O
which	O
is	O
a	O
selective	O
α7	B-GP
-	I-GP
nicotinic	I-GP
acetylcholine	I-GP
receptor	I-GP
(	O
nAChR	B-GP
)	O
inhibitor	O
and	O
si	O
-	O
RNA	O
of	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	I-GP
2	I-GP
(	O
NFATc2	B-GP
),	O
were	O
used	O
to	O
verify	O
the	O
molecular	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
effect	O
.	O

Results	O

Data	O
showed	O
that	O
nicotine	B-CD
inhibited	O
cartilage	O
repair	O
function	O
by	O
suppressing	O
SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP
(	O
Sox9	B-GP
)	O
in	O
regenerated	O
tissues	O
.	O

Further	O
in	O
vitro	O
study	O
demonstrated	O
that	O
nicotine	B-CD
enhanced	O
intracellular	O
Ca2	O
+	O
and	O
activity	O
of	O
calcineurin	B-GP
(	O
CaN	B-GP
)	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
increased	O
the	O
nucleic	O
expressions	O
of	O
NFATc2	B-GP
and	O
the	O
bindings	O
to	O
SOX9	B-GP
promoter	O
,	O
and	O
thus	O
reduced	O
the	O
acetylation	O
of	O
H3K9	O
and	O
H3K14	O
in	O
SOX9	B-GP
promoter	O
.	O

Conclusions	O

Findings	O
from	O
this	O
study	O
demonstrated	O
that	O
nicotine	B-CD
suppressed	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
which	O
offers	O
insight	O
into	O
the	O
risk	O
assessment	O
of	O
cartilage	O
defect	O
repair	O
in	O
a	O
nicotine	B-CD
exposure	O
population	O
and	O
its	O
therapeutic	O
target	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13287	O
-	O
018	O
-	O
0853	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

Articular	O
cartilage	O
is	O
composed	O
of	O
chondrocytes	O
and	O
extracellular	O
matrix	O
,	O
which	O
primarily	O
consists	O
of	O
collagen	B-GP
II	I-GP
and	O
proteoglycans	O
[	O
1	O
].	O

It	O
covers	O
the	O
metaphysis	O
of	O
long	O
bones	O
and	O
provides	O
shock	O
absorption	O
and	O
lubrication	O
to	O
diarthrodial	O
joints	O
.	O

Cartilage	O
tissue	O
has	O
poor	O
self	O
-	O
healing	O
capacity	O
because	O
it	O
is	O
avascular	O
and	O
thus	O
has	O
inadequate	O
access	O
to	O
progenitor	O
cells	O
from	O
blood	O
and	O
bone	O
marrow	O
(	O
BM	O
),	O
which	O
facilitate	O
regeneration	O
[	O
2	O
].	O

The	O
articular	O
cartilage	O
defect	O
is	O
accompanied	O
by	O
pain	O
and	O
loss	O
of	O
function	O
,	O
and	O
progressive	O
breakdown	O
leads	O
to	O
degenerative	B-DS
disorders	I-DS
,	O
such	O
as	O
osteoarthritis	B-DS
,	O
which	O
can	O
seriously	O
affect	O
a	O
patient	O
’	O
s	O
life	O
and	O
work	O
.	O

Epidemiological	O
studies	O
had	O
indicated	O
that	O
cartilage	O
defects	O
were	O
found	O
in	O
60	O
%	O
of	O
patients	O
who	O
undergone	O
arthroscopic	O
surgery	O
and	O
that	O
the	O
main	O
population	O
included	O
young	O
adults	O
[	O
3	O
].	O

Therefore	O
,	O
the	O
optional	O
repair	O
and	O
regeneration	O
of	O
cartilage	O
defect	O
is	O
an	O
important	O
issue	O
in	O
medical	O
research	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
can	O
be	O
isolated	O
from	O
various	O
tissues	O
and	O
can	O
differentiate	O
into	O
chondrogenic	O
lineage	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
,	O
5	O
].	O

In	O
2002	O
,	O
Wakitani	O
et	O
al	O
.	O
[	O
6	O
]	O
applied	O
bone	O
marrow	O
mesenchymal	O
stem	O
cell	O
(	O
BMSC	O
)	O
transplantations	O
to	O
repair	O
human	B-OG
articular	O
cartilage	O
defects	O
in	O
osteoarthritic	O
knee	O
joints	O
and	O
observed	O
that	O
the	O
cartilage	O
defects	O
were	O
partially	O
covered	O
with	O
hyaline	O
cartilage	O
-	O
like	O
tissue	O
,	O
which	O
highlighted	O
the	O
availability	O
of	O
autologous	O
culture	O
-	O
expanded	O
BMSC	O
transplantation	O
for	O
the	O
repair	O
of	O
articular	O
cartilage	O
defects	O
in	O
humans	B-OG
.	O

Since	O
then	O
,	O
numerous	O
studies	O
on	O
using	O
BMSCs	O
to	O
repair	O
cartilage	O
lesions	O
,	O
from	O
preclinical	O
findings	O
to	O
clinical	O
application	O
,	O
have	O
been	O
performed	O
as	O
BMSCs	O
can	O
be	O
easily	O
obtained	O
and	O
used	O
[	O
7	O
].	O

The	O
transplantation	O
of	O
BMSCs	O
has	O
become	O
one	O
of	O
the	O
main	O
methods	O
for	O
treating	O
cartilage	O
defects	O
[	O
8	O
–	O
10	O
].	O

However	O
,	O
the	O
majority	O
focused	O
on	O
how	O
to	O
optimize	O
the	O
microenvironment	O
or	O
improve	O
the	O
efficiency	O
of	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
and	O
there	O
was	O
no	O
concern	O
about	O
adverse	O
factors	O
in	O
the	O
differentiation	O
process	O
.	O

As	O
a	O
key	O
component	O
of	O
smoking	O
,	O
nicotine	B-CD
has	O
negative	O
effects	O
on	O
tissue	O
repair	O
and	O
healing	O
[	O
11	O
,	O
12	O
].	O

An	O
epidemiological	O
study	O
had	O
demonstrated	O
that	O
nicotine	B-DS
abuse	I-DS
was	O
a	O
high	O
-	O
risk	O
factor	O
that	O
influences	O
the	O
clinical	O
outcome	O
of	O
cartilage	O
defects	O
repair	O
of	O
the	O
knee	O
[	O
13	O
].	O

Our	O
previous	O
study	O
indicated	O
that	O
prenatal	O
nicotine	B-CD
exposure	O
induced	O
fetal	O
articular	O
dyschondroplasia	O
[	O
14	O
].	O
The	O
epiphyseal	O
cartilage	O
development	O
is	O
a	O
process	O
of	O
proliferation	O
and	O
differentiation	O
of	O
MSCs	O
[	O
15	O
],	O
in	O
which	O
nicotine	B-CD
can	O
interfere	O
with	O
the	O
chondrogenic	O
differentiation	O
of	O
MSCs	O
in	O
vivo	O
.	O

The	O
process	O
of	O
repairing	O
cartilage	O
defects	O
is	O
also	O
a	O
process	O
of	O
chondrogenic	O
differentiation	O
of	O
stem	O
cells	O
[	O
16	O
];	O
therefore	O
,	O
nicotine	B-CD
may	O
have	O
an	O
adverse	O
effect	O
on	O
the	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defects	O
.	O

Our	O
previous	O
work	O
has	O
demonstrated	O
that	O
nicotine	B-CD
could	O
suppress	O
the	O
chondrogenic	O
differentiation	O
potential	O
of	O
BMSCs	O
and	O
result	O
in	O
poorly	O
differentiated	O
cartilage	O
[	O
17	O
].	O

However	O
,	O
the	O
mechanism	O
is	O
still	O
unclear	O
.	O

SRY	B-GP
-	I-GP
type	I-GP
high	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP
(	O
Sox9	B-GP
)	O
is	O
a	O
key	O
regulator	O
and	O
controls	O
the	O
expression	O
of	O
the	O
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
(	O
Col2A1	B-GP
)	O
gene	O
in	O
the	O
initiation	O
stage	O
of	O
MSC	O
chondrogenic	O
differentiation	O
[	O
18	O
].	O

During	O
primary	O
chondrogenesis	O
,	O
which	O
is	O
activated	O
by	O
transforming	B-GP
growth	I-GP
factor	I-GP
beta	I-GP
(	O
TGF	B-GP
-	I-GP
β	I-GP
),	O
Sox9	B-GP
binds	O
to	O
essential	O
sequences	O
in	O
the	O
Col2A1	B-GP
gene	O
enhancers	O
and	O
initiates	O
its	O
expression	O
[	O
19	O
].	O
The	O
functional	O
modulation	O
of	O
Sox9	B-GP
is	O
a	O
critical	O
step	O
for	O
the	O
initiation	O
of	O
chondrogenesis	O
and	O
is	O
mainly	O
regulated	O
by	O
histone	B-GP
acetylation	O
[	O
20	O
].	O

The	O
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cells	I-GP
(	O
NFAT	B-GP
)	O
transcription	B-GP
factor	I-GP
NFATp	B-GP
(	O
NFATc2	B-GP
)	O
is	O
a	O
repressor	O
of	O
chondrogenesis	O
[	O
21	O
]	O
and	O
can	O
interact	O
with	O
histone	B-GP
deacetylase	I-GP
(	O
HDAC	B-GP
)	O
proteins	O
to	O
induce	O
gene	O
silencing	O
[	O
22	O
].	O

Calcineurin	B-GP
(	O
CaN	B-GP
),	O
an	O
upstream	O
molecule	O
of	O
NFATc2	B-GP
,	O
is	O
induced	O
by	O
increased	O
Ca2	O
+	O
and	O
can	O
translocate	O
the	O
dephosphorylated	O
NFATc2	B-GP
into	O
the	O
nucleus	O
[	O
23	O
].	O

The	O
stimulus	O
of	O
nicotine	B-CD
can	O
increase	O
the	O
intracellular	O
Ca2	O
+	O
of	O
MSCs	O
through	O
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP
(	O
nAChR	B-GP
)	O
[	O
24	O
].	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
nicotine	B-CD
could	O
decrease	O
Sox9	B-GP
’	O
s	O
promoter	O
histone	B-GP
acetylation	O
and	O
inhibit	O
its	O
expression	O
through	O
HDAC	B-GP
recruitment	O
by	O
the	O
activated	O
nAChR	B-GP
/	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFAT	B-GP
pathway	O
in	O
BMSCs	O
.	O

In	O
this	O
study	O
,	O
we	O
confirmed	O
that	O
nicotine	B-CD
interfered	O
with	O
BMSC	O
transplantation	O
repair	O
of	O
cartilage	O
defects	O
by	O
inhibiting	O
Sox9	B-GP
expression	O
in	O
vivo	O
and	O
that	O
nicotine	B-CD
-	O
induced	O
Sox9	B-GP
gene	O
suppression	O
via	O
nAChRs	B-GP
is	O
mediated	O
directly	O
by	O
decreasing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
.	O

Methods	O

Animal	B-OG
studies	O

Animal	B-OG
experiments	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Committee	O
on	O
the	O
Ethics	O
of	O
Animal	B-OG
Experiments	O
of	O
the	O
Wuhan	O
University	O
School	O
of	O
Medicine	O
(	O
No	O
.	O
14016	O
).	O

The	O
animal	B-OG
experimental	O
procedures	O
were	O
performed	O
in	O
accordance	O
with	O
the	O
Guidelines	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	B-OG
(	O
eighth	O
edition	O
)	O
from	O
the	O
National	O
Research	O
Council	O
of	O
the	O
United	O
States	O
National	O
Academies	O
,	O
and	O
performed	O
in	O
the	O
Center	O
for	O
Animal	B-OG
Experiment	O
of	O
Wuhan	O
University	O
(	O
Wuhan	O
,	O
China	O
),	O
which	O
was	O
accredited	O
by	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
of	O
Laboratory	O
Animal	B-OG
Care	O
International	O
(	O
AAALAC	O
International	O
).	O

Female	O
(	O
weighing	O
180	O
–	O
220	O
g	O
)	O
and	O
male	O
(	O
weighing	O
260	O
–	O
300	O
g	O
)	O
Wistar	B-OG
rats	I-OG
at	O
12	O
weeks	O
old	O
were	O
obtained	O
from	O
the	O
Experimental	O
Center	O
of	O
the	O
Medical	O
Scientific	O
Academy	O
of	O
Hubei	O
(	O
no	O
.	O
2008	O
–	O
0005	O
).	O

Rats	B-OG
were	O
housed	O
in	O
metal	O
cages	O
with	O
wire	O
-	O
mesh	O
floors	O
in	O
an	O
air	O
-	O
conditioned	O
room	O
under	O
standard	O
conditions	O
(	O
room	O
temperature	O
:	O
18	O
–	O
22	O
°	O
C	O
;	O
humidity	O
:	O
40	O
–	O
60	O
%;	O
light	O
cycle	O
:	O
12	O
h	O
light	O
-	O
dark	O
cycle	O
;	O
10	O
–	O
15	O
air	O
changes	O
per	O
hour	O
)	O
and	O
allowed	O
free	O
access	O
to	O
rat	B-OG
chow	O
and	O
tap	O
water	O
.	O

Rats	B-OG
were	O
randomly	O
distributed	O
into	O
control	O
(	O
BMSCs	O
)	O
and	O
experimental	O
(	O
BMSCs	O
+	O
nicotine	B-CD
)	O
groups	O
(	O
n	O
=	O
8	O
for	O
each	O
group	O
).	O

The	O
cartilage	O
defect	O
model	O
in	O
the	O
two	O
groups	O
followed	O
the	O
method	O
described	O
by	O
Chung	O
et	O
al	O
.	O
[	O
25	O
].	O

In	O
brief	O
,	O
anesthesia	O
was	O
performed	O
with	O
an	O
intraperitoneal	O
injection	O
of	O
3	O
.	O
5	O
ml	O
/	O
kg	O
of	O
10	O
%	O
chloral	O
hydrate	O
.	O

In	O
each	O
case	O
,	O
after	O
cleaning	O
with	O
10	O
%	O
betadine	O
solution	O
,	O
right	O
knee	O
joints	O
of	O
each	O
rat	B-OG
were	O
sterilely	O
draped	O
and	O
opened	O
using	O
an	O
anteromedial	O
approach	O
.	O

The	O
patellae	O
were	O
laterally	O
dislocated	O
,	O
and	O
full	O
-	O
thickness	O
articular	O
cartilage	O
defects	O
(	O
2	O
mm	O
in	O
diameter	O
)	O
were	O
created	O
in	O
trochlear	O
grooves	O
by	O
carefully	O
drilling	O
in	O
a	O
vertical	O
direction	O
using	O
a	O
2	O
-	O
mm	O
drill	O
.	O

Drilling	O
was	O
performed	O
in	O
3	O
mm	O
deep	O
through	O
subchondral	O
bone	O
.	O

After	O
removing	O
cartilage	O
and	O
bone	O
debris	O
,	O
boundaries	O
around	O
the	O
drill	O
were	O
trimmed	O
using	O
a	O
surgical	O
knife	O
and	O
washed	O
out	O
.	O

The	O
mixture	O
containing	O
BMSCs	O
(	O
2	O
×	O
106	O
cells	O
/	O
ml	O
)	O
and	O
1	O
.	O
25	O
%	O
alginate	O
in	O
0	O
.	O
15	O
M	O
saline	O
[	O
26	O
]	O
was	O
then	O
transplanted	O
into	O
the	O
full	O
-	O
thickness	O
defect	O
in	O
the	O
right	O
knee	O
.	O

Following	O
implantation	O
,	O
patellar	O
retinaculum	O
and	O
overlying	O
soft	O
tissues	O
were	O
closed	O
in	O
layers	O
.	O

Rats	B-OG
were	O
allowed	O
to	O
move	O
knee	O
joints	O
freely	O
in	O
their	O
cages	O
without	O
restriction	O
.	O

An	O
intraperitoneal	O
injection	O
of	O
4	O
×	O
105	O
U	O
of	O
penicillin	B-CD
(	O
Harbin	O
Pharmaceutical	O
Group	O
,	O
Shanghai	O
,	O
China	O
)	O
was	O
administered	O
immediately	O
after	O
implantation	O
and	O
once	O
daily	O
for	O
1	O
week	O
.	O

Clinical	O
signs	O
were	O
observed	O
daily	O
during	O
the	O
study	O
period	O
.	O

Animals	B-OG
were	O
sacrificed	O
at	O
12	O
weeks	O
post	O
-	O
implantation	O
to	O
assess	O
cartilage	O
repair	O
statuses	O
.	O

The	O
experimental	O
group	O
was	O
injected	O
with	O
nicotine	B-CD
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
at	O
1	O
.	O
0	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
).	O

As	O
a	O
preliminary	O
study	O
,	O
defects	O
of	O
the	O
same	O
size	O
(	O
2	O
mm	O
diameter	O
and	O
3	O
mm	O
deep	O
)	O
were	O
created	O
,	O
and	O
the	O
cartilage	O
repair	O
with	O
no	O
treatment	O
or	O
alginate	O
only	O
was	O
observed	O
.	O

At	O
12	O
weeks	O
post	O
-	O
transplantation	O
,	O
the	O
defects	O
showed	O
very	O
poor	O
cartilage	O
repair	O
(	O
Additional	O
file	O
1	O
),	O
whose	O
surface	O
was	O
concave	O
,	O
irregular	O
or	O
sometimes	O
empty	O
in	O
the	O
middle	O
and	O
few	O
regenerated	O
tissues	O
could	O
be	O
seen	O
at	O
peripheral	O
regions	O
,	O
meaning	O
that	O
this	O
size	O
of	O
articular	O
cartilage	O
defect	O
in	O
a	O
rat	B-OG
joint	O
is	O
a	O
critical	O
-	O
size	O
defect	O
that	O
cannot	O
heal	O
by	O
itself	O
.	O

Therefore	O
,	O
a	O
defect	O
only	O
without	O
BMSC	O
transplantation	O
(	O
no	O
treatment	O
or	O
alginate	O
only	O
)	O
was	O
not	O
included	O
in	O
the	O
present	O
study	O
.	O

Gross	O
and	O
histological	O
evaluations	O

Rats	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
with	O
an	O
intraperitoneal	O
injection	O
of	O
3	O
.	O
5	O
ml	O
/	O
kg	O
of	O
10	O
%	O
chloral	O
hydrate	O
.	O

The	O
entire	O
right	O
knee	O
was	O
dissected	O
,	O
and	O
a	O
distal	O
part	O
of	O
the	O
femur	O
was	O
then	O
extirpated	O
.	O

The	O
samples	O
from	O
each	O
group	O
were	O
examined	O
and	O
photographed	O
to	O
evaluate	O
the	O
degree	O
of	O
defect	O
repair	O
(	O
0	O
–	O
4	O
),	O
integration	O
to	O
border	O
zone	O
(	O
0	O
–	O
4	O
),	O
and	O
macroscopic	O
appearance	O
(	O
0	O
–	O
4	O
)	O
according	O
to	O
the	O
International	O
Cartilage	O
Repair	O
Society	O
(	O
ICRS	O
)	O
macroscopic	O
assessment	O
scale	O
for	O
cartilage	O
repair	O
[	O
27	O
].	O

After	O
gross	O
examination	O
,	O
samples	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
decalcified	O
in	O
20	O
%	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
(	O
pH	O
7	O
.	O
4	O
)	O
for	O
21	O
d	O
,	O
and	O
embedded	O
in	O
paraffin	O
.	O

Serial	O
5	O
-	O
mm	O
thick	O
sections	O
were	O
cut	O
in	O
a	O
horizontal	O
plane	O
across	O
the	O
joint	O
.	O

Two	O
sections	O
within	O
every	O
consecutive	O
ten	O
sections	O
were	O
stained	O
with	O
Safranin	O
-	O
O	O
/	O
Fast	B-CD
green	I-CD
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
the	O
one	O
with	O
better	O
morphology	O
was	O
used	O
for	O
quantification	O
.	O

The	O
cartilage	O
repair	O
was	O
scored	O
by	O
two	O
blinded	O
authors	O
(	O
K	O
.	O
T	O
.	O
and	O
Y	O
.	O
D	O
.)	O
using	O
a	O
method	O
described	O
by	O
Wakitani	O
[	O
28	O
].	O

In	O
brief	O
,	O
each	O
section	O
was	O
assigned	O
a	O
score	O
,	O
which	O
was	O
the	O
sum	O
of	O
cell	O
morphology	O
(	O
0	O
–	O
4	O
),	O
matrix	O
-	O
staining	O
(	O
0	O
–	O
3	O
),	O
surface	O
regularity	O
(	O
0	O
–	O
3	O
),	O
thickness	O
of	O
cartilage	O
(	O
0	O
–	O
3	O
),	O
and	O
integration	O
of	O
donor	O
with	O
host	O
(	O
0	O
–	O
3	O
).	O

The	O
expression	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
in	O
the	O
regenerated	O
tissue	O
was	O
analyzed	O
by	O
immunohistological	O
staining	O
.	O

After	O
antigen	O
retrieval	O
by	O
boiling	O
the	O
samples	O
in	O
sodium	O
citrate	O
buffer	O
,	O
the	O
sections	O
were	O
blocked	O
in	O
serum	O
for	O
30	O
min	O
,	O
followed	O
by	O
incubation	O
with	O
the	O
primary	O
antibody	B-GP
in	O
a	O
humidified	O
chamber	O
at	O
4	O
°	O
C	O
overnight	O
.	O

A	O
biotinylated	O
secondary	O
antibody	B-GP
was	O
added	O
for	O
30	O
min	O
on	O
day	O
2	O
,	O
followed	O
by	O
an	O
avidin	B-GP
-	O
biotinylated	O
horseradish	B-OG
peroxidase	B-GP
complex	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
directions	O
.	O

Finally	O
,	O
the	O
peroxidase	B-GP
activity	O
was	O
revealed	O
by	O
immersion	O
in	O
DAB	O
substrate	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
rabbit	B-OG
anti	O
-	O
Sox9	B-GP
,	O
and	O
rabbit	B-OG
anti	O
-	O
Col2A1	B-GP
(	O
both	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
).	O

To	O
characterize	O
the	O
changes	O
in	O
immunostaining	O
,	O
the	O
mean	O
optical	O
densities	O
(	O
MODs	O
)	O
were	O
obtained	O
from	O
ten	O
areas	O
of	O
regenerated	O
tissue	O
from	O
five	O
separate	O
samples	O
.	O

Culture	O
of	O
BMSCs	O
and	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O

The	O
isolation	O
and	O
culture	O
of	O
rat	B-OG
BMSCs	O
from	O
the	O
tibias	O
and	O
femurs	O
of	O
4	O
-	O
week	O
-	O
old	O
Wistar	B-OG
rats	I-OG
were	O
performed	O
as	O
described	O
previously	O
[	O
17	O
].	O

Briefly	O
,	O
the	O
rats	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
after	O
anesthesia	O
(	O
intraperitoneal	O
injection	O
of	O
10	O
%	O
chloral	O
hydrate	O
)	O
and	O
sterilized	O
using	O
75	O
%	O
ethanol	O
for	O
10	O
min	O
before	O
surgery	O
.	O

After	O
dissecting	O
the	O
metaphyseal	O
ends	O
of	O
the	O
bones	O
under	O
sterile	O
conditions	O
,	O
the	O
bone	O
marrow	O
cells	O
were	O
flushed	O
out	O
using	O
Dulbecco	O
’	O
s	O
modified	O
Eagle	O
’	O
s	O
medium	O
(	O
DMEM	O
)/	O
F12	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Gibco	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
),	O
50	O
mg	O
/	O
ml	O
of	O
L	B-CD
-	I-CD
ascorbic	I-CD
acid	I-CD
(	O
Sigma	O
-	O
Aldrich	O
),	O
1	O
%	O
glutamine	B-CD
(	O
Sigma	O
-	O
Aldrich	O
),	O
100	O
mg	O
/	O
ml	O
of	O
streptomycin	B-CD
and	O
penicillin	B-CD
(	O
Sigma	O
-	O
Aldrich	O
),	O
and	O
centrifuged	O
at	O
1000	O
rpm	O
for	O
5	O
min	O
.	O

The	O
cells	O
were	O
resuspended	O
and	O
expanded	O
in	O
T	O
-	O
25	O
flasks	O
(	O
Cyagen	O
Biosciences	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
with	O
DMEM	O
/	O
F12	O
medium	O
and	O
incubated	O
at	O
37	O
°	O
C	O
under	O
conditions	O
of	O
5	O
%	O
CO2	O
.	O

The	O
medium	O
was	O
changed	O
every	O
3	O
days	O
.	O

Upon	O
reaching	O
70	O
%–	O
80	O
%	O
confluence	O
,	O
adherent	O
cells	O
were	O
trypsinized	O
,	O
harvested	O
,	O
and	O
expanded	O
.	O

Cells	O
that	O
had	O
undergone	O
three	O
passages	O
were	O
used	O
in	O
subsequent	O
experiments	O
.	O

Chondrogenic	O
differentiation	O
of	O
BMSCs	O
was	O
performed	O
following	O
the	O
method	O
described	O
in	O
our	O
previous	O
work	O
[	O
17	O
].	O

Monolayer	O
culture	O
cells	O
in	O
T	O
-	O
25	O
flasks	O
were	O
trypsinized	O
,	O
washed	O
,	O
and	O
centrifuged	O
.	O

The	O
isolated	O
BMSCs	O
were	O
suspended	O
at	O
a	O
concentration	O
of	O
6	O
×	O
106	O
cells	O
/	O
ml	O
in	O
a	O
1	O
.	O
25	O
%	O
alginate	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
0	O
.	O
15	O
M	O
NaCl	O
,	O
and	O
then	O
the	O
cell	O
suspension	O
was	O
slowly	O
dropped	O
into	O
a	O
102	O
mM	O
CaCl2	O
solution	O
.	O

The	O
beads	O
were	O
cultured	O
in	O
six	O
-	O
well	O
plates	O
under	O
conditions	O
of	O
5	O
%	O
O2	O
with	O
DMEM	O
/	O
F12	O
medium	O
containing	O
1	O
%	O
insulin	B-GP
,	O
transferrin	B-GP
and	O
selenous	O
(	O
ITS	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
),	O
100	O
nM	O
dexamethasone	B-CD
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
10	O
ng	O
/	O
ml	O
transforming	B-GP
growth	I-GP
factor	I-GP
-	I-GP
β1	I-GP
(	O
TGF	B-GP
-	I-GP
β1	I-GP
)	O
(	O
PeproTech	O
Rocky	O
Hill	O
,	O
NJ	O
,	O
USA	O
).	O

During	O
the	O
period	O
of	O
chondrogenic	O
differentiation	O
,	O
the	O
culture	O
medium	O
with	O
or	O
without	O
nicotine	B-CD
at	O
concentrations	O
of	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100μM	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
BMSCs	O
treated	O
with	O
nicotine	B-CD
for	O
24	O
h	O
were	O
used	O
in	O
the	O
experiments	O
for	O
molecular	O
mechanism	O
detection	O
.	O

RNA	O
interference	O

siRNAs	O
for	O
NFATc2	B-GP
(	O
L	O
-	O
011778	O
)	O
were	O
purchased	O
from	O
Gene	O
Pharma	O
(	O
Shanghai	O
Gene	O
Pharma	O
Co	O
.).	O

The	O
scramble	O
-	O
sense	O
siRNA	O
targeted	O
the	O
sequence	O
5	O
’-	O
GGAAGCUACAGUGGAUAAATT	O
-	O
3	O
′,	O
and	O
the	O
scramble	O
antisense	O
siRNA	O
targeted	O
the	O
sequence	O
5	O
’-	O
UUUAUCCACUGUAGCUUCCTT	O
-	O
3	O
′.	O

In	O
brief	O
,	O
passage	O
3	O
BMSCs	O
were	O
plated	O
to	O
obtain	O
70	O
–	O
80	O
%	O
confluence	O
in	O
six	O
-	O
well	O
plates	O
and	O
transfected	O
with	O
si	O
-	O
NFATc2	B-GP
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
),	O
negative	O
control	O
siRNA	O
or	O
Lipofectamine	O
2000	O
only	O
.	O

After	O
6	O
h	O
of	O
transfection	O
,	O
fresh	O
medium	O
was	O
exchanged	O
.	O

The	O
expression	O
of	O
NFATc2	B-GP
was	O
detected	O
using	O
RT	O
-	O
qPCR	O
and	O
Western	O
blotting	O
.	O

Calcium	O
imaging	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP

P3	O
BMSC	O
cultures	O
in	O
35	O
mm	O
glass	O
-	O
bottomed	O
plates	O
were	O
prepared	O
.	O

The	O
cells	O
were	O
washed	O
using	O
Hank	O
’	O
s	O
solution	O
three	O
times	O
and	O
incubated	O
in	O
dye	O
loading	O
solution	O
containing	O
1μM	O
Fluo	O
-	O
3	O
AM	O
(	O
DoJinDo	O
,	O
Shanghai	O
,	O
China	O
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
and	O
then	O
at	O
room	O
temperature	O
for	O
an	O
additional	O
30	O
min	O
.	O

Before	O
nicotine	B-CD
stimulation	O
,	O
PBS	O
buffer	O
was	O
used	O
to	O
wash	O
the	O
cells	O
three	O
times	O
.	O

The	O
fluorescence	O
was	O
measured	O
after	O
the	O
addition	O
of	O
0	O
.	O
1	O
,	O
1	O
,	O
10	O
,	O
and	O
100	O
μM	O
nicotine	B-CD
.	O

Measurements	O
were	O
performed	O
in	O
a	O
laser	O
scanning	O
confocal	O
microscope	O
(	O
Carl	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
)	O
by	O
collecting	O
data	O
points	O
every	O
5	O
s	O
over	O
20	O
min	O
using	O
LCS	O
Lite	O
confocal	O
software	O
.	O

The	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
was	O
measured	O
using	O
a	O
calcineurin	B-GP
assay	O
kit	O
(	O
A068	O
,	O
Nanjing	O
Jiancheng	O
Bioengineering	O
Institute	O
,	O
Nanjing	O
,	O
China	O
).	O

In	O
short	O
,	O
the	O
protein	O
of	O
BMSCs	O
was	O
extracted	O
and	O
quantified	O
,	O
the	O
enzymatic	O
reaction	O
was	O
initiated	O
using	O
calmodulin	B-GP
and	O
p	O
-	O
nitrophenyl	O
phosphate	O
(	O
PNPP	O
)	O
as	O
a	O
substrate	O
,	O
and	O
then	O
the	O
inorganic	O
phosphorus	O
content	O
was	O
measured	O
.	O

The	O
enzyme	O
activity	O
unit	O
of	O
calcineurin	B-GP
was	O
defined	O
as	O
the	O
amount	O
of	O
1	O
M	O
inorganic	O
phosphorus	O
produced	O
by	O
decomposing	O
1	O
mg	O
calcineurin	B-GP
from	O
the	O
substrate	O
PNPP	B-GP
per	O
hour	O
,	O
and	O
the	O
results	O
were	O
expressed	O
as	O
U	O
/	O
mg	O
protein	O
.	O

Reverse	O
transcription	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O

Total	O
RNA	O
from	O
regenerated	O
tissues	O
and	O
BMSCs	O
was	O
extracted	O
using	O
the	O
Trizol	O
(	O
Invitrogen	O
)	O
reagent	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

The	O
RNA	O
was	O
reverse	O
transcribed	O
using	O
a	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
kit	O
.	O

The	O
cDNA	O
was	O
amplified	O
using	O
a	O
one	O
-	O
step	O
polymerase	B-GP
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
reaction	O
.	O

The	O
PCR	O
products	O
of	O
all	O
of	O
the	O
subtypes	O
of	O
nAChR	B-GP
were	O
separated	O
by	O
electrophoresis	O
on	O
2	O
%	O
agarose	O
gels	O
.	O

The	O
relative	O
mRNA	O
expression	O
levels	O
of	O
the	O
Sox9	B-GP
and	O
Col2A1	B-GP
were	O
normalized	O
to	O
the	O
level	O
of	O
glyceraldehyde	B-GP
3	I-GP
-	I-GP
phosphate	I-GP
dehydrogenase	I-GP
(	O
GAPDH	B-GP
).	O

The	O
rat	B-OG
primer	O
sequences	O
and	O
annealing	O
temperatures	O
used	O
are	O
shown	O
in	O
Table	O
1	O
.	O
Table	O
1Primer	O
used	O
for	O
qPCRGeneForward	O
PrimerReverse	O
PrimerAnnealGAPDHGCAAGTTCAACGGCACAGGCCAGTAGACTCCACGACA60	O
°	O
CCol2A1GAGTGGAAGAGCGGAGACTACTGCTCCATGTTGCAGAAGACTTTCA60	O
°	O
CSox9CCAGCAAGAACAAGCCACACCTTGCCCAGAGTCTTGCTGA60	O
°	O
Cα3	O
-	O
nAChRGGTGGATGACAAGACCAAAGCAGGGCAGGTAGAAGACAAGCA60	O
°	O
Cα4	O
-	O
nAChRCACGGTCTTCGTGCTCAATGTCCTTGGTTGCAGATGTCACTC62	O
°	O
Cα5	O
-	O
nAChRGCTGCGCTGCTCTTGATGGTCGTATGTCCACGAGCCGAAT60	O
°	O
Cα7	O
-	O
nAChRACAATACTTCGCCAGCACCAGGCATTTTGCCACCATCAGG60	O
°	O
Cβ2	O
-	O
nAChRGGAGTGGGAAGATTACCGCCTCAAGTCGTCGTGGTTCTCGTTGCG60	O
°	O
Cβ4	O
-	O
nAChRGATTCTCCCAAGTCAGAACCTTTAAGCTGGAGATTTGATGTGGTTA60	O
°	O
CAbbreviations	O
:	O
PCR	O
polymerase	O
chain	O
reaction	O
,	O
GAPDH	B-GP
glyceraldehyde	B-GP
phosphate	I-GP
dehydrogenase	I-GP
,	O
Col2A1	B-GP
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
gene	O
,	O
Sox9	B-GP
SRY	O
-	O
type	O
high	O
mobility	O
group	O
box9	O
,	O
nAChR	B-GP
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP

Western	O
blotting	O

To	O
obtain	O
total	O
protein	O
,	O
the	O
cells	O
were	O
harvested	O
and	O
dissolved	O
in	O
RIPA	O
(	O
Beyotime	O
,	O
Nanjing	O
,	O
China	O
)	O
buffer	O
.	O

The	O
protein	O
concentrations	O
were	O
determined	O
by	O
a	O
BCA	O
protein	O
assay	O
kit	O
.	O

Equal	O
amounts	O
of	O
protein	O
lysates	O
(	O
40	O
mg	O
/	O
lane	O
)	O
were	O
loaded	O
and	O
resolved	O
on	O
10	O
%	O
sodium	O
-	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
then	O
were	O
transferred	O
onto	O
nitrocellulose	O
filters	O
and	O
probed	O
with	O
rabbit	B-OG
anti	O
-	O
Col2A1	B-GP
,	O
Sox9	B-GP
,	O
β	B-GP
-	I-GP
actin	I-GP
,	O
histone	B-GP
3	I-GP
,	O
NFATc2	B-GP
(	O
1	O
:	O
900	O
)	O
(	O
all	O
from	O
Santa	O
Cruz	O
Biotechnology	O
),	O
and	O
p	O
-	O
NFATc2	B-GP
(	O
1	O
:	O
500	O
)	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
antibodies	B-GP
at	O
4	O
°	O
C	O
overnight	O
.	O

After	O
incubation	O
with	O
a	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
secondary	O
antibody	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
),	O
the	O
blots	O
were	O
developed	O
by	O
enhanced	O
chemiluminescence	O
following	O
the	O
manufacturer	O
’	O
s	O
protocol	O
and	O
were	O
visualized	O
by	O
exposure	O
to	O
a	O
Fusion	O
FX	O
system	O
(	O
VilberLourmat	O
,	O
Marne	O
-	O
la	O
-	O
Vallee	O
,	O
France	O
).	O

The	O
protein	O
amounts	O
in	O
electrophoresis	O
gels	O
were	O
analyzed	O
with	O
the	O
Quantity	O
One	O
4	O
.	O
6	O
analysis	O
software	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

All	O
solutions	O
in	O
this	O
procedure	O
contained	O
a	O
mixture	O
of	O
protease	B-GP
and	O
phosphatase	B-GP
inhibitors	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
were	O
performed	O
as	O
previously	O
described	O
[	O
29	O
].	O

In	O
brief	O
,	O
6	O
×	O
106	O
cells	O
were	O
fixed	O
with	O
1	O
%	O
formaldehyde	O
and	O
quenched	O
by	O
glycine	B-CD
.	O

The	O
cells	O
were	O
washed	O
three	O
times	O
with	O
PBS	O
and	O
then	O
harvested	O
in	O
ChIP	O
lysis	O
buffer	O
(	O
50	O
mMTris	O
-	O
HCl	O
,	O
pH	O
8	O
.	O
0	O
,	O
1	O
%	O
SDS	O
and	O
5	O
mM	O
EDTA	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
).	O

DNA	O
was	O
sonicated	O
to	O
400	O
–	O
600	O
bp	O
before	O
extensive	O
centrifugation	O
.	O

Four	O
volumes	O
of	O
ChIP	O
dilution	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
0	O
,	O
150	O
mM	O
NaCl	O
,	O
2	O
mM	O
EDTA	O
and	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
)	O
were	O
added	O
to	O
the	O
supernatant	O
.	O

The	O
resulting	O
lysate	O
was	O
then	O
incubated	O
with	O
protein	B-GP
G	I-GP
beads	O
(	O
GE	O
Healthcare	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
and	O
H3K9	O
(	O
Abcam	O
),	O
H3K14	O
(	O
Abcam	O
)	O
antibodies	B-GP
at	O
4	O
°	O
C	O
overnight	O
.	O

The	O
beads	O
were	O
washed	O
five	O
times	O
and	O
DNA	O
was	O
eluted	O
in	O
ChIP	O
elution	O
buffer	O
(	O
0	O
.	O
1	O
M	O
NaHCO3	O
,	O
1	O
%	O
SDS	O
and	O
30	O
μg	O
/	O
ml	O
proteinase	B-GP
K	I-GP
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
).	O

The	O
elution	O
was	O
incubated	O
at	O
65	O
°	O
C	O
overnight	O
and	O
DNA	O
was	O
extracted	O
with	O
a	O
DNA	O
purification	O
kit	O
(	O
Tiangen	O
Biotech	O
,	O
Beijing	O
,	O
China	O
).	O

The	O
purified	O
DNA	O
was	O
assayed	O
by	O
quantitative	O
PCR	O
assays	O
were	O
repeated	O
at	O
least	O
three	O
times	O
.	O

Data	O
were	O
expressed	O
as	O
a	O
percentage	O
of	O
input	O
DNA	O
.	O

The	O
primer	O
information	O
is	O
in	O
Table	O
2	O
.	O
Table	O
2Primer	O
used	O
for	O
ChIPTranscriptSense	O
primerAntisense	O
primerProductAnneaSox9	O
(	O
327	O
~	O
429	O
)	O
GCTCGGAACTGTCTGGAAACGAAACCAGGGCTACTTGCAC103	O
bp60	O
°	O
CCol2A1	O
(	O
413	O
~	O
546	O
)	O
GCACCTAGGCGATCTGGTTAGAGCTGCTGGCTGACTCTTT134	O
bp60	O
°	O
CAbbreviations	O
:	O
ChiP	O
chromatin	O
immunoprecipitation	O
,	O
Col2A1	B-GP
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
gene	O
,	O
Sox9	B-GP
SRY	O
-	O
type	O
high	O
mobility	O
group	O
box	O
9	O

Immunoprecipitation	O

Immunoprecipitation	O
was	O
performed	O
following	O
the	O
method	O
described	O
in	O
a	O
previous	O
study	O
[	O
30	O
].	O

Cell	O
lysates	O
from	O
BMSCs	O
were	O
prepared	O
in	O
NP40	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
pH	O
7	O
.	O
4	O
,	O
150	O
mM	O
NaCl	O
,	O
0	O
.	O
5	O
%	O
NP40	O
,	O
all	O
from	O
Sigma	O
)	O
or	O
high	O
-	O
salt	O
lysis	O
buffer	O
(	O
20	O
mM	O
HEPES	O
pH	O
7	O
.	O
4	O
,	O
10	O
%	O
glycerol	B-CD
,	O
0	O
.	O
35	O
M	O
NaCl	O
,	O
1	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
mM	O
DTT	O
,	O
all	O
from	O
Sigma	O
-	O
Aldrich	O
)	O
with	O
proteinase	B-GP
inhibitors	O
.	O

The	O
supernatant	O
was	O
then	O
incubated	O
with	O
protein	B-GP
G	I-GP
beads	O
(	O
GE	O
Healthcare	O
)	O
and	O
the	O
NFATc2	B-GP
antibody	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
°	O
C	O
for	O
4	O
h	O
.	O

Beads	O
conjugated	O
with	O
the	O
lysates	O
and	O
antibodies	B-GP
were	O
collected	O
by	O
centrifugation	O
and	O
washed	O
three	O
times	O
with	O
lysis	O
buffer	O
.	O

The	O
final	O
amount	O
of	O
wash	O
buffer	O
was	O
aspirated	O
and	O
SDS	O
loading	O
buffer	O
was	O
added	O
to	O
the	O
beads	O
.	O

The	O
prepared	O
proteins	O
were	O
resolved	O
using	O
10	O
%	O
SDS	O
-	O
PAGE	O
and	O
then	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

Finally	O
,	O
the	O
membranes	O
were	O
incubated	O
with	O
antibodies	B-GP
against	O
HDAC1	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
for	O
12	O
h	O
.	O

Chemiluminescence	O
was	O
detected	O
using	O
the	O
abovementioned	O
ECL	O
system	O
.	O

Statistical	O
analysis	O

SPSS	O
17	O
(	O
SPSS	O
Science	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
was	O
used	O
for	O
data	O
analysis	O
.	O

Quantitative	O
data	O
were	O
expressed	O
as	O
the	O
means	O
±	O
SEM	O
.	O

Data	O
of	O
two	O
groups	O
were	O
evaluated	O
with	O
independent	O
sample	O
Student	O
’	O
s	O
t	O
tests	O
,	O
and	O
the	O
comparisons	O
among	O
more	O
than	O
two	O
groups	O
were	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
Dunnett	O
’	O
s	O
post	O
hoc	O
Student	O
’	O
s	O
t	O
tests	O
.	O

The	O
macroscopic	O
and	O
histological	O
score	O
was	O
evaluated	O
using	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O

Nicotine	B-CD
had	O
an	O
adverse	O
effect	O
on	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defect	O

To	O
evaluate	O
the	O
impact	O
of	O
nicotine	B-CD
on	O
cartilage	O
defect	O
repair	O
,	O
we	O
used	O
a	O
femoral	O
trochlear	O
cartilage	O
defect	O
rat	B-OG
model	O
,	O
which	O
was	O
repaired	O
by	O
BMSC	O
transplantation	O
.	O

Nicotine	B-CD
was	O
injected	O
at	O
1	O
.	O
0	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
/	O
d	O
).	O

The	O
effect	O
of	O
nicotine	B-CD
on	O
cartilage	O
repair	O
was	O
analyzed	O
.	O

At	O
12	O
weeks	O
post	O
-	O
transplantation	O
,	O
no	O
abnormal	O
findings	O
suggested	O
rejection	O
or	O
infection	B-DS
,	O
such	O
as	O
severe	O
inflammation	O
or	O
extensive	O
fibrosis	O
,	O
and	O
no	O
synovial	O
edema	O
was	O
observed	O
in	O
either	O
group	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
defects	O
were	O
covered	O
with	O
smooth	O
regenerated	O
tissues	O
with	O
surrounding	O
cartilage	O
,	O
and	O
the	O
tissues	O
were	O
well	O
integrated	O
with	O
the	O
surrounding	O
cartilage	O
although	O
there	O
remained	O
part	O
of	O
a	O
depressed	O
tissue	O
with	O
a	O
demarcating	O
border	O
<	O
1	O
mm	O
(	O
Fig	O
.	O
1a	O
).	O

Safranin	O
O	O
staining	O
showed	O
that	O
the	O
cartilage	O
defect	O
was	O
filled	O
to	O
the	O
full	O
depth	O
and	O
smooth	O
regenerated	O
tissues	O
with	O
good	O
column	O
alignment	O
,	O
which	O
were	O
well	O
integrated	O
with	O
both	O
edges	O
of	O
normal	O
cartilage	O
,	O
and	O
the	O
graft	O
had	O
a	O
normal	O
matrix	O
-	O
staining	O
compared	O
with	O
adjacent	O
cartilage	O
.	O

The	O
cell	O
morphology	O
was	O
similar	O
to	O
the	O
native	O
cartilage	O
,	O
which	O
was	O
round	O
or	O
ovoid	O
shaped	O
in	O
neat	O
rows	O
and	O
obvious	O
lacuna	O
(	O
Fig	O
.	O
1d	O
).	O

In	O
the	O
experimental	O
group	O
,	O
part	O
of	O
the	O
regenerated	O
tissues	O
had	O
a	O
fibrillated	O
surface	O
,	O
most	O
parts	O
of	O
the	O
defects	O
were	O
filled	O
with	O
regenerated	O
tissues	O
level	O
with	O
the	O
surrounding	O
cartilage	O
,	O
little	O
was	O
clearly	O
distinguishable	O
from	O
the	O
normal	O
cartilage	O
,	O
and	O
part	O
of	O
the	O
graft	O
had	O
a	O
fibrillated	O
surface	O
(	O
Fig	O
.	O
1b	O
).	O

The	O
marked	O
reduced	O
safranin	B-CD
-	I-CD
O	I-CD
staining	O
was	O
exhibited	O
in	O
regenerated	O
tissues	O
,	O
which	O
fully	O
covered	O
the	O
defect	O
.	O

The	O
cell	O
morphology	O
was	O
almost	O
the	O
same	O
as	O
fibrocartilage	O
,	O
which	O
showed	O
an	O
irregular	O
arrangement	O
and	O
no	O
lacuna	O
(	O
Fig	O
.	O
1e	O
).	O

The	O
macroscopic	O
scores	O
of	O
the	O
control	O
group	O
were	O
much	O
higher	O
than	O
those	O
of	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
1c	O
),	O
and	O
the	O
microscopic	O
scores	O
in	O
the	O
control	O
group	O
were	O
much	O
lower	O
than	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
1f	O
).	O

The	O
result	O
suggested	O
that	O
the	O
transplantation	O
of	O
BMSCs	O
with	O
alginate	O
could	O
effectively	O
repair	O
the	O
cartilage	O
defect	O
as	O
the	O
regenerated	O
tissue	O
was	O
almost	O
the	O
same	O
as	O
hyaline	O
cartilage	O
.	O

Nicotine	B-CD
had	O
an	O
obvious	O
adverse	O
effect	O
on	O
cell	O
morphology	O
of	O
the	O
regenerated	O
tissue	O
and	O
synthesis	O
of	O
cartilage	O
matrix	O
.	O
Fig	O
.	O
1Effects	O
of	O
nicotine	B-CD
on	O
the	O
repair	O
of	O
the	O
cartilage	O
defect	O
with	O
BMSCs	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
and	O
b	O
Macroscopic	O
observation	O
of	O
cartilage	O
repair	O
(×	O
100	O
).	O
c	O
Macroscopic	O
scores	O
of	O
cartilage	O
repair	O
.	O
d	O
and	O
e	O
Safranin	O
-	O
O	O
and	O
fast	O
green	O
staining	O
of	O
cartilage	O
repair	O
(×	O
100	O
).	O
f	O
Histological	O
scores	O
of	O
cartilage	O
repair	O
.	O

Data	O
represent	O
mean	O
±	O
SD	O
(	O
n	O
=	O
8	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O
Scale	O
bar	O
=	O
200	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
.	O

Nicotine	B-CD
inhibited	O
cartilage	O
repair	O
by	O
suppressing	O
Sox9	B-GP
expression	O

To	O
explore	O
the	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
suppression	O
on	O
the	O
chondrogenic	O
cartilage	O
repair	O
of	O
the	O
cartilage	O
defect	O
,	O
we	O
measured	O
the	O
expression	O
of	O
matrix	O
and	O
Sox9	B-GP
in	O
the	O
regenerated	O
tissues	O
.	O

Immunohistochemical	O
staining	O
of	O
sections	O
with	O
Col2A1	B-GP
and	O
Sox9	B-GP
antibodies	O
showed	O
the	O
proteins	O
in	O
the	O
regenerated	O
tissue	O
stained	O
positive	O
.	O

The	O
staining	O
of	O
Col2A1	B-GP
was	O
stronger	O
in	O
the	O
control	O
group	O
than	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
2a	O
and	O
b	O
),	O
similar	O
to	O
Sox9	B-GP
(	O
Fig	O
.	O
2d	O
and	O
e	O
).	O

The	O
mean	O
optical	O
densities	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
were	O
reduced	O
in	O
the	O
experimental	O
group	O
(	O
Fig	O
.	O
2c	O
and	O
f	O
).	O

RNA	O
was	O
extracted	O
from	O
the	O
regenerated	O
tissues	O
of	O
both	O
groups	O
,	O
and	O
the	O
mRNA	O
expression	O
of	O
aggrecan	B-GP
,	O
Col2A1	B-GP
,	O
and	O
Sox9	B-GP
in	O
the	O
experimental	O
group	O
were	O
decreased	O
(	O
Fig	O
.	O
2g	O
),	O
which	O
was	O
consistent	O
with	O
protein	O
expression	O
by	O
immunostaining	O
.	O

These	O
findings	O
demonstrated	O
that	O
nicotine	B-CD
inhibited	O
the	O
expression	O
of	O
Col2A1	B-GP
and	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

As	O
Sox9	B-GP
is	O
the	O
upstream	O
cellular	O
signal	O
of	O
Col2A1	B-GP
,	O
we	O
concluded	O
that	O
nicotine	B-CD
decreased	O
the	O
expression	O
of	O
Col2A1	B-GP
by	O
suppressing	O
Sox9	B-GP
and	O
then	O
negatively	O
influenced	O
the	O
cartilage	O
defect	O
repair	O
.	O
Fig	O
.	O
2Effects	O
of	O
nicotine	B-CD
on	O
the	O
regenerated	O
tissue	O
of	O
cartilage	O
defect	O
with	O
BMSCs	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
and	O
b	O
Immunohistological	O
staining	O
of	O
Col2A1	B-GP
in	O
regenerated	O
tissue	O
(×	O
100	O
).	O
c	O
Quantification	O
of	O
the	O
MOD	O
of	O
Col2A1	B-GP
.	O
d	O
and	O
e	O
Immunohistological	O
staining	O
of	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
(×	O
100	O
).	O
f	O
Quantification	O
of	O
the	O
MOD	O
of	O
Sox9	B-GP
.	O
g	O
mRNA	O
expression	O
of	O
Col2A	B-GP
,	O
aggrecan	B-GP
and	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

Data	O
represent	O
mean	O
±	O
SD	O
(	O
n	O
=	O
8	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O
Scale	O
bar	O
=	O
200	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
,	O
MOD	O
mean	O
optical	O
density	O
,	O
Sox9	B-GP
SRY	O
-	O
type	O
high	O
-	O
mobility	O
group	O
box	O
9	O

Nicotine	B-CD
increased	O
the	O
intracellular	O
Ca2	O
+	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
through	O
α7	B-GP
-	I-GP
nAChR	I-GP

To	O
investigate	O
the	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
suppression	O
on	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
0	O
.	O
1	O
to	O
100μM	O
nicotine	B-CD
treatment	O
was	O
used	O
in	O
BMSCs	O
.	O

The	O
intracellular	O
signals	O
were	O
tested	O
to	O
verify	O
whether	O
the	O
Ca2	O
+/	O
CaN	B-GP
/	O
NFAT	B-GP
pathway	O
mediated	O
the	O
inhibitory	O
effect	O
of	O
nicotine	B-CD
.	O

We	O
performed	O
a	O
calcium	O
imaging	O
assay	O
for	O
P3	O
BMSCs	O
.	O

The	O
results	O
showed	O
that	O
the	O
fluorescence	O
intensity	O
of	O
BMSCs	O
increased	O
5	O
–	O
10	O
min	O
after	O
administering	O
nicotine	B-CD
and	O
that	O
the	O
slope	O
of	O
the	O
fluorescence	O
intensity	O
curve	O
was	O
different	O
,	O
which	O
grew	O
gradually	O
with	O
increasing	O
nicotine	B-CD
exposure	O
.	O

Nicotine	B-CD
elicited	O
an	O
increase	O
of	O
intracellular	O
calcium	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
3a	O
).	O

The	O
onset	O
time	O
of	O
nicotine	B-CD
in	O
our	O
research	O
was	O
5	O
–	O
10	O
min	O
due	O
to	O
the	O
process	O
of	O
nicotine	B-CD
’	O
s	O
diffusion	O
into	O
BMSCs	O
.	O

Thus	O
,	O
we	O
measured	O
the	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
in	O
0	O
.	O
5	O
h	O
after	O
nicotine	B-CD
stimulus	O
and	O
found	O
that	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
was	O
also	O
increased	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
3b	O
).	O
Fig	O
.	O
3Effects	O
of	O
nicotine	B-CD
on	O
intracellular	O
Ca2	O
+	O
concentration	O
and	O
phosphatase	B-GP
activity	O
of	O
calcineurin	B-GP
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
immediately	O
(	O
a	O
and	O
d	O
)	O
and	O
30	O
mins	O
(	O
b	O
)	O
after	O
nicotine	B-CD
stimulus	O
of	O
in	O
-	O
vitro	O
culture	O
.	O
a	O
Change	O
of	O
fluorescence	O
intensity	O
of	O
Ca2	O
+	O
after	O
the	O
stimulus	O
of	O
nicotine	B-CD
at	O
different	O
concentrations	O
.	O
b	O
Change	O
of	O
fluorescence	O
intensity	O
of	O
calcineurin	B-GP
phosphatase	I-GP
activity	O
of	O
CaN	B-GP
calcineurin	B-GP
after	O
the	O
stimulus	O
of	O
nicotine	B-CD
at	O
different	O
concentrations	O
.	O
c	O
Expression	O
of	O
the	O
subtypes	O
of	O
nAChR	B-GP
in	O
BMSCs	O
.	O
d	O
Effects	O
of	O
MLA	O
on	O
nicotine	B-CD
’	O
s	O
augmentation	O
of	O
intracellular	O
Ca2	O
+	O
concentration	O
in	O
BMSCs	O
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
Scale	O
bar	O
=	O
100	O
μm	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
CaN	B-GP
calcineurin	B-GP
,	O
MLA	O
methyllycaconitine	O
,	O
nAChR	B-GP
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP
,	O

Because	O
nAChR	B-GP
in	O
MSCs	O
has	O
a	O
large	O
Ca2	O
+	O
permeability	O
and	O
induces	O
elevated	O
intracellular	O
free	O
calcium	O
by	O
releasing	O
intracellular	O
calcium	O
stores	O
,	O
we	O
verified	O
whether	O
nicotine	B-CD
exerted	O
its	O
effect	O
through	O
nAChR	B-GP
in	O
BMSCs	O
.	O

Total	O
RNA	O
and	O
proteins	O
were	O
extracted	O
from	O
BMSCs	O
,	O
and	O
an	O
examination	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
showed	O
that	O
α7	B-GP
-	I-GP
nAchR	I-GP
was	O
expressed	O
in	O
BMSCs	O
(	O
Fig	O
.	O
3c	O
).	O

We	O
found	O
that	O
10μM	O
methyllycaconitine	B-CD
(	O
MLA	O
),	O
the	O
specific	O
antagonist	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
conversely	O
eliminated	O
the	O
nicotine	B-CD
-	O
induced	O
calcium	O
influx	O
(	O
Fig	O
.	O
3d	O
),	O
implying	O
that	O
the	O
effect	O
of	O
nicotine	B-CD
on	O
BMSCs	O
was	O
fulfilled	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O

Nicotine	B-CD
suppressed	O
Sox9	B-GP
by	O
activating	O
the	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
pathway	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP

Nicotine	B-CD
exposure	O
increased	O
the	O
concentration	O
of	O
Ca2	O
+	O
and	O
calcineurin	B-GP
phosphatase	I-GP
activity	O
increased	O
over	O
a	O
short	O
period	O
.	O

To	O
detect	O
the	O
molecular	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
negative	O
effect	O
,	O
BMSCs	O
were	O
treated	O
with	O
nicotine	B-CD
at	O
different	O
times	O
to	O
detect	O
the	O
expression	O
change	O
of	O
Sox9	B-GP
.	O

The	O
results	O
showed	O
that	O
the	O
mRNA	O
expression	O
of	O
Sox9	B-GP
decreased	O
in	O
24	O
h	O
after	O
nicotine	B-CD
exposure	O
(	O
Fig	O
.	O
4a	O
-	O
c	O
),	O
and	O
the	O
protein	O
expression	O
of	O
Sox9	B-GP
also	O
declined	O
(	O
Fig	O
.	O
4d	O
and	O
e	O
).	O

The	O
NFAT	B-GP
protein	O
has	O
calcineurin	B-GP
binding	O
sites	O
in	O
the	O
regulatory	O
domain	O
and	O
is	O
regulated	O
by	O
Ca2	O
+	O
and	O
calmodulin	B-GP
-	I-GP
dependent	I-GP
serine	I-GP
phosphatase	I-GP
calcineurin	I-GP
[	O
22	O
];	O
therefore	O
,	O
we	O
extracted	O
the	O
total	O
protein	O
,	O
cytoplasmic	O
proteins	O
and	O
nucleoproteins	B-GP
and	O
found	O
that	O
although	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
expression	O
of	O
NFATc2	B-GP
of	O
whole	O
cells	O
(	O
Fig	O
.	O
4f	O
and	O
g	O
),	O
the	O
expression	O
of	O
nucleic	O
NFATc2	B-GP
protein	O
was	O
elevated	O
(	O
Fig	O
.	O
4h	O
and	O
i	O
)	O
and	O
the	O
cytoplasm	O
phosphorylated	O
NFATc2	B-GP
was	O
reduced	O
by	O
nicotine	B-CD
(	O
Fig	O
.	O
4j	O
and	O
k	O
),	O
indicating	O
that	O
NFATc2	B-GP
was	O
rapidly	O
dephosphorylated	O
and	O
localized	O
to	O
the	O
nucleus	O
following	O
nicotine	B-CD
treatment	O
and	O
that	O
the	O
dephosphorylated	O
NFATc2	B-GP
remains	O
in	O
the	O
nucleus	O
in	O
the	O
continued	O
presence	O
of	O
nicotine	B-CD
.	O

To	O
further	O
verify	O
the	O
molecular	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
Sox9	B-GP
,	O
we	O
performed	O
RNAi	O
-	O
mediated	O
stable	O
knockdown	O
of	O
NFATc2	B-GP
expression	O
in	O
cultured	O
BMSCs	O
.	O
NFATc2	B-GP
expression	O
was	O
significantly	O
suppressed	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
(	O
Fig	O
.	O
4l	O
and	O
m	O
).	O

The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
Sox9	B-GP
had	O
no	O
change	O
when	O
10	O
μM	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
were	O
given	O
0	O
.	O
5	O
h	O
before	O
the	O
nicotine	B-CD
exposure	O
(	O
Fig	O
.	O
4n	O
and	O
o	O
),	O
implying	O
that	O
interventions	O
aimed	O
at	O
α7	B-GP
-	I-GP
nAChR	I-GP
and	O
NFATc2	B-GP
could	O
reverse	O
nicotine	B-CD
’	O
s	O
suppressive	O
effect	O
on	O
the	O
expression	O
of	O
Sox9	B-GP
.	O

Therefore	O
,	O
nicotine	B-CD
suppressed	O
Sox9	B-GP
by	O
activating	O
the	O
Ca2	O
+/	O
calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
pathway	O
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O
Fig	O
.	O
4Effects	O
of	O
nicotine	B-CD
on	O
Sox9	B-GP
and	O
NFATc2	B-GP
expression	O
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
8	O
h	O
.	O
b	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
16	O
h	O
.	O
c	O
mRNA	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
24	O
h	O
.	O
d	O
and	O
e	O
Protein	O
expression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
24	O
h	O
.	O
f	O
and	O
g	O
Expression	O
of	O
NFATc2	B-GP
in	O
nucleoproteins	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
24	O
h	O
.	O
h	O
and	O
i	O
Expression	O
of	O
phosphorylated	O
NFATc2	B-GP
in	O
the	O
cytoplasm	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
24	O
h	O
.	O
j	O
and	O
k	O
Expression	O
of	O
NFATc2	B-GP
in	O
total	O
protein	O
with	O
stimulus	O
of	O
nicotine	B-CD
for	O
24	O
h	O
.	O
l	O
and	O
m	O
Effect	O
of	O
Si	O
-	O
NFATc2	B-GP
in	O
BMSCs	O
.	O
n	O
and	O
o	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
Sox9	B-GP
in	O
BMSCs	O
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
,	O
MLA	O
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP
,	O
Sox9	B-GP
SRY	O
-	O
type	O
high	O
-	O
mobility	O
group	O
box	O
9	B-GP

Nicotine	B-CD
decreased	O
the	O
histone	B-GP
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
in	O
BMSCs	O

Nicotine	B-CD
exposure	O
resulted	O
in	O
the	O
dephosphorylation	O
and	O
increased	O
the	O
nucleic	O
translocation	O
of	O
NFATc2	B-GP
,	O
and	O
then	O
NFATc2	B-GP
could	O
bind	O
to	O
a	O
site	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
target	O
gene	O
and	O
play	O
a	O
role	O
in	O
the	O
downregulation	O
of	O
gene	O
expression	O
[	O
23	O
].	O

Given	O
the	O
finding	O
that	O
nicotine	B-CD
exposure	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
Sox9	B-GP
expression	O
,	O
our	O
investigation	O
further	O
focused	O
on	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
.	O

The	O
result	O
of	O
ChIP	O
analysis	O
indicated	O
that	O
the	O
binding	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
on	O
the	O
Sox9	B-GP
promoter	O
was	O
increased	O
(	O
Fig	O
.	O
5c	O
and	O
d	O
)	O
and	O
that	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
on	O
the	O
Sox9	B-GP
promoter	O
were	O
reduced	O
(	O
Fig	O
.	O
5a	O
and	O
b	O
)	O
while	O
a	O
decreased	O
binding	O
of	O
Sox9	B-GP
on	O
Col2A1	B-GP
was	O
also	O
observed	O
(	O
Fig	O
.	O
5e	O
).	O

The	O
above	O
changes	O
induced	O
by	O
nicotine	B-CD
were	O
characterized	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
when	O
treatment	O
of	O
10	O
μM	O
MLA	O
or	O
si	O
-	O
NFATc2	B-GP
was	O
performed	O
before	O
nicotine	B-CD
exposure	O
,	O
the	O
levels	O
of	O
H3K9ac	O
and	O
H3K14ac	O
were	O
rescued	O
to	O
the	O
level	O
of	O
untreated	O
control	O
(	O
Fig	O
.	O
5f	O
and	O
g	O
),	O
and	O
the	O
induced	O
binding	O
of	O
Sox9	B-GP
on	O
Col2A1	B-GP
was	O
also	O
reversed	O
(	O
Fig	O
.	O
5h	O
).	O

Therefore	O
,	O
nicotine	B-CD
treatment	O
resulted	O
in	O
dephosphorylation	O
and	O
increased	O
nucleic	O
translocation	O
of	O
NFATc2	B-GP
.	O

Then	O
,	O
NFATc2	B-GP
and	O
HDAC1	B-GP
bound	O
on	O
the	O
Sox9	B-GP
promoter	O
reduced	O
the	O
levels	O
of	O
H3K9ac	O
and	O
H3K14ac	O
on	O
the	O
Sox9	B-GP
promoter	O
and	O
decreased	O
Sox9	B-GP
expression	O
.	O

Reduced	O
binding	O
of	O
Sox9	B-GP
with	O
Col2A1	B-GP
further	O
decreased	O
Col2A1	B-GP
expression	O
.	O
Fig	O
.	O
5Effects	O
of	O
nicotine	B-CD
on	O
histone	B-GP
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
in	O
BMSCs	O
.	O

Assay	O
were	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
Change	O
of	O
H3K9	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
b	O
Change	O
of	O
H3K14	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
c	O
Change	O
of	O
NFATc2	B-GP
binding	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
d	O
Change	O
of	O
1	O
binding	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
e	O
Change	O
of	O
Sox9	B-GP
binding	O
on	O
the	O
enhancer	O
of	O
Col2A1	B-GP
.	O
f	O
Effects	O
of	O
methyllycaconitine	O
(	O
MLA	O
)	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
H3K9	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
g	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
H3K14	O
acetylation	O
on	O
the	O
promoter	O
of	O
Sox9	B-GP
.	O
h	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
Sox9	B-GP
binding	O
on	O
the	O
enhancer	O
of	O
Col2A1	B-GP
.	O

Data	O
represent	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
Col2A1	B-GP
α1	O
chain	O
of	O
type	B-GP
II	I-GP
collagen	I-GP
,	O
HDAC1	B-GP
histone	B-GP
deacetylase1	I-GP
,	O
MLA	B-GP
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP
,	O
Sox9	B-GP
SRY	O
-	B-GP
type	I-GP
high	I-GP
-	I-GP
mobility	I-GP
group	I-GP
box	I-GP
9	I-GP

Nicotine	B-CD
increased	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP

HDACs	B-GP
participate	O
in	O
decreasing	O
the	O
histone	B-GP
acetylation	O
level	O
of	O
gene	O
promoters	O
.	O

The	O
transcriptional	O
activity	O
of	O
NFAT	B-GP
proteins	O
can	O
regulate	O
gene	O
expression	O
negatively	O
depending	O
on	O
which	O
binding	O
partners	O
are	O
involved	O
.	O

Nicotine	B-CD
exposure	O
resulted	O
in	O
the	O
binding	O
of	O
NFATc2	B-GP
to	O
Sox9	B-GP
and	O
decreasing	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
in	O
the	O
Sox9	B-GP
promoter	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
nicotine	B-CD
-	O
induced	O
decreased	O
level	O
of	O
H3K9ac	O
and	O
H3K14ac	O
in	O
the	O
Sox9	B-GP
promoter	O
,	O
we	O
used	O
immunoprecipitation	O
to	O
measure	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC	B-GP
.	O

The	O
result	O
showed	O
that	O
the	O
interaction	O
of	O
NFATc2	B-GP
with	O
HDAC1	B-GP
was	O
enhanced	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
after	O
nicotine	B-CD
exposure	O
(	O
Fig	O
.	O
6a	O
),	O
and	O
no	O
significant	O
change	O
of	O
interaction	O
was	O
observed	O
when	O
Si	B-GP
-	O
NFATc2	B-GP
and	O
MLA	B-GP
were	O
used	O
before	O
nicotine	B-CD
treatment	O
(	O
Fig	O
.	O
6b	O
).	O

These	O
results	O
implied	O
that	O
NFATc2	B-GP
could	O
bind	O
to	O
the	O
Sox9	B-GP
promoter	O
and	O
recruit	O
HDAC1	B-GP
,	O
which	O
also	O
binds	O
to	O
the	O
Sox9	B-GP
promoter	O
to	O
form	O
the	O
complex	O
,	O
and	O
the	O
latter	O
could	O
reduce	O
H3K9ac	O
and	O
H3K14ac	O
levels	O
in	O
the	O
Sox9	B-GP
promoter	O
and	O
decrease	O
the	O
expression	O
of	O
Sox9	B-GP
.	O
Fig	O
.	O
6Effects	O
of	O
nicotine	B-CD
on	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
in	O
BMSCs	O
.	O

Assay	O
was	O
performed	O
after	O
24	O
h	O
of	O
in	O
vitro	O
culture	O
.	O
a	O
Interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
under	O
stimulus	O
of	O
nicotine	B-CD
with	O
different	O
concentrations	O
.	O
b	O
Effects	O
of	O
MLA	O
and	O
Si	O
-	O
NFATc2	B-GP
on	O
the	O
interaction	O
of	O
NFATc2	B-GP
and	O
HDAC1	B-GP
induced	O
by	O
nicotine	B-CD
.	O

IgG	B-GP
is	O
a	O
negative	O
control	O
.	O

Input	O
is	O
a	O
positive	O
control	O
.	O

NFATc2	B-GP
is	O
the	O
precipitated	O
protein	O
.	O

HDAC1	B-GP
is	O
the	O
protein	O
of	O
interest	O
.	O
BMSCs	O
bone	O
marrow	O
mesenchymal	O
stem	O
cells	O
,	O
HDAC1	B-GP
histone	B-GP
deacetylase1	I-GP
,	O
MLA	O
methyllycaconitine	O
,	O
NFATc2	B-GP
nuclear	B-GP
factor	I-GP
of	I-GP
activated	I-GP
T	I-GP
cell	I-GP
2	I-GP

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
first	O
verified	O
the	O
adverse	O
effect	O
of	O
nicotine	B-CD
on	O
the	O
chondrogenic	O
repair	O
function	O
of	O
BMSCs	O
in	O
rat	B-OG
articular	O
cartilage	O
defects	O
and	O
proposed	O
that	O
Sox9	B-GP
plays	O
a	O
key	O
role	O
in	O
this	O
process	O
.	O

Based	O
on	O
our	O
previous	O
study	O
,	O
we	O
further	O
confirmed	O
nicotine	B-CD
’	O
s	O
suppression	O
of	O
Col2A1	B-GP
expression	O
and	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
,	O
the	O
mechanism	O
of	O
which	O
may	O
involve	O
decreasing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
through	O
activation	O
of	O
Ca2	O
+/	O
CaN	B-GP
/	O
NFAT	B-GP
signaling	O
.	O

The	O
altered	O
gene	O
expression	O
and	O
promoter	O
acetylation	O
patterns	O
could	O
be	O
blocked	O
by	O
antagonism	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
indicating	O
that	O
the	O
direct	O
effect	O
of	O
nicotine	B-CD
is	O
mediated	O
by	O
α7	B-GP
-	I-GP
nAChR	I-GP
.	O

Therefore	O
,	O
nicotine	B-CD
could	O
interfere	O
with	O
cartilage	O
repair	O
through	O
suppressing	O
Sox9	B-GP
expression	O
in	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

Nicotine	B-CD
is	O
a	O
high	O
-	O
risk	O
factor	O
for	O
many	O
diseases	O
and	O
has	O
negative	O
effects	O
on	O
soft	O
and	O
bony	O
tissue	O
healing	O
[	O
11	O
,	O
12	O
],	O
which	O
can	O
also	O
influence	O
the	O
repair	O
of	O
cartilage	O
defects	O
and	O
suppress	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
[	O
13	O
,	O
17	O
].	O

However	O
,	O
the	O
mechanism	O
of	O
nicotine	B-CD
’	O
s	O
adverse	O
effect	O
is	O
still	O
unclear	O
.	O

Previous	O
researches	O
had	O
clarified	O
the	O
chondrogenic	O
potential	O
of	O
MSCs	O
involved	O
in	O
cartilage	O
regeneration	O
[	O
28	O
,	O
31	O
].	O

Similarly	O
,	O
the	O
regenerated	O
tissue	O
in	O
our	O
study	O
could	O
have	O
been	O
differentiated	O
from	O
BMSCs	O
.	O

In	O
addition	O
to	O
their	O
differentiation	O
potential	O
,	O
the	O
paracrine	O
action	O
of	O
MSCs	O
was	O
also	O
believed	O
to	O
contribute	O
to	O
their	O
therapeutic	O
effects	O
[	O
32	O
,	O
33	O
],	O
unknown	O
factors	O
secreted	O
from	O
BMSCs	O
may	O
stimulate	O
chondrogenic	O
differentiation	O
in	O
the	O
repair	O
process	O
.	O

Thus	O
,	O
we	O
believed	O
the	O
mechanism	O
of	O
cartilage	O
repair	O
in	O
defect	O
was	O
associated	O
with	O
chondrogenic	O
differentiation	O
and	O
the	O
secretive	O
action	O
of	O
BMSCs	O
.	O
Sox9	B-GP
is	O
a	O
key	O
transcriptional	B-GP
factor	I-GP
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
chondrocyte	O
differentiation	O
and	O
cartilage	O
formation	O
[	O
18	O
].	O

In	O
the	O
initial	O
stage	O
of	O
chondrogenesis	O
,	O
mesenchymal	O
stem	O
cells	O
condense	O
and	O
then	O
differentiate	O
into	O
chondrocytes	O
.	O
Sox9	B-GP
can	O
bind	O
to	O
essential	O
sequences	O
in	O
the	O
Col2A1	B-GP
gene	O
at	O
chondrocyte	O
-	O
specific	O
enhancers	O
and	O
activate	O
its	O
expression	O
,	O
and	O
Sox9	B-GP
has	O
been	O
identified	O
as	O
a	O
regulator	O
of	O
the	O
chondrocyte	O
lineage	O
[	O
34	O
].	O

Research	O
had	O
shown	O
that	O
the	O
inactivation	O
of	O
Sox9	B-GP
in	O
limb	O
buds	O
before	O
mesenchymal	O
condensation	O
resulted	O
in	O
a	O
complete	O
absence	O
of	O
cartilage	O
.	O

A	O
delayed	O
development	O
of	O
cartilage	O
can	O
also	O
be	O
induced	O
when	O
the	O
Sox9	B-GP
gene	O
is	O
inactivated	O
after	O
chondrogenic	O
mesenchymal	O
condensation	O
[	O
35	O
].	O

Thus	O
,	O
Sox9	B-GP
is	O
essential	O
in	O
the	O
condensed	O
stage	O
of	O
MSCs	O
and	O
subsequent	O
differentiation	O
in	O
the	O
process	O
of	O
cartilage	O
formation	O
[	O
15	O
].	O

In	O
addition	O
,	O
Sox9	B-GP
also	O
plays	O
an	O
essential	O
role	O
in	O
the	O
physiological	O
control	O
of	O
cartilaginous	O
tissues	O
[	O
36	O
].	O

BMSCs	O
with	O
Sox9	B-GP
gene	O
transfer	O
by	O
adenovirus	B-OG
could	O
promote	O
cartilage	O
defect	O
repair	O
[	O
37	O
].	O

Therefore	O
,	O
Sox9	B-GP
also	O
play	O
an	O
important	O
role	O
in	O
cartilage	O
repair	O
using	O
BMSCs	O
.	O

Our	O
results	O
found	O
that	O
nicotine	B-CD
reduced	O
Sox9	B-GP
expression	O
in	O
the	O
regenerated	O
tissue	O
in	O
the	O
cartilage	O
defect	O
area	O
,	O
which	O
demonstrated	O
that	O
nicotine	B-CD
has	O
an	O
adverse	O
effect	O
on	O
cartilage	O
repair	O
through	O
the	O
suppression	O
of	O
Sox9	B-GP
in	O
regenerated	O
tissue	O
.	O

Histone	B-GP
acetyltransferases	I-GP
(	O
HATs	B-GP
)	O
and	O
HDACs	B-GP
are	O
two	O
classes	O
of	O
histone	B-GP
acetylation	I-GP
enzymes	I-GP
,	O
which	O
determine	O
the	O
acetylation	O
status	O
of	O
histones	B-GP
of	O
genes	O
.	O

The	O
activated	O
balance	O
of	O
HATs	B-GP
and	O
HDACs	B-GP
affects	O
the	O
regulation	O
of	O
gene	O
expression	O
[	O
38	O
].	O

The	O
reduction	O
of	O
acetylation	O
in	O
the	O
transcriptional	O
regulatory	O
regions	O
often	O
leads	O
to	O
the	O
inhibition	O
of	O
gene	O
expression	O
[	O
39	O
].	O

The	O
Sox9	B-GP
-	O
based	O
transcriptional	O
complex	O
,	O
including	O
CBP	B-GP
/	O
p300	B-GP
,	O
which	O
has	O
an	O
intrinsic	O
HATs	B-GP
activity	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
initiation	O
of	O
chondrogenic	O
differentiation	O
of	O
MSCs	O
[	O
19	O
].	O

Thus	O
,	O
the	O
expression	O
of	O
Sox9	B-GP
itself	O
is	O
mainly	O
regulated	O
by	O
histone	B-GP
acetylation	O
[	O
20	O
].	O

Histone	O
acetylation	O
is	O
concentrated	O
mainly	O
on	O
histone	B-GP
3	I-GP
and	O
histone	B-GP
4	I-GP
[	O
40	O
],	O
and	O
H3K9	O
and	O
H3K14	O
acetylation	O
often	O
co	O
-	O
occur	O
at	O
many	O
gene	O
regulatory	O
elements	O
and	O
adjust	O
the	O
gene	O
expression	O
in	O
stem	O
cells	O
[	O
41	O
].	O

Based	O
on	O
these	O
data	O
,	O
we	O
focused	O
on	O
nicotine	B-CD
’	O
s	O
regulation	O
of	O
H3K9	O
and	O
H3K14	O
acetylation	O
of	O
Sox9	B-GP
during	O
the	O
process	O
of	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

We	O
observed	O
that	O
nicotine	B-CD
could	O
reduce	O
the	O
expression	O
of	O
Sox9	B-GP
through	O
decreasing	O
H3K9	O
and	O
H3K14	O
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
and	O
finally	O
suppress	O
the	O
chondrogenic	O
differentiation	O
potential	O
of	O
BMSCs	O
.	O

Our	O
in	O
vitro	O
data	O
are	O
consistent	O
with	O
the	O
in	O
vivo	O
results	O
where	O
nicotine	B-CD
directly	O
decreased	O
the	O
expression	O
of	O
Sox9	B-GP
through	O
α7	B-GP
-	I-GP
nAChR	I-GP
by	O
suppressing	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
during	O
the	O
process	O
of	O
BMSCs	O
chondrogenic	O
differentiation	O
.	O

NFAT	B-GP
is	O
a	O
family	O
of	O
transcription	B-GP
factors	I-GP
critical	O
in	O
regulating	O
early	O
gene	O
transcription	O
in	O
response	O
to	O
T	B-GP
cell	I-GP
receptor	I-GP
-	O
mediated	O
signals	O
in	O
lymphocytes	O
[	O
42	O
].	O
NFATc2	B-GP
is	O
a	O
repressor	O
of	O
chondrogenesis	O
[	O
21	O
]	O
and	O
can	O
induce	O
gene	O
silencing	O
through	O
interaction	O
with	O
HDAC	B-GP
[	O
22	O
].	O

Our	O
study	O
demonstrated	O
that	O
NFATc2	B-GP
could	O
bind	O
with	O
Sox9	B-GP
and	O
recruit	O
HDAC1	B-GP
to	O
decrease	O
the	O
histone	B-GP
acetylation	O
of	O
theSox9	O
promoter	O
.	O

Calcineurin	B-GP
(	O
also	O
called	O
protein	B-GP
phosphatase	I-GP
2B	I-GP
),	O
the	O
only	O
serine	B-GP
/	I-GP
threonine	I-GP
protein	I-GP
phosphatase	I-GP
under	O
the	O
control	O
of	O
Ca2	O
+/	O
calmodulin	B-GP
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
coupling	O
of	O
Ca2	O
+	O
signals	O
to	O
cellular	O
responses	O
[	O
43	O
].	O

Ca2	O
+	O
is	O
the	O
upstream	O
signaling	O
molecule	O
of	O
calcineurin	B-GP
,	O
and	O
the	O
increased	O
Ca2	O
+	O
can	O
activate	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
.	O

The	O
complex	O
regulation	O
of	O
calcineurin	B-GP
can	O
dephosphorylate	O
phosphorylated	O
serine	B-CD
/	B-GP
threonine	I-GP
proteins	I-GP
and	O
initiate	O
multiple	O
pathways	O
.	O

NFATc2	B-GP
is	O
the	O
downstream	O
signal	O
of	O
calcineurin	B-GP
[	O
44	O
],	O
and	O
the	O
response	O
to	O
an	O
increase	O
of	O
intracellular	O
Ca2	O
+	O
is	O
dependent	O
upon	O
the	O
dephosphorylation	O
of	O
NFATc2	B-GP
by	O
calcineurin	B-GP
.	O

The	O
activated	O
calcineurin	B-GP
controls	O
the	O
translocation	O
of	O
NFAT	B-GP
proteins	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
regulates	O
the	O
expression	O
of	O
target	O
genes	O
[	O
23	O
].	O

Neuronal	O
nAchR	O
is	O
usually	O
in	O
excitable	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
and	O
controls	O
the	O
influx	O
and	O
efflux	O
of	O
Na	O
+,	O
K	O
+,	O
and	O
Ca2	O
+	O
[	O
45	O
].	O

Recent	O
studies	O
found	O
that	O
nAchR	B-GP
was	O
also	O
in	O
non	O
-	O
excitable	O
cells	O
outside	O
the	O
nervous	O
system	O
[	O
24	O
,	O
46	O
],	O
providing	O
physiologic	O
functions	O
in	O
these	O
cells	O
[	O
47	O
],	O
in	O
which	O
Ca2	O
+	O
plays	O
an	O
important	O
role	O
in	O
a	O
signaling	O
cascade	O
activated	O
by	O
nAchR	B-GP
.	O

Stimulation	O
of	O
MSCs	O
with	O
nicotine	B-CD
induced	O
increases	O
of	O
intracellular	O
Ca2	O
+	O
concentration	O
and	O
initiated	O
the	O
downstream	O
pathway	O
of	O
cascade	O
activation	O
while	O
MLA	O
,	O
which	O
is	O
the	O
specific	O
antagonist	O
of	O
α7	B-GP
-	I-GP
nAChR	I-GP
,	O
could	O
inhibit	O
the	O
calcium	O
influx	O
[	O
48	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
α7	B-GP
-	I-GP
nAChR	I-GP
was	O
presented	O
in	O
BMSCs	O
and	O
a	O
nicotine	B-CD
stimulus	O
could	O
increase	O
intracellular	O
Ca2	O
+	O
and	O
the	O
enzyme	O
activity	O
of	O
calcineurin	B-GP
of	O
BMSCs	O
.	O

The	O
expression	O
of	O
dephosphorylated	O
NFATc2	B-GP
in	O
the	O
cytoplasm	O
decreased	O
and	O
NFATc2	B-GP
in	O
the	O
nucleus	O
increased	O
.	O

Therefore	O
,	O
nicotine	B-CD
could	O
activate	O
Ca2	O
+/	O
Calcineurin	B-GP
/	O
NFAT	B-GP
signaling	O
in	O
BMSCs	O
throughα7	O
-	O
nAChR	B-GP
,	O
resulting	O
in	O
recruitment	O
of	O
HDAC1	B-GP
,	O
which	O
decreased	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
and	O
finally	O
inhibited	O
BMSC	O
chondrogenic	O
differentiation	O
.	O

The	O
dose	O
of	O
nicotine	B-CD
exposure	O
in	O
our	O
study	O
is	O
2	O
mg	O
/	O
kg	O
/	O
d	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
animal	B-OG
studies	O
[	O
49	O
,	O
50	O
].	O

According	O
to	O
a	O
previous	O
investigation	O
,	O
an	O
average	O
tobacco	B-OG
rod	O
contains	O
10	O
–	O
14	O
mg	O
of	O
nicotine	B-CD
,	O
and	O
on	O
average	O
,	O
approximately	O
1	O
.	O
5	O
mg	O
of	O
nicotine	B-CD
is	O
absorbed	O
systemically	O
during	O
smoking	O
[	O
51	O
].	O

Based	O
on	O
the	O
dose	O
–	O
conversion	O
correlation	O
between	O
humans	B-OG
and	O
rats	B-OG
(	O
human	B-OG
:	O
rats	B-OG
=	O
1	O
:	O
6	O
.	O
17	O
)	O
[	O
52	O
],	O
the	O
dose	O
of	O
nicotine	B-CD
exposure	O
in	O
the	O
present	O
study	O
is	O
equivalent	O
to	O
the	O
nicotine	B-CD
exposure	O
in	O
an	O
adult	O
weighing	O
approximately	O
70	O
kg	O
smoking	O
2	O
.	O
3	O
cigarettes	O
per	O
day	O
(	O
calculated	O
as	O
follows	O
:	O
2	O
mg	O
/	O
kg	O
/	O
d	O
÷	O
6	O
.	O
17	O
×	O
70	O
kg	O
÷	O
10	O
mg	O
/	O
cigarette	O
=	O
2	O
.	O
3	O
cigarettes	O
/	O
d	O
).	O

The	O
definition	O
of	O
nicotine	B-DS
dependence	I-DS
is	O
the	O
equivalent	O
of	O
more	O
than	O
ten	O
cigarettes	O
per	O
day	O
,	O
and	O
each	O
cigarette	O
contains	O
at	O
least	O
0	O
.	O
5	O
mg	O
nicotine	B-CD
[	O
53	O
].	O

The	O
dose	O
of	O
nicotine	B-CD
in	O
our	O
study	O
was	O
lower	O
than	O
the	O
actual	O
exposure	O
of	O
nicotine	B-DS
dependence	I-DS
in	O
daily	O
life	O
.	O

The	O
present	O
results	O
showed	O
the	O
obvious	O
impact	O
of	O
nicotine	B-CD
on	O
cartilage	O
repair	O
.	O

Thus	O
nicotine	B-CD
’	O
s	O
adverse	O
effect	O
with	O
nicotine	B-DS
dependence	I-DS
would	O
be	O
more	O
serious	O
.	O

The	O
concentration	O
of	O
nicotine	B-CD
(	O
0	O
.	O
01	O
–	O
10	O
μM	O
)	O
used	O
in	O
our	O
chondrogenic	O
differentiation	O
model	O
is	O
consistent	O
with	O
those	O
often	O
used	O
in	O
pluripotent	O
stem	O
cell	O
studies	O
[	O
54	O
,	O
55	O
].	O

The	O
blood	O
concentrations	O
of	O
nicotine	B-CD
during	O
daily	O
smoking	O
are	O
0	O
.	O
06	O
μM	O
to	O
0	O
.	O
23	O
μM	O
[	O
56	O
],	O
the	O
initial	O
concentration	O
of	O
nicotine	B-CD
in	O
our	O
study	O
was	O
0	O
.	O
1	O
μM	O
,	O
which	O
was	O
within	O
the	O
range	O
of	O
a	O
daily	O
smoker	O
’	O
s	O
nicotinic	O
blood	O
concentration	O
and	O
could	O
suppress	O
the	O
chondrogenic	O
differentiation	O
of	O
BMSCs	O
.	O

Based	O
on	O
the	O
principle	O
of	O
toxicology	O
,	O
we	O
set	O
a	O
concentration	O
gradient	O
from	O
0	O
.	O
1	O
to	O
100	O
μM	O
.	O

The	O
result	O
showed	O
that	O
nicotinic	O
suppression	O
on	O
BMSC	O
chondrogenic	O
differentiation	O
has	O
concentration	O
-	O
dependent	O
characteristics	O
.	O

Although	O
the	O
largest	O
nicotine	B-CD
exposure	O
used	O
in	O
the	O
present	O
study	O
was	O
100	O
μM	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
the	O
plasma	O
nicotine	B-CD
level	O
of	O
nicotine	B-DS
dependence	I-DS
,	O
the	O
result	O
was	O
the	O
most	O
obvious	O
and	O
the	O
reversing	O
experiment	O
verified	O
the	O
key	O
point	O
of	O
the	O
molecular	O
mechanism	O
in	O
this	O
concentration	O
,	O
which	O
is	O
also	O
helpful	O
in	O
clarifying	O
the	O
molecular	O
mechanism	O
.	O

Conclusions	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
nicotine	B-CD
at	O
a	O
dose	O
under	O
the	O
actual	O
exposure	O
of	O
nicotine	B-DS
dependence	O
in	O
daily	O
life	O
had	O
an	O
adverse	O
effect	O
on	O
the	O
chondrogenic	O
repair	O
of	O
BMSCs	O
in	O
cartilage	O
defects	O
and	O
that	O
nicotine	B-CD
suppressed	O
BMSC	O
chondrogenic	O
differentiation	O
via	O
the	O
activation	O
Ca2	O
+/	O
Calcineurin	B-GP
/	O
NFATc2	B-GP
signaling	O
,	O
which	O
decreased	O
the	O
histone	B-GP
acetylation	O
of	O
the	O
Sox9	B-GP
promoter	O
region	O
.	O

The	O
current	O
study	O
offers	O
insight	O
into	O
the	O
risk	O
assessment	O
of	O
cartilage	O
defect	O
repair	O
in	O
a	O
nicotine	B-CD
exposure	O
population	O
,	O
advising	O
individuals	O
to	O
avoid	O
the	O
negative	O
impact	O
of	O
nicotine	B-CD
on	O
BMSC	O
cartilage	O
repair	O
to	O
achieve	O
high	O
-	O
quality	O
repair	O
of	O
cartilage	O
tissue	O
.	O

Additional	O
file	O

Additional	O
file	O
1	O
:	O
Macroscopic	O
observation	O
of	O
cartilage	O
defect	O
with	O
no	O
treatment	O
and	O
alginate	O
transplantation	O
in	O
a	O
rat	B-OG
model	O
after	O
12	O
weeks	O
.	O
a	O
Cartilage	O
defect	O
with	O
no	O
treatment	O
.	O
b	O
Cartilage	O
defect	O
with	O
alginate	O
only	O
.	O

(	O
DOCX	O
413	O
kb	O
)	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s13287	O
-	O
018	O
-	O
0853	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Antidepressant	O
-	O
Like	O
Effects	O
of	O
Fractions	O
Prepared	O
from	O
Danzhi	O
-	O
Xiaoyao	O
-	O
San	O
Decoction	O
in	O
Rats	B-OG
with	O
Chronic	O
Unpredictable	O
Mild	O
Stress	O
:	O
Effects	O
on	O
Hypothalamic	O
-	O
Pituitary	O
-	O
Adrenal	O
Axis	O
,	O
Arginine	B-GP
Vasopressin	I-GP
,	O
and	O
Neurotransmitters	O

Academic	O
Editor	O
:	O
Maria	O
Camilla	O
Bergonzi	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
two	O
fractions	O
,	O
including	O
petroleum	B-CD
ether	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
)	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
)	O
prepared	O
from	O
the	O
Danzhi	O
-	O
xiaoyao	O
-	O
san	O
(	O
DZXYS	O
)	O
by	O
using	O
chronic	O
unpredictable	O
mild	O
stress	O
-	O
induced	O
depressive	O
rat	B-OG
model	O
.	O

The	O
results	O
indicated	O
that	O
DZXYS	O
could	O
ameliorate	O
the	O
depression	B-DS
-	O
like	O
behavior	O
in	O
chronic	O
stress	O
model	O
of	O
rats	B-OG
.	O

The	O
inhibition	O
of	O
hyperactivity	O
of	O
HPA	O
axis	O
and	O
the	O
modulation	O
of	O
monoamine	B-CD
and	O
amino	B-CD
acid	I-CD
neurotransmitters	O
in	O
the	O
hippocampus	O
may	O
be	O
the	O
important	O
mechanisms	O
underlying	O
the	O
action	O
of	O
DZXYS	O
antidepressant	O
-	O
like	O
effect	O
in	O
chronically	O
stressed	O
rats	B-OG
.	O

1	O
.	O

Introduction	O

Depression	B-DS
is	O
the	O
commonest	O
psychiatric	B-DS
disorder	I-DS
with	O
such	O
main	O
clinical	O
features	O
as	O
significant	O
and	O
lasting	O
depression	B-DS
,	O
mental	O
retardation	B-DS
,	O
cognitive	B-DS
impairment	I-DS
,	O
and	O
depression	B-DS
and	O
somatic	O
symptoms	O
.	O

Furthermore	O
,	O
depression	B-DS
is	O
a	O
risk	O
factor	O
for	O
the	O
onset	O
of	O
type	B-DS
2	I-DS
diabetes	I-DS
mellitus	I-DS
,	O
hypertension	B-DS
,	O
coronary	B-DS
heart	I-DS
disease	I-DS
,	O
cancer	B-DS
,	O
and	O
so	O
on	O
[	O
1	O
],	O
which	O
is	O
projected	O
to	O
become	O
the	O
second	O
biggest	O
contributor	O
to	O
the	O
global	O
burden	O
of	O
disease	O
and	O
disability	O
by	O
2020	O
according	O
to	O
WHO	O
'	O
s	O
prediction	O
.	O

Monoamine	O
neurotransmitters	O
disorder	O
and	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
hyperactivity	O
,	O
widely	O
recognized	O
,	O
are	O
the	O
two	O
important	O
mechanisms	O
of	O
the	O
occurrence	O
of	O
depression	B-DS
.	O

At	O
present	O
,	O
based	O
on	O
the	O
hypothesis	O
of	O
monoamine	O
neurotransmitters	O
function	O
deficiency	O
,	O
antidepression	O
drugs	O
,	O
such	O
as	O
the	O
tricyclic	O
antidepressants	O
(	O
TCAs	O
),	O
the	O
selective	O
serotonin	B-CD
reuptake	O
inhibitors	O
(	O
SSRIs	O
),	O
the	O
selective	O
norepinephrine	B-CD
reuptake	O
inhibitors	O
(	O
SNRIs	O
),	O
the	O
selective	O
norepinephrine	B-CD
-	O
dopamine	B-CD
reuptake	O
inhibitors	O
,	O
and	O
the	O
monoamine	B-GP
oxidase	I-GP
inhibitors	O
(	O
MAOIs	O
),	O
have	O
been	O
developed	O
,	O
which	O
are	O
mainly	O
by	O
inhibiting	O
the	O
transporter	O
function	O
of	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
),	O
dopamine	B-CD
(	O
DA	O
),	O
and	O
norepinephrine	B-CD
(	O
NE	O
)	O
to	O
block	O
the	O
reuptake	O
of	O
monoamine	O
neurotransmitters	O
to	O
increase	O
the	O
concentration	O
of	O
those	O
neurotransmitters	O
mentioned	O
above	O
in	O
synaptic	O
cleft	O
to	O
improve	O
the	O
symptoms	O
of	O
depression	B-DS
.	O

But	O
now	O
,	O
the	O
efficacy	O
of	O
those	O
drugs	O
has	O
been	O
faced	O
with	O
serious	O
challenges	O
[	O
2	O
].	O

It	O
is	O
noted	O
that	O
inhibition	O
of	O
HPA	O
axis	O
activity	O
is	O
a	O
very	O
effective	O
antidepressant	O
treatment	O
,	O
but	O
so	O
far	O
new	O
antidepression	O
drugs	O
taking	O
the	O
HPA	O
axis	O
as	O
the	O
target	O
have	O
not	O
been	O
successfully	O
tested	O
by	O
the	O
clinical	O
trials	O
[	O
3	O
].	O

Therefore	O
,	O
the	O
need	O
for	O
more	O
effective	O
and	O
safer	O
antidepression	O
drugs	O
continues	O
to	O
command	O
attention	O
in	O
neuropsychopharmacology	O
within	O
the	O
psychotherapeutic	O
community	O
.	O

Nowadays	O
,	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
has	O
offered	O
prospective	O
alternative	O
therapy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

The	O
records	O
of	O
treating	O
mental	B-DS
disorders	I-DS
could	O
be	O
found	O
in	O
ancient	O
medicinal	O
books	O
,	O
and	O
herbal	O
decoction	O
Danzhi	O
-	O
xiaoyao	O
-	O
san	O
(	O
DZXYS	O
),	O
also	O
called	O
Jiawei	O
-	O
xiaoyao	O
-	O
san	O
,	O
is	O
one	O
of	O
the	O
most	O
popular	O
classical	O
ones	O
.	O

The	O
first	O
description	O
of	O
DZXYS	O
is	O
recorded	O
in	O
Jiaozhu	O
Furen	O
Liangfang	O
“	O
Edited	O
and	O
Commented	O
Effective	O
Formulae	O
for	O
Woman	O
”	O
written	O
by	O
Xue	O
Yi	O
(	O
1487	O
–	O
1559	O
)	O
in	O
Ming	O
Dynasty	O
.	O

This	O
herbal	O
formula	O
is	O
composed	O
of	O
the	O
following	O
herbs	O
:	O
Radix	B-OG
Bupleuri	I-OG
,	O
Paeoniae	B-OG
Radix	I-OG
Alba	I-OG
,	O
Angelica	B-OG
sinensis	I-OG
,	O
bighead	B-OG
atractylodes	I-OG
rhizome	O
,	O
Poria	B-OG
cocos	I-OG
,	O
bark	O
of	O
tree	B-OG
peony	I-OG
root	O
,	O
Fructus	O
Gardeniae	O
,	O
Mentha	B-OG
haplocalyx	I-OG
,	O
and	O
Licorice	B-OG
.	O

It	O
is	O
well	O
known	O
that	O
DZXYS	O
decoction	O
plays	O
an	O
important	O
role	O
in	O
the	O
clinical	O
therapy	O
of	O
depression	B-DS
-	I-DS
related	I-DS
disorders	I-DS
in	O
China	O
[	O
4	O
,	O
5	O
].	O

In	O
Chinese	O
medicinal	O
theory	O
,	O
DZXYS	O
decoction	O
exhibits	O
therapeutic	O
effects	O
by	O
releasing	O
constraint	O
and	O
encouraging	O
the	O
free	O
-	O
flow	O
of	O
liver	O
qi	O
,	O
clearing	O
liver	O
heat	O
,	O
nourishing	O
blood	O
,	O
and	O
invigorating	O
spleen	O
.	O

Although	O
this	O
decoction	O
has	O
been	O
used	O
frequently	O
,	O
thus	O
far	O
,	O
it	O
remains	O
unclear	O
as	O
to	O
which	O
active	O
fraction	O
of	O
the	O
DZXYS	O
is	O
responsible	O
for	O
the	O
antidepressant	O
effect	O
and	O
its	O
possible	O
regulatory	O
mechanism	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
two	O
fractions	O
,	O
including	O
petroleum	B-CD
ether	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
)	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
)	O
prepared	O
from	O
the	O
DZXYS	O
by	O
using	O
chronic	O
unpredictable	O
mild	O
stress	O
-	O
(	O
CUMS	O
-)	O
induced	O
depressive	B-DS
rat	B-OG
model	O
.	O

The	O
underlying	O
mechanism	O
of	O
antidepression	O
was	O
mainly	O
explored	O
by	O
measuring	O
the	O
function	O
of	O
HPA	O
axis	O
and	O
the	O
contents	O
of	O
monoamine	B-CD
and	O
amino	B-CD
acid	I-CD
neurotransmitters	O
in	O
hippocampus	O
.	O

In	O
addition	O
,	O
as	O
a	O
neuropeptide	B-GP
,	O
the	O
arginine	B-GP
vasopressin	I-GP
(	O
AVP	B-GP
)	O
contents	O
in	O
plasma	O
and	O
hypothalamus	O
were	O
detected	O
in	O
the	O
study	O
in	O
order	O
to	O
further	O
explore	O
the	O
antidepressant	O
mechanisms	O
of	O
DZXYS	O
in	O
modulating	O
HPA	O
axis	O
.	O

2	O
.	O

Materials	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Plant	B-OG
Materials	O

Medical	O
plants	B-OG
(	O
dried	O
crude	O
herbs	O
)	O
used	O
for	O
preparation	O
of	O
DZXYS	O
were	O
purchased	O
from	O
Medicinal	O
Materials	O
Company	O
of	O
Guangzhou	O
,	O
Guangzhou	O
,	O
China	O
,	O
and	O
authenticated	O
by	O
Professor	O
Ming	O
-	O
Ping	O
Liu	O
,	O
Chinese	O
Materia	O
Medica	O
College	O
,	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
.	O

DZXYS	O
consists	O
of	O
nine	O
dried	O
crude	O
herbs	O
listed	O
in	O
Table	O
1	O
.	O

The	O
ratio	O
of	O
Radix	O
Bupleuri	B-OG
,	O
Paeoniae	B-OG
Radix	I-OG
Alba	I-OG
,	O
Angelica	B-OG
sinensis	I-OG
,	O
bighead	B-OG
atractylodes	I-OG
rhizome	O
,	O
Poria	B-OG
cocos	I-OG
,	O
bark	O
of	O
tree	B-OG
peony	I-OG
root	O
,	O
Fructus	O
Gardeniae	B-OG
,	O
Mentha	B-OG
haplocalyx	I-OG
,	O
and	O
Licorice	B-OG
is	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
1	O
:	O
1	O
.	O

The	O
voucher	O
specimens	O
were	O
conserved	O
at	O
the	O
herbal	O
herbarium	O
of	O
Chinese	O
Materia	O
Medica	O
College	O
,	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Guangzhou	O
,	O
China	O
.	O

The	O
voucher	O
specimens	O
of	O
the	O
herbal	O
materials	O
were	O
deposited	O
for	O
possible	O
future	O
comparison	O
.	O

2	O
.	O
2	O
.	O

Preparation	O
of	O
Fractions	O
from	O
DZXYS	O

The	O
crude	O
powdered	O
mixture	O
of	O
DZXYS	O
,	O
5000	O
g	O
,	O
according	O
to	O
the	O
prescription	O
proportion	O
,	O
was	O
added	O
with	O
petroleum	B-CD
ether	O
(	O
bp	O
60	O
–	O
90	O
°	O
C	O
)	O
and	O
then	O
water	O
-	O
bath	O
-	O
heated	O
and	O
refluxed	O
for	O
4	O
times	O
(	O
2	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
and	O
1	O
.	O
5	O
h	O
);	O
the	O
petroleum	O
-	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
,	O
yield	O
:	O
1	O
.	O
24	O
%)	O
and	O
precipitate	O
were	O
obtained	O
.	O

The	O
precipitate	O
was	O
extracted	O
for	O
3	O
times	O
(	O
2	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
and	O
1	O
.	O
5	O
h	O
)	O
with	O
boiling	O
water	O
,	O
and	O
then	O
the	O
combined	O
water	O
extracts	O
were	O
filtered	O
and	O
concentrated	O
to	O
2500	O
mL	O
solution	O
which	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
and	O
fractionated	O
by	O
the	O
addition	O
of	O
1710	O
mL	O
of	O
95	O
%	O
ethyl	O
alcohol	O
(	O
EtOH	O
)	O
to	O
give	O
a	O
water	O
-	O
EtOH	O
soluble	O
supernatant	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
,	O
the	O
yield	O
:	O
25	O
.	O
9	O
%).	O

FA	O
and	O
FB	O
were	O
lyophilized	O
into	O
dry	O
powders	O
.	O

In	O
this	O
paper	O
,	O
the	O
doses	O
of	O
FA	O
and	O
FB	O
were	O
expressed	O
in	O
terms	O
of	O
dried	O
weight	O
of	O
herbal	O
material	O
used	O
for	O
extraction	O
per	O
unit	O
body	O
weight	O
of	O
experimental	O
rats	B-OG
(	O
g	O
/	O
kg	O
).	O

2	O
.	O
3	O
.	O

Drugs	O
,	O
Reagents	O
,	O
and	O
Chemicals	O

Imipramine	B-CD
hydrochloride	I-CD
(	O
IMI	O
)	O
was	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

The	O
assay	O
kits	O
of	O
corticosterone	B-CD
(	O
CORT	O
),	O
corticotrophin	B-GP
-	I-GP
releasing	I-GP
hormone	I-GP
(	O
CRH	B-GP
),	O
adrenocorticotropin	B-GP
(	O
ACTH	B-GP
),	O
and	O
arginine	B-GP
vasopressin	I-GP
(	O
AVP	B-GP
)	O
were	O
purchased	O
from	O
Nanjing	O
Jiancheng	O
Institute	O
of	O
Biotechnology	O
,	O
Nanjing	O
,	O
China	O
.	O

The	O
standard	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
),	O
dopamine	B-CD
(	O
DA	O
),	O
and	O
norepinephrine	B-CD
(	O
NE	O
)	O
were	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

Disodium	O
ethylenediaminetetraacetate	O
(	O
EDTA	O
)	O
and	O
the	O
standard	O
amino	B-CD
acids	I-CD
including	O
glutamic	B-CD
acid	I-CD
(	O
Glu	O
),	O
aspartic	B-CD
acid	I-CD
(	O
Asp	O
),	O
γ	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
),	O
and	O
taurine	B-CD
(	O
Tau	O
)	O
were	O
obtained	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

All	O
other	O
reagents	O
used	O
were	O
of	O
analytical	O
grade	O
.	O

2	O
.	O
4	O
.	O

Experimental	O
Animals	B-OG

Male	O
Wistar	B-OG
rats	I-OG
weighing	O
180	O
–	O
220	O
g	O
were	O
purchased	O
from	O
the	O
Laboratory	O
Animal	O
Center	O
of	O
Nanfang	O
Medical	O
University	O
,	O
Guangzhou	O
,	O
China	O
.	O

Animals	B-OG
were	O
allowed	O
1	O
week	O
to	O
adapt	O
to	O
the	O
surroundings	O
before	O
beginning	O
any	O
experimentation	O
.	O

Animals	B-OG
were	O
maintained	O
on	O
a	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
under	O
controlled	O
temperature	O
of	O
22	O
±	O
2	O
°	O
C	O
and	O
had	O
free	O
access	O
to	O
food	O
and	O
water	O
.	O

All	O
animals	B-OG
handling	O
procedures	O
were	O
performed	O
in	O
strict	O
accordance	O
with	O
the	O
China	O
legislation	O
on	O
the	O
use	O
and	O
care	O
of	O
laboratory	O
animals	B-OG
and	O
were	O
approved	O
by	O
the	O
Animal	B-OG
Experimentation	O
Ethics	O
Committee	O
of	O
the	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
.	O

All	O
efforts	O
were	O
made	O
to	O
minimize	O
the	O
number	O
and	O
suffering	O
of	O
animals	B-OG
needed	O
to	O
produce	O
reliable	O
data	O
.	O

2	O
.	O
5	O
.	O

Chronic	O
Unpredictable	O
Mild	O
Stress	O
(	O
CUMS	O
)	O

The	O
stress	O
procedure	O
performed	O
here	O
mainly	O
referred	O
to	O
Willner	O
[	O
6	O
]	O
with	O
some	O
modifications	O
.	O

Briefly	O
,	O
the	O
CUMS	O
protocol	O
consisted	O
of	O
the	O
sequential	O
application	O
of	O
a	O
variety	O
of	O
unpredictable	O
mild	O
stressors	O
:	O
(	O
1	O
)	O
food	O
deprivation	O
for	O
24	O
hours	O
,	O
(	O
2	O
)	O
water	O
deprivation	O
for	O
24	O
hours	O
,	O
(	O
3	O
)	O
exposure	O
to	O
an	O
empty	O
bottle	O
for	O
1	O
hour	O
,	O
(	O
4	O
)	O
cage	O
tilt	O
(	O
45	O
°)	O
for	O
7	O
hours	O
,	O
(	O
5	O
)	O
overnight	O
illumination	O
,	O
(	O
6	O
)	O
soiled	O
cage	O
(	O
200	O
mL	O
water	O
in	O
100	O
g	O
sawdust	O
bedding	O
)	O
for	O
24	O
hours	O
,	O
(	O
7	O
)	O
forced	O
swimming	O
at	O
8	O
°	O
C	O
for	O
6	O
minutes	O
,	O
(	O
8	O
)	O
physical	O
restraint	O
for	O
2	O
hours	O
,	O
and	O
(	O
9	O
)	O
exposure	O
to	O
a	O
foreign	O
object	O
(	O
e	O
.	O
g	O
.,	O
a	O
piece	O
of	O
plastic	O
)	O
for	O
24	O
hours	O
.	O

These	O
stressors	O
were	O
randomly	O
scheduled	O
over	O
a	O
one	O
-	O
week	O
period	O
and	O
repeated	O
throughout	O
the	O
4	O
weeks	O
of	O
experiment	O
(	O
Figure	O
1	O
).	O

Nonstressed	O
animals	B-OG
were	O
left	O
undisturbed	O
in	O
their	O
home	O
cages	O
except	O
during	O
housekeeping	O
procedures	O
such	O
as	O
cage	O
cleaning	O
.	O

2	O
.	O
6	O
.	O

Treatment	O
of	O
Animals	B-OG

In	O
experiments	O
,	O
animals	B-OG
were	O
randomized	O
into	O
seven	O
groups	O
of	O
ten	O
individuals	O
.	O

The	O
control	O
animals	B-OG
were	O
unstressed	O
and	O
intragastrically	O
given	O
daily	O
2	O
mL	O
distilled	O
water	O
.	O

For	O
another	O
six	O
groups	O
,	O
the	O
animals	B-OG
were	O
treated	O
simultaneously	O
with	O
CUMS	O
.	O

The	O
drugs	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
/	O
day	O
,	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
and	O
IMI	O
at	O
20	O
mg	O
/	O
kg	O
/	O
day	O
,	O
suspended	O
in	O
distilled	O
water	O
)	O
were	O
intragastrically	O
given	O
daily	O
1	O
h	O
before	O
the	O
stress	O
exposure	O
for	O
the	O
entire	O
4	O
weeks	O
.	O

Following	O
each	O
stress	O
session	O
,	O
animals	B-OG
were	O
returned	O
to	O
their	O
home	O
cages	O
and	O
were	O
able	O
to	O
access	O
food	O
and	O
water	O
freely	O
for	O
the	O
remainder	O
of	O
the	O
day	O
.	O

2	O
.	O
7	O
.	O

Rat	B-OG
Sucrose	B-CD
Preference	O
Test	O

Sucrose	B-CD
preference	O
test	O
was	O
carried	O
out	O
at	O
the	O
end	O
of	O
4	O
-	O
week	O
CUMS	O
exposure	O
.	O

The	O
test	O
was	O
performed	O
as	O
described	O
previously	O
[	O
7	O
]	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
after	O
one	O
week	O
of	O
the	O
single	O
cage	O
feeding	O
adaptation	O
,	O
the	O
rats	B-OG
received	O
a	O
week	O
of	O
double	O
bottle	O
training	O
.	O

One	O
bottle	O
was	O
1	O
%	O
sucrose	B-CD
solution	O
(	O
w	O
/	O
v	O
)	O
100	O
mL	O
(	O
in	O
the	O
cage	O
on	O
the	O
left	O
),	O
another	O
was	O
pure	O
water	O
100	O
mL	O
(	O
in	O
the	O
cage	O
on	O
the	O
right	O
),	O
and	O
two	O
bottles	O
were	O
fixed	O
.	O

Sucrose	B-CD
solution	O
and	O
pure	O
water	O
were	O
added	O
every	O
morning	O
.	O

After	O
one	O
-	O
week	O
training	O
,	O
the	O
rats	B-OG
were	O
deprived	O
of	O
water	O
and	O
food	O
for	O
24	O
hours	O
,	O
and	O
then	O
1	O
h	O
sucrose	B-CD
solution	O
consumption	O
experiments	O
were	O
conducted	O
to	O
measure	O
the	O
basis	O
of	O
sucrose	B-CD
preference	O
at	O
9	O
:	O
00	O
am	O
in	O
which	O
rats	B-OG
were	O
housed	O
in	O
individual	O
cages	O
and	O
were	O
free	O
to	O
access	O
two	O
bottles	O
.	O

After	O
4	O
weeks	O
of	O
experiment	O
,	O
the	O
sucrose	B-CD
preference	O
was	O
conducted	O
again	O
by	O
the	O
method	O
described	O
above	O
.	O

The	O
sucrose	B-CD
preference	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
sucrose	B-CD
preference	O
(%)	O
=	O
sucrose	B-CD
consumption	O
/	O
total	O
liquid	O
consumption	O
×	O
100	O
%	O
[	O
8	O
].	O

2	O
.	O
8	O
.	O

Forced	O
Swimming	O
Test	O
(	O
FST	O
)	O

The	O
forced	O
swimming	O
test	O
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Porsolt	O
[	O
9	O
]	O
with	O
modifications	O
.	O

Briefly	O
,	O
rats	B-OG
were	O
forced	O
to	O
swim	O
in	O
a	O
transparent	O
glass	O
vessel	O
(	O
25	O
cm	O
in	O
height	O
and	O
14	O
cm	O
in	O
diameter	O
)	O
filled	O
with	O
15	O
cm	O
of	O
water	O
at	O
24	O
±	O
1	O
°	O
C	O
.	O

The	O
total	O
duration	O
of	O
immobility	O
(	O
seconds	O
)	O
was	O
measured	O
during	O
the	O
last	O
4	O
minutes	O
of	O
a	O
single	O
6	O
-	O
minute	O
test	O
session	O
[	O
10	O
].	O

Rats	B-OG
were	O
considered	O
immobile	O
when	O
they	O
ceased	O
struggling	O
and	O
remained	O
floating	O
motionless	O
in	O
the	O
water	O
except	O
the	O
movements	O
necessary	O
to	O
keep	O
their	O
heads	O
above	O
the	O
water	O
.	O

Decrease	O
in	O
the	O
duration	O
of	O
immobility	O
during	O
the	O
FST	O
was	O
taken	O
as	O
a	O
measure	O
of	O
antidepressant	O
activity	O
.	O

2	O
.	O
9	O
.	O

Tail	O
Suspension	O
Test	O
(	O
TST	O
)	O

The	O
duration	O
of	O
immobility	O
time	O
induced	O
by	O
tail	O
suspension	O
was	O
measured	O
according	O
to	O
the	O
method	O
of	O
Steru	O
[	O
11	O
].	O

Rats	B-OG
both	O
acoustically	O
and	O
visually	O
isolated	O
were	O
suspended	O
above	O
the	O
floor	O
by	O
adhesive	O
tape	O
placed	O
approximately	O
1	O
cm	O
from	O
the	O
tip	O
of	O
the	O
tail	O
.	O

The	O
remaining	O
immobile	O
time	O
of	O
TST	O
was	O
quantified	O
for	O
6	O
min	O
.	O

Rats	B-OG
were	O
considered	O
immobile	O
only	O
when	O
they	O
hung	O
passively	O
and	O
completely	O
motionless	O
.	O

2	O
.	O
10	O
.	O

Open	O
-	O
Field	O
Test	O
(	O
OFT	O
)	O

The	O
OFT	O
was	O
based	O
on	O
the	O
method	O
of	O
Archer	O
[	O
12	O
].	O

The	O
OFT	O
apparatus	O
consisted	O
of	O
a	O
clear	O
acrylic	O
box	O
(	O
100	O
cm	O
×	O
100	O
cm	O
×	O
50	O
cm	O
)	O
with	O
a	O
lid	O
.	O

The	O
floor	O
was	O
divided	O
by	O
drawn	O
lines	O
into	O
36	O
areas	O
of	O
about	O
25	O
sq	O
.	O
cm	O
.	O

The	O
test	O
was	O
performed	O
in	O
a	O
light	O
-	O
and	O
sound	O
-	O
attenuated	O
shield	O
box	O
with	O
a	O
dim	O
light	O
.	O

The	O
locomotor	O
activity	O
counts	O
and	O
the	O
rearing	O
counts	O
were	O
recorded	O
for	O
5	O
min	O
.	O

All	O
test	O
sessions	O
were	O
recorded	O
by	O
a	O
video	O
camera	O
.	O

Between	O
subjects	O
,	O
the	O
box	O
was	O
thoroughly	O
cleaned	O
with	O
cotton	O
and	O
95	O
%	O
ethanol	O
.	O

2	O
.	O
11	O
.	O

CORT	B-GP
,	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
Contents	O
in	O
Plasma	O
Assays	O

After	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
all	O
rats	B-OG
were	O
sacrificed	O
by	O
decapitation	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
am	O
in	O
the	O
laboratory	O
.	O

After	O
decapitation	O
,	O
the	O
blood	O
samples	O
were	O
collected	O
into	O
heparinized	O
Eppendorf	O
tubes	O
and	O
immediately	O
centrifuged	O
for	O
1	O
min	O
(	O
10	O
,	O
000	O
rpm	O
)	O
at	O
4	O
°	O
C	O
to	O
separate	O
plasma	O
,	O
which	O
was	O
then	O
frozen	O
at	O
−	O
20	O
°	O
C	O
until	O
subsequent	O
assays	O
.	O

CORT	B-GP
,	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
contents	O
in	O
plasma	O
were	O
determined	O
by	O
using	O
competitive	O
radioimmunoassay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

2	O
.	O
12	O
.	O

CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
Contents	O
in	O
Hypothalamus	O
Assays	O

After	O
decapitation	O
,	O
the	O
brains	O
were	O
rapidly	O
removed	O
and	O
immersed	O
into	O
the	O
boiling	O
saline	O
for	O
5	O
min	O
.	O

Hypothalamus	O
was	O
dissected	O
according	O
to	O
the	O
method	O
described	O
by	O
Yan	O
et	O
al	O
.	O
[	O
13	O
],	O
weighed	O
,	O
and	O
then	O
homogenized	O
in	O
0	O
.	O
2	O
mL	O
of	O
1	O
M	O
acetic	O
acid	O
solution	O
.	O

After	O
incubation	O
for	O
100	O
minutes	O
at	O
room	O
temperature	O
,	O
homogenate	O
solution	O
was	O
mixed	O
with	O
0	O
.	O
2	O
mL	O
of	O
1	O
M	O
NaOH	O
solution	O
and	O
centrifuged	O
for	O
20	O
min	O
(	O
3500	O
rpm	O
)	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatants	O
were	O
collected	O
and	O
stored	O
at	O
−	O
40	O
°	O
C	O
.	O

Radioimmunoassay	O
was	O
performed	O
to	O
measure	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
in	O
hypothalamus	O
following	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

2	O
.	O
13	O
.	O

Monoamine	B-CD
and	O
Amino	B-CD
Acid	I-CD
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
Determination	O

After	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
all	O
rats	B-OG
were	O
sacrificed	O
by	O
decapitation	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
am	O
in	O
the	O
laboratory	O
.	O

After	O
decapitation	O
,	O
the	O
whole	O
rat	B-OG
brains	O
were	O
rapidly	O
removed	O
and	O
the	O
hippocampus	O
was	O
carefully	O
dissected	O
according	O
to	O
the	O
method	O
described	O
previously	O
[	O
14	O
].	O

The	O
contents	O
of	O
5	O
-	O
HT	O
,	O
5	O
-	O
hydroxyindoleacetic	O
acid	O
(	O
5	O
-	O
HIAA	O
),	O
DA	O
,	O
and	O
NE	O
in	O
hippocampus	O
were	O
determined	O
by	O
using	O
an	O
electrochemical	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
EC	O
-	O
HPLC	O
).	O

Tissues	O
were	O
placed	O
in	O
0	O
.	O
1	O
N	O
perchloric	O
acid	O
(	O
including	O
0	O
.	O
1	O
%	O
aminothiopropionic	O
acid	O
),	O
then	O
sonicated	O
,	O
and	O
centrifuged	O
twice	O
for	O
20	O
min	O
at	O
10	O
,	O
000	O
rpm	O
.	O

The	O
supernatants	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
being	O
analyzed	O
for	O
the	O
contents	O
of	O
DA	O
,	O
5	O
-	O
HT	O
,	O
and	O
NE	O
.	O

The	O
pellets	O
were	O
digested	O
in	O
1	O
mL	O
of	O
0	O
.	O
5	O
N	O
NaOH	O
for	O
measurements	O
of	O
protein	O
concentration	O
using	O
Bio	O
-	O
Rad	O
assay	O
reagents	O
.	O

For	O
EC	O
-	O
HPLC	O
analysis	O
,	O
samples	O
were	O
loaded	O
onto	O
a	O
Waters	O
7125	O
plus	O
autosampler	O
(	O
Waters	O
,	O
Milford	O
,	O
USA	O
)	O
and	O
the	O
mobile	O
phase	O
was	O
delivered	O
at	O
a	O
constant	O
rate	O
of	O
1	O
mL	O
/	O
min	O
by	O
a	O
Waters	O
Model	O
515	O
pump	O
(	O
Waters	O
,	O
Milford	O
,	O
USA	O
)	O
through	O
a	O
C18	O
,	O
5	O
mm	O
,	O
250	O
mm	O
×	O
4	O
.	O
6	O
mm	O
analytical	O
column	O
(	O
HiQsil	O
,	O
Japan	O
)	O
placed	O
in	O
a	O
column	O
heater	O
(	O
35	O
°	O
C	O
).	O

The	O
LC	O
amperometric	O
potential	O
was	O
set	O
to	O
0	O
.	O
75	O
V	O
with	O
reference	O
to	O
an	O
Ag	O
-	O
AgCl	O
reference	O
electrode	O
and	O
the	O
sensitivity	O
of	O
the	O
detector	O
was	O
modified	O
according	O
to	O
the	O
content	O
of	O
amines	B-CD
in	O
the	O
sample	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0	O
.	O
1	O
M	O
monosodium	O
phosphate	O
,	O
0	O
.	O
15	O
mM	O
EDTA	O
,	O
2	O
mM	O
NaCl	O
,	O
1	O
.	O
4	O
mM	O
octyl	O
sodium	O
sulfate	O
,	O
and	O
12	O
%	O
methanol	O
.	O

The	O
signal	O
from	O
the	O
detector	O
was	O
recorded	O
and	O
the	O
data	O
was	O
analyzed	O
using	O
a	O
N2000	O
Workstation	O
(	O
Institute	O
of	O
Intelligent	O
Information	O
Engineering	O
,	O
Zhejiang	O
University	O
,	O
Zhejiang	O
,	O
China	O
).	O

The	O
monoamine	B-CD
neurotransmitter	O
contents	O
were	O
expressed	O
as	O
ng	O
/	O
g	O
weight	O
of	O
tissue	O
.	O

Amino	B-CD
acids	I-CD
in	O
hippocampus	O
were	O
determined	O
by	O
OPA	O
precolumn	O
derivatization	O
and	O
RP	O
-	O
HPLC	O
with	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
Hewlett	O
-	O
Packed	O
1100	O
series	O
,	O
USA	O
).	O

The	O
derivatization	O
procedure	O
was	O
accomplished	O
by	O
an	O
online	O
autoinjector	O
.	O

The	O
derivatives	O
were	O
separated	O
on	O
a	O
Hypersil	O
ODS	O
and	O
the	O
signals	O
were	O
detected	O
with	O
a	O
programmable	O
fluorospectrophotometer	O
detector	O
.	O

Mobile	O
phase	O
A	O
was	O
10	O
mmol	O
/	O
L	O
,	O
PH	O
7	O
.	O
2	O
sodium	O
phosphate	O
buffer	O
(	O
PB	O
)	O
containing	O
0	O
.	O
5	O
%	O
(	O
φ	O
)	O
tetrahydrofuran	O
,	O
and	O
B	O
was	O
PB	O
-	O
methanol	O
-	O
acetonitrile	O
(	O
50	O
:	O
35	O
:	O
15	O
by	O
volume	O
).	O

The	O
elution	O
program	O
was	O
100	O
%	O
A	O
with	O
0	O
%	O
B	O
at	O
the	O
start	O
(	O
0	O
min	O
)	O
and	O
0	O
%	O
A	O
with	O
100	O
%	O
B	O
at	O
the	O
end	O
(	O
25	O
min	O
)	O
of	O
the	O
program	O
.	O

OPA	O
-	O
reactive	O
compounds	O
were	O
detected	O
at	O
excitation	O
wavelength	O
of	O
340	O
nm	O
and	O
emission	O
wavelength	O
of	O
450	O
nm	O
,	O
and	O
chromatograms	O
were	O
analyzed	O
.	O

2	O
.	O
14	O
.	O

Statistical	O
Analysis	O

The	O
data	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
).	O

The	O
significance	O
of	O
the	O
difference	O
was	O
statistically	O
evaluated	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
as	O
well	O
as	O
the	O
least	O
significant	O
difference	O
test	O
.	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

3	O
.	O

Results	O

3	O
.	O
1	O
.	O

Sucrose	B-CD
Preference	O
Test	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
CUMS	O
decreased	O
the	O
sucrose	B-CD
preference	O
in	O
rats	B-OG
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
sucrose	B-CD
preference	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
2	O
).	O

3	O
.	O
2	O
.	O

Forced	O
Swimming	O
Test	O
(	O
FST	O
)	O
in	O
Each	O
Group	O

In	O
FST	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
duration	O
of	O
immobility	O
in	O
rats	B-OG
with	O
CUMS	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
duration	O
of	O
immobility	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
3	O
).	O

3	O
.	O
3	O
.	O

Tail	O
Suspension	O
Test	O
(	O
TST	O
)	O
in	O
Each	O
Group	O

In	O
TST	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
duration	O
of	O
immobility	O
in	O
rats	B-OG
with	O
CUMS	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
duration	O
of	O
immobility	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
4	O
).	O

3	O
.	O
4	O
.	O

Open	O
-	O
Field	O
Test	O
(	O
OFT	O
)	O
in	O
Each	O
Group	O

In	O
the	O
OFT	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
the	O
locomotor	O
activity	O
and	O
the	O
rearing	O
counts	O
for	O
5	O
min	O
were	O
lower	O
in	O
the	O
rats	B-OG
with	O
CUMS	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
results	O
showed	O
that	O
the	O
rats	B-OG
with	O
CUMS	O
appeared	O
to	O
have	O
depressant	O
-	O
like	O
behavioral	O
changes	O
.	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
and	O
the	O
rearing	O
counts	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
5	O
).	O

3	O
.	O
5	O
.	O

CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
Contents	O
in	O
Plasma	O
and	O
Hypothalamus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
2	O
,	O
CUMS	O
significantly	O
increased	O
the	O
contents	O
of	O
CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
plasma	O
in	O
rats	B-OG
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
contents	O
of	O
CRH	B-GP
and	O
ACTH	B-GP
in	O
hypothalamus	O
in	O
rats	B-OG
with	O
CUMS	O
were	O
also	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
CUMS	B-DS
group	O
,	O
FA	O
at	O
0	O
.	O
172	O
g	O
/	O
kg	O
,	O
FB	O
at	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
contents	O
in	O
plasma	O
and	O
hypothalamus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
6	O
.	O

AVP	B-GP
Contents	O
in	O
Plasma	O
and	O
Hypothalamus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
3	O
,	O
CUMS	O
significantly	O
increased	O
the	O
AVP	B-GP
contents	O
both	O
in	O
hypothalamus	O
and	O
in	O
plasma	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
AVP	B-GP
contents	O
could	O
be	O
significantly	O
decreased	O
in	O
both	O
hypothalamus	O
and	O
plasma	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
7	O
.	O

Monoamine	O
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
4	O
and	O
Figures	O
6	O
and	O
7	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
CUMS	B-DS
markedly	O
decreased	O
the	O
contents	O
of	O
5	O
-	O
HT	O
and	O
DA	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
increased	O
the	O
NE	O
content	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
contents	O
of	O
5	O
-	O
HT	O
and	O
DA	O
and	O
decreased	O
the	O
content	O
of	O
NE	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

As	O
a	O
positive	O
control	O
,	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
could	O
increase	O
the	O
5	O
-	O
HT	O
content	O
and	O
decrease	O
the	O
NE	O
content	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
but	O
had	O
no	O
effect	O
on	O
DA	O
.	O

As	O
a	O
metabolite	O
of	O
serotonin	B-CD
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
could	O
be	O
used	O
as	O
an	O
index	O
for	O
the	O
turnover	O
of	O
5	O
-	O
HT	O
[	O
15	O
,	O
16	O
].	O

Here	O
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
was	O
calculated	O
.	O

The	O
amount	O
of	O
5	O
-	O
HIAA	O
was	O
not	O
altered	O
in	O
hippocampus	O
of	O
rat	B-OG
with	O
CUMS	O
(	O
Table	O
4	O
).	O

FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
as	O
well	O
as	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
elevated	O
the	O
amount	O
of	O
5	O
-	O
HIAA	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
significantly	O
increased	O
by	O
CUMS	O
,	O
which	O
could	O
be	O
reversed	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
).	O

3	O
.	O
8	O
.	O

Amino	B-CD
Acid	I-CD
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
in	O
Each	O
Group	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
GABA	O
and	O
Tau	B-GP
contents	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
the	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
8	O
)	O
but	O
had	O
no	O
effects	O
on	O
GABA	O
and	O
Tau	O
.	O

4	O
.	O

Discussion	O

Traditional	O
Chinese	O
medicine	O
has	O
offered	O
a	O
possible	O
therapy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

DZXYS	O
,	O
an	O
ancient	O
Chinese	O
herbal	O
decoction	O
,	O
has	O
been	O
used	O
in	O
Chinese	O
medicinal	O
herbal	O
mixture	O
for	O
antidepression	O
.	O

However	O
,	O
its	O
action	O
mechanism	O
has	O
not	O
been	O
revealed	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
provided	O
different	O
lines	O
of	O
evidence	O
to	O
support	O
the	O
antidepression	O
role	O
of	O
DZXYS	B-CD
in	O
CUMS	O
rat	B-OG
model	O
system	O
.	O

The	O
pathogenesis	O
of	O
depression	B-DS
model	O
established	O
by	O
using	O
stress	O
factors	O
is	O
more	O
consistent	O
with	O
that	O
of	O
depression	B-DS
in	O
human	B-OG
beings	O
.	O

The	O
symptoms	O
such	O
as	O
reduced	O
activity	O
,	O
decreased	O
exploratory	O
behavior	O
,	O
and	O
reduced	O
sucrose	B-CD
preference	O
appear	O
in	O
stressed	O
animals	B-OG
,	O
which	O
are	O
similar	O
to	O
the	O
changes	O
of	O
behavior	O
and	O
the	O
loss	O
of	O
interest	O
or	O
pleasure	O
in	O
the	O
clinical	O
diagnosis	O
of	O
depression	B-DS
[	O
17	O
].	O

The	O
CUMS	O
model	O
of	O
depression	B-DS
is	O
accepted	O
as	O
a	O
valuable	O
method	O
for	O
evaluating	O
antidepressant	O
effects	O
in	O
animals	B-OG
.	O

In	O
the	O
present	O
study	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
prepared	O
from	O
DZXYS	O
exhibited	O
a	O
significant	O
increase	O
of	O
sucrose	B-CD
preference	O
in	O
the	O
rats	B-OG
with	O
CUMS	O
.	O

The	O
FST	O
,	O
TST	O
,	O
and	O
OFT	O
are	O
the	O
most	O
widely	O
used	O
as	O
behavioral	O
tools	O
for	O
assessing	O
antidepressant	O
activity	O
[	O
18	O
,	O
19	O
].	O

Characteristic	O
of	O
rat	B-OG
behaviors	O
scored	O
in	O
both	O
tests	O
is	O
termed	O
immobility	O
,	O
which	O
reflects	O
behavioral	O
despair	O
as	O
seen	O
in	O
human	B-OG
depression	B-DS
.	O

The	O
duration	O
of	O
immobility	O
time	O
in	O
rats	B-OG
that	O
are	O
trapped	O
and	O
forced	O
to	O
swim	O
is	O
closely	O
related	O
to	O
helplessness	O
[	O
20	O
].	O

It	O
was	O
observed	O
from	O
our	O
results	O
that	O
there	O
was	O
significant	O
prolongation	O
of	O
immobility	O
time	O
in	O
these	O
groups	O
after	O
modeling	O
.	O

The	O
two	O
fractions	O
at	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
respectively	O
,	O
could	O
significantly	O
decrease	O
the	O
duration	O
of	O
immobility	O
both	O
in	O
FST	O
and	O
in	O
TST	O
and	O
significantly	O
increase	O
the	O
locomotor	O
activity	O
in	O
OFT	O
.	O

These	O
results	O
may	O
further	O
confirm	O
that	O
the	O
DZXYS	B-GP
has	O
an	O
antidepressant	O
activity	O
.	O

The	O
nervous	O
system	O
and	O
the	O
endocrine	O
system	O
are	O
closely	O
related	O
,	O
which	O
constitute	O
a	O
complete	O
network	O
to	O
maintain	O
homeostasis	O
.	O

HPA	O
axis	O
activation	O
and	O
the	O
resulting	O
increase	O
in	O
glucocorticoid	B-CD
(	O
GC	O
)	O
secretion	O
are	O
the	O
two	O
most	O
important	O
features	O
of	O
the	O
stress	O
response	O
.	O

When	O
in	O
stress	O
state	O
,	O
the	O
hypothalamus	O
releases	O
CRH	B-GP
and	O
AVP	B-GP
in	O
response	O
to	O
a	O
stressor	O
,	O
which	O
in	O
turn	O
activate	O
the	O
secretion	O
of	O
ACTH	B-GP
from	O
the	O
pituitary	O
,	O
which	O
finally	O
stimulates	O
the	O
secretion	O
of	O
cortisol	B-CD
(	O
in	O
humans	B-OG
)	O
or	O
CORT	O
(	O
in	O
rodents	B-OG
)	O
from	O
the	O
adrenal	O
cortex	O
[	O
21	O
].	O

From	O
the	O
actual	O
situation	O
of	O
human	B-OG
depression	B-DS
,	O
stressful	O
life	O
events	O
play	O
an	O
important	O
role	O
in	O
depression	B-DS
.	O

Stressor	O
or	O
stressful	O
environment	O
usually	O
precedes	O
depressive	O
symptoms	O
,	O
which	O
leads	O
to	O
neurobiochemical	O
changes	O
associated	O
with	O
depression	B-DS
[	O
17	O
].	O

Since	O
the	O
1970s	O
,	O
people	O
have	O
found	O
that	O
the	O
HPA	O
axis	O
is	O
involved	O
in	O
the	O
pathological	O
mechanism	O
of	O
depression	B-DS
.	O

Many	O
studies	O
suggested	O
that	O
HPA	O
axis	O
activation	O
results	O
in	O
some	O
of	O
the	O
symptoms	O
and	O
signs	O
in	O
depression	B-DS
[	O
22	O
].	O

Moreover	O
,	O
it	O
has	O
been	O
found	O
that	O
the	O
damage	O
of	O
HPA	O
axis	O
is	O
more	O
severe	O
in	O
patients	O
with	O
refractory	O
depression	B-DS
[	O
23	O
].	O

Hyperactivity	O
of	O
HPA	O
axis	O
often	O
occurs	O
in	O
both	O
depressed	O
patients	O
and	O
animal	B-OG
models	O
,	O
which	O
is	O
mainly	O
presented	O
as	O
hypersecreted	O
CRH	B-GP
and	O
higher	O
contents	O
of	O
ACTH	B-GP
and	O
GC	O
[	O
24	O
,	O
25	O
].	O

Combined	O
with	O
receptors	O
in	O
multiple	O
target	O
tissues	O
(	O
including	O
HPA	O
axis	O
),	O
GC	O
could	O
exert	O
physiological	O
effects	O
.	O

When	O
in	O
state	O
of	O
stress	O
,	O
GC	O
is	O
hypersecreted	O
and	O
then	O
combined	O
with	O
glucocorticoid	B-GP
receptor	I-GP
(	O
GR	B-GP
),	O
thereby	O
inhibiting	O
the	O
hypothalamus	O
to	O
secrete	O
CRF	B-GP
and	O
AVP	B-GP
by	O
negative	O
feedback	O
to	O
restore	O
the	O
hyperactivated	O
HPA	O
axis	O
to	O
the	O
basal	O
level	O
.	O

However	O
,	O
chronic	O
stress	O
could	O
result	O
in	O
the	O
state	O
of	O
persistent	O
hyperactivity	O
of	O
the	O
HPA	O
axis	O
;	O
excessive	O
GC	O
constantly	O
stimulates	O
GR	B-GP
,	O
which	O
leads	O
to	O
the	O
injury	O
of	O
hippocampal	O
neurons	O
and	O
the	O
dysfunction	O
of	O
emotion	O
regulation	O
center	O
,	O
and	O
then	O
induces	O
depression	B-DS
[	O
26	O
].	O

As	O
observed	O
in	O
our	O
experiment	O
,	O
the	O
CUMS	O
could	O
significantly	O
increase	O
the	O
contents	O
of	O
CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
both	O
plasma	O
and	O
hypothalamus	O
in	O
rats	B-OG
,	O
accompanied	O
by	O
the	O
depressive	O
-	O
like	O
behavioral	O
alterations	O
;	O
thus	O
,	O
we	O
confirmed	O
that	O
HPA	O
axis	O
hyperactivity	O
is	O
related	O
to	O
the	O
pathogenesis	O
of	O
depression	B-DS
.	O

Results	O
from	O
the	O
present	O
study	O
demonstrated	O
that	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
prepared	O
from	O
DZXYS	O
could	O
significantly	O
decrease	O
the	O
CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
contents	O
in	O
plasma	O
and	O
hypothalamus	O
,	O
which	O
suggested	O
that	O
antidepressant	O
effects	O
exerted	O
by	O
DZXYS	O
were	O
partly	O
due	O
to	O
inhibiting	O
the	O
hyperactivity	O
of	O
the	O
HPA	O
axis	O
.	O

Some	O
previous	O
studies	O
have	O
shown	O
that	O
there	O
are	O
significant	O
increases	O
of	O
AVP	B-GP
neurons	O
expression	O
and	O
AVP	B-GP
level	O
in	O
the	O
paraventricular	O
nucleus	O
,	O
AVP	B-GP
reactivity	O
in	O
the	O
pituitary	O
,	O
and	O
AVP	B-GP
mRNA	O
expression	O
in	O
the	O
supraoptic	O
nucleus	O
in	O
depressed	O
patients	O
[	O
27	O
,	O
28	O
],	O
which	O
also	O
suggests	O
that	O
AVP	B-GP
changes	O
in	O
the	O
paraventricular	O
nucleus	O
and	O
supraoptic	O
nucleus	O
may	O
be	O
the	O
basis	O
for	O
the	O
onset	O
of	O
depression	B-DS
.	O

In	O
addition	O
,	O
AVP	B-GP
level	O
in	O
the	O
plasma	O
in	O
depressed	O
patients	O
is	O
higher	O
than	O
that	O
in	O
the	O
healthy	O
control	O
group	O
,	O
which	O
is	O
related	O
to	O
the	O
severity	O
of	O
the	O
disease	O
[	O
29	O
].	O

AVP	B-GP
,	O
a	O
nonapeptide	O
synthesized	O
in	O
hypothalamic	O
nuclei	O
,	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
HPA	O
axis	O
representing	O
a	O
major	O
component	O
of	O
the	O
stress	O
response	O
.	O

CRH	B-GP
and	O
AVP	B-GP
act	O
synergistically	O
in	O
bringing	O
about	O
ACTH	B-GP
release	O
from	O
the	O
corticotropes	O
of	O
the	O
anterior	O
pituitary	O
,	O
which	O
in	O
turn	O
stimulates	O
cortisol	B-CD
output	O
from	O
the	O
adrenal	O
cortex	O
.	O

AVP	B-GP
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
depression	B-DS
by	O
regulating	O
the	O
HPA	O
axis	O
function	O
[	O
30	O
].	O

In	O
order	O
to	O
further	O
explore	O
the	O
effect	O
of	O
DZXYS	O
on	O
HPA	O
axis	O
,	O
the	O
levels	O
of	O
AVP	B-GP
in	O
plasma	O
and	O
hypothalamus	O
were	O
measured	O
in	O
the	O
present	O
study	O
.	O

Our	O
results	O
showed	O
that	O
,	O
in	O
rats	B-OG
with	O
CUMS	O
,	O
AVP	B-GP
levels	O
significantly	O
increased	O
in	O
plasma	O
and	O
hypothalamus	O
,	O
which	O
could	O
be	O
significantly	O
reversed	O
by	O
the	O
treatment	O
of	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
).	O

Combined	O
with	O
the	O
results	O
of	O
HPA	O
axis	O
determination	O
in	O
our	O
study	O
,	O
it	O
suggested	O
that	O
DZXYS	O
could	O
regulate	O
the	O
HPA	O
axis	O
by	O
acting	O
on	O
the	O
AVP	B-GP
to	O
exert	O
antidepressant	O
effect	O
.	O

As	O
a	O
significant	O
contribution	O
to	O
depression	B-DS
,	O
“	O
monoamine	O
hypothesis	O
”	O
has	O
been	O
proposed	O
in	O
the	O
20th	O
century	O
,	O
thereby	O
setting	O
up	O
the	O
foundation	O
for	O
today	O
'	O
s	O
antidepressant	O
treatment	O
.	O

Monoamine	O
neurotransmitters	O
,	O
such	O
as	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
,	O
are	O
the	O
important	O
bioactive	O
substances	O
in	O
central	O
nervous	O
system	O
which	O
participate	O
in	O
many	O
physiological	O
activities	O
of	O
the	O
body	O
,	O
including	O
emotion	O
,	O
learning	O
,	O
and	O
memory	O
.	O

NE	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
arousal	O
and	O
is	O
involved	O
in	O
the	O
brain	O
reward	O
system	O
and	O
learning	O
and	O
memory	O
function	O
.	O

The	O
concentration	O
of	O
NE	O
in	O
the	O
hypothalamus	O
is	O
significantly	O
decreased	O
,	O
which	O
suggests	O
that	O
the	O
dysfunction	O
of	O
central	O
NE	O
is	O
related	O
to	O
depression	B-DS
[	O
31	O
].	O

Dysfunction	O
of	O
5	O
-	B-GP
HT	O
is	O
related	O
to	O
depressed	B-DS
mood	O
,	O
anxiety	B-DS
,	O
inhibition	O
of	O
movement	O
,	O
loss	O
of	O
appetite	O
,	O
sleep	B-DS
disorders	I-DS
,	O
circadian	B-DS
rhythm	I-DS
disorders	I-DS
,	O
and	O
so	O
on	O
in	O
depression	B-DS
[	O
32	O
].	O

Dopamine	B-CD
(	O
DA	O
)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
motivation	O
,	O
volition	O
,	O
interest	O
/	O
pleasure	O
,	O
and	O
attention	O
/	O
concentration	O
,	O
all	O
of	O
which	O
are	O
likely	O
to	O
be	O
impaired	O
in	O
depressed	O
patients	O
.	O

Several	O
previous	O
reports	O
have	O
suggested	O
that	O
depression	B-DS
may	O
often	O
be	O
accompanied	O
by	O
a	O
relative	O
hypodopaminergic	O
state	O
[	O
33	O
].	O

According	O
to	O
the	O
“	O
monoamine	B-CD
hypothesis	O
,”	O
the	O
decreased	O
releasing	O
and	O
lower	O
contents	O
in	O
the	O
synapse	O
of	O
5	O
-	O
HT	O
,	O
DA	O
,	O
or	O
NE	O
in	O
central	O
nervous	O
system	O
are	O
involved	O
in	O
pathogenesis	O
of	O
depression	B-DS
.	O

Thus	O
,	O
it	O
is	O
well	O
known	O
that	O
many	O
antidepressant	O
drugs	O
currently	O
in	O
use	O
exert	O
effects	O
by	O
regulating	O
the	O
reuptake	O
and	O
metabolic	O
balance	O
of	O
monoamine	O
neurotransmitters	O
[	O
34	O
].	O

Our	O
experimental	O
results	O
showed	O
that	O
the	O
5	O
-	O
HT	O
and	O
DA	O
contents	O
significantly	O
decreased	O
,	O
while	O
the	O
NE	O
content	O
and	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
significantly	O
increased	O
in	O
hippocampus	O
in	O
rats	B-OG
,	O
accompanied	O
by	O
the	O
depressive	O
-	O
like	O
behavioral	O
alterations	O
,	O
which	O
confirm	O
that	O
the	O
dysfunction	O
of	O
monoamine	B-CD
neurotransmitters	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
depression	B-DS
.	O

Amino	B-CD
acid	I-CD
neurotransmitters	O
can	O
be	O
divided	O
into	O
two	O
types	O
of	O
excitatory	O
amino	B-CD
acid	I-CD
and	O
inhibitory	O
amino	B-CD
acid	I-CD
;	O
the	O
former	O
includes	O
Glu	O
and	O
Asp	O
,	O
while	O
GABA	O
and	O
Tau	O
belong	O
to	O
the	O
latter	O
.	O

Some	O
of	O
the	O
studies	O
,	O
whether	O
in	O
rodent	O
models	O
of	O
depression	B-DS
or	O
in	O
depressed	O
patients	O
,	O
indicate	O
that	O
the	O
increase	O
of	O
the	O
Glu	O
concentration	O
is	O
closely	O
related	O
to	O
depression	B-DS
[	O
35	O
].	O

As	O
an	O
important	O
inhibitory	O
neurotransmitter	O
in	O
the	O
brain	O
,	O
GABA	O
decreases	O
significantly	O
in	O
the	O
patients	O
of	O
depression	B-DS
[	O
36	O
].	O

Therefore	O
,	O
the	O
change	O
of	O
the	O
ratio	O
of	O
excitatory	O
/	O
inhibitory	O
amino	B-CD
acid	I-CD
in	O
the	O
brain	O
has	O
an	O
important	O
influence	O
on	O
the	O
incidence	O
of	O
depression	B-DS
[	O
37	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
significantly	O
increased	O
,	O
while	O
the	O
GABA	O
and	O
Tau	B-GP
contents	O
decreased	O
in	O
hippocampus	O
in	O
depressed	O
rats	B-OG
;	O
it	O
is	O
suggested	O
that	O
CUMS	O
could	O
lead	O
to	O
the	O
imbalance	O
of	O
excitatory	O
/	O
inhibitory	O
amino	B-CD
acids	I-CD
in	O
the	O
brain	O
,	O
which	O
may	O
account	O
for	O
the	O
mechanism	O
underlying	O
the	O
behavioral	O
changes	O
in	O
rats	B-OG
.	O

In	O
the	O
rat	B-OG
and	O
other	O
mammalian	O
species	O
,	O
including	O
human	B-OG
beings	O
,	O
HPA	O
axis	O
and	O
neurotransmitters	O
system	O
are	O
closely	O
interacted	O
in	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
(	O
particularly	O
in	O
hippocampus	O
)	O
and	O
greatly	O
involved	O
in	O
stress	B-DS
related	I-DS
disorder	I-DS
[	O
38	O
,	O
39	O
].	O

Under	O
the	O
chronic	O
stress	O
,	O
as	O
high	O
concentration	O
of	O
GC	O
could	O
induce	O
the	O
liver	O
to	O
produce	O
tryptophan	B-GP
pyrrole	I-GP
enzyme	I-GP
,	O
it	O
could	O
degrade	O
the	O
tryptophan	B-CD
in	O
the	O
blood	O
.	O

Tryptophan	B-CD
is	O
the	O
precursor	O
of	O
5	O
-	O
HT	O
and	O
its	O
reduction	O
could	O
lead	O
to	O
synthesis	O
of	O
5	O
-	O
HT	O
and	O
so	O
lead	O
to	O
5	O
-	O
HT	O
content	O
decrease	O
in	O
the	O
brain	O
,	O
thus	O
causing	O
depressive	O
symptoms	O
[	O
40	O
].	O

In	O
a	O
stress	O
state	O
,	O
HPA	O
axis	O
function	O
becomes	O
hyperactive	O
and	O
5	O
-	O
HT	O
synthesis	O
significantly	O
decreases	O
as	O
a	O
result	O
of	O
insufficient	O
tryptophan	B-CD
transported	O
into	O
the	O
CNS	O
[	O
41	O
].	O

Moreover	O
,	O
high	O
concentration	O
of	O
GC	O
can	O
make	O
5	B-GP
-	I-GP
HT	I-GP
transporter	I-GP
(	O
5	B-GP
-	I-GP
HTT	I-GP
)	O
expression	O
increase	O
in	O
hippocampus	O
,	O
amygdala	O
,	O
dorsal	O
raphe	O
nucleus	O
,	O
and	O
other	O
brain	O
areas	O
by	O
GR	B-GP
dependent	O
manner	O
.	O

The	O
increased	O
5	O
-	O
HTT	O
will	O
increase	O
the	O
reuptake	O
of	O
5	O
-	O
HT	O
in	O
synaptic	O
cleft	O
,	O
which	O
aggravates	O
the	O
decrease	O
of	O
5	O
-	O
HT	O
concentration	O
and	O
the	O
severity	O
of	O
the	O
symptoms	O
in	O
depressed	O
patients	O
[	O
42	O
].	O

Stress	O
can	O
affect	O
the	O
excitability	O
of	O
neurons	O
of	O
locus	O
coeruleus	O
(	O
LC	O
),	O
raphe	O
nucleus	O
,	O
and	O
substantia	O
nigra	O
by	O
HPA	O
axis	O
and	O
5	O
-	O
HT	O
and	O
NE	O
/	O
DA	O
play	O
an	O
important	O
role	O
in	O
the	O
change	O
of	O
emotion	O
and	O
mood	O
[	O
43	O
].	O

In	O
the	O
study	O
of	O
social	O
stress	O
in	O
mice	B-OG
,	O
by	O
using	O
the	O
intracellular	O
recording	O
technique	O
in	O
vitro	O
,	O
it	O
is	O
found	O
that	O
CRH	B-GP
can	O
directly	O
activate	O
noradrenergic	O
neurons	O
of	O
the	O
LC	O
,	O
thus	O
resulting	O
in	O
the	O
increase	O
of	O
NE	O
in	O
the	O
brain	O
[	O
44	O
].	O

In	O
addition	O
,	O
some	O
of	O
the	O
studies	O
indicate	O
that	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
can	O
stimulate	O
the	O
hypothalamus	O
to	O
secret	O
CRH	B-GP
,	O
which	O
suggest	O
that	O
a	O
positive	O
feedback	O
neural	O
circuit	O
exists	O
between	O
hypothalamic	O
neurons	O
and	O
neurons	O
secreting	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
[	O
45	O
].	O

In	O
chronic	O
stress	O
,	O
high	O
GC	O
concentration	O
may	O
increase	O
the	O
releasing	O
of	O
excitatory	O
amino	B-CD
acid	I-CD
from	O
the	O
synaptic	O
vesicle	O
of	O
the	O
glutamatergic	O
nerve	O
endings	O
and	O
inhibit	O
its	O
reuptake	O
at	O
the	O
same	O
time	O
,	O
which	O
causes	O
the	O
persistent	O
increase	O
of	O
excitatory	O
amino	B-CD
acid	I-CD
[	O
46	O
].	O

The	O
accumulation	O
of	O
Glu	O
can	O
cause	O
hippocampal	O
toxicity	O
,	O
and	O
the	O
high	O
level	O
of	O
extracellular	O
Glu	O
may	O
in	O
turn	O
make	O
the	O
HPA	O
axis	O
more	O
hyperactive	O
to	O
secrete	O
more	O
GC	O
[	O
47	O
].	O

Glu	O
directly	O
injected	O
into	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
in	O
hypothalamus	O
could	O
accelerate	O
the	O
release	O
of	O
ACTH	B-GP
[	O
48	O
].	O

GABA	O
could	O
inhibit	O
the	O
releasing	O
of	O
ACTH	B-GP
,	O
CORT	B-GP
,	O
and	O
CRH	B-GP
in	O
hypothalamus	O
and	O
reregulate	O
the	O
hyperactivity	O
of	O
HPA	O
axis	O
;	O
Tau	B-GP
,	O
as	O
an	O
inhibitory	O
amino	B-CD
acid	I-CD
,	O
has	O
the	O
synergistic	O
action	O
with	O
GABA	O
to	O
exert	O
the	O
effect	O
on	O
inhibiting	O
the	O
activation	O
of	O
HPA	O
axis	O
[	O
49	O
,	O
50	O
].	O

Our	O
data	O
indicated	O
that	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
5	O
-	O
HT	O
and	O
DA	O
contents	O
and	O
decreased	O
the	O
NE	O
content	O
in	O
the	O
hippocampus	O
;	O
meanwhile	O
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
in	O
rats	B-OG
with	O
CUMS	B-DS
could	O
be	O
reversed	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
which	O
may	O
account	O
for	O
primary	O
monoamine	O
neurotransmitters	O
regulating	O
mechanism	O
underlying	O
DZXYS	O
antidepressant	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
although	O
having	O
no	O
effects	O
on	O
GABA	O
and	O
Tau	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
,	O
which	O
suggested	O
that	O
DZXYS	O
could	O
reduce	O
the	O
excitatory	O
toxicity	O
caused	O
by	O
the	O
accumulation	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
in	O
depressed	O
rats	B-OG
,	O
partly	O
regulating	O
the	O
imbalance	O
of	O
the	O
ratio	O
of	O
excitatory	O
/	O
inhibitory	O
amino	B-CD
acid	I-CD
that	O
may	O
be	O
involved	O
in	O
its	O
antidepressant	O
effects	O
.	O

There	O
is	O
a	O
close	O
relationship	O
between	O
HAP	O
and	O
neurotransmitters	O
in	O
regulating	O
emotion	O
and	O
behavior	O
in	O
depression	B-DS
[	O
51	O
].	O

As	O
observed	O
in	O
our	O
experiment	O
,	O
it	O
could	O
be	O
speculated	O
that	O
the	O
amelioration	O
produced	O
by	O
DZXYS	O
on	O
the	O
neurotransmitter	O
system	O
may	O
be	O
associated	O
with	O
its	O
effect	O
on	O
HPA	O
axis	O
.	O

However	O
,	O
the	O
cellular	O
and	O
molecular	O
biological	O
mechanism	O
of	O
exerting	O
regulating	O
effect	O
of	O
DZXYS	O
between	O
the	O
HPA	O
axis	O
and	O
neurotransmitters	O
remains	O
to	O
be	O
further	O
studied	O
in	O
the	O
future	O
.	O

In	O
conclusion	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
antidepressant	O
effects	O
of	O
two	O
fractions	O
(	O
petroleum	O
ether	O
soluble	O
fraction	O
,	O
FA	O
,	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
,	O
FB	O
)	O
prepared	O
from	O
DZXYS	O
were	O
observed	O
.	O

The	O
results	O
demonstrated	O
that	O
DZXYS	O
could	O
ameliorate	O
the	O
depression	B-DS
-	O
like	O
behavior	O
in	O
chronic	O
stress	O
model	O
of	O
rats	B-OG
.	O

The	O
mechanisms	O
of	O
action	O
of	O
DZXYS	O
might	O
be	O
accounted	O
for	O
by	O
inhibiting	O
hyperactivity	O
of	O
HPA	O
axis	O
and	O
modulating	O
monoamine	B-CD
and	O
amino	B-CD
acid	I-CD
neurotransmitters	O
in	O
the	O
hippocampus	O
.	O

Thus	O
,	O
we	O
confirmed	O
that	O
DZXYS	O
has	O
the	O
potential	O
to	O
be	O
a	O
beneficial	O
remedy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

Because	O
of	O
multiple	O
using	O
of	O
plants	B-OG
in	O
a	O
traditional	O
herbal	O
medicine	O
and	O
the	O
complexity	O
of	O
the	O
pathological	O
mechanism	O
of	O
depression	B-DS
,	O
it	O
is	O
undoubted	O
that	O
there	O
exist	O
more	O
other	O
active	O
fractions	O
from	O
DZXYS	O
and	O
further	O
regulatory	O
mechanisms	O
of	O
DZXYS	O
in	O
antidepression	O
.	O

These	O
works	O
are	O
currently	O
being	O
conducted	O
in	O
our	O
laboratory	O
.	O

Schedule	O
of	O
chronic	O
unpredictable	O
mild	O
stress	O
(	O
CUMS	O
)	O
procedure	O
.	O

The	O
CUMS	O
protocol	O
consisted	O
of	O
the	O
sequential	O
application	O
of	O
a	O
variety	O
of	O
unpredictable	O
mild	O
stressors	O
.	O

These	O
stressors	O
were	O
randomly	O
scheduled	O
over	O
a	O
one	O
-	O
week	O
period	O
from	O
day	O
1	O
to	O
day	O
7	O
and	O
repeated	O
for	O
4	O
weeks	O
during	O
the	O
entire	O
experiment	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
sucrose	B-CD
consumption	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
FST	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
TST	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
OFT	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
DA	O
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
NE	O
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
Glu	O
,	O
Asp	O
,	O
GABA	O
,	O
and	O
Tau	B-GP
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
05	O
and	O
∗∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

Different	O
components	O
in	O
the	O
formula	O
of	O
DZXYS	O
.	O

Pharmaceutical	O
name	O

Family	O
name	O

Plant	B-OG
part	O

Chinese	O
name	O

Radix	O
Bupleuri	O

Umbelliferae	O

Root	O

Chai	O
hu	O

Paeoniae	O
Radix	O
Alba	O

Ranunculaceae	O

Root	O

Bai	O
shao	O

Angelica	O
sinensis	O

Umbelliferae	O

Root	O

Dang	O
gui	O

Bighead	O
atractylodes	O
rhizome	O

Compositae	O

Rhizoma	B-DS

Bai	O
zhu	O

Poria	B-OG
cocos	O

Polyporaceae	O

Sclerotium	O

Fu	B-OG
ling	O

Bark	O
of	O
tree	B-OG
peony	O
root	O

Ranunculaceae	O

Root	O
-	O
bark	O

Mu	O
dan	O
pi	O

Fructus	O
Gardeniae	O

Rubiaceae	B-OG

Fruit	O

Zhi	O
zi	O

Mentha	O
haplocalyx	O

Lamiaceae	O

Leaf	O

Bo	O
he	O

Licorice	B-CD

Leguminosae	O

Root	O

Gan	O
cao	O

The	O
contents	O
of	O
CORT	B-GP
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
plasma	O
and	O
hypothalamus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

CORT	O

CRH	B-GP

ACTH	B-GP

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
ng	O
/	O
g	O
)	O

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
ng	O
/	O
g	O
)	O

Control	O

—	O

12	O
.	O
60	O
±	O
6	O
.	O
88	O

3	O
.	O
31	O
±	O
0	O
.	O
64	O

20	O
.	O
65	O
±	O
12	O
.	O
52	O

42	O
.	O
11	O
±	O
19	O
.	O
55	O

19	O
.	O
65	O
±	O
8	O
.	O
97	O

CUMS	O

—	O

22	O
.	O
69	O
±	O
13	O
.	O
49	O
∗	O

7	O
.	O
38	O
±	O
1	O
.	O
78	O
∗	O

36	O
.	O
74	O
±	O
8	O
.	O
73	O
∗	O

51	O
.	O
44	O
±	O
25	O
.	O
80	O
∗	O

22	O
.	O
79	O
±	O
7	O
.	O
33	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

22	O
.	O
32	O
±	O
13	O
.	O
31	O

7	O
.	O
37	O
±	O
1	O
.	O
63	O

35	O
.	O
35	O
±	O
8	O
.	O
02	O

50	O
.	O
56	O
±	O
24	O
.	O
71	O

22	O
.	O
42	O
±	O
7	O
.	O
32	O

0	O
.	O
172	O

14	O
.	O
74	O
±	O
10	O
.	O
30	O
##	O

5	O
.	O
33	O
±	O
0	O
.	O
79	O
#	O

23	O
.	O
02	O
±	O
12	O
.	O
8	O
##	O

46	O
.	O
83	O
±	O
23	O
.	O
32	O
##	O

20	O
.	O
83	O
±	O
6	O
.	O
92	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

20	O
.	O
00	O
±	O
6	O
.	O
71	O

7	O
.	O
25	O
±	O
1	O
.	O
77	O

33	O
.	O
36	O
±	O
10	O
.	O
57	O

51	O
.	O
32	O
±	O
10	O
.	O
28	O

22	O
.	O
26	O
±	O
9	O
.	O
20	O

3	O
.	O
608	O

10	O
.	O
91	O
±	O
3	O
.	O
30	O
##	O

3	O
.	O
95	O
±	O
0	O
.	O
12	O
##	O

16	O
.	O
04	O
±	O
9	O
.	O
34	O
##	O

44	O
.	O
47	O
±	O
20	O
.	O
31	O
#	O

20	O
.	O
59	O
±	O
6	O
.	O
88	O
#	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

10	O
.	O
23	O
±	O
3	O
.	O
21	O
##	O

3	O
.	O
67	O
±	O
0	O
.	O
13	O
##	O

15	O
.	O
44	O
±	O
9	O
.	O
02	O
##	O

42	O
.	O
26	O
±	O
20	O
.	O
01	O
##	O

19	O
.	O
13	O
±	O
6	O
.	O
76	O
##	O

The	O
AVP	B-GP
contents	O
in	O
plasma	O
and	O
hypothalamus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

AVP	B-GP

Plasma	O
(	O
pg	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
pg	O
/	O
mg	O
)	O

Control	O

—	O

14	O
.	O
70	O
±	O
4	O
.	O
80	O

58	O
.	O
50	O
±	O
17	O
.	O
80	O

CUMS	O

—	O

25	O
.	O
20	O
±	O
7	O
.	O
30	O
∗	O

309	O
.	O
20	O
±	O
70	O
.	O
41	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

24	O
.	O
23	O
±	O
7	O
.	O
12	O

306	O
.	O
20	O
±	O
70	O
.	O
33	O

0	O
.	O
172	O

12	O
.	O
60	O
±	O
3	O
.	O
20	O
#	O

267	O
.	O
40	O
±	O
58	O
.	O
60	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

23	O
.	O
74	O
±	O
7	O
.	O
10	O

301	O
.	O
60	O
±	O
70	O
.	O
70	O

3	O
.	O
608	O

12	O
.	O
30	O
±	O
3	O
.	O
40	O
##	O

173	O
.	O
20	O
±	O
20	O
.	O
90	O
##	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

11	O
.	O
21	O
±	O
3	O
.	O
12	O
##	O

168	O
.	O
53	O
±	O
20	O
.	O
11	O
##	O

The	O
contents	O
of	O
5	O
-	O
HT	O
,	O
5	O
-	O
HIAA	O
,	O
and	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
ratio	O
in	O
hippocampus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

5	O
-	O
HT	O
(	O
ng	O
/	O
g	O
wet	O
tissue	O
)	O

5	O
-	O
HIAA	O
(	O
ng	O
/	O
g	O
wet	O
tissue	O
)	O

5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O

Control	O

—	O

428	O
.	O
3	O
±	O
171	O
.	O
2	O

376	O
.	O
3	O
±	O
210	O
.	O
3	O

1	O
.	O
04	O
±	O
0	O
.	O
41	O

CUMS	O

—	O

213	O
.	O
7	O
±	O
142	O
.	O
4	O
∗∗	O

387	O
.	O
6	O
±	O
146	O
.	O
6	O

1	O
.	O
62	O
±	O
0	O
.	O
82	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

262	O
.	O
5	O
±	O
145	O
.	O
8	O

370	O
.	O
6	O
±	O
107	O
.	O
8	O

1	O
.	O
58	O
±	O
0	O
.	O
83	O

0	O
.	O
172	O

447	O
.	O
8	O
±	O
236	O
.	O
7	O
#	O

436	O
.	O
8	O
±	O
311	O
.	O
2	O

1	O
.	O
02	O
±	O
0	O
.	O
46	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

301	O
.	O
2	O
±	O
146	O
.	O
5	O

378	O
.	O
7	O
±	O
118	O
.	O
1	O

1	O
.	O
57	O
±	O
0	O
.	O
79	O

3	O
.	O
608	O

468	O
.	O
2	O
±	O
139	O
.	O
3	O
##	O

487	O
.	O
2	O
±	O
83	O
.	O
2	O
#	O

0	O
.	O
97	O
±	O
0	O
.	O
56	O
#	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

479	O
.	O
5	O
±	O
148	O
.	O
7	O
##	O

509	O
.	O
3	O
±	O
84	O
.	O
7	O
#	O

1	O
.	O
01	O
±	O
0	O
.	O
33	O
#	O

The	O
use	O
of	O
reproductive	O
healthcare	O
at	O
commune	O
health	O
stations	O
in	O
a	O
changing	O
health	O
system	O
in	O
Vietnam	O

Background	O

With	O
health	O
sector	O
reform	O
in	O
Vietnam	O
moving	O
towards	O
greater	O
pluralism	O
,	O
commune	O
health	O
stations	O
(	O
CHSs	O
)	O
have	O
been	O
subject	O
to	O
growing	O
competition	O
from	O
private	O
health	O
services	O
and	O
increasing	O
numbers	O
of	O
patients	O
bypassing	O
CHSs	O
for	O
higher	O
-	O
level	O
health	O
facilities	O
.	O

This	O
study	O
describes	O
the	O
pattern	O
of	O
reproductive	O
health	O
(	O
RH	O
)	O
and	O
family	O
planning	O
(	O
FP	O
)	O
service	O
utilization	O
among	O
women	O
at	O
CHSs	O
and	O
other	O
health	O
facilities	O
,	O
and	O
explores	O
socio	O
-	O
demographic	O
determinants	O
of	O
RH	O
service	O
utilization	O
at	O
the	O
CHS	O
level	O
.	O

Methods	O

This	O
study	O
was	O
based	O
on	O
a	O
cross	O
-	O
sectional	O
survey	O
conducted	O
in	O
Thua	O
Thien	O
Hue	O
and	O
Vinh	O
Long	O
provinces	O
,	O
using	O
a	O
multi	O
-	O
stage	O
cluster	O
sampling	O
technique	O
.	O

Questionnaire	O
-	O
based	O
interviews	O
with	O
978	O
ever	O
-	O
married	O
women	O
at	O
reproductive	O
age	O
provided	O
data	O
on	O
socio	O
-	O
demographic	O
characteristics	O
,	O
current	O
use	O
of	O
FP	O
methods	O
,	O
history	O
of	O
RH	O
service	O
use	O
,	O
and	O
the	O
health	O
facility	O
attended	O
for	O
their	O
most	O
recent	O
services	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
were	O
used	O
to	O
identify	O
socio	O
-	O
demographic	O
determinants	O
of	O
their	O
use	O
of	O
CHS	O
RH	O
services	O
.	O

Results	O

Eighty	O
nine	O
percent	O
of	O
ever	O
-	O
married	O
women	O
reported	O
current	O
use	O
of	O
birth	O
control	O
with	O
49	O
%	O
choosing	O
intra	O
-	O
uterine	O
device	O
(	O
IUD	O
).	O

Eighty	O
nine	O
percent	O
of	O
pregnant	O
women	O
attended	O
facility	O
-	O
based	O
antenatal	O
care	O
(	O
ANC	O
)	O
with	O
62	O
%	O
having	O
at	O
least	O
3	O
check	O
-	O
ups	O
during	O
their	O
latest	O
pregnancy	O
.	O

Ninety	O
one	O
percent	O
of	O
mothers	O
had	O
their	O
last	O
delivery	O
in	O
a	O
health	O
facility	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
respondents	O
used	O
CHS	O
for	O
IUD	O
insertion	O
,	O
55	O
%	O
for	O
antenatal	O
check	O
-	O
ups	O
,	O
and	O
77	O
%	O
gynecological	O
examination	O
.	O

District	O
and	O
provincial	O
/	O
central	O
hospitals	O
dominated	O
the	O
provision	O
of	O
delivery	O
service	O
,	O
used	O
by	O
57	O
%	O
of	O
mothers	O
for	O
their	O
latest	O
delivery	O
.	O

The	O
percentage	O
of	O
women	O
opting	O
for	O
private	O
ANC	O
services	O
was	O
reported	O
at	O
35	O
%,	O
though	O
the	O
use	O
of	O
private	O
delivery	O
services	O
was	O
low	O
(	O
11	O
%).	O

Women	O
who	O
were	O
farmers	O
,	O
earning	O
a	O
lower	O
income	O
,	O
having	O
more	O
than	O
2	O
children	O
,	O
and	O
living	O
in	O
a	O
rural	O
area	O
were	O
more	O
likely	O
than	O
others	O
to	O
use	O
ANC	O
,	O
delivery	O
,	O
and	O
/	O
or	O
gynecological	O
check	O
-	O
up	O
services	O
at	O
the	O
CHS	O
.	O

Conclusions	O

Women	O
choice	O
of	O
providers	O
for	O
FP	O
and	O
RH	O
services	O
that	O
help	O
them	O
plan	O
and	O
protect	O
their	O
pregnancies	O
is	O
driven	O
by	O
socio	O
-	O
economic	O
factors	O
.	O

While	O
the	O
CHS	O
retains	O
significant	O
utilization	O
rates	O
,	O
it	O
is	O
under	O
challenge	O
by	O
preferences	O
for	O
hospital	O
-	O
based	O
delivery	O
and	O
the	O
growing	O
use	O
of	O
private	O
ANC	O
services	O
.	O

Background	O

With	O
the	O
introduction	O
of	O
its	O
""""	O
Doi	O
Moi	O
""""	O
or	O
'	O
renovation	O
'	O
policy	O
in	O
1986	O
,	O
Vietnam	O
has	O
shifted	O
from	O
a	O
centrally	O
planned	O
towards	O
a	O
market	O
-	O
oriented	O
economy	O
.	O

Health	O
sector	O
reform	O
has	O
introduced	O
user	O
fees	O
in	O
public	O
hospitals	O
and	O
legalized	O
private	O
practice	O
.	O

In	O
urban	O
centers	O
in	O
particular	O
,	O
the	O
private	O
health	O
sector	O
has	O
been	O
growing	O
rapidly	O
,	O
and	O
increasingly	O
is	O
in	O
competition	O
with	O
the	O
public	O
sector	O
in	O
providing	O
health	O
services	O
.	O

These	O
changes	O
have	O
produced	O
profound	O
effects	O
on	O
the	O
use	O
of	O
health	O
services	O
at	O
state	O
health	O
facilities	O
,	O
including	O
RH	O
care	O
at	O
the	O
local	O
CHS	O
-	O
the	O
basic	O
unit	O
of	O
the	O
primary	O
healthcare	O
system	O
in	O
Vietnam	O
[	O
1	O
,	O
2	O
].	O

To	O
date	O
,	O
no	O
study	O
has	O
examined	O
the	O
use	O
of	O
FP	O
and	O
primary	O
RH	O
services	O
in	O
the	O
context	O
of	O
the	O
current	O
healthcare	O
system	O
in	O
Vietnam	O
,	O
as	O
it	O
shifts	O
from	O
a	O
state	O
monopoly	O
to	O
a	O
more	O
pluralist	O
system	O
.	O

To	O
address	O
this	O
shortcoming	O
,	O
this	O
study	O
aims	O
to	O
describe	O
the	O
pattern	O
of	O
FP	O
and	O
RH	O
service	O
utilization	O
among	O
women	O
at	O
the	O
CHS	O
and	O
other	O
state	O
and	O
private	O
facilities	O
,	O
and	O
to	O
explore	O
socio	O
-	O
demographic	O
determinants	O
of	O
RH	O
service	O
utilization	O
at	O
the	O
CHS	O
level	O
.	O

It	O
is	O
intended	O
to	O
inform	O
policy	O
and	O
program	O
reviews	O
that	O
will	O
strengthen	O
the	O
CHS	O
primary	O
RH	O
network	O
in	O
the	O
changing	O
health	O
system	O
of	O
Vietnam	O
.	O

The	O
state	O
health	O
system	O
in	O
Vietnam	O
consists	O
of	O
4	O
levels	O
:	O
the	O
national	O
level	O
with	O
the	O
Ministry	O
of	O
Health	O
and	O
central	O
hospitals	O
;	O
the	O
provincial	O
level	O
with	O
the	O
Provincial	O
Department	O
of	O
Health	O
and	O
provincial	O
hospitals	O
;	O
the	O
district	O
level	O
with	O
district	O
health	O
centers	O
and	O
district	O
hospitals	O
;	O
and	O
the	O
communal	O
level	O
with	O
CHSs	O
.	O

RH	O
and	O
FP	O
services	O
are	O
available	O
at	O
all	O
-	O
level	O
state	O
health	O
facilities	O
:	O
central	O
,	O
provincial	O
,	O
district	O
hospitals	O
and	O
CHSs	O
.	O

Despite	O
the	O
changes	O
in	O
the	O
health	O
sector	O
,	O
the	O
CHS	O
retains	O
its	O
responsibilities	O
as	O
the	O
primary	O
access	O
point	O
to	O
primary	O
RH	O
and	O
FP	O
services	O
subsidized	O
by	O
the	O
state	O
budget	O
,	O
and	O
is	O
required	O
to	O
meet	O
government	O
numerical	O
targets	O
on	O
basic	O
RH	O
and	O
FP	O
service	O
use	O
indicators	O
.	O

Every	O
CHS	O
is	O
staffed	O
by	O
at	O
least	O
one	O
midwife	O
who	O
acts	O
as	O
the	O
focal	O
point	O
for	O
RH	O
services	O
,	O
including	O
antenatal	O
and	O
post	O
-	O
natal	O
care	O
,	O
delivery	O
,	O
gynecological	O
examination	O
and	O
treatment	O
,	O
and	O
FP	O
services	O
such	O
as	O
IUD	O
,	O
oral	O
contraceptives	O
,	O
and	O
condoms	O
.	O

Some	O
CHSs	O
located	O
close	O
to	O
a	O
hospital	O
are	O
restricted	O
from	O
providing	O
delivery	O
services	O
.	O

Local	O
residents	O
are	O
entitled	O
to	O
free	O
services	O
at	O
their	O
local	O
CHS	O
but	O
not	O
at	O
the	O
CHS	O
in	O
other	O
communes	O
.	O

In	O
addition	O
to	O
everyday	O
RH	O
services	O
,	O
CHSs	O
are	O
entrusted	O
with	O
responsibilities	O
to	O
register	O
and	O
manage	O
all	O
pregnant	O
women	O
in	O
the	O
commune	O
,	O
conducting	O
1	O
-	O
day	O
monthly	O
antenatal	O
check	O
-	O
ups	O
.	O

There	O
are	O
also	O
3	O
-	O
day	O
semi	O
-	O
annual	O
RH	O
campaigns	O
based	O
at	O
the	O
CHS	O
with	O
assistance	O
of	O
midwifes	O
or	O
doctors	O
from	O
the	O
district	O
hospital	O
.	O

The	O
primary	O
purpose	O
of	O
these	O
campaigns	O
is	O
early	O
detection	O
and	O
treatment	O
of	O
reproductive	B-DS
tract	I-DS
infections	I-DS
(	O
RTIs	B-DS
)	O
including	O
sexually	B-DS
transmitted	I-DS
infections	I-DS
,	O
based	O
on	O
clinical	O
examination	O
[	O
3	O
].	O

Since	O
the	O
restructuring	O
of	O
the	O
national	O
population	O
program	O
,	O
there	O
is	O
a	O
network	O
of	O
population	O
collaborators	O
affiliated	O
with	O
the	O
local	O
CHS	O
,	O
who	O
have	O
basic	O
training	O
in	O
RH	O
health	O
education	O
and	O
services	O
.	O

Population	O
collaborators	O
conduct	O
regular	O
outreach	O
communication	O
activities	O
,	O
providing	O
RH	O
counseling	O
and	O
contraceptives	O
(	O
e	O
.	O
g	O
.	O
condoms	O
,	O
pills	O
),	O
and	O
referring	O
couples	O
to	O
the	O
CHS	O
for	O
further	O
FP	O
and	O
RH	O
services	O
such	O
as	O
IUD	O
insertion	O
,	O
gynecological	O
and	O
antenatal	O
check	O
-	O
ups	O
[	O
4	O
].	O

Private	O
healthcare	O
services	O
in	O
Vietnam	O
comprise	O
three	O
differing	O
service	O
structures	O
[	O
5	O
,	O
6	O
].	O

Private	O
hospital	O
care	O
is	O
principally	O
located	O
in	O
major	O
cities	O
.	O

Compared	O
to	O
state	O
hospitals	O
,	O
they	O
have	O
a	O
reputation	O
for	O
their	O
access	O
to	O
more	O
advanced	O
diagnostic	O
and	O
therapeutic	O
technology	O
,	O
and	O
their	O
capacity	O
to	O
provide	O
technically	O
demanding	O
services	O
.	O

Private	O
outpatient	O
clinics	O
are	O
operated	O
by	O
individuals	O
or	O
groups	O
of	O
full	O
-	O
or	O
part	O
-	O
time	O
physicians	O
in	O
urban	O
,	O
sub	O
-	O
urban	O
and	O
rural	O
areas	O
,	O
under	O
a	O
license	O
from	O
provincial	O
health	O
authorities	O
.	O

They	O
largely	O
provide	O
general	O
or	O
specialized	O
health	O
services	O
for	O
middle	O
income	O
patients	O
.	O

Third	O
,	O
""""	O
mobile	O
""""	O
private	O
practitioners	O
--	O
who	O
can	O
be	O
nurses	O
,	O
assistant	O
doctors	O
,	O
or	O
retired	O
doctors	O
--	O
are	O
commonly	O
present	O
in	O
rural	O
areas	O
,	O
providing	O
health	O
services	O
from	O
their	O
own	O
homes	O
without	O
a	O
license	O
.	O

These	O
health	O
practitioners	O
are	O
not	O
included	O
as	O
part	O
of	O
the	O
formal	O
health	O
system	O
,	O
although	O
they	O
play	O
an	O
important	O
role	O
in	O
providing	O
basic	O
health	O
services	O
[	O
6	O
].	O

For	O
RH	O
services	O
at	O
the	O
commune	O
level	O
,	O
private	O
providers	O
include	O
doctors	O
or	O
practitioners	O
(	O
e	O
.	O
g	O
.	O
midwives	O
,	O
assistant	O
doctors	O
),	O
and	O
traditional	O
birth	O
attendants	O
,	O
who	O
provide	O
home	O
-	O
based	O
delivery	O
services	O
[	O
7	O
,	O
8	O
].	O

In	O
addition	O
,	O
local	O
pharmacies	O
can	O
offer	O
the	O
commercial	O
sale	O
of	O
birth	O
control	O
commodities	O
such	O
as	O
oral	O
contraceptives	O
,	O
without	O
prescription	O
.	O

With	O
the	O
reduction	O
in	O
government	O
subsidies	O
for	O
CHS	O
facilities	O
,	O
equipment	O
,	O
and	O
human	B-OG
resources	O
development	O
,	O
the	O
quality	O
of	O
health	O
services	O
at	O
CHSs	O
has	O
been	O
perceived	O
as	O
deteriorating	O
and	O
is	O
associated	O
with	O
less	O
-	O
qualified	O
health	O
staff	O
,	O
outdated	O
equipment	O
,	O
limited	O
drugs	O
and	O
supplies	O
[	O
2	O
].	O

At	O
the	O
same	O
time	O
,	O
the	O
private	O
sector	O
has	O
been	O
increasingly	O
popular	O
and	O
is	O
associated	O
with	O
convenient	O
opening	O
hours	O
,	O
more	O
competent	O
staff	O
,	O
better	O
equipment	O
,	O
and	O
effective	O
drug	O
prescriptions	O
[	O
9	O
].	O

Reports	O
suggest	O
that	O
increasingly	O
,	O
patients	O
are	O
seeking	O
care	O
at	O
private	O
clinics	O
or	O
bypassing	O
their	O
local	O
CHS	O
for	O
higher	O
level	O
health	O
facilities	O
,	O
willing	O
to	O
pay	O
higher	O
fees	O
based	O
on	O
their	O
perceptions	O
of	O
better	O
quality	O
and	O
enhanced	O
technology	O
[	O
1	O
,	O
2	O
,	O
10	O
,	O
11	O
].	O

The	O
Study	O
Sites	O

This	O
study	O
is	O
part	O
of	O
the	O
baseline	O
assessment	O
of	O
a	O
project	O
supported	O
by	O
Marie	O
Stopes	O
International	O
Vietnam	O
,	O
that	O
aims	O
to	O
create	O
public	O
-	O
private	O
partnerships	O
to	O
improve	O
access	O
to	O
services	O
and	O
the	O
quality	O
of	O
primary	O
RH	O
care	O
,	O
in	O
two	O
provinces	O
,	O
Thua	O
Thien	O
Hue	O
and	O
Vinh	O
Long	O
,	O
in	O
Vietnam	O
.	O

Thua	O
Thien	O
Hue	O
is	O
located	O
in	O
the	O
center	O
of	O
Viet	O
Nam	O
with	O
a	O
total	O
population	O
of	O
1	O
,	O
143	O
,	O
500	O
,	O
of	O
which	O
284	O
,	O
149	O
women	O
are	O
at	O
reproductive	O
age	O
(	O
15	O
-	O
49	O
).	O

The	O
province	O
has	O
1	O
central	O
hospital	O
,	O
9	O
district	O
hospitals	O
,	O
and	O
152	O
CHSs	O
located	O
in	O
urban	O
,	O
semi	O
-	O
urban	O
,	O
rural	O
,	O
and	O
mountainous	O
areas	O
.	O

Based	O
in	O
the	O
Mekong	O
delta	O
region	O
,	O
Vinh	O
Long	O
province	O
has	O
a	O
population	O
of	O
1	O
,	O
057	O
,	O
000	O
.	O

The	O
state	O
health	O
care	O
network	O
consists	O
of	O
107	O
CHSs	O
,	O
8	O
district	O
hospitals	O
,	O
and	O
1	O
provincial	O
hospital	O
.	O

People	O
in	O
districts	O
bordering	O
with	O
Can	O
Tho	O
city	O
may	O
seek	O
RH	O
services	O
at	O
the	O
Can	O
Tho	O
central	O
hospital	O
.	O

Almost	O
all	O
CHSs	O
in	O
the	O
2	O
provinces	O
are	O
staffed	O
by	O
a	O
doctor	O
[	O
4	O
].	O

Studies	O
sites	O
included	O
1	O
urban	O
district	O
(	O
Hue	O
city	O
),	O
2	O
rural	O
districts	O
of	O
Thua	O
Thien	O
Hue	O
,	O
and	O
3	O
rural	O
districts	O
of	O
Vinh	O
Long	O
.	O

As	O
these	O
districts	O
received	O
no	O
external	O
support	O
for	O
primary	O
RH	O
care	O
,	O
they	O
can	O
be	O
considered	O
to	O
represent	O
the	O
baseline	O
for	O
state	O
provided	O
RH	O
services	O
.	O

In	O
each	O
of	O
these	O
districts	O
,	O
the	O
state	O
primary	O
healthcare	O
network	O
was	O
well	O
-	O
established	O
,	O
with	O
each	O
commune	O
having	O
a	O
CHS	O
and	O
a	O
team	O
of	O
population	O
collaborators	O
.	O

In	O
contrast	O
,	O
RH	O
private	O
clinics	O
were	O
mostly	O
concentrated	O
in	O
urban	O
areas	O
,	O
and	O
were	O
often	O
run	O
by	O
a	O
gynecologist	O
working	O
in	O
a	O
major	O
hospital	O
.	O

Only	O
3	O
out	O
of	O
5	O
rural	O
districts	O
had	O
a	O
gynecologist	O
working	O
in	O
the	O
district	O
hospital	O
and	O
2	O
rural	O
districts	O
in	O
Vinh	O
Long	O
had	O
an	O
accredited	O
private	O
RH	O
clinic	O
(	O
i	O
.	O
e	O
.	O
with	O
a	O
license	O
from	O
provincial	O
health	O
authorities	O
)	O
operated	O
by	O
this	O
specialist	O
[	O
12	O
].	O

Methods	O

The	O
study	O
was	O
a	O
cross	O
-	O
sectional	O
survey	O
,	O
using	O
a	O
multi	O
-	O
stage	O
cluster	O
sampling	O
design	O
to	O
recruit	O
participants	O
.	O

The	O
first	O
stage	O
selected	O
5	O
communes	O
from	O
each	O
of	O
the	O
selected	O
districts	O
,	O
using	O
proportional	O
to	O
population	O
size	O
techniques	O
,	O
totaling	O
30	O
communes	O
in	O
the	O
2	O
provinces	O
.	O

The	O
second	O
stage	O
involved	O
the	O
random	O
selection	O
of	O
1	O
village	O
or	O
residential	O
group	O
in	O
each	O
commune	O
where	O
30	O
households	O
were	O
randomly	O
drawn	O
for	O
interviews	O
of	O
all	O
women	O
at	O
reproductive	O
age	O
(	O
15	O
-	O
49	O
).	O

In	O
total	O
,	O
900	O
households	O
with	O
1	O
417	O
women	O
were	O
included	O
in	O
this	O
study	O
.	O

Data	O
was	O
collected	O
using	O
questionnaire	O
-	O
based	O
interviews	O
,	O
consisting	O
of	O
mutiple	O
-	O
choice	O
questions	O
on	O
respondents	O
'	O
socio	O
-	O
demographic	O
characteristics	O
(	O
e	O
.	O
g	O
.	O
age	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
education	O
,	O
number	O
of	O
living	O
children	O
,	O
income	O
),	O
their	O
RH	O
and	O
FP	O
service	O
use	O
(	O
see	O
Additional	O
File	O
1	O
).	O

Women	O
were	O
also	O
asked	O
about	O
the	O
health	O
facility	O
where	O
they	O
attended	O
antenatal	O
care	O
during	O
their	O
last	O
pregnancy	O
or	O
received	O
their	O
most	O
recent	O
gynecological	O
examination	O
,	O
and	O
the	O
place	O
where	O
they	O
had	O
their	O
latest	O
delivery	O
.	O

These	O
three	O
RH	O
services	O
were	O
considered	O
to	O
constitute	O
basic	O
RH	O
healthcare	O
provided	O
at	O
the	O
local	O
CHS	O
or	O
other	O
state	O
health	O
facilities	O
in	O
Vietnam	O
.	O

Women	O
were	O
interviewed	O
at	O
home	O
by	O
a	O
trained	O
interviewer	O
who	O
was	O
a	O
member	O
of	O
the	O
commune	O
Women	O
'	O
s	O
Union	O
.	O

Data	O
collection	O
was	O
completed	O
from	O
April	O
to	O
May	O
,	O
2010	O
.	O

As	O
mentioned	O
earlier	O
,	O
the	O
research	O
was	O
undertaken	O
as	O
a	O
baseline	O
survey	O
,	O
commissioned	O
by	O
Marie	O
Stopes	O
International	O
Vietnam	O
for	O
planning	O
an	O
intervention	O
in	O
the	O
2	O
selected	O
provinces	O
.	O

Ethical	O
approval	O
was	O
given	O
by	O
the	O
Ethic	O
Committee	O
of	O
the	O
Thua	O
Thien	O
Hue	O
and	O
Vinh	O
Long	O
Provincial	O
Departments	O
of	O
Health	O
.	O

Data	O
were	O
entered	O
into	O
Epi	O
Info	O
,	O
then	O
transferred	O
to	O
STATA	O
version	O
9	O
.	O
0	O
for	O
processing	O
and	O
analyses	O
.	O

Ten	O
percent	O
of	O
questionnaires	O
were	O
double	O
entered	O
to	O
check	O
consistency	O
.	O

Data	O
analyses	O
consisted	O
of	O
two	O
sequential	O
steps	O
.	O

First	O
,	O
descriptive	O
analysis	O
was	O
performed	O
of	O
the	O
socio	O
-	O
demographic	O
characteristics	O
of	O
all	O
study	O
participants	O
and	O
the	O
frequency	O
distributions	O
of	O
variables	O
of	O
interest	O
,	O
including	O
the	O
current	O
use	O
of	O
FP	O
method	O
(	O
s	O
),	O
history	O
of	O
ANC	O
,	O
delivery	O
,	O
and	O
gynecological	O
check	O
-	O
up	O
service	O
use	O
,	O
and	O
the	O
health	O
facility	O
where	O
women	O
attended	O
for	O
their	O
most	O
recent	O
service	O
.	O

Second	O
,	O
logistic	O
regression	O
analyses	O
were	O
performed	O
of	O
factors	O
related	O
to	O
the	O
use	O
of	O
the	O
following	O
services	O
in	O
the	O
local	O
CHS	O
:	O
(	O
i	O
)	O
antenatal	O
check	O
ups	O
during	O
the	O
last	O
pregnancy	O
,	O
(	O
ii	O
)	O
their	O
latest	O
delivery	O
,	O
and	O
(	O
iii	O
)	O
their	O
most	O
recent	O
gynecological	O
examination	O
.	O

The	O
dependent	O
variable	O
was	O
based	O
on	O
whether	O
or	O
not	O
women	O
who	O
visited	O
a	O
health	O
facility	O
for	O
these	O
services	O
reported	O
selecting	O
their	O
local	O
CHS	O
.	O

Independent	O
variables	O
of	O
interests	O
included	O
:	O
women	B-OG
'	O
s	O
age	O
(	O
above	O
vs	O
.	O
below	O
the	O
median	O
),	O
number	O
of	O
living	O
children	O
(	O
having	O
2	O
children	O
or	O
less	O
vs	O
.	O
3	O
children	O
or	O
more	O
),	O
religion	O
(	O
Buddhist	O
,	O
Catholic	O
,	O
other	O
,	O
and	O
none	O
),	O
ethnicity	O
(	O
majority	O
vs	O
.	O
minority	O
),	O
occupation	O
(	O
farming	O
vs	O
.	O
other	O
),	O
education	O
(	O
secondary	O
school	O
or	O
less	O
vs	O
.	O
high	O
school	O
or	O
more	O
),	O
income	O
(	O
4	O
quartile	O
groups	O
),	O
current	O
living	O
location	O
(	O
urban	O
vs	O
.	O
rural	O
),	O
and	O
study	O
province	O
(	O
Vinh	O
Long	O
vs	O
.	O
Thua	O
Thien	O
Hue	O
).	O

The	O
statistical	O
model	O
for	O
the	O
use	O
of	O
CHS	O
delivery	O
services	O
excluded	O
those	O
who	O
required	O
a	O
cesarean	O
section	O
and	O
those	O
who	O
reported	O
that	O
delivery	O
service	O
was	O
unavailable	O
at	O
their	O
local	O
CHS	O
at	O
the	O
time	O
the	O
women	O
gave	O
birth	O
.	O

Each	O
socio	O
-	O
demographic	O
variable	O
was	O
analyzed	O
first	O
as	O
a	O
univariate	O
predictor	O
to	O
obtain	O
a	O
crude	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
).	O

Significantly	O
related	O
variables	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
subsequently	O
included	O
in	O
a	O
multivariate	O
analysis	O
to	O
obtain	O
an	O
adjusted	O
OR	O
and	O
95	O
%	O
CI	O
.	O

Only	O
factors	O
that	O
were	O
significantly	O
associated	O
with	O
the	O
outcome	O
variable	O
in	O
the	O
multi	O
-	O
variate	O
analytical	O
model	O
were	O
retained	O
in	O
the	O
final	O
reduced	O
model	O
.	O

Results	O

The	O
sample	O
consisted	O
of	O
678	O
women	O
(	O
48	O
%)	O
in	O
Vinh	O
Long	O
and	O
739	O
women	O
(	O
52	O
%)	O
in	O
Thua	O
Thien	O
Hue	O
.	O

Median	O
age	O
was	O
31	O
.	O

Sixty	O
-	O
six	O
percent	O
of	O
respondents	O
were	O
married	O
;	O
31	O
%	O
were	O
single	O
,	O
and	O
3	O
%	O
were	O
widowed	O
or	O
divorced	O
.	O

The	O
demographic	O
characteristics	O
of	O
respondents	O
are	O
presented	O
in	O
Table	O
1	O
.	O

Socio	O
-	O
demographic	O
characteristics	O
of	O
surveyed	O
respondents	O
(	O
n	O
=	O
1417	O
)	O

Variable	O

n	O

%	O

Variable	O

n	O

%	O

Province	O


Vinh	O
Long	O

678	O

48	O

Religion	O


Thua	O
Thien	O
Hue	O

739	O

52	O

Buddhist	O

556	O

39	O


Age	O

Catholic	O

75	O

5	O


<	O
=	O
31	O

740	O

52	O

Other	O

58	O

4	O


>	O
31	O

677	O

48	O

None	O

728	O

52	O


Marital	O
status	O

Occupation	O


Single	O

439	O

31	O

Farmer	O

570	O

40	O


Ever	O
-	O
married	O

978	O

69	O

Non	O
-	O
farming	O
job	O

847	O

60	O


Number	O
of	O
children	O

Location	O
of	O
living	O


None	O

435	O

33	O

Urban	O

213	O

15	O


1	O
or	O
2	O

635	O

45	O

Rural	O

1204	O

85	O


>	O
2	O

307	O

32	O

Income	O


Education	O

1st	O
quartile	O

356	O

25	O


Secondary	O
school	O
or	O
less	O

960	O

68	O

2nd	O
quartile	O

416	O

29	O


High	O
school	O
or	O
more	O

457	O

32	O

3rd	O
quartile	O

296	O

21	O


4th	O
quartile	O

349	O

25	O

FP	O
service	O
use	O

Among	O
439	O
single	O
women	O
,	O
only	O
13	O
(	O
3	O
%)	O
reported	O
having	O
a	O
current	O
sexual	O
partner	O
,	O
and	O
9	O
reported	O
current	O
use	O
of	O
a	O
birth	O
control	O
method	O
.	O

Given	O
these	O
small	O
numbers	O
,	O
analyses	O
of	O
FP	O
service	O
use	O
were	O
limited	O
to	O
ever	O
-	O
married	O
participants	O
(	O
n	O
=	O
978	O
).	O

The	O
rate	O
of	O
FP	O
service	O
use	O
among	O
ever	O
-	O
married	O
women	O
was	O
88	O
.	O
5	O
%	O
after	O
excluding	O
those	O
who	O
reported	O
not	O
using	O
a	O
birth	O
control	O
due	O
to	O
one	O
of	O
the	O
following	O
reasons	O
:	O
being	O
pregnant	O
,	O
having	O
just	O
given	O
birth	O
,	O
or	O
being	O
menopausal	O
.	O

IUD	O
appears	O
to	O
be	O
the	O
most	O
common	O
method	O
,	O
utilized	O
by	O
49	O
%	O
of	O
women	O
,	O
followed	O
by	O
condoms	O
(	O
16	O
%),	O
oral	O
contraceptives	O
(	O
15	O
%),	O
and	O
the	O
rhythm	O
method	O
(	O
14	O
%).	O

Male	O
or	O
female	O
sterilization	O
was	O
used	O
by	O
5	O
.	O
5	O
%,	O
and	O
injected	O
contraceptives	O
by	O
3	O
.	O
8	O
%	O
of	O
married	O
women	O
.	O

The	O
sum	O
of	O
these	O
percentages	O
was	O
104	O
%	O
as	O
a	O
few	O
women	O
reported	O
concurrent	O
use	O
of	O
condoms	O
and	O
the	O
rhythm	O
method	O
.	O

Regarding	O
the	O
source	O
of	O
FP	O
services	O
,	O
71	O
%	O
of	O
the	O
464	O
women	O
using	O
IUDs	O
reported	O
visiting	O
the	O
local	O
CHS	O
,	O
with	O
19	O
%	O
selecting	O
district	O
hospitals	O
,	O
8	O
%	O
private	O
clinics	O
,	O
and	O
2	O
%	O
other	O
facilities	O
for	O
their	O
last	O
IUD	O
insertion	O
.	O

For	O
condoms	O
and	O
other	O
contraceptives	O
(	O
e	O
.	O
g	O
.	O
oral	O
,	O
injections	O
),	O
the	O
CHS	O
appears	O
to	O
be	O
the	O
major	O
source	O
,	O
reported	O
by	O
61	O
%	O
women	O
,	O
followed	O
by	O
population	O
collaborators	O
(	O
37	O
%),	O
and	O
then	O
pharmacies	O
(	O
18	O
%).	O

Only	O
5	O
%	O
of	O
women	O
had	O
obtained	O
these	O
birth	O
control	O
supplies	O
from	O
a	O
hospital	O
,	O
with	O
2	O
%	O
using	O
a	O
private	O
clinic	O
(	O
Table	O
2	O
).	O

The	O
total	O
percentage	O
of	O
123	O
%	O
reflects	O
the	O
availability	O
of	O
contraceptives	O
from	O
multiple	O
sources	O
.	O

Sources	O
of	O
FP	O
services	O

Health	O
facility	O

Last	O
IUD	O
insertion	O
(	O
n	O
=	O
464	O
)	O

Condoms	O
/	O
other	O
contraceptives	O

n	O

%	O

n	O

%	O


CHS	B-GP

329	O

71	O
.	O
0	O

345	O

60	O
.	O
8	O


Pop	O
.	O

Collaborators	O

NA	O

NA	O

208	O

36	O
.	O
7	O


Pharmacy	O

NA	O

NA	O

102	O

18	O
.	O
0	O


Dist	O
.	O

Hospital	O

86	O

18	O
.	O
5	O

24	O

4	O
.	O
2	O


Provincial	O
/	O
central	O
hospital	O
hospital	O

8	O

1	O
.	O
7	O

5	O

0	O
.	O
9	O


Private	O
clinics	O

37	O

8	O
.	O
0	O

11	O

1	O
.	O
9	O


Other	O

4	O

0	O
.	O
9	O

11	O

1	O
.	O
9	O

NA	O
:	O
Not	O
applicable	O

Antenatal	O
care	O
service	O
use	O

Of	O
964	O
women	O
who	O
had	O
ever	O
experienced	O
a	O
pregnancy	O
,	O
857	O
(	O
89	O
%)	O
reported	O
having	O
facility	O
-	O
based	O
antenatal	O
care	O
with	O
62	O
%	O
having	O
at	O
least	O
3	O
check	O
-	O
ups	O
during	O
their	O
last	O
pregnancy	O
.	O

Among	O
these	O
857	O
women	O
,	O
more	O
than	O
half	O
(	O
55	O
%)	O
used	O
the	O
CHS	O
,	O
35	O
%	O
private	O
clinics	O
,	O
and	O
31	O
%	O
the	O
district	O
hospital	O
.	O

Approximately	O
10	O
%	O
of	O
women	O
went	O
to	O
the	O
provincial	O
or	O
central	O
hospital	O
for	O
this	O
service	O
.	O

The	O
total	O
percentage	O
was	O
greater	O
than	O
100	O
%,	O
as	O
women	O
may	O
visit	O
multiple	O
health	O
facilities	O
during	O
the	O
gestational	O
period	O
(	O
Table	O
3	O
).	O

The	O
use	O
of	O
antenatal	O
check	O
-	O
up	O
and	O
delivery	O
service	O
by	O
health	O
facility	O

Health	O
Facility	O

Antenatal	O
check	O
-	O
up	O
(	O
n	O
=	O
857	O
)	O

Delivery	O
(	O
n	O
=	O
942	O
)	O

Gyn	O
.	O
examination	O
(	O
n	O
=	O
759	O
)	O


n	O

%	O

n	O

%	O

n	O

%	O

CHS	B-GP

473	O

55	O
.	O
2	O

181	O

19	O
.	O
2	O

585	O

77	O
.	O
1	O


Dist	O
.	O
hospital	O

269	O

31	O
.	O
4	O

351	O

37	O
.	O
3	O

62	O

8	O
.	O
2	O


Prov	O
./	O
Cent	O
.	O
hospital	O

84	O

9	O
.	O
8	O

188	O

20	O
.	O
0	O

24	O

3	O
.	O
2	O


Private	O
clinic	O

303	O

35	O
.	O
4	O

106	O

11	O
.	O
3	O

80	O

10	O
.	O
5	O


Home	O

NA	O

NA	O

66	O

7	O
.	O
0	O

NA	O

NA	O


Self	O
-	O
delivery	O

NA	O

NA	O

22	O

2	O
.	O
2	O

NA	O

NA	O


Other	O

6	O

0	O
.	O
7	O

28	O

3	O
.	O
0	O

8	O

1	O
.	O
0	O

NA	O
:	O
Not	O
applicable	O

Analyses	O
of	O
data	O
by	O
provinces	O
found	O
that	O
in	O
Thua	O
Thien	O
Hue	O
,	O
the	O
local	O
CHS	O
was	O
the	O
most	O
favorable	O
service	O
provider	O
in	O
rural	O
districts	O
,	O
attracting	O
76	O
%	O
of	O
women	O
,	O
compared	O
to	O
district	O
hospitals	O
(	O
34	O
%),	O
and	O
private	O
clinics	O
(	O
15	O
%).	O

In	O
the	O
city	O
,	O
private	O
clinics	O
ranked	O
first	O
,	O
visited	O
by	O
50	O
%	O
of	O
women	O
,	O
with	O
the	O
local	O
CHS	O
and	O
district	O
hospital	O
each	O
reporting	O
access	O
by	O
32	O
%	O
of	O
women	O
.	O

In	O
both	O
settings	O
,	O
around	O
5	O
%	O
of	O
women	O
reported	O
visiting	O
Hue	O
central	O
hospital	O
for	O
ANC	O
services	O
during	O
their	O
last	O
pregnancy	O
(	O
Figure	O
1	O
).	O

In	O
Vinh	O
Long	O
where	O
the	O
survey	O
only	O
included	O
rural	O
communes	O
,	O
an	O
almost	O
equal	O
proportion	O
of	O
women	O
(	O
47	O
%	O
and	O
46	O
%)	O
reported	O
using	O
CHSs	O
and	O
private	O
clinics	O
,	O
with	O
29	O
%	O
visiting	O
the	O
district	O
hospital	O
,	O
and	O
15	O
%	O
going	O
to	O
the	O
provincial	O
or	O
central	O
hospital	O
for	O
ANC	O
services	O
(	O
Figure	O
2	O
).	O

Health	O
facility	O
visited	O
for	O
antenatal	O
check	O
-	O
ups	O
at	O
the	O
latest	O
pregnancy	O
in	O
Thua	O
Thien	O
Hue	O
(	O
n	O
=	O
402	O
).	O

Health	O
facility	O
visited	O
for	O
antenatal	O
check	O
-	O
ups	O
at	O
the	O
latest	O
pregnancy	O
in	O
Vinh	O
Long	O
(	O
n	O
=	O
455	O
).	O

Delivery	O
service	O
use	O

Of	O
942	O
women	O
who	O
reported	O
a	O
delivery	O
,	O
854	O
(	O
91	O
%)	O
had	O
their	O
latest	O
delivery	O
in	O
a	O
health	O
facility	O
.	O

The	O
district	O
hospital	O
was	O
selected	O
by	O
the	O
highest	O
proportion	O
of	O
women	O
(	O
37	O
%),	O
followed	O
by	O
provincial	O
or	O
central	O
hospitals	O
(	O
20	O
%),	O
then	O
CHS	O
(	O
19	O
%),	O
and	O
private	O
providers	O
(	O
11	O
%).	O

Only	O
7	O
%	O
of	O
women	O
had	O
home	O
-	O
based	O
delivery	O
with	O
a	O
birth	O
attendant	O
and	O
2	O
%	O
practised	O
self	O
-	O
delivery	O
(	O
Table	O
3	O
).	O

Gynecological	O
check	O
-	O
up	O
service	O
use	O

Sixty	O
four	O
percent	O
of	O
surveyed	O
women	O
(	O
n	O
=	O
759	O
)	O
reported	O
having	O
undertaken	O
gynecological	O
check	O
-	O
ups	O
.	O

During	O
the	O
most	O
recent	O
check	O
-	O
up	O
,	O
the	O
highest	O
percentage	O
(	O
77	O
%)	O
visited	O
the	O
local	O
CHS	O
,	O
11	O
%	O
opted	O
for	O
private	O
clinics	O
,	O
8	O
%	O
went	O
to	O
the	O
district	O
hospital	O
.	O

Only	O
3	O
%	O
went	O
to	O
the	O
provincial	O
/	O
central	O
hospital	O
for	O
this	O
service	O
(	O
Table	O
3	O
).	O

Socio	O
-	O
demographic	O
determinants	O
of	O
RH	O
service	O
use	O
at	O
the	O
local	O
CHS	O

Table	O
4	O
presents	O
the	O
results	O
of	O
the	O
logistic	O
regression	O
analyses	O
.	O

The	O
analyses	O
found	O
that	O
the	O
CHS	O
antenatal	O
check	O
-	O
up	O
and	O
gynecological	O
examination	O
services	O
were	O
both	O
strongly	O
related	O
to	O
number	O
of	O
children	O
(<	O
=	O
2	O
vs	O
.	O
>	O
2	O
),	O
religion	O
(	O
Buddhist	O
vs	O
.	O
each	O
of	O
other	O
groups	O
:	O
Catholic	O
,	O
non	O
-	O
Buddhist	O
and	O
non	O
-	O
Catholic	O
,	O
and	O
non	O
-	O
religious	O
affiliation	O
),	O
occupation	O
(	O
farmers	O
vs	O
.	O
other	O
groups	O
:	O
government	O
cadres	O
,	O
factory	O
workers	O
,	O
small	O
traders	O
,	O
and	O
students	O
),	O
and	O
self	O
-	O
reported	O
income	O
(	O
first	O
quartile	O
vs	O
.	O
each	O
of	O
other	O
3	O
quartiles	O
).	O

Women	O
with	O
more	O
than	O
2	O
children	O
,	O
having	O
a	O
non	O
-	O
Buddhist	O
/	O
non	O
-	O
religious	O
affiliation	O
,	O
or	O
living	O
in	O
Thua	O
Thien	O
Hue	O
(	O
compared	O
to	O
Vinh	O
Long	O
)	O
were	O
more	O
likely	O
than	O
others	O
to	O
attend	O
antenatal	O
check	O
-	O
ups	O
during	O
their	O
latest	O
pregnancy	O
,	O
or	O
to	O
have	O
their	O
most	O
recent	O
gynecological	O
examination	O
at	O
their	O
local	O
CHS	O
.	O

Women	O
with	O
a	O
non	O
-	O
farming	O
occupation	O
or	O
earning	O
a	O
higher	O
income	O
were	O
less	O
likely	O
than	O
others	O
to	O
visit	O
their	O
local	O
CHS	O
for	O
these	O
two	O
services	O
.	O

Regarding	O
delivery	O
service	O
use	O
,	O
mothers	O
of	O
minority	O
ethnic	O
groups	O
were	O
more	O
likely	O
than	O
those	O
of	O
the	O
majority	O
ethnic	O
group	O
to	O
have	O
their	O
latest	O
delivery	O
at	O
the	O
local	O
CHS	O
,	O
which	O
was	O
also	O
true	O
for	O
non	O
-	O
Buddhist	O
/	O
non	O
-	O
religious	O
mothers	O
compared	O
with	O
Buddhist	O
mothers	O
.	O

Women	O
from	O
non	O
-	O
farming	O
occupations	O
,	O
or	O
earning	O
a	O
higher	O
income	O
,	O
were	O
less	O
likely	O
to	O
choose	O
CHS	O
-	O
based	O
delivery	O
.	O

It	O
is	O
noted	O
that	O
the	O
use	O
of	O
CHS	O
antenatal	O
check	O
-	O
up	O
service	O
was	O
significantly	O
related	O
to	O
living	O
location	O
,	O
with	O
rural	O
women	O
more	O
likely	O
than	O
their	O
urban	O
counterparts	O
to	O
use	O
this	O
CHS	O
service	O
.	O

None	O
of	O
women	O
in	O
the	O
city	O
reported	O
having	O
their	O
latest	O
delivery	O
at	O
the	O
CHS	O
.	O

Factors	O
related	O
to	O
the	O
use	O
of	O
RH	O
services	O
available	O
at	O
the	O
local	O
CHS	O
(	O
Reduced	O
logistic	O
regression	O
model	O
)	O

Factors	O

Category	O

OR	O
(	O
95	O
%	O
CI	O
)	O

Antenatal	O
check	O
-	O
up	O
(	O
n	O
=	O
835	O
)	O

Delivery	O
(	O
n	O
=	O
577	O
)	O

Gynecological	O
check	O
-	O
up	O
(	O
n	O
=	O
718	O
)	O


Children	O

<	O
=	O
2	O

Ref	O

Ref	O

Ref	O


>	O
2	O

1	O
.	O
61	O
(	O
1	O
.	O
13	O
-	O
2	O
.	O
31	O
)	O

NS	O

1	O
.	O
62	O
(	O
1	O
.	O
01	O
-	O
2	O
.	O
06	O
)	O


Religion	O

Buddhist	O

Ref	O

Ref	O

Ref	O


Catholic	O

2	O
.	O
91	O
(	O
1	O
.	O
36	O
-	O
6	O
.	O
25	O
)	O

3	O
.	O
05	O
(	O
1	O
.	O
49	O
-	O
6	O
.	O
26	O
)	O

3	O
.	O
19	O
(	O
1	O
.	O
04	O
-	O
9	O
.	O
85	O
)	O


Other	O

3	O
.	O
10	O
(	O
1	O
.	O
39	O
-	O
6	O
.	O
90	O
)	O

2	O
.	O
85	O
(	O
1	O
.	O
16	O
-	O
7	O
.	O
01	O
)	O

7	O
.	O
91	O
(	O
2	O
.	O
24	O
-	O
27	O
.	O
97	O
)	O


None	O

2	O
.	O
01	O
(	O
1	O
.	O
38	O
-	O
2	O
.	O
92	O
)	O

2	O
.	O
17	O
(	O
1	O
.	O
39	O
-	O
3	O
.	O
38	O
)	O

3	O
.	O
60	O
(	O
2	O
.	O
36	O
-	O
5	O
.	O
49	O
)	O


Ethnicity	O

Majority	O

Ref	O

Ref	O

Ref	O


Minority	O

NS	O

2	O
.	O
20	O
(	O
1	O
.	O
32	O
-	O
3	O
.	O
69	O
)	O

NS	O


Occupation	O

Farming	O

Ref	O

Ref	O

Ref	O


Non	O
-	O
farming	O

0	O
.	O
64	O
(	O
0	O
.	O
45	O
-	O
0	O
.	O
90	O
)	O

0	O
.	O
22	O
(	O
0	O
.	O
15	O
-	O
033	O
)	O

0	O
.	O
72	O
(	O
0	O
.	O
57	O
-	O
0	O
.	O
91	O
)	O


Living	O
location	O

Urban	O

Ref	O

Ref	O

Ref	O


Rural	O

2	O
.	O
79	O
(	O
1	O
.	O
59	O
-	O
4	O
.	O
91	O
)	O

ND	O

NS	O


Province	O

Vinh	O
Long	O

Ref	O

Ref	O

Ref	O


Thua	O
Thien	O
Hue	O

2	O
.	O
83	O
(	O
1	O
.	O
88	O
-	O
4	O
.	O
26	O
)	O

NS	O

3	O
.	O
33	O
(	O
2	O
.	O
11	O
-	O
5	O
.	O
26	O
)	O


Income	O

1st	O
quartile	O

Ref	O

Ref	O

Ref	O


2nd	O
quartile	O

0	O
.	O
79	O
(	O
0	O
.	O
53	O
-	O
1	O
.	O
17	O
)	O

0	O
.	O
73	O
(	O
0	O
.	O
47	O
-	O
1	O
.	O
13	O
)	O

0	O
.	O
41	O
(	O
0	O
.	O
24	O
-	O
0	O
.	O
71	O
)	O


3rd	O
quartile	O

0	O
.	O
52	O
(	O
0	O
.	O
33	O
-	O
0	O
.	O
83	O
)	O

0	O
.	O
57	O
(	O
0	O
.	O
34	O
-	O
0	O
.	O
97	O
)	O

0	O
.	O
40	O
(	O
0	O
.	O
22	O
-	O
0	O
.	O
75	O
)	O


4th	O
quartile	O

0	O
.	O
42	O
(	O
0	O
.	O
26	O
-	O
0	O
.	O
67	O
)	O

0	O
.	O
33	O
(	O
0	O
.	O
18	O
-	O
0	O
.	O
61	O
)	O

0	O
.	O
34	O
(	O
0	O
.	O
18	O
-	O
0	O
.	O
63	O
)	O

NS	O
:	O
not	O
statistically	O
significant	O
so	O
not	O
included	O
in	O
the	O
model	O
;	O
ND	O
:	O
the	O
variable	O
is	O
excluded	O
because	O
none	O
of	O
the	O
urban	O
women	O
reported	O
delivery	O
at	O
CHSs	O

Discussion	O

This	O
study	O
is	O
among	O
the	O
first	O
examining	O
the	O
pattern	O
of	O
RH	O
and	O
FP	O
service	O
utilization	O
at	O
the	O
CHS	O
and	O
in	O
other	O
health	O
facilities	O
in	O
the	O
context	O
of	O
change	O
in	O
the	O
healthcare	O
system	O
in	O
Vietnam	O
.	O

With	O
basic	O
RH	O
services	O
available	O
from	O
a	O
range	O
of	O
health	O
facilities	O
,	O
women	O
in	O
Vietnam	O
,	O
especially	O
those	O
in	O
urbanized	O
areas	O
,	O
have	O
been	O
given	O
a	O
range	O
of	O
alternatives	O
.	O

However	O
,	O
state	O
services	O
continue	O
to	O
dominate	O
,	O
though	O
private	O
services	O
are	O
playing	O
a	O
significant	O
role	O
.	O

In	O
general	O
,	O
the	O
local	O
CHS	O
appears	O
to	O
be	O
the	O
most	O
frequently	O
used	O
health	O
facility	O
for	O
FP	O
,	O
ANC	O
,	O
and	O
gynecological	O
examination	O
services	O
,	O
all	O
free	O
or	O
heavily	O
subsidized	O
.	O

Hospitals	O
dominate	O
the	O
provision	O
of	O
delivery	O
services	O
.	O

There	O
were	O
marked	O
differentials	O
in	O
women	O
'	O
s	O
selection	O
of	O
service	O
providers	O
for	O
ANC	O
and	O
delivery	O
services	O
between	O
rural	O
and	O
urban	O
areas	O
.	O

Data	O
on	O
behavioral	O
RH	O
care	O
indicators	O
in	O
the	O
selected	O
districts	O
were	O
impressive	O
with	O
a	O
very	O
high	O
proportion	O
of	O
married	O
women	O
currently	O
using	O
a	O
birth	O
control	O
method	O
,	O
high	O
rates	O
of	O
pregnant	O
women	O
having	O
sufficient	O
ANC	O
and	O
giving	O
birth	O
at	O
a	O
health	O
facility	O
.	O

These	O
data	O
were	O
comparable	O
with	O
the	O
national	O
-	O
level	O
statistics	O
over	O
the	O
past	O
5	O
years	O
[	O
13	O
]	O
that	O
reported	O
high	O
national	O
rates	O
of	O
contraceptive	O
use	O
(	O
80	O
%-	O
90	O
%),	O
at	O
least	O
3	O
antenatal	O
visits	O
in	O
pregnant	O
women	O
(	O
87	O
%),	O
and	O
deliveries	O
attended	O
by	O
trained	O
health	O
personnel	O
(	O
95	O
%	O
or	O
higher	O
)	O
[	O
14	O
,	O
15	O
].	O

The	O
pattern	O
of	O
birth	O
control	O
methods	O
currently	O
used	O
was	O
also	O
keeping	O
with	O
the	O
national	O
data	O
that	O
reported	O
IUD	O
to	O
be	O
the	O
most	O
popular	O
method	O
applied	O
by	O
around	O
56	O
%	O
of	O
married	O
couples	O
[	O
14	O
].	O

The	O
high	O
levels	O
of	O
contraceptive	O
use	O
,	O
with	O
the	O
local	O
CHS	O
as	O
the	O
major	O
supplier	O
,	O
indicates	O
that	O
the	O
model	O
of	O
providing	O
FP	O
services	O
in	O
Vietnam	O
is	O
effective	O
,	O
and	O
able	O
to	O
meet	O
local	O
needs	O
.	O

Historically	O
,	O
the	O
CHS	O
has	O
been	O
serving	O
as	O
the	O
primary	O
access	O
point	O
for	O
FP	O
services	O
under	O
the	O
national	O
population	O
and	O
family	O
planning	O
program	O
since	O
early	O
1960s	O
.	O

Over	O
time	O
,	O
the	O
CHS	O
has	O
gained	O
a	O
reputation	O
for	O
its	O
provision	O
of	O
subsidized	O
FP	O
services	O
,	O
with	O
delivery	O
of	O
FP	O
services	O
strengthened	O
by	O
the	O
population	O
collaborator	O
network	O
,	O
providing	O
women	O
with	O
easy	O
access	O
to	O
low	O
-	O
cost	O
,	O
community	O
-	O
based	O
services	O
.	O

The	O
contribution	O
of	O
the	O
local	O
pharmacy	O
is	O
also	O
significant	O
,	O
diversifying	O
the	O
provision	O
of	O
condoms	O
or	O
other	O
contraceptive	O
commodities	O
at	O
the	O
commune	O
level	O
.	O

The	O
hospital	O
and	O
private	O
providers	O
appear	O
to	O
have	O
a	O
little	O
role	O
in	O
the	O
provision	O
of	O
IUD	O
services	O
and	O
other	O
FP	O
commodities	O
(	O
i	O
.	O
e	O
.	O
condoms	O
or	O
pills	O
).	O

The	O
CHS	O
also	O
appears	O
to	O
be	O
a	O
major	O
provider	O
for	O
antenatal	O
check	O
-	O
ups	O
,	O
particularly	O
in	O
the	O
rural	O
area	O
,	O
although	O
the	O
number	O
of	O
private	O
antenatal	O
service	O
users	O
was	O
significant	O
.	O

This	O
finding	O
counters	O
previous	O
studies	O
that	O
reported	O
lower	O
use	O
of	O
primary	O
healthcare	O
and	O
outpatient	O
treatment	O
services	O
at	O
CHSs	O
compared	O
to	O
private	O
clinics	O
or	O
hospitals	O
[	O
1	O
,	O
16	O
].	O

Antenatal	O
care	O
check	O
-	O
ups	O
at	O
the	O
CHS	O
are	O
subsidized	O
and	O
accompanied	O
by	O
free	O
pre	O
-	O
natal	O
tetanus	B-DS
vaccination	O
,	O
and	O
the	O
CHS	O
is	O
proactive	O
in	O
inviting	O
mothers	O
to	O
register	O
for	O
the	O
monthly	O
antenatal	O
clinic	O
when	O
their	O
pregnancy	O
is	O
confirmed	O
.	O

However	O
,	O
while	O
CHSs	O
continue	O
to	O
dominate	O
the	O
provision	O
of	O
ANC	O
services	O
,	O
a	O
preference	O
for	O
delivery	O
in	O
hospitals	O
was	O
clear	O
in	O
these	O
districts	O
,	O
a	O
finding	O
consistent	O
with	O
rising	O
economic	O
status	O
and	O
increasing	O
patient	O
expectations	O
of	O
the	O
health	O
system	O
in	O
Vietnam	O
[	O
2	O
,	O
8	O
,	O
17	O
].	O

Living	O
location	O
affects	O
the	O
selection	O
of	O
ANC	O
service	O
providers	O
,	O
with	O
rural	O
women	O
more	O
likely	O
than	O
their	O
urban	O
counterparts	O
to	O
use	O
the	O
CHS	O
.	O

The	O
same	O
differential	O
was	O
not	O
seen	O
in	O
the	O
choice	O
of	O
services	O
relating	O
to	O
delivery	O
,	O
with	O
women	O
living	O
in	O
rural	O
areas	O
as	O
likely	O
to	O
choose	O
a	O
hospital	O
as	O
those	O
in	O
the	O
city	O
.	O

In	O
both	O
settings	O
,	O
district	O
hospitals	O
have	O
become	O
the	O
most	O
popular	O
provider	O
for	O
this	O
service	O
,	O
while	O
the	O
role	O
of	O
the	O
local	O
CHS	O
has	O
tended	O
to	O
diminish	O
.	O

Our	O
data	O
support	O
earlier	O
studies	O
that	O
found	O
a	O
low	O
use	O
of	O
CHS	O
delivery	O
services	O
,	O
with	O
most	O
women	O
preferring	O
district	O
hospital	O
-	O
based	O
delivery	O
because	O
of	O
the	O
perceived	O
better	O
quality	O
of	O
services	O
for	O
both	O
mothers	O
and	O
newborn	O
[	O
7	O
,	O
8	O
].	O

The	O
data	O
also	O
support	O
the	O
qualitative	O
study	O
in	O
these	O
provinces	O
that	O
noted	O
the	O
2	O
-	O
child	O
population	O
control	O
policy	O
has	O
made	O
couples	O
more	O
cautious	O
about	O
outcomes	O
for	O
their	O
baby	O
,	O
choosing	O
hospital	O
-	O
based	O
delivery	O
where	O
they	O
are	O
more	O
confident	O
in	O
provider	O
'	O
s	O
expertise	O
and	O
equipment	O
,	O
and	O
life	O
saving	O
emergency	O
care	O
is	O
readily	O
available	O
[	O
4	O
].	O

The	O
high	O
use	O
of	O
gynecological	O
check	O
-	O
up	O
services	O
at	O
the	O
local	O
CHS	O
was	O
attributed	O
in	O
part	O
to	O
the	O
national	O
RH	O
semi	O
-	O
annual	O
campaign	O
.	O

Although	O
this	O
national	O
campaign	O
is	O
aimed	O
at	O
early	O
detection	O
and	O
treatment	O
of	O
RTIs	O
,	O
population	O
-	O
based	O
studies	O
conducted	O
within	O
the	O
last	O
10	O
years	O
,	O
including	O
one	O
study	O
in	O
Thua	O
Thien	O
Hue	O
,	O
reported	O
a	O
prevalence	O
of	O
RTIs	O
ranging	O
from	O
21	O
%	O
to	O
39	O
%	O
among	O
women	O
of	O
reproductive	O
age	O
[	O
18	O
-	O
20	O
].	O

The	O
RTIs	O
prevalence	O
was	O
found	O
to	O
be	O
even	O
higher	O
in	O
hospital	O
-	O
or	O
clinic	O
-	O
based	O
studies	O
,	O
though	O
these	O
were	O
subject	O
to	O
selection	O
bias	O
[	O
21	O
,	O
22	O
].	O

While	O
RTIs	O
can	O
change	O
overtime	O
and	O
vary	O
by	O
provinces	O
,	O
such	O
high	O
prevalence	O
raises	O
questions	O
around	O
the	O
strategic	O
use	O
of	O
CHS	O
-	O
based	O
free	O
gynecological	O
check	O
-	O
ups	O
during	O
the	O
national	O
semi	O
-	O
annual	O
RH	O
campaign	O
,	O
with	O
questions	O
over	O
the	O
quality	O
and	O
efficacy	O
of	O
this	O
service	O
as	O
an	O
intervention	O
strategy	O
.	O

Private	O
physicians	O
were	O
important	O
providers	O
for	O
ANC	O
services	O
in	O
both	O
rural	O
and	O
urban	O
areas	O
,	O
despite	O
their	O
uneven	O
geographical	O
distribution	O
.	O

With	O
RH	O
private	O
clinics	O
mostly	O
concentrated	O
in	O
urban	O
areas	O
,	O
using	O
private	O
services	O
not	O
only	O
incurred	O
higher	O
fees	O
,	O
but	O
also	O
travel	O
expenses	O
for	O
rural	O
women	O
.	O

Yet	O
,	O
a	O
significant	O
proportion	O
of	O
rural	O
women	O
used	O
private	O
clinics	O
during	O
their	O
latest	O
pregnancy	O
.	O

Previous	O
studies	O
report	O
criticism	O
of	O
state	O
facilities	O
and	O
a	O
preference	O
for	O
reproductive	O
healthcare	O
provided	O
at	O
private	O
clinics	O
,	O
though	O
,	O
paradoxically	O
,	O
these	O
private	O
clinics	O
are	O
serviced	O
by	O
physicians	O
who	O
routinely	O
work	O
in	O
state	O
health	O
facilities	O
[	O
23	O
].	O

In	O
the	O
private	O
clinics	O
,	O
clients	O
may	O
be	O
entitled	O
to	O
direct	O
access	O
to	O
more	O
senior	O
clinicians	O
,	O
and	O
find	O
staff	O
more	O
responsive	O
,	O
compared	O
to	O
their	O
reception	O
in	O
state	O
services	O
[	O
23	O
].	O

While	O
CHSs	O
maintained	O
dominance	O
in	O
provision	O
of	O
ANC	O
services	O
,	O
there	O
was	O
a	O
clear	O
upwards	O
trend	O
for	O
the	O
use	O
of	O
private	O
antenatal	O
services	O
,	O
consistent	O
with	O
trends	O
for	O
other	O
health	O
service	O
use	O
in	O
Vietnam	O
[	O
1	O
,	O
2	O
].	O

In	O
essence	O
,	O
the	O
patterns	O
of	O
RH	O
service	O
provider	O
choice	O
were	O
driven	O
by	O
socio	O
-	O
economic	O
and	O
geographic	O
factors	O
.	O

Women	O
of	O
lower	O
socio	O
-	O
economic	O
status	O
,	O
who	O
were	O
farmers	O
,	O
earning	O
a	O
lower	O
income	O
,	O
having	O
more	O
than	O
2	O
children	O
,	O
and	O
living	O
in	O
a	O
rural	O
area	O
were	O
more	O
likely	O
to	O
use	O
antenatal	O
,	O
delivery	O
,	O
and	O
/	O
or	O
gynecological	O
check	O
-	O
up	O
services	O
at	O
the	O
local	O
CHS	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
previous	O
studies	O
that	O
found	O
the	O
poor	O
tend	O
to	O
use	O
the	O
CHS	O
more	O
frequently	O
than	O
the	O
rich	O
[	O
1	O
,	O
24	O
].	O

Among	O
the	O
2	O
provinces	O
,	O
a	O
higher	O
percentage	O
of	O
women	O
in	O
Thua	O
Thien	O
Hue	O
reported	O
visiting	O
their	O
local	O
CHS	O
for	O
ANC	O
and	O
gynecological	O
check	O
up	O
services	O
.	O

This	O
difference	O
can	O
be	O
explained	O
by	O
the	O
higher	O
number	O
of	O
CHSs	O
in	O
sampled	O
communes	O
in	O
Thua	O
Thien	O
Hue	O
staffed	O
by	O
a	O
doctor	O
(	O
13	O
),	O
compared	O
to	O
those	O
in	O
Vinh	O
Long	O
(	O
10	O
)	O
[	O
25	O
].	O

In	O
Vinh	O
Long	O
,	O
2	O
of	O
3	O
districts	O
included	O
in	O
the	O
survey	O
had	O
an	O
accredited	O
private	O
RH	O
clinic	O
,	O
while	O
there	O
were	O
none	O
in	O
rural	O
districts	O
of	O
Thua	O
Thien	O
Hue	O
.	O

This	O
was	O
reflected	O
in	O
the	O
findings	O
that	O
more	O
rural	O
women	O
in	O
Vinh	O
Long	O
used	O
antenatal	O
check	O
-	O
ups	O
at	O
private	O
clinics	O
and	O
fewer	O
of	O
them	O
used	O
this	O
service	O
at	O
the	O
CHS	O
compared	O
to	O
their	O
counterparts	O
in	O
Thua	O
Thien	O
Hue	O
,	O
though	O
in	O
both	O
provinces	O
,	O
there	O
were	O
low	O
levels	O
of	O
delivery	O
in	O
private	O
facilities	O
.	O

This	O
difference	O
also	O
indicates	O
a	O
shift	O
from	O
CHSs	O
to	O
private	O
doctors	O
for	O
ANC	O
services	O
where	O
they	O
are	O
locally	O
accessible	O
,	O
reducing	O
the	O
use	O
for	O
services	O
delivered	O
through	O
the	O
CHS	O
system	O
.	O

The	O
study	O
findings	O
should	O
be	O
considered	O
in	O
conjunction	O
with	O
the	O
limitations	O
of	O
the	O
research	O
.	O

The	O
sample	O
was	O
drawn	O
from	O
districts	O
purposively	O
selected	O
for	O
the	O
intervention	O
project	O
,	O
and	O
thus	O
not	O
representative	O
for	O
the	O
whole	O
province	O
.	O

Although	O
the	O
percentage	O
of	O
women	O
who	O
have	O
a	O
current	O
sexual	O
partner	O
(	O
3	O
%)	O
was	O
consistent	O
with	O
national	O
data	O
on	O
prevalence	O
of	O
premarital	O
sex	O
among	O
young	O
women	O
(	O
5	O
.	O
2	O
%),	O
[	O
26	O
]	O
the	O
sample	O
of	O
unmarried	O
women	O
was	O
too	O
small	O
for	O
meaningful	O
statistical	O
analyses	O
.	O

Data	O
were	O
self	O
-	O
reported	O
,	O
and	O
may	O
incur	O
recall	O
bias	O
with	O
regards	O
to	O
the	O
history	O
of	O
RH	O
service	O
use	O
,	O
particularly	O
with	O
ANC	O
and	O
delivery	O
services	O
.	O

Conclusions	O

Although	O
the	O
CHS	O
in	O
this	O
study	O
retains	O
significant	O
utilization	O
rates	O
and	O
constitutes	O
an	O
important	O
provider	O
of	O
primary	O
RH	O
services	O
,	O
it	O
is	O
under	O
challenge	O
on	O
three	O
fronts	O
.	O

The	O
first	O
challenge	O
is	O
from	O
the	O
significant	O
use	O
of	O
private	O
practice	O
for	O
ANC	O
,	O
where	O
clients	O
have	O
direct	O
access	O
to	O
higher	O
grades	O
of	O
health	O
care	O
providers	O
,	O
and	O
are	O
willing	O
to	O
pay	O
higher	O
fees	O
for	O
their	O
perceptions	O
of	O
better	O
quality	O
of	O
care	O
.	O

Secondly	O
,	O
although	O
the	O
semi	O
-	O
annual	O
gynecological	O
screening	O
continues	O
to	O
attract	O
significant	O
numbers	O
of	O
women	O
with	O
its	O
subsidized	O
service	O
,	O
its	O
effectiveness	O
as	O
a	O
population	O
strategy	O
is	O
questionable	O
,	O
and	O
the	O
quality	O
of	O
services	O
needs	O
evaluation	O
.	O

Thirdly	O
,	O
the	O
preference	O
for	O
delivery	O
in	O
district	O
hospitals	O
over	O
CHS	O
is	O
marked	O
,	O
and	O
arguably	O
,	O
government	O
services	O
would	O
do	O
well	O
to	O
move	O
towards	O
strengthened	O
referral	O
services	O
and	O
shared	O
care	O
with	O
the	O
CHS	O
,	O
rather	O
than	O
invest	O
in	O
duplication	O
of	O
these	O
functions	O
at	O
both	O
levels	O
.	O

To	O
address	O
these	O
challenges	O
,	O
the	O
CHS	B-GP
system	O
needs	O
to	O
be	O
responsive	O
to	O
specific	O
local	O
needs	O
.	O

In	O
areas	O
with	O
accessible	O
alternative	O
health	O
services	O
reducing	O
the	O
need	O
for	O
CHS	O
services	O
,	O
rationalizing	O
of	O
services	O
is	O
needed	O
.	O

Those	O
CHSs	O
that	O
attempt	O
to	O
function	O
in	O
the	O
shadow	O
of	O
hospital	O
facilities	O
need	O
to	O
be	O
protected	O
by	O
referral	O
practices	O
and	O
clear	O
differentiation	O
of	O
services	O
to	O
avoid	O
unnecessary	O
provision	O
of	O
routine	O
RH	O
care	O
by	O
more	O
costly	O
staff	O
,	O
in	O
higher	O
cost	O
level	O
facilities	O
.	O

At	O
the	O
same	O
time	O
,	O
efforts	O
should	O
be	O
made	O
to	O
improve	O
service	O
quality	O
at	O
the	O
local	O
CHS	O
as	O
the	O
economy	O
improves	O
and	O
clients	O
demonstrate	O
growing	O
demand	O
for	O
higher	O
quality	O
services	O
.	O

With	O
the	O
reduction	O
in	O
government	O
subsidies	O
,	O
a	O
responsive	O
payment	O
scheme	O
must	O
be	O
developed	O
at	O
the	O
CHS	O
level	O
that	O
generates	O
income	O
for	O
the	O
sustainable	O
provision	O
of	O
quality	O
services	O
,	O
but	O
retains	O
subsidized	O
services	O
for	O
the	O
poor	O
who	O
continue	O
to	O
rely	O
on	O
their	O
local	O
CHS	O
for	O
basic	O
reproductive	O
healthcare	O
.	O

Abbreviations	O

ANC	O
:	O
Antenatal	O
care	O
;	O
CHS	O
:	O
Commune	O
Health	O
Station	O
;	O
CI	O
:	O
Confidence	O
Interval	O
;	O
FP	O
:	O
Family	O
Planning	O
;	O
IUD	O
:	O
Intra	O
uterine	O
device	O
;	O
RH	O
:	O
Reproductive	O
Health	O
;	O
OR	O
:	O
Odd	O
Ratios	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

AN	O
conceived	O
research	O
ideas	O
,	O
developed	O
research	O
protocol	O
and	O
data	O
collection	O
tools	O
,	O
and	O
conducted	O
data	O
collection	O
and	O
data	O
entry	O
.	O

AN	O
performed	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
with	O
input	O
from	O
PH	O
.	O

PH	O
made	O
a	O
substantial	O
contribution	O
in	O
revising	O
the	O
manuscript	O
for	O
intellectual	O
content	O
.	O

All	O
authors	O
reviewed	O
and	O
approved	O
the	O
final	O
version	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1472	O
-	O
6963	O
/	O
11	O
/	O
237	O
/	O
prepub	O

Supplementary	O
Material	O

Additional	O
file	O
1	O

Study	O
questionnaire	O
.	O

Click	O
here	O
for	O
file	O

Ammonia	O
-	O
lowering	O
activities	O
and	O
carbamoyl	B-GP
phosphate	I-GP
synthetase	I-GP
1	I-GP
(	O
Cps1	B-GP
)	O
induction	O
mechanism	O
of	O
a	O
natural	O
flavonoid	B-CD

Objective	O

Ammonia	O
detoxification	O
is	O
essential	O
for	O
physiological	O
well	O
-	O
being	O
,	O
and	O
the	O
urea	B-CD
cycle	O
in	O
liver	O
plays	O
a	O
predominant	O
role	O
in	O
ammonia	O
disposal	O
.	O

Nobiletin	B-CD
(	O
NOB	O
),	O
a	O
natural	O
dietary	O
flavonoid	B-CD
,	O
is	O
known	O
to	O
exhibit	O
various	O
physiological	O
efficacies	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
a	O
potential	O
role	O
of	O
NOB	O
in	O
ammonia	O
control	O
and	O
the	O
underlying	O
cellular	O
mechanism	O
.	O

Materials	O
/	O
methods	O

C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
were	O
fed	O
with	O
regular	O
chow	O
(	O
RC	O
),	O
high	O
-	O
fat	O
(	O
HFD	O
)	O
or	O
high	O
-	O
protein	O
diet	O
(	O
HPD	O
)	O
and	O
treated	O
with	O
either	O
vehicle	O
or	O
NOB	O
.	O

Serum	O
and	O
/	O
or	O
urine	O
levels	O
of	O
ammonia	O
and	O
urea	B-CD
were	O
measured	O
.	O

Liver	O
expression	O
of	O
genes	O
encoding	O
urea	B-CD
cycle	B-GP
enzymes	I-GP
and	O
C	B-GP
/	I-GP
EBP	I-GP
transcription	B-GP
factors	I-GP
was	O
determined	O
over	O
the	O
circadian	O
cycle	O
.	O

Luciferase	B-GP
reporter	O
assays	O
were	O
carried	O
out	O
to	O
investigate	O
function	O
of	O
CCAAT	O
consensus	O
elements	O
on	O
the	O
carbamoyl	B-GP
phosphate	I-GP
synthetase	I-GP
(	O
Cps1	B-GP
)	O
gene	O
promoter	O
.	O

A	O
circadian	O
clock	B-GP
-	O
deficient	O
mouse	B-OG
mutant	O
,	O
ClockΔ19	O
/	O
Δ19	O
,	O
was	O
utilized	O
to	O
examine	O
a	O
requisite	O
role	O
of	O
the	O
circadian	O
clock	B-GP
in	O
mediating	O
NOB	O
induction	O
of	O
Cps1	B-GP
.	O

Results	O

NOB	O
was	O
able	O
to	O
lower	O
serum	O
ammonia	O
levels	O
in	O
mice	B-OG
fed	O
with	O
RC	O
,	O
HFD	O
or	O
HPD	O
.	O

Compared	O
with	O
RC	O
,	O
HFD	O
repressed	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
Cps1	B-GP
,	O
encoding	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
the	O
urea	B-CD
cycle	O
.	O

Interestingly	O
,	O
NOB	O
rescued	O
CPS1	B-GP
protein	O
levels	O
under	O
the	O
HFD	O
condition	O
via	O
induction	O
of	O
the	O
transcription	B-GP
factors	I-GP
C	B-GP
/	I-GP
EBPα	I-GP
and	O
C	B-GP
/	I-GP
EBPβ	I-GP
.	O

Expression	O
of	O
other	O
urea	B-GP
cycle	I-GP
genes	I-GP
was	O
also	O
decreased	O
by	O
HFD	O
relative	O
to	O
RC	O
and	O
again	O
restored	O
by	O
NOB	O
to	O
varying	O
degrees	O
,	O
which	O
,	O
in	O
conjunction	O
with	O
Cps1	B-GP
promoter	O
reporter	O
analysis	O
,	O
suggested	O
a	O
C	B-GP
/	I-GP
EBP	I-GP
-	O
dependent	O
mechanism	O
for	O
the	O
co	O
-	O
induction	O
of	O
urea	B-CD
cycle	O
genes	O
by	O
NOB	O
.	O

In	O
comparison	O
,	O
HPD	B-DS
markedly	O
increased	O
CPS1	B-GP
levels	O
relative	O
to	O
RC	O
,	O
yet	O
NOB	O
did	O
not	O
further	O
enrich	O
CPS1	B-GP
to	O
a	O
significant	O
extent	O
.	O

Using	O
the	O
circadian	O
mouse	B-OG
mutant	O
ClockΔ19	O
/	O
Δ19	O
,	O
we	O
also	O
showed	O
that	O
a	O
functional	O
circadian	O
clock	B-GP
,	O
known	O
to	O
modulate	O
C	B-GP
/	I-GP
EBP	I-GP
and	O
CPS1	B-GP
expression	O
,	O
was	O
required	O
for	O
NOB	O
induction	O
of	O
CPS1	B-GP
under	O
the	O
HFD	O
condition	O
.	O

Conclusion	O

NOB	O
,	O
a	O
dietary	O
flavonoid	B-CD
,	O
exhibits	O
a	O
broad	O
activity	O
in	O
ammonia	O
control	O
across	O
varying	O
diets	O
,	O
and	O
regulates	O
urea	B-CD
cycle	O
function	O
via	O
C	B-GP
/	I-GP
EBP	I-GP
-	O
and	O
clock	B-GP
-	O
dependent	O
regulatory	O
mechanisms	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12986	O
-	O
015	O
-	O
0020	O
-	O
7	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Introduction	O

Ammonia	O
detoxification	O
is	O
an	O
essential	O
bodily	O
function	O
required	O
for	O
nitrogen	O
homeostasis	O
and	O
physiological	O
well	O
-	O
being	O
[	O
1	O
–	O
3	O
].	O

Ammonia	O
molecules	O
are	O
produced	O
mainly	O
through	O
catabolism	O
of	O
amino	B-CD
acid	I-CD
and	O
other	O
nitrogenous	O
metabolites	O
in	O
tissues	O
,	O
and	O
also	O
via	O
amino	B-CD
acid	I-CD
deamination	O
and	O
urea	B-CD
salvage	O
by	O
gut	B-OG
bacteria	I-OG
[	O
1	O
,	O
4	O
].	O

Whereas	O
a	O
small	O
portion	O
of	O
ammonia	O
is	O
removed	O
via	O
direct	O
renal	O
excretion	O
,	O
the	O
urea	B-CD
cycle	O
in	O
the	O
liver	O
plays	O
a	O
predominant	O
role	O
in	O
ammonia	O
disposal	O
,	O
converting	O
ammonia	O
to	O
the	O
relatively	O
harmless	O
urea	B-CD
for	O
excretion	O
[	O
5	O
,	O
6	O
].	O

The	O
urea	B-CD
cycle	O
consists	O
of	O
five	O
enzymatic	O
reactions	O
sequentially	O
taking	O
place	O
in	O
the	O
mitochondrial	O
matrix	O
and	O
the	O
cytoplasm	O
of	O
periportal	O
hepatocytes	O
[	O
7	O
,	O
8	O
].	O

Carbamoyl	B-GP
phosphate	I-GP
synthetase	I-GP
1	I-GP
(	O
CPS1	B-GP
)	O
catalyzes	O
the	O
first	O
reaction	O
wherein	O
ammonia	O
and	O
bicarbonate	O
combine	O
to	O
form	O
carbamoyl	O
phosphate	O
,	O
and	O
mice	B-OG
deficient	O
in	O
Cps1	B-GP
suffered	O
pronounced	O
hyperammonemia	B-DS
and	O
neonatal	O
lethality	O
[	O
9	O
].	O

As	O
a	O
strikingly	O
abundant	O
protein	O
comprising	O
as	O
much	O
as	O
20	O
%	O
of	O
total	O
mitochondrial	B-GP
matrix	I-GP
protein	I-GP
mass	O
[	O
10	O
],	O
CPS1	B-GP
is	O
also	O
subjected	O
to	O
diverse	O
molecular	O
and	O
cellular	O
regulation	O
.	O

Besides	O
the	O
classically	O
known	O
allosteric	O
activator	O
N	B-GP
-	O
acetylglutamate	O
(	O
NAG	B-GP
),	O
CPS1	B-GP
level	O
and	O
activity	O
are	O
also	O
regulated	O
by	O
complex	O
molecular	O
and	O
physiological	O
mechanisms	O
[	O
7	O
,	O
11	O
–	O
16	O
].	O

Furthermore	O
,	O
coordinate	O
induction	O
of	O
urea	B-CD
cycle	O
components	O
has	O
also	O
been	O
reported	O
at	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
levels	O
[	O
7	O
,	O
17	O
].	O

An	O
emerging	O
cellular	O
mechanism	O
for	O
nitrogen	O
homeostasis	O
is	O
our	O
intrinsic	O
biological	O
timer	O
,	O
the	O
circadian	O
clock	B-GP
[	O
18	O
,	O
19	O
].	O

In	O
mammals	B-OG
,	O
core	O
clock	B-GP
genes	O
form	O
interlocked	O
feedback	O
loops	O
,	O
driving	O
gene	O
expression	O
to	O
regulate	O
various	O
metabolic	O
pathways	O
[	O
20	O
–	O
22	O
].	O

Several	O
earlier	O
studies	O
have	O
implicated	O
a	O
role	O
of	O
the	O
clock	B-GP
in	O
protein	O
or	O
nitrogen	O
metabolism	O
[	O
23	O
–	O
25	O
].	O

More	O
recently	O
,	O
it	O
was	O
shown	O
that	O
the	O
transcription	B-GP
factor	I-GP
Klf15	B-GP
is	O
encoded	O
by	O
a	O
clock	B-GP
-	O
controlled	O
gene	O
,	O
and	O
that	O
Klf15	B-GP
maintains	O
nitrogen	O
balance	O
via	O
regulation	O
of	O
the	O
second	O
urea	B-CD
cycle	O
gene	O
Otc	B-GP
[	O
19	O
].	O

Furthermore	O
,	O
genomic	O
and	O
proteomic	O
studies	O
have	O
also	O
demonstrated	O
circadian	O
variation	O
of	O
Cps1	B-GP
mRNA	O
and	O
protein	O
expression	O
in	O
mouse	B-OG
liver	O
,	O
although	O
discrepancies	O
remain	O
concerning	O
mRNA	O
oscillation	O
and	O
protein	O
peaks	O
[	O
26	O
–	O
29	O
].	O

Apart	O
from	O
the	O
clock	B-GP
being	O
an	O
intrinsic	O
regulator	O
,	O
diet	O
is	O
an	O
external	O
factor	O
that	O
profoundly	O
influences	O
nitrogen	O
homeostasis	O
and	O
ammonia	O
metabolism	O
.	O

Dietary	O
management	O
for	O
genetic	O
hyperammonemia	B-DS
,	O
mainly	O
including	O
protein	O
restriction	O
and	O
supplementation	O
of	O
urea	B-CD
cycle	O
substrate	O
,	O
serves	O
to	O
attenuate	O
ammonia	O
generation	O
and	O
/	O
or	O
bolster	O
ammonia	O
disposal	O
[	O
3	O
,	O
30	O
–	O
32	O
].	O

On	O
the	O
other	O
hand	O
,	O
dietary	O
challenges	O
also	O
strongly	O
influence	O
ammonia	O
metabolism	O
and	O
detoxification	O
.	O

For	O
example	O
,	O
the	O
ureagenic	O
capacity	O
of	O
the	O
urea	B-CD
cycle	O
,	O
while	O
far	O
exceeding	O
demand	O
under	O
normal	O
conditions	O
[	O
14	O
],	O
has	O
been	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
response	O
to	O
greater	O
metabolic	O
challenge	O
[	O
7	O
,	O
33	O
].	O

However	O
,	O
ammonia	O
control	O
under	O
varying	O
diet	O
conditions	O
is	O
not	O
well	O
characterized	O
,	O
and	O
little	O
is	O
known	O
regarding	O
functional	O
dietary	O
components	O
for	O
ammonia	O
control	O
besides	O
metabolic	O
substrates	O
[	O
30	O
,	O
34	O
].	O

Here	O
,	O
we	O
report	O
novel	O
ammonia	O
-	O
lowering	O
activities	O
and	O
clock	B-GP
-	O
dependent	O
mechanism	O
for	O
urea	B-CD
cycle	O
regulation	O
of	O
a	O
natural	O
polyphenolic	O
flavonoid	B-CD
,	O
Nobiletin	B-CD
(	O
NOB	O
).	O

Materials	O
and	O
methods	O

Animals	B-OG

All	O
animal	B-OG
husbandry	O
and	O
experimental	O
procedures	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
approved	O
IACUC	O
guidelines	O
and	O
animal	B-OG
protocols	O
by	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
Houston	O
(	O
UTHealth	O
).	O

All	O
mice	B-OG
,	O
male	O
and	O
on	O
the	O
C57BL	O
/	O
6	O
background	O
,	O
were	O
group	O
-	O
housed	O
with	O
2	O
–	O
4	O
animals	B-OG
/	O
cage	O
under	O
12	O
:	O
12	O
light	O
/	O
dark	O
(	O
12	O
:	O
12	O
LD	O
)	O
cycles	O
or	O
constant	O
darkness	O
(	O
DD	O
)	O
when	O
indicated	O
.	O

The	O
point	O
of	O
light	O
-	O
on	O
is	O
considered	O
as	O
Zeitgeber	O
Time	O
(	O
ZT	O
)	O
0	O
,	O
whereas	O
the	O
onset	O
of	O
subjective	O
day	O
during	O
DD	O
is	O
considered	O
as	O
Circadian	O
Time	O
(	O
CT	O
)	O
0	O
.	O

Animals	B-OG
were	O
ad	O
libitum	O
fed	O
with	O
regular	O
chow	O
(	O
RC	O
;	O
LabDiet	O
5001	O
),	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
;	O
Research	O
Diets	O
D12492	O
)	O
or	O
high	O
-	O
protein	O
diet	O
(	O
HPD	O
;	O
Research	O
Diets	O
D04080301	O
).	O

Nobiletin	B-CD
was	O
obtained	O
from	O
commercial	O
sources	O
including	O
Sigma	O
and	O
Selleck	O
,	O
and	O
administered	O
via	O
oral	O
gavage	O
(	O
200	O
mg	O
/	O
kg	O
in	O
0	O
.	O
5	O
%	O
Sodium	O
carboxymethyl	O
cellulose	O
)	O
every	O
other	O
day	O
.	O

Ammonia	O
and	O
urea	B-CD
assays	O

Blood	O
and	O
urine	O
samples	O
were	O
collected	O
at	O
ZT6	O
and	O
ZT18	O
.	O

For	O
determination	O
of	O
serum	O
ammonia	O
and	O
urea	B-CD
concentrations	O
,	O
we	O
employed	O
assay	O
kits	O
(	O
Sigma	O
,	O
AA0100	O
and	O
MAK006	O
,	O
respectively	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocols	O
.	O

Plasmids	O

The	O
proximal	O
Cps1	B-GP
enhancer	O
[	O
16	O
]	O
was	O
cloned	O
into	O
pGL3	O
Basic	O
(	O
Promega	O
)	O
using	O
C57BL6	B-OG
/	I-OG
J	I-OG
mouse	I-OG
genomic	O
DNA	O
as	O
PCR	O
template	O
with	O
pF	O
and	O
pR	O
primers	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
).	O

Site	O
-	O
directed	O
PCR	O
mutagenesis	O
was	O
performed	O
to	O
introduce	O
mutations	O
on	O
the	O
C	B-GP
/	I-GP
EBP	I-GP
binding	O
site	O
using	O
P	O
-	O
C	O
/	O
EBPmutF	O
and	O
P	O
-	O
C	O
/	O
EBPmutR	O
primers	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
).	O

Likewise	O
,	O
the	O
distal	O
enhancer	O
[	O
35	O
]	O
was	O
cloned	O
into	O
pGL3	O
Basic	O
using	O
dF	O
and	O
dR	O
primers	O
.	O

Three	O
C	B-GP
/	I-GP
EBP	I-GP
binding	O
sites	O
in	O
the	O
distal	O
enhancer	O
region	O
were	O
incorporated	O
by	O
DNA	O
synthesis	O
(	O
GeneScript	O
).	O

C	B-GP
/	I-GP
EBPα	I-GP
expression	O
vector	O
was	O
purchased	O
from	O
Addgene	O
(	O
ID12550	O
).	O

Luciferase	B-GP
reporter	O
assays	O

For	O
the	O
luminescence	O
assay	O
,	O
Hepa1	O
-	O
6	O
cells	O
(	O
ATCC	O
,	O
CRL	O
-	O
1830	O
)	O
were	O
plated	O
the	O
day	O
before	O
transfection	O
at	O
2	O
×	O
104	O
cells	O
per	O
well	O
in	O
96	O
-	O
well	O
plates	O
.	O

Cells	O
were	O
transfected	O
with	O
the	O
indicated	O
vectors	O
with	O
Renilla	B-OG
luciferase	B-GP
vector	O
for	O
internal	O
control	O
.	O

Twenty	O
four	O
hours	O
after	O
transfection	O
,	O
media	O
was	O
changed	O
to	O
recording	O
media	O
as	O
previously	O
described	O
[	O
36	O
]	O
and	O
treated	O
with	O
different	O
concentrations	O
of	O
Nobiletin	B-CD
.	O

Sealed	O
cultures	O
were	O
placed	O
in	O
an	O
EnVision	O
microplate	O
reader	O
(	O
Perkin	O
Elmer	O
)	O
and	O
bioluminescence	O
from	O
the	O
tissue	O
was	O
recorded	O
.	O

Real	O
-	O
time	O
qPCR	O
and	O
Western	O
blot	O
analyses	O

Total	O
RNAs	O
purified	O
by	O
using	O
Trizol	O
were	O
used	O
for	O
cDNA	O
synthesis	O
and	O
real	O
-	O
time	O
qPCR	O
was	O
performed	O
with	O
an	O
Agilent	O
MaxPro3000	O
Thermocycler	O
using	O
SyBR	O
green	O
reaction	O
mix	O
(	O
GenDEPOT	O
).	O

The	O
qPCR	O
primers	O
used	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
:	O
Table	O
S2	O
.	O

Tissue	O
collection	O
and	O
Western	O
blotting	O
was	O
performed	O
as	O
described	O
previously	O
[	O
37	O
,	O
38	O
].	O

Briefly	O
,	O
liver	O
tissue	O
samples	O
were	O
dissected	O
from	O
the	O
same	O
lobular	O
regions	O
in	O
different	O
animals	B-OG
to	O
ensure	O
experimental	O
consistency	O
.	O

The	O
samples	O
were	O
immediately	O
frozen	O
in	O
liquid	O
nitrogen	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
prior	O
to	O
use	O
.	O

The	O
harvested	O
liver	O
tissues	O
were	O
homogenized	O
in	O
extraction	O
buffer	O
containing	O
0	O
.	O
1	O
%	O
TritonX	O
-	O
100	O
.	O

Protein	O
samples	O
were	O
separated	O
by	O
12	O
or	O
6	O
%	O
SDS	O
-	O
polyacrylamide	O
gel	O
then	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Anti	O
-	O
CPS1	B-GP
(	O
Abcam	O
),	O
anti	O
-	O
C	B-GP
/	I-GP
EBPα	I-GP
(	O
Cell	O
Signaling	O
),	O
anti	O
-	O
C	B-GP
/	I-GP
EBPβ	I-GP
(	O
Abcam	O
)	O
antibodies	B-GP
were	O
used	O
.	O

Quantitation	O
of	O
Western	O
blot	O
results	O
was	O
carried	O
out	O
by	O
using	O
ImageJ	O
software	O
(	O
NIH	O
).	O

Immunohistochemistry	O

Liver	O
tissues	O
(	O
right	O
lateral	O
lobe	O
)	O
were	O
collected	O
at	O
the	O
indicated	O
times	O
and	O
immediately	O
fixed	O
in	O
10	O
%	O
buffered	O
formalin	B-CD
.	O

For	O
immunohistochemistry	O
,	O
20	O
-	O
μm	O
sections	O
were	O
collected	O
using	O
a	O
VibroSlice	O
microtome	O
(	O
World	O
Precision	O
Instruments	O
)	O
and	O
processed	O
free	O
floating	O
.	O

Sections	O
were	O
incubated	O
with	O
rabbit	B-OG
anti	O
-	O
CPS1	B-GP
(	O
1	O
:	O
10	O
,	O
000	O
;	O
Abcam	O
),	O
followed	O
by	O
Alexa	O
Fluor	O
546	O
rabbit	B-OG
secondary	O
antibody	B-GP
(	O
1	O
:	O
1000	O
;	O
Invitrogen	O
).	O

After	O
30	O
min	O
of	O
DAPI	O
staining	O
(	O
5	O
μM	O
),	O
Vectashield	O
mounting	O
media	O
(	O
Vector	O
Labs	O
)	O
was	O
used	O
to	O
mount	O
the	O
liver	O
slices	O
.	O

Section	O
images	O
were	O
acquired	O
and	O
analyzed	O
by	O
using	O
a	O
Nikon	O
A1R	O
confocal	O
microscope	O
.	O

SDS	O
-	O
PAGE	O
and	O
mass	O
spectrometry	O

Liver	O
extracts	O
were	O
separated	O
on	O
SDS	O
-	O
PAGE	O
gels	O
and	O
minimally	O
stained	O
with	O
Coomassie	B-CD
blue	I-CD
.	O

The	O
MW	O
164KD	O
band	O
was	O
excised	O
and	O
digested	O
with	O
trypsin	B-GP
.	O

The	O
sample	O
was	O
subjected	O
to	O
mass	O
spectrometry	O
protein	O
ID	O
at	O
the	O
BCM	O
Proteome	O
Core	O
Facility	O
using	O
a	O
Velos	O
-	O
Orbitrap	O
mass	O
spectrometer	O
.	O

Spectral	O
data	O
were	O
then	O
identified	O
by	O
using	O
Proteome	O
Discoverer	O
Suites	O
with	O
Mascot	O
(	O
Orbitrap	O
data	O
)	O
software	O
[	O
39	O
].	O

Statistical	O
analysis	O

Unless	O
otherwise	O
stated	O
,	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Data	O
were	O
analyzed	O
using	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
-	O
hoc	O
analysis	O
using	O
Dunnett	O
’	O
s	O
multiple	O
comparison	O
tests	O
or	O
two	O
-	O
way	O
ANOVA	O
followed	O
by	O
post	O
-	O
hoc	O
analysis	O
using	O
Bonferroni	O
test	O
as	O
appropriate	O
.	O

A	O
value	O
of	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

Results	O

NOB	O
improves	O
ammonium	O
detoxification	O

Among	O
a	O
growing	O
number	O
of	O
bioactive	O
polyphenols	B-CD
,	O
Nobiletin	B-CD
(	O
NOB	O
)	O
is	O
a	O
citrus	B-OG
-	O
derived	O
dietary	O
flavonoid	B-CD
with	O
diverse	O
physiological	O
functions	O
[	O
40	O
–	O
43	O
].	O

More	O
recently	O
,	O
NOB	O
has	O
been	O
shown	O
to	O
display	O
a	O
protective	O
role	O
against	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)-	O
induced	O
obesity	B-DS
and	O
other	O
metabolic	O
dysfunctions	O
[	O
44	O
–	O
46	O
].	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
NOB	O
in	O
nitrogen	O
homeostasis	O
,	O
we	O
examined	O
serum	O
ammonium	O
levels	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
under	O
different	O
diets	O
.	O

Under	O
RC	O
,	O
NOB	O
did	O
not	O
significantly	O
affect	O
body	O
weight	O
(	O
Fig	O
.	O
1a	O
).	O

Consistent	O
with	O
previous	O
findings	O
[	O
44	O
,	O
45	O
],	O
NOB	O
ameliorated	O
body	O
weight	O
gain	O
under	O
HFD	O
(	O
Fig	O
.	O
1a	O
).	O

Importantly	O
however	O
,	O
under	O
both	O
diets	O
,	O
NOB	O
markedly	O
reduced	O
serum	O
ammonium	O
levels	O
(	O
Fig	O
.	O
1b	O
).	O

At	O
Zeitgeber	O
Time	O
(	O
ZT	O
)	O
6	O
corresponding	O
to	O
mid	O
-	O
day	O
(	O
inactive	O
phase	O
),	O
NOB	O
led	O
to	O
a	O
more	O
pronounced	O
reduction	O
for	O
HFD	O
than	O
RC	O
(	O
27	O
.	O
5	O
%	O
vs	O
14	O
.	O
4	O
%)	O
(	O
Fig	O
.	O
1b	O
,	O
left	O
).	O

Ammonia	O
-	O
lowering	O
activities	O
of	O
NOB	O
were	O
also	O
observed	O
at	O
ZT18	O
corresponding	O
to	O
mid	O
-	O
night	O
when	O
mice	B-OG
were	O
active	O
(	O
Fig	O
.	O
1b	O
,	O
right	O
).	O

Whereas	O
attenuated	O
serum	O
ammonia	O
levels	O
were	O
observed	O
in	O
HFD	O
.	O
Veh	O
than	O
RC	O
.	O
Veh	O
,	O
likely	O
due	O
to	O
lower	O
protein	O
content	O
in	O
HFD	O
than	O
RC	O
(	O
20	O
%	O
vs	O
.	O
29	O
%	O
in	O
calories	O
),	O
NOB	O
treatment	O
diminished	O
the	O
ammonia	O
levels	O
in	O
both	O
diets	O
by	O
similar	O
degrees	O
.	O
Fig	O
.	O
1Nobiletin	O
(	O
NOB	O
)	O
lowers	O
serum	O
ammonia	O
levels	O
.	O
a	O
Body	O
weight	O
change	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
fed	O
with	O
regular	O
chow	O
(	O
RC	O
)	O
or	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
and	O
treated	O
with	O
either	O
vehicle	O
(	O
Veh	O
)	O
or	O
Nobiletin	B-CD
(	O
NOB	O
)	O
for	O
10	O
weeks	O
(	O
n	O
=	O
11	O
–	O
12	O
).	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
b	O
Serum	O
ammonia	O
levels	O
at	O
Zeitgeber	O
Time	O
(	O
ZT	O
)	O
6	O
and	O
18	O
in	O
the	O
mice	B-OG
described	O
in	O
(	O
a	O
).	O

ZT0	O
corresponds	O
to	O
the	O
onset	O
of	O
light	O
phase	O
.	O
c	O
Body	O
weight	O
change	O
of	O
WT	O
mice	B-OG
fed	O
with	O
RC	O
or	O
high	O
-	O
protein	O
diet	O
(	O
HPD	O
)	O
and	O
treated	O
with	O
either	O
Veh	O
or	O
NOB	O
for	O
4	O
weeks	O
(	O
n	O
=	O
6	O
–	O
7	O
).	O
d	O
Serum	O
ammonia	O
levels	O
at	O
ZT6	O
and	O
ZT18	O
in	O
the	O
mice	B-OG
described	O
in	O
(	O
c	O
).	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

For	O
panels	O
b	O
and	O
d	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
:	O
Veh	O
vs	O
.	O
NOB	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
;	O
RC	O
vs	O
.	O
HFD	O
or	O
HPD	O
,	O
††	O
p	O
<	O
0	O
.	O
01	O

We	O
next	O
investigated	O
effects	O
of	O
NOB	O
under	O
high	O
-	O
protein	O
diet	O
(	O
HPD	O
),	O
corresponding	O
to	O
enhanced	O
protein	O
metabolism	O
and	O
ammonia	O
flux	O
[	O
19	O
].	O

NOB	O
did	O
not	O
significantly	O
affect	O
body	O
weight	O
in	O
these	O
mice	B-OG
(	O
Fig	O
.	O
1c	O
).	O

At	O
ZT6	O
,	O
serum	O
ammonia	O
levels	O
were	O
similar	O
between	O
RC	O
and	O
HPD	O
,	O
and	O
NOB	O
showed	O
a	O
modest	O
trend	O
of	O
reducing	O
serum	O
ammonia	O
levels	O
(	O
Fig	O
.	O
1d	O
,	O
left	O
).	O

Importantly	O
,	O
during	O
the	O
active	O
phase	O
at	O
ZT18	O
when	O
serum	O
ammonia	O
levels	O
were	O
significantly	O
elevated	O
in	O
HPD	O
,	O
NOB	O
robustly	O
reduced	O
serum	O
ammonia	O
to	O
RC	O
levels	O
(	O
Fig	O
.	O
1d	O
,	O
right	O
).	O

Together	O
,	O
these	O
results	O
indicated	O
a	O
broad	O
role	O
of	O
NOB	O
in	O
reducing	O
serum	O
ammonia	O
content	O
at	O
both	O
active	O
and	O
inactive	O
circadian	O
phases	O
under	O
RC	O
,	O
HFD	O
and	O
HPD	O
conditions	O
.	O

Furthermore	O
,	O
NOB	O
more	O
strongly	O
reduced	O
serum	O
ammonia	O
levels	O
under	O
HFD	O
and	O
HPD	O
at	O
ZT6	O
and	O
ZT18	O
respectively	O
,	O
serving	O
to	O
normalize	O
the	O
exaggerated	O
circadian	O
variation	O
between	O
active	O
and	O
inactive	O
phases	O
in	O
these	O
diets	O
compared	O
with	O
RC	O
.	O

Diet	O
-	O
specific	O
effects	O
of	O
NOB	O
on	O
CPS1	B-GP
expression	O

Carbamoyl	B-GP
phosphate	I-GP
synthetase	I-GP
I	I-GP
(	O
CPS1	B-GP
)	O
has	O
been	O
shown	O
to	O
accumulate	O
in	O
a	O
circadian	O
manner	O
;	O
however	O
,	O
CPS1	B-GP
proteins	O
are	O
exceedingly	O
abundant	O
and	O
discrepancy	O
in	O
circadian	O
pattern	O
exists	O
[	O
26	O
,	O
27	O
].	O

We	O
therefore	O
conducted	O
Western	O
blotting	O
to	O
examine	O
CPS1	B-GP
protein	O
levels	O
in	O
mouse	B-OG
liver	O
over	O
circadian	O
time	O
course	O
.	O

While	O
largely	O
unchanged	O
between	O
Veh	O
and	O
NOB	O
treatment	O
under	O
RC	O
conditions	O
based	O
on	O
2	O
-	O
way	O
ANOVA	O
,	O
CPS1	B-GP
levels	O
were	O
significantly	O
reduced	O
in	O
HFD	O
.	O
Veh	O
compared	O
with	O
RC	O
(	O
Fig	O
.	O
2a	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S1A	O
)	O
[	O
47	O
].	O

Strikingly	O
,	O
NOB	O
restored	O
CPS1	B-GP
in	O
HFD	O
to	O
RC	O
levels	O
(	O
Fig	O
.	O
2a	O
).	O

We	O
also	O
confirmed	O
the	O
above	O
results	O
using	O
Coomassie	O
staining	O
followed	O
by	O
mass	O
spectrometry	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S1B	O
and	O
Table	O
S3	O
).	O

Furthermore	O
,	O
confocal	O
microscopy	O
using	O
anti	O
-	O
CPS1	B-GP
antibody	B-GP
also	O
clearly	O
showed	O
recovered	O
CPS1	B-GP
in	O
livers	O
from	O
HFD	O
.	O
NOB	O
mice	B-OG
relative	O
to	O
HFD	O
.	O
Veh	O
(	O
Fig	O
.	O
2b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S1C	O
).	O

Real	O
-	O
time	O
qPCR	O
analysis	O
further	O
revealed	O
strong	O
repression	O
of	O
Cps1	B-GP
messenger	O
levels	O
by	O
HFD	O
relative	O
to	O
RC	O
(	O
Fig	O
.	O
2c	O
),	O
consistent	O
with	O
its	O
effect	O
on	O
CPS1	B-GP
proteins	O
.	O

Importantly	O
,	O
NOB	O
restored	O
Cps1	B-GP
mRNA	O
expression	O
,	O
mirroring	O
the	O
changes	O
in	O
CPS1	B-GP
protein	O
.	O
Fig	O
.	O
2NOB	O
modulates	O
Cps1	B-GP
mRNA	O
and	O
protein	O
expression	O
.	O
a	O
Total	O
protein	O
extracts	O
were	O
prepared	O
from	O
liver	O
samples	O
collected	O
from	O
the	O
four	O
diet	O
/	O
treatment	O
groups	O
of	O
wild	O
-	O
type	O
mice	B-OG
at	O
the	O
indicated	O
circadian	O
time	O
points	O
(	O
n	O
=	O
3	O
).	O

Western	O
blotting	O
analysis	O
was	O
performed	O
using	O
anti	O
-	O
CPS1	B-GP
antibody	B-GP
.	O
RC	O
regular	O
chow	O
,	O
HFD	O
high	O
-	O
fat	O
diet	O
,	O
Veh	O
vehicle	O
,	O
NOB	O
Nobiletin	B-CD
.	O

The	O
results	O
shown	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

See	O
Additional	O
file	O
1	O
:	O
Figure	O
S1A	O
for	O
quantitative	O
analysis	O
.	O
b	O
Immunohistochemical	O
staining	O
of	O
CPS1	B-GP
in	O
liver	O
sections	O
from	O
mice	B-OG
with	O
the	O
indicated	O
diet	O
and	O
treatment	O
at	O
ZT2	O
.	O
c	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Cps1	B-GP
in	O
liver	O
samples	O
collected	O
as	O
in	O
(	O
a	O
).	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
differences	O
between	O
HFD	O
.	O
Veh	O
and	O
other	O
three	O
groups	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O
d	O
Western	O
blotting	O
analysis	O
of	O
protein	O
lysates	O
of	O
liver	O
samples	O
collected	O
at	O
ZT	O
6	O
and	O
18	O
from	O
mice	B-OG
with	O
the	O
indicated	O
diet	O
and	O
treatment	O
(	O
n	O
=	O
3	O
).	O

HPD	O
indicates	O
high	O
-	O
protein	O
diet	O
.	O

The	O
images	O
shown	O
to	O
the	O
left	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Quantitation	O
of	O
Western	O
blots	O
was	O
carried	O
out	O
and	O
the	O
results	O
,	O
presented	O
as	O
mean	O
±	O
SEM	O
,	O
are	O
shown	O
in	O
the	O
lower	O
panel	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
,	O
RC	O
vs	O
.	O
HPD	O
,	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
e	O
Real	O
-	O
time	O
qPCR	O
analysis	O
was	O
carried	O
out	O
using	O
total	O
RNAs	O
extracted	O
from	O
the	O
liver	O
samples	O
described	O
in	O
(	O
d	O
).	O

The	O
results	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
,	O
RC	O
vs	O
.	O
HPD	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O

We	O
also	O
examined	O
effects	O
of	O
HPD	O
on	O
CPS1	B-GP
levels	O
.	O

HPD	O
enhanced	O
the	O
abundance	O
of	O
CPS1	B-GP
by	O
approximately	O
20	O
%	O
(	O
Fig	O
.	O
2d	O
),	O
suggesting	O
a	O
role	O
of	O
CPS1	B-GP
induction	O
to	O
cope	O
with	O
increased	O
dietary	O
protein	O
intake	O
.	O

HPD	O
feeding	O
exerted	O
similar	O
modest	O
inducing	O
effects	O
on	O
Cps1	B-GP
mRNA	O
compared	O
with	O
RC	O
(	O
Fig	O
.	O
2e	O
).	O

NOB	O
treatment	O
,	O
on	O
the	O
other	O
hand	O
,	O
did	O
not	O
further	O
increase	O
CPS1	B-GP
protein	O
level	O
under	O
HPD	B-DS
(	O
Fig	O
.	O
2d	O
),	O
yet	O
seemed	O
to	O
alter	O
the	O
mRNA	O
expression	O
with	O
a	O
slight	O
increase	O
at	O
ZT18	O
(	O
Fig	O
.	O
2e	O
).	O

These	O
results	O
indicated	O
opposing	O
effects	O
of	O
HFD	O
and	O
HPD	O
on	O
Cps1	B-GP
expression	O
,	O
suggesting	O
that	O
ammonia	O
-	O
lowering	O
activities	O
of	O
NOB	O
entail	O
diet	O
-	O
specific	O
CPS1	B-GP
regulatory	O
mechanisms	O
.	O

NOB	O
restored	O
levels	O
of	O
C	B-GP
/	I-GP
EBP	I-GP
transcription	I-GP
factors	I-GP
repressed	O
under	O
HFD	O

We	O
next	O
focused	O
on	O
HFD	O
where	O
the	O
above	O
results	O
indicated	O
NOB	O
-	O
mediated	O
transcriptional	O
induction	O
of	O
Cps1	B-GP
.	O

The	O
transcription	B-GP
factors	I-GP
C	B-GP
/	I-GP
EBPα	I-GP
and	O
C	B-GP
/	I-GP
EBPβ	I-GP
are	O
known	O
to	O
play	O
important	O
roles	O
in	O
energy	O
homeostasis	O
and	O
urea	B-CD
cycle	O
expression	O
[	O
7	O
,	O
48	O
,	O
49	O
].	O

Consistent	O
with	O
previous	O
results	O
[	O
50	O
],	O
liver	O
expression	O
of	O
both	O
Cebp	B-GP
genes	O
exhibited	O
clear	O
circadian	O
oscillation	O
in	O
RC	O
;	O
somewhat	O
surprisingly	O
,	O
NOB	O
moderately	O
elevated	O
Cebpa	B-GP
expression	O
,	O
yet	O
strongly	O
repressed	O
Cebpb	B-GP
(	O
Fig	O
.	O
3a	O
).	O

HFD	O
significantly	O
dampened	O
levels	O
and	O
circadian	O
amplitude	O
(	O
peak	O
/	O
trough	O
difference	O
)	O
of	O
both	O
Cebp	B-GP
mRNA	O
expression	O
,	O
and	O
interestingly	O
also	O
reversed	O
their	O
circadian	O
phase	O
.	O

NOB	O
treatment	O
largely	O
restored	O
Cebpa	B-GP
mRNA	O
expression	O
(	O
ZT14	O
)	O
and	O
circadian	O
phase	O
relative	O
to	O
RC	O
(	O
Fig	O
.	O
3a	O
).	O
Fig	O
.	O
3NOB	O
rescued	O
Cebpa	B-GP
and	O
Cebpb	B-GP
mRNA	O
and	O
protein	O
circadian	O
expression	O
in	O
the	O
liver	O
from	O
HFD	O
fed	O
mice	B-OG
.	O
a	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Cebpa	B-GP
and	O
Cebpb	B-GP
in	O
livers	O
collected	O
at	O
the	O
indicated	O
circadian	O
times	O
from	O
mice	B-OG
with	O
the	O
indicated	O
diet	O
and	O
treatment	O
as	O
in	O
Fig	O
.	O
2a	O
.	O

Student	O
’	O
s	O
t	O
-	O
test	O
:	O
RC	O
.	O
Veh	O
vs	O
.	O
HFD	O
.	O
Veh	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
HFD	O
.	O
Veh	O
vs	O
.	O
HFD	O
.	O
NOB	O
,	O
†	O
p	O
<	O
0	O
.	O
05	O
.	O
b	O
Western	O
blotting	O
was	O
performed	O
using	O
total	O
liver	O
protein	O
lysates	O
with	O
the	O
indicated	O
antibodies	O
.	O

The	O
results	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

See	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
for	O
quantitative	O
analysis	O

HFD	O
also	O
significantly	O
down	O
-	O
regulated	O
protein	O
levels	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
,	O
the	O
active	O
form	O
[	O
51	O
],	O
across	O
the	O
circadian	O
cycle	O
(	O
HFD	O
.	O
Veh	O
vs	O
.	O
RC	O
.	O
Veh	O
;	O
Fig	O
.	O
3b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S2A	O
).	O

In	O
comparison	O
,	O
the	O
amount	O
of	O
p30	B-GP
,	O
the	O
truncated	O
form	O
lacking	O
the	O
N	O
-	O
terminal	O
transactivation	O
domain	O
,	O
was	O
also	O
reduced	O
,	O
albeit	O
to	O
a	O
lesser	O
degree	O
(	O
Fig	O
.	O
3b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S2B	O
).	O

Compared	O
with	O
Veh	O
,	O
NOB	O
did	O
not	O
show	O
significant	O
effects	O
on	O
p42	O
/	O
p30	O
levels	O
in	O
RC	O
,	O
yet	O
appeared	O
to	O
reverse	O
their	O
reduction	O
by	O
HFD	O
to	O
RC	O
levels	O
(	O
Fig	O
.	O
3b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S2A	O
).	O

HFD	O
was	O
previously	O
reported	O
to	O
increase	O
C	B-GP
/	I-GP
EBPβ	I-GP
(	O
LAP	B-GP
and	O
LIP	B-GP
)	O
levels	O
in	O
mouse	B-OG
liver	O
[	O
52	O
].	O

In	O
comparison	O
,	O
our	O
circadian	O
analysis	O
revealed	O
a	O
C	B-GP
/	I-GP
EBPβ	I-GP
(	O
LAP	B-GP
)	O
phase	O
shift	O
in	O
HFD	O
(	O
Fig	O
.	O
3b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S2C	O
).	O

Whereas	O
both	O
RC	O
.	O
Veh	O
and	O
RC	O
.	O
NOB	O
showed	O
peak	O
C	B-GP
/	I-GP
EBPβ	I-GP
expression	O
at	O
ZT20	O
,	O
HFD	O
shifted	O
the	O
peak	O
to	O
ZT14	O
,	O
with	O
HFD	O
.	O
NOB	O
displaying	O
a	O
slight	O
increase	O
over	O
HFD	O
.	O
Veh	O
(	O
Fig	O
.	O
3b	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S2C	O
).	O

These	O
results	O
illustrated	O
circadian	O
-	O
and	O
diet	O
-	O
dependent	O
expression	O
patterns	O
of	O
C	B-GP
/	I-GP
EBPs	I-GP
and	O
a	O
novel	O
function	O
of	O
NOB	O
in	O
restoring	O
C	B-GP
/	I-GP
EBP	I-GP
levels	O
repressed	O
by	O
HFD	O
.	O

C	B-GP
/	I-GP
EBP	I-GP
site	O
mutations	O
on	O
the	O
Cps1	B-GP
promoter	O
abolished	O
NOB	O
effects	O

Previous	O
studies	O
have	O
identified	O
both	O
proximal	O
and	O
distal	O
C	B-GP
/	I-GP
EBP	I-GP
sites	O
in	O
the	O
Cps1	B-GP
promoter	O
[	O
16	O
,	O
35	O
,	O
53	O
].	O

We	O
next	O
generated	O
reporter	O
constructs	O
containing	O
either	O
the	O
intact	O
Cps1	B-GP
promoter	O
or	O
mutant	O
promoters	O
respectively	O
deficient	O
in	O
either	O
C	B-GP
/	I-GP
EBP	I-GP
sites	O
(	O
Fig	O
.	O
4a	O
).	O

NOB	O
was	O
found	O
to	O
dose	O
-	O
dependently	O
activate	O
reporter	O
expression	O
from	O
the	O
WT	O
construct	O
with	O
an	O
intact	O
promoter	O
(	O
Fig	O
.	O
4b	O
and	O
c	O
).	O

Distal	O
mutations	O
markedly	O
repressed	O
the	O
reporter	O
expression	O
,	O
yet	O
seemed	O
to	O
at	O
least	O
partially	O
retain	O
NOB	O
response	O
as	O
NOB	O
increased	O
mutant	O
reporter	O
expression	O
relative	O
to	O
DMSO	O
(	O
Fig	O
.	O
4b	O
).	O

In	O
comparison	O
,	O
while	O
not	O
significantly	O
affecting	O
the	O
baseline	O
expression	O
level	O
,	O
proximal	O
mutations	O
abolished	O
NOB	O
dose	O
-	O
dependent	O
induction	O
seen	O
in	O
the	O
WT	O
construct	O
(	O
Fig	O
.	O
4c	O
).	O

C	B-GP
/	I-GP
EBPα	I-GP
co	O
-	O
transfection	O
activated	O
both	O
proximal	O
and	O
distal	O
WT	O
reporter	O
expression	O
,	O
but	O
showed	O
no	O
effects	O
on	O
mutant	O
constructs	O
in	O
the	O
absence	O
of	O
NOB	O
.	O

These	O
results	O
suggested	O
that	O
the	O
proximal	O
C	B-GP
/	I-GP
EBP	I-GP
consensus	O
site	O
plays	O
a	O
major	O
role	O
in	O
mediating	O
the	O
NOB	O
induction	O
of	O
Cps1	B-GP
.	O
Fig	O
.	O
4C	O
/	O
EBP	B-GP
binding	O
site	O
mutations	O
in	O
proximal	O
and	O
distal	O
Cps1	B-GP
enhancer	O
regions	O
impaired	O
NOB	O
-	O
mediated	O
reporter	O
activation	O
.	O
a	O
Diagram	O
of	O
distal	O
and	O
proximal	O
C	B-GP
/	I-GP
EBP	I-GP
sites	O
on	O
the	O
Cps1	B-GP
promoter	O
region	O
.	O
b	O
and	O
c	O
Hepa1	O
-	O
6	O
cells	O
were	O
transfected	O
with	O
reporter	O
constructs	O
containing	O
wild	O
-	O
type	O
(	O
WT	O
;	O
white	O
bars	O
)	O
and	O
C	B-GP
/	I-GP
EBP	I-GP
binding	O
site	O
mutated	O
(	O
black	O
bars	O
)	O
enhancer	O
regions	O
,	O
and	O
treated	O
with	O
NOB	O
at	O
the	O
indicated	O
doses	O
.	O

Co	O
-	O
transfection	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
expression	O
construct	O
was	O
also	O
carried	O
out	O
in	O
parallel	O
.	O

Each	O
value	O
represented	O
mean	O
±	O
SEM	O
of	O
three	O
replicates	O
from	O
a	O
single	O
assay	O
.	O

The	O
results	O
are	O
representative	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O
b	O
and	O
c	O
show	O
results	O
from	O
reporter	O
constructs	O
containing	O
distal	O
and	O
proximal	O
WT	O
and	O
mutant	O
enhancers	O
respectively	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
:	O
significant	O
main	O
effects	O
of	O
plasmid	O
construct	O
,	O
(	O
b	O
)	O
F	O
=	O
81	O
.	O
43	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
(	O
c	O
)	O
F	O
=	O
254	O
.	O
97	O
,	O
p	O
<	O
0	O
.	O
0001	O
;	O
NOB	O
concentration	O
effect	O
,	O
(	O
b	O
)	O
F	O
=	O
47	O
.	O
39	O
,	O
p	O
<	O
0	O
.	O
0001	O
,	O
(	O
c	O
)	O
F	O
=	O
42	O
.	O
01	O
,	O
p	O
<	O
0	O
.	O
0001	O
;	O
and	O
a	O
significant	O
interaction	O
between	O
constructs	O
and	O
NOB	O
concentration	O
,	O
(	O
b	O
)	O
F	O
=	O
23	O
,	O
p	O
<	O
0	O
.	O
0001	O
,	O
(	O
c	O
)	O
F	O
=	O
24	O
.	O
37	O
,	O
p	O
<	O
0	O
.	O
0001	O

Transcriptional	O
regulation	O
of	O
other	O
urea	B-CD
cycle	O
genes	O
by	O
NOB	O
under	O
HFD	O

A	O
number	O
of	O
pioneering	O
studies	O
have	O
provided	O
strong	O
evidence	O
for	O
co	O
-	O
regulation	O
of	O
urea	B-CD
cycle	O
genes	O
by	O
diets	O
,	O
hormones	O
,	O
cAMP	O
and	O
other	O
factors	O
,	O
likely	O
as	O
an	O
evolutionary	O
strategy	O
to	O
efficiently	O
perform	O
ureagenesis	O
in	O
response	O
to	O
various	O
internal	O
and	O
external	O
cues	O
[	O
8	O
,	O
20	O
,	O
35	O
,	O
54	O
–	O
56	O
].	O

In	O
particular	O
,	O
C	B-GP
/	I-GP
EBP	I-GP
sites	O
are	O
found	O
on	O
several	O
urea	B-CD
cycle	O
genes	O
(	O
Fig	O
.	O
5a	O
)	O
[	O
7	O
,	O
8	O
].	O

Under	O
RC	O
,	O
NOB	O
treatment	O
showed	O
only	O
modest	O
effects	O
on	O
expression	O
of	O
the	O
four	O
other	O
urea	B-CD
cycle	O
genes	O
(	O
Otc	B-GP
,	O
Ass1	B-GP
,	O
Asl	B-GP
,	O
Arg1	B-GP
)	O
relative	O
to	O
Veh	O
controls	O
(	O
Fig	O
.	O
5b	O
-	O
e	O
).	O

Strikingly	O
,	O
whereas	O
HFD	O
generally	O
repressed	O
their	O
mRNA	O
levels	O
and	O
also	O
elicited	O
strong	O
phase	O
shifts	O
(	O
Fig	O
.	O
5	O
),	O
NOB	O
enhanced	O
their	O
expression	O
and	O
/	O
or	O
amplitude	O
,	O
and	O
interestingly	O
also	O
correct	O
circadian	O
phases	O
.	O

Note	O
that	O
a	O
putative	O
C	B-GP
/	I-GP
EBP	I-GP
site	O
on	O
the	O
Ass1	B-GP
promoter	O
has	O
not	O
been	O
reported	O
,	O
suggesting	O
a	O
secondary	O
effect	O
by	O
C	B-GP
/	I-GP
EBP	I-GP
or	O
other	O
transcriptional	O
mechanisms	O
[	O
35	O
].	O

Since	O
C	B-GP
/	I-GP
EBPs	I-GP
are	O
master	O
regulators	O
of	O
overall	O
hepatic	O
metabolic	O
circuits	O
including	O
glucose	B-CD
and	O
lipid	O
metabolism	O
,	O
coordinate	O
regulation	O
of	O
urea	B-CD
cycle	O
genes	O
by	O
C	B-GP
/	I-GP
EBPs	I-GP
may	O
enable	O
metabolic	O
cross	O
-	O
talk	O
between	O
nitrogen	O
homeostasis	O
and	O
energy	O
metabolism	O
[	O
55	O
,	O
57	O
].	O
Fig	O
.	O
5NOB	O
coordinately	O
enhanced	O
urea	B-CD
cycle	O
gene	O
expression	O
.	O
a	O
Diagram	O
of	O
C	B-GP
/	I-GP
EBP	I-GP
sites	O
on	O
the	O
genomic	O
regions	O
for	O
urea	B-CD
cycle	O
genes	O
including	O
Otc	B-GP
,	O
Ass1	B-GP
,	O
Asl	B-GP
,	O
and	O
Arg1	B-GP
.	O
b	O
-	O
e	O
Liver	O
samples	O
were	O
collected	O
from	O
the	O
four	O
diet	O
/	O
treatment	O
groups	O
of	O
wild	O
-	O
type	O
mice	B-OG
at	O
the	O
indicated	O
circadian	O
time	O
points	O
.	O

Total	O
RNAs	O
were	O
purified	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
using	O
primers	O
for	O
the	O
four	O
urea	B-CD
cycle	O
genes	O
,	O
including	O
Otc	B-GP
(	O
b	O
),	O
Ass1c	O
,	O
Asl	O
d	O
and	O
Arg1	B-GP
e	O
.	O
RC	O
regular	O
chow	O
,	O
HFD	O
high	O
-	O
fat	O
diet	O
,	O
Veh	O
vehicle	O
,	O
NOB	O
Nobiletin	B-CD
.	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
3	O
).	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
,	O
RC	O
.	O
Veh	O
vs	O
.	O
HFD	O
.	O
Veh	O
,	O
a	O
p	O
<	O
0	O
.	O
0001	O
,	O
b	O
p	O
<	O
0	O
.	O
01	O
,	O
c	O
p	O
<	O
0	O
.	O
05	O
,	O
d	O
p	O
<	O
0	O
.	O
01	O
.	O

Student	O
’	O
s	O
t	O
-	O
test	O
,	O
HFD	O
.	O
Veh	O
vs	O
.	O
HFD	O
.	O
NOB	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O

Circadian	O
ClockΔ19	O
/	O
Δ19	O
mutant	O
mice	B-OG
displayed	O
attenuated	O
CPS1	B-GP
and	O
C	B-GP
/	I-GP
EBP	I-GP
levels	O

Consistent	O
with	O
previous	O
studies	O
[	O
27	O
,	O
50	O
,	O
58	O
],	O
our	O
data	O
thus	O
far	O
indicated	O
that	O
both	O
Cps1	B-GP
and	O
Cebp	B-GP
genes	O
are	O
subjected	O
to	O
circadian	O
control	O
and	O
display	O
rhythmic	O
patterns	O
of	O
expression	O
.	O

To	O
directly	O
examine	O
whether	O
the	O
circadian	O
clock	B-GP
plays	O
an	O
essential	O
role	O
in	O
Cps1	B-GP
regulation	O
,	O
we	O
employed	O
ClockΔ19	O
/	O
Δ19	O
mutant	O
mice	B-OG
(	O
Clk	B-GP
)	O
which	O
express	O
a	O
dominant	O
negative	O
version	O
of	O
CLOCK	B-GP
proteins	O
and	O
thus	O
are	O
severely	O
impaired	O
in	O
circadian	O
rhythms	O
[	O
59	O
,	O
60	O
].	O

Compared	O
with	O
WT	O
,	O
CPS1	B-GP
,	O
C	B-GP
/	I-GP
EBPα	I-GP
p30	O
and	O
C	B-GP
/	I-GP
EBPβ	I-GP
protein	O
levels	O
were	O
markedly	O
reduced	O
and	O
became	O
largely	O
arrhythmic	O
in	O
Clk	B-GP
under	O
RC	O
feeding	O
and	O
constant	O
darkness	O
(	O
DD	O
)	O
conditions	O
(	O
Fig	O
.	O
6a	O
and	O
see	O
also	O
quantification	O
in	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
).	O

In	O
comparison	O
,	O
p42	B-GP
expression	O
and	O
oscillation	O
were	O
maintained	O
in	O
Clk	B-GP
mice	B-OG
,	O
yet	O
interestingly	O
displayed	O
a	O
reversed	O
circadian	O
phase	O
pattern	O
(	O
Fig	O
.	O
6a	O
and	O
Additional	O
file	O
1	O
:	O
Figure	O
S3B	O
).	O

These	O
observations	O
illustrated	O
gene	O
-	O
or	O
isoform	O
-	O
specific	O
circadian	O
expression	O
regulation	O
.	O

Furthermore	O
,	O
pronounced	O
expression	O
changes	O
in	O
C	B-GP
/	I-GP
EBP	I-GP
subunits	O
were	O
observed	O
in	O
the	O
mutant	O
mice	B-OG
,	O
including	O
both	O
phase	O
shifts	O
and	O
reduced	O
levels	O
(	O
p30	B-GP
and	O
C	B-GP
/	I-GP
EBPβ	I-GP
).	O
Cps1	B-GP
and	O
Cebpa	B-GP
mRNA	O
expression	O
was	O
also	O
compromised	O
in	O
the	O
mutant	O
mice	B-OG
,	O
showing	O
strongly	O
reduced	O
levels	O
and	O
dampened	O
circadian	O
amplitude	O
(	O
Fig	O
.	O
6b	O
).	O

In	O
comparison	O
,	O
Cebpb	B-GP
mRNA	O
expression	O
exhibited	O
a	O
marked	O
phase	O
shift	O
in	O
the	O
mutant	O
compared	O
with	O
WT	O
(	O
Fig	O
.	O
6b	O
,	O
bottom	O
),	O
while	O
maintaining	O
a	O
normal	O
amplitude	O
.	O

Whereas	O
CPS1	B-GP
levels	O
were	O
lower	O
in	O
Clk	B-GP
than	O
WT	O
,	O
neither	O
HFD	O
nor	O
NOB	O
in	O
mutant	O
mice	B-OG
conferred	O
significant	O
changes	O
(	O
Fig	O
.	O
6c	O
;	O
lower	O
panel	O
:	O
quantification	O
).	O

These	O
results	O
together	O
indicated	O
a	O
critical	O
role	O
of	O
a	O
functional	O
clock	B-GP
to	O
mediate	O
NOB	O
induction	O
of	O
CPS1	B-GP
.	O
Fig	O
.	O
6NOB	O
restored	O
Cps1	B-GP
and	O
Cebp	B-GP
mRNA	O
and	O
protein	O
levels	O
in	O
a	O
clock	B-GP
-	O
dependent	O
manner	O
.	O
a	O
Liver	O
samples	O
were	O
collected	O
at	O
the	O
indicated	O
Circadian	O
Times	O
(	O
CT	O
)	O
from	O
regular	O
chow	O
-	O
fed	O
WT	O
and	O
Clock	B-GP
Δ19	O
/	O
Δ19	O
mutant	O
(	O
Clk	B-GP
)	O
mice	B-OG
(	O
n	O
=	O
3	O
)	O
in	O
constant	O
darkness	O
(	O
DD	O
)	O
when	O
the	O
circadian	O
clock	B-GP
free	O
runs	O
devoid	O
of	O
light	O
cue	O
.	O

CT0	O
corresponds	O
to	O
the	O
onset	O
of	O
subjective	O
day	O
.	O

Western	O
blotting	O
was	O
performed	O
using	O
total	O
protein	O
extracts	O
from	O
the	O
liver	O
samples	O
with	O
the	O
indicated	O
antibodies	O
.	O

See	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
for	O
quantitative	O
analysis	O
.	O
b	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Cps1	B-GP
,	O
Cebpa	B-GP
and	O
Cebpb	B-GP
was	O
carried	O
out	O
using	O
total	O
RNAs	O
extracted	O
from	O
the	O
liver	O
samples	O
described	O
in	O
(	O
a	O
).	O
Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
,	O
WT	O
vs	O
.	O
Clk	B-GP
,	O
Cps1	B-GP
,	O
Cebpb	B-GP
p	O
<	O
0	O
.	O
01	O
;	O
Cebpa	B-GP
p	O
<	O
0	O
.	O
05	O
.	O

Student	O
’	O
s	O
t	O
-	O
test	O
,	O
WT	O
vs	O
.	O
Clk	B-GP
,	O
Cps1	B-GP
:	O
CT4	B-GP
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
Cebpa	B-GP
:	O
CT8	B-GP
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
Cebpb	B-GP
:	O
CT8	B-GP
,	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O
c	O
Western	O
blot	O
analysis	O
of	O
CPS1	B-GP
protein	O
levels	O
in	O
liver	O
samples	O
collected	O
at	O
ZT8	O
and	O
ZT20	O
from	O
WT	O
and	O
Clk	B-GP
mice	B-OG
subjected	O
to	O
the	O
indicated	O
diet	O
and	O
treatment	O
.	O
RC	O
regular	O
chow	O
,	O
HFD	O
high	O
-	O
fat	O
diet	O
,	O
Veh	O
vehicle	O
,	O
NOB	O
Nobiletin	B-CD
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
,	O
WT	O
vs	O
.	O
individual	O
Clk	B-GP
groups	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O

NOB	O
modulated	O
serum	O
and	O
urine	O
urea	B-CD
content	O

Finally	O
,	O
to	O
further	O
elucidate	O
a	O
modulatory	O
role	O
of	O
NOB	O
in	O
nitrogen	O
homeostasis	O
,	O
we	O
measured	O
urea	B-CD
content	O
in	O
serum	O
and	O
urine	O
at	O
both	O
day	O
-	O
and	O
night	O
-	O
time	O
.	O

In	O
RC	O
,	O
serum	O
urea	B-CD
levels	O
were	O
mildly	O
reduced	O
in	O
the	O
NOB	O
group	O
at	O
both	O
day	O
-	O
and	O
night	O
-	O
time	O
(	O
ZT6	O
and	O
18	O
)	O
(	O
Fig	O
.	O
7a	O
),	O
whereas	O
the	O
urine	O
urea	B-CD
levels	O
showed	O
the	O
opposite	O
trend	O
,	O
suggesting	O
increased	O
urine	O
urea	B-CD
excretion	O
by	O
NOB	O
(	O
Fig	O
.	O
7b	O
).	O

In	O
comparison	O
,	O
HFD	O
feeding	O
led	O
to	O
lower	O
serum	O
urea	B-CD
levels	O
than	O
RC	O
(	O
Fig	O
.	O
7a	O
).	O

More	O
importantly	O
,	O
HFD	O
showed	O
a	O
reverse	O
NOB	O
response	O
;	O
specifically	O
,	O
NOB	O
increased	O
serum	O
urea	B-CD
and	O
concomitantly	O
reduced	O
renal	O
urea	B-CD
excretion	O
,	O
particularly	O
at	O
ZT18	O
(	O
Fig	O
.	O
7b	O
).	O

These	O
results	O
further	O
illustrated	O
a	O
modulatory	O
role	O
of	O
NOB	O
in	O
nitrogen	O
homeostasis	O
.	O
Fig	O
.	O
7Effects	O
of	O
NOB	O
on	O
urea	B-CD
production	O
.	O
a	O
and	O
b	O
Serum	O
(	O
a	O
)	O
and	O
urine	O
(	O
b	O
)	O
urea	B-CD
levels	O
at	O
ZT6	O
and	O
ZT18	O
in	O
WT	O
mice	B-OG
treated	O
with	O
Veh	O
or	O
NOB	O
under	O
RC	O
(	O
n	O
=	O
7	O
)	O
or	O
HFD	O
(	O
n	O
=	O
4	O
).	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Student	O
’	O
s	O
t	O
-	O
test	O
,	O
Veh	O
vs	O
.	O
NOB	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
RC	O
vs	O
.	O
HFD	O
,	O
†	O
p	O
<	O
0	O
.	O
05	O
,	O
††	O
p	O
<	O
0	O
.	O
01	O

Discussion	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrated	O
a	O
broad	O
effect	O
of	O
the	O
natural	O
flavonoid	B-CD
NOB	O
in	O
reducing	O
serum	O
ammonia	O
levels	O
under	O
varying	O
diet	O
conditions	O
.	O

NOB	O
and	O
other	O
related	O
polymethoxylated	B-CD
flavonoids	I-CD
are	O
dietary	O
components	O
generally	O
showing	O
favorable	O
pharmacokinetic	O
profiles	O
[	O
61	O
,	O
62	O
],	O
and	O
mouse	B-OG
and	O
human	B-OG
studies	O
revealed	O
promising	O
efficacy	O
of	O
NOB	O
against	O
the	O
metabolic	B-DS
syndrome	I-DS
without	O
significant	O
toxicity	O
[	O
40	O
,	O
44	O
,	O
45	O
,	O
63	O
].	O

The	O
current	O
work	O
illustrated	O
a	O
novel	O
function	O
of	O
NOB	O
in	O
ammonia	O
disposal	O
,	O
extending	O
the	O
long	O
list	O
of	O
physiological	O
benefits	O
associated	O
with	O
NOB	O
and	O
other	O
natural	O
flavonoids	B-CD
[	O
63	O
,	O
64	O
].	O

In	O
light	O
of	O
these	O
beneficial	O
attributes	O
,	O
it	O
warrants	O
further	O
investigation	O
whether	O
NOB	O
can	O
be	O
incorporated	O
into	O
dietary	O
management	O
for	O
congenital	O
and	O
injury	O
-	O
induced	O
hyperammonemia	B-DS
.	O

Our	O
study	O
revealed	O
broad	O
ammonia	O
-	O
lowering	O
activities	O
of	O
NOB	O
in	O
mice	B-OG
fed	O
with	O
RC	O
,	O
HFD	O
or	O
HPD	O
,	O
ostensibly	O
utilizing	O
distinct	O
,	O
diet	O
-	O
specific	O
mechanisms	O
.	O

Whereas	O
transcriptional	O
activation	O
of	O
CPS1	B-GP
via	O
C	B-GP
/	I-GP
EBP	I-GP
induction	O
seems	O
to	O
operate	O
under	O
HFD	O
,	O
NOB	O
treatment	O
in	O
conjunction	O
with	O
RC	O
and	O
HPD	O
feeding	O
appeared	O
not	O
to	O
elicit	O
significant	O
CPS1	B-GP
induction	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
RC	O
where	O
NOB	O
similarly	O
reduced	O
serum	O
ammonia	O
at	O
both	O
ZT6	O
and	O
ZT18	O
,	O
in	O
HFD	O
and	O
HPD	O
NOB	O
more	O
strongly	O
diminished	O
the	O
relative	O
high	O
ammonia	O
levels	O
in	O
respective	O
diets	O
(	O
ZT6	O
for	O
HFD	O
and	O
ZT18	O
for	O
HPD	O
).	O

As	O
a	O
result	O
,	O
NOB	O
functions	O
to	O
reverse	O
the	O
exaggerated	O
ammonia	O
variation	O
between	O
the	O
active	O
and	O
inactive	O
phases	O
,	O
essentially	O
normalizing	O
circadian	O
ammonia	O
rhythm	O
in	O
HFD	O
and	O
HPD	O
to	O
RC	O
levels	O
.	O

Given	O
the	O
remarkably	O
diverse	O
cellular	O
pathways	O
known	O
to	O
be	O
modulated	O
by	O
NOB	O
and	O
other	O
flavonoids	B-CD
,	O
various	O
molecular	O
and	O
cellular	O
mechanisms	O
may	O
underlie	O
such	O
mechanistic	O
and	O
functional	O
plasticity	O
[	O
63	O
–	O
67	O
].	O

Besides	O
transcriptional	O
regulation	O
(	O
C	B-GP
/	I-GP
EBP	I-GP
,	O
glucocorticoid	B-GP
receptor	I-GP
,	O
CREB	B-GP
and	O
HNF3	B-GP
)	O
and	O
the	O
allosteric	O
cofactor	O
NAG	O
[	O
7	O
,	O
17	O
],	O
recent	O
mechanistic	O
studies	O
have	O
also	O
underscored	O
the	O
importance	O
of	O
post	O
-	O
translational	O
modifications	O
(	O
PTMs	O
)	O
for	O
CPS1	B-GP
protein	O
activity	O
[	O
11	O
–	O
13	O
,	O
47	O
].	O

Other	O
urea	B-CD
cycle	O
genes	O
may	O
also	O
serve	O
as	O
the	O
primary	O
target	O
;	O
one	O
such	O
candidate	O
is	O
Otc	B-GP
,	O
especially	O
given	O
its	O
functional	O
connection	O
with	O
the	O
circadian	O
clock	B-GP
[	O
19	O
].	O

Finally	O
,	O
NOB	O
may	O
also	O
attenuate	O
HPD	O
-	O
induced	O
bacterial	O
production	O
of	O
ammonia	O
by	O
amino	B-CD
acid	I-CD
deamination	O
and	O
urea	B-CD
hydrolysis	O
[	O
4	O
].	O

Our	O
analysis	O
revealed	O
differential	O
responses	O
of	O
serum	O
and	O
urine	O
urea	B-CD
levels	O
to	O
NOB	O
treatment	O
in	O
HFD	O
.	O

Urea	B-CD
represents	O
the	O
most	O
predominant	O
circulating	O
nitrogen	O
reservoir	O
,	O
and	O
blood	O
urea	B-CD
nitrogen	O
(	O
BUN	O
)	O
level	O
is	O
known	O
to	O
be	O
regulated	O
by	O
multiple	O
factors	O
including	O
protein	O
intake	O
,	O
protein	O
metabolism	O
and	O
renal	O
function	O
[	O
1	O
,	O
5	O
].	O

HFD	O
contains	O
lower	O
protein	O
content	O
than	O
RC	O
(	O
20	O
%	O
vs	O
.	O
29	O
%	O
in	O
calories	O
),	O
and	O
NOB	O
acts	O
to	O
attenuate	O
ammonia	O
levels	O
by	O
activating	O
urea	B-CD
cycle	O
gene	O
expression	O
.	O

Thus	O
,	O
urea	B-CD
may	O
be	O
salvaged	O
to	O
maintain	O
nitrogen	O
balance	O
in	O
the	O
HFD	O
.	O
NOB	O
condition	O
.	O

For	O
example	O
,	O
urine	O
excretion	O
rate	O
/	O
volume	O
and	O
renal	O
reabsorption	O
of	O
water	O
/	O
mineral	O
/	O
urea	B-CD
are	O
tightly	O
coupled	O
to	O
regulate	O
osmotic	O
pressure	O
,	O
which	O
may	O
in	O
turn	O
modulate	O
serum	O
and	O
urine	O
urea	B-CD
levels	O
.	O

However	O
,	O
a	O
direct	O
role	O
of	O
NOB	O
in	O
renal	O
function	O
remains	O
to	O
be	O
elucidated	O
.	O

Amino	B-CD
acid	I-CD
levels	O
in	O
human	B-OG
blood	O
have	O
been	O
shown	O
to	O
exhibit	O
robust	O
circadian	O
oscillation	O
,	O
concordant	O
with	O
results	O
from	O
a	O
yeast	B-OG
metabolic	O
cycle	O
resembling	O
mammalian	O
circadian	O
rhythm	O
[	O
68	O
–	O
70	O
].	O

In	O
parallel	O
with	O
fluctuating	O
amino	B-CD
acid	I-CD
levels	O
over	O
the	O
daily	O
cycle	O
,	O
CPS1	B-GP
and	O
several	O
other	O
urea	B-CD
cycle	O
components	O
exhibited	O
circadian	O
mRNA	O
and	O
protein	O
expression	O
patterns	O
[	O
27	O
].	O

However	O
,	O
much	O
conflictory	O
evidence	O
has	O
also	O
been	O
reported	O
with	O
regard	O
to	O
Cps1	B-GP
circadian	O
expression	O
[	O
26	O
,	O
28	O
,	O
29	O
].	O

Our	O
experiments	O
,	O
using	O
specific	O
primers	O
and	O
antibodies	O
,	O
revealed	O
weak	O
oscillation	O
of	O
Cps1	B-GP
mRNA	O
and	O
protein	O
.	O

Interestingly	O
,	O
NOB	O
appeared	O
to	O
augment	O
CPS1	B-GP
protein	O
oscillation	O
under	O
RC	O
,	O
and	O
also	O
enhanced	O
CPS1	B-GP
levels	O
under	O
HFD	O
in	O
a	O
circadian	O
clock	B-GP
-	O
dependent	O
manner	O
.	O

One	O
possible	O
mechanism	O
of	O
circadian	O
regulation	O
may	O
depend	O
on	O
C	B-GP
/	I-GP
EBPs	I-GP
as	O
their	O
expression	O
is	O
subjected	O
to	O
clock	B-GP
control	O
[	O
50	O
],	O
although	O
other	O
mechanisms	O
likely	O
exist	O
[	O
19	O
].	O

Of	O
note	O
,	O
we	O
observed	O
distinct	O
circadian	O
changes	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
and	O
p30	B-GP
isoforms	O
in	O
ClockΔ19	O
/	O
Δ19	O
mutant	O
mice	B-OG
relative	O
to	O
WT	O
,	O
suggesting	O
a	O
possible	O
circadian	O
regulation	O
of	O
alternative	O
translation	O
.	O

Currently	O
,	O
work	O
in	O
our	O
lab	O
aims	O
to	O
further	O
understand	O
the	O
detailed	O
mechanism	O
underlying	O
the	O
interaction	O
between	O
the	O
clock	B-GP
,	O
diet	O
and	O
NOB	O
in	O
nitrogen	O
homeostasis	O
.	O

Conclusion	O

In	O
this	O
current	O
study	O
,	O
we	O
present	O
physiological	O
evidence	O
indicating	O
that	O
NOB	O
exhibits	O
a	O
broad	O
activity	O
in	O
ammonia	O
control	O
in	O
mice	B-OG
fed	O
with	O
varying	O
diets	O
.	O

Molecular	O
experiments	O
further	O
revealed	O
that	O
NOB	O
regulates	O
urea	B-CD
cycle	O
function	O
via	O
C	B-GP
/	I-GP
EBP	I-GP
-	O
and	O
circadian	O
clock	B-GP
-	O
dependent	O
regulatory	O
mechanisms	O
.	O

These	O
observations	O
together	O
demonstrate	O
a	O
novel	O
physiological	O
function	O
and	O
cellular	O
mechanism	O
of	O
a	O
natural	O
dietary	O
flavonoid	B-CD
in	O
nitrogen	O
homeostasis	O
.	O

Primers	O
for	O
construction	O
of	O
reporter	O
constructs	O
.	O
Table	O
S2	O
.	O
Primers	O
for	O
real	O
-	O
time	O
qPCR	O
analysis	O
.	O
Table	O
S3	O
.	O
Mass	O
spectrometry	O
data	O
table	O
for	O
the	O
164KD	O
band	O
shown	O
in	O
the	O
Additional	O
file	O
1	O
:	O
Figure	O
S1B	O
.	O
Figure	O
S1	O
.	O
NOB	O
modulates	O
CPS1	B-GP
expression	O
.	O
(	O
A	O
)	O
Quantification	O
of	O
CPS1	B-GP
protein	O
levels	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
2a	O
.	O

RC	O
,	O
regular	O
chow	O
;	O
HFD	O
,	O
high	O
-	O
fat	O
diet	O
;	O
Veh	O
,	O
vehicle	O
;	O
NOB	O
,	O
Nobiletin	B-CD
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
differences	O
between	O
HFD	O
.	O
Veh	O
and	O
other	O
three	O
groups	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Furthermore	O
,	O
one	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
tests	O
shows	O
significant	O
difference	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
ZT	O
time	O
points	O
in	O
RC	O
.	O
Veh	O
but	O
not	O
in	O
other	O
groups	O
.	O
(	O
B	O
)	O
Coomassie	B-CD
blue	I-CD
staining	O
of	O
CPS1	B-GP
.	O

Mouse	B-OG
liver	O
protein	O
lysates	O
were	O
separated	O
on	O
SDS	O
-	O
PAGE	O
gel	O
and	O
stained	O
with	O
Coomassie	B-CD
blue	I-CD
.	O

The	O
predominant	O
164KD	O
band	O
was	O
validated	O
by	O
mass	O
spectrometry	O
as	O
CPS1	B-GP
(	O
Table	O
S3	O
).	O
(	O
C	O
)	O
Control	O
microscopy	O
images	O
for	O
Fig	O
.	O
2b	O
using	O
rabbit	B-OG
IgG	B-GP
.	O
Figure	O
S2	O
.	O
NOB	O
rescued	O
C	B-GP
/	I-GP
EBP	I-GP
protein	O
circadian	O
expression	O
in	O
the	O
liver	O
from	O
HFD	O
fed	O
mice	B-OG
.	O
(	O
A	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
protein	O
levels	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
3b	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
difference	O
between	O
RC	O
.	O
Veh	O
and	O
HFD	O
.	O
Veh	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
indicating	O
diet	O
effect	O
on	O
the	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
expression	O
level	O
.	O

Importantly	O
,	O
RC	O
.	O
NOB	O
was	O
not	O
significantly	O
different	O
from	O
HFD	O
.	O
NOB	O
,	O
suggesting	O
NOB	O
reversed	O
the	O
reducing	O
effect	O
of	O
HFD	O
on	O
the	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
expression	O
.	O
(	O
B	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p30	O
protein	O
levels	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
3b	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
difference	O
between	O
RC	O
.	O
Veh	O
and	O
HFD	O
.	O
Veh	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
but	O
RC	O
.	O
NOB	O
and	O
HFD	O
.	O
NOB	O
was	O
not	O
significantly	O
different	O
,	O
again	O
suggesting	O
NOB	O
reversed	O
the	O
reducing	O
effect	O
of	O
HFD	O
on	O
the	O
p30	B-GP
expression	O
.	O
(	O
C	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPβ	I-GP
protein	O
levels	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
3b	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
difference	O
between	O
RC	O
.	O
Veh	O
and	O
HFD	O
.	O
Veh	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
but	O
RC	O
.	O
NOB	O
and	O
HFD	O
.	O
NOB	O
was	O
not	O
significantly	O
different	O
.	O
Figure	O
S3	O
.	O
NOB	O
restored	O
CPS1	B-GP
and	O
C	B-GP
/	I-GP
EBP	I-GP
protein	O
levels	O
in	O
a	O
clock	B-GP
-	O
dependent	O
manner	O
.	O
(	O
A	O
)	O
Quantification	O
of	O
CPS1	B-GP
protein	O
levels	O
under	O
constant	O
darkness	O
(	O
DD	O
)	O
conditions	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
6a	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
difference	O
between	O
WT	O
and	O
Clk	O
(	O
Clock	O
Δ19	O
/	O
Δ19	O
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O
(	O
B	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p42	O
protein	O
levels	O
under	O
constant	O
darkness	O
(	O
DD	O
)	O
conditions	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
6a	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
differences	O
between	O
WT	O
and	O
Clk	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O
(	O
C	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPα	I-GP
p30	O
protein	O
levels	O
under	O
constant	O
darkness	O
(	O
DD	O
)	O
conditions	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
6a	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
difference	O
between	O
WT	O
and	O
Clk	B-GP
(	O
p	O
<	O
0	O
.	O
01	O
).	O
(	O
D	O
)	O
Quantification	O
of	O
C	B-GP
/	I-GP
EBPβ	I-GP
protein	O
levels	O
under	O
constant	O
darkness	O
(	O
DD	O
)	O
conditions	O
from	O
three	O
independent	O
experiments	O
including	O
the	O
blot	O
shown	O
in	O
Fig	O
.	O
6a	O
.	O

Two	O
-	O
way	O
ANOVA	O
with	O
Bonferroni	O
post	O
-	O
hoc	O
tests	O
shows	O
significant	O
statistical	O
difference	O
between	O
WT	O
and	O
Clk	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Kazunari	O
Nohara	O
and	O
Youngmin	O
Shin	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O

KN	O
and	O
BH	O
carried	O
out	O
the	O
physiological	O
assays	O
.	O

YS	O
,	O
NP	O
and	O
KJ	O
carried	O
out	O
the	O
molecular	O
studies	O
.	O

NK	O
analyzed	O
promoter	O
sequences	O
and	O
gene	O
expression	O
.	O

KN	O
,	O
NP	O
and	O
SY	O
performed	O
the	O
statistical	O
analysis	O
.	O

SY	O
and	O
ZC	O
conceived	O
of	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Childhood	O
traumas	O
as	O
a	O
risk	O
factor	O
for	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
young	O
women	B-OG
and	O
men	B-OG
living	O
in	O
urban	O
informal	O
settlements	O
in	O
South	O
Africa	O
:	O
A	O
cross	O
-	O
sectional	O
study	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Childhood	O
traumas	O
,	O
in	O
the	O
form	O
of	O
physical	O
,	O
sexual	O
,	O
and	O
emotional	B-DS
abuse	I-DS
and	O
neglect	B-DS
,	O
are	O
globally	O
widespread	O
and	O
highly	O
prevalent	O
,	O
and	O
associated	O
with	O
a	O
range	O
of	O
subsequent	O
poor	O
health	O
outcomes	O
.	O

This	O
study	O
sought	O
to	O
understand	O
the	O
relationship	O
between	O
physical	O
,	O
sexual	O
and	O
emotional	B-DS
childhood	I-DS
abuse	I-DS
and	O
subsequent	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
young	O
people	O
(	O
18	O
–	O
30	O
)	O
living	O
in	O
urban	O
informal	O
settlements	O
in	O
Durban	O
,	O
South	O
Africa	O
.	O

Data	O
came	O
from	O
self	O
-	O
completed	O
questionnaires	O
amongst	O
680	O
women	O
and	O
677	O
men	O
comprising	O
the	O
baseline	O
of	O
the	O
Stepping	O
Stones	O
and	O
Creating	O
Futures	O
intervention	O
trial	O
.	O

Men	O
and	O
women	O
were	O
analysed	O
separately	O
.	O

Logistic	O
regression	O
models	O
assessed	O
the	O
relationship	O
between	O
six	O
HIV	B-OG
-	O
risk	O
behaviours	O
and	O
four	O
measures	O
of	O
trauma	O
:	O
the	O
form	O
of	O
trauma	O
,	O
the	O
severity	O
of	O
each	O
trauma	O
,	O
the	O
range	O
of	O
traumas	O
,	O
and	O
overall	O
severity	O
of	O
childhood	O
trauma	O
.	O

Childhood	O
traumas	O
were	O
incredibly	O
prevalent	O
in	O
this	O
population	O
.	O

All	O
childhood	O
traumas	O
were	O
associated	O
with	O
a	O
range	O
of	O
HIV	B-OG
-	O
risk	O
behaviours	O
.	O

This	O
was	O
for	O
the	O
ever	O
/	O
never	O
trauma	O
,	O
as	O
well	O
as	O
the	O
severity	O
of	O
each	O
type	O
of	O
trauma	O
,	O
the	O
range	O
of	O
trauma	O
,	O
and	O
overall	O
severity	O
of	O
childhood	O
trauma	O
.	O

Despite	O
the	O
wider	O
harsh	O
contexts	O
of	O
urban	O
informal	O
settlements	O
,	O
childhood	O
traumas	O
still	O
play	O
a	O
significant	O
role	O
in	O
shaping	O
subsequent	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
young	O
people	O
.	O

Interventions	O
to	O
reduce	O
childhood	O
traumas	O
for	O
populations	O
in	O
informal	O
settlements	O
need	O
to	O
be	O
developed	O
.	O

In	O
addition	O
,	O
trauma	O
focused	O
therapies	O
need	O
to	O
be	O
considered	O
as	O
part	O
of	O
wider	O
HIV	B-OG
-	O
prevention	O
interventions	O
for	O
young	O
adults	O
.	O

Trial	O
registration	O
:	O
ClinicalTrials	O
.	O
gov	O
NCT03022370	O

Introduction	O

Childhood	O
traumas	O
,	O
in	O
the	O
form	O
of	O
physical	O
,	O
sexual	O
,	O
and	O
emotional	B-DS
abuse	I-DS
and	O
neglect	B-DS
,	O
are	O
globally	O
widespread	O
and	O
highly	O
prevalent	O
[	O
1	O
,	O
2	O
].	O

A	O
systematic	O
review	O
of	O
population	O
-	O
based	O
studies	O
estimated	O
that	O
amongst	O
2	O
–	O
17	O
year	O
olds	O
,	O
the	O
minimum	O
prevalence	O
of	O
past	O
-	O
year	O
physical	B-DS
abuse	I-DS
was	O
at	O
least	O
50	O
%	O
for	O
Africa	O
,	O
Asia	O
,	O
and	O
Northern	O
America	O
and	O
over	O
30	O
%	O
for	O
Latin	O
America	O
[	O
1	O
].	O

For	O
youth	O
aged	O
2	O
to	O
14	O
,	O
estimated	O
prevalence	O
of	O
past	O
-	O
year	O
violence	O
was	O
up	O
to	O
80	O
%	O
in	O
Africa	O
[	O
1	O
].	O

In	O
South	O
Africa	O
,	O
a	O
multi	O
-	O
community	O
sample	O
of	O
children	O
aged	O
10	O
–	O
17	O
,	O
found	O
prevalence	O
of	O
lifetime	O
physical	B-DS
abuse	I-DS
was	O
56	O
.	O
3	O
%,	O
emotional	B-DS
abuse	I-DS
35	O
.	O
5	O
%	O
and	O
sexual	B-DS
abuse	I-DS
9	O
%	O
[	O
3	O
].	O

Overall	O
,	O
in	O
the	O
South	O
African	O
multi	O
-	O
community	O
sample	O
of	O
children	O
just	O
over	O
two	O
-	O
thirds	O
(	O
68	O
.	O
9	O
%)	O
reported	O
any	O
lifetime	O
abuse	O
and	O
a	O
quarter	O
(	O
27	O
.	O
1	O
%)	O
reported	O
experiencing	O
multiple	O
forms	O
of	O
abuse	O
[	O
3	O
].	O

In	O
a	O
young	O
adult	O
rural	O
population	O
(	O
15	O
–	O
26	O
)	O
in	O
South	O
Africa	O
,	O
39	O
.	O
1	O
%	O
of	O
women	O
and	O
16	O
.	O
7	O
%	O
of	O
men	O
had	O
experienced	O
sexual	B-DS
abuse	I-DS
,	O
while	O
89	O
.	O
3	O
%	O
of	O
women	O
and	O
94	O
.	O
4	O
%	O
of	O
men	O
had	O
experienced	O
physical	O
punishment	O
as	O
children	O
[	O
4	O
].	O

As	O
well	O
as	O
being	O
a	O
human	B-OG
rights	O
violation	O
,	O
experiences	O
of	O
childhood	O
traumas	O
have	O
short	O
and	O
long	O
-	O
term	O
impacts	O
on	O
people	O
’	O
s	O
health	O
.	O

Women	B-OG
and	O
men	O
who	O
have	O
experienced	O
childhood	O
traumas	O
are	O
more	O
likely	O
to	O
report	O
a	O
range	O
of	O
sexual	O
risk	O
behaviours	O
[	O
5	O
],	O
including	O
more	O
likely	O
to	O
trade	O
sex	O
for	O
cash	O
[	O
6	O
],	O
experience	O
or	O
perpetrate	O
intimate	B-DS
partner	I-DS
violence	I-DS
(	O
IPV	B-DS
)	O
[	O
7	O
,	O
8	O
],	O
engage	O
in	O
risky	O
alcohol	B-CD
use	O
,	O
and	O
drug	O
use	O
[	O
4	O
,	O
5	O
],	O
and	O
have	O
more	O
sex	O
partners	O
[	O
6	O
].	O

In	O
South	O
Africa	O
,	O
a	O
longitudinal	O
study	O
showed	O
those	O
who	O
experienced	O
childhood	O
traumas	O
were	O
also	O
more	O
likely	O
to	O
acquire	O
HIV	B-OG
[	O
4	O
].	O

Globally	O
,	O
urban	O
informal	O
settlements	O
are	O
rapidly	O
growing	O
as	O
the	O
global	O
population	O
urbanises	O
[	O
9	O
].	O

Urban	O
informal	O
settlements	O
,	O
while	O
providing	O
substantial	O
opportunities	O
associated	O
with	O
urban	O
economies	O
,	O
are	O
also	O
settings	O
with	O
significant	O
health	O
challenges	O
.	O

Studies	O
suggest	O
that	O
HIV	B-OG
prevalence	O
and	O
violence	O
against	O
women	B-OG
in	O
informal	O
settlements	O
are	O
higher	O
than	O
in	O
formal	O
settlements	O
[	O
10	O
–	O
12	O
].	O

There	O
is	O
some	O
suggestion	O
that	O
urban	O
residency	O
may	O
also	O
increase	O
experiences	O
of	O
childhood	O
traumas	O
[	O
13	O
].	O

Despite	O
this	O
,	O
there	O
is	O
little	O
evidence	O
about	O
the	O
relationship	O
between	O
childhood	O
traumas	O
and	O
current	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
residents	O
of	O
informal	O
settlements	O
.	O

In	O
this	O
paper	O
,	O
we	O
seek	O
to	O
describe	O
the	O
associations	O
between	O
sexual	O
,	O
physical	O
,	O
and	O
emotional	B-DS
childhood	I-DS
traumas	I-DS
amongst	O
women	O
and	O
men	O
resident	O
in	O
informal	O
settlements	O
in	O
eThekwini	O
,	O
South	O
Africa	O
and	O
their	O
subsequent	O
HIV	B-OG
-	O
risk	O
behaviours	O
.	O

We	O
draw	O
on	O
data	O
from	O
the	O
baseline	O
of	O
the	O
Stepping	O
Stones	O
and	O
Creating	O
Futures	O
trial	O
,	O
a	O
cluster	O
randomized	O
control	O
trial	O
(	O
RCT	O
)	O
assessing	O
the	O
impact	O
of	O
this	O
gender	O
transformative	O
and	O
livelihood	O
strengthening	O
intervention	O
on	O
women	B-OG
’	O
s	O
experience	O
,	O
and	O
men	B-OG
’	O
s	O
perpetration	O
,	O
of	O
IPV	O
[	O
14	O
].	O

We	O
assess	O
whether	O
experience	O
of	O
each	O
type	O
of	O
childhood	O
trauma	O
is	O
independently	O
associated	O
with	O
HIV	B-OG
-	O
risk	O
;	O
whether	O
there	O
is	O
a	O
dose	O
response	O
for	O
each	O
type	O
of	O
childhood	O
trauma	O
and	O
HIV	B-OG
-	O
risk	O
;	O
whether	O
the	O
range	O
of	O
childhood	O
traumas	O
experienced	O
is	O
independently	O
associated	O
with	O
HIV	B-OG
-	O
risk	O
;	O
and	O
whether	O
the	O
overall	O
severity	O
of	O
childhood	O
trauma	O
is	O
independently	O
associated	O
with	O
HIV	B-OG
-	O
risk	O
.	O

Methods	O

Data	O
are	O
drawn	O
from	O
N	O
=	O
680	O
women	O
and	O
N	O
=	O
677	O
men	O
who	O
participated	O
in	O
the	O
baseline	O
assessment	O
for	O
the	O
Stepping	O
Stones	O
and	O
Creating	O
Futures	O
RCT	O
,	O
carried	O
out	O
in	O
urban	O
informal	O
settlements	O
near	O
Durban	O
,	O
South	O
Africa	O
between	O
September	O
2015	O
and	O
September	O
2016	O
.	O

Women	O
and	O
men	O
between	O
18	O
and	O
30	O
,	O
who	O
were	O
out	O
of	O
school	O
,	O
not	O
in	O
formal	O
work	O
and	O
resident	O
in	O
an	O
informal	O
settlement	O
,	O
were	O
eligible	O
to	O
participate	O
.	O

We	O
worked	O
with	O
Project	O
Empower	O
,	O
a	O
local	O
implementing	O
agency	O
,	O
experienced	O
in	O
informal	O
settlement	O
interventions	O
,	O
to	O
identify	O
potential	O
participants	O
through	O
community	O
meetings	O
and	O
snow	O
-	O
ball	O
sampling	O
.	O

The	O
study	O
comprised	O
34	O
clusters	O
with	O
19	O
–	O
21	O
women	O
and	O
16	O
–	O
22	O
men	O
per	O
cluster	O
[	O
14	O
].	O

At	O
recruitment	O
,	O
participants	O
were	O
not	O
blinded	O
to	O
study	O
arm	O
.	O

Those	O
in	O
the	O
intervention	O
arm	O
received	O
R100	O
(~	O
US	O
$	O
7	O
)	O
and	O
those	O
in	O
the	O
control	O
arm	O
received	O
R300	O
(~	O
US	O
$	O
21	O
)	O
for	O
completion	O
of	O
the	O
baseline	O
survey	O
instrument	O
.	O

Ethical	O
approval	O
for	O
the	O
study	O
was	O
received	O
from	O
the	O
University	O
of	O
KwaZulu	O
-	O
Natal	O
and	O
the	O
South	O
African	O
Medical	O
Research	O
Council	O
.	O

Further	O
information	O
on	O
procedures	O
is	O
described	O
elsewhere	O
[	O
14	O
].	O

Data	O
collection	O

Once	O
enrolled	O
into	O
the	O
study	O
,	O
participants	O
self	O
-	O
completed	O
structured	O
questionnaires	O
.	O

Questionnaires	O
were	O
on	O
study	O
provided	O
cellphones	O
,	O
and	O
available	O
in	O
isiZulu	O
,	O
Xhosa	O
,	O
and	O
English	O
and	O
had	O
built	O
in	O
logic	O
and	O
skip	O
patterns	O
.	O

Questionnaires	O
had	O
been	O
tested	O
prior	O
to	O
roll	O
-	O
out	O
with	O
young	O
people	O
from	O
informal	O
settlements	O
,	O
and	O
young	O
people	O
were	O
confident	O
in	O
using	O
cellphones	O
and	O
this	O
approach	O
to	O
data	O
collection	O
.	O

If	O
literacy	O
was	O
an	O
issue	O
,	O
same	O
sex	O
trained	O
fieldworkers	O
were	O
able	O
to	O
support	O
questionnaire	O
completion	O
,	O
through	O
face	O
-	O
to	O
-	O
face	O
interviews	O
with	O
participants	O
entering	O
the	O
data	O
,	O
and	O
interviewers	O
reading	O
out	O
questions	O
.	O

Few	O
participants	O
(<	O
5	O
%)	O
required	O
this	O
support	O
,	O
and	O
as	O
such	O
,	O
it	O
was	O
unlikely	O
to	O
influence	O
responses	O
given	O
the	O
small	O
number	O
of	O
cases	O
.	O

Measures	O

Six	O
variables	O
,	O
which	O
have	O
been	O
associated	O
with	O
HIV	B-OG
-	O
risk	O
in	O
a	O
range	O
of	O
studies	O
from	O
across	O
Africa	O
,	O
were	O
identified	O
as	O
outcome	O
variables	O
for	O
the	O
analysis	O
.	O

Transactional	O
sex	O
in	O
the	O
past	O
year	O
with	O
a	O
casual	O
or	O
once	O
-	O
off	O
sexual	O
partner	O
.	O

Five	O
questions	O
asked	O
about	O
whether	O
a	O
woman	O
had	O
sex	O
with	O
a	O
man	B-OG
because	O
she	O
expected	O
to	O
receive	O
,	O
or	O
did	O
receive	O
a	O
range	O
of	O
items	O
,	O
including	O
cash	O
,	O
a	O
place	O
to	O
stay	O
,	O
drugs	O
,	O
school	O
fees	O
,	O
airtime	O
,	O
or	O
anything	O
else	O
she	O
could	O
not	O
afford	O
[	O
15	O
].	O

One	O
,	O
or	O
more	O
,	O
positive	O
responses	O
to	O
any	O
of	O
the	O
five	O
questions	O
was	O
coded	O
as	O
engaging	O
in	O
transactional	O
sex	O
.	O

Men	O
were	O
asked	O
whether	O
they	O
thought	O
a	O
woman	O
had	O
sex	O
with	O
them	O
because	O
she	O
expected	O
to	O
receive	O
items	O
[	O
16	O
].	O

Sexual	O
partners	O
in	O
past	O
year	O
.	O

We	O
asked	O
three	O
questions	O
about	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
.	O

We	O
asked	O
about	O
the	O
number	O
of	O
main	O
sexual	O
partners	O
,	O
casual	O
sexual	O
partners	O
or	O
khwapheni	O
,	O
and	O
once	O
-	O
off	O
sexual	O
partners	O
.	O

In	O
each	O
instance	O
,	O
a	O
cutoff	O
score	O
of	O
4	O
or	O
more	O
was	O
used	O
in	O
the	O
logistic	O
regression	O
and	O
analysis	O
kept	O
each	O
type	O
of	O
sex	O
partner	O
separate	O
.	O

Condom	O
use	O
at	O
last	O
sex	O
.	O

A	O
single	O
question	O
asked	O
about	O
condom	O
use	O
in	O
last	O
sex	O
act	O
.	O

Responses	O
were	O
either	O
yes	O
or	O
no	O
.	O

Physical	O
and	O
/	O
or	O
sexual	O
IPV	O
perpetration	O
(	O
men	O
)	O
and	O
experience	O
(	O
women	B-OG
)	O
in	O
the	O
past	O
year	O
.	O

Eight	O
items	O
,	O
five	O
physical	O
IPV	O
and	O
three	O
sexual	O
IPV	O
,	O
were	O
asked	O
.	O

Men	O
were	O
asked	O
about	O
perpetration	O
and	O
women	O
about	O
experience	O
of	O
IPV	O
.	O

Questions	O
were	O
based	O
on	O
the	O
WHO	O
multi	O
-	O
country	O
survey	O
on	O
violence	O
against	O
women	B-OG
[	O
17	O
]	O
and	O
adapted	O
and	O
extensively	O
tested	O
in	O
South	O
Africa	O
[	O
18	O
].	O

Responses	O
for	O
each	O
item	O
were	O
never	O
,	O
once	O
,	O
few	O
,	O
and	O
many	O
.	O

A	O
positive	O
response	O
to	O
any	O
of	O
the	O
eight	O
items	O
led	O
to	O
a	O
person	O
being	O
coded	O
as	O
having	O
perpetrated	O
IPV	O
(	O
men	O
)	O
and	O
experienced	O
IPV	O
(	O
women	B-OG
)	O
in	O
the	O
past	O
year	O
.	O

Non	O
-	O
partner	O
sexual	B-DS
violence	I-DS
perpetration	O
(	O
men	O
)	O
and	O
experience	O
(	O
women	B-OG
)	O
in	O
the	O
past	O
year	O
.	O

Six	O
items	O
asked	O
about	O
women	B-OG
’	O
s	O
experience	O
and	O
men	O
’	O
s	O
perpetration	O
of	O
non	O
-	O
partner	O
sexual	O
violence	B-DS
,	O
including	O
gang	O
rape	O
.	O

Scales	O
had	O
been	O
developed	O
and	O
extensively	O
tested	O
in	O
South	O
Africa	O
[	O
19	O
].	O

Responses	O
were	O
never	O
,	O
once	O
,	O
few	O
and	O
many	O
.	O

Harmful	O
alcohol	B-CD
use	O
.	O

Alcohol	O
use	O
was	O
assessed	O
using	O
the	O
Alcohol	B-DS
Use	I-DS
Disorder	I-DS
Identification	O
Test	O
(	O
AUDIT	O
)	O
scale	O
.	O

Ten	O
items	O
asked	O
about	O
past	O
year	O
alcohol	B-CD
use	O
,	O
with	O
scores	O
summed	O
.	O

A	O
cut	O
-	O
off	O
score	O
of	O
8	O
or	O
more	O
indicated	O
potential	O
harmful	O
alcohol	B-CD
use	O
[	O
20	O
],	O
and	O
the	O
same	O
cut	O
-	O
off	O
score	O
was	O
used	O
for	O
women	O
and	O
men	O
.	O

Childhood	O
traumas	O
were	O
the	O
exposure	O
variable	O
.	O

Eleven	O
items	O
asked	O
about	O
childhood	O
traumas	O
and	O
were	O
based	O
on	O
the	O
on	O
the	O
short	O
form	O
of	O
the	O
Childhood	O
Trauma	O
Questionnaire	O
[	O
21	O
]	O
and	O
modifications	O
already	O
undertaken	O
in	O
South	O
Africa	O
[	O
4	O
].	O

As	O
all	O
participants	O
were	O
18	O
or	O
older	O
,	O
participants	O
were	O
asked	O
,	O
“	O
before	O
I	O
reached	O
18	O
I	O
…”	O
Five	O
items	O
asked	O
about	O
emotional	B-DS
abuse	I-DS
and	O
neglect	B-DS
.	O

Three	O
items	O
asked	O
about	O
physical	B-DS
abuse	I-DS
and	O
witnessing	O
of	O
violence	O
.	O

Three	O
items	O
asked	O
about	O
experiencing	O
sexual	B-DS
abuse	I-DS
.	O

Responses	O
were	O
on	O
a	O
four	O
-	O
point	O
Likert	O
scale	O
,	O
never	O
,	O
sometimes	O
,	O
often	O
,	O
very	O
often	O
.	O

Childhood	O
traumas	O
were	O
summarized	O
in	O
four	O
ways	O
.	O

First	O
,	O
each	O
type	O
of	O
trauma	O
(	O
emotional	O
,	O
physical	O
,	O
sexual	O
)	O
was	O
dichotomized	O
into	O
a	O
never	O
/	O
ever	O
binary	O
.	O

Second	O
,	O
a	O
straight	O
score	O
of	O
severity	O
for	O
each	O
type	O
of	O
trauma	O
was	O
created	O
through	O
simple	O
summation	O
of	O
scores	O
for	O
individual	O
items	O
.	O

Third	O
,	O
the	O
range	O
of	O
traumas	O
was	O
assessed	O
by	O
classifying	O
participants	O
into	O
those	O
who	O
had	O
experienced	O
no	O
trauma	O
,	O
only	O
one	O
type	O
,	O
two	O
types	O
,	O
or	O
all	O
three	O
types	O
.	O

Finally	O
,	O
a	O
direct	O
summation	O
of	O
all	O
items	O
provided	O
an	O
overall	O
childhood	O
trauma	O
severity	O
score	O
.	O

Socio	O
-	O
demographic	O
measures	O
includes	O
age	O
,	O
educational	O
level	O
including	O
whether	O
a	O
person	O
had	O
passed	O
matric	O
(	O
high	O
school	O
leaving	O
),	O
and	O
household	O
food	O
insecurity	O
.	O

Depression	B-DS
was	O
assessed	O
using	O
The	O
Centre	O
for	O
Epidemiologic	O
Studies	O
Depression	B-DS
Scale	O
(	O
CES	O
-	O
D	O
)	O
scale	O
[	O
22	O
]	O
and	O
had	O
been	O
used	O
in	O
South	O
Africa	O
previously	O
[	O
23	O
,	O
24	O
].	O

Twenty	O
items	O
asked	O
about	O
depressive	O
symptoms	O
in	O
the	O
past	O
week	O
,	O
with	O
responses	O
ranging	O
from	O
never	O
to	O
everyday	O
(	O
α	O
=	O
0	O
.	O
88	O
).	O

Analysis	O

Men	O
and	O
women	O
were	O
analysed	O
separately	O
,	O
and	O
analyses	O
included	O
adjustment	O
for	O
cluster	O
sampling	O
.	O

Descriptive	O
statistics	O
for	O
the	O
socio	O
-	O
demographic	O
measures	O
and	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
were	O
first	O
constructed	O
.	O

We	O
then	O
compiled	O
descriptive	O
statistics	O
of	O
the	O
different	O
forms	O
of	O
childhood	O
traumas	O
,	O
including	O
summaries	O
for	O
each	O
type	O
and	O
the	O
range	O
of	O
traumas	O
.	O

For	O
analysis	O
,	O
Gaussian	O
regression	O
models	O
,	O
reporting	O
odds	O
ratios	O
and	O
adjusting	O
for	O
clustering	O
,	O
age	O
education	O
,	O
current	O
food	O
security	O
,	O
earnings	O
,	O
depressive	O
symptoms	O
,	O
length	O
of	O
time	O
living	O
in	O
community	O
and	O
study	O
arm	O
,	O
were	O
constructed	O
for	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
.	O

Model	O
1	O
examined	O
whether	O
a	O
person	O
had	O
experienced	O
childhood	O
trauma	O
(	O
emotional	O
,	O
physical	O
,	O
sexual	O
)	O
at	O
all	O
and	O
whether	O
it	O
was	O
significantly	O
associated	O
with	O
each	O
HIV	B-OG
-	O
risk	O
variable	O
.	O

In	O
model	O
2	O
,	O
each	O
childhood	O
trauma	O
was	O
treated	O
as	O
a	O
score	O
to	O
indicate	O
the	O
severity	O
of	O
the	O
trauma	O
and	O
assessment	O
was	O
made	O
as	O
to	O
whether	O
this	O
independently	O
predicted	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
.	O

Model	O
3	O
assessed	O
whether	O
the	O
range	O
of	O
traumas	O
experienced	O
was	O
independently	O
associated	O
with	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
.	O

Model	O
4	O
looked	O
at	O
overall	O
severity	O
of	O
childhood	O
trauma	O
and	O
its	O
relationship	O
to	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
.	O

Results	O

In	O
total	O
680	O
women	O
and	O
677	O
men	O
were	O
recruited	O
into	O
the	O
study	O
.	O

There	O
were	O
few	O
differences	O
between	O
women	O
and	O
men	O
in	O
terms	O
of	O
age	O
and	O
education	O
level	O
(	O
Table	O
1	O
).	O

More	O
men	O
than	O
women	O
reported	O
HIV	B-OG
-	O
risk	O
behaviours	O
,	O
particularly	O
transactional	O
sex	O
with	O
a	O
causal	O
or	O
once	O
-	O
off	O
partner	O
,	O
and	O
the	O
number	O
of	O
all	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
.	O

Condom	O
use	O
in	O
the	O
last	O
year	O
was	O
similar	O
,	O
as	O
was	O
IPV	O
experience	O
/	O
perpetration	O
and	O
non	O
-	O
partner	O
sexual	B-DS
violence	I-DS
experience	O
/	O
perpetration	O
.	O

Men	O
reported	O
higher	O
levels	O
of	O
harmful	O
alcohol	B-CD
use	O
than	O
women	O
(	O
43	O
.	O
3	O
%	O
and	O
23	O
.	O
1	O
%	O
respectively	O
).	O

Mean	O
AUDIT	O
scores	O
for	O
men	O
were	O
7	O
.	O
8	O
(	O
min	O
-	O
max	O
scores	O
0	O
–	O
40	O
),	O
and	O
for	O
women	O
4	O
.	O
3	O
(	O
min	O
-	O
max	O
scores	O
0	O
–	O
38	O
).	O

Distribution	O
of	O
socio	O
-	O
demographic	O
characteristics	O
and	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
women	O
and	O
men	O
.	O

Women	O
(	O
n	O
=	O
680	O
)	O

Men	O
(	O
n	O
=	O
677	O
)	O

Socio	O
-	O
demographics	O

n	O
(%)	O

n	O
(%)	O

Age	O
:	O
18	O
–	O
19	O

84	O
(	O
12	O
.	O
4	O
)	O

70	O
(	O
10	O
.	O
3	O
)	O

20	O
–	O
24	O

325	O
(	O
47	O
.	O
8	O
)	O

355	O
(	O
52	O
.	O
4	O
)	O

25	O
–	O
30	O

271	O
(	O
39	O
.	O
9	O
)	O

252	O
(	O
37	O
.	O
2	O
)	O

Education	O
Primary	O
only	O

55	O
(	O
8	O
.	O
1	O
)	O

77	O
(	O
11	O
.	O
4	O
)	O

Secondary	O
(	O
no	O
matric	O
)	O

419	O
(	O
61	O
.	O
6	O
)	O

393	O
(	O
58	O
.	O
1	O
)	O

Matric	O
or	O
beyond	O

206	O
(	O
30	O
.	O
3	O
)	O

207	O
(	O
30	O
.	O
6	O
)	O

HIV	B-OG
-	O
risk	O
behaviours	O

Transactional	O
sex	O
past	O
12m	O

275	O
(	O
42	O
.	O
6	O
)	O

338	O
(	O
50	O
.	O
7	O
)	O

4	O
or	O
more	O
main	O
sexual	O
partners	O
past	O
12m	O

61	O
(	O
9	O
.	O
5	O
)	O

156	O
(	O
23	O
.	O
4	O
)	O

4	O
or	O
more	O
causal	O
sexual	O
partners	O
past	O
12m	O

19	O
(	O
3	O
.	O
0	O
)	O

122	O
(	O
18	O
.	O
3	O
)	O

4	O
or	O
more	O
once	O
off	O
sexual	O
partner	O
past	O
12m	O

13	O
(	O
2	O
.	O
0	O
)	O

129	O
(	O
19	O
.	O
3	O
)	O

Condom	O
use	O
at	O
last	O
sex	O

320	O
(	O
54	O
.	O
1	O
)	O

395	O
(	O
60	O
.	O
3	O
)	O

IPV	O
experience	O
/	O
perpetration	O
past	O
12m	O

443	O
(	O
65	O
.	O
2	O
)	O

384	O
(	O
56	O
.	O
9	O
)	O

Non	O
-	O
partner	O
sexual	O
violence	B-DS
experience	O
/	O
perpetration	O
past	O
12m	O

224	O
(	O
32	O
.	O
9	O
)	O

262	O
(	O
38	O
.	O
8	O
)	O

Harmful	O
alcohol	B-CD
use	O

157	O
(	O
23	O
.	O
1	O
)	O

294	O
(	O
43	O
.	O
4	O
)	O

Mean	O
alcohol	B-CD
use	O
scores	O
(	O
range	O
)	O

4	O
.	O
3	O
(	O
0	O
–	O
38	O
)	O

7	O
.	O
8	O
(	O
0	O
–	O
40	O
)	O

Overall	O
prevalence	O
of	O
childhood	O
traumas	O
were	O
high	O
.	O
Table	O
2	O
shows	O
the	O
distribution	O
of	O
different	O
forms	O
of	O
childhood	O
abuse	B-DS
.	O

Emotional	B-DS
abuse	I-DS
was	O
very	O
common	O
with	O
almost	O
three	O
-	O
quarters	O
of	O
women	O
(	O
72	O
.	O
4	O
%)	O
and	O
just	O
over	O
three	O
-	O
quarters	O
of	O
men	O
(	O
77	O
.	O
9	O
%)	O
reporting	O
emotional	B-DS
abuse	I-DS
or	O
neglect	O
growing	O
up	O
.	O

All	O
types	O
of	O
emotional	B-DS
abuse	I-DS
were	O
common	O
,	O
with	O
the	O
exception	O
of	O
parents	O
being	O
“	O
too	O
drunk	O
or	O
drugged	O
to	O
look	O
after	O
me	O
”,	O
where	O
only	O
around	O
one	O
quarter	O
of	O
women	O
and	O
men	O
reported	O
this	O
.	O

Physical	B-DS
abuse	I-DS
and	O
witnessing	O
of	O
violence	O
in	O
the	O
home	O
was	O
common	O
and	O
reported	O
by	O
about	O
three	O
quarters	O
of	O
participants	O
.	O

The	O
most	O
common	O
form	O
of	O
physical	B-DS
abuse	I-DS
was	O
being	O
beaten	O
with	O
a	O
belt	O
,	O
stick	O
,	O
or	O
something	O
hard	O
,	O
with	O
about	O
two	O
-	O
thirds	O
of	O
women	O
and	O
men	O
reporting	O
having	O
experienced	O
this	O
at	O
least	O
once	O
.	O

Sexual	B-DS
abuse	I-DS
was	O
the	O
least	O
form	O
of	O
childhood	O
trauma	O
,	O
although	O
still	O
very	O
high	O
.	O

One	O
third	O
of	O
women	O
(	O
36	O
.	O
0	O
%)	O
and	O
almost	O
a	O
half	O
of	O
men	O
(	O
47	O
.	O
9	O
%)	O
reported	O
at	O
least	O
one	O
type	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Experiencing	O
more	O
than	O
one	O
form	O
of	O
childhood	B-DS
abuse	I-DS
was	O
also	O
common	O
.	O

For	O
women	O
,	O
39	O
.	O
1	O
%	O
reported	O
two	O
forms	O
of	O
childhood	B-DS
abuse	I-DS
,	O
and	O
27	O
.	O
7	O
%	O
three	O
types	O
of	O
childhood	B-DS
abuse	I-DS
,	O
while	O
for	O
men	O
31	O
.	O
6	O
%	O
reported	O
two	O
forms	O
,	O
and	O
40	O
.	O
2	O
%	O
all	O
three	O
forms	O
of	O
childhood	B-DS
abuse	I-DS
.	O

Frequency	O
and	O
range	O
of	O
childhood	O
traumas	O
amongst	O
women	O
and	O
men	O
.	O

Women	B-OG

Men	O

Emotional	B-DS
abuse	I-DS
/	O
neglect	O

Never	O
,	O
n	O
(%)	O

Sometimes	O
,	O
n	O
(%)	O

Often	O
,	O
n	O
(%)	O

Very	O
often	O
,	O
n	O
(%)	O

Never	O
,	O
n	O
(%)	O

Sometimes	O
,	O
n	O
(%)	O

Often	O
,	O
n	O
(%)	O

Very	O
often	O
,	O
n	O
(%)	O

I	O
lived	O
in	O
different	O
households	O
at	O
different	O
times	O

406	O
(	O
59	O
.	O
7	O
)	O

169	O
(	O
24	O
.	O
9	O
)	O

63	O
(	O
9	O
.	O
3	O
)	O

42	O
(	O
6	O
.	O
2	O
)	O

355	O
(	O
52	O
.	O
6	O
)	O

203	O
(	O
30	O
.	O
1	O
)	O

67	O
(	O
9	O
.	O
9	O
)	O

50	O
(	O
7	O
.	O
4	O
)	O

I	O
was	O
told	O
I	O
was	O
lazy	O
or	O
stupid	O
or	O
weak	O
by	O
someone	O
in	O
my	O
family	O

384	O
(	O
56	O
.	O
5	O
)	O

180	O
(	O
26	O
.	O
5	O
)	O

72	O
(	O
10	O
.	O
6	O
)	O

44	O
(	O
6	O
.	O
5	O
)	O

360	O
(	O
53	O
.	O
3	O
)	O

220	O
(	O
32	O
.	O
6	O
)	O

49	O
(	O
7	O
.	O
3	O
)	O

46	O
(	O
6	O
.	O
8	O
)	O

I	O
was	O
insulted	O
or	O
humiliated	O
by	O
someone	O
in	O
my	O
family	O
in	O
front	O
of	O
other	O
people	O

398	O
(	O
58	O
.	O
5	O
)	O

185	O
(	O
27	O
.	O
2	O
)	O

51	O
(	O
7	O
.	O
5	O
)	O

46	O
(	O
6	O
.	O
8	O
)	O

382	O
(	O
56	O
.	O
6	O
)	O

197	O
(	O
29	O
.	O
2	O
)	O

51	O
(	O
7	O
.	O
6	O
)	O

45	O
(	O
6	O
.	O
7	O
)	O

one	O
or	O
both	O
of	O
my	O
parents	O
were	O
too	O
drunk	O
or	O
drugged	O
to	O
take	O
care	O
of	O
me	O

552	O
(	O
81	O
.	O
2	O
)	O

69	O
(	O
10	O
.	O
2	O
)	O

28	O
(	O
4	O
.	O
1	O
)	O

31	O
(	O
4	O
.	O
6	O
)	O

497	O
(	O
73	O
.	O
6	O
)	O

101	O
(	O
15	O
.	O
0	O
)	O

45	O
(	O
6	O
.	O
7	O
)	O

32	O
(	O
4	O
.	O
7	O
)	O

I	O
spent	O
time	O
outside	O
the	O
home	O
and	O
none	O
of	O
the	O
adults	O
at	O
home	O
knew	O
where	O
I	O
was	O

487	O
(	O
71	O
.	O
6	O
)	O

139	O
(	O
20	O
.	O
4	O
)	O

38	O
(	O
5	O
.	O
6	O
)	O

16	O
(	O
2	O
.	O
4	O
)	O

383	O
(	O
56	O
.	O
7	O
)	O

213	O
(	O
31	O
.	O
6	O
)	O

47	O
(	O
7	O
.	O
0	O
)	O

32	O
(	O
4	O
.	O
7	O
)	O

Physical	O
abuse	B-DS
/	O
witnessing	O

I	O
saw	O
or	O
heard	O
my	O
mother	O
being	O
beaten	O
by	O
her	O
husband	O
or	O
boyfriend	O

476	O
(	O
70	O
.	O
0	O
)	O

128	O
(	O
18	O
.	O
8	O
)	O

39	O
(	O
5	O
.	O
7	O
)	O

37	O
(	O
5	O
.	O
4	O
)	O

439	O
(	O
65	O
.	O
0	O
)	O

143	O
(	O
21	O
.	O
2	O
)	O

54	O
(	O
8	O
.	O
0	O
)	O

39	O
(	O
5	O
.	O
8	O
)	O

I	O
was	O
beaten	O
at	O
home	O
with	O
a	O
belt	O
or	O
stick	O
or	O
whip	O
or	O
something	O
else	O
which	O
was	O
hard	O

262	O
(	O
38	O
.	O
5	O
)	O

275	O
(	O
40	O
.	O
4	O
)	O

72	O
(	O
10	O
.	O
6	O
)	O

71	O
(	O
10	O
.	O
4	O
)	O

223	O
(	O
33	O
.	O
0	O
)	O

289	O
(	O
42	O
.	O
8	O
)	O

88	O
(	O
13	O
.	O
0	O
)	O

75	O
(	O
11	O
.	O
1	O
)	O

I	O
was	O
beaten	O
so	O
hard	O
at	O
home	O
that	O
it	O
left	O
a	O
mark	O
or	O
bruise	O

428	O
(	O
62	O
.	O
9	O
)	O

154	O
(	O
22	O
.	O
7	O
)	O

55	O
(	O
8	O
.	O
1	O
)	O

43	O
(	O
6	O
.	O
3	O
)	O

412	O
(	O
61	O
.	O
0	O
)	O

177	O
(	O
26	O
.	O
2	O
)	O

44	O
(	O
6	O
.	O
5	O
)	O

42	O
(	O
6	O
.	O
2	O
)	O

Sexual	B-DS
abuse	I-DS

someone	O
touched	O
my	O
buttocks	O
or	O
genitals	O
or	O
made	O
me	O
touch	O
them	O
when	O
I	O
did	O
not	O
want	O
to	O

545	O
(	O
80	O
.	O
2	O
)	O

102	O
(	O
15	O
.	O
0	O
)	O

21	O
(	O
3	O
.	O
1	O
)	O

12	O
(	O
1	O
.	O
8	O
)	O

474	O
(	O
70	O
.	O
2	O
)	O

139	O
(	O
20	O
.	O
6	O
)	O

38	O
(	O
5	O
.	O
6	O
)	O

24	O
(	O
3	O
.	O
6	O
)	O

I	O
had	O
sex	O
with	O
a	O
wo	O
(	O
man	B-OG
)	O
who	O
was	O
more	O
than	O
5	O
years	O
older	O
than	O
me	O

533	O
(	O
78	O
.	O
4	O
)	O

77	O
(	O
11	O
.	O
3	O
)	O

46	O
(	O
6	O
.	O
8	O
)	O

24	O
(	O
3	O
.	O
5	O
)	O

460	O
(	O
68	O
.	O
2	O
)	O

153	O
(	O
22	O
.	O
7	O
)	O

44	O
(	O
6	O
.	O
5	O
)	O

18	O
(	O
2	O
.	O
7	O
)	O

I	O
had	O
sex	O
with	O
someone	O
because	O
I	O
was	O
threatened	O
or	O
frightened	O
or	O
forced	O

567	O
(	O
83	O
.	O
4	O
)	O

65	O
(	O
9	O
.	O
6	O
)	O

31	O
(	O
4	O
.	O
6	O
)	O

17	O
(	O
2	O
.	O
5	O
)	O

554	O
(	O
82	O
.	O
1	O
)	O

82	O
(	O
12	O
.	O
2	O
)	O

26	O
(	O
3	O
.	O
9	O
)	O

13	O
(	O
1	O
.	O
9	O
)	O

Never	O
,	O
n	O
(%)	O

Ever	O
,	O
(	O
n	O
%)	O

Never	O
,	O
n	O
(%)	O

Ever	O
,	O
(	O
n	O
%)	O

Emotional	B-DS
abuse	I-DS
ever	O

188	O
(	O
27	O
.	O
7	O
)	O

492	O
(	O
72	O
.	O
4	O
)	O

154	O
(	O
22	O
.	O
8	O
)	O

521	O
(	O
77	O
.	O
9	O
)	O

Physical	B-DS
abuse	I-DS
ever	O

197	O
(	O
29	O
.	O
0	O
)	O

483	O
(	O
71	O
.	O
0	O
)	O

167	O
(	O
24	O
.	O
7	O
)	O

508	O
(	O
75	O
.	O
3	O
)	O

Sexual	B-DS
abuse	I-DS
ever	O

435	O
(	O
64	O
.	O
0	O
)	O

245	O
(	O
36	O
.	O
0	O
)	O

352	O
(	O
52	O
.	O
2	O
)	O

323	O
(	O
47	O
.	O
9	O
)	O

Range	O
of	O
Abuse	O

None	O
n	O
(%)	O

One	O
Form	O
,	O
n	O
(%)	O

Two	O
Forms	O
,	O
n	O
(%)	O

Three	O
Forms	O
,	O
n	O
(%)	O

None	O
n	O
(%)	O

One	O
Form	O
,	O
n	O
(%)	O

Two	O
Forms	O
,	O
n	O
(%)	O

Three	O
Forms	O
,	O
n	O
(%)	O

102	O
(	O
15	O
.	O
0	O
)	O

124	O
(	O
18	O
.	O
2	O
)	O

266	O
(	O
39	O
.	O
1	O
)	O

188	O
(	O
27	O
.	O
7	O
)	O

78	O
(	O
11	O
.	O
6	O
)	O

113	O
(	O
16	O
.	O
7	O
)	O

213	O
(	O
31	O
.	O
6	O
)	O

271	O
(	O
40	O
.	O
2	O
)	O

For	O
women	O
,	O
transactional	O
sex	O
in	O
the	O
past	O
year	O
was	O
associated	O
with	O
ever	O
experiencing	O
emotional	B-DS
abuse	I-DS
,	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
ever	O
experiencing	O
sexual	B-DS
abuse	I-DS
,	O
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
(	O
Table	O
3	O
).	O

Having	O
four	O
or	O
more	O
main	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
,	O
and	O
having	O
four	O
or	O
more	O
casual	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
were	O
both	O
associated	O
with	O
any	O
sexual	B-DS
abuse	I-DS
,	O
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
for	O
women	O
.	O

Women	O
reporting	O
more	O
than	O
four	O
once	O
-	O
off	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
were	O
more	O
likely	O
to	O
report	O
ever	O
being	O
sexually	O
abused	O
.	O

Non	O
-	O
condom	O
use	O
was	O
associated	O
with	O
ever	O
experiencing	O
emotional	B-DS
abuse	I-DS
,	O
and	O
ever	O
experiencing	O
physical	B-DS
abuse	I-DS
.	O

Past	O
year	O
IPV	O
experience	O
was	O
associated	O
with	O
any	O
emotional	B-DS
abuse	I-DS
,	O
ever	O
physical	B-DS
abuse	I-DS
,	O
severity	O
of	O
physical	B-DS
abuse	I-DS
,	O
any	O
sexual	B-DS
abuse	I-DS
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
in	O
childhood	O
.	O

Experience	O
of	O
non	O
-	O
partner	B-DS
sexual	I-DS
violence	I-DS
and	O
harmful	O
alcohol	B-CD
use	O
were	O
both	O
associated	O
with	O
any	O
emotional	B-DS
abuse	I-DS
,	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
any	O
physical	B-DS
abuse	I-DS
and	O
severity	O
of	O
physical	B-DS
abuse	I-DS
,	O
and	O
any	O
sexual	B-DS
abuse	I-DS
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Adjusted	O
odds	O
ratios	O
for	O
women	O
and	O
men	O
for	O
each	O
HIV	B-OG
-	O
risk	O
behaviour	O
and	O
form	O
of	O
childhood	O
trauma	O
.	O

Emotional	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Emotional	B-DS
abuse	I-DS
score	O
(	O
model	O
2	O
)	O

Physical	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Physical	O
abuse	B-DS
score	O
(	O
model	O
2	O
)	O

Sexual	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Sexual	B-DS
abuse	I-DS
score	O
(	O
model	O
2	O
)	O

Range	O
of	O
abuse	O
(	O
none	O
-	O
three	O
,	O
model	O
3	O
)	O

Childhood	O
trauma	O
score	O
(	O
model	O
4	O
)	O

Women	B-OG

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

Transactional	O
sex	O

1	O
.	O
85	O
(	O
1	O
.	O
25	O
–	O
2	O
.	O
75	O
)**	O

1	O
.	O
14	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
22	O
)***	O

1	O
.	O
17	O
(	O
0	O
.	O
80	O
–	O
1	O
.	O
69	O
)	O

1	O
.	O
06	O
(	O
0	O
.	O
97	O
–	O
1	O
.	O
16	O
)	O

1	O
.	O
52	O
(	O
1	O
.	O
07	O
–	O
2	O
.	O
16	O
)*	O

1	O
.	O
23	O
(	O
1	O
.	O
09	O
–	O
1	O
.	O
39	O
)**	O

1	O
.	O
30	O
(	O
1	O
.	O
09	O
–	O
1	O
.	O
55	O
)**	O

1	O
.	O
07	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
11	O
)***	O

Main	O
partners	O
past12m	O

1	O
.	O
16	O
(	O
0	O
.	O
60	O
–	O
2	O
.	O
24	O
)	O

1	O
.	O
06	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
17	O
)	O

1	O
.	O
09	O
(	O
0	O
.	O
58	O
–	O
2	O
.	O
05	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
20	O
)	O

2	O
.	O
44	O
(	O
1	O
.	O
38	O
–	O
4	O
.	O
29	O
)**	O

1	O
.	O
19	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
38	O
)*	O

1	O
.	O
35	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
84	O
)	O

1	O
.	O
04	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
10	O
)	O

Casual	O
partners	O
past12m	O

1	O
.	O
87	O
(	O
0	O
.	O
50	O
–	O
7	O
.	O
00	O
)	O

1	O
.	O
16	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
38	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
33	O
–	O
2	O
.	O
98	O
)	O

1	O
.	O
12	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
40	O
)	O

6	O
.	O
17	O
(	O
2	O
.	O
05	O
–	O
18	O
.	O
51	O
)**	O

1	O
.	O
25	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
56	O
)*	O

2	O
.	O
00	O
(	O
1	O
.	O
08	O
–	O
3	O
.	O
71	O
)*	O

1	O
.	O
09	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
18	O
)	O

Once	O
off	O
sexual	O
partners	O
past12m	O

1	O
.	O
85	O
(	O
0	O
.	O
38	O
–	O
9	O
.	O
08	O
)	O

1	O
.	O
11	O
(	O
0	O
.	O
90	O
–	O
1	O
.	O
37	O
)	O

1	O
.	O
10	O
(	O
0	O
.	O
28	O
–	O
4	O
.	O
33	O
)	O

1	O
.	O
03	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
38	O
)	O

4	O
.	O
74	O
(	O
1	O
.	O
34	O
–	O
16	O
.	O
78	O
)*	O

1	O
.	O
13	O
(	O
0	O
.	O
83	O
–	O
1	O
.	O
53	O
)	O

1	O
.	O
89	O
(	O
0	O
.	O
90	O
–	O
3	O
.	O
96	O
)	O

1	O
.	O
05	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
17	O
)	O

Condom	O
use	O
at	O
last	O
sex	O

0	O
.	O
68	O
(	O
0	O
.	O
46	O
–	O
1	O
.	O
01	O
)*	O

0	O
.	O
97	O
(	O
0	O
.	O
91	O
–	O
1	O
.	O
04	O
)	O

0	O
.	O
60	O
(	O
0	O
.	O
41	O
–	O
0	O
.	O
88	O
)**	O

0	O
.	O
97	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
06	O
)	O

1	O
.	O
07	O
(	O
0	O
.	O
75	O
–	O
1	O
.	O
52	O
)	O

0	O
.	O
98	O
(	O
0	O
.	O
88	O
–	O
1	O
.	O
10	O
)	O

0	O
.	O
84	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
00	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
02	O
)	O

IPV	O
(	O
experience	O
)	O

1	O
.	O
76	O
(	O
1	O
.	O
21	O
–	O
2	O
.	O
56	O
)**	O

1	O
.	O
06	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
14	O
)	O

2	O
.	O
16	O
(	O
1	O
.	O
51	O
–	O
3	O
.	O
10	O
)***	O

1	O
.	O
13	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
25	O
)**	O

1	O
.	O
44	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
08	O
)*	O

1	O
.	O
17	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
34	O
)*	O

1	O
.	O
46	O
(	O
1	O
.	O
23	O
–	O
1	O
.	O
74	O
)***	O

1	O
.	O
05	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
10	O
)**	O

Non	O
-	O
partner	O
sexual	O
violence	O
(	O
experience	O
)	O

2	O
.	O
67	O
(	O
1	O
.	O
69	O
–	O
4	O
.	O
21	O
)***	O

1	O
.	O
22	O
(	O
1	O
.	O
14	O
–	O
1	O
.	O
31	O
)***	O

1	O
.	O
66	O
(	O
1	O
.	O
11	O
–	O
2	O
.	O
48	O
)**	O

1	O
.	O
15	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
26	O
)**	O

2	O
.	O
71	O
(	O
1	O
.	O
90	O
–	O
3	O
.	O
88	O
)***	O

1	O
.	O
33	O
(	O
1	O
.	O
18	O
–	O
1	O
.	O
50	O
)***	O

1	O
.	O
81	O
(	O
1	O
.	O
48	O
–	O
2	O
.	O
21	O
)***	O

1	O
.	O
11	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
15	O
)***	O

Harmful	O
alcohol	B-CD
use	O

2	O
.	O
74	O
(	O
1	O
.	O
61	O
–	O
4	O
.	O
68	O
)***	O

1	O
.	O
19	O
(	O
1	O
.	O
11	O
–	O
1	O
.	O
29	O
)***	O

1	O
.	O
96	O
(	O
1	O
.	O
21	O
–	O
3	O
.	O
19	O
)**	O

1	O
.	O
14	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
26	O
)**	O

2	O
.	O
26	O
(	O
1	O
.	O
51	O
–	O
3	O
.	O
39	O
)***	O

1	O
.	O
30	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
46	O
)***	O

1	O
.	O
80	O
(	O
1	O
.	O
42	O
–	O
2	O
.	O
28	O
)***	O

1	O
.	O
10	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
14	O
)***	O

Emotional	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Emotional	B-DS
abuse	I-DS
score	O
(	O
model	O
2	O
)	O

Physical	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Physical	O
abuse	B-DS
score	O
(	O
model	O
2	O
)	O

Sexual	B-DS
abuse	I-DS
ever	O
(	O
model	O
1	O
)	O

Sexual	B-DS
abuse	I-DS
score	O
(	O
model	O
2	O
)	O

Range	O
of	O
abuse	O
(	O
none	O
-	O
three	O
,	O
model	O
3	O
)	O

Childhood	O
trauma	O
score	O
(	O
model	O
4	O
)	O

Men	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

aOR	O
(	O
95	O
%	O
CI	O
)	O

Transactional	O
sex	O

1	O
.	O
72	O
(	O
1	O
.	O
15	O
–	O
2	O
.	O
58	O
)**	O

1	O
.	O
18	O
(	O
1	O
.	O
10	O
–	O
1	O
.	O
26	O
)***	O

1	O
.	O
36	O
(	O
0	O
.	O
93	O
–	O
1	O
.	O
98	O
)	O

1	O
.	O
09	O
(	O
1	O
.	O
00	O
–	O
1	O
.	O
19	O
)*	O

2	O
.	O
90	O
(	O
2	O
.	O
07	O
–	O
4	O
.	O
05	O
)***	O

1	O
.	O
52	O
(	O
1	O
.	O
32	O
–	O
1	O
.	O
74	O
)***	O

1	O
.	O
54	O
(	O
1	O
.	O
30	O
–	O
1	O
.	O
84	O
)***	O

1	O
.	O
09	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
13	O
)***	O

Main	O
partners	O
past12m	O

1	O
.	O
24	O
(	O
0	O
.	O
77	O
–	O
1	O
.	O
99	O
)	O

1	O
.	O
11	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
19	O
)**	O

1	O
.	O
19	O
(	O
0	O
.	O
76	O
–	O
1	O
.	O
85	O
)	O

1	O
.	O
11	O
(	O
1	O
.	O
01	O
–	O
1	O
.	O
22	O
)*	O

2	O
.	O
63	O
(	O
1	O
.	O
76	O
–	O
3	O
.	O
91	O
)***	O

1	O
.	O
29	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
46	O
)***	O

1	O
.	O
39	O
(	O
1	O
.	O
13	O
–	O
1	O
.	O
71	O
)**	O

1	O
.	O
07	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
11	O
)**	O

Casual	O
partners	O
past12m	O

1	O
.	O
79	O
(	O
1	O
.	O
01	O
–	O
3	O
.	O
17	O
)*	O

1	O
.	O
14	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
23	O
)**	O

1	O
.	O
59	O
(	O
0	O
.	O
95	O
–	O
2	O
.	O
69	O
)	O

1	O
.	O
13	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
25	O
)*	O

2	O
.	O
57	O
(	O
1	O
.	O
65	O
–	O
4	O
.	O
00	O
)***	O

1	O
.	O
31	O
(	O
1	O
.	O
15	O
–	O
1	O
.	O
48	O
)***	O

1	O
.	O
57	O
(	O
1	O
.	O
23	O
–	O
2	O
.	O
01	O
)***	O

1	O
.	O
08	O
(	O
1	O
.	O
04	O
–	O
1	O
.	O
12	O
)***	O

Once	O
off	O
sexual	O
partners	O
past12m	O

2	O
.	O
04	O
(	O
1	O
.	O
14	O
–	O
3	O
.	O
66	O
)*	O

1	O
.	O
10	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
19	O
)*	O

1	O
.	O
65	O
(	O
0	O
.	O
98	O
–	O
2	O
.	O
77	O
)	O

1	O
.	O
10	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
21	O
)	O

2	O
.	O
82	O
(	O
1	O
.	O
81	O
–	O
4	O
.	O
40	O
)***	O

1	O
.	O
32	O
(	O
1	O
.	O
16	O
–	O
1	O
.	O
50	O
)***	O

1	O
.	O
67	O
(	O
1	O
.	O
31	O
–	O
2	O
.	O
14	O
)***	O

1	O
.	O
06	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
11	O
)**	O

Condom	O
use	O
at	O
last	O
sex	O

0	O
.	O
85	O
(	O
0	O
.	O
56	O
–	O
1	O
.	O
28	O
)	O

0	O
.	O
95	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
01	O
)	O

0	O
.	O
58	O
(	O
0	O
.	O
39	O
–	O
0	O
.	O
86	O
)**	O

0	O
.	O
95	O
(	O
0	O
.	O
87	O
–	O
1	O
.	O
03	O
)	O

0	O
.	O
87	O
(	O
0	O
.	O
63	O
–	O
1	O
.	O
21	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
10	O
)	O

0	O
.	O
84	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
00	O
)*	O

0	O
.	O
98	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
01	O
)	O

IPV	O
(	O
perpetration	O
)	O

2	O
.	O
02	O
(	O
1	O
.	O
36	O
–	O
2	O
.	O
99	O
)***	O

1	O
.	O
14	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
22	O
)***	O

1	O
.	O
91	O
(	O
1	O
.	O
32	O
–	O
2	O
.	O
77	O
)**	O

1	O
.	O
16	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
27	O
)**	O

2	O
.	O
32	O
(	O
1	O
.	O
67	O
–	O
3	O
.	O
22	O
)***	O

1	O
.	O
39	O
(	O
1	O
.	O
21	O
–	O
1	O
.	O
58	O
)***	O

1	O
.	O
60	O
(	O
1	O
.	O
35	O
–	O
1	O
.	O
89	O
)***	O

1	O
.	O
09	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
13	O
)***	O

Non	O
-	O
partner	O
sexual	O
violence	O
(	O
perpetration	O
)	O

2	O
.	O
21	O
(	O
1	O
.	O
42	O
–	O
3	O
.	O
45	O
)***	O

1	O
.	O
17	O
(	O
1	O
.	O
10	O
–	O
1	O
.	O
25	O
)***	O

1	O
.	O
85	O
(	O
1	O
.	O
23	O
–	O
2	O
.	O
77	O
)**	O

1	O
.	O
15	O
(	O
1	O
.	O
05	O
–	O
1	O
.	O
25	O
)**	O

3	O
.	O
98	O
(	O
2	O
.	O
80	O
–	O
5	O
.	O
67	O
)***	O

1	O
.	O
68	O
(	O
1	O
.	O
47	O
–	O
1	O
.	O
92	O
)***	O

1	O
.	O
92	O
(	O
1	O
.	O
58	O
–	O
2	O
.	O
34	O
)***	O

1	O
.	O
11	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
15	O
)***	O

Harmful	O
alcohol	B-CD
use	O

1	O
.	O
97	O
(	O
1	O
.	O
29	O
–	O
3	O
.	O
00	O
)***	O

1	O
.	O
23	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
20	O
)***	O

2	O
.	O
11	O
(	O
1	O
.	O
42	O
–	O
3	O
.	O
15	O
)***	O

1	O
.	O
15	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
26	O
)**	O

1	O
.	O
74	O
(	O
1	O
.	O
25	O
–	O
2	O
.	O
43	O
)**	O

1	O
.	O
10	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
22	O
)	O

1	O
.	O
50	O
(	O
1	O
.	O
26	O
–	O
1	O
.	O
79	O
)***	O

1	O
.	O
06	O
(	O
1	O
.	O
03	O
–	O
1	O
.	O
10	O
)***	O

All	O
models	O
control	O
for	O
:	O
age	O
,	O
education	O
,	O
food	O
security	O
,	O
earnings	O
,	O
depression	B-DS
,	O
intervention	O
arm	O
,	O
length	O
of	O
time	O
living	O
in	O
community	O

Levels	O
of	O
significance	O
:	O

*	O
p	O
<	O
0	O
.	O
05	O
;	O

**	O
p	O
<	O
0	O
.	O
01	O
;	O

***	O
p	O
<	O
0	O
.	O
0001	O

For	O
men	O
,	O
transactional	O
sex	O
in	O
the	O
past	O
year	O
was	O
associated	O
with	O
ever	O
experiencing	O
emotional	B-DS
abuse	I-DS
and	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
severity	O
of	O
physical	B-DS
abuse	I-DS
,	O
and	O
any	O
sexual	B-DS
abuse	I-DS
,	O
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Four	O
or	O
more	O
main	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
was	O
associated	O
with	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
any	O
physical	B-DS
abuse	I-DS
,	O
severity	O
of	O
physical	B-DS
abuse	I-DS
,	O
any	O
sexual	B-DS
abuse	I-DS
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Four	O
or	O
more	O
casual	O
sexual	O
partners	O
in	O
the	O
past	O
year	O
was	O
associated	O
with	O
any	O
emotional	B-DS
violence	I-DS
and	O
severity	O
of	O
emotional	B-DS
violence	I-DS
,	O
severity	O
of	O
physical	B-DS
violence	I-DS
,	O
and	O
any	O
sexual	B-DS
abuse	I-DS
,	O
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Four	O
or	O
more	O
once	O
-	O
off	O
sexual	O
partners	O
was	O
associated	O
with	O
any	O
emotional	B-DS
abuse	I-DS
,	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
any	O
physical	B-DS
abuse	I-DS
,	O
and	O
any	O
sexual	B-DS
abuse	I-DS
,	O
and	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

Not	O
using	O
a	O
condom	O
at	O
last	O
sex	O
was	O
associated	O
with	O
any	O
experience	O
of	O
physical	B-DS
abuse	I-DS
.	O

Perpetration	O
of	O
IPV	O
and	O
non	O
-	O
partner	B-DS
sexual	I-DS
violence	I-DS
and	O
harmful	O
alcohol	B-CD
use	O
were	O
all	O
associated	O
with	O
ever	O
experiencing	O
emotional	B-DS
abuse	I-DS
,	O
severity	O
of	O
emotional	B-DS
abuse	I-DS
,	O
ever	O
physical	B-DS
abuse	I-DS
,	O
severity	O
of	O
physical	B-DS
abuse	I-DS
,	O
and	O
ever	O
sexual	B-DS
abuse	I-DS
.	O

IPV	O
perpetration	O
,	O
and	O
non	O
-	O
partner	B-DS
sexual	I-DS
violence	I-DS
perpetration	O
was	O
also	O
associated	O
with	O
severity	O
of	O
sexual	B-DS
abuse	I-DS
.	O

For	O
women	O
the	O
range	O
of	O
childhood	B-DS
abuse	I-DS
experienced	O
was	O
significantly	O
associated	O
with	O
transactional	O
sex	O
,	O
four	O
or	O
more	O
main	O
sexual	O
partners	O
,	O
four	O
or	O
more	O
causal	O
sexual	O
partners	O
,	O
experiencing	O
IPV	O
,	O
non	O
-	O
partner	O
sexual	B-DS
violence	I-DS
,	O
not	O
using	O
a	O
condom	O
use	O
at	O
last	O
sex	O
and	O
harmful	O
alcohol	B-CD
use	O
.	O

The	O
overall	O
severity	O
of	O
childhood	O
trauma	O
for	O
women	O
was	O
associated	O
with	O
transactional	O
sex	O
,	O
four	O
or	O
more	O
casual	O
partners	O
in	O
the	O
past	O
year	O
,	O
past	O
year	O
experience	O
of	O
IPV	O
,	O
non	O
-	O
partner	O
sexual	O
violence	O
,	O
and	O
harmful	O
alcohol	B-CD
use	O
.	O

For	O
men	B-OG
,	O
the	O
range	O
of	O
childhood	B-DS
abuse	I-DS
experienced	O
and	O
overall	O
childhood	O
trauma	O
scores	O
had	O
similar	O
associations	O
.	O

They	O
were	O
both	O
independently	O
associated	O
with	O
transactional	O
sex	O
,	O
four	O
or	O
more	O
main	O
partners	O
,	O
casual	O
partners	O
or	O
once	O
off	O
partners	O
,	O
and	O
IPV	O
and	O
non	O
-	O
partner	O
violence	O
perpetration	O
,	O
and	O
harmful	O
alcohol	O
use	O
.	O

The	O
range	O
of	O
childhood	B-DS
abuse	I-DS
experienced	O
for	O
men	B-OG
was	O
also	O
independently	O
associated	O
with	O
not	O
using	O
a	O
condom	O
at	O
last	O
sex	O
.	O

Discussion	O

The	O
experience	O
of	O
violence	O
and	O
abuse	O
during	O
childhood	O
for	O
this	O
vulnerable	O
,	O
and	O
relatively	O
young	O
population	O
,	O
was	O
exceedingly	O
high	O
:	O
75	O
.	O
0	O
%	O
of	O
women	O
and	O
88	O
.	O
4	O
%	O
of	O
men	O
reported	O
experiencing	O
any	O
childhood	O
trauma	O
.	O

All	O
forms	O
of	O
childhood	O
trauma	O
were	O
associated	O
with	O
a	O
range	O
of	O
current	O
HIV	B-OG
-	O
risk	O
behaviours	O
,	O
and	O
this	O
was	O
true	O
for	O
ever	O
experiencing	O
a	O
variety	O
of	O
types	O
of	O
trauma	O
,	O
the	O
severity	O
of	O
trauma	O
,	O
the	O
range	O
of	O
traumas	O
experienced	O
,	O
and	O
overall	O
severity	O
of	O
childhood	O
trauma	O
.	O

The	O
high	O
prevalence	O
of	O
childhood	O
trauma	O
observed	O
here	O
is	O
somewhat	O
higher	O
than	O
other	O
studies	O
in	O
South	O
Africa	O
,	O
suggesting	O
that	O
childhood	O
abuse	O
remains	O
a	O
major	O
challenge	O
that	O
needs	O
tackling	O
in	O
South	O
Africa	O
.	O

It	O
also	O
reinforces	O
the	O
growing	O
evidence	O
suggesting	O
informal	O
settlements	O
are	O
particular	O
sites	O
of	O
vulnerability	O
for	O
childhood	O
trauma	O
[	O
13	O
]	O
as	O
well	O
as	O
sites	O
of	O
poor	O
health	O
more	O
widely	O
[	O
11	O
],	O
and	O
yet	O
under	O
-	O
resourced	O
in	O
terms	O
of	O
access	O
to	O
services	O
and	O
less	O
focused	O
on	O
by	O
interventions	O
[	O
10	O
,	O
12	O
,	O
25	O
].	O

The	O
models	O
adjusted	O
for	O
length	O
of	O
residency	O
in	O
the	O
community	O
,	O
but	O
did	O
not	O
specifically	O
assess	O
where	O
participants	O
had	O
grown	O
up	O
,	O
nor	O
where	O
they	O
had	O
experienced	O
the	O
childhood	O
traumas	O
they	O
reported	O
.	O

For	O
men	B-OG
,	O
there	O
was	O
a	O
much	O
higher	O
prevalence	O
of	O
sexual	B-DS
abuse	I-DS
in	O
childhood	O
than	O
in	O
many	O
other	O
studies	O
in	O
South	O
Africa	O
.	O

In	O
this	O
study	O
,	O
47	O
.	O
9	O
%	O
of	O
men	O
reported	O
any	O
form	O
of	O
childhood	O
sexual	B-DS
abuse	I-DS
.	O

This	O
is	O
much	O
higher	O
than	O
a	O
younger	O
,	O
rural	O
cohort	O
,	O
where	O
16	O
.	O
7	O
%	O
reported	O
any	O
sexual	B-DS
abuse	I-DS
[	O
4	O
],	O
and	O
9	O
%	O
in	O
a	O
much	O
younger	O
(	O
10	O
–	O
17	O
)	O
probability	O
sample	O
[	O
3	O
].	O

While	O
in	O
a	O
representative	O
household	O
sample	O
of	O
men	B-OG
in	O
South	O
Africa	O
,	O
9	O
.	O
6	O
%	O
reported	O
any	O
sexual	O
victimisation	O
(	O
rape	O
)	O
by	O
a	O
man	B-OG
[	O
26	O
].	O

However	O
,	O
the	O
rate	O
of	O
sexual	B-DS
abuse	I-DS
seen	O
is	O
only	O
slightly	O
higher	O
than	O
a	O
school	O
-	O
based	O
survey	O
where	O
36	O
.	O
8	O
%	O
of	O
male	O
students	O
reported	O
any	O
form	O
of	O
sexual	B-DS
abuse	I-DS
[	O
27	O
].	O

The	O
high	O
levels	O
of	O
reported	O
sexual	B-DS
abuse	I-DS
was	O
not	O
driven	O
by	O
any	O
single	O
item	O
;	O
29	O
.	O
8	O
%	O
reported	O
being	O
touched	O
against	O
their	O
will	O
,	O
31	O
.	O
9	O
%	O
reported	O
sex	O
with	O
woman	O
5	O
years	O
older	O
,	O
and	O
17	O
.	O
9	O
%	O
reported	O
being	O
raped	O
and	O
coerced	O
into	O
sex	O
,	O
suggesting	O
that	O
it	O
was	O
not	O
an	O
issue	O
with	O
translation	O
or	O
comprehension	O
of	O
questions	O
.	O

The	O
analysis	O
suggests	O
that	O
broadly	O
for	O
women	B-OG
and	O
men	O
,	O
all	O
forms	O
of	O
childhood	O
traumas	O
are	O
associated	O
with	O
current	O
HIV	B-OG
-	O
risk	O
behaviours	O
.	O

This	O
relationship	O
holds	O
true	O
whether	O
the	O
analysis	O
is	O
looking	O
at	O
ever	O
experience	O
of	O
different	O
forms	O
of	O
childhood	O
trauma	O
,	O
or	O
the	O
severity	O
of	O
childhood	O
traumas	O
experienced	O
.	O

This	O
reflects	O
a	O
growing	O
body	O
of	O
global	O
research	O
that	O
also	O
outlines	O
the	O
close	O
relationship	O
between	O
childhood	O
trauma	O
and	O
HIV	B-OG
-	O
vulnerability	O
for	O
women	B-OG
and	O
men	B-OG
[	O
4	O
–	O
6	O
,	O
28	O
].	O

There	O
was	O
some	O
variation	O
in	O
the	O
relationships	O
across	O
women	B-OG
and	O
men	B-OG
however	O
.	O

For	O
women	O
and	O
men	O
sexual	B-DS
abuse	I-DS
was	O
independently	O
associated	O
with	O
all	O
HIV	B-OG
-	O
risk	O
behaviours	O
(	O
apart	O
from	O
condom	O
use	O
),	O
reflecting	O
the	O
fact	O
that	O
sexual	B-DS
abuse	I-DS
seems	O
to	O
be	O
a	O
major	O
driver	O
of	O
long	O
-	O
term	O
health	O
impact	O
.	O

For	O
women	O
,	O
the	O
number	O
of	O
past	O
year	O
sex	O
partners	O
tended	O
not	O
to	O
be	O
as	O
strongly	O
associated	O
with	O
physical	O
or	O
emotional	B-DS
abuse	I-DS
,	O
or	O
the	O
range	O
or	O
overall	O
severity	O
of	O
childhood	O
trauma	O
,	O
but	O
this	O
was	O
not	O
the	O
case	O
with	O
men	O
.	O

This	O
may	O
reflect	O
different	O
approaches	O
to	O
internalizing	O
and	O
externalizing	O
of	O
behaviours	O
,	O
whereby	O
there	O
is	O
a	O
tendency	O
for	O
men	B-OG
to	O
externalize	O
traumatic	O
behaviours	O
,	O
while	O
women	B-OG
internalize	O
following	O
traumatic	O
experiences	O
[	O
28	O
].	O

It	O
was	O
also	O
evident	O
from	O
the	O
analysis	O
that	O
the	O
range	O
of	O
childhood	O
trauma	O
(	O
model	O
3	O
)	O
and	O
the	O
cumulative	O
severity	O
of	O
childhood	O
trauma	O
(	O
model	O
4	O
)	O
were	O
both	O
independently	O
associated	O
with	O
HIV	B-OG
-	O
risk	O
.	O

In	O
other	O
populations	O
,	O
including	O
those	O
experiencing	O
significant	O
trauma	O
during	O
adulthood	O
,	O
a	O
similar	O
relationship	O
is	O
seen	O
[	O
28	O
–	O
30	O
],	O
suggesting	O
that	O
the	O
impact	O
of	O
childhood	O
traumas	O
continues	O
to	O
shape	O
people	O
’	O
s	O
lives	O
over	O
and	O
above	O
any	O
subsequent	O
traumatic	O
experiences	O
.	O

Furthermore	O
,	O
approximately	O
two	O
-	O
thirds	O
of	O
women	B-OG
and	O
men	B-OG
experienced	O
two	O
or	O
more	O
types	O
of	O
trauma	O
,	O
highlighting	O
the	O
close	O
overlap	O
between	O
different	O
trauma	O
types	O
and	O
that	O
there	O
is	O
likely	O
to	O
be	O
a	O
cumulative	O
impact	O
.	O

The	O
analysis	O
also	O
highlighted	O
how	O
women	O
and	O
men	O
who	O
experienced	O
physical	B-DS
abuse	I-DS
or	O
witnessed	O
violence	O
in	O
their	O
home	O
were	O
more	O
likely	O
to	O
perpetrate	O
IPV	O
(	O
men	O
)	O
or	O
experience	O
it	O
(	O
women	O
)	O
later	O
in	O
life	O
.	O

This	O
co	O
-	O
occurrence	O
of	O
physical	B-DS
abuse	I-DS
and	O
witnessing	O
violence	O
in	O
childhood	O
is	O
increasingly	O
recognized	O
as	O
a	O
key	O
driver	O
of	O
IPV	O
[	O
31	O
]	O
and	O
has	O
been	O
seen	O
in	O
multiple	O
settings	O
globally	O
[	O
8	O
,	O
31	O
].	O

The	O
data	O
suggested	O
that	O
there	O
were	O
weaker	O
relationships	O
between	O
childhood	O
traumas	O
and	O
condom	O
use	O
at	O
last	O
sex	O
for	O
women	O
and	O
men	O
.	O

For	O
women	O
not	O
using	O
a	O
condom	O
at	O
last	O
sex	O
was	O
only	O
associated	O
with	O
ever	O
emotional	B-DS
abuse	I-DS
,	O
ever	O
physical	B-DS
abuse	I-DS
,	O
and	O
the	O
range	O
of	O
abuse	O
experienced	O
.	O

While	O
for	O
men	B-OG
,	O
it	O
was	O
only	O
associated	O
with	O
ever	O
physical	B-DS
abuse	I-DS
and	O
the	O
range	O
of	O
abuse	O
experienced	O
.	O

There	O
are	O
a	O
number	O
of	O
possible	O
explanations	O
for	O
the	O
relatively	O
weak	O
associations	O
compared	O
to	O
other	O
HIV	B-OG
-	O
risk	O
behaviours	O
examined	O
.	O

First	O
,	O
we	O
did	O
not	O
control	O
for	O
type	O
of	O
partner	O
that	O
people	O
reported	O
last	O
having	O
sex	O
with	O
.	O

Condom	O
use	O
amongst	O
couples	O
trying	O
to	O
get	O
pregnant	O
,	O
in	O
long	O
-	O
term	O
relationships	O
,	O
or	O
women	O
on	O
long	O
-	O
term	O
contraceptives	O
will	O
decrease	O
[	O
32	O
,	O
33	O
].	O

Second	O
,	O
condom	O
use	O
is	O
often	O
poorly	O
reported	O
in	O
surveys	O
,	O
and	O
as	O
such	O
these	O
relationships	O
are	O
poorly	O
understood	O
.	O

The	O
exceedingly	O
high	O
levels	O
of	O
sexual	B-DS
abuse	I-DS
amongst	O
this	O
sample	O
,	O
alongside	O
the	O
particularly	O
consistent	O
and	O
strong	O
relationship	O
between	O
sexual	B-DS
abuse	I-DS
and	O
HIV	B-OG
-	O
risk	O
behaviours	O
in	O
this	O
population	O
,	O
as	O
well	O
in	O
other	O
studies	O
,	O
highlights	O
sexual	B-DS
abuse	I-DS
in	O
childhood	O
as	O
a	O
key	O
driver	O
of	O
poor	O
health	O
[	O
6	O
,	O
34	O
]	O
and	O
suggests	O
there	O
is	O
need	O
for	O
further	O
research	O
on	O
this	O
topic	O
.	O

At	O
a	O
very	O
basic	O
level	O
,	O
understanding	O
why	O
the	O
levels	O
of	O
sexual	B-DS
abuse	I-DS
in	O
the	O
population	O
are	O
so	O
high	O
is	O
critical	O
.	O

In	O
addition	O
,	O
this	O
study	O
did	O
not	O
ask	O
about	O
the	O
sex	O
of	O
perpetrators	O
of	O
sexual	B-DS
abuse	I-DS
(	O
apart	O
from	O
in	O
one	O
item	O
).	O

There	O
is	O
research	O
in	O
South	O
Africa	O
showing	O
that	O
boys	O
and	O
young	O
men	B-OG
experience	O
sexual	B-DS
abuse	I-DS
by	O
women	B-OG
as	O
well	O
as	O
men	B-OG
[	O
26	O
,	O
35	O
].	O

There	O
may	O
be	O
important	O
differences	O
by	O
sex	O
of	O
perpetrator	O
in	O
terms	O
of	O
prevalence	O
,	O
and	O
long	O
-	O
term	O
impacts	O
.	O

Understanding	O
the	O
prevalence	O
,	O
forms	O
and	O
impacts	O
of	O
childhood	O
sexual	B-DS
abuse	I-DS
amongst	O
young	O
men	B-OG
and	O
boys	O
remains	O
a	O
key	O
research	O
challenge	O
to	O
enable	O
a	O
meaningful	O
response	O
to	O
be	O
constructed	O
.	O

There	O
are	O
a	O
number	O
of	O
limitations	O
to	O
the	O
study	O
.	O

Data	O
are	O
cross	O
-	O
sectional	O
and	O
as	O
such	O
relationships	O
may	O
be	O
bi	O
-	O
directional	O
,	O
and	O
longitudinal	O
studies	O
are	O
required	O
to	O
establish	O
the	O
temporality	O
of	O
associations	O
.	O

The	O
retrospective	O
nature	O
of	O
questions	O
may	O
mean	O
reporting	O
of	O
childhood	O
experiences	O
is	O
weaker	O
,	O
and	O
there	O
may	O
be	O
some	O
level	O
of	O
confusion	O
around	O
when	O
specific	O
acts	O
occurred	O
i	O
.	O
e	O
.	O
before	O
or	O
after	O
the	O
age	O
of	O
18	O
for	O
some	O
participants	O
.	O

Studies	O
suggest	O
that	O
recall	O
bias	O
may	O
lead	O
to	O
an	O
under	O
-	O
reporting	O
of	O
events	O
in	O
childhood	O
[	O
36	O
],	O
as	O
such	O
,	O
the	O
impact	O
of	O
retrospective	O
reporting	O
of	O
childhood	O
traumas	O
on	O
the	O
analysis	O
is	O
unclear	O
,	O
again	O
suggesting	O
the	O
need	O
for	O
prospective	O
studies	O
.	O

Finally	O
,	O
the	O
sample	O
were	O
self	O
-	O
selecting	O
into	O
an	O
intervention	O
evaluation	O
and	O
are	O
therefore	O
not	O
representative	O
of	O
the	O
population	O
of	O
young	O
people	O
living	O
in	O
urban	O
informal	O
settlements	O
.	O

Inclusion	O
criteria	O
mean	O
those	O
in	O
formal	O
employment	O
or	O
school	O
were	O
not	O
included	O
in	O
the	O
study	O
.	O

The	O
analysis	O
highlights	O
the	O
importance	O
of	O
reducing	O
all	O
forms	O
of	O
childhood	O
traumas	O
as	O
a	O
way	O
to	O
reduce	O
subsequent	O
HIV	B-OG
-	O
risk	O
amongst	O
young	O
women	B-OG
and	O
men	B-OG
.	O

An	O
increasing	O
number	O
of	O
interventions	O
have	O
shown	O
the	O
potential	O
to	O
reduce	O
harsh	O
parenting	O
across	O
the	O
global	O
south	O
[	O
37	O
]	O
and	O
modifying	O
and	O
implementing	O
these	O
in	O
informal	O
settlements	O
remains	O
a	O
critical	O
challenge	O
.	O

Another	O
response	O
to	O
this	O
analysis	O
is	O
to	O
consider	O
how	O
the	O
range	O
of	O
current	O
HIV	B-OG
and	O
IPV	O
-	O
prevention	O
interventions	O
already	O
being	O
implemented	O
can	O
include	O
components	O
on	O
reducing	O
the	O
traumatic	O
effects	O
of	O
childhood	O
trauma	O
as	O
part	O
of	O
their	O
wider	O
intervention	O
.	O

A	O
range	O
of	O
trauma	O
-	O
focused	O
cognitive	O
behavioural	O
interventions	O
[	O
38	O
,	O
39	O
]	O
may	O
have	O
an	O
important	O
role	O
to	O
play	O
in	O
achieving	O
this	O
.	O

Conclusion	O

Despite	O
the	O
huge	O
challenges	O
for	O
people	O
living	O
in	O
informal	O
settlements	O
such	O
as	O
poverty	O
,	O
gender	O
inequalities	O
,	O
and	O
lack	O
of	O
access	O
to	O
services	O
,	O
which	O
independently	O
shape	O
HIV	B-OG
-	O
risk	O
behaviours	O
,	O
this	O
study	O
highlights	O
that	O
childhood	O
traumas	O
remained	O
a	O
salient	O
driver	O
of	O
HIV	B-OG
-	O
risk	O
behaviours	O
amongst	O
young	O
people	O
.	O

As	O
the	O
analysis	O
showed	O
,	O
young	O
people	O
’	O
s	O
experiences	O
of	O
all	O
forms	O
of	O
childhood	O
trauma	O
,	O
specifically	O
emotional	B-DS
abuse	I-DS
and	O
neglect	O
,	O
physical	B-DS
abuse	I-DS
,	O
and	O
sexual	B-DS
abuse	I-DS
were	O
exceedingly	O
high	O
in	O
this	O
population	O
.	O

Additionally	O
,	O
there	O
were	O
incredibly	O
consistent	O
findings	O
across	O
women	B-OG
and	O
men	O
,	O
whereby	O
childhood	O
traumas	O
,	O
assessed	O
in	O
a	O
wide	O
variety	O
of	O
ways	O
were	O
consistently	O
associated	O
with	O
a	O
range	O
of	O
HIV	B-OG
-	O
risk	O
behaviours	O
.	O

As	O
such	O
,	O
despite	O
the	O
immediacy	O
of	O
many	O
of	O
the	O
problems	O
of	O
young	O
people	O
living	O
in	O
informal	O
settlements	O
,	O
there	O
remains	O
a	O
pressing	O
need	O
to	O
reduce	O
the	O
experiences	O
of	O
childhood	O
traumas	O
and	O
their	O
long	O
-	O
term	O
effects	O
.	O

Supporting	O
information	O

Dataset	O
for	O
analysis	O
of	O
women	O
.	O

(	O
CSV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Dataset	O
for	O
analysis	O
of	O
men	O
.	O

(	O
CSV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
Herpes	O
Zoster	O
in	O
Europe	O
:	O
a	O
critical	O
review	O

Background	O

Herpes	B-DS
zoster	I-DS
(	O
HZ	B-DS
)	O
or	O
“	O
shingles	O
”	O
is	O
common	O
in	O
persons	O
aged	O
50	O
years	O
or	O
over	O
.	O

HZ	B-DS
is	O
characterised	O
by	O
a	O
painful	O
dermatological	O
rash	O
which	O
typically	O
resolves	O
in	O
approximately	O
one	O
month	O
.	O

Persistent	O
pain	O
for	O
months	O
or	O
years	O
after	O
rash	O
onset	O
,	O
however	O
,	O
is	O
a	O
common	O
complication	O
of	O
HZ	B-DS
;	O
referred	O
to	O
as	O
post	B-DS
-	I-DS
herpetic	I-DS
neuralgia	I-DS
(	O
PHN	B-DS
).	O

Both	O
HZ	B-DS
and	O
PHN	B-DS
have	O
a	O
significant	O
impact	O
on	O
patients	O
’	O
lives	O
,	O
with	O
considerable	O
implications	O
for	O
healthcare	O
systems	O
and	O
wider	O
society	O
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
provide	O
comprehensive	O
documentation	O
and	O
critical	O
appraisal	O
of	O
published	O
data	O
concerning	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	O
in	O
Europe	O
.	O

Methods	O

Systematic	O
literature	O
searches	O
were	O
conducted	O
in	O
Medline	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
EconLit	O
,	O
HEED	O
and	O
CRD	O
databases	O
.	O

Searches	O
were	O
conducted	O
in	O
July	O
2014	O
and	O
restricted	O
to	O
articles	O
published	O
in	O
the	O
past	O
20	O
years	O
.	O

Articles	O
were	O
selected	O
for	O
full	O
review	O
by	O
two	O
independent	O
researchers	O
in	O
accordance	O
with	O
predefined	O
eligibility	O
criteria	O
.	O

Results	O

From	O
a	O
review	O
of	O
1619	O
abstracts	O
,	O
53	O
eligible	O
articles	O
,	O
were	O
identified	O
which	O
reported	O
data	O
concerning	O
healthcare	O
resource	O
use	O
(	O
n	O
=	O
38	O
),	O
direct	O
costs	O
(	O
n	O
=	O
20	O
),	O
indirect	O
costs	O
(	O
n	O
=	O
16	O
),	O
total	O
costs	O
(	O
n	O
=	O
10	O
)	O
and	O
impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
(	O
n	O
=	O
21	O
).	O

Findings	O
highlight	O
that	O
PHN	B-DS
is	O
associated	O
with	O
greater	O
impairments	O
in	O
HRQoL	O
and	O
higher	O
costs	O
of	O
management	O
than	O
HZ	O
.	O

For	O
both	O
HZ	B-DS
and	O
PHN	B-DS
,	O
pain	O
severity	O
is	O
a	O
significant	O
predictor	O
of	O
impact	O
on	O
individuals	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

While	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
increase	O
with	O
age	O
,	O
age	O
does	O
not	O
appear	O
to	O
be	O
a	O
key	O
driver	O
of	O
overall	O
costs	O
for	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Specifically	O
,	O
while	O
direct	O
costs	O
(	O
e	O
.	O
g	O
.	O
GP	O
,	O
specialists	O
,	O
medications	O
,	O
hospitalisations	O
)	O
tend	O
to	O
be	O
higher	O
for	O
older	O
patients	O
,	O
indirect	O
costs	O
(	O
e	O
.	O
g	O
.	O
work	O
time	O
missed	O
)	O
are	O
higher	O
for	O
younger	O
patients	O
.	O

Conclusions	O

Available	O
evidence	O
highlights	O
that	O
HZ	B-DS
and	O
PHN	B-DS
result	O
in	O
significant	O
humanistic	O
and	O
economic	O
burden	O
for	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
societies	O
.	O

A	O
tendency	O
to	O
focus	O
upon	O
healthcare	O
resource	O
use	O
and	O
the	O
direct	O
costs	O
of	O
management	O
at	O
the	O
expense	O
of	O
other	O
impacts	O
(	O
e	O
.	O
g	O
.	O
informal	O
caregivers	O
and	O
formal	O
social	O
care	O
)	O
may	O
result	O
in	O
an	O
underestimation	O
of	O
the	O
true	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Background	O

Herpes	B-DS
zoster	I-DS
(	O
HZ	B-DS
),	O
also	O
known	O
as	O
shingles	B-DS
,	O
is	O
caused	O
by	O
the	O
reactivation	O
of	O
the	O
varicella	B-OG
zoster	I-OG
virus	I-OG
(	O
VZV	B-OG
).	O

Primary	B-DS
infection	I-DS
with	O
VZV	B-OG
usually	O
occurs	O
during	O
childhood	O
,	O
manifesting	O
as	O
chickenpox	B-DS
,	O
after	O
which	O
the	O
virus	B-OG
lies	O
dormant	O
[	O
1	O
].	O

The	O
great	O
majority	O
(	O
95	O
%)	O
[	O
2	O
]	O
of	O
the	O
population	O
hosts	O
VZV	B-OG
and	O
approximately	O
one	O
in	O
four	O
persons	O
will	O
develop	O
HZ	B-DS
in	O
their	O
lifetime	O
through	O
reactivation	O
,	O
leading	O
to	O
an	O
estimated	O
1	O
.	O
7	O
million	O
episodes	O
in	O
Europe	O
annually	O
[	O
3	O
].	O

VZV	B-OG
reactivation	O
is	O
primarily	O
related	O
to	O
an	O
age	O
-	O
related	O
decline	O
in	O
VZV	B-OG
-	O
specific	O
immunity	O
;	O
it	O
is	O
well	O
documented	O
that	O
the	O
incidence	O
of	O
HZ	B-DS
increases	O
with	O
age	O
,	O
with	O
the	O
majority	O
of	O
cases	O
occurring	O
in	O
patients	O
over	O
50	O
years	O
of	O
age	O
[	O
4	O
].	O

HZ	B-DS
is	O
characterized	O
by	O
a	O
painful	O
dermatomal	O
rash	O
,	O
which	O
most	O
commonly	O
presents	O
on	O
the	O
trunk	O
and	O
lumbar	O
regions	O
.	O

HZ	O
,	O
however	O
,	O
may	O
present	O
along	O
any	O
nerve	O
including	O
the	O
ophthalmic	O
division	O
of	O
the	O
trigeminal	O
nerve	O
where	O
it	O
can	O
affect	O
the	O
eye	O
.	O

Herpes	B-DS
Zoster	I-DS
Ophthalmicus	I-DS
(	O
HZO	B-DS
)	O
occurs	O
in	O
10	O
-	O
20	O
%	O
of	O
all	O
HZ	B-DS
cases	O
and	O
in	O
some	O
cases	O
can	O
lead	O
to	O
ocular	O
complications	O
[	O
5	O
].	O

The	O
dermatological	O
rash	O
and	O
pain	O
associated	O
with	O
HZ	B-DS
typically	O
resolves	O
within	O
one	O
month	O
of	O
presentation	O
[	O
4	O
];	O
however	O
,	O
long	O
-	O
term	O
complications	O
can	O
arise	O
.	O

Post	B-DS
-	I-DS
herpetic	I-DS
neuralgia	I-DS
(	O
PHN	B-DS
)	O
is	O
the	O
most	O
common	O
and	O
debilitating	O
complication	O
of	O
HZ	B-DS
,	O
occurring	O
in	O
approximately	O
10	O
-	O
20	O
%	O
of	O
all	O
sufferers	O
[	O
6	O
-	O
8	O
]	O
and	O
as	O
many	O
as	O
50	O
%	O
of	O
those	O
aged	O
85	O
years	O
and	O
over	O
[	O
9	O
].	O

PHN	B-DS
is	O
a	O
neuropathic	B-DS
syndrome	I-DS
manifesting	O
as	O
on	O
-	O
going	O
pain	O
along	O
the	O
nerves	O
in	O
the	O
area	O
of	O
the	O
prior	O
HZ	O
rash	O
and	O
typically	O
involves	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
spontaneous	O
aching	O
or	O
burning	O
;	O
paroxysmal	O
shooting	O
pains	O
;	O
allodynia	O
,	O
and	O
hyperalgesia	O
[	O
9	O
,	O
10	O
].	O

There	O
is	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
PHN	B-DS
;	O
however	O
,	O
PHN	B-DS
is	O
often	O
defined	O
as	O
pain	O
persisting	O
for	O
90	O
days	O
from	O
HZ	B-DS
rash	O
onset	O
[	O
4	O
,	O
6	O
,	O
10	O
,	O
11	O
].	O

While	O
HZ	B-DS
is	O
an	O
acute	O
experience	O
that	O
typically	O
resolves	O
within	O
one	O
month	O
,	O
in	O
the	O
majority	O
of	O
sufferers	O
,	O
PHN	B-DS
persists	O
for	O
at	O
least	O
6	O
months	O
with	O
some	O
patients	O
experiencing	O
PHN	B-DS
for	O
years	O
[	O
12	O
-	O
15	O
].	O

As	O
expected	O
given	O
the	O
relationship	O
to	O
HZ	B-DS
,	O
the	O
incidence	O
of	O
PHN	B-DS
increases	O
markedly	O
with	O
age	O
[	O
16	O
-	O
18	O
].	O

The	O
incidence	O
of	O
PHN	B-DS
is	O
also	O
linked	O
to	O
the	O
severity	O
of	O
pain	O
experienced	O
during	O
the	O
prior	O
HZ	B-DS
episode	O
(	O
among	O
other	O
predictors	O
such	O
as	O
the	O
severity	O
of	O
the	O
dermatomal	O
rash	O
and	O
prodromal	O
symptoms	O
)	O
[	O
19	O
],	O
with	O
those	O
patients	O
experiencing	O
the	O
highest	O
levels	O
of	O
pain	O
during	O
HZ	B-DS
presentation	O
being	O
most	O
at	O
risk	O
of	O
developing	O
PHN	B-DS
[	O
20	O
].	O

As	O
conditions	O
primarily	O
affecting	O
older	O
persons	O
,	O
many	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
may	O
already	O
experience	O
significant	O
deficits	O
in	O
health	O
status	O
.	O

Findings	O
from	O
a	O
number	O
of	O
articles	O
indicate	O
that	O
the	O
pain	O
and	O
resulting	O
discomfort	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
can	O
have	O
a	O
substantial	O
negative	O
and	O
widespread	O
impact	O
on	O
patients	O
’	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
patients	O
’	O
ability	O
to	O
engage	O
in	O
activities	O
of	O
daily	O
living	O
[	O
7	O
,	O
20	O
-	O
25	O
].	O

In	O
addition	O
to	O
the	O
burden	O
encountered	O
by	O
the	O
individual	O
with	O
HZ	B-DS
,	O
the	O
condition	O
is	O
also	O
associated	O
with	O
considerable	O
economic	O
burden	O
.	O

For	O
example	O
,	O
considerable	O
costs	O
to	O
healthcare	O
systems	O
[	O
26	O
-	O
31	O
]	O
arise	O
from	O
the	O
care	O
provision	O
for	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
,	O
including	O
visits	O
to	O
primary	O
care	O
(	O
general	O
practitioner	O
)	O
and	O
outpatient	O
secondary	O
/	O
tertiary	O
care	O
(	O
specialist	O
pain	O
clinics	O
and	O
ophthalmologists	O
),	O
inpatient	O
visits	O
(	O
hospitalisations	O
)	O
and	O
prescription	O
costs	O
.	O

Furthermore	O
,	O
HZ	B-DS
and	O
PHN	B-DS
are	O
also	O
associated	O
with	O
significant	O
indirect	O
costs	O
,	O
primarily	O
in	O
terms	O
of	O
loss	O
of	O
productivity	O
for	O
younger	O
patients	O
[	O
7	O
,	O
21	O
,	O
23	O
,	O
24	O
,	O
28	O
,	O
32	O
].	O

Finally	O
,	O
as	O
conditions	O
occurring	O
in	O
retired	O
and	O
older	O
patients	O
,	O
HZ	B-DS
and	O
PHN	B-DS
can	O
also	O
have	O
significant	O
consequences	O
for	O
the	O
caregivers	O
of	O
patients	O
including	O
partners	O
,	O
relatives	O
,	O
and	O
friends	O
of	O
people	O
with	O
the	O
conditions	O
[	O
7	O
].	O

Such	O
details	O
,	O
however	O
,	O
may	O
often	O
go	O
unreported	O
and	O
are	O
not	O
often	O
communicated	O
in	O
the	O
research	O
literature	O
.	O

Evidence	O
for	O
the	O
efficacy	O
of	O
a	O
VZV	B-OG
vaccine	O
in	O
the	O
prevention	O
of	O
HZ	B-DS
and	O
PHN	B-DS
episodes	O
and	O
attenuation	O
of	O
the	O
severity	O
of	O
HZ	B-DS
and	O
PHN	B-DS
episodes	O
and	O
associated	O
impact	O
has	O
been	O
documented	O
in	O
recent	O
years	O
[	O
11	O
,	O
33	O
].	O

In	O
order	O
to	O
understand	O
the	O
value	O
of	O
preventative	O
strategies	O
,	O
a	O
complete	O
understanding	O
of	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
is	O
required	O
.	O

While	O
a	O
significant	O
body	O
of	O
literature	O
has	O
sought	O
to	O
determine	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
society	O
within	O
EU	O
countries	O
,	O
to	O
date	O
,	O
no	O
comprehensive	O
review	O
of	O
these	O
studies	O
has	O
been	O
conducted	O
.	O

The	O
aim	O
of	O
this	O
review	O
,	O
therefore	O
,	O
is	O
to	O
provide	O
a	O
comprehensive	O
and	O
holistic	O
overview	O
of	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	O
and	O
PHN	O
in	O
Europe	O
as	O
reported	O
within	O
the	O
published	O
peer	O
-	O
reviewed	O
literature	O
.	O

Methods	O

Published	O
peer	O
-	O
reviewed	O
articles	O
were	O
identified	O
via	O
systematic	O
searches	O
conducted	O
in	O
the	O
following	O
biomedical	O
and	O
economic	O
databases	O
:	O
EMBASE	O
,	O
Medline	O
,	O
PsycINFO	O
,	O
EconLit	O
,	O
Health	O
Economic	O
Evaluations	O
Database	O
(	O
HEED	O
)	O
and	O
the	O
Centre	O
for	O
Reviews	O
and	O
Dissemination	O
databases	O
at	O
the	O
University	O
of	O
York	O
.	O

Searches	O
and	O
reviews	O
were	O
conducted	O
in	O
accordance	O
with	O
the	O
Cochrane	O
systematic	O
review	O
guidelines	O
[	O
34	O
].	O

A	O
range	O
of	O
disease	O
-	O
related	O
,	O
economic	O
,	O
societal	O
and	O
HRQoL	O
-	O
related	O
keywords	O
was	O
utilized	O
to	O
capture	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
(	O
see	O
Table	O
1	O
).	O

Searches	O
were	O
conducted	O
in	O
July	O
2014	O
and	O
were	O
restricted	O
to	O
articles	O
published	O
in	O
the	O
last	O
20	O
years	O
.	O

Although	O
data	O
relating	O
to	O
the	O
EU	O
was	O
the	O
primary	O
focus	O
of	O
this	O
review	O
,	O
no	O
limits	O
regarding	O
study	O
country	O
or	O
article	O
language	O
were	O
implemented	O
during	O
the	O
search	O
stage	O
(	O
so	O
to	O
not	O
exclude	O
potentially	O
relevant	O
articles	O
).	O

Instead	O
,	O
articles	O
focused	O
on	O
the	O
EU	O
were	O
prioritized	O
as	O
part	O
of	O
the	O
article	O
selection	O
process	O
.	O
Table	O
1Search	O
terms	O
Databases	O
searched	O
Disease	O
search	O
terms	O
Economic	O
,	O
humanistic	O
and	O
societal	O
burden	O
search	O
terms	O
•	O
Medline	O
“	O
Herpes	O
Zoster	O
”	O
OR	O
“	O
Shingles	O
”	O
OR	O
“	O
Post	O
-	O
herpetic	O
Neuralgia	O
”	O
OR	O
“	O
Post	O
herpetic	O
Neuralgia	O
”	O
OR	O
“	O
Postherpetic	O
Neuralgia	O
”	O
OR	O
“	O
PHN	O
”“	O
Burden	O
”	O
OR	O
“	O
Humanistic	O
”	O
OR	O
“	O
quality	O
of	O
life	O
”	O
OR	O
“	O
QOL	O
”	O
OR	O
“	O
HRQOL	O
”	O
OR	O
“	O
cost	O
”	O
OR	O
“	O
economic	O
”	O
OR	O
“	O
resource	O
”	O
OR	O
“	O
society	O
”	O
OR	O
“	O
societal	O
”	O
OR	O
“	O
family	O
”	O
OR	O
“	O
relatives	O
”	O
OR	O
“	O
Caregiver	O
”	O
OR	O
“	O
care	O
$”	O
OR	O
“	O
activities	O
of	O
daily	O
living	O
”	O
OR	O
“	O
ADLS	O
”	O
OR	O
“	O
daily	O
activities	O
”	O
OR	O
“	O
cost	O
of	O
illness	O
”	O
OR	O
“	O
autonomy	O
”	O
OR	O
“	O
hospitalisation	O
”	O
OR	O
“	O
hospitalization	O
”	O
•	O
Embase	O
•	O
PscyINFO	O
•	O
EconLit	O
.	O
•	O
Health	O
Economic	O
Evaluations	O
Database	O
(	O
HEED	O
)	O
•	O
Centre	O
for	O
Reviews	O
and	O
Dissemination	O
databases	O
:	O
-	O
Database	O
of	O
Abstracts	O
of	O
Reviews	O
of	O
Effects	O
(	O
DARE	O
),	O
-	O
Health	O
Technology	O
Assessment	O
(	O
HTA	O
)	O
-	O
NHS	O
Economic	O
Evaluation	O
Database	O
(	O
NHS	O
EED	O
)	O

In	O
accordance	O
with	O
Cochrane	O
review	O
guidelines	O
[	O
35	O
],	O
all	O
abstracts	O
were	O
reviewed	O
by	O
two	O
researchers	O
independently	O
according	O
to	O
formal	O
inclusion	O
/	O
exclusion	O
criteria	O
(	O
Table	O
2	O
).	O

For	O
inclusion	O
in	O
the	O
review	O
,	O
abstracts	O
were	O
required	O
present	O
information	O
specific	O
to	O
adult	O
patients	O
in	O
the	O
EU	O
and	O
to	O
contain	O
information	O
pertaining	O
to	O
the	O
key	O
search	O
terms	O
(	O
see	O
Table	O
1	O
).	O

In	O
instances	O
were	O
aforementioned	O
details	O
were	O
not	O
clear	O
from	O
the	O
abstract	O
,	O
full	O
text	O
articles	O
were	O
obtained	O
to	O
confirm	O
whether	O
the	O
article	O
should	O
be	O
included	O
/	O
excluded	O
.	O

Real	O
world	O
data	O
,	O
observational	O
studies	O
,	O
effectiveness	O
studies	O
,	O
qualitative	O
studies	O
,	O
economic	O
evaluations	O
and	O
cost	O
studies	O
were	O
all	O
considered	O
relevant	O
for	O
review	O
.	O

The	O
final	O
list	O
of	O
abstracts	O
and	O
articles	O
for	O
full	O
in	O
-	O
depth	O
review	O
was	O
agreed	O
following	O
consensus	O
between	O
the	O
authors	O
.	O
Table	O
2	O
Study	O
Inclusion	O
/	O
exclusion	O
criteria	O
Inclusion	O
criteria	O
Exclusion	O
criteria	O
Country	O
setting	O
Present	O
data	O
from	O
a	O
country	O
in	O
the	O
EU	O
or	O
EU	O
in	O
general	O
Only	O
present	O
data	O
from	O
a	O
non	O
-	O
EU	O
country	O
.	O

No	O
data	O
specific	O
to	O
the	O
EU	O
.	O
Population	O
Adults	O
with	O
HZ	B-DS
or	O
PHN	B-DS
Children	O
Focus	O
mainly	O
on	O
chicken	B-OG
pox	I-OG
Immunodepressed	O
patients	O
only	O
(	O
e	O
.	O
g	O
.	O
HIV	B-OG
patients	O
)	O
Studies	O
that	O
contain	O
information	O
on	O
key	O
search	O
terms	O
(	O
inc	O
.	O

QoL	O
,	O
burden	O
,	O
productivity	O
)	O
Studies	O
that	O
do	O
NOT	O
contain	O
information	O
on	O
key	O
search	O
terms	O
Study	O
design	O
Real	O
world	O
data	O
,	O
observational	O
studies	O
,	O
effectiveness	O
,	O
qualitative	O
research	O
and	O
cost	O
studies	O
Clinical	O
trials	O
of	O
efficacy	O
and	O
safety	O
of	O
treatments	O
presenting	O
QoL	O
data	O
as	O
secondary	O
endpoint	O
only	O
Clinical	O
trials	O
of	O
Zostavax	O
Focus	O
mainly	O
on	O
epidemiological	O
evidence	O
(	O
e	O
.	O
g	O
.	O
incidence	O
,	O
prevalence	O
etc	O
.)	O
Publication	O
type	O
For	O
conference	O
abstracts	O
,	O
exclusion	O
if	O
manuscript	O
corresponding	O
to	O
this	O
abstract	O
and	O
presenting	O
equivalent	O
information	O
is	O
already	O
published	O

Data	O
extraction	O
tables	O
were	O
developed	O
to	O
accurately	O
record	O
information	O
from	O
the	O
articles	O
chosen	O
for	O
review	O
.	O

Of	O
importance	O
was	O
information	O
related	O
to	O
the	O
study	O
aims	O
,	O
design	O
and	O
outcomes	O
of	O
interest	O
,	O
sample	O
characteristics	O
,	O
country	O
of	O
study	O
,	O
resource	O
use	O
data	O
,	O
cost	O
data	O
(	O
direct	O
and	O
indirect	O
)	O
and	O
any	O
patient	O
-	O
reported	O
impacts	O
of	O
HZ	O
and	O
PHN	O
.	O

All	O
referenced	O
costs	O
are	O
provided	O
in	O
Euros	O
and	O
have	O
been	O
adjusted	O
to	O
the	O
same	O
price	O
year	O
(	O
2015	O
)	O
based	O
on	O
annual	O
average	O
rate	O
of	O
change	O
(%)	O
in	O
the	O
Harmonised	O
Index	O
of	O
Consumer	O
Prices	O
[	O
36	O
].	O

Results	O

Search	O
results	O

Figure	O
1	O
provides	O
an	O
overview	O
of	O
the	O
article	O
selection	O
process	O
.	O

A	O
total	O
of	O
1619	O
titles	O
and	O
abstracts	O
were	O
reviewed	O
against	O
the	O
inclusion	O
/	O
exclusion	O
criteria	O
,	O
resulting	O
in	O
78	O
EU	O
based	O
articles	O
for	O
full	O
text	O
review	O
.	O

A	O
further	O
25	O
articles	O
were	O
excluded	O
following	O
full	O
text	O
review	O
,	O
leaving	O
a	O
total	O
of	O
53	O
studies	O
to	O
be	O
included	O
in	O
this	O
review	O
.	O
Figure	O
1	O
Overview	O
of	O
study	O
selection	O
for	O
review	O
.	O

Overview	O
of	O
selected	O
articles	O

A	O
summary	O
of	O
the	O
53	O
articles	O
selected	O
for	O
inclusion	O
in	O
the	O
review	O
(	O
including	O
study	O
countries	O
,	O
population	O
,	O
data	O
presented	O
)	O
is	O
provided	O
in	O
Table	O
3	O
.	O
Table	O
3	O
Overview	O
of	O
included	O
studies	O
Author	O
and	O
year	O
Country	O
perspective	O
Population	O
Healthcare	O
utilisation	O
Economic	O
data	O
HRQoL	O
HZ	O
HZ	B-DS
and	O
PHN	O
PHN1	O
PHN3	O
PHN	B-DS
Other	O
/	O
Undefined	O
Direct	O
costs	O
Indirect	O
costs	O
Total	O
costs	O
Annemans	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
26	O
]	O
Belgium	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XBayas	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
37	O
]	O
Spain	O
CataloniaX	O
✓	O
XXX	O
✓✓	O
XXXBerrut	O
,	O
G	O
.	O
and	O
C	O
.	O

Baptiste	O
(	O
2013	O
)	O
[	O
38	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXBlein	O
,	O
C	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
39	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXBilcke	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
40	O
]	O
BelgiumX	O
✓	O
X	O
✓	O
X	O
✓✓✓	O
XXBouhassira	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
15	O
]	O
France	O
✓✓	O
X	O
✓	O
XXXXX	O
✓	O
Bresse	O
,	O
X	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
41	O
]	O
France	O
✓	O
XX	O
✓	O
X	O
✓	O
XXXXBricout	O
,	O
H	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
42	O
]	O
Italy	O
✓	O
XXXXXX	O
✓	O
X	O
✓	O
Bricout	O
,	O
H	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
42	O
]	O
Italy	O
✓	O
XX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Brisson	O
et	O
al	O
.	O
(	O
2003	O
)	O
[	O
43	O
]	O
England	O
&	O
WalesX	O
✓	O
XX	O
✓✓✓✓✓	O
XCastro	O
-	O
Lopes	O
,	O
J	O
.	O

M	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
44	O
]	O
PortugalXXXX	O
✓✓	O
XXX	O
✓	O
Cebrian	O
-	O
Cuenca	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
27	O
]	O
Spain	O
,	O
Valencia	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XChidiac	O
et	O
al	O
.	O
(	O
2001	O
)	O
[	O
21	O
]	O
France	O
✓✓	O
XX	O
✓✓	O
XXX	O
✓	O
De	O
Juanes	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
45	O
]	O
Spain	O
MadridX	O
✓	O
XX	O
✓✓✓	O
XXXDi	O
Legami	O
et	O
al	O
.	O
(	O
2007	O
)	O
[	O
46	O
]	O
Italy	O
–	O
Piemonte	O
✓	O
XXX	O
✓✓✓	O
XXXEdmunds	O
et	O
al	O
.	O
(	O
2001	O
)	O
[	O
47	O
]	O
England	O
and	O
WalesX	O
✓✓	O
XX	O
✓✓	O
XXXFranco	O
,	O
E	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
48	O
]	O
Italy	O
✓	O
XX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Garcia	O
-	O
Doval	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
49	O
]	O
Spain	O
✓	O
XXX	O
✓✓	O
XXXXGater	O
,	O
A	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
50	O
]	O
UK	O
✓	O
XXXX	O
✓	O
XXX	O
✓	O
Gauthier	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
28	O
]	O
UK	O
✓	O
X	O
✓✓	O
X	O
✓✓	O
XX	O
✓	O
Gialloreti	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
29	O
]	O
Italy	O
✓	O
X	O
✓✓	O
X	O
✓✓✓✓	O
XGil	O
et	O
al	O
.	O
(	O
2004	O
)	O
[	O
51	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
52	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
-	O
Prieto	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
53	O
]	O
Spain	O
✓	O
XXXX	O
✓✓	O
XXXGil	O
-	O
Prieto	O
,	O
R	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
54	O
]	O
Spain	O
✓	O
XXXX	O
✓	O
XXXXGonzalez	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
55	O
]	O
France	O
✓	O
XXXX	O
✓	O
XXXXLionis	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
56	O
]	O
Greece	O
✓	O
X	O
✓	O
XXXXXX	O
✓	O
Loncar	O
,	O
Z	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
57	O
]	O
Croatia	O
✓	O
XXXX	O
✓	O
XXX	O
✓	O
Lukas	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
58	O
]	O
Germany	O
,	O
Spain	O
,	O
Portugal	O
,	O
the	O
Netherlands	O
,	O
Belgium	O
,	O
Sweden	O
and	O
Switzerland	O
✓✓	O
X	O
✓	O
XXX	O
✓	O
X	O
✓	O
Mesquita	O
,	O
M	O
.	O
and	O
F	O
.	O

Froes	O
(	O
2013	O
)	O
[	O
59	O
]	O
Portugal	O
✓	O
XXXX	O
✓	O
XXXXMick	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
30	O
]	O
FranceX	O
✓	O
X	O
✓	O
X	O
✓✓✓✓	O
XMoore	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
60	O
]	O
UKX	O
✓✓✓	O
XXX	O
✓	O
XXMorant	O
-	O
Talamante	O
,	O
N	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
61	O
]	O
Spain	O
✓	O
XXXX	O
✓	O
XXXXMordarski	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
62	O
]	O
PolandXXXX	O
✓	O
XXXX	O
✓	O
Nilsson	O
,	O
J	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
63	O
]	O
SwedenX	O
✓	O
XXXXX	O
✓✓	O
XPierik	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
64	O
]	O
Holland	O
/	O
the	O
Netherlands	O
✓	O
XXXX	O
✓	O
XXXXRabaud	O
,	O
C	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
65	O
]	O
France	O
✓	O
X	O
✓✓	O
X	O
✓	O
XXX	O
✓	O
Rehm	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
66	O
]	O
14	O
European	O
countries	O
(	O
countries	O
not	O
specified	O
)	O
XX	O
✓	O
XXXXXX	O
✓	O
Schiffner	O
-	O
Rohe	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
67	O
]	O
Germany	O
✓	O
X	O
✓	O
XX	O
✓✓	O
X	O
✓	O
XScott	O
et	O
al	O
.	O
(	O
2003	O
)	O
[	O
68	O
]	O
UK	O
✓	O
XX	O
✓	O
XXXXX	O
✓	O
Scott	O
et	O
al	O
.	O
(	O
2006	O
)	O
[	O
7	O
]	O
UKX	O
✓	O
X	O
✓	O
XXX	O
✓✓✓	O
Serpell	O
,	O
M	O
.,	O
et	O
al	O
.	O
(	O
2014	O
)	O
[	O
14	O
]	O
UKXXX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Sicras	O
-	O
Mainar	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
69	O
]	O
Spain	O
✓✓	O
XX	O
✓✓✓✓✓	O
XSouliotis	O
,	O
K	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
70	O
]	O
GreeceX	O
✓	O
XXXX	O
✓✓	O
XXStudahl	O
,	O
M	O
.,	O
et	O
al	O
.	O
(	O
2013	O
)	O
[	O
71	O
]	O
Sweden	O
✓	O
XXXX	O
✓	O
XXXXSzucs	O
(	O
2011	O
)	O
[	O
72	O
]	O
Switzerland	O
✓	O
XX	O
✓✓	O
X	O
✓✓✓	O
XUltsch	O
et	O
al	O
.	O
(	O
2011	O
)	O
[	O
73	O
]	O
Germany	O
✓	O
XX	O
✓	O
X	O
✓	O
XXXXUltsch	O
et	O
al	O
.	O
(	O
2012	O
)	O
[	O
31	O
]	O
Germany	O
✓	O
XX	O
✓	O
X	O
✓✓✓✓	O
XVan	O
Hoek	O
et	O
al	O
.	O
(	O
2009	O
)	O
[	O
74	O
]	O
England	O
and	O
Wales	O
✓	O
XX	O
✓	O
X	O
✓✓	O
XXXVan	O
Seventer	O
et	O
al	O
.	O
(	O
2006	O
)	O
[	O
25	O
]	O
France	O
,	O
Germany	O
,	O
Italy	O
,	O
Netherlands	O
,	O
Spain	O
,	O
UKXXX	O
✓	O
X	O
✓	O
XXX	O
✓	O
Volpi	O
et	O
al	O
.	O
(	O
2007	O
)	O
[	O
75	O
]	O
Italy	O
✓	O
XXXXXXXX	O
✓	O
Volpi	O
et	O
al	O
.	O
(	O
2008	O
)	O
[	O
76	O
]	O
Italy	O
✓✓	O
X	O
✓✓	O
XXXX	O
✓	O
Weinke	O
et	O
al	O
.	O
(	O
2010	O
)	O
[	O
77	O
]	O
Germany	O
✓	O
XX	O
✓	O
XXX	O
✓	O
X	O
✓✓	O
and	O
x	O
indicate	O
the	O
presence	O
/	O
absence	O
of	O
evidence	O
,	O
respectively	O
.	O

The	O
references	O
selected	O
for	O
review	O
presented	O
data	O
from	O
14	O
European	O
countries	O
with	O
the	O
majority	O
(	O
n	O
=	O
39	O
,	O
73	O
.	O
6	O
%)	O
of	O
articles	O
providing	O
data	O
from	O
the	O
‘	O
Big	O
5	O
’	O
EU	O
countries	O
(	O
UK	O
;	O
Spain	O
;	O
France	O
;	O
Germany	O
&	O
Italy	O
).	O

Of	O
the	O
included	O
references	O
,	O
39	O
reported	O
data	O
specifically	O
attributed	O
to	O
HZ	B-DS
patients	O
and	O
35	O
reported	O
data	O
specifically	O
attributed	O
to	O
PHN	B-DS
patients	O
.	O

Data	O
attributed	O
to	O
a	O
combined	O
HZ	B-DS
and	O
PHN	B-DS
population	O
was	O
included	O
in	O
15	O
references	O
.	O

The	O
references	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
were	O
all	O
published	O
between	O
2000	O
and	O
2014	O
.	O

Data	O
presented	O
in	O
reviewed	O
references	O
was	O
categorized	O
as	O
follows	O
:	O
1	O
)	O
Healthcare	O
utilisation	O
in	O
terms	O
of	O
rates	O
of	O
medical	O
visits	O
,	O
hospitalisations	O
and	O
medication	O
prescribed	O
,	O
2	O
)	O
Direct	O
costs	O
corresponding	O
to	O
the	O
management	O
of	O
HZ	B-DS
/	O
PHN	B-DS
,	O
3	O
)	O
Indirect	O
costs	O
,	O
4	O
)	O
Total	O
costs	O
and	O
5	O
)	O
Health	O
related	O
quality	O
of	O
life	O
and	O
humanistic	O
burden	O
.	O

Of	O
note	O
,	O
some	O
references	O
contained	O
data	O
pertaining	O
to	O
multiple	O
categories	O
.	O

Healthcare	O
utilisation	O

Information	O
regarding	O
healthcare	O
resource	O
was	O
included	O
in	O
38	O
of	O
the	O
identified	O
references	O
(	O
as	O
summarized	O
in	O
Table	O
3	O
).	O

Data	O
indicated	O
that	O
HZ	B-DS
and	O
PHN	B-DS
are	O
associated	O
with	O
considerable	O
healthcare	O
utilisation	O
,	O
with	O
increased	O
resource	O
use	O
associated	O
with	O
increasing	O
age	O
and	O
the	O
presence	O
of	O
PHN	B-DS
.	O

Data	O
concerning	O
healthcare	O
utilisation	O
was	O
presented	O
in	O
terms	O
of	O
rates	O
of	O
medical	O
visits	O
(	O
including	O
GP	O
and	O
specialist	O
visits	O
),	O
hospitalisations	O
(	O
including	O
duration	O
of	O
stay	O
),	O
use	O
of	O
medications	O
and	O
additional	O
diagnostic	O
/	O
laboratory	O
procedures	O
.	O

Medical	O
visits	O

The	O
majority	O
of	O
patients	O
presenting	O
with	O
HZ	B-DS
will	O
consult	O
their	O
GP	O
at	O
least	O
once	O
[	O
43	O
,	O
50	O
].	O

Reflecting	O
the	O
chronic	O
nature	O
of	O
PHN	B-DS
,	O
higher	O
rates	O
of	O
medical	O
visits	O
(	O
GP	O
and	O
specialist	O
visits	O
)	O
have	O
been	O
reported	O
in	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
29	O
,	O
50	O
].	O

For	O
example	O
,	O
reports	O
from	O
a	O
study	O
in	O
Italy	O
indicated	O
that	O
patients	O
over	O
the	O
age	O
of	O
50	O
with	O
HZ	B-DS
made	O
approximately	O
1	O
.	O
9	O
visits	O
to	O
their	O
GP	O
.	O

By	O
contrast	O
,	O
the	O
reported	O
number	O
of	O
visits	O
among	O
patients	O
with	O
PHN	B-DS
was	O
11	O
.	O
9	O
and	O
12	O
.	O
0	O
(	O
PHN	B-DS
-	O
1	O
month	O
and	O
PHN	B-DS
3	O
-	O
months	O
definitions	O
,	O
respectively	O
)	O
[	O
29	O
].	O

The	O
proportion	O
of	O
patients	O
referred	O
to	O
specialists	O
(	O
74	O
%	O
PHN	B-DS
versus	O
18	O
%	O
HZ	B-DS
)	O
and	O
the	O
number	O
of	O
specialist	O
visits	O
per	O
case	O
(	O
3	O
.	O
5	O
and	O
3	O
.	O
9	O
for	O
PHN	B-DS
-	O
1	O
month	O
and	O
PHN	B-DS
3	O
-	O
months	O
vs	O
0	O
.	O
2	O
for	O
HZ	B-DS
)	O
were	O
also	O
higher	O
for	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
.	O

More	O
frequent	O
specialist	O
visits	O
have	O
also	O
been	O
reported	O
among	O
patients	O
with	O
HZO	B-DS
compared	O
to	O
those	O
with	O
HZ	B-DS
[	O
21	O
].	O

The	O
average	O
annual	O
incidence	O
of	O
herpes	B-OG
zoster	I-OG
GP	O
-	O
consultations	O
has	O
been	O
reported	O
to	O
increase	O
with	O
age	O
from	O
32	O
.	O
8	O
/	O
10	O
,	O
000	O
among	O
those	O
aged	O
<	O
60	O
years	O
,	O
to	O
93	O
.	O
1	O
and	O
113	O
.	O
2	O
/	O
10	O
,	O
000	O
among	O
those	O
aged	O
60	O
–	O
64	O
years	O
and	O
≥	O
65	O
years	O
respectively	O
[	O
64	O
].	O

Similarly	O
,	O
the	O
average	O
number	O
of	O
specialist	O
visits	O
was	O
also	O
higher	O
in	O
patients	O
over	O
the	O
age	O
of	O
50	O
compared	O
to	O
those	O
over	O
the	O
age	O
of	O
14	O
[	O
27	O
].	O

Hospitalisations	O

The	O
rates	O
of	O
hospitalisations	O
due	O
to	O
HZ	B-DS
and	O
/	O
or	O
PHN	B-DS
reported	O
in	O
the	O
literature	O
(	O
generally	O
derived	O
from	O
national	O
or	O
insurance	O
databases	O
of	O
hospital	O
admissions	O
)	O
suggest	O
that	O
increased	O
rates	O
of	O
hospitalisation	O
are	O
also	O
associated	O
with	O
increasing	O
age	O
[	O
55	O
,	O
71	O
].	O

More	O
frequent	O
hospitalisations	O
have	O
also	O
been	O
observed	O
among	O
patients	O
with	O
PHN	B-DS
when	O
compared	O
to	O
patients	O
with	O
HZ	B-DS
across	O
studies	O
in	O
Italy	O
[	O
29	O
],	O
Belgium	O
[	O
40	O
],	O
France	O
[	O
55	O
],	O
Germany	O
[	O
73	O
],	O
Spain	O
[	O
37	O
,	O
45	O
,	O
49	O
,	O
51	O
,	O
52	O
,	O
61	O
].	O
and	O
Portugal	O
[	O
59	O
].	O

There	O
are	O
also	O
reports	O
of	O
a	O
greater	O
rate	O
of	O
hospitalisations	O
among	O
female	O
HZ	B-DS
patients	O
compared	O
to	O
male	O
HZ	B-DS
patients	O
at	O
across	O
all	O
age	O
groups	O
[	O
71	O
].	O

The	O
average	O
length	O
of	O
inpatient	O
stay	O
for	O
PHN	B-DS
(	O
10	O
.	O
2	O
±	O
8	O
.	O
6	O
days	O
)	O
has	O
been	O
reported	O
to	O
be	O
higher	O
than	O
those	O
associated	O
with	O
HZ	B-DS
(	O
7	O
.	O
8	O
±	O
5	O
.	O
4	O
days	O
)	O
[	O
29	O
].	O

The	O
average	O
duration	O
of	O
stay	O
in	O
hospital	O
among	O
HZ	B-DS
patients	O
also	O
appears	O
to	O
be	O
influenced	O
by	O
age	O
[	O
47	O
,	O
74	O
].	O

For	O
example	O
,	O
analysis	O
of	O
Hospital	O
Episode	O
Statistics	O
(	O
2002	O
–	O
2005	O
)	O
from	O
England	O
indicates	O
the	O
average	O
length	O
of	O
stay	O
among	O
HZ	B-DS
/	O
PHN	B-DS
patients	O
aged	O
60	O
–	O
64	O
is	O
9	O
.	O
3	O
days	O
whereas	O
those	O
aged	O
85	O
–	O
90	O
is	O
22	O
.	O
3	O
days	O
[	O
74	O
].	O

Comparisons	O
between	O
HZ	B-DS
and	O
HZO	B-DS
patients	O
over	O
50	O
years	O
of	O
age	O
also	O
indicate	O
longer	O
hospital	O
stays	O
in	O
patients	O
with	O
HZO	B-DS
(	O
9	O
.	O
8	O
vs	O
7	O
.	O
8	O
days	O
)	O
[	O
38	O
].	O

Medication	O
use	O

It	O
is	O
reported	O
that	O
up	O
to	O
100	O
%	O
of	O
PHN	B-DS
patients	O
and	O
83	O
.	O
2	O
%	O
of	O
patients	O
with	O
HZ	B-DS
receive	O
medication	O
for	O
their	O
condition	O
across	O
all	O
ages	O
[	O
31	O
].	O

Polypharmacy	O
is	O
common	O
among	O
HZ	B-DS
patients	O
with	O
HZ	B-DS
patients	O
reported	O
to	O
be	O
taking	O
at	O
least	O
4	O
different	O
medications	O
on	O
average	O
and	O
PHN	B-DS
patients	O
reported	O
to	O
be	O
taking	O
5	O
medications	O
[	O
50	O
].	O

This	O
could	O
potentially	O
have	O
wider	O
implications	O
as	O
polypharmacy	O
is	O
known	O
to	O
be	O
a	O
major	O
cause	O
of	O
drug	O
interactions	O
and	O
issues	O
with	O
treatment	O
adherence	O
and	O
safety	O
[	O
78	O
].	O

The	O
types	O
of	O
medication	O
used	O
has	O
been	O
reported	O
to	O
vary	O
depending	O
on	O
the	O
population	O
being	O
considered	O
(	O
HZ	B-DS
or	O
PHN	B-DS
)	O
[	O
14	O
,	O
21	O
,	O
29	O
,	O
50	O
].	O

Indeed	O
,	O
current	O
treatment	O
of	O
HZ	B-DS
aims	O
to	O
relieve	O
pain	O
,	O
to	O
limit	O
the	O
spread	O
and	O
duration	O
of	O
the	O
dermatomal	O
lesions	O
and	O
(	O
when	O
started	O
within	O
72	O
hours	O
of	O
rash	O
onset	O
)	O
to	O
prevent	O
or	O
alleviate	O
complications	O
associated	O
with	O
HZ	B-DS
.	O

By	O
contrast	O
,	O
for	O
PHN	B-DS
,	O
the	O
focus	O
of	O
medications	O
is	O
to	O
alleviate	O
pain	O
[	O
79	O
,	O
80	O
].	O

The	O
amount	O
of	O
available	O
information	O
regarding	O
medication	O
use	O
in	O
EU	O
countries	O
was	O
somewhat	O
limited	O
;	O
however	O
available	O
evidence	O
from	O
the	O
literature	O
suggests	O
that	O
,	O
despite	O
the	O
availability	O
of	O
European	O
Guidelines	O
for	O
the	O
management	O
of	O
HZ	B-DS
[	O
80	O
,	O
81	O
],	O
medication	O
prescribing	O
practices	O
(	O
for	O
the	O
treatment	O
of	O
PHN	B-DS
in	O
particular	O
)	O
are	O
not	O
consistent	O
across	O
countries	O
[	O
14	O
,	O
21	O
,	O
25	O
,	O
29	O
,	O
44	O
,	O
50	O
].	O

An	O
observational	O
study	O
of	O
PHN	B-DS
patients	O
over	O
the	O
age	O
of	O
50	O
conducted	O
in	O
France	O
,	O
Germany	O
,	O
Italy	O
,	O
Netherlands	O
,	O
Spain	O
and	O
the	O
UK	O
(	O
n	O
=	O
84	O
),	O
for	O
example	O
,	O
reported	O
that	O
neuropathic	O
pain	O
medications	O
(	O
89	O
%),	O
analgesics	O
(	O
64	O
%)	O
and	O
anticonvulsants	O
(	O
52	O
%)	O
were	O
most	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
PHN	B-DS
[	O
25	O
].	O

However	O
,	O
a	O
study	O
conducted	O
in	O
the	O
UK	O
reported	O
that	O
antidepressants	O
were	O
most	O
commonly	O
prescribed	O
for	O
PHN	O
followed	O
by	O
level	O
1	O
and	O
2	O
analgesics	O
(	O
59	O
.	O
2	O
%,	O
55	O
.	O
3	O
%	O
and	O
50	O
%	O
respectively	O
)	O
[	O
14	O
].	O

Similarly	O
,	O
studies	O
in	O
Italy	O
and	O
Portugal	O
have	O
reported	O
that	O
anticonvulsants	O
to	O
be	O
the	O
most	O
commonly	O
prescribed	O
treatment	O
for	O
PHN	B-DS
,	O
followed	O
by	O
opioid	O
analgesics	O
[	O
29	O
,	O
44	O
].	O

Where	O
reported	O
,	O
medication	O
usage	O
for	O
the	O
treatment	O
of	O
HZ	B-DS
was	O
consistent	O
across	O
studies	O
;	O
with	O
antivirals	O
(	O
typically	O
taken	O
for	O
7	O
days	O
)	O
the	O
most	O
commonly	O
prescribed	O
treatment	O
[	O
14	O
,	O
21	O
,	O
29	O
,	O
42	O
,	O
50	O
,	O
71	O
].	O

Of	O
note	O
,	O
despite	O
the	O
widespread	O
use	O
of	O
pharmacological	O
therapies	O
for	O
the	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
,	O
reports	O
from	O
patients	O
indicate	O
dissatisfaction	O
with	O
treatments	O
,	O
particularly	O
in	O
regards	O
to	O
perceived	O
efficacy	O
[	O
14	O
,	O
50	O
].	O

Diagnostic	O
/	O
laboratory	O
procedures	O

Details	O
of	O
additional	O
investigations	O
among	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
were	O
reported	O
from	O
studies	O
in	O
France	O
,	O
Italy	O
,	O
Spain	O
and	O
the	O
UK	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
29	O
,	O
50	O
].	O

Additional	O
investigations	O
reported	O
included	O
blood	O
and	O
urine	O
tests	O
,	O
assessments	O
of	O
inflammation	O
(	O
e	O
.	O
g	O
.	O
erythrocyte	O
sedimentation	O
rate	O
,	O
C	B-GP
-	I-GP
reactive	I-GP
protein	I-GP
level	O
),	O
ophthalmological	O
/	O
ontological	O
examinations	O
,	O
radiology	O
,	O
X	O
-	O
ray	O
,	O
electrocardiograms	O
and	O
ultrasound	O
.	O

Further	O
diagnostic	O
or	O
laboratory	O
examinations	O
were	O
reported	O
in	O
28	O
.	O
0	O
%	O
of	O
incident	O
cases	O
of	O
HZ	B-DS
among	O
an	O
Italian	O
sample	O
of	O
immunocompetent	O
individuals	O
,	O
with	O
the	O
mean	O
number	O
of	O
procedures	O
and	O
examinations	O
reported	O
to	O
be	O
2	O
.	O
6	O
per	O
case	O
[	O
29	O
].	O

By	O
comparison	O
,	O
rates	O
of	O
additional	O
investigations	O
reported	O
in	O
France	O
,	O
Spain	O
and	O
the	O
UK	O
were	O
lower	O
[	O
14	O
,	O
21	O
,	O
27	O
,	O
50	O
],	O
with	O
evidence	O
suggesting	O
that	O
rates	O
of	O
additional	O
investigations	O
were	O
higher	O
in	O
those	O
with	O
PHN	B-DS
(	O
10	O
–	O
12	O
.	O
5	O
%	O
compared	O
to	O
HZ	B-DS
(	O
4	O
.	O
4	O
-	O
9	O
%)	O
[	O
14	O
,	O
21	O
,	O
50	O
].	O

Additional	O
investigations	O
are	O
also	O
more	O
likely	O
among	O
those	O
patients	O
with	O
HZO	B-DS
compared	O
to	O
HZ	B-DS
[	O
21	O
].	O

Direct	O
costs	O
of	O
management	O

Direct	O
costs	O
of	O
the	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
were	O
reported	O
in	O
20	O
studies	O
.	O

The	O
reviewed	O
articles	O
presented	O
data	O
from	O
Spain	O
[	O
27	O
,	O
37	O
,	O
45	O
,	O
51	O
-	O
53	O
,	O
69	O
],	O
the	O
UK	O
[	O
7	O
,	O
28	O
,	O
43	O
,	O
47	O
,	O
74	O
],	O
France	O
[	O
30	O
],	O
Italy	O
[	O
29	O
,	O
46	O
],	O
Germany	O
[	O
31	O
,	O
67	O
],	O
Belgium	O
[	O
26	O
,	O
40	O
],	O
Greece	O
[	O
70	O
]	O
and	O
Switzerland	O
[	O
72	O
].	O

Outpatient	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
diagnostic	O
tests	O
and	O
medications	O
),	O
hospitalization	O
and	O
inpatient	O
costs	O
were	O
identified	O
in	O
the	O
literature	O
as	O
key	O
contributors	O
to	O
the	O
overall	O
cost	O
burden	O
of	O
HZ	O
and	O
PHN	O
.	O

Outpatient	O
costs	O

Studies	O
in	O
Belgium	O
[	O
26	O
],	O
Germany	O
[	O
31	O
,	O
67	O
],	O
Italy	O
[	O
29	O
]	O
and	O
the	O
UK	O
[	O
28	O
]	O
have	O
consistently	O
reported	O
higher	O
outpatient	O
management	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
diagnostic	O
tests	O
and	O
medications	O
)	O
among	O
patients	O
who	O
go	O
on	O
to	O
develop	O
PHN	B-DS
.	O

For	O
example	O
,	O
mean	O
direct	O
costs	O
of	O
outpatient	O
management	O
have	O
been	O
reported	O
as	O
€	O
107	O
.	O
98	O
per	O
HZ	B-DS
episode	O
and	O
€	O
406	O
.	O
04	O
and	O
€	O
485	O
.	O
51	O
per	O
PHN	B-DS
episode	O
(	O
1	O
-	O
and	O
3	O
-	O
month	O
definition	O
respectively	O
)	O
[	O
28	O
]	O
a	O
.	O

In	O
addition	O
,	O
costs	O
for	O
outpatient	O
management	O
of	O
HZ	B-DS
and	O
PHN	B-DS
have	O
been	O
reported	O
to	O
increase	O
markedly	O
with	O
pain	O
severity	O
[	O
26	O
,	O
28	O
].	O

For	O
example	O
,	O
outpatient	O
costs	O
among	O
HZ	B-DS
patients	O
ranging	O
from	O
€	O
85	O
.	O
89	O
(	O
no	O
pain	O
)	O
to	O
€	O
178	O
.	O
32	O
(	O
severe	O
pain	O
)	O
per	O
case	O
have	O
been	O
reported	O
in	O
the	O
UK	O
.	O

Reported	O
differences	O
are	O
more	O
pronounced	O
among	O
PHN	B-DS
patients	O
with	O
costs	O
per	O
case	O
ranging	O
from	O
€	O
237	O
.	O
90	O
/	O
284	O
.	O
80	O
(	O
PHN1	B-GP
/	O
PHN3	B-GP
)	O
among	O
patients	O
with	O
mild	O
pain	O
to	O
€	O
741	O
.	O
91	O
/	O
878	O
.	O
88	O
(	O
PHN1	B-GP
/	O
PHN3	B-GP
)	O
among	O
patients	O
with	O
severe	O
pain	O
[	O
28	O
]	O
a	O
.	O

Key	O
differences	O
in	O
the	O
attribution	O
of	O
outpatient	O
costs	O
for	O
HZ	B-DS
and	O
PHN	B-DS
have	O
been	O
reported	O
for	O
Italy	O
;	O
for	O
patients	O
that	O
did	O
not	O
develop	O
PHN	B-DS
,	O
the	O
majority	O
of	O
the	O
cost	O
of	O
management	O
has	O
been	O
reported	O
to	O
be	O
due	O
to	O
the	O
cost	O
of	O
medication	O
(	O
83	O
%)	O
whereas	O
for	O
patients	O
that	O
develop	O
PHN	B-DS
a	O
greater	O
proportion	O
of	O
cost	O
was	O
attributed	O
to	O
diagnostic	O
and	O
investigative	O
procedures	O
[	O
29	O
].	O

Other	O
studies	O
,	O
however	O
,	O
indicate	O
costs	O
of	O
diagnostic	O
procedures	O
to	O
be	O
the	O
smallest	O
contributor	O
to	O
outpatient	O
costs	O
among	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
(	O
PHN	B-DS
-	O
1	O
and	O
PHN	B-DS
-	O
3	O
)	O
[	O
27	O
].	O

While	O
the	O
average	O
cost	O
of	O
outpatient	O
management	O
per	O
case	O
is	O
higher	O
for	O
patients	O
with	O
PHN	B-DS
than	O
for	O
patients	O
with	O
HZ	B-DS
,	O
when	O
considering	O
overall	O
burden	O
of	O
disease	O
at	O
a	O
country	O
level	O
,	O
the	O
overall	O
cost	O
of	O
disease	O
is	O
higher	O
for	O
HZ	O
.	O

This	O
is	O
primarily	O
a	O
result	O
of	O
the	O
higher	O
incidence	O
rates	O
of	O
HZ	B-DS
.	O

These	O
differences	O
were	O
highlighted	O
by	O
one	O
study	O
which	O
investigated	O
the	O
annual	O
cost	O
of	O
HZ	O
and	O
PHN	O
to	O
healthcare	O
providers	O
located	O
in	O
England	O
and	O
Wales	O
[	O
47	O
].	O

Based	O
on	O
an	O
estimated	O
260	O
,	O
995	O
episodes	O
of	O
HZ	B-DS
occurring	O
annually	O
,	O
with	O
14	O
%	O
of	O
cases	O
developing	O
PHN	B-DS
,	O
an	O
estimated	O
€	O
76	O
.	O
39	O
milliona	O
is	O
spent	O
on	O
the	O
management	O
of	O
HZ	B-DS
(	O
including	O
PHN	B-DS
).	O

Of	O
this	O
,	O
€	O
52	O
.	O
32	O
million	O
was	O
attributable	O
to	O
HZ	B-DS
(€	O
22	O
.	O
47	O
m	O
due	O
to	O
hospitalisation	O
,	O
€	O
19	O
.	O
26	O
m	O
due	O
to	O
prescription	O
medications	O
and	O
€	O
9	O
.	O
63	O
m	O
due	O
to	O
GP	O
consultations	O
)	O
and	O
€	O
24	O
.	O
07	O
million	O
to	O
PHN1	O
(	O
cost	O
breakdown	O
not	O
provided	O
).	O

Similar	O
findings	O
are	O
reported	O
in	O
Germany	O
where	O
statutory	O
health	O
insurance	O
bills	O
have	O
been	O
estimated	O
at	O
€	O
115	O
.	O
5	O
m	O
;	O
€	O
93	O
.	O
5	O
m	O
attributed	O
to	O
HZ	O
treatment	O
and	O
€	O
22	O
m	O
attributed	O
to	O
treatment	O
of	O
PHN	B-DS
[	O
31	O
].	O

Hospitalisation	O
and	O
inpatient	O
costs	O

Hospitalisation	O
costs	O
contribute	O
significantly	O
to	O
the	O
overall	O
direct	O
cost	O
of	O
managing	O
HZ	B-DS
and	O
PHN	B-DS
.	O

Rates	O
of	O
hospitalisation	O
and	O
duration	O
of	O
stay	O
were	O
found	O
to	O
be	O
higher	O
for	O
PHN	B-DS
than	O
for	O
HZ	B-DS
,	O
and	O
to	O
increase	O
with	O
increasing	O
age	O
,	O
translating	O
into	O
higher	O
inpatient	O
costs	O
for	O
patients	O
that	O
develop	O
PHN	B-DS
(	O
Table	O
4	O
)	O
[	O
18	O
,	O
24	O
,	O
33	O
,	O
70	O
].	O

Note	O
that	O
data	O
on	O
hospitalisations	O
and	O
inpatient	O
costs	O
was	O
primarily	O
extracted	O
from	O
a	O
range	O
of	O
national	O
and	O
insurance	O
databases	O
in	O
each	O
country	O
.	O

No	O
studies	O
identified	O
provided	O
a	O
breakdown	O
of	O
the	O
cost	O
elements	O
that	O
are	O
included	O
in	O
a	O
‘	O
hospital	O
stay	O
’.	O
Table	O
4	O
Mean	O
cost	O
per	O
hospitalised	O
case	O
of	O
HZ	B-DS
/	O
PHN	B-DS
,	O
by	O
country	O
Country	O
HZ	O
/	O
PHN	O
HZ	O
(	O
without	O
PHN	O
)	O
PHN	O
Belgium	O
[	O
40	O
]-€	O
5	O
,	O
982	O
(€	O
798	O
-	O
31	O
,	O
689	O
)-(	O
all	O
ages	O
)	O
France	O
[	O
41	O
]-€	O
2	O
,	O
774	O
.	O
28	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
731	O
.	O
09	O
(	O
50	O
+	O
years	O
)	O
Germany	O
[	O
31	O
]-€	O
4	O
,	O
189	O
.	O
74	O
(	O
50	O
+	O
years	O
)€	O
4	O
,	O
279	O
.	O
68	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
282	O
.	O
64	O
(	O
all	O
ages	O
)€	O
4	O
,	O
112	O
.	O
03	O
(	O
all	O
ages	O
)	O
Italy	O
[	O
29	O
]-€	O
3	O
,	O
188	O
.	O
16	O
±	O
€	O
1	O
,	O
614	O
.	O
99	O
(	O
50	O
+	O
years	O
)€	O
3	O
,	O
451	O
.	O
38	O
±	O
€	O
3	O
,	O
248	O
.	O
43	O
(	O
50	O
+	O
years	O
)	O
Spain	O
[	O
37	O
,	O
45	O
,	O
52	O
,	O
53	O
]€	O
3	O
,	O
366	O
.	O
4	O
-	O
4	O
,	O
505	O
.	O
6	O
€	O
5	O
,	O
019	O
.	O
84	O
(	O
aged	O
40	O
–	O
49	O
)€	O
5	O
,	O
108	O
.	O
04	O
(	O
aged	O
50	O
–	O
59	O
)(	O
all	O
ages	O
)€	O
4	O
,	O
495	O
.	O
68	O
–	O
5	O
,	O
139	O
.	O
54	O
(	O
aged	O
50	O
–	O
59	O
)€	O
4	O
,	O
732	O
.	O
56	O
(	O
aged	O
60	O
–	O
69	O
)€	O
4	O
,	O
210	O
.	O
92	O
–	O
4	O
,	O
782	O
.	O
96	O
(	O
aged	O
60	O
–	O
69	O
)€	O
4	O
,	O
478	O
.	O
04	O
(	O
70	O
+)€	O
4	O
,	O
062	O
.	O
24	O
–	O
4	O
,	O
556	O
.	O
16	O
(	O
aged	O
70	O
+)	O

Indirect	O
costs	O

Indirect	O
costs	O
considered	O
in	O
the	O
EU	O
literature	O
were	O
mainly	O
related	O
to	O
costs	O
associated	O
with	O
sick	O
leave	O
(	O
absenteeism	O
).	O

Seventeen	O
articles	O
reported	O
data	O
on	O
sick	O
leave	O
due	O
to	O
HZ	B-DS
and	O
PHN	B-DS
and	O
the	O
costs	O
that	O
this	O
incurs	O
[	O
7	O
,	O
26	O
,	O
27	O
,	O
29	O
-	O
31	O
,	O
40	O
,	O
42	O
,	O
58	O
,	O
60	O
,	O
63	O
,	O
69	O
,	O
70	O
,	O
72	O
,	O
73	O
,	O
77	O
,	O
82	O
].	O

Absenteeism	O
due	O
to	O
HZ	B-DS
and	O
PHN	B-DS
is	O
a	O
significant	O
cost	O
driver	O
,	O
with	O
increased	O
costs	O
found	O
to	O
be	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
[	O
29	O
,	O
31	O
,	O
72	O
]	O
and	O
increased	O
levels	O
of	O
pain	O
experienced	O
[	O
26	O
,	O
72	O
].	O

Up	O
to	O
65	O
%	O
of	O
employed	O
patients	O
report	O
work	O
absence	O
due	O
to	O
their	O
disease	O
[	O
77	O
].	O

Costs	O
associated	O
with	O
absenteeism	O
varied	O
across	O
EU	O
countries	O
.	O

In	O
France	O
,	O
these	O
costs	O
accounted	O
for	O
up	O
to	O
30	O
%	O
of	O
the	O
costs	O
of	O
management	O
of	O
HZ	O
from	O
the	O
societal	O
perspective	O
and	O
up	O
to	O
10	O
%	O
of	O
the	O
costs	O
of	O
management	O
for	O
PHN	B-DS
in	O
patients	O
aged	O
50	O
years	O
and	O
over	O
[	O
30	O
].	O

In	O
Germany	O
,	O
the	O
mean	O
annual	O
cost	O
of	O
sick	O
leave	O
due	O
to	O
HZ	B-DS
was	O
€	O
1	O
,	O
504	O
per	O
patient	O
(	O
increasing	O
to	O
€	O
1	O
,	O
826	O
for	O
patients	O
over	O
the	O
age	O
of	O
50	O
),	O
with	O
patients	O
missing	O
an	O
average	O
of	O
12	O
.	O
5	O
days	O
from	O
work	O
.	O

The	O
costs	O
associated	O
with	O
PHN	B-DS
were	O
found	O
to	O
be	O
higher	O
at	O
€	O
7	O
,	O
183	O
(€	O
7	O
.	O
590	O
for	O
patients	O
over	O
50	O
)	O
with	O
patients	O
missing	O
an	O
average	O
of	O
2	O
months	O
from	O
work	O
[	O
31	O
].	O

The	O
average	O
costs	O
associated	O
with	O
absenteeism	O
were	O
found	O
to	O
be	O
lower	O
in	O
Italy	O
and	O
Switzerland	O
than	O
those	O
reported	O
for	O
Germany	O
[	O
29	O
,	O
72	O
].	O

Average	O
costs	O
for	O
patients	O
over	O
the	O
age	O
of	O
50	O
in	O
Italy	O
were	O
€	O
684	O
per	O
case	O
of	O
HZ	B-DS
and	O
€	O
978	O
per	O
case	O
of	O
PHN	B-DS
[	O
29	O
].	O

In	O
Switzerland	O
,	O
reported	O
costs	O
of	O
sick	O
leave	O
per	O
case	O
for	O
patients	O
with	O
varying	O
levels	O
of	O
pain	O
were	O
as	O
follows	O
:	O
mild	O
pain	O
(	O
HZ	O
€	O
335	O
;	O
PHN	O
381	O
),	O
moderate	O
pain	O
(	O
HZ	O
€	O
421	O
;	O
PHN	O
€	O
1	O
,	O
018	O
),	O
severe	O
pain	O
(	O
HZ	O
€	O
1	O
,	O
837	O
;	O
PHN	O
€	O
2	O
,	O
443	O
)	O
b	O
[	O
72	O
].	O

In	O
Spain	O
,	O
the	O
findings	O
from	O
an	O
observational	O
study	O
[	O
27	O
]	O
of	O
130	O
HZ	B-DS
patients	O
aged	O
19	O
–	O
45	O
(	O
median	O
age	O
of	O
63	O
.	O
5	O
yrs	O
)	O
who	O
were	O
observed	O
for	O
1	O
year	O
suggest	O
that	O
an	O
average	O
of	O
4	O
.	O
3	O
hours	O
of	O
work	O
were	O
missed	O
per	O
patient	O
at	O
a	O
cost	O
of	O
€	O
52	O
.	O
98	O
.	O

This	O
study	O
also	O
found	O
that	O
a	O
total	O
of	O
6	O
work	O
hours	O
were	O
lost	O
by	O
carers	O
across	O
the	O
study	O
sample	O
of	O
130	O
,	O
resulting	O
in	O
a	O
total	O
loss	O
of	O
€	O
86	O
.	O
31	O
.	O

The	O
cost	O
and	O
time	O
implications	O
of	O
time	O
taken	O
off	O
work	O
by	O
carers	O
were	O
also	O
considered	O
in	O
two	O
further	O
studies	O
that	O
were	O
conducted	O
in	O
Belgium	O
and	O
the	O
UK	O
respectively	O
.	O

The	O
study	O
conducted	O
in	O
Belgium	O
found	O
that	O
14	O
/	O
184	O
patients	O
reported	O
that	O
someone	O
else	O
could	O
not	O
go	O
to	O
work	O
due	O
to	O
their	O
illness	O
for	O
between	O
0	O
.	O
5	O
-	O
10days	O
,	O
resulting	O
in	O
an	O
average	O
loss	O
of	O
€	O
52	O
per	O
case	O
due	O
to	O
carer	O
absenteeism	O
[	O
40	O
].	O

For	O
the	O
study	O
conducted	O
in	O
the	O
UK	O
,	O
among	O
70	O
HZ	B-DS
patients	O
,	O
a	O
total	O
of	O
52	O
work	O
days	O
were	O
lost	O
by	O
their	O
carers	O
[	O
7	O
].	O

However	O
as	O
the	O
majority	O
of	O
the	O
reviewed	O
studies	O
usually	O
do	O
not	O
report	O
the	O
cost	O
burden	O
associated	O
with	O
time	O
lost	O
by	O
carers	O
this	O
cost	O
is	O
likely	O
to	O
be	O
underestimated	O
.	O

Total	O
costs	O
of	O
management	O

A	O
total	O
of	O
10	O
studies	O
reported	O
the	O
total	O
cost	O
per	O
case	O
of	O
HZ	B-DS
and	O
/	O
or	O
PHN	B-DS
in	O
EU	O
countries	O
,	O
taking	O
into	O
account	O
both	O
direct	O
costs	O
(	O
including	O
medical	O
visits	O
,	O
medications	O
and	O
hospitalisations	O
)	O
and	O
indirect	O
costs	O
(	O
including	O
time	O
missed	O
from	O
work	O
).	O

Table	O
5	O
presents	O
the	O
average	O
cost	O
per	O
case	O
in	O
each	O
country	O
based	O
on	O
the	O
data	O
that	O
was	O
detailed	O
in	O
the	O
reviewed	O
literature	O
.	O

Overall	O
,	O
higher	O
costs	O
were	O
consistently	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
and	O
increased	O
levels	O
of	O
pain	O
.	O

Of	O
note	O
,	O
whilst	O
HZ	B-DS
and	O
PHN	B-DS
are	O
associated	O
with	O
higher	O
costs	O
to	O
healthcare	O
providers	O
in	O
elderly	O
populations	O
,	O
costs	O
to	O
society	O
in	O
terms	O
of	O
time	O
missed	O
for	O
work	O
tends	O
to	O
be	O
lower	O
,	O
so	O
the	O
total	O
costs	O
overall	O
are	O
similar	O
across	O
age	O
groups	O
[	O
60	O
].	O
Table	O
5	O
Mean	O
total	O
cost	O
of	O
management	O
per	O
HZ	B-DS
or	O
PHN	B-DS
case	O
Country	O
Population	O
age	O
Cost	O
per	O
case	O
HZ	O
PHN1	O
*	O
PHN3	O
^	O
Belgium	O
[	O
26	O
]	O
Aged	O
≥	O
50	O
€	O
118	O
(	O
no	O
pain	O
)€	O
156	O
.	O
94	O
(	O
mild	O
pain	O
)€	O
329	O
.	O
22	O
(	O
mild	O
pain	O
)€	O
1	O
,	O
150	O
.	O
50	O
(	O
severe	O
pain	O
)€	O
1	O
,	O
085	O
.	O
60	O
(	O
severe	O
pain	O
)€	O
2	O
,	O
037	O
.	O
86	O
(	O
severe	O
pain	O
)	O
France	O
[	O
30	O
]	O
Aged	O
≥	O
50	O
€	O
419	O
.	O
87	O
(	O
271	O
–	O
586	O
)€	O
672	O
.	O
76	O
(	O
451	O
–	O
968	O
)-	O
Germany	O
[	O
31	O
]	O
Aged	O
≥	O
50	O
€	O
388	O
.	O
30	O
(	O
354	O
–	O
425	O
)-€	O
1	O
,	O
427	O
.	O
80	O
(	O
1	O
,	O
002	O
-	O
1	O
,	O
917	O
)	O
Germany	O
[	O
67	O
]	O
Aged	O
≥	O
50	O
€	O
729	O
.	O
57	O
€	O
2	O
,	O
167	O
.	O
89Italy	O
[	O
29	O
]	O
Aged	O
≥	O
50	O
€	O
888	O
.	O
06	O
-€	O
1	O
,	O
66	O
.	O
65Spain	O
[	O
27	O
]	O
Aged	O
>	O
14	O
Overall	O
:	O
€	O
446	O
.	O
04	O
(	O
SD	O
508	O
.	O
58	O
)€	O
647	O
.	O
82	O
(	O
SD	O
684	O
.	O
4	O
)€	O
968	O
.	O
78	O
(	O
SD	O
803	O
.	O
58	O
)	O
50	O
-	O
59	O
:	O
€	O
282	O
.	O
06	O
(	O
SD	O
273	O
.	O
15	O
)	O
60	O
-	O
69	O
:€	O
510	O
.	O
52	O
(	O
SD	O
512	O
.	O
73	O
)	O
>	O
70	O
:	O
€	O
422	O
.	O
91	O
(	O
SD	O
388	O
.	O
66	O
)	O
Spain	O
[	O
69	O
]	O
Aged	O
>	O
30	O
€	O
460	O
.	O
95	O
€	O
1	O
,	O
956	O
.	O
15	O
-	O
Sweden	O
[	O
63	O
]	O
All	O
ages	O
€	O
902	O
.	O
88	O
(	O
HZ	B-DS
and	O
PHN	B-DS
)	O
Switzerland	O
[	O
72	O
]	O
Aged	O
≥	O
50	O
€	O
394	O
.	O
46	O
(	O
no	O
pain	O
)-€	O
381	O
.	O
15	O
(	O
no	O
pain	O
)€	O
1	O
,	O
835	O
.	O
57	O
(	O
severe	O
pain	O
)€	O
2	O
,	O
442	O
.	O
99	O
(	O
severe	O
pain	O
)	O
UK	O
[	O
7	O
]	O
Not	O
specified	O
€	O
793	O
.	O
60	O
(	O
31	O
–	O
6	O
,	O
394	O
)--(	O
all	O
ages	O
)	O
Aged	O
+	O
65	O
:	O
€	O
788	O
.	O
48	O
*	O
PHN	B-DS
defined	O
as	O
pain	O
persisting	O
for	O
one	O
month	O
following	O
resolution	O
of	O
HZ	B-DS
rash	O
.^	O
PHN	B-DS
defined	O
as	O
pain	O
persisting	O
for	O
three	O
months	O
following	O
resolution	O
of	O
HZ	B-DS
rash	O
.	O

The	O
total	O
annual	O
cost	O
(	O
direct	O
and	O
indirect	O
costs	O
)	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
a	O
country	O
level	O
basis	O
was	O
only	O
available	O
for	O
the	O
UK	O
[	O
43	O
],	O
France	O
[	O
30	O
],	O
Germany	O
[	O
31	O
],	O
Italy	O
[	O
29	O
]	O
and	O
Sweden	O
[	O
63	O
].	O

Two	O
studies	O
presented	O
data	O
separately	O
for	O
the	O
cost	O
of	O
HZ	B-DS
and	O
PHN	B-DS
and	O
patients	O
over	O
the	O
age	O
of	O
50	O
[	O
29	O
,	O
31	O
].	O

Further	O
details	O
are	O
provided	O
in	O
Figure	O
2	O
.	O
Figure	O
2	O
Estimated	O
total	O
cost	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
considering	O
outpatient	O
,	O
hospitalisation	O
and	O
indirect	O
costs	O
.	O

Humanistic	O
burden	O
and	O
impact	O
on	O
quality	O
of	O
life	O

A	O
total	O
of	O
21	O
EU	O
studies	O
[	O
7	O
,	O
14	O
,	O
15	O
,	O
21	O
,	O
25	O
,	O
28	O
,	O
42	O
,	O
44	O
,	O
48	O
,	O
50	O
,	O
56	O
-	O
58	O
,	O
62	O
,	O
65	O
,	O
66	O
,	O
68	O
,	O
75	O
-	O
77	O
]	O
reported	O
data	O
on	O
the	O
humanistic	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
,	O
with	O
the	O
significant	O
negative	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
patients	O
’	O
HRQOL	O
consistently	O
reported	O
.	O

Of	O
note	O
,	O
pain	O
experienced	O
due	O
to	O
the	O
disease	O
was	O
found	O
to	O
interfere	O
with	O
many	O
aspects	O
of	O
patient	O
’	O
s	O
daily	O
life	O
.	O

Greater	O
interference	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
pain	O
[	O
25	O
,	O
83	O
]	O
and	O
the	O
presence	O
of	O
PHN	B-DS
was	O
associated	O
with	O
a	O
greater	O
impact	O
on	O
most	O
domains	O
of	O
HRQoL	O
[	O
14	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

Patients	O
also	O
reported	O
consequences	O
for	O
their	O
family	O
and	O
social	O
circle	O
when	O
suffering	O
from	O
HZ	B-DS
or	O
PHN	B-DS
[	O
58	O
,	O
77	O
,	O
84	O
].	O

Pain	O
and	O
interference	O
with	O
daily	O
activities	O

Reports	O
within	O
the	O
reviewed	O
literature	O
indicate	O
that	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
experience	O
moderate	O
-	O
severe	O
pain	O
.	O

Ratings	O
of	O
average	O
and	O
worst	O
pain	O
reported	O
in	O
the	O
literature	O
are	O
higher	O
among	O
PHN	B-DS
patients	O
compared	O
to	O
HZ	B-DS
patients	O
[	O
14	O
,	O
41	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

A	O
number	O
of	O
the	O
reviewed	O
articles	O
provided	O
data	O
from	O
the	O
Zoster	O
Brief	O
Pain	O
Inventory	O
(	O
ZBPI	O
)	O
and	O
the	O
Modified	O
Brief	O
Pain	O
Short	O
Form	O
(	O
mBPI	O
-	O
SF	O
)	O
c	O
–	O
derivative	O
measures	O
of	O
the	O
Brief	O
Pain	O
Inventory	O
(	O
BPI	O
)	O
which	O
require	O
patients	O
to	O
rate	O
the	O
level	O
of	O
interference	O
they	O
experience	O
on	O
a	O
scale	O
of	O
0	O
–	O
10	O
(‘	O
does	O
not	O
interfere	O
’	O
–	O
‘	O
completely	O
interferes	O
’),	O
across	O
seven	O
health	O
status	O
domain	O
;	O
general	O
activity	O
,	O
mood	O
,	O
walking	O
ability	O
,	O
normal	O
work	O
,	O
social	O
relations	O
,	O
sleep	O
and	O
enjoyment	O
of	O
life	O
.	O

Table	O
6	O
presents	O
the	O
mean	O
scores	O
for	O
patients	O
with	O
HZ	B-DS
and	O
PHN	B-DS
from	O
five	O
studies	O
.	O

In	O
general	O
,	O
reports	O
of	O
pain	O
interference	O
on	O
all	O
seven	O
health	O
status	O
domains	O
were	O
greater	O
among	O
patients	O
experiencing	O
PHN	B-DS
compared	O
to	O
patients	O
with	O
HZ	B-DS
[	O
14	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

HZ	B-DS
and	O
PHN	B-DS
patients	O
reported	O
sleep	O
to	O
be	O
the	O
aspect	O
of	O
their	O
daily	O
lives	O
most	O
affected	O
by	O
pain	O
(	O
4	O
.	O
5	O
-	O
4	O
.	O
9	O
and	O
6	O
.	O
3	O
-	O
6	O
.	O
5	O
mean	O
scores	O
respectively	O
),	O
while	O
walking	O
ability	O
was	O
the	O
least	O
affected	O
in	O
HZ	B-DS
patients	O
(	O
1	O
.	O
7	O
-	O
4	O
.	O
0	O
mean	O
score	O
)	O
and	O
enjoyment	O
of	O
life	O
was	O
least	O
affected	O
in	O
PHN	B-DS
patients	O
(	O
3	O
.	O
8	O
-	O
5	O
.	O
2	O
mean	O
score	O
)	O
[	O
14	O
,	O
15	O
,	O
50	O
,	O
58	O
,	O
77	O
].	O

Increased	O
levels	O
of	O
pain	O
are	O
reported	O
to	O
be	O
associated	O
with	O
increased	O
levels	O
of	O
interference	O
[	O
25	O
,	O
83	O
].	O

Levels	O
of	O
pain	O
interference	O
,	O
however	O
,	O
do	O
not	O
appear	O
to	O
be	O
associated	O
with	O
age	O
.	O

Lukas	O
et	O
al	O
.	O
[	O
58	O
]	O
presented	O
pain	O
interference	O
data	O
separately	O
for	O
six	O
European	O
countries	O
included	O
in	O
the	O
study	O
.	O

While	O
differences	O
in	O
the	O
level	O
of	O
interference	O
observed	O
varied	O
from	O
country	O
to	O
country	O
,	O
the	O
domains	O
of	O
health	O
status	O
most	O
affected	O
was	O
largely	O
consistent	O
.	O
Table	O
6	O
Level	O
of	O
pain	O
interference	O
across	O
seven	O
health	O
state	O
domains	O
as	O
assessed	O
by	O
the	O
ZBPI	O
(	O
or	O
similar	O
instrument	O
)	O
Health	O
state	O
domains	O
HZ	O
(	O
mean	O
scores	O
)	O
PHN	O
(	O
mean	O
scores	O
)	O
General	O
activity	O
3	O
.	O
8	O
-	O
4	O
.	O
43	O
.	O
1	O
-	O
5	O
.	O
7	O
Mood	O
3	O
.	O
4	O
-	O
4	O
.	O
53	O
.	O
4	O
-	O
5	O
.	O
9	O
Walking	O
ability	O
1	O
.	O
7	O
-	O
4	O
.	O
01	O
.	O
7	O
-	O
5	O
.	O
8	O
Normal	O
work	O
3	O
.	O
3	O
-	O
4	O
.	O
42	O
.	O
9	O
-	O
6	O
.	O
1	O
Social	O
relations	O
2	O
.	O
1	O
-	O
3	O
.	O
52	O
.	O
1	O
-	O
5	O
.	O
4	O
Sleep	O
4	O
.	O
5	O
-	O
4	O
.	O
96	O
.	O
3	O
-	O
6	O
.	O
5	O
Enjoyment	O
of	O
life	O
3	O
.	O
6	O
-	O
4	O
.	O
03	O
.	O
8	O
-	O
5	O
.	O
2Data	O
from	O
Bouhassira	O
2012	O
[	O
15	O
],	O
Gater	O
2014	O
[	O
50	O
],	O
Lukas	O
2012	O
[	O
58	O
],	O
Serpell	O
2014	O
[	O
14	O
],	O
Weinke	O
2010	O
[	O
77	O
].	O

Impact	O
on	O
general	O
health	O
-	O
related	O
quality	O
of	O
life	O

A	O
number	O
of	O
studies	O
have	O
included	O
generic	O
HRQoL	O
measures	O
such	O
as	O
the	O
SF	O
-	O
12	O
[	O
15	O
,	O
83	O
],	O
SF	O
-	O
36	O
[	O
14	O
,	O
21	O
,	O
50	O
],	O
EQ	O
-	O
5D	O
[	O
7	O
,	O
14	O
,	O
25	O
,	O
50	O
]	O
and	O
Short	O
Italian	O
Questionnaire	O
(	O
SIQ	O
)	O
[	O
75	O
,	O
76	O
]	O
to	O
assess	O
HRQoL	O
in	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
.	O

Generally	O
,	O
HRQoL	O
has	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
levels	O
of	O
reported	O
pain	O
[	O
14	O
,	O
25	O
,	O
50	O
,	O
83	O
]	O
and	O
the	O
poorest	O
HRQoL	O
has	O
been	O
observed	O
for	O
patients	O
with	O
PHN	B-DS
[	O
14	O
,	O
21	O
,	O
50	O
].	O

Consideration	O
of	O
HRQoL	O
scores	O
from	O
normative	O
populations	O
indicates	O
an	O
inverse	O
relationship	O
between	O
age	O
and	O
HRQoL	O
.	O

As	O
a	O
condition	O
mainly	O
inflicting	O
the	O
elderly	O
,	O
therefore	O
,	O
HRQoL	O
is	O
already	O
considerably	O
compromised	O
in	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
.	O

Nonetheless	O
,	O
recent	O
research	O
indicates	O
that	O
both	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
demonstrate	O
statistically	O
significant	O
and	O
clinically	O
relevant	O
deficits	O
in	O
HRQoL	O
when	O
scores	O
for	O
validated	O
measures	O
of	O
HRQoL	O
(	O
e	O
.	O
g	O
.	O
SF	O
-	O
36	O
and	O
EQ	O
-	O
5D	O
)	O
among	O
these	O
populations	O
are	O
compared	O
to	O
those	O
from	O
aged	O
-	O
matched	O
normative	O
samples	O
(	O
Figures	O
3	O
and	O
4	O
)	O
[	O
14	O
,	O
50	O
].	O
Figure	O
3	O
Comparison	O
of	O
SF	O
-	O
36	O
domain	O
and	O
component	O
scores	O
for	O
HZ	B-DS
patients	O
compared	O
to	O
age	O
-	O
matched	O
norms	O
[	O
50	O
].	O
No	O
*	O
s	O
p	O
≥	O
0	O
.	O
05	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
>	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
†	O
=	O
clinically	O
meaningful	O
PF	O
=	O
Physical	O
functioning	O
,	O
R	O
-	O
P	O
=	O
Role	O
-	O
physical	O
,	O
BP	O
=	O
Bodily	O
pain	O
,	O
GH	B-GP
=	O
General	O
health	O
,	O
V	O
=	O
Vitality	O
,	O
SF	O
=	O
Social	O
functioning	O
,	O
R	O
-	O
E	O
=	O
Role	O
-	O
emotional	O
,	O
MH	O
=	O
Mental	O
health	O
,	O
PCS	O
=	O
Physical	O
component	O
summary	O
,	O
MCS	O
=	O
Mental	O
component	O
summary	O
.	O
Note	O
:	O
Data	O
collected	O
on	O
initial	O
presentation	O
of	O
HZ	B-DS
to	O
healthcare	O
professional	O
and	O
then	O
again	O
7	O
-	O
14	O
days	O
later	O
(	O
follow	O
-	O
up	O
).	O
Figure	O
4	O
Comparison	O
of	O
SF	O
-	O
36	O
domain	O
and	O
component	O
scores	O
for	O
PHN	B-DS
patients	O
compared	O
to	O
age	O
-	O
matched	O
norms	O
[	O
14	O
].	O
No	O
*	O
s	O
p	O
≥	O
0	O
.	O
05	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O
†	O
=	O
clinically	O
meaningful	O
PF	O
=	O
Physical	O
functioning	O
,	O
R	O
-	O
P	O
=	O
Role	O
-	O
physical	O
,	O
BP	O
=	O
Bodily	O
pain	O
,	O
GH	O
=	O
General	O
health	O
,	O
V	O
=	O
Vitality	O
,	O
SF	O
=	O
Social	O
functioning	O
,	O
R	O
-	O
E	O
=	O
Role	O
-	O
emotional	O
,	O
MH	O
=	O
Mental	O
health	O
,	O
PCS	O
=	O
Physical	O
component	O
summary	O
,	O
MCS	O
=	O
Mental	O
component	O
summary	O
.	O

Impact	O
on	O
mood	O
and	O
mental	O
well	O
-	O
being	O

Data	O
presented	O
across	O
studies	O
demonstrates	O
that	O
patients	O
experience	O
a	O
negative	O
impact	O
on	O
their	O
mood	O
and	O
mental	O
well	O
-	O
being	O
,	O
with	O
patients	O
reporting	O
stress	O
,	O
anxiety	B-DS
and	O
depressive	O
symptoms	O
[	O
14	O
,	O
15	O
,	O
50	O
,	O
56	O
,	O
58	O
,	O
76	O
,	O
77	O
].	O

Across	O
studies	O
,	O
a	O
range	O
of	O
instruments	O
have	O
been	O
used	O
to	O
assess	O
the	O
impact	O
of	O
HZ	O
and	O
PHN	B-DS
on	O
mood	O
,	O
including	O
the	O
Hospital	O
Anxiety	B-DS
and	O
Depression	B-DS
scale	O
(	O
HADS	O
)	O
[	O
7	O
,	O
15	O
],	O
10	O
,	O
47	O
Short	O
Italian	O
Questionnaire	O
(	O
SIQ	O
)	O
[	O
75	O
,	O
76	O
],	O
the	O
Short	O
Anxiety	B-DS
Screening	O
Test	O
(	O
SAST	O
)	O
[	O
56	O
]	O
and	O
bespoke	O
questions	O
[	O
58	O
,	O
77	O
].	O

Up	O
to	O
29	O
%	O
of	O
patients	O
with	O
HZ	B-DS
reported	O
feelings	O
of	O
moderate	O
anxiety	B-DS
or	O
depression	B-DS
,	O
rising	O
to	O
43	O
%	O
in	O
patients	O
with	O
PHN	B-DS
.	O

Further	O
,	O
a	O
larger	O
percentage	O
of	O
PHN	B-DS
patients	O
reported	O
extreme	O
anxiety	B-DS
or	O
depression	B-DS
(	O
11	O
%	O
vs	O
.	O
5	O
%)	O
[	O
58	O
,	O
77	O
],	O
evidencing	O
that	O
mood	O
and	O
mental	O
well	O
-	O
being	O
issues	O
are	O
greater	O
for	O
PHN	B-DS
patients	O
.	O

The	O
majority	O
of	O
patients	O
reported	O
experiencing	O
stress	O
some	O
of	O
the	O
time	O
(	O
up	O
to	O
78	O
%	O
for	O
HZ	B-DS
and	O
91	O
%	O
for	O
PHN	B-DS
)	O
or	O
most	O
of	O
the	O
time	O
(	O
up	O
to	O
19	O
%	O
HZ	B-DS
and	O
41	O
%	O
PHN	B-DS
)	O
[	O
58	O
,	O
77	O
].	O

Impact	O
on	O
family	O
and	O
social	O
relations	O

Up	O
to	O
50	O
%	O
of	O
patients	O
with	O
HZ	B-DS
and	O
81	O
%	O
of	O
patients	O
with	O
PHN	B-DS
reported	O
consequences	O
for	O
their	O
family	O
members	O
and	O
social	O
circle	O
[	O
58	O
,	O
77	O
].	O

Despite	O
the	O
high	O
proportion	O
of	O
patients	O
reporting	O
impacts	O
on	O
their	O
social	O
and	O
family	O
lives	O
,	O
only	O
three	O
studies	O
assessed	O
this	O
issue	O
beyond	O
comparing	O
scores	O
on	O
social	O
dimensions	O
of	O
instruments	O
such	O
as	O
the	O
ZBPI	O
or	O
SF	O
-	O
36	O
[	O
58	O
,	O
77	O
,	O
84	O
].	O

In	O
one	O
study	O
in	O
particular	O
,	O
one	O
fifth	O
of	O
the	O
respondents	O
felt	O
isolated	O
from	O
their	O
family	O
and	O
friends	O
while	O
suffering	O
from	O
HZ	B-DS
or	O
PHN	B-DS
,	O
with	O
19	O
%	O
and	O
27	O
%	O
of	O
patients	O
respectively	O
reporting	O
reduced	O
communication	O
during	O
their	O
illness	O
[	O
58	O
].	O

Of	O
note	O
,	O
impacts	O
were	O
not	O
limited	O
to	O
the	O
patient	O
themselves	O
,	O
with	O
findings	O
from	O
a	O
qualitative	O
focus	O
group	O
of	O
patient	O
’	O
s	O
relatives	O
demonstrating	O
that	O
relatives	O
were	O
worried	O
and	O
stressed	O
by	O
the	O
impact	O
of	O
HZ	O
on	O
the	O
patients	O
[	O
84	O
].	O

Discussion	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
provide	O
a	O
holistic	O
overview	O
of	O
the	O
published	O
literature	O
concerning	O
the	O
humanistic	O
,	O
economic	O
and	O
societal	O
burden	O
of	O
HZ	O
and	O
PHN	B-DS
in	O
Europe	O
.	O

The	O
reviewed	O
evidence	O
highlights	O
the	O
significant	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
for	O
patients	O
,	O
healthcare	O
systems	O
and	O
wider	O
society	O
.	O

A	O
number	O
of	O
key	O
findings	O
are	O
noted	O
.	O

Firstly	O
,	O
the	O
direct	O
costs	O
of	O
managing	O
HZ	B-DS
represent	O
a	O
significant	O
proportion	O
of	O
the	O
total	O
costs	O
associated	O
with	O
the	O
disease	O
,	O
with	O
higher	O
costs	O
associated	O
with	O
the	O
presence	O
of	O
PHN	B-DS
and	O
with	O
greater	O
pain	O
severity	O
.	O

Secondly	O
,	O
absenteeism	O
was	O
identified	O
as	O
a	O
significant	O
cost	O
driver	O
(	O
albeit	O
in	O
a	O
small	O
number	O
of	O
studies	O
),	O
with	O
up	O
to	O
65	O
%	O
of	O
employed	O
patients	O
reporting	O
work	O
absence	O
due	O
to	O
their	O
disease	O
.	O

Lastly	O
,	O
research	O
suggests	O
that	O
age	O
,	O
pain	O
severity	O
and	O
the	O
presence	O
of	O
PHN	B-DS
are	O
the	O
key	O
drivers	O
of	O
burden	O
to	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

In	O
Europe	O
the	O
percentage	O
of	O
people	O
aged	O
65	O
years	O
or	O
over	O
is	O
projected	O
to	O
increase	O
from	O
17	O
.	O
1	O
%	O
(	O
84	O
.	O
6million	O
)	O
in	O
2008	O
to	O
30	O
.	O
0	O
%	O
(	O
151	O
.	O
5	O
million	O
)	O
in	O
2060	O
[	O
85	O
].	O

This	O
demographic	O
shift	O
is	O
likely	O
to	O
have	O
a	O
profound	O
influence	O
on	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
and	O
may	O
contribute	O
to	O
increased	O
concern	O
among	O
European	O
healthcare	O
authorities	O
;	O
particularly	O
if	O
economic	O
crisis	O
and	O
healthcare	O
budget	O
constrains	O
persist	O
in	O
the	O
long	O
term	O
.	O

Findings	O
from	O
this	O
review	O
indicate	O
that	O
the	O
direct	O
costs	O
of	O
HZ	B-DS
and	O
PHN	B-DS
management	O
are	O
greater	O
for	O
older	O
patients	O
.	O

In	O
addition	O
,	O
older	O
adults	O
typically	O
have	O
lower	O
HRQoL	O
than	O
younger	O
adults	O
(	O
deficits	O
which	O
are	O
more	O
pronounced	O
with	O
the	O
presence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
)	O
and	O
may	O
be	O
less	O
able	O
to	O
complete	O
activities	O
of	O
daily	O
living	O
and	O
self	O
-	O
care	O
unassisted	O
.	O

The	O
potential	O
implications	O
of	O
an	O
aging	O
population	O
to	O
wider	O
society	O
,	O
therefore	O
,	O
are	O
wide	O
reaching	O
.	O

Limitations	O
of	O
the	O
current	O
literature	O
and	O
potential	O
gaps	O
that	O
provide	O
opportunities	O
for	O
future	O
research	O

A	O
number	O
of	O
limitations	O
concerning	O
the	O
currently	O
available	O
body	O
of	O
evidence	O
were	O
identified	O
.	O

Inconsistencies	O
in	O
data	O

There	O
is	O
currently	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
PHN	B-DS
and	O
a	O
lack	O
of	O
consistency	O
in	O
the	O
definition	O
of	O
PHN	B-DS
employed	O
in	O
studies	O
was	O
evident	O
throughout	O
the	O
review	O
.	O

This	O
presents	O
a	O
number	O
of	O
challenges	O
when	O
attempting	O
to	O
accurately	O
understand	O
the	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
.	O

For	O
example	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
prevalence	O
of	O
PHN	B-DS
varies	O
dramatically	O
depending	O
on	O
the	O
point	O
at	O
which	O
HZ	B-DS
-	O
related	O
pain	O
becomes	O
classified	O
as	O
PHN	B-DS
(	O
PHN1	B-GP
or	O
PHN3	B-GP
)	O
[	O
86	O
].	O

Accurately	O
attributing	O
costs	O
to	O
HZ	O
and	O
PHN	B-DS
and	O
determining	O
the	O
overall	O
cost	O
burden	O
of	O
the	O
conditions	O
,	O
therefore	O
,	O
is	O
difficult	O
.	O

Similarly	O
,	O
cost	O
per	O
case	O
may	O
vary	O
dramatically	O
depending	O
on	O
the	O
definition	O
employed	O
.	O

For	O
this	O
reason	O
,	O
PHN	B-DS
definitions	O
employed	O
in	O
the	O
referenced	O
studies	O
have	O
been	O
highlighted	O
throughout	O
this	O
review	O
and	O
should	O
be	O
considered	O
when	O
interpreting	O
the	O
findings	O
from	O
individual	O
studies	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
lack	O
of	O
consistency	O
in	O
the	O
use	O
of	O
International	O
Classification	O
of	O
Diseases	O
(	O
ICD	O
)	O
codes	O
used	O
to	O
identify	O
PHN	B-DS
patients	O
in	O
clinical	O
practice	O
.	O

As	O
a	O
result	O
,	O
there	O
may	O
be	O
a	O
significant	O
proportion	O
of	O
PHN	B-DS
patients	O
who	O
have	O
not	O
been	O
considered	O
in	O
these	O
studies	O
;	O
consequently	O
decreasing	O
confidence	O
in	O
the	O
accuracy	O
of	O
estimates	O
regarding	O
the	O
burden	O
of	O
PHN	B-DS
.	O

A	O
lack	O
of	O
consistency	O
in	O
the	O
ways	O
in	O
which	O
data	O
had	O
been	O
collected	O
provides	O
further	O
difficulties	O
in	O
interpreting	O
and	O
comparing	O
the	O
available	O
data	O
across	O
studies	O
,	O
with	O
databases	O
,	O
patient	O
records	O
and	O
patient	O
surveys	O
all	O
utilized	O
.	O

For	O
example	O
,	O
rates	O
of	O
resource	O
use	O
were	O
derived	O
from	O
a	O
range	O
of	O
sources	O
including	O
:	O
analysis	O
of	O
patient	O
records	O
or	O
an	O
observed	O
sample	O
,	O
patient	O
responses	O
to	O
surveys	O
and	O
national	O
and	O
insurance	O
databases	O
,	O
with	O
each	O
of	O
these	O
methods	O
having	O
their	O
own	O
limitations	O
.	O

The	O
use	O
of	O
databases	O
is	O
a	O
valuable	O
way	O
of	O
gathering	O
data	O
at	O
a	O
national	O
level	O
,	O
however	O
it	O
assumes	O
information	O
is	O
recorded	O
consistently	O
and	O
accurately	O
across	O
databases	O
and	O
that	O
the	O
database	O
has	O
adequate	O
and	O
representative	O
population	O
coverage	O
.	O

Analysis	O
of	O
patient	O
records	O
assumes	O
information	O
is	O
accurately	O
recorded	O
by	O
GPs	O
,	O
who	O
have	O
a	O
myriad	O
of	O
demands	O
on	O
their	O
time	O
,	O
and	O
analysis	O
of	O
patient	O
’	O
s	O
responses	O
assumes	O
accuracy	O
in	O
their	O
recall	O
.	O

Of	O
note	O
,	O
the	O
incidence	O
of	O
hospitalisations	O
were	O
largely	O
based	O
on	O
rates	O
derived	O
from	O
databases	O
in	O
different	O
countries	O
,	O
or	O
rates	O
recorded	O
in	O
observed	O
samples	O
,	O
thus	O
inaccuracies	O
may	O
occur	O
when	O
these	O
data	O
are	O
extrapolated	O
to	O
the	O
country	O
population	O
.	O

Variation	O
in	O
reports	O
of	O
healthcare	O
resource	O
use	O
,	O
indirect	O
costs	O
and	O
humanistic	O
burden	O
are	O
also	O
likely	O
to	O
have	O
resulted	O
from	O
inconsistency	O
in	O
the	O
time	O
frame	O
that	O
different	O
studies	O
considered	O
relevant	O
.	O

With	O
respect	O
to	O
the	O
literature	O
on	O
economic	O
burden	O
,	O
it	O
is	O
understood	O
that	O
costs	O
are	O
likely	O
to	O
vary	O
between	O
countries	O
in	O
terms	O
of	O
the	O
cost	O
of	O
medical	O
resources	O
,	O
medical	O
visits	O
and	O
prescribed	O
medications	O
.	O

Currently	O
these	O
differences	O
are	O
not	O
reflected	O
in	O
the	O
published	O
literature	O
and	O
in	O
some	O
cases	O
,	O
the	O
cost	O
of	O
treating	O
a	O
case	O
of	O
HZ	B-DS
or	O
PHN	B-DS
were	O
calculated	O
inconsistently	O
,	O
with	O
some	O
studies	O
presenting	O
the	O
cost	O
per	O
treated	O
case	O
while	O
others	O
presented	O
the	O
average	O
across	O
all	O
patients	O
.	O

As	O
such	O
there	O
was	O
a	O
wide	O
variation	O
between	O
studies	O
.	O

Only	O
one	O
study	O
provided	O
costs	O
(	O
per	O
treated	O
case	O
)	O
for	O
the	O
different	O
types	O
of	O
medications	O
used	O
to	O
treat	O
HZ	B-DS
or	O
PHN	B-DS
[	O
46	O
].	O

Similarly	O
,	O
no	O
studies	O
provided	O
breakdown	O
or	O
clarification	O
of	O
cost	O
elements	O
included	O
in	O
a	O
‘	O
hospital	O
stay	O
’.	O

Great	O
caution	O
,	O
therefore	O
,	O
should	O
be	O
taken	O
in	O
comparing	O
and	O
interpreting	O
the	O
available	O
data	O
.	O

Furthermore	O
this	O
highlights	O
an	O
unmet	O
need	O
for	O
data	O
that	O
clearly	O
distinguishes	O
between	O
HZ	B-DS
and	O
PHN	B-DS
and	O
also	O
for	O
‘	O
per	O
treated	O
case	O
’	O
data	O
for	O
a	O
wide	O
range	O
of	O
EU	O
countries	O
.	O

A	O
further	O
notable	O
limitation	O
was	O
that	O
data	O
were	O
not	O
available	O
for	O
all	O
EU	O
countries	O
.	O

Despite	O
comprehensive	O
database	O
searches	O
,	O
in	O
which	O
no	O
restrictions	O
on	O
country	O
of	O
interest	O
or	O
language	O
of	O
publication	O
were	O
implemented	O
,	O
cost	O
burden	O
data	O
for	O
the	O
majority	O
of	O
Eastern	O
European	O
countries	O
was	O
not	O
identified	O
.	O

The	O
majority	O
of	O
studies	O
,	O
instead	O
,	O
focus	O
primarily	O
on	O
the	O
UK	O
,	O
Spain	O
,	O
France	O
,	O
Italy	O
,	O
Belgium	O
and	O
Germany	O
.	O

Gaps	O
in	O
evidence	O

A	O
number	O
of	O
evidence	O
gaps	O
were	O
identified	O
,	O
some	O
of	O
which	O
provide	O
opportunities	O
for	O
future	O
research	O
.	O

A	O
key	O
gap	O
identified	O
in	O
the	O
available	O
evidence	O
pool	O
relates	O
to	O
how	O
indirect	O
costs	O
are	O
assessed	O
.	O

While	O
a	O
number	O
of	O
EU	O
studies	O
presented	O
data	O
on	O
the	O
time	O
missed	O
from	O
work	O
and	O
associated	O
costs	O
,	O
data	O
on	O
productivity	O
while	O
at	O
work	O
and	O
associated	O
costs	O
is	O
lacking	O
.	O

Studies	O
in	O
the	O
US	O
and	O
Canada	O
,	O
however	O
,	O
report	O
that	O
presenteeism	O
could	O
account	O
for	O
up	O
to	O
75	O
%	O
of	O
the	O
cost	O
burden	O
associated	O
with	O
work	O
loss	O
[	O
87	O
]	O
and	O
that	O
an	O
average	O
of	O
46	O
hours	O
were	O
lost	O
(	O
per	O
employed	O
patient	O
)	O
due	O
to	O
presenteeism	O
[	O
88	O
].	O

In	O
Europe	O
,	O
decisions	O
regarding	O
access	O
and	O
reimbursement	O
of	O
medical	O
interventions	O
are	O
predominately	O
driven	O
by	O
considerations	O
of	O
cost	O
-	O
effectiveness	O
.	O

Consideration	O
of	O
the	O
impact	O
of	O
conditions	O
as	O
reported	O
by	O
patients	O
themselves	O
,	O
however	O
,	O
provides	O
important	O
information	O
regarding	O
unmet	O
need	O
and	O
the	O
efficacy	O
of	O
medical	O
interventions	O
.	O

A	O
number	O
of	O
studies	O
assessing	O
aspects	O
of	O
humanistic	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
were	O
identified	O
.	O

However	O
,	O
there	O
are	O
number	O
of	O
notable	O
limitations	O
.	O

Firstly	O
,	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
was	O
generally	O
assessed	O
using	O
disease	O
specific	O
questionnaires	O
(	O
such	O
as	O
the	O
ZBPI	O
)	O
or	O
‘	O
bespoke	O
’	O
questions	O
which	O
have	O
not	O
been	O
tested	O
or	O
validated	O
.	O

There	O
was	O
only	O
limited	O
use	O
of	O
generic	O
HRQoL	O
instruments	O
in	O
the	O
EU	O
studies	O
conducted	O
to	O
date	O
.	O

However	O
,	O
data	O
from	O
such	O
instruments	O
are	O
valuable	O
for	O
quantifying	O
burden	O
with	O
reference	O
to	O
the	O
normative	O
population	O
and	O
patients	O
with	O
other	O
diseases	O
–	O
data	O
that	O
is	O
important	O
for	O
contextualizing	O
the	O
relative	O
burden	O
associated	O
with	O
HZ	B-DS
and	O
PHN	B-DS
.	O

The	O
available	O
evidence	O
does	O
not	O
typically	O
look	O
beyond	O
the	O
pain	O
which	O
accompanies	O
or	O
persists	O
beyond	O
the	O
rash	O
and	O
the	O
omission	O
of	O
other	O
factors	O
that	O
can	O
impact	O
on	O
patients	O
’	O
quality	O
of	O
life	O
(	O
e	O
.	O
g	O
.	O
fatigue	O
,	O
stomach	O
upsets	O
,	O
allodynia	O
,	O
and	O
numbness	O
).	O

This	O
should	O
be	O
addressed	O
,	O
preferably	O
through	O
a	O
combination	O
of	O
quantitative	O
and	O
qualitative	O
research	O
,	O
the	O
latter	O
of	O
which	O
was	O
notably	O
lacking	O
in	O
the	O
literature	O
.	O

Finally	O
,	O
the	O
lack	O
of	O
literature	O
relating	O
to	O
the	O
wider	O
societal	O
burden	O
potentially	O
caused	O
by	O
HZ	B-DS
and	O
PHN	B-DS
(	O
particularly	O
with	O
respect	O
to	O
the	O
impact	O
on	O
caregivers	O
and	O
the	O
broader	O
implications	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
provision	O
of	O
formal	O
and	O
informal	O
social	O
care	O
)	O
may	O
be	O
considered	O
a	O
critical	O
gap	O
.	O

To	O
date	O
burden	O
among	O
informal	O
caregivers	O
has	O
rarely	O
been	O
considered	O
,	O
and	O
only	O
in	O
terms	O
of	O
time	O
lost	O
from	O
work	O
.	O

Significantly	O
,	O
this	O
omits	O
the	O
potential	O
impacts	O
of	O
providing	O
informal	O
care	O
to	O
patients	O
that	O
may	O
not	O
have	O
resulted	O
in	O
time	O
lost	O
from	O
work	O
(	O
e	O
.	O
g	O
.	O
negative	O
impact	O
on	O
the	O
health	O
and	O
well	O
-	O
being	O
of	O
caregivers	O
).	O

Furthermore	O
,	O
consideration	O
of	O
healthcare	O
resource	O
use	O
and	O
the	O
economic	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
has	O
typically	O
focussed	O
on	O
impacts	O
within	O
the	O
healthcare	O
system	O
;	O
the	O
broader	O
implications	O
of	O
HZ	O
and	O
PHN	B-DS
are	O
rarely	O
appreciated	O
.	O

For	O
example	O
,	O
the	O
functional	O
deficits	O
observed	O
among	O
HZ	B-DS
and	O
PHN	B-DS
patients	O
that	O
may	O
lead	O
to	O
a	O
loss	O
of	O
autonomy	O
and	O
increased	O
reliance	O
on	O
formal	O
paid	O
care	O
have	O
not	O
been	O
estimated	O
.	O

Beyond	O
some	O
evidence	O
of	O
direct	O
and	O
indirect	O
costs	O
related	O
to	O
the	O
disease	O
,	O
the	O
potential	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
on	O
the	O
social	O
care	O
system	O
remains	O
unknown	O
.	O

Conclusions	O

This	O
literature	O
review	O
highlights	O
the	O
burden	O
faced	O
by	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
due	O
to	O
HZ	O
and	O
PHN	B-DS
in	O
Europe	O
.	O

While	O
the	O
incidence	O
of	O
HZ	B-DS
and	O
PHN	B-DS
increases	O
with	O
age	O
,	O
the	O
total	O
cost	O
per	O
case	O
of	O
HZ	B-DS
and	O
PHN	B-DS
management	O
is	O
not	O
necessarily	O
age	O
-	O
dependent	O
.	O

Pain	O
severity	O
was	O
associated	O
with	O
increased	O
costs	O
for	O
both	O
HZ	B-DS
and	O
PHN	B-DS
,	O
and	O
,	O
as	O
a	O
chronic	O
condition	O
,	O
costs	O
were	O
higher	O
for	O
patients	O
experiencing	O
PHN	B-DS
.	O

No	O
study	O
fully	O
addressed	O
the	O
humanistic	O
and	O
economic	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
to	O
patients	O
,	O
their	O
families	O
and	O
society	O
as	O
a	O
whole	O
.	O

Based	O
on	O
the	O
reviewed	O
evidence	O
and	O
an	O
assessment	O
of	O
the	O
gaps	O
in	O
the	O
evidence	O
base	O
,	O
it	O
is	O
likely	O
that	O
the	O
true	O
burden	O
of	O
HZ	B-DS
and	O
PHN	B-DS
is	O
underestimated	O
in	O
the	O
Europe	O
.	O

Further	O
research	O
is	O
required	O
to	O
build	O
a	O
holistic	O
understanding	O
of	O
the	O
impact	O
of	O
HZ	B-DS
and	O
PHN	B-DS
to	O
patients	O
,	O
healthcare	O
systems	O
and	O
society	O
.	O

Endnotes	O

a	O
*	O
Costs	O
originally	O
reported	O
in	O
2006	O
GBP	O
sterling	O
(£),	O
converted	O
to	O
euros	O
(€)	O
using	O
the	O
following	O
conversion	O
rate	O
£	O
1	O
=	O
€	O
1	O
.	O
18	O
.	O

b	O
*	O
Costs	O
originally	O
reported	O
in	O
2006	O
Swiss	O
francs	O
(	O
CHF	O
),	O
converted	O
to	O
euros	O
(€)	O
using	O
the	O
following	O
conversion	O
rate	O
1CHF	O
=	O
€	O
0	O
.	O
81	O
.	O

cAlthough	O
2	O
studies	O
do	O
not	O
report	O
a	O
specific	O
instrument	O
,	O
items	O
reported	O
appear	O
to	O
be	O
derived	O
from	O
the	O
ZBPI	O
(	O
38	O
,	O
55	O
).	O

Competing	O
interests	O

AG	O
and	O
RM	O
are	O
/	O
were	O
employees	O
of	O
Adelphi	O
Values	O
,	O
a	O
health	O
outcomes	O
agency	O
commissioned	O
by	O
Sanofi	O
Pasteur	O
MSD	O
,	O
to	O
conduct	O
,	O
analyse	O
and	O
communicate	O
findings	O
from	O
this	O
research	O
on	O
their	O
behalf	O
.	O

MU	O
and	O
EP	O
are	O
employees	O
of	O
Sanofi	O
Pasteur	O
MSD	O
,	O
a	O
provider	O
of	O
a	O
herpes	B-DS
zoster	I-DS
vaccine	O
approved	O
in	O
the	O
European	O
Union	O
.	O

The	O
authors	O
have	O
no	O
other	O
competing	O
interests	O
to	O
declare	O
.	O

Authors	O
’	O
contributions	O

AG	O
and	O
EP	O
designed	O
the	O
study	O
.	O

RA	O
and	O
AG	O
conducted	O
the	O
literature	O
searches	O
,	O
determined	O
eligibility	O
of	O
studies	O
for	O
inclusion	O
in	O
the	O
review	O
and	O
were	O
responsible	O
for	O
primary	O
data	O
extraction	O
and	O
analysis	O
.	O

EP	O
and	O
MU	O
contributed	O
to	O
the	O
analysis	O
.	O

AG	O
,	O
EP	O
and	O
MU	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Overexpression	O
of	O
Rice	B-OG
Black	I-OG
-	I-OG
Streaked	I-OG
Dwarf	I-OG
Virus	I-OG
P7	I-OG
-	I-OG
1	I-OG
in	O
Arabidopsis	B-OG
Results	O
in	O
Male	O
Sterility	O
Due	O
to	O
Non	O
-	O
Dehiscent	O
Anthers	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
FS	O
QX	O
TX	O
YZ	O
.	O

Performed	O
the	O
experiments	O
:	O
FS	O
XY	O
.	O

Analyzed	O
the	O
data	O
:	O
FS	O
QX	O
YF	O
YX	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
TZ	O
YF	O
.	O

Wrote	O
the	O
paper	O
:	O
FS	O
YZ	O
.	O

Rice	B-OG
black	I-OG
-	I-OG
streaked	I-OG
dwarf	I-OG
virus	I-OG
(	O
RBSDV	B-OG
),	O
a	O
member	O
of	O
the	O
genus	O
Fijivirus	B-OG
in	O
the	O
family	O
Reoviridae	B-OG
,	O
is	O
propagatively	O
transmitted	O
by	O
the	O
small	O
brown	B-OG
planthopper	I-OG
(	O
Laodelphax	B-OG
striatellus	I-OG
Fallén	O
).	O

RBSDV	B-DS
causes	O
rice	B-OG
black	B-DS
-	I-DS
streaked	I-DS
dwarf	I-DS
and	O
maize	B-OG
rough	B-DS
dwarf	I-DS
diseases	I-DS
,	O
which	O
lead	O
to	O
severe	O
yield	O
losses	O
in	O
crops	O
in	O
China	O
.	O

Although	O
several	O
RBSDV	B-OG
proteins	O
have	O
been	O
studied	O
in	O
detail	O
,	O
the	O
functions	O
of	O
the	O
nonstructural	B-GP
protein	I-GP
P7	B-GP
-	I-GP
1	I-GP
are	O
still	O
largely	O
unknown	O
.	O

To	O
investigate	O
the	O
role	O
of	O
the	O
P7	B-GP
-	I-GP
1	I-GP
protein	O
in	O
virus	B-OG
pathogenicity	O
,	O
transgenic	O
Arabidopsis	B-OG
thaliana	I-OG
plants	B-OG
were	O
generated	O
in	O
which	O
the	O
P7	B-GP
-	I-GP
1	I-GP
gene	O
was	O
expressed	O
under	O
the	O
control	O
of	O
the	O
35S	O
promoter	O
.	O

The	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
-	O
transgenic	O
Arabidopsis	B-OG
plants	B-OG
(	O
named	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
)	O
were	O
male	B-DS
sterility	O
.	O

Flowers	O
and	O
pollen	O
from	O
P7	O
-	O
1	O
-	O
transgenic	O
plants	B-OG
were	O
of	O
normal	O
size	O
and	O
shape	O
,	O
and	O
anthers	O
developed	O
to	O
the	O
normal	O
size	O
but	O
failed	O
to	O
dehisce	O
.	O

The	O
non	O
-	O
dehiscent	O
anthers	O
observed	O
in	O
P7	O
-	O
1	O
-	O
OE	O
were	O
attributed	O
to	O
decreased	O
lignin	O
content	O
in	O
the	O
anthers	O
.	O

Furthermore	O
,	O
the	O
reactive	O
oxygen	O
species	O
levels	O
were	O
quite	O
low	O
in	O
the	O
transgenic	O
plants	B-OG
compared	O
with	O
the	O
wild	O
type	O
.	O

These	O
results	O
indicate	O
that	O
ectopic	O
expression	O
of	O
the	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
protein	O
in	O
A	B-OG
.	I-OG
thaliana	I-OG
causes	O
male	O
sterility	O
,	O
possibly	O
through	O
the	O
disruption	O
of	O
the	O
lignin	O
biosynthesis	O
and	O
H2O2	O
-	O
dependent	O
polymerization	O
pathways	O
.	O

Introduction	O

Rice	B-OG
black	I-OG
-	I-OG
streaked	I-OG
dwarf	I-OG
virus	I-OG
(	O
RBSDV	B-OG
),	O
a	O
member	O
of	O
the	O
genus	O
Fijivirus	B-OG
in	O
the	O
family	O
Reoviridae	B-OG
,	O
causes	O
rice	B-OG
black	B-DS
-	I-DS
streaked	I-DS
dwarf	I-DS
and	O
maize	B-OG
rough	B-DS
dwarf	I-DS
diseases	I-DS
,	O
which	O
lead	O
to	O
severe	O
yield	O
losses	O
in	O
crops	O
in	O
China	O
,	O
Japan	O
,	O
Korea	O
,	O
and	O
other	O
Asian	O
countries	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
3	O
].	O

The	O
virus	B-OG
is	O
propagatively	O
transmitted	O
by	O
the	O
small	O
brown	B-OG
planthopper	I-OG
(	O
SBPH	B-OG
:	O
Laodelphax	B-OG
striatellus	I-OG
Fallén	O
)	O
in	O
a	O
persistent	O
circulative	O
manner	O
[	O
1	O
],	O
[	O
3	O
]–[	O
5	O
].	O

Plants	B-OG
infected	O
with	O
RBSDV	B-OG
typically	O
exhibit	O
symptoms	O
such	O
as	O
stunting	O
,	O
darkening	O
of	O
leaves	O
,	O
and	O
white	O
waxy	O
or	O
black	O
-	O
streaked	O
swellings	O
along	O
the	O
veins	O
on	O
the	O
backs	O
of	O
the	O
leaf	O
blades	O
and	O
sheaths	O
[	O
1	O
],	O
[	O
3	O
]–[	O
5	O
].	O

The	O
RBSDV	B-OG
virion	O
is	O
composed	O
of	O
icosahedral	O
,	O
two	O
-	O
layered	O
particles	O
approximately	O
75	O
–	O
80	O
nm	O
in	O
diameter	O
and	O
10	O
segments	O
of	O
double	O
-	O
stranded	O
genomic	O
RNA	O
(	O
dsRNA	O
),	O
which	O
are	O
designed	O
S1	O
to	O
S10	O
with	O
increasing	O
order	O
of	O
electrophoretic	O
mobility	O
in	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
PAGE	O
)	O
[	O
6	O
],	O
[	O
7	O
].	O

S1	O
encodes	O
a	O
putative	O
169	O
-	O
kDa	O
RNA	B-GP
-	I-GP
dependent	I-GP
RNA	I-GP
polymerase	I-GP
,	O
while	O
S2	O
and	O
S4	O
encode	O
a	O
major	O
core	O
structural	O
protein	O
and	O
the	O
outer	O
shell	O
B	O
-	O
spike	O
protein	B-GP
,	O
respectively	O
[	O
6	O
],	O
[	O
7	O
],	O
[	O
8	O
].	O

The	O
protein	O
encoded	O
by	O
S3	O
contains	O
a	O
conserved	O
motif	O
and	O
is	O
a	O
putative	B-GP
guanylyltransferase	I-GP
[	O
9	O
].	O

Western	O
blotting	O
analysis	O
of	O
viral	O
particles	O
has	O
suggested	O
that	O
the	O
minor	O
core	B-GP
capsid	I-GP
protein	I-GP
and	O
major	O
outer	B-GP
capsid	I-GP
protein	I-GP
are	O
encoded	O
by	O
S8	O
and	O
S10	O
,	O
respectively	O
[	O
8	O
],	O
[	O
10	O
],	O
[	O
11	O
].	O

Immunoelectron	O
microscopy	O
has	O
revealed	O
that	O
S9	O
ORF1	O
P9	B-GP
-	I-GP
1	I-GP
is	O
a	O
nonstructural	O
protein	O
that	O
accumulates	O
in	O
the	O
intracellular	O
viroplasms	O
in	O
infected	O
plants	B-OG
and	O
insects	B-OG
[	O
8	O
].	O

P9	B-GP
-	I-GP
1	I-GP
,	O
a	O
thermostable	O
,	O
α	O
-	O
helical	O
protein	O
,	O
self	O
-	O
interacts	O
to	O
form	O
dimers	O
and	O
is	O
the	O
minimal	O
viral	O
component	O
required	O
for	O
viroplasm	O
formation	O
[	O
12	O
].	O

The	O
protein	O
encoded	O
by	O
S6	B-GP
is	O
a	O
viral	O
RNA	O
silencing	B-GP
suppressor	I-GP
and	O
has	O
an	O
intrinsic	O
ability	O
to	O
interact	O
with	O
P9	B-GP
-	I-GP
1	I-GP
[	O
13	O
]–[	O
15	O
].	O

P7	B-GP
-	I-GP
1	I-GP
is	O
a	O
nonstructural	O
protein	O
containing	O
363	O
amino	B-CD
acids	I-CD
(	O
with	O
a	O
molecular	O
mass	O
of	O
41	O
.	O
0	O
kDa	O
)	O
that	O
is	O
translated	O
from	O
S7	O
ORF1	O
.	O

P7	B-GP
-	I-GP
1	I-GP
accumulates	O
in	O
tubule	O
-	O
like	O
structures	O
in	O
infected	O
plant	B-OG
and	O
planthopper	O
cells	O
,	O
suggesting	O
that	O
P7	B-GP
-	I-GP
1	I-GP
is	O
one	O
of	O
the	O
constituents	O
of	O
these	O
structures	O
[	O
8	O
].	O

Recent	O
studies	O
demonstrate	O
that	O
RBSDV	B-OG
P7	I-OG
-	I-OG
1	I-OG
forms	O
punctuate	O
points	O
at	O
plasmodesmata	O
in	O
Nicotiana	B-OG
benthamiana	I-OG
leaves	O
[	O
16	O
].	O

Tubule	O
-	O
forming	O
and	O
plasmodesmatal	O
localization	O
of	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
are	O
usually	O
thought	O
to	O
be	O
involved	O
in	O
cell	O
-	O
to	O
-	O
cell	O
movement	O
of	O
the	O
virus	B-OG
in	O
plant	B-OG
and	O
insect	B-OG
cells	O
.	O

However	O
,	O
little	O
else	O
is	O
known	O
about	O
the	O
characteristics	O
and	O
functions	O
of	O
P7	O
-	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
that	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
is	O
a	O
pathogenicity	O
determinant	O
and	O
that	O
this	O
protein	O
affects	O
normal	O
plant	B-OG
development	O
when	O
expressed	O
as	O
transgenes	O
in	O
Arabidopsis	B-OG
.	O

RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
transgenic	O
Arabidopsis	B-OG
plants	B-OG
exhibited	O
male	B-DS
sterility	I-DS
phenotype	O
caused	O
by	O
a	O
defect	O
of	O
secondary	O
wall	O
lignification	O
in	O
the	O
anther	O
endothecium	O
and	O
failure	O
of	O
anther	O
dehiscence	O
.	O

Furthermore	O
,	O
non	O
-	O
dehiscent	O
anthers	O
observed	O
in	O
transgenic	O
plants	B-OG
were	O
accompanied	O
by	O
decreased	O
levels	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
).	O

These	O
results	O
suggest	O
that	O
impairment	O
in	O
lignin	O
biosynthesis	O
and	O
the	O
H2O2	O
-	O
dependent	O
polymerization	O
in	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
over	O
-	O
expressing	O
Arabidopsis	B-OG
plants	B-OG
cause	O
male	B-DS
sterility	O
.	O

Materials	O
and	O
Methods	O

Virus	B-OG
Isolates	O
,	O
Vectors	O
,	O
and	O
Plant	B-OG
Materials	O

Rice	B-OG
plants	B-OG
infected	O
with	O
RBSDV	B-OG
were	O
collected	O
from	O
Jiangsu	O
Province	O
in	O
China	O
under	O
the	O
permission	O
of	O
Plant	B-OG
Protection	O
Station	O
of	O
Jiangsu	O
Province	O
,	O
China	O
.	O

Young	O
instar	O
nymphs	O
of	O
SBPHs	B-OG
(	O
small	O
brown	B-OG
planthopper	I-OG
,	O
L	B-OG
.	I-OG
striatellus	I-OG
)	O
were	O
fed	O
RBSDV	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
for	O
2	O
days	O
to	O
acquire	O
the	O
virus	B-OG
.	O

A	O
dot	O
immunobinding	O
assay	O
(	O
DIBA	O
)	O
[	O
3	O
]	O
showed	O
that	O
20	O
–	O
30	O
%	O
of	O
adult	O
insects	B-OG
were	O
viruliferous	O
.	O

A	O
virus	B-OG
-	O
free	O
planthopper	B-OG
population	O
was	O
generated	O
using	O
a	O
pair	O
of	O
recently	O
hatched	O
nymphs	O
,	O
and	O
nonvirulence	O
was	O
confirmed	O
using	O
reverse	O
transcription	O
-	O
polymerase	B-GP
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Viruliferous	O
or	O
virus	B-OG
-	O
free	O
SBPHs	O
were	O
reared	O
on	O
healthy	O
rice	B-OG
seedlings	O
(	O
Oryza	B-OG
sativa	I-OG
L	I-OG
.	I-OG
japonica	I-OG
.	O
cv	O
.	O

Wuyujing	O
No	O
.	O
3	O
)	O
in	O
glass	O
vessels	O
at	O
22	O
°	O
C	O
under	O
alternating	O
photoperiods	O
of	O
14	O
h	O
of	O
light	O
and	O
10	O
h	O
of	O
dark	O
.	O

Arabidopsis	B-OG
(	O
Col	O
-	O
0	O
)	O
seeds	O
were	O
donated	O
by	O
Prof	O
.	O

Hansong	O
Dong	O
(	O
College	O
of	O
Plant	B-OG
Protection	O
,	O
Nanjing	O
Agricultural	O
University	O
,	O
Nanjing	O
,	O
China	O
).	O

Plants	B-OG
were	O
grown	O
in	O
potting	O
soil	O
in	O
a	O
growth	O
chamber	O
at	O
24	O
°	O
C	O
under	O
200	O
µE	O
·	O
m	O
−	O
2	O
·	O
s	O
−	O
1	O
illumination	O
and	O
16	O
-	O
h	O
light	O
/	O
8	O
-	O
h	O
dark	O
cycle	O
conditions	O
.	O

RBSDV	B-OG
Inoculation	O
Assay	O

Rice	B-OG
plants	B-OG
(	O
Oryza	B-OG
sativa	I-OG
L	I-OG
.	I-OG
japonica	I-OG
.	I-OG
cv	O
.	O

Nipponbare	O
)	O
were	O
inoculated	O
with	O
10	O
viruliferous	O
(	O
RBSDV	B-OG
)	O
or	O
virus	B-OG
-	O
free	O
(	O
mock	O
)	O
nymphs	O
per	O
plant	B-OG
(	O
4	O
or	O
5	O
leaves	O
)	O
and	O
were	O
kept	O
in	O
a	O
growth	O
chamber	O
containing	O
30	O
plants	B-OG
.	O

After	O
incubation	O
at	O
22	O
°	O
C	O
for	O
4	O
days	O
under	O
artificial	O
light	O
,	O
planthoppers	O
were	O
removed	O
.	O

Plants	B-OG
were	O
maintained	O
in	O
field	O
conditions	O
for	O
symptom	O
development	O
.	O

Construction	O
of	O
Overexpression	O
Vector	O
and	O
Arabidopsis	B-OG
Transformation	O

To	O
generate	O
the	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	B-GP
overexpression	O
plasmid	O
,	O
the	O
coding	O
region	O
of	O
the	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
gene	O
(	O
from	O
+	O
1	O
to	O
+	O
1	O
,	O
089	O
bp	O
)	O
was	O
amplified	O
with	O
primers	O
containing	O
the	O
SacI	B-GP
and	O
BamHI	B-GP
sites	O
(	O
Table	O
S1	O
).	O

The	O
resulting	O
PCR	O
product	O
was	O
digested	O
with	O
SacI	B-GP
and	O
BamHI	B-GP
and	O
ligated	O
into	O
the	O
SacI	B-GP
-	O
BamHI	B-GP
-	O
cleaved	O
pCHF3	O
vector	O
.	O

After	O
DNA	O
sequencing	O
,	O
the	O
RBSDV	B-OG
P7	I-OG
-	I-OG
1	I-OG
overexpression	O
plasmid	O
was	O
introduced	O
into	O
Agrobacterium	B-OG
tumefaciens	I-OG
(	O
strain	O
EHA105	O
),	O
and	O
the	O
transformation	O
of	O
Arabidopsis	B-OG
thaliana	I-OG
Col	O
-	B-OG
0	I-OG
ecotype	O
was	O
performed	O
by	O
the	O
floral	O
-	O
dip	O
method	O
[	O
17	O
].	O

Homozygous	O
T3	O
generation	O
plants	B-OG
were	O
screened	O
for	O
kanamycin	B-CD
resistance	O
and	O
identified	O
with	O
genome	O
PCR	O
.	O

RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
gene	O
sequence	O
has	O
been	O
deposited	O
in	O
NCBI	O
Genbank	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
)	O
under	O
the	O
accession	O
number	O
of	O
KF532967	O
.	O

Qenome	O
DNA	O
PCR	O

Arabidopsis	B-OG
genome	O
DNA	O
was	O
isolated	O
from	O
leaves	O
using	O
SQ	O
Plant	B-OG
DNA	O
Kit	O
(	O
Omega	O
Bioservices	O
;	O
Norcross	O
,	O
GA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

PCR	O
reaction	O
was	O
performed	O
using	O
10	O
µl	O
Premix	O
Taq	O
(	O
TAKARA	O
;	O
Dalian	O
,	O
China	O
),	O
0	O
.	O
2	O
µM	O
RBSDV	O
S7	O
-	O
1	O
specific	O
forward	O
and	O
reverse	O
primers	O
(	O
Table	O
S1	O
),	O
and	O
1	O
µl	O
DNA	O
in	O
a	O
total	O
volume	O
of	O
20	O
µl	O
.	O

All	O
samples	O
were	O
subjected	O
to	O
denaturation	O
for	O
5	O
min	O
at	O
95	O
°	O
C	O
,	O
followed	O
by	O
30	O
cycles	O
of	O
95	O
°	O
C	O
for	O
30	O
s	O
,	O
58	O
°	O
C	O
for	O
30	O
s	O
and	O
72	O
°	O
C	O
for	O
1	O
min	O
.	O

PCR	O
products	O
were	O
detected	O
using	O
agarose	O
gel	O
electrophoresis	O
,	O
and	O
images	O
were	O
obtained	O
using	O
the	O
Bio	O
-	O
Rad	O
Molecular	O
Imager	O
Gel	O
Doc	O
XR	O
System	O
(	O
Bio	O
-	O
Rad	O
;	O
Hercules	O
;	O
CA	O
,	O
USA	O
)	O
after	O
staining	O
with	O
ethidium	B-CD
bromide	I-CD
.	O

Quantitative	O
Real	O
-	O
time	O
PCR	O

Quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
was	O
performed	O
using	O
SsoFast	O
EvaGreen	O
Supermix	O
(	O
Bio	O
-	O
Rad	O
;	O
Hercules	O
;	O
CA	O
,	O
USA	O
)	O
in	O
a	O
Bio	O
-	O
Rad	O
iQ5	O
Real	O
-	O
Time	O
PCR	O
system	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
leaves	O
using	O
the	O
RNAiso	O
Plus	O
reagent	O
(	O
TAKARA	O
;	O
Dalian	O
,	O
China	O
)	O
and	O
reverse	O
transcribed	O
using	O
M	O
-	O
MLV	O
Reverse	B-GP
Transcriptase	I-GP
(	O
Promega	O
;	O
Fitchburg	O
;	O
WI	O
,	O
USA	O
),	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

The	O
EF1α	B-GP
gene	O
,	O
which	O
is	O
highly	O
conserved	O
and	O
constitutively	O
expressed	O
in	O
eukaryotes	B-OG
[	O
18	O
],	O
was	O
used	O
as	O
a	O
reference	O
control	O
.	O

Each	O
quantitative	O
PCR	O
reaction	O
was	O
performed	O
using	O
10	O
µl	O
SsoFast	O
EvaGreen	O
Supermix	O
,	O
0	O
.	O
2	O
µM	O
forward	O
and	O
reverse	O
primers	O
,	O
and	O
1	O
µl	O
cDNA	O
in	O
a	O
total	O
volume	O
of	O
20	O
µl	O
.	O

All	O
samples	O
were	O
subjected	O
to	O
denaturation	O
for	O
3	O
min	O
at	O
95	O
°	O
C	O
,	O
followed	O
by	O
40	O
cycles	O
of	O
95	O
°	O
C	O
for	O
10	O
s	O
and	O
58	O
°	O
C	O
for	O
20	O
s	O
.	O

SYBR	O
Green	O
absorbance	O
was	O
detected	O
at	O
58	O
°	O
C	O
.	O

All	O
reactions	O
were	O
conducted	O
in	O
triplicate	O
.	O

Amplicon	O
dissociation	O
curves	O
,	O
i	O
.	O
e	O
.,	O
melting	O
curves	O
,	O
were	O
recorded	O
after	O
cycle	O
40	O
by	O
heating	O
from	O
60	O
°	O
C	O
to	O
95	O
°	O
C	O
at	O
a	O
ramp	O
speed	O
of	O
1	O
.	O
9	O
°	O
C	O
·	O
min	O
−	O
1	O
.	O

Data	O
were	O
analyzed	O
using	O
iQ5	O
software	O
(	O
Bio	O
-	O
Rad	O
;	O
Hercules	O
;	O
CA	O
,	O
USA	O
).	O
Table	O
S1	O
shows	O
information	O
regarding	O
additional	O
genes	O
and	O
primers	O
employed	O
in	O
this	O
study	O
.	O

Observation	O
of	O
Lignified	O
Secondary	O
Wall	O
Thickening	O

For	O
ethidium	B-CD
bromide	I-CD
staining	O
,	O
fresh	O
anthers	O
were	O
washed	O
in	O
10	O
mM	O
PBS	O
and	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
Tween20	B-CD
for	O
10	O
min	O
and	O
10	O
mM	O
PBS	O
for	O
10	O
min	O
,	O
followed	O
by	O
staining	O
with	O
0	O
.	O
05	O
%	O
(	O
w	O
/	O
v	O
)	O
ethidium	B-CD
bromide	I-CD
(	O
1	O
h	O
,	O
room	O
temperature	O
).	O

The	O
anthers	O
were	O
then	O
washed	O
(	O
10	O
mM	O
PBS	O
,	O
10	O
min	O
),	O
and	O
the	O
stained	O
tissues	O
were	O
mounted	O
on	O
a	O
glass	O
slide	O
and	O
examined	O
using	O
Zeiss	O
LSM710	O
confocal	O
microscopy	O
(	O
Carl	O
Zeiss	O
Microscopy	O
GmbH	O
;	O
Jena	O
,	O
Germany	O
)	O
under	O
red	O
fluorescence	O
at	O
543	O
nm	O
excitation	O
[	O
19	O
].	O

To	O
study	O
lignin	O
autofluorescence	O
,	O
the	O
anthers	O
were	O
cleared	O
in	O
70	O
%	O
(	O
v	O
/	O
v	O
)	O
lactic	B-CD
acid	I-CD
for	O
3	O
days	O
at	O
60	O
°	O
C	O
,	O
and	O
the	O
cleared	O
tissues	O
were	O
examined	O
using	O
Zeiss	O
LSM710	O
confocal	O
microscopy	O
(	O
Carl	O
Zeiss	O
Microscopy	O
GmbH	O
;	O
Jena	O
,	O
Germany	O
)	O
under	O
UV	O
light	O
excitation	O
.	O

For	O
phloroglucinol	B-CD
–	O
HCl	O
staining	O
,	O
flowers	O
were	O
fixed	O
in	O
FAA	O
solution	O
overnight	O
and	O
decolorized	O
with	O
an	O
ethanol	O
series	O
.	O

The	O
flowers	O
were	O
then	O
stained	O
with	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
phloroglucinol	B-CD
in	O
92	O
%	O
ethanol	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
the	O
tissues	O
were	O
mounted	O
with	O
18	O
.	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
HCl	O
,	O
and	O
red	O
staining	O
was	O
immediately	O
monitored	O
using	O
Leica	O
M125	O
microscopy	O
(	O
Leica	O
Microsystems	O
;	O
Bannockburn	O
;	O
IL	O
,	O
USA	O
).	O

Histochemical	O
Detection	O
of	O
ROS	O
,	O
H2O2	O
,	O
and	O
O2	O
−	O
Radical	O

The	O
accumulation	O
of	O
ROS	O
was	O
visualized	O
by	O
a	O
fluoluminescence	O
assay	O
with	O
2	O
,	O
7	O
-	O
dichlorofluorescein	O
diacetate	O
(	O
DCFH	O
-	O
DA	O
),	O
which	O
emits	O
green	O
fluorescence	O
when	O
oxidized	O
by	O
ROS	O
.	O

In	O
this	O
assay	O
,	O
anthers	O
were	O
infiltrated	O
with	O
a	O
100	O
µM	O
/	O
ml	O
aquatic	O
solution	O
of	O
DCFH	O
-	O
DA	O
(	O
Sigma	O
;	O
St	O
.	O
Louis	O
;	O
MO	O
,	O
USA	O
)	O
and	O
subsequently	O
observed	O
with	O
Zeiss	O
LSM710	O
confocal	O
microscopy	O
(	O
Carl	O
Zeiss	O
Microscopy	O
GmbH	O
;	O
Jena	O
,	O
Germany	O
)	O
under	O
GFP	B-GP
fluorescent	O
light	O
.	O

The	O
H2O2	O
and	O
O2	O
−	O
levels	O
were	O
measured	O
by	O
3	O
,	O
3	O
′-	O
diaminobenzidine	O
(	O
DAB	O
)	O
and	O
nitroblue	B-CD
tetrazolium	I-CD
(	O
NBT	O
)	O
(	O
Sigma	O
;	O
St	O
.	O
Louis	O
;	O
MO	O
,	O
USA	O
)	O
staining	O
,	O
respectively	O
[	O
20	O
].	O

Anthers	O
were	O
infiltrated	O
in	O
DAB	O
solution	O
(	O
0	O
.	O
1	O
%	O
w	O
/	O
v	O
,	O
pH	O
3	O
.	O
8	O
)	O
and	O
incubated	O
overnight	O
in	O
darkness	O
at	O
22	O
°	O
C	O
.	O

Alternatively	O
,	O
the	O
anthers	O
were	O
infiltrated	O
in	O
NBT	O
solution	O
(	O
0	O
.	O
1	O
%	O
w	O
/	O
v	O
)	O
in	O
10	O
mM	O
PBS	O
(	O
pH	O
7	O
.	O
8	O
)	O
containing	O
10	O
mM	O
NaN3	O
and	O
then	O
incubated	O
in	O
darkness	O
at	O
22	O
°	O
C	O
for	O
1	O
h	O
.	O

After	O
incubation	O
,	O
the	O
stained	O
tissues	O
were	O
decolorized	O
with	O
acetic	O
acid	O
:	O
glycerol	B-CD
:	O
ethanol	O
(	O
1	O
∶	O
1	O
∶	O
3	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
solution	O
at	O
95	O
°	O
C	O
for	O
10	O
min	O
and	O
then	O
photographed	O
using	O
Leica	O
M125	O
microscopy	O
(	O
Leica	O
Microsystems	O
;	O
Bannockburn	O
;	O
IL	O
,	O
USA	O
).	O

Scanning	O
Electron	O
Microscopy	O

Tissue	O
samples	O
of	O
wild	O
-	O
type	O
and	O
P7	O
-	O
1	O
-	O
OE	O
flower	O
bud	O
clusters	O
were	O
fixed	O
overnight	O
in	O
50	O
mM	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
pH	O
6	O
.	O
8	O
)	O
containing	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
glutaraldehyde	B-CD
and	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
paraformaldehyde	O
at	O
4	O
°	O
C	O
.	O

The	O
fixed	O
tissues	O
were	O
rinsed	O
twice	O
(	O
15	O
min	O
each	O
)	O
with	O
100	O
mM	O
PBS	O
at	O
RT	O
.	O

The	O
tissues	O
were	O
dehydrated	O
in	O
a	O
graded	O
ethanol	O
series	O
.	O

Then	O
,	O
the	O
samples	O
were	O
coated	O
with	O
gold	O
and	O
examined	O
in	O
an	O
S	O
-	O
3000N	O
Scanning	O
Electron	O
Microscope	O
(	O
Hitachi	O
;	O
Tokyo	O
,	O
Japan	O
)	O
at	O
an	O
accelerating	O
voltage	O
of	O
10	O
kV	O
.	O

Results	O

Reproductive	O
Development	O
Symptoms	O
Caused	O
by	O
RBSDV	B-DS
Infection	I-DS
in	O
Rice	B-OG
Plants	B-OG

The	O
growth	O
and	O
development	O
of	O
rice	B-OG
plants	B-OG
were	O
affected	O
by	O
RBSDV	B-DS
infection	I-DS
.	O

The	O
typical	O
symptoms	O
of	O
RBSDV	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
include	O
severe	O
stunting	O
and	O
darkening	O
of	O
leaves	O
[	O
3	O
]–[	O
5	O
].	O

However	O
,	O
reproductive	O
development	O
in	O
rice	B-OG
plants	B-OG
infected	O
by	O
RBSDV	B-OG
has	O
not	O
previously	O
been	O
studied	O
in	O
detail	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
reproductive	O
development	O
phenotype	O
of	O
RBSDV	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
,	O
which	O
were	O
inoculated	O
by	O
viruliferous	O
planthoppers	B-OG
,	O
and	O
we	O
allowed	O
disease	O
symptoms	O
to	O
develop	O
under	O
field	O
conditions	O
.	O

Two	O
month	O
after	O
inoculation	O
,	O
the	O
infected	O
rice	B-OG
plants	B-OG
showed	O
significantly	O
stunted	O
growth	O
(	O
Figure	O
1A	O
)	O
and	O
produced	O
poor	O
spikelets	O
(	O
Figure	O
1D	O
).	O

At	O
flowering	O
stage	O
,	O
the	O
spikelets	O
of	O
infected	O
rice	B-OG
plants	B-OG
had	O
viable	O
pollen	O
grains	O
(	O
Figure	O
1C	O
),	O
but	O
the	O
anthers	O
failed	O
to	O
dehisce	O
(	O
Figure	O
1B	O
)	O
compared	O
with	O
mock	O
rice	B-OG
plants	B-OG
which	O
were	O
inoculated	O
by	O
virus	B-OG
-	O
free	O
planthoppers	O
.	O

As	O
a	O
result	O
,	O
at	O
grain	O
filling	O
stage	O
the	O
infected	O
rice	B-OG
plant	B-OG
showed	O
partial	O
to	O
complete	O
spikelet	O
sterility	O
(	O
Figure	O
1E	O
).	O

Symptoms	O
of	O
rice	B-OG
plants	B-OG
infected	O
with	O
Rice	B-OG
black	I-OG
-	I-OG
streaked	I-OG
dwarf	I-OG
virus	I-OG
(	O
RBSDV	B-OG
).	O

(	O
A	O
)	O
The	O
stunted	O
symptom	O
of	O
rice	O
caused	O
by	O
RBSDV	B-DS
infection	I-DS
.	O

(	O
B	O
–	O
C	O
)	O
RBSDV	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
showing	O
non	O
-	O
dehiscent	O
anthers	O
(	O
B	O
)	O
but	O
normal	O
viable	O
pollen	O
stained	O
with	O
I2	O
(	O
C	O
).	O

(	O
D	O
–	O
E	O
)	O
The	O
spikelets	O
of	O
RBSDV	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
at	O
flowering	O
(	O
D	O
)	O
and	O
at	O
the	O
grain	O
filling	O
period	O
(	O
E	O
).	O

Rice	B-OG
plants	B-OG
were	O
inoculated	O
with	O
viruliferous	O
(	O
RBSDV	B-OG
)	O
or	O
virus	B-OG
-	O
free	O
SBPHs	O
(	O
mock	O
).	O

Expression	O
of	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
Protein	O
Cause	O
Male	O
Sterility	O
due	O
to	O
Non	O
-	O
dehiscent	O
Anthers	O
in	O
Arabidopsis	B-OG

To	O
determine	O
whether	O
proteins	O
encoded	O
by	O
RBSDV	B-OG
contributed	O
to	O
the	O
variation	O
in	O
anther	O
dehiscence	O
and	O
spikelet	O
fertility	O
of	O
virus	B-OG
-	O
infected	O
rice	B-OG
plants	B-OG
,	O
we	O
investigated	O
the	O
effects	O
of	O
P7	B-GP
-	I-GP
1	I-GP
on	O
Arabidopsis	B-OG
plants	B-OG
.	O

Specifically	O
,	O
we	O
expressed	O
the	O
full	O
-	O
length	O
P7	B-GP
-	I-GP
1	I-GP
cDNA	O
,	O
under	O
the	O
control	O
of	O
the	O
35S	O
-	O
CaMV	B-OG
promoter	O
,	O
in	O
transgenic	O
Arabidopsis	B-OG
plants	B-OG
.	O

The	O
transgenic	O
plants	B-OG
that	O
constitutively	O
expressed	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
were	O
selected	O
using	O
kanamycin	B-CD
medium	O
(	O
Figure	O
S1A	O
)	O
and	O
confirmed	O
by	O
genomic	O
PCR	O
(	O
Figure	O
S1B	O
)	O
and	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
(	O
Figure	O
S1C	O
).	O

T3	O
generation	O
plants	B-OG
from	O
transgenic	O
lines	O
exhibiting	O
high	O
levels	O
of	O
overexpression	O
of	O
P7	B-GP
-	I-GP
1	I-GP
(	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
#	O
1	O
,	O
#	O
2	O
,	O
and	O
#	O
5	O
)	O
were	O
selected	O
for	O
further	O
study	O
.	O

During	O
the	O
vegetative	O
growth	O
stage	O
,	O
the	O
growth	O
and	O
development	O
of	O
P7	O
-	O
1	O
-	O
OE	O
#	O
1	O
,	O
#	O
2	O
,	O
#	O
5	O
,	O
and	O
wild	O
-	O
type	O
Arabidopsis	B-OG
seedlings	O
were	O
indistinguishable	O
(	O
Figure	O
2A	O
).	O

However	O
,	O
all	O
transgenic	O
lines	O
(	O
P7	O
-	O
1	O
-	O
OE	O
#	O
1	O
,	O
#	O
2	O
,	O
and	O
#	O
5	O
)	O
showed	O
significant	O
abnormalities	O
during	O
reproductive	O
growth	O
.	O

Following	O
fertilization	O
,	O
siliques	O
of	O
wild	O
-	O
type	O
plants	B-OG
elongated	O
and	O
set	O
seeds	O
.	O

But	O
in	O
transgenic	O
plants	B-OG
,	O
siliques	O
remained	O
small	O
,	O
producing	O
no	O
seeds	O
,	O
indicating	O
the	O
high	O
degree	O
of	O
sterility	O
of	O
Arabidopsis	B-OG
plants	B-OG
ectopically	O
expressing	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
(	O
Figure	O
2B	O
and	O
2C	O
).	O

Ectopic	O
expression	O
of	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
causes	O
male	B-DS
sterility	I-DS
in	O
Arabidopsis	B-OG
.	O

(	O
A	O
)	O
Phenotypes	O
of	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
during	O
vegetative	O
growth	O
.	O

(	O
B	O
)	O
Phenotypes	O
of	O
P7	O
-	O
1	O
transgenic	O
lines	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
during	O
reproductive	O
development	O
.	O

(	O
C	O
)	O
Silique	O
phenotypes	O
of	O
P7	O
-	O
1	O
transgenic	O
lines	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
.	O

(	O
D	O
)	O
Developmental	O
series	O
of	O
P7	O
-	O
1	O
-	O
OE	O
and	O
wild	O
-	O
type	O
flowers	O
during	O
anther	O
stages	O
12	O
to	O
14	O
.	O

To	O
investigate	O
the	O
cause	O
of	O
the	O
sterile	O
phenotype	O
in	O
transgenic	O
plants	B-OG
overexpressing	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
,	O
we	O
examined	O
the	O
flowers	O
under	O
a	O
microscope	O
.	O

These	O
observations	O
revealed	O
that	O
in	O
wild	O
-	O
type	O
flowers	O
,	O
the	O
anthers	O
started	O
to	O
dehisce	O
at	O
stage	O
13	O
[	O
21	O
],	O
and	O
pollen	O
grains	O
were	O
released	O
to	O
the	O
stigmatic	O
papilla	O
(	O
Figure	O
2D	O
).	O

However	O
,	O
at	O
stage	O
13	O
,	O
P7	O
-	O
1	O
-	O
OE	O
transgenic	O
anthers	O
did	O
not	O
dehisce	O
normally	O
,	O
resulting	O
in	O
the	O
failure	O
to	O
release	O
pollen	O
grains	O
to	O
the	O
stigmatic	O
papilla	O
(	O
Figure	O
2D	O
).	O

Even	O
at	O
late	O
stage	O
14	O
,	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
remained	O
closed	O
,	O
and	O
no	O
pollen	O
grains	O
were	O
released	O
(	O
Figure	O
2D	O
,	O
Figure	O
S2A	O
).	O

Analysis	O
of	O
anther	O
morphology	O
by	O
scanning	O
electron	O
microscopy	O
showed	O
that	O
at	O
late	O
stage	O
13	O
,	O
wild	O
-	O
type	O
anthers	O
spilt	O
open	O
along	O
the	O
stomium	O
and	O
released	O
pollen	O
grains	O
,	O
whereas	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
remained	O
intact	O
,	O
and	O
no	O
pollen	O
grains	O
were	O
observed	O
(	O
Figure	O
3A	O
).	O

Scanning	O
electron	O
microscopy	O
and	O
Alexander	O
staining	O
revealed	O
that	O
the	O
pollen	O
grains	O
within	O
the	O
indehisced	O
anthers	O
of	O
P7	O
-	O
1	O
-	O
OE	O
plants	B-OG
were	O
morphologically	O
normal	O
(	O
Figure	O
3B	O
)	O
and	O
viable	O
(	O
Figure	O
S2B	O
and	O
S2C	O
).	O

In	O
addition	O
,	O
when	O
used	O
for	O
hand	O
pollination	O
,	O
the	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
pollen	O
grains	O
could	O
fertilize	O
egg	O
cells	O
(	O
Figure	O
S3	O
).	O

These	O
observations	O
indicate	O
that	O
the	O
sterility	O
of	O
the	O
P7	B-GP
-	O
1	O
-	O
OE	O
lines	O
is	O
caused	O
solely	O
by	O
defective	O
anther	O
dehiscence	O
.	O

Scanning	O
electron	O
micrographs	O
of	O
anthers	O
(	O
A	O
)	O
and	O
pollen	O
grains	O
(	O
B	O
)	O
of	O
P7	O
-	O
1	O
transgenic	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
.	O

P7	O
-	O
1	O
-	O
OE	O
Anthers	O
have	O
Reduced	O
Endothecium	O
Secondary	O
Wall	O
Lignification	O

Secondary	O
wall	O
lignification	O
,	O
which	O
mainly	O
occurs	O
around	O
the	O
endothecial	O
cells	O
,	O
is	O
thought	O
to	O
be	O
critical	O
for	O
generating	O
the	O
forces	O
required	O
for	O
anther	O
dehiscence	O
[	O
22	O
].	O

In	O
wild	O
-	O
type	O
plants	B-OG
,	O
when	O
the	O
anthers	O
were	O
stained	O
with	O
ethidium	O
bromide	O
and	O
visualized	O
by	O
confocal	O
microscopy	O
,	O
lignified	O
secondary	O
walls	O
could	O
be	O
observed	O
in	O
the	O
endothecium	O
as	O
bands	O
of	O
striated	O
spring	O
-	O
like	O
thickenings	O
at	O
stages	O
12	O
and	O
13	O
(	O
Figure	O
4A	O
bottom	O
).	O

By	O
contrast	O
,	O
this	O
thickening	O
was	O
absent	O
in	O
the	O
P7	O
-	O
1	O
-	O
OE	O
plants	B-OG
(	O
Figure	O
4A	O
top	O
).	O

To	O
confirm	O
the	O
anther	O
wall	O
structure	O
,	O
lactic	B-CD
acid	I-CD
was	O
used	O
to	O
clear	O
the	O
anthers	O
.	O

Under	O
UV	O
-	O
illumination	O
,	O
a	O
net	O
-	O
like	O
structure	O
of	O
autofluorescent	O
material	O
could	O
be	O
seen	O
at	O
stage	O
12	O
or	O
13	O
in	O
wild	O
-	O
type	O
plants	B-OG
,	O
indicating	O
that	O
there	O
was	O
lignification	O
of	O
the	O
anther	O
wall	O
(	O
Figure	O
4B	O
,	O
bottom	O
).	O

However	O
,	O
these	O
structures	O
were	O
not	O
found	O
in	O
the	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
plants	B-OG
(	O
Figure	O
4B	O
,	O
top	O
).	O

Furthermore	O
,	O
we	O
investigated	O
the	O
lignification	O
patterns	O
in	O
both	O
wild	O
-	O
type	O
and	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
using	O
phloroglucinol	B-CD
staining	O
,	O
which	O
is	O
a	O
histochemical	O
stain	O
commonly	O
used	O
for	O
specifically	O
staining	O
lignin	O
[	O
23	O
].	O

Phloroglucinol	B-CD
-	O
stained	O
substances	O
accumulated	O
to	O
a	O
high	O
degree	O
in	O
wild	O
-	O
type	O
anthers	O
during	O
their	O
development	O
,	O
both	O
at	O
stage	O
13	O
and	O
after	O
flowering	O
(	O
Figure	O
5A	O
and	O
5B	O
).	O

By	O
contrast	O
,	O
phloroglucinol	B-CD
staining	O
was	O
not	O
observed	O
in	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
during	O
flower	O
development	O
(	O
Figure	O
5A	O
and	O
5B	O
).	O

Moreover	O
,	O
the	O
expression	O
levels	O
of	O
the	O
lignin	O
biosynthesis	O
genes	O
4CL	B-GP
(	O
4	B-GP
-	I-GP
coumarate	I-GP
:	I-GP
CoAligase	I-GP
),	O
CCoAOMT	B-GP
(	O
caffeoyl	B-GP
CoA	I-GP
O	I-GP
-	I-GP
methyltransferase	I-GP
),	O
and	O
C3H	B-GP
(	O
cinnamic	B-GP
acid	I-GP
3	I-GP
-	I-GP
hydroxylase	I-GP
)	O
were	O
low	O
in	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
flowers	O
,	O
especially	O
at	O
stage	O
13	O
or	O
later	O
,	O
compared	O
with	O
wild	O
-	O
type	O
flowers	O
(	O
Figure	O
5C	O
).	O

For	O
example	O
,	O
at	O
flowers	O
development	O
13	O
stage	O
,	O
the	O
relative	O
expression	O
level	O
of	O
4CL	O
,	O
CCoAOMT	B-GP
were	O
0	O
.	O
8	O
,	O
0	O
.	O
3	O
in	O
P7	O
-	O
1	O
-	O
OE	O
plants	B-OG
but	O
1	O
.	O
3	O
,	O
0	O
.	O
7	O
in	O
wild	O
-	O
type	O
plants	B-OG
.	O

Endothecial	O
secondary	O
wall	O
thickening	O
in	O
anthers	O
from	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
plants	B-OG
.	O

(	O
A	O
)	O
Anthers	O
were	O
stained	O
with	O
ethidium	O
bromide	O
and	O
visualized	O
by	O
confocal	O
microscopy	O
.	O

Secondary	O
thickening	O
occurs	O
in	O
the	O
endothecium	O
(	O
indicated	O
by	O
an	O
arrow	O
).	O

Thickening	O
is	O
clearly	O
observed	O
in	O
WT	O
but	O
is	O
reduced	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
endothecium	O
.	O

(	O
B	O
)	O
Lactic	B-CD
acid	I-CD
-	O
cleared	O
anthers	O
visualized	O
by	O
confocal	O
microscopy	O
.	O

The	O
secondary	O
thickening	O
network	O
is	O
clearly	O
observed	O
in	O
WT	O
plants	B-OG
,	O
but	O
not	O
in	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
(	O
P7	O
-	O
1	O
-	O
OE	O
).	O

Histochemical	O
staining	O
of	O
lignin	O
components	O
in	O
P7	O
-	O
1	O
transgenic	O
and	O
WT	O
Arabidopsis	B-OG
.	O

(	O
A	O
)	O
Phloroglucinol	B-CD
staining	O
of	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
flowers	O
.	O

Phloroglucinol	B-CD
-	O
stained	O
material	O
was	O
highly	O
accumulated	O
in	O
WT	O
anthers	O
but	O
not	O
in	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
during	O
flower	O
development	O
.	O

(	O
B	O
)	O
Magnified	O
views	O
of	O
P7	O
-	O
1	O
-	O
OE	O
and	O
WT	O
anthers	O
stained	O
with	O
phloroglucinol	B-CD
.	O

(	O
C	O
)	O
The	O
expression	O
levels	O
of	O
4CL	B-GP
(	O
4	O
-	O
coumarate	O
:	O
CoAligase	O
),	O
CCoAOMT	B-GP
(	O
caffeoyl	B-GP
CoA	I-GP
O	I-GP
-	I-GP
methyltransferase	I-GP
),	O
and	O
C3H	B-GP
(	O
cinnamic	B-GP
acid	I-GP
3	I-GP
-	I-GP
hydroxylase	I-GP
)	O
were	O
detected	O
in	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
flowers	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
with	O
the	O
EF1a	B-GP
gene	O
as	O
an	O
internal	O
standard	O
.	O

Results	O
were	O
presented	O
as	O
means	O
±	O
SE	O
from	O
three	O
replications	O
.	O

Anthers	O
of	O
P7	O
-	O
1	O
-	O
OE	O
Plants	B-OG
have	O
Reduced	O
ROS	O
Level	O

To	O
assess	O
whether	O
the	O
sterility	O
of	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
flowers	O
was	O
related	O
to	O
plant	B-OG
signaling	O
molecules	O
,	O
we	O
measured	O
the	O
ROS	O
and	O
NO	O
(	O
nitric	O
oxide	O
)	O
levels	O
in	O
both	O
transgenic	O
and	O
wild	O
-	O
type	O
anthers	O
using	O
florescence	O
staining	O
.	O

Our	O
results	O
clearly	O
demonstrated	O
that	O
there	O
was	O
no	O
difference	O
in	O
NO	O
content	O
between	O
P7	O
-	O
1	O
-	O
OE	O
and	O
wild	O
-	O
type	O
anthers	O
(	O
Figure	O
S4	O
).	O

However	O
,	O
the	O
transgenic	O
anthers	O
accumulated	O
significantly	O
lower	O
levels	O
of	O
ROS	O
than	O
wild	O
-	O
type	O
plants	B-OG
(	O
Figure	O
6A	O
).	O

We	O
further	O
investigated	O
ROS	O
production	O
in	O
anthers	O
during	O
development	O
by	O
histochemical	O
staining	O
.	O

P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
anthers	O
produced	O
low	O
levels	O
of	O
H2O2	O
(	O
Figure	O
6B	O
,	O
DAB	O
staining	O
)	O
but	O
equivalent	O
amounts	O
of	O
O2	O
−	O
(	O
Figure	O
S5	O
,	O
NBT	O
staining	O
)	O
compared	O
with	O
wild	O
-	O
type	O
plants	B-OG
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
low	O
ROS	O
levels	O
in	O
P7	O
-	O
1	O
-	O
OE	O
anthers	O
,	O
we	O
analyzed	O
the	O
expression	O
levels	O
of	O
genes	O
in	O
the	O
ROS	O
network	O
.	O

The	O
expression	O
levels	O
of	O
some	O
genes	O
that	O
encode	O
ROS	O
-	O
scavenging	O
enzymes	O
,	O
e	O
.	O
g	O
.,	O
cytosolic	B-GP
ascorbate	I-GP
peroxidase1	I-GP
(	O
cAPX1	B-GP
),	O
ascorbate	B-GP
peroxidase2	I-GP
(	O
APX2	B-GP
),	O
and	O
Fe	B-GP
superoxide	I-GP
dismutase	I-GP
(	O
FSD1	B-GP
),	O
increased	O
in	O
the	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
anthers	O
about	O
2	O
-	O
fold	O
higher	O
than	O
in	O
wild	O
-	O
type	O
,	O
but	O
the	O
levels	O
of	O
ROS	O
-	O
producing	O
related	O
genes	O
,	O
e	O
.	O
g	O
.,	O
respiratory	B-GP
burst	I-GP
oxidase	I-GP
homolog	I-GP
A	I-GP
(	O
RBOHA	B-GP
)	O
and	O
respiratory	B-GP
burst	I-GP
oxidase	I-GP
homolog	I-GP
B	I-GP
(	O
RBOHB	B-GP
),	O
were	O
reduced	O
in	O
the	O
transgenic	O
anthers	O
compared	O
with	O
the	O
wild	O
type	O
(	O
Figure	O
6C	O
).	O

These	O
results	O
show	O
that	O
the	O
accumulation	O
of	O
ROS	O
in	O
anthers	O
prior	O
to	O
dehiscence	O
is	O
nearly	O
absent	O
when	O
RBSDV	B-GP
P7	O
-	O
1	O
is	O
ectopically	O
expressed	O
.	O

Anthers	O
from	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
exhibit	O
low	O
ROS	O
and	O
H2O2	O
contents	O
compared	O
with	O
WT	O
plants	B-OG
.	O

(	O
A	O
)	O
ROS	O
was	O
detected	O
by	O
staining	O
with	O
DCFH	O
-	O
DA	O
and	O
visualized	O
by	O
confocal	O
microscopy	O
.	O

(	O
B	O
)	O
H2O2	O
was	O
detected	O
by	O
staining	O
with	O
DAB	O
.	O

(	O
C	O
)	O
The	O
expression	O
levels	O
of	O
cytosolic	O
ascorbate	B-GP
peroxidase1	I-GP
(	O
cAPX1	B-GP
),	O
ascorbate	B-GP
peroxidase2	I-GP
(	O
APX2	B-GP
),	O
Fe	B-GP
superoxide	I-GP
dismutase	I-GP
(	O
FSD1	B-GP
),	O
respiratory	B-GP
burst	I-GP
oxidase	I-GP
homolog	I-GP
A	I-GP
(	O
RBOHA	B-GP
),	O
and	O
respiratory	B-GP
burst	I-GP
oxidase	I-GP
homolog	I-GP
B	I-GP
(	O
RBOHB	B-GP
)	O
were	O
detected	O
in	O
P7	B-GP
-	I-GP
1	I-GP
transgenic	O
(	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
flowers	O
using	O
qRT	O
-	O
PCR	O
with	O
the	O
EF1a	B-GP
gene	O
as	O
an	O
internal	O
standard	O
.	O

Results	O
were	O
presented	O
as	O
means	O
±	O
SE	O
from	O
three	O
replications	O
.	O

Discussion	O

Rice	B-OG
black	O
-	B-DS
streaked	O
dwarf	O
and	O
maize	B-OG
rough	B-DS
dwarf	I-DS
diseases	I-DS
,	O
which	O
are	O
caused	O
by	O
RBSDV	B-DS
,	O
lead	O
to	O
severe	O
yield	O
losses	O
in	O
crops	O
in	O
southeast	O
Asian	O
countries	O
,	O
especially	O
China	O
[	O
3	O
],	O
[	O
4	O
].	O

Although	O
a	O
great	O
deal	O
of	O
effort	O
has	O
been	O
made	O
to	O
elucidate	O
the	O
interactions	O
between	O
the	O
virus	B-OG
,	O
insect	B-OG
vectors	O
,	O
and	O
host	O
and	O
environmental	O
conditions	O
,	O
few	O
RBSDV	B-OG
proteins	O
involved	O
in	O
pathogenesis	O
have	O
been	O
identified	O
,	O
and	O
the	O
biochemical	O
basis	O
of	O
disease	O
symptom	O
development	O
remains	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
our	O
results	O
suggest	O
that	O
RBSDV	O
P7	O
-	O
1	O
is	O
a	O
novel	O
determinant	O
of	O
disease	O
symptom	O
development	O
.	O

First	O
,	O
RBSDV	B-DS
infection	I-DS
caused	O
alterations	O
in	O
anther	O
development	O
in	O
rice	B-OG
plants	B-OG
,	O
resulting	O
in	O
partial	O
sterility	O
due	O
to	O
non	O
-	O
dehiscent	O
anthers	O
(	O
Figure	O
1	O
).	O

Furthermore	O
,	O
overexpressing	O
RBSDV	B-OG
P7	I-OG
-	B-GP
1	I-GP
in	O
Arabidopsis	B-OG
produced	O
plants	B-OG
with	O
male	O
sterility	O
resulting	O
from	O
non	O
-	O
dehiscent	O
anthers	O
(	O
Figure	O
2	O
),	O
which	O
approximately	O
mimicked	O
the	O
disease	O
symptoms	O
observed	O
in	O
rice	B-OG
anthers	O
.	O

The	O
non	O
-	O
dehiscent	O
anther	O
phenotype	O
of	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
was	O
correlated	O
with	O
reduced	O
secondary	O
wall	O
lignification	O
in	O
the	O
endothecium	O
and	O
decreased	O
ROS	O
levels	O
in	O
the	O
anthers	O
(	O
Figure	O
5	O
and	O
6	O
).	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
is	O
likely	O
to	O
be	O
a	O
pivotal	O
determinant	O
of	O
plant	B-OG
sterility	O
symptoms	O
caused	O
by	O
RBSDV	B-OG
.	O

Previous	O
studies	O
using	O
immunoelectron	O
analysis	O
have	O
revealed	O
that	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
accumulates	O
in	O
tubular	O
structures	O
in	O
virus	B-OG
-	O
infected	O
maize	B-OG
plants	B-OG
and	O
in	O
insects	B-OG
[	O
8	O
].	O

Furthermore	O
,	O
P7	O
-	O
1	O
of	O
SRBSDV	B-OG
(	O
southern	B-OG
rice	I-OG
black	I-OG
-	I-OG
streaked	I-OG
dwarf	I-OG
virus	I-OG
),	O
which	O
is	O
most	O
closely	O
related	O
to	O
RBSDV	B-OG
,	O
has	O
the	O
intrinsic	O
ability	O
to	O
form	O
tubules	O
growing	O
from	O
the	O
non	O
-	O
host	O
insect	B-OG
cell	O
surface	O
in	O
the	O
absence	O
of	O
other	O
virus	B-OG
proteins	O
[	O
24	O
].	O

Recent	O
researches	O
using	O
live	O
-	O
cell	O
imaging	O
in	O
Nicotiana	B-OG
benthamiana	I-OG
leaves	O
also	O
demonstrate	O
that	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
protein	O
forms	O
punctuate	O
points	O
at	O
plasmodesmata	O
[	O
16	O
].	O

RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
characteristics	O
of	O
tubule	O
-	O
forming	O
and	O
plasmodesmata	O
localization	O
suggest	O
that	O
this	O
protein	O
might	O
be	O
involved	O
in	O
virus	B-OG
intercellular	O
movement	O
,	O
in	O
infected	O
insect	B-OG
and	O
plant	B-OG
cells	O
.	O

The	O
pathogenesis	O
of	O
tubular	O
proteins	O
during	O
viral	O
morphogenesis	O
has	O
been	O
reported	O
in	O
studies	O
of	O
other	O
members	O
of	O
the	O
family	O
Reoviridae	B-OG
.	O
For	O
example	O
,	O
BTV	B-OG
(	O
bluetongue	B-OG
virus	I-OG
)	O
nonstructural	O
tubular	O
protein	O
NS1	B-GP
plays	O
a	O
direct	O
role	O
in	O
cellular	O
pathogenesis	O
[	O
25	O
].	O

RDV	B-OG
(	O
rice	B-OG
dwarf	I-OG
virus	I-OG
)	O
nonstructural	O
tubular	O
protein	O
Pns10	B-GP
functions	O
as	O
a	O
viral	O
suppressor	O
of	O
RNA	O
silencing	O
and	O
plays	O
important	O
roles	O
in	O
enhancing	O
viral	O
replication	O
,	O
systemic	O
movement	O
,	O
and	O
invasion	O
of	O
new	O
tissues	O
[	O
26	O
].	O

Therefore	O
,	O
the	O
tubular	O
proteins	O
of	O
reoviruses	B-OG
have	O
multiple	O
functions	O
in	O
viral	O
morphogenesis	O
,	O
viral	B-DS
infection	I-DS
,	O
and	O
virulence	O
.	O

In	O
support	O
of	O
this	O
notion	O
,	O
our	O
data	O
show	O
that	O
overexpression	O
of	O
RBSDV	B-OG
tubular	B-GP
protein	I-GP
P7	I-GP
-	I-GP
1	I-GP
in	O
Arabidopsis	B-OG
causes	O
male	B-DS
sterility	I-DS
,	O
which	O
mimics	O
the	O
phenotype	O
observed	O
in	O
rice	B-OG
flowers	O
infected	O
with	O
the	O
virus	B-OG
.	O

It	O
will	O
be	O
interesting	O
to	O
examine	O
whether	O
RBSDV	B-OG
P7	B-GP
-	B-OG
1	I-OG
,	O
like	O
RDV	B-OG
Pns10	B-GP
,	O
can	O
function	O
as	O
a	O
viral	O
suppressor	O
of	O
RNA	O
silencing	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
that	O
the	O
male	B-DS
sterility	O
of	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
transgenic	O
plants	B-OG
was	O
due	O
to	O
the	O
failure	O
of	O
anther	O
dehiscence	O
and	O
pollen	O
release	O
,	O
which	O
may	O
have	O
been	O
caused	O
by	O
the	O
lack	O
of	O
lignification	O
in	O
the	O
anther	O
endothecium	O
(	O
Figure	O
4	O
and	O
5	O
).	O

Actually	O
,	O
secondary	O
lignified	O
thickening	O
in	O
the	O
endothecium	O
is	O
critical	O
for	O
providing	O
the	O
mechanical	O
force	O
required	O
for	O
anther	O
dehiscence	O
[	O
22	O
],	O
[	O
27	O
],	O
[	O
28	O
].	O

This	O
mechanism	O
has	O
been	O
demonstrated	O
experimentally	O
by	O
analyzing	O
Arabidopsis	B-OG
mutants	O
such	O
as	O
myb26	B-GP
[	O
29	O
]–[	O
31	O
],	O
NST1	B-GP
(	O
SECONDARYWALL	B-GP
THICKENING	I-GP
PROMOTING	I-GP
FACTOR1	I-GP
),	O
and	O
NST2	B-GP
[	O
32	O
].	O

In	O
these	O
mutants	O
,	O
reduced	O
lignification	O
of	O
anther	O
endothecium	O
results	O
in	O
anther	O
indehiscent	O
and	O
male	O
sterility	O
.	O

Furthermore	O
,	O
the	O
triple	O
ccc	B-GP
mutant	O
,	O
which	O
carries	O
mutations	O
in	O
monolignol	O
biosynthesis	O
genes	O
,	O
including	O
CCR1	B-GP
(	O
cinnamoyl	B-GP
CoA	I-GP
reductase1	I-GP
),	O
CAD	B-GP
c	I-GP
(	O
cinnamyl	B-GP
alcohol	I-GP
dehydrogenase	I-GP
c	I-GP
),	O
and	O
CAD	B-GP
d	I-GP
,	O
displays	O
severe	O
male	O
sterility	O
due	O
to	O
the	O
lack	O
of	O
lignification	O
in	O
the	O
anther	O
endothecium	O
[	O
19	O
].	O

Here	O
,	O
we	O
showed	O
that	O
the	O
transcriptional	O
levels	O
of	O
the	O
lignin	O
biosynthesis	O
genes	O
4CL	B-GP
,	O
CCoAOMT	B-GP
,	O
and	O
C3H	B-GP
were	O
reduced	O
in	O
the	O
flowers	O
of	O
RBSDV	B-OG
P7	I-OG
-	I-OG
1	I-OG
transgenic	O
plants	B-OG
compared	O
with	O
the	O
flowers	O
of	O
wild	O
-	O
type	O
plants	B-OG
(	O
Figure	O
5	O
),	O
although	O
the	O
expression	O
levels	O
of	O
CCR1	B-GP
,	O
CAD	B-GP
c	I-GP
,	O
and	O
CAD	B-GP
d	I-GP
were	O
unchanged	O
in	O
the	O
transgenic	O
plants	B-OG
(	O
data	O
not	O
shown	O
).	O

Thus	O
,	O
the	O
reduced	O
lignification	O
of	O
anthers	O
is	O
responsible	O
for	O
male	B-DS
sterility	I-DS
in	O
P7	B-GP
-	I-GP
1	I-GP
-	O
OE	O
transgenic	O
plants	B-OG
.	O

It	O
is	O
well	O
-	O
established	O
that	O
secondary	O
lignification	O
in	O
cell	O
walls	O
is	O
dependent	O
on	O
the	O
oxidative	O
coupling	O
of	O
monolignol	B-CD
to	O
form	O
the	O
polymer	O
lignin	O
,	O
which	O
is	O
catalyzed	O
by	O
H2O2	B-GP
-	I-GP
dependent	I-GP
peroxidases	I-GP
and	O
O2	B-GP
-	I-GP
dependent	I-GP
laccase	I-GP
[	O
33	O
],	O
[	O
34	O
].	O

In	O
the	O
endodermal	O
cells	O
of	O
roots	O
,	O
subcellular	O
precision	O
of	O
lignin	O
polymerization	O
is	O
achieved	O
by	O
restricted	O
,	O
localized	O
peroxidase	B-GP
activity	O
and	O
the	O
production	O
of	O
ROS	O
substrate	O
[	O
35	O
].	O

In	O
the	O
secondary	O
thickening	O
that	O
occurs	O
in	O
anthers	O
,	O
lignin	O
polymerization	O
is	O
dependent	O
on	O
the	O
H2O2	O
contents	O
.	O

For	O
example	O
,	O
Arabidopsis	B-OG
plants	B-OG
ectopically	O
expressing	O
gamma	B-GP
carbonic	I-GP
anhydrase	I-GP
2	I-GP
(	O
CA2	B-GP
)	O
have	O
significantly	O
lower	O
ROS	O
contents	O
than	O
wild	O
type	O
,	O
which	O
results	O
in	O
a	O
reduction	O
in	O
the	O
H2O2	O
-	O
dependent	O
polymerization	O
pathway	O
for	O
lignin	O
formation	O
during	O
anther	O
development	O
and	O
accordingly	O
,	O
causes	O
male	O
sterility	O
[	O
36	O
].	O

Our	O
data	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
RBSDV	B-GP
P7	B-GP
-	I-GP
1	I-GP
in	O
Arabidopsis	B-OG
causes	O
male	B-DS
sterility	I-DS
in	O
conjunction	O
with	O
low	O
ROS	O
contents	O
in	O
anthers	O
compared	O
with	O
wild	O
-	O
type	O
plants	B-OG
(	O
Figure	O
6	O
).	O

Thus	O
,	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
the	O
male	B-DS
sterility	O
of	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
is	O
primarily	O
achieved	O
by	O
the	O
combinatorial	O
action	O
of	O
reduced	O
monolignol	O
and	O
ROS	O
contents	O
.	O

In	O
the	O
future	O
,	O
it	O
will	O
be	O
important	O
to	O
untangle	O
the	O
relationship	O
between	O
reduced	O
production	O
of	O
ROS	O
or	O
lignin	O
and	O
RBSDV	O
tubular	O
protein	O
P7	B-GP
-	I-GP
1	I-GP
.	O

Such	O
information	O
would	O
significantly	O
deepen	O
our	O
mechanistic	O
understanding	O
of	O
the	O
role	O
of	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
in	O
viral	O
virulence	O
.	O

Supporting	O
Information	O

Molecular	O
identity	O
of	O
RBSDV	B-OG
P7	B-GP
-	I-GP
1	I-GP
transgenic	O
Arabidopsis	B-OG
plants	B-OG
.	O
(	O
A	O
)	O
Selection	O
of	O
P7	B-GP
-	I-GP
1	I-GP
transgenic	O
lines	O
on	O
MS	O
medium	O
with	O
kanamycin	B-CD
or	O
without	O
kanamycin	B-CD
(	O
MS	O
).	O

(	O
B	O
)	O
Genome	O
DNA	O
PCR	O
showing	O
that	O
P7	O
-	O
1	O
was	O
integrated	O
as	O
a	O
unit	O
in	O
the	O
transgenic	O
lines	O
.	O
EF1α	O
was	O
used	O
to	O
control	O
for	O
DNA	O
loading	O
.	O

(	O
C	O
)	O
qRT	O
-	O
PCR	O
analysis	O
showing	O
the	O
expression	O
of	O
P7	O
-	O
1	O
in	O
wild	O
-	O
type	O
and	O
three	O
independent	O
transgenic	O
lines	O
using	O
the	O
EF1a	B-GP
gene	O
as	O
an	O
internal	O
standard	O
.	O

Results	O
were	O
presented	O
as	O
means	O
±	O
SE	O
from	O
three	O
replications	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Alexander	O
staining	O
of	O
pollen	O
of	O
P7	O
-	O
1	O
transgenic	O
and	O
wild	O
-	O
type	O
Arabidopsis	B-OG
plants	B-OG
.	O
(	O
A	O
)	O
Cytological	O
comparisons	O
of	O
P7	O
-	O
1	O
transgenic	O
lines	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
anthers	O
during	O
development	O
.	O

(	O
B	O
,	O
C	O
)	O
Alexander	O
staining	O
pollen	O
of	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Hand	O
-	O
pollinated	O
pollen	O
grains	O
from	O
P7	O
-	O
1	O
transgenic	O
plants	B-OG
could	O
fertilize	O
egg	O
cells	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

NO	O
detected	O
by	O
staining	O
with	O
DAF	O
-	O
FM	O
DA	O
in	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
anthers	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

O2	O
−	O
detected	O
by	O
staining	O
with	O
NBT	O
in	O
P7	O
-	O
1	O
transgenic	O
(	O
P7	O
-	O
1	O
-	O
OE	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
Arabidopsis	B-OG
anthers	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

List	O
of	O
primers	O
used	O
in	O
this	O
study	O
.	O

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Neurotoxic	O
kynurenine	B-CD
metabolism	O
is	O
increased	O
in	O
the	O
dorsal	O
hippocampus	O
and	O
drives	O
distinct	O
depressive	O
behaviors	O
during	O
inflammation	O

The	O
kynurenine	B-CD
pathway	O
of	O
tryptophan	B-CD
metabolism	O
has	O
an	O
important	O
role	O
in	O
mediating	O
the	O
behavioral	O
effects	O
of	O
inflammation	O
,	O
which	O
has	O
implications	O
in	O
understanding	O
neuropsychiatric	O
comorbidity	O
and	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O

Inhibition	O
of	O
the	O
rate	O
-	O
limiting	O
enzyme	O
,	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
),	O
prevents	O
the	O
development	O
of	O
many	O
of	O
these	O
inflammation	O
-	O
induced	O
preclinical	O
behaviors	O
.	O

However	O
,	O
dysregulation	O
in	O
the	O
balance	O
of	O
downstream	O
metabolism	O
,	O
where	O
neuroactive	O
kynurenines	B-CD
are	O
generated	O
,	O
is	O
hypothesized	O
to	O
be	O
a	O
functionally	O
important	O
pathogenic	O
feature	O
of	O
inflammation	O
-	O
induced	O
depression	B-DS
.	O

Here	O
we	O
utilized	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
to	O
directly	O
test	O
the	O
hypothesis	O
that	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
causes	O
depressive	O
-	O
like	O
behavior	O
following	O
peripheral	O
immune	O
activation	O
.	O

Wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)-	O
deficient	O
(	O
KMO	O
−/−)	O
mice	B-OG
were	O
administered	O
either	O
lipopolysaccharide	O
(	O
LPS	O
,	O
0	O
.	O
5	O
mg	O
kg	O
−	O
1	O
)	O
or	O
saline	O
intraperitoneally	O
.	O

Depressive	O
-	O
like	O
behavior	O
was	O
measured	O
across	O
multiple	O
domains	O
24	O
h	O
after	O
immune	O
challenge	O
.	O

LPS	O
precipitated	O
a	O
robust	O
depressive	O
-	O
like	O
phenotype	O
,	O
but	O
KMO	O
−/−	O
mice	B-OG
were	O
specifically	O
protected	O
from	O
LPS	O
-	O
induced	O
immobility	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
and	O
reduced	O
spontaneous	O
alternations	O
in	O
the	O
Y	O
-	O
maze	O
.	O

Direct	O
administration	O
of	O
3	O
-	O
hydroxykynurenine	O
,	O
the	O
metabolic	O
product	O
of	O
KMO	O
,	O
caused	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
depressive	O
-	O
like	O
behaviors	O
.	O

Mice	B-OG
with	O
targeted	O
deletion	O
of	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
),	O
the	O
enzyme	O
that	O
generates	O
quinolinic	B-CD
acid	I-CD
,	O
were	O
similarly	O
challenged	O
with	O
LPS	O
.	O

Similar	O
to	O
KMO	B-GP
−/−	I-GP
mice	B-OG
,	O
LPS	O
failed	O
to	O
increase	O
immobility	O
during	O
the	O
TST	O
.	O

Whereas	O
kynurenine	B-CD
metabolism	O
was	O
generally	O
increased	O
in	O
behaviorally	O
salient	O
brain	O
regions	O
,	O
a	O
distinct	O
shift	O
toward	O
KMO	B-GP
-	O
dependent	O
kynurenine	B-CD
metabolism	O
occurred	O
in	O
the	O
dorsal	O
hippocampus	O
in	O
response	O
to	O
LPS	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
KMO	B-GP
is	O
a	O
pivotal	O
mediator	O
of	O
hippocampal	O
-	O
dependent	O
depressive	O
-	O
like	O
behaviors	O
induced	O
by	O
peripheral	O
LPS	O
challenge	O
.	O

Introduction	O

Although	O
it	O
remains	O
a	O
major	O
health	O
burden	O
worldwide	O
,	O
the	O
etiology	O
of	O
depression	B-DS
remains	O
unclear	O
.	O

Recent	O
studies	O
indicate	O
that	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
may	O
contribute	O
to	O
the	O
development	O
of	O
depression	B-DS
,	O
1	O
particularly	O
as	O
a	O
comorbidity	O
.	O

Patients	O
undergoing	O
cytokine	B-GP
immunotherapy2	O
or	O
healthy	O
volunteers	O
who	O
receive	O
immune	O
activating	O
agents	O
,	O
such	O
as	O
endotoxin3	O
,	O
4	O
or	O
vaccines5	O
,	O
6	O
in	O
an	O
experimental	O
setting	O
,	O
report	O
developing	O
depression	B-DS
symptoms	O
spanning	O
multiple	O
dimensions	O
(	O
for	O
example	O
,	O
mood	O
,	O
anhedonia	O
,	O
cognition	O
,	O
neurovegetative	O
and	O
anxiety	B-DS
).	O

The	O
time	O
course	O
and	O
severity	O
of	O
these	O
symptoms	O
are	O
positively	O
correlated	O
with	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
levels	O
.	O
4	O
,	O
5	O
Consistent	O
with	O
these	O
clinical	O
observations	O
,	O
peripheral	O
immune	O
activation	O
in	O
rodent	B-OG
models	O
precipitates	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
-	O
dependent7	O
,	O
8	O
,	O
9	O
depressive	O
-	O
and	O
anxiety	B-DS
-	O
like	O
behaviors	O
.	O

Peripheral	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
signal	O
to	O
the	O
brain	O
via	O
multiple	O
routes10	O
and	O
activate	O
the	O
resident	O
immune	O
cells	O
of	O
the	O
brain	O
,	O
microglia	O
.	O

Activated	O
microglia	O
,	O
in	O
turn	O
,	O
secrete	O
cytokines	B-GP
and	O
chemokines	B-GP
,	O
generate	O
oxidative	O
stress	O
molecules	O
and	O
alter	O
local	O
metabolic	O
processes	O
.	O
11	O
Disruption	O
in	O
the	O
balance	O
of	O
tryptophan	B-CD
metabolism	O
along	O
the	O
kynurenine	B-CD
pathway	O
is	O
a	O
putative	O
mechanism	O
linking	O
inflammation	O
,	O
microglia	O
and	O
depression	B-DS
.	O

The	O
rate	O
-	O
limiting	O
enzyme	O
that	O
metabolizes	O
tryptophan	B-CD
to	O
kynurenine	B-CD
,	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
,	O
Figure	O
1	O
),	O
is	O
potently	O
upregulated	O
by	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
.	O
12	O
Inflammation	O
-	O
associated	O
depression	B-DS
scores	O
in	O
human	B-OG
patients	O
are	O
associated	O
with	O
an	O
elevated	O
kynurenine	B-CD
/	O
tryptophan	B-CD
ratio	O
,	O
an	O
indicator	O
of	O
IDO	B-GP
activity	O
,	O
13	O
and	O
numerous	O
preclinical	O
mouse	B-OG
models	O
have	O
established	O
IDO	B-GP
-	O
dependent	O
kynurenine	B-CD
metabolism	O
as	O
an	O
important	O
mediator	O
of	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
.	O
14	O
,	O
15	O
,	O
16	O
,	O
17	O
,	O
18	O
Interestingly	O
,	O
microglia	O
are	O
the	O
predominant	O
cells	O
expressing	O
the	O
enzyme	O
(	O
kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
,	O
KMO	B-GP
,	O
Figure	O
1	O
)	O
for	O
the	O
generation	O
of	O
neurotoxic	O
kynurenine	B-CD
metabolites	O
,	O
and	O
reports	O
in	O
both	O
human19	O
and	O
in	O
mice20	O
have	O
implicated	O
microglial	O
-	O
derived21	O
,	O
22	O
downstream	O
neurotoxic	O
kynurenine	B-CD
metabolites	O
in	O
the	O
pathogenesis	O
of	O
inflammation	B-DS
-	O
associated	B-DS
depression	I-DS
;	O
however	O
,	O
mechanistic	O
studies	O
are	O
yet	O
to	O
be	O
performed	O
.	O

Kynurenine	B-CD
metabolism	O
in	O
the	O
brain	O
results	O
in	O
accumulation	O
of	O
two	O
major	O
neuroactive	O
end	O
products	O
,	O
kynurenic	B-CD
acid	I-CD
(	O
KA	O
)	O
and	O
quinolinic	B-CD
acid	I-CD
(	O
QA	O
;	O
Figure	O
1	O
).	O

Under	O
basal	O
conditions	O
,	O
most	O
kynurenine	B-CD
is	O
metabolized	O
by	O
astrocytes	O
to	O
KA	O
,	O
an	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
and	O
α7	B-GP
-	O
nicotinic	B-GP
acetylcholine	I-GP
receptor	I-GP
antagonist	O
.	O
23	O
,	O
24	O
However	O
,	O
inflammation	O
and	O
subsequent	O
microglial	O
activation	O
is	O
reported	O
to	O
shift	O
kynurenine	B-CD
metabolism	O
toward	O
KMO	B-GP
-	O
dependent	O
production	O
of	O
QA	O
.	O
20	O
,	O
25	O
QA	O
,	O
an	O
NMDAR	B-GP
agonist	O
,	O
can	O
be	O
particularly	O
disruptive	O
to	O
the	O
neuronal	O
environment	O
at	O
higher	O
concentrations	O
,	O
not	O
only	O
by	O
elevating	O
the	O
potential	O
for	O
glutamate	B-CD
excitotoxicty	O
but	O
also	O
by	O
precipitating	O
oxidative	O
damage26	O
and	O
potentiating	O
pro	O
-	O
inflammation	O
.	O

A	O
neurotoxic	O
shift	O
in	O
kynurenine	B-CD
metabolism	O
favoring	O
the	O
production	O
of	O
KMO	O
-	O
dependent	O
metabolites	O
is	O
hypothesized	O
to	O
mediate	O
inflammation	O
-	O
associated	O
behavior	O
changes	O
.	O
27	O
Increased	O
levels	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
QA	O
in	O
patients	O
undergoing	O
interferon	B-GP
-	I-GP
α	I-GP
immunotherapy	O
were	O
positively	O
correlated	O
to	O
more	O
severe	O
depression	B-DS
scores	O
.	O
19	O
A	O
similar	O
elevation	O
in	O
central	O
QA	O
and	O
its	O
neurotoxic	O
precursor	O
,	O
3	O
-	O
hydroxykynurenine	O
(	O
3	O
-	O
HK	O
),	O
was	O
measured	O
in	O
mice	B-OG
injected	O
peripherally	O
with	O
lipopolysaccharide	O
(	O
LPS	O
).	O

Importantly	O
,	O
LPS	O
-	O
challenged	O
mice	B-OG
also	O
exhibit	O
depressive	O
-	O
and	O
anxiety	B-DS
-	O
like	O
behaviors	O
concomitant	O
with	O
the	O
elevations	O
in	O
neurotoxic	O
metabolites	O
.	O
20	O
Whereas	O
evidence	O
implicates	O
KMO	B-GP
-	O
dependent	O
kynurenine	B-CD
metabolism	O
as	O
a	O
likely	O
pathogenic	O
mechanism	O
underlying	O
inflammation	O
-	O
induced	O
depression	B-DS
,	O
28	O
until	O
recently	O
,	O
no	O
preclinical	O
genetic	O
models	O
were	O
available	O
to	O
directly	O
test	O
this	O
hypothesis	O
and	O
brain	O
-	O
penetrant	O
KMO	B-GP
inhibitors	O
are	O
not	O
commercially	O
available	O
.	O

In	O
order	O
to	O
determine	O
whether	O
KMO	B-GP
-	O
dependent	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
mediates	O
the	O
depressive	O
-	O
like	O
behavioral	O
changes	O
following	O
peripheral	O
immune	O
challenge	O
,	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
were	O
generated	O
with	O
targeted	O
deletion	O
of	O
either	O
the	O
KMO	B-GP
or	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
gene	O
.	O

Inflammation	O
-	O
induced	O
depressive	O
behaviors	O
were	O
precipitated	O
in	O
control	O
or	O
transgenic	O
mice	B-OG
using	O
the	O
well	O
-	O
established	O
peripheral	O
LPS	O
challenge	O
model	O
.	O
29	O
,	O
30	O
3	O
-	O
HK	O
,	O
the	O
initial	O
substrate	O
for	O
neurotoxic	O
kynurenine	B-CD
pathway	O
metabolism	O
,	O
was	O
directly	O
administered	O
to	O
naive	O
mice	B-OG
to	O
determine	O
the	O
behavioral	O
consequences	O
of	O
increased	O
KMO	B-GP
-	O
dependent	O
kynurenine	B-CD
metabolites	O
.	O

Because	O
it	O
had	O
previously	O
only	O
been	O
investigated	O
at	O
the	O
whole	O
-	O
brain	O
level	O
,	O
changes	O
in	O
downstream	O
neuroactive	O
kynurenine	B-CD
metabolism	O
in	O
behaviorally	O
salient	O
discrete	O
brain	O
regions	O
were	O
characterized	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
following	O
LPS	O
challenge	O
.	O

These	O
novel	O
data	O
have	O
important	O
ramifications	O
for	O
not	O
only	O
our	O
understanding	O
of	O
neuropsychiatric	O
pathology	O
during	O
inflammation	O
,	O
but	O
also	O
for	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

Materials	O
and	O
methods	O

Animals	B-OG

All	O
animal	B-OG
care	O
and	O
use	O
was	O
carried	O
out	O
in	O
accord	O
with	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	B-OG
,	O
8th	O
edition	O
(	O
NRC	O
)	O
and	O
approved	O
by	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
at	O
The	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
San	O
Antonio	O
.	O

General	O
health	O
of	O
the	O
mice	B-OG
was	O
monitored	O
daily	O
.	O

Knockout	O
first	O
,	O
conditional	O
ready	O
KMO	O
and	O
HAAO	B-GP
transgenic	O
mice	B-OG
(	O
Kmotm1a	B-GP
(	O
KOMP	O
)	O
Wtsi	B-GP
and	O
Haaotm1a	B-GP
(	O
KOMP	O
)	O
Wtsi	O
)	O
on	O
a	O
C57BL	O
/	O
6N	O
background	O
were	O
designed	O
and	O
generated	O
by	O
the	O
Mouse	B-OG
Biology	O
Program	O
(	O
MBP	O
,	O
www	O
.	O
mousebiology	O
.	O
org	O
)	O
at	O
the	O
University	O
of	O
California	O
Davis	O
(	O
UC	O
Davis	O
).	O

The	O
MBP	B-GP
was	O
supported	O
by	O
the	O
Knock	O
-	O
Out	O
Mouse	B-OG
Project	O
(	O
KOMP	O
),	O
a	O
trans	O
-	O
NIH	O
initiative	O
,	O
and	O
the	O
CSD	O
Consortium	O
,	O
composed	O
of	O
the	O
Children	O
'	O
s	O
Hospital	O
Oakland	O
Research	O
Institute	O
(	O
CHORI	O
),	O
the	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
and	O
UC	O
Davis	O
.	O

Vectors	O
,	O
embryonic	O
stem	O
cells	O
and	O
gene	O
information	O
related	O
to	O
these	O
mouse	B-OG
strains	O
are	O
available	O
at	O
the	O
KOMP	O
Repository	O
(	O
www	O
.	O
komp	O
.	O
org	O
)	O
maintained	O
by	O
UC	O
Davis	O
and	O
CHORI	O
.	O

Briefly	O
,	O
C57BL	B-OG
/	I-OG
6N	I-OG
mouse	I-OG
embryonic	O
stem	O
cells	O
were	O
injected	O
with	O
a	O
vector	O
containing	O
a	O
transgenic	O
cassette	O
directed	O
for	O
the	O
target	O
gene	O
(	O
Figures	O
2a	O
and	O
c	O
).	O

Stem	O
cells	O
were	O
selected	O
for	O
site	O
-	O
specific	O
integration	O
of	O
the	O
transgene	O
,	O
microinjected	O
into	O
C57BL	B-OG
/	I-OG
6N	I-OG
mouse	I-OG
blastocysts	O
and	O
implanted	O
into	O
C57BL	O
/	B-OG
6N	O
female	O
mice	B-OG
.	O
31	O
During	O
transcription	O
,	O
the	O
proper	O
incorporation	O
of	O
the	O
transgene	O
into	O
the	O
target	O
gene	O
results	O
in	O
gene	O
-	O
trapping	O
between	O
the	O
reporter	O
gene	O
(	O
lacZ	B-GP
)	O
from	O
the	O
cassette	O
and	O
the	O
endogenous	O
gene	O
.	O
32	O
When	O
these	O
transcripts	O
become	O
spliced	O
together	O
,	O
an	O
insertion	O
mutation	O
is	O
created	O
resulting	O
in	O
a	O
non	O
-	O
functional	O
target	O
protein	O
.	O

The	O
presence	O
of	O
the	O
Kmo	B-GP
transgene	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
of	O
genomic	O
DNA	O
using	O
the	O
following	O
primers	O
:	O
5	O
′-	O
ACCAGTCAGCAGGTCCTTGTTT	O
-	O
3	O
′	O
(	O
WT	O
forward	O
primer	O
),	O
5	O
′-	O
CGCGTCGAGAAGTTCCTATTCC	O
-	O
3	O
′	O
(	O
Kmo	B-GP
transgene	O
forward	O
primer	O
)	O
and	O
5	O
′-	O
AACCCATGTTACCGTCACACAC	O
-	O
3	O
′	O
(	O
common	O
reverse	O
primer	O
;	O
Figure	O
2b	O
).	O

The	O
Haao	B-GP
transgene	O
was	O
confirmed	O
in	O
the	O
same	O
manner	O
using	O
the	O
following	O
primers	O
:	O
5	O
′-	O
GATAAGGGATTGGGGGTGTG	O
-	O
3	O
′	O
(	O
WT	O
forward	O
primer	O
),	O
5	O
′-	O
GAAAGTATAGGAACTTCGTCGAGAT	O
-	O
3	O
′	O
(	O
Haao	B-GP
transgene	O
forward	O
primer	O
)	O
and	O
5	O
′-	O
GCCAAGGTCCTTACAGTGGA	O
-	O
3	O
′	O
(	O
common	O
reverse	O
primer	O
;	O
Figure	O
2d	O
).	O

Functional	O
deletion	O
of	O
the	O
target	O
gene	O
was	O
confirmed	O
using	O
validated	O
Taqman	O
Gene	O
Expression	O
assays	O
(	O
Mm01321343_m1	O
(	O
Kmo	O
)	O
and	O
Mm00517945_m1	O
(	O
Haao	O
);	O
Life	O
Technologies	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
amplification	O
of	O
steady	O
-	O
state	O
mRNA	O
(	O
data	O
not	O
shown	O
).	O

Upon	O
confirmation	O
of	O
a	O
knockout	O
genotype	O
,	O
mice	B-OG
were	O
back	O
-	O
crossed	O
with	O
C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
(	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
;	O
stock	O
#	O
000664	O
)	O
for	O
five	O
generations	O
to	O
maintain	O
the	O
in	O
-	O
house	O
breeding	O
colonies	O
.	O

C57BL	B-OG
/	I-OG
6J	I-OG
mice	I-OG
were	O
used	O
to	O
supplement	O
the	O
WT	O
littermate	O
control	O
group	O
when	O
needed	O
,	O
after	O
confirming	O
that	O
there	O
was	O
not	O
a	O
significant	O
difference	O
in	O
the	O
phenotypic	O
or	O
metabolic	O
responses	O
to	O
LPS	O
(	O
data	O
not	O
shown	O
).	O

Three	O
to	O
five	O
-	O
month	O
-	O
old	O
male	O
mice	B-OG
were	O
used	O
for	O
all	O
experiments	O
.	O
Ad	O
libitum	O
food	O
and	O
water	O
access	O
was	O
provided	O
at	O
all	O
times	O
.	O

Two	O
weeks	O
before	O
testing	O
,	O
mice	B-OG
were	O
individually	O
housed	O
in	O
a	O
modified	O
reverse	O
light	O
cycle	O
(	O
lights	O
on	O
2300	O
–	O
1100	O
hours	O
),	O
gently	O
handled	O
and	O
weighed	O
each	O
day	O
.	O

Treatments	O

LPS	O
(	O
Escherichia	B-OG
coli	I-OG
,	O
serotype	O
0127	O
:	O
B8	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
was	O
prepared	O
in	O
endotoxin	O
-	O
free	O
saline	O
on	O
the	O
morning	O
of	O
injections	O
.	O

LPS	O
(	O
0	O
.	O
5	O
mg	O
kg	O
−	O
1	O
)	O
or	O
saline	O
was	O
injected	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.)	O
24	O
h	O
before	O
behavioral	O
assessments	O
and	O
tissue	O
collection	O
.	O

3	O
-	O
HK	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
dissolved	O
in	O
0	O
.	O
5	O
N	O
HCl	O
at	O
a	O
concentration	O
of	O
4	O
×,	O
diluted	O
to	O
2	O
×	O
with	O
0	O
.	O
5	O
N	O
NaOH	O
and	O
to	O
1	O
×	O
with	O
0	O
.	O
2M	O
(	O
2	O
×)	O
phosphate	O
-	O
buffered	O
saline	O
.	O

3	O
-	O
HK	O
was	O
administered	O
subcutaneously	O
at	O
0	O
.	O
0	O
,	O
3	O
.	O
33	O
or	O
10	O
mg	O
kg	O
−	O
1	O
30	O
min	O
before	O
behavioral	O
testing	O
or	O
tissue	O
collection	O
,	O
which	O
was	O
previously	O
established	O
as	O
the	O
time	O
of	O
peak	O
brain	O
concentrations	O
following	O
peripheral	O
kynurenine	B-CD
administration	O
.	O
33	O

Treatment	O
groups	O
:	O
WT	O
and	O
KMO	O
−/−	O
mice	B-OG
were	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
WT	O
n	O
=	O
36	O
;	O
KMO	B-GP
−/−	I-GP
n	O
=	O
24	O
)	O
or	O
LPS	O
(	O
WT	O
n	O
=	O
37	O
;	O
KMO	O
−/−	O
n	O
=	O
24	O
),	O
followed	O
by	O
behavioral	O
testing	O
(	O
Figure	O
3	O
)	O
and	O
tissue	O
collection	O
(	O
Table	O
1	O
)	O
at	O
24	O
h	O
.	O

WT	O
mice	B-OG
were	O
injected	O
peripherally	O
(	O
subcutaneously	O
)	O
with	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
27	O
),	O
3	O
.	O
33	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
17	O
)	O
or	O
10	O
mg	O
kg	O
−	O
1	O
(	O
n	O
=	O
20	O
)	O
3	O
-	O
HK	O
,	O
followed	O
by	O
either	O
behavior	O
or	O
tissue	O
collection	O
(	O
Figure	O
4	O
).	O

WT	O
and	O
HAAO	O
−/−	O
mice	B-OG
were	O
also	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
WT	O
n	O
=	O
26	O
;	O
HAAO	O
−/−	O
n	O
=	O
29	O
)	O
or	O
LPS	O
(	O
WT	O
n	O
=	O
29	O
;	O
HAAO	B-GP
−/−	I-GP
n	O
=	O
31	O
),	O
followed	O
by	O
behavioral	O
assessment	O
(	O
Figure	O
5	O
)	O
and	O
tissue	O
collection	O
(	O
Table	O
1	O
)	O
at	O
24	O
h	O
.	O

Finally	O
,	O
WT	O
mice	B-OG
were	O
treated	O
(	O
i	O
.	O
p	O
.)	O
with	O
either	O
saline	O
(	O
n	O
=	O
12	O
)	O
or	O
LPS	O
(	O
n	O
=	O
12	O
)	O
and	O
brain	O
regions	O
were	O
microdissected	O
(	O
Tables	O
2	O
and	O
3	O
)	O
at	O
24	O
h	O
.	O

Animals	B-OG
were	O
randomly	O
assigned	O
to	O
treatment	O
groups	O
within	O
the	O
appropriate	O
genotype	O
,	O
and	O
data	O
were	O
collected	O
and	O
analyzed	O
by	O
a	O
treatment	O
-	O
blind	O
observer	O
.	O

Previous	O
studies	O
conducted	O
by	O
our	O
laboratory	O
using	O
similar	O
treatments	O
and	O
behaviors	O
were	O
used	O
to	O
determine	O
group	O
sample	O
size	O
,	O
which	O
provide	O
adequate	O
effect	O
size	O
.	O
16	O
,	O
33	O
,	O
34	O

Behavioral	O
testing	O

Locomotor	O
activity	O
and	O
open	O
field	O
test	O

Exploratory	O
locomotor	O
activity	O
and	O
anxiety	B-DS
-	O
like	O
behavior	O
were	O
assessed	O
24	O
h	O
post	O
-	O
LPS	O
by	O
placing	O
mice	B-OG
in	O
a	O
dimly	O
lit	O
(~	O
5	O
lux	O
)	O
40	O
×	O
40	O
cm	O
open	O
field	O
(	O
OF	O
)	O
chamber	O
for	O
5	O
min	O
.	O

Activity	O
in	O
the	O
OF	O
was	O
video	O
-	O
recorded	O
and	O
assessed	O
for	O
total	O
horizontal	O
distance	O
traveled	O
and	O
time	O
spent	O
in	O
the	O
central	O
or	O
outer	O
areas	O
using	O
Ethovision	O
XT	O
7	O
.	O
1	O
analysis	O
software	O
(	O
Noldus	O
,	O
Leesburg	O
,	O
VA	O
,	O
USA	O
)	O
as	O
previously	O
described	O
.	O
16	O
The	O
chamber	O
was	O
cleaned	O
with	O
70	O
%	O
ethanol	O
after	O
each	O
individual	O
test	O
.	O

Sucrose	B-CD
preference	O

Three	O
days	O
before	O
LPS	O
treatment	O
,	O
mice	B-OG
were	O
trained	O
using	O
a	O
two	O
-	O
bottle	O
(	O
water	O
and	O
1	O
%	O
sucrose	B-CD
)	O
testing	O
paradigm	O
.	O

Following	O
LPS	O
injections	O
,	O
sucrose	B-CD
preference	O
(	O
SP	O
)	O
was	O
assessed	O
as	O
an	O
index	O
of	O
anhedonia	O
-	O
like	O
behavior	O
as	O
previously	O
described	O
and	O
calculated	O
as	O
(	O
sucrose	B-CD
intake	O
)/(	O
water	O
+	O
sucrose	B-CD
intake	O
)	O
×	O
100	O
.	O
16	O
To	O
control	O
for	O
potential	O
place	O
preference	O
,	O
bottles	O
were	O
placed	O
on	O
the	O
outside	O
edge	O
of	O
the	O
wire	O
food	O
hopper	O
and	O
their	O
relative	O
location	O
was	O
alternated	O
daily	O
.	O

Tail	O
suspension	O
test	O

Immediately	O
after	O
the	O
OF	O
test	O
,	O
behavioral	O
despair	O
was	O
measured	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
),	O
as	O
previously	O
described	O
.	O
14	O
Immobility	O
during	O
the	O
6	O
min	O
test	O
was	O
scored	O
by	O
a	O
trained	O
treatment	O
-	O
blinded	O
observer	O
.	O

Any	O
mice	B-OG
that	O
climbed	O
their	O
tail	O
,	O
which	O
occurred	O
in	O
fewer	O
than	O
5	O
%	O
of	O
experimental	O
mice	B-OG
,	O
were	O
excluded	O
from	O
subsequent	O
data	O
analysis	O
.	O

Y	O
-	O
Maze	O

Mice	B-OG
were	O
placed	O
in	O
the	O
maze	O
and	O
allowed	O
to	O
freely	O
explore	O
for	O
8	O
min	O
.	O

The	O
movement	O
and	O
location	O
of	O
the	O
mouse	B-OG
was	O
recorded	O
from	O
an	O
overhead	O
camera	O
,	O
and	O
the	O
distance	O
traveled	O
and	O
sequence	O
of	O
arm	O
entries	O
were	O
scored	O
from	O
the	O
video	O
archive	O
.	O

An	O
entry	O
was	O
scored	O
only	O
when	O
the	O
mouse	B-OG
'	O
s	O
full	O
body	O
(	O
minus	O
tail	O
)	O
had	O
entered	O
2	O
-	O
cm	O
deep	O
into	O
the	O
arm	O
.	O

A	O
spontaneous	O
alternation	O
occurred	O
when	O
the	O
mouse	B-OG
entered	O
each	O
of	O
the	O
three	O
different	O
arms	O
sequentially	O
before	O
making	O
a	O
return	O
entry	O
to	O
an	O
already	O
visited	O
arm	O
.	O

Behavioral	O
timeline	O

Before	O
treatment	O
(	O
saline	O
or	O
LPS	O
i	O
.	O
p	O
.),	O
mice	B-OG
were	O
trained	O
on	O
the	O
two	O
-	O
bottle	O
SP	O
testing	O
paradigm	O
,	O
and	O
then	O
SP	O
data	O
were	O
collected	O
during	O
the	O
24	O
h	O
following	O
treatment	O
and	O
before	O
behavioral	O
testing	O
.	O

At	O
24	O
h	O
following	O
treatment	O
,	O
mice	B-OG
underwent	O
testing	O
in	O
the	O
OF	O
and	O
TST	O
or	O
the	O
Y	O
-	O
maze	O
immediately	O
followed	O
by	O
tissue	O
collection	O
(	O
as	O
described	O
below	O
).	O

For	O
peripheral	O
3	O
-	O
HK	O
experiments	O
,	O
mice	B-OG
were	O
injected	O
subcutaneously	O
30	O
min	O
before	O
either	O
the	O
TST	O
,	O
OF	O
,	O
Y	O
-	O
maze	O
,	O
a	O
shortened	O
2	O
h	O
SP	O
test	O
or	O
tissue	O
collection	O
.	O

Liquid	O
chromatography	O
/	O
mass	O
spectrometry	O

Either	O
following	O
behavior	O
at	O
~	O
25	O
h	O
post	O
-	O
LPS	O
treatment	O
or	O
30	O
min	O
following	O
subcutaneous	O
3	O
-	O
HK	O
administration	O
,	O
tissues	O
were	O
collected	O
for	O
analysis	O
.	O

Mice	B-OG
were	O
killed	O
by	O
carbon	O
dioxide	O
asphyxiation	O
and	O
venous	O
blood	O
was	O
collected	O
into	O
heparinized	O
tubes	O
for	O
separation	O
of	O
plasma	O
.	O

Then	O
,	O
mice	B-OG
were	O
immediately	O
perfused	O
with	O
ice	O
-	O
cold	O
heparinized	O
sterile	O
saline	O
before	O
collection	O
of	O
whole	O
-	O
brain	O
or	O
microdissection	O
of	O
dorsal	O
hippocampus	O
,	O
ventral	O
hippocampus	O
,	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
.	O

Microdissections	O
were	O
conducted	O
using	O
a	O
brain	O
matrix	O
(	O
Stoelting	O
,	O
Wood	O
Dale	O
,	O
IL	O
,	O
USA	O
)	O
and	O
serial	O
1	O
-	O
mm	O
coronal	O
brain	O
sections	O
(	O
based	O
on	O
stereological	O
coordinates	O
in	O
a	O
mouse	B-OG
brain	O
atlas35	O
).	O

All	O
tissue	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
use	O
.	O

Samples	O
were	O
prepared	O
for	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
and	O
analyzed	O
for	O
kynurenine	B-CD
metabolites	O
as	O
previously	O
described	O
.	O
20	O
Briefly	O
,	O
thawed	O
plasma	O
samples	O
were	O
diluted	O
with	O
5	O
×	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
and	O
1	O
mM	O
internal	O
standards	O
,	O
transferred	O
to	O
Amicon	O
Ultra	O
filters	O
(	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
and	O
centrifuged	O
at	O
13	O
500	O
g	O
for	O
1	O
hour	O
at	O
4	O
°	O
C	O
.	O

Frozen	O
brain	O
tissue	O
was	O
diluted	O
with	O
3	O
×	O
0	O
.	O
2	O
%	O
acetic	O
acid	O
and	O
1	O
mM	O
internal	O
standards	O
and	O
then	O
homogenized	O
at	O
4	O
°	O
C	O
using	O
an	O
Omni	O
International	O
Bead	O
Ruptor	O
24	O
Homogenizer	O
(	O
Kennesaw	O
,	O
GA	O
,	O
USA	O
)	O
with	O
1	O
.	O
4	O
mm	O
zirconium	O
ceramic	O
oxide	O
beads	O
(	O
Omni	O
International	O
)	O
and	O
settings	O
of	O
(	O
pulse	O
duration	O
:	O
45	O
s	O
,	O
pulse	O
number	O
:	O
2	O
,	O
rest	O
interval	O
:	O
15	O
s	O
).	O

The	O
brain	O
homogenate	O
was	O
filtered	O
as	O
the	O
plasma	O
.	O

LC	O
/	O
MS	O
was	O
performed	O
on	O
a	O
Thermo	O
Fisher	O
Scientific	O
Q	O
Exactive	O
mass	O
spectrometer	O
(	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
with	O
online	O
separation	O
by	O
a	O
Thermo	O
Fisher	O
Scientific	O
Dionex	O
UltiMate	O
3000	O
HPLC	O
and	O
the	O
resulting	O
data	O
were	O
analyzed	O
using	O
Xcalibur	O
2	O
.	O
2	O
(	O
Thermo	O
Fisher	O
Scientific	O
)	O
in	O
the	O
Mass	O
Spectrometry	O
Core	O
Facility	O
at	O
the	O
University	O
of	O
Texas	O
Health	O
Science	O
Center	O
at	O
San	O
Antonio	O
.	O

QA	O
and	O
3	O
-	O
HAA	O
were	O
not	O
reliably	O
measured	O
in	O
microdissected	O
brain	O
region	O
samples	O
because	O
of	O
small	O
sample	O
size	O
,	O
nor	O
was	O
QA	O
reliably	O
detected	O
in	O
whole	O
-	O
brain	O
samples	O
.	O

Statistical	O
analysis	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SigmaPlot	O
12	O
.	O
0	O
(	O
Systat	O
Software	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
and	O
data	O
represent	O
group	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Behavioral	O
data	O
are	O
presented	O
as	O
%	O
Saline	O
(	O
saline	O
or	O
LPS	O
i	O
.	O
p	O
.)	O
or	O
%	O
Vehicle	O
(	O
3	O
-	O
HK	O
subcutaneous	O
)	O
and	O
were	O
calculated	O
based	O
on	O
saline	O
within	O
the	O
individual	O
genotype	O
or	O
on	O
vehicle	O
.	O

Spurious	O
data	O
were	O
identified	O
as	O
previously	O
described33	O
and	O
analyzed	O
with	O
either	O
a	O
one	O
-	O
tailed	O
t	O
-	O
test	O
,	O
a	O
one	O
-	O
or	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
.	O

When	O
a	O
significant	O
interaction	O
was	O
identified	O
,	O
post	O
hoc	O
analyses	O
were	O
completed	O
using	O
the	O
Holm	O
–	O
Sidak	O
method	O
for	O
pairwise	O
multiple	O
comparisons	O
to	O
identify	O
significant	O
differences	O
between	O
groups	O
.	O

Significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
within	O
-	O
group	O
differences	O
are	O
denoted	O
as	O
such	O
(*),	O
whereas	O
significant	O
same	O
treatment	O
between	O
-	O
group	O
differences	O
are	O
denoted	O
as	O
such	O
(+).	O

Results	O

KMO	B-GP
mediates	O
distinct	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O

Mice	B-OG
were	O
tested	O
in	O
the	O
TST	O
(	O
Figure	O
3a	O
)	O
24	O
h	O
after	O
i	O
.	O
p	O
.	O

LPS	O
or	O
saline	O
,	O
and	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
was	O
identified	O
.	O

WT	O
mice	B-OG
exhibited	O
a	O
significant	O
increase	O
in	O
duration	O
spent	O
immobile	O
following	O
LPS	O
injections	O
(	O
P	O
=	O
0	O
.	O
029	O
versus	O
saline	O
),	O
similar	O
to	O
previously	O
observed	O
LPS	O
effects	O
in	O
the	O
TST	O
.	O
14	O
However	O
,	O
LPS	O
failed	O
to	O
cause	O
an	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

LPS	O
caused	O
a	O
significant	O
reduction	O
in	O
SP	O
(	O
Figure	O
3b	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
that	O
was	O
not	O
different	O
between	O
genotypes	O
,	O
and	O
similarly	O
the	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
of	O
an	O
OF	O
was	O
significantly	O
reduced	O
by	O
LPS	O
-	O
independent	O
of	O
genotype	O
(	O
Figure	O
2c	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Thigmotaxis	O
(	O
Figure	O
3d	O
),	O
wall	O
-	O
hugging	O
behavior	O
,	O
was	O
increased	O
after	O
LPS	O
in	O
both	O
WT	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
KMO	B-GP
−/−	I-GP
(	O
P	O
<	O
0	O
.	O
001	O
)	O
mice	B-OG
,	O
but	O
to	O
a	O
greater	O
extent	O
in	O
the	O
KMO	B-GP
-	O
deficient	O
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Overall	O
distance	O
traveled	O
in	O
the	O
OF	O
was	O
reduced	O
modestly	O
,	O
but	O
significantly	O
,	O
by	O
LPS	O
treatment	O
(	O
Supplementary	O
Figure	O
1A	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
independent	O
of	O
genotype	O
,	O
as	O
was	O
LPS	O
-	O
induced	O
reduction	O
in	O
body	O
weight	O
(	O
Supplementary	O
Figure	O
1B	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
(	O
F1	O
,	O
23	O
=	O
5	O
.	O
10	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
was	O
apparent	O
for	O
spontaneous	O
alternations	O
during	O
the	O
Y	O
-	O
maze	O
test	O
(	O
Figure	O
3e	O
),	O
where	O
LPS	O
reduced	O
alternations	O
in	O
WT	O
(	O
P	O
=	O
0	O
.	O
046	O
),	O
but	O
not	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

3	O
-	O
HK	O
dose	O
-	O
dependently	O
induces	O
a	O
depressive	O
-	O
like	O
behavioral	O
phenotype	O

3	O
-	O
HK	O
was	O
administered	O
subcutaneously	O
30	O
min	O
before	O
behavioral	O
testing	O
at	O
the	O
indicated	O
doses	O
.	O

3	O
-	O
HK	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
during	O
the	O
TST	O
(	O
Figure	O
4a	O
,	O
P	O
=	O
0	O
.	O
012	O
).	O

SP	O
,	O
measured	O
during	O
a	O
2	O
-	O
h	O
probe	O
beginning	O
30	O
min	O
post	O
injection	O
,	O
was	O
unaffected	O
by	O
3	O
-	O
HK	O
administration	O
(	O
Figure	O
4b	O
).	O

The	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
of	O
an	O
OF	O
was	O
significantly	O
increased	O
by	O
3	O
-	O
HK	O
administration	O
(	O
Figure	O
4c	O
,	O
P	O
=	O
0	O
.	O
013	O
);	O
however	O
,	O
thigmotaxis	O
behavior	O
failed	O
to	O
reach	O
significance	O
(	O
Figure	O
4c	O
).	O

Importantly	O
,	O
general	O
locomotor	O
activity	O
in	O
the	O
OF	O
,	O
as	O
evaluated	O
by	O
distance	O
traveled	O
,	O
was	O
not	O
significantly	O
affected	O
by	O
3	O
-	O
HK	O
administration	O
(	O
data	O
not	O
shown	O
).	O

Similar	O
to	O
TST	O
immobility	O
,	O
exogenous	O
3	O
-	O
HK	O
administration	O
significantly	O
reduced	O
spontaneous	O
alternations	O
during	O
the	O
Y	O
-	O
maze	O
test	O
(	O
Figure	O
4e	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Peripheral	O
3	O
-	O
HK	O
administration	O
dose	O
-	O
dependently	O
increased	O
3	O
-	O
HK	O
concentration	O
in	O
the	O
plasma	O
(	O
Figure	O
4f	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
line	O
with	O
behavioral	O
changes	O
observed	O
.	O

Similarly	O
,	O
central	O
concentrations	O
of	O
3	O
-	O
HK	O
(	O
Figure	O
4g	O
)	O
were	O
dose	O
-	O
dependently	O
elevated	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
response	O
to	O
peripheral	O
3	O
-	O
HK	O
injections	O
.	O

HAAO	B-GP
null	O
mice	B-OG
are	O
protected	O
from	O
peripheral	O
LPS	O
-	O
induced	O
behavioral	O
despair	O

Twenty	O
-	O
four	O
hours	O
after	O
LPS	O
or	O
saline	O
treatment	O
,	O
depressive	O
-	O
like	O
behaviors	O
were	O
assessed	O
in	O
HAAO	O
−/−	O
or	O
WT	O
.	O

LPS	O
administration	O
caused	O
a	O
40	O
%	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
WT	O
mice	B-OG
in	O
the	O
TST	O
;	O
however	O
,	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
were	O
entirely	O
protected	O
from	O
this	O
effect	O
(	O
Figure	O
5a	O
,	O
P	O
=	O
0	O
.	O
013	O
).	O

HAAO	B-GP
−/−	I-GP
mice	B-OG
had	O
similar	O
LPS	O
treatment	O
responses	O
as	O
WT	O
mice	B-OG
when	O
assessed	O
for	O
anhedonia	O
and	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

Following	O
LPS	O
treatment	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
SP	O
caused	O
by	O
LPS	O
(	O
Figure	O
5b	O
)	O
in	O
both	O
HAAO	B-GP
−/−	I-GP
and	O
WT	O
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
although	O
no	O
interaction	O
was	O
present	O
,	O
a	O
modest	O
but	O
significant	O
overall	O
reduction	O
in	O
SP	O
was	O
apparent	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
(	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
the	O
OF	O
test	O
,	O
LPS	O
caused	O
a	O
reduction	O
in	O
the	O
duration	O
of	O
time	O
spent	O
in	O
the	O
central	O
area	O
(	O
Figure	O
5c	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
an	O
increase	O
in	O
thigmotaxis	O
behavior	O
(	O
Figure	O
5d	O
,	O
P	O
<	O
0	O
.	O
001	O
);	O
however	O
,	O
there	O
was	O
no	O
significant	O
effect	O
of	O
genotype	O
.	O

Similar	O
to	O
KMO	B-GP
−/−	I-GP
mice	B-OG
,	O
distance	O
traveled	O
during	O
the	O
OF	O
(	O
Supplementary	O
Figure	O
1C	O
)	O
was	O
reduced	O
24	O
h	O
following	O
LPS	O
treatment	O
independent	O
of	O
genotype	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
LPS	O
precipitated	O
a	O
reduction	O
in	O
body	O
weight	O
that	O
was	O
not	O
different	O
between	O
genotypes	O
(	O
Supplementary	O
Figure	O
1D	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
addition	O
,	O
there	O
was	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
in	O
spontaneous	O
alternations	O
assessed	O
in	O
the	O
Y	O
-	O
maze	O
(	O
Figure	O
5e	O
,	O
P	O
=	O
0	O
.	O
011	O
),	O
in	O
which	O
LPS	O
treatment	O
induced	O
a	O
reduction	O
in	O
WT	O
mice	B-OG
(	O
P	O
=	O
0	O
.	O
041	O
)	O
and	O
not	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
.	O

Characterization	O
of	O
brain	O
and	O
plasma	O
kynurenine	B-CD
metabolism	O
in	O
KMO	B-GP
and	O
HAAO	B-GP
knockout	O
mice	B-OG

Full	O
statistical	O
analysis	O
is	O
indicated	O
in	O
the	O
table	O
,	O
and	O
,	O
for	O
the	O
sake	O
of	O
clarity	O
,	O
parsimonious	O
reporting	O
of	O
significant	O
effects	O
are	O
reported	O
here	O
.	O

To	O
determine	O
the	O
consequence	O
of	O
targeted	O
deletions	O
of	O
Kmo	B-GP
and	O
Haao	B-GP
genes	O
on	O
central	O
kynurenine	B-CD
pathway	O
metabolism	O
(	O
Figure	O
1	O
),	O
cerebral	O
levels	O
of	O
tryptophan	B-CD
and	O
kynurenine	B-CD
metabolites	O
were	O
measured	O
in	O
WT	O
,	O
KMO	B-GP
−/−	I-GP
and	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
24	O
h	O
after	O
LPS	O
or	O
saline	O
administration	O
(	O
Table	O
1	O
).	O

There	O
was	O
a	O
significant	O
main	O
effect	O
of	O
both	O
treatment	O
and	O
genotype	O
on	O
the	O
concentration	O
of	O
central	O
tryptophan	B-CD
(	O
μM	O
,	O
Row	O
1	O
).	O

Consistent	O
with	O
previous	O
findings	O
,	O
20	O
LPS	O
treatment	O
resulted	O
in	O
an	O
elevation	O
in	O
central	O
kynurenine	B-CD
levels	O
(	O
μM	O
,	O
Row	O
2	O
)	O
in	O
WT	O
,	O
KMO	B-GP
−/−	I-GP
and	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
genotype	O
and	O
treatment	O
as	O
KMO	O
−/−	O
mice	B-OG
had	O
substantially	O
higher	O
brain	O
kynurenine	B-CD
levels	O
.	O

3	O
-	O
HK	O
(	O
μM	O
,	O
Row	B-GP
3	I-GP
)	O
was	O
not	O
detected	O
in	O
the	O
brain	O
of	O
KMO	B-GP
−/−	I-GP
mice	B-OG
,	O
and	O
was	O
higher	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
relative	O
to	O
WT	O
mice	B-OG
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
LPS	O
-	O
induced	O
increase	O
in	O
3	O
-	O
HK	O
in	O
WT	O
mice	B-OG
,	O
whereas	O
there	O
was	O
no	O
treatment	O
effect	O
in	O
HAAO	O
−/−	O
mice	B-OG
.	O

Downstream	O
of	O
3	O
-	O
HK	O
,	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
genotype	O
and	O
treatment	O
on	O
the	O
concentration	O
of	O
central	O
3	O
-	O
HAA	O
(	O
μM	O
,	O
Row	O
4	O
).	O

This	O
effect	O
is	O
largely	O
driven	O
by	O
the	O
elevation	O
of	O
central	O
3	O
-	O
HAA	O
in	O
HAAO	O
−/−	O
mice	B-OG
.	O

QA	O
was	O
not	O
reliably	O
detected	O
in	O
any	O
of	O
the	O
brain	O
samples	O
in	O
our	O
study	O
.	O

KA	O
(	O
μM	O
,	O
Row	B-GP
6	I-GP
)	O
was	O
markedly	O
elevated	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
and	O
decreased	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
,	O
with	O
no	O
significant	O
effect	O
of	O
LPS	O
.	O

Plasma	O
tryptophan	B-CD
levels	O
(	O
μM	O
,	O
Row	O
7	O
)	O
varied	O
between	O
genotype	O
,	O
but	O
were	O
significantly	O
reduced	O
by	O
LPS	O
in	O
WT	O
,	O
KMO	B-GP
−/−	I-GP
and	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
.	O

Kynurenine	B-CD
levels	O
(	O
μM	O
,	O
Row	O
8	O
)	O
were	O
substantially	O
higher	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
overall	O
.	O

3	O
-	O
HK	O
(	O
μM	O
,	O
Row	O
9	O
)	O
was	O
detected	O
in	O
plasma	O
of	O
all	O
mice	B-OG
,	O
although	O
near	O
the	O
lower	O
limit	O
of	O
detection	O
in	O
KMO	O
−/−	O
mice	B-OG
.	O

LPS	O
increased	O
3	O
-	O
HK	O
levels	O
in	O
both	O
WT	O
and	O
HAAO	O
−/−	O
mice	B-OG
,	O
but	O
not	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

Plasma	O
3	O
-	O
HAA	O
(	O
μM	O
,	O
Row	B-GP
10	I-GP
)	O
was	O
not	O
detected	O
in	O
WT	O
or	O
KMO	O
−/−	O
mice	B-OG
,	O
and	O
there	O
was	O
no	O
LPS	O
treatment	O
effect	O
in	O
HAAO	O
−/−	O
mice	B-OG
.	O

QA	O
levels	O
(	O
μM	O
,	O
Row	O
11	O
)	O
varied	O
by	O
genotype	O
with	O
no	O
effect	O
of	O
treatment	O
.	O

Finally	O
,	O
there	O
was	O
a	O
significant	O
genotype	O
×	O
treatment	O
interaction	O
in	O
the	O
concentration	O
of	O
plasma	O
KA	O
(	O
μM	O
,	O
Row	O
12	O
).	O

This	O
effect	O
was	O
driven	O
by	O
a	O
25	O
–	O
30	O
-	O
fold	O
increase	O
in	O
KA	O
levels	O
in	O
the	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

Overall	O
,	O
LPS	O
reduced	O
plasma	O
KA	O
levels	O
.	O

Kynurenine	B-CD
metabolism	O
within	O
discrete	O
,	O
behaviorally	O
relevant	O
,	O
brain	O
regions	O
following	O
peripheral	O
immune	O
challenge	O
with	O
LPS	O

Full	O
statistical	O
analysis	O
is	O
indicated	O
in	O
the	O
table	O
,	O
and	O
,	O
for	O
the	O
sake	O
of	O
clarity	O
,	O
parsimonious	O
reporting	O
of	O
significant	O
effects	O
are	O
reported	O
here	O
.	O

To	O
determine	O
whether	O
region	O
-	O
specific	O
differences	O
in	O
kynurenine	B-CD
metabolism	O
underlie	O
the	O
distinct	O
neurotoxic	O
metabolism	O
-	O
dependent	O
behavioral	O
profile	O
,	O
brain	O
region	O
metabolite	O
concentrations	O
were	O
determined	O
24	O
h	O
post	O
-	O
saline	O
or	O
LPS	O
treatment	O
(	O
Table	O
2	O
).	O

In	O
the	O
dorsal	O
hippocampus	O
,	O
both	O
tryptophan	B-CD
and	O
kynurenine	B-CD
concentrations	O
(	O
μM	O
)	O
increased	O
following	O
LPS	O
treatment	O
.	O

Neuroactive	O
kynurenine	B-CD
metabolism	O
also	O
increased	O
with	O
elevations	O
in	O
3	O
-	O
HK	O
(	O
μM	O
),	O
3	O
-	O
HAA	O
(	O
μM	O
)	O
and	O
XA	O
(	O
μM	O
),	O
whereas	O
KA	O
(	O
μM	O
)	O
remained	O
unchanged	O
.	O

XA	O
has	O
been	O
reported	O
to	O
influence	O
synaptic	O
transmission	O
as	O
a	O
metabotropic	B-GP
glutamate	I-GP
receptor	I-GP
group	I-GP
II	I-GP
ligand	O
and	O
a	O
vesicular	B-GP
glutamate	I-GP
transporter	I-GP
inhibitor	O
.	O
36	O
,	O
37	O
In	O
the	O
ventral	O
hippocampus	O
,	O
LPS	O
treatment	O
also	O
increased	O
kynurenine	B-CD
and	O
XA	O
.	O

However	O
,	O
no	O
other	O
metabolites	O
were	O
altered	O
by	O
LPS	O
.	O

In	O
the	O
central	O
amygdala	O
,	O
tryptophan	B-CD
and	O
kynurenine	B-CD
concentrations	O
increased	O
in	O
response	O
to	O
LPS	O
treatment	O
.	O

3	O
-	O
HK	O
,	O
XA	O
and	O
KA	O
were	O
also	O
significantly	O
elevated	O
following	O
LPS	O
treatment	O
.	O

In	O
the	O
nucleus	O
accumbens	O
,	O
tryptophan	B-CD
and	O
all	O
kynurenine	B-CD
metabolites	O
were	O
increased	O
following	O
LPS	O
treatment	O
as	O
in	O
the	O
central	O
amygdala	O
.	O

3	O
-	O
HAA	O
was	O
not	O
detected	O
in	O
either	O
the	O
central	O
amygdala	O
or	O
the	O
nucleus	O
accumbens	O
.	O

To	O
compare	O
the	O
relative	O
LPS	O
effect	O
between	O
brain	O
regions	O
,	O
metabolite	O
changes	O
were	O
normalized	O
as	O
%	O
saline	O
and	O
analyzed	O
(	O
Table	O
3	O
).	O

There	O
was	O
a	O
main	O
effect	O
of	O
region	O
on	O
tryptophan	B-CD
concentration	O
change	O
following	O
LPS	O
treatment	O
,	O
whereby	O
tryptophan	B-CD
was	O
significantly	O
higher	O
in	O
the	O
central	O
amygdala	O
than	O
the	O
ventral	O
or	O
dorsal	O
hippocampus	O
.	O

LPS	O
-	O
induced	O
increases	O
in	O
kynurenine	B-CD
,	O
3	O
-	O
HK	O
and	O
XA	O
were	O
comparable	O
across	O
the	O
different	O
brain	O
regions	O
.	O

Although	O
3	O
-	O
HAA	O
was	O
not	O
detected	O
in	O
the	O
central	O
amygdala	O
or	O
nucleus	O
accumbens	O
,	O
it	O
was	O
increased	O
to	O
a	O
greater	O
extent	O
in	O
dorsal	O
compared	O
with	O
ventral	O
hippocampus	O
.	O

There	O
was	O
also	O
a	O
significant	O
effect	O
of	O
region	O
on	O
LPS	O
-	O
induced	O
KA	O
.	O

This	O
effect	O
was	O
driven	O
by	O
significantly	O
greater	O
LPS	O
-	O
induced	O
increase	O
in	O
nucleus	O
accumbens	O
and	O
central	O
amygdala	O
compared	O
with	O
hippocampal	O
subregions	O
.	O

Discussion	O

The	O
kynurenine	B-CD
pathway	O
of	O
tryptophan	B-CD
metabolism	O
has	O
been	O
heavily	O
implicated	O
as	O
a	O
pathogenic	O
factor	O
in	O
the	O
development	O
of	O
depression	B-DS
,	O
particularly	O
within	O
the	O
context	O
of	O
inflammation	O
-	O
associated	O
depression	B-DS
.	O

We	O
and	O
others	O
have	O
demonstrated	O
that	O
IDO	B-GP
,	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
kynurenine	B-CD
metabolism	O
(	O
Figure	O
1	O
),	O
directly	O
mediates	O
the	O
induction	O
of	O
depressive	O
-	O
like	O
behaviors	O
in	O
response	O
to	O
peripheral	O
immune	O
challenge	O
in	O
preclinical	O
models	O
.	O
14	O
,	O
16	O
,	O
33	O
However	O
,	O
the	O
generation	O
of	O
neuroactive	O
kynurenine	B-CD
metabolites	O
occurs	O
downstream	O
of	O
IDO	B-GP
.	O
20	O
Whereas	O
emergent	O
clinical	O
and	O
preclinical	O
data	O
suggest	O
that	O
shifting	O
the	O
balance	O
of	O
downstream	O
kynurenine	B-CD
metabolism	O
to	O
favor	O
production	O
of	O
neurotoxic	O
kynurenines	B-CD
drives	O
depressive	O
symptoms	O
,	O
19	O
,	O
20	O
no	O
mechanistic	O
studies	O
have	O
been	O
performed	O
to	O
directly	O
test	O
this	O
hypothesis	O
.	O

Here	O
,	O
we	O
utilized	O
two	O
novel	O
transgenic	O
mouse	B-OG
strains	O
with	O
targeted	O
deletion	O
of	O
either	O
KMO	B-GP
or	O
HAAO	B-GP
(	O
Figure	O
1	O
)	O
to	O
determine	O
whether	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
causes	O
the	O
development	O
of	O
depressive	O
behaviors	O
following	O
peripheral	O
immune	O
activation	O
with	O
LPS	O
(	O
bacterial	O
endotoxin	O
).	O

KMO	B-GP
−/−	I-GP
mice	B-OG
do	O
not	O
generate	O
detectible	O
3	O
-	O
HK	O
in	O
the	O
brain	O
before	O
or	O
after	O
LPS	O
challenge	O
(	O
Table	O
1	O
).	O

In	O
contrast	O
to	O
inhibition	O
of	O
IDO	B-GP
,	O
targeted	O
deletion	O
of	O
KMO	B-GP
inhibited	O
only	O
a	O
specific	O
subset	O
of	O
LPS	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
(	O
Figure	O
3	O
).	O

Direct	O
administration	O
of	O
3	O
-	O
HK	O
,	O
the	O
metabolic	O
product	O
of	O
KMO	O
,	O
induced	O
the	O
development	O
of	O
depressive	O
-	O
like	O
behaviors	O
that	O
were	O
attenuated	O
in	O
the	O
KMO	O
−/−	O
mice	B-OG
(	O
Figure	O
4	O
).	O

Although	O
QA	O
was	O
not	O
reliably	O
detected	O
in	O
brain	O
tissue	O
(	O
Table	O
1	O
),	O
a	O
reduction	O
in	O
neurotoxic	O
metabolism	O
would	O
presumably	O
result	O
in	O
the	O
generation	O
of	O
less	O
QA	O
.	O

Therefore	O
,	O
LPS	O
-	O
induced	O
depressive	O
behavior	O
was	O
measured	O
in	O
HAAO	O
−/−	O
mice	B-OG
,	O
and	O
these	O
mice	B-OG
were	O
also	O
protected	O
from	O
the	O
development	O
of	O
the	O
same	O
specific	O
depressive	O
-	O
like	O
behaviors	O
(	O
Figure	O
5	O
).	O

Together	O
,	O
these	O
data	O
confirm	O
that	O
KMO	B-GP
-	O
and	O
HAAO	B-GP
-	O
dependent	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
directly	O
mediates	O
the	O
development	O
of	O
inflammation	O
-	O
induced	O
behavior	O
despair	O
and	O
working	B-DS
memory	I-DS
deficits	I-DS
;	O
behaviors	O
regulated	O
by	O
hippocampal	O
-	O
dependent	O
neurocircuitry	O
.	O

Previous	O
research	O
in	O
this	O
area	O
has	O
suffered	O
from	O
an	O
overall	O
lack	O
of	O
functional	O
precision	O
,	O
as	O
studies	O
that	O
measured	O
kynurenine	B-CD
metabolism	O
downstream	O
of	O
IDO	B-GP
have	O
evaluated	O
only	O
CSF	O
in	O
patients	O
or	O
whole	O
-	O
brain	O
tissue	O
in	O
rodents	B-OG
.	O
19	O
,	O
20	O
For	O
example	O
,	O
Raison	O
et	O
al	O
.	O
19	O
showed	O
that	O
the	O
concentration	O
of	O
QA	O
in	O
the	O
CSF	O
was	O
positively	O
correlated	O
with	O
depression	B-DS
scores	O
of	O
controls	O
and	O
subjects	O
receiving	O
interferon	B-GP
immunotherapy	O
.	O
19	O
In	O
addition	O
,	O
the	O
first	O
preclinical	O
study	O
to	O
investigate	O
the	O
role	O
of	O
QA	O
in	O
driving	O
depressive	O
symptoms	O
showed	O
that	O
LPS	O
-	O
induced	O
depressive	O
behaviors	O
could	O
be	O
mitigated	O
in	O
inbred	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
by	O
the	O
NMDAR	B-GP
,	O
ketamine	B-CD
,	O
suggesting	O
a	O
pathogenic	O
role	O
for	O
QA	O
.	O
20	O
Metabolic	O
analysis	O
in	O
the	O
study	O
by	O
Walker	O
et	O
al	O
.	O
20	O
indicated	O
that	O
LPS	O
caused	O
a	O
shift	O
toward	O
neurotoxic	O
metabolism	O
in	O
whole	O
-	O
brain	O
tissue	O
of	O
a	O
separate	O
group	O
of	O
CD	B-OG
-	I-OG
1	I-OG
outbred	O
mice	B-OG
.	O
20	O
Here	O
,	O
we	O
report	O
,	O
for	O
we	O
believe	O
the	O
first	O
time	O
,	O
direct	O
evidence	O
that	O
directly	O
implicates	O
KMO	B-GP
-	O
dependent	O
kynurenine	B-CD
metabolism	O
in	O
LPS	O
-	O
induced	O
depression	B-DS
.	O

Further	O
,	O
as	O
only	O
specific	O
behaviors	O
were	O
mitigated	O
by	O
genetic	O
inhibition	O
of	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
,	O
the	O
data	O
suggested	O
that	O
kynurenine	B-CD
metabolism	O
might	O
differ	O
between	O
discrete	O
brain	O
regions	O
.	O

Indeed	O
,	O
Frenois	O
et	O
al	O
.	O
38	O
demonstrated	O
that	O
neuronal	O
activation	O
following	O
peripheral	O
LPS	O
challenge	O
of	O
C57BL6	B-OG
/	I-OG
J	I-OG
mice	I-OG
(	O
measured	O
by	O
FosB	B-GP
/	O
Δ	O
FosB	B-GP
immunohistochemistry	O
)	O
was	O
not	O
uniformly	O
increased	O
.	O
38	O
Rather	O
,	O
discrete	O
regions	O
with	O
known	O
relevance	O
to	O
depressive	O
behavioral	O
domains	O
were	O
more	O
strongly	O
increased	O
,	O
including	O
hippocampus	O
,	O
nucleus	O
accumbens	O
and	O
central	O
amygdala	O
.	O
38	O

Whereas	O
a	O
previous	O
report	O
by	O
Giorgini	O
et	O
al	O
.	O
39	O
characterized	O
the	O
metabolic	O
changes	O
that	O
occur	O
in	O
response	O
to	O
a	O
KMO	B-GP
deficiency	O
in	O
a	O
separate	O
strain	O
of	O
mice	B-OG
,	O
39	O
the	O
data	O
in	O
Figure	O
3	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
a	O
KMO	B-GP
genetic	O
deletion	O
on	O
the	O
behavioral	O
consequences	O
of	O
peripheral	O
LPS	O
administration	O
.	O

KMO	B-GP
−/−	I-GP
mice	B-OG
have	O
disrupted	O
central	O
and	O
peripheral	O
kynurenine	B-CD
metabolism	O
(	O
Table	O
1	O
)	O
in	O
a	O
similar	O
pattern	O
to	O
this	O
previous	O
study	O
.	O
39	O
Interestingly	O
,	O
baseline	O
kynurenine	B-CD
levels	O
are	O
significantly	O
elevated	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
without	O
any	O
apparent	O
changes	O
to	O
baseline	O
depressive	O
-	O
like	O
phenotype	O
.	O

This	O
is	O
seemingly	O
in	O
contrast	O
to	O
previous	O
data	O
from	O
our	O
laboratory	O
,	O
and	O
others	O
demonstrating	O
that	O
direct	O
administration	O
of	O
kynurenine	B-CD
can	O
induce	O
deficits	O
in	O
novel	O
object	O
recognition	O
and	O
spatial	O
working	O
memory	O
alter	O
fear	O
conditioning	O
and	O
induce	O
anhedonia	B-DS
.	O
16	O
,	O
33	O
,	O
40	O
,	O
41	O
,	O
42	O
It	O
is	O
possible	O
that	O
the	O
accumulation	O
of	O
kynurenine	B-CD
over	O
time	O
through	O
development	O
allows	O
the	O
system	O
to	O
adjust	O
preventing	O
any	O
potential	O
behavioral	O
changes	O
.	O

Peripheral	O
LPS	O
treatment	O
in	O
KMO	B-GP
−/−	I-GP
mice	B-OG
precipitates	O
an	O
increase	O
in	O
central	O
kynurenine	B-CD
without	O
any	O
changes	O
in	O
central	O
3	O
-	O
HK	O
.	O

The	O
metabolite	O
analyses	O
from	O
HAAO	O
−/−	O
mice	B-OG
(	O
Table	O
1	O
)	O
are	O
the	O
first	O
from	O
a	O
genetic	O
mutant	O
model	O
targeted	O
at	O
this	O
enzyme	O
that	O
metabolizes	O
3	O
-	O
HAA	O
to	O
QA	O
.	O

Although	O
QA	O
was	O
not	O
reliably	O
detected	O
in	O
any	O
brain	O
tissue	O
sample	O
,	O
both	O
central	O
3	O
-	O
HK	O
and	O
3	O
-	O
HAA	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
were	O
increased	O
over	O
WT	O
levels	O
,	O
as	O
would	O
be	O
predicted	O
in	O
mice	B-OG
lacking	O
the	O
enzyme	O
to	O
metabolize	O
3	O
-	O
HAA	O
to	O
QA	O
.	O

In	O
the	O
plasma	O
,	O
3	O
-	O
HK	O
and	O
3	O
-	O
HAA	O
were	O
similarly	O
elevated	O
in	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
;	O
however	O
,	O
QA	O
was	O
still	O
detectable	O
,	O
indicating	O
the	O
potential	O
for	O
an	O
alternate	O
metabolic	O
source	O
of	O
QA	O
.	O

Although	O
surprising	O
,	O
this	O
peripheral	O
QA	O
is	O
unable	O
to	O
cross	O
the	O
blood	O
–	O
brain	O
barrier	O
and	O
therefore	O
has	O
no	O
direct	O
impact	O
on	O
central	O
QA	O
concentrations	O
and	O
does	O
not	O
contribute	O
to	O
the	O
behavioral	O
phenotype	O
of	O
HAAO	O
−/−	O
mice	B-OG
.	O

It	O
is	O
well	O
accepted	O
that	O
depressive	O
symptoms	O
occur	O
across	O
multiple	O
behavioral	O
domains	O
,	O
and	O
that	O
distinct	O
regions	O
of	O
the	O
brain	O
are	O
critical	O
to	O
each	O
of	O
the	O
various	O
domains	O
of	O
depressive	O
-	O
like	O
behavior	O
.	O

In	O
fact	O
,	O
this	O
is	O
the	O
basic	O
tenet	O
of	O
the	O
National	O
Institute	O
of	O
Mental	O
Health	O
'	O
s	O
(	O
NIMH	O
)	O
Research	O
Domain	O
Criteria	O
(	O
RDoC	O
,	O
http	O
://	O
www	O
.	O
nimh	O
.	O
nih	O
.	O
gov	O
/	O
research	O
-	O
priorities	O
/	O
rdoc	O
/	O
index	O
.	O
shtml	O
)	O
framework	O
to	O
guide	O
mental	O
health	O
research	O
.	O
43	O
,	O
44	O
Preclinical	O
neuropsychiatric	O
research	O
necessarily	O
employs	O
an	O
RDoC	O
framework	O
that	O
deconstructs	O
a	O
behavioral	O
phenotype	O
(	O
neuropsychiatric	B-DS
disorders	I-DS
being	O
modeled	O
)	O
into	O
core	O
behaviors	O
(	O
analogous	O
to	O
symptoms	O
)	O
that	O
are	O
functionally	O
controlled	O
by	O
primary	O
neurocircuits	O
in	O
discrete	O
brain	O
regions	O
.	O

To	O
determine	O
whether	O
increased	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
generates	O
the	O
metabolic	O
substrates	O
to	O
cause	O
the	O
distinct	O
depressive	O
-	O
like	O
behaviors	O
observed	O
in	O
Figures	O
3	O
and	O
5	O
,	O
kynurenine	B-CD
metabolites	O
were	O
measured	O
in	O
the	O
dorsal	O
hippocampus	O
,	O
ventral	O
hippocampus	O
,	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
of	O
C57BL6	B-OG
/	I-OG
J	I-OG
mice	I-OG
(	O
Table	O
2	O
),	O
the	O
same	O
background	O
strain	O
of	O
the	O
KMO	O
−/−	O
and	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
,	O
at	O
24	O
h	O
post	O
treatment	O
.	O

These	O
regions	O
were	O
chosen	O
for	O
their	O
relevance	O
to	O
depression	B-DS
in	O
humans	B-OG
as	O
well	O
as	O
the	O
individual	O
behaviors	O
analyzed	O
in	O
this	O
study	O
following	O
peripheral	O
inflammation	O
.	O
45	O
,	O
46	O
,	O
47	O
,	O
48	O
Immobility	O
during	O
the	O
TST	O
and	O
spontaneous	O
alternations	O
in	O
Y	O
-	O
maze	O
are	O
behaviors	O
known	O
to	O
require	O
hippocampal	O
function	O
,	O
and	O
their	O
analogous	O
depressive	O
symptoms	O
are	O
behavioral	O
despair	O
and	O
working	O
memory	O
.	O
49	O
,	O
50	O
,	O
51	O
However	O
,	O
SP	O
requires	O
reward	O
circuitry	O
of	O
the	O
nucleus	O
accumbens	O
,	O
and	O
reduced	O
preference	O
reflects	O
an	O
anhedonia	O
-	O
like	O
phenotype	O
.	O
46	O
Behavior	O
in	O
the	O
OF	O
reflects	O
anxiety	B-DS
-	O
like	O
states	O
that	O
involve	O
amygdala	O
activity	O
.	O
52	O
,	O
53	O

Consistent	O
with	O
previous	O
studies	O
,	O
LPS	O
caused	O
a	O
reduction	O
in	O
circulating	O
tryptophan	B-CD
levels	O
and	O
a	O
robust	O
increase	O
in	O
the	O
concentration	O
of	O
kynurenine	B-CD
in	O
both	O
the	O
periphery	O
and	O
in	O
each	O
brain	O
region	O
analyzed	O
(	O
Tables	O
1	O
and	O
2	O
).	O

However	O
,	O
an	O
interesting	O
pattern	O
was	O
noted	O
in	O
the	O
metabolic	O
profile	O
downstream	O
of	O
kynurenine	B-CD
.	O

Neurotoxic	O
metabolites	O
were	O
generally	O
increased	O
across	O
each	O
brain	O
region	O
,	O
but	O
KA	O
was	O
also	O
significantly	O
increased	O
in	O
central	O
amygdala	O
and	O
nucleus	O
accumbens	O
.	O

Only	O
the	O
dorsal	O
hippocampus	O
reflected	O
a	O
clear	O
shift	O
toward	O
neurotoxic	O
and	O
neuromodulatory	O
(	O
KMO	B-GP
-	O
dependent	O
)	O
metabolism	O
without	O
a	O
parallel	O
increase	O
in	O
the	O
opposing	O
KAT	B-GP
-	O
dependent	O
metabolic	O
branch	O
.	O

The	O
specific	O
behaviors	O
known	O
to	O
involve	O
hippocampal	O
activity	O
were	O
mitigated	O
by	O
genetic	O
inhibition	O
of	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
(	O
in	O
KMO	O
−/−	O
and	O
HAAO	O
−/−	O
mice	B-OG
)	O
and	O
precipitated	O
by	O
direct	O
administration	O
of	O
3	O
-	O
HK	O
.	O

The	O
hippocampus	O
was	O
the	O
only	O
discrete	O
brain	O
region	O
where	O
LPS	O
treatment	O
resulted	O
in	O
a	O
clear	O
and	O
unbalanced	O
shift	O
toward	O
the	O
generation	O
of	O
KMO	B-GP
-	O
dependent	O
metabolites	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
contemporary	O
hypothesis	O
that	O
disrupting	O
the	O
metabolic	O
balance	O
of	O
the	O
kynurenine	B-CD
pathway	O
,	O
rather	O
than	O
simply	O
increasing	O
overall	O
kynurenine	B-CD
metabolism	O
,	O
defines	O
the	O
functional	O
pathogenic	O
context	O
by	O
which	O
kynurenine	B-CD
metabolism	O
mediates	O
the	O
behavioral	O
effects	O
of	O
inflammation	O
.	O
27	O
,	O
28	O
Further	O
,	O
these	O
data	O
support	O
recent	O
findings	O
from	O
our	O
laboratory	O
,	O
demonstrating	O
that	O
peripheral	O
LPS	O
induces	O
brain	O
region	O
-	O
dependent	O
changes	O
in	O
the	O
balance	O
of	O
kynurenine	B-CD
metabolites	O
,	O
specifically	O
favoring	O
neurotoxic	O
metabolite	O
production	O
in	O
the	O
hippocampus	O
.	O
34	O
Recent	O
data	O
characterizing	O
the	O
regional	O
characteristics	O
of	O
microglia	O
throughout	O
the	O
brain	O
demonstrated	O
that	O
not	O
all	O
microglia	O
express	O
the	O
same	O
functional	O
expression	O
markers	O
.	O
54	O
Specifically	O
,	O
it	O
was	O
noted	O
that	O
microglia	O
in	O
the	O
hippocampus	O
were	O
more	O
responsive	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
earning	O
them	O
the	O
label	O
‘	O
immunovigilant	O
'.	O
54	O
This	O
hyper	O
-	O
responsive	O
state	O
of	O
hippocampal	O
microglia	O
could	O
underlie	O
the	O
region	O
-	O
specific	O
elevation	O
in	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
described	O
in	O
Table	O
2	O
.	O

Recent	O
clinical	O
data	O
demonstrated	O
that	O
,	O
following	O
a	O
suicide	O
attempt	O
in	O
depressed	O
patients	O
,	O
CSF	O
QA	O
remains	O
elevated	O
while	O
CSF	O
KA	O
stayed	O
decreased	O
.	O
55	O
In	O
patients	O
with	O
mastocytosis	B-DS
,	O
associated	O
with	O
comorbid	O
depression	B-DS
and	O
inflammation	O
,	O
plasma	O
QA	O
and	O
plasma	O
KA	O
were	O
found	O
to	O
be	O
elevated	O
.	O
56	O
More	O
specifically	O
,	O
in	O
depressed	O
patients	O
,	O
the	O
serum	O
KA	O
/	O
QA	O
ratio	O
(	O
neuroprotective	O
ratio	O
)	O
was	O
positively	O
correlated	O
with	O
increasing	O
volumes	O
of	O
the	O
hippocampus	O
and	O
amygdala	O
.	O
57	O

Previous	O
data	O
in	O
mice	B-OG
with	O
either	O
genetic	O
or	O
systemic	O
inhibition	O
of	O
IDO	B-GP
clearly	O
indicate	O
a	O
pivotal	O
role	O
for	O
kynurenine	B-CD
metabolism	O
in	O
mediating	O
depressive	O
-	O
like	O
behaviors	O
in	O
response	O
to	O
peripheral	O
immune	O
challenge	O
.	O

The	O
general	O
increase	O
in	O
kynurenine	B-CD
metabolism	O
across	O
each	O
brain	O
region	O
(	O
Table	O
2	O
)	O
that	O
was	O
identified	O
in	O
this	O
study	O
supports	O
the	O
conclusions	O
of	O
a	O
broad	O
importance	O
of	O
IDO	B-GP
in	O
mediating	O
the	O
effects	O
of	O
LPS	O
.	O

However	O
,	O
targeting	O
IDO	B-GP
does	O
not	O
provide	O
any	O
indication	O
of	O
which	O
neuroactive	O
downstream	O
metabolites	O
are	O
responsible	O
for	O
driving	O
inflammation	O
-	O
induced	O
behavioral	O
phenotypes	O
.	O

Whereas	O
the	O
previous	O
study	O
by	O
Walker	O
et	O
al	O
.	O
20	O
found	O
that	O
both	O
LPS	O
-	O
induced	O
increases	O
in	O
immobility	O
and	O
reduction	O
in	O
SP	O
could	O
be	O
mitigated	O
by	O
the	O
NMDAR	B-GP
antagonist	O
,	O
ketamine	B-CD
,	O
a	O
direct	O
pathogenic	O
role	O
for	O
QA	O
action	O
on	O
NMDARs	B-GP
can	O
only	O
be	O
speculated	O
.	O
20	O
Here	O
,	O
we	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
a	O
shift	O
toward	O
neurotoxic	O
metabolism	O
in	O
the	O
hippocampus	O
mediates	O
the	O
behavioral	O
deficits	O
following	O
peripheral	O
LPS	O
.	O

In	O
contrast	O
to	O
the	O
data	O
from	O
Walker	O
et	O
al	O
.,	O
20	O
we	O
found	O
that	O
LPS	O
-	O
induced	O
reductions	O
in	O
SP	O
were	O
not	O
KMO	B-GP
-	O
or	O
HAAO	B-GP
-	O
dependent	O
,	O
as	O
their	O
data	O
suggested	O
.	O

This	O
discrepancy	O
could	O
be	O
the	O
result	O
of	O
strain	O
-	O
related	O
differences	O
in	O
LPS	O
-	O
induced	O
metabolism	O
of	O
CD	B-GP
-	I-GP
1	I-GP
versus	O
C57BL6	B-OG
/	I-OG
J	I-OG
mice	I-OG
,	O
or	O
more	O
likely	O
other	O
neuroactive	O
kynurenines	B-CD
are	O
responsible	O
for	O
driving	O
the	O
LPS	O
-	O
induced	O
anhedonia	O
phenotype	O
,	O
such	O
as	O
XA	O
or	O
KA	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
chronic	O
alterations	O
in	O
kynurenine	B-CD
metabolites	O
that	O
exist	O
in	O
the	O
conventional	O
KMO	B-GP
and	O
HAAO	B-GP
null	O
mice	B-OG
results	O
in	O
a	O
compensatory	O
recalibration	O
of	O
the	O
reward	O
system	O
,	O
as	O
the	O
effects	O
of	O
acute	O
and	O
subchronic	O
elevations	O
in	O
KA	O
on	O
the	O
dopaminergic	O
system	O
are	O
well	O
established	O
.	O
58	O
,	O
59	O
Although	O
no	O
baseline	O
differences	O
in	O
SP	O
were	O
observed	O
,	O
it	O
is	O
of	O
interest	O
to	O
note	O
that	O
the	O
LPS	O
-	O
stimulated	O
increase	O
in	O
nucleus	O
accumbens	O
KA	O
could	O
locally	O
decrease	O
extracellular	O
dopamine	B-CD
,	O
similar	O
to	O
a	O
previously	O
demonstrated	O
effect	O
of	O
exogenous	O
KA	O
application	O
to	O
the	O
striatum	O
.	O
60	O
This	O
local	O
reduction	O
in	O
extracellular	O
DA	O
could	O
contribute	O
to	O
the	O
development	O
of	O
anhedonia	O
behavior	O
following	O
LPS	O
treatment	O
.	O

Direct	O
administration	O
of	O
exogenous	O
kynurenine	B-CD
has	O
been	O
utilized	O
in	O
a	O
number	O
of	O
contexts	O
that	O
result	O
in	O
behavioral	O
changes	O
.	O
40	O
,	O
41	O
,	O
59	O
Our	O
previous	O
work	O
demonstrated	O
that	O
exogenous	O
kynurenine	B-CD
acutely	O
precipitates	O
a	O
depressive	O
-	O
like	O
phenotype	O
similar	O
to	O
LPS	O
.	O
16	O
Chronic	O
administration	O
of	O
kynurenine	B-CD
during	O
early	O
development	O
or	O
to	O
adult	O
mice	B-OG
has	O
also	O
been	O
used	O
to	O
elevate	O
KA	O
levels	O
in	O
the	O
brain	O
,	O
resulting	O
in	O
deficits	O
in	O
sensorimotor	O
gating	O
,	O
attentional	O
processing	O
of	O
environmental	O
stimuli	O
,	O
spatial	O
working	O
memory	O
and	O
contextual	O
learning	O
memory	O
.	O
40	O
,	O
41	O
,	O
61	O
The	O
data	O
here	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
exogenously	O
administered	O
peripheral	O
3	O
-	O
HK	O
is	O
able	O
to	O
precipitate	O
the	O
development	O
of	O
behavioral	O
despair	O
in	O
the	O
TST	O
,	O
impair	O
working	O
memory	O
in	O
the	O
Y	O
-	O
maze	O
and	O
induce	O
anxiety	B-DS
-	O
like	O
behavior	O
assessed	O
in	O
the	O
OF	O
.	O

Of	O
note	O
,	O
general	O
locomotor	O
activity	O
in	O
the	O
OF	O
(	O
Supplementary	O
Figure	O
1A	O
,	O
1C	O
),	O
although	O
confirmatory	O
of	O
a	O
positive	O
effect	O
of	O
LPS	O
,	O
was	O
not	O
correlated	O
to	O
depressive	O
-	O
like	O
behaviors	O
in	O
any	O
of	O
the	O
testing	O
paradigms	O
.	O

This	O
effect	O
of	O
LPS	O
in	O
the	O
OF	O
is	O
similar	O
to	O
previously	O
published	O
data	O
from	O
our	O
laboratory	O
,	O
demonstrating	O
that	O
duration	O
in	O
the	O
central	O
area	O
(	O
anxiety	B-DS
-	O
like	O
behavior	O
)	O
does	O
not	O
depend	O
on	O
locomotor	O
activity	O
.	O
16	O
Although	O
the	O
open	O
was	O
conducted	O
under	O
low	O
-	O
light	O
conditions	O
and	O
more	O
light	O
might	O
provide	O
a	O
greater	O
ethological	O
conflict	O
for	O
assessing	O
anxiety	B-DS
-	O
like	O
behavior	O
,	O
the	O
primary	O
purpose	O
of	O
this	O
assessment	O
was	O
to	O
determine	O
the	O
impact	O
of	O
treatment	O
on	O
locomotor	O
activity	O
.	O

Together	O
,	O
these	O
data	O
significantly	O
enhance	O
our	O
understanding	O
of	O
the	O
metabolic	O
substrates	O
that	O
mediate	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behavior	O
.	O

Whereas	O
a	O
majority	O
of	O
brain	O
kynurenine	B-CD
is	O
supplied	O
by	O
the	O
circulation	O
,	O
62	O
these	O
data	O
indicate	O
that	O
downstream	O
metabolism	O
is	O
a	O
regionally	O
regulated	O
process	O
with	O
implications	O
for	O
behavioral	O
pathology	O
.	O

Our	O
data	O
indicate	O
that	O
hippocampal	O
-	O
dependent	O
behaviors	O
may	O
be	O
particularly	O
vulnerable	O
to	O
neurotoxic	O
dysregulation	O
of	O
kynurenine	B-CD
metabolism	O
,	O
which	O
could	O
also	O
have	O
larger	O
implications	O
in	O
the	O
context	O
of	O
neurodegenerative	B-DS
disease	I-DS
and	O
chronic	O
inflammatory	O
conditions	O
.	O

Therapeutic	O
manipulation	O
of	O
the	O
kynurenine	B-CD
metabolic	O
pathway	O
remains	O
a	O
potentially	O
valuable	O
strategy	O
for	O
alleviating	O
depressive	O
symptoms	O
,	O
particularly	O
in	O
the	O
context	O
of	O
inflammation	O
and	O
comorbidity	O
.	O

Supplementary	O
Information	O
accompanies	O
the	O
paper	O
on	O
the	O
Translational	O
Psychiatry	O
website	O
(	O
http	O
://	O
www	O
.	O
nature	O
.	O
com	O
/	O
tp	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
kynurenine	B-CD
pathway	O
of	O
tryptophan	B-CD
metabolism	O
.	O

In	O
the	O
kynurenine	B-CD
pathway	O
,	O
tryptophan	B-CD
is	O
metabolized	O
to	O
kynurenine	B-CD
by	O
indoleamine	B-GP
2	I-GP
,	I-GP
3	I-GP
-	I-GP
dioxygenase	I-GP
(	O
IDO	B-GP
),	O
an	O
enzyme	O
that	O
is	O
upregulated	O
by	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
.	O

Kynurenine	B-CD
is	O
then	O
either	O
metabolized	O
to	O
kynurenic	B-CD
acid	I-CD
(	O
KA	O
)	O
by	O
kynurenine	B-GP
aminotransferases	I-GP
(	O
KATs	B-GP
),	O
or	O
to	O
3	O
-	O
hydroxykynurenine	O
(	O
3	O
-	O
HK	O
,	O
red	O
)	O
by	O
kynurenine	B-GP
-	I-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
,	O
purple	O
).	O

Under	O
basal	O
conditions	O
,	O
most	O
of	O
kynurenine	B-CD
in	O
the	O
brain	O
is	O
metabolized	O
to	O
KA	O
,	O
a	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
and	O
α7	B-GP
-	I-GP
nicotinic	I-GP
acetylcholine	I-GP
(	I-GP
α7nACh	I-GP
)	I-GP
receptor	I-GP
antagonist	O
.	O

However	O
,	O
neuroinflammation	O
and	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
will	O
shift	O
kynurenine	B-CD
metabolism	O
through	O
KMO	O
to	O
3	O
-	O
HK	O
.	O

Then	O
,	O
further	O
metabolism	O
occurs	O
to	O
3	O
-	O
hydroxyanthranilic	O
acid	O
(	O
3	O
-	O
HAA	O
)	O
by	O
kynureninase	B-GP
(	O
KYNU	B-GP
),	O
and	O
then	O
3	O
-	O
HAA	O
is	O
metabolized	O
to	O
quinolinic	B-CD
acid	I-CD
(	O
QA	O
,	O
red	O
)	O
by	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
,	O
purple	O
).	O

During	O
neuroinflammation	O
,	O
QA	O
is	O
the	O
major	O
end	O
product	O
of	O
the	O
kynurenine	B-CD
pathway	O
,	O
a	O
metabolite	O
that	O
is	O
a	O
NMDA	B-GP
receptor	I-GP
agonist	O
and	O
an	O
oxidative	O
stressor	O
.	O

3	O
-	O
HK	O
can	O
also	O
be	O
metabolized	O
to	O
xanthurenic	B-CD
acid	I-CD
(	O
XA	O
)	O
by	O
KATs	O
when	O
substrate	O
levels	O
are	O
high	O
enough	O
.	O

This	O
branch	O
of	O
metabolites	O
(	O
3	O
-	O
HK	O
,	O
3	O
-	O
HAA	O
,	O
QA	O
,	O
XA	O
)	O
is	O
considered	O
to	O
be	O
neurotoxic	O
(	O
orange	O
box	O
)	O
as	O
they	O
can	O
contribute	O
to	O
oxidative	O
stress	O
and	O
glutamate	B-CD
excitotoxicity	O
.	O

In	O
the	O
studies	O
described	O
,	O
two	O
genetic	O
mouse	B-OG
models	O
were	O
used	O
(	O
KMO	B-GP
and	O
HAAO	B-GP
knockouts	O
)	O
to	O
target	O
neurotoxic	O
kynurenine	B-CD
metabolism	O
(	O
indicated	O
by	O
purple	O
‘	O
no	O
'	O
symbol	O
).	O

Kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)	O
and	O
3	B-GP
-	I-GP
hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
transgene	O
construct	O
.	O

(	O
a	O
)	O
The	O
KMO	O
transgene	O
vector	O
was	O
designed	O
with	O
a	O
neomycin	B-CD
(	O
neo	O
)	O
selection	O
cassette	O
to	O
test	O
for	O
site	O
-	O
specific	O
integration	O
of	O
the	O
transgene	O
.	O

Proper	O
incorporation	O
of	O
the	O
transgene	O
results	O
in	O
gene	O
-	O
trapping	O
between	O
the	O
reporter	O
gene	O
(	O
lacZ	B-GP
)	O
from	O
the	O
cassette	O
and	O
the	O
Kmo	B-GP
gene	O
during	O
transcription	O
.	O

When	O
these	O
transcripts	O
become	O
spliced	O
together	O
,	O
an	O
insertion	O
mutation	O
is	O
created	O
resulting	O
in	O
a	O
non	O
-	O
functional	O
KMO	B-GP
protein	O
and	O
a	O
KMO	B-GP
−/−	I-GP
mouse	B-OG
.	O

The	O
vector	O
also	O
includes	O
recombination	O
sites	O
(	O
Flp	B-GP
recombination	O
target	O
(	O
FRT	O
),	O
loxP	O
)	O
that	O
can	O
be	O
used	O
to	O
create	O
a	O
conditional	O
-	O
ready	O
mouse	B-OG
targeted	O
for	O
the	O
gene	O
of	O
interest	O
(	O
that	O
is	O
,	O
KMO	B-GP
-	O
floxed	O
).	O

(	O
b	O
)	O
The	O
presence	O
of	O
the	O
transgene	O
in	O
KMO	O
transgenic	O
mice	B-OG
were	O
confirmed	O
using	O
RT	O
-	O
PCR	O
for	O
either	O
the	O
wild	O
-	O
type	O
allele	O
(	O
476	O
-	O
bp	O
band	O
)	O
or	O
the	O
transgenic	O
allele	O
(	O
592	O
-	O
bp	O
band	O
),	O
as	O
indicated	O
in	O
a	O
.	O

(	O
c	O
)	O
The	O
HAAO	B-GP
transgene	O
vector	O
was	O
designed	O
identical	O
to	O
the	O
KMO	B-GP
transgene	O
(	O
a	O
),	O
targeting	O
the	O
HAAO	B-GP
genetic	O
sequence	O
.	O

(	O
d	O
)	O
The	O
presence	O
of	O
the	O
HAAO	B-GP
transgene	O
was	O
confirmed	O
in	O
the	O
same	O
manner	O
as	O
the	O
KMO	B-GP
transgene	O
using	O
a	O
RT	O
-	O
PCR	O
reaction	O
for	O
the	O
wild	O
-	O
type	O
allele	O
(	O
516	O
bp	O
)	O
and	O
for	O
the	O
transgenic	O
allele	O
(	O
594	O
bp	O
).	O

Kynurenine	B-GP
3	I-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	B-GP
)	O
knockout	O
mice	B-OG
are	O
protected	O
from	O
distinct	O
inflammation	O
-	O
induced	O
depressive	O
-	O
like	O
behaviors	O
.	O

(	O
a	O
)	O
Twenty	O
-	O
four	O
hours	O
following	O
injection	O
with	O
either	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
saline	O
,	O
wild	O
type	O
(	O
WT	O
)	O
and	O
KMO	B-GP
−/−	I-GP
mice	B-OG
were	O
tested	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
to	O
assess	O
behavioral	O
despair	O
.	O

LPS	O
increases	O
duration	O
spent	O
immobile	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
WT	O
mice	B-OG
but	O
not	O
in	O
KMO	O
−/−	O
mice	B-OG
.	O

(	O
b	O
)	O
Sucrose	B-CD
and	O
water	O
intake	O
were	O
recorded	O
for	O
the	O
24h	O
following	O
LPS	O
or	O
saline	O
injections	O
and	O
were	O
used	O
to	O
calculate	O
sucrose	B-CD
preference	O
(	O
SP	O
)	O
to	O
assess	O
anhedonia	O
-	O
like	O
behavior	O
.	O

LPS	O
treatment	O
resulted	O
in	O
a	O
characteristic	O
reduction	O
in	O
SP	O
in	O
both	O
WT	O
and	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

(	O
c	O
)	O
Similarly	O
,	O
at	O
24	O
h	O
post	O
treatment	O
,	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
the	O
center	O
of	O
the	O
open	O
field	O
(	O
OF	O
)	O
was	O
recorded	O
as	O
an	O
index	O
of	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

(	O
d	O
)	O
Duration	O
spent	O
near	O
the	O
walls	O
of	O
the	O
OF	O
or	O
thigmotaxis	O
behavior	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Saline	O
)	O
was	O
also	O
recorded	O
to	O
asses	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

In	O
both	O
OF	O
assessments	O
(	O
c	O
,	O
d	O
),	O
LPS	O
treatment	O
resulted	O
in	O
similar	O
elevations	O
in	O
anxiety	B-DS
-	O
like	O
behavior	O
in	O
WT	O
and	O
KMO	B-GP
−/−	I-GP
mice	B-OG
.	O

(	O
e	O
)	O
Spontaneous	O
alterations	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
between	O
the	O
three	O
arms	O
of	O
a	O
Y	O
-	O
maze	O
were	O
recorded	O
as	O
an	O
index	O
of	O
working	O
memory	O
.	O

LPS	O
treatment	O
resulted	O
in	O
a	O
significant	O
deficit	O
in	O
spontaneous	O
alterations	O
in	O
WT	O
mice	B-OG
but	O
KMO	B-GP
−/−	I-GP
mice	B-OG
were	O
unaffected	O
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
n	O
=	O
13	O
–	O
29	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
between	O
saline	O
and	O
LPS	O
within	O
the	O
same	O
genotype	O
.	O
+	O
Post	O
hoc	O
comparison	O
to	O
WT	O
with	O
the	O
same	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
treatment	O
.	O
*,+	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**,++	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***,+++	O
P	O
<	O
0	O
.	O
001	O
.	O

3	O
-	O
Hydroxykynurenine	O
(	O
3	O
-	O
HK	O
)	O
administration	O
induces	O
behavioral	O
despair	O
and	O
working	O
memory	O
deficits	O
.	O

(	O
a	O
)	O
The	O
metabolite	O
produced	O
by	O
kynurenine	B-CD
3	B-GP
-	I-GP
monooxygenase	I-GP
(	O
KMO	O
),	O
3	O
-	O
HK	O
,	O
was	O
injected	O
subcutaneously	O
30	O
min	O
before	O
assessing	O
behavioral	O
despair	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
).	O

3	O
-	O
HK	O
was	O
administered	O
at	O
doses	O
of	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
and	O
resulted	O
in	O
an	O
increased	O
immobile	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Vehicle	O
).	O

(	O
b	O
)	O
Sucrose	B-CD
preference	O
(	O
SP	O
)	O
was	O
measured	O
2	O
h	O
beginning	O
30	O
min	O
post	O
-	O
subcutaneous	O
3	O
-	O
HK	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
),	O
and	O
anhedonia	O
-	O
like	O
behavior	O
was	O
unaffected	O
by	O
peripheral	O
3	O
-	O
HK	O
.	O

Thirty	O
minutes	O
following	O
3	O
-	O
HK	O
subcutaneous	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
),	O
activity	O
was	O
recorded	O
in	O
the	O
open	O
field	O
(	O
OF	O
)	O
to	O
determine	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

3	O
-	O
HK	O
decreased	O
the	O
duration	O
(	O
seconds	O
,	O
represented	O
as	O
%	O
Vehicle	O
;	O
(	O
c	O
)	O
in	O
the	O
center	O
of	O
the	O
OF	O
while	O
there	O
was	O
no	O
impact	O
of	O
3	O
-	O
HK	O
on	O
(	O
d	O
)	O
thigmotoxis	O
behavior	O
.	O

Working	O
memory	O
was	O
also	O
assessed	O
in	O
the	O
Y	O
-	O
maze	O
30	O
min	O
following	O
subcutaneous	O
administration	O
(	O
0	O
.	O
0	O
mg	O
kg	O
−	O
1	O
(	O
vehicle	O
),	O
3	O
.	O
33	O
and	O
10	O
mg	O
kg	O
−	O
1	O
)	O
of	O
3	O
-	O
HK	O
.	O

(	O
e	O
)	O
Spontaneous	O
alterations	O
(%	O
Vehicle	O
)	O
decreased	O
following	O
treatment	O
with	O
3	O
-	O
HK	O
.	O

(	O
f	O
)	O
Plasma	O
3	O
-	O
HK	O
concentrations	O
(	O
μM	O
)	O
increased	O
following	O
administration	O
of	O
3	O
-	O
HK	O
.	O

(	O
g	O
)	O
Similarly	O
,	O
3	O
-	O
HK	O
(	O
μM	O
)	O
assessed	O
in	O
brain	O
tissue	O
was	O
elevated	O
by	O
peripheral	O
3	O
-	O
HK	O
treatment	O
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
n	O
=	O
5	O
-	O
16	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
to	O
saline	O
or	O
vehicle	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

3	B-GP
-	I-GP
Hydroxyanthranilic	I-GP
acid	I-GP
dioxygenase	I-GP
(	O
HAAO	B-GP
)	O
transgenic	O
mice	B-OG
are	O
shielded	O
from	O
inflammation	O
-	O
induced	O
behavioral	O
despair	O
.	O

(	O
a	O
)	O
HAAO	O
−/−	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OG
were	O
assessed	O
for	O
duration	O
spent	O
immobile	O
(	O
s	O
)	O
in	O
the	O
TST	O
24	O
h	O
following	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
saline	O
injections	O
.	O

Whereas	O
LPS	O
treatment	O
increased	O
immobile	O
duration	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
WT	O
mice	B-OG
,	O
HAAO	B-GP
−/−	I-GP
mice	B-OG
were	O
protected	O
from	O
this	O
LPS	O
-	O
induced	O
change	O
in	O
behavior	O
.	O

(	O
b	O
)	O
Following	O
LPS	O
treatment	O
,	O
both	O
WT	O
and	O
HAAO	O
−/−	O
mice	B-OG
had	O
a	O
reduction	O
in	O
sucrose	B-CD
preference	O
(	O
SP	O
)	O
representing	O
anhedonia	O
-	O
like	O
behavior	O
.	O

(	O
c	O
)	O
In	O
addition	O
,	O
behavior	O
in	O
the	O
open	O
field	O
(	O
OF	O
)	O
was	O
analyzed	O
for	O
the	O
effect	O
of	O
LPS	O
treatment	O
on	O
duration	O
spent	O
in	O
the	O
center	O
of	O
the	O
arena	O
(	O
represented	O
as	O
%	O
Saline	O
),	O
an	O
index	O
of	O
anxiety	B-DS
-	O
like	O
behavior	O
.	O

LPS	O
reduced	O
time	O
spent	O
in	O
the	O
central	O
area	O
similarly	O
in	O
both	O
genotypes	O
.	O

(	O
d	O
)	O
Further	O
,	O
thigmotaxis	O
(	O
duration	O
)	O
was	O
extracted	O
from	O
the	O
OF	O
behavior	O
(	O
represented	O
as	O
%	O
Saline	O
),	O
which	O
was	O
increased	O
by	O
LPS	O
treatment	O
both	O
in	O
WT	O
and	O
HAAO	O
−/−	O
mice	B-OG
.	O

(	O
e	O
)	O
Spontaneous	O
alternations	O
(	O
represented	O
as	O
%	O
Saline	O
)	O
in	O
a	O
Y	O
-	O
maze	O
,	O
an	O
assessment	O
of	O
working	O
memory	O
,	O
were	O
reduced	O
by	O
LPS	O
treatment	O
only	O
in	O
WT	O
mice	B-OG
and	O
not	O
in	O
HAAO	O
−/−	O
mice	B-OG
.	O

Data	O
represent	O
sample	O
means	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O
and	O
were	O
analyzed	O
using	O
a	O
two	O
-	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
),	O
followed	O
by	O
the	O
Holm	O
–	O
Sidak	O
method	O
for	O
pairwise	O
multiple	O
comparisons	O
.	O
n	O
=	O
11	O
–	O
22	O
mice	B-OG
per	O
group	O
.	O
*	O
Main	O
effect	O
or	O
post	O
hoc	O
comparison	O
between	O
saline	O
and	O
LPS	O
within	O
the	O
same	O
genotype	O
.	O
+	O
Post	O
hoc	O
comparison	O
to	O
WT	O
with	O
the	O
same	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
treatment	O
.	O
*,+	O
P	O
<	O
0	O
.	O
05	O
–	O
0	O
.	O
01	O
;	O
**,++	O
P	O
<	O
0	O
.	O
01	O
–	O
0	O
.	O
001	O
;	O
***,+++	O
P	O
<	O
0	O
.	O
001	O
.	O


Genotype	O

Main	O
effects	O

Interaction	O


WT	O

KMO	B-GP
−/−	I-GP

HAAO	B-GP
−/−	I-GP

Treatment	O
P	O
-	O
value	O

Genotype	O
P	O
-	O
value	O

Treatment	O
×	O
genotype	O


Saline	O

LPS	O

Saline	O

LPS	O

Saline	O

LPS	O




Brain	O
metabolites	O
(	O
μM	O
)	O

Tryptophan	B-CD

31	O
.	O
20	O
(	O
2	O
.	O
1	O
)	O

34	O
.	O
44	O
(	O
2	O
.	O
9	O
)	O

37	O
.	O
54	O
(	O
8	O
.	O
0	O
)	O

45	O
.	O
25	O
(	O
8	O
.	O
0	O
)	O

55	O
.	O
49	O
(	O
3	O
.	O
3	O
)	O

67	O
.	O
96	O
(	O
0	O
.	O
9	O
)	O

P	O
<	O
0	O
.	O
05	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

Kynurenine	B-CD

0	O
.	O
17	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
06	O
)**	O

2	O
.	O
95	O
(	O
0	O
.	O
2	O
)+++	O

3	O
.	O
82	O
(	O
0	O
.	O
3	O
)***,+++	O

0	O
.	O
32	O
(	O
0	O
.	O
05	O
)	O

2	O
.	O
02	O
(	O
0	O
.	O
1	O
)***,+++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

3	O
-	O
HK	O

0	O
.	O
044	O
(	O
0	O
.	O
007	O
)	O

0	O
.	O
17	O
(	O
0	O
.	O
03	O
)***	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

0	O
.	O
54	O
(	O
0	O
.	O
2	O
)	O

0	O
.	O
51	O
(	O
0	O
.	O
08	O
)	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

3	O
-	O
HAA	O

0	O
.	O
29	O
(	O
0	O
.	O
06	O
)	O

0	O
.	O
25	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
26	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
12	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
99	O
(	O
0	O
.	O
07	O
)+++	O

0	O
.	O
44	O
(	O
0	O
.	O
05	O
)***,++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

QA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

KA	O

0	O
.	O
12	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
10	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
37	O
(	O
0	O
.	O
08	O
)	O

0	O
.	O
31	O
(	O
0	O
.	O
05	O
)	O

0	O
.	O
021	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
038	O
(	O
0	O
.	O
001	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O


Plasma	O
metabolites	O
(	O
μM	O
)	O

Tryptophan	B-CD

96	O
.	O
00	O
(	O
4	O
.	O
7	O
)	O

78	O
.	O
36	O
(	O
7	O
.	O
4	O
)	O

65	O
.	O
72	O
(	O
3	O
.	O
9	O
)	O

49	O
.	O
39	O
(	O
2	O
.	O
6	O
)	O

120	O
.	O
62	O
(	O
9	O
.	O
5	O
)	O

98	O
.	O
23	O
(	O
3	O
.	O
0	O
)	O

P	O
<	O
0	O
.	O
05	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

Kynurenine	B-CD

0	O
.	O
80	O
(	O
0	O
.	O
06	O
)	O

2	O
.	O
41	O
(	O
0	O
.	O
1	O
)	O

11	O
.	O
13	O
(	O
2	O
.	O
0	O
)	O

9	O
.	O
86	O
(	O
0	O
.	O
3	O
)	O

0	O
.	O
88	O
(	O
0	O
.	O
08	O
)	O

3	O
.	O
19	O
(	O
0	O
.	O
4	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

3	O
-	O
HK	O

0	O
.	O
083	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
45	O
(	O
0	O
.	O
03	O
)***	O

0	O
.	O
0098	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
017	O
(	O
0	O
.	O
006	O
)+++	O

0	O
.	O
13	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
87	O
(	O
0	O
.	O
08	O
)***,+++	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

2	O
.	O
17	O
(	O
0	O
.	O
27	O
)	O

3	O
.	O
16	O
(	O
1	O
.	O
0	O
)	O

n	O
/	O
a	O

n	O
/	O
a	O

n	O
/	O
a	O

QA	O

0	O
.	O
39	O
(	O
0	O
.	O
03	O
)	O

0	O
.	O
48	O
(	O
0	O
.	O
08	O
)	O

0	O
.	O
24	O
(	O
0	O
.	O
008	O
)	O

0	O
.	O
30	O
(	O
0	O
.	O
004	O
)	O

0	O
.	O
64	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
58	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O

P	O
<	O
0	O
.	O
001	O

n	O
.	O
s	O
.	O

KA	O

0	O
.	O
94	O
(	O
0	O
.	O
1	O
)	O

0	O
.	O
59	O
(	O
0	O
.	O
07	O
)	O

31	O
.	O
45	O
(	O
5	O
.	O
3	O
)+++	O

15	O
.	O
78	O
(	O
0	O
.	O
8	O
)***,+++	O

0	O
.	O
24	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
21	O
(	O
0	O
.	O
02	O
)	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

P	O
<	O
0	O
.	O
001	O

Brain	O
region	O

Metabolite	O
(	O
μM	O
)	O

Treatment	O
(	O
i	O
.	O
p	O
.)	O

t	O
-	O
Test	O
,	O
P	O
-	O
value	O



Saline	O

LPS	O


Dorsal	O
hippocampus	O

Tryptophan	B-CD

102	O
.	O
93	O
(	O
5	O
.	O
1	O
)	O

129	O
.	O
83	O
(	O
4	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


Kynurenine	B-CD

0	O
.	O
39	O
(	O
0	O
.	O
03	O
)	O

1	O
.	O
02	O
(	O
0	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
13	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
19	O
(	O
0	O
.	O
02	O
)*	O

P	O
<	O
0	O
.	O
05	O


3	O
-	O
HAA	O

1	O
.	O
35	O
(	O
0	O
.	O
06	O
)	O

1	O
.	O
86	O
(	O
0	O
.	O
1	O
)**	O

P	O
<	O
0	O
.	O
01	O


KA	O

0	O
.	O
095	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
13	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O


XA	O

0	O
.	O
0085	O
(	O
0	O
.	O
001	O
)	O

0	O
.	O
023	O
(	O
0	O
.	O
003	O
)**	O

P	O
<	O
0	O
.	O
01	O






Ventral	O
hippocampus	O

Tryptophan	B-CD

95	O
.	O
38	O
(	O
4	O
.	O
5	O
)	O

122	O
.	O
83	O
(	O
9	O
.	O
2	O
)	O

n	O
.	O
s	O
.	O


Kynurenine	B-CD

0	O
.	O
33	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
85	O
(	O
0	O
.	O
04	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
12	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
15	O
(	O
0	O
.	O
02	O
)	O

n	O
.	O
s	O
.	O


3	O
-	O
HAA	O

1	O
.	O
62	O
(	O
0	O
.	O
08	O
)	O

1	O
.	O
60	O
(	O
0	O
.	O
2	O
)	O

n	O
.	O
s	O
.	O


KA	O

0	O
.	O
12	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
14	O
(	O
0	O
.	O
03	O
)	O

n	O
.	O
s	O
.	O


XA	O

0	O
.	O
012	O
(	O
0	O
.	O
001	O
)	O

0	O
.	O
024	O
(	O
0	O
.	O
003	O
)*	O

P	O
<	O
0	O
.	O
05	O






Central	O
amygdala	O

Tryptophan	B-CD

119	O
.	O
34	O
(	O
5	O
.	O
7	O
)	O

218	O
.	O
78	O
(	O
17	O
.	O
0	O
)***	O

P	O
<	O
0	O
.	O
001	O


Kynurenine	B-CD

0	O
.	O
46	O
(	O
0	O
.	O
04	O
)	O

1	O
.	O
60	O
(	O
0	O
.	O
1	O
)***	O

P	O
<	O
0	O
.	O
001	O


3	O
-	O
HK	O

0	O
.	O
11	O
(	O
0	O
.	O
01	O
)	O

0	O
.	O
19	O
(	O
0	O
.	O
03	O
)*	O

P	O
<	O
0	O
.	O
05	O


3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O


KA	O

0	O
.	O
12	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
40	O
(	O
0	O
.	O
1	O
)*	O

P	O
<	O
0	O
.	O
05	O


XA	O

0	O
.	O
0076	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
015	O
(	O
0	O
.	O
002	O
)**	O

P	O
<	O
0	O
.	O
01	O






Nucleus	O
accumbens	O

Tryptophan	B-CD

112	O
.	O
82	O
(	O
9	O
.	O
8	O
)	O

167	O
.	O
35	O
(	O
19	O
.	O
3	O
)*	O

P	O
<	O
0	O
.	O
05	O


Kynurenine	B-CD

0	O
.	O
45	O
(	O
0	O
.	O
07	O
)	O

1	O
.	O
59	O
(	O
0	O
.	O
3	O
)**	O

P	O
<	O
0	O
.	O
01	O


3	O
-	O
HK	O

0	O
.	O
14	O
(	O
0	O
.	O
02	O
)	O

0	O
.	O
24	O
(	O
0	O
.	O
02	O
)**	O

P	O
<	O
0	O
.	O
01	O


3	O
-	O
HAA	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

n	O
/	O
a	O


KA	O

0	O
.	O
20	O
(	O
0	O
.	O
04	O
)	O

0	O
.	O
78	O
(	O
0	O
.	O
2	O
)**	O

P	O
<	O
0	O
.	O
01	O


XA	O

0	O
.	O
0073	O
(	O
0	O
.	O
002	O
)	O

0	O
.	O
016	O
(	O
0	O
.	O
002	O
)*	O

P	O
<	O
0	O
.	O
05	O

Metabolite	O
(%	O
saline	O
)	O

Brain	O
region	O

ANOVA	O
,	O
P	O
-	O
value	O


Dorsal	O
hippocampus	O

Ventral	O
hippocampus	O

Central	O
amygdala	O

Nucleus	O
accumbens	O


Tryptophan	B-CD

126	O
.	O
14	O
(	O
4	O
.	O
2	O
)	O

128	O
.	O
78	O
(	O
10	O
.	O
1	O
)	O

183	O
.	O
33	O
(	O
15	O
.	O
1	O
)	O

148	O
.	O
33	O
(	O
18	O
.	O
0	O
)	O

P	O
<	O
0	O
.	O
01	O

Kynurenine	B-CD

259	O
.	O
03	O
(	O
19	O
.	O
8	O
)	O

254	O
.	O
37	O
(	O
14	O
.	O
6	O
)	O

344	O
.	O
91	O
(	O
26	O
.	O
7	O
)	O

356	O
.	O
87	O
(	O
70	O
.	O
5	O
)	O

n	O
.	O
s	O
.	O

3	O
-	O
HK	O

146	O
.	O
92	O
(	O
16	O
.	O
5	O
)	O

127	O
.	O
98	O
(	O
14	O
.	O
7	O
)	O

170	O
.	O
49	O
(	O
25	O
.	O
2	O
)	O

169	O
.	O
22	O
(	O
15	O
.	O
0	O
)	O

n	O
.	O
s	O
.	O

3	O
-	O
HAA	O

137	O
.	O
72	O
(	O
11	O
.	O
1	O
)	O

99	O
.	O
30	O
(	O
12	O
.	O
6	O
)	O

n	O
.	O
d	O
.	O

n	O
.	O
d	O
.	O

P	O
<	O
0	O
.	O
05	O

KA	O

133	O
.	O
54	O
(	O
20	O
.	O
1	O
)	O

109	O
.	O
07	O
(	O
25	O
.	O
9	O
)	O

323	O
.	O
49	O
(	O
110	O
.	O
3	O
)	O

391	O
.	O
40	O
(	O
93	O
.	O
6	O
)	O

P	O
<	O
0	O
.	O
01	O

XA	O

268	O
.	O
78	O
(	O
37	O
.	O
2	O
)	O

201	O
.	O
84	O
(	O
28	O
.	O
4	O
)	O

200	O
.	O
66	O
(	O
29	O
.	O
0	O
)	O

224	O
.	O
32	O
(	O
38	O
.	O
5	O
)	O

n	O
.	O
s	O
.	O

The	O
Link	O
between	O
Musculoskeletal	O
Pain	O
,	O
Lifestyle	O
Behaviors	O
,	O
Exercise	O
Self	O
-	O
Efficacy	O
,	O
and	O
Quality	O
of	O
Life	O
in	O
Overweight	O
and	O
Obese	O
Individuals	O

Objective	O

To	O
determine	O
the	O
extent	O
musculoskeletal	O
(	O
MS	O
)	O
pain	O
in	O
the	O
low	O
back	O
and	O
knee	O
(	O
weight	O
-	O
bearing	O
(	O
WB	O
)	O
joints	O
),	O
shoulder	O
and	O
wrist	O
(	O
non	O
-	O
weight	O
bearing	O
joints	O
),	O
and	O
exercise	O
self	O
-	O
efficacy	O
mediates	O
associations	O
between	O
overweight	O
and	O
obesity	B-DS
levels	O
based	O
on	O
BMI	O
(	O
4	O
levels	O
:	O
overweight	O
,	O
obese	O
class	O
I	O
,	O
II	O
,	O
or	O
III	O
),	O
physical	O
function	O
,	O
emotional	O
role	O
,	O
social	O
interference	O
,	O
and	O
physical	O
activity	O
(	O
PA	O
)	O
levels	O
.	O

Design	O

Cross	O
-	O
sectional	O
study	O
.	O

Setting	O

Four	O
long	O
-	O
term	O
nursing	O
home	O
facilities	O
in	O
the	O
Northeast	O
U	O
.	O
S	O
.	O

Participants	O

99	O
overweight	O
or	O
obese	O
(	O
BMI	O
>	O
25	O
)	O
nursing	O
home	O
employees	O
.	O

Interventions	O

Self	O
-	O
reported	O
survey	O
administered	O
to	O
employees	O
who	O
met	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

Main	O
Outcome	O
Measure	O
(	O
s	O
)	O

General	O
health	O
status	O
,	O
physical	O
function	O
,	O
emotional	O
role	O
,	O
Exercise	O
Self	O
-	O
Efficacy	O
Scale	O
(	O
ESE	O
),	O
physical	O
activity	O
(	O
PA	O
),	O
and	O
frequency	O
of	O
pain	O
at	O
each	O
joint	O
.	O

Results	O

Reported	O
pain	O
frequency	O
were	O
66	O
.	O
3	O
%,	O
54	O
.	O
4	O
%,	O
42	O
.	O
2	O
%,	O
and	O
24	O
.	O
1	O
%	O
for	O
lower	O
back	O
,	O
knee	O
,	O
shoulder	O
,	O
and	O
wrist	O
,	O
respectively	O
.	O

Higher	O
obesity	B-DS
levels	O
were	O
associated	O
with	O
lower	O
physical	O
function	O
(	O
r	O
=−	O
0	O
.	O
109	O
,	O
p	O
=	O
0	O
.	O
284	O
).	O

PA	O
decreased	O
with	O
higher	O
obesity	B-DS
levels	O
(	O
r	O
=−	O
0	O
.	O
248	O
,	O
p	O
<	O
0	O
.	O
05	O
),	O
particularly	O
in	O
moderate	O
PA	O
(	O
r	O
=−	O
0	O
.	O
293	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Obesity	B-DS
was	O
associated	O
with	O
a	O
lower	O
ESE	O
(	O
r	O
=−	O
0	O
.	O
239	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Wrist	O
pain	O
significantly	O
mediated	O
the	O
effect	O
of	O
obesity	B-DS
on	O
moderate	O
physical	O
function	O
,	O
emotional	O
role	O
,	O
and	O
ESE	O
.	O

ESE	O
was	O
a	O
significant	O
mediator	O
between	O
obesity	B-DS
and	O
moderate	O
and	O
vigorous	O
PA	O
.	O

Conclusions	O

Overweight	O
and	O
obese	O
nursing	O
home	O
employees	O
are	O
at	O
higher	O
risk	O
for	O
developing	O
musculoskeletal	B-DS
disorders	I-DS
due	O
to	O
high	O
demand	O
,	O
low	O
control	O
jobs	O
,	O
and	O
the	O
associated	O
biomedical	O
compromises	O
while	O
working	O
.	O

To	O
increase	O
the	O
effectiveness	O
of	O
weight	O
loss	O
interventions	O
for	O
this	O
population	O
,	O
the	O
mediating	O
effects	O
of	O
MS	B-DS
pain	O
with	O
higher	O
levels	O
of	O
obesity	B-DS
should	O
be	O
considered	O
.	O

Introduction	O

Within	O
the	O
last	O
20	O
years	O
,	O
prevalence	O
rates	O
of	O
obesity	B-DS
have	O
dramatically	O
risen	O
from	O
10	O
%	O
to	O
more	O
than	O
30	O
%	O
in	O
the	O
United	O
States	O
[	O
1	O
].	O

In	O
the	O
year	O
2015	O
,	O
it	O
has	O
been	O
estimated	O
that	O
about	O
75	O
%	O
of	O
adults	O
will	O
be	O
overweight	O
or	O
obese	O
,	O
and	O
41	O
%	O
of	O
U	O
.	O
S	O
.	O
adults	O
will	O
be	O
obese	O
[	O
2	O
].	O

Current	O
trends	O
show	O
that	O
obesity	B-DS
is	O
associated	O
with	O
increased	O
prevalence	O
of	O
adverse	O
health	O
conditions	O
,	O
including	O
coronary	B-DS
heart	I-DS
disease	I-DS
,	O
cancers	B-DS
(	O
endometrial	O
,	O
breast	O
,	O
and	O
colon	O
),	O
hypertension	B-DS
,	O
stroke	B-DS
,	O
dyslipidemia	B-DS
,	O
type	B-DS
2	I-DS
diabetes	I-DS
,	O
respiratory	O
problems	O
,	O
and	O
musculoskeletal	O
conditions	O
[	O
1	O
,	O
3	O
].	O

These	O
conditions	O
are	O
also	O
referred	O
to	O
as	O
Obesity	B-DS
-	O
related	O
Comorbidities	O
(	O
ORCs	O
),	O
and	O
have	O
a	O
substantial	O
impact	O
on	O
morbidity	O
rates	O
[	O
4	O
].	O

In	O
the	O
U	O
.	O
S	O
.,	O
approximately	O
280	O
,	O
000	O
to	O
325	O
,	O
000	O
deaths	O
each	O
year	O
are	O
attributable	O
to	O
obesity	B-DS
[	O
5	O
,	O
6	O
].	O

Obesity	B-DS
and	O
its	O
comorbidities	O
are	O
also	O
associated	O
with	O
changes	O
in	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
in	O
overweight	O
and	O
obese	O
individuals	O
,	O
an	O
outcome	O
involving	O
substantial	O
decreases	O
in	O
physical	O
and	O
mental	O
health	O
[	O
3	O
,	O
7	O
–	O
15	O
].	O

Increased	O
adiposity	O
in	O
overweight	O
and	O
obese	O
individuals	O
are	O
associated	O
with	O
mechanical	O
and	O
structural	O
changes	O
that	O
may	O
impact	O
physical	O
health	O
and	O
induce	O
musculoskeletal	O
conditions	O
[	O
3	O
,	O
8	O
,	O
16	O
–	O
19	O
].	O

Higher	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
may	O
lead	O
to	O
increased	O
loading	O
on	O
individual	O
joints	O
and	O
localized	O
inflammation	O
,	O
which	O
contribute	O
to	O
muscle	O
and	O
bone	O
loss	O
,	O
joint	O
misalignment	O
,	O
and	O
postural	O
changes	O
[	O
3	O
,	O
17	O
,	O
19	O
–	O
23	O
].	O

These	O
biomechanical	O
and	O
physiological	O
alterations	O
add	O
to	O
the	O
development	O
of	O
pain	O
,	O
musculoskeletal	O
conditions	O
and	O
joint	B-DS
disease	I-DS
[	O
3	O
,	O
8	O
,	O
24	O
].	O

Musculoskeletal	O
pain	O
in	O
various	O
body	O
sites	O
have	O
shown	O
positive	O
associations	O
with	O
increased	O
BMI	O
[	O
25	O
–	O
35	O
].	O

Understanding	O
the	O
mediating	O
effect	O
in	O
Weight	O
-	O
Bearing	O
(	O
WB	O
)	O
versus	O
Non	O
-	O
Weight	O
-	O
Bearing	O
(	O
NWB	O
)	O
joints	O
is	O
needed	O
to	O
expound	O
the	O
role	O
of	O
pain	O
in	O
the	O
BMI	O
-	O
HRQOL	O
relationship	O
.	O

Previous	O
research	O
has	O
shown	O
strong	O
associations	O
between	O
obesity	B-DS
and	O
self	O
-	O
efficacy	O
,	O
defined	O
as	O
an	O
individual	O
’	O
s	O
confidence	O
in	O
their	O
ability	O
to	O
perform	O
a	O
specific	O
behavior	O
to	O
achieve	O
a	O
particular	O
outcome	O
[	O
36	O
].	O

Individuals	O
with	O
a	O
high	O
BMI	O
consistently	O
report	O
a	O
lower	O
exercise	O
self	O
-	O
efficacy	O
(	O
ESE	O
),	O
suggesting	O
less	O
confidence	O
in	O
their	O
ability	O
to	O
change	O
or	O
keep	O
up	O
with	O
an	O
exercise	O
regimen	O
.	O

Decreases	O
in	O
ESE	O
are	O
positively	O
correlated	O
with	O
decreases	O
in	O
physical	O
activity	O
(	O
PA	O
)	O
levels	O
[	O
32	O
,	O
37	O
].	O

In	O
recent	O
weight	O
-	O
loss	O
interventions	O
that	O
targeted	O
ESE	O
,	O
modest	O
to	O
large	O
weight	O
reductions	O
of	O
5	O
–	O
10	O
kg	O
led	O
to	O
significant	O
increases	O
in	O
ESE	O
[	O
38	O
,	O
39	O
].	O

However	O
,	O
these	O
findings	O
need	O
to	O
be	O
further	O
elucidated	O
through	O
statistical	O
models	O
that	O
posit	O
ESE	O
as	O
a	O
mechanism	O
by	O
which	O
obesity	B-DS
affects	O
PA	O
level	O
[	O
32	O
,	O
35	O
,	O
39	O
,	O
40	O
].	O

ORCs	O
have	O
been	O
tested	O
as	O
potential	O
mediators	O
that	O
explain	O
part	O
of	O
the	O
adverse	O
effect	O
of	O
obesity	B-DS
on	O
HRQOL	O
outcomes	O
[	O
7	O
,	O
13	O
,	O
15	O
,	O
32	O
–	O
36	O
].	O

J	O
-	O
shaped	O
associations	O
between	O
obesity	B-DS
and	O
BMI	O
indicate	O
that	O
lower	O
HRQOL	O
was	O
observed	O
in	O
those	O
with	O
abnormal	O
body	O
weight	O
(	O
underweight	O
,	O
overweight	O
,	O
and	O
obese	O
individuals	O
)	O
[	O
5	O
].	O

In	O
particular	O
,	O
pain	O
in	O
2	O
–	O
4	O
sites	O
partially	O
mediated	O
about	O
22	O
–	O
44	O
%	O
of	O
the	O
association	O
between	O
obesity	B-DS
and	O
HRQOL	O
,	O
suggesting	O
that	O
obesity	B-DS
’	O
s	O
adverse	O
effect	O
on	O
HRQOL	O
may	O
be	O
manifested	O
through	O
musculoskeletal	O
pain	O
[	O
13	O
].	O

Explanatory	O
models	O
that	O
estimate	O
the	O
musculoskeletal	O
pain	O
as	O
a	O
mediator	O
in	O
this	O
relationship	O
would	O
be	O
useful	O
in	O
the	O
development	O
of	O
future	O
interventions	O
for	O
the	O
overweight	O
and	O
obese	O
population	O
[	O
24	O
,	O
41	O
].	O

The	O
present	O
study	O
seeks	O
to	O
evaluate	O
the	O
prevalence	O
of	O
musculoskeletal	O
pain	O
in	O
a	O
group	O
of	O
overweight	O
and	O
obese	O
individuals	O
and	O
to	O
identify	O
the	O
mediating	O
effect	O
of	O
pain	O
and	O
ESE	O
in	O
the	O
relationship	O
between	O
obesity	B-DS
,	O
PA	O
,	O
and	O
specific	O
HRQOL	O
items	O
.	O

We	O
hypothesize	O
that	O
:	O
1	O
)	O
musculoskeletal	O
pain	O
prevalence	O
will	O
be	O
high	O
in	O
both	O
WB	O
and	O
NWB	O
joints	O
;	O
2	O
)	O
increased	O
obesity	B-DS
will	O
indicate	O
lower	O
HRQOL	O
;	O
3	O
)	O
pain	O
will	O
partially	O
mediate	O
relationships	O
between	O
BMI	O
,	O
HRQOL	O
,	O
and	O
PA	O
;	O
and	O
4	O
)	O
ESE	O
will	O
partially	O
mediate	O
the	O
BMI	O
-	O
PA	O
relationship	O
.	O

Materials	O
and	O
Methods	O

Design	O

A	O
cross	O
-	O
sectional	O
observational	O
study	O
.	O

Participants	O

The	O
study	O
sample	O
included	O
ninety	O
-	O
nine	O
overweight	O
and	O
obese	O
nursing	O
home	O
employees	O
who	O
were	O
at	O
risk	O
for	O
type	B-DS
2	I-DS
diabetes	I-DS
based	O
on	O
diabetes	B-DS
risk	O
score	O
>	O
8	O
,	O
indicating	O
that	O
risk	O
is	O
high	O
for	O
having	O
pre	O
-	O
diabetes	B-DS
presently	O
[	O
42	O
,	O
60	O
].	O

Participants	O
were	O
recruited	O
from	O
four	O
long	O
-	O
term	O
care	O
facilities	O
located	O
in	O
the	O
Northeast	O
United	O
States	O
,	O
and	O
were	O
required	O
to	O
sign	O
an	O
IRB	O
-	O
approved	O
consent	O
form	O
.	O

Measures	O

Body	O
Mass	O
Index	O
(	O
BMI	O
)	O

Trained	O
health	O
educators	O
measured	O
height	O
(	O
nearest	O
mm	O
)	O
and	O
weight	O
(	O
nearest	O
0	O
.	O
1	O
kg	O
)	O
using	O
a	O
calibrated	O
Seca	O
700	O
physician	O
balance	O
beam	O
scale	O
.	O

BMI	O
was	O
calculated	O
as	O
weight	O
(	O
kg	O
)	O
divided	O
by	O
height	O
(	O
m2	O
)	O
and	O
categorized	O
based	O
on	O
CDC	O
recommendations	O
of	O
overweight	O
(	O
25	O
–	O
29	O
.	O
99	O
kg	O
/	O
m2	O
),	O
obese	O
class	O
I	O
(	O
30	O
–	O
34	O
.	O
99	O
kg	O
/	O
m2	O
),	O
obese	O
class	O
II	O
(	O
35	O
–	O
39	O
.	O
99	O
kg	O
/	O
m2	O
),	O
and	O
(>	O
40	O
kg	O
/	O
m2	O
)	O
[	O
61	O
].	O

Participant	O
questionnaire	O

A	O
standardized	O
questionnaire	O
was	O
distributed	O
to	O
all	O
participants	O
.	O

The	O
questionnaire	O
obtained	O
information	O
on	O
demographics	O
,	O
Musculoskeletal	O
Pain	O
,	O
Physical	O
Activity	O
(	O
PA	O
),	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
HRQOL	O
),	O
and	O
Exercise	O
Self	O
-	O
Efficacy	O
(	O
ESE	O
).	O

Musculoskeletal	O
pain	O
was	O
defined	O
as	O
frequency	O
of	O
pain	O
in	O
the	O
WB	O
joints	O
(	O
low	O
back	O
and	O
knee	O
)	O
and	O
NWB	O
joints	O
(	O
shoulder	O
and	O
wrist	O
-	O
forearm	O
)	O
and	O
asked	O
how	O
often	O
on	O
hourly	O
,	O
daily	O
,	O
weekly	O
,	O
or	O
monthly	O
basis	O
the	O
participants	O
felt	O
pain	O
.	O

Physical	O
Activity	O
(	O
PA	O
)	O
was	O
first	O
assessed	O
using	O
a	O
question	O
on	O
self	O
-	O
reported	O
typical	O
current	O
PA	O
not	O
specific	O
to	O
work	O
.	O

Three	O
other	O
questions	O
obtained	O
information	O
on	O
performance	O
of	O
mild	O
,	O
moderate	O
,	O
or	O
vigorous	O
PA	O
for	O
a	O
30	O
-	O
minute	O
duration	O
during	O
a	O
typical	O
7	O
-	O
day	O
week	O
.	O

Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
HRQOL	O
)	O
was	O
evaluated	O
with	O
5	O
survey	O
items	O
from	O
the	O
Short	O
Form	O
Survey	O
(	O
SF	O
-	O
12	O
),	O
a	O
validated	O
health	O
survey	O
.	O

General	O
Health	O
Status	O
was	O
defined	O
as	O
self	O
-	O
reported	O
general	O
health	O
using	O
the	O
first	O
SF	O
-	O
12	O
question	O
that	O
asked	O
how	O
the	O
individual	O
perceived	O
their	O
health	O
.	O

Physical	O
Function	O
was	O
assessed	O
using	O
the	O
second	O
and	O
third	O
SF	O
-	O
12	O
questions	O
,	O
and	O
asked	O
if	O
the	O
individual	O
perceived	O
their	O
health	O
to	O
limit	O
them	O
in	O
moderate	O
activities	O
(	O
moving	O
a	O
table	O
,	O
pushing	O
a	O
vacuum	O
cleaner	O
,	O
bowling	O
,	O
or	O
playing	O
golf	O
)	O
and	O
vigorous	O
activities	O
(	O
climbing	O
several	O
flights	O
of	O
stairs	O
).	O

Emotional	O
Role	O
was	O
assessed	O
using	O
the	O
sixth	O
and	O
seventh	O
SF	O
-	O
12	O
question	O
and	O
asked	O
how	O
often	O
the	O
participant	O
accomplished	O
less	O
than	O
they	O
would	O
like	O
and	O
done	O
work	O
less	O
carefully	O
in	O
their	O
work	O
or	O
regular	O
daily	O
activities	O
as	O
a	O
result	O
of	O
any	O
emotional	B-DS
problems	I-DS
.	O

Social	O
Interference	O
was	O
assessed	O
using	O
the	O
last	O
SF	O
-	O
12	O
questions	O
and	O
asked	O
if	O
the	O
individual	O
perceived	O
their	O
joint	O
problem	O
to	O
interfere	O
with	O
social	O
activities	O
with	O
family	O
or	O
friends	O
.	O

Exercise	O
Self	O
-	O
Efficacy	O
(	O
ESE	O
)	O
was	O
calculated	O
with	O
a	O
summary	O
score	O
comprised	O
of	O
11	O
questions	O
from	O
the	O
Sallis	O
(	O
1998	O
)	O
ESE	O
Scale	O
.	O

Participants	O
were	O
given	O
questions	O
regarding	O
exercise	O
-	O
related	O
activities	O
and	O
asked	O
how	O
confident	O
they	O
were	O
that	O
they	O
could	O
keep	O
it	O
up	O
for	O
6	O
months	O
.	O

Statistical	O
Analysis	O

Expectation	O
-	O
maximization	O
imputation	O

Data	O
was	O
analyzed	O
using	O
the	O
SPSS	O
software	O
version	O
21	O
.	O
0	O
and	O
utilized	O
Preacher	O
&	O
Hayes	O
(	O
2008	O
)	O
Indirect	O
Bootstrapping	O
Macro	O
.	O

Composite	O
scores	O
were	O
created	O
for	O
the	O
ESE	O
scale	O
.	O

Little	O
’	O
s	O
Missing	O
Completely	O
at	O
Random	O
(	O
MCAR	O
)	O
test	O
was	O
executed	O
for	O
missing	O
data	O
(>	O
5	O
%),	O
and	O
Expectation	O
-	O
Maximization	O
was	O
subsequently	O
performed	O
using	O
SPSS	O
Missing	O
Value	O
Analysis	O
imputation	O
to	O
create	O
maximum	O
likelihood	O
estimates	O
for	O
randomly	O
missing	O
data	O
(	O
p	O
=	O
0	O
.	O
265	O
).	O

Descriptive	O
statistics	O
and	O
associations	O

Descriptive	O
and	O
frequency	O
analysis	O
were	O
used	O
to	O
analyze	O
MS	B-DS
pain	O
prevalence	O
.	O

Variables	O
were	O
reverse	O
coded	O
if	O
needed	O
.	O

Normality	O
was	O
assessed	O
using	O
histograms	O
and	O
frequencies	O
for	O
all	O
variables	O
and	O
outcomes	O
.	O

Total	O
exercise	O
self	O
-	O
efficacy	O
score	O
was	O
calculated	O
from	O
a	O
series	O
of	O
questions	O
.	O

Correlational	O
analyses	O
using	O
Pearson	O
’	O
s	O
Correlation	O
were	O
used	O
to	O
analyze	O
direct	O
relationships	O
between	O
levels	O
of	O
obesity	B-DS
,	O
general	O
health	O
,	O
physical	O
function	O
,	O
emotional	O
role	O
,	O
social	O
interference	O
,	O
physical	O
activity	O
levels	O
,	O
and	O
exercise	O
self	O
-	O
efficacy	O
.	O

Benferroni	O
correction	O
was	O
calculated	O
to	O
restrict	O
significance	O
to	O
a	O
more	O
conservative	O
p	O
-	O
value	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
to	O
reduce	O
Type	O
I	O
error	O
.	O

Observed	O
(	O
Manifest	O
)	O
variables	O
and	O
path	O
analysis	O
(	O
SEM	O
)	O

Path	O
analysis	O
via	O
structural	O
equation	O
modeling	O
(	O
SEM	O
)	O
and	O
bootstrapping	O
is	O
a	O
useful	O
statistical	O
approach	O
to	O
examine	O
mediation	O
between	O
observed	O
variables	O
,	O
and	O
was	O
used	O
to	O
examine	O
direct	O
and	O
indirect	O
effects	O
within	O
the	O
two	O
theoretically	O
driven	O
models	O
on	O
this	O
dataset	O
.	O

Path	O
was	O
first	O
tested	O
with	O
the	O
Obesity	B-DS
,	O
Musculoskeletal	O
Pain	O
,	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
(	O
OMH	O
)	O
with	O
musculoskeletal	O
pain	O
in	O
four	O
sites	O
as	O
mediator	O
variables	O
(	O
Figure	O
1	O
).	O

SEM	O
was	O
also	O
performed	O
for	O
the	O
Obesity	B-DS
,	O
Exercise	O
Self	O
-	O
Efficacy	O
,	O
Physical	O
activity	O
(	O
OEP	O
)	O
model	O
with	O
ESE	O
as	O
the	O
mediator	O
variable	O
(	O
Figure	O
2	O
).	O

Bootstrapping	O
at	O
a	O
95	O
%	O
confidence	O
interval	O
was	O
used	O
to	O
determine	O
significance	O
of	O
indirect	O
effects	O
.	O

Proportions	O
of	O
mediation	O
were	O
calculated	O
using	O
Microsoft	O
Excel	O
via	O
algorithm	O
supported	O
by	O
Kenny	O
(	O
2014	O
).	O

As	O
indicated	O
in	O
Figure	O
1	O
,	O
the	O
Obesity	B-DS
,	O
Musculoskeletal	O
Pain	O
,	O
Health	O
-	O
Related	O
Quality	O
of	O
life	O
(	O
OMH	O
)	O
model	O
identifies	O
level	O
of	O
obesity	B-DS
,	O
musculoskeletal	O
pain	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
,	O
physical	O
activity	O
levels	O
,	O
and	O
exercise	O
self	O
-	O
efficacy	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
OMH	O
model	O
predicts	O
a	O
higher	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
)	O
will	O
result	O
in	O
a	O
lower	O
self	O
-	O
reported	O
HRQOL	O
,	O
PA	O
level	O
,	O
and	O
ESE	O
,	O
and	O
that	O
higher	O
frequency	O
of	O
musculoskeletal	O
pain	O
will	O
indirectly	O
affect	O
the	O
relationship	O
,	O
resulting	O
in	O
a	O
lower	O
score	O
of	O
these	O
three	O
outcomes	O
.	O

As	O
indicated	O
in	O
Figure	O
2	O
,	O
the	O
Obesity	B-DS
,	O
Exercise	O
Self	O
-	O
Efficacy	O
,	O
Physical	O
Activity	O
(	O
OEP	O
)	O
model	O
identifies	O
the	O
level	O
of	O
obesity	B-DS
,	O
exercise	O
self	O
-	O
efficacy	O
,	O
and	O
physical	O
activity	O
outcomes	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
OEP	O
model	O
predicts	O
a	O
higher	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
)	O
will	O
result	O
in	O
a	O
lower	O
self	O
-	O
reported	O
PA	O
outcome	O
,	O
and	O
that	O
a	O
lower	O
ESE	O
summary	O
score	O
will	O
indirectly	O
affect	O
the	O
relationship	O
,	O
resulting	O
in	O
a	O
lower	O
self	O
-	O
reported	O
PA	O
outcome	O
.	O

Results	O

Participant	O
characteristics	O

Table	O
1	O
depicts	O
participant	O
demographics	O
and	O
body	O
weight	O
distribution	O
.	O

The	O
sample	O
reported	O
an	O
overall	O
pain	O
prevalence	O
of	O
68	O
.	O
7	O
%	O
in	O
the	O
low	O
back	O
,	O
55	O
.	O
6	O
%	O
in	O
the	O
knee	O
,	O
47	O
.	O
5	O
%	O
in	O
the	O
shoulder	O
,	O
and	O
29	O
.	O
3	O
%	O
in	O
the	O
wrist	O
/	O
forearm	O
region	O
.	O

Figure	O
3	O
indicates	O
the	O
frequency	O
of	O
WB	O
and	O
NWB	O
joint	O
pain	O
among	O
participants	O
.	O

Joint	O
pain	O
resided	O
dominantly	O
in	O
the	O
WB	O
joints	O
for	O
weekly	O
and	O
monthly	O
occurrences	O
.	O

However	O
,	O
when	O
considering	O
daily	O
frequency	O
,	O
participants	O
reported	O
that	O
the	O
dominant	O
joint	O
pain	O
sites	O
resided	O
in	O
the	O
knee	O
and	O
shoulder	O
(	O
Figure	O
3	O
).	O

Associations	O
between	O
Obesity	B-DS
,	O
HRQOL	O
,	O
PA	O
,	O
and	O
ESE	O

Table	O
2	O
shows	O
Pearson	O
’	O
s	O
correlations	O
between	O
the	O
level	O
of	O
obesity	B-DS
and	O
HRQOL	O
,	O
Physical	O
Activity	O
Levels	O
,	O
and	O
Exercise	O
Self	O
-	O
Efficacy	O
.	O

There	O
was	O
significance	O
negative	O
relationship	O
between	O
obesity	B-DS
and	O
physical	O
function	O
for	O
vigorous	O
activities	O
(	O
r	O
=−	O
0	O
.	O
308	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
suggesting	O
that	O
as	O
obesity	B-DS
increased	O
,	O
physical	O
function	O
in	O
climbing	O
stairs	O
,	O
decreased	O
(	O
Table	O
2	O
).	O

Though	O
significance	O
was	O
not	O
achieved	O
,	O
a	O
negative	O
relationship	O
with	O
moderate	O
physical	O
function	O
was	O
also	O
shown	O
(	O
r	O
=−	O
0	O
.	O
109	O
).	O

Additionally	O
,	O
associations	O
between	O
BMI	O
and	O
current	O
physical	O
activity	O
,	O
moderate	O
physical	O
activity	O
,	O
and	O
exercise	O
self	O
-	O
efficacy	O
were	O
also	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Table	O
2	O
).	O

Obesity	B-DS
had	O
a	O
significant	O
negative	O
relationship	O
with	O
current	O
PA	O
(	O
r	O
=−	O
0	O
.	O
248	O
,	O
p	O
=	O
0	O
.	O
013	O
),	O
and	O
moderate	O
PA	O
(	O
r	O
=−	O
0	O
.	O
293	O
,	O
p	O
=	O
0	O
.	O
003	O
).	O

Additionally	O
,	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
mild	O
PA	O
(	O
r	O
=−	O
0	O
.	O
129	O
,	O
p	O
=	O
0	O
.	O
202	O
)	O
and	O
vigorous	O
PA	O
(	O
r	O
=−	O
0	O
.	O
176	O
,	O
p	O
=	O
0	O
.	O
082	O
)	O
were	O
also	O
negative	O
,	O
but	O
did	O
not	O
reach	O
significance	O
.	O

Path	O
analysis	O
and	O
structural	O
equation	O
model	O

Obesity	B-DS
-	O
musculoskeletal	O
pain	O
-	O
health	O
related	O
quality	O
of	O
life	O
(	O
OMH	O
)	O
Model	O

Out	O
of	O
the	O
11	O
models	O
used	O
to	O
assess	O
the	O
multiple	O
variables	O
under	O
the	O
theoretical	O
OMH	O
model	O
,	O
the	O
four	O
models	O
that	O
tested	O
wrist	O
pain	O
as	O
the	O
mediator	O
between	O
level	O
of	O
obesity	B-DS
,	O
physical	O
function	O
,	O
emotional	O
function	O
,	O
and	O
exercise	O
self	O
-	O
efficacy	O
,	O
indicated	O
significant	O
indirect	O
effects	O
and	O
are	O
presented	O
in	O
Tables	O
3	O
–	O
7	O
.	O

Table	O
3	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
musculoskeletal	O
pain	O
frequency	O
in	O
four	O
anatomical	O
joints	O
,	O
and	O
physical	O
function	O
.	O

As	O
shown	O
in	O
Table	O
3	O
the	O
wrist	O
-	O
forearm	O
joint	O
significantly	O
mediated	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
moderate	O
physical	O
function	O
at	O
about	O
77	O
.	O
7	O
%.	O

Table	O
4	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
musculoskeletal	O
pain	O
frequency	O
in	O
four	O
anatomical	O
joints	O
,	O
and	O
the	O
role	O
of	O
emotions	O
in	O
accomplishing	O
less	O
at	O
work	O
or	O
at	O
home	O
.	O

As	O
shown	O
in	O
Table	O
4	O
,	O
the	O
wrist	O
-	O
forearm	O
joint	O
significantly	O
mediated	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
emotional	O
role	O
in	O
regards	O
to	O
accomplishing	O
less	O
.	O

The	O
proportion	O
of	O
mediation	O
was	O
approximately	O
35	O
.	O
2	O
%.	O

Table	O
5	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
musculoskeletal	O
pain	O
frequency	O
in	O
four	O
anatomical	O
joints	O
,	O
and	O
physical	O
function	O
in	O
a	O
moderate	O
activity	O
.	O

Table	O
5	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
musculoskeletal	O
pain	O
frequency	O
in	O
four	O
anatomical	O
joints	O
,	O
and	O
physical	O
function	O
in	O
a	O
moderate	O
activity	O
.	O

As	O
shown	O
in	O
Table	O
5	O
,	O
the	O
wrist	O
-	O
forearm	O
joint	O
also	O
significantly	O
mediated	O
the	O
association	O
between	O
obesity	B-DS
and	O
emotional	O
role	O
regarding	O
being	O
less	O
careful	O
.	O

Table	O
6	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
musculoskeletal	O
pain	O
frequency	O
in	O
four	O
anatomical	O
joints	O
,	O
and	O
the	O
total	O
exercise	O
self	O
-	O
efficacy	O
score	O
.	O

As	O
shown	O
in	O
Table	O
6	O
,	O
the	O
wrist	O
-	O
forearm	O
region	O
significantly	O
mediated	O
the	O
association	O
between	O
obesity	B-DS
and	O
ESE	O
of	O
about	O
17	O
.	O
7	O
%.	O

Obesity	B-DS
-	O
Exercise	O
Self	O
Efficacy	O
-	O
Physical	O
Activity	O
(	O
OEP	O
)	O
Model	O

Out	O
of	O
the	O
four	O
models	O
used	O
to	O
assess	O
the	O
multiple	O
variables	O
under	O
the	O
theoretical	O
OMH	O
model	O
,	O
the	O
three	O
models	O
that	O
tested	O
exercise	O
self	O
-	O
efficacy	O
as	O
the	O
mediator	O
between	O
level	O
of	O
obesity	B-DS
,	O
current	O
physical	O
activity	O
,	O
moderate	O
physical	O
activity	O
,	O
and	O
vigorous	O
physical	O
activity	O
indicated	O
significant	O
indirect	O
effects	O
and	O
are	O
presented	O
in	O
Table	O
7	O
.	O

Table	O
7	O
depicts	O
the	O
mediation	O
results	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
BMI	O
),	O
the	O
total	O
exercise	O
self	O
-	O
efficacy	O
score	O
,	O
and	O
levels	O
of	O
physical	O
activity	O
.	O

ESE	O
had	O
significant	O
indirect	O
effect	O
on	O
the	O
outcomes	O
of	O
current	O
PA	O
,	O
moderate	O
PA	O
,	O
and	O
vigorous	O
PA	O
.	O

For	O
current	O
physical	O
activity	O
,	O
a	O
16	O
.	O
44	O
%	O
mediating	O
effect	O
was	O
indicated	O
,	O
while	O
a	O
26	O
.	O
42	O
%	O
proportion	O
of	O
mediation	O
occurred	O
in	O
moderate	O
PA	O
.	O

Lastly	O
,	O
ESE	O
had	O
the	O
largest	O
proportion	O
of	O
mediation	O
on	O
vigorous	O
PA	O
at	O
about	O
44	O
.	O
8	O
%	O
(	O
Table	O
7	O
).	O

Discussion	O

This	O
study	O
aimed	O
to	O
understand	O
associations	O
between	O
obesity	B-DS
and	O
specific	O
health	O
-	O
related	O
quality	O
of	O
life	O
items	O
,	O
physical	O
activity	O
levels	O
,	O
and	O
exercise	O
self	O
-	O
efficacy	O
,	O
in	O
addition	O
to	O
testing	O
two	O
theoretically	O
driven	O
statistical	O
models	O
;	O
the	O
OMH	O
and	O
OEP	O
models	O
.	O

Our	O
results	O
are	O
in	O
line	O
with	O
previous	O
research	O
and	O
support	O
our	O
first	O
hypothesis	O
of	O
a	O
higher	O
prevalence	O
of	O
WB	O
and	O
NWB	O
musculoskeletal	O
pain	O
in	O
overweight	O
and	O
obese	O
nursing	O
home	O
employees	O
compared	O
to	O
general	O
nursing	O
home	O
employee	O
population	O
.	O

Comparatively	O
,	O
our	O
samples	O
’	O
prevalence	O
rates	O
are	O
higher	O
compared	O
to	O
general	O
nursing	O
home	O
employees	O
.	O

In	O
a	O
study	O
by	O
Miranda	O
et	O
al	O
.,	O
their	O
cohort	O
of	O
344	O
nursing	O
home	O
workers	O
indicated	O
the	O
prevalence	O
of	O
musculoskeletal	O
pain	O
to	O
be	O
34	O
%	O
in	O
the	O
low	O
back	O
and	O
approximately	O
25	O
%	O
each	O
in	O
the	O
knee	O
,	O
wrist	O
/	O
hands	O
and	O
shoulder	O
region	O
[	O
56	O
].	O

Another	O
survey	O
on	O
nursing	O
home	O
personnel	O
indicated	O
a	O
pain	O
prevalence	O
of	O
50	O
.	O
5	O
%	O
in	O
the	O
low	O
back	O
,	O
25	O
.	O
8	O
%	O
in	O
the	O
knee	O
,	O
27	O
.	O
9	O
%	O
in	O
the	O
shoulder	O
,	O
and	O
17	O
.	O
8	O
%	O
in	O
the	O
wrist	O
[	O
62	O
].	O

Higher	O
prevalence	O
of	O
pain	O
in	O
all	O
joints	O
may	O
be	O
explained	O
by	O
associations	O
with	O
increased	O
BMI	O
[	O
62	O
–	O
66	O
].	O

Associations	O
between	O
obesity	B-DS
and	O
HRQOL	O
outcomes	O
directionally	O
supported	O
the	O
second	O
hypothesis	O
,	O
with	O
significance	O
found	O
in	O
the	O
negative	O
relationship	O
between	O
obesity	B-DS
and	O
physical	O
function	O
for	O
vigorous	O
activities	O
,	O
suggesting	O
that	O
as	O
obesity	B-DS
increased	O
,	O
physical	O
function	O
in	O
climbing	O
stairs	O
,	O
decreased	O
.	O

Though	O
significance	O
was	O
not	O
achieved	O
,	O
a	O
negative	O
relationship	O
with	O
moderate	O
physical	O
function	O
was	O
also	O
shown	O
(	O
Table	O
2	O
).	O

These	O
results	O
are	O
in	O
line	O
with	O
previous	O
research	O
reporting	O
stronger	O
associations	O
with	O
higher	O
BMI	O
and	O
physical	O
components	O
of	O
the	O
SF	O
-	O
12	O
health	O
profile	O
[	O
5	O
,	O
14	O
,	O
15	O
,	O
62	O
–	O
67	O
].	O

In	O
particular	O
,	O
Yamakawa	O
and	O
colleagues	O
,	O
showed	O
that	O
ambulation	O
,	O
a	O
functional	O
activity	O
,	O
is	O
negatively	O
related	O
to	O
obesity	B-DS
,	O
supporting	O
our	O
results	O
.	O

In	O
addition	O
,	O
negative	O
relationships	O
were	O
expressed	O
between	O
obesity	B-DS
and	O
general	O
health	O
(	O
r	O
=−	O
0	O
.	O
191	O
).	O

The	O
findings	O
from	O
Heo	O
et	O
al	O
.	O
support	O
our	O
general	O
health	O
association	O
,	O
reporting	O
that	O
compared	O
with	O
desirable	O
weight	O
adults	O
,	O
underweight	O
,	O
overweight	O
,	O
and	O
obese	O
adults	O
were	O
significantly	O
more	O
likely	O
to	O
report	O
poor	O
to	O
fair	O
general	O
health	O
status	O
.	O

An	O
increase	O
in	O
emotional	O
role	O
limitations	O
and	O
social	O
interference	O
(	O
r	O
=	O
0	O
.	O
137	O
and	O
r	O
=	O
0	O
.	O
004	O
,	O
respectively	O
)	O
were	O
shown	O
coincident	O
with	O
higher	O
BMI	O
,	O
although	O
associations	O
were	O
not	O
significant	O
.	O

These	O
results	O
are	O
supported	O
by	O
the	O
results	O
of	O
Jia	O
&	O
Lubetkin	O
that	O
show	O
HRQOL	O
scores	O
are	O
significantly	O
lower	O
for	O
overweight	O
and	O
obese	O
participants	O
.	O

Several	O
other	O
studies	O
support	O
these	O
results	O
that	O
there	O
is	O
a	O
direct	O
relationship	O
between	O
level	O
of	O
obesity	B-DS
(	O
indicated	O
using	O
increased	O
BMI	O
),	O
and	O
greater	O
HRQOL	O
impairment	O
[	O
5	O
,	O
14	O
,	O
15	O
,	O
33	O
,	O
67	O
,	O
68	O
].	O

Similar	O
associations	O
are	O
reported	O
in	O
other	O
studies	O
between	O
obesity	B-DS
and	O
depression	B-DS
and	O
/	O
or	O
mental	O
health	O
impairment	O
[	O
10	O
,	O
69	O
–	O
71	O
].	O

Specifically	O
,	O
Jia	O
&	O
Lubetkin	O
showed	O
that	O
mental	O
component	O
scores	O
on	O
the	O
SF	O
-	O
12	O
were	O
most	O
impaired	O
at	O
the	O
extremes	O
of	O
BMI	O
(	O
underweight	O
and	O
obese	O
class	O
III	O
),	O
further	O
supporting	O
the	O
positive	O
association	O
within	O
our	O
data	O
.	O

Additionally	O
,	O
the	O
National	O
Obesity	B-DS
Observatory	O
(	O
NOO	O
)	O
has	O
indicated	O
that	O
several	O
studies	O
posit	O
a	O
bi	O
-	O
directional	O
relationship	O
between	O
mental	O
health	O
and	O
obesity	B-DS
,	O
in	O
that	O
lower	O
mental	O
health	O
may	O
contribute	O
to	O
obesity	B-DS
,	O
and	O
higher	O
obesity	B-DS
may	O
contribute	O
to	O
lower	O
mental	O
health	O
[	O
72	O
].	O

Obesity	B-DS
had	O
a	O
significant	O
negative	O
relationship	O
with	O
current	O
PA	O
and	O
moderate	O
PA	O
(	O
Table	O
2	O
).	O

Additionally	O
,	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
mild	O
PA	O
and	O
vigorous	O
PA	O
were	O
also	O
negative	O
,	O
but	O
did	O
not	O
reach	O
significance	O
(	O
Table	O
2	O
).	O

These	O
results	O
are	O
supported	O
and	O
explained	O
,	O
in	O
part	O
,	O
to	O
the	O
mechanical	O
-	O
structural	O
changes	O
that	O
have	O
been	O
proposed	O
to	O
cause	O
decrease	O
in	O
ambulation	O
and	O
change	O
in	O
gait	O
patterns	O
[	O
3	O
,	O
25	O
,	O
29	O
,	O
45	O
].	O

Hills	O
and	O
colleagues	O
reported	O
that	O
obese	O
individuals	O
had	O
changes	O
in	O
foot	O
structure	O
,	O
with	O
higher	O
plantar	O
pressure	O
under	O
their	O
longitudinal	O
arch	O
and	O
on	O
metatarsal	O
heads	O
during	O
both	O
standing	O
and	O
walking	O
,	O
making	O
it	O
more	O
likely	O
to	O
feel	O
discomfort	O
[	O
73	O
].	O

Previous	O
literature	O
have	O
also	O
reported	O
reductions	O
in	O
knee	O
range	O
of	O
motion	O
[	O
18	O
,	O
31	O
,	O
74	O
].	O

Overweight	O
and	O
obese	O
individuals	O
have	O
been	O
shown	O
to	O
walk	O
with	O
shorter	O
step	O
length	O
,	O
lower	O
cadence	O
,	O
and	O
lower	O
velocity	O
due	O
to	O
excessive	O
adipose	O
tissue	O
on	O
the	O
inside	O
of	O
the	O
thigh	O
[	O
31	O
,	O
74	O
].	O

Yamakawa	O
et	O
al	O
.	O
and	O
a	O
systematic	O
review	O
by	O
Nantel	O
support	O
that	O
walking	O
is	O
indicative	O
of	O
increasing	O
PA	O
level	O
and	O
mobility	O
.	O

Therefore	O
with	O
increased	O
weight	O
,	O
ambulation	O
becomes	O
more	O
energy	O
intensive	O
and	O
uncomfortable	O
,	O
resulting	O
in	O
further	O
sedentary	O
behavior	O
and	O
obesity	B-DS
[	O
25	O
].	O

Though	O
ambulation	O
was	O
not	O
directly	O
assessed	O
in	O
our	O
study	O
,	O
PA	O
decline	O
may	O
be	O
attributed	O
to	O
similar	O
mechanisms	O
.	O

In	O
addition	O
,	O
aerobic	O
capacity	O
in	O
obese	O
individuals	O
has	O
been	O
shown	O
to	O
be	O
lower	O
than	O
normal	O
weight	O
individuals	O
[	O
75	O
].	O

These	O
mechanisms	O
proposed	O
by	O
previous	O
researchers	O
offer	O
some	O
support	O
for	O
our	O
results	O
that	O
increases	O
in	O
obesity	B-DS
may	O
result	O
in	O
a	O
decrease	O
of	O
PA	O
level	O
.	O

ESE	O
expressed	O
a	O
significant	O
negative	O
relationship	O
with	O
obesity	B-DS
(	O
Table	O
2	O
).	O

This	O
trend	O
is	O
supported	O
by	O
current	O
as	O
literature	O
in	O
that	O
an	O
individual	O
’	O
s	O
BMI	O
increased	O
,	O
their	O
level	O
of	O
ESE	O
decreased	O
[	O
32	O
].	O

While	O
we	O
did	O
not	O
assess	O
postmenopausal	O
prevalence	O
,	O
the	O
majority	O
of	O
the	O
participant	O
population	O
was	O
30	O
–	O
49	O
years	O
old	O
.	O

This	O
suggests	O
a	O
need	O
for	O
addressing	O
exercise	O
self	O
-	O
efficacy	O
in	O
this	O
population	O
in	O
order	O
to	O
increase	O
an	O
individual	O
’	O
s	O
confidence	O
that	O
they	O
can	O
start	O
or	O
keep	O
up	O
exercise	O
and	O
lose	O
weight	O
,	O
to	O
counter	O
the	O
effects	O
of	O
being	O
overweight	O
or	O
obese	O
.	O

Trost	O
and	O
colleagues	O
found	O
significant	O
results	O
indicating	O
that	O
their	O
obese	O
participants	O
were	O
significantly	O
less	O
confident	O
in	O
their	O
ability	O
to	O
overcome	O
barriers	O
to	O
physical	O
activity	O
,	O
to	O
ask	O
parents	O
to	O
provide	O
opportunities	O
for	O
physical	O
activity	O
,	O
and	O
to	O
choose	O
physically	O
active	O
pursuits	O
over	O
sedentary	O
ones	O
[	O
32	O
].	O

In	O
our	O
third	O
hypothesis	O
,	O
the	O
mediated	O
structural	O
hypothesis	O
of	O
the	O
OMH	B-DS
model	O
was	O
supported	O
for	O
partial	O
mediation	O
in	O
some	O
outcome	O
variables	O
.	O

Wrist	O
-	O
forearm	O
pain	O
,	O
significantly	O
mediated	O
(	O
95	O
%	O
CI	O
:	O
−	O
0	O
.	O
1050	O
,	O
−	O
0	O
.	O
0036	O
)	O
about	O
29	O
.	O
7	O
%	O
of	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
moderate	O
physical	O
function	O
(	O
Table	O
3	O
).	O

This	O
suggests	O
that	O
the	O
adverse	O
effects	O
of	O
obesity	B-DS
on	O
moderate	O
physical	O
function	O
may	O
be	O
manifested	O
in	O
part	O
,	O
through	O
wrist	O
-	O
forearm	O
pain	O
.	O

Since	O
our	O
population	O
was	O
primarily	O
female	O
(	O
approximately	O
91	O
%),	O
these	O
results	O
closely	O
align	O
with	O
findings	O
from	O
Fowler	O
-	O
Brown	O
and	O
colleagues	O
,	O
which	O
showed	O
a	O
22	O
–	O
44	O
%	O
partial	O
mediation	O
of	O
bodily	O
pain	O
with	O
physical	O
function	O
in	O
women	O
.	O

Furthermore	O
,	O
their	O
study	O
found	O
that	O
bodily	O
pain	O
was	O
significantly	O
associated	O
with	O
disability	O
,	O
performance	O
,	O
and	O
physical	O
function	O
[	O
13	O
].	O

A	O
study	O
by	O
Heo	O
et	O
al	O
.	O
found	O
that	O
attenuation	O
in	O
the	O
association	O
between	O
obesity	B-DS
and	O
functional	O
impairment	O
was	O
largely	O
explained	O
by	O
medical	O
comorbid	O
conditions	O
,	O
and	O
indicated	O
the	O
presence	O
of	O
joint	O
pain	O
and	O
mental	O
health	O
problems	O
further	O
reduced	O
the	O
odds	O
ratios	O
in	O
this	O
relationship	O
[	O
10	O
].	O

The	O
wrist	O
-	O
forearm	O
joint	O
also	O
significantly	O
mediated	O
35	O
.	O
2	O
%	O
of	O
the	O
relationship	O
between	O
the	O
role	O
of	O
emotions	O
in	O
accomplishing	O
less	O
at	O
work	O
and	O
at	O
home	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
0010	O
,	O
0	O
.	O
1520	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
0015	O
,	O
0	O
.	O
0985	O
)	O
(	O
Table	O
4	O
).	O

Pain	O
has	O
been	O
supported	O
to	O
be	O
a	O
deterrent	O
to	O
activities	O
of	O
daily	O
living	O
(	O
ADLs	O
),	O
and	O
has	O
been	O
supported	O
by	O
recent	O
reviews	O
[	O
3	O
,	O
8	O
,	O
9	O
].	O

Additionally	O
,	O
Heo	O
et	O
al	O
.	O
found	O
in	O
their	O
mediation	O
analysis	O
that	O
the	O
effects	O
of	O
high	O
BMI	O
on	O
HRQOL	O
were	O
significantly	O
attenuated	O
when	O
musculoskeletal	O
pain	O
and	O
obesity	B-DS
-	O
related	O
comorbidities	O
were	O
included	O
in	O
the	O
models	O
.	O

Other	O
studies	O
assessing	O
international	O
differences	O
in	O
chronic	O
widespread	O
musculoskeletal	O
pain	O
showed	O
that	O
excess	O
prevalence	O
in	O
countries	O
of	O
Eastern	O
Europe	O
were	O
associated	O
with	O
poorer	O
physical	O
health	O
and	O
psychosocial	O
factors	O
(	O
stressful	O
life	O
events	O
)	O
[	O
9	O
,	O
76	O
,	O
77	O
].	O

These	O
findings	O
offer	O
some	O
support	O
for	O
our	O
results	O
that	O
wrist	O
-	O
forearm	O
pain	O
is	O
a	O
critical	O
component	O
in	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
emotional	O
role	O
in	O
accomplishing	O
less	O
at	O
work	O
or	O
at	O
home	O
.	O

In	O
assessing	O
emotional	O
role	O
of	O
being	O
less	O
careful	O
at	O
work	O
or	O
at	O
home	O
,	O
the	O
wrist	O
-	O
forearm	O
joint	O
significantly	O
expressed	O
inconsistent	O
mediation	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
0015	O
,	O
0	O
.	O
0985	O
),	O
with	O
the	O
indirect	O
effect	O
creating	O
a	O
larger	O
direct	O
effect	O
than	O
the	O
total	O
effect	O
(	O
Table	O
5	O
).	O

This	O
suggests	O
that	O
the	O
wrist	O
-	O
forearm	O
may	O
actually	O
decrease	O
the	O
role	O
of	O
emotions	O
in	O
being	O
less	O
careful	O
due	O
to	O
pain	O
,	O
and	O
make	O
the	O
individual	O
more	O
careful	O
.	O

One	O
potential	O
explanation	O
could	O
be	O
the	O
fear	O
-	O
avoidance	O
model	O
[	O
41	O
,	O
78	O
],	O
which	O
postulates	O
that	O
an	O
acute	O
episode	O
of	O
pain	O
may	O
cause	O
the	O
individual	O
to	O
develop	O
pain	O
-	O
related	O
fear	O
that	O
results	O
in	O
attention	O
to	O
pain	O
and	O
guarded	O
movements	O
,	O
however	O
should	O
be	O
conditional	O
only	O
to	O
those	O
who	O
reported	O
wrist	O
-	O
forearm	O
pain	O
.	O

In	O
our	O
sample	O
,	O
an	O
acute	O
episode	O
of	O
wrist	O
-	O
forearm	O
pain	O
may	O
have	O
resulted	O
in	O
more	O
attention	O
to	O
activities	O
requiring	O
heavy	O
use	O
of	O
the	O
joint	O
,	O
and	O
contribute	O
to	O
careful	O
behavior	O
.	O

This	O
may	O
have	O
long	O
-	O
term	O
implications	O
in	O
that	O
these	O
individuals	O
may	O
develop	O
a	O
chronic	O
condition	O
due	O
to	O
the	O
adaptations	O
initiated	O
from	O
feeling	O
acute	O
pain	O
.	O

Lastly	O
,	O
the	O
pain	O
in	O
the	O
wrist	O
-	O
forearm	O
region	O
also	O
significantly	O
mediated	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
ESE	O
(	O
95	O
%	O
CI	O
:	O
−	O
0	O
.	O
1510	O
,	O
−	O
0	O
.	O
0137	O
),	O
at	O
about	O
17	O
.	O
6	O
%	O
(	O
Table	O
6	O
).	O

This	O
suggests	O
the	O
adverse	O
effects	O
of	O
obesity	B-DS
on	O
lower	O
ESE	O
may	O
be	O
manifested	O
in	O
part	O
,	O
due	O
to	O
wrist	O
-	O
forearm	O
pain	O
.	O

Coinciding	O
with	O
previous	O
research	O
,	O
lower	O
ESE	O
has	O
consistently	O
been	O
associated	O
with	O
obesity	B-DS
,	O
and	O
is	O
also	O
associated	O
with	O
musculoskeletal	O
pain	O
[	O
40	O
].	O

In	O
particular	O
,	O
obese	O
females	O
have	O
been	O
reported	O
to	O
have	O
lower	O
self	O
-	O
efficacy	O
regarding	O
physical	O
activities	O
and	O
this	O
must	O
be	O
addressed	O
in	O
order	O
to	O
increase	O
compliance	O
with	O
exercise	O
[	O
18	O
].	O

In	O
our	O
last	O
hypothesis	O
,	O
the	O
mediated	O
structural	O
hypothesis	O
of	O
the	O
OEP	O
model	O
was	O
supported	O
for	O
partial	O
mediation	O
in	O
almost	O
all	O
variables	O
except	O
for	O
mild	O
PA	O
.	O

ESE	O
significantly	O
mediated	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
current	O
PA	O
levels	O
(	O
95	O
%	O
CI	O
:	O
−	O
0	O
.	O
1348	O
,	O
−	O
0	O
.	O
0001	O
)	O
of	O
about	O
16	O
.	O
4	O
%.	O

This	O
furthers	O
previous	O
research	O
regarding	O
obese	O
adolescents	O
[	O
34	O
,	O
35	O
,	O
39	O
]	O
in	O
that	O
not	O
only	O
does	O
ESE	O
at	O
baseline	O
predict	O
subsequent	O
levels	O
of	O
PA	O
,	O
but	O
is	O
an	O
explanatory	O
variable	O
in	O
the	O
relationship	O
between	O
increased	O
BMI	O
and	O
decreased	O
physical	O
activity	O
behavior	O
.	O

ESE	O
also	O
significantly	O
mediated	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
moderate	O
physical	O
activity	O
levels	O
(	O
95	O
%	O
CI	O
:	O
−	O
0	O
.	O
1595	O
,	O
−	O
0	O
.	O
0156	O
)	O
with	O
about	O
26	O
.	O
4	O
%,	O
as	O
well	O
as	O
vigorous	O
physical	O
activity	O
levels	O
(	O
95	O
%	O
CI	O
:	O
−	O
0	O
.	O
1365	O
,	O
−	O
0	O
.	O
0171	O
)	O
of	O
about	O
44	O
.	O
8	O
%.	O

These	O
results	O
coincide	O
and	O
further	O
research	O
by	O
Trost	O
,	O
Kerr	O
,	O
Ward	O
,	O
and	O
Pate	O
,	O
in	O
which	O
obese	O
children	O
not	O
only	O
exhibited	O
significantly	O
lower	O
daily	O
accumulations	O
of	O
moderate	O
and	O
vigorous	O
physical	O
activity	O
,	O
but	O
also	O
significantly	O
lower	O
levels	O
of	O
physical	O
activity	O
self	O
-	O
efficacy	O
.	O

However	O
,	O
our	O
results	O
show	O
that	O
ESE	O
is	O
a	O
significant	O
partial	O
mediator	O
of	O
the	O
adverse	O
effect	O
of	O
obesity	B-DS
on	O
physical	O
activity	O
behaviors	O
in	O
this	O
sample	O
of	O
overweight	O
and	O
obesity	B-DS
.	O

Building	O
confidence	O
of	O
overweight	O
and	O
obese	O
individuals	O
,	O
who	O
intend	O
to	O
start	O
physical	O
activities	O
,	O
even	O
if	O
the	O
intensity	O
is	O
low	O
,	O
has	O
been	O
shown	O
to	O
be	O
important	O
specifically	O
for	O
females	O
,	O
who	O
report	O
lower	O
confidence	O
in	O
physical	O
activity	O
[	O
18	O
].	O

Study	O
Limitations	O

Although	O
height	O
and	O
weight	O
were	O
measured	O
by	O
trained	O
health	O
educators	O
,	O
other	O
variables	O
utilized	O
self	O
-	O
reported	O
survey	O
components	O
which	O
may	O
result	O
in	O
an	O
under	O
-	O
reporting	O
or	O
over	O
-	O
reporting	O
of	O
pain	O
symptoms	O
.	O

Our	O
sample	O
size	O
was	O
small	O
.	O

Since	O
this	O
was	O
also	O
a	O
cross	O
-	O
sectional	O
study	O
,	O
causation	O
cannot	O
be	O
determined	O
using	O
these	O
associations	O
and	O
statistical	O
models	O
.	O

The	O
reverse	O
associations	O
may	O
occur	O
in	O
that	O
musculoskeletal	O
pain	O
may	O
affect	O
obesity	B-DS
,	O
as	O
also	O
supported	O
by	O
previous	O
reviews	O
[	O
3	O
,	O
8	O
,	O
9	O
,	O
24	O
].	O

Future	O
studies	O
should	O
focus	O
on	O
testing	O
the	O
model	O
in	O
reverse	O
and	O
for	O
causality	O
,	O
as	O
well	O
as	O
obtaining	O
a	O
larger	O
population	O
for	O
more	O
pronounced	O
relationships	O
.	O

Our	O
measures	O
of	O
physical	O
activity	O
and	O
physical	O
function	O
were	O
limited	O
,	O
and	O
had	O
some	O
overlaps	O
in	O
work	O
and	O
exercise	O
allocations	O
,	O
which	O
should	O
be	O
segregated	O
in	O
future	O
questions	O
.	O

In	O
addition	O
,	O
other	O
factors	O
have	O
been	O
proposed	O
as	O
possible	O
mediators	O
in	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
HRQOL	O
outcomes	O
,	O
such	O
as	O
obesity	B-DS
-	O
related	O
comorbidities	O
,	O
and	O
should	O
be	O
tested	O
in	O
addition	O
to	O
joint	O
pain	O
in	O
future	O
models	O
.	O

Conclusion	O

Our	O
data	O
indicate	O
that	O
being	O
overweight	O
and	O
obese	O
is	O
an	O
important	O
correlate	O
of	O
impaired	O
HRQOL	O
,	O
Physical	O
Activity	O
,	O
and	O
ESE	O
.	O

In	O
addition	O
,	O
high	O
-	O
risk	O
occupations	O
such	O
as	O
the	O
nursing	O
home	O
population	O
have	O
a	O
high	O
prevalence	O
of	O
musculoskeletal	O
pain	O
in	O
WB	O
and	O
NWB	O
joints	O
.	O

The	O
results	O
from	O
the	O
empirical	O
test	O
of	O
the	O
OMH	O
and	O
OEP	O
model	O
suggest	O
that	O
experiencing	O
pain	O
may	O
be	O
a	O
mechanism	O
by	O
which	O
obesity	B-DS
affects	O
impaired	O
HRQOL	O
,	O
lower	O
PA	O
levels	O
,	O
and	O
lower	O
ESE	O
.	O

Specifically	O
,	O
the	O
WB	O
joints	O
seem	O
to	O
have	O
a	O
larger	O
influence	O
on	O
vigorous	O
physical	O
activity	O
and	O
function	O
,	O
and	O
NWB	O
joints	O
(	O
particularly	O
the	O
wrist	O
-	O
forearm	O
)	O
have	O
a	O
larger	O
influence	O
on	O
moderate	O
physical	O
activities	O
and	O
function	O
.	O

Lower	O
ESE	O
is	O
also	O
a	O
significant	O
partial	O
mediator	O
in	O
the	O
relationship	O
between	O
obesity	B-DS
and	O
physical	O
activity	O
,	O
particularly	O
in	O
moderate	O
and	O
vigorous	O
physical	O
activities	O
,	O
and	O
should	O
also	O
be	O
addressed	O
in	O
weight	O
-	O
loss	O
programs	O
for	O
overweight	O
and	O
obese	O
adults	O
with	O
or	O
without	O
joint	O
pain	O
.	O

Theoretical	O
Model	O
of	O
Obesity	B-DS
,	O
Musculoskeletal	O
Pain	O
,	O
and	O
Health	O
-	O
Related	O
Quality	O
of	O
Life	O
Outcomes	O
(	O
OMH	O
).	O

Theoretical	O
Model	O
of	O
Obesity	B-DS
,	O
Exercise	O
Self	O
-	O
Efficacy	O
,	O
and	O
Physical	O
Activity	O
Outcomes	O
(	O
OEP	O
).	O

Musculoskeletal	O
Pain	O
Distribution	O
among	O
Participants	O
.	O

General	O
Demographic	O
Characteristics	O
of	O
Participants	O
(	O
n	O
=	O
99	O
).	O

Characteristic	O

N	O

n	O
%	O

Age	O

18	O
–	O
29	O

6	O

6	O
%	O

30	O
–	O
49	O

51	O

52	O
%	O

50	O
–	O
64	O

35	O

35	O
%	O

>	O
65	O

6	O

6	O
%	O

Gender	O

Male	O

9	O

9	O
%	O

Female	O

90	O

91	O
%	O

BMI	O

Overweight	O

20	O

20	O
.	O
2	O
%	O

Obese	O
Class	O
I	O

34	O

34	O
.	O
3	O
%	O

Obese	O
Class	O
II	O

23	O

23	O
.	O
2	O
%	O

Obese	O
Class	O
III	O

22	O

22	O
.	O
2	O
%	O

Education	O

Less	O
than	O
High	O
School	O

8	O

8	O
%	O

High	O
School	O
(	O
Secondary	O
)	O

39	O

39	O
%	O

College	O
/	O
Professional	O

45	O

45	O
%	O

Post	O
-	O
Graduate	O

7	O

7	O
%	O

Ethnicity	O

African	O
American	O

40	O

40	O
%	O

Caucasian	O

47	O

48	O
%	O

Other	O

12	O

12	O
%	O

Job	O

Administration	O
/	O
Clerical	O

12	O

12	O
%	O

CNA	O
/	O
GNA	O

30	O

30	O
%	O

LPN	B-GP

14	O

14	O
%	O

RN	O

13	O

13	O
%	O

Other	O

30	O

30	O
%	O

Associations	O
between	O
Level	O
of	O
Obesity	B-DS
,	O
Health	O
-	O
Related	O
Quality	O
of	O
life	O
,	O
Physical	O
Activity	O
,	O
and	O
Exercise	O
Self	O
-	O
Efficacy	O
.	O

GeneralHealth	O

PhysicalFunction	O
(	O
Moderate	O
)	O

PhysicalFunction	O
(	O
Vigorous	O
)	O

EmotionalRole	O
(	O
Accomplish	O
Less	O
)	O

EmotionalRole	O
(	O
LessCareful	O
)	O

SocialInterference	O

CurrentPhysicalActivity	O

MildPhysicalActivity	O

ModeratePhysicalActivity	O

VigorousPhysicalActivity	O

ExerciseSelf	O
-	O
Efficacy	O

BMI	O
Correlation	O
Coefficient	O

−	O
0	O
.	O
191	O

−	O
0	O
.	O
109	O

−	O
0	O
.	O
308	O

0	O
.	O
137	O

0	O
.	O
004	O

0	O
.	O
005	O

−	O
0	O
.	O
248	O

−	O
0	O
.	O
129	O

−	O
0	O
.	O
293	O

−	O
0	O
.	O
176	O

−	O
0	O
.	O
239	O

Significance	O
(	O
2	O
-	O
tailed	O
)	O

0	O
.	O
059	O

0	O
.	O
284	O

0	O
.	O
002	O

0	O
.	O
178	O

0	O
.	O
969	O

0	O
.	O
961	O

0	O
.	O
013	O

0	O
.	O
202	O

0	O
.	O
003	O

0	O
.	O
082	O

0	O
.	O
017	O

Mediation	O
Results	O
on	O
Moderate	O
Physical	O
Function	O
in	O
Participants	O
(	O
n	O
=	O
99	O
).	O

Path	O
A	O

Path	O
B	O

Path	O
C	O

Direct	O
Effect	O

Indirect	O
Effect	O

Total	O
Effect	O

Proportion	O
Mediated	O

Bootstrapped	O
95	O
%	O
CI	O

(	O
Path	O
C	O
′)	O

(	O
Bootstrapped	O
Path	O
A	O
*	O
B	O
)	O

(	O
Path	O
C	O
)	O

1	O
-	O
c	O
′/	O
c	O

(	O
Lower	O
Bound	O
,	O
Upper	O
Bound	O
)	O

Mediator	O

Path	O
Coefficient	O
(	O
b	O
)	O

Low	O
Back	O

0	O
.	O
1073	O

−	O
0	O
.	O
1175	O

−	O
0	O
.	O
042	O

−	O
0	O
.	O
0294	O

−	O
0	O
.	O
0117	O

−	O
0	O
.	O
0411	O

0	O
.	O
3	O

−	O
0	O
.	O
0473	O
,	O
0	O
.	O
0122	O

Knee	O

0	O
.	O
0595	O

−	O
0	O
.	O
0626	O

−	O
0	O
.	O
042	O

−	O
0	O
.	O
0383	O

−	O
0	O
.	O
0031	O

−	O
0	O
.	O
0414	O

0	O
.	O
0880952	O

−	O
0	O
.	O
0274	O
,	O
0	O
.	O
0135	O

Shoulder	O

−	O
0	O
.	O
0482	O

−	O
0	O
.	O
0865	O

−	O
0	O
.	O
042	O

−	O
0	O
.	O
0462	O

0	O
.	O
0041	O

−	O
0	O
.	O
0421	O

−	O
0	O
.	O
1	O

−	O
0	O
.	O
0211	O
,	O
0	O
.	O
0392	O

Wrist	O
-	O
forearm	O

0	O
.	O
2037	O

−	O
0	O
.	O
1598	O

−	O
0	O
.	O
042	O

−	O
0	O
.	O
0094	O

−	O
0	O
.	O
0341	O

−	O
0	O
.	O
0435	O

0	O
.	O
7761905	O

−	O
0	O
.	O
1050	O
,	O
−	O
0	O
.	O
0036	O

Mediation	O
Results	O
on	O
Emotional	O
Role	O
(	O
Accomplishing	O
Less	O
)	O
in	O
Participants	O
(	O
n	O
=	O
99	O
).	O

Path	O
A	O

Path	O
B	O

Path	O
C	O

Direct	O
Effect	O

Indirect	O
Effect	O

Total	O
Effect	O

Proportion	O
Mediated	O

Bootstrapped	O
95	O
%	O
CI	O

(	O
Path	O
C	O
′)	O

(	O
Bootstrapped	O
Path	O
A	O
*	O
B	O
)	O

(	O
Path	O
C	O
)	O

1	O
-	O
c	O
′/	O
c	O

(	O
Lower	O
Bound	O
,	O
Upper	O
Bound	O
)	O

Mediator	O

Path	O
Coefficient	O
(	O
b	O
)	O

Low	O
Back	O

0	O
.	O
1073	O

0	O
.	O
1966	O

0	O
.	O
1216	O

0	O
.	O
1005	O

0	O
.	O
0223	O

−	O
0	O
.	O
0182	O

0	O
.	O
1735197	O

−	O
0	O
.	O
0182	O
,	O
0	O
.	O
0881	O

Knee	O

0	O
.	O
0595	O

0	O
.	O
0911	O

0	O
.	O
1216	O

0	O
.	O
1161	O

0	O
.	O
0072	O

0	O
.	O
1233	O

0	O
.	O
0452303	O

−	O
0	O
.	O
0152	O
,	O
0	O
.	O
0623	O

Shoulder	O

−	O
0	O
.	O
0482	O

0	O
.	O
1023	O

0	O
.	O
1216	O

0	O
.	O
1265	O

−	O
0	O
.	O
0032	O

0	O
.	O
1233	O

−	O
0	O
.	O
0402961	O

−	O
0	O
.	O
0592	O
,	O
0	O
.	O
0218	O

Wrist	O
-	O
forearm	O

0	O
.	O
2037	O

0	O
.	O
2102	O

0	O
.	O
1216	O

0	O
.	O
0788	O

0	O
.	O
0434	O

0	O
.	O
1222	O

0	O
.	O
3519737	O

0	O
.	O
0010	O
,	O
0	O
.	O
1520	O

Mediation	O
Results	O
on	O
Emotional	O
Role	O
(	O
Less	O
Careful	O
)	O
in	O
Participants	O
(	O
n	O
=	O
99	O
).	O

Path	O
A	O

Path	O
B	O

Path	O
C	O

Direct	O
Effect	O

Indirect	O
Effect	O

Total	O
Effect	O

Proportion	O
Mediated	O

Bootstrapped	O
95	O
%	O
CI	O

(	O
Path	O
C	O
′)	O

(	O
Bootstrapped	O
Path	O
A	O
*	O
B	O
)	O

(	O
Path	O
C	O
)	O

1	O
-	O
c	O
′/	O
c	O

(	O
Lower	O
Bound	O
,	O
Upper	O
Bound	O
)	O

Mediator	O

Path	O
Coefficient	O
(	O
b	O
)	O

Low	O
Back	O

0	O
.	O
1073	O

0	O
.	O
1355	O

0	O
.	O
003	O

−	O
0	O
.	O
0115	O

0	O
.	O
0155	O

0	O
.	O
004	O

4	O
.	O
8333333	O

−	O
0	O
.	O
0117	O
,	O
0	O
.	O
0711	O

Knee	O

0	O
.	O
0595	O

0	O
.	O
095	O

0	O
.	O
003	O

−	O
0	O
.	O
0026	O

0	O
.	O
0075	O

0	O
.	O
0049	O

1	O
.	O
8666667	O

−	O
0	O
.	O
0168	O
,	O
0	O
.	O
0564	O

Shoulder	O

−	O
0	O
.	O
0482	O

0	O
.	O
0736	O

0	O
.	O
003	O

0	O
.	O
0066	O

−	O
0	O
.	O
0031	O

0	O
.	O
0035	O

−	O
1	O
.	O
2	O

−	O
0	O
.	O
0507	O
,	O
0	O
.	O
0162	O

Wrist	O
-	O
forearm	O

0	O
.	O
2037	O

0	O
.	O
1712	O

0	O
.	O
003	O

−	O
0	O
.	O
0318	O

0	O
.	O
0335	O

0	O
.	O
0017	O

11	O
.	O
6	O

0	O
.	O
0015	O
,	O
0	O
.	O
0985	O

Mediation	O
Results	O
on	O
Exercise	O
Self	O
-	O
Efficacy	O
in	O
Nursing	O
Home	O
Employees	O
(	O
n	O
=	O
99	O
).	O

Path	O
A	O

Path	O
B	O

Path	O
C	O

Direct	O
Effect	O

Indirect	O
Effect	O

Total	O
Effect	O

Proportion	O
Mediated	O

Bootstrapped	O
95	O
%	O
CI	O

(	O
Path	O
C	O
′)	O

(	O
Bootstrapped	O
Path	O
A	O
*	O
B	O
)	O

(	O
Path	O
C	O
)	O

1	O
-	O
c	O
′/	O
c	O

(	O
Lower	O
Bound	O
,	O
Upper	O
Bound	O
)	O

Mediator	O

Path	O
Coefficient	O
(	O
b	O
)	O

Low	O
Back	O

0	O
.	O
1073	O

−	O
0	O
.	O
1212	O

−	O
0	O
.	O
3377	O

−	O
0	O
.	O
3247	O

−	O
0	O
.	O
0152	O

−	O
0	O
.	O
3399	O

0	O
.	O
0384957	O

−	O
0	O
.	O
0949	O
,	O
0	O
.	O
0109	O

Knee	O

0	O
.	O
0595	O

−	O
0	O
.	O
0369	O

−	O
0	O
.	O
3377	O

−	O
0	O
.	O
3355	O

−	O
0	O
.	O
0032	O

−	O
0	O
.	O
3387	O

0	O
.	O
0065147	O

−	O
0	O
.	O
0575	O
,	O
0	O
.	O
0177	O

Shoulder	O

−	O
0	O
.	O
0482	O

−	O
0	O
.	O
0262	O

−	O
0	O
.	O
3377	O

−	O
0	O
.	O
339	O

0	O
.	O
0036	O

−	O
0	O
.	O
3354	O

−	O
0	O
.	O
0038496	O

−	O
0	O
.	O
0206	O
,	O
0	O
.	O
0478	O

Wrist	O
-	O
forearm	O

0	O
.	O
2037	O

−	O
0	O
.	O
2925	O

−	O
0	O
.	O
3377	O

−	O
0	O
.	O
2781	O

−	O
0	O
.	O
0583	O

−	O
0	O
.	O
3364	O

0	O
.	O
176488	O

−	O
0	O
.	O
1510	O
,	O
−	O
0	O
.	O
0137	O

Mediation	O
Results	O
on	O
Physical	O
Activity	O
Levels	O
in	O
Nursing	O
Home	O
Employees	O
(	O
n	O
=	O
99	O
).	O

Path	O
A	O

Path	O
B	O

Path	O
C	O

Direct	O
Effect	O

Indirect	O
Effect	O

Total	O
Effect	O

Proportion	O
Mediated	O
by	O
ESE	O

Bootstrapped	O
95	O
%	O
CI	O

(	O
Path	O
C	O
′)	O

(	O
Bootstrapped	O
Path	O
A	O
*	O
B	O
)	O

(	O
Direct	O
Effect	O
+	O
Indirect	O
Effect	O
)	O

1	O
-	O
c	O
′/	O
c	O

(	O
Lower	O
Bound	O
,	O
Upper	O
Bound	O
)	O

Outcome	O
Measures	O

Path	O
Coefficient	O
(	O
b	O
)	O

Current	O
Physical	O
Activity	O

−	O
0	O
.	O
3635	O

0	O
.	O
116	O

−	O
0	O
.	O
2567	O

−	O
0	O
.	O
2145	O

−	O
0	O
.	O
0428	O

−	O
0	O
.	O
2573	O

0	O
.	O
1643942	O

−	O
0	O
.	O
1348	O
,	O
−	O
0	O
.	O
0001	O

Mild	O
Physical	O
Activity	O

−	O
0	O
.	O
3635	O

0	O
.	O
0537	O

−	O
0	O
.	O
1095	O

−	O
0	O
.	O
0899	O

−	O
0	O
.	O
0205	O

−	O
0	O
.	O
1104	O

0	O
.	O
1789954	O

−	O
0	O
.	O
0986	O
,	O
0	O
.	O
0234	O

Moderate	O
Physical	O
Activity	O
(	O
PA	O
)	O

−	O
0	O
.	O
3635	O

0	O
.	O
1868	O

−	O
0	O
.	O
2566	O

−	O
0	O
.	O
1888	O

−	O
0	O
.	O
0684	O

−	O
0	O
.	O
2572	O

0	O
.	O
2642245	O

−	O
0	O
.	O
1595	O
,	O
−	O
0	O
.	O
0156	O

Vigorous	O
Physical	O
Activity	O
(	O
PA	O
)	O

−	O
0	O
.	O
3635	O

0	O
.	O
1743	O

−	O
0	O
.	O
1415	O

−	O
0	O
.	O
0781	O

−	O
0	O
.	O
0631	O

−	O
0	O
.	O
1412	O

0	O
.	O
4480565	O

−	O
0	O
.	O
1365	O
,	O
−	O
0	O
.	O
0171	O

Assessment	O
of	O
the	O
circulating	O
cell	O
-	O
free	O
DNA	O
marker	O
association	O
with	O
diagnosis	O
and	O
prognostic	O
prediction	O
in	O
patients	O
with	O
lymphoma	B-DS
:	O
a	O
single	O
-	O
center	O
experience	O

Circulating	O
cell	O
-	O
free	O
DNA	O
(	O
ccfDNA	O
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
the	O
clinical	O
characteristics	O
and	O
prognosis	O
of	O
cancer	B-DS
patients	O
.	O

Our	O
objective	O
was	O
to	O
assess	O
whether	O
the	O
concentration	O
and	O
integrity	O
index	O
of	O
ccfDNA	O
in	O
plasma	O
may	O
be	O
useful	O
for	O
diagnosing	O
and	O
monitoring	O
the	O
progression	O
of	O
patients	O
with	O
lymphoma	B-DS
.	O

We	O
included	O
plasma	O
samples	O
from	O
174	O
lymphoma	B-DS
patients	O
and	O
80	O
healthy	O
individuals	O
.	O

The	O
total	O
concentration	O
of	O
ccfDNA	O
was	O
determined	O
using	O
a	O
fluorometry	O
method	O
,	O
and	O
the	O
DNA	O
integrity	O
index	O
(	O
DII	O
),	O
which	O
is	O
the	O
ratio	O
of	O
longer	O
to	O
shorter	O
DNA	O
fragments	O
,	O
for	O
the	O
APP	B-GP
gene	O
was	O
detected	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

The	O
median	O
levels	O
of	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
in	O
patients	O
with	O
lymphoma	B-DS
were	O
significantly	O
higher	O
than	O
those	O
in	O
controls	O
(	O
both	O
P	O
<	O
0	O
.	O
0001	O
).	O

Increases	O
in	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
associated	O
with	O
advanced	O
stage	O
disease	O
,	O
elevated	O
lactate	B-GP
dehydrogenase	I-GP
levels	O
,	O
and	O
a	O
higher	O
prognosis	O
score	O
.	O

In	O
patients	O
with	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
(	O
DLBCL	B-DS
),	O
high	O
levels	O
of	O
ccfDNA	O
(	O
both	O
concentration	O
and	O
the	O
DII	O
)	O
showed	O
an	O
inferior	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
;	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
).	O

Our	O
study	O
provides	O
quantitative	O
and	O
qualitative	O
evidence	O
in	O
favor	O
of	O
using	O
ccfDNA	O
analysis	O
in	O
lymphoma	B-DS
patients	O
for	O
diagnostic	O
and	O
prognostic	O
assessments	O
.	O

Introduction	O

Lymphoma	B-DS
,	O
which	O
is	O
a	O
common	O
cancer	B-DS
of	I-DS
the	I-DS
hematopoietic	I-DS
system	I-DS
,	O
represents	O
a	O
heterogeneous	O
collection	O
of	O
diseases	O
with	O
different	O
biological	O
characteristics	O
and	O
clinical	O
outcomes	O
.	O

In	O
China	O
,	O
more	O
than	O
80	O
,	O
000	O
new	O
cases	O
of	O
lymphoma	B-DS
and	O
an	O
estimated	O
52	O
,	O
000	O
deaths	O
attributed	O
to	O
lymphoma	B-DS
were	O
reported	O
in	O
2015	O
[	O
1	O
].	O

The	O
overall	O
survival	O
of	O
patients	O
with	O
lymphoma	B-DS
tends	O
to	O
be	O
poor	O
primarily	O
because	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
most	O
patients	O
are	O
already	O
in	O
the	O
late	O
stages	O
and	O
thus	O
lose	O
the	O
opportunity	O
for	O
timely	O
treatment	O
[	O
2	O
].	O

Therefore	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
a	O
noninvasive	O
tool	O
to	O
improve	O
the	O
diagnosis	O
and	O
prognostic	O
evaluation	O
of	O
lymphoma	B-DS
patients	O
.	O

Circulating	O
cell	O
-	O
free	O
DNA	O
(	O
ccfDNA	O
)	O
are	O
DNA	O
fragments	O
circulating	O
within	O
the	O
bloodstream	O
and	O
can	O
be	O
obtained	O
by	O
a	O
simple	O
blood	O
collection	O
.	O

Mendel	O
and	O
Metais	O
first	O
reported	O
the	O
existence	O
of	O
ccfDNA	O
in	O
1948	O
[	O
3	O
],	O
and	O
the	O
presence	O
of	O
ccfDNA	O
has	O
been	O
identified	O
in	O
inflammatory	B-DS
disease	I-DS
[	O
4	O
],	O
autoimmune	B-DS
disease	I-DS
[	O
5	O
],	O
trauma	O
[	O
6	O
],	O
and	O
myocardial	B-DS
infarction	I-DS
[	O
7	O
].	O

Recently	O
,	O
quantifying	O
ccfDNA	O
levels	O
has	O
been	O
proposed	O
as	O
a	O
potential	O
biomarker	O
to	O
detect	O
malignant	B-DS
tumors	I-DS
.	O

A	O
study	O
by	O
Leon	O
et	O
al	O
.	O
[	O
8	O
]	O
suggested	O
that	O
compared	O
with	O
that	O
of	O
healthy	O
individuals	O
,	O
the	O
concentration	O
of	O
ccfDNA	O
was	O
significantly	O
increased	O
in	O
cancer	B-DS
patients	O
;	O
furthermore	O
,	O
this	O
phenomenon	O
was	O
confirmed	O
by	O
other	O
studies	O
on	O
breast	B-DS
tumors	I-DS
[	O
9	O
],	O
colorectal	B-DS
cancer	I-DS
[	O
10	O
],	O
lung	B-DS
cancer	I-DS
[	O
11	O
],	O
and	O
other	O
cancer	B-DS
types	O
[	O
12	O
].	O

The	O
ccfDNA	O
released	O
into	O
the	O
bloodstream	O
is	O
thought	O
to	O
originate	O
from	O
either	O
passive	O
release	O
from	O
apoptotic	O
and	O
necrotic	O
cells	O
or	O
active	O
secretion	O
from	O
nucleated	O
cells	O
such	O
as	O
lymphocytes	O
.	O

Unlike	O
uniformly	O
truncated	O
DNA	O
released	O
from	O
apoptotic	O
cells	O
,	O
ccfDNA	O
released	O
from	O
necrotic	O
tumor	B-DS
cells	O
varies	O
in	O
size	O
,	O
which	O
may	O
lead	O
to	O
elevated	O
levels	O
of	O
long	O
fragments	O
of	O
DNA	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
malignant	B-DS
diseases	I-DS
[	O
13	O
].	O

Several	O
studies	O
have	O
demonstrated	O
that	O
compared	O
to	O
that	O
of	O
healthy	O
individuals	O
,	O
the	O
DNA	O
integrity	O
index	O
(	O
DII	O
),	O
which	O
is	O
calculated	O
as	O
the	O
ratio	O
of	O
longer	O
to	O
shorter	O
DNA	O
fragments	O
,	O
was	O
increased	O
in	O
patients	O
with	O
cancers	B-DS
[	O
14	O
–	O
16	O
].	O

Although	O
the	O
presence	O
of	O
ccfDNA	O
has	O
been	O
widely	O
studied	O
in	O
malignant	B-DS
tumors	I-DS
,	O
there	O
are	O
only	O
few	O
reports	O
regarding	O
ccfDNA	O
in	O
lymphoproliferative	B-DS
diseases	I-DS
.	O

It	O
has	O
been	O
hypothesized	O
that	O
ccfDNA	O
may	O
be	O
a	O
good	O
candidate	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
lymphoma	B-DS
because	O
some	O
studies	O
have	O
shown	O
that	O
the	O
concentration	O
of	O
ccfDNA	O
could	O
be	O
a	O
diagnostic	O
and	O
predictive	O
biomarker	O
in	O
lymphoma	B-DS
patients	O
[	O
17	O
,	O
18	O
];	O
however	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
studies	O
that	O
have	O
investigated	O
the	O
predictive	O
value	O
of	O
ccfDNA	O
integrity	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
value	O
of	O
the	O
concentration	O
and	O
integrity	O
of	O
ccfDNA	O
in	O
diagnosing	O
lymphoma	B-DS
patients	O
and	O
analyzed	O
these	O
parameters	O
to	O
identify	O
associations	O
with	O
clinical	O
characteristics	O
and	O
prognosis	O
.	O

Materials	O
and	O
methods	O

Population	O

There	O
were	O
174	O
lymphoma	B-DS
patients	O
enrolled	O
in	O
this	O
study	O
.	O

Among	O
the	O
included	O
lymphoma	B-DS
cases	O
,	O
126	O
were	O
B	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
lymphoma	I-DS
(	O
B	B-DS
-	I-DS
NHL	I-DS
),	O
with	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
(	O
DLBCL	B-DS
,	O
n	O
=	O
98	O
)	O
as	O
the	O
most	O
common	O
subtype	O
.	O

There	O
were	O
18	O
,	O
9	O
,	O
and	O
21	O
patients	O
diagnosed	O
with	O
HL	B-DS
,	O
T	B-DS
cell	I-DS
non	I-DS
-	I-DS
HL	I-DS
(	O
T	O
-	O
NHL	B-DS
),	O
and	O
extranodal	B-DS
NK	I-DS
/	I-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
(	O
NK	B-DS
/	O
TCL	B-DS
),	O
respectively	O
.	O

The	O
diagnosis	O
of	O
all	O
patients	O
was	O
histologically	O
confirmed	O
.	O

Patient	O
samples	O
were	O
obtained	O
from	O
West	O
China	O
Hospital	O
of	O
Sichuan	O
University	O
between	O
September	O
2014	O
and	O
January	O
2016	O
.	O

Plasma	O
samples	O
were	O
collected	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
.	O

The	O
median	O
follow	O
-	O
up	O
time	O
was	O
13	O
.	O
5	O
months	O
and	O
ranged	O
from	O
1	O
to	O
36	O
months	O
.	O

The	O
main	O
patient	O
characteristics	O
are	O
provided	O
in	O
Table	O
1	O
.	O
Table	O
1Main	O
characteristics	O
of	O
patients	O
included	O
in	O
the	O
studyTotalHLB	O
-	O
NHLT	B-DS
-	O
NHLNK	O
/	O
TCLDLBCLOthers	O
(	O
n	O
=	O
174	O
)(	O
n	O
=	O
18	O
)(	O
n	O
=	O
98	O
)(	O
n	O
=	O
28	O
)(	O
n	O
=	O
9	O
)(	O
n	O
=	O
21	O
)	O
Gender	O
Male107106117613	O
Female678371138Age	O
(	O
range	O
),	O
years	O
≤	O
60117156116718	O
>	O
60573371223Stage	O
I	O
–	O
IIA6924211114	O
IIB	O
–	O
IV10516561787B	O
-	O
symptoms	O
No916601429	B-CD
Yes83123814712Bulky	O
disease	O
No153138426921	O
Yes21514200Lactate	O
dehydrogenase	O
Normal9694817814	O
Elevated789501117IPI	O
Low	O
(	O
0	O
or	O
1	O
)	O
56	O
–	O
39836	O
Intermediate	O
low	O
(	O
2	O
)	O
38	O
–	O
225110	O
Intermediate	O
high	O
(	O
3	O
)	O
27	O
–	O
13815	O
High	O
(	O
4	O
or	O
5	O
)	O
35	O
–	O
24740IPS	O
0	O
–	O
2	O
–	O
9	O
––––	O
≥	O
3	O
–	O
9	O
––––	O
Data	O
were	O
presented	O
as	O
n	O
HL	B-DS
,	O
Hodgkin	B-DS
’	I-DS
s	I-DS
lymphoma	I-DS
;	O
B	B-DS
-	I-DS
NHL	I-DS
,	O
B	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
;	O
DLBCL	B-DS
,	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
;	O
Others	O
group	O
included	O
9	O
follicular	B-DS
lymphoma	I-DS
,	O
7	O
small	B-DS
cell	I-DS
lymphoma	I-DS
/	O
chronic	B-DS
lymphocytic	I-DS
leukemia	I-DS
,	O
6	O
marginal	B-DS
zone	I-DS
lymphoma	I-DS
,	O
5	O
mantle	B-DS
cell	I-DS
lymphoma	I-DS
and	O
1	O
Burkitt	B-DS
lymphoma	I-DS
;	O
T	B-DS
-	I-DS
NHL	I-DS
,	O
T	B-DS
cell	I-DS
non	I-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
,	O
included	O
in	O
4	O
peripheral	B-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
,	O
3	O
anaplastic	B-DS
large	I-DS
-	I-DS
cell	I-DS
lymphoma	I-DS
,	O
2	O
angioimmunoblastic	B-DS
T	I-DS
cell	I-DS
lymphoma	I-DS
;	O
NK	B-DS
/	O
TCL	B-DS
,	O
extranodal	O
NK	O
/	O
T	B-DS
cell	I-DS
lymphoma	I-DS
;	O
IPI	O
,	O
international	O
prognostic	O
index	O
;	O
IPS	O
,	O
international	O
prognostic	O
score	O

A	O
control	O
group	O
consisting	O
of	O
80	O
healthy	O
individuals	O
was	O
included	O
to	O
establish	O
the	O
normal	O
range	O
of	O
ccfDNA	O
levels	O
in	O
plasma	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
patients	O
and	O
controls	O
according	O
to	O
the	O
institutional	O
guidelines	O
,	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
Human	B-OG
Research	O
Ethics	O
Committee	O
of	O
the	O
West	O
China	O
Hospital	O
of	O
Sichuan	O
University	O
.	O

Sample	O
collection	O
and	O
DNA	O
extraction	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
into	O
tubes	O
containing	O
EDTA	O
and	O
centrifuged	O
(	O
2000	O
×	O
g	O
,	O
10	O
min	O
,	O
4	O
°	O
C	O
)	O
within	O
4	O
h	O
of	O
collection	O
.	O

To	O
prevent	O
cellular	O
DNA	O
contamination	O
,	O
the	O
plasma	O
supernatants	O
were	O
carefully	O
removed	O
and	O
recentrifuged	O
(	O
16	O
,	O
000	O
×	O
g	O
;	O
10	O
min	O
at	O
4	O
°	O
C	O
).	O

The	O
prepared	O
plasma	O
samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
further	O
analysis	O
.	O

ccfDNA	O
was	O
extracted	O
using	O
the	O
MagMAX	O
™	O
Cell	O
-	O
Free	O
DNA	O
Isolation	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

The	O
isolated	O
ccfDNA	O
was	O
eluted	O
in	O
20	O
μl	O
of	O
the	O
provided	O
solution	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
prior	O
to	O
quantitative	O
and	O
qualitative	O
analyses	O
.	O

Quantification	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O

Quantification	O
of	O
ccfDNA	O
was	O
performed	O
by	O
fluorometry	O
using	O
the	O
Qubit	O
®	O
dsDNA	O
HS	O
Assay	O
Kit	O
(	O
Molecular	O
Probes	O
,	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocols	O
,	O
and	O
the	O
plates	O
were	O
read	O
in	O
a	O
Qubit	O
®	O
3	O
.	O
0	O
fluorometer	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

The	O
ccfDNA	O
concentrations	O
were	O
determined	O
from	O
a	O
standard	O
curve	O
obtained	O
using	O
the	O
standard	O
stock	O
(	O
provided	O
by	O
the	O
manufacturer	O
).	O

Two	O
repeated	O
tests	O
were	O
performed	O
for	O
each	O
set	O
of	O
concentration	O
measurements	O
and	O
the	O
resulting	O
data	O
were	O
averaged	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
of	O
DNA	O
fragments	O

The	O
integrity	O
of	O
ccfDNA	O
in	O
plasma	O
was	O
determined	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
quantitative	O
assay	O
was	O
based	O
on	O
amplification	O
of	O
the	O
APP	B-GP
gene	O
(	O
amyloid	B-GP
beta	I-GP
precursor	I-GP
protein	I-GP
,	O
chromosome	O
21q21	O
.	O
3	O
,	O
accession	O
NM_000484	O
);	O
the	O
lengths	O
of	O
the	O
two	O
amplicons	O
were	O
67	O
and	O
180	O
bp	O
and	O
were	O
obtained	O
using	O
two	O
primer	O
pairs	O
as	O
reported	O
previously	O
[	O
19	O
].	O

The	O
primer	O
set	O
for	O
APP67	B-GP
amplified	O
both	O
shorter	O
(	O
truncated	O
by	O
apoptosis	O
)	O
and	O
longer	O
DNA	O
fragments	O
(	O
truncated	O
by	O
nonapoptotic	O
means	O
),	O
whereas	O
the	O
APP180	B-GP
amplified	O
only	O
the	O
longer	O
DNA	O
fragments	O
.	O

Quantification	O
of	O
ccfDNA	O
fragments	O
was	O
performed	O
using	O
the	O
CFX96	O
Touch	O
™	O
Real	O
-	O
Time	O
instrument	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

The	O
reaction	O
mixture	O
for	O
each	O
direct	O
quantitative	O
real	O
-	O
time	O
PCR	O
comprised	O
12	O
.	O
5	O
μl	O
of	O
SYBR	O
®	O
Premix	O
Ex	O
Taq	O
™	O
II	O
(	O
TaKaRa	O
,	O
Shiga	O
,	O
Japan	O
),	O
1	O
μl	O
(	O
0	O
.	O
4	O
μM	O
)	O
of	O
each	O
primer	O
,	O
and	O
2	O
μl	O
DNA	O
in	O
a	O
total	O
reaction	O
volume	O
of	O
20	O
μl	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
are	O
as	O
follows	O
:	O
APP67	B-GP
:	O
forward	O
,	O
5	O
′-	O
TCAGGTTGACGCCGCTGT	O
-	O
3	O
′	O
and	O
reverse	O
,	O
5	O
′-	O
TTCGTAGCCG	O
TTCTGCTGC	O
-	O
3	O
′;	O
and	O
APP180	B-GP
:	O
forward	O
,	O
5	O
′-	O
TCAGGTTGACGCCGCTGT	O
-	O
3	O
′	O
and	O
reverse	O
,	O
5	O
′-	O
TCTATAAATGGACACCGATGGGTAGT	O
-	O
3	O
′.	O

The	O
real	O
-	O
time	O
PCR	O
protocol	O
included	O
an	O
initial	O
denaturation	O
step	O
at	O
95	O
°	O
C	O
for	O
30	O
s	O
followed	O
by	O
40	O
cycles	O
of	O
denaturation	O
at	O
95	O
°	O
C	O
for	O
5	O
s	O
and	O
annealing	O
at	O
64	O
°	O
C	O
for	O
30	O
s	O
.	O

A	O
melting	O
curve	O
analysis	O
was	O
conducted	O
to	O
confirm	O
PCR	O
product	O
specificity	O
,	O
and	O
the	O
DNA	O
copy	O
number	O
of	O
each	O
sample	O
was	O
determined	O
using	O
a	O
standard	O
curve	O
with	O
serial	O
dilutions	O
(	O
2	O
×	O
10	O
−	O
1	O
−	O
2	O
×	O
105	O
ng	O
/	O
ml	O
)	O
of	O
human	B-OG
genomic	O
DNA	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
;	O
200	O
μg	O
/	O
ml	O
).	O

All	O
samples	O
were	O
analyzed	O
in	O
duplicate	O
,	O
and	O
a	O
negative	O
control	O
(	O
without	O
template	O
)	O
was	O
included	O
in	O
each	O
plate	O
.	O

All	O
quantitative	O
real	O
-	O
time	O
PCR	O
assays	O
were	O
performed	O
in	O
a	O
blinded	O
fashion	O
without	O
knowledge	O
of	O
the	O
specimen	O
identity	O
.	O

Statistical	O
analysis	O

Comparison	O
of	O
the	O
relative	O
expression	O
levels	O
of	O
ccfDNA	O
(	O
including	O
concentration	O
and	O
the	O
DII	O
)	O
between	O
patients	O
and	O
controls	O
was	O
performed	O
by	O
applying	O
the	O
nonparametric	O
Mann	O
-	O
Whitney	O
test	O
.	O

Analysis	O
of	O
receiver	O
operating	O
characteristics	O
(	O
ROC	O
)	O
curves	O
and	O
binary	O
logistic	O
regression	O
were	O
performed	O
to	O
evaluate	O
the	O
diagnostic	O
performance	O
of	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
in	O
lymphoma	B-DS
.	O

The	O
relationship	O
between	O
the	O
levels	O
of	O
ccfDNA	O
and	O
the	O
clinicopathological	O
features	O
of	O
lymphoma	B-DS
patients	O
was	O
estimated	O
as	O
appropriate	O
per	O
variable	O
type	O
.	O

In	O
detail	O
,	O
differences	O
in	O
the	O
ccfDNA	O
levels	O
among	O
the	O
different	O
groups	O
of	O
categorical	O
parameters	O
were	O
analyzed	O
by	O
either	O
the	O
nonparametric	O
Mann	O
-	O
Whitney	O
test	O
for	O
binary	O
variables	O
or	O
the	O
respective	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
the	O
parameters	O
consisting	O
of	O
several	O
independent	O
groups	O
.	O

The	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
approach	O
and	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
were	O
used	O
to	O
determine	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
).	O

PFS	O
was	O
defined	O
as	O
the	O
time	O
from	O
initial	O
diagnosis	O
until	O
disease	O
progression	O
/	O
relapse	O
or	O
death	O
from	O
any	O
cause	O
.	O

A	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
indicated	O
statistical	O
significance	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
SPSS	O
software	O
version	O
22	O
.	O
0	O
(	O
IBM	O
Corp	O
.,	O
Armonk	O
,	O
NY	O
)	O
and	O
MedCalc	O
software	O
version	O
15	O
.	O
10	O
(	O
MedCalc	O
Software	O
,	O
Ostend	O
,	O
Belgium	O
).	O

Results	O

Concentration	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
healthy	O
individuals	O
and	O
lymphoma	B-DS
patients	O

The	O
median	O
concentration	O
of	O
ccfDNA	O
in	O
the	O
80	O
healthy	O
individuals	O
tested	O
was	O
209	O
.	O
0	O
ng	O
/	O
ml	O
(	O
mean	O
222	O
.	O
5	O
ng	O
/	O
ml	O
,	O
range	O
100	O
.	O
0	O
–	O
456	O
.	O
0	O
ng	O
/	O
ml	O
);	O
however	O
,	O
in	O
patients	O
with	O
lymphoma	B-DS
(	O
n	O
=	O
174	O
),	O
this	O
concentration	O
was	O
significantly	O
higher	O
(	O
median	O
686	O
.	O
0	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
with	O
greater	O
variability	O
among	O
the	O
patients	O
(	O
mean	O
1407	O
.	O
6	O
ng	O
/	O
ml	O
,	O
range	O
100	O
.	O
0	O
–	O
14	O
,	O
180	O
.	O
0	O
ng	O
/	O
ml	O
).	O

Elevated	O
ccfDNA	O
concentration	O
levels	O
were	O
observed	O
in	O
patients	O
with	O
HL	B-DS
(	O
n	O
=	O
18	O
,	O
median	O
681	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
988	O
.	O
8	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
DLBCL	B-DS
(	O
n	O
=	O
98	O
,	O
median	O
845	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1722	O
.	O
2	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
other	O
types	O
of	O
B	B-DS
-	I-DS
NHL	I-DS
(	O
n	O
=	O
28	O
,	O
median	O
332	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1096	O
.	O
3	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
T	O
-	O
NHL	B-DS
(	O
n	O
=	O
9	O
,	O
median	O
942	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
1247	O
.	O
0	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
and	O
NK	O
/	O
TCL	O
(	O
n	O
=	O
21	O
,	O
median	O
662	O
.	O
0	O
ng	O
/	O
ml	O
,	O
mean	O
782	O
.	O
7	O
ng	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
1a	O
).	O
Fig	O
.	O
1Circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
in	O
the	O
plasma	O
of	O
lymphoma	B-DS
patients	O
.	O

Box	O
plots	O
showed	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
of	O
a	O
concentrations	O
and	O
b	O
DII	O
in	O
healthy	O
controls	O
and	O
patients	O
with	O
lymphoma	B-DS
,	O
presented	O
as	O
median	O
value	O
(	O
black	O
line	O
),	O
interquartile	O
range	O
(	O
box	O
),	O
and	O
5th	O
and	O
95th	O
percentiles	O
(	O
whiskers	O
)	O

To	O
assess	O
the	O
diagnostic	O
accuracy	O
of	O
the	O
ccfDNA	O
levels	O
in	O
lymphoma	B-DS
patients	O
,	O
an	O
ROC	O
curve	O
analysis	O
was	O
conducted	O
,	O
and	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
calculated	O
as	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
0	O
.	O
66	O
–	O
0	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
for	O
HL	B-DS
,	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
0	O
.	O
80	O
–	O
0	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
DLBCL	B-DS
,	O
and	O
0	O
.	O
79	O
(	O
95	O
%	O
CI	O
0	O
.	O
70	O
–	O
0	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
NK	O
/	O
TCL	O
,	O
suggesting	O
a	O
moderate	O
discriminatory	O
power	O
.	O

For	O
HL	B-DS
,	O
the	O
sensitivity	O
and	O
specificity	O
were	O
61	O
and	O
100	O
%,	O
respectively	O
,	O
at	O
a	O
cut	O
-	O
off	O
of	O
456	O
.	O
0	O
ng	O
/	O
ml	O
;	O
for	O
DLBCL	B-DS
,	O
73	O
and	O
94	O
%	O
at	O
a	O
cut	O
-	O
off	O
of	O
340	O
.	O
0	O
ng	O
/	O
ml	O
,	O
and	O
for	O
NK	O
/	O
TCL	O
,	O
71	O
and	O
96	O
%	O
at	O
a	O
cut	O
-	O
off	O
of	O
392	O
.	O
0	O
ng	O
/	O
ml	O
.	O

Based	O
on	O
these	O
results	O
,	O
elevated	O
levels	O
of	O
ccfDNA	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
lymphoma	B-DS
.	O

When	O
analyzed	O
as	O
a	O
logistic	O
regression	O
model	O
,	O
a	O
10	O
.	O
0	O
ng	O
/	O
ml	O
increase	O
in	O
the	O
ccfDNA	O
concentration	O
increased	O
the	O
lymphoma	B-DS
risk	O
by	O
7	O
.	O
3	O
%	O
(	O
odds	O
ratio	O
1	O
.	O
073	O
;	O
95	O
%	O
CI	O
1	O
.	O
045	O
–	O
1	O
.	O
102	O
).	O

Integrity	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
healthy	O
individuals	O
and	O
lymphoma	B-DS
patients	O

The	O
DII	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
quantitative	O
real	O
-	O
time	O
PCR	O
results	O
using	O
the	O
two	O
primer	O
sets	O
as	O
follows	O
:	O
QAPP180	O
/	O
QAPP67	O
.	O

Because	O
the	O
annealing	O
sites	O
of	O
APP67	B-GP
are	O
contained	O
within	O
the	O
APP180	B-GP
annealing	O
sites	O
,	O
the	O
DII	O
would	O
be	O
1	O
.	O
0	O
when	O
the	O
template	O
DNA	O
was	O
not	O
truncated	O
and	O
0	O
.	O
0	O
when	O
all	O
of	O
the	O
template	O
DNA	O
was	O
truncated	O
into	O
fragments	O
smaller	O
than	O
180	O
bp	O
.	O

The	O
median	O
DII	O
in	O
patients	O
with	O
lymphoma	B-DS
was	O
0	O
.	O
39	O
(	O
mean	O
0	O
.	O
42	O
,	O
range	O
0	O
.	O
11	O
–	O
0	O
.	O
97	O
),	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
normal	O
control	O
subjects	O
(	O
median	O
0	O
.	O
21	O
,	O
mean	O
0	O
.	O
22	O
,	O
range	O
0	O
.	O
07	O
–	O
0	O
.	O
49	O
;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Elevated	O
DII	O
values	O
were	O
observed	O
in	O
patients	O
with	O
HL	B-DS
(	O
median	O
0	O
.	O
37	O
,	O
mean	O
0	O
.	O
40	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
DLBCL	B-DS
(	O
median	O
0	O
.	O
43	O
,	O
mean	O
0	O
.	O
46	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
other	O
types	O
of	O
B	B-DS
-	I-DS
NHL	I-DS
(	O
median	O
0	O
.	O
34	O
,	O
mean	O
0	O
.	O
35	O
,	O
P	O
=	O
0	O
.	O
002	O
),	O
T	O
-	O
NHL	B-DS
(	O
median	O
0	O
.	O
42	O
,	O
mean	O
0	O
.	O
41	O
,	O
P	O
=	O
0	O
.	O
008	O
),	O
and	O
NK	O
/	O
TCL	O
(	O
median	O
0	O
.	O
33	O
,	O
mean	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
001	O
),	O
respectively	O
(	O
Fig	O
.	O
1b	O
).	O

Using	O
the	O
ROC	O
analysis	O
,	O
the	O
AUC	O
of	O
the	O
ccfDNA	O
DII	O
was	O
0	O
.	O
83	O
(	O
95	O
%	O
CI	O
0	O
.	O
74	O
–	O
0	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
HL	B-DS
,	O
0	O
.	O
90	O
(	O
95	O
%	O
CI	O
0	O
.	O
83	O
–	O
0	O
.	O
93	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
DLBCL	B-DS
,	O
and	O
0	O
.	O
81	O
(	O
95	O
%	O
CI	O
0	O
.	O
72	O
–	O
0	O
.	O
88	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
for	O
NK	O
/	O
TCL	O
.	O

Additionally	O
,	O
the	O
ROC	O
analysis	O
assessed	O
whether	O
a	O
combination	O
of	O
the	O
raw	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
could	O
improve	O
the	O
diagnostic	O
ability	O
compared	O
with	O
using	O
the	O
concentration	O
alone	O
.	O

The	O
results	O
showed	O
that	O
the	O
AUC	O
was	O
significantly	O
increased	O
after	O
the	O
addition	O
of	O
the	O
DII	O
to	O
the	O
ccfDNA	O
concentration	O
in	O
patients	O
with	O
DLBCL	B-DS
(	O
0	O
.	O
86	O
vs	O
.	O
0	O
.	O
91	O
;	O
Z	O
=	O
2	O
.	O
697	O
,	O
P	O
=	O
0	O
.	O
007	O
;	O
Fig	O
.	O
2	O
);	O
whereas	O
in	O
patients	O
with	O
either	O
HL	O
or	O
NK	O
/	O
TCL	O
,	O
there	O
was	O
only	O
a	O
trend	O
of	O
increased	O
AUC	O
observed	O
(	O
0	O
.	O
75	O
vs	O
.	O
0	O
.	O
84	O
;	O
Z	O
=	O
1	O
.	O
714	O
,	O
P	O
=	O
0	O
.	O
087	O
and	O
0	O
.	O
79	O
vs	O
.	O
0	O
.	O
88	O
;	O
Z	O
=	O
1	O
.	O
646	O
,	O
P	O
=	O
0	O
.	O
0997	O
,	O
respectively	O
).	O
Fig	O
.	O
2The	O
receiver	O
operating	O
characteristic	O
curves	O
of	O
the	O
circulating	O
cell	O
-	O
free	O
DNA	O
concentration	O
and	O
its	O
combination	O
with	O
DII	O
in	O
patients	O
with	O
DLBCL	B-DS
.	O

The	O
AUC	O
of	O
concentration	O
and	O
model	O
of	O
concentration	O
+	O
DII	O
was	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
0	O
.	O
80	O
–	O
0	O
.	O
90	O
)	O
and	O
0	O
.	O
91	O
(	O
95	O
%	O
CI	O
0	O
.	O
86	O
–	O
0	O
.	O
95	O
),	O
respectively	O
(	O
Z	O
=	O
2	O
.	O
697	O
,	O
P	O
=	O
0	O
.	O
007	O
).	O

DII	O
,	O
DNA	O
integrity	O
index	O
;	O
AUC	O
,	O
area	O
under	O
the	O
curve	O

Correlation	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
and	O
clinicopathological	O
features	O
in	O
lymphoma	B-DS
patients	O

To	O
assess	O
the	O
clinical	O
significance	O
of	O
ccfDNA	O
levels	O
,	O
we	O
analyzed	O
the	O
clinicopathological	O
correlations	O
in	O
the	O
total	O
lymphoma	B-DS
group	O
but	O
restricted	O
the	O
analysis	O
to	O
patients	O
with	O
DLBCL	B-DS
;	O
in	O
this	O
patient	O
subset	O
,	O
the	O
adverse	O
prognostic	O
factors	O
advanced	O
stage	O
disease	O
(	O
stage	O
IIB	O
–	O
IV	O
)	O
and	O
elevated	O
LDH	B-GP
levels	O
were	O
associated	O
with	O
increased	O
ccfDNA	O
levels	O
and	O
DII	O
(	O
Table	O
2	O
).	O

In	O
patients	O
with	O
DLBCL	B-DS
,	O
the	O
presence	O
of	O
B	O
-	O
symptoms	O
was	O
also	O
correlated	O
with	O
increases	O
in	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
.	O

As	O
a	O
consequence	O
,	O
patients	O
with	O
an	O
adverse	O
prognostic	O
score	O
had	O
higher	O
levels	O
of	O
ccfDNA	O
,	O
which	O
was	O
significant	O
among	O
all	O
lymphoma	B-DS
patients	O
and	O
DLBCL	B-DS
patients	O
[	O
20	O
,	O
21	O
].	O

Otherwise	O
,	O
no	O
statistical	O
significance	O
was	O
observed	O
when	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
analyzed	O
with	O
regard	O
to	O
other	O
clinical	O
parameters	O
such	O
as	O
age	O
,	O
gender	O
,	O
and	O
bulky	O
disease	O
.	O
Table	O
2Plasma	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
and	O
clinicopathologic	O
features	O
in	O
lymphoma	B-DS
patientsAll	O
patientsDLBCLConcentrationDIIConcentrationDIIGender	O
Male660	O
.	O
0	O
(	O
290	O
.	O
0	O
–	O
1684	O
.	O
0	O
)	O
0	O
.	O
38	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
54	O
)	O
764	O
.	O
0	O
(	O
352	O
.	O
0	O
–	O
1868	O
.	O
5	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
56	O
)	O
Female702	O
.	O
0	O
(	O
284	O
.	O
0	O
–	O
2000	O
.	O
0	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
53	O
)	O
1118	O
.	O
0	O
(	O
295	O
.	O
0	O
–	O
3080	O
.	O
0	O
)	O
0	O
.	O
48	O
(	O
0	O
.	O
35	O
–	O
0	O
.	O
59	O
)	O
P	O
0	O
.	O
7690	O
.	O
2340	O
.	O
5070	O
.	O
558Age	O
(	O
range	O
),	O
years	O
≤	O
60702	O
.	O
0	O
(	O
260	O
.	O
0	O
–	O
1868	O
.	O
5	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
53	O
)	O
802	O
.	O
0	O
(	O
287	O
.	O
0	O
–	O
2430	O
.	O
0	O
)	O
0	O
.	O
47	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
56	O
)	O
>	O
60656	O
.	O
0	O
(	O
355	O
.	O
0	O
–	O
1847	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
55	O
)	O
888	O
.	O
0	O
(	O
384	O
.	O
0	O
–	O
2220	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
58	O
)	O
P	O
0	O
.	O
4140	O
.	O
8560	O
.	O
6680	O
.	O
965Stage	O
I	O
–	O
IIA482	O
.	O
0	O
(	O
238	O
.	O
5	O
–	O
1081	O
.	O
0	O
)	O
0	O
.	O
34	O
(	O
0	O
.	O
28	O
–	O
0	O
.	O
47	O
)	O
488	O
.	O
0	O
(	O
262	O
.	O
8	O
–	O
1048	O
.	O
0	O
)	O
0	O
.	O
35	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
48	O
)	O
IIB	O
–	O
IV896	O
.	O
0	O
(	O
351	O
.	O
0	O
–	O
2330	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
56	O
)	O
1395	O
.	O
0	O
(	O
449	O
.	O
5	O
–	O
2720	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
41	O
–	O
0	O
.	O
62	O
)	O
P	O
0	O
.	O
003	O
0	O
.	O
0001	O
0	O
.	O
006	O
<	O
0	O
.	O
0001	O
B	O
-	O
symptoms	O
No496	O
.	O
0	O
(	O
267	O
.	O
0	O
–	O
1426	O
.	O
0	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
52	O
)	O
523	O
.	O
0	O
(	O
293	O
.	O
0	O
–	O
1672	O
.	O
8	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
54	O
)	O
Yes736	O
.	O
0	O
(	O
348	O
.	O
0	O
–	O
2240	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
32	O
–	O
0	O
.	O
54	O
)	O
1657	O
.	O
0	O
(	O
433	O
.	O
0	O
–	O
3520	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
39	O
–	O
0	O
.	O
63	O
)	O
P	O
0	O
.	O
1040	O
.	O
251	O
0	O
.	O
034	O
0	O
.	O
013	O
Bulky	O
disease	O
No662	O
.	O
0	O
(	O
287	O
.	O
0	O
–	O
1661	O
.	O
5	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
53	O
)	O
783	O
.	O
0	O
(	O
320	O
.	O
5	O
–	O
2330	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
55	O
)	O
Yes1011	O
.	O
0	O
(	O
269	O
.	O
0	O
–	O
2434	O
.	O
5	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
31	O
–	O
0	O
.	O
59	O
)	O
1148	O
.	O
0	O
(	O
334	O
.	O
5	O
–	O
2161	O
.	O
8	O
)	O
0	O
.	O
45	O
(	O
0	O
.	O
35	O
–	O
0	O
.	O
61	O
)	O
P	O
0	O
.	O
4310	O
.	O
4060	O
.	O
7410	O
.	O
737Lactate	O
dehydrogenase	O
Normal472	O
.	O
0	O
(	O
230	O
.	O
8	O
–	O
978	O
.	O
0	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
49	O
)	O
455	O
.	O
0	O
(	O
248	O
.	O
5	O
–	O
1114	O
.	O
0	O
)	O
0	O
.	O
39	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
52	O
)	O
Elevated1200	O
.	O
0	O
(	O
400	O
.	O
0	O
–	O
3020	O
.	O
0	O
)	O
0	O
.	O
43	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
59	O
)	O
1629	O
.	O
5	O
(	O
517	O
.	O
0	O
–	O
3520	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
38	O
–	O
0	O
.	O
63	O
)	O
P	O
<	O
0	O
.	O
0001	O
0	O
.	O
006	O
<	O
0	O
.	O
0001	O
0	O
.	O
003	O
Prognostic	O
score	O
Low	O
risk482	O
.	O
0	O
(	O
248	O
.	O
0	O
–	O
1024	O
.	O
0	O
)	O
0	O
.	O
37	O
(	O
0	O
.	O
29	O
–	O
0	O
.	O
51	O
)	O
522	O
.	O
0	O
(	O
267	O
.	O
5	O
–	O
1771	O
.	O
0	O
)	O
0	O
.	O
41	O
(	O
0	O
.	O
30	O
–	O
0	O
.	O
52	O
)	O
High	O
risk942	O
.	O
0	O
(	O
402	O
.	O
0	O
–	O
2600	O
.	O
0	O
)	O
0	O
.	O
42	O
(	O
0	O
.	O
34	O
–	O
0	O
.	O
57	O
)	O
1620	O
.	O
0	O
(	O
493	O
.	O
0	O
–	O
2870	O
.	O
0	O
)	O
0	O
.	O
52	O
(	O
0	O
.	O
39	O
–	O
0	O
.	O
66	O
)	O
P	O
0	O
.	O
001	O
0	O
.	O
01	O
0	O
.	O
002	O
0	O
.	O
005	O
Data	O
were	O
presented	O
as	O
median	O
(	O
IQR	O
25	O
–	O
75	O
);	O
IQR	O
,	O
interquartile	O
range	O
;	O
circulating	O
cell	O
-	O
free	O
DNA	O
analysis	O
included	O
in	O
concentration	O
and	O
DII	O
levels	O
;	O
DII	O
,	O
DNA	O
integrity	O
index	O
.	O

The	O
IPI	O
score	O
was	O
used	O
for	O
patients	O
with	O
non	B-DS
-	I-DS
Hodgkin	I-DS
’	I-DS
s	I-DS
lymphoma	I-DS
and	O
the	O
IPS	O
score	O
for	O
patients	O
with	O
Hodgkin	B-DS
’	I-DS
s	I-DS
lymphoma	I-DS
.	O

IPI	O
scores	O
0	O
and	O
1	O
were	O
considered	O
low	O
risk	O
,	O
2	O
and	O
3	O
as	O
high	O
risk	O
,	O
while	O
with	O
IPS	O
scores	O
0	O
–	O
2	O
were	O
considered	O
as	O
low	O
risk	O
and	O
3	O
as	O
high	O
risk	O
P	O
value	O
,	O
comparison	O
between	O
the	O
two	O
strata	O
of	O
each	O
individual	O
variable	O
.	O
P	O
values	O
below	O
0	O
.	O
05	O
were	O
shown	O
in	O
italics	O

Prognostic	O
significance	O
of	O
circulating	O
cell	O
-	O
free	O
DNA	O
in	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
patients	O

The	O
role	O
of	O
the	O
ccfDNA	O
levels	O
at	O
the	O
time	O
of	O
diagnosis	O
as	O
a	O
prognostic	O
marker	O
was	O
analyzed	O
in	O
patients	O
with	O
DLBCL	B-DS
,	O
who	O
constituted	O
the	O
largest	O
diagnostic	O
entity	O
included	O
in	O
this	O
study	O
.	O

The	O
most	O
discriminatory	O
cut	O
-	O
offs	O
for	O
2	O
-	O
year	O
PFS	O
were	O
identified	O
by	O
ROC	O
.	O

The	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
analyzed	O
as	O
dichotomic	O
variables	O
using	O
1586	O
ng	O
/	O
ml	O
and	O
0	O
.	O
61	O
as	O
the	O
cut	O
-	O
off	O
points	O
,	O
respectively	O
.	O

As	O
shown	O
in	O
the	O
Kaplan	O
-	O
Meier	O
curves	O
for	O
the	O
different	O
levels	O
of	O
ccfDNA	O
concentration	O
,	O
patients	O
with	O
a	O
ccfDNA	O
concentration	O
>	O
1586	O
ng	O
/	O
ml	O
had	O
a	O
2	O
-	O
year	O
probability	O
of	O
PFS	O
of	O
only	O
44	O
%	O
(	O
95	O
%	O
CI	O
15	O
–	O
73	O
%),	O
whereas	O
patients	O
with	O
a	O
ccfDNA	O
concentration	O
≤	O
1586	O
ng	O
/	O
ml	O
had	O
significantly	O
higher	O
probability	O
of	O
2	O
-	O
year	O
PFS	O
at	O
78	O
%	O
(	O
95	O
%	O
CI	O
55	O
–	O
99	O
%;	O
P	O
=	O
0	O
.	O
001	O
;	O
Fig	O
.	O
3a	O
).	O

The	O
prognostic	O
value	O
of	O
ccfDNA	O
fragmentation	O
on	O
PFS	O
was	O
also	O
evaluated	O
using	O
the	O
DII	O
.	O

Patients	O
showing	O
a	O
DII	O
>	O
0	O
.	O
61	O
had	O
a	O
59	O
%	O
probability	O
of	O
2	O
-	O
year	O
PFS	O
(	O
95	O
%	O
CI	O
38	O
–	O
79	O
%),	O
which	O
was	O
significantly	O
shorter	O
than	O
that	O
in	O
patients	O
with	O
a	O
DII	O
≤	O
0	O
.	O
61	O
(	O
87	O
%,	O
95	O
%	O
CI	O
69	O
–	O
100	O
%,	O
P	O
<	O
0	O
.	O
0001	O
;	O
Fig	O
.	O
3b	O
).	O
Fig	O
.	O
3Survival	O
curves	O
of	O
DLBCL	B-DS
patients	O
stratified	O
by	O
circulating	O
cell	O
-	O
free	O
DNA	O
levels	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curve	O
and	O
log	O
-	O
rank	O
test	O
according	O
to	O
a	O
concentration	O
and	O
b	O
DII	O
determined	O
by	O
ccfDNA	O
analysis	O
were	O
using	O
the	O
cut	O
-	O
offs	O
identified	O
by	O
means	O
of	O
ROC	O
for	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
P	O
value	O
noted	O
in	O
the	O
figure	O
).	O

ccfDNA	O
,	O
circulating	O
cell	O
-	O
free	O
DNA	O
;	O
DII	O
,	O
DNA	O
integrity	O
index	O
;	O
ROC	O
,	O
receiver	O
operating	O
characteristic	O

Following	O
the	O
univariate	O
analysis	O
,	O
we	O
found	O
that	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
associated	O
with	O
PFS	O
;	O
moreover	O
,	O
advanced	O
stage	O
,	O
B	O
-	O
symptoms	O
,	O
and	O
elevated	O
LDH	B-GP
levels	O
were	O
significant	O
adverse	O
factors	O
(	O
Table	O
3	O
).	O

Thus	O
,	O
these	O
variables	O
were	O
assessed	O
in	O
a	O
multivariate	O
Cox	O
regression	O
model	O
,	O
which	O
showed	O
that	O
the	O
DII	O
appeared	O
to	O
be	O
a	O
statistically	O
independent	O
prognostic	O
factor	O
(	O
HR	O
=	O
3	O
.	O
04	O
,	O
95	O
%	O
CI	O
1	O
.	O
197	O
–	O
7	O
.	O
696	O
;	O
P	O
=	O
0	O
.	O
019	O
),	O
whereas	O
the	O
ccfDNA	O
concentration	O
was	O
not	O
significant	O
in	O
this	O
multivariate	O
analysis	O
(	O
HR	O
=	O
1	O
.	O
45	O
,	O
95	O
%	O
CI	O
0	O
.	O
490	O
–	O
4	O
.	O
263	O
;	O
P	O
=	O
0	O
.	O
504	O
).	O
Table	O
3Univariable	O
Cox	O
regression	O
models	O
for	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
in	O
diffuse	B-DS
large	I-DS
B	I-DS
cell	I-DS
lymphoma	I-DS
patientsHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueGender	O
(	O
male	O
)	O
1	O
.	O
128	O
(	O
0	O
.	O
454	O
–	O
2	O
.	O
799	O
)	O
0	O
.	O
796Age	O
(>	O
60	O
years	O
)	O
1	O
.	O
196	O
(	O
0	O
.	O
495	O
–	O
2	O
.	O
886	O
)	O
0	O
.	O
692Advanced	O
stage7	O
.	O
977	O
(	O
1	O
.	O
856	O
–	O
34	O
.	O
29	O
)	O
0	O
.	O
005	O
B	O
-	O
symptoms6	O
.	O
639	O
(	O
2	O
.	O
404	O
–	O
18	O
.	O
33	O
)	O
<	O
0	O
.	O
0001	O
Bulky	O
disease0	O
.	O
571	O
(	O
0	O
.	O
133	O
–	O
2	O
.	O
456	O
)	O
0	O
.	O
452Elevated	O
LDH4	O
.	O
545	O
(	O
1	O
.	O
522	O
–	O
13	O
.	O
57	O
)	O
0	O
.	O
007	O
Elevated	O
ccfDNA	O
Concentration4	O
.	O
270	O
(	O
1	O
.	O
653	O
–	O
11	O
.	O
03	O
)	O
0	O
.	O
003	O
DII5	O
.	O
165	O
(	O
2	O
.	O
187	O
–	O
12	O
.	O
19	O
)	O
<	O
0	O
.	O
0001	O
Data	O
were	O
presented	O
as	O
HR	O
(	O
95	O
%	O
CI	O
);	O
HR	O
,	O
hazard	O
ratio	O
;	O
CI	O
,	O
confidence	O
interval	O
.	O

ccfDNA	O
,	O
circulating	O
cell	O
-	O
free	O
DNA	O
;	O
elevated	O
ccfDNA	O
was	O
included	O
in	O
both	O
concentration	O
and	O
DII	O
levels	O
P	O
values	O
below	O
0	O
.	O
05	O
were	O
shown	O
in	O
italics	O

Discussion	O

This	O
study	O
reveals	O
that	O
compared	O
to	O
healthy	O
individuals	O
,	O
patients	O
with	O
lymphoma	B-DS
frequently	O
have	O
higher	O
concentrations	O
and	O
longer	O
strands	O
of	O
ccfDNA	O
at	O
the	O
time	O
of	O
diagnosis	O
,	O
which	O
correlates	O
with	O
clinical	O
parameters	O
and	O
was	O
demonstrated	O
to	O
be	O
a	O
negative	O
predictor	O
of	O
DLBCL	B-DS
patients	O
’	O
outcome	O
.	O

Recently	O
,	O
studies	O
conducted	O
in	O
various	O
malignancies	O
have	O
shown	O
that	O
ccfDNA	O
levels	O
are	O
significantly	O
increased	O
in	O
cancer	B-DS
[	O
22	O
,	O
23	O
].	O

Our	O
work	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
levels	O
were	O
elevated	O
in	O
patients	O
with	O
lymphoma	B-DS
.	O

The	O
analysis	O
of	O
the	O
histological	O
subsets	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
levels	O
varied	O
according	O
to	O
the	O
lymphoma	B-DS
subtype	O
.	O

Unfortunately	O
,	O
the	O
B	O
-	B-DS
NHL	B-DS
and	O
T	O
-	O
NHL	B-DS
cohorts	O
were	O
insufficient	O
to	O
perform	O
a	O
significant	O
histological	O
subtype	O
analysis	O
.	O

There	O
are	O
only	O
few	O
reports	O
that	O
studied	O
the	O
clinical	O
impact	O
of	O
ccfDNA	O
levels	O
on	O
lymphoma	B-DS
patients	O
and	O
were	O
mainly	O
oriented	O
to	O
analyze	O
the	O
correlation	O
between	O
an	O
increase	O
in	O
the	O
ccfDNA	O
concentration	O
with	O
disease	O
risk	O
and	O
adverse	O
clinical	O
performance	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
other	O
analytical	O
parameters	O
exhibited	O
by	O
ccfDNA	O
such	O
as	O
the	O
DII	O
have	O
not	O
been	O
studied	O
in	O
lymphoma	B-DS
patients	O
.	O

Here	O
,	O
we	O
confirmed	O
the	O
usefulness	O
of	O
detecting	O
the	O
quantity	O
and	O
quality	O
of	O
ccfDNA	O
as	O
a	O
diagnostic	O
tool	O
for	O
lymphoma	B-DS
.	O

Data	O
from	O
our	O
ROC	O
analysis	O
showed	O
that	O
the	O
AUC	O
of	O
the	O
concentration	O
to	O
distinguish	O
HL	B-DS
,	O
DLBCL	B-DS
,	O
and	O
NK	O
/	O
TCL	O
patients	O
from	O
normal	O
controls	O
was	O
0	O
.	O
75	O
,	O
0	O
.	O
86	O
,	O
and	O
0	O
.	O
79	O
,	O
respectively	O
;	O
furthermore	O
,	O
the	O
AUC	O
of	O
the	O
DII	O
was	O
higher	O
than	O
that	O
of	O
the	O
concentration	O
(	O
0	O
.	O
83	O
,	O
0	O
.	O
90	O
,	O
and	O
0	O
.	O
81	O
for	O
HL	B-DS
,	O
DLBCL	B-DS
,	O
and	O
NK	O
/	O
TCL	O
,	O
respectively	O
),	O
indicating	O
that	O
the	O
ccfDNA	O
concentration	O
alone	O
appeared	O
to	O
be	O
insufficient	O
for	O
a	O
high	O
-	O
quality	O
diagnostic	O
performance	O
.	O

Hohaus	O
et	O
al	O
.	O
[	O
17	O
]	O
conducted	O
a	O
diagnostic	O
analysis	O
of	O
the	O
ccfDNA	O
concentration	O
for	O
patients	O
with	O
HL	B-DS
and	O
DLBCL	B-DS
and	O
found	O
that	O
the	O
maximum	O
sensitivity	O
and	O
specificity	O
did	O
not	O
exceed	O
75	O
%,	O
making	O
this	O
parameter	O
an	O
unlikely	O
candidate	O
for	O
lymphoma	B-DS
screening	O
.	O

Our	O
study	O
found	O
that	O
for	O
DLBCL	B-DS
patients	O
,	O
there	O
was	O
an	O
added	O
incremental	O
diagnostic	O
value	O
when	O
the	O
ccfDNA	O
concentration	O
was	O
combined	O
with	O
the	O
DII	O
.	O

Regarding	O
the	O
clinical	O
correlation	O
of	O
ccfDNA	O
levels	O
in	O
lymphoma	B-DS
patients	O
,	O
we	O
observed	O
an	O
association	O
between	O
the	O
ccfDNA	O
levels	O
and	O
a	O
number	O
of	O
clinical	O
parameters	O
that	O
indicate	O
a	O
worse	O
prognosis	O
such	O
as	O
advanced	O
stage	O
disease	O
,	O
the	O
presence	O
of	O
B	O
-	O
symptoms	O
,	O
elevated	O
LDH	B-GP
levels	O
,	O
and	O
high	O
IPI	O
score	O
;	O
these	O
correlations	O
suggest	O
that	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
might	O
reflect	O
actively	O
proliferating	O
disease	O
and	O
lymphoma	B-DS
burden	O
.	O

Nevertheless	O
,	O
a	O
literature	O
analysis	O
highlights	O
the	O
confusion	O
regarding	O
these	O
ccfDNA	O
parameters	O
with	O
tumor	B-DS
burden	O
and	O
predicting	O
a	O
therapeutic	O
response	O
.	O

Hohaus	O
et	O
al	O
.	O
[	O
17	O
]	O
also	O
observed	O
significant	O
associations	O
between	O
the	O
ccfDNA	O
concentration	O
and	O
some	O
adverse	O
parameters	O
,	O
whereas	O
a	O
study	O
by	O
Jones	O
et	O
al	O
.	O
[	O
18	O
]	O
found	O
that	O
the	O
ccfDNA	O
concentration	O
was	O
not	O
indicative	O
of	O
lymphoma	B-DS
burden	O
once	O
therapy	O
had	O
commenced	O
;	O
they	O
reported	O
that	O
only	O
lymphoma	B-DS
-	O
specific	O
DNA	O
such	O
as	O
Epstein	B-OG
-	I-OG
Barr	I-OG
virus	I-OG
DNA	O
could	O
be	O
used	O
to	O
monitor	O
the	O
disease	O
response	O
in	O
lymphoma	B-DS
patients	O
.	O

In	O
addition	O
,	O
both	O
the	O
ccfDNA	O
concentration	O
and	O
the	O
DII	O
were	O
not	O
significantly	O
different	O
between	O
germinal	O
center	O
B	O
cell	O
type	O
and	O
non	O
-	O
germinal	O
center	O
B	O
cell	O
type	O
DLBCL	B-DS
based	O
on	O
the	O
Hans	O
classification	O
system	O
(	O
data	O
not	O
shown	O
).	O

We	O
assessed	O
the	O
prognostic	O
significance	O
of	O
ccfDNA	O
levels	O
in	O
patients	O
with	O
DLBCL	B-DS
.	O

Our	O
data	O
showed	O
that	O
high	O
concentrations	O
of	O
ccfDNA	O
and	O
an	O
elevated	O
DII	O
were	O
strongly	O
correlated	O
with	O
poor	O
outcome	O
in	O
patients	O
with	O
DLBCL	B-DS
,	O
which	O
has	O
already	O
been	O
reported	O
[	O
17	O
].	O

However	O
,	O
our	O
study	O
data	O
revealed	O
that	O
the	O
ccfDNA	O
concentration	O
was	O
insufficient	O
as	O
an	O
independent	O
prognostic	O
factor	O
compared	O
to	O
other	O
existing	O
and	O
validated	O
adverse	O
factors	O
such	O
as	O
disease	O
stage	O
or	O
elevated	O
LDH	B-GP
levels	O
[	O
24	O
].	O

The	O
origin	O
of	O
ccfDNA	O
is	O
still	O
unclear	O
.	O

In	O
healthy	O
individuals	O
,	O
the	O
ccfDNA	O
concentration	O
is	O
low	O
,	O
which	O
is	O
ascribed	O
to	O
the	O
efficient	O
removal	O
of	O
most	O
nonliving	O
cells	O
from	O
circulation	O
by	O
phagocytes	O
.	O

Schwarzenbach	O
et	O
al	O
.	O
[	O
25	O
]	O
proposed	O
that	O
ccfDNA	O
could	O
be	O
released	O
by	O
either	O
apoptosis	O
or	O
necrosis	O
and	O
found	O
that	O
the	O
predominant	O
fragment	O
length	O
of	O
ccfDNA	O
frequently	O
occurred	O
in	O
multiples	O
of	O
180	O
bp	O
,	O
which	O
is	O
typical	O
of	O
DNA	O
released	O
from	O
apoptotic	O
cells	O
.	O

However	O
,	O
the	O
presence	O
of	O
larger	O
fragments	O
such	O
as	O
those	O
found	O
in	O
cancer	B-DS
patients	O
suggested	O
that	O
ccfDNA	O
could	O
also	O
be	O
derived	O
from	O
necrotic	O
cells	O
.	O

Moreover	O
,	O
some	O
studies	O
have	O
attributed	O
a	O
notable	O
fraction	O
of	O
ccfDNA	O
to	O
active	O
release	O
from	O
lymphocytes	O
[	O
26	O
].	O

ccfDNA	O
is	O
not	O
specific	O
to	O
neoplastic	O
conditions	O
as	O
increased	O
levels	O
have	O
also	O
been	O
identified	O
in	O
inflammatory	O
and	O
autoimmune	B-DS
diseases	I-DS
.	O

An	O
association	O
between	O
a	O
high	O
concentration	O
of	O
ccfDNA	O
and	O
poor	O
prognosis	O
may	O
be	O
linked	O
to	O
tumor	B-DS
burden	O
[	O
27	O
];	O
however	O
,	O
changes	O
in	O
the	O
total	O
ccfDNA	O
concentration	O
may	O
reflect	O
not	O
only	O
changes	O
in	O
circulating	O
tumor	B-DS
DNA	O
(	O
ctDNA	O
)	O
but	O
also	O
in	O
other	O
conditions	O
that	O
may	O
lead	O
to	O
an	O
increase	O
in	O
ccfDNA	O
,	O
including	O
infection	B-DS
or	O
chemotherapy	O
drug	O
-	O
induced	O
release	O
of	O
normal	O
ccfDNA	O
into	O
the	O
circulation	O
.	O

ctDNA	O
is	O
a	O
specific	O
ccfDNA	O
released	O
by	O
tumor	B-DS
cells	O
,	O
which	O
contains	O
genetic	O
and	O
epigenetic	O
alterations	O
concordant	O
with	O
those	O
of	O
the	O
primary	O
tumor	B-DS
.	O

This	O
may	O
explain	O
why	O
our	O
data	O
showed	O
the	O
levels	O
of	O
ccfDNA	O
in	O
HL	B-DS
patients	O
were	O
as	O
high	O
as	O
in	O
NHL	B-DS
patients	O
and	O
indicated	O
that	O
the	O
overall	O
concentration	O
of	O
ccfDNA	O
was	O
not	O
an	O
independent	O
significant	O
prognostic	O
factor	O
of	O
survival	O
to	O
some	O
extent	O
.	O

Actually	O
,	O
our	O
results	O
showed	O
the	O
limitations	O
of	O
analyzing	O
only	O
the	O
total	O
ccfDNA	O
levels	O
,	O
as	O
focusing	O
on	O
tumor	B-DS
-	O
specific	O
ccfDNA	O
might	O
serve	O
as	O
a	O
more	O
adequate	O
surrogate	O
biomarker	O
.	O

For	O
solid	B-DS
tumors	I-DS
,	O
many	O
studies	O
have	O
validated	O
that	O
genetic	O
alterations	O
detected	O
in	O
ctDNA	O
correspond	O
to	O
the	O
primary	O
tumor	B-DS
and	O
that	O
the	O
levels	O
of	O
ctDNA	O
could	O
assess	O
the	O
tumor	B-DS
response	O
and	O
even	O
provide	O
an	O
earlier	O
indication	O
of	O
disease	O
progression	O
[	O
28	O
–	O
30	O
].	O

Roschewski	O
et	O
al	O
.	O
[	O
31	O
]	O
reported	O
that	O
monitoring	O
ctDNA	O
could	O
identify	O
patients	O
with	O
DLBCL	B-DS
who	O
are	O
at	O
risk	O
of	O
recurrence	O
before	O
the	O
manifestation	O
of	O
clinical	O
evidence	O
of	O
disease	O
,	O
and	O
interim	O
ctDNA	O
may	O
be	O
a	O
promising	O
biomarker	O
to	O
identify	O
patients	O
at	O
high	O
risk	O
of	O
treatment	O
failure	O
.	O

However	O
,	O
additional	O
studies	O
on	O
ctDNA	O
are	O
required	O
to	O
prove	O
its	O
value	O
in	O
clinical	O
practice	O
.	O

Thus	O
,	O
as	O
the	O
ccfDNA	O
levels	O
could	O
still	O
reflect	O
disease	O
progression	O
[	O
32	O
],	O
they	O
remain	O
a	O
useful	O
biomarker	O
to	O
monitor	O
disease	O
status	O
,	O
especially	O
when	O
combined	O
with	O
other	O
parameters	O
such	O
as	O
the	O
DII	O
or	O
ctDNA	O
levels	O
.	O

In	O
this	O
study	O
,	O
it	O
should	O
be	O
noted	O
that	O
ccfDNA	O
extraction	O
was	O
performed	O
using	O
the	O
magnetic	O
bead	O
method	O
,	O
which	O
is	O
based	O
on	O
the	O
principle	O
of	O
nucleic	O
acid	O
adsorption	O
and	O
release	O
via	O
magnetic	O
beads	O
.	O

The	O
most	O
commonly	O
used	O
DNA	O
extraction	O
methods	O
include	O
the	O
phenol	O
-	O
chloroform	O
method	O
,	O
sodium	O
iodide	O
method	O
,	O
and	O
magnetic	O
bead	O
method	O
as	O
well	O
as	O
the	O
use	O
of	O
commercial	O
DNA	O
isolation	O
kits	O
[	O
33	O
].	O

Pan	O
et	O
al	O
.	O
[	O
34	O
]	O
compared	O
the	O
phenol	O
-	O
chloroform	B-CD
method	O
,	O
commercial	O
kits	O
,	O
and	O
magnetic	O
bead	O
method	O
in	O
the	O
detection	O
of	O
mycobacterium	B-OG
tuberculosis	I-OG
DNA	O
and	O
found	O
that	O
the	O
magnetic	O
bead	O
method	O
had	O
the	O
highest	O
DNA	O
extraction	O
efficiency	O
and	O
the	O
best	O
reproducibility	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
demonstrated	O
that	O
the	O
quantification	O
and	O
integrity	O
analysis	O
of	O
ccfDNA	O
from	O
the	O
plasma	O
of	O
patients	O
with	O
lymphoma	B-DS
might	O
be	O
a	O
useful	O
noninvasive	O
technique	O
for	O
clinical	O
practice	O
.	O

In	O
patients	O
with	O
DLBCL	B-DS
,	O
high	O
levels	O
of	O
ccfDNA	O
and	O
an	O
elevated	O
integrity	O
index	O
were	O
associated	O
with	O
poor	O
prognosis	O
,	O
although	O
,	O
based	O
on	O
our	O
results	O
,	O
only	O
the	O
DII	O
was	O
an	O
independent	O
adverse	O
factor	O
for	O
PFS	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
prospective	O
studies	O
with	O
larger	O
cohorts	O
and	O
a	O
longer	O
follow	O
-	O
up	O
should	O
be	O
initiated	O
to	O
assess	O
the	O
utility	O
of	O
ccfDNA	O
analysis	O
,	O
especially	O
using	O
tumor	B-DS
-	O
specific	O
ccfDNA	O
.	O

Complex	O
Admixture	O
Preceded	O
and	O
Followed	O
the	O
Extinction	O
of	O
Wisent	O
in	O
the	O
Wild	O

Retracing	O
complex	O
population	O
processes	O
that	O
precede	O
extreme	O
bottlenecks	O
may	O
be	O
impossible	O
using	O
data	O
from	O
living	O
individuals	O
.	O

The	O
wisent	O
(	O
Bison	B-OG
bonasus	I-OG
),	O
Europe	O
’	O
s	O
largest	O
terrestrial	O
mammal	B-OG
,	O
exemplifies	O
such	O
a	O
population	O
history	O
,	O
having	O
gone	O
extinct	O
in	O
the	O
wild	O
but	O
subsequently	O
restored	O
by	O
captive	O
breeding	O
efforts	O
.	O

Using	O
low	O
coverage	O
genomic	O
data	O
from	O
modern	O
and	O
historical	O
individuals	O
,	O
we	O
investigate	O
population	O
processes	O
occurring	O
before	O
and	O
after	O
this	O
extinction	O
.	O

Analysis	O
of	O
aligned	O
genomes	O
supports	O
the	O
division	O
of	O
wisent	O
into	O
two	O
previously	O
recognized	O
subspecies	O
,	O
but	O
almost	O
half	O
of	O
the	O
genomic	O
alignment	O
contradicts	O
this	O
population	O
history	O
as	O
a	O
result	O
of	O
incomplete	O
lineage	O
sorting	O
and	O
admixture	O
.	O

Admixture	O
between	O
subspecies	O
populations	O
occurred	O
prior	O
to	O
extinction	O
and	O
subsequently	O
during	O
the	O
captive	O
breeding	O
program	O
.	O

Admixture	O
with	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
is	O
also	O
widespread	O
but	O
results	O
from	O
ancient	O
events	O
rather	O
than	O
recent	O
hybridization	O
with	O
domestics	O
.	O

Our	O
study	O
demonstrates	O
the	O
huge	O
potential	O
of	O
historical	O
genomes	O
for	O
both	O
studying	O
evolutionary	O
histories	O
and	O
for	O
guiding	O
conservation	O
strategies	O
.	O

Introduction	O

The	O
last	O
known	O
wild	O
wisent	O
,	O
or	O
European	B-OG
bison	I-OG
(	O
Bison	B-OG
bonasus	I-OG
),	O
was	O
shot	O
and	O
killed	O
in	O
1927	O
,	O
marking	O
the	O
extinction	O
of	O
this	O
species	O
in	O
the	O
wild	O
(	O
Pucek	O
1991	O
).	O

As	O
a	O
result	O
of	O
an	O
intensive	O
captive	O
breeding	O
program	O
and	O
a	O
series	O
of	O
re	O
-	O
establishments	O
,	O
today	O
the	O
species	O
again	O
occupies	O
part	O
of	O
its	O
former	O
range	O
in	O
Central	O
and	O
Eastern	O
Europe	O
.	O

The	O
total	O
population	O
of	O
free	O
-	O
ranging	O
wisent	O
now	O
stands	O
at	O
over	O
5	O
,	O
000	O
individuals	O
(	O
Raczyński	O
2014	O
),	O
and	O
the	O
International	O
Union	O
for	O
Conservation	O
of	O
Nature	O
has	O
downgraded	O
the	O
conservation	O
status	O
of	O
wisent	O
to	O
threatened	O
(	O
Olech	O
2008	O
).	O

In	O
historical	O
times	O
,	O
wisent	O
ranged	O
extensively	O
across	O
semi	O
-	O
open	O
habitats	O
and	O
broadleaved	O
,	O
mixed	O
and	O
coniferous	O
forests	O
in	O
Western	O
Europe	O
,	O
from	O
what	O
is	O
today	O
France	O
in	O
the	O
west	O
to	O
the	O
Volga	O
River	O
and	O
the	O
Caucasus	O
in	O
the	O
east	O
,	O
with	O
the	O
northernmost	O
range	O
limits	O
around	O
60	O
°	O
north	O
(	O
fig	O
.	O
1	O
;	O
Kuemmerle	O
et	O
al	O
.	O

2011	O
;	O
Kerley	O
et	O
al	O
.	O

2012	O
;	O
Bocherens	O
et	O
al	O
.	O

2015	O
).	O

However	O
,	O
ongoing	O
habitat	O
fragmentation	O
and	O
overhunting	O
eradicated	O
most	O
populations	O
.	O

By	O
the	O
end	O
of	O
the	O
19th	O
century	O
,	O
there	O
were	O
only	O
two	O
populations	O
of	O
wisent	O
left	O
in	O
the	O
wild	O
that	O
were	O
assigned	O
to	O
separate	O
subspecies	O
:	O
in	O
Białowieża	O
Forest	O
(	O
Lowland	O
wisent	O
,	O
B	O
.	O
b	B-OG
.	I-OG
bonasus	I-OG
)	O
and	O
in	O
the	O
western	O
Caucasus	O
Mountains	O
(	O
Caucasian	O
wisent	O
,	O
B	O
.	O
b	B-OG
.	I-OG
caucasicus	I-OG
).	O

Finally	O
,	O
even	O
these	O
populations	O
collapsed	O
;	O
the	O
last	O
wild	O
Lowland	O
wisent	O
was	O
shot	O
in	O
Poland	O
in	O
1919	O
followed	O
by	O
the	O
last	O
Caucasian	O
animal	B-OG
in	O
1927	O
(	O
Pucek	O
1991	O
).	O
Fig	O
.	O
1Map	O
of	O
Western	O
Europe	O
showing	O
the	O
putative	O
historical	O
range	O
of	O
Lowland	O
wisent	O
(	O
shaded	O
green	O
)	O
and	O
Caucasian	O
wisent	O
(	O
shaded	O
grey	O
)	O
based	O
on	O
bone	O
remains	O
and	O
written	O
records	O
(	O
according	O
to	O
Benecke	O
2005	O
;	O
Kuemmerle	O
et	O
al	O
.	O

2011	O
;	O
Tokarska	O
et	O
al	O
.	O

2011	O
;	O
Bocherens	O
et	O
al	O
.	O

2015	O
)	O
and	O
sample	O
locations	O
.	O

Black	O
circles	O
indicate	O
contemporary	O
free	O
-	O
ranging	O
modern	O
L	O
line	O
herds	O
and	O
white	O
circles	O
indicate	O
modern	O
LC	O
line	O
herds	O
.	O

Purple	O
and	O
peach	O
circles	O
denote	O
the	O
locations	O
of	O
investigated	O
modern	O
L	O
(	O
MdL1	B-GP
,	O
MdL2	B-GP
)	O
and	O
LC	O
(	O
MdLC	O
)	O
line	O
wisent	O
,	O
respectively	O
,	O
orange	O
squares	O
show	O
the	O
location	O
of	O
the	O
Holocene	O
Lowland	O
wisent	O
(	O
Bb1	O
–	O
3	O
)	O
and	O
blue	O
and	O
yellow	O
triangles	O
indicate	O
historical	O
founding	O
wisent	O
from	O
the	O
Pszczyna	O
population	O
(	O
PLANTA	O
and	O
PLATEN	O
)	O
and	O
the	O
extinct	O
Caucasian	O
wisent	O
(	O
Cc1	O
–	O
3	O
),	O
respectively	O
.	O

In	O
1924	O
,	O
the	O
captive	O
population	O
consisted	O
of	O
only	O
54	O
individuals	O
(	O
29	O
males	O
and	O
25	O
females	O
).	O

However	O
,	O
the	O
actual	O
founding	O
captive	O
population	O
of	O
wisent	O
was	O
considerably	O
smaller	O
,	O
and	O
is	O
thought	O
to	O
comprise	O
of	O
just	O
12	O
individuals	O
(	O
Slatis	O
1960	O
).	O

All	O
but	O
one	O
of	O
these	O
12	O
founders	O
were	O
Lowland	O
wisent	O
,	O
almost	O
half	O
of	O
which	O
came	O
from	O
a	O
population	O
established	O
in	O
1865	O
in	O
Pless	O
(	O
now	O
Pszczyna	O
,	O
Poland	O
).	O

The	O
remaining	O
founder	O
was	O
a	O
Caucasian	O
wisent	O
bull	B-OG
named	O
M100	O
KAUKASUS	O
that	O
represented	O
the	O
last	O
surviving	O
pure	O
Caucasian	O
wisent	O
in	O
captivity	O
.	O

The	O
modern	O
herds	O
that	O
are	O
derived	O
from	O
this	O
founding	O
population	O
are	O
managed	O
as	O
two	O
separate	O
genetic	O
lines	O
.	O

The	O
Lowland	O
line	O
(	O
L	O
)	O
derives	O
from	O
seven	O
Lowland	O
founders	O
(	O
4	O
males	O
and	O
3	O
females	O
),	O
and	O
is	O
thus	O
considered	O
to	O
represent	O
a	O
pure	O
Lowland	O
wisent	O
lineage	O
.	O

The	O
Lowland	O
-	O
Caucasian	O
(	O
LC	O
)	O
line	O
originates	O
from	O
all	O
12	O
founders	O
(	O
5	O
males	O
,	O
7	O
females	O
),	O
which	O
included	O
the	O
last	O
remaining	O
Caucasian	O
wisent	O
bull	O
(	O
Slatis	O
1960	O
).	O

Descendants	O
of	O
the	O
LC	O
line	O
thus	O
represent	O
a	O
mixture	O
of	O
Lowland	O
and	O
Caucasian	O
wisent	O
ancestry	O
.	O

Although	O
the	O
wisent	O
restitution	O
undoubtedly	O
represents	O
a	O
tremendous	O
conservation	O
success	O
,	O
several	O
factors	O
may	O
limit	O
the	O
long	O
-	O
term	O
viability	O
of	O
the	O
species	O
,	O
many	O
of	O
which	O
are	O
applicable	O
to	O
ex	O
-	O
situ	O
conservation	O
strategies	O
in	O
general	O
.	O

A	O
factor	O
that	O
has	O
received	O
particular	O
attention	O
is	O
that	O
of	O
reduced	O
genetic	O
variability	O
,	O
which	O
may	O
be	O
correlated	O
with	O
a	O
lowered	O
resistance	O
to	O
disease	O
and	O
parasites	O
in	O
wisent	O
(	O
Karbowiak	O
et	O
al	O
.	O

2014a	O
,	O
b	O
;	O
Majewska	O
et	O
al	O
.	O

2014	O
;	O
Panasiewicz	O
et	O
al	O
.	O

2015	O
),	O
and	O
also	O
seriously	O
impacts	O
conservation	O
programs	O
for	O
other	O
threatened	O
species	O
(	O
Altizer	O
et	O
al	O
.	O

2007	O
).	O

Although	O
genetic	O
variability	O
among	O
living	O
wisent	O
herds	O
has	O
been	O
widely	O
investigated	O
using	O
a	O
variety	O
of	O
genetic	O
markers	O
(	O
Gralak	O
et	O
al	O
.	O

2004	O
;	O
Luenser	O
et	O
al	O
.	O

2005	O
;	O
Radwan	O
et	O
al	O
.	O

2007	O
;	O
Wójcik	O
et	O
al	O
.	O

2009	O
;	O
Babik	O
et	O
al	O
.	O

2012	O
;	O
Tokarska	O
,	O
Kawałko	O
,	O
et	O
al	O
.	O

2009	O
;	O
Tokarska	O
,	O
Marshall	O
,	O
et	O
al	O
.	O

2009	O
;	O
Tokarska	O
et	O
al	O
.	O

2015	O
),	O
studies	O
at	O
the	O
level	O
of	O
the	O
complete	O
genome	O
have	O
been	O
far	O
less	O
frequent	O
.	O

A	O
recent	O
study	O
(	O
Gautier	O
et	O
al	O
.	O

2016	O
)	O
presented	O
moderate	O
-	O
coverage	O
(∼	O
10	O
×)	O
genomic	O
data	O
from	O
two	O
modern	O
L	O
line	O
wisent	O
.	O

They	O
found	O
levels	O
of	O
heterozygosity	O
in	O
these	O
individuals	O
to	O
be	O
similar	O
to	O
that	O
found	O
in	O
modern	O
domestic	O
cow	B-OG
breeds	O
.	O

However	O
,	O
levels	O
of	O
genetic	O
variability	O
occurring	O
prior	O
to	O
extinction	O
of	O
wisent	O
in	O
the	O
wild	O
,	O
and	O
any	O
potential	O
loss	O
of	O
genetic	O
variability	O
following	O
the	O
establishment	O
of	O
the	O
captive	O
breeding	O
population	O
,	O
remains	O
unquantified	O
.	O

A	O
second	O
threat	O
for	O
wisent	O
is	O
potential	O
hybridization	O
with	O
domestic	O
cattle	B-OG
(	O
Bos	B-OG
taurus	I-OG
).	O

Although	O
F1	O
hybrid	O
bulls	B-OG
are	O
sterile	O
,	O
hybrid	O
female	O
offspring	O
are	O
not	O
(	O
Basrur	O
1968	O
),	O
and	O
would	O
therefore	O
have	O
the	O
potential	O
to	O
reintegrate	O
back	O
into	O
the	O
wild	O
population	O
.	O

The	O
bison	B-OG
lineage	O
(	O
including	O
wisent	O
,	O
American	B-OG
bison	I-OG
and	O
the	O
extinct	O
steppe	B-OG
bison	I-OG
)	O
is	O
thought	O
to	O
have	O
diverged	O
from	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
around	O
0	O
.	O
85	O
–	O
1	O
.	O
7	O
YBP	O
,	O
and	O
likely	O
included	O
an	O
extended	O
period	O
of	O
geneflow	O
(	O
Gautier	O
et	O
al	O
.	O

2016	O
).	O

Analysis	O
of	O
genomic	O
data	O
from	O
modern	O
wisent	O
has	O
suggested	O
,	O
in	O
addition	O
,	O
more	O
recent	O
admixture	O
between	O
wisent	O
and	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
(	O
Gautier	O
et	O
al	O
.	O

2016	O
).	O

However	O
,	O
the	O
timing	O
of	O
admixture	O
,	O
in	O
particular	O
whether	O
it	O
preceded	O
or	O
followed	O
the	O
establishment	O
of	O
the	O
captive	O
breeding	O
program	O
,	O
remains	O
uncertain	O
.	O

Such	O
information	O
is	O
critical	O
to	O
assess	O
the	O
magnitude	O
of	O
the	O
threat	O
that	O
domestic	O
cattle	B-OG
admixture	O
represents	O
to	O
the	O
long	O
term	O
viability	O
and	O
integrity	O
of	O
living	O
wisent	O
populations	O
.	O

Here	O
we	O
present	O
low	O
-	O
coverage	O
whole	O
genome	O
sequencing	O
data	O
from	O
modern	O
and	O
historical	O
wisent	O
,	O
including	O
representatives	O
from	O
both	O
modern	O
genetic	O
lines	O
,	O
from	O
the	O
original	O
founding	O
population	O
,	O
and	O
from	O
the	O
extinct	O
Caucasian	O
wisent	O
subspecies	O
.	O

Using	O
these	O
data	O
,	O
we	O
are	O
able	O
to	O
track	O
changes	O
in	O
genetic	O
variability	O
through	O
the	O
wisent	O
extinction	O
and	O
their	O
subsequent	O
restitution	O
.	O

Furthermore	O
,	O
by	O
inclusion	O
of	O
historical	O
individuals	O
,	O
we	O
not	O
only	O
detect	O
admixture	O
between	O
wisent	O
subspecies	O
and	O
between	O
wisent	O
and	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
,	O
but	O
also	O
place	O
these	O
events	O
along	O
an	O
absolute	O
timescale	O
of	O
pre	O
-	O
or	O
post	O
-	O
extinction	O
age	O
.	O

Our	O
results	O
demonstrate	O
the	O
huge	O
potential	O
of	O
genomic	O
approaches	O
,	O
in	O
particular	O
applied	O
to	O
historical	O
samples	O
,	O
for	O
studying	O
evolutionary	O
histories	O
and	O
also	O
for	O
the	O
conservation	O
management	O
of	O
endangered	O
species	O
.	O

Results	O

Sequencing	O
of	O
Wisent	O
Genomes	O

We	O
conducted	O
shotgun	O
sequencing	O
of	O
wisent	O
genomes	O
using	O
Illumina	O
technology	O
and	O
mapped	O
the	O
resulting	O
sequence	O
reads	O
to	O
the	O
reference	O
genome	O
assembly	O
of	O
the	O
Asian	O
water	B-OG
buffalo	I-OG
,	O
Bubalus	B-OG
bubalis	I-OG
(	O
GenBank	O
accession	O
no	O
.	O

GCA_000471725	O
.	O
1	O
),	O
which	O
represents	O
an	O
outgroup	O
to	O
the	O
wisent	O
/	O
Bos	B-OG
cattle	B-OG
lineage	O
(	O
supplementary	O
fig	O
.	O

S1	O
,	O
supplementary	O
material	O
online	O
;	O
Hassanin	O
et	O
al	O
.	O

2012	O
,	O
2013	O
).	O

Although	O
the	O
reference	O
genome	O
assembly	O
of	O
Bos	B-OG
taurus	I-OG
would	O
provide	O
a	O
more	O
complete	O
assembly	O
and	O
evolutionarily	O
less	O
-	O
diverged	O
reference	O
for	O
mapping	O
,	O
we	O
did	O
not	O
use	O
this	O
reference	O
at	O
it	O
may	O
have	O
led	O
to	O
biased	O
estimates	O
of	O
admixture	O
between	O
wisent	O
and	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
,	O
in	O
particular	O
at	O
lower	O
levels	O
of	O
genomic	O
coverage	O
.	O

In	O
total	O
,	O
we	O
sequenced	O
seven	O
individuals	O
that	O
we	O
divide	O
into	O
three	O
categories	O
.	O

Detailed	O
sample	O
information	O
,	O
including	O
provenance	O
,	O
is	O
provided	O
in	O
table	O
1	O
and	O
sample	O
localities	O
are	O
shown	O
in	O
fig	O
.	O
1	O
.	O
Table	O
1Basic	O
Information	O
about	O
Sampled	O
Individuals	O
.	O
Sample	O
CodeSample	O
NameTaxonGroupSample	O
LocationSample	O
OriginTissue	O
TypeYear	O
of	O
Death	O
*/	O
Radiocarbon	O
AgeWater	O
Buffalo	O
nDNA	O
Mapping	O
Coverage	O
/	O
mtDNA	O
CoverageMdL1Z3Bison	O
bonasusModern	O
Lowland	O
line	O
(	O
L	O
)	O
Białowieża	O
Forest	O
,	O
Polish	O
part	O
,	O
PolandKidney20061	O
.	O
59	O
(	O
n	O
)	O
MdL2868Białowieża	O
Forest	O
,	O
Belarusian	O
part	O
,	O
BelarusMuscles20091	O
.	O
63	O
(	O
n	O
)	O
MdLCDyModern	O
Lowland	O
-	O
Caucasian	O
line	O
(	O
LC	O
)	O
Dydiowa	O
,	O
Bieszczady	O
Mountains	O
,	O
PolandMuscles20121	O
.	O
49	O
(	O
n	O
)	O
PLANTAF42	O
PLANTABison	O
b	O
.	O
bonasusFoundersPszczyna	O
,	O
PolandUpper	O
Silesian	O
Museum	O
,	O
Bytom	O
,	O
PolandHorns19311	O
.	O
50	O
(	O
n	O
)	O
PLATENM158	O
PLATEN19331	O
.	O
39	O
(	O
n	O
)	O
Cc18853Bison	O
b	O
.	O
caucasicusCaucasian	O
wisentKuban	O
Oblast	O
,	O
RussiaZoological	O
Institute	O
RAS	O
,	O
Sankt	O
Petersburg	O
,	O
RussiaSkull	O
bones1911	O
*	O
1	O
.	O
07	O
(	O
n	O
)	O
Cc222533North	O
Ossetia	O
-	O
Alania	O
,	O
RussiaState	O
Darwin	O
Museum	O
,	O
Moscow	O
,	O
Russia1949	O
*	O
0	O
.	O
92	O
(	O
n	O
)	O
Cc3AF005Holocene	O
Caucasian	O
wisentSevan	O
Lake	O
region	O
,	O
ArmeniaHorn	O
core14C	O
:	O
4972	O
±	O
2958	O
.	O
10	O
(	O
mt	O
)	O
OxA	O
-	O
319355724	O
–	O
5657Bb1BS587Bison	O
b	O
.	O
bonasusHolocene	O
Lowland	O
wisentStyria	O
,	O
AustriaVMNH	O
H	O
-	O
1981	O
-	O
28	O
-	O
6Tibia14C	O
:	O
1480	O
±	O
70115	O
.	O
56	O
(	O
mt	O
)	O
VERA	O
01451511	O
–	O
1302Bb2BS589VMNH	O
H	O
-	O
1977	O
-	O
49	O
-	O
1Femur14C	O
:	O
1980	O
±	O
45165	O
.	O
75	O
(	O
mt	O
)	O
VERA	O
01421987	O
–	O
1886Bb3BS607Upper	O
Austria	O
,	O
AustriaVMNH	O
H	O
-	O
1979	O
-	O
48	O
-	O
1Femur14C	O
:	O
1370	O
±	O
5014	O
.	O
10	O
(	O
mt	O
)	O
VERA	O
01431338	O
-	O
1265Note	O
.—	O
The	O
last	O
column	O
is	O
the	O
average	O
coverage	O
for	O
each	O
sample	O
after	O
mapping	O
it	O
to	O
either	O
the	O
water	O
buffalo	O
(	O
Bubalus	O
bubalis	O
)	O
nuclear	O
reference	O
genome	O
(	O
GenBank	O
accession	O
no	O
.	O

GCA_000471725	O
.	O
1	O
)	O
or	O
the	O
American	B-OG
bison	I-OG
(	O
Bison	B-OG
bison	I-OG
)	O
mitochondrial	O
reference	O
genome	O
(	O
GenBank	O
accession	O
no	O
.	O

NC_012346	O
.	O
1	O
).*	O
For	O
Caucasian	O
individuals	O
(	O
Cc1	O
,	O
Cc2	O
)	O
year	O
of	O
collecting	O
the	O
sample	O
is	O
given	O
.	O

VNHM	O
,	O
Vienna	O
Museum	O
of	O
Natural	O
History	O
.	O
n	O
;	O
nuclear	O
,	O
mt	O
;	O
mitochondrial	O
.	O

Radiocarbon	O
dates	O
include	O
the	O
14C	O
age	O
(	O
years	O
before	O
present	O
;	O
yr	O
BP	O
),	O
14C	O
accession	O
(	O
where	O
known	O
),	O
and	O
calibrated	O
age	O
BP	O
(	O
1σ	O
).	O

Calibrated	O
dates	O
follow	O
the	O
IntCal13	O
calibration	O
curve	O
.	O

Modern	O
wisent	O
—	O
three	O
modern	O
individuals	O
representing	O
both	O
genetic	O
lines	O
.	O

These	O
comprise	O
two	O
individuals	O
from	O
the	O
L	O
line	O
(	O
MdL1	O
,	O
mean	O
read	O
depth	O
1	O
.	O
59	O
×;	O
and	O
MdL2	O
,	O
mean	O
read	O
depth	O
1	O
.	O
63	O
×;	O
from	O
the	O
Polish	O
and	O
Belarusian	O
parts	O
of	O
the	O
Białowieża	O
Forest	O
,	O
respectively	O
)	O
and	O
one	O
individual	O
from	O
the	O
LC	O
line	O
(	O
MdLC	O
,	O
from	O
Dydiowa	O
in	O
the	O
Bieszczady	O
Mountains	O
,	O
mean	O
read	O
depth	O
1	O
.	O
49	O
×).	O

Founding	O
wisent	O
—	O
two	O
individuals	O
assignable	O
to	O
the	O
Lowland	O
wisent	O
subspecies	O
B	O
.	B-OG
b	I-OG
.	I-OG
bonasus	I-OG
from	O
the	O
initial	O
breeding	O
population	O
originating	O
from	O
Pszczyna	O
,	O
both	O
of	O
which	O
contributed	O
to	O
the	O
establishment	O
of	O
both	O
the	O
L	O
and	O
the	O
LC	O
genetic	O
lines	O
:	O
foundress	O
F42	O
PLANTA	O
(	O
1904	O
–	O
1931	O
,	O
mean	O
read	O
depth	O
1	O
.	O
82	O
×)	O
and	O
her	O
male	O
offspring	O
,	O
M158	O
PLATEN	O
(	O
1926	O
–	O
1933	O
,	O
mean	O
read	O
depth	O
1	O
.	O
36	O
×),	O
who	O
was	O
fathered	O
by	O
another	O
founder	O
M45	O
PLEBEJER	O
(	O
1917	O
–	O
1937	O
).	O

Caucasian	O
wisent	O
—	O
two	O
individuals	O
from	O
the	O
early	O
1900	O
'	O
s	O
representing	O
the	O
now	O
extinct	O
Caucasian	O
wisent	O
subspecies	O
B	B-OG
.	I-OG
b	I-OG
.	I-OG
caucasicus	I-OG
(	O
Cc1	O
,	O
from	O
Kuban	O
Oblast	O
,	O
mean	O
read	O
depth	O
1	O
.	O
17	O
×;	O
and	O
Cc2	O
,	O
from	O
North	O
Ossetia	O
-	O
Alania	O
,	O
mean	O
read	O
depth	O
0	O
.	O
92	O
×).	O

For	O
each	O
individual	O
,	O
we	O
collapsed	O
mapped	O
reads	O
into	O
a	O
single	O
pseudo	O
-	O
haploid	O
genome	O
sequence	O
by	O
randomly	O
selecting	O
a	O
single	O
high	O
quality	O
nucleotide	B-CD
from	O
the	O
read	O
stack	O
at	O
each	O
position	O
of	O
the	O
reference	O
genome	O
,	O
following	O
the	O
procedure	O
described	O
by	O
Cahill	O
et	O
al	O
.	O
(	O
2013	O
,	O
2015	O
).	O

This	O
procedure	O
disregards	O
heterozygous	O
positions	O
,	O
where	O
only	O
one	O
allele	O
will	O
be	O
sampled	O
,	O
but	O
should	O
not	O
introduce	O
any	O
biases	O
in	O
allele	O
sampling	O
.	O

Ancient	O
DNA	O
fragments	O
frequently	O
contain	O
miscoding	O
lesions	O
resulting	O
from	O
postmortem	O
DNA	O
degradation	O
,	O
the	O
most	O
common	O
of	O
which	O
involves	O
the	O
deamination	O
of	O
cytosine	B-CD
to	O
uracil	B-CD
,	O
which	O
causes	O
C	O
to	O
T	O
substitutions	O
in	O
the	O
resulting	O
data	O
(	O
Dabney	O
,	O
Meyer	O
,	O
et	O
al	O
.	O

2013	O
).	O

This	O
pattern	O
is	O
present	O
at	O
varying	O
levels	O
in	O
sequence	O
data	O
from	O
our	O
historical	O
samples	O
(	O
supplementary	O
fig	O
.	O

S2	O
–	O
S5	O
,	O
Supplementary	O
Material	O
online	O
),	O
and	O
so	O
we	O
restricted	O
all	O
subsequent	O
analyses	O
to	O
transversion	O
sites	O
only	O
to	O
avoid	O
any	O
confounding	O
effects	O
of	O
DNA	O
damage	O
.	O

Genomic	O
Divergence	O

We	O
investigated	O
patterns	O
of	O
nuclear	O
genomic	O
divergence	O
among	O
wisent	O
by	O
conducting	O
pairwise	O
comparisons	O
of	O
the	O
number	O
of	O
transversion	O
differences	O
occurring	O
along	O
a	O
sliding	O
window	O
of	O
1	O
Mb	O
,	O
producing	O
a	O
distribution	O
of	O
genomic	O
divergence	O
for	O
each	O
wisent	O
pair	O
.	O

The	O
resulting	O
probability	O
densities	O
showed	O
that	O
nuclear	O
genomic	O
divergence	O
is	O
broadly	O
similar	O
among	O
all	O
modern	O
and	O
founding	O
wisent	O
(	O
fig	O
.	O
2A	O
).	O

The	O
two	O
founding	O
individuals	O
,	O
PLANTA	O
and	O
PLATEN	O
,	O
are	O
somewhat	O
less	O
diverged	O
from	O
one	O
another	O
than	O
either	O
is	O
from	O
all	O
modern	O
wisent	O
(	O
fig	O
.	O
2A	O
),	O
reflecting	O
their	O
mother	O
-	O
son	O
relationship	O
.	O

Slightly	O
increased	O
divergence	O
is	O
observed	O
between	O
the	O
modern	O
LC	O
line	O
individual	O
(	O
MdLC	O
)	O
and	O
all	O
modern	O
and	O
founding	O
wisent	O
(	O
fig	O
.	O
2A	O
),	O
which	O
may	O
reflect	O
the	O
increased	O
component	O
of	O
Caucasian	O
wisent	O
ancestry	O
in	O
this	O
individual	O
resulting	O
from	O
the	O
captive	O
breeding	O
program	O
.	O
Fig	O
.	O
2Pairwise	O
genomic	O
divergence	O
among	O
wisent	O
.	O

A	O
,	O
B	O
,	O
C	O
,	O
show	O
probability	O
densities	O
for	O
pairwise	O
transversion	O
divergence	O
(	O
x	O
axes	O
)	O
along	O
a	O
sliding	O
window	O
of	O
1	O
Mb	O
.	O

Individual	O
plots	O
show	O
all	O
pairwise	O
comparisons	O
among	O
modern	O
and	O
founding	O
individuals	O
(	O
A	O
);	O
comparisons	O
of	O
modern	O
and	O
founding	O
individuals	O
and	O
Caucasian	O
wisent	O
Cc1	O
(	O
B	O
);	O
and	O
comparisons	O
of	O
Caucasian	O
wisent	O
Cc2	O
and	O
all	O
other	O
individuals	O
(	O
C	O
).	O

Specific	O
comparisons	O
discussed	O
in	O
the	O
text	O
are	O
identified	O
by	O
colors	O
,	O
according	O
to	O
the	O
key	O
at	O
the	O
top	O
right	O
of	O
each	O
plot	O
.	O

Schematic	O
neighbor	O
-	O
joining	O
phylogeny	O
based	O
on	O
whole	O
genome	O
distances	O
(	O
D	O
).	O

Genomic	O
divergence	O
between	O
Caucasian	O
and	O
both	O
modern	O
and	O
founding	O
wisent	O
greatly	O
exceeds	O
that	O
occurring	O
between	O
the	O
latter	O
two	O
groups	O
(	O
fig	O
.	O
2A	O
–	O
C	O
).	O

Substantial	O
divergence	O
is	O
also	O
found	O
between	O
the	O
two	O
Caucasian	O
wisent	O
individuals	O
.	O

One	O
of	O
these	O
Caucasian	O
wisent	O
(	O
Cc1	O
)	O
was	O
found	O
to	O
be	O
less	O
diverged	O
from	O
modern	O
and	O
founding	O
wisent	O
than	O
other	O
Caucasian	O
wisent	O
individual	O
(	O
Cc2	O
),	O
suggesting	O
the	O
presence	O
of	O
not	O
only	O
substantial	O
genetic	O
diversity	O
but	O
also	O
substantial	O
population	O
structure	O
in	O
the	O
extinct	O
Caucasian	O
wisent	O
subspecies	O
.	O

We	O
also	O
investigated	O
mitochondrial	O
genome	O
variability	O
among	O
all	O
individuals	O
subjected	O
to	O
nuclear	O
genome	O
sequencing	O
,	O
in	O
addition	O
to	O
seven	O
other	O
modern	O
wisent	O
(	O
supplementary	O
table	O
S1	O
,	O
Supplementary	O
Material	O
online	O
).	O

Sequence	O
analysis	O
revealed	O
that	O
all	O
investigated	O
modern	O
wisent	O
,	O
both	O
founding	O
wisent	O
,	O
and	O
a	O
single	O
historical	O
Caucasian	O
wisent	O
(	O
Cc1	O
),	O
share	O
a	O
single	O
haplotype	O
.	O

The	O
haplotype	O
occurring	O
in	O
the	O
second	O
historical	O
Caucasian	O
wisent	O
(	O
Cc2	O
)	O
differed	O
from	O
this	O
widely	O
shared	O
haplotype	O
by	O
a	O
single	O
transition	O
site	O
.	O

These	O
results	O
hint	O
at	O
a	O
major	O
loss	O
of	O
mitochondrial	O
haplotype	O
diversity	O
prior	O
to	O
the	O
extinction	O
of	O
wisent	O
in	O
the	O
wild	O
.	O

This	O
inference	O
is	O
supported	O
by	O
additional	O
haplotypes	O
that	O
we	O
recovered	O
from	O
three	O
ancient	O
late	O
Holocene	O
Lowland	O
wisent	O
from	O
Austria	O
(	O
the	O
range	O
of	O
calibrated	O
age	O
is	O
from	O
ca	O
.	O

1	O
.	O
3	O
kyr	O
to	O
1	O
.	O
9	O
kyr	O
)	O
and	O
one	O
ancient	O
middle	O
Holocene	O
Caucasian	O
wisent	O
from	O
Armenia	O
(	O
ca	O
.	O

5	O
.	O
7	O
kyr	O
).	O

All	O
these	O
ancient	O
haplotypes	O
are	O
substantially	O
divergent	O
from	O
those	O
found	O
in	O
modern	O
and	O
historical	O
wisent	O
,	O
suggesting	O
a	O
substantial	O
loss	O
of	O
haplotype	O
diversity	O
,	O
potentially	O
within	O
the	O
last	O
∼	O
1	O
,	O
300	O
years	O
.	O

Neighbor	O
-	O
joining	O
phylogenetic	O
analysis	O
of	O
total	O
nuclear	O
genomic	O
divergence	O
supports	O
paraphyly	O
of	O
Caucasian	O
wisent	O
(	O
fig	O
.	O
2D	O
),	O
as	O
does	O
analysis	O
of	O
mitochondrial	O
haplotypes	O
(	O
supplementary	O
fig	O
.	O

S1	O
,	O
Supplementary	O
Material	O
online	O
).	O

We	O
further	O
investigated	O
the	O
population	O
history	O
of	O
wisent	O
by	O
dividing	O
aligned	O
nuclear	O
genome	O
sequences	O
into	O
non	O
-	O
overlapping	O
1	O
Mb	O
blocks	O
and	O
subjecting	O
each	O
block	O
to	O
maximum	O
-	O
likelihood	O
phylogenetic	O
analysis	O
.	O

For	O
this	O
analysis	O
,	O
we	O
included	O
both	O
Caucasian	O
wisent	O
and	O
both	O
modern	O
L	O
line	O
wisent	O
as	O
representatives	O
of	O
the	O
Lowland	O
wisent	O
subspecies	O
,	O
with	O
water	B-OG
buffalo	I-OG
as	O
outgroup	O
.	O

Founding	O
wisent	O
and	O
the	O
modern	O
LC	O
line	O
wisent	O
were	O
not	O
included	O
to	O
avoid	O
any	O
confounding	O
effects	O
of	O
direct	O
ancestor	O
-	O
descendent	O
relationships	O
and	O
documented	O
Caucasian	O
wisent	O
introgression	O
(	O
Slatis	O
1960	O
)	O
on	O
phylogenetic	O
interpretation	O
,	O
respectively	O
.	O

We	O
found	O
that	O
57	O
%	O
of	O
the	O
investigated	O
genomic	O
blocks	O
support	O
reciprocal	O
monophyly	O
of	O
Caucasian	O
and	O
Lowland	O
wisent	O
(	O
fig	O
.	O
3	O
).	O

We	O
therefore	O
conclude	O
that	O
this	O
most	O
likely	O
represents	O
the	O
true	O
population	O
history	O
.	O

All	O
alternative	O
topologies	O
occur	O
,	O
individually	O
,	O
at	O
a	O
much	O
lower	O
frequency	O
.	O

Nevertheless	O
,	O
almost	O
half	O
of	O
the	O
genome	O
sequence	O
alignment	O
of	O
these	O
individuals	O
contradicts	O
the	O
true	O
population	O
history	O
.	O
Fig	O
.	O
3Population	O
history	O
of	O
Lowland	O
and	O
Caucasian	O
wisent	O
,	O
estimated	O
using	O
two	O
representatives	O
of	O
each	O
.	O

The	O
pie	O
chart	O
shows	O
the	O
percentage	O
of	O
1	O
Mb	O
genomic	O
blocks	O
supporting	O
each	O
alternatively	O
rooted	O
tree	O
topology	O
.	O

This	O
indicates	O
fraction	O
of	O
genome	O
blocks	O
returning	O
both	O
wisent	O
subspecies	O
as	O
reciprocally	O
monophyletic	O
.	O

Dark	O
and	O
light	O
blue	O
colors	O
show	O
the	O
next	O
most	O
frequently	O
encountered	O
topologies	O
in	O
which	O
Caucasian	O
wisent	O
are	O
paraphyletic	O
(	O
dark	O
blue	O
:	O
Cc2	O
most	O
divergent	O
,	O
and	O
light	O
blue	O
:	O
Cc1	O
most	O
divergent	O
,	O
the	O
first	O
of	O
which	O
is	O
compatible	O
with	O
estimates	O
pairwise	O
genomic	O
divergence	O
;	O
see	O
fig	O
2D	O
).	O

In	O
order	O
to	O
interpret	O
wisent	O
genomic	O
divergence	O
in	O
the	O
context	O
of	O
total	O
species	O
genetic	O
diversity	O
,	O
we	O
obtained	O
data	O
from	O
the	O
NCBI	O
Short	O
Read	O
Archive	O
for	O
seven	O
domestic	O
cattle	B-OG
and	O
seven	O
yak	B-OG
(	O
Bos	B-OG
grunniens	I-OG
;	O
supplementary	O
table	O
S4	O
,	O
Supplementary	O
Material	O
online	O
)	O
and	O
subjected	O
them	O
to	O
the	O
same	O
analysis	O
pipeline	O
.	O

Genomic	O
divergence	O
among	O
modern	O
wisent	O
was	O
found	O
to	O
be	O
similar	O
to	O
that	O
found	O
among	O
domestic	O
cattle	B-OG
,	O
and	O
exceeded	O
that	O
found	O
among	O
yak	B-OG
(	O
fig	O
.	O
4	O
).	O

We	O
conducted	O
equivalent	O
comparisons	O
for	O
modern	O
wisent	O
and	O
these	O
other	O
bovid	B-OG
species	O
but	O
with	O
the	O
inclusion	O
of	O
transition	O
as	O
well	O
as	O
transversion	O
sites	O
.	O

Interestingly	O
,	O
the	O
distribution	O
of	O
genomic	O
divergence	O
for	O
pairs	O
of	O
wisent	O
was	O
bimodal	O
in	O
all	O
cases	O
(	O
fig	O
.	O
4	O
),	O
but	O
the	O
relative	O
levels	O
of	O
genomic	O
divergence	O
between	O
species	O
were	O
similar	O
to	O
that	O
measured	O
using	O
only	O
transversion	O
sites	O
.	O
Fig	O
.	O
4Comparison	O
of	O
pairwise	O
genomic	O
divergence	O
within	O
three	O
bovid	B-OG
species	O
:	O
wisent	O
(	O
Bison	B-OG
bonasus	I-OG
),	O
domestic	O
cattle	B-OG
(	O
Bos	B-OG
taurus	I-OG
),	O
and	O
yak	B-OG
(	O
Bos	B-OG
grunniens	I-OG
).	O

Probability	O
densities	O
were	O
calculated	O
along	O
a	O
sliding	O
window	O
of	O
1	O
Mb	O
from	O
transversions	O
only	O
(	O
A	O
),	O
and	O
from	O
transitions	O
and	O
transversions	O
(	O
B	O
).	O

For	O
wisent	O
,	O
only	O
modern	O
samples	O
included	O
.	O

Wisent	O
Geneflow	O
and	O
Admixture	O

We	O
investigated	O
patterns	O
of	O
admixture	O
among	O
wisent	O
using	O
the	O
D	O
statistic	O
test	O
for	O
admixture	O
(	O
Green	O
et	O
al	O
.	O

2010	O
).	O

This	O
test	O
identifies	O
any	O
imbalance	O
in	O
the	O
number	O
of	O
derived	O
alleles	O
that	O
either	O
of	O
two	O
closely	O
related	O
individuals	O
share	O
with	O
a	O
candidate	O
introgressor	O
.	O

A	O
significant	O
excess	O
of	O
derived	O
alleles	O
shared	O
between	O
one	O
individual	O
and	O
the	O
introgressor	O
provides	O
evidence	O
of	O
admixture	O
between	O
them	O
(	O
Durand	O
et	O
al	O
.	O

2011	O
).	O

For	O
all	O
D	O
statistic	O
tests	O
,	O
we	O
used	O
water	B-OG
buffalo	I-OG
(	O
Bubalus	B-OG
bubalis	I-OG
)	O
as	O
outgroup	O
for	O
allele	O
polarization	O
.	O

We	O
first	O
investigated	O
patterns	O
of	O
derived	O
allele	O
sharing	O
among	O
modern	O
wisent	O
,	O
and	O
found	O
no	O
statistically	O
significant	O
signal	O
of	O
admixture	O
between	O
the	O
modern	O
LC	O
line	O
individual	O
and	O
either	O
modern	O
L	O
line	O
individual	O
(	O
supplementary	O
table	O
S5	O
,	O
Supplementary	O
Material	O
online	O
).	O

Between	O
modern	O
and	O
founding	O
wisent	O
,	O
we	O
found	O
that	O
modern	O
L	O
line	O
wisent	O
share	O
a	O
significantly	O
greater	O
number	O
of	O
derived	O
alleles	O
with	O
founding	O
wisent	O
than	O
the	O
modern	O
LC	O
line	O
individual	O
does	O
(	O
fig	O
.	O
5A	O
),	O
indicating	O
a	O
greater	O
contribution	O
of	O
the	O
two	O
founding	O
wisent	O
investigated	O
here	O
to	O
the	O
L	O
line	O
,	O
relative	O
to	O
the	O
LC	O
line	O
,	O
which	O
is	O
consistent	O
with	O
pedigrees	O
(	O
Slatis	O
1960	O
).	O
Fig	O
.	O
5Results	O
of	O
D	O
statistical	O
analysis	O
.	O

Red	O
and	O
grey	O
points	O
show	O
significant	O
and	O
nonsignificant	O
D	O
values	O
(	O
x	O
axis	O
),	O
respectively	O
,	O
and	O
show	O
:	O
the	O
genetic	O
contribution	O
of	O
the	O
founders	O
(	O
F	O
)	O
to	O
the	O
modern	O
individuals	O
(	O
A	O
);	O
Caucasian	O
wisent	O
(	O
Cc	O
)	O
admixture	O
with	O
modern	O
L	O
and	O
LC	O
herds	O
(	O
MdL	O
and	O
MdLC	O
)	O
and	O
one	O
founder	O
,	O
PLANTA	O
,	O
relative	O
to	O
the	O
least	O
Caucasian	O
admixed	O
wisent	O
,	O
founder	O
PLATEN	O
(	O
B	O
);	O
Caucasian	O
wisent	O
admixture	O
among	O
modern	O
wisent	O
(	O
C	O
);	O
apparent	O
cattle	B-OG
(	O
DC	O
)	O
admixture	O
with	O
all	O
investigated	O
wisent	O
(	O
W	O
)	O
relative	O
to	O
aurochs	O
(	O
Aur	O
)	O
(	O
D	O
);	O
variance	O
in	O
cattle	B-OG
/	O
aurochs	O
admixture	O
among	O
wisent	O
(	O
W	O
)	O
compared	O
to	O
PLATEN	O
(	O
E	O
).	O

Detailed	O
D	O
statistic	O
results	O
are	O
provided	O
in	O
supplementary	O
table	O
S5	O
,	O
Supplementary	O
Material	O
online	O
.	O

We	O
then	O
investigated	O
admixture	O
involving	O
Caucasian	O
wisent	O
.	O

We	O
found	O
a	O
significant	O
excess	O
of	O
derived	O
allele	O
sharing	O
between	O
one	O
founding	O
wisent	O
,	O
PLANTA	O
,	O
and	O
one	O
Caucasian	O
wisent	O
,	O
Cc2	B-GP
,	O
relative	O
to	O
the	O
other	O
founding	O
wisent	O
,	O
her	O
son	O
PLATEN	O
(	O
fig	O
.	O
5B	O
).	O

This	O
indicates	O
that	O
a	O
proportion	O
of	O
the	O
genome	O
of	O
PLANTA	O
can	O
be	O
attributed	O
to	O
admixture	O
with	O
Caucasian	O
wisent	O
.	O

Furthermore	O
,	O
we	O
can	O
deduce	O
that	O
PLEBEJER	O
,	O
the	O
father	O
of	O
PLATEN	O
,	O
must	O
have	O
possessed	O
a	O
lower	O
level	O
of	O
Caucasian	O
wisent	O
admixture	O
than	O
PLANTA	O
,	O
and	O
that	O
PLATEN	O
himself	O
was	O
likely	O
admixed	O
to	O
some	O
degree	O
through	O
inheritance	O
from	O
PLANTA	O
.	O

The	O
detection	O
of	O
admixture	O
involving	O
one	O
Caucasian	O
wisent	O
(	O
Cc2	O
)	O
but	O
not	O
the	O
other	O
(	O
Cc1	O
)	O
further	O
supports	O
the	O
existence	O
of	O
genetic	O
structure	O
in	O
Caucasian	O
wisent	O
inferred	O
from	O
estimates	O
of	O
genomic	O
divergence	O
(	O
fig	O
.	O
2B	O
and	O
C	O
).	O

Next	O
,	O
we	O
investigated	O
evidence	O
of	O
Caucasian	O
wisent	O
admixture	O
among	O
modern	O
wisent	O
.	O

Consistent	O
with	O
expectations	O
,	O
we	O
found	O
that	O
the	O
modern	O
LC	O
line	O
individual	O
(	O
MdLC	O
)	O
shares	O
an	O
excess	O
of	O
derived	O
alleles	O
with	O
one	O
of	O
the	O
Caucasian	O
wisent	O
(	O
Cc1	O
)	O
relative	O
to	O
modern	O
L	O
line	O
individuals	O
(	O
fig	O
.	O
5C	O
).	O

We	O
did	O
not	O
,	O
however	O
,	O
detect	O
such	O
an	O
excess	O
between	O
the	O
modern	O
LC	O
line	O
individual	O
and	O
the	O
second	O
Caucasian	O
wisent	O
(	O
Cc2	O
),	O
relative	O
to	O
the	O
modern	O
L	O
line	O
individuals	O
.	O

We	O
can	O
therefore	O
infer	O
that	O
the	O
last	O
surviving	O
Caucasian	O
wisent	O
,	O
KAUKASUS	O
,	O
whose	O
living	O
descendants	O
comprise	O
the	O
modern	O
LC	O
line	O
,	O
was	O
more	O
closely	O
related	O
to	O
Caucasian	O
wisent	O
individual	O
Cc1	B-GP
that	O
to	O
individual	O
Cc2	B-GP
.	O

We	O
further	O
investigated	O
Caucasian	O
ancestry	O
in	O
the	O
genome	O
of	O
the	O
modern	O
LC	O
line	O
individual	O
by	O
performing	O
phylogenetic	O
analysis	O
of	O
non	O
-	O
overlapping	O
1	O
Mb	O
genomic	O
blocks	O
.	O

The	O
fragmented	O
water	B-OG
buffalo	I-OG
reference	O
genome	O
assembly	O
precludes	O
examination	O
of	O
the	O
variance	O
in	O
ancestry	O
along	O
entire	O
chromosomes	O
.	O

To	O
achieve	O
this	O
,	O
we	O
instead	O
mapped	O
reads	O
to	O
the	O
reference	O
genome	O
of	O
the	O
domesticated	O
zebu	B-OG
cattle	B-OG
,	O
Bos	B-OG
indicus	I-OG
,	O
which	O
was	O
itself	O
generated	O
by	O
mapping	O
short	O
read	O
data	O
to	O
the	O
chromosome	O
-	O
level	O
assembly	O
of	O
B	B-OG
.	I-OG
taurus	I-OG
(	O
Canavez	O
et	O
al	O
.	O

2012	O
).	O

Any	O
potential	O
biases	O
introduced	O
by	O
using	O
a	O
cattle	B-OG
reference	O
are	O
mitigated	O
by	O
selecting	O
this	O
cattle	B-OG
breed	O
originating	O
from	O
a	O
domestication	O
center	O
on	O
the	O
Indian	O
subcontinent	O
(	O
Loftus	O
et	O
al	O
.	O

1994	O
),	O
which	O
is	O
geographically	O
distant	O
from	O
the	O
historical	O
distribution	O
of	O
wisent	O
.	O

Analysis	O
of	O
aligned	O
1	O
Mb	O
genomic	O
blocks	O
involved	O
the	O
modern	O
LC	O
line	O
wisent	O
(	O
MdLC	O
),	O
the	O
founding	O
wisent	O
(	O
PLATEN	O
)	O
that	O
was	O
found	O
to	O
be	O
least	O
admixed	O
with	O
Caucasian	O
wisent	O
,	O
Caucasian	O
wisent	O
(	O
Cc1	O
)	O
and	O
domestic	O
cattle	B-OG
,	O
with	O
water	B-OG
buffalo	I-OG
as	O
outgroup	O
.	O

Of	O
the	O
investigated	O
genomic	O
blocks	O
,	O
we	O
find	O
that	O
22	O
%	O
return	O
the	O
modern	O
LC	O
line	O
and	O
Caucasian	O
wisent	O
as	O
monophyletic	O
(	O
fig	O
.	O
6	O
),	O
and	O
may	O
therefore	O
represent	O
introgressed	O
segments	O
of	O
Caucasian	O
wisent	O
ancestry	O
in	O
this	O
modern	O
LC	O
line	O
individual	O
.	O

Around	O
8	O
%	O
of	O
these	O
blocks	O
are	O
likely	O
to	O
result	O
from	O
incomplete	O
lineage	O
sorting	O
,	O
based	O
on	O
the	O
frequency	O
of	O
occurrence	O
of	O
the	O
opposing	O
topology	O
(	O
fig	O
.	O
6	O
),	O
producing	O
an	O
overall	O
estimate	O
of	O
14	O
%	O
of	O
the	O
genome	O
of	O
the	O
modern	O
LC	O
individual	O
that	O
results	O
from	O
Caucasian	O
wisent	O
admixture	O
,	O
most	O
likely	O
inherited	O
from	O
the	O
bull	B-OG
KAUKASUS	O
.	O

In	O
addition	O
to	O
providing	O
an	O
estimate	O
of	O
admixture	O
proportions	O
,	O
our	O
method	O
is	O
also	O
able	O
to	O
accurately	O
map	O
admixed	O
segments	O
of	O
the	O
genome	O
(	O
fig	O
.	O
6A	O
).	O

Many	O
of	O
these	O
segments	O
span	O
multiple	O
megabase	O
blocks	O
.	O

For	O
example	O
,	O
a	O
contiguous	O
22	O
Mb	O
admixed	O
block	O
is	O
observed	O
on	O
chromosome	O
4	O
,	O
which	O
may	O
span	O
as	O
much	O
as	O
33	O
Mb	O
under	O
the	O
assumption	O
that	O
intervening	O
blocks	O
with	O
missing	O
data	O
are	O
linked	O
to	O
adjacent	O
ones	O
.	O

Relative	O
admixture	O
proportions	O
also	O
vary	O
among	O
chromosomes	O
in	O
this	O
individual	O
.	O

For	O
example	O
,	O
chromosome	O
27	O
almost	O
entirely	O
lacks	O
Caucasian	O
wisent	O
ancestry	O
whereas	O
around	O
50	O
%	O
of	O
chromosomes	O
4	O
and	O
15	O
are	O
likely	O
derived	O
from	O
admixture	O
.	O
Fig	O
.	O
6Genomic	O
admixture	O
map	O
(	O
A	O
)	O
of	O
Caucasian	O
wisent	O
ancestry	O
in	O
the	O
modern	O
LC	O
line	O
individual	O
(	O
MdLC	O
).	O

Colored	O
blocks	O
indicate	O
1	O
Mb	O
genomic	O
blocks	O
returning	O
alternative	O
tree	O
topologies	O
,	O
blue	O
blocks	O
are	O
compatible	O
with	O
the	O
species	O
tree	O
;	O
yellow	O
blocks	O
return	O
the	O
monophly	O
of	O
the	O
modern	O
LC	O
line	O
and	O
Caucasian	O
wisent	O
,	O
and	O
likely	O
result	O
from	O
admixture	O
and	O
to	O
a	O
lesser	O
extent	O
incomplete	O
lineage	O
sorting	O
;	O
red	O
blocks	O
return	O
the	O
monophyly	O
of	O
PLATEN	O
and	O
Caucasian	O
wisent	O
and	O
likely	O
result	O
from	O
incomplete	O
lineage	O
sorting	O
.	O
“	O
X	O
”	O
shows	O
blocks	O
with	O
missing	O
data	O
.	O

The	O
pie	O
chart	O
(	O
B	O
)	O
shows	O
the	O
percentage	O
of	O
1	O
Mb	O
genomic	O
supporting	O
each	O
tree	O
topology	O
identified	O
by	O
colors	O
,	O
according	O
to	O
the	O
key	O
presented	O
above	O
.	O

Finally	O
,	O
we	O
investigated	O
evidence	O
of	O
Caucasian	O
wisent	O
ancestry	O
in	O
the	O
modern	O
L	O
line	O
.	O

We	O
found	O
that	O
both	O
modern	O
L	O
line	O
wisent	O
share	O
a	O
significant	O
excess	O
of	O
derived	O
alleles	O
with	O
Caucasian	O
wisent	O
(	O
fig	O
.	O
5B	O
),	O
relative	O
to	O
founding	O
wisent	O
.	O

Thus	O
,	O
modern	O
L	O
line	O
individuals	O
appear	O
more	O
admixed	O
with	O
Caucasian	O
wisent	O
than	O
the	O
two	O
founding	O
wisent	O
investigated	O
here	O
.	O

This	O
admixture	O
signal	O
could	O
result	O
from	O
either	O
variable	O
admixture	O
proportions	O
among	O
founding	O
individuals	O
,	O
or	O
recent	O
geneflow	O
between	O
the	O
L	O
and	O
LC	O
lines	O
,	O
although	O
D	O
statistic	O
comparison	O
of	O
modern	O
individuals	O
failed	O
to	O
detect	O
the	O
latter	O
(	O
see	O
above	O
).	O

We	O
further	O
investigated	O
these	O
alternative	O
hypotheses	O
by	O
comparing	O
the	O
sizes	O
of	O
putatively	O
admixed	O
genomic	O
blocks	O
.	O

Recent	O
geneflow	O
results	O
in	O
large	O
contiguous	O
genomic	O
blocks	O
derived	O
from	O
admixture	O
in	O
the	O
genomes	O
of	O
the	O
recipient	O
population	O
,	O
which	O
are	O
broken	O
up	O
over	O
time	O
as	O
a	O
result	O
of	O
recombination	O
.	O

Pedigree	O
information	O
provides	O
an	O
approximate	O
date	O
for	O
geneflow	O
from	O
Caucasian	O
wisent	O
into	O
the	O
modern	O
LC	O
line	O
around	O
90	O
years	O
ago	O
(	O
15	O
–	O
22	O
generations	O
),	O
the	O
result	O
of	O
which	O
are	O
many	O
intact	O
multi	O
-	O
megabase	O
genomic	O
blocks	O
derived	O
from	O
Caucasian	O
wisent	O
in	O
the	O
modern	O
LC	O
line	O
individual	O
(	O
fig	O
.	O
6	O
).	O

We	O
compared	O
the	O
sizes	O
of	O
these	O
blocks	O
with	O
those	O
of	O
putative	O
Caucasian	O
wisent	O
ancestry	O
in	O
a	O
modern	O
L	O
line	O
individual	O
,	O
and	O
found	O
the	O
abundance	O
of	O
large	O
blocks	O
to	O
be	O
considerably	O
lower	O
in	O
the	O
latter	O
(	O
fig	O
.	O
7	O
).	O

This	O
rejects	O
recent	O
admixture	O
and	O
instead	O
supports	O
variable	O
admixture	O
proportions	O
among	O
the	O
founding	O
herd	O
in	O
explaining	O
the	O
observed	O
signal	O
of	O
Caucasian	O
wisent	O
admixture	O
in	O
this	O
modern	O
L	O
line	O
individual	O
.	O
Fig	O
.	O
7Variation	O
in	O
the	O
sizes	O
of	O
genomic	O
blocks	O
in	O
modern	O
L	O
(	O
blue	O
)	O
and	O
LC	O
(	O
red	O
)	O
likely	O
resulting	O
from	O
Caucasian	O
wisent	O
admixture	O
.	O

Plots	O
show	O
cumulative	O
probability	O
densities	O
calculated	O
at	O
a	O
scale	O
of	O
1	O
Mb	O
.	O

Genomic	O
blocks	O
in	O
the	O
LC	O
line	O
wisent	O
(	O
red	O
)	O
result	O
from	O
admixture	O
occurring	O
around	O
90	O
years	O
ago	O
;	O
the	O
lower	O
abundance	O
of	O
larger	O
admixed	O
blocks	O
in	O
the	O
modern	O
L	O
line	O
wisent	O
support	O
that	O
this	O
admixture	O
event	O
preceded	O
the	O
former	O
.	O

The	O
plots	O
have	O
been	O
truncated	O
to	O
aid	O
visualization	O
,	O
and	O
single	O
blocks	O
of	O
18	O
and	O
22	O
Mb	O
in	O
the	O
LC	O
line	O
individual	O
are	O
not	O
shown	O
.	O

The	O
largest	O
block	O
size	O
detected	O
in	O
the	O
modern	O
L	O
line	O
individual	O
was	O
8	O
Mb	O
.	O

Admixture	O
with	O
the	O
Bos	B-OG
Cattle	I-OG
Lineage	O

We	O
investigated	O
potential	O
admixture	O
between	O
wisent	O
and	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
using	O
pseudo	O
-	O
haploid	O
sequences	O
generated	O
from	O
short	O
read	O
data	O
of	O
two	O
domestic	O
Holstein	B-OG
cows	I-OG
and	O
an	O
ancient	O
aurochs	O
(	O
Bos	B-OG
primigenius	I-OG
;	O
Park	O
et	O
al	O
.	O

2015	O
),	O
the	O
extinct	O
species	O
from	O
which	O
cattle	B-OG
were	O
domesticated	O
and	O
that	O
lived	O
sympatrically	O
with	O
wisent	O
up	O
until	O
its	O
extinction	O
around	O
400	O
years	O
ago	O
(	O
van	O
Vuure	O
2005	O
).	O

First	O
,	O
we	O
looked	O
for	O
significant	O
differences	O
in	O
derived	O
allele	O
sharing	O
between	O
cattle	B-OG
and	O
wisent	O
,	O
relative	O
to	O
the	O
aurochs	O
.	O

We	O
found	O
that	O
all	O
investigated	O
wisent	O
share	O
a	O
significant	O
excess	O
of	O
derived	O
alleles	O
with	O
cattle	B-OG
relative	O
to	O
aurochs	B-OG
(	O
fig	O
.	O
5D	O
).	O

This	O
suggests	O
either	O
admixture	O
between	O
wisent	O
and	O
domestic	O
cattle	B-OG
,	O
or	O
alternatively	O
,	O
admixture	O
with	O
aurochs	O
,	O
if	O
aurochs	O
populations	O
were	O
highly	O
structured	O
and	O
the	O
admixing	O
individuals	O
were	O
from	O
a	O
population	O
more	O
closely	O
related	O
to	O
domestic	O
cattle	B-OG
than	O
the	O
British	O
aurochs	O
used	O
in	O
this	O
analysis	O
.	O

We	O
also	O
compared	O
derived	O
allele	O
sharing	O
with	O
cattle	B-OG
among	O
the	O
individual	O
wisent	O
.	O

We	O
found	O
that	O
all	O
modern	O
wisent	O
investigated	O
here	O
share	O
a	O
significant	O
excess	O
of	O
derived	O
alleles	O
with	O
cattle	B-OG
relative	O
to	O
any	O
founding	O
or	O
Caucasian	O
wisent	O
(	O
fig	O
.	O
5E	O
).	O

Variable	O
admixture	O
was	O
also	O
observed	O
among	O
founding	O
wisent	O
.	O

Specifically	O
,	O
PLANTA	O
shares	O
more	O
derived	O
alleles	O
with	O
domestic	O
cattle	B-OG
than	O
either	O
Caucasian	O
wisent	O
or	O
PLATEN	O
do	O
.	O

Since	O
D	O
statistic	O
is	O
a	O
relative	O
test	O
,	O
and	O
PLATEN	O
is	O
the	O
offspring	O
of	O
admixed	O
founder	O
PLANTA	O
,	O
it	O
is	O
reasonable	O
to	O
infer	O
that	O
PLATEN	O
is	O
also	O
admixed	O
to	O
some	O
extent	O
,	O
however	O
.	O

Finally	O
,	O
using	O
the	O
f	O
^	O
statistic	O
(	O
Durand	O
et	O
al	O
.	O

2011	O
),	O
we	O
estimated	O
a	O
fraction	O
of	O
2	O
.	O
4	O
–	O
3	O
.	O
2	O
%	O
of	O
the	O
genomes	O
of	O
the	O
modern	O
wisent	O
that	O
could	O
be	O
attributed	O
to	O
admixture	O
with	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
,	O
above	O
that	O
occurring	O
in	O
the	O
founding	O
wisent	O
(	O
supplementary	O
table	O
S6	O
,	O
Supplementary	O
Material	O
online	O
).	O

This	O
increased	O
admixture	O
signal	O
observed	O
in	O
all	O
modern	O
wisent	O
relative	O
to	O
founding	O
wisent	O
could	O
result	O
from	O
either	O
variable	O
admixture	O
proportions	O
among	O
the	O
founding	O
herd	O
from	O
which	O
all	O
modern	O
wisent	O
are	O
derived	O
,	O
or	O
alternatively	O
,	O
from	O
recent	O
admixture	O
with	O
modern	O
cattle	B-OG
.	O

However	O
,	O
the	O
fact	O
that	O
we	O
do	O
not	O
find	O
evidence	O
of	O
any	O
complete	O
genomic	O
1	O
Mb	O
blocks	O
resulting	O
from	O
cattle	B-OG
admixture	O
in	O
the	O
modern	O
LC	O
line	O
individual	O
(	O
fig	O
.	O
6A	O
)	O
argues	O
strongly	O
against	O
recent	O
cattle	B-OG
admixture	O
,	O
and	O
instead	O
supports	O
variable	O
admixture	O
among	O
the	O
founding	O
herd	O
in	O
explaining	O
the	O
excess	O
of	O
derived	O
alleles	O
shared	O
among	O
domestic	O
cattle	B-OG
and	O
modern	O
wisent	O
.	O

Discussion	O

Retracing	O
complex	O
population	O
histories	O
can	O
be	O
challenging	O
.	O

In	O
particular	O
,	O
admixture	O
involving	O
populations	O
or	O
species	O
that	O
are	O
now	O
extinct	O
may	O
be	O
impossible	O
based	O
solely	O
on	O
data	O
from	O
living	O
individuals	O
(	O
Hofreiter	O
et	O
al	O
.	O

2015	O
).	O

Through	O
the	O
use	O
of	O
low	O
-	O
coverage	O
genomic	O
data	O
from	O
modern	O
and	O
historical	O
wisent	O
,	O
including	O
from	O
the	O
now	O
extinct	O
Caucasian	O
wisent	O
subspecies	O
,	O
we	O
have	O
revealed	O
the	O
complexity	O
of	O
wisent	O
evolution	O
.	O

This	O
complex	O
history	O
involved	O
not	O
only	O
admixture	O
resulting	O
directly	O
from	O
the	O
captive	O
breeding	O
program	O
,	O
but	O
also	O
older	O
processes	O
occurring	O
prior	O
to	O
their	O
extinction	O
in	O
the	O
wild	O
,	O
which	O
included	O
admixture	O
with	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
(	O
fig	O
.	O
8	O
).	O
Fig	O
.	O
8Schematic	O
diagram	O
showing	O
inferred	O
admixture	O
among	O
wisent	O
,	O
and	O
among	O
wisent	O
and	O
the	O
cattle	B-OG
/	O
aurochs	B-OG
lineage	O
.	O

Arrows	O
indicate	O
the	O
direction	O
of	O
the	O
geneflow	O
.	O

Black	O
lines	O
indicate	O
admixture	O
between	O
wisent	O
and	O
cattle	B-OG
/	O
aurochs	O
,	O
yellow	O
lines	O
/	O
arrow	O
—	O
between	O
Caucasian	O
and	O
founding	O
or	O
modern	O
wisent	O
respectively	O
,	O
and	O
the	O
blue	O
arrow	O
—	O
from	O
founders	O
to	O
modern	O
wisent	O
.	O

Wisent	O
Evolution	O
and	O
Admixture	O

The	O
accepted	O
view	O
of	O
wisent	O
evolution	O
is	O
of	O
two	O
distinct	O
subspecies	O
,	O
Lowland	O
wisent	O
and	O
Caucasian	O
wisent	O
,	O
that	O
both	O
underwent	O
dramatic	O
population	O
declines	O
,	O
with	O
the	O
last	O
few	O
surviving	O
individuals	O
serving	O
as	O
founders	O
of	O
the	O
modern	O
L	O
(	O
Lowland	O
only	O
)	O
and	O
LC	O
(	O
Lowland	O
and	O
Caucasian	O
)	O
lines	O
(	O
Pucek	O
et	O
al	O
.	O

2004	O
).	O

Our	O
results	O
show	O
that	O
this	O
model	O
is	O
an	O
oversimplification	O
.	O

We	O
find	O
evidence	O
of	O
at	O
least	O
two	O
highly	O
differentiated	O
populations	O
within	O
Caucasian	O
wisent	O
,	O
with	O
one	O
of	O
these	O
showing	O
greater	O
pairwise	O
similarities	O
with	O
Lowland	O
wisent	O
than	O
with	O
the	O
second	O
Caucasian	O
population	O
,	O
at	O
the	O
level	O
of	O
the	O
complete	O
genome	O
(	O
fig	O
.	O
2	O
).	O

However	O
,	O
analysis	O
of	O
aligned	O
nuclear	O
genomic	O
blocks	O
from	O
four	O
individuals	O
returns	O
Caucasian	O
and	O
Lowland	O
wisent	O
as	O
reciprocally	O
monophyletic	O
across	O
slightly	O
more	O
than	O
half	O
of	O
the	O
genomic	O
alignment	O
(	O
fig	O
.	O
3	O
),	O
providing	O
support	O
that	O
this	O
topology	O
reflects	O
the	O
true	O
history	O
of	O
population	O
divergence	O
.	O

Thus	O
,	O
among	O
any	O
two	O
Caucasian	O
wisent	O
and	O
any	O
two	O
modern	O
(	O
or	O
founding	O
Lowland	O
)	O
wisent	O
,	O
we	O
may	O
expect	O
that	O
any	O
single	O
locus	O
has	O
only	O
around	O
50	O
%	O
probability	O
of	O
reflecting	O
the	O
true	O
history	O
of	O
population	O
divergence	O
.	O

Moreover	O
,	O
increased	O
sampling	O
of	O
individuals	O
is	O
likely	O
to	O
further	O
reduce	O
this	O
proportion	O
,	O
potentially	O
to	O
such	O
an	O
extent	O
that	O
,	O
at	O
a	O
given	O
sampling	O
level	O
,	O
the	O
true	O
evolutionary	O
history	O
cannot	O
be	O
untangled	O
from	O
the	O
effects	O
of	O
random	O
drift	O
and	O
more	O
recent	O
admixture	O
.	O

This	O
result	O
reinforces	O
the	O
notion	O
that	O
phylogeny	O
-	O
based	O
interpretation	O
may	O
be	O
inappropriate	O
at	O
the	O
level	O
of	O
the	O
complete	O
genome	O
,	O
and	O
that	O
alternative	O
,	O
more	O
flexible	O
models	O
will	O
be	O
required	O
to	O
keep	O
pace	O
with	O
our	O
ability	O
to	O
generate	O
such	O
data	O
(	O
Hofreiter	O
et	O
al	O
.	O

2015	O
).	O

A	O
further	O
implied	O
assumption	O
of	O
the	O
traditional	O
view	O
of	O
wisent	O
evolution	O
is	O
that	O
,	O
with	O
the	O
exception	O
of	O
the	O
Caucasian	O
bull	O
KAUKASUS	O
,	O
all	O
founding	O
wisent	O
represented	O
“	O
pure	O
”	O
Lowland	O
wisent	O
(	O
Pucek	O
et	O
al	O
.	O

2004	O
;	O
Tokarska	O
et	O
al	O
.	O

2015	O
).	O

On	O
this	O
basis	O
,	O
the	O
modern	O
L	O
line	O
that	O
is	O
derived	O
only	O
from	O
the	O
latter	O
can	O
also	O
be	O
considered	O
as	O
pure	O
Lowland	O
wisent	O
,	O
referable	O
to	O
the	O
subspecies	O
B	B-OG
.	O
b	B-OG
.	I-OG
bonasus	I-OG
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
the	O
notion	O
of	O
wisent	O
subspecies	O
purity	O
is	O
flawed	O
in	O
the	O
sense	O
that	O
founding	O
Lowland	O
individuals	O
were	O
in	O
fact	O
admixed	O
with	O
Caucasian	O
wisent	O
to	O
varying	O
degrees	O
.	O

We	O
demonstrate	O
this	O
,	O
both	O
directly	O
for	O
the	O
founder	O
PLANTA	O
in	O
comparison	O
to	O
another	O
founder	O
,	O
her	O
son	O
PLATEN	O
,	O
and	O
also	O
indirectly	O
,	O
by	O
the	O
elevated	O
signal	O
of	O
Caucasian	O
wisent	O
admixture	O
in	O
modern	O
L	O
line	O
wisent	O
,	O
relative	O
to	O
these	O
founders	O
,	O
most	O
likely	O
a	O
result	O
of	O
inheritance	O
from	O
other	O
founding	O
individuals	O
not	O
included	O
in	O
this	O
analysis	O
(	O
fig	O
.	O
7	O
).	O

The	O
notion	O
of	O
subspecies	O
purity	O
therefore	O
disregards	O
the	O
fact	O
that	O
admixture	O
between	O
Caucasian	O
and	O
Lowland	O
wisent	O
almost	O
certainly	O
occurred	O
prior	O
to	O
the	O
extinction	O
of	O
wisent	O
in	O
the	O
wild	O
,	O
and	O
such	O
admixture	O
could	O
therefore	O
be	O
regarded	O
as	O
part	O
of	O
the	O
normal	O
population	O
processes	O
and	O
dynamics	O
of	O
this	O
species	O
.	O

The	O
notion	O
of	O
subspecies	O
purity	O
has	O
driven	O
efforts	O
to	O
ensure	O
that	O
free	O
-	O
living	O
L	O
and	O
LC	O
herds	O
do	O
not	O
come	O
into	O
contact	O
(	O
Pucek	O
et	O
al	O
.	O

2004	O
),	O
and	O
also	O
motivated	O
genetic	O
investigations	O
of	O
living	O
populations	O
that	O
may	O
have	O
been	O
recipients	O
of	O
geneflow	O
from	O
the	O
opposing	O
genetic	O
line	O
(	O
Tokarska	O
et	O
al	O
.	O

2015	O
).	O

The	O
latter	O
study	O
investigated	O
the	O
modern	O
L	B-OG
line	O
population	O
that	O
currently	O
inhabits	O
the	O
eastern	O
,	O
Belarusian	O
part	O
of	O
the	O
Białowieża	O
Forest	O
.	O

Some	O
individuals	O
were	O
found	O
to	O
possess	O
a	O
microsatellite	O
allele	O
that	O
was	O
common	O
among	O
Caucasian	O
wisent	O
but	O
absent	O
in	O
all	O
studied	O
Lowland	O
wisent	O
,	O
which	O
these	O
authors	O
interpreted	O
as	O
evidence	O
of	O
recent	O
admixture	O
with	O
the	O
modern	O
LC	O
line	O
.	O

Although	O
the	O
individual	O
from	O
this	O
population	O
(	O
modern	O
L	O
line	O
,	O
MdL2	O
)	O
that	O
we	O
sequenced	O
does	O
not	O
possess	O
this	O
putative	O
Caucasian	O
wisent	O
allele	O
,	O
we	O
nevertheless	O
detected	O
evidence	O
of	O
Caucasian	O
wisent	O
admixture	O
above	O
that	O
occurring	O
in	O
founding	O
wisent	O
for	O
this	O
individual	O
(	O
fig	O
.	O
5	O
).	O

However	O
,	O
the	O
small	O
size	O
of	O
admixed	O
blocks	O
,	O
in	O
addition	O
to	O
non	O
-	O
significant	O
D	O
comparisons	O
of	O
modern	O
lines	O
,	O
supports	O
variable	O
Caucasian	O
wisent	O
admixture	O
among	O
founding	O
wisent	O
in	O
explaining	O
this	O
result	O
,	O
which	O
may	O
also	O
account	O
for	O
the	O
occurrence	O
of	O
putative	O
Caucasian	O
wisent	O
alleles	O
in	O
other	O
individuals	O
from	O
this	O
population	O
.	O

Future	O
studies	O
of	O
such	O
individuals	O
using	O
the	O
methodology	O
applied	O
here	O
would	O
provide	O
a	O
robust	O
test	O
of	O
these	O
alternative	O
hypotheses	O
.	O

Wisent	O
Conservation	O
and	O
De	O
-	O
Extinction	O

The	O
issue	O
of	O
low	O
genetic	O
variability	O
among	O
living	O
wisent	O
is	O
considered	O
as	O
cause	O
for	O
concern	O
,	O
and	O
has	O
been	O
inferred	O
by	O
several	O
population	O
-	O
level	O
studies	O
using	O
various	O
molecular	O
and	O
biochemical	O
markers	O
,	O
such	O
as	O
blood	O
-	O
group	O
systems	O
and	O
blood	O
serum	O
proteins	O
(	O
Sipko	O
et	O
al	O
.	O

1995	O
;	O
Gębczyński	O
and	O
Tomaszewska	O
-	O
Guszkiewicz	O
1987	O
;	O
Hartl	O
and	O
Pucek	O
1994	O
;	O
Sipko	O
et	O
al	O
.	O

1997	O
),	O
mtDNA	O
(	O
this	O
study	O
;	O
Tiedemann	O
et	O
al	O
.	O

1998	O
;	O
Burzyńska	O
et	O
al	O
.	O

1999	O
;	O
Wójcik	O
et	O
al	O
.	O

2009	O
;	O
Hassanin	O
et	O
al	O
.	O

2012	O
),	O
nuclear	O
gene	O
sequences	O
(	O
Burzyńska	O
and	O
Topczewski	O
1995	O
;	O
Radwan	O
et	O
al	O
.	O

2007	O
;	O
Babik	O
et	O
al	O
.	O

2012	O
;	O
Hassanin	O
et	O
al	O
.	O

2013	O
),	O
microsatellites	O
(	O
Gralak	O
et	O
al	O
.	O

2004	O
;	O
Luenser	O
et	O
al	O
.	O

2005	O
;	O
Tokarska	O
,	O
Kawałko	O
,	O
et	O
al	O
.	O

2009	O
;	O
Tokarska	O
,	O
Marshall	O
,	O
et	O
al	O
.	O

2009	O
)	O
and	O
SNPs	O
(	O
Tokarska	O
,	O
Marshall	O
,	O
et	O
al	O
.	O

2009	O
,	O
Tokarska	O
et	O
al	O
.	O

2015	O
).	O

In	O
apparent	O
contrast	O
to	O
these	O
results	O
,	O
whole	O
-	O
genome	O
heterozygosity	O
in	O
modern	O
wisent	O
has	O
been	O
shown	O
to	O
be	O
similar	O
to	O
that	O
found	O
within	O
domestic	O
cow	B-OG
breeds	O
(	O
Gautier	O
et	O
al	O
.	O

2016	O
).	O

Our	O
results	O
further	O
support	O
this	O
finding	O
using	O
measures	O
of	O
pairwise	O
genomic	O
divergences	O
among	O
modern	O
and	O
founding	O
wisent	O
,	O
which	O
are	O
approximately	O
equal	O
to	O
or	O
greater	O
than	O
that	O
found	O
between	O
pairs	O
of	O
cattle	B-OG
or	O
yak	B-OG
,	O
respectively	O
.	O

However	O
,	O
the	O
bimodal	O
distributions	O
observed	O
for	O
pairwise	O
comparisons	O
based	O
on	O
transitions	O
and	O
transversions	O
for	O
modern	O
wisent	O
suggests	O
that	O
,	O
among	O
any	O
pair	O
of	O
modern	O
wisent	O
,	O
large	O
chromosomal	O
blocks	O
will	O
show	O
high	O
genetic	O
similarity	O
,	O
which	O
is	O
indicative	O
of	O
inbreeding	O
,	O
and	O
has	O
been	O
shown	O
previously	O
using	O
SNP	O
array	O
data	O
(	O
Pertoldi	O
et	O
al	O
.	O

2009	O
).	O

Overall	O
,	O
the	O
wisent	O
captive	O
breeding	O
program	O
,	O
based	O
on	O
a	O
founding	O
herd	O
of	O
just	O
12	O
individuals	O
,	O
appears	O
to	O
have	O
succeeded	O
in	O
retaining	O
reasonable	O
levels	O
of	O
genetic	O
variability	O
in	O
modern	O
populations	O
.	O

Nevertheless	O
,	O
the	O
extinction	O
of	O
wisent	O
in	O
the	O
wild	O
was	O
clearly	O
accompanied	O
by	O
a	O
major	O
loss	O
of	O
total	O
genetic	O
diversity	O
.	O

Divergent	O
mitochondrial	O
haplotypes	O
detected	O
in	O
ancient	O
wisent	O
appear	O
to	O
have	O
been	O
entirely	O
lost	O
from	O
modern	O
populations	O
,	O
which	O
our	O
results	O
suggest	O
may	O
possess	O
only	O
a	O
single	O
haplotype	O
.	O

Moreover	O
,	O
substantial	O
pairwise	O
nuclear	O
genomic	O
divergences	O
detected	O
between	O
modern	O
and	O
historical	O
Caucasian	O
wisent	O
indicate	O
a	O
huge	O
loss	O
of	O
diversity	O
following	O
the	O
extinction	O
of	O
the	O
latter	O
population	O
.	O

A	O
fraction	O
of	O
the	O
genepool	O
of	O
extinct	O
Caucasian	O
wisent	O
survives	O
in	O
the	O
genomes	O
of	O
modern	O
individuals	O
.	O

Our	O
results	O
provide	O
not	O
only	O
a	O
direct	O
measure	O
of	O
this	O
admixture	O
in	O
a	O
modern	O
LC	O
line	O
individual	O
,	O
but	O
also	O
allow	O
us	O
to	O
map	O
with	O
relative	O
accuracy	O
chromosomal	O
segments	O
that	O
are	O
inherited	O
from	O
Caucasian	O
wisent	O
.	O

Although	O
sometimes	O
controversial	O
,	O
the	O
concept	O
of	O
de	O
-	O
extinction	O
has	O
generated	O
considerable	O
interest	O
(	O
Sherkow	O
and	O
Greely	O
2013	O
),	O
and	O
attempts	O
are	O
currently	O
underway	O
to	O
generate	O
animals	B-OG
that	O
,	O
at	O
least	O
superficially	O
,	O
resemble	O
the	O
quagga	B-OG
(	O
Equus	B-OG
quagga	I-OG
;	O
Heywood	O
2013	O
),	O
an	O
extinct	O
subspecies	O
of	O
plains	B-OG
zebra	I-OG
,	O
and	O
also	O
the	O
aurochs	B-OG
(	O
van	O
Vuure	O
2005	O
),	O
by	O
careful	O
selective	O
breeding	O
of	O
their	O
living	O
relatives	O
.	O

In	O
both	O
of	O
these	O
cases	O
,	O
selective	O
breeding	O
and	O
the	O
ultimate	O
success	O
of	O
the	O
project	O
are	O
based	O
solely	O
on	O
morphological	O
criteria	O
.	O

Our	O
study	O
demonstrates	O
that	O
,	O
at	O
least	O
in	O
principle	O
,	O
by	O
generating	O
chromosomal	O
admixture	O
maps	O
for	O
multiple	O
living	O
representatives	O
of	O
the	O
LC	O
line	O
,	O
it	O
would	O
be	O
possible	O
to	O
selectively	O
breed	O
an	O
animal	B-OG
that	O
is	O
,	O
at	O
the	O
genomic	O
level	O
,	O
highly	O
similar	O
to	O
a	O
Caucasian	O
wisent	O
.	O

Admixture	O
with	O
the	O
Bos	B-OG
Cattle	I-OG
Lineage	O

Hybridization	O
of	O
wild	O
species	O
with	O
their	O
domesticated	O
close	O
relatives	O
is	O
a	O
subject	O
of	O
considerable	O
discussion	O
and	O
concern	O
for	O
conservation	O
management	O
(	O
Ellstrand	O
et	O
al	O
.	O

2010	O
).	O

Previous	O
studies	O
have	O
found	O
evidence	O
of	O
admixture	O
with	O
the	O
Bos	B-OG
cattle	B-OG
lineage	O
in	O
modern	O
L	O
line	O
wisent	O
(	O
Gautier	O
et	O
al	O
.	O

2016	O
).	O

We	O
extend	O
this	O
result	O
by	O
demonstrating	O
that	O
such	O
admixture	O
is	O
widespread	O
across	O
wisent	O
,	O
including	O
both	O
modern	O
genetic	O
lines	O
,	O
representatives	O
of	O
the	O
original	O
founding	O
herd	O
,	O
and	O
also	O
extinct	O
Caucasian	O
wisent	O
.	O

This	O
admixture	O
post	O
-	O
dates	O
the	O
common	O
ancestor	O
of	O
English	O
aurochs	B-OG
and	O
taurine	O
cattle	B-OG
,	O
and	O
involved	O
a	O
representative	O
of	O
the	O
latter	O
lineage	O
.	O

However	O
,	O
the	O
precise	O
identity	O
of	O
the	O
introgressor	O
—	O
aurochs	O
or	O
domestic	O
cattle	B-OG
—	O
is	O
less	O
certain	O
,	O
given	O
the	O
lack	O
of	O
knowledge	O
of	O
population	O
structure	O
in	O
aurochs	O
.	O

Testing	O
these	O
two	O
alternatives	O
would	O
require	O
data	O
from	O
additional	O
aurochs	O
populations	O
from	O
within	O
the	O
core	O
distribution	O
of	O
wisent	O
,	O
and	O
would	O
be	O
a	O
valuable	O
direction	O
for	O
future	O
research	O
.	O

The	O
timing	O
of	O
admixture	O
also	O
has	O
implications	O
for	O
conservation	O
management	O
.	O

Specifically	O
,	O
the	O
removal	O
of	O
individuals	O
resulting	O
from	O
very	O
recent	O
hybridization	O
may	O
be	O
deemed	O
appropriate	O
(	O
Halbert	O
and	O
Derr	O
2007	O
).	O

The	O
small	O
size	O
of	O
cattle	B-OG
admixed	O
blocks	O
in	O
modern	O
wisent	O
(	O
at	O
least	O
undetectable	O
at	O
a	O
1	O
Mb	O
scale	O
)	O
clearly	O
rejects	O
very	O
recent	O
cattle	B-OG
admixture	O
for	O
the	O
individuals	O
investigated	O
here	O
.	O

Instead	O
,	O
admixture	O
must	O
have	O
occurred	O
prior	O
to	O
the	O
establishment	O
of	O
the	O
captive	O
breeding	O
program	O
,	O
and	O
the	O
admixture	O
signal	O
detected	O
in	O
modern	O
wisent	O
results	O
from	O
inheritance	O
from	O
the	O
founders	O
that	O
were	O
admixed	O
with	O
cattle	B-OG
to	O
varying	O
degrees	O
.	O

Thus	O
,	O
based	O
on	O
the	O
current	O
evidence	O
,	O
cattle	B-OG
introgression	O
appears	O
of	O
low	O
concern	O
for	O
wisent	O
conservation	O
for	O
the	O
following	O
reasons	O
:	O
(	O
1	O
)	O
admixture	O
does	O
not	O
appear	O
to	O
have	O
occurred	O
since	O
the	O
establishment	O
of	O
the	O
captive	O
breeding	O
program	O
,	O
although	O
screening	O
of	O
additional	O
individuals	O
may	O
be	O
desirable	O
to	O
further	O
support	O
this	O
generalization	O
;	O
(	O
2	O
)	O
the	O
number	O
of	O
intervening	O
generations	O
separating	O
living	O
wisent	O
from	O
the	O
F1	O
hybrids	O
is	O
likely	O
sufficient	O
that	O
all	O
living	O
wisent	O
are	O
admixed	O
to	O
some	O
extent	O
(	O
Chang	O
1999	O
);	O
and	O
(	O
3	O
)	O
our	O
results	O
may	O
in	O
fact	O
reflect	O
admixture	O
with	O
aurochs	O
,	O
rather	O
than	O
domestic	O
cattle	B-OG
,	O
although	O
this	O
hypothesis	O
requires	O
further	O
investigation	O
.	O

An	O
Exemplar	O
for	O
the	O
Study	O
of	O
Admixture	O

The	O
ability	O
to	O
detect	O
admixture	O
is	O
of	O
key	O
importance	O
for	O
both	O
evolutionary	O
and	O
applied	O
conservation	O
studies	O
.	O

However	O
,	O
interpretation	O
of	O
a	O
significant	O
signal	O
of	O
admixture	O
,	O
in	O
terms	O
of	O
both	O
evolutionary	O
inference	O
and	O
the	O
formulation	O
of	O
management	O
strategies	O
,	O
may	O
require	O
information	O
its	O
timing	O
.	O

Using	O
seven	O
low	O
-	O
coverage	O
wisent	O
genomes	O
from	O
both	O
modern	O
and	O
historical	O
wisent	O
we	O
have	O
revealed	O
multiple	O
instances	O
of	O
admixture	O
,	O
but	O
moreover	O
,	O
because	O
the	O
approximate	O
age	O
of	O
introgression	O
of	O
Caucasian	O
wisent	O
into	O
the	O
modern	O
LC	O
line	O
is	O
known	O
,	O
through	O
comparisons	O
of	O
the	O
sizes	O
of	O
likely	O
admixed	O
genomic	O
segments	O
we	O
have	O
inferred	O
the	O
relative	O
ages	O
of	O
other	O
admixture	O
events	O
.	O

This	O
unique	O
historical	O
information	O
,	O
coupled	O
with	O
the	O
ability	O
to	O
recover	O
genomic	O
data	O
from	O
historical	O
samples	O
,	O
establish	O
wisent	O
as	O
an	O
exemplary	O
taxon	O
for	O
the	O
study	O
of	O
admixture	O
in	O
wild	O
populations	O
.	O

As	O
new	O
analytical	O
methods	O
for	O
studying	O
admixture	O
are	O
developed	O
,	O
wisent	O
can	O
serve	O
as	O
a	O
valuable	O
empirical	O
test	O
of	O
both	O
their	O
performance	O
and	O
utility	O
.	O

Materials	O
and	O
Methods	O

Complete	O
details	O
of	O
all	O
samples	O
and	O
specimens	O
used	O
in	O
this	O
study	O
are	O
shown	O
in	O
table	O
1	O
.	O

Laboratory	O
Methods	O
,	O
Modern	O
Samples	O

DNA	O
was	O
extracted	O
from	O
tissue	O
samples	O
of	O
three	O
modern	O
wisent	O
using	O
either	O
a	O
DNeasy	O
Blood	O
and	O
Tissue	O
Kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
sample	O
MdL1	O
)	O
or	O
by	O
phenol	O
/	O
chloroform	B-CD
extraction	O
(	O
Sambrook	O
and	O
Russell	O
2001	O
).	O

We	O
mechanically	O
sheared	O
the	O
DNA	O
of	O
the	O
modern	O
samples	O
using	O
a	O
Covaris	O
S220	O
sonicator	O
to	O
an	O
average	O
fragment	O
length	O
of	O
500	O
bp	O
and	O
prepared	O
indexed	O
Illumina	O
libraries	O
from	O
500	O
ng	O
of	O
each	O
modern	O
DNA	O
extract	O
using	O
a	O
published	O
double	O
-	O
stranded	O
protocol	O
(	O
Meyer	O
and	O
Kircher	O
2010	O
)	O
with	O
modifications	O
(	O
Fortes	O
and	O
Paijmans	O
2015	O
).	O

Library	O
molecules	O
from	O
450	O
bp	O
to	O
1000	O
bp	O
were	O
then	O
selected	O
using	O
a	O
Pippin	O
Prep	O
Instrument	O
(	O
Sage	O
Science	O
).	O

Laboratory	O
Methods	O
,	O
Historical	O
Samples	O

DNA	O
extraction	O
from	O
four	O
museum	O
specimens	O
as	O
well	O
as	O
sequencing	O
library	O
preparation	O
steps	O
preceding	O
amplification	O
were	O
performed	O
in	O
a	O
dedicated	O
ancient	O
DNA	O
laboratory	O
(	O
Evolutionary	O
Adaptive	O
Genomics	O
Group	O
,	O
Potsdam	O
University	O
,	O
Germany	O
).	O

DNA	O
extracts	O
were	O
prepared	O
from	O
horn	O
and	O
bone	O
powder	O
obtained	O
by	O
grinding	O
in	O
a	O
mixer	O
mill	O
(	O
MM	O
400	O
,	O
RETSCH	O
).	O

DNA	O
extraction	O
followed	O
the	O
protocol	O
of	O
Dabney	O
,	O
Knapp	O
,	O
et	O
al	O
.	O
(	O
2013	O
),	O
except	O
for	O
horn	O
samples	O
where	O
we	O
used	O
a	O
different	O
digestion	O
buffer	O
containing	O
10mM	O
Tris	O
buffer	O
(	O
pH	O
8	O
.	O
0	O
),	O
10	O
mM	O
NaCl	O
,	O
5	O
mM	O
CaCl2	O
,	O
2	O
.	O
5	O
mM	O
EDTA	O
(	O
pH	O
8	O
.	O
0	O
),	O
2	O
%	O
SDS	O
(	O
Shapiro	O
and	O
Hofreiter	O
2012	O
).	O

The	O
museum	O
samples	O
were	O
already	O
fragmented	O
due	O
to	O
degradation	O
,	O
so	O
were	O
not	O
sonicated	O
.	O

We	O
used	O
25	O
µl	O
of	O
each	O
DNA	O
extract	O
to	O
construct	O
single	O
-	O
stranded	O
indexed	O
Illumina	O
libraries	O
according	O
to	O
the	O
protocol	O
of	O
Gansauge	O
and	O
Meyer	O
(	O
2013	O
).	O

Sequencing	O

Final	O
library	O
concentrations	O
and	O
the	O
distribution	O
of	O
insert	O
sizes	O
were	O
determined	O
using	O
a	O
2200	O
TapeStation	O
(	O
Agilent	O
Technologies	O
)	O
and	O
Qubit	O
HS	O
-	O
assay	O
(	O
Thermo	O
Fisher	O
Scientific	O
),	O
respectively	O
.	O

Each	O
library	O
was	O
then	O
sequenced	O
using	O
an	O
Illumina	O
NextSeq	O
500	O
instrument	O
.	O

For	O
modern	O
libraries	O
we	O
used	O
a	O
High	O
Output	O
Kit	O
(	O
75	O
bp	O
paired	O
-	O
end	O
sequencing	O
),	O
for	O
libraries	O
obtained	O
from	O
historical	O
horn	O
samples	O
we	O
used	O
High	O
Output	O
Kits	O
(	O
75	O
bp	O
single	O
-	O
end	O
and	O
150	O
bp	O
paired	O
-	O
end	O
)	O
and	O
each	O
library	O
built	O
from	O
historical	O
bone	O
samples	O
was	O
sequenced	O
separately	O
with	O
High	O
Output	O
Kits	O
(	O
75	O
bp	O
single	O
-	O
end	O
and	O
paired	O
-	O
end	O
).	O

Full	O
details	O
of	O
sequencing	O
results	O
are	O
provided	O
in	O
supplementary	O
tables	O
S2	O
and	O
S3	O
,	O
Supplementary	O
Material	O
online	O
.	O

Whole	O
genome	O
shotgun	O
sequencing	O
data	O
produced	O
for	O
this	O
study	O
are	O
available	O
in	O
the	O
NCBI	O
Short	O
Read	O
Archive	O
as	O
SAMN05950802	O
–	O
SAMN05950808	O
.	O

Data	O
Processing	O
,	O
Mapping	O
and	O
Pseudo	O
-	O
Haploidization	O

For	O
paired	O
-	O
end	O
data	O
,	O
we	O
trimmed	O
adapter	O
sequences	O
and	O
merged	O
overlapping	O
read	O
pairs	O
using	O
SeqPrep	O
(	O
https	O
://	O
github	O
.	O
com	O
/	O
jstjohn	O
/	O
SeqPrep	O
),	O
requiring	O
a	O
minimum	O
read	O
length	O
of	O
30	O
bp	O
(-	O
L	O
30	O
),	O
minimum	O
overlap	O
of	O
15	O
bp	O
(-	O
o	O
15	O
),	O
and	O
a	O
minimum	O
merge	O
quality	O
of	O
13	O
(-	O
q	O
13	O
).	O

Adapters	O
occurring	O
at	O
the	O
3	O
′	O
ends	O
of	O
single	O
-	O
end	O
reads	O
were	O
trimmed	O
using	O
cutadapt	O
(	O
Martin	O
2011	O
),	O
also	O
requiring	O
a	O
minimum	O
length	O
of	O
reads	O
of	O
30	O
(-	O
m	O
30	O
).	O

We	O
then	O
mapped	O
the	O
resulting	O
data	O
to	O
the	O
zebu	B-OG
(	O
Bos	B-OG
indicus	I-OG
;	O
GenBank	O
accession	O
no	O
.	O

GCA_000247795	O
.	O
2	O
)	O
and	O
water	B-OG
buffalo	I-OG
(	O
Bubalus	B-OG
bubalis	I-OG
;	O
GenBank	O
accession	O
no	O
.	O

GCA_000471725	O
.	O
1	O
)	O
nuclear	O
genomes	O
and	O
wisent	O
mitochondrial	O
genome	O
(	O
GenBank	O
accession	O
no	O
.	O
KY055664	B-CD
)	O
using	O
BWA	O
aln	O
version	O
0	O
.	O
7	O
.	O
8	O
(	O
Li	O
and	O
Durbin	O
2009	O
)	O
with	O
default	O
0	O
.	O
04	O
mismatch	O
value	O
.	O

We	O
removed	O
duplicate	O
reads	O
likely	O
resulting	O
from	O
PCR	O
amplification	O
using	O
samtools	O
rmdup	O
(	O
Li	O
et	O
al	O
.	O

2009	O
).	O

Detailed	O
descriptions	O
of	O
the	O
mapping	O
results	O
are	O
provided	O
in	O
supplementary	O
tables	O
S2	O
and	O
S3	O
,	O
Supplementary	O
Material	O
online	O
.	O

We	O
then	O
generated	O
pseudo	O
-	O
haploid	O
sequences	O
as	O
described	O
by	O
Cahill	O
et	O
al	O
.	O
(	O
2015	O
)	O
and	O
used	O
these	O
for	O
further	O
analysis	O
.	O

Pairwise	O
Genomic	O
Divergence	O

Pairwise	O
genomic	O
divergence	O
was	O
calculated	O
by	O
dividing	O
genomic	O
alignments	O
into	O
non	O
-	O
overlapping	O
1	O
Mb	O
blocks	O
and	O
calculating	O
the	O
proportion	O
of	O
transversions	O
,	O
or	O
transitions	O
plus	O
transversions	O
(	O
comparisons	O
of	O
modern	O
individuals	O
only	O
),	O
for	O
each	O
pair	O
of	O
individuals	O
,	O
accounting	O
for	O
the	O
presence	O
of	O
missing	O
data	O
.	O

Blocks	O
with	O
>	O
75	O
%	O
missing	O
data	O
were	O
disregarded	O
.	O

Probability	O
densities	O
were	O
generated	O
by	O
kernel	O
density	O
estimation	O
in	O
R	O
(	O
R	O
Core	O
Team	O
2014	O
)	O
using	O
default	O
parameters	O
.	O

Full	O
details	O
of	O
comparative	O
data	O
generated	O
for	O
domestic	O
cattle	B-OG
and	O
yak	B-OG
(	O
data	O
from	O
the	O
NCBI	O
Short	O
Read	O
Archive	O
)	O
are	O
provided	O
in	O
supplementary	O
table	O
S4	O
,	O
Supplementary	O
Material	O
online	O
.	O

Mitochondrial	O
Genome	O
Analysis	O

In	O
addition	O
to	O
the	O
mitochondrial	O
genomes	O
generated	O
from	O
the	O
three	O
modern	O
and	O
four	O
historical	O
specimens	O
,	O
we	O
obtained	O
mitogenomes	O
from	O
seven	O
other	O
modern	O
wisent	O
with	O
Sanger	O
technology	O
and	O
from	O
four	O
ancient	O
Holocene	O
wisent	O
individuals	O
using	O
hybridisation	O
capture	O
(	O
supplementary	O
table	O
S1	O
,	O
Supplementary	O
Material	O
online	O
).	O

These	O
ancient	O
samples	O
were	O
radiocarbon	O
dated	O
at	O
either	O
the	O
Oxford	O
University	O
Radiocarbon	O
Accelerator	O
Unit	O
(	O
Oxford	O
,	O
UK	O
)	O
using	O
ultrafiltered	O
collagen	B-GP
and	O
accelerator	O
mass	O
spectrometry	O
(	O
Ramsey	O
,	O
Gigham	O
,	O
et	O
al	O
.	O

2004	O
;	O
Ramsey	O
,	O
Higham	O
,	O
et	O
al	O
.	O

2004	O
)	O
or	O
the	O
VERA	O
-	O
Laboratorium	O
Institut	O
für	O
Isotopenforschung	O
und	O
Kernphysik	O
(	O
Vienna	O
,	O
Austria	O
).	O

We	O
calibrated	O
radiocarbon	O
dates	O
using	O
the	O
IntCal13	O
calibration	O
curve	O
(	O
Reimer	O
et	O
al	O
.	O

2013	O
)	O
in	O
OxCal	O
v4	O
.	O
2	O
(	O
https	O
://	O
c14	O
.	O
arch	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/	O
oxcal	O
/	O
OxCal	O
.	O
html	O
).	O

DNA	O
was	O
extracted	O
from	O
the	O
Holocene	O
B	B-OG
.	I-OG
b	I-OG
.	I-OG
bonasus	I-OG
samples	O
(	O
Bb1	O
-	O
Bb3	O
)	O
at	O
the	O
Henry	O
Wellcome	O
Ancient	O
Biomolecules	O
Centre	O
(	O
Oxford	O
University	O
,	O
UK	O
),	O
following	O
Shapiro	O
et	O
al	O
.	O
(	O
2004	O
).	O

We	O
extracted	O
the	O
Holocene	O
B	B-OG
.	I-OG
b	I-OG
.	I-OG
caucasicus	I-OG
sample	O
(	O
Cc3	O
)	O
in	O
the	O
specialist	O
Paleogenomics	O
facility	O
at	O
UC	O
Santa	O
Cruz	O
,	O
following	O
Rohland	O
et	O
al	O
.	O
(	O
2010	O
).	O

DNA	O
library	O
construction	O
,	O
mitochondrial	O
target	O
enrichment	O
,	O
sequencing	O
,	O
and	O
sequence	O
data	O
processing	O
protocols	O
for	O
the	O
four	O
Holocene	O
samples	O
followed	O
approach	O
four	O
in	O
Heintzman	O
et	O
al	O
.	O
(	O
2016	O
),	O
except	O
that	O
the	O
whole	O
mitochondrial	O
genome	O
consensus	O
sequence	O
was	O
retained	O
.	O

The	O
mean	O
read	O
depth	O
of	O
these	O
Holocene	O
consensus	O
sequences	O
ranged	O
from	O
14	O
.	O
1	O
to	O
165	O
.	O
7	O
×.	O

The	O
consensus	O
sequences	O
for	O
the	O
four	O
Holocene	O
and	O
one	O
historic	O
Caucasian	O
wisent	O
have	O
been	O
deposited	O
in	O
GenBank	O
with	O
accession	O
numbers	O
KX553930	O
–	O
KX553934	O
.	O

The	O
mitogenomic	O
sequence	O
from	O
the	O
remaining	O
modern	O
and	O
historic	O
samples	O
has	O
been	O
submitted	O
to	O
GenBank	O
with	O
accession	O
number	O
KY055664	O
(	O
supplementary	O
table	O
S1	O
,	O
Supplementary	O
Material	O
online	O
).	O

We	O
assessed	O
phylogenetic	O
relationships	O
among	O
wisent	O
mitochondrial	O
haplotypes	O
,	O
as	O
well	O
as	O
their	O
placement	O
within	O
the	O
wider	O
bovine	O
(	O
tribe	O
Bovini	B-OG
)	O
tree	O
.	O

Wisent	O
sequences	O
were	O
aligned	O
with	O
those	O
of	O
12	O
other	O
bovin	B-OG
taxa	O
,	O
including	O
the	O
extinct	O
steppe	B-OG
bison	I-OG
(	O
Bison	B-OG
priscus	I-OG
)	O
and	O
aurochs	B-OG
(	O
Bos	B-OG
primigenius	I-OG
)	O
(	O
supplementary	O
table	O
S1	O
,	O
Supplementary	O
Material	O
online	O
).	O

We	O
excluded	O
two	O
previously	O
published	O
wisent	O
mitochondrial	O
genomes	O
from	O
the	O
phylogenetic	O
analysis	O
(	O
GenBank	O
accessions	O
:	O
HQ223450	O
,	O
HM045017	O
/	O
NC_014044	O
),	O
as	O
these	O
sequences	O
were	O
considered	O
problematic	O
.	O

Specifically	O
,	O
HQ223450	O
has	O
multiple	O
insertions	O
totaling	O
9	O
bp	O
in	O
the	O
ND4	B-GP
coding	O
region	O
,	O
and	O
HM045017	O
/	O
NC_014044	O
has	O
multiple	O
indels	O
and	O
point	O
mutations	O
concentrated	O
in	O
the	O
large	O
rRNA	O
and	O
ND3	B-GP
coding	O
regions	O
.	O

Sequence	O
alignment	O
,	O
partitioning	O
,	O
model	O
testing	O
,	O
and	O
phylogenetic	O
and	O
associated	O
statistical	O
support	O
methods	O
followed	O
the	O
ordinal	O
-	O
level	O
analyses	O
of	O
Heintzman	O
et	O
al	O
.	O
(	O
2015	O
),	O
except	O
that	O
we	O
used	O
the	O
B	B-OG
.	I-OG
bison	I-OG
reference	O
mitochondrial	O
genome	O
(	O
NC_012346	O
)	O
for	O
partitioning	O
.	O

We	O
selected	O
the	O
following	O
models	O
of	O
molecular	O
evolution	O
for	O
the	O
six	O
partitions	O
:	O
GTR	B-GP
+	O
I	O
+	O
G	O
(	O
CP1	B-GP
,	O
3803	O
bp	O
;	O
rRNAs	O
,	O
2541	O
bp	O
),	O
GTR	B-GP
+	O
G	O
(	O
CP3	B-GP
,	O
3803	O
bp	O
),	O
HKY	O
+	O
I	O
+	O
G	O
(	O
CP2	B-GP
,	O
3803	O
bp	O
;	O
tRNAs	O
,	O
1526	O
bp	O
;	O
control	O
region	O
,	O
927	O
bp	O
).	O

We	O
used	O
the	O
saola	B-OG
(	O
Pseudoryx	O
nghetinhensis	O
;	O
supplementary	O
table	O
S1	O
,	O
Supplementary	O
Material	O
online	O
)	O
as	O
outgroup	O
in	O
both	O
the	O
maximum	O
likelihood	O
and	O
Bayesian	O
analyses	O
,	O
following	O
Bibi	O
(	O
2013	O
).	O

D	O
Statistic	O
Tests	O

The	O
D	O
statistic	O
involves	O
four	O
genomes	O
:	O
a	O
genome	O
from	O
each	O
of	O
two	O
sister	O
populations	O
(	O
P1	O
and	O
P2	O
),	O
a	O
genome	O
from	O
a	O
third	O
population	O
as	O
the	O
potential	O
source	O
of	O
introgression	O
(	O
P3	O
),	O
and	O
an	O
outgroup	O
genome	O
(	O
O	O
)	O
to	O
identify	O
the	O
ancestral	O
state	O
(	O
identified	O
as	O
the	O
A	O
allele	O
).	O

We	O
identified	O
variable	O
positions	O
at	O
which	O
P3	O
possessed	O
the	O
derived	O
allele	O
(	O
B	O
)	O
and	O
presence	O
of	O
the	O
derived	O
allele	O
is	O
variable	O
among	O
P1	O
and	O
P2	O
,	O
leading	O
to	O
two	O
possible	O
patterns	O
:	O
either	O
ABBA	O
or	O
BABA	O
.	O

Under	O
the	O
scenario	O
of	O
incomplete	O
lineage	O
sorting	O
without	O
geneflow	O
these	O
patterns	O
should	O
occur	O
with	O
equal	O
frequency	O
and	O
the	O
expected	O
D	O
value	O
will	O
be	O
zero	O
.	O

An	O
excess	O
of	O
ABBA	O
or	O
BABA	O
patterns	O
is	O
interpreted	O
as	O
evidence	O
of	O
admixture	O
.	O

However	O
,	O
it	O
might	O
also	O
arise	O
from	O
nonrandom	O
mating	O
in	O
the	O
ancestral	O
population	O
due	O
to	O
population	O
structure	O
(	O
Eriksson	O
and	O
Manica	O
2012	O
).	O

To	O
determine	O
the	O
ancestral	O
state	O
we	O
used	O
the	O
water	B-OG
buffalo	I-OG
genome	O
.	O

In	O
all	O
tests	O
involving	O
data	O
mapped	O
to	O
the	O
zebu	B-OG
genome	O
,	O
we	O
took	O
into	O
consideration	O
the	O
autosomes	O
only	O
.	O

We	O
performed	O
a	O
total	O
of	O
105	O
comparisons	O
considering	O
all	O
possible	O
combinations	O
of	O
wisent	O
,	O
all	O
wisent	O
with	O
either	O
domestic	O
cattle	B-OG
or	O
aurochs	O
as	O
candidate	O
admixer	O
,	O
and	O
domestic	O
cattle	B-OG
and	O
aurochs	O
with	O
all	O
wisent	O
as	O
candidate	O
admixer	O
.	O

These	O
results	O
are	O
reported	O
in	O
supplementary	O
table	O
S4	O
,	O
Supplementary	O
Material	O
online	O
.	O
f	O
^	O
test	O
(	O
Green	O
et	O
al	O
.	O

2010	O
;	O
Durand	O
et	O
al	O
.	O

2011	O
)	O
was	O
used	O
to	O
estimate	O
the	O
proportion	O
of	O
the	O
genome	O
derived	O
from	O
admixture	O
.	O

This	O
test	O
requires	O
two	O
individuals	O
of	O
the	O
candidate	O
introgressor	O
species	O
that	O
are	O
not	O
themselves	O
admixed	O
.	O

For	O
our	O
datasets	O
this	O
was	O
possible	O
only	O
for	O
admixture	O
involving	O
the	O
cattle	B-OG
/	O
aurochs	B-OG
lineage	O
.	O

For	O
both	O
D	O
statistic	O
and	O
f	O
^	O
test	O
,	O
significance	O
was	O
assessed	O
using	O
a	O
weighted	O
block	O
jackknife	O
using	O
1	O
Mb	O
blocks	O
(	O
Green	O
et	O
al	O
.	O

2010	O
;	O
Durand	O
et	O
al	O
.	O

2011	O
).	O

The	O
weighted	O
block	O
jackknife	O
tests	O
if	O
admixture	O
signals	O
are	O
uniform	O
across	O
the	O
whole	O
genome	O
and	O
therefore	O
reflect	O
the	O
same	O
population	O
history	O
.	O

By	O
removing	O
one	O
at	O
a	O
time	O
blocks	O
of	O
adjacent	O
sites	O
(	O
larger	O
than	O
the	O
extent	O
of	O
linkage	O
disequilibrium	O
)	O
and	O
computing	O
the	O
variance	O
of	O
the	O
D	O
statistic	O
or	O
f	O
^	O
values	O
over	O
the	O
entire	O
genome	O
M	O
times	O
leaving	O
each	O
block	O
of	O
the	O
genome	O
in	O
turn	O
,	O
and	O
then	O
multiplying	O
by	O
M	O
and	O
taking	O
the	O
square	O
root	O
we	O
generated	O
the	O
standard	O
error	O
.	O

The	O
number	O
of	O
standard	O
errors	O
by	O
which	O
D	O
or	O
f	O
^	O
differs	O
from	O
zero	O
is	O
the	O
Z	O
score	O
.	O

The	O
results	O
with	O
Z	O
scores	O
greater	O
than	O
3	O
in	O
absolute	O
value	O
were	O
qualified	O
as	O
statistically	O
significant	O
(	O
Green	O
et	O
al	O
.	O

2010	O
).	O

Nuclear	O
Genome	O
Phylogenetic	O
Tests	O

The	O
aligned	O
pseudohaploid	O
sequences	O
,	O
generated	O
by	O
mapping	O
reads	O
to	O
the	O
Bos	B-OG
indicus	I-OG
reference	O
,	O
were	O
divided	O
into	O
non	O
-	O
overlapping	O
blocks	O
of	O
1	O
Mb	O
.	O

If	O
each	O
of	O
the	O
five	O
taxa	O
contained	O
no	O
more	O
than	O
50	O
%	O
gaps	O
within	O
a	O
window	O
,	O
the	O
sequence	O
data	O
were	O
recoded	O
into	O
binary	O
characters	O
to	O
only	O
score	O
transversions	O
(	O
Rs	O
:	O
0	O
,	O
Ys	O
:	O
1	O
),	O
otherwise	O
the	O
window	O
was	O
recorded	O
as	O
having	O
insufficient	O
data	O
.	O

A	O
Maximum	O
Likelihood	O
phylogeny	O
under	O
the	O
BINGAMMA	O
model	O
and	O
with	O
the	O
water	B-OG
buffalo	I-OG
as	O
outgroup	O
was	O
then	O
computed	O
for	O
each	O
alignment	O
with	O
sufficient	O
data	O
using	O
RaxML	O
(	O
Stamatakis	O
2014	O
).	O

The	O
topology	O
of	O
each	O
phylogeny	O
was	O
evaluated	O
using	O
a	O
custom	O
Perl	O
script	O
that	O
made	O
use	O
of	O
the	O
ETE3	O
software	O
(	O
Huerta	O
-	O
Cepas	O
et	O
al	O
.	O

2016	O
).	O

The	O
lengths	O
of	O
admixed	O
genomic	O
regions	O
were	O
estimated	O
by	O
counting	O
the	O
number	O
of	O
consecutive	O
1	O
Mb	O
blocks	O
returning	O
the	O
respective	O
tree	O
topology	O
.	O

Due	O
to	O
the	O
presence	O
of	O
blocks	O
with	O
insufficient	O
data	O
,	O
these	O
measurements	O
are	O
likely	O
to	O
be	O
underestimates	O
.	O

Evaluation	O
of	O
the	O
lengths	O
of	O
genomic	O
regions	O
was	O
conducted	O
using	O
the	O
empirical	O
cumulative	O
distribution	O
function	O
in	O
R	O
,	O
with	O
default	O
parameters	O
.	O

Supplementary	O
Material	O

Supplementary	O
data	O
are	O
available	O
at	O
Molecular	O
Biology	O
and	O
Evolution	O
online	O
.	O

Author	O
Contributions	O

K	O
.	O
W	O
.,	O
J	O
.	O
M	O
.	O
S	O
.,	O
A	O
.	O
B	O
.,	O
and	O
M	O
.	O
H	O
.	O
conceived	O
the	O
study	O
;	O
A	O
.	O
B	O
.,	O
K	O
.	O
W	O
.,	O
J	O
.	O
L	O
.	O
A	O
.	O
P	O
.,	O
and	O
P	O
.	O
D	O
.	O
H	O
.	O
designed	O
laboratory	O
experiments	O
;	O
K	O
.	O
W	O
.,	O
U	O
.	O
T	O
.,	O
G	O
.	O
X	O
.,	O
P	O
.	O
D	O
.	O
H	O
.,	O
and	O
B	O
.	O
S	O
.	O
performed	O
lab	O
work	O
;	O
K	O
.	O
W	O
.,	O
S	O
.	O
H	O
.,	O
A	O
.	O
B	O
.,	O
J	O
.	O
A	O
.	O
C	O
.,	O
J	O
.	O
L	O
.	O
A	O
.	O
P	O
.,	O
and	O
P	O
.	O
D	O
.	O
H	O
.	O
coordinated	O
data	O
analysis	O
;	O
K	O
.	O
W	O
.,	O
S	O
.	O
H	O
.,	O
A	O
.	O
B	O
.,	O
and	O
P	O
.	O
D	O
.	O
H	O
.	O
performed	O
data	O
analysis	O
;	O
K	O
.	O
W	O
.,	O
A	O
.	O
B	O
.,	O
and	O
M	O
.	O
H	O
.	O
coordinated	O
writing	O
of	O
the	O
manuscript	O
;	O
K	O
.	O
W	O
.,	O
J	O
.	O
M	O
.	O
S	O
.,	O
and	O
M	O
.	O
H	O
.	O
obtained	O
funding	O
;	O
G	O
.	O
B	O
.,	O
A	O
.	O
N	O
.	O
B	O
.,	O
J	O
.	O
J	O
.	O
C	O
.,	O
R	O
.	O
D	O
.,	O
N	O
.	O
M	O
.,	O
H	O
.	O
O	O
.,	O
M	O
.	O
T	O
.,	O
S	O
.	O
T	O
.	O
T	O
.,	O
J	O
.	O
M	O
.	O
W	O
.,	O
and	O
W	O
.	O
Ż	O
.	O
provided	O
samples	O
.	O

All	O
authors	O
read	O
,	O
gave	O
comments	O
and	O
helped	O
revise	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

Supplementary	O
Material	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Associate	O
editor	O
:	O
Rasmus	O
Nielsen	O

Navigating	O
the	O
journey	O
of	O
Aboriginal	O
childhood	O
disability	O
:	O
a	O
qualitative	O
study	O
of	O
carers	O
’	O
interface	O
with	O
services	O

Background	O

The	O
disadvantage	O
experienced	O
by	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
with	O
a	O
disability	O
is	O
well	O
recognized	O
.	O

The	O
long	O
term	O
consequences	O
of	O
failing	O
to	O
address	O
disability	O
on	O
health	O
,	O
education	O
and	O
employment	O
underlies	O
the	O
importance	O
of	O
early	O
intervention	O
.	O

Caregivers	O
experience	O
a	O
disproportionate	O
burden	O
and	O
have	O
challenges	O
accessing	O
services	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
carer	O
journey	O
of	O
accessing	O
support	O
and	O
services	O
.	O

Methods	O

We	O
conducted	O
in	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
with	O
nineteen	O
parents	O
and	O
carers	O
of	O
Aboriginal	O
children	O
aged	O
0	O
–	O
8	O
years	O
.	O

The	O
children	O
were	O
patients	O
at	O
a	O
child	O
developmental	O
clinic	O
at	O
a	O
metropolitan	O
area	O
Aboriginal	O
health	O
service	O
in	O
Eastern	O
Australia	O
.	O

Interpretive	O
phenomenological	O
analysis	O
was	O
applied	O
to	O
transcribed	O
verbatim	O
accounts	O
.	O

Results	O

Four	O
themes	O
were	O
developed	O
using	O
the	O
‘	O
journey	O
’	O
metaphor	O
to	O
describe	O
the	O
carer	O
pathway	O
of	O
accessing	O
support	O
and	O
services	O
at	O
the	O
community	O
,	O
service	O
and	O
policy	O
levels	O
.	O

Themes	O
included	O
1	O
)	O
the	O
need	O
for	O
increased	O
signage	O
within	O
communities	O
via	O
community	O
education	O
,	O
information	O
and	O
awareness	O
,	O
2	O
)	O
wrong	O
way	O
signs	O
,	O
roundabouts	O
and	O
roadblocks	O
encountered	O
when	O
accessing	O
services	O
,	O
3	O
)	O
alternate	O
routes	O
can	O
facilitate	O
the	O
journey	O
,	O
and	O
4	O
)	O
incompatibility	O
of	O
inflexible	O
bureaucratic	O
road	O
rules	O
and	O
lived	O
realities	O
.	O

Conclusions	O

The	O
challenges	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
are	O
indisputable	O
and	O
these	O
can	O
be	O
compounded	O
for	O
people	O
experiencing	O
socio	O
-	O
economic	O
disadvantage	O
and	O
marginalisation	O
.	O

Overcoming	O
challenges	O
to	O
service	O
access	O
faced	O
by	O
carers	O
of	O
Aboriginal	O
children	O
with	O
a	O
disability	O
will	O
require	O
investment	O
in	O
community	O
,	O
services	O
and	O
policy	O
to	O
tailor	O
culturally	O
appropriate	O
models	O
of	O
care	O
.	O

Electronic	O
supplementary	O
material	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12913	O
-	O
016	O
-	O
1926	O
-	O
0	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O

Disparity	O
in	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
childhood	O
disability	O
-	O
impact	O
on	O
outcomes	O

The	O
opportunity	O
for	O
health	O
,	O
social	O
development	O
,	O
education	O
and	O
wellbeing	O
in	O
people	O
with	O
disabilities	O
can	O
be	O
easily	O
blighted	O
by	O
adverse	O
social	O
and	O
environmental	O
forces	O
and	O
commonly	O
the	O
needs	O
of	O
individuals	O
can	O
be	O
invisible	O
[	O
1	O
].	O

In	O
Australia	O
,	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
peoples	O
suffer	O
worse	O
health	O
and	O
more	O
disadvantage	O
than	O
other	O
Australians	O
,	O
the	O
effects	O
of	O
which	O
are	O
exacerbated	O
by	O
dispossession	O
,	O
disempowerment	O
and	O
racism	O
[	O
2	O
,	O
3	O
].	O

The	O
disparities	O
between	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
and	O
other	O
Australian	O
children	O
are	O
also	O
highlighted	O
in	O
experiences	O
of	O
disability	O
[	O
4	O
–	O
6	O
].	O

Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
are	O
more	O
likely	O
to	O
experience	O
hearing	O
loss	O
[	O
7	O
–	O
9	O
],	O
linked	O
to	O
higher	O
rates	O
of	O
middle	B-DS
ear	I-DS
disease	I-DS
such	O
as	O
otitis	B-DS
media	I-DS
[	O
4	O
],	O
and	O
to	O
require	O
assistance	O
with	O
self	O
-	O
care	O
,	O
mobility	O
or	O
communication	O
than	O
other	O
children	O
[	O
10	O
].	O

Disparities	O
have	O
also	O
been	O
reported	O
in	O
the	O
prevalence	O
of	O
developmental	B-DS
delay	I-DS
[	O
11	O
].	O

The	O
high	O
prevalence	O
of	O
disability	O
can	O
have	O
life	O
-	O
long	O
negative	O
consequences	O
on	O
health	O
,	O
education	O
and	O
employment	O
outcomes	O
for	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
[	O
9	O
,	O
12	O
].	O

Evidence	O
links	O
low	O
educational	O
achievement	O
to	O
involvement	O
in	O
the	O
criminal	O
justice	O
system	O
[	O
13	O
].	O

On	O
average	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
youth	O
are	O
detained	O
within	O
the	O
juvenile	O
justice	O
system	O
at	O
24	O
times	O
the	O
rate	O
of	O
other	O
youth	O
[	O
6	O
]	O
and	O
are	O
4	O
to	O
5	O
times	O
more	O
likely	O
to	O
have	O
an	O
intellectual	B-DS
disability	I-DS
than	O
the	O
general	O
population	O
[	O
14	O
].	O

Adolescents	O
coming	O
into	O
contact	O
with	O
the	O
juvenile	O
justice	O
system	O
are	O
more	O
likely	O
to	O
be	O
incarcerated	O
as	O
an	O
adult	O
[	O
15	O
].	O

The	O
World	O
Health	O
Organization	O
recognizes	O
the	O
importance	O
of	O
social	O
determinants	O
in	O
influencing	O
health	O
outcomes	O
,	O
and	O
the	O
Close	O
the	O
Gap	O
Campaign	O
is	O
an	O
important	O
focus	O
of	O
Australian	O
government	O
and	O
non	O
-	O
government	O
organisations	O
to	O
address	O
the	O
needs	O
of	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
people	O
.	O

Internationally	O
,	O
indigenous	O
children	O
with	O
a	O
disability	O
are	O
considered	O
‘	O
doubly	O
disadvantaged	O
’	O
[	O
16	O
,	O
17	O
].	O

A	O
recent	O
longitudinal	O
cohort	O
study	O
of	O
development	O
in	O
urban	O
Aboriginal	O
children	O
found	O
that	O
high	O
levels	O
of	O
socio	O
-	O
economic	O
disadvantage	O
are	O
a	O
predictor	O
for	O
developmental	O
progress	O
[	O
18	O
].	O

While	O
the	O
high	O
levels	O
of	O
socio	O
-	O
economic	O
disadvantage	O
increases	O
the	O
chance	O
of	O
having	O
a	O
disability	O
,	O
the	O
high	O
rates	O
of	O
disability	O
can	O
contribute	O
to	O
socio	O
-	O
economic	O
disadvantage	O
,	O
thus	O
reinforcing	O
a	O
life	O
-	O
long	O
cycle	O
[	O
6	O
].	O

Impact	O
of	O
service	O
access	O
barriers	O
on	O
early	O
intervention	O

Early	O
intervention	O
is	O
crucial	O
to	O
counteracting	O
the	O
negative	O
impact	O
of	O
disability	O
for	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
[	O
4	O
].	O

It	O
is	O
necessary	O
to	O
facilitate	O
timely	O
access	O
of	O
children	O
and	O
their	O
families	O
to	O
appropriate	O
health	O
services	O
,	O
social	O
support	O
services	O
and	O
treatment	O
.	O

This	O
involves	O
interacting	O
with	O
a	O
health	O
care	O
system	O
that	O
is	O
not	O
always	O
accommodating	O
of	O
unique	O
,	O
socio	O
-	O
cultural	O
needs	O
.	O

Involvement	O
of	O
sectors	O
other	O
than	O
health	O
,	O
such	O
as	O
education	O
and	O
social	O
services	O
,	O
is	O
also	O
required	O
for	O
effective	O
early	O
intervention	O
but	O
increases	O
the	O
complexity	O
of	O
engagement	O
[	O
18	O
–	O
20	O
].	O

Carers	O
report	O
a	O
number	O
of	O
barriers	O
to	O
accessing	O
early	O
intervention	O
and	O
support	O
services	O
[	O
21	O
].	O

Lack	O
of	O
awareness	O
of	O
appropriate	O
disability	O
services	O
,	O
frequent	O
absence	O
of	O
culturally	O
appropriate	O
support	O
,	O
insufficient	O
resources	O
to	O
provide	O
care	O
,	O
and	O
a	O
loss	O
of	O
social	O
-	O
capital	O
-	O
based	O
support	O
due	O
to	O
fractured	O
family	O
and	O
community	O
structures	O
have	O
been	O
reported	O
as	O
barriers	O
to	O
service	O
access	O
which	O
impedes	O
early	O
intervention	O
[	O
21	O
,	O
22	O
].	O

A	O
holistic	O
approach	O
to	O
service	O
access	O

Improving	O
service	O
access	O
is	O
important	O
to	O
addressing	O
health	O
disparities	O
[	O
23	O
].	O

Influencing	O
factors	O
exist	O
at	O
the	O
micro	O
,	O
meso	O
and	O
macro	O
levels	O
[	O
24	O
–	O
27	O
].	O

A	O
holistic	O
approach	O
is	O
required	O
when	O
addressing	O
service	O
access	O
issues	O
for	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
families	O
of	O
a	O
child	O
with	O
a	O
disability	O
[	O
25	O
,	O
28	O
].	O

Desirable	O
outcomes	O
are	O
unlikely	O
to	O
be	O
achieved	O
if	O
the	O
interdependency	O
of	O
influencing	O
factors	O
is	O
not	O
addressed	O
.	O

For	O
example	O
,	O
carers	O
play	O
a	O
central	O
role	O
as	O
navigators	O
of	O
their	O
child	O
’	O
s	O
care	O
[	O
29	O
],	O
thus	O
,	O
exploring	O
the	O
experiences	O
of	O
carers	O
is	O
imperative	O
in	O
understanding	O
service	O
access	O
for	O
children	O
with	O
a	O
disability	O
.	O

Data	O
on	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
children	O
with	O
a	O
disability	O
are	O
limited	O
,	O
particularly	O
in	O
urban	O
populations	O
and	O
this	O
inhibits	O
adequate	O
service	O
planning	O
[	O
30	O
].	O

Although	O
over	O
half	O
of	O
the	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
population	O
live	O
in	O
urban	O
or	O
regional	O
areas	O
,	O
most	O
of	O
the	O
research	O
on	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
childhood	O
disability	O
is	O
on	O
rural	O
or	O
remote	O
populations	O
[	O
24	O
,	O
31	O
–	O
33	O
].	O

It	O
is	O
important	O
to	O
address	O
this	O
gap	O
in	O
knowledge	O
as	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
populations	O
can	O
be	O
less	O
visible	O
in	O
urban	O
areas	O
and	O
available	O
services	O
are	O
not	O
necessarily	O
appropriate	O
or	O
accessible	O
[	O
21	O
,	O
32	O
,	O
34	O
,	O
35	O
].	O

To	O
address	O
this	O
paucity	O
of	O
information	O
,	O
we	O
investigated	O
the	O
experiences	O
of	O
Aboriginal	O
carers	O
to	O
inform	O
service	O
planning	O
and	O
access	O
to	O
early	O
intervention	O
.	O

Methods	O

We	O
aimed	O
to	O
describe	O
the	O
carer	O
experience	O
of	O
accessing	O
support	O
and	O
services	O
and	O
investigate	O
the	O
barriers	O
and	O
facilitators	O
to	O
service	O
access	O
from	O
the	O
perspective	O
of	O
carers	O
.	O

We	O
used	O
a	O
socio	O
-	O
ecological	O
framework	O
to	O
situate	O
carers	O
’	O
experiences	O
at	O
the	O
macro	O
-	O
(	O
government	O
),	O
exo	O
-	O
(	O
organizational	O
)	O
and	O
meso	O
-	O
(	O
provider	O
/	O
community	O
)	O
system	O
levels	O
in	O
recognition	O
of	O
the	O
interaction	O
and	O
inter	O
-	O
dependence	O
of	O
these	O
environmental	O
factors	O
.	O

The	O
carer	O
,	O
child	O
and	O
family	O
are	O
positioned	O
within	O
the	O
centre	O
,	O
or	O
the	O
individual	O
-	O
level	O
,	O
of	O
the	O
socio	O
-	O
ecological	O
framework	O
.	O

The	O
micro	O
-	O
level	O
(	O
individual	O
)	O
experiences	O
included	O
caring	O
for	O
the	O
child	O
and	O
family	O
,	O
challenges	O
and	O
facilitators	O
to	O
this	O
caring	O
,	O
carer	O
health	O
and	O
wellbeing	O
and	O
associated	O
financial	O
expenses	O
and	O
non	O
-	O
economic	O
costs	O
(	O
manuscript	O
under	O
review	O
).	O

This	O
paper	O
reports	O
on	O
the	O
carers	O
’	O
interaction	O
with	O
systems	O
beyond	O
their	O
immediate	O
family	O
;	O
that	O
being	O
,	O
the	O
community	O
,	O
service	O
and	O
policy	O
levels	O
of	O
the	O
framework	O
in	O
pursuit	O
of	O
optimal	O
outcomes	O
for	O
their	O
child	O
with	O
a	O
disability	O
.	O

To	O
understand	O
carers	O
’	O
experiences	O
and	O
perspectives	O
of	O
seeking	O
and	O
obtaining	O
health	O
and	O
social	O
service	O
supports	O
for	O
their	O
children	O
,	O
we	O
used	O
a	O
phenomenological	O
approach	O
[	O
36	O
].	O

Context	O
,	O
participants	O
and	O
recruitment	O

Participants	O
were	O
parents	O
or	O
informal	O
primary	O
carers	O
(	O
hereafter	O
,	O
carers	O
)	O
of	O
children	O
aged	O
0	O
–	O
8	O
years	O
who	O
were	O
patients	O
at	O
a	O
child	O
development	O
clinic	O
at	O
a	O
metropolitan	O
area	O
Aboriginal	O
health	O
service	O
.	O

The	O
clinic	O
caters	O
to	O
children	O
with	O
developmental	B-DS
problems	I-DS
aged	O
from	O
birth	O
to	O
16	O
years	O
and	O
deals	O
with	O
the	O
identification	O
and	O
management	O
of	O
conditions	O
such	O
as	O
attention	B-DS
deficit	I-DS
hyperactivity	I-DS
disorder	I-DS
,	O
behavioural	O
problems	O
and	O
developmental	B-DS
delays	I-DS
.	O

Clinic	O
staff	O
informed	O
potential	O
participants	O
about	O
the	O
study	O
and	O
supplied	O
information	O
sheets	O
and	O
flyers	O
to	O
interested	O
parties	O
.	O

The	O
term	O
disability	O
was	O
deliberately	O
kept	O
broad	O
to	O
include	O
a	O
range	O
of	O
disability	O
experiences	O
including	O
mild	O
,	O
moderate	O
and	O
severe	O
,	O
involving	O
physical	O
,	O
intellectual	O
or	O
developmental	O
issues	O
.	O

Recruitment	O
continued	O
until	O
no	O
new	O
issues	O
emerged	O
.	O

Data	O
collection	O

The	O
research	O
team	O
was	O
co	O
-	O
led	O
by	O
Aboriginal	O
and	O
non	O
-	O
Aboriginal	O
team	O
members	O
,	O
each	O
with	O
designated	O
tasks	O
and	O
expertise	O
,	O
who	O
frequently	O
met	O
to	O
discuss	O
research	O
processes	O
,	O
debrief	O
about	O
ongoing	O
data	O
collection	O
,	O
and	O
strategize	O
to	O
overcome	O
logistical	O
challenges	O
.	O

To	O
capture	O
the	O
range	O
of	O
experiences	O
and	O
perspectives	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
,	O
we	O
conducted	O
in	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
at	O
two	O
time	O
-	O
points	O
with	O
each	O
participant	O
.	O

Initial	O
interviews	O
were	O
conducted	O
at	O
the	O
health	O
facility	O
in	O
private	O
clinic	O
rooms	O
with	O
one	O
of	O
two	O
researchers	O
trained	O
in	O
qualitative	O
methods	O
(	O
AA	O
&	O
BB	O
).	O

These	O
interviews	O
lasted	O
approximately	O
20	O
–	O
60	O
min	O
and	O
often	O
occurred	O
opportunistically	O
while	O
waiting	O
for	O
or	O
immediately	O
following	O
their	O
child	O
’	O
s	O
clinic	O
appointment	O
.	O

Children	O
sometimes	O
were	O
in	O
the	O
room	O
during	O
interviews	O
,	O
usually	O
playing	O
or	O
sleeping	O
,	O
because	O
no	O
other	O
supervision	O
was	O
available	O
.	O

Follow	O
-	O
up	O
interviews	O
were	O
conducted	O
with	O
participants	O
to	O
ascertain	O
and	O
document	O
activities	O
related	O
to	O
the	O
child	O
’	O
s	O
disability	O
,	O
services	O
sought	O
,	O
interactions	O
with	O
health	O
or	O
other	O
service	O
professionals	O
,	O
and	O
barriers	O
and	O
facilitators	O
to	O
support	O
since	O
the	O
first	O
interview	O
.	O

Follow	O
-	O
up	O
interviews	O
took	O
place	O
via	O
telephone	O
if	O
participants	O
were	O
unable	O
to	O
attend	O
the	O
service	O
in	O
person	O
.	O

All	O
follow	O
-	O
up	O
interviews	O
were	O
conducted	O
within	O
6	O
–	O
12	O
months	O
of	O
the	O
initial	O
interviews	O
according	O
to	O
the	O
preference	O
and	O
availability	O
of	O
participants	O
.	O

Participants	O
were	O
reimbursed	O
for	O
travel	O
and	O
child	O
care	O
expenses	O
incurred	O
as	O
a	O
result	O
of	O
participation	O
.	O

Data	O
collection	O
took	O
place	O
from	O
April	O
2013	O
to	O
June	O
2015	O
.	O

Interviewers	O

The	O
Aboriginal	O
leaders	O
and	O
cultural	O
mentors	O
of	O
the	O
project	O
were	O
unable	O
to	O
undertake	O
interviews	O
given	O
their	O
management	O
roles	O
at	O
the	O
health	O
facility	O
.	O

This	O
meant	O
that	O
the	O
non	O
-	O
Aboriginal	O
team	O
members	O
,	O
who	O
worked	O
in	O
another	O
area	O
of	O
the	O
health	O
service	O
one	O
or	O
more	O
days	O
each	O
week	O
,	O
were	O
designated	O
to	O
conduct	O
the	O
interviews	O
whenever	O
clinic	O
staff	O
telephoned	O
with	O
an	O
eligible	O
consenting	O
participant	O
.	O

One	O
of	O
these	O
interviewers	O
was	O
a	O
general	O
practitioner	O
(	O
GP	O
)	O
at	O
the	O
health	O
service	O
and	O
a	O
university	O
academic	O
.	O

She	O
had	O
met	O
some	O
of	O
the	O
participants	O
previously	O
in	O
the	O
context	O
of	O
primary	O
care	O
consultations	O
,	O
however	O
she	O
was	O
not	O
involved	O
directly	O
in	O
the	O
child	O
’	O
s	O
healthcare	O
or	O
the	O
clinic	O
.	O

Prior	O
to	O
commencing	O
interviews	O
,	O
she	O
explained	O
the	O
research	O
role	O
to	O
participants	O
as	O
separate	O
to	O
her	O
GP	O
role	O
.	O

As	O
a	O
non	O
-	O
Aboriginal	O
woman	O
having	O
worked	O
part	O
-	O
time	O
for	O
over	O
twenty	O
years	O
at	O
the	O
health	O
service	O
where	O
this	O
research	O
was	O
conducted	O
,	O
this	O
interviewer	O
had	O
extensive	O
knowledge	O
and	O
experience	O
within	O
the	O
local	O
community	O
and	O
health	O
service	O
.	O

The	O
second	O
interviewer	O
,	O
also	O
a	O
non	O
-	O
Aboriginal	O
woman	O
,	O
had	O
qualifications	O
in	O
psychology	O
and	O
was	O
a	O
health	O
services	O
researcher	O
based	O
at	O
a	O
university	O
.	O

She	O
had	O
been	O
a	O
weekly	O
visiting	O
counsellor	O
at	O
the	O
health	O
service	O
for	O
8	O
years	O
.	O

Two	O
local	O
Aboriginal	O
elders	O
(	O
CC	O
&	O
DD	O
)	O
co	O
-	O
led	O
this	O
project	O
and	O
acted	O
as	O
cultural	O
mentors	O
who	O
contributed	O
to	O
the	O
study	O
design	O
,	O
recruitment	O
and	O
analysis	O
.	O

At	O
each	O
stage	O
,	O
they	O
offered	O
perspectives	O
of	O
findings	O
conveyed	O
in	O
repeated	O
discussions	O
with	O
the	O
interviewers	O
.	O

Each	O
described	O
their	O
positioning	O
in	O
relation	O
to	O
this	O
research	O
and	O
described	O
their	O
conscious	O
biases	O
to	O
clarify	O
their	O
interpretations	O
.	O

Some	O
,	O
but	O
not	O
all	O
,	O
members	O
of	O
this	O
team	O
had	O
the	O
experience	O
of	O
parenting	O
or	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
.	O

The	O
interviewers	O
met	O
periodically	O
to	O
debrief	O
and	O
consider	O
interview	O
proceedings	O
.	O

Each	O
provided	O
important	O
insights	O
that	O
informed	O
the	O
others	O
’	O
interpretations	O
.	O

The	O
cultural	O
mentors	O
and	O
GP	O
interviewer	O
provided	O
service	O
and	O
community	O
context	O
from	O
Aboriginal	O
and	O
non	O
-	O
Aboriginal	O
perspectives	O
,	O
respectively	O
,	O
while	O
the	O
university	O
interviewer	O
offered	O
a	O
less	O
entrenched	O
experience	O
of	O
the	O
community	O
,	O
yet	O
with	O
an	O
appreciation	O
of	O
historical	O
and	O
social	O
context	O
.	O

The	O
semi	O
-	O
structured	O
interviews	O
attended	O
primarily	O
to	O
the	O
carer	O
’	O
s	O
own	O
narrative	O
.	O

Interview	O
topics	O
were	O
derived	O
from	O
a	O
literature	O
review	O
[	O
24	O
],	O
experience	O
and	O
expertise	O
of	O
cultural	O
mentors	O
who	O
were	O
also	O
carers	O
,	O
and	O
the	O
social	O
determinants	O
of	O
health	O
and	O
social	O
capital	O
frameworks	O
[	O
2	O
,	O
17	O
,	O
37	O
]	O
(	O
Additional	O
file	O
1	O
).	O

During	O
interviews	O
,	O
we	O
explored	O
participant	O
’	O
s	O
experiences	O
with	O
the	O
child	O
’	O
s	O
disability	O
,	O
their	O
meanings	O
and	O
interpretations	O
of	O
these	O
experiences	O
,	O
and	O
their	O
experiences	O
seeking	O
and	O
obtaining	O
support	O
and	O
services	O
.	O

Attention	O
was	O
paid	O
to	O
experiences	O
of	O
intake	O
and	O
triage	O
,	O
respite	O
use	O
and	O
need	O
,	O
allied	O
health	O
service	O
access	O
and	O
needs	O
and	O
preferences	O
for	O
information	O
,	O
services	O
and	O
support	O
.	O

Limited	O
demographic	O
and	O
health	O
-	O
related	O
information	O
was	O
collected	O
during	O
the	O
interviews	O
.	O

Upon	O
the	O
follow	O
-	O
up	O
interview	O
,	O
the	O
interviewer	O
summarised	O
thematic	O
content	O
of	O
the	O
previous	O
interview	O
with	O
participants	O
to	O
seek	O
confirmation	O
of	O
its	O
validity	O
[	O
38	O
].	O

Any	O
noted	O
discrepancies	O
were	O
discussed	O
,	O
clarified	O
and	O
resolved	O
to	O
the	O
satisfaction	O
of	O
the	O
participant	O
.	O

Data	O
analysis	O
and	O
trustworthiness	O

Analysis	O
began	O
with	O
development	O
of	O
a	O
contact	O
summary	O
sheet	O
with	O
key	O
demographic	O
information	O
and	O
emergent	O
issues	O
[	O
39	O
]	O
for	O
each	O
interview	O
.	O

Interpretative	O
phenomenological	O
analysis	O
(	O
IPA	O
)	O
was	O
used	O
to	O
analyse	O
carers	O
’	O
experiences	O
[	O
36	O
]	O
as	O
this	O
approach	O
centres	O
on	O
individuals	O
ascribing	O
meaning	O
to	O
their	O
experiences	O
in	O
their	O
interactions	O
with	O
the	O
environment	O
.	O

IPA	O
is	O
a	O
set	O
of	O
systematic	O
processes	O
that	O
shift	O
from	O
phenomenological	O
to	O
interpretive	O
while	O
focusing	O
on	O
the	O
participant	O
’	O
s	O
perspective	O
and	O
understandings	O
in	O
different	O
contexts	O
[	O
36	O
].	O

It	O
is	O
an	O
iterative	O
,	O
inductive	O
and	O
flexible	O
approach	O
involving	O
close	O
reading	O
and	O
re	O
-	O
reading	O
of	O
transcripts	O
while	O
note	O
-	O
taking	O
in	O
margins	O
,	O
‘	O
bracketing	O
’	O
the	O
analyst	O
’	O
s	O
critical	O
perspective	O
,	O
recording	O
critical	O
and	O
interpretive	O
comments	O
in	O
a	O
reflexive	O
diary	O
;	O
re	O
-	O
reading	O
the	O
text	O
and	O
identifying	O
codes	O
and	O
themes	O
that	O
best	O
capture	O
the	O
essential	O
qualities	O
of	O
that	O
interview	O
while	O
also	O
looking	O
for	O
connections	O
between	O
themes	O
;	O
revisiting	O
earlier	O
transcripts	O
to	O
re	O
-	O
consider	O
data	O
;	O
clustering	O
themes	O
and	O
concepts	O
and	O
developing	O
an	O
overall	O
structure	O
using	O
excerpts	O
from	O
interviews	O
;	O
and	O
re	O
-	O
assessing	O
and	O
revising	O
new	O
themes	O
against	O
earlier	O
data	O
[	O
40	O
].	O

One	O
researcher	O
(	O
AA	O
)	O
undertook	O
preliminary	O
analysis	O
wherein	O
transcripts	O
were	O
read	O
,	O
notes	O
added	O
to	O
the	O
document	O
,	O
and	O
a	O
coding	O
system	O
developed	O
to	O
elucidate	O
categories	O
.	O

To	O
facilitate	O
rigor	O
,	O
a	O
second	O
researcher	O
(	O
EE	O
)	O
independently	O
coded	O
unmarked	O
transcripts	O
[	O
41	O
].	O

The	O
interviewers	O
had	O
frequent	O
informal	O
and	O
formal	O
discussions	O
regarding	O
code	O
development	O
and	O
emerging	O
findings	O
with	O
the	O
lead	O
cultural	O
mentor	O
(	O
CC	O
)	O
who	O
provided	O
formative	O
insights	O
throughout	O
the	O
data	O
collection	O
and	O
preliminary	O
analysis	O
period	O
;	O
divergences	O
in	O
the	O
coding	O
scheme	O
were	O
discussed	O
until	O
consensus	O
was	O
reached	O
.	O

The	O
remaining	O
interviews	O
were	O
coded	O
according	O
to	O
the	O
developed	O
scheme	O
,	O
yet	O
emergent	O
categories	O
were	O
documented	O
and	O
considered	O
throughout	O
the	O
analysis	O
.	O

Categories	O
were	O
then	O
collapsed	O
into	O
themes	O
.	O

Preliminary	O
and	O
developed	O
themes	O
were	O
discussed	O
with	O
the	O
full	O
project	O
team	O
prior	O
to	O
cessation	O
of	O
analysis	O
and	O
this	O
was	O
followed	O
by	O
another	O
extensive	O
discussion	O
of	O
key	O
themes	O
with	O
the	O
lead	O
cultural	O
mentor	O
.	O

Transcript	O
excerpts	O
which	O
supported	O
each	O
theme	O
were	O
copied	O
into	O
a	O
Microsoft	O
Word	O
file	O
along	O
with	O
supporting	O
field	O
notes	O
.	O

All	O
supporting	O
evidence	O
was	O
then	O
considered	O
,	O
contextualised	O
and	O
written	O
into	O
an	O
account	O
illustrating	O
participants	O
’	O
experiences	O
and	O
perspectives	O
[	O
42	O
].	O

To	O
further	O
enhance	O
credibility	O
and	O
trustworthiness	O
,	O
stakeholder	O
checks	O
were	O
undertaken	O
[	O
41	O
],	O
whereby	O
preliminary	O
analysis	O
of	O
findings	O
was	O
presented	O
to	O
clinic	O
staff	O
,	O
some	O
of	O
whom	O
were	O
also	O
carers	O
of	O
an	O
Aboriginal	O
child	O
with	O
a	O
disability	O
.	O

Additional	O
feedback	O
from	O
this	O
group	O
was	O
incorporated	O
into	O
theme	O
development	O
.	O

Ethical	O
considerations	O

Ethical	O
approval	O
was	O
granted	O
by	O
the	O
Aboriginal	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
AH	O
&	O
MRC	O
)	O
(	O
762	O
/	O
10	O
)	O
and	O
University	O
of	O
Technology	O
Sydney	O
Human	B-OG
Research	O
Ethics	O
Committee	O
(	O
UTS	O
HREC	O
2011	O
-	O
417R	O
).	O

The	O
study	O
adhered	O
to	O
key	O
principles	O
for	O
research	O
with	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
peoples	O
as	O
espoused	O
by	O
the	O
AH	O
&	O
MRC	O
.	O

Briefly	O
,	O
these	O
included	O
the	O
involvement	O
in	O
and	O
control	O
of	O
all	O
research	O
stages	O
by	O
the	O
Aboriginal	O
health	O
service	O
,	O
direct	O
consultation	O
with	O
members	O
of	O
the	O
community	O
affected	O
by	O
the	O
research	O
,	O
reimbursement	O
of	O
expenses	O
associated	O
with	O
participation	O
,	O
and	O
intended	O
outcomes	O
that	O
inform	O
the	O
design	O
and	O
delivery	O
of	O
needed	O
culturally	O
appropriate	O
services	O
for	O
children	O
and	O
their	O
families	O
and	O
are	O
aimed	O
at	O
increasing	O
the	O
community	O
’	O
s	O
knowledge	O
of	O
and	O
ways	O
to	O
access	O
support	O
and	O
services	O
[	O
43	O
].	O

Confidentiality	O
of	O
discussions	O
was	O
assured	O
and	O
participants	O
were	O
advised	O
that	O
their	O
care	O
or	O
status	O
at	O
the	O
health	O
service	O
would	O
be	O
influenced	O
neither	O
by	O
participation	O
nor	O
divulgence	O
.	O

Permission	O
to	O
audio	O
record	O
interviews	O
was	O
obtained	O
from	O
each	O
participant	O
.	O

Names	O
were	O
replaced	O
with	O
pseudonyms	O
and	O
identifying	O
information	O
was	O
removed	O
following	O
verbatim	O
transcription	O
of	O
recordings	O
.	O

Study	O
findings	O
are	O
reported	O
according	O
to	O
the	O
consolidated	O
criteria	O
for	O
reporting	O
qualitative	O
research	O
guidelines	O
[	O
44	O
].	O

Availability	O
of	O
data	O
and	O
materials	O

The	O
data	O
supporting	O
the	O
conclusions	O
of	O
this	O
article	O
are	O
included	O
within	O
the	O
article	O
in	O
the	O
form	O
of	O
interview	O
excerpts	O
.	O

Full	O
interview	O
transcripts	O
remain	O
the	O
property	O
of	O
the	O
participating	O
Aboriginal	O
Community	O
Controlled	O
Health	O
Organization	O
.	O

The	O
journey	O
metaphor	O

Pathways	O
and	O
journeys	O
have	O
increasingly	O
been	O
used	O
to	O
depict	O
experiences	O
of	O
health	O
conditions	O
and	O
service	O
use	O
as	O
these	O
terms	O
reflect	O
movement	O
or	O
progression	O
,	O
not	O
always	O
in	O
a	O
linear	O
direction	O
,	O
but	O
generally	O
resulting	O
in	O
an	O
accumulation	O
or	O
loss	O
of	O
knowledge	O
or	O
other	O
resources	O
over	O
time	O
[	O
45	O
].	O

We	O
often	O
refer	O
to	O
gaining	O
new	O
experience	O
or	O
skills	O
as	O
‘	O
going	O
on	O
a	O
journey	O
’.	O

This	O
metaphor	O
implies	O
that	O
there	O
is	O
a	O
process	O
,	O
a	O
starting	O
point	O
and	O
a	O
destination	O
on	O
which	O
people	O
travel	O
,	O
usually	O
figuratively	O
,	O
in	O
acquisition	O
of	O
information	O
or	O
resources	O
.	O

This	O
is	O
often	O
an	O
ongoing	O
process	O
that	O
involves	O
a	O
series	O
of	O
points	O
and	O
opportunities	O
for	O
learning	O
and	O
this	O
occurs	O
over	O
a	O
long	O
span	O
of	O
time	O
.	O

Some	O
continue	O
along	O
a	O
pre	O
-	O
determined	O
route	O
or	O
course	O
of	O
action	O
,	O
while	O
others	O
forge	O
a	O
path	O
as	O
a	O
result	O
of	O
circumstances	O
or	O
opportunity	O
.	O

The	O
term	O
‘	O
clinical	O
pathway	O
’	O
is	O
used	O
in	O
health	O
to	O
depict	O
standardised	O
,	O
evidence	O
-	O
based	O
multidisciplinary	O
management	O
plans	O
,	O
of	O
a	O
sequence	O
of	O
interventions	O
,	O
timeframes	O
,	O
milestones	O
and	O
expected	O
outcomes	O
for	O
a	O
patient	O
group	O
[	O
46	O
].	O

These	O
pathways	O
are	O
often	O
depicted	O
in	O
resources	O
to	O
map	O
the	O
patient	O
journey	O
,	O
to	O
foster	O
an	O
understanding	O
of	O
the	O
whole	O
pathway	O
(	O
including	O
environmental	O
influences	O
)	O
and	O
its	O
distinct	O
components	O
,	O
including	O
specific	O
steps	O
or	O
critical	O
points	O
along	O
the	O
care	O
pathway	O
[	O
47	O
].	O

Pathways	O
to	O
service	O
delivery	O
have	O
likewise	O
been	O
depicted	O
as	O
roadmaps	O
.	O

Although	O
we	O
had	O
not	O
anticipated	O
,	O
originally	O
,	O
use	O
of	O
metaphor	O
to	O
help	O
us	O
understand	O
caregiving	O
or	O
care	O
-	O
seeking	O
behaviour	O
,	O
we	O
became	O
aware	O
of	O
the	O
symbols	O
,	O
words	O
and	O
metaphors	O
used	O
to	O
convey	O
interpretations	O
of	O
meaning	O
[	O
45	O
].	O

We	O
began	O
the	O
analysis	O
process	O
by	O
trying	O
to	O
describe	O
what	O
we	O
saw	O
in	O
experiences	O
.	O

Metaphors	O
arose	O
from	O
our	O
and	O
participants	O
’	O
descriptive	O
language	O
related	O
to	O
the	O
experiences	O
.	O

The	O
visual	O
representation	O
of	O
these	O
types	O
of	O
concepts	O
through	O
metaphors	O
aligns	O
with	O
the	O
narrative	O
approach	O
of	O
telling	O
stories	O
that	O
values	O
the	O
spoken	O
word	O
and	O
oral	O
history	O
tradition	O
in	O
Aboriginal	O
culture	O
and	O
is	O
considered	O
a	O
respectful	O
research	O
technique	O
[	O
48	O
].	O

Following	O
the	O
second	O
stakeholder	O
check	O
with	O
cultural	O
mentors	O
(	O
CC	O
&	O
DD	O
)	O
this	O
depiction	O
was	O
deemed	O
a	O
culturally	O
congruent	O
representation	O
of	O
the	O
findings	O
.	O

We	O
link	O
the	O
findings	O
to	O
this	O
metaphor	O
in	O
an	O
effort	O
to	O
communicate	O
this	O
complex	O
phenomenon	O
.	O

Results	O

Participants	O
were	O
19	O
carers	O
of	O
Aboriginal	O
children	O
.	O

They	O
were	O
all	O
women	B-OG
,	O
more	O
than	O
half	O
of	O
whom	O
(	O
n	O
=	O
10	O
)	O
were	O
lone	O
carers	O
(	O
without	O
a	O
partner	O
or	O
spouse	O
),	O
and	O
were	O
taking	O
care	O
of	O
60	O
children	O
at	O
home	O
,	O
half	O
of	O
whom	O
were	O
identified	O
as	O
having	O
a	O
disability	O
or	O
developmental	B-DS
delay	I-DS
.	O

The	O
majority	O
of	O
participants	O
were	O
the	O
mothers	O
of	O
the	O
children	O
(	O
n	O
=	O
16	O
),	O
and	O
three	O
were	O
grandmothers	O
.	O

Factors	O
that	O
influenced	O
carer	O
journeys	O
to	O
access	O
support	O
and	O
services	O
reflected	O
their	O
interactions	O
with	O
community	O
,	O
service	O
and	O
policy	O
levels	O
.	O

Themes	O
depicting	O
these	O
journeys	O
included	O
:	O
need	O
for	O
increased	O
signage	O
via	O
community	O
education	O
,	O
information	O
and	O
awareness	O
;	O
wrong	O
way	O
signs	O
,	O
roundabouts	O
and	O
roadblocks	O
encountered	O
when	O
accessing	O
services	O
;	O
alternate	O
routes	O
can	O
facilitate	O
the	O
journey	O
;	O
and	O
the	O
incompatibility	O
of	O
inflexible	O
bureaucratic	O
road	O
rules	O
and	O
lived	O
realities	O
.	O

Need	O
for	O
‘	O
increased	O
signage	O
’	O
within	O
communities	O
via	O
community	O
education	O
,	O
information	O
and	O
awareness	O

The	O
community	O
,	O
defined	O
as	O
an	O
informal	O
network	O
of	O
extended	O
family	O
,	O
friends	O
and	O
other	O
carers	O
,	O
played	O
a	O
key	O
role	O
in	O
carers	O
’	O
accessing	O
support	O
and	O
services	O
.	O

Due	O
to	O
this	O
influence	O
,	O
carers	O
emphasised	O
the	O
need	O
for	O
investment	O
in	O
building	O
community	O
capacity	O
as	O
a	O
support	O
mechanism	O
through	O
increased	O
education	O
,	O
information	O
and	O
awareness	O
.	O

Carers	O
accessed	O
advice	O
and	O
recommendations	O
from	O
community	O
members	O
on	O
the	O
developmental	O
progress	O
of	O
children	O
and	O
available	O
services	O
.	O

Some	O
carers	O
experienced	O
tension	O
between	O
respecting	O
community	O
advice	O
while	O
knowing	O
something	O
is	O
wrong	O
with	O
their	O
child	O
.	O

Community	O
advice	O
in	O
this	O
context	O
is	O
inclusive	O
of	O
cultural	O
advice	O
as	O
identified	O
by	O
carers	O
.	O

Advice	O
by	O
community	O
members	O
that	O
there	O
was	O
nothing	O
wrong	O
with	O
a	O
child	O
contributed	O
to	O
delays	O
in	O
seeking	O
diagnoses	O
and	O
treatment	O
.	O
“	O
Yeah	O
,	O
you	O
let	O
things	O
slide	O
.	O

You	O
just	O
–	O
it	O
’	O
s	O
not	O
that	O
you	O
don	O
’	O
t	O
want	O
to	O
put	O
the	O
effort	O
into	O
it	O
and	O
go	O
and	O
sit	O
around	O
and	O
take	O
them	O
out	O
of	O
school	O
or	O
anything	O
like	O
that	O
,	O
it	O
’	O
s	O
just	O
you	O
’	O
ve	O
got	O
your	O
elder	O
saying	O
to	O
you	O
,	O
“	O
No	O
,	O
they	O
’	O
re	O
right	O
.	O

They	O
’	O
re	O
right	O
.	O

Don	O
’	O
t	O
worry	O
about	O
it	O
.	O

They	O
’	O
ll	O
pick	O
up	O
in	O
their	O
own	O
time	O
,”	O
and	O
sometimes	O
they	O
don	O
’	O
t	O
.”	O
(	O
Rita	O
)	O

The	O
lack	O
of	O
community	O
education	O
,	O
information	O
and	O
awareness	O
around	O
disability	O
and	O
available	O
services	O
evidently	O
impeded	O
access	O
to	O
support	O
and	O
services	O
.	O
“	O
It	O
’	O
s	O
not	O
advertised	O
that	O
they	O
have	O
this	O
other	O
health	O
service	O
that	O
’	O
s	O
provided	O
for	O
black	O
kids	B-OG
…	O
But	O
yeah	O
.	O

It	O
’	O
s	O
not	O
known	O
…	O
That	O
’	O
s	O
what	O
my	O
thing	O
is	O
…	O
But	O
how	O
many	O
other	O
people	O
are	O
missing	O
out	O
?”	O
(	O
Laura	O
)	O

Carer	O
preferences	O
to	O
address	O
this	O
lack	O
of	O
clear	O
direction	O
and	O
mapping	O
were	O
access	O
to	O
a	O
local	O
database	O
of	O
preferred	O
providers	O
and	O
building	O
a	O
community	O
of	O
carers	O
through	O
support	O
groups	O
.	O

Carers	O
identified	O
that	O
they	O
would	O
prefer	O
to	O
have	O
the	O
database	O
and	O
support	O
groups	O
organised	O
and	O
hosted	O
through	O
the	O
local	O
Aboriginal	O
health	O
service	O
.	O
“	O
I	O
think	O
that	O
that	O
would	O
be	O
something	O
that	O
would	O
be	O
helpful	O
for	O
us	O
to	O
just	O
be	O
able	O
to	O
have	O
some	O
sort	O
of	O
connection	O
to	O
other	O
families	O
,	O
in	O
particular	O
Aboriginal	O
families	O
…	O
and	O
whether	O
the	O
[	O
Aboriginal	O
health	O
service	O
]	O
can	O
,	O
sort	O
of	O
,	O
do	O
that	O
.”	O
(	O
Ainslee	O
)	O

Wrong	O
way	O
signs	O
,	O
roundabouts	O
and	O
roadblocks	O
encountered	O
when	O
accessing	O
services	O

Carers	O
encountered	O
a	O
number	O
of	O
obstacles	O
when	O
attempting	O
to	O
access	O
and	O
interface	O
with	O
health	O
and	O
support	O
services	O
.	O

Many	O
carer	O
journeys	O
involved	O
referrals	O
to	O
and	O
interaction	O
with	O
multiple	O
service	O
providers	O
including	O
occupational	O
therapists	O
(	O
OT	O
),	O
speech	O
therapists	O
,	O
physiotherapists	O
,	O
paediatricians	O
and	O
GPs	O
.	O

In	O
navigating	O
this	O
pathway	O
independently	O
,	O
there	O
were	O
accounts	O
of	O
providers	O
qualifying	O
the	O
extent	O
of	O
their	O
service	O
leading	O
to	O
inconsistent	O
service	O
access	O
.“	O
I	O
would	O
ring	O
a	O
private	O
speech	O
and	O
private	O
OT	O
,	O
and	O
stuff	O
and	O
a	O
lot	O
of	O
them	O
would	O
say	O
,	O
okay	O
,	O
but	O
we	O
don	O
’	O
t	O
deal	O
with	O
children	O
with	O
significant	O
disabilities	O
…	O
you	O
need	O
to	O
go	O
to	O
your	O
GP	O
,	O
and	O
it	O
would	O
be	O
like	O
[	O
laughs	O
]	O
a	O
sort	O
of	O
a	O
catch	O
-	O
22	O
…	O
It	O
would	O
just	O
be	O
round	O
in	O
circles	O
…	O
it	O
just	O
really	O
wasn	O
’	O
t	O
helpful	O
at	O
all	O
.”	O
(	O
Ainslee	O
)	O

Delays	O
to	O
assessment	O
and	O
treatment	O
caused	O
by	O
long	O
waitlists	O
were	O
a	O
significant	O
roadblock	O
encountered	O
by	O
carers	O
.	O

Long	O
waitlists	O
for	O
needed	O
procedures	O
could	O
lead	O
to	O
children	O
missing	O
school	O
,	O
lack	O
of	O
developmental	O
progress	O
and	O
stress	O
for	O
carers	O
.	O
“	O
And	O
I	O
said	O
,	O
I	O
understand	O
there	O
is	O
kids	O
that	O
are	O
a	O
lot	O
worse	O
than	O
[	O
child	O
].	O

I	O
do	O
understand	O
that	O
.	O

It	O
’	O
s	O
just	O
,	O
with	O
this	O
waiting	O
list	O
,	O
he	O
’	O
d	O
probably	O
be	O
able	O
to	O
speak	O
by	O
then	O
,	O
he	O
wouldn	O
’	O
t	O
even	O
need	O
it	O
…	O
And	O
then	O
I	O
got	O
upset	O
,	O
and	O
I	O
said	O
to	O
my	O
mum	O
,	O
it	O
’	O
s	O
like	O
no	O
-	O
one	O
’	O
s	O
out	O
there	O
that	O
wants	O
to	O
help	O
.”	O
(	O
Tabitha	O
)	O
“	O
Waiting	O
and	O
waiting	O
for	O
appointments	O
,	O
you	O
know	O
,	O
like	O
,	O
nothing	O
gets	O
done	O
straight	O
away	O
…	O
it	O
’	O
s	O
just	O
such	O
a	O
long	O
process	O
…	O
I	O
am	O
no	O
closer	O
now	O
than	O
I	O
was	O
then	O
.	O

That	O
’	O
s	O
the	O
frustrating	O
part	O
about	O
it	O
.”	O
(	O
Nadia	O
)	O

Only	O
one	O
carer	O
expressed	O
lack	O
of	O
concern	O
regarding	O
waitlists	O
stating	O
that	O
they	O
are	O
a	O
“	O
part	O
of	O
life	O
”	O
(	O
Rita	O
).	O

Contributing	O
to	O
this	O
acceptance	O
was	O
contextualizing	O
the	O
carers	O
’	O
own	O
situation	O
against	O
the	O
belief	O
that	O
there	O
is	O
always	O
someone	O
whose	O
need	O
is	O
greater	O
.	O

Lack	O
of	O
follow	O
-	O
up	O
led	O
to	O
children	O
falling	O
through	O
the	O
treatment	O
gap	O
due	O
to	O
missed	O
opportunities	O
for	O
timely	O
access	O
to	O
support	O
and	O
services	O
.	O

In	O
one	O
case	O
an	O
initial	O
needs	O
assessment	O
generated	O
a	O
list	O
of	O
required	O
therapeutic	O
interventions	O
for	O
one	O
child	O
but	O
no	O
follow	O
-	O
up	O
contact	O
was	O
made	O
to	O
link	O
the	O
carer	O
with	O
the	O
required	O
services	O
.	O

Despite	O
the	O
carer	O
following	O
-	O
up	O
there	O
had	O
been	O
no	O
additional	O
contact	O
made	O
with	O
her	O
or	O
consolidation	O
of	O
these	O
supports	O
.	O

Carers	O
identified	O
that	O
lack	O
of	O
follow	O
-	O
up	O
was	O
also	O
sometimes	O
due	O
to	O
clerical	O
errors	O
.“	O
We	O
went	O
and	O
had	O
the	O
very	O
first	O
assessment	O
where	O
[	O
government	O
service	O
]	O
said	O
,	O
yeah	O
,	O
she	O
needs	O
OT	O
,	O
she	O
needs	O
speech	O
,	O
she	O
needs	O
physio	O
and	O
we	O
never	O
heard	O
from	O
them	O
again	O
.	O

It	O
was	O
,	O
sort	O
of	O
,	O
like	O
…	O
they	O
would	O
ring	O
us	O
and	O
–	O
and	O
,	O
um	O
,	O
say	O
that	O
,	O
you	O
know	O
,	O
we	O
’	O
re	O
still	O
,	O
sort	O
of	O
,	O
on	O
the	O
waiting	O
list	O
…	O
and	O
it	O
got	O
to	O
two	O
years	O
and	O
we	O
’	O
d	O
,	O
sort	O
of	O
,	O
had	O
nothing	O
…	O
I	O
spoke	O
to	O
them	O
and	O
they	O
,	O
sort	O
of	O
,	O
said	O
,	O
well	O
we	O
’	O
ll	O
find	O
out	O
what	O
’	O
s	O
happening	O
and	O
it	O
just	O
,	O
sort	O
of	O
,	O
never	O
eventuated	O
.”	O
(	O
Ainslee	O
)	O
“	O
I	O
thought	O
I	O
signed	O
everything	O
and	O
I	O
thought	O
everything	O
got	O
faxed	O
through	O
.	O

Actually	O
,	O
everything	O
got	O
faxed	O
through	O
to	O
[	O
children	O
’	O
s	O
hospital	O
]	O
and	O
they	O
,	O
um	O
,	O
lost	O
the	O
paper	O
and	O
then	O
it	O
had	O
to	O
be	O
re	O
-	O
faxed	O
through	O
.	O

So	O
,	O
yeah	O
and	O
I	O
had	O
to	O
re	O
-	O
sign	O
all	O
the	O
papers	O
.	O

Not	O
much	O
–	O
like	O
I	O
didn	O
’	O
t	O
know	O
much	O
about	O
that	O
then	O
because	O
I	O
thought	O
everything	O
was	O
going	O
ahead	O
,	O
going	O
through	O
,	O
thought	O
everything	O
was	O
fine	O
.”	O
(	O
Samantha	O
)	O

Lack	O
of	O
assistance	O
from	O
service	O
providers	O
impeded	O
attempts	O
at	O
accessing	O
support	O
and	O
services	O
.	O

Carers	O
described	O
a	O
lack	O
of	O
assistance	O
in	O
seeking	O
funding	O
for	O
services	O
such	O
as	O
teachers	O
aids	O
as	O
well	O
as	O
in	O
managing	O
behavioural	O
problems	O
.	O

This	O
had	O
a	O
significant	O
impact	O
on	O
the	O
health	O
and	O
well	O
-	O
being	O
of	O
some	O
carers	O
.	O
“	O
He	O
was	O
more	O
or	O
less	O
going	O
to	O
be	O
a	O
forgotten	O
child	O
and	O
if	O
he	O
didn	O
’	O
t	O
keep	O
up	O
his	O
grades	O
they	O
weren	O
’	O
t	O
going	O
to	O
keep	O
him	O
back	O
but	O
they	O
weren	O
’	O
t	O
going	O
to	O
give	O
him	O
no	O
more	O
help	O
….	O
but	O
it	O
had	O
me	O
at	O
breaking	O
point	O
where	O
I	O
really	O
felt	O
like	O
I	O
was	O
having	O
a	O
nervous	O
breakdown	O
.	O

I	O
’	O
ve	O
been	O
in	O
tears	O
taking	O
him	O
to	O
school	O
,	O
bringing	O
him	O
home	O
.”	O
(	O
Rita	O
)	O

Many	O
participants	O
did	O
not	O
have	O
access	O
to	O
private	O
transportation	O
.	O

Difficulty	O
attending	O
appointments	O
without	O
private	O
transport	O
was	O
a	O
prominent	O
roadblock	O
for	O
carers	O
.	O

The	O
majority	O
of	O
carers	O
had	O
no	O
private	O
means	O
of	O
transport	O
which	O
compounded	O
difficulties	O
associated	O
with	O
attending	O
multiple	O
appointments	O
at	O
multiple	O
services	O
.	O

Some	O
carers	O
described	O
having	O
to	O
begin	O
the	O
journey	O
hours	O
well	O
in	O
advance	O
of	O
appointments	O
if	O
referrals	O
were	O
made	O
to	O
geographically	O
distant	O
areas	O
.	O

Caring	O
for	O
more	O
than	O
one	O
child	O
with	O
a	O
disability	O
added	O
another	O
layer	O
of	O
complexity	O
for	O
carers	O
especially	O
if	O
the	O
children	O
attended	O
separate	O
schools	O
.	O
“	O
So	O
they	O
wanted	O
me	O
,	O
pick	O
her	O
up	O
and	O
then	O
bring	O
her	O
here	O
,	O
drop	O
her	O
off	O
.	O

I	O
said	O
,	O
no	O
,	O
no	O
,	O
no	O
,	O
no	O
,	O
it	O
’	O
s	O
too	O
complicated	O
for	O
me	O
.	O

Pick	O
up	O
the	O
boys	O
,	O
you	O
go	O
to	O
the	O
school	O
,	O
oh	O
no	O
,	O
we	O
can	O
’	O
t	O
do	O
that	O
.”	O
(	O
Helen	O
)	O

The	O
extra	O
cost	O
of	O
using	O
taxis	O
caused	O
additional	O
stress	O
for	O
carers	O
.	O

Carers	O
who	O
used	O
public	O
transport	O
to	O
avoid	O
this	O
cost	O
experienced	O
difficulty	O
with	O
managing	O
children	O
,	O
especially	O
when	O
they	O
required	O
a	O
stroller	O
or	O
wheelchair	O
.	O

Addressing	O
these	O
roadblocks	O
was	O
particularly	O
important	O
in	O
facilitating	O
access	O
to	O
assessment	O
services	O
in	O
order	O
to	O
get	O
a	O
diagnosis	O
.	O

Without	O
a	O
diagnosis	O
it	O
was	O
difficult	O
for	O
carers	O
to	O
access	O
support	O
and	O
services	O
.“	O
The	O
school	O
actually	O
told	O
me	O
that	O
they	O
would	O
not	O
help	O
until	O
[	O
child	O
]	O
did	O
have	O
an	O
MRI	O
to	O
see	O
if	O
there	O
was	O
something	O
wrong	O
because	O
I	O
’	O
ll	O
quote	O
the	O
words	O
of	O
the	O
principal	O
,	O
“	O
He	O
is	O
like	O
he	O
has	O
got	O
a	O
locked	O
door	O
and	O
we	O
cannot	O
find	O
the	O
key	O
to	O
open	O
it	O
.	O

Until	O
we	O
find	O
the	O
key	O
to	O
open	O
it	O
,	O
we	O
cannot	O
do	O
no	O
more	O
with	O
him	O
.	O

We	O
just	O
have	O
to	O
leave	O
that	O
door	O
locked	O
”.”	O
(	O
Rita	O
)	O

For	O
some	O
carers	O
,	O
obtaining	O
a	O
diagnosis	O
to	O
access	O
support	O
and	O
services	O
was	O
influenced	O
by	O
whether	O
their	O
child	O
’	O
s	O
condition	O
was	O
acute	O
or	O
non	O
-	O
acute	O
.	O

Comparison	O
of	O
carer	O
journeys	O
suggest	O
that	O
children	O
with	O
more	O
acute	O
conditions	O
fit	O
better	O
into	O
the	O
streamlined	O
medical	O
model	O
of	O
care	O
compared	O
to	O
children	O
who	O
have	O
non	O
-	O
acute	O
conditions	O
which	O
are	O
not	O
as	O
severe	O
or	O
easy	O
to	O
diagnose	O
.	O

Alternate	O
routes	O
can	O
facilitate	O
the	O
journey	O

In	O
the	O
face	O
of	O
roadblocks	O
,	O
alternate	O
routes	O
in	O
the	O
form	O
of	O
models	O
of	O
care	O
that	O
differ	O
to	O
the	O
Western	O
bio	O
-	O
medical	O
approach	O
and	O
supportive	O
administrative	O
staff	O
and	O
organisation	O
procedures	O
enabled	O
carers	O
to	O
access	O
support	O
and	O
services	O
.	O

A	O
model	O
of	O
care	O
that	O
viewed	O
the	O
needs	O
of	O
the	O
child	O
and	O
carer	O
holistically	O
,	O
provided	O
a	O
one	O
-	O
stop	O
-	O
shop	O
and	O
implemented	O
a	O
centralised	O
team	O
-	O
based	O
approach	O
was	O
identified	O
as	O
important	O
by	O
a	O
number	O
of	O
carers	O
.	O

Many	O
carers	O
accessed	O
this	O
alternate	O
route	O
to	O
support	O
and	O
services	O
through	O
local	O
Aboriginal	O
Community	O
Controlled	O
Health	O
Organisations	O
(	O
ACCHOs	O
),	O
yet	O
access	O
was	O
limited	O
.	O

Providing	O
support	O
and	O
services	O
through	O
a	O
holistic	O
lens	O
was	O
essential	O
for	O
carers	O
as	O
a	O
broad	O
range	O
of	O
personal	O
and	O
environmental	O
factors	O
influence	O
the	O
experience	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
and	O
the	O
ability	O
to	O
access	O
support	O
and	O
services	O
.	O
“	O
This	O
is	O
why	O
I	O
keep	O
coming	O
back	O
here	O
,	O
because	O
they	O
were	O
fantastic	O
.	O

Ah	O
,	O
um	O
,	O
not	O
only	O
do	O
they	O
help	O
with	O
[	O
child	O
],	O
they	O
help	O
with	O
housing	O
,	O
they	O
help	O
with	O
me	O
with	O
my	O
ex	O
-	O
husband	O
,	O
you	O
know	O
what	O
I	O
mean	O
.	O

Um	O
,	O
they	O
help	O
me	O
with	O
getting	O
some	O
counselling	O
…”	O
(	O
Jocelyn	O
)	O

The	O
convenience	O
of	O
a	O
one	O
-	O
stop	O
-	O
shop	O
and	O
centralised	O
team	O
-	O
based	O
approach	O
was	O
also	O
important	O
.	O

At	O
a	O
local	O
Aboriginal	O
health	O
service	O
convenience	O
was	O
ensured	O
by	O
holding	O
all	O
health	O
records	O
in	O
one	O
place	O
,	O
linking	O
appointments	O
with	O
different	O
internal	O
services	O
so	O
they	O
were	O
scheduled	O
in	O
close	O
succession	O
,	O
and	O
acting	O
as	O
a	O
conduit	O
to	O
external	O
services	O
when	O
required	O
.	O

Supportive	O
administrative	O
staff	O
and	O
organisation	O
procedures	O
facilitated	O
carer	O
access	O
to	O
support	O
and	O
services	O
.	O

Key	O
administrative	O
personnel	O
were	O
identified	O
as	O
important	O
to	O
facilitative	O
organisation	O
procedures	O
.	O

One	O
carer	O
reported	O
that	O
a	O
former	O
manager	O
used	O
to	O
make	O
sure	O
that	O
“	O
everyone	O
was	O
doing	O
what	O
they	O
were	O
supposed	O
to	O
be	O
doing	O
”	O
(	O
Helen	O
),	O
however	O
when	O
the	O
staff	O
member	O
left	O
the	O
organisation	O
,	O
this	O
carer	O
had	O
difficulty	O
reaching	O
the	O
service	O
by	O
phone	O
.	O

The	O
positive	O
impacts	O
of	O
organisation	O
procedures	O
were	O
characterised	O
by	O
flexibility	O
with	O
payment	O
procedures	O
and	O
maintaining	O
confidentiality	O
.	O
“	O
Our	O
chemist	O
is	O
really	O
good	O
.	O

Like	O
,	O
you	O
know	O
,	O
if	O
you	O
’	O
re	O
short	O
of	O
cash	O
they	O
let	O
you	O
,	O
you	O
know	O
,	O
pay	O
it	O
next	O
time	O
.	O

I	O
mean	O
,	O
little	O
things	O
like	O
that	O
…	O
they	O
are	O
very	O
good	O
down	O
there	O
.	O

Very	O
confidential	O
…	O
They	O
don	O
’	O
t	O
yell	O
out	O
…	O
[	O
loud	O
voice	O
]	O
“	O
Your	O
Ritalin	O
is	O
ready	O
.”	O
Or	O
,	O
“	O
Your	O
Concerta	O
’	O
s	O
ready	O
”.”	O
(	O
Laura	O
)	O

Incompatibility	O
of	O
inflexible	O
bureaucratic	O
road	O
rules	O
and	O
lived	O
realities	O

Policies	O
guiding	O
government	O
agencies	O
and	O
funding	O
bodies	O
have	O
far	O
reaching	O
effects	O
on	O
carer	O
journeys	O
to	O
access	O
support	O
and	O
services	O
.	O

Many	O
carer	O
interactions	O
with	O
government	O
agencies	O
were	O
defined	O
by	O
barriers	O
generated	O
from	O
inflexible	O
rules	O
and	O
bureaucratic	O
processes	O
.	O

Carers	O
’	O
accounts	O
indicated	O
that	O
the	O
lived	O
reality	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
is	O
not	O
supported	O
or	O
acknowledged	O
by	O
current	O
policy	O
and	O
this	O
negatively	O
impacted	O
their	O
experiences	O
and	O
ability	O
to	O
care	O
for	O
their	O
child	O
.	O

Carers	O
described	O
incidents	O
where	O
agencies	O
were	O
unable	O
to	O
accommodate	O
their	O
specific	O
needs	O
due	O
to	O
inflexible	O
rules	O
.	O

Accessing	O
financial	O
assistance	O
from	O
Centrelink	O
to	O
assist	O
with	O
caregiving	O
related	O
responsibilities	O
was	O
particularly	O
difficult	O
due	O
to	O
rigid	O
eligibility	O
criteria	O
.	O

This	O
had	O
implications	O
for	O
carer	O
employment	O
and	O
support	O
payments	O
.	O
“…	O
the	O
Carer	O
’	O
s	O
Allowance	O
loan	O
was	O
supposed	O
to	O
be	O
coming	O
up	O
,	O
and	O
I	O
wanted	O
to	O
pay	O
the	O
rest	O
of	O
it	O
off	O
to	O
get	O
another	O
loan	O
for	O
[	O
children	O
’	O
s	O
hospital	O
],	O
because	O
I	O
have	O
to	O
pay	O
for	O
an	O
overnight	O
stay	O
with	O
her	O
,	O
and	O
for	O
one	O
of	O
these	O
tests	O
I	O
have	O
to	O
pay	O
for	O
it	O
.	O

And	O
they	O
won	O
’	O
t	O
be	O
able	O
to	O
help	O
me	O
until	O
the	O
27	O
th	O
of	O
this	O
month	O
.	O

And	O
my	O
appointment	O
is	O
on	O
the	O
25	O
th	O
.”	O
(	O
Lesley	O
)	O

The	O
Department	O
of	O
Housing	O
(	O
DoH	O
)	O
was	O
another	O
government	O
agency	O
many	O
carers	O
interacted	O
with	O
which	O
was	O
also	O
defined	O
by	O
inflexible	O
rules	O
.	O

Carers	O
described	O
DoH	O
expectations	O
of	O
clients	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
as	O
inappropriate	O
.	O

The	O
strict	O
requirements	O
for	O
obtaining	O
housing	O
assistance	O
can	O
negatively	O
impact	O
carers	O
accessing	O
support	O
and	O
services	O
for	O
their	O
child	O
with	O
the	O
lack	O
of	O
assistance	O
perceived	O
as	O
dismissiveness	O
.“…	O
they	O
still	O
wanted	O
me	O
to	O
look	O
for	O
,	O
for	O
pretty	O
much	O
three	O
houses	O
a	O
day	O
,	O
um	O
,	O
um	O
and	O
I	O
’	O
ve	O
got	O
no	O
personal	O
transport	O
…	O
I	O
told	O
the	O
Department	O
of	O
Housing	O
,	O
you	O
know	O
,	O
“	O
You	O
are	O
expecting	O
me	O
to	O
drag	O
my	O
daughter	O
around	O
with	O
a	O
disability	O
to	O
look	O
for	O
houses	O
.”	O
They	O
wanted	O
–	O
they	O
said	O
they	O
wanted	O
me	O
to	O
go	O
out	O
to	O
[	O
suburb	O
1	O
]	O
and	O
everything	O
.	O

Like	O
[	O
suburb	O
2	O
],	O
and	O
then	O
I	O
said	O
,	O
“	O
Like	O
why	O
would	O
I	O
go	O
out	O
to	O
[	O
suburb	O
2	O
]	O
when	O
my	O
family	O
is	O
in	O
[	O
suburb	O
3	O
]?”…	O
and	O
I	O
’	O
m	O
like	O
,	O
“	O
Yeah	O
,	O
but	O
I	O
can	O
’	O
t	O
live	O
in	O
[	O
suburb	O
2	O
]	O
or	O
[	O
suburb	O
1	O
]	O
or	O
anywhere	O
I	O
have	O
no	O
support	O
,”	O
and	O
they	O
were	O
like	O
,	O
“	O
Oh	O
well	O
,	O
it	O
doesn	O
’	O
t	O
matter	O
,	O
as	O
long	O
as	O
,	O
um	O
,	O
you	O
get	O
a	O
house	O
”.”	O
(	O
Samantha	O
)	O

Bureaucratic	O
requirements	O
of	O
government	O
funding	O
mechanisms	O
and	O
support	O
services	O
reinforce	O
rigid	O
eligibility	O
criteria	O
that	O
mean	O
some	O
children	O
don	O
’	O
t	O
receive	O
the	O
support	O
they	O
require	O
.	O

The	O
rigid	O
eligibility	O
criteria	O
of	O
age	O
-	O
based	O
funding	O
structures	O
was	O
identified	O
as	O
an	O
issue	O
influencing	O
the	O
quality	O
of	O
specialists	O
that	O
children	O
with	O
a	O
disability	O
have	O
access	O
to	O
.	O
“	O
So	O
yep	O
,	O
it	O
doesn	O
’	O
t	O
help	O
a	O
lot	O
of	O
the	O
families	O
that	O
have	O
the	O
younger	O
kids	O
and	O
that	O
’	O
s	O
why	O
-	O
and	O
I	O
’	O
ve	O
always	O
said	O
that	O
that	O
’	O
s	O
why	O
they	O
don	O
’	O
t	O
get	O
seen	O
to	O
the	O
right	O
people	O
because	O
of	O
the	O
financial	O
cost	O
of	O
that	O
.”	O
(	O
Grace	O
)	O

Rigid	O
eligibility	O
criteria	O
for	O
accessible	O
Aboriginal	O
education	O
officers	O
(	O
AEOs	O
),	O
who	O
act	O
as	O
liaison	O
and	O
support	O
workers	O
within	O
schools	O
,	O
also	O
impacted	O
partnerships	O
between	O
schools	O
and	O
carers	O
.	O

One	O
school	O
did	O
not	O
have	O
the	O
required	O
percentage	O
of	O
Aboriginal	O
children	O
to	O
qualify	O
for	O
a	O
dedicated	O
AEO	O
.	O

For	O
this	O
carer	O
it	O
was	O
important	O
to	O
have	O
access	O
to	O
the	O
support	O
of	O
an	O
AEO	O
as	O
they	O
play	O
an	O
important	O
support	O
role	O
to	O
the	O
carer	O
getting	O
across	O
their	O
point	O
of	O
view	O
as	O
a	O
third	O
party	O
in	O
the	O
school	O
-	O
carer	O
partnership	O
.	O
“	O
So	O
,	O
yeah	O
,	O
it	O
’	O
s	O
not	O
feeling	O
like	O
you	O
’	O
re	O
ganged	O
up	O
on	O
,	O
kind	O
of	O
thing	O
.”	O
(	O
Rita	O
)	O

Discussion	O

Carers	O
’	O
descriptions	O
of	O
their	O
attempts	O
to	O
access	O
support	O
for	O
their	O
child	O
with	O
a	O
disability	O
were	O
akin	O
to	O
a	O
journey	O
:	O
sometimes	O
they	O
did	O
not	O
know	O
where	O
to	O
go	O
(	O
as	O
a	O
result	O
of	O
poor	O
signage	O
),	O
they	O
went	O
around	O
in	O
circles	O
,	O
in	O
the	O
wrong	O
direction	O
,	O
had	O
to	O
make	O
u	O
-	O
turns	O
and	O
encountered	O
roadblocks	O
and	O
traffic	O
.	O

For	O
many	O
who	O
set	O
out	O
on	O
a	O
journey	O
,	O
they	O
eventually	O
arrive	O
at	O
a	O
destination	O
,	O
but	O
these	O
carers	O
were	O
still	O
traveling	O
,	O
as	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
is	O
a	O
lifelong	O
voyage	O
.	O

Some	O
carers	O
received	O
directional	O
assistance	O
along	O
the	O
way	O
;	O
people	O
who	O
unlocked	O
gates	O
and	O
facilitated	O
access	O
to	O
needed	O
resources	O
.	O

For	O
instance	O
,	O
the	O
role	O
of	O
community	O
both	O
facilitated	O
and	O
obfuscated	O
carers	O
’	O
service	O
access	O
.	O

Community	O
influence	O
has	O
likewise	O
been	O
identified	O
in	O
culturally	O
and	O
linguistically	O
diverse	O
(	O
CALD	O
)	O
carers	O
wherein	O
extended	O
family	O
and	O
community	O
members	O
sometimes	O
presented	O
a	O
barrier	O
to	O
access	O
by	O
denying	O
presence	O
of	O
a	O
disability	O
[	O
49	O
].	O

Another	O
Australian	O
study	O
of	O
CALD	O
carers	O
’	O
perceptions	O
of	O
preventive	O
health	O
care	O
for	O
their	O
children	O
found	O
that	O
social	O
influence	O
plays	O
a	O
key	O
role	O
in	O
identification	O
of	O
developmental	O
problems	O
and	O
the	O
need	O
to	O
access	O
services	O
[	O
50	O
].	O

In	O
their	O
review	O
of	O
vulnerable	O
groups	O
access	O
to	O
healthcare	O
,	O
Dixon	O
-	O
Woods	O
et	O
al	O
.	O
[	O
51	O
]	O
found	O
that	O
people	O
from	O
socio	O
-	O
economically	O
disadvantaged	O
backgrounds	O
are	O
less	O
likely	O
to	O
present	O
for	O
services	O
due	O
to	O
the	O
normalization	O
of	O
poor	O
health	O
within	O
their	O
communities	O
and	O
a	O
fear	O
of	O
being	O
‘	O
blamed	O
’	O
by	O
health	O
care	O
professionals	O
[	O
51	O
].	O

Rather	O
than	O
not	O
recognizing	O
the	O
need	O
to	O
get	O
help	O
,	O
the	O
‘	O
wait	O
and	O
see	O
’	O
approach	O
advised	O
by	O
some	O
community	O
members	O
may	O
reflect	O
the	O
Aboriginal	O
world	O
view	O
of	O
health	O
[	O
52	O
]	O
whereby	O
disability	O
is	O
‘	O
part	O
of	O
a	O
continuum	O
from	O
perfect	O
wellbeing	O
to	O
death	O
’	O
[	O
32	O
]	O
compared	O
to	O
the	O
more	O
narrow	O
medical	O
definition	O
.	O

Gilroy	O
et	O
al	O
.	O
[	O
53	O
]	O
assert	O
that	O
labeling	O
individuals	O
as	O
disabled	O
is	O
offensive	O
to	O
some	O
Aboriginal	O
communities	O
and	O
associated	O
with	O
past	O
government	O
policies	O
that	O
led	O
to	O
removal	O
of	O
children	O
from	O
families	O
[	O
53	O
].	O

It	O
is	O
also	O
suggested	O
that	O
in	O
some	O
Aboriginal	O
communities	O
support	O
and	O
care	O
for	O
a	O
person	O
with	O
a	O
disability	O
is	O
viewed	O
as	O
the	O
responsibility	O
of	O
family	O
and	O
kinship	O
networks	O
and	O
outside	O
help	O
viewed	O
as	O
questioning	O
family	O
competence	O
[	O
22	O
,	O
53	O
].	O

Despite	O
impacting	O
carer	O
access	O
to	O
services	O
,	O
the	O
resilience	O
and	O
strength	O
of	O
Aboriginal	O
communities	O
in	O
caring	O
for	O
each	O
other	O
represents	O
a	O
key	O
resource	O
that	O
requires	O
investment	O
.	O

Community	O
capacity	O
can	O
be	O
built	O
by	O
increasing	O
‘	O
signage	O
’	O
via	O
community	O
education	O
,	O
information	O
and	O
awareness	O
of	O
disability	O
and	O
services	O
.	O

The	O
multiple	O
roadblocks	O
described	O
throughout	O
carers	O
’	O
journeys	O
are	O
significant	O
barriers	O
to	O
accessing	O
services	O
and	O
support	O
.	O

The	O
impact	O
of	O
transport	O
is	O
a	O
particularly	O
important	O
consideration	O
and	O
is	O
reflected	O
in	O
other	O
studies	O
of	O
service	O
access	O
[	O
51	O
,	O
54	O
,	O
55	O
].	O

For	O
carers	O
,	O
services	O
that	O
provided	O
transport	O
to	O
and	O
from	O
appointments	O
were	O
invaluable	O
and	O
facilitated	O
service	O
access	O
.	O

Having	O
to	O
wait	O
months	O
to	O
access	O
services	O
and	O
confusion	O
caused	O
by	O
interaction	O
with	O
multiple	O
service	O
providers	O
has	O
also	O
been	O
found	O
in	O
an	O
Australian	O
study	O
of	O
the	O
experiences	O
of	O
CALD	O
carers	O
accessing	O
developmental	O
assessment	O
services	O
[	O
49	O
]	O
suggesting	O
the	O
widespread	O
nature	O
of	O
these	O
barriers	O
.	O

Roadblocks	O
are	O
particularly	O
concerning	O
as	O
accessing	O
assessment	O
services	O
to	O
obtain	O
a	O
diagnosis	O
is	O
essential	O
in	O
being	O
able	O
to	O
access	O
support	O
and	O
services	O
[	O
54	O
].	O

Removing	O
those	O
barriers	O
may	O
help	O
patients	O
seek	O
and	O
access	O
the	O
medical	O
care	O
they	O
need	O
.	O

Dedicated	O
patient	O
navigators	O
may	O
be	O
a	O
solution	O
to	O
overcome	O
these	O
barriers	O
by	O
bridging	O
the	O
gap	O
between	O
carers	O
and	O
the	O
various	O
service	O
systems	O
involved	O
[	O
55	O
].	O

A	O
patient	O
navigator	O
is	O
akin	O
to	O
a	O
tour	O
guide	O
who	O
assists	O
patients	O
to	O
navigate	O
their	O
way	O
through	O
complex	O
systems	O
,	O
helping	O
to	O
remove	O
patient	O
-	O
level	O
barriers	O
to	O
reduce	O
delays	O
in	O
accessing	O
services	O
[	O
56	O
,	O
57	O
].	O

The	O
patient	O
navigator	O
model	O
can	O
be	O
a	O
key	O
‘	O
weapon	O
’	O
against	O
health	O
disparities	O
that	O
certain	O
groups	O
face	O
[	O
56	O
,	O
58	O
].	O

A	O
study	O
of	O
the	O
experiences	O
of	O
Aboriginal	O
patients	O
with	O
cancer	B-DS
accessing	O
diagnosis	O
and	O
treatment	O
found	O
that	O
a	O
patient	O
navigator	O
model	O
would	O
help	O
facilitate	O
mainstream	O
service	O
access	O
for	O
patients	O
[	O
59	O
].	O

Involving	O
Aboriginal	O
liaison	O
officers	O
in	O
these	O
roles	O
is	O
a	O
way	O
to	O
foster	O
cultural	O
security	O
[	O
60	O
].	O

Focus	O
groups	O
with	O
key	O
stakeholders	O
and	O
Aboriginal	O
carers	O
have	O
also	O
identified	O
that	O
patient	O
navigators	O
in	O
the	O
form	O
of	O
dedicated	O
disability	O
support	O
workers	O
within	O
Aboriginal	O
health	O
services	O
would	O
help	O
in	O
raising	O
awareness	O
of	O
available	O
support	O
and	O
services	O
for	O
families	O
[	O
21	O
].	O

While	O
a	O
patient	O
navigator	O
could	O
help	O
carers	O
to	O
by	O
-	O
pass	O
roadblocks	O
at	O
the	O
service	O
level	O
,	O
responsive	O
service	O
systems	O
are	O
critical	O
to	O
the	O
model	O
’	O
s	O
efficacy	O
.	O

Responsive	O
services	O
systems	O
that	O
are	O
informed	O
by	O
the	O
views	O
of	O
both	O
carers	O
and	O
the	O
workforces	O
responsible	O
for	O
service	O
delivery	O
,	O
especially	O
the	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
workforce	O
,	O
are	O
important	O
to	O
understanding	O
the	O
needs	O
of	O
carers	O
and	O
developing	O
responsive	O
strategies	O
to	O
address	O
them	O
[	O
61	O
].	O

Guiding	O
principles	O
for	O
responsive	O
service	O
systems	O
include	O
sharing	O
ownership	O
and	O
responsibility	O
for	O
change	O
,	O
responding	O
to	O
the	O
needs	O
of	O
families	O
in	O
the	O
context	O
of	O
where	O
they	O
live	O
,	O
as	O
well	O
as	O
the	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
workforce	O
,	O
working	O
together	O
from	O
the	O
micro	O
to	O
macro	O
levels	O
,	O
and	O
building	O
on	O
the	O
existing	O
strengths	O
of	O
families	O
and	O
relevant	O
workforces	O
[	O
61	O
].	O

The	O
use	O
of	O
alternate	O
routes	O
or	O
service	O
models	O
is	O
important	O
.	O

Future	O
planning	O
of	O
service	O
and	O
support	O
models	O
should	O
consider	O
the	O
elements	O
identified	O
by	O
carers	O
as	O
most	O
important	O
including	O
a	O
holistic	O
view	O
of	O
the	O
needs	O
of	O
the	O
child	O
and	O
carer	O
,	O
one	O
-	O
stop	O
-	O
shop	O
for	O
services	O
and	O
operationalizing	O
a	O
centralized	O
team	O
-	O
based	O
approach	O
.	O

These	O
elements	O
are	O
typically	O
embodied	O
in	O
the	O
model	O
of	O
care	O
provided	O
by	O
ACCHOs	O
and	O
argued	O
to	O
be	O
a	O
vital	O
part	O
of	O
improving	O
health	O
and	O
wellbeing	O
outcomes	O
for	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
peoples	O
[	O
62	O
].	O

The	O
incompatibility	O
between	O
inflexible	O
bureaucratic	O
policy	O
requirements	O
and	O
the	O
demands	O
and	O
challenges	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
was	O
a	O
significant	O
part	O
of	O
carer	O
journeys	O
.	O

Meeting	O
inflexible	O
requirements	O
for	O
eligibility	O
to	O
respite	O
services	O
and	O
funding	O
has	O
elsewhere	O
been	O
described	O
as	O
‘	O
jumping	O
through	O
hoops	O
’	O
[	O
54	O
].	O

Given	O
the	O
multiple	O
complex	O
needs	O
of	O
these	O
families	O
and	O
frequent	O
interaction	O
with	O
government	O
departments	O
,	O
Butler	O
et	O
al	O
.	O
[	O
55	O
]	O
recommend	O
that	O
modification	O
of	O
inflexible	O
policy	O
requirements	O
is	O
essential	O
if	O
design	O
of	O
policies	O
and	O
programs	O
are	O
to	O
improve	O
service	O
access	O
for	O
parents	O
in	O
vulnerable	O
families	O
[	O
55	O
].	O

Limitations	O

Participants	O
were	O
purposefully	O
sampled	O
in	O
order	O
to	O
facilitate	O
in	O
-	O
depth	O
exploration	O
of	O
their	O
experiences	O
.	O

However	O
,	O
self	O
-	O
selection	O
bias	O
along	O
with	O
a	O
small	O
sample	O
size	O
means	O
that	O
these	O
findings	O
are	O
not	O
necessarily	O
generalizable	O
to	O
other	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
populations	O
or	O
to	O
indigenous	O
populations	O
globally	O
.	O

All	O
data	O
were	O
self	O
-	O
reported	O
reflecting	O
carers	O
’	O
individual	O
experiences	O
and	O
perspectives	O
.	O

Further	O
research	O
into	O
the	O
experiences	O
of	O
service	O
providers	O
would	O
help	O
contribute	O
to	O
a	O
more	O
comprehensive	O
picture	O
of	O
barriers	O
and	O
facilitators	O
to	O
service	O
access	O
.	O

Follow	O
-	O
up	O
interviews	O
were	O
conducted	O
within	O
a	O
12	O
month	O
period	O
despite	O
more	O
prolonged	O
service	O
access	O
journeys	O
.	O

All	O
participants	O
in	O
this	O
study	O
were	O
women	B-OG
,	O
hence	O
the	O
perspectives	O
of	O
male	O
carers	O
is	O
needed	O
.	O

Conclusions	O

The	O
challenges	O
of	O
caring	O
for	O
a	O
child	O
with	O
a	O
disability	O
are	O
indisputable	O
.	O

The	O
socio	O
-	O
economic	O
challenges	O
and	O
marginalisation	O
experienced	O
by	O
many	O
Aboriginal	O
and	O
Torres	O
Strait	O
Islander	O
people	O
compound	O
these	O
challenges	O
.	O

Building	O
community	O
awareness	O
of	O
disability	O
services	O
and	O
support	O
,	O
increasing	O
access	O
to	O
alternate	O
routes	O
to	O
care	O
,	O
and	O
consideration	O
of	O
roadblocks	O
and	O
disadvantageous	O
road	O
rules	O
in	O
service	O
delivery	O
as	O
well	O
as	O
ways	O
of	O
overcoming	O
them	O
are	O
important	O
to	O
facilitating	O
service	O
access	O
.	O

Topic	O
guide	O
for	O
interview	O
with	O
parent	O
/	O
carer	O
.	O

(	O
DOCX	O
13	O
kb	O
)	O

Higher	O
Dimensional	O
Meta	O
-	O
State	O
Analysis	O
Reveals	O
Reduced	O
Resting	O
fMRI	O
Connectivity	O
Dynamism	O
in	O
Schizophrenia	B-DS
Patients	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RLM	O
MY	O
VDC	O
.	O

Performed	O
the	O
experiments	O
:	O
RLM	O
.	O

Analyzed	O
the	O
data	O
:	O
RLM	O
.	O

Wrote	O
the	O
paper	O
:	O
RLM	O
MY	O
VDC	O
JAT	O
DM	O
AP	O
GP	O
TA	O
.	O

Contributed	O
data	O
:	O
JAT	O
DM	O
AP	O
GP	O
.	O

Resting	O
-	O
state	O
functional	O
brain	O
imaging	O
studies	O
of	O
network	O
connectivity	O
have	O
long	O
assumed	O
that	O
functional	O
connections	O
are	O
stationary	O
on	O
the	O
timescale	O
of	O
a	O
typical	O
scan	O
.	O

Interest	O
in	O
moving	O
beyond	O
this	O
simplifying	O
assumption	O
has	O
emerged	O
only	O
recently	O
.	O

The	O
great	O
hope	O
is	O
that	O
training	O
the	O
right	O
lens	O
on	O
time	O
-	O
varying	O
properties	O
of	O
whole	O
-	O
brain	O
network	O
connectivity	O
will	O
shed	O
additional	O
light	O
on	O
previously	O
concealed	O
brain	O
activation	O
patterns	O
characteristic	O
of	O
serious	O
neurological	O
or	O
psychiatric	B-DS
disorders	I-DS
.	O

We	O
present	O
evidence	O
that	O
multiple	O
explicitly	O
dynamical	O
properties	O
of	O
time	O
-	O
varying	O
whole	O
-	O
brain	O
network	O
connectivity	O
are	O
strongly	O
associated	O
with	O
schizophrenia	B-DS
,	O
a	O
complex	O
mental	B-DS
illness	I-DS
whose	O
symptomatic	O
presentation	O
can	O
vary	O
enormously	O
across	O
subjects	O
.	O

As	O
with	O
so	O
much	O
brain	O
-	O
imaging	O
research	O
,	O
a	O
central	O
challenge	O
for	O
dynamic	O
network	O
connectivity	O
lies	O
in	O
determining	O
transformations	O
of	O
the	O
data	O
that	O
both	O
reduce	O
its	O
dimensionality	O
and	O
expose	O
features	O
that	O
are	O
strongly	O
predictive	O
of	O
important	O
population	O
characteristics	O
.	O

Our	O
paper	O
introduces	O
an	O
elegant	O
,	O
simple	O
method	O
of	O
reducing	O
and	O
organizing	O
data	O
around	O
which	O
a	O
large	O
constellation	O
of	O
mutually	O
informative	O
and	O
intuitive	O
dynamical	O
analyses	O
can	O
be	O
performed	O
.	O

This	O
framework	O
combines	O
a	O
discrete	O
multidimensional	O
data	O
-	O
driven	O
representation	O
of	O
connectivity	O
space	O
with	O
four	O
core	O
dynamism	O
measures	O
computed	O
from	O
large	O
-	O
scale	O
properties	O
of	O
each	O
subject	O
’	O
s	O
trajectory	O
,	O
ie	O
.,	O
properties	O
not	O
identifiable	O
with	O
any	O
specific	O
moment	O
in	O
time	O
and	O
therefore	O
reasonable	O
to	O
employ	O
in	O
settings	O
lacking	O
inter	O
-	O
subject	O
time	O
-	O
alignment	O
,	O
such	O
as	O
resting	O
-	O
state	O
functional	O
imaging	O
studies	O
.	O

Our	O
analysis	O
exposes	O
pronounced	O
differences	O
between	O
schizophrenia	B-DS
patients	O
(	O
Nsz	O
=	O
151	O
)	O
and	O
healthy	O
controls	O
(	O
Nhc	O
=	O
163	O
).	O

Time	O
-	O
varying	O
whole	O
-	O
brain	O
network	O
connectivity	O
patterns	O
are	O
found	O
to	O
be	O
markedly	O
less	O
dynamically	O
active	O
in	O
schizophrenia	B-DS
patients	O
,	O
an	O
effect	O
that	O
is	O
even	O
more	O
pronounced	O
in	O
patients	O
with	O
high	O
levels	O
of	O
hallucinatory	O
behavior	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
demonstration	O
that	O
high	O
-	O
level	O
dynamic	O
properties	O
of	O
whole	O
-	O
brain	O
connectivity	O
,	O
generic	O
enough	O
to	O
be	O
commensurable	O
under	O
many	O
decompositions	O
of	O
time	O
-	O
varying	O
connectivity	O
data	O
,	O
exhibit	O
robust	O
and	O
systematic	O
differences	O
between	O
schizophrenia	B-DS
patients	O
and	O
healthy	O
controls	O
.	O

Introduction	O

Many	O
neurological	O
,	O
cognitive	O
and	O
psychiatric	B-DS
disorders	I-DS
have	O
been	O
shown	O
to	O
affect	O
connectivity	O
between	O
functional	O
brain	O
networks	O
[	O
1	O
–	O
24	O
]	O
even	O
in	O
so	O
-	O
called	O
""""	O
resting	O
""""	O
conditions	O
where	O
subjects	O
are	O
not	O
engaged	O
in	O
a	O
task	O
.	O

Network	O
connectivity	O
is	O
typically	O
assessed	O
as	O
a	O
stationary	O
feature	O
of	O
the	O
data	O
,	O
inferred	O
from	O
the	O
correlation	O
or	O
mutual	O
information	O
between	O
pairs	O
of	O
network	O
activation	O
timecourses	O
that	O
extend	O
through	O
the	O
duration	O
of	O
the	O
scan	O
.	O

Although	O
a	O
useful	O
simplification	O
,	O
there	O
is	O
no	O
a	O
priori	O
reason	O
to	O
believe	O
that	O
network	O
correlations	O
are	O
stationary	O
,	O
especially	O
in	O
the	O
resting	O
brain	O
.	O

In	O
fact	O
,	O
one	O
might	O
expect	O
cross	O
-	O
network	O
connections	O
to	O
vary	O
and	O
evolve	O
as	O
subjects	O
experience	O
different	O
thoughts	O
,	O
degrees	O
of	O
drowsiness	O
,	O
memories	O
and	O
emotional	O
states	O
.	O

Far	O
from	O
being	O
canonical	O
,	O
scan	O
duration	O
is	O
simply	O
one	O
of	O
the	O
unavoidably	O
fixed	O
features	O
of	O
any	O
functional	O
imaging	O
study	O
.	O

Thus	O
,	O
averaging	O
evidence	O
of	O
connectivity	O
over	O
an	O
entire	O
resting	O
fMRI	O
scan	O
puts	O
researchers	O
at	O
risk	O
of	O
obscuring	O
distinct	O
,	O
meaningful	O
connectivity	O
regimes	O
that	O
subjects	O
are	O
passing	O
through	O
(	O
Fig	O
1A	O
and	O
1B	O
).	O

Recent	O
investigations	O
of	O
dynamic	O
connectivity	O
have	O
in	O
fact	O
shown	O
not	O
only	O
that	O
connections	O
are	O
varying	O
through	O
time	O
[	O
25	O
–	O
36	O
],	O
but	O
that	O
this	O
variation	O
takes	O
different	O
forms	O
in	O
different	O
demographic	O
[	O
35	O
]	O
and	O
diagnostic	O
[	O
16	O
,	O
26	O
,	O
30	O
,	O
32	O
,	O
33	O
,	O
37	O
–	O
39	O
]	O
groups	O

Dynamic	O
Connectivity	O
,	O
Single	O
and	O
Higher	O
Dimensional	O
Representations	O
(	O
A	O
)	O
Example	O
of	O
two	O
network	O
timecourses	O
whose	O
correlation	O
evaluated	O
over	O
their	O
entire	O
duration	O
is	O
0	O
.	O
4	O
;	O
(	O
B	O
)	O
One	O
of	O
the	O
many	O
different	O
ways	O
that	O
a	O
pair	O
of	O
long	O
timecourses	O
can	O
have	O
correlation	O
coefficient	O
of	O
0	O
.	O
4	O
is	O
to	O
pass	O
through	O
the	O
two	O
distinct	O
,	O
identifiable	O
connectivity	O
regimes	O
shown	O
here	O
.	O

The	O
existence	O
of	O
the	O
two	O
connectivity	O
regimes	O
and	O
the	O
transitions	O
between	O
them	O
are	O
completely	O
obscured	O
by	O
looking	O
at	O
correlation	O
on	O
a	O
longer	O
timescale	O
;	O
(	O
C	O
and	O
D	O
)	O
Too	O
crude	O
a	O
dimensionality	O
-	O
reduction	O
of	O
the	O
state	O
space	O
can	O
create	O
serious	O
distortions	O
of	O
the	O
dynamics	O
being	O
analyzed	O
.	O

Dynamically	O
active	O
and	O
mobile	O
trajectories	O
(	O
C	O
)	O
can	O
appear	O
constant	O
under	O
the	O
reduction	O
,	O
while	O
those	O
barely	O
moving	O
from	O
their	O
starting	O
position	O
(	O
D	O
)	O
can	O
seem	O
highly	O
dynamic	O
;	O
(	O
E	O
)	O
Shifting	O
up	O
one	O
dimension	O
and	O
characterizing	O
the	O
same	O
trajectories	O
by	O
vectors	O
reflecting	O
their	O
position	O
In	O
a	O
discrete	O
2	O
-	O
dimensional	O
state	O
space	O
yields	O
much	O
better	O
qualitative	O
agreement	O
between	O
the	O
geometric	O
trajectories	O
and	O
their	O
symbolic	O
representations	O
.	O

Most	O
work	O
on	O
dynamic	O
functional	O
network	O
connectivity	O
(	O
dFNC	O
)	O
to	O
date	O
has	O
been	O
focused	O
on	O
computing	O
and	O
statistically	O
summarizing	O
cross	O
-	O
network	O
correlations	O
evaluated	O
separately	O
on	O
successive	O
sliding	O
windows	O
through	O
the	O
original	O
scan	O
-	O
length	O
network	O
timecourses	O
[	O
16	O
,	O
25	O
,	O
26	O
,	O
30	O
,	O
32	O
,	O
33	O
,	O
35	O
,	O
37	O
,	O
38	O
,	O
40	O
,	O
41	O
].	O

The	O
resulting	O
window	O
-	O
indexed	O
correlation	O
matrices	O
,	O
called	O
windowed	O
functional	O
network	O
connectivity	O
matrices	O
(	O
wFNC	O
),	O
record	O
snapshots	O
of	O
network	O
connectivity	O
evolving	O
in	O
time	O
.	O

The	O
collection	O
of	O
wFNCs	O
for	O
a	O
given	O
subject	O
yields	O
N	O
(	O
N	O
−	O
1	O
)	O
2	O
length	O
-	O
T	O
timeseries	O
,	O
one	O
for	O
each	O
of	O
network	O
-	O
pair	O
correlation	O
,	O
where	O
T	O
is	O
the	O
number	O
of	O
windows	O
and	O
N	O
the	O
number	O
of	O
networks	O
.	O

The	O
very	O
first	O
investigations	O
[	O
25	O
,	O
26	O
]	O
of	O
dynamic	O
FNC	O
used	O
clustering	O
as	O
a	O
dimensionality	O
reduction	O
tool	O
,	O
collapsing	O
a	O
d	O
=	O
N	O
(	O
N	O
−	O
1	O
)	O
N	O
>	O
1000	O
dimensional	O
connectivity	O
space	O
to	O
just	O
one	O
dimension	O
(	O
ie	O
.,	O
replacing	O
an	O
over	O
1000	O
-	O
dimensional	O
object	O
with	O
the	O
index	O
i	O
∈	O
{	O
1	O
,	O
2	O
,…,	O
k	O
}	O
of	O
the	O
cluster	O
to	O
which	O
it	O
belongs	O
).	O

Although	O
some	O
interesting	O
results	O
have	O
emerged	O
from	O
this	O
initial	O
work	O
,	O
collapsing	O
connectivity	O
space	O
onto	O
a	O
single	O
dimension	O
is	O
the	O
crudest	O
possible	O
dimension	O
-	O
reduction	O
.	O

A	O
reduction	O
of	O
this	O
magnitude	O
inevitably	O
obscures	O
and	O
distorts	O
important	O
features	O
of	O
dynamical	O
network	O
-	O
coupling	O
behavior	O
(	O
Fig	O
1C	O
,	O
1D	O
and	O
1E	O
)	O
that	O
might	O
characterize	O
clinically	O
or	O
demographically	O
defined	O
groups	O

Our	O
approach	O
models	O
windowed	O
FNCs	O
as	O
weighted	O
sums	O
of	O
maximally	O
independent	O
connectivity	O
patterns	O
(	O
CPs	O
)	O
(	O
Fig	O
2C	O
and	O
2D	O
),	O
Fig	O
3A	O
and	O
3B	O
).	O

Each	O
wFNC	O
is	O
recast	O
as	O
a	O
discretized	O
vector	O
of	O
CP	B-GP
weights	O
,	O
called	O
a	O
meta	O
-	O
state	O
(	O
Fig	O
2	O
(	O
A	O
),	O
Fig	O
3	O
(	O
C	O
)).	O

This	O
specific	O
approach	O
was	O
motivated	O
by	O
a	O
desire	O
to	O
understand	O
network	O
connectivity	O
dynamics	O
in	O
terms	O
of	O
(	O
not	O
necessarily	O
observable	O
)	O
patterns	O
of	O
signed	O
network	O
pair	O
correlations	O
that	O
“	O
pipe	O
in	O
”	O
and	O
fade	O
out	O
of	O
observed	O
wFNCs	O
in	O
a	O
relatively	O
independent	O
manner	O
.	O

We	O
introduce	O
a	O
set	O
of	O
simple	O
dynamism	O
measures	O
easily	O
calculated	O
from	O
subject	O
trajectories	O
through	O
the	O
induced	O
discrete	O
five	O
-	O
dimensional	O
state	O
-	O
space	O
,	O
finding	O
consistent	O
,	O
significant	O
and	O
replicable	O
differences	O
in	O
connectivity	O
dynamics	O
between	O
schizophrenia	B-DS
patients	O
and	O
healthy	O
controls	O
(	O
Fig	O
2B	O
and	O
2D	O
).	O

While	O
the	O
temporal	O
behavior	O
of	O
specific	O
network	O
-	O
pair	O
correlations	O
might	O
be	O
of	O
interest	O
in	O
certain	O
narrowly	O
tailored	O
questions	O
,	O
it	O
seems	O
natural	O
to	O
address	O
complex	O
brain	B-DS
diseases	I-DS
that	O
encompass	O
diverse	O
categories	O
and	O
combinations	O
of	O
symptoms	O
at	O
a	O
more	O
aggregated	O
level	O
,	O
examining	O
how	O
patterns	O
or	O
aggregates	O
of	O
network	O
-	O
pair	O
correlations	O
evolve	O
en	O
masse	O
in	O
afflicted	O
populations	O
.	O

Schizophrenia	B-DS
is	O
such	O
a	O
disease	O
,	O
and	O
at	O
the	O
whole	O
-	O
brain	O
level	O
,	O
we	O
find	O
very	O
robust	O
evidence	O
of	O
reduced	O
dynamic	O
fluidity	O
and	O
range	O
in	O
network	O
correlation	O
structure	O
for	O
patients	O
suffering	O
from	O
this	O
varied	O
and	O
complex	B-DS
disorder	I-DS
.	O

The	O
simultaneous	O
weighted	O
contributions	O
,	O
called	O
meta	O
-	O
states	O
,	O
of	O
whole	O
-	O
brain	O
patterns	O
of	O
connectivity	O
to	O
subject	O
wFNCs	O
change	O
less	O
often	O
,	O
and	O
shift	O
between	O
a	O
smaller	O
number	O
of	O
more	O
similar	O
meta	O
-	O
states	O
in	O
schizophrenia	B-DS
patients	O
than	O
in	O
healthy	O
controls	O
(	O
Fig	O
2	O
(	O
D	O
)).	O

Supporting	O
a	O
meta	O
-	O
state	O
approach	O
is	O
the	O
fact	O
that	O
this	O
finding	O
holds	O
for	O
sets	O
of	O
whole	O
-	O
brain	O
network	O
connectivity	O
patterns	O
,	O
generally	O
quite	O
different	O
from	O
each	O
other	O
,	O
derived	O
using	O
various	O
data	O
-	O
driven	O
approaches	O
,	O
including	O
temporal	O
independent	O
component	O
analysis	O
(	O
ICA	O
),	O
spatial	O
ICA	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
k	O
-	O
means	O
.	O

Meta	O
-	O
State	O
Dynamic	O
FNC	O
:	O
High	O
Level	O
Schematics	O
(	O
A	O
)	O
Schematic	O
showing	O
connectivity	O
decomposed	O
into	O
,	O
for	O
simplicity	O
,	O
binary	O
weighted	O
sums	O
of	O
connectivity	O
patterns	O
,	O
yielding	O
meta	O
-	O
states	O
in	O
{	O
0	O
,	O
1	O
}	O
s4	O
;	O
(	O
B	O
)	O
Histograms	O
of	O
maximal	O
uninterrupted	O
periods	O
spent	O
in	O
any	O
fixed	O
meta	O
-	O
state	O
for	O
patients	O
(	O
red	O
)	O
and	O
controls	O
(	O
blue	O
)	O
(	O
C	O
)	O
A	O
connectivity	O
pattern	O
in	O
which	O
network	O
-	O
pair	O
connections	O
are	O
signed	O
and	O
non	O
-	O
binary	O
(	O
for	O
example	O
,	O
given	O
by	O
correlations	O
)	O
and	O
in	O
graph	O
(	O
right	O
)	O
and	O
matrix	O
(	O
left	O
)	O
forms	O
;	O
(	O
D	O
)	O
Schematic	O
illustration	O
of	O
differences	O
in	O
dynamical	O
patterns	O
of	O
network	O
connectivity	O
between	O
schizophrenia	B-DS
patients	O
and	O
healthy	O
controls	O
.	O

Controls	O
exhibit	O
more	O
,	O
and	O
more	O
diverse	O
,	O
connectivity	O
states	O
changing	O
from	O
one	O
connectivity	O
pattern	O
to	O
another	O
more	O
often	O
than	O
patients	O
.	O

Temporal	O
ICA	O
Schematic	O
with	O
Examples	O
of	O
Single	O
Window	O
Weighted	O
CPs	O
and	O
Discretized	O
Time	O
-	O
Varying	O
CP	O
Weights	O
(	O
A	O
)	O
Schematic	O
displaying	O
stages	O
involved	O
in	O
producing	O
CPs	O
;	O
top	O
row	O
illustrates	O
the	O
initial	O
decomposition	O
of	O
fMRI	O
data	O
into	O
network	O
spatial	O
maps	O
and	O
corresponding	O
timecourses	O
using	O
group	O
spatial	O
ICA	O
(	O
GICA	O
);	O
bottom	O
row	O
shows	O
decomposition	O
of	O
window	O
-	O
indexed	O
correlation	O
matrices	O
computed	O
on	O
sliding	O
windows	O
through	O
the	O
network	O
timecourses	O
(	O
left	O
-	O
hand	O
side	O
of	O
equation	O
)	O
produced	O
by	O
spatial	O
ICA	O
on	O
fMRI	O
data	O
summarized	O
in	O
the	O
top	O
row	O
into	O
temporally	O
independent	O
CPs	O
(	O
matrix	O
W	O
on	O
right	O
hand	O
side	O
of	O
equation	O
)	O
using	O
temporal	O
ICA	O
;	O
(	O
B	O
)	O
Example	O
of	O
an	O
observed	O
wFNC	O
expressed	O
as	O
weighted	O
sum	O
of	O
the	O
five	O
displayed	O
tICA	O
CPs	O
;	O
(	O
C	O
)	O
One	O
subject	O
'	O
s	O
CP	O
timecourses	O
(	O
top	O
left	O
)	O
transformed	O
into	O
the	O
signed	O
quartile	O
discretization	O
(	O
top	O
right	O
)	O
with	O
times	O
at	O
which	O
each	O
discretized	O
timecourse	O
changes	O
from	O
one	O
level	O
to	O
another	O
(	O
bottom	O
and	O
example	O
of	O
one	O
time	O
-	O
indexed	O
5	O
-	O
vector	O
of	O
timecourse	O
values	O
converted	O
into	O
a	O
meta	O
-	O
state	O
of	O
signed	O
quartile	O
values	O
(	O
bottom	O
right	O
).	O

Methods	O
and	O
Materials	O

Sample	O
and	O
Data	O
Acquisition	O

Resting	O
state	O
functional	O
magnetic	O
resonance	O
imaging	O
data	O
(	O
162	O
volumes	O
of	O
echo	O
planar	O
imaging	O
BOLD	O
fMRI	O
,	O
TR	O
=	O
2	O
sec	O
.)	O
[	O
26	O
,	O
37	O
]	O
was	O
collected	O
from	O
163	O
healthy	O
controls	O
(	O
117	O
males	O
,	O
46	O
females	O
;	O
mean	O
age	O
36	O
.	O
9	O
)	O
and	O
151	O
age	O
and	O
gender	O
matched	O
patients	O
with	O
schizophrenia	B-DS
(	O
114	O
males	O
,	O
37	O
females	O
;	O
mean	O
age	O
37	O
.	O
8	O
)	O
during	O
eyes	O
closed	O
condition	O
at	O
7	O
different	O
sites	O
across	O
the	O
United	O
States	O
(	O
Table	O
1	O
).	O

Inclusion	O
criteria	O
for	O
the	O
patients	O
were	O
a	O
schizophrenia	B-DS
diagnosis	O
based	O
on	O
the	O
structured	O
clinical	O
interview	O
for	O
DSM	O
-	O
IV	O
-	O
TR	O
axis	B-DS
I	O
disorders	O
(	O
SCID	O
-	O
I	O
/	O
P	O
)	O
[	O
42	O
].	O

All	O
patients	O
were	O
clinically	O
stable	O
on	O
antipsychotic	O
medication	O
for	O
at	O
least	O
2	O
months	O
,	O
and	O
had	O
an	O
illness	O
duration	O
of	O
minimally	O
one	O
year	O
.	O

Clinical	O
assessments	O
for	O
the	O
patients	O
included	O
the	O
positive	O
and	O
negative	O
syndrome	O
scale	O
(	O
PANSS	O
)	O
[	O
43	O
].	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
study	O
participants	O
,	O
including	O
permission	O
to	O
share	O
de	O
-	O
identified	O
data	O
between	O
the	O
centers	O
and	O
with	O
the	O
wider	O
research	O
community	O
.	O

This	O
analysis	O
of	O
existing	O
data	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
at	O
the	O
University	O
of	O
New	O
Mexico	O
.	O

Demographic	O
Information	O
.	O

Subject	O
Demographic	O
Information	O

Schizophrenia	B-DS
Patient	O
(	O
SZ	B-DS
)	O

151	O

Healthy	O
Control	O
(	O
HC	O
)	O

162	O

Male	O

231	O
(	O
SZ	O
=	O
114	O
)	O

Female	O

83	O
(	O
SZ	O
=	O
37	O
)	O

Ages	O
18	O
–	O
30	O

108	O
(	O
SZ	O
=	O
52	O
)	O

Ages	O
31	O
–	O
60	O

206	O
(	O
SZ	O
=	O
99	O
)	O

Data	O
Preprocessing	O

A	O
combination	O
of	O
toolboxes	O
(	O
AFNI1	O
,	O
SPM2	O
,	O
GIFT3	O
)	O
and	O
custom	O
code	O
written	O
in	O
Matlab	O
were	O
employed	O
in	O
the	O
pre	O
-	O
processing	O
pipeline	O
.	O

Rigid	O
body	O
motion	O
correction	O
was	O
performed	O
with	O
the	O
INRIAlign	O
[	O
44	O
]	O
toolbox	O
in	O
SPM	O
to	O
correct	O
for	O
subject	O
head	O
motion	O
,	O
followed	O
by	O
slice	O
-	O
timing	O
correction	O
to	O
account	O
for	O
timing	O
differences	O
in	O
slice	O
acquisition	O
.	O

Data	O
was	O
then	O
despiked	O
using	O
AFNI3s	O
3dDespike	O
algorithm	O
to	O
mitigate	O
the	O
impact	O
of	O
outliers	O
and	O
despiked	O
fMRI	O
data	O
was	O
subsequently	O
warped	O
to	O
a	O
Montreal	O
Neurological	O
Institute	O
(	O
MNI	O
)	O
template	O
,	O
then	O
resampled	O
to	O
3	O
mm3	O
isotropic	O
voxels	O
.	O

Instead	O
of	O
Gaussian	O
smoothing	O
,	O
we	O
smoothed	O
the	O
data	O
to	O
6	O
mm	O
full	O
width	O
at	O
half	O
maximum	O
(	O
FWHM	O
)	O
using	O
AFNI3s	O
BlurToFWHM	O
algorithm	O
which	O
performs	O
smoothing	O
by	O
a	O
conservative	O
finite	O
difference	O
approximation	O
to	O
the	O
diffusion	O
equation	O
.	O

This	O
approach	O
has	O
been	O
shown	O
to	O
reduce	O
scanner	O
specific	O
variability	O
in	O
smoothness	O
providing	O
“	O
smoothness	O
equivalence	O
”	O
to	O
data	O
across	O
sites	O
[	O
45	O
].	O

Finally	O
,	O
prior	O
to	O
performing	O
group	O
independent	O
component	O
analysis	O
,	O
each	O
voxel	O
time	O
course	O
was	O
variance	O
normalized	O
as	O
this	O
approach	O
has	O
been	O
shown	O
to	O
yield	O
better	O
decompositions	O
of	O
subcortical	O
and	O
cortical	O
sources	O
.	O

Decomposition	O
into	O
Functional	O
Networks	O

After	O
preprocessing	O
,	O
the	O
functional	O
imaging	O
data	O
from	O
all	O
subjects	O
was	O
decomposed	O
into	O
a	O
set	O
of	O
100	O
statistically	O
independent	O
spatial	O
regions	O
with	O
common	O
time	O
course	O
profile	O
using	O
group	O
independent	O
component	O
analysis	O
(	O
GICA	O
),	O
implemented	O
by	O
the	O
GIFT	O
toolbox	O
(	O
http	O
://	O
mialab	O
.	O
mrn	O
.	O
org	O
/	O
software	O
/	O
gift	O
).	O

Of	O
these	O
100	O
components	O
,	O
47	O
were	O
identified	O
as	O
intrinsic	O
connectivity	O
networks	O
(	O
ICNs	O
)	O
using	O
the	O
procedures	O
described	O
in	O
our	O
earlier	O
work	O
[	O
26	O
,	O
37	O
].	O

Subject	O
-	O
specific	O
spatial	O
maps	O
and	O
time	O
courses	O
were	O
obtained	O
using	O
spatio	O
-	O
temporal	O
regression	O
.	O

The	O
subject	O
ICN	O
time	O
courses	O
were	O
detrended	O
,	O
orthogonalized	O
with	O
respect	O
to	O
motion	O
parameters	O
,	O
despiked	O
by	O
replacing	O
outlier	O
time	O
points	O
with	O
3rd	O
order	O
spline	O
fit	O
to	O
cleaner	O
neighboring	O
points	O
,	O
and	O
filtered	O
using	O
a	O
5th	O
order	O
Butterworth	O
filter	O
with	O
a	O
passband	O
of	O
0	O
.	O
01	O
to	O
0	O
.	O
15	O
Hz	O
.	O

Windowed	O
Functional	O
Network	O
Connectivity	O
Matrices	O
(	O
wFNCs	O
)	O

Windowed	O
functional	O
network	O
connectivity	O
(	O
wFNC	O
)	O
is	O
evaluated	O
by	O
computing	O
pairwise	O
correlations	O
between	O
windowed	O
segments	O
of	O
ICN	O
timecourses	O
using	O
a	O
tapered	O
rectangular	O
window	O
of	O
length	O
of	O
22	O
TRs	O
(	O
44	O
seconds	O
),	O
advancing	O
1	O
TR	O
at	O
each	O
step	O
.	O

To	O
improve	O
correlation	O
estimates	O
on	O
timecourses	O
of	O
shorter	O
length	O
,	O
we	O
impose	O
an	O
L1	O
constraint	O
on	O
the	O
inverse	O
covariance	O
matrix	O
using	O
the	O
G	O
-	O
LASSO	O
framework	O
[	O
45	O
],	O
with	O
regularization	O
parameter	O
optimized	O
subject	O
-	O
wise	O
by	O
evaluating	O
the	O
log	O
-	O
likelihood	O
of	O
each	O
subject	O
’	O
s	O
unseen	O
data	O
in	O
a	O
cross	O
-	O
validation	O
framework	O
.	O

Basis	O
Correlation	O
Patterns	O
(	O
CPs	O
)	O

Recent	O
work	O
[	O
16	O
,	O
25	O
,	O
26	O
,	O
37	O
,	O
46	O
]	O
on	O
functional	O
network	O
connectivity	O
dynamics	O
has	O
used	O
clustering	O
algorithms	O
to	O
identify	O
a	O
small	O
set	O
of	O
prototype	O
connectivity	O
“	O
states	O
”.	O

Observed	O
wFNCs	O
are	O
replaced	O
by	O
the	O
prototype	O
states	O
they	O
most	O
resemble	O
,	O
allowing	O
connectivity	O
dynamics	O
to	O
be	O
described	O
as	O
a	O
process	O
of	O
moving	O
from	O
one	O
to	O
another	O
of	O
these	O
summary	O
states	O
.	O

In	O
this	O
work	O
,	O
we	O
present	O
a	O
flexible	O
,	O
intuitive	O
framework	O
for	O
studying	O
network	O
connectivity	O
dynamics	O
.	O

The	O
model	O
order	O
of	O
five	O
,	O
used	O
in	O
all	O
decompositions	O
presented	O
here	O
,	O
was	O
chosen	O
in	O
an	O
effort	O
to	O
balance	O
tractability	O
of	O
complex	O
linearly	O
additive	O
effects	O
with	O
a	O
desire	O
for	O
richly	O
featured	O
basis	O
correlation	O
pattern	O
sets	O
.	O

To	O
assess	O
the	O
sensitivity	O
of	O
our	O
results	O
to	O
perturbation	O
of	O
this	O
parameter	O
,	O
we	O
also	O
performed	O
our	O
analysis	O
on	O
model	O
orders	O
ranging	O
from	O
three	O
to	O
seven	O
,	O
and	O
found	O
overall	O
results	O
to	O
be	O
consistent	O
with	O
the	O
model	O
order	O
chosen	O
as	O
the	O
focus	O
of	O
this	O
paper	O
,	O
providing	O
additional	O
confidence	O
in	O
the	O
robustness	O
of	O
the	O
framework	O
and	O
the	O
main	O
dynamical	O
metrics	O
presented	O
here	O
.	O

Temporally	O
Independent	O
Connectivity	O
Patterns	O

Our	O
objective	O
is	O
to	O
express	O
time	O
-	O
varying	O
wFNCs	O
as	O
weighted	O
sums	O
of	O
correlation	O
patterns	O
whose	O
contributions	O
change	O
independently	O
of	O
each	O
other	O
in	O
time	O
(	O
see	O
Fig	O
3	O
(	O
A	O
)	O
and	O
3	O
(	O
B	O
)),	O
allowing	O
us	O
to	O
develop	O
a	O
richer	O
picture	O
of	O
the	O
interplay	O
between	O
connectivity	O
patterns	O
that	O
are	O
strongly	O
present	O
in	O
the	O
data	O
.	O

This	O
objective	O
explicitly	O
permits	O
collections	O
of	O
basis	O
connectivity	O
patterns	O
featuring	O
:	O

Two	O
or	O
more	O
patterns	O
in	O
which	O
some	O
subset	O
of	O
network	O
-	O
pairs	O
share	O
the	O
same	O
correlation	O
strength	O
.	O

Individual	O
patterns	O
that	O
do	O
not	O
strongly	O
resemble	O
empirically	O
observed	O
wFNCs	O
.	O

To	O
achieve	O
this	O
goal	O
we	O
apply	O
group	O
temporal	O
independent	O
component	O
analysis	O
(	O
tICA	O
)	O
(	O
Fig	O
3	O
(	O
A	O
))	O
[	O
30	O
]	O
to	O
wFNC	O
matrices	O
concatenated	O
along	O
the	O
subject	O
×	O
time	O
dimension	O
,	O
decomposing	O
this	O
concatenated	O
1081	O
network	O
-	O
pair	O
correlations	O
×	O
136	O
time	O
windows	O
×	O
314	O
subject	O
structure	O
into	O
five	O
maximally	O
mutually	O
independent	O
timecourses	O
(	O
because	O
we	O
are	O
performing	O
this	O
analysis	O
at	O
the	O
group	O
level	O
,	O
these	O
are	O
in	O
fact	O
length	O
136	O
∙	O
314	O
=	O
42	O
,	O
704	O
subject	O
×	O
time	O
“	O
courses	O
”),	O
each	O
with	O
an	O
associated	O
47	O
×	O
47	O
connectivity	O
pattern	O
(	O
a	O
modular	O
component	O
of	O
the	O
mixing	O
matrix	O
)	O
that	O
is	O
shared	O
across	O
subjects	O
(	O
Fig	O
3	O
(	O
A	O
)).	O

In	O
the	O
text	O
above	O
,	O
for	O
convenience	O
,	O
we	O
will	O
refer	O
to	O
the	O
connectivity	O
patterns	O
as	O
components	O
,	O
even	O
though	O
it	O
is	O
the	O
subject	O
×	O
timecourses	O
that	O
are	O
being	O
estimated	O
by	O
tICA	O
.	O

In	O
this	O
decomposition	O
,	O
individual	O
wFNCs	O
are	O
specified	O
as	O
weighted	O
sums	O
of	O
the	O
five	O
CPs	O
,	O
yielding	O
a	O
5	O
-	O
dimensional	O
characterization	O
of	O
each	O
subject	O
’	O
s	O
1081	O
-	O
dimensional	O
connectivity	O
structure	O
in	O
each	O
time	O
window	O
.	O

The	O
dynamical	O
object	O
of	O
investigation	O
is	O
now	O
a	O
set	O
of	O
136	O
time	O
-	O
indexed	O
five	O
-	O
vectors	O
per	O
subject	O
that	O
representing	O
the	O
contributions	O
of	O
five	O
1081	O
-	O
dimensional	O
CPs	O
to	O
the	O
observed	O
wFNCs	O
.	O

The	O
tICA	O
decomposition	O
of	O
wFNC	O
data	O
produces	O
CPs	O
whose	O
weights	O
in	O
each	O
time	O
-	O
indexed	O
five	O
-	O
vector	O
are	O
maximally	O
mutually	O
independent	O
[	O
28	O
–	O
30	O
].	O

These	O
tICA	O
CPs	O
are	O
thus	O
patterns	O
whose	O
additive	O
contributions	O
to	O
observed	O
wFNCs	O
“	O
pipe	O
in	O
”	O
and	O
fade	O
out	O
in	O
a	O
relatively	O
independent	O
manner	O
.	O

Although	O
the	O
window	O
-	O
wise	O
CP	O
weights	O
in	O
the	O
tICA	O
decomposition	O
are	O
as	O
independent	O
as	O
possible	O
,	O
intrinsic	O
dependencies	O
within	O
the	O
data	O
ensure	O
that	O
the	O
weights	O
are	O
not	O
formally	O
independent	O
,	O
i	O
.	O
e	O
.	O
P	O
(	O
a1	O
≤	O
w1	O
≤	O
b1	O
,…,	O
a5	O
≤	O
w5	O
≤	O
b5	O
)≠∏	O
k	O
=	O
15P	O
(	O
ak	O
≤	O
wk	O
≤	O
bk	O
).	O

The	O
five	O
-	O
vectors	O
thus	O
hold	O
information	O
not	O
available	O
by	O
analyzing	O
elements	O
separately	O
,	O
but	O
maximizing	O
temporal	O
independence	O
keeps	O
the	O
state	O
-	O
space	O
from	O
collapsing	O
onto	O
a	O
lower	O
-	O
dimensional	O
space	O
,	O
ie	O
.	O
if	O
CP	O
#	O
1	O
and	O
CP	O
#	O
2	O
are	O
systematically	O
mutually	O
dependent	O
then	O
only	O
one	O
is	O
necessary	O
and	O
the	O
state	O
space	O
becomes	O
four	O
-	O
dimensional	O
.	O

Reducing	O
the	O
systematic	O
dependencies	O
between	O
CPs	O
ensures	O
we	O
are	O
taking	O
maximal	O
advantage	O
of	O
the	O
dimensionality	O
in	O
which	O
the	O
dynamics	O
have	O
been	O
defined	O
.	O

Although	O
we	O
have	O
chosen	O
to	O
focus	O
on	O
maximally	O
temporally	O
independent	O
correlation	O
patterns	O
produced	O
by	O
applying	O
temporal	O
ICA	O
to	O
the	O
windowed	O
FNCs	O
(	O
Fig	O
3	O
(	O
A	O
)),	O
we	O
were	O
interested	O
in	O
understanding	O
how	O
sensitive	O
the	O
results	O
obtained	O
might	O
be	O
to	O
our	O
choice	O
of	O
method	O
for	O
extracting	O
correlation	O
patterns	O
from	O
the	O
windowed	O
FNCs	O
.	O

Thus	O
we	O
performed	O
the	O
same	O
analysis	O
on	O
correlation	O
patterns	O
obtained	O
from	O
three	O
other	O
commonly	O
utilized	O
data	O
-	O
driven	O
methods	O
:	O
spatial	O
independent	O
component	O
analysis	O
(	O
sICA	O
),	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
kmeans	O
clustering	O
.	O

We	O
also	O
explored	O
the	O
role	O
of	O
model	O
order	O
within	O
the	O
temporal	O
ICA	O
framework	O
by	O
repeating	O
our	O
analysis	O
for	O
temporal	O
ICAs	O
producing	O
2	O
,	O
3	O
,	O
6	O
and	O
7	O
(	O
small	O
perturbations	O
of	O
the	O
featured	O
5	O
correlation	O
pattern	O
case	O
).	O

Alternative	O
Decompositions	O
into	O
CPs	O
:	O
Spatial	O
ICA	O
,	O
Principal	O
Components	O
and	O
K	O
-	O
means	O
Cluster	O
Centroids	O

We	O
perform	O
a	O
group	O
(	O
spatial	O
)	O
independent	O
component	O
analysis	O
(	O
GICA	O
)	O
on	O
the	O
wFNC	O
data	O
using	O
protocols	O
directly	O
analogous	O
those	O
employed	O
for	O
higher	O
-	O
dimensional	O
fMRI	O
data	O
[	O
39	O
,	O
43	O
].	O

The	O
basis	O
correlation	O
patterns	O
obtained	O
by	O
group	O
sICA	O
are	O
maximally	O
spatially	O
(	O
cell	O
-	O
wise	O
)	O
independent	O
,	O
but	O
neither	O
mutually	O
orthogonal	O
nor	O
informative	O
about	O
the	O
way	O
dFNC	O
variance	O
is	O
organized	O
(	O
Fig	O
4	O
(	O
A	O
,	O
Row	O
2	O
)).	O

For	O
a	O
set	O
of	O
mutually	O
orthogonal	O
basis	O
patterns	O
whose	O
structure	O
explicitly	O
reflects	O
dominant	O
directions	O
of	O
data	O
variance	O
,	O
we	O
use	O
the	O
first	O
five	O
components	O
of	O
a	O
PCA	O
along	O
the	O
subject	O
×	O
time	O
dimension	O
of	O
the	O
concatenated	O
wFNC	O
data	O
(	O
Fig	O
4	O
(	O
A	O
,	O
Row	O
3	O
)).	O

The	O
timecourses	O
for	O
sICA	B-GP
(	O
resp	O
.	O

PCA	O
)	O
correlation	O
patterns	O
are	O
obtained	O
by	O
regressing	O
each	O
subject	O
'	O
s	O
wFNC	O
data	O
at	O
each	O
time	O
window	O
on	O
the	O
set	O
of	O
sICA	O
(	O
resp	O
.	O

PCA	O
)	O
correlation	O
patterns	O
.	O

Correlation	O
Patterns	O
Produced	O
by	O
Different	O
Algorithms	O
and	O
by	O
Temporal	O
ICA	O
at	O
Different	O
Model	O
Orders	O
(	O
A	O
)	O
Different	O
data	O
-	O
driven	O
decompositions	O
of	O
the	O
wFNCs	O
yield	O
different	O
sets	O
of	O
correlation	O
patterns	O
;	O
correlation	O
patterns	O
produced	O
,	O
from	O
top	O
to	O
bottom	O
,	O
by	O
tICA	O
,	O
sICA	O
,	O
PCA	O
,	O
K	O
-	O
means	O
,	O
all	O
with	O
model	O
order	O
five	O
;	O
(	O
B	O
)	O
Different	O
model	O
-	O
orders	O
of	O
tICA	O
applied	O
to	O
the	O
wFNCs	O
yield	O
growing	O
collections	O
of	O
correlation	O
patters	O
with	O
two	O
recurring	O
patterns	O
(	O
Row	O
1	O
,	O
Columnss	O
1	O
and	O
3	O
);	O
tICA	O
correlation	O
patterns	O
,	O
from	O
top	O
to	O
bottom	O
,	O
for	O
model	O
orders	O
three	O
through	O
seven	O
.	O

In	O
addition	O
to	O
ICA	O
and	O
PCA	O
techniques	O
,	O
we	O
also	O
apply	O
k	O
-	O
means	O
clustering	O
to	O
the	O
windowed	O
FNCs	O
.	O

Using	O
Matlab	O
’	O
s	O
implementation	O
of	O
k	O
-	O
means	O
clustering	O
with	O
the	O
squared	O
Euclidean	O
distance	O
,	O
500	O
iterates	O
and	O
150	O
replicates	O
,	O
we	O
partition	O
the	O
set	O
of	O
wFNCs	O
into	O
five	O
clusters	O
whose	O
centroids	O
are	O
treated	O
as	O
basis	O
correlation	O
patterns	O
(	O
Fig	O
4	O
(	O
A	O
,	O
Row	O
4	O
)).	O

We	O
investigate	O
the	O
time	O
-	O
varying	O
joint	O
contributions	O
of	O
these	O
CPs	O
using	O
two	O
forms	O
of	O
weighted	O
k	O
-	O
means	O
timecourses	O
.	O

The	O
first	O
,	O
directly	O
analogous	O
to	O
the	O
sICA	O
and	O
PCA	O
timecourses	O
,	O
is	O
a	O
linearly	O
additive	O
weighting	O
obtained	O
by	O
regressing	O
wFNC	O
data	O
on	O
the	O
kmeans	O
CPs	O
.	O

The	O
second	O
characterizes	O
each	O
wFNC	O
by	O
a	O
five	O
-	O
vector	O
with	O
weights	O
based	O
on	O
the	O
L2	O
distances	O
of	O
the	O
wFNCs	O
from	O
each	O
kmeans	O
CP	O
.	O

Specifically	O
,	O
for	O
subject	O
k	O
'	O
s	O
time	O
t	O
wFNC	O
,	O
F	O
(	O
k	O
)(	O
t	O
),	O
we	O
have	O
the	O
five	O
vector	O
w	O
(	O
k	O
)(	O
t	O
)=(	O
w1	O
(	O
k	O
)(	O
t	O
),	O
w2	O
(	O
k	O
)(	O
t	O
),	O
w3	O
(	O
k	O
)(	O
t	O
),	O
w4	O
(	O
k	O
)(	O
t	O
),	O
w5	O
(	O
k	O
)(	O
t	O
))	O
whose	O
ith	O
element	O
wi	O
(	O
k	O
)=	O
1	O
−‖	O
F	O
(	O
k	O
)(	O
t	O
)−	O
Ci	O
‖	O
2	O
∑	O
j	O
=	O
15	O
‖	O
F	O
(	O
k	O
)(	O
t	O
)−	O
Cj	O
‖	O
2	O
,	O
where	O
Cj	O
is	O
the	O
jth	O
kmeans	O
CP	O
.	O

For	O
consistency	O
with	O
the	O
other	O
decompositions	O
we	O
report	O
the	O
results	O
from	O
regressing	O
wFNC	O
data	O
on	O
k	O
-	O
means	O
CPs	O
,	O
but	O
results	O
using	O
the	O
alternative	O
weighting	O
system	O
presented	O
the	O
same	O
directionality	O
and	O
significance	O
.	O

Timecourse	O
Discretization	O

We	O
convert	O
the	O
original	O
real	O
-	O
valued	O
weight	O
vectors	O
to	O
discrete	O
meta	O
-	O
states	O
(	O
Fig	O
3	O
(	O
C	O
))	O
by	O
replacing	O
each	O
CP	O
weight	O
with	O
a	O
value	O
in	O
±{	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
}	O
according	O
to	O
its	O
signed	O
quartile	O
:	O
the	O
vector	O
w	O
(	O
k	O
)(	O
t	O
)=(	O
w1	O
(	O
k	O
)(	O
t	O
),	O
w2	O
(	O
k	O
)(	O
t	O
),	O
w3	O
(	O
k	O
)(	O
t	O
),	O
w4	O
(	O
k	O
)(	O
t	O
),	O
w5	O
(	O
k	O
)(	O
t	O
))	O
of	O
subject	O
k	O
'	O
s	O
time	O
t	O
component	O
weights	O
is	O
converted	O
to	O
λ	O
(	O
k	O
)(	O
t	O
)=(	O
λ1	O
(	O
k	O
)(	O
t	O
),	O
λ2	O
(	O
k	O
)(	O
t	O
),	O
λ3	O
(	O
k	O
)(	O
t	O
),	O
λ4	O
(	O
k	O
)(	O
t	O
),	O
λ5	O
(	O
k	O
)(	O
t	O
))	O
where	O
λi	O
(	O
k	O
)∈{±	O
1	O
,±	O
2	O
,±	O
3	O
,±	O
4	O
}	O
indicating	O
the	O
quartile	O
of	O
the	O
(	O
same	O
-	O
sign	O
)	O
weights	O
each	O
wi	O
(	O
k	O
)	O
falls	O
into	O
.	O

When	O
λi	O
(	O
k	O
)=	O
l	O
∈{±	O
1	O
,±	O
2	O
,±	O
3	O
,±	O
4	O
},	O
component	O
i	O
is	O
said	O
to	O
be	O
occupied	O
at	O
level	O
l	O
.	O

The	O
length	O
-	O
five	O
vectors	O
(	O
λ1	O
(	O
k	O
)(	O
t	O
),	O
λ2	O
(	O
k	O
)(	O
t	O
),	O
λ3	O
(	O
k	O
)(	O
t	O
),	O
λ4	O
(	O
k	O
)(	O
t	O
),	O
λ5	O
(	O
k	O
)(	O
t	O
))	O
are	O
referred	O
to	O
as	O
meta	O
-	O
states	O
.	O

Discretization	O
of	O
sICA	O
,	O
principal	O
component	O
and	O
weighted	O
k	O
-	O
means	O
timecourses	O
follows	O
the	O
tICA	O
procedure	O
exactly	O
.	O

2	O
.	O
9	O
Diagnosis	O
Effects	O

We	O
employ	O
a	O
linear	O
model	O
,	O
y	O
=	O
β0	O
+	O
βageXage	O
+	O
βgenderXgender	O
+	O
βdiagnosisXdiagnosis	O
+	O
ε	O
to	O
estimate	O
the	O
effect	O
of	O
diagnosis	O
on	O
the	O
various	O
measures	O
investigated	O
here	O
.	O

The	O
diagnosis	O
variable	O
is	O
binary	O
,	O
with	O
SZ	B-DS
coded	O
as	O
'	O
1	O
'	O
and	O
HC	O
as	O
'	O
0	O
',	O
so	O
βdiagnosis	O
>	O
0	O
indicates	O
a	O
positive	O
correlation	O
with	O
SZ	B-DS
and	O
βdiagnosis	O
<	O
0	O
shows	O
a	O
negative	O
correlation	O
with	O
SZ	B-DS
.	O

We	O
generally	O
report	O
or	O
display	O
the	O
value	O
of	O
βdiagnosis	O
when	O
its	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
corrected	O
p	O
-	O
value	O
is	O
less	O
than	O
0	O
.	O
05	O
.	O

Results	O

Our	O
meta	O
-	O
state	O
dynamical	O
framework	O
exposes	O
important	O
features	O
of	O
whole	O
-	O
brain	O
connectivity	O
dynamics	O
that	O
seem	O
to	O
emerge	O
specifically	O
at	O
this	O
level	O
of	O
analysis	O
;	O
network	O
timecourses	O
[	O
1	O
],	O
windowed	O
network	O
timecourses	O
,	O
and	O
even	O
individual	O
network	O
-	O
pair	O
wFNC	O
values	O
,	O
for	O
example	O
,	O
exhibit	O
more	O
high	O
-	O
frequency	O
power	O
in	O
schizophrenia	B-DS
patients	O
than	O
in	O
controls	O
,	O
a	O
phenomenon	O
that	O
dissolves	O
the	O
whole	O
brain	O
meta	O
-	O
state	O
level	O
(	O
see	O
Discussion	O
section	O
).	O

The	O
persistence	O
of	O
our	O
findings	O
across	O
a	O
variety	O
of	O
approaches	O
to	O
identifying	O
individual	O
states	O
from	O
the	O
data	O
suggests	O
we	O
are	O
observing	O
robust	O
phenomena	O
at	O
this	O
particular	O
scale	O
of	O
analysis	O
.	O

To	O
gauge	O
the	O
robustness	O
of	O
our	O
findings	O
,	O
we	O
applied	O
the	O
meta	O
-	O
state	O
analytical	O
framework	O
to	O
tICA	O
decompositions	O
with	O
smaller	O
(	O
model	O
orders	O
=	O
3	O
,	O
4	O
)	O
and	O
larger	O
(	O
model	O
orders	O
=	O
6	O
,	O
7	O
)	O
sets	O
of	O
CPs	O
,	O
and	O
also	O
to	O
collections	O
of	O
five	O
CPs	O
produced	O
using	O
group	O
spatial	O
ICA	O
(	O
GICA	O
),	O
PCA	O
and	O
k	O
-	O
means	O
clustering	O
(	O
Fig	O
4	O
(	O
A	O
)).	O

Broad	O
Reduction	O
of	O
Dynamic	O
Fluidity	O
and	O
Range	O
in	O
Schizophrenia	B-DS
Patients	O

The	O
state	O
space	O
X	O
induced	O
by	O
our	O
discretized	O
five	O
-	O
dimensional	O
characterization	O
of	O
connectivity	O
is	O
a	O
five	O
-	O
dimensional	O
lattice	O
with	O
a	O
set	O
of	O
five	O
mutually	O
orthogonal	O
co	O
-	O
dimension	O
one	O
hyperplanes	O
through	O
the	O
origin	O
removed	O
(	O
Fig	O
5	O
).	O

Planar	O
projection	O
of	O
the	O
discrete	O
five	O
-	O
dimensional	O
state	O
space	O
.	O

Each	O
removed	O
hyperplane	O
is	O
the	O
zero	O
set	O
of	O
one	O
of	O
the	O
dimensions	O
(	O
these	O
hyperplanes	O
are	O
not	O
part	O
of	O
X	O
because	O
the	O
range	O
of	O
our	O
signed	O
-	O
quartile	O
discretization	O
is	O
{±	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
}.	O

The	O
space	O
contains	O
C	O
≡	O
85	O
=	O
32	O
,	O
768	O
distinct	O
points	O
(	O
meta	O
-	O
states	O
),	O
of	O
which	O
cR	O
=	O
14	O
,	O
025	O
are	O
realized	O
at	O
some	O
point	O
in	O
time	O
by	O
some	O
subject	O
.	O

Individual	O
subjects	O
can	O
visit	O
at	O
most	O
T	O
=	O
136	O
meta	O
-	O
states	O
,	O
and	O
our	O
sample	O
of	O
N	O
=	O
314	O
subjects	O
allows	O
for	O
entire	O
sample	O
to	O
visit	O
at	O
most	O
NT	O
=	O
42	O
,	O
704	O
meta	O
-	O
states	O
.	O

Although	O
the	O
entire	O
study	O
includes	O
more	O
state	O
visits	O
(	O
42	O
,	O
704	O
)	O
than	O
points	O
in	O
the	O
X	O
,	O
more	O
than	O
half	O
(	O
C	O
-	O
cR	O
=	O
18	O
,	O
743	O
or	O
57	O
.	O
2	O
%)	O
of	O
the	O
points	O
in	O
X	O
are	O
never	O
visited	O
.	O

The	O
combinatorics	O
make	O
a	O
full	O
exploration	O
of	O
ways	O
unvisited	O
states	O
distribute	O
in	O
X	O
prohibitive	O
,	O
but	O
some	O
high	O
-	O
level	O
facts	O
about	O
how	O
individual	O
subjects	O
sample	O
the	O
state	O
space	O
are	O
readily	O
established	O
.	O

Our	O
analysis	O
focuses	O
on	O
four	O
global	O
metrics	O
of	O
connectivity	O
dynamism	O
:	O

The	O
number	O
of	O
times	O
that	O
subjects	O
switch	O
from	O
one	O
meta	O
-	O
state	O
to	O
another	O
(	O
denoted	O
by	O
s	O
)	O

The	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
subjects	O
occupy	O
during	O
their	O
scans	O
(	O
denoted	O
by	O
n	O
)	O

The	O
range	O
of	O
meta	O
-	O
states	O
subjects	O
occupy	O
,	O
ie	O
.,	O
the	O
largest	O
L1	O
distance	O
between	O
occupied	O
meta	O
-	O
states	O
(	O
denoted	O
by	O
r	O
)	O

The	O
overall	O
distance	O
traveled	O
by	O
each	O
subject	O
through	O
the	O
state	O
space	O
(	O
the	O
sum	O
of	O
the	O
L1	O
distances	O
between	O
successive	O
meta	O
-	O
states	O
,	O
denoted	O
by	O
d	O
)	O

The	O
first	O
measure	O
captures	O
how	O
often	O
a	O
subject	O
switches	O
between	O
meta	O
-	O
states	O
,	O
without	O
accounting	O
for	O
how	O
many	O
or	O
how	O
divergent	O
the	O
meta	O
-	O
states	O
are	O
(	O
one	O
could	O
switch	O
between	O
two	O
very	O
similar	O
states	O
in	O
rapid	O
succession	O
).	O

The	O
second	O
records	O
the	O
number	O
distinct	O
meta	O
-	O
states	O
are	O
passed	O
through	O
.	O

Since	O
there	O
are	O
32	O
,	O
768	O
distinct	O
meta	O
-	O
states	O
available	O
,	O
a	O
very	O
high	O
ratio	O
of	O
n	O
to	O
the	O
number	O
of	O
time	O
points	O
implies	O
high	O
s	O
;	O
a	O
very	O
high	O
ratio	O
of	O
n	O
to	O
the	O
number	O
of	O
possible	O
meta	O
-	O
states	O
implies	O
high	O
r	O
.	O

The	O
third	O
measure	O
indicates	O
how	O
divergent	O
the	O
meta	O
-	O
states	O
occupied	O
are	O
.	O

The	O
value	O
of	O
r	O
,	O
except	O
when	O
identically	O
zero	O
,	O
need	O
not	O
imply	O
anything	O
about	O
s	O
or	O
n	O
.	O

It	O
is	O
a	O
lower	O
bound	O
for	O
d	O
.	O

The	O
final	O
measure	O
,	O
d	O
,	O
incorporates	O
information	O
from	O
the	O
other	O
three	O
without	O
being	O
fully	O
determined	O
by	O
them	O
.	O

It	O
is	O
maximized	O
when	O
a	O
subject	O
switches	O
frequently	O
between	O
two	O
meta	O
-	O
states	O
at	O
distal	O
boundaries	O
of	O
the	O
state	O
space	O
.	O

We	O
find	O
consistent	O
and	O
pervasive	O
evidence	O
(	O
Table	O
2	O
)	O
of	O
reduced	O
FNC	O
dynamism	O
among	O
schizophrenia	B-DS
patients	O
with	O
respect	O
to	O
each	O
of	O
the	O
four	O
metrics	O
above	O
,	O
and	O
across	O
all	O
four	O
data	O
-	O
driven	O
decompositions	O
of	O
observed	O
wFNCs	O
into	O
collections	O
of	O
basis	O
CPs	O
:	O

SZ	B-DS
exhibit	O
diminished	O
dynamic	O
fluidity	O
:	O
Schizophrenia	B-DS
patients	O
occupy	O
fewer	O
meta	O
-	O
states	O
than	O
healthy	O
controls	O
(	O
mean	O
HC	O
=	O
73	O
.	O
2	O
meta	O
-	O
states	O
,	O
mean	O
SZ	B-DS
=	O
67	O
.	O
4	O
meta	O
-	O
states	O
;	O
diagnosis	O
effect	O
in	O
regression	O
=	O
-	O
5	O
.	O
65	O
,	O
P	O
-	O
value	O
=	O
3	O
.	O
93	O
e	O
-	O
006	O
).	O

(	O
Fig	O
6	O
(	O
A	O
),	O
Table	O
2	O
,	O
Table	O
3	O
)	O
Schizophrenia	B-DS
patients	O
change	O
from	O
one	O
meta	O
-	O
state	O
to	O
another	O
less	O
often	O
than	O
healthy	O
controls	O
(	O
mean	O
HC	O
=	O
74	O
.	O
04	O
changes	O
,	O
mean	O
SZ	B-DS
=	O
68	O
.	O
58	O
changes	O
;	O
diagnosis	O
effect	O
in	O
regression	O
=	O
-	O
5	O
.	O
32	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
72	O
e	O
-	O
006	O
).	O

(	O
Fig	O
6	O
(	O
B	O
),	O
Table	O
2	O
,	O
Table	O
3	O
)	O

SZ	B-DS
operate	O
over	O
a	O
restricted	O
dynamic	O
range	O
:	O
Schizophrenia	B-DS
patients	O
remain	O
trapped	O
in	O
a	O
smaller	O
radius	O
hypercube	O
of	O
the	O
state	O
space	O
than	O
do	O
healthy	O
controls	O
,	O
as	O
measured	O
by	O
the	O
maximal	O
L1	O
-	O
distance	O
between	O
occupied	O
meta	O
-	O
states	O
(	O
mean	O
HC	O
=	O
16	O
.	O
77	O
diameter	O
,	O
mean	O
SZ	O
=	O
14	O
.	O
77	O
diameter	O
;	O
diagnosis	O
effect	O
in	O
regression	O
=	O
-	O
2	O
.	O
20	O
,	O
P	O
-	O
value	O
=	O
6	O
.	O
62	O
e	O
-	O
008	O
).	O

(	O
Fig	O
7	O
(	O
A	O
),	O
Table	O
2	O
,	O
Table	O
3	O
)	O
Schizophrenia	B-DS
patients	O
traverse	O
less	O
overall	O
distance	O
,	O
evaluated	O
by	O
summed	O
L1	O
distance	O
between	O
successive	O
meta	O
-	O
states	O
,	O
through	O
the	O
state	O
space	O
than	O
do	O
healthy	O
controls	O
(	O
mean	O
HC	O
=	O
91	O
.	O
55	O
overall	O
distance	O
,	O
mean	O
SZ	B-DS
=	O
83	O
.	O
80	O
overall	O
distance	O
;	O
diagnosis	O
effect	O
in	O
regression	O
=	O
-	O
9	O
.	O
69	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
89	O
e	O
-	O
006	O
).	O

(	O
Fig	O
7	O
(	O
B	O
),	O
Table	O
2	O
,	O
Table	O
3	O
).	O

Effect	O
of	O
Schizophrenia	B-DS
on	O
Dynamic	O
Fluidity	O
Measures	O
(	O
A	O
)	O
Number	O
of	O
meta	O
-	O
states	O
realized	O
;	O
(	O
middle	O
column	O
)	O
boxplot	O
showing	O
median	O
,	O
quartiles	O
and	O
outliers	O
plus	O
mean	O
for	O
each	O
group	O
,	O
and	O
diagnosis	O
effect	O
from	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
with	O
associated	O
p	O
-	O
value	O
;	O
(	O
leftmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
healthy	O
subject	O
,	O
with	O
the	O
88	O
distinct	O
meta	O
-	O
states	O
shown	O
underneath	O
;	O
(	O
rightmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
schizophrenia	B-DS
patient	O
,	O
with	O
the	O
23	O
distinct	O
meta	O
-	O
states	O
shown	O
underneath	O
;	O
(	O
B	O
)	O
Number	O
of	O
timepoints	O
at	O
which	O
subjects	O
change	O
between	O
meta	O
-	O
states	O
;	O
(	O
middle	O
column	O
)	O
boxplot	O
showing	O
median	O
,	O
quartiles	O
and	O
outliers	O
plus	O
mean	O
for	O
each	O
group	O
,	O
and	O
diagnosis	O
effect	O
from	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
with	O
associated	O
p	O
-	O
value	O
;	O
(	O
leftmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
healthy	O
subject	O
,	O
with	O
the	O
87	O
timepoints	O
at	O
which	O
meta	O
-	O
state	O
changes	O
shown	O
above	O
;	O
(	O
rightmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
schizophrenia	B-DS
patient	O
,	O
with	O
the	O
33	O
timepoints	O
at	O
which	O
meta	O
-	O
state	O
changes	O
shown	O
above	O
.	O

Effect	O
of	O
Schizophrenia	B-DS
on	O
Dynamic	O
Range	O
Measures	O
(	O
A	O
)	O
Maximally	O
different	O
(	O
in	O
the	O
L1	O
sense	O
)	O
meta	O
-	O
states	O
that	O
subjects	O
realize	O
;	O
(	O
middle	O
column	O
)	O
boxplot	O
showing	O
median	O
,	O
quartiles	O
and	O
outliers	O
plus	O
mean	O
for	O
each	O
group	O
,	O
and	O
diagnosis	O
effect	O
from	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
with	O
associated	O
p	O
-	O
value	O
;	O
(	O
leftmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
healthy	O
subject	O
,	O
with	O
the	O
two	O
most	O
divergent	O
realized	O
meta	O
-	O
states	O
(	O
L1	O
distance	O
=	O
21	O
)	O
shown	O
underneath	O
;	O
(	O
rightmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
schizophrenia	B-DS
patient	O
,	O
with	O
the	O
two	O
most	O
divergent	O
realized	O
meta	O
-	O
states	O
(	O
L1	O
distance	O
=	O
8	O
)	O
shown	O
underneath	O
;	O
(	O
B	O
)	O
Total	O
distance	O
traveled	O
(	O
summed	O
L1	O
distance	O
between	O
successive	O
meta	O
-	O
states	O
)	O
in	O
the	O
state	O
space	O
;	O
(	O
middle	O
column	O
)	O
boxplot	O
showing	O
median	O
,	O
quartiles	O
and	O
outliers	O
plus	O
mean	O
for	O
each	O
group	O
,	O
and	O
diagnosis	O
effect	O
from	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
with	O
associated	O
p	O
-	O
value	O
;	O
(	O
leftmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
healthy	O
subject	O
,	O
with	O
the	O
timeseries	O
of	O
cumulative	O
distance	O
traveled	O
(	O
increasing	O
to	O
117	O
at	O
final	O
timepoint	O
)	O
shown	O
above	O
;	O
(	O
rightmost	O
column	O
)	O
The	O
time	O
-	O
indexed	O
meta	O
-	O
states	O
of	O
a	O
sample	O
schizophrenia	B-DS
patient	O
,	O
with	O
timeseries	O
of	O
cumulative	O
distance	O
traveled	O
(	O
increasing	O
to	O
37	O
at	O
final	O
timepoint	O
)	O
shown	O
above	O
.	O

Age	O
and	O
gender	O
-	O
corrected	O
effects	O
of	O
SZ	B-DS
on	O
four	O
general	O
dynamism	O
measures	O
(	O
rows	O
)	O
under	O
four	O
different	O
decompositions	O
of	O
the	O
wFNC	O
data	O
into	O
sets	O
of	O
five	O
correlation	O
patterns	O
(	O
columns	O
).	O

Method	O
of	O
Decomposing	O
wFNCs	O
into	O
CPs	O

tICA	O

sICA	B-GP

PCA	O

K	O
-	O
means	O

Number	O
of	O
Distinct	O
Meta	O
-	O
States	O

-	O
5	O
.	O
65	O

-	O
2	O
.	O
63	O

-	O
5	O
.	O
78	O

-	O
6	O
.	O
52	O

p	O
=	O
3	O
.	O
93e	O
-	O
006	O
)	O

(	O
p	O
=	O
0	O
.	O
007	O
)	O

(	O
p	O
=	O
6	O
.	O
03e	O
-	O
008	O
)	O

(	O
p	O
=	O
1	O
.	O
52e	O
-	O
007	O
)	O

Number	O
of	O
Meta	O
-	O
State	O
Changes	O

-	O
5	O
.	O
32	O

-	O
2	O
.	O
59	O

-	O
4	O
.	O
80	O

-	O
5	O
.	O
57	O

(	O
p	O
=	O
1	O
.	O
41e	O
-	O
008	O
)	O

(	O
p	O
=	O
0	O
.	O
003	O
)	O

(	O
p	O
=	O
5	O
.	O
88e	O
-	O
007	O
)	O

(	O
p	O
=	O
8	O
.	O
23e	O
-	O
007	O
)	O

L1	O
Span	O
of	O
Realized	O
Meta	O
-	O
States	O

-	O
2	O
.	O
20	O

-	O
1	O
.	O
29	O

-	O
2	O
.	O
22	O

-	O
2	O
.	O
71	O

(	O
p	O
=	O
6	O
.	O
62e	O
-	O
008	O
)	O

(	O
p	O
=	O
2	O
.	O
71e	O
-	O
006	O
)	O

(	O
p	O
=	O
2	O
.	O
09e	O
-	O
010	O
)	O

(	O
p	O
=	O
1	O
.	O
52e	O
-	O
009	O
)	O

Total	O
Distance	O
Traveled	O
in	O
State	O
Space	O

-	O
9	O
.	O
69	O

-	O
4	O
.	O
29	O

-	O
6	O
.	O
78	O

-	O
10	O
.	O
04	O

(	O
p	O
=	O
1	O
.	O
89e	O
-	O
006	O
)	O

(	O
p	O
=	O
0	O
.	O
0009	O
)	O

(	O
p	O
=	O
1	O
.	O
76e	O
-	O
006	O
)	O

(	O
p	O
=	O
5	O
.	O
31e	O
-	O
007	O
)	O

Displayed	O
effects	O
and	O
p	O
-	O
values	O
are	O
from	O
the	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
.	O

Age	O
and	O
gender	O
-	O
corrected	O
effects	O
of	O
SZ	B-DS
on	O
four	O
general	O
dynamism	O
measures	O
(	O
rows	O
)	O
computed	O
over	O
tICA	O
decompositions	O
of	O
different	O
model	O
orders	O
(	O
columns	O
).	O

Displayed	O
effects	O
and	O
p	O
-	O
values	O
are	O
from	O
the	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
.	O

Number	O
of	O
tICA	O
CPs	O

3	O

4	O

5	O

6	O

7	O

Number	O
of	O
Distinct	O

-	O
5	O
.	O
36	O

-	O
6	O
.	O
28	O

-	O
5	O
.	O
65	O

-	O
5	O
.	O
45	O

-	O
5	O
.	O
80	O

Meta	O
-	O
States	O

(	O
p	O
=	O
4	O
.	O
26e	O
-	O
006	O
)	O

(	O
p	O
=	O
1	O
.	O
86e	O
-	O
007	O
)	O

(	O
p	O
=	O
4	O
.	O
11e	O
-	O
006	O
)	O

(	O
p	O
=	O
5	O
.	O
64e	O
-	O
007	O
)	O

(	O
p	O
=	O
2	O
.	O
37e	O
-	O
009	O
)	O

Number	O
of	O
Meta	O
-	O
State	O

-	O
3	O
.	O
93	O

-	O
5	O
.	O
06	O

-	O
2	O
.	O
20	O

-	O
5	O
.	O
15	O

-	O
5	O
.	O
48	O

Changes	O

(	O
p	O
=	O
9	O
.	O
64e	O
-	O
005	O
)	O

(	O
p	O
=	O
3	O
.	O
09e	O
-	O
006	O
)	O

(	O
p	O
=	O
6	O
.	O
62e	O
-	O
008	O
)	O

(	O
p	O
=	O
4	O
.	O
98e	O
-	O
007	O
)	O

(	O
p	O
=	O
6	O
.	O
22e	O
-	O
009	O
)	O

L1	O
Span	O
of	O
Realized	O

-	O
1	O
.	O
24	O

-	O
1	O
.	O
93	O

-	O
1	O
.	O
94	O

-	O
2	O
.	O
64	O

-	O
3	O
.	O
07	O

Meta	O
-	O
States	O

(	O
p	O
=	O
7	O
.	O
33e	O
-	O
005	O
)	O

(	O
p	O
=	O
1	O
.	O
52e	O
-	O
007	O
)	O

(	O
p	O
=	O
3	O
.	O
11e	O
-	O
005	O
)	O

(	O
p	O
=	O
2	O
.	O
62e	O
-	O
008	O
)	O

(	O
p	O
=	O
1	O
.	O
65e	O
-	O
009	O
)	O

Total	O
Distance	O
Travel	O
-	O

-	O
5	O
.	O
02	O

-	O
7	O
.	O
50	O

-	O
7	O
.	O
53	O

-	O
11	O
.	O
04	O

-	O
14	O
.	O
60	O

ed	O
in	O
State	O
Space	O

(	O
p	O
=	O
2	O
.	O
68e	O
-	O
004	O
)	O

(	O
p	O
=	O
8	O
.	O
47e	O
-	O
006	O
)	O

(	O
p	O
=	O
1	O
.	O
01e	O
-	O
005	O
)	O

(	O
p	O
=	O
1	O
.	O
06e	O
-	O
006	O
)	O

(	O
p	O
=	O
1	O
.	O
37e	O
-	O
006	O
)	O

Although	O
schizophrenia	B-DS
patients	O
exhibit	O
diverse	O
symptoms	O
[	O
43	O
]	O
ranging	O
from	O
blunted	O
affect	O
and	O
withdrawal	O
to	O
grandiosity	O
,	O
the	O
hallmark	O
psychotic	O
symptoms	O
of	O
the	O
disease	O
,	O
delusions	O
and	O
hallucinations	O
,	O
are	O
of	O
special	O
interest	O
.	O

Initial	O
investigations	O
of	O
connectivity	O
dynamism	O
at	O
the	O
symptom	O
level	O
show	O
mixed	O
effects	O
of	O
the	O
main	O
psychotic	O
underpinnings	O
of	O
schizophrenia	B-DS
with	O
delusions	O
having	O
weakly	O
dynamism	O
-	O
amplifying	O
effects	O
and	O
hallucinations	O
presenting	O
significant	O
and	O
pervasive	O
dynamism	O
-	O
suppressing	O
effects	O
(	O
Fig	O
8	O
).	O

Effect	O
of	O
Main	O
Psychotic	O
Symptoms	O
of	O
Schizophrenia	B-DS
on	O
Connectivity	O
Dynamism	O
Measures	O
Significant	O
(	O
α	O
<	O
0	O
.	O
05	O
)	O
effects	O
of	O
hallmark	O
psychotic	O
symptoms	O
of	O
SZ	B-DS
on	O
each	O
of	O
the	O
four	O
dynamism	O
measures	O
from	O
regression	O
on	O
all	O
thirty	O
symptom	O
scores	O
from	O
the	O
PANSS	O
scale	O
along	O
with	O
gender	O
and	O
age	O
as	O
covariates	O
.	O

The	O
effect	O
of	O
delusions	O
on	O
L1	O
Span	O
of	O
Realized	O
Meta	O
-	O
States	O
has	O
p	O
-	O
value	O
=	O
0	O
.	O
023	O
.	O

The	O
p	O
-	O
values	O
associated	O
to	O
the	O
effects	O
of	O
hallucinatory	O
behavior	O
on	O
each	O
of	O
the	O
four	O
measures	O
given	O
along	O
the	O
x	O
-	O
axis	O
are	O
,	O
from	O
left	O
to	O
right	O
:	O
0	O
.	O
005	O
,	O
0	O
.	O
003	O
,	O
0	O
.	O
003	O
,	O
and	O
0	O
.	O
010	O
.	O

Schizophrenia	B-DS
Patients	O
have	O
more	O
Hub	O
States	O
than	O
Controls	O

Although	O
healthy	O
subjects	O
on	O
average	O
pass	O
through	O
a	O
significantly	O
larger	O
number	O
of	O
distinct	O
connective	O
meta	O
-	O
states	O
during	O
their	O
resting	O
fMRI	O
scans	O
(	O
Fig	O
6	O
(	O
A	O
)),	O
it	O
is	O
patients	O
that	O
include	O
a	O
larger	O
set	O
of	O
distinct	O
meta	O
-	O
states	O
among	O
those	O
they	O
visit	O
more	O
than	O
three	O
times	O
.	O

More	O
concretely	O
,	O
healthy	O
subjects	O
visit	O
a	O
significantly	O
larger	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
at	O
least	O
once	O
,	O
while	O
patients	O
visit	O
a	O
significantly	O
larger	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
at	O
least	O
four	O
times	O
(	O
Fig	O
9	O
,	O
Fig	O
10A	O
,	O
10B	O
and	O
10C	O
)).	O

The	O
overall	O
dominance	O
of	O
healthy	O
controls	O
is	O
taking	O
place	O
entirely	O
via	O
the	O
number	O
of	O
different	O
""""	O
filler	O
""""	O
meta	O
-	O
states	O
they	O
touch	O
on	O
briefly	O
while	O
passing	O
between	O
meta	O
-	O
states	O
they	O
visit	O
more	O
often	O
.	O

Basic	O
Results	O
on	O
Hub	O
Meta	O
-	O
States	O
and	O
Schizophrenia	B-DS
(	O
A	O
)	O
Bar	O
plots	O
for	O
HC	O
and	O
SZ	B-DS
of	O
number	O
of	O
subjects	O
(	O
y	O
-	O
axis	O
)	O
with	O
hubs	O
of	O
exactly	O
the	O
indicated	O
levels	O
(	O
x	O
-	O
axis	O
);	O
(	O
B	O
)	O
Bar	O
plots	O
for	O
HC	O
and	O
SZ	B-DS
of	O
number	O
of	O
subjects	O
(	O
y	O
-	O
axis	O
)	O
with	O
hubs	O
of	O
at	O
least	O
the	O
indicated	O
level	O
(	O
x	O
-	O
axis	O
).	O

Results	O
of	O
Comprehensive	O
Investigation	O
of	O
Hub	O
Meta	O
-	O
States	O
and	O
Schizophrenia	B-DS
(	O
A	O
)	O
Histograms	O
of	O
within	O
-	O
subject	O
mean	O
meta	O
-	O
state	O
recurrence	O
rate	O
(	O
average	O
number	O
of	O
re	O
-	O
visitations	O
made	O
to	O
the	O
meta	O
-	O
states	O
realized	O
)	O
and	O
SZ	B-DS
regression	O
effect	O
on	O
this	O
quantity	O
(	O
SZ	O
effect	O
=	O
0	O
.	O
86	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
0001	O
);	O
(	O
B	O
)	O
SZ	O
effect	O
on	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
with	O
indicated	O
within	O
-	O
subject	O
recurrence	O
rate	O
(	O
inset	O
zooms	O
on	O
rates	O
3	O
–	O
18	O
)	O
along	O
with	O
SZ	B-DS
effect	O
on	O
the	O
largest	O
number	O
of	O
visits	O
to	O
the	O
same	O
state	O
(	O
SZ	O
effect	O
=	O
1	O
.	O
42	O
,	O
p	O
-	O
value	O
=	O
4	O
.	O
96e	O
-	O
005	O
(	O
also	O
see	O
(	O
C	O
)	O
for	O
distribution	O
));	O
(	O
C	O
)	O
Number	O
of	O
subjects	O
whose	O
most	O
visited	O
meta	O
-	O
state	O
had	O
indicated	O
recurrence	O
rate	O
;	O
(	O
D	O
)	O
Mean	O
longest	O
uninterrupted	O
period	O
of	O
hub	O
state	O
occupancy	O
(	O
recall	O
that	O
level	O
k	O
hubs	O
are	O
occupied	O
k	O
times	O
,	O
not	O
necessarily	O
in	O
uninterrupted	O
stretches	O
)	O
and	O
SZ	O
regression	O
effect	O
(	O
SZ	O
effect	O
=	O
1	O
.	O
18	O
,	O
p	O
-	O
value	O
=	O
4	O
.	O
60e	O
-	O
005	O
);	O
(	O
E	O
)	O
Effect	O
of	O
SZ	O
on	O
hub	O
saturation	O
,	O
evaluated	O
separately	O
for	O
hubs	O
of	O
each	O
level	O
k	O
,	O
k	O
=	O
4	O
,	O
5	O
,…,	O
36	O
.	O

Saturation	O
positively	O
correlated	O
with	O
SZ	B-DS
in	O
red	O
(	O
dark	O
red	O
indicates	O
effects	O
significant	O
0	O
.	O
05	O
level	O
after	O
FDR	O
correction	O
),	O
negatively	O
correlated	O
with	O
saturation	O
in	O
blue	O
.	O

(	O
F	O
)	O
Boxplot	O
of	O
saturation	O
index	O
over	O
all	O
hubs	O
for	O
HC	O
and	O
SZ	B-DS
with	O
group	O
means	O
(	O
μSZ	O
=	O
5	O
.	O
2	O
,	O
μHC	O
=	O
5	O
.	O
6	O
)	O
and	O
SZ	B-DS
regression	O
effect	O
on	O
this	O
quantity	O
(	O
SZ	B-DS
effect	O
=	O
0	O
.	O
34	O
,	O
p	O
-	O
value	O
=	O
4	O
.	O
88e	O
-	O
005	O
);	O
All	O
SZ	B-DS
effects	O
and	O
associated	O
p	O
-	O
values	O
are	O
from	O
the	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
.	O

The	O
reported	O
regressions	O
include	O
the	O
patient	O
with	O
an	O
order	O
-	O
36	O
hub	O
(	O
ie	O
,	O
they	O
are	O
for	O
the	O
displayed	O
data	O
,	O
and	O
we	O
did	O
want	O
to	O
provide	O
evidence	O
that	O
hubs	O
of	O
higher	O
order	O
are	O
achievable	O
).	O

In	O
regressions	O
omitting	O
this	O
extreme	O
observation	O
,	O
both	O
the	O
direction	O
and	O
significance	O
level	O
of	O
displayed	O
effects	O
were	O
preserved	O
(	O
p	O
-	O
values	O
were	O
on	O
order	O
e	O
-	O
005	O
or	O
e	O
-	O
006	O
).	O

The	O
meta	O
-	O
states	O
that	O
a	O
subject	O
returns	O
to	O
four	O
or	O
more	O
times	O
are	O
the	O
subject	O
'	O
s	O
hub	O
states	O
;	O
those	O
that	O
the	O
subject	O
visits	O
at	O
least	O
once	O
but	O
no	O
more	O
than	O
three	O
times	O
are	O
the	O
subject	O
'	O
s	O
transient	O
states	O
.	O

A	O
state	O
that	O
is	O
visited	O
k	O
≥	O
4	O
times	O
is	O
called	O
a	O
level	O
-	O
k	O
hub	O
.	O

In	O
our	O
data	O
,	O
the	O
complete	O
set	O
of	O
level	O
-	O
k	O
hubs	O
for	O
k	O
≥	O
4	O
consists	O
of	O
2117	O
meta	O
-	O
states	O
,	O
accounting	O
for	O
approximately	O
6	O
%	O
of	O
whole	O
state	O
space	O
(	O
C	O
=	O
32	O
,	O
768	O
)	O
space	O
and	O
15	O
%	O
of	O
the	O
points	O
that	O
are	O
ever	O
visited	O
at	O
least	O
once	O
by	O
some	O
subject	O
(	O
cR	O
=	O
14	O
,	O
025	O
)	O
(	O
Fig	O
11	O
).	O

Every	O
subject	O
in	O
this	O
study	O
has	O
a	O
level	O
-	O
k	O
hub	O
for	O
k	O
=	O
4	O
(	O
Fig	O
9	O
(	O
A	O
))	O
and	O
only	O
one	O
subject	O
has	O
a	O
level	O
-	O
k	O
hub	O
for	O
k	O
>	O
18	O
(	O
Fig	O
9	O
(	O
B	O
)).	O

Not	O
only	O
do	O
patients	O
exhibit	O
a	O
larger	O
number	O
of	O
distinct	O
hub	O
meta	O
-	O
states	O
during	O
their	O
scans	O
(	O
Fig	O
10A	O
and	O
10B	O
),	O
Fig	O
11	O
),	O
they	O
tend	O
to	O
spend	O
longer	O
uninterrupted	O
periods	O
than	O
controls	O
occupying	O
these	O
meta	O
-	O
states	O
(	O
Fig	O
10C	O
,	O
10D	O
and	O
10E	O
)).	O

A	O
patient	O
,	O
for	O
example	O
,	O
with	O
some	O
level	O
-	O
20	O
hub	O
is	O
more	O
likely	O
to	O
spend	O
three	O
uninterrupted	O
time	O
intervals	O
of	O
lengths	O
5	O
,	O
7	O
and	O
8	O
in	O
that	O
meta	O
-	O
state	O
,	O
while	O
a	O
healthy	O
subject	O
is	O
more	O
likely	O
to	O
spend	O
eight	O
uninterrupted	O
intervals	O
of	O
lengths	O
2	O
,	O
1	O
,	O
4	O
,	O
1	O
,	O
2	O
,	O
1	O
,	O
6	O
and	O
3	O
in	O
one	O
of	O
its	O
level	O
-	O
20	O
hub	O
states	O
.	O

A	O
subject	O
whose	O
longest	O
uninterrupted	O
occupancy	O
of	O
a	O
level	O
-	O
k	O
hub	O
is	O
a	O
large	O
relative	O
to	O
k	O
is	O
said	O
to	O
saturate	O
that	O
hub	O
;	O
level	O
-	O
k	O
hubs	O
whose	O
longest	O
uninterrupted	O
periods	O
of	O
occupancy	O
are	O
large	O
relative	O
to	O
k	O
are	O
absorbing	O
hubs	O
.	O

The	O
level	O
-	O
k	O
hubs	O
that	O
subjects	O
land	O
on	O
k	O
times	O
but	O
always	O
move	O
on	O
from	O
quickly	O
are	O
transitory	O
hubs	O
.	O

Patients	O
have	O
more	O
hubs	O
than	O
controls	O
,	O
and	O
these	O
hubs	O
are	O
more	O
absorbing	O
(	O
Fig	O
10D	O
,	O
10E	O
and	O
10F	O
)).	O

Number	O
of	O
Distinct	O
Meta	O
-	O
States	O
Occupied	O
Multiple	O
Times	O
by	O
any	O
Subject	O
(	O
A	O
)	O
Bar	O
plot	O
of	O
number	O
of	O
meta	O
-	O
states	O
with	O
indicated	O
within	O
-	O
subject	O
recurrence	O
rates	O
for	O
full	O
population	O
with	O
fitted	O
power	O
law	O
(	O
α	O
=	O
-	O
323	O
);	O
(	O
B	O
)	O
Power	O
laws	O
fitted	O
separately	O
for	O
HC	O
(	O
α	O
=	O
-	O
3	O
.	O
36	O
)	O
and	O
SZ	O
(	O
α	O
=	O
-	O
2	O
.	O
30	O
)	O
to	O
number	O
of	O
meta	O
-	O
states	O
with	O
given	O
within	O
-	O
subject	O
recurrence	O
rates	O
.	O

Although	O
there	O
are	O
multiple	O
supportable	O
ways	O
to	O
quantify	O
the	O
degree	O
to	O
which	O
level	O
-	O
k	O
hubs	O
are	O
absorbing	O
or	O
saturated	O
,	O
we	O
have	O
chosen	O
to	O
employ	O
the	O
following	O
within	O
-	O
subject	O
measure	O
of	O
level	O
-	O
k	O
saturation	O
:	O
ψk	O
(	O
s	O
)=(	O
longestuninterruptedoccupancyofalevelkhub	O
)(#	O
oftimesthemaximallevelkoccupancyoccurs	O
)	O
max	O
(	O
1	O
,(#	O
oflevelkhubs	O
))	O

ψk	O
(	O
s	O
)=	O
kdmax	O
(	O
1	O
,	O
d	O
)=	O
k	O
when	O
subject	O
s	O
has	O
d	O
level	O
-	O
k	O
hubs	O
,	O
each	O
of	O
which	O
the	O
subject	O
spends	O
k	O
consecutive	O
time	O
points	O
in	O
.	O

Otherwise	O
,	O
ψk	O
(	O
s	O
)=	O
k	O
′	O
d	O
′	O
max	O
(	O
1	O
,	O
d	O
)≤	O
k	O
,	O
where	O
k	O
'≤	O
k	O
is	O
the	O
maximal	O
uninterrupted	O
occupancy	O
of	O
one	O
of	O
the	O
subject	O
'	O
s	O
d	O
level	O
-	O
k	O
hubs	O
and	O
d	O
'≤	O
d	O
is	O
the	O
number	O
level	O
-	O
k	O
hubs	O
that	O
the	O
subject	O
occupies	O
for	O
an	O
uninterrupted	O
period	O
of	O
length	O
k	O
'.	O

The	O
idea	O
is	O
to	O
capture	O
,	O
in	O
a	O
way	O
that	O
gives	O
more	O
""""	O
credit	O
""""	O
for	O
saturations	O
of	O
higher	O
-	O
level	O
hubs	O
,	O
the	O
extent	O
to	O
which	O
a	O
subject	O
utilizes	O
the	O
available	O
visits	O
to	O
his	O
or	O
her	O
level	O
-	O
k	O
hubs	O
in	O
uninterrupted	O
occupation	O
.	O

The	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
visited	O
exactly	O
n	O
times	O
by	O
some	O
subject	O
decays	O
exponentially	O
with	O
recurrence	O
rate	O
(	O
Fig	O
11	O
).	O

The	O
rate	O
of	O
decay	O
is	O
slower	O
for	O
patients	O
than	O
controls	O
(	O
Fig	O
11	O
(	O
B	O
)).	O

The	O
number	O
of	O
subjects	O
returning	O
to	O
any	O
meta	O
-	O
state	O
at	O
least	O
m	O
times	O
,	O
follows	O
a	O
roughly	O
right	O
-	O
skewed	O
normal	O
distribution	O
with	O
respect	O
to	O
the	O
maximum	O
return	O
rate	O
m	O
(	O
Fig	O
10	O
(	O
C	O
)).	O

Every	O
subject	O
has	O
at	O
least	O
one	O
hub	O
,	O
ie	O
.	O
they	O
visit	O
some	O
meta	O
-	O
state	O
four	O
or	O
more	O
times	O
.	O

Only	O
eleven	O
subjects	O
(	O
3	O
%	O
of	O
the	O
total	O
),	O
however	O
,	O
visit	O
no	O
state	O
more	O
than	O
four	O
times	O
(	O
Fig	O
10	O
(	O
C	O
)).	O

The	O
average	O
maximum	O
return	O
rate	O
is	O
8	O
.	O
4	O
for	O
patients	O
and	O
7	O
.	O
2	O
for	O
controls	O
.	O

Fewer	O
than	O
10	O
%	O
of	O
subjects	O
return	O
to	O
any	O
state	O
more	O
than	O
eleven	O
times	O
(	O
Fig	O
10	O
(	O
C	O
)).	O

And	O
in	O
terms	O
of	O
the	O
state	O
space	O
,	O
just	O
over	O
0	O
.	O
1	O
%	O
of	O
states	O
are	O
visited	O
more	O
than	O
eleven	O
times	O
by	O
some	O
subject	O
(	O
Fig	O
10	O
(	O
B	O
),	O
Fig	O
11	O
).	O

It	O
is	O
also	O
the	O
case	O
that	O
patients	O
move	O
significantly	O
more	O
smoothly	O
through	O
the	O
state	O
space	O
than	O
do	O
healthy	O
controls	O
,	O
ie	O
.	O
the	O
average	O
L1	O
distance	O
between	O
successive	O
meta	O
-	O
states	O
is	O
smaller	O
in	O
the	O
patient	O
population	O
(	O
SZ	B-DS
Effect	O
=	O
-	O
0	O
.	O
08	O
,	O
P	O
-	O
value	O
=	O
3	O
.	O
04	O
e	O
-	O
008	O
).	O

Trajectories	O
of	O
Groups	O
of	O
Schizophrenia	B-DS
Patients	O
More	O
Likely	O
to	O
Intersect	O
at	O
Common	O
Meta	O
-	O
Sates	O
than	O
are	O
Trajectories	O
of	O
Healthy	O
Controls	O

As	O
noted	O
above	O
,	O
the	O
discrete	O
5	O
-	O
dimensional	O
state	O
space	O
in	O
which	O
we	O
are	O
studying	O
dynamics	O
is	O
large	O
relative	O
to	O
the	O
length	O
of	O
the	O
trajectories	O
(	O
the	O
state	O
space	O
X	O
contains	O
32	O
,	O
768	O
points	O
while	O
trajectories	O
consist	O
of	O
only	O
136	O
observed	O
timepoints	O
).	O

Absence	O
of	O
inter	O
-	O
subject	O
temporal	O
alignment	O
in	O
resting	O
fMRI	O
means	O
that	O
most	O
subjects	O
start	O
at	O
some	O
arbitrary	O
point	O
in	O
the	O
state	O
space	O
,	O
move	O
around	O
for	O
136	O
timepoints	O
in	O
a	O
manner	O
at	O
least	O
moderately	O
constrained	O
by	O
their	O
arbitrary	O
“	O
initial	O
condition	O
”,	O
and	O
need	O
not	O
intersect	O
any	O
other	O
subject	O
trajectories	O
at	O
all	O
.	O

For	O
schizophrenia	B-DS
patients	O
this	O
problem	O
is	O
more	O
pronounced	O
since	O
they	O
realize	O
fewer	O
meta	O
-	O
states	O
,	O
change	O
meta	O
-	O
state	O
less	O
often	O
and	O
remain	O
trapped	O
in	O
a	O
smaller	O
radial	O
neighborhood	O
of	O
their	O
arbitrary	O
starting	O
point	O
.	O

This	O
makes	O
it	O
all	O
the	O
more	O
interesting	O
to	O
note	O
that	O
pairs	O
of	O
schizophrenia	B-DS
patients	O
are	O
significantly	O
more	O
likely	O
to	O
have	O
trajectories	O
that	O
intersect	O
than	O
are	O
healthy	O
controls	O
.	O

They	O
are	O
in	O
fact	O
more	O
likely	O
than	O
pairs	O
of	O
controls	O
to	O
have	O
trajectories	O
that	O
intersect	O
up	O
to	O
ten	O
times	O
(	O
Fig	O
12	O
(	O
B	O
)).	O

The	O
odds	O
that	O
the	O
trajectory	O
of	O
a	O
patient	O
and	O
that	O
of	O
a	O
control	O
intersect	O
are	O
lower	O
still	O
(	O
Fig	O
12	O
(	O
B	O
)).	O

It	O
is	O
also	O
the	O
case	O
that	O
the	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
(	O
points	O
in	O
X	O
)	O
realized	O
by	O
more	O
than	O
a	O
handful	O
of	O
subjects	O
,	O
i	O
.	O
e	O
.,	O
for	O
which	O
there	O
exist	O
three	O
or	O
more	O
subjects	O
whose	O
trajectories	O
intersect	O
at	O
that	O
point	O
is	O
very	O
small	O
(	O
1751	O
,	O
or	O
about	O
½	O
of	O
1	O
%	O
of	O
the	O
points	O
in	O
X	O
).	O

Although	O
individual	O
schizophrenia	B-DS
patients	O
realize	O
fewer	O
meta	O
-	O
states	O
than	O
do	O
healthy	O
controls	O
,	O
it	O
is	O
also	O
the	O
case	O
that	O
a	O
significantly	O
larger	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
are	O
realized	O
by	O
collections	O
of	O
three	O
or	O
more	O
schizophrenia	B-DS
patients	O
than	O
by	O
groups	O
of	O
healthy	O
controls	O
(	O
Fig	O
12	O
(	O
A	O
)).	O

Meta	O
-	O
States	O
Realized	O
at	O
Least	O
Once	O
by	O
Multiple	O
Subjects	O
(	O
A	O
)	O
Bar	O
plot	O
of	O
number	O
of	O
meta	O
-	O
states	O
realized	O
by	O
two	O
or	O
more	O
subjects	O
(	O
number	O
of	O
subjects	O
in	O
the	O
collection	O
jointly	O
realizing	O
some	O
meta	O
-	O
state	O
on	O
the	O
x	O
-	O
axis	O
),	O
shown	O
separately	O
for	O
patients	O
and	O
healthy	O
controls	O
.	O

No	O
meta	O
-	O
state	O
whatsoever	O
is	O
realized	O
by	O
more	O
than	O
7	O
different	O
healthy	O
subjects	O
.	O

Fewer	O
than	O
50	O
(	O
of	O
32	O
,	O
768	O
)	O
meta	O
-	O
states	O
are	O
realized	O
by	O
more	O
than	O
6	O
patients	O
.	O

A	O
two	O
-	O
sample	O
T	O
-	O
test	O
shows	O
that	O
the	O
number	O
NSZ	O
of	O
patients	O
jointly	O
realizing	O
some	O
meta	O
-	O
state	O
is	O
significantly	O
larger	O
than	O
the	O
number	O
NHC	O
of	O
controls	O
respectively	O
jointly	O
realizing	O
some	O
meta	O
-	O
state	O
;	O
(	O
B	O
)	O
Bar	O
plot	O
of	O
the	O
number	O
of	O
subject	O
-	O
pairs	O
that	O
jointly	O
realize	O
indicated	O
(	O
x	O
-	O
axis	O
)	O
number	O
of	O
meta	O
-	O
states	O
,	O
shown	O
separately	O
for	O
pairs	O
of	O
controls	O
,	O
pairs	O
of	O
patients	O
and	O
mixed	O
pairs	O
consisting	O
of	O
one	O
patient	O
and	O
one	O
control	O
.	O

A	O
two	O
-	O
sample	O
T	O
-	O
text	O
shows	O
that	O
the	O
average	O
number	O
of	O
intersection	O
points	O
(	O
jointly	O
realized	O
meta	O
-	O
states	O
)	O
for	O
SZ	B-DS
subject	O
pairs	O
is	O
significantly	O
larger	O
than	O
the	O
average	O
number	O
of	O
intersection	O
points	O
for	O
HC	O
subject	O
pairs	O
.	O

Discussion	O

We	O
have	O
introduced	O
a	O
flexible	O
,	O
robust	O
framework	O
for	O
analyzing	O
dynamic	O
network	O
connectivity	O
in	O
terms	O
of	O
a	O
small	O
set	O
of	O
whole	O
-	O
brain	O
correlation	O
patterns	O
that	O
combine	O
additively	O
to	O
form	O
(	O
or	O
approximate	O
)	O
observed	O
time	O
-	O
varying	O
windowed	O
FNCs	O
,	O
and	O
whose	O
simultaneous	O
contributions	O
,	O
in	O
magnitude	O
and	O
direction	O
,	O
are	O
maximally	O
mutually	O
independent	O
.	O

We	O
investigate	O
the	O
temporally	O
-	O
indexed	O
sequence	O
of	O
length	O
-	O
five	O
CP	B-GP
weight	O
vectors	O
,	O
or	O
meta	O
-	O
states	O
.	O

At	O
this	O
level	O
,	O
we	O
find	O
very	O
strong	O
statistical	O
evidence	O
that	O
:	O

SZ	B-OG
exhibit	O
diminished	O
dynamic	O
fluidity	O
:	O
SZ	B-OG
switch	O
less	O
frequently	O
between	O
five	O
-	O
dimensional	O
meta	O
-	O
states	O
(	O
Fig	O
6	O
,	O
Table	O
2	O
,	O
Table	O
3	O
)	O
SZ	B-OG
occupy	O
a	O
smaller	O
number	O
of	O
distinct	O
meta	O
-	O
states	O
during	O
their	O
scans	O
(	O
Fig	O
6	O
,	O
Table	O
2	O
,	O
Table	O
3	O
)	O

SZ	O
operate	O
over	O
a	O
restricted	O
in	O
dynamic	O
range	O
:	O
SZ	O
remain	O
trapped	O
in	O
a	O
smaller	O
radius	O
hypercube	O
of	O
the	O
state	O
space	O
(	O
Fig	O
7	O
,	O
Table	O
2	O
,	O
Table	O
3	O
)	O
SZs	O
cover	O
less	O
distance	O
as	O
they	O
move	O
through	O
the	O
state	O
space	O
(	O
Fig	O
7	O
,	O
Table	O
2	O
,	O
Table	O
3	O
)	O

Simultaneously	O
considering	O
these	O
results	O
and	O
combining	O
their	O
implications	O
,	O
what	O
emerges	O
is	O
a	O
picture	O
of	O
generally	O
more	O
cautious	O
,	O
sluggish	O
patient	O
trajectories	O
through	O
constrained	O
regions	O
of	O
connectivity	O
space	O
,	O
contrasted	O
with	O
the	O
relatively	O
quick	O
,	O
fluid	O
,	O
more	O
sprawling	O
trajectories	O
of	O
healthy	O
subjects	O
.	O

Deeper	O
investigations	O
of	O
meta	O
-	O
state	O
occupancy	O
,	O
recurrence	O
,	O
span	O
and	O
change	O
patterns	O
however	O
reveal	O
a	O
richer	O
and	O
more	O
nuanced	O
perspective	O
on	O
the	O
distinctive	O
ways	O
patients	O
and	O
controls	O
move	O
dynamically	O
through	O
connectivity	O
space	O
.	O

Schizophrenia	B-DS
patients	O
,	O
for	O
example	O
,	O
tend	O
to	O
have	O
a	O
larger	O
number	O
of	O
relatively	O
more	O
absorbing	O
hub	O
states	O
than	O
controls	O
.	O

Patients	O
travel	O
less	O
distance	O
through	O
the	O
state	O
space	O
from	O
one	O
time	O
point	O
to	O
the	O
next	O
on	O
average	O
,	O
and	O
the	O
largest	O
k	O
≥	O
4	O
for	O
which	O
patients	O
have	O
a	O
level	O
-	O
k	O
hub	O
tends	O
to	O
exceed	O
that	O
for	O
healthy	O
controls	O
.	O

Although	O
not	O
statistically	O
significant	O
,	O
it	O
is	O
also	O
the	O
case	O
that	O
the	O
directional	O
effect	O
of	O
schizophrenia	B-DS
diagnosis	O
on	O
the	O
number	O
and	O
span	O
of	O
states	O
that	O
are	O
the	O
outgoing	O
targets	O
of	O
hubs	O
is	O
positive	O
(	O
Fig	O
13	O
).	O

Locally	O
,	O
in	O
the	O
immediate	O
neighborhood	O
of	O
hubs	O
,	O
the	O
schizophrenia	B-DS
patients	O
seem	O
slightly	O
more	O
dynamic	O
than	O
controls	O
,	O
while	O
globally	O
they	O
are	O
significantly	O
less	O
so	O
.	O

Dynamism	O
measures	O
restricted	O
to	O
immediate	O
neighborhoods	O
of	O
higher	O
-	O
level	O
hubs	O
.	O

We	O
examine	O
the	O
number	O
and	O
the	O
span	O
of	O
incoming	O
and	O
outgoing	O
meta	O
-	O
states	O
connected	O
to	O
each	O
hub	O
of	O
level	O
8	O
and	O
over	O
.	O

The	O
interval	O
was	O
selected	O
so	O
that	O
more	O
than	O
a	O
third	O
of	O
HCs	O
and	O
of	O
SZs	B-DS
have	O
level	O
-	O
k	O
hubs	O
for	O
k	O
≥	O
the	O
lower	O
bound	O
of	O
the	O
interval	O
.	O

The	O
values	O
are	O
not	O
integers	O
because	O
we	O
average	O
over	O
each	O
segment	O
during	O
which	O
a	O
given	O
hub	O
is	O
occupied	O
for	O
a	O
subject	O
,	O
ie	O
.	O
the	O
subject	O
first	O
visits	O
some	O
level	O
k	O
hub	O
for	O
3	O
consecutive	O
timepoints	O
and	O
then	O
later	O
visits	O
the	O
same	O
hub	O
again	O
for	O
k	O
-	O
3	O
consecutive	O
timepoints	O
.	O

Each	O
separate	O
occupancy	O
has	O
its	O
own	O
outgoing	O
target	O
,	O
which	O
might	O
or	O
might	O
not	O
be	O
identical	O
.	O

Since	O
the	O
number	O
of	O
distinct	O
segments	O
of	O
occupancy	O
of	O
a	O
given	O
hub	O
affect	O
the	O
overall	O
number	O
and	O
range	O
of	O
the	O
targets	O
of	O
that	O
hub	O
,	O
we	O
rescale	O
by	O
1numberofsegments	O
resulting	O
in	O
non	O
-	O
integer	O
valued	O
measures	O
.	O

(	O
A	O
)	O
The	O
number	O
(	O
rescaled	O
as	O
indicated	O
)	O
of	O
distinct	O
target	O
meta	O
-	O
states	O
of	O
fixed	O
hubs	O
;	O
(	O
B	O
)	O
The	O
span	O
(	O
maximal	O
L1	O
distance	O
between	O
,	O
also	O
rescaled	O
as	O
indicated	O
above	O
)	O
of	O
target	O
meta	O
-	O
states	O
of	O
fixed	O
hubs	O
.	O

Although	O
both	O
groups	O
have	O
hub	O
states	O
that	O
they	O
return	O
to	O
relatively	O
often	O
,	O
any	O
routing	O
role	O
these	O
hubs	O
play	O
is	O
significantly	O
less	O
efficient	O
in	O
patients	O
than	O
controls	O
and	O
also	O
somewhat	O
more	O
erratic	O
:	O
patients	O
have	O
more	O
hubs	O
of	O
each	O
level	O
,	O
their	O
hubs	O
hold	O
incoming	O
trajectories	O
longer	O
,	O
and	O
ultimately	O
release	O
trajectories	O
to	O
a	O
slightly	O
wider	O
range	O
of	O
targets	O
.	O

We	O
see	O
an	O
analogous	O
scaling	O
phenomenon	O
when	O
we	O
make	O
an	O
upward	O
adjustment	O
to	O
the	O
number	O
of	O
visits	O
to	O
a	O
state	O
required	O
for	O
it	O
to	O
qualify	O
as	O
having	O
been	O
occupied	O
.	O

If	O
the	O
threshold	O
is	O
one	O
visit	O
,	O
then	O
controls	O
visit	O
significantly	O
more	O
states	O
.	O

When	O
the	O
threshold	O
is	O
shifted	O
upward	O
to	O
four	O
or	O
more	O
visits	O
,	O
then	O
it	O
is	O
patients	O
that	O
are	O
sampling	O
a	O
larger	O
number	O
of	O
states	O
(	O
Fig	O
10	O
).	O

Finally	O
,	O
although	O
patients	O
are	O
individually	O
occupying	O
fewer	O
states	O
and	O
moving	O
smaller	O
distances	O
in	O
the	O
state	O
space	O
,	O
their	O
trajectories	O
are	O
nonetheless	O
more	O
likely	O
to	O
intersect	O
at	O
some	O
meta	O
-	O
state	O
than	O
are	O
trajectories	O
of	O
healthy	O
subjects	O
(	O
Fig	O
12	O
(	O
B	O
))	O
and	O
the	O
set	O
of	O
distinct	O
meta	O
-	O
states	O
that	O
are	O
in	O
the	O
joint	O
intersection	O
of	O
some	O
collection	O
of	O
patients	O
is	O
almost	O
always	O
(	O
except	O
in	O
the	O
case	O
of	O
pairs	O
of	O
subjects	O
)	O
larger	O
than	O
the	O
set	O
of	O
points	O
that	O
sit	O
in	O
the	O
joint	O
intersection	O
of	O
a	O
similarly	O
sized	O
collection	O
of	O
controls	O
(	O
Fig	O
12	O
(	O
A	O
)).	O

Our	O
findings	O
demonstrate	O
the	O
flexibility	O
,	O
sensitivity	O
,	O
and	O
robustness	O
of	O
the	O
meta	O
-	O
state	O
framework	O
for	O
dynamical	O
analysis	O
proposed	O
here	O
.	O

Schizophrenia	B-DS
is	O
a	O
complex	O
illness	O
that	O
presents	O
with	O
enormous	O
variation	O
of	O
symptom	O
combinations	O
and	O
intensities	O
,	O
and	O
its	O
effects	O
on	O
resting	O
fMRI	O
are	O
commensurately	O
complex	O
.	O

Most	O
studies	O
to	O
date	O
have	O
taken	O
a	O
static	O
point	O
of	O
view	O
,	O
assuming	O
the	O
characteristic	O
of	O
interest	O
to	O
be	O
stationary	O
on	O
the	O
timescale	O
of	O
the	O
scan	O
.	O

Such	O
studies	O
have	O
yielded	O
consistent	O
evidence	O
that	O
at	O
both	O
voxel	O
and	O
network	O
levels	O
that	O
the	O
signals	O
of	O
schizophrenia	B-DS
patients	O
contain	O
more	O
high	O
frequency	O
content	O
than	O
healthy	O
controls	O
[	O
1	O
,	O
47	O
].	O

Supporting	O
the	O
so	O
-	O
called	O
dysconnectivity	O
hypothesis	O
[	O
48	O
]	O
about	O
schizophrenia	B-DS
,	O
static	O
functional	O
network	O
connectivity	O
analyses	O
have	O
consistently	O
revealed	O
diminished	O
network	O
connectivity	O
strengths	O
in	O
schizophrenia	B-DS
patients	O
[	O
7	O
,	O
49	O
–	O
53	O
],	O
and	O
more	O
specifically	O
altered	O
connectivity	O
between	O
auditory	O
,	O
visual	O
and	O
somatosensory	O
networks	O
(	O
AVSNs	O
)	O
and	O
also	O
between	O
subcortical	O
(	O
SC	O
)	O
networks	O
and	O
AVSNs	O
[	O
26	O
,	O
37	O
].	O

Many	O
of	O
these	O
findings	O
appear	O
to	O
hold	O
even	O
when	O
the	O
stationarity	O
assumption	O
is	O
lifted	O
as	O
evidenced	O
by	O
significantly	O
more	O
negative	O
SZ	O
timecourse	O
values	O
(	O
Fig	O
14	O
)	O
for	O
CPs	O
that	O
feature	O
strong	O
positive	O
intra	O
-	O
AVSN	O
correlations	O
and	O
strong	O
negative	O
SC	O
-	O
to	O
-	O
AVSN	O
connections	O
(	O
Fig	O
4	O
(	O
A	O
),	O
Top	O
row	O
).	O

Effect	O
of	O
Schizophrenia	B-DS
on	O
Dynamic	O
Roles	O
of	O
Individual	O
tICA	O
Correlation	O
Patterns	O
(	O
Fig	O
4	O
(	O
A	O
),	O
Row	O
1	O
).	O

Red	O
(	O
or	O
bars	O
pointing	O
upward	O
)	O
indicate	O
positive	O
correlation	O
with	O
SZ	B-DS
.	O

Only	O
effects	O
significant	O
at	O
the	O
0	O
.	O
05	O
level	O
following	O
FDR	O
-	O
correction	O
are	O
displayed	O
.	O

(	O
A	O
)	O
SZ	B-DS
effects	O
on	O
the	O
number	O
of	O
times	O
each	O
discretized	O
CP	O
timecourse	O
(	O
y	O
-	O
axis	O
),	O
assumes	O
values	O
indicated	O
on	O
the	O
x	O
-	O
axis	O
;	O
(	O
B	O
)	O
SZ	B-DS
effects	O
on	O
binned	O
counts	O
(	O
x	O
-	O
axis	O
)	O
of	O
the	O
number	O
of	O
timepoints	O
each	O
discretized	O
CP	O
timecourse	O
spends	O
consecutively	O
the	O
most	O
negative	O
level	O
,	O
-	O
4	O
;	O
(	O
C	O
)	O
SZ	O
effect	O
on	O
the	O
number	O
of	O
correlation	O
patterns	O
simultaneously	O
contributing	O
in	O
their	O
anti	O
-	O
state	O
form	O
,	O
ie	O
.	O
on	O
the	O
number	O
of	O
timepoints	O
at	O
which	O
a	O
subject	O
'	O
s	O
meta	O
-	O
state	O
contains	O
the	O
indicated	O
number	O
(	O
x	O
-	O
axis	O
)	O
of	O
negative	O
values	O
;	O
(	O
D	O
)	O
SZ	B-DS
effects	O
,	O
component	O
-	O
wise	O
for	O
CPs	O
that	O
exhibit	O
strong	O
positive	O
AVSN	O
correlations	O
,	O
on	O
the	O
number	O
of	O
transitions	O
between	O
levels	O
indicated	O
on	O
x	O
-	O
axis	O
and	O
y	O
-	O
axis	O
;	O
All	O
diagnosis	O
effects	O
and	O
p	O
-	O
values	O
are	O
from	O
the	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
.	O

For	O
example	O
,	O
the	O
window	O
-	O
wise	O
spectrum	O
of	O
windowed	O
network	O
timecourses	O
in	O
schizophrenia	B-DS
patients	O
have	O
more	O
high	O
frequency	O
content	O
than	O
those	O
of	O
healthy	O
controls	O
(	O
Fig	O
15	O
).	O

In	O
the	O
timecourses	O
of	O
individual	O
wFNC	O
network	O
-	O
pair	O
correlations	O
,	O
schizophrenia	B-DS
patients	O
also	O
exhibit	O
greater	O
high	O
frequency	O
power	O
,	O
though	O
the	O
effect	O
is	O
weaker	O
statistically	O
than	O
for	O
network	O
and	O
voxel	O
timecourses	O
(	O
Fig	O
15	O
,	O
first	O
three	O
columns	O
).	O

Shen	O
et	O
al	O
[	O
54	O
]	O
have	O
reported	O
mixed	O
effects	O
of	O
SZ	B-DS
on	O
low	O
-	O
frequency	O
power	O
in	O
windowed	O
network	O
-	O
pair	O
correlation	O
timeseries	O
,	O
with	O
patients	O
exhibiting	O
less	O
low	O
frequency	O
power	O
than	O
controls	O
in	O
DMN	O
-	O
to	O
-	O
sensorimotor	O
and	O
DMN	O
-	O
to	O
-	O
cerebellum	O
connections	O
.	O

EEG	O
microstate	O
studies	O
[	O
55	O
–	O
58	O
]	O
that	O
identify	O
common	O
patterns	O
of	O
millisecond	O
-	O
scale	O
activation	O
from	O
spatially	O
segmented	O
brain	O
regions	O
also	O
indicate	O
a	O
higher	O
rate	O
of	O
pattern	O
-	O
shifting	O
among	O
schizophrenia	B-DS
patients	O
.	O

In	O
contrast	O
,	O
our	O
investigation	O
of	O
whole	O
-	O
brain	O
ensembles	O
of	O
network	O
-	O
pair	O
correlations	O
has	O
yielded	O
highly	O
robust	O
findings	O
of	O
diminished	O
connectivity	O
dynamism	O
for	O
schizophrenia	B-DS
patients	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
recent	O
results	O
on	O
dynamic	O
graph	O
metrics	O
,	O
which	O
inherently	O
involve	O
ensembles	O
of	O
nodal	O
connections	O
[	O
59	O
]	O
and	O
with	O
the	O
disappearance	O
of	O
positive	O
high	O
-	O
frequency	O
spectral	O
SZ	O
effects	O
on	O
ensemble	O
-	O
scale	O
timeseries	O
(	O
Fig	O
15	O
,	O
last	O
two	O
columns	O
).	O

The	O
results	O
we	O
present	O
are	O
fundamentally	O
different	O
in	O
kind	O
from	O
those	O
obtained	O
in	O
static	O
settings	O
.	O

Our	O
work	O
concerns	O
the	O
adaptive	O
fluidity	O
and	O
range	O
of	O
functional	O
brain	O
connectivity	O
at	O
a	O
broad	O
multi	O
-	O
network	O
scale	O
–	O
both	O
intrinsically	O
dynamic	O
phenomena	O
that	O
do	O
not	O
have	O
static	O
analogues	O
.	O

In	O
future	O
work	O
however	O
we	O
plan	O
to	O
investigate	O
connections	O
between	O
these	O
high	O
-	O
level	O
dynamic	O
features	O
that	O
suggest	O
group	O
differences	O
in	O
connectonomic	O
adaptivity	O
and	O
the	O
underlying	O
strength	O
,	O
modularity	O
and	O
other	O
key	O
characteristics	O
of	O
static	O
and	O
structural	O
connectomes	O
.	O

It	O
seems	O
possible	O
,	O
for	O
example	O
that	O
the	O
consistent	O
findings	O
[	O
1	O
,	O
7	O
,	O
48	O
–	O
53	O
]	O
of	O
diminished	O
connectivity	O
strength	O
and	O
weakened	O
connectome	O
-	O
wide	O
modularity	O
among	O
schizophrenia	B-DS
patients	O
reflect	O
a	O
degradation	O
of	O
communication	O
pathways	O
that	O
enable	O
rapid	O
and	O
widespread	O
reorganization	O
of	O
network	O
relationships	O
.	O

Effect	O
of	O
Schizophrenia	B-DS
on	O
Spectral	O
Power	O
as	O
Data	O
is	O
Transformed	O
from	O
Voxels	O
to	O
Networks	O
to	O
Meta	O
-	O
States	O
SZ	O
effects	O
on	O
the	O
spectral	O
power	O
for	O
inputs	O
(	O
Columns	O
1	O
–	O
4	O
)	O
to	O
the	O
meta	O
-	O
state	O
dynamic	O
connectivity	O
framework	O
and	O
its	O
output	O
(	O
Column	O
5	O
)	O
(	O
red	O
indicates	O
positive	O
correlation	O
with	O
SZ	O
);	O
(	O
Column	O
1	O
)	O
(	O
A	O
)	O
SZ	O
effects	O
on	O
network	O
TC	O
spectra	O
;	O
(	O
F	O
)	O
Effects	O
from	O
(	O
A	O
)	O
that	O
survive	O
FDR	O
correction	O
at	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
J	O
)	O
SZ	O
effect	O
on	O
average	O
spectral	O
power	O
over	O
all	O
network	O
TCs	O
;	O
(	O
O	O
)	O
Effects	O
from	O
(	O
J	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
Column	O
2	O
)	O
(	O
B	O
)	O
SZ	O
effect	O
on	O
windowed	O
network	O
TC	O
spectra	O
;	O
(	O
G	O
)	O
Effects	O
from	O
(	O
B	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
K	O
)	O
SZ	O
effect	O
on	O
the	O
average	O
spectral	O
power	O
over	O
all	O
windowed	O
network	O
TCs	O
;	O
(	O
P	O
)	O
Effects	O
from	O
(	O
K	O
)	O
that	O
survive	O
FDR	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
Column	O
3	O
)	O
(	O
C	O
)	O
SZ	O
effects	O
on	O
wFNC	O
network	O
-	O
pair	O
correlation	O
spectra	O
;	O
(	O
H	O
)	O
Effects	O
from	O
(	O
C	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
L	O
)	O
SZ	O
effect	O
on	O
average	O
spectral	O
power	O
over	O
all	O
wFNC	O
network	O
-	O
pair	O
correlations	O
;	O
(	O
Q	O
)	O
Effects	O
from	O
(	O
L	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
D	O
)	O
SZ	O
effects	O
on	O
tICA	O
correlation	O
pattern	O
TCs	O
;	O
(	O
I	O
)	O
Effects	O
from	O
(	O
D	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
M	O
)	O
SZ	O
effect	O
on	O
average	O
spectral	O
power	O
over	O
all	O
tICA	O
correlation	O
pattern	O
TCs	O
;	O
(	O
R	O
)	O
Effects	O
from	O
(	O
M	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
(	O
E	O
)	O
SZ	O
effect	O
on	O
spectral	O
power	O
of	O
the	O
timeseries	O
that	O
is	O
'	O
1	O
'	O
when	O
a	O
five	O
-	O
dimensional	O
meta	O
-	O
state	O
changes	O
to	O
a	O
different	O
meta	O
-	O
state	O
and	O
'	O
0	O
'	O
otherwise	O
;	O
(	O
N	O
)	O
Effects	O
from	O
(	O
E	O
)	O
that	O
survive	O
FDR	O
-	O
correction	O
at	O
the	O
0	O
.	O
05	O
significance	O
level	O
;	O
All	O
diagnosis	O
effects	O
and	O
p	O
-	O
values	O
are	O
from	O
the	O
regression	O
model	O
specified	O
in	O
the	O
Methods	O
section	O
.	O

The	O
work	O
we	O
present	O
adds	O
an	O
important	O
new	O
layer	O
to	O
the	O
growing	O
constellation	O
of	O
robust	O
findings	O
specific	O
to	O
certain	O
scales	O
or	O
forms	O
of	O
analysis	O
that	O
may	O
,	O
eventually	O
combine	O
to	O
produce	O
powerful	O
predictive	O
fMRI	O
signatures	O
for	O
this	O
highly	O
complex	O
disease	O
.	O

Secondary	O
damage	O
in	O
left	O
-	O
sided	O
frontal	O
white	O
matter	O
detected	O
by	O
diffusion	O
tensor	O
imaging	O
is	O
correlated	O
with	O
executive	B-DS
dysfunction	I-DS
in	O
patients	O
with	O
acute	B-DS
infarction	I-DS
at	O
the	O
ipsilateral	O
posterior	O
corona	O
radiata	O

Background	O

Executive	B-DS
dysfunction	I-DS
has	O
been	O
observed	O
in	O
patients	O
with	O
left	B-DS
-	I-DS
sided	I-DS
anterior	I-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
.	O

However	O
,	O
whether	O
left	O
-	O
sided	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
could	O
cause	O
executive	O
dysfunction	O
is	O
unclear	O
.	O

Also	O
,	O
whether	O
secondary	O
damage	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
following	O
ipsilateral	O
posterior	O
corona	B-DS
radiata	I-DS
infarct	I-DS
is	O
causal	O
or	O
not	O
and	O
contributes	O
to	O
the	O
occurrence	O
and	O
development	O
of	O
executive	B-DS
dysfunction	I-DS
,	O
is	O
still	O
uncertain	O
.	O

Methods	O

Twelve	O
patients	O
with	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
underwent	O
diffusion	O
tensor	O
imaging	O
(	O
DTI	O
)	O
and	O
an	O
executive	O
functional	O
assessment	O
at	O
week	O
1	O
(	O
W1	O
),	O
week	O
4	O
(	O
W4	O
),	O
and	O
week	O
12	O
(	O
W12	O
)	O
after	O
onset	O
.	O

Color	O
duplex	O
sonography	O
and	O
Transcranial	O
Duplex	O
Scanning	O
(	O
TCD	O
)	O
were	O
performed	O
at	O
W1	O
and	O
W12	O
.	O

Twelve	O
healthy	O
volunteers	O
of	O
similar	O
ages	O
and	O
educational	O
histories	O
were	O
examined	O
as	O
controls	O
and	O
assessed	O
once	O
.	O

Results	O

In	O
the	O
patients	O
,	O
we	O
observed	O
an	O
increased	O
mean	O
diffusivity	O
(	O
MD	O
)	O
and	O
a	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
from	O
W1	O
to	O
W12	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
cerebral	O
blood	O
flow	O
in	O
patients	O
between	O
W1	O
and	O
W12	O
according	O
to	O
the	O
result	O
of	O
Color	O
duplex	O
sonography	O
and	O
TCD	O
.	O

Patients	O
showed	O
progressively	O
impaired	O
executive	O
function	O
during	O
12	O
weeks	O
.	O

Significant	O
correlations	O
were	O
found	O
between	O
increased	O
MD	O
and	O
decreased	O
FA	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
with	O
impaired	O
degree	O
of	O
executive	O
function	O
.	O

Conclusions	O

This	O
study	O
demonstrates	O
that	O
DTI	O
detected	O
secondary	O
damage	O
in	O
left	O
-	O
sided	O
frontal	O
white	O
matter	O
in	O
patients	O
with	O
acute	B-DS
infarction	I-DS
at	O
the	O
ipsilateral	O
posterior	O
corona	O
radiata	O
.	O

This	O
change	O
may	O
be	O
correlated	O
with	O
executive	O
functional	O
changes	O
in	O
these	O
patients	O
.	O

Background	O

The	O
term	O
‘	O
executive	O
functions	O
’	O
is	O
used	O
to	O
describe	O
high	O
-	O
order	O
cognitive	O
processes	O
which	O
include	O
control	O
,	O
integration	O
,	O
organization	O
and	O
maintenance	O
of	O
other	O
cognitive	O
abilities	O
[	O
1	O
].	O

Executive	O
dysfunction	B-DS
might	O
predict	O
poor	O
functional	O
outcome	O
of	O
patients	O
with	O
stroke	B-DS
[	O
2	O
].	O

The	O
frontal	O
lobes	O
have	O
extensive	O
connections	O
with	O
portions	O
of	O
the	O
limbic	O
system	O
,	O
the	O
basal	O
ganglia	O
,	O
and	O
the	O
thalamus	O
.	O

The	O
frontal	O
-	O
subcortical	O
white	O
matter	O
connections	O
as	O
well	O
as	O
the	O
frontal	O
lobe	O
are	O
well	O
known	O
to	O
be	O
functionally	O
critical	O
in	O
the	O
control	O
of	O
executive	O
function	O
[	O
3	O
].	O

Lesions	O
of	O
not	O
only	O
the	O
prefrontal	O
cortex	O
but	O
subcortical	O
areas	O
result	O
in	O
executive	B-DS
dysfunction	I-DS
[	O
4	O
],[	O
5	O
].	O

In	O
particular	O
,	O
damage	O
of	O
frontal	O
white	O
matter	O
,	O
which	O
is	O
an	O
important	O
region	O
in	O
frontal	O
-	O
subcortical	O
circuitry	O
,	O
results	O
in	O
this	O
executive	B-DS
dysfunction	I-DS
[	O
6	O
].	O

Recently	O
,	O
accumulating	O
studies	O
have	O
shown	O
histopathological	O
and	O
radiological	O
changes	O
occurring	O
in	O
nonischemic	O
remote	O
brain	O
regions	O
that	O
have	O
synaptic	O
connections	O
with	O
the	O
primary	O
lesion	O
site	O
.	O

For	O
example	O
,	O
after	O
cerebral	B-DS
infarction	I-DS
in	O
the	O
middle	O
cerebral	O
artery	O
(	O
MCA	O
)	O
territory	O
,	O
neuronal	O
and	O
/	O
or	O
axonal	O
degeneration	O
,	O
loss	O
,	O
dysfunction	O
and	O
gliosis	O
have	O
been	O
found	O
in	O
the	O
ipsilateral	O
thalamus	O
,	O
substantia	O
nigra	O
,	O
and	O
distal	O
pyramidal	O
tract	O
,	O
all	O
of	O
which	O
were	O
remote	O
from	O
the	O
MCA	O
territory	O
[	O
7	O
]–[	O
12	O
].	O

The	O
corona	O
radiata	O
is	O
the	O
core	O
of	O
the	O
hemispheric	O
white	O
matter	O
,	O
and	O
its	O
infarction	O
may	O
compromise	O
the	O
integrity	O
of	O
the	O
frontal	O
-	O
subcortical	O
white	O
matter	O
connections	O
.	O

A	O
study	O
of	O
patients	O
with	O
stroke	B-DS
scanned	O
by	O
traditional	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
showed	O
that	O
ischemic	O
infarctive	O
lesions	O
affecting	O
the	O
left	O
-	O
sided	O
anterior	O
corona	O
radiata	O
caused	O
executive	O
dysfunction	O
[	O
4	O
].	O

The	O
disruption	O
of	O
frontal	O
-	O
subcortical	O
circuitry	O
was	O
considered	O
to	O
be	O
responsible	O
for	O
this	O
executive	B-DS
dysfunction	I-DS
.	O

However	O
,	O
whether	O
the	O
left	O
-	O
sided	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
could	O
cause	O
executive	O
dysfunction	O
is	O
unclear	O
.	O

Moreover	O
,	O
the	O
underlying	O
pathogenesis	O
,	O
especially	O
whether	O
secondary	O
damage	O
in	O
other	O
areas	O
,	O
such	O
as	O
frontal	O
white	O
matter	O
in	O
frontal	O
-	O
subcortical	O
circuitry	O
,	O
due	O
to	O
anterograde	O
and	O
/	O
or	O
retrograde	O
degeneration	O
following	O
focal	O
corona	B-DS
radiata	I-DS
infarction	I-DS
,	O
is	O
a	O
causal	O
phenomenon	O
and	O
is	O
involved	O
in	O
the	O
dysfunction	O
,	O
is	O
still	O
uncertain	O
.	O

The	O
recent	O
development	O
of	O
diffusion	O
tensor	O
imaging	O
(	O
DTI	O
),	O
an	O
MRI	O
technique	O
,	O
has	O
shown	O
promise	O
for	O
detecting	O
microstructural	O
changes	O
which	O
are	O
not	O
identified	O
by	O
traditional	O
MRI	O
.	O

For	O
example	O
,	O
progressive	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
values	O
in	O
the	O
pyramidal	O
tract	O
,	O
proximal	O
and	O
distal	O
to	O
a	O
subcortical	B-DS
cerebral	I-DS
infarct	I-DS
or	O
pontine	B-DS
infarct	I-DS
over	O
1	O
to	O
12	O
weeks	O
,	O
were	O
found	O
;	O
this	O
means	O
important	O
loss	O
of	O
structural	O
components	O
in	O
the	O
pyramidal	O
tract	O
above	O
and	O
below	O
the	O
primary	O
infarcts	O
[	O
11	O
],[	O
12	O
].	O

In	O
patients	O
with	O
ischemic	B-DS
leukoaraiosis	I-DS
(	O
ILA	B-DS
),	O
increased	O
mean	O
diffusivity	O
(	O
MD	O
)	O
and	O
decreased	O
FA	O
were	O
observed	O
in	O
the	O
frontal	O
and	O
occipital	O
white	O
matter	O
which	O
illustrated	O
axonal	O
loss	O
in	O
the	O
regions	O
[	O
6	O
].	O

These	O
studies	O
suggest	O
potential	O
secondary	O
damage	O
in	O
white	O
matter	O
might	O
be	O
observed	O
by	O
DTI	O
after	O
corona	B-DS
radiata	I-DS
infarction	I-DS
.	O

In	O
this	O
study	O
we	O
tested	O
the	O
hypothesis	O
that	O
there	O
is	O
axonal	O
loss	O
in	O
the	O
left	O
-	O
sided	O
frontal	O
white	O
matter	O
in	O
patients	O
following	O
acute	O
ipsilateral	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
as	O
revealed	O
by	O
DTI	O
.	O

We	O
also	O
examined	O
correlations	O
of	O
the	O
DTI	O
parameters	O
with	O
executive	O
function	O
in	O
these	O
patients	O
.	O

Methods	O

Participants	O

The	O
research	O
protocol	O
was	O
approved	O
by	O
the	O
Medical	O
Ethical	O
Committee	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
,	O
Sun	O
Yat	O
-	O
Sen	O
University	O
,	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

We	O
selected	O
12	O
consecutive	O
patients	O
(	O
7	O
male	O
,	O
5	O
female	O
)	O
between	O
October	O
2008	O
and	O
May	O
2013	O
in	O
the	O
Department	O
of	O
Neurology	O
and	O
Stroke	B-DS
Center	O
,	O
the	O
First	O
Affiliated	O
Hospital	O
,	O
Sun	O
Yat	O
-	O
Sen	O
University	O
,	O
within	O
7	O
days	O
of	O
a	O
focal	O
infarct	O
in	O
the	O
left	O
posterior	O
corona	O
radiata	O
,	O
without	O
any	O
other	O
signal	O
abnormalities	O
on	O
T1	O
-	O
weighted	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
T1	O
-	O
FLAIR	O
)	O
and	O
T2	O
-	O
weighted	O
images	O
.	O

Patients	O
with	O
ILA	B-DS
,	O
significant	O
cerebral	B-DS
atrophy	I-DS
,	O
unstable	O
vital	O
signs	O
or	O
a	O
history	O
of	O
central	B-DS
nervous	I-DS
system	I-DS
disorders	I-DS
were	O
excluded	O
.	O

Demographic	O
characteristics	O
and	O
vascular	O
risk	O
factors	O
were	O
recorded	O
in	O
each	O
patient	O
.	O

All	O
patients	O
were	O
investigated	O
with	O
conventional	O
MRI	O
,	O
DTI	O
and	O
executive	O
functional	O
assessments	O
at	O
1	O
week	O
(	O
6	O
.	O
3	O
±	O
1	O
.	O
1	O
days	O
,	O
W1	O
),	O
4	O
weeks	O
(	O
30	O
.	O
1	O
±	O
2	O
.	O
8	O
days	O
,	O
W4	O
),	O
and	O
12	O
weeks	O
(	O
92	O
.	O
8	O
±	O
5	O
.	O
8	O
days	O
,	O
W12	O
)	O
following	O
a	O
pre	O
-	O
defined	O
protocol	O
.	O

Infarct	O
volume	O
was	O
estimated	O
from	O
the	O
T2	O
-	O
weighted	O
FLAIR	O
images	O
at	O
W12	O
.	O

For	O
every	O
patient	O
,	O
we	O
looked	O
for	O
a	O
control	O
of	O
the	O
similar	O
age	O
(±	O
3	O
years	O
)	O
and	O
educational	O
history	O
(±	O
2	O
years	O
)	O
with	O
no	O
current	O
or	O
previous	O
neurological	O
or	O
psychiatric	B-DS
disease	I-DS
.	O

Twelve	O
controls	O
were	O
recruited	O
over	O
the	O
same	O
period	O
and	O
examined	O
once	O
by	O
DTI	O
and	O
an	O
executive	O
functional	O
assessment	O
.	O

MRI	O
protocol	O

MRIs	O
were	O
performed	O
using	O
a	O
1	O
.	O
5	O
-	O
tesla	O
MRI	O
system	O
(	O
Signa	O
General	O
Electric	O
Medical	O
Systems	O
,	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
)	O
equipped	O
with	O
gradient	O
hardware	O
allowing	O
up	O
to	O
23	O
mT	O
/	O
m	O
.	O

T1	O
-	O
FLAIR	O
,	O
fast	O
spin	O
echo	O
T2	O
-	O
weighted	O
imaging	O
,	O
traditional	O
FLAIR	O
and	O
DTI	O
were	O
performed	O
.	O

Typical	O
acquisition	O
parameters	O
of	O
conventional	O
MRI	O
were	O
:	O
T1	O
-	O
FLAIR	O
(	O
6	O
mm	O
thick	O
,	O
2	O
mm	O
gap	O
,	O
TR	O
1	O
,	O
475	O
ms	O
/	O
TE	O
21	O
.	O
3	O
ms	O
/	O
TI	O
750	O
.	O
0	O
ms	O
),	O
T2	O
-	O
FLAIR	O
(	O
3	O
mm	O
thick	O
,	O
0	O
mm	O
gap	O
,	O
TR	O
8	O
,	O
000	O
ms	O
/	O
TE	O
120	O
.	O
0	O
ms	O
/	O
TI	O
2	O
,	O
200	O
ms	O
).	O

DTI	O
was	O
obtained	O
with	O
an	O
echo	O
planar	O
imaging	O
(	O
EPI	O
)	O
sequence	O
(	O
3	O
mm	O
thick	O
,	O
0	O
mm	O
gap	O
,	O
TR	O
10	O
,	O
000	O
/	O
TE	O
100	O
ms	O
,	O
NEX	O
=	O
1	O
,	O
matrix	O
128	O
×	O
128	O
,	O
field	O
of	O
view	O
24	O
×	O
24	O
cm	O
).	O

DTI	O
was	O
acquired	O
with	O
a	O
b	O
factor	O
of	O
1	O
,	O
000	O
s	O
/	O
mm2	O
and	O
diffusion	O
-	O
sensitive	O
gradients	O
were	O
applied	O
along	O
15	O
gradient	O
directions	O
.	O

In	O
addition	O
,	O
a	O
reference	O
image	O
without	O
diffusion	O
weighting	O
(	O
b	O
=	O
0	O
s	O
/	O
mm2	O
)	O
was	O
acquired	O
.	O

Fifteen	O
repeats	O
were	O
acquired	O
and	O
averaged	O
to	O
improve	O
signal	O
to	O
noise	O
ratio	O
.	O

The	O
scanning	O
baseline	O
was	O
parallel	O
to	O
the	O
antero	O
-	O
posterior	O
commissural	O
(	O
AC	O
-	O
PC	O
)	O
line	O
.	O

Axial	O
slices	O
were	O
obtained	O
using	O
a	O
fast	O
spin	O
echo	O
T2	O
(	O
3	O
mm	O
thick	O
,	O
0	O
mm	O
gap	O
,	O
TR	O
5	O
,	O
660	O
ms	O
/	O
TE	O
107	O
.	O
7	O
ms	O
).	O

Image	O
post	O
-	O
processing	O

An	O
experienced	O
radiographer	O
carried	O
out	O
image	O
post	O
-	O
processing	O
without	O
knowing	O
the	O
purpose	O
of	O
the	O
study	O
.	O

The	O
DTI	O
data	O
were	O
transferred	O
to	O
a	O
workstation	O
and	O
spatially	O
filtered	O
using	O
a	O
median	O
3	O
×	O
3	O
filter	O
.	O

Acquiring	O
the	O
DTI	O
data	O
with	O
the	O
dual	O
-	O
echo	O
EPI	O
sequence	O
and	O
ramp	O
sampling	O
considerably	O
reduced	O
,	O
but	O
did	O
not	O
eliminate	O
,	O
the	O
geometric	O
distortions	O
.	O

We	O
corrected	O
the	O
residual	O
distortions	O
by	O
registering	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
with	O
the	O
reference	O
image	O
using	O
the	O
two	O
-	O
dimensional	O
module	O
of	O
the	O
automated	O
image	O
registration	O
package	O
(	O
eight	O
-	O
parameter	O
with	O
perspective	O
)	O
[	O
13	O
].	O

With	O
this	O
correction	O
,	O
the	O
DTI	O
parameters	O
were	O
calculated	O
on	O
a	O
pixel	O
-	O
by	O
-	O
pixel	O
basis	O
.	O

Using	O
ADW4	O
.	O
2	O
Software	O
(	O
Signa	O
General	O
Electric	O
Medical	O
Systems	O
,	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
),	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
were	O
manually	O
delineated	O
in	O
the	O
left	O
and	O
right	O
frontal	O
white	O
matter	O
(	O
an	O
area	O
of	O
150	O
mm2	O
)	O
defined	O
as	O
quasi	O
-	O
circular	O
,	O
the	O
white	O
matter	O
around	O
the	O
posterior	O
horn	O
(	O
an	O
area	O
of	O
224	O
mm2	O
)	O
defined	O
as	O
quasi	O
-	O
circular	O
,	O
the	O
centrum	O
semiovale	O
defined	O
as	O
ellipse	O
(	O
an	O
area	O
of	O
780	O
mm2	O
)	O
on	O
a	O
slice	O
from	O
the	O
FLAIR	O
images	O
and	O
then	O
transferred	O
to	O
the	O
DTI	O
image	O
on	O
the	O
same	O
slice	O
(	O
Figure	O
1	O
).	O

The	O
thalami	O
were	O
also	O
observed	O
at	O
the	O
same	O
times	O
.	O

According	O
to	O
the	O
methods	O
used	O
by	O
Hervé	O
et	O
al	O
.,	O
the	O
medial	O
boundaries	O
of	O
the	O
thalami	O
were	O
verified	O
by	O
the	O
limits	O
of	O
cerebrospinal	O
fluid	O
-	O
containing	O
ventricle	O
on	O
T2	O
-	O
FLAIR	O
,	O
and	O
the	O
lateral	O
limits	O
were	O
defined	O
by	O
the	O
internal	O
capsule	O
on	O
FA	O
maps	O
[	O
14	O
].	O

DTI	O
maps	O
were	O
calculated	O
at	O
W1	O
and	O
on	O
follow	O
-	O
up	O
scans	O
.	O

The	O
quantitative	O
MD	O
(	O
derived	O
from	O
the	O
trace	O
of	O
the	O
diffusion	O
tensor	O
,	O
MD	O
=	O
trace	O
(	O
D	O
)/	O
3	O
)	O
and	O
FA	O
data	O
in	O
frontal	O
white	O
matter	O
obtained	O
at	O
different	O
time	O
points	O
were	O
analyzed	O
.	O

Ischemic	O
lesion	O
and	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
are	O
shown	O
in	O
the	O
traditional	O
magnetic	O
resonance	O
and	O
diffusion	O
tensor	O
magnetic	O
resonance	O
images	O
from	O
a	O
patient	O
with	O
acute	B-DS
infarction	I-DS
at	O
the	O
left	O
posterior	O
corona	O
radiata	O
.	O

(	O
A	O
)	O
T1	O
-	O
FLAIR	O
obtained	O
at	O
week	O
1	O
(	O
W1	O
)	O
after	O
stroke	B-DS
show	O
a	O
hypointense	O
area	O
at	O
the	O
left	O
posterior	O
corona	O
radiata	O
.	O
(	O
B	O
)	O
T2	O
-	O
weighted	O
image	O
and	O
(	O
C	O
)	O
T2	O
-	O
FLAIR	O
images	O
obtained	O
at	O
W1	O
show	O
a	O
hyperintense	O
area	O
at	O
the	O
left	O
posterior	O
corona	O
radiata	O
.	O
(	O
D	O
),	O
(	O
E	O
)	O
and	O
(	O
F	O
)	O
show	O
the	O
lesion	O
at	O
W12	O
.	O
(	O
G	O
),	O
(	O
I	O
)	O
and	O
(	O
K	O
)	O
mean	O
diffusivity	O
images	O
and	O
(	O
H	O
),	O
(	O
J	O
)	O
and	O
(	O
L	O
)	O
fractional	O
anisotropy	O
images	O
show	O
ROIs	O
in	O
the	O
left	O
and	O
right	O
frontal	O
white	O
matter	O
,	O
posterior	O
periventricular	O
white	O
matter	O
and	O
centrum	O
semiovale	O
.	O

Color	O
duplex	O
sonography	O
and	O
transcranial	O
duplex	O
scanning	O
(	O
TCD	O
)	O

The	O
examinations	O
with	O
Color	O
duplex	O
sonography	O
of	O
the	O
extracranial	O
carotid	O
arteries	O
were	O
performed	O
with	O
the	O
patients	O
at	O
W1	O
and	O
W12	O
and	O
controls	O
at	O
recruitment	O
.	O

All	O
measurements	O
were	O
performed	O
by	O
the	O
angiologist	O
who	O
was	O
blinded	O
for	O
the	O
clinical	O
status	O
of	O
the	O
study	O
patients	O
and	O
controls	O
.	O

The	O
internal	O
carotid	O
artery	O
(	O
ICA	O
)	O
was	O
explored	O
using	O
a	O
10	O
-	O
MHz	O
linear	O
-	O
array	O
transducer	O
(	O
GE	O
LOGIQ5	O
ultrasound	O
system	O
,	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
).	O

The	O
subjects	O
were	O
in	O
the	O
supine	O
position	O
with	O
their	O
heads	O
slightly	O
elevated	O
and	O
turned	O
25	O
°	O
to	O
40	O
°	O
to	O
the	O
contralateral	O
side	O
for	O
the	O
ICA	O
measurements	O
.	O

Peak	O
systolic	O
velocity	O
(	O
PSV	O
)	O
and	O
end	O
diastolic	O
velocity	O
(	O
EDV	O
)	O
were	O
measured	O
1	O
to	O
2	O
cm	O
above	O
the	O
carotid	O
bulb	O
in	O
the	O
ICAs	O
.	O

Intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
and	O
luminal	O
diameter	O
(	O
DIA	O
)	O
of	O
the	O
ICAs	O
were	O
measured	O
on	O
magnified	O
B	O
-	O
mode	O
.	O

The	O
distance	O
between	O
the	O
leading	O
edge	O
of	O
the	O
luminal	O
echo	O
and	O
the	O
leading	O
edge	O
of	O
the	O
media	O
/	O
adventitia	O
echo	O
was	O
measured	O
as	O
the	O
IMT	O
.	O

The	O
patients	O
underwent	O
TCD	O
scanning	O
at	O
W1	O
and	O
W12	O
and	O
controls	O
were	O
scanned	O
at	O
recruitment	O
.	O

Bilateral	O
mean	O
flow	O
velocity	O
was	O
continuously	O
and	O
simultaneously	O
monitored	O
by	O
a	O
2	O
-	O
MHz	O
phased	O
array	O
transducer	O
(	O
Philips	O
SONOS	O
5500	O
,	O
Eindhoven	O
,	O
the	O
Netherlands	O
)	O
by	O
the	O
angiologist	O
who	O
was	O
not	O
familiar	O
with	O
the	O
clinical	O
status	O
of	O
the	O
study	O
patients	O
and	O
controls	O
.	O

The	O
highest	O
signal	O
was	O
sought	O
at	O
a	O
depth	O
ranging	O
(	O
anterior	O
cerebral	O
artery	O
:	O
61	O
to	O
75	O
mm	O
;	O
middle	O
cerebral	O
artery	O
:	O
46	O
to	O
55	O
mm	O
,	O
posterior	O
cerebral	O
artery	O
:	O
56	O
to	O
70	O
mm	O
)	O
through	O
the	O
temporal	O
bone	O
window	O
.	O

Mean	O
flow	O
velocity	O
was	O
calculated	O
and	O
recorded	O
automatically	O
when	O
the	O
‘	O
record	O
’	O
function	O
of	O
the	O
Doppler	O
instrument	O
was	O
activated	O
.	O

Assessment	O
of	O
executive	O
dysfunction	O

A	O
‘	O
brief	O
executive	O
assessment	O
’	O
was	O
also	O
conducted	O
which	O
include	O
four	O
tests	O
often	O
used	O
clinically	O
:	O
the	O
Trail	O
making	O
B	O
-	O
A	O
test	O
,	O
the	O
Verbal	O
fluency	O
assessment	O
,	O
the	O
Digit	O
span	O
backwards	O
test	O
and	O
the	O
Digit	O
symbol	O
test	O
.	O

This	O
has	O
been	O
considered	O
to	O
be	O
a	O
sensitive	O
tool	O
for	O
detecting	O
deficits	O
in	O
patients	O
and	O
distinguishing	O
these	O
deficits	O
from	O
the	O
cognitive	O
effects	O
of	O
healthy	O
aging	O
[	O
6	O
],[	O
15	O
].	O

Because	O
elderly	O
Chinese	O
patients	O
are	O
unfamiliar	O
with	O
the	O
English	O
language	O
,	O
the	O
Trail	O
making	O
B	O
-	O
A	O
test	O
(	O
Chinese	O
version	O
)	O
and	O
Verbal	O
fluency	O
test	O
(	O
Chinese	O
version	O
)	O
were	O
applied	O
[	O
6	O
],[	O
16	O
],[	O
17	O
].	O

The	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
was	O
also	O
applied	O
because	O
it	O
is	O
often	O
used	O
clinically	O
as	O
a	O
standard	O
measure	O
of	O
dementia	B-DS
severity	O
.	O

Statistical	O
analysis	O

MD	O
and	O
FA	O
values	O
obtained	O
at	O
W1	O
,	O
W4	O
,	O
and	O
W12	O
in	O
patients	O
were	O
first	O
compared	O
with	O
those	O
of	O
controls	O
with	O
a	O
two	O
-	O
tailed	O
Student	O
’	O
s	O
t	O
-	O
test	O
.	O

Executive	O
assessments	O
were	O
compared	O
between	O
the	O
patient	O
and	O
the	O
control	O
groups	O
using	O
a	O
Student	O
’	O
s	O
t	O
-	O
test	O
.	O

These	O
parameters	O
and	O
clinical	O
scores	O
then	O
were	O
analyzed	O
using	O
Fisher	O
’	O
s	O
Least	O
Significant	O
Difference	O
(	O
LSD	O
)	O
test	O
for	O
multiple	O
testing	O
.	O

The	O
Color	O
duplex	O
sonography	O
and	O
TCD	O
parameters	O
obtained	O
at	O
W1	O
and	O
W12	O
were	O
compared	O
with	O
a	O
two	O
-	O
tailed	O
Student	O
’	O
s	O
t	O
-	O
test	O
.	O

Spearman	O
rank	O
correlation	O
analysis	O
was	O
used	O
to	O
determine	O
associations	O
between	O
changes	O
in	O
brief	O
executive	O
assessment	O
scores	O
and	O
the	O
DTI	O
parameter	O
changes	O
in	O
left	O
frontal	O
white	O
matter	O
and	O
thalamus	O
.	O

The	O
changes	O
in	O
executive	O
function	O
scores	O
over	O
time	O
and	O
the	O
DTI	O
parameter	O
changes	O
were	O
defined	O
as	O
follows	O
:	O

ΔExecutive	O
scores	O
or	O
DTI	O
Parameter	O
values	O
=	O
Value	O
measured	O
at	O
W12	O
−	O
value	O
measured	O
at	O
W1	O

Results	O

Participants	O

Twelve	O
patients	O
(	O
seven	O
male	O
and	O
five	O
female	O
)	O
and	O
twelve	O
controls	O
(	O
seven	O
male	O
and	O
five	O
female	O
)	O
were	O
recruited	O
in	O
the	O
study	O
.	O

All	O
patients	O
and	O
controls	O
were	O
right	O
-	O
handed	O
.	O

Each	O
patient	O
had	O
one	O
or	O
more	O
vascular	O
risk	O
factor	O
(	O
Table	O
1	O
).	O

Patient	O
demographics	O
and	O
clinical	O
data	O

Number	O

Age	O
(	O
years	O
)	O

Gender	O

Educational	O
history	O
(	O
years	O
)	O

Vascular	O
factors	O

Volume	O
of	O
lesion	O
(	O
mm3	O
)	O

1	O

59	O

M	O

8	O

Hypertension	B-DS

11	O
,	O
160	O

2	O

67	O

F	O

6	O

Hypertension	B-DS
,	O
hypercholesterolemia	B-DS
,	O
diabetes	B-DS
mellitus	I-DS

14	O
,	O
000	O

3	O

66	O

M	O

18	O

Hypertension	B-DS
,	O
tobacco	O
use	O
,	O
overweight	O

13	O
,	O
300	O

4	O

57	O

F	O

7	O

Hypertension	B-DS
,	O
diabetes	B-DS
mellitus	I-DS

9	O
,	O
690	O

5	O

66	O

M	O

8	O

Hypertension	B-DS
,	O
diabetes	B-DS
mellitus	I-DS

6	O
,	O
790	O

6	O

65	O

M	O

6	O

Tobacco	O
use	O

8	O
,	O
450	O

7	O

46	O

F	O

11	O

Hypercholesterolemia	B-DS

7	O
,	O
370	O

8	O

69	O

F	O

6	O

Hypertension	B-DS

10	O
,	O
810	O

9	O

63	O

M	O

8	O

Hypertension	B-DS
,	O
tobacco	O
use	O

16	O
,	O
200	O

10	O

48	O

F	O

8	O

Hypertension	B-DS

9	O
,	O
660	O

11	O

65	O

M	O

12	O

Hypertension	B-DS
,	O
diabetes	B-DS
mellitus	I-DS
,	O
tobacco	O
use	O
,	O
overweight	O

12	O
,	O
150	O

12	O

50	O

M	O

5	O

Hypertension	B-DS
,	O
diabetes	B-DS
mellitus	I-DS

8	O
,	O
810	O

F	O
:	O
female	O
;	O
M	O
:	O
male	O
;	O
FLAIR	O
:	O
fluid	O
attenuated	O
inversion	O
recovery	O
.	O

The	O
volume	O
of	O
the	O
infarcted	O
lesion	O
was	O
calculated	O
on	O
T2	O
-	O
FLAIR	O
images	O
at	O
week	O
12	O
(	O
W12	O
).	O

Controls	O
were	O
matched	O
for	O
age	O
and	O
educational	O
history	O
.	O

MRI	O
data	O

Participants	O
completed	O
all	O
traditional	O
MRI	O
and	O
DTI	O
examinations	O
.	O

Within	O
the	O
first	O
week	O
from	O
stroke	B-DS
onset	O
,	O
T2	O
-	O
weighted	O
and	O
T2	O
-	O
FLAIR	O
images	O
showed	O
focal	O
hyperintensity	O
confined	O
to	O
the	O
left	O
-	O
sided	O
posterior	O
corona	O
radiata	O
in	O
each	O
patient	O
(	O
Figure	O
1B	O
and	O
C	O
),	O
and	O
there	O
was	O
no	O
abnormal	O
signal	O
in	O
other	O
regions	O
.	O

At	O
W12	O
,	O
no	O
signal	O
abnormality	O
was	O
detected	O
on	O
T1	O
,	O
T2	O
-	O
weighted	O
,	O
and	O
T2	O
-	O
FLAIR	O
images	O
outside	O
the	O
territory	O
of	O
the	O
left	O
posterior	O
corona	O
radiata	O
(	O
Figure	O
1D	O
,	O
E	O
and	O
F	O
).	O

The	O
infarct	O
volume	O
varied	O
from	O
6	O
,	O
790	O
to	O
16	O
,	O
200	O
mm3	O
(	O
10	O
,	O
699	O
±	O
2	O
,	O
818	O
mm3	O
)	O
on	O
T2	O
images	O
at	O
W12	O
.	O

No	O
definite	O
abnormal	O
signals	O
were	O
observed	O
in	O
controls	O
.	O

In	O
controls	O
,	O
in	O
the	O
absence	O
of	O
any	O
significant	O
difference	O
between	O
the	O
left	O
and	O
right	O
regions	O
for	O
MD	O
(	O
mean	O
values	O
:	O
frontal	O
white	O
matter	O
0	O
.	O
804	O
±	O
0	O
.	O
109	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
and	O
0	O
.	O
809	O
±	O
0	O
.	O
108	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
;	O
posterior	O
periventricular	O
white	O
matter	O
0	O
.	O
824	O
±	O
0	O
.	O
099	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
and	O
0	O
.	O
816	O
±	O
0	O
.	O
088	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
;	O
centrum	O
semiovale	O
0	O
.	O
764	O
±	O
0	O
.	O
093	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
and	O
0	O
.	O
771	O
±	O
0	O
.	O
095	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
;	O
thalamus	O
0	O
.	O
836	O
±	O
0	O
.	O
069	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
and	O
0	O
.	O
840	O
±	O
0	O
.	O
075	O
×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
,	O
respectively	O
,	O
all	O
P	O
>	O
0	O
.	O
05	O
)	O
and	O
FA	O
(	O
mean	O
values	O
:	O
frontal	O
white	O
matter	O
0	O
.	O
421	O
±	O
0	O
.	O
057	O
and	O
0	O
.	O
433	O
±	O
0	O
.	O
102	O
;	O
posterior	O
periventricular	O
white	O
matter	O
0	O
.	O
451	O
±	O
0	O
.	O
057	O
and	O
0	O
.	O
449	O
±	O
0	O
.	O
056	O
;	O
centrum	O
semiovale	O
0	O
.	O
392	O
±	O
0	O
.	O
063	O
and	O
0	O
.	O
397	O
±	O
0	O
.	O
065	O
;	O
thalamus	O
0	O
.	O
345	O
±	O
0	O
.	O
051	O
and	O
0	O
.	O
343	O
±	O
0	O
.	O
049	O
,	O
respectively	O
,	O
all	O
P	O
>	O
0	O
.	O
05	O
),	O
the	O
data	O
obtained	O
in	O
the	O
left	O
regions	O
in	O
controls	O
were	O
selected	O
to	O
compare	O
those	O
values	O
in	O
patients	O
.	O

MD	O
and	O
FA	O
values	O
at	O
W1	O
in	O
the	O
left	O
and	O
right	O
regions	O
(	O
frontal	O
white	O
matter	O
,	O
posterior	O
periventricular	O
white	O
matter	O
,	O
centrum	O
semiovale	O
and	O
thalamus	O
)	O
were	O
not	O
significantly	O
different	O
compared	O
with	O
those	O
of	O
controls	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

There	O
was	O
a	O
significant	O
increase	O
of	O
MD	O
and	O
decrease	O
of	O
FA	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
from	O
W1	O
to	O
W12	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

No	O
obvious	O
MD	O
or	O
FA	O
value	O
changes	O
were	O
found	O
in	O
the	O
right	O
frontal	O
white	O
matter	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

There	O
were	O
no	O
significant	O
differences	O
of	O
MD	O
and	O
FA	O
in	O
the	O
left	O
and	O
right	O
posterior	O
periventricular	O
white	O
matter	O
and	O
centrum	O
semiovale	O
from	O
W1	O
to	O
W12	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

In	O
the	O
thalamus	O
,	O
a	O
significant	O
increase	O
of	O
MD	O
in	O
the	O
left	O
thalamus	O
was	O
found	O
between	O
W1	O
and	O
W12	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
no	O
obvious	O
MD	O
value	O
changes	O
were	O
found	O
in	O
right	O
thalamus	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

There	O
was	O
no	O
significant	O
difference	O
of	O
the	O
FA	O
values	O
in	O
left	O
and	O
right	O
thalami	O
between	O
W1	O
and	O
W12	O
.	O

No	O
significant	O
differences	O
of	O
MD	O
and	O
FA	O
in	O
the	O
posterior	O
periventricular	O
white	O
matter	O
or	O
centrum	O
semiovale	O
were	O
detected	O
from	O
W1	O
to	O
W12	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
(	O
Table	O
2	O
).	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
parameter	O
values	O
in	O
frontal	O
white	O
matter	O
,	O
posterior	O
periventricular	O
white	O
matter	O
,	O
centrum	O
semiovale	O
and	O
thalamus	O
in	O
patients	O
and	O
controls	O
(	O
mean	O
±	O
SD	O
)	O

Region	O

MD	O
(×	O
10	O
−	O
3	O
mm2	O
/	O
s	O
)	O

FA	O

W1	O

W4	O

W12	O

W1	O

W4	O

W12	O

Patients	O







LFWM	O

0	O
.	O
824	O
±	O
0	O
.	O
095a	O

0	O
.	O
815	O
±	O
0	O
.	O
080	O

0	O
.	O
904	O
±	O
0	O
.	O
107bc	O

0	O
.	O
388	O
±	O
0	O
.	O
056a	O

0	O
.	O
374	O
±	O
0	O
.	O
062	O

0	O
.	O
313	O
±	O
0	O
.	O
054bc	O

RFWM	O

0	O
.	O
825	O
±	O
0	O
.	O
089	O

0	O
.	O
821	O
±	O
0	O
.	O
088	O

0	O
.	O
831	O
±	O
0	O
.	O
084	O

0	O
.	O
387	O
±	O
0	O
.	O
062	O

0	O
.	O
385	O
±	O
0	O
.	O
063	O

0	O
.	O
395	O
±	O
0	O
.	O
063	O

LPPWM	O

0	O
.	O
837	O
±	O
0	O
.	O
102	O

0	O
.	O
836	O
±	O
0	O
.	O
096	O

0	O
.	O
839	O
±	O
0	O
.	O
087	O

0	O
.	O
452	O
±	O
0	O
.	O
062	O

0	O
.	O
447	O
±	O
0	O
.	O
061	O

0	O
.	O
431	O
±	O
0	O
.	O
063	O

RPPWM	O

0	O
.	O
853	O
±	O
0	O
.	O
114	O

0	O
.	O
835	O
±	O
0	O
.	O
094	O

0	O
.	O
822	O
±	O
0	O
.	O
085	O

0	O
.	O
444	O
±	O
0	O
.	O
053	O

0	O
.	O
451	O
±	O
0	O
.	O
059	O

0	O
.	O
447	O
±	O
0	O
.	O
053	O

LCS	O

0	O
.	O
766	O
±	O
0	O
.	O
112	O

0	O
.	O
754	O
±	O
0	O
.	O
087	O

0	O
.	O
729	O
±	O
0	O
.	O
104	O

0	O
.	O
387	O
±	O
0	O
.	O
058	O

0	O
.	O
381	O
±	O
0	O
.	O
060	O

0	O
.	O
362	O
±	O
0	O
.	O
055	O

RCS	O

0	O
.	O
772	O
±	O
0	O
.	O
110	O

0	O
.	O
765	O
±	O
0	O
.	O
098	O

0	O
.	O
783	O
±	O
0	O
.	O
105	O

0	O
.	O
383	O
±	O
0	O
.	O
059	O

0	O
.	O
391	O
±	O
0	O
.	O
062	O

0	O
.	O
393	O
±	O
0	O
.	O
064	O

L	O
thalamus	O

0	O
.	O
846	O
±	O
0	O
.	O
080a	O

0	O
.	O
830	O
±	O
0	O
.	O
097	O

0	O
.	O
949	O
±	O
0	O
.	O
065bc	O

0	O
.	O
338	O
±	O
0	O
.	O
038	O

0	O
.	O
334	O
±	O
0	O
.	O
037	O

0	O
.	O
323	O
±	O
0	O
.	O
032	O

R	O
thalamus	O

0	O
.	O
839	O
±	O
0	O
.	O
788	O

0	O
.	O
840	O
±	O
0	O
.	O
081	O

0	O
.	O
841	O
±	O
0	O
.	O
083	O

0	O
.	O
344	O
±	O
0	O
.	O
042	O

0	O
.	O
344	O
±	O
0	O
.	O
043	O

0	O
.	O
342	O
±	O
0	O
.	O
040	O

Controls	O







LFWM	O

0	O
.	O
804	O
±	O
0	O
.	O
109	O

0	O
.	O
421	O
±	O
0	O
.	O
057	O

LPPWM	O

0	O
.	O
824	O
±	O
0	O
.	O
099	O

0	O
.	O
451	O
±	O
0	O
.	O
057	O

LCS	O

0	O
.	O
764	O
±	O
0	O
.	O
093	O

0	O
.	O
392	O
±	O
0	O
.	O
063	O

L	O
thalamus	O

0	O
.	O
836	O
±	O
0	O
.	O
069	O

0	O
.	O
345	O
±	O
0	O
.	O
051	O

Abbreviations	O
:	O
FA	O
,	O
fractional	O
anisotropy	O
;	O
LCS	O
,	O
left	O
centrum	O
semiovale	O
;	O
LFWM	O
,	O
left	O
frontal	O
white	O
matter	O
;	O
LPPWM	O
,	O
left	O
posterior	O
periventricular	O
white	O
matter	O
;	O
LCS	O
,	O
left	O
centrum	O
semiovale	O
;	O
L	O
thalamus	O
,	O
left	O
thalamus	O
;	O
MD	O
,	O
mean	O
diffusivity	O
;	O
R	O
thalamus	O
,	O
right	O
thalamus	O
;	O
RCS	O
,	O
right	O
centrum	O
semiovale	O
;	O
RFWM	O
,	O
right	O
frontal	O
white	O
matter	O
;	O
RPPWM	O
,	O
right	O
posterior	O
periventricular	O
white	O
matter	O
;	O
W1	O
,	O
the	O
first	O
week	O
;	O
W4	O
,	O
the	O
fourth	O
week	O
;	O
W12	O
,	O
the	O
12th	O
week	O
.	O

aP	O
<	O
0	O
.	O
05	O
,	O
LSD	O
test	O
,	O
comparison	O
between	O
W1	O
and	O
W12	O
;	O
bP	O
<	O
0	O
.	O
05	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
comparison	O
between	O
the	O
control	O
and	O
patient	O
groups	O
;	O
cP	O
<	O
0	O
.	O
05	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
comparison	O
in	O
the	O
left	O
and	O
right	O
region	O
of	O
patients	O
at	O
W12	O
.	O

The	O
controls	O
were	O
examined	O
only	O
once	O
when	O
they	O
were	O
recruited	O
.	O

Color	O
duplex	O
sonography	O
and	O
TCD	O
data	O

The	O
Color	O
duplex	O
examination	O
of	O
luminal	O
diameter	O
and	O
IMT	O
measurements	O
were	O
performed	O
in	O
all	O
the	O
ICAs	O
of	O
the	O
subjects	O
.	O

The	O
mean	O
values	O
of	O
all	O
data	O
were	O
given	O
in	O
Table	O
3	O
.	O

We	O
did	O
not	O
find	O
any	O
differences	O
of	O
IMT	O
,	O
DIA	O
,	O
PSV	O
and	O
EDV	O
detected	O
at	O
W1	O
and	O
W12	O
in	O
patients	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

Ultrasound	O
parameters	O
of	O
the	O
left	O
and	O
right	O
internal	O
carotid	O
artery	O
(	O
mean	O
±	O
SD	O
)	O

Group	O

Left	O
IMT	O
(	O
mm	O
)	O

Right	O
IMT	O
(	O
mm	O
)	O

Left	O
DIA	O
(	O
mm	O
)	O

Right	O
DIA	O
(	O
mm	O
)	O

Left	O
SPV	O
(	O
cm	O
/	O
s	O
)	O

Right	O
SPV	O
(	O
cm	O
/	O
s	O
)	O

Left	O
EDV	O
(	O
cm	O
/	O
s	O
)	O

Right	O
EDV	O
(	O
cm	O
/	O
s	O
)	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

Patients	O

1	O
.	O
21	O
±	O
0	O
.	O
13	O

1	O
.	O
22	O
±	O
0	O
.	O
14	O

1	O
.	O
18	O
±	O
0	O
.	O
09	O

1	O
.	O
18	O
±	O
0	O
.	O
10	O

4	O
.	O
86	O
±	O
0	O
.	O
63	O

4	O
.	O
84	O
±	O
0	O
.	O
61	O

4	O
.	O
97	O
±	O
0	O
.	O
55	O

5	O
.	O
02	O
±	O
0	O
.	O
58	O

61	O
±	O
9	O
.	O
8	O

65	O
±	O
11	O
.	O
1	O

58	O
±	O
8	O
.	O
7	O

60	O
±	O
9	O
.	O
4	O

24	O
.	O
3	O
±	O
3	O
.	O
8	O

24	O
.	O
5	O
±	O
3	O
.	O
7	O

23	O
.	O
9	O
±	O
3	O
.	O
7	O

24	O
.	O
1	O
±	O
3	O
.	O
8	O

Controls	O

1	O
.	O
02	O
±	O
0	O
.	O
19	O

1	O
.	O
04	O
±	O
0	O
.	O
22	O

5	O
.	O
20	O
±	O
0	O
.	O
68	O

5	O
.	O
37	O
±	O
0	O
.	O
73	O

52	O
±	O
8	O
.	O
5	O

53	O
±	O
8	O
.	O
3	O

23	O
.	O
5	O
±	O
5	O
.	O
6	O

24	O
.	O
0	O
±	O
6	O
.	O
1	O

Abbreviations	O
:	O
DIA	O
,	O
luminal	O
diameter	O
;	O
EDV	O
,	O
end	O
diastolic	O
velocity	O
;	O
IMT	O
,	O
intima	O
-	O
media	O
thickness	O
;	O
PSV	O
,	O
peak	O
systolic	O
velocity	O
;	O
W1	O
,	O
the	O
first	O
week	O
,	O
W12	O
,	O
the	O
12th	O
week	O
.	O

The	O
controls	O
were	O
examined	O
only	O
once	O
when	O
they	O
were	O
recruited	O
.	O

All	O
subjects	O
had	O
accessible	O
cranial	O
window	O
for	O
TCD	O
and	O
underwent	O
0	O
.	O
5	O
to	O
1	O
hour	O
of	O
TCD	O
monitoring	O
.	O

Mean	O
flow	O
velocity	O
values	O
(	O
MFV	O
)	O
were	O
shown	O
in	O
Table	O
4	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
of	O
MFV	O
detected	O
in	O
anterior	O
cerebral	O
artery	O
(	O
ACA	O
),	O
MCA	O
and	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
at	O
W1	O
and	O
W12	O
in	O
patients	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
).	O

Values	O
of	O
the	O
mean	O
flow	O
velocity	O
(	O
cm	O
/	O
s	O
)	O
in	O
the	O
left	O
and	O
right	O
anterior	O
cerebral	O
artery	O
(	O
ACA	O
),	O
middle	O
cerebral	O
artery	O
(	O
MCA	O
)	O
and	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
(	O
mean	O
±	O
SD	O
)	O

Group	O

Left	O
ACA	O

Right	O
ACA	O

Left	O
MCA	O

Right	O
MCA	O

Left	O
PCA	O

Right	O
PCA	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

W1	O

W12	O

Patients	O

55	O
.	O
17	O
±	O
9	O
.	O
53	O

53	O
.	O
85	O
±	O
9	O
.	O
94	O

49	O
.	O
74	O
±	O
9	O
.	O
13	O

50	O
.	O
65	O
±	O
8	O
.	O
06	O

58	O
.	O
94	O
±	O
15	O
.	O
42	O

60	O
.	O
07	O
±	O
11	O
.	O
26	O

63	O
.	O
12	O
±	O
13	O
.	O
63	O

63	O
.	O
26	O
±	O
12	O
.	O
65	O

38	O
.	O
8	O
±	O
10	O
.	O
76	O

37	O
.	O
21	O
±	O
8	O
.	O
10	O

38	O
.	O
17	O
±	O
12	O
.	O
40	O

38	O
.	O
99	O
±	O
13	O
.	O
02	O

Controls	O

46	O
.	O
62	O
±	O
7	O
.	O
05	O

47	O
.	O
81	O
±	O
8	O
.	O
89	O

64	O
.	O
95	O
±	O
9	O
.	O
35	O

62	O
.	O
88	O
±	O
5	O
.	O
40	O

37	O
.	O
20	O
±	O
5	O
.	O
65	O

36	O
.	O
97	O
±	O
6	O
.	O
13	O

Abbreviations	O
:	O
W1	O
,	O
the	O
first	O
week	O
;	O
W12	O
,	O
the	O
12th	O
week	O
.	O

The	O
controls	O
were	O
examined	O
only	O
once	O
when	O
they	O
were	O
recruited	O
.	O

Cognitive	B-DS
deficit	I-DS

There	O
were	O
no	O
significant	O
differences	O
in	O
MMSE	O
,	O
Verbal	O
fluency	O
assessment	O
and	O
Digit	O
span	O
backwards	O
test	O
between	O
patients	O
and	O
controls	O
at	O
W1	O
.	O

The	O
significant	O
difference	O
of	O
Trail	O
making	O
B	O
-	O
A	O
and	O
Digit	O
symbol	O
tests	O
were	O
found	O
between	O
patients	O
and	O
controls	O
at	O
W1	O
.	O

Mean	O
scores	O
on	O
the	O
Trail	O
making	O
B	O
-	O
A	O
test	O
,	O
Verbal	O
fluency	O
assessment	O
,	O
Digit	O
span	O
backwards	O
and	O
Digit	O
symbol	O
tests	O
for	O
patients	O
were	O
significantly	O
changed	O
between	O
W1	O
and	O
W12	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

There	O
was	O
statistical	O
difference	O
in	O
the	O
presence	O
of	O
Trail	O
making	O
B	O
-	O
A	O
,	O
Verbal	O
fluency	O
assessment	O
and	O
Digit	O
symbol	O
tests	O
between	O
patients	O
and	O
controls	O
at	O
W4	O
and	O
W12	O
,	O
and	O
Digit	O
span	O
backwards	O
test	O
at	O
W12	O
(	O
Table	O
5	O
).	O

Cognitive	O
functional	O
scores	O
of	O
patients	O
and	O
controls	O
(	O
mean	O
±	O
SD	O
)	O


Patients	O

Controls	O

W1	O

W4	O

W12	O

MMSE	O

26	O
.	O
8	O
±	O
1	O
.	O
6	O

25	O
.	O
4	O
±	O
2	O
.	O
3	O

25	O
.	O
0	O
±	O
1	O
.	O
7	O

29	O
.	O
3	O
±	O
1	O
.	O
5	O

Trail	O
making	O
B	O
-	O
A	O
test	O

160	O
.	O
3	O
±	O
54	O
.	O
7ab	O

181	O
.	O
8	O
±	O
52	O
.	O
1b	O

224	O
.	O
1	O
±	O
55	O
.	O
1b	O

77	O
.	O
2	O
±	O
33	O
.	O
3	O

Verbal	O
fluency	O
assessment	O

40	O
.	O
8	O
±	O
10	O
.	O
3a	O

33	O
.	O
9	O
±	O
11	O
.	O
0b	O

26	O
.	O
9	O
±	O
11	O
.	O
0b	O

42	O
.	O
4	O
±	O
8	O
.	O
1	O

Digit	O
span	O
backwards	O
test	O

7	O
.	O
3	O
±	O
1	O
.	O
5a	O

6	O
.	O
3	O
±	O
1	O
.	O
4	O

5	O
.	O
7	O
±	O
1	O
.	O
3b	O

7	O
.	O
0	O
±	O
1	O
.	O
7	O

Digit	O
symbol	O
test	O

32	O
.	O
6	O
±	O
6	O
.	O
5ab	O

26	O
.	O
6	O
±	O
6	O
.	O
5b	O

22	O
.	O
3	O
±	O
4	O
.	O
9b	O

45	O
.	O
6	O
±	O
9	O
.	O
2	O

Abbreviations	O
:	O
MMSE	O
,	O
Mini	O
-	O
Mental	O
State	O
Examination	O
;	O
W1	O
,	O
within	O
the	O
first	O
week	O
;	O
W4	O
,	O
the	O
fourth	O
week	O
;	O
W12	O
,	O
the	O
12th	O
week	O
.	O

aP	O
<	O
0	O
.	O
05	O
,	O
LSD	O
test	O
,	O
comparison	O
between	O
W1	O
and	O
W12	O
in	O
patients	O
;	O
bP	O
<	O
0	O
.	O
05	O
,	O
Student	O
’	O
s	O
t	O
-	O
test	O
,	O
comparison	O
between	O
the	O
control	O
and	O
patient	O
groups	O
.	O

Correlations	O
between	O
DTI	O
and	O
executive	O
function	O
in	O
patients	O

As	O
illustrated	O
in	O
Figure	O
2	O
,	O
the	O
Spearman	O
rank	O
correlational	O
analyses	O
showed	O
that	O
the	O
MD	O
and	O
FA	O
changes	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
correlated	O
with	O
the	O
executive	O
function	O
changes	O
in	O
patients	O
.	O

There	O
were	O
only	O
weak	O
correlations	O
between	O
the	O
MD	O
changes	O
in	O
the	O
left	O
thalamus	O
and	O
Trail	O
making	O
B	O
-	O
A	O
test	O
(	O
Spearman	O
coefficient	O
of	O
rank	O
correlation	O
rs	O
=	O
0	O
.	O
488	O
,	O
P	O
=	O
0	O
.	O
098	O
)	O
and	O
Digit	O
symbol	O
test	O
(	O
Spearman	O
coefficient	O
of	O
rank	O
correlation	O
rs	O
=	O
−	O
0	O
.	O
552	O
,	O
P	O
=	O
0	O
.	O
063	O
).	O

Scatter	O
plot	O
with	O
lines	O
of	O
best	O
fit	O
showing	O
the	O
relationship	O
between	O
the	O
change	O
values	O
of	O
diffusivity	O
(	O
mean	O
diffusivity	O
and	O
fractional	O
anisotropy	O
)	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
and	O
the	O
change	O
values	O
of	O
executive	O
function	O
(	O
trail	O
making	O
B	O
-	O
A	O
,	O
verbal	O
fluency	O
assessment	O
,	O
digit	O
span	O
backwards	O
and	O
digit	O
symbol	O
tests	O
)	O
in	O
patients	O
from	O
W1	O
to	O
W12	O
.	O
A	O
-	O
H	O
show	O
the	O
relationship	O
between	O
Δmean	O
diffusivity	O
and	O
Δtrail	O
making	O
B	O
-	O
A	O
(	O
A	O
),	O
Δverbal	O
fluency	O
(	O
B	O
),	O
Δdigit	O
span	O
backwards	O
(	O
C	O
),	O
Δdigit	O
symbol	O
(	O
D	O
),	O
and	O
between	O
Δfractional	O
anisotropy	O
and	O
Δtrail	O
making	O
B	O
-	O
A	O
(	O
E	O
),	O
Δverbal	O
fluency	O
(	O
F	O
),	O
Δdigit	O
span	O
backwards	O
(	O
G	O
),	O
Δdigit	O
symbol	O
(	O
H	O
).	O

Discussion	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
prospective	O
study	O
using	O
DTI	O
to	O
observe	O
secondary	O
changes	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
remote	O
from	O
the	O
ipsilateral	O
posterior	O
corona	O
radiata	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
focal	O
cerebral	B-DS
infarcts	I-DS
can	O
lead	O
to	O
remote	O
tissue	O
alterations	O
within	O
connected	O
regions	O
related	O
to	O
Wallerian	O
degeneration	O
[	O
8	O
],[	O
10	O
],[	O
18	O
]–[	O
21	O
].	O

Because	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
traditional	O
MRI	O
are	O
insufficiently	O
sensitive	O
and	O
difficult	O
to	O
quantify	O
the	O
microstructural	O
changes	O
,	O
DTI	O
was	O
used	O
in	O
this	O
study	O
.	O

DTI	O
is	O
able	O
to	O
characterize	O
brain	O
tissue	O
structure	O
by	O
measurement	O
of	O
water	O
diffusion	O
,	O
expressed	O
as	O
two	O
indices	O
,	O
MD	O
and	O
FA	O
.	O

MD	O
is	O
a	O
parameter	O
of	O
magnitude	O
of	O
average	O
molecular	O
motion	O
considered	O
in	O
all	O
directions	O
.	O

FA	O
is	O
a	O
quantitative	O
measure	O
of	O
directional	O
bias	O
in	O
the	O
diffusion	O
profile	O
.	O

A	O
significant	O
increase	O
of	O
MD	O
and	O
decrease	O
of	O
FA	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
was	O
found	O
between	O
W1	O
and	O
W12	O
,	O
but	O
there	O
were	O
no	O
significant	O
changes	O
between	O
W1	O
and	O
W4	O
,	O
and	O
between	O
W4	O
and	O
W12	O
.	O

The	O
abnormal	O
diffusion	O
observed	O
suggest	O
that	O
the	O
secondary	O
damage	O
is	O
cumulative	O
from	O
W1	O
to	O
W12	O
.	O

Such	O
changes	O
in	O
MD	O
and	O
FA	O
in	O
the	O
frontal	O
white	O
matter	O
have	O
also	O
been	O
described	O
in	O
patients	O
with	O
ILA	B-DS
,	O
which	O
is	O
suggestive	O
of	O
axonal	O
structural	O
loss	O
in	O
the	O
regions	O
[	O
6	O
].	O

Also	O
,	O
the	O
increased	O
MD	O
and	O
decrease	O
of	O
FA	O
may	O
be	O
correlated	O
with	O
executive	O
functional	O
changes	O
.	O

Frontal	O
-	O
subcortical	O
circuit	O
was	O
defined	O
as	O
including	O
the	O
frontal	O
cortex	O
,	O
caudate	O
,	O
pallidum	O
,	O
thalamus	O
,	O
genu	O
of	O
internal	O
capsule	O
,	O
anterior	O
internal	O
capsule	O
,	O
anterior	O
corona	O
radiata	O
,	O
and	O
anterior	O
centrum	O
semiovale	O
[	O
3	O
].	O

In	O
this	O
study	O
,	O
executive	B-DS
dysfunction	I-DS
was	O
found	O
in	O
the	O
patients	O
with	O
left	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
.	O

A	O
possible	O
explanation	O
for	O
this	O
is	O
that	O
the	O
region	O
itself	O
is	O
a	O
structure	O
in	O
the	O
executive	O
functional	O
circuit	O
.	O

Another	O
more	O
possible	O
mechanism	O
of	O
the	O
executive	O
changes	O
in	O
the	O
patients	O
is	O
secondary	O
degeneration	O
due	O
to	O
the	O
disruption	O
of	O
axons	O
in	O
the	O
frontal	O
white	O
matter	O
that	O
links	O
the	O
frontal	O
cortex	O
to	O
other	O
structures	O
in	O
the	O
executive	O
functional	O
circuit	O
.	O

The	O
correlation	O
of	O
MD	O
and	O
FA	O
alteration	O
in	O
the	O
left	O
posterior	O
white	O
matter	O
with	O
executive	O
performance	O
supports	O
this	O
hypothesis	O
.	O

Our	O
previous	O
study	O
has	O
shown	O
that	O
gray	O
matter	O
volumes	O
decreased	O
significantly	O
in	O
the	O
ipsilateral	O
supplementary	O
motor	O
area	O
and	O
contralateral	O
insula	O
from	O
W1	O
to	O
W12	O
in	O
patients	O
with	O
undergoing	O
acute	B-DS
subcortical	I-DS
infarction	I-DS
.	O

The	O
changes	O
of	O
gray	O
matter	O
volumes	O
in	O
the	O
ipsilesional	O
supplementary	O
motor	O
area	O
correlated	O
with	O
the	O
changes	O
of	O
motor	O
function	O
and	O
activities	O
of	O
daily	O
living	O
[	O
22	O
].	O

In	O
the	O
present	O
study	O
,	O
a	O
significant	O
increase	O
of	O
MD	O
in	O
the	O
left	O
thalamus	O
was	O
found	O
over	O
time	O
,	O
which	O
is	O
suggestive	O
of	O
an	O
important	O
loss	O
of	O
thalamic	O
structural	O
components	O
.	O

Within	O
the	O
thalamus	O
,	O
secondary	O
damage	O
has	O
been	O
also	O
reported	O
by	O
Hervé	O
et	O
al	O
.	O
and	O
our	O
team	O
in	O
patients	O
after	O
an	O
acute	O
isolated	O
MCA	O
territory	O
infarction	O
[	O
8	O
],[	O
14	O
].	O

A	O
weak	O
correlation	O
between	O
the	O
MD	O
changes	O
in	O
the	O
left	O
thalamus	O
and	O
executive	O
function	O
was	O
found	O
in	O
this	O
study	O
,	O
which	O
means	O
secondary	O
damage	O
of	O
the	O
left	O
thalamus	O
is	O
possibly	O
involved	O
in	O
inhibiting	O
executive	O
function	O
.	O

The	O
lack	O
of	O
FA	O
changes	O
may	O
be	O
related	O
to	O
the	O
absence	O
of	O
isolated	O
bundles	O
of	O
parallel	O
fibers	O
within	O
the	O
thalamus	O
[	O
14	O
].	O

We	O
failed	O
to	O
find	O
significant	O
diffusion	O
changes	O
in	O
the	O
posterior	O
periventricular	O
white	O
matter	O
or	O
centrum	O
semiovale	O
.	O

It	O
is	O
possible	O
that	O
only	O
the	O
most	O
significant	O
diffusion	O
changes	O
were	O
detected	O
by	O
our	O
method	O
and	O
more	O
widespread	O
secondary	O
damages	O
occur	O
in	O
other	O
areas	O
.	O

Longer	O
follow	O
-	O
up	O
and	O
more	O
sophisticated	O
image	O
analysis	O
techniques	O
may	O
be	O
required	O
for	O
determining	O
secondary	O
damage	O
in	O
other	O
regions	O
remote	O
to	O
an	O
infarction	B-DS
.	O

In	O
our	O
patients	O
,	O
there	O
was	O
no	O
abnormal	O
signal	O
in	O
the	O
frontal	O
area	O
at	O
W1	O
and	O
W12	O
,	O
which	O
means	O
no	O
new	O
ischemic	O
lesions	O
exist	O
in	O
the	O
frontal	O
area	O
between	O
W1	O
and	O
W12	O
.	O

There	O
was	O
also	O
no	O
significant	O
change	O
of	O
blood	O
flow	O
in	O
the	O
frontal	O
area	O
between	O
W1	O
and	O
W12	O
in	O
patients	O
as	O
measured	O
by	O
the	O
evaluation	O
of	O
carotid	B-DS
artery	I-DS
stenosis	I-DS
and	O
hemodynamics	O
of	O
ACA	O
,	O
MCA	O
and	O
PCA	O
performed	O
with	O
Color	O
duplex	O
sonography	O
and	O
TCD	O
,	O
suggesting	O
that	O
frontal	O
dysfunction	O
would	O
not	O
be	O
attributed	O
to	O
potential	O
hemodynamic	O
changes	O
.	O

Vataja	O
et	O
al	O
.	O
reported	O
significant	O
executive	O
dysfunction	O
in	O
patients	O
with	O
anterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
,	O
but	O
failed	O
to	O
find	O
executive	O
change	O
in	O
patients	O
with	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
[	O
4	O
].	O

In	O
this	O
study	O
,	O
however	O
,	O
we	O
observed	O
a	O
poor	O
executive	O
performance	O
in	O
patients	O
with	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
.	O

The	O
difference	O
between	O
our	O
study	O
and	O
that	O
of	O
Vataja	O
et	O
al	O
.	O
was	O
that	O
our	O
study	O
included	O
patients	O
without	O
white	B-DS
matter	I-DS
lesions	I-DS
(	O
WMLs	O
)	O
and	O
cerebral	B-DS
atrophy	I-DS
.	O

WMLs	O
were	O
described	O
radiologically	O
as	O
LKA	O
in	O
periventricular	O
white	O
matter	O
,	O
and	O
subcortical	O
,	O
deep	O
,	O
watershed	O
areas	O
.	O

Executive	B-DS
dysfunction	I-DS
has	O
been	O
found	O
to	O
associate	O
with	O
the	O
degree	O
of	O
WMLs	O
assessed	O
by	O
MRI	O
,	O
DTI	O
or	O
MR	O
spectroscopy	O
[	O
6	O
],[	O
23	O
]–[	O
26	O
].	O

Cerebral	B-DS
atrophy	I-DS
was	O
also	O
related	O
to	O
executive	B-DS
dysfunction	I-DS
[	O
26	O
],[	O
27	O
].	O

In	O
this	O
study	O
,	O
executive	O
change	O
might	O
be	O
observed	O
more	O
easily	O
owing	O
to	O
posterior	O
corona	O
radiata	O
while	O
effects	O
of	O
WMLs	O
and	O
cerebral	B-DS
atrophy	I-DS
were	O
removed	O
.	O

In	O
addition	O
,	O
executive	O
function	O
assessment	O
was	O
different	O
in	O
the	O
two	O
studies	O
.	O

Digit	O
span	O
backwards	O
and	O
Digit	O
symbol	O
tests	O
were	O
applied	O
in	O
this	O
study	O
.	O

The	O
former	O
reflects	O
working	O
memory	O
performance	O
;	O
the	O
latter	O
requires	O
multiple	O
cognitive	O
abilities	O
including	O
attention	O
,	O
psychomotor	O
speed	O
,	O
complex	O
scanning	O
,	O
visual	O
tracking	O
,	O
and	O
immediate	O
memory	O
[	O
15	O
],[	O
28	O
],[	O
29	O
].	O

The	O
scores	O
of	O
Digit	O
span	O
backwards	O
and	O
Digit	O
symbol	O
tests	O
were	O
decreased	O
significantly	O
,	O
which	O
means	O
above	O
-	O
mentioned	O
components	O
of	O
executive	B-DS
dysfunction	I-DS
exist	O
in	O
the	O
patients	O
with	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
.	O

Besides	O
,	O
increased	O
Trail	O
making	O
B	O
-	O
A	O
and	O
decreased	O
Verbal	O
fluency	O
assessment	O
scores	O
were	O
found	O
,	O
which	O
implies	O
dysfunction	O
of	O
cognitive	O
set	O
shifting	O
,	O
mental	O
flexibility	O
and	O
strategies	O
for	O
word	O
retrieval	O
in	O
these	O
patients	O
.	O

Conclusion	O

Executive	O
dysfunction	B-DS
was	O
observed	O
in	O
the	O
patients	O
with	O
left	O
posterior	B-DS
corona	I-DS
radiata	I-DS
infarction	I-DS
.	O

The	O
axonal	O
loss	O
in	O
the	O
left	O
frontal	O
white	O
matter	O
after	O
stroke	B-DS
was	O
detected	O
by	O
DTI	O
.	O

The	O
abnormalities	O
of	O
MD	O
and	O
FA	O
in	O
the	O
region	O
may	O
be	O
correlated	O
with	O
executive	O
function	O
changes	O
in	O
the	O
patients	O
.	O

Abbreviations	O

ACA	O
:	O
anterior	O
cerebral	O
artery	O

CT	O
:	O
computed	O
tomography	O

DIA	O
:	O
luminal	O
diameter	O

DTI	O
:	O
diffusion	O
tensor	O
imaging	O

EDV	O
:	O
end	O
diastolic	O
velocity	O

EPI	O
:	O
echo	O
planar	O
imaging	O

FA	O
:	O
fractional	O
anisotropy	O

ICA	O
:	O
iInternal	O
carotid	O
artery	O

ILA	B-GP
:	O
ischemic	B-DS
leukoaraiosis	I-DS

IMT	O
:	O
Intima	O
-	O
media	O
thickness	O

LSD	O
:	O
Least	O
Significant	O
Difference	O

MCA	O
:	O
middle	O
cerebral	O
artery	O

MD	O
:	O
mean	O
diffusivity	O

MFV	O
:	O
Mean	O
flow	O
velocity	O
values	O

MMSE	O
:	O
Mini	O
-	O
Mental	O
State	O
Examination	O

MRI	O
:	O
magnetic	O
resonance	O
imaging	O

PCA	O
:	O
posterior	O
cerebral	O
artery	O

PSV	O
:	O
peak	O
systolic	O
velocity	O

TCD	O
:	O
Transcranial	O
Duplex	O
Scanning	O

T1	O
-	O
FLAIR	O
:	O
T1	O
-	O
weighted	O
fluid	O
attenuatedion	O
inversion	O
recovery	O

WMLs	O
:	O
white	O
matter	O
lesions	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O

CL	O
designed	O
the	O
study	O
,	O
collected	O
the	O
data	O
and	O
wrote	O
the	O
manuscript	O
,	O
CD	O
carried	O
out	O
image	O
post	O
-	O
processing	O
,	O
GL	O
conducted	O
the	O
MR	O
images	O
analysis	O
,	O
LC	O
and	O
JZ	O
assisted	O
with	O
the	O
data	O
collection	O
,	O
JL	O
assisted	O
with	O
the	O
statistical	O
analysis	O
,	O
ZO	O
assisted	O
with	O
the	O
data	O
collection	O
,	O
YZ	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
AX	O
interpreted	O
the	O
results	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Psychometric	O
properties	O
of	O
the	O
Dresden	O
Body	O
Image	O
Questionnaire	O
:	O
A	O
multiple	O
-	O
group	O
confirmatory	O
factor	O
analysis	O
across	O
sex	O
and	O
age	O
in	O
a	O
Dutch	O
non	O
-	O
clinical	O
sample	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O

Background	O

Body	O
image	O
has	O
implications	O
for	O
psychosocial	O
functioning	O
and	O
quality	O
of	O
life	O
and	O
its	O
disturbance	O
is	O
reported	O
in	O
a	O
broad	O
range	O
of	O
psychiatric	B-DS
disorders	I-DS
.	O

In	O
view	O
of	O
the	O
lack	O
of	O
instruments	O
in	O
Dutch	O
measuring	O
body	O
image	O
as	O
a	O
broad	O
concept	O
,	O
we	O
set	O
out	O
to	O
make	O
an	O
instrument	O
available	O
that	O
reflects	O
the	O
multidimensional	O
character	O
of	O
this	O
construct	O
by	O
including	O
more	O
dimensions	O
than	O
physical	O
appearance	O
.	O

The	O
Dresden	O
Körperbildfragebogen	O
(	O
DBIQ	O
,	O
Dresden	O
Body	O
Image	O
Questionnaire	O
)	O
particularly	O
served	O
this	O
purpose	O
.	O

The	O
DBIQ	O
consists	O
of	O
35	O
items	O
and	O
five	O
subscales	O
:	O
body	O
acceptance	O
,	O
sexual	O
fulfillment	O
,	O
physical	O
contact	O
,	O
vitality	O
,	O
and	O
self	O
-	O
aggrandizement	O
.	O

The	O
main	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
the	O
Dutch	O
translation	O
of	O
the	O
Dresden	O
Body	O
Image	O
Questionnaire	O
(	O
DBIQ	O
-	O
NL	O
)	O
in	O
a	O
non	O
-	O
clinical	O
sample	O
.	O

Methods	O

The	O
psychometric	O
properties	O
of	O
the	O
DBIQ	O
-	O
NL	O
were	O
examined	O
in	O
a	O
non	O
-	O
clinical	O
sample	O
of	O
988	O
respondents	O
aged	O
between	O
18	O
and	O
65	O
.	O

We	O
investigated	O
the	O
subscales	O
'	O
internal	O
consistency	O
and	O
test	O
-	O
retest	O
reliability	O
.	O

In	O
order	O
to	O
establish	O
construct	O
validity	O
we	O
evaluated	O
the	O
association	O
with	O
a	O
related	O
construct	O
,	O
body	O
cathexis	O
,	O
and	O
with	O
indices	O
of	O
self	O
-	O
esteem	O
and	O
psychological	O
wellbeing	O
.	O

The	O
factor	O
structure	O
of	O
the	O
DBIQ	O
-	O
NL	O
was	O
examined	O
via	O
confirmatory	O
factor	O
analysis	O
(	O
CFA	O
).	O

The	O
equivalence	O
of	O
the	O
measurement	O
model	O
across	O
sex	O
and	O
age	O
was	O
evaluated	O
by	O
multiplegroup	O
confirmatory	O
factor	O
analyses	O
.	O

Results	O

Confirmatory	O
factor	O
analyses	O
showed	O
a	O
structure	O
in	O
accordance	O
with	O
the	O
original	O
scale	O
,	O
where	O
model	O
fit	O
was	O
improved	O
significantly	O
by	O
moving	O
one	O
item	O
to	O
another	O
subscale	O
.	O

Multiple	O
group	O
confirmatory	O
factor	O
analysis	O
across	O
sex	O
and	O
age	O
demonstrated	O
partial	O
strong	O
invariance	O
.	O

Internal	O
consistency	O
was	O
good	O
with	O
little	O
overlap	O
between	O
the	O
subscales	O
.	O

Temporal	O
reliability	O
and	O
construct	O
validity	O
were	O
satisfactory	O
.	O

Conclusion	O

Results	O
indicate	O
that	O
the	O
DBIQ	O
-	O
NL	O
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
for	O
non	O
-	O
clinical	O
subjects	O
.	O

This	O
provides	O
a	O
sound	O
basis	O
for	O
further	O
investigation	O
of	O
the	O
DBIQ	O
-	O
NL	O
in	O
a	O
clinical	O
sample	O
.	O

Introduction	O

The	O
term	O
‘	O
body	O
image	O
’	O
has	O
been	O
used	O
to	O
describe	O
a	O
variety	O
of	O
body	O
-	O
related	O
phenomena	O
,	O
including	O
perceptions	O
,	O
cognitions	O
,	O
affects	O
,	O
and	O
awareness	O
with	O
regard	O
to	O
the	O
body	O
[	O
1	O
,	O
2	O
].	O

Unlike	O
the	O
term	O
seems	O
to	O
suggest	O
,	O
not	O
only	O
the	O
way	O
we	O
evaluate	O
our	O
appearance	O
is	O
part	O
of	O
our	O
body	O
image	O
,	O
but	O
also	O
our	O
attitude	O
towards	O
bodily	O
experiences	O
in	O
interaction	O
with	O
others	O
,	O
sense	O
of	O
body	O
ownership	O
[	O
3	O
]	O
and	O
our	O
evaluation	O
of	O
our	O
body	O
in	O
terms	O
of	O
functionality	O
and	O
vitality	O
[	O
4	O
].	O

Aspects	O
of	O
body	O
image	O
have	O
impact	O
on	O
psychosocial	O
functioning	O
[	O
5	O
,	O
6	O
]	O
and	O
its	O
disturbances	O
are	O
associated	O
with	O
poorer	O
psychological	O
adjustment	O
in	O
non	O
-	O
clinical	O
samples	O
[	O
7	O
–	O
10	O
].	O

Negative	O
or	O
disturbed	O
body	O
image	O
has	O
also	O
been	O
reported	O
in	O
a	O
broad	O
range	O
of	O
psychiatric	B-DS
disorders	I-DS
[	O
11	O
,	O
12	O
].	O

Disturbed	O
body	O
image	O
in	O
eating	B-DS
disordered	I-DS
female	O
patients	O
has	O
been	O
extensively	O
researched	O
and	O
documented	O
[	O
13	O
–	O
15	O
].	O

There	O
is	O
emerging	O
evidence	O
that	O
mood	B-DS
disorders	I-DS
[	O
16	O
],	O
anxiety	B-DS
disorders	I-DS
[	O
17	O
],	O
trauma	B-DS
-	I-DS
related	I-DS
disorders	I-DS
[	O
18	O
–	O
20	O
],	O
sexual	B-DS
disorders	I-DS
[	O
21	O
,	O
22	O
]	O
and	O
schizophrenia	B-DS
[	O
23	O
]	O
are	O
also	O
associated	O
with	O
negative	O
or	O
disturbed	O
body	O
image	O
.	O

The	O
overall	O
impression	O
is	O
that	O
body	O
image	O
is	O
affected	O
in	O
a	O
diverse	O
range	O
of	O
mental	O
health	O
problems	O
.	O

However	O
,	O
despite	O
the	O
increasing	O
awareness	O
and	O
recognition	O
in	O
clinical	O
practice	O
of	O
body	O
image	O
problems	O
in	O
other	O
than	O
appearance	O
-	O
related	O
psychopathologies	B-DS
,	O
sound	O
measurement	O
of	O
body	O
image	O
providing	O
evidence	O
of	O
this	O
phenomenon	O
is	O
still	O
scarce	O
in	O
most	O
psychiatric	B-DS
disorders	I-DS
.	O

To	O
date	O
,	O
the	O
Body	O
Attitude	O
Test	O
is	O
the	O
sole	O
well	O
-	O
researched	O
self	O
-	O
report	O
instrument	O
measuring	O
body	O
image	O
available	O
in	O
Dutch	O
[	O
24	O
,	O
25	O
].	O

However	O
,	O
this	O
instrument	O
is	O
specifically	O
developed	O
for	O
measuring	O
body	O
attitude	O
in	O
anorexic	O
women	B-OG
.	O

In	O
view	O
of	O
the	O
lack	O
of	O
multi	O
-	O
purpose	O
instruments	O
in	O
Dutch	O
,	O
we	O
set	O
out	O
to	O
make	O
an	O
instrument	O
available	O
that	O
reflects	O
the	O
multidimensional	O
character	O
of	O
this	O
construct	O
by	O
including	O
more	O
dimensions	O
than	O
physical	O
appearance	O
.	O

As	O
our	O
aim	O
was	O
to	O
gain	O
insight	O
in	O
the	O
way	O
psychopathology	O
and	O
body	O
image	O
are	O
associated	O
,	O
this	O
instrument	O
needed	O
to	O
be	O
suitable	O
for	O
both	O
a	O
broad	O
-	O
ranged	O
clinical	O
population	O
as	O
well	O
as	O
for	O
a	O
non	O
-	O
clinical	O
population	O
so	O
as	O
to	O
facilitate	O
comparisons	O
.	O

The	O
Dresdner	O
Körperbildfragebogen	O
(	O
DBIQ	O
,	O
Dresden	O
Body	O
Image	O
Questionnaire	O
)	O
[	O
26	O
,	O
27	O
]	O
particularly	O
serves	O
this	O
purpose	O
.	O

The	O
DBIQ	O
,	O
consisting	O
of	O
35	O
items	O
,	O
does	O
not	O
cover	O
all	O
aspects	O
that	O
form	O
part	O
of	O
the	O
umbrella	O
term	O
body	O
image	O
,	O
but	O
focuses	O
on	O
thoughts	O
,	O
beliefs	O
,	O
and	O
conceptual	O
aspects	O
of	O
patient	O
’	O
s	O
body	O
experiences	O
in	O
five	O
different	O
domains	O
:	O
body	O
acceptance	O
,	O
sexual	O
fulfillment	O
,	O
the	O
evaluation	O
of	O
physical	O
contact	O
,	O
experienced	O
vitality	O
,	O
and	O
self	O
-	O
aggrandizement	O
,	O
a	O
measure	O
of	O
how	O
the	O
body	O
is	O
actively	O
used	O
in	O
social	O
interactions	O
to	O
enhance	O
self	O
-	O
esteem	O
.	O

The	O
importance	O
of	O
the	O
dimensions	O
physical	O
contact	O
and	O
sexuality	O
is	O
largely	O
unknown	O
,	O
although	O
they	O
are	O
often	O
mentioned	O
by	O
patients	O
as	O
problematic	O
[	O
28	O
,	O
29	O
].	O

Furthermore	O
,	O
in	O
a	O
factor	O
analytic	O
evaluation	O
of	O
a	O
preliminary	O
version	O
of	O
the	O
DBIQ	O
,	O
body	O
contact	O
as	O
well	O
as	O
sexuality	O
emerged	O
as	O
separate	O
factors	O
[	O
26	O
].	O

Clinical	O
relevance	O
together	O
with	O
the	O
psychometric	O
indication	O
of	O
the	O
importance	O
of	O
these	O
aspects	O
,	O
make	O
its	O
inclusion	O
worthwhile	O
.	O

The	O
first	O
evaluation	O
of	O
the	O
psychometric	O
qualities	O
of	O
the	O
original	O
DBIQ	O
in	O
a	O
clinical	O
sample	O
was	O
promising	O
[	O
26	O
].	O

The	O
main	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
the	O
Dutch	O
translation	O
of	O
the	O
DBIQ	O
(	O
DBIQ	O
-	O
NL	O
)	O
in	O
a	O
non	O
-	O
clinical	O
sample	O
.	O

First	O
,	O
we	O
investigated	O
the	O
subscales	O
’	O
internal	O
consistency	O
and	O
test	O
-	O
retest	O
reliability	O
.	O

In	O
order	O
to	O
establish	O
construct	O
validity	O
of	O
the	O
DBIQ	O
-	O
NL	O
we	O
evaluated	O
the	O
association	O
with	O
specific	O
related	O
constructs	O
,	O
namely	O
body	O
satisfaction	O
,	O
comfort	O
with	O
touch	O
and	O
fatigue	O
,	O
expecting	O
high	O
correlations	O
for	O
the	O
DBIQ	O
-	O
NL	O
with	O
these	O
measures	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
associations	O
with	O
general	O
indices	O
of	O
psychosocial	O
wellbeing	O
and	O
self	O
-	O
esteem	O
,	O
expecting	O
moderate	O
to	O
high	O
correlations	O
with	O
these	O
measures	O
.	O

The	O
factor	O
structure	O
of	O
the	O
DBIQ	O
-	O
NL	O
was	O
examined	O
via	O
confirmatory	O
factor	O
analysis	O
(	O
CFA	O
).	O
Exploration	O
of	O
differences	O
regarding	O
gender	O
and	O
age	O
formed	O
the	O
second	O
objective	O
of	O
our	O
study	O
,	O
since	O
both	O
factors	O
are	O
known	O
to	O
affect	O
body	O
image	O
.	O

Gender	O
differences	O
in	O
body	O
image	O
have	O
received	O
considerable	O
attention	O
[	O
30	O
–	O
32	O
].	O

Research	O
shows	O
that	O
women	B-OG
are	O
generally	O
more	O
preoccupied	O
and	O
dissatisfied	O
with	O
their	O
bodies	O
than	O
men	B-OG
[	O
33	O
].	O

Gender	O
differences	O
with	O
respect	O
to	O
specific	O
issues	O
such	O
as	O
physical	O
contact	O
and	O
sexual	O
fulfillment	O
,	O
represented	O
by	O
separate	O
subscales	O
in	O
the	O
DBIQ	O
,	O
also	O
were	O
deemed	O
worth	O
investigating	O
.	O

Based	O
on	O
results	O
from	O
a	O
Flemish	O
version	O
of	O
the	O
DBIQ	O
in	O
a	O
students	O
’	O
sample	O
[	O
34	O
],	O
it	O
might	O
be	O
hypothesized	O
that	O
no	O
gender	O
differences	O
exist	O
with	O
regard	O
to	O
physical	O
contact	O
.	O

With	O
regard	O
to	O
gender	O
differences	O
in	O
reported	O
sexual	O
fulfillment	O
it	O
might	O
be	O
hypothesized	O
,	O
based	O
on	O
results	O
from	O
Dutch	O
population	O
surveys	O
[	O
35	O
],	O
that	O
sexual	O
fulfillment	O
is	O
higher	O
in	O
men	O
than	O
in	O
women	O
.	O

Contrary	O
to	O
gender	O
differences	O
,	O
age	O
effects	O
on	O
body	O
image	O
are	O
still	O
poorly	O
researched	O
[	O
31	O
,	O
36	O
].	O

Since	O
younger	O
aged	O
samples	O
are	O
overrepresented	O
in	O
body	O
image	O
research	O
,	O
comparisons	O
of	O
different	O
age	O
groups	O
are	O
scarce	O
.	O

Krauss	O
et	O
al	O
.	O
[	O
37	O
]	O
have	O
noted	O
a	O
clear	O
need	O
for	O
research	O
on	O
body	O
image	O
in	O
middle	O
-	O
aged	O
and	O
older	O
adults	O
.	O

The	O
non	O
-	O
clinical	O
sample	O
enables	O
further	O
investigation	O
of	O
specific	O
aspects	O
of	O
body	O
image	O
in	O
middle	O
-	O
aged	O
adults	O
and	O
comparison	O
with	O
a	O
younger	O
group	O
.	O

Group	O
comparisons	O
of	O
scale	O
scores	O
are	O
only	O
meaningful	O
in	O
case	O
of	O
measurement	O
invariance	O
across	O
groups	O
.	O

Therefore	O
,	O
the	O
equivalence	O
of	O
the	O
measurement	O
model	O
across	O
sex	O
and	O
age	O
using	O
Multiple	O
-	O
Group	O
Confirmatory	O
Factor	O
Analyses	O
(	O
MG	O
-	O
CFA	O
)	O
was	O
evaluated	O
in	O
this	O
study	O
as	O
well	O
,	O
extending	O
the	O
work	O
by	O
Pöhlmann	O
et	O
al	O
.	O
[	O
26	O
,	O
27	O
].	O

Method	O

Participants	O

Data	O
were	O
obtained	O
from	O
two	O
samples	O
with	O
a	O
total	O
of	O
988	O
(	O
sample	O
1	O
,	O
n	O
=	O
761	O
;	O
sample	O
2	O
,	O
n	O
=	O
227	O
)	O
respondents	O
between	O
18	O
and	O
65	O
years	O
old	O
,	O
consisting	O
of	O
583	O
(	O
433	O
;	O
150	O
)	O
women	O
and	O
403	O
(	O
326	O
;	O
77	O
)	O
men	O
(	O
sex	O
was	O
unknown	O
for	O
two	O
respondents	O
).	O

In	O
both	O
samples	O
age	O
showed	O
a	O
bimodal	O
distribution	O
and	O
was	O
therefore	O
divided	O
in	O
two	O
categories	O
,	O
younger	O
than	O
38	O
years	O
,	O
and	O
38	O
years	O
and	O
older	O
,	O
based	O
on	O
visual	O
inspection	O
(	O
sample	O
1	O
:	O
<	O
38	O
,	O
n	O
=	O
540	O
;	O
≥	O
38	O
:	O
n	O
=	O
221	O
;	O
sample	O
2	O
:	O
<	O
38	O
,	O
n	O
=	O
151	O
;	O
≥	O
38	O
:	O
n	O
=	O
76	O
;	O
see	O
S1	O
Fig	O
.	O
for	O
more	O
information	O
on	O
distribution	O
of	O
age	O
in	O
the	O
two	O
samples	O
).	O

Women	B-OG
and	O
men	B-OG
were	O
equally	O
distributed	O
across	O
the	O
two	O
categories	O
.	O
Mage	O
of	O
sample	O
1	O
was	O
30	O
.	O
90	O
(	O
SDage	O
=	O
13	O
.	O
62	O
),	O
of	O
sample	O
2	O
33	O
.	O
28	O
(	O
SDage	O
=	O
13	O
.	O
22	O
).	O

The	O
distinction	O
between	O
the	O
two	O
samples	O
was	O
made	O
based	O
on	O
the	O
moment	O
of	O
recruitment	O
(	O
see	O
procedure	O
).	O

Sample	O
2	O
was	O
offered	O
a	O
partly	O
different	O
set	O
of	O
extra	O
instruments	O
compared	O
to	O
sample	O
1	O
.	O

Measures	O

Dresden	O
Body	O
Image	O
Questionnaire	O

The	O
Dresden	O
Body	O
Image	O
Questionnaire	O
(	O
DBIQ	O
)	O
[	O
26	O
,	O
27	O
]	O
is	O
a	O
35	O
-	O
item	O
scale	O
(	O
see	O
Table	O
1	O
)	O
with	O
positively	O
and	O
negatively	O
worded	O
items	O
(	O
reversely	O
coded	O
)	O
that	O
consists	O
of	O
five	O
subscales	O
:	O
body	O
acceptance	O
(	O
e	O
.	O
g	O
.,	O
“	O
I	O
wish	O
I	O
had	O
a	O
different	O
body	O
”),	O
vitality	O
(	O
e	O
.	O
g	O
.,	O
“	O
I	O
am	O
physically	O
fit	O
”),	O
physical	O
contact	O
(	O
e	O
.	O
g	O
.,	O
“	O
I	O
do	O
not	O
like	O
people	O
touching	O
me	O
”),	O
sexual	O
fulfillment	O
(	O
e	O
.	O
g	O
.,	O
“	O
I	O
am	O
very	O
satisfied	O
with	O
my	O
sexual	O
experiences	O
“),	O
and	O
self	O
-	O
aggrandizement	O
(	O
e	O
.	O
g	O
.,	O
“	O
I	O
use	O
my	O
body	O
to	O
attract	O
attention	O
”).	O

Level	O
of	O
agreement	O
is	O
scored	O
on	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
ranging	O
from	O
1	O
=	O
not	O
at	O
all	O
to	O
5	O
=	O
fully	O
.	O

Higher	O
scores	O
indicate	O
a	O
more	O
positive	O
body	O
image	O
.	O

Dresden	O
Body	O
Image	O
Questionnaire	O
(	O
DBIQ	O
),	O
English	O
versiona	O
.	O

1	O
.	O
a	O

I	O
move	O
gracefully	O
.	O

2	O
.	O
v	O

I	O
often	O
feel	O
physically	O
run	O
down	O
.	O

(	O
R	O
)	O

3	O
.	O
v	O

I	O
lack	O
energy	O
and	O
motivation	O
.	O

(	O
R	O
)	O

4	O
.	O
s	O

I	O
experience	O
intense	O
and	O
pleasurable	O
feelings	O
during	O
sex	O
.	O

5	O
.	O
p	O

Physical	O
contact	O
is	O
important	O
for	O
me	O
to	O
express	O
closeness	O
.	O

6	O
.	O
v	O

I	O
often	O
feel	O
physically	O
exhausted	O
.	O

(	O
R	O
)	O

7	O
.	O
a	O

There	O
are	O
lots	O
of	O
situations	O
in	O
which	O
I	O
feel	O
happy	O
about	O
my	O
body	O
.	O

8	O
.	O
v	O

I	O
am	O
physically	O
fit	O
.	O

9	O
.	O
s	O

I	O
am	O
very	O
satisfied	O
with	O
my	O
sexual	O
experiences	O
.	O

10	O
.	O
a	O

Other	O
people	O
find	O
me	O
attractive	O
.	O

11	O
.	O
p	O

I	O
look	O
for	O
physical	O
intimacy	O
and	O
affection	O

12	O
.	O
a	O

I	O
like	O
my	O
body	O
.	O

13	O
.	O
a	O

I	O
find	O
it	O
pleasant	O
and	O
exhilarating	O
when	O
someone	O
looks	O
at	O
me	O
attentively	O
.	O

14	O
.	O
v	O

I	O
have	O
lots	O
of	O
energy	O
.	O

15	O
.	O
a	O

I	O
choose	O
clothing	O
that	O
hides	O
the	O
shape	O
of	O
my	O
body	O
.	O

(	O
R	O
)	O

16	O
.	O
s	O

I	O
think	O
sex	O
is	O
an	O
important	O
part	O
of	O
life	O
.	O

17	O
.	O
v	O

I	O
am	O
in	O
good	O
physical	O
condition	O
.	O

18	O
.	O
a	O

I	O
often	O
feel	O
uncomfortable	O
about	O
my	O
body	O
.	O

(	O
R	O
)	O

19	O
.	O
p	O

I	O
do	O
not	O
like	O
people	O
touching	O
me	O
.	O

(	O
R	O
)	O

20	O
.	O
a	O

I	O
feel	O
more	O
valued	O
when	O
someone	O
pays	O
attention	O
to	O
my	O
body	O
.	O

21	O
.	O
s	O

I	O
am	O
able	O
to	O
lay	O
aside	O
my	O
inhibitions	O
in	O
sexual	O
situations	O
.	O

22	O
.	O
p	O

I	O
like	O
it	O
when	O
people	O
put	O
their	O
arms	O
around	O
me	O
.	O

23	O
.	O
a	O

I	O
wish	O
I	O
had	O
a	O
different	O
body	O
.	O

(	O
R	O
)	O

24	O
.	O
p	O

I	O
consciously	O
avoid	O
touching	O
other	O
people	O
.	O

(	O
R	O
)	O

25	O
.	O
a	O

I	O
am	O
satisfied	O
with	O
my	O
appearance	O
.	O

26	O
.	O
v	O

I	O
quickly	O
reach	O
my	O
physical	O
limits	O
.	O

(	O
R	O
)	O

27	O
.	O
s	O

I	O
am	O
able	O
to	O
enjoy	O
my	O
sexuality	O
.	O

28	O
.	O
a	O

If	O
I	O
could	O
change	O
something	O
about	O
my	O
body	O
,	O
I	O
would	O
do	O
it	O
.	O

(	O
R	O
)	O

29	O
.	O
a	O

My	O
body	O
is	O
expressive	O
.	O

30	O
.	O
p	O

I	O
only	O
allow	O
a	O
few	O
people	O
to	O
touch	O
me	O
.	O

(	O
R	O
)	O

31	O
.	O
a	O

I	O
use	O
my	O
body	O
to	O
attract	O
attention	O
.	O

32	O
.	O
v	O

I	O
am	O
physically	O
strong	O
and	O
resilient	O
.	O

33	O
.	O
a	O

I	O
like	O
showing	O
my	O
body	O
.	O

34	O
.	O
a	O

I	O
like	O
to	O
be	O
the	O
centre	O
of	O
attention	O
.	O

35	O
.	O
s	O

My	O
sexual	O
experiences	O
are	O
satisfying	O
.	O

Note	O
:	O
R	O
=	O
scored	O
in	O
the	O
reversed	O
direction	O
.	O
a	O
=	O
subscale	O
self	O
-	O
aggrandizement	O
;	O
b	O
=	O
subscale	O
body	O
acceptance	O
;	O
p	O
=	O
subscale	O
physical	O
contact	O
;	O
s	O
=	O
subscale	O
sexual	O
fulfillment	O
;	O
v	O
=	O
subscale	O
vitality	O
.	O

a	O
.	O

Dresdner	O
Körperbildfragebogen	O
(	O
DKB	O
-	O
35	O
),	O
original	O
version	O
in	O
German	O
;	O
for	O
Dutch	O
version	O
,	O
see	O
S1	O
Table	O
.	O

The	O
development	O
of	O
the	O
DBIQ	O
was	O
based	O
on	O
factor	O
analytic	O
evaluation	O
of	O
three	O
German	O
questionnaires	O
measuring	O
body	O
image	O
[	O
38	O
],	O
namely	O
the	O
“	O
Fragebogen	O
zum	O
Körperbild	O
”	O
(	O
FKB	O
-	O
20	O
)	O
[	O
39	O
],	O
the	O
“	O
Fragebogen	O
zur	O
Bewertung	O
des	O
eigenen	O
Körpers	O
”	O
(	O
FBeK	O
)	O
[	O
40	O
,	O
41	O
]	O
and	O
the	O
“	O
Frankfurter	O
Körper	O
Konzept	O
Skalen	O
”	O
(	O
FKKS	O
)	O
[	O
42	O
].	O

In	O
a	O
German	O
non	O
-	O
clinical	O
sample	O
[	O
27	O
]	O
(	O
n	O
=	O
418	O
),	O
Cronbach	O
’	O
s	O
α	O
for	O
the	O
subscales	O
were	O
:	O
body	O
acceptance	O
.	O
93	O
,	O
vitality	O
.	O
94	O
,	O
physical	O
contact	O
.	O
83	O
,	O
sexual	O
fulfillment	O
.	O
91	O
,	O
and	O
self	O
-	O
aggrandizement	O
.	O
81	O
.	O

Correlations	O
between	O
the	O
subscales	O
varied	O
between	O
r	O
=	O
.	O
37	O
(	O
sexual	O
fulfillment	O
and	O
self	O
-	O
aggrandizement	O
)	O
and	O
r	O
=	O
.	O
65	O
(	O
body	O
acceptance	O
and	O
vitality	O
),	O
indicating	O
the	O
overlap	O
between	O
the	O
subscales	O
to	O
be	O
small	O
to	O
medium	O
.	O

A	O
confirmatory	O
factor	O
analysis	O
was	O
conducted	O
[	O
26	O
]	O
in	O
a	O
sample	O
of	O
560	O
German	O
patients	O
with	O
psychosomatic	B-DS
disorders	I-DS
(	O
CFI	O
=	O
.	O
90	O
;	O
RMSEA	O
=	O
.	O
06	O
,	O
other	O
fit	O
indices	O
not	O
available	O
).	O

A	O
study	O
on	O
505	O
students	O
(	O
M	O
=	O
21	O
.	O
64	O
,	O
SD	O
=	O
2	O
.	O
14	O
)	O
using	O
a	O
Flemish	O
Dutch	O
translation	O
[	O
34	O
],	O
somewhat	O
different	O
from	O
the	O
translation	O
presently	O
used	O
,	O
reported	O
Cronbach	O
’	O
s	O
α	O
for	O
the	O
subscales	O
between	O
.	O
77	O
and	O
.	O
90	O
.	O

Correlations	O
between	O
the	O
subscales	O
varied	O
between	O
r	O
=	O
.	O
13	O
and	O
r	O
=	O
.	O
59	O
.	O

In	O
the	O
present	O
Dutch	O
sample	O
Cronbach	O
’	O
s	O
α	O
for	O
the	O
subscales	O
varied	O
from	O
α	O
=	O
.	O
83	O
for	O
self	O
-	O
aggrandizement	O
to	O
α	O
=	O
.	O
92	O
for	O
sexual	O
fulfillment	O
.	O

Correlations	O
between	O
the	O
subscales	O
varied	O
between	O
r	O
=	O
.	O
31	O
(	O
vitality	O
and	O
physical	O
contact	O
)	O
to	O
r	O
=	O
.	O
65	O
(	O
physical	O
contact	O
and	O
sexual	O
fulfillment	O
).	O

The	O
Dutch	O
translation	O
of	O
the	O
DBIQ	O
(	O
DBIQ	O
-	O
NL	O
,	O
see	O
S1	O
Table	O
)	O
was	O
performed	O
by	O
using	O
the	O
parallel	O
blind	O
technique	O
[	O
43	O
].	O

First	O
,	O
three	O
bilingual	O
translators	O
separately	O
performed	O
a	O
translation	O
.	O

The	O
translations	O
were	O
then	O
compared	O
and	O
differences	O
were	O
discussed	O
until	O
agreement	O
was	O
reached	O
.	O

Body	O
Cathexis	O
Scale	O

The	O
Body	O
Cathexis	O
Scale	O
(	O
BCS	O
),	O
here	O
used	O
to	O
establish	O
the	O
association	O
between	O
the	O
total	O
score	O
of	O
the	O
DBIQ	O
with	O
body	O
satisfaction	O
,	O
was	O
originally	O
developed	O
by	O
Secord	O
and	O
Jourard	O
[	O
44	O
]	O
to	O
assess	O
the	O
degree	O
of	O
satisfaction	O
with	O
parts	O
and	O
processes	O
of	O
the	O
body	O
.	O

The	O
original	O
scale	O
has	O
46	O
items	O
,	O
but	O
most	O
recent	O
studies	O
utilize	O
a	O
40	O
-	O
item	O
version	O
[	O
45	O
].	O

Subjects	O
evaluate	O
body	O
characteristics	O
according	O
to	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
,	O
ranging	O
from	O
strongly	O
negative	O
to	O
strongly	O
positive	O
,	O
with	O
higher	O
scores	O
reflecting	O
greater	O
body	O
satisfaction	O
.	O

Although	O
some	O
authors	O
[	O
46	O
]	O
objected	O
to	O
the	O
use	O
of	O
anatomical	O
as	O
well	O
as	O
physiological	O
aspects	O
in	O
the	O
BCS	O
,	O
we	O
follow	O
Orlandi	O
et	O
al	O
.	O
[	O
47	O
],	O
who	O
state	O
that	O
the	O
BCS	O
is	O
a	O
useful	O
instrument	O
to	O
address	O
satisfaction	O
with	O
the	O
body	O
and	O
judge	O
the	O
emphasis	O
on	O
bodily	O
functions	O
next	O
to	O
body	O
parts	O
to	O
be	O
an	O
advantage	O
.	O

This	O
is	O
in	O
line	O
with	O
recent	O
studies	O
[	O
48	O
,	O
49	O
]	O
stressing	O
the	O
importance	O
of	O
describing	O
the	O
body	O
in	O
functional	O
terms	O
.	O

The	O
validity	O
and	O
reliability	O
of	O
the	O
Dutch	O
version	O
[	O
50	O
]	O
are	O
satisfactory	O
.	O

Cronbach	O
’	O
s	O
α	O
for	O
the	O
present	O
sample	O
was	O
.	O
95	O
.	O

Comfort	O
in	O
touch	O
(	O
subscale	O
of	O
the	O
Body	O
Investment	O
Scale	O
)	O

Since	O
no	O
reference	O
is	O
made	O
in	O
the	O
BCS	O
to	O
physical	O
contact	O
,	O
a	O
subscale	O
of	O
the	O
Body	O
Investment	O
Scale	O
(	O
BIS	O
)	O
[	O
51	O
]	O
was	O
used	O
to	O
establish	O
the	O
association	O
with	O
the	O
subscale	O
‘	O
physical	O
contact	O
’	O
of	O
the	O
DBIQ	O
.	O

The	O
BIS	O
was	O
developed	O
to	O
assess	O
emotional	O
investment	O
in	O
the	O
body	O
and	O
consists	O
of	O
24	O
items	O
scored	O
on	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
ranging	O
from	O
strongly	O
disagree	O
to	O
strongly	O
agree	O
with	O
higher	O
scores	O
for	O
more	O
emotional	O
investment	O
.	O

The	O
subscale	O
physical	O
contact	O
of	O
the	O
BIS	O
comprises	O
of	O
six	O
items	O
with	O
statements	O
like	O
“	O
I	O
enjoy	O
physical	O
contact	O
with	O
other	O
people	O
”.	O

The	O
BIS	O
has	O
adequate	O
psychometric	O
characteristics	O
[	O
51	O
,	O
52	O
].	O

In	O
the	O
present	O
study	O
a	O
Cronbach	O
’	O
s	O
α	O
of	O
.	O
78	O
was	O
found	O
for	O
the	O
subscale	O
‘	O
comfort	O
in	O
touch	O
’.	O

Checklist	O
Individual	O
Strength	O

As	O
the	O
BCS	O
does	O
not	O
include	O
items	O
on	O
vitality	O
the	O
Checklist	O
Individual	O
Strength	O
(	O
CIS	O
)	O
[	O
53	O
]	O
was	O
used	O
to	O
establish	O
the	O
construct	O
validity	O
of	O
this	O
subscale	O
of	O
the	O
DBIQ	O
.	O

The	O
CIS	O
is	O
an	O
originally	O
Dutch	O
language	O
20	O
-	O
item	O
self	O
-	O
report	O
questionnaire	O
capturing	O
fatigue	O
in	O
four	O
dimensions	O
:	O
subjective	O
experience	O
of	O
fatigue	O
(“	O
I	O
feel	O
tired	O
”),	O
reduction	O
in	O
motivation	O
(“	O
I	O
feel	O
no	O
desire	O
to	O
do	O
anything	O
”),	O
reduction	O
in	O
activity	O
(“	O
I	O
don	O
’	O
t	O
do	O
much	O
during	O
the	O
day	O
”)	O
and	O
reduction	O
in	O
concentration	O
(“	O
My	O
thoughts	O
easily	O
wander	O
”)	O
and	O
has	O
been	O
used	O
in	O
a	O
broad	O
range	O
of	O
groups	O
:	O
healthy	O
subjects	O
,	O
diverse	O
groups	O
of	O
working	O
adults	O
,	O
people	O
with	O
chronic	O
fatigue	O
as	O
well	O
as	O
people	O
with	O
multiple	B-DS
sclerosis	I-DS
[	O
54	O
].	O

By	O
adding	O
the	O
four	O
dimensions	O
a	O
CIS	B-DS
total	O
score	O
can	O
be	O
calculated	O
.	O

Respondents	O
rate	O
the	O
extent	O
to	O
which	O
each	O
statement	O
is	O
true	O
for	O
them	O
on	O
a	O
7	O
-	O
point	O
Likert	O
scale	O
ranging	O
from	O
Yes	O
,	O
that	O
is	O
true	O
to	O
No	O
,	O
that	O
is	O
not	O
true	O
.	O

A	O
higher	O
score	O
indicates	O
more	O
fatigue	O
.	O

Fatigue	O
as	O
measured	O
with	O
the	O
CIS	B-DS
may	O
be	O
regarded	O
as	O
the	O
opposite	O
of	O
vitality	O
.	O

In	O
their	O
description	O
and	O
evaluation	O
of	O
measures	O
of	O
fatigue	O
,	O
Hewlett	O
et	O
al	O
.	O
[	O
55	O
]	O
evaluated	O
the	O
CIS	O
as	O
a	O
useful	O
generic	O
scale	O
and	O
research	O
tool	O
,	O
with	O
no	O
significant	O
respondent	O
or	O
administrative	O
burden	O
.	O

The	O
CIS	O
has	O
demonstrated	O
satisfactory	O
psychometric	O
properties	O
[	O
54	O
,	O
56	O
].	O

For	O
the	O
present	O
study	O
,	O
Cronbach	O
’	O
s	O
α	O
was	O
.	O
94	O
.	O

Rosenberg	O
Self	O
-	O
esteem	O
Scale	O

The	O
Rosenberg	O
Self	O
-	O
Esteem	O
Scale	O
(	O
RSES	O
)	O
[	O
57	O
],	O
Dutch	O
version	O
[	O
58	O
],	O
is	O
a	O
brief	O
10	O
-	O
item	O
measure	O
of	O
global	O
self	O
-	O
esteem	O
that	O
evaluates	O
one	O
’	O
s	O
overall	O
feelings	O
of	O
self	O
-	O
worth	O
using	O
a	O
4	O
-	O
point	O
scale	O
(	O
1	O
=	O
strongly	O
disagree	O
,	O
4	O
=	O
strongly	O
agree	O
).	O

Scores	O
range	O
from	O
10	O
to	O
40	O
,	O
with	O
higher	O
scores	O
reflecting	O
higher	O
self	O
-	O
esteem	O
.	O

The	O
validity	O
and	O
reliability	O
of	O
the	O
Dutch	O
version	O
are	O
satisfactory	O
[	O
59	O
].	O

The	O
internal	O
consistency	O
in	O
the	O
present	O
study	O
was	O
.	O
87	O
.	O

Outcome	O
Questionnaire	O

The	O
Outcome	O
Questionnaire	O
(	O
OQ	O
-	O
45	O
)	O
[	O
60	O
]	O
is	O
a	O
45	O
-	O
item	O
scale	O
measuring	O
three	O
domains	O
of	O
psychological	O
well	O
-	O
being	O
:	O
subjective	O
discomfort	O
(“	O
I	O
feel	O
no	O
interest	O
in	O
things	O
”),	O
interpersonal	O
relations	O
(“	O
I	O
am	O
satisfied	O
with	O
my	O
relationships	O
with	O
others	O
”),	O
and	O
social	O
role	O
performance	O
(“	O
I	O
feel	O
that	O
I	O
am	O
doing	O
well	O
at	O
work	O
/	O
school	O
”).	O

The	O
OQ	O
-	O
45	O
is	O
rated	O
on	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
ranging	O
from	O
never	O
to	O
almost	O
always	O
with	O
higher	O
scores	O
for	O
more	O
distress	O
.	O

In	O
a	O
non	O
-	O
clinical	O
group	O
,	O
Cronbach	O
’	O
s	O
α	O
was	O
.	O
93	O
for	O
the	O
original	O
total	O
scale	O
[	O
60	O
]	O
and	O
.	O
92	O
in	O
the	O
Dutch	O
version	O
[	O
61	O
].	O

Cronbach	O
’	O
s	O
α	O
in	O
the	O
present	O
study	O
was	O
.	O
90	O
.	O

Procedure	O

The	O
research	O
was	O
conducted	O
in	O
agreement	O
with	O
the	O
VU	O
University	O
Amsterdam	O
guideline	O
for	O
research	O
for	O
educational	O
purposes	O
,	O
allowing	O
students	O
to	O
collect	O
data	O
with	O
the	O
use	O
of	O
questionnaires	O
in	O
healthy	O
groups	O
of	O
respondents	O
when	O
participation	O
is	O
voluntary	O
and	O
data	O
are	O
analysed	O
anonymously	O
.	O

We	O
consulted	O
the	O
Medical	O
Ethics	O
Review	O
Committee	O
of	O
VU	O
University	O
about	O
the	O
study	O
,	O
and	O
the	O
committee	O
waived	O
the	O
requirement	O
for	O
ethical	O
approval	O
.	O

Data	O
collection	O
was	O
done	O
during	O
an	O
undergraduate	O
course	O
in	O
measurement	O
and	O
statistics	O
at	O
the	O
Faculty	O
of	O
Human	B-OG
Movement	O
Sciences	O
,	O
VU	O
University	O
Amsterdam	O
,	O
resulting	O
in	O
a	O
convenience	O
sample	O
.	O

Students	O
in	O
two	O
successive	O
courses	O
were	O
encouraged	O
to	O
forward	O
an	O
e	O
-	O
mail	O
with	O
a	O
link	O
to	O
the	O
questionnaires	O
to	O
individuals	O
in	O
their	O
personal	O
network	O
.	O

No	O
participatory	O
incentives	O
were	O
offered	O
.	O

Participants	O
completed	O
all	O
questionnaires	O
without	O
personal	O
details	O
through	O
a	O
secured	O
online	O
system	O
and	O
with	O
all	O
materials	O
removed	O
from	O
this	O
system	O
after	O
completing	O
the	O
data	O
collection	O
;	O
data	O
analysis	O
was	O
done	O
anonymously	O
.	O

Information	O
about	O
the	O
aim	O
of	O
the	O
study	O
and	O
the	O
voluntary	O
and	O
anonymous	O
nature	O
of	O
participation	O
was	O
given	O
before	O
participants	O
entered	O
the	O
study	O
.	O

In	O
this	O
way	O
consent	O
was	O
secured	O
when	O
participants	O
completed	O
the	O
questionnaire	O
and	O
no	O
formal	O
informed	O
consent	O
was	O
necessary	O
.	O

Of	O
the	O
respondents	O
all	O
were	O
given	O
the	O
DBIQ	O
-	O
NL	O
to	O
fill	O
out	O
.	O

Of	O
the	O
respondents	O
included	O
via	O
students	O
in	O
the	O
first	O
course	O
(	O
sample	O
1	O
in	O
Table	O
2	O
)	O
361	O
(	O
sample	O
1a	O
)	O
were	O
asked	O
to	O
also	O
complete	O
the	O
Body	O
Cathexis	O
Scale	O
(	O
BCS	O
)	O
[	O
44	O
],	O
and	O
356	O
others	O
(	O
sample	O
1b	O
)	O
to	O
complete	O
the	O
Rosenberg	O
Self	O
-	O
Esteem	O
Scale	O
(	O
RSES	O
)	O
[	O
57	O
],	O
the	O
Checklist	O
Individual	O
Strength	O
(	O
CIS	O
)	O
[	O
53	O
]	O
and	O
the	O
subscale	O
‘	O
comfort	O
in	O
touch	O
’	O
of	O
the	O
Body	O
Investment	O
Scale	O
(	O
BIS	O
)	O
[	O
51	O
].	O

Respondents	O
(	O
n	O
=	O
227	O
)	O
recruited	O
by	O
the	O
students	O
in	O
the	O
second	O
course	O
(	O
sample	O
2	O
)	O
also	O
completed	O
the	O
Outcome	O
Questionnaire	O
(	O
OQ	O
-	O
45	O
)	O
[	O
60	O
]	O
and	O
the	O
Rosenberg	O
Self	O
-	O
esteem	O
Scale	O
.	O

To	O
assess	O
temporal	O
reliability	O
,	O
56	O
respondents	O
of	O
sample	O
2	O
completed	O
the	O
DBIQ	O
-	O
NL	O
a	O
second	O
time	O
after	O
14	O
days	O
.	O

44	O
respondents	O
only	O
completed	O
the	O
DBIQ	O
-	O
NL	O
and	O
did	O
not	O
fill	O
in	O
any	O
additional	O
questionnaires	O
.	O

Mean	O
scores	O
and	O
mean	O
differences	O
sex	O
and	O
age	O
DBIQ	O
-	O
NL	O
samples	O
and	O
validation	O
measures	O
.	O

full	O
sample	O

women	O

men	O

age	O
<	O
38	O

age	O
≥	O
38	O

Sample	O

(	O
sub	O
)	O
scale	O

n	O

Mean	O

SD	O

n	O

Mean	O

SD	O

n	O

Mean	O

SD	O

d	O

n	O

Mean	O

SD	O

n	O

Mean	O

SD	O

d	O

1	O

DBIQ	O
-	O
NL	O

755	O
*	O

3	O
.	O
66	O

0	O
.	O
45	O

430	O

3	O
.	O
56	O

0	O
.	O
44	O

323	O

3	O
.	O
79	O

0	O
.	O
43	O

0	O
.	O
53	O

537	O

3	O
.	O
71	O

0	O
.	O
44	O

218	O

3	O
.	O
53	O

0	O
.	O
45	O

0	O
.	O
40	O

1a	O

BCS	O

361	O

3	O
.	O
68	O

0	O
.	O
54	O

216	O

3	O
.	O
61	O

0	O
.	O
53	O

145	O

3	O
.	O
79	O

0	O
.	O
54	O

0	O
.	O
34	O

228	O

3	O
.	O
70	O

0	O
.	O
53	O

133	O

3	O
.	O
64	O

0	O
.	O
56	O

0	O
.	O
11	O

1b	O

RSES	O

356	O

3	O
.	O
26	O

0	O
.	O
47	O

191	O

3	O
.	O
15	O

0	O
.	O
45	O

163	O

3	O
.	O
39	O

0	O
.	O
44	O

0	O
.	O
54	O

272	O

3	O
.	O
25	O

0	O
.	O
47	O

84	O

3	O
.	O
28	O

0	O
.	O
44	O

0	O
.	O
07	O

1b	O

BIS	O
-	O
touch	O

356	O

3	O
.	O
77	O

0	O
.	O
61	O

191	O

3	O
.	O
73	O

0	O
.	O
56	O

163	O

3	O
.	O
81	O

0	O
.	O
66	O

0	O
.	O
13	O

272	O

3	O
.	O
80	O

0	O
.	O
63	O

84	O

3	O
.	O
66	O

0	O
.	O
54	O

0	O
.	O
24	O

1b	O

CIS	B-DS

356	O

2	O
.	O
97	O

1	O
.	O
02	O

191	O

3	O
.	O
11	O

1	O
.	O
02	O

163	O

2	O
.	O
81	O

0	O
.	O
99	O

0	O
.	O
30	O

272	O

2	O
.	O
98	O

1	O
.	O
00	O

84	O

2	O
.	O
96	O

1	O
.	O
09	O

0	O
.	O
02	O

2	O

DBIQ	O
-	O
NL	O

227	O

3	O
.	O
57	O

0	O
.	O
39	O

150	O

3	O
.	O
53	O

0	O
.	O
39	O

77	O

3	O
.	O
64	O

0	O
.	O
40	O

0	O
.	O
28	O

151	O

3	O
.	O
59	O

0	O
.	O
40	O

76	O

3	O
.	O
53	O

0	O
.	O
38	O

0	O
.	O
15	O

OQ	O
-	O
45	O

227	O

1	O
.	O
96	O

0	O
.	O
38	O

150	O

1	O
.	O
98	O

0	O
.	O
31	O

77	O

1	O
.	O
93	O

0	O
.	O
45	O

0	O
.	O
13	O

151	O

1	O
.	O
96	O

0	O
.	O
40	O

76	O

1	O
.	O
94	O

0	O
.	O
36	O

0	O
.	O
05	O

RSES	O

225	O

3	O
.	O
32	O

0	O
.	O
46	O

149	O

3	O
.	O
26	O

0	O
.	O
45	O

76	O

3	O
.	O
44	O

0	O
.	O
45	O

0	O
.	O
40	O

149	O

3	O
.	O
31	O

0	O
.	O
48	O

76	O

3	O
.	O
34	O

0	O
.	O
41	O

0	O
.	O
07	O

Note	O
:	O
d	O
=	O
Cohen	O
’	O
s	O
d	O
;	O
DBIQ	O
-	O
NL	O
=	O
Dresden	O
Body	O
Image	O
Questionnaire	O
,	O
Dutch	O
translation	O
;	O
OQ	O
-	O
45	O
=	O
Outcome	O
Questionnaire	O
;	O
RSES	O
=	O
Rosenberg	O
Self	O
-	O
esteem	O
Scale	O

BCS	O
=	O
Body	O
Cathexis	O
Scale	O
;	O
BIS	O
-	O
touch	O
=	O
subscale	O
comfort	O
with	O
physical	O
touch	O
Body	O
Investment	O
Scale	O
;	O
CIS	O
=	O
Checklist	O
Individual	O
Strength	O
.	O

*	O
For	O
six	O
participants	O
,	O
no	O
total	O
scores	O
were	O
available	O
.	O

Data	O
analysis	O

SPSS	O
17	O
.	O
00	O
for	O
Windows	O
was	O
used	O
for	O
general	O
statistical	O
analyses	O
.	O

Mean	O
differences	O
between	O
subgroups	O
are	O
expressed	O
in	O
Cohen	O
’	O
s	O
d	O
and	O
considered	O
large	O
if	O
>	O
.	O
80	O
,	O
moderate	O
between	O
.	O
50	O
and	O
.	O
79	O
and	O
small	O
between	O
.	O
20	O
and	O
.	O
49	O
[	O
62	O
].	O

In	O
calculating	O
means	O
we	O
limited	O
missing	O
values	O
to	O
one	O
for	O
all	O
subscales	O
and	O
two	O
for	O
total	O
mean	O
scores	O
.	O

Test	O
-	O
retest	O
reliability	O
was	O
established	O
by	O
intraclass	O
correlation	O
(	O
ICC	O
).	O

ICC	O
>	O
.	O
75	O
was	O
considered	O
as	O
excellent	O
and	O
between	O
.	O
40	O
and	O
.	O
75	O
as	O
acceptable	O
[	O
63	O
].	O

Construct	O
validity	O
was	O
investigated	O
by	O
correlations	O
.	O

We	O
expected	O
a	O
moderate	O
correlation	O
of	O
body	O
image	O
total	O
score	O
with	O
body	O
satisfaction	O
,	O
because	O
the	O
DBIQ	O
is	O
aimed	O
to	O
measure	O
a	O
broader	O
concept	O
of	O
body	O
image	O
.	O

We	O
also	O
expected	O
moderate	O
correlations	O
of	O
body	O
image	O
total	O
score	O
with	O
self	O
-	O
esteem	O
and	O
psychological	O
well	O
-	O
being	O
.	O

Furthermore	O
,	O
high	O
correlations	O
are	O
expected	O
between	O
the	O
subscale	O
‘	O
vitality	O
’	O
of	O
the	O
DBIQ	O
-	O
NL	O
and	O
fatigue	O
as	O
measured	O
with	O
the	O
CIS	O
and	O
between	O
the	O
‘	O
physical	O
contact	O
’	O
subscale	O
of	O
the	O
DBIQ	O
-	O
NL	O
and	O
the	O
comfort	O
in	O
touch	O
subscale	O
of	O
the	O
BIS	O
.	O

The	O
factorial	O
structure	O
of	O
the	O
translated	O
version	O
was	O
tested	O
by	O
confirmatory	O
factor	O
analysis	O
(	O
CFA	O
).	O

Analyses	O
were	O
conducted	O
with	O
Mplus	O
Version	O
5	O
.	O
1	O
[	O
64	O
],	O
using	O
the	O
robust	O
full	O
-	O
information	O
maximum	O
likelihood	O
(	O
MLR	O
)	O
estimator	O
to	O
correct	O
for	O
the	O
skew	O
distribution	O
of	O
several	O
items	O
and	O
missing	O
item	O
responses	O
[	O
65	O
].	O

In	O
view	O
of	O
the	O
sufficiently	O
large	O
sample	O
size	O
and	O
focus	O
on	O
model	O
selection	O
and	O
fit	O
,	O
the	O
5	O
-	O
point	O
Likert	O
items	O
were	O
treated	O
as	O
continuous	O
measures	O
[	O
66	O
].	O

Complete	O
descriptives	O
for	O
all	O
items	O
used	O
for	O
the	O
CFA	O
are	O
provided	O
in	O
S2	O
Table	O
.	O

Because	O
a	O
five	O
factor	O
model	O
was	O
shown	O
to	O
be	O
adequate	O
for	O
the	O
German	O
questionnaire	O
,	O
we	O
investigated	O
the	O
fit	O
of	O
this	O
model	O
to	O
the	O
Dutch	O
samples	O
,	O
aiming	O
to	O
obtain	O
fit	O
measures	O
close	O
to	O
those	O
of	O
the	O
German	O
model	O
.	O

We	O
could	O
not	O
reasonably	O
expect	O
equivalent	O
fit	O
measures	O
as	O
the	O
study	O
is	O
not	O
an	O
exact	O
replication	O
study	O
.	O

The	O
three	O
essential	O
changes	O
with	O
respect	O
to	O
Pöhlmann	O
et	O
al	O
.’	O
s	O
[	O
26	O
]	O
study	O
,	O
(	O
1	O
)	O
translation	O
of	O
the	O
items	O
,	O
(	O
2	O
)	O
non	O
-	O
clinical	O
samples	O
,	O
and	O
(	O
3	O
)	O
using	O
a	O
CFA	O
model	O
without	O
correlated	O
errors	O
,	O
were	O
expected	O
to	O
lead	O
to	O
a	O
decrease	O
in	O
model	O
fit	O
[	O
67	O
,	O
68	O
].	O

Because	O
each	O
type	O
of	O
index	O
provides	O
different	O
information	O
about	O
model	O
fit	O
[	O
69	O
],	O
we	O
chose	O
to	O
report	O
a	O
broad	O
range	O
of	O
indices	O
and	O
also	O
included	O
standardized	O
root	O
mean	O
square	O
residual	O
(	O
SRMR	O
)	O
and	O
Tucker	O
Lewis	O
index	O
(	O
TLI	O
),	O
in	O
addition	O
to	O
the	O
CFI	O
and	O
RMSEA	O
reported	O
in	O
the	O
CFA	O
on	O
the	O
German	O
items	O
[	O
26	O
].	O

The	O
RMSEA	O
(	O
Root	O
Mean	O
Square	O
Error	O
of	O
Approximation	O
)	O
represents	O
the	O
fit	O
of	O
the	O
estimated	O
covariance	O
matrix	O
to	O
the	O
populations	O
covariance	O
matrix	O
[	O
70	O
].	O

It	O
is	O
regarded	O
as	O
one	O
of	O
the	O
most	O
informative	O
fit	O
indices	O
due	O
to	O
its	O
sensitivity	O
to	O
the	O
number	O
of	O
estimated	O
parameters	O
in	O
the	O
model	O
and	O
therefore	O
favouring	O
parsimonious	O
models	O
.	O

As	O
a	O
rule	O
of	O
thumb	O
,	O
RMSEA	O
values	O
less	O
than	O
.	O
08	O
suggest	O
adequate	O
model	O
fit	O
and	O
RMSEA	O
values	O
less	O
than	O
.	O
05	O
suggest	O
good	O
model	O
fit	O
[	O
71	O
].	O

The	O
SRMR	O
(	O
Standardised	O
Root	O
Mean	O
square	O
Residual	O
)	O
is	O
the	O
standardized	O
square	O
root	O
of	O
the	O
difference	O
between	O
the	O
residuals	O
of	O
the	O
sample	O
covariance	O
matrix	O
and	O
the	O
hypothesised	O
covariance	O
model	O
.	O

An	O
SRMR	O
between	O
.	O
05	O
and	O
.	O
10	O
indicates	O
an	O
acceptable	O
fit	O
and	O
values	O
less	O
than	O
.	O
05	O
indicate	O
good	O
fit	O
[	O
72	O
].	O

The	O
CFI	O
(	O
Comparitive	O
Fit	O
Index	O
)	O
[	O
73	O
]	O
compares	O
the	O
sample	O
covariance	O
matrix	O
with	O
a	O
null	O
model	O
of	O
uncorrelated	O
latent	O
variables	O
.	O

The	O
CFI	O
is	O
one	O
of	O
the	O
most	O
commonly	O
reported	O
fit	O
indices	O
due	O
to	O
being	O
one	O
of	O
the	O
measures	O
least	O
effected	O
by	O
sample	O
size	O
and	O
is	O
often	O
reported	O
together	O
with	O
the	O
TLI	O
(	O
Tucker	O
Lewis	O
Index	O
),	O
a	O
comparative	O
fit	O
index	O
slightly	O
differing	O
from	O
the	O
CFI	O
in	O
its	O
approach	O
to	O
sample	O
size	O
and	O
handling	O
of	O
the	O
effect	O
of	O
model	O
complexity	O
[	O
69	O
].	O

CFI	O
and	O
TLI	O
values	O
in	O
the	O
range	O
between	O
.	O
90	O
and	O
.	O
95	O
may	O
be	O
regarded	O
as	O
indicative	O
of	O
acceptable	O
model	O
fit	O
[	O
69	O
].	O

Although	O
there	O
is	O
discussion	O
on	O
which	O
fit	O
-	O
indices	O
are	O
the	O
most	O
relevant	O
,	O
it	O
is	O
now	O
common	O
practice	O
to	O
test	O
the	O
fit	O
of	O
the	O
CFA	O
with	O
at	O
least	O
the	O
ones	O
used	O
here	O
.	O

Thus	O
,	O
conclusions	O
about	O
the	O
fit	O
of	O
the	O
model	O
can	O
be	O
based	O
on	O
the	O
consistency	O
between	O
fit	O
-	O
indices	O
.	O

When	O
fit	O
-	O
indices	O
fall	O
in	O
marginal	O
ranges	O
,	O
it	O
is	O
especially	O
important	O
to	O
consider	O
the	O
consistency	O
of	O
the	O
model	O
fit	O
as	O
expressed	O
by	O
the	O
various	O
types	O
of	O
fit	O
indices	O
in	O
tandem	O
with	O
the	O
particular	O
aspects	O
of	O
the	O
analytic	O
situation	O
[	O
69	O
].	O

Inadequate	O
fit	O
measures	O
are	O
an	O
indication	O
of	O
model	O
misspecification	O
.	O

Modification	O
indices	O
can	O
be	O
used	O
to	O
adjust	O
the	O
model	O
specification	O
in	O
order	O
to	O
improve	O
model	O
fit	O
.	O

First	O
,	O
the	O
five	O
-	O
factor	O
model	O
(	O
without	O
correlated	O
errors	O
)	O
was	O
estimated	O
,	O
using	O
sample	O
1	O
.	O

Modification	O
indices	O
were	O
inspected	O
to	O
detect	O
possible	O
improvements	O
with	O
respect	O
to	O
dimensionality	O
.	O

We	O
refrained	O
from	O
including	O
correlated	O
errors	O
in	O
view	O
of	O
the	O
multiple	O
group	O
confirmatory	O
factor	O
analysis	O
(	O
MG	O
-	O
CFA	O
),	O
which	O
does	O
not	O
allow	O
correlated	O
errors	O
.	O

We	O
performed	O
multiple	O
-	O
group	O
analyses	O
with	O
respect	O
to	O
gender	O
and	O
age	O
after	O
investigating	O
the	O
overall	O
five	O
-	O
factor	O
structure	O
of	O
the	O
DBIQ	O
-	O
NL	O
,	O
because	O
MG	O
-	O
CFA	O
provides	O
the	O
opportunity	O
to	O
identify	O
items	O
that	O
are	O
non	O
-	O
invariant	O
across	O
groups	O
.	O

Invariance	O
is	O
a	O
prerequisite	O
for	O
individual	O
and	O
group	O
comparisons	O
to	O
reflect	O
true	O
differences	O
[	O
69	O
,	O
74	O
],	O
not	O
due	O
to	O
systematic	O
differences	O
in	O
interpretation	O
of	O
items	O
due	O
to	O
respondents	O
’	O
group	O
membership	O
.	O

The	O
extent	O
of	O
measurement	O
invariance	O
was	O
evaluated	O
in	O
a	O
series	O
of	O
three	O
models	O
.	O

In	O
model	O
A	O
,	O
specifying	O
‘	O
configural	O
invariance	O
’,	O
the	O
same	O
factor	O
structure	O
is	O
imposed	O
on	O
the	O
two	O
groups	O
(	O
formed	O
by	O
either	O
sex	O
or	O
age	O
)	O
In	O
the	O
next	O
model	O
(	O
B	O
),	O
specifying	O
‘	O
weak	O
invariance	O
’,	O
the	O
factor	O
loadings	O
are	O
constrained	O
to	O
be	O
equal	O
across	O
groups	O
.	O

In	O
Model	O
C	O
,	O
‘	O
strong	O
invariance	O
’,	O
the	O
factor	O
loadings	O
and	O
intercepts	O
are	O
constrained	O
to	O
be	O
equal	O
across	O
groups	O
.	O

The	O
model	O
selection	O
was	O
performed	O
by	O
testing	O
invariance	O
by	O
the	O
Scaled	O
Difference	O
in	O
Chi	O
-	O
Squares	O
(	O
SDCS	O
)	O
test	O
[	O
75	O
]	O
for	O
nested	O
models	O
estimated	O
with	O
MLR	O
.	O

Inspection	O
of	O
size	O
and	O
consistency	O
of	O
factor	O
loadings	O
were	O
performed	O
to	O
further	O
evaluate	O
model	O
fit	O
[	O
69	O
].	O

This	O
sequential	O
model	O
estimation	O
procedure	O
to	O
study	O
measurement	O
invariance	O
is	O
used	O
since	O
lack	O
of	O
strong	O
factorial	O
invariance	O
will	O
contaminate	O
estimates	O
of	O
group	O
mean	O
differences	O
[	O
74	O
].	O

It	O
is	O
widely	O
acknowledged	O
however	O
,	O
that	O
the	O
requirement	O
of	O
strong	O
factorial	O
invariance	O
may	O
be	O
too	O
strict	O
and	O
unrealistic	O
a	O
goal	O
for	O
group	O
comparisons	O
.	O

Consequently	O
,	O
Byrne	O
et	O
al	O
.	O
[	O
76	O
]	O
introduced	O
the	O
concept	O
of	O
partial	O
invariance	O
in	O
which	O
only	O
a	O
subset	O
of	O
parameters	O
in	O
each	O
subscale	O
must	O
be	O
invariant	O
whereas	O
others	O
are	O
allowed	O
to	O
vary	O
between	O
the	O
groups	O
.	O

In	O
this	O
procedure	O
,	O
fit	O
diagnostics	O
(	O
e	O
.	O
g	O
.,	O
modification	O
indices	O
)	O
can	O
assist	O
the	O
researcher	O
to	O
identify	O
specific	O
items	O
that	O
are	O
non	O
-	O
invariant	O
across	O
groups	O
[	O
69	O
].	O

In	O
our	O
analysis	O
partial	O
invariance	O
was	O
investigated	O
by	O
inspecting	O
modification	O
indices	O
to	O
determine	O
which	O
cross	O
-	O
group	O
equality	O
constraint	O
most	O
significantly	O
contributed	O
to	O
lack	O
of	O
fit	O
;	O
the	O
model	O
was	O
re	O
-	O
estimated	O
after	O
freeing	O
that	O
constraint	O
and	O
this	O
process	O
was	O
reiterated	O
as	O
needed	O
[	O
77	O
].	O

Partial	O
invariance	O
of	O
certain	O
items	O
signals	O
qualitative	O
group	O
differences	O
that	O
render	O
exact	O
between	O
-	O
group	O
comparisons	O
with	O
respect	O
to	O
subscales	O
including	O
these	O
items	O
possibly	O
less	O
meaningful	O
.	O

The	O
importance	O
of	O
any	O
violation	O
of	O
factorial	O
invariance	O
should	O
be	O
judged	O
in	O
relation	O
to	O
the	O
intended	O
use	O
of	O
the	O
measure	O
in	O
practice	O
[	O
78	O
]	O
and	O
may	O
also	O
be	O
dependent	O
on	O
the	O
number	O
of	O
affected	O
items	O
.	O

The	O
implications	O
of	O
the	O
findings	O
with	O
respect	O
to	O
measurement	O
invariance	O
are	O
further	O
investigated	O
by	O
comparing	O
the	O
original	O
(	O
sub	O
-)	O
scale	O
scores	O
to	O
the	O
adjusted	O
(	O
sub	O
-)	O
scale	O
scores	O
.	O

Moreover	O
,	O
the	O
correlations	O
between	O
the	O
full	O
and	O
reduced	O
scale	O
and	O
subscales	O
were	O
investigated	O
,	O
as	O
well	O
as	O
the	O
change	O
in	O
standardized	O
factor	O
loadings	O
.	O

Note	O
that	O
all	O
(	O
sub	O
-)	O
scale	O
scores	O
are	O
calculated	O
as	O
average	O
scores	O
,	O
which	O
are	O
unweighted	O
and	O
therefore	O
not	O
affected	O
by	O
(	O
changes	O
in	O
)	O
factor	O
loadings	O
.	O

Results	O

Table	O
2	O
presents	O
total	O
mean	O
scores	O
and	O
standard	O
deviations	O
in	O
both	O
DBIQ	O
-	O
NL	O
samples	O
as	O
well	O
as	O
means	O
and	O
standard	O
deviations	O
for	O
the	O
questionnaires	O
used	O
for	O
validation	O
.	O

Mean	O
group	O
differences	O
between	O
women	O
and	O
men	O
and	O
between	O
younger	O
and	O
older	O
participants	O
are	O
also	O
included	O
.	O

Test	O
-	O
retest	O
reliability	O

The	O
intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
between	O
test	O
and	O
retest	O
scores	O
on	O
the	O
DBIQ	O
-	O
NL	O
scale	O
were	O
.	O
88	O
and	O
on	O
the	O
DBIQ	O
-	O
NL	O
subscales	O
.	O
82	O
for	O
vitality	O
,	O
.	O
80	O
for	O
body	O
acceptance	O
,	O
.	O
78	O
for	O
self	O
-	O
aggrandizement	O
,	O
.	O
79	O
for	O
sexual	O
fulfillment	O
,	O
and	O
.	O
64	O
for	O
physical	O
contact	O
.	O

Test	O
and	O
retest	O
scores	O
were	O
calculated	O
using	O
the	O
original	O
composition	O
of	O
the	O
German	O
version	O
(	O
Model	O
1	O
).	O

Construct	O
validity	O

Pearson	O
’	O
s	O
r	O
between	O
the	O
DBIQ	O
-	O
NL	O
and	O
Body	O
Cathexis	O
Scale	O
(	O
BCS	O
)	O
correlated	O
r	O
=	O
.	O
60	O
(	O
see	O
Table	O
3	O
).	O

The	O
subscale	O
vitality	O
of	O
the	O
DBIQ	O
-	O
NL	O
correlated	O
r	O
=	O
-.	O
70	O
with	O
the	O
Checklist	O
Individual	O
Strength	O
(	O
CIS	O
)	O
and	O
the	O
subscale	O
physical	O
contact	O
of	O
the	O
DBIQ	O
-	O
NL	O
correlated	O
r	O
=	O
.	O
72	O
with	O
the	O
subscale	O
comfort	O
with	O
physical	O
touch	O
of	O
the	O
Body	O
Investment	O
Scale	O
(	O
BIS	O
).	O

Correlation	O
between	O
DBIQ	O
-	O
NL	O
and	O
the	O
Outcome	O
Questionnaire	O
(	O
OQ	O
-	O
45	O
)	O
was	O
-.	O
51	O
.	O

DBIQ	O
-	O
NL	O
and	O
Rosenberg	O
Self	O
-	O
esteem	O
Scale	O
(	O
RSES	O
)	O
showed	O
a	O
correlation	O
of	O
r	O
=	O
.	O
44	O
.	O

All	O
correlations	O
were	O
in	O
the	O
expected	O
direction	O
and	O
of	O
medium	O
to	O
large	O
size	O
.	O

Correlations	O
between	O
DBIQ	O
-	O
NL	O
and	O
BCS	O
were	O
notably	O
higher	O
for	O
men	O
than	O
for	O
women	B-OG
.	O

Correlations	O
between	O
DBIQ	O
-	O
NL	O
and	O
OQ	O
-	O
45	O
and	O
between	O
DBIQ	O
-	O
NL	O
and	O
RSES	O
were	O
higher	O
for	O
age	O
<	O
38	O
than	O
for	O
age	O
≥	O
38	O
.	O

The	O
subscale	O
vitality	O
correlated	O
notably	O
lower	O
with	O
the	O
CIS	B-DS
in	O
the	O
younger	O
group	O
than	O
in	O
the	O
older	O
group	O
.	O

Correlations	O
were	O
calculated	O
using	O
the	O
five	O
-	O
factor	O
model	O
identical	O
to	O
the	O
original	O
German	O
version	O
(	O
Model	O
1	O
).	O

The	O
correlations	O
between	O
the	O
measures	O
that	O
were	O
used	O
for	O
construct	O
validation	O
and	O
the	O
DBIQ	O
-	O
NL	O
were	O
recalculated	O
(	O
see	O
Table	O
3	O
)	O
after	O
the	O
DBIQ	O
-	O
NL	O
was	O
revised	O
on	O
the	O
basis	O
of	O
the	O
CFA	O
,	O
as	O
reported	O
in	O
the	O
following	O
section	O
.	O

Correlations	O
in	O
Pearson	O
’	O
s	O
r	O
of	O
original	O
and	O
revised	O
DBIQ	O
scale	O
and	O
original	O
and	O
revised	O
subscale	O
‘	O
physical	O
contact	O
’	O
with	O
validation	O
instruments	O
(	O
Model	O
1	O
and	O
Model	O
2	O
).	O

DBIQ	O
-	O
NL	O
(	O
35	O
items	O
;	O
model	O
1	O
)	O

DBIQ	O
-	O
NL	O
(	O
31	O
items	O
;	O
model	O
2	O
)	O

Total	O
sample	O

female	O

male	O

young	O

old	O

Total	O
sample	O

female	O

male	O

young	O

old	O

BCSa	O

.	O
60	O

.	O
53	O

.	O
70	O

.	O
58	O

.	O
64	O

.	O
59	O

.	O
53	O

.	O
67	O

.	O
56	O

.	O
64	O

OQ	O
-	O
45b	O

-.	O
51	O

-.	O
49	O

-.	O
52	O

-.	O
54	O

-.	O
40	O

-.	O
50	O

-.	O
50	O

-.	O
50	O

-.	O
53	O

-.	O
43	O

RSESc	O

.	O
44	O

.	O
38	O

.	O
42	O

.	O
49	O

.	O
35	O

.	O
45	O

.	O
40	O

.	O
43	O

.	O
50	O

.	O
37	O

subscale	O
physical	O
contact	O
(	O
6	O
items	O
)	O

subscale	O
physical	O
contact	O
(	O
4	O
items	O
)	O

BIS	O
-	O
touchd	O

.	O
72	O

.	O
77	O

.	O
67	O

.	O
71	O

.	O
77	O

66	O

.	O
71	O

.	O
61	O

.	O
64	O

.	O
72	O

subscale	O
vitality	O

subscale	O
vitality	O
(	O
as	O
in	O
Model	O
1	O
)	O

CISd	B-GP

-.	O
70	O

-.	O
67	O

-.	O
73	O

-.	O
66	O

-.	O
83	O

-.	O
70	O

-.	O
67	O

-.	O
73	O

-.	O
66	O

-.	O
83	O

Note	O
:	O
DBIQ	O
-	O
NL	O
=	O
Dresden	O
Body	O
Image	O
Questionnaire	O
,	O
Dutch	O
translation	O
;	O
OQ	O
-	O
45	O
=	O
Outcome	O
Questionnaire	O
;	O
RSES	O
=	O
Rosenberg	O
Self	O
-	O
esteem	O
Scale	O
;	O
BCS	O
=	O
Body	O
Cathexis	O
Scale	O
;	O
BIS	O
-	O
touch	O
=	O
subscale	O
comfort	O
with	O
physical	O
touch	O
Body	O
Investment	O
Scale	O
;	O
CIS	O
=	O
Checklist	O
Individual	O
Strength	O
.	O

For	O
description	O
of	O
the	O
samples	O
1a	O
,	O
1b	O
,	O
and	O
2	O
,	O
see	O
procedure	O
and	O
Table	O
2	O
.	O

a	O
sample	O
1a	O

b	O
sample	O
2	O

c	O
samples	O
1b	O
and	O
2	O

d	O
sample	O
1b	O

Confirmatory	O
factor	O
analysis	O
and	O
measurement	O
invariance	O
on	O
sample	O
1	O

First	O
,	O
a	O
five	O
-	O
factor	O
model	O
identical	O
to	O
the	O
original	O
German	O
version	O
was	O
specified	O
(	O
Model	O
1	O
).	O

Next	O
,	O
based	O
on	O
inspection	O
of	O
the	O
modification	O
indices	O
of	O
this	O
model	O
a	O
five	O
-	O
factor	O
model	O
(	O
Model	O
2	O
)	O
with	O
item	O
33	O
(“	O
I	O
like	O
showing	O
my	O
body	O
”)	O
loading	O
on	O
self	O
-	O
aggrandizement	O
instead	O
of	O
body	O
acceptance	O
was	O
evaluated	O
.	O

Goodness	O
of	O
fit	O
indices	O
of	O
both	O
models	O
are	O
shown	O
in	O
Table	O
4	O
.	O

The	O
modification	O
indices	O
for	O
correlated	O
errors	O
suggested	O
partly	O
the	O
same	O
(	O
between	O
reversed	O
items	O
23	O
“	O
I	O
wish	O
I	O
had	O
a	O
different	O
body	O
”	O
and	O
28	O
“	O
If	O
I	O
could	O
change	O
something	O
about	O
my	O
body	O
,	O
I	O
would	O
do	O
it	O
”),	O
and	O
partly	O
different	O
correlated	O
errors	O
(	O
between	O
reversed	O
items	O
24	O
“	O
I	O
consciously	O
avoid	O
touching	O
other	O
people	O
”	O
and	O
19	O
“	O
I	O
do	O
not	O
like	O
people	O
touching	O
me	O
”),	O
as	O
reported	O
by	O
Pöhlmann	O
et	O
al	O
.	O
[	O
26	O
].	O

DBIQ	O
-	O
NL	O
:	O
Confirmatory	O
factor	O
analysis	O
,	O
goodness	O
of	O
fit	O
indices	O
of	O
Model	O
1	O
,	O
2	O
,	O
and	O
3	O
and	O
measurement	O
invariance	O
across	O
sex	O
and	O
age	O
of	O
Model	O
2	O
.	O

Model	O

χ2	O

df	O

scl	O

Δ	O
χ2	O

Δ	O
df	O

Ts	O

RMSEA	O
(	O
90	O
%	O
CI	O
)	O

SRMR	O

CFI	O

TLI	O

Model	O
1	O

Original	O
35	O
Item	O
Scale	O

2169	O

550	O

1	O
.	O
265	O

.	O
062	O
(.	O
059	O
-.	O
065	O
)	O

.	O
070	O

.	O
828	O

.	O
814	O

Model	O
2	O

Adapted	O
35	O
Item	O
Scale	O
a	O

1965	O

550	O

1	O
.	O
268	O

.	O
058	O
(.	O
055	O
-.	O
061	O
)	O

.	O
067	O

.	O
850	O

.	O
838	O

Measurement	O
Invariance	O
Sex	O

Model	O
2sA	O

configural	O
invariance	O

2692	O

1100	O

1	O
.	O
268	O

.	O
062	O
(.	O
059	O
-.	O
065	O
)	O

.	O
074	O

.	O
832	O

.	O
818	O

Model	O
2sB	O

weak	O
invariance	O

2721	O

1130	O

1	O
.	O
276	O

29	O

30	O

18	O
.	O
4	O

.	O
061	O
(.	O
058	O
-.	O
064	O
)	O

.	O
077	O

.	O
832	O

.	O
823	O

Model	O
2sC	O

strong	O
invariance	O

2905	O

1160	O

1	O
.	O
322	O

184	O

30	O

60	O
.	O
2	O
**	O

.	O
063	O
(.	O
060	O
-.	O
066	O
)	O

.	O
081	O

.	O
816	O

.	O
811	O

Model	O
2sC	O
-	O
1	O

partial	O
strong	O
item	O
19	O

2869	O

1158	O

1	O
.	O
317	O

148	O

28	O

49	O
.	O
8	O
*	O

.	O
062	O
(.	O
060	O
-.	O
065	O
)	O

.	O
080	O

.	O
819	O

.	O
814	O

Model	O
2sC	O
-	O
2	O

partial	O
strong	O
items	O
19	O
,	O
30	O

2827	O

1156	O

1	O
.	O
315	O

106	O

26	O

35	O
.	O
2	O
*	O

.	O
062	O
(.	O
059	O
-.	O
065	O
)	O

.	O
079	O

.	O
823	O

.	O
818	O

Model	O
2sC	O
-	O
3	O

partial	O
strong	O
items	O
19	O
,	O
30	O
,	O
15	O

2804	O

1154	O

1	O
.	O
313	O

83	O

24	O

27	O
.	O
1	O

.	O
061	O
(.	O
059	O
-.	O
064	O
)	O

.	O
078	O

.	O
826	O

.	O
820	O

Measurement	O
Invariance	O
Age	O

Model	O
2aA	O

configural	O
invariance	O

2623	O

1100	O

1	O
.	O
253	O

.	O
060	O
(.	O
057	O
-.	O
063	O
)	O

.	O
073	O

.	O
842	O

.	O
829	O

Model	O
2aB	O

weak	O
invariance	O

2645	O

1130	O

1	O
.	O
247	O

22	O

30	O

21	O
.	O
4	O

.	O
059	O
(.	O
056	O
-.	O
062	O
)	O

.	O
075	O

.	O
843	O

.	O
835	O

Model	O
2aC	O

strong	O
invariance	O

2796	O

1160	O

1	O
.	O
291	O

151	O

30	O

51	O
.	O
2	O
**	O

.	O
061	O
(.	O
058	O
-.	O
064	O
)	O

.	O
078	O

.	O
831	O

.	O
826	O

Model	O
2aC	O
-	O
1	O

partial	O
strong	O
item	O
15	O

2771	O

1158	O

1	O
.	O
289	O

126	O

28	O

42	O
.	O
2	O
*	O

.	O
061	O
(.	O
058	O
-.	O
063	O
)	O

.	O
078	O

.	O
833	O

.	O
828	O

Model	O
2aC	O
-	O
2	O

partial	O
strong	O
items	O
15	O
,	O
28	O

2754	O

1156	O

1	O
.	O
286	O

109	O

26	O

36	O
.	O
5	O

.	O
060	O
(.	O
058	O
-.	O
064	O
)	O

.	O
077	O

.	O
835	O

.	O
830	O

Model	O
3	O

Reduced	O
31	O
Item	O
Scale	O

1459	O

424	O

1	O
.	O
271	O

506	O

126	O

402	O
.	O
2	O
**	O

.	O
057	O
(.	O
053	O
-.	O
060	O
)	O

.	O
063	O

.	O
877	O

.	O
865	O

Note	O
:	O
DBIQ	O
-	O
NL	O
=	O
Dresden	O
Body	O
Image	O
Questionnaire	O
,	O
Dutch	O
translation	O
;	O
χ2	O
=	O
chi	O
square	O
;	O
df	O
=	O
degrees	O
of	O
freedom	O
;	O
scl	O
=	O
scaling	O
correction	O
factor	O
;	O
Ts	O
=	O
Scaled	O
.	O

Difference	O
in	O
Chi	O
-	O
Squares	O
(	O
SDCS	O
)	O
test	O
statistic	O
;	O
RMSEA	O
=	O
root	O
mean	O
square	O
error	O
of	O
approximation	O
;	O
90	O
%	O
CI	O
=	O
90	O
%	O
confidence	O
interval	O
of	O
the	O
RMSEA	O
;	O
SRMR	O
=	O
standardized	O
root	O
mean	O
square	O
residual	O
;	O
CFI	O
=	O
comparative	O
fit	O
index	O
;	O
TLI	O
=	O
Tucker	O
Lewis	O
index	O
.	O

a	O
Adapted	O
model	O
with	O
item	O
33	O
not	O
loading	O
on	O
the	O
factor	O
acceptance	O
but	O
on	O
self	O
-	O
aggrandizement	O
(	O
modification	O
index	O
item	O
33	O
=	O
184	O
.	O
979	O
).	O

*	O
p	O
<	O
.	O
01	O
.	O

**	O
p	O
<	O
.	O
001	O
.	O

The	O
best	O
fitting	O
model	O
(	O
Model	O
2	O
)	O
was	O
further	O
evaluated	O
for	O
measurement	O
invariance	O
in	O
a	O
multiple	O
group	O
confirmatory	O
factor	O
analysis	O
(	O
MG	O
-	O
CFA	O
)	O
with	O
sex	O
and	O
age	O
as	O
grouping	O
variables	O
.	O

Models	O
2A	O
-	O
2C	O
show	O
measurement	O
invariance	O
tests	O
for	O
sex	O
(	O
2sA	O
-	O
2sC	O
)	O
and	O
age	O
(	O
2aA	O
-	O
2aC	O
)	O
respectively	O
.	O

As	O
can	O
be	O
seen	O
with	O
respect	O
to	O
sex	O
as	O
grouping	O
variable	O
,	O
constraining	O
the	O
factor	O
loadings	O
to	O
be	O
equal	O
across	O
groups	O
(	O
2sB	O
)	O
is	O
accompanied	O
by	O
only	O
a	O
slight	O
decrease	O
in	O
CFI	O
and	O
a	O
non	O
-	O
significant	O
increase	O
in	O
chi	O
square	O
.	O

Therefore	O
,	O
factor	O
loadings	O
can	O
be	O
considered	O
as	O
invariant	O
across	O
sex	O
.	O

In	O
model	O
2sC	O
factor	O
loadings	O
as	O
well	O
as	O
intercepts	O
are	O
constrained	O
to	O
be	O
equal	O
across	O
men	B-OG
and	O
women	B-OG
.	O

This	O
restriction	O
leads	O
to	O
a	O
considerable	O
loss	O
of	O
model	O
fit	O
,	O
which	O
may	O
indicate	O
that	O
men	B-OG
and	O
women	B-OG
interpret	O
questionnaire	O
items	O
in	O
different	O
ways	O
.	O

The	O
same	O
holds	O
true	O
for	O
the	O
model	O
fits	O
constraining	O
factor	O
loadings	O
and	O
intercepts	O
to	O
be	O
equal	O
across	O
the	O
two	O
age	O
groups	O
:	O
a	O
model	O
fit	O
with	O
only	O
factor	O
loadings	O
constrained	O
(	O
2aB	O
)	O
leads	O
to	O
a	O
non	O
-	O
significant	O
increase	O
in	O
chi	O
square	O
.	O

However	O
,	O
when	O
both	O
factor	O
loadings	O
and	O
intercepts	O
are	O
constrained	O
(	O
2aC	O
)	O
a	O
considerable	O
loss	O
of	O
model	O
fit	O
is	O
found	O
.	O

Based	O
on	O
inspection	O
of	O
the	O
modification	O
indices	O
,	O
the	O
following	O
items	O
were	O
identified	O
as	O
contributing	O
to	O
lack	O
of	O
strong	O
invariance	O
across	O
sex	O
:	O
item	O
19	O
(“	O
I	O
do	O
not	O
like	O
people	O
touching	O
me	O
”),	O
item	O
30	O
(“	O
I	O
only	O
allow	O
a	O
few	O
people	O
to	O
touch	O
me	O
”),	O
and	O
item	O
15	O
(“	O
I	O
choose	O
clothing	O
that	O
hides	O
the	O
shape	O
of	O
my	O
body	O
”).	O

In	O
model	O
2sC	O
-	O
3	O
the	O
intercepts	O
of	O
these	O
three	O
items	O
were	O
freely	O
estimated	O
for	O
men	O
and	O
women	O
providing	O
the	O
best	O
model	O
fit	O
for	O
partial	O
strong	O
invariance	O
across	O
sex	O
.	O

On	O
average	O
,	O
men	O
score	O
higher	O
on	O
these	O
items	O
than	O
women	O
(	O
Table	O
2	O
).	O

With	O
regard	O
to	O
age	O
,	O
items	O
15	O
(“	O
I	O
choose	O
clothing	O
that	O
hides	O
the	O
shape	O
of	O
my	O
body	O
”)	O
and	O
28	O
(“	O
If	O
I	O
could	O
change	O
something	O
about	O
my	O
body	O
,	O
I	O
would	O
do	O
it	O
”)	O
were	O
identified	O
as	O
contributing	O
to	O
lack	O
of	O
strong	O
invariance	O
.	O

For	O
item	O
15	O
,	O
the	O
younger	O
age	O
group	O
scores	O
higher	O
on	O
average	O
,	O
whereas	O
for	O
item	O
28	O
,	O
the	O
older	O
age	O
group	O
scores	O
higher	O
.	O

The	O
partial	O
strong	O
invariance	O
model	O
represented	O
in	O
model	O
2aC	O
-	O
2	O
with	O
the	O
intercepts	O
of	O
these	O
two	O
items	O
estimated	O
freely	O
represents	O
the	O
best	O
fit	O
.	O

Fit	O
of	O
the	O
revised	O
model	O

A	O
revised	O
31	O
-	O
item	O
model	O
,	O
from	O
which	O
the	O
4	O
items	O
(	O
items	O
15	O
,	O
19	O
,	O
28	O
,	O
30	O
)	O
primarily	O
responsible	O
for	O
lack	O
of	O
invariance	O
across	O
sex	O
and	O
age	O
were	O
deleted	O
,	O
was	O
evaluated	O
.	O

This	O
model	O
was	O
fit	O
to	O
Sample	O
1	O
and	O
reported	O
as	O
Model	O
3	O
in	O
Table	O
4	O
.	O

Compared	O
to	O
the	O
fit	O
of	O
the	O
full	O
35	O
-	O
item	O
model	O
(	O
Model	O
2	O
),	O
the	O
revised	O
31	O
-	O
item	O
model	O
showed	O
a	O
better	O
fit	O
in	O
all	O
fit	O
measures	O
.	O

Means	O
of	O
the	O
revised	O
subscales	O

Table	O
5	O
presents	O
scores	O
of	O
the	O
DBIQ	O
-	O
NL	O
total	O
scale	O
and	O
subscales	O
for	O
Model	O
2	O
as	O
well	O
as	O
for	O
the	O
revised	O
31	O
-	O
item	O
model	O
,	O
in	O
which	O
the	O
four	O
items	O
contributing	O
most	O
to	O
lack	O
of	O
invariance	O
across	O
sex	O
and	O
age	O
were	O
deleted	O
.	O

Scores	O
on	O
total	O
scale	O
DBIQ	O
-	O
NL	O
and	O
subscales	O
based	O
on	O
Model	O
2	O
,	O
with	O
and	O
without	O
items	O
15	O
,	O
28	O
(	O
subscale	O
body	O
acceptance	O
),	O
19	O
,	O
and	O
30	O
(	O
subscale	O
physical	O
contact	O
).	O

Full	O
sample	O

Women	B-OG

Men	O

age	O
<	O
38	O

age	O
≥	O
38	O

n	O
=	O
761	O

n	O
=	O
433	O

n	O
=	O
326	O

n	O
=	O
540	O

n	O
=	O
221	O

n	O
items	O

(	O
sub	O
)	O
scale	O
(	O
items	O
)	O

Mean	O

SD	O

Mean	O

SD	O

Mean	O

SD	O

d	O

Mean	O

SD	O

Mean	O

SD	O

d	O

35	O

DBIQ	O
-	O
NL	O

3	O
.	O
66	O

0	O
.	O
45	O

3	O
.	O
56	O

0	O
.	O
44	O

3	O
.	O
79	O

0	O
.	O
43	O

0	O
.	O
53	O

3	O
.	O
71	O

0	O
.	O
44	O

3	O
.	O
53	O

0	O
.	O
45	O

0	O
.	O
40	O

31	O

DBIQ	O
-	O
NL	O

3	O
.	O
65	O

0	O
.	O
45	O

3	O
.	O
56	O

0	O
.	O
44	O

3	O
.	O
77	O

0	O
.	O
44	O

0	O
.	O
48	O

3	O
.	O
71	O

0	O
.	O
44	O

3	O
.	O
51	O

0	O
.	O
46	O

0	O
.	O
44	O

8	O

Vitality	O
(	O
2	O
,	O
3	O
,	O
6	O
,	O
8	O
,	O
14	O
,	O
17	O
,	O
26	O
,	O
32	O
)	O

3	O
.	O
87	O

0	O
.	O
58	O

3	O
.	O
76	O

0	O
.	O
58	O

4	O
.	O
02	O

0	O
.	O
55	O

0	O
.	O
46	O

3	O
.	O
91	O

0	O
.	O
55	O

3	O
.	O
78	O

0	O
.	O
66	O

0	O
.	O
21	O

7	O

Body	O
Acc	O
.	O

(	O
7	O
,	O
12	O
,	O
15	O
,	O
18	O
,	O
23	O
,	O
25	O
,	O
28	O
)	O

3	O
.	O
83	O

0	O
.	O
67	O

3	O
.	O
70	O

0	O
.	O
69	O

4	O
.	O
00	O

0	O
.	O
60	O

0	O
.	O
46	O

3	O
.	O
85	O

0	O
.	O
67	O

3	O
.	O
79	O

0	O
.	O
68	O

0	O
.	O
09	O

5	O

Body	O
Acc	O
.	O

(	O
7	O
,	O
12	O
,	O
18	O
,	O
23	O
,	O
25	O
)*	O

3	O
.	O
87	O

0	O
.	O
69	O

3	O
.	O
74	O

0	O
.	O
71	O

4	O
.	O
03	O

0	O
.	O
62	O

0	O
.	O
44	O

3	O
.	O
89	O

0	O
.	O
68	O

3	O
.	O
82	O

0	O
.	O
69	O

0	O
.	O
10	O

8	O

Self	O
-	O
aggr	O
.	O

(	O
1	O
,	O
10	O
,	O
13	O
,	O
20	O
,	O
29	O
,	O
31	O
,	O
33	O
,	O
34	O
)	O

3	O
.	O
12	O

0	O
.	O
55	O

3	O
.	O
06	O

0	O
.	O
56	O

3	O
.	O
19	O

0	O
.	O
56	O

0	O
.	O
23	O

3	O
.	O
23	O

0	O
.	O
53	O

2	O
.	O
86	O

0	O
.	O
52	O

0	O
.	O
70	O

6	O

Phys	O
.	O

Contact	O
(	O
5	O
,	O
11	O
,	O
19	O
,	O
22	O
,	O
24	O
,	O
30	O
)	O

3	O
.	O
80	O

0	O
.	O
60	O

3	O
.	O
76	O

0	O
.	O
61	O

3	O
.	O
86	O

0	O
.	O
59	O

0	O
.	O
17	O

3	O
.	O
84	O

0	O
.	O
59	O

3	O
.	O
71	O

0	O
.	O
62	O

0	O
.	O
21	O

4	O

Phys	O
.	O

Contact	O
(	O
5	O
,	O
11	O
,	O
22	O
,	O
24	O
)*	O

3	O
.	O
85	O

0	O
.	O
61	O

3	O
.	O
87	O

0	O
.	O
60	O

3	O
.	O
81	O

0	O
.	O
60	O

-	O
0	O
.	O
10	O

3	O
.	O
89	O

0	O
.	O
59	O

3	O
.	O
75	O

0	O
.	O
63	O

0	O
.	O
23	O

6	O

Sexual	O
Fulfillment	O
(	O
4	O
,	O
9	O
,	O
16	O
,	O
21	O
,	O
27	O
,	O
35	O
)	O

3	O
.	O
78	O

0	O
.	O
71	O

3	O
.	O
60	O

0	O
.	O
72	O

4	O
.	O
01	O

0	O
.	O
64	O

0	O
.	O
60	O

3	O
.	O
83	O

0	O
.	O
69	O

3	O
.	O
65	O

0	O
.	O
74	O

0	O
.	O
25	O

Note	O
:	O
DBIQ	O
-	O
NL	O
=	O
Dresden	O
Body	O
Image	O
Questionnaire	O
,	O
Dutch	O
translation	O
;	O
Self	O
-	O
aggr	O
.	O
=	O
Self	O
-	O
aggrandizement	O
;	O
Body	O
Acc	O
.	O
=	O
Body	O
Acceptance	O
;	O
Phys	O
.	O

Contact	O
=	O
Physical	O
Contact	O

*	O
Adapted	O
scale	O
with	O
items	O
removed	O
based	O
upon	O
MGCFA	O
outcomes	O
.	O

Total	O
mean	O
scores	O
were	O
hardly	O
influenced	O
by	O
deleting	O
items	O
15	O
,	O
19	O
,	O
28	O
,	O
and	O
30	O
with	O
changes	O
of	O
less	O
than	O
0	O
.	O
02	O
in	O
size	O
.	O

The	O
correlation	O
between	O
the	O
full	O
and	O
reduced	O
scale	O
was	O
.	O
99	O
.	O

Scores	O
on	O
the	O
subscale	O
body	O
acceptance	O
(	O
with	O
items	O
15	O
and	O
28	O
deleted	O
)	O
changed	O
at	O
most	O
0	O
.	O
04	O
points	O
.	O

The	O
correlation	O
between	O
the	O
full	O
and	O
reduced	O
sub	O
-	O
scale	O
was	O
.	O
96	O
.	O

Mean	O
scores	O
for	O
the	O
subscale	O
physical	O
contact	O
increased	O
slightly	O
(.	O
05	O
)	O
for	O
the	O
whole	O
group	O
when	O
items	O
19	O
and	O
30	O
were	O
deleted	O
;	O
the	O
correlation	O
between	O
the	O
original	O
and	O
adapted	O
sub	O
-	O
scale	O
was	O
.	O
92	O
;	O
Mean	O
scores	O
were	O
.	O
11	O
higher	O
for	O
women	B-OG
and	O
showed	O
a	O
decrease	O
of	O
.	O
05	O
for	O
men	B-OG
.	O

Mean	O
differences	O
on	O
the	O
subscales	O
between	O
age	O
groups	O
and	O
between	O
women	O
and	O
men	O
were	O
small	O
to	O
medium	O
(	O
Cohen	O
’	O
s	O
d	O
<.	O

0	O
.	O
50	O
),	O
with	O
the	O
exception	O
of	O
medium	O
differences	O
between	O
women	O
and	O
men	O
on	O
the	O
subscale	O
sexual	O
fulfillment	O
(	O
d	O
=	O
0	O
.	O
60	O
)	O
and	O
between	O
the	O
younger	O
and	O
older	O
age	O
group	O
on	O
the	O
subscale	O
self	O
-	O
aggrandizement	O
(	O
d	O
=	O
0	O
.	O
70	O
).	O

Differences	O
were	O
in	O
the	O
same	O
direction	O
,	O
with	O
men	O
scoring	O
higher	O
than	O
women	O
and	O
the	O
younger	O
age	O
group	O
scoring	O
higher	O
than	O
the	O
older	O
age	O
group	O
.	O

The	O
only	O
exception	O
were	O
men	O
scoring	O
slightly	O
lower	O
than	O
women	O
on	O
the	O
reduced	O
physical	O
contact	O
subscale	O
(	O
d	O
=	O
0	O
.	O
10	O
).	O

For	O
standardized	O
factor	O
loadings	O
of	O
the	O
full	O
and	O
reduced	O
item	O
sub	O
-	O
scales	O
see	O
S3	O
Table	O
.	O

Discussion	O

Structure	O
of	O
the	O
(	O
sub	O
)	O
scales	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
psychometric	O
properties	O
of	O
the	O
DBIQ	O
in	O
a	O
non	O
-	O
clinical	O
Dutch	O
sample	O
.	O

Moreover	O
,	O
the	O
work	O
done	O
by	O
the	O
developers	O
of	O
the	O
original	O
scale	O
[	O
26	O
,	O
27	O
]	O
was	O
extended	O
by	O
evaluating	O
the	O
equivalence	O
of	O
the	O
measurement	O
model	O
across	O
sex	O
and	O
age	O
.	O

For	O
our	O
evaluation	O
of	O
the	O
psychometric	O
properties	O
we	O
used	O
a	O
large	O
convenience	O
sample	O
with	O
a	O
gender	O
and	O
age	O
distribution	O
deviating	O
from	O
the	O
Dutch	O
general	O
population	O
.	O

Whereas	O
the	O
investigation	O
of	O
age	O
invariance	O
of	O
the	O
DBIQ	O
was	O
in	O
fact	O
facilitated	O
by	O
the	O
bimodal	O
age	O
distribution	O
,	O
the	O
sample	O
does	O
not	O
provide	O
information	O
on	O
the	O
distribution	O
of	O
DBIQ	O
scores	O
across	O
the	O
general	O
population	O
(	O
e	O
.	O
g	O
.	O
with	O
the	O
purpose	O
of	O
computing	O
norm	O
scores	O
).	O

Confirmatory	O
Factor	O
Analysis	O
based	O
on	O
the	O
five	O
-	O
factor	O
structure	O
of	O
the	O
original	O
German	O
questionnaire	O
,	O
showed	O
adequate	O
fit	O
in	O
the	O
translated	O
version	O
for	O
RMSEA	O
and	O
SRMR	O
,	O
but	O
mediocre	O
fit	O
for	O
CFI	O
and	O
TLI	O
[	O
69	O
].	O

Adaptation	O
of	O
the	O
model	O
based	O
on	O
inspection	O
of	O
the	O
modification	O
indices	O
led	O
to	O
improvement	O
of	O
model	O
fit	O
.	O

In	O
this	O
adaptation	O
,	O
the	O
item	O
“	O
I	O
like	O
showing	O
my	O
body	O
”	O
was	O
moved	O
from	O
the	O
subscale	O
body	O
acceptance	O
to	O
the	O
subscale	O
self	O
-	O
aggrandizement	O
.	O

This	O
is	O
in	O
line	O
with	O
the	O
results	O
of	O
the	O
principal	O
component	O
analysis	O
by	O
Probst	O
et	O
al	O
.	O
[	O
34	O
],	O
which	O
revealed	O
higher	O
loadings	O
on	O
the	O
subscale	O
self	O
-	O
aggrandizement	O
for	O
the	O
item	O
“	O
I	O
like	O
showing	O
my	O
body	O
”	O
than	O
on	O
the	O
original	O
subscale	O
.	O

Even	O
though	O
German	O
and	O
Dutch	O
are	O
closely	O
related	O
languages	O
,	O
a	O
slight	O
semantic	O
difference	O
may	O
have	O
occurred	O
,	O
suggesting	O
that	O
the	O
Dutch	O
translation	O
emphasizes	O
the	O
pleasure	O
of	O
showing	O
one	O
’	O
s	O
body	O
,	O
whereas	O
the	O
original	O
item	O
was	O
meant	O
to	O
measure	O
body	O
acceptance	O
.	O

A	O
semantic	O
explanation	O
is	O
more	O
plausible	O
than	O
a	O
cultural	O
difference	O
in	O
the	O
interpretation	O
of	O
this	O
item	O
.	O

Based	O
on	O
the	O
fit	O
indices	O
and	O
considering	O
that	O
reallocating	O
one	O
item	O
is	O
an	O
acceptable	O
model	O
change	O
when	O
an	O
instrument	O
is	O
used	O
in	O
a	O
different	O
cultural	O
setting	O
or	O
language	O
[	O
61	O
],	O
the	O
adapted	O
model	O
was	O
used	O
for	O
further	O
evaluations	O
.	O

After	O
comparing	O
the	O
quality	O
of	O
the	O
goodness	O
of	O
fit	O
indices	O
,	O
as	O
recommended	O
by	O
[	O
79	O
],	O
with	O
findings	O
from	O
previous	O
research	O
based	O
on	O
the	O
German	O
inventory	O
,	O
we	O
judge	O
the	O
psychometric	O
properties	O
of	O
the	O
DBIQ	O
-	O
NL	O
as	O
sufficient	O
to	O
warrant	O
further	O
research	O
on	O
the	O
scale	O
and	O
its	O
properties	O
,	O
in	O
a	O
Dutch	O
clinical	O
population	O
.	O

While	O
being	O
aware	O
of	O
new	O
developments	O
in	O
scale	O
analysis	O
by	O
Exploratory	O
Structural	O
Equation	O
Modeling	O
to	O
remedy	O
the	O
overly	O
strict	O
CFA	O
requirements	O
[	O
68	O
,	O
80	O
],	O
we	O
refrained	O
from	O
applying	O
this	O
method	O
in	O
order	O
to	O
obtain	O
a	O
close	O
comparison	O
between	O
the	O
DBIQ	O
-	O
NL	O
and	O
the	O
original	O
DBIQ	O
by	O
following	O
a	O
similar	O
evaluation	O
procedure	O
.	O

Based	O
on	O
[	O
67	O
,	O
79	O
],	O
it	O
was	O
to	O
be	O
expected	O
that	O
the	O
DBIQ	O
-	O
NL	O
would	O
show	O
a	O
reduced	O
goodness	O
of	O
fit	O
compared	O
to	O
the	O
original	O
scale	O
,	O
in	O
which	O
the	O
reported	O
CFI	O
only	O
just	O
met	O
the	O
often	O
used	O
threshold	O
of	O
0	O
.	O
90	O
.	O

A	O
multiple	O
-	O
group	O
confirmatory	O
factor	O
analysis	O
showed	O
configural	O
invariance	O
.	O

The	O
equal	O
item	O
intercepts	O
hypothesis	O
,	O
implying	O
factorial	O
invariance	O
,	O
however	O
,	O
was	O
not	O
supported	O
for	O
all	O
subscales	O
across	O
sex	O
and	O
age	O
.	O

When	O
testing	O
partial	O
factorial	O
invariance	O
,	O
four	O
items	O
were	O
identified	O
that	O
contributed	O
to	O
the	O
lack	O
of	O
strong	O
invariance	O
across	O
sex	O
(	O
item	O
19	O
,	O
30	O
)	O
or	O
age	O
(	O
item	O
28	O
)	O
or	O
across	O
both	O
groups	O
(	O
item	O
15	O
)	O
indicating	O
that	O
interpretation	O
of	O
the	O
meaning	O
of	O
these	O
items	O
and	O
therefore	O
the	O
item	O
scores	O
might	O
depend	O
on	O
group	O
membership	O
.	O

Replication	O
of	O
the	O
procedure	O
by	O
fitting	O
a	O
final	O
model	O
in	O
sample	O
1	O
without	O
these	O
items	O
supported	O
the	O
best	O
,	O
although	O
moderate	O
,	O
fit	O
of	O
this	O
31	O
-	O
item	O
scale	O
.	O

Next	O
to	O
the	O
technical	O
identification	O
of	O
these	O
differing	O
items	O
,	O
there	O
are	O
arguments	O
from	O
a	O
qualitative	O
perspective	O
as	O
to	O
why	O
these	O
items	O
differ	O
across	O
groups	O
.	O

Some	O
items	O
suggest	O
interesting	O
patterns	O
.	O

In	O
items	O
19	O
and	O
30	O
,	O
differing	O
across	O
sex	O
,	O
being	O
touched	O
by	O
others	O
is	O
the	O
central	O
issue	O
.	O

These	O
items	O
may	O
be	O
interpreted	O
differently	O
by	O
men	B-OG
and	O
women	B-OG
since	O
the	O
latter	O
are	O
more	O
often	O
the	O
object	O
of	O
undesired	O
physical	O
contact	O
.	O

Invariance	O
across	O
sex	O
in	O
item	O
15	O
(“	O
I	O
choose	O
clothing	O
that	O
hides	O
the	O
shape	O
of	O
my	O
body	O
”)	O
could	O
be	O
explained	O
by	O
the	O
fact	O
that	O
for	O
men	B-OG
,	O
in	O
contrast	O
to	O
women	B-OG
,	O
clothing	O
is	O
not	O
a	O
well	O
-	O
known	O
strategy	O
to	O
camouflage	O
less	O
accepted	O
parts	O
of	O
the	O
body	O
[	O
81	O
].	O

The	O
differences	O
across	O
age	O
for	O
this	O
item	O
might	O
be	O
indicative	O
for	O
age	O
-	O
or	O
cohort	O
-	O
related	O
cultural	O
differences	O
with	O
regard	O
to	O
showing	O
the	O
body	O
.	O

Item	O
28	O
(“	O
If	O
I	O
could	O
change	O
something	O
about	O
my	O
body	O
,	O
I	O
would	O
do	O
it	O
”)	O
might	O
mean	O
something	O
different	O
for	O
the	O
older	O
age	O
group	O
,	O
in	O
light	O
of	O
physical	O
impairments	O
or	O
other	O
confrontations	O
with	O
unwelcome	O
bodily	O
changes	O
.	O

Millsap	O
and	O
Kwok	O
[	O
78	O
]	O
describe	O
the	O
option	O
of	O
using	O
a	O
shortened	O
version	O
of	O
the	O
scale	O
that	O
omits	O
the	O
items	O
that	O
performed	O
differently	O
across	O
groups	O
,	O
at	O
the	O
same	O
time	O
warning	O
that	O
this	O
option	O
results	O
in	O
as	O
many	O
versions	O
of	O
the	O
scale	O
as	O
there	O
are	O
invariance	O
studies	O
.	O

A	O
second	O
option	O
is	O
to	O
retain	O
all	O
items	O
when	O
the	O
net	O
impact	O
of	O
the	O
differences	O
on	O
the	O
total	O
score	O
is	O
small	O
[	O
78	O
].	O

This	O
is	O
indeed	O
the	O
case	O
in	O
the	O
present	O
non	O
-	O
clinical	O
sample	O
.	O

Also	O
due	O
to	O
the	O
limited	O
number	O
of	O
affected	O
items	O
,	O
partial	O
invariance	O
only	O
slightly	O
affects	O
the	O
differences	O
between	O
sex	O
and	O
age	O
groups	O
in	O
mean	O
total	O
scores	O
on	O
the	O
DBIQ	O
-	O
NL	O
and	O
subscales	O
.	O

Therefore	O
,	O
adaptations	O
need	O
not	O
be	O
made	O
when	O
the	O
scale	O
is	O
used	O
to	O
gain	O
global	O
information	O
on	O
body	O
image	O
in	O
non	O
-	O
clinical	O
groups	O
.	O

However	O
,	O
when	O
the	O
focus	O
is	O
on	O
gathering	O
information	O
with	O
respect	O
to	O
differences	O
on	O
the	O
issue	O
of	O
physical	O
contact	O
across	O
the	O
sexes	O
or	O
on	O
the	O
theme	O
of	O
body	O
acceptance	O
among	O
different	O
age	O
groups	O
,	O
a	O
score	O
without	O
the	O
items	O
violating	O
invariance	O
could	O
be	O
relevant	O
.	O

Reliability	O
and	O
validity	O

The	O
DBIQ	O
-	O
NL	O
and	O
its	O
five	O
subscales	O
showed	O
adequate	O
internal	O
consistency	O
.	O

Test	O
-	O
retest	O
reliability	O
was	O
also	O
adequate	O
,	O
although	O
based	O
on	O
a	O
rather	O
small	O
sample	O
.	O

Good	O
construct	O
validity	O
was	O
found	O
with	O
moderate	O
associations	O
with	O
body	O
satisfaction	O
(	O
BCS	O
)	O
as	O
expected	O
since	O
the	O
DBIQ	O
aims	O
to	O
measure	O
a	O
broad	O
concept	O
of	O
body	O
image	O
whereas	O
in	O
the	O
BCS	O
appearance	O
-	O
related	O
issues	O
are	O
prominent	O
.	O

The	O
higher	O
correlations	O
between	O
total	O
score	O
on	O
the	O
DBIQ	O
and	O
body	O
satisfaction	O
(	O
BCS	O
)	O
for	O
men	B-OG
than	O
for	O
women	B-OG
can	O
possibly	O
be	O
explained	O
by	O
this	O
difference	O
since	O
earlier	O
studies	O
found	O
that	O
women	B-OG
are	O
likely	O
to	O
give	O
a	O
greater	O
emphasis	O
than	O
men	B-OG
to	O
appearance	O
as	O
part	O
of	O
the	O
concept	O
body	O
image	O
[	O
30	O
,	O
82	O
].	O

The	O
moderate	O
associations	O
between	O
the	O
DBIQ	O
-	O
NL	O
and	O
the	O
OQ	O
-	O
45	O
and	O
RSES	O
confirm	O
the	O
relation	O
between	O
body	O
image	O
,	O
psychosocial	O
well	O
-	O
being	O
and	O
self	O
-	O
esteem	O
and	O
its	O
importance	O
when	O
assessing	O
non	O
-	O
clinical	O
samples	O
[	O
5	O
,	O
6	O
].	O

Correlations	O
between	O
the	O
subscales	O
were	O
relatively	O
small	O
,	O
providing	O
support	O
for	O
the	O
multidimensionality	O
of	O
the	O
instrument	O
.	O

Validation	O
of	O
the	O
subscales	O
for	O
physical	O
contact	O
and	O
vitality	O
by	O
correlating	O
these	O
with	O
other	O
indices	O
showed	O
good	O
construct	O
validity	O
.	O

Implications	O
for	O
the	O
use	O
of	O
the	O
DBIQ	O
-	O
NL	O
and	O
further	O
research	O

The	O
present	O
study	O
on	O
the	O
psychometric	O
properties	O
of	O
the	O
DBIQ	O
in	O
a	O
Dutch	O
non	O
-	O
clinical	O
sample	O
shows	O
a	O
factor	O
structure	O
and	O
model	O
fit	O
that	O
are	O
satisfactory	O
and	O
motivate	O
further	O
study	O
.	O

In	O
view	O
of	O
our	O
aim	O
to	O
make	O
an	O
instrument	O
available	O
in	O
Dutch	O
language	O
measuring	O
body	O
image	O
as	O
a	O
multifaceted	O
construct	O
in	O
a	O
non	O
-	O
clinical	O
as	O
well	O
as	O
in	O
a	O
clinical	O
population	O
,	O
future	O
research	O
will	O
have	O
to	O
address	O
a	O
variety	O
of	O
clinical	O
samples	O
.	O

These	O
further	O
evaluations	O
should	O
also	O
pay	O
attention	O
to	O
measurement	O
invariance	O
across	O
sex	O
and	O
age	O
.	O

Another	O
issue	O
of	O
importance	O
in	O
clinical	O
samples	O
is	O
the	O
intimate	O
and	O
for	O
a	O
substantial	O
group	O
of	O
patients	O
possibly	O
trauma	O
related	O
nature	O
of	O
the	O
subscale	O
sexual	O
fulfillment	O
.	O

Applicability	O
of	O
this	O
subscale	O
still	O
needs	O
to	O
be	O
evaluated	O
.	O

On	O
the	O
other	O
hand	O
,	O
because	O
both	O
clinicians	O
and	O
patients	O
seem	O
to	O
be	O
reluctant	O
to	O
discuss	O
issues	O
concerning	O
sexuality	O
,	O
a	O
reluctance	O
that	O
may	O
also	O
be	O
related	O
to	O
cultural	O
or	O
religious	O
background	O
,	O
addressing	O
sexuality	O
in	O
a	O
self	O
-	O
report	O
questionnaire	O
may	O
also	O
make	O
it	O
easier	O
for	O
both	O
client	O
and	O
therapist	O
to	O
pay	O
attention	O
to	O
this	O
relevant	O
theme	O
[	O
28	O
].	O

A	O
recent	O
study	O
using	O
the	O
DBIQ	O
-	O
NL	O
in	O
a	O
broad	O
clinical	O
sample	O
including	O
mood	B-DS
disorders	I-DS
,	O
anxiety	B-DS
disorders	I-DS
,	O
adjustment	B-DS
disorder	I-DS
,	O
post	B-DS
-	I-DS
traumatic	I-DS
stress	I-DS
disorder	I-DS
,	O
eating	B-DS
disorders	I-DS
,	O
schizophrenia	B-DS
and	O
other	O
psychotic	B-DS
disorders	I-DS
[	O
83	O
]	O
gave	O
a	O
first	O
indication	O
of	O
the	O
clinical	O
usefulness	O
of	O
the	O
scale	O
.	O

The	O
study	O
suggests	O
that	O
body	O
image	O
is	O
a	O
common	O
problem	O
occurring	O
in	O
most	O
patients	O
with	O
mental	B-DS
disorders	I-DS
.	O

Body	O
acceptance	O
and	O
sexual	O
fulfillment	O
were	O
the	O
most	O
differentiating	O
aspects	O
of	O
body	O
image	O
between	O
diagnoses	O
.	O

Surprisingly	O
,	O
vitality	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
various	O
disorders	O
.	O

It	O
may	O
be	O
concluded	O
that	O
the	O
DBIQ	O
has	O
potential	O
surplus	O
value	O
in	O
the	O
field	O
of	O
body	O
image	O
since	O
it	O
covers	O
a	O
broad	O
range	O
of	O
body	O
image	O
dimensions	O
and	O
includes	O
important	O
dimensions	O
such	O
as	O
touch	O
and	O
sexuality	O
that	O
are	O
not	O
well	O
represented	O
in	O
other	O
measures	O
of	O
body	O
image	O
.	O

Supporting	O
information	O

Distribution	O
of	O
age	O
in	O
the	O
two	O
samples	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Dresden	O
Body	O
Image	O
Questionnaire	O
(	O
DBIQ	O
),	O
Dutch	O
version	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

DBIQ	O
-	O
NL	O
:	O
Item	O
means	O
and	O
standard	O
deviations	O
sample	O
1	O
;	O
item	O
means	O
and	O
standard	O
deviations	O
per	O
sex	O
and	O
age	O
group	O
sample	O
1	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Standardized	O
factor	O
loadings	O
full	O
and	O
reduced	O
item	O
sub	O
-	O
scales	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Sample	O
1	O
.	O

(	O
SAV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Sample	O
2	O
.	O

(	O
SAV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

CD4	B-GP
+	O
T	O
Cells	O
Expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
Contribute	O
to	O
HIV	B-OG
Persistence	O
during	O
ART	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RF	O
SGD	O
SRL	O
RPS	O
NC	O
.	O

Performed	O
the	O
experiments	O
:	O
RF	O
WB	O
MBL	O
GK	O
SD	O
MK	O
.	O

Analyzed	O
the	O
data	O
:	O
RF	O
WH	O
PB	O
MK	O
LE	O
RH	O
ES	O
FMH	O
.	O

Wrote	O
the	O
paper	O
:	O
RF	O
PB	O
SGD	O
SRL	O
RPS	O
NC	O
.	O

Exhaustion	O
of	O
Activated	O
CD8	B-GP
T	O
cells	O
Predicts	O
Disease	O
Progression	O
in	O
Primary	O
HIV	B-DS
-	I-DS
1	I-DS
Infection	I-DS

HIV	B-OG
persists	O
in	O
a	O
small	O
pool	O
of	O
latently	O
infected	O
cells	O
despite	O
antiretroviral	O
therapy	O
(	O
ART	O
).	O

Identifying	O
cellular	O
markers	O
expressed	O
at	O
the	O
surface	O
of	O
these	O
cells	O
may	O
lead	O
to	O
novel	O
therapeutic	O
strategies	O
to	O
reduce	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
.	O

We	O
hypothesized	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
immune	O
checkpoint	O
molecules	O
would	O
be	O
enriched	O
in	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
.	O

Expression	O
levels	O
of	O
7	O
immune	B-GP
checkpoint	I-GP
molecules	I-GP
(	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	O
)	O
as	O
well	O
as	O
4	O
markers	O
of	O
HIV	B-OG
persistence	O
(	O
integrated	O
and	O
total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
and	O
cell	O
-	O
associated	O
unspliced	O
HIV	B-OG
RNA	O
)	O
were	O
measured	O
in	O
PBMCs	O
from	O
48	O
virally	O
suppressed	O
individuals	O
.	O

Using	O
negative	O
binomial	O
regression	O
models	O
,	O
we	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
immune	O
checkpoint	O
molecules	O
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
independently	O
predicted	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

Quantification	O
of	O
HIV	B-OG
genomes	O
in	O
highly	O
purified	O
cell	O
subsets	O
from	O
blood	O
further	O
revealed	O
that	O
expressions	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
associated	O
with	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
cell	O
subsets	O
.	O

CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
the	O
three	O
markers	O
were	O
highly	O
enriched	O
for	O
integrated	O
viral	O
genomes	O
(	O
median	O
of	O
8	O
.	O
2	O
fold	O
compared	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
).	O

Importantly	O
,	O
most	O
cells	O
carrying	O
inducible	O
HIV	B-OG
genomes	O
expressed	O
at	O
least	O
one	O
of	O
these	O
markers	O
(	O
median	O
contribution	O
of	O
cells	O
expressing	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
PD	B-GP
-	I-GP
1	I-GP
or	O
TIGIT	B-GP
to	O
the	O
inducible	O
reservoir	O
=	O
76	O
%).	O

Our	O
data	O
provide	O
evidence	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
alone	O
or	O
in	O
combination	O
are	O
enriched	O
for	O
persistent	O
HIV	B-OG
during	O
ART	O
and	O
suggest	O
that	O
immune	O
checkpoint	O
blockers	O
directed	O
against	O
these	O
receptors	O
may	O
represent	O
valuable	O
tools	O
to	O
target	O
latently	O
infected	O
cells	O
in	O
virally	O
suppressed	O
individuals	O
.	O

Author	O
Summary	O

The	O
persistence	O
of	O
HIV	B-OG
in	O
a	O
small	O
pool	O
of	O
long	O
-	O
lived	O
latently	O
infected	O
resting	O
CD4	B-GP
+	O
T	O
cells	O
is	O
a	O
major	O
barrier	O
to	O
viral	O
eradication	O
.	O

Identifying	O
cellular	O
markers	O
that	O
are	O
preferentially	O
expressed	O
at	O
the	O
surface	O
of	O
latently	O
infected	O
cells	O
may	O
lead	O
to	O
novel	O
therapeutic	O
strategies	O
to	O
cure	O
HIV	B-DS
infection	I-DS
.	O

We	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
markers	O
preferentially	O
expressed	O
at	O
the	O
surface	O
of	O
infected	O
cells	O
in	O
individuals	O
receiving	O
ART	O
.	O

CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
these	O
markers	O
were	O
highly	O
enriched	O
for	O
cells	O
carrying	O
HIV	B-OG
.	O

Our	O
results	O
suggest	O
that	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
may	O
represent	O
new	O
molecular	O
targets	O
to	O
interfere	O
with	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

Introduction	O

Although	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
is	O
highly	O
effective	O
at	O
suppressing	O
HIV	B-OG
replication	O
,	O
viral	O
reservoirs	O
persist	O
despite	O
treatment	O
and	O
lead	O
to	O
rapid	O
viral	O
rebound	O
when	O
ART	O
is	O
interrupted	O
[	O
1	O
–	O
4	O
].	O

A	O
major	O
step	O
to	O
achieve	O
natural	O
control	O
of	O
HIV	B-OG
replication	O
after	O
ART	O
cessation	O
would	O
be	O
to	O
eliminate	O
,	O
or	O
at	O
least	O
reduce	O
,	O
the	O
number	O
of	O
long	O
-	O
lived	O
infected	O
cells	O
from	O
which	O
HIV	B-OG
reignite	O
infection	B-DS
.	O

The	O
characterization	O
of	O
cell	O
surface	O
markers	O
that	O
could	O
identify	O
HIV	B-OG
-	O
infected	O
cells	O
persisting	O
during	O
ART	O
is	O
a	O
research	O
priority	O
towards	O
an	O
HIV	B-OG
cure	O
[	O
5	O
]	O
as	O
it	O
could	O
lead	O
to	O
the	O
development	O
of	O
novel	O
eradication	O
strategies	O
.	O

Several	O
subsets	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harbor	O
replication	O
-	O
competent	O
HIV	B-OG
during	O
ART	O
.	O

These	O
CD4	B-GP
+	O
T	O
cells	O
are	O
usually	O
defined	O
on	O
the	O
basis	O
of	O
their	O
differentiation	O
stage	O
[	O
6	O
–	O
8	O
],	O
functionality	O
or	O
homing	O
potential	O
[	O
9	O
,	O
10	O
].	O

Central	O
memory	O
(	O
TCM	O
)	O
and	O
transitional	O
memory	O
(	O
TTM	O
)	O
CD4	B-GP
+	O
T	O
cells	O
were	O
identified	O
as	O
the	O
major	O
cellular	O
reservoirs	O
for	O
HIV	B-OG
during	O
ART	O
[	O
6	O
].	O

More	O
recently	O
,	O
a	O
less	O
differentiated	O
subset	O
of	O
long	O
-	O
lived	O
cells	O
with	O
high	O
self	O
-	O
renewal	O
capacity	O
,	O
the	O
stem	O
-	O
cell	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
TSCM	O
),	O
has	O
been	O
identified	O
as	O
a	O
main	O
contributor	O
to	O
long	O
-	O
term	O
HIV	B-OG
persistence	O
[	O
7	O
,	O
8	O
].	O

The	O
functional	O
and	O
homing	O
capacities	O
of	O
CD4	B-GP
+	O
T	O
cells	O
also	O
dictate	O
their	O
capacity	O
to	O
serve	O
as	O
persistent	O
reservoirs	O
for	O
HIV	B-OG
:	O
Th17	O
and	O
Th1	O
/	O
Th17	O
CD4	B-GP
+	O
T	O
cells	O
as	O
well	O
as	O
cells	O
expressing	O
CCR6	B-GP
and	O
CXCR3	B-GP
show	O
increasing	O
contribution	O
to	O
the	O
viral	O
reservoir	O
with	O
duration	O
of	O
ART	O
[	O
11	O
,	O
12	O
].	O

Immune	O
checkpoint	O
molecules	O
(	O
ICs	O
)	O
are	O
co	O
-	O
inhibitory	O
receptors	O
which	O
down	O
-	O
modulate	O
immune	O
responses	O
to	O
prevent	O
hyper	O
-	O
immune	O
activation	O
,	O
minimize	O
collateral	O
damage	O
,	O
and	O
maintain	O
peripheral	O
self	O
-	O
tolerance	O
[	O
13	O
].	O

ICs	O
are	O
up	O
regulated	O
upon	O
T	O
-	O
cell	O
activation	O
and	O
constrain	O
the	O
effector	O
response	O
through	O
feedback	O
inhibition	O
.	O

Overexpression	O
of	O
these	O
molecules	O
is	O
associated	O
with	O
T	O
-	O
cell	O
exhaustion	O
and	O
dysfunction	O
in	O
cancer	B-DS
and	O
chronic	B-DS
viral	I-DS
infections	I-DS
,	O
including	O
HIV	B-OG
[	O
14	O
–	O
17	O
].	O

We	O
hypothesized	O
that	O
ICs	O
,	O
through	O
their	O
ability	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
,	O
will	O
favour	O
HIV	B-OG
latency	O
during	O
ART	O
,	O
and	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	O
would	O
be	O
enriched	O
for	O
persistent	O
HIV	B-OG
in	O
individuals	O
receiving	O
ART	O
.	O

We	O
focused	O
our	O
analysis	O
on	O
7	O
ICs	O
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
(	O
programmed	B-GP
cell	I-GP
death	I-GP
-	I-GP
1	I-GP
),	O
CTLA	B-GP
-	I-GP
4	I-GP
(	O
cytotoxic	B-GP
T	I-GP
-	I-GP
lymphocyte	I-GP
-	I-GP
associated	I-GP
protein	I-GP
4	I-GP
),	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
lymphocyte	B-GP
activation	I-GP
gene	I-GP
3	I-GP
),	O
TIGIT	B-GP
(	O
T	B-GP
-	I-GP
cell	I-GP
immunoglobulin	I-GP
and	O
ITIM	O
domain	O
),	O
TIM	B-GP
-	I-GP
3	I-GP
(	O
T	B-GP
cell	I-GP
immunoglobulin	I-GP
and	O
mucin	B-GP
3	I-GP
),	O
CD160	B-GP
and	O
2B4	O
(	O
CD244	B-GP
).	O

PD	B-GP
-	I-GP
1	I-GP
,	O
a	O
member	O
of	O
the	O
B7	B-GP
-	O
CD28	B-GP
superfamily	O
,	O
enforces	O
an	O
inhibitory	O
program	O
that	O
blocks	O
further	O
TCR	B-GP
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
and	O
cytokine	B-GP
production	O
[	O
18	O
,	O
19	O
].	O

In	O
HIV	B-DS
infection	I-DS
,	O
high	O
levels	O
of	O
PD	B-GP
-	I-GP
1	I-GP
are	O
associated	O
with	O
T	O
cell	O
exhaustion	O
[	O
14	O
–	O
16	O
,	O
20	O
]	O
and	O
incomplete	O
immunological	O
response	O
to	O
ART	O
[	O
21	O
].	O

CTLA	B-GP
-	I-GP
4	I-GP
,	O
a	O
CD28	B-GP
homolog	O
,	O
regulates	O
the	O
amplitude	O
of	O
T	O
-	O
cell	O
activation	O
by	O
both	O
outcompeting	O
CD28	B-GP
in	O
binding	O
CD80	B-GP
and	O
CD86	B-GP
,	O
as	O
well	O
as	O
actively	O
delivering	O
inhibitory	O
signals	O
to	O
T	O
cells	O
[	O
13	O
].	O

TIGIT	B-GP
,	O
which	O
also	O
belongs	O
to	O
the	O
B7	B-GP
/	O
CD28	B-GP
superfamily	O
,	O
acts	O
as	O
a	O
co	O
-	O
inhibitory	O
molecule	O
by	O
directly	O
down	O
regulating	O
proliferation	O
of	O
human	B-OG
T	O
cells	O
[	O
22	O
],	O
but	O
also	O
by	O
modulating	O
cytokine	B-GP
secretion	O
of	O
DCs	O
,	O
decreasing	O
IL	B-GP
-	I-GP
12	I-GP
and	O
enhancing	O
IL	B-GP
-	I-GP
10	I-GP
productions	O
[	O
23	O
].	O

TIGIT	B-GP
has	O
been	O
recently	O
associated	O
with	O
CD8	B-GP
+	O
T	O
-	O
cell	O
dysfunction	O
during	O
HIV	B-DS
infection	I-DS
[	O
24	O
].	O

The	O
expression	O
of	O
2B4	B-GP
(	O
CD244	B-GP
),	O
a	O
member	O
of	O
the	O
signalling	B-GP
lymphocyte	B-GP
activation	I-GP
molecule	I-GP
(	O
SLAM	B-GP
)	O
is	O
also	O
modulated	O
on	O
T	O
cells	O
during	O
HIV	B-DS
infection	I-DS
[	O
17	O
,	O
25	O
].	O

LAG	B-GP
-	I-GP
3	I-GP
,	O
a	O
member	O
of	O
the	O
immunoglobulin	B-GP
superfamily	O
,	O
is	O
structurally	O
highly	O
homologous	O
to	O
the	O
CD4	B-GP
receptor	I-GP
and	O
share	O
MHC	B-GP
-	I-GP
II	I-GP
as	O
a	O
ligand	O
[	O
26	O
].	O

Its	O
expression	O
on	O
T	O
regulatory	O
cells	O
plays	O
a	O
role	O
in	O
the	O
modulation	O
of	O
T	O
cell	O
homeostasis	O
and	O
effector	O
T	O
cell	O
responses	O
[	O
27	O
,	O
28	O
].	O

TIM	B-GP
-	I-GP
3	I-GP
is	O
also	O
an	O
immunoglobulin	B-GP
superfamily	O
member	O
and	O
its	O
expression	O
is	O
increased	O
on	O
HIV	B-OG
-	O
specific	O
CD8	B-GP
+	O
and	O
CD4	B-GP
+	O
T	O
cells	O
[	O
29	O
,	O
30	O
].	O

Finally	O
,	O
CD160	B-GP
,	O
through	O
its	O
binding	O
to	O
its	O
ligand	O
Herpes	B-OG
Virus	B-GP
Entry	I-GP
Mediator	I-GP
(	O
HVEM	B-GP
),	O
an	O
atypical	O
member	O
of	O
TNF	B-GP
-	I-GP
receptor	I-GP
superfamily	O
,	O
delivers	O
a	O
co	O
-	O
inhibitory	O
signalling	O
to	O
CD4	B-GP
+	O
T	O
cells	O
or	O
CD8	B-GP
+	O
T	O
cells	O
dampening	O
their	O
activation	O
in	O
HIV	B-OG
-	O
infected	O
individuals	O
[	O
31	O
,	O
32	O
].	O

To	O
assess	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
these	O
ICs	O
and	O
HIV	B-OG
persistence	O
,	O
we	O
analysed	O
the	O
association	O
between	O
their	O
levels	O
of	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
in	O
individuals	O
receiving	O
ART	O
for	O
at	O
least	O
3	O
years	O
.	O

Materials	O
and	O
Methods	O

Study	O
participants	O

Forty	O
-	O
eight	O
HIV	B-OG
-	O
infected	O
participants	O
receiving	O
suppressive	O
ART	O
were	O
recruited	O
at	O
the	O
University	O
of	O
California	O
San	O
Francisco	O
(	O
UCSF	O
)	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
.	O

Participants	O
were	O
receiving	O
ART	O
for	O
>	O
3	O
years	O
,	O
had	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
>	O
350	O
cells	O
/	O
μl	O
and	O
HIV	B-OG
RNA	O
<	O
40	O
copies	O
/	O
mL	O
as	O
measured	O
by	O
the	O
Abbott	O
real	O
time	O
HIV	B-OG
-	I-OG
1	I-OG
PCR	O
for	O
at	O
least	O
3	O
years	O
.	O

Whole	O
blood	O
(	O
50mL	O
)	O
was	O
collected	O
by	O
regular	O
blood	O
draw	O
.	O

For	O
cell	O
sorting	O
experiments	O
,	O
27	O
HIV	B-OG
-	O
infected	O
individuals	O
were	O
enrolled	O
at	O
UCSF	O
and	O
at	O
VGTIFL	O
and	O
underwent	O
leukapheresis	O
.	O

Ethics	O
statement	O

All	O
subjects	O
signed	O
informed	O
consent	O
forms	O
approved	O
by	O
the	O
UCSF	O
and	O
Martin	O
Memorial	O
Health	O
Systems	O
review	O
boards	O
(	O
IRB	O
#	O
10	O
–	O
1320	O
,	O
Ref	O
#	O
068192	O
and	O
FWA	O
#	O
00004139	O
,	O
respectively	O
).	O

Immunophenotyping	O

PBMCs	O
were	O
isolated	O
from	O
peripheral	O
blood	O
and	O
leukapheresis	O
using	O
previously	O
described	O
methods	O
[	O
6	O
,	O
33	O
].	O

Cryopreserved	O
PBMCs	O
were	O
thawed	O
,	O
washed	O
and	O
stained	O
for	O
phenotyping	O
or	O
cell	O
sorting	O
.	O

Two	O
antibody	B-GP
panels	O
were	O
used	O
to	O
measure	O
the	O
expression	O
of	O
IC	O
in	O
subsets	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
.	O

The	O
same	O
antibody	B-GP
backbone	O
was	O
used	O
in	O
the	O
two	O
panels	O
:	O
CD3	B-GP
-	O
Alexa700	O
(	O
clone	O
UCHT1	O
,	O
BD	O
#	O
557943	O
),	O
CD4	B-GP
-	O
QDot605	O
(	O
clone	O
S3	O
.	O
5	O
,	O
Invitrogen	O
#	O
Q10008	O
),	O
CD8	B-GP
-	O
PB	O
(	O
clone	O
RPA	O
-	O
T8	O
,	O
BD	O
#	O
558207	O
),	O
CD14	B-GP
-	O
V500	O
(	O
clone	O
M5E2	O
,	O
BD	O
#	O
561391	O
),	O
CD19	B-GP
-	O
AmCyan	O
(	O
clone	O
SJ25C1	O
,	O
BD	O
#	O
339190	O
),	O
LIVE	O
/	O
DEAD	O
Aqua	O
marker	O
(	O
Invitrogen	O
#	O
L34957	O
),	O
CD45RA	B-GP
-	O
APC	B-GP
-	O
H7	O
(	O
clone	O
HI100	O
,	O
BD	O
#	O
560674	O
),	O
CD27	B-GP
-	O
BV650	O
(	O
clone	O
O323	O
,	O
Biolegend	O
#	O
302828	O
)	O
and	O
CCR7	B-GP
-	O
PE	B-GP
-	O
Cy7	O
(	O
clone	O
3D12	O
,	O
BD	O
#	O
557648	O
).	O

The	O
following	O
antibodies	B-GP
were	O
added	O
to	O
this	O
backbone	O
:	O
PD	B-GP
-	I-GP
1	I-GP
-	O
AF647	O
(	O
clone	O
EH12	O
.	O
1	O
,	O
BD	O
#	O
560838	O
),	O
CTLA	B-GP
-	I-GP
4	I-GP
-	O
PE	B-GP
(	O
clone	O
BNI3	O
,	O
BD	O
#	O
555853	O
),	O
LAG	B-GP
-	I-GP
3	I-GP
-	O
FITC	O
(	O
R	O
&	O
D	O
#	O
FAB2319F	O
),	O
TIGIT	B-GP
-	O
PerCP	B-GP
-	O
eF710	B-GP
(	O
clone	O
MBSA43	O
,	O
eBioscience	O
#	O
46	O
-	O
9500	O
-	O
41	O
),	O
TIM	B-GP
-	I-GP
3	I-GP
-	O
PE	B-GP
(	O
clone	O
F38	O
-	O
2E2	O
,	O
Biolegend	O
#	O
345006	O
),	O
CD160	B-GP
-	O
AF488	O
(	O
clone	O
By55	O
,	O
eBioscience	O
#	O
53	O
–	O
1609	O
),	O
2B4	O
-	O
PerCP	B-GP
-	O
Cy5	B-GP
.	I-GP
5	I-GP
(	O
clone	O
C1	O
.	O
7	O
,	O
Biolegend	O
#	O
329515	O
).	O

For	O
expression	O
of	O
all	O
ICs	O
,	O
gates	O
were	O
defined	O
using	O
fluorescence	O
minus	O
one	O
controls	O
.	O

CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
were	O
identified	O
by	O
CD27	B-GP
,	O
CD45RA	B-GP
,	O
and	O
CCR7	B-GP
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
after	O
exclusion	O
of	O
dump	O
positive	O
cells	O
(	O
LIVE	O
/	O
DEAD	O
,	O
CD14	B-GP
and	O
CD19	B-GP
).	O

ICs	O
were	O
measured	O
in	O
gated	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
including	O
naïve	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
+	O
CD27	B-GP
+),	O
central	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
+	O
CD27	B-GP
+),	O
transitional	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
+),	O
effector	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
-)	O
and	O
terminally	O
differentiated	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
-	O
CD4	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
-	O
CD27	B-GP
-).	O

Data	O
was	O
acquired	O
on	O
a	O
BD	O
LSR	O
II	O
flow	O
cytometer	O
using	O
the	O
FACSDiva	O
software	O
(	O
Becton	O
Dickinson	O
)	O
and	O
analysed	O
using	O
Flow	O
Jo	O
version	O
9	O
(	O
Treestar	O
).	O

Cell	O
sorting	O

Central	O
,	O
transitional	O
and	O
effector	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

The	O
antibodies	B-GP
used	O
for	O
sorting	O
were	O
similar	O
than	O
those	O
used	O
for	O
phenotyping	O
with	O
the	O
exception	O
of	O
CD27	B-GP
-	O
QDot655	O
(	O
clone	O
CLB	O
-	O
27	O
/	O
1	O
,	O
Invitrogen	O
#	O
Q10066	O
).	O

In	O
a	O
second	O
set	O
of	O
experiments	O
,	O
total	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD4	B-GP
+	O
CD45RA	B-GP
-)	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

Sorted	O
cells	O
were	O
collected	O
using	O
an	O
ARIA	O
FACS	O
sorter	O
(	O
Becton	O
Dickinson	O
).	O

Isolation	O
of	O
total	O
CD4	B-GP
+	O
T	O
cells	O

Total	O
CD4	B-GP
+	O
T	O
cells	O
were	O
isolated	O
from	O
cryopreserved	O
PBMCs	O
using	O
magnetic	O
depletion	O
as	O
per	O
the	O
manufacturer	O
’	O
s	O
protocol	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
Vancouver	O
,	O
Canada	O
).	O

Quantification	O
of	O
integrated	O
,	O
total	O
and	O
2	O
-	O
LTR	O
circles	O
HIV	B-OG
DNA	O
,	O
cell	O
associated	O
unspliced	O
HIV	B-OG
RNA	O
and	O
Tat	B-GP
/	O
rev	B-GP
inducible	O
multiply	O
spliced	O
HIV	B-OG
RNA	O

Total	O
CD4	B-GP
+	O
T	O
cells	O
or	O
sorted	O
CD4	B-GP
+	O
T	O
cell	O
subsets	O
were	O
used	O
to	O
measure	O
the	O
frequency	O
of	O
cells	O
harboring	O
HIV	B-OG
DNA	O
(	O
total	O
,	O
integrated	O
and	O
2	O
-	O
LTR	O
circles	O
)	O
by	O
real	O
time	O
nested	O
PCR	O
as	O
previously	O
described	O
[	O
34	O
]	O
(	O
S1A	O
Text	O
).	O

The	O
CA	O
-	O
US	O
RNA	O
was	O
measured	O
by	O
real	O
time	O
nested	O
PCR	O
as	O
previously	O
described	O
[	O
35	O
].	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
with	O
inducible	O
multiply	O
spliced	O
HIV	B-OG
RNA	O
was	O
determined	O
using	O
Tat	B-GP
/	O
rev	B-GP
inducible	O
limiting	O
dilution	O
assay	O
(	O
TILDA	O
)	O
[	O
36	O
].	O

Statistical	O
analysis	O

Data	O
distributions	O
were	O
assessed	O
through	O
descriptive	O
statistics	O
and	O
scatter	O
plots	O
.	O

Negative	O
binomial	O
regression	O
models	O
were	O
run	O
for	O
each	O
set	O
of	O
comparisons	O
with	O
the	O
percentage	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	O
being	O
the	O
predictor	O
and	O
the	O
measure	O
of	O
HIV	B-OG
persistence	O
the	O
outcome	O
.	O

We	O
chose	O
this	O
approach	O
for	O
reasons	O
described	O
previously	O
[	O
12	O
,	O
35	O
],	O
and	O
for	O
consistency	O
with	O
those	O
previous	O
publications	O
(	O
S1B	O
Text	O
).	O

The	O
approach	O
allowed	O
us	O
to	O
fit	O
models	O
adjusting	O
for	O
the	O
effects	O
of	O
absolute	O
current	O
or	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
,	O
which	O
were	O
examined	O
for	O
all	O
combinations	O
of	O
IC	O
predictors	O
and	O
HIV	B-OG
persistence	O
outcome	O
measures	O
.	O

In	O
addition	O
,	O
the	O
negative	O
binomial	O
regression	O
models	O
take	O
into	O
account	O
that	O
copies	O
/	O
input	O
is	O
measured	O
with	O
less	O
precision	O
when	O
the	O
number	O
of	O
copies	O
is	O
lower	O
and	O
when	O
the	O
amount	O
of	O
input	O
is	O
lower	O
.	O

The	O
methods	O
also	O
permit	O
proper	O
quantitative	O
use	O
of	O
instances	O
where	O
zero	O
copies	O
were	O
present	O
in	O
the	O
specimen	O
assayed	O
,	O
without	O
a	O
need	O
for	O
ad	O
hoc	O
modifications	O
to	O
permit	O
taking	O
logarithms	O
.	O

We	O
did	O
not	O
evaluate	O
the	O
results	O
of	O
alternative	O
analysis	O
methods	O
and	O
did	O
not	O
choose	O
the	O
methods	O
post	O
-	O
hoc	O
based	O
on	O
the	O
results	O
that	O
they	O
produced	O
.	O

Analyses	O
were	O
run	O
in	O
Stata	O
version	O
13	O
.	O
1	O
(	O
Stata	O
Corp	O
,	O
College	O
Station	O
,	O
TX	O
).	O

For	O
TILDA	O
results	O
analysis	O
,	O
we	O
estimated	O
the	O
within	O
-	O
person	O
fold	O
difference	O
in	O
TILDA	O
between	O
the	O
2	O
cell	O
subsets	O
analyzed	O
(	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
any	O
versus	O
none	O
of	O
the	O
ICs	O
)	O
by	O
fitting	O
a	O
maximum	O
likelihood	O
model	O
to	O
the	O
raw	O
data	O
on	O
numbers	O
of	O
positive	O
and	O
negative	O
wells	O
at	O
each	O
dilution	O
(	O
S1C	O
Text	O
).	O

Results	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
markers	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O

To	O
determine	O
the	O
relationship	O
between	O
ICs	O
and	O
HIV	B-OG
persistence	O
,	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
on	O
suppressive	O
ART	O
for	O
a	O
median	O
time	O
(	O
IQR	O
)	O
of	O
8	O
.	O
5	O
years	O
(	O
5	O
.	O
0	O
–	O
12	O
.	O
4	O
)	O
and	O
a	O
median	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
(	O
IQR	O
)	O
of	O
684	O
cells	O
/	O
μL	O
(	O
533	O
–	O
858	O
)	O
were	O
recruited	O
(	O
Table	O
1	O
).	O

The	O
expressions	O
of	O
7	O
ICs	O
on	O
CD4	B-GP
+	O
T	O
cells	O
(	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	O
)	O
were	O
measured	O
by	O
multiparametric	O
flow	O
cytometry	O
(	O
S1	O
Fig	O
).	O

The	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
ICs	O
were	O
variable	O
(	O
median	O
(	O
IQR	O
)	O
of	O
16	O
.	O
7	O
%	O
(	O
13	O
.	O
2	O
–	O
22	O
.	O
7	O
),	O
12	O
.	O
2	O
%	O
(	O
8	O
.	O
8	O
–	O
16	O
.	O
4	O
),	O
12	O
.	O
0	O
%	O
(	O
8	O
.	O
9	O
–	O
16	O
.	O
1	O
),	O
9	O
.	O
5	O
%	O
(	O
3	O
.	O
5	O
–	O
18	O
.	O
5	O
),	O
1	O
.	O
1	O
%	O
(	O
0	O
.	O
8	O
–	O
2	O
.	O
5	O
),	O
0	O
.	O
8	O
%	O
(	O
0	O
.	O
6	O
–	O
1	O
.	O
5	O
)	O
and	O
0	O
.	O
7	O
%	O
(	O
0	O
.	O
6	O
–	O
1	O
.	O
0	O
)	O
for	O
TIGIT	B-GP
,	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
2B4	B-GP
,	O
CD160	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
and	O
CTLA	B-GP
-	I-GP
4	I-GP
respectively	O
)	O
(	O
Fig	O
1A	O
).	O

Clinical	O
demographics	O
of	O
the	O
cohorts	O
.	O

Characteristics	O

Cohort	O
1	O
(	O
N	O
=	O
48	O
)	O

Cohort	O
2	O
(	O
N	O
=	O
31	O
)	O

Gender	O
,	O
n	O
(%)	O

Male	O

46	O
(	O
96	O
%)	O

29	O
(	O
94	O
%)	O

Female	O

1	O
(	O
2	O
%)	O

2	O
(	O
6	O
%)	O

Transgender	O

1	O
(	O
2	O
%)	O

0	O
(	O
0	O
%)	O

Age	O
,	O
years	O
median	O
(	O
IQR	O
)	O

57	O
(	O
50	O
–	O
62	O
)	O

50	O
(	O
50	O
–	O
62	O
)	O

Viral	O
load	O
,	O
cop	O
/	O
mL	O

<	O
50	O

<	O
50	O

Nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

197	O
(	O
110	O
–	O
285	O
)	O
a	O

42	O
(	O
14	O
–	O
179	O
)	O
b	O

Current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

684	O
(	O
530	O
–	O
862	O
)	O

526	O
(	O
420	O
–	O
702	O
)	O

Current	O
CD8	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
cells	O
/	O
μl	O
median	O
(	O
IQR	O
)	O

914	O
(	O
639	O
–	O
1091	O
)	O

830	O
(	O
617	O
–	O
1135	O
)	O

CD4	B-GP
/	O
CD8	B-GP
ratio	O
median	O
(	O
IQR	O
)	O

0	O
.	O
77	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
17	O
)	O

0	O
.	O
64	O
(	O
0	O
.	O
40	O
–	O
0	O
.	O
91	O
)	O

ART	O
,	O
years	O
median	O
(	O
IQR	O
)	O

8	O
.	O
5	O
(	O
5	O
.	O
0	O
–	O
12	O
.	O
4	O
)	O

8	O
.	O
8	O
(	O
6	O
.	O
2	O
–	O
12	O
.	O
6	O
)	O
c	O

Data	O
only	O
available	O
for	O
(	O
a	O
)	O
N	O
=	O
45	O
,	O
(	O
b	O
)	O
N	O
=	O
27	O
,	O
(	O
c	O
)	O
N	O
=	O
24	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	O
are	O
associated	O
with	O
virological	O
markers	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

(	O
A	O
)	O
Expression	O
of	O
7	O
ICs	O
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
(	O
n	O
=	O
48	O
).	O

Data	O
is	O
represented	O
as	O
percentage	O
of	O
CD4	B-GP
+	O
T	O
cells	O
and	O
horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
B	O
)	O
Size	O
of	O
the	O
HIV	B-OG
reservoir	O
measured	O
by	O
integrated	O
HIV	B-OG
DNA	O
,	O
total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
represented	O
as	O
copies	O
per	O
million	O
CD4	B-GP
+	O
T	O
cells	O
and	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
represented	O
as	O
copies	O
per	O
million	O
copies	O
of	O
18S	O
.	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
and	O
open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

(	O
C	O
),	O
(	O
D	O
),	O
(	O
E	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Effect	O
sizes	O
for	O
the	O
associations	O
are	O
as	O
follows	O
:	O
(	O
C	O
)	O
A	O
2	O
-	O
fold	O
increase	O
in	O
the	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
43	O
-	O
fold	O
increase	O
in	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cell	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
(	O
D	O
)	O
a	O
2	O
-	O
fold	O
higher	O
percentage	O
of	O
TIGIT	B-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
91	O
-	O
fold	O
higher	O
integrated	O
HIV	B-OG
DNA	O
and	O
(	O
E	O
)	O
a	O
2	O
-	O
fold	O
higher	O
percentage	O
of	O
LAG	B-GP
-	I-GP
3	I-GP
+	O
CD4	B-GP
+	O
T	O
cell	O
was	O
associated	O
with	O
1	O
.	O
62	O
-	O
fold	O
higher	O
integrated	O
HIV	B-OG
DNA	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

The	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
was	O
determined	O
by	O
measuring	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
total	O
HIV	B-OG
DNA	O
and	O
2	O
-	O
LTR	O
circles	O
as	O
well	O
as	O
cell	O
-	O
associated	O
unspliced	O
(	O
CA	O
-	O
US	O
)	O
HIV	B-OG
RNA	O
(	O
Fig	O
1B	O
and	O
S1	O
Table	O
).	O

Total	O
HIV	B-OG
DNA	O
and	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
were	O
detected	O
in	O
all	O
samples	O
tested	O
,	O
whereas	O
integrated	O
HIV	B-OG
DNA	O
and	O
2	O
-	O
LTR	O
circles	O
were	O
detected	O
in	O
98	O
%,	O
and	O
80	O
%	O
of	O
the	O
samples	O
,	O
respectively	O
.	O

We	O
evaluated	O
the	O
association	O
between	O
markers	O
of	O
HIV	B-OG
persistence	O
and	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
ICs	O
using	O
a	O
negative	O
binomial	O
regression	O
model	O
that	O
was	O
adjusted	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
when	O
indicated	O
(	O
Table	O
2	O
and	O
S2	O
–	O
S4	O
Tables	O
).	O

Using	O
these	O
tailored	O
analytical	O
methods	O
for	O
HIV	B-OG
reservoir	O
measurements	O
,	O
we	O
identified	O
3	O
ICs	O
for	O
which	O
the	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
was	O
statistically	O
significantly	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
Fig	O
1C	O
–	O
1E	O
and	O
Table	O
2	O
).	O

These	O
correlations	O
persisted	O
after	O
adjusting	O
for	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
but	O
were	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
a	O
clinical	O
parameter	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
reservoir	O
during	O
ART	O
[	O
6	O
,	O
37	O
,	O
38	O
].	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
integrated	O
HIV	B-OG
DNA	O
and	O
IC	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Outcome	O

Predictor	O
a	O

Unadjusted	O

Adjusted	O
for	O
Current	O
CD4	B-GP

Adjusted	O
for	O
Nadir	O
CD4	B-GP

Result	O
(	O
95	O
%	O
CI	O
)	O
c	O
,	O
d	O

p	O
-	O
value	O
e	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Integrated	O
HIV	B-OG
DNA	O
b	O

PD1	B-GP
+	O

1	O
.	O
43	O
(	O
1	O
.	O
08	O
to	O
1	O
.	O
90	O
)	O

0	O
.	O
012	O

1	O
.	O
17	O
(	O
0	O
.	O
91	O
to	O
1	O
.	O
50	O
)	O

0	O
.	O
220	O

1	O
.	O
39	O
(	O
1	O
.	O
05	O
to	O
1	O
.	O
82	O
)	O

0	O
.	O
020	O

CTLA	B-GP
-	I-GP
4	I-GP
+	O

1	O
.	O
50	O
(	O
0	O
.	O
90	O
to	O
2	O
.	O
51	O
)	O

0	O
.	O
120	O

1	O
.	O
18	O
(	O
0	O
.	O
73	O
to	O
1	O
.	O
91	O
)	O

0	O
.	O
500	O

1	O
.	O
43	O
(	O
0	O
.	O
88	O
to	O
2	O
.	O
35	O
)	O

0	O
.	O
150	O

LAG	O
-	O
3	O
+	O

1	O
.	O
62	O
(	O
1	O
.	O
07	O
to	O
2	O
.	O
45	O
)	O

0	O
.	O
022	O

1	O
.	O
07	O
(	O
0	O
.	O
69	O
to	O
1	O
.	O
65	O
)	O

0	O
.	O
760	O

1	O
.	O
58	O
(	O
1	O
.	O
07	O
to	O
2	O
.	O
35	O
)	O

0	O
.	O
023	O

TIGIT	O
+	O

1	O
.	O
91	O
(	O
1	O
.	O
11	O
to	O
3	O
.	O
28	O
)	O

0	O
.	O
020	O

1	O
.	O
54	O
(	O
0	O
.	O
91	O
to	O
2	O
.	O
60	O
)	O

0	O
.	O
110	O

1	O
.	O
87	O
(	O
1	O
.	O
10	O
to	O
3	O
.	O
16	O
)	O

0	O
.	O
020	O

TIM	O
-	O
3	O
+	O

1	O
.	O
28	O
(	O
0	O
.	O
83	O
to	O
1	O
.	O
97	O
)	O

0	O
.	O
260	O

1	O
.	O
24	O
(	O
0	O
.	O
85	O
to	O
1	O
.	O
80	O
)	O

0	O
.	O
260	O

1	O
.	O
38	O
(	O
0	O
.	O
89	O
to	O
2	O
.	O
14	O
)	O

0	O
.	O
160	O

CD160	B-GP
+	O

1	O
.	O
07	O
(	O
0	O
.	O
82	O
to	O
1	O
.	O
39	O
)	O

0	O
.	O
620	O

0	O
.	O
90	O
(	O
0	O
.	O
69	O
to	O
1	O
.	O
17	O
)	O

0	O
.	O
420	O

1	O
.	O
13	O
(	O
0	O
.	O
86	O
to	O
1	O
.	O
48	O
)	O

0	O
.	O
370	O

2B4	O
+	O

1	O
.	O
06	O
(	O
0	O
.	O
83	O
to	O
1	O
.	O
36	O
)	O

0	O
.	O
630	O

0	O
.	O
92	O
(	O
0	O
.	O
71	O
to	O
1	O
.	O
18	O
)	O

0	O
.	O
500	O

1	O
.	O
10	O
(	O
0	O
.	O
87	O
to	O
1	O
.	O
39	O
)	O

0	O
.	O
440	O

a	O
Percentage	O
CD4	B-GP
+	O
T	O
cells	O
that	O
express	O
Immune	O
Checkpoint	O
Molecules	O

b	O
Integrated	O
HIV	B-OG
DNA	O
units	O
(	O
copies	O
/	O
million	O
CD4	B-GP
+	O
T	O
cells	O
)	O

c	O
95	O
%	O
CI	O
=	O
95	O
%	O
confidence	O
interval	O

d	O
Result	O
interpretation	O
:	O
fold	O
-	O
change	O
in	O
the	O
outcome	O
(	O
marker	O
of	O
HIV	B-OG
persistence	O
)	O
for	O
each	O
unit	O
change	O
of	O
the	O
predictor	O
(	O
Immune	O
Checkpoint	O
Molecules	O
).	O

All	O
predictors	O
were	O
log2	O
transformed	O
,	O
so	O
results	O
here	O
are	O
interpreted	O
as	O
the	O
change	O
in	O
the	O
outcome	O
for	O
each	O
doubling	O
of	O
the	O
predictor	O

e	O
Statistically	O
significant	O
p	O
values	O
are	O
<	O
0	O
.	O
05	O
and	O
are	O
bold	O

The	O
frequency	O
of	O
PD	B-GP
-	I-GP
1	I-GP
expressing	O
CD4	B-GP
+	O
T	O
cells	O
was	O
also	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
total	O
HIV	B-OG
DNA	O
(	O
S3	O
Table	O
),	O
but	O
only	O
marginally	O
(	O
1	O
.	O
23	O
-	O
fold	O
effect	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
when	O
the	O
model	O
was	O
adjusted	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
.	O

CA	O
-	O
US	O
HIV	B-OG
RNA	O
and	O
2	O
-	O
LTR	O
circles	O
did	O
not	O
show	O
statistically	O
significant	O
correlation	O
with	O
any	O
IC	O
expression	O
levels	O
,	O
with	O
the	O
exception	O
of	O
a	O
negative	O
association	O
between	O
the	O
frequency	O
of	O
CD160	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
2	O
-	O
LTR	O
circles	O
that	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
(	O
S3	O
and	O
S4	O
Tables	O
).	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
is	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O

ICs	O
are	O
co	O
-	O
expressed	O
on	O
exhausted	O
CD4	B-GP
+	O
and	O
CD8	B-GP
+	O
T	O
cells	O
during	O
untreated	O
HIV	B-DS
infection	I-DS
[	O
39	O
].	O

Using	O
a	O
Boolean	O
gating	O
strategy	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
our	O
cohort	O
of	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
receiving	O
suppressive	O
ART	O
(	O
Fig	O
2A	O
and	O
2B	O
).	O

The	O
majority	O
of	O
CD4	B-GP
+	O
T	O
cells	O
did	O
not	O
express	O
any	O
of	O
these	O
markers	O
(	O
median	O
(	O
IQR	O
)	O
of	O
65	O
.	O
8	O
%	O
(	O
59	O
.	O
0	O
–	O
72	O
.	O
4	O
))	O
(	O
S6	O
Table	O
).	O

Less	O
than	O
10	O
%	O
(	O
8	O
.	O
5	O
%)	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressed	O
more	O
than	O
one	O
of	O
these	O
markers	O
and	O
0	O
.	O
9	O
%	O
simultaneously	O
expressed	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

We	O
further	O
assessed	O
if	O
the	O
frequency	O
of	O
these	O
discrete	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
was	O
associated	O
with	O
markers	O
of	O
HIV	B-OG
persistence	O
.	O

Using	O
the	O
negative	O
binomial	O
regression	O
model	O
,	O
we	O
found	O
that	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
not	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
and	O
negatively	O
correlated	O
to	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
002	O
,	O
Table	O
3	O
and	O
Fig	O
2C	O
).	O

Conversely	O
,	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cell	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
and	O
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
001	O
,	O
Table	O
3	O
and	O
Fig	O
2F	O
).	O

Interestingly	O
,	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
TIGIT	B-GP
with	O
either	O
PD	B-GP
-	I-GP
1	I-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
also	O
positively	O
associated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
(	O
p	O
=	O
0	O
.	O
002	O
and	O
p	O
=	O
0	O
.	O
029	O
respectively	O
,	O
Table	O
3	O
and	O
Fig	O
2D	O
and	O
2E	O
).	O

Although	O
several	O
of	O
these	O
associations	O
were	O
less	O
or	O
no	O
longer	O
statistically	O
significant	O
when	O
the	O
model	O
was	O
adjusted	O
for	O
the	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
,	O
the	O
association	O
between	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
and	O
the	O
frequency	O
of	O
triple	O
positive	O
cells	O
(	O
PD	B-GP
-	I-GP
1	I-GP
+,	O
LAG	B-GP
-	I-GP
3	I-GP
+	O
and	O
TIGIT	B-GP
+)	O
remained	O
statistically	O
significant	O
after	O
adjustment	O
(	O
p	O
=	O
0	O
.	O
038	O
).	O

Adjusting	O
for	O
duration	O
of	O
ART	O
did	O
not	O
produce	O
any	O
substantial	O
changes	O
to	O
the	O
results	O
from	O
the	O
unadjusted	O
analysis	O
(	O
all	O
fold	O
-	O
effects	O
adjusted	O
for	O
ART	O
duration	O
within	O
7	O
%	O
of	O
those	O
unadjusted	O
).	O

All	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identifies	O
a	O
unique	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
that	O
strongly	O
predicts	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
is	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

(	O
A	O
)	O
Frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	O
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
–(	O
P	O
-	O
T	O
-	O
L	O
-),	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
P	O
+),	O
TIGIT	O
single	O
+	O
(	O
T	O
+),	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
(	O
L	O
+),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
double	O
+	O
(	O
P	O
+	O
T	O
+),	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
T	O
+	O
L	O
+),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
P	O
+	O
L	O
+)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
(	O
P	O
+	O
T	O
+	O
L	O
+))	O
determined	O
by	O
Boolean	O
gating	O
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
B	O
)	O
Venn	O
diagram	O
showing	O
the	O
pattern	O
of	O
co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

(	O
C	O
),	O
(	O
D	O
),	O
(	O
E	O
),	O
(	O
F	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
none	O
of	O
these	O
markers	O
(	O
triple	O
–),	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
(	O
double	O
+),	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
double	O
+)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
triple	O
+),	O
respectively	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Effect	O
sizes	O
for	O
the	O
associations	O
are	O
as	O
follows	O
:	O
(	O
C	O
)	O
0	O
.	O
69	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
—	O
CD4	B-GP
+	O
T	O
cells	O
,	O
(	O
D	O
)	O
1	O
.	O
18	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
,	O
(	O
E	O
)	O
1	O
.	O
30	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
(	O
F	O
)	O
1	O
.	O
94	O
-	O
fold	O
-	O
change	O
in	O
integrated	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	O
-	B-GP
3	I-GP
triple	O
+	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
Integrated	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	O
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

Outcome	O

Predictor	O
a	O

Unadjusted	O

Adjusted	O
for	O
Current	O
CD4	B-GP

Adjusted	O
for	O
Nadir	O
CD4	B-GP

Adjusted	O
for	O
ART	O
duration	O

Result	O
(	O
95	O
%	O
CI	O
)	O
c	O
,	O
d	O

p	O
-	O
value	O
e	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Result	O
(	O
95	O
%	O
CI	O
)	O

p	O
-	O
value	O

Integrated	O
HIV	B-OG
DNA	O
b	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	O
-	O
3	O
triple	O
–	O
f	O

0	O
.	O
69	O
(	O
0	O
.	O
54	O
to	O
0	O
.	O
87	O
)	O

0	O
.	O
002	O

0	O
.	O
82	O
(	O
0	O
.	O
65	O
to	O
1	O
.	O
03	O
)	O

0	O
.	O
084	O

0	O
.	O
70	O
(	O
0	O
.	O
56	O
to	O
0	O
.	O
86	O
)	O

0	O
.	O
001	O

0	O
.	O
68	O
(	O
0	O
.	O
54	O
–	O
0	O
.	O
85	O
)	O

0	O
.	O
001	O

PD	O
-	O
1	O
single	O
+	O
f	O

1	O
.	O
24	O
(	O
0	O
.	O
90	O
to	O
1	O
.	O
70	O
)	O

0	O
.	O
187	O

1	O
.	O
09	O
(	O
0	O
.	O
80	O
to	O
1	O
.	O
48	O
)	O

0	O
.	O
578	O

1	O
.	O
28	O
(	O
0	O
.	O
94	O
to	O
1	O
.	O
75	O
)	O

0	O
.	O
118	O

1	O
.	O
32	O
(	O
0	O
.	O
93	O
–	O
1	O
.	O
88	O
)	O

0	O
.	O
12	O

TIGIT	O
single	O
+	O

1	O
.	O
06	O
(	O
0	O
.	O
99	O
to	O
1	O
.	O
14	O
)	O

0	O
.	O
106	O

1	O
.	O
05	O
(	O
0	O
.	O
98	O
to	O
1	O
.	O
12	O
)	O

0	O
.	O
210	O

1	O
.	O
06	O
(	O
0	O
.	O
99	O
to	O
1	O
.	O
13	O
)	O

0	O
.	O
111	O

1	O
.	O
06	O
(	O
0	O
.	O
98	O
–	O
1	O
.	O
14	O
)	O

0	O
.	O
13	O

LAG	O
-	O
3	O
single	O
+	O

1	O
.	O
00	O
(	O
0	O
.	O
95	O
to	O
1	O
.	O
05	O
)	O

0	O
.	O
963	O

0	O
.	O
97	O
(	O
0	O
.	O
92	O
to	O
1	O
.	O
02	O
)	O

0	O
.	O
176	O

1	O
.	O
00	O
(	O
0	O
.	O
94	O
to	O
1	O
.	O
05	O
)	O

0	O
.	O
848	O

1	O
.	O
00	O
(	O
0	O
.	O
95	O
–	O
1	O
.	O
05	O
)	O

0	O
.	O
86	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
double	O
+	O

1	O
.	O
18	O
(	O
1	O
.	O
07	O
to	O
1	O
.	O
31	O
)	O

0	O
.	O
002	O

1	O
.	O
13	O
(	O
1	O
.	O
00	O
to	O
1	O
.	O
26	O
)	O

0	O
.	O
042	O

1	O
.	O
17	O
(	O
1	O
.	O
06	O
to	O
1	O
.	O
30	O
)	O

0	O
.	O
003	O

1	O
.	O
19	O
(	O
1	O
.	O
07	O
–	O
1	O
.	O
32	O
)	O

0	O
.	O
001	O

TIGIT	O
/	O
LAG	O
-	O
3	O
double	O
+	O

1	O
.	O
30	O
(	O
1	O
.	O
03	O
to	O
1	O
.	O
64	O
)	O

0	O
.	O
029	O

1	O
.	O
16	O
(	O
0	O
.	O
97	O
to	O
1	O
.	O
38	O
)	O

0	O
.	O
100	O

1	O
.	O
27	O
(	O
1	O
.	O
04	O
to	O
1	O
.	O
55	O
)	O

0	O
.	O
018	O

1	O
.	O
29	O
(	O
1	O
.	O
02	O
–	O
1	O
.	O
65	O
)	O

0	O
.	O
037	O

LAG	B-GP
-	I-GP
3	I-GP
/	O
PD	B-GP
-	I-GP
1	I-GP
double	O
+	O

1	O
.	O
08	O
(	O
0	O
.	O
96	O
to	O
1	O
.	O
23	O
)	O

0	O
.	O
206	O

1	O
.	O
01	O
(	O
0	O
.	O
88	O
to	O
1	O
.	O
16	O
)	O

0	O
.	O
910	O

1	O
.	O
09	O
(	O
0	O
.	O
96	O
to	O
1	O
.	O
25	O
)	O

0	O
.	O
175	O

1	O
.	O
11	O
(	O
0	O
.	O
96	O
–	O
1	O
.	O
23	O
)	O

0	O
.	O
15	O

PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	O
-	B-GP
3	I-GP
triple	O
+	O

1	O
.	O
94	O
(	O
1	O
.	O
33	O
to	O
2	O
.	O
83	O
)	O

0	O
.	O
001	O

1	O
.	O
45	O
(	O
1	O
.	O
02	O
to	O
2	O
.	O
05	O
)	O

0	O
.	O
038	O

1	O
.	O
86	O
(	O
1	O
.	O
26	O
to	O
2	O
.	O
72	O
)	O

0	O
.	O
002	O

1	O
.	O
92	O
(	O
1	O
.	O
31	O
–	O
2	O
.	O
81	O
)	O

0	O
.	O
001	O

a	O
Percentage	O
CD4	B-GP
+	O
T	O
cells	O
that	O
express	O
Immune	O
Checkpoint	O
Molecules	O

b	O
Integrated	O
HIV	B-OG
DNA	O
units	O
(	O
copies	O
/	O
million	O
CD4	B-GP
+	O
T	O
cells	O
)	O

c	O
95	O
%	O
CI	O
=	O
95	O
%	O
confidence	O
interval	O

d	O
Result	O
interpretation	O
:	O
fold	O
-	O
change	O
in	O
the	O
outcome	O
(	O
marker	O
of	O
HIV	B-OG
persistence	O
)	O
for	O
each	O
one	O
point	O
increase	O
in	O
the	O
percent	O
of	O
cells	O
expressing	O
the	O
predictor	O
(	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	O
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
)	O

e	O
Statistically	O
significant	O
p	O
values	O
are	O
<	O
0	O
.	O
05	O
and	O
are	O
bold	O

f	O
These	O
predictors	O
vary	O
more	O
than	O
others	O
,	O
so	O
results	O
are	O
scaled	O
to	O
be	O
per	O
10	O
point	O
increase	O
in	O
percent	O
of	O
cells	O
,	O
rather	O
than	O
per	O
one	O
point	O
increase	O

When	O
the	O
negative	O
binomial	O
regression	O
model	O
was	O
used	O
to	O
assess	O
the	O
relationship	O
between	O
Total	O
HIV	B-OG
DNA	O
,	O
2	O
-	O
LTR	O
circles	O
,	O
CA	O
-	O
US	O
RNA	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
no	O
association	O
show	O
statistically	O
significant	O
,	O
with	O
the	O
exception	O
of	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
total	O
HIV	B-OG
DNA	O
and	O
the	O
frequency	O
of	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
p	O
=	O
0	O
.	O
005	O
,	O
1	O
.	O
10	O
-	O
fold	O
-	O
change	O
in	O
total	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
CD4	B-GP
+	O
T	O
cells	O
)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
(	O
p	O
=	O
0	O
.	O
017	O
,	O
1	O
.	O
40	O
-	O
fold	O
-	O
change	O
in	O
total	O
HIV	B-OG
DNA	O
for	O
1	O
point	O
increase	O
in	O
percentage	O
of	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
double	O
+	O
CD4	B-GP
+	O
T	O
cells	O
).	O

Expressions	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
during	O
ART	O

HIV	B-OG
persists	O
preferentially	O
in	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
[	O
6	O
–	O
8	O
].	O

To	O
determine	O
the	O
role	O
played	O
by	O
ICs	O
in	O
each	O
individual	O
CD4	B-GP
+	O
T	O
-	O
cell	O
memory	O
subset	O
,	O
we	O
first	O
analyzed	O
the	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
the	O
3	O
ICs	O
we	O
identified	O
to	O
be	O
associated	O
with	O
HIV	B-OG
persistence	O
,	O
on	O
naïve	O
(	O
TN	O
),	O
central	O
memory	O
(	O
TCM	O
),	O
transitional	O
memory	O
(	O
TTM	O
),	O
effector	O
memory	O
(	O
TEM	O
)	O
and	O
terminally	O
differentiated	O
(	O
TTD	O
)	O
cells	O
in	O
48	O
HIV	B-OG
-	O
infected	O
participants	O
(	O
Cohort	O
1	O
:	O
clinical	O
characteristics	O
in	O
Table	O
1	O
)	O
(	O
Fig	O
3A	O
,	O
3B	O
and	O
3C	O
respectively	O
).	O

As	O
expected	O
,	O
TN	O
cells	O
expressed	O
low	O
levels	O
of	O
these	O
ICs	O
.	O

The	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
or	O
LAG	O
-	O
3	O
increased	O
with	O
differentiation	O
,	O
with	O
TEM	O
cells	O
displaying	O
the	O
highest	O
levels	O
of	O
expression	O
of	O
these	O
markers	O
.	O

The	O
highest	O
frequency	O
of	O
TIGIT	B-GP
+	O
cells	O
was	O
found	O
within	O
the	O
TTM	O
subset	O
.	O

These	O
results	O
demonstrated	O
that	O
the	O
subsets	O
of	O
memory	O
cells	O
that	O
were	O
previously	O
shown	O
to	O
harbor	O
persistent	O
HIV	B-OG
during	O
ART	O
express	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
.	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
during	O
ART	O
.	O

(	O
A	O
),	O
(	O
B	O
),	O
(	O
C	O
)	O
Frequencies	O
of	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
(	O
naïve	O
(	O
TN	O
),	O
central	O
memory	O
(	O
TCM	O
),	O
transitional	O
memory	O
(	O
TTM	O
),	O
effector	O
memory	O
(	O
TEM	O
)	O
and	O
terminally	O
differentiated	O
(	O
TD	O
))	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
with	O
interquartile	O
ranges	O
.	O

(	O
D	O
),	O
(	O
E	O
),	O
(	O
F	O
)	O
Frequencies	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
in	O
TCM	O
,	O
TTM	O
and	O
TEM	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
(	O
n	O
=	O
12	O
),	O
TIGIT	B-GP
(	O
n	O
=	O
9	O
)	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
n	O
=	O
7	O
),	O
respectively	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
HIV	B-OG
copy	O
number	O
in	O
million	O
cells	O
of	O
a	O
given	O
subset	O
.	O

P	O
values	O
were	O
obtained	O
from	O
negative	O
binomial	O
regression	O
analysis	O
.	O

Significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
are	O
designated	O
by	O
a	O
p	O
value	O
in	O
bold	O
.	O

Open	O
circles	O
represent	O
the	O
limit	O
of	O
detection	O
in	O
the	O
negative	O
samples	O
(	O
based	O
on	O
cell	O
input	O
).	O

To	O
determine	O
whether	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
cells	O
more	O
likely	O
to	O
carry	O
persistent	O
HIV	B-OG
in	O
virally	O
suppressed	O
participants	O
,	O
individual	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
a	O
subset	O
of	O
subjects	O
who	O
underwent	O
leukapheresis	O
(	O
Cohort	O
2	O
:	O
clinical	O
characteristics	O
in	O
Table	O
1	O
)	O
and	O
the	O
results	O
were	O
analyzed	O
by	O
negative	O
binomial	O
regression	O
model	O
(	O
S5	O
Table	O
).	O

The	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
was	O
moderately	O
higher	O
in	O
PD	B-GP
-	I-GP
1	I-GP
expressing	O
TTM	O
when	O
compared	O
to	O
their	O
PD	B-GP
-	I-GP
1	I-GP
negative	O
counterparts	O
(	O
p	O
=	O
0	O
.	O
053	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
5	O
)	O
(	O
Fig	O
3D	O
).	O

TEM	O
cells	O
expressing	O
TIGIT	O
were	O
enriched	O
for	O
integrated	O
genomes	O
when	O
compared	O
to	O
their	O
TIGIT	O
-	O
counterparts	O
(	O
p	O
=	O
0	O
.	O
001	O
,	O
fold	O
-	O
difference	O
=	O
2	O
.	O
7	O
)	O
(	O
Fig	O
3E	O
).	O

Finally	O
,	O
all	O
the	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
(	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
)	O
expressing	O
LAG	O
-	O
3	O
were	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
when	O
compared	O
to	O
their	O
negative	O
counterparts	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
003	O
,	O
fold	O
-	O
difference	O
=	O
1	O
.	O
8	O
and	O
p	O
=	O
0	O
.	O
030	O
,	O
fold	O
-	O
difference	O
=	O
2	O
.	O
5	O
respectively	O
)	O
(	O
Fig	O
3F	O
).	O

All	O
together	O
these	O
results	O
indicate	O
that	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
enrich	O
for	O
infected	O
cells	O
in	O
distinct	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cell	O
subsets	O
in	O
individuals	O
on	O
ART	O
.	O

We	O
calculated	O
the	O
contribution	O
of	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
to	O
the	O
total	O
reservoir	O
by	O
taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
subsets	O
within	O
the	O
CD4	B-GP
compartment	O
and	O
their	O
relative	O
infection	B-DS
frequencies	O
.	O

The	O
mean	O
contributions	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
29	O
%,	O
34	O
%	O
and	O
31	O
%,	O
respectively	O
(	O
S2	O
Fig	O
).	O

As	O
a	O
comparator	O
,	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
contributed	O
43	O
%,	O
27	O
%	O
and	O
24	O
%	O
to	O
the	O
pool	O
of	O
infected	O
cells	O
in	O
these	O
same	O
virally	O
suppressed	O
individuals	O
.	O

These	O
data	O
indicate	O
that	O
a	O
third	O
of	O
the	O
reservoir	O
is	O
encompassed	O
in	O
cells	O
expressing	O
each	O
individual	O
marker	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
highly	O
enriches	O
in	O
HIV	B-OG
-	O
infected	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
during	O
ART	O

We	O
then	O
determined	O
if	O
the	O
combination	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
would	O
further	O
enrich	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
during	O
ART	O
.	O

The	O
average	O
frequency	O
of	O
cells	O
expressing	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
of	O
these	O
markers	O
in	O
the	O
memory	O
CD4	B-GP
+	O
T	O
compartment	O
(	O
CD45RA	B-GP
-)	O
from	O
our	O
cohort	O
of	O
48	O
individuals	O
(	O
Table	O
1	O
)	O
indicated	O
that	O
an	O
average	O
of	O
33	O
%	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressed	O
one	O
of	O
the	O
3	O
IC	O
only	O
,	O
12	O
%	O
expressed	O
2	O
and	O
2	O
%	O
expressed	O
the	O
3	O
markers	O
simultaneously	O
.	O

Large	O
numbers	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
were	O
sorted	O
based	O
on	O
their	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
from	O
5	O
individuals	O
.	O

The	O
combination	O
of	O
these	O
3	O
markers	O
allowed	O
us	O
to	O
sort	O
eight	O
subsets	O
of	O
cells	O
to	O
high	O
purity	O
,	O
namely	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
-,	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+,	O
TIGIT	B-GP
single	O
+,	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+,	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
cells	O
.	O

The	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
was	O
measured	O
by	O
qPCR	O
in	O
each	O
sorted	O
subset	O
(	O
S3	O
Fig	O
)	O
and	O
the	O
mean	O
frequency	O
for	O
each	O
category	O
was	O
calculated	O
relative	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
(	O
Fig	O
4B	O
).	O

Memory	O
CD4	B-GP
+	O
T	O
cells	O
showed	O
a	O
gradual	O
enrichment	O
in	O
HIV	B-OG
-	O
infected	O
cells	O
when	O
expressing	O
an	O
increasing	O
number	O
of	O
ICs	O
.	O

Memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
were	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
up	O
to	O
10	O
times	O
more	O
when	O
compared	O
to	O
total	O
CD4	B-GP
+	O
T	O
cells	O
,	O
with	O
a	O
median	O
fold	O
increase	O
(	O
IQR	O
)	O
of	O
8	O
.	O
15	O
(	O
4	O
.	O
92	O
–	O
9	O
.	O
59	O
).	O

These	O
results	O
demonstrated	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
a	O
combination	O
of	O
ICs	O
were	O
highly	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identifies	O
HIV	B-OG
-	O
infected	O
cells	O
during	O
ART	O
.	O

(	O
A	O
)	O
Pie	O
chart	O
representing	O
the	O
frequencies	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
and	O
/	O
or	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

Coloured	O
bars	O
on	O
the	O
right	O
side	O
designate	O
categories	O
of	O
ICs	O
expressing	O
cells	O
:	O
Triple	O
-:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
—	O
in	O
blue	O
;	O
single	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+,	O
TIGIT	B-GP
single	O
+,	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
in	O
green	O
;	O
double	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
double	O
+,	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+,	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
in	O
orange	O
and	O
triple	O
+:	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
in	O
red	O
.	O

(	O
B	O
)	O
Frequency	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
represented	O
as	O
a	O
fold	O
change	O
over	O
frequency	O
in	O
total	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Mean	O
values	O
and	O
standard	O
deviations	O
from	O
5	O
independent	O
donors	O
are	O
represented	O
(	O
n	O
=	O
5	O
).	O

(	O
C	O
)	O
Frequency	O
of	O
cells	O
harboring	O
inducible	O
msRNA	O
measured	O
by	O
TILDA	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
any	O
(	O
i	O
.	O
e	O
.	O
at	O
least	O
one	O
)	O
versus	O
none	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
mLPT	B-GP
+	O
and	O
mLPT	B-GP
-	O
respectively	O
).	O

P	O
value	O
and	O
fold	O
-	O
difference	O
were	O
obtained	O
from	O
a	O
maximum	O
likelihood	O
model	O
.	O

As	O
the	O
majority	O
of	O
HIV	B-OG
genomes	O
,	O
even	O
when	O
integrated	O
,	O
are	O
defective	O
[	O
40	O
],	O
we	O
assessed	O
if	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
identify	O
cells	O
in	O
which	O
HIV	B-OG
production	O
can	O
be	O
induced	O
.	O

As	O
the	O
frequency	O
of	O
triple	O
positive	O
cells	O
was	O
too	O
low	O
to	O
perform	O
this	O
experiment	O
,	O
we	O
sorted	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
(	O
CD45RA	B-GP
-)	O
expressing	O
any	O
(	O
i	O
.	O
e	O
.	O
at	O
least	O
one	O
)	O
versus	O
none	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
mLPT	B-GP
+	O
and	O
mLPT	B-GP
-	O
respectively	O
).	O

We	O
measured	O
the	O
frequency	O
of	O
cells	O
in	O
each	O
population	O
that	O
transcribe	O
multiply	O
spliced	O
HIV	B-OG
RNA	O
molecules	O
upon	O
induction	O
with	O
PMA	O
/	O
ionomycin	B-CD
using	O
the	O
Tat	B-GP
/	O
rev	B-GP
induced	O
limiting	O
dilution	O
assay	O
(	O
TILDA	O
)	O
[	O
36	O
].	O

Tat	B-GP
/	O
rev	O
transcripts	O
were	O
detectable	O
by	O
TILDA	O
in	O
both	O
cell	O
subsets	O
from	O
all	O
of	O
the	O
8	O
individuals	O
tested	O
.	O

The	O
rate	O
of	O
inducible	O
virus	B-OG
per	O
million	O
cells	O
was	O
estimated	O
in	O
our	O
maximum	O
likelihood	O
model	O
to	O
average	O
3	O
.	O
0	O
-	O
fold	O
higher	O
in	O
mLPT	O
+	O
cells	O
than	O
in	O
mLPT	O
-	O
cells	O
from	O
the	O
same	O
participant	O
(	O
95	O
%	O
CI	O
1	O
.	O
0	O
to	O
9	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
049	O
,	O
S1C	O
Text	O
)	O
(	O
Fig	O
4C	O
).	O

Taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
cell	O
subsets	O
,	O
the	O
contribution	O
of	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
to	O
the	O
total	O
pool	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
infected	O
with	O
inducible	O
HIV	B-OG
genomes	O
was	O
calculated	O
.	O

This	O
contribution	O
ranged	O
from	O
30	O
to	O
98	O
%	O
(	O
median	O
of	O
76	O
%),	O
indicating	O
that	O
the	O
majority	O
of	O
inducible	O
HIV	B-OG
genomes	O
were	O
found	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
.	O

These	O
experiments	O
provide	O
evidence	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
/	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
inducible	O
proviruses	O
during	O
ART	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
identified	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
novel	O
markers	O
of	O
cells	O
that	O
are	O
more	O
frequently	O
infected	O
in	O
HIV	B-OG
-	O
infected	O
individuals	O
receiving	O
suppressive	O
ART	O
.	O

Co	O
-	O
expression	O
of	O
the	O
3	O
ICs	O
identified	O
a	O
unique	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
that	O
was	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
and	O
that	O
was	O
highly	O
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
.	O

Finally	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
are	O
the	O
major	O
contributors	O
to	O
the	O
pool	O
of	O
inducible	O
HIV	B-OG
genomes	O
during	O
ART	O
.	O

The	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIM	B-GP
-	I-GP
3	I-GP
were	O
similar	O
to	O
those	O
reported	O
by	O
other	O
groups	O
[	O
41	O
–	O
44	O
],	O
indicating	O
that	O
the	O
cohort	O
of	O
participants	O
used	O
for	O
this	O
study	O
is	O
likely	O
to	O
be	O
representative	O
of	O
the	O
HIV	B-OG
population	O
receiving	O
suppressive	O
ART	O
.	O

In	O
addition	O
,	O
the	O
association	O
between	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	B-GP
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
carrying	O
HIV	B-OG
proviruses	O
was	O
in	O
agreement	O
with	O
previously	O
reported	O
findings	O
[	O
6	O
,	O
24	O
,	O
41	O
].	O

We	O
found	O
positive	O
associations	O
between	O
the	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIGIT	B-GP
in	O
CD4	B-GP
+	O
T	O
cells	O
and	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
.	O

Of	O
note	O
,	O
these	O
three	O
markers	O
showed	O
the	O
strongest	O
inverse	O
associations	O
with	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
among	O
the	O
7	O
markers	O
we	O
examined	O
,	O
suggesting	O
a	O
link	O
between	O
T	O
cell	O
homeostasis	O
and	O
HIV	B-OG
persistence	O
(	O
S4A	O
,	O
S4B	O
and	O
S4C	O
Fig	O
).	O

The	O
associations	O
between	O
individual	O
IC	O
expression	O
and	O
HIV	B-OG
persistence	O
marker	O
were	O
substantially	O
smaller	O
and	O
no	O
longer	O
statistically	O
significant	O
after	O
adjusting	O
for	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
.	O

These	O
findings	O
from	O
the	O
negative	O
binomial	O
regression	O
models	O
suggest	O
that	O
the	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
count	O
is	O
an	O
important	O
predictor	O
of	O
the	O
size	O
of	O
the	O
HIV	B-OG
reservoir	O
when	O
measured	O
as	O
the	O
frequency	O
of	O
cells	O
harboring	O
proviral	O
genomes	O
[	O
6	O
,	O
37	O
].	O

Importantly	O
,	O
and	O
in	O
contrast	O
to	O
cells	O
expressing	O
a	O
single	O
marker	O
,	O
the	O
frequency	O
of	O
cells	O
co	O
-	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
was	O
strongly	O
associated	O
with	O
the	O
size	O
of	O
the	O
reservoir	O
and	O
remained	O
after	O
adjusting	O
for	O
nadir	O
and	O
current	O
CD4	B-GP
+	O
T	O
-	O
cell	O
counts	O
.	O

This	O
result	O
reinforces	O
the	O
possibility	O
of	O
a	O
direct	O
—	O
and	O
maybe	O
synergistic	O
—	O
role	O
for	O
these	O
molecules	O
in	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
simultaneously	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
positively	O
correlated	O
with	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
HLADR	B-GP
/	O
CD38	B-GP
(	O
p	O
=	O
0	O
.	O
003	O
,	O
r	O
=	O
0	O
.	O
42	O
)	O
and	O
Ki67	B-GP
(	O
p	O
=	O
0	O
.	O
022	O
,	O
r	O
=	O
0	O
.	O
33	O
)	O
(	O
S1D	O
and	O
S1E	O
Text	O
and	O
S4D	O
and	O
S4E	O
Fig	O
).	O

These	O
associations	O
suggest	O
that	O
the	O
persistence	O
of	O
the	O
small	O
pool	O
of	O
cells	O
expressing	O
the	O
3	O
markers	O
is	O
associated	O
with	O
T	O
cell	O
activation	O
and	O
proliferation	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
strong	O
negative	O
association	O
between	O
CD160	B-GP
expression	O
and	O
2	O
-	O
LTR	O
circles	O
.	O

Notably	O
,	O
this	O
correlation	O
remained	O
after	O
adjusting	O
for	O
current	O
and	O
nadir	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
findings	O
is	O
that	O
CD160	B-GP
+	O
cells	O
may	O
be	O
preferential	O
targets	O
for	O
infection	B-DS
and	O
depletion	O
during	O
ART	O
,	O
which	O
would	O
explain	O
the	O
strong	O
negative	O
association	O
between	O
the	O
frequency	O
of	O
CD160	B-GP
+	O
CD4	B-GP
+	O
T	O
cells	O
and	O
a	O
putative	O
marker	O
of	O
persistent	O
viral	O
replication	O
.	O

By	O
sorting	O
TCM	O
,	O
TTM	O
and	O
TEM	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
we	O
observed	O
that	O
cells	O
expressing	O
these	O
markers	O
were	O
enriched	O
for	O
HIV	B-OG
-	O
infected	O
cells	O
in	O
different	O
memory	O
CD4	B-GP
+	O
T	O
-	O
cells	O
subsets	O
during	O
ART	O
.	O

While	O
LAG	B-GP
-	I-GP
3	I-GP
enriched	O
for	O
integrated	O
HIV	B-OG
DNA	O
in	O
all	O
memory	O
subsets	O
(	O
TCM	O
,	O
TTM	O
,	O
and	O
TEM	O
),	O
PD	B-GP
-	I-GP
1	I-GP
and	O
TIGIT	O
enriched	O
for	O
HIV	B-OG
genomes	O
exclusively	O
in	O
TTM	O
and	O
TEM	O
cells	O
,	O
respectively	O
.	O

These	O
observations	O
suggest	O
that	O
ICs	O
may	O
exert	O
different	O
pro	O
-	O
latency	O
effects	O
in	O
subsets	O
endowed	O
with	O
distinct	O
proliferative	O
and	O
activation	O
status	O
.	O

One	O
may	O
hypothesize	O
that	O
different	O
ICs	O
provide	O
infected	O
cells	O
with	O
different	O
selective	O
advantage	O
to	O
persist	O
by	O
counteracting	O
distinct	O
stimuli	O
specific	O
to	O
an	O
individual	O
memory	O
cell	O
subset	O
.	O

Further	O
investigations	O
will	O
be	O
needed	O
to	O
characterize	O
the	O
mechanisms	O
by	O
which	O
these	O
ICs	O
may	O
specifically	O
contribute	O
to	O
HIV	B-OG
persistence	O
within	O
these	O
distinct	O
subsets	O
.	O

Overall	O
,	O
the	O
majority	O
of	O
inducible	O
HIV	B-OG
genomes	O
were	O
found	O
in	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
at	O
least	O
one	O
of	O
these	O
markers	O
(	O
median	O
of	O
76	O
%).	O

Although	O
triple	O
negative	O
cells	O
also	O
contain	O
inducible	O
HIV	B-OG
genomes	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
there	O
is	O
an	O
enrichment	O
for	O
inducible	O
viral	O
genomes	O
in	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
markers	O
.	O

Importantly	O
,	O
we	O
found	O
a	O
gradual	O
enrichment	O
in	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
that	O
express	O
multiple	O
ICs	O
simultaneously	O
.	O

This	O
observation	O
mirrors	O
the	O
synergistic	O
mechanisms	O
of	O
action	O
of	O
these	O
receptors	O
to	O
dampen	O
T	O
cell	O
functions	O
.	O

Indeed	O
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
PD	B-GP
-	I-GP
1	I-GP
are	O
commonly	O
co	O
-	O
expressed	O
on	O
exhausted	O
or	O
dysfunctional	O
T	O
cells	O
in	O
models	O
of	O
chronic	B-DS
infections	I-DS
[	O
45	O
],	O
autoimmune	B-DS
diseases	I-DS
[	O
46	O
],	O
and	O
cancers	B-DS
[	O
47	O
,	O
48	O
].	O

Potential	O
synergistic	O
functions	O
were	O
highlighted	O
in	O
murine	O
models	O
of	O
autoimmune	B-DS
diseases	I-DS
[	O
49	O
].	O

Anti	O
-	O
LAG	B-GP
-	I-GP
3	I-GP
blocking	O
mAb	O
has	O
recently	O
entered	O
clinical	O
testing	O
in	O
cancer	B-DS
in	O
monotherapy	O
or	O
in	O
combination	O
therapy	O
with	O
anti	O
-	O
PD	B-GP
-	I-GP
1	I-GP
(	O
NCT01968109	O
).	O

Additionally	O
,	O
TIGIT	B-GP
is	O
co	O
-	O
expressed	O
with	O
PD	B-GP
-	I-GP
1	I-GP
on	O
activated	O
CD8	B-GP
+	O
tumor	B-DS
-	O
infiltrating	O
lymphocytes	O
from	O
patients	O
with	O
melanoma	B-DS
[	O
50	O
].	O

Blockages	O
of	O
TIGIT	B-GP
and	O
PD	B-GP
-	I-GP
1	I-GP
synergize	O
to	O
improve	O
T	O
cell	O
proliferation	O
,	O
cytokines	B-GP
production	O
and	O
degranulation	O
in	O
vivo	O
in	O
melanoma	B-DS
treatment	O
and	O
in	O
vitro	O
in	O
HIV	B-DS
infection	I-DS
[	O
24	O
,	O
50	O
].	O

All	O
together	O
,	O
these	O
studies	O
indicate	O
that	O
ICs	O
can	O
synergize	O
to	O
repress	O
T	O
cell	O
functions	O
and	O
suggest	O
that	O
these	O
synergies	O
may	O
also	O
play	O
a	O
role	O
in	O
HIV	B-OG
persistence	O
during	O
ART	O
.	O

The	O
expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIM	B-GP
-	I-GP
3	I-GP
on	O
CD4	B-GP
+	O
and	O
CD8	B-GP
+	O
T	O
cells	O
prior	O
to	O
ART	O
was	O
recently	O
identified	O
as	O
a	O
strong	O
predictor	O
of	O
time	O
to	O
viral	O
rebound	O
after	O
treatment	O
interruption	O
in	O
the	O
SPARTAC	O
study	O
[	O
43	O
].	O

It	O
is	O
possible	O
that	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
these	O
markers	O
before	O
ART	O
represent	O
a	O
preferential	O
niche	O
for	O
the	O
establishment	O
of	O
a	O
stable	O
reservoir	O
for	O
HIV	B-OG
and	O
that	O
latently	O
infected	O
cells	O
expressing	O
these	O
markers	O
preferentially	O
persist	O
during	O
ART	O
,	O
as	O
suggested	O
by	O
our	O
observations	O
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
a	O
discrete	O
subset	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
as	O
an	O
important	O
predictor	O
of	O
the	O
frequency	O
of	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
during	O
ART	O
.	O

Of	O
note	O
,	O
the	O
expression	O
of	O
TIGIT	B-GP
before	O
ART	O
initiation	O
was	O
not	O
measured	O
in	O
the	O
SPARTAC	O
study	O
and	O
further	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
if	O
this	O
IC	O
could	O
also	O
represent	O
a	O
pre	O
-	O
ART	O
predictor	O
of	O
viral	O
rebound	O
.	O

Our	O
data	O
provide	O
a	O
rationale	O
for	O
the	O
use	O
of	O
immune	B-GP
checkpoint	I-GP
blockers	O
(	O
ICBs	O
)	O
to	O
target	O
latently	O
infected	O
cells	O
during	O
ART	O
.	O

Targeting	O
ICs	O
by	O
ICBs	O
,	O
a	O
novel	O
class	O
of	O
molecules	O
in	O
development	O
in	O
oncology	O
,	O
may	O
have	O
a	O
double	O
benefit	O
in	O
the	O
context	O
of	O
HIV	B-OG
remission	O
by	O
both	O
targeting	O
latently	O
infected	O
cells	O
and	O
restoring	O
HIV	B-OG
-	O
specific	O
T	O
cell	O
immunity	O
.	O

By	O
enhancing	O
T	O
cell	O
activation	O
and	O
increasing	O
viral	O
transcription	O
,	O
ICBs	O
may	O
facilitate	O
HIV	B-OG
reactivation	O
in	O
latently	O
infected	O
cells	O
when	O
used	O
alone	O
or	O
in	O
combination	O
with	O
latency	O
reversing	O
agents	O
.	O

The	O
anti	O
-	O
CTLA	B-GP
-	I-GP
4	I-GP
antibody	B-GP
iplimumab	B-CD
was	O
recently	O
shown	O
to	O
significantly	O
increase	O
CA	O
-	O
US	O
HIV	B-OG
RNA	O
in	O
an	O
HIV	B-OG
-	O
infected	O
individual	O
on	O
ART	O
,	O
consistent	O
with	O
latency	O
reversal	O
[	O
51	O
].	O

An	O
alternative	O
mechanism	O
of	O
action	O
of	O
some	O
ICBs	O
would	O
be	O
to	O
directly	O
deplete	O
cells	O
expressing	O
these	O
markers	O
,	O
as	O
observed	O
with	O
the	O
anti	O
-	O
CTLA	B-GP
-	I-GP
4	I-GP
ipilumimab	B-CD
,	O
which	O
induces	O
direct	O
elimination	O
of	O
CTLA	B-GP
-	I-GP
4	I-GP
+	O
regulatory	O
T	O
cells	O
in	O
tumor	B-DS
tissue	O
in	O
patients	O
with	O
melanoma	B-DS
[	O
52	O
].	O

Our	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
antibodies	B-GP
with	O
effector	O
functions	O
targeting	O
PD	B-GP
-	I-GP
1	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
TIGIT	B-GP
may	O
significantly	O
reduce	O
the	O
size	O
of	O
the	O
latent	O
HIV	B-OG
reservoir	O
during	O
ART	O
by	O
targeting	O
cells	O
in	O
which	O
HIV	B-OG
persists	O
.	O

Several	O
limitations	O
are	O
associated	O
with	O
our	O
study	O
.	O

We	O
have	O
not	O
adjusted	O
p	O
-	O
values	O
for	O
multiple	O
comparisons	O
,	O
because	O
such	O
adjustment	O
would	O
neglect	O
the	O
biological	O
relationships	O
among	O
our	O
positive	O
results	O
and	O
would	O
require	O
that	O
each	O
analysis	O
detract	O
from	O
the	O
others	O
,	O
rather	O
than	O
reinforcing	O
one	O
another	O
when	O
there	O
is	O
biological	O
coherence	O
[	O
53	O
]	O
(	O
S1F	O
Text	O
).	O

Nevertheless	O
,	O
our	O
evidence	O
may	O
be	O
weaker	O
than	O
if	O
it	O
had	O
arisen	O
from	O
a	O
narrower	O
set	O
of	O
analyses	O
,	O
and	O
,	O
in	O
any	O
case	O
,	O
additional	O
studies	O
will	O
be	O
needed	O
to	O
confirm	O
the	O
hypotheses	O
supported	O
by	O
our	O
results	O
.	O

Most	O
of	O
our	O
analyses	O
were	O
performed	O
using	O
integrated	O
HIV	B-OG
DNA	O
as	O
a	O
marker	O
of	O
HIV	B-OG
persistence	O
.	O

We	O
chose	O
this	O
readout	O
as	O
it	O
was	O
applicable	O
to	O
small	O
subsets	O
of	O
CD4	B-GP
+	O
T	O
cells	O
on	O
which	O
measures	O
of	O
replication	O
competent	O
HIV	B-OG
cannot	O
be	O
performed	O
.	O

The	O
majority	O
of	O
viral	O
genomes	O
persisting	O
during	O
ART	O
are	O
known	O
to	O
be	O
defective	O
[	O
40	O
,	O
54	O
],	O
and	O
although	O
our	O
experiments	O
indicate	O
that	O
cells	O
that	O
express	O
ICs	O
can	O
produce	O
multiply	O
spliced	O
RNA	O
upon	O
activation	O
(	O
TILDA	O
),	O
they	O
do	O
not	O
demonstrate	O
that	O
replication	O
competent	O
virus	B-OG
persists	O
in	O
these	O
cells	O
.	O

In	O
addition	O
,	O
our	O
results	O
are	O
limited	O
to	O
circulating	O
T	O
cells	O
.	O

It	O
is	O
possible	O
and	O
indeed	O
likely	O
that	O
the	O
biology	O
of	O
ICs	O
expression	O
and	O
HIV	B-OG
persistence	O
will	O
differ	O
in	O
tissues	O
,	O
particularly	O
in	O
secondary	O
lymphoid	O
tissues	O
where	O
many	O
of	O
the	O
ligands	O
for	O
these	O
receptors	O
are	O
likely	O
to	O
be	O
expressed	O
.	O

A	O
better	O
understanding	O
of	O
the	O
nature	O
of	O
the	O
cells	O
that	O
encompass	O
the	O
latent	O
HIV	B-OG
reservoir	O
is	O
a	O
prerequisite	O
to	O
the	O
development	O
of	O
novel	O
curative	O
strategies	O
.	O

Despite	O
similarities	O
in	O
their	O
mechanisms	O
of	O
action	O
,	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
likely	O
to	O
be	O
non	O
-	O
redundant	O
in	O
their	O
functions	O
.	O

Blocking	O
these	O
pathways	O
simultaneously	O
may	O
show	O
synergies	O
in	O
latency	O
reversal	O
,	O
as	O
suggested	O
by	O
their	O
synergistic	O
activities	O
in	O
the	O
restoration	O
of	O
T	O
cell	O
immunity	O
.	O

Supporting	O
Information	O

Materials	O
&	O
Methods	O
supporting	O
information	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Gating	O
strategy	O
of	O
7	O
ICs	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

Expression	O
of	O
PD	B-GP
-	I-GP
1	I-GP
,	O
CTLA	B-GP
-	I-GP
4	I-GP
,	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
TIGIT	B-GP
,	O
TIM	B-GP
-	I-GP
3	I-GP
,	O
CD160	B-GP
and	O
2B4	O
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
individuals	O
receiving	O
suppressive	O
ART	O
(	O
n	O
=	O
48	O
).	O

Representative	O
dot	O
plots	O
from	O
one	O
participant	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Contribution	O
of	O
ICs	O
expressing	O
cells	O
to	O
the	O
HIV	B-OG
reservoir	O
pool	O
.	O

The	O
contribution	O
of	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
(	O
A	O
),	O
TIGIT	B-GP
(	O
B	O
)	O
or	O
LAG	B-GP
-	I-GP
3	I-GP
(	O
C	O
)	O
to	O
the	O
total	O
HIV	B-OG
reservoir	O
by	O
taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
subsets	O
within	O
the	O
CD4	B-GP
compartment	O
and	O
their	O
relative	O
infection	B-DS
frequencies	O
(	O
n	O
=	O
12	O
,	O
n	O
=	O
9	O
and	O
n	O
=	O
7	O
,	O
respectively	O
).	O

Horizontal	O
bars	O
indicate	O
median	O
values	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Frequency	O
of	O
memory	O
CD4	B-GP
+	O
T	O
cells	O
harboring	O
integrated	O
HIV	B-OG
DNA	O
in	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
–(	O
LPT	O
-),	O
PD	B-GP
-	I-GP
1	I-GP
single	O
+	O
(	O
P	O
),	O
TIGIT	B-GP
single	O
+	O
(	O
T	O
),	O
LAG	B-GP
-	I-GP
3	I-GP
single	O
+	O
(	O
L	O
),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	B-GP
double	O
+	O
(	O
PT	O
),	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
LT	O
),	O
PD	B-GP
-	I-GP
1	I-GP
/	O
LAG	B-GP
-	I-GP
3	I-GP
double	O
+	O
(	O
LP	O
)	O
and	O
PD	B-GP
-	I-GP
1	I-GP
/	O
TIGIT	O
/	O
LAG	B-GP
-	I-GP
3	I-GP
triple	O
+	O
(	O
LPT	O
+)	O
cells	O
.	O

Raw	O
data	O
from	O
the	O
5	O
subjects	O
presented	O
in	O
Fig	O
4B	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	B-GP
and	O
LAG	B-GP
-	I-GP
3	I-GP
are	O
associated	O
with	O
markers	O
of	O
activation	O
/	O
proliferation	O
.	O

(	O
A	O
),	O
(	O
B	O
),	O
(	O
C	O
)	O
Associations	O
between	O
the	O
current	O
CD4	B-GP
+	O
T	O
cell	O
counts	O
and	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	I-GP
,	O
respectively	O
.	O

P	O
,	O
r	O
values	O
were	O
obtained	O
from	O
Spearman	O
’	O
s	O
ranked	O
analysis	O
.	O

(	O
D	O
),	O
(	O
E	O
)	O
Associations	O
between	O
the	O
frequency	O
of	O
CD4	B-GP
+	O
T	O
cells	O
co	O
-	O
expressing	O
PD	B-GP
-	I-GP
1	I-GP
,	O
TIGIT	O
and	O
LAG	B-GP
-	I-GP
3	I-GP
and	O
the	O
frequencies	O
of	O
CD4	B-GP
+	O
T	O
cells	O
expression	O
HLA	B-GP
-	I-GP
DR	I-GP
/	O
CD38	B-GP
and	O
Ki67	B-GP
respectively	O
.	O

P	O
,	O
r	O
values	O
were	O
obtained	O
from	O
Spearman	O
’	O
s	O
ranked	O
analysis	O
.	O

(	O
EPS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Virological	O
markers	O
of	O
HIV	B-OG
persistence	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
Total	O
HIV	B-OG
DNA	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
2	O
-	O
LTR	O
circles	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
assess	O
the	O
relationship	O
between	O
cell	O
-	O
associated	O
US	O
HIV	B-OG
RNA	O
and	O
Immune	O
Checkpoints	O
expression	O
on	O
CD4	B-GP
+	O
T	O
cells	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Negative	O
binomial	O
regression	O
models	O
to	O
compare	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
expressing	O
the	O
Immune	O
Checkpoint	O
Molecule	O
with	O
integrated	O
HIV	B-OG
DNA	O
in	O
cells	O
not	O
expressing	O
the	O
Immune	O
Checkpoint	O
Molecule	O
.	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Frequencies	O
of	O
ICs	O
on	O
CD4	B-GP
+	O
T	O
cells	O
in	O
cohort	O
1	O
(	O
n	O
=	O
48	O
).	O

(	O
DOCX	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Neural	O
,	O
biomechanical	O
,	O
and	O
physiological	O
factors	O
involved	O
in	O
sex	O
-	O
related	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
isometric	O
torque	O
development	O

Communicated	O
by	O
Toshio	O
Moritani	O
.	O

Objective	O

Recent	O
research	O
has	O
reported	O
that	O
lower	O
maximal	O
rate	O
of	O
torque	O
development	O
(	O
dτ	O
/	O
dt	O
max	O
)	O
exhibited	O
by	O
females	O
,	O
relative	O
to	O
males	O
,	O
during	O
knee	O
extension	O
can	O
be	O
accounted	O
for	O
by	O
normalization	O
to	O
a	O
maximal	O
voluntary	O
contraction	O
(	O
MVC	O
);	O
however	O
,	O
this	O
was	O
not	O
seen	O
in	O
the	O
upper	O
limb	O
.	O

Purpose	O

The	O
aim	O
of	O
the	O
current	O
work	O
was	O
to	O
examine	O
the	O
contribution	O
of	O
maximum	O
strength	O
(	O
τmax	O
),	O
twitch	O
contraction	O
time	O
(	O
CT	O
),	O
muscle	O
fiber	O
condition	O
velocity	O
(	O
MFCV	O
),	O
and	O
rate	O
of	O
muscle	O
activation	O
(	O
Q30	O
)	O
to	O
sex	O
-	O
differences	O
in	O
the	O
dτ	O
/	O
dt	O
max	O
during	O
maximal	O
isometric	O
dorsiflexion	O
.	O

Methods	O

Thirty	O
-	O
eight	O
participants	O
(	O
20	O
males	O
;	O
18	O
females	O
)	O
performed	O
both	O
maximal	O
voluntary	O
and	O
evoked	O
isometric	O
contractions	O
of	O
the	O
tibialis	O
anterior	O
across	O
3	O
days	O
.	O

Ten	O
maximal	O
compound	O
muscle	O
action	O
potentials	O
were	O
elicited	O
and	O
subsequently	O
followed	O
by	O
three	O
,	O
5	O
-	O
s	O
contractions	O
.	O

From	O
the	O
recordings	O
,	O
MFCV	O
,	O
dτ	O
/	O
dt	O
max	O
,	O
τmax	O
,	O
CT	O
,	O
electromechanical	O
delay	O
(	O
EMD	O
),	O
root	O
-	O
mean	O
squared	O
(	O
RMS	O
)	O
amplitude	O
,	O
peak	O
-	O
to	O
-	O
peak	O
voltage	O
(	O
Vpp	O
),	O
and	O
Q30	O
were	O
calculated	O
.	O

Results	O

An	O
ANCOVA	O
showed	O
that	O
τmax	O
accounted	O
for	O
all	O
the	O
sex	O
-	O
differences	O
in	O
dτ	O
/	O
dt	O
max	O
(	O
p	O
=	O
0	O
.	O
96	O
).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
with	O
respect	O
to	O
MFCV	O
,	O
RMS	O
amplitude	O
,	O
Vpp	O
amplitude	O
,	O
or	O
CT	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
sex	O
-	O
difference	O
in	O
dτ	O
/	O
dt	O
max	O
,	O
τmax	O
,	O
and	O
Q30	O
.	O

Females	O
had	O
longer	O
evoked	O
EMD	O
times	O
compared	O
with	O
males	O
(	O
15	O
.	O
69	O
±	O
10	O
.	O
57	O
ms	O
versus	O
9	O
.	O
95	O
±	O
3	O
.	O
46	O
ms	O
;	O
p	O
=	O
0	O
.	O
01	O
),	O
but	O
the	O
voluntary	O
EMD	O
times	O
were	O
not	O
different	O
.	O

Conclusion	O

The	O
current	O
research	O
supports	O
the	O
work	O
by	O
Hannah	O
et	O
al	O
.	O

Exp	O
Physiol	O
97	O
:	O
618	O
–	O
629	O
,	O
(	O
2012	O
)	O
that	O
normalization	O
to	O
MVC	O
in	O
the	O
quadriceps	O
is	O
able	O
to	O
account	O
for	O
all	O
sex	O
-	O
differences	O
in	O
rate	O
of	O
toque	O
development	O
in	O
the	O
lower	O
limb	O
.	O

Introduction	O

The	O
rate	O
of	O
tension	O
development	O
has	O
received	O
increased	O
attention	O
as	O
a	O
critical	O
aspect	O
of	O
dynamic	O
muscle	O
performance	O
during	O
activities	O
of	O
daily	O
living	O
(	O
e	O
.	O
g	O
.,	O
balance	O
maintenance	O
)	O
and	O
sport	O
performance	O
(	O
Aagaard	O
et	O
al	O
.	O
2002	O
;	O
LaRoche	O
et	O
al	O
.	O
2010	O
;	O
Paasuke	O
et	O
al	O
.	O
2001	O
;	O
Pijnapples	O
et	O
al	O
.	O
2008	O
;	O
Schultz	O
et	O
al	O
.	O
1997	O
;	O
Tillin	O
et	O
al	O
.	O
2013	O
).	O

A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
there	O
is	O
an	O
inextricable	O
link	O
between	O
the	O
ultimate	O
strength	O
of	O
the	O
muscle	O
and	O
its	O
rate	O
of	O
tension	O
development	O
(	O
Andersen	O
and	O
Aagaard	O
2006	O
;	O
Holtermann	O
et	O
al	O
.	O
2007	O
).	O

However	O
,	O
neural	O
factors	O
can	O
also	O
play	O
an	O
important	O
role	O
,	O
as	O
training	O
-	O
related	O
increases	O
in	O
the	O
maximal	O
rate	O
of	O
tension	O
development	O
are	O
associated	O
with	O
an	O
increase	O
in	O
muscle	O
activation	O
at	O
the	O
onset	O
of	O
contraction	O
(	O
Van	O
Cutsem	O
et	O
al	O
.	O
1998	O
;	O
Van	O
Cutsem	O
and	O
Duchateau	O
2005	O
).	O

Inglis	O
et	O
al	O
.	O
(	O
2013	O
)	O
recently	O
showed	O
that	O
neural	O
factors	O
also	O
play	O
a	O
role	O
in	O
sex	O
-	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
tension	O
development	O
in	O
the	O
upper	O
limb	O
.	O

Maximum	O
strength	O
was	O
used	O
as	O
a	O
covariate	O
and	O
was	O
only	O
able	O
to	O
account	O
for	O
a	O
portion	O
of	O
the	O
sex	O
-	O
differences	O
.	O

The	O
addition	O
of	O
a	O
second	O
variable	O
,	O
the	O
maximum	O
rate	O
of	O
electromyographic	O
(	O
EMG	O
)	O
activity	O
at	O
the	O
onset	O
of	O
contraction	O
(	O
Q30	O
),	O
was	O
able	O
to	O
eliminate	O
statistically	O
significant	O
sex	O
-	O
differences	O
.	O

Given	O
the	O
inherent	O
relationship	O
between	O
muscle	O
strength	O
and	O
the	O
maximum	O
rate	O
of	O
tension	O
development	O
,	O
few	O
studies	O
have	O
explored	O
additional	O
mechanisms	O
that	O
would	O
explain	O
sex	O
-	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
tension	O
development	O
(	O
Aagaard	O
et	O
al	O
.	O
2002	O
;	O
Andersen	O
and	O
Aagaard	O
2006	O
;	O
Folland	O
et	O
al	O
.	O
2014	O
;	O
Van	O
Cutsem	O
et	O
al	O
.	O
1998	O
).	O

However	O
,	O
sex	O
-	O
differences	O
in	O
lower	O
extremity	O
musculoskeletal	O
injury	O
rates	O
(	O
DiStefano	O
et	O
al	O
.	O
2015	O
)	O
and	O
falls	O
incidences	O
(	O
Hess	O
and	O
Woollacott	O
2005	O
;	O
Stevens	O
and	O
Sogolow	O
2005	O
)	O
may	O
be	O
linked	O
back	O
to	O
this	O
critical	O
aspect	O
of	O
muscle	O
contraction	O
(	O
Bento	O
et	O
al	O
.	O
2010	O
).	O

Hannah	O
et	O
al	O
.	O
(	O
2012	O
)	O
explored	O
potential	O
neural	O
and	O
biomechanical	O
factors	O
involved	O
in	O
sex	O
-	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
tension	O
development	O
in	O
the	O
quadriceps	O
,	O
in	O
addition	O
to	O
maximum	O
strength	O
.	O

Twitch	O
properties	O
,	O
electromechanical	O
delay	O
,	O
and	O
muscle	O
activation	O
using	O
surface	O
EMG	O
(	O
sEMG	O
)	O
were	O
also	O
assessed	O
.	O

Consistent	O
with	O
the	O
more	O
general	O
findings	O
for	O
the	O
relationship	O
between	O
maximum	O
strength	O
and	O
the	O
rate	O
of	O
tension	O
development	O
,	O
when	O
the	O
peak	O
rate	O
of	O
tension	O
development	O
was	O
normalized	O
with	O
respect	O
to	O
maximum	O
isometric	O
strength	O
of	O
the	O
muscle	O
,	O
the	O
sex	O
-	O
differences	O
were	O
completely	O
eliminated	O
.	O

The	O
results	O
by	O
Hannah	O
et	O
al	O
.	O
(	O
2012	O
)	O
in	O
the	O
lower	O
limb	O
are	O
contrary	O
to	O
the	O
finding	O
of	O
Inglis	O
et	O
al	O
.	O
(	O
2013	O
)	O
who	O
showed	O
a	O
role	O
for	O
neural	O
factors	O
in	O
the	O
upper	O
limb	O
.	O

It	O
may	O
be	O
hypothesized	O
that	O
since	O
males	O
and	O
females	O
were	O
more	O
comparable	O
in	O
absolute	O
strength	O
in	O
the	O
quadriceps	O
(	O
Δ33	O
%)	O
than	O
the	O
biceps	O
(	O
Δ55	O
.	O
5	O
%;	O
Inglis	O
et	O
al	O
.	O
2013	O
),	O
strength	O
may	O
entirely	O
explain	O
sex	O
-	O
differences	O
in	O
the	O
rate	O
of	O
tension	O
development	O
in	O
the	O
lower	O
limb	O
.	O

In	O
contrast	O
,	O
the	O
difference	O
in	O
maximum	O
strength	O
between	O
males	O
and	O
females	O
in	O
the	O
upper	O
limb	O
observed	O
by	O
Inglis	O
et	O
al	O
.	O
(	O
2013	O
)	O
was	O
much	O
greater	O
(	O
Δ55	O
.	O
5	O
%),	O
possibly	O
allowing	O
for	O
additional	O
factors	O
,	O
such	O
as	O
the	O
rate	O
of	O
muscle	O
activation	O
,	O
to	O
play	O
a	O
role	O
.	O

Inglis	O
et	O
al	O
.	O
(	O
2013	O
)	O
explored	O
the	O
possibility	O
that	O
the	O
interpretation	O
of	O
the	O
results	O
may	O
differ	O
based	O
on	O
normalization	O
to	O
maximum	O
voluntary	O
strength	O
versus	O
the	O
use	O
of	O
a	O
covariate	O
approach	O
.	O

It	O
was	O
found	O
that	O
normalization	O
to	O
maximum	O
voluntary	O
strength	O
also	O
failed	O
to	O
account	O
for	O
all	O
sex	O
-	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
tension	O
development	O
.	O

Since	O
there	O
is	O
a	O
strong	O
relationship	O
between	O
maximum	O
strength	O
and	O
the	O
rate	O
of	O
tension	O
development	O
,	O
sex	O
-	O
differences	O
may	O
be	O
accounted	O
for	O
by	O
maximum	O
strength	O
only	O
when	O
the	O
two	O
groups	O
are	O
‘	O
more	O
’	O
comparable	O
with	O
respect	O
to	O
maximal	O
strength	O
as	O
exists	O
in	O
the	O
lower	O
limb	O
compared	O
with	O
the	O
upper	O
limb	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
males	O
and	O
females	O
are	O
more	O
comparable	O
in	O
maximal	O
isometric	O
dorsiflexion	O
strength	O
(	O
Δ28	O
.	O
9	O
%)	O
and	O
identical	O
with	O
respect	O
to	O
root	O
-	O
mean	O
-	O
square	O
(	O
RMS	O
)	O
sEMG	O
magnitude	O
(	O
Heyward	O
et	O
al	O
.	O
1986	O
;	O
Hoffman	O
et	O
al	O
.	O
1979	O
;	O
Lenhardt	O
et	O
al	O
.	O
2009	O
).	O

Unfortunately	O
,	O
Lenhardt	O
et	O
al	O
.	O
2009	O
did	O
not	O
assess	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
.	O

The	O
28	O
.	O
9	O
%	O
strength	O
difference	O
between	O
the	O
sexes	O
is	O
consistent	O
with	O
Holmbäck	O
et	O
al	O
.	O
(	O
2003	O
)	O
who	O
concluded	O
that	O
muscle	O
cross	O
-	O
sectional	O
area	O
was	O
the	O
principal	O
determinant	O
of	O
dorsiflexion	O
strength	O
.	O

In	O
general	O
,	O
the	O
muscle	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
TA	O
in	O
males	O
is	O
only	O
20	O
%	O
larger	O
than	O
that	O
for	O
females	O
(	O
Holmbäck	O
et	O
al	O
.	O
2003	O
;	O
Jaworowski	O
et	O
al	O
.	O
2002	O
).	O

The	O
purpose	O
of	O
this	O
paper	O
was	O
to	O
determine	O
if	O
sex	O
-	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
isometric	O
dorsiflexion	O
torque	O
development	O
are	O
determined	O
by	O
maximum	O
isometric	O
dorsiflexion	O
torque	O
alone	O
or	O
other	O
factors	O
as	O
observed	O
for	O
the	O
upper	O
limb	O
where	O
the	O
strength	O
differences	O
are	O
more	O
pronounced	O
.	O

Based	O
on	O
the	O
work	O
of	O
Hannah	O
et	O
al	O
.	O
(	O
2012	O
),	O
it	O
was	O
hypothesized	O
that	O
maximum	O
isometric	O
strength	O
would	O
account	O
for	O
sex	O
-	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
in	O
the	O
TA	O
,	O
because	O
males	O
and	O
females	O
are	O
more	O
comparable	O
in	O
maximum	O
isometric	O
strength	O
in	O
the	O
lower	O
limb	O
.	O

Studying	O
mechanisms	O
behind	O
sex	O
-	O
differences	O
in	O
distal	O
muscles	O
that	O
are	O
responsible	O
for	O
balance	O
and	O
explosive	O
activity	O
can	O
guide	O
specific	O
training	O
interventions	O
or	O
rehabilitation	O
techniques	O
.	O

Methods	O

Participants	O

A	O
power	O
analysis	O
was	O
performed	O
prior	O
to	O
data	O
collection	O
based	O
on	O
research	O
by	O
Lenhardt	O
et	O
al	O
.	O
(	O
2009	O
),	O
showing	O
that	O
a	O
subject	O
pool	O
of	O
18	O
males	O
and	O
females	O
was	O
sufficient	O
to	O
show	O
differences	O
in	O
the	O
rate	O
of	O
muscle	O
activation	O
(	O
Q30	O
).	O

However	O
,	O
to	O
protect	O
against	O
subject	O
drop	O
out	O
,	O
40	O
subjects	O
(	O
males	O
and	O
females	O
)	O
were	O
recruited	O
.	O

Pre	O
-	O
tension	O
on	O
the	O
load	O
cell	O
was	O
observed	O
in	O
two	O
female	O
subjects	O
,	O
so	O
their	O
data	O
was	O
removed	O
from	O
the	O
analysis	O
.	O

Thus	O
,	O
38	O
healthy	O
Brock	O
University	O
Kinesiology	O
students	O
(	O
20	O
males	O
and	O
18	O
females	O
)	O
were	O
analyzed	O
in	O
this	O
study	O
.	O

The	O
participants	O
were	O
free	O
of	O
any	O
orthopedic	O
or	O
neuromuscular	B-DS
disorders	I-DS
,	O
right	O
leg	O
dominant	O
,	O
and	O
provided	O
written	O
informed	O
consent	O
prior	O
to	O
study	O
participation	O
in	O
accordance	O
with	O
the	O
Brock	O
University	O
Research	O
Ethics	O
Board	O
guidelines	O
(	O
REB	O
-	O
02	O
-	O
284	O
).	O

Each	O
participant	O
was	O
familiarized	O
with	O
the	O
Electromyographic	O
Kinesiology	O
Laboratory	O
prior	O
to	O
the	O
first	O
testing	O
session	O
.	O

Prior	O
to	O
testing	O
,	O
participants	O
were	O
asked	O
about	O
their	O
history	O
of	O
physical	O
activity	O
and	O
weight	O
training	O
(	O
years	O
of	O
experience	O
)	O
as	O
well	O
as	O
the	O
duration	O
(	O
hours	O
per	O
week	O
and	O
per	O
day	O
)	O
and	O
the	O
percentage	O
of	O
weight	O
training	O
focusing	O
on	O
the	O
upper	O
body	O
or	O
lower	O
body	O
.	O

Experimental	O
setup	O
and	O
scheduling	O

All	O
testing	O
was	O
performed	O
as	O
the	O
participant	O
sat	O
in	O
a	O
custom	O
built	O
testing	O
chair	O
designed	O
to	O
isolate	O
the	O
dorsiflexors	O
during	O
maximal	O
isometric	O
contractions	O
.	O

Participants	O
sat	O
with	O
their	O
hip	O
and	O
knee	O
joints	O
secured	O
at	O
90	O
°	O
of	O
flexion	O
and	O
the	O
ankle	O
joint	O
secured	O
at	O
110	O
°	O
of	O
plantar	O
flexion	O
(	O
Inglis	O
et	O
al	O
.	O
2011	O
).	O

Slight	O
plantar	O
flexion	O
was	O
chosen	O
as	O
previous	O
research	O
has	O
shown	O
that	O
a	O
certain	O
degree	O
of	O
plantar	O
flexion	O
produces	O
a	O
maximal	O
torque	O
and	O
110	O
°	O
may	O
place	O
the	O
TA	O
closer	O
to	O
optimal	O
length	O
for	O
both	O
maximal	O
evoked	O
and	O
voluntary	O
dorsiflexion	O
torque	O
production	O
,	O
which	O
considers	O
the	O
lever	O
arm	O
length	O
(	O
Marsh	O
et	O
al	O
.	O
1981	O
).	O

A	O
load	O
cell	O
(	O
JR3	O
,	O
Woodland	O
,	O
CA	O
,	O
USA	O
)	O
was	O
secured	O
under	O
the	O
foot	O
plate	O
of	O
which	O
the	O
foot	O
was	O
restrained	O
by	O
a	O
minimally	O
padded	O
steel	O
bar	O
located	O
proximal	O
to	O
the	O
metatarsals	O
for	O
all	O
torque	O
recordings	O
(	O
Christie	O
et	O
al	O
.	O
2009	O
).	O

There	O
were	O
3	O
days	O
of	O
testing	O
to	O
assess	O
the	O
reliability	O
of	O
the	O
measures	O
as	O
participants	O
can	O
exhibit	O
a	O
learning	O
effect	O
during	O
maximal	O
strength	O
assessment	O
(	O
Green	O
et	O
al	O
.	O
2014	O
).	O

On	O
each	O
day	O
,	O
participants	O
were	O
asked	O
to	O
perform	O
the	O
same	O
tasks	O
.	O

These	O
tasks	O
included	O
both	O
voluntary	O
isometric	O
maximal	O
dorsiflexion	O
contractions	O
and	O
maximal	O
evoked	O
isometric	O
torque	O
.	O

Each	O
of	O
the	O
three	O
testing	O
days	O
was	O
separated	O
by	O
at	O
least	O
48	O
h	O
to	O
avoid	O
any	O
complications	O
,	O
which	O
may	O
arise	O
as	O
a	O
result	O
of	O
fatigue	O
.	O

sEMG	O
recordings	O

Participants	O
lay	O
supine	O
on	O
a	O
gurney	O
,	O
so	O
that	O
the	O
most	O
prominent	O
TA	O
motor	O
point	O
may	O
be	O
electrically	O
identified	O
using	O
a	O
metallic	O
probe	O
over	O
the	O
skin	O
surface	O
(	O
Christie	O
et	O
al	O
.	O
2005	O
).	O

The	O
lowest	O
possible	O
current	O
that	O
produced	O
a	O
minimally	O
visible	O
twitch	O
was	O
taken	O
as	O
the	O
motor	O
point	O
(	O
Calder	O
and	O
Gabriel	O
2007	O
).	O

Following	O
motor	O
point	O
identification	O
,	O
the	O
recording	O
areas	O
were	O
shaved	O
,	O
mildly	O
abraded	O
(	O
NuPrep	O
;	O
Weaver	O
and	O
Co	O
.,	O
Aurora	O
,	O
CO	O
),	O
and	O
finally	O
cleansed	O
with	O
alcohol	B-CD
to	O
minimize	O
skin	O
–	O
electrode	O
input	O
impedance	O
.	O

The	O
sEMG	O
recording	O
electrode	O
had	O
three	O
parallel	O
stainless	O
steel	O
bars	O
which	O
resulted	O
in	O
two	O
bipolar	O
signals	O
.	O

Each	O
stainless	O
steel	O
bar	O
was	O
1	O
mm	O
in	O
diameter	O
,	O
10	O
mm	O
long	O
,	O
and	O
was	O
mounted	O
with	O
an	O
interbar	O
distance	O
of	O
5	O
mm	O
.	O

The	O
recording	O
electrode	O
was	O
prepared	O
with	O
double	O
-	O
sided	O
adhesive	O
tape	O
,	O
electrolyte	O
gel	O
(	O
Signal	O
Gel	O
;	O
Parker	O
Laboratories	O
,	O
Inc	O
.,	O
Fairfield	O
,	O
New	O
Jersey	O
),	O
and	O
placed	O
in	O
line	O
with	O
the	O
muscle	O
fibers	O
,	O
1	O
cm	O
distal	O
to	O
the	O
motor	O
point	O
.	O

Alignment	O
and	O
final	O
placement	O
of	O
the	O
electrodes	O
for	O
recording	O
MFCV	O
followed	O
the	O
procedures	O
outlined	O
in	O
McIntosh	O
and	O
Gabriel	O
(	O
2012	O
).	O

Finally	O
,	O
a	O
ground	O
electrode	O
(	O
CF5000	O
;	O
Axelgaard	O
)	O
was	O
placed	O
on	O
the	O
lateral	O
malleolus	O
(	O
McIntosh	O
and	O
Gabriel	O
2012	O
).	O

Electrode	O
–	O
skin	O
input	O
impedance	O
(	O
Grass	O
EZM5	O
,	O
Astro	O
-	O
Med	O
Inc	O
.,	O
West	O
Warwick	O
,	O
RI	O
)	O
was	O
assessed	O
before	O
and	O
after	O
the	O
experiment	O
to	O
ensure	O
it	O
remained	O
below	O
10	O
kΩ	O
.	O

Skin	O
temperature	O
(	O
Electrotherm	O
TM99A	O
;	O
Cooper	O
Instrument	O
Corp	O
.,	O
Middlefield	O
,	O
Connecticut	O
)	O
was	O
also	O
monitored	O
before	O
and	O
after	O
the	O
experiment	O
to	O
verify	O
that	O
there	O
was	O
no	O
change	O
,	O
which	O
could	O
affect	O
the	O
stability	O
of	O
the	O
myoelectric	O
signal	O
.	O

sEMG	O
was	O
band	O
-	O
pass	O
filtered	O
(	O
between	O
10	O
and	O
1000	O
Hz	O
)	O
and	O
amplified	O
(	O
Grass	O
P511	O
;	O
Astro	O
-	O
Med	O
)	O
to	O
maximize	O
the	O
resolution	O
on	O
a	O
16	O
-	O
bit	O
analog	O
-	O
to	O
-	O
digital	O
converter	O
(	O
MI	O
PCI	O
-	O
6052E	O
;	O
National	O
Instruments	O
,	O
Austin	O
,	O
TX	O
).	O

All	O
signals	O
were	O
collected	O
at	O
5000	O
Hz	O
and	O
acquired	O
on	O
a	O
computer	O
-	O
based	O
data	O
acquisition	O
system	O
(	O
DASYLab	O
;	O
DASYTEC	O
National	O
Instruments	O
,	O
Amherst	O
,	O
New	O
Hampshire	O
).	O

The	O
data	O
were	O
stored	O
on	O
a	O
PC	O
(	O
Celeron	O
;	O
Dell	O
,	O
Round	O
Rock	O
,	O
Texas	O
)	O
for	O
offline	O
analysis	O
.	O

The	O
data	O
window	O
for	O
the	O
sEMG	O
analysis	O
of	O
the	O
maximal	O
voluntary	O
contraction	O
was	O
500	O
ms	O
,	O
terminating	O
before	O
the	O
middle	O
of	O
the	O
contraction	O
(	O
Inglis	O
et	O
al	O
.	O
2013	O
).	O

The	O
sEMG	O
signals	O
were	O
up	O
-	O
sampled	O
to	O
25	O
kHz	O
prior	O
to	O
calculating	O
the	O
cross	O
-	O
correlation	O
coefficient	O
to	O
increase	O
the	O
time	O
resolution	O
of	O
the	O
action	O
potential	O
propagation	O
(	O
Farina	O
and	O
Merletti	O
2004	O
).	O

Muscle	O
fiber	O
conduction	O
velocity	O
calculation	O
was	O
based	O
on	O
the	O
time	O
delay	O
identified	O
by	O
the	O
peak	O
of	O
the	O
cross	O
-	O
correlation	O
function	O
and	O
the	O
known	O
interbar	O
distance	O
of	O
5	O
mm	O
.	O

The	O
root	O
-	O
mean	O
-	O
square	O
(	O
RMS	O
)	O
amplitude	O
of	O
sEMG	O
activity	O
was	O
also	O
calculated	O
.	O

The	O
rate	O
of	O
muscle	O
activation	O
was	O
calculated	O
by	O
first	O
rectifying	O
the	O
sEMG	O
data	O
and	O
then	O
numerically	O
integrating	O
the	O
first	O
30	O
ms	O
starting	O
from	O
the	O
sEMG	O
onset	O
(	O
Q30	O
)	O
that	O
represents	O
the	O
rate	O
of	O
increase	O
in	O
the	O
sEMG	O
over	O
the	O
first	O
30	O
ms	O
of	O
muscle	O
activity	O
(	O
Gottlieb	O
et	O
al	O
.	O
1989	O
).	O

Electromechanical	O
delay	O
(	O
EMD	O
)	O
comprises	O
an	O
important	O
portion	O
of	O
the	O
rate	O
of	O
tension	O
development	O
phase	O
of	O
the	O
contraction	O
(	O
Gabriel	O
et	O
al	O
.	O
2001	O
),	O
where	O
changes	O
in	O
motor	O
unit	O
activity	O
patterns	O
have	O
been	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
maximal	O
rate	O
of	O
torque	O
development	O
(	O
Van	O
Cutsem	O
et	O
al	O
.	O
1998	O
).	O

Electromechanical	O
delay	O
was	O
determined	O
from	O
the	O
time	O
lag	O
between	O
the	O
onset	O
of	O
dorsiflexion	O
torque	O
and	O
sEMG	O
.	O

sEMG	O
onset	O
threshold	O
was	O
identified	O
as	O
the	O
first	O
point	O
of	O
the	O
sEMG	O
signal	O
to	O
rise	O
above	O
the	O
95	O
%	O
confidence	O
interval	O
for	O
baseline	O
noise	O
and	O
to	O
remain	O
above	O
the	O
95	O
%	O
confidence	O
interval	O
for	O
20	O
ms	O
(	O
Di	O
Fabio	O
1987	O
).	O

Visual	O
inspection	O
was	O
utilized	O
to	O
ensure	O
the	O
accuracy	O
of	O
the	O
established	O
threshold	O
’	O
s	O
ability	O
to	O
detect	O
either	O
torque	O
or	O
sEMG	O
onset	O
(	O
Inglis	O
et	O
al	O
.	O
2013	O
).	O

Evoked	O
isometric	O
compound	O
muscle	O
action	O
potentials	O

Compound	O
muscle	O
action	O
potentials	O
were	O
evoked	O
through	O
a	O
cathode	O
stimulating	O
electrode	O
placed	O
over	O
the	O
fibular	O
nerve	O
along	O
with	O
an	O
anode	O
placed	O
on	O
the	O
medial	O
condyle	O
of	O
the	O
fibula	O
to	O
evoke	O
an	O
isometric	O
dorsiflexion	O
twitch	O
contraction	O
.	O

The	O
evoked	O
potentials	O
were	O
monitored	O
on	O
an	O
oscilloscope	O
(	O
VC	O
-	O
6525	O
;	O
Hitachi	O
)	O
to	O
ensure	O
that	O
a	O
consistent	O
maximal	O
response	O
had	O
been	O
achieved	O
for	O
ten	O
stimulations	O
.	O

The	O
peak	O
-	O
to	O
-	O
peak	O
voltage	O
(	O
Vpp	O
)	O
was	O
extracted	O
from	O
the	O
CMAP	O
,	O
while	O
contraction	O
time	O
(	O
CT	O
)	O
was	O
obtained	O
from	O
the	O
torque	O
-	O
time	O
curve	O
.	O

Evoked	O
contraction	O
time	O
(	O
CT	O
)	O
was	O
calculated	O
from	O
the	O
time	O
difference	O
between	O
the	O
CMAP	O
onset	O
to	O
its	O
time	O
to	O
peak	O
tension	O
(	O
Dahmane	O
et	O
al	O
.	O
2005	O
).	O

Contraction	O
time	O
is	O
used	O
in	O
this	O
paper	O
to	O
separate	O
differences	O
in	O
the	O
rate	O
of	O
torque	O
development	O
associated	O
with	O
voluntary	O
control	O
versus	O
muscle	O
fibers	O
properties	O
.	O

Ultimately	O
,	O
it	O
was	O
important	O
to	O
determine	O
if	O
potential	O
sex	O
-	O
difference	O
in	O
Q30	O
could	O
be	O
due	O
to	O
the	O
initial	O
differences	O
in	O
peripheral	O
factors	O
(	O
MFCV	O
,	O
Vpp	O
,	O
or	O
CT	O
)	O
or	O
overall	O
voluntary	O
activation	O
(	O
RMS	O
).	O

Maximal	O
voluntary	O
isometric	O
dorsiflexion	O
contractions	O

After	O
the	O
evoked	O
contractions	O
,	O
a	O
15	O
-	O
min	O
rest	O
period	O
was	O
given	O
.	O

Participants	O
then	O
performed	O
three	O
voluntary	O
maximal	O
effort	O
isometric	O
dorsiflexion	O
contractions	O
by	O
pulling	O
with	O
the	O
top	O
of	O
their	O
foot	O
against	O
a	O
padded	O
metal	O
plate	O
while	O
minimizing	O
toe	O
extension	O
.	O

During	O
the	O
MVC	O
’	O
s	O
,	O
each	O
participant	O
was	O
asked	O
to	O
contract	O
“	O
as	O
hard	O
and	O
as	O
fast	O
as	O
possible	O
”	O
with	O
an	O
emphasis	O
on	O
the	O
“	O
hard	O
”	O
(	O
Sahaly	O
et	O
al	O
.	O
2001	O
).	O

Each	O
contraction	O
lasted	O
approximately	O
5	O
s	O
in	O
duration	O
and	O
was	O
separated	O
by	O
a	O
5	O
-	O
min	O
rest	O
period	O
.	O

The	O
force	O
data	O
were	O
converted	O
to	O
torque	O
values	O
using	O
the	O
lever	O
arm	O
length	O
,	O
measured	O
from	O
the	O
ankle	O
joint	O
to	O
the	O
metatarsals	O
,	O
where	O
the	O
load	O
cell	O
was	O
located	O
.	O

A	O
target	O
line	O
was	O
given	O
which	O
represented	O
110	O
%	O
of	O
the	O
previously	O
determined	O
maximal	O
effort	O
,	O
which	O
was	O
identified	O
in	O
real	O
time	O
on	O
an	O
oscilloscope	O
.	O

Furthermore	O
,	O
during	O
each	O
voluntary	O
contraction	O
,	O
the	O
participants	O
were	O
verbally	O
encouraged	O
to	O
surpass	O
the	O
target	O
line	O
.	O

Figure	O
1	O
shows	O
a	O
representative	O
torque	O
trace	O
,	O
rate	O
of	O
change	O
in	O
torque	O
,	O
and	O
surface	O
electromyographic	O
activity	O
of	O
the	O
tibialis	O
anterior	O
during	O
a	O
maximal	O
effort	O
dorsiflexion	O
contraction	O
.	O

The	O
manner	O
in	O
which	O
the	O
signals	O
were	O
collected	O
is	O
described	O
below	O
.	O
Fig	O
.	O
1Torque	O
(	O
τ	O
)	O
(	O
dark	O
grey	O
),	O
surface	O
electromyographic	O
activity	O
(	O
light	O
grey	O
),	O
and	O
the	O
rate	O
of	O
torque	O
development	O
(	O
black	O
)	O
over	O
the	O
first	O
second	O
of	O
a	O
trial	O
for	O
a	O
male	O
representative	O
subject	O
.	O

The	O
first	O
vertical	O
line	O
(	O
black	O
)	O
represents	O
the	O
EMG	O
onset	O
;	O
the	O
second	O
vertical	O
line	O
(	O
grey	O
)	O
represents	O
the	O
torque	O
onset	O

Maximum	O
rate	O
of	O
torque	O
development	O
was	O
calculated	O
from	O
the	O
equation	O
provided	O
by	O
Andersen	O
and	O
Aagaard	O
(	O
2006	O
).	O

The	O
calculation	O
involves	O
determining	O
the	O
slope	O
(	O
Δτ	O
/	O
Δt	O
)	O
over	O
non	O
-	O
overlapping	O
,	O
successive	O
20	O
ms	O
intervals	O
,	O
starting	O
from	O
the	O
onset	O
of	O
the	O
torque	O
-	O
time	O
curve	O
.	O

The	O
onset	O
was	O
determined	O
as	O
the	O
point	O
in	O
the	O
signal	O
where	O
the	O
rate	O
of	O
change	O
surpassed	O
1	O
%	O
of	O
the	O
maximal	O
rate	O
of	O
torque	O
development	O
(	O
dτ	O
/	O
dt	O
max	O
).	O

The	O
dτ	O
/	O
dt	O
max	O
was	O
then	O
the	O
maximum	O
slope	O
,	O
which	O
is	O
synonymous	O
with	O
the	O
‘	O
peak	O
’	O
of	O
the	O
dτ	O
/	O
dt	O
curve	O
(	O
Gabriel	O
et	O
al	O
.	O
2001	O
).	O

Statistical	O
analysis	O

Statistical	O
analysis	O
was	O
conducted	O
in	O
two	O
stages	O
:	O
first	O
,	O
to	O
evaluate	O
the	O
reliability	O
of	O
the	O
criterion	O
measures	O
using	O
the	O
intraclass	O
correlational	O
analysis	O
of	O
variance	O
technique	O
for	O
males	O
and	O
females	O
,	O
separately	O
;	O
second	O
,	O
significant	O
differences	O
between	O
males	O
and	O
females	O
(	O
Sex	O
)	O
in	O
the	O
magnitude	O
of	O
the	O
means	O
,	O
and	O
changes	O
in	O
the	O
means	O
across	O
test	O
sessions	O
(	O
Days	O
),	O
and	O
the	O
interaction	O
(	O
Sex	O
×	O
Days	O
)	O
was	O
evaluated	O
using	O
a	O
repeated	O
-	O
measures	O
analysis	O
of	O
covariance	O
to	O
determine	O
the	O
impact	O
of	O
potential	O
variables	O
that	O
may	O
underlie	O
sex	O
-	O
differences	O
in	O
the	O
rate	O
of	O
torque	O
development	O
.	O

Intraclass	O
correlation	O

Intraclass	O
correlational	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
performed	O
to	O
evaluate	O
the	O
reliability	O
of	O
the	O
criterion	O
measures	O
for	O
each	O
group	O
,	O
which	O
requires	O
the	O
consideration	O
of	O
both	O
the	O
stability	O
of	O
means	O
and	O
the	O
consistency	O
of	O
scores	O
.	O

A	O
one	O
-	O
way	O
repeated	O
-	O
measures	O
ANOVA	O
was	O
used	O
to	O
assess	O
the	O
stability	O
of	O
means	O
across	O
the	O
three	O
test	O
sessions	O
,	O
while	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
model	O
2	O
,	O
k	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
consistency	O
of	O
scores	O
within	O
subjects	O
.	O

We	O
adopted	O
the	O
convention	O
delineated	O
by	O
Fleiss	O
(	O
1986	O
)	O
where	O
an	O
intraclass	O
correlation	O
coefficient	O
(	O
R	O
)	O
below	O
0	O
.	O
40	O
indicates	O
poor	O
reliability	O
,	O
between	O
0	O
.	O
40	O
and	O
0	O
.	O
75	O
is	O
fair	O
reliability	O
,	O
while	O
values	O
greater	O
than	O
0	O
.	O
75	O
represent	O
excellent	O
reliability	O
.	O

The	O
magnitude	O
of	O
the	O
intraclass	O
correlation	O
coefficient	O
was	O
further	O
evaluated	O
using	O
the	O
standard	O
error	O
of	O
measurement	O
(	O
SEM	O
)	O
within	O
an	O
individual	O
(	O
Green	O
et	O
al	O
.	O
2015	O
).	O

The	O
SEM	O
was	O
calculated	O
as	O
the	O
square	O
of	O
the	O
mean	O
square	O
error	O
for	O
the	O
ANOVA	O
table	O
using	O
the	O
variables	O
‘	O
Sex	O
’	O
and	O
‘	O
Day	O
’	O
(	O
Weir	O
and	O
Cockerham	O
1984	O
).	O

The	O
intrasubject	O
coefficient	O
of	O
variation	O
was	O
the	O
grand	O
mean	O
across	O
the	O
three	O
test	O
sessions	O
divided	O
by	O
the	O
SEM	O
.	O

Analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O

A	O
repeated	O
-	O
measures	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
was	O
then	O
used	O
to	O
determine	O
the	O
impact	O
of	O
a	O
covariate	O
on	O
significant	O
differences	O
between	O
males	O
and	O
females	O
with	O
respect	O
to	O
the	O
dτ	O
/	O
dt	O
max	O
development	O
.	O

Maximal	O
torque	O
and	O
Q30	O
were	O
the	O
primary	O
variables	O
of	O
interest	O
.	O

However	O
,	O
EMD	O
,	O
MFCV	O
,	O
and	O
twitch	O
contraction	O
time	O
(	O
CT	O
)	O
were	O
also	O
explored	O
.	O

All	O
statistical	O
procedures	O
were	O
performed	O
using	O
SAS	O
statistical	O
software	O
(	O
SAS	O
Institute	O
Inc	O
.,	O
Cary	O
,	O
NC	O
)	O
with	O
alpha	O
set	O
at	O
the	O
0	O
.	O
05	O
probability	O
level	O
.	O

The	O
means	O
±	O
standard	O
deviations	O
(	O
SD	O
)	O
for	O
each	O
measure	O
are	O
reported	O
below	O
.	O

Results	O

Participant	O
characteristics	O

The	O
means	O
and	O
standard	O
deviations	O
for	O
the	O
participant	O
’	O
s	O
characteristics	O
are	O
given	O
in	O
Table	O
1	O
.	O

Significant	O
differences	O
were	O
seen	O
in	O
all	O
anthropometric	O
measurements	O
between	O
males	O
and	O
females	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
hours	O
per	O
week	O
engaged	O
in	O
physical	O
activity	O
or	O
weight	O
lifting	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

The	O
grand	O
means	O
and	O
standard	O
deviations	O
for	O
the	O
criterion	O
measures	O
across	O
the	O
three	O
test	O
sessions	O
for	O
males	O
and	O
females	O
are	O
presented	O
in	O
tables	O
for	O
the	O
voluntary	O
and	O
evoked	O
contractions	O
(	O
see	O
Tables	O
2	O
,	O
3	O
).	O
Table	O
1Demographic	O
characteristics	O
of	O
the	O
study	O
participantsMeasureFemales	O
(	O
N	O
=	O
18	O
)	O
M	O
±	O
SDMales	O
(	O
N	O
=	O
20	O
)	O
M	O
±	O
SDDifference	O
%	O
Age	O
(	O
years	O
)	O
24	O
±	O
3	O
.	O
324	O
±	O
2	O
.	O
40Height	O
(	O
m	O
)	O
1	O
.	O
6	O
±	O
0	O
.	O
11	O
.	O
8	O
±	O
0	O
.	O
111	O
.	O
1	O
*	O
Mass	O
(	O
kg	O
)	O
56	O
.	O
5	O
±	O
8	O
.	O
579	O
.	O
7	O
±	O
3	O
.	O
929	O
.	O
1	O
*	O
Body	O
mass	O
index	O
(	O
kg	O
/	O
m2	O
)	O
21	O
.	O
4	O
±	O
2	O
.	O
224	O
.	O
4	O
±	O
0	O
.	O
812	O
.	O
3	O
*	O
Foot	O
length	O
(	O
cm	O
)	O
23	O
.	O
7	O
±	O
0	O
.	O
728	O
.	O
5	O
±	O
1	O
.	O
516	O
.	O
8	O
*	O
Leg	O
length	O
(	O
cm	O
)	O
39	O
.	O
2	O
±	O
1	O
.	O
847	O
.	O
3	O
±	O
2	O
.	O
317	O
.	O
1	O
*	O
Leg	O
girth	O
(	O
cm	O
)	O
37	O
.	O
0	O
±	O
1	O
.	O
740	O
.	O
4	O
±	O
1	O
.	O
98	O
.	O
4	O
*	O
Physical	O
activity	O
(	O
hours	O
/	O
week	O
)	O
7	O
.	O
5	O
±	O
3	O
.	O
49	O
.	O
3	O
±	O
2	O
.	O
219	O
.	O
4Weight	O
-	O
lifting	O
(	O
hours	O
/	O
week	O
)	O
4	O
.	O
4	O
±	O
3	O
.	O
75	O
.	O
5	O
±	O
2	O
.	O
820	O
.	O
0Significant	O
differences	O
were	O
set	O
at	O
a	O
p	O
<	O
0	O
.	O
05	O
level	O
and	O
are	O
indicated	O
with	O
*	O
Table	O
2Data	O
under	O
the	O
voluntary	O
condition	O
Female	O
vMFCV	O
(	O
m	O
/	O
s	O
)	O
vEMD	O
(	O
ms	O
)	O
vRTDpk	O
(	O
Nm	O
/	O
s	O
)	O
vTorque	O
(	O
Nm	O
)	O
Q30	O
(	O
mV	O
x	O
s	O
)	O
RMS	O
(	O
mV	O
)	O
Test	O
Day	O
(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)	O
15	O
.	O
16	O
±	O
1	O
.	O
6137	O
.	O
19	O
±	O
11	O
.	O
0681	O
.	O
15	O
±	O
33	O
.	O
6529	O
.	O
10	O
±	O
7	O
.	O
967	O
.	O
90	O
±	O
5	O
.	O
270	O
.	O
21	O
±	O
0	O
.	O
1025	O
.	O
28	O
±	O
1	O
.	O
4033	O
.	O
86	O
±	O
10	O
.	O
0782	O
.	O
74	O
±	O
36	O
.	O
0229	O
.	O
17	O
±	O
7	O
.	O
788	O
.	O
26	O
±	O
6	O
.	O
970	O
.	O
21	O
±	O
0	O
.	O
1335	O
.	O
33	O
±	O
1	O
.	O
6927	O
.	O
09	O
±	O
5	O
.	O
3091	O
.	O
43	O
±	O
34	O
.	O
8827	O
.	O
10	O
±	O
6	O
.	O
618	O
.	O
20	O
±	O
6	O
.	O
740	O
.	O
17	O
±	O
0	O
.	O
11Grand5	O
.	O
26	O
±	O
1	O
.	O
5532	O
.	O
71	O
±	O
9	O
.	O
94	O
*	O
85	O
.	O
11	O
±	O
34	O
.	O
5128	O
.	O
46	O
±	O
7	O
.	O
398	O
.	O
12	O
±	O
6	O
.	O
260	O
.	O
20	O
±	O
0	O
.	O
11	O
SEM	O
0	O
.	O
678	O
.	O
0210	O
.	O
352	O
.	O
763	O
.	O
060	O
.	O
03	O
R	O
0	O
.	O
810	O
.	O
350	O
.	O
910	O
.	O
860	O
.	O
760	O
.	O
92	O
Male	O
Test	O
Day14	O
.	O
92	O
±	O
0	O
.	O
9932	O
.	O
92	O
±	O
12	O
.	O
48160	O
.	O
03	O
±	O
70	O
.	O
2957	O
.	O
31	O
±	O
17	O
.	O
125	O
.	O
80	O
±	O
2	O
.	O
910	O
.	O
18	O
±	O
0	O
.	O
1125	O
.	O
13	O
±	O
1	O
.	O
2532	O
.	O
52	O
±	O
12	O
.	O
08157	O
.	O
04	O
±	O
70	O
.	O
0058	O
.	O
52	O
±	O
21	O
.	O
694	O
.	O
83	O
±	O
3	O
.	O
210	O
.	O
18	O
±	O
0	O
.	O
1334	O
.	O
70	O
±	O
1	O
.	O
0933	O
.	O
08	O
±	O
13	O
.	O
74142	O
.	O
01	O
±	O
82	O
.	O
0156	O
.	O
97	O
±	O
20	O
.	O
545	O
.	O
26	O
±	O
2	O
.	O
730	O
.	O
17	O
±	O
0	O
.	O
08Grand4	O
.	O
92	O
±	O
1	O
.	O
1132	O
.	O
84	O
±	O
12	O
.	O
57153	O
.	O
03	O
±	O
73	O
.	O
4757	O
.	O
60	O
±	O
19	O
.	O
555	O
.	O
30	O
±	O
3	O
.	O
010	O
.	O
18	O
±	O
0	O
.	O
11	O
SEM	O
0	O
.	O
556	O
.	O
1230	O
.	O
298	O
.	O
061	O
.	O
880	O
.	O
06	O
R	O
0	O
.	O
760	O
.	O
700	O
.	O
830	O
.	O
830	O
.	O
610	O
.	O
72	O
Percent	O
Difference	O
6	O
.	O
50	O
.	O
444	O
.	O
4	O
*	O
50	O
.	O
6	O
*	O
34	O
.	O
7	O
*	O
10Means	O
(	O
M	O
)	O
and	O
standard	O
deviations	O
(	O
SD	O
)	O
for	O
voluntary	O
muscle	O
fiber	O
conduction	O
velocity	O
(	O
vMFCV	O
),	O
voluntary	O
electromechanical	O
delay	O
(	O
vEMD	O
),	O
voluntary	O
peak	O
rate	O
of	O
torque	O
development	O
(	O
vRTDpk	O
),	O
voluntary	O
maximum	O
torque	O
(	O
vTorque	O
),	O
voluntary	O
rate	O
of	O
EMG	O
increase	O
over	O
the	O
first	O
30	O
ms	O
(	O
Q30	O
),	O
and	O
voluntary	O
root	O
-	O
mean	O
squared	O
amplitude	O
(	O
RMS	O
).	O

Significant	O
differences	O
were	O
set	O
at	O
a	O
p	O
<	O
0	O
.	O
05	O
level	O
and	O
are	O
indicated	O
with	O
*	O
Table	O
3Data	O
under	O
the	O
evoked	O
condition	O
Female	O
eMFCV	O
(	O
m	O
/	O
s	O
)	O
eEMD	O
(	O
ms	O
)	O
eRTDpk	O
(	O
Nm	O
/	O
s	O
)	O
eTorque	O
(	O
Nm	O
)	O
Vpp	O
(	O
mV	O
)	O
CT	O
(	O
ms	O
)	O
Test	O
Day	O
(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)(	O
M	O
±	O
SD	O
)	O
14	O
.	O
22	O
±	O
1	O
.	O
7616	O
.	O
71	O
±	O
11	O
.	O
2146	O
.	O
07	O
±	O
18	O
.	O
412	O
.	O
59	O
±	O
1	O
.	O
432	O
.	O
17	O
±	O
0	O
.	O
9277	O
.	O
20	O
±	O
17	O
.	O
6324	O
.	O
11	O
±	O
0	O
.	O
9915	O
.	O
38	O
±	O
10	O
.	O
9846	O
.	O
75	O
±	O
18	O
.	O
432	O
.	O
69	O
±	O
1	O
.	O
282	O
.	O
22	O
±	O
0	O
.	O
9180	O
.	O
74	O
±	O
12	O
.	O
1834	O
.	O
34	O
±	O
1	O
.	O
5114	O
.	O
97	O
±	O
10	O
.	O
0246	O
.	O
25	O
±	O
14	O
.	O
432	O
.	O
68	O
±	O
1	O
.	O
102	O
.	O
07	O
±	O
0	O
.	O
9869	O
.	O
21	O
±	O
22	O
.	O
78Grand4	O
.	O
22	O
±	O
1	O
.	O
4315	O
.	O
69	O
±	O
10	O
.	O
5746	O
.	O
36	O
±	O
16	O
.	O
872	O
.	O
66	O
±	O
1	O
.	O
252	O
.	O
16	O
±	O
0	O
.	O
9275	O
.	O
72	O
±	O
18	O
.	O
37	O
SEM	O
0	O
.	O
504	O
.	O
254	O
.	O
130	O
.	O
280	O
.	O
364	O
.	O
41	O
R	O
0	O
.	O
880	O
.	O
840	O
.	O
940	O
.	O
950	O
.	O
850	O
.	O
91	O
Male	O
Test	O
Day14	O
.	O
33	O
±	O
1	O
.	O
5010	O
.	O
57	O
±	O
3	O
.	O
30106	O
.	O
48	O
±	O
39	O
.	O
665	O
.	O
89	O
±	O
2	O
.	O
332	O
.	O
59	O
±	O
1	O
.	O
1468	O
.	O
65	O
±	O
7	O
.	O
4724	O
.	O
71	O
±	O
1	O
.	O
6610	O
.	O
17	O
±	O
4	O
.	O
56101	O
.	O
01	O
±	O
41	O
.	O
675	O
.	O
54	O
±	O
2	O
.	O
482	O
.	O
51	O
±	O
1	O
.	O
1379	O
.	O
55	O
±	O
11	O
.	O
9834	O
.	O
17	O
±	O
0	O
.	O
999	O
.	O
12	O
±	O
2	O
.	O
06104	O
.	O
50	O
±	O
35	O
.	O
125	O
.	O
86	O
±	O
1	O
.	O
992	O
.	O
73	O
±	O
1	O
.	O
0176	O
.	O
60	O
±	O
8	O
.	O
09Grand4	O
.	O
40	O
±	O
1	O
.	O
409	O
.	O
95	O
±	O
3	O
.	O
46104	O
.	O
00	O
±	O
38	O
.	O
315	O
.	O
77	O
±	O
2	O
.	O
242	O
.	O
61	O
±	O
1	O
.	O
0874	O
.	O
93	O
±	O
10	O
.	O
33	O
SEM	O
0	O
.	O
762	O
.	O
278	O
.	O
570	O
.	O
450	O
.	O
402	O
.	O
32	O
R	O
0	O
.	O
710	O
.	O
570	O
.	O
950	O
.	O
960	O
.	O
870	O
.	O
64	O
Percent	O
Differences	O
4	O
.	O
136	O
.	O
6	O
*	O
55	O
.	O
4	O
*	O
53	O
.	O
9	O
*	O
17	O
.	O
20	O
.	O
01Means	O
(	O
M	O
)	O
and	O
standard	O
deviations	O
(	O
SD	O
)	O
for	O
evoked	O
muscle	O
fiber	O
conduction	O
velocity	O
(	O
eMFCV	O
),	O
evoked	O
electromechanical	O
delay	O
(	O
eEMD	O
),	O
evoked	O
peak	O
rate	O
of	O
torque	O
development	O
(	O
eRTDpk	O
),	O
evoked	O
maximum	O
torque	O
(	O
eTorque	O
),	O
evoked	O
peak	O
-	O
peak	O
voltage	O
(	O
Vpp	O
),	O
and	O
the	O
evoked	O
contraction	O
time	O
(	O
CT	O
).	O

Significant	O
differences	O
were	O
set	O
at	O
a	O
p	O
<	O
0	O
.	O
05	O
level	O
and	O
are	O
indicated	O
with	O
*	O

Reliability	O
analysis	O

Table	O
2	O
shows	O
that	O
the	O
consistency	O
of	O
scores	O
within	O
subjects	O
for	O
the	O
criterion	O
measures	O
obtained	O
during	O
the	O
voluntary	O
contractions	O
for	O
females	O
was	O
excellent	O
(	O
R	O
=	O
0	O
.	O
76	O
–	O
92	O
)	O
except	O
for	O
EMD	O
which	O
had	O
an	O
intraclass	O
correlation	O
coefficient	O
of	O
R	O
=	O
0	O
.	O
35	O
(	O
see	O
Table	O
2	O
).	O

Female	O
participants	O
exhibited	O
a	O
27	O
.	O
2	O
%	O
reduction	O
in	O
EMD	O
from	O
session	O
1	O
to	O
session	O
3	O
(	O
F	O
[	O
2	O
,	O
51	O
]	O
=	O
5	O
.	O
83	O
,	O
p	O
=	O
0	O
.	O
0045	O
).	O

The	O
lack	O
of	O
stability	O
,	O
as	O
assess	O
by	O
the	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
resulted	O
in	O
a	O
reduced	O
intraclass	O
correlation	O
coefficient	O
.	O

However	O
,	O
the	O
intrasubject	O
coefficient	O
of	O
variation	O
(	O
Grand	O
Mean	O
/	O
SEM	O
)	O
was	O
24	O
.	O
5	O
%,	O
which	O
was	O
deemed	O
acceptable	O
for	O
further	O
analyses	O
(	O
Green	O
et	O
al	O
.	O
2015	O
).	O

The	O
means	O
of	O
the	O
criterion	O
measures	O
generated	O
during	O
voluntary	O
contractions	O
as	O
shown	O
in	O
Table	O
2	O
were	O
highly	O
stable	O
across	O
test	O
sessions	O
in	O
males	O
,	O
while	O
the	O
consistency	O
of	O
scores	O
within	O
subjects	O
ranged	O
from	O
fair	O
to	O
excellent	O
(	O
R	O
=	O
0	O
.	O
61	O
–	O
83	O
).	O

The	O
higher	O
intrasubject	O
variation	O
(	O
56	O
.	O
8	O
%)	O
for	O
males	O
Q30	O
resulted	O
in	O
a	O
lower	O
intraclass	O
correlation	O
coefficient	O
(	O
R	O
=	O
0	O
.	O
61	O
),	O
but	O
was	O
still	O
acceptable	O
.	O

The	O
same	O
was	O
true	O
for	O
the	O
criterion	O
measures	O
generated	O
during	O
evoked	O
contractions	O
(	O
R	O
=	O
0	O
.	O
85	O
–	O
95	O
)	O
and	O
Table	O
3	O
shows	O
that	O
consistency	O
of	O
scores	O
within	O
subjects	O
for	O
the	O
criterion	O
measures	O
obtained	O
during	O
the	O
evoked	O
contractions	O
in	O
males	O
ranged	O
from	O
fair	O
to	O
excellent	O
(	O
R	O
=	O
0	O
.	O
57	O
–	O
96	O
).	O

The	O
lowest	O
intraclass	O
correlation	O
coefficient	O
was	O
for	O
EMD	O
,	O
but	O
it	O
had	O
an	O
intrasubject	O
coefficient	O
of	O
variation	O
of	O
only	O
22	O
.	O
8	O
%.	O

While	O
there	O
was	O
a	O
slight	O
decrease	O
in	O
the	O
means	O
across	O
sessions	O
,	O
a	O
limited	O
range	O
of	O
scores	O
contributed	O
to	O
a	O
decreased	O
intraclass	O
correlation	O
coefficient	O
.	O

Thus	O
,	O
the	O
measure	O
was	O
still	O
deemed	O
acceptable	O
for	O
further	O
analyses	O
.	O

Between	O
groups	O
analyses	O

A	O
repeated	O
-	O
measures	O
ANOVA	O
revealed	O
a	O
significant	O
difference	O
between	O
groups	O
and	O
across	O
days	O
for	O
voluntary	O
maximal	O
dorsiflexion	O
isometric	O
torque	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
45	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
001	O
).	O

Males	O
had	O
on	O
average	O
a	O
50	O
.	O
6	O
%	O
greater	O
torque	O
output	O
than	O
females	O
.	O

The	O
difference	O
between	O
males	O
and	O
females	O
with	O
respect	O
to	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
was	O
similar	O
in	O
magnitude	O
.	O

The	O
maximum	O
rate	O
of	O
torque	O
development	O
was	O
44	O
.	O
6	O
%	O
greater	O
in	O
males	O
than	O
for	O
females	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
16	O
.	O
46	O
,	O
p	O
=	O
0	O
.	O
0003	O
).	O

In	O
contrast	O
,	O
females	O
had	O
a	O
34	O
.	O
7	O
%	O
greater	O
rate	O
of	O
increase	O
in	O
muscle	O
activation	O
as	O
assessed	O
by	O
Q30	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
4	O
.	O
30	O
,	O
p	O
=	O
0	O
.	O
0454	O
).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
males	O
and	O
females	O
with	O
respect	O
to	O
EMD	O
,	O
RMS	O
amplitude	O
,	O
or	O
MFCV	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
9635	O
;	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
31	O
,	O
p	O
=	O
0	O
.	O
5834	O
;	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
86	O
,	O
p	O
=	O
0	O
.	O
3598	O
,	O
respectively	O
).	O

Similar	O
to	O
the	O
voluntary	O
contractions	O
,	O
maximal	O
evoked	O
dorsiflexion	O
torque	O
was	O
53	O
.	O
9	O
%	O
greater	O
for	O
males	O
than	O
for	O
females	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
28	O
.	O
52	O
,	O
p	O
=	O
0	O
.	O
001	O
),	O
and	O
males	O
also	O
had	O
a	O
comparably	O
greater	O
maximum	O
rate	O
of	O
torque	O
development	O
of	O
55	O
.	O
4	O
%	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
13	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
0006	O
).	O

The	O
EMD	O
was	O
36	O
.	O
6	O
%	O
shorter	O
for	O
males	O
than	O
for	O
females	O
during	O
the	O
evoked	O
contractions	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
7	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
0119	O
).	O

In	O
contrast	O
,	O
MFCV	O
,	O
evoked	O
CT	O
,	O
and	O
Vpp	O
of	O
the	O
CMAP	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
22	O
,	O
p	O
=	O
0	O
.	O
6451	O
;	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
03	O
,	O
p	O
=	O
0	O
.	O
8589	O
;	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
2	O
.	O
42	O
,	O
p	O
=	O
0	O
.	O
1288	O
,	O
respectively	O
).	O

Analysis	O
of	O
covariance	O

When	O
maximal	O
torque	O
was	O
used	O
as	O
the	O
covariate	O
in	O
the	O
repeated	O
-	O
measures	O
ANCOVA	O
for	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
,	O
the	O
difference	O
between	O
means	O
decreased	O
to	O
1	O
.	O
2	O
%	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
0	O
.	O
01	O
,	O
p	O
=	O
0	O
.	O
9264	O
).	O

The	O
rate	O
of	O
increase	O
in	O
muscle	O
activation	O
(	O
Q30	O
)	O
was	O
not	O
assessed	O
as	O
a	O
covariate	O
,	O
because	O
females	O
were	O
actually	O
greater	O
than	O
males	O
.	O

The	O
only	O
other	O
significant	O
difference	O
between	O
males	O
and	O
females	O
was	O
EMD	O
during	O
evoked	O
contractions	O
.	O

However	O
,	O
evoked	O
EMD	O
had	O
little	O
impact	O
as	O
a	O
covariate	O
.	O

Sex	O
-	O
related	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
were	O
reduced	O
to	O
33	O
.	O
8	O
%,	O
which	O
were	O
still	O
significant	O
(	O
F	O
[	O
1	O
,	O
36	O
]	O
=	O
8	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
0067	O
).	O

Discussion	O

The	O
main	O
finding	O
of	O
the	O
current	O
work	O
was	O
that	O
maximum	O
torque	O
was	O
able	O
to	O
account	O
for	O
almost	O
all	O
of	O
the	O
sex	O
-	O
related	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
,	O
as	O
the	O
percent	O
difference	O
in	O
least	O
-	O
square	O
means	O
was	O
reduced	O
to	O
1	O
.	O
2	O
%	O
when	O
using	O
maximum	O
torque	O
as	O
a	O
covariate	O
.	O

There	O
also	O
were	O
no	O
significant	O
differences	O
between	O
males	O
and	O
females	O
in	O
sEMG	O
RMS	O
amplitude	O
magnitude	O
as	O
observed	O
by	O
Lenhardt	O
et	O
al	O
.	O
(	O
2009	O
).	O

The	O
absence	O
of	O
sex	O
-	O
differences	O
in	O
the	O
sEMG	O
signal	O
amplitude	O
,	O
Vpp	O
,	O
and	O
CT	O
may	O
reflect	O
a	O
comparable	O
number	O
of	O
hours	O
per	O
week	O
of	O
training	O
for	O
the	O
two	O
groups	O
(	O
Aagaard	O
et	O
al	O
.	O
2002	O
).	O

Contraction	O
time	O
was	O
used	O
in	O
the	O
study	O
to	O
determine	O
if	O
differences	O
in	O
the	O
maximal	O
rate	O
of	O
torque	O
development	O
were	O
associated	O
with	O
either	O
descending	O
voluntary	O
control	O
or	O
peripheral	O
factors	O
associated	O
with	O
muscle	O
composition	O
(	O
Close	O
1972	O
).	O

Based	O
on	O
the	O
fact	O
,	O
no	O
sex	O
-	O
related	O
differences	O
in	O
the	O
CT	O
(	O
0	O
.	O
01	O
%)	O
were	O
found	O
suggests	O
that	O
the	O
two	O
groups	O
were	O
also	O
similar	O
with	O
respect	O
to	O
muscle	O
fiber	O
composition	O
,	O
which	O
is	O
consistent	O
with	O
other	O
research	O
(	O
Hicks	O
and	O
McCartney	O
1996	O
).	O

Based	O
on	O
the	O
work	O
of	O
Lenhardt	O
et	O
al	O
.	O
(	O
2009	O
),	O
it	O
was	O
expected	O
that	O
males	O
and	O
females	O
would	O
be	O
more	O
comparable	O
in	O
maximum	O
strength	O
in	O
the	O
lower	O
limb	O
than	O
the	O
upper	O
limb	O
,	O
which	O
is	O
consistent	O
with	O
other	O
studies	O
on	O
sex	O
-	O
differences	O
in	O
maximum	O
strength	O
(	O
Heyward	O
et	O
al	O
.	O
1986	O
;	O
Hoffman	O
et	O
al	O
.	O
1979	O
).	O

Instead	O
,	O
a	O
50	O
.	O
6	O
%	O
difference	O
was	O
observed	O
,	O
which	O
was	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
previously	O
observed	O
for	O
the	O
upper	O
limb	O
(	O
Inglis	O
et	O
al	O
.	O
2013	O
).	O

One	O
reason	O
may	O
be	O
related	O
to	O
differences	O
in	O
the	O
cross	O
-	O
sectional	O
area	O
(	O
CSA	O
)	O
of	O
the	O
TA	O
in	O
the	O
present	O
sample	O
versus	O
that	O
of	O
Lenhardt	O
et	O
al	O
.	O
(	O
2009	O
).	O

Although	O
CSA	O
was	O
not	O
directly	O
measured	O
,	O
the	O
males	O
and	O
females	O
in	O
this	O
study	O
had	O
a	O
larger	O
difference	O
in	O
lower	O
leg	O
girth	O
(	O
8	O
.	O
4	O
%)	O
than	O
the	O
5	O
.	O
2	O
%	O
observed	O
by	O
Lenhardt	O
et	O
al	O
.	O
(	O
2009	O
),	O
which	O
may	O
suggest	O
a	O
larger	O
difference	O
in	O
TA	O
CSA	O
.	O

The	O
large	O
difference	O
in	O
maximum	O
strength	O
between	O
males	O
and	O
females	O
was	O
associated	O
with	O
a	O
comparably	O
large	O
difference	O
in	O
the	O
maximum	O
rate	O
of	O
isometric	O
dorsiflexion	O
torque	O
development	O
(	O
44	O
.	O
6	O
%).	O

Greater	O
co	O
-	O
activation	O
of	O
the	O
antagonist	O
muscle	O
group	O
in	O
females	O
could	O
contribute	O
to	O
both	O
lower	O
maximum	O
strength	O
and	O
rate	O
of	O
torque	O
development	O
.	O

Macaluso	O
et	O
al	O
.	O
(	O
2002	O
)	O
showed	O
that	O
females	O
may	O
use	O
greater	O
antagonist	O
co	O
-	O
activation	O
to	O
stabilize	O
the	O
joint	O
due	O
to	O
greater	O
joint	O
laxity	O
,	O
smaller	O
agonist	O
musculature	O
,	O
and	O
potentially	O
lower	O
quality	O
muscle	O
mass	O
(	O
torque	O
/	O
CSA	O
),	O
as	O
has	O
been	O
seen	O
in	O
older	O
versus	O
younger	O
adults	O
(	O
Solomonow	O
et	O
al	O
.	O
1988	O
;	O
Thelen	O
et	O
al	O
.	O
1996	O
).	O

However	O
,	O
antagonist	O
co	O
-	O
activation	O
was	O
not	O
measured	O
in	O
this	O
study	O
as	O
it	O
is	O
markedly	O
lower	O
during	O
isometric	O
contractions	O
compared	O
with	O
dynamic	O
contractions	O
and	O
particularly	O
lower	O
when	O
the	O
muscle	O
is	O
placed	O
in	O
a	O
shortened	O
position	O
as	O
in	O
this	O
study	O
(	O
Pasquet	O
et	O
al	O
.	O
2006	O
).	O

There	O
were	O
several	O
novel	O
findings	O
in	O
this	O
study	O
.	O

First	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
males	O
and	O
females	O
with	O
respect	O
to	O
MFCV	O
.	O

This	O
result	O
may	O
be	O
due	O
to	O
comparable	O
muscle	O
fiber	O
diameters	O
between	O
the	O
sexes	O
,	O
which	O
is	O
a	O
large	O
determinant	O
of	O
MFCV	O
(	O
Lange	O
et	O
al	O
.	O
2002	O
;	O
Lindstrom	O
and	O
Magnusson	O
1977	O
;	O
Merletti	O
et	O
al	O
.	O
1995	O
;	O
Nishihara	O
et	O
al	O
.	O
2005	O
;	O
Zwarts	O
1989	O
).	O

It	O
has	O
been	O
shown	O
that	O
type	O
I	O
(	O
slow	O
twitch	O
)	O
fibers	O
are	O
situated	O
predominately	O
in	O
the	O
anterior	O
portion	O
of	O
the	O
TA	O
(	O
Henriksson	O
-	O
Larsén	O
et	O
al	O
.	O
1983	O
).	O

Moreover	O
,	O
it	O
is	O
a	O
general	O
result	O
that	O
,	O
while	O
males	O
have	O
larger	O
fiber	O
diameters	O
than	O
females	O
,	O
the	O
type	O
I	O
muscle	O
fiber	O
diameters	O
in	O
females	O
are	O
larger	O
than	O
their	O
type	O
II	O
muscle	O
fibers	O
.	O

The	O
small	O
interelectrode	O
distance	O
(	O
5	O
mm	O
)	O
will	O
record	O
from	O
a	O
small	O
pick	O
-	O
up	O
volume	O
that	O
encapsulates	O
these	O
superficial	O
type	O
I	O
fibers	O
of	O
the	O
TA	O
,	O
which	O
are	O
comparable	O
in	O
muscle	O
fiber	O
diameter	O
between	O
the	O
sexes	O
.	O

A	O
second	O
novel	O
finding	O
is	O
that	O
there	O
were	O
pronounced	O
sex	O
-	O
differences	O
in	O
Q30	O
that	O
were	O
not	O
evident	O
in	O
either	O
the	O
voluntary	O
(	O
RMS	O
)	O
or	O
evoked	O
(	O
Vpp	O
)	O
sEMG	O
magnitude	O
.	O

Females	O
were	O
significantly	O
greater	O
than	O
males	O
with	O
respect	O
to	O
the	O
rate	O
of	O
muscle	O
activation	O
as	O
assessed	O
by	O
Q30	O
.	O

The	O
difference	O
increased	O
further	O
(	O
4	O
%)	O
with	O
repeated	O
testing	O
.	O

This	O
change	O
was	O
also	O
associated	O
with	O
a	O
significant	O
training	O
-	O
related	O
reduction	O
in	O
voluntary	O
EMD	O
associated	O
with	O
repeated	O
testing	O
.	O

This	O
reduction	O
in	O
voluntary	O
EMG	O
but	O
“	O
not	O
”	O
evoked	O
EMG	O
,	O
and	O
highlights	O
the	O
change	O
in	O
neural	O
control	O
(	O
Gabriel	O
and	O
Boucher	O
1998	O
).	O

We	O
suggest	O
that	O
the	O
greater	O
Q30	O
and	O
reduction	O
in	O
voluntary	O
EMD	O
for	O
females	O
were	O
associated	O
with	O
a	O
different	O
motor	O
unit	O
activity	O
pattern	O
at	O
the	O
onset	O
of	O
muscle	O
contraction	O
.	O

However	O
,	O
it	O
is	O
not	O
possible	O
to	O
distinguish	O
exact	O
motor	O
unit	O
behavior	O
that	O
may	O
be	O
responsible	O
for	O
the	O
sex	O
-	O
related	O
differences	O
in	O
the	O
rate	O
of	O
increase	O
in	O
surface	O
EMG	O
.	O

Van	O
Cutsem	O
et	O
al	O
.	O
(	O
1998	O
)	O
established	O
a	O
link	O
between	O
the	O
maximum	O
rate	O
of	O
isometric	O
dorsiflexion	O
torque	O
,	O
the	O
rate	O
of	O
increase	O
in	O
sEMG	O
,	O
and	O
the	O
incidence	O
of	O
doublets	O
associated	O
with	O
progressive	O
resistive	O
training	O
.	O

Similarly	O
,	O
Gabriel	O
et	O
al	O
.	O
(	O
2001	O
)	O
found	O
that	O
only	O
three	O
training	O
sessions	O
were	O
sufficient	O
to	O
produce	O
an	O
increase	O
in	O
the	O
maximum	O
rate	O
of	O
isometric	O
elbow	O
extension	O
torque	O
development	O
and	O
mean	O
spike	O
frequency	O
of	O
the	O
sEMG	O
signal	O
during	O
the	O
torque	O
development	O
phase	O
of	O
the	O
contraction	O
in	O
female	O
participants	O
.	O

Bojsen	O
-	O
Moller	O
et	O
al	O
.	O
(	O
2005	O
)	O
reported	O
a	O
positive	O
correlation	O
between	O
the	O
rate	O
of	O
torque	O
development	O
and	O
tendon	O
structure	O
stiffness	O
,	O
indicating	O
that	O
30	O
%	O
of	O
the	O
variation	O
in	O
torque	O
development	O
can	O
be	O
accounted	O
for	O
by	O
the	O
tendons	O
mechanical	O
properties	O
.	O

Winter	O
and	O
Brookes	O
(	O
1991	O
)	O
further	O
hypothesized	O
that	O
joint	O
laxity	O
might	O
also	O
play	O
a	O
role	O
in	O
the	O
tension	O
development	O
phase	O
of	O
the	O
contraction	O
as	O
reflected	O
in	O
the	O
EMD	O
.	O

We	O
believe	O
that	O
the	O
greater	O
rate	O
of	O
increase	O
in	O
sEMG	O
activation	O
for	O
females	O
reflects	O
a	O
compensatory	O
mechanism	O
to	O
transmit	O
force	O
to	O
the	O
tendon	O
more	O
effectively	O
,	O
as	O
evident	O
in	O
the	O
observed	O
decrease	O
in	O
voluntary	O
EMD	O
(	O
Kubo	O
et	O
al	O
.	O
2003	O
;	O
Wilkerson	O
and	O
Mason	O
2000	O
;	O
Winter	O
and	O
Brookes	O
1991	O
).	O

In	O
support	O
of	O
this	O
idea	O
,	O
Rozzi	O
et	O
al	O
.	O
(	O
1999	O
)	O
have	O
shown	O
that	O
females	O
exhibited	O
greater	O
integrated	O
sEMG	O
activity	O
upon	O
landing	O
from	O
a	O
jump	O
as	O
a	O
compensatory	O
mechanism	O
for	O
greater	O
knee	O
joint	O
laxity	O
,	O
which	O
includes	O
both	O
the	O
musculotendinous	O
unit	O
and	O
ligamentous	O
restraint	O
.	O

Limitations	O

sEMG	O
can	O
only	O
provide	O
an	O
indirect	O
measurement	O
of	O
differences	O
and	O
underlying	O
changes	O
in	O
motor	O
unit	O
activity	O
patterns	O
.	O

Similarly	O
,	O
the	O
use	O
of	O
CT	O
to	O
look	O
at	O
fiber	O
composition	O
differences	O
only	O
allows	O
the	O
association	O
of	O
either	O
similarities	O
or	O
differences	O
.	O

Although	O
the	O
possible	O
influence	O
of	O
different	O
muscle	O
structures	O
and	O
sizes	O
in	O
males	O
versus	O
females	O
was	O
discussed	O
in	O
the	O
paper	O
,	O
not	O
directly	O
measuring	O
it	O
with	O
ultrasound	O
is	O
a	O
limitation	O
.	O

It	O
was	O
also	O
assumed	O
that	O
there	O
were	O
differences	O
in	O
TA	O
tendon	O
stiffness	O
without	O
having	O
actually	O
measured	O
it	O
.	O

Moreover	O
,	O
caution	O
must	O
be	O
applied	O
when	O
extrapolating	O
the	O
results	O
to	O
older	O
adults	O
.	O

The	O
use	O
of	O
a	O
healthy	O
college	O
aged	O
population	O
may	O
not	O
account	O
for	O
differences	O
between	O
the	O
sexes	O
with	O
aging	O
,	O
such	O
as	O
the	O
loss	O
of	O
type	O
II	O
fibers	O
,	O
which	O
may	O
render	O
the	O
sexes	O
more	O
similar	O
in	O
the	O
6th	O
and	O
7th	O
decades	O
.	O

Conclusion	O

The	O
results	O
support	O
the	O
work	O
of	O
Hannah	O
et	O
al	O
.	O
(	O
2012	O
)	O
as	O
maximal	O
strength	O
of	O
the	O
TA	O
as	O
a	O
covariate	O
accounted	O
for	O
nearly	O
all	O
of	O
the	O
sex	O
-	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
torque	O
development	O
.	O

This	O
was	O
true	O
,	O
even	O
though	O
the	O
difference	O
in	O
maximal	O
strength	O
was	O
quite	O
pronounced	O
(	O
50	O
.	O
6	O
%).	O

Thus	O
,	O
the	O
hypothesis	O
that	O
maximum	O
strength	O
accounts	O
for	O
sex	O
-	O
differences	O
in	O
the	O
maximum	O
rate	O
of	O
tension	O
development	O
in	O
the	O
lower	O
limb	O
due	O
solely	O
to	O
the	O
fact	O
that	O
males	O
and	O
females	O
are	O
more	O
comparable	O
in	O
maximum	O
strength	O
than	O
in	O
the	O
upper	O
limb	O
was	O
not	O
supported	O
.	O

Rather	O
,	O
the	O
maximum	O
strength	O
accounted	O
for	O
sex	O
-	O
difference	O
in	O
the	O
maximum	O
rate	O
of	O
tension	O
development	O
despite	O
a	O
large	O
discrepancy	O
in	O
strength	O
between	O
males	O
and	O
females	O
.	O

Furthermore	O
,	O
females	O
had	O
a	O
greater	O
rate	O
of	O
increase	O
in	O
sEMG	O
activation	O
,	O
and	O
exhibited	O
a	O
significant	O
reduction	O
in	O
EMD	O
with	O
repeated	O
testing	O
,	O
suggesting	O
that	O
they	O
might	O
utilize	O
a	O
different	O
motor	O
unit	O
activity	O
pattern	O
at	O
the	O
onset	O
of	O
contraction	O
.	O

Future	O
research	O
may	O
focus	O
on	O
training	O
modalities	O
and	O
rehabilitation	O
techniques	O
that	O
could	O
optimize	O
RTD	O
rather	O
than	O
only	O
focusing	O
on	O
maximum	O
strength	O
to	O
assist	O
an	O
older	O
population	O
in	O
balance	O
maintenance	O
and	O
recovery	O
from	O
imbalance	O
.	O

Real	O
-	O
time	O
analysis	O
of	O
gut	O
flora	O
in	O
Entamoeba	B-OG
histolytica	I-OG
infected	O
patients	O
of	O
Northern	O
India	O

Background	O

Amebic	B-DS
dysentery	I-DS
is	O
caused	O
by	O
the	O
protozoan	O
parasite	O
Entamoeba	B-OG
histolytica	I-OG
and	O
the	O
ingestion	O
of	O
quadrinucleate	O
cyst	B-DS
of	O
E	B-OG
.	I-OG
histolytica	I-OG
from	O
fecally	O
contaminated	O
food	O
or	O
water	O
initiates	O
infection	B-DS
.	O

Excystation	O
occurs	O
in	O
the	O
lumen	O
of	O
small	O
intestine	O
,	O
where	O
motile	O
and	O
potentially	O
invasive	O
trophozoites	O
germinate	O
from	O
cysts	B-DS
.	O

The	O
ability	O
of	O
trophozoites	O
to	O
interact	O
and	O
digest	O
gut	O
bacteria	B-OG
is	O
apparently	O
important	O
for	O
multiplication	O
of	O
the	O
parasite	O
and	O
its	O
pathogenicity	O
;	O
however	O
the	O
contribution	O
of	O
resident	O
bacterial	O
flora	O
is	O
not	O
well	O
understood	O
.	O

We	O
quantified	O
the	O
population	O
of	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Ruminococcus	B-OG
,	O
Lactobacillus	B-OG
,	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
,	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
,	O
Eubacterium	B-OG
,	O
Campylobacter	B-OG
,	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Sulphur	B-OG
reducing	O
bacteria	B-OG
using	O
genus	O
specific	O
primers	O
in	O
healthy	O
(	O
N	O
=	O
22	O
)	O
vs	O
amebic	O
patients	O
(	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
,	O
N	O
=	O
17	O
)	O
stool	O
samples	O
by	O
Real	O
-	O
time	O
PCR	O
.	O

Results	O

Absolute	O
quantification	O
of	O
Bacteroides	B-OG
(	O
p	O
=	O
.	O
001	O
),	O
Closrtridium	B-OG
coccoides	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
Lactobacillus	B-OG
(	O
p	O
=	O
0	O
.	O
037	O
),	O
Campylobacter	B-OG
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
and	O
Eubacterium	B-OG
(	O
p	O
=	O
0	O
.	O
038	O
)	O
show	O
significant	O
drop	O
in	O
their	O
population	O
however	O
,	O
significant	O
increase	O
in	O
Bifdobacterium	B-OG
(	O
p	O
=	O
0	O
.	O
009	O
)	O
was	O
observed	O
where	O
as	O
the	O
population	O
of	O
Ruminococcus	B-OG
(	O
p	O
=	O
0	O
.	O
33	O
)	O
remained	O
unaltered	O
in	O
healthy	O
vs	O
amebic	O
patients	O
(	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
).	O

We	O
also	O
report	O
high	O
prevalence	O
of	O
nimE	B-GP
gene	O
in	O
stool	O
samples	O
of	O
both	O
healthy	O
volunteers	O
and	O
amebic	O
patients	O
.	O

No	O
significant	O
decrease	O
in	O
nimE	B-GP
gene	O
copy	O
number	O
was	O
observed	O
before	O
and	O
after	O
the	O
treatment	O
with	O
antiamebic	O
drug	O
.	O

Conclusions	O

Our	O
results	O
show	O
significant	O
alteration	O
in	O
predominant	O
gut	O
bacteria	B-OG
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
.	O

The	O
frequent	O
episodes	O
of	O
intestinal	O
amoebic	B-DS
dysentery	I-DS
thus	O
result	O
in	O
depletion	O
of	O
few	O
predominant	O
genera	O
in	O
gut	O
that	O
may	O
lead	O
to	O
poor	O
digestion	O
and	O
absorption	O
of	O
food	O
in	O
intestine	O
.	O

It	O
further	O
disturbs	O
the	O
homeostasis	O
between	O
gut	O
epithelium	O
and	O
bacterial	O
flora	O
.	O

The	O
decrease	O
in	O
beneficial	O
bacterial	O
population	O
gives	O
way	O
to	O
dysbiosis	O
of	O
gut	O
bacteria	B-OG
which	O
may	O
contribute	O
to	O
final	O
outcome	O
of	O
the	O
disease	O
.	O

Increase	O
in	O
the	O
copy	O
number	O
of	O
nimE	B-GP
gene	O
harboring	O
bacteria	B-OG
in	O
our	O
population	O
reflects	O
possible	O
decrease	O
in	O
the	O
availability	O
of	O
metronidazole	B-CD
drug	O
during	O
treatment	O
of	O
amoebiasis	B-DS
.	O

Background	O

Entamoeba	B-OG
histolytica	I-OG
,	O
a	O
micro	O
-	O
aerophilic	O
intestinal	O
protozoan	O
parasite	O
and	O
the	O
causative	O
agent	O
of	O
invasive	O
amoebiasis	B-DS
(	O
colitis	B-DS
and	O
amoebic	B-DS
liver	I-DS
abscess	I-DS
),	O
remains	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
developing	O
countries	O
[	O
1	O
].	O

It	O
is	O
well	O
known	O
that	O
the	O
parasite	B-OG
is	O
constantly	O
interacting	O
with	O
the	O
intestinal	O
gut	O
flora	O
however	O
the	O
contribution	O
of	O
the	O
flora	O
in	O
the	O
manifestation	O
of	O
the	O
disease	O
is	O
poorly	O
understood	O
.	O

The	O
human	B-OG
gastrointestinal	O
(	O
GI	O
)	O
tract	O
is	O
nutrient	O
-	O
rich	O
environment	O
packed	O
with	O
a	O
complex	O
and	O
dynamic	O
consortia	O
of	O
trillions	O
of	O
microbes	B-OG
[	O
2	O
].	O
The	O
vast	O
majority	O
reside	O
in	O
our	O
colon	O
where	O
densities	O
approach	O
1011	O
-	O
1012	O
cells	O
/	O
ml	O
,	O
the	O
highest	O
density	O
recorded	O
for	O
any	O
microbial	O
habitat	O
[	O
3	O
].	O

About	O
500	O
–	O
1000	O
bacterial	O
species	O
colonize	O
the	O
adult	O
intestine	O
,	O
with	O
30	O
–	O
40	O
species	O
comprising	O
up	O
to	O
97	O
%	O
of	O
the	O
total	O
population	O
[	O
4	O
,	O
5	O
].	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Eubacterium	B-OG
,	O
Clostridium	B-OG
,	O
Peptococcus	B-OG
,	O
Peptostreptococcus	B-OG
,	O
Lactobacillus	B-OG
and	O
Ruminococcus	B-OG
are	O
considered	O
to	O
be	O
predominant	O
genera	O
whereas	O
Enterococcus	B-OG
,	O
Methanobrevibacter	B-OG
and	O
sulphur	B-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
)	O
remain	O
as	O
the	O
subdominant	O
genera	O
[	O
6	O
].	O

The	O
entire	O
system	O
of	O
the	O
human	B-OG
gut	O
microbiota	O
functions	O
as	O
a	O
‘	O
microbial	O
organ	O
’	O
within	O
the	O
intestine	O
,	O
which	O
contributes	O
to	O
diverse	O
mammalian	O
processes	O
including	O
protective	O
functions	O
against	O
pathogens	O
and	O
immune	O
-	O
system	O
modulation	O
,	O
the	O
metabolic	O
function	O
of	O
fermenting	O
non	O
-	O
digestible	O
dietary	O
fiber	O
,	O
anaerobic	O
metabolism	O
of	O
peptides	O
and	O
proteins	O
that	O
results	O
in	O
the	O
recovery	O
of	O
metabolic	O
energy	O
for	O
the	O
host	O
[	O
7	O
].	O

The	O
microbial	O
diversity	O
of	O
the	O
human	B-OG
gut	O
is	O
the	O
result	O
of	O
co	O
-	O
evolution	O
between	O
microbial	O
communities	O
and	O
their	O
hosts	O
.	O

Microbial	O
community	O
structure	O
is	O
a	O
very	O
important	O
factor	O
that	O
can	O
influence	O
predisposition	O
to	O
specific	O
diseases	O
in	O
certain	O
host	O
contexts	O
[	O
8	O
].	O

Ingestion	O
of	O
the	O
cyst	B-DS
of	O
E	B-OG
.	I-OG
histolytica	I-OG
through	O
fecally	O
contaminated	O
food	O
or	O
water	O
initiates	O
infection	B-DS
.	O

Excystation	O
in	O
the	O
intestinal	O
lumen	O
produces	O
trophozoites	O
and	O
colitis	B-DS
results	O
when	O
the	O
trophozoites	O
penetrate	O
the	O
mucus	O
layer	O
and	O
damages	O
intestinal	O
tissues	O
[	O
9	O
].	O

The	O
trophozoites	O
proliferate	O
in	O
lumen	O
and	O
phagocytose	O
resident	O
flora	O
.	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	O
are	O
quite	O
selective	O
in	O
respect	O
to	O
their	O
interactions	O
with	O
different	O
bacterial	O
species	O
and	O
only	O
those	O
bacteria	B-OG
which	O
have	O
the	O
appropriate	O
recognition	O
molecules	O
get	O
attached	O
and	O
ingested	O
[	O
10	O
].	O

It	O
has	O
been	O
observed	O
that	O
the	O
nuclear	O
DNA	O
content	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	O
growing	O
in	O
axenic	O
cultures	O
is	O
at	O
least	O
10	O
fold	O
higher	O
than	O
in	O
xenic	O
cultures	O
and	O
re	O
-	O
association	O
of	O
axenic	O
cultures	O
with	O
their	O
bacterial	O
flora	O
led	O
to	O
a	O
reduction	O
of	O
DNA	O
content	O
attaining	O
the	O
original	O
xenic	O
values	O
indicating	O
a	O
flexible	O
nature	O
of	O
the	O
parasite	O
genome	O
[	O
11	O
].	O

Fluctuations	O
in	O
gut	O
flora	O
have	O
been	O
reported	O
both	O
in	O
acute	O
diarrhea	O
and	O
antibiotic	O
associated	O
diarrhea	O
[	O
12	O
],	O
but	O
very	O
few	O
reports	O
are	O
available	O
on	O
status	O
of	O
gut	O
flora	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
.	O

Earlier	O
studies	O
in	O
our	O
laboratory	O
[	O
1	O
]	O
have	O
recorded	O
fluctuations	O
in	O
the	O
gut	O
flora	O
by	O
a	O
qualitative	O
method	O
during	O
disease	O
conditions	O
.	O

5	O
-	O
Nitroimidazole	O
drugs	O
are	O
still	O
used	O
as	O
first	O
line	O
of	O
defense	O
against	O
amoebic	O
and	O
other	O
infections	B-DS
caused	O
by	O
anaerobes	B-OG
.	O

These	O
drugs	O
are	O
administered	O
as	O
pro	O
drugs	O
and	O
one	O
electron	O
reduction	O
of	O
nitro	O
group	O
converts	O
the	O
pro	O
drug	O
into	O
an	O
active	O
drug	O
[	O
13	O
].	O

Enzymatic	O
modification	O
mediated	O
by	O
nim	B-GP
-	O
class	O
of	O
genes	O
is	O
a	O
well	O
characterized	O
resistance	O
mechanism	O
.	O

Certain	O
Bacteroides	B-OG
species	O
which	O
are	O
members	O
of	O
the	O
normal	O
colonic	O
human	B-OG
microflora	O
harbor	O
nim	O
genes	O
[	O
14	O
].	O

Our	O
study	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
the	O
Entamoeba	B-OG
histolytica	I-OG
(	O
but	O
not	O
E	B-OG
.	I-OG
dispar	I-OG
)	O
is	O
an	O
invasive	O
organism	O
and	O
invades	O
the	O
mucus	O
layer	O
and	O
subsequently	O
the	O
intestinal	O
epithelium	O
for	O
colonization	O
using	O
the	O
pathogenic	O
factors	O
.	O

In	O
this	O
context	O
we	O
attempted	O
to	O
study	O
the	O
fluctuations	O
in	O
the	O
gut	O
microbiota	O
that	O
contributes	O
to	O
substantial	O
metabolic	O
changes	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
infected	O
individuals	O
compared	O
to	O
healthy	O
individuals	O
.	O

In	O
the	O
present	O
study	O
we	O
used	O
Real	O
Time	O
PCR	O
for	O
absolute	O
quantification	O
of	O
predominant	O
gut	O
bacterial	O
population	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
patients	O
suffering	O
from	O
dysentery	B-DS
for	O
5	O
–	O
7	O
days	O
.	O

We	O
also	O
quantified	O
the	O
copy	O
number	O
of	O
nim	B-GP
gene	O
in	O
stool	O
sample	O
of	O
healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
patients	O
.	O

Methods	O

Study	O
subjects	O
&	O
fecal	O
sample	O
collection	O

Stool	O
samples	O
of	O
healthy	O
person	O
(	O
without	O
any	O
enteric	B-DS
disease	I-DS
)	O
were	O
collected	O
as	O
controls	O
from	O
volunteers	O
of	O
a	O
community	O
in	O
Delhi	O
.	O

Initial	O
survey	O
involved	O
discussion	O
with	O
the	O
focus	O
group	O
and	O
informed	O
consent	O
was	O
taken	O
from	O
participating	O
volunteers	O
for	O
the	O
study	O
.	O

Volunteers	O
in	O
age	O
group	O
of	O
21	O
–	O
40	O
year	O
(	O
mean	O
age	O
31	O
year	O
)	O
were	O
randomly	O
recruited	O
.	O

Subjects	O
who	O
have	O
taken	O
any	O
antibiotic	O
/	O
antiamoebic	O
drug	O
or	O
suffered	O
from	O
any	O
gastrointestinal	B-DS
disorder	I-DS
in	O
past	O
one	O
month	O
before	O
sample	O
collection	O
were	O
not	O
included	O
in	O
the	O
study	O
.	O

Twenty	O
two	O
stool	O
samples	O
were	O
collected	O
from	O
healthy	O
volunteers	O
.	O

Clinical	O
diagnosis	O
of	O
amoebic	B-DS
colitis	I-DS
was	O
based	O
on	O
standard	O
criteria	O
:	O
patients	O
experiencing	O
days	O
to	O
weeks	O
of	O
dysentery	B-DS
(	O
stool	O
with	O
blood	O
and	O
mucus	O
)	O
or	O
diarrhea	O
with	O
cramps	O
followed	O
by	O
abdominal	O
pain	O
and	O
/	O
or	O
weight	O
loss	O
.	O

The	O
sub	O
acute	O
onset	O
of	O
the	O
disease	O
was	O
a	O
helpful	O
clue	O
in	O
the	O
differential	O
diagnosis	O
because	O
bacillary	B-DS
dysentery	I-DS
caused	O
by	O
Shigella	B-OG
,	O
Salmonella	B-OG
,	O
Campylobacter	B-OG
and	O
EHEC	B-OG
E	B-OG
.	I-OG
coli	I-OG
mostly	O
lead	O
to	O
a	O
abrupt	O
onset	O
of	O
the	O
disease	O
[	O
15	O
].	O

Since	O
we	O
did	O
not	O
take	O
samples	O
from	O
individuals	O
administered	O
with	O
any	O
antibiotic	O
,	O
therefore	O
cases	O
of	O
antibiotic	O
associated	O
diarrhea	O
were	O
excluded	O
.	O

Stool	O
samples	O
of	O
chronic	O
/	O
acute	O
diarrhea	O
as	O
diagnosed	O
by	O
Gastroenterologist	O
were	O
collected	O
from	O
Gastroenterology	O
department	O
of	O
All	O
India	O
Institute	O
of	O
Medical	O
Sciences	O
&	O
Safdarjung	O
hospitals	O
,	O
New	O
Delhi	O
.	O

The	O
samples	O
were	O
transported	O
to	O
the	O
laboratory	O
at	O
4	O
°	O
C	O
within	O
2	O
hrs	O
and	O
stored	O
at	O
-	O
20	O
°	O
C	O
until	O
processed	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
research	O
ethics	O
board	O
of	O
respective	O
institutes	O
.	O

The	O
samples	O
(	O
n	O
=	O
550	O
)	O
were	O
collected	O
with	O
the	O
informed	O
consent	O
of	O
the	O
patients	O
.	O

Enrichment	O
of	O
entamoeba	O
cysts	B-DS

Cysts	O
were	O
enriched	O
following	O
the	O
protocol	O
of	O
Knight	O
et	O
al	O
.,	O
1976	O
[	O
16	O
]	O
with	O
slight	O
modifications	O
.	O

Briefly	O
,	O
fecal	O
samples	O
(	O
1gm	O
)	O
were	O
homogenized	O
in	O
10	O
ml	O
of	O
autoclaved	O
distilled	O
water	O
,	O
strained	O
through	O
cheesecloth	O
in	O
50	O
ml	O
falcon	O
tube	O
.	O

This	O
suspension	O
was	O
centrifuged	O
at	O
2000	O
rpm	O
for	O
5	O
min	O
and	O
pellet	O
was	O
re	O
-	O
dissolved	O
in	O
10	O
ml	O
of	O
10	O
%	O
formaldehyde	O
.	O

3	O
ml	O
of	O
diethyl	O
ether	O
was	O
added	O
to	O
the	O
tube	O
and	O
this	O
mixture	O
was	O
vortexed	O
and	O
incubated	O
at	O
RT	O
for	O
30	O
min	O
.	O

The	O
mixture	O
was	O
subjected	O
to	O
centrifugation	O
at	O
2000	O
rpm	O
for	O
5	O
min	O
,	O
supernatant	O
was	O
removed	O
and	O
pellet	O
was	O
washed	O
with	O
double	O
distilled	O
water	O
.	O

The	O
Pellet	O
containing	O
concentrated	O
cyst	B-DS
was	O
re	O
-	O
dissolved	O
in	O
400	O
μl	O
T10E1	O
buffer	O
.	O

Cysts	O
in	O
T10E1	O
buffer	O
was	O
subjected	O
to	O
freeze	O
-	O
thaw	O
cycle	O
and	O
thereafter	O
to	O
sonication	O
in	O
order	O
to	O
obtain	O
crude	O
DNA	O
for	O
Dot	O
-	O
blot	O
hybridization	O
experiment	O
.	O

Screening	O
of	O
samples	O
by	O
dot	O
blot	O
hybridization	O

The	O
crude	O
cyst	B-DS
DNA	O
was	O
denatured	O
by	O
addition	O
of	O
NaOH	O
to	O
final	O
concentration	O
of	O
0	O
.	O
25	O
N	O
in	O
a	O
total	O
volume	O
of	O
300	O
μl	O
.	O

The	O
DNA	O
was	O
kept	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
and	O
then	O
transferred	O
on	O
to	O
ice	O
.	O

The	O
GS	O
+	O
nylon	O
membrane	O
of	O
required	O
size	O
was	O
cut	O
and	O
saturated	O
in	O
0	O
.	O
4	O
M	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
5	O
for	O
15	O
min	O
and	O
the	O
DNA	O
were	O
spotted	O
on	O
to	O
the	O
membrane	O
with	O
the	O
help	O
of	O
mini	O
-	O
fold	O
apparatus	O
from	O
Whatman	O
,	O
Germany	O
.	O

The	O
blots	O
were	O
air	O
dried	O
and	O
UV	O
cross	O
linked	O
before	O
hybridization	O
.	O

We	O
used	O
4	O
.	O
5	O
kb	O
rDNA	O
fragment	O
(	O
EcoRI	B-GP
to	O
Hind	B-GP
III	I-GP
site	O
)	O
from	O
HMe	O
region	O
of	O
EhR1	B-GP
(	O
rDNA	O
plasmid	O
in	O
HM1	O
:	O
IMSS	O
strain	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
)	O
as	O
probe	O
for	O
detection	O
of	O
Entamoeba	B-OG
positive	O
samples	O
that	O
include	O
both	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
(	O
Figure	O
1A	O
)	O
[	O
17	O
].	O

Screening	O
of	O
stool	O
samples	O
by	O
Dot	O
-	O
Blot	O
method	O
.	O
(	O
A	O
)	O
Linear	O
map	O
of	O
EhRI	O
episome	O
(	O
24	O
.	O
5	O
kb	O
)	O
showing	O
the	O
position	O
of	O
HMe	O
probe	O
(	O
4	O
.	O
5	O
kb	O
in	O
size	O
)	O
common	O
for	O
both	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
),	O
E	O
-	O
EcoR1	B-GP
site	O
and	O
H	O
-	O
Hind	B-GP
III	I-GP
site	O
;	O
rDNA	O
I	O
and	O
rDNA	O
II	O
represent	O
two	O
inverted	O
repeats	O
of	O
transcription	O
units	O
with	O
various	O
restriction	O
sites	O
and	O
repeats	O
(	O
B	O
)	O
Representative	O
figure	O
of	O
Dot	O
-	O
blot	O
analysis	O
of	O
stool	O
sample	O
using	O
HMe	O
probe	O
.	O

Rows	O
1	O
to	O
6	O
(	O
column	O
A	O
-	O
D	O
)	O
represent	O
spots	O
of	O
DNA	O
from	O
stool	O
samples	O
.	O

About	O
20	O
ng	O
of	O
DNA	O
was	O
loaded	O
on	O
each	O
spot	O
in	O
triplicate	O
on	O
nylon	O
membrane	O
.	O

Row	O
7	O
was	O
blank	O
.	O

Row	O
8	O
(	O
column	O
A	O
)	O
E	B-OG
.	I-OG
histolytica	I-OG
HM1	O
:	O
IMSS	O
genomic	O
DNA	O
as	O
positive	O
control	O
;	O
(	O
column	O
B	O
)	O
E	B-OG
.	I-OG
dispar	I-OG
SAW760	O
genomic	O
DNA	O
as	O
positive	O
control	O
;	O
(	O
column	O
C	O
)	O
E	B-OG
.	I-OG
Coli	I-OG
DH5α	I-OG
as	O
negative	O
control	O
;	O
(	O
column	O
D	O
)	O
Plasmid	O
with	O
cloned	O
HMe	O
as	O
positive	O
control	O
.	O

All	O
samples	O
were	O
loaded	O
in	O
triplicate	O
.	O

Experimental	O
details	O
are	O
provided	O
in	O
material	O
and	O
methods	O
.	O

Genomic	O
DNA	O
extraction	O

DNA	O
was	O
extracted	O
from	O
the	O
Dot	O
blot	O
positive	O
samples	O
.	O

An	O
aliquot	O
of	O
200	O
mg	O
stool	O
sample	O
was	O
used	O
for	O
isolation	O
using	O
QIAamp	O
mini	O
stool	O
kit	O
(	O
QIAGEN	O
,	O
Germany	O
)	O
as	O
per	O
manufacturer	O
’	O
s	O
guidelines	O
.	O

While	O
isolating	O
DNA	O
from	O
the	O
stool	O
samples	O
through	O
the	O
above	O
kit	O
,	O
pGEMT	O
-	O
easy	O
plasmid	O
containg	O
240	O
bp	O
fragment	O
of	O
glycoprotein	B-GP
B	I-GP
(	O
gB	B-GP
)	O
gene	O
of	O
phocine	B-OG
virus	I-OG
(	O
20	O
ng	O
/	O
200	O
μl	O
of	O
ASL	O
buffer	O
)	O
was	O
added	O
in	O
ASL	O
buffer	O
as	O
internal	O
control	O
during	O
the	O
isolation	O
of	O
genomic	O
DNA	O
[	O
18	O
].	O

PCR	O
analysis	O
of	O
Dot	O
blot	O
positive	O
samples	O

To	O
differentiate	O
Dot	O
-	O
blot	O
positive	O
samples	O
into	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
,	O
primers	O
were	O
designed	O
from	O
EhSINE2	O
for	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
from	O
18	O
S	O
and	O
ITS2	O
region	O
of	O
rDNA	O
circle	O
for	O
E	B-OG
.	I-OG
dispar	I-OG
respectively	O
(	O
Figure	O
2A	O
&	O
B	O
).	O
Primer	O
sequences	O
were	O
as	O
follows	O
;	O
Eh	B-GP
-	O
F	O
5	O
’-	O
GTCAGAGACACCACATGAA	O
-	O
3	O
’,	O
Eh	B-GP
-	O
R	O
5	O
’-	O
GAGACCCCTTAAAGAAAC	O
-	O
CC	O
-	O
3	O
’	O
and	O
Ed	O
-	O
F	O
5	O
’-	O
GAAGAAACATTGTTTCTAAATCCAA	O
-	O
3	O
’	O
&	O
Ed	O
-	O
R	O
5	O
’-	O
TTTATTAA	O
CTC	O
ACTTATA	O
-	O
3	O
’	O
[	O
19	O
].	O

Screening	O
of	O
Stool	O
samples	O
by	O
PCR	O
.	O
(	O
A	O
)	O
Schematic	O
representation	O
of	O
location	O
of	O
Entamoeba	B-OG
histolytica	I-OG
specific	O
primer	O
.	O

BH16197	O
is	O
Genbank	O
accession	O
number	O
of	O
Entamoeba	B-OG
histolytica	I-OG
SINE	O
-	O
2	O
(	O
EhSINE2	O
)	O
element	O
;	O
(	O
B	O
)	O
Schematic	O
representation	O
of	O
location	O
of	O
Entamoeba	B-OG
dispar	I-OG
specific	O
primer	O
from	O
rDNA	O
molecule	O
.	O

18	O
S	O
,	O
5	O
.	O
8	O
S	O
and	O
28	O
S	O
are	O
corresponding	O
ribosomal	O
gene	O
sequences	O
and	O
ITS	O
-	O
1	O
and	O
ITS	O
-	O
2	O
refers	O
to	O
internal	O
transcribed	O
spacer	O
1	O
and	O
2	O
;	O
(	O
C	O
)	O
Detection	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
in	O
stool	O
DNA	O
sample	O
using	O
E	B-OG
.	I-OG
histolytica	I-OG
specific	O
primers	O
,	O
Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
2	O
=	O
EhHM1	O
genomic	O
DNA	O
as	O
positive	O
control	O
,	O
Lane	O
3	O
&	O
4	O
stool	O
sample	O
DNA	O
,	O
Lane	O
5	O
=	O
Genomic	O
DNA	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
SAW760	O
as	O
negative	O
control	O
.	O
Sample	O
in	O
lane	O
4	O
is	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
;	O
(	O
D	O
)	O
Detection	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
in	O
Stool	O
sample	O
using	O
E	B-OG
.	I-OG
dispar	I-OG
specific	O
primers	O
.	O

Lane	O
1	O
=	O
Marker	O
1	O
kb	O
,	O
Lane	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
stool	O
sample	O
DNA	O
,	O
Lane	O
6	O
=	O
Genomic	O
DNA	O
of	O
E	B-OG
.	I-OG
dispar	I-OG
as	O
positive	O
control	O
.	O

Sample	O
in	O
Lane	O
3	O
and	O
5	O
are	O
E	B-OG
.	I-OG
dispar	I-OG
positive	O
.	O

Lane	O
4	O
stool	O
sample	O
is	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
and	O
was	O
used	O
as	O
negative	O
control	O
.	O

Primer	O
designing	O
for	O
detection	O
of	O
predominant	O
genera	O
of	O
gut	O
flora	O

Primer	O
sets	O
were	O
designed	O
to	O
differentiate	O
and	O
quantitate	O
the	O
following	O
major	O
anaerobic	O
genera	O
–	O
Bacteroides	B-OG
,	O
Clostridium	B-OG
,	O
Campylobacter	B-OG
,	O
Bifidobacterium	B-OG
,	O
Ruminococcus	B-OG
,	O
Eubacterium	B-OG
,	O
Lactobacillus	B-OG
,	O
Methanobrevibacter	B-OG
and	O
Sulfate	B-OG
-	I-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
).	O
16S	O
rRNA	O
gene	O
was	O
targeted	O
for	O
designing	O
primers	O
except	O
for	O
SRB	B-GP
(	O
Table	O
1	O
).	O

Sulphate	O
reducing	O
gene	O
was	O
targeted	O
for	O
quantifying	O
members	O
of	O
SRB	O
.	O

Primers	O
were	O
commercially	O
obtained	O
from	O
Sigma	O
-	O
aldrich	O
,	O
USA	O
.	O

Genus	O
specific	O
16S	O
rRNA	O
targeted	O
bacterial	O
primers	O
used	O
in	O
this	O
study	O

Sr	O
no	O
.	O

Genus	O

Primer	O
sequence	O

PCR	O
Product	O
(	O
bp	O
)	O

Tm	O
(	O
ºC	O
)	O

References	O

1	O
.	O

Methanobrevibactr	O

F	O
5	O
’-	O
CGATGCGGACTTGGTGTTG	O
-	O
3	O
’	O

184	O

59	O
.	O
7	O

[	O
21	O
]	O

R	O
5	O
’-	O
TGTCGCCTCTGGTGAGATGTC	O
-	O
3	O
’	O


59	O
.	O
8	O


2	O
.	O

Peptostreptococcus	O

F	O
5	O
’-	O
AACTCCGGTGGTATCAGATG	O
-	O
3	O
’	O

270	O

55	O
.	O
4	O

[	O
1	O
]	O

R	O
5	O
’-	O
GGGGCTTCTGAGTCAGGTA	O
-	O
3	O
’	O


56	O
.	O
4	O


3	O
.	O

Ruminococcus	O

F	O
5	O
’-	O
GAAAGCGTGGGGAGCAAACAGG	O
-	O
3	O
’	O

302	O

65	O
.	O
8	O

[	O
21	O
]	O

R	O
5	O
’-	O
GACGACAACCATGCACCACCTG	O
-	O
3	O
’	O


64	O
.	O
4	O


4	O
.	O

Eubacterium	O

F	O
5	O
’-	O
GTAGTCCACGCCGTAAACGATG	O
-	O
3	O
’	O

278	O

60	O
.	O
4	O

[	O
21	O
]	O

R	O
5	O
’-	O
ACACGAGCTGACGACAACCATG	O
-	O
3	O
’	O


62	O
.	O
4	O


5	O
.	O

Bacteroides	O

F	O
5	O
’-	O
GGGGTTCTGAGAGGAAG	O
-	O
3	O
’	O

115	O

54	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
GCTACTTGGCTGGTTCAG	O
-	O
3	O
’	O


56	O
.	O
0	O


6	O
.	O

Lactobacillus	O

F	O
5	O
’-	O
GCAGCAGTAGGGAATCTTCCA	O
-	O
3	O
’	O

340	O

64	O
.	O
0	O

[	O
25	O
]	O

R	O
5	O
’-	O
GCATTYCACCGCTACACATG	O
-	O
3	O
’	O


58	O
.	O
0	O


7	O
.	O

Clostridium	B-OG
leptum	I-OG
subgroup	O

F	O
5	O
’-	O
CGTCAGCTCGTGTCGTGAGAT	O
-	O
3	O
’	O

125	O

60	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
CGTCATCCCCACCTTCCTCC	O
-	O
3	O
’	O


62	O
.	O
5	O


8	O
.	O

Clostridium	B-OG
coccoides	I-OG
subgroup	O

F	O
5	O
’-	O
GCCACATTGGGACTGAGA	O
-	O
3	O
’	O

170	O

56	O
.	O
0	O

This	O
study	O

R	O
5	O
’-	O
GCTTCTTAGTCAGGTACCG	O
-	O
3	O
’	O


58	O
.	O
0	O


9	O
.	O

Campylobacter	O

F	O
5	O
’-	O
AGGGAATATTGCGCAATGGGGGAAA	O
-	O
3	O
’	O

180	O

58	O
.	O
0	O

[	O
21	O
]	O

R	O
5	O
’-	O
GATTCCGAGTAACGCTTGCACCCT	O
-	O
3	O
’	O


59	O
.	O
0	O


10	O
.	O

Bifidobacterium	O

F	O
5	O
’-	O
GATTCTGGCTCAGGATGAACGC	O
-	O
3	O
’	O

231	O

61	O
.	O
9	O

[	O
21	O
]	O

R	O
5	O
’-	O
CTGATAGGACGCGACCCCAT	O
-	O
3	O
’	O


60	O
.	O
8	O


11	O
.	O

Sulfate	O
-	B-GP
reducing	O
bacteria	B-OG
(	O
APS	B-GP
reductase	I-GP
subunit	I-GP
A	I-GP
gene	O
)	O

F	O
5	O
’-	O
TGGCAGATMATGATYMACGG	O
-	O
3	O
’	O

396	O

54	O
.	O

This	O
study	O

R	O
5	O
’-	O
GGCCGTAACCGTCCTTGAA	O
-	O
3	O
’	O


54	O
.	O
0	O


Primers	O
for	O
detection	O
and	O
quantification	O
of	O
nim	B-GP
gene	O

Primers	O
were	O
designed	O
from	O
nim	B-GP
gene	O
after	O
Stephanie	O
Trinh	O
et	O
al	O
.	O
[	O
14	O
].	O

Primer	O
sequences	O
were	O
as	O
follows	O
;	O
NIM	B-GP
-	O
F	O
(	O
5	O
’-	O
ATGTTCAGAGAAATGCGGCGTAAGCG	O
-	O
3	O
’)	O
and	O
NIM	B-GP
-	O
R	O
(	O
5	O
’-	O
GCTTCCTTGCCTGTCAT	O
GTGCTC	O
-	O
3	O
’).	O

Primers	O
Nim	O
-	O
F	O
and	O
Nim	O
-	O
R	O
designed	O
by	O
us	O
amplify	O
all	O
the	O
members	O
of	O
nim	B-GP
gene	O
family	O
viz	O
.	O
nimA	B-GP
,	O
nimB	B-GP
,	O
nimC	B-GP
,	O
nimD	B-GP
and	O
nimE	B-GP
.	O

Primers	O
were	O
commercially	O
synthesized	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
USA	O
.	O

Primers	O
NIM	O
-	O
F	O
&	O
R	O
did	O
not	O
amplify	O
genomic	O
DNA	O
derived	O
from	O
axenic	O
culture	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
HM1	I-OG
-	O
IMSS	O
[	O
1	O
]	O
and	O
blast	O
result	O
of	O
the	O
selected	O
primers	O
did	O
not	O
show	O
any	O
homology	O
with	O
E	B-OG
.	I-OG
histolytica	I-OG
genome	O
.	O

NIM	O
-	O
F	O
&	O
R	O
primers	O
amplified	O
458	O
bp	O
fragment	O
of	O
nim	B-GP
gene	O
from	O
stool	O
sample	O
DNA	O
.	O

This	O
amplified	O
fragment	O
of	O
458	O
bp	O
was	O
cloned	O
in	O
pGEMT	O
-	O
easy	O
vector	O
and	O
sequenced	O
to	O
ensure	O
the	O
amplification	O
of	O
correct	O
gene	O
.	O

The	O
clone	O
was	O
subsequently	O
used	O
as	O
a	O
standard	O
for	O
quantification	O
of	O
nim	B-GP
gene	O
by	O
Real	O
Time	O
-	O
PCR	O
.	O

PCR	O
-	O
RFLP	O
of	O
nim	B-GP
gene	O

Primers	O
NIM	B-GP
-	O
F	O
and	O
NIM	B-GP
-	O
R	O
were	O
used	O
to	O
amplify	O
all	O
the	O
members	O
of	O
nim	B-GP
gene	O
family	O
from	O
stool	O
sample	O
DNA	O
.	O

Members	O
of	O
nim	B-GP
gene	O
family	O
were	O
differentiated	O
by	O
digesting	O
the	O
PCR	O
product	O
with	O
restriction	B-GP
enzymes	I-GP
HpaII	B-GP
and	O
TaqI	B-GP
.	O

HpaII	B-GP
digests	O
nimA	B-GP
,	O
nimC	B-GP
,	O
nimD	B-GP
at	O
different	O
loci	O
but	O
not	O
nimB	B-GP
and	O
nimE	B-GP
where	O
as	O
TaqI	B-GP
digests	O
nimA	B-GP
,	O
nimB	B-GP
,	O
nimE	B-GP
at	O
different	O
loci	O
but	O
not	O
nimC	B-GP
and	O
nimD	B-GP
[	O
19	O
].	O

Reference	O
strains	O

Genus	O
specific	O
primers	O
were	O
used	O
to	O
amplify	O
respected	O
genera	O
from	O
DNA	O
of	O
stool	O
sample	O
of	O
healthy	O
individual	O
.	O

The	O
amplified	O
product	O
was	O
cloned	O
and	O
sequenced	O
and	O
sequences	O
were	O
deposited	O
in	O
EMBL	O
database	O
to	O
obtain	O
the	O
accession	O
numbers	O
(	O
Table	O
2	O
).	O
These	O
16S	O
rRNA	O
gene	O
fragment	O
containing	O
plasmids	O
were	O
used	O
as	O
reference	O
strains	O
.	O

Accession	O
number	O
of	O
reference	O
strain	O
used	O
in	O
the	O
study	O

Bacteria	B-OG

Source	O

Accession	O
no	O
.	O

Bacteroides	O

Stool	O
of	O
healthy	O
individual	O

AM117604	O

Methanobrevibacter	O

Stool	O
of	O
healthy	O
individual	O

FN813615	B-CD

Eubacterium	O

Stool	O
of	O
healthy	O
individual	O

FN813614	O

Lactobacillus	O

Stool	O
of	O
healthy	O
individual	O

AM042701	O

Bifidobacterium	O

Stool	O
of	O
healthy	O
individual	O

AM042698	O

Clostridium	O

Stool	O
of	O
healthy	O
individual	O

AM042697	O

Campylobacter	O

Stool	O
of	O
healthy	O
individual	O

AM042699	O

Ruminococcus	O

Stool	O
of	O
healthy	O
individual	O

FN823053	B-CD

Sulfate	O
-	O
reducing	O
bacteria	B-OG

Stool	O
of	O
healthy	O
individual	O

FN995351	B-CD

Real	O
time	O
PCR	O
analysis	O
of	O
bacterial	O
population	O

Quantification	O
was	O
done	O
using	O
ABI	O
-	O
7500	O
machine	O
and	O
power	O
syber	O
green	O
PCR	O
master	O
mix	O
kit	O
from	O
Applied	O
Biosystems	O
,	O
USA	O
.	O

Standard	O
curve	O
was	O
the	O
method	O
of	O
choice	O
for	O
absolute	O
quantification	O
of	O
bacteria	B-OG
.	O

Standard	O
curve	O
was	O
made	O
using	O
serial	O
dilutions	O
of	O
plasmid	O
(	O
containing	O
16S	O
rRNA	O
gene	O
fragment	O
)	O
of	O
known	O
concentrations	O
on	O
tenfold	O
basis	O
.	O

With	O
the	O
molecular	O
weight	O
of	O
the	O
plasmid	O
and	O
insert	O
known	O
,	O
it	O
is	O
possible	O
to	O
calculate	O
the	O
copy	O
number	O
as	O
follows	O
:	O

Step	O
1	O
:	O
Determining	O
molecular	O
weight	O
(	O
mw	O
)	O

Weight	O
in	O
Daltons	O
(	O
g	O
/	O
mol	O
)	O
=	O
(	O
bp	O
size	O
of	O
double	O
stranded	O
product	O
)(	O
330	O
Da	O
x	O
2nt	O
/	O
bp	O
)	O

Step	O
2	O
:	O
Molecular	O
weight	O
to	O
copy	O
number	O

X	O
g	O
/	O
mol	O
/	O
Avogadro	O
’	O
s	O
number	O
(	O
6	O
.	O
023	O
×	O
1023	O
molecules	O
/	O
mole	O
)	O
=	O
X	O
g	O
/	O
molecule	O

Where	O
X	O
=	O
the	O
weight	O
of	O
one	O
molecule	O
or	O
copy	O

Where	O
bp	O
=	O
base	O
pairs	O
,	O
nt	O
=	O
nucleotides	B-CD
[	O
20	O
]	O

Real	O
time	O
PCR	O
runs	O
were	O
performed	O
in	O
96	O
well	O
optical	O
plates	O
(	O
each	O
containing	O
1x	O
PCR	O
master	O
mix	O
,	O
4	O
pm	O
/	O
μl	O
forward	O
and	O
reverse	O
primer	O
(	O
optimized	O
concentration	O
)	O
and	O
1μl	O
plasmid	O
DNA	O
of	O
tenfold	O
dilutions	O
or	O
1μl	O
DNA	O
from	O
samples	O
in	O
20μl	O
reaction	O
)	O
for	O
40	O
cycles	O
using	O
an	O
ABI	O
7500	O
sequence	O
detector	O
(	O
Applied	O
biosystems	O
).	O

Default	O
7500	O
cycle	O
conditions	O
were	O
used	O
with	O
only	O
change	O
in	O
the	O
annealing	O
temperature	O
.	O

A	O
standard	O
curve	O
was	O
drawn	O
by	O
plotting	O
the	O
natural	O
log	O
of	O
the	O
threshold	O
cycle	O
(	O
Ct	O
)	O
against	O
the	O
natural	O
log	O
of	O
the	O
number	O
of	O
molecules	O
.	O

Melting	O
curves	O
were	O
obtained	O
from	O
55	O
°	O
C	O
to	O
90	O
°	O
C	O
,	O
with	O
fluorescence	O
measurements	O
taken	O
at	O
every	O
1	O
°	O
C	O
increase	O
in	O
temperature	O
.	O

All	O
reactions	O
were	O
carried	O
out	O
in	O
triplicate	O
along	O
with	O
a	O
non	O
-	O
template	O
control	O
.	O

Ct	O
values	O
were	O
calculated	O
under	O
default	O
settings	O
for	O
the	O
absolute	O
quantification	O
using	O
the	O
software	O
provided	O
with	O
the	O
instrument	O
.	O

The	O
equation	O
drawn	O
from	O
the	O
graph	O
was	O
used	O
to	O
calculate	O
the	O
precise	O
number	O
of	O
target	O
molecule	O
(	O
plasmid	O
copy	O
no	O
.	O
or	O
number	O
of	O
bacteria	B-OG
)	O
tested	O
in	O
same	O
reaction	O
plate	O
as	O
standard	O
as	O
well	O
as	O
in	O
sample	O
.	O

Statistical	O
analysis	O

Graph	O
of	O
respective	O
bacterial	O
population	O
is	O
plotted	O
as	O
mean	O
value	O
with	O
standard	O
error	O
.	O

Each	O
sample	O
was	O
analyzed	O
in	O
triplicate	O
for	O
calculation	O
of	O
significant	O
differences	O
in	O
bacterial	O
population	O
by	O
the	O
Man	O
-	O
Whitney	O
test	O
.	O

P	O
values	O
of	O
0	O
.	O
05	O
or	O
below	O
considered	O
as	O
significant	O
.	O

Paired	O
samples	O
collected	O
from	O
healthy	O
volunteers	O
before	O
and	O
after	O
satronidazole	B-CD
treatment	O
were	O
analyzed	O
by	O
Wilcoxon	O
matched	O
-	O
pairs	O
signed	O
rank	O
test	O
(	O
two	O
tailed	O
).	O

Analysis	O
was	O
done	O
using	O
GraphPad	O
Prism	O
-	O
5	O
software	O
.	O

Results	O

Screening	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O

DNA	O
from	O
concentrated	O
cyst	B-DS
was	O
subjected	O
to	O
Dot	O
-	O
blot	O
hybridization	O
.	O

Dot	O
blot	O
analysis	O
of	O
550	O
samples	O
yielded	O
39	O
samples	O
(	O
7	O
%)	O
that	O
were	O
positive	O
for	O
Entamoeba	B-OG
(	O
Figure	O
1B	O
).	O

The	O
DNA	O
from	O
Entamoeba	B-OG
positive	O
samples	O
were	O
subjected	O
to	O
PCR	O
using	O
species	O
specific	O
primers	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
and	O
E	B-OG
.	I-OG
dispar	I-OG
(	O
Figure	O
2C	O
&	O
D	O
).	O
Out	O
of	O
39	O
samples	O
,	O
17	O
samples	O
(	O
43	O
%)	O
were	O
positive	O
for	O
E	B-OG
.	I-OG
histolytica	I-OG
.	O

None	O
of	O
the	O
samples	O
in	O
our	O
study	O
population	O
were	O
found	O
positive	O
for	O
both	O
the	O
species	O
of	O
the	O
parasite	O
.	O

Quantification	O
of	O
predominant	O
flora	O

High	O
quality	O
DNA	O
isolated	O
from	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
stool	O
sample	O
was	O
subjected	O
to	O
Real	O
Time	O
analysis	O
to	O
assess	O
the	O
predominant	O
gut	O
flora	O
that	O
included	O
Bacteroides	B-OG
,	O
Bifidobacterium	B-OG
,	O
Eubacterium	B-OG
,	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
,	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
,	O
Lactobacillus	B-OG
and	O
Ruminococcus	B-OG
.	O
Two	O
subdominant	O
genera	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Sulphur	B-OG
reducing	I-OG
bacteria	I-OG
(	O
SRB	B-OG
)	O
were	O
also	O
quantified	O
.	O

Validation	O
of	O
primers	O
designed	O
by	O
us	O
for	O
the	O
above	O
genera	O
have	O
already	O
been	O
reported	O
[	O
21	O
].	O

In	O
addition	O
to	O
the	O
above	O
primers	O
,	O
here	O
we	O
report	O
a	O
Real	O
time	O
analysis	O
of	O
nim	O
gene	O
copy	O
number	O
for	O
which	O
a	O
standard	O
curve	O
and	O
amplification	O
curve	O
have	O
been	O
drawn	O
that	O
shows	O
specific	O
and	O
efficient	O
quantification	O
with	O
slope	O
=	O
−	O
3	O
.	O
6	O
and	O
R2	O
=	O
0	O
.	O
998	O
(	O
Figure	O
3A	O
&	O
B	O
).	O

Real	O
-	O
time	O
analysis	O
for	O
quantification	O
of	O
different	O
bacterial	O
genera	O
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
.	O
(	O
A	O
)	O
Bacteroides	B-OG
(	O
B	O
)	O
Clostridium	B-OG
coccoides	I-OG
subgroup	O
(	O
C	O
)	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
D	O
)	O
Lactobacillus	B-OG
(	O
E	O
)	O
Campylobacter	B-OG
(	O
F	O
)	O
Eubacterium	B-OG
.	O
P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

Our	O
analysis	O
reveals	O
that	O
during	O
healthy	O
conditions	O
,	O
the	O
members	O
of	O
Bacteroides	B-OG
were	O
the	O
most	O
abundant	O
in	O
number	O
among	O
the	O
predominant	O
targeted	O
genera	O
.	O

However	O
,	O
a	O
significant	O
decrease	O
was	O
observed	O
in	O
population	O
of	O
Bacteroides	B-OG
(	O
p	O
=	O
.	O
001	O
)	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
when	O
compared	O
to	O
that	O
of	O
Healthy	O
control	O
samples	O
(	O
Figure	O
4A	O
).	O

Simultaneously	O
,	O
we	O
also	O
observed	O
a	O
significant	O
decrease	O
in	O
the	O
population	O
of	O
Closrtridium	B-OG
coccoides	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
002	O
),	O
Clostridium	B-OG
leptum	I-OG
subgroup	O
(	O
p	O
=	O
0	O
.	O
0001	O
),	O
Lactobacillus	B-OG
(	O
p	O
=	O
0	O
.	O
037	O
),	O
Campylobacter	B-OG
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
and	O
Eubacterium	B-OG
(	O
p	O
=	O
0	O
.	O
038	O
)	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
in	O
comparison	O
to	O
control	O
(	O
Figure	O
4B	O
,	O
C	O
,	O
D	O
,	O
E	O
and	O
F	O
respectively	O
).	O

Surprisingly	O
,	O
we	O
observed	O
a	O
significant	O
rise	O
in	O
the	O
population	O
of	O
Bifidobacterium	B-OG
(	O
p	O
=	O
0	O
.	O
009	O
)	O
in	O
amebic	O
samples	O
when	O
compared	O
with	O
healthy	O
control	O
samples	O
(	O
Figure	O
5B	O
).	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
population	O
of	O
Rumminococcus	B-OG
(	O
p	O
=	O
0	O
.	O
33	O
)	O
(	O
Figure	O
5A	O
).	O

Though	O
we	O
did	O
not	O
observe	O
any	O
significant	O
change	O
in	O
the	O
population	O
of	O
Methanobrevibacter	B-OG
(	O
p	O
=	O
0	O
.	O
96	O
)	O
and	O
Sulphur	O
reducing	O
bacteria	B-OG
(	O
p	O
=	O
0	O
.	O
88	O
)	O
in	O
amoebic	O
samples	O
but	O
the	O
prevalence	O
rate	O
was	O
reduced	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S1A	O
&	O
B	O
).	O

Real	O
-	O
time	O
analysis	O
of	O
population	O
of	O
(	O
A	O
)	O
Rumminococcus	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
(	O
B	O
)	O
Bifidobacterium	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
(	O
Eh	O
+	O
ve	O
)	O
samples	O
.	O
P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

Detection	O
and	O
identification	O
of	O
nim	B-GP
gene	O
in	O
stool	O
samples	O
.	O
(	O
A	O
)	O
Detection	O
of	O
nim	O
gene	O
using	O
nim	O
gene	O
specific	O
primers	O
.	O

Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
2	O
=	O
clone	O
of	O
nim	B-GP
gene	O
as	O
positive	O
control	O
,	O
Lane	O
3	O
–	O
5	O
=	O
DNA	O
from	O
stool	O
samples	O
from	O
healthy	O
volunteer	O
,	O
Lane	O
6	O
–	O
8	O
=	O
DNA	O
from	O
stool	O
samples	O
from	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
and	O
Lane	O
9	O
=	O
No	O
template	O
control	O
PCR	O
(	O
B	O
)	O
Restriction	O
map	O
of	O
TaqI	B-GP
restriction	O
sites	O
in	O
458	O
bp	O
nimE	O
gene	O
fragment	O
.	O

(	O
C	O
)	O
HpaII	B-GP
does	O
not	O
digest	O
nimE	B-GP
,	O
where	O
as	O
digestion	O
of	O
nimE	B-GP
by	O
TaqI	B-GP
generates	O
four	O
fragment	O
of	O
274	O
bp	O
,	O
155	O
bp	O
,	O
6	O
bp	O
and	O
25	O
bp	O
.	O

Lane	O
1	O
=	O
Marker	O
100	O
bp	O
,	O
Lane	O
H1	O
,	O
H2	O
,	O
E1	O
and	O
E2	O
show	O
RFLP	O
profile	O
of	O
PCR	O
product	O
digested	O
with	O
HpaII	B-GP
;	O
Lane	O
H3	O
,	O
H4	O
,	O
E3	O
and	O
E4	O
show	O
RFLP	O
profile	O
of	O
PCR	O
product	O
digested	O
with	O
TaqI	B-GP
.	O

H1	O
-	O
H4	O
,	O
DNA	O
from	O
stool	O
samples	O
of	O
Healthy	O
volunteers	O
and	O
E1	O
-	O
E4	O
are	O
DNA	O
from	O
stool	O
samples	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
.	O

Copy	O
no	O
.	O
of	O
nim	B-GP
gene	O

We	O
found	O
the	O
presence	O
of	O
nim	B-GP
genes	O
in	O
72	O
.	O
7	O
%	O
of	O
control	O
stool	O
samples	O
(	O
n	O
=	O
22	O
)	O
and	O
in	O
41	O
%	O
of	O
Entamoeba	B-OG
histolytica	I-OG
infected	O
patients	O
(	O
n	O
=	O
17	O
)	O
by	O
PCR	O
(	O
Figure	O
6A	O
).	O

Further	O
the	O
amplified	O
product	O
was	O
cloned	O
and	O
sequenced	O
.	O

BLAST	O
analysis	O
revealed	O
99	O
%	O
sequence	O
homology	O
with	O
nimE	B-GP
gene	O
(	O
Accession	O
no	O
.	O
AM117602	O
.	O
1	O
),	O
a	O
member	O
of	O
nim	B-GP
gene	O
family	O
[	O
22	O
].	O

Subsequently	O
,	O
the	O
PCR	O
products	O
from	O
all	O
the	O
samples	O
of	O
healthy	O
and	O
amebic	O
individuals	O
were	O
subjected	O
to	O
RFLP	O
analysis	O
using	O
HpaII	B-GP
and	O
TaqI	B-GP
restriction	B-GP
enzymes	I-GP
.	O

PCR	O
-	O
RFLP	O
pattern	O
confirmed	O
the	O
presence	O
of	O
only	O
nimE	B-GP
gene	O
in	O
all	O
the	O
samples	O
analyzed	O
(	O
Figure	O
6B	O
&	O
C	O
).	O

Real	O
time	O
analysis	O
of	O
nim	O
gene	O
in	O
the	O
stool	O
samples	O
exhibited	O
sample	O
to	O
sample	O
variation	O
(	O
4	O
×	O
102	O
to	O
4	O
×	O
105	O
copies	O
)	O
in	O
the	O
both	O
category	O
of	O
samples	O
.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
copy	O
no	O
.	O
of	O
nim	B-GP
gene	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
vs	O
samples	O
from	O
healthy	O
persons	O
(	O
p	O
=	O
0	O
.	O
025	O
)	O
(	O
Figure	O
3C	O
).	O

Detemination	O
of	O
copy	O
number	O
of	O
nimE	B-GP
gene	O
by	O
Real	O
-	O
time	O
PCR	O
.	O
(	O
A	O
)	O
Standard	O
curve	O
,	O
slope	O
=	O
−	O
3	O
.	O
6	O
and	O
R2	O
=	O
0	O
.	O
998	O
showing	O
good	O
efficiency	O
.	O

(	O
B	O
)	O
Dissociation	O
curve	O
showing	O
specific	O
amplification	O
of	O
target	O
(	O
nimE	O
gene	O
)	O
and	O
NTC	O
=	O
No	O
template	O
control	O
.	O

(	O
C	O
)	O
Absolute	O
quantification	O
of	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
.	O

(	O
D	O
)	O
Absolute	O
quantification	O
of	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
stool	O
sample	O
DNA	O
of	O
Healthy	O
volunteers	O
before	O
and	O
after	O
satronidazole	B-CD
treatment	O
.	O

P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O

CI	O
stands	O
for	O
confidence	O
interval	O
.	O

To	O
see	O
the	O
effect	O
of	O
antiamoebic	O
drug	O
Satronidazole	B-CD
(	O
Alchem	O
pharmaceuticals	O
)	O
on	O
nim	O
gene	O
copy	O
number	O
,	O
healthy	O
volunteers	O
(	O
n	O
=	O
5	O
)	O
were	O
advised	O
to	O
take	O
the	O
drug	O
(	O
300	O
mg	O
tablets	O
)	O
twice	O
daily	O
after	O
meals	O
for	O
4	O
days	O
and	O
copy	O
of	O
nim	O
gene	O
was	O
quantified	O
before	O
and	O
after	O
the	O
treatment	O
using	O
the	O
primers	O
described	O
here	O
.	O

Wilcoxon	O
matched	O
-	O
pairs	O
signed	O
rank	O
test	O
(	O
two	O
tailed	O
)	O
analysis	O
of	O
copy	O
no	O
.	O
of	O
nim	O
gene	O
shows	O
no	O
significant	O
change	O
(	O
p	O
=	O
0	O
.	O
125	O
)	O
in	O
stool	O
samples	O
collected	O
before	O
and	O
after	O
treatment	O
(	O
Figure	O
3D	O
).	O

Discussion	O

Infection	B-DS
by	O
E	B-OG
.	I-OG
histolytica	I-OG
is	O
normally	O
initiated	O
by	O
the	O
ingestion	O
of	O
fecally	O
contaminated	O
water	O
or	O
food	O
containing	O
E	B-OG
.	I-OG
histolytica	I-OG
cysts	B-DS
.	O

Phagocytosis	O
of	O
colonic	O
bacteria	B-OG
has	O
been	O
considered	O
as	O
a	O
possible	O
stimulus	O
to	O
induce	O
the	O
invasive	O
behavior	O
by	O
the	O
parasite	B-OG
[	O
23	O
].	O

Adult	O
gut	O
microbiota	B-OG
are	O
quite	O
stable	O
in	O
individuals	O
and	O
can	O
even	O
be	O
restored	O
after	O
perturbation	O
[	O
24	O
,	O
25	O
].	O

Our	O
earlier	O
results	O
have	O
shown	O
significant	O
changes	O
in	O
expression	O
of	O
EhCaBP	B-GP
and	O
LPG	B-GP
only	O
after	O
the	O
axenic	O
E	B-OG
.	I-OG
histolytica	I-OG
had	O
been	O
adapted	O
to	O
grow	O
with	O
bacterial	O
flora	O
for	O
a	O
number	O
of	O
generatiom	O
,	O
and	O
not	O
in	O
short	O
term	O
culture	O
[	O
26	O
].	O

In	O
the	O
present	O
study	O
we	O
tried	O
to	O
evaluate	O
perturbations	O
in	O
commensal	O
gut	O
flora	O
caused	O
as	O
result	O
of	O
E	B-DS
.	I-DS
histolytica	I-DS
infection	I-DS
using	O
Real	O
Time	O
PCR	O
.	O

qPCR	O
methodology	O
is	O
less	O
expensive	O
,	O
more	O
quantitative	O
and	O
is	O
more	O
efficient	O
in	O
terms	O
of	O
time	O
and	O
operation	O
[	O
27	O
].	O

The	O
absolute	O
proportions	O
of	O
eight	O
predominant	O
commensal	O
and	O
two	O
subdominant	O
genera	O
were	O
quantified	O
successfully	O
in	O
our	O
samples	O
.	O

Bacteroides	B-OG
species	O
are	O
a	O
pleomorphic	O
group	O
of	O
non	O
-	O
spore	O
forming	O
gram	O
-	O
negative	B-OG
anaerobic	I-OG
bacteria	I-OG
.	O

Bacteroides	B-OG
are	O
the	O
most	O
dominant	O
part	O
of	O
the	O
normal	O
indigenous	O
flora	O
in	O
the	O
human	B-OG
gut	O
.	O
Bacteroides	B-OG
are	O
mostly	O
represented	O
by	O
Bacteroides	B-OG
ovatus	I-OG
,	O
Bacteroides	B-OG
uniformis	I-OG
Bacteroides	B-OG
vulgatus	I-OG
,	O
Bacteroides	B-OG
thetaiotaomicron	I-OG
,	O
Bacteroides	B-OG
distasonis	I-OG
,	O
and	O
less	O
frequently	O
by	O
Bacteroides	B-OG
eggerthii	I-OG
and	O
Bacteroides	B-OG
fragilis	I-OG
.	O
These	O
bacteria	B-OG
are	O
significant	O
contributors	O
to	O
the	O
carbohydrate	B-CD
metabolism	O
,	O
nutrition	O
and	O
health	O
of	O
humans	B-OG
and	O
animals	B-OG
.	O

In	O
1999	O
Hooper	O
et	O
al	O
.	O
demonstrated	O
that	O
B	B-OG
.	I-OG
thetaiotaomicron	I-OG
can	O
modify	O
intestinal	O
fucosylation	O
in	O
a	O
complex	O
interaction	O
mediated	O
by	O
fucose	B-CD
repressor	O
gene	O
and	O
a	O
signaling	O
system	O
[	O
28	O
].	O

The	O
significant	O
decrease	O
in	O
population	O
of	O
Bacteroides	B-OG
during	O
disease	O
condition	O
dampens	O
the	O
beneficial	O
effects	O
of	O
this	O
genera	O
to	O
host	O
.	O

In	O
the	O
human	B-OG
intestinal	O
tract	O
,	O
Eubacterium	B-OG
is	O
the	O
second	O
most	O
common	O
genus	O
after	O
the	O
genus	O
Bacteroides	B-OG
.	O
The	O
genus	O
Eubacterium	B-OG
comprises	O
a	O
nutritionally	O
diverse	O
group	O
of	O
organisms	O
.	O

The	O
members	O
of	O
genus	O
Eubacterium	B-OG
are	O
known	O
to	O
produce	O
butyrate	O
[	O
29	O
],	O
degrade	O
flavonoids	B-CD
(	O
from	O
vegetables	O
,	O
fruits	O
,	O
nuts	O
,	O
and	O
tea	O
)	O
[	O
30	O
]	O
and	O
are	O
implicated	O
in	O
steroid	B-CD
and	O
bile	O
transformation	O
in	O
intestine	O
[	O
31	O
].	O

The	O
decrease	O
in	O
population	O
of	O
Eubacterium	B-OG
sp	I-OG
.	O
observed	O
in	O
our	O
study	O
may	O
reduce	O
the	O
butyrate	B-CD
production	O
and	O
may	O
also	O
affect	O
the	O
capacity	O
of	O
the	O
host	O
in	O
proper	O
digestion	O
of	O
the	O
above	O
ingredients	O
of	O
food	O
.	O

Bifidobacterium	B-OG
species	O
are	O
common	O
inhabitants	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
they	O
have	O
received	O
special	O
attention	O
because	O
of	O
their	O
health	O
-	O
promoting	O
effects	O
in	O
humans	B-OG
.	O

Members	O
of	O
Bifidobacteria	B-OG
produce	O
enough	O
acetate	O
(	O
SCFA	O
)	O
in	O
proximal	O
and	O
distal	O
colon	O
by	O
fermentation	O
of	O
glucose	B-CD
and	O
fructose	B-CD
[	O
32	O
].	O

Members	O
of	O
both	O
Bifidobacteria	B-OG
and	O
Ruminococcus	B-OG
-	O
Ruminococcus	B-OG
torques	O
and	O
Bifidobacterium	B-OG
bifidum	I-OG
are	O
thought	O
to	O
ferment	O
mucin	B-GP
and	O
compete	O
to	O
colonise	O
this	O
substrate	O
for	O
their	O
energy	O
source	O
[	O
33	O
].	O

Our	O
result	O
shows	O
a	O
significant	O
increase	O
in	O
population	O
of	O
Bifidobacterium	B-OG
but	O
no	O
change	O
in	O
population	O
of	O
Rumminococcous	O
despite	O
decrease	O
in	O
population	O
of	O
several	O
other	O
targeted	O
genera	O
.	O

It	O
is	O
quite	O
well	O
known	O
that	O
mucus	O
secretion	O
is	O
increased	O
in	O
E	B-DS
.	I-DS
histolytica	I-DS
infection	I-DS
especially	O
during	O
dysentery	B-DS
which	O
is	O
probably	O
result	O
of	O
a	O
mechanism	O
exerted	O
by	O
intestinal	O
epithelial	O
cells	O
to	O
counter	O
the	O
adherence	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
trophozoites	B-OG
to	O
intestinal	O
epithelial	O
surface	O
.	O

The	O
protozoan	O
parasite	O
Entamoeba	B-OG
histolytica	I-OG
cleaves	O
Mucin	B-GP
2	I-GP
(	O
MUC2	B-GP
)	O
in	O
the	O
non	O
-	O
glycosylated	O
oligomerization	O
domains	O
by	O
cysteine	B-GP
protease	I-GP
,	O
thus	O
breaking	O
down	O
the	O
macromolecular	O
structure	O
and	O
reducing	O
mucus	O
viscosity	O
[	O
34	O
].	O

Perhaps	O
under	O
this	O
condition	O
,	O
a	O
cross	O
-	O
talk	O
between	O
the	O
mucosal	O
layer	O
,	O
bacteria	B-OG
and	O
the	O
parasite	B-OG
initiates	O
.	O

As	O
a	O
result	O
,	O
the	O
intestinal	O
epithelial	O
cells	O
tend	O
to	O
produce	O
more	O
of	O
mucin	B-GP
for	O
protection	O
that	O
promotes	O
colonization	O
of	O
Bifidobacteria	B-OG
in	O
one	O
hand	O
and	O
on	O
the	O
other	O
hand	O
the	O
parasite	O
competes	O
to	O
more	O
release	O
of	O
mucin	B-GP
for	O
its	O
adhesion	O
to	O
epithelial	O
layer	O
.	O
Bifidobacteria	B-OG
longum	I-OG
are	O
known	O
to	O
protect	O
the	O
gut	O
from	O
enteropathogenic	B-DS
infection	I-DS
through	O
production	O
of	O
acetate	O
[	O
32	O
]	O
and	O
acetate	O
is	O
major	O
energy	O
source	O
for	O
colonocytes	O
but	O
a	O
fine	O
balance	O
in	O
population	O
of	O
different	O
bacterial	O
genera	O
of	O
gut	O
is	O
needed	O
for	O
healthy	O
colon	O
.	O

The	O
C	B-OG
.	I-OG
leptum	I-OG
subgroup	O
and	O
C	B-OG
.	I-OG
coccoides	I-OG
subgroup	O
are	O
one	O
of	O
the	O
most	O
predominant	O
populations	O
of	O
human	B-OG
fecal	O
microflora	O
which	O
contains	O
a	O
large	O
number	O
of	O
butyrate	O
-	O
producing	O
bacteria	B-OG
[	O
35	O
,	O
36	O
].	O

Butyrate	B-CD
is	O
a	O
SCFA	O
(	O
Short	O
chain	O
fatty	B-CD
acids	I-CD
)	O
having	O
a	O
strong	O
effect	O
on	O
the	O
cell	O
cycle	O
and	O
acts	O
as	O
anti	O
-	O
inflammatory	O
molecule	O
in	O
the	O
gut	O
.	O

Effects	O
on	O
mucosal	O
defense	O
include	O
improved	O
tight	O
junction	O
assembly	O
,	O
antimicrobial	O
secretion	O
and	O
mucin	B-GP
expression	O
[	O
37	O
].	O

The	O
decrease	O
in	O
population	O
of	O
members	O
of	O
C	B-OG
.	I-OG
leptum	I-OG
subgroup	O
and	O
C	B-OG
.	I-OG
coccoides	I-OG
subgroup	O
observed	O
here	O
leads	O
to	O
decrease	O
in	O
the	O
production	O
of	O
SCFA	O
and	O
hence	O
renders	O
the	O
host	O
more	O
susceptible	O
for	O
future	O
infections	B-DS
.	O

The	O
genus	O
Lactobacillus	B-OG
comprises	O
a	O
large	O
heterogenous	O
group	O
of	O
low	O
G	O
+	O
C	O
gram	O
positive	O
,	O
non	O
sporulating	O
,	O
anaerobic	O
bacteria	B-OG
belonging	O
to	O
phylum	O
Firmicutes	B-OG
.	O
Lactobacilli	B-OG
are	O
known	O
to	O
fortify	O
epithelial	O
barrier	O
by	O
various	O
mechanism	O
such	O
as	O
induction	O
of	O
mucin	B-GP
secretion	O
,	O
enhancement	O
of	O
tight	O
-	O
junction	O
functioning	O
,	O
upregulation	O
of	O
cytoprotective	O
heat	B-GP
shock	I-GP
proteins	I-GP
and	O
prevention	O
of	O
apoptosis	O
of	O
epithelial	O
cells	O
[	O
38	O
].	O

Probiotic	O
strains	O
of	O
Lactobacillus	B-OG
are	O
known	O
to	O
prevent	O
infectious	O
diarrhea	O
,	O
antibiotic	O
associated	O
diarrhea	O
and	O
diarrhea	O
in	O
children	O
who	O
are	O
unusually	O
more	O
susceptible	O
as	O
a	O
result	O
of	O
poor	O
nutrition	O
,	O
impaired	O
immune	O
status	O
or	O
frequent	O
exposure	O
to	O
pathogens	O
[	O
39	O
].	O

We	O
observed	O
significant	O
decrease	O
in	O
population	O
of	O
Lactobacillus	B-OG
in	O
gut	O
flora	O
of	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
as	O
compared	O
to	O
that	O
of	O
healthy	O
individuals	O
that	O
support	O
our	O
earlier	O
observation	O
made	O
by	O
semi	O
quantitative	O
method	O
[	O
1	O
].	O

Methanobrevibacter	B-OG
smithii	I-OG
is	O
the	O
dominant	O
archaeon	B-OG
in	O
human	B-OG
gut	O
that	O
affects	O
the	O
specificity	O
and	O
efficiency	O
of	O
bacterial	O
digestion	O
of	O
dietary	O
polysaccharides	O
,	O
thereby	O
influencing	O
host	O
calorie	O
harvest	O
and	O
adiposity	O
[	O
40	O
].	O

It	O
has	O
been	O
suggested	O
that	O
the	O
low	O
and	O
variable	O
prevalence	O
of	O
Methanobrevibacter	B-OG
smithii	I-OG
and	O
Methanosphaera	B-OG
stadtmanae	I-OG
DNA	O
in	O
human	B-OG
stool	O
contrasts	O
with	O
the	O
paramount	O
role	O
of	O
these	O
methanogenic	O
archaea	B-OG
in	O
digestion	O
processes	O
and	O
hypothesized	O
that	O
this	O
contrast	O
is	O
a	O
consequence	O
of	O
the	O
inefficiencies	O
of	O
current	O
protocols	O
for	O
archaea	B-OG
DNA	O
extraction	O
[	O
41	O
].	O

In	O
our	O
samples	O
prevalence	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
in	O
healthy	O
individuals	O
stool	O
samples	O
was	O
27	O
.	O
27	O
%	O
and	O
that	O
was	O
further	O
reduced	O
to	O
11	O
.	O
7	O
%	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
.	O

Real	O
-	O
time	O
analysis	O
shows	O
no	O
significant	O
alteration	O
in	O
population	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
.	O

Variation	O
in	O
the	O
loads	O
of	O
M	B-OG
.	I-OG
smithii	I-OG
under	O
different	O
pathophysiological	O
condition	O
such	O
as	O
during	O
amebiasis	B-DS
has	O
not	O
been	O
reported	O
so	O
far	O
.	O

Suphate	O
reducing	O
bacteria	B-OG
(	O
SRB	B-OG
)	O
are	O
a	O
group	O
of	O
non	O
spore	O
forming	O
,	O
gram	O
negative	O
,	O
dissimilatory	O
sulphate	O
reducing	O
,	O
anaerobic	B-OG
bacteria	B-OG
.	O

SRB	O
can	O
be	O
isolated	O
from	O
the	O
intestinal	O
tract	O
of	O
humans	B-OG
and	O
various	O
environmental	O
sources	O
.	O

Intestinal	O
SRB	O
’	O
s	O
growth	O
and	O
resultant	O
hydrogen	O
sulfide	O
production	O
have	O
been	O
implicated	O
to	O
damage	O
the	O
gastrointestinal	O
tract	O
and	O
thereby	O
contribute	O
to	O
chronic	B-DS
intestinal	I-DS
disorders	I-DS
[	O
42	O
].	O
Desulfovibrio	B-OG
fairfieldensis	I-OG
and	O
D	B-OG
.	I-OG
desulfuricans	I-OG
have	O
been	O
associated	O
with	O
incidence	O
of	O
bacteremia	B-DS
and	O
D	B-OG
.	I-OG
vulgaris	I-OG
has	O
been	O
associated	O
with	O
intra	B-DS
-	I-DS
abdominal	I-DS
infections	I-DS
[	O
43	O
].	O

The	O
prevalence	O
of	O
Sulphate	O
reducing	O
bacteria	B-OG
was	O
36	O
.	O
36	O
%	O
in	O
healthy	O
and	O
11	O
.	O
7	O
%	O
in	O
amoebic	O
individuals	O
stool	O
samples	O
.	O

However	O
,	O
the	O
change	O
was	O
not	O
statistically	O
significant	O
.	O

The	O
genus	O
Campylobacter	B-OG
is	O
notorious	O
for	O
causing	O
gastroenritis	B-DS
by	O
C	B-OG
.	I-OG
jejuni	I-OG
but	O
uncultured	O
Campylobacter	B-OG
species	O
e	O
.	O
g	O
.	O
Campylobacter	B-OG
hominis	I-OG
whose	O
role	O
is	O
not	O
clear	O
yet	O
,	O
do	O
exist	O
in	O
lower	O
gastrointestinal	O
tract	O
of	O
healthy	O
humans	B-OG
[	O
44	O
].	O

We	O
observed	O
significant	O
decrease	O
in	O
population	O
of	O
Campylobacter	B-OG
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
individual	O
as	O
compared	O
to	O
healthy	O
individuals	O
.	O

As	O
our	O
primers	O
were	O
genus	O
specific	O
,	O
so	O
decrease	O
in	O
Campylobacter	B-OG
was	O
genera	O
specific	O
and	O
not	O
species	O
specific	O
.	O

Significant	O
increase	O
in	O
the	O
population	O
of	O
Campylobacter	B-OG
has	O
been	O
observed	O
in	O
IBD	B-DS
[	O
21	O
]	O
but	O
we	O
did	O
not	O
find	O
the	O
same	O
trend	O
in	O
amoebic	O
patients	O
.	O

Several	O
species	O
of	O
Bacteroides	B-OG
are	O
known	O
to	O
harbor	O
nim	B-GP
genes	O
e	O
.	O
g	O
.	O
B	B-OG
.	I-OG
fragilis	I-OG
,	O
B	B-OG
.	I-OG
distasonis	I-OG
,	O
B	B-OG
.	I-OG
thetaiotaomicron	I-OG
,	O
B	B-OG
.	I-OG
vulgatus	I-OG
,	O
B	B-OG
.	I-OG
ovatus	I-OG
but	O
wide	O
differences	O
in	O
MIC	O
values	O
of	O
metronidazole	B-CD
are	O
observed	O
,	O
ranging	O
from	O
1	O
.	O
5	O
to	O
>	O
256	O
mg	O
/	O
L	O
and	O
some	O
are	O
also	O
found	O
above	O
the	O
therapeutic	O
breakpoint	O
of	O
16	O
mg	O
/	O
L	O
[	O
45	O
].	O
Though	O
the	O
population	O
of	O
Bacteroides	B-OG
is	O
decreased	O
significantly	O
in	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
patients	O
however	O
we	O
have	O
observed	O
high	O
copy	O
no	O
.	O
of	O
nimE	B-GP
gene	O
in	O
the	O
same	O
.	O

We	O
attribute	O
this	O
increase	O
to	O
the	O
presence	O
of	O
plasmid	O
coded	O
nimE	B-GP
gene	O
as	O
has	O
been	O
observed	O
earlier	O
in	O
Veillonella	B-OG
sp	O
.	O

[	O
46	O
].	O

Future	O
analyses	O
that	O
target	O
specific	O
members	O
of	O
the	O
Bacteroides	B-OG
group	O
will	O
shed	O
further	O
light	O
on	O
the	O
species	O
involved	O
in	O
the	O
expansion	O
of	O
nimE	B-GP
gene	O
.	O
In	O
2006	O
,	O
Rani	O
et	O
al	O
.	O
reported	O
presence	O
of	O
nim	B-GP
gene	O
in	O
stool	O
samples	O
of	O
amebic	O
individuals	O
but	O
not	O
in	O
healthy	O
individuals	O
[	O
1	O
]	O
but	O
our	O
result	O
show	O
high	O
prevalence	O
rate	O
of	O
nim	B-GP
gene	O
even	O
in	O
healthy	O
individuals	O
irrespective	O
of	O
the	O
disease	O
.	O

However	O
in	O
a	O
hospital	O
based	O
study	O
carried	O
out	O
in	O
Greece	O
revealed	O
low	O
level	O
of	O
prevalence	O
of	O
nim	B-GP
gene	O
in	O
isolates	O
of	O
different	O
anaerobic	O
bacterial	O
species	O
from	O
hospitalized	O
patients	O
[	O
47	O
].	O

Though	O
the	O
presence	O
of	O
nim	B-GP
gene	O
in	O
gut	O
of	O
healthy	O
north	O
Indian	O
population	O
is	O
shocking	O
but	O
this	O
may	O
be	O
explained	O
due	O
to	O
easy	O
over	O
the	O
counter	O
drug	O
availability	O
in	O
India	O
.	O

Results	O
on	O
healthy	O
individuals	O
undergoing	O
Satronidazole	B-CD
treatment	O
indicate	O
that	O
nimE	B-GP
gene	O
copy	O
number	O
does	O
not	O
show	O
significant	O
reduction	O
.	O

It	O
can	O
therefore	O
be	O
assumed	O
that	O
nimE	B-GP
gene	O
harboring	O
Bacteroides	B-OG
probably	O
cause	O
inactivation	O
of	O
nitroimidazole	O
drug	O
and	O
thereby	O
reduce	O
the	O
bioavailability	O
of	O
drug	O
to	O
the	O
parasite	O
and	O
hence	O
may	O
help	O
in	O
sustaining	O
the	O
infection	B-DS
.	O

Conclusion	O

The	O
metabolic	O
activities	O
of	O
the	O
predominant	O
gut	O
flora	O
have	O
a	O
significant	O
effect	O
on	O
the	O
health	O
of	O
the	O
human	B-OG
colon	O
.	O

The	O
current	O
findings	O
of	O
depleted	O
populations	O
of	O
metabolically	O
important	O
bacteria	B-OG
like	O
Bacteroides	B-OG
,	O
C	B-OG
.	I-OG
leptum	I-OG
and	O
C	B-OG
.	I-OG
coccoides	I-OG
sub	I-OG
groups	O
,	O
Lactobacillus	B-OG
sp	I-OG
.,	O
Eubacterium	B-OG
sp	I-OG
.,	O
and	O
Campylobacter	B-OG
sp	I-OG
.	O
add	O
to	O
our	O
knowledge	O
of	O
the	O
changes	O
in	O
the	O
GI	O
tracts	O
of	O
amebic	O
patients	O
.	O

Such	O
changes	O
in	O
bacterial	O
population	O
in	O
the	O
normal	O
microbiota	B-OG
could	O
have	O
considerable	O
consequences	O
in	O
terms	O
of	O
functional	O
potential	O
of	O
gut	O
flora	O
and	O
could	O
result	O
in	O
metabolic	O
conditions	O
favorable	O
for	O
the	O
establishment	O
of	O
opportunistic	O
pathogens	O
(	O
e	O
.	O
g	O
.	O
Clostridium	B-OG
difficile	I-OG
).	O

However	O
,	O
our	O
study	O
cannot	O
conclude	O
that	O
observed	O
changes	O
in	O
the	O
gut	O
flora	O
is	O
the	O
cause	O
or	O
effect	O
of	O
the	O
infection	B-DS
or	O
the	O
effect	O
of	O
dysenteric	O
mechanism	O
per	O
se	O
by	O
the	O
parasite	O
.	O

Our	O
findings	O
could	O
potentially	O
guide	O
implementation	O
of	O
dietary	O
/	O
probiotic	O
interventions	O
that	O
impact	O
the	O
gut	O
microbiota	O
and	O
improve	O
GI	O
health	O
in	O
individuals	O
infected	O
with	O
Entamoeba	B-OG
histolytica	I-OG
.	O

Abbreviations	O

SRB	O
:	O
Sulphur	O
reducing	O
bacteria	B-OG
;	O
RFLP	O
:	O
Restriction	O
fragment	O
length	O
polymorphism	O
;	O
MUC2	B-GP
:	O
Mucin	B-GP
2	I-GP
;	O
SCFA	O
:	O
Short	O
-	O
chain	O
.	O

Competing	O
interests	O

We	O
declare	O
that	O
no	O
competing	O
interests	O
exist	O
among	O
the	O
authors	O

Authors	O
’	O
contributions	O

JP	O
conceived	O
and	O
coordinated	O
the	O
study	O
.	O

AKV	O
carried	O
out	O
the	O
bacterial	O
quantification	O
experiments	O
.	O

AKV	O
and	O
RV	O
conducted	O
the	O
copy	O
number	O
calculation	O
experiments	O
.	O

JP	O
and	O
AKV	O
drafted	O
the	O
manuscript	O
and	O
conducted	O
the	O
statistical	O
analysis	O
.	O

VA	O
made	O
the	O
diagnosis	O
of	O
the	O
patients	O
,	O
interpretation	O
of	O
data	O
and	O
collaborated	O
in	O
collection	O
of	O
the	O
samples	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

Additional	O
file	O
1	O

Real	O
time	O
analysis	O
of	O
population	O
of	O
(	O
A	O
)	O
Methanobrevibacter	O
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
samples	O
(	O
B	O
)	O
Sulphur	O
reducing	O
bacteria	B-OG
in	O
Healthy	O
vs	O
E	B-OG
.	I-OG
histolytica	I-OG
positive	O
sample	O
.	O

P	O
value	O
=	O
.	O
05	O
or	O
below	O
was	O
considered	O
significant	O
.	O
Cl	O
stands	O
for	O
confidence	O
interval	O
.	O

Click	O
here	O
for	O
file	O

Genetics	O
of	O
longevity	O
.	O
data	O
from	O
the	O
studies	O
on	O
Sicilian	O
centenarians	O

The	O
demographic	O
and	O
social	O
changes	O
of	O
the	O
past	O
decades	O
have	O
determined	O
improvements	O
in	O
public	O
health	O
and	O
longevity	O
.	O

So	O
,	O
the	O
number	O
of	O
centenarians	O
is	O
increasing	O
as	O
a	O
worldwide	O
phenomenon	O
.	O

Scientists	O
have	O
focused	O
their	O
attention	O
on	O
centenarians	O
as	O
optimal	O
model	O
to	O
address	O
the	O
biological	O
mechanisms	O
of	O
""""	O
successful	O
and	O
unsuccessful	O
ageing	O
"""."	O

They	O
are	O
equipped	O
to	O
reach	O
the	O
extreme	O
limits	O
of	O
human	B-OG
life	O
span	O
and	O
,	O
most	O
importantly	O
,	O
to	O
show	O
relatively	O
good	O
health	O
,	O
being	O
able	O
to	O
perform	O
their	O
routine	O
daily	O
life	O
and	O
to	O
escape	O
fatal	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
such	O
as	O
cardiovascular	B-DS
diseases	I-DS
and	O
cancer	B-DS
.	O

Thus	O
,	O
particular	O
attention	O
has	O
been	O
centered	O
on	O
their	O
genetic	O
background	O
and	O
immune	O
system	O
.	O

In	O
this	O
review	O
,	O
we	O
report	O
our	O
data	O
gathered	O
for	O
over	O
10	O
years	O
in	O
Sicilian	O
centenarians	O
.	O

Based	O
on	O
results	O
obtained	O
,	O
we	O
suggest	O
longevity	O
as	O
the	O
result	O
of	O
an	O
optimal	O
performance	O
of	O
immune	O
system	O
and	O
an	O
over	O
-	O
expression	O
of	O
anti	O
-	O
inflammatory	O
sequence	O
variants	O
of	O
immune	O
/	O
inflammatory	O
genes	O
.	O

However	O
,	O
as	O
well	O
known	O
,	O
genetic	O
,	O
epigenetic	O
,	O
stochastic	O
and	O
environmental	O
factors	O
seem	O
to	O
have	O
a	O
crucial	O
role	O
in	O
ageing	O
and	O
longevity	O
.	O

Epigenetics	O
is	O
associated	O
with	O
ageing	O
,	O
as	O
demonstrated	O
in	O
many	O
studies	O
.	O

In	O
particular	O
,	O
ageing	O
is	O
associated	O
with	O
a	O
global	O
loss	O
of	O
methylation	O
state	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
future	O
studies	O
will	O
be	O
to	O
analyze	O
the	O
weight	O
of	O
epigenetic	O
changes	O
in	O
ageing	O
and	O
longevity	O
.	O

Introduction	O

Data	O
from	O
centenarian	O
offspring	O

As	O
well	O
known	O
,	O
life	O
expectancy	O
is	O
a	O
familial	O
trait	O
and	O
longevity	O
is	O
determined	O
by	O
different	O
factors	O
.	O

In	O
particular	O
,	O
the	O
environmental	O
milieu	O
and	O
genetic	O
background	O
play	O
a	O
central	O
role	O
.	O

As	O
demonstrated	O
by	O
many	O
epidemiological	O
studies	O
,	O
family	O
members	O
of	O
long	O
-	O
lived	O
subjects	O
have	O
a	O
significant	O
survival	O
advantage	O
compared	O
to	O
general	O
population	O
.	O

In	O
this	O
context	O
,	O
the	O
study	O
of	O
centenarian	O
offspring	O
(	O
CO	O
),	O
a	O
group	O
of	O
healthy	O
elderly	O
people	O
with	O
a	O
familiar	O
history	O
of	O
longevity	O
,	O
might	O
help	O
gerontologists	O
to	O
better	O
identify	O
the	O
correlation	O
between	O
genetic	O
profile	O
and	O
hope	O
of	O
a	O
healthy	O
ageing	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
CO	O
,	O
like	O
their	O
centenarian	O
parents	O
,	O
have	O
genetic	O
and	O
immune	O
system	O
advantages	O
,	O
which	O
reflect	O
a	O
minor	O
risk	O
to	O
develop	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
such	O
as	O
cardiovascular	B-DS
diseases	I-DS
,	O
hypertension	B-DS
or	O
diabetes	B-DS
mellitus	I-DS
as	O
well	O
as	O
cancer	B-DS
[	O
1	O
,	O
2	O
].	O

The	O
lower	O
cardiovascular	B-DS
disease	I-DS
risk	O
in	O
CO	O
suggests	O
the	O
probability	O
that	O
CO	O
have	O
some	O
protective	O
factors	O
against	O
atherosclerosis	B-DS
,	O
such	O
as	O
a	O
good	O
lipid	O
profile	O
.	O

Male	O
CO	O
have	O
higher	O
plasma	O
HDL	O
-	O
C	O
levels	O
and	O
lower	O
plasma	O
LDL	O
-	O
C	O
levels	O
.	O

Since	O
lipid	O
profile	O
is	O
directly	O
correlated	O
to	O
atherosclerotic	B-DS
cardiovascular	I-DS
diseases	I-DS
,	O
this	O
metabolic	O
feature	O
could	O
preserve	O
CO	O
both	O
to	O
develop	O
these	O
diseases	O
and	O
,	O
as	O
consequence	O
,	O
to	O
reach	O
a	O
healthy	O
ageing	O
and	O
longer	O
survival	O
[	O
3	O
].	O

Furthermore	O
,	O
Rose	O
et	O
al	O
.	O
[	O
4	O
]	O
reported	O
that	O
centenarians	O
and	O
CO	O
show	O
significantly	O
higher	O
levels	O
of	O
heteroplasmy	O
in	O
mtDNA	O
control	O
region	O
than	O
controls	O
,	O
a	O
favorable	O
condition	O
for	O
longevity	O
.	O

In	O
these	O
last	O
years	O
,	O
some	O
researchers	O
have	O
speculated	O
about	O
the	O
distinctive	O
immunological	O
profile	O
of	O
offspring	O
enriched	O
for	O
longevity	O
respect	O
to	O
the	O
immunological	O
features	O
of	O
coeval	O
elderly	O
.	O

The	O
cytomegalovirus	B-OG
(	O
CMV	B-OG
)	O
is	O
one	O
of	O
the	O
most	O
common	O
viruses	B-OG
that	O
affect	O
elderly	O
people	O
.	O

Many	O
evidences	O
have	O
shown	O
that	O
CMV	B-DS
infection	I-DS
may	O
influence	O
the	O
T	O
cell	O
subset	O
distribution	O
,	O
having	O
an	O
essential	O
role	O
in	O
immunosenescence	O
[	O
5	O
-	O
7	O
].	O

CMV	B-DS
infection	I-DS
is	O
strongly	O
related	O
to	O
both	O
a	O
reduction	O
of	O
CD8	B-GP
+	O
CD45	B-GP
+	O
CCR7	B-GP
+	O
CD27	B-GP
+	O
CD28	B-GP
+	O
naïve	O
T	O
cells	O
and	O
to	O
a	O
contemporarily	O
increase	O
of	O
CD8	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
-	O
CD28	B-GP
-	O
late	O
differentiated	O
effector	O
memory	O
and	O
CD45RA	B-GP
-	O
re	O
-	O
expressing	O
T	O
cells	O
.	O

These	O
parameters	O
are	O
considered	O
typical	O
of	O
immunosenescence	O
in	O
elderly	O
.	O

Recently	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
CMV	B-OG
-	O
seropositive	O
offspring	O
of	O
long	O
-	O
lived	O
people	O
don	O
'	O
t	O
show	O
the	O
age	O
-	O
associated	O
decrease	O
of	O
naïve	O
T	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
memory	O
T	O
cell	O
subsets	O
above	O
described	O
do	O
not	O
increase	O
in	O
offspring	O
of	O
long	O
-	O
lived	O
families	O
,	O
differently	O
from	O
that	O
observed	O
in	O
age	O
-	O
matched	O
controls	O
[	O
8	O
].	O

It	O
has	O
been	O
also	O
demonstrated	O
that	O
CMV	B-OG
-	O
seropositive	O
offspring	O
of	O
long	O
-	O
lived	O
people	O
have	O
reduced	O
levels	O
of	O
CD8	B-GP
+	O
T	O
cells	O
expressing	O
CD57	B-GP
and	O
KLRG1	B-GP
,	O
sometimes	O
referred	O
as	O
""""	O
marker	O
of	O
senescence	O
""","	O
when	O
compared	O
to	O
their	O
CMV	B-OG
-	O
infected	O
age	O
-	O
matched	O
controls	O
.	O

The	O
reduction	O
of	O
effector	O
memory	O
T	O
cells	O
lacking	O
the	O
expression	O
of	O
CD27	B-GP
and	O
CD28	B-GP
and	O
expressing	O
CD57	B-GP
and	O
KLRG1	B-GP
,	O
observed	O
in	O
CMV	B-OG
-	O
infected	O
offspring	O
could	O
explain	O
their	O
high	O
proliferative	O
response	O
against	O
CMV	B-OG
.	O

The	O
CMV	B-OG
-	O
seropositive	O
offspring	O
have	O
also	O
shown	O
significantly	O
lower	O
CRP	B-GP
levels	O
compared	O
to	O
their	O
CMV	B-OG
-	O
seropositive	O
age	O
-	O
matched	O
controls	O
that	O
could	O
be	O
related	O
to	O
a	O
lower	O
pro	O
-	O
inflammatory	O
status	O
[	O
8	O
].	O

During	O
ageing	O
,	O
B	O
cell	O
compartment	O
also	O
shows	O
significant	O
modifications	O
in	O
numbers	O
and	O
functions	O
[	O
9	O
-	O
12	O
].	O

In	O
fact	O
,	O
advanced	O
age	O
is	O
per	O
se	O
a	O
condition	O
characterized	O
by	O
lack	O
of	O
B	O
clonotypic	O
immune	O
response	O
to	O
new	O
extracellular	O
pathogens	O
.	O

In	O
any	O
event	O
,	O
data	O
are	O
suggesting	O
that	O
the	O
loss	O
of	O
naive	O
B	O
cells	O
could	O
represent	O
a	O
hallmark	O
of	O
immunosenescence	O
[	O
13	O
].	O

On	O
the	O
other	O
hand	O
,	O
a	O
B	O
cell	O
population	O
lacking	O
of	O
both	O
IgD	B-GP
and	O
CD27	B-GP
resulted	O
increased	O
in	O
healthy	O
elderly	O
[	O
14	O
].	O

We	O
have	O
suggested	O
that	O
this	O
IgD	B-GP
-	O
CD27	B-GP
-	O
B	O
cell	O
subset	O
is	O
a	O
population	O
of	O
memory	O
B	O
cells	O
lacking	O
CD27	B-GP
,	O
a	O
typical	O
memory	O
marker	O
,	O
likely	O
considered	O
a	O
late	O
memory	O
exhausted	O
B	O
cell	O
subset	O
(	O
Table	O
1	O
)	O
[	O
14	O
-	O
16	O
].	O

This	O
population	O
resulted	O
also	O
increased	O
in	O
active	O
Lupus	B-DS
patients	O
[	O
17	O
],	O
in	O
healthy	O
subjects	O
challenged	O
with	O
respiratory	O
syncitial	O
virus	B-OG
[	O
18	O
],	O
and	O
in	O
HIV	B-OG
patients	O
[	O
19	O
].	O

CO	O
don	O
'	O
t	O
show	O
the	O
typical	O
naïve	O
/	O
memory	O
B	O
cell	O
shift	O
observed	O
in	O
elderly	O
.	O

Although	O
a	O
decreased	O
B	O
cell	O
count	O
was	O
observed	O
in	O
CO	O
and	O
their	O
age	O
-	O
matched	O
controls	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
naïve	O
B	O
cells	O
(	O
IgD	B-GP
+	O
CD27	B-GP
-)	O
were	O
more	O
abundant	O
and	O
DN	O
B	O
cells	O
(	O
IgD	B-GP
-	O
CD27	B-GP
-)	O
were	O
significantly	O
decreased	O
,	O
as	O
looked	O
similarly	O
in	O
young	O
people	O
[	O
20	O
].	O

This	O
B	O
cells	O
distribution	O
in	O
CO	O
could	O
suggest	O
that	O
antigenic	O
load	O
or	O
inflammatory	O
environment	O
play	O
a	O
central	O
role	O
in	O
exhaustion	O
of	O
the	O
B	O
cell	O
branch	O
.	O

It	O
is	O
well	O
documented	O
that	O
the	O
quality	O
and	O
the	O
size	O
of	O
the	O
humoral	O
immune	O
response	O
declines	O
with	O
age	O
[	O
15	O
,	O
21	O
-	O
26	O
].	O

This	O
change	O
is	O
characterized	O
by	O
lower	O
antibody	B-GP
responses	O
and	O
decreased	O
production	O
of	O
high	O
affinity	O
antibodies	B-GP
.	O

The	O
evaluation	O
of	O
IgM	B-GP
secreted	O
in	O
CO	O
serum	O
shows	O
that	O
the	O
values	O
are	O
within	O
the	O
range	O
of	O
the	O
levels	O
observed	O
in	O
young	O
subjects	O
[	O
20	O
].	O

In	O
this	O
way	O
,	O
CO	O
could	O
have	O
a	O
bigger	O
advantage	O
to	O
fight	O
against	O
new	O
infections	B-DS
and	O
appropriately	O
respond	O
to	O
vaccinations	O
,	O
giving	O
them	O
a	O
selective	O
advantage	O
for	O
longevity	O
in	O
healthiness	O
.	O

Main	O
modifications	O
of	O
B	O
cells	O
and	O
B	O
cells	O
products	O
in	O
elderly	O
human	B-OG
observed	O
in	O
our	O
laboratory	O

B	O
cells	O
or	O
B	O
cells	O
products	O

Changes	O

References	O

Total	O
B	O
cells	O
(	O
percentage	O
)	O

↓	O

[	O
9	O
]	O

CD19	B-GP
+	O
CD5	B-GP
+	O
B1	O
cells	O
(	O
percentage	O
and	O
absolute	O
number	O
)	O

↓	O

[	O
10	O
]	O

IgG	B-GP
,	O
IgA	B-GP

↑	O

[	O
11	O
]	O

IgM	B-GP
,	O
IgD	B-GP

↓	O

[	O
11	O
]	O

IgE	B-GP

=	O

[	O
11	O
]	O

Autoantibodies	B-GP

↑	O

[	O
12	O
]	O

Naive	O
(	O
IgD	B-GP
+	O
CD27	B-GP
-)	O

↓	O

[	O
13	O
]	O

DN	O
(	O
IgD	B-GP
-	O
CD27	B-GP
-)	O

↑	O

[	O
14	O
-	O
16	O
]	O

In	O
conclusion	O
,	O
individuals	O
genetically	O
enriched	O
for	O
longevity	O
possess	O
immune	O
different	O
signatures	O
respect	O
to	O
those	O
of	O
the	O
general	O
population	O
(	O
Table	O
2	O
).	O

This	O
suggests	O
the	O
idea	O
of	O
the	O
""""	O
familiar	O
youth	O
""""	O
of	O
the	O
immune	O
system	O
.	O

In	O
addition	O
,	O
the	O
lower	O
pro	O
-	O
inflammatory	O
status	O
in	O
CMV	B-OG
-	O
infected	O
offspring	O
of	O
long	O
-	O
lived	O
people	O
might	O
represent	O
an	O
optimal	O
advantage	O
for	O
healthy	O
longevity	O
and	O
against	O
mortality	O
associated	O
to	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
.	O

Cellular	O
and	O
humoral	O
immune	O
modification	O
in	O
offspring	O
from	O
longevity	O
families	O
compared	O
to	O
their	O
AM	O
controls	O

T	O
and	O
B	O
cell	O
Phenotypes	O
and	O
Products	O

Changes	O

References	O

Naïve	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
+	O
CD27	B-GP
+	O
CD28	B-GP
+)	O

Increase	O

[	O
8	O
]	O

Late	O
differentiated	O
effector	O
memory	O
T	O
cells	O
(	O
CD3	B-GP
+	O
CD8	B-GP
+	O
CD45RA	B-GP
-	O
CCR7	B-GP
-	O
CD27	B-GP
-	O
CD28	B-GP
-)	O

Decrease	O

[	O
8	O
]	O

TEMRA	O
(	O
CD3	B-GP
+	O
CD8	B-GP
+	O
CD45RA	B-GP
+	O
CCR7	B-GP
-	O
CD27	B-GP
-	O
CD28	B-GP
-)	O

Decrease	O

[	O
8	O
]	O

Naïve	O
B	O
cells	O
(	O
IgD	B-GP
+	O
CD27	B-GP
-)	O

Increase	O

[	O
20	O
]	O

Double	O
Negative	O
B	O
cells	O
(	O
IgG	B-GP
+/	O
IgA	B-GP
+	O
IgD	B-GP
-	O
CD27	B-GP
-)	O

Decrease	O

[	O
20	O
]	O

Serum	O
IgM	B-GP

Increase	O

[	O
20	O
]	O

Gender	O
and	O
longevity	O

A	O
characteristic	O
enigma	O
of	O
longevity	O
is	O
the	O
gender	O
and	O
the	O
social	O
phenomenon	O
of	O
""""	O
feminization	O
of	O
old	O
age	O
"""."	O

The	O
demographic	O
and	O
social	O
changes	O
of	O
the	O
past	O
decades	O
,	O
responsible	O
for	O
longevity	O
and	O
the	O
improvements	O
in	O
public	O
health	O
,	O
have	O
created	O
new	O
and	O
often	O
very	O
dissimilar	O
realties	O
for	O
women	B-OG
and	O
men	B-OG
.	O

People	O
are	O
all	O
aware	O
that	O
they	O
differ	O
in	O
their	O
anatomy	O
and	O
physiology	O
,	O
but	O
also	O
in	O
more	O
complex	O
traits	O
,	O
such	O
as	O
lifespan	O
(	O
in	O
Italy	O
,	O
78	O
.	O
8	O
years	O
for	O
men	B-OG
and	O
84	O
.	O
1	O
years	O
for	O
women	B-OG
,	O
respectively	O
)	O
and	O
mortality	O
[	O
27	O
-	O
29	O
].	O

No	O
conclusive	O
explanation	O
for	O
these	O
new	O
differences	O
is	O
actually	O
demonstrated	O
.	O

An	O
intricate	O
interaction	O
between	O
environmental	O
,	O
social	O
structural	O
,	O
behavioural	O
(	O
i	O
.	O
e	O
.	O
the	O
complex	O
pattern	O
of	O
roles	O
and	O
values	O
that	O
define	O
what	O
is	O
thought	O
as	O
masculine	O
and	O
feminine	O
)	O
and	O
genetic	O
factors	O
have	O
been	O
suggested	O
as	O
the	O
more	O
probable	O
reason	O
[	O
30	O
-	O
32	O
].	O

From	O
a	O
genetic	O
prospective	O
,	O
our	O
suggestion	O
based	O
on	O
the	O
studies	O
in	O
Sicilian	O
population	O
supports	O
a	O
female	O
-	O
specific	O
gene	O
-	O
longevity	O
association	O
,	O
by	O
emphasizing	O
the	O
paradoxical	O
role	O
of	O
socio	O
-	O
cultural	O
habits	O
in	O
female	O
longevity	O
[	O
33	O
].	O

This	O
concerns	O
the	O
HFE	B-GP
gene	O
,	O
the	O
most	O
telomeric	O
HLA	B-GP
class	I-GP
I	I-GP
gene	O
,	O
codifying	O
for	O
a	O
class	O
I	O
α	O
chain	O
,	O
the	O
HFE	B-GP
protein	O
,	O
which	O
seemingly	O
no	O
longer	O
participates	O
in	O
immunity	O
.	O

It	O
has	O
lost	O
its	O
ability	O
to	O
bind	O
peptides	O
due	O
to	O
a	O
definitive	O
closure	O
of	O
the	O
antigen	O
binding	O
cleft	O
that	O
prevents	O
peptide	O
binding	O
and	O
presentation	O
.	O

The	O
HFE	B-GP
protein	O
,	O
expressed	O
on	O
crypt	O
enterocytes	O
of	O
the	O
duodenum	O
,	O
regulates	O
the	O
iron	O
uptake	O
by	O
intestinal	O
cells	O
,	O
having	O
acquired	O
the	O
ability	O
to	O
form	O
complex	O
with	O
the	O
receptor	O
for	O
iron	O
-	B-GP
binding	I-GP
transferring	I-GP
.	O

Mutations	O
in	O
HFE	B-GP
gene	O
are	O
associated	O
with	O
hereditary	B-DS
hemochromatosis	I-DS
,	O
a	O
disorder	O
caused	O
by	O
excessive	O
iron	O
uptake	O
[	O
34	O
,	O
35	O
].	O

Three	O
common	O
mutations	O
,	O
C282Y	O
,	O
H63D	O
and	O
S65C	O
,	O
have	O
been	O
identified	O
in	O
HFE	B-DS
gene	O
.	O

In	O
particular	O
,	O
the	O
C282Y	O
mutation	O
(	O
a	O
cysteine	B-CD
-	O
to	O
-	O
tyrosine	B-CD
mutation	O
at	O
amino	B-CD
acid	I-CD
282	O
)	O
destroys	O
its	O
ability	O
to	O
make	O
up	O
a	O
heterodimer	O
with	O
β2	B-GP
-	I-GP
microglobulin	I-GP
.	O

The	O
defective	O
HFE	B-GP
protein	O
fails	O
to	O
associate	O
to	O
the	O
transferring	B-GP
receptor	O
,	O
and	O
the	O
complex	O
cannot	O
be	O
transported	O
to	O
the	O
surface	O
of	O
the	O
duodenal	O
crypt	O
cells	O
.	O

As	O
a	O
consequence	O
,	O
in	O
homozygous	O
people	O
,	O
two	O
to	O
three	O
times	O
the	O
normal	O
amount	O
of	O
iron	O
is	O
absorbed	O
from	O
food	O
by	O
the	O
intestine	O
,	O
resulting	O
in	O
end	O
-	O
organ	O
damage	O
and	O
reducing	O
lifespan	O
.	O

Two	O
other	O
mutations	O
,	O
H63D	O
(	O
a	O
histidine	B-CD
to	O
aspartate	B-CD
at	O
amino	B-CD
acid	I-CD
63	O
)	O
and	O
S65C	O
(	O
a	O
serine	B-CD
to	O
cysteine	B-CD
at	O
amino	B-CD
acid	I-CD
65	O
),	O
are	O
associated	O
with	O
milder	O
forms	O
of	O
this	O
disease	O
[	O
34	O
,	O
35	O
].	O

An	O
association	O
between	O
C282Y	O
mutation	O
and	O
longevity	O
characterizes	O
the	O
Sicilian	O
population	O
studied	O
[	O
33	O
].	O

In	O
particular	O
,	O
women	O
carriers	O
of	O
C282Y	O
mutation	O
had	O
a	O
higher	O
frequency	O
among	O
the	O
oldest	O
old	O
compared	O
to	O
control	O
women	O
(	O
Table	O
3	O
).	O

Thus	O
,	O
the	O
C282Y	O
mutation	O
may	O
confer	O
a	O
selective	O
advantage	O
in	O
terms	O
of	O
longevity	O
in	O
Sicilian	O
women	B-OG
.	O

Considering	O
the	O
historical	O
and	O
social	O
context	O
in	O
which	O
the	O
generation	O
of	O
women	B-OG
under	O
study	O
lived	O
,	O
our	O
data	O
seem	O
to	O
propose	O
that	O
the	O
possession	O
of	O
iron	O
-	O
sparing	O
alleles	O
significantly	O
increases	O
the	O
possibility	O
for	O
women	B-OG
to	O
reach	O
longevity	O
.	O

For	O
instance	O
,	O
in	O
Sicily	O
,	O
many	O
pregnancies	O
and	O
an	O
iron	O
-	O
poor	O
diet	O
,	O
consisting	O
mainly	O
in	O
grains	O
,	O
vegetables	O
,	O
and	O
fruits	O
,	O
were	O
still	O
the	O
rule	O
for	O
women	O
born	O
at	O
the	O
beginning	O
of	O
last	O
century	O
.	O

In	O
fact	O
,	O
meat	O
was	O
available	O
for	O
men	B-OG
but	O
not	O
for	O
women	B-OG
;	O
this	O
clearly	O
explains	O
how	O
genetic	O
background	O
also	O
interacts	O
with	O
culture	O
habits	O
[	O
30	O
,	O
31	O
,	O
33	O
].	O

Data	O
from	O
our	O
investigations	O
in	O
Sicilian	O
population	O


Gene	O

Alleles	O
of	O
genetic	O
variants	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

P	O


N	O
=	O
35	O
females	O

N	O
=	O
106	O
females	O


HFE	B-GP

C282	O

47	O
(	O
84	O
%)	O

132	O
(	O
0	O
%)	O

8	O
.	O
3	O
×	O
10	O
-	O
5	O
[	O
33	O
]	O

282Y	O

9	O
(	O
16	O
%)	O

0	O
(	O
0	O
%)	O


Genes	O

Alleles	O
of	O
SNPs	O
or	O
genetic	O
variants	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

MI	O
patients	O
(<	O
55	O
years	O
)	O

P	O


N	O
=	O
55	O
males	O

N	O
=	O
127	O
males	O

N	O
=	O
105	O
males	O


TLR4	B-GP

+	O
896A	O

94	O
(	O
85	O
.	O
4	O
%)	O

239	O
(	O
94	O
.	O
1	O
%)	O

205	O
(	O
97	O
.	O
6	O
%)	O

<	O
0	O
.	O
001	O
[	O
49	O
]	O

+	O
896	O
G	O

16	O
(	O
14	O
.	O
6	O
%)	O

15	O
(	O
5	O
.	O
9	O
%)	O

5	O
(	O
2	O
.	O
4	O
%)	O


N	O
=	O
123	O
males	O

N	O
=	O
136	O
males	O

N	O
=	O
133	O
males	O


CCR5	B-GP

WT	O

221	O
(	O
89	O
.	O
8	O
%)	O

252	O
(	O
92	O
.	O
6	O
%)	O

263	O
(	O
98	O
.	O
8	O
%)	O

0	O
.	O
00006	O
[	O
48	O
]	O

Δ32	O

25	O
(	O
10	O
.	O
2	O
%)	O

20	O
(	O
7	O
.	O
4	O
%)	O

3	O
(	O
1	O
.	O
2	O
%)	O


N	O
=	O
96	O
males	O

N	O
=	O
170	O
males	O

N	O
=	O
140	O
males	O


Cox	O
-	O
2	O

-	O
765	O
G	O

122	O
(	O
63	O
.	O
5	O
%)	O

240	O
(	O
70	O
.	O
6	O
%)	O

232	O
(	O
82	O
.	O
8	O
%)	O

0	O
.	O
000007	O
[	O
47	O
]	O

-	O
765	O
C	O

70	O
(	O
36	O
.	O
5	O
%)	O

100	O
(	O
29	O
.	O
4	O
%)	O

48	O
(	O
17	O
.	O
2	O
%)	O

5	O
-	O
Lo	O

-	O
1708	O
G	O

180	O
(	O
93	O
.	O
7	O
%)	O

302	O
(	O
88	O
.	O
8	O
%)	O

224	O
(	O
80	O
%)	O

0	O
.	O
00003	O
[	O
47	O
]	O

-	O
1708A	O

12	O
(	O
6	O
.	O
3	O
%)	O

38	O
(	O
11	O
.	O
2	O
%)	O

56	O
(	O
20	O
%)	O

0	O
.	O
001	O

21	O
C	O

176	O
(	O
91	O
.	O
7	O
%)	O

299	O
(	O
88	O
%)	O

225	O
(	O
80	O
.	O
4	O
%)	O

21	O
T	O

16	O
(	O
8	O
.	O
3	O
%)	O

41	O
(	O
12	O
%)	O

55	O
(	O
19	O
.	O
6	O
%)	O


Genes	O

Alleles	O
of	O
SNPs	O
or	O
genetic	O
variants	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

PC	O
patients	O
(<	O
55	O
years	O
)	O

P	O


N	O
=	O
55	O
males	O

N	O
=	O
125	O
males	O

N	O
=	O
50	O
males	O


TLR4	B-GP

+	O
896A	O

94	O
(	O
85	O
%)	O

235	O
(	O
94	O
%)	O

99	O
(	O
99	O
%)	O

0	O
.	O
001	O
[	O
54	O
]	O

+	O
896	O
G	O

16	O
(	O
15	O
%)	O

15	O
(	O
6	O
%)	O

1	O
(	O
1	O
%)	O


Cox	O
-	O
2	O

-	O
765	O
G	O

67	O
(	O
61	O
%)	O

176	O
(	O
70	O
%)	O

77	O
(	O
77	O
%)	O

0	O
.	O
05	O

5	O
-	O
Lo	O

-	O
765	O
C	O

43	O
(	O
39	O
%)	O

74	O
(	O
30	O
%)	O

23	O
(	O
23	O
%)	O

0	O
.	O
0007	O

-	O
1708	O
G	O

104	O
(	O
95	O
%)	O

223	O
(	O
89	O
%)	O

77	O
(	O
77	O
%)	O

-	O
1708A	O

6	O
(	O
5	O
%)	O

27	O
(	O
11	O
%)	O

23	O
(	O
23	O
%)	O


N	O
=	O
53	O
males	O

N	O
=	O
50	O
males	O


CCR5	B-GP

WT	O

95	O
(	O
89	O
.	O
6	O
%)	O

97	O
(	O
97	O
%)	O

0	O
.	O
03	O
[	O
53	O
]	O

Δ32	O

11	O
(	O
10	O
.	O
4	O
%)	O

3	O
(	O
3	O
%)	O


Gene	O

Alleles	O
of	O
SNPs	O
or	O
genetic	O
variants	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

BF	O
patients	O
(	O
30	O
-	O
60	O
years	O
)	O

P	O


N	O
=	O
42	O
females	O

N	O
=	O
42	O
females	O

N	O
=	O
42	O
females	O


TLR4	B-GP

+	O
896A	O

81	O
(	O
96	O
.	O
4	O
%)	O

78	O
(	O
92	O
.	O
9	O
%)	O

76	O
(	O
90	O
.	O
4	O
%)	O

0	O
.	O
003	O
[	O
55	O
]	O

+	O
896	O
G	O

3	O
(	O
3	O
.	O
6	O
%)	O

6	O
(	O
7	O
.	O
1	O
%)	O

8	O
(	O
9	O
.	O
6	O
%)	O

Our	O
data	O
,	O
showing	O
the	O
relevance	O
of	O
C282Y	O
for	O
women	B-OG
survival	O
to	O
late	O
age	O
,	O
allow	O
adding	O
another	O
piece	O
of	O
evidence	O
to	O
the	O
complex	O
puzzle	O
of	O
genetic	O
and	O
environmental	O
factors	O
involved	O
in	O
control	O
of	O
lifespan	O
in	O
humans	B-OG
.	O

The	O
complex	O
interaction	O
of	O
environmental	O
,	O
historical	O
and	O
genetic	O
factors	O
,	O
differently	O
characterizing	O
the	O
various	O
parts	O
of	O
a	O
country	O
,	O
i	O
.	O
e	O
.	O
Italy	O
,	O
likely	O
plays	O
an	O
important	O
role	O
in	O
determining	O
the	O
gender	O
-	O
specific	O
probability	O
of	O
attaining	O
longevity	O
[	O
30	O
,	O
31	O
,	O
33	O
,	O
36	O
].	O

Role	O
of	O
innate	O
immunity	O
genes	O
in	O
longevity	O
:	O
the	O
paradigmatic	O
case	O
of	O
TLR4	B-GP
,	O
CCR5	B-GP
,	O
COX	B-GP
-	I-GP
2	I-GP
and	O
5	O
-	O
LO	O
genes	O

According	O
to	O
evolutionary	O
ageing	O
theories	O
,	O
most	O
of	O
the	O
parameters	O
influencing	O
immunosenescence	O
appear	O
to	O
be	O
under	O
genetic	O
control	O
[	O
32	O
,	O
37	O
,	O
38	O
].	O

An	O
example	O
is	O
given	O
by	O
the	O
innate	O
immune	O
system	O
,	O
involved	O
in	O
neutralizing	O
infectious	O
agents	O
[	O
39	O
].	O

It	O
plays	O
a	O
beneficial	O
role	O
until	O
the	O
time	O
of	O
reproduction	O
and	O
parental	O
care	O
.	O

In	O
old	O
age	O
,	O
a	O
period	O
largely	O
not	O
foreseen	O
by	O
evolution	O
,	O
it	O
can	O
determine	O
an	O
opposite	O
and	O
detrimental	O
effect	O
through	O
chronic	O
inflammatory	O
responses	O
"("""	O
antagonistic	O
pleiotropy	O
""")"	O
[	O
38	O
,	O
40	O
].	O

Genetic	O
pro	O
-/	O
anti	O
-	O
inflammatory	O
variations	O
in	O
innate	O
immune	O
response	O
are	O
,	O
indeed	O
,	O
thought	O
to	O
influence	O
the	O
susceptibility	O
of	O
age	B-DS
-	I-DS
related	I-DS
human	B-OG
diseases	B-DS
,	O
by	O
altering	O
host	O
response	O
to	O
environmental	O
and	O
endogenous	O
stress	O
[	O
41	O
].	O

Thus	O
,	O
they	O
are	O
able	O
to	O
determine	O
a	O
negative	O
or	O
positive	O
control	O
of	O
inflammation	O
,	O
by	O
affecting	O
both	O
interactions	O
between	O
host	O
and	O
microbes	B-OG
and	O
survival	O
of	O
the	O
individual	O
and	O
attainment	O
of	O
longevity	O
.	O

Furthermore	O
,	O
they	O
appear	O
both	O
to	O
be	O
responsible	O
,	O
at	O
least	O
in	O
large	O
part	O
,	O
for	O
different	O
men	B-OG
and	O
women	B-OG
strategies	O
to	O
achieve	O
longevity	O
,	O
and	O
to	O
contribute	O
to	O
the	O
preferential	O
sex	O
dimorphism	O
of	O
the	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
[	O
30	O
,	O
31	O
,	O
33	O
].	O

From	O
our	O
investigations	O
in	O
Sicilian	O
population	O
,	O
TLR4	B-GP
,	O
CCR5	B-GP
,	O
Cox2	B-GP
,	O
5	O
-	O
Lo	O
genes	O
can	O
be	O
considered	O
good	O
examples	O
.	O

They	O
provide	O
an	O
ideal	O
model	O
to	O
understand	O
the	O
different	O
implications	O
of	O
their	O
genetic	O
variants	O
in	O
the	O
risk	O
of	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
i	O
.	O
e	O
.	O
atherosclerosis	B-DS
and	O
prostate	B-DS
cancer	I-DS
(	O
PC	B-DS
),	O
and	O
reciprocally	O
in	O
increased	O
chance	O
to	O
attain	O
longevity	O
.	O

TLR4	B-GP
gene	O
(	O
number	O
accession	O
of	O
GenBank	O
:	O
NM	O
-	O
138554	O
.	O
1	O
)	O
codifies	O
the	O
best	O
understood	O
TLR	B-GP
member	O
involved	O
in	O
recognition	O
of	O
LPS	O
,	O
the	O
prototypic	O
TLR4	B-GP
ligand	O
,	O
and	O
other	O
exogenous	O
and	O
endogenous	O
(	O
i	O
.	O
e	O
.	O
HSPs	B-GP
,	O
hyaluronic	B-GP
acid	I-GP
,	O
β	B-GP
-	I-GP
defensin	I-GP
-	I-GP
2	I-GP
,	O
ox	O
-	O
LDL	O
,	O
fibronectin	B-GP
and	O
amyloid	B-GP
peptide	I-GP
)	O
ligands	O
.	O

TLR4	B-GP
activation	O
implies	O
a	O
downstream	O
signaling	O
mediated	O
by	O
several	O
intracellular	O
adaptor	O
molecules	O
and	O
the	O
consequent	O
activation	O
of	O
transcription	B-GP
factors	I-GP
,	O
such	O
as	O
NF	B-GP
-	I-GP
kB	I-GP
.	O

This	O
determines	O
the	O
production	O
of	O
different	O
pro	O
/	O
anti	O
-	O
inflammatory	O
mediators	O
.	O

These	O
lasts	O
,	O
such	O
as	O
IL	B-GP
-	I-GP
10	I-GP
,	O
are	O
produced	O
by	O
the	O
parallel	O
activation	O
of	O
anti	O
-	O
inflammatory	O
pathways	O
to	O
limit	O
the	O
potential	O
tissue	O
damage	O
from	O
excessive	O
activation	O
of	O
the	O
innate	O
immune	O
system	O
[	O
42	O
].	O

SNPs	O
seem	O
to	O
modulate	O
both	O
TLR4	B-GP
activity	O
and	O
function	O
.	O

In	O
human	B-OG
,	O
only	O
two	O
SNPs	O
,	O
+	O
896A	O
/	O
G	O
(	O
Asp299Gly	O
;	O
rs4986790	O
)	O
and	O
+	O
1196	O
C	O
/	O
T	O
(	O
Thr399Ile	O
;	O
rs4986791	O
),	O
have	O
a	O
frequency	O
>	O
5	O
%.	O

They	O
induce	O
a	O
blunted	O
response	O
to	O
LPS	O
,	O
as	O
first	O
suggested	O
by	O
Arbour	O
et	O
al	O
.,	O
and	O
are	O
phenotypically	O
associated	O
to	O
changes	O
in	O
the	O
production	O
of	O
cytokines	B-GP
,	O
principally	O
those	O
carrying	O
the	O
Asp299Gly	O
mutation	O
[	O
43	O
-	O
45	O
].	O

Accordingly	O
,	O
recent	O
literature	O
data	O
suggest	O
the	O
ability	O
of	O
this	O
SNP	O
to	O
modulate	O
the	O
risk	O
of	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
[	O
42	O
].	O

The	O
CCR5	B-GP
gene	O
(	O
number	O
accession	O
of	O
GenBank	O
:	O
NM	O
-	O
00579	O
)	O
codifies	O
for	O
a	O
G	B-GP
protein	I-GP
-	I-GP
coupled	I-GP
chemokine	I-GP
receptor	I-GP
,	O
which	O
regulates	O
trafficking	O
and	O
effector	O
functions	O
of	O
memory	O
/	O
effector	O
Th1	O
cells	O
,	O
macrophages	O
,	O
NK	O
cells	O
and	O
immature	O
dendritic	O
cells	O
.	O

CCR5	B-GP
and	O
its	O
ligands	O
are	O
important	O
molecules	O
in	O
viral	O
pathogenesis	O
.	O

Recent	O
evidence	O
has	O
also	O
demonstrated	O
the	O
role	O
of	O
CCR5	B-GP
in	O
a	O
variety	O
of	O
human	B-OG
diseases	O
,	O
ranging	O
from	O
infectious	O
and	O
inflammatory	B-DS
age	I-DS
-	I-DS
related	I-DS
diseases	I-DS
to	O
cancer	B-DS
.	O

A	O
notable	O
variant	O
of	O
CCR5	B-GP
gene	O
is	O
a	O
32	O
bp	O
(	O
Δ32	O
)	O
deletion	O
,	O
which	O
causes	O
a	O
frame	O
shift	O
mutation	O
in	O
exon	O
4	O
(	O
CCR5Δ32	O
;	O
rs333	O
)	O
and	O
determines	O
stop	O
protein	O
maturation	O
and	O
loss	O
of	O
expression	O
of	O
functional	O
CCR5	B-GP
receptor	I-GP
[	O
46	O
].	O

Accordingly	O
,	O
it	O
seems	O
to	O
have	O
a	O
protective	O
role	O
against	O
CVD	B-DS
and	O
other	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
such	O
as	O
PC	O
.	O

It	O
,	O
indeed	O
,	O
determines	O
a	O
slower	O
progression	O
of	O
atherogenesis	O
or	O
cancerogenesis	O
as	O
a	O
consequence	O
of	O
an	O
attenuated	O
inflammatory	O
response	O
.	O

COX	B-GP
-	I-GP
2	I-GP
gene	O
maps	O
in	O
the	O
1q25	O
chromosome	O
and	O
codifies	O
for	O
the	O
Cox	B-GP
-	I-GP
2	I-GP
enzyme	O
involved	O
in	O
the	O
conversion	O
of	O
arachidonic	B-CD
acid	I-CD
to	O
prostaglandins	B-CD
.	O

Polymorphisms	O
regulate	O
its	O
expression	O
and	O
hence	O
prostanoid	O
biosynthesis	O
.	O

In	O
particular	O
,	O
it	O
has	O
been	O
identified	O
a	O
guanine	B-CD
to	O
cytosine	B-CD
substitution	O
at	O
position	O
-	O
765	O
G	O
/	O
C	O
,	O
located	O
within	O
a	O
putative	O
binding	O
site	O
for	O
the	O
transcription	B-GP
factor	I-GP
Sp1	B-GP
,	O
associated	O
to	O
a	O
reduction	O
in	O
the	O
risk	O
of	O
clinical	O
cardiovascular	O
events	O
.	O

COX	B-GP
-	I-GP
2	I-GP
is	O
expressed	O
at	O
low	O
levels	O
in	O
most	O
tissues	O
,	O
but	O
its	O
expression	O
enhances	O
under	O
inflammatory	O
stimuli	O
and	O
in	O
inflammatory	O
age	O
-	O
related	O
processes	O
,	O
i	O
.	O
e	O
.	O
atherosclerosis	B-DS
,	O
rheumatoid	B-DS
diseases	I-DS
and	O
cancer	B-DS
[	O
47	O
].	O

The	O
5	O
-	O
LO	O
gene	O
maps	O
in	O
the	O
chromosome	O
10q11	O
.	O
2	O
and	O
codifies	O
the	O
5	O
-	O
Lo	O
enzyme	O
involved	O
in	O
the	O
synthesis	O
of	O
LTs	O
.	O

The	O
5	O
-	O
LO	O
pathway	O
has	O
been	O
associated	O
to	O
atherosclerosis	B-DS
in	O
mouse	B-OG
and	O
human	B-OG
histological	O
studies	O
.	O

Several	O
SNPs	O
have	O
been	O
described	O
.	O

In	O
particular	O
,	O
the	O
-	O
1708	O
G	O
/	O
A	O
,	O
-	O
1761	O
G	O
/	O
A	O
and	O
21	O
C	O
/	O
T	O
SNPs	O
in	O
promoter	O
region	O
and	O
exon	O
-	O
1	O
of	O
5	O
-	O
LO	O
gene	O
modify	O
the	O
gene	O
transcription	O
or	O
the	O
putative	O
protein	O
[	O
47	O
].	O

An	O
over	O
-	O
expression	O
of	O
anti	O
-	O
inflammatory	O
CCR5Δ32	O
variant	O
,	O
+	O
896	O
G	O
(	O
299Gly	O
)	O
TLR4	B-GP
allele	O
,	O
-	O
765	O
C	O
Cox	O
-	O
2	O
allele	O
,	O
-	O
1708	O
G	O
and	O
21	O
C	O
5	O
-	O
Lo	O
alleles	O
characterizes	O
male	O
Sicilian	O
centenarians	O
(	O
Table	O
3	O
)	O
[	O
47	O
-	O
49	O
].	O

So	O
,	O
male	O
centenarians	O
are	O
people	O
who	O
seem	O
genetically	O
equipped	O
for	O
defeating	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
.	O

They	O
present	O
SNPs	O
in	O
the	O
immune	O
system	O
genome	O
(	O
i	O
.	O
e	O
.	O
SNPs	O
or	O
other	O
genetic	O
variations	O
,	O
located	O
within	O
the	O
promoter	O
regions	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
)	O
which	O
,	O
regulating	O
the	O
immune	O
-	O
inflammatory	O
responses	O
,	O
seem	O
to	O
be	O
associated	O
to	O
longevity	O
[	O
30	O
-	O
32	O
].	O

Furthermore	O
,	O
centenarians	O
are	O
characterized	O
by	O
marked	O
delay	O
or	O
escape	O
from	O
age	O
-	O
associated	O
diseases	O
,	O
responsible	O
for	O
the	O
high	O
mortality	O
in	O
earlier	O
ages	O
.	O

In	O
particular	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
centenarian	O
offspring	O
have	O
an	O
increased	O
likelihood	O
of	O
surviving	O
to	O
100	O
years	O
and	O
show	O
a	O
reduced	O
prevalence	O
of	O
age	O
associated	O
diseases	O
,	O
such	O
as	O
CVD	B-DS
,	O
and	O
lower	O
prevalence	O
of	O
CVD	B-DS
risk	O
factors	O
[	O
1	O
,	O
30	O
-	O
32	O
,	O
50	O
]	O
Thus	O
,	O
genes	O
involved	O
in	O
CVD	B-DS
may	O
play	O
an	O
opposite	O
role	O
in	O
human	B-OG
male	O
longevity	O
.	O

Our	O
data	O
in	O
male	O
Sicilian	O
population	O
confirm	O
this	O
suggestion	O
and	O
emphasize	O
the	O
role	O
of	O
antagonistic	O
pleiotropy	O
in	O
ageing	O
and	O
longevity	O
[	O
51	O
,	O
52	O
].	O

A	O
high	O
frequency	O
of	O
proinflammatory	O
CCR5wt	O
variant	O
,	O
+	O
896A	O
TLR4	B-GP
allele	O
,	O
-	O
765	O
G	O
Cox	O
-	O
2	O
allele	O
,	O
1708A	O
and	O
21	O
T	O
5	O
-	O
Lo	O
alleles	O
characterizes	O
male	O
Sicilian	O
patients	O
affected	O
by	O
MI	B-DS
(	O
Table	O
3	O
)	O
[	O
47	O
-	O
49	O
].	O

In	O
a	O
recent	O
study	O
,	O
we	O
also	O
found	O
a	O
similar	O
overexpression	O
of	O
these	O
proinflammatory	O
SNPs	O
in	O
male	O
Sicilian	O
patients	O
affected	O
by	O
PC	B-DS
(	O
Table	O
3	O
).	O

Opposite	O
data	O
were	O
obtained	O
in	O
male	O
centenarians	O
[	O
53	O
,	O
54	O
].	O

In	O
contrast	O
,	O
female	O
Sicilian	O
centenarians	O
have	O
a	O
different	O
frequency	O
of	O
the	O
alleles	O
of	O
+	O
896A	O
/	O
G	O
TLR4	B-GP
SNP	O
than	O
that	O
observed	O
in	O
male	O
Sicilian	O
centenarians	O
.	O

In	O
particular	O
,	O
female	O
Sicilian	O
centenarians	O
show	O
an	O
over	O
-	O
expression	O
of	O
the	O
pro	O
-	O
inflammatory	O
+	O
896A	O
TLR4	B-GP
allele	O
respect	O
to	O
female	O
patients	O
affected	O
by	O
Boutonneuse	O
fever	B-DS
and	O
age	O
-	O
matched	O
controls	O
(	O
Table	O
3	O
)	O
[	O
55	O
].	O

On	O
the	O
other	O
hand	O
,	O
pro	O
-	O
inflammatory	O
responses	O
are	O
evolutionary	O
programmed	O
to	O
resist	O
fatal	O
infections	B-DS
.	O

Thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
the	O
genetic	O
background	O
of	O
people	O
that	O
survive	O
to	O
an	O
advanced	O
age	O
may	O
be	O
protective	O
against	O
infections	B-DS
[	O
55	O
].	O

Based	O
on	O
our	O
data	O
,	O
we	O
suggest	O
that	O
Sicilian	O
men	B-OG
and	O
women	B-OG
may	O
follow	O
different	O
trajectories	O
to	O
reach	O
longevity	O
.	O

For	O
men	B-OG
it	O
might	O
be	O
more	O
important	O
to	O
control	O
atherogenesis	O
and	O
cancerogenesis	O
,	O
whereas	O
for	O
women	B-OG
it	O
might	O
be	O
more	O
important	O
to	O
control	O
infectious	B-DS
diseases	I-DS
[	O
30	O
,	O
31	O
].	O

In	O
order	O
to	O
confirm	O
our	O
suggestions	O
on	O
the	O
biological	O
effects	O
of	O
+	O
896A	O
/	O
G	O
TLR4	B-GP
SNP	O
and	O
its	O
role	O
in	O
the	O
pathophysiology	O
of	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
studied	O
(	O
i	O
.	O
e	O
.	O
MI	O
and	O
PC	O
)	O
and	O
longevity	O
,	O
we	O
recently	O
assessed	O
the	O
levels	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
eicosanoids	O
in	O
LPS	O
-	O
stimulated	O
whole	O
blood	O
samples	O
from	O
50	O
young	O
healthy	O
Sicilians	O
,	O
screened	O
for	O
the	O
presence	O
of	O
this	O
SNP	O
.	O

Both	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
and	O
eicosanoids	O
were	O
significantly	O
lower	O
in	O
carriers	O
bearing	O
the	O
+	O
896	O
G	O
TLR4	B-GP
allele	O
,	O
whereas	O
the	O
anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
10	I-GP
values	O
were	O
higher	O
[	O
56	O
].	O

This	O
suggests	O
the	O
ability	O
of	O
the	O
+	O
896	O
G	O
TLR4	B-GP
allele	O
to	O
mediate	O
a	O
better	O
control	O
of	O
inflammatory	O
responses	O
induced	O
by	O
chronic	O
stimuli	O
,	O
so	O
likely	O
decreasing	O
the	O
effects	O
of	O
atherogenetic	O
damage	O
and	O
prostate	O
carcinogens	O
.	O

On	O
the	O
basis	O
of	O
data	O
reported	O
herein	O
,	O
some	O
suggestions	O
can	O
be	O
drawn	O
.	O

First	O
,	O
pathogen	O
load	O
,	O
by	O
interacting	O
with	O
the	O
host	O
genotype	O
,	O
determines	O
the	O
type	O
and	O
intensity	O
of	O
inflammatory	O
responses	O
,	O
according	O
to	O
the	O
pro	O
-	O
inflammatory	O
status	O
and	O
tissue	O
injury	O
,	O
implicated	O
in	O
the	O
patho	O
-	O
physiology	O
of	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
.	O

Second	O
,	O
adequate	O
control	O
of	O
inflammatory	O
response	O
might	O
reduce	O
the	O
risk	O
of	O
these	O
diseases	O
,	O
and	O
,	O
reciprocally	O
,	O
might	O
increase	O
the	O
chance	O
of	O
extended	O
survival	O
in	O
an	O
environment	O
with	O
reduced	O
pathogen	O
load	O
.	O

Accordingly	O
,	O
a	O
higher	O
frequency	O
of	O
the	O
anti	O
-	O
inflammatory	O
+	O
896	O
G	O
TLR4	B-GP
allele	O
has	O
been	O
observed	O
in	O
centenarians	O
[	O
49	O
].	O

Cytokine	B-GP
profile	O
:	O
a	O
biomarker	O
for	O
successful	O
ageing	O

Cytokines	B-GP
are	O
considered	O
key	O
players	O
in	O
maintaining	O
lymphocyte	O
homeostasis	O
[	O
57	O
,	O
58	O
].	O

Their	O
function	O
is	O
not	O
limited	O
to	O
induce	O
response	O
after	O
an	O
immune	O
insult	O
,	O
but	O
they	O
can	O
modulate	O
the	O
nature	O
of	O
response	O
(	O
cytotoxic	O
,	O
humoral	O
,	O
cell	O
mediated	O
,	O
inflammatory	O
or	O
allergic	O
)	O
or	O
,	O
in	O
contrast	O
,	O
they	O
may	O
cause	O
non	O
-	O
responsiveness	O
and	O
active	O
immune	O
suppression	O
[	O
58	O
].	O

Furthermore	O
,	O
sequence	O
variations	O
in	O
several	O
cytokine	B-GP
genes	O
,	O
such	O
as	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
genes	O
,	O
have	O
been	O
demonstrated	O
to	O
be	O
associated	O
with	O
successful	O
ageing	O
and	O
longevity	O
[	O
58	O
].	O

On	O
the	O
other	O
hand	O
,	O
individual	O
changes	O
in	O
type	O
and	O
intensity	O
of	O
immune	O
response	O
affecting	O
life	O
span	O
expectancy	O
and	O
health	O
ageing	O
seem	O
to	O
have	O
a	O
genetic	O
component	O
.	O

A	O
well	O
-	O
preserved	O
immune	O
function	O
characterizing	O
the	O
successful	O
ageing	O
has	O
been	O
found	O
in	O
centenarians	O
[	O
38	O
].	O

Recent	O
evidence	O
suggests	O
that	O
centenarians	O
seem	O
to	O
be	O
genetically	O
equipped	O
gene	O
polymorphism	O
for	O
overcame	O
the	O
major	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
and	O
polymorphisms	O
in	O
immune	O
system	O
genes	O
involved	O
in	O
regulation	O
of	O
immune	O
responses	O
have	O
been	O
found	O
associated	O
to	O
longevity	O
.	O

In	O
particular	O
,	O
associations	O
between	O
both	O
cytokine	B-GP
gene	O
polymorphisms	O
and	O
longevity	O
,	O
and	O
differential	O
gender	O
longevity	O
in	O
males	O
and	O
females	O
,	O
and	O
reciprocally	O
to	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
have	O
been	O
demonstrated	O
[	O
38	O
,	O
58	O
,	O
59	O
].	O

Our	O
data	O
in	O
Sicilian	O
population	O
confirm	O
these	O
associations	O
and	O
suggest	O
that	O
differences	O
in	O
the	O
genetic	O
regulation	O
of	O
immune	O
inflammatory	O
processes	O
might	O
explain	O
the	O
reason	O
why	O
some	O
people	O
but	O
not	O
others	O
develop	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
and	O
why	O
some	O
develop	O
a	O
greater	O
inflammatory	O
response	O
than	O
others	O
.	O

In	O
particular	O
,	O
this	O
suggestion	O
seems	O
to	O
be	O
suitable	O
for	O
some	O
SNPs	O
in	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
genes	O
(	O
Table	O
4	O
)	O
[	O
60	O
-	O
63	O
].	O

Cytokine	B-GP
data	O
from	O
our	O
studies	O
in	O
Sicilian	O
population	O


Gene	O

Genotypes	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

P	O


N	O
=	O
31	O
males	O

N	O
=	O
161	O
males	O


IL	B-GP
-	I-GP
10	I-GP

-	O
1082GG	O

18	O
(	O
58	O
%)	O

55	O
(	O
34	O
%)	O

<	O
0	O
.	O
025	O
[	O
61	O
]	O

-	O
1083GA	O

9	O
(	O
29	O
%)	O

88	O
(	O
55	O
%)	O

-	O
1082AA	O

4	O
(	O
13	O
%)	O

18	O
(	O
11	O
%)	O


N	O
=	O
72	O
males	O

N	O
=	O
115	O
males	O


IL	B-GP
-	I-GP
10	I-GP

-	O
1082GG	O

33	O
(	O
46	O
%)	O

32	O
(	O
28	O
%)	O

0	O
.	O
019	O
[	O
62	O
]	O

-	O
1083GA	O

34	O
(	O
47	O
%)	O

64	O
(	O
56	O
%)	O

-	O
1082AA	O

5	O
(	O
7	O
%)	O

19	O
(	O
16	O
%)	O


Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

MI	O
patients	O
(<	O
55	O
years	O
)	O

P	O


N	O
=	O
52	O
males	O

N	O
=	O
110	O
males	O

N	O
=	O
90	O
males	O


IL	B-GP
-	I-GP
10	I-GP

-	O
1082GG	O

25	O
(	O
48	O
.	O
1	O
%)	O

26	O
(	O
23	O
.	O
6	O
%)	O

17	O
(	O
18	O
.	O
9	O
%)	O

0	O
.	O
003	O
[	O
63	O
]	O

-	O
1083GA	O

23	O
(	O
44	O
.	O
2	O
%)	O

56	O
(	O
50	O
.	O
9	O
%)	O

29	O
(	O
32	O
.	O
2	O
%)	O

-	O
1082AA	O

6	O
(	O
11	O
.	O
5	O
%)	O

28	O
(	O
25	O
.	O
5	O
%)	O

44	O
(	O
48	O
.	O
9	O
%)	O


Genes	O

Alleles	O
of	O
SNP	O

Centenarians	O

Young	O
controls	O
(<	O
55	O
years	O
)	O

P	O

N	O
=	O
142	O
females	O

N	O
=	O
90	O
females	O

IFN	B-GP
-	I-GP
γ	I-GP

+	O
874	O
T	O

102	O
(	O
35	O
.	O
9	O
%)	O

85	O
(	O
47	O
.	O
2	O
%)	O

0	O
.	O
02	O
[	O
60	O
]	O

+	O
874A	O

182	O
(	O
64	O
.	O
1	O
%)	O

95	O
(	O
52	O
.	O
8	O
%)	O

IFN	B-GP
-	I-GP
γ	I-GP
gene	O
codifies	O
for	O
a	O
cytokine	B-GP
involved	O
in	O
defense	O
against	O
viruses	B-OG
and	O
intracellular	O
pathogens	O
,	O
and	O
in	O
induction	O
of	O
immune	O
mediated	O
inflammatory	O
responses	O
.	O

Its	O
production	O
is	O
genetically	O
regulated	O
.	O

A	O
variable	O
length	O
CA	O
repeat	O
sequence	O
in	O
the	O
first	O
intron	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
gene	O
has	O
been	O
described	O
to	O
be	O
associated	O
with	O
high	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
.	O

Furthermore	O
,	O
a	O
SNP	O
,	O
T	O
to	O
A	O
(+	O
874	O
T	O
/	O
A	O
),	O
at	O
59	O
end	O
of	O
the	O
CA	O
repeat	O
region	O
has	O
been	O
described	O
and	O
T	O
presence	O
has	O
been	O
related	O
to	O
high	O
-	O
producing	O
microsatellite	O
allele	O
2	O
.	O

This	O
SNP	O
coincides	O
with	O
a	O
putative	O
NF	B-GP
-	I-GP
κB	I-GP
binding	O
site	O
,	O
which	O
might	O
have	O
functional	O
consequences	O
for	O
transcription	O
of	O
IFN	B-GP
-	I-GP
γ	I-GP
gene	O
.	O

Thus	O
,	O
this	O
SNP	O
might	O
directly	O
influence	O
IFN	B-GP
-	I-GP
γ	I-GP
production	O
levels	O
associated	O
to	O
CA	O
microsatellite	O
marker	O
[	O
60	O
].	O

IL	B-GP
-	I-GP
10	I-GP
gene	O
codifies	O
for	O
IL	B-GP
-	I-GP
10	I-GP
cytokine	B-GP
.	O

IL	B-GP
-	I-GP
10	I-GP
is	O
produced	O
by	O
macrophages	O
,	O
T	O
and	O
B	O
cells	O
.	O

It	O
is	O
one	O
of	O
the	O
major	O
immune	O
-	O
regulatory	O
cytokines	B-GP
,	O
usually	O
considered	O
to	O
mediate	O
potent	O
down	O
-	O
regulation	O
of	O
inflammatory	O
responses	O
.	O

IL	B-GP
-	I-GP
10	I-GP
production	O
,	O
independently	O
on	O
interaction	O
with	O
other	O
cytokine	B-GP
gene	O
products	O
,	O
is	O
generally	O
controlled	O
by	O
several	O
polymorphic	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
IL	B-GP
-	I-GP
10	I-GP
gene	O
.	O

Multiple	O
SNPs	O
have	O
been	O
identified	O
in	O
human	B-OG
IL	B-GP
-	I-GP
10	I-GP
5	O
'	O
flanking	O
region	O
and	O
some	O
of	O
these	O
(	O
i	O
.	O
e	O
.	O
-	O
592	O
,	O
-	O
819	O
,	O
-	O
1082	O
)	O
combine	O
with	O
microsatellite	O
alleles	O
to	O
form	O
haplotype	O
associated	O
with	O
differential	O
IL	B-GP
-	I-GP
10	I-GP
production	O
.	O

These	O
three	O
SNPs	O
in	O
the	O
IL	B-GP
-	I-GP
10	I-GP
proximal	O
gene	O
region	O
(	O
considered	O
potential	O
targets	O
for	O
transcription	B-GP
regulating	I-GP
factors	I-GP
)	O
might	O
be	O
involved	O
in	O
genetic	O
control	O
of	O
IL	B-GP
-	I-GP
10	I-GP
production	O
,	O
even	O
if	O
contrasting	O
literature	O
data	O
have	O
been	O
reported	O
.	O

In	O
particular	O
,	O
the	O
homozygous	O
-	O
1082GG	O
genotype	O
seems	O
to	O
be	O
associated	O
with	O
higher	O
IL	B-GP
-	I-GP
10	I-GP
production	O
respect	O
to	O
G	O
/	O
A	O
heterozygous	O
and	O
AA	O
homozygous	O
genotypes	O
.	O

Furthermore	O
,	O
this	O
SNP	O
seems	O
to	O
be	O
functionally	O
relevant	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
-	O
1082	O
A	O
carriers	O
(	O
low	O
producers	O
)	O
seem	O
likely	O
develop	O
a	O
major	O
number	O
of	O
chronic	B-DS
inflammatory	I-DS
diseases	I-DS
[	O
61	O
-	O
63	O
].	O

Our	O
results	O
demonstrated	O
an	O
increase	O
of	O
subjects	O
carrying	O
the	O
-	O
1082	O
G	O
IL	B-GP
-	I-GP
10	I-GP
allele	O
in	O
centenarian	O
men	O
[	O
61	O
-	O
63	O
].	O

This	O
allele	O
is	O
associated	O
to	O
significantly	O
increased	O
IL	B-GP
-	I-GP
10	I-GP
production	O
.	O

Conversely	O
,	O
we	O
observed	O
that	O
the	O
frequency	O
of	O
-	O
1082A	O
allele	O
,	O
associated	O
to	O
low	O
IL	B-GP
-	I-GP
10	I-GP
production	O
,	O
was	O
significantly	O
higher	O
in	O
MI	O
patients	O
(	O
Table	O
4	O
)	O
[	O
63	O
].	O

Thus	O
,	O
high	O
IL	B-GP
-	I-GP
10	I-GP
production	O
seems	O
to	O
be	O
protective	O
vs	O
.	O
MI	O
and	O
a	O
possible	O
biomarker	O
for	O
longevity	O
.	O

People	O
with	O
exceptional	O
longevity	O
have	O
genetic	O
factors	O
(	O
i	O
.	O
e	O
.	O
protective	O
factors	O
for	O
CVD	B-DS
)	O
that	O
modulate	O
ageing	O
processes	O
[	O
63	O
].	O

This	O
supports	O
the	O
opinion	O
that	O
a	O
genetic	O
background	O
protective	O
against	O
CVD	B-DS
is	O
a	O
component	O
of	O
longevity	O
.	O

On	O
the	O
other	O
hand	O
,	O
our	O
immune	O
system	O
has	O
evolved	O
to	O
control	O
pathogens	O
and	O
pro	O
-	O
inflammatory	O
responses	O
are	O
likely	O
programmed	O
by	O
evolution	O
to	O
resist	O
fatal	O
infections	B-DS
.	O

From	O
this	O
prospective	O
,	O
low	O
IL	B-GP
-	I-GP
10	I-GP
production	O
is	O
correlated	O
with	O
increased	O
resistance	O
to	O
pathogens	O
.	O

In	O
older	O
ages	O
not	O
evolutionally	O
programmed	O
,	O
increased	O
IL	B-GP
-	I-GP
10	I-GP
levels	O
might	O
better	O
control	O
inflammatory	O
responses	O
induced	O
by	O
chronic	O
vessel	O
damage	O
and	O
reduce	O
the	O
risk	O
for	O
atherogenetic	O
complications	O
.	O

These	O
conditions	O
might	O
permit	O
to	O
achieve	O
exceptional	O
ages	O
in	O
an	O
environmental	O
with	O
a	O
reduced	O
pathogen	O
load	O
[	O
63	O
].	O

In	O
contrast	O
,	O
female	O
Sicilian	O
centenarians	O
are	O
characterized	O
by	O
an	O
over	O
-	O
expression	O
of	O
+	O
874	O
INF	B-GP
-	I-GP
γ	I-GP
allele	O
(	O
Table	O
4	O
)	O
[	O
60	O
].	O

The	O
INF	B-GP
-	I-GP
γ	I-GP
production	O
is	O
also	O
influenced	O
by	O
hormonal	O
control	O
fundamentally	O
mediated	O
by	O
17β	O
extradiol	O
.	O

Hormonal	O
regulation	O
of	O
this	O
cytokine	B-GP
has	O
been	O
suggested	O
to	O
modulate	O
,	O
in	O
part	O
,	O
the	O
ability	O
of	O
estrogens	B-CD
to	O
potentiate	O
many	O
types	O
of	O
immune	O
responses	O
and	O
to	O
influence	O
the	O
disproportionate	O
susceptibility	O
of	O
women	B-OG
for	O
immune	B-DS
-	I-DS
inflammatory	I-DS
diseases	I-DS
.	O

Thus	O
,	O
gene	O
variants	O
representing	O
genetic	O
advantage	O
for	O
one	O
gender	O
might	O
not	O
be	O
reciprocally	O
relevant	O
for	O
the	O
other	O
gender	O
in	O
terms	O
of	O
successful	O
or	O
unsuccessful	O
ageing	O
[	O
60	O
].	O

The	O
data	O
from	O
Sicilian	O
investigation	O
add	O
another	O
piece	O
to	O
complex	O
puzzle	O
of	O
genetic	O
and	O
environmental	O
factors	O
involved	O
in	O
the	O
control	O
of	O
life	O
span	O
expectancy	O
in	O
humans	B-OG
.	O

Studies	O
on	O
cytokine	B-GP
gene	O
SNPs	O
may	O
promise	O
to	O
individuate	O
a	O
complex	O
network	O
of	O
trans	O
-	O
inactive	O
genes	O
able	O
to	O
influence	O
the	O
type	O
and	O
strength	O
of	O
immune	O
responses	O
to	O
environmental	O
stressors	O
,	O
and	O
as	O
final	O
result	O
,	O
conditioning	O
individual	O
life	O
expectancy	O
[	O
60	O
-	O
63	O
].	O

On	O
the	O
other	O
hand	O
,	O
we	O
recently	O
suggested	O
the	O
possibility	O
to	O
use	O
cytokine	B-GP
profile	O
as	O
biomarker	O
of	O
successful	O
ageing	O
,	O
by	O
evaluating	O
through	O
Lumines	O
technology	O
cytokine	B-GP
serum	O
levels	O
in	O
44	O
Sicilian	O
nonagenarians	O
and	O
79	O
control	O
subjects	O
(	O
aged	O
between	O
30	O
and	O
50	O
years	O
old	O
)	O
[	O
64	O
].	O

IFN	B-GP
-	I-GP
γ	I-GP
and	O
IL	B-GP
-	I-GP
2	I-GP
levels	O
are	O
unmodified	O
,	O
suggesting	O
a	O
substantial	O
maintenance	O
of	O
relevant	O
T	O
functions	O
.	O

In	O
addition	O
,	O
a	O
significant	O
increase	O
of	O
IL	B-GP
-	I-GP
12	I-GP
serum	O
levels	O
was	O
observed	O
.	O

This	O
condition	O
might	O
be	O
associated	O
with	O
the	O
increase	O
of	O
NK	O
cell	O
function	O
with	O
ageing	O
.	O

Furthermore	O
,	O
an	O
increase	O
of	O
IL	B-GP
-	I-GP
13	I-GP
and	O
a	O
reduction	O
of	O
IL	B-GP
-	I-GP
4	I-GP
were	O
found	O
.	O

Thus	O
,	O
the	O
maintenance	O
of	O
some	O
effector	O
'	O
s	O
mechanisms	O
of	O
immune	O
-	O
response	O
characterizes	O
advanced	O
ages	O
.	O

From	O
a	O
general	O
point	O
of	O
view	O
,	O
our	O
data	O
firstly	O
confirm	O
the	O
age	O
-	O
related	O
remodeling	O
of	O
cytokine	B-GP
network	O
.	O

Furthermore	O
,	O
they	O
underline	O
the	O
presence	O
of	O
unchanged	O
levels	O
of	O
some	O
crucial	O
cytokines	B-GP
useful	O
in	O
preserving	O
key	O
immune	O
function	O
in	O
long	O
-	O
living	O
persons	O
[	O
64	O
].	O

Future	O
perspectives	O

The	O
ageing	O
process	O
and	O
longevity	O
are	O
multi	O
-	O
factorial	O
events	O
.	O

Genetic	O
,	O
epigenetic	O
,	O
stochastic	O
and	O
environmental	O
factors	O
seem	O
to	O
have	O
a	O
crucial	O
role	O
in	O
ageing	O
and	O
longevity	O
.	O

Epigenetic	O
is	O
associated	O
to	O
ageing	O
,	O
as	O
shown	O
in	O
the	O
major	O
number	O
of	O
studies	O
.	O

In	O
particular	O
,	O
ageing	O
is	O
associated	O
to	O
a	O
global	O
loss	O
of	O
methylation	O
state	O
[	O
65	O
].	O

In	O
addition	O
,	O
tissue	O
-	O
dependent	O
age	O
-	O
related	O
hypermetylation	O
of	O
specific	O
DNA	O
regions	O
have	O
been	O
observed	O
.	O

Thus	O
,	O
it	O
can	O
be	O
concluded	O
that	O
epigenetic	O
age	O
-	O
related	O
modification	O
are	O
stochastic	O
and	O
no	O
linked	O
to	O
specific	O
DNA	O
region	O
,	O
while	O
epigenetic	O
changes	O
linked	O
to	O
specific	O
environmental	O
stimuli	O
are	O
limited	O
in	O
specific	O
DNA	O
region	O
[	O
66	O
,	O
67	O
].	O

These	O
observations	O
have	O
led	O
to	O
address	O
the	O
research	O
on	O
epigenomics	O
and	O
its	O
implication	O
in	O
ageing	O
and	O
longevity	O
.	O

Epigenomics	O
is	O
the	O
systematic	O
study	O
of	O
the	O
global	O
gene	O
expression	O
changes	O
due	O
to	O
epigenetic	O
processes	O
,	O
but	O
not	O
to	O
DNA	O
base	O
sequence	O
changes	O
.	O

Epigenetic	O
processes	O
consist	O
in	O
heritable	O
modification	O
that	O
result	O
in	O
a	O
selective	O
gene	O
expression	O
or	O
repression	O
and	O
consequently	O
in	O
phenotype	O
changes	O
[	O
68	O
].	O

These	O
changes	O
include	O
nucleosome	O
positioning	O
,	O
post	O
-	O
translation	O
histone	B-GP
modifications	O
,	O
action	O
of	O
small	O
RNAs	O
,	O
DNA	O
replication	O
timing	O
,	O
heterochromatinization	O
and	O
DNA	O
methylation	O
[	O
69	O
].	O

This	O
last	O
one	O
consists	O
in	O
the	O
addition	O
of	O
a	O
methyl	O
group	O
(-	O
CH3	O
)	O
in	O
the	O
carbon	O
5	O
of	O
cytosines	B-CD
,	O
particularly	O
in	O
the	O
CpG	B-CD
dinucleotide	I-CD
.	O

This	O
condition	O
particularly	O
concerns	O
the	O
CpG	O
islands	O
(	O
CpGIs	O
),	O
located	O
at	O
the	O
regulatory	O
site	O
of	O
gene	O
promoter	O
regions	O
.	O

Methylation	O
rate	O
is	O
associated	O
to	O
transcriptional	O
regulation	O
.	O

In	O
particular	O
,	O
gene	O
silencing	O
is	O
associated	O
to	O
increase	O
of	O
-	O
CH3	O
groups	O
on	O
DNA	O
,	O
conversely	O
hypometylation	O
of	O
CGIs	O
is	O
associated	O
to	O
an	O
open	O
chromatin	O
state	O
resulting	O
in	O
gene	O
expression	O
[	O
70	O
].	O

Although	O
the	O
association	O
between	O
ageing	O
and	O
epigenetic	O
is	O
a	O
real	O
evidence	O
,	O
processes	O
involved	O
are	O
not	O
clear	O
.	O

Certainly	O
,	O
the	O
nutrition	O
affects	O
epigenetic	O
modifications	O
.	O

Nutrients	O
can	O
be	O
active	O
on	O
specific	O
sites	O
.	O

For	O
example	O
,	O
vitamin	B-CD
B12	I-CD
,	O
vitamin	B-CD
B6	I-CD
,	O
riboflavin	B-CD
,	O
methionine	B-CD
,	O
choline	B-CD
and	O
betaine	B-CD
,	O
well	O
known	O
as	O
folates	B-CD
,	O
regulate	O
levels	O
of	O
S	O
-	O
adenosylmethionine	O
and	O
S	O
-	O
adenosylhomocysteine	O
,	O
donor	O
of	O
-	O
CH3	O
group	O
and	O
methyltransferase	B-GP
inhibitor	O
respectively	O
[	O
71	O
].	O

Curcumin	B-CD
,	O
resveratrol	B-CD
,	O
polyphenols	O
and	O
flavonoids	B-CD
,	O
phytoestrogen	O
,	O
and	O
lycopene	B-CD
are	O
also	O
considered	O
key	O
nutritional	O
factors	O
both	O
for	O
regulation	O
of	O
enzyme	O
involved	O
in	O
acetylation	O
and	O
deacetylation	O
mechanism	O
and	O
for	O
one	O
-	O
carbon	O
metabolism	O
[	O
71	O
,	O
72	O
].	O

A	O
diet	O
rich	O
in	O
vegetables	O
and	O
fruit	O
,	O
such	O
as	O
Mediterranean	O
diet	O
,	O
may	O
contain	O
these	O
nutrients	O
.	O

Sicilian	O
centenarians	O
are	O
characterized	O
to	O
observe	O
this	O
kind	O
of	O
diet	O
,	O
as	O
we	O
reported	O
[	O
73	O
].	O

Since	O
genetic	O
and	O
environmental	O
factors	O
contribute	O
to	O
longevity	O
,	O
it	O
may	O
suggest	O
that	O
epigenetic	O
events	O
associated	O
to	O
the	O
modifications	O
diet	O
-	O
induced	O
are	O
very	O
important	O
for	O
successful	O
ageing	O
processes	O
.	O

Furthermore	O
,	O
several	O
literature	O
data	O
reported	O
a	O
possible	O
link	O
between	O
epigenetic	O
and	O
several	O
age	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
such	O
as	O
cancer	B-DS
,	O
metabolic	B-DS
syndrome	I-DS
,	O
diabetes	B-DS
and	O
neurodegenerative	B-DS
disorders	I-DS
.	O

Stable	O
propagation	O
of	O
gene	O
expression	O
from	O
cell	O
to	O
cell	O
during	O
disease	O
pathogenesis	O
is	O
regulated	O
by	O
epigenetic	O
mechanisms	O
.	O

For	O
example	O
,	O
during	O
the	O
diabetes	B-DS
onset	O
epigenetic	O
changes	O
act	O
on	O
insulin	B-GP
and	O
insulin	B-GP
metabolism	O
regulating	O
the	O
gene	O
coding	O
[	O
74	O
].	O

In	O
particular	O
,	O
a	O
recent	O
study	O
has	O
demonstrated	O
that	O
human	B-OG
insulin	B-GP
gene	O
and	O
mouse	B-OG
insulin	B-GP
2	I-GP
gene	O
expression	O
are	O
under	O
control	O
of	O
epigenetic	O
changes	O
in	O
CpGIs	O
.	O

Insulin	B-GP
non	O
expressing	O
cells	O
are	O
,	O
indeed	O
,	O
methylated	O
in	O
the	O
promoter	O
region	O
of	O
insulin	B-GP
coding	O
gene	O
,	O
while	O
insulin	B-GP
expressing	O
cells	O
are	O
completely	O
demethylated	O
in	O
the	O
same	O
site	O
resulting	O
in	O
insulin	B-GP
gene	O
expression	O
[	O
75	O
].	O

Another	O
study	O
on	O
monozygotic	O
twin	O
has	O
demonstrated	O
that	O
insulin	B-DS
resistance	I-DS
is	O
also	O
under	O
control	O
of	O
DNA	O
methylation	O
[	O
76	O
].	O

Alterations	O
in	O
insulin	B-GP
pathway	O
are	O
known	O
to	O
be	O
involved	O
in	O
metabolic	B-DS
disease	I-DS
,	O
such	O
as	O
metabolic	B-DS
syndrome	I-DS
,	O
insulin	B-DS
resistance	I-DS
and	O
type	B-DS
2	I-DS
diabetes	I-DS
.	O

Recent	O
data	O
also	O
support	O
the	O
existence	O
of	O
a	O
correlation	O
between	O
these	O
alterations	O
and	O
Alzheimer	B-DS
'	I-DS
s	I-DS
disease	I-DS
.	O

In	O
the	O
light	O
of	O
these	O
observations	O
,	O
the	O
purpose	O
of	O
our	O
future	O
studies	O
will	O
be	O
to	O
evaluate	O
the	O
weight	O
of	O
epigenetic	O
changes	O
in	O
ageing	O
and	O
longevity	O
,	O
using	O
centenarians	O
as	O
super	O
-	O
controls	O
.	O

Abbreviations	O

AD	B-DS
:	O
Alzheimer	B-DS
'	I-DS
s	I-DS
disease	I-DS
;	O
BF	O
:	O
Boutonnese	B-DS
fever	O
;	O
CCR5	B-GP
:	O
CC	B-GP
chemokine	I-GP
receptor	I-GP
5	I-GP
;	O
COX	B-GP
-	I-GP
2	I-GP
:	O
Cyclo	B-GP
-	I-GP
oxygenase	I-GP
2	I-GP
;	O
CRP	B-GP
:	O
C	B-GP
reactive	I-GP
protein	I-GP
;	O
CVD	B-DS
:	O
Cardiovascular	B-DS
disease	I-DS
;	O
HSPs	B-GP
:	O
Heat	B-GP
-	I-GP
shock	I-GP
proteins	I-GP
;	O
INF	B-GP
-	I-GP
γ	I-GP
:	O
Interferon	B-GP
-	I-GP
γ	I-GP
;	O
IL	B-GP
-	I-GP
6	I-GP
:	O
Interleukin	B-GP
-	I-GP
6	I-GP
;	O
IL	B-GP
-	I-GP
10	I-GP
:	O
Interleukin	B-GP
-	I-GP
10	I-GP
;	O
5	O
-	O
LO	O
:	O
5	O
-	O
lipoxygenase	O
;	O
LPS	O
:	O
Lipopolysaccharide	O
;	O
LTs	O
:	O
Leukotrienes	O
;	O
MI	O
:	O
Myocardial	B-DS
infarction	I-DS
;	O
ox	O
-	O
LDL	O
:	O
Oxidized	O
-	O
Low	O
Density	O
Lipoproteins	O
;	O
PC	O
:	O
Prostate	B-DS
cancer	I-DS
;	O
PGs	O
:	O
Prostaglandins	B-CD
;	O
SNPs	O
:	O
Single	O
nucleotide	O
polymorphisms	O
;	O
TLR4	B-GP
:	O
Toll	B-GP
-	I-GP
like	I-GP
-	I-GP
receptor	I-GP
-	I-GP
4	I-GP
;	O
TNF	B-GP
-	I-GP
α	I-GP
:	O
Tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

CRB	O
,	O
GA	O
,	O
SB	O
,	O
MB	O
,	O
AM	O
and	O
GCR	O
wrote	O
the	O
first	O
draft	O
.	O

Subsequent	O
drafts	O
were	O
written	O
by	O
CRB	O
,	O
who	O
had	O
the	O
overall	O
supervision	O
of	O
the	O
review	O
processing	O
.	O

All	O
authors	O
edited	O
the	O
paper	O
and	O
approved	O
its	O
final	O
version	O
.	O

Molecular	O
Cloning	O
,	O
Characterization	O
and	O
Expression	O
Analysis	O
of	O
Two	O
Members	O
of	O
the	O
Pht1	B-GP
Family	O
of	O
Phosphate	B-GP
Transporters	I-GP
in	O
Glycine	B-OG
max	I-OG

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
ZW	O
GX	O
JG	O
HX	O
.	O

Performed	O
the	O
experiments	O
:	O
ZW	O
RG	O
GH	O
.	O

Analyzed	O
the	O
data	O
:	O
ZW	O
JZ	O
.	O

Wrote	O
the	O
paper	O
:	O
ZW	O
HX	O
.	O

Background	O

Phosphorus	O
is	O
one	O
of	O
the	O
macronutrients	O
essential	O
for	O
plant	B-OG
growth	O
and	O
development	O
.	O

The	O
acquisition	O
and	O
translocation	O
of	O
phosphate	O
are	O
pivotal	O
processes	O
of	O
plant	B-OG
growth	O
.	O

In	O
a	O
large	O
number	O
of	O
plants	B-OG
,	O
phosphate	O
uptake	O
by	O
roots	O
and	O
translocation	O
within	O
the	O
plant	B-OG
are	O
presumed	O
to	O
occur	O
via	O
a	O
phosphate	O
/	O
proton	O
cotransport	O
mechanism	O
.	O

Principal	O
Findings	O

We	O
cloned	O
two	O
cDNAs	O
from	O
soybean	B-OG
(	O
Glycine	B-OG
max	I-OG
),	O
GmPT1	B-GP
and	O
GmPT2	B-GP
,	O
which	O
show	O
homology	O
to	O
the	O
phosphate	B-GP
/	I-GP
proton	I-GP
cotransporter	I-GP
PHO84	B-GP
from	O
the	O
budding	O
yeast	B-OG
Saccharomyces	B-OG
cerevisiae	I-OG
.	O

The	O
amino	B-CD
acid	I-CD
sequence	O
of	O
the	O
products	O
predicted	O
from	O
GmPT1	B-GP
and	O
GmPT2	B-GP
share	O
61	O
%	O
and	O
63	O
%	O
identity	O
,	O
respectively	O
,	O
with	O
the	O
PHO84	O
in	O
amino	B-CD
acid	I-CD
sequence	O
.	O

The	O
deduced	O
structure	O
of	O
the	O
encoded	O
proteins	O
revealed	O
12	O
membrane	O
-	O
spanning	O
domains	O
with	O
a	O
central	O
hydrophilic	O
region	O
.	O

The	O
molecular	O
mass	O
values	O
are	O
∼	O
58	O
.	O
7	O
kDa	O
for	O
GmPT1	B-GP
and	O
∼	O
58	O
.	O
6	O
kDa	O
for	O
GmPT2	B-GP
.	O

Transiently	O
expressed	O
GFP	B-GP
–	O
protein	O
fusions	O
provide	O
direct	O
evidence	O
that	O
the	O
two	O
Pi	B-GP
transporters	I-GP
are	O
located	O
in	O
the	O
plasma	O
membrane	O
.	O

Uptake	O
of	O
radioactive	O
orthophosphate	O
by	O
the	O
yeast	B-OG
mutant	O
MB192	O
showed	O
that	O
GmPT1	B-GP
and	O
GmPT2	B-GP
are	O
dependent	O
on	O
pH	O
and	O
uptake	O
is	O
reduced	O
by	O
the	O
addition	O
of	O
uncouplers	O
of	O
oxidative	O
phosphorylation	O
.	O

The	O
K	O
m	O
for	O
phosphate	O
uptake	O
by	O
GmPT1	B-GP
and	O
GmPT2	B-GP
is	O
6	O
.	O
65	O
mM	O
and	O
6	O
.	O
63	O
mM	O
,	O
respectively	O
.	O

A	O
quantitative	O
real	O
time	O
RT	O
-	O
PCR	O
assay	O
indicated	O
that	O
these	O
two	O
genes	O
are	O
expressed	O
in	O
the	O
roots	O
and	O
shoots	O
of	O
seedlings	O
whether	O
they	O
are	O
phosphate	O
-	O
deficient	O
or	O
not	O
.	O

Deficiency	O
of	O
phosphorus	O
caused	O
a	O
slight	O
change	O
of	O
the	O
expression	O
levels	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
.	O

Conclusions	O

The	O
results	O
of	O
our	O
experiments	O
show	O
that	O
the	O
two	O
phosphate	B-GP
transporters	I-GP
have	O
low	O
affinity	O
and	O
the	O
corresponding	O
genes	O
are	O
constitutively	O
expressed	O
.	O

Thereby	O
,	O
the	O
two	O
phosphate	B-GP
transporters	I-GP
can	O
perform	O
translocation	O
of	O
phosphate	O
within	O
the	O
plant	B-OG
.	O

Introduction	O

Phosphorus	O
is	O
one	O
of	O
the	O
most	O
important	O
macronutrients	O
required	O
for	O
plant	B-OG
growth	O
and	O
metabolism	O
,	O
and	O
is	O
the	O
key	O
component	O
of	O
nucleic	O
acids	O
,	O
phospholipids	O
and	O
energy	O
-	O
providing	O
ATP	O
as	O
well	O
as	O
several	O
enzymes	O
and	O
coenzymes	O
.	O

Phosphorus	O
is	O
involved	O
in	O
energy	O
metabolism	O
,	O
activation	O
of	O
metabolic	O
intermediates	O
,	O
carbon	O
assimilation	O
,	O
photosynthesis	O
,	O
respiration	O
,	O
signal	O
transduction	O
and	O
enzyme	O
regulation	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
3	O
].	O

In	O
soil	O
,	O
plants	B-OG
acquire	O
phosphorus	O
in	O
the	O
form	O
of	O
orthophosphate	O
(	O
Pi	O
)	O
[	O
4	O
],	O
[	O
5	O
],	O
[	O
6	O
].	O

Phosphate	O
is	O
the	O
second	O
most	O
frequently	O
limiting	O
macronutrient	O
for	O
plant	B-OG
growth	O
mainly	O
because	O
it	O
exists	O
in	O
the	O
soil	O
in	O
complex	O
,	O
insoluble	O
,	O
inorganic	O
and	O
organic	O
forms	O
that	O
cannot	O
be	O
acquired	O
directly	O
by	O
the	O
plant	B-OG
[	O
4	O
],	O
[	O
7	O
].	O

For	O
this	O
reason	O
,	O
the	O
concentration	O
of	O
Pi	O
in	O
soil	O
solution	O
can	O
be	O
as	O
high	O
as	O
10	O
µM	O
but	O
is	O
present	O
more	O
often	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
µM	O
[	O
8	O
].	O

Plants	B-OG
respond	O
to	O
phosphate	O
deficiency	O
by	O
increasing	O
the	O
rate	O
of	O
Pi	O
uptake	O
by	O
roots	O
[	O
4	O
],	O
and	O
upregulation	O
of	O
the	O
synthesis	O
of	O
a	O
carrier	O
system	O
is	O
believed	O
to	O
contribute	O
to	O
the	O
observed	O
increase	O
of	O
Pi	O
acquisition	O
[	O
9	O
].	O

There	O
are	O
two	O
Pi	O
transport	O
systems	O
required	O
by	O
plants	B-OG
to	O
facilitate	O
absorption	O
from	O
diverse	O
environments	O
and	O
enable	O
subsequent	O
transportation	O
to	O
all	O
of	O
the	O
cells	O
and	O
subcellular	O
compartments	O
within	O
the	O
plant	B-OG
.	O

Kinetic	O
characterization	O
of	O
the	O
Pi	O
uptake	O
system	O
of	O
whole	O
plants	B-OG
[	O
10	O
],	O
[	O
11	O
]	O
and	O
cultured	O
cells	O
[	O
12	O
]	O
suggests	O
a	O
high	O
-	O
affinity	O
transport	O
operating	O
in	O
the	O
low	O
micromolar	O
range	O
and	O
a	O
low	O
-	O
affinity	O
system	O
operating	O
at	O
higher	O
concentrations	O
(	O
millimolar	O
range	O
)	O
[	O
7	O
],	O
[	O
13	O
],	O
[	O
14	O
],	O
[	O
15	O
],	O
[	O
16	O
].	O

Because	O
the	O
concentration	O
of	O
Pi	O
in	O
soil	O
solution	O
seldom	O
exceeds	O
10	O
µM	O
[	O
8	O
],	O
the	O
high	O
-	O
affinity	O
transport	O
is	O
assumed	O
to	O
be	O
the	O
predominant	O
system	O
responsible	O
for	O
Pi	O
uptake	O
.	O

Thus	O
,	O
a	O
number	O
of	O
Pi	B-GP
transporters	I-GP
might	O
function	O
primarily	O
in	O
Pi	O
uptake	O
at	O
the	O
soil	O
–	O
root	O
interface	O
,	O
whereas	O
the	O
others	O
might	O
participate	O
predominantly	O
in	O
translocation	O
within	O
the	O
plant	B-OG
and	O
/	O
or	O
transport	O
within	O
certain	O
tissues	O
or	O
cell	O
types	O
.	O

After	O
uptake	O
into	O
the	O
roots	O
,	O
Pi	O
is	O
mainly	O
translocated	O
symplastically	O
to	O
the	O
xylem	O
parenchyma	O
cells	O
,	O
and	O
secretion	O
into	O
the	O
xylem	O
for	O
long	O
-	O
distance	O
translocation	O
to	O
the	O
shoot	O
is	O
facilitated	O
by	O
another	O
type	O
of	O
transporter	B-GP
-	I-GP
like	I-GP
protein	I-GP
[	O
8	O
],	O
[	O
17	O
].	O

In	O
plants	B-OG
that	O
are	O
not	O
Pi	O
-	O
deficient	O
,	O
most	O
of	O
the	O
Pi	O
uptake	O
by	O
the	O
roots	O
is	O
transported	O
in	O
the	O
xylem	O
to	O
growing	O
leaves	O
.	O

In	O
Pi	O
-	O
starved	O
plants	B-OG
,	O
however	O
,	O
the	O
limited	O
supply	O
of	O
Pi	O
from	O
roots	O
to	O
shoots	O
is	O
augmented	O
by	O
increased	O
mobilization	O
of	O
stored	O
Pi	O
in	O
older	O
leaves	O
and	O
retranslocation	O
to	O
both	O
younger	O
leaves	O
and	O
growing	O
roots	O
,	O
from	O
where	O
Pi	O
can	O
again	O
be	O
recycled	O
to	O
the	O
shoot	O
[	O
18	O
].	O

Consequently	O
,	O
the	O
uptake	O
and	O
allocation	O
of	O
Pi	O
in	O
plants	B-OG
requires	O
multiple	O
transport	O
systems	O
that	O
must	O
function	O
in	O
concert	O
to	O
maintain	O
homeostasis	O
throughout	O
growth	O
and	O
development	O
[	O
19	O
].	O

Remobilization	O
of	O
phosphate	O
stored	O
in	O
leaves	O
has	O
been	O
demonstrated	O
and	O
the	O
existence	O
of	O
a	O
Pi	B-GP
transporter	I-GP
that	O
facilitates	O
this	O
process	O
has	O
been	O
inferred	O
.	O

Rae	O
et	O
al	O
.	O
have	O
identified	O
several	O
genes	O
in	O
a	O
barley	B-OG
genomic	O
library	O
that	O
appear	O
to	O
be	O
members	O
of	O
the	O
Pht1	B-GP
gene	O
family	O
.	O

The	O
sequence	O
of	O
HORvu	B-GP
;	O
Pht1	B-GP
;	O
6	O
suggested	O
that	O
it	O
is	O
also	O
a	O
member	O
of	O
the	O
Pht1	B-GP
gene	O
family	O
.	O

The	O
estimated	O
K	O
m	O
of	O
HORvu	O
;	O
Pht1	B-GP
;	O
6	O
is	O
38561	O
µM	O
,	O
which	O
is	O
characteristic	O
of	O
a	O
low	O
-	O
affinity	O
transporter	O
.	O
HORvu	O
;	O
Pht1	B-GP
;	I-GP
6	I-GP
is	O
expressed	O
in	O
the	O
above	O
-	O
ground	O
part	O
of	O
the	O
plant	B-OG
with	O
strongest	O
expression	O
in	O
old	O
leaves	O
and	O
flag	O
leaves	O
and	O
is	O
less	O
responsive	O
to	O
external	O
concentrations	O
of	O
Pi	O
,	O
indicating	O
that	O
Pht1	B-GP
;	I-GP
6	I-GP
is	O
unlikely	O
to	O
function	O
in	O
the	O
uptake	O
of	O
Pi	O
by	O
roots	O
from	O
soil	O
.	O

Both	O
of	O
these	O
organs	O
are	O
known	O
to	O
have	O
a	O
role	O
in	O
the	O
nutrition	O
of	O
developing	O
grains	O
.	O

The	O
expression	O
of	O
Pht1	B-GP
;	O
6	O
in	O
these	O
organs	O
suggested	O
that	O
it	O
might	O
also	O
play	O
a	O
role	O
in	O
the	O
remobilization	O
of	O
nutrients	O
during	O
grain	O
development	O
.	O

Furthermore	O
,	O
in	O
situ	O
hybridization	O
showed	O
that	O
Pht1	B-GP
;	O
6	O
is	O
expressed	O
in	O
the	O
phloem	O
of	O
vascular	O
bundles	O
in	O
leaves	O
and	O
ears	O
.	O

Taken	O
together	O
,	O
HORvu	B-GP
;	O
Pht1	B-GP
;	O
6	O
probably	O
functions	O
in	O
the	O
remobilization	O
of	O
stored	O
Pi	O
from	O
leaves	O
[	O
20	O
].	O

In	O
rice	B-OG
,	O
expression	O
of	O
OsPht1	B-GP
;	I-GP
2	I-GP
(	O
OsPT2	B-GP
)	O
is	O
increased	O
significantly	O
in	O
response	O
to	O
Pi	O
deficiency	O
in	O
root	O
and	O
shoot	O
.	O

By	O
using	O
transgenic	O
rice	B-OG
plants	B-OG
expressing	O
the	O
GUS	B-GP
reporter	O
gene	O
,	O
OsPT2	B-GP
was	O
localized	O
exclusively	O
in	O
the	O
stele	O
of	O
primary	O
and	O
lateral	O
roots	O
.	O

The	O
knock	O
-	O
down	O
of	O
OsPT2	B-GP
by	O
RNA	O
interference	O
significantly	O
decreased	O
long	O
-	O
distance	O
transport	O
of	O
Pi	O
from	O
root	O
to	O
shoot	O
.	O

These	O
data	O
suggested	O
OsPT2	B-GP
functions	O
in	O
translocation	O
of	O
the	O
stored	O
Pi	O
in	O
the	O
plant	B-OG
[	O
21	O
].	O

In	O
conclusion	O
,	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
have	O
a	O
wide	O
range	O
of	O
roles	O
in	O
Pi	O
uptake	O
and	O
translocation	O
within	O
the	O
plant	B-OG
and	O
are	O
required	O
to	O
facilitate	O
the	O
movement	O
of	O
phosphate	O
between	O
subcellular	O
compartments	O
and	O
organelles	O
.	O

However	O
,	O
most	O
studies	O
of	O
Pi	B-GP
transporters	I-GP
in	O
plants	B-OG
have	O
focused	O
on	O
the	O
roots	O
.	O

Soybean	B-OG
(	O
Glycine	B-OG
max	I-OG
L	O
.	O

Merr	O
.)	O
is	O
one	O
of	O
the	O
most	O
economically	O
important	O
leguminous	O
seed	O
crops	O
that	O
provide	O
the	O
majority	O
of	O
plant	B-OG
proteins	O
,	O
and	O
more	O
than	O
a	O
quarter	O
of	O
the	O
world	O
'	O
s	O
food	O
and	O
animal	B-OG
feed	O
[	O
22	O
],	O
[	O
23	O
].	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
report	O
of	O
soybean	B-OG
Pi	B-GP
transporters	I-GP
in	O
the	O
literature	O
.	O

Here	O
,	O
we	O
report	O
the	O
characterization	O
of	O
two	O
Pi	B-GP
transporters	I-GP
from	O
soybean	B-OG
.	O

The	O
two	O
genes	O
are	O
designated	O
GmPT1	B-GP
and	O
GmPT2	B-GP
according	O
to	O
the	O
rules	O
recommended	O
by	O
the	O
Commission	O
on	O
Plant	B-OG
Gene	O
Nomenclature	O
.	O

The	O
sequences	O
of	O
the	O
two	O
genes	O
share	O
great	O
similarity	O
with	O
that	O
of	O
the	O
plant	B-OG
proton	B-GP
–	I-GP
Pi	I-GP
cotransporter	I-GP
.	O

The	O
primary	O
functions	O
of	O
these	O
genes	O
appear	O
to	O
be	O
as	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
within	O
the	O
plant	B-OG
.	O

Results	O

Cloning	O
and	O
Computational	O
Sequence	O
Analysis	O

We	O
identified	O
two	O
single	O
copy	O
Pi	B-GP
transporter	I-GP
genes	O
in	O
soybean	B-OG
located	O
on	O
chromosomes	O
Gm10	O
(	O
41	O
,	O
391	O
,	O
168	O
–	O
41	O
,	O
393	O
,	O
008	O
)	O
and	O
Gm20	O
(	O
42	O
,	O
980	O
,	O
124	O
–	O
42	O
,	O
981	O
,	O
928	O
).	O

These	O
genes	O
are	O
designated	O
GmPT1	B-GP
(	O
accession	O
number	O
HQ392508	O
)	O
and	O
GmPT2	B-GP
(	O
accession	O
number	O
HQ392509	O
),	O
respectively	O
.	O
GmPT1	B-GP
is	O
1841	O
-	O
bp	O
long	O
(	O
Figure	O
1A	O
)	O
and	O
contains	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
536	O
amino	B-CD
acid	I-CD
polypeptide	O
(	O
molecular	O
mass	O
58730	O
.	O
46	O
Da	O
).	O
GmPT2	B-GP
is	O
1802	O
bp	O
long	O
(	O
Figure	O
1A	O
)	O
and	O
contains	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
536	O
amino	B-CD
acid	I-CD
polypeptide	O
(	O
molecular	O
mass	O
58627	O
.	O
29	O
Da	O
).	O

Interestingly	O
,	O
the	O
open	O
reading	O
frame	O
in	O
both	O
genes	O
spans	O
base	O
pairs	O
23	O
–	O
1633	O
.	O

These	O
genes	O
are	O
88	O
.	O
7	O
%	O
similar	O
in	O
nucleotide	B-CD
sequence	O
and	O
97	O
.	O
9	O
%	O
similar	O
in	O
amino	B-CD
acid	I-CD
sequence	O
.	O

The	O
two	O
polypeptides	O
share	O
the	O
greatest	O
degree	O
of	O
similarity	O
with	O
the	O
characterized	O
Pi	B-GP
transporters	I-GP
from	O
mouse	B-OG
-	I-OG
ear	I-OG
cress	I-OG
(	O
Arabidopsis	B-OG
thaliana	I-OG
)	O
[	O
14	O
],	O
[	O
25	O
],	O
tomato	B-OG
(	O
Lycopersicon	B-OG
esculentum	I-OG
L	I-OG
.)	I-OG
[	O
15	O
],	O
potato	B-OG
(	O
Solanum	B-OG
tuberosum	I-OG
L	I-OG
.)	I-OG
[	O
26	O
]	O
and	O
barrel	B-OG
clover	I-OG
(	O
Medicago	B-OG
truncatula	I-OG
)	O
[	O
27	O
].	O

The	O
two	O
Pi	B-GP
transporters	I-GP
from	O
soybean	B-OG
have	O
a	O
very	O
high	O
degree	O
of	O
identity	O
with	O
fungal	O
Pi	B-GP
transporters	I-GP
from	O
the	O
mycorrhizal	O
fungus	B-OG
Glomus	B-OG
versiforme	I-OG
(	O
GvPT	B-GP
)	O
and	O
the	O
budding	O
yeast	B-OG
Saccharomyces	B-OG
cerevisiae	I-OG
(	O
PHO84	O
).	O

GmPT1	B-GP
shows	O
76	O
%	O
and	O
61	O
%	O
and	O
GmPT2	B-GP
shows	O
76	O
%	O
and	O
63	O
%	O
amino	B-CD
acid	I-CD
sequence	O
identity	O
with	O
GvPT	B-GP
(	O
accession	O
number	O
Q00908	O
)	O
and	O
PHO84	O
(	O
accession	O
number	O
P25297	O
),	O
respectively	O
.	O

DNA	O
gel	O
analysis	O
of	O
two	O
soybean	B-OG
Pi	B-GP
transporters	I-GP
.	O

DNA	O
gel	O
-	O
blot	O
analysis	O
of	O
GmPT1	O
and	O
GmPT2	O
(	O
A	O
).	O

Lanes	O
2	O
and	O
3	O
contain	O
GmPT1	O
and	O
GmPT2	O
,	O
respectively	O
.	O

The	O
size	O
markers	O
are	O
shown	O
to	O
the	O
right	O
and	O
left	O
of	O
the	O
figure	O
.	O

The	O
expression	O
profile	O
of	O
the	O
two	O
proteins	O
in	O
different	O
parts	O
of	O
the	O
soybean	B-OG
seedling	O
(	O
B	O
).	O

Seven	O
days	O
old	O
soybean	B-OG
seedlings	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
with	O
cons15	O
as	O
the	O
control	O
.	O

Structure	O
of	O
the	O
Soybean	B-OG
Pi	B-GP
Transporters	I-GP

Hydropathy	O
plots	O
of	O
the	O
deduced	O
polypeptides	O
suggest	O
that	O
GmPT1	B-GP
and	O
GmPT2	B-GP
consist	O
of	O
12	O
membrane	O
-	O
spanning	O
regions	O
(	O
Figure	O
2	O
),	O
a	O
feature	O
shared	O
by	O
other	O
Pi	B-GP
transporters	I-GP
,	O
irrespective	O
of	O
the	O
level	O
of	O
affinity	O
[	O
14	O
],	O
[	O
15	O
],	O
[	O
19	O
],	O
[	O
20	O
],	O
[	O
25	O
],	O
[	O
26	O
],	O
[	O
27	O
],	O
[	O
28	O
],	O
[	O
29	O
],	O
[	O
30	O
],	O
[	O
31	O
],	O
[	O
32	O
],	O
[	O
33	O
],	O
[	O
34	O
],	O
[	O
35	O
].	O
Computational	O
modeling	O
of	O
the	O
encoded	O
proteins	O
predicted	O
a	O
conserved	O
secondary	O
structure	O
containing	O
12	O
transmembrane	O
(	O
TM	O
)	O
domains	O
with	O
a	O
large	O
hydrophilic	O
loop	O
between	O
TM6	O
and	O
TM7	O
(	O
Figure	O
2A	O
)	O
and	O
the	O
hydrophilic	O
N	O
and	O
C	O
termini	O
located	O
in	O
the	O
cytoplasm	O
(	O
Figure	O
2B	O
).	O

The	O
amino	B-CD
acid	I-CD
sequences	O
are	O
similar	O
to	O
those	O
of	O
the	O
other	O
members	O
of	O
the	O
Pht1	B-GP
family	O
of	O
Pi	B-GP
transporters	I-GP
(	O
Figure	O
3	O
).	O

Several	O
amino	B-CD
acid	I-CD
domains	O
are	O
highly	O
conserved	O
between	O
these	O
two	O
Pi	B-GP
transporters	I-GP
and	O
include	O
sites	O
for	O
protein	B-GP
kinase	I-GP
C	I-GP
and	O
casein	B-GP
kinase	I-GP
II	I-GP
-	O
facilitated	O
phosphorylation	O
,	O
as	O
well	O
as	O
N	O
-	O
glycosylation	O
(	O
Figure	O
2B	O
).	O

The	O
existence	O
of	O
a	O
number	O
of	O
conserved	O
putative	O
phosphorylation	O
sites	O
present	O
within	O
the	O
Pht1	B-GP
family	O
suggested	O
that	O
regulation	O
of	O
the	O
transporters	O
might	O
occur	O
at	O
the	O
post	O
-	O
translational	O
level	O
as	O
well	O
[	O
6	O
],	O
[	O
9	O
].	O

Predicted	O
topology	O
of	O
GmPT1	O
and	O
GmPT2	O
.	O

Hydrophobicity	O
profiles	O
of	O
GmPT1	O
and	O
GmPT2	O
(	O
A	O
).	O

Hydropathy	O
values	O
for	O
a	O
window	O
of	O
14	O
residues	O
were	O
calculated	O
by	O
DNAMAN	O
version	O
6	O
.	O
0	O
.	O
3	O
.	O
93	O
using	O
algorithms	O
presented	O
by	O
Kyte	O
and	O
Doolittle	O
[	O
62	O
].	O

Hydrophobic	O
regions	O
correspond	O
to	O
positive	O
index	O
numbers	O
.	O

The	O
arabic	O
numerals	O
refer	O
to	O
putative	O
membrane	O
-	O
spanning	O
domains	O
.	O

A	O
topological	O
model	O
for	O
GmPT1	O
and	O
GmPT2	O
(	O
B	O
).	O

The	O
membrane	O
-	O
spanning	O
domains	O
of	O
GmPT1and	B-GP
GmPT2	B-GP
were	O
predicted	O
by	O
HMMTOP	O
[	O
52	O
]	O
and	O
their	O
numbering	O
is	O
indicated	O
by	O
arabic	O
numerals	O
1	O
–	O
12	O
.	O

The	O
model	O
was	O
drawn	O
with	O
the	O
aid	O
of	O
TOPO2	O
software	O
(	O
http	O
://	O
www	O
.	O
sacs	O
.	O
ucsf	O
.	O
edu	O
/	O
TOPO2	O
/).	O

Enlarged	O
symbols	O
indicate	O
sites	O
of	O
significant	O
structure	O
–	O
function	O
importance	O
:	O
red	O
,	O
N	O
-	O
glycosylation	O
;	O
green	O
,	O
protein	B-GP
kinase	I-GP
C	I-GP
phosphorylation	O
;	O
blue	O
,	O
casein	B-GP
kinase	I-GP
II	I-GP
phosphorylation	O
;	O
cyan	O
,	O
tyrosine	B-GP
kinase	I-GP
phosphorylation	O
;	O
purple	O
,	O
Amidation	O
;	O
and	O
magenta	O
,	O
N	O
-	O
myristoylation	O
.	O

Phylogenetic	O
relationship	O
between	O
GmPT1	B-GP
,	O
GmPT2	B-GP
and	O
other	O
plant	B-OG
and	O
fungal	O
Pi	B-GP
transporters	I-GP
.	O

Proteins	O
(	O
and	O
accession	O
numbers	O
):	O
PHO84	B-GP
(	O
P25297	O
)	O
from	O
Saccharomyces	B-OG
cerevisiae	I-OG
;	O
GvPT	B-GP
(	O
Q00908	O
)	O
from	O
Glomus	B-OG
versiforme	I-OG
;	O
GiPT	B-GP
(	O
AAL37552	O
)	O
from	O
Glomus	B-OG
intraradices	I-OG
;	O
Pht1	B-GP
;	O
1	O
(	O
Y07682	O
),	O
Pht1	B-GP
;	O
2	O
(	O
Y07681	O
)	O
Pht1	B-GP
;	O
3	O
(	O
O48639	O
)	O
and	O
Pht2	B-GP
;	O
1	O
(	O
CAC15560	O
)	O
from	O
Arabidopsis	B-OG
thaliana	I-OG
;	O
StPT1	B-GP
(	O
Q43650	O
)	O
and	O
StPT2	B-GP
(	O
Q41479	O
)	O
from	O
Solanum	B-OG
tuberosum	I-OG
;	O
MtPT1	B-GP
(	O
O22301	O
)	O
and	O
MtPT2	B-GP
(	O
O22302	O
)	O
from	O
Medicago	B-OG
truncatula	I-OG
;	O
LePT1	B-GP
(	O
O24029	O
)	O
and	O
LePT2	B-GP
(	O
O22549	O
)	O
from	O
Lycopersicon	B-OG
esculentum	I-OG
;	O
LaPT1	B-GP
(	O
AAK01938	O
)	O
and	O
LaPT2	B-GP
(	O
AAK38197	O
)	O
from	O
Lupinus	B-OG
albus	I-OG
;	O
NtPT1	B-GP
(	O
AAF74025	O
)	O
from	O
Nicotiana	B-OG
tabacum	I-OG
;	O
OsPT1	B-GP
(	O
AAN39042	O
)	O
and	O
OsPT2	B-GP
(	O
AAN39043	O
)	O
from	O
Oryza	B-OG
sativa	I-OG
;	O
and	O
GmPT1	B-GP
(	O
HQ392508	O
)	O
and	O
GmPT2	B-GP
(	O
HQ392509	O
)	O
from	O
Glycine	B-OG
max	I-OG
.	O

Subcellular	O
localization	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP

The	O
TBpred	O
Prediction	O
Server	O
[	O
36	O
]	O
(	O
http	O
://	O
www	O
.	O
imtech	O
.	O
res	O
.	O
in	O
/	O
raghava	O
/	O
tbpred	O
/)	O
was	O
used	O
for	O
searches	O
that	O
yielded	O
unambiguous	O
results	O
with	O
positive	O
scores	O
for	O
the	O
integral	B-GP
membrane	I-GP
protein	I-GP
(	O
data	O
not	O
shown	O
).	O

To	O
verify	O
the	O
subcellular	O
locations	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
,	O
a	O
green	B-GP
fluorescent	I-GP
protein	I-GP
(	O
GFP	B-GP
)-	O
tagged	O
gene	O
was	O
fused	O
to	O
the	O
3	O
′	O
end	O
of	O
the	O
open	O
reading	O
frame	O
of	O
the	O
GmPT1	B-GP
or	O
GmPT2	B-GP
genes	O
.	O

The	O
chimeric	O
genes	O
were	O
placed	O
under	O
the	O
control	O
of	O
the	O
CaMV35S	O
promoter	O
and	O
the	O
constructs	O
were	O
transformed	O
into	O
onion	O
epidermal	O
cell	O
by	O
particle	O
bombarded	O
.	O

As	O
a	O
control	O
,	O
a	O
second	O
set	O
of	O
cells	O
was	O
bombarded	O
with	O
the	O
empty	O
vector	O
pBI	O
-	O
121	O
-	O
GFP	B-GP
.	O

The	O
cells	O
were	O
then	O
examined	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
to	O
determine	O
the	O
location	O
of	O
the	O
GmPT1	B-GP
/	O
GFP	B-GP
and	O
GmPT2	B-GP
/	O
GFP	B-GP
fusion	O
proteins	O
.	O

A	O
clear	O
GFP	B-GP
signal	O
was	O
observed	O
at	O
the	O
periphery	O
of	O
cells	O
bombarded	O
with	O
the	O
GmPT1	B-GP
/	O
GFP	B-GP
or	O
GmPT2	B-GP
/	O
GFP	B-GP
construction	O
(	O
Figure	O
4A	O
–	O
C	O
and	O
G	O
–	O
I	O
for	O
GmPT1	B-GP
and	O
GmPT2	B-GP
,	O
respectively	O
),	O
whereas	O
the	O
signal	O
was	O
seen	O
throughout	O
cells	O
expressing	O
free	O
GFP	B-GP
(	O
Figure	O
4D	O
–	O
F	O
).	O

Localization	O
of	O
the	O
GmPT1	B-GP
/	O
GFP	B-GP
and	O
GmPT2	B-GP
/	O
GFP	B-GP
fusion	O
proteins	O
to	O
the	O
periphery	O
of	O
the	O
cells	O
indicated	O
that	O
the	O
two	O
proteins	O
are	O
targeted	O
to	O
the	O
plasma	O
membrane	O
.	O

This	O
is	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
biochemical	O
studies	O
and	O
together	O
these	O
data	O
suggest	O
that	O
the	O
GmPT1	B-GP
and	O
GmPT2	B-GP
proteins	O
are	O
located	O
in	O
the	O
plasma	O
membrane	O
.	O

Subcellular	O
localization	O
of	O
GmPT1	B-GP
/	O
GFP	B-GP
and	O
GmPT2	B-GP
/	O
GFP	B-GP
fusion	O
.	O

Images	O
showing	O
onion	O
epidermal	O
cells	O
expressing	O
GmPT1	O
/	O
GFP	B-GP
(	O
A	O
–	O
C	O
),	O
empty	O
vector	O
(	O
D	O
–	O
F	O
)	O
and	O
GmPT2	O
/	O
GFP	B-GP
(	O
G	O
–	O
I	O
)	O
fusion	O
protein	O
examined	O
under	O
fluorescent	O
-	O
field	O
illumination	O
(	O
A	O
,	O
D	O
and	O
G	O
)	O
to	O
examine	O
GFP	B-GP
fluorescence	O
;	O
under	O
bright	O
-	O
field	O
illumination	O
(	O
B	O
,	O
E	O
and	O
H	O
)	O
and	O
by	O
confocal	O
microscopy	O
for	O
the	O
overlay	O
of	O
bright	O
and	O
fluorescent	O
illumination	O
(	O
C	O
,	O
F	O
and	O
I	O
).	O

The	O
scale	O
bars	O
represent	O
100	O
µM	O
.	O

Functional	O
and	O
Biochemical	O
Analysis	O
in	O
Yeast	B-OG

We	O
used	O
uptake	O
studies	O
with	O
inhibitors	O
to	O
confirm	O
the	O
pH	O
dependence	O
of	O
Pi	O
transport	O
(	O
Table	O
1	O
).	O

Pi	O
transport	O
activity	O
was	O
assessed	O
at	O
pH	O
values	O
in	O
the	O
range	O
4	O
–	O
7	O
.	O

Differences	O
were	O
detected	O
in	O
the	O
activity	O
profiles	O
but	O
the	O
uptake	O
rate	O
was	O
maximal	O
at	O
pH	O
4	O
and	O
increased	O
as	O
the	O
pH	O
was	O
reduced	O
from	O
7	O
to	O
4	O
in	O
each	O
case	O
(	O
Figure	O
5	O
).	O

To	O
investigate	O
this	O
influence	O
of	O
a	O
proton	O
motive	O
force	O
on	O
Pi	O
transport	O
activity	O
,	O
the	O
uncouplers	O
2	O
,	O
4	O
-	O
dinitrophenol	O
(	O
2	O
,	O
4	O
-	O
DNP	O
)	O
and	O
carbonyl	O
cyanide	O
m	O
-	O
chlorophenylhydrazone	O
(	O
CCCP	O
),	O
which	O
destroy	O
pH	O
gradients	O
across	O
membranes	O
,	O
were	O
applied	O
.	O

DNP	O
at	O
a	O
concentration	O
of	O
100	O
µM	O
reduced	O
the	O
Pi	O
uptake	O
rate	O
to	O
79	O
%	O
(	O
GmPT1	O
)	O
and	O
82	O
%	O
(	O
GmPT2	O
)	O
compared	O
with	O
100	O
%	O
uptake	O
in	O
the	O
inhibitor	O
-	O
free	O
control	O
.	O

The	O
rate	O
of	O
uptake	O
was	O
reduced	O
to	O
77	O
%	O
(	O
GmPT1	O
)	O
and	O
80	O
%	O
(	O
GmPT2	O
)	O
by	O
100	O
µM	O
CCCP	O
and	O
,	O
to	O
82	O
%	O
(	O
GmPT1	O
)	O
and	O
83	O
%	O
(	O
GmPT2	O
)	O
by	O
100	O
µM	O
Vanadate	B-CD
,	O
an	O
inhibitor	O
of	O
P	B-GP
-	I-GP
type	I-GP
H	I-GP
+-	I-GP
ATPases	I-GP
.	O

The	O
transporter	O
rate	O
was	O
decreased	O
significantly	O
compared	O
to	O
that	O
in	O
the	O
control	O
(	O
Table	O
1	O
).	O

These	O
results	O
confirmed	O
the	O
hypothesis	O
that	O
Pi	O
/	O
H	O
+	O
cotransport	O
via	O
GmPT1	B-GP
and	O
GmPT2	B-GP
depends	O
on	O
the	O
pH	O
gradient	O
across	O
the	O
cell	O
membrane	O
that	O
is	O
maintained	O
by	O
the	O
endogenous	O
plasma	O
membrane	O
H	B-GP
+-	I-GP
ATPases	I-GP
.	O

Moreover	O
,	O
competition	O
studies	O
showed	O
that	O
different	O
anions	O
did	O
not	O
reduce	O
the	O
Pi	O
uptake	O
rate	O
,	O
demonstrating	O
the	O
high	O
degree	O
of	O
specificity	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
for	O
Pi	O
.	O

Strains	O
carrying	O
the	O
GmPT1	B-GP
or	O
GmPT2	B-GP
cDNA	O
generally	O
uptake	O
Pi	O
at	O
rates	O
similar	O
to	O
those	O
of	O
the	O
vector	O
controls	O
at	O
millimolar	O
concentrations	O
of	O
Pi	O
(	O
Figure	O
5	O
).	O

Inorganic	O
phosphate	O
(	O
Pi	O
)	O
uptake	O
as	O
a	O
function	O
of	O
external	O
pH	O
.	O

Pi	O
uptake	O
rates	O
for	O
yeast	B-OG
MB192	O
cells	O
expressing	O
the	O
indicated	O
GmPT1	B-GP
,	O
GmPT2	O
or	O
carrying	O
the	O
control	O
vector	O
and	O
wild	O
type	O
yeast	B-OG
cell	O
were	O
determined	O
in	O
medium	O
at	O
the	O
indicated	O
pH	O
value	O
.	O

Values	O
shown	O
are	O
the	O
mean	O
±	O
SE	O
for	O
three	O
independent	O
experiments	O
.	O

Pharmacology	O
and	O
specificity	O
of	O
GmPT1	O
and	O
GmPT2	O
.	O

Inhibitor	O

32P	O
uptake	O
(%	O
of	O
the	O
control	O
)	O

GmPT1Mean	O
±	O
SE	O

GmPT2Mean	O
±	O
SE	O

CCCP	O
(	O
10	O
µM	O
)	O

93	O
±	O
0	O
.	O
04	O

96	O
±	O
0	O
.	O
06	O

CCCP	O
(	O
100	O
µM	O
)	O

77	O
±	O
0	O
.	O
02	O

80	O
±	O
0	O
.	O
05	O

DNP	O
(	O
10	O
µM	O
)	O

92	O
±	O
0	O
.	O
02	O

94	O
±	O
0	O
.	O
07	O

DNP	O
(	O
100	O
µM	O
)	O

79	O
±	O
0	O
.	O
05	O

82	O
±	O
0	O
.	O
01	O

Vanadate	B-CD
(	O
10	O
µM	O
)	O

92	O
±	O
0	O
.	O
02	O

96	O
±	O
0	O
.	O
05	O

Vanadate	B-CD
(	O
100	O
µM	O
)	O

82	O
±	O
0	O
.	O
03	O

83	O
±	O
0	O
.	O
04	O

NH4Cl	O
(	O
5	O
mM	O
)	O

78	O
±	O
0	O
.	O
08	O

76	O
±	O
0	O
.	O
05	O

KCl	O
(	O
5	O
mM	O
)	O

75	O
±	O
0	O
.	O
03	O

72	O
±	O
0	O
.	O
07	O

NaAc	O
(	O
5	O
mM	O
)	O

77	O
±	O
0	O
.	O
08	O

78	O
±	O
0	O
.	O
04	O

CCCP	O
,	O
carbonyl	O
cyanide	O
m	O
-	O
chlorophenylhydrazone	O
.	O

DNP	O
,	O
2	O
,	O
4	O
-	O
dinitrophenol	O
.	O

Inhibitors	O
were	O
added	O
to	O
yeast	B-OG
cells	O
30	O
s	O
before	O
addition	O
of	O
labeled	O
Pi	O
.	O

All	O
assays	O
were	O
done	O
at	O
pH	O
4	O
.	O

Values	O
for	O
each	O
treatment	O
were	O
derived	O
from	O
three	O
independent	O
measurements	O
.	O

Water	O
was	O
used	O
as	O
the	O
control	O
treatment	O
.	O

It	O
was	O
the	O
pioneering	O
work	O
of	O
Emmanuel	O
Epstein	O
that	O
demonstrated	O
ion	O
uptake	O
processes	O
across	O
the	O
plasma	O
membrane	O
follow	O
Michaelis	O
–	O
Menten	O
kinetics	O
[	O
37	O
],	O
[	O
38	O
].	O

In	O
uptake	O
experiments	O
with	O
radioactive	O
Pi	O
,	O
the	O
rate	O
of	O
transport	O
was	O
linear	O
with	O
time	O
during	O
the	O
first	O
5	O
min	O
of	O
uptake	O
under	O
the	O
conditions	O
applied	O
[	O
30	O
],	O
[	O
31	O
].	O

In	O
three	O
parallel	O
experiments	O
,	O
the	O
Lineweaver	O
–	O
Burk	O
diagram	O
,	O
calculated	O
using	O
reciprocal	O
uptake	O
velocities	O
at	O
5	O
min	O
after	O
addition	O
of	O
32Pi	O
,	O
indicated	O
that	O
Pi	O
uptake	O
facilitated	O
by	O
GmPT1and	O
GmPT2	O
followed	O
Michaelis	O
–	O
Menten	O
kinetics	O
with	O
an	O
apparent	O
K	O
m	O
value	O
of	O
6	O
.	O
65	O
mM	O
and	O
6	O
.	O
63	O
mM	O
,	O
respectively	O
,	O
(	O
Figure	O
6A	O
and	O
B	O
).	O

Thus	O
,	O
GmPT1	B-GP
and	O
GmPT2	B-GP
are	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
that	O
are	O
dependent	O
on	O
the	O
proton	O
gradient	O
across	O
the	O
plasma	O
membrane	O
.	O

Lineweaver	O
–	O
Burk	O
plots	O
of	O
GmPT1	O
and	O
GmPT2	O
.	O

Lineweaver	O
–	O
Burk	O
plot	O
of	O
Pi	O
uptake	O
of	O
strains	O
MB192	O
-	O
GmPT1	O
and	O
MB192	O
-	O
GmPT2	O
versus	O
external	O
Pi	O
concentrations	O
that	O
were	O
used	O
to	O
estimate	O
K	O
m	O
.	O

Expression	O
pattern	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP

Root	O
,	O
stem	O
and	O
leaf	O
tissues	O
of	O
7	O
-	O
day	O
-	O
old	O
soybean	B-OG
seedlings	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
(	O
Figure	O
1B	O
).	O

Expression	O
of	O
the	O
two	O
Pi	B-GP
transporters	I-GP
was	O
enhanced	O
in	O
both	O
root	O
and	O
shoot	O
during	O
the	O
first	O
48	O
h	O
of	O
Pi	O
starvation	O
.	O

The	O
expression	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
in	O
seedling	O
tissues	O
was	O
increased	O
during	O
the	O
3	O
h	O
after	O
the	O
Pi	O
-	O
sufficient	O
treated	O
seedlings	O
were	O
transferred	O
to	O
a	O
Pi	O
-	O
deficient	O
solution	O
at	O
48	O
h	O
compared	O
to	O
the	O
expression	O
measured	O
in	O
Pi	O
-	O
sufficient	O
plants	B-OG
(	O
Figure	O
7A	O
,	O
C	O
and	O
E	O
for	O
GmPT1	B-GP
and	O
G	O
,	O
I	O
and	O
K	O
for	O
GmPT2	B-GP
).	O

The	O
transcript	O
levels	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
were	O
little	O
changed	O
in	O
plants	B-OG
that	O
were	O
grown	O
in	O
half	O
-	O
strength	O
nutrient	O
solution	O
for	O
7	O
days	O
and	O
then	O
transferred	O
to	O
a	O
Pi	O
-	O
sufficient	O
solution	O
.	O

A	O
decrease	O
in	O
the	O
transcript	O
abundance	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
in	O
the	O
leaf	O
,	O
stem	O
and	O
root	O
of	O
hydroponically	O
grown	O
soybean	B-OG
seedlings	O
was	O
apparent	O
within	O
3	O
h	O
of	O
Pi	O
deprivation	O
(	O
Figure	O
7	O
B	O
,	O
D	O
and	O
F	O
for	O
GmPT1	B-GP
and	O
H	O
,	O
J	O
and	O
L	O
for	O
GmPT2	B-GP
).	O

In	O
conclusion	O
,	O
the	O
expression	O
level	O
of	O
the	O
two	O
genes	O
was	O
not	O
altered	O
markedly	O
and	O
the	O
change	O
tendencies	O
were	O
complicated	O
irrespective	O
of	O
how	O
the	O
seedlings	O
were	O
treated	O
.	O

Therefore	O
,	O
the	O
GmPT1	B-GP
and	O
GmPT2	B-GP
soybean	B-OG
Pi	B-GP
transporters	I-GP
were	O
constitutively	O
expressed	O
.	O

Expression	O
levels	O
of	O
GmPT1	B-GP
(	O
A	O
–	O
F	O
)	O
and	O
GmPT2	B-GP
(	O
G	O
–	O
L	O
)	O
during	O
Pi	O
treatment	O
.	O

The	O
7	O
-	O
day	O
-	O
old	O
seedlings	O
were	O
grown	O
by	O
hydroponic	O
culture	O
with	O
0	O
.	O
5	O
×	O
Hoagland	O
solution	O
containing	O
5	O
µM	O
Pi	O
(	O
A	O
,	O
C	O
,	O
E	O
,	O
G	O
,	O
I	O
and	O
K	O
)	O
or	O
1	O
mM	O
Pi	O
(	O
B	O
,	O
D	O
,	O
F	O
,	O
H	O
,	O
J	O
and	O
L	O
).	O

Seedling	O
tissues	O
were	O
harvested	O
at	O
0	O
,	O
1	O
.	O
0	O
,	O
3	O
.	O
0	O
,	O
12	O
.	O
0	O
,	O
24	O
.	O
0	O
and	O
48	O
.	O
0	O
h	O
after	O
treatment	O
(	O
on	O
the	O
dash	O
-	O
dot	O
line	O
at	O
the	O
left	O
).	O

After	O
treatment	O
for	O
48	O
h	O
,	O
the	O
deficient	O
/	O
sufficient	O
Pi	O
-	O
treated	O
seedlings	O
were	O
transferred	O
to	O
sufficient	O
/	O
deficient	O
Pi	O
in	O
Hoagland	O
solution	O
,	O
respectively	O
.	O

Seedling	O
tissues	O
were	O
sampled	O
at	O
0	O
,	O
1	O
.	O
0	O
and	O
3	O
.	O
0	O
h	O
after	O
changing	O
the	O
nutrient	O
solution	O
(	O
on	O
the	O
dash	O
-	O
dot	O
line	O
at	O
the	O
right	O
).	O

Leaf	O
,	O
A	O
and	O
B	O
,	O
G	O
and	O
H	O
;	O
stem	O
,	O
C	O
and	O
D	O
,	O
I	O
and	O
J	O
;	O
and	O
root	O
,	O
E	O
and	O
F	O
,	O
K	O
and	O
L	O
.	O

Discussion	O

GmPT1	B-GP
and	O
GmPT2	B-GP
are	O
members	O
of	O
the	O
Pht1	B-GP
family	O

Our	O
studies	O
provide	O
the	O
first	O
insights	O
into	O
the	O
molecular	O
nature	O
of	O
the	O
proteins	O
involved	O
in	O
phosphate	O
transport	O
in	O
the	O
soybean	B-OG
and	O
reveal	O
that	O
soybean	B-OG
has	O
phosphate	B-GP
transporters	I-GP
with	O
sequence	O
similarity	O
to	O
proton	B-GP
-	I-GP
coupled	I-GP
symporters	I-GP
from	O
a	O
large	O
number	O
of	O
plants	B-OG
and	O
fungi	B-OG
.	O

These	O
transporters	B-GP
belong	O
to	O
the	O
phosphate	B-GP
:	I-GP
H	I-GP
+	I-GP
symporter	I-GP
(	O
PHS	B-GP
)	I-GP
transporter	I-GP
family	O
of	O
the	O
major	O
facilitator	O
superfamily	O
[	O
39	O
].	O

Phylogenetically	O
,	O
the	O
Pi	B-GP
transporters	I-GP
in	O
plants	B-OG
and	O
fungi	B-OG
belong	O
to	O
a	O
closely	O
related	O
family	O
,	O
even	O
though	O
the	O
similarity	O
between	O
the	O
plant	B-OG
transporters	O
is	O
significantly	O
higher	O
than	O
that	O
between	O
plants	B-OG
and	O
fungi	B-OG
transporters	O
[	O
14	O
].	O

These	O
genes	O
have	O
been	O
grouped	O
into	O
the	O
Pht1	B-GP
family	O
of	O
proton	B-GP
–	I-GP
Pi	I-GP
cotransporters	I-GP
[	O
40	O
],	O
which	O
are	O
energized	O
by	O
the	O
plasma	O
membrane	O
proton	B-GP
ATPase	I-GP
[	O
4	O
].	O

In	O
addition	O
,	O
at	O
least	O
one	O
phosphorylation	O
site	O
and	O
one	O
N	O
-	O
glycosylation	O
site	O
among	O
the	O
potential	O
protein	O
modification	O
sites	O
are	O
completely	O
conserved	O
in	O
all	O
plant	B-OG
transporters	O
[	O
14	O
],	O
[	O
15	O
],	O
[	O
26	O
],	O
[	O
33	O
].	O

GmPT1	B-GP
and	O
GmPT2	B-GP
are	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP

The	O
results	O
of	O
uptake	O
and	O
kinetic	O
studies	O
led	O
us	O
to	O
conclude	O
that	O
both	O
GmPT1	B-GP
and	O
GmPT2	B-GP
probably	O
have	O
a	O
low	O
affinity	O
for	O
Pi	O
at	O
millimolar	O
concentrations	O
,	O
similar	O
to	O
the	O
endogenous	O
yeast	B-OG
low	O
-	O
affinity	O
Pi	O
uptake	O
system	O
.	O

It	O
has	O
been	O
reported	O
that	O
Δpho87Δpho89Δpho90Δpho91	O
cells	O
in	O
a	O
wild	O
type	O
strain	O
do	O
not	O
show	O
any	O
significant	O
defect	O
in	O
Pi	O
uptake	O
under	O
high	O
-	O
Pi	O
conditions	O
;	O
meanwhile	O
,	O
the	O
loss	O
of	O
at	O
least	O
one	O
low	O
-	O
affinity	O
Pi	B-GP
transporter	I-GP
could	O
result	O
in	O
an	O
insufficient	O
Pi	O
uptake	O
similar	O
to	O
the	O
case	O
of	O
PHO84	B-GP
inactivation	O
under	O
Pi	O
-	O
limiting	O
conditions	O
[	O
41	O
].	O

These	O
results	O
revealed	O
that	O
the	O
inactivation	O
of	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
does	O
not	O
result	O
in	O
a	O
substantial	O
defect	O
in	O
Pi	O
uptake	O
,	O
even	O
though	O
these	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
Pi	O
uptake	O
.	O

The	O
high	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
are	O
inducible	O
in	O
plants	B-OG
and	O
fungi	B-OG
,	O
whereas	O
the	O
low	O
-	O
affinity	O
transporters	O
are	O
expressed	O
constitutively	O
.	O

The	O
Pht2	B-GP
family	O
in	O
Arabidopsis	B-OG
is	O
considered	O
to	O
be	O
composed	O
of	O
low	O
-	O
affinity	O
proton	O
/	B-GP
Pi	I-GP
symporters	I-GP
,	O
the	O
expression	O
of	O
which	O
is	O
high	O
in	O
shoots	O
and	O
is	O
not	O
altered	O
substantially	O
during	O
Pi	O
starvation	O
.	O

The	O
apparent	O
low	O
-	O
affinity	O
proton	O
/	O
Pi	B-GP
symporters	I-GP
that	O
are	O
highly	O
expressed	O
around	O
vascular	O
bundles	O
suggests	O
that	O
those	O
symporters	O
play	O
a	O
role	O
in	O
loading	O
shoot	O
organs	O
with	O
Pi	O
[	O
40	O
].	O

The	O
profile	O
of	O
a	O
Pi	B-GP
transporter	I-GP

The	O
uptake	O
and	O
distribution	O
of	O
Pi	O
in	O
plants	B-OG
requires	O
multiple	O
Pi	O
transport	O
systems	O
that	O
must	O
function	O
in	O
concert	O
to	O
maintain	O
homeostasis	O
throughout	O
growth	O
and	O
development	O
.	O

Phosphate	O
uptake	O
in	O
plants	B-OG
is	O
an	O
energy	O
-	O
mediated	O
co	O
-	O
transport	O
process	O
driven	O
by	O
a	O
proton	O
gradient	O
generated	O
by	O
plasma	O
membrane	O
H	B-GP
+-	I-GP
ATPases	I-GP
[	O
6	O
],	O
[	O
42	O
],	O
[	O
43	O
],	O
[	O
44	O
].	O

At	O
millimolar	O
concentrations	O
of	O
intracellular	O
Pi	O
,	O
Pi	O
uptake	O
is	O
accomplished	O
by	O
transport	O
of	O
the	O
anion	O
across	O
the	O
membrane	O
coupled	O
to	O
the	O
transport	O
of	O
protons	O
(	O
H	O
+-	O
symport	O
).	O

Therefore	O
,	O
the	O
driving	O
force	O
for	O
Pi	O
influx	O
is	O
the	O
proton	O
gradient	O
generated	O
by	O
the	O
H	B-GP
+-	I-GP
ATPases	I-GP
(	O
Figure	O
8	O
).	O

It	O
has	O
been	O
assumed	O
that	O
plant	B-OG
Pi	B-GP
transporters	I-GP
are	O
proton	O
/	B-GP
Pi	I-GP
co	I-GP
-	I-GP
transporters	I-GP
with	O
a	O
stoichiometry	O
of	O
2	O
–	O
4	O
H	O
+/	O
Pi	O
[	O
2	O
].	O

By	O
complementation	O
of	O
a	O
knock	O
-	O
out	O
of	O
endogenous	O
high	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
of	O
various	O
yeast	B-OG
mutants	O
,	O
or	O
by	O
measuring	O
the	O
increase	O
of	O
Pi	O
uptake	O
in	O
transformed	O
plant	B-OG
cells	O
,	O
several	O
Pi	B-GP
transporters	I-GP
of	O
many	O
plant	B-OG
species	O
have	O
shown	O
common	O
properties	O
,	O
indicating	O
that	O
there	O
is	O
an	O
electrochemical	O
proton	O
gradient	O
across	O
the	O
plasma	O
membrane	O
[	O
6	O
],	O
[	O
20	O
],	O
[	O
26	O
],	O
[	O
27	O
],	O
[	O
30	O
],	O
[	O
31	O
],	O
[	O
45	O
].	O

The	O
Pi	B-GP
transporter	I-GP
mechanism	O
in	O
the	O
plant	B-OG
cell	O
.	O

A	O
membrane	O
-	O
integral	O
proton	B-GP
ATPase	I-GP
undirectionally	O
extrudes	O
protons	O
(	O
H	O
+)	O
at	O
the	O
expense	O
of	O
ATP	O
.	O

The	O
proton	O
concentration	O
gradient	O
and	O
membrane	O
potential	O
generated	O
constitute	O
a	O
proton	O
electrochemical	O
potential	O
(	O
ΔμH	O
)	O
across	O
the	O
membrane	O
.	O

Proton	O
movement	O
along	O
the	O
concentration	O
and	O
electrical	O
gradients	O
facilitates	O
Pi	O
movement	O
by	O
Pi	B-GP
transporters	I-GP
against	O
a	O
steep	O
concentration	O
gradient	O
.	O

Meanwhile	O
,	O
the	O
efflux	O
mechanism	O
helps	O
to	O
maintain	O
Pi	O
homeostasis	O
in	O
the	O
cells	O
.	O

The	O
transport	O
of	O
Pi	O
across	O
plant	B-OG
membranes	O
driven	O
by	O
the	O
proton	O
/	O
Pi	B-GP
co	B-GP
-	I-GP
transporter	I-GP
mechanism	O
is	O
pH	O
dependent	O
.	O

The	O
observed	O
increase	O
of	O
Pi	O
uptake	O
rates	O
in	O
response	O
to	O
decreasing	O
pH	O
is	O
consistent	O
with	O
the	O
operation	O
of	O
a	O
proton	B-GP
/	I-GP
Pi	I-GP
symporter	I-GP
.	O

Our	O
experiments	O
show	O
that	O
the	O
peak	O
of	O
Pi	O
uptake	O
is	O
at	O
pH	O
4	O
.	O
0	O
(	O
Figure	O
5	O
),	O
which	O
reflects	O
the	O
fact	O
that	O
the	O
transport	O
mechanism	O
is	O
a	O
proton	O
/	O
Pi	O
symport	O
.	O

The	O
reduced	O
uptake	O
rate	O
(	O
Table	O
1	O
)	O
in	O
the	O
presence	O
of	O
uncouplers	O
of	O
pH	O
gradients	O
across	O
membranes	O
,	O
such	O
as	O
DNP	O
and	O
CCCP	O
,	O
favors	O
the	O
latter	O
interpretation	O
.	O

This	O
view	O
is	O
supported	O
by	O
the	O
finding	O
that	O
addition	O
of	O
glucose	B-CD
before	O
the	O
uptake	O
experiment	O
with	O
radioactive	O
Pi	O
enhances	O
the	O
uptake	O
capacity	O
of	O
transformants	O
.	O

This	O
effect	O
could	O
be	O
caused	O
by	O
an	O
enhanced	O
proton	O
extrusion	O
that	O
might	O
result	O
from	O
preincubation	O
with	O
glucose	B-CD
.	O

We	O
have	O
demonstrated	O
the	O
Pi	O
transport	O
activity	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
,	O
which	O
are	O
low	O
-	O
affinity	O
transporters	B-GP
in	O
soybean	B-OG
,	O
are	O
dependent	O
on	O
the	O
electrochemical	O
gradient	O
of	O
protons	O
as	O
indicated	O
by	O
the	O
pH	O
dependence	O
and	O
the	O
pharmacological	O
assay	O
.	O

Transiently	O
expressed	O
GFP	B-GP
protein	O
fusions	O
provide	O
direct	O
evidence	O
that	O
the	O
two	O
Pi	B-GP
transporters	I-GP
are	O
located	O
in	O
the	O
plasma	O
membrane	O
(	O
Figure	O
4	O
).	O

The	O
results	O
suggested	O
also	O
that	O
the	O
encoded	O
proteins	O
function	O
in	O
the	O
plasma	O
membrane	O
.	O

Low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
play	O
important	O
roles	O
in	O
Pi	O
homeostasis	O
within	O
plants	B-OG

The	O
transport	O
of	O
Pi	O
across	O
membranes	O
is	O
a	O
pivotal	O
step	O
in	O
the	O
regulation	O
of	O
Pi	O
use	O
.	O

Plants	B-OG
require	O
multiple	O
Pi	O
transport	O
systems	O
to	O
facilitate	O
acquisition	O
of	O
Pi	O
from	O
diverse	O
environments	O
and	O
to	O
enable	O
its	O
subsequent	O
transport	O
to	O
all	O
of	O
the	O
cells	O
and	O
subcellular	O
compartments	O
of	O
the	O
plant	B-OG
[	O
8	O
].	O

The	O
low	O
concentration	O
of	O
Pi	O
commonly	O
found	O
in	O
the	O
soil	O
solution	O
[	O
8	O
]	O
has	O
led	O
to	O
the	O
hypothesis	O
that	O
only	O
high	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
can	O
function	O
for	O
the	O
uptake	O
of	O
Pi	O
across	O
the	O
plasma	O
membrane	O
of	O
root	O
epidermal	O
cells	O
,	O
whereas	O
the	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
could	O
be	O
responsible	O
for	O
transport	O
of	O
Pi	O
within	O
the	O
plant	B-OG
[	O
20	O
].	O

Initially	O
,	O
Pi	O
is	O
transported	O
into	O
root	O
epidermal	O
cells	O
and	O
subsequently	O
loaded	O
into	O
the	O
xylem	O
for	O
translocation	O
to	O
the	O
aerial	O
portions	O
of	O
the	O
plant	B-OG
.	O

Under	O
conditions	O
of	O
Pi	O
deficiency	O
,	O
Pi	O
can	O
be	O
retranslocated	O
from	O
shoot	O
tissues	O
to	O
the	O
roots	O
via	O
the	O
phloem	O
[	O
2	O
],	O
[	O
4	O
],	O
[	O
11	O
].	O

Two	O
A	B-OG
.	I-OG
thaliana	I-OG
mutants	O
exhibiting	O
altered	O
phosphate	O
accumulation	O
have	O
been	O
described	O
,	O
among	O
which	O
the	O
pho1	B-GP
mutant	O
is	O
deficient	O
in	O
the	O
translocation	O
of	O
Pi	O
from	O
the	O
roots	O
to	O
the	O
shoots	O
[	O
46	O
],	O
whereas	O
a	O
mutation	O
at	O
the	O
pho2	B-GP
locus	O
resulted	O
in	O
excessive	O
accumulation	O
of	O
Pi	O
in	O
the	O
leaves	O
[	O
47	O
],	O
[	O
48	O
].	O

OsPT2	B-GP
is	O
a	O
low	O
-	O
affinity	O
Pi	B-GP
transporter	I-GP
that	O
is	O
expressed	O
in	O
the	O
root	O
stele	O
and	O
leaf	O
phloem	O
and	O
xylem	O
.	O

On	O
the	O
basis	O
of	O
its	O
tissue	O
-	O
specific	O
expression	O
pattern	O
,	O
OsPT2	B-GP
is	O
assumed	O
to	O
function	O
in	O
translocation	O
of	O
stored	O
Pi	O
in	O
rice	B-OG
[	O
21	O
].	O

Over	O
-	O
expression	O
of	O
OsPT2	B-GP
(	O
PT2	B-GP
(	O
O	O
))	O
in	O
transgenic	O
plants	B-OG
resulted	O
in	O
accumulation	O
of	O
excess	O
shoot	O
Pi	O
and	O
growth	O
retardation	O
similar	O
to	O
that	O
of	O
rice	B-OG
pho2	B-GP
mutants	O
under	O
Pi	O
-	O
sufficient	O
conditions	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
concentration	O
of	O
Pi	O
in	O
either	O
shoot	O
or	O
root	O
between	O
wild	O
type	O
and	O
PT2	O
(	O
O	O
)	O
under	O
Pi	O
-	O
deficient	O
conditions	O
.	O

These	O
results	O
suggest	O
that	O
over	O
-	O
expression	O
of	O
OsPT2	B-GP
increases	O
Pi	O
uptake	O
and	O
translocation	O
of	O
Pi	O
from	O
root	O
to	O
shoot	O
,	O
resulting	O
in	O
the	O
accumulation	O
of	O
excess	O
Pi	O
in	O
shoots	O
under	O
abundant	O
Pi	O
conditions	O
[	O
49	O
].	O

Knock	O
-	O
down	O
of	O
OsPT2	B-GP
transgenic	O
line	O
r2	O
-	O
1	O
have	O
shown	O
that	O
the	O
concentration	O
of	O
Pi	O
in	O
the	O
shoot	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
wild	O
type	O
[	O
21	O
];	O
therefore	O
,	O
OsPT2	B-GP
is	O
responsible	O
for	O
translocation	O
of	O
the	O
stored	O
Pi	O
in	O
the	O
plant	B-OG
.	O

When	O
the	O
supply	O
of	O
Pi	O
is	O
limited	O
,	O
plants	B-OG
grow	O
more	O
roots	O
,	O
increase	O
the	O
rate	O
of	O
Pi	O
uptake	O
by	O
roots	O
from	O
soil	O
solution	O
,	O
retranslocate	O
Pi	O
from	O
older	O
leaves	O
,	O
and	O
deplete	O
the	O
vacuolar	O
stores	O
of	O
Pi	O
.	O

There	O
is	O
also	O
significant	O
retranslocation	O
of	O
Pi	O
in	O
the	O
phloem	O
from	O
older	O
leaves	O
to	O
the	O
growing	O
shoot	O
and	O
from	O
the	O
shoot	O
to	O
the	O
root	O
.	O

In	O
Pi	O
-	O
deficient	O
plants	B-OG
,	O
the	O
restricted	O
supply	O
of	O
Pi	O
to	O
the	O
shoots	O
from	O
the	O
roots	O
via	O
the	O
xylem	O
is	O
supplemented	O
by	O
increased	O
mobilization	O
of	O
stored	O
P	O
in	O
the	O
older	O
leaves	O
and	O
retranslocation	O
to	O
both	O
the	O
younger	O
leaves	O
and	O
growing	O
roots	O
.	O

This	O
process	O
involves	O
both	O
the	O
depletion	O
of	O
Pi	O
stores	O
and	O
the	O
breakdown	O
of	O
organic	O
P	O
in	O
the	O
older	O
leaves	O
.	O

A	O
curious	O
feature	O
of	O
Pi	O
-	O
starved	O
plants	B-OG
is	O
that	O
approximately	O
one	O
-	O
half	O
of	O
the	O
Pi	O
translocated	O
from	O
the	O
shoot	O
to	O
the	O
root	O
in	O
the	O
phloem	O
is	O
then	O
transferred	O
to	O
the	O
xylem	O
and	O
recycled	O
back	O
to	O
the	O
shoot	O
[	O
4	O
].	O

Low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
in	O
the	O
Pht1	B-GP
family	O
are	O
now	O
thought	O
to	O
play	O
this	O
role	O
in	O
translocation	O
of	O
Pi	O
within	O
the	O
plant	B-OG
,	O
and	O
this	O
has	O
been	O
inferred	O
from	O
the	O
spatial	O
expression	O
of	O
these	O
genes	O
in	O
several	O
different	O
plant	B-OG
species	O
[	O
7	O
],	O
[	O
30	O
],	O
[	O
49	O
],	O
[	O
50	O
].	O

In	O
conclusion	O
,	O
low	O
-	O
affinity	O
Pi	B-GP
transporters	I-GP
play	O
important	O
roles	O
in	O
Pi	O
homeostasis	O
within	O
plants	B-OG
.	O

Prospects	O

Under	O
conditions	O
of	O
Pi	O
starvation	O
,	O
soybean	B-OG
can	O
display	O
its	O
unique	O
strategies	O
to	O
improve	O
its	O
acquisition	O
and	O
remobilization	O
of	O
Pi	O
.	O

In	O
addition	O
,	O
the	O
physiological	O
and	O
molecular	O
processes	O
in	O
soybean	B-OG
under	O
conditions	O
of	O
Pi	O
deficiency	O
appear	O
more	O
complex	O
.	O

Therefore	O
,	O
a	O
global	O
survey	O
of	O
Pi	B-GP
transporter	I-GP
expression	O
in	O
response	O
to	O
Pi	O
starvation	O
is	O
necessary	O
to	O
understand	O
the	O
network	O
of	O
gene	O
expression	O
related	O
to	O
Pi	O
acquisition	O
,	O
translocation	O
,	O
recycling	O
and	O
signal	O
transduction	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
temporal	O
and	O
spatial	O
expression	O
patterns	O
of	O
Pi	B-GP
transporters	I-GP
from	O
soybean	B-OG
seedlings	O
subjected	O
to	O
Pi	O
starvation	O
.	O

A	O
BLAST	O
search	O
of	O
the	O
soybean	B-OG
genome	O
,	O
combined	O
with	O
cDNA	O
cloning	O
,	O
showed	O
that	O
soybean	B-OG
possibly	O
contains	O
nine	O
Pi	B-GP
transporter	I-GP
genes	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
expression	O
levels	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
,	O
but	O
there	O
could	O
be	O
other	O
Pi	B-GP
transporters	I-GP
in	O
soybean	B-OG
,	O
which	O
raises	O
the	O
question	O
of	O
whether	O
other	O
Pi	B-GP
transporters	I-GP
can	O
affect	O
Pi	O
acquisition	O
,	O
translocation	O
and	O
remobilization	O
and	O
what	O
is	O
the	O
relative	O
contribution	O
of	O
these	O
genes	O
to	O
overall	O
Pi	B-GP
transporter	I-GP
function	O
in	O
plants	B-OG
?	O

Multiple	O
Pi	B-GP
transporter	I-GP
genes	O
could	O
result	O
in	O
finer	O
control	O
over	O
protein	O
expression	O
;	O
if	O
so	O
,	O
how	O
does	O
each	O
of	O
these	O
genes	O
respond	O
to	O
deficiency	O
of	O
Pi	O
stress	O
?	O

Future	O
studies	O
of	O
the	O
expression	O
of	O
all	O
soybean	B-OG
Pi	B-GP
transporters	I-GP
in	O
response	O
to	O
different	O
concentrations	O
of	O
Pi	O
could	O
address	O
these	O
questions	O
,	O
providing	O
better	O
understanding	O
of	O
the	O
function	O
of	O
Pi	B-GP
transporter	I-GP
genes	O
in	O
soybean	B-OG
.	O

Materials	O
and	O
Methods	O

Plant	B-OG
material	O
and	O
growth	O
conditions	O

Surface	O
-	O
sterilized	O
soybean	B-OG
seeds	O
(	O
G	B-OG
.	I-OG
max	I-OG
cv	O
.	O

gantai	O
)	O
were	O
sown	O
in	O
sterile	O
,	O
acid	O
-	O
washed	O
quartz	O
sand	O
irrigated	O
with	O
0	O
.	O
5	O
×	O
Hoagland	O
solution	O
containing	O
5	O
µM	O
Pi	O
.	O

The	O
seedings	O
were	O
maintained	O
in	O
a	O
growth	O
chamber	O
with	O
70	O
%	O
relative	O
humidity	O
and	O
a	O
cycle	O
of	O
16	O
h	O
light	O
at	O
29	O
°	O
C	O
/	O
8	O
h	O
dark	O
at	O
23	O
°	O
C	O
.	O

After	O
7	O
days	O
,	O
fresh	O
roots	O
were	O
harvested	O
for	O
gene	O
cloning	O
.	O

At	O
the	O
same	O
time	O
,	O
whole	O
plants	B-OG
were	O
transferred	O
to	O
0	O
.	O
5	O
×	O
Hoagland	O
solution	O
for	O
a	O
Pi	B-DS
-	O
deficiency	O
time	O
-	O
course	O
experiment	O
.	O

For	O
the	O
experiment	O
,	O
7	O
-	O
day	O
-	O
old	O
seedlings	O
were	O
grown	O
by	O
hydroponic	O
culture	O
with	O
0	O
.	O
5	O
×	O
Hoagland	O
solution	O
containing	O
5	O
µM	O
Pi	O
(	O
Pi	O
deficient	O
)	O
or	O
1	O
mM	O
Pi	O
(	O
Pi	O
sufficient	O
),	O
respectively	O
.	O

All	O
seedling	O
tissues	O
were	O
harvested	O
at	O
0	O
,	O
1	O
.	O
0	O
,	O
3	O
.	O
0	O
,	O
12	O
.	O
0	O
,	O
24	O
.	O
0	O
and	O
48	O
.	O
0	O
h	O
after	O
treatment	O
.	O

After	O
Pi	O
deficient	O
/	O
sufficient	O
treatment	O
for	O
48	O
h	O
,	O
the	O
seedlings	O
were	O
transferred	O
to	O
Hoagland	O
solution	O
with	O
sufficient	O
/	O
deficient	O
Pi	O
,	O
respectively	O
.	O

Seedling	O
tissues	O
were	O
sampled	O
at	O
0	O
,	O
1	O
.	O
0	O
,	O
and	O
3	O
.	O
0	O
h	O
after	O
transplanting	O
:	O
the	O
time	O
points	O
for	O
sampling	O
were	O
0	O
,	O
1	O
.	O
0	O
,	O
3	O
.	O
0	O
,	O
12	O
.	O
0	O
,	O
24	O
.	O
0	O
,	O
48	O
.	O
0	O
,	O
49	O
.	O
0	O
,	O
51	O
.	O
0	O
and	O
60	O
.	O
0	O
h	O
.	O

Gene	O
Cloning	O

Using	O
the	O
OsPT2	B-GP
nucleotide	B-CD
sequence	O
(	O
accession	O
number	O
AF536962	O
)	O
as	O
the	O
query	O
,	O
a	O
BALSTN	O
[	O
24	O
]	O
search	O
was	O
done	O
on	O
the	O
web	O
page	O
of	O
the	O
phytozome	O
(	O
http	O
://	O
www	O
.	O
phytozome	O
.	O
net	O
/	O
search	O
.	O
php	O
?	O
show	O
=	O
blast	O
)	O
to	O
identify	O
sequences	O
containing	O
OsPT2	B-GP
orthologs	O
in	O
the	O
soybean	B-OG
genomic	O
database	O
.	O

This	O
resulted	O
in	O
the	O
identification	O
of	O
two	O
cDNA	O
clones	O
designated	O
GmPT1	B-GP
and	O
GmPT2	B-GP
.	O

Two	O
pairs	O
of	O
primers	O
were	O
used	O
for	O
PCR	O
amplification	O
:	O
for	O
GmPT1	O

forward	O
5	O
′-	O
CAGGTAGCTGAGTTAGTGAGTGA	O
-	O
3	O
′	O

reverse	O
5	O
′-	O
CACGTATGATTTAGACAACACTTC	O
-	O
3	O
′	O

for	O
GmPT2	O

forward	O
5	O
′-	O
CAGGTAGCAGAGTTAGTGAGTAAT	O
-	O
3	O
′	O

reverse	O
5	O
′-	O
ACAAGAATGAAATACACACCC	O
-	O
3	O
′	O

Full	O
-	O
length	O
cDNA	O
was	O
amplified	O
from	O
the	O
root	O
cDNA	O
template	O
,	O
using	O
the	O
primers	O
at	O
the	O
end	O
of	O
the	O
cDNA	O
sequence	O
,	O
and	O
then	O
cloned	O
into	O
the	O
pMD	O
-	O
19	O
Simple	O
T	O
vector	O
(	O
Takara	O
)	O
for	O
sequence	O
verification	O
.	O

Sequence	O
Analysis	O

Sequence	O
analysis	O
was	O
done	O
with	O
ANTHEPROT	O
[	O
51	O
],	O
Lasergene	O
version	O
7	O
.	O
0	O
.	O
1	O
and	O
DNAMAN	O
version	O
6	O
.	O
0	O
.	O
3	O
.	O
93	O
software	O
.	O

Transmembrane	O
regions	O
and	O
subcellular	O
localization	O
were	O
predicted	O
by	O
HMMTOP	O
[	O
52	O
]	O
(	O
http	O
://	O
www	O
.	O
enzim	O
.	O
hu	O
/	O
hmmtop	O
/	O
index	O
.	O
html	O
)	O
and	O
the	O
TBpred	O
prediction	O
server	O
[	O
36	O
]	O
(	O
http	O
://	O
www	O
.	O
imtech	O
.	O
res	O
.	O
in	O
/	O
raghava	O
/	O
tbpred	O
/),	O
respectively	O
.	O

We	O
used	O
ScanProsite	O
to	O
scan	O
the	O
protein	O
sequences	O
for	O
the	O
occurrence	O
of	O
patterns	O
stored	O
in	O
the	O
PROSITE	O
database	O
[	O
53	O
].	O

The	O
ScanProsite	O
tools	O
are	O
available	O
on	O
the	O
ExPaSy	O
Molecular	O
Biology	O
of	O
Geneva	O
(	O
Switzerland	O
)	O
website	O
(	O
http	O
://	O
expasy	O
.	O
org	O
/	O
tools	O
/	O
scanprosite	O
/).	O

Multiple	O
sequence	O
alignment	O
was	O
done	O
with	O
ClustalW	O
[	O
54	O
].	O

MEGA	O
4	O
[	O
55	O
]	O
was	O
used	O
for	O
analysis	O
of	O
the	O
phylogenetic	O
relationships	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
and	O
other	O
Pi	B-GP
transporters	I-GP
.	O

The	O
evolutionary	O
history	O
was	O
inferred	O
using	O
the	O
neighbor	O
-	O
joining	O
method	O
.	O

The	O
bootstrap	O
consensus	O
tree	O
inferred	O
from	O
1000	O
replicates	O
was	O
taken	O
to	O
represent	O
the	O
evolutionary	O
history	O
of	O
the	O
taxa	O
analyzed	O
.	O

Branches	O
corresponding	O
to	O
partitions	O
reproduced	O
in	O
less	O
than	O
<	O
60	O
%	O
bootstrap	O
replicates	O
were	O
collapsed	O
.	O

The	O
percentage	O
of	O
replicate	O
trees	O
in	O
which	O
the	O
associated	O
taxa	O
clustered	O
together	O
in	O
the	O
bootstrap	O
test	O
(	O
1000	O
replicates	O
)	O
are	O
shown	O
next	O
to	O
the	O
branches	O
(	O
next	O
to	O
the	O
branches	O
).	O

The	O
evolutionary	O
distances	O
were	O
computed	O
using	O
the	O
Poisson	O
correction	O
method	O
and	O
are	O
in	O
units	O
of	O
the	O
number	O
of	O
amino	B-CD
acid	I-CD
substitutions	O
per	O
site	O
.	O

All	O
positions	O
containing	O
gaps	O
and	O
missing	O
data	O
were	O
eliminated	O
from	O
the	O
dataset	O
(	O
complete	O
deletion	O
option	O
).	O

There	O
are	O
460	O
positions	O
in	O
the	O
final	O
dataset	O
.	O

Subcellular	O
Localization	O

GFP	B-GP
was	O
fused	O
to	O
the	O
3	O
′	O
ends	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
.	O

When	O
expressed	O
in	O
onion	B-OG
epidermal	O
cells	O
,	O
these	O
gene	O
fusions	O
gave	O
rise	O
to	O
Pi	B-GP
transporter	I-GP
::	O
GFP	B-GP
fusion	O
proteins	O
.	O

A	O
PCR	O
-	O
generated	O
Xba	B-GP
I	I-GP
–	O
BamH	B-GP
I	I-GP
fragment	O
containing	O
the	O
open	O
reading	O
frame	O
of	O
GmPT1	B-GP
and	O
the	O
Xba	B-GP
I	I-GP
–	O
Xba	B-GP
I	I-GP
fragment	O
containing	O
the	O
open	O
reading	O
frame	O
of	O
GmPT2	B-GP
were	O
subcloned	O
in	O
-	O
frame	O
upstream	O
of	O
the	O
GFP	B-GP
gene	O
in	O
plasmid	O
pBI	O
-	O
121	O
-	O
GFP	B-GP
.	O

The	O
primers	O
were	O
:	O

for	O
GmPT1	O

forward	O
5	O
′-	O
GCTCTAGAATGGCGGGAGGACAACTAG	O
-	O
3	O
′	O

reverse	O
5	O
′-	O
CGGGATCCAACTGGAACCGTCCTA	O
-	O
3	O
′	O

for	O
GmPT2	O

forward	O
5	O
′-	O
GCT	O
CTAGAATGGCAGGAGGACAACTAG	O
-	O
3	O
′	O

reverse	O
5	O
′-	O
GCT	O
CTAGAAACTGGAACCGTCCTAGC	O
-	O
3	O
′	O

Expression	O
of	O
the	O
gene	O
fusions	O
was	O
controlled	O
by	O
the	O
CaMV35S	O
-	O
promoter	O
.	O

DNA	O
of	O
the	O
chimeric	O
genes	O
CaMV35S	B-GP
-	O
GmPT1	B-GP
and	O
CaMV35S	O
-	O
GmPT2	B-GP
and	O
the	O
pBI	O
-	O
121	O
-	O
GFP	B-GP
empty	O
vector	O
were	O
introduced	O
into	O
onion	O
epidermal	O
cells	O
by	O
a	O
particle	O
bombardment	O
system	O
(	O
Biolistic	O
PDS	O
-	O
1000	O
/	O
He	O
System	O
;	O
BioRad	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Bombarded	O
samples	O
were	O
kept	O
in	O
the	O
dark	O
at	O
room	O
temperature	O
for	O
∼	O
24	O
h	O
and	O
then	O
examined	O
under	O
a	O
Leica	O
TCS	O
SP2	O
confocal	O
microscope	O
.	O

Yeast	B-OG
Manipulations	O
and	O
Pi	O
Uptake	O
Assays	O

The	O
open	O
reading	O
frames	O
of	O
GmPT1	B-GP
and	O
GmPT2	B-GP
were	O
separately	O
subcloned	O
into	O
yeast	B-OG
expression	O
vector	O
p112A1NE	O
[	O
56	O
]	O
to	O
create	O
GmPT1	B-GP
/	O
p112A1NE	O
and	O
GmPT2	B-GP
/	O
p112A1NE	O
,	O
where	O
expression	O
of	O
GmPT1	B-GP
or	O
GmPT2	B-GP
gene	O
was	O
driven	O
by	O
the	O
alcohol	B-GP
dehydrogenase	I-GP
promoter	I-GP
1	I-GP
(	O
ADH1	B-GP
).	O

These	O
constructs	O
were	O
transformed	O
into	O
the	O
yeast	B-OG
mutant	O
MB192	O
(	O
MATa	O
pho3	B-GP
-	I-GP
1	I-GP
Δpho84	O
::	O
HIS3	B-GP
ade2	B-GP
leu2	B-GP
-	I-GP
3	I-GP
,	O
112	O
his3	B-GP
-	O
532	O
trp1	B-GP
-	O
289	O
ura3	B-GP
-	I-GP
1	I-GP
,	O
2	O
can1	B-GP
)	O
[	O
28	O
]	O
as	O
described	O
[	O
57	O
].	O

The	O
yeast	B-OG
cells	O
were	O
grown	O
until	O
the	O
logarithmic	O
phase	O
(	O
when	O
the	O
absorbance	O
at	O
600	O
nm	O
was	O
1	O
.	O
0	O
)	O
on	O
YNB	O
liquid	O
medium	O
(	O
Difco	O
,	O
Chemie	O
Brunschwig	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
),	O
harvested	O
,	O
washed	O
three	O
times	O
with	O
Pi	O
-	O
free	O
medium	O
(	O
YNB	O
medium	O
containing	O
an	O
equimolar	O
concentration	O
of	O
potassium	O
chloride	O
instead	O
of	O
potassium	O
phosphate	O
),	O
then	O
suspended	O
in	O
the	O
same	O
medium	O
and	O
incubated	O
at	O
30	O
°	O
C	O
for	O
10	O
min	O
.	O

Different	O
extracellular	O
pH	O
values	O
in	O
the	O
range	O
4	O
.	O
0	O
–	O
7	O
.	O
0	O
were	O
used	O
for	O
the	O
pH	O
-	O
dependent	O
Pi	O
uptake	O
experiments	O
.	O

Washed	O
and	O
Pi	O
-	O
starved	O
cells	O
were	O
suspended	O
and	O
activated	O
with	O
20	O
%	O
(	O
w	O
/	O
v	O
)	O
glucose	B-CD
to	O
guarantee	O
optimal	O
energization	O
of	O
the	O
plasma	O
membrane	O
to	O
5	O
%.	O

Then	O
1	O
ml	O
of	O
1	O
mM	O
32Pi	O
(	O
final	O
concentration	O
of	O
Pi	O
0	O
.	O
25	O
mM	O
)	O
was	O
added	O
,	O
mixed	O
and	O
the	O
cells	O
were	O
incubated	O
with	O
shaking	O
at	O
30	O
°	O
C	O
for	O
5	O
min	O
.	O

Uptake	O
was	O
stopped	O
by	O
addition	O
of	O
4	O
ml	O
of	O
ice	O
-	O
cold	O
water	O
and	O
the	O
cells	O
were	O
harvested	O
immediately	O
on	O
glass	O
microfiber	O
filters	O
(	O
Whatman	O
®	O
GF	O
/	O
F	O
grade	O
)	O
by	O
vacuum	O
filtration	O
.	O

The	O
filters	O
were	O
washed	O
twice	O
with	O
4	O
ml	O
of	O
ice	O
-	O
cold	O
water	O
then	O
transferred	O
to	O
scintillation	O
vials	O
and	O
radioactivity	O
was	O
measured	O
by	O
a	O
Beckman	O
LS	O
6500	O
Scintillation	O
Counter	O
.	O

Six	O
different	O
concentrations	O
of	O
Pi	O
(	O
2000	O
,	O
1000	O
,	O
500	O
,	O
250	O
,	O
100	O
and	O
50	O
µM	O
)	O
were	O
used	O
to	O
derive	O
the	O
value	O
of	O
K	O
m	O
from	O
the	O
double	O
reciprocal	O
Lineweaver	O
–	O
Burk	O
plot	O
,	O
which	O
is	O
less	O
susceptible	O
to	O
skewing	O
as	O
a	O
consequence	O
of	O
the	O
multiple	O
kinetics	O
components	O
;	O
therefore	O
,	O
K	O
m	O
is	O
an	O
aggregate	O
value	O
reflecting	O
the	O
contribution	O
of	O
many	O
individual	O
kinetic	O
constants	O
[	O
58	O
].	O

For	O
inhibition	O
studies	O
,	O
the	O
reagents	O
given	O
in	O
Table	O
1	O
were	O
added	O
30	O
s	O
before	O
addition	O
of	O
the	O
labeled	O
Pi	O
.	O

Mes	O
(	O
2	O
-(	O
N	O
-	O
morpholino	O
)	O
ethanesulfonic	O
acid	O
)	O
buffer	O
at	O
a	O
final	O
concentration	O
of	O
25	O
mM	O
was	O
used	O
to	O
determine	O
transport	O
activity	O
at	O
different	O
pH	O
values	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O

RNA	O
was	O
extracted	O
from	O
root	O
and	O
shoot	O
samples	O
using	O
TRIzol	O
®	O
reagent	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

RT	O
-	O
PCR	O
for	O
the	O
target	O
genes	O
,	O
GmPT1	B-GP
and	O
GmPT2	O
and	O
cons7	O
(	O
accession	O
number	O
AW310136	O
)	O
[	O
59	O
]	O
using	O
gene	O
-	O
specific	O
primers	O
followed	O
the	O
protocol	O
as	O
described	O
[	O
60	O
].	O

PCR	O
was	O
done	O
in	O
triplicate	O
using	O
a	O
reaction	O
solution	O
containing	O
TaqMan	O
buffer	O
,	O
0	O
.	O
4	O
µM	O
forward	O
and	O
reverse	O
primers	O
and	O
0	O
.	O
3	O
µM	O
probe	O
was	O
done	O
with	O
the	O
ABI	O
7500	O
Fast	O
Real	O
-	O
Time	O
PCR	O
system	O
.	O

(	O
Applied	O
Biosystems	O
).	O

Expression	O
levels	O
were	O
normalized	O
according	O
to	O
cons7	O
and	O
fold	O
change	O
was	O
calculated	O
using	O
the	O
method	O
[	O
61	O
].	O

The	O
following	O
gene	O
-	O
specific	O
primers	O
and	O
probe	O
were	O
used	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
:	O

for	O
GmPT1	O

5	O
′-	O
CTTATGCTTATGGTTCTGTGTTCC	O
-	O
3	O
′,	O

5	O
′-	O
CAGACATAATTGTAGCTGATAGAGG	O
-	O
3	O
′	O

5	O
′-(	O
FAM	O
)	O
CACCACCAATCCCAAAGTCAAGCCA	O
(	O
TAMRA	O
)-	O
3	O
′	O

for	O
GmPT2	O

5	O
′-	O
GGCTTAACTCTTATGCTTATGGTTG	O
-	O
3	O
′,	O

5	O
′-	O
CATGATTGTAGCTGATAGAGGGTAG	O
-	O
3	O
′	O

5	O
′-(	O
FAM	O
)	O
CACCACCAATCCCAAAGCCAAGCCA	O
(	O
TAMRA	O
)-	O
3	O
′	O

for	O
cons7	O

5	O
′-	O
TATAAACCTGGAGGATGCACTAGC	O
-	O
3	O
′	O

5	O
′-	O
GTACATGGGAACCGTCATTCATC	O
-	O
3	O
′	O

5	O
′-(	O
FAM	O
)	O
AACGGAAGCCTCAGAACCACACTTG	O
(	O
TAMRA	O
)-	O
3	O
′	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
diacylglycerol	B-GP
kinase	I-GP
family	O
of	O
proteins	O
and	O
identification	O
of	O
multiple	O
highly	O
-	O
specific	O
conserved	O
inserts	O
and	O
deletions	O
within	O
the	O
catalytic	O
domain	O
that	O
are	O
distinctive	O
characteristics	O
of	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Diacylglycerol	B-GP
kinase	I-GP
(	O
DGK	B-GP
)	O
family	O
of	O
proteins	O
,	O
which	O
phosphorylates	O
diacylglycerol	B-CD
into	O
phosphatidic	B-CD
acid	I-CD
,	O
play	O
important	O
role	O
in	O
controlling	O
diverse	O
cellular	O
processes	O
in	O
eukaryotic	O
organisms	O
.	O

Most	O
vertebrate	B-OG
species	O
contain	O
10	O
different	O
DGK	B-GP
isozymes	O
,	O
which	O
are	O
grouped	O
into	O
5	O
different	O
classes	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
functional	O
domains	O
.	O

However	O
,	O
the	O
relationships	O
among	O
different	O
DGK	B-GP
isozymes	O
or	O
how	O
they	O
have	O
evolved	O
from	O
a	O
common	O
ancestor	O
is	O
unclear	O
.	O

The	O
catalytic	O
domain	O
constitutes	O
the	O
single	O
largest	O
sequence	O
element	O
within	O
the	O
DGK	B-GP
proteins	O
that	O
is	O
commonly	O
and	O
uniquely	O
shared	O
by	O
all	O
family	O
members	O
,	O
but	O
there	O
is	O
limited	O
understanding	O
of	O
the	O
overall	O
function	O
of	O
this	O
domain	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
used	O
the	O
catalytic	O
domain	O
sequences	O
to	O
construct	O
a	O
phylogenetic	O
tree	O
for	O
the	O
DGK	B-GP
family	O
members	O
from	O
representatives	O
of	O
the	O
main	O
vertebrate	B-OG
classes	O
and	O
have	O
also	O
examined	O
the	O
distributions	O
of	O
various	O
DGK	B-GP
isozymes	O
in	O
eukaryotic	O
phyla	O
.	O

In	O
a	O
tree	O
based	O
on	O
catalytic	O
domain	O
sequences	O
,	O
the	O
DGK	B-GP
homologs	O
belonging	O
to	O
different	O
classes	O
formed	O
strongly	O
supported	O
clusters	O
which	O
were	O
separated	O
by	O
long	O
branches	O
,	O
and	O
the	O
different	O
isozymes	O
within	O
each	O
class	O
also	O
generally	O
formed	O
monophyletic	O
groupings	O
.	O

Further	O
,	O
our	O
analysis	O
of	O
the	O
sequence	O
alignments	O
of	O
catalytic	O
domains	O
has	O
identified	O
>	O
10	O
novel	O
sequence	O
signatures	O
consisting	O
of	O
conserved	O
signature	O
indels	O
(	O
inserts	O
or	O
deletions	O
,	O
CSIs	O
)	O
that	O
are	O
distinctive	O
characteristics	O
of	O
either	O
particular	O
classes	O
of	O
DGK	B-GP
isozymes	O
,	O
or	O
are	O
commonly	O
shared	O
by	O
members	O
of	O
two	O
or	O
more	O
classes	O
of	O
DGK	B-GP
isozymes	O
.	O

The	O
conserved	O
indels	O
in	O
protein	O
sequences	O
are	O
known	O
to	O
play	O
important	O
functional	O
roles	O
in	O
the	O
proteins	O
/	O
organisms	O
where	O
they	O
are	O
found	O
.	O

Thus	O
,	O
our	O
identification	O
of	O
multiple	O
highly	O
specific	O
CSIs	O
that	O
are	O
distinguishing	O
characteristics	O
of	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
points	O
to	O
the	O
existence	O
of	O
important	O
differences	O
in	O
the	O
catalytic	O
domain	O
function	O
among	O
the	O
DGK	B-GP
isozymes	O
.	O

The	O
identified	O
CSIs	O
in	O
conjunction	O
with	O
the	O
results	O
of	O
blast	O
searches	O
on	O
species	O
distribution	O
of	O
DGK	B-GP
isozymes	O
also	O
provide	O
useful	O
insights	O
into	O
the	O
evolutionary	O
relationships	O
among	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
.	O

Introduction	O

Diacylglycerol	B-CD
(	O
DAG	O
)	O
and	O
phosphatidic	B-CD
acid	I-CD
(	O
PA	O
)	O
are	O
two	O
main	O
signalling	O
molecules	O
within	O
eukaryotic	O
cells	O
which	O
,	O
through	O
their	O
interactions	O
with	O
different	O
effector	O
proteins	O
,	O
play	O
central	O
roles	O
in	O
regulating	O
diverse	O
cellular	O
processes	O
[	O
1	O
–	O
6	O
].	O

The	O
main	O
source	O
of	O
DAG	O
in	O
cells	O
is	O
via	O
the	O
hydrolysis	O
of	O
phosphoinositides	B-CD
by	O
the	O
enzyme	O
phospholipase	B-GP
C	I-GP
in	O
response	O
to	O
a	O
variety	O
of	O
extracellular	O
stimuli	O
including	O
growth	O
factors	O
and	O
hormones	O
.	O

The	O
DAG	O
produced	O
serves	O
as	O
a	O
substrate	O
for	O
the	O
enzyme	O
DAG	B-GP
kinase	I-GP
(	O
DGK	B-GP
),	O
which	O
phosphorylates	O
it	O
into	O
PA	O
.	O

Due	O
to	O
the	O
ability	O
of	O
DGK	B-GP
to	O
convert	O
one	O
important	O
signalling	O
molecule	O
(	O
DAG	O
)	O
into	O
another	O
(	O
PA	O
),	O
the	O
activity	O
of	O
DGK	B-GP
in	O
different	O
cells	O
is	O
tightly	O
controlled	O
for	O
maintenance	O
of	O
normal	O
physiological	O
conditions	O
[	O
1	O
–	O
6	O
].	O

Because	O
DGK	B-GP
plays	O
an	O
important	O
role	O
in	O
controlling	O
diverse	O
cellular	O
processes	O
including	O
development	O
,	O
cell	O
division	O
and	O
proliferation	O
,	O
neuronal	O
and	O
immune	O
responses	O
,	O
vascular	O
traffic	O
,	O
apoptosis	O
,	O
cytoskeletal	O
reorganization	O
,	O
etc	O
.	O
multiples	O
forms	O
of	O
DGK	B-GP
are	O
generally	O
found	O
in	O
most	O
eukaryotic	O
organisms	O
[	O
1	O
–	O
10	O
].	O

In	O
mammalian	O
species	O
,	O
where	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
has	O
been	O
best	O
studied	O
,	O
10	O
different	O
isozymes	O
of	O
DGK	B-GP
,	O
designated	O
as	O
α	O
,	O
β	O
,	O
γ	O
,	O
δ	O
,	O
ε	O
,	O
ζ	O
,	O
η	O
,	O
θ	O
,	O
ι	O
and	O
κ	O
,	O
differing	O
in	O
their	O
biochemical	O
properties	O
,	O
tissue	O
distributions	O
,	O
as	O
well	O
as	O
their	O
lengths	O
(	O
ranging	O
from	O
567	O
aa	O
to	O
>	O
1150	O
aa	O
)	O
have	O
been	O
identified	O
[	O
1	O
–	O
6	O
,	O
11	O
].	O

Based	O
on	O
sequence	O
similarities	O
between	O
these	O
isozymes	O
and	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
functional	O
domains	O
,	O
the	O
known	O
DGK	B-GP
members	O
have	O
been	O
grouped	O
into	O
5	O
different	O
classes	O
or	O
Types	O
(	O
Fig	O
1	O
)	O
[	O
1	O
–	O
6	O
,	O
11	O
,	O
12	O
].	O

All	O
of	O
these	O
isozymes	O
share	O
in	O
common	O
a	O
large	O
catalytic	O
domain	O
,	O
which	O
is	O
sometimes	O
divided	O
into	O
two	O
parts	O
–	O
catalytic	O
and	O
accessory	O
domains	O
,	O
and	O
2	O
or	O
3	O
cysteine	B-CD
-	O
rich	O
domains	O
,	O
referred	O
to	O
as	O
the	O
C1	O
domains	O
[	O
reviewed	O
in	O
[	O
1	O
–	O
6	O
,	O
12	O
,	O
13	O
]].	O

The	O
simplest	O
and	O
shortest	O
(	O
567	O
aa	O
)	O
of	O
these	O
isozymes	O
is	O
DGK	B-GP
-	I-GP
ε	I-GP
,	O
sole	O
member	O
of	O
the	O
class	O
III	O
DGK	B-GP
,	O
which	O
contains	O
only	O
the	O
commonly	O
shared	O
catalytic	O
domain	O
and	O
the	O
two	O
C1	O
domains	O
.	O

In	O
addition	O
,	O
DGK	B-GP
-	I-GP
ε	I-GP
also	O
contains	O
a	O
conserved	O
helical	O
segment	O
near	O
its	O
N	O
-	O
terminal	O
end	O
that	O
is	O
indicated	O
to	O
play	O
an	O
important	O
role	O
in	O
its	O
membrane	O
interaction	O
[	O
12	O
,	O
13	O
].	O

The	O
class	O
I	O
DGKs	B-GP
(	O
α	O
,	O
β	O
and	O
γ	O
isozymes	O
),	O
in	O
addition	O
to	O
containing	O
the	O
commonly	O
shared	O
domains	O
,	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
two	O
EF	O
-	O
hand	O
motifs	O
and	O
a	O
conserved	O
domain	O
of	O
unknown	O
function	O
near	O
the	O
N	O
-	O
terminal	O
end	O
[	O
1	O
–	O
6	O
,	O
11	O
,	O
12	O
].	O

Novel	O
characteristics	O
of	O
the	O
class	O
II	O
DGK	B-GP
isozymes	O
(	O
δ	O
,	O
η	O
and	O
κ	O
isoforms	O
)	O
include	O
the	O
presence	O
of	O
a	O
plecstrin	B-GP
homology	O
(	O
PH	O
)	O
domain	O
,	O
a	O
sterile	O
α	O
motif	O
(	O
SAM	O
)	O
domain	O
and	O
a	O
large	O
insert	O
within	O
the	O
catalytic	O
domain	O
separating	O
it	O
into	O
two	O
parts	O
.	O

The	O
class	O
IV	O
DGKs	B-GP
(	O
ζ	O
and	O
ι	O
isoforms	O
)	O
are	O
distinguished	O
from	O
the	O
others	O
due	O
to	O
their	O
containing	O
a	O
sequence	O
homologous	O
to	O
the	O
MARCKS	B-GP
phosphorylation	O
site	O
domain	O
and	O
four	O
ankyrin	B-GP
repeats	O
near	O
the	O
C	O
-	O
terminal	O
end	O
.	O

Lastly	O
,	O
DGK	B-GP
-	I-GP
θ	I-GP
is	O
the	O
sole	O
member	O
of	O
the	O
class	O
V	O
DGK	B-GP
and	O
it	O
contains	O
three	O
C1	O
domains	O
,	O
a	O
Gly	O
-	O
Pro	O
rich	O
domain	O
and	O
a	O
PH	O
-	O
domain	O
-	O
like	O
region	O
with	O
overlapping	O
RAS	B-GP
-	O
associating	O
domain	O
[	O
1	O
–	O
6	O
,	O
11	O
].	O

The	O
unique	O
domains	O
present	O
in	O
DGK	B-GP
isozymes	O
,	O
through	O
their	O
interactions	O
with	O
various	O
regulatory	O
proteins	O
and	O
other	O
molecules	O
present	O
in	O
different	O
cells	O
and	O
tissues	O
,	O
play	O
key	O
roles	O
in	O
the	O
diverse	O
physiological	O
functions	O
exhibited	O
by	O
different	O
DGK	B-GP
isozymes	O
[	O
1	O
–	O
6	O
].	O

Sequence	O
characteristics	O
of	O
different	O
forms	O
of	O
DGK	B-GP
isozymes	O
that	O
are	O
found	O
in	O
mammalian	O
/	O
vertebrate	B-OG
species	O
.	O

The	O
ten	O
known	O
isozymes	O
are	O
grouped	O
into	O
five	O
Classes	O
(	O
or	O
Types	O
)	O
and	O
a	O
schematic	O
of	O
the	O
known	O
main	O
functional	O
domains	O
in	O
these	O
isozymes	O
is	O
shown	O
.	O

Abbreviations	O
;	O
PH	O
,	O
plecstrin	B-GP
homology	O
;	O
MARCKS	B-GP
,	O
sequence	O
similar	O
to	O
the	O
MARCKS	B-GP
phosphorylation	O
site	O
;	O
SAM	O
,	O
sterile	O
α	O
motif	O
.	O

The	O
information	O
for	O
the	O
presence	O
of	O
different	O
domains	O
in	O
the	O
DGK	B-GP
isozymesis	O
based	O
on	O
the	O
following	O
reviews	O
[	O
1	O
–	O
6	O
,	O
11	O
,	O
12	O
].	O

Although	O
the	O
differences	O
in	O
the	O
structural	O
characteristics	O
of	O
DGK	B-GP
isozymes	O
and	O
their	O
involvement	O
in	O
diverse	O
cellular	O
functions	O
are	O
widely	O
known	O
[	O
1	O
–	O
6	O
],	O
there	O
is	O
limited	O
(	O
or	O
no	O
)	O
information	O
available	O
at	O
present	O
as	O
to	O
how	O
different	O
DGK	B-GP
isozymes	O
,	O
or	O
the	O
different	O
classes	O
of	O
DGKs	B-GP
,	O
are	O
related	O
to	O
each	O
other	O
,	O
and	O
have	O
possibly	O
evolved	O
from	O
a	O
common	O
ancestor	O
.	O

There	O
is	O
also	O
limited	O
understanding	O
of	O
the	O
distributions	O
of	O
DGK	B-GP
isozymes	O
in	O
eukaryotic	O
organisms	O
other	O
than	O
mammals	B-OG
[	O
3	O
,	O
10	O
,	O
14	O
–	O
16	O
].	O

Knowledge	O
of	O
the	O
species	O
distribution	O
and	O
evolutionary	O
relationships	O
among	O
DGK	B-GP
isozymes	O
can	O
provide	O
useful	O
insights	O
into	O
their	O
physiological	O
functions	O
.	O

Within	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
,	O
the	O
catalytic	O
domain	O
constitutes	O
the	O
single	O
largest	O
sequence	O
element	O
that	O
is	O
commonly	O
and	O
uniquely	O
shared	O
by	O
all	O
of	O
the	O
family	O
members	O
[	O
1	O
–	O
6	O
,	O
11	O
].	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
used	O
the	O
catalytic	O
domain	O
sequences	O
to	O
construct	O
a	O
phylogenetic	O
tree	O
for	O
the	O
DGK	B-GP
family	O
members	O
.	O

Additionally	O
,	O
and	O
more	O
importantly	O
,	O
our	O
analysis	O
of	O
the	O
sequence	O
alignment	O
of	O
the	O
catalytic	O
domain	O
has	O
identified	O
large	O
numbers	O
of	O
novel	O
sequence	O
signatures	O
in	O
the	O
forms	O
of	O
conserved	O
inserts	O
and	O
deletions	O
(	O
indels	O
)	O
that	O
are	O
distinctive	O
of	O
either	O
particular	O
classes	O
of	O
DGK	B-GP
isozymes	O
,	O
or	O
are	O
commonly	O
shared	O
by	O
members	O
of	O
two	O
or	O
more	O
classes	O
of	O
DGK	B-GP
isozymes	O
.	O

These	O
results	O
point	O
to	O
the	O
existence	O
of	O
important	O
differences	O
in	O
the	O
function	O
of	O
catalytic	O
domain	O
for	O
different	O
classes	O
of	O
DGK	B-GP
isozymes	O
and	O
are	O
also	O
useful	O
in	O
understanding	O
the	O
evolutionary	O
relationships	O
among	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
.	O

Methods	O

Phylogenetic	O
tree	O
construction	O
and	O
identification	O
of	O
conserved	O
indels	O
in	O
the	O
catalytic	O
domain	O
sequences	O

The	O
protein	O
sequences	O
of	O
all	O
ten	O
DGK	B-GP
isozymes	O
from	O
representatives	O
of	O
the	O
main	O
vertebrate	B-OG
groups	O
were	O
retrieved	O
from	O
the	O
NCBI	O
nr	O
database	O
.	O

In	O
most	O
cases	O
,	O
sequences	O
were	O
obtained	O
from	O
the	O
following	O
species	O
covering	O
the	O
diversity	O
of	O
the	O
vertebrate	B-OG
phylum	O
:	O
Mammals	B-OG
(	O
Homo	B-OG
sapiens	I-OG
,	O
Rattus	B-OG
novergicus	I-OG
),	O
Birds	B-OG
(	O
Serinus	B-OG
canaria	I-OG
,	O
Sturnus	B-OG
vulgaris	I-OG
),	O
Reptiles	B-OG
(	O
Protobothrops	B-OG
mucrosquamatus	I-OG
,	O
Python	B-OG
bivittatus	I-OG
),	O
Amphibia	B-OG
(	O
Xenopus	B-OG
tropicalis	I-OG
)	O
and	O
Fishes	B-OG
(	O
Pundamilia	B-OG
nyererei	I-OG
,	O
Maylandia	B-OG
zebra	I-OG
).	O

The	O
information	O
for	O
accession	O
numbers	O
and	O
sequence	O
lengths	O
of	O
different	O
DGK	B-GP
homologs	O
that	O
were	O
used	O
for	O
phylogenetic	O
studies	O
is	O
provided	O
in	O
the	O
S1	O
Table	O
.	O

Multiple	O
sequence	O
alignments	O
of	O
different	O
DGK	B-GP
isozymes	O
were	O
created	O
using	O
the	O
Clustal	O
X	O
ver	O
.	O

2	O
.	O
0	O
program	O
[	O
17	O
],	O
and	O
based	O
on	O
these	O
alignments	O
,	O
sequences	O
corresponding	O
to	O
the	O
commonly	O
shared	O
catalytic	O
domain	O
were	O
identified	O
.	O

The	O
large	O
insert	O
present	O
within	O
the	O
catalytic	O
domain	O
(	O
CD	O
)	O
of	O
Type	B-GP
II	O
DGK	B-GP
homologs	O
was	O
excluded	O
from	O
these	O
alignments	O
.	O

The	O
resulting	O
sequences	O
for	O
the	O
DGK	B-GP
CDs	O
were	O
then	O
realigned	O
and	O
,	O
based	O
on	O
these	O
alignments	O
,	O
a	O
segment	O
of	O
364	O
aa	O
was	O
identified	O
that	O
showed	O
good	O
conservation	O
amongst	O
different	O
DGK	B-GP
classes	O
.	O

This	O
sequence	O
alignment	O
,	O
which	O
was	O
used	O
for	O
phylogenetic	O
analysis	O
,	O
is	O
provided	O
in	O
S1	O
Fig	O
.	O

All	O
of	O
the	O
columns	O
with	O
sequence	O
gaps	O
were	O
not	O
considered	O
during	O
tree	O
construction	O
leaving	O
a	O
total	O
of	O
260	O
aligned	O
positions	O
that	O
were	O
used	O
for	O
phylogenetic	O
analysis	O
.	O

The	O
evolutionary	O
history	O
based	O
on	O
this	O
sequence	O
alignment	O
was	O
inferred	O
using	O
the	O
Maximum	O
likelihood	O
(	O
ML	O
)	O
method	O
,	O
with	O
100	O
bootstrap	O
replication	O
,	O
using	O
the	O
MEGA	O
6	O
[	O
18	O
]	O
based	O
on	O
the	O
Jones	O
–	O
Taylor	O
–	O
Thornton	O
(	O
JTT	O
)	O
model	O
[	O
19	O
].	O

The	O
tree	O
with	O
the	O
highest	O
log	O
likelihood	O
(-	O
7845	O
.	O
5131	O
)	O
is	O
shown	O
.	O

The	O
numbers	O
shown	O
on	O
the	O
branches	O
identifies	O
clades	O
in	O
which	O
the	O
associated	O
taxa	O
clustered	O
together	O
>	O
50	O
%	O
time	O
in	O
bootstrap	O
replicates	O
.	O

Sequence	O
alignments	O
of	O
the	O
DGK	B-GP
homologs	O
were	O
also	O
examined	O
for	O
the	O
presence	O
of	O
conserved	O
indels	O
(	O
insertions	O
or	O
deletions	O
)	O
which	O
were	O
flanked	O
on	O
both	O
sides	O
by	O
at	O
least	O
5	O
–	O
6	O
conserved	O
residues	O
in	O
the	O
neighboring	O
30	O
–	O
40	O
amino	B-CD
acids	I-CD
and	O
which	O
appeared	O
to	O
be	O
specifically	O
present	O
in	O
either	O
a	O
particular	O
class	O
of	O
DGK	B-GP
isozymes	O
,	O
or	O
which	O
were	O
shared	O
by	O
the	O
DGK	B-GP
homologs	O
from	O
more	O
one	O
than	O
classes	O
[	O
20	O
–	O
22	O
].	O

For	O
conserved	O
indels	O
meeting	O
these	O
criteria	O
,	O
additional	O
Blastp	O
searches	O
were	O
carried	O
out	O
using	O
the	O
NCBI	O
NR	O
(	O
non	O
-	O
redundant	O
)	O
database	O
to	O
determine	O
the	O
specificity	O
of	O
the	O
indels	O
for	O
the	O
DGK	B-GP
classes	O
of	O
isozymes	O
.	O

These	O
blast	O
results	O
were	O
examined	O
for	O
the	O
presence	O
/	O
absence	O
of	O
the	O
identified	O
CSIs	O
in	O
top	O
500	O
blast	O
hits	O
.	O

SIG_CREATE	O
and	O
SIG_STYLE	O
programs	O
(	O
available	O
on	O
Gleans	O
.	O
net	O
)	O
were	O
used	O
to	O
format	O
and	O
create	O
the	O
signature	O
CSIs	O
files	O
shown	O
here	O
[	O
22	O
,	O
23	O
].	O

Due	O
to	O
space	O
limitations	O
,	O
sequence	O
information	O
for	O
only	O
1	O
–	O
2	O
representative	O
species	O
from	O
each	O
vertebrate	B-OG
group	O
(	O
viz	O
.	O
generally	O
the	O
same	O
as	O
those	O
employed	O
for	O
phylogenetic	O
studies	O
for	O
mammals	B-OG
,	O
birds	B-OG
,	O
fishes	B-OG
,	O
reptiles	B-OG
and	O
amphibians	B-OG
)	O
for	O
different	O
DGK	B-GP
isozymes	O
is	O
shown	O
in	O
the	O
alignment	O
files	O
.	O

However	O
,	O
unless	O
otherwise	O
noted	O
,	O
all	O
of	O
the	O
described	O
CSIs	O
are	O
specifically	O
present	O
in	O
the	O
indicated	O
groups	O
/	O
classes	O
of	O
DGK	B-GP
isozymes	O
,	O
in	O
different	O
vertebrate	B-OG
species	O
,	O
where	O
the	O
distribution	O
of	O
these	O
CSIs	O
was	O
studied	O
in	O
detail	O
.	O

The	O
presence	O
or	O
absence	O
of	O
different	O
DGK	B-GP
isozymes	O
in	O
members	O
from	O
different	O
kingdoms	O
and	O
main	O
phyla	O
of	O
eukaryotes	B-OG
was	O
assessed	O
by	O
carrying	O
out	O
Blastp	O
searches	O
on	O
sequences	O
of	O
different	O
DGK	B-GP
isozymes	O
from	O
human	B-OG
and	O
mouse	B-OG
species	O
against	O
annotated	O
members	O
of	O
specific	O
kingdoms	O
or	O
phyla	O
present	O
in	O
the	O
NCBI	O
nr	O
database	O
.	O

These	O
searches	O
were	O
carried	O
out	O
using	O
the	O
entire	O
sequences	O
of	O
the	O
DGK	B-GP
isozymes	O
as	O
well	O
as	O
utilizing	O
sequences	O
fonly	O
the	O
catalytic	O
domain	O
sequence	O
.	O

Based	O
on	O
significant	O
hits	O
observed	O
in	O
these	O
Blast	O
searches	O
,	O
and	O
to	O
which	O
DGK	B-GP
isozymes	O
the	O
observed	O
hits	O
exhibited	O
maximal	O
similarity	O
,	O
tentative	O
inferences	O
regarding	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
DGK	B-GP
isozymes	O
in	O
deeper	O
branching	O
eukaryotic	O
taxa	O
were	O
made	O
.	O

Results	O

Phylogenetic	O
analysis	O
of	O
the	O
DGK	B-GP
isozymes	O
based	O
on	O
catalytic	O
domain	O
sequences	O

The	O
DGK	B-GP
isozymes	O
differ	O
considerably	O
from	O
each	O
other	O
in	O
their	O
sequence	O
lengths	O
and	O
different	O
domains	O
present	O
in	O
them	O
(	O
see	O
introduction	O
and	O
Fig	O
1	O
).	O

Pairwise	O
sequence	O
comparison	O
studies	O
(	O
unpublished	O
)	O
indicate	O
that	O
the	O
overall	O
sequence	O
similarity	O
between	O
members	O
of	O
different	O
classes	O
is	O
in	O
the	O
range	O
of	O
15	O
–	O
30	O
%	O
and	O
much	O
of	O
the	O
observed	O
similarity	O
is	O
seen	O
within	O
the	O
commonly	O
shared	O
catalytic	O
domain	O
.	O

Based	O
on	O
sequence	O
alignments	O
of	O
DGK	B-GP
homologs	O
from	O
representatives	O
of	O
different	O
groups	O
of	O
vertebrates	B-OG
,	O
conserved	O
regions	O
from	O
the	O
catalytic	O
domain	O
which	O
could	O
be	O
properly	O
aligned	O
amongst	O
different	O
DGK	B-GP
classes	O
were	O
identified	O
and	O
these	O
were	O
subjected	O
to	O
phylogenetic	O
analyses	O
.	O

A	O
maximum	O
-	O
likelihood	O
tree	O
based	O
on	O
100	O
bootstrap	O
samples	O
of	O
this	O
sequence	O
region	O
was	O
constructed	O
using	O
the	O
JTT	O
model	O
(	O
see	O
Methods	O
)	O
to	O
infer	O
the	O
evolutionary	O
relationships	O
amongst	O
different	O
DGK	B-GP
homologs	O
.	O

The	O
tree	O
shown	O
in	O
Fig	O
2	O
is	O
based	O
on	O
260	O
aligned	O
positions	O
that	O
were	O
left	O
after	O
removal	O
of	O
all	O
insertions	O
and	O
deletions	O
.	O

In	O
this	O
phylogenetic	O
tree	O
(	O
Fig	O
2	O
),	O
DGK	B-GP
homologs	O
belonging	O
to	O
all	O
five	O
classes	O
or	O
Types	O
formed	O
strongly	O
supported	O
clusters	O
.	O

These	O
clusters	O
were	O
separated	O
by	O
long	O
branches	O
indicating	O
that	O
the	O
DGK	B-GP
sequences	O
for	O
different	O
classes	O
have	O
diverged	O
considerably	O
from	O
each	O
other	O
even	O
within	O
the	O
conserved	O
catalytic	O
domain	O
.	O

Within	O
each	O
DGK	B-GP
class	O
,	O
homologs	O
belonging	O
to	O
different	O
DGK	B-GP
isozymes	O
also	O
generally	O
formed	O
separate	O
clusters	O
,	O
except	O
for	O
the	O
homologs	O
of	O
kappa	O
and	O
zeta	O
isozymes	O
which	O
exhibited	O
polyphyletic	O
branching	O
and	O
were	O
separated	O
into	O
two	O
clusters	O
.	O

The	O
branches	O
separating	O
different	O
DGK	B-GP
isozymes	O
within	O
any	O
given	O
class	O
were	O
generally	O
short	O
indicating	O
that	O
the	O
isozymes	O
within	O
different	O
classes	O
are	O
very	O
similar	O
to	O
each	O
other	O
.	O

Based	O
on	O
the	O
phylogenetic	O
tree	O
,	O
some	O
information	O
regarding	O
relationships	O
among	O
different	O
isozymes	O
within	O
different	O
classes	O
can	O
also	O
be	O
gleaned	O
.	O

In	O
this	O
tree	O
,	O
DGK	B-GP
homologs	O
belonging	O
to	O
the	O
classes	O
I	O
and	O
IV	O
grouped	O
together	O
but	O
there	O
was	O
only	O
weak	O
support	O
(	O
clustered	O
together	O
in	O
51	O
%	O
of	O
bootstrap	O
samples	O
)	O
for	O
this	O
grouping	O
.	O

Within	O
the	O
class	O
I	O
isozymes	O
,	O
the	O
DGK	B-GP
-	I-GP
α	I-GP
homologs	O
formed	O
outgroups	O
relative	O
to	O
a	O
cluster	O
consisting	O
of	O
the	O
DGK	B-GP
-	I-GP
β	I-GP
and	O
DGK	B-GP
-	I-GP
γ	I-GP
homologs	O
,	O
indicating	O
that	O
the	O
sequences	O
from	O
the	O
latter	O
two	O
groups	O
are	O
more	O
closely	O
related	O
.	O

Similarly	O
,	O
within	O
the	O
class	O
II	O
isozymes	O
,	O
a	O
grouping	O
of	O
DGK	B-GP
-	I-GP
δ	I-GP
and	O
DGK	B-GP
-	I-GP
η	I-GP
homologs	O
was	O
supported	O
by	O
the	O
observed	O
bootstrap	O
score	O
,	O
with	O
the	O
DGK	B-GP
-	I-GP
κ	I-GP
sequences	O
forming	O
an	O
outgroup	O
of	O
this	O
cluster	O
.	O

Lastly	O
,	O
in	O
the	O
tree	O
shown	O
in	O
Fig	O
2	O
,	O
which	O
was	O
rooted	O
at	O
midpoint	O
,	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
and	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
formed	O
the	O
most	O
outlying	O
clades	O
.	O

A	O
maximum	O
-	O
likelihood	O
tree	O
for	O
the	O
DGK	B-GP
isozymes	O
from	O
representative	O
vertebrate	B-OG
species	O
based	O
on	O
the	O
conserved	O
regions	O
in	O
catalytic	O
domain	O
.	O

The	O
accession	O
numbers	O
of	O
different	O
sequences	O
which	O
were	O
used	O
for	O
tree	O
construction	O
are	O
shown	O
after	O
the	O
species	O
names	O
.	O

The	O
tree	O
was	O
constructed	O
as	O
described	O
in	O
the	O
Methods	O
section	O
and	O
the	O
branches	O
which	O
were	O
supported	O
by	O
>	O
50	O
%	O
bootstrap	O
scores	O
are	O
marked	O
.	O

The	O
tree	O
shown	O
was	O
rooted	O
at	O
midpoint	O
and	O
drawn	O
to	O
scale	O
,	O
with	O
branch	O
lengths	O
measured	O
in	O
the	O
number	O
of	O
substitutions	O
per	O
site	O
.	O

Different	O
DGK	B-GP
isozymes	O
as	O
well	O
as	O
the	O
five	O
main	O
classes	O
are	O
marked	O
.	O

Conserved	O
signatures	O
indels	O
in	O
the	O
catalytic	O
domain	O
shared	O
by	O
different	O
classes	O
of	O
DGK	B-GP
isozymes	O

In	O
the	O
tree	O
shown	O
in	O
Fig	O
2	O
,	O
while	O
the	O
distinction	O
between	O
different	O
DGK	B-GP
classes	O
was	O
strongly	O
supported	O
,	O
the	O
nodes	O
connecting	O
these	O
classes	O
had	O
low	O
bootstrap	O
scores	O
indicating	O
that	O
the	O
evolutionary	O
relationships	O
among	O
different	O
DGK	B-GP
classes	O
were	O
not	O
reliably	O
resolved	O
.	O

Thus	O
,	O
other	O
molecular	O
sequence	O
based	O
approaches	O
which	O
can	O
provide	O
insights	O
are	O
needed	O
.	O

Conserved	O
signature	O
indels	O
(	O
CSIs	O
)	O
represent	O
an	O
important	O
class	O
of	O
molecular	O
markers	O
that	O
have	O
been	O
used	O
in	O
the	O
past	O
to	O
resolve	O
a	O
number	O
of	O
important	O
evolutionary	O
questions	O
[	O
21	O
,	O
24	O
–	O
27	O
].	O

The	O
CSIs	O
that	O
are	O
useful	O
for	O
evolutionary	O
studies	O
are	O
generally	O
of	O
fixed	O
lengths	O
,	O
present	O
at	O
specific	O
positions	O
iparticular	O
genes	O
/	O
proteins	O
,	O
and	O
they	O
are	O
flanked	O
on	O
both	O
sides	O
by	O
conserved	O
regions	O
to	O
ensure	O
that	O
they	O
constitute	O
reliable	O
characteristics	O
[	O
21	O
,	O
25	O
,	O
27	O
,	O
28	O
].	O

The	O
CSIs	O
in	O
genes	O
/	O
proteins	O
sequences	O
generally	O
result	O
from	O
rare	O
genetic	O
changes	O
and	O
the	O
most	O
parsimonious	O
explanation	O
to	O
account	O
for	O
their	O
shared	O
presence	O
in	O
a	O
given	O
gene	O
or	O
protein	O
from	O
a	O
specific	O
group	O
of	O
species	O
is	O
that	O
the	O
genetic	O
change	O
giving	O
rise	O
to	O
the	O
CSI	O
occurred	O
in	O
a	O
common	O
ancestor	O
of	O
the	O
indicated	O
group	O
and	O
then	O
it	O
was	O
vertically	O
inherited	O
by	O
the	O
other	O
group	O
members	O
[	O
21	O
,	O
22	O
,	O
25	O
,	O
29	O
].	O

Due	O
to	O
the	O
discrete	O
natures	O
of	O
the	O
CSIs	O
and	O
the	O
fact	O
that	O
they	O
are	O
located	O
within	O
conserved	O
regions	O
,	O
their	O
presence	O
or	O
absence	O
in	O
different	O
lineages	O
or	O
proteins	O
is	O
generally	O
not	O
affected	O
by	O
factors	O
such	O
as	O
differences	O
in	O
evolutionary	O
rates	O
among	O
different	O
species	O
,	O
or	O
proteins	O
,	O
and	O
long	O
-	O
branch	O
attraction	O
artefacts	O
[	O
21	O
,	O
24	O
–	O
26	O
].	O

We	O
have	O
examined	O
the	O
sequence	O
alignment	O
of	O
catalytic	O
domains	O
from	O
DGK	B-GP
homologs	O
for	O
the	O
presence	O
of	O
CSIs	O
and	O
these	O
analyses	O
have	O
identified	O
a	O
number	O
of	O
useful	O
CSIs	O
that	O
are	O
specifically	O
shared	O
by	O
particular	O
groups	O
of	O
DGK	B-GP
isozymes	O
.	O

When	O
a	O
conserved	O
indel	O
is	O
present	O
in	O
a	O
given	O
protein	O
,	O
to	O
infer	O
whether	O
the	O
observed	O
indel	O
is	O
an	O
insert	O
or	O
a	O
deletion	O
,	O
information	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indel	O
in	O
the	O
ancestral	O
state	O
of	O
the	O
protein	O
is	O
needed	O
[	O
22	O
].	O

In	O
most	O
cases	O
,	O
such	O
information	O
could	O
be	O
obtained	O
by	O
determining	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indel	O
in	O
species	O
which	O
are	O
ancestral	O
to	O
those	O
containing	O
the	O
indel	O
[	O
25	O
,	O
27	O
,	O
28	O
,	O
30	O
].	O

In	O
some	O
instances	O
,	O
if	O
two	O
proteins	O
have	O
evolved	O
by	O
an	O
ancient	O
gene	O
duplication	O
event	O
,	O
then	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indel	O
in	O
the	O
other	O
protein	O
has	O
also	O
proven	O
useful	O
to	O
infer	O
whether	O
the	O
observed	O
indel	O
is	O
an	O
insert	O
or	O
a	O
deletion	O
[	O
25	O
,	O
30	O
].	O

However	O
,	O
due	O
to	O
the	O
uniqueness	O
of	O
the	O
DGK	B-GP
catalytic	O
domain	O
sequence	O
for	O
the	O
eukaryotic	O
homologs	O
,	O
no	O
suitable	O
outgroup	O
is	O
available	O
for	O
determining	O
the	O
ancestral	O
state	O
of	O
the	O
protein	O
or	O
reliably	O
inferring	O
whether	O
a	O
given	O
CSI	O
represents	O
an	O
insertion	O
within	O
a	O
certain	O
class	O
of	O
DGK	B-GP
homologs	O
or	O
a	O
deletion	O
in	O
the	O
rest	O
of	O
the	O
DGK	B-GP
homologs	O
.	O

Hence	O
,	O
our	O
use	O
of	O
the	O
term	O
insert	O
(	O
s	O
)	O
or	O
deletion	O
(	O
s	O
)	O
to	O
describe	O
the	O
identified	O
CSIs	O
is	O
only	O
in	O
reference	O
to	O
the	O
presence	O
or	O
absence	O
of	O
the	O
same	O
or	O
similar	O
sequence	O
characteristics	O
in	O
other	O
classes	O
of	O
DGK	B-GP
homologs	O
.	O

Additionally	O
,	O
it	O
should	O
also	O
be	O
acknowledged	O
that	O
while	O
the	O
presence	O
or	O
absence	O
of	O
a	O
CSI	O
within	O
a	O
given	O
conserved	O
region	O
can	O
be	O
reliably	O
identified	O
(	O
due	O
to	O
the	O
sequence	O
conservation	O
of	O
flanking	O
regions	O
),	O
it	O
is	O
often	O
difficult	O
to	O
specify	O
the	O
exact	O
location	O
of	O
the	O
CSI	O
within	O
a	O
conserved	O
region	O
.	O

This	O
is	O
especially	O
true	O
when	O
the	O
sequences	O
of	O
different	O
taxa	O
or	O
homologs	O
that	O
are	O
being	O
compared	O
differ	O
considerably	O
from	O
each	O
other	O
and	O
there	O
is	O
no	O
structural	O
information	O
available	O
for	O
the	O
proteins	O
to	O
guide	O
the	O
sequence	O
alignments	O
for	O
correct	O
placement	O
of	O
the	O
CSI	O
.	O

Due	O
to	O
this	O
limitation	O
,	O
the	O
positions	O
of	O
various	O
CSIs	O
in	O
the	O
sequence	O
alignment	O
shown	O
here	O
represent	O
their	O
most	O
likely	O
positions	O
based	O
on	O
our	O
judgement	O
of	O
the	O
sequence	O
conservation	O
of	O
the	O
flanking	O
regions	O
.	O

However	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
in	O
the	O
optimal	O
alignment	O
that	O
could	O
be	O
supported	O
by	O
other	O
data	O
the	O
actual	O
positions	O
of	O
some	O
of	O
these	O
CSIs	O
might	O
be	O
shifted	O
by	O
a	O
few	O
residues	O
either	O
to	O
the	O
left	O
or	O
on	O
the	O
right	O
.	O

Information	O
regarding	O
the	O
characteristics	O
of	O
various	O
CSIs	O
that	O
have	O
been	O
identified	O
by	O
our	O
analysis	O
is	O
provided	O
below	O
.	O

The	O
first	O
of	O
the	O
identified	O
CSIs	O
within	O
the	O
catalytic	O
domain	O
is	O
a	O
16	O
–	O
24	O
aa	O
insert	O
(	O
marked	O
signature	O
❶	O
in	O
Fig	O
3	O
)	O
that	O
is	O
uniquely	O
found	O
in	O
all	O
of	O
the	O
Class	O
I	O
DGK	B-GP
homologs	O
from	O
different	O
species	O
.	O

The	O
observed	O
CSI	O
is	O
present	O
in	O
a	O
conserved	O
region	O
near	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
catalytic	O
domain	O
and	O
its	O
shared	O
presence	O
by	O
all	O
DGK	B-GP
-	I-GP
α	I-GP
,	O
-	O
β	O
and	O
-	O
γ	O
homologs	O
provides	O
further	O
evidence	O
of	O
the	O
close	O
and	O
specific	O
relationship	O
among	O
these	O
isozymes	O
belonging	O
to	O
class	O
I	O
DGKs	B-GP
.	O

For	O
DGK	B-GP
-	I-GP
α	I-GP
and	O
DGK	B-GP
-	I-GP
γ	I-GP
,	O
interesting	O
differences	O
are	O
also	O
seen	O
in	O
the	O
length	O
of	O
this	O
CSI	O
amongst	O
the	O
vertebrate	B-OG
species	O
.	O

For	O
DGK	B-GP
-	I-GP
α	I-GP
,	O
in	O
contrast	O
to	O
the	O
fishes	B-OG
(	O
e	O
.	O
g	O
.	O
Pundamila	B-OG
nyererei	I-OG
and	O
Maylinda	B-OG
zebra	I-OG
),	O
homologs	O
found	O
in	O
mammals	B-OG
(	O
e	O
.	O
g	O
.	O
humans	B-OG
,	O
Rattus	B-OG
novergicus	I-OG
),	O
birds	B-OG
(	O
Serinus	B-OG
canaria	I-OG
)	O
and	O
amphibians	B-OG
(	O
Xenopus	B-OG
tropocalis	I-OG
)	O
are	O
6	O
aa	O
longer	O
,	O
suggesting	O
that	O
an	O
additional	O
insert	O
within	O
the	O
DGK	B-GP
-	I-GP
α	I-GP
likely	O
occurred	O
in	O
a	O
common	O
ancestor	O
of	O
the	O
latter	O
groups	O
of	O
vertebrate	B-OG
species	O
.	O

Similarly	O
,	O
for	O
DGK	B-GP
-	I-GP
γ	I-GP
,	O
the	O
birds	B-OG
and	O
reptiles	B-OG
harbor	O
a	O
longer	O
insert	O
in	O
contrast	O
to	O
that	O
present	O
in	O
mammals	B-OG
.	O

Interestingly	O
,	O
the	O
homologs	O
for	O
DGK	B-GP
-	I-GP
γ	I-GP
were	O
not	O
detected	O
in	O
fishes	B-OG
and	O
amphibian	B-OG
species	O
.	O

In	O
addition	O
to	O
the	O
CSI	O
shown	O
in	O
Fig	O
3	O
,	O
DGK	B-GP
homologs	O
contain	O
one	O
additional	O
2	O
aa	O
conserved	O
insert	O
(	O
marked	O
Sig	O
❷A	O
in	O
Fig	O
4	O
),	O
which	O
is	O
also	O
commonly	O
shared	O
by	O
the	O
class	O
I	O
DGK	B-GP
homologs	O
.	O

In	O
the	O
same	O
position	O
,	O
where	O
this	O
2	O
aa	O
CSI	O
is	O
found	O
in	O
class	O
I	O
homologs	O
,	O
a	O
4	O
aa	O
insert	O
(	O
marked	O
as	O
Sig	O
❷B	O
)	O
is	O
present	O
in	O
the	O
DGK	B-GP
-	I-GP
ί	I-GP
and	O
DGK	B-GP
-	I-GP
ζ	I-GP
homologs	O
(	O
class	O
IV	O
isozymes	O
).	O

These	O
signatures	O
serve	O
to	O
distinguish	O
the	O
Class	O
I	O
and	O
Class	O
IV	O
DGK	B-GP
homologs	O
from	O
all	O
others	O
and	O
the	O
presence	O
of	O
the	O
inserts	O
in	O
the	O
same	O
position	O
only	O
in	O
these	O
two	O
classes	O
of	O
homologs	O
suggests	O
that	O
they	O
may	O
be	O
more	O
closely	O
related	O
to	O
each	O
other	O
than	O
to	O
the	O
other	O
DGK	B-GP
classes	O
.	O

In	O
close	O
proximity	O
of	O
signatures	O
❷A	O
,	O
B	O
,	O
another	O
CSI	O
consisting	O
of	O
2	O
aa	O
deletion	O
(	O
denoted	O
by	O
❸	O
and	O
highlighted	O
in	O
light	O
blue	O
color	O
)	O
is	O
uniquely	O
present	O
in	O
the	O
DGK	B-GP
-	O
θ	O
homologs	O
.	O

Excerpts	O
from	O
the	O
sequence	O
alignment	O
of	O
DGK	B-GP
isozymes	O
showing	O
a	O
conserved	O
insert	O
(	O
marked	O
as	O
Sig	O
❶	O
)	O
within	O
the	O
catalytic	O
domain	O
that	O
is	O
a	O
unique	O
characteristic	O
of	O
the	O
Class	O
I	O
DGK	B-GP
homologs	O
.	O

The	O
insert	O
shown	O
is	O
present	O
in	O
a	O
conserved	O
region	O
as	O
the	O
dashes	O
(-)	O
in	O
the	O
alignment	O
denote	O
identity	O
with	O
the	O
amino	B-CD
acid	I-CD
shown	O
on	O
the	O
top	O
line	O
.	O

Sequence	O
information	O
is	O
shown	O
for	O
only	O
1	O
–	O
2	O
representative	O
species	O
from	O
different	O
main	O
groups	O
within	O
the	O
vertebrates	B-OG
.	O

However	O
,	O
this	O
insert	O
is	O
specific	O
for	O
the	O
Class	B-GP
I	I-GP
DGK	B-GP
homologs	O
from	O
all	O
other	O
vertebrates	B-OG
species	O
examined	O
.	O

The	O
second	O
column	O
shows	O
the	O
Genbank	O
ID	O
numbers	O
of	O
different	O
sequences	O
.	O

The	O
numbers	O
on	O
top	O
of	O
the	O
alignment	O
show	O
the	O
location	O
of	O
the	O
depicted	O
sequence	O
in	O
two	O
reference	O
DGK	O
sequences	O
.	O

The	O
first	O
number	O
outside	O
of	O
the	O
parenthesis	O
indicates	O
the	O
sequence	O
position	O
in	O
the	O
human	B-OG
DGK	B-GP
-	I-GP
γ	I-GP
homolog	O
(	O
accession	O
number	O
NP_001337	O
.	O
2	O
)	O
shown	O
on	O
the	O
first	O
line	O
of	O
the	O
alignment	O
,	O
whereas	O
the	O
numbers	O
within	O
the	O
parenthesis	O
correspond	O
to	O
the	O
location	O
of	O
this	O
sequence	O
in	O
athe	O
reference	O
human	B-OG
DGK	B-GP
-	I-GP
ε	I-GP
homolog	O
(	O
accession	O
number	O
NP_003638	O
).	O

The	O
vertebrate	B-OG
species	O
for	O
which	O
the	O
sequences	O
are	O
shown	O
include	O
the	O
following	O
groups	O
:	O
Mammals	B-OG
—	O
Homo	B-OG
sapiens	I-OG
and	O
Rattus	B-OG
novergicus	I-OG
;	O
Birds	B-OG
—	O
Serinus	B-OG
canaria	I-OG
and	O
Sturnus	B-OG
vulgaris	I-OG
;	O
Reptiles	B-OG
—	O
Protobothrops	B-OG
mucrosquamatus	I-OG
and	O
Python	B-OG
bivittatus	I-OG
;	O
Amphibians	B-OG
—	O
Xenopus	B-OG
tropicalis	I-OG
and	O
Fish	B-OG
—	O
Pundamilia	B-OG
nyererei	I-OG
and	O
Maylandia	B-OG
zebra	I-OG
.	O

Partial	O
sequence	O
alignment	O
of	O
the	O
DGK	B-GP
catalytic	O
domain	O
showing	O
a	O
number	O
of	O
signatures	O
that	O
are	O
specific	O
for	O
different	O
DGK	B-GP
isozymes	O
.	O

In	O
the	O
position	O
marked	O
Sig❷A	O
,	O
B	O
,	O
a	O
2	O
aa	O
insert	O
is	O
specifically	O
present	O
in	O
all	O
class	O
I	O
DGK	B-GP
homologs	O
,	O
whereas	O
in	O
the	O
same	O
position	O
a	O
4	O
aa	O
insert	O
is	O
found	O
in	O
the	O
class	O
II	O
DGK	B-GP
isozymes	O
.	O

Another	O
signature	O
marked	O
❸	O
consists	O
of	O
a	O
2	O
aa	O
deletion	O
that	O
is	O
uniquely	O
present	O
in	O
the	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
.	O

The	O
signatures	O
shown	O
are	O
specific	O
for	O
the	O
indicated	O
DGK	B-GP
isoforms	O
in	O
sequenced	O
vertebrate	B-OG
species	O
.	O

The	O
dashes	O
(-)	O
in	O
the	O
alignment	O
denote	O
identity	O
with	O
the	O
amino	B-CD
acid	I-CD
on	O
the	O
top	O
and	O
the	O
Genbank	O
ID	O
numbers	O
for	O
these	O
sequences	O
are	O
provided	O
in	O
Fig	O
3	O
.	O

Our	O
analysis	O
has	O
also	O
identified	O
another	O
CSI	O
consisting	O
of	O
a	O
1	O
aa	O
deletion	O
in	O
a	O
highly	O
conserved	O
region	O
(	O
denoted	O
as	O
Sig	O
❹	O
in	O
Fig	O
5	O
),	O
which	O
is	O
commonly	O
shared	O
by	O
all	O
of	O
the	O
Class	O
I	O
and	O
Class	O
IV	O
DGK	B-GP
homologs	O
.	O

This	O
CSI	O
,	O
in	O
conjunction	O
with	O
the	O
signatures	O
❷A	O
,	O
B	O
(	O
Fig	O
4	O
)	O
and	O
the	O
grouping	O
together	O
of	O
the	O
members	O
of	O
these	O
two	O
classes	O
in	O
the	O
phylogenetic	O
tree	O
(	O
Fig	O
2	O
),	O
provides	O
evidence	O
that	O
the	O
homologs	O
from	O
these	O
two	O
classes	O
are	O
specifically	O
related	O
to	O
each	O
other	O
.	O

In	O
the	O
proximity	O
of	O
Sig	O
❹	O
,	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
also	O
contain	O
a	O
1	O
aa	O
deletion	O
(	O
marked	O
as	O
Sig	O
❺	O
,	O
shown	O
in	O
light	O
green	O
color	O
).	O

Although	O
,	O
the	O
CSIs	O
❹	O
and	O
❺	O
are	O
placed	O
in	O
different	O
positions	O
in	O
Fig	O
5	O
,	O
due	O
to	O
limited	O
sequence	O
similarity	O
observed	O
for	O
the	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
in	O
the	O
vicinity	O
of	O
this	O
indel	O
,	O
it	O
is	O
possible	O
that	O
the	O
indel	O
in	O
DGK	B-GP
-	I-GP
θ	I-GP
(	O
marked	O
as	O
Sig	O
❺	O
)	O
also	O
occurred	O
in	O
the	O
same	O
position	O
as	O
in	O
the	O
Class	O
I	O
and	O
Class	O
IV	O
DGK	B-GP
isozymes	O
.	O

In	O
that	O
case	O
,	O
the	O
indel	O
marked	O
as	O
❹	O
would	O
be	O
a	O
shared	O
characteristic	O
of	O
the	O
Class	O
I	O
,	O
Class	O
IV	O
and	O
Class	O
V	O
DGK	B-GP
isozymes	O
.	O

Excerpts	O
from	O
the	O
multiple	O
sequence	O
alignment	O
of	O
catalytic	O
domain	O
from	O
DGK	B-GP
isozymes	O
showing	O
a	O
1	O
aa	O
conserved	O
indel	O
(	O
deletion	O
)	O
(	O
marked	O
❹	O
)	O
that	O
is	O
commonly	O
shared	O
by	O
the	O
class	O
I	O
and	O
class	O
IV	O
isozymes	O
.	O

In	O
the	O
proximity	O
of	O
Sig	O
❹	O
,	O
a	O
1	O
aa	O
deletion	O
is	O
also	O
present	O
in	O
the	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
(	O
marked	O
as	O
signature	O
❺	O
).	O

Although	O
these	O
two	O
indels	O
are	O
placed	O
in	O
different	O
positions	O
,	O
the	O
possibility	O
that	O
they	O
have	O
occurred	O
in	O
the	O
same	O
position	O
as	O
❹	O
cannot	O
be	O
excluded	O
.	O

The	O
class	O
II	O
DGK	B-GP
homologs	O
are	O
known	O
to	O
contain	O
a	O
large	O
insert	O
in	O
the	O
middle	O
of	O
the	O
catalytic	O
domain	O
.	O

In	O
the	O
same	O
location	O
,	O
where	O
this	O
large	O
insert	O
is	O
present	O
in	O
the	O
class	O
II	O
homologs	O
,	O
the	O
DGK	B-GP
homologs	O
belonging	O
to	O
other	O
classes	O
are	O
also	O
found	O
to	O
contain	O
smaller	O
CSIs	O
of	O
specific	O
lengths	O
that	O
serve	O
to	O
distinguish	O
them	O
from	O
each	O
other	O
(	O
Fig	O
6	O
).	O

The	O
Class	O
I	O
DGK	B-GP
homologs	O
contain	O
two	O
different	O
CSIs	O
(	O
a	O
5	O
aa	O
deletion	O
and	O
a	O
2	O
aa	O
deletion	O
,	O
denoted	O
as	O
Sig	O
❻	O
)	O
in	O
this	O
region	O
whereas	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
homologs	O
(	O
class	O
III	O
)	O
all	O
have	O
an	O
8	O
aa	O
deletion	O
in	O
this	O
position	O
(	O
marked	O
as	O
Sig	O
❽	O
).	O

The	O
location	O
of	O
the	O
large	O
insert	O
in	O
the	O
Class	O
II	O
DGK	B-GP
homologs	O
is	O
marked	O
by	O
Sig	O
❼	O
.	O

In	O
addition	O
,	O
the	O
DGK	B-GP
-	I-GP
θ	I-GP
and	O
DGK	B-GP
-	I-GP
ί	I-GP
isozymes	O
can	O
also	O
be	O
distinguished	O
from	O
others	O
by	O
the	O
presence	O
of	O
1	O
aa	O
CSIs	O
(	O
deletions	O
)	O
that	O
appear	O
specific	O
for	O
these	O
isoforms	O
.	O

Lastly	O
,	O
two	O
additional	O
CSIs	O
are	O
present	O
in	O
the	O
catalytic	O
domain	O
in	O
the	O
proximity	O
of	O
the	O
predicted	O
ATP	O
-	O
binding	O
site	O
[	O
2	O
,	O
31	O
,	O
32	O
]	O
shown	O
in	O
the	O
sequence	O
alignment	O
in	O
Fig	O
7	O
.	O

One	O
of	O
these	O
CSIs	O
,	O
a	O
2	O
aa	O
insert	O
,	O
is	O
specific	O
for	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
homologs	O
(	O
marked	O
as	O
Sig	O
❾	O
),	O
whereas	O
in	O
a	O
nearby	O
region	O
,	O
both	O
DGK	B-GP
-	O
θ	O
as	O
well	O
as	O
DGK	B-GP
-	O
ε	O
are	O
found	O
to	O
contain	O
CSIs	O
of	O
different	O
lengths	O
in	O
the	O
same	O
position	O
(	O
marked	O
as	O
Sig	O
❿A	O
,	O
B	O
).	O

However	O
,	O
the	O
sequence	O
of	O
the	O
ATP	O
binding	O
motif	O
(	O
G	O
-	O
X	O
-	O
G	O
-	O
X	O
-	O
X	O
-	O
G	O
)	O
is	O
nearly	O
perfectly	O
conserved	O
in	O
all	O
DGK	B-GP
-	O
isozymes	O
in	O
vertebrates	B-OG
,	O
with	O
the	O
exception	O
of	O
DGK	B-GP
-	I-GP
κ	O
isoform	O
,	O
where	O
a	O
Ser	O
is	O
present	O
in	O
place	O
of	O
the	O
last	O
Gly	B-CD
residue	O
in	O
the	O
mammalian	O
homologs	O
.	O

A	O
number	O
of	O
other	O
residues	O
flanking	O
the	O
ATP	O
-	O
binding	O
motif	O
are	O
also	O
either	O
completely	O
or	O
highly	O
conserved	O
in	O
all	O
DGK	B-GP
isozymes	O
.	O

Partial	O
sequence	O
alignment	O
of	O
DGK	B-GP
isozymes	O
showing	O
a	O
region	O
of	O
the	O
catalytic	O
domain	O
where	O
indels	O
of	O
different	O
lengths	O
are	O
present	O
in	O
different	O
DGK	B-GP
isozymes	O
.	O

Signatures	O
marked	O
❻	O
are	O
specific	O
for	O
class	O
I	O
DGKs	B-GP
,	O
the	O
large	O
deletion	O
marked	O
❼	O
is	O
a	O
shared	O
characteristic	O
of	O
class	O
II	O
DGKs	B-GP
and	O
the	O
CSI	O
marked	O
as	O
❽	O
is	O
present	O
in	O
different	O
DGK	B-GP
-	I-GP
θ	I-GP
homologs	O
.	O

Excerpts	O
from	O
the	O
sequence	O
alignment	O
of	O
DGK	B-GP
isozymes	O
showing	O
a	O
number	O
of	O
CSIs	O
that	O
are	O
specific	O
for	O
the	O
DGK	B-GP
-	I-GP
θ	I-GP
and	O
DGK	B-GP
-	I-GP
ε	I-GP
isozymes	O
.	O

The	O
2	O
aa	O
insert	O
marked	O
as	O
Sig❾	O
is	O
only	O
found	O
in	O
DGK	B-GP
-	I-GP
ε	I-GP
homologs	O
,	O
whereas	O
in	O
a	O
nearby	O
region	O
,	O
both	O
DGK	B-GP
-	O
θ	O
as	O
well	O
as	O
DGK	B-GP
-	I-GP
ε	I-GP
are	O
found	O
to	O
contain	O
CSIs	O
of	O
different	O
lengths	O
in	O
the	O
same	O
position	O
(	O
marked	O
as	O
Sig	O
❿A	O
,	O
B	O
).	O

These	O
CSIs	O
are	O
located	O
in	O
the	O
proximity	O
of	O
ATP	O
-	O
binding	O
motif	O
(	O
shown	O
in	O
red	O
),	O
which	O
is	O
conserved	O
in	O
all	O
isozymes	O
.	O

Distribution	O
of	O
DGK	B-GP
isozymes	O
within	O
the	O
domain	O
Eukarya	O

Much	O
of	O
the	O
work	O
on	O
DGK	B-GP
isozymes	O
has	O
been	O
carried	O
out	O
in	O
mammalian	O
systems	O
and	O
is	O
limited	O
to	O
humans	B-OG
and	O
rodent	B-OG
species	O
.	O

In	O
addition	O
,	O
somework	O
has	O
been	O
carried	O
out	O
on	O
documenting	O
and	O
studying	O
the	O
functions	O
of	O
DGK	B-GP
isozymes	O
in	O
other	O
eukaryotic	O
organisms	O
such	O
as	O
Drosophila	B-OG
,	O
nematodes	B-OG
,	O
slime	B-OG
molds	I-OG
and	O
plants	B-OG
[	O
3	O
,	O
6	O
,	O
10	O
,	O
14	O
–	O
16	O
,	O
33	O
–	O
35	O
].	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
all	O
of	O
the	O
different	O
DGK	B-GP
isozymes	O
are	O
present	O
in	O
different	O
vertebrate	B-OG
classes	O
and	O
other	O
deeper	O
branching	O
eukaryotic	O
phyla	O
.	O

To	O
gain	O
insights	O
in	O
these	O
regards	O
,	O
we	O
have	O
examined	O
the	O
species	O
distributions	O
of	O
various	O
DGK	B-GP
isozymes	O
in	O
different	O
eukaryotic	O
kingdoms	O
and	O
phyla	O
.	O

These	O
studies	O
were	O
carried	O
out	O
as	O
described	O
in	O
the	O
Methods	O
section	O
and	O
their	O
results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

The	O
subphylum	O
vertebrata	O
,	O
which	O
encompasses	O
all	O
of	O
the	O
large	O
animal	B-OG
species	O
,	O
contains	O
five	O
main	O
groups	O
:	O
fishes	B-OG
,	O
amphibians	B-OG
,	O
birds	B-OG
,	O
reptiles	B-OG
and	O
mammals	B-OG
.	O

Of	O
the	O
known	O
DGK	B-GP
isozymes	O
,	O
homologs	O
of	O
DGK	B-GP
-	I-GP
α	I-GP
,	O
-	O
β	O
,	O
-	O
δ	O
,	O
-	O
η	O
,	O
-	O
ζ	O
,	O
-	O
θ	O
and	O
-	O
ε	O
were	O
broadly	O
distributed	O
in	O
all	O
major	O
groups	O
within	O
the	O
vertebrates	B-OG
.	O

While	O
homologs	O
of	O
DGK	B-GP
-	I-GP
κ	I-GP
were	O
mainly	O
found	O
in	O
mammals	B-OG
,	O
birds	B-OG
and	O
some	O
fishes	B-OG
and	O
reptiles	B-OG
,	O
homologs	O
of	O
DGK	B-GP
-	I-GP
γ	I-GP
were	O
not	O
detected	O
in	O
fishes	B-OG
and	O
amphibians	B-OG
.	O

In	O
the	O
invertebrate	B-OG
phyla	O
that	O
were	O
examined	O
(	O
viz	O
.	O

Arthropoda	B-OG
,	O
Nematoda	B-OG
,	O
Mollusca	B-OG
and	O
Cnidarians	B-OG
),	O
homologs	O
that	O
were	O
most	O
similar	O
to	O
DGK	B-GP
-	I-GP
ε	I-GP
,	O
DGK	B-GP
-	I-GP
θ	I-GP
,	O
DGK	B-GP
-	I-GP
ζ	I-GP
,	O
DGK	B-GP
-	I-GP
β	I-GP
and	O
DGK	B-GP
-	I-GP
δ	I-GP
were	O
detected	O
in	O
either	O
all	O
or	O
most	O
species	O
from	O
phyla	O
,	O
whereas	O
homologs	O
for	O
the	O
other	O
DGK	B-GP
isozymes	O
were	O
generally	O
not	O
detected	O
or	O
their	O
presence	O
could	O
not	O
be	O
reliably	O
ascertained	O
.	O

In	O
accordance	O
with	O
earlier	O
studies	O
,	O
homologs	O
showing	O
significant	O
similarity	O
to	O
the	O
DGK	B-GP
isozymes	O
were	O
not	O
detected	O
in	O
Fungi	B-OG
[	O
3	O
,	O
4	O
,	O
6	O
],	O
but	O
in	O
plants	B-OG
,	O
homologs	O
that	O
were	O
most	O
similar	O
to	O
the	O
β	O
-	O
and	O
γ	O
-	O
isozymes	O
were	O
detected	O
[	O
3	O
,	O
10	O
].	O

Blast	O
searches	O
were	O
also	O
carried	O
out	O
against	O
members	O
of	O
a	O
number	O
of	O
protists	B-OG
phyla	O
(	O
viz	O
.	O

Plasmodium	B-OG
,	O
Euglenezoa	B-OG
,	O
Amoebozoa	B-OG
),	O
which	O
form	O
the	O
deepest	O
branching	O
lineages	O
within	O
the	O
eukaryotes	B-OG
.	O

Except	O
for	O
an	O
isolated	O
hit	O
showing	O
limited	O
similarity	O
to	O
these	O
proteins	O
,	O
the	O
presence	O
of	O
DGK	B-GP
-	I-GP
isozymes	I-GP
in	O
these	O
species	O
could	O
not	O
be	O
reliably	O
ascertained	O
.	O

Distribution	O
of	O
different	O
DGK	B-GP
isozymes	O
in	O
the	O
main	O
phyla	O
of	O
vertebrates	B-OG
and	O
other	O
eukaryotes	B-OG
.	O

Eukaryotic	O
Groups	O

DAG	B-GP
kinase	I-GP
isoforms	O

α	O

β	O

γ	O

δ	O

η	O

κ	O

ι	O

ζ	O

ε	O

θ	O

Mammals	B-OG
(	O
144	O
)	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

Amphibians	O
(	O
1	O
)	O

+	O

+	O

-	O

+	O

+	O

-	O

+	O

+	O

+	O

+	O

Birds	B-OG
(	O
61	O
)	O

-	O
3	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

+	O

Reptiles	O
(	O
11	O
)	O

+	O

+	O

+	O

+	O

+/-	O

-	O
3	O

+/-	O

+	O

+	O

+	O

Teleost	O
Fishes	O
(	O
35	O
)	O

+	O

+	O

-	O

+	O

+	O

+/-	O

+	O

+	O

+	O

+	O

Plants	B-OG
(	O
81	O
)	O

-	O
1	O

+	O

+	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

Fungi	O
(	O
704	O
)	O

-	O

-	O
3	O

-	O
3	O

-	O

-	O

-	O

-	O

-	O

-	O

-	O

Plasmodium	B-OG
(	O
45	O
)	O

-	O
1	O

-	O

+/-	O
2	O

+/-	O
2	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

Amoebozoa	O
(	O
16	O
)	O

-	O
1	O

-	O

+/-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

+/-	O
1	O

-	O
1	O

Nematoda	O
(	O
47	O
)	O

-	O

+	O

-	O

+/-	O
2	O

-	O
1	O

-	O
1	O

+/-	O
2	O

+/-	O
2	O

+	O

+	O

Mollusca	O
(	O
5	O
)	O

-	O

+	O

-	O

+	O

-	O

-	O

-	O

+	O

+	O

+	O

Cnidarians	O
(	O
5	O
)	O

-	O

-	O

-	O
3	O

-	O
3	O

+/-	O

-	O

-	O

+	O

+	O

+	O

Arthropoda	B-OG
(	O
107	O
)	O

-	O
1	O

+/-	O
2	O

-	O
1	O

-	O

+	O

-	O

+/-	O
1	O

+/-	O
2	O

+	O

+	O

Platyhelminthes	B-OG
(	O
7	O
)	O

-	O

-	O

-	O

-	O

-	O

-	O

+	O

+/-	O

-	O

+	O

Euglenozoa	O
(	O
47	O
)	O

+/-	O
2	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

-	O
1	O

+/-	O
1	O

-	O
1	O

The	O
presence	O
or	O
absence	O
of	O
different	O
DGK	B-GP
isoforms	O
in	O
the	O
indicated	O
groups	O
was	O
determined	O
based	O
on	O
blastp	O
searches	O
on	O
the	O
annotated	O
genomes	O
in	O
the	O
NCBI	O
nr	O
database	O
as	O
described	O
in	O
the	O
Methods	O
section	O
.	O

The	O
numbers	O
in	O
parenthesis	O
after	O
the	O
group	O
names	O
indicatedthe	O
numbers	O
of	O
annotated	O
genomes	O
that	O
were	O
present	O
in	O
the	O
NCBI	O
nr	O
database	O
from	O
the	O
given	O
group	O
.	O

(+/-)	O
indicates	O
that	O
only	O
some	O
species	O
may	O
contain	O
the	O
isoform	O
.	O

1No	O
isoform	O
was	O
specified	O
however	O
the	O
top	O
5	O
hits	O
show	O
limited	O
similarity	O
to	O
the	O
indicated	O
isoform	O
.	O

2No	O
isoform	O
was	O
specified	O
however	O
the	O
top	O
5	O
hits	O
are	O
most	O
similar	O
to	O
the	O
indicated	O
isoform	O
.	O

3Limited	O
similarity	O
(	O
less	O
than	O
3	O
hits	O
for	O
the	O
isoform	O
of	O
interest	O
).	O

Discussion	O

Most	O
vertebrate	B-OG
species	O
contain	O
10	O
different	O
DGK	B-GP
isozymes	O
which	O
are	O
grouped	O
into	O
5	O
different	O
classes	O
or	O
types	O
(	O
Fig	O
1	O
).	O

The	O
DGKs	B-GP
from	O
different	O
classes	O
are	O
distinguished	O
from	O
each	O
other	O
by	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
functional	O
domains	O
;	O
however	O
,	O
all	O
of	O
them	O
share	O
a	O
large	O
catalytic	O
domain	O
(	O
CD	O
),	O
as	O
well	O
as	O
two	O
cysteine	B-CD
-	O
rich	O
domains	O
.	O

In	O
the	O
simplest	O
of	O
the	O
DGK	B-GP
isozymes	O
,	O
DGK	B-GP
-	I-GP
ε	I-GP
(	O
sole	O
member	O
of	O
class	O
III	O
DGK	B-GP
),	O
the	O
catalytic	O
domain	O
(>	O
300	O
aa	O
)	O
makes	O
up	O
nearly	O
60	O
%	O
of	O
the	O
entire	O
protein	O
and	O
thus	O
it	O
comprises	O
the	O
single	O
largest	O
sequence	O
element	O
specific	O
for	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
.	O

In	O
contrast	O
,	O
the	O
cysteine	B-CD
-	O
rich	O
C1	O
domains	O
are	O
of	O
short	O
lengths	O
(~	O
50	O
aa	O
),	O
show	O
considerable	O
sequence	O
variation	O
,	O
and	O
they	O
are	O
also	O
present	O
in	O
numerous	O
other	O
proteins	O
including	O
the	O
protein	B-GP
kinase	I-GP
C	I-GP
family	O
of	O
proteins	O
[	O
2	O
–	O
4	O
,	O
12	O
,	O
36	O
].	O

Due	O
to	O
the	O
prominence	O
and	O
uniqueness	O
of	O
the	O
catalytic	O
domain	O
for	O
the	O
DGK	B-GP
family	O
of	O
proteins	O
,	O
analysis	O
of	O
its	O
sequence	O
provides	O
an	O
important	O
resource	O
for	O
gaining	O
an	O
understanding	O
of	O
the	O
evolution	O
of	O
this	O
protein	O
family	O
as	O
well	O
as	O
functional	O
differences	O
among	O
its	O
members	O
.	O

Our	O
analyses	O
of	O
the	O
catalytic	O
domain	O
sequences	O
presented	O
here	O
have	O
identified	O
many	O
novel	O
sequence	O
features	O
that	O
are	O
specific	O
for	O
different	O
types	O
of	O
DGKs	B-GP
and	O
provide	O
useful	O
insights	O
into	O
the	O
evolution	O
of	O
this	O
protein	O
family	O
.	O

In	O
a	O
phylogenetic	O
tree	O
based	O
on	O
CD	O
sequences	O
,	O
DGK	B-GP
homologs	O
belonging	O
to	O
different	O
classes	O
formed	O
strongly	O
supported	O
clusters	O
,	O
which	O
were	O
separated	O
by	O
long	O
branches	O
.	O

The	O
observed	O
results	O
indicate	O
strongly	O
that	O
apart	O
from	O
the	O
other	O
known	O
differences	O
in	O
different	O
types	O
of	O
DGK	B-GP
homologs	O
(	O
see	O
[	O
1	O
–	O
6	O
])	O
their	O
catalytic	O
domain	O
sequences	O
have	O
also	O
diverged	O
considerably	O
from	O
each	O
other	O
and	O
provide	O
clear	O
distinction	O
among	O
different	O
types	O
of	O
DGK	B-GP
homologs	O
.	O

In	O
contrast	O
,	O
the	O
DGK	B-GP
isozymes	O
within	O
each	O
DGK	B-GP
class	O
were	O
tightly	O
clustered	O
in	O
the	O
phylogenetic	O
tree	O
indicating	O
that	O
their	O
catalytic	O
domain	O
sequences	O
are	O
very	O
similar	O
.	O

A	O
major	O
focus	O
of	O
the	O
present	O
work	O
was	O
on	O
identifying	O
novel	O
sequence	O
features	O
within	O
the	O
CD	O
,	O
which	O
are	O
specific	O
for	O
either	O
a	O
particular	O
type	O
of	O
DGK	B-GP
homologs	O
or	O
which	O
are	O
commonly	O
shared	O
by	O
members	O
of	O
different	O
DGK	B-GP
classes	O
.	O

A	O
large	O
number	O
of	O
sequence	O
motifs	O
or	O
signatures	O
,	O
in	O
the	O
forms	O
of	O
CSIs	O
,	O
have	O
been	O
identified	O
in	O
the	O
present	O
work	O
and	O
a	O
summary	O
of	O
the	O
identified	O
CSIs	O
,	O
their	O
DGK	B-GP
class	O
specificity	O
and	O
location	O
within	O
the	O
catalytic	O
domain	O
is	O
provided	O
in	O
Fig	O
8	O
.	O

Locations	O
of	O
the	O
different	O
CSIs	O
in	O
the	O
CD	O
are	O
indicated	O
using	O
the	O
sequence	O
of	O
the	O
human	B-OG
DGK	B-GP
-	I-GP
ε	I-GP
isoform	O
as	O
reference	O
(	O
accession	O
number	O
NP_003638	O
).	O

A	O
summary	O
diagram	O
indicating	O
the	O
locations	O
of	O
the	O
CSIs	O
within	O
the	O
catalytic	O
domain	O
that	O
are	O
specific	O
for	O
different	O
DGK	B-GP
classes	O
.	O

The	O
locations	O
of	O
the	O
CSIs	O
are	O
marked	O
using	O
the	O
catalytic	O
domain	O
sequence	O
for	O
the	O
human	B-OG
DGK	B-GP
-	I-GP
ε	I-GP
isoform	O
(	O
accession	O
number	O
NP_003638	O
)	O
as	O
reference	O
.	O

As	O
seen	O
from	O
Fig	O
8	O
,	O
DGK	B-GP
homologs	O
of	O
all	O
five	O
classes	O
can	O
be	O
clearly	O
distinguished	O
from	O
each	O
other	O
by	O
the	O
presence	O
of	O
specific	O
CSIs	O
that	O
are	O
uniquely	O
found	O
in	O
them	O
.	O

For	O
class	O
I	O
,	O
class	O
III	O
,	O
class	O
IV	O
and	O
class	O
V	O
DGK	B-GP
homologs	O
,	O
multiple	O
CSIs	O
specific	O
for	O
these	O
groups	O
were	O
identified	O
.	O

The	O
described	O
signatures	O
are	O
uniquely	O
present	O
in	O
all	O
members	O
of	O
the	O
indicated	O
classes	O
from	O
vertebrate	B-OG
species	O
(	O
the	O
main	O
focus	O
of	O
the	O
present	O
work	O
)	O
indicating	O
that	O
the	O
genetic	O
changes	O
responsible	O
for	O
these	O
CSIs	O
first	O
occurred	O
in	O
the	O
ancestors	O
of	O
specific	O
DGK	B-GP
isoforms	O
,	O
and	O
they	O
were	O
then	O
retained	O
in	O
the	O
descendent	O
species	O
.	O

Further	O
,	O
according	O
to	O
the	O
definition	O
of	O
the	O
CSI	O
(	O
s	O
)	O
used	O
in	O
our	O
work	O
,	O
the	O
large	O
insert	O
(>	O
300	O
aa	O
)	O
within	O
the	O
class	O
II	O
DGK	B-GP
members	O
[	O
2	O
–	O
6	O
,	O
12	O
],	O
also	O
represents	O
a	O
CSI	O
(	O
marked	O
as	O
Sig	O
❼	O
)	O
specific	O
for	O
the	O
class	O
II	O
DGK	B-GP
homologs	O
.	O

The	O
sequence	O
region	O
in	O
the	O
CD	O
where	O
this	O
large	O
CSI	O
is	O
found	O
in	O
class	O
II	O
homologs	O
,	O
it	O
is	O
flanked	O
on	O
both	O
sides	O
by	O
several	O
residues	O
that	O
are	O
conserved	O
in	O
all	O
DGK	B-GP
homologs	O
.	O

Within	O
this	O
conserved	O
region	O
,	O
CSIs	O
of	O
specific	O
lengths	O
(	O
Sig	O
❻	O
,	O
❽	O
and	O
❽A	O
)	O
which	O
are	O
distinctive	O
characteristics	O
of	O
the	O
other	O
classes	O
of	O
DGK	B-GP
homologs	O
are	O
also	O
found	O
.	O

Based	O
on	O
the	O
differences	O
in	O
the	O
lengths	O
of	O
the	O
CSIs	O
in	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
,	O
this	O
region	O
is	O
predicted	O
to	O
specify	O
important	O
functional	O
differences	O
in	O
the	O
properties	O
of	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
.	O

Another	O
noteworthy	O
CSI	O
within	O
the	O
CD	O
is	O
a	O
16	O
–	O
24	O
aa	O
insert	O
(	O
Sig	O
❶	O
in	O
Fig	O
3	O
)	O
that	O
is	O
uniquely	O
found	O
in	O
all	O
of	O
the	O
Class	O
I	O
DGK	B-GP
homologs	O
.	O

Some	O
of	O
the	O
identified	O
CSIs	O
were	O
also	O
commonly	O
shared	O
by	O
members	O
from	O
two	O
different	O
DGK	O
types	O
.	O

For	O
example	O
,	O
the	O
CSI	O
in	O
Sig	O
❹	O
(	O
Fig	O
5	O
)	O
is	O
commonly	O
shared	O
by	O
class	O
I	O
and	O
IV	O
,	O
and	O
also	O
possibly	O
class	O
V	O
(	O
Sig	O
❺	O
),	O
DGK	B-GP
homologs	O
.	O

A	O
closer	O
relationship	O
between	O
class	O
I	O
and	O
IV	O
homologs	O
is	O
also	O
suggested	O
by	O
Sig❷A	O
,	O
B	O
,	O
where	O
inserts	O
that	O
are	O
either	O
2	O
aa	O
or	O
4	O
aa	O
long	O
are	O
specifically	O
present	O
in	O
these	O
two	O
classes	O
of	O
DGK	B-GP
homologs	O
and	O
by	O
the	O
observed	O
branching	O
pattern	O
of	O
these	O
homologs	O
in	O
the	O
phylogenetic	O
tree	O
.	O

In	O
another	O
instance	O
(	O
Sig❿A	O
,	O
B	O
),	O
CSIs	O
of	O
different	O
lengths	O
(	O
3	O
aa	O
and	O
4	O
aa	O
)	O
in	O
the	O
same	O
position	O
are	O
a	O
uniquely	O
present	O
in	O
theε	O
-	O
and	O
θ	O
-	O
classes	O
of	O
DGK	B-GP
-	O
homologs	O
.	O

Different	O
lengths	O
of	O
CSIs	O
in	O
the	O
same	O
position	O
in	O
specific	O
classes	O
of	O
DGK	B-GP
homologs	O
can	O
results	O
from	O
several	O
possibilities	O
.	O

First	O
,	O
it	O
is	O
possible	O
that	O
independent	O
genetic	O
changes	O
have	O
occurred	O
in	O
the	O
ancestor	O
(	O
s	O
)	O
of	O
specific	O
DGK	B-GP
classes	O
,	O
giving	O
rise	O
to	O
CSIs	O
of	O
different	O
lengths	O
.	O

However	O
,	O
in	O
some	O
cases	O
such	O
as	O
Sig❷A	O
,	O
B	O
(	O
and	O
also	O
Sig❿A	O
,	O
B	O
),	O
it	O
is	O
also	O
possible	O
that	O
initially	O
a	O
genetic	O
change	O
leading	O
to	O
either	O
2	O
aa	O
or	O
4	O
aa	O
insert	O
occurred	O
in	O
a	O
common	O
ancestor	O
of	O
the	O
class	O
I	O
and	O
IV	O
DGK	B-GP
homologs	O
,	O
and	O
then	O
another	O
insertion	O
or	O
deletion	O
event	O
occurred	O
in	O
the	O
same	O
position	O
in	O
the	O
ancestor	O
of	O
one	O
of	O
these	O
two	O
groups	O
leading	O
to	O
the	O
observed	O
differences	O
in	O
the	O
lengths	O
of	O
the	O
CSIs	O
in	O
these	O
two	O
classes	O
.	O

Although	O
it	O
is	O
difficult	O
to	O
distinguish	O
between	O
these	O
two	O
possibilities	O
,	O
the	O
fact	O
that	O
the	O
class	O
I	O
and	O
class	O
IV	O
DGK	B-GP
homologs	O
also	O
contain	O
another	O
uniquely	O
shared	O
CSI	O
(	O
viz	O
.	O

Sig❹	O
)	O
and	O
they	O
branch	O
together	O
in	O
the	O
phylogenetic	O
tree	O
corroborate	O
the	O
view	O
that	O
the	O
homologs	O
from	O
these	O
two	O
classes	O
are	O
closely	O
related	O
and	O
that	O
the	O
CSI	O
❷A	O
,	O
B	O
initially	O
occurred	O
in	O
a	O
common	O
ancestor	O
of	O
these	O
two	O
classes	O
.	O

There	O
is	O
limited	O
understanding	O
at	O
present	O
concerning	O
the	O
overall	O
function	O
of	O
the	O
catalytic	O
domain	O
for	O
eukaryotic	O
DGKs	B-GP
[	O
1	O
–	O
5	O
,	O
31	O
].	O

Some	O
differences	O
have	O
been	O
recently	O
reported	O
in	O
the	O
activities	O
of	O
different	O
classes	O
of	O
DGKs	B-GP
towards	O
1	O
-	O
monoacylglycerol	O
and	O
2	O
-	O
monoacylglycerol	O
[	O
11	O
].	O

The	O
catalytic	O
domain	O
contains	O
a	O
highly	O
-	O
conserved	O
sequence	O
motif	O
(	O
G	O
-	O
X	O
-	O
G	O
-	O
X	O
-	O
X	O
-	O
G	O
)	O
similar	O
to	O
that	O
present	O
in	O
the	O
ATP	O
-	O
binding	O
sites	O
of	O
other	O
protein	B-GP
kinases	I-GP
[	O
2	O
,	O
31	O
,	O
32	O
].	O

The	O
importance	O
of	O
this	O
motif	O
for	O
the	O
functioning	O
of	O
DGKs	B-GP
has	O
been	O
established	O
by	O
mutational	O
studies	O
[	O
2	O
,	O
31	O
,	O
37	O
].	O

The	O
CDs	O
from	O
DGK	B-GP
-	I-GP
ε	I-GP
,	O
-	O
ζ	O
,	O
and	O
-	O
θ	O
proteins	O
exhibit	O
very	O
little	O
DGK	B-GP
activity	O
when	O
expressed	O
as	O
isolated	O
subunits	O
[	O
2	O
].	O

This	O
and	O
other	O
observations	O
have	O
led	O
to	O
the	O
suggestion	O
that	O
the	O
proper	O
functioning	O
of	O
the	O
CD	O
for	O
mammalian	O
DGKs	B-GP
requires	O
interactions	O
with	O
other	O
motifs	O
(	O
proteins	O
)	O
[	O
1	O
–	O
5	O
,	O
31	O
].	O

However	O
,	O
our	O
knowledge	O
of	O
the	O
sequence	O
motifs	O
in	O
the	O
CD	O
that	O
may	O
facilitate	O
its	O
interactions	O
with	O
other	O
proteins	O
/	O
effectors	O
molecules	O
,	O
and	O
how	O
different	O
DGK	B-GP
isozymes	O
,	O
or	O
classes	O
of	O
isozymes	O
,	O
differ	O
in	O
this	O
regard	O
is	O
very	O
limited	O
.	O

The	O
lack	O
of	O
structural	O
information	O
for	O
the	O
CD	O
for	O
eukaryotic	O
DGKs	B-GP
is	O
also	O
a	O
major	O
hindrance	O
in	O
understanding	O
its	O
function	O
.	O

In	O
this	O
context	O
,	O
our	O
identification	O
of	O
multiples	O
CSIs	O
within	O
the	O
CD	O
that	O
are	O
specific	O
for	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
is	O
of	O
much	O
interest	O
and	O
significance	O
.	O

Based	O
on	O
earlier	O
work	O
,	O
the	O
CSIs	O
in	O
protein	O
sequences	O
are	O
known	O
to	O
play	O
important	O
functional	O
roles	O
in	O
the	O
organisms	O
in	O
which	O
they	O
are	O
found	O
[	O
38	O
–	O
42	O
].	O

The	O
mutational	O
changes	O
in	O
the	O
CSIs	O
affect	O
proper	O
functioning	O
of	O
the	O
proteins	O
as	O
well	O
as	O
cell	O
growth	O
,	O
and	O
both	O
large	O
and	O
small	O
CSIs	O
are	O
indicated	O
to	O
be	O
significant	O
in	O
this	O
regard	O
[	O
38	O
].	O

Further	O
,	O
extensive	O
work	O
on	O
CSIs	O
show	O
that	O
they	O
are	O
generally	O
located	O
in	O
protein	O
structures	O
in	O
surface	O
loops	O
[	O
39	O
,	O
42	O
–	O
45	O
],	O
which	O
are	O
indicated	O
to	O
play	O
important	O
roles	O
in	O
mediating	O
protein	O
-	O
protein	O
interactions	O
[	O
39	O
,	O
44	O
,	O
46	O
–	O
49	O
].	O

Based	O
on	O
these	O
observations	O
,	O
it	O
can	O
be	O
hypothesized	O
(	O
predicted	O
)	O
that	O
the	O
CSIs	O
in	O
the	O
CD	O
that	O
are	O
specific	O
for	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
should	O
also	O
be	O
playing	O
important	O
roles	O
in	O
the	O
interactions	O
of	O
different	O
DGK	B-GP
isozymes	O
with	O
specific	O
proteins	O
(	O
or	O
other	O
target	O
molecules	O
)	O
that	O
may	O
be	O
responsible	O
for	O
the	O
differences	O
in	O
the	O
cellular	O
functions	O
of	O
the	O
different	O
DGK	B-GP
isozymes	O
.	O

Thus	O
,	O
further	O
studies	O
on	O
understanding	O
the	O
cellular	O
functions	O
of	O
the	O
identified	O
CSIs	O
,	O
and	O
the	O
specific	O
interactions	O
that	O
they	O
may	O
be	O
involved	O
in	O
,	O
could	O
provide	O
important	O
insights	O
regarding	O
the	O
biochemical	O
basis	O
of	O
the	O
differences	O
in	O
the	O
functions	O
of	O
different	O
DGK	B-GP
isozymes	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
apart	O
from	O
the	O
CSIs	O
that	O
are	O
specific	O
for	O
different	O
classes	O
of	O
DGKs	B-GP
,	O
sequence	O
alignments	O
shown	O
in	O
Figs	O
2	O
–	O
7	O
and	O
S1	O
Fig	O
also	O
contain	O
large	O
numbers	O
of	O
specific	O
amino	B-CD
acid	I-CD
substitutions	O
(	O
or	O
polymorphisms	O
)	O
that	O
are	O
specific	O
for	O
particular	O
classes	O
of	O
DGK	B-GP
homologs	O
.	O

These	O
sequence	O
polymorphisms	O
constitute	O
another	O
type	O
of	O
molecular	O
signature	O
,	O
which	O
are	O
also	O
expected	O
to	O
be	O
of	O
functional	O
significance	O
[	O
12	O
,	O
38	O
].	O

The	O
DGK	B-GP
family	O
of	O
proteins	O
,	O
due	O
to	O
their	O
key	O
roles	O
in	O
controlling	O
the	O
cellular	O
concentrations	O
of	O
two	O
important	O
signalling	O
molecules	O
and	O
thereby	O
controlling	O
diverse	O
cellular	O
processes	O
,	O
are	O
targets	O
for	O
development	O
of	O
novel	O
therapeutics	O
for	O
treatment	O
of	O
cancer	B-DS
,	O
neuronal	O
,	O
metabolic	O
and	O
inflammatory	B-DS
diseases	I-DS
[	O
9	O
,	O
50	O
–	O
57	O
].	O

In	O
this	O
context	O
,	O
the	O
CSIs	O
identified	O
in	O
the	O
present	O
work	O
,	O
which	O
are	O
specific	O
for	O
different	O
classes	O
of	O
DGK	B-GP
homologs	O
and	O
predicted	O
to	O
play	O
important	O
roles	O
in	O
the	O
cellular	O
functions	O
of	O
these	O
isoforms	O
,	O
thus	O
provide	O
potentially	O
useful	O
drug	O
targets	O
[	O
58	O
].	O

The	O
DGK	B-GP
isozymes	O
are	O
primarily	O
found	O
in	O
eukaryotic	O
organisms	O
.	O

Although	O
a	O
protein	O
exhibiting	O
DGK	B-GP
activity	O
is	O
present	O
in	O
many	O
bacteria	B-OG
[	O
4	O
,	O
5	O
,	O
59	O
,	O
60	O
],	O
it	O
shows	O
minimal	O
similarity	O
(	O
15	O
–	O
18	O
%)	O
over	O
a	O
short	O
length	O
,	O
and	O
with	O
multiple	O
intervening	O
gaps	O
,	O
to	O
the	O
eukaryotic	O
DGKs	B-GP
[	O
13	O
]	O
[	O
61	O
].	O

The	O
bacterial	O
DGK	B-GP
homologs	O
are	O
short	O
in	O
comparison	O
to	O
the	O
eukaryotic	O
proteins	O
and	O
they	O
do	O
not	O
contain	O
any	O
of	O
the	O
canonical	O
sequence	O
features	O
(	O
viz	O
.	O
catalytic	O
domain	O
and	O
cysteine	B-CD
-	O
rich	O
C1	O
domains	O
),	O
which	O
are	O
shared	O
characteristics	O
of	O
all	O
eukaryotic	O
DGK	B-GP
homologs	O
[	O
2	O
,	O
4	O
,	O
5	O
,	O
12	O
,	O
59	O
].	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
bacterial	O
DGK	B-GP
homologs	O
are	O
evolutionarily	O
unrelated	O
to	O
the	O
eukaryotic	O
counterparts	O
,	O
and	O
that	O
the	O
proteins	O
exhibiting	O
DGK	B-GP
activity	O
have	O
evolved	O
independently	O
in	O
bacteria	B-OG
.	O

In	O
view	O
of	O
the	O
importance	O
of	O
DGK	B-GP
isozymes	O
in	O
cellular	O
signalling	O
processes	O
and	O
their	O
involvement	O
in	O
a	O
wide	O
variety	O
of	O
cellular	O
functions	O
,	O
it	O
is	O
of	O
much	O
interest	O
to	O
know	O
how	O
this	O
large	O
family	O
of	O
proteins	O
has	O
evolved	O
.	O

The	O
phylogenetic	O
approach	O
employed	O
in	O
this	O
work	O
was	O
able	O
to	O
clearly	O
distinguish	O
the	O
five	O
different	O
classes	O
of	O
DGKs	B-GP
;	O
however	O
,	O
as	O
the	O
canonical	O
DGK	B-GP
homologs	O
are	O
only	O
found	O
in	O
eukaryotic	O
organisms	O
,	O
it	O
was	O
difficult	O
to	O
root	O
the	O
tree	O
and	O
determine	O
how	O
members	O
of	O
different	O
DGK	B-GP
classes	O
are	O
related	O
to	O
each	O
other	O
and	O
which	O
of	O
these	O
DGK	B-GP
isozymes	O
is	O
ancestral	O
.	O

The	O
CSIs	O
in	O
protein	O
sequences	O
provide	O
another	O
useful	O
means	O
for	O
understanding	O
the	O
evolutionary	O
relationships	O
among	O
distantly	O
related	O
species	O
;	O
however	O
,	O
in	O
the	O
present	O
instance	O
,	O
due	O
to	O
the	O
absence	O
of	O
a	O
suitable	O
outgroup	O
,	O
it	O
was	O
difficult	O
to	O
establish	O
the	O
ancestral	O
state	O
of	O
the	O
DGK	B-GP
protein	O
sequence	O
and	O
reliably	O
infer	O
whether	O
the	O
observed	O
CSIs	O
are	O
insertions	O
or	O
deletions	O
in	O
the	O
indicated	O
classes	O
of	O
DGK	B-GP
homologs	O
.	O

Although	O
the	O
present	O
work	O
does	O
not	O
resolve	O
how	O
different	O
classes	O
of	O
DGK	B-GP
proteins	O
have	O
originated	O
from	O
a	O
common	O
ancestor	O
and	O
which	O
of	O
these	O
isoforms	O
is	O
most	O
ancestral	O
,	O
the	O
results	O
presented	O
here	O
show	O
that	O
of	O
the	O
different	O
classes	O
of	O
DGKs	B-GP
,	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
,	O
-	O
θ	O
and	O
-	O
ζ	O
isoforms	O
are	O
most	O
widely	O
distributed	O
in	O
eukaryotic	O
organisms	O
.	O

In	O
addition	O
to	O
their	O
nearly	O
ubiquitous	O
presence	O
in	O
vertebrate	B-OG
species	O
,	O
the	O
homologs	O
for	O
these	O
isoforms	O
are	O
also	O
indicated	O
to	O
be	O
present	O
in	O
most	O
invertebrate	B-OG
species	O
.	O

In	O
contrast	O
,	O
homologs	O
for	O
the	O
other	O
DGK	B-GP
isozymes	O
were	O
not	O
detected	O
in	O
a	O
number	O
of	O
invertebrate	B-OG
phyla	O
(	O
Table	O
1	O
).	O

Although	O
more	O
detailed	O
studies	O
are	O
needed	O
to	O
establish	O
with	O
certainty	O
the	O
identity	O
of	O
the	O
DGK	B-GP
isoforms	O
that	O
are	O
present	O
in	O
deep	O
branching	O
eukaryotic	O
phyla	O
,	O
the	O
observed	O
broader	O
distribution	O
of	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
,	O
DGK	B-GP
-	I-GP
θ	I-GP
and	O
DGK	B-GP
-	I-GP
ζ	I-GP
isoforms	O
within	O
eukaryotic	O
organisms	O
suggests	O
that	O
one	O
of	O
these	O
isoforms	O
likely	O
represent	O
the	O
ancestral	O
form	O
of	O
the	O
protein	O
.	O

Of	O
these	O
isoforms	O
,	O
DGK	B-GP
-	I-GP
ε	I-GP
represents	O
the	O
most	O
rudimentary	O
form	O
of	O
the	O
protein	O
containing	O
all	O
of	O
the	O
main	O
sequence	O
features	O
that	O
are	O
commonly	O
shared	O
by	O
all	O
other	O
DGK	B-GP
family	O
members	O
.	O

Further	O
,	O
DGK	B-GP
-	I-GP
ε	I-GP
is	O
the	O
only	O
isoform	O
which	O
shows	O
specificity	O
for	O
a	O
particular	O
substrate	O
i	O
.	O
e	O
.	O
arachidonoyl	O
-	O
containing	O
diacylglycerol	B-CD
[	O
2	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
62	O
].	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
the	O
DGK	B-GP
-	I-GP
ε	I-GP
originated	O
first	O
,	O
and	O
all	O
other	O
DGK	B-GP
isoforms	O
originated	O
from	O
it	O
by	O
acquisition	O
of	O
different	O
domains	O
and	O
other	O
identified	O
signatures	O
.	O

However	O
,	O
the	O
present	O
study	O
is	O
based	O
only	O
on	O
the	O
analyses	O
of	O
the	O
catalytic	O
domain	O
sequences	O
and	O
further	O
work	O
on	O
the	O
analyses	O
of	O
other	O
sequence	O
regions	O
of	O
the	O
DGK	B-GP
protein	O
family	O
could	O
provide	O
additional	O
useful	O
information	O
to	O
clarify	O
the	O
relationships	O
among	O
different	O
DGK	B-GP
isoforms	O
.	O

Supporting	O
information	O

Edited	O
multiple	O
sequence	O
alignment	O
of	O
the	O
catalytic	O
domain	O
for	O
different	O
DGK	B-GP
isozymes	O
that	O
was	O
used	O
for	O
phylogenetic	O
tree	O
construction	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Sequence	O
information	O
for	O
different	O
DGK	B-GP
homologs	O
used	O
in	O
phylogenetic	O
studies	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Preferential	O
Enhancement	O
of	O
Sensory	O
and	O
Motor	O
Axon	O
Regeneration	O
by	O
Combining	O
Extracellular	O
Matrix	O
Components	O
with	O
Neurotrophic	O
Factors	O

These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

After	O
peripheral	B-DS
nerve	I-DS
injury	O
,	O
motor	O
and	O
sensory	O
axons	O
are	O
able	O
to	O
regenerate	O
but	O
inaccuracy	O
of	O
target	O
reinnervation	O
leads	O
to	O
poor	O
functional	O
recovery	O
.	O

Extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
and	O
neurotrophic	O
factors	O
(	O
NTFs	O
)	O
exert	O
their	O
effect	O
on	O
different	O
neuronal	O
populations	O
creating	O
a	O
suitable	O
environment	O
to	O
promote	O
axonal	O
growth	O
.	O

Here	O
,	O
we	O
assessed	O
in	O
vitro	O
and	O
in	O
vivo	O
the	O
selective	O
effects	O
of	O
combining	O
different	O
ECM	O
components	O
with	O
NTFs	O
on	O
motor	O
and	O
sensory	O
axons	O
regeneration	O
and	O
target	O
reinnervation	O
.	O

Organotypic	O
cultures	O
with	O
collagen	B-GP
,	O
laminin	B-GP
and	O
nerve	B-GP
growth	I-GP
factor	I-GP
(	O
NGF	B-GP
)/	O
neurotrophin	B-GP
-	I-GP
3	I-GP
(	O
NT3	B-GP
)	O
or	O
collagen	B-GP
,	O
fibronectin	B-GP
and	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
)	O
selectively	O
enhanced	O
sensory	O
neurite	O
outgrowth	O
of	O
DRG	O
neurons	O
and	O
motor	O
neurite	O
outgrowth	O
from	O
spinal	O
cord	O
slices	O
respectively	O
.	O

For	O
in	O
vivo	O
studies	O
,	O
the	O
rat	B-OG
sciatic	O
nerve	O
was	O
transected	O
and	O
repaired	O
with	O
a	O
silicone	O
tube	O
filled	O
with	O
a	O
collagen	B-GP
and	O
laminin	B-GP
matrix	O
with	O
NGF	B-GP
/	O
NT3	B-GP
encapsulated	O
in	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
(	O
PLGA	O
)	O
microspheres	O
(	O
MP	O
)	O
(	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
),	O
or	O
a	O
collagen	B-GP
and	O
fibronectin	B-GP
matrix	O
with	O
BDNF	B-GP
in	O
PLGA	O
MPs	O
(	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
).	O

Retrograde	O
labeling	O
and	O
functional	O
tests	O
showed	O
that	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
increased	O
the	O
number	O
of	O
regenerated	O
sensory	O
neurons	O
and	O
improved	O
sensory	O
functional	O
recovery	O
,	O
whereas	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
preferentially	O
increased	O
regenerated	O
motoneurons	O
and	O
enhanced	O
motor	O
functional	O
recovery	O
.	O

Therefore	O
,	O
combination	O
of	O
ECM	O
molecules	O
with	O
NTFs	O
may	O
be	O
a	O
good	O
approach	O
to	O
selectively	O
enhance	O
motor	O
and	O
sensory	O
axons	O
regeneration	O
and	O
promote	O
appropriate	O
target	O
reinnervation	O
.	O

1	O
.	O

Introduction	O

After	O
peripheral	O
nerve	O
injury	O
,	O
transected	O
axons	O
in	O
the	O
distal	O
stump	O
are	O
disconnected	O
from	O
the	O
neuronal	O
body	O
and	O
undergo	O
Wallerian	O
degeneration	O
,	O
thus	O
leading	O
to	O
denervation	O
of	O
peripheral	O
organs	O
[	O
1	O
].	O

Axotomized	O
neurons	O
switch	O
to	O
a	O
growth	O
state	O
,	O
and	O
non	O
-	O
neuronal	O
cells	O
in	O
the	O
distal	O
stump	O
undergo	O
activation	O
and	O
dedifferentiation	O
to	O
sustain	O
nerve	O
regeneration	O
[	O
2	O
,	O
3	O
].	O

Even	O
though	O
axons	O
are	O
able	O
to	O
regenerate	O
after	O
nerve	O
transection	O
,	O
axons	O
grow	O
randomly	O
among	O
the	O
endoneurial	O
tubules	O
in	O
the	O
distal	O
nerve	O
,	O
so	O
that	O
the	O
accuracy	O
of	O
target	O
reinnervation	O
is	O
usually	O
poor	O
,	O
resulting	O
in	O
limited	O
functional	O
recovery	O
[	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
].	O

Therefore	O
,	O
a	O
pro	O
-	O
regenerative	O
environment	O
that	O
selectively	O
guides	O
motor	O
and	O
sensory	O
axons	O
to	O
regenerate	O
into	O
different	O
branches	O
of	O
the	O
injured	O
nerve	O
may	O
be	O
useful	O
to	O
increase	O
the	O
options	O
of	O
specific	O
target	O
reinnervation	O
.	O

Selective	O
regeneration	O
of	O
different	O
axonal	O
populations	O
would	O
be	O
also	O
useful	O
in	O
the	O
field	O
of	O
neuroprosthetics	O
,	O
as	O
separating	O
motor	O
axons	O
from	O
sensory	O
axons	O
in	O
mixed	O
nerves	O
will	O
functionally	O
improve	O
selective	O
recording	O
and	O
stimulation	O
for	O
providing	O
bidirectional	O
communication	O
with	O
the	O
prosthesis	O
[	O
8	O
,	O
9	O
].	O

After	O
peripheral	B-DS
nerve	I-DS
injury	I-DS
,	O
the	O
generation	O
of	O
a	O
pro	O
-	O
regenerative	O
environment	O
involves	O
the	O
upregulation	O
and	O
secretion	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
,	O
such	O
as	O
collagen	B-GP
type	I-GP
IV	I-GP
,	O
laminin	B-GP
and	O
fibronectin	B-GP
,	O
and	O
the	O
secretion	O
of	O
different	O
neurotrophic	B-GP
factors	I-GP
(	O
NTFs	O
),	O
such	O
as	O
nerve	B-GP
growth	I-GP
factor	I-GP
(	O
NGF	B-GP
),	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
),	O
neurotrophin	B-GP
-	I-GP
3	I-GP
(	O
NT3	B-GP
),	O
and	O
glial	B-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
GDNF	B-GP
),	O
among	O
others	O
[	O
10	O
].	O

ECM	O
components	O
interact	O
with	O
integrin	B-GP
heterodimer	I-GP
receptors	I-GP
that	O
are	O
highly	O
expressed	O
in	O
growth	O
cones	O
and	O
non	O
-	O
neuronal	O
cells	O
,	O
both	O
during	O
development	O
and	O
after	O
injury	O
[	O
11	O
,	O
12	O
],	O
promoting	O
axonal	O
guidance	O
,	O
cell	O
adhesion	O
and	O
migration	O
.	O

For	O
instance	O
,	O
laminin	B-GP
substrates	O
enhance	O
elongation	O
of	O
sensory	O
neurites	O
in	O
vitro	O
when	O
compared	O
to	O
collagen	B-GP
or	O
fibronectin	B-GP
containing	O
scaffolds	O
,	O
whereas	O
fibronectin	B-GP
substrates	O
promote	O
neurite	O
elongation	O
of	O
motor	O
neurons	O
from	O
SC	O
slices	O
in	O
vitro	O
[	O
13	O
,	O
14	O
].	O

On	O
the	O
other	O
hand	O
,	O
the	O
interaction	O
between	O
NTFs	O
and	O
their	O
different	O
receptors	O
,	O
such	O
as	O
Trk	B-GP
/	O
p75	B-GP
receptors	I-GP
or	O
GDNFR	B-GP
/	O
RET	B-GP
receptors	I-GP
,	O
promotes	O
survival	O
and	O
axonal	O
regeneration	O
of	O
different	O
neuronal	O
populations	O
.	O

For	O
example	O
,	O
we	O
found	O
that	O
NGF	B-GP
selectively	O
promotes	O
sensory	O
neurite	O
outgrowth	O
,	O
whereas	O
BDNF	B-GP
or	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
(	O
FGF	B-GP
)	O
preferentially	O
increase	O
motor	O
neurite	O
outgrowth	O
in	O
vitro	O
[	O
15	O
].	O

Several	O
reports	O
have	O
demonstrated	O
that	O
the	O
pattern	O
of	O
NTFs	O
expressed	O
in	O
denervated	O
Schwann	O
cells	O
after	O
nerve	O
injury	O
is	O
different	O
between	O
motor	O
and	O
sensory	O
nerve	O
branches	O
,	O
and	O
that	O
motor	O
and	O
sensory	O
axons	O
also	O
express	O
different	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
that	O
may	O
promote	O
differential	O
binding	O
to	O
ECM	B-GP
molecules	I-GP
[	O
16	O
,	O
17	O
,	O
18	O
,	O
19	O
].	O

Manipulation	O
of	O
some	O
of	O
these	O
differential	O
biomarkers	O
may	O
play	O
a	O
role	O
in	O
promoting	O
selective	O
regeneration	O
of	O
different	O
axonal	O
populations	O
and	O
improving	O
subsequent	O
accurate	O
reinnervation	O
.	O

However	O
,	O
the	O
majority	O
of	O
the	O
studies	O
have	O
only	O
investigated	O
the	O
effect	O
of	O
these	O
molecules	O
individually	O
,	O
disregarding	O
the	O
synergistic	O
interactions	O
of	O
ECM	O
molecules	O
with	O
NTFs	O
[	O
20	O
].	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
tested	O
whether	O
the	O
combination	O
of	O
different	O
NTFs	O
and	O
ECM	O
components	O
,	O
that	O
were	O
previously	O
shown	O
to	O
produce	O
a	O
selective	O
although	O
limited	O
stimulus	O
for	O
either	O
sensory	O
or	O
motor	O
axons	O
regeneration	O
[	O
14	O
,	O
21	O
],	O
was	O
able	O
to	O
produce	O
a	O
synergistic	O
and	O
selective	O
pro	O
-	O
regenerative	O
effect	O
on	O
motor	O
and	O
sensory	O
neurons	O
.	O

Briefly	O
,	O
addition	O
of	O
both	O
LM	O
and	O
NGF	B-GP
/	O
NT3	B-GP
or	O
FN	B-GP
and	O
BDNF	B-GP
increased	O
the	O
amount	O
of	O
sensory	O
and	O
motor	O
neurite	O
outgrowth	O
,	O
respectively	O
,	O
in	O
culture	O
models	O
.	O

Moreover	O
,	O
these	O
effects	O
were	O
maintained	O
in	O
vivo	O
in	O
adult	O
animals	B-OG
as	O
sensory	O
and	O
motor	O
axonal	O
regeneration	O
as	O
well	O
as	O
functional	O
recovery	O
was	O
enhanced	O
after	O
treating	O
nerve	B-DS
injuries	I-DS
with	O
a	O
nerve	O
conduit	O
prefilled	O
with	O
the	O
same	O
combinations	O
of	O
NTFs	O
and	O
ECM	O
components	O
.	O

2	O
.	O

Results	O

2	O
.	O
1	O
.	O

In	O
Vitro	O
Effects	O
of	O
Combining	O
Neurotrophic	O
Factors	O
(	O
NTFs	O
)	O
and	O
Extracellular	O
Matrix	O
(	O
ECM	O
)	O
Substrates	O
on	O
Neurite	O
Outgrowth	O

To	O
study	O
the	O
effect	O
of	O
different	O
combinations	O
of	O
NTFs	O
and	O
ECM	O
components	O
on	O
motor	O
and	O
sensory	O
neurons	O
outgrowth	O
,	O
we	O
first	O
performed	O
an	O
in	O
vitro	O
screening	O
using	O
spinal	O
cord	O
(	O
SC	O
)	O
slices	O
and	O
DRG	O
explants	O
.	O

In	O
cultures	O
of	O
SC	O
slices	O
(	O
Figure	O
1	O
),	O
addition	O
of	O
FN	B-GP
to	O
the	O
matrix	O
doubled	O
the	O
maximum	O
neurite	O
length	O
whereas	O
addition	O
of	O
LM	O
did	O
not	O
increase	O
it	O
compared	O
to	O
the	O
control	O
COL	B-GP
matrix	O
(	O
Figure	O
1J	O
).	O

Addition	O
of	O
BDNF	B-GP
but	O
not	O
of	O
NGF	B-GP
/	O
NT3	B-GP
to	O
the	O
different	O
substrates	O
enhanced	O
neurite	O
length	O
.	O

Furthermore	O
,	O
the	O
combination	O
of	O
FN	B-GP
+	O
BDNF	B-GP
significantly	O
enhanced	O
maximum	O
neurite	O
length	O
and	O
density	O
of	O
neurites	O
compared	O
to	O
the	O
other	O
single	O
and	O
combined	O
groups	O
.	O

Thus	O
,	O
while	O
groups	O
with	O
either	O
FN	B-GP
or	O
BDNF	B-GP
present	O
an	O
increase	O
in	O
the	O
amount	O
and	O
length	O
of	O
neurites	O
,	O
the	O
combination	O
of	O
the	O
two	O
factors	O
shows	O
a	O
synergistic	O
effect	O
with	O
significant	O
differences	O
with	O
respect	O
to	O
all	O
the	O
other	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
LM	O
or	O
NGF	B-GP
/	O
NT3	B-GP
alone	O
or	O
combined	O
did	O
not	O
show	O
any	O
improvement	O
(	O
Figure	O
1J	O
–	O
L	O
).	O

In	O
DRG	O
explants	O
(	O
Figure	O
2	O
),	O
addition	O
of	O
LM	O
or	O
FN	B-GP
into	O
the	O
collagen	B-GP
matrix	O
similarly	O
enhanced	O
the	O
maximum	O
neurite	O
length	O
(	O
Figure	O
2J	O
)	O
compared	O
to	O
collagen	B-GP
alone	O
.	O

The	O
addition	O
of	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
into	O
COL	B-GP
,	O
LM	O
and	O
FN	B-GP
substrates	O
enhanced	O
maximum	O
neurite	O
length	O
compared	O
with	O
COL	B-GP
substrate	O
except	O
COL	B-GP
+	O
BDNF	B-GP
cultures	O
.	O

It	O
is	O
noteworthy	O
that	O
only	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
group	O
showed	O
differences	O
in	O
maximum	O
neurite	O
length	O
with	O
respect	O
to	O
all	O
the	O
other	O
culture	O
conditions	O
except	O
with	O
LM	O
+	O
BDNF	B-GP
.	O

The	O
addition	O
of	O
NGF	B-GP
and	O
NT3	B-GP
enhanced	O
significantly	O
the	O
density	O
of	O
neurites	O
in	O
all	O
the	O
substrates	O
,	O
being	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
the	O
most	O
prominent	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
BDNF	B-GP
only	O
promoted	O
neurite	O
growth	O
with	O
LM	O
but	O
not	O
when	O
combined	O
with	O
COL	B-GP
or	O
FN	B-GP
(	O
Figure	O
2L	O
).	O

These	O
results	O
indicate	O
that	O
combination	O
of	O
FN	B-GP
+	O
BDNF	B-GP
shows	O
synergistic	O
effects	O
on	O
motor	O
neurons	O
promoting	O
neurite	O
elongation	O
and	O
arborization	O
,	O
with	O
weaker	O
effect	O
on	O
sensory	O
elongation	O
,	O
whereas	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
is	O
the	O
only	O
condition	O
that	O
exhibits	O
a	O
synergistic	O
effects	O
on	O
sensory	O
but	O
not	O
on	O
motor	O
neurons	O
based	O
on	O
the	O
enhancement	O
observed	O
in	O
neurite	O
elongation	O
and	O
arborization	O
.	O

2	O
.	O
2	O
.	O

In	O
Vivo	O
Effects	O
of	O
Combination	O
of	O
NTF	O
and	O
ECM	O
Substrates	O
on	O
Nerve	O
Regeneration	O

We	O
performed	O
first	O
an	O
in	O
vivo	O
study	O
in	O
which	O
the	O
sciatic	O
nerve	O
was	O
transected	O
and	O
repaired	O
with	O
silicone	O
tubes	O
filled	O
with	O
matrices	O
composed	O
of	O
COL	B-GP
,	O
COL	B-GP
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
,	O
LM	O
,	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
,	O
COL	B-GP
+	O
MP	O
.	O
BDNF	B-GP
,	O
and	O
FN	B-GP
and	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
to	O
elucidate	O
if	O
the	O
conditions	O
with	O
a	O
more	O
relevant	O
effect	O
in	O
vitro	O
had	O
a	O
similar	O
effect	O
in	O
vivo	O
.	O

The	O
three	O
NTFs	O
(	O
NGF	B-GP
,	O
NT3	B-GP
and	O
BDNF	B-GP
)	O
were	O
encapsulated	O
in	O
PLGA	O
microspheres	O
to	O
allow	O
a	O
sustained	O
release	O
during	O
the	O
time	O
that	O
axons	O
regenerate	O
across	O
the	O
tube	O
[	O
21	O
].	O

All	O
rats	B-OG
showed	O
evidence	O
of	O
axonal	O
regeneration	O
,	O
as	O
judged	O
by	O
the	O
retrograde	O
labeling	O
of	O
motor	O
and	O
sensory	O
neurons	O
with	O
Fluorogold	O
(	O
FG	O
)	O
(	O
Figure	O
3A	O
–	O
F	O
).	O

Regarding	O
the	O
number	O
of	O
regenerated	O
motor	O
neurons	O
,	O
all	O
groups	O
with	O
addition	O
of	O
ECM	O
and	O
NTFs	O
showed	O
significant	O
differences	O
with	O
respect	O
to	O
the	O
COL	B-GP
group	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
Figure	O
3G	O
),	O
being	O
the	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
group	O
the	O
one	O
with	O
the	O
highest	O
effect	O
,	O
that	O
was	O
also	O
significantly	O
higher	O
compared	O
to	O
all	O
other	O
groups	O
except	O
with	O
FN	B-GP
.	O

For	O
sensory	O
neurons	O
,	O
the	O
group	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
showed	O
the	O
highest	O
number	O
of	O
regenerated	O
neurons	O
,	O
and	O
all	O
other	O
groups	O
had	O
better	O
results	O
than	O
the	O
COL	B-GP
control	O
(	O
Figure	O
3H	O
).	O

We	O
then	O
tested	O
whether	O
this	O
preferential	O
effect	O
is	O
maintained	O
in	O
a	O
long	O
term	O
study	O
.	O

For	O
this	O
purpose	O
,	O
we	O
compared	O
groups	O
of	O
rats	B-OG
similar	O
to	O
the	O
short	O
term	O
study	O
but	O
leaving	O
an	O
8	O
mm	O
gap	O
between	O
stumps	O
,	O
since	O
this	O
more	O
challenging	O
gap	O
allows	O
to	O
better	O
elucidate	O
differences	O
between	O
groups	O
[	O
22	O
],	O
and	O
applying	O
the	O
FG	O
retrotracer	O
to	O
the	O
tibial	O
nerve	O
at	O
the	O
ankle	O
at	O
75	O
dpi	O
.	O

In	O
this	O
case	O
,	O
no	O
significant	O
differences	O
in	O
the	O
number	O
of	O
regenerated	O
motor	O
neurons	O
were	O
observed	O
between	O
groups	O
(	O
Figure	O
3I	O
).	O

However	O
,	O
more	O
regenerated	O
sensory	O
neurons	O
were	O
counted	O
in	O
the	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
group	O
compared	O
to	O
the	O
other	O
four	O
groups	O
(	O
Figure	O
3J	O
).	O

Despite	O
the	O
preferential	O
effects	O
observed	O
in	O
vitro	O
appear	O
less	O
marked	O
in	O
vivo	O
,	O
these	O
results	O
indicate	O
that	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
mainly	O
favors	O
motor	O
axon	O
regeneration	O
,	O
whereas	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
is	O
more	O
effective	O
to	O
promote	O
sensory	O
axon	O
regeneration	O
.	O

2	O
.	O
3	O
.	O

Combination	O
of	O
FN	B-GP
and	O
BDNF	B-GP
Promotes	O
Motor	O
Functional	O
Recovery	O
at	O
Long	O
Term	O

We	O
tested	O
if	O
the	O
effects	O
seen	O
on	O
regeneration	O
in	O
the	O
short	O
and	O
long	O
term	O
studies	O
had	O
impact	O
on	O
muscle	O
reinnervation	O
and	O
functional	O
recovery	O
.	O

Nerve	O
conduction	O
tests	O
provided	O
first	O
evidence	O
of	O
reinnervation	O
of	O
the	O
TA	O
muscle	O
at	O
45	O
dpi	O
in	O
all	O
the	O
groups	O
(	O
Figure	O
4A	O
).	O

The	O
amplitude	O
of	O
the	O
CMAP	O
increased	O
during	O
the	O
follow	O
-	O
up	O
.	O

At	O
60	O
dpi	O
,	O
the	O
FN	O
+	O
MP	O
.	O
BDNF	B-GP
group	O
showed	O
higher	O
amplitude	O
than	O
all	O
the	O
other	O
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

FN	B-GP
group	O
also	O
showed	O
significant	O
differences	O
with	O
respect	O
to	O
COL	B-GP
group	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
all	O
groups	O
reached	O
similar	O
CMAP	O
amplitude	O
at	O
75	O
dpi	O
.	O

In	O
the	O
more	O
distal	O
plantar	O
muscles	O
,	O
reinnervation	O
started	O
later	O
compared	O
to	O
TA	O
muscle	O
.	O

In	O
this	O
case	O
,	O
the	O
CMAP	O
amplitude	O
at	O
75	O
dpi	O
was	O
significantly	O
higher	O
in	O
FN	O
+	O
MP	O
.	O
BDNF	B-GP
group	O
compared	O
to	O
all	O
the	O
other	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
,	O
Figure	O
4B	O
).	O

No	O
differences	O
in	O
the	O
CMAP	O
latency	O
were	O
observed	O
between	O
groups	O
.	O

These	O
results	O
suggest	O
that	O
an	O
intratubular	O
matrix	O
containing	O
FN	B-GP
and	O
BDNF	B-GP
promotes	O
motor	O
axon	O
regeneration	O
and	O
reinnervation	O
of	O
target	O
muscles	O
,	O
whereas	O
LM	O
and	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
groups	O
showed	O
values	O
similar	O
to	O
the	O
COL	B-GP
control	O
group	O
.	O

The	O
faster	O
muscle	O
reinnervation	O
found	O
in	O
group	O
FN	O
+	O
MP	O
.	O
BDNF	B-GP
is	O
of	O
relevance	O
considering	O
the	O
longer	O
distance	O
that	O
has	O
to	O
be	O
regenerated	O
in	O
injured	O
human	B-OG
nerves	O
.	O

2	O
.	O
4	O
.	O

Combination	O
of	O
LM	O
and	O
NGF	B-GP
/	O
NT3	O
Promotes	O
Sensory	O
Functional	O
Recovery	O
at	O
Long	O
Term	O

In	O
parallel	O
,	O
we	O
assessed	O
sensory	O
functional	O
recovery	O
to	O
mechanical	O
and	O
thermal	O
stimuli	O
in	O
the	O
hind	O
paw	O
.	O

For	O
the	O
pinprick	O
test	O
,	O
LM	O
and	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
groups	O
presented	O
the	O
first	O
positive	O
response	O
at	O
30	O
dpi	O
,	O
whereas	O
no	O
response	O
was	O
observed	O
in	O
the	O
other	O
groups	O
at	O
this	O
time	O
point	O
.	O

At	O
later	O
time	O
points	O
,	O
all	O
groups	O
showed	O
positive	O
responses	O
,	O
being	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
the	O
only	O
group	O
with	O
significantly	O
higher	O
scores	O
compared	O
to	O
the	O
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
4C	O
).	O

Withdrawal	O
responses	O
to	O
heat	O
stimulation	O
in	O
the	O
plantar	O
test	O
showed	O
similar	O
results	O
to	O
the	O
ones	O
observed	O
for	O
the	O
pinprick	O
.	O

Denervated	O
paws	O
did	O
not	O
respond	O
to	O
the	O
hot	O
stimuli	O
on	O
the	O
lateral	O
region	O
until	O
45	O
dpi	O
and	O
at	O
this	O
time	O
point	O
group	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
showed	O
a	O
shorter	O
latency	O
compared	O
to	O
control	O
,	O
FN	B-GP
and	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
Figure	O
4D	O
),	O
indicating	O
that	O
more	O
sensory	O
fibers	O
arrived	O
to	O
the	O
plantar	O
skin	O
of	O
the	O
paw	O
.	O

However	O
,	O
all	O
groups	O
showed	O
similar	O
latency	O
at	O
60	O
and	O
75	O
dpi	O
.	O

To	O
further	O
corroborate	O
the	O
functional	O
results	O
,	O
skin	O
reinnervation	O
of	O
the	O
lateral	O
paw	O
pads	O
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

In	O
all	O
the	O
rats	B-OG
PGP	B-GP
immunolabeling	O
showed	O
regenerated	O
nerve	O
fibers	O
that	O
surrounded	O
the	O
SG	O
tubules	O
,	O
reached	O
the	O
subepidermal	O
nerve	O
plexus	O
,	O
and	O
extended	O
to	O
intraepidermal	O
terminals	O
and	O
Meissner	O
corpuscles	O
at	O
the	O
papillae	O
(	O
Figure	O
4E	O
–	O
J	O
).	O

Group	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
had	O
significantly	O
higher	O
number	O
of	O
IENF	B-GP
than	O
all	O
the	O
other	O
groups	O
(	O
Figure	O
4K	O
).	O

Similarly	O
,	O
the	O
number	O
of	O
reinnervated	O
SGs	O
was	O
highest	O
in	O
group	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
,	O
although	O
only	O
significantly	O
from	O
groups	O
COL	O
and	O
LM	O
(	O
Figure	O
4L	O
).	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
LM	O
and	O
NGF	B-GP
/	O
NT3	B-GP
enhances	O
sensory	O
axons	O
regeneration	O
and	O
skin	O
reinnervation	O
by	O
populations	O
of	O
sensory	O
neurons	O
that	O
contribute	O
to	O
thermal	O
and	O
mechanical	O
sensibility	O
,	O
and	O
less	O
markedly	O
of	O
sympathetic	O
fibers	O
innervating	O
the	O
SGs	O
.	O

3	O
.	O

Discussion	O

NTFs	O
and	O
ECM	O
components	O
both	O
have	O
important	O
roles	O
in	O
nerve	O
regeneration	O
after	O
injury	O
,	O
including	O
effects	O
on	O
Schwann	O
cell	O
migration	O
and	O
differentiation	O
,	O
neuronal	O
survival	O
,	O
cell	O
adhesion	O
and	O
axonal	O
growth	O
[	O
10	O
,	O
23	O
].	O

To	O
corroborate	O
the	O
preferential	O
effect	O
of	O
NGF	B-GP
,	O
NT	B-GP
-	I-GP
3	I-GP
and	O
LM	O
on	O
sensory	O
neurons	O
and	O
BDNF	B-GP
and	O
FN	B-GP
on	O
motor	O
neurons	O
[	O
15	O
,	O
24	O
,	O
25	O
,	O
26	O
,	O
27	O
],	O
we	O
cultured	O
DRG	O
explants	O
and	O
spinal	O
cord	O
slices	O
.	O

Organotypic	O
cultures	O
are	O
multicellular	O
in	O
vitro	O
models	O
in	O
which	O
neurons	O
and	O
growing	O
neurites	O
share	O
similar	O
differentiation	O
and	O
development	O
patterns	O
with	O
in	O
vivo	O
conditions	O
[	O
28	O
]	O
while	O
they	O
are	O
still	O
in	O
contact	O
with	O
Schwann	O
cells	O
and	O
fibroblasts	O
.	O

In	O
this	O
way	O
,	O
DRG	O
explants	O
have	O
been	O
long	O
used	O
to	O
study	O
axonal	O
growth	O
and	O
regeneration	O
of	O
the	O
sensory	O
nervous	O
system	O
[	O
29	O
,	O
30	O
]	O
as	O
DRG	O
contain	O
the	O
soma	O
of	O
pseudounipolar	O
sensory	O
neurons	O
that	O
project	O
growing	O
neurites	O
outside	O
the	O
ganglion	O
.	O

On	O
the	O
other	O
hand	O
,	O
neurites	O
growing	O
from	O
the	O
ventral	O
areas	O
of	O
the	O
spinal	O
cord	O
arise	O
from	O
motoneurons	O
of	O
the	O
ventral	O
horn	O
instead	O
of	O
other	O
interneurons	O
[	O
31	O
]	O
making	O
this	O
3D	O
culture	O
an	O
useful	O
model	O
for	O
studying	O
regeneration	O
of	O
motor	O
neurites	O
in	O
vitro	O
[	O
32	O
].	O

Taking	O
into	O
account	O
that	O
some	O
NTFs	O
show	O
an	O
attractive	O
or	O
repulsive	O
effect	O
depending	O
on	O
the	O
presence	O
of	O
different	O
ECM	O
molecules	O
[	O
33	O
],	O
we	O
performed	O
a	O
screening	O
of	O
possible	O
combinations	O
added	O
to	O
a	O
collagen	B-GP
gel	O
substrate	O
to	O
investigate	O
if	O
the	O
preferential	O
effects	O
of	O
ECM	O
components	O
and	O
NTFs	O
could	O
be	O
synergistically	O
added	O
in	O
DRG	O
and	O
SC	O
postnatal	O
cultures	O
.	O

We	O
observed	O
an	O
increased	O
effect	O
of	O
LM	O
and	O
NGF	B-GP
+	O
NT3	B-GP
on	O
sensory	O
neurite	O
outgrowth	O
in	O
DRG	O
explants	O
,	O
whereas	O
this	O
combination	O
did	O
not	O
increase	O
motor	O
neurite	O
length	O
.	O

On	O
the	O
other	O
hand	O
,	O
BDNF	B-GP
combined	O
with	O
FN	B-GP
promoted	O
a	O
synergic	O
effect	O
on	O
motor	O
neurite	O
outgrowth	O
with	O
small	O
effects	O
on	O
DRG	O
explants	O
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
effect	O
on	O
regenerating	O
proprioceptive	O
neurites	O
[	O
14	O
].	O

The	O
synergistic	O
effect	O
can	O
be	O
exemplified	O
for	O
BDNF	B-GP
,	O
that	O
promotes	O
sensory	O
neurite	O
outgrowth	O
in	O
the	O
presence	O
of	O
LM	O
but	O
not	O
when	O
is	O
added	O
alone	O
.	O

These	O
proregenerative	O
effects	O
may	O
be	O
mediated	O
by	O
the	O
differential	O
expression	O
of	O
integrin	B-GP
and	O
NTF	B-GP
receptors	I-GP
in	O
regenerating	O
neurons	O
.	O

It	O
has	O
been	O
described	O
that	O
after	O
injury	O
integrin	B-GP
receptors	I-GP
α7β1	B-GP
and	O
α5β1	B-GP
are	O
upregulated	O
in	O
both	O
motor	O
and	O
sensory	O
neurons	O
[	O
14	O
,	O
34	O
],	O
whereas	O
high	O
affinity	O
TrkA	B-GP
and	O
TrkC	B-GP
receptors	I-GP
are	O
expressed	O
in	O
sensory	O
neurons	O
and	O
TrKB	B-GP
is	O
mainly	O
expressed	O
in	O
motoneurons	O
and	O
in	O
a	O
low	O
percentage	O
of	O
sensory	O
neurons	O
[	O
35	O
].	O

It	O
can	O
be	O
hypothesized	O
that	O
the	O
partially	O
selective	O
in	O
vitro	O
effects	O
of	O
NTFs	O
may	O
be	O
enhanced	O
by	O
the	O
presence	O
of	O
certain	O
ECM	O
molecules	O
in	O
the	O
substrate	O
.	O

In	O
fact	O
,	O
it	O
has	O
been	O
reported	O
that	O
the	O
pro	O
-	O
regenerative	O
effects	O
of	O
NGF	B-GP
and	O
NT3	B-GP
are	O
reduced	O
after	O
blocking	O
the	O
α7	B-GP
subunit	O
of	O
integrins	B-GP
in	O
sensory	O
neurons	O
[	O
36	O
],	O
and	O
that	O
synergistic	O
actions	O
between	O
integrins	B-GP
and	O
NTF	B-GP
receptors	I-GP
may	O
be	O
attributed	O
to	O
the	O
sustained	O
activation	O
of	O
Src	B-GP
and	O
the	O
downstream	O
signaling	O
Akt	B-GP
intermediate	O
[	O
37	O
].	O

On	O
the	O
other	O
hand	O
,	O
NTFs	O
may	O
also	O
modulate	O
the	O
expression	O
of	O
different	O
integrin	B-GP
receptor	I-GP
subunits	O
,	O
whose	O
upregulation	O
is	O
low	O
in	O
adult	O
compared	O
to	O
their	O
expression	O
in	O
early	O
postnatal	O
animals	B-OG
[	O
38	O
].	O

Actually	O
,	O
NGF	B-GP
contributes	O
to	O
enhance	O
ECM	O
signaling	O
by	O
promoting	O
axonal	O
transport	O
and	O
accumulation	O
of	O
β1	B-GP
integrin	I-GP
in	O
growth	O
cones	O
,	O
thus	O
enhancing	O
neurite	O
outgrowth	O
[	O
39	O
].	O

Since	O
the	O
optimal	O
developmental	O
window	O
of	O
regeneration	O
varies	O
from	O
E11	O
–	O
E15	O
in	O
the	O
chick	B-OG
spinal	O
cord	O
to	O
P7	O
in	O
rats	B-OG
[	O
40	O
]	O
and	O
the	O
effects	O
of	O
different	O
ECM	O
molecules	O
in	O
vitro	O
are	O
lost	O
when	O
switching	O
from	O
postnatal	O
P7	O
to	O
weaned	O
P21	O
rats	B-OG
[	O
14	O
],	O
it	O
was	O
necessary	O
to	O
confirm	O
in	O
a	O
model	O
of	O
peripheral	B-DS
nerve	I-DS
injury	O
and	O
regeneration	O
in	O
vivo	O
the	O
effects	O
observed	O
in	O
cultures	O
.	O

The	O
in	O
vivo	O
results	O
demonstrated	O
that	O
introduction	O
of	O
a	O
collagen	B-GP
matrix	O
enriched	O
with	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
or	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
within	O
the	O
tube	O
used	O
for	O
nerve	O
repair	O
in	O
adult	O
rats	B-OG
promoted	O
preferential	O
regeneration	O
of	O
sensory	O
and	O
motor	O
axons	O
respectively	O
.	O

The	O
NTFs	O
were	O
encapsulated	O
in	O
PLGA	O
microspheres	O
as	O
they	O
have	O
been	O
approved	O
by	O
the	O
FDA	O
as	O
a	O
drug	O
delivery	O
system	O
[	O
41	O
]	O
and	O
we	O
have	O
recently	O
demonstrated	O
that	O
they	O
do	O
not	O
interfere	O
with	O
axon	O
regeneration	O
and	O
their	O
slow	O
release	O
over	O
more	O
than	O
30	O
days	O
provides	O
more	O
sustained	O
support	O
for	O
nerve	O
regeneration	O
with	O
respect	O
to	O
addition	O
of	O
free	O
NTFs	O
[	O
21	O
].	O

All	O
the	O
treated	O
groups	O
showed	O
an	O
increased	O
number	O
of	O
retrogradely	O
traced	O
motor	O
and	O
sensory	O
neurons	O
that	O
had	O
regenerated	O
their	O
axons	O
to	O
the	O
site	O
of	O
tracer	O
application	O
distal	O
to	O
the	O
tube	O
,	O
compared	O
to	O
the	O
control	O
COL	O
group	O
.	O

This	O
is	O
a	O
positive	O
indication	O
that	O
the	O
design	O
and	O
the	O
concentrations	O
of	O
encapsulated	O
NTFs	O
and	O
ECM	O
components	O
did	O
not	O
cause	O
detrimental	O
effects	O
such	O
as	O
the	O
candy	O
store	O
effect	O
[	O
42	O
]	O
or	O
neuronal	O
death	O
induced	O
by	O
high	O
concentration	O
of	O
NTFs	O
[	O
43	O
].	O

However	O
,	O
the	O
preferential	O
effect	O
mediated	O
by	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
and	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
treatments	O
was	O
more	O
modest	O
compared	O
to	O
the	O
in	O
vitro	O
experiments	O
.	O

This	O
comparative	O
reduction	O
may	O
be	O
explained	O
because	O
of	O
the	O
more	O
complex	O
environment	O
present	O
in	O
the	O
regenerating	O
nerve	O
.	O

After	O
nerve	O
injury	O
,	O
ECM	O
components	O
are	O
synthesized	O
and	O
secreted	O
by	O
non	O
-	O
neuronal	O
cells	O
such	O
as	O
Schwann	O
cells	O
and	O
fibroblasts	O
[	O
44	O
],	O
whereas	O
NTFs	O
are	O
expressed	O
by	O
both	O
neuronal	O
and	O
non	O
-	O
neuronal	O
cells	O
[	O
16	O
,	O
45	O
,	O
46	O
].	O

Furthermore	O
,	O
non	O
-	O
neuronal	O
cells	O
involved	O
in	O
Wallerian	O
degeneration	O
also	O
express	O
integrins	B-GP
and	O
NTF	B-GP
receptors	I-GP
.	O

Therefore	O
,	O
the	O
in	O
vivo	O
implant	O
of	O
a	O
matrix	O
containing	O
ECM	O
components	O
and	O
NTFs	O
in	O
the	O
nerve	O
conduit	O
does	O
not	O
only	O
influence	O
the	O
injured	O
neurons	O
,	O
but	O
also	O
acts	O
on	O
the	O
migrating	O
non	O
-	O
neuronal	O
cells	O
inside	O
the	O
intratubular	O
matrix	O
.	O

Hence	O
,	O
the	O
activation	O
of	O
non	O
-	O
neuronal	O
cells	O
would	O
contribute	O
with	O
proregenerative	O
non	O
-	O
specific	O
cues	O
and	O
decrease	O
the	O
effects	O
of	O
the	O
selective	O
factors	O
introduced	O
in	O
the	O
exogenous	O
matrix	O
.	O

On	O
the	O
other	O
hand	O
,	O
although	O
we	O
still	O
found	O
in	O
vivo	O
a	O
significant	O
preferential	O
regeneration	O
of	O
sensory	O
neurons	O
in	O
animals	B-OG
treated	O
with	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
and	O
of	O
motor	O
neurons	O
in	O
animals	B-OG
treated	O
with	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
,	O
the	O
differences	O
in	O
the	O
amount	O
of	O
regenerated	O
neurons	O
were	O
reduced	O
from	O
the	O
short	O
to	O
the	O
long	O
term	O
study	O
.	O

We	O
can	O
discard	O
that	O
this	O
could	O
be	O
related	O
to	O
an	O
inefficient	O
supply	O
of	O
NTFs	O
as	O
we	O
have	O
previously	O
shown	O
that	O
NTF	O
encapsulation	O
in	O
MPs	O
improved	O
regeneration	O
of	O
both	O
motor	O
and	O
sensory	O
axons	O
,	O
and	O
that	O
PLGA	O
MPs	O
are	O
able	O
to	O
sustain	O
release	O
of	O
these	O
NTFs	O
longer	O
than	O
a	O
month	O
[	O
21	O
].	O

The	O
most	O
plausible	O
explanation	O
for	O
the	O
reduced	O
effect	O
observed	O
would	O
be	O
that	O
most	O
axons	O
had	O
passed	O
the	O
site	O
of	O
tracer	O
application	O
at	O
75	O
dpi	O
,	O
and	O
thus	O
we	O
were	O
not	O
able	O
to	O
detect	O
differences	O
that	O
occurred	O
at	O
earlier	O
time	O
.	O

Although	O
retrolabeling	O
of	O
regenerating	O
neurons	O
is	O
a	O
useful	O
technique	O
to	O
assess	O
the	O
differential	O
effect	O
of	O
local	O
treatments	O
,	O
functional	O
restitution	O
is	O
the	O
most	O
important	O
outcome	O
after	O
nerve	O
injury	O
[	O
47	O
].	O

Thus	O
,	O
in	O
the	O
long	O
term	O
in	O
vivo	O
study	O
we	O
evaluated	O
functional	O
recovery	O
of	O
both	O
motor	O
and	O
sensory	O
targets	O
.	O

Electrophysiological	O
results	O
demonstrated	O
that	O
muscle	O
reinnervation	O
started	O
earlier	O
and	O
achieved	O
higher	O
levels	O
in	O
the	O
FN	O
+	O
MP	O
.	O
BDNF	B-GP
group	O
than	O
in	O
all	O
the	O
other	O
groups	O
.	O

An	O
increased	O
regeneration	O
rate	O
improves	O
muscle	O
reinnervation	O
,	O
particularly	O
of	O
distal	O
muscles	O
in	O
the	O
limb	O
,	O
as	O
shown	O
in	O
the	O
foot	O
muscles	O
in	O
this	O
study	O
,	O
reducing	O
the	O
detrimental	O
consequences	O
of	O
chronic	O
denervation	O
[	O
48	O
].	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
showed	O
earlier	O
sensory	O
responses	O
to	O
both	O
mechanical	O
and	O
thermal	O
stimuli	O
,	O
confirming	O
the	O
results	O
seen	O
in	O
the	O
retrotracer	O
study	O
.	O

We	O
also	O
demonstrated	O
an	O
increased	O
number	O
of	O
sensory	O
axons	O
reinnervating	O
the	O
epidermis	O
and	O
of	O
sympathetic	O
axons	O
reinnervating	O
the	O
SGs	O
in	O
the	O
skin	O
in	O
the	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
group	O
.	O

This	O
parallel	O
effect	O
could	O
be	O
explained	O
by	O
the	O
proregenerative	O
role	O
of	O
NGF	B-GP
on	O
sensory	O
as	O
well	O
as	O
on	O
sympathetic	O
neurons	O
[	O
49	O
].	O

4	O
.	O

Materials	O
and	O
Methods	O

4	O
.	O
1	O
.	O

Ethics	O
Statement	O

In	O
vitro	O
(	O
procedure	O
#	O
1963M	O
)	O
and	O
in	O
vivo	O
(	O
procedure	O
#	O
1162MM	O
)	O
experimental	O
procedures	O
were	O
approved	O
in	O
30	O
June	O
2015	O
and	O
in	O
29	O
May	O
2015	O
respectively	O
by	O
the	O
animal	B-OG
and	O
human	B-OG
experimentation	O
ethics	O
committee	O
(	O
CEEAH	O
)	O
of	O
the	O
Universitat	O
Autonoma	O
de	O
Barcelona	O
in	O
accordance	O
with	O
the	O
European	O
Communities	O
Council	O
Directive	O
2010	O
/	O
63	O
/	O
EU	O
.	O

4	O
.	O
2	O
.	O

In	O
Vitro	O
Study	O
on	O
Organotypic	O
Cultures	O

Organotypic	O
cultures	O
were	O
prepared	O
as	O
previously	O
described	O
in	O
detail	O
[	O
32	O
].	O

Briefly	O
,	O
a	O
3	O
mg	O
/	O
mL	O
collagen	B-GP
solution	O
was	O
prepared	O
by	O
mixing	O
rat	B-OG
tail	O
collagen	B-GP
type	I-GP
I	I-GP
(#	O
354236	O
,	O
Corning	O
,	O
Wiesbaden	O
,	O
Germany	O
)	O
with	O
PBS	O
(	O
D8537	B-CD
,	O
Sigma	O
,	O
Tres	O
Cantos	O
,	O
Spain	O
)	O
and	O
sodium	O
bicarbonate	O
at	O
0	O
.	O
3	O
mg	O
/	O
mL	O
,	O
and	O
diluting	O
1	O
:	O
10	O
with	O
basal	O
Eagle	O
’	O
s	O
medium	O
(	O
10	O
×,	O
Gibco	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
).	O

NTF	O
enriched	O
substrates	O
were	O
prepared	O
by	O
adding	O
BDNF	B-GP
at	O
50	O
ng	O
/	O
mL	O
(	O
Peprotech	O
,	O
London	O
,	O
UK	O
)	O
or	O
NGF	B-GP
and	O
NT3	B-GP
(	O
Peprotech	O
)	O
at	O
25	O
ng	O
/	O
mL	O
each	O
,	O
and	O
fibronectin	B-GP
(	O
BD	O
Bioscences	O
,	O
Vienna	O
,	O
Austria	O
)	O
or	O
laminin	B-GP
type	I-GP
I	I-GP
(	O
Sigma	O
)	O
to	O
a	O
20	O
%	O
final	O
volume	O
.	O

Single	O
30	O
µL	O
drops	O
of	O
the	O
prepared	O
matrices	O
were	O
deposited	O
on	O
poly	O
-	O
d	O
-	O
lysine	O
(	O
Sigma	O
)	O
coated	O
coverslips	O
,	O
which	O
were	O
placed	O
in	O
Petri	O
dishes	O
or	O
24	O
-	O
well	O
multidishes	O
(	O
Iwaki	O
,	O
Asahi	O
Technoglass	O
,	O
Chiba	O
,	O
Japan	O
),	O
and	O
kept	O
in	O
the	O
incubator	O
at	O
37	O
°	O
C	O
and	O
5	O
%	O
CO2	O
for	O
two	O
hours	O
to	O
induce	O
collagen	B-GP
gel	O
formation	O
.	O

Collagen	B-GP
gel	O
was	O
mixed	O
with	O
PBS	O
(	O
COL	O
)	O
and	O
used	O
as	O
control	O
.	O

Collagen	B-GP
gels	O
were	O
also	O
combined	O
with	O
NGF	B-GP
/	O
NT3	B-GP
(	O
COL	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP
)	O
or	O
BDNF	B-GP
(	O
COL	B-GP
+	O
BDNF	B-GP
).	O

Similarly	O
,	O
laminin	B-GP
and	O
fibronectin	B-GP
-	O
enriched	O
gels	O
were	O
combined	O
with	O
PBS	O
(	O
LM	O
and	O
FN	B-GP
,	O
respectively	O
),	O
NGF	B-GP
+	O
NT3	B-GP
(	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
and	O
FN	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP
,	O
respectively	O
)	O
or	O
BDNF	B-GP
(	O
LM	O
+	O
BDNF	B-GP
and	O
FN	B-GP
+	O
BDNF	B-GP
,	O
respectively	O
)	O
(	O
see	O
Table	O
1	O
).	O

The	O
lumbar	O
spinal	O
cord	O
(	O
SC	O
,	O
n	O
=	O
6	O
–	O
8	O
/	O
group	O
)	O
and	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
,	O
n	O
=	O
7	O
–	O
8	O
/	O
group	O
)	O
were	O
harvested	O
from	O
7	O
-	O
day	O
-	O
old	O
Sprague	B-OG
-	I-OG
Dawley	I-OG
rats	I-OG
,	O
placed	O
in	O
cold	O
Gey	O
’	O
s	O
balanced	O
salt	O
solution	O
(	O
Sigma	O
)	O
enriched	O
with	O
6	O
mg	O
/	O
mL	O
glucose	B-CD
and	O
cleaned	O
.	O

SC	O
350	O
µm	O
thick	O
slices	O
and	O
DRG	O
explants	O
were	O
placed	O
on	O
gelled	O
collagen	B-GP
droplets	O
,	O
prepared	O
as	O
indicated	O
above	O
,	O
and	O
covered	O
with	O
a	O
second	O
30	O
µL	O
drop	O
.	O

The	O
embedded	O
samples	O
were	O
placed	O
in	O
the	O
incubator	O
for	O
45	O
min	O
before	O
adding	O
Neurobasal	O
medium	O
(	O
NB	O
,	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
),	O
supplemented	O
with	O
B27	O
(	O
Life	O
Technologies	O
),	O
glutamine	B-CD
and	O
penicillin	B-CD
/	O
streptomycin	B-CD
(	O
Sigma	O
).	O

SC	O
slices	O
were	O
cultured	O
for	O
4	O
days	O
,	O
and	O
DRG	O
explants	O
for	O
2	O
days	O
.	O

Then	O
,	O
cultures	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
for	O
30	O
min	O
,	O
and	O
incubated	O
for	O
48	O
h	O
with	O
primary	O
antibody	O
mouse	B-OG
RT97	O
(	O
1	O
:	O
200	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
Iowa	O
City	O
,	O
IA	O
,	O
USA	O
)	O
at	O
4	O
°	O
C	O
.	O

After	O
washes	O
,	O
the	O
sections	O
were	O
incubated	O
with	O
secondary	O
antibody	O
AF594	O
conjugated	O
donkey	B-OG
anti	O
-	O
mouse	B-OG
(	O
1	O
:	O
200	O
,	O
Life	O
Technologies	O
)	O
overnight	O
at	O
4	O
°	O
C	O
.	O

For	O
DRG	O
and	O
SC	O
visualization	O
,	O
samples	O
were	O
mounted	O
on	O
slides	O
using	O
Mowiol	O
with	O
DAPI	O
(	O
100	O
ng	O
/	O
mL	O
,	O
Sigma	O
)	O
for	O
nuclear	O
staining	O
.	O

Olympus	O
BX51	O
fluorescence	O
microscope	O
(	O
Olympus	O
,	O
Hamburg	O
,	O
Germany	O
)	O
attached	O
to	O
a	O
DP73	O
camera	O
was	O
used	O
to	O
obtain	O
images	O
of	O
different	O
areas	O
using	O
cellSens	O
Entry	O
software	O
(	O
version	O
1	O
.	O
12	O
,	O
Olympus	O
),	O
different	O
parts	O
of	O
each	O
sample	O
were	O
merged	O
using	O
Adobe	O
Photoshop	O
CS3	O
(	O
Adobe	O
System	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
).	O

To	O
analyze	O
the	O
length	O
of	O
neurites	O
,	O
ImageJ	O
software	O
(	O
NIH	O
,	O
available	O
on	O
:	O
http	O
://	O
rsb	O
.	O
info	O
.	O
nih	O
.	O
gov	O
/	O
ij	O
/)	O
resolution	O
parameters	O
were	O
fixed	O
and	O
the	O
three	O
longest	O
neurites	O
were	O
followed	O
from	O
the	O
ventral	O
horn	O
(	O
spinal	O
cord	O
)	O
or	O
ganglion	O
boundary	O
(	O
DRG	O
)	O
to	O
their	O
ending	O
projections	O
.	O

Whole	O
culture	O
images	O
of	O
the	O
DRG	O
and	O
the	O
ventral	O
horn	O
of	O
the	O
SC	O
were	O
analyzed	O
with	O
the	O
Neurite	O
-	O
J	O
plug	O
-	O
in	O
[	O
50	O
]	O
for	O
ImageJ	O
software	O
,	O
and	O
the	O
number	O
of	O
neurites	O
grown	O
at	O
different	O
distances	O
from	O
the	O
explant	O
was	O
compared	O
between	O
sets	O
of	O
cultures	O
.	O

To	O
facilitate	O
the	O
visualization	O
of	O
differences	O
between	O
groups	O
,	O
the	O
area	O
under	O
the	O
curve	O
of	O
each	O
group	O
was	O
converted	O
to	O
a	O
bar	O
plot	O
.	O

4	O
.	O
3	O
.	O

In	O
Vivo	O
Study	O
of	O
Peripheral	O
Nerve	O
Regeneration	O

Female	O
Sprague	B-OG
-	I-OG
Dawley	I-OG
rats	I-OG
weighing	O
between	O
250	O
–	O
300	O
g	O
were	O
used	O
.	O

Animals	B-OG
had	O
ad	O
libitum	O
access	O
to	O
food	O
and	O
water	O
and	O
were	O
kept	O
under	O
a	O
standard	O
light	O
-	O
dark	O
cycle	O
of	O
12	O
:	O
12	O
h	O
.	O

All	O
efforts	O
were	O
made	O
to	O
minimize	O
pain	O
and	O
animal	B-OG
distress	O
during	O
surgery	O
.	O

Rats	B-OG
were	O
anaesthetized	O
with	O
ketamine	B-CD
/	O
xylacine	B-CD
(	O
90	O
/	O
10	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.),	O
the	O
sciatic	O
nerve	O
was	O
exposed	O
at	O
the	O
midthigh	O
and	O
sectioned	O
90	O
mm	O
from	O
the	O
tip	O
of	O
the	O
third	O
toe	O
,	O
and	O
a	O
nerve	O
portion	O
resected	O
.	O

A	O
silicone	O
tube	O
was	O
then	O
sutured	O
with	O
10	O
-	O
0	O
monofilament	O
sutures	O
to	O
each	O
nerve	O
stump	O
leaving	O
a	O
6	O
mm	O
gap	O
between	O
both	O
nerve	O
ends	O
for	O
the	O
short	O
term	O
study	O
or	O
8	O
mm	O
gap	O
for	O
the	O
long	O
term	O
study	O
.	O

Animals	B-OG
were	O
kept	O
for	O
20	O
days	O
post	O
-	O
injury	O
(	O
dpi	O
)	O
(	O
short	O
term	O
)	O
or	O
75	O
dpi	O
(	O
long	O
term	O
)	O
to	O
allow	O
axonal	O
regeneration	O
before	O
testing	O
.	O

Each	O
of	O
the	O
three	O
NTFs	O
(	O
NGF	B-GP
,	O
NT3	B-GP
,	O
and	O
BDNF	B-GP
)	O
were	O
encapsulated	O
in	O
microspheres	O
as	O
previously	O
described	O
[	O
51	O
]	O
and	O
added	O
to	O
a	O
collagen	B-GP
solution	O
to	O
reach	O
a	O
final	O
concentration	O
of	O
2	O
µg	O
/	O
mL	O
for	O
BDNF	B-GP
and	O
1	O
µg	O
/	O
mL	O
for	O
NGF	B-GP
and	O
NT3	B-GP
respectively	O
.	O

Each	O
preparation	O
of	O
NTF	O
was	O
then	O
added	O
to	O
ECM	O
solutions	O
prepared	O
as	O
for	O
the	O
cultures	O
,	O
i	O
.	O
e	O
.,	O
collagen	B-GP
at	O
3	O
mg	O
/	O
mL	O
,	O
collagen	B-GP
supplemented	O
with	O
laminin	B-GP
20	O
%	O
(	O
v	O
/	O
v	O
),	O
and	O
collagen	B-GP
supplemented	O
with	O
fibronectin	B-GP
20	O
%	O
(	O
v	O
/	O
v	O
).	O

Silicone	O
tubes	O
8	O
or	O
10	O
mm	O
long	O
with	O
an	O
internal	O
diameter	O
of	O
2	O
mm	O
were	O
filled	O
with	O
one	O
of	O
the	O
mixtures	O
containing	O
different	O
combinations	O
of	O
ECM	O
substrates	O
and	O
encapsulated	O
NTF	O
.	O

In	O
order	O
to	O
promote	O
fibril	O
alignment	O
,	O
the	O
collagen	B-GP
solution	O
was	O
left	O
to	O
gel	O
vertically	O
for	O
12	O
h	O
before	O
surgery	O
[	O
52	O
].	O

Therefore	O
,	O
there	O
were	O
7	O
experimental	O
groups	O
for	O
short	O
and	O
5	O
for	O
long	O
term	O
experiments	O
(	O
n	O
=	O
6	O
per	O
group	O
,	O
see	O
Table	O
1	O
).	O

4	O
.	O
4	O
.	O

Retrograde	O
Labeling	O
and	O
Neuronal	O
Counting	O

To	O
quantify	O
motor	O
and	O
sensory	O
regenerated	O
neurons	O
at	O
short	O
term	O
(	O
20	O
dpi	O
),	O
rats	B-OG
were	O
anaesthetized	O
with	O
ketamine	B-CD
/	O
xylacine	B-CD
and	O
the	O
sciatic	O
nerve	O
was	O
exposed	O
and	O
transected	O
8	O
mm	O
distal	O
to	O
the	O
distal	O
end	O
of	O
the	O
silicone	O
tube	O
to	O
apply	O
Fluorogold	O
(	O
FG	O
;	O
5	O
%;	O
Fluorochrome	O
Inc	O
.,	O
Denver	O
,	O
CO	O
,	O
USA	O
)	O
as	O
a	O
retrotracer	O
[	O
53	O
].	O

Briefly	O
,	O
5	O
µL	O
of	O
FG	O
were	O
applied	O
to	O
the	O
end	O
of	O
the	O
nerve	O
for	O
1	O
h	O
,	O
then	O
the	O
retrotracer	O
was	O
washed	O
with	O
saline	O
to	O
remove	O
any	O
residues	O
of	O
the	O
tracer	O
and	O
the	O
wound	O
sutured	O
in	O
planes	O
.	O

Similarly	O
,	O
for	O
the	O
long	O
term	O
study	O
(	O
75	O
dpi	O
)	O
FG	O
was	O
also	O
applied	O
to	O
the	O
tibial	O
nerve	O
at	O
the	O
ankle	O
level	O
.	O

After	O
tracer	O
application	O
,	O
the	O
rats	B-OG
were	O
allowed	O
to	O
survive	O
for	O
7	O
days	O
,	O
then	O
,	O
they	O
were	O
deeply	O
anesthetized	O
and	O
transcardially	O
perfused	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
.	O

The	O
lumbar	O
segment	O
(	O
L3	O
–	O
L6	O
)	O
of	O
the	O
SC	O
and	O
the	O
L4	O
and	O
L5	O
DRG	O
were	O
removed	O
,	O
postfixed	O
at	O
4	O
°	O
C	O
for	O
1	O
h	O
and	O
transferred	O
to	O
30	O
%	O
sucrose	B-CD
in	O
PBS	O
.	O

Samples	O
were	O
cut	O
in	O
a	O
cryostat	O
longitudinally	O
in	O
40	O
and	O
20	O
µm	O
thick	O
sections	O
respectively	O
,	O
mounted	O
s	O
severed	O
he	O
tube	O
on	O
slides	O
,	O
heated	O
at	O
35	O
°	O
C	O
for	O
1	O
h	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
in	O
the	O
dark	O
.	O

DRG	O
and	O
SC	O
sections	O
were	O
observed	O
with	O
an	O
Olympus	O
BX51	O
fluorescence	O
microscope	O
and	O
the	O
fractionator	O
principle	O
[	O
54	O
]	O
was	O
used	O
to	O
quantify	O
the	O
number	O
of	O
labeled	O
neurons	O
.	O

4	O
.	O
5	O
.	O

Assessment	O
of	O
Muscle	O
Reinnervation	O

Functional	O
reinnervation	O
of	O
target	O
muscles	O
was	O
assessed	O
at	O
7	O
,	O
30	O
,	O
45	O
,	O
60	O
and	O
75	O
dpi	O
by	O
means	O
of	O
nerve	O
conduction	O
tests	O
.	O

Animals	B-OG
were	O
anesthetized	O
with	O
ketamine	B-CD
/	O
xylacine	B-CD
and	O
the	O
sciatic	O
nerve	O
was	O
stimulated	O
by	O
transcutaneous	O
electrodes	O
placed	O
at	O
the	O
sciatic	O
notch	O
.	O

The	O
amplitudes	O
(	O
M	O
wave	O
)	O
of	O
the	O
compound	O
muscle	O
action	O
potentials	O
(	O
CMAP	O
)	O
of	O
tibialis	O
anterior	O
(	O
TA	O
)	O
and	O
plantar	O
interossei	O
muscles	O
(	O
PL	O
)	O
were	O
recorded	O
(	O
mV	O
)	O
after	O
placing	O
monopolar	O
needle	O
electrodes	O
in	O
the	O
muscle	O
bellies	O
and	O
the	O
reference	O
in	O
the	O
fourth	O
toe	O
[	O
55	O
].	O

Values	O
of	O
the	O
contralateral	O
intact	O
limb	O
were	O
used	O
as	O
control	O
.	O

During	O
the	O
tests	O
,	O
the	O
rat	B-OG
body	O
temperature	O
was	O
maintained	O
by	O
means	O
of	O
a	O
thermostated	O
warming	O
flat	O
coil	O
.	O

Animals	B-OG
were	O
anesthetized	O
with	O
ketamine	B-CD
/	O
xylacine	B-CD
and	O
the	O
sciatic	O
nerve	O
was	O
stimulated	O
by	O
transcutaneous	O
electrodes	O
placed	O
at	O
the	O
sciatic	O
notch	O
.	O

4	O
.	O
6	O
.	O

Assessment	O
of	O
Skin	O
Nociceptive	O
Reinnervation	O

The	O
progression	O
of	O
nociceptive	O
reinnervation	O
of	O
the	O
hind	O
paw	O
was	O
assessed	O
by	O
means	O
of	O
the	O
pinprick	O
test	O
and	O
thermal	O
sensitivity	O
at	O
7	O
,	O
30	O
,	O
45	O
,	O
60	O
and	O
75	O
dpi	O
.	O

For	O
the	O
pinprick	O
test	O
,	O
animals	B-OG
were	O
gently	O
kept	O
in	O
a	O
cloth	O
with	O
the	O
sole	O
of	O
the	O
injured	O
paw	O
facing	O
upward	O
,	O
and	O
the	O
skin	O
was	O
stimulated	O
with	O
a	O
needle	O
progressively	O
from	O
proximal	O
to	O
distal	O
at	O
specific	O
sites	O
of	O
the	O
lateral	O
side	O
of	O
the	O
hind	O
paw	O
plantar	O
surface	O
[	O
56	O
].	O

Fast	O
withdrawal	O
of	O
the	O
hindpaw	O
after	O
stimulation	O
was	O
identified	O
as	O
a	O
clear	O
pain	O
reaction	O
and	O
thus	O
a	O
sign	O
of	O
functional	O
skin	O
reinnervation	O
.	O

The	O
mean	O
number	O
of	O
positive	O
responses	O
in	O
every	O
tested	O
area	O
was	O
calculated	O
per	O
group	O
at	O
each	O
day	O
of	O
testing	O
.	O

Thermal	O
sensitivity	O
was	O
evaluated	O
using	O
a	O
Plantar	O
test	O
algesimeter	O
(	O
Ugo	O
Basile	O
,	O
Comerio	O
,	O
Italy	O
)	O
[	O
57	O
].	O

Rats	B-OG
were	O
individually	O
placed	O
in	O
Plexiglas	O
cubicles	O
(	O
20	O
×	O
20	O
×	O
14	O
(	O
h	O
)	O
cm	O
)	O
with	O
an	O
elevated	O
Plexiglas	O
floor	O
in	O
a	O
room	O
at	O
constant	O
temperature	O
(	O
24	O
±	O
0	O
.	O
5	O
°	O
C	O
).	O

The	O
beam	O
of	O
a	O
low	O
intensity	O
lamp	O
(	O
40	O
mW	O
/	O
cm2	O
)	O
was	O
pointed	O
to	O
the	O
lateral	O
part	O
in	O
the	O
hind	O
paw	O
plantar	O
surface	O
with	O
a	O
heating	O
rate	O
of	O
1	O
°	O
C	O
/	O
s	O
to	O
elicit	O
activation	O
of	O
unmyelinated	O
C	O
fibers	O
.	O

A	O
cutoff	O
time	O
of	O
exposure	O
to	O
limit	O
possible	O
tissue	O
damage	O
was	O
set	O
at	O
20	O
s	O
.	O

The	O
latency	O
(	O
in	O
seconds	O
)	O
of	O
hindpaw	O
withdrawal	O
from	O
the	O
thermal	O
stimulus	O
was	O
recorded	O
as	O
the	O
mean	O
of	O
3	O
tests	O
per	O
paw	O
.	O

A	O
5	O
-	O
min	O
resting	O
period	O
was	O
set	O
between	O
each	O
trial	O
.	O

4	O
.	O
7	O
.	O

Evaluation	O
of	O
Skin	O
and	O
Sweat	O
Gland	O
Reinnervation	O

For	O
assessing	O
skin	O
reinnervation	O
,	O
plantar	O
pads	O
corresponding	O
to	O
the	O
lateral	O
side	O
were	O
removed	O
at	O
the	O
end	O
of	O
the	O
functional	O
follow	O
-	O
up	O
.	O

Cryotome	O
sections	O
60	O
µm	O
thick	O
were	O
processed	O
for	O
immunolabeling	O
against	O
protein	O
gene	O
product	O
(	O
PGP	O
)	O
9	O
.	O
5	O
(	O
rabbit	B-OG
;	O
1	O
:	O
1000	O
;	O
UltraClone	O
,	O
Cambridge	O
,	O
UK	O
),	O
a	O
pan	O
-	O
neuronal	O
marker	O
.	O

Secondary	O
antibodies	B-GP
were	O
conjugated	O
to	O
Cy3	O
.	O

Sections	O
were	O
observed	O
with	O
an	O
Olympus	O
BX51	O
fluorescence	O
microscope	O
to	O
visualize	O
immunoreactive	O
nerve	O
fibers	O
that	O
had	O
reinnervated	O
the	O
epidermis	O
and	O
the	O
sweat	O
glands	O
(	O
SG	O
).	O

For	O
analysis	O
,	O
images	O
of	O
three	O
sections	O
of	O
each	O
sample	O
were	O
collected	O
with	O
an	O
Olympus	O
DP73	O
digital	O
camera	O
,	O
the	O
number	O
of	O
intraepidermal	O
nerve	O
fibers	O
(	O
IENFs	O
)	O
was	O
counted	O
in	O
a	O
1	O
-	O
mm	O
-	O
long	O
segment	O
of	O
the	O
footpad	O
epidermis	O
and	O
the	O
number	O
of	O
reinnervated	O
SGs	O
in	O
the	O
whole	O
pad	O
was	O
also	O
quantified	O
[	O
58	O
].	O

4	O
.	O
8	O
.	O

Data	O
Analysis	O

Data	O
are	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Results	O
were	O
statistically	O
analyzed	O
using	O
GraphPad	O
Prism	O
(	O
version	O
6	O
.	O
01	O
,	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
).	O

One	O
-	O
and	O
two	O
-	O
way	O
ANOVA	O
followed	O
by	O
Bonferroni	O
’	O
s	O
post	O
hoc	O
test	O
for	O
comparison	O
between	O
groups	O
were	O
used	O
.	O

Statistical	O
significance	O
was	O
considered	O
when	O
p	O
-	O
value	O
was	O
<	O
0	O
.	O
05	O
.	O

5	O
.	O

Conclusions	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
that	O
the	O
interaction	O
between	O
FN	B-GP
+	O
BDNF	B-GP
and	O
between	O
LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP
has	O
synergistic	O
effects	O
to	O
preferentially	O
enhance	O
motor	O
and	O
sensory	O
axon	O
regeneration	O
,	O
respectively	O
,	O
in	O
vitro	O
.	O

Furthermore	O
,	O
these	O
effects	O
are	O
maintained	O
in	O
vivo	O
in	O
adult	O
animals	B-OG
as	O
motor	O
and	O
sensory	O
axonal	O
regeneration	O
and	O
functional	O
recovery	O
was	O
enhanced	O
after	O
treating	O
nerve	O
injuries	O
with	O
a	O
nerve	O
conduit	O
prefilled	O
with	O
the	O
same	O
combinations	O
of	O
NTFs	O
and	O
ECM	O
components	O
.	O

(	O
A	O
–	O
I	O
)	O
RT97	O
stained	O
neurites	O
from	O
spinal	O
cord	O
slices	O
cultured	O
within	O
a	O
3D	O
collagen	B-GP
matrix	O
alone	O
,	O
and	O
with	O
addition	O
of	O
NGF	B-GP
/	O
NT3	B-GP
or	O
brain	B-GP
-	I-GP
derived	I-GP
neurotrophic	I-GP
factor	I-GP
(	O
BDNF	B-GP
)	O
(	O
A	O
–	O
C	O
);	O
with	O
20	O
%	O
laminin	B-GP
,	O
plus	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
(	O
D	O
–	O
F	O
);	O
and	O
with	O
20	O
%	O
fibronectin	B-GP
,	O
plus	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
(	O
G	O
–	O
I	O
);	O
plots	O
representing	O
maximum	O
neurite	O
length	O
in	O
the	O
different	O
DRG	O
culture	O
conditions	O
(	O
J	O
);	O
quantification	O
of	O
the	O
number	O
of	O
neurites	O
grown	O
at	O
increasing	O
distance	O
from	O
the	O
DRG	O
body	O
,	O
dashed	O
line	O
represents	O
the	O
values	O
for	O
COL	B-GP
control	O
group	O
(	O
100	O
%)	O
(	O
K	O
);	O
and	O
plots	O
of	O
the	O
quantified	O
area	O
under	O
each	O
curve	O
of	O
K	O
graph	O
(	O
L	O
).	O

Data	O
expressed	O
as	O
mean	O
±	O
SEM	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
A	O
–	O
I	O
)	O
RT97	O
stained	O
neurites	O
from	O
DRG	O
neurons	O
cultured	O
within	O
a	O
3D	O
collagen	B-GP
matrix	O
alone	O
,	O
and	O
with	O
addition	O
of	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
(	O
A	O
–	O
C	O
);	O
with	O
20	O
%	O
laminin	B-GP
,	O
plus	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
(	O
D	O
–	O
F	O
);	O
and	O
with	O
20	O
%	O
fibronectin	B-GP
,	O
plus	O
NGF	B-GP
/	O
NT3	B-GP
or	O
BDNF	B-GP
(	O
G	O
–	O
I	O
);	O
(	O
J	O
)	O
plots	O
representing	O
maximum	O
neurite	O
length	O
in	O
the	O
different	O
culture	O
conditions	O
,	O
dashed	O
line	O
represents	O
the	O
values	O
for	O
COL	B-GP
control	O
group	O
(	O
100	O
%);	O
(	O
K	O
)	O
quantification	O
of	O
the	O
number	O
of	O
neurites	O
grown	O
at	O
increasing	O
distance	O
from	O
the	O
cord	O
slice	O
;	O
and	O
(	O
L	O
)	O
plots	O
of	O
the	O
quantified	O
area	O
under	O
each	O
curve	O
of	O
K	O
graph	O
.	O

Data	O
expressed	O
as	O
mean	O
±	O
SEM	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
A	O
–	O
F	O
)	O
Representative	O
micrographs	O
of	O
neurons	O
retrolabeled	O
with	O
FG	O
in	O
the	O
spinal	O
cord	O
(	O
A	O
–	O
C	O
);	O
and	O
DRG	O
(	O
D	O
–	O
F	O
)	O
of	O
rats	B-OG
after	O
sciatic	O
nerve	O
section	O
and	O
repair	O
with	O
a	O
nerve	O
conduit	O
filled	O
:	O
with	O
COL	B-GP
(	O
A	O
,	O
D	O
);	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
(	O
B	O
,	O
E	O
);	O
or	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
(	O
C	O
,	O
F	O
).	O

(	O
G	O
–	O
H	O
)	O
Histogram	O
of	O
the	O
number	O
of	O
regenerated	O
motor	O
neurons	O
in	O
the	O
spinal	O
cord	O
(	O
G	O
)	O
and	O
sensory	O
neurons	O
in	O
the	O
DRG	O
(	O
H	O
)	O
in	O
the	O
short	O
term	O
(	O
20	O
days	O
after	O
injury	O
)	O
study	O
.	O

(	O
I	O
,	O
J	O
)	O
Histogram	O
of	O
the	O
number	O
of	O
regenerated	O
motor	O
neurons	O
in	O
the	O
spinal	O
cord	O
(	O
I	O
)	O
and	O
sensory	O
neurons	O
in	O
the	O
DRG	O
(	O
J	O
)	O
after	O
application	O
of	O
FG	O
retrotracer	O
at	O
the	O
ankle	O
level	O
75	O
days	O
after	O
injury	O
.	O

Data	O
expressed	O
as	O
mean	O
±	O
SEM	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

FN	O
+	O
MP	O
.	O
BDNF	B-GP
and	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
enhance	O
motor	O
and	O
sensory	O
functional	O
recovery	O
,	O
respectively	O
.	O

(	O
A	O
,	O
B	O
)	O
Mean	O
amplitude	O
of	O
the	O
CMAP	O
in	O
TA	O
(	O
A	O
)	O
and	O
PL	O
(	O
B	O
)	O
muscles	O
during	O
follow	O
-	O
up	O
.	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
FN	O
+	O
MP	O
.	O
BDNF	B-GP
vs	O
.	O
all	O
other	O
groups	O
referenced	O
by	O
the	O
color	O
of	O
the	O
star	O
.	O

(	O
C	O
)	O
Pinprick	O
score	O
in	O
the	O
different	O
groups	O
during	O
follow	O
-	O
up	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
D	O
)	O
Latency	O
of	O
withdrawal	O
response	O
to	O
thermal	O
stimuli	O
in	O
the	O
lateral	O
part	O
of	O
the	O
paw	O
during	O
follow	O
-	O
up	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	O
vs	O
.	O
all	O
other	O
groups	O
referenced	O
by	O
the	O
color	O
of	O
the	O
star	O
.	O

(	O
E	O
–	O
J	O
)	O
Representative	O
images	O
of	O
plantar	O
pads	O
immunolabeled	O
against	O
PGP	O
in	O
:	O
an	O
intact	O
rat	B-OG
(	O
E	O
);	O
COL	O
(	O
F	O
);	O
LM	O
(	O
G	O
);	O
LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP
(	O
H	O
);	O
FN	O
(	O
I	O
);	O
and	O
FN	B-GP
+	O
MP	O
.	O
BDNF	B-GP
(	O
J	O
)	O
treated	O
animals	B-OG
.	O

Insets	O
:	O
Detail	O
of	O
axons	O
stained	O
with	O
PGP	O
innervating	O
epidermis	O
and	O
SGs	O
.	O

(	O
K	O
,	O
L	O
)	O
Percentage	O
of	O
reinnervated	O
IENF	O
(	O
K	O
)	O
and	O
reinnervated	O
SGs	O
(	O
L	O
)	O
vs	O
.	O
intact	O
values	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
01	O
and	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Data	O
is	O
presented	O
as	O
mean	O
±	O
SEM	O
.	O

Experimental	O
conditions	O
evaluated	O
in	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

Group	O

Abbreviation	O

N	O

Description	O

In	O
Vitro	O
Condition	O

Collagen	B-GP

COL	O

8	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O

Collagen	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP

COL	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP

7	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
supplemented	O
with	O
NGF	B-GP
and	O
NT3	B-GP
(	O
25	O
+	O
25	O
ng	O
/	O
mL	O
)	O

Collagen	B-GP
+	O
BDNF	B-GP

COL	O
+	O
BDNF	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
supplemented	O
with	O
BDNF	B-GP
(	O
50	O
ng	O
/	O
mL	O
)	O

Laminin	O

LM	O

8	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
laminin	B-GP
type	I-GP
I	I-GP

Laminin	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP

LM	O
+	O
NGF	B-GP
/	O
NT3	B-GP

7	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
laminin	B-GP
type	I-GP
I	I-GP
and	O
NGF	B-GP
+	O
NT3	B-GP
(	O
25	O
+	O
25	O
ng	O
/	O
mL	O
)	O

Laminin	O
+	O
BDNF	B-GP

LM	O
+	O
BDNF	B-GP

7	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
laminin	B-GP
type	I-GP
I	I-GP
and	O
BDNF	B-GP
(	O
50	O
ng	O
/	O
mL	O
)	O

Fibronectin	B-GP

FN	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
fibronectin	B-GP

Fibronectin	B-GP
+	O
NGF	B-GP
/	O
NT	B-GP
-	I-GP
3	I-GP

FN	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
fibronectin	B-GP
and	O
NGF	B-GP
+	O
NT3	O
(	O
25	O
+	O
25	O
ng	O
/	O
mL	O
)	O

Fibronectin	B-GP
+	O
BDNF	B-GP

FN	O
+	O
BDNF	B-GP

7	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
fibronectin	B-GP
and	O
BDNF	B-GP
(	O
50	O
ng	O
/	O
mL	O
)	O

In	O
Vivo	O
Condition	O

Collagen	B-GP

COL	O

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O

Laminin	O

LM	O

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
laminin	B-GP
type	I-GP
I	I-GP

Collagen	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP
*	O

MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
NGF	B-GP
+	O
NT3	O
(	O
1	O
+	O
1	O
µg	O
/	O
mL	O
)	O
encapsulated	O
in	O
PLGA	O
microspheres	O

Laminin	B-GP
+	O
NGF	B-GP
/	O
NT3	B-GP

LM	O
+	O
MP	O
.	O
NGF	B-GP
/	O
NT3	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
laminin	B-GP
type	I-GP
I	I-GP
and	O
NGF	B-GP
+	O
NT3	O
(	O
1	O
+	O
1	O
µg	O
/	O
mL	O
)	O
encapsulated	O
in	O
PLGA	O
microspheres	O

Fibronectin	B-GP

FN	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
fibronectin	B-GP

Collagen	B-GP
+	O
BDNF	B-GP
*	O

MP	O
.	O
BDNF	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
2	O
µg	O
/	O
mL	O
of	O
BDNF	B-GP
encapsulated	O
in	O
PLGA	O
microspheres	O

Fibronectin	B-GP
+	O
BDNF	B-GP

FN	O
+	O
MP	O
.	O
BDNF	B-GP

6	O

Collagen	B-GP
type	I-GP
I	I-GP
(	O
3	O
mg	O
/	O
mL	O
)	O
gel	O
containing	O
20	O
%	O
fibronectin	B-GP
and	O
2	O
µg	O
/	O
ml	O
of	O
BDNF	B-GP
encapsulated	O
in	O
PLGA	O
microspheres	O

Identification	O
and	O
application	O
of	O
keto	B-GP
acids	I-GP
transporters	I-GP
in	O
Yarrowia	B-OG
lipolytica	I-OG

Production	O
of	O
organic	O
acids	O
by	O
microorganisms	B-OG
is	O
of	O
great	O
importance	O
for	O
obtaining	O
building	O
-	O
block	O
chemicals	O
from	O
sustainable	O
biomass	O
.	O

Extracellular	O
accumulation	O
of	O
organic	O
acids	O
involved	O
a	O
series	O
of	O
transporters	B-GP
,	O
which	O
play	O
important	O
roles	O
in	O
the	O
accumulation	O
of	O
specific	O
organic	O
acid	O
while	O
lack	O
of	O
systematic	O
demonstration	O
in	O
eukaryotic	O
microorganisms	B-OG
.	O

To	O
circumvent	O
accumulation	O
of	O
by	O
-	O
product	O
,	O
efforts	O
have	O
being	O
orchestrated	O
to	O
carboxylate	O
transport	O
mechanism	O
for	O
potential	O
clue	O
in	O
Yarrowia	B-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
.	O

Six	O
endogenous	O
putative	B-GP
transporter	I-GP
genes	O
,	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
and	O
YALI0E32901g	O
,	O
were	O
identified	O
.	O

Transport	O
characteristics	O
and	O
substrate	O
specificities	O
were	O
further	O
investigated	O
using	O
a	O
carboxylate	O
-	O
transport	O
-	O
deficient	O
Saccharomyces	B-OG
cerevisiae	I-OG
strain	O
.	O

These	O
transporters	B-GP
were	O
expressed	O
in	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
to	O
assess	O
their	O
roles	O
in	O
regulating	O
extracellular	O
keto	B-CD
acids	I-CD
accumulation	O
.	O

In	O
a	O
Y	B-OG
.	I-OG
lipolytica	I-OG
T1	O
line	O
over	O
expressing	O
YALI0B19470g	O
,	O
α	O
-	O
ketoglutarate	O
accumulated	O
to	O
46	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
,	O
whereas	O
the	O
concentration	O
of	O
pyruvate	B-CD
decreased	O
to	O
12	O
.	O
3	O
g	O
·	O
L	O
−	O
1	O
.	O

Systematic	O
identification	O
of	O
these	O
keto	B-GP
acids	I-GP
transporters	I-GP
would	O
provide	O
clues	O
to	O
further	O
improve	O
the	O
accumulation	O
of	O
specific	O
organic	O
acids	O
with	O
higher	O
efficiency	O
in	O
eukaryotic	O
microorganisms	B-OG
.	O

Light	O
have	O
been	O
shed	O
on	O
economic	O
feasibility	O
of	O
production	O
of	O
organic	O
acids	O
by	O
microorganisms	B-OG
,	O
expecially	O
considering	O
the	O
finiteness	O
of	O
fossil	O
raw	O
materials1	O
.	O

Although	O
organic	O
acids	O
occupy	O
a	O
key	O
position	O
among	O
the	O
building	O
-	O
block	O
chemicals	O
,	O
economic	O
production	O
by	O
microorganisms	B-OG
is	O
still	O
a	O
big	O
chagllenge	O
to	O
replace	O
petroleum	O
-	O
derived	O
commodity	O
chemicals2	O
.	O

In	O
particular	O
,	O
bio	O
-	O
based	O
production	O
of	O
organic	O
acids	O
is	O
unharnessed	O
by	O
low	O
titres	O
,	O
low	O
yield	O
and	O
accumution	O
of	O
by	O
-	O
products345	O
.	O

The	O
metabolism	O
and	O
accumulation	O
of	O
α	O
-	O
ketoglutaric	O
acid	O
(	O
α	B-GP
-	O
KG	O
)	O
are	O
subjected	O
to	O
a	O
higher	O
level	O
of	O
regulation	O
than	O
other	O
organic	O
acids	O
involved	O
in	O
central	O
carbon	O
metabolism6	O
,	O
as	O
α	B-GP
-	I-GP
KG	I-GP
occupies	O
a	O
key	O
position	O
in	O
both	O
carbon	O
central	O
metabolism7	O
and	O
the	O
regulation	O
of	O
the	O
carbon	O
–	O
nitrogen	O
balance8	O
.	O

Metabolic	O
strategies	O
concerning	O
the	O
following	O
have	O
been	O
investigated	O
for	O
α	O
-	O
KG	O
production	O
:	O
regulation	O
of	O
key	O
enzymes	O
,	O
including	O
pyruvate	B-GP
dehydrogenase	I-GP
complex9	I-GP
,	O
pyruvate	B-GP
carboxylase10	I-GP
,	O
fumarase3	B-GP
,	O
aconitase11	B-GP
,	O
isocitrate	B-GP
lyase12	I-GP
,	O
isocitrate	B-GP
dehydrogenase13	I-GP
and	O
components	O
of	O
the	O
α	B-GP
-	I-GP
ketoglutarate	I-GP
dehydrogenase	I-GP
complex14	I-GP
;	O
and	O
co	O
-	O
factor	O
engineering	O
of	O
acetyl	O
-	O
CoA	O
biosynthesis	O
and	O
regeneration15	O
.	O

Extracellular	O
accumulation	O
of	O
non	O
-	O
target	O
carboxylates	B-CD
is	O
a	O
common	O
problem	O
for	O
the	O
production	O
of	O
carboxylates1617	B-CD
.	O

Manipulation	O
of	O
transporters	B-GP
has	O
been	O
an	O
efficient	O
tool	O
to	O
improve	O
the	O
productivity	O
for	O
target	O
carboxylates5	B-CD
.	O

A	O
successful	O
metabolic	O
engineering	O
approach	O
for	O
the	O
over	O
-	O
synthesis	O
of	O
organic	O
acids	O
also	O
requires	O
incorporation	O
of	O
an	O
appropriate	O
exporter	O
to	O
increase	O
productivity18	O
.	O

A	O
comparative	O
study	O
revealed	O
that	O
the	O
highest	O
malate	B-CD
yield	O
was	O
obtained	O
once	O
the	O
malate	B-GP
transporter	I-GP
was	O
recruited	O
in	O
the	O
mutants19	O
.	O

Lactate	B-CD
production	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG
could	O
be	O
significantly	O
improved	O
with	O
the	O
combined	O
expression	O
of	O
lactate	B-GP
dehydrogenase	I-GP
and	O
the	O
lactate	B-GP
transporter20	I-GP
.	O

Although	O
many	O
studies	O
have	O
described	O
the	O
mechanisms	O
of	O
action	O
and	O
regulation	O
for	O
carboxylate	O
transport	O
in	O
yeast2021	O
,	O
Y	B-OG
.	I-OG
lipolytica	I-OG
orthologous	O
gene	O
of	O
the	O
carboxylate	B-GP
transporter	I-GP
have	O
not	O
yet	O
been	O
identified	O
.	O

In	O
this	O
study	O
,	O
a	O
number	O
of	O
carboxylate	B-GP
transporters	I-GP
were	O
identified	O
from	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
,	O
which	O
exhibits	O
flexibility	O
in	O
substrate	O
specificity	O
.	O

The	O
duplication	O
of	O
endogenous	O
transporters	B-GP
might	O
provide	O
a	O
powerful	O
tool	O
to	O
ensure	O
efficient	O
carboxylate	O
synthesis	O
and	O
maintain	O
homeostasis	O
of	O
the	O
intracellular	O
environment	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
a	O
competitive	O
dual	O
effect	O
—	O
a	O
significant	O
increase	O
in	O
α	B-GP
-	I-GP
KG	I-GP
production	O
with	O
a	O
sharp	O
decrease	O
in	O
pyruvate	B-CD
(	O
PA	O
)	O
accumulation	O
resulted	O
from	O
overexpression	O
of	O
YALI0B19470g	O
.	O

This	O
result	O
suggests	O
a	O
new	O
and	O
promising	O
strategy	O
for	O
gene	O
manipulation	O
that	O
can	O
efficiently	O
address	O
α	B-GP
-	I-GP
KG	I-GP
accumulation	O
.	O

The	O
identification	O
of	O
these	O
transporters	B-GP
also	O
have	O
uncovered	O
the	O
mechanisms	O
of	O
extracellular	O
accumulation	O
of	O
diverse	O
organic	O
acids	O
in	O
genome	O
level	O
,	O
and	O
provides	O
new	O
clues	O
to	O
orchestrate	O
competition	O
of	O
extracellular	O
accumulation	O
between	O
target	O
and	O
non	O
-	O
target	O
carboxylates	B-CD
in	O
yeast	B-OG
and	O
other	O
eukaryotic	O
microorganisms	B-OG
.	O

Results	O

Bioinformatics	O
analysis	O
of	O
potential	O
carboxylate	B-GP
transporters	I-GP
in	O
Y	B-OG
.	I-OG
lipolytica	I-OG

To	O
screen	O
putative	O
carboxylate	B-GP
transporters	I-GP
,	O
6611	O
proteins	O
encoded	O
by	O
Y	B-OG
.	I-OG
lipolytica	I-OG
CLIB122	O
genome	O
were	O
obtained	O
from	O
the	O
UniProt	O
database	O
.	O

Of	O
these	O
,	O
1104	O
proteins	O
(	O
Supplementary	O
S1	O
)	O
were	O
predicted	O
as	O
transmembrane	B-GP
proteins	I-GP
by	O
TMHMM	O
v	O
.	O
2	O
.	O
0	O
(	O
Fig	O
.	O
1A	O
).	O

Subsequently	O
,	O
117	O
proteins	O
were	O
excluded	O
from	O
this	O
set	O
,	O
due	O
to	O
the	O
presence	O
of	O
a	O
possible	O
signal	O
peptide	O
at	O
the	O
N	O
terminus	O
,	O
as	O
predicted	O
by	O
SignalP	O
4	O
.	O
1	O
.	O

A	O
sequence	O
search	O
using	O
a	O
conserved	O
carboxylate	B-GP
transporter	I-GP
signature	O
of	O
JEN	B-GP
family	O
,	O
NXXS	O
/	O
THXS	O
/	O
TQDXXXT	O
,	O
identified	O
six	O
putative	O
proteins	O
encoded	O
by	O
the	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
,	O
and	O
YALI0E32901g	O
genes	O
,	O
which	O
exhibited	O
high	O
similarity	O
to	O
the	O
signature	O
sequence	O
.	O

A	O
multiple	O
sequence	O
alignment	O
of	O
these	O
sequences	O
using	O
homologous	O
carboxylate	B-GP
transporter	I-GP
sequences	O
from	O
other	O
fungi	B-OG
confirmed	O
the	O
presence	O
of	O
the	O
conserved	O
sequence	O
(	O
Fig	O
.	O
1B	O
).	O

In	O
addition	O
,	O
a	O
high	O
level	O
of	O
sequence	O
similarity	O
among	O
these	O
putative	B-GP
transporters	I-GP
and	O
the	O
characterized	O
carboxylate	B-GP
transporters	I-GP
was	O
illustrated	O
by	O
two	O
BLAST	O
(	O
http	O
://	O
blast	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/)	O
protocols	O
,	O
in	O
which	O
ScJen1p	B-GP
and	O
KlJen2p	B-GP
were	O
used	O
as	O
query	O
sequences222324	O
.	O

In	O
these	O
cases	O
,	O
the	O
identity	O
to	O
ScJen1p	B-GP
and	O
to	O
KlJen2p	B-GP
were	O
prospected	O
,	O
respectively	O
(	O
Fig	O
.	O
2	O
).	O
In	O
silico	O
analysis	O
of	O
these	O
protein	O
sequences	O
using	O
the	O
TMRPres2D	O
tool	O
revealed	O
that	O
the	O
conserved	O
sequence	O
was	O
located	O
in	O
the	O
predicted	O
transmembrane	O
helices	O
(	O
Fig	O
.	O
3	O
).	O

Hence	O
,	O
these	O
transmembrane	B-GP
proteins	I-GP
were	O
suspected	O
to	O
be	O
potential	O
carboxylate	B-GP
transporters	I-GP
.	O

Exogenous	O
keto	B-CD
acid	I-CD
treatment	O

To	O
uncover	O
the	O
response	O
of	O
carboxylate	B-GP
transporter	I-GP
candidates	O
for	O
uptake	O
of	O
exogenous	O
keto	B-CD
acids	I-CD
,	O
glucose	B-CD
-	O
grown	O
(	O
repression	O
condition	O
)	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	O
-	O
Z06	O
cells	O
were	O
transferred	O
at	O
the	O
exponential	O
phase	O
to	O
YPK	O
or	O
YPP	O
medium	O
(	O
A	O
large	O
amount	O
exogenous	O
organic	O
acids	O
were	O
accumulated	O
in	O
yeast	B-OG
cells	O
,	O
Supplementary	O
S2	O
).	O

Initially	O
,	O
neither	O
α	B-GP
-	I-GP
KG	I-GP
nor	O
PA	B-GP
was	O
detected	O
in	O
these	O
cultures	O
.	O

During	O
the	O
first	O
hour	O
,	O
the	O
intracellular	O
concentration	O
of	O
both	O
carboxylates	O
increased	O
quickly	O
to	O
maximums	O
of	O
3	O
.	O
90	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
for	O
α	B-GP
-	I-GP
KG	I-GP
and	O
1	O
.	O
67	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
for	O
PA	O
in	O
α	B-GP
-	I-GP
KG	I-GP
-	O
and	O
PA	O
-	O
treated	O
cells	O
,	O
respectively	O
.	O

After	O
incubation	O
in	O
YPK	O
or	O
YPP	O
medium	O
for	O
1	O
h	O
,	O
the	O
concentration	O
of	O
α	B-GP
-	I-GP
KG	I-GP
gradually	O
decreased	O
1	O
h	O
to	O
3	O
h	O
,	O
until	O
the	O
minimum	O
of	O
0	O
.	O
85	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
was	O
reached	O
.	O

During	O
this	O
period	O
,	O
the	O
content	O
of	O
PA	O
also	O
decreased	O
to	O
0	O
.	O
23	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
(	O
Fig	O
.	O
4A	O
).	O

To	O
assay	O
the	O
effects	O
of	O
exogenous	O
carboxylates	B-CD
on	O
the	O
expression	O
profiles	O
of	O
these	O
potential	O
transporters	B-GP
,	O
the	O
expression	O
of	O
these	O
genes	O
were	O
examined	O
by	O
qRT	O
-	O
PCR	O
,	O
using	O
RNA	O
extracted	O
at	O
0	O
h	O
as	O
the	O
control	O
.	O

When	O
intracellular	O
α	B-GP
-	I-GP
KG	I-GP
levels	O
increased	O
,	O
the	O
expression	O
of	O
YALI0D20108g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
and	O
YALI0E32901g	O
decreased	O
by	O
3	O
.	O
72	O
±	O
0	O
.	O
91	O
-	O
fold	O
,	O
3	O
.	O
88	O
±	O
0	O
.	O
34	O
-	O
fold	O
,	O
2	O
.	O
47	O
±	O
0	O
.	O
52	O
-	O
fold	O
,	O
and	O
1	O
.	O
60	O
±	O
0	O
.	O
18	O
-	O
fold	O
,	O
respectively	O
,	O
whereas	O
the	O
expression	O
of	O
YALI0B19470g	O
and	O
YALI0C15488g	O
increased	O
by	O
9	O
.	O
39	O
±	O
0	O
.	O
82	O
-	O
fold	O
and	O
4	O
.	O
32	O
±	O
0	O
.	O
83	O
-	O
fold	O
,	O
respectively	O
.	O

Exogenous	O
PA	O
had	O
a	O
similar	O
effect	O
on	O
expression	O
,	O
albeit	O
to	O
different	O
levels	O
.	O

When	O
incubated	O
with	O
PA	O
,	O
expression	O
of	O
YALI0D20108g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
and	O
YALI0E32901g	O
decreased	O
by	O
5	O
.	O
83	O
±	O
0	O
.	O
81	O
-	O
fold	O
,	O
4	O
.	O
04	O
±	O
1	O
.	O
04	O
-	O
fold	O
,	O
6	O
.	O
44	O
±	O
0	O
.	O
98	O
-	O
fold	O
,	O
and	O
15	O
.	O
88	O
±	O
1	O
.	O
94	O
-	O
fold	O
,	O
respectively	O
,	O
whereas	O
expression	O
of	O
YALI0B19470g	O
and	O
YALI0C15488g	O
increased	O
by	O
2	O
.	O
83	O
±	O
0	O
.	O
21	O
-	O
fold	O
and	O
9	O
.	O
72	O
±	O
0	O
.	O
22	O
-	O
fold	O
,	O
respectively	O
(	O
Fig	O
.	O
4B	O
).	O

Hence	O
,	O
we	O
concluded	O
that	O
transport	O
of	O
both	O
keto	B-CD
acids	I-CD
should	O
be	O
predominantly	O
mediated	O
by	O
YALI0B19470p	O
and	O
YALI0C15488p	O
.	O

Assessment	O
of	O
putative	O
genes	O
using	O
heterologous	O
expression	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG

To	O
assess	O
their	O
possible	O
roles	O
in	O
carboxylate	O
transport	O
,	O
null	O
mutants	O
of	O
endogenous	O
transporters	B-GP
were	O
constructed	O
by	O
gene	O
disruption	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	I-OG
.	O

The	O
ScJEN1	B-GP
deletion	O
mutant	O
displayed	O
reduced	O
growth	O
on	O
lactate	B-CD
,	O
acetate	O
,	O
PA	O
,	O
malate	B-CD
,	O
and	O
α	O
-	O
KG	O
compared	O
to	O
the	O
parental	O
strain	O
.	O

To	O
completely	O
abolish	O
the	O
uptake	O
by	O
endogenous	O
transporters	B-GP
,	O
the	O
Ady2p	B-GP
was	O
also	O
disrupted	O
in	O
W1	O
strain	O
.	O

In	O
contrast	O
,	O
the	O
W2	O
strain	O
,	O
in	O
which	O
both	O
ScJEN1	B-GP
and	O
ScADY2	B-GP
were	O
disrupted	O
,	O
cannot	O
grow	O
on	O
lactate	B-CD
,	O
acetate	O
,	O
PA	O
,	O
malate	B-CD
,	O
and	O
α	O
-	O
KG	O
containing	O
media	O
.	O

Moreover	O
,	O
the	O
parental	O
strain	O
as	O
well	O
as	O
the	O
W1	O
and	O
W2	O
strains	O
did	O
not	O
grow	O
on	O
citrate	B-CD
(	O
Fig	O
.	O
5	O
).	O

All	O
putative	B-GP
transporter	I-GP
genes	O
were	O
introduced	O
into	O
the	O
W2	O
strain	O
by	O
genetic	O
transformation	O
based	O
on	O
Δhis3	O
complementation	O
.	O

The	O
resulting	O
strains	O
grew	O
well	O
on	O
all	O
sources	O
including	O
citrate	B-CD
,	O
supporting	O
the	O
conclusion	O
that	O
these	O
genes	O
encode	O
carboxylate	B-GP
transporters	I-GP
(	O
Fig	O
.	O
5	O
).	O

Substrate	O
specificity	O
assay	O

To	O
investigate	O
the	O
substrate	O
specificity	O
of	O
these	O
proteins	O
,	O
glucose	B-CD
-	O
grown	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
and	O
mutants	O
were	O
incubated	O
in	O
YPA	O
,	O
YPL	O
,	O
YPP	O
,	O
YPM	O
,	O
YPK	O
,	O
and	O
YPC	O
medium	O
for	O
2	O
h	O
after	O
exhaustion	O
of	O
the	O
endogenous	O
carbon	O
source	O
in	O
saline	O
water	O
.	O

The	O
intracellular	O
carboxylate	O
content	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	O
-	O
1D	O
cells	O
was	O
measured	O
(	O
Table	O
1	O
),	O
revealing	O
that	O
2	O
.	O
22	O
±	O
0	O
.	O
21	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
lactate	B-CD
,	O
0	O
.	O
94	O
±	O
0	O
.	O
14	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
PA	O
,	O
3	O
.	O
14	O
±	O
0	O
.	O
24	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
malate	B-CD
,	O
and	O
1	O
.	O
29	O
±	O
0	O
.	O
12	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
α	B-GP
-	I-GP
KG	I-GP
were	O
present	O
.	O

In	O
addition	O
,	O
acetate	O
and	O
citrate	B-CD
were	O
not	O
detected	O
in	O
cells	O
incubated	O
in	O
the	O
corresponding	O
carboxylate	O
-	O
containing	O
medium	O
.	O

As	O
no	O
carboxylates	O
were	O
detected	O
in	O
the	O
double	O
deletion	O
cells	O
,	O
we	O
concluded	O
that	O
ScJen1p	B-GP
and	O
ScAdy2p	B-GP
deletions	O
influenced	O
the	O
transport	O
of	O
PA	O
,	O
malate	B-CD
,	O
and	O
α	B-GP
-	I-GP
KG	I-GP
.	O

The	O
transport	O
of	O
α	B-GP
-	I-GP
KG	I-GP
was	O
restored	O
in	O
all	O
heterogeneous	O
transporter	B-GP
-	O
containing	O
strains	O
,	O
with	O
the	O
highest	O
accumulation	O
(	O
1	O
.	O
41	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
)	O
occurring	O
in	O
the	O
W4	O
strain	O
.	O

Among	O
the	O
set	O
,	O
only	O
the	O
W4	O
could	O
accumulate	O
PA	O
intracellularly	O
(	O
0	O
.	O
17	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
).	O

Based	O
on	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
YALI0B19470g	O
and	O
YALI0D24607g	O
encode	O
proteins	O
that	O
transport	O
dicarboxylates	B-CD
and	O
tricarboxylates	B-CD
.	O

In	O
addition	O
to	O
PA	O
,	O
W4	O
cells	O
(	O
containing	O
YALI0C15488p	O
)	O
also	O
accumulated	O
acetate	O
,	O
malate	B-CD
,	O
α	B-GP
-	I-GP
KG	I-GP
,	O
and	O
citrate	B-CD
,	O
indicating	O
the	O
corresponding	O
protein	O
also	O
transported	O
these	O
carboxylates	B-CD
.	O

In	O
a	O
similar	O
manner	O
,	O
we	O
conclude	O
the	O
proteins	O
encoded	O
by	O
the	O
corresponding	O
genes	O
transport	O
the	O
following	O
carboxylates	B-CD
:	O
YALI0C21406p	O
for	O
lactate	B-CD
,	O
malate	B-CD
,	O
α	B-GP
-	I-GP
KG	I-GP
,	O
and	O
citrate	B-CD
;	O
YALI0D20108p	O
for	O
lactate	B-CD
,	O
α	B-GP
-	I-GP
KG	I-GP
and	O
citrate	B-CD
,	O
and	O
YALI0E32901p	O
for	O
acetate	O
,	O
malate	B-CD
,	O
and	O
citrate	B-CD
.	O

Copy	O
number	O
analysis	O
of	O
putative	O
transporter	B-GP
genes	O
in	O
recombinant	O
strains	O

In	O
order	O
to	O
estimate	O
copy	O
number	O
of	O
each	O
expression	O
cassette	O
that	O
integrated	O
in	O
genome	O
of	O
recombinant	O
strains	O
,	O
quantitative	O
-	O
PCR	O
(	O
qPCR	O
)	O
analysis	O
was	O
carried	O
out	O
.	O
ACT1	B-GP
was	O
utilized	O
as	O
an	O
endogenous	O
control26	O
.	O

With	O
comparison	O
to	O
ACT1	B-GP
,	O
no	O
obvious	O
relative	O
changes	O
of	O
these	O
transporters	O
were	O
observed	O
(	O
Fig	O
.	O
6	O
).	O

This	O
indicated	O
that	O
these	O
transporter	B-GP
genes	O
were	O
presented	O
in	O
a	O
single	O
copy	O
in	O
parental	O
strain	O
,	O
respectively	O
.	O

After	O
individual	O
transportation	O
of	O
each	O
endogenous	O
transporters	B-GP
gene	O
into	O
cells	O
of	O
parental	O
strain	O
,	O
relative	O
changes	O
of	O
2	O
.	O
54	O
±	O
0	O
.	O
22	O
-	O
fold	O
for	O
YALI0B19470g	O
,	O
2	O
.	O
33	O
±	O
0	O
.	O
27	O
-	O
fold	O
for	O
YALI0C15488g	O
,	O
2	O
.	O
62	O
±	O
0	O
.	O
33	O
-	O
fold	O
for	O
YALI0C21406g	O
,	O
2	O
.	O
28	O
±	O
0	O
.	O
19	O
-	O
fold	O
for	O
YALI0D24607g	O
,	O
2	O
.	O
39	O
±	O
0	O
.	O
26	O
-	O
fold	O
for	O
YALI0D20108g	O
and	O
2	O
.	O
55	O
±	O
0	O
.	O
32	O
-	O
fold	O
for	O
YALI0E32901g	O
were	O
observed	O
,	O
which	O
indicated	O
one	O
more	O
copy	O
of	O
each	O
transporter	B-GP
gene	O
existed	O
per	O
genome	O
in	O
corresponding	O
recombinant	O
strain	O
(	O
Fig	O
.	O
6	O
).	O

The	O
effects	O
of	O
transporter	B-GP
genes	O
on	O
carboxylate	O
accumulation	O
in	O
Y	B-OG
.	I-OG
lipolytica	I-OG

As	O
previously	O
reported	O
carboxylate	B-GP
transporter	I-GP
possess	O
bi	O
-	O
functions	O
for	O
carboxylate	O
influx	O
and	O
efflux25	O
.	O

To	O
clarify	O
the	O
roles	O
of	O
these	O
transporters	B-GP
on	O
carboxylate	O
extracellular	O
accumulation	O
,	O
they	O
were	O
overexpressed	O
in	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
.	O

The	O
hp4d	B-GP
promoter	O
was	O
used	O
to	O
increase	O
the	O
transcription	O
of	O
these	O
genes	O
,	O
and	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
and	O
YALI0E32901g	O
expression	O
was	O
improved	O
by	O
23	O
.	O
34	O
±	O
2	O
.	O
67	O
-	O
fold	O
,	O
8	O
.	O
53	O
±	O
0	O
.	O
90	O
-	O
fold	O
,	O
9	O
.	O
32	O
±	O
0	O
.	O
82	O
-	O
fold	O
,	O
11	O
.	O
79	O
±	O
1	O
.	O
32	O
-	O
fold	O
,	O
3	O
.	O
37	O
±	O
0	O
.	O
49	O
-	O
fold	O
and	O
10	O
.	O
50	O
±	O
0	O
.	O
97	O
-	O
fold	O
,	O
respectively	O
(	O
Fig	O
.	O
7	O
).	O

Due	O
to	O
the	O
flexible	O
substrate	O
specificity	O
of	O
these	O
transporters	B-GP
,	O
the	O
accumulation	O
of	O
PA	O
and	O
α	B-GP
-	I-GP
KG	I-GP
increased	O
in	O
T5	O
cells	O
,	O
and	O
the	O
ratio	O
of	O
extracellular	O
α	B-GP
-	I-GP
KG	I-GP
/	O
PA	O
decreased	O
from	O
2	O
.	O
06	O
to	O
1	O
.	O
87	O
compared	O
to	O
the	O
wild	O
-	O
type	O
strain	O
.	O

This	O
ratio	O
also	O
decreased	O
in	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
and	O
YALI0E32901g	O
overexpressing	O
strains	O
,	O
as	O
only	O
extracellular	O
PA	O
increased	O
for	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
and	O
T6	O
.	O

A	O
competitive	O
dual	O
effect	O
was	O
observed	O
for	O
strain	O
T1	O
:	O
the	O
transport	O
of	O
α	B-GP
-	I-GP
KG	I-GP
increased	O
dramatically	O
,	O
whereas	O
the	O
concentration	O
of	O
PA	O
dropped	O
by	O
30	O
.	O
6	O
%,	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
ratio	O
of	O
extracellular	O
α	B-GP
-	I-GP
KG	I-GP
/	O
PA	O
from	O
2	O
.	O
06	O
to	O
3	O
.	O
79	O
(	O
Fig	O
.	O
8	O
).	O

The	O
intracellular	O
carboxylate	O
content	O
,	O
Cin	O
(	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
),	O
was	O
also	O
determined	O
(	O
Table	O
2	O
).	O

The	O
intracellular	O
accumulation	O
of	O
α	B-GP
-	I-GP
KG	I-GP
decreased	O
from	O
0	O
.	O
026	O
±	O
0	O
.	O
005	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
to	O
0	O
.	O
014	O
±	O
0	O
.	O
002	O
,	O
0	O
.	O
023	O
±	O
0	O
.	O
003	O
,	O
0	O
.	O
014	O
±	O
0	O
.	O
002	O
and	O
0	O
.	O
020	O
±	O
0	O
.	O
002	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
for	O
strains	O
T1	O
,	O
T4	O
,	O
T5	O
and	O
T6	O
.	O

The	O
intracellular	O
accumulation	O
of	O
PA	O
decreased	O
from	O
0	O
.	O
034	O
±	O
0	O
.	O
006	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
to	O
0	O
.	O
009	O
±	O
0	O
.	O
002	O
,	O
0	O
.	O
029	O
±	O
0	O
.	O
003	O
,	O
0	O
.	O
017	O
±	O
0	O
.	O
002	O
and	O
0	O
.	O
025	O
±	O
0	O
.	O
002	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
in	O
strains	O
T1	O
,	O
T4	O
,	O
T5	O
and	O
T6	O
respectively	O
.	O

Compared	O
to	O
the	O
wild	O
-	O
type	O
strain	O
,	O
the	O
growth	O
yield	O
decreased	O
from	O
11	O
.	O
17	O
±	O
1	O
.	O
08	O
g	O
·	O
L	O
−	O
1	O
to	O
8	O
.	O
45	O
±	O
0	O
.	O
72	O
,	O
8	O
.	O
27	O
±	O
0	O
.	O
89	O
,	O
8	O
.	O
34	O
±	O
0	O
.	O
76	O
,	O
8	O
.	O
47	O
±	O
0	O
.	O
61	O
,	O
8	O
.	O
36	O
±	O
0	O
.	O
88	O
and	O
7	O
.	O
40	O
±	O
0	O
.	O
71	O
g	O
·	O
L	O
−	O
1	O
for	O
strains	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
T5	O
and	O
T6	O
,	O
respectively	O
,	O
suggesting	O
that	O
enhanced	O
carboxylate	O
transportation	O
caused	O
the	O
shift	O
in	O
carbon	O
flux	O
from	O
cellular	O
growth	O
to	O
carboxylate	O
accumulation	O
.	O

The	O
combination	O
of	O
increased	O
carboxylate	O
accumulation	O
with	O
decreased	O
cell	O
growth	O
lead	O
to	O
a	O
sharp	O
increase	O
in	O
the	O
yield	O
of	O
α	O
-	O
KG	O
and	O
PA	O
,	O
Yα	O
-	O
KG	O
/	O
DCW	O
and	O
YPA	O
/	O
DCW	O
.	O

Finally	O
,	O
the	O
ratio	O
of	O
extracellular	O
carboxylate	O
to	O
intracellular	O
carboxylate	O
increased	O
,	O
and	O
maximum	O
values	O
of	O
2399	O
.	O
71	O
±	O
241	O
.	O
63	O
for	O
α	B-GP
-	I-GP
KG	I-GP
and	O
1685	O
.	O
20	O
±	O
208	O
.	O
56	O
for	O
PA	B-GP
were	O
observed	O
for	O
the	O
T1	O
strain	O
.	O

Based	O
on	O
these	O
observations	O
,	O
overexpression	O
of	O
YALI0A9470g	O
was	O
considered	O
the	O
best	O
strategy	O
to	O
enhance	O
α	B-GP
-	I-GP
KG	I-GP
transport	O
and	O
reduce	O
PA	O
accumulation	O
.	O

Discussion	O

The	O
object	O
of	O
the	O
current	O
work	O
was	O
to	O
screen	O
and	O
identify	O
carboxylate	B-GP
transporters	I-GP
,	O
then	O
determine	O
whether	O
the	O
identified	O
proteins	O
regulate	O
accumulation	O
of	O
non	O
-	O
target	O
carboxylates	B-CD
.	O

The	O
duplication	O
of	O
transporters	B-GP
and	O
the	O
flexible	O
substrate	O
specificity	O
demonstrated	O
by	O
the	O
identified	O
carboxylate	B-GP
transporters	I-GP
facilitated	O
extracellular	O
accumulation	O
of	O
carboxylates	B-CD
.	O

Moreover	O
,	O
knowledge	O
of	O
the	O
examined	O
carboxylate	O
transport	O
mechanism	O
is	O
a	O
prerequisite	O
for	O
improving	O
carboxylate	O
synthesis	O
through	O
metabolic	O
engineering	O
.	O

The	O
results	O
provide	O
new	O
insights	O
for	O
regulating	O
extracellular	O
carboxylate	O
accumulation	O
in	O
similar	O
eukaryotic	O
microorganisms	B-OG
.	O

To	O
circumvent	O
the	O
issue	O
of	O
PA	O
accumulation	O
,	O
previous	O
studies	O
have	O
focused	O
mainly	O
on	O
the	O
regulation	O
of	O
intrinsic	O
forces	O
that	O
redistribute	O
carbon	O
flux	O
from	O
other	O
intermediates	O
to	O
α	O
-	O
KG	O
production	O
.	O

Expression	O
of	O
PA	B-GP
carboxylase10	I-GP
,	O
malate	B-GP
dehydrogenase	I-GP
,	O
and	O
fumarase3	B-GP
dramatically	O
decreased	O
the	O
accumulation	O
of	O
PA	O
.	O

A	O
strategy	O
to	O
regulate	O
co	O
-	O
factor	O
regeneration	O
resulted	O
in	O
remarkable	O
reduction	O
of	O
extracellular	O
PA15	O
.	O

However	O
,	O
as	O
PA	O
has	O
a	O
pivotal	O
role	O
in	O
the	O
regulation	O
of	O
carbon	O
metabolism20	O
,	O
these	O
modifications	O
could	O
not	O
entirely	O
overcome	O
PA	O
accumulation	O
.	O

As	O
accumulation	O
of	O
carboxylate	O
is	O
believed	O
to	O
be	O
a	O
yeast	B-OG
defense	O
response	O
to	O
severe	O
environmental	O
conditions27	O
,	O
regulation	O
of	O
carboxylate	O
transportation	O
process	O
might	O
be	O
another	O
potent	O
route	O
for	O
enhancement	O
of	O
α	B-GP
-	I-GP
KG	I-GP
production	O
.	O

The	O
carboxylate	O
transport	O
process	O
of	O
yeast	B-OG
is	O
an	O
intensively	O
investigated	O
field20	O
.	O

The	O
S	B-OG
.	I-OG
cerevisiae	I-OG
ScJEN1	B-GP
and	O
ScADY2	B-GP
genes	O
were	O
identified	O
as	O
key	O
carboxylate	B-GP
transporters2829	I-GP
.	O

The	O
duplication	O
of	O
transporters	B-GP
has	O
been	O
strongly	O
implicated	O
in	O
the	O
utilization	O
of	O
organic	O
acids	O
as	O
a	O
carbon	O
source24	O
.	O

In	O
Kluyveromyces	B-OG
lactis	I-OG
,	O
the	O
presence	O
of	O
two	O
carboxylate	B-GP
transporters	I-GP
,	O
Jen1p	B-GP
and	O
Jen2p	B-GP
,	O
guaranteed	O
efficient	O
uptake	O
of	O
lactic	B-CD
acid	I-CD
as	O
a	O
substrate	O
from	O
a	O
lactic	B-CD
-	I-CD
acid	I-CD
-	O
producing	O
habitat30	O
.	O

As	O
the	O
cells	O
of	O
Y	B-OG
.	I-OG
lipolytica	I-OG
harbored	O
a	O
powerful	O
potential	O
to	O
use	O
a	O
wide	O
range	O
of	O
substrates	O
as	O
a	O
sources	O
of	O
carbon	O
and	O
energy31	O
,	O
these	O
results	O
indicated	O
that	O
powerful	O
carboxylate	B-GP
transporters	I-GP
that	O
maintain	O
intracellular	O
environment	O
homeostasis	O
.	O

A	O
previous	O
study	O
reported	O
that	O
reduction	O
of	O
by	O
-	O
product	O
resulted	O
in	O
enhanced	O
synthesis	O
of	O
target	O
carboxylate	O
by	O
de	O
-	O
repression	O
of	O
the	O
feedback	O
inhibition3	O
.	O

It	O
was	O
speculated	O
that	O
the	O
enhanced	O
synthesis	O
of	O
α	B-GP
-	I-GP
KG	I-GP
could	O
be	O
achieved	O
through	O
de	O
-	O
repression	O
of	O
the	O
feedback	O
inhibition	O
by	O
efflux	O
of	O
intermediates	O
.	O

In	O
Y	B-OG
.	I-OG
lipolytica	I-OG
,	O
efficient	O
carboxylate	O
transport	O
was	O
achieved	O
by	O
the	O
duplication	O
of	O
iso	O
-	O
functional	O
transporters	B-GP
.	O

Evolution	O
analysis	O
and	O
motif	O
identification	O
confirmed	O
that	O
a	O
precursor	O
form	O
of	O
Jen1p	B-GP
,	O
preJen1p	B-GP
,	O
arose	O
from	O
the	O
duplication	O
of	O
an	O
ancestral	O
Jen2p32	B-GP
.	O

In	O
S	B-OG
.	I-OG
cerevisiae	I-OG
,	O
the	O
transport	O
capacity	O
and	O
substrate	O
affinity	O
of	O
Jen1p	B-GP
were	O
determined	O
by	O
the	O
conserved	O
NXXS	O
/	O
THXS	O
/	O
TQDXXXT	O
sequence33	O
.	O

Presence	O
of	O
this	O
signature	O
sequence	O
also	O
determined	O
the	O
flexibility	O
of	O
substrate	O
specificity	O
for	O
these	O
transporters	O
.	O

Previously	O
,	O
Jen1p	B-GP
was	O
induced	O
by	O
lactate	B-CD
,	O
PA	O
,	O
and	O
propionate	O
,	O
whereas	O
Ady2p	B-GP
and	O
Jen2p	B-GP
were	O
induced	O
by	O
acetate2930	O
.	O

Expression	O
of	O
transporters	B-GP
from	O
Y	B-OG
.	I-OG
lipolytica	I-OG
displayed	O
different	O
responses	O
to	O
exogenous	O
carbon	O
source	O
,	O
and	O
single	O
carboxylate	O
induced	O
multiple	O
transporters	B-GP
.	O

The	O
roles	O
of	O
these	O
carboxylate	B-GP
transporters	I-GP
were	O
assayed	O
via	O
double	O
their	O
copy	O
numbers	O
in	O
the	O
genomic	O
DNA	O
of	O
α	O
-	O
KG	O
producer	O
.	O

One	O
more	O
copy	O
of	O
each	O
endogenous	O
carboxylate	B-GP
transporter	I-GP
was	O
observed	O
(	O
Fig	O
.	O
6	O
).	O

Our	O
observation	O
that	O
overexpression	O
of	O
carboxylate	B-GP
transporters	I-GP
resulted	O
in	O
enhanced	O
accumulation	O
of	O
extracellular	O
carboxylates	B-CD
(	O
Fig	O
.	O
7	O
).	O

Previously	O
,	O
uncovered	O
the	O
mechanism	O
for	O
malate	B-CD
efflux	O
was	O
mediated	O
by	O
monoanionic	O
malate	B-CD
concentration	O
gradient	O
,	O
in	O
which	O
the	O
proton	O
symport	O
was	O
major	O
force25	O
.	O

Similar	O
to	O
the	O
observations	O
that	O
production	O
of	O
carboxylate	O
was	O
benefited	O
from	O
overexpression	O
of	O
carboxylate	B-GP
transporter1334	I-GP
,	O
the	O
efflux	O
of	O
carboxylate	O
accompanied	O
by	O
symport	O
of	O
proton	O
was	O
speculated25	O
.	O

Based	O
on	O
measurement	O
of	O
total	O
content	O
of	O
mixture	O
of	O
monoanionic	O
,	O
dianionic	O
and	O
undissociated	O
form	O
of	O
the	O
carboxylates	O
,	O
the	O
intracellular	O
content	O
of	O
carboxylates	O
was	O
not	O
correlated	O
with	O
extracellular	O
carboxylate	O
content	O
.	O

While	O
,	O
the	O
reported	O
carboxylate	B-GP
transporter	I-GP
was	O
specific	O
for	O
monoanionic	O
form	O
of	O
carboxylate	O
for	O
efflux	O
,	O
the	O
efflux	O
specificity	O
of	O
this	O
series	O
of	O
transporter	B-GP
would	O
be	O
the	O
key	O
to	O
the	O
contradictory	O
observation	O
in	O
future	O
studies	O
.	O

Methods	O

Strains	O
and	O
plasmids	O

All	O
strains	O
used	O
in	O
this	O
study	O
were	O
summarized	O
in	O
Table	O
3	O
.	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
,	O
an	O
α	B-GP
-	I-GP
KG	I-GP
producing	O
wild	O
-	O
type	O
strain	O
,	O
was	O
previously	O
screened	O
by	O
our	O
lab35	O
.	O

The	O
plasmid	O
p0	O
(	O
hph	O
)	O
was	O
previously	O
constructed	O
based	O
on	O
plasmid	O
p0	O
.	O

The	O
p0	O
could	O
integrate	O
a	O
single	O
copy	O
of	O
exogenous	O
sequence	O
via	O
recombinant	O
at	O
the	O
locus	O
of	O
XRP2	O
in	O
the	O
genome	O
of	O
Y	B-OG
.	I-OG
lipolytica10	I-OG
.	O

The	O
hygromycin	B-GP
phosphotransferase	I-GP
encoded	O
by	O
hph	B-GP
was	O
amplified	O
from	O
plasmid	O
pUB4	O
-	O
CRE	O
and	O
was	O
used	O
to	O
replace	O
the	O
URA3	B-GP
sequence	O
in	O
plasmid	O
p01536	O
.	O

Plasmids	O
were	O
propagated	O
in	O
Escherichia	B-OG
.	I-OG
coli	I-OG
JM109	I-OG
.	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
(	O
MATα	B-GP
,	O
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
)	O
from	O
EUROSARF	O
(	O
Frankfurt	O
,	O
Germany	O
)	O
and	O
the	O
pY13	O
-	O
TEF1	B-GP
plasmid	O
was	O
used	O
for	O
heterologous	O
expression	O
of	O
potential	O
transporters	B-GP
.	O

Media	O
and	O
culture	O
conditions	O

E	B-OG
.	I-OG
coli	I-OG
was	O
cultured	O
in	O
Luria	O
broth	O
(	O
LB	O
)	O
medium	O
(	O
5	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
extract	O
,	O
10	O
g	O
·	O
L	O
−	O
1	O
peptone	O
,	O
10	O
g	O
·	O
L	O
−	O
1	O
NaCl	O
)	O
supplemented	O
100	O
mg	O
·	O
L	O
−	O
1	O
ampicillin	B-CD
when	O
necessary	O
.	O

Yeast	B-OG
strains	O
were	O
cultured	O
in	O
YPD	O
medium	O
(	O
10	O
g	O
·	O
L	O
−	O
1yeast	O
extract	O
,	O
20	O
g	O
·	O
L	O
−	O
1	O
peptone	O
,	O
and	O
20	O
g	O
·	O
L	O
−	O
1	O
dextrose	O
)	O
or	O
YNB	O
medium	O
(	O
20	O
g	O
·	O
L	O
−	O
1	O
glucose	B-CD
,	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
)	O
supplemented	O
with	O
50	O
μg	O
·	O
mL	O
−	O
1	O
uracil	B-CD
,	O
leucine	B-CD
,	O
tryptophan	B-CD
and	O
histidine	B-CD
when	O
necessary	O
.	O

The	O
following	O
media	O
were	O
used	O
for	O
carboxylate	O
treatment	O
:	O
YPA	O
(	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
50	O
g	O
·	O
L	O
−	O
1	O
acetate	O
,	O
pH	O
7	O
.	O
0	O
),	O
YPL	O
(	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
50	O
g	O
·	O
L	O
−	O
1	O
lactate	B-CD
,	O
pH	O
7	O
.	O
0	O
),	O
YPP	O
(	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
and	O
50	O
g	O
·	O
L	O
−	O
1	O
PA	O
,	O
pH	O
7	O
.	O
0	O
),	O
YPM	O
(	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
50	O
g	O
·	O
L	O
−	O
1	O
malate	B-CD
,	O
pH	O
7	O
.	O
0	O
),	O
YPK	O
(	O
10	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
extract	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
and	O
100	O
g	O
·	O
L	O
−	O
1	O
α	B-GP
-	I-GP
KG	I-GP
,	O
pH	O
7	O
.	O
0	O
),	O
YPC	O
(	O
1	O
.	O
7	O
g	O
·	O
L	O
−	O
1	O
yeast	B-OG
nitrogen	O
base	O
without	O
amino	B-CD
acids	I-CD
,	O
5	O
g	O
·	O
L	O
−	O
1	O
(	O
NH4	O
)	O
2SO4	O
,	O
50	O
g	O
·	O
L	O
−	O
1	O
citrate	B-CD
,	O
pH	O
7	O
.	O
0	O
).	O

The	O
seed	O
-	O
culture	O
media	O
(	O
dextrose	B-CD
,	O
20	O
g	O
·	O
L	O
−	O
1	O
;	O
peptone	O
,	O
10	O
g	O
·	O
L	O
−	O
1	O
;	O
KH2PO4	O
,	O
1	O
g	O
·	O
L	O
−	O
1	O
;	O
and	O
MgSO4	O
·	O
7H2O	O
,	O
0	O
.	O
5	O
g	O
·	O
L	O
−	O
1	O
,	O
pH	O
5	O
.	O
5	O
)	O
and	O
fermentation	O
media	O
(	O
glycerol	B-CD
,	O
100	O
g	O
·	O
L	O
−	O
1	O
;	O
(	O
NH4	O
)	O
2SO4	O
,	O
3	O
g	O
·	O
L	O
−	O
1	O
;	O
KH2PO4	O
,	O
3	O
g	O
·	O
L	O
−	O
1	O
;	O
MgSO4	O
·	O
7H2O	O
,	O
1	O
.	O
2	O
g	O
·	O
L	O
−	O
1	O
;	O
NaCl	O
,	O
0	O
.	O
5	O
g	O
·	O
L	O
−	O
1	O
;	O
K2HPO4	O
,	O
0	O
.	O
1	O
g	O
·	O
L	O
−	O
1	O
;	O
and	O
thiamine	O
-	O
HCl	O
4	O
×	O
10	O
−	O
7	O
g	O
·	O
L	O
−	O
1	O
,	O
pH	O
4	O
.	O
5	O
)	O
were	O
described	O
previously37	O
.	O

Bioinformatic	O
analysis	O
and	O
genome	O
-	O
wide	O
prediction	O
of	O
transmembrane	B-GP
proteins	I-GP

The	O
6611	O
putative	O
proteins	O
encoded	O
by	O
Y	B-OG
.	I-OG
lipolytica	I-OG
CLIB122	O
genomic	O
DNA	O
were	O
obtained	O
from	O
UniProt	O
(	O
http	O
://	O
www	O
.	O
uniprot	O
.	O
org	O
/).	O

A	O
genome	O
-	O
wide	O
analysis	O
using	O
a	O
transmembrane	O
-	O
helix	O
sequence	O
was	O
performed	O
following	O
a	O
method	O
described	O
previously3839	O
.	O

For	O
each	O
protein	O
,	O
the	O
transmembrane	B-GP
protein	I-GP
topology	O
was	O
predicted	O
using	O
TMHMM	O
(	O
http	O
://	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
TMHMM	O
/).	O

The	O
predicted	O
result	O
was	O
visualized	O
using	O
the	O
TMRPres2D	O
tool40	O
.	O

The	O
following	O
values	O
were	O
used	O
to	O
discriminate	O
helical	O
proteins	O
from	O
other	O
proteins41	O
:	O
(	O
i	O
)	O
the	O
number	O
of	O
predicted	O
transmembrane	O
helices	O
;	O
(	O
ii	O
)	O
the	O
expected	O
number	O
of	O
residues	O
in	O
the	O
transmembrane	O
helices	O
;	O
and	O
(	O
iii	O
)	O
the	O
expected	O
number	O
of	O
transmembrane	O
helices	O
.	O

To	O
avoid	O
false	O
prediction	O
,	O
we	O
also	O
analyzed	O
all	O
proteins	O
with	O
putative	O
transmembrane	O
helices	O
at	O
the	O
N	O
terminus	O
with	O
SignalP	O
(	O
http	O
://	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
SignalP	O
/)	O
to	O
predict	O
whether	O
the	O
sequence	O
encoded	O
a	O
signal	O
peptide42	O
.	O

All	O
screened	O
transmembrane	B-GP
proteins	I-GP
were	O
used	O
for	O
sequence	O
-	O
similarity	O
searches	O
using	O
BLAST	O
(	O
http	O
://	O
blast	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/)	O
to	O
identify	O
orthologs	O
that	O
have	O
been	O
characterized	O
as	O
carboxylate	B-GP
transporters	I-GP
.	O

Keto	B-CD
acid	I-CD
treatment	O

The	O
cells	O
of	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
were	O
streaked	O
onto	O
YPD	O
slants	O
from	O
glycerol	B-CD
stocks	O
.	O

Cells	O
grown	O
in	O
glucose	B-CD
were	O
harvested	O
at	O
the	O
exponential	O
phase	O
.	O

After	O
a	O
2	O
h	O
treatment	O
in	O
saline	O
water	O
,	O
cells	O
were	O
transferred	O
to	O
100	O
mL	O
YPK	O
or	O
100	O
mL	O
YPP	O
and	O
incubated	O
at	O
28	O
°	O
C	O
.	O

PA	O
-	O
or	O
α	B-GP
-	O
KG	B-GP
-	O
treated	O
cells	O
were	O
collected	O
at	O
regular	O
time	O
intervals	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
analysis	O
and	O
determination	O
of	O
intracellular	O
carboxylate	O
content	O
.	O

YPA	O
,	O
YPL	O
,	O
YPP	O
,	O
YPM	O
,	O
YPK	O
,	O
and	O
YPC	O
media	O
,	O
supplemented	O
as	O
necessary	O
with	O
50	O
μg	O
·	O
mL	O
−	O
1	O
uracil	B-CD
,	O
leucine	B-CD
,	O
tryptophan	B-CD
,	O
and	O
histidine	B-CD
,	O
were	O
used	O
to	O
assay	O
carboxylate	O
transportation	O
of	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	O
.	O
PK2	O
-	O
1D	O
cells	O
and	O
derivatives	O
.	O

Yeast	B-OG
cells	O
were	O
harvested	O
by	O
centrifugation	O
at	O
10	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
,	O
and	O
washed	O
twice	O
with	O
cold	O
distilled	O
water	O
.	O

The	O
dry	O
cell	O
weight	O
was	O
determined	O
according	O
to	O
protocol	O
described	O
previously37	O
.	O

The	O
intracellular	O
carboxylate	O
content	O
was	O
determined	O
according	O
to	O
the	O
method	O
previously	O
,	O
with	O
little	O
modification43	O
.	O

Harvested	O
cells	O
were	O
stored	O
in	O
liquid	O
nitrogen	O
until	O
extraction	O
of	O
intracellular	O
organic	O
acid	O
which	O
was	O
followed	O
by	O
cell	O
disruption	O
of	O
according	O
to	O
a	O
protocol	O
described	O
previously44	O
.	O

Supernatants	O
were	O
used	O
for	O
determination	O
of	O
intracellular	O
carboxylate	O
concentrations	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
).	O

The	O
intracellular	O
concentration	O
of	O
carboxylate	O
was	O
expressed	O
in	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O

The	O
cells	O
of	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	O
-	B-OG
Z06	I-OG
were	O
harvested	O
,	O
centrifuged	O
at	O
10	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
,	O
and	O
immediately	O
frozen	O
in	O
liquid	O
nitrogen	O
until	O
RNA	O
extraction	O
.	O

Total	O
RNA	O
was	O
extracted	O
using	O
Trizol	O
reagent	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
),	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

cDNA	O
was	O
synthesized	O
from	O
5	O
μg	O
total	O
RNA	O
using	O
the	O
PrimeScript	O
RT	O
Reagent	O
Kit	O
Perfect	O
Real	O
Time	O
(	O
Takara	O
,	O
Dalian	O
,	O
China	O
).	O

qRT	O
-	O
PCR	O
was	O
performed	O
with	O
the	O
synthesized	O
cDNA	O
and	O
primers	O
listed	O
in	O
Table	O
4	O
using	O
the	O
SYBR	O
Premix	O
Ex	O
TaqTM	O
Kit	O
(	O
Taraka	O
,	O
Dalian	O
,	O
China	O
)	O
and	O
a	O
LightCycler	O
480	O
II	O
Real	O
-	O
time	O
PCR	O
instrument	O
(	O
Roche	O
Applied	O
Science	O
,	O
Mannheim	O
,	O
Germany	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
and	O
mean	O
values	O
were	O
used	O
for	O
further	O
calculations	O
.	O

Fold	O
changes	O
were	O
determined	O
by	O
the	O
2	O
-	O
ΔΔCT	O
method	O
and	O
normalized	O
to	O
the	O
ACT1	B-GP
gene45	O
.	O

Disruption	O
of	O
the	O
ScJEN1	B-GP
and	O
ScADY2	B-GP
genes	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG

To	O
disrupt	O
the	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
JEN1	B-GP
and	O
ADY2	B-GP
genes	O
,	O
two	O
disruption	O
cassettes	O
were	O
constructed	O
using	O
a	O
protocol	O
described	O
previously46	O
.	O

The	O
loxP	O
-	O
URA3	B-GP
-	O
loxP	O
and	O
loxP	O
-	O
LEU2	B-GP
-	O
loxP	B-GP
modules	O
were	O
amplified	O
from	O
plasmids	O
pUG72	O
and	O
pUG73	O
,	O
respectively	O
,	O
with	O
oligonucleotides	O
JEN	O
-	O
MF	B-GP
/	O
JEN	O
-	O
MR	B-GP
,	O
ADY	O
-	O
MF	O
/	O
ADY	O
-	O
MR	B-GP
,	O
respectively	O
(	O
Table	O
5	O
).	O

Two	O
fragments	O
of	O
ScJEN1	B-GP
were	O
amplified	O
from	O
S	B-OG
.	I-OG
cerevisiae	I-OG
genomic	O
DNA	O
and	O
were	O
subsequently	O
flanked	O
by	O
the	O
loxP	B-GP
-	O
URA3	B-GP
-	O
loxP	B-GP
module	O
to	O
generate	O
the	O
JEN1	B-GP
disruption	O
cassette	O
.	O
ScADY2	B-GP
fragments	O
,	O
PCR	O
-	O
amplified	O
from	O
S	B-OG
.	I-OG
cerevisiae	I-OG
genomic	O
DNA	O
,	O
were	O
flanked	O
with	O
the	O
loxP	B-GP
-	O
LEU2	B-GP
-	O
loxP	B-GP
module	O
to	O
generate	O
the	O
ADY2	B-GP
disruption	O
cassette	O
.	O

The	O
disruption	O
cassettes	O
were	O
introduced	O
into	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	O
1D	O
with	O
a	O
previously	O
described	O
protocol46	O
,	O
and	O
the	O
resulting	O
line	O
,	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	O
1D	O
Δjen1	O
,	O
is	O
referred	O
to	O
as	O
W1	O
.	O

The	O
ADY2	B-GP
disruption	O
cassette	O
was	O
introduced	O
into	O
this	O
W1	O
strain	O
,	O
and	O
the	O
resulting	O
double	O
deletion	O
strain	O
is	O
referred	O
to	O
as	O
W2	O
.	O

Heterologous	O
expression	O
of	O
putative	O
transporter	O
genes	O
in	O
S	B-OG
.	I-OG
cerevisiae	I-OG
W2	I-OG

Six	O
putative	B-GP
transporter	I-GP
genes	O
,	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
,	O
and	O
YALI0E32901g	O
,	O
were	O
amplified	O
from	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
genomic	O
DNA	O
with	O
the	O
primers	O
listed	O
in	O
Table	O
6	O
.	O

The	O
amplified	O
fragments	O
were	O
introduced	O
into	O
BamHI	B-GP
–	O
EcoRI	B-GP
sites	O
of	O
the	O
pY13	O
-	O
TEF1	B-GP
expression	O
vector	O
,	O
resulting	O
in	O
the	O
pY13	O
-	O
TEF1	B-GP
-	O
470	O
,	O
pY13	O
-	O
TEF1	B-GP
-	O
488	O
,	O
pY13	O
-	O
TEF1	B-GP
-	O
406	O
,	O
pY13	O
-	O
TEF1	B-GP
-	O
607	O
,	O
pY13	O
-	O
TEF1	B-GP
-	O
108	O
,	O
and	O
pY13	O
-	O
TEF1	B-GP
-	O
901	O
plasmids	O
,	O
respectively	O
.	O

These	O
vectors	O
were	O
introduced	O
into	O
S	B-OG
.	I-OG
cerevisiae	I-OG
W2	I-OG
using	O
a	O
previously	O
described	O
protocol	O
,	O
and	O
the	O
resulting	O
lines	O
are	O
referred	O
to	O
as	O
W3	O
,	O
W4	O
,	O
W5	O
,	O
W6	O
,	O
W7	O
,	O
and	O
W8	O
,	O
respectively	O
.	O

Overexpression	O
of	O
putative	O
transporter	O
genes	O
in	O
Y	B-OG
.	I-OG
lipolytica	I-OG

The	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
,	O
and	O
YALI0E32901g	O
open	O
reading	O
frames	O
were	O
PCR	O
-	O
amplified	O
from	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
genomic	O
DNA	O
with	O
the	O
oligonucleotides	O
listed	O
in	O
Table	O
7	O
.	O

The	O
amplified	O
fragments	O
were	O
digested	O
with	O
Eco	B-GP
RI	I-GP
and	O
Bam	B-GP
HI	I-GP
or	O
Not	B-GP
I	I-GP
and	O
were	O
subsequently	O
inserted	O
into	O
the	O
integrative	O
expression	O
vector	O
p0	O
(	O
hph	O
),	O
resulting	O
in	O
p0	O
(	O
hph	O
)-	O
470	O
,	O
p0	O
(	O
hph	O
)-	O
488	O
,	O
p0	O
(	O
hph	O
)-	O
406	O
,	O
p0	O
(	O
hph	O
)-	O
607	O
,	O
p0	O
(	O
hph	O
)-	O
108	O
,	O
and	O
p0	O
(	O
hph	O
)-	O
901	O
,	O
respectively	O
.	O

These	O
vectors	O
were	O
digested	O
with	O
AvrII	B-GP
,	O
purified	O
,	O
and	O
transformed	O
into	O
Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	I-OG
-	I-OG
Z06	I-OG
using	O
a	O
previously	O
described	O
protocol47	O
.	O

The	O
resulting	O
transformants	O
,	O
Y	B-OG
.	I-OG
lipolytica	I-OG
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
T5	O
,	O
and	O
T6	O
,	O
respectively	O
,	O
were	O
screened	O
on	O
YPD	O
plates	O
containing	O
400	O
mg	O
·	O
L	O
−	O
1	O
hygromycin	B-CD
B	I-CD
and	O
verified	O
with	O
the	O
oligonucleotides	O
listed	O
in	O
Table	O
7	O
.	O

Copy	O
number	O
analysis	O

In	O
order	O
to	O
determine	O
the	O
copy	O
number	O
of	O
the	O
integrative	O
expression	O
cassettes	O
in	O
the	O
recombinant	O
strains	O
,	O
a	O
qPCR	O
analysis	O
was	O
performed	O
on	O
the	O
genomic	O
DNA	O
template	O
using	O
ACT1	O
as	O
the	O
internal	O
control26	O
.	O

Genomic	O
DNA	O
from	O
parental	O
strain	O
(	O
WSH	O
-	O
Z06	O
)	O
and	O
six	O
recombinant	O
strains	O
(	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
T5	O
and	O
T6	O
)	O
were	O
isolated	O
after	O
disruption	O
of	O
yeast	B-OG
cells	O
with	O
glass	O
beads	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MI	O
)	O
by	O
FastPrep	O
24	O
(	O
MP	O
Biomedicals	O
,	O
Santa	O
Ana	O
,	O
CA	O
).	O

qPCR	O
was	O
performed	O
with	O
the	O
5	O
ng	O
genomic	O
DNA	O
and	O
primers	O
listed	O
in	O
Table	O
4	O
using	O
the	O
SYBR	O
Premix	O
Ex	O
TaqTM	O
Kit	O
(	O
Taraka	O
,	O
Dalian	O
,	O
China	O
)	O
and	O
a	O
LightCycler	O
480	O
II	O
Real	O
-	O
time	O
PCR	O
instrument	O
(	O
Roche	O
Applied	O
Science	O
,	O
Mannheim	O
,	O
Germany	O
).	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
and	O
mean	O
values	O
were	O
used	O
for	O
further	O
calculations	O
.	O

Fold	O
changes	O
were	O
determined	O
by	O
the	O
2	O
−	O
ΔΔCT	O
method	O
and	O
normalized	O
to	O
the	O
ACT1	B-GP
gene45	O
.	O

Shake	O
flask	O
culture	O

Shake	O
flask	O
culture	O
was	O
performed	O
in	O
500	O
mL	O
flasks	O
containing	O
50	O
mL	O
fermentation	O
medium	O
following	O
the	O
protocol	O
stated	O
previously35	O
.	O

A	O
yeast	B-OG
seed	O
culture	O
was	O
inoculated	O
from	O
an	O
agar	O
slant	O
and	O
incubated	O
in	O
a	O
500	O
mL	O
flask	O
containing	O
50	O
mL	O
medium	O
for	O
18	O
h	O
on	O
a	O
rotary	O
shaker	O
at	O
28	O
°	O
C	O
.	O

The	O
culture	O
was	O
used	O
to	O
inoculate	O
500	O
mL	O
flasks	O
containing	O
50	O
mL	O
fermentation	O
medium	O
.	O

An	O
inoculum	O
volume	O
of	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
was	O
used	O
for	O
α	B-GP
-	I-GP
KG	I-GP
accumulation	O
assay	O
.	O

Flask	O
cultures	O
were	O
incubated	O
in	O
a	O
shaker	O
at	O
200	O
r	O
·	O
min	O
−	O
1	O
for	O
144	O
h	O
at	O
28	O
°	O
C	O
.	O

HPLC	O
analysis	O

Samples	O
taken	O
from	O
shake	O
flask	O
culture	O
were	O
centrifuged	O
at	O
10	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
.	O

The	O
supernatant	O
was	O
diluted	O
50	O
times	O
and	O
filtered	O
through	O
a	O
membrane	O
(	O
pore	O
size	O
=	O
0	O
.	O
22	O
μm	O
).	O
α	O
-	B-GP
KG	I-GP
,	O
pyruvic	B-CD
acid	I-CD
,	O
acetate	O
,	O
lactate	B-CD
,	O
malate	B-CD
,	O
and	O
citrate	B-CD
present	O
in	O
the	O
supernatant	O
were	O
simultaneously	O
determined	O
by	O
HPLC	O
(	O
Agilent	O
1200	O
series	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
with	O
an	O
Aminex	O
HPX	O
-	O
87H	O
column	O
(	O
300	O
mm	O
×	O
7	O
.	O
8	O
mm	O
;	O
Bio	O
-	O
Rad	O
Laboratories	O
Inc	O
.,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

The	O
mobile	O
phase	O
was	O
5	O
mmol	O
L	O
−	O
1	O
sulfuric	O
acid	O
in	O
distilled	O
,	O
de	O
-	O
ionized	O
water	O
filtered	O
to	O
0	O
.	O
22	O
μm	O
.	O

The	O
mobile	O
phase	O
flow	O
rate	O
was	O
0	O
.	O
6	O
mL	O
min	O
−	O
1	O
.	O

The	O
column	O
temperature	O
was	O
maintained	O
at	O
35	O
°	O
C	O
,	O
and	O
the	O
injection	O
volume	O
was	O
10	O
μL	O
.	O
α	O
-	O
KG	O
,	O
pyruvic	B-CD
acid	I-CD
,	O
acetate	O
,	O
lactate	B-CD
,	O
malate	B-CD
,	O
and	O
citrate	B-CD
were	O
detected	O
with	O
a	O
UV	O
detector	O
(	O
wavelength	O
at	O
210	O
nm	O
)	O
37	O
.	O

To	O
determine	O
the	O
intracellular	O
carboxylates	O
,	O
cells	O
taken	O
from	O
shake	O
flask	O
culture	O
were	O
disrupted	O
and	O
lysates	O
were	O
centrifuged	O
at	O
10	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
.	O

The	O
carboxylate	O
content	O
in	O
supernatant	O
was	O
determined	O
by	O
HPLC	O
followed	O
the	O
protocol	O
above	O
.	O

Author	O
Contributions	O

G	O
.	O
H	O
.	O
W	O
.	O
and	O
Z	O
.	O
J	O
.	O
W	O
.	O
designed	O
the	O
experiments	O
and	O
wrote	O
the	O
paper	O
.	O

G	O
.	O
H	O
.	O
W	O
.	O
and	O
L	O
.	O
P	O
.	O
R	O
.	O
performed	O
the	O
experiments	O
.	O

G	O
.	O
C	O
.	O
D	O
.	O
and	O
J	O
.	O
C	O
.	O
conceived	O
the	O
project	O
,	O
analyzed	O
the	O
data	O
and	O
wrote	O
the	O
paper	O
.	O

C	O
.	O
M	O
.	O
analyzed	O
the	O
data	O
.	O

Supplementary	O
Material	O

Supplementary	O
Information	O

(	O
A	O
)	O
Number	O
of	O
predicted	O
transmembrane	O
helices	O
in	O
identified	O
putative	O
membrane	O
proteins	O
.	O

(	O
B	O
)	O
Multiple	O
sequence	O
alignment	O
of	O
amino	B-CD
acids	I-CD
sequences	O
from	O
available	O
yeast	B-OG
carboxylate	B-GP
transporter	I-GP
sequences	O
.	O

The	O
results	O
showed	O
that	O
28	O
orthologs	O
of	O
the	O
JEN	B-GP
family	O
from	O
Aspergillus	B-OG
oryzae	I-OG
,	O
Aspergillus	B-OG
fumigatus	I-OG
,	O
Aspergillus	B-OG
nidulans	I-OG
,	O
Y	B-OG
.	I-OG
lipolytica	I-OG
,	O
Kluyveromyces	B-OG
lactis	I-OG
,	O
Candida	B-OG
albicans	I-OG
,	O
Kluyveromyces	B-OG
thermotolerans	I-OG
,	O
S	B-OG
.	I-OG
cerevisiae	I-OG
,	O
Debaryomyces	B-OG
hansenii	I-OG
and	O
Neurospora	B-OG
crassa	I-OG
had	O
highly	O
conserved	O
sequences	O
.	O

The	O
name	O
of	O
these	O
orthologs	O
was	O
based	O
on	O
protein	O
ID	O
in	O
NCBI	O
database	O
,	O
as	O
one	O
potential	O
JEN1	B-GP
from	O
N	B-OG
.	I-OG
crassa	I-OG
could	O
not	O
find	O
in	O
the	O
database	O
,	O
it	O
was	O
named	O
as	O
Q9P732	O
based	O
on	O
protein	O
ID	O
from	O
Uniprot	O
.	O

The	O
phylogenetic	O
tree	O
of	O
carboxylate	B-GP
proteins	I-GP
was	O
constructed	O
using	O
the	O
neighbor	O
-	O
joining	O
method	O
.	O

Bootstrap	O
values	O
>	O
50	O
%	O
are	O
shown	O
at	O
the	O
branch	O
points	O
.	O

One	O
thousand	O
bootstrap	O
replications	O
were	O
performed	O
using	O
the	O
MEGA	O
5	O
.	O
0	O
software48	O
.	O

(	O
A	O
)	O
YALI0B19470p	O
,	O
(	O
B	O
)	O
YALI0C15488p	O
,	O
(	O
C	O
)	O
YALI0C21406p	O
,	O
(	O
D	O
)	O
YALI0D24607p	O
,	O
(	O
E	O
)	O
YALI0D20108p	O
,	O
(	O
F	O
)	O
YALI0E32901p	O
.	O

The	O
conserved	O
signature	O
sequence	O
was	O
illustrated	O
in	O
red	O
in	O
every	O
putative	B-GP
carboxylate	I-GP
transporter	I-GP
.	O

(	O
A	O
)	O
Open	O
square	O
:	O
α	O
-	O
KG	O
,	O
open	O
circle	O
:	O
PA	O
.	O

The	O
change	O
of	O
concentration	O
of	O
α	B-GP
-	I-GP
KG	I-GP
and	O
PA	O
exhibited	O
the	O
same	O
trend	O
during	O
throughout	O
the	O
treatment	O
.	O

(	O
B	O
)	O
Expression	O
profile	O
of	O
putative	O
transporter	O
genes	O
at	O
1	O
h	O
,	O
at	O
which	O
time	O
the	O
intracellular	O
contents	O
of	O
α	B-GP
-	O
KG	O
and	O
PA	O
were	O
greatest	O
.	O

White	O
:	O
PA	O
treatment	O
;	O
black	O
:	O
α	O
-	O
KG	O
treatment	O
.	O

WT	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
;	O
W1	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1	O
;	O
W2	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	O
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
;	O
W3	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
470	O
);	O
W4	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
488	O
);	O
W5	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
406	O
);	O
W6	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
607	O
);	O
W7	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
108	O
);	O
W8	O
:	O
S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	O
PK2	B-GP
-	O
1D	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
901	O
).	O

(	O
A	O
)	O
YPD	O
,	O
(	O
B	O
)	O
YPA	O
,	O
(	O
C	O
)	O
YPL	O
,	O
(	O
D	O
)	O
YPP	O
,	O
(	O
E	O
)	O
YPM	O
,	O
(	O
F	O
)	O
YPK	O
,	O
(	O
G	O
)	O
YPC	O
.	O

Copy	O
number	O
of	O
YALI0B19470g	O
in	O
T1	O
,	O
YALI0C15488g	O
in	O
T2	O
,	O
YALI0C21406g	O
in	O
T3	O
,	O
YALI0D24607g	O
in	O
T4	O
,	O
YALI0D20108g	O
in	O
T5	O
and	O
YALI0E32901g	O
in	O
T6	O
were	O
determined	O
through	O
qPCR	O
analysis	O
.	O

As	O
ACT1	B-GP
existed	O
in	O
one	O
copy	O
per	O
Y	B-OG
.	I-OG
lipolytica	I-OG
genome	O
,	O
copy	O
number	O
of	O
putative	B-GP
transporter	I-GP
genes	O
in	O
wild	O
-	O
type	O
strain	O
(	O
white	O
)	O
and	O
recombinants	O
(	O
grey	O
)	O
was	O
expressed	O
as	O
relative	O
change	O
.	O

With	O
comparison	O
to	O
ACT1	B-GP
,	O
one	O
more	O
copy	O
of	O
each	O
transporter	O
gene	O
was	O
determined	O
in	O
corresponding	O
recombinants	O
.	O

RNA	O
extracted	O
from	O
glucose	B-CD
-	O
grown	O
cells	O
of	O
the	O
T1	O
,	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
T5	O
,	O
and	O
T6	O
strains	O
was	O
subjected	O
to	O
qRT	O
-	O
PCR	O
.	O

The	O
strains	O
T1	O
-	O
T6	O
were	O
mutant	O
variants	O
in	O
which	O
plasmid	O
p0	O
(	O
hph	O
)-	O
470	O
,	O
p0	O
(	O
hph	O
)-	O
488	O
,	O
p0	O
(	O
hph	O
)-	O
406	O
p0	O
(	O
hph	O
)-	O
607	O
,	O
p0	O
(	O
hph	O
)-	O
108	O
and	O
p0	O
(	O
hph	O
)-	O
901	O
were	O
individually	O
expressed	O
in	O
the	O
wild	O
-	O
type	O
strain	O
.	O

The	O
transcription	O
of	O
YALI0B19470g	O
,	O
YALI0C15488g	O
,	O
YALI0C21406g	O
,	O
YALI0D24607g	O
,	O
YALI0D20108g	O
,	O
and	O
YALI0E32901g	O
increased	O
by	O
23	O
.	O
34	O
±	O
2	O
.	O
67	O
-	O
fold	O
,	O
8	O
.	O
53	O
±	O
0	O
.	O
90	O
-	O
fold	O
,	O
9	O
.	O
32	O
±	O
0	O
.	O
82	O
-	O
fold	O
,	O
11	O
.	O
79	O
±	O
1	O
.	O
32	O
-	O
fold	O
,	O
3	O
.	O
37	O
±	O
0	O
.	O
49	O
-	O
fold	O
and	O
10	O
.	O
50	O
±	O
0	O
.	O
97	O
-	O
fold	O
,	O
respectively	O
.	O

White	O
:	O
α	O
-	O
KG	O
;	O
black	O
:	O
PA	O
.	O

The	O
strains	O
T1	O
–	O
T6	O
were	O
mutant	O
variants	O
in	O
which	O
plasmid	O
p0	O
(	O
hph	O
)-	O
470	O
,	O
p0	O
(	O
hph	O
)-	O
488	O
,	O
p0	O
(	O
hph	O
)-	O
406	O
p0	O
(	O
hph	O
)-	O
607	O
,	O
p0	O
(	O
hph	O
)-	O
108	O
and	O
p0	O
(	O
hph	O
)-	O
901	O
were	O
individually	O
expressed	O
in	O
the	O
wild	O
-	O
type	O
strain	O
.	O

The	O
transport	O
of	O
PA	O
was	O
enhanced	O
in	O
all	O
mutants	O
except	O
the	O
T1	O
strain	O
.	O

Extracellular	O
PA	O
concentration	O
increased	O
from	O
17	O
.	O
77	O
±	O
0	O
.	O
72	O
g	O
·	O
L	O
−	O
1	O
to	O
20	O
.	O
22	O
±	O
0	O
.	O
98	O
,	O
20	O
.	O
95	O
±	O
0	O
.	O
62	O
,	O
21	O
.	O
06	O
±	O
1	O
.	O
03	O
,	O
23	O
.	O
53	O
±	O
0	O
.	O
98	O
,	O
and	O
21	O
.	O
79	O
±	O
1	O
.	O
0	O
0	O
g	O
·	O
L	O
−	O
1	O
in	O
cells	O
of	O
the	O
T2	O
,	O
T3	O
,	O
T4	O
,	O
T5	O
,	O
and	O
T6	O
strains	O
,	O
respectively	O
,	O
and	O
decreased	O
by	O
30	O
.	O
6	O
%	O
to	O
the	O
concentration	O
of	O
12	O
.	O
32	O
±	O
1	O
.	O
31	O
g	O
·	O
L	O
−	O
1	O
for	O
T1	O
strain	O
.	O

The	O
content	O
of	O
α	B-GP
-	I-GP
KG	I-GP
varied	O
slightly	O
in	O
strain	O
T2	O
,	O
T3	O
,	O
T4	O
and	O
T6	O
,	O
while	O
the	O
content	O
of	O
the	O
dicarboxylate	O
increased	O
to	O
46	O
.	O
66	O
±	O
2	O
.	O
59	O
-	O
and	O
44	O
.	O
02	O
±	O
1	O
.	O
87	O
g	O
·	O
L	O
−	O
1	O
in	O
strain	O
T1	O
and	O
T5	O
.	O

Strain	O

Genotype	O

Acetate	O

Lactate	B-CD

PA	O

Malate	B-OG

α	O
-	O
KG	O

Citrate	B-CD

WT	O

S	B-OG
.	I-OG
cerevisiae	I-OG
,	O
CEN	O
.	O
PK2	B-OG
-	O
1D	O

/*	O

2	O
.	O
22	O
±	O
0	O
.	O
21	O

0	O
.	O
94	O
±	O
0	O
.	O
12	O

3	O
.	O
14	O
±	O
0	O
.	O
24	O

1	O
.	O
29	O
±	O
0	O
.	O
12	O

/	O

W1	O

S	B-OG
.	I-OG
cerevisiae	I-OG
,	O
CEN	O
.	B-OG
PK2	I-OG
-	O
1D	O
Δjen1	O

/	O

/	O

/	O

0	O
.	O
05	O
±	O
0	O
.	O
01	O

0	O
.	O
86	O
±	O
0	O
.	O
08	O

/	O

W2	O

S	B-OG
.	I-OG
cerevisiae	I-OG
,	O
CEN	O
.	B-OG
PK2	I-OG
-	O
1D	O
Δjen1Δady2	O

/	O

/	O

/	O

/	O

/	O

/	O

W3	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
470	O
)	O

/	O

/	O

/	O

0	O
.	O
15	O
±	O
0	O
.	O
01	O

0	O
.	O
09	O
±	O
0	O
.	O
01	O

0	O
.	O
04	O
±	O
0	O
.	O
01	O

W4	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
488	O
)	O

0	O
.	O
81	O
±	O
0	O
.	O
07	O

/	O

0	O
.	O
17	O
±	O
0	O
.	O
03	O

0	O
.	O
11	O
±	O
0	O
.	O
01	O

1	O
.	O
41	O
±	O
0	O
.	O
19	O

0	O
.	O
08	O
±	O
0	O
.	O
01	O

W5	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
406	O
)	O

/	O

0	O
.	O
53	O
±	O
0	O
.	O
04	O

/	O

0	O
.	O
09	O
±	O
0	O
.	O
01	O

0	O
.	O
77	O
±	O
0	O
.	O
06	O

0	O
.	O
04	O
±	O
0	O
.	O
01	O

W6	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	O
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
607	O
)	O

/	O

/	O

/	O

0	O
.	O
09	O
±	O
0	O
.	O
01	O

0	O
.	O
56	O
±	O
0	O
.	O
06	O

0	O
.	O
05	O
±	O
0	O
.	O
01	O

W7	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
108	O
)	O

/	O

0	O
.	O
67	O
±	O
0	O
.	O
09	O

/	O

/	O

0	O
.	O
38	O
±	O
0	O
.	O
04	O

0	O
.	O
09	O
±	O
0	O
.	O
01	O

W8	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	O
,	O
Δjen1Δady2	O
(	O
pY13	O
-	O
TEF1	B-GP
-	O
901	O
)	O

0	O
.	O
66	O
±	O
0	O
.	O
04	O

/	O

/	O

0	O
.	O
11	O
±	O
0	O
.	O
01	O

0	O
.	O
39	O
±	O
0	O
.	O
03	O

0	O
.	O
03	O
±	O
0	O
.	O
01	O



Cin	O
(	O
μmol	O
·(	O
mg	O
·	O
DCW	O
)−	O
1	O
)	O



Ratioex	O
/	O
in	O

Strain	O

DCW	O
(	O
g	O
·	O
L	O
−	O
1	O
)	O

α	O
-	O
KG	O

PA	O

Yα	O
-	O
KG	O
/	O
DCW	O
(	O
g	O
·	O
g	O
−	O
1	O
)	O

YPA	O
/	O
DCW	O
(	O
g	O
·	O
g	O
−	O
1	O
)	O

α	O
-	O
KG	O

PA	O

WSH	O
-	O
Z06	O

11	O
.	O
17	O
±	O
1	O
.	O
08	O

0	O
.	O
026	O
±	O
0	O
.	O
005	O

0	O
.	O
034	O
±	O
0	O
.	O
006	O

3	O
.	O
28	O
±	O
0	O
.	O
32	O

0	O
.	O
23	O
±	O
0	O
.	O
03	O

860	O
.	O
35	O
±	O
78	O
.	O
45	O

531	O
.	O
45	O
±	O
48	O
.	O
97	O

T1	O

8	O
.	O
45	O
±	O
0	O
.	O
72	O

0	O
.	O
014	O
±	O
0	O
.	O
002	O

0	O
.	O
009	O
±	O
0	O
.	O
002	O

4	O
.	O
94	O
±	O
0	O
.	O
52	O

0	O
.	O
30	O
±	O
0	O
.	O
04	O

2399	O
.	O
71	O
±	O
241	O
.	O
63	O

1685	O
.	O
20	O
±	O
208	O
.	O
56	O

T2	O

8	O
.	O
27	O
±	O
0	O
.	O
89	O

0	O
.	O
027	O
±	O
0	O
.	O
003	O

0	O
.	O
032	O
±	O
0	O
.	O
004	O

3	O
.	O
90	O
±	O
0	O
.	O
42	O

0	O
.	O
25	O
±	O
0	O
.	O
03	O

975	O
.	O
27	O
±	O
109	O
.	O
21	O

769	O
.	O
61	O
±	O
84	O
.	O
21	O

T3	O

8	O
.	O
34	O
±	O
0	O
.	O
76	O

0	O
.	O
030	O
±	O
0	O
.	O
005	O

0	O
.	O
033	O
±	O
0	O
.	O
005	O

4	O
.	O
13	O
±	O
0	O
.	O
44	O

0	O
.	O
24	O
±	O
0	O
.	O
02	O

938	O
.	O
78	O
±	O
96	O
.	O
32	O

779	O
.	O
42	O
±	O
94	O
.	O
38	O

T4	O

8	O
.	O
47	O
±	O
0	O
.	O
61	O

0	O
.	O
023	O
±	O
0	O
.	O
003	O

0	O
.	O
029	O
±	O
0	O
.	O
003	O

3	O
.	O
91	O
±	O
0	O
.	O
38	O

0	O
.	O
31	O
±	O
0	O
.	O
04	O

1161	O
.	O
29	O
±	O
125	O
.	O
76	O

865	O
.	O
52	O
±	O
90	O
.	O
76	O

T5	O

8	O
.	O
36	O
±	O
0	O
.	O
88	O

0	O
.	O
013	O
±	O
0	O
.	O
002	O

0	O
.	O
017	O
±	O
0	O
.	O
002	O

4	O
.	O
71	O
±	O
0	O
.	O
46	O

0	O
.	O
59	O
±	O
0	O
.	O
06	O

2358	O
.	O
20	O
±	O
359	O
.	O
79	O

1641	O
.	O
53	O
±	O
178	O
/	O
94	O

T6	O

7	O
.	O
40	O
±	O
0	O
.	O
71	O

0	O
.	O
020	O
±	O
0	O
.	O
002	O

0	O
.	O
025	O
±	O
0	O
.	O
002	O

5	O
.	O
27	O
±	O
0	O
.	O
61	O

0	O
.	O
36	O
±	O
0	O
.	O
04	O

1756	O
.	O
27	O
±	O
193	O
.	O
1	O

1343	O
.	O
41	O
±	O
147	O
.	O
89	O

Strain	O

Genotype	O
and	O
remarks	O

S	B-OG
.	I-OG
cerevisiae	I-OG
CEN	I-OG
.	I-OG
PK2	I-OG
-	I-OG
1D	I-OG

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP

W1	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP

W2	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP

W3	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
470	O
)	O

W4	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
488	O
)	O

W5	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
406	O
)	O

W6	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
607	O
)	O

W7	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
108	O
)	O

W8	O

MATα	B-GP
Δura3	O
-	O
52	O
;	O
Δtrp1	O
-	O
289	O
;	O
Δleu2	O
-	O
3	O
,	O
112	O
;	O
Δhis3	O
-	O
1	O
;	O
MAL2	B-GP
-	O
8C	O
;	O
SUC2	B-GP
;	O
Δjen1	O
::	O
URA3	B-GP
;	O
Δady2	O
::	O
LEU2	B-GP
(	O
pY13	O
-	O
TEF1	B-GP
-	O
901	O
)	O

Y	B-OG
.	I-OG
lipolytica	I-OG
WSH	O
-	O
Z06	O

Wild	O
-	O
type	O

T1	O

Wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
470	O
)	O

T2	O

Wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
488	O
)	O

T3	O

Wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
406	O
)	O

T4	O

Wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
607	O
)	O

T5	O

wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
108	O
)	O

T6	O

Wild	O
-	O
type	O
(	O
p0	O
(	O
hph	O
)-	O
901	O
)	O

Gene	O

Primers	O

Sequence	O
(	O
5	O
'-	O
3	O
')	O

Product	O
size	O
(	O
bp	O
)	O

YALI0B19470g	O

YALIOB19470	O
-	O
F	O

CAACAAGGAAGACAACAG	O

153	O


YALIOB19470	O
-	O
R	O

AGGTAGGTGAACATAAGC	O


YALI0C15488g	O

YALIOC15488	O
-	O
F	O

GCAACCATCTCAGCCATTC	O

199	O


YALIOC15488	O
-	O
R	O

GTAACCTCGCATCTTCAGC	O


YALI0C21406g	O

YALIOC21406	O
-	O
F	O

GCAGACCTACCAGCAGTTC	O

171	O


YALIOC21406	O
-	O
R	O

ACGACACAGAGCAAGTATCC	O


YALI0D20108g	O

YALIOD20108	O
-	O
F	O

TGCTACAGGAAGGCTATGC	O

135	O


YALIOD20108	O
-	O
R	O

GGAAGATGATGATGAGAACAGG	O


YALI0D24607g	O

YALIOD24607	O
-	O
F	O

CTGCTTGTAGGTGGTGAC	O

104	O


YALIOD24607	B-CD
-	O
R	O

GAGTGCTGAGTGATAAATACG	O


YALI0E32901g	O

YALIOE32901	O
-	O
F	O

TCTATGATTACGGTAAGGTTATG	O

188	O


YALIOE32901	O
-	O
R	O

GACTCGCTCAAGGTTCTC	O


ACT1	B-GP

ACT1	B-GP
-	O
F	O

AAGTCCAACCGAGAGAAGATG	O

132	O


ACT1	B-GP
-	O
R	O

ACCAGAGTCAAGAACGATACC	O


Primers	O

Sequence	O
(	O
5	O
'-	O
3	O
')	O

Description	O

JEN	O
-	O
L	O
-	O
F	O

GGATCCATGTCGTCGTCAATTACAGATG	O

BamHI	O

JEN	O
-	O
L	O
-	O
R	O

ATGTGCAGTAAGGACGTAAATC	O


JEN	O
-	O
R	O
-	O
F	O

AAAGGCTATATTAGGTGCCG	O


JEN	O
-	O
R	O
-	O
R	O

GAATTCTTGTTCAACAATGTCACTAATCG	O

EcoRI	O

JEN	O
-	O
M	O
-	O
F	O

GATTTACGTCCTTACTGCACATGTGAAAACCTCTGACACATGC	O


JEN	O
-	O
M	O
-	O
R	O

CGGCACCTAATATAGCCTTTGCCTTTGAGTGAGCTGATACC	O


ADY	O
-	O
L	O
-	O
F	O

GGATCCATGTCTGACAAGGAACAAACGAG	O

BamHI	O

ADY	O
-	O
L	O
-	O
R	O

CCACCATAAAACATAGCACAACC	O


ADY	O
-	O
R	O
-	O
F	O

GATTGCTGGTATTTGGGAGATAG	O


ADY	O
-	O
R	O
-	O
R	O

CCTAGGCCCTTTCAGTAGATGGTAATGGG	O

AvrII	O

ADY	O
-	O
M	O
-	O
F	O

GGTTGTGCTATGTTTTATGGTGGGCATAGGCCACTAGTGGATCTG	O


ADY	O
-	O
M	O
-	O
R	O

CTATCTCCCAAATACCAGCAATCCAGCTGAAGCTTCGTACGC	O


Primers	O

Sequence	O
(	O
5	O
'-	O
3	O
')	O

Description	O

YALI0D20108g	O
-	O
F2	O

CGGGATCCATGAATTTTGACAACTTCCCAGC	O

BamHI	O

YALI0D20108g	O
-	O
R2	O

GGAATTCTTATCGAGTATCGCTCGAAGAAC	O

EcoRI	O

YALI0C21406g	O
-	O
F2	O

GGACTAGTATGGATCTCGACAACTACCCTCC	O

BamHI	O

YALI0C21406g	O
-	O
R2	O

GGAATTCTCACTTTTGGGATCCGGGG	O

EcoRI	O

YALI0B19470g	O
-	O
F2	O

CGGGATCCATGCCCATCACAGTTTCACAAG	O

BamHI	O

YALI0B19470g	O
-	O
R2	O

GGAATTCTTAACGAGTGAGATTGGTGTCG	O

EcoRI	O

YALI0C15488g	O
-	O
F2	O

CGGGATCCATGGATTTGGACAACCTCCC	O

BamHI	O

YALI0C15488g	O
-	O
R2	O

GGAATTCCTACTTAGTAGCATTGGTGTCAACTC	O

EcoRI	O

YALI0D24607g	O
-	O
F2	O

CGGGATCCATGACCCAGTCGTACGAAGTC	O

BamHI	O

YALI0D24607g	O
-	O
R2	O

GGAATTCCTAATGAACACTTCCAACAGTGG	O

EcoRI	O

YALI0E32901g	O
-	O
F2	O

CGGGATCCATGGAAGCTCCTAATCTCTCG	O

BamHI	O

YALI0E32901g	O
-	O
R2	O

GGAATTCTACTTGGACTCGTAGGGGGA	O

EcoRI	O

Primers	O

Sequence	O
(	O
5	O
'-	O
3	O
')	O

Description	O

YALI0D20108g	O
-	O
F1	O

CGGGATCCATGAATTTTGACAACTTCCCAG	O

BamHI	O

YALI0D20108g	O
-	O
R1	O

GGAATTCTTATCGAGTATCGCTCGAAGAAC	O

EcoRI	O

YALI0C21406g	O
-	O
F1	O

GGAATTCATGGATCTCGACAACTACCCTC	O

EcoRI	O

YALI0C21406g	O
-	O
R1	O

TTGCGGCCGCTCACTTTTGGGATCCGGG	O

NotI	O

YALI0B19470g	O
-	O
F1	O

CGGGATCCATGCCCATCACAGTTTCACAAG	O

BamHI	O

YALI0B19470g	O
-	O
R1	O

GGAATTCTTAACGAGTGAGATTGGTGTCG	O

EcoRI	O

YALI0C15488g	O
-	O
F1	O

CGGGATCCATGGATTTGGACAACCTCCC	O

BamHI	O

YALI0C15488g	O
-	O
R1	O

GGAATTCCTACTTAGTAGCATTGGTGTCAACTC	O

EcoRI	O

YALI0D24607g	O
-	O
F1	O

CGGGATCCATGACCCAGTCGTACGAAGTC	O

BamHI	O

YALI0D24607g	O
-	O
R1	O

GGAATTCCTAATGAACACTTCCAACAGTGG	O

EocRI	O

YALI0E32901g	O
-	O
F1	O

CGGGATCCATGGAAGCTCCTAATCTCTCGC	O

BamHI	O

YALI0E32901g	O
-	O
R1	O

GGAATTCTTACTTGGACTCGTAGGGGGA	O

EcoRI	O

VB	O
-	O
F	O

CGTTTGCCAGCCACAGATT	O


V	O
-	O
YALI0D20108g	O
-	O
R	O

GCGTTTGCCAGCCACAGAT	O


V	O
-	O
YALI0C21406g	O
-	O
R	O

GTAGATGCAGGCAGCACCG	O


V	O
-	O
YALI0B19470g	O
-	O
R	O

AAGACAGAGGCGTTGATACCG	O


V	O
-	O
YALI0C15488g	O
-	O
R	O

TGCGAGGTTACCAAGCTGAT	O


V	O
-	O
YALI0D24607g	O
-	O
R	O

GACAAACGCCCAGGGATAG	O


V	O
-	O
YALI0E32901g	O
-	O
R	O

TGTCCATCTGCTTGCCCTC	O


Activation	O
of	O
mesenchymal	O
stem	O
cells	O
by	O
macrophages	O
promotes	O
tumor	B-DS
progression	O
through	O
immune	O
suppressive	O
effects	O

Cancer	B-DS
development	O
and	O
progression	O
is	O
linked	O
to	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
).	O

Distinct	O
TAMs	O
subsets	O
perform	O
either	O
protective	O
or	O
pathogenic	O
effects	O
in	O
cancer	B-DS
.	O

A	O
protective	O
role	O
in	O
carcinogenesis	O
has	O
been	O
described	O
for	O
M1	O
macrophages	O
,	O
which	O
activate	O
antitumor	O
mechanisms	O
.	O

By	O
comparison	O
,	O
TAMs	O
isolated	O
from	O
solid	O
and	O
metastatic	B-DS
tumors	I-DS
have	O
a	O
suppressive	O
M2	O
-	O
like	O
phenotype	O
,	O
which	O
could	O
support	O
multiple	O
aspects	O
of	O
tumor	B-DS
progression	O
.	O

Currently	O
,	O
it	O
has	O
not	O
been	O
clearly	O
understood	O
how	O
macrophages	O
in	O
tumor	B-DS
-	O
associated	O
stroma	O
could	O
be	O
hijacked	O
to	O
support	O
tumor	B-DS
growth	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
actively	O
interact	O
with	O
components	O
of	O
the	O
innate	O
immune	O
system	O
and	O
display	O
both	O
anti	O
-	O
inflammatory	O
and	O
pro	O
-	O
inflammatory	O
effects	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
MSCs	O
could	O
favor	O
the	O
tumor	B-DS
to	O
escape	O
from	O
immunologic	O
surveillance	O
in	O
the	O
presence	O
of	O
M1	O
macrophages	O
.	O

We	O
found	O
that	O
MSCs	O
educated	O
by	O
M1	O
condition	O
medium	O
(	O
cMSCs	O
)	O
possessed	O
a	O
greatly	O
enhanced	O
ability	O
in	O
promoting	O
tumor	B-DS
growth	O
in	O
vivo	O
.	O

Examination	O
of	O
cytokines	B-GP
/	O
chemokines	B-GP
showed	O
that	O
the	O
cMSCs	O
acquired	O
a	O
regulatory	O
profile	O
,	O
which	O
expressed	O
high	O
levels	O
of	O
iNOS	B-GP
and	O
MCP1	B-GP
.	O

Consistent	O
with	O
an	O
elevated	O
MCP1	B-GP
expression	O
in	O
cMSCs	O
,	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
depended	O
on	O
MCP1	B-GP
mediated	O
macrophage	O
recruitment	O
to	O
tumor	B-DS
sites	O
.	O

Furthermore	O
,	O
IL	B-GP
-	I-GP
6	I-GP
secreted	O
by	O
the	O
cMSCs	O
could	O
polarize	O
infiltrated	O
TAMs	O
into	O
M2	O
-	O
like	O
macrophages	O
.	O

Therefore	O
,	O
when	O
macrophages	O
changed	O
into	O
M1	O
pro	O
-	O
inflammation	O
type	O
in	O
tumor	B-DS
microenvironment	O
,	O
the	O
MSCs	O
would	O
act	O
as	O
poor	O
sensors	O
and	O
switchers	O
to	O
accelerate	O
tumor	B-DS
growth	O
.	O

INTRODUCTION	O

Cancers	B-DS
develop	O
in	O
complex	O
tumor	B-DS
microenvironments	O
,	O
which	O
include	O
cells	O
such	O
as	O
endothelial	O
cells	O
,	O
immune	O
cells	O
,	O
tumor	B-DS
-	O
associated	O
macrophages	O
(	O
TAMs	O
),	O
and	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
[	O
1	O
].	O

Non	O
-	O
cancerous	O
stromal	O
cells	O
have	O
different	O
capabilities	O
to	O
induce	O
both	O
tumor	B-DS
-	O
promoting	O
and	O
tumor	B-DS
-	O
antagonizing	O
effects	O
[	O
2	O
].	O

The	O
contradictory	O
phenomenon	O
brings	O
us	O
a	O
problem	O
how	O
the	O
tumor	B-DS
-	O
associated	O
stroma	O
at	O
the	O
primary	O
sites	O
is	O
hijacked	O
to	O
support	O
tumor	B-DS
growth	O
.	O

The	O
key	O
mechanisms	O
may	O
focus	O
on	O
the	O
role	O
of	O
macrophages	O
,	O
immune	O
suppressor	O
cells	O
,	O
MSCs	O
,	O
the	O
vasculature	O
and	O
various	O
other	O
components	O
of	O
a	O
tumor	B-DS
-	O
supportive	O
microenvironment	O
.	O

Macrophages	O
are	O
resident	O
phagocytic	O
cells	O
in	O
tissues	O
,	O
which	O
play	O
important	O
roles	O
in	O
steady	O
-	O
state	O
tissue	O
homoeostasis	O
by	O
removing	O
cellular	O
debris	O
and	O
apoptotic	O
cells	O
.	O

Although	O
macrophages	O
are	O
classically	O
regarded	O
as	O
key	O
effector	O
cells	O
during	O
immune	O
defense	O
,	O
numerous	O
studies	O
have	O
demonstrated	O
a	O
clear	O
role	O
for	O
TAMs	O
in	O
supporting	O
various	O
aspects	O
of	O
tumor	B-DS
development	O
[	O
3	O
].	O

An	O
explanation	O
for	O
the	O
disparate	O
roles	O
of	O
macrophages	O
during	O
normal	O
tissue	O
homeostasis	O
and	O
carcinogenesis	O
lies	O
in	O
their	O
phenotype	O
[	O
4	O
].	O

At	O
the	O
extremes	O
of	O
their	O
phenotypic	O
continuum	O
,	O
macrophages	O
range	O
from	O
an	O
M1	O
to	O
M2	O
polarization	O
status	O
:	O
classically	O
activated	O
M1	O
macrophages	O
have	O
an	O
anti	O
-	O
tumorigenic	O
role	O
;	O
on	O
the	O
other	O
hand	O
,	O
alternatively	O
activated	O
M2	O
macrophages	O
promote	O
anti	O
-	O
inflammatory	O
responses	O
and	O
have	O
pro	O
-	O
tumorigenic	O
functions	O
.	O

Currently	O
,	O
we	O
do	O
not	O
fully	O
understand	O
how	O
macrophages	O
initially	O
switch	O
from	O
being	O
anti	O
-	O
tumor	B-DS
to	O
pro	O
-	O
tumorigenic	O
at	O
the	O
onset	O
of	O
disease	O
[	O
5	O
].	O

MSCs	O
are	O
one	O
of	O
the	O
major	O
components	O
of	O
the	O
tumor	B-DS
stroma	O
and	O
there	O
is	O
a	O
close	O
interaction	O
between	O
MSCs	O
and	O
the	O
immune	O
system	O
[	O
6	O
–	O
9	O
].	O

MSCs	O
have	O
been	O
shown	O
to	O
interact	O
with	O
a	O
variety	O
of	O
adaptive	O
immune	O
cells	O
including	O
T	O
cells	O
,	O
B	O
cells	O
and	O
dendritic	O
cells	O
[	O
10	O
].	O

Recently	O
,	O
it	O
was	O
demonstrated	O
that	O
the	O
MSCs	O
actively	O
interacted	O
with	O
components	O
of	O
the	O
innate	O
immune	O
system	O
and	O
that	O
through	O
these	O
interactions	O
,	O
they	O
displayed	O
both	O
anti	O
-	O
inflammatory	O
and	O
pro	O
-	O
inflammatory	O
effects	O
[	O
11	O
,	O
12	O
].	O

Within	O
the	O
innate	O
immune	O
system	O
,	O
it	O
was	O
well	O
established	O
that	O
macrophages	O
were	O
key	O
players	O
in	O
initiating	O
and	O
controlling	O
inflammation	O
and	O
the	O
MSCs	O
could	O
influence	O
macrophage	O
functions	O
[	O
13	O
,	O
14	O
].	O

In	O
a	O
tumor	B-DS
microenvironment	O
,	O
the	O
MSCs	O
are	O
often	O
constantly	O
exposed	O
to	O
immune	O
cells	O
and	O
inflammatory	B-GP
cytokines	I-GP
/	O
chemokines	B-GP
.	O

They	O
may	O
have	O
acquired	O
functions	O
that	O
are	O
distinct	O
from	O
those	O
of	O
normal	O
MSCs	O
[	O
15	O
].	O

The	O
unique	O
features	O
may	O
play	O
a	O
role	O
in	O
regulating	O
the	O
tumor	B-DS
microenvironment	O
and	O
ultimately	O
affecting	O
tumor	B-DS
progression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
MSCs	O
could	O
favor	O
a	O
tumor	B-DS
to	O
escape	O
from	O
immunologic	O
surveillance	O
in	O
an	O
environment	O
of	O
M1	O
macrophages	O
.	O

To	O
assess	O
the	O
possible	O
effects	O
of	O
M1	O
macrophages	O
on	O
the	O
MSCs	O
in	O
tumor	B-DS
growth	O
,	O
we	O
treated	O
MSCs	O
with	O
condition	O
medium	O
derived	O
from	O
M1	O
macrophages	O
(	O
cMSCs	O
),	O
characterized	O
by	O
their	O
tumor	B-DS
-	O
promoting	O
activity	O
and	O
phenotype	O
,	O
and	O
studied	O
the	O
mechanism	O
of	O
the	O
cMSCs	O
in	O
affecting	O
tumor	B-DS
growth	O
in	O
comparison	O
to	O
normal	O
MSCs	O
.	O

We	O
found	O
that	O
M1	O
macrophages	O
could	O
activate	O
the	O
MSCs	O
to	O
adopt	O
a	O
regulatory	O
phenotype	O
,	O
and	O
the	O
cMSCs	O
promoted	O
tumor	B-DS
growth	O
by	O
iNOS	B-GP
and	O
MCP1	B-GP
.	O

Therefore	O
,	O
this	O
study	O
revealed	O
that	O
the	O
MSCs	O
sensed	O
and	O
controlled	O
inflammation	O
to	O
promote	O
tumor	B-DS
growth	O
in	O
a	O
pro	O
-	O
inflammatory	O
environment	O
.	O

RESULTS	O

cMSCs	O
had	O
more	O
potential	O
than	O
untreated	O
-	O
MSCs	O
to	O
promote	O
tumor	B-DS
growth	O

Macrophage	O
cell	O
-	O
line	O
RAW264	O
.	O
7	O
cell	O
exposure	O
to	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
drive	O
M1	O
polarization	O
with	O
potentiated	O
cytotoxic	O
and	O
antitumoral	O
properties	O
.	O

To	O
confirm	O
the	O
M1	O
macrophage	O
phenotype	O
,	O
the	O
expression	O
of	O
iNOS	B-GP
(	O
M1	O
macrophage	O
marker	O
)	O
examined	O
by	O
a	O
FACS	O
analysis	O
clearly	O
increased	O
,	O
while	O
the	O
expression	O
of	O
CD11b	B-GP
(	O
macrophage	O
marker	O
)	O
remained	O
unchanged	O
(	O
Figure	O
S1A	O
).	O

Macrophage	O
M1	O
polarization	O
was	O
also	O
assessed	O
at	O
the	O
mRNA	O
level	O
using	O
real	O
-	O
time	O
PCR	O
by	O
measuring	O
the	O
expression	O
of	O
several	O
classical	O
M1	O
markers	O
:	O
TNFα	B-GP
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
and	O
iNOS	B-GP
.	O

An	O
increased	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
iNOS	B-GP
expression	O
profile	O
was	O
obtained	O
by	O
incubation	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
.	O

We	O
also	O
checked	O
the	O
expression	O
at	O
the	O
mRNA	O
level	O
of	O
several	O
M2	O
markers	O
(	O
IL	B-GP
-	I-GP
10	I-GP
,	O
Arg	B-GP
-	I-GP
1	I-GP
and	O
FIZZ	B-GP
-	I-GP
1	I-GP
)	O
in	O
M1	O
macrophages	O
,	O
but	O
in	O
our	O
conditions	O
,	O
we	O
observed	O
no	O
significant	O
expression	O
of	O
these	O
genes	O
.	O

In	O
addition	O
,	O
the	O
mRNA	O
abundance	O
of	O
signal	B-GP
regulatory	I-GP
protein	I-GP
-	I-GP
a	I-GP
(	O
SIRPα	B-GP
)	O
was	O
significantly	O
reduced	O
(	O
Figure	O
S1A	O
).	O

SIRPα	B-GP
is	O
a	O
membrane	B-GP
receptor	I-GP
expressed	O
by	O
macrophages	O
.	O

The	O
interactions	O
of	O
CD47	B-GP
-	O
SIRPα	B-GP
form	O
a	O
barrier	O
for	O
antibody	B-GP
-	O
mediated	O
tumor	B-DS
cell	O
destruction	O
[	O
16	O
].	O

In	O
order	O
to	O
study	O
the	O
effects	O
of	O
M1	O
macrophages	O
on	O
cancer	B-DS
cell	O
response	O
in	O
vivo	O
,	O
prior	O
to	O
implantation	O
of	O
M1	O
macrophages	O
,	O
breast	B-DS
cancer	I-DS
models	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
were	O
set	O
up	O
.	O

Two	O
hours	O
after	O
M1	O
macrophages	O
had	O
been	O
injected	O
into	O
tumor	B-DS
sites	O
,	O
we	O
found	O
that	O
M1	O
macrophages	O
exhibited	O
radical	O
scavenging	O
potential	O
since	O
the	O
amount	O
of	O
tumor	B-DS
cells	O
remaining	O
was	O
10	O
%	O
compared	O
to	O
the	O
control	O
group	O
(	O
Figure	O
S1B	O
).	O

Therefore	O
,	O
incubation	O
of	O
macrophages	O
with	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
LPS	O
induces	O
their	O
polarization	O
into	O
M1	O
macrophages	O
,	O
and	O
M1	O
-	O
polarized	O
macrophages	O
have	O
strong	O
antitumor	O
activity	O
to	O
elicit	O
tumor	B-DS
disruption	O
.	O

To	O
investigate	O
the	O
characterization	O
of	O
the	O
cMSCs	O
,	O
MSCs	O
were	O
isolated	O
from	O
murine	O
bone	O
marrow	O
.	O

The	O
morphology	O
of	O
the	O
mouse	B-OG
MSCs	O
displayed	O
a	O
homogenous	O
spindle	O
-	O
shaped	O
population	O
.	O

FACS	O
was	O
used	O
to	O
identify	O
the	O
surface	O
marker	O
expression	O
of	O
the	O
MSCs	O
.	O

High	O
expression	O
of	O
CD29	B-GP
,	O
CD73	B-GP
,	O
CD90	B-GP
and	O
CD105	B-GP
was	O
observed	O
,	O
but	O
CD34	B-GP
and	O
CD45	B-GP
were	O
down	O
-	O
regulated	O
(	O
data	O
not	O
shown	O
).	O

MSC	O
were	O
stimulated	O
by	O
the	O
medium	O
from	O
M1	O
macrophages	O
for	O
24	O
hours	O
to	O
achieve	O
the	O
cMSCs	O
.	O

To	O
determine	O
whether	O
the	O
cMSCs	O
could	O
promote	O
human	B-OG
tumor	B-DS
growth	O
,	O
we	O
injected	O
the	O
cMSCs	O
into	O
immune	O
deficient	O
mice	B-OG
with	O
human	B-OG
carcinoma	B-DS
cells	O
,	O
while	O
untreated	O
MSCs	O
were	O
used	O
as	O
controls	O
.	O

When	O
co	O
-	O
injected	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
breast	B-DS
cancer	I-DS
cells	O
,	O
the	O
cMSCs	O
but	O
not	O
the	O
untreated	O
MSC	O
remarkably	O
increased	O
the	O
tumor	B-DS
-	O
initiating	O
ability	O
and	O
tumor	B-DS
growth	O
(	O
Figure	O
1A	O
,	O
1D	O
).	O

We	O
also	O
tested	O
the	O
effect	O
of	O
the	O
cMSCs	O
on	O
hepatocellular	B-DS
HCC	I-DS
-	O
LM3	O
-	O
FLUC	O
tumor	B-DS
growth	O
in	O
vivo	O
.	O

Similar	O
to	O
the	O
breast	B-DS
cancer	I-DS
model	O
,	O
the	O
cMSCs	O
caused	O
a	O
tumor	B-DS
-	O
promoting	O
effect	O
in	O
the	O
hepatocellular	B-DS
carcinoma	I-DS
model	O
as	O
compared	O
to	O
the	O
untreated	O
control	O
MSCs	O
group	O
(	O
Figure	O
1B	O
,	O
1E	O
).	O

The	O
cMSCs	O
also	O
led	O
to	O
a	O
significant	O
tumor	B-DS
promotion	O
of	O
malignant	O
glioblastoma	B-DS
U87MG	O
-	O
FLUC	O
cells	O
(	O
Figure	O
1C	O
,	O
1F	O
).	O

Furthermore	O
,	O
after	O
the	O
cMSCs	O
were	O
co	O
-	O
injected	O
with	O
murine	O
4T1	O
-	O
FLUC	O
cells	O
into	O
a	O
fat	O
pad	O
of	O
normal	O
mice	B-OG
,	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
the	O
control	O
MSCs	O
in	O
promoting	O
tumor	B-DS
growth	O
(	O
data	O
not	O
shown	O
).	O

Therefore	O
,	O
the	O
cMSCs	O
displayed	O
greater	O
potential	O
to	O
promote	O
tumor	B-DS
growth	O
in	O
comparison	O
to	O
the	O
untreated	O
MSCs	O
.	O

cMSCs	O
promoted	O
tumor	B-DS
growth	O
in	O
vivo	O
to	O
a	O
greater	O
extent	O
than	O
untreated	O
-	O
MSCs	O

(	O
A	O
–	O
C	O
)	O
D	O
-	O
Luciferin	O
induced	O
bioluminescence	O
obtained	O
in	O
breast	O
(	O
A	O
),	O
liver	O
(	O
B	O
),	O
and	O
brain	O
(	O
C	O
)	O
cancer	B-DS
mice	B-OG
co	O
-	O
injected	O
with	O
cMSCs	O
,	O
MSCs	O
or	O
PBS	O
.	O

cMSCs	O
-	O
treated	O
mice	B-OG
displayed	O
a	O
significant	O
increase	O
in	O
tumor	B-DS
growth	O
.	O

(	O
D	O
–	O
F	O
)	O
Quantification	O
of	O
the	O
bioluminescent	O
signal	O
in	O
corresponding	O
breast	O
(	O
D	O
),	O
liver	O
(	O
E	O
),	O
and	O
brain	O
(	O
F	O
)	O
tumors	B-DS
after	O
treatments	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
MSCs	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
PBS	O
group	O
.	O

Stimulated	O
by	O
M1	O
medium	O
altering	O
the	O
cytokine	B-GP
/	O
chemokine	B-GP
expression	O
in	O
the	O
cMSCs	O

The	O
MSCs	O
affect	O
cancer	B-DS
progression	O
through	O
a	O
number	O
of	O
secreted	O
factors	O
triggering	O
activation	O
of	O
various	O
mechanisms	O
.	O

The	O
genetic	O
abnormalities	O
in	O
specific	O
genes	O
in	O
the	O
cMSCs	O
may	O
account	O
for	O
the	O
tumor	B-DS
-	O
promotion	O
activity	O
by	O
the	O
cMSCs	O
.	O

To	O
investigate	O
how	O
the	O
cMSCs	O
achieve	O
their	O
tumor	B-DS
-	O
promoting	O
effect	O
and	O
how	O
they	O
differ	O
from	O
untreated	O
MSCs	O
,	O
we	O
examined	O
the	O
gene	O
expression	O
profiling	O
of	O
the	O
cMSCs	O
.	O

Using	O
real	O
-	O
time	O
PCR	O
,	O
we	O
found	O
that	O
the	O
transcript	O
levels	O
of	O
iNOS	B-GP
,	O
MCP1	B-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
were	O
markedly	O
higher	O
in	O
the	O
cMSCs	O
than	O
in	O
untreated	O
MSCs	O
.	O

However	O
,	O
the	O
levels	O
of	O
CXCL9	B-GP
and	O
CXCL10	B-GP
were	O
lower	O
(	O
Figure	O
2A	O
).	O

A	O
previous	O
study	O
reported	O
a	O
new	O
MSCs	O
paradigm	O
by	O
specific	O
TLR	B-GP
-	O
priming	O
:	O
TLR4	B-GP
-	O
primed	O
MSC1	O
and	O
TLR3	B-GP
-	O
primed	O
MSC2	O
[	O
17	O
].	O

We	O
used	O
real	O
-	O
time	O
PCR	O
to	O
identify	O
additional	O
TLR	B-GP
genes	O
that	O
might	O
be	O
affected	O
,	O
and	O
found	O
that	O
TLR2	B-GP
,	O
TLR3	B-GP
,	O
and	O
TLR4	B-GP
were	O
induced	O
at	O
high	O
levels	O
in	O
the	O
cMSCs	O
compared	O
to	O
untreated	O
MSCs	O
.	O

Specifically	O
,	O
TLR3	B-GP
expression	O
was	O
increased	O
about	O
20	O
-	O
fold	O
after	O
M1	O
medium	O
treatment	O
(	O
Figure	O
2B	O
).	O

Furthermore	O
,	O
we	O
examined	O
the	O
chemotactic	O
potential	O
of	O
the	O
cMSCs	O
in	O
vitro	O
using	O
transwell	O
migration	O
assays	O
,	O
and	O
found	O
that	O
the	O
cMSCs	O
elicited	O
a	O
more	O
robust	O
migration	O
response	O
than	O
the	O
MSCs	O
(	O
Figure	O
2C	O
,	O
2D	O
).	O

Characterization	O
of	O
the	O
cMSCs	O

(	O
A	O
)	O
The	O
effects	O
of	O
the	O
M1	O
-	O
conditioned	O
medium	O
on	O
the	O
activation	O
of	O
various	O
gene	O
expressions	O
in	O
the	O
MSCs	O
were	O
assessed	O
by	O
using	O
real	O
-	O
time	O
PCR	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
B	O
)	O
The	O
expression	O
of	O
TLRs	B-GP
of	O
the	O
cMSCs	O
was	O
assessed	O
by	O
real	O
-	O
time	O
PCR	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
C	O
–	O
D	O
)	O
The	O
migration	O
ability	O
of	O
the	O
cMSCs	O
was	O
evaluated	O
.	O

(	O
C	O
)	O
Representative	O
images	O
of	O
the	O
MSCs	O
(	O
upper	O
)	O
and	O
cMSCs	O
(	O
lower	O
)	O
in	O
response	O
to	O
FBS	O
in	O
a	O
transwell	O
assay	O
.	O

Scale	O
bar	O
=	O
50	O
μm	O
.	O

(	O
D	O
)	O
Average	O
number	O
of	O
migrated	O
cells	O
in	O
a	O
transwell	O
migration	O
assay	O
.	O

Results	O
are	O
mean	O
values	O
±	O
SEM	O
of	O
five	O
different	O
fields	O
from	O
four	O
independent	O
experiments	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
versus	O
MSCs	O
.	O

(	O
E	O
–	O
F	O
)	O
Tumor	B-DS
-	O
associated	O
leukocytes	O
differ	O
among	O
the	O
cMSCs	O
and	O
MSCs	O
treated	O
groups	O
.	O

(	O
E	O
)	O
Immunohistochemical	O
staining	O
for	O
CD45	B-GP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
in	O
4T1	O
-	O
FLUC	O
breast	B-DS
tumors	I-DS
14	O
days	O
after	O
co	O
-	O
injection	O
.	O

Scale	O
bars	O
=	O
50	O
μm	O
.	O

(	O
F	O
)	O
A	O
larger	O
number	O
of	O
CD45	B-GP
positive	O
bone	O
marrow	O
cells	O
were	O
stained	O
in	O
the	O
cMSCs	O
implantation	O
group	O
than	O
in	O
the	O
MSCs	O
and	O
the	O
PBS	O
injection	O
groups	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
MSCs	O
group	O
.	O

Abbreviations	O
:	O
HPF	O
,	O
high	O
-	O
power	O
field	O
.	O

Cancers	B-DS
develop	O
in	O
a	O
complex	O
tissue	O
environment	O
which	O
usually	O
contains	O
bone	O
marrow	O
derived	O
cells	O
.	O

We	O
employed	O
CD45	B-GP
+	O
to	O
identify	O
tumor	B-DS
-	O
associated	O
bone	O
marrow	O
cells	O
14	O
days	O
after	O
co	O
-	O
injection	O
with	O
4T1	O
-	O
FLUC	O
cells	O
and	O
cMSCs	O
or	O
untreated	O
MSCs	O
,	O
and	O
found	O
that	O
there	O
was	O
a	O
great	O
expansion	O
of	O
the	O
populations	O
of	O
CD45	B-GP
+	O
cells	O
in	O
tumors	B-DS
,	O
an	O
effect	O
that	O
was	O
dramatically	O
greater	O
with	O
the	O
cMSCs	O
than	O
untreated	O
MSCs	O
(	O
Figure	O
2E	O
,	O
2F	O
).	O

These	O
data	O
suggested	O
that	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
the	O
untreated	O
MSCs	O
in	O
recruiting	O
CD45	B-GP
+	O
cells	O
to	O
tumor	B-DS
sites	O
.	O

In	O
view	O
of	O
the	O
immunosuppressive	O
ability	O
of	O
the	O
MSCs	O
,	O
we	O
examined	O
whether	O
cMSCs	O
have	O
immunosuppressive	O
function	O
.	O

The	O
splenocytes	O
were	O
activated	O
with	O
ConA	B-GP
followed	O
by	O
expansion	O
with	O
IL	B-GP
-	I-GP
2	I-GP
for	O
72	O
hours	O
.	O

We	O
co	O
-	O
cultured	O
the	O
activated	O
splenocytes	O
with	O
cMSCs	O
or	O
untreated	O
MSCs	O
.	O

The	O
results	O
showed	O
that	O
although	O
the	O
MSCs	O
could	O
not	O
inhibit	O
the	O
proliferation	O
of	O
splenocytes	O
,	O
the	O
inhibitory	O
effects	O
of	O
the	O
cMSCs	O
on	O
splenocytes	O
proliferation	O
were	O
significantly	O
increased	O
(	O
Figure	O
S2	O
).	O

cMSCs	O
exert	O
tumor	B-DS
promotion	O
of	O
the	O
required	O
iNOS	B-GP

High	O
concentrations	O
of	O
nitric	O
oxide	O
are	O
known	O
to	O
inhibit	O
immune	O
responses	O
to	O
promote	O
tumor	B-DS
growth	O
[	O
18	O
].	O

As	O
shown	O
above	O
,	O
iNOS	B-GP
mRNA	O
was	O
up	O
-	O
regulated	O
significantly	O
in	O
the	O
cMSCs	O
(	O
Figure	O
2A	O
).	O

To	O
investigate	O
the	O
role	O
of	O
nitric	O
oxide	O
,	O
its	O
production	O
was	O
shut	O
down	O
using	O
siRNA	O
to	O
inhibit	O
the	O
expression	O
of	O
iNOS	B-GP
.	O

RT	O
-	O
PCR	O
and	O
real	O
-	O
time	O
PCR	O
were	O
performed	O
to	O
assess	O
the	O
expression	O
of	O
iNOS	B-GP
in	O
cMSCs	O
to	O
further	O
confirm	O
the	O
transfection	O
efficiency	O
of	O
iNOS	B-GP
siRNA	O
.	O

iNOS	B-GP
expression	O
was	O
markedly	O
decreased	O
in	O
the	O
cMSCs	O
treated	O
by	O
iNOS	B-GP
siRNA	O
but	O
not	O
in	O
the	O
cMSCs	O
treated	O
by	O
control	O
-	O
siRNA	O
(	O
Figure	O
3A	O
),	O
which	O
showed	O
more	O
than	O
an	O
80	O
%	O
inhibitory	O
efficiency	O
rate	O
(	O
Figure	O
3B	O
).	O

Moreover	O
,	O
in	O
mixed	O
co	O
-	O
cultures	O
of	O
splenocytes	O
and	O
cMSCs	O
pre	O
-	O
treated	O
with	O
iNOS	B-GP
siRNA	O
or	O
iNOS	B-GP
inhibitor	O
1400	O
W	O
,	O
splenocyte	O
proliferation	O
was	O
restored	O
to	O
a	O
normal	O
level	O
(	O
Figure	O
S2	O
).	O

The	O
results	O
strongly	O
suggested	O
that	O
nitric	O
oxide	O
produced	O
by	O
the	O
cMSCs	O
mediated	O
the	O
suppression	O
of	O
splenocytes	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
4T1	O
tumor	B-DS
-	O
promoting	O
ability	O
of	O
the	O
cMSCs	O
was	O
dependent	O
upon	O
the	O
expression	O
of	O
iNOS	B-GP
(	O
Figure	O
3C	O
–	O
3D	O
).	O

Therefore	O
,	O
these	O
data	O
supported	O
that	O
immunosuppression	O
mediated	O
by	O
the	O
cMSCs	O
via	O
nitric	O
oxide	O
play	O
an	O
important	O
role	O
in	O
favoring	O
tumor	B-DS
cells	O
growth	O
.	O

The	O
growth	O
of	O
the	O
tumor	B-DS
favored	O
by	O
the	O
cMSCs	O
in	O
vivo	O
can	O
be	O
inhibited	O
by	O
iNOS	B-GP
siRNA	O

To	O
determine	O
the	O
effect	O
of	O
iNOS	B-GP
in	O
the	O
cMSCs	O
,	O
the	O
cMSCs	O
were	O
transfected	O
with	O
iNOS	B-GP
siRNA	O
or	O
control	O
siRNA	O
.	O

Mice	B-OG
were	O
divided	O
into	O
the	O
si	O
-	O
iNOS	B-GP
/	O
cMSCs	O
group	O
and	O
si	O
-	O
control	O
/	O
cMSCs	O
group	O
.	O

(	O
A	O
)	O
RT	O
-	O
PCR	O
showed	O
that	O
the	O
expression	O
of	O
iNOS	B-GP
was	O
decreased	O
in	O
the	O
cMSCs	O
in	O
which	O
transfections	O
of	O
iNOS	B-GP
siRNA	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
.	O

(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
inhibitory	O
efficiency	O
was	O
more	O
than	O
80	O
%	O
compared	O
with	O
the	O
control	O
siRNA	O
in	O
the	O
cMSCs	O
.	O

(	O
C	O
)	O
cMSCs	O
transfected	O
by	O
iNOS	B-GP
siRNA	O
did	O
not	O
support	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
.	O

(	O
D	O
)	O
Quantification	O
of	O
the	O
bioluminescent	O
signal	O
(	O
C	O
)	O
in	O
tumors	B-DS
after	O
treatments	O
.	O

MCP1	B-GP
-	O
mediated	O
macrophage	O
trafficking	O
is	O
critical	O
for	O
the	O
tumor	B-DS
-	O
promoting	O
effects	O
of	O
the	O
cMSCs	O

As	O
shown	O
above	O
,	O
the	O
cMSCs	O
were	O
more	O
effective	O
than	O
untreated	O
MSCs	O
in	O
recruiting	O
CD45	B-GP
+	O
cells	O
at	O
tumor	B-DS
sites	O
(	O
Figure	O
2E	O
),	O
which	O
may	O
include	O
monocytes	O
/	O
macrophages	O
,	O
B	O
cells	O
and	O
T	O
cells	O
.	O

Monocytes	O
/	O
macrophages	O
are	O
essential	O
for	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
MSCs	O
isolated	O
from	O
tumor	B-DS
sites	O
[	O
14	O
].	O

To	O
determine	O
whether	O
monocytes	O
/	O
macrophages	O
mediated	O
the	O
tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
,	O
we	O
depleted	O
systemic	O
monocytes	O
/	O
macrophages	O
with	O
clodronate	B-CD
liposomes	O
(	O
Clo	O
-	O
Lip	O
)	O
followed	O
by	O
injecting	O
mixtures	O
of	O
cMSCs	O
or	O
MSCs	O
with	O
4T1	O
tumor	B-DS
cells	O
into	O
mice	B-OG
14	O
days	O
after	O
transplantation	O
which	O
detected	O
the	O
tumor	B-DS
growth	O
by	O
BLI	O
.	O

We	O
found	O
that	O
depletion	O
of	O
monocytes	O
/	O
macrophages	O
in	O
our	O
system	O
had	O
an	O
effect	O
on	O
cMSCs	O
-	O
promoted	O
tumor	B-DS
growth	O
(	O
Figure	O
4A	O
),	O
indicating	O
that	O
monocytes	O
/	O
macrophages	O
are	O
indispensable	O
for	O
tumor	B-DS
growth	O
enhancement	O
induced	O
by	O
the	O
cMSCs	O
.	O

Tumor	B-DS
-	O
promoting	O
effect	O
of	O
the	O
cMSCs	O
relied	O
on	O
the	O
MCP1	B-GP
to	O
recruit	O
TAMs	O

(	O
A	O
)	O
Ablation	O
of	O
monocytes	O
/	O
macrophages	O
by	O
clodronate	O
liposomes	O
abolished	O
the	O
tumor	B-DS
-	O
promoting	O
activity	O
of	O
the	O
cMSCs	O
.	O

(	O
B	O
–	O
D	O
)	O
cMSCs	O
were	O
transfected	O
with	O
MCP1	B-GP
siRNA	O
.	O

Impact	O
of	O
MCP1	B-GP
deficiency	O
on	O
cMSCs	O
tumor	B-DS
promoting	O
effects	O
was	O
detected	O
.	O

Animals	B-OG
were	O
divided	O
into	O
the	O
si	O
-	O
MCP1	B-GP
/	O
cMSCs	O
group	O
and	O
si	O
-	O
control	O
/	O
cMSCs	O
group	O
.	O

(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
expression	O
of	O
MCP1	B-GP
was	O
decreased	O
in	O
the	O
MSCs	O
in	O
which	O
transfections	O
of	O
MCP1	B-GP
siRNA	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
.	O

(	O
C	O
)	O
The	O
in	O
vivo	O
growth	O
of	O
the	O
tumor	B-DS
favored	O
by	O
the	O
cMSCs	O
could	O
be	O
inhibited	O
by	O
MCP1	B-GP
siRNA	O
.	O

4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
was	O
detected	O
by	O
BLI	O
after	O
establishing	O
the	O
breast	B-DS
carcinoma	I-DS
model	O
.	O

(	O
D	O
)	O
Representative	O
flow	O
cytometry	O
data	O
show	O
the	O
frequency	O
of	O
CD206	B-GP
macrophages	O
from	O
the	O
tumor	B-DS
and	O
peripheral	O
blood	O
of	O
4T1	O
bearing	O
control	O
mice	B-OG
.	O

MCP	B-GP
-	I-GP
1	I-GP
is	O
the	O
CCR2	B-GP
ligand	O
.	O

The	O
chemokine	B-GP
receptor	I-GP
CCR2	B-GP
is	O
known	O
to	O
be	O
expressed	O
on	O
monocytes	O
/	O
macrophages	O
.	O

Most	O
notably	O
,	O
MCP1	B-GP
,	O
the	O
major	O
chemokine	B-GP
for	O
macrophage	O
trafficking	O
,	O
was	O
expressed	O
at	O
a	O
high	O
level	O
by	O
the	O
cMSCs	O
,	O
but	O
not	O
by	O
the	O
untreated	O
MSCs	O
(	O
Figure	O
2A	O
),	O
suggesting	O
that	O
cMSCs	O
-	O
produced	O
MCP1	B-GP
may	O
play	O
an	O
important	O
role	O
in	O
cMSCs	O
-	O
promoted	O
tumor	B-DS
growth	O
.	O

To	O
examine	O
this	O
possibility	O
,	O
we	O
performed	O
MCP1	B-GP
knock	O
down	O
in	O
the	O
cMSCs	O
using	O
siRNA	O
.	O

We	O
found	O
that	O
siRNA	O
targeting	O
MCP1	B-GP
was	O
capable	O
of	O
inhibiting	O
MCP1	B-GP
in	O
the	O
cMSCs	O
(	O
Figure	O
4B	O
).	O

To	O
establish	O
the	O
role	O
of	O
cMSCs	O
-	O
expressed	O
MCP1	B-GP
in	O
tumor	B-DS
growth	O
promotion	O
and	O
macrophage	O
infiltration	O
in	O
vivo	O
,	O
we	O
co	O
-	O
transplanted	O
MCP1	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cells	O
into	O
C57BL	B-OG
/	I-OG
6	I-OG
mice	I-OG
.	O

We	O
found	O
that	O
the	O
tumor	B-DS
promoting	O
activity	O
of	O
the	O
cMSCs	O
was	O
largely	O
MCP1	B-GP
dependent	O
since	O
it	O
was	O
significantly	O
blocked	O
by	O
adding	O
MCP1	B-GP
siRNA	O
(	O
Figure	O
4C	O
).	O

MCP1	B-GP
could	O
induce	O
emigration	O
of	O
macrophages	O
from	O
the	O
bone	O
marrow	O
to	O
the	O
periphery	O
.	O

Furthermore	O
,	O
the	O
infiltrated	O
CD206	B-GP
positive	O
macrophages	O
in	O
the	O
blood	O
and	O
tumor	B-DS
sites	O
in	O
mice	B-OG
who	O
were	O
administered	O
cMSCs	O
and	O
were	O
treated	O
by	O
MCP1	B-GP
siRNA	O
or	O
control	O
siRNA	O
were	O
examined	O
by	O
flow	O
cytometry	O
.	O

We	O
found	O
that	O
an	O
MCP1	B-GP
deficiency	O
led	O
to	O
a	O
significant	O
reduction	O
in	O
CD206	B-GP
positive	O
macrophages	O
in	O
both	O
tumor	B-DS
tissues	O
and	O
peripheral	O
blood	O
(	O
Figure	O
4D	O
),	O
indicating	O
that	O
MCP1	B-GP
is	O
critical	O
for	O
trafficking	O
CD206	B-GP
+	O
macrophages	O
.	O

Altogether	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
cMSCs	O
probably	O
exert	O
their	O
tumor	B-DS
-	O
promoting	O
effect	O
by	O
recruiting	O
macrophages	O
to	O
tumor	B-DS
sites	O
through	O
the	O
production	O
of	O
MCP1	B-GP
.	O

cMSCs	O
convert	O
macrophages	O
into	O
M2	O
-	O
like	O
cells	O
to	O
promote	O
tumor	B-DS
growth	O

Macrophages	O
recruited	O
by	O
MCP1	B-GP
may	O
polarize	O
into	O
an	O
M1	O
or	O
M2	O
subset	O
in	O
a	O
tumor	B-DS
microenvironment	O
.	O

An	O
M2	O
polarized	O
population	O
promotes	O
tumor	B-DS
progression	O
.	O

To	O
examine	O
whether	O
the	O
cMSCs	O
remodel	O
the	O
phenotype	O
of	O
TAM	O
,	O
macrophages	O
and	O
cMSCs	O
were	O
co	O
-	O
incubated	O
in	O
a	O
transwell	O
for	O
24	O
hours	O
.	O

When	O
macrophages	O
were	O
further	O
examined	O
for	O
their	O
M1	O
/	O
M2	O
gene	O
expression	O
profile	O
by	O
real	O
-	O
time	O
PCR	O
,	O
we	O
found	O
that	O
macrophages	O
co	O
-	O
cultured	O
with	O
cMSCs	O
expressed	O
high	O
levels	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
and	O
SIRPα	B-GP
(	O
Figure	O
5A	O
),	O
comprising	O
an	O
M2	O
-	O
preferential	O
gene	O
signature	O
in	O
comparison	O
to	O
control	O
macrophages	O
.	O

Interestingly	O
,	O
these	O
cMSCs	O
-	O
educated	O
macrophages	O
differed	O
slightly	O
from	O
the	O
traditional	O
M2	O
type	O
,	O
since	O
they	O
expressed	O
a	O
low	O
level	O
of	O
Arg	B-GP
-	I-GP
1	I-GP
.	O

Meanwhile	O
,	O
FACS	O
analysis	O
showed	O
that	O
the	O
increase	O
in	O
the	O
frequency	O
of	O
CD206	B-GP
+	O
cells	O
caused	O
by	O
the	O
cMSCs	O
was	O
detected	O
(	O
Figure	O
5D	O
).	O

The	O
results	O
suggested	O
that	O
the	O
cMSCs	O
generated	O
macrophages	O
with	O
a	O
similar	O
M2	O
phenotype	O
.	O

Moreover	O
,	O
to	O
determine	O
whether	O
M2	O
-	O
like	O
macrophages	O
treated	O
by	O
cMSCs	O
stimulate	O
the	O
growth	O
of	O
mammary	B-DS
cancer	I-DS
cells	O
in	O
vivo	O
,	O
we	O
injected	O
4T1	O
-	O
FLUC	O
cells	O
into	O
the	O
mammary	O
fat	O
pads	O
of	O
mice	B-OG
either	O
alone	O
or	O
coupled	O
with	O
M2	O
-	O
like	O
macrophages	O
.	O

The	O
accumulation	O
of	O
4T1	O
-	O
FLUC	O
cancer	B-DS
cells	O
in	O
the	O
mammary	O
fat	O
pads	O
was	O
increased	O
significantly	O
and	O
observed	O
by	O
BLI	O
and	O
bioluminescence	O
tomography	O
(	O
BLT	O
)	O
at	O
14	O
days	O
after	O
the	O
inoculation	O
as	O
compared	O
with	O
4T1	O
-	O
FLUC	O
cells	O
alone	O
(	O
Figure	O
5B	O
,	O
Movies	O
S1	O
and	O
S2	O
).	O

The	O
cMSCs	O
promoted	O
the	O
polarization	O
of	O
TAMs	O
into	O
M2	O
-	O
like	O
cells	O
through	O
IL	B-GP
-	I-GP
6	I-GP

(	O
A	O
)	O
Real	O
-	O
time	O
PCR	O
showed	O
that	O
the	O
cMSCs	O
educated	O
macrophages	O
increased	O
the	O
expression	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
and	O
SIRPα	B-GP
compared	O
to	O
untreated	O
macrophages	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
;	O
**	O
P	O
<	O
0	O
.	O
01	O
.	O

(	O
B	O
)	O
The	O
growth	O
of	O
the	O
tumor	B-DS
was	O
favored	O
by	O
macrophages	O
stimulated	O
by	O
the	O
cMSCs	O
for	O
in	O
vivo	O
studies	O
.	O

(	O
C	O
–	O
D	O
)	O
Blocking	O
IL	B-GP
-	I-GP
6	I-GP
inhibited	O
cMSCs	O
-	O
mediated	O
induction	O
of	O
M2	O
-	O
like	O
macrophages	O
.	O

(	O
C	O
)	O
The	O
effects	O
of	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
antibody	O
on	O
the	O
activation	O
of	O
various	O
gene	O
expressions	O
in	O
the	O
cMSCs	O
were	O
assessed	O
by	O
using	O
real	O
-	O
time	O
PCR	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
.	O

(	O
D	O
)	O
Characterization	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
treated	O
or	O
untreated	O
by	O
IL	B-GP
-	I-GP
6	I-GP
antibody	O
.	O

Previous	O
findings	O
showed	O
that	O
secretory	O
factors	O
play	O
an	O
essential	O
role	O
in	O
MSCs	O
induced	O
polarization	O
of	O
M2	O
macrophages	O
[	O
11	O
].	O

In	O
this	O
study	O
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
were	O
expressed	O
at	O
higher	O
levels	O
in	O
the	O
cMSCs	O
than	O
MSCs	O
,	O
thus	O
we	O
explored	O
whether	O
these	O
secretory	O
factors	O
contributed	O
to	O
the	O
polarization	O
of	O
TAM	O
toward	O
an	O
M2	O
-	O
like	O
phenotype	O
.	O

Hence	O
,	O
macrophages	O
were	O
co	O
-	O
cultured	O
with	O
cMSCs	O
in	O
transwells	O
in	O
the	O
presence	O
specific	O
neutralizing	O
antibodies	B-GP
for	O
IL	B-GP
-	I-GP
6	I-GP
and	O
COX	B-GP
-	I-GP
2	I-GP
for	O
24	O
hours	O
,	O
and	O
M2	O
macrophage	O
characteristics	O
were	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
and	O
flow	O
cytometry	O
.	O

We	O
showed	O
that	O
the	O
addition	O
of	O
neutralizing	O
antibodies	B-GP
specific	O
for	O
IL	B-GP
-	I-GP
6	I-GP
significantly	O
decreased	O
the	O
mRNA	O
expression	O
of	O
FIZZ	B-GP
-	I-GP
1	I-GP
,	O
MCP1	B-GP
,	O
SIRPα	B-GP
,	O
and	O
reduced	O
the	O
percentage	O
of	O
CD206	B-GP
positive	O
cells	O
,	O
as	O
compared	O
with	O
the	O
co	O
-	O
culture	O
control	O
treated	O
with	O
nonspecific	O
antibodies	B-GP
(	O
Figure	O
5C	O
,	O
5D	O
).	O

Therefore	O
,	O
these	O
results	O
suggested	O
that	O
IL	B-GP
-	I-GP
6	I-GP
contributed	O
to	O
the	O
induction	O
of	O
M2	O
-	O
like	O
macrophages	O
mediated	O
by	O
co	O
-	O
culturing	O
with	O
cMSCs	O
.	O

DISCUSSION	O

The	O
inflammatory	O
response	O
can	O
promote	O
carcinogenesis	O
;	O
one	O
of	O
the	O
major	O
challenges	O
in	O
understanding	O
the	O
connection	O
between	O
inflammation	O
and	O
cancer	B-DS
is	O
to	O
identify	O
the	O
triggering	O
events	O
that	O
lead	O
to	O
the	O
inflammatory	O
responses	O
which	O
can	O
promote	O
tumorigenesis	O
.	O

Our	O
findings	O
demonstrated	O
an	O
event	O
of	O
cancer	B-DS
development	O
induced	O
by	O
inflammation	O
:	O
when	O
the	O
microenvironment	O
became	O
M1	O
pro	O
-	O
inflammatory	O
,	O
the	O
MSCs	O
acquired	O
a	O
regulatory	O
phenotype	O
and	O
promoted	O
tumor	B-DS
growth	O
.	O

The	O
tumor	B-DS
-	O
promoting	O
abilities	O
required	O
iNOS	B-GP
and	O
TAMs	O
;	O
TAMs	O
were	O
recruited	O
by	O
MCP1	B-GP
and	O
further	O
polarized	O
into	O
an	O
M2	O
-	O
like	O
phenotype	O
to	O
affect	O
tumorigenesis	O
.	O

We	O
use	O
Figure	O
6	O
to	O
describe	O
this	O
effect	O
.	O

These	O
results	O
thus	O
establish	O
a	O
mechanistic	O
link	O
between	O
the	O
M1	O
macrophage	O
and	O
tumor	B-DS
cells	O
via	O
MSCs	O
.	O

Proposed	O
model	O
depicted	O
the	O
interaction	O
between	O
macrophages	O
and	O
the	O
MSCs	O
in	O
promoting	O
tumor	B-DS
growth	O

M1	O
macrophages	O
could	O
activate	O
the	O
MSCs	O
to	O
adopt	O
a	O
regulatory	O
phenotype	O
,	O
and	O
the	O
cMSCs	O
promoted	O
tumor	B-DS
growth	O
by	O
iNOS	B-GP
,	O
MCP1	B-GP
and	O
induced	O
macrophages	O
toward	O
M2	O
-	O
like	O
macrophages	O
.	O

The	O
tumor	B-DS
microenvironment	O
is	O
a	O
complex	O
cellular	O
,	O
molecular	O
network	O
.	O

In	O
this	O
network	O
,	O
one	O
kind	O
of	O
cell	O
may	O
be	O
subjected	O
to	O
influences	O
from	O
various	O
stimuli	O
.	O

In	O
our	O
experiments	O
,	O
the	O
cMSCs	O
could	O
become	O
a	O
potent	O
immune	O
-	O
regulatory	O
component	O
.	O

A	O
previous	O
study	O
found	O
that	O
the	O
concomitant	O
presence	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
could	O
induce	O
the	O
immunosuppressive	O
functions	O
of	O
the	O
MSCs	O
,	O
as	O
these	O
cytokine	B-GP
combinations	O
provoke	O
the	O
expression	O
of	O
high	O
levels	O
of	O
CXCL9	B-GP
,	O
CXCL10	B-GP
and	O
iNOS	B-GP
[	O
18	O
].	O

In	O
our	O
experimental	O
setting	O
,	O
CXCL9	B-GP
and	O
CXCL10	B-GP
were	O
expressed	O
at	O
low	O
levels	O
in	O
the	O
cMSCs	O
.	O

These	O
differences	O
may	O
suggest	O
that	O
the	O
combination	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
could	O
not	O
completely	O
mimic	O
the	O
microenvironment	O
formed	O
by	O
M1	O
macrophages	O
.	O

The	O
key	O
factor	O
of	O
this	O
tumor	B-DS
promoting	O
pathway	O
is	O
the	O
MSCs	O
.	O

Recently	O
,	O
the	O
immune	O
modulatory	O
property	O
of	O
the	O
MSCs	O
has	O
been	O
extensively	O
studied	O
by	O
investigators	O
[	O
12	O
].	O

The	O
MSCs	O
influenced	O
both	O
adaptive	O
and	O
innate	O
immune	O
responses	O
.	O

The	O
ability	O
of	O
the	O
MSCs	O
to	O
control	O
an	O
inflammatory	O
environment	O
has	O
been	O
used	O
in	O
inflammatory	B-DS
associated	I-DS
disease	I-DS
,	O
including	O
myocardial	B-DS
infarction	I-DS
[	O
19	O
],	O
peritonitis	B-DS
[	O
20	O
],	O
and	O
sepsis	B-DS
[	O
21	O
].	O

In	O
addition	O
to	O
polarization	O
of	O
macrophages	O
,	O
the	O
MSCs	O
could	O
also	O
polarize	O
into	O
two	O
distinctly	O
acting	O
phenotypes	O
following	O
specific	O
TLR	B-GP
-	O
activation	O
including	O
MSC1	O
and	O
MSC2	O
[	O
17	O
,	O
22	O
].	O

MSC1	O
was	O
pro	O
-	O
inflammatory	O
,	O
and	O
MSC2	O
showed	O
anti	O
-	O
inflammatory	O
properties	O
.	O

MSC1	O
-	O
based	O
treatment	O
of	O
established	O
tumors	B-DS
in	O
an	O
immune	O
competent	O
model	O
attenuated	O
tumor	B-DS
growth	O
and	O
metastasis	O
in	O
contrast	O
to	O
MSC	O
-	O
or	O
MSC2	O
-	O
treated	O
animals	B-OG
in	O
which	O
tumor	B-DS
growth	O
and	O
spread	O
was	O
increased	O
[	O
23	O
].	O

In	O
our	O
experiments	O
,	O
we	O
found	O
that	O
the	O
cMSCs	O
could	O
significantly	O
promote	O
tumor	B-DS
growth	O
,	O
recruit	O
CD45	B-GP
positive	O
bone	O
marrow	O
cells	O
in	O
vivo	O
,	O
and	O
had	O
immunosuppressive	O
potential	O
.	O

Meanwhile	O
,	O
Quantitative	O
PCR	O
showed	O
that	O
the	O
transcript	O
levels	O
of	O
iNOS	B-GP
and	O
TLR3	B-GP
were	O
markedly	O
higher	O
in	O
the	O
cMSCs	O
than	O
in	O
the	O
untreated	O
MSCs	O
.	O

Overall	O
,	O
these	O
results	O
may	O
suggest	O
that	O
the	O
cMSCs	O
had	O
a	O
regulatory	O
-	O
like	O
profile	O
similar	O
to	O
MSC2	O
.	O

Previous	O
reports	O
indicated	O
that	O
the	O
MSCs	O
may	O
be	O
involved	O
in	O
cancer	B-DS
initiation	O
in	O
vivo	O
and	O
the	O
MSCs	O
may	O
spontaneously	O
transform	O
into	O
malignant	O
cells	O
in	O
vitro	O
[	O
24	O
].	O

It	O
is	O
clear	O
that	O
the	O
MSCs	O
secrete	O
a	O
number	O
of	O
paracrine	O
factors	O
that	O
may	O
influence	O
tumor	B-DS
growth	O
[	O
25	O
,	O
26	O
].	O

However	O
,	O
the	O
exact	O
mechanisms	O
of	O
MSCs	O
-	O
mediated	O
tumor	B-DS
growth	O
are	O
still	O
debated	O
,	O
especially	O
with	O
regards	O
to	O
immunosuppression	O
.	O

Previous	O
data	O
found	O
that	O
the	O
prevention	O
of	O
graft	O
-	O
versus	O
-	O
host	O
disease	B-DS
by	O
the	O
MSCs	O
was	O
dependent	O
on	O
iNOS	B-GP
,	O
and	O
that	O
bone	O
marrow	O
-	O
derived	O
MSCs	O
could	O
exert	O
immunosuppressive	O
effects	O
by	O
iNOS	B-GP
to	O
favor	O
B16	O
melanoma	B-DS
cell	O
growth	O
[	O
18	O
].	O

In	O
our	O
experiments	O
,	O
cMSCs	O
-	O
mediated	O
immune	O
regulatory	O
effects	O
occurred	O
via	O
iNOS	B-GP
in	O
vitro	O
.	O

After	O
iNOS	B-GP
gene	O
knockdown	O
,	O
the	O
immune	O
suppression	O
and	O
tumor	B-DS
growth	O
enhancement	O
of	O
the	O
cMSCs	O
were	O
reduced	O
.	O

These	O
results	O
suggested	O
that	O
NO	O
-	O
mediated	O
immunosuppression	O
by	O
the	O
cMSCs	O
was	O
required	O
in	O
tumor	B-DS
progression	O
.	O

Additionally	O
,	O
macrophages	O
are	O
the	O
main	O
cells	O
in	O
the	O
tumor	B-DS
microenvironment	O
[	O
27	O
].	O

A	O
previous	O
study	O
showed	O
that	O
tumor	B-DS
-	O
educated	O
mesenchymal	O
stromal	O
cells	O
recruit	O
macrophages	O
via	O
CCR2	B-GP
[	O
15	O
].	O

In	O
our	O
experiments	O
,	O
we	O
found	O
that	O
the	O
cMSCs	O
could	O
recruit	O
macrophages	O
to	O
tumor	B-DS
sites	O
,	O
render	O
macrophages	O
into	O
M2	O
-	O
like	O
cells	O
,	O
and	O
consequently	O
enhance	O
tumor	B-DS
growth	O
.	O

Therefore	O
,	O
the	O
cMSCs	O
could	O
create	O
a	O
negative	O
-	O
feedback	O
loop	O
with	O
macrophages	O
in	O
the	O
tumor	B-DS
microenvironment	O
.	O

With	O
the	O
presence	O
of	O
pathogens	O
or	O
tissue	O
damage	O
,	O
the	O
negative	O
-	O
feedback	O
loop	O
may	O
be	O
initiated	O
by	O
tumor	B-DS
cells	O
following	O
accelerated	O
growth	O
.	O

In	O
the	O
tumor	B-DS
microenvironment	O
,	O
the	O
expression	O
of	O
various	O
immune	O
mediators	O
and	O
modulators	O
as	O
well	O
as	O
the	O
abundance	O
and	O
activation	O
state	O
of	O
different	O
cell	O
types	O
dictate	O
in	O
which	O
direction	O
the	O
balance	O
is	O
tipped	O
and	O
whether	O
tumor	B-DS
-	O
promoting	O
inflammation	O
or	O
antitumor	O
immunity	O
will	O
ensue	O
.	O

In	O
our	O
experiments	O
,	O
when	O
exposed	O
to	O
sufficient	O
levels	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
in	O
the	O
M1	O
medium	O
,	O
the	O
MSCs	O
responded	O
to	O
adopting	O
an	O
immune	O
regulatory	O
phenotype	O
to	O
dampen	O
inflammation	O
and	O
promote	O
tumor	B-DS
growth	O
.	O

Our	O
research	O
may	O
inspire	O
a	O
subsequent	O
study	O
especially	O
in	O
how	O
inflammation	O
induces	O
tumor	B-DS
development	O
.	O

MATERIALS	O
AND	O
METHODS	O

Reagents	O

Recombinant	O
mouse	B-OG
TNFα	B-GP
,	O
interferon	B-GP
(	O
IFNγ	B-GP
),	O
granulocyte	B-GP
macrophage	I-GP
-	I-GP
colony	I-GP
stimulating	I-GP
factor	I-GP
(	O
GM	B-GP
-	I-GP
CSF	I-GP
),	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
interleukin	B-GP
(	B-GP
IL	I-GP
)-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
2	I-GP
and	O
IL	B-GP
-	I-GP
15	I-GP
were	O
from	O
Pepro	O
Tech	O
(	O
London	O
,	O
UK	O
).	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

Monoclonal	O
rat	B-OG
anti	O
-	O
mouse	B-OG
antibodies	O
against	O
CD29	B-GP
,	O
CD44	B-GP
,	O
CD45	B-GP
,	O
and	O
CD11b	B-GP
were	O
from	O
BD	O
Biosciences	O
;	O
and	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
inducible	B-GP
nitric	I-GP
oxide	I-GP
synthase	I-GP
(	O
iNOS	B-GP
)	O
and	O
CD206	B-GP
monoclonal	O
antibodies	B-GP
were	O
from	O
Abcam	O
.	O

Alexa	O
Fluor	O
594	O
and	O
Alexa	O
Fluor	O
488	O
-	O
conjugated	O
secondary	O
antibodies	B-GP
were	O
from	O
Invitrogen	O
.	O

Cell	O
culture	O

The	O
human	B-OG
breast	B-DS
carcinoma	I-DS
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
,	O
human	B-OG
HCC	B-DS
-	O
LM3	O
-	O
FLUC	O
hepatoma	B-DS
cells	O
,	O
human	B-OG
U87MG	O
-	O
FLUC	O
glioma	B-DS
cells	O
and	O
murine	O
4T1	O
-	O
FLUC	O
breast	B-DS
cancer	I-DS
cells	O
were	O
stably	O
transfected	O
with	O
a	O
lentiviral	O
vector	O
containing	O
a	O
firefly	B-OG
luciferase	B-GP
reporter	O
gene	O
were	O
first	O
selected	O
in	O
vitro	O
,	O
and	O
then	O
injected	O
into	O
immune	O
-	O
deficient	O
or	O
normal	O
mice	B-OG
.	O

Murine	O
macrophage	O
-	O
like	O
cells	O
RAW264	O
.	O
7	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
’	O
medium	O
(	O
Gibco	O
),	O
M1	O
-	O
polarized	O
macrophages	O
were	O
prepared	O
by	O
stimulating	O
RAW264	O
.	O
7	O
macrophages	O
with	O
100	O
IU	O
/	O
ml	O
IFNγ	B-GP
plus	O
10	O
ng	O
/	O
ml	O
LPS	O
overnight	O
.	O

MSCs	O
were	O
collected	O
from	O
the	O
bone	O
marrow	O
of	O
the	O
tibia	O
and	O
femurs	O
of	O
mice	B-OG
aged	O
6	O
–	O
10	O
weeks	O
.	O

Animal	B-OG
model	O

Female	O
C57BL	B-OG
/	I-OG
6	I-OG
nude	I-OG
mice	I-OG
(	O
6	O
–	O
7	O
weeks	O
old	O
)	O
were	O
purchased	O
from	O
the	O
Department	O
of	O
Experimental	O
Animals	B-OG
,	O
Peking	O
University	O
Health	O
Science	O
Center	O
.	O

Animal	B-OG
experiments	O
were	O
performed	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
Committee	O
at	O
Peking	O
University	O
(	O
Permit	O
Number	O
:	O
2011	O
-	O
0039	O
).	O

Mice	B-OG
were	O
housed	O
in	O
a	O
specific	O
pathogen	O
-	O
free	O
colony	O
in	O
the	O
animal	B-OG
facility	O
,	O
and	O
100	O
μl	O
of	O
2	O
×	O
106	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
FLUC	O
cells	O
,	O
or	O
100	O
μl	O
of	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
were	O
injected	O
into	O
the	O
mammary	O
glands	O
of	O
mice	B-OG
to	O
establish	O
the	O
orthotopic	O
breast	B-DS
cancer	I-DS
model	O
respectively	O
.	O

The	O
orthotopic	O
liver	O
mouse	O
models	O
were	O
established	O
by	O
injecting	O
100	O
μl	O
of	O
2	O
×	O
106	O
HCC	B-DS
-	O
LM3	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
into	O
the	O
liver	O
of	O
BALB	B-OG
/	I-OG
c	I-OG
nude	I-OG
mice	I-OG
.	O

For	O
orthotopic	O
brain	B-DS
tumor	I-DS
models	O
,	O
10	O
μl	O
of	O
2	O
×	O
105	O
U87MG	O
-	O
FLUC	O
cells	O
suspended	O
in	O
saline	O
were	O
implanted	O
manually	O
2	O
mm	O
anterior	O
and	O
2	O
mm	O
to	O
the	O
right	O
of	O
the	O
bregma	O
in	O
the	O
brains	O
of	O
mice	B-OG
.	O

After	O
the	O
injection	O
,	O
the	O
surface	O
was	O
cleaned	O
with	O
a	O
sterile	O
cotton	O
swab	O
,	O
and	O
the	O
burr	O
hole	O
was	O
filled	O
with	O
bone	O
wax	O
.	O

To	O
detect	O
the	O
effect	O
of	O
the	O
cMSCs	O
on	O
tumor	B-DS
growth	O
,	O
breast	O
,	O
liver	O
,	O
and	O
brain	B-DS
carcinoma	I-DS
cells	O
were	O
injected	O
either	O
alone	O
or	O
coupled	O
with	O
the	O
MSCs	O
into	O
nude	B-OG
mice	I-OG
.	O

The	O
MSCs	O
were	O
treated	O
with	O
M1	O
medium	O
or	O
left	O
untreated	O
.	O

Tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
.	O

Mice	B-OG
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
MSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
co	O
-	O
injection	O
of	O
1	O
×	O
106	O
MSCs	O
and	O
tumor	B-DS
cells	O
in	O
PBS	O
;	O
the	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
the	O
same	O
amount	O
of	O
M1	O
medium	O
-	O
treated	O
MSCs	O
and	O
cancer	B-DS
cells	O
;	O
and	O
the	O
control	O
(	O
PBS	O
)	O
group	O
received	O
only	O
PBS	O
and	O
cancer	B-DS
cells	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
determine	O
the	O
effect	O
of	O
iNOS	B-GP
in	O
the	O
cMSCs	O
,	O
4T1	O
-	O
FLUC	O
tumor	B-DS
cell	O
growth	O
was	O
detected	O
by	O
BLI	O
after	O
establishing	O
the	O
breast	B-DS
carcinoma	I-DS
model	O
.	O

Animals	B-OG
were	O
divided	O
into	O
two	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
si	O
-	O
iNOS	B-GP
/	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
1	O
×	O
106	O
iNOS	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
in	O
100	O
μl	O
of	O
PBS	O
;	O
and	O
the	O
control	O
(	O
si	O
-	O
control	O
/	O
cMSCs	O
)	O
group	O
also	O
received	O
1	O
×	O
106	O
control	O
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
tumor	B-DS
cells	O
in	O
100	O
μl	O
of	O
PBS	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
examine	O
the	O
effect	O
of	O
macrophages	O
on	O
tumor	B-DS
growth	O
in	O
vivo	O
,	O
mice	B-OG
were	O
injected	O
with	O
approximately	O
110	O
mg	O
/	O
kg	O
of	O
clodronate	B-CD
liposomes	O
I	O
.	O
P	O
.	O
or	O
equal	O
volume	O
of	O
PBS	O
liposomes	O
.	O

Then	O
,	O
1	O
×	O
106	O
MSCs	O
or	O
cMSCs	O
were	O
co	O
-	O
injected	O
with	O
4T1	O
-	O
FLUC	O
cells	O
.	O

Tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
on	O
day	O
14	O
.	O

To	O
determine	O
the	O
effect	O
of	O
MCP1	B-GP
on	O
cMSCs	O
,	O
cMSCs	O
were	O
transfected	O
with	O
MCP1	B-GP
siRNA	O
.	O

Animals	B-OG
were	O
divided	O
into	O
two	O
groups	O
(	O
n	O
=	O
6	O
per	O
group	O
):	O
the	O
si	O
-	O
MCP1	B-GP
/	O
cMSCs	O
group	O
,	O
in	O
which	O
mice	B-OG
received	O
1	O
×	O
106	O
MCP1	B-GP
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
4T1	O
-	O
FLUC	O
cells	O
in	O
100	O
μl	O
of	O
PBS	O
;	O
and	O
the	O
control	O
(	O
si	O
-	O
control	O
/	O
cMSCs	O
)	O
group	O
also	O
received	O
1	O
×	O
106	O
control	O
siRNA	O
treated	O
cMSCs	O
and	O
2	O
×	O
106	O
tumor	B-DS
cells	O
in	O
100	O
μl	O
of	O
PBS	O
.	O

Mice	B-OG
were	O
matched	O
for	O
age	O
and	O
gender	O
in	O
each	O
experiment	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
on	O
tumor	B-DS
growth	O
,	O
cMSCs	O
educated	O
macrophages	O
were	O
co	O
-	O
injected	O
with	O
4T1	O
-	O
FLUC	O
cells	O
,	O
and	O
tumor	B-DS
cell	O
growth	O
was	O
evaluated	O
by	O
BLI	O
.	O

BLI	O

BLI	O
was	O
performed	O
using	O
the	O
Xenogen	O
IVIS	O
Lumina	O
II	O
system	O
(	O
Perkin	O
Elmer	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
as	O
detailed	O
previously	O
[	O
28	O
,	O
29	O
].	O

Real	O
-	O
time	O
PCR	O

Total	O
RNA	O
was	O
extracted	O
from	O
cell	O
pellets	O
using	O
Trizol	O
Reagent	O
(	O
Invitrogen	O
)	O
and	O
treated	O
with	O
RNase	B-GP
-	O
free	O
DNase	B-GP
I	I-GP
(	O
Qiagen	O
,	O
USA	O
).	O

First	O
-	O
strand	O
cDNA	O
synthesis	O
was	O
performed	O
using	O
an	O
ABI	O
High	O
-	O
Capacity	O
cDNA	O
RT	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
USA	O
).	O

Then	O
,	O
RT	O
-	O
PCR	O
and	O
Real	O
-	O
time	O
PCR	O
were	O
done	O
.	O

Primers	O
used	O
in	O
PCR	O
are	O
listed	O
in	O
Table	O
S1	O
,	O
including	O
interleukin	B-GP
-	I-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
(	O
MCP1	B-GP
),	O
Macrophage	B-GP
inflammatory	I-GP
protein	I-GP
-	I-GP
1β	I-GP
(	O
MIP	B-GP
-	I-GP
1β	I-GP
),	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
interleukin	B-GP
-	I-GP
19	I-GP
(	O
IL	B-GP
-	I-GP
19	I-GP
),	O
matrix	B-GP
metalloproteinase	I-GP
-	I-GP
2	I-GP
(	O
MMP	B-GP
-	I-GP
2	I-GP
),	O
arginase	B-GP
type	I-GP
1	I-GP
(	O
Arg	B-GP
-	I-GP
1	I-GP
),	O
inflammatory	B-GP
zone	I-GP
1	I-GP
(	O
FIZZ	B-GP
-	I-GP
1	I-GP
),	O
interleukin	B-GP
-	I-GP
10	I-GP
(	O
IL	B-GP
-	I-GP
10	I-GP
),	O
CD47	B-GP
,	O
and	O
signal	B-GP
regulatory	I-GP
protein	I-GP
alpha	I-GP
(	O
SIRPα	B-GP
).	O

The	O
total	O
amount	O
of	O
mRNA	O
was	O
normalized	O
to	O
endogenous	O
GAPDH	B-GP
mRNA	O
.	O

Real	O
-	O
time	O
PCR	O
was	O
performed	O
in	O
triplicate	O
with	O
the	O
Fast	O
Start	O
Universal	O
SYBR	O
Green	O
Master	O
(	O
ROX	O
;	O
Roche	O
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
the	O
iCycler	O
iQ52	O
.	O
0	O
Standard	O
Edition	O
Optical	O
System	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

To	O
assess	O
the	O
gene	O
expression	O
of	O
the	O
cMSCs	O
,	O
the	O
MSCs	O
were	O
seeded	O
onto	O
12	O
-	O
well	O
plates	O
(	O
Corning	O
,	O
USA	O
)	O
at	O
a	O
density	O
of	O
2	O
×	O
105	O
cells	O
/	O
well	O
and	O
incubated	O
overnight	O
.	O

The	O
medium	O
was	O
replaced	O
with	O
a	O
fresh	O
M1	O
medium	O
and	O
cultured	O
for	O
24	O
h	O
,	O
after	O
which	O
real	O
-	O
time	O
PCR	O
analysis	O
was	O
performed	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
.	O

To	O
examine	O
the	O
gene	O
expression	O
of	O
the	O
cMSCs	O
educated	O
macrophages	O
,	O
RAW264	O
.	O
7	O
macrophages	O
were	O
co	O
-	O
cultured	O
with	O
cMSCs	O
in	O
a	O
transwell	O
for	O
24	O
hours	O
.	O

The	O
upper	O
part	O
was	O
the	O
MSCs	O
,	O
and	O
the	O
lower	O
portion	O
included	O
macrophages	O
.	O

Then	O
,	O
real	O
-	O
time	O
PCR	O
analysis	O
was	O
performed	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
triplicate	O
.	O

Immunohistochemistry	O

Tumors	B-DS
were	O
washed	O
thoroughly	O
in	O
PBS	O
and	O
embedded	O
in	O
the	O
optimal	O
cutting	O
temperature	O
medium	O
(	O
OCT	O
)	O
(	O
Sakura	O
Finetek	O
,	O
Torrance	O
,	O
CA	O
,	O
USA	O
).	O

Cryosections	O
(	O
5	O
–	O
6	O
μm	O
)	O
were	O
cut	O
and	O
stained	O
with	O
antibodies	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

To	O
quantify	O
tumor	B-DS
-	O
associated	O
bone	O
marrow	O
cell	O
recruitment	O
,	O
the	O
tumor	B-DS
sections	O
were	O
stained	O
with	O
rat	B-OG
anti	O
-	O
mouse	B-OG
CD45	B-GP
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
),	O
and	O
the	O
percentage	O
of	O
CD45	B-GP
-	O
positive	O
cells	O
was	O
determined	O
by	O
counting	O
the	O
number	O
of	O
cells	O
in	O
six	O
random	O
fields	O
(	O
400	O
×	O
magnification	O
)	O
from	O
three	O
histology	O
sections	O
.	O

Counting	O
was	O
performed	O
by	O
two	O
“	O
blinded	O
”	O
independent	O
investigators	O
.	O

Alexa	O
Fluor	O
594	O
-	O
conjugated	O
donkey	B-OG
anti	O
-	O
rat	B-OG
secondary	O
antibody	B-GP
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
applied	O
appropriately	O
.	O

DAPI	O
was	O
used	O
for	O
nuclear	O
counterstaining	O
.	O

Short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
synthesis	O
and	O
transient	O
transfection	O

The	O
siRNA	O
sequences	O
of	O
iNOS	B-GP
(	O
Sense	O
:	O
5	O
′-	O
CAGCTGGGCTGTACAAACCdTdT	O
-	O
3	O
;	O
Antisense	O
:	O
5	O
′-	O
CATTGGAAGTGAAGCGTTTCGdTdT	O
-	O
3	O
′)	O
and	O
MCP1	B-GP
(	O
Sense	O
:	O
5	O
′-	O
AAUUGAUUUAGCGUACACGdTdT	O
-	O
3	O
;	O
Antisense	O
:	O
5	O
′-	O
CGUGUACGCUAAAUCAAUUdTdT	O
-	O
3	O
′)	O
were	O
designed	O
by	O
using	O
Oligoengine	O
software	O
and	O
confirmed	O
by	O
the	O
nucleotide	B-CD
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
(	O
BLAST	O
)	O
searches	O
.	O

Transfections	O
were	O
performed	O
with	O
a	O
Lipofectamine	O
2000	O
kit	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cells	O
(	O
1	O
–	O
3	O
×	O
106	O
)	O
grown	O
to	O
a	O
confluency	O
of	O
50	O
–	O
60	O
%	O
in	O
10	O
cm	O
Petri	O
dishes	O
were	O
transfected	O
with	O
the	O
siRNA	O
sequence	O
,	O
and	O
then	O
the	O
cells	O
were	O
harvested	O
48	O
hours	O
after	O
transfection	O
.	O

Flow	O
cytometry	O

For	O
macrophage	O
surface	O
marker	O
analysis	O
,	O
macrophages	O
were	O
incubated	O
with	O
fluorescent	O
labeled	O
rat	B-OG
anti	O
-	O
mouse	B-OG
CD11b	B-GP
,	O
iNOS	B-GP
,	O
and	O
CD206	B-GP
antibodies	B-GP
(	O
BD	O
Biosciences	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

To	O
measure	O
macrophage	O
infiltration	O
in	O
the	O
tumor	B-DS
sites	O
and	O
blood	O
,	O
the	O
tumor	B-DS
cells	O
and	O
peripheral	O
cells	O
were	O
stained	O
with	O
Alexa	O
Fluor	O
®	O
594	O
-	O
conjugated	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
CD206	B-GP
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
)	O
and	O
FITC	O
-	O
labeled	O
anti	O
-	O
mouse	B-OG
F4	B-GP
/	I-GP
80	I-GP
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
).	O

Statistical	O
analysis	O

All	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
SEM	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
used	O
to	O
determine	O
the	O
intergroup	O
differences	O
.	O

Least	O
significant	O
difference	O
(	O
equal	O
variances	O
)	O
and	O
Dunnett	O
'	O
s	O
T3	O
(	O
non	O
-	O
equal	O
variances	O
)	O
post	O
hoc	O
tests	O
were	O
used	O
for	O
testing	O
the	O
differences	O
between	O
groups	O
.	O

All	O
tests	O
were	O
two	O
-	O
tailed	O
,	O
and	O
differences	O
were	O
considered	O
statistically	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

SUPPLEMENTARY	O
MATERIALS	O
FIGURES	O
AND	O
TABLE	O

CONFLICTS	O
OF	O
INTEREST	O

The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interests	O
.	O

Renal	B-DS
Angiomyolipoma	I-DS
:	O
The	O
Good	O
,	O
the	O
Bad	O
,	O
and	O
the	O
Ugly	O

Angiomyolipomas	B-DS
(	O
AMLs	B-DS
)	O
are	O
the	O
most	O
common	O
benign	O
renal	B-DS
tumours	I-DS
.	O

Most	O
of	O
these	O
neoplasms	B-DS
are	O
found	O
incidentally	O
on	O
imaging	O
.	O

However	O
,	O
symptomatic	O
presentation	O
does	O
exist	O
.	O

Renal	O
AMLs	B-DS
are	O
typically	O
composed	O
of	O
smooth	O
muscle	O
,	O
blood	O
vessels	O
,	O
and	O
adipose	O
tissue	O
.	O

Because	O
of	O
the	O
abundant	O
fat	O
tissue	O
,	O
they	O
give	O
a	O
characteristic	O
appearance	O
on	O
imaging	O
and	O
are	O
therefore	O
easily	O
diagnosed	O
.	O

However	O
,	O
sometimes	O
they	O
contain	O
too	O
little	O
fat	O
to	O
be	O
detected	O
.	O

This	O
increases	O
the	O
difficulty	O
in	O
differentiating	O
them	O
from	O
renal	B-DS
cell	I-DS
carcinoma	I-DS
(	O
RCC	B-DS
).	O

Management	O
of	O
AML	B-DS
is	O
based	O
on	O
clinical	O
presentation	O
and	O
should	O
be	O
individualized	O
for	O
every	O
patient	O
.	O

Treatment	O
modalities	O
range	O
from	O
active	O
surveillance	O
to	O
more	O
invasive	O
approaches	O
.	O

Introduction	O

Angiomyolipomas	B-DS
(	O
AMLs	B-DS
)	O
are	O
the	O
most	O
frequent	O
benign	B-DS
renal	B-DS
tumour	I-DS
,	O
with	O
a	O
prevalence	O
varying	O
between	O
0	O
.	O
2	O
%	O
and	O
0	O
.	O
6	O
%	O
and	O
a	O
strong	O
female	O
predilection	O
.	O

They	O
occur	O
as	O
sporadic	O
,	O
isolated	O
entities	O
in	O
80	O
%	O
of	O
cases	O
.	O

The	O
remaining	O
20	O
%	O
of	O
AMLs	B-DS
develop	O
in	O
association	O
with	O
tuberosclerosis	B-DS
complex	I-DS
(	O
TSC	B-DS
)	O
or	O
pulmonary	B-DS
lymphangioleiomyomatosis	I-DS
(	O
LAM	B-DS
)	O
[	O
12	O
].	O

AMLs	B-DS
are	O
considered	O
as	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	B-DS
.	O

Many	O
types	O
display	O
different	O
pathology	O
,	O
radiological	O
features	O
,	O
and	O
clinical	O
behaviour	O
,	O
although	O
they	O
all	O
consist	O
of	O
variable	O
proportions	O
of	O
the	O
same	O
three	O
elements	O
:	O
smooth	O
muscle	O
,	O
blood	O
vessels	O
,	O
and	O
adipose	O
tissue	O
[	O
23	O
].	O

Imaging	O
plays	O
a	O
central	O
role	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
renal	B-DS
AMLs	I-DS
.	O

The	O
detection	O
of	O
adipose	O
tissue	O
is	O
the	O
fundamental	O
diagnostic	O
criterion	O
of	O
a	O
classic	O
AML	B-DS
[	O
2	O
].	O

However	O
,	O
a	O
minority	O
of	O
AMLs	B-DS
lack	O
visually	O
detectable	O
fat	O
on	O
imaging	O
,	O
making	O
it	O
harder	O
to	O
distinguish	O
from	O
renal	B-DS
cell	I-DS
carcinoma	I-DS
(	O
RCC	B-DS
).	O

Therefore	O
,	O
accurate	O
preoperative	O
diagnosis	O
of	O
renal	B-DS
AMLs	I-DS
is	O
critical	O
to	O
prevent	O
unnecessary	O
nephrectomies	O
and	O
preserve	O
renal	O
functions	O
[	O
4	O
].	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
radiological	O
classification	O
of	O
renal	B-DS
AML	I-DS
that	O
contributes	O
to	O
the	O
understanding	O
and	O
diagnosis	O
of	O
the	O
different	O
types	O
and	O
the	O
appropriate	O
therapeutic	O
management	O
and	O
follow	O
-	O
up	O
.	O

Classifications	O

Clinical	O
Classification	O

About	O
80	O
%	O
of	O
AMLs	B-DS
present	O
as	O
isolated	O
entities	O
,	O
most	O
commonly	O
manifesting	O
in	O
middle	O
-	O
aged	O
women	O
.	O

They	O
tend	O
to	O
be	O
single	O
and	O
small	O
and	O
rarely	O
progress	O
to	O
cause	O
significant	O
morbidity	O
[	O
35	O
].	O

In	O
the	O
remainder	O
20	O
%	O
of	O
cases	O
,	O
AMLs	B-DS
occur	O
in	O
association	O
with	O
TSC	B-DS
or	O
,	O
less	O
commonly	O
,	O
as	O
part	O
of	O
LAM	B-DS
.	O

Relative	O
to	O
the	O
sporadic	O
form	O
of	O
AML	B-DS
,	O
these	O
hereditary	O
lesions	O
affect	O
both	O
genders	O
equally	O
and	O
manifest	O
at	O
a	O
younger	O
age	O
.	O

They	O
are	O
likely	O
to	O
be	O
multiple	O
,	O
large	O
,	O
and	O
bilateral	O
,	O
and	O
are	O
prone	O
to	O
grow	O
and	O
be	O
more	O
aggressive	O
[	O
357	O
].	O

AMLs	B-DS
are	O
observed	O
in	O
approximately	O
75	O
%	O
of	O
patients	O
with	O
TSC	B-DS
.	O

TSC	B-DS
is	O
an	O
autosomal	B-DS
dominant	I-DS
multisystem	I-DS
disorder	I-DS
characterized	O
by	O
the	O
development	O
of	O
benign	B-DS
tumours	I-DS
(	O
hamartomas	B-DS
)	O
in	O
multiple	O
organs	O
throughout	O
the	O
body	O
.	O

The	O
main	O
organs	O
involved	O
are	O
the	O
brain	O
,	O
skin	O
,	O
lung	O
,	O
and	O
kidney	O
[	O
8	O
].	O

TSC	B-GP
is	O
caused	O
by	O
mutations	O
in	O
one	O
of	O
two	O
genes	O
,	O
TSC1	B-GP
and	O
TSC2	B-GP
,	O
which	O
encode	O
the	O
proteins	O
hamartin	B-GP
and	O
tuberin	B-GP
,	O
respectively	O
.	O

These	O
proteins	O
interact	O
with	O
each	O
other	O
to	O
form	O
a	O
tumour	B-DS
suppressor	O
complex	O
,	O
which	O
inhibits	O
the	O
mammalian	B-GP
target	I-GP
of	I-GP
rapamycin	I-GP
(	O
mTOR	B-GP
)	O
pathway	O
.	O

This	O
pathway	O
is	O
important	O
for	O
angiogenesis	O
,	O
protein	O
synthesis	O
,	O
and	O
cell	O
growth	O
.	O

Defective	O
or	O
deficient	O
TSC1	B-GP
or	O
TSC2	B-GP
activity	O
leads	O
to	O
unchecked	O
activation	O
of	O
mTOR	B-GP
and	O
formation	O
of	O
characteristic	O
hamartomas	B-DS
[	O
267	O
].	O

AMLs	B-DS
may	O
also	O
develop	O
in	O
patients	O
with	O
LAM	B-DS
.	O

This	O
rare	O
disorder	O
may	O
occur	O
sporadically	O
,	O
in	O
the	O
absence	O
of	O
other	O
diseases	O
,	O
but	O
is	O
common	O
in	O
patients	O
with	O
TSC	B-DS
.	O

It	O
is	O
characterized	O
by	O
diffuse	O
interstitial	O
proliferation	O
of	O
smooth	O
muscle	O
cells	O
(	O
LAM	O
cells	O
)	O
and	O
the	O
presence	O
of	O
thin	O
-	O
walled	O
cysts	B-DS
distributed	O
throughout	O
the	O
lungs	O
.	O

These	O
LAM	O
cells	O
have	O
mutations	O
in	O
the	O
same	O
TSC1	B-GP
and	O
TSC2	B-GP
genes	O
[	O
67	O
].	O

Histological	O
Classification	O

Renal	B-DS
AML	I-DS
can	O
be	O
classified	O
histologically	O
as	O
typical	O
(	O
triphasic	O
)	O
or	O
atypical	O
(	O
monophasic	O
or	O
epithelioid	O
)	O
[	O
5	O
].	O

Most	O
AMLs	O
contain	O
all	O
three	O
components	O
,	O
namely	O
dilated	O
blood	O
vessels	O
(	O
angio	O
),	O
smooth	O
muscle	O
cells	O
(	O
myo	O
),	O
and	O
mature	O
adipocytes	O
(	O
lipo	O
),	O
in	O
various	O
proportions	O
.	O

They	O
are	O
classified	O
as	O
triphasic	O
tumours	B-DS
.	O

However	O
,	O
some	O
tumours	B-DS
consist	O
almost	O
exclusively	O
of	O
one	O
component	O
,	O
while	O
other	O
elements	O
are	O
present	O
in	O
very	O
small	O
amounts	O
.	O

They	O
are	O
called	O
monophasic	O
.	O

At	O
last	O
,	O
the	O
epithelioid	O
variant	O
of	O
AML	B-DS
contains	O
numerous	O
epithelioid	O
muscle	O
cells	O
with	O
abundant	O
eosinophilic	O
and	O
granular	O
cytoplasm	O
and	O
few	O
or	O
no	O
fat	O
cells	O
.	O

These	O
tumours	B-DS
have	O
a	O
tendency	O
toward	O
malignant	O
transformation	O
and	O
can	O
be	O
locally	O
aggressive	O
.	O

Histologically	O
,	O
they	O
can	O
resemble	O
and	O
be	O
misdiagnosed	O
as	O
RCC	B-DS
.	O

However	O
,	O
distinction	O
of	O
epithelioid	O
AMLs	B-DS
from	O
RCC	B-DS
is	O
possible	O
by	O
the	O
presence	O
of	O
immunohistochemistry	O
markers	O
,	O
such	O
as	O
smooth	O
muscle	O
markers	O
(	O
caldesmon	B-GP
and	O
smooth	B-GP
muscle	I-GP
actin	I-GP
)	O
and	O
melanocytic	O
markers	O
(	O
HMB	B-GP
-	I-GP
45	I-GP
antigen	O
and	O
melan	B-GP
-	I-GP
A	I-GP
)	O
[	O
2345	O
].	O

Radiological	O
Classification	O

There	O
is	O
a	O
growing	O
body	O
of	O
literature	O
describing	O
findings	O
and	O
techniques	O
that	O
may	O
be	O
used	O
to	O
distinguish	O
renal	B-DS
AMLs	I-DS
.	O

A	O
lack	O
of	O
a	O
generally	O
accepted	O
and	O
standardized	O
terminology	O
or	O
classification	O
of	O
AML	B-DS
fuels	O
the	O
persisting	O
confusion	O
.	O

In	O
this	O
review	O
,	O
a	O
radiological	O
classification	O
reported	O
by	O
two	O
groups	O
of	O
authors	O
will	O
be	O
discussed	O
.	O

A	O
recent	O
article	O
hypothesized	O
that	O
renal	B-DS
AMLs	I-DS
can	O
be	O
classified	O
according	O
to	O
CT	O
and	O
MRI	O
findings	O
using	O
quantitative	O
values	O
.	O

They	O
classified	O
these	O
tumours	B-DS
as	O
fat	O
-	O
rich	O
,	O
fat	O
-	O
poor	O
,	O
or	O
fat	O
-	O
invisible	O
,	O
based	O
on	O
the	O
amount	O
of	O
fat	O
detected	O
on	O
imaging	O
studies	O
.	O

To	O
distinguish	O
these	O
different	O
types	O
,	O
a	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
was	O
placed	O
in	O
the	O
most	O
hypodense	O
area	O
of	O
the	O
lesion	O
to	O
measure	O
the	O
attenuation	O
value	O
.	O

A	O
lesion	O
was	O
defined	O
as	O
fat	O
-	O
rich	O
when	O
the	O
ROI	O
measured	O
≤	O
–	O
10	O
Hounsfield	O
units	O
(	O
HU	O
)	O
on	O
unenhanced	O
CT	O
(	O
UECT	O
).	O

However	O
,	O
UECT	O
could	O
not	O
differentiate	O
fat	O
-	O
poor	O
from	O
fat	O
-	O
invisible	O
AML	B-DS
.	O

Therefore	O
chemical	O
shift	O
imaging	O
(	O
CSI	O
)	O
MRI	O
was	O
introduced	O
.	O

This	O
modality	O
provides	O
a	O
higher	O
sensitivity	O
for	O
fat	O
detection	O
than	O
UECT	O
.	O

As	O
in	O
UECT	O
,	O
the	O
most	O
signal	O
-	O
dropped	O
area	O
was	O
detected	O
and	O
a	O
ROI	O
was	O
placed	O
within	O
.	O

On	O
CSI	O
-	O
MRI	O
,	O
fat	O
-	O
poor	O
AML	B-DS
was	O
characterized	O
when	O
the	O
tumour	B-DS
-	O
to	O
-	O
spleen	O
ratio	O
(	O
TSR	O
)	O
was	O
<	O
0	O
.	O
71	O
or	O
the	O
signal	O
intensity	O
index	O
(	O
SII	O
)	O
was	O
>	O
16	O
.	O
5	O
%.	O

Because	O
of	O
too	O
little	O
fat	O
,	O
fat	O
-	O
invisible	O
AML	B-DS
was	O
defined	O
having	O
a	O
TSR	O
≥	O
0	O
.	O
71	O
and	O
a	O
SII	O
≤	O
16	O
.	O
5	O
%	O
[	O
910	O
].	O

This	O
classification	O
showed	O
an	O
almost	O
perfect	O
inter	O
-	O
reader	O
agreement	O
,	O
which	O
means	O
it	O
is	O
feasible	O
for	O
radiologists	O
to	O
apply	O
in	O
practice	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
understand	O
that	O
detection	O
of	O
the	O
most	O
hypodense	O
area	O
on	O
CT	O
or	O
most	O
signal	O
-	O
dropped	O
area	O
on	O
MRI	O
and	O
placement	O
of	O
the	O
ROI	O
within	O
is	O
crucial	O
.	O

A	O
mislocation	O
or	O
inappropriate	O
size	O
of	O
the	O
ROI	O
may	O
change	O
the	O
type	O
of	O
AML	B-DS
,	O
with	O
misclassification	O
and	O
unwanted	O
procedures	O
as	O
a	O
result	O
.	O

Another	O
disadvantage	O
is	O
the	O
fact	O
that	O
different	O
CT	O
and	O
MR	O
scanners	O
may	O
produce	O
different	O
attenuation	O
numbers	O
and	O
signal	O
intensities	O
,	O
leading	O
to	O
a	O
wrong	O
classification	O
.	O

For	O
example	O
,	O
if	O
an	O
AML	B-DS
is	O
measured	O
–	O
9	O
HU	O
at	O
one	O
CT	O
scanner	O
,	O
it	O
will	O
be	O
classified	O
as	O
fat	O
-	O
poor	O
.	O

However	O
,	O
if	O
another	O
scanner	O
describes	O
the	O
lesion	O
as	O
–	O
11	O
HU	O
,	O
it	O
will	O
be	O
classified	O
as	O
fat	O
-	O
rich	O
.	O

Although	O
the	O
difference	O
of	O
2	O
HU	O
is	O
very	O
minimal	O
and	O
probably	O
insignificant	O
,	O
the	O
management	O
is	O
completely	O
different	O
[	O
910	O
].	O

Another	O
review	O
article	O
proposed	O
a	O
classification	O
based	O
on	O
clinical	O
,	O
histologic	O
,	O
and	O
imaging	O
features	O
.	O

First	O
,	O
the	O
authors	O
divided	O
renal	B-DS
AMLs	I-DS
into	O
sporadic	O
and	O
hereditary	O
.	O

Histologically	O
,	O
they	O
classified	O
sporadic	O
AMLs	B-DS
into	O
benign	O
triphasic	O
type	O
and	O
potentially	O
malignant	O
epithelioid	O
type	O
[	O
34	O
].	O

Benign	O
triphasic	O
type	O
was	O
further	O
divided	O
into	O
fat	O
-	O
rich	O
and	O
fat	O
-	O
poor	O
AML	B-DS
using	O
imaging	O
modalities	O
.	O

While	O
fat	O
-	O
rich	O
AML	B-DS
contained	O
enough	O
fat	O
to	O
be	O
detected	O
on	O
UECT	O
(	O
ROI	O
≤	O
–	O
10	O
HU	O
),	O
fat	O
-	O
poor	O
AML	B-DS
did	O
not	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
was	O
further	O
classified	O
into	O
three	O
subtypes	O
,	O
based	O
on	O
the	O
amount	O
and	O
distribution	O
of	O
adipocytes	O
within	O
the	O
lesion	O
and	O
other	O
imaging	O
features	O
:	O
hyperattenuating	O
AML	B-DS
,	O
isoattenuating	O
AML	B-DS
,	O
and	O
AML	B-DS
with	O
epithelial	B-DS
cysts	I-DS
.	O

Hyperattenuating	O
AML	B-DS
was	O
hyperattenuating	O
compared	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
(>	O
45	O
HU	O
),	O
homogeneously	O
enhancing	O
on	O
contrast	O
enhanced	O
CT	O
,	O
and	O
T2	O
-	O
hypointense	O
on	O
MRI	O
.	O

On	O
the	O
contrary	O
,	O
isoattenuating	O
AML	B-DS
was	O
characterized	O
by	O
attenuation	O
numbers	O
close	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
(	O
between	O
–	O
10	O
and	O
45	O
HU	O
).	O

These	O
lower	O
attenuation	O
levels	O
were	O
caused	O
by	O
the	O
presence	O
of	O
fat	O
cells	O
,	O
sufficient	O
in	O
quantity	O
to	O
lower	O
the	O
overall	O
attenuation	O
relative	O
to	O
hyperattenuating	O
AMLs	O
,	O
but	O
too	O
few	O
in	O
one	O
area	O
to	O
be	O
detected	O
on	O
regular	O
imaging	O
.	O

Finally	O
,	O
AMLs	B-DS
with	O
epithelial	B-DS
cysts	I-DS
could	O
be	O
distinguished	O
by	O
the	O
presence	O
of	O
epithelial	B-DS
cysts	I-DS
,	O
with	O
the	O
non	O
-	O
cystic	O
parts	O
appearing	O
similar	O
to	O
hyperattenuating	O
AML	B-DS
.	O

Radiological	O
features	O
of	O
this	O
rare	O
subtype	O
could	O
not	O
be	O
fully	O
described	O
,	O
due	O
to	O
the	O
lack	O
of	O
data	O
[	O
34	O
].	O

Epithelioid	O
AMLs	B-DS
,	O
that	O
can	O
be	O
potentially	O
malignant	O
and	O
metastasize	O
,	O
showed	O
hyperattenuation	O
on	O
UECT	O
,	O
heterogeneously	O
enhancement	O
on	O
contrast	O
enhanced	O
CT	O
,	O
and	O
T2	O
-	O
hypointensity	O
on	O
MRI	O
.	O

These	O
findings	O
were	O
caused	O
by	O
the	O
epithelioid	O
muscle	O
component	O
and	O
the	O
intratumoral	O
haemorrhage	O
and	O
necrosis	O
[	O
3410	O
].	O

There	O
are	O
limitations	O
associated	O
with	O
the	O
classification	O
described	O
above	O
.	O

First	O
,	O
the	O
requirement	O
of	O
clinical	O
and	O
pathological	O
information	O
makes	O
it	O
difficult	O
for	O
radiologists	O
to	O
use	O
in	O
daily	O
practice	O
.	O

Second	O
,	O
there	O
are	O
problems	O
in	O
applying	O
the	O
imaging	O
criteria	O
for	O
classifying	O
isoattenuating	O
AML	B-DS
.	O

The	O
authors	O
reported	O
isoattenuating	O
AML	B-DS
being	O
an	O
AML	B-DS
with	O
attenuation	O
values	O
between	O
–	O
10	O
and	O
45	O
HU	O
on	O
UECT	O
.	O

However	O
,	O
simple	O
renal	B-DS
cysts	I-DS
have	O
attenuation	O
numbers	O
ranging	O
between	O
–	O
10	O
and	O
10	O
and	O
appear	O
definitely	O
hypoattenuating	O
,	O
while	O
renal	O
masses	O
measuring	O
>	O
40	O
HU	O
frequently	O
appear	O
hyperattenuating	O
.	O

So	O
,	O
because	O
of	O
the	O
wide	O
range	O
of	O
AML	B-DS
attenuation	O
values	O
,	O
“	O
isoattenuating	O
AML	B-DS
”	O
does	O
not	O
seem	O
to	O
be	O
an	O
appropriate	O
term	O
.	O

Furthermore	O
,	O
the	O
authors	O
did	O
not	O
suggest	O
a	O
quantitative	O
threshold	O
for	O
CSI	O
-	O
MRI	O
,	O
which	O
means	O
that	O
radiologists	O
cannot	O
classify	O
AML	B-DS
using	O
TSR	O
or	O
SII	O
[	O
9	O
].	O

In	O
conclusion	O
,	O
the	O
classification	O
first	O
described	O
is	O
the	O
most	O
easily	O
applicable	O
in	O
practice	O
.	O

Radiologists	O
can	O
categorize	O
renal	B-DS
AMLs	I-DS
as	O
fat	O
-	O
rich	O
,	O
fat	O
-	O
poor	O
,	O
and	O
fat	O
-	O
invisible	O
,	O
according	O
to	O
the	O
amount	O
of	O
fat	O
detected	O
on	O
UECT	O
or	O
CSI	O
-	O
MRI	O
.	O

However	O
,	O
attention	O
should	O
be	O
paid	O
to	O
fit	O
the	O
ROI	O
within	O
the	O
right	O
area	O
of	O
the	O
fat	O
tissue	O
,	O
otherwise	O
many	O
fat	O
-	O
rich	O
or	O
fat	O
-	O
poor	O
AMLs	O
may	O
be	O
misclassified	O
as	O
fat	O
-	O
poor	O
or	O
fat	O
-	O
invisible	O
.	O

Table	O
1	O
summarizes	O
the	O
features	O
of	O
this	O
classification	O
.	O

Radiological	O
classification	O
of	O
renal	B-DS
AML	I-DS
[	O
9	O
].	O

UECT	O
Region	O
of	O
interest	O
(	O
ROI	O
)	O

MRI	O
-	O
CSI	O
Tumour	B-DS
-	O
to	O
-	O
spleen	O
ratio	O
(	O
TSR	O
)	O

MRI	O
-	O
CSI	O
Signal	O
intensity	O
index	O
(	O
SII	O
)	O


Fat	O
-	O
rich	O
AML	B-DS

≤	O
–	O
10	O
HU	O

<	O
0	O
.	O
71	O

>	O
16	O
.	O
5	O
%	O

Fat	O
-	O
poor	O
AML	B-DS

>	O
–	O
10	O
HU	O

<	O
0	O
.	O
71	O

>	O
16	O
.	O
5	O
%	O

Fat	O
-	O
invisible	O
AML	O

>	O
–	O
10	O
HU	O

≥	O
0	O
.	O
71	O

≤	O
16	O
.	O
5	O
%	O

Diagnosis	O

Clinical	O
Presentation	O

The	O
increased	O
use	O
of	O
cross	O
-	O
sectional	O
imaging	O
and	O
advances	O
in	O
imaging	O
technology	O
explain	O
that	O
the	O
majority	O
(>	O
80	O
%)	O
of	O
AMLs	B-DS
are	O
now	O
incidentally	O
found	O
.	O

Most	O
patients	O
are	O
asymptomatic	O
when	O
they	O
receive	O
the	O
diagnosis	O
of	O
an	O
AML	B-DS
[	O
2	O
].	O

Symptomatic	O
presentation	O
is	O
most	O
frequently	O
related	O
to	O
spontaneous	O
retroperitoneal	O
haemorrhage	O
,	O
although	O
this	O
is	O
seen	O
in	O
less	O
than	O
15	O
%	O
of	O
cases	O
[	O
2	O
].	O

This	O
may	O
lead	O
to	O
shock	O
in	O
one	O
-	O
third	O
of	O
patients	O
.	O

Therefore	O
,	O
risk	O
of	O
a	O
life	O
-	O
threatening	O
bleeding	O
is	O
the	O
main	O
clinical	O
concern	O
in	O
a	O
patient	O
diagnosed	O
with	O
AML	B-DS
.	O

Other	O
symptoms	O
and	O
signs	O
include	O
a	O
palpable	O
mass	O
,	O
flank	O
pain	O
,	O
haematuria	O
,	O
anaemia	B-DS
,	O
urinary	B-DS
tract	I-DS
infection	I-DS
,	O
or	O
renal	B-DS
failure	I-DS
[	O
1112	O
].	O

In	O
contrast	O
to	O
the	O
benign	O
prognosis	O
of	O
classic	O
renal	B-DS
AMLs	I-DS
,	O
the	O
epithelioid	O
variant	O
may	O
undergo	O
malignant	O
transformation	O
,	O
although	O
this	O
is	O
rare	O
.	O

This	O
is	O
manifested	O
by	O
local	O
aggressiveness	O
,	O
including	O
lymphadenopathy	O
,	O
and	O
distal	O
metastases	O
.	O

The	O
larger	O
the	O
tumour	B-DS
,	O
the	O
more	O
likely	O
it	O
is	O
to	O
spread	O
[	O
311	O
].	O

In	O
TSC	B-DS
and	O
LAM	B-DS
,	O
the	O
disease	O
process	O
tends	O
to	O
be	O
more	O
aggressive	O
compared	O
to	O
the	O
sporadic	O
form	O
.	O

This	O
implicates	O
that	O
symptomatic	O
presentation	O
is	O
more	O
common	O
in	O
this	O
subgroup	O
[	O
612	O
].	O

In	O
TSC	B-DS
,	O
hamartomas	B-DS
are	O
formed	O
in	O
multiple	O
organs	O
throughout	O
the	O
body	O
,	O
leading	O
to	O
a	O
variety	O
of	O
symptoms	O
.	O

About	O
90	O
%	O
of	O
patients	O
with	O
TSC	B-DS
have	O
skin	O
manifestations	O
,	O
with	O
a	O
range	O
from	O
facial	B-DS
angiofibromas	I-DS
to	O
hypomelanotic	O
macules	O
.	O

Neurological	O
symptoms	O
,	O
including	O
epilepsy	B-DS
,	O
behavioural	O
problems	O
,	O
and	O
cognitive	B-DS
impairment	I-DS
,	O
occur	O
in	O
up	O
to	O
85	O
%	O
of	O
patients	O
.	O

Renal	B-DS
AMLs	I-DS
are	O
present	O
in	O
approximately	O
75	O
%	O
of	O
patients	O
with	O
TSC	B-DS
and	O
manifest	O
as	O
bilateral	O
and	O
multiple	B-DS
tumours	I-DS
,	O
with	O
a	O
high	O
tendency	O
to	O
grow	O
and	O
cause	O
spontaneous	O
bleeding	O
.	O

LAM	B-DS
,	O
in	O
association	O
with	O
TSC	B-DS
or	O
in	O
the	O
sporadic	O
form	O
,	O
is	O
characterised	O
by	O
cystic	O
changes	O
within	O
the	O
lung	O
parenchyma	O
.	O

This	O
may	O
lead	O
to	O
chylous	B-DS
pleural	I-DS
effusions	I-DS
,	O
recurrent	O
pneumothoraces	O
,	O
and	O
cystic	B-DS
lung	I-DS
disease	I-DS
[	O
2678	O
].	O

Imaging	O
Findings	O

Typical	O
renal	B-DS
AML	I-DS
can	O
be	O
diagnosed	O
accurately	O
based	O
on	O
imaging	O
findings	O
.	O

The	O
demonstration	O
of	O
macroscopic	O
fat	O
within	O
a	O
lesion	O
is	O
the	O
hallmark	O
feature	O
on	O
all	O
modalities	O
.	O

However	O
,	O
AML	B-DS
represent	O
a	O
diagnostic	O
challenge	O
for	O
every	O
imaging	O
method	O
in	O
case	O
of	O
haemorrhage	O
,	O
calcification	O
,	O
necrosis	O
,	O
or	O
low	O
fat	O
content	O
.	O

All	O
imaging	O
features	O
of	O
renal	B-DS
AML	I-DS
are	O
summarized	O
in	O
Table	O
2	O
.	O

Imaging	O
features	O
of	O
renal	B-DS
AML	I-DS
[	O
23491011	O
].	O

US	O

UECT	O

MRI	O
-	O
T1	O

MRI	O
-	O
T2	O

MRI	O
-	O
CSI	O


Fat	O
-	O
rich	O
AML	B-DS

Markedly	O
hyperechoic	O

Hypoattenuating	O

Signal	O
loss	O
on	O
FS	O

Hyperintense	O

Decrease	O
in	O
signal	O
intensity	O

Fat	O
-	O
poor	O
AML	B-DS

Slightly	O
hyperechoic	O

Heterogeneously	O
isoattenuating	O
or	O
hyperattenuating	O

+/–	O
signal	O
loss	O
on	O
FS	O

Heterogeneously	O
or	O
homogeneosly	O
hypointense	O

Decrease	O
in	O
signal	O
intensity	O

Fat	O
-	O
invisible	O
AML	O

Isoechoic	O

Homogeneously	O
hyperattenuating	O

No	O
signal	O
loss	O
on	O
FS	O

Homogeneously	O
hypointense	O

No	O
decrease	O
in	O
signal	O
intensity	O

Note	O
:	O
FS	O
=	O
fat	O
suppression	O
;	O
+/–	O
=	O
loss	O
of	O
signal	O
on	O
fat	O
-	O
suppressed	O
MRI	O
may	O
or	O
may	O
not	O
be	O
present	O
.	O

Ultrasound	O

The	O
classical	O
appearance	O
of	O
a	O
fat	O
-	O
rich	O
AML	B-DS
on	O
ultrasound	O
(	O
US	O
)	O
is	O
that	O
of	O
a	O
hyperechoic	O
lesion	O
with	O
a	O
posterior	O
acoustic	O
shadow	O
(	O
Figure	O
1	O
).	O

The	O
hyperechoic	O
nature	O
of	O
a	O
classic	O
AML	B-DS
is	O
the	O
result	O
of	O
the	O
combination	O
of	O
its	O
fat	O
,	O
blood	O
vessel	O
,	O
and	O
muscle	O
contents	O
,	O
while	O
the	O
shadowing	O
is	O
due	O
to	O
the	O
multiple	O
tissue	O
interfaces	O
between	O
those	O
different	O
elements	O
[	O
11	O
].	O

The	O
echogenicity	O
of	O
the	O
mass	O
is	O
the	O
same	O
as	O
or	O
greater	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
[	O
234	O
].	O

However	O
,	O
this	O
hyperechogenicity	O
is	O
not	O
a	O
constant	O
finding	O
.	O

As	O
the	O
amount	O
of	O
fat	O
deceases	O
,	O
the	O
echogenicity	O
of	O
the	O
lesion	O
decreases	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
has	O
a	O
mixed	O
echotexture	O
,	O
being	O
hyperechoic	O
and	O
isoechoic	O
compared	O
with	O
renal	O
parenchyma	O
.	O

Fat	O
-	O
invisible	O
AML	O
is	O
homogenously	O
isoechoic	O
with	O
respect	O
to	O
renal	O
parenchyma	O
.	O

The	O
echogenicity	O
of	O
both	O
tumours	B-DS
is	O
less	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
.	O

It	O
is	O
challenging	O
to	O
differentiate	O
them	O
from	O
other	O
renal	O
lesions	O
such	O
as	O
RCC	B-DS
,	O
which	O
has	O
an	O
echogenicity	O
that	O
is	O
also	O
less	O
than	O
that	O
of	O
the	O
renal	O
sinus	O
[	O
3410	O
].	O

The	O
lack	O
of	O
sensitivity	O
of	O
US	O
at	O
defining	O
small	O
renal	O
masses	O
implicates	O
that	O
the	O
diagnostic	O
reliability	O
of	O
this	O
imaging	O
modality	O
is	O
not	O
high	O
enough	O
to	O
allow	O
it	O
to	O
be	O
used	O
for	O
diagnosing	O
renal	B-DS
AMLs	I-DS
in	O
daily	O
practice	O
[	O
211	O
].	O

Additional	O
imaging	O
studies	O
may	O
be	O
needed	O
to	O
confirm	O
the	O
diagnosis	O
,	O
i	O
.	O
e	O
.	O
the	O
presence	O
of	O
fat	O
.	O

US	O
image	O
showing	O
a	O
fat	O
-	O
rich	O
AML	B-DS
(	O
arrow	O
).	O

The	O
tumour	B-DS
is	O
more	O
hyperechoic	O
than	O
the	O
right	O
renal	O
sinus	O
(	O
asterisk	O
)	O
[	O
10	O
].	O

Computed	O
Tomography	O

The	O
imaged	O
-	O
based	O
detection	O
of	O
fat	O
generally	O
starts	O
with	O
CT	O
.	O

As	O
on	O
US	O
,	O
the	O
characteristics	O
of	O
AMLs	O
on	O
UECT	O
may	O
vary	O
due	O
to	O
variable	O
quantities	O
of	O
angiogenic	O
,	O
myogenic	O
,	O
and	O
fatty	O
elements	O
.	O

The	O
presence	O
of	O
ROIs	O
containing	O
attenuations	O
of	O
–	O
10	O
HU	O
or	O
less	O
is	O
a	O
reliable	O
sign	O
of	O
an	O
area	O
of	O
adipose	O
tissue	O
[	O
34	O
].	O

Therefore	O
,	O
detecting	O
fat	O
is	O
feasible	O
in	O
most	O
fat	O
-	O
rich	O
AMLs	O
(	O
Figure	O
2	O
).	O

However	O
,	O
some	O
fat	O
-	O
rich	O
AMLs	O
contain	O
very	O
small	O
areas	O
of	O
fat	O
,	O
which	O
may	O
not	O
be	O
recognized	O
at	O
CT	O
.	O

Therefore	O
,	O
the	O
acquisition	O
of	O
thin	O
slice	O
sections	O
(	O
1	O
.	O
5	O
–	O
3	O
.	O
0	O
mm	O
)	O
and	O
obtaining	O
attenuation	O
measurements	O
using	O
small	O
ROIs	O
or	O
even	O
pixel	O
values	O
may	O
be	O
needed	O
.	O

Several	O
authors	O
reported	O
a	O
higher	O
sensitivity	O
for	O
detecting	O
small	O
foci	O
of	O
fat	O
when	O
using	O
pixel	O
mapping	O
,	O
using	O
a	O
line	O
or	O
square	O
of	O
four	O
pixels	O
.	O

In	O
fat	O
-	O
poor	O
AMLs	O
,	O
UECT	O
cannot	O
show	O
a	O
hypoattenuating	O
area	O
measuring	O
less	O
than	O
–	O
10	O
HU	O
.	O

The	O
attenuation	O
values	O
of	O
such	O
lesions	O
range	O
widely	O
,	O
according	O
to	O
the	O
size	O
or	O
location	O
of	O
a	O
ROI	O
:	O
when	O
a	O
ROI	O
is	O
placed	O
in	O
a	O
region	O
of	O
muscle	O
cells	O
and	O
vessels	O
,	O
the	O
lesion	O
attenuation	O
will	O
be	O
higher	O
than	O
when	O
a	O
ROI	O
is	O
placed	O
in	O
an	O
area	O
that	O
consists	O
mostly	O
of	O
fat	O
cells	O
.	O

For	O
this	O
reason	O
,	O
fat	O
-	O
poor	O
AMLs	O
are	O
heterogeneously	O
isoattenuating	O
or	O
hyperattenuating	O
.	O

On	O
the	O
contrary	O
,	O
fat	O
-	O
invisible	O
AMLs	O
appear	O
homogenously	O
hyperattenuating	O
(	O
Figure	O
3	O
).	O

Because	O
they	O
contain	O
too	O
little	O
fat	O
cells	O
,	O
UECT	O
is	O
not	O
able	O
to	O
show	O
any	O
fat	O
attenuation	O
in	O
these	O
lesions	O
.	O

So	O
wherever	O
a	O
ROI	O
is	O
placed	O
in	O
fat	O
-	O
invisible	O
AMLs	O
,	O
their	O
attenuation	O
numbers	O
tend	O
to	O
be	O
higher	O
and	O
fairly	O
constant	O
compared	O
with	O
those	O
of	O
fat	O
-	O
poor	O
AMLs	O
[	O
91011	O
].	O

UECT	O
showing	O
bilateral	O
and	O
multiple	O
AMLs	B-DS
in	O
a	O
patient	O
with	O
TSC	B-DS
.	O

Each	O
lesion	O
contains	O
attenuation	O
numbers	O
less	O
than	O
–	O
10	O
HU	O
,	O
consistent	O
with	O
fat	O
-	O
rich	O
AML	B-DS
[	O
3	O
].	O

UECT	O
demonstrating	O
a	O
left	O
solid	O
renal	O
lesion	O
(	O
arrow	O
).	O

It	O
appears	O
homogeneously	O
hyperdense	O
and	O
has	O
attenuation	O
values	O
as	O
high	O
as	O
44	O
HU	O
,	O
consistent	O
with	O
fat	O
-	O
invisible	O
AML	B-DS
[	O
9	O
].	O

There	O
are	O
several	O
other	O
variants	O
in	O
which	O
an	O
AML	B-DS
can	O
appear	O
on	O
UECT	O
.	O

Frequently	O
,	O
a	O
perirenal	O
or	O
intratumoural	O
haemorrhage	O
is	O
present	O
(	O
Figure	O
4	O
).	O

This	O
hyperdense	O
collection	O
may	O
obscure	O
the	O
fat	O
,	O
leading	O
to	O
misdiagnosing	O
a	O
simple	O
AML	B-DS
as	O
a	O
renal	B-DS
cancer	I-DS
[	O
2	O
].	O

Lesions	O
that	O
contain	O
fat	O
and	O
calcifications	O
also	O
represent	O
a	O
diagnostic	O
challenge	O
.	O

As	O
the	O
presence	O
of	O
adipose	O
tissue	O
is	O
highly	O
suggestive	O
of	O
AML	B-DS
,	O
the	O
presence	O
of	O
calcification	O
raises	O
the	O
possibility	O
of	O
renal	B-DS
cancer	I-DS
.	O

However	O
,	O
several	O
authors	O
reported	O
the	O
existence	O
of	O
both	O
AMLs	B-DS
with	O
calcification	O
and	O
RCCs	B-DS
having	O
fat	O
without	O
calcification	O
[	O
111314	O
].	O

Another	O
,	O
less	O
frequent	O
appearance	O
is	O
that	O
of	O
necrosis	O
within	O
a	O
lesion	O
,	O
being	O
rather	O
typical	O
for	O
epithelioid	O
AMLs	B-DS
[	O
34	O
].	O

Contrast	O
-	O
enhanced	O
CT	O
showing	O
two	O
features	O
:	O
a	O
perirenal	O
hematoma	O
and	O
enhancing	O
lesion	O
with	O
aneurysm	O
formation	O
(	O
arrowhead	O
)	O
and	O
a	O
thrombus	O
in	O
the	O
IVC	O
(	O
arrow	O
)	O
[	O
15	O
].	O

Contrast	O
-	O
enhanced	O
CT	O
is	O
not	O
routinely	O
indicated	O
in	O
diagnosing	O
renal	B-DS
AMLs	I-DS
,	O
but	O
should	O
be	O
performed	O
in	O
selected	O
cases	O
.	O

Frequently	O
,	O
large	O
AMLs	O
contain	O
dilated	O
blood	O
vessels	O
that	O
have	O
the	O
potential	O
of	O
rupturing	O
and	O
bleeding	O
.	O

Whenever	O
tumour	B-DS
bleeding	O
is	O
suspected	O
,	O
it	O
is	O
essential	O
to	O
identify	O
the	O
tortuous	O
vessels	O
using	O
contrast	O
-	O
enhanced	O
CT	O
,	O
before	O
therapeutic	O
embolization	O
can	O
be	O
scheduled	O
[	O
1015	O
].	O

Magnetic	O
Resonance	O
Imaging	O

In	O
the	O
diagnosis	O
of	O
AML	B-DS
,	O
MRI	O
is	O
equivalent	O
in	O
accuracy	O
to	O
CT	O
.	O

Several	O
MRI	O
sequences	O
can	O
be	O
used	O
.	O

The	O
classical	O
approach	O
is	O
to	O
locate	O
fat	O
within	O
a	O
mass	O
by	O
comparing	O
T1	O
-	O
weighted	O
images	O
with	O
and	O
without	O
frequency	O
selective	O
fat	O
suppression	O
.	O

A	O
classic	O
fat	O
-	O
rich	O
AML	B-DS
appears	O
T1	O
-	O
hypointense	O
with	O
and	O
T1	O
-	O
hyperintense	O
without	O
fat	O
suppression	O
[	O
234	O
].	O

However	O
,	O
this	O
T1	O
-	O
hyperintensity	O
is	O
not	O
a	O
specific	O
characteristic	O
of	O
AML	B-DS
and	O
can	O
also	O
be	O
present	O
in	O
RCC	B-DS
and	O
haemorrhagic	B-DS
cysts	I-DS
.	O

Moreover	O
,	O
fat	O
-	O
invisible	O
AMLs	O
contain	O
too	O
little	O
fat	O
to	O
show	O
any	O
hypointensity	O
on	O
fat	O
-	O
suppressed	O
T1	O
-	O
weighted	O
images	O
.	O

In	O
such	O
cases	O
,	O
other	O
techniques	O
may	O
help	O
in	O
differentiating	O
between	O
those	O
entities	O
[	O
1116	O
].	O

More	O
recently	O
,	O
the	O
application	O
of	O
MRI	O
artefacts	O
has	O
been	O
suggested	O
to	O
evaluate	O
fat	O
in	O
renal	B-DS
tumours	I-DS
.	O

One	O
of	O
them	O
,	O
the	O
chemical	O
shift	O
artefact	O
,	O
is	O
due	O
to	O
the	O
differences	O
between	O
resonance	O
frequencies	O
of	O
fat	O
and	O
water	O
.	O

This	O
results	O
in	O
alternating	O
high	O
and	O
low	O
signals	O
in	O
the	O
frequency	O
encoding	O
direction	O
on	O
opposed	O
-	O
phase	O
imaging	O
.	O

This	O
out	O
-	O
of	O
-	O
phase	O
cancellation	O
effect	O
between	O
fat	O
and	O
water	O
gives	O
rise	O
to	O
another	O
MRI	O
artefact	O
,	O
called	O
the	O
black	O
boundary	O
or	O
India	O
ink	O
artefact	O
.	O

This	O
artificially	O
created	O
black	O
line	O
is	O
located	O
at	O
the	O
junction	O
of	O
fat	O
(	O
present	O
in	O
AML	B-DS
cells	O
)	O
and	O
water	O
(	O
present	O
in	O
renal	O
parenchyma	O
)	O
and	O
results	O
in	O
a	O
sharp	O
delineation	O
of	O
the	O
muscle	O
-	O
fat	O
boundary	O
(	O
Figure	O
5	O
).	O

This	O
sign	O
is	O
indicative	O
of	O
an	O
AML	B-DS
[	O
341116	O
].	O

It	O
is	O
especially	O
useful	O
in	O
fat	O
-	O
poor	O
AMLs	O
and	O
very	O
small	O
lesions	O
,	O
in	O
which	O
the	O
typical	O
T1	O
features	O
may	O
not	O
be	O
noticeable	O
[	O
2	O
].	O

However	O
,	O
fat	O
-	O
invisible	O
AMLs	O
do	O
not	O
show	O
this	O
decrease	O
in	O
signal	O
intensity	O
,	O
because	O
they	O
contain	O
too	O
little	O
fat	O
cells	O
[	O
10	O
].	O

Opposed	O
-	O
phase	O
T1	O
-	O
weighted	O
MR	O
image	O
with	O
a	O
hyperintense	O
renal	O
mass	O
.	O

The	O
India	O
ink	O
artefact	O
(	O
arrow	O
)	O
is	O
present	O
at	O
the	O
interface	O
of	O
the	O
lesion	O
with	O
the	O
kidney	O
[	O
16	O
].	O

T2	O
-	O
weighted	O
images	O
can	O
also	O
be	O
used	O
for	O
diagnosing	O
AML	B-DS
.	O

Fat	O
-	O
rich	O
AML	B-DS
typically	O
is	O
hyperintense	O
with	O
respect	O
to	O
renal	O
parenchyma	O
.	O

It	O
has	O
hyperintense	O
foci	O
within	O
a	O
hypointense	O
background	O
,	O
because	O
areas	O
of	O
fat	O
are	O
distributed	O
among	O
blood	O
vessels	O
and	O
muscle	O
cells	O
.	O

Fat	O
-	O
poor	O
AML	B-DS
is	O
either	O
homogeneous	O
or	O
heterogeneous	O
hypointense	O
compared	O
with	O
renal	O
tissue	O
,	O
depending	O
on	O
the	O
distribution	O
of	O
its	O
areas	O
of	O
fat	O
.	O

If	O
these	O
areas	O
are	O
small	O
but	O
diffuse	O
,	O
the	O
signal	O
intensity	O
is	O
homogeneous	O
,	O
while	O
it	O
is	O
heterogeneous	O
when	O
fat	O
cells	O
are	O
located	O
focal	O
.	O

Finally	O
,	O
fat	O
-	O
invisible	O
AML	B-DS
is	O
homogeneously	O
hypointense	O
in	O
comparison	O
to	O
renal	O
parenchyma	O
on	O
T2	O
,	O
because	O
of	O
the	O
dominance	O
of	O
the	O
muscle	O
component	O
and	O
the	O
paucity	O
of	O
adipose	O
tissue	O
[	O
23410	O
].	O

Contrast	O
-	O
enhanced	O
MRI	O
has	O
a	O
limited	O
role	O
in	O
the	O
diagnosis	O
of	O
AML	B-DS
.	O

After	O
intravenous	O
administration	O
of	O
gadolinium	O
,	O
renal	O
AMLs	O
show	O
hypointense	O
compared	O
to	O
renal	O
parenchyma	O
.	O

However	O
,	O
these	O
enhancement	O
characteristics	O
appear	O
to	O
be	O
similar	O
to	O
those	O
of	O
hypovascular	O
RCCs	B-DS
[	O
1117	O
].	O

Percutaneous	O
Biopsy	O

Most	O
AMLs	B-DS
can	O
be	O
diagnosed	O
with	O
imaging	O
by	O
identifying	O
intralesional	O
fat	O
.	O

However	O
,	O
in	O
select	O
cases	O
,	O
the	O
use	O
of	O
imaging	O
alone	O
is	O
insufficient	O
and	O
percutaneous	O
renal	O
biopsy	O
may	O
be	O
necessary	O
for	O
correctly	O
diagnosing	O
the	O
renal	O
mass	O
,	O
thus	O
avoiding	O
unnecessary	O
treatment	O
.	O

Nowadays	O
,	O
percutaneous	O
biopsy	O
is	O
increasingly	O
used	O
to	O
differentiate	O
between	O
benign	O
and	O
malignant	O
renal	O
lesions	O
[	O
1819	O
].	O

Currently	O
,	O
percutaneous	O
renal	O
biopsy	O
is	O
recommended	O
only	O
for	O
differentiating	O
fat	O
-	O
invisible	O
AML	B-DS
from	O
RCC	B-DS
,	O
if	O
both	O
CT	O
and	O
MR	O
images	O
are	O
inconclusive	O
.	O

A	O
fat	O
-	O
invisible	O
AML	B-DS
typically	O
appears	O
as	O
a	O
hyperattenuating	O
mass	O
that	O
enhance	O
homogenously	O
on	O
UECT	O
.	O

Although	O
this	O
presentation	O
is	O
uncommon	O
for	O
a	O
RCC	B-DS
,	O
both	O
pathologies	O
may	O
appear	O
identical	O
on	O
imaging	O
.	O

In	O
these	O
cases	O
,	O
the	O
mass	O
should	O
be	O
evaluated	O
with	O
MRI	O
.	O

While	O
a	O
fat	O
-	O
invisible	O
AML	B-DS
is	O
homogenously	O
hypointense	O
on	O
T2	O
-	O
weighted	O
MR	O
images	O
,	O
clear	O
cell	O
RCC	B-DS
appears	O
hyperintense	O
[	O
9	O
].	O

However	O
,	O
the	O
papillary	O
subtype	O
of	O
RCC	B-DS
appears	O
also	O
hypointense	O
.	O

Therefore	O
,	O
percutaneous	O
biopsy	O
is	O
required	O
to	O
differentiate	O
fat	O
-	O
invisible	O
AML	B-DS
and	O
papillary	B-DS
RCC	I-DS
when	O
a	O
small	O
(	O
less	O
than	O
3	O
cm	O
),	O
T2	O
-	O
hypointense	O
renal	O
mass	O
without	O
evidence	O
of	O
intratumoural	O
fat	O
is	O
encountered	O
[	O
18	O
].	O

If	O
the	O
lesion	O
is	O
larger	O
(	O
more	O
than	O
3	O
cm	O
)	O
or	O
if	O
there	O
is	O
evidence	O
of	O
haemorrhage	O
,	O
percutaneous	O
biopsy	O
may	O
be	O
skipped	O
.	O

Proceeding	O
directly	O
to	O
a	O
suitable	O
treatment	O
may	O
be	O
a	O
more	O
appropriate	O
option	O
,	O
both	O
to	O
avoid	O
further	O
bleeding	O
and	O
because	O
epithelioid	O
AML	B-DS
and	O
RCC	B-DS
are	O
more	O
presumable	O
[	O
3	O
].	O

Differential	O
Diagnosis	O

Over	O
the	O
last	O
decades	O
,	O
the	O
detection	O
of	O
small	O
renal	O
masses	O
definitely	O
increased	O
by	O
the	O
increased	O
use	O
of	O
cross	O
-	O
sectional	O
imaging	O
studies	O
.	O

A	O
lot	O
of	O
these	O
incidentally	O
found	O
renal	O
lesions	O
are	O
usually	O
presumed	O
to	O
be	O
RCC	B-DS
and	O
are	O
treated	O
as	O
such	O
.	O

However	O
,	O
a	O
recent	O
study	O
showed	O
that	O
21	O
.	O
5	O
%	O
of	O
those	O
lesions	O
turned	O
out	O
to	O
be	O
benign	O
after	O
surgery	O
.	O

AML	B-DS
accounted	O
for	O
nearly	O
half	O
of	O
this	O
group	O
of	O
benign	O
masses	O
.	O

This	O
shows	O
that	O
the	O
differentiation	O
between	O
AML	B-DS
and	O
RCC	B-DS
remains	O
difficult	O
in	O
routine	O
practice	O
[	O
202122	O
].	O

As	O
already	O
repeatedly	O
stated	O
above	O
,	O
classic	O
AML	B-DS
can	O
be	O
distinguished	O
from	O
RCC	B-DS
by	O
the	O
presence	O
of	O
macroscopic	O
fat	O
in	O
sufficient	O
quantity	O
to	O
be	O
detected	O
on	O
UECT	O
.	O

However	O
,	O
in	O
4	O
–	O
5	O
%	O
of	O
AML	B-DS
cases	O
,	O
no	O
fat	O
can	O
be	O
visualized	O
on	O
CT	O
,	O
increasing	O
the	O
difficulty	O
in	O
differentiating	O
it	O
from	O
RCC	B-DS
.	O

Correctly	O
diagnosing	O
this	O
fat	O
-	O
poor	O
and	O
fat	O
-	O
invisible	O
AML	B-DS
requires	O
sufficient	O
clinical	O
and	O
imaging	O
information	O
.	O

Clinical	O
information	O
supporting	O
a	O
diagnosis	O
of	O
AML	B-DS
includes	O
a	O
younger	O
age	O
,	O
female	O
sex	O
,	O
and	O
asymptomatic	O
presentation	O
.	O

Imaging	O
findings	O
that	O
should	O
raise	O
the	O
suspicion	O
of	O
AML	B-DS
include	O
the	O
absence	O
of	O
calcification	O
,	O
the	O
absence	O
of	O
perinephric	O
collateral	O
vessels	O
,	O
multiple	O
lesions	O
,	O
hyperattenuation	O
in	O
comparison	O
to	O
renal	O
parenchyma	O
on	O
UECT	O
,	O
and	O
hypointensity	O
on	O
T2	O
-	O
weighted	O
MRI	O
.	O

However	O
,	O
because	O
these	O
characteristic	O
features	O
are	O
not	O
present	O
in	O
every	O
AML	B-DS
and	O
exceptions	O
do	O
exist	O
,	O
no	O
single	O
finding	O
or	O
modality	O
is	O
perfectly	O
accurate	O
[	O
2021222324	O
].	O

Treatment	O

As	O
most	O
renal	B-DS
AMLs	I-DS
are	O
diagnosed	O
incidentally	O
in	O
asymptomatic	O
patients	O
,	O
therapeutic	O
interventions	O
are	O
required	O
in	O
a	O
minority	O
of	O
patients	O
.	O

Potential	O
interventions	O
include	O
selective	O
renal	O
artery	O
embolization	O
,	O
nephron	O
-	O
sparing	O
surgery	O
,	O
complete	O
nephrectomy	O
,	O
cryo	O
-	O
and	O
radiofrequency	O
ablation	O
,	O
and	O
treatment	O
with	O
mTOR	B-GP
inhibitors	O
.	O

Indications	O

Historically	O
,	O
the	O
main	O
indications	O
for	O
intervention	O
have	O
been	O
the	O
presence	O
of	O
symptoms	O
,	O
the	O
presence	O
in	O
women	O
of	O
childbearing	O
age	O
,	O
suspicion	O
of	O
malignancy	O
,	O
and	O
size	O
larger	O
than	O
4	O
cm	O
.	O

The	O
use	O
of	O
a	O
4	O
cm	O
tumour	B-DS
size	O
as	O
a	O
criterion	O
for	O
treatment	O
comes	O
from	O
a	O
frequently	O
quoted	O
review	O
published	O
in	O
1986	O
[	O
21119	O
].	O

The	O
authors	O
of	O
this	O
review	O
reported	O
that	O
82	O
%	O
of	O
patients	O
with	O
renal	B-DS
AMLs	I-DS
larger	O
than	O
4	O
cm	O
experienced	O
symptoms	O
and	O
51	O
%	O
of	O
them	O
presented	O
with	O
active	O
retroperitoneal	O
haemorrhage	O
.	O

Other	O
early	O
series	O
showed	O
that	O
patients	O
with	O
tumours	B-DS
larger	O
than	O
4	O
cm	O
had	O
interval	O
growth	O
and	O
needed	O
treatment	O
more	O
often	O
.	O

They	O
all	O
suggested	O
4	O
cm	O
as	O
the	O
limit	O
above	O
which	O
an	O
intervention	O
should	O
be	O
considered	O
.	O

This	O
threshold	O
has	O
been	O
widely	O
adopted	O
for	O
many	O
years	O
,	O
although	O
the	O
understanding	O
of	O
the	O
biology	O
and	O
management	O
of	O
the	O
disease	O
have	O
changed	O
significantly	O
since	O
then	O
[	O
252627	O
].	O

However	O
,	O
this	O
threshold	O
has	O
recently	O
been	O
questioned	O
.	O

Recent	O
studies	O
do	O
not	O
support	O
the	O
4	O
cm	O
size	O
criterion	O
.	O

One	O
author	O
found	O
that	O
only	O
30	O
%	O
of	O
AMLs	B-DS
larger	O
than	O
4	O
cm	O
were	O
symptomatic	O
[	O
2	O
].	O

Another	O
one	O
showed	O
that	O
using	O
a	O
cut	O
-	O
off	O
of	O
4	O
cm	O
as	O
predictor	O
of	O
haemorrhage	O
has	O
a	O
lower	O
specificity	O
than	O
an	O
aneurysm	B-DS
size	O
of	O
5	O
mm	O
.	O

In	O
other	O
series	O
,	O
the	O
angiographic	O
appearance	O
of	O
AMLs	B-DS
was	O
used	O
for	O
analysing	O
them	O
.	O

They	O
found	O
that	O
lesions	O
with	O
high	O
vascularity	O
(	O
multiple	O
,	O
large	O
,	O
tortuous	O
vessels	O
)	O
were	O
more	O
likely	O
to	O
require	O
intervention	O
for	O
bleeding	O
.	O

All	O
this	O
evidence	O
would	O
suggest	O
that	O
,	O
although	O
tumour	B-DS
diameter	O
is	O
important	O
,	O
the	O
size	O
of	O
related	O
aneurysms	O
and	O
the	O
vascularity	O
of	O
the	O
AML	B-DS
may	O
ultimately	O
be	O
more	O
significant	O
[	O
1127	O
].	O

As	O
most	O
AMLs	B-DS
now	O
are	O
found	O
incidentally	O
,	O
physicians	O
are	O
challenged	O
by	O
a	O
treatment	O
dilemma	O
when	O
an	O
AML	B-DS
in	O
an	O
asymptomatic	O
patient	O
reaches	O
the	O
4	O
-	O
cm	O
threshold	O
.	O

They	O
are	O
worried	O
that	O
these	O
“	O
large	O
”	O
lesions	O
may	O
rupture	O
and	O
cause	O
life	O
-	O
threatening	O
bleeding	O
.	O

Consequently	O
,	O
AMLs	O
are	O
often	O
imaged	O
intensively	O
and	O
repeatedly	O
,	O
and	O
treated	O
empirically	O
once	O
they	O
attain	O
a	O
diameter	O
of	O
4	O
cm	O
[	O
26	O
].	O

The	O
current	O
guidelines	O
of	O
the	O
European	O
Association	O
of	O
Urology	O
recommend	O
intervention	O
in	O
well	O
-	O
selected	O
cases	O
,	O
including	O
symptomatic	O
tumours	B-DS
,	O
large	O
lesions	O
,	O
presence	O
in	O
women	O
of	O
childbearing	O
age	O
,	O
and	O
poor	O
access	O
to	O
follow	O
-	O
up	O
or	O
emergency	O
care	O
.	O

A	O
size	O
threshold	O
for	O
treatment	O
,	O
however	O
,	O
remains	O
controversial	O
[	O
2242526	O
].	O

Active	O
Surveillance	O

Once	O
the	O
initial	O
diagnostic	O
evaluations	O
are	O
completed	O
and	O
indications	O
for	O
treatment	O
are	O
not	O
present	O
,	O
active	O
surveillance	O
should	O
be	O
used	O
to	O
monitor	O
progression	O
of	O
known	O
tumours	B-DS
and	O
development	O
of	O
new	O
ones	O
[	O
29	O
].	O

For	O
sporadic	O
AML	B-DS
,	O
there	O
are	O
currently	O
no	O
guidelines	O
on	O
the	O
frequency	O
of	O
imaging	O
studies	O
neither	O
on	O
which	O
modality	O
should	O
be	O
used	O
.	O

These	O
decisions	O
are	O
likely	O
to	O
be	O
institution	O
dependent	O
and	O
should	O
be	O
guided	O
by	O
the	O
individual	O
clinical	O
scenario	O
[	O
2	O
].	O

Annual	O
repeat	O
of	O
imaging	O
seems	O
to	O
be	O
appropriate	O
for	O
small	O
,	O
solitary	O
lesions	O
.	O

For	O
hereditary	O
AML	B-DS
,	O
the	O
International	O
Tuberous	B-DS
Sclerosis	I-DS
Complex	O
Consensus	O
recommends	O
the	O
use	O
of	O
MRI	O
,	O
because	O
of	O
its	O
increased	O
sensitivity	O
in	O
the	O
detection	O
of	O
adipose	O
tissue	O
.	O

Annual	O
clinical	O
evaluation	O
of	O
renal	O
function	O
and	O
blood	O
pressure	O
is	O
also	O
required	O
in	O
these	O
cases	O
[	O
192830	O
].	O

Embolization	O

Historically	O
,	O
there	O
was	O
a	O
greater	O
tendency	O
towards	O
surgery	O
in	O
the	O
treatment	O
of	O
renal	B-DS
AMLs	I-DS
.	O

They	O
were	O
often	O
excised	O
because	O
malignancy	O
could	O
not	O
be	O
excluded	O
.	O

However	O
,	O
this	O
has	O
shifted	O
,	O
as	O
AMLs	B-DS
can	O
now	O
be	O
confidently	O
recognized	O
at	O
imaging	O
.	O

Selective	O
transarterial	O
embolization	O
is	O
now	O
the	O
first	O
-	O
line	O
treatment	O
option	O
,	O
especially	O
in	O
the	O
event	O
of	O
acute	O
bleeding	O
or	O
hemodynamic	O
instability	O
[	O
25	O
].	O

Many	O
clinicians	O
favour	O
embolization	O
and	O
reserve	O
surgery	O
for	O
patients	O
with	O
uncontrollable	O
symptoms	O
,	O
vascular	B-DS
malformations	I-DS
,	O
failure	O
of	O
embolization	O
,	O
and	O
rare	O
diagnostic	O
uncertainty	O
.	O

When	O
surgery	O
needs	O
to	O
be	O
performed	O
,	O
preoperative	O
embolization	O
of	O
the	O
lesion	O
may	O
be	O
taken	O
into	O
consideration	O
in	O
reducing	O
the	O
difficulty	O
and	O
complications	O
of	O
tumourectomy	B-DS
or	O
nephrectomy	O
[	O
11192732	O
].	O

Embolization	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
percentage	O
of	O
side	O
effects	O
(	O
42	O
.	O
8	O
%),	O
although	O
most	O
of	O
these	O
are	O
post	O
-	O
embolization	O
syndromes	O
.	O

This	O
self	O
-	O
limiting	O
condition	O
is	O
characterized	O
by	O
fever	O
,	O
flank	O
pain	O
,	O
leucocytosis	B-DS
,	O
nausea	O
,	O
and	O
vomiting	O
within	O
the	O
first	O
three	O
days	O
after	O
the	O
procedure	O
,	O
and	O
it	O
is	O
managed	O
conservatively	O
with	O
standard	O
supportive	O
care	O
.	O

Routine	O
prophylaxis	O
,	O
including	O
antipyretics	O
,	O
antiemetics	O
and	O
analgesia	O
,	O
may	O
play	O
a	O
role	O
in	O
periprocedural	O
management	O
[	O
227	O
].	O

Other	O
complications	O
,	O
including	O
non	O
-	O
target	O
embolization	O
of	O
normal	O
parenchyma	O
or	O
renal	B-DS
infarction	I-DS
with	O
abscess	B-DS
forming	O
,	O
are	O
uncommon	O
[	O
111932	O
].	O

In	O
general	O
though	O
,	O
arterial	O
embolization	O
is	O
a	O
well	O
-	O
tolerated	O
procedure	O
.	O

Although	O
it	O
is	O
now	O
seen	O
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
patients	O
with	O
AMLs	B-DS
,	O
both	O
regrowth	O
and	O
repeated	O
haemorrhage	O
after	O
embolization	O
remain	O
a	O
concern	O
.	O

The	O
effect	O
of	O
embolization	O
may	O
vary	O
,	O
because	O
of	O
the	O
varying	O
amounts	O
of	O
adipose	O
,	O
vascular	O
,	O
and	O
smooth	O
muscle	O
tissue	O
in	O
the	O
lesions	O
.	O

Different	O
authors	O
showed	O
in	O
their	O
series	O
a	O
need	O
for	O
reembolization	O
varying	O
from	O
17	O
%	O
till	O
37	O
%	O
[	O
323334	O
].	O

Surgery	O

Surgical	O
excision	O
in	O
the	O
form	O
of	O
partial	O
or	O
radical	O
nephrectomy	O
is	O
the	O
only	O
treatment	O
that	O
completely	O
removes	O
the	O
renal	O
mass	O
,	O
although	O
recurrence	O
from	O
other	O
parts	O
of	O
the	O
kidney	O
may	O
occur	O
.	O

Every	O
surgery	O
should	O
rely	O
on	O
a	O
nephron	O
sparing	O
approach	O
whenever	O
possible	O
[	O
25	O
].	O

Parenchymal	O
preservation	O
is	O
even	O
more	O
important	O
in	O
patients	O
with	O
TSC	B-DS
or	O
LAM	B-DS
,	O
because	O
of	O
the	O
multifocal	O
disease	O
pattern	O
and	O
the	O
higher	O
recurrence	O
rate	O
.	O

Nephrectomy	O
is	O
indicated	O
only	O
when	O
a	O
renal	B-DS
AML	I-DS
is	O
very	O
large	O
,	O
when	O
suspicion	O
of	O
malignancy	O
is	O
high	O
,	O
and	O
when	O
other	O
treatment	O
options	O
cannot	O
be	O
performed	O
.	O

However	O
,	O
in	O
an	O
emergency	O
setting	O
,	O
a	O
nephrectomy	O
can	O
be	O
lifesaving	O
[	O
3132	O
].	O

Ablation	O

When	O
comparing	O
current	O
treatment	O
methods	O
,	O
cryoablation	O
and	O
percutaneous	O
radiofrequency	O
ablation	O
appear	O
to	O
be	O
attractive	O
alternatives	O
to	O
embolization	O
or	O
surgery	O
.	O

Different	O
series	O
demonstrate	O
good	O
efficacy	O
with	O
minimal	O
complications	O
,	O
few	O
repeat	O
treatments	O
,	O
and	O
no	O
recurrences	O
.	O

However	O
,	O
reports	O
of	O
the	O
use	O
of	O
these	O
minimal	O
invasive	O
techniques	O
are	O
confined	O
to	O
small	O
and	O
asymptomatic	O
lesions	O
[	O
19	O
].	O

Little	O
evidence	O
is	O
available	O
on	O
the	O
application	O
in	O
larger	O
or	O
symptomatic	O
tumours	B-DS
.	O

Overall	O
,	O
ablation	O
has	O
shown	O
some	O
promise	O
in	O
the	O
treatment	O
of	O
a	O
specific	O
AML	B-DS
group	O
that	O
some	O
would	O
say	O
should	O
be	O
managed	O
by	O
active	O
surveillance	O
[	O
23334	O
].	O

Drugs	O

The	O
identification	O
of	O
mutations	O
in	O
TSC1	B-GP
and	O
TSC2	B-GP
and	O
the	O
existence	O
of	O
a	O
licensed	O
drug	O
targeting	O
the	O
mTOR	B-GP
pathway	O
,	O
lead	O
to	O
rapid	O
translation	O
of	O
mTOR	B-GP
inhibitors	O
to	O
patients	O
with	O
TSC	B-GP
and	O
LAM	B-DS
.	O

These	O
medicines	O
interrupt	O
further	O
tumour	B-DS
progression	O
and	O
promote	O
reversion	O
of	O
existing	O
lesions	O
.	O

Sirolimus	B-CD
,	O
also	O
known	O
as	O
rapamycin	B-CD
,	O
was	O
the	O
first	O
mTOR	B-GP
inhibitor	O
analysed	O
in	O
treating	O
hereditary	O
AML	B-DS
.	O

It	O
was	O
originally	O
developed	O
as	O
immunosuppressant	O
for	O
use	O
in	O
organ	O
transplantation	O
.	O

Overall	O
,	O
sirolimus	B-CD
was	O
well	O
tolerated	O
in	O
these	O
early	O
studies	O
,	O
with	O
mouth	B-DS
ulcers	I-DS
,	O
skin	B-DS
lesions	I-DS
,	O
dyslipidaemia	B-DS
,	O
and	O
proteinuria	O
as	O
most	O
commonly	O
encountered	O
side	O
effects	O
.	O

It	O
is	O
now	O
approved	O
for	O
treatment	O
of	O
LAM	B-DS
[	O
6	O
].	O

Everolimus	B-CD
,	O
another	O
mTOR	B-GP
inhibitor	O
and	O
rapamycine	B-CD
derivative	O
,	O
has	O
been	O
studied	O
the	O
most	O
.	O

Currently	O
,	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicines	O
Agency	O
approve	O
this	O
agent	O
for	O
treating	O
AML	B-DS
in	O
the	O
setting	O
of	O
TSC	B-DS
[	O
323536	B-CD
].	O

The	O
position	O
of	O
mTOR	B-GP
inhibitors	O
in	O
the	O
management	O
of	O
sporadic	O
AML	B-DS
still	O
remains	O
to	O
be	O
determined	O
[	O
2	O
].	O

For	O
asymptomatic	O
AMLs	B-DS
in	O
TSC	B-DS
and	O
LAM	B-DS
that	O
are	O
enlarging	O
and	O
larger	O
than	O
3	O
cm	O
,	O
recent	O
guidelines	O
suggest	O
that	O
mTOR	B-GP
inhibition	O
currently	O
is	O
the	O
most	O
effective	O
first	O
-	O
line	O
treatment	O
.	O

The	O
demonstrated	O
tolerability	O
so	O
far	O
to	O
date	O
is	O
superior	O
to	O
the	O
renal	B-DS
impairment	I-DS
caused	O
by	O
AML	B-DS
progression	O
and	O
is	O
preferable	O
to	O
other	O
treatment	O
modalities	O
[	O
28	O
].	O

Another	O
concern	O
for	O
treating	O
physicians	O
is	O
how	O
long	O
the	O
treatment	O
with	O
those	O
drugs	O
should	O
continue	O
,	O
as	O
the	O
effect	O
of	O
mTOR	B-GP
inhibition	O
is	O
reversible	O
.	O

To	O
continue	O
the	O
treatment	O
for	O
AML	B-DS
,	O
consideration	O
should	O
be	O
given	O
to	O
long	O
-	O
term	O
complications	O
,	O
cost	O
,	O
and	O
safety	O
,	O
compared	O
with	O
other	O
treatment	O
options	O
[	O
3236	O
].	O

Conclusion	O

Renal	B-DS
AML	I-DS
is	O
the	O
most	O
prevalent	O
benign	O
neoplasm	B-DS
of	I-DS
the	I-DS
kidney	I-DS
.	O

It	O
has	O
a	O
variable	O
and	O
heterogeneous	O
nature	O
,	O
with	O
the	O
potential	O
to	O
pose	O
serious	O
diagnostic	O
challenges	O
in	O
clinical	O
practice	O
.	O

The	O
characteristics	O
of	O
classic	O
AMLs	B-DS
are	O
well	O
described	O
,	O
but	O
the	O
radiological	O
distinction	O
between	O
non	O
-	O
classic	O
AMLs	B-DS
and	O
RCCs	B-DS
continues	O
to	O
be	O
difficult	O
.	O

Knowledge	O
of	O
the	O
different	O
types	O
,	O
their	O
classification	O
,	O
and	O
their	O
radiologic	O
appearance	O
will	O
help	O
radiologists	O
in	O
making	O
a	O
correct	O
diagnosis	O
.	O

When	O
an	O
AML	B-DS
is	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
a	O
renal	O
lesion	O
that	O
does	O
not	O
demonstrate	O
classical	O
features	O
,	O
confirmatory	O
imaging	O
,	O
percutaneous	O
renal	O
biopsy	O
,	O
or	O
surgical	O
excision	O
should	O
be	O
performed	O
.	O

Several	O
invasive	O
,	O
non	O
-	O
invasive	O
,	O
and	O
pharmacologic	O
treatment	O
options	O
exist	O
.	O

Careful	O
surveillance	O
before	O
and	O
after	O
treatment	O
is	O
necessary	O
,	O
particularly	O
for	O
patients	O
with	O
TSC	B-DS
or	O
LAM	B-DS
.	O

Without	O
proper	O
management	O
,	O
renal	B-DS
AML	I-DS
may	O
have	O
serious	O
consequences	O
.	O

Responses	O
of	O
the	O
summer	O
Asian	O
-	O
Pacific	O
zonal	O
thermal	O
contrast	O
and	O
the	O
associated	O
evolution	O
of	O
atmospheric	O
circulation	O
to	O
transient	O
orbital	O
changes	O
during	O
the	O
Holocene	O

This	O
study	O
investigates	O
the	O
response	O
of	O
large	O
-	O
scale	O
atmospheric	O
circulation	O
over	O
the	O
Asian	O
-	O
Pacific	O
sector	O
and	O
precipitation	O
over	O
eastern	O
China	O
to	O
transient	O
orbital	O
changes	O
during	O
the	O
Holocene	O
summer	O
using	O
an	O
intermediate	O
-	O
complexity	O
climate	O
model	O
.	O

Corresponding	O
to	O
variations	O
in	O
the	O
incoming	O
solar	O
radiation	O
,	O
the	O
eddy	O
sea	O
level	O
pressure	O
(	O
SLP	O
)	O
exhibited	O
an	O
out	O
-	O
of	O
-	O
phase	O
relationship	O
between	O
the	O
North	O
Pacific	O
and	O
the	O
Eurasian	O
landmass	O
that	O
was	O
similar	O
to	O
the	O
present	O
-	O
day	O
Asia	O
-	O
Pacific	O
Oscillation	O
(	O
APO	O
)	O
pattern	O
and	O
was	O
defined	O
as	O
the	O
paleo	O
-	O
APO	O
.	O

Its	O
index	O
presented	O
an	O
increasing	O
trend	O
,	O
which	O
implies	O
the	O
enhancement	O
of	O
a	O
zonal	O
thermal	O
contrast	O
between	O
Asia	O
and	O
the	O
North	O
Pacific	O
.	O

Associated	O
with	O
the	O
strengthening	O
of	O
the	O
paleo	O
-	O
APO	O
was	O
the	O
westward	O
shift	O
in	O
North	O
Pacific	O
high	O
pressure	O
.	O

Accordingly	O
,	O
there	O
was	O
less	O
/	O
more	O
summer	O
precipitation	O
over	O
both	O
the	O
middle	O
reach	O
of	O
the	O
Yangtze	O
River	O
and	O
Southwest	O
China	O
/	O
over	O
North	O
China	O
.	O

The	O
high	O
-	O
resolution	O
stalagmite	O
δ18O	O
records	O
further	O
support	O
this	O
decrease	O
in	O
the	O
model	O
precipitation	O
.	O

Along	O
with	O
the	O
strengthening	O
of	O
paleo	O
-	O
APO	O
from	O
the	O
early	O
Holocene	O
to	O
the	O
present	O
,	O
the	O
eddy	O
SLP	O
anomalies	O
exhibited	O
a	O
decreasing	O
/	O
increasing	O
trend	O
over	O
the	O
Eurasian	O
landmass	O
/	O
the	O
North	O
Pacific	O
,	O
with	O
a	O
phase	O
change	O
of	O
approximately	O
4	O
.	O
5	O
ka	O
BP	O
,	O
and	O
they	O
both	O
moved	O
westward	O
.	O

Meanwhile	O
,	O
a	O
less	O
rainfall	O
belt	O
over	O
eastern	O
China	O
exhibited	O
northward	O
propagation	O
from	O
southern	O
China	O
.	O

The	O
East	O
Asian	O
summer	O
monsoon	O
(	O
EASM	O
)	O
is	O
an	O
important	O
component	O
of	O
global	O
climate	O
systems	O
and	O
plays	O
significant	O
roles	O
in	O
global	O
energy	O
and	O
hydrological	O
cycles	O
.	O

Therefore	O
,	O
it	O
is	O
viewed	O
as	O
the	O
life	O
blood	O
providing	O
the	O
key	O
precipitation	O
for	O
agriculture1	O
.	O

However	O
,	O
some	O
extreme	O
variations	O
in	O
the	O
EASM	O
also	O
cause	O
harmful	O
drought	O
and	O
flooding	O
events2	O
.	O

In	O
particular	O
,	O
under	O
recent	O
global	O
warming	O
,	O
the	O
EASM	O
experienced	O
a	O
weakening	O
trend	O
,	O
with	O
severe	O
droughts	O
over	O
northern	O
China	O
and	O
disastrous	O
floods	O
over	O
the	O
Yangtze	O
River	O
valley3	O
.	O

Therefore	O
,	O
understanding	O
the	O
natural	O
variability	O
of	O
EASM	O
and	O
predicting	O
its	O
long	O
-	O
term	O
changes	O
in	O
a	O
warming	O
climate	O
are	O
helpful	O
for	O
disaster	O
mitigation	O
.	O

The	O
Holocene	O
is	O
another	O
significant	O
warming	O
period	O
that	O
occurred	O
since	O
the	O
last	O
glacial	O
period	O
.	O

Studies	O
of	O
EASM	O
during	O
the	O
Holocene	O
may	O
help	O
us	O
understand	O
the	O
mechanisms	O
responsible	O
for	O
the	O
natural	O
variability	O
of	O
EASM	O
under	O
a	O
warming	O
scenario	O
,	O
which	O
has	O
been	O
of	O
increasing	O
interest	O
during	O
the	O
past	O
decade456789101112	O
.	O

Some	O
studies	O
of	O
high	O
-	O
resolution	O
and	O
precisely	O
dated	O
contemporaneous	O
speleothem	O
δ18O	O
records	O
from	O
caves	O
have	O
indicated	O
a	O
long	O
-	O
term	O
downward	O
trend	O
of	O
the	O
EASM	O
precipitation	O
during	O
the	O
Holocene1314	O
.	O

This	O
trend	O
may	O
be	O
a	O
response	O
to	O
the	O
decreasing	O
solar	O
insolation	O
over	O
the	O
Northern	O
Hemisphere	O
(	O
NH	O
).	O

However	O
,	O
the	O
associated	O
mechanisms	O
remain	O
unknown	O
.	O

In	O
the	O
summer	O
,	O
a	O
remarkable	O
tropospheric	O
zonal	O
thermal	O
contrast	O
arises	O
between	O
the	O
warmer	O
Eurasian	O
continent	O
and	O
the	O
cooler	O
North	O
Pacific	O
or	O
Indian	O
Ocean	O
.	O

Some	O
in	O
-	O
depth	O
studies	O
have	O
explored	O
the	O
variations	O
in	O
the	O
thermal	O
contrast	O
and	O
their	O
links	O
with	O
EASM	O
and	O
precipitation	O
on	O
multiple	O
time	O
scales315161718	O
.	O

Recently	O
,	O
a	O
large	O
-	O
scale	O
summertime	O
teleconnection	O
pattern	O
of	O
the	O
tropospheric	O
temperature	O
over	O
the	O
extratropical	O
NH	O
,	O
with	O
opposite	O
anomalous	O
centers	O
between	O
Asia	O
and	O
the	O
North	O
Pacific	O
,	O
was	O
proposed	O
as	O
the	O
Asian	O
-	O
Pacific	O
Oscillation	O
(	O
APO	O
)	O
19	O
.	O

A	O
higher	O
(	O
lower	O
)	O
APO	O
index	O
often	O
represents	O
a	O
stronger	O
(	O
weaker	O
)	O
thermal	O
contrast	O
between	O
the	O
Eurasian	O
continent	O
and	O
the	O
North	O
Pacific	O
Ocean	O
.	O

The	O
APO	O
index	O
also	O
sufficiently	O
represents	O
the	O
long	O
-	O
term	O
changes	O
in	O
the	O
EASM	O
rainfall	O
over	O
the	O
past	O
century20	O
and	O
millennium21222324	O
.	O

Climate	O
models	O
have	O
been	O
widely	O
used	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
mechanisms	O
of	O
Holocene	O
climate	O
changes	O
.	O

In	O
particular	O
,	O
the	O
first	O
,	O
second	O
and	O
third	O
phases	O
of	O
the	O
Paleoclimate	O
Modeling	O
Inter	O
-	O
comparison	O
Project	O
(	O
PMIP1	O
,	O
PIMP2	O
,	O
and	O
PIMP3	O
)	O
focused	O
on	O
the	O
Mid	O
-	O
Holocene	O
,	O
6	O
ka	O
before	O
the	O
present	O
(	O
ka	O
BP	O
).	O

Some	O
equilibrium	O
simulations	O
(	O
viz	O
.,	O
“	O
snapshot	O
”)	O
were	O
applied	O
to	O
compare	O
the	O
characteristics	O
and	O
mechanisms	O
of	O
climate	O
change	O
over	O
China	O
between	O
the	O
Mid	O
-	O
Holocene	O
and	O
the	O
present	O
,	O
in	O
which	O
the	O
concentration	O
of	O
atmospheric	O
CO2	O
was	O
held	O
at	O
280	O
ppm252627282930	O
.	O

Zhou	O
and	O
Zhao31	O
examined	O
the	O
APO	O
variation	O
and	O
associated	O
summer	O
precipitation	O
anomalies	O
using	O
the	O
CCSM3	O
simulation	O
in	O
PIMP2	O
.	O

Their	O
results	O
presented	O
a	O
pattern	O
of	O
northwest	O
-	O
southeast	O
inclination	O
in	O
the	O
Mid	O
-	O
Holocene	O
,	O
which	O
mainly	O
results	O
from	O
the	O
incoming	O
solar	O
radiation	O
differences	O
caused	O
by	O
changes	O
in	O
the	O
orbital	O
parameters	O
.	O

Moreover	O
,	O
to	O
understand	O
climatic	O
evolutions	O
over	O
the	O
entire	O
Holocene	O
period	O
,	O
some	O
transient	O
simulations	O
under	O
the	O
forcing	O
of	O
orbital	O
changes	O
were	O
also	O
performed	O
with	O
different	O
complexity	O
climate	O
models	O
and	O
accelerated	O
schemes323334353637383940	O
.	O

Although	O
climate	O
simulations	O
for	O
the	O
Holocene	O
have	O
made	O
great	O
progress	O
,	O
a	O
number	O
of	O
questions	O
remain	O
unanswered	O
.	O

For	O
example	O
,	O
how	O
do	O
large	O
-	O
scale	O
circulations	O
respond	O
to	O
the	O
NH	O
decreasing	O
incoming	O
solar	O
radiation	O
during	O
the	O
Holocene	O
summer	O
?	O

Does	O
this	O
response	O
cause	O
a	O
significant	O
difference	O
between	O
land	O
and	O
ocean	O
?	O

If	O
so	O
,	O
how	O
do	O
they	O
affect	O
the	O
EASM	O
hydrological	O
climate	O
?	O

What	O
are	O
the	O
evolving	O
characteristics	O
of	O
atmospheric	O
circulation	O
in	O
the	O
Holocene	O
?	O

With	O
these	O
questions	O
in	O
mind	O
,	O
we	O
use	O
an	O
intermediate	O
-	O
complexity	O
climate	O
model	O
to	O
perform	O
a	O
transient	O
simulation	O
with	O
an	O
acceleration	O
factor	O
of	O
10	O
years	O
,	O
under	O
the	O
orbital	O
changes	O
during	O
the	O
past	O
10	O
ka	O
BP	O
,	O
and	O
investigate	O
an	O
APO	O
-	O
like	O
large	O
-	O
scale	O
teleconnection	O
over	O
the	O
Asian	O
-	O
Pacific	O
sector	O
and	O
the	O
associated	O
rainfall	O
anomalies	O
over	O
eastern	O
China	O
.	O

Meanwhile	O
,	O
some	O
simulated	O
results	O
are	O
compared	O
with	O
the	O
proxy	O
data	O
.	O

The	O
remainder	O
of	O
this	O
paper	O
is	O
organized	O
as	O
follows	O
.	O

The	O
UVic	O
Model	O
,	O
data	O
,	O
and	O
methods	O
are	O
introduced	O
in	O
the	O
next	O
section	O
.	O

In	O
the	O
result	O
section	O
,	O
the	O
responses	O
of	O
large	O
-	O
scale	O
circulations	O
to	O
orbital	O
changes	O
are	O
analyzed	O
and	O
compared	O
with	O
proxies	O
;	O
and	O
the	O
EASM	O
circulation	O
and	O
hydrological	O
climate	O
evolutions	O
associated	O
with	O
the	O
APO	O
-	O
like	O
large	O
-	O
scale	O
teleconnection	O
during	O
the	O
Holocene	O
are	O
investigated	O
.	O

A	O
summary	O
and	O
a	O
further	O
discussion	O
are	O
provided	O
in	O
the	O
last	O
section	O
.	O

Model	O
,	O
Experiment	O
,	O
Forcing	O
,	O
Data	O
and	O
Methods	O

Model	O
and	O
transient	O
experiment	O

The	O
UVic	O
Model	O
(	O
version	O
2	O
.	O
9	O
)	O
developed	O
by	O
the	O
University	O
of	O
Victoria	O
,	O
Canada	O
couples	O
the	O
atmospheric	O
,	O
oceanic	O
,	O
sea	O
ice	O
,	O
and	O
land	O
surface	O
model	O
components	O
,	O
and	O
it	O
has	O
a	O
resolution	O
of	O
3	O
.	O
6	O
°	O
×	O
1	O
.	O
8	O
°	O
in	O
longitude	O
and	O
latitude	O
.	O

The	O
atmospheric	O
model	O
comprises	O
a	O
single	O
layer	O
(	O
that	O
is	O
,	O
a	O
vertically	O
integrated	O
energy	O
-	O
moisture	O
balance	O
model	O
).	O

The	O
ocean	O
component	O
comes	O
from	O
version	O
2	O
.	O
2	O
of	O
the	O
GFDL	O
Modular	O
Ocean	O
Model	O
,	O
with	O
19	O
-	O
vertical	O
levels	O
.	O

The	O
land	O
surface	O
model	O
employs	O
the	O
MOSES	O
(	O
Met	O
Office	O
Surface	O
Exchange	O
Scheme	O
)	O
model	O
.	O

The	O
UVic	O
Model	O
is	O
often	O
used	O
as	O
a	O
tool	O
for	O
understanding	O
the	O
physical	O
process	O
and	O
feedback	O
in	O
the	O
climate	O
system	O
on	O
long	O
timescales	O
,	O
and	O
is	O
widely	O
used	O
in	O
paleoclimate	O
,	O
present	O
climate	O
,	O
and	O
future	O
climate	O
studies4142434445	O
.	O

This	O
model	O
could	O
reasonably	O
reproduce	O
temperature	O
,	O
precipitation	O
,	O
and	O
ocean	O
circulation	O
,	O
with	O
relatively	O
small	O
errors	O
,	O
even	O
compared	O
with	O
the	O
coupled	O
General	O
Circulation	O
Model	O
(	O
GCM	O
)	O
42	O
.	O

However	O
,	O
the	O
internal	O
high	O
-	O
frequency	O
variations	O
of	O
almost	O
all	O
of	O
the	O
variables	O
on	O
interannual	O
and	O
interdecadal	O
timescales	O
in	O
the	O
UVic	O
Model	O
are	O
weaker	O
compared	O
with	O
those	O
of	O
the	O
complex	O
atmospheric	O
models46	O
.	O

Therefore	O
,	O
the	O
UVic	O
Model	O
is	O
mainly	O
used	O
to	O
investigate	O
the	O
climate	O
processes	O
and	O
feedback	O
on	O
long	O
timescales42	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
perform	O
five	O
experiments	O
with	O
different	O
initial	O
fields	O
to	O
test	O
the	O
uncertainty	O
of	O
the	O
model	O
results	O
.	O

An	O
ensemble	O
mean	O
of	O
variables	O
is	O
used	O
,	O
and	O
the	O
spreads	O
of	O
the	O
time	O
series	O
from	O
the	O
ensemble	O
mean	O
are	O
identified	O
.	O

Because	O
of	O
limited	O
computer	O
capabilities	O
,	O
simulations	O
with	O
acceleration	O
factors	O
between	O
10	O
and	O
100	O
have	O
been	O
applied	O
to	O
long	O
-	O
term	O
climate	O
studies	O
,	O
and	O
they	O
yield	O
similar	O
results47	O
.	O

In	O
the	O
present	O
study	O
,	O
following	O
Kutzbach	O
et	O
al	O
.	O
35	O
,	O
we	O
begin	O
with	O
orbital	O
parameters	O
at	O
10	O
ka	O
BP	O
,	O
and	O
they	O
are	O
advanced	O
by	O
10	O
years	O
at	O
the	O
end	O
of	O
each	O
model	O
year	O
(	O
that	O
is	O
,	O
with	O
an	O
acceleration	O
factor	O
of	O
10	O
).	O

The	O
UVic	O
model	O
is	O
spun	O
up	O
for	O
two	O
thousand	O
years	O
before	O
the	O
acceleration	O
and	O
is	O
then	O
integrated	O
for	O
1001	O
model	O
years	O
.	O

Sea	O
level	O
air	O
temperature	O
(	O
SLAT	O
),	O
sea	O
level	O
pressure	O
(	O
SLP	O
),	O
and	O
precipitation	O
are	O
used	O
to	O
analyze	O
the	O
climatic	O
variations	O
.	O

According	O
to	O
the	O
UVic	O
Model	O
,	O
we	O
calculate	O
SLP	O
from	O
the	O
output	O
of	O
SLAT	O
(	O
Ts	O
)	O
as	O
follows42	O
:	O


where	O
R	O
is	O
the	O
gas	O
constant	O
of	O
dry	O
air	O
(	O
287	O
J	O
kg	O
−	O
1	O
K	O
−	O
1	O
);	O
ρ	O
is	O
the	O
air	O
density	O
;	O
and	O
ρ	O
=	O
a	O
+	O
bTs	O
.	O

This	O
relationship	O
between	O
ρ	O
and	O
Ts	O
has	O
been	O
demonstrated	O
as	O
reasonable	O
by	O
the	O
atmospheric	O
reanalysis	O
data	O
of	O
both	O
the	O
National	O
Centers	O
for	O
Environmental	O
Prediction	O
-	O
National	O
Centers	O
for	O
Atmospheric	O
Research	O
(	O
NCEP	O
-	O
NCAR	O
)	O
and	O
the	O
European	O
Centre	O
for	O
Medium	O
-	O
range	O
Weather	O
Forecasts	O
(	O
ECMWF	O
)	O
42	O
.	O

In	O
this	O
study	O
,	O
we	O
calculate	O
a	O
and	O
b	O
using	O
the	O
air	O
temperature	O
and	O
SLP	O
of	O
the	O
1981	O
–	O
2010	O
NCEP	O
-	O
NCAR	O
reanalysis	O
.	O

Transient	O
Orbital	O
Forcing	O

Due	O
to	O
the	O
precession	O
effect	O
,	O
the	O
incoming	O
solar	O
radiation	O
is	O
redistributed	O
over	O
months	O
of	O
a	O
year	O
during	O
the	O
past	O
10	O
ka	O
.	O
Figure	O
1a	O
shows	O
the	O
month	O
-	O
year	O
cross	O
section	O
of	O
the	O
transient	O
incoming	O
solar	O
radiation	O
along	O
30	O
°	O
N	O
that	O
is	O
used	O
in	O
this	O
study4849	O
.	O

The	O
incoming	O
solar	O
radiation	O
exhibits	O
a	O
decreasing	O
trend	O
in	O
the	O
warm	O
season	O
(	O
May	O
-	O
August	O
),	O
with	O
a	O
maximum	O
variation	O
exceeding	O
32	O
.	O
5	O
W	O
·	O
m	O
−	O
2	O
,	O
an	O
increasing	O
trend	O
in	O
the	O
cold	O
season	O
(	O
October	O
-	O
March	O
),	O
with	O
a	O
maximum	O
variation	O
exceeding	O
27	O
.	O
5	O
W	O
·	O
m	O
−	O
2	O
,	O
and	O
an	O
increase	O
(	O
decrease	O
)	O
before	O
5	O
ka	O
and	O
a	O
subsequent	O
decrease	O
(	O
increase	O
)	O
in	O
September	O
(	O
April	O
).	O

The	O
summer	O
incoming	O
solar	O
radiation	O
from	O
June	O
to	O
August	O
along	O
the	O
30	O
°	O
N	O
(	O
Fig	O
.	O
1b	O
)	O
presents	O
an	O
obvious	O
declining	O
trend	O
,	O
ranging	O
from	O
491	O
to	O
462	O
W	O
·	O
m	O
−	O
2	O
during	O
the	O
Holocene	O
.	O

A	O
previous	O
study	O
indicated	O
that	O
the	O
application	O
of	O
different	O
calendars	O
in	O
the	O
paleoclimate	O
simulation	O
could	O
induce	O
artificial	O
phase	O
shifts	O
in	O
solar	O
insolation	O
forcing	O
and	O
climatic	O
responses50	O
.	O

Such	O
a	O
“	O
calendar	O
effect	O
”	O
in	O
each	O
month	O
due	O
to	O
the	O
precession	O
might	O
be	O
modified	O
by	O
the	O
fixed	O
angular	O
calendar	O
according	O
to	O
Chen	O
et	O
al	O
.	O
51	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
variation	O
in	O
summer	O
(	O
June	O
,	O
July	O
and	O
August	O
,	O
JJA	O
)	O
atmospheric	O
circulation	O
after	O
the	O
above	O
modification	O
.	O

Proxy	O
and	O
Reanalysis	O
Data	O

To	O
evaluate	O
the	O
simulated	O
SLAT	O
/	O
sea	O
surface	O
temperature	O
(	O
SST	O
)	O
over	O
the	O
Eurasian	O
continent	O
/	O
the	O
North	O
Pacific	O
(	O
a	O
key	O
region	O
of	O
SLAT	O
/	O
SST	O
anomalies	O
associated	O
with	O
orbital	O
forcing	O
),	O
we	O
employ	O
the	O
oxygen	O
isotope	O
record	O
from	O
the	O
Guliya	O
ice	O
cap	O
(	O
at	O
81	O
.	O
5	O
°	O
E	O
,	O
35	O
.	O
2	O
°	O
N	O
)	O
of	O
western	O
China525354	O
and	O
the	O
reconstructed	O
northern	O
California	O
SST	O
(	O
at	O
124	O
.	O
9	O
°	O
W	O
,	O
41	O
.	O
7	O
°	O
N	O
)	O
over	O
the	O
North	O
Pacific5556	O
,	O
which	O
have	O
the	O
ability	O
to	O
indicate	O
summer	O
conditions	O
.	O

Their	O
locations	O
are	O
shown	O
in	O
Fig	O
.	O
2b	O
.	O

The	O
Guliya	O
temperature	O
proxy	O
over	O
the	O
past	O
130	O
ka	O
,	O
drilled	O
from	O
the	O
Guliya	O
ice	O
cap	O
,	O
is	O
recorded	O
as	O
a	O
fluctuation	O
in	O
the	O
concentration	O
of	O
oxygen	O
18	O
(	O
δ18O	O
)	O
(	O
hereinafter	O
Guliya	O
δ18O	O
record	O
)	O
in	O
a	O
unit	O
of	O
Vienna	O
Pee	O
Dee	O
Belemnite	O
(	O
VPDB	O
).	O

The	O
monthly	O
concentration	O
of	O
δ18O	O
in	O
Guliya	O
is	O
shown	O
to	O
be	O
highly	O
related	O
to	O
the	O
local	O
monthly	O
surface	O
air	O
temperature57	O
.	O

Further	O
studies	O
disclosed	O
that	O
the	O
Guliya	O
δ18O	O
record	O
could	O
indicate	O
summer	O
temperatures	O
over	O
the	O
Tibetan	O
Plateau	O
during	O
the	O
past	O
130	O
ka4458	O
.	O

The	O
Northern	O
California	O
SST	O
was	O
reconstructed	O
from	O
the	O
alkenone	B-CD
in	O
the	O
Ocean	O
Drilling	O
Program	O
(	O
ODP	O
)	O
Site	O
1019	O
(	O
ODP	O
1019	O
),	O
with	O
a	O
water	O
depth	O
of	O
980	O
m55	O
.	O

Generally	O
speaking	O
,	O
the	O
alkenone	B-CD
SST	O
of	O
ODP	O
1019	O
represents	O
the	O
annual	O
mean	O
SST	O
.	O

Because	O
the	O
annual	O
mean	O
SST	O
over	O
the	O
region	O
110	O
°	O
W	O
–	O
120	O
°	O
W	O
,	O
35	O
°	O
N	O
–	O
45	O
°	O
N	O
in	O
the	O
present	O
-	O
day	O
climate	O
is	O
highly	O
related	O
to	O
the	O
local	O
June	O
–	O
July	O
SST	O
,	O
with	O
a	O
correlation	O
coefficient	O
of	O
0	O
.	O
82	O
during	O
1981	O
–	O
2010	O
(	O
exceeding	O
the	O
99	O
.	O
9	O
%	O
confidence	O
level	O
),	O
the	O
annual	O
mean	O
SST	O
over	O
the	O
eastern	O
North	O
Pacific	O
might	O
be	O
used	O
to	O
indicate	O
the	O
equivalent	O
variation	O
in	O
the	O
local	O
June	O
-	O
July	O
averaged	O
SST	O
.	O

Moreover	O
,	O
the	O
annual	O
mean	O
SST	O
is	O
correlated	O
with	O
the	O
summer	O
North	O
Pacific	O
mean	O
SLP	O
over	O
the	O
region	O
120	O
°	O
W	O
–	O
180	O
°,	O
15	O
–	O
60	O
°	O
N	O
,	O
with	O
a	O
correlation	O
coefficient	O
of	O
−	O
0	O
.	O
39	O
(	O
exceeding	O
the	O
95	O
%	O
confidence	O
level	O
).	O

This	O
correlation	O
is	O
higher	O
than	O
that	O
between	O
the	O
annual	O
mean	O
SST	O
and	O
the	O
winter	O
North	O
Pacific	O
SLP	O
(−	O
0	O
.	O
25	O
,	O
not	O
significant	O
at	O
the	O
95	O
%	O
confidence	O
level	O
),	O
which	O
suggests	O
that	O
the	O
annual	O
mean	O
SST	O
over	O
the	O
eastern	O
North	O
Pacific	O
could	O
better	O
indicate	O
the	O
summer	O
North	O
Pacific	O
SLP	O
instead	O
of	O
the	O
winter	O
one	O
.	O

Therefore	O
,	O
we	O
employ	O
the	O
alkenone	B-CD
SST	O
of	O
ODP	O
1019	O
to	O
indicate	O
the	O
summer	O
(	O
June	O
–	O
July	O
)	O
SST	O
.	O

The	O
ODP	O
sites	O
1014	O
and	O
1016	O
,	O
adjacent	O
to	O
the	O
ODP	O
1019	O
,	O
could	O
indicate	O
the	O
variation	O
of	O
SLP	O
over	O
the	O
North	O
Pacific	O
and	O
their	O
reconstructed	O
SSTs	O
show	O
a	O
similar	O
low	O
-	O
frequency	O
SST	O
variation59	O
.	O

It	O
is	O
concluded	O
that	O
the	O
ODP	O
1019	O
SST	O
may	O
also	O
represent	O
the	O
variability	O
in	O
the	O
North	O
Pacific	O
high	O
pressure	O
like	O
the	O
ODP	O
sites	O
1014	O
and	O
1016	O
SST	O
.	O

Due	O
to	O
a	O
low	O
resolution	O
of	O
the	O
reconstructed	O
SSTs	O
in	O
the	O
ODP	O
sites	O
1014	O
and	O
1016	O
during	O
the	O
Holocene	O
,	O
we	O
use	O
the	O
reconstructed	O
northern	O
California	O
SST	O
in	O
the	O
ODP	O
1019	O
for	O
evaluating	O
the	O
simulated	O
SST	O
over	O
the	O
North	O
Pacific	O
.	O

Furthermore	O
,	O
we	O
also	O
use	O
the	O
reconstructed	O
July	O
temperatures	O
with	O
high	O
temporal	O
resolutions	O
over	O
the	O
middle	O
-	O
west	O
part	O
of	O
North	O
America60	O
and	O
Western	O
Europe	O
(	O
68	O
°	O
22	O
′	O
N	O
,	O
18	O
°	O
42	O
′	O
E	O
)	O
61	O
(	O
shown	O
in	O
Fig	O
.	O

S1a	O
,	O
b	O
)	O
to	O
further	O
examine	O
the	O
capability	O
of	O
the	O
model	O
.	O

To	O
evaluate	O
the	O
variation	O
in	O
the	O
model	O
summer	O
precipitation	O
over	O
eastern	O
China	O
,	O
five	O
high	O
-	O
resolution	O
speleothem	O
δ18O	O
records	O
at	O
Dongge	O
Cave	O
(	O
108	O
.	O
08	O
°	O
E	O
,	O
25	O
.	O
28	O
°	O
N	O
)	O
61	O
,	O
Lianhua	O
Cave	O
(	O
109	O
.	O
53	O
°	O
E	O
,	O
29	O
.	O
48	O
°	O
N	O
)	O
6	O
,	O
Sanbao	O
Cave	O
(	O
110	O
.	O
43	O
°	O
E	O
,	O
31	O
.	O
67	O
°	O
N	O
)	O
7	O
,	O
Heshang	O
Cave	O
(	O
110	O
.	O
42	O
°	O
E	O
,	O
30	O
.	O
45	O
°	O
N	O
)	O
9	O
,	O
and	O
Jiuxian	O
Cave	O
(	O
109	O
.	O
1	O
°	O
E	O
,	O
30	O
.	O
57	O
°	O
N	O
)	O
5	O
,	O
released	O
on	O
a	O
website	O
from	O
the	O
World	O
Data	O
Center	O
for	O
Paleoclimatology	O
,	O
are	O
employed	O
to	O
compare	O
with	O
the	O
simulated	O
summer	O
precipitation	O
during	O
the	O
Holocene	O
.	O

These	O
records	O
were	O
derived	O
from	O
karst	O
caves	O
in	O
the	O
middle	O
reach	O
of	O
the	O
Yangtze	O
River	O
,	O
one	O
of	O
the	O
key	O
regions	O
of	O
EASM	O
where	O
the	O
Meiyu	O
rain	O
belt	O
appears	O
.	O

Previous	O
studies	O
have	O
argued	O
that	O
the	O
signal	O
of	O
the	O
oxygen	O
isotope	O
composition	O
(	O
δ18O	O
)	O
in	O
speleothem	O
represents	O
precipitation	O
variations63646566	O
.	O

Caley	O
et	O
al	O
.	O
67	O
proposed	O
that	O
the	O
speleothem	O
δ18O	O
in	O
South	O
Asia	O
represents	O
a	O
change	O
in	O
hydrology	O
.	O

Their	O
results	O
suggested	O
that	O
the	O
calcite	O
δ18O	O
signal	O
of	O
South	O
Asian	O
speleothem	O
is	O
mainly	O
,	O
but	O
not	O
entirely	O
,	O
controlled	O
by	O
δ18O	O
in	O
precipitation	O
changes	O
.	O

Furthermore	O
,	O
δ18O	O
in	O
precipitation	O
over	O
South	O
Asia	O
is	O
correlated	O
to	O
the	O
northern	O
tropical	O
Indian	O
Ocean	O
which	O
is	O
one	O
of	O
the	O
important	O
moisture	O
sources	O
of	O
East	O
Asian	O
monsoon	O
precipitation	O
.	O

Moreover	O
,	O
the	O
East	O
Asian	O
speleothem	O
δ18O	O
may	O
relate	O
to	O
the	O
ratio	O
of	O
moisture	O
from	O
the	O
Bay	O
of	O
Bengal	O
(	O
BOB	O
)	O
and	O
the	O
Northwest	O
Pacific68	O
.	O

In	O
a	O
modern	O
climate	O
,	O
precipitation	O
over	O
eastern	O
China	O
is	O
highly	O
correlated	O
with	O
moisture	O
over	O
the	O
BOB	O
and	O
the	O
Northwest	O
Pacific	O
;	O
that	O
is	O
,	O
a	O
change	O
of	O
δ18O	O
in	O
precipitation	O
is	O
the	O
most	O
important	O
factor	O
affecting	O
the	O
variation	O
of	O
the	O
speleothem	O
δ18O	O
records	O
in	O
eastern	O
China	O
.	O

Therefore	O
,	O
we	O
use	O
these	O
records	O
as	O
a	O
hydrologic	O
factor	O
and	O
compare	O
them	O
with	O
the	O
most	O
important	O
hydrological	O
factors	O
such	O
as	O
precipitation	O
.	O

Moreover	O
,	O
we	O
also	O
use	O
monthly	O
mean	O
air	O
temperature	O
and	O
SLP	O
of	O
the	O
NCEP	O
-	O
NCAR	O
reanalysis69	O
with	O
a	O
horizontal	O
resolution	O
of	O
2	O
.	O
5	O
°	O
and	O
the	O
monthly	O
Hadley	O
SST	O
with	O
1	O
°	O
in	O
both	O
longitude	O
and	O
latitude70	O
.	O

Statistical	O
Methods	O

Regression	O
and	O
correlation	O
analyses	O
are	O
used	O
to	O
investigate	O
the	O
relationship	O
between	O
two	O
variables	O
.	O

An	O
Empirical	O
Orthogonal	O
Function	O
(	O
EOF	O
)	O
analysis	O
with	O
area	O
-	O
weighting	O
is	O
employed	O
to	O
examine	O
the	O
leading	O
mode	O
of	O
the	O
eddy	O
SLP	O
.	O

A	O
composite	O
analysis	O
between	O
the	O
higher	O
and	O
lower	O
indices	O
is	O
used	O
to	O
analyze	O
variations	O
in	O
a	O
variable	O
.	O

The	O
confidence	O
tests	O
in	O
this	O
study	O
are	O
all	O
based	O
on	O
a	O
Student	O
’	O
s	O
t	O
-	O
test	O
.	O

Results	O

Response	O
of	O
eddy	O
SLP	O
over	O
the	O
Asian	O
-	O
Pacific	O
sector	O
to	O
incoming	O
solar	O
insolation	O

Figure	O
2a	O
shows	O
the	O
regressed	O
model	O
summer	O
eddy	O
SLP	O
()	O
against	O
the	O
incoming	O
solar	O
radiation	O
along	O
30	O
°	O
N	O
,	O
in	O
which	O
the	O
is	O
defined	O
as	O
the	O
difference	O
of	O
SLP	O
from	O
the	O
global	O
zonal	O
mean	O
.	O

The	O
anomaly	O
pattern	O
associated	O
with	O
incoming	O
solar	O
radiation	O
presents	O
a	O
zonal	O
dipole	O
,	O
with	O
positive	O
anomalies	O
over	O
Europe	O
,	O
Asia	O
and	O
North	O
Africa	O
and	O
negative	O
anomalies	O
over	O
the	O
North	O
Pacific	O
Ocean	O
and	O
North	O
America	O
,	O
which	O
indicate	O
a	O
large	O
-	O
scale	O
out	O
-	O
of	O
-	O
phase	O
relationship	O
between	O
Eurasia	O
and	O
the	O
extratropical	O
North	O
Pacific	O
.	O

The	O
maximum	O
positive	O
center	O
is	O
8	O
Pa	O
/	O
W	O
·	O
m	O
−	O
2	O
,	O
larger	O
compared	O
with	O
the	O
absolute	O
value	O
of	O
the	O
negative	O
center	O
(−	O
5	O
Pa	O
/	O
W	O
·	O
m	O
−	O
2	O
).	O

This	O
result	O
indicates	O
that	O
when	O
the	O
over	O
the	O
East	O
Hemisphere	O
landmass	O
is	O
higher	O
(	O
lower	O
),	O
it	O
is	O
lower	O
(	O
higher	O
)	O
over	O
the	O
North	O
Pacific	O
Ocean	O
and	O
the	O
North	O
America	O
landmass	O
.	O

Furthermore	O
,	O
the	O
decrease	O
in	O
the	O
incoming	O
solar	O
radiation	O
is	O
associated	O
with	O
both	O
a	O
decrease	O
of	O
the	O
over	O
Eurasia	O
and	O
North	O
Africa	O
and	O
an	O
increase	O
over	O
the	O
North	O
Pacific	O
and	O
North	O
America	O
,	O
which	O
corresponds	O
to	O
a	O
strong	O
thermal	O
contrast	O
between	O
the	O
Eurasian	O
-	O
North	O
African	O
region	O
and	O
the	O
North	O
Pacific	O
-	O
North	O
American	O
region	O
.	O

In	O
fact	O
,	O
the	O
out	O
-	O
of	O
-	O
phase	O
relationship	O
presented	O
in	O
Fig	O
.	O
2a	O
is	O
also	O
a	O
major	O
feature	O
of	O
variability	O
.	O

The	O
EOF	O
analysis	O
on	O
the	O
summer	O
eddy	O
SLP	O
shows	O
that	O
the	O
leading	O
EOF	O
mode	O
(	O
Fig	O
.	O
2b	O
)	O
of	O
the	O
eddy	O
SLP	O
,	O
accounting	O
for	O
98	O
.	O
2	O
%	O
of	O
the	O
total	O
variance	O
,	O
depicts	O
a	O
zonal	O
out	O
-	O
of	O
-	O
phase	O
structure	O
with	O
negative	O
anomalies	O
over	O
the	O
Eurasian	O
and	O
North	O
African	O
landmass	O
and	O
positive	O
anomalies	O
over	O
the	O
North	O
Pacific	O
,	O
similar	O
to	O
those	O
shown	O
in	O
Fig	O
.	O
2a	O
.	O

The	O
spatial	O
correlation	O
coefficient	O
between	O
the	O
regressed	O
field	O
(	O
in	O
Fig	O
.	O
2a	O
)	O
and	O
the	O
leading	O
EOF	O
mode	O
(	O
Fig	O
.	O
2b	O
)	O
is	O
0	O
.	O
99	O
(	O
significant	O
at	O
the	O
99	O
.	O
9	O
%	O
confidence	O
level	O
).	O

As	O
shown	O
in	O
Fig	O
.	O
2c	O
,	O
a	O
decreasing	O
trend	O
of	O
the	O
incoming	O
solar	O
radiation	O
is	O
corresponded	O
to	O
an	O
increasing	O
trend	O
in	O
the	O
PC1	O
.	O

This	O
result	O
indicates	O
that	O
the	O
summer	O
over	O
Eurasia	O
/	O
the	O
North	O
Pacific	O
and	O
North	O
America	O
decreases	O
/	O
increases	O
in	O
the	O
Holocene	O
,	O
which	O
may	O
lead	O
to	O
an	O
anomalous	O
zonal	O
contrast	O
of	O
the	O
between	O
the	O
Eurasian	O
landmass	O
and	O
the	O
North	O
Pacific	O
Ocean	O
.	O

Moreover	O
,	O
the	O
anomalous	O
pattern	O
of	O
the	O
during	O
the	O
Holocene	O
is	O
closely	O
associated	O
with	O
the	O
orbital	O
forcing	O
.	O

To	O
examine	O
the	O
reliability	O
of	O
the	O
simulation	O
,	O
referring	O
to	O
some	O
key	O
regions	O
of	O
the	O
anomalous	O
centers	O
in	O
Fig	O
.	O
2b	O
,	O
we	O
select	O
reconstructions	O
of	O
the	O
Guliya	O
record	O
and	O
the	O
northern	O
California	O
SST	O
at	O
the	O
ODP	O
1019	O
.	O

The	O
reconstructed	O
northern	O
California	O
SST	O
displays	O
a	O
low	O
frequent	O
variation	O
,	O
with	O
a	O
decreasing	O
trend	O
from	O
10	O
ka	O
to	O
6	O
.	O
4	O
ka	O
BP	O
and	O
an	O
increasing	O
trend	O
during	O
the	O
period	O
from	O
6	O
.	O
4	O
ka	O
BP	O
to	O
the	O
present	O
(	O
Fig	O
.	O
3a	O
).	O

A	O
high	O
frequent	O
variation	O
on	O
the	O
century	O
-	O
to	O
-	O
millennium	O
scales	O
is	O
superposed	O
over	O
this	O
low	O
frequent	O
variation	O
.	O

The	O
simulated	O
June	O
–	O
July	O
averaged	O
Northeast	O
Pacific	O
SST	O
also	O
indicates	O
a	O
decrease	O
during	O
the	O
epoch	O
10	O
–	O
5	O
ka	O
BP	O
and	O
then	O
an	O
increase	O
from	O
5	O
ka	O
BP	O
to	O
the	O
present	O
.	O

The	O
spread	O
of	O
the	O
ensemble	O
mean	O
June	O
–	O
July	O
Northeast	O
Pacific	O
SST	O
varies	O
within	O
small	O
fluctuation	O
,	O
approximately	O
from	O
0	O
.	O
05	O
in	O
the	O
early	O
Holocene	O
to	O
0	O
.	O
02	O
°	O
C	O
in	O
the	O
middle	O
and	O
late	O
Holocene	O
,	O
which	O
indicates	O
a	O
small	O
uncertainty	O
in	O
the	O
simulation	O
.	O

It	O
is	O
evident	O
that	O
the	O
simulated	O
and	O
reconstructed	O
SSTs	O
over	O
the	O
Northeast	O
Pacific	O
show	O
similar	O
lower	O
frequency	O
variations	O
during	O
the	O
Holocene	O
.	O
Figure	O
3b	O
displays	O
the	O
curves	O
of	O
the	O
simulated	O
summer	O
Guliya	O
SLAT	O
and	O
the	O
Guliya	O
δ18O	O
record	O
during	O
the	O
past	O
10	O
ka	O
.	O

The	O
Guliya	O
δ18O	O
record	O
,	O
indicating	O
a	O
summer	O
temperature	O
over	O
the	O
Tibetan	O
Plateau	O
,	O
presents	O
a	O
decrease	O
during	O
the	O
period	O
of	O
10	O
–	O
4	O
.	O
5	O
ka	O
BP	O
and	O
an	O
increase	O
from	O
4	O
.	O
5	O
ka	O
BP	O
to	O
the	O
present	O
.	O

The	O
simulated	O
summer	O
temperature	O
over	O
the	O
Guliya	O
region	O
also	O
shows	O
a	O
similar	O
lower	O
-	O
frequency	O
variation	O
,	O
with	O
a	O
decrease	O
during	O
10	O
–	O
4	O
.	O
5	O
ka	O
BP	O
and	O
an	O
increase	O
from	O
4	O
.	O
5	O
ka	O
BP	O
to	O
the	O
present	O
.	O

Uncertainties	O
in	O
the	O
ensemble	O
simulations	O
of	O
the	O
Guliya	O
temperature	O
show	O
little	O
spread	O
,	O
which	O
thereby	O
supports	O
a	O
more	O
stable	O
simulation	O
of	O
the	O
UVic	O
Model	O
.	O

Thus	O
,	O
the	O
simulated	O
Guliya	O
SLAT	O
reproduces	O
well	O
the	O
lower	O
-	O
frequency	O
variation	O
of	O
the	O
Guliya	O
δ18O	O
record	O
(	O
namely	O
,	O
the	O
summer	O
temperature	O
variation	O
over	O
the	O
Tibet	O
Plateau	O
).	O
Figure	O
S1	O
shows	O
the	O
simulated	O
and	O
reconstructed	O
July	O
temperatures	O
over	O
the	O
mid	O
-	O
western	O
part	O
of	O
the	O
United	O
States	O
and	O
Western	O
Europe	O
.	O

The	O
simulated	O
July	O
SLAT	O
over	O
the	O
mid	O
-	O
western	O
part	O
of	O
the	O
United	O
States	O
presents	O
a	O
declining	O
trend	O
during	O
the	O
Holocene	O
,	O
which	O
also	O
appears	O
in	O
the	O
reconstructed	O
time	O
series	O
(	O
Fig	O
.	O

S1a	O
).	O

Meanwhile	O
,	O
the	O
July	O
temperature	O
variation	O
over	O
the	O
mid	O
-	O
western	O
part	O
of	O
the	O
United	O
States	O
is	O
similar	O
to	O
that	O
of	O
the	O
North	O
Pacific	O
center	O
of	O
the	O
paleo	O
-	O
APO	O
pattern	O
.	O

Moreover	O
,	O
the	O
reconstructed	O
July	O
temperature	O
over	O
Western	O
Europe	O
also	O
supports	O
the	O
model	O
simulation	O
on	O
the	O
long	O
-	O
time	O
scales	O
(	O
Fig	O
.	O

S1b	O
).	O

The	O
consistency	O
suggests	O
the	O
reliability	O
of	O
the	O
simulated	O
results	O
over	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
differences	O
in	O
SLP	O
between	O
Asia	O
and	O
the	O
North	O
Pacific	O
may	O
be	O
used	O
to	O
indicate	O
the	O
contrasts	O
in	O
surface	O
air	O
temperature	O
between	O
these	O
two	O
regions15161718	O
.	O

In	O
fact	O
,	O
the	O
anomalous	O
patterns	O
shown	O
in	O
both	O
Fig	O
.	O
2a	O
,	O
b	O
are	O
similar	O
to	O
the	O
eddy	O
SLP	O
anomalies	O
associated	O
with	O
APO	O
in	O
the	O
present	O
-	O
day	O
climate	O
(	O
during	O
1948	O
–	O
2014	O
),	O
in	O
which	O
the	O
APO	O
is	O
a	O
leading	O
mode	O
of	O
the	O
tropospheric	O
eddy	O
temperature	O
and	O
its	O
index	O
is	O
defined	O
as	O
the	O
reference19	O
.	O

In	O
the	O
present	O
day	O
(	O
Fig	O
.	O
4	O
),	O
negative	O
/	O
positive	O
anomalies	O
of	O
SLP	O
appear	O
over	O
North	O
Africa	O
and	O
Asia	O
/	O
the	O
North	O
Pacific	O
and	O
North	O
America	O
,	O
which	O
indicate	O
weaker	O
than	O
normal	O
Asian	O
landmass	O
low	O
pressure	O
and	O
stronger	O
than	O
normal	O
North	O
Pacific	O
high	O
pressure	O
.	O

Therefore	O
,	O
the	O
anomalous	O
pattern	O
of	O
SLP	O
in	O
the	O
UVic	O
Model	O
(	O
shown	O
in	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
is	O
called	O
the	O
paleo	O
-	O
APO	O
pattern	O
.	O

Referring	O
to	O
the	O
positions	O
of	O
positive	O
and	O
negative	O
SLP	O
anomalies	O
in	O
Fig	O
.	O
2a	O
,	O
b	O
,	O
we	O
define	O
the	O
paleo	O
-	O
APO	O
index	O
as	O
a	O
difference	O
in	O
the	O
simulated	O
normalized	O
between	O
the	O
North	O
Pacific	O
(	O
150	O
°	O
E	O
–	O
110	O
°	O
W	O
,	O
15	O
°–	O
60	O
°	O
N	O
)	O
and	O
the	O
Eurasian	O
landmass	O
(	O
10	O
°–	O
110	O
°	O
E	O
,	O
15	O
°–	O
60	O
°	O
N	O
).	O

The	O
summer	O
paleo	O
-	O
APO	O
index	O
shows	O
an	O
increasing	O
trend	O
,	O
similar	O
to	O
the	O
variability	O
of	O
PC1	O
(	O
Fig	O
.	O
5a	O
).	O

This	O
result	O
suggests	O
that	O
the	O
paleo	O
-	O
APO	O
index	O
may	O
reasonably	O
indicate	O
a	O
variation	O
in	O
the	O
leading	O
mode	O
of	O
the	O
eddy	O
SLP	O
.	O

Meanwhile	O
,	O
the	O
summer	O
solar	O
radiation	O
insolation	O
along	O
30	O
°	O
N	O
(	O
Fig	O
.	O
1b	O
)	O
changes	O
from	O
the	O
top	O
to	O
the	O
valley	O
.	O

Thus	O
,	O
when	O
the	O
NH	O
summer	O
incoming	O
solar	O
radiation	O
decreases	O
during	O
the	O
Holocene	O
,	O
the	O
surface	O
thermal	O
contrast	O
between	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
increases	O
.	O

Figure	O
5b	O
shows	O
the	O
climatological	O
anomalies	O
of	O
the	O
over	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
during	O
the	O
summer	O
.	O

The	O
Eurasian	O
varies	O
from	O
−	O
0	O
.	O
5	O
hPa	O
to	O
0	O
.	O
75	O
hPa	O
and	O
the	O
North	O
Pacific	O
changes	O
from	O
0	O
.	O
6	O
hPa	O
to	O
−	O
1	O
hPa	O
,	O
which	O
indicates	O
a	O
larger	O
varying	O
range	O
over	O
Eurasia	O
(	O
1	O
.	O
6	O
hPa	O
)	O
than	O
over	O
the	O
North	O
Pacific	O
(	O
1	O
.	O
25	O
hPa	O
)	O
and	O
also	O
suggests	O
a	O
larger	O
response	O
of	O
the	O
eddy	O
SLP	O
over	O
Eurasia	O
compared	O
with	O
that	O
over	O
the	O
North	O
Pacific	O
.	O

Meanwhile	O
,	O
the	O
shows	O
a	O
decreasing	O
trend	O
over	O
Eurasia	O
and	O
an	O
increasing	O
trend	O
over	O
the	O
North	O
Pacific	O
during	O
the	O
Holocene	O
,	O
which	O
also	O
leads	O
to	O
an	O
increased	O
trend	O
of	O
the	O
paleo	O
-	O
APO	O
index	O
during	O
the	O
Holocene	O
.	O

Compared	O
to	O
the	O
North	O
Pacific	O
,	O
therefore	O
,	O
the	O
land	O
response	O
to	O
the	O
orbital	O
forcing	O
possibly	O
plays	O
a	O
more	O
important	O
role	O
in	O
modulating	O
the	O
zonal	O
thermal	O
contrast	O
between	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
.	O

Figure	O
6a	O
depicts	O
the	O
composite	O
summer	O
model	O
SLP	O
in	O
the	O
higher	O
and	O
lower	O
paleo	O
-	O
APO	O
indices	O
.	O

The	O
North	O
Pacific	O
high	O
pressure	O
has	O
the	O
central	O
values	O
of	O
1020	O
hPa	O
in	O
the	O
higher	O
and	O
lower	O
paleo	O
-	O
APO	O
years	O
,	O
but	O
exhibits	O
a	O
larger	O
domain	O
in	O
the	O
higher	O
paleo	O
-	O
APO	O
years	O
than	O
in	O
the	O
lower	O
paleo	O
-	O
APO	O
years	O
,	O
which	O
suggests	O
a	O
stronger	O
North	O
Pacific	O
high	O
pressure	O
in	O
the	O
higher	O
paleo	O
-	O
APO	O
phase	O
.	O

The	O
western	O
boundary	O
of	O
the	O
North	O
Pacific	O
high	O
pressure	O
in	O
the	O
higher	O
paleo	O
-	O
APO	O
phase	O
moves	O
westward	O
along	O
115	O
°	O
E	O
compared	O
with	O
the	O
lower	O
paleo	O
-	O
APO	O
phase	O
.	O

That	O
is	O
,	O
the	O
increasing	O
(	O
decreasing	O
)	O
trend	O
of	O
the	O
over	O
the	O
North	O
Pacific	O
(	O
Eurasia	O
)	O
implies	O
a	O
stronger	O
and	O
more	O
westward	O
high	O
pressure	O
over	O
the	O
North	O
Pacific	O
.	O

The	O
analyses	O
presented	O
here	O
show	O
that	O
the	O
response	O
of	O
the	O
eddy	O
SLP	O
to	O
orbital	O
forcing	O
displays	O
an	O
APO	O
-	O
like	O
pattern	O
,	O
with	O
positive	O
and	O
negative	O
anomalies	O
of	O
the	O
in	O
the	O
North	O
Pacific	O
and	O
Eurasia	O
,	O
respectively	O
.	O

Corresponding	O
to	O
the	O
NH	O
’	O
s	O
summer	O
reduced	O
incoming	O
solar	O
radiation	O
during	O
the	O
Holocene	O
,	O
the	O
paleo	O
-	O
APO	O
index	O
shows	O
an	O
increasing	O
trend	O
.	O

The	O
response	O
of	O
the	O
Eurasian	O
landmass	O
plays	O
a	O
more	O
important	O
role	O
due	O
to	O
a	O
(	O
an	O
)	O
decreasing	O
(	O
increasing	O
)	O
trend	O
of	O
the	O
over	O
Eurasia	O
(	O
the	O
North	O
Pacific	O
).	O

Meanwhile	O
,	O
the	O
increasing	O
trend	O
of	O
the	O
over	O
the	O
North	O
Pacific	O
indicates	O
a	O
stronger	O
and	O
more	O
westward	O
high	O
pressure	O
over	O
the	O
North	O
Pacific	O
.	O

Summer	O
hydrology	O
anomalies	O
over	O
eastern	O
China	O
associated	O
with	O
the	O
paleo	O
-	O
APO	O
at	O
the	O
precession	O

Many	O
studies	O
on	O
the	O
present	O
-	O
day	O
climate	O
have	O
shown	O
that	O
the	O
thermal	O
contrasts	O
between	O
the	O
East	O
Asian	O
landmass	O
and	O
its	O
adjacent	O
oceans	O
exerts	O
a	O
strong	O
influence	O
on	O
the	O
hydrological	O
climate	O
in	O
the	O
EASM	O
region	O
and	O
that	O
a	O
strong	O
and	O
westward	O
high	O
pressure	O
over	O
the	O
North	O
Pacific	O
could	O
strengthen	O
the	O
northward	O
transport	O
of	O
water	O
vapor	O
over	O
the	O
EASM	O
region	O
,	O
with	O
more	O
rainfall	O
over	O
North	O
China	O
and	O
less	O
rainfall	O
over	O
the	O
Yangtze	O
River	O
valleys315197172	O
.	O

When	O
the	O
paleo	O
-	O
APO	O
index	O
is	O
high	O
,	O
the	O
domain	O
(	O
central	O
intensity	O
)	O
of	O
the	O
North	O
Pacific	O
high	O
pressure	O
is	O
larger	O
(	O
stronger	O
)	O
compared	O
with	O
that	O
in	O
the	O
low	O
paleo	O
-	O
APO	O
index	O
,	O
and	O
the	O
western	O
part	O
of	O
the	O
North	O
Pacific	O
high	O
pressure	O
moves	O
westward	O
(	O
Fig	O
.	O
6a	O
).	O

This	O
variation	O
in	O
the	O
North	O
Pacific	O
high	O
pressure	O
favors	O
transport	O
of	O
water	O
moisture	O
toward	O
northern	O
China73	O
.	O

As	O
a	O
result	O
,	O
precipitation	O
is	O
often	O
less	O
over	O
the	O
Yangtze	O
River	O
.	O

At	O
the	O
precession	O
,	O
the	O
variability	O
of	O
thermal	O
contrasts	O
indicated	O
by	O
the	O
paleo	O
-	O
APO	O
index	O
is	O
also	O
associated	O
with	O
precipitation	O
over	O
eastern	O
China	O
.	O
Figure	O
6b	O
shows	O
the	O
summer	O
rainfall	O
anomalies	O
over	O
eastern	O
China	O
that	O
are	O
associated	O
with	O
the	O
paleo	O
-	O
APO	O
index	O
.	O

In	O
this	O
figure	O
,	O
the	O
rainfall	O
anomalies	O
present	O
a	O
meridional	O
“	O
positive	O
-	O
negative	O
-	O
positive	O
”	O
anomalous	O
pattern	O
,	O
with	O
negative	O
anomalies	O
along	O
the	O
Yangtze	O
River	O
and	O
over	O
Southwest	O
China	O
and	O
positive	O
rainfall	O
anomalies	O
over	O
North	O
China	O
.	O

This	O
anomalous	O
pattern	O
is	O
also	O
a	O
major	O
feature	O
of	O
the	O
leading	O
EOF	O
mode	O
of	O
summer	O
rainfall	O
over	O
eastern	O
China	O
during	O
the	O
Holocene	O
(	O
not	O
shown	O
).	O

Recent	O
studies	O
have	O
suggested	O
that	O
the	O
speleothem	O
δ18O	O
records	O
in	O
eastern	O
China	O
represent	O
the	O
changes	O
in	O
the	O
hydrological	O
climate	O
and	O
are	O
mainly	O
a	O
result	O
of	O
the	O
δ18O	O
changes	O
in	O
precipitation	O
.	O

Hence	O
,	O
we	O
compare	O
the	O
simulated	O
rainfall	O
with	O
five	O
speleothem	O
δ18O	O
records	O
over	O
Southwest	O
China	O
and	O
the	O
middle	O
valley	O
of	O
the	O
Yangtze	O
River	O
(	O
100	O
°–	O
112	O
°	O
E	O
,	O
22	O
°–	O
32	O
°	O
N	O
),	O
one	O
key	O
region	O
of	O
the	O
EASM	O
precipitation	O
and	O
an	O
important	O
path	O
of	O
moisture	O
transport	O
from	O
the	O
Indian	O
Ocean	O
(	O
Fig	O
.	O
7	O
).	O

The	O
speleothem	O
δ18O	O
record	O
at	O
Dongge	O
Cave	O
(	O
Fig	O
.	O
7a	O
)	O
has	O
generally	O
shown	O
a	O
decreasing	O
trend	O
before	O
a	O
slight	O
increase	O
trend	O
since	O
3	O
.	O
5	O
ka	O
BP	O
,	O
which	O
indicates	O
the	O
declining	O
precipitation	O
and	O
the	O
obvious	O
decadal	O
-	O
and	O
century	O
-	O
scale	O
fluctuations	O
.	O

Similarly	O
,	O
the	O
speleothem	O
δ18O	O
records	O
at	O
Lianhua	O
Cave	O
(	O
Fig	O
.	O
7b	O
),	O
Sanbao	O
Cave	O
(	O
Fig	O
.	O
7c	O
),	O
Heshang	O
Cave	O
(	O
Fig	O
.	O
7d	O
),	O
and	O
Jiuxian	O
Cave	O
(	O
Fig	O
.	O
7e	O
)	O
also	O
exhibit	O
a	O
downward	O
trend	O
during	O
the	O
Holocene	O
.	O

The	O
simulated	O
summer	O
precipitation	O
similarly	O
presents	O
a	O
decreasing	O
trend	O
before	O
4	O
ka	O
and	O
an	O
increasing	O
trend	O
afterwards	O
,	O
indicating	O
wetter	O
conditions	O
in	O
the	O
lower	O
paleo	O
-	O
APO	O
years	O
and	O
drier	O
conditions	O
in	O
the	O
higher	O
paleo	O
-	O
APO	O
years	O
,	O
similar	O
to	O
the	O
variation	O
in	O
the	O
speleothem	O
δ18O	O
records	O
.	O

This	O
result	O
further	O
supports	O
the	O
reliability	O
of	O
the	O
simulation	O
.	O

Atmospheric	O
circulation	O
anomalies	O
associated	O
with	O
the	O
paleo	O
-	O
APO	O
evolution	O

In	O
this	O
analysis	O
,	O
we	O
use	O
transient	O
simulation	O
to	O
examine	O
the	O
evolution	O
of	O
the	O
paleo	O
-	O
APO	O
and	O
associated	O
atmospheric	O
circulation	O
and	O
precipitation	O
.	O

It	O
is	O
seen	O
in	O
Fig	O
.	O
5a	O
that	O
the	O
paleo	O
-	O
APO	O
index	O
exhibits	O
an	O
increasing	O
trend	O
in	O
approximately	O
half	O
of	O
the	O
precession	O
period	O
.	O

According	O
to	O
the	O
paleo	O
-	O
APO	O
index	O
,	O
we	O
chose	O
9	O
.	O
0	O
,	O
6	O
.	O
5	O
,	O
4	O
.	O
8	O
,	O
2	O
.	O
5	O
,	O
and	O
0	O
ka	O
BP	O
to	O
analyze	O
the	O
evolution	O
of	O
atmospheric	O
circulation	O
.	O
Figure	O
8	O
shows	O
the	O
summer	O
eddy	O
SLP	O
anomalies	O
(	O
from	O
the	O
climatological	O
mean	O
)	O
at	O
9	O
.	O
0	O
,	O
6	O
.	O
5	O
,	O
4	O
.	O
8	O
,	O
2	O
.	O
5	O
and	O
0	O
ka	O
BP	O
.	O

At	O
9	O
ka	O
BP	O
(	O
Fig	O
.	O
8a	O
),	O
there	O
are	O
negative	O
SLP	O
anomalies	O
over	O
the	O
North	O
Pacific	O
,	O
with	O
a	O
maximum	O
negative	O
value	O
of	O
−	O
0	O
.	O
8	O
hPa	O
,	O
and	O
there	O
are	O
positive	O
SLP	O
anomalies	O
over	O
Eurasia	O
,	O
with	O
a	O
maximum	O
value	O
of	O
1	O
.	O
5	O
hPa	O
.	O

These	O
features	O
suggest	O
a	O
stronger	O
negative	O
phase	O
of	O
the	O
paleo	O
-	O
APO	O
.	O

At	O
6	O
.	O
5	O
ka	O
BP	O
(	O
Fig	O
.	O
8b	O
),	O
the	O
eddy	O
SLP	O
anomalies	O
depict	O
a	O
similar	O
pattern	O
to	O
that	O
at	O
9	O
ka	O
BP	O
,	O
with	O
relatively	O
lower	O
SLP	O
anomalies	O
over	O
both	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
,	O
indicating	O
a	O
moderate	O
negative	O
phase	O
of	O
the	O
paleo	O
-	O
APO	O
.	O

At	O
4	O
.	O
8	O
ka	O
BP	O
(	O
Fig	O
.	O
8c	O
),	O
small	O
positive	O
eddy	O
anomalies	O
move	O
from	O
Eurasia	O
to	O
West	O
Europe	O
,	O
North	O
Africa	O
,	O
North	O
America	O
,	O
and	O
the	O
tropical	O
eastern	O
Pacific	O
,	O
whereas	O
the	O
other	O
regions	O
are	O
covered	O
by	O
small	O
negative	O
anomalies	O
.	O

This	O
distribution	O
of	O
the	O
eddy	O
SLP	O
anomalies	O
suggests	O
a	O
very	O
weak	O
paleo	O
-	O
APO	O
phase	O
at	O
4	O
.	O
8	O
ka	O
BP	O
.	O

The	O
eddy	O
SLP	O
anomalies	O
indicate	O
a	O
moderate	O
positive	O
phase	O
of	O
the	O
paleo	O
-	O
APO	O
at	O
2	O
.	O
5	O
ka	O
BP	O
(	O
Fig	O
.	O
8d	O
),	O
which	O
is	O
opposite	O
to	O
the	O
value	O
at	O
6	O
.	O
5	O
ka	O
BP	O
.	O

At	O
the	O
present	O
day	O
(	O
Fig	O
.	O
8e	O
),	O
the	O
paleo	O
-	O
APO	O
further	O
intensifies	O
,	O
with	O
larger	O
anomalies	O
over	O
the	O
North	O
Pacific	O
-	O
North	O
Atlantic	O
region	O
and	O
Eurasia	O
.	O

Thus	O
,	O
the	O
paleo	O
-	O
APO	O
changes	O
from	O
a	O
negative	O
phase	O
to	O
a	O
positive	O
one	O
during	O
the	O
Holocene	O
.	O

Figure	O
9	O
shows	O
the	O
evolution	O
of	O
the	O
eddy	O
SLP	O
anomalies	O
along	O
30	O
°	O
N	O
during	O
the	O
Holocene	O
.	O

There	O
is	O
an	O
anomalous	O
SLP	O
center	O
at	O
the	O
longitudes	O
30	O
°	O
W	O
–	O
120	O
°	O
E	O
during	O
10	O
–	O
5	O
.	O
5	O
ka	O
,	O
with	O
a	O
maximum	O
positive	O
value	O
of	O
1	O
hPa	O
along	O
50	O
°	O
E	O
at	O
9	O
ka	O
BP	O
.	O

As	O
time	O
goes	O
on	O
,	O
the	O
positive	O
anomalies	O
of	O
the	O
eddy	O
SLP	O
decrease	O
and	O
turn	O
to	O
the	O
negative	O
ones	O
after	O
5	O
.	O
5	O
ka	O
BP	O
.	O

The	O
strongest	O
negative	O
anomalies	O
appear	O
along	O
40	O
°	O
E	O
at	O
the	O
present	O
day	O
.	O

Over	O
the	O
North	O
African	O
and	O
Asian	O
landmasses	O
along	O
30	O
°	O
N	O
,	O
the	O
anomalous	O
SLP	O
center	O
moves	O
slightly	O
westward	O
during	O
the	O
Holocene	O
.	O

During	O
the	O
period	O
10	O
–	O
5	O
ka	O
,	O
negative	O
SLP	O
anomalies	O
appears	O
over	O
the	O
longitudes	O
120	O
°	O
E	O
–	O
30	O
°	O
W	O
,	O
with	O
a	O
center	O
of	O
−	O
0	O
.	O
6	O
hPa	O
along	O
140	O
°	O
W	O
–	O
180	O
°	O
and	O
a	O
relatively	O
weak	O
center	O
along	O
60	O
°	O
W	O
.	O

Similarly	O
,	O
the	O
negative	O
SLP	O
anomalies	O
decrease	O
,	O
turn	O
to	O
positive	O
values	O
,	O
and	O
reach	O
the	O
present	O
-	O
day	O
largest	O
values	O
.	O

The	O
negative	O
center	O
at	O
150	O
°	O
W	O
at	O
10	O
ka	O
BP	O
turns	O
to	O
a	O
positive	O
one	O
at	O
170	O
°	O
E	O
at	O
the	O
present	O
day	O
,	O
which	O
suggests	O
a	O
westward	O
shift	O
of	O
SLP	O
anomalies	O
over	O
the	O
North	O
Pacific	O
.	O

However	O
,	O
no	O
obvious	O
shift	O
in	O
SLP	O
anomalies	O
is	O
seen	O
over	O
the	O
North	O
Atlantic	O
during	O
the	O
Holocene	O
.	O

We	O
also	O
display	O
the	O
time	O
-	O
latitude	O
cross	O
section	O
of	O
summer	O
mean	O
precipitation	O
anomalies	O
(	O
from	O
the	O
climatological	O
mean	O
)	O
over	O
eastern	O
China	O
along	O
110	O
°	O
E	O
(	O
Fig	O
.	O
10	O
).	O

At	O
10	O
ka	O
BP	O
,	O
there	O
is	O
a	O
meridional	O
dipole	O
pattern	O
of	O
rainfall	O
anomalies	O
,	O
with	O
positive	O
anomalies	O
south	O
of	O
36	O
°	O
N	O
and	O
negative	O
anomalies	O
at	O
higher	O
latitudes	O
.	O

Afterwards	O
,	O
the	O
positive	O
and	O
negative	O
anomalies	O
gradually	O
weaken	O
and	O
turn	O
to	O
negative	O
and	O
positive	O
values	O
,	O
respectively	O
,	O
in	O
which	O
negative	O
rainfall	O
anomalies	O
from	O
southern	O
China	O
show	O
a	O
northward	O
propagation	O
to	O
36	O
°	O
N	O
.	O

An	O
opposite	O
dipole	O
appears	O
between	O
5	O
.	O
5	O
ka	O
BP	O
and	O
2	O
.	O
5	O
ka	O
BP	O
.	O

After	O
that	O
,	O
a	O
triple	O
pattern	O
appears	O
over	O
eastern	O
China	O
,	O
with	O
positive	O
precipitation	O
anomalies	O
south	O
of	O
30	O
°	O
N	O
and	O
north	O
of	O
36	O
°	O
N	O
and	O
negative	O
precipitation	O
anomalies	O
near	O
the	O
Yangtze	O
River	O
.	O

These	O
results	O
indicate	O
that	O
when	O
the	O
paleo	O
-	O
APO	O
pattern	O
moves	O
from	O
a	O
negative	O
phase	O
to	O
a	O
positive	O
one	O
during	O
the	O
Holocene	O
,	O
the	O
rainfall	O
belt	O
exhibits	O
a	O
northward	O
propagation	O
from	O
southern	O
China	O
.	O

Summary	O
and	O
Discussion	O

We	O
employed	O
the	O
intermediate	O
-	O
complexity	O
UVic	O
Model	O
to	O
investigate	O
the	O
response	O
of	O
summer	O
large	O
-	O
scale	O
circulation	O
over	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
and	O
the	O
associated	O
precipitation	O
anomalies	O
over	O
eastern	O
China	O
to	O
the	O
transient	O
orbit	O
forcing	O
during	O
the	O
Holocene	O
.	O

A	O
decrease	O
in	O
the	O
NH	O
summer	O
incoming	O
solar	O
radiation	O
is	O
corresponded	O
to	O
an	O
out	O
-	O
of	O
-	O
phase	O
relationship	O
of	O
the	O
summer	O
eddy	O
SLP	O
over	O
the	O
Asian	O
-	O
Pacific	O
region	O
,	O
with	O
positive	O
anomalies	O
over	O
the	O
Asia	O
-	O
Europe	O
-	O
African	O
continent	O
and	O
negative	O
anomalies	O
over	O
the	O
North	O
Pacific	O
and	O
North	O
America	O
,	O
which	O
reflect	O
the	O
leading	O
mode	O
of	O
the	O
eddy	O
SLP	O
during	O
the	O
Holocene	O
.	O

This	O
anomalous	O
pattern	O
is	O
similar	O
to	O
that	O
associated	O
with	O
the	O
present	O
-	O
day	O
APO	O
,	O
called	O
the	O
paleo	O
-	O
APO	O
.	O

The	O
paleo	O
-	O
APO	O
index	O
exhibits	O
an	O
upward	O
trend	O
during	O
the	O
Holocene	O
,	O
which	O
indicates	O
an	O
increase	O
in	O
the	O
zonal	O
thermal	O
contrast	O
between	O
the	O
North	O
Pacific	O
and	O
Eurasia	O
.	O

Such	O
a	O
trend	O
is	O
possibly	O
due	O
to	O
a	O
decrease	O
in	O
the	O
over	O
the	O
Eurasian	O
landmass	O
and	O
an	O
increase	O
in	O
the	O
over	O
the	O
North	O
Pacific	O
,	O
and	O
there	O
is	O
a	O
larger	O
varying	O
range	O
over	O
Eurasia	O
than	O
over	O
the	O
North	O
Pacific	O
.	O

This	O
result	O
suggests	O
that	O
the	O
response	O
of	O
atmospheric	O
circulation	O
over	O
the	O
Eurasian	O
landmass	O
to	O
orbital	O
forcing	O
is	O
larger	O
than	O
that	O
over	O
the	O
North	O
Pacific	O
,	O
possibly	O
playing	O
a	O
more	O
important	O
role	O
in	O
modulating	O
the	O
zonal	O
thermal	O
contrast	O
between	O
Eurasia	O
and	O
the	O
North	O
Pacific	O
.	O

A	O
higher	O
paleo	O
-	O
APO	O
index	O
during	O
the	O
Holocene	O
is	O
corresponded	O
to	O
a	O
stronger	O
high	O
-	O
pressure	O
system	O
over	O
the	O
North	O
Pacific	O
that	O
moves	O
more	O
westward	O
,	O
which	O
favors	O
the	O
northward	O
transport	O
of	O
water	O
vapor	O
toward	O
northern	O
China	O
.	O

Accordingly	O
,	O
there	O
is	O
more	O
precipitation	O
over	O
northern	O
China	O
and	O
less	O
rainfall	O
over	O
the	O
middle	O
and	O
lower	O
reaches	O
of	O
the	O
Yangtze	O
River	O
during	O
the	O
summer	O
.	O

This	O
decrease	O
in	O
the	O
simulated	O
precipitation	O
over	O
the	O
middle	O
and	O
lower	O
reaches	O
of	O
the	O
Yangtze	O
River	O
is	O
supported	O
by	O
the	O
local	O
speleothem	O
proxy	O
data	O
during	O
the	O
Holocene	O
.	O

The	O
paleo	O
-	O
APO	O
experiences	O
a	O
half	O
-	O
precession	O
cycle	O
during	O
the	O
Holocene	O
.	O

During	O
the	O
early	O
Holocene	O
,	O
the	O
paleo	O
-	O
APO	O
pattern	O
presents	O
a	O
negative	O
phase	O
with	O
positive	O
SLP	O
anomalies	O
over	O
the	O
Eurasian	O
landmass	O
and	O
negative	O
SLP	O
anomalies	O
over	O
the	O
North	O
Pacific	O
.	O

These	O
positive	O
(	O
negative	O
)	O
anomalies	O
over	O
the	O
Eurasian	O
landmass	O
(	O
North	O
Pacific	O
and	O
North	O
Atlantic	O
)	O
decrease	O
and	O
turn	O
into	O
negative	O
(	O
positive	O
)	O
anomalies	O
,	O
which	O
indicate	O
a	O
change	O
in	O
the	O
paleo	O
-	O
APO	O
pattern	O
from	O
a	O
negative	O
phase	O
to	O
a	O
positive	O
one	O
.	O

The	O
negative	O
centers	O
over	O
the	O
North	O
Africa	O
-	O
Asian	O
region	O
and	O
the	O
North	O
Pacific	O
move	O
westward	O
.	O

Meanwhile	O
,	O
the	O
rainfall	O
belt	O
exhibits	O
a	O
northward	O
propagation	O
from	O
southern	O
China	O
,	O
and	O
a	O
meridional	O
dipole	O
pattern	O
of	O
rainfall	O
anomalies	O
during	O
the	O
early	O
Holocene	O
gradually	O
turns	O
into	O
the	O
present	O
-	O
day	O
triple	O
pattern	O
.	O

Zhou74	O
evaluated	O
the	O
performance	O
of	O
33	O
models	O
of	O
the	O
Coupled	O
Model	O
Intercomparison	O
Project	O
Phase	O
5	O
(	O
CMIP5	O
)	O
in	O
simulating	O
the	O
summer	O
APO	O
,	O
and	O
projected	O
its	O
variation	O
under	O
warming	O
climate	O
scenarios	O
(	O
RCP4	O
.	O
5	O
and	O
RCP8	O
.	O
5	O
).	O

His	O
findings	O
suggested	O
that	O
the	O
intensity	O
of	O
APO	B-GP
under	O
a	O
warming	O
climate	O
is	O
weaker	O
than	O
the	O
present	O
day	O
.	O

Similarly	O
,	O
with	O
the	O
reduced	O
trend	O
of	O
incoming	O
solar	O
radiation	O
in	O
the	O
Holocene	O
summer	O
,	O
the	O
paleo	O
-	O
APO	O
index	O
exhibits	O
an	O
increasing	O
trend	O
,	O
which	O
is	O
also	O
supported	O
by	O
Zhou	O
’	O
s	O
results	O
.	O

The	O
summer	O
precipitation	O
anomalies	O
over	O
eastern	O
China	O
associated	O
with	O
the	O
APO	O
were	O
investigated	O
using	O
the	O
reanalysis	O
and	O
gauge	O
data19	O
.	O

The	O
result	O
exhibits	O
more	O
rainfall	O
anomalies	O
over	O
northern	O
China	O
and	O
less	O
rainfall	O
over	O
the	O
Yangtze	O
River	O
.	O

This	O
relationship	O
between	O
APO	O
and	O
summer	O
precipitation	O
over	O
eastern	O
China	O
occurs	O
not	O
only	O
during	O
1900	O
–	O
200920	O
and	O
past	O
150	O
years71	O
but	O
also	O
throughout	O
the	O
past	O
millennium2122232475	O
.	O

Summer	O
rainfall	O
anomalies	O
associated	O
with	O
the	O
paleo	O
-	O
APO	O
during	O
the	O
Holocene	O
also	O
exhibit	O
a	O
similar	O
pattern	O
,	O
which	O
implies	O
that	O
this	O
relationship	O
between	O
APO	O
and	O
summer	O
rainfall	O
over	O
eastern	O
China	O
also	O
occurs	O
on	O
a	O
longer	O
precessional	O
scale	O
.	O

Furthermore	O
,	O
variations	O
in	O
the	O
paleo	O
-	O
APO	O
and	O
associated	O
rainfall	O
over	O
eastern	O
China	O
also	O
need	O
more	O
analyses	O
using	O
the	O
General	O
Circulation	O
Model	O
to	O
better	O
understand	O
the	O
underlying	O
mechanisms	O
and	O
processes	O
.	O

Ice	O
-	O
sheet	O
changes	O
are	O
often	O
considered	O
as	O
an	O
important	O
external	O
forcing	O
factor	O
of	O
climate	O
change	O
.	O

They	O
experienced	O
a	O
rapid	O
change	O
in	O
the	O
early	O
Holocene	O
(	O
Fig	O
.	O

S2a	O
).	O

At	O
that	O
time	O
,	O
the	O
ice	O
-	O
sheet	O
covered	O
the	O
northeast	O
portion	O
of	O
North	O
America	O
(	O
Fig	O
.	O

S2b	O
)	O
and	O
exerted	O
a	O
strong	O
influence	O
on	O
climate	O
change	O
by	O
changing	O
the	O
surface	O
albedo	O
and	O
the	O
solar	O
insolation76	O
.	O

Some	O
studies	O
have	O
shown	O
that	O
temperature	O
anomalies	O
caused	O
by	O
ice	O
-	O
sheet	O
forcing	O
represent	O
planetary	O
-	O
scale	O
waves	O
in	O
the	O
extratropical	O
northern	O
hemispheric	O
in	O
winter	O
and	O
annual	O
mean	O
fields77	O
.	O

However	O
,	O
summer	O
temperature	O
anomalies	O
forced	O
by	O
ice	O
sheets	O
are	O
confined	O
in	O
the	O
northeastern	O
part	O
of	O
North	O
America	O
and	O
the	O
northern	O
part	O
of	O
the	O
North	O
Atlantic	O
,	O
which	O
implies	O
a	O
small	O
effect	O
of	O
the	O
ice	O
-	O
sheet	O
forcing	O
on	O
summer	O
temperature	O
over	O
the	O
extratropical	O
Asian	O
-	O
Pacific	O
sector77	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
examine	O
the	O
impacts	O
of	O
ice	O
-	O
sheets	O
in	O
the	O
early	O
Holocene	O
on	O
the	O
paleo	O
-	O
APO	O
pattern	O
and	O
its	O
variability	O
by	O
performing	O
a	O
simulation	O
under	O
both	O
orbital	O
and	O
ice	O
-	O
sheet	O
forcings	O
.	O

The	O
results	O
indicate	O
that	O
the	O
leading	O
mode	O
of	O
the	O
summer	O
eddy	O
SLP	O
under	O
both	O
orbital	O
and	O
ice	O
-	O
sheet	O
forcings	O
(	O
Fig	O
.	O

S3a	O
)	O
are	O
very	O
similar	O
to	O
that	O
under	O
the	O
orbital	O
forcing	O
alone	O
except	O
that	O
the	O
positive	O
values	O
over	O
the	O
northern	O
part	O
of	O
the	O
North	O
Atlantic	O
become	O
larger	O
compared	O
to	O
the	O
ice	O
-	O
sheet	O
forcing	O
(	O
Fig	O
.	O
2b	O
).	O

The	O
PC	O
of	O
the	O
leading	O
mode	O
(	O
Fig	O
.	O

S3b	O
)	O
generally	O
exhibits	O
an	O
increasing	O
trend	O
that	O
is	O
consistent	O
with	O
that	O
in	O
Fig	O
.	O
2c	O
,	O
although	O
with	O
a	O
weak	O
fluctuation	O
in	O
the	O
early	O
Holocene	O
.	O

Our	O
simulation	O
further	O
supports	O
that	O
ice	O
sheet	O
changes	O
in	O
the	O
early	O
Holocene	O
have	O
a	O
weak	O
influence	O
on	O
the	O
summer	O
extratropical	O
paleo	O
-	O
APO	O
pattern	O
.	O

Additional	O
Information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Xiao	O
,	O
D	O
.	O
et	O
al	O
.	O

Responses	O
of	O
the	O
summer	O
Asian	O
-	O
Pacific	O
zonal	O
thermal	O
contrast	O
and	O
the	O
associated	O
evolution	O
of	O
atmospheric	O
circulation	O
to	O
transient	O
orbital	O
changes	O
during	O
the	O
Holocene	O
.	O
Sci	O
.	O

Rep	O
.	O
6	O
,	O
35816	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
srep35816	O
(	O
2016	O
).	O

Supplementary	O
Material	O

Supplementary	O
Information	O

Author	O
Contributions	O
D	O
.	O
X	O
.	O
performed	O
the	O
numerical	O
analysis	O
and	O
led	O
the	O
interpretation	O
of	O
the	O
results	O
and	O
writing	O
of	O
the	O
paper	O
.	O

P	O
.	O
Z	O
.	O
conceived	O
the	O
idea	O
and	O
designed	O
and	O
revised	O
the	O
paper	O
.	O

Y	O
.	O
W	O
.	O
and	O
X	O
.	O
Z	O
.	O
contributed	O
to	O
interpreting	O
the	O
results	O
.	O

(	O
a	O
)	O
Annual	O
cycles	O
of	O
the	O
incoming	O
solar	O
radiation	O
anomaly	O
along	O
30	O
°	O
N	O
relative	O
to	O
the	O
climatological	O
mean	O
over	O
the	O
past	O
10	O
ka	O
and	O
(	O
b	O
)	O
the	O
summer	O
incoming	O
solar	O
radiation	O
along	O
30	O
°	O
N	O
.	O

The	O
abscissa	O
is	O
time	O
before	O
the	O
present	O
(	O
1950	O
AD	O
),	O
and	O
the	O
ordinate	O
in	O
(	O
a	O
)	O
is	O
the	O
month	O
of	O
the	O
year	O
.	O

(	O
a	O
)	O
Regressed	O
eddy	O
SLP	O
(	O
Unit	O
:	O
Pa	O
/	O
W	O
·	O
m	O
−	O
2	O
)	O
on	O
the	O
JJA	O
incoming	O
solar	O
radiation	O
along	O
30	O
°	O
N	O
,	O
in	O
which	O
values	O
exceeding	O
the	O
95	O
%	O
confidence	O
level	O
are	O
plotted	O
.	O

(	O
b	O
)	O
Leading	O
EOF	O
mode	O
of	O
the	O
eddy	O
SLP	O
,	O
in	O
which	O
the	O
green	O
circle	O
and	O
square	O
indicate	O
the	O
locations	O
of	O
the	O
Guliya	O
ice	O
core	O
and	O
the	O
ODP	O
1019	O
,	O
respectively	O
.	O

(	O
c	O
)	O
The	O
PC1	O
and	O
JJA	O
incoming	O
solar	O
radiation	O
along	O
30	O
°	O
N	O
during	O
the	O
past	O
10	O
ka	O
BP	O
,	O
in	O
which	O
the	O
gray	O
shaded	O
area	O
represents	O
the	O
spread	O
of	O
the	O
ensemble	O
mean	O
PC1	O
.	O

These	O
figures	O
were	O
generated	O
by	O
the	O
Grid	O
Analysis	O
and	O
Display	O
System	O
(	O
GrADS	O
)	O
Version	O
2	O
.	O
0	O
.	O
1	O
.	O
oga	O
.	O
1	O
Copyright	O
(	O
c	O
)	O
1988	O
–	O
2011	O
by	O
Brian	O
Doty	O
and	O
the	O
Institute	O
for	O
Global	O
Environment	O
and	O
Society	O
(	O
IGES	O
)	O
(	O
ftp	O
://	O
cola	O
.	O
gmu	O
.	O
edu	O
/	O
grads	O
/	O
2	O
.	O
0	O
/	O
old	O
/).	O

(	O
a	O
)	O
Reconstructed	O
SST	O
(	O
unit	O
:	O
°	O
C	O
;	O
green	O
)	O
at	O
the	O
ODP	O
1019	O
and	O
simulated	O
June	O
-	O
July	O
SST	O
(	O
unit	O
:	O
°	O
C	O
;	O
red	O
)	O
over	O
the	O
northeastern	O
Pacific	O
(	O
110	O
°	O
W	O
–	O
120	O
°	O
W	O
,	O
35	O
°	O
N	O
–	O
45	O
°	O
N	O
),	O
in	O
which	O
the	O
gray	O
shaded	O
area	O
represents	O
the	O
spread	O
from	O
the	O
model	O
ensemble	O
mean	O
.	O

(	O
b	O
)	O
Same	O
as	O
(	O
a	O
)	O
but	O
for	O
the	O
oxygen	O
isotope	O
record	O
in	O
the	O
Guliya	O
ice	O
core	O
(	O
unit	O
:	O
VPDB	O
;	O
green	O
)	O
and	O
the	O
simulated	O
summer	O
SLAT	O
(	O
unit	O
:	O
°	O
C	O
;	O
red	O
)	O
over	O
80	O
°	O
E	O
–	O
85	O
°	O
E	O
,	O
33	O
°	O
N	O
–	O
38	O
°	O
N	O
.	O

The	O
shaded	O
areas	O
are	O
significant	O
at	O
95	O
%	O
confidence	O
levels	O
and	O
the	O
green	O
contours	O
are	O
zero	O
.	O

This	O
figure	O
is	O
generated	O
by	O
the	O
Grid	O
Analysis	O
and	O
Display	O
System	O
(	O
GrADS	O
)	O
Version	O
2	O
.	O
0	O
.	O
1	O
.	O
oga	O
.	O
1	O
Copyright	O
(	O
c	O
)	O
1988	O
–	O
2011	O
by	O
Brian	O
Doty	O
and	O
the	O
Institute	O
for	O
Global	O
Environment	O
and	O
Society	O
(	O
IGES	O
)	O
(	O
ftp	O
://	O
cola	O
.	O
gmu	O
.	O
edu	O
/	O
grads	O
/	O
2	O
.	O
0	O
/	O
old	O
/).	O

(	O
a	O
)	O
The	O
paleo	O
-	O
APO	O
index	O
and	O
PC1	O
in	O
Fig	O
.	O
2b	O
and	O
(	O
b	O
)	O
anomaly	O
from	O
climatological	O
mean	O
over	O
the	O
Eurasian	O
continent	O
and	O
the	O
North	O
Pacific	O
Ocean	O
over	O
the	O
past	O
10	O
ka	O
.	O

(	O
a	O
)	O
Composite	O
SLP	O
filed	O
in	O
the	O
high	O
(	O
during	O
the	O
period	O
0	O
.	O
09	O
–	O
0	O
ka	O
BP	O
;	O
orange	O
)	O
and	O
low	O
(	O
during	O
the	O
period	O
10	O
–	O
9	O
.	O
91	O
ka	O
BP	O
;	O
blue	O
)	O
paleo	O
-	O
APO	O
index	O
years	O
,	O
in	O
which	O
the	O
contours	O
of	O
1018	O
hPa	O
are	O
thickened	O
to	O
denote	O
the	O
domain	O
of	O
the	O
North	O
Pacific	O
high	O
pressure	O
zone	O
.	O

(	O
b	O
)	O
Regression	O
of	O
summer	O
precipitation	O
(	O
unit	O
:	O
mm	O
)	O
over	O
eastern	O
China	O
on	O
the	O
paleo	O
-	O
APO	O
index	O
,	O
in	O
which	O
the	O
locations	O
of	O
stalagmite	O
proxy	O
data	O
at	O
the	O
Jiuxian	O
Cave	O
,	O
Sanbao	O
Cave	O
,	O
Heshang	O
Cave	O
Dongge	O
Cave	O
,	O
and	O
Lianhua	O
Cave	O
are	O
also	O
given	O
and	O
values	O
exceeding	O
significance	O
at	O
the	O
95	O
%	O
confidence	O
level	O
are	O
plotted	O
.	O

This	O
figure	O
is	O
generated	O
by	O
the	O
Grid	O
Analysis	O
and	O
Display	O
System	O
(	O
GrADS	O
)	O
Version	O
2	O
.	O
0	O
.	O
1	O
.	O
oga	O
.	O
1	O
Copyright	O
(	O
c	O
)	O
1988	O
–	O
2011	O
by	O
Brian	O
Doty	O
and	O
the	O
Institute	O
for	O
Global	O
Environment	O
and	O
Society	O
(	O
IGES	O
)	O
(	O
ftp	O
://	O
cola	O
.	O
gmu	O
.	O
edu	O
/	O
grads	O
/	O
2	O
.	O
0	O
/	O
old	O
/).	O

(	O
a	O
)	O
The	O
Dongge	O
Cave	O
δ18O	O
record	O
(	O
red	O
)	O
and	O
the	O
simulated	O
July	O
precipitation	O
over	O
100	O
°	O
E	O
–	O
112	O
°	O
E	O
,	O
22	O
°	O
N	O
–	O
32	O
°	O
N	O
(	O
green	O
;	O
mm	O
),	O
(	O
b	O
)	O
the	O
Lianhua	O
Cave	O
δ18O	O
record	O
,	O
(	O
c	O
)	O
the	O
Sanbao	O
Cave	O
δ18O	O
record	O
,	O
(	O
d	O
)	O
the	O
Heshang	O
Cave	O
δ18O	O
record	O
,	O
and	O
(	O
e	O
)	O
the	O
Jiuxian	O
Cave	O
δ18O	O
record	O
.	O

Anomalies	O
in	O
the	O
ensemble	O
mean	O
summer	O
eddy	O
SLP	O
(	O
unit	O
:	O
hPa	O
)	O
from	O
the	O
climatological	O
mean	O
at	O
9	O
(	O
a	O
),	O
6	O
.	O
5	O
(	O
b	O
),	O
4	O
.	O
8	O
(	O
c	O
),	O
2	O
.	O
5	O
(	O
d	O
),	O
and	O
0	O
(	O
e	O
)	O
ka	O
BP	O
.	O

This	O
figure	O
is	O
generated	O
by	O
the	O
Grid	O
Analysis	O
and	O
Display	O
System	O
(	O
GrADS	O
)	O
Version	O
2	O
.	O
0	O
.	O
1	O
.	O
oga	O
.	O
1	O
Copyright	O
(	O
c	O
)	O
1988	O
–	O
2011	O
by	O
Brian	O
Doty	O
and	O
the	O
Institute	O
for	O
Global	O
Environment	O
and	O
Society	O
(	O
IGES	O
)	O
(	O
ftp	O
://	O
cola	O
.	O
gmu	O
.	O
edu	O
/	O
grads	O
/	O
2	O
.	O
0	O
/	O
old	O
/).	O

Web	O
-	O
Based	O
Interventions	O
Targeting	O
Cardiovascular	O
Risk	O
Factors	O
in	O
Middle	O
-	O
Aged	O
and	O
Older	O
People	O
:	O
A	O
Systematic	O
Review	O
and	O
Meta	O
-	O
Analysis	O

Background	O

Web	O
-	O
based	O
interventions	O
can	O
improve	O
single	O
cardiovascular	O
risk	O
factors	O
in	O
adult	O
populations	O
.	O

In	O
view	O
of	O
global	O
aging	O
and	O
the	O
associated	O
increasing	O
burden	O
of	O
cardiovascular	B-DS
disease	I-DS
,	O
older	O
people	O
form	O
an	O
important	O
target	O
population	O
as	O
well	O
.	O

Objective	O

In	O
this	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
,	O
we	O
evaluated	O
whether	O
Web	O
-	O
based	O
interventions	O
for	O
cardiovascular	O
risk	O
factor	O
management	O
reduce	O
the	O
risk	O
of	O
cardiovascular	B-DS
disease	I-DS
in	O
older	O
people	O
.	O

Methods	O

Embase	O
,	O
Medline	O
,	O
Cochrane	O
and	O
CINAHL	O
were	O
systematically	O
searched	O
from	O
January	O
1995	O
to	O
November	O
2014	O
.	O

Search	O
terms	O
included	O
cardiovascular	O
risk	O
factors	O
and	O
diseases	O
(	O
specified	O
),	O
Web	O
-	O
based	O
interventions	O
(	O
and	O
synonyms	O
)	O
and	O
randomized	O
controlled	O
trial	O
.	O

Two	O
authors	O
independently	O
performed	O
study	O
selection	O
,	O
data	O
-	O
extraction	O
and	O
risk	O
of	O
bias	O
assessment	O
.	O

In	O
a	O
meta	O
-	O
analysis	O
,	O
outcomes	O
regarding	O
treatment	O
effects	O
on	O
cardiovascular	O
risk	O
factors	O
(	O
blood	O
pressure	O
,	O
glycated	O
hemoglobin	B-GP
A1c	O
(	O
HbA1C	O
),	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B-CD
,	O
smoking	O
status	O
,	O
weight	O
and	O
physical	O
inactivity	O
)	O
and	O
incident	O
cardiovascular	B-DS
disease	I-DS
were	O
pooled	O
with	O
random	O
effects	O
models	O
.	O

Results	O

A	O
total	O
of	O
57	O
studies	O
(	O
N	O
=	O
19	O
,	O
862	O
)	O
fulfilled	O
eligibility	O
criteria	O
and	O
47	O
studies	O
contributed	O
to	O
the	O
meta	O
-	O
analysis	O
.	O

A	O
significant	O
reduction	O
in	O
systolic	O
blood	O
pressure	O
(	O
mean	O
difference	O
–	O
2	O
.	O
66	O
mmHg	O
,	O
95	O
%	O
CI	O
–	O
3	O
.	O
81	O
to	O
–	O
1	O
.	O
52	O
),	O
diastolic	O
blood	O
pressure	O
(	O
mean	O
difference	O
–	O
1	O
.	O
26	O
mmHg	O
,	O
95	O
%	O
CI	O
–	O
1	O
.	O
92	O
to	O
–	O
0	O
.	O
60	O
),	O
HbA1c	O
level	O
(	O
mean	O
difference	O
–	O
0	O
.	O
13	O
%,	O
95	O
%	O
CI	O
–	O
0	O
.	O
22	O
to	O
–	O
0	O
.	O
05	O
),	O
LDL	O
cholesterol	B-CD
level	O
(	O
mean	O
difference	O
–	O
2	O
.	O
18	O
mg	O
/	O
dL	O
,	O
95	O
%	O
CI	O
–	O
3	O
.	O
96	O
to	O
–	O
0	O
.	O
41	O
),	O
weight	O
(	O
mean	O
difference	O
–	O
1	O
.	O
34	O
kg	O
,	O
95	O
%	O
CI	O
–	O
1	O
.	O
91	O
to	O
–	O
0	O
.	O
77	O
),	O
and	O
an	O
increase	O
of	O
physical	O
activity	O
(	O
standardized	O
mean	O
difference	O
0	O
.	O
25	O
,	O
95	O
%	O
CI	O
0	O
.	O
10	O
-	O
0	O
.	O
39	O
)	O
in	O
the	O
Web	O
-	O
based	O
intervention	O
group	O
was	O
found	O
.	O

The	O
observed	O
effects	O
were	O
more	O
pronounced	O
in	O
studies	O
with	O
short	O
(<	O
12	O
months	O
)	O
follow	O
-	O
up	O
and	O
studies	O
that	O
combined	O
the	O
Internet	O
application	O
with	O
human	B-OG
support	O
(	O
blended	O
care	O
).	O

No	O
difference	O
in	O
incident	O
cardiovascular	B-DS
disease	I-DS
was	O
found	O
between	O
groups	O
(	O
6	O
studies	O
).	O

Conclusions	O

Web	O
-	O
based	O
interventions	O
have	O
the	O
potential	O
to	O
improve	O
the	O
cardiovascular	O
risk	O
profile	O
of	O
older	O
people	O
,	O
but	O
the	O
effects	O
are	O
modest	O
and	O
decline	O
with	O
time	O
.	O

Currently	O
,	O
there	O
is	O
insufficient	O
evidence	O
for	O
an	O
effect	O
on	O
incident	O
cardiovascular	B-DS
disease	I-DS
.	O

A	O
focus	O
on	O
long	O
-	O
term	O
effects	O
,	O
clinical	O
endpoints	O
,	O
and	O
strategies	O
to	O
increase	O
sustainability	O
of	O
treatment	O
effects	O
is	O
recommended	O
for	O
future	O
studies	O
.	O

Introduction	O

The	O
field	O
of	O
eHealth	O
is	O
expanding	O
the	O
potential	O
of	O
contemporary	O
medicine	O
[	O
1	O
].	O

Global	O
aging	O
and	O
its	O
associated	O
burden	O
of	O
cardiovascular	B-DS
disease	I-DS
may	O
expand	O
the	O
scope	O
for	O
innovative	O
Internet	O
interventions	O
[	O
2	O
,	O
3	O
].	O

Current	O
cardiovascular	O
risk	O
management	O
programs	O
in	O
primary	O
care	O
will	O
become	O
too	O
expensive	O
and	O
,	O
although	O
they	O
are	O
highly	O
effective	O
in	O
research	O
settings	O
[	O
4	O
-	O
6	O
],	O
their	O
effectiveness	O
is	O
markedly	O
lower	O
in	O
daily	O
life	O
[	O
7	O
].	O

This	O
evidence	O
-	O
practice	O
gap	O
has	O
several	O
causes	O
[	O
8	O
].	O

Adherence	O
to	O
life	O
-	O
long	O
lifestyle	O
and	O
medication	O
regimens	O
is	O
a	O
serious	O
challenge	O
,	O
illustrated	O
by	O
long	O
-	O
term	O
adherence	O
rates	O
in	O
chronic	B-DS
diseases	I-DS
that	O
average	O
as	O
low	O
as	O
50	O
%	O
[	O
9	O
,	O
10	O
].	O

Web	O
-	O
based	O
interventions	O
are	O
cheap	O
,	O
have	O
a	O
wide	O
reach	O
,	O
and	O
they	O
enable	O
self	O
-	O
management	O
[	O
11	O
].	O

This	O
renders	O
Web	O
-	O
based	O
interventions	O
potentially	O
powerful	O
and	O
scalable	O
tools	O
to	O
enhance	O
sustained	O
adherence	O
in	O
cardiovascular	O
risk	O
management	O
[	O
12	O
].	O

Older	O
people	O
form	O
an	O
important	O
target	O
population	O
because	O
cardiovascular	O
risk	O
reduction	O
appears	O
effective	O
until	O
old	O
age	O
[	O
13	O
-	O
16	O
].	O

In	O
2012	O
,	O
42	O
%	O
of	O
European	O
people	O
aged	O
between	O
55	O
and	O
74	O
years	O
used	O
the	O
Internet	O
and	O
this	O
number	O
is	O
increasing	O
[	O
17	O
].	O

Meta	O
-	O
analyses	O
showed	O
that	O
Web	O
-	O
based	O
interventions	O
targeting	O
single	O
cardiovascular	O
risk	O
factors	O
can	O
induce	O
improvements	O
in	O
adult	O
populations	O
[	O
18	O
-	O
21	O
].	O

However	O
,	O
optimal	O
cardiovascular	O
prevention	O
and	O
risk	O
management	O
practice	O
,	O
as	O
affirmed	O
by	O
the	O
European	O
Society	O
of	O
Cardiology	O
[	O
22	O
]	O
and	O
the	O
American	O
Heart	O
Association	O
[	O
23	O
],	O
requires	O
targeting	O
the	O
complete	O
cardiovascular	O
risk	O
profile	O
.	O

This	O
is	O
particularly	O
applicable	O
for	O
older	O
people	O
,	O
who	O
often	O
have	O
multiple	O
risk	O
factors	O
or	O
already	O
suffered	O
a	O
cardiovascular	O
event	O
.	O

A	O
comprehensive	O
approach	O
would	O
increase	O
the	O
value	O
of	O
Web	O
-	O
based	O
interventions	O
for	O
daily	O
practice	O
.	O

Currently	O
,	O
little	O
is	O
known	O
about	O
the	O
effectiveness	O
of	O
Web	O
-	O
based	O
interventions	O
in	O
older	O
people	O
.	O

In	O
this	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
,	O
we	O
aim	O
to	O
answer	O
the	O
question	O
whether	O
Web	O
-	O
based	O
interventions	O
for	O
cardiovascular	O
risk	O
factor	O
management	O
reduce	O
cardiovascular	O
risk	O
and	O
disease	O
in	O
older	O
people	O
.	O

Methods	O

Search	O
Strategy	O
and	O
Selection	O
of	O
Eligible	O
Studies	O

We	O
performed	O
a	O
systematic	O
literature	O
search	O
for	O
randomized	O
controlled	O
trials	O
(	O
RCT	O
)	O
on	O
Web	O
-	O
based	O
interventions	O
in	O
older	O
people	O
targeting	O
one	O
or	O
more	O
cardiovascular	O
risk	O
factors	O
and	O
/	O
or	O
disease	O
.	O

Methods	O
were	O
predefined	O
in	O
a	O
research	O
protocol	O
using	O
the	O
PRISMA	O
checklist	O
and	O
the	O
Systematic	O
Reviews	O
Guidelines	O
of	O
the	O
Center	O
of	O
Reviews	O
and	O
Dissemination	O
(	O
Multimedia	O
Appendix	O
1	O
).	O

We	O
defined	O
Web	O
-	O
based	O
interventions	O
as	O
Web	O
-	O
based	O
participant	O
-	O
centered	O
treatment	O
or	O
prevention	O
programs	O
delivered	O
via	O
the	O
Internet	O
and	O
interacting	O
with	O
the	O
participant	O
in	O
a	O
tailored	O
fashion	O
[	O
24	O
,	O
25	O
].	O

Internet	O
had	O
to	O
be	O
the	O
main	O
medium	O
through	O
which	O
the	O
intervention	O
was	O
delivered	O
,	O
but	O
other	O
media	O
(	O
phone	O
,	O
face	O
-	O
to	O
-	O
face	O
)	O
could	O
be	O
included	O
too	O
.	O

We	O
excluded	O
the	O
following	O
eHealth	O
interventions	O
:	O
telemonitoring	O
,	O
telemedicine	O
,	O
and	O
mobile	O
phone	O
-	O
mediated	O
interventions	O
.	O

The	O
target	O
of	O
the	O
intervention	O
had	O
to	O
be	O
one	O
or	O
more	O
cardiovascular	O
risk	O
factors	O
and	O
/	O
or	O
cardiovascular	B-DS
disease	I-DS
.	O

Thus	O
,	O
we	O
included	O
interventions	O
for	O
both	O
primary	O
and	O
secondary	O
prevention	O
of	O
cardiovascular	B-DS
disease	I-DS
[	O
22	O
].	O

The	O
target	O
population	O
had	O
to	O
have	O
a	O
mean	O
age	O
of	O
50	O
years	O
or	O
older	O
and	O
could	O
have	O
a	O
mixed	O
level	O
of	O
cardiovascular	O
risk	O
(	O
one	O
or	O
more	O
cardiovascular	O
risk	O
factors	O
or	O
established	O
cardiovascular	B-DS
disease	I-DS
).	O

Main	O
outcomes	O
of	O
interest	O
were	O
incident	O
cardiovascular	B-DS
disease	I-DS
(	O
myocardial	B-DS
infarction	I-DS
,	O
angina	B-DS
pectoris	I-DS
,	O
heart	B-DS
failure	I-DS
,	O
stroke	B-DS
or	O
transient	B-DS
ischemic	I-DS
attack	I-DS
,	O
and	O
peripheral	B-DS
arterial	I-DS
disease	I-DS
),	O
cardiovascular	O
mortality	O
and	O
overall	O
mortality	O
,	O
and	O
changes	O
in	O
cardiovascular	O
risk	O
factors	O
including	O
blood	O
pressure	O
(	O
BP	O
),	O
glycated	O
hemoglobin	B-GP
A1c	O
(	O
HbA1c	O
),	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B-CD
,	O
smoking	O
status	O
,	O
weight	O
,	O
level	O
of	O
physical	O
exercise	O
,	O
or	O
a	O
composite	O
cardiovascular	O
risk	O
score	O
.	O

We	O
performed	O
a	O
comprehensive	O
literature	O
search	O
in	O
the	O
EMBASE	O
,	O
Medline	O
,	O
CINAHL	O
,	O
and	O
Cochrane	O
databases	O
from	O
1995	O
onward	O
(	O
because	O
the	O
Internet	O
was	O
not	O
widely	O
available	O
before	O
then	O
).	O

Key	O
search	O
terms	O
were	O
cardiovascular	O
risk	O
factors	O
and	O
diseases	O
(	O
separate	O
diseases	O
and	O
risk	O
factors	O
specified	O
),	O
terms	O
related	O
to	O
aspects	O
of	O
cardiovascular	O
risk	O
management	O
(	O
eg	O
,	O
diet	O
,	O
exercise	O
,	O
BP	O
control	O
),	O
Web	O
-	O
based	O
interventions	O
(	O
including	O
all	O
definitions	O
and	O
synonyms	O
),	O
and	O
RCT	O
/	O
review	O
/	O
meta	O
-	O
analysis	O
.	O

The	O
search	O
was	O
last	O
updated	O
on	O
November	O
3	O
,	O
2014	O
by	O
CRB	O
.	O

The	O
comprehensive	O
search	O
strategy	O
is	O
provided	O
in	O
Multimedia	O
Appendix	O
2	O
.	O

Studies	O
were	O
included	O
if	O
(	O
1	O
)	O
they	O
were	O
on	O
Web	O
-	O
based	O
interventions	O
targeting	O
cardiovascular	O
risk	O
factors	O
and	O
/	O
or	O
disease	O
,	O
(	O
2	O
)	O
study	O
design	O
was	O
a	O
RCT	O
,	O
(	O
3	O
)	O
at	O
least	O
50	O
patients	O
were	O
included	O
,	O
(	O
4	O
)	O
mean	O
age	O
was	O
at	O
least	O
50	O
years	O
,	O
(	O
5	O
)	O
the	O
duration	O
of	O
the	O
intervention	O
was	O
4	O
or	O
more	O
weeks	O
and	O
follow	O
-	O
up	O
was	O
3	O
or	O
more	O
months	O
,	O
(	O
6	O
)	O
at	O
least	O
one	O
of	O
the	O
outcomes	O
of	O
our	O
interest	O
was	O
reported	O
,	O
and	O
(	O
7	O
)	O
language	O
was	O
English	O
.	O

Study	O
selection	O
was	O
performed	O
by	O
two	O
independent	O
researchers	O
(	O
CRB	O
and	O
BS	O
)	O
by	O
means	O
of	O
screening	O
of	O
titles	O
and	O
abstracts	O
,	O
and	O
thereafter	O
reading	O
full	O
texts	O
on	O
the	O
basis	O
of	O
the	O
inclusion	O
criteria	O
.	O

If	O
two	O
publications	O
described	O
the	O
same	O
trial	O
,	O
the	O
paper	O
that	O
reported	O
the	O
primary	O
outcomes	O
of	O
the	O
trial	O
was	O
included	O
.	O

Disagreements	O
were	O
resolved	O
by	O
discussion	O
or	O
by	O
a	O
third	O
investigator	O
(	O
ER	O
).	O

We	O
assessed	O
reviews	O
and	O
meta	O
-	O
analyses	O
encountered	O
with	O
our	O
search	O
strategy	O
to	O
check	O
for	O
additional	O
relevant	O
articles	O
.	O

Data	O
Extraction	O

Two	O
reviewers	O
(	O
BS	O
and	O
CRB	O
)	O
extracted	O
data	O
using	O
a	O
predefined	O
data	O
extraction	O
form	O
(	O
Multimedia	O
Appendix	O
3	O
)	O
for	O
half	O
of	O
the	O
included	O
articles	O
and	O
checked	O
each	O
other	O
’	O
s	O
results	O
.	O

Extracted	O
information	O
included	O
study	O
characteristics	O
,	O
patient	O
baseline	O
characteristics	O
,	O
characteristics	O
of	O
the	O
intervention	O
and	O
control	O
conditions	O
,	O
and	O
available	O
data	O
on	O
clinical	O
and	O
intermediate	O
outcomes	O
.	O

For	O
BP	O
,	O
glucose	B-CD
control	O
,	O
weight	O
,	O
lipids	O
,	O
and	O
physical	O
activity	O
level	O
,	O
we	O
extracted	O
all	O
baseline	O
and	O
follow	O
-	O
up	O
levels	O
,	O
change	O
scores	O
or	O
mean	O
differences	O
.	O

Corresponding	O
authors	O
were	O
contacted	O
if	O
needed	O
.	O

We	O
used	O
an	O
adapted	O
Cochrane	O
Risk	O
of	O
Bias	O
Tool	O
to	O
evaluate	O
randomization	O
procedures	O
,	O
representativeness	O
of	O
study	O
populations	O
,	O
blinding	O
of	O
outcome	O
assessors	O
(	O
blinding	O
of	O
participants	O
was	O
usually	O
not	O
possible	O
due	O
to	O
study	O
design	O
),	O
completeness	O
of	O
outcome	O
data	O
,	O
and	O
completeness	O
of	O
reporting	O
.	O

Meta	O
-	O
Analysis	O

For	O
categorical	O
variables	O
,	O
we	O
calculated	O
odds	O
ratios	O
with	O
95	O
%	O
confidence	O
intervals	O
.	O

We	O
estimated	O
pooled	O
odds	O
ratios	O
with	O
Mantel	O
-	O
Haenszel	O
random	O
-	O
effects	O
models	O
.	O

For	O
continuous	O
outcomes	O
,	O
mean	O
differences	O
or	O
standardized	O
mean	O
differences	O
(	O
Hedges	O
’	O
g	O
effect	O
sizes	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
were	O
calculated	O
.	O

We	O
estimated	O
pooled	O
effects	O
with	O
DerSimonian	O
and	O
Laird	O
random	O
-	O
effects	O
models	O
.	O

All	O
HbA1c	O
values	O
were	O
converted	O
to	O
percentages	O
.	O

All	O
LDL	O
cholesterol	B-CD
values	O
were	O
converted	O
to	O
mg	O
/	O
dL	O
.	O

All	O
weight	O
values	O
were	O
converted	O
to	O
kg	O
.	O

For	O
level	O
of	O
physical	O
activity	O
,	O
which	O
was	O
assessed	O
with	O
various	O
instruments	O
,	O
we	O
calculated	O
standardized	O
mean	O
differences	O
and	O
95	O
%	O
confidence	O
intervals	O
.	O

If	O
mean	O
differences	O
or	O
standardized	O
mean	O
differences	O
were	O
reported	O
,	O
we	O
included	O
them	O
directly	O
in	O
the	O
pooled	O
analyses	O
.	O

If	O
not	O
,	O
we	O
calculated	O
change	O
scores	O
(	O
difference	O
between	O
baseline	O
and	O
follow	O
-	O
up	O
within	O
group	O
)	O
or	O
values	O
assessed	O
at	O
follow	O
-	O
up	O
.	O

If	O
values	O
were	O
measured	O
at	O
multiple	O
time	O
points	O
,	O
we	O
used	O
the	O
values	O
recorded	O
at	O
the	O
last	O
follow	O
-	O
up	O
contact	O
.	O

For	O
studies	O
with	O
multiple	O
arms	O
,	O
we	O
included	O
only	O
one	O
intervention	O
arm	O
in	O
the	O
meta	O
-	O
analysis	O
in	O
order	O
not	O
to	O
create	O
“	O
unit	O
-	O
of	O
-	O
analysis	O
”	O
error	O
by	O
double	O
counting	O
the	O
control	O
group	O
.	O

Where	O
possible	O
,	O
we	O
selected	O
the	O
Internet	O
-	O
only	O
intervention	O
arm	O
.	O

No	O
data	O
were	O
imputed	O
.	O

We	O
estimated	O
pooled	O
effects	O
for	O
all	O
single	O
cardiovascular	O
risk	O
factors	O
.	O

To	O
address	O
the	O
overall	O
question	O
of	O
efficacy	O
of	O
Web	O
-	O
based	O
interventions	O
for	O
cardiovascular	O
risk	O
factor	O
management	O
,	O
we	O
evaluated	O
the	O
effect	O
on	O
cardiovascular	O
composite	O
scores	O
,	O
clinical	O
outcomes	O
(	O
cardiovascular	O
morbidity	O
and	O
mortality	O
),	O
and	O
pooled	O
the	O
standardized	O
primary	O
outcomes	O
of	O
all	O
studies	O
.	O

We	O
used	O
the	O
primary	O
outcomes	O
as	O
defined	O
by	O
the	O
authors	O
of	O
the	O
studies	O
.	O

Funnel	O
plots	O
were	O
inspected	O
to	O
assess	O
for	O
potential	O
publication	O
bias	O
.	O

Statistical	O
heterogeneity	O
was	O
assessed	O
using	O
Q	O
and	O
I2	O
tests	O
.	O

We	O
explored	O
reasons	O
for	O
heterogeneity	O
by	O
jackknife	O
analysis	O
and	O
subgroup	O
analyses	O
.	O

We	O
assessed	O
the	O
following	O
factors	O
in	O
subgroup	O
analyses	O
:	O
study	O
duration	O
(	O
predefined	O
,	O
short	O
term	O
[<	O
12	O
months	O
]	O
versus	O
long	O
term	O
[≥	O
12	O
months	O
]),	O
type	O
of	O
cardiovascular	O
prevention	O
(	O
primary	O
versus	O
secondary	O
)	O
[	O
22	O
],	O
and	O
type	O
of	O
intervention	O
(	O
Internet	O
only	O
or	O
“	O
blended	O
”	O
[	O
Internet	O
application	O
combined	O
with	O
human	B-OG
support	O
]).	O

Subgroup	O
analyses	O
were	O
performed	O
on	O
the	O
studies	O
used	O
for	O
the	O
analysis	O
on	O
primary	O
outcomes	O
only	O
.	O

The	O
latter	O
subgroup	O
analysis	O
(	O
on	O
type	O
of	O
intervention	O
)	O
consisted	O
of	O
two	O
separate	O
analyses	O
,	O
one	O
to	O
evaluate	O
the	O
Internet	O
-	O
only	O
interventions	O
versus	O
the	O
control	O
conditions	O
and	O
one	O
to	O
evaluate	O
the	O
blended	O
interventions	O
versus	O
control	O
conditions	O
.	O

In	O
case	O
a	O
study	O
tested	O
both	O
types	O
of	O
interventions	O
with	O
a	O
multiple	O
-	O
arm	O
design	O
,	O
the	O
appropriate	O
arm	O
was	O
included	O
for	O
each	O
analysis	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
mixed	O
effects	O
meta	O
-	O
regression	O
using	O
the	O
unrestricted	O
maximum	O
likelihood	O
method	O
to	O
explore	O
the	O
association	O
between	O
study	O
duration	O
and	O
effect	O
size	O
(	O
standardized	O
primary	O
outcome	O
).	O

Last	O
,	O
we	O
performed	O
sensitivity	O
analyses	O
for	O
the	O
different	O
domains	O
of	O
the	O
risk	O
-	O
of	O
-	O
bias	O
assessment	O
by	O
repeating	O
the	O
analysis	O
on	O
standardized	O
primary	O
outcomes	O
in	O
subgroups	O
of	O
studies	O
with	O
low	O
risk	O
of	O
bias	O
versus	O
studies	O
with	O
an	O
unclear	O
or	O
high	O
risk	O
of	O
bias	O
.	O

For	O
this	O
analysis	O
,	O
we	O
wanted	O
to	O
include	O
all	O
studies	O
that	O
contributed	O
to	O
one	O
of	O
the	O
meta	O
-	O
analyses	O
.	O

Therefore	O
,	O
we	O
complemented	O
the	O
sample	O
of	O
studies	O
with	O
defined	O
primary	O
outcomes	O
that	O
were	O
cardiovascular	O
risk	O
factors	O
of	O
interest	O
with	O
studies	O
that	O
had	O
not	O
defined	O
their	O
primary	O
outcome	O
.	O

If	O
there	O
was	O
no	O
defined	O
primary	O
outcome	O
,	O
we	O
used	O
the	O
cardiovascular	O
risk	O
factor	O
that	O
was	O
targeted	O
most	O
directly	O
in	O
the	O
intervention	O
studied	O
.	O

We	O
used	O
Review	O
Manager	O
5	O
.	O
2	O
to	O
draw	O
the	O
risk	O
-	O
of	O
-	O
bias	O
assessment	O
figure	O
and	O
to	O
calculate	O
standard	O
deviations	O
or	O
95	O
%	O
confidence	O
intervals	O
in	O
cases	O
where	O
only	O
standard	O
errors	O
were	O
available	O
in	O
the	O
original	O
data	O
.	O

We	O
used	O
Microsoft	O
Office	O
Excel	O
version	O
10	O
,	O
SPSS	O
version	O
20	O
,	O
and	O
Comprehensive	O
Meta	O
Analysis	O
version	O
2	O
.	O
2	O
.	O
064	O
for	O
the	O
statistical	O
analyses	O
.	O

Results	O

Study	O
Selection	O

The	O
search	O
yielded	O
5251	O
papers	O
after	O
removal	O
of	O
duplicates	O
.	O

We	O
did	O
not	O
identify	O
additional	O
studies	O
by	O
searching	O
reference	O
lists	O
.	O

After	O
screening	O
of	O
titles	O
and	O
abstracts	O
,	O
462	O
papers	O
remained	O
.	O

Review	O
of	O
these	O
full	O
texts	O
resulted	O
in	O
57	O
RCTs	O
(	O
corresponding	O
with	O
84	O
papers	O
)	O
that	O
fulfilled	O
the	O
selection	O
criteria	O
and	O
were	O
included	O
in	O
the	O
systematic	O
review	O
.	O

We	O
contacted	O
16	O
authors	O
to	O
request	O
additional	O
data	O
:	O
nine	O
authors	O
responded	O
and	O
three	O
authors	O
complied	O
with	O
our	O
request	O
.	O

Out	O
of	O
this	O
final	O
selection	O
,	O
47	O
studies	O
could	O
be	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
(	O
see	O
Figure	O
1	O
for	O
PRISMA	O
flowchart	O
).	O

Prisma	O
flowchart	O
illustrating	O
literature	O
search	O
.	O

Study	O
Characteristics	O

The	O
57	O
RCTs	O
included	O
19	O
,	O
862	O
individuals	O
(	O
Tables	O
1	O
-	O
5	O
).	O

Study	O
sample	O
size	O
ranged	O
from	O
61	O
to	O
2140	O
participants	O
.	O

Median	O
study	O
duration	O
was	O
9	O
months	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
6	O
,	O
range	O
3	O
-	O
60	O
months	O
).	O

The	O
mean	O
dropout	O
rate	O
was	O
15	O
%	O
(	O
range	O
0	O
%-	O
62	O
%).	O

The	O
mean	O
age	O
of	O
the	O
study	O
populations	O
ranged	O
from	O
50	O
to	O
71	O
years	O
.	O

In	O
only	O
7	O
studies	O
were	O
all	O
participants	O
older	O
than	O
50	O
years	O
of	O
age	O
.	O

All	O
participants	O
had	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-DS
disease	I-DS
:	O
46	O
studies	O
conducted	O
primary	O
prevention	O
(	O
control	O
of	O
cardiovascular	O
risk	O
factors	O
or	O
diabetes	B-DS
)	O
and	O
11	O
studies	O
conducted	O
secondary	O
prevention	O
.	O

In	O
41	O
studies	O
,	O
the	O
intervention	O
targeted	O
a	O
single	O
cardiovascular	O
risk	O
factor	O
;	O
in	O
16	O
studies	O
,	O
multiple	O
risk	O
factors	O
were	O
addressed	O
.	O

We	O
found	O
no	O
studies	O
on	O
interventions	O
for	O
smoking	O
cessation	O
meeting	O
our	O
inclusion	O
criteria	O
.	O

In	O
most	O
studies	O
,	O
the	O
primary	O
outcome	O
was	O
change	O
in	O
a	O
specific	O
cardiovascular	O
risk	O
factor	O
targeted	O
by	O
the	O
intervention	O
.	O

Sixteen	O
studies	O
reported	O
on	O
clinical	O
outcomes	O
including	O
new	O
cardiovascular	O
events	O
[	O
26	O
-	O
31	O
]	O
and	O
mortality	O
rates	O
[	O
29	O
-	O
41	O
]	O
as	O
a	O
part	O
of	O
adverse	O
event	O
monitoring	O
.	O

All	O
interventions	O
included	O
lifestyle	O
education	O
and	O
were	O
participant	O
-	O
centered	O
.	O

Forty	O
-	O
four	O
studies	O
stimulated	O
self	O
-	O
management	O
by	O
means	O
of	O
goal	O
setting	O
and	O
self	O
-	O
monitoring	O
.	O

Half	O
of	O
interventions	O
were	O
stand	O
-	O
alone	O
Internet	O
platforms	O
and	O
the	O
other	O
half	O
were	O
“	O
blended	O
”	O
(	O
ie	O
,	O
the	O
platforms	O
were	O
supported	O
by	O
a	O
nurse	O
or	O
another	O
health	O
care	O
professional	O
).	O

Intervention	O
usage	O
was	O
reported	O
by	O
22	O
studies	O
.	O

The	O
median	O
percentage	O
of	O
participants	O
logging	O
in	O
to	O
the	O
intervention	O
platform	O
was	O
72	O
%	O
(	O
range	O
33	O
%-	O
100	O
%).	O

Quality	O
Assessment	O

Methodological	O
quality	O
of	O
the	O
included	O
studies	O
varied	O
(	O
Multimedia	O
Appendix	O
4	O
).	O

Most	O
studies	O
adequately	O
described	O
the	O
randomization	O
and	O
allocation	O
concealment	O
procedures	O
.	O

Due	O
to	O
the	O
nature	O
of	O
the	O
interventions	O
,	O
none	O
of	O
the	O
studies	O
had	O
a	O
double	O
-	O
blind	O
design	O
.	O

In	O
20	O
studies	O
,	O
outcome	O
assessors	O
were	O
blinded	O
[	O
27	O
,	O
29	O
,	O
30	O
,	O
32	O
,	O
34	O
-	O
40	O
,	O
42	O
,	O
52	O
,	O
54	O
,	O
57	O
,	O
59	O
,	O
61	O
,	O
64	O
,	O
67	O
,	O
81	O
],	O
in	O
19	O
studies	O
blinding	O
was	O
not	O
mentioned	O
or	O
unclear	O
[	O
28	O
,	O
31	O
,	O
33	O
,	O
41	O
,	O
43	O
,	O
44	O
,	O
46	O
,	O
48	O
,	O
53	O
,	O
56	O
,	O
60	O
,	O
63	O
,	O
65	O
,	O
69	O
,	O
71	O
,	O
74	O
,	O
76	O
,	O
77	O
,	O
80	O
],	O
and	O
in	O
18	O
studies	O
outcome	O
assessors	O
were	O
not	O
blinded	O
[	O
26	O
,	O
45	O
,	O
47	O
,	O
49	O
-	O
51	O
,	O
55	O
,	O
58	O
,	O
62	O
,	O
66	O
,	O
68	O
,	O
70	O
,	O
72	O
,	O
73	O
,	O
75	O
,	O
78	O
,	O
79	O
,	O
82	O
].	O

Effect	O
of	O
Web	O
-	O
Based	O
Interventions	O
on	O
Single	O
Risk	O
Factors	O

Of	O
the	O
57	O
studies	O
included	O
in	O
the	O
systemic	O
review	O
,	O
47	O
studies	O
[	O
26	O
-	O
32	O
,	O
34	O
-	O
42	O
,	O
44	O
-	O
53	O
,	O
55	O
-	O
60	O
,	O
62	O
,	O
64	O
-	O
68	O
,	O
70	O
,	O
73	O
,	O
74	O
,	O
76	O
-	O
79	O
,	O
81	O
,	O
82	O
]	O
provided	O
sufficient	O
information	O
to	O
be	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
.	O

The	O
mean	O
age	O
of	O
the	O
study	O
populations	O
of	O
these	O
46	O
studies	O
had	O
the	O
same	O
range	O
as	O
the	O
complete	O
sample	O
of	O
57	O
studies	O
.	O

Systolic	O
and	O
Diastolic	O
Blood	O
Pressure	O

The	O
pooled	O
analysis	O
showed	O
a	O
significant	O
reduction	O
in	O
both	O
systolic	O
and	O
diastolic	O
BP	O
favoring	O
the	O
intervention	O
(	O
26	O
studies	O
;	O
n	O
=	O
7720	O
;	O
Figures	O
2	O
and	O
3	O
).	O

For	O
systolic	O
BP	O
,	O
the	O
weighted	O
mean	O
difference	O
was	O
–	O
2	O
.	O
66	O
mmHg	O
(	O
95	O
%	O
CI	O
–	O
3	O
.	O
81	O
to	O
–	O
1	O
.	O
52	O
;	O
I2	O
=	O
53	O
%).	O

For	O
diastolic	O
BP	O
,	O
the	O
weighted	O
mean	O
difference	O
was	O
–	O
1	O
.	O
26	O
mmHg	O
(	O
95	O
%	O
CI	O
–	O
1	O
.	O
92	O
to	O
–	O
0	O
.	O
60	O
;	O
I2	O
=	O
46	O
%).	O

Characteristics	O
of	O
the	O
studies	O
included	O
for	O
the	O
systematic	O
review	O
:	O
interventions	O
targeting	O
diabetes	B-DS
.	O
a	O

Study	O

Setting	O
and	O
study	O
length	O

Participants	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

Sex	O
(%	O
female	O
)	O

Intervention	O

Control	O

Primary	O
;	O
secondary	O
outcomes	O

Bond	O
2010	O
[	O
42	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

62	O
people	O
with	O
DM	B-DS
via	O
university	O
/	O
veteran	O
clinic	O

67	O
.	O
2	O
(	O
6	O
.	O
0	O
)	O

45	O

Website	O
:	O
education	O
,	O
self	O
-	O
monitoring	O
(	O
glucose	B-CD
,	O
exercise	O
,	O
weight	O
,	O
BP	O
,	O
medication	O
),	O
forum	O
;	O
nurse	O
support	O
(	O
email	O
,	O
chat	O
)	O

Standard	O
diabetes	B-DS
care	O

HbA1c	O
,	O
BP	O
,	O
weight	O
,	O
total	O
cholesterol	B-CD
,	O
HDL	O
cholesterol	B-CD

IDEATEL	O
2000	O
-	O
2010	O
[	O
34	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
60	O
m	O

1665	O
Medicare	O
recipients	O
with	O
DM	O

70	O
.	O
9	O
(	O
6	O
.	O
7	O
)	O

63	O

Online	O
home	O
telemedicine	O
unit	O
:	O
nurse	O
support	O
(	O
video	O
chat	O
),	O
Web	O
portal	O
for	O
self	O
-	O
monitoring	O
(	O
glucose	B-CD
,	O
BP	O
),	O
education	O

Standard	O
diabetes	B-DS
care	O

HbA1c	O
,	O
systolic	O
BP	O
,	O
diastolic	O
BP	O
,	O
total	O
cholesterol	B-CD
,	O
LDL	O
cholesterol	B-CD

D	O
-	O
net	O
2001	O
[	O
43	O
]	O

4	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
10	O
m	O

320	O
people	O
with	O
DM2	O
,	O
Internet	O
,	O
from	O
16	O
GPs	O

59	O
(	O
9	O
.	O
2	O
)	O

53	O

Website	O
:	O
(	O
1	O
)	O
Self	O
-	O
management	O
(	O
glucose	B-CD
),	O
coach	O
support	O
;	O
(	O
2	O
)	O
education	O
,	O
forum	O
;	O
(	O
3	O
)	O
1	O
and	O
2	O
combinedb	O

(	O
4	O
)	O
Information	O
on	O
medical	O
and	O
lifestyle	O
aspects	O
of	O
diabetes	B-DS

Not	O
defined	O
;	O
behavioral	O
,	O
biological	O
,	O
and	O
psychosocial	O
outcomes	O

My	O
path	O
2010	O
[	O
44	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

463	O
Medicare	O
recipients	O
with	O
DM2	O
,	O
BMI	O
≥	O
25	O
kg	O
/	O
m2	O
or	O
≥	O
1	O
CV	O
risk	O
factor	O
,	O
Internet	O

58	O
.	O
4	O
(	O
9	O
.	O
2	O
)	O

50	O

(	O
1	O
)	O
Website	O
for	O
computer	O
-	O
assisted	O
self	O
-	O
management	O
(	O
CASM	O
):	O
goal	O
setting	O
,	O
monitoring	O
(	O
HbA1c	O
,	O
BP	O
,	O
cholesterol	B-CD
),	O
forum	O
,	O
education	O
;	O
b	O
,	O
c	O
(	O
2	O
)	O
CASM	O
+	O
social	O
support	O
(	O
coach	O
,	O
group	O
sessions	O
)	O
b	O
,	O
c	O

(	O
3	O
)	O
Computer	O
-	O
based	O
health	O
risk	O
appraisal	O
,	O
no	O
key	O
features	O
of	O
CASM	O

Behavior	O
changes	O
in	O
diet	O
,	O
physical	O
activity	O
,	O
medication	O
adherence	O

My	O
care	O
team	O
2005	O
[	O
45	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

104	O
people	O
with	O
DM	B-DS
,	O
HbA1c	O
≥	O
9	O
.	O
0	O
%	O
via	O
veteran	O
clinic	O

63	O
.	O
5	O
(	O
7	O
.	O
0	O
)	O

0	O
.	O
5	O

Website	O
:	O
self	O
-	O
management	O
(	O
glucose	B-CD
,	O
BP	O
),	O
education	O
,	O
reminders	O
(	O
phone	O
);	O
care	O
manager	O
support	O

DM	O
self	O
-	O
management	O
training	O
,	O
usual	O
care	O

HbA1c	O
and	O
BP	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
m	O

Mobile	O
DM	O
2011	O
[	O
32	O
]	O

4	O
-	O
arm	O
cluster	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

26	O
physician	O
practices	O
with	O
163	O
people	O
with	O
DM	B-DS
and	O
HbA1c	O
≥	O
7	O
.	O
5	O
%	O

52	O
.	O
8	O
(	O
8	O
.	O
1	O
)	O

50	O

(	O
2	O
)	O
Self	O
-	O
management	O
via	O
website	O
+	O
mobile	O
phone	O
,	O
patient	O
informs	O
doctor	O
;	O
b	O
(	O
3	O
)	O
2	O
+	O
doctor	O
access	O
to	O
data	O
;	O
(	O
4	O
)	O
3	O
+	O
advice	O
from	O
doctorc	O

(	O
1	O
)	O
Care	O
as	O
usual	O

Change	O
in	O
HbA1c	O
over	O
1	O
year	O

Avdal	O
2011	O
[	O
46	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Turkey	O
;	O
6	O
m	O

122	O
people	O
with	O
DM2	O
,	O
Internet	O
from	O
clinic	O

51	O
(	O
7	O
.	O
3	O
)	O

51	O

Website	O
:	O
review	O
risk	O
profile	O
,	O
messaging	O
to	O
researcher	O
,	O
daily	O
glucose	B-CD
monitoring	O

Education	O
and	O
usual	O
care	O

HbA1c	O
,	O
attendance	O
rates	O
at	O
outpatient	O
clinic	O

Cho	O
2006	O
[	O
47	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
South	O
Korea	O
;	O
30	O
m	O

80	O
people	O
with	O
DM	O
,	O
Internet	O
from	O
clinic	O

53	O
(	O
9	O
)	O

39	O

Website	O
:	O
monitoring	O
(	O
glucose	B-CD
,	O
medication	O
,	O
BP	O
,	O
weight	O
,	O
lifestyle	O
),	O
nurse	O
feedback	O
,	O
medication	O
alterations	O

Conventional	O
note	O
-	O
keeping	O
record	O
system	O

HbA1c	O
and	O
HbA1c	O
fluctuation	O
index	O

Lorig	O
2010	O
[	O
48	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

761	O
people	O
with	O
DM2	O
,	O
Internet	O

54	O
.	O
3	O
(	O
9	O
.	O
9	O
)	O

73	O

Self	O
-	O
management	O
website	O
with	O
peer	O
support	O
:	O
lessons	O
,	O
action	O
plans	O
,	O
bulletin	O
board	O
,	O
messaging	O

Care	O
as	O
usual	O

HbA1C	O
level	O
at	O
6	O
and	O
18	O
months	O

Grant	O
2008	O
[	O
49	O
]	O

2	O
-	O
arm	O
cluster	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

244	O
people	O
with	O
DM	B-DS
,	O
HbA1c	O
>	O
7	O
.	O
0	O
%	O
from	O
11	O
primary	O
clinics	O

56	O
.	O
1	O
(	O
11	O
.	O
6	O
)	O

49	O

Online	O
personal	O
health	O
record	O
:	O
education	O
,	O
diabetes	B-DS
care	O
plan	O
,	O
agenda	O
,	O
messaging	O
,	O
prescription	O
refills	O

Access	O
to	O
general	O
website	O
Patient	O
Gateway	O

Changes	O
in	O
HbA1c	O
,	O
BP	O
,	O
and	O
LDL	O
cholesterol	B-CD

McMahon	O
2012	O
[	O
50	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

151	O
people	O
with	O
DM	B-DS
,	O
HbA1c	O
>	O
8	O
.	O
5	O
%	O
from	O
veteran	O
health	O
services	O

60	O
.	O
2	O
(	O
10	O
.	O
8	O
)	O

5	O

(	O
1	O
)	O
Self	O
-	O
monitoring	O
via	O
phone	O
(	O
BP	O
,	O
glucose	B-CD
);	O
(	O
2	O
)	O
website	O
:	O
self	O
-	O
monitoring	O
(	O
BP	O
,	O
glucose	B-CD
),	O
education	O
,	O
support	O
by	O
care	O
managersb	O
,	O
c	O

(	O
3	O
)	O
Website	O
with	O
links	O
to	O
other	O
DM	O
websites	O
;	O
usual	O
care	O

Change	O
in	O
HbA1c	O
and	O
BP	O
over	O
time	O

Ralston	O
2009	O
[	O
51	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

83	O
people	O
with	O
DM2	O
,	O
HbA1c	O
≥	O
7	O
.	O
0	O
%	O
and	O
Internet	O
from	O
clinic	O
:	O
65	O
%	O
with	O
2	O
CV	O
risk	O
factors	O

57	O
.	O
3	O
(—)	O

52	O

Electronic	O
medical	O
record	O
:	O
self	O
-	O
monitoring	O
(	O
glucose	B-CD
,	O
exercise	O
,	O
diet	O
,	O
medication	O
),	O
support	O
by	O
care	O
manager	O
,	O
usual	O
care	O
visits	O

Usual	O
care	O
visits	O

Change	O
in	O
HbA1c	O

Kwon	O
2004	O
[	O
52	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
South	O
Korea	O
;	O
3	O
m	O

110	O
people	O
with	O
DM2	O
,	O
Internet	O
from	O
clinic	O
:	O
27	O
%	O
hypertension	B-DS

54	O
.	O
1	O
(	O
9	O
.	O
1	O
)	O

33	O

Website	O
:	O
self	O
-	O
monitoring	O
(	O
glucose	B-CD
),	O
reminders	O
,	O
professor	O
/	O
nurse	O
/	O
dietician	O
-	O
support	O

Monthly	O
visit	O
to	O
diabetes	B-DS
specialist	O

HbA1c	O

EMPOWER	O
-	O
D	O
2013	O
[	O
39	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

415	O
people	O
with	O
DM	B-DS
and	O
HbA1c	O
≥	O
7	O
.	O
5	O
%	O
from	O
clinic	O

53	O
.	O
7	O
(	O
10	O
.	O
2	O
)	O

40	O

Online	O
health	O
record	O
:	O
risk	O
estimation	O
,	O
self	O
-	O
monitoring	O
(	O
glucose	B-CD
,	O
diet	O
,	O
exercise	O
,	O
BP	O
),	O
nurse	O
support	O
,	O
own	O
doctor	O
informed	O

Usual	O
care	O

HbA1c	O
at	O
12	O
m	O

REDEEM	O
2013	O
[	O
53	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

392	O
people	O
with	O
DM2	O
,	O
Internet	O
from	O
community	O
centers	O

56	O
.	O
1	O
(	O
9	O
.	O
6	O
)	O

54	O

(	O
1	O
)	O
CASM	O
website	O
:	O
goal	O
setting	O
;	O
self	O
-	O
monitoring	O
(	O
HbA1c	O
,	O
BP	O
,	O
cholesterol	B-CD
);	O
8	O
phone	O
calls	O
;	O
b	O
(	O
2	O
)	O
Computer	O
-	O
assisted	O
self	O
-	O
management	O
+	O
problem	O
solving	O
treatment	O
(	O
CASP	O
):	O
CASM	O
+	O
8	O
sessions	O
problem	O
solving	O

Computer	O
health	O
risk	O
appraisal	O
,	O
education	O
,	O
same	O
phone	O
calls	O
as	O
intervention	O

Diabetes	B-DS
distress	O
;	O
HbA1c	O
,	O
physical	O
activity	O
,	O
medication	O
compliance	O

a	O
Abbreviations	O
:	O
BP	O
:	O
blood	O
pressure	O
;	O
CASM	O
:	O
computer	O
-	O
assisted	O
self	O
-	O
management	O
;	O
CASP	O
:	O
computer	O
-	O
assisted	O
self	O
-	O
management	O
+	O
problem	O
solving	O
treatment	O
;	O
CV	O
:	O
cardiovascular	O
;	O
DM	B-DS
:	O
diabetes	B-DS
mellitus	I-DS
;	O
DM2	O
:	O
type	B-DS
2	I-DS
diabetes	I-DS
mellitus	I-DS
;	O
GP	O
:	O
general	O
practitioner	O
;	O
HbA1c	O
;	O
glycated	O
hemoglobin	B-GP
A1c	O
;	O
HDL	O
:	O
high	O
-	O
density	O
lipoprotein	O
;	O
LDL	O
:	O
low	O
-	O
density	O
lipoprotein	O
.	O

b	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
all	O
analyses	O
.	O

c	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
the	O
subgroup	O
analysis	O
on	O
blended	O
interventions	O
.	O

Effect	O
on	O
systolic	O
blood	O
pressure	O
(	O
26	O
studies	O
).	O

Characteristics	O
of	O
the	O
studies	O
included	O
for	O
the	O
systematic	O
review	O
:	O
interventions	O
targeting	O
blood	O
pressure	O
.	O
a	O

Study	O

Setting	O
and	O
study	O
length	O

Participants	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

Sex	O
(%	O
female	O
)	O

Intervention	O

Control	O

Primary	O
;	O
secondary	O
outcomes	O

e	O
-	O
BP	O
2008	O
[	O
29	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

778	O
people	O
with	O
Internet	O
,	O
hypertension	B-DS
,	O
from	O
GPs	O
:	O
61	O
.	O
1	O
%	O
obese	O

59	O
.	O
1	O
(	O
8	O
.	O
5	O
)	O

52	O

(	O
1	O
)	O
Website	O
:	O
BP	O
self	O
-	O
monitoring	O
;	O
b	O
(	O
2	O
)	O
1	O
+	O
pharmacist	O
supportc	O

General	O
website	O
:	O
personal	O
medical	O
record	O

Change	O
in	O
diastolic	O
,	O
systolic	O
and	O
mean	O
BP	O

Nolan	O
2012	O
[	O
54	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Canada	O
;	O
4	O
m	O

387	O
people	O
with	O
hypertension	B-DS
via	O
website	O
:	O
41	O
%	O
obese	O

56	O
.	O
5	O
(	O
7	O
.	O
4	O
)	O

59	O

BP	O
action	O
plan	O
website	O
:	O
assessing	O
motivational	O
readiness	O
,	O
advice	O
,	O
feedback	O
,	O
education	O

E	O
-	O
newsletters	O

Change	O
in	O
diastolic	O
and	O
systolic	O
BP	O
,	O
and	O
pulse	O
pressure	O

Bove	O
2013	O
[	O
55	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

241	O
people	O
with	O
elevated	O
BP	B-DS
from	O
2	O
clinics	O

59	O
.	O
6	O
(	O
13	O
.	O
6	O
)	O

65	O

Website	O
+	O
telephone	O
system	O
:	O
education	O
,	O
self	O
-	O
monitoring	O
(	O
BP	O
,	O
weight	O
,	O
exercise	O
),	O
online	O
nurse	O
support	O
,	O
doctor	O
informed	O

Provision	O
of	O
data	O
from	O
initial	O
assessment	O
,	O
usual	O
care	O

Proportion	O
of	O
participants	O
with	O
controlled	O
BP	B-DS
at	O
6	O
m	O

Madsen	O
2008	O
[	O
56	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Denmark	O
;	O
6	O
m	O

236	O
people	O
with	O
hypertension	B-DS
from	O
10	O
GPs	O

55	O
.	O
9	O
(	O
11	O
.	O
7	O
)	O

50	O

Website	O
:	O
self	O
-	O
monitoring	O
(	O
BP	O
),	O
feedback	O
from	O
own	O
doctor	O
by	O
email	O

Usual	O
care	O

Change	O
in	O
ambulatory	O
systolic	O
BP	O
-	O
at	O
6	O
m	O

Magid	O
2013	O
[	O
57	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

348	O
people	O
with	O
hypertension	B-DS
from	O
10	O
clinics	O

60	O
(	O
11	O
)	O

40	O

Written	O
educational	O
material	O
,	O
website	O
:	O
self	O
-	O
monitoring	O
(	O
BP	O
),	O
pharmacist	O
support	O
,	O
doctor	O
informed	O
,	O
reminders	O

Written	O
education	O
material	O
,	O
usual	O
care	O

Proportion	O
of	O
participants	O
with	O
controlled	O
BP	B-DS
at	O
6	O
m	O

McKinstry	O
2013	O
[	O
38	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Scotland	O
;	O
6	O
m	O

401	O
people	O
with	O
hypertension	B-DS
from	O
20	O
GPs	O

60	O
.	O
7	O
(	O
11	O
.	O
2	O
)	O

40	O

Telemonitoring	O
unit	O
+	O
website	O
:	O
self	O
-	O
monitoring	O
(	O
BP	O
),	O
feedback	O
from	O
own	O
doctor	O

Usual	O
care	O

Mean	O
ambulatory	O
BP	O
at	O
6	O
m	O

Thiboutot	O
2013	O
[	O
58	O
]	O

2	O
-	O
arm	O
cluster	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

500	O
patients	O
with	O
elevated	O
BP	O
from	O
54	O
GPs	O

60	O
.	O
5	O
(	O
11	O
.	O
9	O
)	O

58	O

Website	O
:	O
self	O
-	O
monitoring	O
(	O
BP	O
,	O
medication	O
),	O
feedback	O
,	O
reminders	O

Different	O
prevention	O
website	O
(	O
eg	O
,	O
breast	O
screening	O
)	O

BP	O
control	O
at	O
12	O
m	O

a	O
Abbreviations	O
:	O
BP	O
:	O
blood	O
pressure	O
;	O
GP	O
:	O
general	O
practitioner	O
.	O

b	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
all	O
analyses	O
.	O

c	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
the	O
subgroup	O
analysis	O
on	O
blended	O
interventions	O
.	O

Characteristics	O
of	O
the	O
studies	O
included	O
for	O
the	O
systematic	O
review	O
:	O
interventions	O
targeting	O
weight	O
loss	O
and	O
weight	O
loss	O
maintenance	O
.	O
a	O

Study	O

Setting	O
and	O
study	O
length	O

Participants	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

Sex	O
(%	O
female	O
)	O

Intervention	O

Control	O

Primary	O
;	O
secondary	O
outcomes	O

Weight	O
loss	O









Appel	O
2011	O
[	O
35	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
24	O
m	O

415	O
people	O
with	O
obesity	B-DS
,	O
≥	O
1	O
CV	O
risk	O
factor	O
,	O
Internet	O
from	O
6	O
primary	O
clinics	O

54	O
(	O
10	O
.	O
2	O
)	O

64	O

(	O
1	O
)	O
Website	O
+	O
mobile	O
coach	O
support	O
:	O
education	O
,	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
diet	O
,	O
exercise	O
),	O
reminders	O
,	O
doctor	O
informed	O
;	O
b	O
,	O
c	O
(	O
2	O
)	O
1	O
+	O
in	O
-	O
person	O
support	O

1	O
(	O
or	O
2	O
)	O
meetings	O
with	O
coach	O
;	O
brochure	O
with	O
websites	O
for	O
weight	O
loss	O

Change	O
in	O
weight	O
from	O
baseline	O
to	O
24	O
m	O


Bennett	O
2012	O
[	O
28	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
24	O
m	O

365	O
obese	O
people	O
with	O
hypertension	B-DS
from	O
3	O
clinics	O

54	O
.	O
6	O
(	O
10	O
.	O
9	O
)	O

69	O

Website	O
/	O
interactive	O
voice	O
response	O
system	O
:	O
self	O
-	O
monitoring	O
weight	O
,	O
setting	O
,	O
coach	O
support	O
(	O
phone	O
),	O
group	O
sessions	O
,	O
education	O

Self	O
-	O
help	O
booklet	O

Change	O
in	O
weight	O
at	O
24	O
m	O


Bennett	O
2010	O
[	O
59	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

101	O
obese	O
people	O
with	O
hypertension	B-DS
,	O
Internet	O
from	O
clinic	O

54	O
.	O
4	O
(	O
8	O
.	O
1	O
)	O

48	O

Website	O
:	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
,	O
behavioral	O
skills	O
education	O
,	O
forum	O
,	O
coach	O
support	O
(	O
online	O
,	O
phone	O
,	O
face	O
-	O
to	O
-	O
face	O
)	O

Folder	O
on	O
healthy	O
weight	O
,	O
usual	O
care	O

Change	O
in	O
weight	O
at	O
12	O
weeks	O


Kraschnewsky	O
2011	O
[	O
60	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

100	O
overweight	O
people	O
,	O
Internet	O
via	O
flyers	O
/	O
Internet	O

50	O
.	O
3	O
(	O
10	O
.	O
9	O
)	O

70	O

Website	O
:	O
target	O
body	O
weight	O
,	O
monitoring	O
,	O
behavioral	O
tips	O
,	O
videos	O
,	O
weight	O
loss	O
plan	O
,	O
tailored	O
feedback	O
,	O
reminders	O

Wait	O
list	O
,	O
people	O
got	O
access	O
to	O
website	O
after	O
12	O
weeks	O

Weight	O
loss	O


Webberd	O
2008	O
[	O
61	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
4	O
m	O

66	O
women	O
,	O
BMI	O
25	O
-	O
40	O
,	O
Internet	O
from	O
advertisements	O

50	O
.	O
0	O
(	O
9	O
.	O
9	O
)	O

100	O

Website	O
:	O
weight	O
loss	O
tips	O
,	O
lessons	O
,	O
message	O
board	O
,	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
diet	O
),	O
chat	O
sessions	O

All	O
features	O
of	O
intervention	O
except	O
for	O
online	O
chat	O
sessions	O

Not	O
defined	O
;	O
weight	O
,	O
BMI	O
,	O
diet	O
,	O
exercise	O


E	O
-	O
LITE	O
2013	O
[	O
36	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
15	O
m	O

241	O
people	O
with	O
a	O
BMI	O
≥	O
25	O
,	O
metabolic	B-DS
syndrome	I-DS
from	O
1	O
clinic	O

52	O
.	O
9	O
(	O
10	O
.	O
6	O
)	O

47	O

(	O
1	O
)	O
Website	O
+	O
12	O
lifestyle	O
classes	O
;	O
c	O
(	O
2	O
)	O
website	O
:	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
exercise	O
),	O
messaging	O
,	O
DVD	O
with	O
lifestyle	O
classesb	O

Usual	O
care	O

Change	O
in	O
BMI	O
from	O
baseline	O
to	O
15	O
m	O


POWER	O
2014	O
[	O
62	O
]	O

4	O
-	O
arm	O
RCT	O
;	O
UK	O
;	O
12	O
m	O

179	O
people	O
with	O
BMI	O
≥	O
30	O
kg	O
/	O
m2	O
or	O
≥	O
28	O
kg	O
/	O
m2	O
+	O
CV	O
risk	O
factors	O
from	O
5	O
GPs	O

51	O
.	O
2	O
(	O
13	O
.	O
1	O
)	O

66	O

(	O
1	O
)	O
Website	O
:	O
12	O
self	O
-	O
management	O
sessions	O
monitoring	O
(	O
weight	O
),	O
nurse	O
support	O
(	O
email	O
);	O
b	O
,	O
c	O
(	O
2	O
)	O
1	O
+	O
3	O
nurse	O
contacts	O
;	O
(	O
3	O
)	O
1	O
+	O
7	O
nurse	O
contacts	O

Usual	O
care	O

Weight	O
at	O
12	O
m	O

Weight	O
loss	O
maintenance	O









Stop	O
Regain	O
2008	O
[	O
41	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
18	O
m	O

314	O
people	O
with	O
10	O
%	O
weight	O
loss	O
in	O
2	O
years	O
,	O
via	O
advertisements	O

51	O
(	O
10	O
)	O

81	O

(	O
1	O
)	O
Website	O
:	O
self	O
-	O
monitoring	O
,	O
email	O
counseling	O
,	O
experts	O
chat	O
;	O
b	O
(	O
2	O
)	O
face	O
-	O
to	O
-	O
face	O
:	O
self	O
-	O
monitoring	O
via	O
phone	O
,	O
weekly	O
group	O
sessions	O

(	O
3	O
)	O
Newsletters	O

Weight	O
gain	O
at	O
18	O
m	O


WLM	O
2008	O
[	O
40	O
]	O

2	O
-	O
phase	O
3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
30	O
m	O

1032	O
people	O
with	O
≥	O
4	O
kg	O
previous	O
weight	O
loss	O
,	O
hypertension	B-DS
,	O
Internet	O
via	O
university	O
/	O
medicare	O

55	O
.	O
6	O
(	O
8	O
.	O
7	O
)	O

63	O

(	O
1	O
)	O
Website	O
:	O
goal	O
setting	O
,	O
action	O
plans	O
,	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
PA	O
,	O
diet	O
),	O
education	O
,	O
bulletin	O
board	O
,	O
reminders	O
,	O
support	O
(	O
email	O
/	O
phone	O
);	O
b	O
(	O
2	O
)	O
personal	O
contact	O
(	O
phone	O
+	O
face	O
-	O
to	O
-	O
face	O
)	O

Printed	O
lifestyle	O
guidelines	O
,	O
1	O
visit	O
with	O
coach	O

Change	O
in	O
weight	O

a	O
Abbreviations	O
:	O
BMI	O
:	O
body	O
mass	O
index	O
;	O
CV	O
:	O
cardiovascular	O
;	O
GP	O
:	O
general	O
practitioner	O
;	O
PA	O
:	O
physical	O
activity	O
.	O

b	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
all	O
analyses	O
.	O

c	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
the	O
subgroup	O
analysis	O
on	O
blended	O
interventions	O
.	O

d	O
Control	O
arm	O
consists	O
of	O
same	O
interactive	O
Internet	O
platform	O
as	O
intervention	O
arm	O
.	O

Characteristics	O
of	O
the	O
studies	O
included	O
for	O
the	O
systematic	O
review	O
:	O
interventions	O
targeting	O
physical	O
activity	O
and	O
cholesterol	B-CD
.	O
a	O

Study	O

Setting	O
and	O
study	O
length	O

Participants	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

Sex	O
(%	O
female	O
)	O

Intervention	O

Control	O

Primary	O
;	O
secondary	O
outcomes	O

Physical	O
activity	O









Richardsonb	O
2010	O
[	O
63	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
4	O
m	O

324	O
patients	O
from	O
clinic	O
:	O
12	O
%	O
CHD	B-DS
,	O
20	O
%	O
DM2	O
,	O
62	O
%	O
BMI	O
>	O
30	O

52	O
.	O
0	O
(	O
11	O
.	O
4	O
)	O

65	O

Website	O
as	O
control	O
+	O
online	O
community	O
forum	O

Website	O
:	O
pedometer	O
,	O
tailored	O
feedback	O

Change	O
in	O
average	O
daily	O
step	O
count	O
,	O
patient	O
attrition	O


Reid	O
2011	O
[	O
30	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Canada	O
;	O
12	O
m	O

223	O
patients	O
with	O
a	O
recent	O
CHD	B-DS
event	O
,	O
Internet	O
via	O
2	O
cardiac	O
centers	O

56	O
.	O
4	O
(	O
9	O
.	O
0	O
)	O

16	O

Website	O
:	O
tutorials	O
,	O
exercise	O
plans	O
,	O
self	O
-	O
monitoring	O
,	O
specialist	O
support	O

Usual	O
care	O
,	O
education	O
booklet	O

Mean	O
steps	O
per	O
day	O


Ferney	O
2009	O
[	O
64	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Australia	O
;	O
6	O
m	O

106	O
inactive	O
residents	O
:	O
58	O
%	O
overweight	O

52	O
.	O
0	O
(	O
4	O
.	O
6	O
)	O

72	O

Website	O
:	O
behavioral	O
strategies	O
,	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
,	O
advice	O
,	O
bulletin	O
board	O
,	O
news	O

Website	O
with	O
minimal	O
interactivity	O

Not	O
defined	O
;	O
physical	O
activity	O
,	O
website	O
use	O


Active	O
after	O
55	O
2013	O
[	O
65	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

405	O
sedentary	O
people	O
with	O
Internet	O
via	O
senior	O
centers	O
/	O
websites	O

60	O
.	O
3	O
(	O
4	O
.	O
9	O
)	O

69	O

Website	O
:	O
education	O
,	O
goal	O
setting	O
,	O
exercise	O
planning	O
,	O
11	O
online	O
exercise	O
lessons	O
,	O
self	O
-	O
monitoring	O
,	O
reminders	O

No	O
access	O
to	O
the	O
intervention	O

Not	O
defined	O
;	O
physical	O
activity	O
,	O
BMI	O


HEART	O
2014	O
[	O
37	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
New	O
Zealand	O
;	O
6	O
m	O

171	O
people	O
with	O
stable	O
CHD	B-DS
,	O
Internet	O
from	O
2	O
hospitals	O

60	O
.	O
2	O
(	O
9	O
.	O
2	O
)	O

19	O

Exercise	O
prescription	O
,	O
behavioral	O
strategies	O
,	O
Website	O
:	O
videos	O
,	O
self	O
-	O
monitoring	O
(	O
exercise	O
),	O
education	O
,	O
reminders	O

Usual	O
care	O

Change	O
in	O
peak	O
oxygen	O
uptake	O
from	O
baseline	O
to	O
6	O
m	O


Philips	O
Direct	O
Life	O
2013	O
[	O
66	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Netherlands	O
;	O
3	O
m	O

235	O
inactive	O
people	O
with	O
Internet	O
through	O
local	O
media	O

64	O
.	O
8	O
(	O
2	O
.	O
9	O
)	O

41	O

Website	O
:	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
(	O
exercise	O
),	O
e	O
-	O
coach	O
feedback	O

Waitlist	O
control	O

Change	O
in	O
physical	O
activity	O


Suboc	O
2014	O
[	O
67	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

114	O
sedentary	O
people	O
through	O
media	O
and	O
Internet	O

63	O
.	O
0	O
(	O
7	O
.	O
0	O
)	O

34	O

(	O
1	O
)	O
Pedometer	O
;	O
(	O
2	O
)	O
website	O
+	O
pedometer	O
:	O
exercise	O
strategies	O
,	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
(	O
exercise	O
)	O
feedback	O
,	O
forumc	O

No	O
intervention	O

Endothelial	O
function	O
;	O
vascular	O
stiffness	O
,	O
step	O
count	O
,	O
exercise	O


Peels	O
2013	O
[	O
68	O
]	O

5	O
-	O
arm	O
cluster	O
RCT	O
;	O
Netherlands	O
;	O
12	O
m	O

2140	O
people	O
from	O
6	O
municipal	O
regions	O
,	O
±	O
50	O
%	O
overweight	O

63	O
.	O
2	O
(	O
8	O
.	O
4	O
)	O

51	O

(	O
1	O
)	O
Printed	O
feedback	O
report	O
;	O
(	O
2	O
)	O
1	O
+	O
local	O
exercise	O
tips	O
;	O
(	O
3	O
)	O
Web	O
-	O
based	O
feedback	O
report	O
;	O
(	O
4	O
)	O
3	O
+	O
local	O
exercise	O
tipsc	O

Waitlist	O
control	O

Physical	O
activity	O

Cholesterol	B-CD









Blochb	O
2006	O
[	O
69	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

171	O
employees	O
with	O
increased	O
cholesterol	B-CD
,	O
DM	O
or	O
CHD	B-DS

54	O
.	O
8	O
(	O
9	O
.	O
4	O
)	O

—	O

(	O
1	O
)	O
Website	O
+	O
financial	O
reward	O
;	O
(	O
2	O
)	O
website	O
+	O
4	O
classes	O
,	O
nurse	O
support	O
(	O
phone	O
)	O

Website	O
,	O
10	O
-	O
year	O
CVD	B-DS
score	O
,	O
monitoring	O
,	O
goals	O
,	O
tailored	O
info	O

LDL	O
cholesterol	B-CD
change	O
at	O
6	O
m	O


Live	O
well	O
2013	O
[	O
70	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

61	O
people	O
with	O
LDL	O
cholesterol	B-CD
≥	O
3	O
.	O
37	O
mmol	O
/	O
L	O
,	O
Internet	O
from	O
primary	O
clinics	O

52	O
.	O
0	O
(	O
12	O
.	O
8	O
)	O

75	O

Web	O
-	O
based	O
rate	O
-	O
your	O
-	O
plate	O
assessment	O
,	O
written	O
educational	O
material	O
,	O
Website	O
:	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
,	O
reminders	O

Web	O
-	O
based	O
rate	O
-	O
your	O
-	O
plate	O
assessment	O

Not	O
defined	O
;	O
cholesterol	B-CD
,	O
weight	O
,	O
Framingham	O
risk	O
score	O

a	O
Abbreviations	O
:	O
BMI	O
:	O
body	O
mass	O
index	O
;	O
CHD	B-DS
:	O
coronary	B-DS
heart	I-DS
disease	I-DS
;	O
CVD	B-DS
:	O
cardiovascular	B-DS
disease	I-DS
;	O
DM	B-DS
:	O
diabetes	B-DS
mellitus	I-DS
;	O
DM2	O
:	O
type	B-DS
2	I-DS
diabetes	I-DS
mellitus	I-DS
;	O
LDL	O
:	O
low	O
-	O
density	O
lipoprotein	O
.	O

b	O
Control	O
arm	O
consists	O
of	O
same	O
interactive	O
Internet	O
platform	O
as	O
intervention	O
arm	O
.	O

c	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
all	O
analyses	O
.	O

Characteristics	O
of	O
the	O
studies	O
included	O
for	O
the	O
systematic	O
review	O
:	O
interventions	O
targeting	O
multiple	O
risk	O
factors	O
.	O
a	O

Study	O

Setting	O
and	O
study	O
length	O

Participants	O

Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O

Sex	O
(%	O
female	O
)	O

Intervention	O

Control	O

Primary	O
;	O
secondary	O
outcomes	O

Lindsay	O
2008	O
[	O
71	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
UK	O
;	O
6	O
m	O

108	O
heart	O
patients	O
living	O
in	O
deprived	O
areas	O

62	O
.	O
9	O
(	O
6	O
.	O
0	O
)	O

33	O

eHealth	O
portal	O
:	O
glossary	O
,	O
education	O
,	O
local	O
community	O
links	O
,	O
discussion	O
forum	O

No	O
access	O
to	O
the	O
eHealth	O
portal	O

Not	O
defined	O
;	O
behavior	O
change	O
(	O
exercise	O
,	O
smoking	O
,	O
diet	O
)	O

Heartcare	O
II	O
2010	O
[	O
72	O
]	O

2	O
-	O
arm	O
cluster	O
RCT	O
;	O
USA	O
;	O
30	O
m	O

282	O
patients	O
with	O
chronic	B-DS
heart	I-DS
disease	I-DS
needing	O
nursing	O
care	O

64	O
.	O
0	O
(	O
12	O
.	O
7	O
)	O

39	O

Personal	O
health	O
record	O
:	O
education	O
,	O
monitoring	O
,	O
communication	O
,	O
goal	O
setting	O
,	O
email	O
,	O
bulletin	O
board	O

Usual	O
care	O
as	O
the	O
home	O
care	O
agencies	O
use	O
to	O
provide	O

Satisfaction	O
with	O
nursing	O
care	O

Hughes	O
2011	O
[	O
73	O
]	O

3	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

423	O
senior	O
university	O
employees	O
with	O
Internet	O
,	O
32	O
%	O
overweight	O
,	O
46	O
%	O
obese	O

51	O
.	O
0	O
(	O
7	O
.	O
0	O
)	O

82	O

(	O
1	O
)	O
Coach	O
for	O
Web	O
-	O
based	O
risk	O
assessment	O
,	O
lifestyle	O
plan	O
,	O
email	O
,	O
phone	O
or	O
in	O
-	O
person	O
contact	O
;	O
c	O
(	O
2	O
)	O
website	O
:	O
risk	O
profile	O
assessment	O
,	O
advice	O
,	O
goal	O
setting	O
,	O
action	O
planningb	O

Printed	O
list	O
of	O
health	O
promotion	O
programs	O

Not	O
defined	O
;	O
diet	O
,	O
exercise	O
,	O
weight	O

Southard	O
2003	O
[	O
26	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

104	O
patients	O
with	O
CHD	B-DS
or	O
heart	B-DS
failure	I-DS
from	O
10	O
hospitals	O
,	O
200	O
GPs	O
,	O
adverts	O

62	O
.	O
3	O
(	O
10	O
.	O
6	O
)	O

25	O

Website	O
+	O
nurse	O
:	O
education	O
,	O
self	O
-	O
monitoring	O
,	O
discussion	O
group	O
,	O
links	O
contact	O
(	O
email	O
,	O
phone	O
or	O
mail	O
),	O
dietician	O

Usual	O
care	O

Not	O
defined	O
;	O
weight	O
,	O
exercise	O
,	O
BP	O
,	O
lipid	O
profile	O
,	O
new	O
CV	O
events	O

Winett	O
2007	O
[	O
74	O
]	O

3	O
-	O
arm	O
cluster	O
RCT	O
;	O
USA	O
;	O
16	O
m	O

14	O
churches	O
with	O
1071	O
members	O
:	O
57	O
%	O
overweight	O
,	O
60	O
%	O
sedentary	O

51	O
.	O
4	O
(	O
15	O
.	O
7	O
)	O

67	O

(	O
1	O
)	O
Website	O
:	O
education	O
,	O
goal	O
setting	O
,	O
pedometer	O
;	O
b	O
(	O
2	O
)	O
1	O
+	O
pulpit	O
supportc	O

Waitlist	O
condition	O

Nutrition	O
improvement	O
,	O
physical	O
activity	O

Vernooij	O
2012	O
[	O
27	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Netherlands	O
;	O
12	O
m	O

330	O
patients	O
with	O
CVD	B-DS
,	O
2	O
risk	O
factors	O
,	O
Internet	O
via	O
2	O
hospitals	O

59	O
.	O
9	O
(	O
8	O
.	O
4	O
)	O

25	O

Website	O
:	O
risk	O
profile	O
,	O
self	O
-	O
monitoring	O
(	O
BP	O
,	O
cholesterol	B-CD
),	O
treatment	O
goal	O
,	O
nurse	O
support	O
,	O
news	O
,	O
medication	O
changes	O

Usual	O
care	O
by	O
specialist	O
or	O
GP	O
,	O
receiving	O
baseline	O
risk	O
profile	O

Relative	O
change	O
in	O
Framingham	O
heart	O
risk	O
score	O
after	O
1	O
year	O

Verheijden	O
2004	O
[	O
75	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Canada	O
;	O
8	O
m	O

146	O
people	O
with	O
increased	O
CV	O
risk	O
,	O
Internet	O
from	O
14	O
GPs	O

63	O
.	O
0	O
(	O
10	O
.	O
5	O
)	O

45	O

Website	O
:	O
tailored	O
information	O
,	O
diet	O
tool	O
,	O
bulletin	O
board	O

Usual	O
care	O

Not	O
defined	O
;	O
BMI	O
,	O
BP	O
,	O
lipid	O
profile	O

Ross	O
2004	O
[	O
33	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

107	O
patients	O
with	O
heart	B-DS
failure	I-DS
,	O
Internet	O
via	O
clinic	O

56	O
.	O
0	O
(-)	O

23	O

Online	O
medical	O
record	O
(	O
clinical	O
notes	O
,	O
laboratory	O
reports	O
,	O
test	O
results	O
),	O
education	O
,	O
nurse	O
support	O

Usual	O
care	O

Change	O
in	O
self	O
-	O
efficacy	O
domain	O

Bove	O
2011	O
[	O
76	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

465	O
people	O
with	O
CVD	B-DS
risk	O
>	O
10	O
%	O
via	O
community	O
,	O
clinics	O
,	O
churches	O

61	O
.	O
0	O
(	O
10	O
.	O
0	O
)	O

46	O

Online	O
telemedicine	O
system	O
:	O
laboratory	O
and	O
medication	O
review	O
,	O
self	O
-	O
monitoring	O
(	O
BP	O
,	O
weight	O
,	O
pedometer	O
),	O
feedback	O
,	O
education	O
,	O
own	O
doctor	O
involved	O

4	O
-	O
months	O
meetings	O
with	O
nurse	O
:	O
review	O
data	O
from	O
logbooks	O

Reduction	O
in	O
Framingham	O
10	O
-	O
year	O
CVD	B-DS
risk	O
score	O

Keyserling	O
2014	O
[	O
31	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
12	O
m	O

385	O
people	O
with	O
CHD	B-DS
risk	O
score	O
≥	O
10	O
%	O
but	O
no	O
CVD	B-DS
from	O
5	O
GPs	O

62	O
.	O
0	O
(	O
7	O
.	O
8	O
)	O

48	O

Website	O
:	O
CHD	B-DS
risk	O
calculator	O
,	O
advice	O
,	O
education	O
,	O
action	O
planning	O
,	O
goal	O
setting	O
.	O

Same	O
CHD	B-DS
risk	O
calculator	O
,	O
but	O
in	O
-	O
person	O
and	O
by	O
phone	O

Framingham	O
10	O
-	O
year	O
CHD	B-DS
risk	O
score	O
at	O
4	O
and	O
12	O
m	O

Zullig	O
2014	O
[	O
77	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
3	O
m	O

96	O
people	O
with	O
CVD	B-DS
or	O
DM	B-DS
from	O
primary	O
clinics	O

36	O
.	O
1	O
(	O
12	O
.	O
2	O
)	O

67	O

CVD	B-DS
risk	O
assessment	O
,	O
website	O
:	O
6	O
modules	O
with	O
risk	O
assessments	O
,	O
goal	O
setting	O
,	O
education	O

Printed	O
information	O
on	O
CVD	B-DS

Not	O
defined	O
;	O
Framingham	O
10	O
-	O
year	O
CVD	B-DS
risk	O
score	O
,	O
BMI	O
,	O
smoking	O
status	O
,	O
systolic	O
BP	O

Activate	O
your	O
Heart	O
2014	O
[	O
78	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
UK	O
;	O
6	O
m	O

95	O
people	O
with	O
stable	O
angina	B-DS
,	O
Internet	O
from	O
9	O
GPs	O

66	O
.	O
2	O
(	O
9	O
.	O
2	O
)	O

25	O

Website	O
:	O
CVD	B-DS
risk	O
assessment	O
,	O
education	O
,	O
goal	O
setting	O
,	O
self	O
-	O
monitoring	O
,	O
email	O
/	O
chat	O
with	O
experts	O

Usual	O
care	O
with	O
GP	O

Change	O
in	O
step	O
count	O
at	O
6	O
weeks	O
and	O
6	O
m	O

e	O
-	O
Care	O
2014	O
[	O
79	O
]	O

2	O
-	O
arm	O
RCT	O
USA	O
6m	O

101	O
people	O
with	O
BMI	O
>	O
26	O
,	O
elevated	O
BP	O
via	O
electronic	O
health	O
records	O

56	O
.	O
9	O
(	O
7	O
.	O
0	O
)	O

42	O

Website	O
+	O
dietician	O
:	O
CVD	B-DS
risk	O
assessment	O
,	O
goal	O
setting	O
,	O
action	O
planning	O
,	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
BP	O
,	O
physical	O
activity	O
,	O
diet	O
)	O

Usual	O
care	O
,	O
printed	O
report	O
for	O
patient	O
and	O
doctor	O

Change	O
in	O
systolic	O
BP	O
,	O
weight	O
and	O
10	O
-	O
year	O
CVD	B-DS
risk	O
score	O

Greene	O
2012	O
[	O
80	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
USA	O
;	O
6	O
m	O

513	O
employees	O
+	O
families	O
45	O
%	O
overweight	O
and	O
48	O
%	O
obese	O

60	O
%	O
older	O
than	O
50	O
years	O

79	O

Printed	O
lifestyle	O
guide	O
,	O
website	O
:	O
online	O
social	O
network	O
,	O
self	O
-	O
monitoring	O
(	O
weight	O
,	O
exercise	O
),	O
goal	O
setting	O
,	O
feedback	O

Printed	O
lifestyle	O
guide	O

Not	O
defined	O
;	O
physical	O
activity	O
,	O
weight	O
,	O
lipid	O
profile	O

Holbrook	O
2009	O
[	O
81	O
]	O

2	O
-	O
arm	O
cluster	O
RCT	O
;	O
Canada	O
;	O
12	O
m	O

46	O
GPs	O
with	O
511	O
people	O
with	O
DM	O
,	O
≥	O
1	O
CV	O
risk	O
factor	O

60	O
.	O
7	O
(	O
12	O
.	O
5	O
)	O

49	O

Personal	O
Web	O
-	O
based	O
profile	O
overview	O
for	O
DM	O
/	O
CVRM	O
care	O
,	O
automated	O
telephone	O
reminders	O
,	O
summary	O
for	O
doctor	O
,	O
doctor	O
involved	O

Usual	O
care	O

Composite	O
score	O
for	O
process	O
of	O
care	O

Diabetes	B-DS
in	O
Check	O
2014	O
[	O
82	O
]	O

2	O
-	O
arm	O
RCT	O
;	O
Australia	O
;	O
9	O
m	O

436	O
people	O
with	O
DM	O
,	O
Internet	O
via	O
DM	O
network	O

58	O
.	O
2	O
(	O
10	O
.	O
3	O
)	O

48	O

Website	O
:	O
self	O
-	O
monitoring	O
(	O
exercise	O
)	O
goal	O
setting	O
,	O
education	O
,	O
discussion	O
board	O

General	O
website	O
with	O
home	O
page	O
and	O
contacts	O
page	O
only	O

Not	O
defined	O
;	O
physical	O
activity	O
,	O
BMI	O

a	O
Abbreviations	O
:	O
BMI	O
:	O
body	O
mass	O
index	O
;	O
BP	O
:	O
blood	O
pressure	O
;	O
CHD	B-DS
:	O
coronary	B-DS
heart	I-DS
disease	I-DS
;	O
CV	O
:	O
cardiovascular	O
;	O
CVD	B-DS
:	O
cardiovascular	B-DS
disease	I-DS
;	O
CVRM	O
:	O
cardiovascular	O
risk	O
management	O
;	O
DM	B-DS
:	O
diabetes	B-DS
mellitus	I-DS
;	O
GP	O
:	O
general	O
practitioner	O
.	O

b	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
all	O
analyses	O
.	O

c	O
For	O
studies	O
with	O
more	O
than	O
2	O
arms	O
,	O
this	O
arm	O
was	O
used	O
for	O
the	O
subgroup	O
analysis	O
on	O
blended	O
interventions	O
.	O

Effect	O
on	O
diastolic	O
blood	O
pressure	O
(	O
26	O
studies	O
).	O

Glycated	O
Hemoglobin	B-GP
A1c	O

A	O
significant	O
reduction	O
in	O
HbA1c	O
level	O
favoring	O
the	O
intervention	O
among	O
patients	O
with	O
type	B-DS
2	I-DS
diabetes	I-DS
mellitus	I-DS
was	O
found	O
(	O
21	O
studies	O
;	O
n	O
=	O
6518	O
;	O
Figure	O
4	O
).	O

The	O
weighted	O
mean	O
difference	O
for	O
HbA1c	O
was	O
–	O
0	O
.	O
13	O
%	O
(	O
95	O
%	O
CI	O
–	O
0	O
.	O
22	O
to	O
–	O
0	O
.	O
05	O
;	O
I2	O
=	O
74	O
%).	O

The	O
jackknife	O
procedure	O
did	O
not	O
reveal	O
one	O
particular	O
study	O
responsible	O
for	O
high	O
heterogeneity	O
.	O

Effect	O
on	O
glycated	O
hemoglobin	B-GP
(	O
21	O
studies	O
).	O

Weight	O

Fifteen	O
studies	O
tested	O
interventions	O
for	O
weight	O
loss	O
and	O
two	O
studies	O
tested	O
interventions	O
for	O
maintenance	O
of	O
weight	O
loss	O
.	O

The	O
pooled	O
analysis	O
(	O
17	O
studies	O
;	O
n	O
=	O
3713	O
;	O
Figure	O
5	O
)	O
showed	O
a	O
significant	O
reduction	O
in	O
weight	O
favoring	O
the	O
intervention	O
(	O
weighted	O
mean	O
difference	O
–	O
1	O
.	O
34	O
kg	O
,	O
95	O
%	O
CI	O
–	O
1	O
.	O
91	O
to	O
–	O
0	O
.	O
77	O
;	O
I2	O
=	O
61	O
%).	O

A	O
sensitivity	O
analysis	O
leaving	O
out	O
the	O
two	O
studies	O
on	O
weight	O
loss	O
maintenance	O
resulted	O
in	O
a	O
similar	O
effect	O
size	O
and	O
level	O
of	O
heterogeneity	O
.	O

The	O
jackknife	O
procedure	O
identified	O
three	O
studies	O
contributing	O
considerably	O
to	O
heterogeneity	O
[	O
35	O
,	O
42	O
,	O
59	O
].	O

Effect	O
on	O
weight	O
(	O
17	O
studies	O
).	O

Low	O
-	O
Density	O
Lipoprotein	O
Cholesterol	B-CD

A	O
small	O
but	O
significant	O
reduction	O
in	O
LDL	O
cholesterol	B-CD
favoring	O
the	O
intervention	O
was	O
found	O
(	O
17	O
studies	O
;	O
n	O
=	O
5035	O
;	O
Figure	O
6	O
;	O
weighted	O
mean	O
difference	O
–	O
2	O
.	O
18	O
mg	O
/	O
dL	O
,	O
95	O
%	O
CI	O
–	O
3	O
.	O
96	O
to	O
–	O
0	O
.	O
41	O
;	O
I2	O
=	O
44	O
%).	O

Effect	O
on	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	B-CD
(	O
17	O
studies	O
).	O

Physical	O
Activity	O

Fourteen	O
studies	O
(	O
n	O
=	O
4444	O
;	O
Figure	O
7	O
)	O
reported	O
the	O
effect	O
on	O
physical	O
activity	O
.	O

Eight	O
studies	O
used	O
self	O
-	O
reported	O
physical	O
activity	O
levels	O
in	O
minutes	O
per	O
week	O
,	O
five	O
studies	O
used	O
daily	O
step	O
counts	O
obtained	O
from	O
pedometers	O
,	O
and	O
one	O
study	O
measured	O
physical	O
activity	O
with	O
accelerometers	O
.	O

Because	O
of	O
the	O
differences	O
in	O
measurement	O
instruments	O
,	O
we	O
calculated	O
standardized	O
mean	O
differences	O
.	O

A	O
small	O
significant	O
difference	O
in	O
increase	O
of	O
physical	O
activity	O
levels	O
was	O
found	O
in	O
favor	O
of	O
the	O
intervention	O
(	O
weighted	O
standardized	O
mean	O
difference	O
0	O
.	O
25	O
,	O
95	O
%	O
CI	O
0	O
.	O
10	O
-	O
0	O
.	O
39	O
;	O
I2	O
=	O
81	O
%),	O
but	O
heterogeneity	O
was	O
high	O
.	O

The	O
jackknife	O
procedure	O
identified	O
one	O
study	O
[	O
65	O
]	O
driving	O
a	O
substantial	O
part	O
of	O
heterogeneity	O
;	O
without	O
this	O
study	O
,	O
I2	O
was	O
68	O
%.	O

Effect	O
of	O
Web	O
-	O
Based	O
Interventions	O
on	O
Overall	O
Cardiovascular	O
Risk	O
Profile	O
,	O
Cardiovascular	O
Morbidity	O
,	O
and	O
Mortality	O

Cardiovascular	O
Composite	O
Scores	O

Nine	O
studies	O
(	O
n	O
=	O
2321	O
;	O
Figure	O
8	O
)	O
reported	O
a	O
cardiovascular	O
composite	O
score	O
.	O

Five	O
studies	O
reported	O
the	O
Framingham	O
10	O
-	O
year	O
cardiovascular	B-DS
disease	I-DS
risk	O
score	O
,	O
three	O
studies	O
reported	O
the	O
Framingham	O
10	O
-	O
year	O
coronary	B-DS
heart	I-DS
disease	I-DS
risk	O
score	O
,	O
and	O
one	O
study	O
reported	O
a	O
clinical	O
composite	O
score	O
based	O
on	O
number	O
of	O
cardiovascular	O
risk	O
factors	O
on	O
target	O
(	O
BP	O
,	O
HbA1c	O
,	O
body	O
mass	O
index	O
,	O
LDL	O
cholesterol	B-CD
,	O
physical	O
activity	O
,	O
albuminuria	O
,	O
foot	B-DS
ulcers	I-DS
,	O
and	O
smoking	O
).	O

Because	O
of	O
the	O
differences	O
between	O
the	O
composite	O
scores	O
,	O
we	O
calculated	O
standardized	O
mean	O
differences	O
.	O

A	O
small	O
significant	O
improvement	O
of	O
the	O
cardiovascular	O
composite	O
scores	O
was	O
found	O
(	O
weighted	O
standardized	O
mean	O
difference	O
–	O
0	O
.	O
10	O
,	O
95	O
%	O
CI	O
–	O
0	O
.	O
18	O
to	O
–	O
0	O
.	O
02	O
;	O
I2	O
=	O
0	O
%).	O

General	O
Effect	O
of	O
Web	O
-	O
Based	O
Interventions	O
on	O
Cardiovascular	O
Risk	O
Factors	O

Finally	O
,	O
we	O
pooled	O
the	O
primary	O
outcomes	O
of	O
the	O
37	O
studies	O
(	O
n	O
=	O
11	O
,	O
021	O
;	O
Figure	O
9	O
)	O
that	O
defined	O
a	O
primary	O
outcome	O
(	O
systolic	O
BP	O
:	O
7	O
studies	O
;	O
HbA1c	O
:	O
13	O
studies	O
;	O
weight	O
:	O
8	O
studies	O
;	O
physical	O
activity	O
:	O
6	O
studies	O
;	O
cardiovascular	O
composite	O
score	O
:	O
3	O
studies	O
).	O

The	O
weighted	O
standardized	O
mean	O
difference	O
was	O
–	O
0	O
.	O
24	O
(	O
95	O
%	O
CI	O
–	O
0	O
.	O
31	O
to	O
–	O
0	O
.	O
16	O
;	O
I2	O
=	O
69	O
%)	O
in	O
favor	O
of	O
the	O
intervention	O
.	O

The	O
jackknife	O
procedure	O
revealed	O
that	O
one	O
study	O
[	O
57	O
]	O
somewhat	O
influenced	O
the	O
heterogeneity	O
;	O
without	O
this	O
study	O
,	O
heterogeneity	O
dropped	O
to	O
64	O
%.	O

The	O
funnel	O
plot	O
(	O
Multimedia	O
Appendix	O
5	O
)	O
indicated	O
that	O
small	O
studies	O
reporting	O
large	O
effects	O
might	O
be	O
overrepresented	O
.	O

The	O
Egger	O
’	O
s	O
test	O
confirmed	O
that	O
the	O
funnel	O
plot	O
was	O
not	O
symmetrical	O
(	O
P	O
=.	O
01	O
).	O

Effect	O
on	O
physical	O
activity	O
(	O
14	O
studies	O
).	O

Effect	O
on	O
cardiovascular	O
composite	O
scores	O
(	O
9	O
studies	O
).	O

General	O
effect	O
on	O
primary	O
outcomes	O
(	O
37	O
studies	O
).	O

Cardiovascular	O
Morbidity	O
and	O
Total	O
Mortality	O

Six	O
studies	O
(	O
n	O
=	O
1904	O
;	O
1	O
short	O
-	O
term	O
and	O
5	O
long	O
-	O
term	O
studies	O
)	O
reported	O
on	O
cardiovascular	O
event	O
rates	O
.	O

The	O
mean	O
length	O
of	O
the	O
studies	O
was	O
13	O
months	O
(	O
range	O
6	O
-	O
24	O
months	O
).	O

The	O
pooled	O
analysis	O
showed	O
no	O
difference	O
in	O
rate	O
between	O
groups	O
(	O
pooled	O
OR	O
0	O
.	O
75	O
,	O
95	O
%	O
CI	O
0	O
.	O
39	O
-	O
1	O
.	O
42	O
;	O
I2	O
=	O
27	O
%;	O
Figure	O
10	O
).	O

Total	O
mortality	O
rates	O
were	O
reported	O
in	O
13	O
studies	O
;	O
in	O
five	O
studies	O
,	O
no	O
deaths	O
occurred	O
and	O
in	O
the	O
other	O
eight	O
studies	O
,	O
there	O
were	O
no	O
differences	O
between	O
groups	O
.	O

Effect	O
on	O
cardiovascular	O
event	O
rates	O
(	O
6	O
studies	O
).	O

Association	O
between	O
study	O
duration	O
and	O
effect	O
size	O
(	O
Hedges	O
'	O
g	O
).	O

One	O
outlier	O
study	O
(	O
Ideatel	O
)	O
was	O
removed	O
from	O
analysis	O
.	O

Subgroup	O
Analyses	O

Results	O
are	O
summarized	O
in	O
Table	O
6	O
.	O

Within	O
the	O
analysis	O
of	O
pooled	O
primary	O
outcomes	O
,	O
the	O
intervention	O
effect	O
was	O
more	O
pronounced	O
in	O
the	O
short	O
-	O
term	O
studies	O
(	O
15	O
studies	O
;	O
n	O
=	O
2934	O
;	O
standardized	O
mean	O
difference	O
–	O
0	O
.	O
43	O
,	O
95	O
%	O
CI	O
–	O
0	O
.	O
57	O
to	O
–	O
0	O
.	O
29	O
;	O
I2	O
=	O
69	O
%)	O
than	O
in	O
the	O
long	O
-	O
term	O
studies	O
(	O
22	O
studies	O
;	O
n	O
=	O
8087	O
;	O
standardized	O
mean	O
difference	O
–	O
0	O
.	O
12	O
,	O
95	O
%	O
CI	O
–	O
0	O
.	O
19	O
to	O
–	O
0	O
.	O
06	O
;	O
I2	O
=	O
41	O
%).	O

The	O
same	O
pattern	O
was	O
found	O
for	O
all	O
other	O
outcomes	O
except	O
for	O
LDL	O
cholesterol	B-CD
(	O
Multimedia	O
Appendix	O
6	O
).	O

There	O
were	O
no	O
substantial	O
differences	O
in	O
effect	O
size	O
between	O
studies	O
on	O
primary	O
prevention	O
versus	O
secondary	O
prevention	O
.	O

To	O
further	O
explore	O
the	O
studies	O
targeting	O
primary	O
prevention	O
,	O
we	O
compared	O
studies	O
with	O
populations	O
of	O
relatively	O
low	O
age	O
(	O
not	O
all	O
participants	O
older	O
than	O
50	O
years	O
,	O
n	O
=	O
29	O
)	O
with	O
studies	O
with	O
populations	O
of	O
older	O
age	O
(	O
all	O
participants	O
older	O
than	O
50	O
years	O
,	O
n	O
=	O
4	O
).	O

The	O
pooled	O
effect	O
size	O
was	O
larger	O
for	O
the	O
studies	O
with	O
older	O
participants	O
(	O
Hedges	O
’	O
g	O
=–	O
0	O
.	O
30	O
)	O
than	O
for	O
the	O
studies	O
with	O
relatively	O
younger	O
participants	O
(	O
Hedges	O
’	O
g	O
=–	O
0	O
.	O
23	O
),	O
but	O
the	O
confidence	O
intervals	O
overlapped	O
largely	O
.	O

We	O
repeated	O
the	O
analysis	O
of	O
pooled	O
primary	O
outcomes	O
on	O
the	O
sample	O
of	O
studies	O
testing	O
an	O
Internet	O
-	O
only	O
and	O
a	O
blended	O
intervention	O
.	O

The	O
intervention	O
effect	O
was	O
more	O
pronounced	O
in	O
the	O
sample	O
of	O
blended	O
studies	O
(	O
26	O
studies	O
;	O
n	O
=	O
7538	O
;	O
standardized	O
mean	O
difference	O
–	O
0	O
.	O
33	O
,	O
95	O
%	O
CI	O
–	O
0	O
.	O
43	O
to	O
–	O
0	O
.	O
22	O
;	O
I2	O
=	O
78	O
%)	O
compared	O
to	O
the	O
sample	O
of	O
Internet	O
-	O
only	O
studies	O
(	O
14	O
studies	O
;	O
n	O
=	O
4280	O
;	O
standardized	O
mean	O
difference	O
–	O
0	O
.	O
15	O
,	O
95	O
%	O
CI	O
–	O
0	O
.	O
23	O
to	O
–	O
0	O
.	O
07	O
;	O
I2	O
=	O
40	O
%).	O

Subgroup	O
analyses	O
within	O
the	O
analysis	O
of	O
standardized	O
primary	O
outcomes	O
.	O

Subgroup	O

N	O
of	O
studies	O

Hedges	O
’	O
g	O

95	O
%	O
CI	O

I2	O

Duration	O
a	O






Short	O
(<	O
12	O
months	O
)	O

15	O

–	O
0	O
.	O
43	O

–	O
0	O
.	O
57	O
,	O
–	O
0	O
.	O
29	O

69	O
%	O


Long	O
(≥	O
12	O
months	O
)	O

22	O

–	O
0	O
.	O
12	O

–	O
0	O
.	O
19	O
,	O
–	O
0	O
.	O
06	O

41	O
%	O

Type	O
of	O
prevention	O
a	O






Primary	O
(	O
including	O
diabetes	B-DS
control	O
)	O

33	O

–	O
0	O
.	O
25	O

–	O
0	O
.	O
32	O
,	O
–	O
0	O
.	O
17	O

72	O
%	O


Secondary	O

4	O

–	O
0	O
.	O
20	O

–	O
0	O
.	O
34	O
,	O
–	O
0	O
.	O
06	O

0	O
%	O

Primary	O
prevention	O
:	O
age	O
subgroups	O
b	O






Not	O
all	O
older	O
than	O
50	O
years	O

29	O

–	O
0	O
.	O
23	O

–	O
0	O
.	O
33	O
,	O
–	O
0	O
.	O
14	O

72	O
%	O


All	O
older	O
than	O
50	O
years	O

4	O

–	O
0	O
.	O
30	O

–	O
0	O
.	O
51	O
,	O
–	O
0	O
.	O
09	O

80	O
%	O

Internet	O
only	O
vs	O
controlc	O

14	O

–	O
0	O
.	O
15	O

–	O
0	O
.	O
23	O
,	O
–	O
0	O
.	O
07	O

40	O
%	O

Blended	O
vs	O
controld	O

26	O

–	O
0	O
.	O
33	O

–	O
0	O
.	O
43	O
,	O
–	O
0	O
.	O
22	O

79	O
%	O

a	O
Subgroup	O
analysis	O
performed	O
in	O
the	O
sample	O
of	O
studies	O
that	O
was	O
used	O
for	O
the	O
analysis	O
of	O
primary	O
outcomes	O
.	O

b	O
Subgroup	O
analysis	O
performed	O
on	O
the	O
sample	O
of	O
studies	O
that	O
targeted	O
primary	O
prevention	O
(	O
including	O
diabetes	B-DS
control	O
).	O

c	O
Subgroup	O
analysis	O
performed	O
on	O
the	O
sample	O
of	O
studies	O
that	O
evaluated	O
an	O
Internet	O
-	O
only	O
intervention	O
.	O

In	O
case	O
a	O
study	O
tested	O
multiple	O
arms	O
,	O
the	O
appropriate	O
arm	O
was	O
included	O
in	O
the	O
analysis	O
.	O

d	O
Subgroup	O
analysis	O
performed	O
on	O
the	O
sample	O
of	O
studies	O
that	O
evaluated	O
a	O
blended	O
intervention	O
.	O

In	O
case	O
a	O
study	O
tested	O
multiple	O
arms	O
,	O
the	O
appropriate	O
arm	O
was	O
included	O
in	O
the	O
analysis	O
.	O

Meta	O
-	O
Regression	O

Because	O
of	O
the	O
fairly	O
consistent	O
finding	O
that	O
treatment	O
effects	O
were	O
higher	O
in	O
short	O
-	O
term	O
studies	O
than	O
in	O
long	O
-	O
term	O
studies	O
,	O
we	O
performed	O
a	O
mixed	O
effects	O
meta	O
-	O
regression	O
to	O
explore	O
the	O
association	O
between	O
study	O
duration	O
and	O
effect	O
size	O
.	O

The	O
effect	O
size	O
seemed	O
to	O
become	O
smaller	O
in	O
studies	O
with	O
longer	O
follow	O
-	O
up	O
,	O
although	O
the	O
association	O
was	O
not	O
significant	O
(	O
Hedges	O
’	O
g	O
=–	O
0	O
.	O
321	O
+	O
0	O
.	O
006	O
*	O
months	O
;	O
P	O
=.	O
07	O
).	O

After	O
removal	O
of	O
one	O
outlier	O
study	O
[	O
34	O
]	O
that	O
had	O
a	O
very	O
long	O
follow	O
-	O
up	O
(	O
5	O
years	O
),	O
the	O
effect	O
size	O
significantly	O
decreased	O
over	O
time	O
in	O
studies	O
lasting	O
3	O
to	O
32	O
months	O
(	O
Hedges	O
’	O
g	O
=–	O
0	O
.	O
415	O
+	O
0	O
.	O
015	O
*	O
months	O
;	O
P	O
=.	O
008	O
;	O
Figure	O
.	O

11	O
).	O

Sensitivity	O
Analyses	O
for	O
the	O
Risk	O
-	O
of	O
-	O
Bias	O
Assessment	O

We	O
performed	O
sensitivity	O
analyses	O
for	O
each	O
of	O
the	O
six	O
domains	O
of	O
bias	O
assessed	O
with	O
the	O
adapted	O
Cochrane	O
Risk	O
of	O
Bias	O
Tool	O
by	O
comparing	O
the	O
standardized	O
primary	O
outcomes	O
of	O
the	O
studies	O
with	O
the	O
low	O
risk	O
and	O
unknown	O
/	O
high	O
risk	O
of	O
bias	O
(	O
Multimedia	O
Appendix	O
7	O
).	O

There	O
were	O
no	O
significant	O
differences	O
in	O
pooled	O
effect	O
sizes	O
in	O
any	O
of	O
the	O
domains	O
except	O
for	O
the	O
domain	O
random	O
sequence	O
generation	O
,	O
in	O
which	O
the	O
pooled	O
effect	O
was	O
significantly	O
larger	O
in	O
the	O
subgroup	O
of	O
studies	O
with	O
unknown	O
/	O
high	O
risk	O
of	O
bias	O
.	O

Discussion	O

In	O
this	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
,	O
we	O
found	O
for	O
people	O
with	O
elevated	O
cardiovascular	O
risk	O
,	O
Web	O
-	O
based	O
interventions	O
lead	O
to	O
improvement	O
of	O
systolic	O
and	O
diastolic	O
BP	O
,	O
HbA1c	O
,	O
weight	O
,	O
LDL	O
cholesterol	B-CD
,	O
physical	O
activity	O
levels	O
,	O
and	O
cardiovascular	O
risk	O
composite	O
scores	O
.	O

Only	O
seven	O
studies	O
included	O
participants	O
all	O
aged	O
50	O
years	O
or	O
older	O
.	O

Therefore	O
,	O
our	O
conclusions	O
apply	O
for	O
the	O
population	O
in	O
middle	O
age	O
and	O
beyond	O
.	O

Effects	O
were	O
more	O
pronounced	O
over	O
the	O
short	O
term	O
(	O
study	O
duration	O
<	O
12	O
months	O
)	O
and	O
in	O
studies	O
that	O
tested	O
a	O
blended	O
intervention	O
(	O
combination	O
of	O
an	O
Internet	O
application	O
and	O
human	B-OG
support	O
).	O

We	O
found	O
no	O
evidence	O
for	O
an	O
effect	O
on	O
incident	O
cardiovascular	B-DS
disease	I-DS
.	O

Our	O
findings	O
on	O
single	O
cardiovascular	O
risk	O
factors	O
are	O
consistent	O
with	O
conclusions	O
of	O
other	O
meta	O
-	O
analyses	O
in	O
younger	O
adult	O
populations	O
[	O
19	O
-	O
21	O
].	O

We	O
found	O
a	O
significant	O
reduction	O
in	O
systolic	O
BP	O
of	O
2	O
.	O
66	O
mmHg	O
.	O

A	O
reduction	O
of	O
3	O
mmHg	O
in	O
systolic	O
BP	O
can	O
lead	O
to	O
an	O
8	O
%	O
reduction	O
in	O
annual	O
stroke	B-DS
mortality	O
rate	O
and	O
a	O
5	O
%	O
reduction	O
in	O
annual	O
coronary	B-DS
heart	I-DS
disease	I-DS
mortality	O
rate	O
[	O
83	O
].	O

We	O
found	O
a	O
reduction	O
of	O
LDL	O
cholesterol	B-CD
of	O
2	O
.	O
18	O
mg	O
/	O
dL	O
(	O
converted	O
=	O
0	O
.	O
06	O
mmol	O
/	O
L	O
).	O

A	O
reduction	O
of	O
0	O
.	O
5	O
mmol	O
/	O
L	O
in	O
LDL	O
cholesterol	B-CD
for	O
at	O
least	O
2	O
years	O
can	O
lead	O
to	O
a	O
reduction	O
in	O
coronary	B-DS
heart	I-DS
disease	I-DS
events	O
of	O
20	O
%	O
[	O
6	O
].	O

Theoretically	O
,	O
assuming	O
a	O
linear	O
relation	O
,	O
a	O
reduction	O
of	O
0	O
.	O
06	O
mmol	O
/	O
L	O
could	O
lead	O
to	O
a	O
2	O
.	O
4	O
%	O
reduction	O
of	O
coronary	B-DS
heart	I-DS
disease	I-DS
events	O
.	O

Thus	O
,	O
the	O
effects	O
on	O
Internet	O
interventions	O
on	O
BP	O
reduction	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
LDL	O
cholesterol	B-CD
reduction	O
,	O
can	O
be	O
clinically	O
relevant	O
at	O
the	O
population	O
level	O
if	O
reductions	O
are	O
maintained	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
on	O
the	O
complete	O
cardiovascular	O
risk	O
profile	O
and	O
prevention	O
of	O
cardiovascular	B-DS
disease	I-DS
,	O
which	O
has	O
not	O
been	O
performed	O
before	O
.	O

One	O
other	O
systematic	O
review	O
without	O
meta	O
-	O
analysis	O
that	O
evaluated	O
Internet	O
interventions	O
for	O
lifestyle	O
change	O
in	O
older	O
people	O
reported	O
that	O
interventions	O
with	O
multiple	O
components	O
are	O
more	O
effective	O
than	O
interventions	O
with	O
a	O
single	O
component	O
[	O
84	O
].	O

We	O
found	O
that	O
the	O
beneficial	O
effects	O
of	O
Web	O
-	O
based	O
interventions	O
decline	O
over	O
time	O
and	O
effects	O
are	O
larger	O
when	O
interventions	O
are	O
combined	O
with	O
human	B-OG
support	O
.	O

Decreasing	O
adherence	O
over	O
time	O
was	O
reported	O
in	O
several	O
studies	O
included	O
in	O
our	O
meta	O
-	O
analysis	O
and	O
could	O
be	O
an	O
important	O
contributor	O
to	O
the	O
decreasing	O
effect	O
over	O
time	O
.	O

We	O
were	O
unable	O
to	O
formally	O
test	O
this	O
because	O
information	O
on	O
adherence	O
and	O
engagement	O
was	O
only	O
reported	O
by	O
22	O
studies	O
and	O
definitions	O
varied	O
widely	O
.	O

The	O
identified	O
effect	O
moderators	O
are	O
not	O
specific	O
to	O
Web	O
-	O
based	O
interventions	O
for	O
cardiovascular	O
risk	O
factors	O
[	O
85	O
,	O
86	O
].	O

Maintenance	O
of	O
behavioral	O
change	O
is	O
notoriously	O
complex	O
and	O
best	O
achieved	O
in	O
longer	O
studies	O
with	O
intensive	O
interventions	O
,	O
more	O
face	O
-	O
to	O
-	O
face	O
,	O
and	O
more	O
follow	O
-	O
up	O
contacts	O
.	O

However	O
,	O
such	O
interventions	O
lead	O
to	O
high	O
attrition	O
rates	O
,	O
probably	O
reflecting	O
selection	O
of	O
the	O
most	O
motivated	O
participants	O
[	O
87	O
].	O

A	O
careful	O
balance	O
should	O
be	O
sought	O
between	O
effectiveness	O
and	O
implementability	O
when	O
designing	O
cardiovascular	O
risk	O
management	O
interventions	O
,	O
whether	O
or	O
not	O
an	O
Internet	O
-	O
based	O
approach	O
is	O
used	O
.	O

Our	O
results	O
do	O
not	O
show	O
a	O
beneficial	O
effect	O
of	O
Web	O
-	O
based	O
interventions	O
on	O
incident	O
cardiovascular	B-DS
disease	I-DS
.	O

Although	O
the	O
declining	O
effect	O
over	O
time	O
could	O
play	O
a	O
role	O
,	O
more	O
likely	O
explanations	O
for	O
these	O
findings	O
are	O
the	O
limited	O
follow	O
-	O
up	O
time	O
of	O
the	O
studies	O
to	O
detect	O
these	O
outcomes	O
(	O
mean	O
length	O
of	O
the	O
studies	O
was	O
13	O
months	O
)	O
and	O
the	O
fact	O
that	O
these	O
outcomes	O
were	O
not	O
the	O
primary	O
focus	O
of	O
these	O
studies	O
.	O

Because	O
of	O
the	O
latter	O
,	O
data	O
collection	O
may	O
not	O
have	O
been	O
systematic	O
and	O
adjudication	O
of	O
the	O
data	O
by	O
an	O
independent	O
committee	O
may	O
be	O
lacking	O
.	O

Therefore	O
,	O
we	O
cannot	O
draw	O
strong	O
conclusions	O
from	O
these	O
findings	O
.	O

The	O
results	O
of	O
this	O
study	O
should	O
be	O
interpreted	O
with	O
caution	O
because	O
of	O
several	O
limitations	O
.	O

The	O
methodological	O
quality	O
of	O
the	O
studies	O
was	O
fair	O
,	O
but	O
none	O
of	O
the	O
studies	O
was	O
double	O
blind	O
,	O
rendering	O
them	O
prone	O
to	O
performance	O
bias	O
.	O

Only	O
20	O
studies	O
had	O
a	O
blinded	O
outcome	O
assessment	O
,	O
so	O
detection	O
bias	O
may	O
also	O
be	O
present	O
.	O

Because	O
the	O
sensitivity	O
analyses	O
for	O
the	O
risk	O
-	O
of	O
-	O
bias	O
assessment	O
did	O
not	O
reveal	O
significant	O
differences	O
between	O
the	O
low	O
risk	O
and	O
unknown	O
/	O
high	O
risk	O
-	O
of	O
-	O
bias	O
subgroups	O
,	O
except	O
for	O
the	O
domain	O
of	O
random	O
sequence	O
generation	O
,	O
we	O
think	O
that	O
our	O
findings	O
have	O
not	O
been	O
largely	O
affected	O
by	O
these	O
potential	O
sources	O
of	O
bias	O
.	O

Another	O
limitation	O
is	O
the	O
substantial	O
heterogeneity	O
in	O
several	O
of	O
the	O
meta	O
-	O
analyses	O
that	O
is	O
,	O
in	O
part	O
,	O
explained	O
by	O
two	O
effect	O
modifiers	O
:	O
study	O
duration	O
and	O
intervention	O
type	O
.	O

Patient	O
groups	O
with	O
a	O
higher	O
burden	O
have	O
a	O
larger	O
window	O
of	O
opportunity	O
for	O
improvement	O
potentially	O
resulting	O
in	O
larger	O
intervention	O
effects	O
[	O
88	O
],	O
which	O
could	O
also	O
have	O
contributed	O
to	O
heterogeneity	O
.	O

We	O
could	O
not	O
draw	O
firm	O
conclusions	O
on	O
the	O
difference	O
between	O
primary	O
and	O
secondary	O
prevention	O
,	O
because	O
only	O
four	O
studies	O
on	O
secondary	O
prevention	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Last	O
,	O
there	O
is	O
a	O
potential	O
for	O
publication	O
bias	O
and	O
small	O
study	O
bias	O
.	O

Most	O
of	O
the	O
studies	O
with	O
small	O
sample	O
sizes	O
reported	O
large	O
effects	O
and	O
similar	O
studies	O
with	O
null	O
findings	O
did	O
not	O
appear	O
in	O
the	O
funnel	O
plots	O
(	O
Multimedia	O
Appendix	O
5	O
).	O

Strengths	O
of	O
our	O
study	O
are	O
the	O
comprehensive	O
search	O
strategy	O
,	O
the	O
quantitative	O
meta	O
-	O
analysis	O
,	O
and	O
the	O
assessment	O
of	O
the	O
effect	O
of	O
Web	O
-	O
based	O
interventions	O
for	O
all	O
cardiovascular	O
risk	O
factors	O
using	O
both	O
intermediate	O
and	O
clinical	O
outcomes	O
.	O

Our	O
search	O
strategy	O
was	O
comprehensive	O
because	O
we	O
used	O
a	O
broad	O
definition	O
of	O
Web	O
-	O
based	O
interventions	O
and	O
only	O
excluded	O
telemedicine	O
and	O
mobile	O
phone	O
interventions	O
.	O

It	O
was	O
not	O
always	O
possible	O
to	O
set	O
Web	O
-	O
based	O
interventions	O
apart	O
from	O
telemedicine	O
and	O
mobile	O
phone	O
interventions	O
.	O

As	O
long	O
as	O
the	O
Web	O
-	O
based	O
program	O
was	O
the	O
main	O
component	O
of	O
the	O
intervention	O
,	O
we	O
judged	O
the	O
study	O
eligible	O
for	O
our	O
systematic	O
review	O
.	O

By	O
pooling	O
the	O
effect	O
sizes	O
on	O
all	O
different	O
cardiovascular	O
risk	O
factors	O
,	O
we	O
aimed	O
to	O
assess	O
the	O
overall	O
effect	O
of	O
an	O
Internet	O
-	O
based	O
approach	O
for	O
people	O
with	O
increased	O
risk	O
of	O
cardiovascular	B-DS
disease	I-DS
.	O

This	O
approach	O
provides	O
insight	O
into	O
the	O
overall	O
potential	O
of	O
Internet	O
-	O
based	O
interventions	O
in	O
this	O
field	O
.	O

Although	O
basic	O
computer	O
literacy	O
as	O
an	O
inclusion	O
criterion	O
probably	O
led	O
to	O
selection	O
of	O
participants	O
with	O
a	O
relatively	O
high	O
socioeconomic	O
status	O
,	O
several	O
studies	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
focused	O
on	O
people	O
from	O
medically	O
underserved	O
areas	O
.	O

Therefore	O
,	O
the	O
external	O
validity	O
of	O
the	O
results	O
might	O
be	O
acceptable	O
and	O
may	O
be	O
generalizable	O
to	O
middle	O
-	O
aged	O
to	O
older	O
primary	O
care	O
populations	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-DS
disease	I-DS
.	O

Our	O
results	O
show	O
that	O
Web	O
-	O
based	O
interventions	O
can	O
be	O
effective	O
in	O
improving	O
the	O
cardiovascular	O
risk	O
factor	O
profile	O
of	O
middle	O
-	O
aged	O
and	O
older	O
people	O
,	O
but	O
effects	O
are	O
modest	O
and	O
can	O
only	O
have	O
clinical	O
relevance	O
on	O
the	O
population	O
level	O
if	O
sustained	O
over	O
time	O
.	O

Considering	O
the	O
current	O
interest	O
and	O
focus	O
on	O
eHealth	O
by	O
policy	O
makers	O
,	O
funding	O
agencies	O
,	O
and	O
a	O
myriad	O
of	O
research	O
and	O
patient	O
organizations	O
[	O
89	O
,	O
90	O
],	O
it	O
is	O
important	O
to	O
evaluate	O
the	O
actual	O
evidence	O
base	O
objectively	O
.	O

Unrealistic	O
expectations	O
of	O
the	O
effectiveness	O
of	O
Web	O
-	O
based	O
interventions	O
obscure	O
the	O
true	O
challenges	O
that	O
have	O
to	O
be	O
overcome	O
first	O
,	O
including	O
testing	O
interventions	O
that	O
were	O
designed	O
specifically	O
for	O
older	O
people	O
,	O
improving	O
methodological	O
robustness	O
of	O
studies	O
,	O
and	O
improving	O
sustainability	O
of	O
effects	O
.	O

On	O
the	O
macro	O
level	O
,	O
trials	O
can	O
assess	O
sustainability	O
by	O
prolonging	O
follow	O
-	O
up	O
,	O
recording	O
clinical	O
events	O
,	O
and	O
measuring	O
surrogate	O
cardiovascular	O
outcomes	O
(	O
eg	O
,	O
BP	O
,	O
cholesterol	B-CD
levels	O
,	O
and	O
weight	O
)	O
at	O
multiple	O
time	O
points	O
(	O
eg	O
,	O
at	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
36	O
months	O
).	O

On	O
the	O
micro	O
level	O
,	O
adherence	O
should	O
be	O
evaluated	O
by	O
studying	O
intervention	O
usage	O
through	O
time	O
with	O
standardized	O
evaluation	O
methods	O
.	O

Sustainability	O
is	O
of	O
particular	O
importance	O
because	O
long	O
-	O
term	O
effects	O
are	O
required	O
for	O
primary	O
and	O
secondary	O
prevention	O
to	O
truly	O
contribute	O
to	O
the	O
prevention	O
of	O
cardiovascular	B-DS
disease	I-DS
.	O

Web	O
-	O
based	O
interventions	O
combined	O
with	O
human	B-OG
support	O
are	O
more	O
promising	O
than	O
Internet	O
-	O
only	O
interventions	O
.	O

Authors	O
'	O
Contributions	O
:	O
CRB	O
had	O
full	O
access	O
to	O
all	O
data	O
in	O
the	O
study	O
and	O
takes	O
responsibility	O
for	O
the	O
integrity	O
of	O
the	O
data	O
and	O
the	O
accuracy	O
of	O
the	O
data	O
analysis	O
.	O

ER	O
,	O
EMvC	O
,	O
WvG	O
,	O
CB	O
,	O
MK	O
,	O
SA	O
,	O
and	O
HS	O
conceived	O
the	O
study	O
.	O

CRB	O
,	O
BS	O
,	O
and	O
ER	O
wrote	O
the	O
study	O
protocol	O
and	O
analysis	O
plan	O
.	O

CRB	O
and	O
BS	O
collected	O
and	O
extracted	O
the	O
data	O
,	O
with	O
support	O
from	O
ER	O
and	O
EMvC	O
.	O

CRB	O
performed	O
the	O
statistical	O
analysis	O
,	O
supported	O
by	O
BS	O
,	O
ER	O
,	O
WB	O
,	O
and	O
WvG	O
.	O

CRB	O
and	O
ER	O
drafted	O
the	O
manuscript	O
and	O
all	O
authors	O
critically	O
revised	O
the	O
manuscript	O
for	O
important	O
intellectual	O
content	O
.	O

Conflicts	O
of	O
Interest	O
:	O
None	O
declared	O
.	O

